<?xml version="1.0" encoding="UTF-8"?>
<recordset>  <record>    <type>JOUR</type>
    <id>100</id>
    <title>Exposure to toxic environmental agents</title>
    <date>2013</date>
    <notes>JEnglishArticle1209 Montgomery Hwy, Birmingham, AL 35216 USAAdamkiewicz G, 2011, AM J PUBLIC HEALTH, V101, pS238, DOI 10.2105/AJPH.2011.300119; American Academy of Pediatrics &amp; American College of Obstetricians and Gynecologists, 2012, GUID PER CAR; Bailin P.D., 2008, PUBLIC AWARENESS DRI; Barr DB, 2007, REPROD TOXICOL, V23, P260, DOI 10.1016/j.reprotox.2007.03.003; Bergman A, 2012, STATE SCI ENDOCRINE; Boekelheide K, 2012, ENVIRON HEALTH PERSP, V120, P1353, DOI 10.1289/ehp.1204934; CDC (Centers for Disease Control and Prevention), 2009, 4 CDCP; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Figa-Talamanca I, 2006, OCCUP MED-OXFORD, V56, P521, DOI 10.1093/occmed/kql114; Hines CJ, 2009, ANN OCCUP HYG, V53, P1, DOI 10.1093/annhyg/men066; Ji K, 2010, ENVIRON RES, V110, P375, DOI 10.1016/j.envres.2010.02.008; Lu CS, 2006, ENVIRON HEALTH PERSP, V114, P260, DOI 10.1289/ehp.8418; McCauley Linda A, 2005, AAOHN J, V53, P313; Morello-Frosch R, 2011, HEALTH AFFAIR, V30, P879, DOI 10.1377/hlthaff.2011.0153; National Research Council, 2009, SCI DEC ADV RISK ASS; Ondeck Michele, 2009, J Perinat Educ, V18, P31, DOI 10.1624/105812409X474690; Pransky G, 2002, AM J IND MED, V42, P117, DOI 10.1002/ajim.10092; Rollin HB, 2009, J ENVIRON MONITOR, V11, P618, DOI 10.1039/b816236k; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P914, DOI 10.1289/ehp.1003170; Sathyanarayana S, 2012, AM J OBSTET GYNECOL, V207, P463, DOI 10.1016/j.ajog.2012.02.004; Sathyanarayana S, 2013, J EXPO SCI ENV EPID, V23, P378, DOI 10.1038/jes.2013.9; Science and Environmental Health Network, 1998, WINGSPR STAT PREC PR; Smith-Spangler C, 2012, ANN INTERN MED, V157, P348, DOI 10.7326/0003-4819-157-5-201209040-00007; Society Endocrine, 2009, END DISR CHEM; Solomon GM, 1996, J OCCUP ENVIRON MED, V38, P705, DOI 10.1097/00043764-199607000-00014; Stern AH, 2003, ENVIRON HEALTH PERSP, V111, P1465, DOI 10.1289/ehp.6187; Sutton P, 2011, PESTICIDES MATTER PR; Sutton P, 2012, AM J OBSTET GYNECOL, V207, P164, DOI 10.1016/j.ajog.2012.01.034; University of California San Francisco, PROF STAT DAT; Vogel SA, 2011, HEALTH AFFAIR, V30, P898, DOI 10.1377/hlthaff.2011.0211; Woodruff TJ, 2003, ENVIRON HEALTH PERSP, V111, P942, DOI 10.1289/ehp.5317; Woodruff TJ, 2011, ENVIRON HEALTH PERSP, V119, P878, DOI 10.1289/ehp.1002727; Woodruff TJ, 2010, ENV IMPACTS REPROD H; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422; Zota AR, 2011, ENVIRON SCI TECHNOL, V45, P7896, DOI 10.1021/es200422b360ELSEVIER SCIENCE INCNEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USAFERTIL STERILOCTDiscipline: Obstetrics &amp; Gynecology; Reproductive Biology225WG</notes>
    <keywords>BIOLOGY; BISPHENOL-A; CANCER; CHEMICALS; CORD BLOOD; DISEASE; ENDOCRINE; Endocrine-disrupting chemicals; ENVIRONMENTAL CHEMICALS; ENVIRONMENTAL-FACTORS; EXPOSURE; IMPACT; Male; phthalate; POPULATION; PRENATAL EXPOSURE; PREVENTION; Prostate; prostate cancer; PROSTATE-CANCER; REPRODUCTIVE HEALTH; RISK; SEMEN QUALITY; SOCIETY; STATEMENT; WOMEN; WORKERS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>931</startpage>
    <endpage>934</endpage>
    <journalfull>Fertility and Sterility</journalfull>
    <issue>4</issue>
    <volume>100</volume>
    <abstract>Reducing exposure to toxic environmental agents is a critical area of intervention for obstetricians, gynecologists, and other reproductive health care professionals. Patient exposure to toxic environmental chemicals and other stressors is ubiquitous, and preconception and prenatal exposure to toxic environmental agents can have a profound and lasting effect on reproductive health across the life course. Prenatal exposure to certain chemicals has been documented to increase the risk of cancer in childhood; adult male exposure to pesticides is linked to altered semen quality, sterility, and prostate cancer; and postnatal exposure to some pesticides can interfere with all developmental stages of reproductive function in adult females, including puberty, menstruation and ovulation, fertility and fecundity, and menopause. Many environmental factors harmful to reproductive health disproportionately affect vulnerable and underserved populations, which leaves some populations, including underserved women, more vulnerable to adverse reproductive health effects than other populations. The evidence that links exposure to toxic environmental agents and adverse reproductive and developmental health outcomes is sufficiently robust, and the American College of Obstetricians and Gynecologists and the American Society for Reproductive Medicine join leading scientists and other clinical practitioners in calling for timely action to identify and reduce exposure to toxic environmental agents while addressing the consequences of such exposure. (Fertil Steril (R) 2013; 100: 931-4. (C) 2013 by American Society for Reproductive Medicine.)</abstract>
    <url>WOS:000324995200022</url>
    <isbnorissn>0015-0282</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>236</id>
    <title>Endocrine Disruptors and Breast Cancer Risk - Time to Consider the Environment</title>
    <authors>Abdel-Rahman,W.M.; Moustafa,Y.M.; Ahmed,B.O.; Mostafa,R.M.</authors>
    <availability>[Abdel-Rahman, Wael M.] Univ Sharjah, Dept Med Lab Sci, Sharjah, U Arab Emirates. [Ahmed, Bassamat O.] Univ Sharjah, Dept Nursing, Coll Hlth Sci, Sharjah, U Arab Emirates. [Mostafa, Randa M.] Univ Sharjah, Dept Basic Med Sci, Coll Med, Sharjah, U Arab Emirates. [Moustafa, Yasser M.] Suez Canal Univ, Coll Pharm, Dept Pharmacol, Ismailia, Egypt.</availability>
    <date>2012</date>
    <notes>JEnglishReviewAbdel-Rahman, WM (reprint author), Univ Sharjah, Dept Med Lab Sci, POB 27272, Sharjah, U Arab Emirateswhassan@sharjah.ac.aeAbdel-Rahman WM, 2008, CURR GENOMICS, V9, P535, DOI 10.2174/138920208786847926; ADAMS NR, 1995, J ANIM SCI, V73, P1509; Allred CD, 2001, CANCER RES, V61, P5045; Allred CD, 2001, CARCINOGENESIS, V22, P1667, DOI 10.1093/carcin/22.10.1667; Andres S, 2011, CRIT REV TOXICOL, V41, P463, DOI 10.3109/10408444.2010.541900; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Becker K, 2009, INT J HYG ENVIR HEAL, V212, P685, DOI 10.1016/j.ijheh.2009.08.002; Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105; BOYLAN ES, 1979, J TOXICOL ENV HEALTH, V5, P1059; Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Canderelli R, 2007, J AM ACAD NURSE PRAC, V19, P635, DOI 10.1111/j.1745-7599.2007.00269.x; Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Cravedi JP, 2007, M S-MED SCI, V23, P198, DOI 10.1051/medsci/2007232198; Crews D, 2000, Q REV BIOL, V75, P243, DOI 10.1086/393498; Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; Darbre PD, 2002, J APPL TOXICOL, V22, P219, DOI 10.1002/jat.860; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Dey S, 2010, BREAST, V19, P417, DOI 10.1016/j.breast.2010.04.005; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dong JY, 2011, BREAST CANCER RES TR, V125, P315, DOI 10.1007/s10549-010-1270-8; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Du MY, 2012, CARCINOGENESIS, V33, P895, DOI 10.1093/carcin/bgs017; Durando M, 2011, J STEROID BIOCHEM, V127, P35, DOI 10.1016/j.jsbmb.2011.04.001; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; El Saghir Nagi S, 2007, Int J Surg, V5, P225, DOI 10.1016/j.ijsu.2006.06.015; Goodman MT, 2009, CANCER PREV RES, V2, P887, DOI 10.1158/1940-6207.CAPR-09-0039; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Grace PB, 2004, CANCER EPIDEM BIOMAR, V13, P698; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; Guha N, 2009, BREAST CANCER RES TR, V118, P395, DOI 10.1007/s10549-009-0321-5; Harner T, 2004, ENVIRON SCI TECHNOL, V38, P4474, DOI 10.1021/es040302r; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Hwang CS, 2006, J STEROID BIOCHEM, V101, P246, DOI 10.1016/j.jsbmb.2006.06.020; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; Iwasaki M, 2008, J CLIN ONCOL, V26, P1677, DOI 10.1200/JCO.2007.13.9964; Izzotti A, 2010, CURR CANCER DRUG TAR, V10, P147; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Ju YH, 2008, CARCINOGENESIS, V29, P2162, DOI 10.1093/carcin/bgn161; Ju YH, 2002, CANCER RES, V62, P2474; Ju YH, 2006, CARCINOGENESIS, V27, P1292, DOI 10.1093/carcin/bgi370; Khan SA, 2011, CANCER PREV RES, V5, P309; Kim H S, 2001, J Toxicol Sci, V26, P111, DOI 10.2131/jts.26.111; Klein CB, 2007, TOXICOL APPL PHARM, V224, P1, DOI 10.1016/j.taap.2007.06.022; Korde LA, 2009, CANCER EPIDEM BIOMAR, V18, P1050, DOI 10.1158/1055-9965.EPI-08-0405; Kortenkamp A, 2011, METAL IONS LIFE SCI, V8, P305, DOI 10.1039/978184973211600305; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lampe JW, 2007, CANCER EPIDEM BIOMAR, V16, P2579, DOI 10.1158/1055-9965.EPI-07-0368; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; LaPensee EW, 2010, CANCER LETT, V290, P167, DOI 10.1016/j.canlet.2009.09.005; Lattrich C, 2011, ANTI-CANCER DRUG, V22, P253, DOI 10.1097/CAD.0b013e3283427bb5; Mahady GB, 2003, MENOPAUSE, V10, P65, DOI 10.1097/01.GME.0000029028.95924.F9; Mai ZM, 2007, CARCINOGENESIS, V28, P1217, DOI 10.1093/carcin/bgm004; Maizlish N, 1990, J OCCUP MED, V32, P90; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Markey CM, 2001, BIOL REPROD, V65, P1215; METZLER M, 1981, CRC CR REV BIOCH MOL, V10, P171, DOI 10.3109/10409238109113599; Molzberger AF, 2012, MOL NUTR FOOD RES, V56, P399, DOI 10.1002/mnfr.201100371; Montales MTE, 2012, CARCINOGENESIS, V33, P652, DOI 10.1093/carcin/bgr317; Mostafa RM, 2007, J MED SCI RES, V2, P33; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Ndahi H, 2000, TECHNOLOGY TEACHER, V16, P18; Nieminen TT, 2012, CANCER EPIDEM BIOMAR, V21, P202, DOI 10.1158/1055-9965.EPI-11-0662; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222; Parkin D M, 2006, BREAST J, V12, P70; Patisaul HB, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.010.2009; Petrakis NL, 1996, CANCER EPIDEM BIOMAR, V5, P785; PIKE MC, 1993, EPIDEMIOL REV, V15, P17; Powell E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030993; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Rajah TT, 2009, PHARMACOLOGY, V84, P68, DOI 10.1159/000226123; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rubin MM, 2007, OBSTET GYNECOL SURV, V62, P548, DOI 10.1097/01.ogx.0000271138.31234.d7; Sahin K, 2011, NUTR CANCER, V63, P1279, DOI 10.1080/01635581.2011.606955; Sanderson T, 2011, TOXICOL SCI, V94, P3; Santell RC, 1997, J NUTR, V127, P263; Seo HS, 2011, ANTICANCER RES, V31, P3301; SETCHELL KDR, 1987, GASTROENTEROLOGY, V93, P225; Setchell KDR, 2011, AM J CLIN NUTR, V94, P1284, DOI 10.3945/ajcn.111.019638; Shu XO, 2009, JAMA-J AM MED ASSOC, V302, P2437, DOI 10.1001/jama.2009.1783; Skinner MK, 2011, REPROD TOXICOL, V31, P337, DOI 10.1016/j.reprotox.2010.10.012; Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007; Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x; Speirs V, 2007, J PATHOL, V211, P499, DOI 10.1002/path.2130; Takahashi S, 2001, MUTAT RES-GEN TOX EN, V490, P199, DOI 10.1016/S1383-5718(00)00161-3; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Taylor RT, 2009, TOXICOL SCI, V107, P1, DOI 10.1093/toxsci/kfn217; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Tsutsui T, 2000, INT J CANCER, V86, P151, DOI 10.1002/(SICI)1097-0215(20000415)86:2&lt;151::AID-IJC1&gt;3.0.CO;2-0; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; van Duursen MBM, 2011, TOXICOLOGY, V289, P67, DOI 10.1016/j.tox.2011.07.005; Viel JF, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-4; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Ward H, 2008, BREAST CANC, V10, P32; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Wittassek M, 2007, INT J HYG ENVIR HEAL, V210, P35, DOI 10.1016/j.ijheh.2006.11.009; Xiao CW, 2008, J NUTR, V138, P1244; YOONESSI M, 1981, NEW YORK STATE J MED, V81, P195; Yurino H, 2004, TOXICOL SCI, V81, P139, DOI 10.1093/toxsci/kfh179; ZIEGLER RG, 1993, J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.18191141ASIAN PACIFIC ORGANIZATION CANCER PREVENTIONGYEONGGI-DOAPJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREAASIAN PAC J CANCER PDiscipline: Oncology244RE</notes>
    <keywords>ASIAN-AMERICAN WOMEN; bisphenol A; BISPHENOL-A ALTERS; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; Carcinogen; CARCINOGENESIS; CELL; CHEMICALS; development; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; ENVIRONMENTAL-FACTORS; Estrogen; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FOOD; GLAND; HEALTH; Hormones; HUMAN HEALTH; IN-UTERO; mammary gland; MAMMARY-GLAND; morphogenesis; MOUSE MAMMARY-GLAND; oncology; ORGANIZATION; PHARMACOLOGY; Phytoestrogen; PHYTOESTROGENS; POSTMENOPAUSAL WOMEN; PRENATAL EXPOSURE; PREVENTION; RISK; Rural; SOY; STIMULATES GROWTH; SYSTEM; toxicology; TUMOR; TUMORS; Urban; xenoestrogen; XENOESTROGENS; YOUNG-WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>5937</startpage>
    <endpage>5946</endpage>
    <journalfull>Asian Pacific Journal of Cancer Prevention</journalfull>
    <issue>12</issue>
    <volume>13</volume>
    <abstract>The term endocrine disruptors is used to describe a variety of natural and manmade substances that have the capacity to potentially interfere with and modify the normal physiology of endocrine system either by mimicking, blocking or modulating the actions of natural endogenous hormones. The rising incidence of breast cancer over the last 50 years and the documented higher incidence in urban as compared to rural areas suggest a relationship to the introduction and increased use of xenoestrogens in our environment. The literature has developed over the last decades where initial experiments on endocrine disruptors did not support an involvement in breast cancer, and then evidence mounted implicating various environmental factors including hormones, endocrine disrupting chemicals and non-endocrine disrupting environmental carcinogens in the pathogenesis of breast cancer. Available data support the hypothesis that exposure to endocrine disruptors in utero leaves a signature on mammary gland morphogenesis so that the resulting dysgenic gland becomes more predisposed to develop tumors upon exposures to additional insults later on during life. Exceptionally, exposure to phytoestrogens could be beneficial to human health. Most of the available data are from well developed countries while the developing countries are still understudied regarding these issues. Here, we raise a note of caution about potential role of environmental toxins including endocrine disruptors in breast cancer development and call for serious measures to be taken by all involved parties in the developing world</abstract>
    <url>WOS:000326406300002</url>
    <isbnorissn>1513-7368</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>103</id>
    <title>Perinatally Administered Bisphenol A as a Potential Mammary Gland Carcinogen in Rats</title>
    <authors>Acevedo,N.; Davis,B.; Schaeberle,C.M.; Sonnenschein,C.; Soto,A.M.</authors>
    <availability>[Acevedo, Nicole; Schaeberle, Cheryl M.; Sonnenschein, Carlos; Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USA. [Davis, Barbara] Tufts Univ, Cummings Sch Vet Med, Dept Pathol, Grafton, MA USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleSoto, AM (reprint author), Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USAana.soto@tufts.eduAyyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Biegel LB, 1998, TOXICOL SCI, V44, P116, DOI 10.1093/toxsci/44.2.116; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; Burridge E., 2008, ICIS CHEM BUSINESS, V274, P48; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; SOTO AM, 1992, ADV MOD ENV, V21, P295; Davis B, 2013, HDB TOXICOLOGIC PATH, V3, P2665; Doerge DR, 2010, TOXICOL LETT, V199, P372, DOI 10.1016/j.toxlet.2010.09.022; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Ikezaki S, 2011, J TOXICOL PATHOL, V24, P37, DOI 10.1293/tox.24.37; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Institute of Laboratory Animal Research National Academy of Sciences, 2011, GUIDE CARE USE LAB A; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; LOTZ W, 1978, J ENDOCRINOL, V76, P507, DOI 10.1677/joe.0.0760507; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Lucas JN, 2007, TOXICOL PATHOL, V35, P199, DOI 10.1080/01926230601156260; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Markey CM, 2001, BIOL REPROD, V65, P1215; Munoz de Toro MM, 2005, ENDOCRINOLOGY, V146, P4138, DOI DOI 10.1210/EN.2005-0340; Murray TJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-267; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; National Toxicology Program, 2010, 548 NTP TR; National Toxicology Program, 2007, 545 NTP TR; Potischman N, 1999, CANCER CAUSE CONTROL, V10, P561, DOI 10.1023/A:1008955110868; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Son WC, 2004, TOXICOL PATHOL, V32, P371, DOI 10.1080/01926230490440871; Soto AM, 2011, BIOESSAYS, V33, P332, DOI 10.1002/bies.201100025; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; United States Environmental Protection Agency, 1993, 80057 CASRN US EPA; U.S. EPA (U.S. Environmental Protection Agency), 2005, TECHN TRANSF NETW AI; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2013, REPROD TOXICOL, V38, P1, DOI 10.1016/j.reprotox.2013.02.002; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wadia PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063902; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; White SS, 2007, TOXICOL SCI, V96, P133, DOI 10.1093/toxsci/kfl177; Ye X, 2008, TALANTA, V76, P865, DOI 10.1016/j.talanta.2008.04.034; Yokota H, 1999, BIOCHEM J, V340, P405, DOI 10.1042/0264-6021:3400405; Zalko D, 2011, CHEMOSPHERE, V82, P424, DOI 10.1016/j.chemosphere.2010.09.058; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.5603569US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPSEPDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology227XS</notes>
    <keywords>ADENOCARCINOMA; ALTERS; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CARCINOMA; CD-1 MICE; CELL; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL; Endocrine-disrupting chemicals; EXPOSURE; GLAND; HUMANS; IN-UTERO EXPOSURE; MAMMARY-GLAND; MAMMARY-GLANDS; PRENATAL EXPOSURE; RAT; RATS; RISK; serum; SPRAGUE-DAWLEY RATS; TISSUE ORGANIZATION; toxicology; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1040</startpage>
    <endpage>1046</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>9</issue>
    <volume>121</volume>
    <abstract>Background: Environmental exposure to bisphenol A (BPA) affects mammary gland development in rodents and primates. Prenatal exposure to environmentally relevant doses of BPA increased the number of intraductal hyperplasias and ductal carcinomas in situ by 50 days of age in Wistar-Furth rats. Objective: We aimed to determine whether BPA exposure of dams during gestation only or throughout lactation affects the incidence of mammary gland neoplasia in female offspring. Methods: We treated pregnant Sprague-Dawley rats with BPA at 0, 0.25, 2.5, 25, or 250 mu g BPA/kg BW/day from gestational day (GD) 9 to birth and from GD9 to postnatal day (PND) 21. Mammary glands from BPA-exposed offspring were examined at four time points for pre-neoplastic and neo-plastic lesions. To assess circulating BPA levels, we exposed pregnant rats to vehicle or 250 mu g BPA/kg BW/day during gestation only or during gestation/lactation and analyzed sera from dams, fetuses, and nursing pups for total and unconjugated BPA. Results: Total and unconjugated BPA were detected in sera from 100% of dams and fetuses and 33% of pups exposed to 250 mu g BPA/kg BW/day. Unconjugated BPA levels in exposed dams and fetuses (gestational) and in exposed dams and pups (gestational/lactational) were within levels found in humans. Preneoplastic lesions developed in BPA-exposed female offspring across all doses as early as PND50. Unexpectedly, mammary gland adenocarcinomas developed in BPA-exposed offspring by PND90. Conclusions: Our findings suggest that developmental exposure to environmentally relevant levels of BPA during gestation and lactation induces mammary gland neoplasms in the absence of any additional carcinogenic treatment. Thus, BPA may act as a complete mammary gland carcinogen</abstract>
    <url>WOS:000325149600018</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>298</id>
    <title>Effect of bisphenol A on human endometrial stromal fibroblasts in vitro</title>
    <authors>Aghajanova,L.; Giudice,L.C.</authors>
    <availability>[Aghajanova, L.; Giudice, L. C.] Univ Calif San Francisco, Dept Obstet Gynecol &amp; Reprod Sci, San Francisco, CA 94143 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleGiudice, LC (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol &amp; Reprod Sci, San Francisco, CA 94143 USAaghajanoval@obgyn.ucsf.edu; giudice@obgyn.ucsf.eduAghajanova L, 2010, ENDOCRINOLOGY, V151, P1341, DOI 10.1210/en.2009-0923; Aghajanova L, 2009, BIOL REPROD, V80, P105, DOI 10.1095/biolreprod.108.070300; [Anonymous], 2008, NTP CERHR MON, P1; Bredhult C, 2009, REPROD TOXICOL, V28, P18, DOI 10.1016/j.reprotox.2009.03.006; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Cobellis L, 2009, BIOMED CHROMATOGR, V23, P1186, DOI 10.1002/bmc.1241; Daftary GS, 2001, CURR OPIN OBSTET GYN, V13, P269, DOI 10.1097/00001703-200106000-00004; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Giudice LC, 2006, SEMIN REPROD MED, V24, P129, DOI 10.1055/s-2006-944418; Han DH, 2002, BIOSCI BIOTECH BIOCH, V66, P1479; Hiroi H, 2004, ENDOCR J, V51, P595, DOI 10.1507/endocrj.51.595; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Kwintkiewicz J, 2009, SEMIN REPROD MED, V27, P43, DOI 10.1055/s-0028-1108009; Kwintkiewicz J, 2010, ENVIRON HEALTH PERSP, V118, P400, DOI 10.1289/ehp.0901161; Lamb JD, 2008, FERTIL STERIL, V90, pS186, DOI DOI 10.1016/I.FERTNSTERT.2008.07.751; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lee YM, 2007, J VET SCI, V8, P27; Lessey BA, 2002, ANN NY ACAD SCI, V955, P265; Luconi M, 2001, MOL CELL ENDOCRINOL, V178, P39, DOI 10.1016/S0303-7207(01)00416-6; Masuyama H, 2004, J BIOL CHEM, V279, P12020, DOI 10.1074/jbc.M312762200; Mok-Lin E, 2010, INT J ANDROL, V33, P385, DOI 10.1111/j.1365-2605.2009.01014.x; Naciff JM, 2010, TOXICOLOGY, V270, P137, DOI 10.1016/j.tox.2010.02.008; Oehlmann J, 2009, PHILOS T R SOC B, V364, P2047, DOI 10.1098/rstb.2008.0242; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Salian S, 2009, LIFE SCI, V85, P742, DOI 10.1016/j.lfs.2009.10.004; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com; Talbi S, 2006, ENDOCRINOLOGY, V147, P1097, DOI 10.1210/en.2005-1075; Talsness CE, 2009, PHILOS T R SOC B, V364, P2079, DOI 10.1098/rstb.2008.0281; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.067; Zhu HT, 2010, ONCOL REP, V23, P129, DOI 10.3892/or_00000614394ELSEVIER SCI LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDREPROD BIOMED ONLINEMARDiscipline: Obstetrics &amp; Gynecology; Reproductive Biology929DH</notes>
    <keywords>ALPHA; Antagonist; apoptosis; Aromatase; BETA; BINDING; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CARCINOGENESIS; CELL; CELLS; decidualization; DEFECTS; Differentiation; ENDOCRINE DISRUPTORS; endometrial stromal cells; Estrogen; eutopic endometrium; EXPOSURE; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GENES; GROWTH; GROWTH-FACTOR; HEALTH; IMPLANTATION; In vitro; IN-VITRO; mechanism; MECHANISMS; METABOLISM; oestrogen; oestrogen receptor; PATHWAY; POPULATION; PPAR; PPAR-gamma; proliferation; PROTEIN; RECEPTOR; RECEPTOR-ALPHA; toxicology; VITRO; VIVO; WOMEN; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>249</startpage>
    <endpage>256</endpage>
    <journalfull>Reproductive Biomedicine Online</journalfull>
    <issue>3</issue>
    <volume>22</volume>
    <abstract>This study evaluated the effects of bisphenol A (BPA) on human endometrial stromal fibroblast (ESF) differentiation and expression of genes involved in oestrogen metabolism. Human ESF from eight hysterectomy specimens were cultured and treated with 5-100 mu mol/l of BPA +/- oestradiol or 8-br-cAMP for 48 h. mRNA expression was analysed by real-time reverse-transcription PCR. 8-br-cAMP-induced human ESF decidualization was confirmed by expression of insulin-like growth factor binding protein-1 (IGFBP1) and prolactin secretion. Short-term exposure (48 h) decreased human ESF proliferation (P &lt; 0.04) not due to apoptosis. High doses of BPA significantly induced IGFBP1 mRNA and protein, decreased P450scc mRNA, reversed the 8-br-cAMP-induced increase in HSD17B2 (oestradiol to oestrone conversion) in a dose-dependent manner and down-regulated HSD17B1 expression (oestrone to oestradiol conversion; P &lt;= 0.03). 8-br-cAMP significantly potentiated this effect (P = 0.028). BPA had no significant effect on aromatase and PPAR gamma expression. The oestrogen-receptor antagonist ICI had no effect on gene expression in BPA-treated cells, and oestrogen receptor alpha, but not oestrogen receptor beta, was significantly down-regulated by high doses of BPA (P = 0.028). BPA has an endocrine-disrupting effect on human ESF function and gene expression but the underlying mechanisms appear not to involve oestrogen-mediated pathways. (C) 2011, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000303040900003</url>
    <isbnorissn>1472-6483</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>142</id>
    <title>An Alkylphenol Mix Promotes Seminoma Derived Cell Proliferation through an ERalpha36-Mediated Mechanism</title>
    <authors>Ajj,H.; Chesnel,A.; Pinel,S.; Plenat,F.; Flament,S.; Dumond,H.</authors>
    <availability>[Ajj, Hussein; Chesnel, Amand; Pinel, Sophie; Plenat, Francois; Flament, Stephane; Dumond, Helene] Univ Lorraine, CNRS, Ctr Rech Automat Nancy, UMR 7039, Vandoeuvre Les Nancy, France.</availability>
    <date>2013</date>
    <notes>JEnglishArticleDumond, H (reprint author), Univ Lorraine, CNRS, Ctr Rech Automat Nancy, UMR 7039, Vandoeuvre Les Nancy, Francehelene.dumond@univ-lorraine.frAnway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; Anway MD, 2008, GENOMICS, V91, P30, DOI 10.1016/j.ygeno.2007.10.002; Barton M, 2012, STEROIDS, V77, P935, DOI 10.1016/j.steroids.2012.04.001; Beiki O, 2010, CANCER EPIDEM BIOMAR, V19, P1053, DOI 10.1158/1055-9965.EPI-09-1190; Berner C, 2011, ANN NUTR METAB, V57, P183, DOI 10.1159/000321514; Beyrouthy MJ, 2009, CANCER RES, V69, P9360, DOI 10.1158/0008-5472.CAN-09-1490; Biswal BK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053003; Borghese B, 2012, AM J PATHOL, V180, P1781, DOI 10.1016/j.ajpath.2012.01.009; Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chedin F, 2011, PROG MOL BIOL TRANSL, V101, P255, DOI 10.1016/B978-0-12-387685-0.00007-X; Chevalier N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034672; Dobrzynska MM, 2012, DRUG CHEM TOXICOL, V35, P36, DOI 10.3109/01480545.2011.586036; Frassinetti S, 2011, ECOTOX ENVIRON SAFE, V74, P253, DOI 10.1016/j.ecoenv.2010.10.039; Fucic A, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-S1-S8; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Hashimoto H, 2010, EPIGENOMICS-UK, V2, P657, DOI 10.2217/EPI.10.44; Hervouet E, 2009, EPIGENETICS, V4, P487; Imura M, 2006, CANCER LETT, V241, P213, DOI 10.1016/j.canlet.2005.10.010; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Kilian E, 2007, ANDROLOGIA, V39, P128, DOI 10.1111/j.1439-0272.2007.00777.x; Kristensen DG, 2012, CANCER GENET-NY, V205, P425, DOI 10.1016/j.cancergen.2012.05.003; Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154; Li ZY, 2012, TOXICOL IN VITRO, V26, P769, DOI 10.1016/j.tiv.2012.05.017; Liao HF, 2012, BIOL CELL, V104, P571, DOI 10.1111/boc.201100109; Long Fan, 2004, In Silico Biology, V4, P395; Main KM, 2010, BEST PRACT RES CL EN, V24, P279, DOI 10.1016/j.beem.2009.10.003; McClusky LM, 2007, TOXICOL SCI, V95, P249, DOI 10.1093/toxsci/kfl141; Minami K, 2010, CLIN CANCER RES, V16, P2751, DOI 10.1158/1078-0432.CCR-09-3338; Mizuno Y, 1993, Nihon Hinyokika Gakkai Zasshi, V84, P1211; Muller S, 1998, ENVIRON TOXICOL PHAR, V5, P257, DOI 10.1016/S1382-6689(98)00009-X; Okamoto K, 2012, INT J UROL, V19, P504, DOI 10.1111/j.1442-2042.2012.02986.x; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Raecker T, 2011, CHEMOSPHERE, V82, P1533, DOI 10.1016/j.chemosphere.2010.11.065; Rajpert-de Meyts Ewa, 2007, Ann N Y Acad Sci, V1120, P168, DOI 10.1196/annals.1411.013; Cyriac Sanju, 2012, Indian J Hum Genet, V18, P119, DOI 10.4103/0971-6866.96679; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; SKAKKEBAEK NE, 1975, ACTA PATH MICRO IM A, VA 83, P127; Sonne SB, 2009, CANCER RES, V69, P5241, DOI 10.1158/0008-5472.CAN-08-4554; Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tong JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015408; Ushida H, 2012, MOL CARCINOGEN, V51, P711, DOI 10.1002/mc.20831; Vega Aurelie, 2012, Front Endocrinol (Lausanne), V3, P150, DOI 10.3389/fendo.2012.00150; Wallacides A, 2012, MOL CELL ENDOCRINOL, V350, P61, DOI 10.1016/j.mce.2011.11.021; Walton EL, 2011, EPIGENETICS-US, V6, P1373, DOI 10.4161/epi.6.11.17978; Wang L, 2010, ONCOL REP, V23, P1109, DOI 10.3892/or_00000739; Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; Willoughby KN, 2005, ENDOCRINE, V26, P161, DOI 10.1385/ENDO:26:2:161; Xue Q, 2007, BIOL REPROD, V77, P681, DOI 10.1095/biolreprod.107.061804; Yang XX, 2012, INT J MOL SCI, V13, P8364, DOI 10.3390/ijms13078364; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhang XT, 2012, ONCOL REP, V27, P2057, DOI 10.3892/or.2012.1722; Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458581PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEAPR 23Discipline: Science &amp; Technology - Other Topics131QH</notes>
    <keywords>4-NONYLPHENOL; ALPHA; BINDING; BIOLOGY; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CARCINOMA; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; cosmetics; DNA METHYLATION; ENDOCRINE; Endocrine disruptor; epigenetics; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR GPER; ESTROGEN-RECEPTORS; Etiology; EXPOSURE; EXPRESSION; GERM-CELLS; in silico; In vitro; IN-VITRO; IN-VIVO; INHIBITOR; Inhibitors; mechanism; METHYLATION; MICE; Microarray; Neoplasia; Nonylphenol; PROGRESSION; proliferation; RATS; RECEPTOR; RISK; SIGNALING PATHWAY; SIGNALING PATHWAYS; TESTICULAR-TUMORS; testis; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>4</issue>
    <volume>8</volume>
    <abstract>Long chain alkylphenols are man-made compounds still present in industrial and agricultural processes. Their main use is domestic and they are widespread in household products, cleansers and cosmetics, leading to a global environmental and human contamination. These molecules are known to exert estrogen-like activities through binding to classical estrogen receptors. In vitro, they can also interact with the G-protein coupled estrogen receptor. Testicular germ cell tumor etiology and progression are proposed to be stimulated by lifelong estrogeno-mimetic exposure. We studied the transduction signaling pathways through which an alkyphenol mixture triggers testicular cancer cell proliferation in vitro and in vivo. Proliferation assays were monitored after exposure to a realistic mixture of 4-tert-octylphenol and 4-nonylphenol of either TCam-2 seminoma derived cells, NT2/D1 embryonal carcinoma cells or testis tumor in xenografted nude mice. Specific pharmacological inhibitors and gene-silencing strategies were used in TCam-2 cells in order to demonstrate that the alkylphenol mix triggers CREB-phosphorylation through a rapid, ER alpha 36-PI3kinase non genomic pathway. Microarray analysis of the mixture target genes revealed that this pathway can modulate the expression of the DNA-methyltransferase-3 (Dnmt3) gene family which is involved in DNA methylation control. Our results highlight a key role for ER alpha 36 in alkylphenol non genomic signaling in testicular germ cell tumors. Hence, ER alpha 36-dependent control of the epigenetic status opens the way for the understanding of the link between endocrine disruptor exposure and the burden of hormone sensitive cancers</abstract>
    <url>WOS:000318008400087</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>67</id>
    <title>Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors</title>
    <authors>Albini,A.; Rosano,C.; Angelini,G.; Amaro,A.; Esposito,A.I.; Maramotti,S.; Noonan,D.M.; Pfeffer,U.</authors>
    <availability>[Albini, A.; Maramotti, S.] IRCCS Arcispedale Santa Maria Nuova, Dept Res &amp; Stat, Reggio Emilia, Italy. [Rosano, C.; Angelini, G.; Amaro, A.; Esposito, A. I.; Pfeffer, U.] IRCCS AOU San Martino IST Ist Nazl Ric Cancro, Genoa, Italy. [Noonan, D. M.] Insubria Univ, Dept Biotechnol &amp; Life Sci, I-21100 Varese, Italy. [Noonan, D. M.] IRCCS MultiMed, Milan, Italy.</availability>
    <date>2014</date>
    <notes>JEnglishArticleNoonan, DM (reprint author), Insubria Univ, Fac Med &amp; Chirurg, Dipartimento Biotecnol &amp; Sci Vita, Viale Dunant 3, I-21100 Varese, Italydouglas.noonan@uninsubria.itAcconcia F, 2004, BIOCHEM BIOPH RES CO, V316, P878, DOI 10.1016/j.bbrc.2004.02.129; ADLERCREUTZ H, 1986, J STEROID BIOCHEM, V25, P791, DOI 10.1016/0022-4731(86)90310-9; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Amaro A. A., 2013, CURR MED CHEM; [Anonymous], 1973, NATURE, V243, P6; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Aurela B, 1999, FOOD ADDIT CONTAM, V16, P571, DOI 10.1080/026520399283713; Bachmeier BE, 2010, CELL PHYSIOL BIOCHEM, V26, P471, DOI 10.1159/000320570; Bainy ACD, 2007, ENVIRON INT, V33, P571, DOI 10.1016/j.envint.2006.11.004; Baker ME, 2004, MOL CELL ENDOCRINOL, V215, P55, DOI 10.1016/j.mce.2003.11.007; Bar-El Dadon S, 2010, J Pediatr Endocrinol Metab, V23, P855; Beatson G., 1896, LANCET, V148, P162, DOI 10.1016/S0140-6736(01)72384-7; Bedell S., 2012, J STEROID BIOCH MOL; BITMAN J, 1968, SCIENCE, V162, P371, DOI 10.1126/science.162.3851.371; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Blom A, 1998, ARCH ENVIRON CON TOX, V34, P306; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cappelletti V, 2003, CELL MOL LIFE SCI, V60, P567, DOI 10.1007/s000180300048; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; Caserta D, 2013, GYNECOL ENDOCRINOL, V29, P444, DOI 10.3109/09513590.2012.758702; Caserta D, 2008, HUM REPROD UPDATE, V14, P59, DOI 10.1093/humupd/dmm025; Cheshenko K, 2008, GEN COMP ENDOCR, V155, P31, DOI 10.1016/j.ygeen.2007.03.005; Choi JS, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-126; Cicatiello L., 2004, J MOL ENDOCRINOL, V32; Cotterchio M, 2008, CANCER CAUSE CONTROL, V19, P259, DOI 10.1007/s10552-007-9089-2; Cotterchio M, 2006, J NUTR, V136, P3046; Coyle YM, 2004, BREAST CANCER RES TR, V84, P273, DOI 10.1023/B:BREA.0000019964.33963.09; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Dallinga JW, 2002, HUM REPROD, V17, P1973, DOI 10.1093/humrep/17.8.1973; Davis SR, 2001, BRIT MED J, V323, P354, DOI 10.1136/bmj.323.7309.354; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Dennis MK, 2011, J STEROID BIOCHEM, V127, P358, DOI 10.1016/j.jsbmb.2011.07.002; Dey S, 2009, MED HYPOTHESES, V72, P652, DOI 10.1016/j.mehy.2008.10.025; Dey S, 2010, BREAST CANCER RES TR, V120, P149, DOI 10.1007/s10549-009-0427-9; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; DiVall SA, 2013, CURR OPIN ENDOCRINOL, V20, P50, DOI 10.1097/MED.0b013e32835b7ee6; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Dorea Jose G, 2005, J Perinatol, V25, P558, DOI 10.1038/sj.jp.7211338; Duffy C, 2007, CA-CANCER J CLIN, V57, P260, DOI 10.3322/CA.57.5.260; Eichenlaub-Ritter U, 2008, MUTAT RES-GEN TOX EN, V651, P82, DOI 10.1016/j.mrgentox.2007.10.014; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Ferrari A, 2009, J OBSTET GYNAECOL RE, V35, P1083, DOI 10.1111/j.1447-0756.2009.01058.x; Ferro P, 2003, INT J MOL MED, V12, P355; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Folmar LC, 2002, AQUAT TOXICOL, V60, P101, DOI 10.1016/S0166-445X(01)00276-4; Fowler PA, 2012, MOL CELL ENDOCRINOL, V355, P231, DOI 10.1016/j.mce.2011.10.021; Fromme H, 2004, INDOOR AIR, V14, P188, DOI 10.1046/j.1600-0668.2003.00223.x; Frye CA, 2012, J NEUROENDOCRINOL, V24, P144, DOI 10.1111/j.1365-2826.2011.02229.x; Funakoshi T, 2006, BIOCHEM BIOPH RES CO, V346, P904, DOI 10.1016/j.bbrc.2006.05.191; Gallo D, 2006, CARCINOGENESIS, V27, P1404, DOI 10.1093/carcin/bgi338; Galluzzo P, 2009, AM J PHYSIOL-CELL PH, V297, pC1249, DOI 10.1152/ajpcell.00188.2009; Gartner S, 2009, J AGR FOOD CHEM, V57, P10675, DOI 10.1021/jf902683m; Geller SE, 2009, MENOPAUSE, V16, P1156, DOI 10.1097/gme.0b013e3181ace49b; George O, 2008, ACS CHEM BIOL, V3, P167, DOI [10.1021/cb700210u, 10.1021/cb6700210u]; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Gobeil F, 2006, CAN J PHYSIOL PHARM, V84, P287, DOI 10.1139/Y05-127; Golden RJ, 1998, CRIT REV TOXICOL, V28, P109, DOI 10.1080/10408449891344191; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P218, DOI 10.1159/000132325; Grace PB, 2004, CANCER EPIDEM BIOMAR, V13, P698; Guzman C, 2007, REV INVEST CLIN, V59, P73; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Handayani R, 2006, J NUTR, V136, P75; Hartman J, 2012, STEROIDS, V77, P1262, DOI 10.1016/j.steroids.2012.07.002; Hawkins MB, 2000, P NATL ACAD SCI USA, V97, P10751, DOI 10.1073/pnas.97.20.10751; Hess-Wilson JK, 2006, BREAST CANCER RES TR, V96, P279, DOI 10.1007/s10549-005-9082-y; Hinrichs B, 2011, J STEROID BIOCHEM, V127, P276, DOI 10.1016/j.jsbmb.2011.08.009; Ho Karen J, 2002, Mol Interv, V2, P219, DOI 10.1124/mi.2.4.219; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Hunt PA, 2009, BIOL REPROD, V81, P807, DOI 10.1095/biolreprod.109.077008; Inoue A, 2007, TOXICOL IN VITRO, V21, P741, DOI 10.1016/j.tiv.2007.01.014; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Irvine DS, 1997, BAILLIERE CLIN OB GY, V11, P655, DOI 10.1016/S0950-3552(97)80005-3; Izzotti A, 2010, CURR CANCER DRUG TAR, V10, P147; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Jenkins S, 2012, J STEROID BIOCHEM, V129, P191, DOI 10.1016/j.jsbmb.2011.06.003; JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387; Jung EM, 2010, TOXICOL IN VITRO, V24, P1538, DOI 10.1016/j.tiv.2010.06.019; Kappenstein Oliver, 2012, EXS, V101, P87, DOI 10.1007/978-3-7643-8340-4_4; Katalinic A, 2008, BREAST CANCER RES TR, V107, P427, DOI 10.1007/s10549-007-9566-z; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kroll G, 2001, PUBLIC UNDERST SCI, V10, P403, DOI 10.1088/0963-6625/10/4/304; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Lappano R, 2012, CURR CANCER DRUG TAR, V12, P531; Lappano R, 2010, MOL CELL ENDOCRINOL, V320, P162, DOI 10.1016/j.mce.2010.02.006; Lappano R, 2009, MOL NUTR FOOD RES, V53, P845, DOI 10.1002/mnfr.200800331; Lappano R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3096; Lee PC, 1996, B ENVIRON CONTAM TOX, V57, P341; Lee YJ, 2003, ARCH PHARM RES, V26, P58; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Levin ER, 2001, J APPL PHYSIOL, V91, P1860; Li KM, 2004, CARCINOGENESIS, V25, P289, DOI 10.1093/carcin/bgg191; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; Linseisen J, 2004, INT J CANCER, V110, P284, DOI 10.1002/ijc.20119; Lopez-Espinosa MJ, 2009, BIOMARKERS, V14, P271, DOI 10.1080/13547500902893744; Low YL, 2005, CANCER EPIDEM BIOMAR, V14, P213; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Mak P, 2006, NEOPLASIA, V8, P896, DOI 10.1593/neo.06538; MAKELA S, 1995, ENVIRON HEALTH PERSP, V103, P123, DOI 10.2307/3432520; Manas ES, 2004, STRUCTURE, V12, P2197, DOI 10.1016/j.str.2004.09.015; Maradonna F, 2009, ANN NY ACAD SCI, V1163, P457, DOI 10.1111/j.1749-6632.2008.03653.x; Marik R, 2011, CANCER BIOL THER, V11, P883, DOI 10.4161/cbt.11.10.15184; Marino M, 2012, STEROIDS, V77, P910, DOI 10.1016/j.steroids.2012.02.019; MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860; Martin-Santamaria S, 2008, ORG BIOMOL CHEM, V6, P3486, DOI 10.1039/b806918b; Massart Francesco, 2005, J Perinatol, V25, P282, DOI 10.1038/sj.jp.7211251; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McEwan IJ, 2004, ESSAYS BIOCHEM, V40, P1; McPherson K, 2000, BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Mitra AK, 2004, J ENVIRON HEALTH, V66, P24; Moon HJ, 2007, J REPROD DEVELOP, V53, P333, DOI 10.1262/jrd.18055; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Mueller SO, 2002, J CHROMATOGR B, V777, P155, DOI 10.1016/S1570-0232(02)00282-9; Navarro CE, 2003, MOL ENDOCRINOL, V17, P1792, DOI 10.1210/me.2003-0040; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Olea N, 1999, TOXICOL IND HEALTH, V15, P151, DOI 10.1191/074823399678846682; Olea N, 1998, EUR J CANCER PREV, V7, pS17; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Patisaul HB, 2010, FRONT NEUROENDOCRIN, V31, P400, DOI 10.1016/j.yfrne.2010.03.003; Pawlak M, 2012, CURR TOP MED CHEM, V12, P486; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; MESSINA MJ, 1994, NUTR CANCER, V21, P113; Petersen JH, 2010, FOOD ADDIT CONTAM A, V27, P1608, DOI 10.1080/19440049.2010.501825; Petersen JH, 2000, FOOD ADDIT CONTAM, V17, P133, DOI 10.1080/026520300283487; PFEFFER U, 1995, CANCER RES, V55, P2158; PFEFFER U, 1993, CANCER RES, V53, P741; Pike ACW, 2000, J STEROID BIOCHEM, V74, P261, DOI 10.1016/S0960-0760(00)00102-3; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Pilsakova L, 2010, PHYSIOL RES, V59, P651; Pratt WB, 2004, ESSAYS BIOCHEM, V40, P41; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Prossnitz ER, 2008, TRENDS PHARMACOL SCI, V29, P116, DOI 10.1016/j.tips.2008.01.001; Pruthi S, 2012, MENOPAUSE, V19, P48, DOI 10.1097/gme.0b013e318223b021; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Rabiau N, 2011, IN VIVO, V25, P917; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Ren LF, 1997, CHEM-BIOL INTERACT, V104, P55, DOI 10.1016/S0009-2797(97)03767-8; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rice S, 2006, ENDOCR-RELAT CANCER, V13, P995, DOI 10.1677/erc.1.01159; Richter DU, 2010, ANTICANCER RES, V30, P1695; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Rosano C, 2011, CURR MED CHEM, V18, P1188; Rosano C, 2012, CURR MED CHEM, V19, P6199; Rothenbacher T, 2010, RAPID COMMUN MASS SP, V24, P21, DOI 10.1002/rcm.4350; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rozman KK, 2006, BIRTH DEFECTS RES B, V77, P485, DOI 10.1002/bdrb.20087; RUSSO J, 1987, LAB INVEST, V57, P112; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sammartino A, 2006, GYNECOL ENDOCRINOL, V22, P646, DOI 10.1080/09513590601010722; Schettler T, 2006, INT J ANDROL, V29, P134, DOI 10.1111/j.1365-2605.2005.00567.x; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; Setchell KDR, 2003, J NUTR, V133, P1027; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; SHARMAN M, 1994, FOOD ADDIT CONTAM, V11, P375; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shiizaki K, 1999, PHYTOTHER RES, V13, P498, DOI 10.1002/(SICI)1099-1573(199909)13:6&lt;498::AID-PTR495&gt;3.3.CO;2-A; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Sotoca AM, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002170; Sotoca AM, 2008, J STEROID BIOCHEM, V112, P171, DOI 10.1016/j.jsbmb.2008.10.002; SZEGO CM, 1967, P NATL ACAD SCI USA, V58, P1711, DOI 10.1073/pnas.58.4.1711; Takada Y, 1997, BIOCHEM BIOPH RES CO, V240, P737, DOI 10.1006/bbrc.1997.7734; Takemura H., 2013, CURR PHARM DES; Terasaka S, 2004, ENVIRON HEALTH PERSP, V112, P773, DOI 10.1289/txg.6753; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; Thanos J, 2006, CANCER CAUSE CONTROL, V17, P1253, DOI 10.1007/s10552-006-0062-2; This P, 2011, MATURITAS, V70, P222, DOI 10.1016/j.maturitas.2011.07.001; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tice JA, 2003, JAMA-J AM MED ASSOC, V290, P207, DOI 10.1001/jama.290.2.207; Tsubura A, 2008, IN VIVO, V22, P191; Tsumura Y, 2001, FOOD ADDIT CONTAM, V18, P569, DOI 10.1080/02652030010028344; Urpi-Sarda M, 2008, ARCH BIOCHEM BIOPHYS, V476, P205, DOI 10.1016/j.abb.2008.05.002; Vajdos FF, 2007, PROTEIN SCI, V16, P897, DOI 10.1110/ps.062729207; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vivacqua A, 2009, MOL ENDOCRINOL, V23, P1815, DOI 10.1210/me.2009-0120; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Vogel VG, 2009, EXPERT REV ANTICANC, V9, P51, DOI 10.1586/14737140.9.1.51; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Xu HE, 2002, NATURE, V415, P813; Xu Q., 2010, J AGR FOOD CHEM; Yeung B.H.Y., 2011, SPERMATOGENESIS, V1, P231; Yohannan S, 2004, P NATL ACAD SCI USA, V101, P959, DOI 10.1073/pnas.0306077101; Yu SJ, 2002, CHEM RES TOXICOL, V15, P1229, DOI 10.1021/tx0255875; Zand RSR, 2000, BREAST CANCER RES TR, V62, P35, DOI 10.1023/A:1006422302173; Zmuda JM, 2006, ONCOLOGY-BASEL, V70, P185, DOI 10.1159/0000938052031BENTHAM SCIENCE PUBL LTDSHARJAHEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATESCURR MED CHEMMARDiscipline: Biochemistry &amp; Molecular Biology; Pharmacology &amp; PharmacyAA9ZN</notes>
    <keywords>AFFINITIES; ALPHA; BETA; BIOLOGY; Biomarkers; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; CELLS; CLASSIFICATION; Endocrine disruptor; ENDOCRINE DISRUPTORS; ER alpha; Estrogen; Estrogen receptor; estrogen receptor-alpha; estrogen receptor-beta; Estrogen receptors; estrogen signaling; ESTROGEN-RECEPTOR; estrogenic activity; ESTROGENS; EXPOSURE; FOOD; GENE-EXPRESSION CHANGES; GPER; GROWTH; GROWTH-FACTOR RECEPTOR; HUMAN ESTROGEN-RECEPTOR; HUMAN HEALTH; In vitro; IN-VITRO; IN-VIVO; Interaction; LIGAND-BINDING DOMAIN; MAMMARY-GLAND DEVELOPMENT; mechanism; MECHANISMS; Phytoestrogen; PHYTOESTROGENS; PLANTS; PLASMA-MEMBRANE; POLLUTANTS; PROTEIN-COUPLED RECEPTOR; Proteomics; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR; RISK; selective estrogen receptor modulators; SPERMATOGENESIS; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1129</startpage>
    <endpage>1145</endpage>
    <journalfull>Current Medicinal Chemistry</journalfull>
    <issue>9</issue>
    <volume>21</volume>
    <abstract>Observations on the role of ovarian hormones in breast cancer growth, as well as interest in contraception, stimulated research into the biology of estrogens. The identification of the classical receptors ER alpha and ER beta and the transmembrane receptor GPER and the resolution of the structure of the ligand bound to its receptor established the principal molecular mechanisms of estrogen action. The presence of estrogen-like compounds in many plants used in traditional medicine or ingested as food ingredients, phytoestrogens, as well as the estrogenic activities of many industrial pollutants and pesticides, xenoestrogens, have prompted investigations into their role in human health. Phyto-and xenoestrogens bind to the estrogen receptors with a lower affinity than the endogenous estrogens and can compete or substitute the hormone. Xenoestrogens, which accumulate in the body throughout life, are believed to increase breast cancer risk, especially in cases of prenatal and prepuberal exposure whereas the role of phytoestrogens is still a matter of debate. At present, the application of phytoestrogens appears to be limited to the treatment of post-menopausal symptoms in women where the production of endogenous estrogens has ceased. In this review we discuss chemistry, structure and classification, estrogen signaling and the consequences of the interactions of estrogens, phytoestrogens and xenoestrogens with their receptors, the complex interactions of endogenous and exogenous ligands, the evaluation of the health risks related to xenoestrogens, and the perspectives toward the synthesis of potent third generation selective estrogen receptor modulators (SERMs)</abstract>
    <url>WOS:000331451700007</url>
    <isbnorissn>0929-8673</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>74</id>
    <title>Endocrine Disruptor Agent Nonyl Phenol Exerts An Estrogen-like Transcriptional Activity on Estrogen Receptor Positive Breast Cancer Cells</title>
    <authors>Amaro,A.A.; Esposito,A.I.; Mirisola,V.; Mehilli,A.; Rosano,C.; Noonan,D.M.; Albini,A.; Pfeffer,U.; Angelini,G.</authors>
    <availability>[Amaro, A. A.; Esposito, A. I.; Mirisola, V.; Pfeffer, U.; Angelini, G.] IRCCS, AUO San Martino IST, I-16132 Genoa, Italy. [Mehilli, A.] Italian Inst Technol, Dept Neurosci, Genoa, Italy. [Rosano, C.] IRCCS, AUO San Martino IST, Biopolymers &amp; Prote Unit, I-16132 Genoa, Italy. [Noonan, D. M.] Univ Studi Insubria, Dept Clin &amp; Biol Sci, I-21100 Varese, Italy. [Albini, A.] IRCCS Arcispedale S Maria Nuova, Reggio Emilia, Italy.</availability>
    <date>2014</date>
    <notes>JEnglishArticlePfeffer, U (reprint author), IRCCS, AUO San Martino IST, Largo Rosanna Benzi 10, I-16132 Genoa, Italyulrich.pfeffer@istge.itAcevedo R, 2005, J APPL TOXICOL, V25, P339, DOI 10.1002/jat.1078; [Anonymous], WHOIPCSIRA1204 INT L; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bachmeier BE, 2010, CELL PHYSIOL BIOCHEM, V26, P471, DOI 10.1159/000320570; Bachmeier BE, 2008, CARCINOGENESIS, V29, P779, DOI 10.1093/carcin/bgm248; Bagadi SAR, 2007, BREAST CANCER RES TR, V104, P277, DOI 10.1007/s10549-006-9422-6; Blom A, 1998, ARCH ENVIRON CON TOX, V34, P306; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cole J. C., 2005, VIRTUAL SCREENING DR; Dennis Glynn Jr, 2003, Genome Biol, V4, pP3, DOI 10.1186/gb-2003-4-5-p3; Eiler S, 2001, PROTEIN EXPRES PURIF, V22, P165, DOI 10.1006/prep.2001.1409; Folmar LC, 2002, AQUAT TOXICOL, V60, P101, DOI 10.1016/S0166-445X(01)00276-4; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guenther K, 2002, ENVIRON SCI TECHNOL, V36, P1676, DOI 10.1021/es010199v; Inoue A, 2007, TOXICOL IN VITRO, V21, P741, DOI 10.1016/j.tiv.2007.01.014; Irizarry R.A., 2003, NUCLEIC ACIDS RES, V15, P31; Kuch HM, 2001, ENVIRON SCI TECHNOL, V35, P3201, DOI 10.1021/es010034m; Lappano R, 2012, CURR CANCER DRUG TAR, V12, P531; Lappano R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3096; Lavado R, 2004, TOXICOL APPL PHARM, V196, P247, DOI 10.1016/j.taap.2003.12.012; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Lee PC, 1996, B ENVIRON CONTAM TOX, V57, P341; McPherson K, 2000, BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Mirisola V, 2009, EUR J CANCER, V45, P2579, DOI 10.1016/j.ejca.2009.06.026; Mitra AK, 2004, J ENVIRON HEALTH, V66, P24; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14&lt;1639::AID-JCC10&gt;3.0.CO;2-B; Mueller PY, 2002, BIOTECHNIQUES, V32, P1372; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Sanner M F, 1999, Pac Symp Biocomput, P401; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Soares A, 2008, ENVIRON INT, V34, P1033, DOI 10.1016/j.envint.2008.01.004; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175380BENTHAM SCIENCE PUBL LTDSHARJAHEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATESCURR MED CHEMFEBDiscipline: Biochemistry &amp; Molecular Biology; Pharmacology &amp; PharmacyAA9YH</notes>
    <keywords>17-BETA-ESTRADIOL; ALPHA; BIOLOGY; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; CELLS; curcumin; ENDOCRINE; Endocrine disruptor; endocrine disruptor (ED); ENDOCRINE DISRUPTORS; environment; ENVIRONMENTAL-POLLUTANTS; ESTRADIOL; Estrogen; Estrogen receptor; estrogen receptor (ER); ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPRESSION; gene expression; gene expression profile; GENE-EXPRESSION; GENE-EXPRESSION CHANGES; GPER; In vitro; IN-VITRO; IN-VIVO; Interaction; LIGAND; Nonylphenol; Nonylphenol (NP); phenol; POLLUTANTS; PROTEIN; PROTEINS; RECEPTOR; RECEPTOR-ALPHA; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>630</startpage>
    <endpage>640</endpage>
    <journalfull>Current Medicinal Chemistry</journalfull>
    <issue>5</issue>
    <volume>21</volume>
    <abstract>Several substances widely dispersed in the environment including hormones, industrial by-products and pollutants exert hormone like activity affecting steroid-responsive physiological systems. These compounds, named endocrine disruptors, are suspected to affect the mammalian reproductive system. However it is still unclear whether these substances are able to elicit estrogen like activity at the low concentrations encountered in the environment. Here we compare the effects of the endocrine disruptor nonylphenol with the effects elicited by 17-beta-estradiol on gene transcription in the human breast cancer cell line MCF7. The correlation of the nonylphenol induced gene expression alterations with a reference profile of estradiol treated cells shows that nonylphenol at a concentration of 100 nM exerts a significant effect on estrogen responsive gene transcription in MCF7 cells. Most of the genes regulated by 17-beta-estradiol respond to the nonylphenol in the same direction though to a much lesser extent. Molecular modeling of the potential interaction of nonylphenol with the estrogen receptor alpha shows that nonylphenol is likely to bind to the estrogen receptor alpha</abstract>
    <url>WOS:000331448500006</url>
    <isbnorissn>0929-8673</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>294</id>
    <title>Analysis of toxicity of tetrabutyltin: comparing with EDC chemicals</title>
    <authors>An,Y.R.; Kim,S.J.; Park,H.W.; Yu,S.Y.; Han,J.; Oh,J.H.; Yoon,S.J.; Hwang,S.Y.</authors>
    <availability>[An, Yu Ri; Hwang, Seung Yong] Hanyang Univ, Dept Biochem, Ansan, Gyeonggi Do, South Korea. [Kim, Seung Jun; Park, Hye-Won; Yu, So Yeon; Hwang, Seung Yong] GenoCheck Co Ltd, Ansan, Gyeonggi Do, South Korea. [Han, Jeong; Hwang, Seung Yong] Hanyang Univ, Dept Bionanotechnol, Ansan, Gyeonggi Do, South Korea. [Oh, Jung-Hwa; Yoon, Seok-Joo] Korea Inst Toxicol, Toxicogen Team, Taejon, South Korea.</availability>
    <date>2011</date>
    <notes>JEnglishArticleHwang, SY (reprint author), Hanyang Univ, Dept Biochem, Ansan, Gyeonggi Do, South Koreasyhwang@hanyang.ac.krBromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; Ellsworth RE, 2009, CLIN EXP METASTAS, V26, P205, DOI 10.1007/s10585-008-9232-9; FERNANDEZ SV, 2009, TOXICOL PATHOL, V38, P110; Gore AC, 2007, CONTEMP ENDOCRINOL S, P1, DOI 10.1007/1-59745-107-X; Hoch M, 2001, APPL GEOCHEM, V16, P719, DOI 10.1016/S0883-2927(00)00067-6; *INT PROGR CHEM SA, 2001, PRINC EV HLTH RISKS, P225; International Programme on Chemical Safety, 2002, GLOB ASS STAT OF THE; Kim JS, 2007, MOL CELL TOXICOL, V3, P208; Maras M, 2006, ENVIRON HEALTH PERSP, V114, P100, DOI 10.1289/ehp.8149; Paul S, 2009, MOL CELL TOXICOL, V5, P67; Reddy BY, 2009, P NATL ACAD SCI USA, V106, P4408, DOI 10.1073/pnas.0809130106; Santos-Sacchi J, 2006, J NEUROSCI, V26, P3992, DOI 10.1523/JNEUROSCI.4548-05.2006; Soares A, 2008, ENVIRON INT, V34, P1033, DOI 10.1016/j.envint.2008.01.004; *UN, 2007, GLOB HARM SYST CLASS, P175; Wang XH, 2010, AQUAT TOXICOL, V99, P413, DOI 10.1016/j.aquatox.2010.06.001162KOREAN SOCIETY TOXICOGENOMICS &amp; TOXICOPROTEOMICS-KSTTGYEONGGI-DOHANYANG UNIV, SCI &amp; TECHNOL BLDG 1, RM 423, SA-DONG, SANGROK-GU, ANSAN, GYEONGGI-DO, 426 791, SOUTH KOREAMOL CELL TOXICOLMAR 31Discipline: Biochemistry &amp; Molecular Biology; Toxicology744UO</notes>
    <keywords>Aging; apoptosis; BIOLOGY; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CELL; chemical safety; CHEMICALS; EDC; Endotoxic; environment; ENVIRONMENTAL CHEMICALS; EXPOSURE; EXPRESSION; GENE; GENES; HazChem Human array; HEALTH; HUMAN-BREAST-CANCER; LINE; Nonylphenol; PREGNANCY; RISK; SOCIETY; Tetrabutyltin; TOXICITY; Toxicogenomics; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>95</startpage>
    <endpage>101</endpage>
    <journalfull>Molecular &amp; Cellular Toxicology</journalfull>
    <issue>1</issue>
    <volume>7</volume>
    <abstract>Exposure to environmental chemicals has been implicated in a number of adverse health effects, including immunotoxic, neurotoxic, reproductive toxic effects, and, above all, cancers. In the present study, we investigated toxicity of three environmental chemicals-bisphenol A (BPA), nonylphenol (NP), and tetrabutyltin (TTBT) in a human breast cancer cell line by HazChem Human array. We then found toxicity markers of TTBT through comparison with BPA and NP. Fifty three genes were differentially expressed and seventeen genes showed similar expression patterns. Ontology analysis showed differential expression of genes related to aging and apoptosis and genes having similarities associated with pregnancy and insemination. In this paper, we revealed potential TTBT toxic markers and endotoxicity of TTBT. This study could be a foundation for additional studies of TIBT toxicity</abstract>
    <url>WOS:000289120400013</url>
    <isbnorissn>1738-642X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>355</id>
    <title>Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor</title>
    <authors>Andersen,R.J.; Mawji,N.R.; Wang,J.; Wang,G.; Haile,S.; Myung,J.K.; Watt,K.; Tam,T.; Yang,Y.C.; Banuelos,C.A.; Williams,D.E.; Mcewan,I.J.; Wang,Y.Z.; Sadar,M.D.</authors>
    <availability>[Mawji, Nasrin R.; Wang, Jun; Wang, Gang; Haile, Simon; Myung, Jae-Kyung; Tam, Teresa; Yang, Yu Chi; Banuelos, Carmen A.; Sadar, Marianne D.] British Columbia Canc Agcy, Dept Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada. [Williams, David E.; Wang, Yuzhou] British Columbia Canc Agcy, Dept Canc Endocrinol, Vancouver, BC V5Z 1L3, Canada. [Andersen, Raymond J.] Univ British Columbia, Vancouver, BC V6T 1Z1, Canada. [Watt, Kate; McEwan, Iain J.] Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.</availability>
    <date>2010</date>
    <notes>JEnglishArticleSadar, MD (reprint author), British Columbia Canc Agcy, Dept Genome Sci Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canadamsadar@bcgsc.caAarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; [Anonymous], 2004, EFSA J, V86, P1; Blaszczyk N, 2004, CLIN CANCER RES, V10, P1860, DOI 10.1158/1078-0432.CCR-0974-3; BRUCHOVSKY N, 2001, P 7 INT C ANDR MED E, P609; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Comuzzi B, 2004, J PATHOL, V204, P159, DOI 10.1002/path.1609; Debes JD, 2003, CANCER RES, V63, P7638; Debes JD, 2002, CANCER RES, V62, P5632; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Kim D, 2002, AM J PATHOL, V160, P219, DOI 10.1016/S0002-9440(10)64365-9; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; Lavery DN, 2008, BIOCHEMISTRY-US, V47, P3360, DOI 10.1021/bi702221e; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Moul J W, 1995, Semin Urol, V13, P157; Nazareth LV, 1996, J BIOL CHEM, V271, P19900; Poole A, 2004, FOOD ADDIT CONTAM, V21, P905, DOI 10.1080/02652030400007294; Quayle SN, 2007, P NATL ACAD SCI USA, V104, P1331, DOI 10.1073/pnas.0606718104; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Stroheker T, 2004, FOOD CHEM TOXICOL, V42, P887, DOI 10.1016/j.fct.2004.01.012; Taplin ME, 1999, CANCER RES, V59, P2511; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Wang G, 2009, CANCER RES, V69, P3433, DOI 10.1158/0008-5472.CAN-08-3506; Wang L, 2006, J BIOL CHEM, V281, P37773, DOI 10.1074/jbc.M608410200; Wilson CM, 1996, MOL CELL ENDOCRINOL, V120, P51, DOI 10.1016/0303-7207(96)03819-1; WONG CI, 1993, J BIOL CHEM, V268, P19004; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.20854134CELL PRESSCAMBRIDGE600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USACANCER CELLJUN 15Discipline: Oncology; Cell Biology613BY</notes>
    <keywords>Androgen; ANDROGEN RECEPTOR; Androgen response element; BIOLOGY; BISPHENOL-A; CANCER; CELL; CREB-BINDING-PROTEIN; CROSS-TALK; EXPRESSION; FACTORS INDUCE; FOOD; GENE; GENES; GROWTH; INDEPENDENT TRANSCRIPTIONAL ACTIVATION; inhibition; INHIBITOR; Interaction; JUN; NUCLEAR RECEPTORS; oncology; proliferation; Prostate; prostate cancer; PROSTATE-CANCER; protein-protein interaction; RECEPTOR; Receptors; SIGNAL-TRANSDUCTION PATHWAYS; Steroid; steroid receptors; STEROID-BINDING; TARGET; TARGET GENES; TOXICITY; TRANSACTIVATION; TRANSCRIPTIONAL ACTIVITIES; TRANSCRIPTIONAL ACTIVITY; XENOGRAFTS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>535</startpage>
    <endpage>546</endpage>
    <journalfull>Cancer Cell</journalfull>
    <issue>6</issue>
    <volume>17</volume>
    <abstract>Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity. Here we identify EPI-001, a small molecule that blocked transactivation of the NTD and was specific for inhibition of AR without attenuating transcriptional activities of related steroid receptors. EPI-001 interacted with the AF-1 region, inhibited protein-protein interactions with AR, and reduced AR interaction with androgen-response elements on target genes. Importantly, EPI-001 blocked androgen-induced proliferation and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing toxicity</abstract>
    <url>WOS:000278952300006</url>
    <isbnorissn>1535-6108</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>362</id>
    <title>Bisphenol A activates Maxi-K (K(Ca)1.1) channels in coronary smooth muscle</title>
    <authors>Asano,S.; Tune,J.D.; Dick,G.M.</authors>
    <availability>[Asano, Shinichi; Dick, Gregory M.] W Virginia Univ, Sch Med, Div Exercise Physiol, Ctr Cardiovasc &amp; Resp Sci, Morgantown, WV 26506 USA. [Tune, Johnathan D.] Indiana Univ, Sch Med, Dept Cellular &amp; Integrat Physiol, Indianapolis, IN USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleDick, GM (reprint author), 1 Med Ctr Dr,POB 9105, Morgantown, WV 26506 USAgdick@hsc.wvu.eduAlexander SPH, 2009, BRIT J PHARMACOL, V158, pS1; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Brenner R, 2000, NATURE, V407, P870; Bukiya AN, 2008, FEBS LETT, V582, P673, DOI 10.1016/j.febslet.2008.01.036; Bukiya AN, 2008, J LIPID RES, V49, P2441, DOI 10.1194/jlr.M800286-JLR200; Bukiya AN, 2007, MOL PHARMACOL, V72, P359, DOI 10.1124/mol.107.034330; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Coiret G, 2007, MOL PHARMACOL, V71, P843, DOI 10.1124/mol.106.028290; Csanady GA, 2002, ARCH TOXICOL, V76, P299, DOI 10.1007/s00204-002-0339-5; Deenadayalu VUP, 2001, AM J PHYSIOL-HEART C, V281, pH1720; Dick GM, 2002, MOL PHARMACOL, V61, P1105, DOI 10.1124/mol.61.5.1105; Dick GM, 2002, BRIT J PHARMACOL, V136, P961, DOI 10.1038/sj.bjp.0704807; Dick GM, 2001, J BIOL CHEM, V276, P44835, DOI 10.1074/jbc.M106851200; Dick GM, 2001, J BIOL CHEM, V276, P34594, DOI 10.1074/jbc.M104689200; Duncan RK, 2005, BIOCHEM PHARMACOL, V70, P47, DOI 10.1016/j.bcp.2005.03.026; Han DH, 2008, J SEX MED, V5, P822, DOI 10.1111/j.1743-6109.2007.00732.x; Hanaoka T, 2002, OCCUP ENVIRON MED, V59, P625, DOI 10.1136/oem.59.9.625; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; King JT, 2006, J NEUROPHYSIOL, V95, P2878, DOI 10.1152/jn.01352.2005; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; Korovkina VP, 2004, J BIOL CHEM, V279, P1217, DOI 10.1074/jbc.M309158200; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lovell PV, 2004, J NEUROPHYSIOL, V91, P561, DOI 10.1152/jn.01101.2002; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Perez GJ, 2005, J BIOL CHEM, V280, P21739, DOI 10.1074/jbc.M413953200; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Savabieasfahani M, 2006, ENDOCRINOLOGY, V147, P5956, DOI 10.1210/en.2006-0805; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Walsh DE, 2005, MOL CELL ENDOCRINOL, V230, P23, DOI 10.1016/j.mce.2004.11.006; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Wetherill YB, 2005, CANCER RES, V65, P54; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Wu X, 2008, J PHYSIOL-LONDON, V586, P1699, DOI 10.1113/jphysiol.2007.149500; Yang Y, 2009, J PHYSIOL-LONDON, V587, P3025, DOI 10.1113/jphysiol.2009.1699204613WILEY-BLACKWELLMALDENCOMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USABRIT J PHARMACOLMAYDiscipline: Pharmacology &amp; Pharmacy583CT</notes>
    <keywords>1; ACUTE MODULATION; ALPHA; BETA; bisphenol; bisphenol A; BISPHENOL-A; BK CHANNELS; BPA; BREAST-CANCER CELLS; CANCER; CELL; CELLS; diabetes; DISEASE; ENDOCRINE; Endocrine disruptor; ESTRADIOL BINDING; EXPOSURE; FOOD; HEALTH; heart; HEART-DISEASE; K(Ca)1; KCNMA1; KCNMB1; large conductance Ca2+; LARGE-CONDUCTANCE; mechanism; MEMBRANE ESTROGEN-RECEPTOR; oestrogen; oestrogen receptor; penitrem A; PHARMACOLOGY; Plastics; POTASSIUM CHANNELS; RECEPTOR; REGULATORY BETA-1 SUBUNIT; Steroid; voltage-sensitive potassium channel; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>160</startpage>
    <endpage>170</endpage>
    <journalfull>British Journal of Pharmacology</journalfull>
    <issue>1</issue>
    <volume>160</volume>
    <abstract>Background and purpose: Bisphenol A (BPA) is used to manufacture plastics, including containers for food into which it may leach. High levels of exposure to this oestrogenic endocrine disruptor are associated with diabetes and heart disease. Oestrogen and oestrogen receptor modulators increase the activity of large conductance Ca2+/voltage-sensitive K+ (Maxi-K; K(Ca)1.1) channels, but the effects of BPA on Maxi-K channels are unknown. We tested the hypothesis that BPA activates Maxi-K channels through a mechanism that depends upon the regulatory beta 1 subunit. Experimental approach: Patch-clamp recordings of Maxi-K channels were made in human and canine coronary smooth muscle cells as well as in AD-293 cells expressing pore-forming alpha or alpha plus beta 1 subunits. Key results: BPA (10 mu M) activated an outward current in smooth muscle cells that was inhibited by penitrem A (1 mu M), a Maxi-K blocker. BPA increased Maxi-K activity in inside-out patches from coronary smooth muscle, but had no effect on single channel conductance. In AD-293 cells with Maxi-K channels composed of alpha subunits alone, 10 mu M BPA did not affect channel activity. When channels in AD-293 cells contained beta 1 subunits, 10 mu M BPA increased channel activity. Effects of BPA were rapid (&lt; 1 min) and reversible. A higher concentration of BPA (100 mu M) increased Maxi-K current independent of the beta 1 subunit. Conclusions and implications: Our data indicate that BPA increased the activity of Maxi-K channels and may represent a basis for some potential toxicological effects</abstract>
    <url>WOS:000276651200015</url>
    <isbnorissn>0007-1188</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>354</id>
    <title>Bisphenol A exposure leads to specific microRNA alterations in placental cells</title>
    <authors>Avissar-Whiting,M.; Veiga,K.R.; Uhl,K.M.; Maccani,M.A.; Gagne,L.A.; Moen,E.L.; Marsit,C.J.</authors>
    <availability>[Marsit, Carmen J.] Brown Univ, Dept Pathol &amp; Lab Med, Div Biol &amp; Med, Providence, RI 02912 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleMarsit, CJ (reprint author), Brown Univ, Dept Pathol &amp; Lab Med, Div Biol &amp; Med, Box G-E5, Providence, RI 02912 USAcarmen_marsit@brown.eduAhmed SR, 2000, TOXICOLOGY, V150, P191; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Babar IA, 2008, FUTURE ONCOL, V4, P289, DOI 10.2217/14796694.4.2.289; BARRANCO SC, 1971, CANCER RES, V31, P1218; Benachour N, 2009, TOXICOL APPL PHARM, V241, P322, DOI 10.1016/j.taap.2009.09.005; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Gabbe S, 2007, OBSTET NORMAL PROBLE; He YH, 2009, ENVIRON RES, V109, P629, DOI 10.1016/j.envres.2009.04.003; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 1999, NATURE, V401, P763; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Iyengar GV, 2001, SCI TOTAL ENVIRON, V280, P221, DOI 10.1016/S0048-9697(01)00827-0; IZZOTTI A, 2008, FASEB J; Jardim MJ, 2009, ENVIRON HEALTH PERSP, V117, P1745, DOI 10.1289/ehp.0900756; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Josson S, 2008, PROSTATE, V68, P1599, DOI 10.1002/pros.20827; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Lin SL, 2008, RNA, V14, P417, DOI 10.1261/rna.874808; MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633; Marsit CJ, 2006, CANCER RES, V66, P10843, DOI 10.1158/0008-5472.CAN-06-1894; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Palanza P, 2008, ENVIRON RES, V108, P150, DOI 10.1016/j.envres.2008.07.023; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Zhou R, 2009, NEUROSCIENCE, V159, P161, DOI 10.1016/j.neuroscience.2008.12.0284149PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLJULDiscipline: Reproductive Biology; Toxicology613BV</notes>
    <keywords>analysis; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; CELLS; CELLULAR STRESS; DEVELOPMENTAL EXPOSURE; epigenetic; epigenetics; ESTRADIOL; EXPOSURE; EXPRESSION; FETAL; FUTURE; HEALTH; IMMUNE-SYSTEM; IN-VITRO; LINE; LINES; mechanism; MECHANISMS; Microarray; microRNA; MICRORNAS; MODULATION; PATHWAY; PLACENTA; proliferation; Prostate; PROSTATE-CANCER; SENSITIVITY; SUSCEPTIBILITY; TOXICITY; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>401</startpage>
    <endpage>406</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>4</issue>
    <volume>29</volume>
    <abstract>Exposure to bisphenol A (BPA) has been observed to alter developmental pathways and cell processes, at least in part, through epigenetic mechanisms. This study sought to investigate the effect of BPA on microRNAs (miRNAs) in human placental cells. miRNA microarray was performed following BPA treatment in three immortalized cytotrophoblast cell lines and the results validated using quantitative real-time PCR. For functional analysis, overexpression constructs were stably transfected into cells that were then assayed for changes in proliferation and response to toxicants. Microarray analysis revealed several miRNAs to be significantly altered in response to BPA treatment in two cell lines. Real-time PCR results confirmed that miR-146a was particularly strongly induced and its overexpression in cells led to slower proliferation as well as higher sensitivity to the DNA damaging agent, bleomycin. Overall, these results suggest that BPA can alter miRNA expression in placental cells, a potentially novel mode of BPA toxicity. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000278951900003</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>263</id>
    <title>Perinatal Exposure to Bisphenol A Increases Adult Mammary Gland Progesterone Response and Cell Number</title>
    <authors>Ayyanan,A.; Laribi,O.; Schuepbach-Mallepell,S.; Schrick,C.; Gutierrez,M.; Tanos,T.; Lefebvre,G.; Rougemont,J.; Yalcin-Ozuysal,O.; Brisken,C.</authors>
    <availability>[Ayyanan, Ayyakkannu; Laribi, Ouahiba; Schuepbach-Mallepell, Sonia; Schrick, Christina; Gutierrez, Maria; Tanos, Tamara; Yalcin-Ozuysal, Ozden; Brisken, Cathrin] Ecole Polytech Fed Lausanne, ISREC Swiss Inst Expt Canc Res, Natl Ctr Competence Mol Oncol, CH-1015 Lausanne, Switzerland. [Lefebvre, Gregory; Rougemont, Jacques] Ecole Polytech Fed Lausanne, Swiss Inst Bioinformat, Bioinformat &amp; Biostat Core Facil, CH-1015 Lausanne, Switzerland. [Laribi, Ouahiba] Ecole Hautes Etud Sante Publ, Rennes, France. [Schuepbach-Mallepell, Sonia] Geneva Med Ctr, Dept Dermatol Immunol, CH-1211 Geneva, Switzerland. [Schrick, Christina] Geneva Med Ctr, Dept Pathol Immunol, CH-1211 Geneva, Switzerland. [Yalcin-Ozuysal, Ozden] Izmir Inst Technol, Dept Mol Biol &amp; Genet, TR-35430 Izmir, Turkey.</availability>
    <date>2011</date>
    <notes>JEnglishArticleBrisken, C (reprint author), SV2-832 Stn 19, CH-1015 Lausanne, Switzerlandcathrin.brisken@epfl.chAsselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053; Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107; BERN HA, 1987, CANCER RES, V47, P4165; Brisken C, 2000, GENE DEV, V14, P650; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Burridge E., 2003, EUR CHEM NEWS, P14; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; HASLAM SZ, 1979, BIOCHEM J, V182, P127; Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HESTON WE, 1971, INT J CANCER, V7, P141, DOI 10.1002/ijc.2910070116; Howdeshell KL, 1999, NATURE, V401, P763; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jones LP, 2010, TOXICOL LETT, V199, P261, DOI 10.1016/j.toxlet.2010.09.008; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Team DC, 2010, R LANG ENV STAT COMP; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Zalko D, 2011, CHEMOSPHERE, V82, P424, DOI 10.1016/j.chemosphere.2010.09.0583317ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAMOL ENDOCRINOLNOVDiscipline: Endocrinology &amp; Metabolism842IP</notes>
    <keywords>ADULT; ALTERS; AMPHIREGULIN; bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; CARCINOGENESIS; CELL; cell death; Cell proliferation; CELL-DEATH; CELL-PROLIFERATION; CHEMICALS; DEATH; DIETHYLSTILBESTROL; ENDOCRINE; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; female; FLUID; FOOD; GENE; GLAND; HEALTH; HUMAN EXPOSURE; IMPACT; INDUCTION; LIGAND; Ligands: Bisphenol A; mammary gland; MAMMARY TISSUE; MAMMARY-GLAND; MAMMARY-GLANDS; MECHANISMS; METABOLISM; MICE; MOUSE STRAINS; NURSA Molecule Pages: Nuclear Receptors: PR; PERINATAL EXPOSURE; POPULATION; progesterone; proliferation; puberty; RECEPTOR; RISK; SENSITIVITY; terminal end buds; TISSUE; WATER; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1915</startpage>
    <endpage>1923</endpage>
    <journalfull>Molecular Endocrinology</journalfull>
    <issue>11</issue>
    <volume>25</volume>
    <abstract>Bisphenol A [BPA, 2,2,-bis (hydroxyphenyl) propane] is one of the highest-volume chemicals produced worldwide. It is detected in body fluids of more than 90% of the human population. Originally synthesized as an estrogenic compound, it is currently utilized to manufacture food and beverage containers resulting in uptake with food and drinks. There is concern that exposure to low doses of BPA, defined as less than or equal to 5 mg/kg body weight /d, may have developmental effects on various hormone-responsive organs including the mammary gland. Here, we asked whether perinatal exposure to a range of low doses of BPA is sufficient to alter mammary gland hormone response later on in life, with a possible impact on breast cancer risk. To mimic human exposure, we added BPA to the drinking water of C57/Bl6 breeding pairs. Analysis of the mammary glands of their daughters at puberty showed that estrogen-dependent transcriptional events were perturbed and the number of terminal end buds, estrogen-induced proliferative structures, was altered in a dose-dependent fashion. Importantly, adult females showed an increase in mammary epithelial cell numbers comparable to that seen in females exposed to diethylbestrol, a compound exposure to which was previously linked to increased breast cancer risk. Molecularly, the mRNAs encoding Wnt-4 and receptor activator of nuclear factor kappa B ligand, two key mediators of hormone function implicated in control of mammary stem cell proliferation and carcinogenesis, showed increased induction by progesterone in the mammary tissue of exposed mice. Thus, perinatal exposure to environmentally relevant doses of BPA alters long-term hormone response that may increase the propensity to develop breast cancer. (Molecular Endocrinology 25: 1915-1923, 2011)</abstract>
    <url>WOS:000296591700008</url>
    <isbnorissn>0888-8809</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>37</id>
    <title>Transcriptional analysis of endocrine disruption using zebrafish and massively parallel sequencing</title>
    <authors>Baker,M.E.; Hardiman,G.</authors>
    <availability>[Baker, Michael E.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Hardiman, Gary] San Diego State Univ, CSRC, San Diego, CA 92182 USA. [Hardiman, Gary] San Diego State Univ, BIMRC, San Diego, CA 92182 USA. [Hardiman, Gary] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.</availability>
    <date>2014</date>
    <notes>JEnglishReviewBaker, ME (reprint author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr 0605, La Jolla, CA 92093 USAmebaker@ucsd.edu; hardiman@musc.eduAanes H, 2011, GENOME RES, V21, P1328, DOI 10.1101/gr.116012.110; Aday AW, 2011, DEV BIOL, V357, P450, DOI 10.1016/j.ydbio.2011.03.007; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099; Baker ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046078; Baker ME, 2005, INTEGR COMP BIOL, V45, P172, DOI 10.1093/icb/45.1.172; Baker ME, 2009, ENVIRON HEALTH PERSP, V117, P223, DOI 10.1289/ehp.11627; BAKER ME, 2012, PRAEGER HDB ENV HLTH, P475; Baker ME, 2011, BIOCHEM PHARMACOL, V82, P1, DOI 10.1016/j.bcp.2011.03.008; Baker ME, 2013, STEROIDS, V78, P337, DOI 10.1016/j.steroids.2012.12.011; Baker ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075553; Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Ben-Moshe Z, 2014, NUCLEIC ACIDS RES, V42, P3750, DOI 10.1093/nar/gkt1359; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Bertrand S, 2011, MOL CELL ENDOCRINOL, V334, P67, DOI 10.1016/j.mce.2010.06.017; Bertrand Stephanie, 2004, Molecular Biology and Evolution, V21, P1923, DOI 10.1093/molbev/msh200; Bhasker CR, 2010, PHARMACOGENOMICS, V11, P481, DOI [10.2217/pgs.10.10, 10.2217/PGS.10.10]; Boland JF, 2013, HUM GENET, V132, P1153, DOI 10.1007/s00439-013-1321-4; Bradford Y, 2011, NUCLEIC ACIDS RES, V39, pD822, DOI 10.1093/nar/gkq1077; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Carneiro MO, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-375; Celiz MD, 2009, ENVIRON TOXICOL CHEM, V28, P2473, DOI 10.1897/09-173.1; Chapman RW, 2013, MOL ECOL, V22, P1485, DOI 10.1111/mec.12254; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen H, 2010, AQUAT TOXICOL, V96, P53, DOI 10.1016/j.aquatox.2009.09.015; Chin CS, 2011, NEW ENGL J MED, V364, P33, DOI 10.1056/NEJMoa1012928; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Colman BP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057189; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959-437X(00)00074-5; Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986; Escriva H, 2000, BIOESSAYS, V22, P717; Fendorf S, 2010, SCIENCE, V328, P1123, DOI 10.1126/science.1172974; Fraser BA, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-202; Frey KG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-96; Funder JW, 2009, HYPERTENSION, V53, P286, DOI 10.1161/HYPERTENSIONAHA.108.119966; Gao H, 2011, MOL CELL ENDOCRINOL, V334, P83, DOI 10.1016/j.mce.2010.09.002; Glenn TC, 2011, MOL ECOL RESOUR, V11, P759, DOI 10.1111/j.1755-0998.2011.03024.x; Gorelick DA, 2011, ENDOCRINOLOGY, V152, P2690, DOI 10.1210/en.2010-1257; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Griffitt RJ, 2013, AQUAT TOXICOL, V130, P192, DOI 10.1016/j.aquatox.2013.01.010; Grun F, 2006, ENDOCRINOLOGY, V147, pS50, DOI 10.1210/en.2005-1129; Hardiman G, 2004, PHARMACOGENOMICS, V5, P487, DOI 10.1517/14622416.5.5.487; Hardiman G, 2008, PHARMACOGENOMICS, V9, P5, DOI 10.2217/14622416.9.1.5; Hawkins UA, 2012, CURR HYPERTENS REP, V14, P573, DOI 10.1007/s11906-012-0297-0; Hegedus Z, 2009, MOL IMMUNOL, V46, P2918, DOI 10.1016/j.molimm.2009.07.002; Heindel JJ, 2009, MOL CELL ENDOCRINOL, V304, P90, DOI 10.1016/j.mce.2009.02.025; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Henley DV, 2006, ENDOCRINOLOGY, V147, pS25, DOI 10.1210/en.2005-1117; Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111; Huang PX, 2010, ANNU REV PHYSIOL, V72, P247, DOI 10.1146/annurev-physiol-021909-135917; Iavicoli I, 2013, INT J MOL SCI, V14, P16732, DOI 10.3390/ijms140816732; Ingraham HA, 2005, CURR OPIN STRUC BIOL, V15, P708, DOI 10.1016/j.sbi.2005.10.009; Johansen SD, 2011, COMP BIOCHEM PHYS D, V6, P18, DOI 10.1016/j.cbd.2010.04.005; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; KATZENELLENBOGEN BS, 1979, ENDOCRINOLOGY, V105, P33; Kelce WR, 1998, REPROD FERT DEVELOP, V10, P105, DOI 10.1071/R98051; KORACH KS, 1988, MOL PHARMACOL, V33, P120; Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280; Korlach J, 2012, CURR OPIN STRUC BIOL, V22, P251, DOI 10.1016/j.sbi.2012.04.002; Korlach J, 2010, METHOD ENZYMOL, V472, P431, DOI 10.1016/S0076-6879(10)72001-2; Krasowski MD, 2011, MOL CELL ENDOCRINOL, V334, P39, DOI 10.1016/j.mce.2010.06.016; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lam HYK, 2012, NAT BIOTECHNOL, V30, P78, DOI 10.1038/nbt.2065; Lambright C, 2000, TOXICOL SCI, V56, P389, DOI 10.1093/toxsci/56.2.389; Lange A, 2009, ENVIRON SCI TECHNOL, V43, P1219, DOI 10.1021/es802661p; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee O, 2012, ENVIRON HEALTH PERSP, V120, P990, DOI 10.1289/ehp.1104433; LETCHER RJ, 2010, SCI TOTAL ENVIRON, V408, P2995, DOI DOI 10.1016/J.SCITOTENV.2009.10.038; Levy Samuel, 2007, PLoS Biol, V5, pe254, DOI 10.1371/journal.pbio.0050254; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; Liu L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364; Luccio-Camelo DC, 2011, J STEROID BIOCHEM, V127, P74, DOI 10.1016/j.jsbmb.2011.04.004; Luo W, 2012, INT J MOL SCI, V13, P14946, DOI 10.3390/ijms131114946; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Markov GV, 2009, P NATL ACAD SCI USA, V106, P11913, DOI 10.1073/pnas.0812138106; Martinerie L, 2013, BIOCHIMIE, V95, P148, DOI 10.1016/j.biochi.2012.09.030; McEwen BS, 2012, P NATL ACAD SCI USA, V109, P17180, DOI 10.1073/pnas.1121254109; Meacham F, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-451; Merriman B, 2012, ELECTROPHORESIS, V33, P3397, DOI 10.1002/elps.201200424; Minoche AE, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-r112; Morris AC, 2011, INVEST OPHTH VIS SCI, V52, P2255, DOI 10.1167/iovs.10-6022; Nelson DR, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0474; Odermatt A, 2008, BIOCHEM PHARMACOL, V76, P1184, DOI 10.1016/j.bcp.2008.07.019; Oehlmann J, 2008, ENVIRON RES, V108, P140, DOI 10.1016/j.envres.2008.07.016; Oehlmann J, 2009, PHILOS T R SOC B, V364, P2047, DOI 10.1098/rstb.2008.0242; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Pareek CS, 2011, J APPL GENET, V52, P413, DOI 10.1007/s13353-011-0057-x; Pascoal S, 2013, MOL ECOL, V22, P1589, DOI 10.1111/mec.12137; Pepke S, 2009, NAT METHODS, V6, pS22, DOI [10.1038/nmeth.1371, 10.1038/NMETH.1371]; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Quail MA, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-341; Rasko DA, 2011, NEW ENGL J MED, V365, P709, DOI 10.1056/NEJMoa1106920; Ribeiro FJ, 2012, GENOME RES, V22, P2270, DOI 10.1101/gr.141515.112; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355; Robertson G, 2010, NAT METHODS, V7, P909, DOI 10.1038/nmeth.1517; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Saili KS, 2013, REPROD TOXICOL, V38, P89, DOI 10.1016/j.reprotox.2013.03.009; Salipante SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065226; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schier AF, 2013, NATURE, V496, P443, DOI 10.1038/nature12094; Segner H, 2009, COMP BIOCHEM PHYS C, V149, P187, DOI 10.1016/j.cbpc.2008.10.099; Sharifi N, 2012, STEROIDS, V77, P719, DOI 10.1016/j.steroids.2012.03.015; Sladek FM, 2011, MOL CELL ENDOCRINOL, V334, P3, DOI 10.1016/j.mce.2010.06.018; Smith R, 2007, NEW ENGL J MED, V356, P271, DOI 10.1056/NEJMra061360; Soares AR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-195; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; Soto AM, 2009, MOL CELL ENDOCRINOL, V304, P3, DOI 10.1016/j.mce.2009.02.020; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Sugiyama N, 2010, TRENDS ENDOCRIN MET, V21, P545, DOI 10.1016/j.tem.2010.05.001; Suzuki S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019534; Swan Shanna H, 2008, Fertil Steril, V89, pe45, DOI 10.1016/j.fertnstert.2007.12.027; Tamura H, 2001, TOXICOL SCI, V60, P56, DOI 10.1093/toxsci/60.1.56; ten Bosch JR, 2008, J MOL DIAGN, V10, P484, DOI 10.2353/jmoldx.2008.080027; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Trachtenberg AJ, 2012, METHODS MOL BIOL, V802, P3, DOI 10.1007/978-1-61779-400-1_1; Trapnell C, 2009, NAT BIOTECHNOL, V27, P455, DOI 10.1038/nbt0509-455; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Tucker T, 2009, AM J HUM GENET, V85, P142, DOI 10.1016/j.ajhg.2009.06.022; Vajda AM, 2008, ENVIRON SCI TECHNOL, V42, P3407, DOI 10.1021/es0720661; Valouev A, 2008, GENOME RES, V18, P1051, DOI 10.1101/gr.076463.108; van Aerle R, 2013, ENVIRON SCI TECHNOL, V47, P8005, DOI 10.1021/es401758d; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Villemur R, 2013, APPL ENVIRON MICROB, V79, P4701, DOI 10.1128/AEM.01239-13; Voelkerding KV, 2009, CLIN CHEM, V55, P641, DOI 10.1373/clinchem.2008.112789; Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Wolf JBW, 2013, MOL ECOL RESOUR, V13, P559, DOI 10.1111/1755-0998.12109; WOOLFE A, 2004, PLOS BIOL, V0003; Xu HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068737; Yamaguchi A, 2005, AQUAT TOXICOL, V72, P239, DOI 10.1016/j.aquatox.2004.12.011; Zhang XJ, 2012, BIOTECHNIQUES, V53, P61, DOI 10.2144/0000113891; Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.0061420BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDJ MOL ENDOCRINOLJUNDiscipline: Endocrinology &amp; MetabolismAQ8EM</notes>
    <keywords>ABNORMALITIES; BIOLOGY; BISPHENOL-A; CANCER; CELL; CHEMICALS; DIFFERENTIAL EXPRESSION ANALYSIS; EMBRYONIC ZEBRAFISH; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; HUMAN GENOME; HUMAN HEALTH; IN-UTERO; massive parallel sequencing; mechanism; METABOLISM; MINERALOCORTICOID RECEPTOR; NUCLEAR HORMONE-RECEPTORS; PACIFIC BIOSCIENCES; RECEPTOR; RNA-SEQ DATA; SINGLE POLYMERASE MOLECULES; steroid receptors; zebrafish</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>R241</startpage>
    <endpage>R256</endpage>
    <journalfull>Journal of Molecular Endocrinology</journalfull>
    <issue>3</issue>
    <volume>52</volume>
    <abstract>Endocrine-disrupting chemicals (EDCs), including plasticizers, pesticides, detergents, and pharmaceuticals, affect a variety of hormone-regulated physiological pathways in humans and wildlife. Many EDCs are lipophilic molecules and bind to hydrophobic pockets in steroid receptors, such as the estrogen receptor and androgen receptor, which are important in vertebrate reproduction and development. Indeed, health effects attributed to EDCs include reproductive dysfunction (e.g. reduced fertility, reproductive tract abnormalities, and skewed male: female sex ratios in fish), early puberty, various cancers, and obesity. A major concern is the effects of exposure to low concentrations of endocrine disruptors in utero and post partum, which may increase the incidence of cancer and diabetes in adults. EDCs affect transcription of hundreds and even thousands of genes, which has created the need for new tools to monitor the global effects of EDCs. The emergence of massive parallel sequencing for investigating gene transcription provides a sensitive tool for monitoring the effects of EDCs on humans and other vertebrates, as well as elucidating the mechanism of action of EDCs. Zebrafish conserve many developmental pathways found in humans, which makes zebrafish a valuable model system for studying EDCs, especially on early organ development because their embryos are translucent. In this article, we review recent advances in massive parallel sequencing approaches with a focus on zebrafish. We make the case that zebrafish exposed to EDCs at different stages of development can provide important insights on EDC effects on human health</abstract>
    <url>WOS:000343056500005</url>
    <isbnorissn>0952-5041</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>383</id>
    <title>The possibility of removal of endocrine disrupters from paper mill waste waters using anaerobic and aerobic biological treatment, membrane bioreactor, ultra-filtration, reverse osmosis and advanced oxidation processes</title>
    <authors>Balabanic,D.; Hermosilla,D.; Blanco,A.; Merayo,N.; Klemencic,A.K.</authors>
    <date>2010</date>
    <notes>SEnglishProceedings PaperAli M, 2001, ADV ENVIRON RES, V5, P175, DOI 10.1016/S1093-0191(00)00055-1; Amat AM, 2005, SOL ENERGY, V79, P393, DOI 10.1016/j.solener.2005.02.021; APHA AWWA WEF, 2005, STAND METH EX WAT WA; Arslan-Alaton I, 2008, DYES PIGMENTS, V78, P117, DOI 10.1016/j.dyepig.2007.11.001; Baban A, 2003, DYES PIGMENTS, V58, P93, DOI 10.1016/S0143-7208(03)00047-0; Birkett JW, 2003, ENDOCRINE DISRUPTERS IN WASTEWATER AND SLUDGE TREATMENT PROCESSES, P1; EPBD recast, OFFICIAL J EUROPEAN; Evans NP, 2004, DOMEST ANIM ENDOCRIN, V26, P61, DOI 10.1016/j.domaniend.2003.09.005; Folmar LC, 2002, AQUAT TOXICOL, V60, P101, DOI 10.1016/S0166-445X(01)00276-4; Gultekin I, 2007, J ENVIRON MANAGE, V85, P816, DOI 10.1016/j.jenvman.2007.07.020; Hamm U., 2005, IPW, V2, P47; Hamm U., 2005, IPW, V1, P45; Ishihara A, 2003, GEN COMP ENDOCR, V134, P36, DOI 10.1016/S0016-6480(03)00197-7; Kimura K, 2007, ENVIRON SCI TECHNOL, V41, P3708, DOI 10.1021/es061684z; Li YJ, 2006, WATER RES, V40, P1119, DOI 10.1016/j.watres.2005.12.042; McKinlay R, 2008, ENVIRON INT, V34, P168, DOI 10.1016/j.envint.2007.07.013; Petrovic M, 2004, ANAL BIOANAL CHEM, V378, P549, DOI 10.1007/s00216-003-2184-7; Pokhrel D, 2004, SCI TOTAL ENVIRON, V333, P37, DOI 10.1016/j.scitotenv.2004.05.017; RAI UN, HLTH HAZARDS HEAVY M; Shokrollahzadeh S, 2008, BIORESOURCE TECHNOL, V99, P6127, DOI 10.1016/j.biortech.2007.12.034; Sun JH, 2008, J HAZARD MATER, V153, P187, DOI 10.1016/j.jhazmat.2007.08.037; Wang YQ, 2005, ANAL BIOANAL CHEM, V383, P857, DOI 10.1007/s00216-005-0082-x; Wintgens T, 2002, DESALINATION, V146, P387, DOI 10.1016/S0011-9164(02)00519-2; Yoon Y, 2006, J MEMBRANE SCI, V270, P88, DOI 10.1016/j.memsci.2005.06.045240WIT PRESSSOUTHAMPTONASHURST LODGE, SOUTHAMPTON SO40 7AA, ASHURST, ENGLANDWIT TRANS ECOL ENVIRDiscipline: Environmental Sciences &amp; Ecology; ToxicologyBUA31</notes>
    <keywords>ABNORMALITIES; ADVANCED OXIDATION PROCESSES; aerobic treatment; Alkylphenol; ALKYLPHENOLS; anaerobic treatment; BINDING; bisphenol; bisphenol A; BISPHENOL-A; CANCER; COMBINATION; development; EFFLUENTS; ENDOCRINE; Endocrine disrupter; ENDOCRINE DISRUPTERS; Endocrine disrupting compounds; environment; FISH; FOOD; Food chain; Hormone; Hormones; HUMANS; membrane filtration; Metals; NANOFILTRATION; OXIDATION; PESTICIDES; PHARMACEUTICALS; photocatalysis; phthalate; Phthalates; PLANT; PLANTS; POLLUTANTS; PULP; REMOVAL; Reproduction; RESPONSES; SPERM; toxicology; waste water; waste water treatment; WASTE-WATER; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>33</startpage>
    <endpage>44</endpage>
    <journalfull>Environmental Toxicology Iii</journalfull>
    <volume>132</volume>
    <abstract>An endocrine disrupter is an exogenous agent that interferes with the synthesis, binding, secretion, transport, action or elimination of natural hormones in the body that are responsible for the maintenance of homeostasis, reproduction, development, and behaviour. Some of them are suspected of causing abnormalities in sperm and increasing hormone-related cancers in humans. Studies have also been published on the estrogen-like responses of endocrine disrupters in wildlife, such as birds, amphibians, reptiles and fish. Endocrine disrupters include a wide variety of pollutants such as alkylphenols, bisphenol A, pesticides, polycyclic aromatic hydrocarbons (PAHs), phthalates, heavy metals, and natural or synthetic hormones. They may be released into the environment in different ways. One of the most important sources of endocrine disrupters are industrial waste waters. The conventional waste water treatment processes are not specifically designed to remove traces of dangerous organic contaminants (except for heavy metals) so the latter are consequently consumed by aquatic organisms and through them may also enter human food chain. In the presented research the following treatments for removing of organic endocrine disrupting compounds from paper mill waste waters were compared: anaerobic biological treatment, membrane bioreactor, and reverse osmosis (pilot plant A), and combined (anaerobic and aerobic) biological treatment, ultra-filtration and reverse osmosis (pilot plant B) at pilot scale and advanced oxidation processes (Fenton, photo-Fenton, photo-catalysis with TiO(2) and ozonation) at laboratory scale. The results indicated that the concentrations of organic endocrine compounds from paper mill waste waters were efficiently reduced (100%) by both combinations of pilot plants, photo-Fenton oxidation (95%) while the ozonation, photo-catalysis with TiO(2) reagent and Fenton reaction was less effective (70-80%)</abstract>
    <url>WOS:000288620800004</url>
    <isbnorissn>1743-3541</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>306</id>
    <title>Presence of Phthalates, Bisphenol A, and Nonylphenol in Paper Mill Wastewaters in Slovenia and Efficiency of Aerobic and Combined Aerobic-Anaerobic Biological Wastewater Treatment Plants for Their Removal</title>
    <authors>Balabanic,D.; Klemencic,A.K.</authors>
    <availability>[Klemencic, Aleksandra Krivograd] Univ Ljubljana, Fac Hlth Sci, Dept Sanit Engn, Ljubljana 1000, Slovenia. [Balabanic, Damjan] Pulp &amp; Paper Inst, Ljubljana 1000, Slovenia. [Balabanic, Damjan] Univ Nova Gorica, Nova Gorica 5000, Slovenia.</availability>
    <date>2011</date>
    <notes>JEnglishArticleKlemencic, AK (reprint author), Univ Ljubljana, Fac Hlth Sci, Dept Sanit Engn, Zdravstvena Pot 5, Ljubljana 1000, Sloveniaaleksandra.krivograd@zf.uni-lj.si[Anonymous], 2003, 58151 ISO; [Anonymous], OFFICIAL J EUROPEA L; [Anonymous], OFFICIAL J EUROPEA L, VL327/1; Baskin LS, 2001, ENVIRON HEALTH PERSP, V109, P1175, DOI 10.1289/ehp.011091175; Birkett JW, 2003, ENDOCRINE DISRUPTERS IN WASTEWATER AND SLUDGE TREATMENT PROCESSES, P1; Bodzek M, 2004, DESALINATION, V162, P121, DOI 10.1016/S0011-9164(04)00035-9; Bolong N, 2009, DESALINATION, V239, P229, DOI 10.1016/j.desal.2008.03.020; Brossa L, 2003, J CHROMATOGR A, V998, P41, DOI 10.1016/S0021-9673(03)00649-6; BULC TG, 2007, J HAZARD MATER, V155, P76; Fernandez MF, 1998, CANCER J - FRANCE, V11, P11; Hamm U., 2005, IPW, V2, P47; Hamm U., 2005, IPW, V1, P45; Johnsen K, 1998, ECOTOX ENVIRON SAFE, V40, P184, DOI 10.1006/eesa.1998.1683; Kimura K, 2007, ENVIRON SCI TECHNOL, V41, P3708, DOI 10.1021/es061684z; Leiviska T, 2008, WATER RES, V42, P3952, DOI 10.1016/j.watres.2008.06.016; Leppanen H, 1999, ENVIRON TOXICOL CHEM, V18, P1498, DOI 10.1897/1551-5028(1999)018&lt;1498:OORARA&gt;2.3.CO;2; Lindstrom-Seppa P, 1998, MAR ENVIRON RES, V46, P273, DOI 10.1016/S0141-1136(97)00074-3; Liu Y, 2003, CHEMOSPHERE, V50, P1, DOI 10.1016/S0045-6535(02)00551-9; *OFF GAZ REP SLOV, 2005, DECR EM SUBST HEAT R, V47, P11; Petrovic M, 2004, ANAL BIOANAL CHEM, V378, P549, DOI 10.1007/s00216-003-2184-7; Pokhrel D, 2004, SCI TOTAL ENVIRON, V333, P37, DOI 10.1016/j.scitotenv.2004.05.017; RAI UN, 2002, HLTH HAZARDS HEAVY M; ROZMAN R, 2008, ECOREMEDIATION, P233; Saunamaki R, 1997, WATER SCI TECHNOL, V35, P235, DOI 10.1016/S0273-1223(96)00936-5; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Shokrollahzadeh S, 2008, BIORESOURCE TECHNOL, V99, P6127, DOI 10.1016/j.biortech.2007.12.034; *SIST ISO, 1996, 10523 SIST ISO; *SIST ISO, 2000, 9562 SIST ISO; *SIST ISO, 1996, 6060 SIST ISO; SPEAROW J, 1999, GENETIC VARIATION SE; Thompson G, 2001, BIORESOURCE TECHNOL, V77, P275, DOI 10.1016/S0960-8524(00)00060-2; Toppari J, 2000, ENVIRONMENTAL ENDOCRINE DISRUPTERS: AN EVOLUTIONARY PERSPECTIVE, P269; Ugurlu M, 2008, FRESEN ENVIRON BULL, V17, P1307; Van Hamme JD, 2003, MICROBIOL MOL BIOL R, V67, P503, DOI 10.1128/MMBR.67.4.503-549.2003; Vass K.K., 1996, Environment and Ecology (Kalyani), V14, P895; Wang YQ, 2005, ANAL BIOANAL CHEM, V383, P857, DOI 10.1007/s00216-005-0082-x; Whittemore A S, 1994, Cancer Surv, V19-20, P309; Wu ZB, 2007, FRESEN ENVIRON BULL, V16, P227; Yu ZR, 2007, J CHROMATOGR A, V1148, P65, DOI 10.1016/j.chroma.2007.02.047394PARLAR SCIENTIFIC PUBLICATIONS (P S P)FREISINGANGERSTR. 12, 85354 FREISING, GERMANYFRESEN ENVIRON BULLDiscipline: Environmental Sciences &amp; Ecology733ZK</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CHINA; CONNECTION; DIBUTYL PHTHALATE; EFFLUENT; EFFLUENTS; EMERGING CONTAMINANTS; ENDOCRINE; Endocrine disrupter; ENDOCRINE DISRUPTERS; Endocrine disrupting compounds; ENDOCRINE-DISRUPTING COMPOUNDS; environment; ESTROGENS; HEALTH; industrial wastewaters; Nonylphenol; PHARMACEUTICALS; phthalate; Phthalates; PLANTS; POLLUTANTS; PULP; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>86</startpage>
    <endpage>92</endpage>
    <journalfull>Fresenius Environmental Bulletin</journalfull>
    <issue>1</issue>
    <volume>20</volume>
    <abstract>Paper mills generate varieties of pollutants depending upon the type of the production process. Raw and biologically treated effluents from two paper mills with different production processes and different biological treatment plants were analysed by COD, BOD(5), AOX as well as by phthalates, bisphenol A, and nonylphenol which are potential endocrine disrupting compounds. Removal efficiency of aerobic and combined aerobic/anaerobic wastewater treatment plants were studied for investigated compounds. The results indicated that dimethyl phthalate, diethyl phthalate, dibutyl phthalate, di(2-ethylhexyl) phthalate, benzyl butyl phthalate, bisphenol A, and nonylphenol were present in raw and biologically treated paper mill effluents. The removal efficiencies of aerobic and combined aerobicanaerobic biological wastewater treatment plants were 87% and 87% for dimethyl phthalate, 79% and 91% for diethyl phthalate, 73% and 88% for dibutyl phthalate, 84% and 78% for di(2-ethylhexyl) phthalate, 86% and 76% for benzyl butyl phthalate, 74% and 79% for bisphenol A, and 71% and 81% for nonylphenol, respectively. Despite relative high removal efficiency of biological wastewater treatment plants for investigated compounds, the concentrations of nonylphenol in treated paper mill effluents exceeded limits of 0.3 mu g/L according to Directive (2008/105/EC)</abstract>
    <url>WOS:000288302800011</url>
    <isbnorissn>1018-4619</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>318</id>
    <title>Negative impact of endocrine-disrupting compounds on human reproductive health</title>
    <authors>Balabanic,D.; Rupnik,M.; Klemencic,A.K.</authors>
    <availability>[Balabanic, Damjan] Pulp &amp; Paper Inst, SI-1000 Ljubljana, Slovenia. [Balabanic, Damjan] Univ Nova Gor, SI-5000 Nova Gorica, Slovenia. [Rupnik, Marjan] Univ Maribor, Inst Physiol, Fac Med, SI-2000 Maribor, Slovenia. [Klemencic, Aleksandra Krivograd] Univ Ljubljana, Fac Hlth Sci, Dept Sanit Engn, SI-1000 Ljubljana, Slovenia.</availability>
    <date>2011</date>
    <notes>JEnglishReviewBalabanic, D (reprint author), Pulp &amp; Paper Inst, Bogisiceva Ulica 8, SI-1000 Ljubljana, Sloveniadamjan.balabanic@gmail.comAbernathy CO, 2003, J NUTR, V133, p1536S; Agency for Toxic Substances and Disease Registry (ATSDR), 1997, TOX PROF SEL POL BIP; ALSALEH I, 1995, ARCH ENVIRON HEALTH, V50, P66; Andersen HR, 2002, TOXICOL APPL PHARM, V179, P1, DOI 10.1006/taap.2001.9347; Anderson HA, 2000, J EXPO ANAL ENV EPID, V10, P755; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Baccarelli A, 2004, TOXICOL LETT, V149, P287, DOI 10.1016/j.toxlet.2003.12.062; BALABANIC D, 2009, PAPIR, V37, P25; Balabanic D, 2011, FRESEN ENVIRON BULL, V20, P86; Barlow NJ, 2003, TOXICOL SCI, V73, P431, DOI 10.1093/toxsci/kfg087; Baskin LS, 2001, ENVIRON HEALTH PERSP, V109, P1175, DOI 10.1289/ehp.011091175; Bellinger DC, 2005, BIRTH DEFECTS RES A, V73, P409, DOI 10.1002/bdra.20127; Bergeron RM, 1999, MOL CELL ENDOCRINOL, V150, P179, DOI 10.1016/S0303-7207(98)00202-0; Birkett JW, 2003, ENDOCRINE DISRUPTERS IN WASTEWATER AND SLUDGE TREATMENT PROCESSES, P1; Brody JG, 2003, ENVIRON HEALTH PERSP, V111, P1007, DOI 10.1289/ehp.6310; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Carbone P, 2006, REPROD TOXICOL, V22, P8, DOI 10.1016/j.reprotox.2006.01.006; CARLSEN E, 1995, ENVIRON HEALTH PERSP, V103, P137, DOI 10.2307/3432523; CARLSEN E, 1992, BRIT MED J, V305, P609; Chamarro E, 2001, WATER RES, V35, P1047, DOI 10.1016/S0043-1354(00)00342-0; Chang S, 2003, ENVIRON SCI TECHNOL, V37, P3158, DOI 10.1021/es0261574; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; Choy C. M. Y., 2003, OBSTET GYNECOL SURV, V58, P325, DOI DOI 10.1097/00006254-200305000-00020; Cincinelli A, 2005, J ENVIRON MONITOR, V7, P1305, DOI 10.1039/b507321a; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11; Colburn T., 1992, ADV MODERN ENV TOXIC, V12; Dargnat C, 2009, SCI TOTAL ENVIRON, V407, P1235, DOI 10.1016/j.scitotenv.2008.10.027; Davis BJ, 2001, TOXICOL SCI, V59, P291, DOI 10.1093/toxsci/59.2.291; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Daxenberger A, 2002, EUR J LIPID SCI TECH, V104, P124, DOI 10.1002/1438-9312(200202)104:2&lt;124::AID-EJLT124&gt;3.3.CO;2-K; Drewes JE, 2005, WATER ENVIRON RES, V77, P12, DOI 10.2175/106143005X41573; EGELAND GM, 1994, AM J EPIDEMIOL, V139, P272; ERNST E, 1991, PHARMACOL TOXICOL, V68, P440; Esplugas S, 2007, J HAZARD MATER, V149, P631, DOI 10.1016/j.jhazmat.2007.07.073; *EUR PARL COUNC EU, 2008, OFF J EUR COMMUNITIE, V384, P84; European Commission, 2000, OFFICIAL J EUROPEA L, VL327, P1; Faqi AS, 1998, TOXICOL APPL PHARM, V150, P383, DOI 10.1006/taap.1998.8433; Finizio A, 1997, CHEMOSPHERE, V34, P131, DOI 10.1016/S0045-6535(96)00355-4; Fisher BE, 1999, ENVIRON HEALTH PERSP, V107, pA18, DOI 10.2307/3434279; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; Fukushima M, 2001, ENVIRON SCI TECHNOL, V35, P1771, DOI 10.1021/es001088j; GarcA-a SA­nchez A, 1992, Sci Total Environ, V116, P243; Gardella JR, 2000, SEMIN REPROD MED, V18, P407, DOI 10.1055/s-2000-13731; Garry VF, 2004, TOXICOL APPL PHARM, V198, P152, DOI 10.1016/j.taap.2003.11.027; Gilpin RK, 2003, DIOXINS HLTH, P89; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; Goad RT, 2004, TOXICOL MECH METHOD, V14, P233, DOI 10.1080/15376520490434476; Goldman L, 2004, PEDIATRICS, V113, P1146; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; Grova N, 2002, J AGR FOOD CHEM, V50, P4640, DOI 10.1021/jf0201071; Gultekin I, 2007, J ENVIRON MANAGE, V85, P816, DOI 10.1016/j.jenvman.2007.07.020; Gwinn MR, 2005, ENVIRON HEALTH PERSP, V113, P1046, DOI 10.1289/ehp.7311; HADDOW A, 1964, BRIT J CANCER, V18, P667, DOI 10.1038/bjc.1964.76; Hamm U., 2005, IPW, V2, P47; Hamm U., 2005, IPW, V1, P45; Hardell L, 2006, INT J ANDROL, V29, P228, DOI 10.1111/j.1365-2605.2005.00622.x; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; Hayes T, 2003, ENVIRON HEALTH PERSP, V111, P568, DOI 10.1289/ehp.5932; Hayes TB, 2002, P NATL ACAD SCI USA, V99, P5476, DOI 10.1073/pnas.082121499; Homma-Takeda S, 2001, TOXICOLOGY, V169, P25, DOI 10.1016/S0300-483X(01)00487-5; *IARC, 1998, POL BIPH, V18, P43; IARC, 1983, MON EV CARC RISK CHE, V32, P1; *IRIS, 2005, ENV PROT AG POL BIPH; Ishihara A, 2003, GEN COMP ENDOCR, V134, P36, DOI 10.1016/S0016-6480(03)00197-7; Jarup L, 2003, BRIT MED BULL, V68, P167, DOI 10.1093/bmb/ldg032; Jeong SH, 2006, TOXICOLOGY, V220, P189, DOI 10.1016/j.tox.2006.01.005; Jiang K, 1997, CHEMOSPHERE, V34, P941; Jobling S, 1996, ENVIRON TOXICOL CHEM, V15, P194, DOI 10.1897/1551-5028(1996)015&lt;0194:IOTGIR&gt;2.3.CO;2; Johansson M, 1998, ENVIRON HEALTH PERSP, V106, P769, DOI 10.2307/3434119; Kang HG, 2004, TOXICOLOGY, V199, P219, DOI 10.1016/j.tox.2004.02.025; Katsumata H, 2004, J PHOTOCH PHOTOBIO A, V162, P297, DOI 10.1016/s1010-6030(03)00374-5; Kawauchi H, 2002, ENDOCRINOLOGY, V143, P4916, DOI 10.1210/en.2002-220810; Kelce WR, 1997, J MOL MED-JMM, V75, P198, DOI 10.1007/s001090050104; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Kim IY, 2004, J REPROD DEVELOP, V50, P245, DOI 10.1262/jrd.50.245; Kolonel LN, 1996, CANCER CAUSE CONTROL, V7, P83, DOI 10.1007/BF00115640; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kulbat E, 2003, POL J ENVIRON STUD, V12, P635; Lemaire G, 2004, TOXICOL APPL PHARM, V196, P235, DOI 10.1016/j.taap.2003.12.011; Li CT, 2003, ENVIRON HEALTH PERSP, V111, P483, DOI 10.1289/ehp.5518; Li MH, 1997, REV TOXICOL, V1, P71; Liu ZH, 2009, SCI TOTAL ENVIRON, V407, P731, DOI 10.1016/j.scitotenv.2008.08.039; LOGANATHAN BG, 1994, AMBIO, V23, P187; Lu SY, 2004, J TOXICOL ENV HEAL A, V67, P1501, DOI 10.1080/15287390490486833; Mabilia R, 2004, ANN CHIM-ROME, V94, P733, DOI 10.1002/adic.200490091; Mackenzie CA, 2005, ENVIRON HEALTH PERSP, V113, P1295, DOI 10.1289/chp.8479; Malato S, 2002, CATAL TODAY, V76, P209, DOI 10.1016/S0920-5861(02)00220-1; Malato S, 2001, ENVIRON SCI TECHNOL, V35, P4359, DOI 10.1021/es000289k; Mankame T, 2004, TOXICOL IND HEALTH, V20, P89, DOI 10.1191/0748233704th098oa; Markey CM, 2001, BIOL REPROD, V65, P1215; Mascolo G, 2008, J HAZARD MATER, V152, P1138, DOI 10.1016/j.jhazmat.2007.07.120; Mathur V, 2002, ENVIRON INT, V28, P331, DOI 10.1016/S0160-4120(02)00031-4; McIntyre BS, 2001, TOXICOL SCI, V62, P236, DOI 10.1093/toxsci/62.2.236; McRill C, 2000, J OCCUP ENVIRON MED, V42, P4, DOI 10.1097/00043764-200001000-00004; MenchiniFabris F, 1996, ANDROLOGIA, V28, P304; Mendola P, 1997, AM J EPIDEMIOL, V146, P955; METZLER M, 2001, ENDOCRINE DISRUPTORS, V1, P63; Meulenberg EP, 2002, EUR J LIPID SCI TECH, V104, P131, DOI 10.1002/1438-9312(200202)104:2&lt;131::AID-EJLT131&gt;3.3.CO;2-S; Mocarelli P, 2008, ENVIRON HEALTH PERSP, V116, P70, DOI 10.1289/ehp.10399; Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182; Muir D, 1999, SCI TOTAL ENVIRON, V230, P83, DOI 10.1016/S0048-9697(99)00037-6; Mukherjee A, 2006, J HEALTH POPUL NUTR, V24, P142; Munoz de Toro MM, 2005, ENDOCRINOLOGY, V146, P4138, DOI DOI 10.1210/EN.2005-0340; Mylchreest E, 1999, TOXICOL APPL PHARM, V156, P81, DOI 10.1006/taap.1999.8643; Mylchreest E, 1998, TOXICOL SCI, V43, P47, DOI 10.1093/toxsci/43.1.47; Nadal M, 2004, ENVIRON POLLUT, V132, P1, DOI 10.1016/j.envpol.2004.04.003; Nampoothiri LP, 2006, REPROD TOXICOL, V21, P179, DOI 10.1016/j.reprotox.2005.07.010; Nicolopoulou-Stamati P, 2001, HUM REPROD UPDATE, V7, P323, DOI 10.1093/humupd/7.3.323; Nimrod AC, 1996, CRIT REV TOXICOL, V26, P335, DOI 10.3109/10408449609012527; Nogueira RFP, 2005, SOL ENERGY, V79, P384, DOI 10.1016/j.solener.2005.02.019; NORDSTROM S, 1979, HEREDITAS, V90, P291; OLIE K, 1977, Chemosphere, V6, P455, DOI 10.1016/0045-6535(77)90035-2; Parks LG, 2000, TOXICOL SCI, V58, P339, DOI 10.1093/toxsci/58.2.339; Perera F, 2002, CANCER EPIDEM BIOMAR, V11, P1134; Perera FP, 2005, ENVIRON HEALTH PERSP, V113, P1062, DOI 10.1289/ehp.7908; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; Petrovic M, 2004, ANAL BIOANAL CHEM, V378, P549, DOI 10.1007/s00216-003-2184-7; Pokhrel D, 2004, SCI TOTAL ENVIRON, V333, P37, DOI 10.1016/j.scitotenv.2004.05.017; Przyrembel H, 2000, ADV EXP MED BIOL, V478, P307; Pulgar R, 2000, ENVIRON HEALTH PERSP, V108, P21, DOI 10.2307/3454291; RAI UN, 2002, HLTH HAZARDS HEAVY M; ROMAN BL, 1998, REPROD DEV TOXICOLOG, P593; Ross G, 2004, ECOTOX ENVIRON SAFE, V59, P275, DOI 10.1016/j.ecoenv.2004.06.003; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Santodonato J, 1997, CHEMOSPHERE, V34, P835, DOI 10.1016/S0045-6535(97)00012-X; Satarug S, 2004, ENVIRON HEALTH PERSP, V112, P1099, DOI 10.1289/ehp.6751; Satoh H, 2003, TOHOKU J EXP MED, V201, P1, DOI 10.1620/tjem.201.1; Schantz SL, 2001, ENVIRON HEALTH PERSP, V109, P1197, DOI 10.2307/3454741; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Schreinemachers DM, 2003, ENVIRON HEALTH PERSP, V111, P1259, DOI 10.1289/ehp.5830; Schuurs AHB, 1999, J DENT, V27, P249, DOI 10.1016/S0300-5712(97)00039-0; Scippo ML, 2004, ANAL BIOANAL CHEM, V378, P664, DOI 10.1007/s00216-003-2251-0; Sharara FI, 1998, FERTIL STERIL, V70, P613, DOI 10.1016/S0015-0282(98)00253-2; Sharpe RM, 2004, BRIT MED J, V328, P447, DOI 10.1136/bmj.328.7437.447; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sharpe RM, 2006, BEST PRACT RES CL EN, V20, P91, DOI 10.1016/j.beem.2005.09.005; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Shen W, 2000, Wei Sheng Yan Jiu, V29, P75; Shultz VD, 2001, TOXICOL SCI, V64, P233, DOI 10.1093/toxsci/64.2.233; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; Simko P, 2002, J CHROMATOGR B, V770, P3; Simoncini T, 2003, EUR J ENDOCRINOL, V148, P281, DOI 10.1530/eje.0.1480281; Sinawat Supat, 2000, Journal of the Medical Association of Thailand, V83, P880; Singer PL, 1949, JAMA-J AM MED ASSOC, V140, P1249; Siu ER, 2009, TOXICOL APPL PHARM, V238, P240, DOI 10.1016/j.taap.2009.01.028; Skakkebaek NE, 2002, HORM RES, V57, P43, DOI 10.1159/000058100; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; SMITH AH, 1992, ENVIRON HEALTH PERSP, V97, P259, DOI 10.2307/3431362; Snyder SA, 2003, ENVIRON ENG SCI, V20, P449, DOI 10.1089/109287503768335931; Soares A, 2008, ENVIRON INT, V34, P1033, DOI 10.1016/j.envint.2008.01.004; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905; Storrs SI, 2004, ENVIRON HEALTH PERSP, V112, P1054, DOI 10.1289/ehp.6821; Sultan C, 2001, MOL CELL ENDOCRINOL, V178, P99, DOI 10.1016/S0303-7207(01)00430-0; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; Tang HW, 1999, J APPL TOXICOL, V19, P167, DOI 10.1002/(SICI)1099-1263(199905/06)19:3&lt;167::AID-JAT560&gt;3.0.CO;2-8; Tao S, 2004, SCI TOTAL ENVIRON, V320, P11, DOI 10.1016/S0048-9697(03)00453-4; Tapio S, 2006, MUTAT RES-REV MUTAT, V612, P215, DOI 10.1016/j.mrrev.2006.02.001; THEOBALD HM, 2003, DIOXINS HLTH, P329; THOMAS JA, 1984, CRC CR REV TOXICOL, V13, P283, DOI 10.3109/10408448409023761; Thompson CJ, 2004, ENDOCRINOLOGY, V145, P1227, DOI 10.1210/en.2003-1475; Thompson G, 2001, BIORESOURCE TECHNOL, V77, P275, DOI 10.1016/S0960-8524(00)00060-2; Tilson Hugh A., 1998, Environmental Health Perspectives, V106, P807, DOI 10.2307/3434193; Tong S., 1999, J ENV MED, V1, P103, DOI DOI 10.1002/(SICI)20103::; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Tsapakis M, 2005, ENVIRON POLLUT, V133, P147, DOI 10.1016/j.envpol.2004.05.012; *US EPA, 1984, 540186013 EPA ENV CR; Vasseur P, 2006, CHEMOSPHERE, V62, P1033, DOI 10.1016/j.chemosphere.2005.05.043; Vethaak AD, 2005, CHEMOSPHERE, V59, P511, DOI 10.1016/j.chemosphere.2004.12.053; Vidal G, 2005, J ENVIRON MANAGE, V74, P317, DOI 10.1016/j.jenvman.2004.09.008; Vinceti M, 2007, SCI TOTAL ENVIRON, V373, P77, DOI 10.1016/j.scitotenv.2006.11.005; Waliszewski SM, 2000, SALUD PUBLICA MEXICO, V42, P384, DOI 10.1590/S0036-36342000000500003; WALTER BA, 1988, TOXICOL APPL PHARM, V96, P258, DOI 10.1016/0041-008X(88)90085-3; Watanabe C, 2003, J ENVIRON SCI HEAL A, V38, P129, DOI 10.1081/ESE-120016885; Weltje L, 2005, HUM EXP TOXICOL, V24, P431, DOI 10.1191/0960327105ht551oa; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; *WHO, 1991, ENV HLTH CRIT 118 IN; Will IBS, 2004, SEP PURIF TECHNOL, V34, P51, DOI 10.1016/S1383-5866(03)00174-6; Wintgens T, 2002, DESALINATION, V146, P387, DOI 10.1016/S0011-9164(02)00519-2; Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L; Xu XR, 2009, J HAZARD MATER, V164, P527, DOI 10.1016/j.jhazmat.2008.08.027; Yoon Y, 2004, J ENVIRON ENG-ASCE, V130, P1460, DOI 10.1061/(ASCE)0733-9372(2004)130:12(1460); Yoon Y, 2006, J MEMBRANE SCI, V270, P88, DOI 10.1016/j.memsci.2005.06.045; Yoshida M, 2002, TOHOKU J EXP MED, V196, P79, DOI 10.1620/tjem.196.79; Zahir F, 2005, ENVIRON TOXICOL PHAR, V20, P351, DOI 10.1016/j.etap.2005.03.007; Zhao JM, 2008, J HAZARD MATER, V155, P305, DOI 10.1016/j.jhazmat.2007.11.07519432CSIRO PUBLISHINGCOLLINGWOOD150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIAREPROD FERT DEVELOPDiscipline: Developmental Biology; Reproductive Biology; Zoology736PF</notes>
    <keywords>ADVANCED OXIDATION PROCESSES; Alkylphenol; ALKYLPHENOLS; ASSOCIATION; BIOLOGY; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CADMIUM; CANCER; CELL; CELLS; Cryptorchidism; CYCLE; DEFECTS; DIOXIN; DIOXINS; DISEASE; DISORDERS; EDC; EDCs; ENDOCRINE; Endocrine disrupter; ENDOCRINE DISRUPTERS; Endocrine disrupting compounds; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENDOCRINE-DISRUPTING COMPOUNDS; ENDOMETRIOSIS; environment; environmental pollutants; ENVIRONMENTAL-POLLUTANTS; fertility; FETAL-RAT TESTES; FOOD; GERM-CELLS; HEALTH; Hormones; HUMANS; IMPACT; IN-UTERO EXPOSURE; Male; MALE SEXUAL-DIFFERENTIATION; Metals; p21; P8; PATHWAY; pediatric; PERSISTENT ORGANIC POLLUTANTS; PERSONAL CARE PRODUCTS; PESTICIDES; PHOTO-FENTON DEGRADATION; phthalate; Phthalates; POLLUTANTS; POLYCHLORINATED-BIPHENYLS; POLYCYCLIC AROMATIC-HYDROCARBONS; PROTEIN; PROTEINS; PULP; Reproduction; reproductive disorders; REPRODUCTIVE HEALTH; reproductive problems; Review; RISK; SPERM; sperm count and quality; TESTICULAR DYSGENESIS SYNDROME; toxicology; UPDATE; waste water; WASTE-WATER TREATMENT; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>403</startpage>
    <endpage>416</endpage>
    <journalfull>Reproduction Fertility and Development</journalfull>
    <issue>3</issue>
    <volume>23</volume>
    <abstract>There is increasing concern about chemical pollutants that are able to mimic hormones, the so-called endocrine-disrupting compounds (EDCs), because of their structural similarity to endogenous hormones, their ability to interact with hormone transport proteins or because of their potential to disrupt hormone metabolic pathways. Thus, the effects of endogenous hormones can be mimicked or, in some cases, completely blocked. A substantial number of environmental pollutants, such as polychlorinated biphenyls, dioxins, polycyclic aromatic hydrocarbons, phthalates, bisphenol A, pesticides, alkylphenols and heavy metals (arsenic, cadmium, lead, mercury), have been shown to disrupt endocrine function. These compounds can cause reproductive problems by decreasing sperm count and quality, increasing the number of testicular germ cells and causing male breast cancer, cryptorchidism, hypospadias, miscarriages, endometriosis, impaired fertility, irregularities of the menstrual cycle, and infertility. Although EDCs may be released into the environment in different ways, the main sources is industrial waste water. The present paper critically reviews the current knowledge of the impact of EDCs on reproductive disorders in humans</abstract>
    <url>WOS:000288505900002</url>
    <isbnorissn>1031-3613</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>432</id>
    <title>Bisphenol A at Low Concentrations Regulates the Expression of Growth Hormone in a Breast Cancer and Placental Cell Line</title>
    <authors>Balakrishnan,B.; Pandey,V.; Perry,J.; Lobie,P.E.; Mitchell,M.D.</authors>
    <availability>[Balakrishnan, Biju; Pandey, Vijay; Perry, Jo; Lobie, Peter E.; Mitchell, Murray D.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand. [Balakrishnan, Biju; Mitchell, Murray D.] Univ Auckland, Natl Res Ctr Growth &amp; Dev, Auckland 1, New Zealand.</availability>
    <date>2009</date>
    <notes>JEnglishMeeting Abstract00SAGE PUBLICATIONS INCTHOUSAND OAKS2455 TELLER RD, THOUSAND OAKS, CA 91320 USAREPROD SCIMARDiscipline: Obstetrics &amp; Gynecology; Reproductive Biology410WU</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CELL-LINE; EXPRESSION; GROWTH; Hormone; LINE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>149A</startpage>
    <endpage>150A</endpage>
    <journalfull>Reproductive Sciences</journalfull>
    <issue>3</issue>
    <volume>16</volume>
    <url>WOS:000263609800279</url>
    <isbnorissn>1933-7191</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>198</id>
    <title>Pregnancy, endocrinian troublemakers, sweeteners and chemical products: what do we know in 2011?</title>
    <authors>Barouki,R.; Fenichel,P.; Houdeau,E.; Buhler,M.</authors>
    <availability>[Barouki, R.] Univ Paris 05, INSERM, UMR S 747, Paris, France. [Fenichel, P.] CHU Nice, INSERM, U895, Nice, France. [Houdeau, E.] INRA, F-31931 Toulouse, France.</availability>
    <date>2012</date>
    <notes>JFrenchArticleBarouki, R (reprint author), Univ Paris 05, INSERM, UMR S 747, Paris, Francechristian.rayr@hautdepage.comClayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Dietert RR, 2010, ENVIRON HEALTH PERSP, V118, P1091, DOI 10.1289/ehp.1001971; Halldorsson TI, 2010, AM J CLIN NUTR, V92, P626, DOI 10.3945/ajcn.2009.28968; Hardell L, 2003, ENVIRON HEALTH PERSP, V111, P930, DOI 10.1289/ehp.5816; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Luque EH, 2001, BIO REPROD, V65, P1215; Marmugi A, 2012, HEPATOLOGY, V55, P395, DOI 10.1002/hep.24685; Munoz-de-Toro M, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1534; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Philippat C, 2012, ENVIRON HEALTH PERSP, V120, P464, DOI 10.1289/ehp.1103634; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Salameh PR, 2003, EUR RESPIR J, V22, P507, DOI 10.1183/09031936.03.00107403150ELSEVIER MASSONMILANOVIA PALEOCAPA 7, 20121 MILANO, ITALYJ GYNECOL OBST BIO RAUGSIDiscipline: Obstetrics &amp; Gynecology004ZA</notes>
    <keywords>BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELLS; CHILDREN; EXPOSURE; HEALTH; PREGNANCY; RISK</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1</startpage>
    <endpage>4</endpage>
    <journalfull>Journal de Gynecologie Obstetrique et Biologie de la Reproduction</journalfull>
    <issue>3</issue>
    <volume>41</volume>
    <url>WOS:000308718900001</url>
    <isbnorissn>0368-2315</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>85</id>
    <title>Evidence for Sexually Dimorphic Associations Between Maternal Characteristics and Anogenital Distance, a Marker of Reproductive Development</title>
    <authors>Barrett,E.S.; Parlett,L.E.; Redmon,J.B.; Swan,S.H.</authors>
    <availability>[Barrett, Emily S.] Univ Rochester, Sch Med &amp; Dent, Dept Obstet &amp; Gynecol, Rochester, NY 14642 USA. [Parlett, Lauren E.] Univ Rochester, Sch Med &amp; Dent, Dept Publ Hlth Sci, Rochester, NY 14642 USA. [Redmon, J. Bruce] Univ Minnesota, Sch Med, Dept Internal Med, Minneapolis, MN 55455 USA. [Swan, Shanna H.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleBarrett, ES (reprint author), Univ Rochester, Sch Med &amp; Dent, Dept Obstet &amp; Gynecol, 601 Elmwood Ave,Box 668, Rochester, NY 14642 USAEmily_barrett@urmc.rochester.eduAnway MD, 2006, J ANDROL, V27, P868, DOI 10.2164/jandrol.106.000349; Arslan AA, 2006, CANCER EPIDEM BIOMAR, V15, P2123, DOI 10.1158/1055-9965.EPI-06-0470; Aschim EL, 2004, INT J ANDROL, V27, P213, DOI 10.1111/j.1365-2605.2004.00473.x; Ball ER, 2010, HORM BEHAV, V57, P313, DOI 10.1016/j.yhbeh.2009.12.013; Ball S, 2013, ULTRASOUND OBST GYN, V41, P33, DOI 10.1002/uog.11209; Barba M, 2006, CANCER CAUSE CONTROL, V17, P395, DOI 10.1007/s10552-005-0481-5; Barlow NJ, 2004, TOXICOL PATHOL, V32, P79, DOI 10.1080/01926230490265894; BERGER NG, 1984, OBSTET GYNECOL, V63, P260; Bukowski R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040199; Castano-Vinyals G, 2012, BJU INT, V110, pE707, DOI 10.1111/j.1464-410X.2012.11516.x; Chen T, 2010, CANCER CAUSE CONTROL, V21, P719, DOI 10.1007/s10552-009-9500-2; Cook MB, 2008, INT J CANCER, V122, P2600, DOI 10.1002/ijc.23424; Cook MB, 2009, INT J EPIDEMIOL, V38, P1532, DOI 10.1093/ije/dyp287; DAHLOF LG, 1978, PHYSIOL BEHAV, V21, P673, DOI 10.1016/0031-9384(78)90149-X; Eisenberg ML, 2012, BJU INT, V110, pE927, DOI 10.1111/j.1464-410X.2012.11154.x; Eisenberg ML, 2012, J UROLOGY, V187, P594, DOI 10.1016/j.juro.2011.10.041; Eisenberg ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018973; Eisenberg ML, 2012, BJU INT, V110, pE711, DOI 10.1111/j.1464-410X.2012.11524.x; Eisenberg ML, 2012, INT J ANDROL, V35, P726, DOI 10.1111/j.1365-2605.2012.01275.x; Ekbom A, 1997, J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; English PB, 2003, CANCER CAUSE CONTROL, V14, P815, DOI 10.1023/B:CACO.0000003812.53344.48; Faupel-Badger JM, 2011, CANCER CAUSE CONTROL, V22, P1587, DOI 10.1007/s10552-011-9835-3; Fowler PA, 2009, J CLIN ENDOCR METAB, V94, P4688, DOI 10.1210/jc.2009-0994; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; Hickey M, 2009, J CLIN ENDOCR METAB, V94, P3714, DOI 10.1210/jc.2009-0544; Hodgson ME, 2004, BREAST CANCER RES, V6, pR656, DOI 10.1186/bcr931; Howdeshell KL, 2008, TOXICOL SCI, V102, P371, DOI 10.1093/toxsci/kfm306; Hsieh MH, 2012, HUM REPROD, V27, P1577, DOI 10.1093/humrep/des087; Hurd PL, 2008, ARCH SEX BEHAV, V37, P9, DOI 10.1007/s10508-007-9259-z; Innes K, 2000, AM J EPIDEMIOL, V152, P1121, DOI 10.1093/aje/152.12.1121; Kaijser M, 2002, PAEDIATR PERINAT EP, V16, P149, DOI 10.1046/j.1365-3016.2002.00397.x; Kemme K, 2007, HORM BEHAV, V51, P387, DOI 10.1016/j.yhbeh.2006.12.009; Kendig EL, 2012, INT J TOXICOL, V31, P537, DOI 10.1177/1091581812463254; Kossack N, 2008, PLOS MED, V5, P669, DOI 10.1371/journal.pmed.0050088; Kurzrock EA, 2000, J UROLOGY, V164, P1786, DOI 10.1016/S0022-5347(05)67107-8; LEVY JR, 1995, P SOC EXP BIOL MED, V208, P60; Lofrano-Porto A, 2007, NEW ENGL J MED, V357, P897, DOI 10.1056/NEJMoa071999; Longnecker MP, 2007, AM J EPIDEMIOL, V165, P1015, DOI 10.1093/aje/kwk109; MacLeod DJ, 2010, INT J ANDROL, V33, P279, DOI 10.1111/j.1365-2605.2009.01005.x; Main KM, 2009, ENDOCRIN DEV, V14, P167, DOI 10.1159/000207485; Manikkam M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046249; Manikkam M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031901; Mendiola J, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-90; Mendiola J, 2011, ENVIRON HEALTH PERSP, V119, P958, DOI 10.1289/ehp.1103421; Miao MH, 2011, BIRTH DEFECTS RES A, V91, P867, DOI 10.1002/bdra.22845; Moller H, 1997, CANCER CAUSE CONTROL, V8, P904, DOI 10.1023/A:1018472530653; Mylchreest E, 1998, TOXICOL SCI, V43, P47, DOI 10.1093/toxsci/43.1.47; Myrskyla M, 2012, DEMOGRAPHY, V49, P1231, DOI 10.1007/s13524-012-0132-x; Newcomb PA, 1997, CANCER EPIDEM BIOMAR, V6, P151; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Papadopoulou E, 2013, PAEDIATR PERINAT EP, V27, P89, DOI 10.1111/ppe.12022; Potischman N, 2005, CANCER EPIDEM BIOMAR, V14, P1514, DOI 10.1158/1055-9965.EPI-04-0869; Richiardi L, 2002, BRIT J CANCER, V87, P545, DOI 10.1038/sj.bjc.6600470; Sabroe S, 1998, INT J CANCER, V78, P140, DOI 10.1002/(SICI)1097-0215(19981005)78:2&lt;140::AID-IJC2&gt;3.0.CO;2-Z; Salazar-Martinez Eduardo, 2004, Environ Health, V3, P8, DOI 10.1186/1476-069X-3-8; Sathyanarayana S, 2010, INT J ANDROL, V33, P317, DOI 10.1111/j.1365-2605.2009.01044.x; Sir-Petermann T, 2002, HUM REPROD, V17, P2573, DOI 10.1093/humrep/17.10.2573; Smits L, 1999, PAEDIATR PERINAT EP, V13, P408; Smits LJ, 2000, SOC BIOL, V47, P18; Smits LJ, 1998, SOC BIOL, V45, P143; Smits LJ, 1997, EPIDEMIOLOGY, V8, P524, DOI 10.1097/00001648-199709000-00009; Smits LJ, 2002, INT J EPIDEMIOL, V31, P349, DOI 10.1093/ije/31.2.349; Sonke GS, 2007, ONCOL RES, V16, P383; St John J C, 1997, Nat Med, V3, P124, DOI 10.1038/nm0297-124c; Steiner AZ, 2010, AM J EPIDEMIOL, V172, P140, DOI 10.1093/aje/kwq092; Suzuki Y, 2012, INT J ANDROL, V35, P236, DOI 10.1111/j.1365-2605.2011.01190.x; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P414, DOI 10.1289/ehp.5927; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P571, DOI 10.1038/bjc.1987.116; Troisi R, 2008, BRIT J CANCER, V99, P1161, DOI 10.1038/sj.bjc.6604639; van den Driesche S, 2011, INT J ANDROL, V34, pE578, DOI 10.1111/j.1365-2605.2011.01175.x; van Weissenbruch MM, 2005, ENDOCRIN DEV, V8, P15; Wang Yu-Chi, 2005, Fertil Steril, V84, P509; Weir HK, 2000, INT J CANCER, V87, P438, DOI 10.1002/1097-0215(20000801)87:3&lt;438::AID-IJC20&gt;3.0.CO;2-1; Weiser M, 2008, SCHIZOPHRENIA BULL, V34, P1042, DOI 10.1093/schbul/sbn109; Weiss HA, 1997, EPIDEMIOLOGY, V8, P181, DOI 10.1097/00001648-199703000-00010; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; Welsh M, 2008, J CLIN INVEST, V118, P1479, DOI 10.1172/JCI34241; Westergaard T, 1998, BRIT J CANCER, V77, P1180, DOI 10.1038/bjc.1998.196; Wisniewski AB, 2003, J UROLOGY, V169, P1582, DOI 10.1097/01.ju.0000046780.23389.e0; Wisniewski AB, 2005, PHYSIOL BEHAV, V84, P327, DOI 10.1016/j.physbeh.2004.12.008; Wuu J, 2002, EUR J CANCER PREV, V11, P283, DOI 10.1097/00008469-200206000-00012841OXFORD UNIV PRESS INCCARYJOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USAAM J EPIDEMIOLJAN 1Discipline: Public, Environmental &amp; Occupational Health280WI</notes>
    <keywords>anogenital distance; BIRTH CHARACTERISTICS; BISPHENOL-A; breast cancer; BREAST-CANCER; BREAST-CANCER RISK; CANCER; DI(N-BUTYL) PHTHALATE; epidemiologic studies; EXPOSURE; FAMILY RECONSTITUTIONS; HORMONE CONCENTRATIONS; HUMANS; IN-UTERO EXPOSURE; Male; maternal age; mechanism; MODEL; PARENTAL AGE; PREGNANCY; PREGNANCY CHARACTERISTICS; prenatal hormones; Reproduction; sex differences; TESTICULAR DYSGENESIS SYNDROME</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>57</startpage>
    <endpage>66</endpage>
    <journalfull>American Journal of Epidemiology</journalfull>
    <issue>1</issue>
    <volume>179</volume>
    <abstract>Data from animal models, historical cohorts, and modern epidemiologic studies have suggested that maternal characteristics can affect reproductive health of offspring; however, distinguishing between prenatal and postnatal contributions is difficult. Anogenital distance (AGD), the distance from the anus to the genitals, is believed to be a biomarker of prenatal androgen exposure in many species, and in humans it has been associated with several adult reproductive health outcomes. We used data from a pregnancy cohort study conducted in 4 US cities from 19992005 to examine whether AGD measurements in infants were associated with maternal self-reported age at conception, age at menarche, age at first birth, parity, and gravidity. AGD was measured in 289 infants (140 male, 149 female) born to study participants. After adjustment for relevant covariates, in linear regression models stratified by infant sex, maternal age was positively associated with AGD in male infants (AGD, anus to penis: 0.50, P 0.002; AGD, anus to scrotum: 0.29, P 0.02) but not female infants. Parity was inversely associated with AGD (anus to scrotum; 1.68, P 0.03) in male infants. No other maternal characteristic predicted AGD in either sex. The mechanism underlying the unexpected relationship between maternal characteristics and AGD is unknown; however, we suggest several possibilities for future study</abstract>
    <url>WOS:000329061100009</url>
    <isbnorissn>0002-9262</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>252</id>
    <title>Bisphenol-A in Canned Food Products: Is It Really Required?</title>
    <authors>Batra,T.</authors>
    <availability>Voice Earth Int, Marlborough, MA 01752 USA.</availability>
    <date>2011</date>
    <notes>JEnglishLetterBatra, T (reprint author), Voice Earth Int, 225 Cedar Hill Rd,Suite 200, Marlborough, MA 01752 USAtbatra@voicefbrearth.orgBenachour N, 2009, TOXICOL APPL PHARM, V241, P322, DOI 10.1016/j.taap.2009.09.005; Bontempo P, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-48; Burridge E., 2003, EUR CHEM NEWS, P14; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Carwile JL, 2011, JAMA-J AM MED ASSOC, V306, P2218, DOI 10.1001/jama.2011.1721; Cavalieri EL, 2010, IUBMB LIFE, V62, P746, DOI 10.1002/iub.376; CERHR, 2007, NTP CERHR EXP PAN RE; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; European Union, 2003, EU RISK ASS REP BPA; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Goodman JE, 2006, CRIT REV TOXICOL, V36, P387, DOI 10.1080/10408440600758317; Howdeshell KL, 1999, NATURE, V401, P763; Lawson C, 2011, BIOL REPROD, V84, P79, DOI 10.1095/biolreprod.110.084814; Morck TJ, 2010, REPROD TOXICOL, V30, P131, DOI 10.1016/j.reprotox.2010.02.007; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P914, DOI 10.1289/ehp.1003170; Schonfelder G, 2002, NEOPLASIA, V4, P98, DOI 10.1038/sj.neo.7900212; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; US EPA, 2004, HIGH PROD VOL HPV CH; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; WEBER L, 2011, BIOL REPROD, V85, P490, DOI DOI 10.1095/BI0LREPR0D.110.090431; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Willhite CC, 2008, J TOXICOL ENV HEAL B, V11, P69, DOI 10.1080/10937400701724303; Zhu HT, 2010, ONCOL REP, V23, P129, DOI 10.3892/or_00000614270INST MEDICAL RESEARCH &amp; OCCUPATIONAL HEALTHZAGREB2 KSAVERSKA ST P O BOX 291, ZAGREB, 00000, CROATIAARH HIG RADA TOKSIKODECDiscipline: Public, Environmental &amp; Occupational Health; Toxicology873GV</notes>
    <keywords>bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELLS; FOOD; HEALTH; HUMAN EXPOSURE; Neoplasia; Occupational; RISK; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>381</startpage>
    <endpage>384</endpage>
    <journalfull>Arhiv Za Higijenu Rada I Toksikologiju</journalfull>
    <issue>4</issue>
    <volume>62</volume>
    <url>WOS:000298870000011</url>
    <isbnorissn>0004-1254</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>145</id>
    <title>Well Water in Karst Regions of Northeastern Wisconsin Contains Estrogenic Factors, Nitrate, and Bacteria</title>
    <authors>Bauer,A.C.; Wingert,S.; Fermanich,K.J.; Zorn,M.E.</authors>
    <availability>[Bauer, Angela C.] Univ Wisconsin, Dept Human Biol, Green Bay, WI 54311 USA. [Wingert, Sarah] Univ Wisconsin, Environm Sci &amp; Policy Grad Program, Green Bay, WI 54311 USA. [Fermanich, Kevin J.; Zorn, Michael E.] Univ Wisconsin, Dept Nat &amp; Appl Sci, Green Bay, WI 54311 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleBauer, AC (reprint author), Univ Wisconsin, Dept Human Biol, 2420 Nicolet Dr, Green Bay, WI 54311 USAbauera@uwgb.eduBradbury K. R., 2010, ASSESSING SEASONAL V; Brown County Wisconsin, 2007, BROWN COUNT AN WAST; Calumet County Wisconsin, 2007, LAND WAT RES MAN PLA; Celico F, 2004, APPL ENVIRON MICROB, V70, P2843, DOI 10.1128/AEM.70.5.2843-2847.2004; Chen M, 2006, WATER QUAL RES J CAN, V41, P351; Cody RP, 2006, APPL STAT SAS PROGRA; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Colburn T., 1996, OUR STOLEN FUTURE AR; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Drewes JE, 2005, WATER ENVIRON RES, V77, P12, DOI 10.2175/106143005X41573; Erb K., 2007, FINAL REPORT NE WISC; Fleming LE, 1999, OCCUP ENVIRON MED, V56, P14; Hanselman TA, 2003, ENVIRON SCI TECHNOL, V37, P5471, DOI 10.1021/es034410+; Hanselman TA, 2006, J ENVIRON QUAL, V35, P695, DOI 10.2134/jeq2005.0282; Harper S., 2006, POLLUT ENG, P22; HERSCHLER RC, 1995, J ANIM SCI, V73, P2873; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hodges LC, 2000, TOXICOL SCI, V54, P355, DOI 10.1093/toxsci/54.2.355; Illinois Department of Agriculture, 2012, TITL 8 AGR AN; Irwin LK, 2001, AQUAT TOXICOL, V55, P49, DOI 10.1016/S0166-445X(01)00159-X; Karr C, 2012, J AGROMEDICINE, V17, P127, DOI 10.1080/1059924X.2012.658009; Kewaunee County Wisconsin, 2010, KEW COUNT LAND WAT R; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; National Oceanic and Atmospheric Association (NOAA), 2009, NAT OC ATM ADM GREEN; NRC, 1999, HORM ACT AG ENV; Panno SV, 2006, GROUND WATER, V44, P697, DOI 10.1111/j.1745-6584.2006.00240.x; Panter GH, 1998, AQUAT TOXICOL, V42, P243, DOI 10.1016/S0166-445X(98)00038-1; Pell AN, 1997, J DAIRY SCI, V80, P2673; Peterson EW, 2000, J ENVIRON QUAL, V29, P826; Sakaue M, 2001, J OCCUP HEALTH, V43, P185, DOI 10.1539/joh.43.185; Shappell NW, 2006, J ENVIRON QUAL, V35, P122, DOI 10.2134/jeq2004.0464; Shappell NW, 2007, ENVIRON SCI TECHNOL, V41, P444, DOI 10.1021/es061268e; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Soliman MA, 2007, WATER ENVIRON RES, V79, P156, DOI 10.2175/106143006X111961; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; TONIOLO PG, 1995, J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Toppari Jorma, 2002, Cad Saude Publica, V18, P413, DOI 10.1590/S0102-311X2002000200005; US EPA, 2009, 816F09004 US EPA; Vesper D.J., 2001, SPELEOGENESIS EVOL K, V1, P1; Weir HK, 2000, INT J CANCER, V87, P438, DOI 10.1002/1097-0215(20000801)87:3&lt;438::AID-IJC20&gt;3.0.CO;2-1; Wendt K., 2007, 10107041A LACH INSTR; Wisconsin Department of Natural Resources, 2010, 140 NR WISC DEP NAT; Wisconsin Department of Natural Resources, 2002, 151 NR WISC DEP NAT450WATER ENVIRONMENT FEDERATIONALEXANDRIA601 WYTHE ST, ALEXANDRIA, VA 22314-1994 USAWATER ENVIRON RESAPRDiscipline: Engineering; Environmental Sciences &amp; Ecology; Marine &amp; Freshwater Biology; Water Resources161CZ</notes>
    <keywords>AQUIFERS; ASSOCIATION; BIOLOGY; BISPHENOL-A EXPOSURE; BREAST-CANCER; CANCER; CHEMICALS; coliform; DISRUPTING CHEMICALS; E-SCREEN ASSAY; EDCs; EFFLUENTS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruption; endocrine disruptors (EDCs); enterococci; environment; Escherichia coli; ESTRADIOL; Estrogenicity; groundwater; HEALTH; INDUCTION; MANURE; nitrate; PHARMACEUTICALS; POLLUTANTS; SAMPLES; WASTE-WATER; WATER; WATER SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>318</startpage>
    <endpage>326</endpage>
    <journalfull>Water Environment Research</journalfull>
    <issue>4</issue>
    <volume>85</volume>
    <abstract>Well water in karst regions is particularly susceptible to contamination by various nonpoint source pollutants such as nitrate, fecal bacteria, and endocrine disrupting chemicals (EDCs). This study analyzed 40 wells in heavily farmed karst areas of northeastern Wisconsin to determine whether these and other pollutants are present, and if so, whether their presence is (1) correlated with other contaminants and (2) exhibits seasonal variation. Nitrate, bacteria, and estrogenicity (indicating the presence of EDCs) were present in at least some of well water samples collected over the course of four time periods between the summers of 2008 and 2009. Although estrogenicity was greatest during the summer months, bacterial contamination was most prevalent during snowmelt. Levels of estrogenicity present in some well water samples approached a threshold concentration that is known to exert endocrine disruption in wildlife. Strong correlations between estrogenicity and other water quality parameters were not found</abstract>
    <url>WOS:000320170500004</url>
    <isbnorissn>1061-4303</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>406</id>
    <title>Blockade of estrogen receptor signaling to improve outlook for medulloblastoma sufferers</title>
    <authors>Belcher,S.M.</authors>
    <availability>Univ Cincinnati, Coll Med, Dept Pharmacol &amp; Cell Biophys, Cincinnati, OH 45267 USA.</availability>
    <date>2009</date>
    <notes>JEnglishEditorial MaterialBelcher, SM (reprint author), Univ Cincinnati, Coll Med, Dept Pharmacol &amp; Cell Biophys, 231 Albert Sabin Way,POB 670575, Cincinnati, OH 45267 USAscott.belcher@uc.eduBatistatou A, 2004, J CANCER RES CLIN, V130, P405, DOI 10.1007/s00432-004-0548-9; Belcher S M, 1999, Brain Res Dev Brain Res, V115, P57; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; Belcher SM, 2009, ENDOCRINOLOGY, V150, P1112, DOI 10.1210/en.2008-1363; Broniscer A, 2000, J CLIN ONCOL, V18, P1246; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Gatta G, 2002, CANCER, V95, P1767, DOI 10.1002/cncr.10833; Gurney JG, 2003, CANCER, V97, P663, DOI 10.1002/cncr.11094; Gurney JG, 2003, J CLIN ENDOCR METAB, V88, P4731, DOI 10.1210/jc.2003-030784; Jakab RL, 2001, J COMP NEUROL, V430, P396, DOI 10.1002/1096-9861(20010212)430:3&lt;396::AID-CNE1039&gt;3.0.CO;2-0; Kirby M, 2004, BIOCHEM BIOPH RES CO, V319, P753, DOI 10.1016/j.bbrc.2004.05.049; Lee SJ, 2001, ANNU REV PHARMACOL, V41, P569, DOI 10.1146/annurev.pharmtox.41.1.569; LESLIE KK, 1994, J SOC GYNECOL INVEST, V1, P238; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Mulhern RK, 2004, LANCET ONCOL, V5, P399, DOI 10.1016/S1470-2045(04)01507-4; Packer RJ, 1999, BRAIN DEV-JPN, V21, P75, DOI 10.1016/S0387-7604(98)00085-0; Puchner MJA, 2004, ANTICANCER RES, V24, P4195; Ries LAG, 1999, NIH PUB, V99-4649; Robins HI, 2006, NEURO-ONCOLOGY, V8, P47, DOI 10.1215/S1522851705000311; Rubin JB, 2002, CANCER CELL, V2, P7, DOI 10.1016/S1535-6108(02)00090-9; Spence AM, 2004, J NEURO-ONCOL, V70, P91, DOI 10.1023/B:NEON.0000040837.68411.97; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wong JK, 2003, J NEUROSCI, V23, P4984; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565261FUTURE MEDICINE LTDLONDONUNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLANDFUTURE ONCOLAUGDiscipline: Oncology489PZ</notes>
    <keywords>1; ACTIVATION; ADULT SURVIVORS; BISPHENOL-A; Brain; BRAIN-TUMORS; CANCER; CELL; CELL-LINE; CHILDHOOD-CANCER SURVIVOR; DEVELOPMENTAL BIOLOGY; ENDOCRINE; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; FUTURE; HIGH-DOSE TAMOXIFEN; MECHANISMS; oncology; RECEPTOR; signaling</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>751</startpage>
    <endpage>754</endpage>
    <journalfull>Future Oncology</journalfull>
    <issue>6</issue>
    <volume>5</volume>
    <url>WOS:000269434400002</url>
    <isbnorissn>1479-6694</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>332</id>
    <title>Fetal and neonatal exposure to the mycotoxin zearalenone induces phenotypic alterations in adult rat mammary gland</title>
    <authors>Belli,P.; Bellaton,C.; Durand,J.; Balleydier,S.; Milhau,N.; Mure,M.; Mornex,J.F.; Benahmed,M.; Le Jan,C.</authors>
    <availability>[Belli, Patrick; Balleydier, Sabine] Ecole Natl Vet Lyon, Serv Anatomopathol, F-69280 Marcy Letoile, France. [Bellaton, Claire; Durand, Jitka; Milhau, Nadege; Mure, Magali; Mornex, Jean-Francois; Le Jan, Christian] Univ Lyon, UMR 754, INRA UCBL ENVL EPHE Retrovirus &amp; Pathol Comparee, IFR Biosci Lyon Sud 128, F-69366 Lyon 07, France. [Benahmed, Mohamed] Hop Archet, INSERM, U895, Ctr Med Mol C3M, F-69280 Nice 02, France.</availability>
    <date>2010</date>
    <notes>JEnglishArticleLe Jan, C (reprint author), Univ Lyon, UMR 754, INRA UCBL ENVL EPHE Retrovirus &amp; Pathol Comparee, IFR Biosci Lyon Sud 128, 50 Ave Tony Garnier, F-69366 Lyon 07, Francelejan@univ-lyon1.frAbramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Althuis MD, 2005, INT J EPIDEMIOL, V34, P405, DOI 10.1093/ije/dyh414; ANDERSON L, 2000, ENVIRON HEALTH PER S, V3, P573; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; BARKER DJP, 1989, LANCET, V2, P577; Bullerman LB, 2007, INT J FOOD MICROBIOL, V119, P140, DOI 10.1016/j.ijfoodmicro.2007.07.035; Dees C, 1997, ENVIRON HEALTH PERSP, V105, P633, DOI 10.2307/3433382; Dey S, 2009, MED HYPOTHESES, V72, P652, DOI 10.1016/j.mehy.2008.10.025; Duffy C, 2007, CA-CANCER J CLIN, V57, P260, DOI 10.3322/CA.57.5.260; DURANDO M, 2007, ENV HLTH PERSPECT, V115, P80; FENTON S, 2006, ENDOCRINOLOGY, V147, pS16; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Fink-Gremmels J, 2007, ANIM FEED SCI TECH, V137, P326, DOI 10.1016/j.anifeedsci.2007.06.008; Heneweer M, 2007, TOXICOL SCI, V99, P303, DOI 10.1093/toxsci/kfm151; Hilakivi-Clarke L, 2007, CURR CANCER DRUG TAR, V7, P465; Irigaray P, 2007, BIOMED PHARMACOTHER, V61, P640, DOI 10.1016/j.biopha.2007.10.006; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Leblanc JC, 2005, FOOD ADDIT CONTAM, V22, P652, DOI 10.1080/02652030500159938; Maire M, 2005, ENDOCRINOLOGY, V146, P5135, DOI 10.1210/en.2005-0592; Mallis LM, 2003, J CHROMATOGR B, V796, P71, DOI 10.1016/j.jchromb.2003.08.003; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2001, BIOL REPROD, V65, P1215; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Parveen M, 2009, FEBS LETT, V583, P2377, DOI 10.1016/j.febslet.2009.06.035; PRELUSKY DB, 1990, J ENVIRON SCI HEAL B, V25, P87, DOI 10.1080/03601239009372678; Scientific Committee on Food (SCF), 2000, OP SCI COMM FOOD F 2; SILBERSTEIN G, 2001, MICROSC RES TECHNIQ, V51, P155; Tomaszewski J, 1998, Ginekol Pol, V69, P363; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vidnes A., 2003, SUBTASK ZEARALENONE, P241; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030344PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLOCTDiscipline: Food Science &amp; Technology; Toxicology659BW</notes>
    <keywords>ADULT; ADULT-RAT; BISPHENOL-A ALTERS; breast; BREAST-CANCER; CANCER; CELLS; DEATH; development; Dietary Exposure; DISORDERS; ENDOCRINE; environmental endocrine disruptors; Estrogen; EXPOSURE; EXPRESSION; female; FEMALE RAT; FEMALE RATS; FETAL; FOOD; GLAND; GLAND DEVELOPMENT; HEALTH; HUMANS; HYPERPLASIA; In utero and perinatal exposure; IN-UTERO; INDUCTION; mammary gland; Mammary gland development; MAMMARY TISSUE; MAMMARY-GLAND; Mycotoxin; NEONATAL EXPOSURE; PHYTOESTROGENS; RAT; RATS; TISSUE; toxicology; TRACT; Wistar; XENOESTROGENS; Zearalenone</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2818</startpage>
    <endpage>2826</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <issue>10</issue>
    <volume>48</volume>
    <abstract>Zearalenone is a mycotoxin that is widespread in cereal food. We questioned whether this mycotoxin, administered during known critical exposure periods such as the fetal period and the first days of life, at doses compatible with mean daily intake in humans, could have an effect on mammary gland development in rodents. Wistar female rats were exposed to zearalenone (0.2 mu g/kg to 5 mg/kg) during the last 14 days of fetal life and the first 5 post-natal days (PND). The mammary tissue was examined for development and maturation by morphologic analyses and immunochemistry. At PND 30, the mean length of terminal buds was significantly enhanced in all of the zearalenone-exposed females (p &lt; 0.05). The mammary tissue, as evaluated by scoring of tissue slides, was significantly more differentiated in the 1 mg/kg treated group than in controls (p &lt; 0.05). At PND 180, mammary tissue was more differentiated in all of the zearalenone treated groups (p &lt; 0.05). At six months, 4 of 18 females exposed to 5 mg/kg of zearalenone presented mammary hyperplasia lesions. The induction of phenotypic alterations by zearalenone administered in utero and in the neonatal period at doses as low as 0.2 mu g/kg suggests that zearalenone could contribute to the induction of breast endocrine disorders. (C) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000282543000039</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>299</id>
    <title>Estrogen-Like Activity of Perfluoroalkyl Acids In Vivo and Interaction with Human and Rainbow Trout Estrogen Receptors In Vitro</title>
    <authors>Benninghoff,A.D.; Bisson,W.H.; Koch,D.C.; Ehresman,D.J.; Kolluri,S.K.; William,D.E.</authors>
    <availability>[Benninghoff, Abby D.] Utah State Univ, Dept Anim Dairy &amp; Vet Sci, Logan, UT 84322 USA. [Benninghoff, Abby D.] Utah State Univ, Grad Program Toxicol, Logan, UT 84322 USA. [Bisson, William H.] Univ Geneva, Pharmaceut Biochem Grp, Sch Pharmaceut Sci, Geneva, Switzerland. [Koch, Daniel C.; Kolluri, Siva K.; William, David E.] Oregon State Univ, Dept Environm &amp; Mol Toxicol, Corvallis, OR 97331 USA. [Ehresman, David J.] 3M Ctr 220 2E 02, Corp Toxicology, Dept Med 3M, St Paul, MN 55133 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleBenninghoff, AD (reprint author), Utah State Univ, Dept Anim Dairy &amp; Vet Sci, 4815 Old Main Hill, Logan, UT 84322 USAabby.benninghoff@usu.eduABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ABDELLATIF AG, 1991, TOXICOL APPL PHARM, V111, P530, DOI 10.1016/0041-008X(91)90257-F; Benninghoff AD, 2008, TOXICOL SCI, V101, P65, DOI 10.1093/toxsci/kfm238; Bisson WH, 2009, J MED CHEM, V52, P5635, DOI 10.1021/jm900199u; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Bosgra S, 2005, TOXICOLOGY, V206, P309, DOI 10.1016/j.tox.2004.07.015; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Calafat AM, 2007, ENVIRON HEALTH PERSP, V115, P1596, DOI 10.1289/ehp.10598; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; De Maria N, 2002, MOL CELL ENDOCRINOL, V193, P59; Eliassen AH, 2008, ADV EXP MED BIOL, V630, P148; Emmett EA, 2006, J OCCUP ENVIRON MED, V48, P759, DOI 10.1097/01.jom.0000232486.07658.74; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; Fromme H, 2009, INT J HYG ENVIR HEAL, V212, P239, DOI 10.1016/j.ijheh.2008.04.007; Guyton KZ, 2009, ENVIRON HEALTH PERSP, V117, P1664, DOI 10.1289/ehp.0900758; HANHIJARVI H, 1988, PROPOSED SPECIES DIF, P409; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Holden PR, 1999, J MOL ENDOCRINOL, V22, P1, DOI 10.1677/jme.0.0220001; Houde M, 2006, ENVIRON SCI TECHNOL, V40, P3463, DOI 10.1021/es052580b; Ishibashi H, 2008, CHEMOSPHERE, V71, P1853, DOI 10.1016/j.chemosphere.2008.01.065; Ishibashi H, 2007, BIOL PHARM BULL, V30, P1358, DOI 10.1248/bpb.30.1358; Ito Y, 2007, J OCCUP HEALTH, V49, P172, DOI 10.1539/joh.49.172; Kannan K, 2002, ENVIRON SCI TECHNOL, V36, P3210, DOI 10.1021/es020519q; Kannan K, 2004, ENVIRON SCI TECHNOL, V38, P4489, DOI 10.1021/es0493446; Kennedy GL, 2004, CRIT REV TOXICOL, V34, P351, DOI 10.1080/10408440490464705; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kudo Naomi, 2003, J Toxicol Sci, V28, P49, DOI 10.2131/jts.28.49; Lai DY, 2004, J ENVIRON SCI HEAL C, V22, P37, DOI 10.1081/GNC-120038005; Liu CS, 2007, AQUAT TOXICOL, V85, P267, DOI 10.1016/j.aquatox.2007.09.009; Liu CS, 2009, AQUAT TOXICOL, V93, P131, DOI 10.1016/j.aquatox.2009.04.005; Liu CS, 2010, AQUAT TOXICOL, V96, P70, DOI 10.1016/j.aquatox.2009.09.012; Maras M, 2006, ENVIRON HEALTH PERSP, V114, P100, DOI 10.1289/ehp.8149; Marchand-Geneste N, 2006, SAR QSAR ENVIRON RES, V17, P93, DOI 10.1080/10659360600562137; Martin JW, 2005, CHEM-BIOL INTERACT, V155, P165, DOI 10.1016/j.cbi.2005.06.007; Martin JW, 2003, ENVIRON TOXICOL CHEM, V22, P189, DOI 10.1897/1551-5028(2003)022&lt;0189:DAOPAI&gt;2.0.CO;2; Matthews J, 2000, J STEROID BIOCHEM, V74, P223, DOI 10.1016/S0960-0760(00)00126-6; MITCHELL AM, 1985, TOXICOL APPL PHARM, V80, P23, DOI 10.1016/0041-008X(85)90097-3; Nabb DL, 2007, TOXICOL SCI, V100, P333, DOI 10.1093/toxsci/kfm230; Nagler JJ, 2007, GENE, V392, P164, DOI 10.1016/j.gene.2006.12.030; NUNEZ O, 1989, AQUAT TOXICOL, V15, P289, DOI 10.1016/0166-445X(89)90042-8; Olsen CA, 2005, COMP BIOCHEM PHYS C, V141, P267, DOI 10.1016/j.cca.2005.07.002; Olsen GW, 2007, ENVIRON HEALTH PERSP, V115, P1298, DOI 10.1289/ehp.10009; Orner GA, 1995, CARCINOGENESIS, V16, P2893, DOI 10.1093/carcin/16.12.2893; Palmer CNA, 1998, MOL PHARMACOL, V53, P14; Persson I, 2000, J STEROID BIOCHEM, V74, P357, DOI 10.1016/S0960-0760(00)00113-8; Shilling AD, 2000, TOXICOL APPL PHARM, V164, P330, DOI 10.1006/taap.2000.8912; Sivanesan D, 2005, J COMPUT AID MOL DES, V19, P213, DOI 10.1007/s10822-005-4788-9; Tilton SC, 2008, ENVIRON HEALTH PERSP, V116, P1047, DOI 10.1289/ehp.11190; Totrov M, 1997, PROTEINS, P215; Totrov M., 2001, PROTEIN LIGAND DOCKI, P603; Villa Erica, 2008, Womens Health (Lond Engl), V4, P41, DOI 10.2217/17455057.4.1.41; Wei YH, 2007, ENVIRON TOXICOL CHEM, V26, P2440, DOI 10.1897/07-008R1.1; YAGER JD, 1991, P SOC EXP BIOL MED, V198, P667; Yeh SH, 2010, ONCOLOGY-BASEL, V78, P172, DOI 10.1159/0003152475526OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIMARDiscipline: Toxicology726SZ</notes>
    <keywords>ACTIVATION; ALPHA; ASSAY; BINDING; BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; CARBON; CARCINOGENESIS; CELL; CHEMICALS; DES; Dietary Exposure; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; EXPOSURE; FLUOROTELOMER ALCOHOLS; GENE; HEALTH; in silico; In vitro; in vivo; IN-SILICO; IN-VITRO; IN-VIVO; INDUCTION; Interaction; LIGAND; LIGAND-BINDING; LIGAND-BINDING DOMAIN; LIGANDS; Liver; LIVER-CANCER; MODEL; molecular docking; Mouse; Nonylphenol; OVARIAN CANCERS; perfluoroalkyl acid; perfluorooctane sulfonate; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR; PROTEIN; PROTEINS; RECEPTOR; Receptors; SEX-HORMONES; toxicology; transcriptional activation; TUMOR PROMOTION; vitellogenin; VITELLOGENIN INDUCTION; VITRO; VIVO; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>42</startpage>
    <endpage>58</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>1</issue>
    <volume>120</volume>
    <abstract>The objectives of this study were to determine the structural characteristics of perfluoroalkyl acids (PFAAs) that confer estrogen-like activity in vivo using juvenile rainbow trout (Oncorhynchus mykiss) as an animal model and to determine whether these chemicals interact directly with the estrogen receptor (ER) using in vitro and in silico species comparison approaches. Perfluorooctanoic (PFOA), perfluorononanoic (PFNA), perfluorodecanoic (PFDA), and perfluoroundecanoic (PFUnDA) acids were all potent inducers of the estrogen-responsive biomarker protein vitellogenin (Vtg) in vivo, although at fairly high dietary exposures. A structure-activity relationship for PFAAs was observed, where eight to ten fluorinated carbons and a carboxylic acid end group were optimal for maximal Vtg induction. These in vivo findings were corroborated by in vitro mechanistic assays for trout and human ER. All PFAAs tested weakly bound to trout liver ER with half maximal inhibitory concentration (IC(50)) values of 15.2-289 mu M. Additionally, PFOA, PFNA, PFDA, PFUnDA, and perlfuorooctane sulfonate (PFOS) significantly enhanced human ER alpha-dependent transcriptional activation at concentrations ranging from 10-1000nM. Finally, we employed an in silico computational model based upon the crystal structure for the human ER alpha ligand-binding domain complexed with E2 to structurally investigate binding of these putative ligands to human, mouse, and trout ER alpha. PFOA, PFNA, PFDA, and PFOS all efficiently docked with ER alpha from different species and formed a hydrogen bond at residue Arg394/398/407 (human/mouse/trout) in a manner similar to the environmental estrogens bisphenol A and nonylphenol. Overall, these data support the contention that several PFAAs are weak environmental xenoestrogens of potential concern</abstract>
    <url>WOS:000287747800004</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>347</id>
    <title>Modeling the Interaction of Binary and Ternary Mixtures of Estradiol with Bisphenol A and Bisphenol AF in an In Vitro Estrogen-Mediated Transcriptional Activation Assay (T47D-KBluc)</title>
    <authors>Bermudez,D.S.; Gray,L.E.; Wilson,V.S.</authors>
    <availability>[Bermudez, Dieldrich S.; Gray, Leon E., Jr.; Wilson, Vickie S.] US EPA, Reprod Toxicol Branch, Toxic Assessment Div, Natl Hlth &amp; Environm Effects Res Lab,Off Res &amp; De, Res Triangle Pk, NC 27711 USA. [Bermudez, Dieldrich S.] N Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27606 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleGray, LE (reprint author), US EPA, Reprod Toxicol Branch, Toxic Assessment Div, Natl Hlth &amp; Environm Effects Res Lab,Off Res &amp; De, Res Triangle Pk, NC 27711 USAgray.earl@epa.govAkahori Y, 2008, TOXICOL IN VITRO, V22, P225, DOI 10.1016/j.tiv.2007.08.004; Aksglaede L, 2006, HUM REPROD UPDATE, V12, P341, DOI 10.1093/humupd/dml018; Bay K, 2004, INT J ANDROL, V27, P266, DOI 10.1111/j.1365-2605.2004.00487.x; Bhavsar SP, 2008, ENVIRON INT, V34, P915, DOI 10.1016/j.envint.2008.02.001; CERHR, 2008, NTP CERHR MON POT HU; Chen M, 2009, ENDOCRINOLOGY, V150, P251, DOI 10.1210/en.2008-0044; Cooke PS, 2004, EXP BIOL MED, V229, P1127; Finley BL, 2003, J TOXICOL ENV HEAL A, V66, P533, DOI 10.1080/15287390390156272; Finstad SE, 2009, CANCER CAUSE CONTROL, V20, P233, DOI 10.1007/s10552-008-9238-2; Hatta T, 2009, ARCH SEX BEHAV, V38, P821, DOI 10.1007/s10508-008-9445-7; Hess RA, 2001, MOL CELL ENDOCRINOL, V178, P29, DOI 10.1016/S0303-7207(01)00412-9; Hong BL, 2009, CHEMOSPHERE, V76, P727, DOI 10.1016/j.chemosphere.2009.05.034; Ikegami S, 2001, CLIN ENDOCRINOL, V55, P789, DOI 10.1046/j.1365-2265.2001.01416.x; JOHNSON MH, 2004, ESSENTIAL REPRODUCIT; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; KLEIN KO, 1994, J CLIN INVEST, V94, P2475, DOI 10.1172/JCI117616; KNOBIL E, 1993, PHYSL REPROD; Lemieux C, 2009, INT J CARDIOL, V136, P200, DOI 10.1016/j.ijcard.2008.04.054; Li J, 2010, TOXICOL IN VITRO, V24, P201, DOI 10.1016/j.tiv.2009.09.008; McCarthy MM, 2008, J NEUROENDOCRINOL, V20, P777, DOI 10.1111/j.1365-2826.2008.01723.x; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; *NTP, 2002, TETR A 79 94 7 REV T; *NTP, 2008, CHEM INF PROF BISP A; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; Rider CV, 2005, TOXICOL SCI, V87, P520, DOI 10.1093/toxsci/kfi247; Rohrmann S, 2009, CANCER EPIDEM BIOMAR, V18, P1484, DOI 10.1158/1055-9965.EPI-08-0817; Safe SH, 1998, ENVIRON HEALTH PERSP, V106, P1051, DOI 10.2307/3434151; Safe SH, 1998, J ANIM SCI, V76, P134; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; Shibata A, 2002, J CLIN ENDOCR METAB, V87, P810, DOI 10.1210/jc.87.2.810; Smith R, 2009, J CLIN ENDOCR METAB, V94, P2066, DOI 10.1210/jc.2008-2257; Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097; Troisi R, 2003, INT J EPIDEMIOL, V32, P455, DOI 10.1093/ije/dyg094; Troisi R, 2003, CANCER CAUSE CONTROL, V14, P347, DOI 10.1023/A:1023934518975; Van den Berg M, 2006, TOXICOL SCI, V93, P223, DOI 10.1093/toxsci/kfl055; Van den Berg M, 1998, ENVIRON HEALTH PERSP, V106, P775, DOI 10.1289/ehp.98106775; Vandenput L, 2009, NAT REV ENDOCRINOL, V5, P437, DOI 10.1038/nrendo.2009.112; Volkel W, 2005, DRUG METAB DISPOS, V33, P1748, DOI 10.1124/dmd.105.005454; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; Yamasaki K, 2003, TOXICOLOGY, V183, P93, DOI 10.1016/S0300-483X(02)00445-64211OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIAUGDiscipline: Toxicology630ZL</notes>
    <keywords>ACTIVATION; ASSAY; Behavior; BETA; bisphenol; bisphenol A; Bisphenol AF; BISPHENOL-A; BPA; CANCER; CANCER CELL-LINE; CELL; CELLS; CHEMICAL-MIXTURES; CHEMICALS; childhood; Cytotoxicity; DEVELOPING BRAIN; DIOXIN-LIKE COMPOUNDS; ENDOGENOUS ESTROGENS; ESTRADIOL; Estrogen; ESTROGENS; EXPOSURE; EXPRESSION; HEALTH; In vitro; IN-VITRO; Interaction; MECHANISMS; mixtures; PREGNANCY; RECEPTOR-BINDING; RISK; RISK-ASSESSMENT; TBBPA; TOXIC EQUIVALENCY FACTORS; toxicology; transcriptional activation; UMBILICAL-CORD BLOOD; UPDATE; UTEROTROPHIC ASSAY; VITRO; WOMEN; xenoestrogen; XENOESTROGENS; YOUNG-WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>477</startpage>
    <endpage>487</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>2</issue>
    <volume>116</volume>
    <abstract>Exposure to xenoestrogens occurs against a backdrop to physiological levels of endogenous estrogens. Endogenous estrogen levels vary from low levels in early childhood to high levels during pregnancy and in young women. However, few studies have addressed how xenoestrogens interact with endogenous estrogens. The current study was designed to characterize the individual dose-response curves of estradiol-17 beta (E(2)), bisphenol A (BPA), tetrabromo-bisphenol A (TBBPA), and bisphenol AF (BPAF, 4,4'-hexafluoroisopropylidene diphenol) on estrogen-dependent luciferase expression in T47D-KBluc cells and to determine how binary (8 x 8 factorial) and ternary (4 x 4 x 4 factorial) mixtures of an endogenous estrogen (E(2)) interact with BPA and/or BPAF. Log EC(50) and hillslope values with SEs, respectively, for individual compounds were as follows: E(2), -12.10M +/- 0.06071, 0.7702 +/- 0.1739; BPA, -6.679M +/- 0.08505, 1.194 +/- 0.2137; and BPAF, -7.648M +/- 0.05527, 1.273 +/- 0.1739. TBBPA was not evaluated in mixture studies because of its minimally estrogenic response at 3 x10(-5)M and elicited cytotoxicity at higher concentrations. Both the binary mixtures of E(2) with BPA and BPAF and the ternary mixture of E(2), BPA, and BPAF behaved in an additive manner. For binary mixtures, as E(2) concentration increased, higher concentrations of BPA and BPAF were necessary to induce a significant increase in the estrogenic response. Understanding the behavior of mixture interactions of xenoestrogens, like BPA and BPAF, with endogenous estrogens will allow a better assessment of the potential risk associated with exposure to these chemicals, individually or as mixtures</abstract>
    <url>WOS:000280315800012</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>387</id>
    <title>Removal of BPA and NPnEOs from Secondary Effluents of Municipal WWTPs by Means of Ozonation</title>
    <authors>Bertanza,G.; Pedrazzani,R.; Papa,M.; Mazzoleni,G.; Steimberg,N.; Caimi,L.; Montani,C.; Dilorenzo,D.</authors>
    <availability>[Bertanza, Giorgio; Papa, Matteo] Univ Brescia, DICATA, I-25123 Brescia, Italy. [Pedrazzani, Roberta] Univ Brescia, DIMI, I-25123 Brescia, Italy. [Mazzoleni, Giovanna; Steimberg, Nathalie; Caimi, Luigi] Univ Brescia, Dipartimento Sci Biomed &amp; Biotecnol, I-25123 Brescia, Italy. [Montani, Claudia; Dilorenzo, Diego] Osped Civile Brescia, Dipartimento Lab, Lab Biotecnol, I-25123 Brescia, Italy.</availability>
    <date>2010</date>
    <notes>JEnglishArticle; Proceedings PaperBertanza, G (reprint author), Univ Brescia, DICATA, Via Branze 43, I-25123 Brescia, Italygiorgio.bertanza@ing.unibs.itAuriol M, 2006, PROCESS BIOCHEM, V41, P525, DOI 10.1016/j.procbio.2005.09.017; AVESANI S, 2008, THESIS U BRESCIA; BENANOU D, 2002, DETERMINATION ALKYLP; DEWET JR, 1987, MOL CELL BIOL, V7, P725; Esplugas S, 2007, J HAZARD MATER, V149, P631, DOI 10.1016/j.jhazmat.2007.07.073; FARRE M, 2002, ANAL CHIM ACTA, V456, P9; Gatidou G, 2007, J CHROMATOGR A, V1138, P32, DOI 10.1016/j.chroma.2006.10.037; Gonzalez S, 2007, CHEMOSPHERE, V67, P335, DOI 10.1016/j.chemosphere.2006.09.056; Gultekin I, 2007, J ENVIRON MANAGE, V85, P816, DOI 10.1016/j.jenvman.2007.07.020; *ISO, 2006, 131 ISO; Joss A, 2008, WATER SCI TECHNOL, V57, P251, DOI 10.2166/wst.2008.825; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Ning B, 2007, CHEMOSPHERE, V68, P1163, DOI 10.1016/j.chemosphere.2007.01.055; Press-Kristensen K, 2008, WATER SCI TECHNOL, V57, P1253, DOI 10.2166/wst.2008.229; Rosenfeldt EJ, 2004, ENVIRON SCI TECHNOL, V38, P5476, DOI 10.1021/es035413p; SALOGNI V, 2008, THESIS U BRESCIA; Stasinakis AS, 2008, WATER RES, V42, P1796, DOI 10.1016/j.watres.2007.11.003; *STOWA, 2005, EXPL STUD WAST TREAT; Ternes T., 2006, HUMAN PHARM HORMONES; Zhang HQ, 2006, WATER SCI TECHNOL, V54, P123, DOI 10.2166/wst.2006.881205TAYLOR &amp; FRANCIS INCPHILADELPHIA325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USAOZONE-SCI ENGDiscipline: Engineering; Environmental Sciences &amp; Ecology606JF</notes>
    <keywords>ADVANCED OXIDATION PROCESSES; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CELLS; Costs; DEGRADATION; Determination; EDC; EDCs; EFFLUENT; EFFLUENTS; ENDOCRINE DISRUPTERS; Endocrine-disrupting chemicals; ESTROGENIC ACTIVITIES; estrogenic activity; Feasibility; GENE; Hormone; Hormones; Kinetics; Municipal Wastewater; Nonylphenol; OXIDATION; Ozone; PHARMACEUTICALS; PLANT; REMOVAL; SEWAGE-TREATMENT; SLUDGE; Tertiary ozonation; WASTE-WATER; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>204</startpage>
    <endpage>208</endpage>
    <journalfull>Ozone-Science &amp; Engineering</journalfull>
    <issue>3</issue>
    <volume>32</volume>
    <abstract>Removal potential of many EDCs by conventional WWTPs is recognized. Nevertheless, in order to reach very low concentrations, further treatment (e.g., chemical oxidation) might be required. In this work, two estrogen-like substances were considered: nonylphenol (NP) (and its parent compounds) and bisphenol A (BPA). The experimental work was conducted at Verona (Northern Italy) WWTP (370,000 p.e.): the effluent was submitted to ozonation in a pilot scale plant. Beside chemical and microbiological analyses, estrogenic activity measurements were also carried out by means of breast cancer MCF-7 cells transfected with the luminescence luciferase gene. Economic feasibility of tertiary ozonation is finally discussed</abstract>
    <url>WOS:000278420100007</url>
    <isbnorissn>0191-9512</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>289</id>
    <title>Effect of biological and chemical oxidation on the removal of estrogenic compounds (NP and BPA) from wastewater: An integrated assessment procedure</title>
    <authors>Bertanza,G.; Pedrazzani,R.; Dal Grande,M.; Papa,M.; Zambarda,V.; Montani,C.; Steimberg,N.; Mazzoleni,G.; Di Lorenzo,D.</authors>
    <availability>[Bertanza, Giorgio; Papa, Matteo] Univ Brescia, DICATA Dept Civil Engn Architecture Land &amp; Enviro, I-25123 Brescia, Italy. [Pedrazzani, Roberta] Univ Brescia, DIMI Dept Mech &amp; Ind Engn, I-25123 Brescia, Italy. [Dal Grande, Mario] Acque Veronesi Scarl, I-37133 Verona, Italy. [Zambarda, Valerio] TZ Engn, I-25015 Desenzano Del Garda, Italy. [Steimberg, Nathalie; Mazzoleni, Giovanna] Univ Brescia, Sch Med, Dept Biomed Sci &amp; Biotechnol, Gen Pathol &amp; Immunol Unit, I-25123 Brescia, Italy. [Montani, Claudia; Di Lorenzo, Diego] Civ Hosp Brescia, Dept Lab Med, Biotechnol Lab, I-25123 Brescia, Italy.</availability>
    <date>2011</date>
    <notes>JEnglishArticleBertanza, G (reprint author), Univ Brescia, DICATA Dept Civil Engn Architecture Land &amp; Enviro, Via Bronze 43, I-25123 Brescia, Italygiorgio.bertanza@ing.unibs.itAHEL M, 1994, WATER RES, V28, P1131, DOI 10.1016/0043-1354(94)90200-3; [Anonymous], 2005, 188571 ISO; *AP IRS CNR, 2003, STAND METH EX WAT; Auriol M, 2006, PROCESS BIOCHEM, V41, P525, DOI 10.1016/j.procbio.2005.09.017; Belmont MA, 2006, ENVIRON TOXICOL CHEM, V25, P29, DOI 10.1897/04-648R.1; Bila D, 2007, CHEMOSPHERE, V69, P736, DOI 10.1016/j.chemosphere.2007.05.016; Bjorkblom C, 2008, CHEMOSPHERE, V73, P1064, DOI 10.1016/j.chemosphere.2008.07.052; Bolong N, 2009, DESALINATION, V239, P229, DOI 10.1016/j.desal.2008.03.020; Cantero M, 2006, J CHROMATOGR A, V1120, P260, DOI 10.1016/j.chroma.2005.12.048; Cespedes R, 2004, ANAL BIOANAL CHEM, V378, P697, DOI 10.1007/s00216-003-2303-5; Chau KY, 1998, EXP CELL RES, V241, P269, DOI 10.1006/excr.1998.4052; Cicek N, 1999, WATER ENVIRON RES, V71, P64, DOI 10.2175/106143099X121481; Clara M, 2004, WATER SCI TECHNOL, V50, P29; Clara M, 2007, WATER RES, V41, P4339, DOI 10.1016/j.watres.2007.06.027; Clara M, 2005, WATER RES, V39, P4797, DOI 10.1016/j.watres.2005.09.015; Clara M, 2005, WATER RES, V39, P97, DOI 10.1016/j.watres.2004.08.036; Clouzot L, 2010, BIORESOURCE TECHNOL, V101, P6425, DOI 10.1016/j.biortech.2010.03.039; Creusot N, 2010, ANAL BIOANAL CHEM, V396, P569, DOI 10.1007/s00216-009-3310-y; DEWET JR, 1987, MOL CELL BIOL, V7, P725; DICORCIA A, 1994, ENVIRON SCI TECHNOL, V28, P850, DOI 10.1021/es00054a016; Esplugas S, 2007, J HAZARD MATER, V149, P631, DOI 10.1016/j.jhazmat.2007.07.073; Farre M, 2002, ANAL CHIM ACTA, V456, P19, DOI 10.1016/S0003-2670(01)00908-4; Fauser P, 2003, WATER RES, V37, P1288, DOI 10.1016/S0043-1354(02)00482-7; Fernandez MP, 2008, WATER RES, V42, P3075, DOI 10.1016/j.watres.2008.02.022; Fernandez MP, 2009, ANAL BIOANAL CHEM, V393, P957, DOI 10.1007/s00216-008-2516-8; Fountoulakis M, 2005, J CHROMATOGR A, V1089, P45, DOI 10.1016/j.chroma.2005.05.109; Fuerhacker M, 2001, SCI TOTAL ENVIRON, V277, P95, DOI 10.1016/S0048-9697(00)00866-4; Gatidou G, 2007, J CHROMATOGR A, V1138, P32, DOI 10.1016/j.chroma.2006.10.037; Gonzalez S, 2007, CHEMOSPHERE, V67, P335, DOI 10.1016/j.chemosphere.2006.09.056; Gonzalez S, 2004, J CHROMATOGR A, V1052, P111, DOI 10.1016/j.chroma.2004.08.047; Gultekin I, 2007, J ENVIRON MANAGE, V85, P816, DOI 10.1016/j.jenvman.2007.07.020; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; Hashimoto T, 2007, WATER RES, V41, P2117, DOI 10.1016/j.watres.2007.02.029; Higashi E, 2007, DRUG METAB DISPOS, V35, P1935, DOI 10.1124/dmd.107.016568; Hjelmborg PS, 2006, ANAL BIOANAL CHEM, V385, P875, DOI 10.1007/s00216-006-0463-9; Huber MM, 2004, ENVIRON SCI TECHNOL, V38, P5177, DOI 10.1021/es035205x; Huntsman BE, 2006, WATER ENVIRON RES, V78, P2397, DOI 10.2175/106143005X72966; Isobe T, 2003, J CHROMATOGR A, V984, P195, DOI 10.1016/S0021-9673(02)01851-4; Jiang JQ, 2005, CHEMOSPHERE, V61, P544, DOI 10.1016/j.chemosphere.2005.02.029; Joss A, 2008, WATER SCI TECHNOL, V57, P251, DOI 10.2166/wst.2008.825; Jugan ML, 2009, SCI TOTAL ENVIRON, V407, P3579, DOI 10.1016/j.scitotenv.2009.01.027; Koh YKK, 2005, B ENVIRON CONTAM TOX, V75, P1098, DOI 10.1007/s00128-005-0862-1; Koh YKK, 2008, ENVIRON TECHNOL, V29, P245, DOI 10.1080/09593330802099122; Koh YKK, 2009, ENVIRON SCI TECHNOL, V43, P6646, DOI 10.1021/es901612v; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Komori K, 2006, WATER SCI TECHNOL, V53, P27, DOI 10.2166/wst.2006.334; Korber W., 2000, CHEMOSPHERE, V40, P1131; Korner W, 2004, ENVIRON HEALTH PERSP, V112, P695, DOI 10.1289/ehp.6715; Lagana A, 2004, ANAL CHIM ACTA, V501, P79, DOI 10.1016/j.aca.2003.09.020; Lee HB, 2005, J CHROMATOGR A, V1094, P122, DOI 10.1016/j.chroma.2005.07.070; Levine AD, 2006, WATER ENVIRON RES, V78, P2276, DOI 10.2175/106143005X82244; Loos R, 2007, CHEMOSPHERE, V66, P690, DOI 10.1016/j.chemosphere.2006.07.060; Loyo-Rosales JE, 2007, ENVIRON SCI TECHNOL, V41, P6815, DOI 10.1021/es070713i; Mart'ianov AA, 2005, TALANTA, V65, P367, DOI 10.1016/j.talanta.2004.07.004; Mispagel C, 2009, ARCH ENVIRON CON TOX, V56, P631, DOI 10.1007/s00244-008-9261-z; Mnif W, 2010, ARCH ENVIRON CON TOX, V59, P1, DOI 10.1007/s00244-009-9438-0; Nakada N, 2006, WATER RES, V40, P3297, DOI 10.1016/j.watres.2006.06.039; Ning B, 2007, CHEMOSPHERE, V68, P1163, DOI 10.1016/j.chemosphere.2007.01.055; PEDRAZZANI R, QUANTIFICATION UNPUB; Planas C, 2002, WATER RES, V36, P982, DOI 10.1016/S0043-1354(01)00306-2; PONS M, 1990, BIOTECHNIQUES, V9, P450; Pothitou P, 2008, CHEMOSPHERE, V73, P1716, DOI 10.1016/j.chemosphere.2008.09.037; Press-Kristensen K, 2008, WATER SCI TECHNOL, V57, P1253, DOI 10.2166/wst.2008.229; Racz L, 2010, J ENVIRON MONITOR, V12, P58, DOI 10.1039/b917298j; Rosenfeldt EJ, 2004, ENVIRON SCI TECHNOL, V38, P5476, DOI 10.1021/es035413p; Sanchez-Avila J, 2009, SCI TOTAL ENVIRON, V407, P4157, DOI 10.1016/j.scitotenv.2009.03.016; Shen G, 2005, CHINESE SCI BULL, V50, P2681, DOI 10.1360/982005-316; Sole M, 2000, ENVIRON SCI TECHNOL, V34, P5076, DOI 10.1021/es991335n; Soto AM, 2006, BEST PRACT RES CL EN, V20, P15, DOI 10.1016/j.beem.2005.09.001; Sousa A, 2010, ARCH ENVIRON CON TOX, V58, P1, DOI 10.1007/s00244-009-9324-9; Spink DC, 2003, CARCINOGENESIS, V24, P1941, DOI 10.1093/carcin/bgg162; Stasinakis AS, 2008, WATER RES, V42, P1796, DOI 10.1016/j.watres.2007.11.003; Sun QF, 2008, ENVIRON TOXICOL PHAR, V25, P20, DOI 10.1016/j.etap.2007.08.003; Svenson A, 2003, WATER RES, V37, P4433, DOI 10.1016/S0043-1354(03)00395-6; Tan BLL, 2007, ENVIRON INT, V33, P654, DOI 10.1016/j.envint.2007.01.008; Ternes T. A., 2006, HUMAN PHARMACEUTICAL; Urban G, 2001, J BIOL CHEM, V276, P27638, DOI 10.1074/jbc.M103512200; Vethaak AD, 2005, CHEMOSPHERE, V59, P511, DOI 10.1016/j.chemosphere.2004.12.053; Vogelsang C, 2006, WATER RES, V40, P3559, DOI 10.1016/j.watres.2006.07.022; Ying GG, 2009, SCI TOTAL ENVIRON, V407, P5147, DOI 10.1016/j.scitotenv.2009.06.002; Zhang HQ, 2006, WATER SCI TECHNOL, V54, P123, DOI 10.2166/wst.2006.8818115PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDWATER RESAPRDiscipline: Engineering; Environmental Sciences &amp; Ecology; Water Resources755VQ</notes>
    <keywords>ACTIVATED-SLUDGE; ACTIVATED-SLUDGE TREATMENT; ASSAY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CHROMATOGRAPHY-MASS SPECTROMETRY; EDC; EDCs; EDCs (Endocrine Disrupting Compounds); ENDOCRINE; Endocrine disrupting compounds; Endocrine-disrupting chemicals; estrogenic activity; Estrogenicity; GENE; HEALTH; HUMAN-BREAST-CANCER; IN-VITRO ASSAYS; Mass balance; MBR treatment; MODEL; Nonylphenol; NONYLPHENOL ETHOXYLATE SURFACTANTS; PERFORMANCE; PERSONAL-CARE PRODUCTS; PLANTS; POLLUTANTS; RECOMBINANT YEAST ASSAY; REDUCTION; Reporter gene assay; SEWAGE-TREATMENT PLANTS; SOLID-PHASE EXTRACTION; SOUTH EAST QUEENSLAND; synergistic effects; Tertiary ozonation; Urban; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2473</startpage>
    <endpage>2484</endpage>
    <journalfull>Water Research</journalfull>
    <issue>8</issue>
    <volume>45</volume>
    <abstract>A major source of the wide presence of EDCs (Endocrine Disrupting Compounds) in water bodies is represented by direct/indirect discharge of sewage. Recent scientific literature reports data about their trace concentration in water, sediments and aquatic organisms, as well as removal efficiencies of different wastewater treatment schemes. Despite the availability of a huge amount of data, some doubts still persist due to the difficulty in evaluating synergistic effects of trace pollutants in complex matrices. In this paper, an integrated assessment procedure was used, based on chemical and biological analyses, in order to compare the performance of two full scale biological wastewater treatment plants (either equipped with conventional settling tanks or with an ultrafiltration membrane unit) and tertiary ozonation (pilot scale). Nonylphenol and bisphenol A were chosen as model EDCs, together with the parent compounds mono- and di-ethoxylated nonylphenol (quantified by means of GC MS). Water estrogenic activity was evaluated by applying the human breast cancer MCF-7 based reporter gene assay. Process parameters (e.g., sludge age, temperature) and conventional pollutants (e.g., COD, suspended solids) were also measured during monitoring campaigns. Conventional activated sludge achieved satisfactory removal of both analytes and estrogenicity. A further reduction of biological activity was exerted by MBR (Membrane Biological Reactor) as well as ozonation; the latter contributed also to decrease EDC concentrations. (C) 2011 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000289968000004</url>
    <isbnorissn>0043-1354</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>62</id>
    <title>Alterations in the Rat Serum Proteome Induced by Prepubertal Exposure to Bisphenol A and Genistein</title>
    <authors>Betancourt,A.; Mobley,J.A.; Wang,J.; Jenkins,S.; Chen,D.Q.; Kojima,K.; Russo,J.; Lamartiniere,C.A.</authors>
    <availability>[Betancourt, Angela; Wang, Jun; Jenkins, Sarah; Lamartiniere, Coral A.] Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Mobley, James A.; Chen, Dongquan; Kojima, Kyoko; Lamartiniere, Coral A.] Univ Alabama Birmingham, Ctr Comprehens Canc, Wallace Tumor Inst 202, Birmingham, AL 35294 USA. [Mobley, James A.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Chen, Dongquan] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL 35294 USA. [Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleLamartiniere, CA (reprint author), Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, 1670 Univ Blvd,Volker Hall 241, Birmingham, AL 35294 USACoral@uab.eduADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; [Anonymous], 1982, NAT TOX PROGR TECHN; Berry WL, 2012, INT J ONCOL, V41, P1701, DOI 10.3892/ijo.2012.1618; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Betancourt AM, 2012, J NUTR, V142, p1382S, DOI 10.3945/jn.111.152058; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4&lt;269::AID-CM1&gt;3.0.CO;2-5; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Caron M., 2007, MOL CELL PROTEOMICS, V7, P6115; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CDC, BREAST CANC STAT; Chen JS, 2012, INT J CANCER, V130, P1302, DOI 10.1002/ijc.26117; Chen WF, 2003, BBA-MOL BASIS DIS, V1638, P187, DOI 10.1016/S0925-4439(03)00082-6; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P567; Conde I, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-174; Correia AL, 2013, GENE DEV, V27, P805, DOI 10.1101/gad.211383.112; Dayon L, 2008, ANAL CHEM, V80, P2921, DOI 10.1021/ac702422x; Deltour S, 2001, BIOCHEM BIOPH RES CO, V287, P427, DOI 10.1006/bbrc.2001.5624; Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Ellison-Zelski SJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-263; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; Fang HY, 2010, J CELL SCI, V123, P1171, DOI 10.1242/jcs.062034; Farshchian M., 2007, CLIN CANCER RES, V13, P5322; FEDI P, 1994, MOL CELL BIOL, V14, P492; Franke AA, 1998, AM J CLIN NUTR, V68, p1466S; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guillory B, 2010, AM J PATHOL, V177, P2635, DOI 10.2353/ajpath.2010.100177; He J., J CELL BIOL, V176, P141; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hortin GL, 2008, CLIN CHEM, V54, P1608, DOI 10.1373/clinchem.2008.108175; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; HUGUET EL, 1994, CANCER RES, V54, P2615; Jackson RS, 2007, CELL CYCLE, V6, P95, DOI 10.4161/cc.6.1.3665; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Kachigan S. K., 1991, MULTIVARIATE STAT AN; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kim T., 2013, EXPERT OPIN THER PAT, V0, P1; Koga F, 2009, ANTICANCER RES, V29, P797; Korkolopoulou P, 2005, HUM PATHOL, V36, P899, DOI 10.1016/j.humpath.2005.06.008; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper G. G., 1998, ENDOCRINOLOGY, V139, P10; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lamartiniere C. A., 1982, 12 C ENV TOX, P192; Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; LEE HP, 1991, LANCET, V337, P1197; Mao JS, 2008, CANCER SCI, V99, P2120, DOI 10.1111/j.1349-7006.2008.00928.x; Matsumoto T, 2009, INT J BIOL MARKER, V24, P282; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; Qian WJ, 2008, MOL CELL PROTEOMICS, V7, P1963, DOI 10.1074/mcp.M800008-MCP200; Radislcy D. C., 2003, ANN M AM SOC CELL BI; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Rowell C, 2005, J NUTR, V135, p2953S; Roy JR, 2009, MED SCI MONITOR, V15, pRA137; Shibao K, 2010, CELL CALCIUM, V48, P315, DOI 10.1016/j.ceca.2010.09.005; Spilka R, 2012, J ONCOL, V2012; Sun PH, 2013, J CANCER RES CLIN, V139, P1129, DOI 10.1007/s00432-013-1421-5; Tabb DL, 2010, J PROTEOME RES, V9, P761, DOI 10.1021/pr9006365; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Wang J, 2011, J PROTEOME RES, V10, P1621, DOI 10.1021/pr100974w; Weatherly DB, 2005, MOL CELL PROTEOMICS, V4, P762, DOI 10.1074/mcp.M400215-MCP200; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wuhr M, 2012, ANAL CHEM, V84, P9214, DOI 10.1021/ac301962s; Yano M, 1996, JPN J CANCER RES, V87, P908; Yi B., 2013, INT J ENDOCRINOL, V2013; Yi JK, 2009, CANCER EPIDEM BIOMAR, V18, P1357, DOI 10.1158/1055-9965.EPI-08-0696; Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343; Zeng Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-19; Zhu CQ, 2007, P NATL ACAD SCI USA, V104, P11754, DOI 10.1073/pnas.0703040104; ZIEGLER RG, 1993, J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819760AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USAJ PROTEOME RESMARDiscipline: Biochemistry &amp; Molecular BiologyAC8AV</notes>
    <keywords>BIOLOGY; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; CELL-CYCLE; CHEMICALS; CYCLE; DATABASE SEARCH; EXPOSURE; EXPRESSION; FOOD; genistein; GROWTH; Mammary cancer; MAMMARY-GLAND; MAMMARY-GLANDS; MASS-SPECTROMETRY; proliferation; prostate cancer; PROSTATE-CANCER; PROTEINS; Proteomics; RAT; RATS; serum; STATISTICAL-MODEL; SUSCEPTIBILITY; TANDEM MASS-SPECTROMETRY; TUMOR-SUPPRESSOR GENE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1502</startpage>
    <endpage>1514</endpage>
    <journalfull>Journal of Proteome Research</journalfull>
    <issue>3</issue>
    <volume>13</volume>
    <abstract>Humans are exposed to an array of chemicals via the food, drink and air, including a significant number that can mimic endogenous hormones. One such chemical is Bisphenol A (BPA), a synthetic chemical that has been shown to cause developmental alterations and to predispose for mammary cancer in rodent models. In contrast, the phytochemical genistein has been reported to suppress chemically induced mammary cancer in rodents, and Asians ingesting a diet high in soy containing genistein have lower incidence of breast and prostate cancers. In this study, we sought to: (1) identify protein biomarkers of susceptibility from blood sera of rats exposed prepubertally to BPA or genistein using Isobaric Tandem Mass Tags quantitative mass spectrometry (TMT-MS) combined with MudPIT technology and, (2) explore the relevance of these proteins to carcinogenesis. Prepubertal exposures to BPA and genistein resulted in altered expression of 63 and 28 proteins in rat sera at postnatal day (PND) 21, and of 9 and 18 proteins in sera at PND35, respectively. This study demonstrates the value of using quantitative proteomic techniques to explore the effect of chemical exposure on the rat serum proteome and its potential for unraveling cellular targets altered by BPA and genistein involved in carcinogenesis</abstract>
    <url>WOS:000332756300030</url>
    <isbnorissn>1535-3893</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>323</id>
    <title>In Utero Exposure to Bisphenol A Shifts the Window of Susceptibility for Mammary Carcinogenesis in the Rat</title>
    <authors>Betancourt,A.M.; Eltoum,I.A.; Desmond,R.A.; Russo,J.; Lamartiniere,C.A.</authors>
    <availability>[Betancourt, Angela M.; Lamartiniere, Coral A.] Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Eltoum, Isam A.; Desmond, Renee A.; Lamartiniere, Coral A.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA. [Eltoum, Isam A.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Desmond, Renee A.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL 35294 USA. [Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleLamartiniere, CA (reprint author), Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, 1670 Univ Blvd,Volker Hall L106, Birmingham, AL 35294 USAcoral@uab.eduBaylin SB, 1998, ADV CANCER RES, V72, P141; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Biles JE, 1997, J AGR FOOD CHEM, V45, P4697, DOI 10.1021/jf970518v; Bouras T, 2001, CANCER RES, V61, P903; BRADLEY CJ, 1976, CANCER RES, V36, P319; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Burridge E, 2003, EUR CHEM NEWS, V14, P17; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; COLLETTE D, 2003, MODELING SURVIVAL DA; DANDEKAR AM, 1982, P NATL ACAD SCI-BIOL, V79, P3987, DOI 10.1073/pnas.79.13.3987; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Everett J W, 1989, Monogr Endocrinol, V32, P1; HASLAM SZ, 1977, P NATL ACAD SCI USA, V74, P4020, DOI 10.1073/pnas.74.9.4020; Henriksen K, 2009, ACTA ONCOL, V48, P522, DOI 10.1080/02841860802676383; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; Hu YF, 1997, INT J ONCOL, V11, P5; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kirkegaard T, 2007, CLIN CANCER RES, V13, P1405, DOI 10.1158/1078-0432.CCR-06-1933; Kurebayashi H, 2005, ARCH TOXICOL, V79, P243, DOI 10.1007/s00204-004-0628-2; Kuroda N, 2003, J PHARMACEUT BIOMED, V30, P1743, DOI 10.1016/S0731-7085(02)00516-2; Lamartiniere CA, 1982, 12 C ENV TOX DAYT OH, P96; Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237; Markey CM, 2001, BIOL REPROD, V65, P1215; MCCORMIC.GM, 1965, BRIT J CANCER, V19, P160, DOI 10.1038/bjc.1965.19; Mc Ilroy M, 2006, ENDOCR-RELAT CANCER, V13, P1135, DOI 10.1677/erc.1.01222; Meyer JS, 2005, MODERN PATHOL, V18, P1067, DOI 10.1038/modpathol.3800388; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; MURAD TM, 1972, CANCER RES, V32, P1404; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Rowell C, 2005, J NUTR, V135, p2953S; RUSSO J, 1979, AM J PATHOL, V96, P721; RUSSO J, 1978, J NATL CANCER I, V61, P1451; RUSSO J, 1977, J NATL CANCER I, V59, P435; RUSSO J, 1983, ENVIRON HEALTH PERSP, V49, P185, DOI 10.2307/3429597; RUSSO J, 1990, LAB INVEST, V62, P1; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; SHINA D, 1975, J NATL CANCER I, P1007; Snyder RW, 2000, TOXICOL APPL PHARM, V168, P225, DOI 10.1006/taap.2000.9051; *US EPA, 1988, 80057 CASRN US EPA; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/mrc839; WELSCH CW, 1985, CANCER RES, V45, P3415; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.10974929US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPNOVDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology674CR</notes>
    <keywords>ADULT; ADULT-RAT; bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; CARCINOMAS; CELL; Cell proliferation; CELL-PROLIFERATION; COACTIVATORS; COATINGS; Differentiation; DISPOSITION; DMBA; ENDOCRINE DISRUPTORS; Estrogen; Estrogen receptor alpha; estrogen receptor-alpha; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; female; FETAL; FOOD; GLAND; GROWTH; GROWTH-FACTOR; HEALTH; IN-UTERO; INHIBITOR; Mammary cancer; mammary gland; MAMMARY-GLAND; Occupational; PRENATAL EXPOSURE; progesterone; proliferation; PROTEIN; PROTEINS; Proteomics; RAT; RATS; RECEPTOR; RECEPTOR-ALPHA; Steroid; SUSCEPTIBILITY; toxicology; TUMOR; TUMORIGENESIS; UTERO EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1614</startpage>
    <endpage>1619</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>11</issue>
    <volume>118</volume>
    <abstract>BACKGROUND: Bisphenol A (BPA) is a ubiquitous environmental chemical with reported endocrine-disrupting properties. OBJECTIVE: Our goal in this study was to determine whether prenatal exposure to BPA predisposes the adult rat mammary gland to carcinogenesis. METHODS: Pregnant rats were treated orally with 0, 25, or 250 mu g BPA/kg body weight (BW) from gestation day (GD) 10 to GD21. For tumorigenesis experiments, prenatally exposed female offspring received a single gavage of 7,12-dimethylbenz(a) anthracene (DMBA; 30 mg/kg BW) on postnatal day (PND) 50, or PND100. RESULTS: Prenatal exposure of the dam to 250 mu g BPA/kg BW combined with a single exposure of female offspring to DMBA on PND100, but not on PND50, significantly increased tumor incidence while decreasing tumor latency compared with the control group. Prenatal exposure of the dam to 250 mu g BPA/kg BW, in the absence of DMBA to the female offspring, increased cell proliferation and elicited differential effects at the protein level at PND100 compared with PND50. Differentially regulated proteins in the mammary gland included estrogen receptor-alpha, progesterone receptor-A, Bcl-2, steroid receptor coactivators, epidermal growth factor receptor, phospho-insulin-like growth factor 1 receptor, and phospho-Raf. CONCLUSIONS: Our study demonstrates that oral prenatal exposure to BPA increases mammary cancer susceptibility in offspring and shifts the window of susceptibility for DMBA-induced tumorigenesis in the rat mammary gland from PND50 to PND100. These changes are accompanied by differential effects of prenatal BPA exposure on the expression of key proteins involved in cell proliferation</abstract>
    <url>WOS:000283711800035</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>366</id>
    <title>Proteomic analysis in mammary glands of rat offspring exposed in utero to bisphenol A</title>
    <authors>Betancourt,A.M.; Mobley,J.A.; Russo,J.; Lamartiniere,C.A.</authors>
    <availability>[Betancourt, Angela M.; Lamartiniere, Coral A.] Univ Alabama, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Mobley, James A.; Lamartiniere, Coral A.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Mobley, James A.] Univ Alabama, Dept Surg, Div Urol, Birmingham, AL 35294 USA. [Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticle; Proceedings PaperLamartiniere, CA (reprint author), Univ Alabama, Dept Pharmacol &amp; Toxicol, 1670 Univ Blvd,Volker Hall 124, Birmingham, AL 35294 USACoral@uab.eduBellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(04)94002-X; Biles JE, 1997, J AGR FOOD CHEM, V45, P4697, DOI 10.1021/jf970518v; BOYLAN ES, 1983, CANCER RES, V43, P4879; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P54; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chen XQ, 2005, J NEUROSCI RES, V79, P114, DOI 10.1002/jnr.20323; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P567; Domoradzki JY, 2004, TOXICOL SCI, V77, P230, DOI 10.1093/toxsci/kfh054; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Ema M, 2001, REPROD TOXICOL, V15, P505, DOI 10.1016/S0890-6238(01)00160-5; FISHER A, 2009, J BIOL CHEM, V284, P3183; Francki A, 2004, J CELL BIOCHEM, V91, P915, DOI 10.1002/jcb.20008; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grille SJ, 2003, CANCER RES, V63, P2172; Heatley M, 1997, ACTA CYTOL, V41, P717; Hiroi T, 2006, ENDOCRINOLOGY, V147, P2773, DOI 10.1210/en.2005-1235; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Kachigan S. K., 1991, MULTIVARIATE STAT AN; Kurebayashi H, 2002, TOXICOL SCI, V68, P32, DOI 10.1093/toxsci/68.1.32; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; Litell R. C., 1996, SAS SYSTEM MIXED MOD; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Long X, 2001, EXP BIOL MED, V226, P477; Markey CM, 2001, BIOL REPROD, V65, P1215; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Mizuo K, 2004, NEUROSCI LETT, V356, P95, DOI 10.1016/j.neulet.2003.11.027; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; *NTP, 1982, NTP PUBL; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Papaconstantinou AD, 2001, TOXICOL SCI, V63, P173, DOI 10.1093/toxsci/63.2.173; Pottenger LH, 2000, TOXICOL SCI, V54, P3, DOI 10.1093/toxsci/54.1.3; Rapp UR, 2006, CANCER CELL, V9, P9, DOI 10.1016/j.ccr.2005.12.022; Rowell C, 2005, J NUTR, V135, p2953S; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Russo I. H., 1989, MONOGRAPHS PATHOLOGY, P233; RUSSO IH, 1978, J NATL CANCER I, V61, P1439; RUSSO J, 1987, LAB INVEST, V57, P112; Sage EH, 1997, NAT MED, V3, P144; SAGE H, 1984, J BIOL CHEM, V259, P3993; Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008-5472.CAN-08-1327; Schonfelder G, 2002, NEOPLASIA, V4, P98, DOI 10.1038/sj.neo.7900212; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V291, P76, DOI 10.1006/bbrc.2002.6407; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; *WHO, 2008, CANC FACTS; XIAO B, 1995, NATURE, V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yamasaki K, 2000, ENVIRON HEALTH PERSP, V108, P1147, DOI 10.2307/3434826; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P14956323ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSJ PROTEOMICSAPR 18SIDiscipline: Biochemistry &amp; Molecular Biology597ND</notes>
    <keywords>14-3-3 PROTEIN; 2D-E; ALTERS; analysis; BIOLOGY; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CELLS; COMBINATION; DIETHYLSTILBESTROL; Differentiation; ENDOCRINE; Endocrine disruptor; EXPOSURE; EXPRESSION; female; FOOD; GLAND; HEALTH; IDENTIFICATION; IN-UTERO; mammary gland; Mammary glands; MAMMARY-GLAND; MAMMARY-GLANDS; Neoplasia; PATHOLOGY; PATHWAY; PERINATAL EXPOSURE; POPULATION; PRENATAL EXPOSURE; proliferation; PROTEIN; PROTEINS; Proteomics; RAT; RATS; signaling; SIGNALING PATHWAY; SIGNALING PATHWAYS; SPARC; SUSCEPTIBILITY; SYSTEM</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1241</startpage>
    <endpage>1253</endpage>
    <journalfull>Journal of Proteomics</journalfull>
    <issue>6</issue>
    <volume>73</volume>
    <abstract>Bisphenol A (BPA) is a ubiquitous environmental contaminant with established endocrine disruptor properties. The objective of our study was to determine the effects of prenatal exposure to BPA on the rat mammary gland proteome in postnatal rats as a first step toward the investigation of translational biomarkers of susceptibility in the human population. Pregnant rats were treated orally with 0, 25 or 250 mu g BPA/kg body weight from days 10 to 21 post-conception. Female offspring were euthanized at 21 and 50 days, and mammary glands were collected. Proteomic analysis was conducted using 2-DE, followed by a combination of MALDI-TOF-TOF and LC-MS/MS, which led to the identification of 21 differentially abundant proteins including vimentin, SPARC and 14-3-3. Western blot analysis of key downstream signaling proteins demonstrated increased phospho-AKT, c-Raf, phospho-ERKs-1 and 2, but decreased TGF-beta in mammary glands of 50 day old rats exposed prenatally to BPA. Our studies indicate for the first time that key proteins involved in signaling pathways such as cellular proliferation are regulated at the protein level by BPA. This data is expected to aid in the understanding of how BPA may be influencing the susceptibility of the mammary gland to cancer transformation. (C) 2010 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000277763800021</url>
    <isbnorissn>1874-3919</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>206</id>
    <title>Altered Carcinogenesis and Proteome in Mammary Glands of Rats after Prepubertal Exposures to the Hormonally Active Chemicals Bisphenol A and Genistein</title>
    <authors>Betancourt,A.M.; Wang,J.; Jenkins,S.; Mobley,J.; Russo,J.; Lamartiniere,C.A.</authors>
    <availability>[Betancourt, Angela M.; Wang, Jun; Jenkins, Sarah; Lamartiniere, Coral A.] Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Mobley, Jim; Lamartiniere, Coral A.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA. [Mobley, Jim] Univ Alabama Birmingham, Dept Surg, Div Urol, Birmingham, AL USA. [Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleLamartiniere, CA (reprint author), Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USACoral@uab.eduADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; An JH, 2009, J PROTEOME RES, V8, P2873, DOI 10.1021/pr900020q; Bae Su-Mi, 2006, Cancer Res Treat, V38, P99, DOI 10.4143/crt.2006.38.2.99; Baylin SB, 1998, ADV CANCER RES, V72, P141; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Biles JE, 1997, J AGR FOOD CHEM, V45, P4697, DOI 10.1021/jf970518v; BOYLAN ES, 1983, CANCER RES, V43, P4879; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; BRINTON LA, 1988, CANCER INVEST, V6, P245, DOI 10.3109/07357908809080645; Brock JW, 2001, J EXPO ANAL ENV EPID, V11, P323, DOI 10.1038/sj.jea.7500174; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chen GA, 2004, J PATHOL, V202, P321, DOI 10.1002/path.1524; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Emoto K, 2001, ANTICANCER RES, V21, P1339; European Food Safety Authority, 2006, EFSA J, V428, P1; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; Fukutake M, 1996, FOOD CHEM TOXICOL, V34, P457, DOI 10.1016/0278-6915(96)87355-8; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; Hsu SJ, 2004, GENOME, V47, P931, DOI 10.1139/G04-043; Huang KC, 2006, INT J CANCER, V118, P2433, DOI 10.1002/ijc.21671; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Ji NY, 2009, INT J MOL MED, V24, P765, DOI 10.3892/ijmm_00000290; JINDAL HK, 1990, J BIOL CHEM, V265, P6540; Kim H, 2006, PROTEOMICS, V6, P3466, DOI 10.1002/pmic.200500629; Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20; LAMARTINIERE CA, 1995, CARCINOGENESIS, V16, P2833, DOI 10.1093/carcin/16.11.2833; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; Lamartiniere CA, 1982, 12 C ENV TOX DAYT OH, P96; Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237; Markey CM, 2001, BIOL REPROD, V65, P1215; MOON RC, 1969, INT J CANCER, V4, P312, DOI 10.1002/ijc.2910040308; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; National Toxicology Program, 1982, NATL TOXICOLOGY PROG, V215, P1; Ohno Y, 2009, BRIT J CANCER, V101, P287, DOI 10.1038/sj.bjc.6605128; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Pottenger LH, 2000, TOXICOL SCI, V54, P3, DOI 10.1093/toxsci/54.1.3; Rowell C, 2005, J NUTR, V135, p2953S; RUSSO IH, 1978, J NATL CANCER I, V61, P1439; RUSSO J, 1979, AM J PATHOL, V96, P721; Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S; Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003; Shu XO, 2001, CANCER EPIDEM BIOMAR, V10, P483; Snyder RW, 2000, TOXICOL APPL PHARM, V168, P225, DOI 10.1006/taap.2000.9051; Titus-Ernstoff L, 1998, CANCER EPIDEM BIOMAR, V7, P783; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; VOLKEL, 2002, CHEM RES TOXICOL, V15, P1281; Wang J, 2011, J PROTEOME RES, V10, P1621, DOI 10.1021/pr100974w; Wang M, 2009, ANTIOXID REDOX SIGN, V11, P2307, DOI 10.1089/ARS.2009.2485; WELSCH CW, 1985, CANCER RES, V45, P3415; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Yao HX, 2009, LUNG CANCER, V65, P41, DOI 10.1016/j.lungcan.2008.10.024; Zhao SH, 2009, MOL VIS, V15, P1231627AMER SOC NUTRITION-ASNBETHESDA9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USAJ NUTRJULDiscipline: Nutrition &amp; Dietetics963AP</notes>
    <keywords>ADULT; ANNEXIN-II; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CARCINOMA; Causation; CELL; CHEMICALS; Chemoprevention; development; DISEASE; diseases; Estrogen; ESTROGENS; EXPOSURE; EXPRESSION; FEMALE RATS; FOOD; genistein; GLAND; HEALTH; IDENTIFICATION; IN-UTERO EXPOSURE; Mammary cancer; mammary gland; MAMMARY-GLAND; MAMMARY-GLANDS; mechanism; MECHANISMS; MENSTRUAL FACTORS; MODEL; nutrition; PROTEIN; PROTEINS; Proteomics; RAT; RATS; RISK; SIGNALING PATHWAY; SIGNALING PATHWAYS; SOY; SUSCEPTIBILITY; toxicology; TUMOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1382S</startpage>
    <endpage>1388S</endpage>
    <journalfull>Journal of Nutrition</journalfull>
    <issue>7</issue>
    <volume>142</volume>
    <abstract>Through our diet, we are exposed to numerous natural and man-made chemicals, including polyphenols with hormone-like properties. The most abundant hormonally active polyphenols are characterized as weak estrogens. These chemicals are hypothesized to interfere with signaling pathways involved in important diseases such as breast cancer, which in most cases is initially estrogen dependent. Two such chemicals are bisphenol A (BPA), a plasticizer, and genistein, a component of soy. In spite of both possessing estrogenic properties, BPA and genistein yield different health outcomes. The exposure of rats during the prepubertal period to BPA increases the susceptibility of adult animals for mammary cancer development, whereas genistein decreases this susceptibility in a chemically induced model. Because both BPA and genistein possess estrogenic properties, it is certainly plausible that additional mechanisms are affected by these chemicals. Hence, it was our goal to investigate at the protein level how exposure to these 2 chemicals can contribute to mammary cancer causation as opposed to cancer chemoprevention. Using 2-dimensional gel electrophoresis followed by MS analysis, we identified differentially regulated proteins from the mammary glands of rats prepubertally exposed to BPA and genistein. Following protein identification, we used immunoblotting techniques to validate the identity and regulation of these proteins and to identify downstream signaling proteins. Our studies highlight the importance of proteomics technology in elucidating signaling pathways altered by exposure to hormonally active chemicals and its potential value in identifying biomarkers for mammary cancer. J. Nutr. 142: 1382S-1388S, 2012</abstract>
    <url>WOS:000305592800029</url>
    <isbnorissn>0022-3166</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>3</id>
    <title>Histone Methyltransferase EZH2 Is Transcriptionally Induced by Estradiol as Well as Estrogenic Endocrine Disruptors Bisphenol-A and Diethylstilbestrol</title>
    <authors>Bhan,A.; Hussain,I.; Ansari,K.I.; Bobzean,S.A.M.; Perrotti,L.I.; Mandel,S.S.</authors>
    <availability>[Bhan, Arunoday; Hussain, Imran; Ansari, Khairul I.; Mandel, Subhrangsu S.] Univ Texas Arlington, Dept Chem &amp; Biochem, Arlington, TX 76019 USA. [Bobzean, Samara A. M.; Perrotti, Linda I.] Univ Texas Arlington, Dept Psychol, Arlington, TX 76019 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleMandel, SS (reprint author), Univ Texas Arlington, Dept Chem &amp; Biochem, Arlington, TX 76019 USAsmandal@uta.eduAkbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052; Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t; Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x; Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263; Ansari KI, 2009, FRONT BIOSCI, V14, P3483, DOI 10.2741/4066; Ansari KI, 2013, MOL ENDOCRINOL, V27, P92, DOI 10.1210/me.2012-1147; Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078; Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x; Ansari KI, 2008, BBA-GENE REGUL MECH, V1779, P66, DOI 10.1016/j.bbagrm.2007.11.006; Ansari KI, 2009, FEBS J, V276, P3299, DOI 10.1111/j.1742-4658.2009.07055.x; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Benachour N, 2009, TOXICOL APPL PHARM, V241, P322, DOI 10.1016/j.taap.2009.09.005; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002; Bhan A, 2014, CHEMMEDCHEM; Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Calle EE, 1996, AM J EPIDEMIOL, V144, P645; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Crawford BD, 2006, ACS CHEM BIOL, V1, P495, DOI 10.1021/cb600367v; Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771; Das J, 2013, BIOORG MED CHEM LETT, V23, P6183, DOI 10.1016/j.bmcl.2013.08.093; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Dimri M, 2010, CARCINOGENESIS, V31, P489, DOI 10.1093/carcin/bgp305; Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461; Eilam-Stock T, 2012, BEHAV NEUROSCI, V126, P175, DOI 10.1037/a0025959; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Fenichel P, 2013, ANN ENDOCRINOL-PARIS, V74, P211, DOI 10.1016/j.ando.2013.04.002; Fiege H, 2000, ULLMANNS ENCY IND CH; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Gibert Y, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-4; Gioiosa L, 2007, HORM BEHAV, V52, P307, DOI 10.1016/j.yhbeh.2007.05.006; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Inagaki T, 2012, ENDOCRINOLOGY, V153, P3357, DOI 10.1210/en.2012-1121; Kasiri S, 2013, RSC ADV, V3, P3260, DOI 10.1039/c2ra22006g; Kerppola TK, 2009, TRENDS CELL BIOL, V19, P692, DOI 10.1016/j.tcb.2009.10.001; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee S, 2006, P NATL ACAD SCI USA, V103, P15392, DOI 10.1073/pnas.0607313103; Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455; Lemmen JG, 2004, ENVIRON HEALTH PERSP, V112, P1544; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012; Maclusky H, 2005, ENV HLTH PERSPECT, V11, P675; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McKenna NJ, 2009, MOL ENDOCRINOL, V23, P740, DOI 10.1210/me.2009-0135; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Saunders PTK, 1997, ADV EXP MED BIOL, V424, P99; Shen L, 2013, ONCOTARGETS THER, V6, P321, DOI 10.2147/OTT.S42453; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Shrestha B, 2012, FEBS J, V279, P3715, DOI 10.1111/j.1742-4658.2012.08733.x; Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrcd1991; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Verma SK, 2013, FUTURE MED CHEM, V5, P1661, DOI 10.4155/fmc.13.136; Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961; Weikert S, 2005, INT J MOL MED, V16, P349; Xu C, 2010, P NATL ACAD SCI USA, V107, P19266, DOI 10.1073/pnas.1008937107; Yearley EJ, 2008, J MOL STRUCT, V890, P240, DOI 10.1016/j.molstruc.2008.03.053; Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59; Zeidler M, 2006, J MOL HISTOL, V37, P219, DOI 10.1007/s10735-006-9042-9990ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDLONDON24-28 OVAL RD, LONDON NW1 7DX, ENGLANDJ MOL BIOLOCT 9SIDiscipline: Biochemistry &amp; Molecular BiologyAR5IC</notes>
    <keywords>AGGRESSIVE BREAST-CANCER; bisphenol A; BREAST-CANCER; CRITICAL ROLES; DIETHYLSTILBESTROL; ENDOCRINE DISRUPTORS; epigenetics; ESTRADIOL; estrogen signaling; EXPRESSION; EZH2; gene expression; GENE-EXPRESSION; GROUP PROTEIN ENHANCER; IN-UTERO EXPOSURE; LONG NONCODING RNA; METHYLASE MLL1; NUCLEAR RECEPTOR COREGULATORS; TUMOR-GROWTH; ZESTE HOMOLOG-2 EZH2</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3426</startpage>
    <endpage>3441</endpage>
    <journalfull>Journal of Molecular Biology</journalfull>
    <issue>20</issue>
    <volume>426</volume>
    <abstract>Enhancer of Zeste homolog 2 (EZH2), a methyltransferase specific to histone 3 lysine 27, is a critical player in gene silencing and is overexpressed in breast cancer. Our studies demonstrate that EZH2 is transcriptionally induced by estradiol in cultured breast cancer cells and in the mammary glands of ovariectomized rats. EZH2 promoter contains multiple functional estrogen-response elements. Estrogen receptors (ERs) and ER coregulators such as mixed lineage leukemia (MLL) histone methylases (MLL2 and MLL3) and histone acetyltransferase CBP/P300 bind to the EZH2 promoter in the presence of estradiol and regulate estradiol-induced EZH2 expression. EZH2 expression is also increased upon exposure to estrogenic endocrine disrupting chemicals (EDCs) such as bisphenol-A (BPA) and diethylstilbestrol (DES). Similar to estradiol, BPA and DES-induced EZH2 expression is coordinated by ERs, MLLs and CBP/P300. In summary, we demonstrate that EZH2 is transcriptionally regulated by estradiol in vitro and in vivo, and its expression is potentially dysregulated upon exposure to estrogenic EDCs. (C) 2014 Published by Elsevier Ltd</abstract>
    <url>WOS:000343617400009</url>
    <isbnorissn>0022-2836</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>46</id>
    <title>Bisphenol-A and diethylstilbestrol exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo</title>
    <authors>Bhan,A.; Hussain,I.; Ansari,K.I.; Bobzean,S.A.M.; Perrotti,L.I.; Mandal,S.S.</authors>
    <availability>[Bhan, Arunoday; Hussain, Imran; Ansari, Khairul I.; Mandal, Subhrangsu S.] Univ Texas Arlington, Dept Chem &amp; Biochem, Arlington, TX 76019 USA. [Bobzean, Samara A. M.; Perrotti, Linda I.] Univ Texas Arlington, Dept Psychol, Arlington, TX 76019 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleMandal, SS (reprint author), Univ Texas Arlington, Dept Chem &amp; Biochem, Arlington, TX 76019 USAsmandal@uta.eduAdamsson NA, 2008, REPROD TOXICOL, V25, P76, DOI 10.1016/j.reprotox.2007.08.001; Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052; Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t; Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x; Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263; Ansari KI, 2009, FRONT BIOSCI, V14, P3483, DOI 10.2741/4066; Ansari KI, 2013, MOL ENDOCRINOL, V27, P92, DOI 10.1210/me.2012-1147; Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078; Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352; Baba K, 2009, TOXICOL SCI, V108, P344, DOI 10.1093/toxsci/kfp025; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Block K, 2000, FASEB J, V14, P1101; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Bulynko YA, 2011, BIOCHEMISTRY-US, V50, P313, DOI 10.1021/bi101762x; Cabili MN, 2011, GENE DEV, V25, P1915; Calle EE, 1996, AM J EPIDEMIOL, V144, P645; Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200; Chen JG, 2006, MOL ENDOCRINOL, V20, P1, DOI 10.1210/me.2005-0192; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461; Eilam-Stock T, 2012, BEHAV NEUROSCI, V126, P175, DOI 10.1037/a0025959; Fenichel P, 2013, ANN ENDOCRINOL-PARIS, V74, P211, DOI 10.1016/j.ando.2013.04.002; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Geng YJ, 2011, J INT MED RES, V39, P2119; Gibert Y, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-4; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; Grun F, 2010, CURR OPIN ENDOCRINOL, V17, P453, DOI 10.1097/MED.0b013e32833ddea0; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Harries LW, 2012, BIOCHEM SOC T, V40, P902, DOI 10.1042/BST20120020; He S, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-102; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hwang HM, 2008, SCI TOTAL ENVIRON, V404, P26, DOI 10.1016/j.scitotenv.2008.05.031; Inagaki T, 2012, ENDOCRINOLOGY, V153, P3357, DOI 10.1210/en.2012-1121; Ishibashi M, 2013, ONCOL REP, V29, P946, DOI 10.3892/or.2012.2219; Jacobs MN, 2008, CURR DRUG METAB, V9, P796, DOI 10.2174/138920008786049294; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kim K, 2012, ONCOGENE, V32, P1616, DOI DOI 10.1038/0NC.2012.193; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee JS, 2008, CANCER LETT, V267, P189, DOI 10.1016/j.canlet.2008.03.013; Lee JW, 2000, EXP MOL MED, V32, P53; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee S, 2008, MOL ENDOCRINOL, V22, P1312, DOI 10.1210/me.2008-0012; Levi F, 1996, EUR J CANCER PREV, V5, P259, DOI 10.1097/00008469-199608000-00006; Li MWM, 2009, INT J BIOCHEM CELL B, V41, P2302, DOI 10.1016/j.biocel.2009.05.016; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Lv XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063516; Maclusky H, 2005, ENV HLTH PERSPECT, V11, P675; Mahoney MM, 2010, TOXICOL APPL PHARM, V247, P98, DOI 10.1016/j.taap.2010.05.017; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2001, BIOL REPROD, V65, P1215; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Milhem M.M., 2011, J CANC SCI THER S, VS5; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Nakagawa T, 2013, BIOCHEM BIOPH RES CO, V436, P319, DOI 10.1016/j.bbrc.2013.05.101; Nakanishi T, 2008, J TOXICOL SCI, V33, P269, DOI 10.2131/jts.33.269; Nanjappa M.K., 2012, BIOL REPROD, V86, P112; Navas JM, 2008, EXPERT OPIN DRUG MET, V4, P605, DOI [10.1517/17425255.4.5.605 , 10.1517/17425250802066483]; Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803; Niland Courtney N, 2012, Front Genet, V3, P25, DOI 10.3389/fgene.2012.00025; Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10; Pan YF, 2011, CHINESE MED J-PEKING, V124, P2378, DOI 10.3760/cma.j.issn.0366-6999.2011.15.023; Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P149, DOI 10.1080/00927870701873115; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qureshi IA, 2010, BRAIN RES, V1338, P20, DOI 10.1016/j.brainres.2010.03.110; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Saunders PTK, 1997, ADV EXP MED BIOL, V424, P99; Schoeters G, 2008, BASIC CLIN PHARMACOL, V102, P168, DOI 10.1111/j.1742-7843.2007.00180.x; Shrestha B, 2012, FEBS J, V279, P3715, DOI 10.1111/j.1742-4658.2012.08733.x; Sierra-Miranda M, 2012, MOL BIOCHEM PARASIT, V185, P36, DOI 10.1016/j.molbiopara.2012.06.005; Sleutels F, 2002, NATURE, V415, P810; Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com; Stangl H, 2002, J ENDOCRINOL, V175, P663, DOI 10.1677/joe.0.1750663; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Umezawa R, 2009, ENDOCRINOLOGY, V150, P3425, DOI 10.1210/en.2008-1738; Valekunja UK, 2013, P NATL ACAD SCI USA, V110, P1554, DOI 10.1073/pnas.1214168110; Vuorinen A, 2013, J STEROID BIOCHEM, V137, P18, DOI 10.1016/j.jsbmb.2013.04.009; Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896; Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107; Wohlfahrt-Veje C, 2009, CLIN ENDOCRINOL, V71, P459, DOI 10.1111/j.1365-2265.2009.03545.x; Wolstenholme JT, 2012, ENDOCRINOLOGY, V153, P3828, DOI 10.1210/en.2012-1195; Xia Tian, 2013, Yichuan, V35, P269, DOI 10.3724/SP.J.1005.2013.00269; Xu XH, 2012, HORM BEHAV, V62, P480, DOI 10.1016/j.yhbeh.2012.08.005; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Yearley EJ, 2008, J MOL STRUCT, V890, P240, DOI 10.1016/j.molstruc.2008.03.053; Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-351022PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMMAYDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; MetabolismAG0OJ</notes>
    <keywords>ACTIVATION; ALTERS; BIOLOGY; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELL-CYCLE; CELLS; CRITICAL ROLES; DIETHYLSTILBESTROL; Endocrine disruption; Endocrine-disrupting chemicals; epigenetics; ESTRADIOL; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; HOTAIR; In vitro; IN-VITRO; IN-VIVO; LncRNA; LONG NONCODING RNA; MAMMARY-GLAND; MAMMARY-GLAND DEVELOPMENT; METABOLISM; METHYLATION; MLL HISTONE METHYLASES; NUCLEAR RECEPTOR SUPERFAMILY; Transcriptional regulation; UTERO EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>160</startpage>
    <endpage>170</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <volume>141</volume>
    <abstract>Antisense transcript, long non-coding RNA HOTAIR is a key player in gene silencing and breast cancer and is transcriptionally regulated by estradiol. Here, we have investigated if HOTAIR expression is misregulated by bisphenol-A (BPA) and diethylstilbestrol (DES). Our findings demonstrate BPA and DES induce HOTAIR expression in cultured human breast cancer cells (MCF7) as well as in vivo in the mammary glands of rat. Luciferase assay showed that HOTAIR promoter estrogen-response-elements (EREs) are induced by BPA and DES. Estrogen-receptors (ERs) and ER-coregulators such as MLL-histone methylases (MLL1 and MLL3) bind to the HOTAIR promoter EREs in the presence of BPA and DES, modify chromatin (histone methylation and acetylation) and lead to gene activation. Knockdown of ERs down-regulated the BPA and DES-induced expression of HOTAIR. In summary, our results demonstrate that BPA and DES exposure alters the epigenetic programming of the HOTAIR promoters leading to its endocrine disruption in vitro and in vivo. Published by Elsevier Ltd</abstract>
    <url>WOS:000335114500019</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>210</id>
    <title>Dental methacrylates may exert genotoxic effects via the oxidative induction of DNA double strand breaks and the inhibition of their repair</title>
    <authors>Blasiak,J.; Synowiec,E.; Tarnawska,J.; Czarny,P.; Poplawski,T.; Reiter,R.J.</authors>
    <availability>[Blasiak, Janusz; Synowiec, Ewelina; Tarnawska, Justyna; Czarny, Piotr; Poplawski, Tomasz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland. [Reiter, Russel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular &amp; Struct Biol, San Antonio, TX 78229 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleBlasiak, J (reprint author), Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Polandjblasiak@biol.uni.lodz.plAn SH, 2011, BMB REP, V44, P211, DOI 10.5483/BMBRep.2011.44.3.211; Bejarano I, 2009, J PINEAL RES, V46, P392, DOI 10.1111/j.1600-079X.2009.00675.x; Blasiak J, 2011, J PINEAL RES, V51, P157, DOI 10.1111/j.1600-079X.2011.00877.x; Blasiak J, 2003, MUTAT RES-GEN TOX EN, V535, P25, DOI 10.1016/S1383-5718(02)00289-9; Blasiak J, 2011, MED SCI MONITOR, V17, P201; Chang HH, 2005, BIOMATERIALS, V26, P745, DOI 10.1016/j.biomaterials.2004.03.021; Drozdz K, 2011, ARCH TOXICOL, V85, P1453, DOI 10.1007/s00204-010-0593-x; Eckhardt A, 2009, BIOMATERIALS, V30, P2006, DOI 10.1016/j.biomaterials.2008.12.045; Emmler J, 2008, DENT MATER, V24, P1670, DOI 10.1016/j.dental.2008.04.001; Ferron-Celma I, 2009, J SURG RES, V153, P224, DOI 10.1016/j.jss.2008.04.024; Gedik Catherine M, 2005, FASEB J, V19, P82; Jung YJ, 2009, AM J DENT, V22, P295; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Kleinsasser NH, 2006, BIOMATERIALS, V27, P1762, DOI 10.1016/j.biomaterials.2005.09.023; Kostoryz EL, 2009, J BIOMED MATER RES B, V88B, P394, DOI 10.1002/jbm.b.31095; Li H, 2008, MECH AGEING DEV, V129, P416, DOI 10.1016/j.mad.2008.02.002; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mavrogonatou E, 2010, BIOMATERIALS, V31, P8530, DOI 10.1016/j.biomaterials.2010.07.074; Noda M, 2002, J DENT RES, V81, P265; Pawlowska E, 2010, MUTAT RES-GEN TOX EN, V696, P122, DOI 10.1016/j.mrgentox.2009.12.019; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Poplawski T, 2009, CHEM-BIOL INTERACT, V180, P69, DOI 10.1016/j.cbi.2009.02.001; Poplawski T, 2010, TOXICOL IN VITRO, V24, P854, DOI 10.1016/j.tiv.2009.12.004; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Reiter RJ, 2010, CURR NEUROPHARMACOL, V8, P194, DOI 10.2174/157015910792246236; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Ribeiro DA, 2006, J MATER SCI-MATER M, V17, P495, DOI 10.1007/s10856-006-8931-5; Ribeiro DA, 2008, ORAL SURG ORAL MED O, V105, P251, DOI 10.1016/j.tripleo.2007.07.045; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schweikl H, 2007, DENT MATER, V23, P688, DOI 10.1016/j.dental.2006.06.021; Schweikl H, 2008, BIOMATERIALS, V29, P1377, DOI 10.1016/j.biomaterials.2007.11.049; Schweikl H, 2006, J DENT RES, V85, P870; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Singh NP, 1997, MUTAT RES-DNA REPAIR, V383, P167, DOI 10.1016/S0921-8777(96)00056-0; Smith CC, 2006, MUTAGENESIS, V21, P185, DOI 10.1093/mutage/ge1019; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3&lt;206::AID-EM8&gt;3.0.CO;2-J; Tsai A. G., 2010, BMC GENOMICS S11, P51; Urcan E, 2010, BIOMATERIALS, V31, P2010, DOI 10.1016/j.biomaterials.2009.11.065; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Wisniewska-Jarosinska M, 2010, MOL BIOL REP, V38, P40064311SPRINGERDORDRECHTVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDSMOL BIOL REPJULDiscipline: Biochemistry &amp; Molecular Biology947CP</notes>
    <keywords>2-hydroxyethyl methacrylate; apoptosis; ASSAY; BIOLOGY; Bis-GMA; bisphenol; Bisphenol A-diglycidyl dimethacrylate; CANCER-CELLS; CELL; CELL-CYCLE ARREST; Comet assay; Cytotoxicity; DAMAGE; DENTISTRY; DIMETHACRYLATE; DNA damage; DNA double-strand breaks; DNA repair; DNA-DAMAGE; GENE; GLYCIDYL METHACRYLATE; HEMA; In vitro; IN-VITRO; INDUCTION; inhibition; mechanism; MECHANISMS; Melatonin; Methacrylate-based dental materials; MICROGEL ELECTROPHORESIS; MODEL; PHOSPHORYLATION; POPULATION; REPAIR; RESIN MONOMERS; Vitamin C; VITAMIN-C; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>7487</startpage>
    <endpage>7496</endpage>
    <journalfull>Molecular Biology Reports</journalfull>
    <issue>7</issue>
    <volume>39</volume>
    <abstract>Methacrylate monomers used in dentistry have been shown to induce DNA double strand breaks (DSBs), one of the most serious DNA damage. In the present work we show that a model dental adhesive consisting of 45% 2-hydroxyethyl methacrylate (HEMA) and 55% bisphenol A-diglycidyl dimethacrylate (Bis-GMA) at concentrations up to 0.25 mM Bis-GMA induced oxidative DNA in cultured primary human gingival fibroblasts (HGFs) as evaluated by the comet assay and probed with human 8-hydroxyguanine DNA-glycosylase 1. HEMA/Bis-GMA induced DSBs in HGFs as assessed by the neutral comet assay and phosphorylation of the H2AX histone and sodium ascorbate or melatonin (5-methoxy-N-acetyltryptamine) both at 50 mu M reduced the DSBs, they also inhibited apoptosis induced by HEMA/Bis-GMA. The adhesive slowed the kinetics of the repair of DNA damage induced by hydrogen peroxide in HGFs, while sodium ascorbate or melatonin improved the efficacy of H2O2-induced damage in the presence of the methacrylates. The adhesive induced a rise in the G2/M cell population, accompanied by a reduction in the S cell population and an increase in G0/G1 cell population. Sodium ascorbate or melatonin elevated the S population and reduced the G2/M population. In conclusion, HEMA/Bis-GMA induce DSBs through, at least in part, oxidative mechanisms, and these compounds may interfere with DSBs repair. Vitamin C or melatonin may reduce the detrimental effects induced by methacrylates applied in dentistry</abstract>
    <url>WOS:000304404600030</url>
    <isbnorissn>0301-4851</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>428</id>
    <title>Gene expression profiling in Ishikawa cells: A fingerprint for estrogen active compounds</title>
    <authors>Boehme,K.; Simon,S.; Mueller,S.O.</authors>
    <availability>[Boehme, Kathleen; Simon, Stephanie; Mueller, Stefan O.] Merck KGaA, Merck Serono, NCD Toxicol Early &amp; Explanatory Toxicol, D-64271 Darmstadt, Germany.</availability>
    <date>2009</date>
    <notes>JEnglishArticleMueller, SO (reprint author), Merck KGaA, Merck Serono, NCD Toxicol Early &amp; Explanatory Toxicol, D-64271 Darmstadt, Germanystefart.o.mueller@merck.deAkimoto S, 2004, PATHOL INT, V54, P688, DOI 10.1111/j.1440-1827.2004.01681.x; ALBERT JL, 1990, CANCER RES, V50, P3306; Allred CD, 2001, CARCINOGENESIS, V22, P1667, DOI 10.1093/carcin/22.10.1667; Bachmann M, 2006, INT J BIOCHEM CELL B, V38, P430, DOI 10.1016/j.biocel.2005.10.010; Barkhem T, 1998, MOL PHARMACOL, V54, P105; Beard J, 2006, SCI TOTAL ENVIRON, V355, P78, DOI 10.1016/j.scitotenv.2005.02.022; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Bhat KPL, 2001, CANCER RES, V61, P7456; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; BREDHULT C, 2008, HUM REPROD, V14, P97; Bredhult C, 2007, REPROD TOXICOL, V23, P550, DOI 10.1016/j.reprotox.2007.03.006; CECIL HC, 1971, J AGR FOOD CHEM, V19, P61, DOI 10.1021/jf60173a049; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Couse JF, 2001, DEV BIOL, V238, P224, DOI 10.1006/dbio.2001.0413; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cristillo AD, 1997, DNA CELL BIOL, V16, P1449, DOI 10.1089/dna.1997.16.1449; Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8.; Delclos KB, 2001, REPROD TOXICOL, V15, P647, DOI 10.1016/S0890-6238(01)00177-0; Diel P, 2000, J STEROID BIOCHEM, V73, P1, DOI 10.1016/S0960-0760(00)00051-0; Erlandsson MC, 2005, APMIS, V113, P317, DOI 10.1111/j.1600-0463.2005.apm_113502.x; Farias EF, 2005, ONCOGENE, V24, P1598, DOI 10.1038/sj.onc.1208347; Fontijn D, 2006, BRIT J CANCER, V94, P1627, DOI 10.1038/sj.bjc.6603157; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Gabriel B, 2004, ANTICANCER RES, V24, P921; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Ghosh MG, 2000, CANCER RES, V60, P6367; Gunderson KL, 2004, GENOME RES, V14, P870, DOI 10.1101/gr.2255804; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Henderson NC, 2004, J BIOL CHEM, V279, P54731, DOI 10.1074/jbc.M408700200; Hengstler JG, 2006, TOXICOLOGY, V220, P232, DOI 10.1016/j.tox.2005.12.2005; Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089; HOLINKA CF, 1986, J STEROID BIOCHEM, V24, P85, DOI 10.1016/0022-4731(86)90036-1; Holm L, 2006, ENVIRON TOXICOL CHEM, V25, P2787, DOI 10.1897/05-619R.1; Howell A, 2000, EUR J CANCER, V36, pS87; HUFF J, 1996, CELLULAR MOL MECH HA; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; *ILL INC, 2005, WHOL GEN EXPR AN US; *ILL INC, 2006, BEADSTUDIO GEN EXPR; Jaga Kushik, 2003, Int J Occup Med Environ Health, V16, P7; JIANG SY, 1992, J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Katoh M, 2001, INT J MOL MED, V8, P657; Katoh M, 2005, INT J MOL MED, V16, P1103; Kim DK, 2004, ANTICANCER RES, V24, P1671; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; Kuhn K, 2004, GENOME RES, V14, P2347, DOI 10.1101/gr.2739104; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; KUIPERGOODMAN T, 1987, REGUL TOXICOL PHARM, V7, P253, DOI 10.1016/0273-2300(87)90037-7; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Lee AJ, 2003, ENDOCRINOLOGY, V144, P3382, DOI 10.1210/en.2003-0192; Levenson AS, 2003, INT J CANCER, V104, P587, DOI 10.1002/ijc.10992; Linsalata M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-191; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MAKELA S, 1994, ENVIRON HEALTH PERSP, V102, P572; Moutsatsou Paraskevi, 2007, Hormones (Athens), V6, P173; Mueller SO, 2003, J BIOL CHEM, V278, P12255, DOI 10.1074/jbc.M203578200; Mueller Stefan O., 2001, Current Opinion in Pharmacology, V1, P613, DOI 10.1016/S1471-4892(01)00105-9; MUELLER SO, 2001, ENDOCRINE DISRUPTORS, P1; Mueller SO, 2003, TOXICOL LETT, V142, P89, DOI 10.1016/S0378-4274(03)00016-X; Mueller SO, 2002, J CHROMATOGR B, V777, P155, DOI 10.1016/S1570-0232(02)00282-9; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Naciff JM, 2009, TOXICOL SCI, V107, P40, DOI 10.1093/toxsci/kfn219; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Newbold R R, 1996, Prog Clin Biol Res, V394, P131; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Papoulias DM, 2003, ENVIRON HEALTH PERSP, V111, P29, DOI 10.1289/ehp.5540; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P351, DOI 10.1080/10937400701876657; Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P322, DOI 10.1080/10937400701876194; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Rice S, 2006, ENDOCR-RELAT CANCER, V13, P995, DOI 10.1677/erc.1.01159; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Roemer K, 2002, DRUGS TODAY, V38, P571, DOI 10.1358/dot.2002.38.8.820097; Safe SH, 2001, REPROD FERT DEVELOP, V13, P307, DOI 10.1071/RD00108; SAVOURET JF, 1991, EMBO J, V10, P1875; Shirai T, 2003, PURE APPL CHEM, V75, P2419, DOI 10.1351/pac200375112419; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Simoncini T, 2003, EUR J ENDOCRINOL, V148, P281, DOI 10.1530/eje.0.1480281; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Steemers FJ, 2005, PHARMACOGENOMICS, V6, P777, DOI 10.2217/14622416.6.7.777; TANAKA T, 1988, MYCOPATHOLOGIA, V101, P157, DOI 10.1007/BF00437032; Tuschl G, 2006, TOXICOLOGY, V218, P205, DOI 10.1016/j.tox.2005.10.017; Tyl RW, 2008, TOXICOL SCI, V104, P362, DOI 10.1093/toxsci/kfn084; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; vom Saal Frederick S., 2005, Birth Defects Research, V73, P140, DOI 10.1002/bdra.20120; Vyhlidal C, 2000, J MOL ENDOCRINOL, V24, P329, DOI 10.1677/jme.0.0240329; WELCH RM, 1969, TOXICOL APPL PHARM, V14, P358, DOI 10.1016/0041-008X(69)90117-3; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; White KA, 2005, J BIOL CHEM, V280, P7829, DOI 10.1074/jbc.M412707200; Withanage GSK, 2001, VET HUM TOXICOL, V43, P6; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Zandbergen F, 2005, BIOCHEM J, V392, P313, DOI 10.1042/BJ20050636; Zava DT, 1997, NUTR CANCER, V27, P31; Zheng Ji-cui, 2007, Zhonghua Yufang Yixue Zazhi, V41, P295; Zidek N, 2007, TOXICOL SCI, V99, P289, DOI 10.1093/toxsci/kfm1319919ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMAPR 1Discipline: Pharmacology &amp; Pharmacy; Toxicology424ZO</notes>
    <keywords>1; 17-ALPHA-ETHYNYL ESTRADIOL; ANTIESTROGEN; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; CELLS; CHEMICALS; DEFECTS; development; DIETARY BISPHENOL-A; DIETHYLSTILBESTROL; DISEASE; diseases; ENDOCRINE; Endocrine active compound; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENDOMETRIAL CANCER; ER; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Estrogenic; EXPRESSION; FOOD; GENE; gene expression; gene expression profile; Gene expression profiling; gene regulation; GENE-EXPRESSION; GENES; genistein; HEALTH; Hormone; Hormones; HUMANS; ICI 182,780; Illumina; IN-VITRO; Ishikawa cells; mechanism; MOLECULAR-MECHANISMS; PHARMACOLOGY; Phytoestrogen; PHYTOESTROGENS; POPULATION; RECEPTOR; RECEPTOR-ALPHA; Regulation; REPRODUCTIVE TOXICITY; RESVERATROL; screening; signaling; SPRAGUE-DAWLEY RATS; Steroid; toxicology; transcriptional activation; Zearalenone</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>85</startpage>
    <endpage>96</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>1</issue>
    <volume>236</volume>
    <abstract>Several anthropogenous and naturally occurring substances, referred to as estrogen active compounds (EACs), are able to interfere with hormone and in particular estrogen receptor signaling. EACs can either cause adverse health effects in humans and wildlife populations or have beneficial effects on estrogen-dependent diseases. The aim of this study was to examine global gene expression profiles in estrogen receptor (ER)-proficient Ishikawa plus and ER-deficient Ishikawa minus endometrial cancer cells treated with selected well-known EACs (Diethylstilbestrol, Genistein, Zearalenone, Resveratrol, Bisphenol A and o,p'-DDT). We also investigated the effect of the pure antiestrogen ICI 182,780 (ICI) on the expression patterns caused by these compounds. Transcript levels were quantified 24 h after compound treatment using Illumina BeadChip Arrays. We identified 87 genes with similar expression changes in response to all EAC treatments in Ishikawa plus. ICI lowered the magnitude or reversed the expression of these genes, indicating ER dependent regulation. Apart from estrogenic gene regulation, Bisphenol A, o,p'-DDT, Zearalenone, Genistein and Resveratrol displayed similarities to ICI in their expression patterns, suggesting mixed estrogenic/antiestrogenic properties. In particular, the predominant antiestrogenic expression response of Resveratrol could be clearly distinguished from the other test compounds, indicating a distinct mechanism of action. Divergent gene expression patterns of the phytoestrogens, as well as weaker estrogenic gene expression regulation determined for the anthropogenous chemicals Bisphenol A and o,p'-DDT, warrants a careful assessment of potential detrimental and/or beneficial effects of EACs. The characteristic expression fingerprints and the identified Subset of putative marker genes can be used for screening chemicals with an unknown mode of action and for predicting their potential to exert endocrine disrupting effects. (C) 2009 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000264607000010</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>337</id>
    <title>Bisphenol A Impairs Estradiol-induced Protective Effects Against DLD-1 Colon Cancer Cell Growth</title>
    <authors>Bolli,A.; Bulzomi,P.; Galluzzo,P.; Acconcia,F.; Marino,M.</authors>
    <availability>[Bolli, Alessandro; Bulzomi, Pamela; Galluzzo, Paola; Acconcia, Filippo; Marino, Maria] Univ Roma Tre, Dept Biol, I-00146 Rome, Italy. [Bolli, Alessandro; Marino, Maria] Natl Inst Biostruct &amp; Biosyst, Rome, Italy.</availability>
    <date>2010</date>
    <notes>JEnglishArticleMarino, M (reprint author), Univ Roma Tre, Dept Biol, Viale Guglielmo Marconi 446, I-00146 Rome, Italym.marino@uniroma3.itAscenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Caiazza F, 2007, BIOCHEM BIOPH RES CO, V359, P102, DOI 10.1016/j.bbrc.2007.05.059; Campbell-Thompson M, 2001, CANCER RES, V61, P632; Crandall CJ, 1999, J WOMEN HEALTH GEN-B, V8, P1155, DOI 10.1089/jwh.1.1999.8.1155; DeCosse J J, 1993, Eur J Cancer Prev, V2, P105, DOI 10.1097/00008469-199303000-00003; Foley EF, 2000, CANCER RES, V60, P245; Franceschi S, 2000, BRIT J CANCER, V82, P1860, DOI 10.1054/bjoc.1999.1084; Galluzzo P, 2007, ENDOCR-RELAT CANCER, V14, P153, DOI 10.1677/ERC-06-0020; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; KONSTANTINOPOUL.PA, 2003, EUR J CANCER, V39, P251; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; Marino M, 2008, CANC THER, V6, P149; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; SCHULTS JR, 1988, BIOPHARMACEUTICAL ST; Slattery ML, 2004, PREV MED, V38, P276, DOI 10.1016/j.ypmed.2003.11.009; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.0102110JOHN WILEY &amp; SONS INCHOBOKEN111 RIVER ST, HOBOKEN, NJ 07030 USAIUBMB LIFESEPDiscipline: Biochemistry &amp; Molecular Biology; Cell Biology665DR</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; ALPHA; analysis; apoptosis; ASSOCIATION; BETA; BINDING; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER CELLS; CANCER-CELL-GROWTH; CANCER-CELLS; CELL; cell growth; CELLS; colon cancer cell line; COLORECTAL-CANCER; COMBINATION; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ER alpha; ER beta; ER-ALPHA; ER-BETA; ER-BETA EXPRESSION; Estrogen; Estrogen receptor; Estrogen receptor alpha; Estrogen receptor beta; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTOR-BETA; EXPOSURE; EXPOSURES; GROWTH; HEALTH; IMPACT; LINE; MIMICS; p21; p38; POPULATION; proliferation; RECEPTOR; RECEPTOR-ALPHA; RISK; RIVER; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>684</startpage>
    <endpage>687</endpage>
    <journalfull>Iubmb Life</journalfull>
    <issue>9</issue>
    <volume>62</volume>
    <abstract>Bisphenol A (BPA), a prototype of endocrine disruptors, mimics 17 beta-estradiol (E2)-induced proliferation in several cancer cells by binding to estrogen receptor alpha (ER alpha). However, scarce and conflicting data are available concerning the effect of BPA on estrogen receptor beta (ER beta)-mediated functions. Here, the detailed analysis of the effect of BPA, alone or in combination with E2, on ER beta-mediated cellular functions is reported in ER beta-expressing colon cancer cell line. BPA binds to ER beta without activating any receptor activities. On the other hand, BPA inhibits E2-induced genomic activity of ER beta as well as ER beta extra-nuclear activities (i.e., ER beta:p38 association and p38 activation). As a consequence, BPA impairs the E2-induced activation of the apoptotic cascade which is at the root of the protective role played by the hormone against colon cancer growth. Thus, women may be considered a highly susceptible population with an increased risk of colon cancers after BPA exposures. (C) 2010 IUBMB IUBMB Life, 62(9): 684-687, 2010</abstract>
    <url>WOS:000283015900005</url>
    <isbnorissn>1521-6543</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>368</id>
    <title>Male reproductive organs are at risk from environmental hazards</title>
    <authors>Bonde,J.P.</authors>
    <availability>Bispebjerg Hosp, Dept Occupat &amp; Environm Med, DK-2400 Copenhagen NV, Denmark.</availability>
    <date>2010</date>
    <notes>JEnglishReviewBonde, JP (reprint author), Bispebjerg Hosp, Dept Occupat &amp; Environm Med, Bispebjerg Bakke 23,Bldg 33, DK-2400 Copenhagen NV, Denmarkjpb@bbh.regionh.dkAbell A, 2000, SCAND J WORK ENV HEA, V26, P492; Andersen AG, 2000, HUM REPROD, V15, P366, DOI 10.1093/humrep/15.2.366; Anderson Diana, 2003, Adv Exp Med Biol, V518, P11; Aneck-Hahn NH, 2007, J ANDROL, V28, P423, DOI 10.2164/jandrol.106.001701; Axmon A, 2006, HUM REPROD, V21, P657, DOI 10.1093/humrep/dei397; BARANSKI B, 1993, ENVIRON HEALTH PERSP, V101, P81, DOI 10.2307/3431380; BONDE JP, 1990, BRIT J IND MED, V47, P508; Bonde J P, 2002, G Ital Med Lav Ergon, V24, P112; Bonde JP, 2006, EPIDEMIOLOGY, V17, P347, DOI 10.1097/01.ede.0000210239.80406.46; Bonde JP, 2002, OCCUP ENVIRON MED, V59, P234, DOI 10.1136/oem.59.4.234; Bonde JP, 1996, OCCUP ENVIRON MED, V53, P511; BONDE JP, 1990, SCAND J WORK ENV HEA, V16, P315; Bonde JP, 1999, INT ARCH OCC ENV HEA, V72, P133, DOI 10.1007/s004200050351; Bonde JPE, 1998, LANCET, V352, P1172, DOI 10.1016/S0140-6736(97)10514-1; Cordier S, 2008, BASIC CLIN PHARMACOL, V102, P176, DOI 10.1111/j.1742-7843.2007.00162.x; De Jager C, 2006, J ANDROL, V27, P16, DOI 10.2164/jandrol.05121; Figa-Talamanca I, 2001, OCCUP MED-OXFORD, V51, P174, DOI 10.1093/occmed/51.3.174; Giwercman A, 1998, ENDOCRIN METAB CLIN, V27, P807, DOI 10.1016/S0889-8529(05)70042-6; HENDERSON J, 1986, Clinical Reproduction and Fertility, V4, P87; Hjollund NHI, 2002, REPROD TOXICOL, V16, P209, DOI 10.1016/S0890-6238(02)00026-6; JENSEN MS, 2008, FERTIL STERIL; Jensen MS, 2005, HUM REPROD, V20, P2559, DOI 10.1093/humrep/dei110; Jensen TK, 2006, OCCUP MED-OXFORD, V56, P544, DOI 10.1093/occmed/kql116; Jensen TK, 1998, AM J EPIDEMIOL, V148, P992; Jensen TK, 2004, AM J EPIDEMIOL, V159, P49, DOI 10.1093/aje/kwh002; Kolstad HA, 1999, INT ARCH OCC ENV HEA, V72, P135, DOI 10.1007/s004200050352; Kumar S, 2004, J OCCUP HEALTH, V46, P1, DOI 10.1539/joh.46.1; LAHDETIE J, 1995, J OCCUP ENVIRON MED, V37, P922; Li YF, 2009, HUM REPROD, V24, P459, DOI 10.1093/humrep/den399; Liu Ping, 2006, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V24, P167; Marchetti F, 1999, BIOL REPROD, V61, P948, DOI 10.1095/biolreprod61.4.948; MIEUSSET R, 1995, INT J ANDROL, V18, P169, DOI 10.1111/j.1365-2605.1995.tb00408.x; MORTENSEN JT, 1988, SCAND J WORK ENV HEA, V14, P27; Oliva A, 2001, HUM REPROD, V16, P1768, DOI 10.1093/humrep/16.8.1768; Perry MJ, 2008, HUM REPROD UPDATE, V14, P233, DOI 10.1093/humupd/dmm039; POTASHNIK G, 1978, FERTIL STERIL, V30, P444; Ramlau-Hansen CH, 2007, AM J EPIDEMIOL, V165, P1372, DOI 10.1093/aje/kwm032; RATCLIFFE JM, 1987, BRIT J IND MED, V44, P317; RATCLIFFE JM, 1989, BRIT J IND MED, V46, P399; Robbins WA, 2008, J ANDROL, V29, P115, DOI 10.2164/jandrol.107.003541; ROWLEY MJ, 1974, RADIAT RES, V59, P665, DOI 10.2307/3574084; SCIALLI AR, 1993, REPROD TOXICOL, V7, P189, DOI 10.1016/0890-6238(93)90223-T; Sheiner EK, 2003, IND HEALTH, V41, P55, DOI 10.2486/indhealth.41.55; Shiau CY, 2004, OCCUP ENVIRON MED, V61, P915, DOI 10.1136/oem.2004.014944; Skakkebaek Niels E., 2003, Hormone Research (Basel), V60, P49, DOI 10.1159/000074499; Spano M, 2005, HUM REPROD, V20, P3488, DOI 10.1093/humrep/dei297; Storgaard L, 2003, EPIDEMIOLOGY, V14, P278, DOI 10.1097/00001648-200305000-00006; Stoy J, 2004, INT J ANDROL, V27, P5, DOI 10.1046/j.0105-6263.2003.00428.x; Thonneau P, 1998, HUM REPROD, V13, P2122, DOI 10.1093/humrep/13.8.2122; Tielemans E, 1999, FERTIL STERIL, V71, P690, DOI 10.1016/S0015-0282(98)00542-1; Toft G, 2006, EPIDEMIOLOGY, V17, P450, DOI 10.1097/01.ede.0000221769.41028.d2; TORKELSON TR, 1961, TOXICOL APPL PHARM, P545; TRASLER JM, 1985, NATURE, V316, P144, DOI 10.1038/316144a0; VANHOORNE M, 1994, ARCH ENVIRON HEALTH, V49, P273; Viskum S, 1999, AM J IND MED, V35, P257, DOI 10.1002/(SICI)1097-0274(199903)35:3&lt;257::AID-AJIM5&gt;3.0.CO;2-#; *WHO, 1998, BOR; WHORTON D, 1977, LANCET, V2, P1259; WYROBEK AJ, 1981, ENVIRON HEALTH PERSP, V40, P255, DOI 10.2307/34292375833NATURE PUBLISHING GROUPNEW YORK75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USAASIAN J ANDROLMARDiscipline: Endocrinology &amp; Metabolism; Urology &amp; Nephrology563ED</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CARBON; CHROMATIN-STRUCTURE; Cryptorchidism; DDT EXPOSURE; diet; DISORDERS; DYSFUNCTION; Epidemiology; EXPOSURE; EXPOSURES; fertility; FETAL; HEALTH; Hormone; HUMAN SPERM; LINE; Male; male reproductive function; MALE-FERTILITY; MALE-INFERTILITY; METABOLISM; Metals; occupation; Occupational; OCCUPATIONAL EXPOSURES; PESTICIDES; phthalate; Phthalates; POLLUTANTS; POPULATION; PRODUCTS; RADIATION; REDUCED SEMEN QUALITY; Reproduction; reproductive disorders; REPRODUCTIVE FUNCTION; REPRODUCTIVE TOXICITY; REPRODUCTIVE-ORGANS; Review; RISK; RISK FACTOR; risk factors; RISK-FACTORS; SEMEN QUALITY; SEXUAL DYSFUNCTION; SPERM; SPERM COUNTS; testis; TISSUE; TISSUES; TOXICITY; UPDATE; WORKERS; YOUNG MEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>152</startpage>
    <endpage>156</endpage>
    <journalfull>Asian Journal of Andrology</journalfull>
    <issue>2</issue>
    <volume>12</volume>
    <abstract>Male reproductive disorders that are of interest from an environmental point of view include sexual dysfunction, infertility, cryptorchidism, hypospadias and testicular cancer. Several reports suggest declining sperm counts and increase of these reproductive disorders in some areas during some time periods past 50 years. Except for testicular cancer this evidence is circumstantial and needs cautious interpretation. However, the male germ line is one of the most sensitive tissues to the damaging effects of ionizing radiation, radiant heat and a number of known toxicants. So far occupational hazards are the best documented risk factors for impaired male reproductive function and include physical exposures (radiant heat, ionizing radiation, high frequency electromagnetic radiation), chemical exposures (some solvents as carbon disulfide and ethylene glycol ethers, some pesticides as dibromochloropropane, ethylendibromide and DDT/DDE, some heavy metals as inorganic lead and mercury) and work processes such as metal welding. Improved working conditions in affluent countries have dramatically decreased known hazardous workplace exposures, but millions of workers in less affluent countries are at risk from reproductive toxicants. New data show that environmental low-level exposure to biopersistent pollutants in the diet may pose a risk to people in all parts of the world. For other toxicants the evidence is only suggestive and further evaluation is needed before conclusions can be drawn. Whether compounds as phthalates, bisphenol A and boron that are present in a large number of industrial and consumer products entails a risk remains to be established. The same applies to psychosocial stressors and use of mobile phones. Finally, there are data indicating a particular vulnerability of the fetal testis to toxicants-for instance maternal tobacco smoking. Time has come where male reproductive toxicity should be addressed form entirely new angles including exposures very early in life</abstract>
    <url>WOS:000275109700003</url>
    <isbnorissn>1008-682X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>380</id>
    <title>Effects of Neonatal Exposure to Bisphenol A on Steroid Regulation of Vascular Endothelial Growth Factor Expression and Endothelial Cell Proliferation in the Adult Rat Uterus</title>
    <authors>Bosquiazzo,V.L.; Varayoud,J.; Munoz-de-Toro,M.; Luque,E.H.; Ramos,J.G.</authors>
    <availability>[Bosquiazzo, Veronica L.; Varayoud, Jorgelina; Munoz-de-Toro, Monica; Luque, Enrique H.; Ramos, Jorge G.] Univ Nacl Litoral, Lab Endocrinol &amp; Tumores Hormonodependientes, Sch Biochem &amp; Biol Sci, RA-3000 Santa Fe, Argentina.</availability>
    <date>2010</date>
    <notes>JEnglishArticleRamos, JG (reprint author), Univ Nacl Litoral, Lab Endocrinol &amp; Tumores Hormonodependientes, Sch Biochem &amp; Biol Sci, Casilla Correo 242, RA-3000 Santa Fe, Argentinagramos@fbcb.unl.edu.arBosquiazzo VL, 2007, REPRODUCTION, V133, P1045, DOI 10.1530/REP-06-0168; Bredhult C, 2007, REPROD TOXICOL, V23, P550, DOI 10.1016/j.reprotox.2007.03.006; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; CHAN YL, 1987, J BIOL CHEM, V262, P1111; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Durrer S, 2007, ENVIRON HEALTH PERSP, V115, P42, DOI 10.1289/ehp.9134; Durrer S, 2005, ENDOCRINOLOGY, V146, P2130, DOI 10.1210/en.2004-1272; Eckhart L, 1999, J BIOL CHEM, V274, P2613, DOI 10.1074/jbc.274.5.2613; *ENV PROT AG, 2008, INT RISK INF SYST SU; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Halder JB, 2000, GENESIS, V26, P213, DOI 10.1002/(SICI)1526-968X(200003)26:3&lt;213::AID-GENE7&gt;3.3.CO;2-D; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Karuri AR, 1998, J ENDOCRINOL, V159, P489, DOI 10.1677/joe.0.1590489; Kashida S, 2001, BIOL REPROD, V64, P317, DOI 10.1095/biolreprod64.1.317; Kass L, 2000, EUR J HISTOCHEM, V44, P185; Kazi AA, 2007, ENDOCRINOLOGY, V148, P2363, DOI 10.1210/en.2006-1394; Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388; Weitlauf H. M., 1994, P391; Lecce G, 2001, J CLIN ENDOCR METAB, V86, P1379, DOI 10.1210/jc.86.3.1379; Long X, 2001, EXP BIOL MED, V226, P477; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Mokry J, 2004, STEM CELLS DEV, V13, P658, DOI 10.1089/scd.2004.13.658; Monje L, 2007, J ENDOCRINOL, V194, P201, DOI 10.1677/JOE-07-0014; Mueller MD, 2003, FERTIL STERIL, V79, P386, DOI 10.1016/S0015-0282(02)04577-6; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Munoz De Toro Monica M., 1998, Pathology Research and Practice, V194, P631; Nishizawa H, 2005, J REPROD DEVELOP, V51, P315, DOI 10.1262/jrd.16008; PERROTAPPLANAT M, 1994, J CLIN ENDOCR METAB, V78, P216, DOI 10.1210/jc.78.1.216; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rabbani MLM, 2001, REPRODUCTION, V122, P85, DOI 10.1530/rep.0.1220085; Ramos JG, 2003, ENDOCRINOLOGY, V144, P3206, DOI 10.1210/en.2002-0198; Ramos JG, 2007, BRAIN RES BULL, V71, P619, DOI 10.1016/j.brainresbull.2006.12.004; Ramos JG, 2002, BIOL REPROD, V67, P735, DOI 10.1095/biolreprod.101.002402; Rider V, 2003, ENDOCRINOLOGY, V144, P5450, DOI 10.1210/en.2003-0890; Rockwell LC, 2002, BIOL REPROD, V67, P1804, DOI 10.1095/biolreprod.102.006700; Schlumpf Margret, 2001, Environmental Health Perspectives, V109, P239, DOI 10.2307/3434691; Schonfelder G, 2004, NEOPLASIA, V6, P584, DOI 10.1593/neo.04217; Sengupta J, 2007, REPRODUCTION, V133, P1199, DOI 10.1530/rep.1.01228; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Takahashi N, 2008, ENDOCRINOLOGY, V149, P253, DOI 10.1210/en.2007-0774; Taylor JA, 2008, REPROD TOXICOL, V25, P169, DOI 10.1016/j.reprotox.2008.01.001; Tominaga T, 2006, TOXICOLOGY, V226, P208, DOI 10.1016/j.tox.2006.07.004; Upmeier A, 2000, ARCH TOXICOL, V74, P431, DOI 10.1007/s002040000144; Varayoud J, 2008, ENDOCRINOLOGY, V149, P5848, DOI 10.1210/en.2008-0651; Varayoud J, 2004, REPRODUCTION, V127, P379, DOI 10.1530/rep.1.00018; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Wetherill YB, 2005, CANCER RES, V65, P54; Yamamoto T, 1999, CHEMOSPHERE, V38, P2569, DOI 10.1016/S0045-6535(98)00464-0; Yi XJ, 1999, CELL TISSUE RES, V296, P339, DOI 10.1007/s004410051294; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-05655312SOC STUDY REPRODUCTIONMADISON1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USABIOL REPRODJANDiscipline: Reproductive Biology533TG</notes>
    <keywords>1; ADULT; ADULT-RAT; ALPHA; BIOLOGY; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; BPA; Brain; BREAST-CANCER CELLS; CANCER; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; DEFECTS; development; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL; DIFFERENTIAL EXPRESSION; Differentiation; ENDOCRINE; ENDOCRINE DISRUPTORS; endothelial cell proliferation; environment; Estrogen; Estrogen receptor; Estrogen receptor alpha; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; FACTOR VEGF; female; FEMALE RAT; FEMALE RATS; female reproductive tract; fertility; FILTER 4-METHYLBENZYLIDENE CAMPHOR; GENE-EXPRESSION; GROWTH; GROWTH-FACTOR; HEALTH; Hormone; IMPLANTATION; INDUCTION; NEONATAL EXPOSURE; Neoplasia; NESTIN EXPRESSION; PATHOLOGY; PATHWAY; proliferation; RAT; RATS; RECEPTOR; RECEPTOR-ALPHA; REGULATORS; Reproduction; RETINOIC ACID; RISK; STEM-CELLS; Steroid; steroid hormone receptors; Thyroid; THYROID-HORMONE; TISSUE; toxicology; UTERINE; UTERINE CERVIX; Uterus; vascular endothelial growth factor; VEGF; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>86</startpage>
    <endpage>95</endpage>
    <journalfull>Biology of Reproduction</journalfull>
    <issue>1</issue>
    <volume>82</volume>
    <abstract>Hormonally controlled vascular changes play a key role in endometrial development and in the differentiation process necessary for implantation. Vascular endothelial growth factor ( VEGF) has emerged as one of the central regulators of the uterine vasculature. Hormonal perturbations during neonatal development may alter sex steroid-dependent regulation of VEGF and may ultimately affect fertility later in life. The aim of this study was to determine whether neonatal exposure to the environmental estrogenic chemical bisphenol A (BPA) affects the adult rat uterine response to hormonal stimuli. Newborn female rats were given s.c. injections of vehicle, BPA (0.05 mg/kg per day or 20 mg/kg per day) or diethylstilbestrol (0.2 mu g/kg per day) on Postnatal Days 1, 3, 5, and 7. To evaluate the long-term effects, rats were ovariectomized at Postnatal Day 80 and submitted to hormonal replacement. Rats neonatally exposed to xenoestrogens showed a decreased induction of uterine endothelial proliferation and a decreased Vegf mRNA expression in response to ovarian steroid treatment. Also, although the estrogen receptor alpha (ESR1) expression was lower in subepithelial cells than in controls, a higher expression of silencing mediator of retinoic acid and thyroid hormone receptor (NCOR1, also known as SMRT) corepressor was evidenced in the same compartment. The results indicate that disturbed Vegf expression in BPA rats could be the result of changes in endocrine pathways, such as an altered induction of ESR1 and/or NCOR1 expression. Because of the importance of VEGF in the implantation process, our data suggest that neonatal BPA exposure might have negative consequences on female fertility</abstract>
    <url>WOS:000272847600010</url>
    <isbnorissn>0006-3363</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>411</id>
    <title>Low Doses of Bisphenol A Promote Human Seminoma Cell Proliferation by Activating PKA and PKG via a Membrane G-Protein-Coupled Estrogen Receptor</title>
    <authors>Bouskine,A.; Nebout,M.; Brucker-Davis,F.; Benahmed,M.; Fenichel,P.</authors>
    <availability>[Fenichel, Patrick] Univ Hosp, Dept Reprod Endocrinol, F-06202 Nice 3, France. [Bouskine, Adil; Nebout, Marielle; Bruecker-Davis, Francoise; Benahmed, Mohamed; Fenichel, Patrick] Univ Nice Sophia Antipolis, Inst Natl Rech Med, INSERM, U895,Team Environm &amp; Reprod Genom &amp; Nongenom Mech, Nice, France.</availability>
    <date>2009</date>
    <notes>JEnglishArticleFenichel, P (reprint author), Univ Hosp, Dept Reprod Endocrinol, F-06202 Nice 3, Francefenichel.p@chu-nice.frAbraham IM, 2003, J NEUROSCI, V23, P5771; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; ALONSOMAGDALENA P, 2005, ENV HLTH PERSPECT, V113, P960; Belcher SM, 2005, ENDOCRINOLOGY, V146, P5397, DOI 10.1210/en.2005-0564; Biles JE, 1997, J AGR FOOD CHEM, V45, P3541, DOI 10.1021/jf970072i; Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1; Bouskine A, 2008, ENDOCRINOLOGY, V149, P565, DOI 10.1210/en.2007-1318; Bouskine A, 2010, INT J ANDROL, V33, P54, DOI 10.1111/j.1365-2605.2009.00950.x; Brucker-Davis F, 2001, ENVIRON HEALTH PERSP, V109, P21, DOI 10.2307/3434843; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chaban VV, 2004, ENDOCRINOLOGY, V145, P3788, DOI 10.1210/en.2004-0149; Chen DB, 2004, ENDOCRINOLOGY, V145, P113, DOI 10.1210/en.2003-0547; Crain DA, 1998, TOXICOL IND HEALTH, V14, P261; Daaka Y, 1997, NATURE, V390, P88; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dos Santos EG, 2002, ENDOCRINOLOGY, V143, P930; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gaskell TL, 2003, J CLIN ENDOCR METAB, V88, P424, DOI 10.1210/jc.2002-020811; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Huyghe Eric, 2007, Eur Urol, V51, P621, DOI 10.1016/j.eururo.2006.08.024; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kinugawa K, 1998, Int J Urol, V5, P282, DOI 10.1111/j.1442-2042.1998.tb00604.x; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Le Mallay V., 1997, J BIOL CHEM, V272, P11902; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551; Markey CM, 2001, BIOL REPROD, V65, P1215; Massaad C, 1999, ENVIRON HEALTH PERSP, V107, P563, DOI 10.2307/3434398; Migliaccio A, 1996, EMBO J, V15, P1292; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Newbold RR, 2004, TOXICOL APPL PHARM, V199, P142, DOI 10.1016/j.taap.2003.11.033; Noguchi S, 2002, TOXICOL LETT, V135, P95, DOI 10.1016/S0378-4274(02)00252-7; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Roger C, 2005, J MOL ENDOCRINOL, V35, P191, DOI 10.1677/jme.1.01704; Roger C, 2004, J PATHOL, V202, P241, DOI 10.1002/path.1509; Santagata S, 2007, AM J SURG PATHOL, V31, P836, DOI 10.1097/PAS.0b013e31802e708a; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; Skakkebaek NE, 1998, APMIS, V106, P3; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Thomas P, 2006, STEROIDS, V71, P310, DOI 10.1016/j.steroids.2005.09.015; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vasudevan N, 2007, ENDOCR REV, V28, P1, DOI 10.1210/er.2005-0021; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.75056678US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPJULDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology465WV</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; AFFINITIES; ALPHA; Antagonist; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; cell cycle; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CREB; CYCLE; developmental programming; DIETHYLSTILBESTROL; Differentiation; E2; ENDOCRINE; Endocrine disruptor; ENDOTHELIAL-CELLS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ER; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; Estrogenic; ESTROGENS; EXPOSURE; FETAL; FETAL EXPOSURE; FLUID; FOOD; GENE-TRANSCRIPTION; GPCR; GPR30; HEALTH; HUMAN SEMINOMA; In vitro; IN-VITRO; INHIBITOR; Inhibitors; KINASE; low dose; Male; mechanism; MECHANISMS; MOUSE MAMMARY-GLAND; Nongenomic; Occupational; p21; PATHWAY; PERINATAL EXPOSURE; PHOSPHORYLATION; PKA; PKG; PLACENTA; PLASMA-MEMBRANE; proliferation; PROTEIN; PROTEIN-KINASE; RECEPTOR; Receptors; REGULATED KINASE; SEALANTS; serum; Steroid; SYNTHETIC ESTROGEN; testicular germ cell cancer; toxicology; TRANSCRIPTION; UPDATE; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1053</startpage>
    <endpage>1058</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>7</issue>
    <volume>117</volume>
    <abstract>BACKGROUND: Fetal exposure to environmental estrogens may contribute to hypofertility and/or to testicular germ cell cancer. However, many of these xenoestrogens have only a weak affinity for the classical estrogen receptors (ERs,) which is 1,000-fold less potent than the affinity of 17 beta-estradiol (E-2). Thus, several mechanisms have been suggested to explain how they could affect male germ cell proliferation at low environmental relevant concentrations. OBJECTIVES: In this study we aimed to explore the possible promoting effect of bisphenol A (BPA) on human testicullar seminoma cells. BPA is a well-recognized estrogenic endocrine disruptor used as a monomer to manufacture polycarbonate plastic and released from resin-lined food or beverage cans or from dental sealants. MFTHODS AND RESULTS. BPA at very low concentrations (10(-9) to 10(-12) M) similar to those found in human fluids stimulated JKT-1 cell proliferation in vitro. BPA activated both cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways and triggered a rapid (15 min) phosphorylation of the transcription factor cAMP response-element-binding protein (CREB) and the cell cycle regulator retinoblastoma protein (Rb). This nongenomic activation did not involve classical ERs because it could not be reversed by ICI 182780 (an ER antagonist) or reproduced either by E-2 or by diethylstilbestrol (a potent synthetic estrogen), which instead triggered a suppressive effect. This activation was reproduced only by E-2 coupled to bovine serum albumin (BSA), which is unable to enter the cell. As with E-2-BSA, BPA promoted JKT-1 cell proliferation through a G-protein-coupled nonclassical membrane ER (GPCR) involving a G alpha, and a G alpha(i)/G alpha(q) Subunit, as shown by the reversible effect observed by the corresponding inhibitors NF449 and pertussis toxin. CONCLUSION: This GPCR-mediated nongenomic action represents-in addition to the classical ER-mediated effect-a new basis for evaluating xenoestrogens such as BPA that, at low doses and with a high affinity for this GPCR, could interfere with the developmental programming of fetal germ cell proliferation and/or differentiation when they cross the placenta</abstract>
    <url>WOS:000267621200022</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>45</id>
    <title>High Intake of Dietary Sugar Enhances Bisphenol A (BPA) Disruption and Reveals Ribosome-Mediated Pathways of Toxicity</title>
    <authors>Branco,A.T.; Lemos,B.</authors>
    <availability>[Branco, Alan T.; Lemos, Bernardo] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Mol &amp; Integrat Physiol Sci Program, Boston, MA 02115 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleLemos, B (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Mol &amp; Integrat Physiol Sci Program, 665 Huntington Ave Bldg 2,Room 219, Boston, MA 02115 USAblemos@hsph.harvard.eduAllard P, 2010, P NATL ACAD SCI USA, V107, P20405, DOI 10.1073/pnas.1010386107; Alonso J, 2006, J PROTEOME RES, V5, P2025, DOI 10.1021/pr0601483; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Baker KD, 2007, CELL METAB, V6, P257, DOI 10.1016/j.cmet.2007.09.002; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Branco AT, 2013, GENETICS, V194, P609, DOI 10.1534/genetics.113.150805; Buchon N, 2013, NAT REV MICROBIOL, V11, P615, DOI 10.1038/nrmicro3074; Burridge E., 2003, EUR CHEM NEWS, P14; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chintapalli VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Gou DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010581; Hunt PA, 2012, P NATL ACAD SCI USA, V109, P17525, DOI 10.1073/pnas.1207854109; Itoh K, 2012, NEUROPATHOLOGY, V32, P447, DOI 10.1111/j.1440-1789.2011.01287.x; Jang CY, 2011, BIOCHEM BIOPH RES CO, V414, P523, DOI 10.1016/j.bbrc.2011.09.099; Jang CY, 2012, BIOCHEM BIOPH RES CO, V429, P57, DOI 10.1016/j.bbrc.2012.10.093; Jang CY, 2012, BIOCHEM BIOPH RES CO, V421, P474, DOI 10.1016/j.bbrc.2012.04.020; Kim HD, 2005, BIOCHEM BIOPH RES CO, V333, P110, DOI 10.1016/j.bbrc.2005.05.079; Kim TS, 2009, J BIOL CHEM, V284, P21201, DOI 10.1074/jbc.M109.018168; Kim TS, 2006, MOL BIOL CELL, V17, P824, DOI 10.1091/mbc.E05-08-0713; King EG, 2012, GENETICS, V191, P935, DOI 10.1534/genetics.112.138537; King EG, 2012, GENOME RES, V22, P1558, DOI 10.1101/gr.134031.111; Kundakovic M, 2013, P NATL ACAD SCI USA, V110, P9956, DOI 10.1073/pnas.1214056110; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lawson C, 2011, BIOL REPROD, V84, P79, DOI 10.1095/biolreprod.110.084814; Lemos B, 2008, SCIENCE, V319, P91, DOI 10.1126/science.1148861; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Lyko F, 2000, MECH DEVELOP, V95, P215, DOI 10.1016/S0925-4773(00)00325-7; Lyne R, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r129; Ma N, 2007, J CELL SCI, V120, P2091, DOI 10.1242/jcs.008771; Mackay TFC, 2012, NATURE, V482, P173, DOI 10.1038/nature10811; Magliano DJ, 2013, J CLIN ENDOCR METAB, V98, P502, DOI 10.1210/jc.2012-3058; Marygold SJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r216; Musselman LP, 2011, DIS MODEL MECH, V4, P842, DOI 10.1242/dmm.007948; Na JB, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003175; Nemeth A, 2011, TRENDS GENET, V27, P149, DOI 10.1016/j.tig.2011.01.002; Nousiainen M, 2006, P NATL ACAD SCI USA, V103, P5391, DOI 10.1073/pnas.0507066103; OCHS RL, 1985, BIOL CELL, V54, P123; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Phalke S, 2009, NAT GENET, V41, P696, DOI 10.1038/ng.360; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Robinson SW, 2013, NUCLEIC ACIDS RES, V41, pD744, DOI 10.1093/nar/gks1141; Sauer G, 2005, MOL CELL PROTEOMICS, V4, P35, DOI 10.1074/mcp.M400158-MCP200; Schaefer M, 2010, NAT GENET, V42, P920, DOI 10.1038/ng1110-920; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Sudmant PH, 2010, SCIENCE, V330, P641, DOI 10.1126/science.1197005; Torres JZ, 2011, CELL, V147, P1309, DOI 10.1016/j.cell.2011.11.020; Townsend J. P., 2002, GENOME BIOL, V3; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Zatsepina OV, 1999, J CELL SCI, V112, P455; Zwarts L, 2011, P NATL ACAD SCI USA, V108, P17070, DOI 10.1073/pnas.1113877108540GENETICS SOCIETY AMERICABETHESDA9650 ROCKVILLE AVE, BETHESDA, MD 20814 USAGENETICSMAYDiscipline: Genetics &amp; HeredityAH1DC</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELL; CELLS; diabetes; DROSOPHILA-MELANOGASTER; EXPOSURE; EXPRESSION; gene expression; GENE-EXPRESSION; HUMAN MITOTIC SPINDLE; INSULIN-RESISTANCE; Interaction; mechanism; MECHANISMS; nucleolus; POPULATION; PROTEIN S3; Proteomics; REVEALS; ribosome; SYNTHETIC POPULATION RESOURCE; testis; TOXICITY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>147</startpage>
    <endpage>157</endpage>
    <journalfull>Genetics</journalfull>
    <issue>1</issue>
    <volume>197</volume>
    <abstract>Bisphenol A (BPA) is an organic compound to which human populations are ubiquitously exposed. Epidemiological data suggest BPA exposure might be associated with higher rates of diabetes and reproductive anomalies. Health concerns also include transgenerational consequences, but these mechanisms are crudely defined. Similarly, little is known about synergistic interactions between BPA and other substances. Here we show that acute and chronic exposure to BPA causes genome-wide modulation of several functionally coherent genetic pathways in the fruit fly Drosophila melanogaster. In particular, BPA exposure causes massive downregulation of testis-specific genes and upregulation of ribosome-associated genes widely expressed across tissues. In addition, it causes the modulation of transposable elements that are specific to the ribosomal DNA loci, suggesting that nucleolar stress might contribute to BPA toxicity. The upregulation of ribosome-associated genes and the impairment of testis-specific gene expression are significantly enhanced upon BPA exposure with a high-sugar diet. Our results suggest that BPA and dietary sugar might functionally interact, with consequences to regulatory programs in both reproductive and somatic tissues</abstract>
    <url>WOS:000335858900011</url>
    <isbnorissn>0016-6731</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>144</id>
    <title>Chlorinated bisphenol A diglycidyl ether (EPI-001) mediates degradation of the androgen receptor in prostate cancer cells</title>
    <authors>Brand,L.J.; Dehm,S.M.</authors>
    <availability>[Brand, Lucas J.; Dehm, Scott M.] Univ Minnesota, Minneapolis, MN USA.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00AMER ASSOC CANCER RESEARCHPHILADELPHIA615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USACANCER RESAPR 151Discipline: OncologyAA6PP</notes>
    <keywords>ANDROGEN RECEPTOR; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; DEGRADATION; oncology; Prostate; prostate cancer; PROSTATE-CANCER; RECEPTOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Cancer Research</journalfull>
    <issue>8</issue>
    <volume>73</volume>
    <url>WOS:000331220600110</url>
    <isbnorissn>0008-5472</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>83</id>
    <title>Indole-3-carbinol attenuates the deleterious gestational effects of bisphenol A exposure on the prostate gland of male F1 rats</title>
    <authors>Brandt,J.Z.; Silveira,L.T.R.; Grassi,T.F.; Anselmo-Franci,J.A.; Favaro,W.J.; Felisbino,S.L.; Barbisan,L.F.; Scarano,W.R.</authors>
    <availability>[Brandt, Joyce Zalotti; Silveira, Livia Teresa R.; Felisbino, Sergio Luis; Barbisan, Luis Fernando; Scarano, Wellerson Rodrigo] Sao Paulo State Univ, Inst Biosci, Dept Morphol, UNESP, BR-18618970 Botucatu, SP, Brazil. [Grassi, Tony Fernando] UNESP, Sch Med, Dept Pathol, BR-18618970 Botucatu, SP, Brazil. [Anselmo-Franci, Janete A.] Univ Sao Paulo FORP USP, Fac Dent, BR-14040904 Ribeirao Preto, SP, Brazil. [Favaro, Wagner Jose] Univ Estadual Campinas, UNICAMP, Inst Biol, BR-13083862 Campinas, SP, Brazil.</availability>
    <date>2014</date>
    <notes>JEnglishArticleScarano, WR (reprint author), Sao Paulo State Univ, Inst Biosci, Dept Morphol, UNESP, BR-18618970 Botucatu, SP, Brazilscarano@ibb.unesp.brAggarwal BB, 2005, CELL CYCLE, V4, P1201; Banerjee PP, 1998, BIOL REPROD, V59, P1163, DOI 10.1095/biolreprod59.5.1163; Barker DJ., 2004, J AM COLL NUTR, V23, P88; Bernoulli J, 2008, PROSTATE, V68, P728, DOI 10.1002/pros.20719; Bosland MC, 1999, EUR UROL, V35, P459, DOI 10.1159/000019879; Broadbent TA, 1998, CURR MED CHEM, V5, P469; Cho HJ, 2011, MOL CARCINOGEN, V50, P100, DOI 10.1002/mc.20698; Colerangle JB, 1997, J STEROID BIOCHEM, V60, P153, DOI 10.1016/S0960-0760(96)00130-6; Dave B, 2005, CARCINOGENESIS, V26, P1793, DOI 10.1093/carcin/bgi131; Della Seta D, 2006, HORM BEHAV, V50, P301, DOI 10.1016/j.yhbeh.2006.03.015; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Doerge DR, 2010, TOXICOL LETT, V199, P372, DOI 10.1016/j.toxlet.2010.09.022; Doerge DR, 2011, TOXICOL APPL PHARM, V255, P261, DOI 10.1016/j.taap.2011.07.009; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Ellem SJ, 2009, ANN NY ACAD SCI, V1155, P174, DOI 10.1111/j.1749-6632.2009.04360.x; Engel SM, 2006, REPROD TOXICOL, V21, P110, DOI 10.1016/j.reprotox.2005.07.007; Fowden AL, 2004, REPRODUCTION, V127, P15; Garcia-Cao I, 2005, EMBO REP, V6, P577, DOI 10.1038/sj.embor.7400421; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Hecht SS, 2004, CANCER EPIDEM BIOMAR, V13, P997; Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Ismail-Beigi F, 2006, AM J PHYSIOL-ENDOC M, V291, P439; Kang JH, 2006, TOXICOLOGY, V226, P79; Kassie F, 2008, CANCER PREV RES, V1, P568, DOI 10.1158/1940-6207.CAPR-08-0064; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim YS, 2005, J NUTR BIOCHEM, V16, P65, DOI 10.1016/j.jnutbio.2004.10.007; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuruto-Niwa R, 2007, CHEMOSPHERE, V66, P1160, DOI 10.1016/j.chemosphere.2006.06.073; Li YW, 2003, J NUTR, V133, P1011; Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604; Lucia MS, 1998, PROSTATE, V36, P49, DOI 10.1002/(SICI)1097-0045(19980615)36:1&lt;49::AID-PROS9&gt;3.0.CO;2-6; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; MARKEY CM, 2001, HANDB ENVIRON CHEM L, V3, P129; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; PRINS GS, 1989, J STEROID BIOCHEM, V33, P319, DOI 10.1016/0022-4731(89)90319-1; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; PUCHTLER H, 1970, HISTOCHEMISTRY, V21, P97, DOI 10.1007/BF00306176; Putz O, 2001, BIOL REPROD, V65, P1506, DOI 10.1095/biolreprod65.5.1506; Reed GA, 2005, CANCER EPIDEM BIOMAR, V14, P1953, DOI 10.1158/1055-9965.EPI-05-0121; REZNIK G, 1981, PROSTATE, V2, P261, DOI 10.1002/pros.2990020304; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Sarkar FH, 2004, J NUTR, V134, p3493S; Scarano WR, 2005, CELL BIOL INT, V29, P778, DOI 10.1016/j.cellbi.2005.05.003; Scarano WR, 2008, INT J EXP PATHOL, V89, P25, DOI 10.1111/j.1365-2613.2007.00559.x; Scarano WR, 2009, TOXICOLOGY, V262, P215, DOI 10.1016/j.tox.2009.06.011; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Souli E, 2008, FOOD CHEM TOXICOL, V46, P863, DOI 10.1016/j.fct.2007.10.026; Steinmetz R, 1997, ENDOCRINOLOGY, V138, P1780, DOI 10.1210/en.138.5.1780; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Sundar SN, 2006, MOL ENDOCRINOL, V20, P3070, DOI 10.1210/me.2005-0263; Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308; TILLEY WD, 1989, PROSTATE, V15, P195, DOI 10.1002/pros.2990150213; Vilamaior PSL, 2006, ANAT REC PART A, V288A, P885, DOI 10.1002/ar.a.20363; Vilamaior PSL, 2000, PROSTATE, V45, P253; Vogel SA., 2009, AM J PUBLIC HEALTH, P559; Wang TTY, 2006, J NUTR BIOCHEM, V17, P659, DOI 10.1016/j.jnutbio.2005.10.012; WEIBEL ER, 1963, LAB INVEST, V12, P131; Welshons WV, 2006, ENDOCRINOLOGY, V147, P56; Weng JR, 2008, CANCER LETT, V262, P153, DOI 10.1016/j.canlet.2008.01.033; Wilson MJ, 2004, EXP MOL PATHOL, V77, P7, DOI 10.1016/j.yexmp.2004.02.004; Wu TY, 2011, MOL CARCINOG, V51, P761; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5; Yoo SD, 2001, J TOXICOL ENV HEAL A, V64, P417, DOI 10.1080/152873901753170740; Yu Z, 2006, CARCINOGENESIS, V27, P2116, DOI 10.1093/carcin/bgl072; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.5603711PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLJANAA3XQ</notes>
    <keywords>AMNIOTIC-FLUID; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER-CELLS; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; Chemoprevention; CYCLE; DEVELOPMENTAL EXPOSURE; ESTROGENIC CHEMICALS; EXPOSURE; EXPRESSION; FOOD; GLAND; IN-VIVO; Indole-3-carbinol; Inflammation; LATERAL PROSTATE; Male; PREGNANCY; Prostate; RAT; RATS; Reproduction; Reproductive toxicology; SPRAGUE-DAWLEY RATS; toxicology; VENTRAL PROSTATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>56</startpage>
    <endpage>66</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <volume>43</volume>
    <abstract>Bisphenol A (BPA) is a chemical that has been investigated for it potential to cause prostate diseases. In this study, pregnant Sprague-Dawley rats were treated with 25 or 250 mu g/kg BPA from gestational day (GD) 10 to GD21 with or without concurrent indole-3-carbinol (I3C) feeding. I3C is a phytochemical, and it affords chemoprotection against many types of neoplasia. Male F1 rats from different litters were euthanized on post-natal day (PND) 21 and PND180. BPA-treated groups showed a significant increase in histopathological lesions, but I3C feeding reversed many of these changes, mainly at PND180. Maternal I3C feeding increased prostate epithelial apoptosis in the BPA-treated groups and across age groups. Furthermore, I3C induced partial normalization of the prostate histoarchitecture. The results pointed to a protective effect of maternal I3C feeding during pregnancy in the BPA-exposed male offspring, thereby indicating reduction in the harmful effects of gestational BPA imprinting on the prostate. (C) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000331028900008</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>379</id>
    <title>Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats</title>
    <authors>Braniste,V.; Jouault,A.; Gaultier,E.; Polizzi,A.; Buisson-Brenac,C.; Leveque,M.; Martin,P.G.; Theodorou,V.; Fioramonti,J.; Houdeau,E.</authors>
    <availability>[Braniste, Viorica; Jouault, Aurore; Gaultier, Eric; Buisson-Brenac, Claire; Leveque, Mathilde; Theodorou, Vassilia; Fioramonti, Jean; Houdeau, Eric] INRA, Neurogastroenterol &amp; Nutr Unit, UMR 1054, F-31027 Toulouse 3, France. [Polizzi, Arnaud; Martin, Pascal G.] INRA, Pharmacol &amp; Toxicol Lab, Unite Rech 66, ToxAlim Res Ctr, F-31027 Toulouse 3, France.</availability>
    <date>2010</date>
    <notes>JEnglishArticleHoudeau, E (reprint author), INRA, Neurogastroenterol &amp; Nutr Unit, UMR 1054, F-31027 Toulouse 3, Franceeric.houdeau@toulouse.inra.frAkingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Bereiter DA, 2005, ARCH ORAL BIOL, V50, P971, DOI 10.1016/j.archoralbio.2005.03.010; Braniste V, 2009, J PHYSIOL-LONDON, V587, P3317, DOI 10.1113/jphysiol.2009.169300; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Campbell-Thompson M, 2001, CANCER RES, V61, P632; CATASSI C, 1995, J PEDIATR GASTR NUTR, V21, P383, DOI 10.1097/00005176-199511000-00003; Colome G, 2007, ACTA PAEDIATR, V96, P69, DOI 10.1111/j.1651-2227.2007.00030.x; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Fruzzetti F, 2007, CONTRACEPTION, V76, P190, DOI 10.1016/j.contraception.2007.05.080; Geibel JP, 2005, ANNU REV PHYSIOL, V67, P471, DOI 10.1146/annurev.physiol.67.031103.153530; Heitkemper Margaret, 2003, Biol Res Nurs, V5, P56, DOI 10.1177/1099800403005001006; Heitkamper MM, 2003, AM J GASTROENTEROL, V98, P420, DOI 10.1016/S0002-9270(02)05901-4; Homma H, 2005, AM J PHYSIOL-GASTR L, V288, pG466, DOI 10.1152/ajpgi.00036.2004; Houdeau E, 2007, GASTROENTEROLOGY, V132, P982, DOI 10.1053/j.gastro.2006.12.028; Ji YP, 2003, J NEUROSCI, V23, P3908; Konstantinopoulos PA, 2003, EUR J CANCER, V39, P1251, DOI 10.1016/S0959-8049(03)00239-9; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuruto-Niwa R, 2007, CHEMOSPHERE, V66, P1160, DOI 10.1016/j.chemosphere.2006.06.073; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Maragou NC, 2008, FOOD ADDIT CONTAM, V25, P373, DOI 10.1080/02652030701509998; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Masyuk AI, 2002, GASTROENTEROLOGY, V122, P545, DOI 10.1053/gast.2002.31035; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Neu J, 2007, NUTR REV, V65, P282, DOI 10.1301/nr.2007.jun.282-285; Oelkers WKH, 1996, STEROIDS, V61, P166, DOI 10.1016/0039-128X(96)00007-4; O'Mahony F, 2008, STEROIDS, V73, P889, DOI 10.1016/j.steroids.2008.01.021; Papka RE, 2001, CELL TISSUE RES, V304, P193, DOI 10.1007/s004410100363; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Schaller JP, 2004, PEDIATR RES, V56, P883, DOI 10.1203/01.PDR.0000145576.42115.5C; Takeyama J, 2001, J CLIN ENDOCR METAB, V86, P2258, DOI 10.1210/jc.86.5.2258; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Turner JR, 2006, AM J PATHOL, V169, P1901, DOI 10.2353/ajpath.2006.060681; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.56034326NATL ACAD SCIENCESWASHINGTON2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USAP NATL ACAD SCI USAJAN 5Discipline: Science &amp; Technology - Other Topics543FX</notes>
    <keywords>ADULT; ADULTHOOD; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; CELLS; development; ENDOCRINE; Endocrine disruptor; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-BETA; ESTROGEN-RECEPTORS; EXPOSURE; EXPRESSION; female; FEMALE RAT; FEMALE RATS; FLUID; FOOD; gut permeability; HEALTH; HUMAN HEALTH; IMPACT; INDUSTRY; Inflammation; low dose; Male; MALE RATS; Migration; NEURONS; pain; PERINATAL EXPOSURE; PERMEABILITY; POLYCARBONATE BABY BOTTLES; RAT; RATS; RECEPTOR; Receptors; reference dose; RISK; ROUTE; SENSITIVITY; sex differences; SEX-DIFFERENCES; Steroid; TISSUE; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>448</startpage>
    <endpage>453</endpage>
    <journalfull>Proceedings of the National Academy of Sciences of the United States of America</journalfull>
    <issue>1</issue>
    <volume>107</volume>
    <abstract>Bisphenol A (BPA), a chemical estrogen widely used in the food-packaging industry and baby bottles, is recovered in human fluids (0.1-10 nM). Recent studies have reported that BPA is hormonally active at low doses, emphasizing the debate of a risk for human health. Estrogen receptors are expressed in the colon, and although the major route of BPA exposure is food, the effects on gut have received no attention. We first examined the endocrine disrupting potency of BPA on colonic paracellular permeability (CPP), experimental colitis, and visceral sensitivity in ovariectomized rats orally exposed to 5 mg/kg/d BPA(i.e., the no observed adverse effect level), 50 mu g/kg/d BPA(i.e., tolerable daily intake), or lower doses. BPA dose-dependently decreased basal CPP, with a half-maximal inhibitory dose of 5.2 mu g/kg/d, 10-fold below the tolerable daily intake. This correlated with an increase in epithelial tight junction sealing, also observed in Caco-2 cells exposed to 10 nMBPA. When ovariectomized rats were fed with BPA at the no observed adverse effect level, the severity of colitis was reduced, whereas the same dose increased pain sensitivity to colorectal stimuli. We then examined the impact of perinatal exposure to BPA on intestinal permeability and inflammatory response in the offspring. In female rats, but not in male rats, perinatal BPA evoked a decrease of CPP in adulthood, whereas the proinflammatory response of colonic mucosa was strengthened. This study first demonstrates that the xenoestrogen BPA at reference doses influences intestinal barrier function and gut nociception. Moreover, perinatal exposure promotes the development of severe inflammation in adult female offspring only</abstract>
    <url>WOS:000273559200078</url>
    <isbnorissn>0027-8424</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>291</id>
    <title>Bisphenol A and children's health</title>
    <authors>Braun,J.M.; Hauser,R.</authors>
    <availability>[Braun, Joe M.; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewHauser, R (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1 14th Floor, Boston, MA 02115 USArhauser@hohp.harvard.eduAlonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Apter D, 1996, EUR J CANCER PREV, V5, P476; Becker K, 2009, INT J HYG ENVIR HEAL, V212, P685, DOI 10.1016/j.ijheh.2009.08.002; Bellinger DC, 2004, ENVIRON RES, V95, P394, DOI 10.1016/j.evnres.2003.07.013; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Braun JM, 2011, ENVIRON HEALTH PERSP, V119, P131, DOI 10.1289/ehp.1002366; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat A. M., 2009, Environmental Health Perspectives, V117, P639; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Cobellis L, 2009, BIOMED CHROMATOGR, V23, P1186, DOI 10.1002/bmc.1241; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; FACTOR A, 1996, MECH THERMAL PHOTODE; Fernandez M, 2009, ENVIRON HEALTH PERSP, V117, P757, DOI 10.1289/ehp.0800267; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Galloway T, 2010, ENVIRON HEALTH PERSP, V118, P1603, DOI 10.1289/ehp.1002367; Greiner E, 2004, CHEM EC HDB; Hanaoka T, 2002, OCCUP ENVIRON MED, V59, P625, DOI 10.1136/oem.59.9.625; Hiroi H, 2004, ENDOCR J, V51, P595, DOI 10.1507/endocrj.51.595; Itoh Hiroaki, 2007, Environmental Health and Preventive Medicine, V12, P258, DOI 10.1007/BF02898033; JACKSON WJ, 1985, PROCESS FOAMING CELL; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Li DK, 2010, J ANDROL, V31, P500, DOI 10.2164/jandrol.110.010413; Meeker JD, 2010, ENVIRON SCI TECHNOL, V44, P1458, DOI 10.1021/es9028292; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Mendiola J, 2010, ENVIRON HEALTH PERSP, V118, P1286, DOI 10.1289/ehp.1002037; Mendola P, 2002, MENT RETARD DEV D R, V8, P188, DOI 10.1002/mrdd.10033; Mok-Lin E, 2010, INT J ANDROL, V33, P385, DOI 10.1111/j.1365-2605.2009.01014.x; Nerin C, 2003, J AGR FOOD CHEM, V51, P5647, DOI 10.1021/jf034330p; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Tan B L L, 2003, Asia Pac J Public Health, V15, P118; Vandeloo MJAM, 2007, EUR J CANCER PREV, V16, P17, DOI 10.1097/01.cej.0000220635.38847.6e; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vogel Sarah A, 2009, Am J Public Health, V99 Suppl 3, pS559, DOI 10.2105/AJPH.2008.159228; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; von Goetz N, 2010, RISK ANAL, V30, P473, DOI 10.1111/j.1539-6924.2009.01345.x; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Wilson NK, 2007, ENVIRON RES, V103, P9, DOI 10.1016/j.envres.2006.04.006; Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Wolff MS, 2008, ENVIRON HEALTH PERSP, V116, P1092, DOI 10.1289/ehp.11007; Wolff MS, 2008, ENVIRON RES, V107, P393, DOI 10.1016/j.envres.2008.03.006; Yang M, 2009, ARCH TOXICOL, V83, P281, DOI 10.1007/s00204-008-0364-0; Ye XB, 2009, INT J HYG ENVIR HEAL, V212, P481, DOI 10.1016/j.ijheh.2009.03.004; Ye XB, 2008, ENVIRON RES, V108, P260, DOI 10.1016/j.envres.2008.07.0145135LIPPINCOTT WILLIAMS &amp; WILKINSPHILADELPHIA530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USACURR OPIN PEDIATRAPRDiscipline: Pediatrics736LJ</notes>
    <keywords>ADULT; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; BREAST-CANCER; CANCER; CELL; childhood; CHILDREN; DEFECTS; development; DYSFUNCTION; EARLY-LIFE; Epidemiology; EXPOSURE; female; FETAL; FOOD; HEALTH; HORMONE CONCENTRATIONS; HUMAN EXPOSURE; NORMAL WOMEN; pediatric; POPULATION; PREVENTION; puberty; Review; RISK; serum; Steroid hormone; URINARY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>233</startpage>
    <endpage>239</endpage>
    <journalfull>Current Opinion in Pediatrics</journalfull>
    <issue>2</issue>
    <volume>23</volume>
    <abstract>Purpose of review Bisphenol A (BPA) is a widely used chemical that has been shown to adversely affect health outcomes in experimental animal studies, particularly following fetal or early life exposure. Despite widespread human exposure in the United States and developed countries, there are limited epidemiological studies on the association of BPA with adverse health outcomes. This review briefly summarizes the epidemiological literature with special emphasis on childhood health outcomes. Recent findings Several studies report correlations between urinary BPA and serum sex steroid hormone concentrations in adults. Two studies report weak associations between urinary BPA concentrations and delayed onset of breast development in girls. One study found a relationship between prenatal BPA exposure and increased hyperactivity and aggression in 2-year-old female children. Summary Additional large prospective cohort studies are needed to confirm and validate findings from animal studies. Even in the absence of epidemiological studies, concern over adverse effects of BPA is warranted given the unique vulnerability of the developing fetus and child. Healthcare providers are encouraged to practice primary prevention and counsel patients to reduce BPA exposures</abstract>
    <url>WOS:000288495900017</url>
    <isbnorissn>1040-8703</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>431</id>
    <title>Diethylstilbstrol (DES) and Bisphenol-A (BPA) Alter EZH2 Expression: An Epigenetic Modification Linking Endocrine Disruption to Breast Cancer</title>
    <authors>Bromer,J.G.; Taylor,H.S.</authors>
    <availability>[Bromer, Jason G.; Taylor, Hugh S.] Yale Univ, Sch Med, New Haven, CT 06520 USA.</availability>
    <date>2009</date>
    <notes>JEnglishMeeting Abstract00SAGE PUBLICATIONS INCTHOUSAND OAKS2455 TELLER RD, THOUSAND OAKS, CA 91320 USAREPROD SCIMARDiscipline: Obstetrics &amp; Gynecology; Reproductive Biology410WU</notes>
    <keywords>BIOLOGY; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; DES; DISRUPTION; ENDOCRINE; Endocrine disruption; epigenetic; EXPRESSION; EZH2</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>90A</startpage>
    <endpage>90A</endpage>
    <journalfull>Reproductive Sciences</journalfull>
    <issue>3</issue>
    <volume>16</volume>
    <url>WOS:000263609800077</url>
    <isbnorissn>1933-7191</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>351</id>
    <title>Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response</title>
    <authors>Bromer,J.G.; Zhou,Y.P.; Taylor,M.B.; Doherty,L.; Taylor,H.S.</authors>
    <availability>[Bromer, Jason G.; Zhou, Yuping; Taylor, Melissa B.; Doherty, Leo; Taylor, Hugh S.] Yale Univ, Sch Med, Dept Obstet Gynecol &amp; Reprod Sci, New Haven, CT 06520 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleTaylor, HS (reprint author), Yale Univ, Sch Med, Dept Obstet Gynecol &amp; Reprod Sci, 333 Cedar St,POB 208068, New Haven, CT 06520 USAhugh.taylor@yale.eduAkbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Block K, 2000, FASEB J, V14, P1101; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Chu MC, 2004, CANCER BIOL THER, V3, P568; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Daftary GS, 2000, SEMIN REPROD MED, V18, P311, DOI 10.1055/s-2000-12568; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Du HL, 2004, ANN NY ACAD SCI, V1034, P152, DOI 10.1196/annals.1335.018; Enokida H, 2005, CLIN CANCER RES, V11, P6582, DOI 10.1158/1078-0432.CCR-05-0658; Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440; Howdeshell KL, 1999, NATURE, V401, P763; Issa JP, 2002, J NUTR, V132, p2388S; Kwon HE, 2004, ANN NY ACAD SCI, V1034, P1, DOI 10.1196/annals.1335.001; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lee B, 2009, BIOL REPROD, V80, P79, DOI 10.1095/biolreprod.108.070391; Lee TS, 2006, ANN NY ACAD SCI, V1091, P218, DOI 10.1196/annals.1378.068; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2001, BIOL REPROD, V65, P1215; Martin R, 2007, J CLIN ENDOCR METAB, V92, P1920, DOI 10.1210/jc.2006-1694; Morrison AG, 2003, DOMEST ANIM ENDOCRIN, V25, P329, DOI 10.1016/j.domaniend.2003.06.004; Mountfort KA, 1997, FOOD ADDIT CONTAM, V14, P737; Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Sakuma M, 2007, CANCER SCI, V98, P380, DOI 10.1111/j.1349-7006.2007.00394.x; Sheehan DM, 2000, P SOC EXP BIOL MED, V224, P57, DOI 10.1046/j.1525-1373.2000.22401.x; Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277; Wu Y, 2005, AM J OBSTET GYNECOL, V193, P371, DOI 10.1016/j.ajog.2005.01.034; Wu Y, 2007, FERTIL STERIL, V87, P24, DOI 10.1016/j.fertnstert.2006.05.077; Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008.5472.CAN-05-28283979FEDERATION AMER SOC EXP BIOLBETHESDA9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USAFASEB JJULDiscipline: Biochemistry &amp; Molecular Biology; Life Sciences &amp; Biomedicine - Other Topics; Cell Biology618HV</notes>
    <keywords>ABERRANT EXPRESSION; ASSAY; BINDING; BIOLOGY; bisphenol A; BISPHENOL-A; BISPHENOL-A EXPOSURE; BPA; CANCER; CD-1 MICE; CELL; Chromatin immunoprecipitation; developmental programming; DIETHYLSTILBESTROL DES; DNA METHYLATION; DNA-methylation; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENDOMETRIOSIS; environment; epigenetic; epigenetics; ER alpha; ER-ALPHA; Estrogen; EXPOSURE; EXPRESSION; FOOD; GENE; gene expression; GENE-EXPRESSION; HEALTH; HOMEOBOX GENE; HOX GENES; HOXA10/Hoxa10; IMPLANTATION; In vitro; in vivo; IN-UTERO; IN-VITRO; IN-VIVO; mechanism; METHYLATION; MICE; PREGNANCY; PROMOTER; PROMOTER METHYLATION; PROTEIN; REPRODUCTIVE-TRACT; SENSITIVITY; TRACT; VITRO; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2273</startpage>
    <endpage>2280</endpage>
    <journalfull>Faseb Journal</journalfull>
    <issue>7</issue>
    <volume>24</volume>
    <abstract>Bisphenol-A (BPA) is a nonsteroidal estrogen that is ubiquitous in the environment. The homeobox gene Hoxa10 controls uterine organogenesis, and its expression is affected by in utero BPA exposure. We hypothesized that an epigenetic mechanism underlies BPA-mediated alterations in Hoxa10 expression. We analyzed the expression pattern and methylation profile of Hoxa10 after in utero BPA exposure. Pregnant CD-1 mice were treated with BPA (5 mg/kg IP) or vehicle control on d 9-16 of pregnancy. Hoxa10 mRNA and protein expression were increased by 25% in the reproductive tract of mice exposed in utero. Bisulfite sequencing revealed that cytosine-guanine dinucleotide methylation was decreased from 67 to 14% in the promoter and from 71 to 3% in the intron of Hoxa10 after in utero BPA exposure. Decreased DNA methylation led to an increase in binding of ER-alpha to the Hoxa10 ERE both in vitro as and in vivo as determined by EMSA and chromatin immunoprecipitation, respectively. Diminished methylation of the ERE-containing promoter sequence resulted in an increase in ERE-driven gene expression in reporter assays. We identify altered methylation as a novel mechanism of BPA-induced altered developmental programming. Permanent epigenetic alteration of ERE sensitivity to estrogen may be a general mechanism through which endocrine disruptors exert their action.-Bromer, J. G., Zhou, Y., Taylor, M. B., Doherty, L., Taylor, H. S.. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. FASEB J. 24, 2273-2280 (2010). www.fasebj.org</abstract>
    <url>WOS:000279343600014</url>
    <isbnorissn>0892-6638</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>181</id>
    <title>Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case-control study</title>
    <authors>Brophy,J.T.; Keith,M.M.; Watterson,A.; Park,R.; Gilbertson,M.; Maticka-Tyndale,E.; Beck,M.; Abu-Zahra,H.; Schneider,K.; Reinhartz,A.; DeMatteo,R.; Luginaah,I.</authors>
    <availability>[Brophy, James T.; Keith, Margaret M.; Watterson, Andrew; Gilbertson, Michael] Univ Stirling, Occupat &amp; Environm Hlth Res Grp, Ctr Publ Hlth &amp; Populat Hlth Res, Stirling FK9 4LA, Scotland. [Brophy, James T.; Keith, Margaret M.; Maticka-Tyndale, Eleanor] Univ Windsor, Dept Sociol Anthropol &amp; Criminol, Windsor, ON N9B 3P4, Canada. [Park, Robert] NIOSH, Educ &amp; Informat Div, Cincinnati, OH 45226 USA. [Beck, Matthias] Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland. [Abu-Zahra, Hakam; Schneider, Kenneth] Windsor Reg Canc Ctr, Windsor, ON N8W 2X3, Canada. [Reinhartz, Abraham; DeMatteo, Robert] Occupat Hlth Clin Ontario Workers, Don Mills, ON M3C 1Y8, Canada. [Luginaah, Isaac] Univ Western Ontario, Dept Geog, Social Sci Ctr, London, ON N6A 5C2, Canada.</availability>
    <date>2012</date>
    <notes>JEnglishArticleBrophy, JT (reprint author), Univ Stirling, Occupat &amp; Environm Hlth Res Grp, Ctr Publ Hlth &amp; Populat Hlth Res, Stirling FK9 4LA, Scotlandjim.brophy@stir.ac.ukAlavanja MCR, 1996, ENVIRON HEALTH PERSP, V104, P362, DOI 10.2307/3432672; Band PR, 2002, LANCET, V360, P1044, DOI 10.1016/S0140-6736(02)11140-8; Band PR, 2000, J OCCUP ENVIRON MED, V42, P284, DOI 10.1097/00043764-200003000-00010; BEALL C, 1995, AM J IND MED, V28, P325, DOI 10.1002/ajim.4700280303; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; BLAIR A, 1993, AM J IND MED, V23, P301, DOI 10.1002/ajim.4700230207; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Brophy JT, 2002, INT J OCCUP ENV HEAL, V8, P346; Brophy JT, RURAL WOMEN IN PRESS, P101; Brophy JT, 2006, ANN NY ACAD SCI, V1076, P765, DOI 10.1196/annals.1371.019; Brown P, 2006, SCI TECHNOL HUM VAL, V31, P499, DOI 10.1177/0162243906289610; Checkoway H, 1989, RES METHODS OCCUPATI; Clapp Richard W., 2008, Reviews on Environmental Health, V23, P1; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Beral V, 2002, LANCET, V360, P187; Davis DL, 1997, ENVIRON HEALTH PERSP, V105, P557; DeMatteo R, 2013, NEW SOLUT IN PRESS; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Environmental Protection Agency, BEV CAN SURF COAT IN; European Commission, STAT ART ASS END DIS; Ewertz M, 2001, ACTA ONCOL, V40, P467; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gammon MD, 2004, ARCH ENVIRON HEALTH, V59, P640; Gardner KM, 2002, AM J IND MED, V42, P296, DOI 10.1002/ajim.10112; Geens T, 2012, FOOD CHEM TOXICOL, V50, P3725, DOI 10.1016/j.fct.2012.07.059; Gilbertson M, 2001, ENVIRON HEALTH PERSP, V109, P827, DOI 10.2307/3454645; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; Gupta PB, 2007, CANCER RES, V67, P2062, DOI 10.1158/0008-5472.CAN-06-3895; Hansen J, 1999, AM J IND MED, V36, P43; Hoyer AP, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-8; Human Resources and Skills Development Canada, NAT OCC CLASS; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Infante P F, 1995, New Solut, V5, P52, DOI 10.2190/NS5.2.j; Institute for Environment and Health, CHEM PURP END DISR C; International Agency for Research on Cancer, 2010, SHIFT WORK PAINT FIR, V98; Ji BT, 2008, AM J IND MED, V51, P100, DOI 10.1002/ajim.20507; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Keikotlhaile BM, 2010, FOOD CHEM TOXICOL, V48, P1, DOI 10.1016/j.fct.2009.10.031; Keith MM, 2001, AM J IND MED, V39, P42, DOI 10.1002/1097-0274(200101)39:1&lt;42::AID-AJIM4&gt;3.0.CO;2-I; Kruk J, 2006, CURR CANC THER REV, V2, P3, DOI 10.2174/157339406775471795; Labreche F, 2010, OCCUP ENVIRON MED, V67, P263, DOI 10.1136/oem.2009.049817; Larsson M, 2008, SCAND J WORK ENV HEA, V34, P267; Lithner D, 2011, SCI TOTAL ENVIRON, V409, P3309, DOI 10.1016/j.scitotenv.2011.04.038; Luginaah IN, 2012, INT J ENVIRON HEAL R, V22, P232, DOI 10.1080/09603123.2011.634386; Mills PK, 2005, INT J OCCUP ENV HEAL, V11, P123; Park RM, 2001, J OCCUP ENVIRON MED, V43, P483, DOI 10.1097/00043764-200105000-00009; Petralia SA, 1998, AM J IND MED, V34, P477, DOI 10.1002/(SICI)1097-0274(199811)34:5&lt;477::AID-AJIM8&gt;3.0.CO;2-N; Petralia SA, 1999, SCAND J WORK ENV HEA, V25, P215; Preston DL, 1993, EPICURE USERS GUIDE; Robert SA, 2004, EPIDEMIOLOGY, V15, P442, DOI 10.1097/01.ede.0000129512.61698.03; Rudel RA, 2007, CANCER, V109, P2635, DOI 10.1002/cncr.22653; Sasco AJ, 2001, APMIS, V109, P321, DOI 10.1034/j.1600-0463.2001.090501.x; SAS-Institute-Inc, 2008, SAS STAT 9 2 US GUID; Siemiatycki J, 1991, RISK FACTORS CANC WO; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Statistics Canada, N AM IND CLASS SYST; Stewart PA, 1996, INT J EPIDEMIOL, V25, P744, DOI 10.1093/ije/25.4.744; Teschke K, 2002, OCCUP ENVIRON MED, V59, P575, DOI 10.1136/oem.59.9.575; Thompson D, 2005, AM J IND MED, V47, P153, DOI 10.1002/ajim.20132; Tirona MT, 2010, CANCER INVEST, V28, P743, DOI 10.3109/07357907.2010.494321; Tomatis L, 1997, CARCINOGENESIS, V18, P97, DOI 10.1093/carcin/18.1.97; Tynes T, 1996, CANCER CAUSE CONTROL, V7, P197, DOI 10.1007/BF00051295; US Department of Health and Human Services, 1998, BREAST CANC COMPR QU; US Food and Drug Administration: Bisphenol A (BPA), US FOOD CONT APPL; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Villeneuve S, 2011, AM J IND MED, V54, P499, DOI 10.1002/ajim.20952; World Health Organization, 1990, INT CLASSIFICATION D; Yang CZ, 2011, ENVIRON HEALTH PERSP, V119, P989, DOI 10.1289/ehp.1003220; Zahm SH, 2003, AM J IND MED, V44, P565, DOI 10.1002/ajim.102707011BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDENVIRON HEALTH-GLOBNOV 19Discipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health068BF</notes>
    <keywords>Agriculture; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; Canning; Carcinogen; CARCINOGENESIS; Casino; CHEMICALS; CLASSIFICATION; DATA-COLLECTION; development; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; Epidemiology; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; FOOD; HEALTH; IMPACT; INDUSTRY; Metals; Occupational; ORGANIZATION; Plastics; RECEPTOR; RISK; RISK-FACTORS; SHANGHAI; toxicology; TUMORS; WOMEN; WORKERS; YOUNG-WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Environmental Health</journalfull>
    <volume>11</volume>
    <abstract>Background: Endocrine disrupting chemicals and carcinogens, some of which may not yet have been classified as such, are present in many occupational environments and could increase breast cancer risk. Prior research has identified associations with breast cancer and work in agricultural and industrial settings. The purpose of this study was to further characterize possible links between breast cancer risk and occupation, particularly in farming and manufacturing, as well as to examine the impacts of early agricultural exposures, and exposure effects that are specific to the endocrine receptor status of tumours. Methods: 1005 breast cancer cases referred by a regional cancer center and 1146 randomly-selected community controls provided detailed data including occupational and reproductive histories. All reported jobs were industry- and occupation-coded for the construction of cumulative exposure metrics representing likely exposure to carcinogens and endocrine disruptors. In a frequency-matched case-control design, exposure effects were estimated using conditional logistic regression. Results: Across all sectors, women in jobs with potentially high exposures to carcinogens and endocrine disruptors had elevated breast cancer risk (OR = 1.42; 95% CI, 1.18-1.73, for 10 years exposure duration). Specific sectors with elevated risk included: agriculture (OR = 1.36; 95% CI, 1.01-1.82); bars-gambling (OR = 2.28; 95% CI, 0.94-5.53); automotive plastics manufacturing (OR = 2.68; 95% CI, 1.47-4.88), food canning (OR = 2.35; 95% CI, 1.00-5.53), and metalworking (OR = 1.73; 95% CI, 1.02-2.92). Estrogen receptor status of tumors with elevated risk differed by occupational grouping. Premenopausal breast cancer risk was highest for automotive plastics (OR = 4.76; 95% CI, 1.58-14.4) and food canning (OR = 5.70; 95% CI, 1.03-31.5). Conclusions: These observations support hypotheses linking breast cancer risk and exposures likely to include carcinogens and endocrine disruptors, and demonstrate the value of detailed work histories in environmental and occupational epidemiology</abstract>
    <url>WOS:000313338800001</url>
    <isbnorissn>1476-069X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>402</id>
    <title>Occupational exposure to potential endocrine disruptors: further development of a job exposure matrix</title>
    <authors>Brouwers,M.M.; van Tongeren,M.; Hirst,A.A.; Bretveld,R.W.; Roeleveld,N.</authors>
    <availability>[Brouwers, M. M.; Bretveld, R. W.; Roeleveld, N.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat &amp; Hlth Technol Assessment, NL-6500 HB Nijmegen, Netherlands. [van Tongeren, M.] Inst Occupat Med, Edinburgh EH8 9SV, Midlothian, Scotland. [Hirst, A. A.] Univ Manchester, Ctr Occupat &amp; Environm Hlth, Manchester, Lancs, England.</availability>
    <date>2009</date>
    <notes>JEnglishArticleRoeleveld, N (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat &amp; Hlth Technol Assessment, POB 9101, NL-6500 HB Nijmegen, Netherlandsn.roeleveld@ebh.umcn.nlAgency for Toxic Substances and Disease Registry, 2002, TOX PROF HEX; Arcaro KF, 1999, TOXICOLOGY, V133, P115, DOI 10.1016/S0300-483X(99)00018-9; Birnbaum LS, 2004, ENVIRON HEALTH PERSP, V112, P9, DOI 10.1289/ehp.6559; Bretveld R, 2007, SCAND J WORK ENV HEA, V33, P13; Bretveld RW, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-30; Center for Disease Control and Prevention, 2005, NAT CTR ENV HLTH PUB; Chia SE, 1997, AM J IND MED, V32, P217, DOI 10.1002/(SICI)1097-0274(199709)32:3&lt;217::AID-AJIM6&gt;3.0.CO;2-U; Colborn T, WIDESPREAD POLLUTANT; *CTR EV RISKS HUM, 2000, US DEP HLTH HUM SERV; Damstra T, 2002, GLOBAL ASSESSMENT ST; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; DOSEMECI M, 1994, EPIDEMIOLOGY, V5, P124, DOI 10.1097/00001648-199401000-00019; *EUR CHEM BUR, RISK ASS REP EX CHEM; Golden R, 2005, CRIT REV TOXICOL, V35, P435, DOI 10.1080/10408440490920104; Heilier JF, 2005, FERTIL STERIL, V84, P305, DOI 10.1016/j.fertnstert.2005.04.001; Hess-Wilson JK, 2006, CANCER LETT, V241, P1, DOI 10.1016/j.canlet.2005.10.006; *HLTH SAF EX, PEST REG UK APPR PRO; *HLTH SAF EX, BIOC PEST; *I ENV HLTH, 2005, W20 I ENV HLTH MED R; Joffe M, 2001, OCCUP ENVIRON MED, V58, P281, DOI 10.1136/oem.58.4.281; Kaltreider Ronald C., 2001, Environmental Health Perspectives, V109, P245, DOI 10.2307/3434692; Kauppinen T, 1998, AM J IND MED, V33, P409, DOI 10.1002/(SICI)1097-0274(199804)33:4&lt;409::AID-AJIM12&gt;3.3.CO;2-F; Kennedy SM, 2000, OCCUP ENVIRON MED, V57, P635, DOI 10.1136/oem.57.9.635; Lindbohm ML, 1999, SCAND J WORK ENV HEA, V25, P44; Luderer U, 2004, AM J IND MED, V46, P614, DOI 10.1002/ajim.20100; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Main KM, 2006, ENVIRON HEALTH PERSP, V114, P270, DOI 10.1289/ehp.8075; McKim JM, 2001, TOXICOL SCI, V63, P37, DOI 10.1093/toxsci/63.1.37; *NAT CTR EV RISKS, 2000, US DEP HLTH HUM SERV; Office for National Statistics, 2000, STAND OCC CLASS 2000, V1; Ohyama K, 2001, ENVIRON HEALTH PERSP, V109, P699, DOI 10.2307/3454786; Omura M, 2000, ENVIRON HEALTH PERSP, V108, P539, DOI 10.2307/3454616; Pierik FH, 2004, ENVIRON HEALTH PERSP, V112, P1570, DOI 10.1289/ehp.7234; Reutman SR, 2002, ENVIRON HEALTH PERSP, V110, P805; Safe S, 2005, TRENDS ENDOCRIN MET, V16, P139, DOI 10.1016/j.tem.2005.03.004; Safe SH, 2000, ENVIRON HEALTH PERSP, V108, P487, DOI 10.2307/3454608; Sandau CD, 2000, ENVIRON SCI TECHNOL, V34, P3871, DOI 10.1021/es001134f; Seidlova-Wuttke D, 2004, TOXICOLOGY, V205, P103, DOI 10.1016/j.tox.2004.06.042; Semple SE, 2004, SCAND J WORK ENV HEA, V30, P241; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Teschke K, 2002, OCCUP ENVIRON MED, V59, P575, DOI 10.1136/oem.59.9.575; The Agency for Toxic Substances and Disease Registry, TOX PROF; Tielemans E, 1999, OCCUP ENVIRON MED, V56, P145; *UK GOV, 2004, VOL AGR RISK RED NON; Van Tongeren M, 2002, ANN OCCUP HYG, V46, P465, DOI 10.1093/annhyg/mef053; Vrijheid M, 2003, OCCUP ENVIRON MED, V60, P543, DOI 10.1136/oem.60.8.543; Queiroz Erika Kaltenecker Retto de, 2006, Cad Saude Publica, V22, P485; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.1754814BMJ PUBLISHING GROUPLONDONBRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLANDOCCUP ENVIRON MEDSEPDiscipline: Public, Environmental &amp; Occupational Health484RA</notes>
    <keywords>1; ALKYLPHENOLIC COMPOUNDS; BINDING-AFFINITY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; brominated flame retardant; BROMINATED FLAME RETARDANTS; CANCER; CELL; CHEMICALS; development; DISEASE; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Epidemiology; EXPOSURE; Exposure assessment; fertility; FLAME RETARDANTS; HEALTH; HYPOSPADIAS; Metals; occupation; Occupational; OCCUPATIONAL-EXPOSURE; PESTICIDES; phthalate; Phthalates; POPULATION; PREVENTION; REPRODUCTIVE HEALTH; RISK; SOLVENT EXPOSURE; TOOL; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>607</startpage>
    <endpage>614</endpage>
    <journalfull>Occupational and Environmental Medicine</journalfull>
    <issue>9</issue>
    <volume>66</volume>
    <abstract>Objectives: The aim was to develop a new up-to-date and comprehensive job exposure matrix (JEM) for estimating exposure to potential endocrine disruptors in epidemiological research. Methods: Chemicals with endocrine disrupting properties were identified from the literature and classified into 10 chemical groups: polycyclic aromatic hydrocarbons (PAHs), polychlorinated organic compounds, pesticides, phthalates, organic solvents, bisphenol A, alkylphenolic compounds, brominated flame retardants, metals and a miscellaneous group. Most chemical groups were divided into three to six subgroups. Focusing on the years 1996-2006, three experts scored the probability of exposure to each chemical group and subgroup for 353 job titles as "unlikely" (0), "possible" (1) or "probable" (2). Job titles with positive exposure probability scores were provided with exposure scenarios that described the reasoning behind the scores. Results: Exposure to any chemical group was unlikely for 238 job titles (67%), whereas 102 (29%) job titles were classified as possibly (17%) or probably (12%) exposed to one or several endocrine disruptors. The remaining 13 job titles provided too little information to classify exposure. PAHs, pesticides, phthalates, organic solvents, alkylphenolic compounds and metals were often linked to a job title in the JEM. The remaining chemical groups were found to involve very few occupations. Conclusions: Despite some important limitations, this JEM could be a valuable tool for exposure assessment in studies on the health risks of endocrine disruptors, especially when task specific information is incorporated. The documented exposure scenarios are meant to facilitate further adjustments to the JEM to allow more widespread use</abstract>
    <url>WOS:000269063400008</url>
    <isbnorissn>1351-0711</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>292</id>
    <title>Estrogenic and androgenic activities in total plasma measured with reporter-gene bioassays: Relevant exposure measures for endocrine disruptors in epidemiologic studies?</title>
    <authors>Brouwers,M.M.; Besselink,H.; Bretveld,R.W.; Anzion,R.; Scheepers,P.T.J.; Brouwer,A.; Roeleveld,N.</authors>
    <availability>[Brouwers, Marijn M.; Bretveld, Reini W.; Anzion, Rob; Scheepers, Paul T. J.; Roeleveld, Nel] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat &amp; Hlth Technol Assessment, NL-6500 HB Nijmegen, Netherlands. [Besselink, Harrie; Brouwer, Abraham] BioDetect Syst BV, Amsterdam, Netherlands.</availability>
    <date>2011</date>
    <notes>JEnglishArticleRoeleveld, N (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat &amp; HTA 133, POB 9101, NL-6500 HB Nijmegen, Netherlandsn.roeleveld@ebh.umcn.nlAlbertssonWikland K, 1997, J CLIN ENDOCR METAB, V82, P541, DOI 10.1210/jc.82.2.541; Allen NE, 2002, CANCER CAUSE CONTROL, V13, P353, DOI 10.1023/A:1015238102830; Arcaro KF, 1999, TOXICOLOGY, V133, P115, DOI 10.1016/S0300-483X(99)00018-9; Ayotte P, 2005, ENVIRON HEALTH PERSP, V113, P1318, DOI 10.1289/ehp.7970; Bilau M, 2008, CHEMOSPHERE, V70, P584, DOI 10.1016/j.chemosphere.2007.07.008; Birnbaum LS, 2004, ENVIRON HEALTH PERSP, V112, P9, DOI 10.1289/ehp.6559; Bretveld R, 2007, SCAND J WORK ENV HEA, V33, P13; Damstra T, 2002, WHO PUBLICATION; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; Den Hond E, 2002, ENVIRON HEALTH PERSP, V110, P771; Department of Health and Human Services, 2005, 3 DEP HLTH HUM SERV; Dhooge W, 2006, ENVIRON HEALTH PERSP, V114, P1670, DOI 10.1289/ehp.9224; Diver MJ, 2003, CLIN ENDOCRINOL, V58, P710, DOI 10.1046/j.1365-2265.2003.01772.x; English KM, 2001, CLIN SCI, V100, P661, DOI 10.1042/CS20010011; Hamers T, 2006, TOXICOL SCI, V92, P157, DOI 10.1093/toxsci/kfj187; Harvey PW, 2004, J APPL TOXICOL, V24, P167, DOI 10.1002/jat.978; Heilier JF, 2005, FERTIL STERIL, V84, P305, DOI 10.1016/j.fertnstert.2005.04.001; Henson MC, 2004, EXP BIOL MED, V229, P383; Hess-Wilson JK, 2006, CANCER LETT, V241, P1, DOI 10.1016/j.canlet.2005.10.006; Koppen G, 2002, CHEMOSPHERE, V48, P811, DOI 10.1016/S0045-6535(02)00111-X; Kruger T, 2008, MOL REPROD DEV, V75, P669, DOI 10.1002/mrd.20747; Houtman CJ, 2006, CHEMOSPHERE, V65, P2244, DOI 10.1016/j.chemosphere.2006.05.043; Lottrup G, 2006, INT J ANDROL, V29, P172, DOI 10.1111/j.1365-2605.2005.00642.x; Luderer U, 2004, AM J IND MED, V46, P614, DOI 10.1002/ajim.20100; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Main KM, 2006, ENVIRON HEALTH PERSP, V114, P270, DOI 10.1289/ehp.8075; McKim JM, 2001, TOXICOL SCI, V63, P37, DOI 10.1093/toxsci/63.1.37; Meerts Ilonka A. T. M., 2001, Environmental Health Perspectives, V109, P399, DOI 10.2307/3454900; Muller M, 2003, EUR J ENDOCRINOL, V149, P583, DOI 10.1530/eje.0.1490583; Murk AJ, 1997, ENVIRON TOXICOL CHEM, V16, P1583, DOI 10.1897/1551-5028(1997)016&lt;1583:TCCALE&gt;2.3.CO;2; Nawrot TS, 2002, ENVIRON HEALTH PERSP, V110, P583; North K, 2000, BJU INT, V85, P107, DOI 10.1046/j.1464-410x.2000.00436.x; Orwoll E, 2006, J CLIN ENDOCR METAB, V91, P1336, DOI 10.1210/jc.2005-1830; Pauwels A, 2001, HUM REPROD, V16, P2050, DOI 10.1093/humrep/16.10.2050; Pedersen M, 2010, ENVIRON INT, V36, P344, DOI 10.1016/j.envint.2010.02.002; Pliskova M, 2005, ENVIRON HEALTH PERSP, V113, P1277, DOI 10.1289/ehp.7745; Schreurs RHMM, 2005, TOXICOL SCI, V83, P264, DOI 10.1093/toxsci/kfi035; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Sonneveld E, 2005, TOXICOL SCI, V83, P136, DOI 10.1093/toxsci/kfi005; Svartberg J, 2003, EUR J ENDOCRINOL, V149, P145, DOI 10.1530/eje.0.1490145; Van den Heuvell RL, 2002, ENVIRON HEALTH PERSP, V110, P595; Van der Linden SC, 2008, ENVIRON SCI TECHNOL, V42, P5814, DOI 10.1021/es702897y; Queiroz Erika Kaltenecker Retto de, 2006, Cad Saude Publica, V22, P485; Warner M, 2005, J EXPO ANAL ENV EPID, V15, P310, DOI 10.1038/sj.jea.7500407; Wenger D, 2008, ANAL BIOANAL CHEM, V390, P2021, DOI 10.1007/s00216-008-1872-8454PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDENVIRON INTAPRDiscipline: Environmental Sciences &amp; Ecology736HH</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; Androgen; ANDROGEN RECEPTOR; BETA; BIOASSAY; BIOAVAILABLE TESTOSTERONE; Biomarkers; BISPHENOL-A; BREAST-CANCER; BROMINATED FLAME RETARDANTS; CALUX; CANCER; CELL; DIOXIN; DIOXIN-LIKE COMPOUNDS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; epidemiologic studies; Epidemiology; Estrogen; Estrogen receptor; Estrogen receptor alpha; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; Exposure assessment; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; HEALTH; LIFE-STYLE; LINE; LINES; MODEL; MODELS; Occupational; OCCUPATIONAL-EXPOSURE; PESTICIDES; PLASMA; POLYCHLORINATED AROMATIC-HYDROCARBONS; RECEPTOR; RECEPTOR-ALPHA; REPRODUCTIVE HEALTH; SAMPLES; serum; toxicology; YOUNG MEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>557</startpage>
    <endpage>564</endpage>
    <journalfull>Environment International</journalfull>
    <issue>3</issue>
    <volume>37</volume>
    <abstract>Measurements of estrogenic and androgenic activities in total plasma with Chemically Activated LUciferase gene expression (CALUX (R)) bioassays could provide biologically relevant measures for exposure to endocrine disruptors in epidemiologic studies. The objective of this study was to explore the effects of a variety of sources of potential endocrine disruptors on estrogenic and androgenic activities in total plasma measured by CALUX (R). Plasma samples and interview data on sources of potential endocrine disruptors were collected from 108 men with different exposures profiles. CALUX (R) measurements (BioDetection Services) involved human U2-OS cell lines controlled by the estrogen receptor alpha and the androgen receptor. Mean differences (beta) in 17 beta-estradiol equivalents (EEQs) and dihydrotestosterone equivalents (AEQs) between exposure groups were estimated using general linear models. Mean plasma AEQs and EEQs were 9.1 x 10(-1) ng/ml and 12.0 pg/ml, respectively. Elevated AEQs were found in smokers (beta 1.9 (95% CI 0.1-3.6) x 10(-1) ng/ml) and heavy drinkers (1.4(0.2-3.1) x 10(-1) ng/ml), and in men occupationally exposed to disinfectants (1.6(0.3-3.5) x 10(-1) ng/ml) or welding/soldering fumes (1.4 (-0.2-2.9)x 10(-1) ng/ml). Occupational exposure to pesticides. disinfectants, and exhaust fumes seemed to be associated with increased plasma EEQs: 1.5 (-0.2-3.2) pg/ml, 2.1 (0.2-3.9) pg/ml, and 2.9 (0.6-52) pg/ml, respectively. Moderate to high plasma dioxin levels, measured in a subgroup by the dioxin-responsive CALUX (R), were accompanied by a 20% increase in AEQs. This is the first study in which CALUX (R) was used to assess hormone activities in total plasma. Although the results are not yet readily interpretable, they indicate that these measurements can be valuable for epidemiologic studies on endocrine disruptors and give direction for further research. (C) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000288481200001</url>
    <isbnorissn>0160-4120</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>286</id>
    <title>Environmental endocrine disruptors: does a sex-related susceptibility exist?</title>
    <authors>Bulzomi,P.; Marino,M.</authors>
    <availability>[Bulzomi, Pamela; Marino, Maria] Univ Roma Tre, Dept Biol, I-00146 Rome, Italy.</availability>
    <date>2011</date>
    <notes>JEnglishArticleMarino, M (reprint author), Univ Roma Tre, Dept Biol, Viale Guglielmo Marconi 446, I-00146 Rome, Italym.marino@uniroma3.itAbdelrahim M, 2006, CANCER RES, V66, P2459, DOI 10.1158/0008-5472.CAN-05-3132; Acconcia F, 2005, MOL BIOL CELL, V16, P231; Acconcia F, 2005, J CELL PHYSIOL, V203, P193, DOI 10.1002/jcp.20219; ANWAY M, 2008, PROSTATE, V68, P515; Arnold JT, 2007, PROSTATE, V67, P1152, DOI 10.1002/pros.20585; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Bagchi G, 2009, TOXICOL APPL PHARM, V238, P101, DOI 10.1016/j.taap.2008.03.015; Bakker J, 2006, NAT NEUROSCI, V9, P220, DOI 10.1038/nn1624; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207; BEITEL LK, 1994, HUM MOL GENET, V3, P21, DOI 10.1093/hmg/3.1.21; Berry PA, 2008, MOL CELL ENDOCRINOL, V288, P30, DOI 10.1016/j.mce.2008.02.024; Birrell SN, 2007, FASEB J, V21, P2285, DOI 10.1096/fj.06-7518rev; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bolli A, 2010, IUBMB LIFE, V62, P684, DOI 10.1002/iub.370; Bulzomi P, 2010, IUBMB LIFE, V62, P51, DOI 10.1002/iub.279; Caiazza F, 2007, BIOCHEM BIOPH RES CO, V359, P102, DOI 10.1016/j.bbrc.2007.05.059; CARSON MC, 2003, J PHARMACOL EXP THER, V30, P839; Cassidy RA, 2005, BREAST CANCER RES TR, V90, P55, DOI 10.1007/s10549-004-2755-0; Castles CG, 1997, J STEROID BIOCHEM, V62, P155, DOI 10.1016/S0960-0760(97)00023-X; Chambliss KL, 2002, STEROIDS, V67, P413, DOI 10.1016/S0039-128X(01)00177-5; Charlier C, 2003, OCCUP ENVIRON MED, V60, P348, DOI 10.1136/oem.60.5.348; Chiam K, 2009, BBA-REV CANCER, V1795, P104, DOI 10.1016/j.bbcan.2008.12.001; Cho LC, 2008, KAOHSIUNG J MED SCI, V24, P227, DOI 10.1016/S1607-551X(08)70146-3; Christian HC, 2000, ENDOCRINOLOGY, V141, P3111, DOI 10.1210/en.141.9.3111; Chuang KH, 2005, MOL ENDOCRINOL, V19, P1200, DOI 10.1210/me.2004-0181; Chuu CP, 2009, CANCER LETT, V275, P86, DOI 10.1016/j.canlet.2008.10.001; Clarke BL, 2009, STEROIDS, V74, P296, DOI 10.1016/j.steroids.2008.10.003; Clotfelter ED, 2004, ANIM BEHAV, V68, P665, DOI 10.1016/j.anbehav.2004.05.004; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Colborn T., 1996, OUR STOLEN FUTURE; Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171; Dang ZC, 2005, TRENDS ENDOCRIN MET, V16, P207, DOI 10.1016/j.tem.2005.05.001; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; DF S, 2007, CLIN ENDOCRINOL, V21, P431; DIAMANTIKANDARA.JP, 2009, ENDOCR REV, V30, P293; Diamanti-Kandarakis E, 2010, HORM METAB RES, V42, P543, DOI 10.1055/s-0030-1252034; di Masi A, 2009, MOL ASPECTS MED, V30, P297, DOI 10.1016/j.mam.2009.04.002; Distefano E, 2002, BBA-MOL CELL BIOL L, V1580, P145, DOI 10.1016/S1388-1981(01)00197-4; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Er F, 2007, CELL CALCIUM, V41, P467, DOI 10.1016/j.ceca.2006.09.003; Erhard HW, 2004, SCI TOTAL ENVIRON, V332, P101, DOI 10.1016/j.scitotenv.2004.04.012; Escande A, 2006, BIOCHEM PHARMACOL, V71, P1459, DOI 10.1016/j.bcp.2006.02.002; Estrada M, 2003, ENDOCRINOLOGY, V144, P3586, DOI 10.1210/en.2002-0164; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fenichel P, 2008, GYNECOL OBSTET FERTI, V36, P969, DOI 10.1016/j.gyobfe.2008.05.006; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Ferguson SA, 2000, NEUROTOXICOLOGY, V21, P947; Foster WG, 2008, J TOXICOL ENV HEAL B, V11, P177, DOI 10.1080/10937400701873456; Fox GA, 2008, J TOXICOL ENV HEAL A, V71, P1; Galati G, 2000, Drug Metabol Drug Interact, V17, P311; Galluzzo P, 2007, ENDOCR-RELAT CANCER, V14, P153, DOI 10.1677/ERC-06-0020; Galluzzo P, 2008, ENDOCRINOLOGY, V149, P2567, DOI 10.1210/en.2007-1173; Galluzzo P, 2009, AM J PHYSIOL-CELL PH, V297, pC1249, DOI 10.1152/ajpcell.00188.2009; Gioiosa L, 2007, HORM BEHAV, V52, P307, DOI 10.1016/j.yhbeh.2007.05.006; Gorski R A, 1985, J Anim Sci, V61 Suppl 3, P38; Greenspan FS, 2004, BASIC CLIN ENDOCRINO; Grun F, 2009, MOL CELL ENDOCRINOL, V304, P19, DOI 10.1016/j.mce.2009.02.018; Guo ZY, 2002, J BIOL CHEM, V277, P29600, DOI 10.1074/jbc.M202997200; Ha MH, 2007, ENVIRON HEALTH PERSP, V115, P1204, DOI 10.1289/ehp.10184; Hansen LG, 1998, ENVIRON HEALTH PERSP, V106, P171, DOI 10.2307/3433919; Hermsen SAB, 2008, TOXICOLOGY, V253, P147, DOI 10.1016/j.tox.2008.09.005; HOND ED, 2002, ENV HLTH PERSPECT, V110, P771; Hotchkiss AK, 2003, PHYSIOL BEHAV, V79, P151, DOI 10.1016/S0031-9384(03)00093-3; Howdeshell KL, 2008, ENVIRON RES, V108, P168, DOI 10.1016/j.envres.2008.08.009; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim EJ, 2008, NEUROCHEM RES, V33, P971, DOI 10.1007/s11064-007-9416-8; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Kohle C, 2007, BIOCHEM PHARMACOL, V73, P1853, DOI 10.1016/j.bcp.2007.01.009; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Kouki T, 2003, HORM BEHAV, V44, P140, DOI 10.1016/S0018-506X(03)00122-3; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kretschmer XC, 2005, CHEM-BIOL INTERACT, V155, P111, DOI 10.1016/j.cbi.2005.06.003; Kris-Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002-9343(01)00995-0; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Langer P, 1998, EUR J ENDOCRINOL, V139, P402, DOI 10.1530/eje.0.1390402; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Lind PM, 2004, TOXICOL LETT, V150, P293, DOI 10.1016/j.toxlet.2004.02.008; Lind PM, 2004, ENVIRON HEALTH PERSP, V112, P359, DOI 10.1289/ehp.6524; Lind PM, 2003, AMBIO, V32, P385, DOI 10.1639/0044-7447(2003)032[0385:BMDIMB]2.0.CO;2; Littleton-Kearney Marguerite, 2004, Biol Res Nurs, V5, P276, DOI 10.1177/1099800403262927; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Lund TD, 2001, BRAIN RES, V914, P92, DOI 10.1016/S0006-8993(01)02779-2; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; Main KM, 2006, ENVIRON HEALTH PERSP, V114, P270, DOI 10.1289/ehp.8075; MANOLAGAS KM, 2002, HORM RES, V57, P385; Marino M, 2001, MOL CELL ENDOCRINOL, V182, P19, DOI 10.1016/S0303-7207(01)00556-1; Marino M, 2008, STEROIDS, V73, P853, DOI 10.1016/j.steroids.2007.12.003; Marino Maria, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P305, DOI 10.2174/1568008054863763; Marino M, 2001, EXP PHYSIOL, V86, P39, DOI 10.1113/eph8602069; Marino M, 2009, NUTR DIET RES PROG, P231; MARINO M, 2007, ENDOCRINE DISRUPTORS; Marino M, 1998, BIOCHEM BIOPH RES CO, V245, P254, DOI 10.1006/bbrc.1998.8413; Marino M, 2002, MOL BIOL CELL, V13, P3720, DOI 10.1091/mbc.E02-03-0153; Markman S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001674; Marsee K, 2006, ENVIRON HEALTH PERSP, V114, P805, DOI 10.1289/ehp.8663; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Masuno H, 2002, J LIPID RES, V43, P676; MCALAVANJA C, 2003, AM J EPIDEMIOL, V157, P800; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McNutt S.H., 1928, J AM VET MED ASSOC, V73, P484; Mendelsohn ME, 2000, J STEROID BIOCHEM, V74, P337, DOI 10.1016/S0960-0760(00)00110-2; Meyer TE, 2007, OCCUP ENVIRON MED, V64, P155, DOI 10.1136/oem.2006.027383; Michels G, 2006, ENDOCRINOLOGY, V147, P5160, DOI 10.1210/en.2006-0186; Michels G, 2008, FRONT NEUROENDOCRIN, V29, P182, DOI 10.1016/j.yfrne.2007.08.004; Miller MD, 2009, ENVIRON HEALTH PERSP, V117, P1033, DOI 10.1289/ehp.0800247; Missmer SA, 2004, FERTIL STERIL, V82, P1501, DOI 10.1016/j.fertnstert.2004.04.065; Monosson E, 1999, TOXICOL IND HEALTH, V15, P65; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; NAKANISHI T, 2008, J TOXICOL SCI, V3, P269; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Nguon K, 2005, Prog Brain Res, V148, P341; Norman AW, 1997, HORMONES; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; O'Malley BW, 2005, MOL ENDOCRINOL, V19, P1402, DOI 10.1210/me.2004-0480; Ottinger MA, 2009, J ENVIRON SCI HEAL C, V27, P286, DOI 10.1080/10590500903310229; Pallottini V., 2008, Infectious Disorders - Drug Targets, V8, P52; Pan GW, 2006, ENVIRON HEALTH PERSP, V114, P1643, DOI 10.1289/ehp.9016; Parks LG, 2000, TOXICOL SCI, V58, P339, DOI 10.1093/toxsci/58.2.339; Patisaul HB, 2006, NEUROTOXICOL TERATOL, V28, P111, DOI 10.1016/j.ntt.2005.11.004; Patisaul HB, 2007, NEUROTOXICOLOGY, V28, P1, DOI 10.1016/j.neuro.2006.10.001; Patisaul HB, 2008, BRAIN RES REV, V57, P352, DOI 10.1016/j.brainresrev.2007.06.008; Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200; Penza M, 2006, ENDOCRINOLOGY, V147, P5740, DOI 10.1210/en.2006-0365; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Pezzato E, 2004, INT J CANCER, V112, P787, DOI 10.1002/ijc.20460; Portigal CL, 2002, TOXICOL APPL PHARM, V179, P185, DOI 10.1006/taap.2002.9371; POULIN R, 1989, ENDOCRINOLOGY, V125, P392; Prince MM, 2006, ENVIRON HEALTH PERSP, V114, P1508, DOI 10.1289/ehp.9175; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins GS, 1997, ENDOCRINOLOGY, V138, P1801, DOI 10.1210/en.138.5.1801; Rajapakse N, 2004, ENVIRON SCI TECHNOL, V38, P6343, DOI 10.1021/es049681e; Reilly JJ, 2005, BEST PRACT RES CL EN, V19, P327, DOI 10.1016/j.beem.2005.04.002; Ren FG, 2000, ONCOGENE, V19, P1924, DOI 10.1038/sj.onc.1203511; Revelli A, 1998, ENDOCR REV, V19, P3, DOI 10.1210/er.19.1.3; Ricote M, 2006, APOPTOSIS, V11, P1969, DOI 10.1007/s10495-006-0086-9; Rier SE, 2001, TOXICOL SCI, V59, P147, DOI 10.1093/toxsci/59.1.147; Roy JR, 2009, MED SCI MONITOR, V15, pRA137; Ruegg J, 2008, MOL ENDOCRINOL, V22, P304, DOI 10.1210/me.2007-0128; SACHS BD, 1988, NEUROENDOCRINOLOGY, V48, P453, DOI 10.1159/000125049; Sarkar Narendra Nath, 2009, Cardiol J, V16, P300; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; Setlur SR, 2005, ADV ANAT PATHOL, V12, P265, DOI 10.1097/01.pap.0000184179.50672.f7; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shipley JM, 2006, TOXICOL APPL PHARM, V213, P87, DOI 10.1016/j.taap.2005.09.011; Sickel MJ, 2000, J NEUROENDOCRINOL, V12, P397; Signorile PG, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-49; Signorile PG, 2010, GEN COMP ENDOCR, V168, P318, DOI 10.1016/j.ygcen.2010.03.030; Simerly RB, 1998, BEHAV BRAIN RES, V92, P195, DOI 10.1016/S0166-4328(97)00191-5; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; Simoncini T, 2000, NATURE, V407, P538; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Somm E, 2009, ENVIRON HEALTH PERSP, V117, P1549, DOI 10.1289/ehp.11342; Srinivas-Shankar U, 2009, FRONT HORM RES, V37, P133, DOI 10.1159/000176050; Stoker TE, 2000, TOXICOL SCI, V58, P50, DOI 10.1093/toxsci/58.1.50; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; SWEDENBORG E, 2010, INT J ANDROL, V3, P288; Swedenborg E, 2010, TOXICOLOGY, V268, P132, DOI 10.1016/j.tox.2009.09.007; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; Totta P, 2005, J NUTR, V135, P2687; Totta P, 2004, IUBMB LIFE, V56, P491, DOI 10.1080/15216540400010792; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; UEDA K, 2009, YAKUGAKU ZASSHI, V12, P1501; Ulubaev A, 2009, CLIN ENDOCRINOL, V71, P607, DOI 10.1111/j.1365-2265.2009.03562.x; Usmani KA, 2006, DRUG METAB DISPOS, V34, P1606, DOI 10.1124/dmd.106.010439; van Maele-Fabry G, 2006, CANCER CAUSE CONTROL, V17, P353, DOI 10.1007/s10552-005-0443-y; Vasiliu O, 2004, HUM REPROD, V19, P1506, DOI 10.1093/humrep/deh292; Vij U, 2004, NATL MED J INDIA, V17, P22; Vine MF, 2000, ENVIRON HEALTH PERSP, V108, P1113, DOI 10.2307/3434822; Vinggaard AM, 2005, TOXICOL SCI, V85, P886, DOI 10.1093/toxsci/kfi150; Vinggaard AM, 2002, TOXICOL SCI, V69, P344, DOI 10.1093/toxsci/69.2.344; Virgili F, 2008, FREE RADICAL BIO MED, V45, P1205, DOI 10.1016/j.freeradbiomed.2008.08.001; Virgili F, 2004, IUBMB LIFE, V56, P145, DOI 10.1080/15216540410001685083; Vladusic EA, 1998, CANCER RES, V58, P210; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wannenes F, 2008, MOL CELL ENDOCRINOL, V292, P11, DOI 10.1016/j.mce.2008.05.018; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Weihua Zhang, 2003, FEBS Letters, V546, P17, DOI 10.1016/S0014-5793(03)00436-8; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; *WHO, 2007, WHO POS STAT US DDT; WILSON EM, 1976, J BIOL CHEM, V251, P5620; Woolcott CG, 2001, CANCER CAUSE CONTROL, V12, P395, DOI 10.1023/A:1011289905751; Yamabe Y, 2000, TOXICOL APPL PHARM, V169, P177, DOI 10.1006/taap.2000.9067; YEH Y, 2000, P NATL ACAD SCI USA, V97, P11256; Zagar Y, 2004, J BIOL CHEM, V279, P2403, DOI 10.1074/jbc.M309132200; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.1711742981974FRONTIERS IN BIOSCIENCE INCIRVINE16471 SCIENTIFIC WAY, IRVINE, CA 92618 USAFRONT BIOSCI-LANDMRKJUN 1Discipline: Biochemistry &amp; Molecular Biology; Cell Biology757OK</notes>
    <keywords>Androgen; ANDROGEN RECEPTOR; apoptosis; BIOLOGY; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELL; DDT; diet; DIOXIN-LIKE CHEMICALS; DISORDERS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; environmental endocrine disruptors; Epidemiology; Estrogen; Estrogen receptors; ESTROGEN-RECEPTOR-ALPHA; female; gender differences; GENE; GENE-EXPRESSION; GENES; HEALTH; Hormones; HUMANS; Immune; IN-UTERO; JUN; Male; mechanism; Metabolic disorders; oestrogen; p21; p38; Plant-derived flavonoids; Prostate; PROSTATE-CANCER CELLS; RESPONSES; Review; SEXUALLY DIMORPHIC NUCLEUS; signal transduction pathways; SIGNAL-TRANSDUCTION PATHWAY; Steroid hormone; STEROID-HORMONES; SUSCEPTIBILITY; TARGET; TISSUE; TISSUES; toxicology; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2478</startpage>
    <endpage>2498</endpage>
    <journalfull>Frontiers in Bioscience-Landmark</journalfull>
    <volume>16</volume>
    <abstract>Several substances present in the environment, now classified as endocrine disruptors (EDs), strongly interfere with both androgen and oestrogen actions in reproductive tissues. However, nowadays it is well recognized that these sex steroid hormones are more than regulators of gonadal functions. In fact, they, in synergy with genes, are responsible of sex-related differences in anatomical, physiological, and behavioral traits which characterize males and females of many vertebrate species, including humans. Thus, even if EDs are present in minute amount (part for trillion) in environment, their effects in male and female physiology could be greater than before expected also prejudicing the sex-steroid hormone-induced integrated physiological responses in women and men. In addition, differences in male and female susceptibility to EDs could be present even if scarce information on this aspect is still available. Here we have reviewed the state of the art on the sex-related susceptibility to EDs underlying the mechanism at the root of these effects</abstract>
    <url>WOS:000290097400006</url>
    <isbnorissn>1093-9946</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>202</id>
    <title>The naringenin-induced proapoptotic effect in breast cancer cell lines holds out against a high bisphenol a background</title>
    <authors>Bulzomi,P.; Bolli,A.; Galluzzo,P.; Acconcia,F.; Ascenzi,P.; Marino,M.</authors>
    <availability>[Bulzomi, Pamela; Bolli, Alessandro; Galluzzo, Paola; Acconcia, Filippo; Ascenzi, Paolo; Marino, Maria] Univ Roma Tre, Dept Biol, I-00146 Rome, Italy. [Ascenzi, Paolo] Univ Roma Tre, Interdept Lab Electron Microscopy, I-00146 Rome, Italy.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMarino, M (reprint author), Univ Roma Tre, Dept Biol, Viale G Marconi 446, I-00146 Rome, Italym.marino@uniroma3.itBolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bolli A, 2010, IUBMB LIFE, V62, P684, DOI 10.1002/iub.370; Bulzomi P, 2010, IUBMB LIFE, V62, P51, DOI 10.1002/iub.279; de Kok TM, 2008, EUR J NUTR, V47, P51, DOI 10.1007/s00394-008-2006-y; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Galluzzo P, 2009, MOL NUTR FOOD RES, V53, P699, DOI 10.1002/mnfr.200800239; Galluzzo P, 2008, ENDOCRINOLOGY, V149, P2567, DOI 10.1210/en.2007-1173; Galluzzo P, 2006, GENES NUTR, V1, P161, DOI 10.1007/BF02829966; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Milner JA, 2006, NUTR CANCER, V56, P216, DOI 10.1207/s15327914nc5602_13; Munguia-Lopez EM, 2005, FOOD ADDIT CONTAM, V22, P892, DOI 10.1080/02652030500163674; Noh KT, 2011, EXP CELL RES, V317, P1663, DOI 10.1016/j.yexcr.2011.03.022; Pan MH, 2011, MOL NUTR FOOD RES, V55, P32, DOI 10.1002/mnfr.201000412; Patisaul HB, 2010, FRONT NEUROENDOCRIN, V31, P400, DOI 10.1016/j.yfrne.2010.03.003; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Recchia AG, 2004, FOOD ADDIT CONTAM, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Totta P, 2004, IUBMB LIFE, V56, P491, DOI 10.1080/15216540400010792; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; van Meeuwen JA, 2007, FOOD CHEM TOXICOL, V45, P2319, DOI 10.1016/j.fct.2007.06.011; Varea O, 2010, STEROIDS, V75, P565, DOI 10.1016/j.steroids.2009.09.006; Virgili F, 2008, FREE RADICAL BIO MED, V45, P1205, DOI 10.1016/j.freeradbiomed.2008.08.001; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Wade MG, 2003, FOOD CHEM TOXICOL, V41, P1517, DOI 10.1016/S0278-6915(03)00168-6; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xiao Y, 2011, TOXICOL IN VITRO, V25, P153, DOI 10.1016/j.tiv.2010.10.010; Xing LN, 2010, TOXICOL SCI, V115, P577, DOI 10.1093/toxsci/kfq081; Yoshida T, 2001, FOOD ADDIT CONTAM A, V18, P69, DOI 10.1080/026520301446412; Yu B, 2010, BIOMED ENVIRON SCI, V23, P357, DOI 10.1016/S0895-3988(10)60076-1316WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAIUBMB LIFEAUGDiscipline: Biochemistry &amp; Molecular Biology; Cell Biology974ZX</notes>
    <keywords>ACTIVATION; Akt; ANTIOXIDANT; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cell lines; BREAST-CANCER; CANCER; CANCER-CELL-GROWTH; CANCER-CELL-PROLIFERATION; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; CHEMICALS; CONTROVERSIES; ENDOCRINE; ENDOCRINE DISRUPTORS; Estrogen; Estrogen receptor; estrogen receptor a; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FOOD; Food contaminant; GENE; GENES; GROWTH; In vitro; IN-VITRO; INDUCED APOPTOTIC CASCADE; LINE; LINES; MECHANISMS; NARINGENIN; p21; p38; PREVENTION; proliferation; PROTEIN; RATS; RECEPTOR; SIGNALS; SUPPRESSION; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>690</startpage>
    <endpage>696</endpage>
    <journalfull>Iubmb Life</journalfull>
    <issue>8</issue>
    <volume>64</volume>
    <abstract>Fruit and vegetable consumption has generally been associated with the prevention or suppression of cancer. However, food could contain a multitude of chemicals (e.g., bisphenol A; BPA) that could synergize or antagonize the effects of diet-derived compounds. Remarkably, food containers (e.g., water and infant bottles) are the largest source of exposure to BPA for human beings. Here, the effects of the coexposure of naringenin (Nar, 1.0 X 10-9 M to 1.0 X 10-4 M) and BPA (1.0 X 10-5 M) in estrogen-dependent breast cancer cell lines expressing (i.e., MCF-7 and T47D) or not expressing (i.e., MDA-MB-231) estrogen receptor a (ERa) are reported. Although both Nar and BPA bind to ERa, they induce opposite effects on breast cancer cell growth. BPA induces cell proliferation, whereas Nar only decreases the number of ERa-positive cells (i.e., MCF-7 and T47D). Notably, even in the presence of BPA, Nar impairs breast cancer cell proliferation by activating caspase-3. The molecular pathways involved require p38 activation, whereas, the BPA-induced AKT activation is completely prevented by the Nar treatment. As a whole, Nar maintains its proapoptotic effects even in the presence of the food contaminant BPA, thus, enlarging the chemopreventive potential of this flavanone. (c) 2012 IUBMB IUBMB Life, 64(8): 690696, 2012</abstract>
    <url>WOS:000306477300006</url>
    <isbnorissn>1521-6543</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>183</id>
    <title>Exposures to Endocrine-Disrupting Chemicals and Age of Menarche in Adolescent Girls in NHANES (2003-2008)</title>
    <authors>Buttke,D.E.; Sircar,K.; Martin,C.</authors>
    <availability>[Buttke, Danielle E.; Sircar, Kanta; Martin, Colleen] Ctr Dis Control &amp; Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleButtke, DE (reprint author), Natl Ctr Environm Hlth, Epidem Intelligence Serv, 4770 Buford Hwy,Mailstop F-57, Chamblee, GA 30341 USAiyk7@cdc.govAkahori Y, 2008, TOXICOL IN VITRO, V22, P225, DOI 10.1016/j.tiv.2007.08.004; Al-Sahab B, 2010, AM J EPIDEMIOL, V173, P64; Barber LB, 2009, ENVIRON SCI TECHNOL, V43, P4843, DOI 10.1021/es803292v; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Bradman A, 2003, ENVIRON HEALTH PERSP, V111, P1779, DOI 10.1289/ehp.6259; Louis GMB, 2008, PEDIATRICS, V121, pS192, DOI 10.1542/peds.1813E; Carel JC, 2006, MOL CELL ENDOCRINOL, V254, P226, DOI 10.1016/j.mce.2006.04.034; CDC, 2011, 4 CDCP; Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z; Chen AM, 2011, ENVIRON RES, V111, P831, DOI 10.1016/j.envres.2011.05.016; Craig ZR, 2011, REPRODUCTION, V142, P633, DOI 10.1530/REP-11-0136; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Deardorff J, 2005, PEDIATRICS, V116, P1451, DOI 10.1542/peds.2005-0542; DENBESTEN C, 1991, TOXICOL APPL PHARM, V111, P69, DOI 10.1016/0041-008X(91)90135-2; Dossus L, 2010, INT J CANCER, V127, P442, DOI 10.1002/ijc.25050; ELWOOD JM, 1977, J NATL CANCER I, V59, P1055; Euling SY, 2008, PEDIATRICS, V121, pS167, DOI 10.1542/peds.2007-1813C; Fang H, 2000, ENVIRON HEALTH PERSP, V108, P723, DOI 10.1289/ehp.00108723; Frontini MG, 2003, INT J OBESITY, V27, P1398, DOI 10.1038/sj.ijo.0802422; Fujita M, 2008, TOHOKU J EXP MED, V216, P297, DOI 10.1620/tjem.216.297; Grummer-Strawn Laurence M., 2010, Morbidity and Mortality Weekly Report, V59, P1; Hauser R, 2009, ENV HLTH PERSPECT, V116, P976; He CY, 2010, AM J EPIDEMIOL, V171, P334, DOI 10.1093/aje/kwp372; Hershberger PA, 2005, CANCER RES, V65, P1598, DOI 10.1158/0008-5472.CAN-04-2694; Himes JH, 2009, J PEDIATR-US, V155, P393, DOI 10.1016/j.jpeds.2009.03.036; Howdeshell KL, 2008, ENVIRON RES, V108, P168, DOI 10.1016/j.envres.2008.08.009; Inoue M, 2007, EUR J CANCER, V16, P116; Jacobson-Dickman E, 2009, CURR OPIN ENDOCRINOL, V16, P25, DOI 10.1097/MED.0b013e328320d560; Joinson C, 2011, BRIT J PSYCHIAT, V198, P17, DOI 10.1192/bjp.bp.110.080861; Kato K, 2005, ANAL CHEM, V77, P2985, DOI 10.1021/ac0481248; Kawaguchi M, 2009, J VET MED SCI, V71, P1027, DOI 10.1292/jvms.71.1027; Korrick SA, 2011, ENVIRON HEALTH PERSP, V119, P1339, DOI 10.1289/ehp.1003102; Krstevska-Konstantinova M, 2001, HUM REPROD, V16, P1020, DOI 10.1093/humrep/16.5.1020; Lee PA, 2001, APMIS, V109, P81, DOI 10.1034/j.1600-0463.2001.d01-107.x; Macsali F, 2011, AM J RESP CRIT CARE, V183, P8, DOI 10.1164/rccm.200912-1886OC; Makita Y, 2008, BASIC CLIN PHARMACOL, V102, P360, DOI 10.1111/j.1742-7843.2007.00179.x; Marsman D., 1995, TOXICITY REPORT SERI, V30; Maskarinec G, 2006, BREAST CANCER RES TR, V98, P45, DOI 10.1007/s10549-005-9129-0; Miao MH, 2011, BIRTH DEFECTS RES A, V91, P867, DOI 10.1002/bdra.22845; Molina-Molina JM, 2008, TOXICOL APPL PHARM, V232, P384, DOI 10.1016/j.taap.2008.07.017; NTP (National Toxicology Program), 2002, REP CARCINOG, V10, P84; NTP (National Toxicology Program), 1987, NTP TECHN REP SER, V319; NTP (National Toxicology Program), 2008, INT J TOXICOL S4, V27, P1; Ozen S, 2012, ENVIRON MONIT ASSESS, V184, P4223, DOI 10.1007/s10661-011-2257-6; Partsch CJ, 2001, HUM REPROD UPDATE, V7, P292, DOI 10.1093/humupd/7.3.292; PHINNEY VG, 1990, ADOLESCENCE, V25, P321; Rokade SA, 2009, INTERNET J BIOL ANTH, V3; Sata F, 1995, INT ARCH OCC ENV HEA, V68, P64; Schell LM, 2010, PHYSIOL BEHAV, V99, P246, DOI 10.1016/j.physbeh.2009.09.015; Selevan SG, 2003, NEW ENGL J MED, V348, P1527, DOI 10.1056/NEJMoa020880; Shaw J, 2009, REPROD TOXICOL, V28, P26, DOI 10.1016/j.reprotox.2009.03.003; Silva MJ, 2007, J CHROMATOGR B, V860, P106, DOI 10.1016/j.jchromb.2007.10.023; STAVRAKY K, 1974, J NATL CANCER I, V53, P647; Stoker TE, 2010, TOXICOL SCI, V117, P45, DOI 10.1093/toxsci/kfq180; Svechnikov K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/684504; Takahashi O, 2011, FOOD CHEM TOXICOL, V49, P49, DOI 10.1016/j.fct.2010.09.029; Teitelbaum SL, 2008, ENVIRON RES, V106, P257, DOI 10.1016/j.envres.2007.09.010; US Environmental Protection Agency, 2010, FED REG, V75, P70248; Vasiliu O, 2004, HUM REPROD, V19, P1506, DOI 10.1093/humrep/deh292; Versonnen BJ, 2003, ENVIRON TOXICOL CHEM, V22, P329, DOI 10.1897/1551-5028(2003)022&lt;0329:IVAIVE&gt;2.0.CO;2; Vo TTB, 2010, REPROD TOXICOL, V29, P306, DOI 10.1016/j.reprotox.2010.01.013; WALLACE LA, 1991, ENVIRON HEALTH PERSP, V95, P7, DOI 10.2307/3431099; WALLACE LA, 1991, TOXICOL IND HEALTH, V7, P203; WALLACE LA, 1995, ENVIRON HEALTH PERSP, V103, P95, DOI 10.2307/3432568; Wang YF, 2002, PEDIATRICS, V110, P903, DOI 10.1542/peds.110.5.903; Wolff MS, 2008, ENVIRON RES, V107, P393, DOI 10.1016/j.envres.2008.03.006; Wronka I, 2010, ANTHROPOL ANZ, V68, P43, DOI 10.1127/0003-5548/2010/0066; Yamasaki Kanji, 2005, Journal of Toxicological Sciences, V30, P1; Ye XY, 2005, ANAL CHEM, V77, P5407, DOI 10.1021/ac050390d; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Zuckerman D, 2001, RIBBON, P67112US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPNOVDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology036ZE</notes>
    <keywords>2,4-dichlorophenol; ADOLESCENCE; ASSOCIATION; BIRTH-WEIGHT; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CHEMICALS; DISEASE; EDCs; Endocrine disrupting chemicals; Endocrine disrupting compounds; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; ENDOMETRIAL CANCER; ENVIRONMENTAL CHEMICALS; ENVIRONMENTAL PHENOLS; Epidemiology; EXPOSURE; FOOD; HEALTH; In vitro; IN-UTERO EXPOSURE; IN-VITRO; MASS-SPECTROMETRY; menarche; METABOLITES; NHANES; nutrition; Occupational; PARABENS; phenol; PHENOLS; phthalate; PHTHALATE METABOLITES; Phthalates; POPULATION; precocious puberty; PREGNANCY; Reproduction; REPRODUCTIVE HEALTH; RISK-FACTORS; SAMPLES; SEXUAL-MATURATION; TOXICITY; toxicology; Triclosan; UNITED-STATES; Urine; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1613</startpage>
    <endpage>1618</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>11</issue>
    <volume>120</volume>
    <abstract>BACKGROUND: The observed age of menarche has fallen, which may have important adverse social and health consequences. Increased exposure to endocrine-disrupting compounds (EDCs) has been associated with adverse reproductive outcomes. OBJECTIVE: Our objective was so assess the relationship between EDC exposure and the age of menarche in adolescent girls. METHODS: We used data from female participants 12-16 years of age who had completed the reproductive health questionnaire and laboratory examination for the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey (NHANES) for years 2003-2008 (2005-2008 for analyses of phthalates and parabens). Exposures were assessed based on creatinine-corrected natural log urine concentrations of selected environmental chemicals and metabolites found in at least 75% of samples in our study sample. We used Cox proportional hazards analysis in SAS 9.2 survey procedures to estimate associations after accounting for censored data among participants who had not reached menarche. We evaluated body mass index (BMI; kilograms per meter squared), family income-to-poverty ratio, race/ethnicity, mother's smoking status during pregnancy, and birth weight as potential confounders. RESULTS: The weighted mean age of menarche was 12.0 years of age. Among 440 girls with both reproductive health and laboratory data, after accounting for BMI and race/ethnicity, we found that 2,5-dichlorophenol (2,5-DCP) and summed environmental phenols (2,5-DCP and 2,4-DCP) were inversely associated with age of menarche [hazard ratios of 1.10; 95% confidence interval (CI): 1.01, 1.19 and 1.09; 95% CI: 1.01, 1.19, respectively]. Other exposures (total parabens, bisphenol A, triclosan, benzophenone-3, total phthalates, and 2,4-DCP) were not significantly associated with age of menarche. CONCLUSIONS: Our findings suggest an association between 2,5-DCP, a potential EDC, and earlier age of menarche in the general U.S. population</abstract>
    <url>WOS:000311070000033</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>189</id>
    <title>Estrogen receptors in human disease</title>
    <authors>Cadenas,C.; Bolt,H.M.</authors>
    <availability>[Cadenas, C.; Bolt, H. M.] TU Dortmund, Leibniz Inst Arbeitsforsch, Leibniz Res Ctr Working Environm &amp; Human Factors, D-44139 Dortmund, Germany.</availability>
    <date>2012</date>
    <notes>JEnglishEditorial MaterialCadenas, C (reprint author), TU Dortmund, Leibniz Inst Arbeitsforsch, Leibniz Res Ctr Working Environm &amp; Human Factors, Ardeystr 67, D-44139 Dortmund, Germanycadenas@ifado.deBolt HM, 2011, ARCH TOXICOL, V85, P1491, DOI 10.1007/s00204-011-0785-z; Brase JC, 2010, CLIN CANCER RES, V16, P2391, DOI 10.1158/1078-0432.CCR-09-2471; Cadenas C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2599; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Hofer N, 2010, ARCH TOXICOL, V84, P541, DOI 10.1007/s00204-010-0524-x; Kammers K, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-478; Petry IB, 2010, CLIN CANCER RES, V16, P451, DOI 10.1158/1078-0432.CCR-09-1617; Romano RM, 2010, ARCH TOXICOL, V84, P309, DOI 10.1007/s00204-009-0494-z; Schmidt M, 2011, BREAST CANCER RES TR, V125, P637, DOI 10.1007/s10549-010-0856-5; Schmidt M, 2012, CLIN CANCER RES, V18, P2695, DOI 10.1158/1078-0432.CCR-11-2210; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Schmidt M, 2009, ANN ONCOL, V20, P258, DOI 10.1093/annonc/mdn590121SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYARCH TOXICOLOCTDiscipline: Toxicology003VW</notes>
    <keywords>BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; COMPREHENSIVE ANALYSIS; DISEASE; ERBB2; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPRESSION; HUMAN-DISEASE; NEGATIVE BREAST-CANCER; PREDICTION; PROGNOSIS; PROTEIN; RECEPTOR; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1489</startpage>
    <endpage>1490</endpage>
    <journalfull>Archives of Toxicology</journalfull>
    <issue>10</issue>
    <volume>86</volume>
    <url>WOS:000308640500001</url>
    <isbnorissn>0340-5761</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>328</id>
    <title>Background bisphenol A in experimental materials and its implication to low-dose in vitro study</title>
    <authors>Cao,X.L.; Corriveau,J.; Popovic,S.; Coughlan,M.C.; Chepelevc,N.; Willmore,W.; Schrader,T.; Jin,X.L.</authors>
    <availability>[Cao, Xu-Liang; Corriveau, Jeannette; Popovic, Svetlana] Hlth Canada, Food Res Div, Bur Chem Safety, Food Directorate, Ottawa, ON K1A 0K9, Canada. [Coughlan, Melanie C.; Schrader, Timothy; Jin, Xiaolei] Hlth Canada, Toxicol Res Div, Bur Chem Safety, Food Directorate, Ottawa, ON K1A 0K9, Canada. [Chepelevc, Nikolai; Willmore, William] Carleton Univ, Inst Biochem, Dept Biol, Ottawa, ON K1S 5B6, Canada. [Chepelevc, Nikolai; Willmore, William] Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada.</availability>
    <date>2010</date>
    <notes>JEnglishArticleCao, XL (reprint author), Hlth Canada, Food Res Div, Bur Chem Safety, Food Directorate, 251 Sir Frederick Banting Driveway,AL 2203D, Ottawa, ON K1A 0K9, CanadaXu-Liang.Cao@hc-sc.gc.caBiswanger C, 2006, IN VITRO CELL DEV-AN, V42, P294; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Cao XL, 2008, J AGR FOOD CHEM, V56, P7919, DOI 10.1021/jf8008712; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Miyatake M, 2006, J NEUROENDOCRINOL, V18, P434, DOI 10.1111/j.1365-2826.2006.01434.x; Satoh K, 2004, FOOD CHEM TOXICOL, V42, P983, DOI 10.1016/j.fct.2004.02.011; U. S. Environmental Protection Agency (EPA), 1993, 80057 US EPA CASRN; Watanabe H, 2003, INT IMMUNOPHARMACOL, V3, P1601, DOI 10.1016/S1567-5769(03)00182-6; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xu JP, 2002, BIOCHEM BIOPH RES CO, V292, P456, DOI 10.1006/bbrc.2002.6644; Yamaguchi H, 2006, TOXICOLOGY, V226, P131, DOI 10.1016/j.tox.2006.06.011155PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDCHEMOSPHEREOCTDiscipline: Environmental Sciences &amp; Ecology673YQ</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CARCINOGENESIS; CELL; Estrogen; FOOD; GC-MS; HEALTH; In vitro; IN-VITRO; low dose; Low-dose study; mechanism; MECHANISMS; MEDIA; NEURONS; QUANTIFICATION; RECEPTOR; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>817</startpage>
    <endpage>820</endpage>
    <journalfull>Chemosphere</journalfull>
    <issue>6</issue>
    <volume>81</volume>
    <abstract>In vitro low-dose studies are important to understand the mechanisms of bisphenol A (BPA) action. BPA doses used in current in vitro studies varied considerably, and doses as low as 10(-15) M have been reported. The actual doses of BPA used in the in vitro low-dose studies were rarely checked analytically, and the background BPA levels in experimental materials, which will determine the lowest BPA dose to be used, should be investigated or considered. In this study, the background BPA levels in various materials typically used in in vitro low-dose studies for BPA were investigated. Background BPA levels from the use of disposable pipettes and pipette tips were low (&lt; 0.20 ng mL(-1) or 0.88 nM). BPA was also detected in several commercial buffer solutions at levels close to the method limit of quantification (LOQ) (0.02 ng mL(-1): 0.088 nM). However, BPA was detected in all cell culture media obtained from various sources at levels ranging from 0.080 to 4.26 ng mL(-1) (or 0.35 to 19 nM) with an average of 0.83 ng mL(-1) (3.5 nM). We suggest that culture media used for low-dose BPA studies should be analysed for background BPA levels prior to use, and the medium with the lowest BPA levels should be used. Crown Copyright (c) 2010 Published by Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000283700500019</url>
    <isbnorissn>0045-6535</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>161</id>
    <title>Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5 alpha-Reductase Isozymes in Rat Prostate</title>
    <authors>Castro,B.; Sanchez,P.; Torres,J.M.; Preda,O.; del Moral,R.G.; Ortega,E.</authors>
    <availability>[Castro, Beatriz; Sanchez, Pilar; Torres, Jesus M.; Ortega, Esperanza] Univ Granada, Sch Med, Dept Biochem &amp; Mol Biol, Granada, Spain. [Torres, Jesus M.; Ortega, Esperanza] Univ Granada, Sch Med, Inst Neurosci, Granada, Spain. [Preda, Ovidiu; del Moral, Raimundo G.] Univ Granada, Sch Med, Dept Pathol, Granada, Spain. [Preda, Ovidiu; del Moral, Raimundo G.] Univ Granada, IBIMER, Granada, Spain.</availability>
    <date>2013</date>
    <notes>JEnglishArticleOrtega, E (reprint author), Univ Granada, Sch Med, Dept Biochem &amp; Mol Biol, Granada, Spainesortega@ugr.esAkingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Arase S, 2011, BIOL REPROD, V84, P734, DOI 10.1095/biolreprod.110.087502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Cantagrel V, 2010, CELL, V142, P203, DOI 10.1016/j.cell.2010.06.001; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; De Flora S, 2011, TOXICOL SCI, V122, P45, DOI 10.1093/toxsci/kfr096; Ellem SJ, 2004, J CLIN ENDOCR METAB, V89, P2434, DOI 10.1210/jc.2003-030933; Fronhoffs S, 2002, MOL CELL PROBE, V16, P99, DOI 10.1006/mcpr.2002.0405; Godoy A, 2011, PROSTATE, V71, P1033, DOI 10.1002/pros.21318; Goodson A, 2004, FOOD ADDIT CONTAM, V21, P1015, DOI 10.1080/02652030400011387; Ho CKM, 2011, NAT REV UROL, V8, P29, DOI 10.1038/nrurol.2010.207; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Imamoto T, 2009, FUTURE ONCOL, V5, P1005, DOI [10.2217/fon.09.82, 10.2217/FON.09.82]; Kahrizi K, 2011, EUR J HUM GENET, V19, P115, DOI 10.1038/ejhg.2010.132; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Kaplan SA, 2012, J UROLOGY, V187, P584, DOI 10.1016/j.juro.2011.10.106; Kwintkiewicz J, 2010, ENVIRON HEALTH PERSP, V118, P400, DOI 10.1289/ehp.0901161; Li J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028840; Morava E, 2010, BRAIN, V133, P3210, DOI 10.1093/brain/awq261; Nelles JL, 2011, EXPERT REV ENDOCRINO, V6, P437, DOI DOI 10.1586/EEM.11.20); Nicholson TM, 2011, DIFFERENTIATION, V82, P184, DOI 10.1016/j.diff.2011.04.006; Ogura Y, 2007, DIFFERENTIATION, V75, P745, DOI 10.1111/j.1432-0436.2007.00177.x; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; ORTEGA E, 1979, EXPERIENTIA, V35, P844, DOI 10.1007/BF01968288; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Ricke WA, 2008, FASEB J, V22, P1512, DOI 10.1096/fj.07-9526com; Rittmaster R, 2008, UROLOGY, V72, P808, DOI 10.1016/j.urology.2008.06.032; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.biochem.63.1.25; SANTTI R, 1994, PROSTATE, V24, P67, DOI 10.1002/pros.2990240204; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Span PN, 1996, EUR J ENDOCRINOL, V134, P386; Takao T, 1999, LIFE SCI, V65, P2351, DOI 10.1016/S0024-3205(99)00502-0; Tan M. Ozgur, 2003, International Urology and Nephrology, V35, P357, DOI 10.1023/B:UROL.0000022909.57112.3e; Taylor JA, 2011, J STEROID BIOCHEM, V127, P83, DOI 10.1016/j.jsbmb.2011.07.005; Thomas LN, 2005, PROSTATE, V63, P231, DOI 10.1002/pros.20188; Torres JM, 2003, PROSTATE, V56, P74, DOI 10.1002/pros.10221; Uemura M, 2008, CANCER SCI, V99, P81, DOI 10.1111/j.1349-7006.2007.00656.x; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Walker DM, 2011, NAT REV ENDOCRINOL, V7, P197, DOI 10.1038/nrendo.2010.215; Welshons WV, 2006, ENDOCRINOLOGY, V147, P56; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xi W, 2011, REPROD TOXICOL, V31, P409, DOI 10.1016/j.reprotox.2010.12.002; Ye LP, 2011, TOXICOL LETT, V207, P137, DOI 10.1016/j.toxlet.2011.09.001486PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEFEB 6Discipline: Science &amp; Technology - Other Topics092WJ</notes>
    <keywords>ADULT; ADULTHOOD; ALTERS; BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARCINOGENESIS; CELL; CHEMICALS; development; Differentiation; DISEASE; DUTASTERIDE; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; ESTRADIOL; Estrogen; ESTROGENS; EXPOSURE; EXPRESSION; FOOD; GLAND; GLYCOSYLATION; HEALTH; HYPERPLASIA; inhibition; mechanism; MECHANISMS; Prostate; prostate cancer; PROSTATE-CANCER; PROTEIN; RAT; RATS; RISK; SRD5A3; toxicology; VENTRAL PROSTATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>2</issue>
    <volume>8</volume>
    <abstract>The high incidence of prostate cancer (PCa) and benign prostatic hypertrophy (BPH) in elderly men is a cause of increasing public health concern. In recent years, various environmental endocrine disruptors, such as bisphenol A (BPA), have been shown to disrupt sexual organs, including the prostate gland. However, the mechanisms underlying these effects remain unclear. Because androgens and estrogens are important factors in prostate physiopathology, our objective was to examine in rat ventral prostate the effects of adult exposure to BPA on 5 alpha-Reductase isozymes (5 alpha-R types 1, 2, and 3) and aromatase, key enzymes in the biosynthesis of dihydrotestosterone and estradiol, respectively. Adult rats were subcutaneously injected for four days with BPA (25, 50, 300, or 600 mu g/Kg/d) dissolved in vehicle. Quantitative RT-PCR, western blot and immunohistochemical analyses showed lower mRNA and protein levels of 5 alpha-R1 and 5 alpha-R2 in BPA-treated groups versus controls but higher mRNA levels of 5 alpha-R3, recently proposed as a biomarker of malignancy. However, BPA treatment augmented mRNA and protein levels of aromatase, whose increase has been described in prostate diseases. BPA-treated rats also evidenced a higher plasma estradiol/testosterone ratio, which is associated with prostate disease. Our results may offer new insights into the role of BPA in the development of prostate disease and may be of great value for studying the prostate disease risk associated with exposure to BPA in adulthood</abstract>
    <url>WOS:000315153400179</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>335</id>
    <title>Is Bisphenol A a Weak Carcinogen like the Natural Estrogens and Diethylstilbestrol?</title>
    <authors>Cavalieri,E.L.; Rogan,E.G.</authors>
    <availability>[Cavalieri, Ercole L.; Rogan, Eleanor G.] Univ Nebraska Med Ctr, Eppley Inst Res Canc &amp; Allied Dis, Omaha, NE 68198 USA. [Cavalieri, Ercole L.; Rogan, Eleanor G.] Univ Nebraska Med Ctr, Dept Environm Agr &amp; Occupat Hlth, Coll Publ Hlth, Omaha, NE 68198 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleCavalieri, EL (reprint author), Univ Nebraska Med Ctr, Eppley Inst Res Canc &amp; Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USAecavalie@unmc.eduAbdo KM, 2001, INHAL TOXICOL, V13, P931; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cavalieri E, 2006, BBA-REV CANCER, V1766, P63, DOI 10.1016/k.bbcan.2006.03.001; Cavalieri EL, 2001, CHEM RES TOXICOL, V14, P1041, DOI 10.1021/tx010042g; Cavalieri EL, 2010, FUTURE ONCOL, V6, P75, DOI [10.2217/fon.09.137, 10.2217/FON.09.137]; Cavalieri EL, 2002, CARCINOGENESIS, V23, P1071, DOI 10.1093/carcin/23.6.1071; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Chakravarti D, 2001, ONCOGENE, V20, P7945, DOI 10.1038/sj.onc.1204969; Edmonds JS, 2004, BIOCHEM BIOPH RES CO, V319, P556, DOI 10.1016/j.bbrc.2004.05.024; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Fernandez SV, 2006, INT J CANCER, V118, P1862, DOI 10.1002/ijc.21590; Gaikwad Nilesh W, 2009, Breast Cancer (Auckl), V3, P1; Gaikwad NW, 2008, INT J CANCER, V122, P1949, DOI 10.1002/ijc.23329; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Jaeg JP, 2004, J AGR FOOD CHEM, V52, P4935, DOI 10.1021/jf049762u; Lareef MH, 2005, INT J ONCOL, V26, P423; LI JJ, 1987, FASEB J, V46, P1858; Li KM, 2004, CARCINOGENESIS, V25, P289, DOI 10.1093/carcin/bgg191; LIEHR JG, 1986, J STEROID BIOCHEM, V24, P353, DOI 10.1016/0022-4731(86)90080-4; Lu F, 2008, CANCER PREV RES, V1, P135, DOI 10.1158/1940-6207.CAPR-08-0037; Lu F, 2007, J STEROID BIOCHEM, V105, P150, DOI 10.1016/j.jsbmb.2006.12.102; Mailander PC, 2006, J STEROID BIOCHEM, V101, P204, DOI 10.1016/j.jsbmb.2006.06.019; Mannisto PT, 1999, PHARMACOL REV, V51, P593; Markushin Y, 2003, CHEM RES TOXICOL, V16, P1107, DOI 10.1021/tx0340854; Markushin Y, 2006, PROSTATE, V66, P1565, DOI 10.1002/pros.20484; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10&lt;2327::AID-CNCR2820471003&gt;3.0.CO;2-Z; MILLER JA, 1970, CANCER RES, V30, P559; Nakagawa Y, 2001, XENOBIOTICA, V31, P113; Newbold RR, 2000, CANCER RES, V60, P235; Qiu SX, 2004, CHEM RES TOXICOL, V17, P1038, DOI 10.1021/tx049953r; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com; Saeed M, 2009, INT J CANCER, V124, P1276, DOI 10.1002/ijc.24113; Saeed M, 2009, FREE RADICAL BIO MED, V47, P1075, DOI 10.1016/j.freeradbiomed.2009.07.020; Saeed M, 2005, STEROIDS, V70, P37, DOI 10.1016/j.steroids.2004.09.012; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Yang L, 2009, PROSTATE, V69, P41, DOI 10.1002/pros.20850; Yue W, 2003, J STEROID BIOCHEM, V86, P477, DOI 10.1016/S0960-0760(03)00377-7; Zahid M, 2007, FREE RADICAL BIO MED, V43, P1534, DOI 10.1016/j.fteeradbiomed.2007.08.005; Zahid M, 2010, FREE RADICAL BIO MED, V48, P318, DOI 10.1016/j.freeradbiomed.2009.11.002; Zahid M, 2006, CHEM RES TOXICOL, V19, P164, DOI 10.1021/tx050229y; Zhao ZL, 2006, CHEM RES TOXICOL, V19, P475, DOI 10.1021/tx0502645; Zhu BT, 1996, J BIOL CHEM, V271, P1357; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1458JOHN WILEY &amp; SONS INCHOBOKEN111 RIVER ST, HOBOKEN, NJ 07030 USAIUBMB LIFEOCTDiscipline: Biochemistry &amp; Molecular Biology; Cell Biology680FU</notes>
    <keywords>4-HYDROXYESTRADIOL; BIOLOGY; bisphenol; bisphenol A; bisphenol A as carcinogen; BISPHENOL-A; BPA; breast; breast cancer; BREAST EPITHELIAL-CELLS; BREAST-CANCER; CANCER; Carcinogen; CARCINOGENESIS; catechol estrogen; CATECHOL ESTROGENS; catechol quinones; CELL; COULD INITIATE CANCER; DIETHYLSTILBESTROL; DNA ADDUCT FORMATION; ESTRADIOL; Estrogen; Estrogen metabolism; ESTROGENS; estrone; EXPOSURE; EXPRESSION; FOOD; FUTURE; GENE; GENES; HEALTH; MAMMARY-GLAND; MCF-10F CELLS; mechanism; MECHANISMS; METABOLISM; METABOLITES; molecular mechanism of cancer initiation; PATHWAY; Prostate; PROSTATE-CANCER; RISK; RIVER; Steroid</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>746</startpage>
    <endpage>751</endpage>
    <journalfull>Iubmb Life</journalfull>
    <issue>10</issue>
    <volume>62</volume>
    <abstract>Bisphenol A (BPA) displays weak estrogenic properties and could be a weak carcinogen by a mechanism similar to that of estrone (E(1)), estradiol (E(2)) and the synthetic estrogen diethylstilbestrol, a human carcinogen. A wide variety of scientific evidence supports the hypothesis that certain estrogen metabolites, predominantly catechol estrogen-3,4-quinones, react with DNA to cause mutations that can lead to the initiation of cancer. One of the major pathways of estrogen metabolism leads to the 4-catechol estrogens, 4-OHE(1)(E(2)), which are oxidized to their quinones, E(1)(E(2))-3,4-Q. The quinones react with DNA to form predominantly the depurinating adducts 4-OHE(1)(E(2))-1-N3Ade and 4-OHE(1)(E(2))-1-N7Gua. This process constitutes the predominant pathway in the initiation of cancer by estrogens. One pathway of BPA metabolism is hydroxylation of one of its symmetric benzene rings to form its catechol, 3-OHBPA. Subsequent oxidation to BPA-3,4-quinone would lead to reaction with DNA to form predominantly the depurinating adducts 3-OHBPA-6-N3Ade and 3-OHBPA-6-N7Gua. The resulting apurinic sites in the DNA could generate mutations in critical genes that can initiate human cancers. The catechol of BPA may also alter expression of estrogen-activating and deactivating enzymes, and/or compete with methoxylation of 4-OHE(1)(E(2)) by catechol-O-methyltransferase, thereby unbalancing the metabolism of estrogens to increase formation of E(1)(E(2))-3,4-Q and the depurinating estrogen-DNA adducts leading to cancer initiation. Thus, exposure to BPA could increase the risk of developing cancer by direct and/or indirect mechanisms. Knowledge of these mechanisms would allow us to begin to understand how BPA may act as a weak carcinogen and would be useful for regulating its use. (C) 2010 IUBMB IUBMB Life, 62(10): 746-751, 2010</abstract>
    <url>WOS:000284218600006</url>
    <isbnorissn>1521-6543</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>322</id>
    <title>The role of reactive oxygen species and hemeoxygenase-1 expression in the cytotoxicity, cell cycle alteration and apoptosis of dental pulp cells induced by BisGMA</title>
    <authors>Chang,M.C.; Chen,L.I.; Chan,C.P.; Lee,J.J.; Wang,T.M.; Yang,T.T.; Lin,P.S.; Lin,H.J.; Chang,H.H.; Jeng,J.H.</authors>
    <availability>[Chang, Mei-Chi] Chang Gung Inst Technol, Biomed Sci Team, Tao Yuan, Taiwan. [Chen, Lin-I; Lee, Jang-Jaer; Wang, Tong-Mei; Lin, Po-Shuen; Chang, Hsiao-Hua; Jeng, Jiiang-Huei] Natl Taiwan Univ Hosp, Lab Dent Pharmacol Toxicol &amp; Mat Biocompatibil, Grad Inst Clin Dent, Taipei, Taiwan. [Chen, Lin-I; Lee, Jang-Jaer; Wang, Tong-Mei; Lin, Po-Shuen; Chang, Hsiao-Hua; Jeng, Jiiang-Huei] Natl Taiwan Univ Hosp, Dept Dent, Taipei, Taiwan. [Chen, Lin-I; Lee, Jang-Jaer; Wang, Tong-Mei; Lin, Po-Shuen; Chang, Hsiao-Hua; Jeng, Jiiang-Huei] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Chan, Chiu-Po] Chang Gung Mem Hosp, Dept Dent, Taipei 10591, Taiwan. [Yang, Ting-Ting] Hsin Chu Gen Hosp, Dept Hlth, Dept Dent, Hsinchu, Taiwan. [Lin, Hsueh-Jen] Show Chwan Mem Hosp, Dept Dent, Changhua, Taiwan.</availability>
    <date>2010</date>
    <notes>JEnglishArticleJeng, JH (reprint author), Natl Taiwan Univ Hosp, Dept Endodont, Lab Pharmacol Toxicol &amp; Mat Biocompatibil, 1 Chang Te St, Taipei, Taiwanjhjeng@ntu.edu.twAccorinte MLR, 2008, CLIN ORAL INVEST, V12, P119, DOI 10.1007/s00784-007-0161-9; Chang HH, 2010, BIOMATERIALS, V31, P6917, DOI 10.1016/j.biomaterials.2010.05.059; Chang HH, 2005, BIOMATERIALS, V26, P745, DOI 10.1016/j.biomaterials.2004.03.021; CHANG MC, 2007, TOXICOL APPL PHARM, V218, P142; Chang MC, 2004, J BIOL CHEM, V279, P50676, DOI 10.1074/jbc.M404465200; Chang MC, 2009, BIOMATERIALS, V30, P4070, DOI 10.1016/j.biomaterials.2009.04.034; Cheng SE, 2010, FREE RADICAL BIO MED, V48, P1410, DOI 10.1016/j.freeradbiomed.2010.02.026; Cooper KL, 2007, TOXICOL APPL PHARM, V218, P119, DOI 10.1016/j.taap.2006.09.020; Costa CAD, 2001, DENT MATER, V17, P230; Eckhardt A, 2009, BIOMATERIALS, V30, P2006, DOI 10.1016/j.biomaterials.2008.12.045; Geurtsen W, 2000, CRIT REV ORAL BIOL M, V11, P333; Hou CC, 2005, ANN NY ACAD SCI, V1042, P235, DOI 10.1196/annals.1338.026; Hume WR, 1996, CRIT REV ORAL BIOL M, V7, P172; Jaffer F, 2002, BIOMATERIALS, V23, P1707, DOI 10.1016/S0142-9612(01)00298-8; Jeng JH, 2006, BRIT J PHARMACOL, V147, P188, DOI 10.1038/sj.bjp.0706462; Jeng JH, 2006, TOXICOLOGY, V223, P235, DOI 10.1016/j.tox.2006.04.033; Jeng JH, 1999, J PERIODONTOL, V70, P1435, DOI 10.1902/jop.1999.70.12.1435; JENG JH, 1994, J DENT RES, V73, P1050; Jeng JH, 2000, CARCINOGENESIS, V21, P1365, DOI 10.1093/carcin/21.7.1365; Kitamura C, 2003, J ENDODONT, V29, P41, DOI 10.1097/00004770-200301000-00011; Kostoryz EL, 2003, J DENT RES, V82, P367; Lee PH, 2006, TOXICOLOGY, V220, P81, DOI 10.1016/j.tox.2005.07.026; Liu HL, 2003, J NEUROCHEM, V86, P1553, DOI 10.1046/j.1471-4159.2003.01978.x; Min KS, 2010, J ENDODONT, V36, P447, DOI 10.1016/j.joen.2009.11.021; Min KS, 2008, J ENDODONT, V34, P983, DOI 10.1016/j.joen.2008.05.012; Min KS, 2007, J ENDODONT, V33, P1342, DOI 10.1016/j.joen.2007.07.012; Murray PE, 2003, OPER DENT, V28, P242; Pae Hyun-Ock, 2009, Immune Netw, V9, P12, DOI 10.4110/in.2009.9.1.12; Perdiguero E, 2004, CELL CYCLE, V3, P733; Reichl FX, 2008, J DENT RES, V87, P378; Schweikl H, 2006, J DENT RES, V85, P870; Schwengberg S, 2005, J DENT, V33, P49, DOI 10.1016/j.jdent.2004.08.001; Seiss M, 2009, DENT MATER, V25, P481, DOI 10.1016/j.dental.2008.08.013; Spagnuolo G, 2004, J DENT RES, V83, P703; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Yoshii E, 1997, J BIOMED MATER RES, V37, P517, DOI 10.1002/(SICI)1097-4636(19971215)37:4&lt;517::AID-JBM10&gt;3.0.CO;2-53623ELSEVIER SCI LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDBIOMATERIALSNOVDiscipline: Engineering; Materials Science666KA</notes>
    <keywords>AGENTS; apoptosis; BIOCOMPATIBILITY; BisGMA; CANCER-CELLS; CARCINOGENESIS; CELL; cell cycle; cell cycle arrest; cell death; CELL-CYCLE; CELL-DEATH; CELLS; CYCLE; Cytotoxicity; DEATH; Dental pulp; Dentin bonding agent; EXPOSURE; EXPRESSION; FIBROBLASTS; GENE; GENES; GROWTH; GUINEA-PIGS; HEME OXYGENASE-1; Hemeoxygenase; Immune; INDUCTION; INHIBITOR; MESSENGER-RNA; ORAL KERATINOCYTES; Oxidative stress; OXYGEN; PROTEIN; PULP; Reactive oxygen species; RESIN MONOMERS; TOXICITY; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>8164</startpage>
    <endpage>8171</endpage>
    <journalfull>Biomaterials</journalfull>
    <issue>32</issue>
    <volume>31</volume>
    <abstract>Biocompatibility of dentin bonding agents (DBAs) and resin composite is important to preserve the pulp vitality after operative restoration. Bisphenol-glycidyl-methacrylate (BisGMA) is one common monomer adding into DBAs and resin. In this study, we found that exposure of human dental pulp cells to BisGMA (&gt;0.1 mm) led to cytotoxicity, G2/M cell cycle arrest and apoptosis as analyzed by propidium iodide (PI) and PI/annexin V dual fluorescent flow cytometry. These events were associated with a decline of cdc2, cdc25C and cyclinB1 expression at both mRNA and protein levels. BisGMA also induced the expression of hemeoxygenase-1 (HO-1), an oxidative stress responsive gene, in pulp cells. Catalase could prevent the BisGMA-induced alteration of cell cycle-related genes (cdc2, cdc25C, cyclinB1) and HO-1 expression in dental pulp cells. Interestingly, Zn-protoporphyrin (2.5-5 mu m), a HO inhibitor, enhanced the BisGMA-induced reactive oxygen species (ROS) production and cytotoxicity. These results suggest that exposure to higher concentrations of BisGMA may stimulate ROS production, cell cycle arrest, apoptosis and cell death. Inducing the expression of HO-1 in dental pulp cells by BisGMA is mediated by ROS production and important to protect dental pulp against the toxicity by monomers present in composite resin and DBAs. (C) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000283112700006</url>
    <isbnorissn>0142-9612</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>55</id>
    <title>Metabolomic Analysis Reveals Metabolic Changes Caused by Bisphenol A in Rats</title>
    <authors>Chen,M.J.; Zhou,K.; Chen,X.J.; Qiao,S.L.; Hu,Y.H.; Xu,B.; Xu,B.; Han,X.M.; Tang,R.; Mao,Z.L.; Dong,C.C.; Wu,D.; Wang,Y.B.; Wang,S.L.; Zhou,Z.M.; Xia,Y.K.; Wang,X.R.</authors>
    <availability>[Chen, Minjian; Zhou, Kun; Chen, Xiaojiao; Qiao, Shanlei; Hu, Yanhui; Xu, Bo; Xu, Bin; Han, Xiumei; Tang, Rong; Mao, Zhilei; Dong, Congcong; Wu, Di; Wang, Shoulin; Zhou, Zuomin; Xia, Yankai; Wang, Xinru] Nanjing Med Univ, Sch Publ Hlth, Inst Toxicol, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China. [Chen, Minjian; Zhou, Kun; Chen, Xiaojiao; Qiao, Shanlei; Hu, Yanhui; Xu, Bo; Xu, Bin; Han, Xiumei; Tang, Rong; Mao, Zhilei; Dong, Congcong; Wu, Di; Wang, Shoulin; Xia, Yankai; Wang, Xinru] Nanjing Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Modern Toxicol, Nanjing 211166, Jiangsu, Peoples R China. [Wang, Yubang] Nanjing Med Univ, Sch Publ Hlth, Safety Assessment &amp; Res Ctr Drug Pesticide &amp; Vet, Nanjing 210029, Jiangsu, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleXia, YK (reprint author), Nanjing Med Univ, Sch Publ Hlth, Inst Toxicol, Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R Chinayankaixia@njmu.edu.cnAbaffy T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013813; BRANCH P, 1995, CANCER RES, V55, P2304; Braybrooke JP, 2000, CANCER CHEMOTH PHARM, V45, P111, DOI 10.1007/s002800050018; Cabaton NJ, 2013, ENVIRON HEALTH PERSP, V121, P586, DOI 10.1289/ehp.1205588; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Chen MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044754; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; Cho SH, 2009, J APPL TOXICOL, V29, P110, DOI 10.1002/jat.1387; Duan B, 2012, INT J CLIN ONCOL, V18, P492; DUVAL M, 1994, BIOCHEM J, V299, P141; Ferreira ID, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-1; Fiehn O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015234; George J, 2000, CLIN BIOCHEM, V33, P563, DOI 10.1016/S0009-9120(00)00170-3; Gika HG, 2008, J CHROMATOGR B, V871, P299, DOI 10.1016/j.jchromb.2008.05.048; Hassan ZK, 2012, OXID MED CELL LONGEV, DOI 10.1155/2012/194829; HORNER WH, 1950, J BIOL CHEM, V187, P15; Khan ZH, 2003, ALIMENT PHARM THERAP, V17, P677, DOI 10.1046/j.0269-2813.2003.01457.x; Ko K, 2008, LAB INVEST, V88, P1121, DOI 10.1038/labinvest.2008.69; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Li H, 2011, NEUROPHARMACOLOGY, V60, P252, DOI 10.1016/j.neuropharm.2010.09.005; LYLES GA, 1989, J PHARM PHARMACOL, V41, P97; MARGISON GP, 1976, BIOCHEM J, V157, P627; Marzocco S, 2004, FREE RADICAL RES, V38, P1143, DOI 10.1080/10715760410001725517; Matsumoto M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00233; Mendiola J, 2010, ENVIRON HEALTH PERSP, V118, P1286, DOI 10.1289/ehp.1002037; MUNRO HN, 1978, AM J CLIN NUTR, V31, P1608; Ooga T, 2011, MOL BIOSYST, V7, P1217, DOI 10.1039/c0mb00141d; Pant J, 2011, J APPL TOXICOL, V31, P698, DOI 10.1002/jat.1647; Park EI, 1999, J BIOL CHEM, V274, P7816, DOI 10.1074/jbc.274.12.7816; Parman T, 2011, TOXICOL SCI, V124, P487, DOI 10.1093/toxsci/kfr238; Patterson AD, 2009, J PROTEOME RES, V8, P4293, DOI 10.1021/pr9004103; Putluri N, 2011, CANCER RES, V71, P7376, DOI 10.1158/0008-5472.CAN-11-1154; Ramautar R, 2011, ELECTROPHORESIS, V32, P52, DOI 10.1002/elps.201000378; Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Stewart JD, 2011, ARCH TOXICOL, V85, P3, DOI 10.1007/s00204-010-0635-4; Teerlink T, 2005, VASC MED, V10, pS73, DOI 10.1191/1358863x05vm597oa; UK Food Standards Agency, 2001, SURV BISPH CANN FOOD; U.S. Environmental Protection Agency, 1993, BISPH A CASRN 80 05; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Wei XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055382; WINDMUELLER HG, 1964, AM J CLIN NUTR, V15, P73; Woo HM, 2009, CLIN CHIM ACTA, V400, P63, DOI 10.1016/j.cca.2008.10.014; Wu HJ, 2013, MUTAT RES-GEN TOX EN, V752, P57, DOI 10.1016/j.mrgentox.2013.01.005; Yang HP, 2004, HEPATOLOGY, V40, P221, DOI 10.1002/hep.20274; Yang YD, 2006, LIFE SCI, V78, P1413, DOI 10.1016/j.lfs.2005.07.014; ZEISEL SH, 1985, BIOCHIM BIOPHYS ACTA, V835, P331, DOI 10.1016/0005-2760(85)90289-9; Zeng J, 2013, ENVIRON SCI TECHNOL, V47, P7457, DOI 10.1021/es400490f; Zhang AH, 2012, J PROTEOMICS, V75, P1079, DOI 10.1016/j.jprot.2011.10.027511OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIAPRDiscipline: ToxicologyAD5LE</notes>
    <keywords>ABNORMALITIES; ALPHA; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER PROGRESSION; CELL; choline; DIMETHYLNITROSAMINE; DNA METHYLATION; DNA-DAMAGE; EXCRETION; EXPOSURE; EXPRESSION; FOOD; Liver; MASS-SPECTROMETRY; mechanism; METABOLISM; METABOLITES; metabolomics; methionine adenosyltransferase; METHYLATION; Oxidative stress; Proteomics; RAT; RATS; REVEALS; S-ADENOSYLMETHIONINE; TOXICITY; URINARY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>256</startpage>
    <endpage>267</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>2</issue>
    <volume>138</volume>
    <abstract>Bisphenol A (BPA) is a widely used material known to cause adverse effects in humans and other mammals. To date, little is known about the global metabolomic alterations caused by BPA using urinalysis. Sprague-Dawley rats were orally administrated BPA at the levels of 0, 0.5 mu g/kg/day and 50 mg/kg/day covering a low dose and a reference dose for 8 weeks. We conducted a capillary electrophoresis in tandem with electrospray ionization time-of-flight mass spectrometry based nontargeted metabolomic analysis using rat urine. To verify the metabolic alteration at both low and high doses, reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were further conducted to analyze hepatic expression of methionine adenosyltransferase I alpha (Mat1a) and methionine adenosyltransferase II alpha (Mat2a). Hepatic S-adenosylmethionine (SAMe) was also analyzed. A total of 199 metabolites were profiled. Statistical analysis and pathway mapping indicated that the most significant metabolic perturbations induced by BPA were the increased biotin and riboflavin excretion, increased synthesis of methylated products, elevated purine nucleotide catabolism, and increased flux through the choline metabolism pathway. We found significantly higher mRNA and protein levels of Mat1a and Mat2a, and significantly higher SAMe levels in rat liver at both low and high doses. These two genes encode critical isoenzymes that catalyze the formation of SAMe, the principal biological methyl donor involved in the choline metabolism. In conclusion, an elevated choline metabolism is underlying the mechanism of highly methylated environment and related metabolic alterations caused by BPA. The data of BPA-elevated accepted biomarkers of injury indicate that BPA induces DNA methylation damage and broad protein degradation, and the increased deleterious metabolites in choline pathway may also be involved in the toxicity of BPA</abstract>
    <url>WOS:000333293500002</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>47</id>
    <title>AroER Tri-Screen Is a Biologically Relevant Assay for Endocrine Disrupting Chemicals Modulating the Activity of Aromatase and/or the Estrogen Receptor</title>
    <authors>Chen,S.A.; Zhou,D.J.; Hsin,L.Y.; Kanaya,N.; Wong,C.; Yip,R.; Sakamuru,S.; Xia,M.H.; Yuan,Y.C.; Witt,K.; Teng,C.</authors>
    <availability>[Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu; Kanaya, Noriko; Wong, Cynthie; Yip, Richard; Yuan, Yate-Ching] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA. [Sakamuru, Srilatha; Xia, Menghang] NIH, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA. [Witt, Kristine; Teng, Christina] NIEHS, Div Natl Toxicol Program, NIH, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleChen, SA (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USAschen@coh.orgAl-Bader M, 2011, EXP THER MED, V2, P537, DOI 10.3892/etm.2011.226; Asarian L, 2006, PHILOS T R SOC B, V361, P1251, DOI 10.1098/rstb.2006.1860; AYUB M, 1988, J STEROID BIOCHEM, V31, P65, DOI 10.1016/0022-4731(88)90207-5; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200; Chen S, 2002, FRONT BIOSCI, V7, pD1712; Chen SA, 2010, P NATL ACAD SCI USA, V107, P11032, DOI 10.1073/pnas.1000917107; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Grube Baiba J., 2001, Journal of Nutrition, V131, P3288; Huang RL, 2011, ENVIRON HEALTH PERSP, V119, P1142, DOI 10.1289/ehp.1002952; Kanaya N, 2013, J STEROID BIOCHEM, V138, P100, DOI 10.1016/j.jsbmb.2013.04.001; Kao YC, 1998, ENVIRON HEALTH PERSP, V106, P85; Kavlock RJ, 1999, CHEMOSPHERE, V39, P1227, DOI 10.1016/S0045-6535(99)00190-3; Kelly CM, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c693; Lui K, 2008, BIOCHEM PHARMACOL, V76, P208, DOI 10.1016/j.bcp.2008.04.011; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Masri S, 2008, CANCER RES, V68, P4910, DOI 10.1158/0008-5472.CAN-08-0303; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Pruitt KD, 2012, NUCLEIC ACIDS RES, V40, pD130, DOI 10.1093/nar/gkr1079; Reed GF, 2002, CLIN DIAGN LAB IMMUN, V9, P1235, DOI 10.1128/CDLI.9.6.1235-1239.2002; Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008-1405; Schug T. T., 2012, BIOSPHENOL A DIOXINS, P381; SIMPSON ER, 1993, CLIN CHEM, V39, P317; Sowers MF, 2001, AM J EPIDEMIOL, V153, P256, DOI 10.1093/aje/153.3.256; Sun XZ, 1997, J STEROID BIOCHEM, V63, P29, DOI 10.1016/S0960-0760(97)00068-X; Tice RR, 2013, ENVIRON HEALTH PERSP, V121, P756, DOI 10.1289/ehp.1205784; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Trosken ER, 2006, TOXICOLOGY, V219, P33, DOI 10.1016/j.tox.2005.10.020; Vinas R, 2013, ENVIRON HEALTH PERSP, V121, P352, DOI 10.1289/ehp.1205826; Vucenik I, 2012, ANN NY ACAD SCI, V1271, P37, DOI 10.1111/j.1749-6632.2012.06750.x; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Xing Y, 2006, NUCLEIC ACIDS RES, V34, P3150, DOI 10.1093/nar/gkl396; YUE W, 1994, CANCER RES, V54, P5092; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Zarn JA, 2003, ENVIRON HEALTH PERSP, V111, P255, DOI 10.1289/ehp.5785; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; ZHOU D, 1990, CANCER RES, V50, P6949; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565410OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIMAYDiscipline: ToxicologyAG0ZN</notes>
    <keywords>17-BETA-ESTRADIOL; ALPHA; Aromatase-expressing cell line; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; CHEMICALS; DISRUPTING CHEMICALS; EDCs; Endocrine disrupting chemicals; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGENS; EXPRESSION; high-throughput screening; INHIBITOR; Inhibitors; MCF-7 CELLS; MECHANISMS; METABOLISM; qHTS; RECEPTOR; RNA-SEQ; STEROID-HORMONES; TAMOXIFEN; Tox21</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>198</startpage>
    <endpage>209</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>1</issue>
    <volume>139</volume>
    <abstract>Endocrine disrupting chemicals (EDCs) interfere with the biosynthesis, metabolism, and functions of steroid hormones, including estrogens and androgens. Aromatase enzyme converts androgen to estrogen. Thus, EDCs against aromatase significantly impact estrogen- and/or androgen-dependent functions, including the development of breast cancer. The current study aimed to develop a biologically relevant cell-based high-throughput screening assay to identify EDCs that act as aromatase inhibitors (AIs), estrogen receptor (ER) agonists, and/or ER antagonists. The AroER tri-screen assay was developed by stable transfection of ER-positive, aromatase-expressing MCF-7 breast cancer cells with an estrogen responsive element (ERE) driven luciferase reporter plasmid. The AroER tri-screen can identify: estrogenic EDCs, which increase luciferase signal without 17 beta-estradiol (E2); anti-estrogenic EDCs, which inhibit the E2-induced luciferase signal; and AI-like EDCs, which suppress a testosterone-induced luciferase signal. The assay was first optimized in a 96-well plate format and then miniaturized into a 1536-well plate format. The AroER tri-screen was demonstrated to be suitable for high-throughput screening in the 1536-well plate format, with a 6.9-fold signal-to-background ratio, a 5.4% coefficient of variation, and a screening window coefficient (Z-factor) of 0.78. The assay suggested that bisphenol A (BPA) functions mainly as an ER agonist. Results from screening the 446 drugs in the National Institutes of Health Clinical Collection revealed 106 compounds that modulated ER and/or aromatase activities. Among these, two AIs (bifonazole and oxiconazole) and one ER agonist (paroxetine) were confirmed through alternative aromatase and ER activity assays. These findings indicate that AroER tri-screen is a useful high-throughput screening system for identifying ER ligands and aromatase-inhibiting chemicals</abstract>
    <url>WOS:000335144600016</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>248</id>
    <title>The Blood-Testis Barrier and Its Implications for Male Contraception</title>
    <authors>Cheng,C.Y.; Mruk,D.D.</authors>
    <availability>[Cheng, C. Yan; Mruk, Dolores D.] Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, New York, NY 10065 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReviewCheng, CY (reprint author), Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, 1230 York Ave, New York, NY 10065 USAy-cheng@popcbr.rockefeller.edu*AG TOX SUBST DIS, 2008, CADM TOX ATSDR CAS S; Ahmed S, 2010, SEMIN CELL DEV BIOL, V21, P350, DOI 10.1016/j.semcdb.2009.11.008; Aitken RJ, 2011, REPRODUCTION, V141, P139, DOI 10.1530/REP-10-0232; Alberts B., 2002, MOL BIOL CELL; Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; Allan CM, 2010, ENDOCRINOLOGY, V151, P2800, DOI 10.1210/en.2009-1477; Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; AMANN RP, 1983, J ANIM SCI, V57, P380; Amann RP, 2008, J ANDROL, V29, P469, DOI 10.2164/jandrol.107.004655; Amory JK, 2011, J ANDROL, V32, P111, DOI 10.2164/jandrol.110.010751; Anderson JM, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002584; ANDERSSON A, 1986, CADMIUM HLTH TOXICOL, V1, P23; Antal MC, 2008, P NATL ACAD SCI USA, V105, P2433, DOI 10.1073/pnas.0712029105; Aoyama Y, 2009, EXP DERMATOL, V18, P404, DOI 10.1111/j.1600-0625.2008.00814.x; Aslam H, 1999, J ENDOCRINOL, V161, P281, DOI 10.1677/joe.0.1610281; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Augustine LM, 2005, DRUG METAB DISPOS, V33, P182, DOI 10.1124/dmd.104.001024; Auharek SA, 2010, J ANAT, V216, P577, DOI 10.1111/j.1469-7580.2010.01219.x; Baker RG, 2011, CELL METAB, V13, P11, DOI 10.1016/j.cmet.2010.12.008; Barraclough J, 2007, NEOPLASIA, V9, P745, DOI 10.1593/neo.07442; Barrett JR, 2009, ENVIRON HEALTH PERSP, V117, pA552; Bart J, 2004, EUR J CANCER, V40, P2064, DOI 10.1016/j.ejca.2004.05.010; BARTKE A, 1995, ENDOCRINOLOGY, V136, P3, DOI 10.1210/en.136.1.3; Bass-Zubek AE, 2009, CURR OPIN CELL BIOL, V21, P708, DOI 10.1016/j.ceb.2009.07.002; Beardsley A, 2006, J ENDOCRINOL, V190, P759, DOI 10.1677/joe.1.06867; Benoff Susan, 2008, Fertil Steril, V89, pe73, DOI 10.1016/j.fertnstert.2007.12.035; Benoff S, 2009, MOL MED, V15, P248, DOI 10.2119/molmed.2008.00104; Benoff S, 2000, HUM REPROD UPDATE, V6, P107, DOI 10.1093/humupd/6.2.107; BERGMANN M, 1983, ANAT EMBRYOL, V168, P269, DOI 10.1007/BF00315821; BERNDTSON WE, 1990, J ANDROL, V11, P429; Beveridge R, 2010, AM J IND MED, V53, P476, DOI 10.1002/ajim.20801; BILLIG H, 1995, ENDOCRINOLOGY, V136, P5, DOI 10.1210/en.136.1.5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blasig IE, 2011, ANTIOXID REDOX SIGN, V15, P1195, DOI 10.1089/ars.2010.3542; Blithe D, 2008, CONTRACEPTION, V78, pS23, DOI 10.1016/j.contraception.2008.03.018; BOEKELHEIDE K, 1991, J ANDROL, V12, P18; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Bonde JP, 2010, ASIAN J ANDROL, V12, P152, DOI 10.1038/aja.2009.83; Bordeleau LJ, 2008, MOL REPROD DEV, V75, P828, DOI 10.1002/mrd.20814; Bouffard G., 1906, ANN I PASTEUR, V20, P539; Boutros T, 2008, PHARMACOL REV, V60, P261, DOI 10.1124/pr.107.00106; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Brehm R, 2007, AM J PATHOL, V171, P19, DOI 10.2353/ajpath.2007.061171; Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Burger H, 2011, DRUG RESIST UPDATE, V14, P22, DOI 10.1016/j.drup.2010.12.002; BYERS SW, 1986, J ANDROL, V7, P59; Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Calabro AR, 2011, J PHARMACOL TOX MET, V63, P47, DOI 10.1016/j.vascn.2010.04.012; Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; Cardoso FL, 2010, BRAIN RES REV, V64, P328, DOI 10.1016/j.brainresrev.2010.05.003; Carette D, 2009, TRAFFIC, V10, P1272, DOI 10.1111/j.1600-0854.2009.00949.x; Carette D, 2010, DEV BIOL, V346, P54, DOI 10.1016/j.ydbio.2010.07.014; Carette D, 2010, BIOCHIMIE, V92, P555, DOI 10.1016/j.biochi.2010.02.003; Carl SM, 2010, MOL PHARMACEUT, V7, P1057, DOI 10.1021/mp900178j; Carlomagno G, 2010, BIOL REPROD, V83, P742, DOI 10.1095/biolreprod.110.085456; Carreau S, 2010, PHILOS T R SOC B, V365, P1571, DOI 10.1098/rstb.2009.0113; Carreau S, 2010, PHILOS T R SOC B, V365, P1517, DOI 10.1098/rstb.2009.0235; Carreau S, 2009, MICROSC RES TECHNIQ, V72, P552, DOI 10.1002/jemt.20703; Cavicchia JC, 1996, ULTRASTRUCT PATHOL, V20, P211; Cerec V, 2007, BIOL REPROD, V76, P241, DOI 10.1095/biolreprod.106.056168; Chang CS, 2004, P NATL ACAD SCI USA, V101, P6876, DOI 10.1073/pnas.0307306101; Chang YC, 2010, J CELL BIOCHEM, V109, P1274, DOI 10.1002/jcb.22517; Chatzizacharias NA, 2010, HISTOL HISTOPATHOL, V25, P1039; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Li Michelle W. M., 2008, Immunology Endocrine &amp; Metabolic Agents in Medicinal Chemistry, V8, P20; Cheng CY, 2010, NAT REV ENDOCRINOL, V6, P380, DOI 10.1038/nrendo.2010.71; Cheng CY, 2010, CONTRACEPTION, V82, P476, DOI 10.1016/j.contraception.2010.03.017; Cheng CY, 2005, CONTRACEPTION, V72, P251, DOI 10.1016/j.contraception.2005.03.008; Cheng CY, 2009, CRIT REV BIOCHEM MOL, V44, P245, DOI 10.1080/10409230903061207; Cheng CY, 2010, MOL CELL ENDOCRINOL, V315, P49, DOI 10.1016/j.mce.2009.08.004; Cheng CY, 2001, BIOL REPROD, V65, P449, DOI 10.1095/biolreprod65.2.449; Cheng CY, 2009, CELL CYCLE, V8, P3493, DOI 10.4161/cc.8.21.9833; Cheng CY, 2011, BIOCHEM J, V435, P553, DOI 10.1042/BJ20102121; Cheng C.Y., 2011, SPERMATOGENESIS, V1, P2, DOI DOI 10.4161/SPMG.1.1.13971; Cheng CY, 2011, SPERMATOGENESIS, V1, P105, DOI DOI 10.4161/SPMG.1.2.15745); Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253; Chiaverini N, 2010, FREE RADICAL RES, V44, P605, DOI 10.3109/10715761003692511; Chimento A, 2010, MOL CELL ENDOCRINOL, V320, P136, DOI 10.1016/j.mce.2010.01.035; CHIMENTO A, 2011, INT J ANDROL; Chinnam M, 2011, CURR TOP DEV BIOL, V94, P129, DOI 10.1016/B978-0-12-380916-2.00005-X; CHIQUOINE A, 1964, ANAT REC, V149, P23, DOI 10.1002/ar.1091490104; Choi YJ, 2010, ENVIRON HEALTH PERSP, V118, P976, DOI 10.1289/ehp.0901751; Chong YP, 2005, BBA-PROTEINS PROTEOM, V1754, P210, DOI 10.1016/j.bbapap.2005.07.027; Chung NPY, 2001, ENDOCRINOLOGY, V142, P1878, DOI 10.1210/en.142.5.1878; Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; CLERMONT Y, 1969, FERTIL STERIL, V20, P805; CLERMONT Y, 1972, PHYSIOL REV, V52, P198; CLERMONT Y., 1959, ARCH ANAT MICROSC ET MORPHOL EXPTL, V48, P37; CLERMONT Y, 1965, ENDOCRINOLOGY, V76, P80; CLERMONT Y, 1963, AM J ANAT, V112, P35, DOI 10.1002/aja.1001120103; Cockcroft S, 2011, CRIT REV BIOCHEM MOL, V46, P89, DOI 10.3109/10409238.2010.538664; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; Com E, 2003, BIOL REPROD, V68, P95, DOI 10.1095/biolreprod.102.005389; COOKE PS, 1992, BIOL REPROD, V46, P146, DOI 10.1095/biolreprod46.1.146; COOKE PS, 1991, ENDOCRINOLOGY, V129, P237; COOKE PS, 1991, ENDOCRINOLOGY, V129, P244; Cordenonsi M, 1997, J CELL SCI, V110, P3131; Cordenonsi M, 1999, EUR J BIOCHEM, V264, P374, DOI 10.1046/j.1432-1327.1999.00616.x; Couse JF, 2001, REPROD FERT DEVELOP, V13, P211, DOI 10.1071/RD00128; Cudicini C, 1997, ENDOCRINOLOGY, V138, P2863, DOI 10.1210/en.138.7.2863; Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6; Dallas S, 2006, PHARMACOL REV, V58, P140, DOI 10.1124/pr.58.2.3; Dalton T, 1996, ENVIRON HEALTH PERSP, V104, P68, DOI 10.2307/3432762; Dalton TP, 2005, P NATL ACAD SCI USA, V102, P3401, DOI 10.1073/pnas.0406085102; de Kretser DM, 1988, PHYSL REPRODUCTION, V1, P837; DE SK, 1993, ENDOCRINOLOGY, V133, P389, DOI 10.1210/en.133.1.389; De Cesaris P, 1999, J BIOL CHEM, V274, P28978, DOI 10.1074/jbc.274.41.28978; DEFRANCA LR, 1995, ANAT REC, V242, P57, DOI 10.1002/ar.1092420108; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dejucq N, 1998, J REPROD IMMUNOL, V41, P291, DOI 10.1016/S0165-0378(98)00065-5; Dejucq N, 1997, J CELL BIOL, V139, P865, DOI 10.1083/jcb.139.4.865; Dejucq N, 1998, ENDOCRINOLOGY, V139, P3081, DOI 10.1210/en.139.7.3081; Delfino FJ, 2003, MOL CELL ENDOCRINOL, V201, P1, DOI 10.1016/S0303-7207(03)00005-4; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; De Rooij DG, 2000, J ANDROL, V21, P776; De Rooij DG, 2009, MICROSC RES TECHNIQ, V72, P580, DOI 10.1002/jemt.20699; Destache CJ, 2009, PROG BRAIN RES, V180, P225, DOI 10.1016/S0079-6123(08)80012-X; de Tassigny XD, 2010, PHYSIOLOGY, V25, P207, DOI 10.1152/physiol.00009.2010; Diamantopoulos N, 2010, J BUON, V15, P421; Dorfel MJ, 2009, ANN NY ACAD SCI, V1165, P69, DOI 10.1111/j.1749-6632.2009.04043.x; Dufour JM, 2004, CELL TRANSPLANT, V13, P1; Dufour JM, 2008, CELL TRANSPLANT, V17, P525; Dupont S, 2000, DEVELOPMENT, V127, P4277; DYM M, 1994, ENDOCR REV, V15, P102, DOI 10.1210/er.15.1.102; Dym M, 1970, Biology Reprod., V3, P308; DYM M, 1973, ANAT REC, V175, P639, DOI 10.1002/ar.1091750402; DYM M, 1977, BIOL REPROD, V17, P390, DOI 10.1095/biolreprod17.3.390; EASTON AS, 2011, BIOL REGULA IN PRESS; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Elias BC, 2009, J BIOL CHEM, V284, P1559, DOI 10.1074/jbc.M804783200; Elkin ND, 2010, TOXICOL SCI, V117, P439, DOI 10.1093/toxsci/kfq210; Enders G, 1993, SERTOLI CELL, P447; Engen JR, 2008, CELL MOL LIFE SCI, V65, P3058, DOI 10.1007/s00018-008-8122-2; Enokizono J, 2008, DRUG METAB DISPOS, V36, P995, DOI 10.1124/dmd.107.019257; Enokizono J, 2007, MOL PHARMACOL, V72, P967, DOI 10.1124/mol.107.034751; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Fahrmayr C, 2010, DRUG METAB REV, V42, P380, DOI 10.3109/03602530903491683; Fallarino F, 2009, J EXP MED, V206, P2511, DOI 10.1084/jem.20090134; Faustman D, 2010, NAT REV DRUG DISCOV, V9, P482, DOI 10.1038/nrd3030; Fawcett D W, 1970, J Reprod Fertil Suppl, V10, P105; FAWCETT DON W., 1961, EXPTL CELL RES SUPPL, V8, P174, DOI 10.1016/0014-4827(61)90347-0; FAWCETT DW, 1959, J BIOPHYS BIOCHEM CY, V5, P453, DOI 10.1083/jcb.5.3.453; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Fijak M, 2011, METHODS MOL BIOL, V677, P459, DOI 10.1007/978-1-60761-869-0_29; Findley MK, 2009, IUBMB LIFE, V61, P431, DOI 10.1002/iub.175; Fiorini C, 2004, REPROD TOXICOL, V18, P413, DOI 10.1016/j.reprotox.2004.01.002; Firat-Karalar EN, 2011, CURR OPIN CELL BIOL, V23, P4, DOI 10.1016/j.ceb.2010.10.007; Flens MJ, 1996, AM J PATHOL, V148, P1237; FLICKING.C, 1967, ANAT REC, V158, P207, DOI 10.1002/ar.1091580210; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996; FRANCA LR, 2011, BIOL REGULA IN PRESS; Franca LR, 1998, BIOL REPROD, V59, P1371, DOI 10.1095/biolreprod59.6.1371; Francavilla F, 2007, FRONT BIOSCI, V12, P2890, DOI 10.2741/2280; Fukumoto M, 2001, LIFE SCI, V69, P247, DOI 10.1016/S0024-3205(01)01063-3; Funakoshi Y, 2011, J CELL PHYSIOL, V226, P888, DOI 10.1002/jcp.22482; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Gilleron J, 2009, INT J BIOCHEM CELL B, V41, P1381, DOI 10.1016/j.biocel.2008.12.008; Gilleron J, 2008, J CELL SCI, V121, P4069, DOI 10.1242/jcs.033373; Gilleron JAcrome, 2009, Commun Integr Biol, V2, P104; GILULA NB, 1976, DEV BIOL, V50, P142, DOI 10.1016/0012-1606(76)90074-9; Golachowska MR, 2010, TRENDS CELL BIOL, V20, P618, DOI 10.1016/j.tcb.2010.08.004; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Goldblum SE, 2011, FASEB J, V25, P144, DOI 10.1096/fj.10-158972; Goldmann E, 1909, BEITR KLIN CHIR, V64, P192; Golubovskaya VM, 2010, ANTI-CANCER AGENT ME, V10, P735; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Goupil S, 2011, J ANDROL, V32, P95, DOI 10.2164/jandrol.110.010462; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Goyer RA, 2004, BIOMETALS, V17, P555, DOI 10.1023/B:BIOM.0000045738.59708.20; Green KJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000125; Green KJ, 2007, J INVEST DERMATOL, V127, P2499, DOI 10.1038/sj.jid.5701015; Greenbaum MP, 2006, P NATL ACAD SCI USA, V103, P4982, DOI 10.1073/pnas.0505123103; GRIMA J, 1992, MOL CELL ENDOCRINOL, V89, P127, DOI 10.1016/0303-7207(92)90219-V; Grima J, 1998, J BIOL CHEM, V273, P21040, DOI 10.1074/jbc.273.33.21040; Grisanti L, 2009, STEM CELLS, V27, P3043, DOI 10.1002/stem.206; Gu XS, 2010, DRUG METAB REV, V42, P482, DOI 10.3109/03602531003654915; Gualtieri AF, 2011, J ENDOCRINOL INVEST, V34, pE102, DOI 10.3275/7272; Guan K, 2007, CIRC RES, V100, P1615, DOI 10.1161/01.RES.0000269182.22798.d9; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Guazzone VA, 2009, MICROSC RES TECHNIQ, V72, P620, DOI 10.1002/jemt.20704; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Haeusgen W, 2011, EUR J CELL BIOL, V90, P536, DOI 10.1016/j.ejcb.2010.11.008; Hamden K, 2009, BIOMED ENVIRON SCI, V22, P381, DOI 10.1016/S0895-3988(10)60015-3; Hamden K, 2008, ASIAN J ANDROL, V10, P837, DOI 10.1111/j.1745-7262.2008.00430.x; Hameed S, 2011, J ENDOCRINOL, V208, P97, DOI 10.1677/JOE-10-0265; Hamer G, 2003, INT J ANDROL, V26, P348, DOI 10.1111/j.1365-2605.2003.00436.x; Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005; Harris AL, 2007, PROG BIOPHYS MOL BIO, V94, P120, DOI 10.1016/j.pbiomolbio.2007.03.011; Harris KP, 2010, TRAFFIC, V11, P1272, DOI 10.1111/j.1600-0854.2010.01102.x; Hartz AMS, 2010, MOL INTERV, V10, P293, DOI 10.1124/mi.10.5.6; HAUGEN TB, 1994, MOL CELL ENDOCRINOL, V105, pR19, DOI 10.1016/0303-7207(94)90177-5; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; HELLER CG, 1964, RECENT PROG HORM RES, V20, P545; Herbst KL, 2002, J CLIN ENDOCR METAB, V87, P3215, DOI 10.1210/jc.87.7.3215; Hermo L, 2010, MICROSC RES TECHNIQ, V73, P364, DOI 10.1002/jemt.20785; Hesketh GG, 2009, J CARDIOVASC PHARM, V54, P263, DOI 10.1097/FJC.0b013e3181ba0811; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; HESS RA, 1990, BIOL REPROD, V43, P525, DOI 10.1095/biolreprod43.3.525; Hess RA, 2008, ADV EXP MED BIOL, P1; HESS RA, 2011, J ANDROL; Hess Rex A, 2003, Reprod Biol Endocrinol, V1, P52, DOI 10.1186/1477-7827-1-52; HEW KW, 1993, BIOL REPROD, V49, P840, DOI 10.1095/biolreprod49.4.840; HEW KW, 1993, TOXICOL APPL PHARM, V121, P15, DOI 10.1006/taap.1993.1123; Hild SA, 2007, J ANDROL, V28, P621, DOI 10.2164/jandrol.106.002295; Hild SA, 2004, BIOL REPROD, V71, P348, DOI 10.1095/biolreprod.103.026989; Hild SA, 2007, ENDOCRINOLOGY, V148, P1784, DOI 10.1210/en.2006-1487; HILSCHER W, 1964, Beitr Pathol Anat, V130, P69; Hogarth CA, 2011, TRENDS ENDOCRIN MET, V22, P136, DOI 10.1016/j.tem.2011.01.001; Hogarth CA, 2010, J CLIN INVEST, V120, P956, DOI 10.1172/JCI41303; Holdcraft RW, 2004, DEVELOPMENT, V131, P459, DOI 10.1242/dev.00957; Hong CY, 2004, MOL CELL BIOL, V24, P2593, DOI 10.1128/MCB.24.7.2593-2604.2004; HOSOYA KI, 2011, BIOL REGULA IN PRESS; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu VW, 2010, CURR OPIN CELL BIOL, V22, P528, DOI 10.1016/j.ceb.2010.05.008; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; HUCKINS C, 1978, ANAT REC, V192, P529, DOI 10.1002/ar.1091920407; Huff J, 2007, INT J OCCUP ENV HEAL, V13, P202; Huhtaniemi I, 2010, PROG BRAIN RES, V181, P273, DOI 10.1016/S0079-6123(08)81015-1; Hunt PA, 2009, BIOL REPROD, V81, P807, DOI 10.1095/biolreprod.109.077008; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Ilic D, 1997, J CELL SCI, V110, P401; Invernici G, 2011, RECENT PAT ANTI-CANC, V6, P58, DOI 10.2174/157489211793979990; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; IVANOV AI, 2011, BIOL REGULA IN PRESS; Jacquillet G, 2007, AM J PHYSIOL-RENAL, V293, pF1450, DOI 10.1152/ajprenal.00223.2007; JANECKI A, 1992, TOXICOL APPL PHARM, V112, P51, DOI 10.1016/0041-008X(92)90278-Z; JANECKI A, 1986, J ANDROL, V7, P69; Jarow JP, 2005, ANN NY ACAD SCI, V1061, P208, DOI 10.1196/annals.1336.023; Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020; Jeong SH, 2001, HUM EXP TOXICOL, V20, P577, DOI 10.1191/096032701718620855; Jin JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012883; John LJ, 2011, ANTIOXID REDOX SIGN, V15, P1255, DOI 10.1089/ars.2011.3892; Jonsson CK, 1999, ENDOCRINOLOGY, V140, P3755, DOI 10.1210/en.140.8.3755; Jorgensen N, 2011, INT J ANDROL, V34, pE37, DOI 10.1111/j.1365-2605.2010.01133.x; Joseph A, 2010, BIOL REPROD, V82, P958, DOI 10.1095/biolreprod.109.080366; Joseph A, 2010, BIOL REPROD, V82, P948, DOI 10.1095/biolreprod.109.079889; Joseph A, 2011, BIOL REPROD, V84, P207, DOI 10.1095/biolreprod.110.087353; Joseph P, 2009, TOXICOL APPL PHARM, V238, P272, DOI 10.1016/j.taap.2009.01.011; Kaitu'u-Lino TJ, 2007, REPRODUCTION, V133, P1169, DOI 10.1530/REP-06-0385; Kalejs M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-4; Kalliokoski A, 2009, BRIT J PHARMACOL, V158, P693, DOI 10.1111/j.1476-5381.2009.00430.x; Kangasniemi M, 1996, BIOL REPROD, V54, P1200, DOI 10.1095/biolreprod54.6.1200; Karssen AM, 2002, J ENDOCRINOL, V175, P251, DOI 10.1677/joe.0.1750251; Karssen AM, 2001, ENDOCRINOLOGY, V142, P2686, DOI 10.1210/en.142.6.2686; Kazi TG, 2010, HUM EXP TOXICOL, V29, P221, DOI 10.1177/0960327109360045; Kerr JB, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P827; Khlifi R, 2010, TOXICOL APPL PHARM, V248, P71, DOI 10.1016/j.taap.2010.08.003; Kierszenbaum AL, 2002, MOL REPROD DEV, V61, P1, DOI 10.1002/mrd.1124.abs; Kim JY, 2011, J CELL SCI, V124, P647, DOI 10.1242/jcs.075770; Kis O, 2010, TRENDS PHARMACOL SCI, V31, P22, DOI 10.1016/j.tips.2009.10.001; Kiziler AR, 2007, BIOL TRACE ELEM RES, V120, P82, DOI 10.1007/s12011-007-8020-8; KJELLSTROM T, 1978, ENVIRON RES, V16, P248, DOI 10.1016/0013-9351(78)90160-3; Klaassen CD, 2010, PHARMACOL REV, V62, P1, DOI 10.1124/pr.109.002014; Kobayashi D, 2007, REPRODUCTION, V134, P651, DOI 10.1530/REP-06-0173; Kodaira H, 2010, J PHARMACOL EXP THER, V333, P788, DOI 10.1124/jpet.109.162321; Koduri S, 2008, ENDOCRINOLOGY, V149, P1850, DOI 10.1210/en.2007-1332; Koepsell H, 2007, PHARM RES, V24, P1227, DOI 10.1007/s11095-9254-z; Kopera IA, 2010, PHILOS T R SOC B, V365, P1593, DOI 10.1098/rstb.2009.0251; Kopf GS, 2008, CONTRACEPTION, V78, pS18, DOI 10.1016/j.contraception.2008.05.001; KORMANO M, 1968, ACTA HISTOCHEM, V30, P133; KORMANO M, 1967, ACTA PHYSIOL SCAND, V71, P125, DOI 10.1111/j.1748-1716.1967.tb03717.x; KORMANO M, 1967, HISTOCHEMISTRY, V9, P327, DOI 10.1007/BF00305816; Koshiba S, 2008, XENOBIOTICA, V38, P863, DOI 10.1080/00498250801986944 ; Koshiba Shoko, 2007, J Exp Ther Oncol, V6, P321; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kruglov AA, 2008, CYTOKINE GROWTH F R, V19, P231, DOI 10.1016/j.cytogfr.2008.04.010; Kwiatkowska K, 2010, CELL MOL LIFE SCI, V67, P3927, DOI 10.1007/s00018-010-0432-5; Lamont KR, 2010, ADV CANCER RES, V107, P137, DOI 10.1016/S0065-230X(10)07005-3; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; Lee J, 1999, ENDOCRINOLOGY, V140, P852, DOI 10.1210/en.140.2.852; Lee NPY, 2005, J CELL PHYSIOL, V202, P344, DOI 10.1002/jcp.20119; Lee NPY, 2004, J ANDROL, V25, P200; Lee NPY, 2003, BIOL REPROD, V68, P489, DOI 10.1095/biolreprod.102.005793; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Li JCH, 2001, J ANDROL, V22, P847; Li LH, 1998, REPROD DEV TOXICOLOG, P655; Li LQ, 2000, MOL PHARMACOL, V58, P335; LI MW, 2011, BIOL REGULA IN PRESS; Li MWM, 2009, INT J BIOCHEM CELL B, V41, P2302, DOI 10.1016/j.biocel.2009.05.016; Li MWM, 2011, SPERMATOGENESIS, V1, P123, DOI DOI 10.4161/SPMG.1.2.16393); Li MWM, 2009, CYTOKINE GROWTH F R, V20, P329, DOI 10.1016/j.cytogfr.2009.07.007; Li MWM, 2009, P NATL ACAD SCI USA, V106, P10213, DOI 10.1073/pnas.0901700106; Li MWM, 2009, TRENDS MOL MED, V15, P159, DOI 10.1016/j.molmed.2009.02.002; Li MWM, 2010, P NATL ACAD SCI USA, V107, P17998, DOI 10.1073/pnas.1007047107; Li MWM, 2006, J ENDOCRINOL, V190, P313, DOI 10.1677/joe.1.06781; Lie PP, 2011, CELL MOL LIFE SCI; Lie PPY, 2009, TRENDS BIOCHEM SCI, V34, P366, DOI 10.1016/j.tibs.2009.03.005; Lie PPY, 2011, INT REV CEL MOL BIO, V286, P223, DOI 10.1016/B978-0-12-385859-7.00005-7; Lie PPY, 2010, INT J BIOCHEM CELL B, V42, P975, DOI 10.1016/j.biocel.2010.02.010; Lie PPY, 2010, PHILOS T R SOC B, V365, P1581, DOI 10.1098/rstb.2009.0261; Lie PPY, 2011, FASEB J, V25, P1244, DOI 10.1096/fj.10-169995; Lie PPY, 2009, FASEB J, V23, P2555, DOI 10.1096/fj.06-070573; Lie PPY, 2010, P NATL ACAD SCI USA, V107, P11411, DOI 10.1073/pnas.1001823107; Lie Pearl P. Y., 2008, Immunology Endocrine &amp; Metabolic Agents in Medicinal Chemistry, V8, P51; Lipinski MM, 1999, ONCOGENE, V18, P7873; Liu J, 2009, TOXICOL APPL PHARM, V238, P209, DOI 10.1016/j.taap.2009.01.029; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829; Lorico A, 2002, BIOCHEM BIOPH RES CO, V291, P617, DOI 10.1006/bbrc.2002.6489; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Loveland KL, 2007, INT J ANDROL, V30, P377, DOI 10.1111/j.1365-2605.2007.00785.x; Lucas B, 2009, BIRTH DEFECTS RES C, V87, P35, DOI 10.1002/bdrc.20145; Lucas TFG, 2008, BIOL REPROD, V78, P101, DOI 10.1095/biolreprod.107.063909; Lui WY, 2007, CYTOKINE GROWTH F R, V18, P299, DOI 10.1016/j.cytogfr.2007.04.009; Lui WY, 2001, ENDOCRINOLOGY, V142, P1865, DOI 10.1210/en.142.5.1865; Lui WY, 2003, INT J ANDROL, V26, P147, DOI 10.1046/j.1365-2605.2003.00410.x; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Lui WY, 2003, BIOL REPROD, V68, P1597, DOI 10.1095/biolreprod.102.011387; Luparello Claudio, 2011, Crit Rev Toxicol, V41, P75, DOI 10.3109/10408444.2010.529104; Lysiak Jeffrey J, 2004, Reprod Biol Endocrinol, V2, P9, DOI 10.1186/1477-7827-2-9; Maeda S, 2011, CELL MOL LIFE SCI, V68, P1115, DOI 10.1007/s00018-010-0551-z; Magin TM, 2007, EXP CELL RES, V313, P2021, DOI 10.1016/j.yexcr.2007.03.005; Mahato D, 2000, ENDOCRINOLOGY, V141, P1273, DOI 10.1210/en.141.3.1273; Mahato D, 2001, MOL CELL ENDOCRINOL, V178, P57, DOI 10.1016/S0303-7207(01)00410-5; MAHIBROWN CA, 1988, AM J REPROD IMMUNOL, V16, P165; Malam Y, 2011, CURR MED CHEM, V18, P1067; Marchiando AM, 2010, J CELL BIOL, V189, P111, DOI 10.1083/jcb.200902153; Marchiando AM, 2010, ANNU REV PATHOL-MECH, V5, P119, DOI 10.1146/annurev.pathol.4.110807.092135; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Martin GS, 2009, CANCER CELL, V16, P176, DOI 10.1016/j.ccr.2009.08.017; Marx A, 2010, FASEB J, V24, P1637, DOI 10.1096/fj.09-148064; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mazaud-Guittot S, 2010, BIOL REPROD, V82, P202, DOI 10.1095/biolreprod.109.078907; McCabe MJ, 2010, ENDOCRINOLOGY, V151, P2911, DOI 10.1210/en.2009-1278; McDuff FKE, 2011, CELL SIGNAL, V23, P6, DOI 10.1016/j.cellsig.2010.07.004; McLachlan RI, 2002, RECENT PROG HORM RES, V57, P149, DOI 10.1210/rp.57.1.149; McLaughlin EA, 2011, MOL CELL ENDOCRINOL, V335, P78, DOI 10.1016/j.mce.2010.04.004; Medina E, 2002, BIOL CELL, V94, P305, DOI 10.1016/S0248-4900(02)00004-7; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Mei H, 2011, REPRODUCTION, V141, P357, DOI 10.1530/REP-10-0432; Meier-Abt F, 2005, J MEMBRANE BIOL, V208, P213, DOI 10.1007/s00232-005-7004-x; Meinhardt A, 2011, MOL CELL ENDOCRINOL, V335, P60, DOI 10.1016/j.mce.2010.03.022; Meistrich ML, 1999, CANCER RES, V59, P3557; Meistrich ML, 2003, TOXICOL SCI, V76, P418, DOI 10.1093/toxsci/kfg237; Melaine N, 2002, BIOL REPROD, V67, P1699, DOI 10.1095/biolreprod.102.003558; Meng J, 2011, BIOL REPROD, V85, P254, DOI 10.1095/biolreprod.110.090621; Meng J, 2005, P NATL ACAD SCI USA, V102, P16696, DOI 10.1073/pnas.0506084102; Merlet J, 2007, P NATL ACAD SCI USA, V104, P3615, DOI 10.1073/pnas.0611421104; Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770; Miething A, 2010, ANN ANAT, V192, P247, DOI 10.1016/j.aanat.2010.06.004; Miller DS, 2008, PHARMACOL REV, V60, P196, DOI 10.1124/pr.107.07109; Mirza M, 2007, ENDOCRINOLOGY, V148, P5459, DOI 10.1210/en.2007-0359; Mirza M, 2006, EXP CELL RES, V312, P817, DOI 10.1016/j.yexcr.2005.11.030; Mital P, 2010, REPRODUCTION, V139, P495, DOI 10.1530/REP-09-0384; Mital P, 2011, BIOL REPROD, V84, P851, DOI 10.1095/biolreprod.110.087452; Mizuno N, 2003, PHARMACOL REV, V55, P425, DOI 10.1124/pr.55.3.1; Mok KW, 2011, REPRODUCTION, V141, P571, DOI 10.1530/REP-10-0464; MOK KW, 2011, INT J ANDROL; Morrow CMK, 2010, PHILOS T R SOC B, V365, P1679, DOI 10.1098/rstb.2010.0025; Mruk D. D., 2010, BIOCHEM J, V433, P253; Mruk DD, 2008, PHARMACOL REV, V60, P146, DOI 10.1124/pr.107.07105; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2011, SPERMATOGENESIS, V1, P47; Mruk DD, 2008, TRENDS ENDOCRIN MET, V19, P57, DOI 10.1016/j.tem.2007.11.002; Mruk DD, 2011, TRENDS PHARMACOL SCI, V32, P99, DOI 10.1016/j.tips.2010.11.007; Mruk DD, 2010, PHILOS T R SOC B, V365, P1621, DOI 10.1098/rstb.2010.0010; Mruk DD, 2004, TRENDS ENDOCRIN MET, V15, P439, DOI 10.1016/j.tem.2004.09.009; Mruk DD, 2008, TRENDS BIOTECHNOL, V26, P90, DOI 10.1016/j.tibtech.2007.10.009; MULLANEY BP, 1993, MOL ENDOCRINOL, V7, P67, DOI 10.1210/me.7.1.67; Nagano MC, 2003, BIOL REPROD, V69, P701, DOI 10.1095/biolreprod.103.016352; Nagaosa Kaz, 2009, Reproduction, V137, P879, DOI 10.1530/REP-08-0460; Nakagawa S, 2010, CURR OPIN STRUC BIOL, V20, P423, DOI 10.1016/j.sbi.2010.05.003; Nakagawa T, 2007, DEV CELL, V12, P195, DOI 10.1016/j.devcel.2007.01.002; Nalam RL, 2009, MOL ENDOCRINOL, V23, P1900, DOI 10.1210/me.2009-0184; Naude PJW, 2011, FEBS J, V278, P888, DOI 10.1111/j.1742-4658.2011.08017.x; He L, 2009, TOXICOL APPL PHARM, V238, P250, DOI 10.1016/j.taap.2009.02.017; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Niemi M, 2011, PHARMACOL REV, V63, P157, DOI 10.1124/pr.110.002857; Ning L, 2010, MOL CANCER RES, V8, P775, DOI 10.1158/1541-7786.MCR-09-0525; NITTA H, 1993, ENDOCRINOLOGY, V132, P1396, DOI 10.1210/en.132.3.1396; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; O'Donnell L, 2011, SPERMATOGENESIS, V1, P14, DOI DOI 10.4161/SPMG.1.1.14525; O'Rand M G, 2007, Soc Reprod Fertil Suppl, V63, P445; O'Bryan MK, 2008, ADV EXP MED BIOL, V636, P92, DOI 10.1007/978-0-387-09597-4_6; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; O'Donnell L, 2009, ENDOCRINOLOGY, V150, P5074, DOI 10.1210/en.2009-0755; Okanlawon A, 1996, J ANDROL, V17, P249; OKUMURA K, 1975, J PHARMACOL EXP THER, V194, P89; ORTH JM, 1982, ANAT REC, V203, P485, DOI 10.1002/ar.1092030408; Page ST, 2008, ENDOCR REV, V29, P465, DOI 10.1210/er.2007-0041; PALOMBI F, 1992, BIOL REPROD, V47, P1173, DOI 10.1095/biolreprod47.6.1173; Pan JL, 2010, ENVIRON GEOCHEM HLTH, V32, P1, DOI 10.1007/s10653-009-9273-2; Paolinelli R, 2011, PHARMACOL RES, V63, P165, DOI 10.1016/j.phrs.2010.11.012; PARIZEK J, 1957, J ENDOCRINOL, V15, P56, DOI 10.1677/joe.0.0150056; PARIZEK J, 1956, NATURE, V177, P1036; PARIZEK J, 1960, J REPROD FERTIL, V1, P294; PARVINEN M, 1982, ENDOCR REV, V3, P404; Paumi CM, 2009, MICROBIOL MOL BIOL R, V73, P577, DOI 10.1128/MMBR.00020-09; PELLETIER RM, 1992, MICROSC RES TECHNIQ, V20, P3, DOI 10.1002/jemt.1070200104; Pelletier RM, 2009, AM J PHYSIOL-REG I, V296, pR743, DOI 10.1152/ajpregu.90751.2008; Pelletier R-M, 2001, TIGHT JUNCTIONS, P599; PELLETIER RM, 1995, J ANDROL, V16, P400; Pelletier RM, 2011, AM J PHYSIOL-REG I, V300, pR121, DOI 10.1152/ajpregu.00500.2010; Pentikainen V, 2001, J CLIN ENDOCR METAB, V86, P4480, DOI 10.1210/jc.86.9.4480; Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077; Phillips BT, 2010, PHILOS T R SOC B, V365, P1663, DOI 10.1098/rstb.2010.0026; Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P188, DOI 10.1080/10937400701873472; Pinton P, 2009, TOXICOL APPL PHARM, V237, P41, DOI 10.1016/j.taap.2009.03.003; Poguntke M, 2010, EXPERT OPIN DRUG MET, V6, P1363, DOI 10.1517/17425255.2010.519700; Pointis G, 2010, PHILOS T R SOC B, V365, P1607, DOI 10.1098/rstb.2009.0114; Pointis G, 2005, BBA-BIOMEMBRANES, V1719, P102, DOI 10.1016/j.bbamem.2005.09.017; Powles T, 2011, HEMATOL ONCOL CLIN N, V25, P517, DOI 10.1016/j.hoc.2011.03.013; Prozialeck WC, 2003, TOXICOL APPL PHARM, V189, P180, DOI 10.1016/S0041-008X(03)00130-3; Prozialeck WC, 2002, TOXICOL APPL PHARM, V182, P255, DOI 10.1006/taap.2002.9422; Prozialeck WC, 2000, TOXICOL APPL PHARM, V164, P231, DOI 10.1006/taap.2000.8905; Prozialeck WC, 1999, BBA-MOL CELL RES, V1451, P93, DOI 10.1016/S0167-4889(99)00077-4; Prozialeck WC, 2008, TOXICOL SCI, V102, P207, DOI 10.1093/toxsci/kfm263; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Raleigh DR, 2011, J CELL BIOL, V193, P565, DOI 10.1083/jcb.201010065; Rappa G, 1999, BIOCHEM PHARMACOL, V58, P557; Ribbert H., 1904, Z ALLG PHYSL, V4, P201; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; RIVIER JE, 1995, J MED CHEM, V38, P2649, DOI 10.1021/jm00014a017; Robaire B, 2003, TRENDS PHARMACOL SCI, V24, P326, DOI 10.1016/S0165-6147(03)00141-X; Roberson EDO, 2010, TRENDS GENET, V26, P415, DOI 10.1016/j.tig.2010.06.006; Robertson KM, 2002, ENDOCRINOLOGY, V143, P2913, DOI 10.1210/en.143.8.2913; Robertson KM, 1999, P NATL ACAD SCI USA, V96, P7986, DOI 10.1073/pnas.96.14.7986; Robey RW, 2010, ANTI-CANCER AGENT ME, V10, P625; Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003; Rochat B, 2009, CURR CANCER DRUG TAR, V9, P652; Roger M, 2011, BIOMATERIALS, V32, P2106, DOI 10.1016/j.biomaterials.2010.11.056; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rottner K, 2010, TRENDS CELL BIOL, V20, P650, DOI 10.1016/j.tcb.2010.08.014; Rouiller-Fabre V, 2009, FOLIA HISTOCHEM CYTO, V47, pS19, DOI 10.2478/v10042-009-0065-4; RUSSELL L, 1977, AM J ANAT, V148, P301, DOI 10.1002/aja.1001480302; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; RUSSELL L, 1977, TISSUE CELL, V9, P475, DOI 10.1016/0040-8166(77)90007-6; Russell LD, 1996, J ANDROL, V17, P615; Russell LD., 1993, SERTOLI CELL, P1; Russell LD, 1996, J ANDROL, V17, P603; RUSSELL LD, 1989, AM J ANAT, V184, P179, DOI 10.1002/aja.1001840302; RUSSELL LD, 1985, INT REV CYTOL, V94, P177, DOI 10.1016/S0074-7696(08)60397-6; Ruwanpura SM, 2010, J ENDOCRINOL, V205, P117, DOI 10.1677/JOE-10-0025; Saitou M, 2000, MOL BIOL CELL, V11, P4131; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Sakkas D, 2010, FERTIL STERIL, V93, P1027, DOI 10.1016/j.fertnstert.2009.10.046; SALANOVA M, 1995, BIOL REPROD, V52, P79, DOI 10.1095/biolreprod52.1.79; Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012; Salian S, 2009, LIFE SCI, V85, P742, DOI 10.1016/j.lfs.2009.10.004; Samy ET, 2000, ENDOCRINOLOGY, V141, P710, DOI 10.1210/en.141.2.710; Santos-Ahmed J, 2011, REPROD TOXICOL, V31, P17, DOI 10.1016/j.reprotox.2010.09.012; Sarkar O, 2008, BIOL REPROD, V78, P445, DOI 10.1095/biolreprod.107.064501; Sato I, 2009, J CELL SCI, V122, P965, DOI 10.1242/jcs.034843; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schell C, 2008, ENDOCRINOLOGY, V149, P1678, DOI 10.1210/en.2007-1064; Schnabolk GW, 2010, J PHARMACOL EXP THER, V334, P927, DOI 10.1124/jpet.110.168765; Schwarz62466AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSBETHESDA9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USAPHARMACOL REVJANDiscipline: Pharmacology &amp; Pharmacy866UC</notes>
    <keywords>AGENTS; ALPHA; BETA; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; blood-testis barrier; CADMIUM; CANCER; CANCER RESISTANCE PROTEIN; CELL; cell cycle; CELL-CYCLE; CELLS; CYCLE; CYCLE PROGRESSION; Cytokine; DAMAGE; development; Differentiation; ECTOPLASMIC SPECIALIZATION DYNAMICS; EFFLUX; ENDOCRINE; Environmental toxicant; ESTROGEN-RECEPTOR-ALPHA; FOCAL ADHESION KINASE; GERM-CELLS; GROWTH; GROWTH-FACTOR-BETA; HEALTH; INFLUX; INJURY; JUNCTIONAL INTERCELLULAR COMMUNICATION; KINASE; kinases; Male; MALE GERM-CELLS; MALE-INFERTILITY; mechanism; MECHANISMS; molecular mechanism; MOLECULAR-MECHANISMS; Neoplasia; NF-KAPPA-B; PHARMACOLOGY; PROGRESSION; PROTEIN; PROTEIN-KINASES; PROTEINS; PUMP; RAT SERTOLI-CELLS; Reproduction; Sertoli cell; SPERMATOGENESIS; STEM-CELLS; TARGET; TESTICULAR AUTOIMMUNE-DISEASE; testis; TISSUE; toxicology; transforming growth factor-beta; TUMOR; TUMOR-NECROSIS-FACTOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>16</startpage>
    <endpage>64</endpage>
    <journalfull>Pharmacological Reviews</journalfull>
    <issue>1</issue>
    <volume>64</volume>
    <abstract>The blood-testis barrier (BTB) is one of the tightest blood-tissue barriers in the mammalian body. It divides the seminiferous epithelium into the basal and the apical (adluminal) compartments. Meiosis I and II, spermiogenesis, and spermiation all take place in a specialized microenvironment behind the BTB in the apical compartment, but spermatogonial renewal and differentiation and cell cycle progression up to the preleptotene spermatocyte stage take place outside of the BTB in the basal compartment of the epithelium. However, the BTB is not a static ultrastructure. Instead, it undergoes extensive restructuring during the seminiferous epithelial cycle of spermatogenesis at stage VIII to allow the transit of preleptotene spermatocytes at the BTB. Yet the immunological barrier conferred by the BTB cannot be compromised, even transiently, during the epithelial cycle to avoid the production of antibodies against meiotic and postmeiotic germ cells. Studies have demonstrated that some unlikely partners, namely adhesion protein complexes (e.g., occludin-ZO-1, N-cadherin-beta-catenin, claudin-5-ZO-1), steroids (e.g., testosterone, estradiol-17 beta), nonreceptor protein kinases (e.g., focal adhesion kinase, c-Src, c-Yes), polarity proteins (e.g., PAR6, Cdc42, 14-3-3), endocytic vesicle proteins (e.g., clathrin, caveolin, dynamin 2), and actin regulatory proteins (e.g., Eps8, Arp2/3 complex), are working together, apparently under the overall influence of cytokines (e.g., transforming growth factor-beta 3, tumor necrosis factor-alpha, interleukin-1 alpha). In short, a "new" BTB is created behind spermatocytes in transit while the "old" BTB above transiting cells undergoes timely degeneration, so that the immunological barrier can be maintained while spermatocytes are traversing the BTB. We also discuss recent findings regarding the molecular mechanisms by which environmental toxicants (e.g., cadmium, bisphenol A) induce testicular injury via their initial actions at the BTB to elicit subsequent damage to germ-cell adhesion, thereby leading to germ-cell loss, reduced sperm count, and male infertility or subfertility. Moreover, we also critically evaluate findings in the field regarding studies on drug transporters in the testis and discuss how these influx and efflux pumps regulate the entry of potential nonhormonal male contraceptives to the apical compartment to exert their effects. Collectively, these findings illustrate multiple potential targets are present at the BTB for innovative contraceptive development and for better delivery of drugs to alleviate toxicant-induced reproductive dysfunction in men</abstract>
    <url>WOS:000298409100002</url>
    <isbnorissn>0031-6997</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>283</id>
    <title>Role of GPER/GPR30 in tumoral testicular germ cells proliferation</title>
    <authors>Chevalier,N.; Bouskine,A.; Fenichel,P.</authors>
    <availability>[Chevalier, Nicolas; Bouskine, Adil; Fenichel, Patrick] Ctr Mediterraneen Med Mol C3M, INSERM, UMR UNS U895, Nice, France. [Chevalier, Nicolas; Bouskine, Adil; Fenichel, Patrick] Univ Nice Sophia Antipolis, Fac Med, Inst Signalisat &amp; Pathol IFR 50, Nice, France. [Chevalier, Nicolas; Fenichel, Patrick] Univ Nice, Ctr Hosp, Hop Archet, Serv Endocrinol Diabetol &amp; Med Reprod, Nice, France.</availability>
    <date>2011</date>
    <notes>JEnglishLetterFenichel, P (reprint author), Ctr Mediterraneen Med Mol C3M, INSERM, UMR UNS U895, Nice, Francefenichel.p@chu-nice.frBouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bouskine A, 2008, ENDOCRINOLOGY, V149, P565, DOI 10.1210/en.2007-1318; Bouskine A, 2010, INT J ANDROL, V33, P54, DOI 10.1111/j.1365-2605.2009.00950.x; CHEVALIER N, 2011, INT J CANC IN PRESS; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Franco R, 2011, CANCER BIOL THER, V11, P609, DOI 10.4161/cbt.11.6.14672; Hardell L, 2003, ENVIRON HEALTH PERSP, V111, P930, DOI 10.1289/ehp.5816; Kinugawa K, 1998, Int J Urol, V5, P282, DOI 10.1111/j.1442-2042.1998.tb00604.x; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; LaPensee EW, 2010, CANCER LETT, V290, P167, DOI 10.1016/j.canlet.2009.09.005; Prossnitz ER, 2008, TRENDS PHARMACOL SCI, V29, P116, DOI 10.1016/j.tips.2008.01.001; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Roger C, 2005, J MOL ENDOCRINOL, V35, P191, DOI 10.1677/jme.1.01704; Sharpe RM, 2010, TOXICOL SCI, V114, P1, DOI 10.1093/toxsci/kfp299; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; VITALE G, 2011, CANCER BIOL THER, V11, P1164LANDES BIOSCIENCEAUSTIN1806 RIO GRANDE ST, AUSTIN, TX 78702 USACANCER BIOL THERJUL 1Discipline: Oncology786GG</notes>
    <keywords>BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CELL; CELLS; GERM-CELLS; GPR30; HEALTH; HUMAN SEMINOMA; oncology; proliferation</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2</startpage>
    <endpage>3</endpage>
    <journalfull>Cancer Biology &amp; Therapy</journalfull>
    <issue>1</issue>
    <volume>12</volume>
    <url>WOS:000292290900002</url>
    <isbnorissn>1538-4047</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>224</id>
    <title>GPR30, the Non-Classical Membrane G Protein Related Estrogen Receptor, Is Overexpressed in Human Seminoma and Promotes Seminoma Cell Proliferation</title>
    <authors>Chevalier,N.; Vega,A.; Bouskine,A.; Siddeek,B.; Michiels,J.F.; Chevallier,D.; Fenichel,P.</authors>
    <availability>[Chevalier, Nicolas; Vega, Aurelie; Bouskine, Adil; Siddeek, Benazir; Fenichel, Patrick] Ctr Mediterrane Med Mol C3M, UNS, INSERM,UMR 1065, Equipe Environm Reprod &amp; Canc Hormonodependants 5, Nice, France. [Chevalier, Nicolas; Vega, Aurelie; Bouskine, Adil; Siddeek, Benazir; Fenichel, Patrick] Univ Nice Sophia Antipolis, Fac Med, Inst Signalisat &amp; Pathol IFR 50, Nice, France. [Chevalier, Nicolas; Vega, Aurelie; Bouskine, Adil; Siddeek, Benazir; Fenichel, Patrick] Ctr Hosp Univ Nice, Hop Archet, Serv Endocrinol Diabet &amp; Med Reprod, Nice, France. [Michiels, Jean-Francois] Ctr Hosp Univ Nice, Hop Pasteur, Lab Anat &amp; Cytol Pathol, Nice, France. [Chevallier, Daniel] Ctr Hosp Univ Nice, Hop Pasteur, Serv Urol, Nice, France.</availability>
    <date>2012</date>
    <notes>JEnglishArticleChevalier, N (reprint author), Ctr Mediterrane Med Mol C3M, UNS, INSERM,UMR 1065, Equipe Environm Reprod &amp; Canc Hormonodependants 5, Nice, Francefenichel.p@chu-nice.frAlbanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Bourdon V, 1998, BIOL REPROD, V58, P591, DOI 10.1095/biolreprod58.2.591; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bouskine A, 2008, ENDOCRINOLOGY, V149, P565, DOI 10.1210/en.2007-1318; Bouskine A, 2010, INT J ANDROL, V33, P54, DOI 10.1111/j.1365-2605.2009.00950.x; Carreau S, 2002, MOL CELL ENDOCRINOL, V193, P137, DOI 10.1016/S0303-7207(02)00107-7; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Cheng SB, 2011, STEROIDS, V76, P892, DOI 10.1016/j.steroids.2011.02.018; Chevalier N, 2012, INT J CANCER, V130, P241, DOI 10.1002/ijc.25972; Chimento A, 2010, MOL CELL ENDOCRINOL, V320, P136, DOI 10.1016/j.mce.2010.01.035; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Franco R, 2011, CANCER BIOL THER, V11, P609, DOI 10.4161/cbt.11.6.14672; Giess M, 2010, J STEROID BIOCHEM, V118, P7, DOI 10.1016/j.jsbmb.2009.09.001; Hardell L, 2006, INT J ANDROL, V29, P228, DOI 10.1111/j.1365-2605.2005.00622.x; Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442; Jones MEE, 2000, BEST PRACT RES CL EN, V14, P505, DOI 10.1053/beem.2000.0094; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Kinugawa K, 1998, Int J Urol, V5, P282, DOI 10.1111/j.1442-2042.1998.tb00604.x; Konstantinopoulos PA, 2003, EUR J CANCER, V39, P1251, DOI 10.1016/S0959-8049(03)00239-9; Lablack A, 1998, CELL TISSUE RES, V294, P279, DOI 10.1007/s004410051178; Langer G, 2010, STEROIDS, V75, P603, DOI 10.1016/j.steroids.2009.12.006; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liu XC, 2009, BIOL REPROD, V80, P1253, DOI 10.1095/biolreprod.108.070250; Loomis AK, 2000, BIOL REPROD, V62, P995, DOI 10.1095/biolreprod62.4.995; Lucas TFG, 2010, BIOL REPROD, V83, P307, DOI 10.1095/biolreprod.110.084160; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Rago V, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-135; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Roger C, 2005, J MOL ENDOCRINOL, V35, P191, DOI 10.1677/jme.1.01704; Roger C, 2004, J PATHOL, V202, P241, DOI 10.1002/path.1509; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; Skakkebaek NE, 1998, APMIS, V106, P3; Smith HO, 2009, GYNECOL ONCOL, V114, P465, DOI 10.1016/j.ygyno.2009.05.015; Teng J, 2008, ENDOCRINOLOGY, V149, P4024, DOI 10.1210/en.2007-1669; Thomas P, 2010, STEROIDS, V75, P595, DOI 10.1016/j.steroids.2009.11.005; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Thomas P, 2006, STEROIDS, V71, P310, DOI 10.1016/j.steroids.2005.09.015; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Zhao Chunyan, 2008, Nucl Recept Signal, V6, pe003, DOI 10.1621/nrs.060034713PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEAPR 4Discipline: Science &amp; Technology - Other Topics953GO</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; ADULT; Antagonist; bisphenol; bisphenol A; BISPHENOL-A; breast; BREAST-CANCER CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; CONNEXIN-43; COUPLED RECEPTOR; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic effects; ESTROGENS; EXPOSURE; EXPRESSION; FETAL; FETAL EXPOSURE; GERM-CELLS; GPER; GPR30; HEALTH; IDENTIFICATION; In vitro; IN-VITRO; LIGAND; LIGANDS; LINE; non-genomic; OVARIAN-CANCER; PROGNOSIS; proliferation; PROTEIN; RECEPTOR; Sertoli cell; Sertoli cells; Signal transduction; TISSUE; VITRO; xenoestrogen; XENOESTROGENS; YOUNG MEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>4</issue>
    <volume>7</volume>
    <abstract>Background: Testicular germ cell tumours are the most frequent cancer of young men with an increasing incidence all over the world. Pathogenesis and reasons of this increase remain unknown but epidemiological and clinical data have suggested that fetal exposure to environmental endocrine disruptors (EEDs) with estrogenic effects, could participate to testicular germ cell carcinogenesis. However, these EEDs (like bisphenol A) are often weak ligands for classical nuclear estrogen receptors. Several research groups recently showed that the non classical membrane G-protein coupled estrogen receptor (GPER/GPR30) mediates the effects of estrogens and several xenoestrogens through rapid non genomic activation of signal transduction pathways in various human estrogen dependent cancer cells (breast, ovary, endometrium). The aim of this study was to demonstrate that GPER was overexpressed in testicular tumours and was able to trigger JKT-1 seminoma cell proliferation. Results: We report here for the first time a complete morphological and functional characterization of GPER in normal and malignant human testicular germ cells. In normal adult human testes, GPER was expressed by somatic (Sertoli cells) and germ cells (spermatogonia and spermatocytes). GPER was exclusively overexpressed in seminomas, the most frequent testicular germ cell cancer, localized at the cell membrane and triggered a proliferative effect on JKT-1 cells in vitro, which was completely abolished by G15 (a GPER selective antagonist) and by siRNA invalidation. Conclusion: These results demonstrate that GPER is expressed by human normal adult testicular germ cells, specifically overexpressed in seminoma tumours and able to trigger seminoma cell proliferation in vitro. It should therefore be considered rather than classical ERs when xeno-estrogens or other endocrine disruptors are assessed in testicular germ cell cancers. It may also represent a prognosis marker and/or a therapeutic target for seminomas</abstract>
    <url>WOS:000304855200067</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>250</id>
    <title>Bisphenol A promotes testicular seminoma cell proliferation through GPER/GPR30</title>
    <authors>Chevalier,N.; Bouskine,A.; Fenichel,P.</authors>
    <availability>[Chevalier, Nicolas; Fenichel, Patrick] Univ Hosp Nice, Dept Reprod Endocrinol, F-06202 Nice 3, France. [Chevalier, Nicolas; Bouskine, Adil; Fenichel, Patrick] Univ Nice Sophia Antipolis, Inst Natl Rech Med INSERM, UMR U895, Team 5, Nice, France.</availability>
    <date>2012</date>
    <notes>JEnglishLetterFenichel, P (reprint author), Univ Hosp Nice, Dept Reprod Endocrinol, 151 Route St Antoine de Ginestiere,BP 3079, F-06202 Nice 3, Francefenichel.p@chu-nice.frAlbanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bouskine A, 2010, INT J ANDROL, V33, P54, DOI 10.1111/j.1365-2605.2009.00950.x; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Hardell L, 2003, ENVIRON HEALTH PERSP, V111, P930, DOI 10.1289/ehp.5816; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Roger C, 2005, J MOL ENDOCRINOL, V35, P191, DOI 10.1677/jme.1.01704; Sharpe RM, 2010, TOXICOL SCI, V114, P1, DOI 10.1093/toxsci/kfp299; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-00211013WILEY-BLACKWELLMALDENCOMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USAINT J CANCERJAN 1Discipline: Oncology859CG</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; EXPRESSION; HEALTH; oncology; proliferation; ROUTE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>241</startpage>
    <endpage>242</endpage>
    <journalfull>International Journal of Cancer</journalfull>
    <issue>1</issue>
    <volume>130</volume>
    <url>WOS:000297851300025</url>
    <isbnorissn>0020-7136</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>424</id>
    <title>The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers</title>
    <authors>Chiam,K.; Tilley,W.D.; Butler,L.M.; Bianco-Miotto,T.</authors>
    <availability>[Chiam, Karen; Tilley, Wayne D.; Butler, Lisa M.; Bianco-Miotto, Tina] Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, Discipline Med, Adelaide, SA 5000, Australia.</availability>
    <date>2009</date>
    <notes>JEnglishReviewBianco-Miotto, T (reprint author), Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, Discipline Med, POB 14 Rundle Mall, Adelaide, SA 5000, Australiatina.bianco-miotto@imvs.sa.gov.auAnway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Aoyagi S, 2007, MOL ENDOCRINOL, V21, P843, DOI 10.1210/me.2006-0244; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Belinsky SA, 2003, CANCER RES, V63, P7089; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cerutti H, 2006, CURR GENET, V50, P81, DOI 10.1007/s00294-006-0078-x; Chan MF, 2000, CURR TOP MICROBIOL, V249, P75; Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Couse JF, 2001, DEV BIOL, V238, P224, DOI 10.1006/dbio.2001.0413; Couse JF, 1997, MOL CARCINOGEN, V19, P236, DOI 10.1002/(SICI)1098-2744(199708)19:4&lt;236::AID-MC4&gt;3.0.CO;2-A; Cruz-Correa M, 2004, GASTROENTEROLOGY, V126, P964, DOI 10.1053/j.gastro.2003.12.051; Cunningham A, 1996, ARCH TOXICOL, V70, P356, DOI 10.1007/s002040050285; Davie JR, 1999, J CELL BIOCHEM, P141; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008; Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Garcia-Manero G, 2005, SEMIN HEMATOL, V42, pS50, DOI 10.1053/j.seminhematol.2005.05.004; GILLOTEAUX J, 1985, SCAN ELECTRON MICROS, P303; Godfrey KM, 2007, PEDIATR RES, V61, p5R, DOI 10.1203/pdr.0b013e318045bedb; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Hark AT, 2000, NATURE, V405, P486; Hilakivi-Clarke L, 2007, CURR CANCER DRUG TAR, V7, P465; Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hudder A, 2008, TOXICOL SCI, V103, P228, DOI 10.1093/toxsci/kfn033; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; JIN SLC, 1992, J BIOL CHEM, V267, P18929; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Karpinets TV, 2005, CARCINOGENESIS, V26, P1323, DOI 10.1093/carcin/bgi079; Kim J, 2003, NUCLEIC ACIDS RES, V31, P6741, DOI 10.1093/nar/gkg909; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Leader JE, 2006, BIOCHEM PHARMACOL, V72, P1589, DOI 10.1016/j.bcp.2006.05.024; Li LC, 2005, J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010; Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147; Li SF, 1997, CANCER RES, V57, P4356; Lu Q, 2006, AGEING RES REV, V5, P449, DOI 10.1016/j.arr.2006.07.001; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; McLachlan JA, 2006, INT J EPIDEMIOL, V35, P868, DOI 10.1093/ije/dyl140; Mellor J, 2006, TRENDS GENET, V22, P320, DOI 10.1016/j.tig.2006.03.008; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nafee TM, 2008, BJOG-INT J OBSTET GY, V115, P158, DOI 10.1111/j.1471-0528.2007.01528.x; Nakao M, 2001, GENE, V278, P25, DOI 10.1016/S0378-1119(01)00721-1; NEWBOLD RR, 1990, CANCER RES, V50, P7677; NEWBOLD RR, 1982, CANCER RES, V42, P2003; Newbold RR, 2004, REPROD TOXICOL, V18, P399, DOI 10.1016/j.reprotox.2004.01.007; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nguyen CT, 2002, CANCER RES, V62, P6456; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; NOMURA T, 1977, CANCER RES, V37, P1099; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Perry AS, 2006, ENDOCR-RELAT CANCER, V13, P357, DOI 10.1677/erc.1.01184; Rajasekhar VK, 2007, STEM CELLS, V25, P2498, DOI 10.1634/stemcells.2006-0608; Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321; Ruiz-Cortes ZT, 2005, MOL ENDOCRINOL, V19, P2991, DOI 10.1210/me.2004-0441; Salozhin SV, 2005, BIOCHEMISTRY-MOSCOW+, V70, P525, DOI 10.1007/s10541-005-0146-8; Sato N, 2003, CANCER RES, V63, P4158; Schulz WA, 2006, J CELL MOL MED, V10, P100, DOI 10.1111/j.1582-4934.2006.tb00293.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shibata A, 2000, EPIDEMIOL REV, V22, P239; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1&lt;112::AID-CNCR16&gt;3.0.CO;2-T; Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342; Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009; Szyf M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P533, DOI 10.1007/s10541-005-0147-7; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Thomassin H, 2001, EMBO J, V20, P1974, DOI 10.1093/emboj/20.8.1974; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Varayoud J, 2008, ENDOCRINOLOGY, V149, P5848, DOI 10.1210/en.2008-0651; VORHERR H, 1979, BIOCHEM PHARMACOL, V28, P1865, DOI 10.1016/0006-2952(79)90638-5; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang ZW, 2006, UROL ONCOL-SEMIN ORI, V24, P152, DOI 10.1016/j.urolonc.2005.11.004959ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSBBA-REV CANCERAPRDiscipline: Biochemistry &amp; Molecular Biology; Biophysics; Oncology435UV</notes>
    <keywords>ADULTHOOD; AGENTS; BIOLOGY; BISPHENOL-A EXPOSURE; breast; BREAST-CANCER; CANCER; Carcinogen; CARCINOGENESIS; CELL; CELLS; development; DISEASE; diseases; DNA METHYLATION; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; epigenetic; epigenetic changes; Epigenome; ESTROGEN-RECEPTOR; EXPOSURE; GENE; GENE-EXPRESSION; HEALTH; HISTONE MODIFICATIONS; Hormone; Hormones; IN-UTERO; MAMMARY-GLAND; mechanism; NEONATAL DIETHYLSTILBESTROL EXPOSURE; oncology; p21; Prostate; PROSTATE-CANCER; RECEPTOR; Regulation; Review; RISK; signaling; STEM-CELLS; SUSCEPTIBILITY; Transcriptional regulation</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>104</startpage>
    <endpage>109</endpage>
    <journalfull>Biochimica et Biophysica Acta-Reviews on Cancer</journalfull>
    <issue>2</issue>
    <volume>1795</volume>
    <abstract>There are numerous diseases associated with abnormal hormonal regulation and these include cancers of the breast and prostate. There is substantial evidence that early hormonal perturbations (in utero or during early development) are associated with increased disease susceptibility later in life. These perturbations may arise from exposure to environmental agents or endocrine disruptors which mimic hormones and disrupt normal hormonal signaling. Epigenetic alterations have often been proposed as the underlying mechanism by which early hormonal perturbations may give rise to disease in adulthood. Currently, there is minimal evidence to support a direct link between early hormonal perturbations and epigenetic modifications; or between epigenetic alterations and subsequent onset of cancer. Given that epigenetic modifications may play an important role in hormone-dependent cancers, it is essential to better understand the relationship between the hormonal environment and epigenetic modifications in both normal and disease states. In this review, we highlight several important studies which support the hypothesis that: hormonal perturbations early in life may result in epigenetic changes that may modify hormone receptor function, thereby contributing to an increased risk of developing hormone-related cancers. (C) 2009 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000265369700003</url>
    <isbnorissn>0304-419X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>152</id>
    <title>Effect of the environmental pollutant bisphenol A dimethacylate (BAD) on Ca2+ movement and viability in OC2 human oral cancer cells</title>
    <authors>Chien,J.M.; Chou,C.T.; Lu,Y.C.; Lu,T.; Chi,C.C.; Tseng,L.L.; Liu,S.I.; Cheng,J.S.; Kuo,C.C.; Liang,W.Z.; Jan,C.R.</authors>
    <availability>[Chien, Jau-Min] Ping Tung Christian Hosp, Dept Pediat, Pingtung 900, Taiwan. [Chou, Chiang-Ting] Chang Gung Univ Sci &amp; Technol, Div Basic Med Sci, Dept Nursing, Chiayi 603, Taiwan. [Chou, Chiang-Ting] Chang Gung Univ Sci &amp; Technol, Chron Dis &amp; Hlth Promot Res Ctr, Chiayi 613, Taiwan. [Lu, Yi-Chau] Kaohsiung Vet Gen Hosp, Dept Orthoped, Kaohsiung 813, Taiwan. [Lu, Ti] Kaohsiung Vet Gen Hosp, Dept Psychiat, Kaohsiung 813, Taiwan. [Chi, Chao-Chuan] Kaohsiung Vet Gen Hosp, Dept Otolaryngol, Kaohsiung 813, Taiwan. [Tseng, Li-Ling] Kaohsiung Vet Gen Hosp, Dept Dent, Kaohsiung 813, Taiwan. [Liu, Shiuh-Inn] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung 813, Taiwan. [Cheng, Jin-Shiung] Yongkang Vet Hosp, Dept Med, Tainan 710, Taiwan. [Kuo, Chun-Chi] Chang Gung Inst Technol, Inst Nursing, Chiayi Campus 613, Taiwan. [Kuo, Chun-Chi] Chang Gung Inst Technol, Dept Nursing, Chiayi Campus 613, Taiwan. [Liang, Wei-Zhe; Jan, Chung-Ren] Kaohsiung Vet Gen Hosp, Dept Med Educ &amp; Res, Kaohsiung 813, Taiwan.</availability>
    <date>2013</date>
    <notes>JEnglishArticleJan, CR (reprint author), Kaohsiung Vet Gen Hosp, Dept Med Educ &amp; Res, Kaohsiung 813, Taiwancrjan@isca.vghks.gov.twBoland EJ, 2006, DENT MATER, V22, P338, DOI 10.1016/j.dental.2005.05.004; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Cannon JM, 2000, BIOMACROMOLECULES, V1, P656, DOI 10.1021/bm005564+; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Darmani H, 2004, J BIOMED MATER RES A, V69A, P637, DOI 10.1002/jmb.a.30029; Florenzano F, 2006, J COMP NEUROL, V498, P58, DOI 10.1002/cne.21013; Ghisari M, 2005, MOL CELL ENDOCRINOL, V244, P31, DOI 10.1016/j.mce.2005.01.013; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hashimoto Y, 2000, Dent Mater J, V19, P245; Huang CC, 2009, HUM EXP TOXICOL, V28, P41, DOI 10.1177/0960327108097436; Ishikawa J, 2003, J IMMUNOL, V170, P4441; Jiang N, 2006, WORLD J GASTROENTERO, V12, P4694; Kuo LN, 2009, HUM EXP TOXICOL, V28, P301, DOI 10.1177/0960327109106548; Ling L, 2009, J DENT RES, V88, P83, DOI 10.1177/0022034508328254; Mlynarcikova A, 2005, MOL CELL ENDOCRINOL, V244, P57, DOI 10.1016/j.mce.2005.02.009; Monroe N, 2001, J DENT RES, V80, P1505; O'Donnell JNR, 2006, J BIOACT COMPAT POL, V21, P169, DOI 10.1177/0883911506064476; Quinn T, 2004, LIFE SCI, V74, P1659, DOI 10.1016/j.lfs.2003.08.030; Schafer TE, 1999, J BIOMED MATER RES, V45, P192, DOI 10.1002/(SICI)1097-4636(19990605)45:3&lt;192::AID-JBM5&gt;3.0.CO;2-A; Shideman CR, 2009, NEUROSCI LETT, V451, P124, DOI 10.1016/j.neulet.2008.12.031; Shieh P, 2010, CHINESE J PHYSIOL, V53, P215, DOI 10.4077/CJP.2010.AMK053; Skrtic D, 2006, ACTA BIOMATER, V2, P85, DOI 10.1016/j.actbio.2005.10.004; Smith RE, 2001, BBA-PROTEIN STRUCT M, V1550, P100, DOI 10.1016/S0167-4838(01)00275-8; Teeguarden JG, 2005, TOXICOL SCI, V85, P823, DOI 10.1093/toxsci/kfi135; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; Tsai JY, 2010, CHINESE J PHYSIOL, V53, P151, DOI 10.4077/CJP.2010.AMK036; Tseng LL, 2011, BASIC CLIN PHARMACOL, V108, P341, DOI 10.1111/j.1742-7843.2010.00662.x; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Wada H, 2004, J DENT RES, V83, P222310ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSENVIRON TOXICOL PHARMARDiscipline: Environmental Sciences &amp; Ecology; Pharmacology &amp; Pharmacy; Toxicology112KM</notes>
    <keywords>apoptosis; bisphenol; bisphenol A; Bisphenol A dimethacylate; BISPHENOL-A; Ca2+; CALCIUM-PHOSPHATE COMPOSITES; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; DIMETHACRYLATE; Estrogenicity; HEALTH; IMPROVED MECHANICAL-PROPERTIES; IN-VITRO; INDICATORS; INFLUX; inhibition; INHIBITOR; NEURONS; OC2; PHARMACOLOGY; PROTEIN; PUMP; RAT; THAPSIGARGIN; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>178</startpage>
    <endpage>184</endpage>
    <journalfull>Environmental Toxicology and Pharmacology</journalfull>
    <issue>2</issue>
    <volume>35</volume>
    <abstract>The environmental pollutant bisphenol A dimethacylate (BAD) has been used as a dental composite. The effect of BAD on cytosolic Ca2+ concentrations ([Ca2+](i)) and viability in OC2 human oral cancer cells was explored. The Ca2+-sensitive fluorescent dye fura-2 was applied to measure [Ca2+](i). BAD induced [Ca2+](i) rises in a concentration-dependent manner. The response was reduced by removing extracellular Ca2+. BAD-evoked Ca2+ entry was suppressed by nifedipine, econazole, and SK&amp;F96365. In Ca2+-free medium, incubation with the endoplasmic reticulum Ca2+ pump inhibitor thapsigargin abolished BAD-induced [Ca2+](i) rise. Inhibition of phospholipase C with U73122 did not alter BAD-induced [Ca2+](i) rise. At 10-30 mu M, BAD inhibited cell viability, which was not reversed by chelating cytosolic Ca2+. BAD (20-30 mu M) also induced apoptosis. Collectively, in OC2 cells, BAD induced a [Ca2+](i) rise by evoking phospholipase C-independent Ca2+ release from the endoplasmic reticulum and Ca2+ entry via store-operated Ca2+ channels. BAD also caused apoptosis. (C) 2012 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000316591100005</url>
    <isbnorissn>1382-6689</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>101</id>
    <title>Approaches to advancing quantitative human health risk assessment of environmental chemicals in the post-genomic era</title>
    <authors>Chiu,W.H.A.; Euling,S.Y.; Scott,C.S.; Subramaniam,R.P.</authors>
    <availability>[Chiu, Weihsueh A.; Euling, Susan Y.; Scott, Cheryl Siegel; Subramaniam, Ravi P.] US EPA, Natl Ctr Environm Assessment, Washington, DC 20460 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleChiu, WHA (reprint author), US EPA, 8623P,2 Potomac Yard,North Bldg,2733 South Crysta, Arlington, VA 22202 USAchiu.weihsueh@epa.govAllen DG, 2004, TOXICOL PATHOL, V32, P393, DOI 10.1080/01926230490440934; Andersen ME, 2008, TOXICOL SCI, V105, P368, DOI 10.1093/toxsci/kfn097; Axelrad DA, 2007, ENVIRON HEALTH PERSP, V115, P609, DOI 10.1289/ehp.9303; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Burgoon LD, 2008, TOXICOL SCI, V104, P412, DOI 10.1093/toxsci/kfn083; Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848; Caporaso NE, 2007, CANCER EPIDEM BIOMAR, V16, P365, DOI 10.1158/1055-9965.EPI-07-0142; CASANOVA M, 1989, FUND APPL TOXICOL, V12, P397, DOI 10.1016/0272-0590(89)90015-8; Chang CH, 2009, AM J EPIDEMIOL, V170, P695, DOI 10.1093/aje/kwp019; Cohen Samuel M, 2004, Toxicol Pathol, V32 Suppl 1, P3, DOI 10.1080/01926230490424969; Collins FS, 2008, SCIENCE, V319, P906, DOI 10.1126/science.1154619; Conolly RB, 2003, TOXICOL SCI, V75, P432, DOI 10.1093/toxsci/kfg182; Conolly RB, 2009, RISK ANAL, V29, P480, DOI 10.1111/j.1539-6924.2008.01165.x; Conolly RB, 2004, TOXICOL SCI, V82, P279, DOI 10.1093/toxsci/kfh223; Conolly RB, 2009, ANN OCCUP HYG, V53, P181, DOI 10.1093/annhyg/men084; Crump KS, 2009, ANN OCCUP HYG, V53, P184, DOI 10.1093/annhyg/men088; Crump KS, 2008, ANN OCCUP HYG, V52, P481, DOI 10.1093/annhyg/men038; Crump K.S., 2010, ENV HLTH PERSPECT, DOI 10.1289/ehp.0901249; Daston GP, 2008, TOXICOL SCI, V105, P233, DOI 10.1093/toxsci/kfn138; David RM, 2006, REGUL TOXICOL PHARM, V45, P55, DOI 10.1016/j.yrtph.2005.12.003; Dix DJ, 2006, NAT BIOTECHNOL, V24, P1108, DOI 10.1038/nbt0906-1108; Dix DJ, 2007, TOXICOL SCI, V95, P5, DOI 10.1093/toxsci/kfl103; Dourson M L, 1983, Regul Toxicol Pharmacol, V3, P224, DOI 10.1016/0273-2300(83)90030-2; El-Masri HA, 1999, TOXICOL APPL PHARM, V158, P221, DOI 10.1006/taap.1999.8715; Evans JS, 2001, RISK ANAL, V21, P697, DOI 10.1111/0272-4332.214144; Feero WG, 2008, JAMA-J AM MED ASSOC, V299, P1351, DOI 10.1001/jama.299.11.1351; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gant TW, 2007, EXPERT OPIN DRUG MET, V3, P599, DOI 10.1517/17425225.3.4.599; Gaylor DW, 2000, RISK ANAL, V20, P245, DOI 10.1111/0272-4332.202023; Georgopoulos PG, 2009, J EXPO SCI ENV EPID, V19, P149, DOI 10.1038/jes.2008.9; Ghosh P, 2008, MUTAT RES-REV MUTAT, V659, P293, DOI 10.1016/j.mrrev.2008.06.003; Ginsberg G, 2009, J TOXICOL ENV HEAL B, V12, P307, DOI 10.1080/10937400903158318; Ginsberg G, 2009, J TOXICOL ENV HEAL B, V12, P473, DOI 10.1080/10937400903158409; Ginsberg G, 2009, J TOXICOL ENV HEAL B, V12, P389, DOI 10.1080/10937400903158375; Gohlke JM, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-46; Griffiths C, 2007, ENVIRON HEALTH PERSP, V115, P841, DOI 10.1289/ehp.9797; Groopman JD, 1999, CARCINOGENESIS, V20, P1, DOI 10.1093/carcin/20.1.1; Grosse SD, 2002, ENVIRON HEALTH PERSP, V110, P563; Gwinn M, 2009, AM J EPIDEMIOL, V170, P703, DOI 10.1093/aje/kwp221; Hattis D, 2002, DRUG CHEM TOXICOL, V25, P403, DOI 10.1081/DCT-120014793; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Hogan K, 1998, ENVIRON HEALTH PERSP, V106, P1557; Ikediobi ON, 2009, CLIN PHARMACOL THER, V86, P28, DOI 10.1038/clpt.2009.30; Ioannidis JP, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159; Jonsson F, 2001, TOXICOL APPL PHARM, V174, P99, DOI 10.1006/taap.2001.9206; Jusko TA, 2008, ENVIRON HEALTH PERSP, V116, P243, DOI 10.1289/ehp.10424; Kavlock RJ, 2008, TOXICOL SCI, V103, P14, DOI 10.1093/toxsci/kfm297; Kavlock RJ, 2009, RISK ANAL, V29, P485, DOI 10.1111/j.1539-6924.2008.01168.x; Khoury MJ, 2005, AM J EPIDEMIOL, V161, P799, DOI 10.1093/aje/kwi113; Khoury MJ, 2009, AM J EPIDEMIOL, V170, P269, DOI 10.1093/aje/kwp119; Khoury MJ, 2009, AM J EPIDEMIOL, V169, P227, DOI 10.1093/aje/kwn351; Khoury MJ, 2009, GENET MED, V11, P488, DOI 10.1097/GIM.0b013e3181a551cc; Lin BK, 2006, AM J EPIDEMIOL, V164, P1, DOI 10.1093/aje/kwj175; Lobenhofer EK, 2004, TOXICOL PATHOL, V32, P482, DOI 10.1080/01926230490483324; Lund E, 2008, CANCER EPIDEM BIOMAR, V17, P2954, DOI 10.1158/1055-9965.EPI-08-0519; Miller MD, 2009, ENVIRON HEALTH PERSP, V117, P1033, DOI 10.1289/ehp.0800247; Mohrenweiser Harvey W, 2004, Toxicol Pathol, V32 Suppl 1, P136, DOI 10.1080/01926230490424671; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Naciff JM, 2005, TOXICOL SCI, V86, P396, DOI 10.1093/toxsci/kfi198; Naciff JM, 2009, TOXICOL SCI, V107, P40, DOI 10.1093/toxsci/kfn219; Naciff JM, 2003, TOXICOL SCI, V72, P314, DOI 10.1093/toxsci/kfg037; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Naciff JM, 2005, ENVIRON HEALTH PERSP, V113, P1164, DOI 10.1289/ehp.7843; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; NCI (National Cancer Institute), 2010, DICT CANC TERMS; Neafsey P, 2009, J TOXICOL ENV HEAL B, V12, P362, DOI 10.1080/10937400903158359; Neafsey P, 2009, J TOXICOL ENV HEAL B, V12, P334, DOI 10.1080/10937400903158342; NRC, 2007, APPL TOX TECHN PRED; NRC (National Research Council), 2007, TOX TEST 21 CENT; NRC (National Research Council), 2008, PHTHAL CUM RISK ASS; NRC (National Research Council), 2009, SCI DEC; Nuwaysir EF, 1999, MOL CARCINOGEN, V24, P153, DOI 10.1002/(SICI)1098-2744(199903)24:3&lt;153::AID-MC1&gt;3.0.CO;2-P; Ovacik A.M, 2010, TOXICOLOGY APPL PHAR; Pery ARR, 2009, RISK ANAL, V29, P1182, DOI 10.1111/j.1539-6924.2009.01242.x; Pesch B, 2004, TOXICOL LETT, V151, P255, DOI 10.1016/j.toxlet.2004.02.020; Quackenbush J, 2007, J EXP BIOL, V210, P1507, DOI 10.1242/jeb.004432; Sen B, 2005, TOXICOLOGY, V215, P214, DOI 10.1016/j.tox.2005.07.008; Slob W, 1998, RISK ANAL, V18, P787, DOI 10.1023/B:RIAN.0000005924.18154.60; Snyder RD, 2001, MUTAT RES-REV MUTAT, V488, P151, DOI 10.1016/S1383-5742(01)00055-2; Subramaniam RP, 2008, RISK ANAL, V28, P907, DOI 10.1111/j.1539-6924.2008.01083.x; Subramaniam RP, 2007, RISK ANAL, V27, P1237, DOI 10.1111/j.1539-6924.2007.00968.x; Tan YM, 2007, J EXPO SCI ENV EPID, V17, P591, DOI 10.1038/sj.jes.7500540; Thomas R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r44; Thomas RS, 2007, TOXICOL SCI, V96, P40, DOI 10.1093/toxsci/kfl171; Thomas RS, 2007, TOXICOL SCI, V97, P55, DOI 10.1093/toxsci/kfm023; Thomas RS, 2009, TOXICOL SCI, V112, P311, DOI 10.1093/toxsci/kfp233; Thomas RS, 2007, TOXICOL SCI, V98, P240, DOI 10.1093/toxsci/kfm092; Thompson CM, 2008, J TOXICOL ENV HEAL B, V11, P519, DOI 10.1080/10937400701724337; Trasande L, 2005, ENVIRON HEALTH PERSP, V113, P590, DOI 10.1289/ehp.7743; U. S. EPA, 1992, FED REGISTER, V57, P24152; U.S. Environmental Protection Agency, 1997, BEN COSTS CLEAN AIR; US EPA, 2006, APPR APPL PHYS BAS P; U.S. EPA, 2009, 1 INT WORKSH VIRT TI; U.S. EPA, 2002, SCI POL COUNC INT PO; US EPA, 2005, EPA630R03003F RISK A; U.S. EPA, 1994, EPA600890066F; U.S. EPA, 2002, EPA630P022002F; U.S. EPA (Environmental Protection Agency), 2005, EPA630P03001B; Vineis P, 2008, MUTAGENESIS, V23, P439, DOI 10.1093/mutage/gen042; Vineis P, 2007, CANCER EPIDEM BIOMAR, V16, P1954, DOI 10.1158/1055-9965.EPI-07-0457; Vineis Paolo, 2006, Environ Health, V5, P21, DOI 10.1186/1476-069X-5-21; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Walker K, 2009, J TOXICOL ENV HEAL B, V12, P440, DOI 10.1080/10937400903158383; Weiss ST, 2008, NAT REV DRUG DISCOV, V7, P568, DOI 10.1038/nrd2520; White L.D., 2010, TOXICOLOGY APPL PHAR; WHO, 2001, GUID DOC US DAT DEV; WHO (World Health Organization), 1993, ENV HLTH CRIT, P155; Woodruff TJ, 2008, ENVIRON HEALTH PERSP, V116, P1568, DOI 10.1289/ehp.11516; Yang LL, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-387; Yu XZ, 2006, TOXICOL SCI, V92, P560, DOI 10.1093/toxsci/kfj1841105ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMSEP 15Discipline: Pharmacology &amp; Pharmacy; Toxicology221OZ</notes>
    <keywords>17-ALPHA-ETHYNYL ESTRADIOL; Biomarkers; BISPHENOL-A; BLOOD LEAD CONCENTRATIONS; CANCER; CARCINOGENESIS; CHEMICALS; DISEASE; DISORDERS; DOSE-RESPONSE; Dose-response assessment; ENVIRONMENTAL CHEMICALS; EXPOSURE; FEMALE REPRODUCTIVE-SYSTEM; GENE-EXPRESSION; HUMAN HEALTH; Human health risk assessment; HUMAN-DISEASE; IMPACT; IN-VIVO; INDUCED RESPIRATORY CANCER; INHALED FORMALDEHYDE; mechanism; MECHANISMS; MODEL; MODELS; Molecular epidemiology; POPULATION; POPULATION-DISTRIBUTION; RISK; Risk assessment; RISK-ASSESSMENT; SUSCEPTIBILITY; TOXICITY; Toxicogenomics; toxicology; Weight of evidence; WIDE ASSOCIATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>309</startpage>
    <endpage>323</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>3</issue>
    <volume>271</volume>
    <abstract>The contribution of genomics and associated technologies to human health risk assessment for environmental chemicals has focused largely on elucidating mechanisms of toxicity, as discussed in other articles in this issue. However, there is interest in moving beyond hazard characterization to making more direct impacts on quantitative risk assessment (QRA) - i.e., the determination of toxicity values for setting exposure standards and cleanup values. We propose that the evolution of QRA of environmental chemicals in the post-genomic era will involve three, somewhat overlapping phases in which different types of approaches begin to mature. The initial focus (in Phase I) has been and continues to be on "augmentation" of weight of evidence using genomic and related technologies qualitatively to increase the confidence in and scientific basis of the results of QRA. Efforts aimed towards "integration" of these data with traditional animal-based approaches, in particular quantitative predictors, or surrogates, for the in vivo toxicity data to which they have been anchored are just beginning to be explored now (in Phase II). In parallel, there is a recognized need for "expansion" of the use of established biomarkers of susceptibility or risk of human diseases and disorders for QRA, particularly for addressing the issues of cumulative assessment and population risk. Ultimately (in Phase III), substantial further advances could be realized by the development of novel molecular and pathway-based biomarkers and statistical and in silica models that build on anticipated progress in understanding the pathways of human diseases and disorders. Such efforts would facilitate a gradual "reorientation" of QRA towards approaches that more directly link environmental exposures to human outcomes. Published by Elsevier Inc</abstract>
    <url>WOS:000324669500003</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>65</id>
    <title>Effect of Bisphenol A on human health and its degradation by microorganisms: a review</title>
    <authors>Chouhan,S.; Yadav,S.K.; Prakash,J.; Swati; Singh,S.P.</authors>
    <availability>[Chouhan, Shikha; Yadav, Satyndra K.; Prakash, Jay; Singh, Surya P.] Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India. [Swati] Banaras Hindu Univ, Fac Sci, Dept Bot, Varanasi 221005, Uttar Pradesh, India.</availability>
    <date>2014</date>
    <notes>JEnglishReviewSingh, SP (reprint author), Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, Indiasuryasinghbhu16@gmail.comAdriani W, 2003, ENVIRON HEALTH PERSP, V111, P395, DOI 10.1289/ehp.5856; Akingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Bautista-Toledo I, 2005, Environ Sci Technol, V39, P6246, DOI 10.1021/es0481169; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Can A, 2005, MOL HUM REPROD, V11, P389, DOI 10.1093/molehr/gah179; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Clark JH, 1992, TXB ENDOCRINOLOGY, P35; Dessi-Fulgheri F, 2002, ENVIRON HEALTH PERSP, V110, P403; Domoradzki JY, 2004, TOXICOL SCI, V77, P230, DOI 10.1093/toxsci/kfh054; Farabollino F, 2002, ENVIRON HEALTH PERSP, V110, P409; Fukuda T, 2001, BIOCHEM BIOPH RES CO, V284, P704, DOI 10.1006/bbrc.2001.5021; Hirano T, 2000, BIOSCI BIOTECH BIOCH, V64, P1958, DOI 10.1271/bbb.64.1958; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 1999, NATURE, V401, P763; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jones DC, 2008, BIOCHEM PHARMACOL, V76, P569, DOI 10.1016/j.bcp.2008.05.010; Kang JH, 2002, ARCH ENVIRON CON TOX, V43, P265, DOI 10.1007/s00244-002-1209-0; Kim JY, 2010, TOXICOL LETT, V193, P200, DOI 10.1016/j.toxlet.2010.01.011; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Li YJ, 2009, TOXICOL SCI, V108, P427, DOI 10.1093/toxsci/kfp024; Liu X, 2007, FEBS J, V274, P6340, DOI 10.1111/j.1742-4658.2007.06152.x; LOBOS JH, 1992, APPL ENVIRON MICROB, V58, P1823; Matsumoto J, 2002, ENVIRON HEALTH PERSP, V110, P193; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Murdoch FE, 1991, MOL CELL ENDOCRINOL, V78, P103; Nakamura K, 2006, J NEUROSCI RES, V84, P1197, DOI 10.1002/jnr.21020; Nakamura K, 2007, NEUROSCI LETT, V420, P100, DOI 10.1016/j.neulet.2007.02.093; Noguchi S, 2002, TOXICOL LETT, V135, P95, DOI 10.1016/S0378-4274(02)00252-7; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Oshiman K, 2007, BIODEGRADATION, V18, P247, DOI 10.1007/s10532-006-9059-5; Patisaul HB, 2006, NEUROTOXICOL TERATOL, V28, P111, DOI 10.1016/j.ntt.2005.11.004; Reinhammar B., 1984, COPPER PROTEINS COPP, P1; Sakai K, 2007, BIOSCI BIOTECH BIOCH, V71, P51, DOI 10.1271/bbb.60351; Sakaue M, 2001, J OCCUP HEALTH, V43, P185, DOI 10.1539/joh.43.185; Sasaki M, 2005, BIODEGRADATION, V16, P449, DOI 10.1007/s10532-004-5023-4; Shin EH, 2007, J MICROBIOL BIOTECHN, V17, P1147; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Sm L, 2005, BIOL PHARM BULL, V28, P201; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Suiko M, 2000, BIOCHEM BIOPH RES CO, V267, P80, DOI 10.1006/bbrc.1999.1935; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Taylor JA, 2008, REPROD TOXICOL, V25, P169, DOI 10.1016/j.reprotox.2008.01.001; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Toyama T, 2009, J BIOSCI BIOENG, V108, P147, DOI 10.1016/j.jbiosc.2009.03.011; Tsutsumi Y, 2001, CHEMOSPHERE, V42, P271, DOI 10.1016/S0045-6535(00)00081-3; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Varayoud J, 2011, ENDOCRINOLOGY, V152, P1101, DOI 10.1210/en.2009-1037; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, P56; Wen C, 2005, APPL BIOCHEM BIOTECH, V120, P0273; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5; Yamamoto T, 2001, CHEMOSPHERE, V42, P415, DOI 10.1016/S0045-6535(00)00079-5; Yamanaka H, 2006, APPL BIOCHEM BIOTECH, V136, P39; Yamanaka H, 2008, J BIOSCI BIOENG, V105, P157, DOI 10.1263/jbb.105.157; Ye XB, 2009, INT J HYG ENVIR HEAL, V212, P481, DOI 10.1016/j.ijheh.2009.03.004; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-1018630SPRINGERNEW YORK233 SPRING ST, NEW YORK, NY 10013 USAANN MICROBIOLMARDiscipline: Biotechnology &amp; Applied Microbiology; MicrobiologyAB2UT</notes>
    <keywords>ANDROGEN RECEPTOR; Biodegradation; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL ESTROGENS; Estrogen; ESTROGEN-RECEPTOR; estrogenic activity; GLAND; HUMAN HEALTH; IN-VITRO; LEYDIG-CELLS; Microbes; MIMICS; PERINATAL EXPOSURE; PRENATAL EXPOSURE; PROTEINS; STRAIN AO1; UP-REGULATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>13</startpage>
    <endpage>21</endpage>
    <journalfull>Annals of Microbiology</journalfull>
    <issue>1</issue>
    <volume>64</volume>
    <abstract>Bisphenol A (BPA), is an industrially important compound and is widely used for the production of polycarbonates and other plastics. Over the past few years, there have been many issues raised all over the world on the use of BPA. BPA is known to possess estrogenic activities; hence, it mimics the role of estrogen once it enters living systems. Thus, it has been placed in the category of compounds called endocrine disruptors. It can cause damage to reproductive organs, thyroid gland, and brain tissues at developmental stages, and most recently it has also been linked to cancer development in humans. Here, in this review, we aim to summarize the various effects of BPA on humans and animals, and at the same time we wish to throw some light on the emerging field of biodegradation of BPA in the natural environment. A few studies conducted recently have tried to isolate BPA-degrading microorganisms from various sites, like water bodies receiving wastes from industries, landfills, etc. In the present scenario, with huge controversies on the use of BPA, we emphasize on bridging the gap between studies, aiming at finding the damage caused by BPA, and the studies which aim at the safe removal of BPA from the environment, with the help of naturally occurring microbes. Once this gap is filled, we will be able to find a way which will allow the use of BPA in manufacturing plastics, without its accumulation in the environment</abstract>
    <url>WOS:000331648300002</url>
    <isbnorissn>1590-4261</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>303</id>
    <title>Developmental basis of disease: environmental impacts</title>
    <authors>Collman,G.W.</authors>
    <availability>NIEHS, Div Extramural Res &amp; Training, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleCollman, GW (reprint author), NIEHS, Div Extramural Res &amp; Training, POB 12233, Res Triangle Pk, NC 27709 USAcollman@niehs.nih.govALTSHULER K, 2003, OCHP PAPER SERIES CH; Apelberg BJ, 2007, ENVIRON HEALTH PERSP, V115, P1670, DOI 10.1289/ehp.10334; BARKER DJP, 1986, LANCET, V1, P1077; BARLOW BK, 2007, REPROD TOXICOL, V23, P257; Barr DB, 2007, REPROD TOXICOL, V23, P260, DOI 10.1016/j.reprotox.2007.03.003; Bauer AK, 2010, ANN NY ACAD SCI, V1203, P113, DOI 10.1111/j.1749-6632.2010.05606.x; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Bradman A, 2005, ENVIRON HEALTH PERSP, V113, P1802, DOI 10.1289/ehp.7894; CDC, 2009, 4 CDC; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Colquhoun DR, 2009, ENVIRON HEALTH PERSP, V117, P832, DOI 10.1289/ehp.11816; DAVIDSON PW, 1994, ENV SCI, V3, P55; Eskenazi B, 2005, ENVIRON HEALTH PERSP, V113, P1419, DOI 10.1289/ehp.7670; Fangstrom B, 2002, ENVIRON HEALTH PERSP, V110, P895; Gillman MW, 2009, EARLY LIFE ORIGINS OF HUMAN HEALTH AND DISEASE, P52, DOI 10.1159/000221153; Groopman John D., 2005, Cancer Biomarkers, V1, P5; Harrill AH, 2009, TOXICOL SCI, V110, P235, DOI 10.1093/toxsci/kfp096; Heindel JJ, 2009, EARLY LIFE ORIGINS H, P42; Herbstman JB, 2010, ENVIRON HEALTH PERSP, V118, P712, DOI 10.1289/ehp.0901340; Hiatt RA, 2009, ENVIRON HEALTH PERSP, V117, P1814, DOI 10.1289/ehp.0800120; Huen K, 2009, ENVIRON HEALTH PERSP, V117, P1632, DOI 10.1289/ehp.0900870; KIMMEL CA, 2005, ENV HLTH PERSPECT, V113, P1415; Lovasi GS, 2011, AM J PUBLIC HEALTH, V101, P63, DOI 10.2105/AJPH.2009.168419; McGlynn KA, 2009, ENVIRON HEALTH PERSP, V117, P1472, DOI 10.1289/ehp.0800389; Nilsson EE, 2008, REPRODUCTION, V135, P713, DOI 10.1530/REP-07-0542; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; *PRES CANC PAN, 2008, RED ENV CANC RISK WH; Schwartz D, 2007, SCIENCE, V316, P695, DOI 10.1126/science.1141331; Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007; Suk WA, 1998, ENVIRON HEALTH PERSP, V106, P817, DOI 10.2307/3434195; van den Berg B J, 1988, Paediatr Perinat Epidemiol, V2, P265; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705; Whyatt RM, 2005, TOXICOL APPL PHARM, V206, P246, DOI 10.1016/j.taap.2004.11.027; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Wolff MS, 2008, ENVIRON HEALTH PERSP, V116, P1092, DOI 10.1289/ehp.11007; Ye XB, 2009, INT J HYG ENVIR HEAL, V212, P481, DOI 10.1016/j.ijheh.2009.03.004371CAMBRIDGE UNIV PRESSCAMBRIDGEEDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLANDJ DEV ORIG HLTH DISFEBDiscipline: Public, Environmental &amp; Occupational Health755LW</notes>
    <keywords>BIOMARKER; Biomarkers; BIRTH; BISPHENOL-A; CANCER; CHEMICALS; DISEASE; early life exposures; EARLY-LIFE; ENVIRONMENTAL CHEMICALS; environmental exposure; EXPOSURE; EXPOSURES; HEALTH; HUMAN HEALTH; IMPACT; nutrition; Occupational; PREGNANCY; Proteomics; Reproduction; RISK; serum; windows of susceptibility; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>49</startpage>
    <endpage>55</endpage>
    <journalfull>Journal of Developmental Origins of Health and Disease</journalfull>
    <issue>1</issue>
    <volume>2</volume>
    <abstract>Exposure to environmental chemicals and other environmental stressors have health impacts on the fetus that may not be apparent until later in life. The concept of developmental origins of disease should be expanded to include these early life exposures in addition to the effects of nutrition and maternal factors. This paper will describe the toxicological, biological and epidemiological issues that are pertinent to conducting research on environmental exposures early in life and their health consequences over the life span</abstract>
    <url>WOS:000289933800007</url>
    <isbnorissn>2040-1744</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>57</id>
    <title>Effects of endocrine disruptors in the development of the female reproductive tract</title>
    <authors>Costa,E.M.F.; Spritzer,P.M.; Hohl,A.; Bachega,T.A.S.S.</authors>
    <availability>[Frade Costa, Elaine Maria] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Hormonios Genet Mol LIM42,Unidade Endocrinol, BR-05403900 Sao Paulo, Brazil. [Spritzer, Poli Mara] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Dept Fisiol, Lab Endocrinol Mol,Div Endocrinol, Porto Alegre, RS, Brazil. [Hohl, Alexandre] Univ Fed Santa Catarina, Univ Hosp, Serv Endocrinol &amp; Metabol, Florianopolis, SC, Brazil. [Bachega, Tania A. S. S.] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Hormonios &amp; Genet Mol LIM42,Unidade Adrenal, BR-05403900 Sao Paulo, Brazil.</availability>
    <date>2014</date>
    <notes>JEnglishReviewBachega, TASS (reprint author), Univ Sao Paulo, Fac Med, Hosp Clin, Lab Hormonios &amp; Genet Mol LIM42, Av Dr Eneas Carvalho Aguiar 155,2 Andar,Bloco 6, BR-05403900 Sao Paulo, Braziltbachega@usp.brAhn HJ, 2012, MOL REPROD DEV, V79, P626, DOI 10.1002/mrd.22070; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Axmon A, 2004, CHEMOSPHERE, V56, P813, DOI 10.1016/j.chemosphere.2004.03.002; Bachega TASS, 2011, ARQ BRAS ENDOCRINOL, V55, P175, DOI 10.1590/S0004-27302011000200011; Bastos AMX, 2013, ARQ BRAS ENDOCRINOL, V57, P346, DOI 10.1590/S0004-27302013000500003; Bigsby R, 1999, ENVIRON HEALTH PERSP, V107, P613, DOI 10.2307/3434553; Brieno-Enriquez MA, 2012, MOL HUM REPROD, V18, P171, DOI 10.1093/molehr/gar074; Buttke DE, 2012, ENVIRON HEALTH PERSP, V120, P1613, DOI 10.1289/ehp.1104748; Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200; Chang JW, 2010, EPIDEMIOLOGY, V21, P56, DOI 10.1097/EDE.0b013e3181c2fc6e; Chao HR, 2007, FOOD CHEM TOXICOL, V45, P259, DOI 10.1016/j.fct.2006.07.032; Christensen Brock C, 2011, Front Genet, V2, P84, DOI 10.3389/fgene.2011.00084; Cooper AR, 2011, FERTIL STERIL, V95, P1890, DOI 10.1016/j.fertnstert.2010.01.016; Costa EMF, 2013, PROENDOCRINO, V4; Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899; Decherf S, 2011, J TOXICOL ENV HEAL B, V14, P423, DOI 10.1080/10937404.2011.578561; Diamanti-Kandarakis E, 2008, CLIN ENDOCRINOL, V69, P634, DOI 10.1111/j.1365-2265.2008.03247.x; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Diamanti-Kandarakis E, 2009, EUR J ENDOCRINOL, V160, P847, DOI 10.1530/EJE-08-0510; Eichenlaub-Ritter U, 2008, MUTAT RES-GEN TOX EN, V651, P82, DOI 10.1016/j.mrgentox.2007.10.014; Farr SL, 2004, AM J EPIDEMIOL, V160, P1194, DOI 10.1093/aje/kwi006; Fernandez M, 2010, ENVIRON HEALTH PERSP, V118, P1217, DOI 10.1289/ehp.0901257; Fortes EM, 2007, ARQ BRAS ENDOCRINOL, V51, P500, DOI 10.1590/S0004-27302007000300021; Gaido KW, 2000, MOL PHARMACOL, V58, P852; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Hanioka N, 1998, ARCH TOXICOL, V72, P387, DOI 10.1007/s002040050518; Hao CJ, 2012, BIOSCIENCE REP, V32, P619, DOI 10.1042/BSR20120042; Hayes TB, 2011, J STEROID BIOCHEM, V127, P64, DOI 10.1016/j.jsbmb.2011.03.015; Hoyer PB, 2001, TOXICOL PATHOL, V29, P91, DOI 10.1080/019262301301418892; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Jinno M, 2011, HUM REPROD, V26, P604, DOI 10.1093/humrep/deq388; Kandaraki E, 2011, J CLIN ENDOCR METAB, V96, pE480, DOI 10.1210/jc.2010-1658; Kappeler CJ, 2012, SYST BIOL REPROD MED, V58, P57, DOI 10.3109/19396368.2011.648820; Kirigaya A, 2009, ZOOL SCI, V26, P704, DOI 10.2108/zsj.26.704; Liem AKD, 2000, FOOD ADDIT CONTAM, V17, P241, DOI 10.1080/026520300283324; MARTINEZ EM, 1991, REPROD TOXICOL, V5, P139, DOI 10.1016/0890-6238(91)90042-E; Mouritsen A, 2010, INT J ANDROL, V33, P346, DOI 10.1111/j.1365-2605.2010.01051.x; Nelson LM, 2009, NEW ENGL J MED, V360, P606, DOI 10.1056/NEJMcp0808697; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Newbold RR, 2004, TOXICOL APPL PHARM, V199, P142, DOI 10.1016/j.taap.2003.11.033; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Pasquali R, 2011, CLIN ENDOCRINOL, V74, P424, DOI 10.1111/j.1365-2265.2010.03956.x; Patisaul HB, 2013, ADV EXP MED BIOL, V784, P455, DOI 10.1007/978-1-4614-6199-9_21; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Uribarri J, 2006, CLIN J AM SOC NEPHRO, V1, P1293, DOI 10.2215/CJN.01270406; Zhou W, 2008, MOL CELL ENDOCRINOL, V283, P12, DOI 10.1016/j.mce.2007.10.010; Zoeller RT, 2006, ENDOCRINOLOGY, V147, P5513, DOI 10.1210/en.2006-1282490SBEM-SOC BRASIL ENDOCRINOLOGIA &amp; METABOLOGIARIO DE JANEIRO, RJRUA HUMAITA, 85 CJ 501, RIO DE JANEIRO, RJ, 22261-000, BRAZILARQ BRAS ENDOCRINOLMARSIDiscipline: Endocrinology &amp; MetabolismAI3SV</notes>
    <keywords>4-VINYLCYCLOHEXENE DIEPOXIDE; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BISPHENOL-A EXPOSURE; CANCER; CELL; CHEMICALS; CHILDREN; diabetes; DISRUPTING CHEMICALS; EDCs; Endocrine disrupting chemicals; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; EXPOSURE; EXPRESSION; female development; FOOD; GLYCATION END-PRODUCTS; INSULIN-RESISTANCE; LEAN WOMEN; mechanism; MECHANISMS; MENSTRUAL-CYCLE CHARACTERISTICS; METABOLISM; Methoxychlor; Mouse; phthalate; Phthalates; Phytoestrogen; PHYTOESTROGENS; polycystic ovary syndrome; POLYCYSTIC-OVARY-SYNDROME; POPULATION; precocious puberty; premature ovarian failure; RECEPTOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>153</startpage>
    <endpage>161</endpage>
    <journalfull>Arquivos Brasileiros de Endocrinologia e Metabologia</journalfull>
    <issue>2</issue>
    <volume>58</volume>
    <abstract>Environmental agencies have identified a growing number of environmental contaminants that have endocrine disrupting activity, and these can become a major public health problem. It is suggested that endocrine disruptors could account for the higher-than-expected increase in the prevalence of some non-communicable diseases, such as obesity, diabetes, thyroid diseases, and some cancers. Several endocrine Disrupting Chemicals (EDCs), such as pesticides, bisphenol A, phthalates, dioxins, and phytoestrogens, can interact with the female reproductive system and lead to endocrine disruption. Initially, it was assumed that EDCs exert their effects by binding to hormone receptors and transcription factors, but it is currently known that they may also alter the expression of enzymes involved in the synthesis or catabolism of steroids. Biomonitoring studies have identified these compounds in adults, children, pregnant women, and fetuses. Among the diseases of the female reproductive tract associated with EDCs exposure are the following: precocious puberty, polycystic ovary syndrome, and premature ovarian failure. The different populations of the world are exposed to a great number of chemicals through different routes of infection; despite the various available studies, there is still much doubt regarding the additive effect of a mixture of EDCs with similar mechanisms of action</abstract>
    <url>WOS:000336783400009</url>
    <isbnorissn>0004-2730</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>437</id>
    <title>Analytical and environmental aspects of the flame retardant tetrabromobisphenol-A and its derivatives</title>
    <authors>Covaci,A.; Voorspoels,S.; Abdallah,M.A.E.; Geens,T.; Harrad,S.; Law,R.J.</authors>
    <availability>[Covaci, Adrian; Geens, Tinne] Univ Antwerp, Dept Pharmaceut Sci, Toxicol Ctr, B-2610 Antwerp, Belgium. [Voorspoels, Stefan] Inst Reference Mat &amp; Measurements, European Commission, Joint Res Ctr, B-2440 Geel, Belgium. [Abdallah, Mohamed Abou-Elwafa; Harrad, Stuart] Univ Birmingham, Sch Geog Earth &amp; Environm Sci, Div Environm Hlth &amp; Risk Management, Birmingham B15 2TT, W Midlands, England. [Law, Robin J.] Cefas Burnham Lab, Ctr Environm Fisheries &amp; Aquaculture Sci, Burnham On Crouch CM0 8HA, Essex, England.</availability>
    <date>2009</date>
    <notes>JEnglishReviewCovaci, A (reprint author), Univ Antwerp, Dept Pharmaceut Sci, Toxicol Ctr, Univ Pl 1, B-2610 Antwerp, Belgiumadrian.covaci@ua.ac.beAbdallah MAE, 2008, ENVIRON SCI TECHNOL, V42, P459, DOI 10.1021/es702378t; Akutsu K, 2003, CHEMOSPHERE, V53, P645, DOI 10.1016/S0045-6535(03)00764-1; ALAEE M, 2003, CONTAM ASSESS 1, V2, P116; ALLARD AS, 1987, APPL ENVIRON MICROB, V53, P839; Altwaiq AM, 2003, ANAL CHIM ACTA, V491, P111, DOI 10.1016/S0003-2670(03)00785-2; Arias PA, 2001, 2 INT WORKSH BROM FL, P17; ASH M, 1997, INDEX FLAM RETARDANT; Berger U, 2004, ANAL CHEM, V76, P441, DOI 10.1021/ac0348672; Bergman A., 1999, ORGANOHALOGEN COMPD, V43, P89; Blanco E, 2005, J CHROMATOGR A, V1071, P205, DOI 10.1016/j.chroma.2004.10.075; Blanco E, 2006, ANAL CHEM, V78, P2772, DOI 10.1021/ac0522512; Brandli RC, 2007, J ENVIRON MONITOR, V9, P465, DOI 10.1039/b617103f; Cariou R, 2005, J CHROMATOGR A, V1100, P144, DOI 10.1016/j.chroma.2005.09.040; CHERNYAK S, 2007, ORGANOHALOGEN COMPT, V69, P994; Chu SG, 2005, J CHROMATOGR A, V1097, P25, DOI 10.1016/j.chroma.2005.08.007; Covaci A, 2007, J CHROMATOGR A, V1153, P145, DOI 10.1016/j.chroma.2006.11.060; Covaci A, 2003, ENVIRON INT, V29, P735, DOI 10.1016/S0160-4120(03)00114-4; Covaci A, 2006, ENVIRON SCI TECHNOL, V40, P3679, DOI 10.1021/es0602492; *DAN ENV PROT AG, 1999, BROM FLAM RET; DEBOER J, 2002, C03302 RIVO; Debrauwer L, 2005, J CHROMATOGR A, V1082, P98, DOI 10.1016/j.chroma.2005.04.060; DESCHRYVER D, 2002, P FLAM RET 2002 C IN; Dettmer FT, 1999, CHEMOSPHERE, V39, P1523, DOI 10.1016/S0045-6535(99)00039-9; DEWIT C, 2007, ORGANOHALOGEN COMPD, V69, P2686; EC, 2001, OFF J EUR COMM L, VL331, P1; EC, 2003, OFF J EUR COMM L, VL037, P19; EISENREICH S, 2007, P 4 INT WORKSH BROM; Eljarrat E, 2004, TRAC-TREND ANAL CHEM, V23, P727, DOI 10.1016/j.trac.2004.07.009; *EUR CHEM BUR, 2007, R3250705ENV1 ECB; *EUR COMM JOINT RE, 2008, EUR RISK AS IN PRESS; *EUR COMM JOINT RE, 2006, HUM HLTH, V63; *EUR FLAM RET ASS, FLAM RET FACT SHEET; European Brominated Flame Retardant Industry Panel (EBFRIP), 2007, EBFRIP QUEST NORW PR; FJELD E, 2004, 4809 NIVA; *FOOD STAND AGE, 2006, BROM CHEM FARM WILD; Food Standards Agency, 2006, BROM CHEM UK DIET IN; Frederiksen M, 2007, INT J ENVIRON AN CH, V87, P1095, DOI 10.1080/03067310701451178; FREDERIKSEN M, 2007, P 4 INT WORKSH BROM; Gallart-Ayala H, 2007, RAPID COMMUN MASS SP, V21, P4039, DOI 10.1002/rcm.3307; Ghisari M, 2005, MOL CELL ENDOCRINOL, V244, P31, DOI 10.1016/j.mce.2005.01.013; GRANBY K, 2007, P 4 INT WORKSH BROM; Gribble GJ, 2000, ENVIRON SCI POLLUT R, V7, P37, DOI 10.1065/espr199910.002; GUTZMAN D, 2004, P 3 INT WORKSH BROM; Hagmar L, 2000, ORGANOHALOGEN COMPOU, V47, P198; Hakk H, 2000, XENOBIOTICA, V30, P881; Hakk H., 2001, 2 INT WORKSH BROM FL; Hamers T, 2006, TOXICOL SCI, V92, P157, DOI 10.1093/toxsci/kfj187; Harrad S, 2008, ENVIRON INT, V34, P232, DOI 10.1016/j.envint.2007.08.008; Hayama T, 2004, J CHROMATOGR B, V809, P131, DOI 10.1016/j.jchromb.2004.06.013; Herzke D, 2005, CHEMOSPHERE, V61, P441, DOI 10.1016/j.chemosphere.2005.01.066; Hites RA, 2004, ENVIRON SCI TECHNOL, V38, P945, DOI 10.1021/es035082g; Inoue K, 2006, ARCH ENVIRON CON TOX, V51, P503, DOI 10.1007/s00244-005-0236-z; Jakobsson K, 2002, CHEMOSPHERE, V46, P709, DOI 10.1016/S0045-6535(01)00235-1; Jin J., 2006, ORGANOHALOGEN COMPD, V68, P85; Johnson-Restrepo B, 2008, CHEMOSPHERE, V70, P1935, DOI 10.1016/j.chemosphere.2007.10.002; Kester MHA, 2002, J CLIN ENDOCR METAB, V87, P1142, DOI 10.1210/jc.87.3.1142; Kikuchi S, 2004, ANAL SCI, V20, P1111, DOI 10.2116/analsci.20.1111; Kitamura S, 2002, BIOCHEM BIOPH RES CO, V293, P554, DOI 10.1016/S0006-291X(02)00262-0; Kitamura S, 2005, LIFE SCI, V76, P1589, DOI 10.1016/j.lfs.2004.08.030; Koppen R, 2006, ANAL BIOANAL CHEM, V384, P1485, DOI 10.1007/s00216-006-0339-z; KORYTAR P, 2005, J CHROMATOGR A, V1100, P20; Kuiper RV, 2007, ARCH TOXICOL, V81, P1, DOI 10.1007/s00204-006-0117-x; Law RJ, 2006, ENVIRON SCI TECHNOL, V40, P2177, DOI 10.1021/es052416o; Law RJ, 2006, CHEMOSPHERE, V64, P187, DOI 10.1016/j.chemosphere.2005.12.007; Lee HB, 2002, WATER QUAL RES J CAN, V37, P681; Leonards P., 2001, P 2 INT WORKSH BROM, P299; Llorca-Porcel J, 2006, ANAL CHIM ACTA, V569, P113, DOI 10.1016/j.aca.2006.03.100; Mariussen E, 2003, NEUROCHEM INT, V43, P533, DOI 10.1016/S0197-0186(03)00044-5; Meerts Ilonka A. T. M., 2001, Environmental Health Perspectives, V109, P399, DOI 10.2307/3454900; Meerts IATM, 2000, TOXICOL SCI, V56, P95, DOI 10.1093/toxsci/56.1.95; Morris S, 2004, ENVIRON SCI TECHNOL, V38, P5497, DOI 10.1021/es049640i; Morris S, 2006, TRAC-TREND ANAL CHEM, V25, P343, DOI 10.1016/j.trac.2005.11.006; Nagayama J., 2000, ORGANOHALOGEN COMPD, V48, P27; Oberg K, 2002, CHEMOSPHERE, V48, P805, DOI 10.1016/S0045-6535(02)00113-3; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Osako M, 2004, CHEMOSPHERE, V57, P1571, DOI 10.1016/j.chemosphere.2004.08.076; Papke O, 2004, TALANTA, V63, P1203, DOI 10.1016/j.talanta.2004.05.033; Peng H, 2007, CHINESE J ANAL CHEM, V35, P549; PLAITIN B, 1998, P FLAM RET 98 C LOND, P139; Pohlein M, 2005, J CHROMATOGR A, V1066, P111, DOI 10.1016/j.chroma.2005.01.036; Polo M, 2006, J CHROMATOGR A, V1124, P11, DOI 10.1016/j.chroma.2006.03.047; PRINS AM, 2000, P FLAM RET 2000 C LO, P77; Pullen S, 2003, TOXICOLOGY, V184, P11, DOI 10.1016/S0300-483X(02)00442-0; Quade S.C., 2003, ORGANOHALOGEN COMPD, V62, P327; Reistad T, 2005, TOXICOL SCI, V83, P89, DOI 10.1093/toxsci/kfh298; Saint-Louis R, 2004, ANALYST, V129, P724, DOI 10.1039/b400743n; Saito K, 2004, CHEMOSPHERE, V57, P373, DOI 10.1016/j.chemosphere.2004.04.050; Sambe H, 2006, J CHROMATOGR A, V1134, P16, DOI 10.1016/j.chroma.2006.08.072; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; SANTILLO D, 2003, GRLTN012003 KNOWL GR; Schlabach M., 2004, ORGANOHALOGEN COMPD, V66, P3730; Schlummer M, 2005, J CHROMATOGR A, V1064, P39, DOI 10.1016/j.chroma.2004.012.016; SELLSTROM U, 1995, CHEMOSPHERE, V31, P3085, DOI 10.1016/0045-6535(95)00167-7; Sjodin A, 2001, ENVIRON SCI TECHNOL, V35, P448, DOI 10.1021/es000077n; Sjodin A., 2000, THESIS STOCKHOLM U S; Sjodin A, 2003, ENVIRON INT, V29, P829, DOI 10.1016/S0160-4120(03)00108-9; Stapleton HM, 2007, ANAL BIOANAL CHEM, V387, P2365, DOI 10.1007/s00216-006-1054-5; Strack S, 2007, CHEMOSPHERE, V67, pS405, DOI 10.1016/j.chemosphere.2006.05.136; Suzuki S, 2006, ANAL SCI, V22, P469, DOI 10.2116/analsci.22.469; Takigami H, 2007, ORGANOHALOGEN COMPD, V69, P2785; Thomsen C, 2007, J CHROMATOGR B, V846, P252, DOI 10.1016/j.jchromb.2006.09.011; Thomsen C, 2001, J ENVIRON MONITOR, V3, P366, DOI 10.1039/b104304h; Thomsen C, 2002, ENVIRON SCI TECHNOL, V36, P1414, DOI 10.1021/es0102282; *UK COMM TOX CHEM, CONS PROD ENV; VASQUEZ AS, 2007, ANAL BIOANAL CHEM, V389, P683; Verslycke TA, 2005, ENVIRON POLLUT, V136, P19, DOI 10.1016/j.envpol.2004.12.008; Voordeckers JW, 2002, ENVIRON SCI TECHNOL, V36, P696, DOI 10.1021/es011081h; Vorkamp K, 2005, ENVIRON SCI TECHNOL, V39, P8199, DOI 10.1021/es0508830; WATANABE I, 1983, B ENVIRON CONTAM TOX, V31, P48, DOI 10.1007/BF01608765; *WHO, ENV HLTH CRIT, V172; Wong MH, 2007, ENVIRON POLLUT, V149, P131, DOI 10.1016/j.envpol.2007.01.044; WORRALL K, 2007, ORGANOHALOGEN COMPD, V69, P698; Xie ZY, 2007, ANAL CHIM ACTA, V584, P333, DOI 10.1016/j.aca.2006.10.062; YAAKOV YB, 2000, P FLAM RET 2000 C LO, P87; Yoshida Y., 2005, ORGANOHALOGEN COMPD, V67, P2127; Yu CH, 2007, J CHROMATOGR A, V1160, P71, DOI 10.1016/j.chroma.2007.05.042; Zalko D, 2006, CHEMOSPHERE, V64, P318, DOI 10.1016/j.chemosphere.2005.12.053; 2006, OFF J EUR COMM, V396, P1; 2000, OFF J EUR COMM L, V273, P5; 1919, RISK REDUCT IN PRESS, V3; 2003, OFF J EUR COMM L, V37, P24; 2006, EFSA J, V328, P112287ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSJ CHROMATOGR AJAN 16Discipline: Biochemistry &amp; Molecular Biology; Chemistry398WT</notes>
    <keywords>1; analysis; Analytical methods; BFR; BIOLOGY; BISPHENOL-A; brominated flame retardant; CANCER CELL-LINE; CELL; CHROMATOGRAPHY-MASS SPECTROMETRY; detection; development; diet; Environmental levels; EXPOSURE; FLAME RETARDANTS; FOOD; HEALTH; HUMAN EXPOSURE; HUMANS; IDENTIFICATION; INDUSTRY; MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; PHENOLIC-COMPOUNDS; POLYBROMINATED DIPHENYL ETHERS; QUANTIFICATION; Regulatory aspects; Review; RISK; Risk assessment; RISK-ASSESSMENT; SEWAGE-SLUDGE; TBBPA; TETRABROMOBISPHENOL-A; TETRACHLOROBISPHENOL-A; toxicology; UNITED-STATES; WATER; WATER SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>346</startpage>
    <endpage>363</endpage>
    <journalfull>Journal of Chromatography A</journalfull>
    <issue>3</issue>
    <volume>1216</volume>
    <abstract>The present article reviews the available literature on the analytical and environmental aspects of tetrabromobisphenol-A (TBBP-A), a currently intensively used brominated flame retardant (BFR). Analytical methods, including sample preparation, chromatographic separation, detection techniques, and quality control are discussed. An important recent development in the analysis of TBBP-A is the growing tendency for liquid chromatographic techniques. At the detection stage, mass-spectrometry is a well-established and reliable technology in the identification and quantification of TBBP-A. Although interlaboratory exercises for BFRs have grown in popularity in the last 10 years, only a few participating laboratories report concentrations for TBBP-A. Environmental levels of TBBP-A in abiotic and biotic matrices are low, probably due to the major use of TBBP-A as reactive FR. As a consequence, the expected human exposure is low. This is in agreement with the EU risk assessment that concluded that there is no risk for humans concerning TBBP-A exposure. Much less analytical and environmental information exists for the various groups of TBBP-A derivatives which are largely used as additive flame retardants. (C) 2008 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000262762900006</url>
    <isbnorissn>0021-9673</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>154</id>
    <title>Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells</title>
    <authors>Dairkee,S.H.; Luciani-Torres,M.G.; Moore,D.H.; Goodson,W.H.</authors>
    <availability>[Dairkee, Shanaz H.; Luciani-Torres, M. Gloria; Moore, Dan H.; Goodson, William H., III] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleDairkee, SH (reprint author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St, San Francisco, CA 94107 USAdairkes@cpmcri.org; goodsow@cpmcri.orgArmengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Chaudhury LR, 2003, J CELL BIOCHEM, V89, P1, DOI 10.1002/jcb.10495; Colerangle JB, 1997, J STEROID BIOCHEM, V60, P153, DOI 10.1016/S0960-0760(96)00130-6; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.1210452; Dookeran KA, 2010, ANN SURG ONCOL, V17, P1398, DOI 10.1245/s10434-009-0889-3; Fajardo AM, 2012, PROSTATE, V72, P612, DOI 10.1002/pros.21464; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gonzalez MA, 2003, J CLIN ONCOL, V21, P4306, DOI 10.1200/JCO.2003.04.121; Goodson WH, 2011, CARCINOGENESIS, V32, P1724, DOI 10.1093/carcin/bgr196; Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507; Gu JJ, 2001, CANCER RES, V61, P1741; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Han XZ, 2012, CARCINOGENESIS, V33, P868, DOI 10.1093/carcin/bgs029; Konstantin C., 1991, AM J PATHOL, V138, P1371; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lykkesfeldt A E, 1986, Breast Cancer Res Treat, V7 Suppl, pS83; Miecznikowski JC, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-573; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ramachandran C, 1999, BREAST CANCER RES TR, V54, P269, DOI 10.1023/A:1006170224414; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724; Schultz-Norton JR, 2007, NUCLEIC ACIDS RES, V35, P5028, DOI 10.1093/nar/gkm533; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; Statistics Canada, BISPH CONC CAN POP 2; Teeguarden JG, 2011, TOXICOL SCI, V123, P48, DOI 10.1093/toxsci/kfr160; Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109; TODOROV IT, 1991, BIOCHEM BIOPH RES CO, V177, P395, DOI 10.1016/0006-291X(91)91996-P; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Verma SP, 1998, ENVIRON HEALTH PERSP, V106, P807, DOI 10.2307/3434124; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Yu J, 2006, CANCER RES, V66, P9461, DOI 10.1158/0008-5472.CAN-06-1895421OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDCARCINOGENESISMARDiscipline: Oncology099NR</notes>
    <keywords>ACTIVATION; ANTIGEN; apoptosis; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; cell cycle; cell death; CELL-CYCLE; CELL-DEATH; CELLS; CHECKPOINT; curcumin; CYCLE; DEATH; EPITHELIAL-CELLS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; GROWTH; HEALTH; LI-FRAUMENI-SYNDROME; LINE; LINES; MAMMALIAN TARGET; MAMMARY-GLAND; oncology; POSTMENOPAUSAL WOMEN; PREVENTION; proliferation; Prostate; PROSTATE-CANCER CELLS; PROTEIN; PROTEINS; RECEPTOR; SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>703</startpage>
    <endpage>712</endpage>
    <journalfull>Carcinogenesis</journalfull>
    <issue>3</issue>
    <volume>34</volume>
    <abstract>Widespread distribution of bisphenol-A (BPA) complicates epidemiological studies of possible carcinogenic effects on the breast because there are few unexposed controls. To address this challenge, we previously developed non-cancerous human high-risk donor breast epithelial cell (HRBEC) cultures, wherein BPA exposure could be controlled experimentally. BPA consistently induced activation of the mammalian target of rapamycin (mTOR) pathwayuaccompanied by dose-dependent evasion of apoptosis and increased proliferationuin HRBECs from multiple donors. Here, we demonstrate key molecular changes underlying BPA-induced cellular reprogramming. In 3/3 BPA-exposed HRBEC cell lines, and in T47D breast cancer cells, proapoptotic negative regulators of the cell cycle (p53, p21(WAF1) and BAX) were markedly reduced, with concomitant increases in proliferation-initiating gene products (proliferating cell nuclear antigen, cyclins, CDKs and phosphorylated pRb). However, simultaneous exposure to BPA and the polyphenol, curcumin, partially or fully reduced the spectrum of effects associated with BPA alone, including mTOR pathway proteins (AKT1, RPS6, pRPS6 and 4EBP1). BPA exposure induced an increase in the ER (Estrogen Receptor): ER ratiouan effect also reversed by curcumin (analysis of variance, P &lt; 0.02 for all test proteins). At the functional level, concurrent curcumin exposure reduced BPA-induced apoptosis evasion and rapid growth kinetics in all cell lines to varying degrees. Moreover, BPA extended the proliferation potential of 6/6 primary finite-life HRBEC culturesuanother effect reduced by curcumin. Even after removal of BPA, 1/6 samples maintained continuous growthua hallmark of cancer. We show that BPA exposure induces aberrant expression of multiple checkpoints that regulate cell survival, proliferation and apoptosis and that such changes can be effectively ameliorated</abstract>
    <url>WOS:000315629000024</url>
    <isbnorissn>0143-3334</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>91</id>
    <title>Endocrine Disruptors Differentially Target ATP-Binding Cassette Transporters in the Blood-Testis Barrier and Affect Leydig Cell Testosterone Secretion In Vitro</title>
    <authors>Dankers,A.C.A.; Roelofs,M.J.E.; Piersma,A.H.; Sweep,F.C.G.J.; Russel,F.G.M.; van den Berg,M.; van Duursen,M.B.M.; Masereeuw,R.</authors>
    <availability>[Dankers, Anita C. A.; Russel, Frans G. M.; Masereeuw, Rosalinde] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol &amp; Toxicol, NL-6500 HB Nijmegen, Netherlands. [Roelofs, Maarke J. E.; Piersma, Aldert H.; van den Berg, Martin; van Duursen, Majorie B. M.] Univ Utrecht, Endocrine Toxicol Res Grp, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands. [Sweep, Fred C. G. J.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, NL-6500 HB Nijmegen, Netherlands. [Roelofs, Maarke J. E.; Piersma, Aldert H.] Natl Inst Publ Hlth &amp; Environm, Ctr Hlth Protect, NL-3720 BA Bilthoven, Netherlands.</availability>
    <date>2013</date>
    <notes>JEnglishArticleMasereeuw, R (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol &amp; Toxicol, Internal Postal Code 149,POB 9101, NL-6500 HB Nijmegen, NetherlandsR.Masereeuw@pharmtox.umcn.nlASCOLI M, 1981, ENDOCRINOLOGY, V108, P88; Bart J, 2004, EUR J CANCER, V40, P2064, DOI 10.1016/j.ejca.2004.05.010; BELANGER B, 1989, J STEROID BIOCHEM, V32, P695, DOI 10.1016/0022-4731(89)90514-1; BurgosTrinidad M, 1997, MOL ENDOCRINOL, V11, P87, DOI 10.1210/me.11.1.87; Canton RF, 2005, TOXICOL SCI, V88, P447, DOI 10.1093/toxsci/kfi325; Chen ZS, 2003, CANCER RES, V63, P4048; Cheng CY, 2012, PHARMACOL REV, V64, P16, DOI 10.1124/pr.110.002790; Choo EF, 2000, DRUG METAB DISPOS, V28, P655; Clewell RA, 2010, TOXICOL IN VITRO, V24, P327, DOI 10.1016/j.tiv.2009.08.003; Dankers ACA, 2012, CELL TISSUE RES, V349, P551, DOI 10.1007/s00441-012-1417-5; Devoto L, 2002, MOL CELL ENDOCRINOL, V186, P137, DOI 10.1016/S0303-7207(01)00654-2; Enokizono J, 2007, MOL PHARMACOL, V72, P967, DOI 10.1124/mol.107.034751; Ge RS, 2006, P NATL ACAD SCI USA, V103, P2719, DOI 10.1073/pnas.0507692103; Heger NE, 2012, ENVIRON HEALTH PERSP, V120, P1137, DOI 10.1289/ehp.1104711; Jensen AA, 2008, INT J ANDROL, V31, P161, DOI 10.1111/j.1365-2605.2008.00870.x; Johnson KJ, 2012, TOXICOL SCI, V129, P235, DOI 10.1093/toxsci/kfs206; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kundakovic M, 2013, P NATL ACAD SCI USA, V110, P9956, DOI 10.1073/pnas.1214056110; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Law RJ, 2006, CHEMOSPHERE, V64, P187, DOI 10.1016/j.chemosphere.2005.12.007; Makker K, 2009, INDIAN J MED RES, V129, P357; Matsuo H, 2009, SCI TRANSL MED, V1, DOI 5; Mazur CS, 2012, TOXICOL SCI, V128, P317, DOI 10.1093/toxsci/kfs167; Mitchell RT, 2012, J CLIN ENDOCR METAB, V97, pE341, DOI 10.1210/jc.2011-2411; Morgan JA, 2012, J BIOL CHEM, V287, P14456, DOI 10.1074/jbc.M111.319681; Ochsenkuhn R, 2003, INT J ANDROL, V26, P195, DOI 10.1046/j.1365-2605.2003.00381.x; Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003; Robillard KR, 2012, J PHARMACOL EXP THER, V340, P96, DOI 10.1124/jpet.111.186916; Roelofs MJE, 2013, TOXICOL APPL PHARM, V268, P309, DOI 10.1016/j.taap.2013.01.033; Russel FGM, 2008, TRENDS PHARMACOL SCI, V29, P200, DOI 10.1016/j.tips.2008.01.006; Schauer UMD, 2006, TOXICOL SCI, V91, P49, DOI 10.1093/toxsci/kfj132; Sharlip ID, 2002, FERTIL STERIL, V77, P873, DOI 10.1016/S0015-0282(02)03105-9; Su LL, 2009, INT J BIOCHEM CELL B, V41, P2578, DOI 10.1016/j.biocel.2009.08.015; Su LL, 2011, J ENDOCRINOL, V208, P207, DOI 10.1677/JOE-10-0363; Trbovich AM, 2004, J STEROID BIOCHEM, V92, P199, DOI 10.1016/j.jsbmb.2004.07.002; Van der Ven LTM, 2008, TOXICOLOGY, V245, P76, DOI 10.1016/j.tox.2007.12.009; van Herwaarden AE, 2007, MOL CELL BIOL, V27, P1247, DOI 10.1128/MCB.01621-06; Wittgen HGM, 2012, MOL PHARMACEUT, V9, P1351, DOI 10.1021/mp200617z; Wittgen HGM, 2011, DRUG METAB DISPOS, V39, P1294, DOI 10.1124/dmd.110.037812; Woodward OM, 2009, P NATL ACAD SCI USA, V106, P10338, DOI 10.1073/pnas.0901249106403OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIDECDiscipline: Toxicology275RQ</notes>
    <keywords>ABC transporters; bisphenol; bisphenol A; BISPHENOL-A; blood-testis barrier; BPA; breast cancer; breast cancer resistance protein; BREAST-CANCER; BROMINATED FLAME RETARDANTS; CANCER; CANCER RESISTANCE PROTEIN; CELL; CELLS; CHEMICALS; EDCs; EFFLUX; ENDOCRINE; Endocrine disrupting chemicals; endocrine disrupting chemicals (EDCs); Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; EXPOSURE; EXPRESSION; In vitro; IN-VITRO; inhibition; Interaction; MA-10 mouse Leydig cells; MALE-INFERTILITY; P-GLYCOPROTEIN; phthalate; Phthalates; PROTEIN; PROTEINS; RATS; RISK; RISK-ASSESSMENT; Steroid hormone; steroidogenesis; TETRABROMOBISPHENOL-A; TISSUE; TOXICITY; toxicology; TYPE-1 RECEPTOR ANTAGONISTS; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>382</startpage>
    <endpage>391</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>2</issue>
    <volume>136</volume>
    <abstract>Endocrine-disrupting chemicals (EDCs) are considered to cause testicular toxicity primarily via interference with steroid hormone function. Alternatively, EDCs could possibly exert their effects by interaction with ATP-binding cassette (ABC) transporters that are expressed in the blood-testis barrier. In this study, we investigated the effects of bisphenol A (BPA), tetrabromobisphenol A (TBBPA), bis(2-ethylhexyl) phthalate, mono(2-ethylhexyl) phthalate, perfluorooctanoic acid (PFOA), and perfluorooctanesulfonic acid (PFOS) on breast cancer resistance protein (BCRP), multidrug resistance proteins 1 and 4 (MRP1 and MRP4), and P-glycoprotein (P-gp) using membrane vesicles overexpressing these transporters. BPA solely inhibited BCRP activity, whereas TBBPA, PFOA, and PFOS inhibited all transporters tested. No effect was observed for the phthalates. Using transporter-overexpressing Madin-Darby canine kidney cells, we show that BPA and PFOA, but not TBBPA, are transported by BCRP, whereas none of the compounds were transported by P-gp. To investigate the toxicological implications of these findings, testosterone secretion and expression of steroidogenic genes were determined in murine Leydig (MA-10) cells upon exposure to the selected EDCs. Only BPA and TBBPA concentration dependently increased testosterone secretion by MA-10 cells to 6- and 46-fold of control levels, respectively. Inhibition of the Mrps by MK-571 completely blocked testosterone secretion elicited by TBBPA, which could not be explained by coinciding changes in expression of steroidogenic genes. Therefore, we hypothesize that transporter-mediated efflux of testosterone precursors out of MA-10 cells is inhibited by TBBPA resulting in higher availability for testosterone production. Our data show the toxicological and clinical relevance of ABC transporters in EDC risk assessment related to testicular toxicity</abstract>
    <url>WOS:000328695500010</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>158</id>
    <title>Environmental oestrogens and breast cancer: long-term low-dose effects of mixtures of various chemical combinations</title>
    <authors>Darbre,P.D.; Fernandez,M.F.</authors>
    <availability>[Darbre, Philippa D.] Univ Reading, Sch Biol Sci, Biomed Sci Sect, Reading RG6 6UB, Berks, England. [Fernandez, Mariana F.] Univ Granada, Lab Med Invest, Granada, Spain. [Fernandez, Mariana F.] San Cecilio Univ Hosp, Granada, Spain.</availability>
    <date>2013</date>
    <notes>JEnglishEditorial MaterialDarbre, PD (reprint author), Univ Reading, Sch Biol Sci, Biomed Sci Sect, Hopkins Bldg, Reading RG6 6UB, Berks, Englandp.d.darbre@reading.ac.ukBarr L, 2012, J APPL TOXICOL, V32, P219, DOI 10.1002/jat.1786; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Cerrillo I, 2006, CHEMOSPHERE, V62, P1917, DOI 10.1016/j.chemosphere.2005.07.024; Calle EE, 1996, LANCET, V347, P1713; Cuzick J, 2008, EUR J CANCER, V44, P2344, DOI 10.1016/j.ejca.2008.07.041; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2012, HORM MOL BIOL CLIN I, V9, P65; Darbre PD, 2010, ANTICANCER RES, V30, P815; Fernandez MF, 2008, CHEMOSPHERE, V71, P1196, DOI 10.1016/j.chemosphere.2007.09.064; Fernandez MF, 2007, CHEMOSPHERE, V66, P377, DOI 10.1016/j.chemosphere.2006.04.065; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Fernandez MF, 2004, ANAL BIOANAL CHEM, V379, P163, DOI 10.1007/s00216-004-2558-5; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henkler F, 2011, J EPIDEMIOL COMMUN H, V65, P1, DOI 10.1136/jech.2008.083881; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Howard SG, 2012, J EPIDEMIOL COMMUN H, V66, P479, DOI 10.1136/jech.2011.133694; Hoyo C, 2009, J EPIDEMIOL COMMUN H, V63, P683, DOI 10.1136/jech.2009.090803; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Kbuk K, 2012, J EPIDEMIOL COMMUNIT, V66, P1; Khanna S, 2012, J APPL TOXICOL; Lopez-Espinosa MJ, 2009, CHEMOSPHERE, V76, P847, DOI 10.1016/j.chemosphere.2009.03.063; Lopez-Espinosa MJ, 2008, CHEMOSPHERE, V73, P967, DOI 10.1016/j.chemosphere.2008.06.039; Banks E, 2003, LANCET, V362, P419; Olea N, 2007, J EPIDEMIOL COMMUN H, V61, P372, DOI 10.1136/jech.2006.047860; Payne J, 2001, ENVIRON HEALTH PERSP, V109, P391, DOI 10.2307/3454899; Porta M, 2004, J EPIDEMIOL COMMUN H, V58, P534, DOI 10.1136/jech.2004.021238; Porta M, 2012, ENVIRON INT, V44, P106, DOI 10.1016/j.envint.2012.02.005; Romano D, 2010, J EPIDEMIOL COMMUN H, V64, P193, DOI 10.1136/jech.2008.085282; Santen RJ, 2010, J CLIN ENDOCRINOL S1, V95, P51; Soto AM, 1997, ENVIRON HEALTH PERSP, V105, P647, DOI 10.2307/3433384; Stein RA, 2012, J EPIDEMIOL COMMUN H, V66, P8, DOI 10.1136/jech.2010.130690; Stuckey A, 2011, CLIN OBSTET GYNECOL, V54, P96, DOI 10.1097/GRF.0b013e3182080056; Tickner JA, 2011, J EPIDEMIOL COMMUN H, V65, P649, DOI 10.1136/jech.2010.112706; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Viso AC, 2009, J EPIDEMIOL COMMUN H, V63, P623, DOI 10.1136/jech.2008.083709; Woodruff TJ, 2010, J EPIDEMIOL COMMUN H, V64, P307, DOI 10.1136/jech.2009.091108376BMJ PUBLISHING GROUPLONDONBRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLANDJ EPIDEMIOL COMMUN HMARDiscipline: Public, Environmental &amp; Occupational Health089MF</notes>
    <keywords>ADIPOSE-TISSUE; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELL; COMBINATION; DIETHYLSTILBESTROL; Environmental oestrogen; EXPOSURE; HEALTH; HORMONE-REPLACEMENT THERAPY; oestrogen; POLLUTANTS; RISK; SOUTHERN SPAIN; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>203</startpage>
    <endpage>205</endpage>
    <journalfull>Journal of Epidemiology and Community Health</journalfull>
    <issue>3</issue>
    <volume>67</volume>
    <url>WOS:000314914000001</url>
    <isbnorissn>0143-005X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>278</id>
    <title>Overlapping nongenomic and genomic actions of thyroid hormone and steroids</title>
    <authors>Davis,P.J.; Lin,H.Y.; Mousa,S.A.; Luidens,M.K.; Hercbergs,A.A.; Wehling,M.; Davis,F.B.</authors>
    <availability>[Davis, Paul J.; Lin, Hung-Yun; Luidens, Mary K.; Davis, Faith B.] Ordway Res Inst, Signal Transduct Lab, Albany, NY 12208 USA. [Davis, Paul J.; Mousa, Shaker A.] Albany Coll Pharm, Pharmaceut Res Inst, Albany, NY USA. [Davis, Paul J.; Luidens, Mary K.] Albany Coll Pharm, Div Endocrinol, Dept Med, Albany, NY USA. [Hercbergs, Aleck A.] Cleveland Clin, Cleveland, OH 44106 USA. [Wehling, Martin] Univ Heidelberg, Fac Med Mannheim, D-6800 Mannheim, Germany.</availability>
    <date>2011</date>
    <notes>JEnglishReviewDavis, PJ (reprint author), Ordway Res Inst, Signal Transduct Lab, 150 New Scotland Ave, Albany, NY 12208 USApdavis@ordwayresearch.orgALTAMIRANO F, 2009, J ENDOCRINOL, V202, P290; BALDAZZI V, 2010, UROL ONCOL 0928; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; CAO HJ, 2009, ENDOCR RES, V34, P101; Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093; Chen YF, 2008, J MOL CELL CARDIOL, V44, P180, DOI 10.1016/j.yjmcc.2007.09.009; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Davis PJ, 2002, J ENDOCRINOL INVEST, V25, P377; Davis PJ, 2010, AM J PHYSIOL-CELL PH, V299, pC1250, DOI 10.1152/ajpcell.00410.2010; Davis PJ, 2000, J BIOL CHEM, V275, P38032, DOI 10.1074/jbc.M002560200; Davis PJ, 2011, ANNU REV PHARMACOL, V51, P99, DOI 10.1146/annurev-pharmtox-010510-100512; Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331; Di Fulvio M, 2000, J ENDOCRINOL, V166, P173, DOI 10.1677/joe.0.1660173; Dinda S, 2002, ONCOGENE, V21, P761, DOI 10.1038/sj.onc.1205136; Frantz S, 2007, J PHYSIOL PHARMACOL, V58, P717; GOLDMAN S, 1993, MOL CELL ENDOCRINOL, V96, P125, DOI 10.1016/0303-7207(93)90102-P; GOODMAN AD, 1980, CANCER RES, V40, P2336; Hatzoglou A, 2005, J CLIN ENDOCR METAB, V90, P893, DOI 10.1210/jc.2004-0801; Heimeier RA, 2010, GEN COMP ENDOCR, V168, P181, DOI 10.1016/j.ygcen.2010.02.016; Heimeier RA, 2009, ENDOCRINOLOGY, V150, P2964, DOI 10.1210/en.2008-1503; Hercbergs AA, 2003, ANTICANCER RES, V23, P617; Ikeda Y, 2010, MOL ENDOCRINOL, V24, P1338, DOI 10.1210/me.2009-0402; JUHASZ B, 2010, CURR PHARM BIOT 0928; Kaneko M, 2008, GEN COMP ENDOCR, V155, P574, DOI 10.1016/j.ygcen.2007.09.009; Kansakar E, 2009, AM SURGEON, V75, P785; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kawaguchi T, 2006, CANCER RES, V66, P11331, DOI 10.1158/0008-5472.CAN-06-1540; Kennessey A, 2006, J BIOL CHEM, V281, P20666; Klemperer JD, 1996, ANN THORAC SURG, V61, P1323, DOI 10.1016/0003-4975(96)00102-6; Kok M, 2009, J NATL CANCER I, V101, P1725, DOI 10.1093/jnci/djp412; Kumar A, 2010, INT J ONCOL, V36, P1067, DOI 10.3892/ijo_00000588; Kuzman JA, 2007, ENDOCRINOLOGY, V148, P3477, DOI 10.1210/en.2007-0099; Levin ER, 2009, TRENDS ENDOCRIN MET, V20, P477, DOI 10.1016/j.tem.2009.06.009; Levin ER, 2008, BREAST CANCER RES TR, V108, P351, DOI 10.1007/s10549-007-9618-4; LIN HY, 2007, THYROID S, V1; LIN HY, 2003, BIOCHEMISTRY-US, V40, P2870; Lin HY, 2007, STEROIDS, V72, P180, DOI 10.1016/j.steroids.2006.11.014; Lin HY, 2009, CELL CYCLE, V8, P1877, DOI 10.4161/cc.8.12.8747; Lin HY, 2008, CARCINOGENESIS, V29, P62, DOI 10.1093/carcin/bgm239; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lin HY, 2009, J STEROID BIOCHEM, V113, P182, DOI 10.1016/j.jsbmb.2008.12.010; Lin HY, 2008, J CELL BIOCHEM, V104, P2131, DOI 10.1002/jcb.21772; Machens A, 2006, CLIN ENDOCRINOL, V65, P500, DOI 10.1111/j.1365-2265.2006.02623.x; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Moeller Lars C, 2006, Nucl Recept Signal, V4, pe020; Narayanan R, 2008, MOL ENDOCRINOL, V22, P2448, DOI 10.1210/me.2008-0160; PRATT RD, 1984, BIOCHIM BIOPHYS ACTA, V805, P405, DOI 10.1016/0167-4889(84)90024-7; Rebbaa A, 2008, ANGIOGENESIS, V11, P269, DOI 10.1007/s10456-008-9110-8; RIESENBECK LM, 2010, WORLD J UROL 1228; SCHMIDINGER M, 2010, CANCER 0915; SHAH JP, 1992, AM J SURG, V164, P658, DOI 10.1016/S0002-9610(05)80729-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Shih A, 2004, ENDOCRINOLOGY, V145, P1708, DOI 10.1210/en.2003-0742; Shih A, 2001, BIOCHEMISTRY-US, V40, P2870, DOI 10.1021/bi001978b; Sun H, 2009, TOXICOL IN VITRO, V23, P950, DOI 10.1016/j.tiv.2009.05.004; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Vasudevan N, 2001, NEUROENDOCRINOLOGY, V74, P309, DOI 10.1159/000054698; Vasudevan N, 2001, J NEUROENDOCRINOL, V13, P779, DOI 10.1046/j.1365-2826.2001.00693.x; YALCIN M, 2009, THYROID, V20, P281; Yalcin M, 2010, J CLIN ENDOCR METAB, V95, P1972, DOI 10.1210/jc.2009-1926; Yalcin M, 2009, ANTICANCER RES, V29, P3825; Zhang S, 2004, BRIT J CANCER, V91, P178, DOI 10.1038/sj.bjc.6601902; Zhao X, 2005, P NATL ACAD SCI USA, V102, P4890, DOI 10.1073/pnas.0501042102; Zhu WQ, 2009, CIRCULATION, V119, P99, DOI 10.1161/CIRCULATIONAHA.108.799700; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.270586712ELSEVIER SCIENCE INCNEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USASTEROIDSAUGSIDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism799YH</notes>
    <keywords>3,5,3 '-Triiodo-L-thyronine; ACTIVATED PROTEIN-KINASE; Androgen; androgens; ANGIOGENESIS; BIOLOGY; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER CELLS; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; CELLS; CYCLE; EPIDERMAL-GROWTH-FACTOR; Estrogen; ESTROGEN-RECEPTOR; ESTROGENS; genomic effects; GLIOMA-CELLS; heart; Hormones; HUMAN-BREAST-CANCER; In vitro; IN-VITRO; KINASE; METABOLISM; Nongenomic; NONGENOMIC ACTIONS; Nuclear receptor; NUCLEAR RECEPTORS; ORGANIZATION; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA; PLASMA-MEMBRANE; proliferation; PROTEIN; RECEPTOR; Receptors; SERINE PHOSPHORYLATION; TARGET; Testosterone; TETRAIODOTHYROACETIC ACID; Thyroxine; TUMOR; TUMORS; VERTEBRATE DEVELOPMENT; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>829</startpage>
    <endpage>833</endpage>
    <journalfull>Steroids</journalfull>
    <issue>9</issue>
    <volume>76</volume>
    <abstract>Nuclear receptors for thyroid hormone and steroids are members of a receptor superfamily with similar molecular organization, but discrete transcriptional functions that define genomic actions of these non-peptide hormones. Nongenomic actions of thyroid hormone and estrogens and androgens are initiated outside the nucleus, at receptors in the plasma membrane or in cytoplasm; these actions are largely regarded to be unique to the respective hormones. However, there is an increasing number of descriptions of overlapping nongenomic and genomic effects of thyroid hormone and estrogens and testosterone. These effects are concentrated in tumor cells, where, for example, estrogens and thyroid hormone have similar mitogen-activate protein kinase (MAPK)-dependent proliferative actions on ER alpha-positive human breast cancer cells, and where dihydrotestosterone also can stimulate proliferation. Steroids and thyroid hormone have similar anti-apoptotic effects in certain tumors. But thyroid hormone and steroids also have overlapping or interacting nongenomic and genomic actions in heart and brain cells. These various effects of thyroid hormone and estrogens and androgens are reviewed here and their possible clinical consequences are enumerated. (C) 2011 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000293322200003</url>
    <isbnorissn>0039-128X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>279</id>
    <title>Upregulation of Clusterin in Prostate and DNA Damage in Spermatozoa from Bisphenol A-Treated Rats and Formation of DNA Adducts in Cultured Human Prostatic Cells</title>
    <authors>De Flora,S.; Micale,R.T.; La Maestra,S.; Izzotti,A.; D'Agostini,F.; Camoirano,A.; Davoli,S.A.; Troglio,M.G.; Rizzi,F.; Davalli,P.; Bettuzzi,S.</authors>
    <availability>[De Flora, Silvio; Micale, Rosanna T.; La Maestra, Sebastiano; Izzotti, Alberto; D'Agostini, Francesco; Camoirano, Anna] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy. [Davoli, Serena A.; Troglio, Maria Giovanna; Rizzi, Federica; Bettuzzi, Saverio] Univ Parma, Dept Expt Med, I-43100 Parma, Italy. [Davalli, Pierpaola] Univ Modena &amp; Reggio Emilia, Dept Biomed Sci, I-41125 Modena, Italy.</availability>
    <date>2011</date>
    <notes>JEnglishArticleDe Flora, S (reprint author), Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italysdf@unige.itASTANCOLLE S, 2000, J ENDOCRINOL, V167, P199; ATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; Berthon P, 1997, INT J CANCER, V73, P910; Bettuzzi S, 2009, ADV CANCER RES, V104, P59, DOI 10.1016/S0065-230X(09)04005-6; BETTUZZI S, 1989, BIOCHEM J, V257, P293; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Bonde JP, 2010, ASIAN J ANDROL, V12, P152, DOI 10.1038/aja.2009.83; Bosland MC., 2000, J NATL CANC I MONOGR, V27, P39; Caccamo AE, 2005, CELL DEATH DIFFER, V12, P101, DOI 10.1038/sj.cdd.4401491; Caccamo AE, 2004, BIOCHEM J, V382, P157; Carruba G, 2007, J CELL BIOCHEM, V102, P899, DOI 10.1002/jcb.21529; Cavalieri E, 2006, ANN NY ACAD SCI, V1089, P286, DOI 10.1196/annals.1386.042; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; COLBORN T, 1992, CHEM INDUCED ALTERAT, P1; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Edmonds JS, 2004, BIOCHEM BIOPH RES CO, V319, P556, DOI 10.1016/j.bbrc.2004.05.024; Ellem SJ, 2004, J CLIN ENDOCR METAB, V89, P2434, DOI 10.1210/jc.2003-030933; Fernandez JL, 2003, J ANDROL, V24, P59; Filippi S, 2002, ENDOCRINOLOGY, V143, P4271, DOI 10.1210/en.2002-220384; Girard FP, 2010, NEOPLASMA, V57, P488, DOI 10.4149/neo_2010_05_488; Hruba E, 2010, TOXICOL LETT, V197, P227, DOI 10.1016/j.toxlet.2010.06.004; *INT AG RES CANC, 1979, IARC MON EV CARC RIS, V21; Izzotti A, 2010, CURR CANCER DRUG TAR, V10, P147; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; KAIGHN ME, 1979, INVEST UROL, V17, P16; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Li DK, 2011, FERTIL STERIL, V95, P625, DOI 10.1016/j.fertnstert.2010.09.026; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; MARINELLI M, 1994, BIOCHEM CELL BIOL, V72, P515; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Minamiyama Y, 2010, FREE RADICAL RES, V44, P1398, DOI 10.3109/10715762.2010.510523; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PIKE MC, 1993, EPIDEMIOL REV, V15, P17; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Stahelin BJ, 1998, J CLIN PATHOL-MOL PA, V51, P204; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Takabashi O, 2001, ARCH TOXICOL, V75, P42, DOI 10.1007/s002040000204; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3&lt;206::AID-EM8&gt;3.0.CO;2-J; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; VANSCHOOTEN FJ, 1990, CARCINOGENESIS, V11, P1677, DOI 10.1093/carcin/11.9.1677; Yang L, 2009, PROSTATE, V69, P41, DOI 10.1002/pros.20850; Yoo SD, 2001, J TOXICOL ENV HEAL A, V64, P417, DOI 10.1080/1528739017531707404614OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIJULDiscipline: Toxicology800CT</notes>
    <keywords>apoptosis; ASSAY; BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BONE; BONE-MARROW; BPA; breast; CANCER; CARCINOGENESIS; CARCINOMA; CELL; cell death; CELL-DEATH; CELLS; clusterin; Comet assay; DAMAGE; DEATH; DNA adducts; DNA damage; DNA-DAMAGE; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; EPITHELIAL-CELLS; ESTROGENS; EXPOSURE; EXPRESSION; female; FEMALE MICE; HEALTH; HUMAN EXPOSURE; IN-VITRO; LINE; LINES; Lipid peroxidation; LIPID-PEROXIDATION; Liver; low dose; Lymphocytes; Male; MAMMARY TISSUE; mechanism; MECHANISMS; MESSENGER-RNA; MICE; Prostate; RAT; RATS; RISK; SPERM; spermatozoa; SPRAGUE-DAWLEY RATS; TISSUE; toxicology; VENTRAL PROSTATE; WATER; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>45</startpage>
    <endpage>51</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>1</issue>
    <volume>122</volume>
    <abstract>Among endocrine disruptors, the xenoestrogen bisphenol A (BPA) deserves particular attention due to widespread human exposure. Besides hormonal effects, BPA has been suspected to be involved in breast and prostate carcinogenesis, which share similar estrogen-related mechanisms. We previously demonstrated that administration of BPA to female mice results in the formation of DNA adducts and proteome alterations in the mammary tissue. Here, we evaluated the ability of BPA, given with drinking water, to induce a variety of biomarker alterations in male Sprague-Dawley rats. In addition, we investigated the formation of DNA adducts in human prostate cell lines. In BPA-treated rats, no DNA damage occurred in surrogate cells including peripheral blood lymphocytes and bone marrow erythrocytes, where no increase of single-strand DNA breaks was detectable by comet assay and the frequency of micronucleated cells was unaffected by BPA. Liver cells were positive at transferase dUTP nick end labeling assay, which detects both single-strand and double-strand breaks and early stage apoptosis. BPA upregulated clusterin expression in atrophic prostate epithelial cells and induced lipid peroxidation and DNA fragmentation in spermatozoa. Significant levels of DNA adducts were formed in prostate cell lines treated either with high-dose BPA for 24 h or low-dose BPA for 2 months. The BPA-related increase of DNA adducts was more pronounced in PNT1a nontumorigenic epithelial cells than in PC3 metastatic carcinoma cells. On the whole, these experimental findings support mechanistically the hypothesis that BPA may play a role in prostate carcinogenesis and may, potentially, affect the quality of sperm</abstract>
    <url>WOS:000293337500006</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>339</id>
    <title>Capillary electrophoresis characterization of molecularly imprinted polymer particles in fast binding with 17 beta-estradiol</title>
    <authors>DeMaleki,Z.; Lai,E.P.C.; Dabek-Zlotorzynska,E.</authors>
    <availability>[DeMaleki, Zack; Lai, Edward. P. C.; Dabek-Zlotorzynska, Ewa] Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada. [Dabek-Zlotorzynska, Ewa] Environm Canada, S&amp;T Branch, Air Qual Res Div, Anal &amp; Air Qual Sect, Ottawa, ON K1A 0H3, Canada.</availability>
    <date>2010</date>
    <notes>JEnglishArticleLai, EPC (reprint author), Carleton Univ, Dept Chem, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canadaedward_lai@carleton.caBesse JP, 2008, TOXICOL LETT, V176, P104, DOI 10.1016/j.toxlet.2007.10.012; Buszewski B, 2007, BIOMED CHROMATOGR, V21, P116, DOI 10.1002/bmc.733; Cajthaml T, 2009, ENVIRON POLLUT, V157, P3325, DOI 10.1016/j.envpol.2009.06.027; Cargouet M, 2006, ENVIRON TOXICOL PHAR, V22, P104, DOI 10.1016/j.etap.2006.01.002; Chiu JH, 2008, J CHROMATOGR B, V875, P383, DOI 10.1016/j.jchromb.2008.09.014; Dabek-Zlotorzynska E, 2007, ELECTROPHORESIS, V28, P3526, DOI 10.1002/elps.200700109; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; Deering CE, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-18; d'Orlye F, 2008, J CHROMATOGR A, V1204, P226, DOI 10.1016/j.chroma.2008.08.008; Falconer IR, 2006, ENVIRON TOXICOL, V21, P181, DOI 10.1002/tox.20172; Gabet V, 2007, TRAC-TREND ANAL CHEM, V26, P1113, DOI 10.1016/j.trac.2007.10.003; Gadd JB, 2010, ENVIRON POLLUT, V158, P730, DOI 10.1016/j.envpol.2009.10.015; Garcia-Canas V, 2007, ELECTROPHORESIS, V28, P4013, DOI 10.1002/elps.200700253; Helle A, 2008, J CHROMATOGR A, V1178, P248, DOI 10.1016/j.chroma.2007.11.041; HOLLAND N, 2009, POLYMER, V51, P1578; Irmak S, 2005, J HAZARD MATER, V126, P54, DOI 10.1016/j.jhazmat.2005.05.045; Jiang TH, 2009, TALANTA, V78, P442, DOI 10.1016/j.talanta.2008.11.047; Kuo YC, 2009, COLLOID SURFACE B, V72, P201, DOI 10.1016/j.colsurfb.2009.04.004; Pereira Mark, 2008, Journal of Nanobiotechnology, V6, P10, DOI 10.1186/1477-3155-6-10; Lai EPC, 2010, J APPL POLYM SCI, V116, P1499, DOI 10.1002/app.31698; Le TT, 2008, INT DAIRY J, V18, P1090, DOI 10.1016/j.idairyj.2008.06.006; Le Noir M, 2007, WATER RES, V41, P2825, DOI 10.1016/j.watres.2007.03.023; Lynn SG, 2008, COMP BIOCHEM PHYS B, V149, P126, DOI 10.1016/j.cbpb.2007.09.001; MASTSUI J, 1995, ANAL CHEM, V67, P4404; Mellado MCM, 2008, J CHROMATOGR A, V1192, P166, DOI 10.1016/j.chroma.2008.03.035; Meng ZH, 2005, ENVIRON SCI TECHNOL, V39, P8958, DOI 10.1021/es0505292; Otieno AC, 2008, J SEP SCI, V31, P3894, DOI 10.1002/jssc.200800412; Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002; Rempel-Hester MA, 2009, ENVIRON RES, V109, P552, DOI 10.1016/j.envres.2009.02.006; Rodriguez-Santiago V, 2008, REV SCI INSTRUM, V79, DOI 10.1063/1.2976779; Sibrian-Vazquez M, 2004, J POLYM SCI POL CHEM, V42, P3668, DOI 10.1002/pola.20186; Singh Y, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-47; Wang MF, 2009, J CHROMATOGR A, V1216, P5011, DOI 10.1016/j.chroma.2009.04.060; Wang XZ, 2009, CHEM ENG RES DES, V87, P874, DOI 10.1016/j.cherd.2008.12.014; Wei ST, 2006, BIOSENS BIOELECTRON, V21, P1943, DOI 10.1016/j.bios.2005.09.017; Zamengo L, 2009, CHEMOSPHERE, V76, P313, DOI 10.1016/j.chemosphere.2009.03.0653610WILEY-V C H VERLAG GMBHWEINHEIMBOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANYJ SEP SCISEPDiscipline: Chemistry660BJ</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; BINDING; Binding kinetics; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CE; CELL; CELLS; DES; detection; DIMETHACRYLATE; DYNAMIC LIGHT-SCATTERING; ESTROGENS; HEALTH; Molecularly imprinted polymer; NANOPARTICLES; RECOGNITION; REMOVAL; SCATTERING; SET; Submicron particles; TISSUE; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2796</startpage>
    <endpage>2803</endpage>
    <journalfull>Journal of Separation Science</journalfull>
    <issue>17-18</issue>
    <volume>33</volume>
    <abstract>Molecularly imprinted polymer (MIP) submicron particles were synthesized, using either ethylene glycol dimethacrylate or trimethylolpropane trimethacrylate as a cross-linker, specifically for recognition of 17 beta-estradiol (E2). HPLC with fluorescence detection (HPLC-FD) results showed that 90(+/- 5)% of E2 bound onto these particles after 2 min of incubation, and 96(+/- 3)% after long equilibrium. The binding capacity was 8(+/- 3) mu mol/g for MIP particles prepared using ethylene glycol dimethacrylate, and 33-43(+/- 8) mu mol/g for using trimethylolpropane trimethacrylate. CE separation of MIP and non-imprinted polymer particles was successful when 50 mM borate buffer (pH 8.5) containing 0.005% w/v EOTrol (TM) LN in reverse polarity (-30 kV) was used. The electrophoretic mobilities of MIP and non-imprinted polymer particles, together with dynamic light scattering measurement of particle sizes, allowed for an estimation of their surface charges. Automated injection of E2 and particles in mixture set a lower limit of 20(+/- 1) s on incubation time for the study of fast binding kinetics. The presence of E2 and bisphenol A (BPA) together tested the selectivity of MIP particles, when the two compounds competed for available binding cavities or sites. Addition of E2 after BPA confirmed E2 occupation of the specific binding cavities, via displacement of BPA</abstract>
    <url>WOS:000282612900031</url>
    <isbnorissn>1615-9306</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>117</id>
    <title>Detection of weak signals of endocrine disrupters in environmental health</title>
    <authors>Dewalque,L.; Charlier,C.</authors>
    <availability>[Dewalque, Lucas; Charlier, Corinne] Domaine Univ Sart Tilman, CHU B35, Serv Toxicol Clin Med Legale Environm &amp; Enterpris, B-4000 Liege, Belgium.</availability>
    <date>2013</date>
    <notes>JFrenchArticleDewalque, L (reprint author), Domaine Univ Sart Tilman, CHU B35, Serv Toxicol Clin Med Legale Environm &amp; Enterpris, B-4000 Liege, Belgiumlucas.dewalque@ulg.ac.be; c.charlier@chu.ulg.ac.beAntonio TA, 2013, INT J HYG ENVIR HEAL, V216, P284, DOI 10.1016/j.ijheh.2012.09.004; Ayotte P, 2005, ENVIRON HEALTH PERSP, V113, P1318, DOI 10.1289/ehp.7970; Balthazart J, 2011, ENDOCRINOLOGY, V152, P2937, DOI 10.1210/en.2011-0277; Bergman A, 2012, STATE SCI ENDOCRINE; Boas M, 2006, EUR J ENDOCRINOL, V154, P599, DOI 10.1530/eje.1.02128; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Brocca D, 2013, 2010 EUROPEAN UNION; BUCK WB, 1979, VET HUM TOXICOL, V21, P277; Calafat AM, 2010, ENVIRON HEALTH PERSP, V118, P679, DOI 10.1289/ehp.0901560; Carpenter David O., 2006, Reviews on Environmental Health, V21, P1; Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200; Charlier C, 2004, CLIN CHEM LAB MED, V42, P222, DOI 10.1515/CCLM.2004.040; Charlier CJ, 2002, CLIN CHEM LAB MED, V40, P361, DOI 10.1515/CCLM.2002.058; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Eubig PA, 2010, ENVIRON HEALTH PERSP, V118, P1654, DOI 10.1289/ehp.0901852; Faroon O., 2012, TOXICOLOGICAL PROFIL; Foster WG, 2002, TOXICOL SCI, V87, P3391; Fulton MH, 2001, ENVIRON TOXICOL CHEM, V20, P37, DOI 10.1897/1551-5028(2001)020&lt;0037:AIIEFA&gt;2.0.CO;2; Grun F, 2009, MOL CELL ENDOCRINOL, V304, P19, DOI 10.1016/j.mce.2009.02.018; Halden RU, 2010, ANNU REV PUBL HEALTH, V31, P179, DOI 10.1146/annurev.publhealth.012809.103714; Hass U, 2007, ENVIRON HEALTH PERSP, V115, P122, DOI 10.1289/ehp.9360; Hatch EE, 2010, INT J ANDROL, V33, P324, DOI 10.1111/j.1365-2605.2009.01035.x; Hauser R, 2008, INT J ANDROL, V31, P112, DOI 10.1111/j.1365-2605.2007.00844.x; Howdeshell KL, 2002, ENVIRON HEALTH PERSP, V110, P337; Jacobs MN, 2004, TOXICOLOGY, V205, P43, DOI 10.1016/j.tox.2004.06.036; Joensen UN, 2009, ENVIRON HEALTH PERSP, V117, P923, DOI 10.1289/ehp.0800517; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Kortenkamp A, 2011, METAL IONS LIFE SCI, V8, P305, DOI 10.1039/978184973211600305; Landrigan PJ, 2011, HEALTH AFFAIR, V30, P842, DOI 10.1377/hlthaff.2011.0151; Lau C, 2007, TOXICOL SCI, V99, P366, DOI 10.1093/toxsci/kfm128; Masset R, 2013, ETAT NAPPES EAU SOUT; Meeker JD, 2011, ENVIRON HEALTH PERSP, V119, P252, DOI 10.1289/ehp.1002238; Meeker JD, 2010, SYST BIOL REPROD MED, V56, P122, DOI 10.3109/19396360903443658; Newbold RR, 2009, MOL CELL ENDOCRINOL, V304, P84, DOI 10.1016/j.mce.2009.02.024; Newbold RR, 2010, HORM-INT J ENDOCRINO, V9, P206; OECD, 2012, TEST END DISR; Olsen GW, 2007, ENVIRON HEALTH PERSP, V115, P1298, DOI 10.1289/ehp.10009; Pirard C, 2012, ENVIRON INT, V48, P78, DOI 10.1016/j.envint.2012.07.003; Quignot N, 2011, ENVIRON RISQUE SANTE, V10, P454, DOI 10.1684/ers.2011.0498; Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002; Stanley S, 2005, PHYSIOL REV, V85, P1131, DOI 10.1152/physrev.00015.2004; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Taylor PJ, 2005, CLIN BIOCHEM, V38, P328, DOI 10.1016/j.clinbiochem.2004.11.007; The Endocrine Disruption Exchange (TEDX), 2011, TEDX LIST POT END DI; Tian YH, 2010, SYNAPSE, V64, P432, DOI 10.1002/syn.20746; Toppari J, 2010, MOL CELL ENDOCRINOL, V324, P39, DOI 10.1016/j.mce.2010.03.011; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; van der Oost R, 2003, ENVIRON TOXICOL PHAR, V13, P57, DOI 10.1016/S1382-6689(02)00126-6; van Meeuwen JA, 2008, TOXICOL APPL PHARM, V230, P372, DOI 10.1016/j.taap.2008.03.002; Williams GR, 2008, J NEUROENDOCRINOL, V20, P784, DOI 10.1111/j.1365-2826.2008.01733.x; Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690; Yamano Yuko, 2008, Environmental Health and Preventive Medicine, V13, P332, DOI 10.1007/s12199-008-0049-6; Yolton K, 2011, NEUROTOXICOL TERATOL, V33, P558, DOI 10.1016/j.ntt.2011.08.003; You L, 2001, MOL CELL ENDOCRINOL, V178, P207, DOI 10.1016/S0303-7207(01)00445-2560JOHN LIBBEY EUROTEXT LTDMONTROUGE127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCEENVIRON RISQUE SANTEJUL-AUGDiscipline: Public, Environmental &amp; Occupational Health208TD</notes>
    <keywords>BIOMARKER; BISPHENOL-A; BREAST-CANCER; CANCER; CELL; CHEMICALS; ENDOCRINE; ENDOCRINE DISRUPTERS; Endocrine disruption; ENDOCRINE DISRUPTORS; environmental exposure; environmental pollutants; EXPOSURE; FISH; HUMAN-REPRODUCTION; HUMANS; IDENTIFICATION; IMPACT; POLLUTANTS; POLYCHLORINATED-BIPHENYLS PCBS; RISK-ASSESSMENT; SEMEN QUALITY; SIGNALS; toxicology; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>345</startpage>
    <endpage>351</endpage>
    <journalfull>Environnement Risques &amp; Sante</journalfull>
    <issue>4</issue>
    <volume>12</volume>
    <abstract>Toxicology laboratories can provide many tools useful for understanding the health impact of endocrine disrupters. They can offer exposure measurement (e. g., identification and quantification of the main pollutants), but can also determine biological impacts, that is, measure effects. These determinations can be performed on water, air or soil, on animals used as sentinels, and also on humans</abstract>
    <url>WOS:000323701500021</url>
    <isbnorissn>1635-0421</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>327</id>
    <title>Urban-rural differences in breast cancer incidence in Egypt (1999-2006)</title>
    <authors>Dey,S.; Soliman,A.S.; Hablas,A.; Seifeldein,I.A.; Ismail,K.; Ramadan,M.; El-Hamzawy,H.; Wilson,M.L.; Banerjee,M.; Boffetta,P.; Harford,J.; Merajver,S.D.</authors>
    <availability>[Dey, Subhojit; Soliman, Amr S.; Wilson, Mark L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Hablas, Ahmad; Ismail, Kadry] Gharbiah Canc Soc, Tanta, Gharbiah, Egypt. [Seifeldein, Ibrahim A.; Ramadan, Mohamed; El-Hamzawy, Hesham] Tanta Canc Ctr, Tanta, Gharbiah, Egypt. [Banerjee, Mousumi] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. [Harford, Joe] NCI, Off Int Affairs, Bethesda, MD 20892 USA. [Merajver, Sofia D.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleDey, S (reprint author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 109 Observ St, Ann Arbor, MI 48109 USAsubhojit@umich.eduAbdel-Gawad S, 2002, WATER SCI TECHNOL, V46, P77; Awadallah RM, 1998, WATER RES, V32, P3080, DOI 10.1016/S0043-1354(98)00069-4; Barakat AO, 2004, ENVIRON INT, V30, P309, DOI 10.1016/S0160-4120(03)00181-8; Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; *CANC ATL IND, NAT CANC REG PROGR; *CAPMAS, CAPMAS REP; DABRE PD, 2003, J APPL TOXICOL, V23, P43; El Saghir Nagi S, 2007, Int J Surg, V5, P225, DOI 10.1016/j.ijsu.2006.06.015; El-Zanaty Fatma, 2006, EGYPT DEMOGRAPHIC HL; Esteban D, 1995, 10 IARC; FREEDMAN LS, CANC INCIDENCE 4 MEM; Freedman LS, 2001, EPIDEMIOLOGY, V12, P131, DOI 10.1097/00001648-200101000-00022; Gouin T, 2007, ENVIRON SCI TECHNOL, V41, P3877, DOI 10.1021/es063015r; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; Harner T, 2004, ENVIRON SCI TECHNOL, V38, P4474, DOI 10.1021/es040302r; Hosny Gihan, 2002, J Egypt Public Health Assoc, V77, P329; Ibrahim A. S., 2007, CANC EGYPT GHARBIAH; Jafari A, 2008, J ENVIRON MONITOR, V10, P861, DOI 10.1039/b802061b; Jaward FM, 2004, ENVIRON SCI TECHNOL, V38, P34, DOI 10.1021/es034705n; Kishk N A, 1999, J Egypt Public Health Assoc, V74, P547; Kitada Y, 2008, CHEMOSPHERE, V71, P2082, DOI 10.1016/j.chemosphere.2008.01.025; Kumari B, 2005, ENVIRON MONIT ASSESS, V105, P111, DOI 10.1007/s10661-005-3159-2; Mansour SA, 2004, TOXICOLOGY, V198, P91, DOI 10.1016/j.tox.2004.01.036; Maskarinec G, 2000, IN VIVO, V14, P115; MOSES M, 1995, DESIGNER POISONS PRO; Ndahi H, 2000, TECHNOLOGY TEACHER, V16, P18; Pant N, 2008, TOXICOL APPL PHARM, V231, P112, DOI 10.1016/j.taap.2008.04.001; Parkin DM, 2002, CANC INCIDENCE 5 CON, VVII; Parkin DM, 2006, BREAST J, V12, pS70, DOI 10.1111/j.1075-122X.2006.00205.x; Pentamwa P, 2008, ANN NY ACAD SCI, V1140, P91, DOI 10.1196/annals.1454.005; Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723; Soliman AS, 2004, INT J ENVIRON HEAL R, V14, P121, DOI 10.1080/0960312042000209534; Soliman AS, 2003, ENVIRON RES, V92, P110, DOI 10.1016/S0013-9351(02)00056-7; SOLTAN ME, 1995, J ENVIRON SCI HEAL A, V30, P1647; Sprague BL, 2008, AM J EPIDEMIOL, V168, P404, DOI 10.1093/aje/kwn143; STURGEON SR, 1995, J NATL CANCER I, V87, P1846, DOI 10.1093/jnci/87.24.1846; Tavani A, 1997, INT J CANCER, V70, P159, DOI 10.1002/(SICI)1097-0215(19970117)70:2&lt;159::AID-IJC4&gt;3.0.CO;2-W; Wittassek M, 2007, INT J HYG ENVIR HEAL, V210, P319, DOI 10.1016/j.ijheh.2007.01.037; *WRI, 1996, PEST IMM SYST PUBL H; Zhang H, 2007, ENVIRON INT, V33, P685, DOI 10.1016/j.envint.2007.02.003; ZIEGLER RG, 1993, J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.18194517CHURCHILL LIVINGSTONEEDINBURGHJOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLANDBREASTOCTDiscipline: Oncology; Obstetrics &amp; Gynecology673XF</notes>
    <keywords>BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER INCIDENCE; CLASSIFICATION; Egypt; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; Epidemiology; EXPOSURE; HEALTH; in vivo; IN-VIVO; Incidence; MORTALITY; oncology; ORGANOCHLORINE PESTICIDES; PASSIVE AIR SAMPLERS; PERSISTENT ORGANIC POLLUTANTS; POLYCHLORINATED-BIPHENYLS; POPULATION; RISK; RISK FACTOR; RISK-FACTORS; Rural; Steroid; toxicology; Urban; Urban-rural; US POPULATION; VIVO; WASTE-WATER; WATER; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>417</startpage>
    <endpage>423</endpage>
    <journalfull>Breast</journalfull>
    <issue>5</issue>
    <volume>19</volume>
    <abstract>Objective: To describe urban rural differences in breast cancer incidence in Gharbiah, Egypt and to investigate if these differences could be explained by known risk factors of breast cancer. Methods: We used data from the population-based cancer registry of Gharbiah, Egypt to assess breast cancer incidence from 1999 through 2006. The Egyptian census provided data on district-specific population, age, and urban rural classification. Incidence patterns of breast cancer by district and age-specific urban rural differences were analyzed. Results: Overall, incidence rate of breast cancer was three to four times higher in urban areas than in rural areas (60.9/10(5)-year for urban areas versus 17.8/10(5)-year for rural areas; IRR = 3.73, 95% CI = 3.30, 4.22). Urban areas had consistently higher incidence of breast cancer across all age-groups for all years. Higher incidence of breast cancer was also seen in the more developed districts of Tanta and El-Mehalla. Conclusions: Higher incidence of breast cancer in urban and more developed populations might be related to higher exposure to xenoestrogens, as well as other endocrine disruptors and genotoxic substances. (C) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000283696800021</url>
    <isbnorissn>0960-9776</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>374</id>
    <title>Urban-rural differences of gynaecological malignancies in Egypt (1999-2002)</title>
    <authors>Dey,S.; Hablas,A.; Seifeldin,I.A.; Ismail,K.; Ramadan,M.; El-Hamzawy,H.; Wilson,M.L.; Banerjee,M.; Boffetta,P.; Harford,J.; Merajver,S.D.; Soliman,A.S.</authors>
    <availability>[Dey, S.; Wilson, M. L.; Soliman, A. S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Hablas, A.; Ismail, K.] Gharbiah Canc Soc, Tanta, Gharbiah, Egypt. [Seifeldin, I. A.; Ramadan, M.; El-Hamzawy, H.] Tanta Canc Ctr, Tanta, Gharbiah, Egypt. [Banerjee, M.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Boffetta, P.] Int Agcy Res Canc, F-69372 Lyon, France. [Harford, J.] NCI, Off Int Affairs, Bethesda, MD 20892 USA. [Merajver, S. D.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleSoliman, AS (reprint author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 109 Observ St, Ann Arbor, MI 48109 USAasoliman@umich.eduBoyle P., 2008, WORLD CANC REPORT; *CAPMAS, CAPMAS REP; CASAGRANDE JT, 1979, LANCET, V2, P170; Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045; Dey S, 2009, MED HYPOTHESES, V72, P652, DOI 10.1016/j.mehy.2008.10.025; DEY S, 2009, BREAST CANC RES TREA; El-Zanaty Fatma, 2006, EGYPT DEMOGRAPHIC HL; *EMRO, WHO COUNTR PROF; Evans Nancy, 2006, STATE EVIDENCE WHAT; Fathalla M F, 1972, Obstet Gynecol Surv, V27, P751, DOI 10.1097/00006254-197211000-00001; Freedman LS, 2006, NIH PUB, V06-5873; Goloubkova T, 2000, ARCH TOXICOL, V74, P92, DOI 10.1007/s002040050658; Gouin T, 2007, ENVIRON SCI TECHNOL, V41, P3877, DOI 10.1021/es063015r; HONIG SF, 1998, SURG BREAST PRINCIPL, P3; Ibrahim A. S., 2007, CANC EGYPT GHARBIAH; Jafari A, 2008, J ENVIRON MONITOR, V10, P861, DOI 10.1039/b802061b; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; Kitada Y, 2008, CHEMOSPHERE, V71, P2082, DOI 10.1016/j.chemosphere.2008.01.025; Kumari B, 2005, ENVIRON MONIT ASSESS, V105, P111, DOI 10.1007/s10661-005-3159-2; La Vecchia C, 2001, EUR J CANCER PREV, V10, P125, DOI 10.1097/00008469-200104000-00002; Pant N, 2008, TOXICOL APPL PHARM, V231, P112, DOI 10.1016/j.taap.2008.04.001; Papaconstantinou AD, 2000, TOXICOL SCI, V56, P332, DOI 10.1093/toxsci/56.2.332; Parkin DM, 2002, CANC INCIDENCE 5 CON, VVIII; Pentamwa P, 2008, ANN NY ACAD SCI, V1140, P91, DOI 10.1196/annals.1454.005; Purdie DM, 2001, BEST PRACT RES CL OB, V15, P341, DOI 10.1053/beog.2000.0180; Soliman AS, 2004, INT J ENVIRON HEAL R, V14, P121, DOI 10.1080/0960312042000209534; Soliman AS, 2003, ENVIRON RES, V92, P110, DOI 10.1016/S0013-9351(02)00056-7; Zhang H, 2007, ENVIRON INT, V33, P685, DOI 10.1016/j.envint.2007.02.0032912WILEY-BLACKWELL PUBLISHING, INCMALDENCOMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USABJOG-INT J OBSTET GYFEBDiscipline: Obstetrics &amp; Gynecology543CJ</notes>
    <keywords>BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER INCIDENCE; Egypt; ENDOMETRIAL CANCER RISK; Epidemiology; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; gynaecologic cancers; HISTORY; Incidence; OVARIAN-CANCER; PERSISTENT ORGANIC POLLUTANTS; PESTICIDES; RECEPTOR; Rural; Urban; Urban-rural; UTERINE; Uterus; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>348</startpage>
    <endpage>355</endpage>
    <journalfull>Bjog-An International Journal of Obstetrics and Gynaecology</journalfull>
    <issue>3</issue>
    <volume>117</volume>
    <abstract>Objective In previous studies, we have shown a three to four times higher urban incidence of breast cancer and estrogen receptor-positive breast cancers in the Gharbiah Province of Egypt. We investigated the urban-rural incidence differences of gynaecologic malignancies (uterine, ovarian and cervical cancers) to explore if they show the same trend that we found for breast cancer. Design Cancer registry-based incidence comparison. Setting Gharbiah population-based cancer registry (GPCR), Tanta, Egypt. Sample All patients with uterine, ovarian and cervical cancer in GPCR from 1999 to 2002. Methods We calculated uterine, ovarian and cervical cancer incidence from 1999 to 2002. For each of the three cancers, we calculated the overall and age-specific rates for the province as a whole, and by urban-rural status, as well as for the eight districts of the province. Results Incidence of all three cancer sites was higher in urban than in rural areas. Uterine cancer showed the highest urban-rural incidence rate ratio (IRR = 6.07, 95% CI = 4.17, 8.85). Uterine cancer also showed the highest urban incidence in the oldest age group (70+ age category, IRR = 14.39, 95% CI = 4.24, 48.87) and in developed districts (Tanta, IRR = 4.14, 95% CI = 0.41, 42.04). Incidence rates by groups of cancer sites showed an increasing gradient of urban incidence for cancers related to hormonal aetiology, mainly of the breast and uterus (IRR = 4.96, 95% CI = 2.86, 8.61). Conclusions The higher urban incidence of uterine cancer, coupled with our previous findings of higher incidence of breast cancer and estrogen receptor positive breast cancer in urban areas in this region, may be suggestive of possible higher exposure to environmental estrogenic compounds, such as xenoestrogens, in urban areas</abstract>
    <url>WOS:000273547200014</url>
    <isbnorissn>1470-0328</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>375</id>
    <title>Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt</title>
    <authors>Dey,S.; Soliman,A.S.; Hablas,A.; Seifeldin,I.A.; Ismail,K.; Ramadan,M.; El-Hamzawy,H.; Wilson,M.L.; Banerjee,M.; Boffetta,P.; Harford,J.; Merajver,S.D.</authors>
    <availability>[Dey, Subhojit; Soliman, Amr S.; Wilson, Mark L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Hablas, Ahmad; Ismail, Kadry] Gharbiah Canc Soc, Tanta, Gharbiah, Egypt. [Seifeldin, Ibrahim A.; Ramadan, Mohamed; El-Hamzawy, Hesham] Tanta Canc Ctr, Tanta, Gharbiah, Egypt. [Banerjee, Mousumi] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Boffetta, Paolo] Int Agcy Res Canc, F-69372 Lyon, France. [Harford, Joe] NCI, Off Int Affairs, Bethesda, MD 20892 USA. [Merajver, Sofia D.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleSoliman, AS (reprint author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 109 Observ St, Ann Arbor, MI 48109 USAasoliman@umich.eduAl-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Anderson WF, 2001, J CLIN ONCOL, V19, P18; Bartow SA, 1998, J MAMMARY GLAND BIOL, V3, P37, DOI 10.1023/A:1026641401184; Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932; Brody JG, 2007, CANCER, V109, P2627, DOI 10.1002/cncr.22656; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; *CANC EGYPT GHARB, 2007, TRIENN REP 2000 2002; *CAPMAS, CAPMAS CENS REP 1996; Chen WY, 2007, NAT CLIN PRACT ONCOL, V4, P415, DOI 10.1038/ncponc0851; Chlebowski RT, 2005, J NATL CANCER I, V97, P439, DOI 10.1093/jnci/dji064; Ciocca DR, 2006, J STEROID BIOCHEM, V102, P32, DOI 10.1016/j.jsbmb.2006.09.008; Colditz GA, 2004, J NATL CANCER I, V96, P218, DOI 10.1093/jnci/djh025; *DAK INC, ERPR PHARM DX INT MA; Desai SB, 2000, BREAST, V9, P267, DOI 10.1054/brst.2000.0134; DEWAILLY E, 1994, J NATL CANCER I, V86, P232, DOI 10.1093/jnci/86.3.232; Dey S, 2009, MED HYPOTHESES, V72, P652, DOI 10.1016/j.mehy.2008.10.025; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; ELZANATY F, 2006, EGYPT DEM HLTH SURV; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Freedman LS, 2006, CANC INCIDENCE 4 MEM; Gouin T, 2007, ENVIRON SCI TECHNOL, V41, P3877, DOI 10.1021/es063015r; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; Hess KR, 2003, BREAST CANCER RES TR, V78, P105, DOI 10.1023/A:1022166517963; Huang WY, 2000, AM J EPIDEMIOL, V151, P703; Jafari A, 2008, J ENVIRON MONITOR, V10, P861, DOI 10.1039/b802061b; Keeling JW, 2000, J PATHOL, V191, P449; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; Kitada Y, 2008, CHEMOSPHERE, V71, P2082, DOI 10.1016/j.chemosphere.2008.01.025; Kumari B, 2005, ENVIRON MONIT ASSESS, V105, P111, DOI 10.1007/s10661-005-3159-2; LaKind JS, 2004, TOXICOL APPL PHARM, V198, P184, DOI 10.1016/j.taap.2003.08.021; Li CI, 2002, CANCER EPIDEM BIOMAR, V11, P601; Li CI, 2003, J CLIN ONCOL, V21, P28, DOI 10.1200/JCO.2003.03.088; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; Manjer J, 2001, INT J CANCER, V91, P580, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1091&gt;3.0.CO;2-V; Marx J, 2003, SCIENCE, V301, P1308, DOI 10.1126/science.301.5638.1308; PARKIN DM, 2002, IARC SC PUBLNS, V155; Parkin DM, 2006, BREAST J, V12, pS70, DOI 10.1111/j.1075-122X.2006.00205.x; Pentamwa P, 2008, ANN NY ACAD SCI, V1140, P91, DOI 10.1196/annals.1454.005; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROBISON AK, 1985, TOXICOL LETT, V27, P109, DOI 10.1016/0378-4274(85)90127-4; Rockhill B, 1998, AM J EPIDEMIOL, V147, P826; Singh SK, 2003, CANCER RES, V63, P5821; Soliman AS, 2004, INT J ENVIRON HEAL R, V14, P121, DOI 10.1080/0960312042000209534; Soliman AS, 2003, ENVIRON RES, V92, P110, DOI 10.1016/S0013-9351(02)00056-7; Solomon GM, 2002, ENVIRON HEALTH PERSP, V110, pA339; Wittassek M, 2007, INT J HYG ENVIR HEAL, V210, P319, DOI 10.1016/j.ijheh.2007.01.037; Woolcott CG, 2001, CANCER CAUSE CONTROL, V12, P395, DOI 10.1023/A:1011289905751; Zhang H, 2007, ENVIRON INT, V33, P685, DOI 10.1016/j.envint.2007.02.0035020SPRINGERNEW YORK233 SPRING ST, NEW YORK, NY 10013 USABREAST CANCER RES TRFEBDiscipline: Oncology545OK</notes>
    <keywords>BISPHENOL-A; breast; breast cancer; Breast cancer incidence; BREAST-CANCER; CANCER; CANCER INCIDENCE; CANCER RISK; CANCER-RISK; Egypt; ENVIRONMENTAL-POLLUTANTS; Epidemiology; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; EXPOSURES; GLAND; HEALTH; Hormone; Hormone receptor status; IDENTIFICATION; Incidence; mammary gland; Mammary stem cells; MAMMARY-GLAND; oncology; PERSISTENT ORGANIC POLLUTANTS; POPULATION; RECEPTOR; RISK; RISK FACTOR; risk factors; RISK-FACTORS; Rural; STEM-CELLS; Steroid; TUMOR; TUMORS; Urban; Urban-rural; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>149</startpage>
    <endpage>160</endpage>
    <journalfull>Breast Cancer Research and Treatment</journalfull>
    <issue>1</issue>
    <volume>120</volume>
    <abstract>Breast cancer incidence is higher in developed countries with higher rates of estrogen receptor positive (ER+) tumors. ER+ tumors are caused by estrogenic exposures although known exposures explain approximately 50% of breast cancer risk. Unknown risk factors causing high breast cancer incidence exist that are estrogenic and development-related. Xenoestrogens are such risk factors but are difficult to study since developed countries lack unexposed populations. Developing countries have urban-rural populations with differential exposure to xenoestrogens. This study assessed urban-rural breast cancer incidence classified by hormone receptor status using data from Gharbiah population-based cancer registry in Egypt from 2001 to 2006. Urban ER+ incidence rate (per 100,000 women) was 2-4 times (IRR = 3.36, 95% CI = 4.84, 2.34) higher than rural incidence rate. ER-incidence rate was 2-3 times (IRR = 1.86, 95% CI = 2.38, 1.45) higher in urban areas than in rural areas. Our findings indicate that urban women may probably have a higher exposure to xenoestrogens</abstract>
    <url>WOS:000273743500016</url>
    <isbnorissn>0167-6806</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>28</id>
    <title>Prenatal Exposure to BPA Alters the Epigenome of the Rat Mammary Gland and Increases the Propensity to Neoplastic Development</title>
    <authors>Dhimolea,E.; Wadia,P.R.; Murray,T.J.; Settles,M.L.; Treitman,J.D.; Sonnenschein,C.; Shioda,T.; Soto,A.M.</authors>
    <availability>[Dhimolea, Eugen; Wadia, Perinaaz R.; Murray, Tessa J.; Treitman, Jo D.; Sonnenschein, Carlos; Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USA. [Settles, Matthew L.] Univ Idaho, Inst Bioinformat &amp; Evolutionary Studies, Moscow, ID 83843 USA. [Shioda, Toshi] Massachusetts Gen Hosp, MGH Ctr Canc Res, Charlestown, MA USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleSoto, AM (reprint author), Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USAana.soto@tufts.eduAcevedo N, 2013, ENVIRON HEALTH PERSP, V121, P1040, DOI 10.1289/ehp.1306734; Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Barker DJP, 2004, ACTA PAEDIATR, V93, P1559, DOI 10.1080/08035250410024772; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Biles JE, 1997, J AGR FOOD CHEM, V45, P3541, DOI 10.1021/jf970072i; BOYLAN ES, 1983, CANCER RES, V43, P4872; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; GRUBBS CJ, 1983, J NATL CANCER I, V70, P209; Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Howdeshell KL, 1999, NATURE, V401, P763; Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Markey CM, 2003, J STEROID BIOCHEM, V83, P235; Markey CM, 2003, EVOL DEV, V5, P1; Munoz de Toro MM, 2005, ENDOCRINOLOGY, V146, P4138, DOI DOI 10.1210/EN.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Rijnkels M, 2010, J MAMMARY GLAND BIOL, V15, P85, DOI 10.1007/s10911-010-9170-4; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Sallout B, 2003, J Obstet Gynaecol, V23, P555; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Singh M, 2000, LAB INVEST, V80, P221; Skakkebaek NE, 1998, APMIS, V106, P3; Sonnenschein C, 2011, CANCER RES, V71, P4334, DOI 10.1158/0008-5472.CAN-11-0639; Sonnenschein C, 1999, SOC CELLS CANC CONTR; Sonnenschein C, 2011, J DEV ORIG HLTH DIS, V2, P9, DOI 10.1017/S2040174411000043; Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5; Soto AM, 2011, BIOESSAYS, V33, P332, DOI 10.1002/bies.201100025; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Susiarjo M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003401; Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109; Trichopoulos D, 1990, Epidemiology, V1, P95; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Wadia PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063902; Weinberg RA, 2006, BIOL CANC; Woodruff TJ, 2011, ENVIRON HEALTH PERSP, V119, P878, DOI 10.1289/ehp.1002727; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Ye X, 2008, TALANTA, V76, P865, DOI 10.1016/j.talanta.2008.04.034570PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEJUL 2Discipline: Science &amp; Technology - Other TopicsAO5BA</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BISPHENOL-A EXPOSURE; BPA; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CARCINOMA; CD-1 MICE; CELL; CELLS; DIETHYLSTILBESTROL; ENDOCRINE DISRUPTORS; ENVIRONMENTAL ESTROGENS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGENS; EXPOSURE; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; IN-UTERO EXPOSURE; Interaction; mechanism; PERINATAL EXPOSURE; RECEPTOR; SUSCEPTIBILITY; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>7</issue>
    <volume>9</volume>
    <abstract>Exposure to environmental estrogens (xenoestrogens) may play a causal role in the increased breast cancer incidence which has been observed in Europe and the US over the last 50 years. The xenoestrogen bisphenol A (BPA) leaches from plastic food/beverage containers and dental materials. Fetal exposure to BPA induces preneoplastic and neoplastic lesions in the adult rat mammary gland. Previous results suggest that BPA acts through the estrogen receptors which are detected exclusively in the mesenchyme during the exposure period by directly altering gene expression, leading to alterations of the reciprocal interactions between mesenchyme and epithelium. This initiates a long sequence of altered morphogenetic events leading to neoplastic transformation. Additionally, BPA induces epigenetic changes in some tissues. To explore this mechanism in the mammary gland, Wistar-Furth rats were exposed subcutaneously via osmotic pumps to vehicle or 250 mu g BPA/kg BW/day, a dose that induced ductal carcinomas in situ. Females exposed from gestational day 9 to postnatal day (PND) 1 were sacrificed at PND4, PND21 and at first estrus after PND50. Genomic DNA (gDNA) was isolated from the mammary tissue and immuno-precipitated using anti-5-methylcytosine antibodies. Detection and quantification of gDNA methylation status using the Nimblegen ChIP array revealed 7412 differentially methylated gDNA segments (out of 58207 segments), with the majority of changes occurring at PND21. Transcriptomal analysis revealed that the majority of gene expression differences between BPA- and vehicle-treated animals were observed later (PND50). BPA exposure resulted in higher levels of pro-activation histone H3K4 trimethylation at the transcriptional initiation site of the alpha-lactalbumin gene at PND4, concomitantly enhancing mRNA expression of this gene. These results show that fetal BPA exposure triggers changes in the postnatal and adult mammary gland epigenome and alters gene expression patterns. These events may contribute to the development of pre-neoplastic and neoplastic lesions that manifest during adulthood</abstract>
    <url>WOS:000341354100019</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>415</id>
    <title>Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement</title>
    <authors>Diamanti-Kandarakis,E.; Bourguignon,J.P.; Giudice,L.C.; Hauser,R.; Prins,G.S.; Soto,A.M.; Zoeller,R.T.; Gore,A.C.</authors>
    <availability>[Gore, Andrea C.] Univ Texas Austin, Coll Pharm, Div Pharmacol &amp; Toxicol, Austin, TX 78712 USA. [Diamanti-Kandarakis, Evanthia] Univ Athens, Sch Med, Laiko Hosp, Dept Med 1,Endocrine Sect, GR-11527 Athens, Greece. [Bourguignon, Jean-Pierre] Ctr Hosp Univ Liege, Dept Pediat, B-4000 Liege, Belgium. [Giudice, Linda C.] Univ Calif San Francisco, Dept Obstet Gynecol &amp; Reprod Sci, San Francisco, CA 94131 USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Prins, Gail S.] Univ Illinois, Dept Urol, Chicago, IL 60612 USA. [Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cell Biol, Boston, MA 02111 USA. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.</availability>
    <date>2009</date>
    <notes>JEnglishReviewGore, AC (reprint author), Univ Texas Austin, Coll Pharm, Div Pharmacol &amp; Toxicol, 1 Univ Stn,A1915, Austin, TX 78712 USAandrea.gore@mail.utexas.eduAbbout DH, 2005, HUM REPROD UPDATE, V11, P357, DOI 10.1093/humupd/dmi013; Abell A, 2000, SCAND J WORK ENV HEA, V26, P492; ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Adibi JJ, 2003, ENVIRON HEALTH PERSP, V111, P1719, DOI 10.1289/ehp.6235; *AG HEALTHC RES QU, 2007, PUBL AG HEALTHC RES; *AG TOX SUBST DIS, 1995, TOX PROF DI N OCT PH; *AG TOX SUBST DIS, 2001, TOX PROF DI N OCT PH; *AG TOX SUBST DIS, 2002, TOX PROF DI N OCT PH; *AG TOX SUBST DIS, 1997, TOX PROF DI N OCT PH; Aho M, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454389; Alavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Amitai Y, 2007, THYROID, V17, P843, DOI 10.1089/thy.2006.0336; NOBLE RL, 1977, CANCER RES, V37, P1929; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058; Anway MD, 2008, PROSTATE, V68, P517, DOI 10.1002/pros.20724; ARAI Y, 1983, INT REV CYTOL, V84, P235, DOI 10.1016/S0074-7696(08)61019-0; Arulmozhiraja S, 2004, CHEM RES TOXICOL, V17, P348, DOI 10.1021/tx0300380; Asuncion M, 2000, J CLIN ENDOCR METAB, V85, P2434, DOI 10.1210/jc.85.7.2434; Atanassova N, 2001, ENDOCRINOLOGY, V142, P874, DOI 10.1210/en.142.2.874; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Ayotte P, 2003, ENVIRON HEALTH PERSP, V111, P1253, DOI 10.1289/ehp.6054; Azziz R, 2006, J CLIN ENDOCR METAB, V91, P4237, DOI 10.1210/jc.2006-0178; Azziz R, 2004, J CLIN ENDOCR METAB, V89, P2745, DOI 10.1210/jc.2003-032046; Azziz R, 2005, J CLIN ENDOCR METAB, V90, P4650, DOI 10.1210/jc.2005-0628; Backlin BM, 2003, VET PATHOL, V40, P175, DOI 10.1354/vp.40-2-175; Baillie-Hamilton PF, 2002, J ALTERN COMPLEM MED, V8, P185, DOI 10.1089/107555302317371479; Baird DD, 2005, REPROD TOXICOL, V20, P81, DOI 10.1016/j.reprotox.2005.01.002; Bansal Ruby, 2005, Brain Res Dev Brain Res, V156, P13; Barker DJP, 2003, EUR J EPIDEMIOL, V18, P733, DOI 10.1023/A:1025388901248; Barthold JS, 2003, J UROLOGY, V170, P2396, DOI 10.1097/01.ju.0000095793.04232.d8; BASTOMSKY CH, 1977, ENDOCRINOLOGY, V101, P292; Bay K, 2006, BEST PRACT RES CL EN, V20, P77, DOI 10.1016/j.beem.2005.09.004; Benbrahim-Tallaa L, 2007, PROSTATE, V67, P135, DOI 10.1002/pros.20479; Benbrahim-Tallaa L, 2007, ENVIRON HEALTH PERSP, V115, P243, DOI 10.1289/ehp.9630; Ben Rhouma K, 2001, HUM EXP TOXICOL, V20, P393, DOI 10.1191/096032701682692946; BERBEL P, 1994, BEHAV BRAIN RES, V64, P9, DOI 10.1016/0166-4328(94)90114-7; Bhatia R, 2005, ENVIRON HEALTH PERSP, V113, P220, DOI 10.1289/ehp.7382; Bisenius ES, 2006, BIOL REPROD, V75, P469, DOI 10.1095/biolreprod.106.052795; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Block K, 2000, FASEB J, V14, P1101; Blount BC, 2007, J EXPO SCI ENV EPID, V17, P400, DOI 10.1038/sj.jes.7500535; Blount BC, 2006, ENVIRON HEALTH PERSP, V114, P1865, DOI 10.1289/ehp.9466; Bogazzi F, 2003, J ENDOCRINOL INVEST, V26, P972; Boisen KA, 2004, LANCET, V363, P1264, DOI 10.1016/S0140-6736(04)15998-9; Boker LK, 2002, J NUTR, V132, P1319; BOYLAN ES, 1979, J TOXICOL ENV HEALTH, V5, P1059; Breivik K, 2002, SCI TOTAL ENVIRON, V290, P181, DOI 10.1016/S0048-9697(01)01075-0; Brouwer A, 1999, ENVIRON HEALTH PERSP, V107, P639, DOI 10.2307/3434557; Brouwer A, 1998, TOXICOL IND HEALTH, V14, P59; BROWN JF, 1994, ENVIRON SCI TECHNOL, V28, P2295, DOI 10.1021/es00062a013; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Brucker-Davis F, 1998, THYROID, V8, P827, DOI 10.1089/thy.1998.8.827; Louis GMB, 2008, PEDIATRICS, V121, pS192, DOI 10.1542/peds.1813E; Bujan L, 1996, BRIT MED J, V312, P471; Buresova M, 2006, PHYSIOL GENOMICS, V26, P226, DOI 10.1152/physiolgenomics.00056.2006; BURNEY R, 2008, OPERATIVE GYNECOLOGI, P253; BUTTRAM VC, 1981, FERTIL STERIL, V36, P433; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2007, CONTEMP ENDOCRINOL S, P253, DOI 10.1007/1-59745-107-X_11; Cao Y, 2009, J EXPO SCI ENV EPID, V19, P223, DOI 10.1038/jes.2008.44; Carbone P, 2006, REPROD TOXICOL, V22, P8, DOI 10.1016/j.reprotox.2006.01.006; CARLSEN E, 1992, BRIT MED J, V305, P609; Carrat X, 2000, INT J PEDIATR OTORHI, V52, P61, DOI 10.1016/S0165-5876(99)00280-3; Caserta D, 2008, HUM REPROD UPDATE, V14, P59, DOI 10.1093/humupd/dmm025; *CDCP, 2005 3 NAT REP HUM E; Ceccarelli I, 2007, NEUROTOXICOL TERATOL, V29, P108, DOI 10.1016/j.ntt.2006.10.011; Cerami C, 1997, P NATL ACAD SCI USA, V94, P13915, DOI 10.1073/pnas.94.25.13915; Chakraborty TR, 2004, EXP BIOL MED, V229, P977; Chan YH, 2007, AM J CLIN NUTR, V86, P938; Chana A, 2002, CHEM RES TOXICOL, V15, P1514, DOI 10.1021/tx025596d; Chang G, 2002, J SUBST ABUSE TREAT, V23, P1, DOI 10.1016/S0740-5472(02)00234-9; Charles LE, 2003, AM J EPIDEMIOL, V157, P683, DOI 10.1093/aje/kwg044; Chauhan KR, 2000, TOXICOL APPL PHARM, V162, P10, DOI 10.1006/taap.1999.8826; CHEN CJ, 1988, LANCET, V1, P414; Chen JG, 2008, ENDOCRINOLOGY, V149, P1173, DOI 10.1210/en.2007-1057; Cheng SY, 2005, TRENDS ENDOCRIN MET, V16, P176, DOI 10.1016/j.tem.2005.03.008; CHORAZY PA, 1995, PEDIATRICS, V96, P148; Christiansen S, 2008, INT J ANDROL, V31, P241, DOI 10.1111/j.1365-2605.2008.00866.x; Chung YW, 1999, B ENVIRON CONTAM TOX, V62, P664; Chung YW, 2001, PHYSIOL BEHAV, V74, P363, DOI 10.1016/S0031-9384(01)00579-0; Cobellis L, 2003, HUM REPROD, V18, P1512, DOI 10.1093/humrep/deg254; Cocco P, 1998, ONCOLOGY-BASEL, V55, P334, DOI 10.1159/000011872; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Cohn BA, 2003, LANCET, V361, P2205, DOI 10.1016/S0140-6736(03)13776-2; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Cook JD, 2007, REPROD SCI, V14, P121, DOI 10.1177/1933719106298401; Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102; Cook R, 2006, ENVIRON HEALTH PERSP, V114, P1631, DOI 10.1289/ehp.8606; Cooke PS, 2004, EXP BIOL MED, V229, P1127; Cooper DS, 2003, J CLIN ENDOCR METAB, V88, P3474, DOI 10.1210/jc.2003-030185; Couse JF, 2001, DEV BIOL, V238, P224, DOI 10.1006/dbio.2001.0413; Cowin PA, 2008, ENVIRON HEALTH PERSP, V116, P923, DOI 10.1289/ehp.11239; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Crews D, 2003, PURE APPL CHEM, V75, P2305, DOI 10.1351/pac200375112305; Crews D, 2007, P NATL ACAD SCI USA, V104, P5942, DOI 10.1073/pnas.0610410104; Crews D, 2006, ENDOCRINOLOGY, V147, pS4, DOI 10.1210/en.2005-1122; Crofton KM, 2004, RISK ANAL, V24, P1665, DOI 10.1111/j.0272-4332.2004.00557.x; Cummings AM, 1996, TOXICOL APPL PHARM, V138, P131, DOI 10.1006/taap.1996.0106; Dallinga JW, 2002, HUM REPROD, V17, P1973, DOI 10.1093/humrep/17.8.1973; Dang ZC, 2003, J BIOL CHEM, V278, P962, DOI 10.1074/jbc.M209483200; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; Davey JC, 2007, TOXICOL SCI, V98, P75, DOI 10.1093/toxsci/kfm013; David R. M., 2001, PATTYS TOXICOLOGY, P635; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; De Ferranti Sarah D, 2007, Diab Vasc Dis Res, V4, P285; De Groef B, 2006, EUR J ENDOCRINOL, V155, P17, DOI 10.1530/eje.1.02190; de Kleijn MJJ, 2002, J NUTR, V132, P276; Delange F., 1989, ENV GOITROGENESIS, P173; de Moura EG, 2005, BIOSCIENCE REP, V25, P251, DOI 10.1007/s10540-005-2888-3; Deodato B, 1999, BRIT J PHARMACOL, V128, P1683, DOI 10.1038/sj.bjp.0702973; Diamanti-Kandarakis E, 2007, HISTOCHEM CELL BIOL, V127, P581, DOI 10.1007/s00418-006-0265-3; Diamanti-Kandarakis E, 2005, HUM REPROD UPDATE, V11, P631, DOI 10.1093/humupd/dmi025; Diamanti-Kandarakis E, 2008, CLIN ENDOCRINOL, V69, P634, DOI 10.1111/j.1365-2265.2008.03247.x; Diamanti-Kandarakis E, 1999, J CLIN ENDOCR METAB, V84, P4006, DOI 10.1210/jc.84.11.4006; Diamanti-Kandarakis E, 2007, J MOL MED-JMM, V85, P1413, DOI 10.1007/s00109-007-0246-6; Dickerson SM, 2007, REV ENDOCR METAB DIS, V8, P143, DOI 10.1007/s11154-007-9048-y; Doerge DR, 2002, ENVIRON HEALTH PERSP, V110, P349; Dolk H, 2004, ENVIRON HEALTH PERSP, V112, P398, DOI 10.1289/ehp.6398; Dowling ALS, 2001, ENDOCRINOLOGY, V142, P390, DOI 10.1210/en.142.1.390; Dowling ALS, 2000, J NEUROSCI, V20, P2255; Dowling ALS, 2000, MOL BRAIN RES, V82, P126, DOI 10.1016/S0169-328X(00)00190-X; DRISCOLL SG, 1980, OBSTET GYNECOL, V56, P537; Dumesic DA, 2007, REV ENDOCR METAB DIS, V8, P127, DOI 10.1007/s11154-007-9046-0; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Duty SM, 2003, EPIDEMIOLOGY, V14, P269, DOI 10.1097/00001648-200305000-00005; Emmen JMA, 2000, ENDOCRINOLOGY, V141, P846, DOI 10.1210/en.141.2.846; ENGLER H, 1982, BIOCHEM PHARMACOL, V31, P3801, DOI 10.1016/0006-2952(82)90296-9; EVERITT JI, 1995, AM J PATHOL, V146, P1556; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Fisch H, 1996, FERTIL STERIL, V65, P1009; Fisher BE, 1999, ENVIRON HEALTH PERSP, V107, pA18, DOI 10.2307/3434279; Fisher JW, 2006, TOXICOL SCI, V90, P87, DOI 10.1093/toxsci/kfj069; FORT P, 1990, J AM COLL NUTR, V9, P164; Foster WG, 2008, J TOXICOL ENV HEAL B, V11, P162, DOI 10.1080/10937400701873274; Franks S, 2000, MOL CELL ENDOCRINOL, V163, P49, DOI 10.1016/S0303-7207(99)00239-7; Fritsche E, 2005, ENVIRON HEALTH PERSP, V113, P871, DOI 10.1289/ehp.7793; FRUMESS RD, 1975, METABOLISM, V24, P547, DOI 10.1016/0026-0495(75)90079-7; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gaitan E, 1989, ENV GOITROGENESIS; GarciaRodriguez J, 1996, ENVIRON HEALTH PERSP, V104, P1090, DOI 10.2307/3433122; GARDNER HD, 2008, AM J PHYSIOL-HEART C, V294, pH198; Garry VF, 1996, ENVIRON HEALTH PERSP, V104, P394, DOI 10.2307/3432683; Gauger KJ, 2004, ENVIRON HEALTH PERSP, V112, P516; Genuis SJ, 2006, HUM REPROD, V21, P2201, DOI 10.1093/humrep/del181; GEORGE FW, 1978, J CLIN ENDOCR METAB, V47, P550; Ginsberg GL, 2007, ENVIRON HEALTH PERSP, V115, P361, DOI 10.1289/ehp.9533; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Glatt CM, 2005, ENVIRON HEALTH PERSP, V113, P1354, DOI 10.1289/ehp.7690; Goldey ES, 1998, TOXICOL SCI, V45, P94, DOI 10.1093/toxsci/45.1.94; GOLDEY ES, 1995, TOXICOL APPL PHARM, V135, P77, DOI 10.1006/taap.1995.1210; Gore AC, 2007, CONTEMP ENDOCRINOL S, P1, DOI 10.1007/1-59745-107-X; Gore AC, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P1789; Gore Andrea C, 2008, Fertil Steril, V89, pe101, DOI 10.1016/j.fertnstert.2007.12.039; Gore AC, 2002, GNRH MASTER MOL REPR; Gore AC, 2002, J NEUROENDOCRINOL, V14, P814, DOI 10.1046/j.1365-2826.2002.00845.x; Gore AC, 2002, MOL CELL ENDOCRINOL, V192, P157, DOI 10.1016/S0303-7207(02)00010-2; Gore AC, 2008, FRONT NEUROENDOCRIN, V29, P358, DOI 10.1016/j.yfrne.2008.02.002; Gore AC, 2001, ENDOCRINE, V14, P235, DOI 10.1385/ENDO:14:2:235; Gore AC, 2006, ENDOCRINOLOGY, V147, pS1, DOI 10.1210/en.2005-1367; GRANHOLM AC, 1985, EXP BRAIN RES, V59, P451; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Green R, 2005, ENVIRON HEALTH PERSP, V113, P1222, DOI 10.1289/chp.7932; Greer MA, 2002, ENVIRON HEALTH PERSP, V110, P927; Grun F, 2006, MOL ENDOCRINOL, V20, P2141, DOI 10.1210/me.2005-0367; Grun F, 2006, ENDOCRINOLOGY, V147, pS50, DOI 10.1210/en.2005-1129; Guo SW, 2004, GYNECOL OBSTET INVES, V57, P157, DOI 10.1159/000076374; Guo YL, 2000, LANCET, V356, P1240, DOI 10.1016/S0140-6736(00)02792-6; Gupta C, 2000, UROL RES, V28, P223; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Halakivi-Clarke L, 2000, Clin Cancer Res, V6, P305; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Hansen LG, 1998, ENVIRON HEALTH PERSP, V106, P171, DOI 10.2307/3433919; Hardell L, 2006, J OCCUP ENVIRON MED, V48, P700, DOI 10.1097/01.jom.0000205989.46603.43; Hardell L, 2003, ENVIRON HEALTH PERSP, V111, P930, DOI 10.1289/ehp.5816; Hardell L, 2006, INT J ANDROL, V29, P228, DOI 10.1111/j.1365-2605.2005.00622.x; Harvey PW, 2007, J APPL TOXICOL, V27, P103, DOI 10.1002/jat.1221; Hatch EE, 2006, AM J EPIDEMIOL, V164, P682, DOI 10.1093/aje/kwj257; Hauser R, 2003, ENVIRON HEALTH PERSP, V111, P1505, DOI 10.1289/ehp.6175; Hauser R, 2006, EPIDEMIOLOGY, V17, P682, DOI 10.1097/01.ede.0000235996.89953.d7; Hemminki K, 2002, INT J CANCER, V99, P229, DOI 10.1002/ijc.10323; Hemminki K, 2002, EUR J CANCER, V38, P2428, DOI 10.1016/S0959-8049(02)00496-3; HENDERSON BE, 1988, BRIT J CANCER, V57, P216, DOI 10.1038/bjc.1988.46; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Herbstman J, 2008, THYROID, V18, P67, DOI [10.1089/thy.2007.0180, 10.1018/thy.2007.0180]; Herbstman JB, 2008, ENVIRON HEALTH PERSP, V116, P1376, DOI 10.1289/ehp.11379; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hofkamp L, 2008, ENVIRON HEALTH PERSP, V116, P867, DOI 10.1289/ehp.10983; Holloway AC, 2007, REPROD TOXICOL, V24, P359, DOI 10.1016/j.reprotox.2007.05.003; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Hosie S, 2000, EUR J PEDIATR SURG, V10, P304, DOI 10.1055/s-2008-1072381; Howdeshell KL, 1999, NATURE, V401, P763; Howdeshell KL, 2002, ENVIRON HEALTH PERSP, V110, P337; Howe SR, 1998, J COATING TECHNOL, V70, P69, DOI 10.1007/BF02720503; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; Hsu PC, 2003, JAMA-J AM MED ASSOC, V289, P2943, DOI 10.1001/jama.289.22.2943; Huang LW, 2004, J ANDROL, V25, P330; Huggins C, 1941, CANCER RES, V1, P293; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Huisman M, 1995, EARLY HUM DEV, V43, P165, DOI 10.1016/0378-3782(95)01674-0; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Ibanez L, 2006, MOL CELL ENDOCRINOL, V254, P22, DOI 10.1016/j.mce.2006.04.010; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Ishido M, 2004, J NEUROSCI RES, V76, P423, DOI 10.1002/jnr.20050; Iwasaki T, 2002, BIOCHEM BIOPH RES CO, V299, P384, DOI 10.1016/S0006-291X(02)02659-1; Jabbar MA, 1997, J AM COLL NUTR, V16, P280; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JEFFERIES JA, 1984, AM J OBSTET GYNECOL, V148, P59; Jemal A, 2006, CA-CANCER J CLIN, V56, P106; Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004; JENKINS S, 2009, ENV HLTH PERSPECT, DOI DOI 10.1289/CHP.11571; JOHNSON LD, 1979, OBSTET GYNECOL, V53, P671; Jonsson BAG, 2005, EPIDEMIOLOGY, V16, P487, DOI 10.1097/01.ede.0000164555.19041.01; Juhler RK, 1999, ARCH ENVIRON CON TOX, V37, P415, DOI 10.1007/s002449900533; Kadlubar FF, 2003, CANCER EPIDEM BIOMAR, V12, P327; Kaipia A, 1997, ANNU REV PHYSIOL, V59, P349, DOI 10.1146/annurev.physiol.59.1.349; Kamijima M, 2004, J OCCUP HEALTH, V46, P109, DOI 10.1539/joh.46.109; Kanayama T, 2005, MOL PHARMACOL, V67, P766, DOI 10.1124/mol.104.008409; Kato Y, 2004, TOXICOL SCI, V81, P309, DOI 10.1093/toxsci/kfh225; Kato Y, 1998, ARCH TOXICOL, V72, P541, DOI 10.1007/s002040050540; Kaufman R H, 1982, Obstet Gynecol Annu, V11, P187; Kavlock R, 2005, CRIT REV TOXICOL, V35, P721, DOI 10.1080/10408440591007377; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Kester MHA, 2002, J CLIN ENDOCR METAB, V87, P1142, DOI 10.1210/jc.87.3.1142; Khan IA, 2001, BIOL REPROD, V64, P955, DOI 10.1095/biolreprod64.3.955; Khan MA, 2003, TOXICOL LETT, V144, P173, DOI 10.1016/S0378-4274(03)00203-0; Khurana S, 2000, ENDOCRINOLOGY, V141, P4512, DOI 10.1210/en.141.12.4512; Kimura-Kuroda Junko, 2005, Brain Res Dev Brain Res, V154, P259; Kitamura S, 2002, BIOCHEM BIOPH RES CO, V293, P554, DOI 10.1016/S0006-291X(02)00262-0; Kitamura S, 2005, TOXICOLOGY, V208, P377, DOI 10.1016/j.tox.2004.11.037; Kohrle J, 2007, BEST PRACT RES CL EN, V21, P173, DOI 10.1016/j.beem.2007.04.001; Koibuchi N, 2000, TRENDS ENDOCRIN MET, V11, P123, DOI 10.1016/S1043-2760(00)00238-1; Kortenkamp A, 2008, INT J ANDROL, V31, P233, DOI 10.1111/j.1365-2605.2007.00862.x; Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474; Kouki T, 2005, BRAIN RES BULL, V64, P449, DOI 10.1016/j.brainresbull.2004.10.002; Kretschmer XC, 2005, CHEM-BIOL INTERACT, V155, P111, DOI 10.1016/j.cbi.2005.06.003; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kristensen P, 1997, Epidemiology, V8, P537, DOI 10.1097/00001648-199709000-00011; Krstevska-Konstantinova M, 2001, HUM REPROD, V16, P1020, DOI 10.1093/humrep/16.5.1020; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuriyama SN, 2007, TOXICOLOGY, V242, P80, DOI 10.1016/j.tox.2007.09.011; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; KWINTKIEWICZ J, 2008, P 55 ANN SCI M SOC G; KWINTKIEWICZ J, 2008, P 41 ANN M SOC STUD; Kwintkiewicz J, 2009, SEMIN REPROD MED, V27, P43, DOI 10.1055/s-0028-1108009; LABIB M, 1989, BRIT MED J, V298, P232; Lambe M, 1996, BREAST CANCER RES TR, V38, P305, DOI 10.1007/BF01806150; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Langer Pavel, 2008, Endocr Regul, V42, P79; LANS MC, 1993, CHEM-BIOL INTERACT, V88, P7, DOI 10.1016/0009-2797(93)90081-9; Larsen SB, 1998, REPROD TOXICOL, V12, P581, DOI 10.1016/S0890-6238(98)00047-1; LEAV I, 1988, J NATL CANCER I, V80, P1045, DOI 10.1093/jnci/80.13.1045; Legro RS, 2006, BEST PRACT RES CL EN, V20, P331, DOI 10.1016/j.beem.2006.03.001; Lemmen JG, 2004, ENVIRON HEALTH PERSP, V112, P1544; Lewis DR, 1999, ENVIRON HEALTH PERSP, V107, P359, DOI 10.2307/3434539; Lewis J B, 1999, Clin Oral Investig, V3, P107, DOI 10.1007/s007840050087; Li SF, 2003, ANN NY ACAD SCI, V983, P161; Lifeng Tan, 2006, Contraception, V73, P92, DOI 10.1016/j.contraception.2005.06.067; Longnecker MP, 2002, AM J EPIDEMIOL, V155, P313, DOI 10.1093/aje/155.4.313; Longnecker MP, 1997, ANNU REV PUBL HEALTH, V18, P211, DOI 10.1146/annurev.publhealth.18.1.211; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; Maffini MV, 2005, AM J PATHOL, V167, P1405, DOI 10.1016/S0002-9440(10)61227-8; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Mahajan R, 2006, ENVIRON HEALTH PERSP, V114, P1205, DOI 10.1289/ehp.8911; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Markey CM, 2001, BIOL REPROD, V65, P1215; Marsh G, 1998, ORGANOHALOGEN COMPD, V37, P305; Martin OV, 2007, TOXICOL SCI, V98, P332, DOI 10.1093/toxsci/kfm008; Martinez-Frias ML, 2004, BIRTH DEFECTS RES A, V70, P75, DOI 10.1002/bdra.10149; McGarvey C, 2001, ENDOCRINOLOGY, V142, P1202, DOI 10.1210/en.142.3.1202; McGlynn KA, 2003, CANCER, V97, P63, DOI 10.1002/cncr.11054; MCKINNEY JD, 1994, ENVIRON HEALTH PERSP, V102, P290; McLachlan JA, 2006, INT J EPIDEMIOL, V35, P868, DOI 10.1093/ije/dyl140; MCLACHLAN JA, 1982, FERTIL STERIL, V38, P364; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; McNatty K P, 2007, Soc Reprod Fertil Suppl, V64, P55; Meeker JD, 2004, ENVIRON HEALTH PERSP, V112, P1665, DOI 10.1289/ehp.7234; Meerts IATM, 2002, TOXICOL SCI, V68, P361, DOI 10.1093/toxsci/68.2.361; Meerts IATM, 2000, TOXICOL SCI, V56, P95, DOI 10.1093/toxsci/56.1.95; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MENDEL CM, 1987, ENDOCRINOLOGY, V120, P1742; Mendola Pauline, 2008, Fertil Steril, V89, pe81, DOI 10.1016/j.fertnstert.2007.12.036; Mestman JH, 1998, ENDOCRIN METAB CLIN, V27, P127, DOI 10.1016/S0889-8529(05)70303-0; MEYER JS, 1977, HUM PATHOL, V8, P67, DOI 10.1016/S0046-8177(77)80066-X; Meyer TE, 2007, OCCUP ENVIRON MED, V64, P155, DOI 10.1136/oem.2006.027383; Missmer SA, 2004, FERTIL STERIL, V82, P1501, DOI 10.1016/j.fertnstert.2004.04.065; Miyazaki W, 2004, J BIOL CHEM, V279, P18195, DOI 10.1074/jbc.M310531200; Mizuyachi K, 2002, REPROD TOXICOL, V16, P299, DOI 10.1016/S0890-6238(02)00024-2; Mocarelli P, 2008, ENVIRON HEALTH PERSP, V116, P70, DOI 10.1289/ehp.10399; Modugno F, 2001, CLIN CANCER RES, V7, P3092; Mol NM, 2002, EUR J ENDOCRINOL, V146, P357, DOI 10.1530/eje.0.1460357; Monosson E, 1999, TOXICOL IND HEALTH, V15, P65; MOORE RA, 1947, ENDOCRINOLOGY NEOPLA, P194; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; MORRISON H, 1993, AM J EPIDEMIOL, V137, P270; Morse DC, 1996, TOXICOL APPL PHARM, V136, P269, DOI 10.1006/taap.1996.0034; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray CW, 2008, J EXPO SCI ENV EPID, V18, P571, DOI 10.1038/sj.jes.7500648; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; National Research Council, 2005, HLTH IMPL PERCHL ING; Nayyar T, 2007, REPROD TOXICOL, V23, P326, DOI 10.1016/j.reprotox.2006.09.007; NEWBOLD R, 1995, ENVIRON HEALTH PERSP, V103, P83, DOI 10.2307/3432514; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Newbold RR, 2002, TOXICOL PATHOL, V30, P611, DOI 10.1080/01926230290105839; Newbold RR, 2007, MOL NUTR FOOD RES, V51, P912, DOI 10.1002/mnfr.200600259; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; NEWHOLD RR, 2007, REPROD TOXICOL, V23, P290; Nguon K, 2005, CEREBELLUM, V4, P112, DOI 10.1080/14734220510007860; Noaksson E, 2001, TOXICOL APPL PHARM, V174, P160, DOI 10.1006/taap.2001.9194; Odum J, 2004, ENVIRON HEALTH PERSP, V112, P1472, DOI 10.1289/ehp.7039; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Oliva A, 2001, HUM REPROD, V16, P1768, DOI 10.1093/humrep/16.8.1768; Osius N, 1999, ENVIRON HEALTH PERSP, V107, P843, DOI 10.2307/3454584; Padungtod C, 2000, J OCCUP ENVIRON MED, V42, P982, DOI 10.1097/00043764-200010000-00004; Palha JA, 2000, ENDOCRINOLOGY, V141, P3267; Palha JA, 2002, NEUROSCIENCE, V113, P837, DOI 10.1016/S0306-4522(02)00228-2; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222; Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019; Parent ME, 2001, EPIDEMIOL REV, V23, P138; Parks LG, 2000, TOXICOL SCI, V58, P339, DOI 10.1093/toxsci/58.2.339; Patisaul HB, 2004, HORM BEHAV, V45, P270, DOI 10.1016/j.yhbeh.2003.12.006; Patisaul HB, 2007, NEUROTOXICOLOGY, V28, P1, DOI 10.1016/j.neuro.2006.10.001; Paulozzi LJ, 1999, ENVIRON HEALTH PERSP, V107, P297, DOI 10.2307/3434597; Paulsen CA, 1996, FERTIL STERIL, V65, P1015; Pearce EN, 2007, J CLIN ENDOCR METAB, V92, P1673, DOI 10.1210/jc.2006-2738; Penza M, 2006, ENDOCRINOLOGY, V147, P5740, DOI 10.1210/en.2006-0365; PHILLIPS DL, 1989, ARCH ENVIRON HEALTH, V44, P351; Pierik FH, 2004, ENVIRON HEALTH PERSP, V112, P1570, DOI 10.1289/ehp.7234; Poirier Paul, 2003, J Cardiopulm Rehabil, V23, P161, DOI 10.1097/00008483-200305000-00001; Porte C, 2006, COMP BIOCHEM PHYS C, V143, P303, DOI 10.1016/j.cbpc.2006.03.004; Power DM, 2000, GEN COMP ENDOCR, V119, P241, DOI 10.1006/gcen.2000.7520; Prince MM, 2006, ENVIRON HEALTH PERSP, V114, P1508, DOI 10.1289/ehp.9175; Prins GS, 2001, REPROD FERT DEVELOP, V13, P241, DOI 10.1071/RD00107; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Quadros PS, 2002, ENDOCRINOLOGY, V143, P3727, DOI 10.1210/en.2002-211438; Raghow S, 2002, CANCER RES, V62, P1370; RAJFER J, 1978, INVEST UROL, V16, P186; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Rasier G, 2007, BIOL REPROD, V77, P734, DOI 10.1095/biolreprod.106.059303; Rasier G, 2008, TOXICOL SCI, V102, P33, DOI 10.1093/toxsci/kfm285; Rathore M, 2002, SCI TOTAL ENVIRON, V295, P207, DOI 10.1016/S0048-9697(02)00094-3; Reddy BS, 2006, BJOG-INT J OBSTET GY, V113, P515, DOI 10.1111/j.1471-0528.2006.00925.x; Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257; REFETOFF S, 1989, ENDOCR REV, V10, P275; Remillard RBJ, 2002, ENVIRON HEALTH PERSP, V110, P853; Richardson SJ, 2007, NEUROSCI LETT, V421, P234, DOI 10.1016/j.neulet.2007.05.040; Richiardi L, 2004, CANCER EPIDEM BIOMAR, V13, P2157; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Richthoff J, 2003, ENVIRON HEALTH PERSP, V111, P409, DOI 10.1289/ehp.5767; Rier SE, 2001, TOXICOL SCI, V59, P147, DOI 10.1093/toxsci/59.1.147; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; Rignell-Hydbom A, 2004, HUM REPROD, V19, P2066, DOI 10.1093/humrep/deh362; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; Rivas A, 2002, ENDOCRINOLOGY, V143, P4797, DOI 10.1021/en.2002-220531; Robbins J, 2000, WERNER INGBARS THYRO, P105; Robbins J, 2002, CLIN CHEM LAB MED, V40, P1183, DOI 10.1515/CCLM.2002.208; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; ROTHSCHILD TC, 1987, CANCER RES, V47, P4508; Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Sandu O, 2005, DIABETES, V54, P2314, DOI 10.2337/diabetes.54.8.2314; Schell LM, 2008, ENVIRON HEALTH PERSP, V116, P806, DOI 10.1289/ehp.10490; Schlumpf M, 2004, TOXICOLOGY, V205, P113, DOI 10.1016/j.tox.2004.06.043; Schlumpf M, 2004, TOXICOLOGY, V199, P109, DOI 10.1016/j.tox.2004.02.015; Schneider MJ, 2001, MOL ENDOCRINOL, V15, P2137, DOI 10.1210/me.15.12.2137; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Schrager S, 2004, AM FAM PHYSICIAN, V69, P2395; Schussler GC, 2000, THYROID, V10, P141, DOI 10.1089/thy.2000.10.141; Schuurmans C, 2002, CURR OPIN NEUROBIOL, V12, P26, DOI 10.1016/S0959-4388(02)00286-6; Schwartz CE, 2005, AM J HUM GENET, V77, P41, DOI 10.1086/431313; Seiwa C, 2004, NEUROENDOCRINOLOGY, V80, P21, DOI 10.1159/000080663; Sharara FI, 1998, FERTIL STERIL, V70, P613, DOI 10.1016/S0015-0282(98)00253-2; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sharpe RM, 2006, BEST PRACT RES CL EN, V20, P91, DOI 10.1016/j.beem.2005.09.005; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Sheehan Daniel M., 1999, Environmental Health Perspectives, V107, P155, DOI 10.2307/3434373; Shi ZQ, 2007, BIOL REPROD, V76, P198, DOI 10.1095/biolreprod.106.053991; Shono T, 2004, J PEDIATR SURG, V39, P217, DOI 10.1016/j.jpedsurg.2003.10.014; Siesser WB, 2005, PSYCHOPHARMACOLOGY, V181, P653, DOI 10.1007/s00213-005-0024-5; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; Simoens S, 2007, HUM REPROD UPDATE, V13, P395, DOI 10.1093/humupd/dmm010; Sinha P, 2007, J OBSTET GYNAECOL, V27, P16, DOI 10.1080/01443610601016685; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Slowikowska-Hilczer J, 2001, J ANDROL, V22, P781; Song KH, 2002, ENDOCRINOLOGY, V143, P2208, DOI 10.1210/en.143.6.2208; SONNENSCHEIN C, 1999, SOC CELL CANC CONTRO; Sonnenschein C, 2008, SEMIN CANCER BIOL, V18, P372, DOI 10.1016/j.semcancer.2008.03.012; Sormo EG, 2005, ENVIRON TOXICOL CHEM, V24, P610, DOI 10.1897/04-017R.1; Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Steinberg RM, 2007, HORM BEHAV, V51, P364, DOI 10.1016/j.yhbeh.2006.12.004; Steinberg RM, 2008, BIOL REPROD, V78, P1091, DOI 10.1095/biolreprod.107.067249; Steiner Mitchell S, 2003, Clin Prostate Cancer, V2, P24, DOI 10.3816/CGC.2003.n.009; Steinmaus C, 2007, ENVIRON HEALTH PERSP, V115, P1333, DOI 10.1289/ehp.10300; Stewart P, 2003, ENVIRON HEALTH PERSP, V111, P1670, DOI 10.1289/ehp.6173; St Germain DL, 2005, THYROID, V15, P905; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; Swan SH, 2000, APMIS, V108, P793, DOI 10.1111/j.1600-0463.2000.tb00001.x; Swan SH, 1997, ENVIRON HEALTH PERSP, V105, P1228; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P1478, DOI 10.1289/ehp.6417; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Takeuchi T, 2006, ENDOCR J, V53, P485, DOI 10.1507/endocrj.K06-032; Talsness CE, 2008, ENVIRON RES, V108, P158, DOI 10.1016/j.envres.2008.08.008; Tan Li-feng, 2005, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V23, P87; Taurog A., 2000, THYROID FUNDAMENTAL, P61; TAUROG A, 1964, MAYO CLIN PROC, V39, P569; THOMAS JA, 1994, J ANDROL, V15, P97; Thomas P, 2004, ENVIRON SCI TECHNOL, V38, P6328, DOI 10.1021/es0403662; Thomsen C, 2002, ENVIRON SCI TECHNOL, V36, P1414, DOI 10.1021/es0102282; Thonneau PE, 2003, J ANDROL, V24, P155; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Tokumoto T, 2007, ENDOCRINOLOGY, V148, P3459, DOI 10.1210/en.2006-1694; Toppari J, 2001, HUM REPROD UPDATE, V7, P282, DOI 10.1093/humupd/7.3.282; Trichopoulos D, 1990, Epidemiology, V1, P95; Tseng LH, 2008, CHEMOSPHERE, V70, P640, DOI 10.1016/j.chemosphere.2007.06.078; Uribarri J, 2007, DIABETES CARE, V30, P2579, DOI 10.2337/dc07-0320; Usmani KA, 2003, DRUG METAB DISPOS, V31, P384, DOI 10.1124/dmd.31.4.384; Usmani KA, 2006, DRUG METAB DISPOS, V34, P1606, DOI 10.1124/dmd.106.010439; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; van Maele-Fabry G, 2006, CANCER CAUSE CONTROL, V17, P353, DOI 10.1007/s10552-005-0443-y; Vermiglio F, 2004, J CLIN ENDOCR METAB, V89, P6054, DOI 10.1210/jc.2004-0571; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; VRANCKX R, 1990, BIOCHEM J, V271, P373; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; Wada K, 2007, J PHARMACOL SCI, V105, P133, DOI 10.1254/jphs.FM0070034; Walker DM, 2007, CONTEMP ENDOCRINOL S, P63, DOI 10.1007/1-59745-107-X_4; Walkowiak J, 2001, LANCET, V358, P1602, DOI 10.1016/S0140-6736(01)06654-5; Walsh DE, 2005, MOL CELL ENDOCRINOL, V230, P23, DOI 10.1016/j.mce.2004.11.006; Waring RH, 2005, MOL CELL ENDOCRINOL, V244, P2, DOI 10.1016/j.mce.2005.02.007; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Watson WH, 2007, TOXICOL SCI, V98, P1, DOI 10.1093/toxsci/kfm111; Weidner IS, 1998, ENVIRON HEALTH PERSP, V106, P793, DOI 10.1289/ehp.98106793; Weir HK, 2000, INT J CANCER, V87, P438, DOI 10.1002/1097-0215(20000801)87:3&lt;438::AID-IJC20&gt;3.0.CO;2-1; West C, 2001, MOL CELL ENDOCRINOL, V185, P51, DOI 10.1016/S0303-7207(01)00632-3; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wetherill YB, 2005, CANCER RES, V65, P54; WHITTEN PL, 1995, P SOC EXP BIOL MED, V208, P82; *WHO, 1995, TETR A DER; WHO, 1997, FLAM RET GEN INTR; WHORTON MD, 1979, J TOXICOL ENV HEALTH, V5, P929; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047;484628ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCR REVJUNDiscipline: Endocrinology &amp; Metabolism455BT</notes>
    <keywords>1; Behavior; BIRTH; BISPHENOL-A ALTERS; Brain; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; cardiovascular; CE; CELL; CHEMICALS; DEFECTS; development; diabetes; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; environment; Epidemiology; ER; ESTROGEN-RECEPTOR-BETA; Estrogenic; female; FETAL-RAT BRAIN; FOOD; GONADOTROPIN-RELEASING-HORMONE; HEALTH; Hormone; Hormones; HUMAN SEMEN QUALITY; HUMANS; In vitro; in vivo; IN-UTERO EXPOSURE; IN-VITRO; IN-VIVO; JUN; Male; mechanism; MECHANISMS; METABOLISM; MODEL; MODELS; Nuclear receptor; NUCLEAR RECEPTORS; Obesity; p21; P8; PATHWAY; pediatric; PERSISTENT ORGANIC POLLUTANTS; PESTICIDES; Plasticizers; Plastics; POLYCHLORINATED-BIPHENYLS PCBS; POLYCYSTIC-OVARY-SYNDROME; PRODUCTS; Prostate; prostate cancer; PROSTATE-CANCER; RECEPTOR; RECEPTOR-GAMMA; Receptors; Reproduction; Review; RISK; SOCIETY; STATEMENT; Steroid; SYSTEM; TESTICULAR DYSGENESIS SYNDROME; Thyroid; toxicology; UPDATE; VITRO; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>293</startpage>
    <endpage>342</endpage>
    <journalfull>Endocrine Reviews</journalfull>
    <issue>4</issue>
    <volume>30</volume>
    <abstract>There is growing interest in the possible health threat posed by endocrine-disrupting chemicals (EDCs), which are substances in our environment, food, and consumer products that interfere with hormone biosynthesis, metabolism, or action resulting in a deviation from normal homeostatic control or reproduction. In this first Scientific Statement of The Endocrine Society, we present the evidence that endocrine disruptors have effects on male and female reproduction, breast development and cancer, prostate cancer, neuroendocrinology, thyroid, metabolism and obesity, and cardiovascular endocrinology. Results from animal models, human clinical observations, and epidemiological studies converge to implicate EDCs as a significant concern to public health. The mechanisms of EDCs involve divergent pathways including (but not limited to) estrogenic, antiandrogenic, thyroid, peroxisome proliferator-activated receptor gamma, retinoid, and actions through other nuclear receptors; steroidogenic enzymes; neurotransmitter receptors and systems; and many other pathways that are highly conserved in wildlife and humans, and which can be modeled in laboratory in vitro and in vivo models. Furthermore, EDCs represent a broad class of molecules such as organochlorinated pesticides and industrial chemicals, plastics and plasticizers, fuels, and many other chemicals that are present in the environment or are in widespread use. We make a number of recommendations to increase understanding of effects of EDCs, including enhancing increased basic and clinical research, invoking the precautionary principle, and advocating involvement of individual and scientific society stakeholders in communicating and implementing changes in public policy and awareness. (Endocrine Reviews 30: 293-342, 2009)</abstract>
    <url>WOS:000266731700001</url>
    <isbnorissn>0163-769X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>404</id>
    <title>Seasonal distribution and modeling of diesel particulate matter in the Southeast US</title>
    <authors>Diaz-Robles,L.A.; Fu,J.S.; Reed,G.D.; DeLucia,A.J.</authors>
    <availability>[Fu, J. S.; Reed, G. D.] Univ Tennessee, Dept Civil &amp; Environm Engn, Knoxville, TN 37996 USA. [Diaz-Robles, L. A.] Catholic Univ Temuco, Sch Environm Engn, Temuco, Chile. [DeLucia, A. J.] E Tennessee State Univ, Dept Surg, Johnson City, TN 37614 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticleFu, JS (reprint author), Univ Tennessee, Dept Civil &amp; Environm Engn, 223 Perkins Hall, Knoxville, TN 37996 USAjsfu@utk.eduArlt VM, 2005, MUTAGENESIS, V20, P399, DOI 10.1093/mutage/gei057; Burtscher H, 2005, J AEROSOL SCI, V36, P896, DOI 10.1016/j.jaerosci.2004.12.001; BYUN DW, 1999, SCI ALGORITHMS EPA M; Carlsten C, 2007, THROMB RES, V120, P849, DOI 10.1016/j.thromres.2007.01.005; CHING J, 2004, MOD 3 C COMM MOD AN; Diaz-Robles LA, 2008, ENVIRON INT, V34, P1, DOI 10.1016/j.envint.2007.06.002; Doraiswamy P, 2007, J AIR WASTE MANAGE, V57, P407, DOI 10.3155/1047-3289.57.4.407; FLANNER MG, 2007, J GEOPHYS RES-ATMOS, V112, P202; Geller MD, 2006, ATMOS ENVIRON, V40, P6988, DOI 10.1016/j.atmosenv.2006.06.018; Hesterberg T, 2006, CRIT REV TOXICOL, V36, P727, DOI 10.1080/10408440600908821; Jacobson MZ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001376; JACOBSON MZ, 2005, J GEOPHYS RES-ATMOS, V110, P105; JACOBSON MZ, 2004, J GEOPHYS RES-ATMOS, V109, P201; Jimenez-Guerrero P, 2008, SCI TOTAL ENVIRON, V390, P323, DOI 10.1016/j.scitotenv.2007.10.025; Kim D, 2002, J AEROSOL SCI, V33, P1609, DOI 10.1016/S0021-8502(02)00119-2; Kleeman MJ, 2000, ENVIRON SCI TECHNOL, V34, P1132, DOI 10.1021/es981276y; Lloyd AC, 2001, J AIR WASTE MANAGE, V51, P809; Marmur A, 2006, ATMOS ENVIRON, V40, P2533, DOI 10.1016/j.atmosenv.2005.12.019; Matsumoto H, 2005, ARCH ENVIRON CON TOX, V48, P459, DOI 10.1007/s00244-003-0243-x; MILLER T, 2005, TDOT FEDERAL HIGHWAY; Monforton C, 2006, AM J PUBLIC HEALTH, V96, P271, DOI 10.2105/AJPH.2005.064410; Moosmuller H, 2001, ENVIRON SCI TECHNOL, V35, P781, DOI 10.1021/es0013935; Morris R, 2005, J AIR WASTE MANAGE, V55, P1683; Mysliwiec MJ, 2002, ENVIRON SCI TECHNOL, V36, P5376, DOI 10.1021/es020832s; Ning Z, 2004, J AEROSOL SCI, V35, P333, DOI 10.1016/j.jaerosci.2003.10.001; *PSU NCAR, 2005, MM5 MOD; REDDY MS, 2007, GEOPHYS RES LETT, V34, P802; Roux AVD, 2006, AM J EPIDEMIOL, V164, P437, DOI 10.1093/aje/kwj186; Ruckerl R, 2007, ENVIRON HEALTH PERSP, V115, P1072, DOI 10.1289/ehp.10021; Ruckerl R, 2006, AM J RESP CRIT CARE, V173, P432, DOI 10.1164/rccm.200507-1123OC; Saiyasitpanich P, 2005, J AIR WASTE MANAGE, V55, P993; Scapellato ML, 2007, CRIT REV TOXICOL, V37, P461, DOI 10.1080/10408440701385622; Schauer JJ, 2003, J EXPO ANAL ENV EPID, V13, P443, DOI 10.1038/sj.jea.7500298; See SW, 2006, J TOXICOL ENV HEAL A, V69, P1909, DOI 10.1080/15287390600751280; Seigneur C, 2003, ENVIRON SCI TECHNOL, V37, P5236, DOI 10.1021/es034433o; Shah SD, 2004, ENVIRON SCI TECHNOL, V38, P2544, DOI 10.1021/es0350583; Shi JP, 2000, ENVIRON SCI TECHNOL, V34, P748, DOI 10.1021/es990530z; Sullivan J, 2007, ENV HLTH, P6; Tesche TW, 2006, ATMOS ENVIRON, V40, P4906, DOI 10.1016/j.atmosenv.2005.08.046; Tomaru M, 2007, INT J MOL MED, V19, P17; Toren K, 2007, OCCUP ENVIRON MED, V64, P515, DOI 10.1136/oem.2006.029488; *UNC CHAP HILL, 2004, SPARS MATR OP KERN E; Urch B, 2005, ENVIRON HEALTH PERSP, V113, P1052, DOI 10.1289/ehp.7785; *USEPA, 2005, NAT EM INV VERS 3 YE; USEPA, 2002, EPA600890057F; *USEPA, 2001, GUID DEM ATT AIR QUA; USEPA, 2007, EPA454B07002; *USEPA, 2005, EPA420R05003; Utell MJ, 2000, ENVIRON HEALTH PERSP, V108, P605, DOI 10.2307/3454396; Vouitsis E, 2005, ATMOS ENVIRON, V39, P1335, DOI 10.1016/j.atmosenv.2004.11.011; Weber R, 2003, J AIR WASTE MANAGE, V53, P84; Wilson NK, 2007, ENVIRON RES, V103, P9, DOI 10.1016/j.envres.2006.04.006; Wilson NK, 2003, J EXPO ANAL ENV EPID, V13, P187, DOI 10.1038/sj.jea.7500270; Zeka A, 2006, INT J EPIDEMIOL, V35, P1347, DOI 10.1093/ije/dyl132; Zheng M, 2002, ENVIRON SCI TECHNOL, V36, P2361, DOI 10.1021/es011275x553PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDENVIRON INTAUGDiscipline: Environmental Sciences &amp; Ecology463FM</notes>
    <keywords>AIR-POLLUTION; analysis; BISPHENOL-A; CANCER; CANCER RISK; CANCER-RISK; CARBON; CMAQ; Composition; DAY-CARE; Diesel particulate matter; EMISSIONS; EXHAUST PARTICLES; EXPOSURES; HEALTH; HEART-DISEASE; Metals; MODEL; Modeling; nitrate; PERFORMANCE; PM(2.5); PRESCHOOL-CHILDREN; RISK; Seasonality; SOURCE APPORTIONMENT; UNITED-STATES; Urban</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>956</startpage>
    <endpage>964</endpage>
    <journalfull>Environment International</journalfull>
    <issue>6</issue>
    <volume>35</volume>
    <abstract>The fine and ultra fine size of diesel particulate mater (DPM) are of great health concern and significantly contribute to the overall cancer risk. In addition, diesel particles may contribute a warming effect on the planet's climate. The composition of these particles is composed principally of elemental carbon (EC) with adsorbed organic compounds, sulfate, nitrate, ammonia, metals, and other trace elements. The purpose of this study was to depict the seasonality and modeling of particulate matter in the Southeastern US produced by the diesel fueled sources (DFSs). The modeling results came from four one-month cases including March, June, September, and December to represent different seasons in 2003 by linking Models-3/CMAQ and SMOKE. The 1999 National Emissions Inventory Version 3 (NEI99) was used in this analysis for point, area, and non-road sources, whereas the National Mobile Inventory Model (NMIM) was used to create the on-road emissions. Three urban areas, Atlanta, Birmingham. and Nashville were selected to analyze the DPM emissions and concentrations. Even though the model performance was not very strong, it could be considered satisfactory to conduct seasonal distribution analysis for DPM. Important hourly DPM seasonality was observed in each city, of which higher values occurred at the morning traffic rush hours. The EC contributions of primary DPM were similar for all three sites (similar to 74%). The results showed that there is no significant daily seasonality of DPM contribution to PM(2.5) for any of these three cities in 2003. The annual DPM contribution to total PM(2.5) for Atlanta, Nashville, and Birmingham were 3.7%, 2.5%, and 2.2%, respectively. Published by Elsevier Ltd</abstract>
    <url>WOS:000267415500018</url>
    <isbnorissn>0160-4120</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>71</id>
    <title>Recent Evidence Regarding Triclosan and Cancer Risk</title>
    <authors>Dinwiddie,M.T.; Terry,P.D.; Chen,J.G.</authors>
    <availability>[Dinwiddie, Michael T.; Terry, Paul D.; Chen, Jiangang] Univ Tennessee, Dept Publ Hlth, Knoxville, TN 37996 USA. [Terry, Paul D.] Univ Tennessee, Dept Surg, Med Ctr, Knoxville, TN 37920 USA.</availability>
    <date>2014</date>
    <notes>JEnglishEditorial MaterialTerry, PD (reprint author), Univ Tennessee, Dept Publ Hlth, Knoxville, TN 37996 USAmdinwidd@utk.edu; pdterry@utk.edu; jchen38@utk.eduAdolfsson-Erici M, 2002, CHEMOSPHERE, V46, P1485, DOI 10.1016/S0045-6535(01)00255-7; Ahn KC, 2008, ENVIRON HEALTH PERSP, V116, P1203, DOI 10.1289/ehp.11200; Allmyr M, 2008, SCI TOTAL ENVIRON, V393, P162, DOI 10.1016/j.scitotenv.2007.12.006; Allmyr M, 2006, SCI TOTAL ENVIRON, V372, P87, DOI 10.1016/j.scitotenv.2006.08.007; Bedoux G, 2012, ENVIRON SCI POLLUT R, V19, P1044, DOI 10.1007/s11356-011-0632-z; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; Calafat AM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3494; Calafat AM, 2006, INT J ANDROL, V29, P166, DOI 10.1111/j.1365-2605.2005.00570.x; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Dann AB, 2011, J APPL TOXICOL, V31, P285, DOI 10.1002/jat.1660; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; Dayan AD, 2007, FOOD CHEM TOXICOL, V45, P125, DOI 10.1016/j.fct.2006.08.009; Deepa PR, 2012, BASIC CLIN PHARMACOL, V110, P494, DOI 10.1111/j.1742-7843.2011.00844.x; Deepa P R, 2010, J Ocul Biol Dis Infor, V3, P117, DOI 10.1007/s12177-011-9065-7; Erler C, 2010, J PEDIATR NURS, V25, P400, DOI 10.1016/j.pedn.2009.05.006; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI [10.2217/fon.10.11, 10.2217/FON.10.11]; Gee RH, 2008, J APPL TOXICOL, V28, P78, DOI 10.1002/jat.1316; Geens T, 2012, CHEMOSPHERE, V87, P796, DOI 10.1016/j.chemosphere.2012.01.002; Henry ND, 2013, J APPL TOXICOL, V33, P265, DOI 10.1002/jat.1736; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Laas E., 2012, BREAST CANC, V2012; Liu BQ, 2002, CANCER CHEMOTH PHARM, V49, P187, DOI 10.1007/s00280-001-0399-x; Lu SY, 2005, CARCINOGENESIS, V26, P153, DOI 10.1093/carcin/bgh278; Moss T, 2000, FOOD CHEM TOXICOL, V38, P361, DOI 10.1016/S0278-6915(99)00164-7; Recchia AG, 2004, FOOD ADDIT CONTAM, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; Rodricks JV, 2010, CRIT REV TOXICOL, V40, P422, DOI 10.3109/10408441003667514; Roy JR, 2009, MED SCI MONITOR, V15, pRA137; Sandborgh-Englund G, 2006, J TOXICOL ENV HEAL A, V69, P1861, DOI 10.1080/15287390600631706; Stoker TE, 2010, TOXICOL SCI, V117, P45, DOI 10.1093/toxsci/kfq180; Toms LML, 2011, CHEMOSPHERE, V85, P1682, DOI 10.1016/j.chemosphere.2011.08.009; Vandhana S, 2013, BBA-MOL CELL BIOL L, V1831, P1458, DOI 10.1016/j.bbalip.2013.06.005320MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J ENV RES PUB HEFEBDiscipline: Environmental Sciences &amp; EcologyAF0WZ</notes>
    <keywords>BISPHENOL-A; BLOOD-SERUM; breast cancer; breast neoplasms; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CELLS; epidemiologic studies; Estrogen; Estrogenicity; EXPOSURE; fatty acid synthesis; FATTY-ACID SYNTHASE; FOOD; HUMAN EXPOSURE; HUMAN HEALTH; HUMAN-MILK; IN-VITRO; Milk; RISK; serum; Triclosan; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2209</startpage>
    <endpage>2217</endpage>
    <journalfull>International Journal of Environmental Research and Public Health</journalfull>
    <issue>2</issue>
    <volume>11</volume>
    <abstract>Triclosan is a broad-spectrum antibacterial commonly used in cosmetics, dentifrices, and other consumer products. The compound's widespread use in consumer products and its detection in breast milk, urine, and serum have raised concerns regarding its potential association with various human health outcomes. Recent evidence suggests that triclosan may play a role in cancer development, perhaps through its estrogenicity or ability to inhibit fatty acid synthesis. Our aims here are to review studies of human exposure levels, to evaluate the results of studies examining the effects of triclosan on cancer development, and to suggest possible directions for future research</abstract>
    <url>WOS:000334436600061</url>
    <isbnorissn>1660-4601</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>176</id>
    <title>Genotoxicity and reproductive toxicity of bisphenol A and X-ray/bisphenol A combination in male mice</title>
    <authors>Dobrzynska,M.M.; Radzikowska,J.</authors>
    <availability>[Dobrzynska, Malgorzata M.; Radzikowska, Joanna] Natl Inst Hyg, Natl Inst Publ Hlth, Dept Radiat Protect &amp; Radiobiol, PL-00791 Warsaw, Poland.</availability>
    <date>2013</date>
    <notes>JEnglishArticleDobrzynska, MM (reprint author), Natl Inst Hyg, Natl Inst Publ Hlth, Dept Radiat Protect &amp; Radiobiol, 24 Chocimska St, PL-00791 Warsaw, Polandmdobrzynska@pzh.gov.plAikawa H., 2004, CELL TISSUE RES, V315, P1119; Al-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Anderson D, 1997, TERATOGEN CARCIN MUT, V17, P45, DOI 10.1002/(SICI)1520-6866(1997)17:2&lt;45::AID-TCM1&gt;3.0.CO;2-E; Anderson Diana, 1997, Journal of Environmental Pathology Toxicology and Oncology, V16, P313; ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X; Ashby J, 2003, TOXICOL SCI, V74, P129, DOI 10.1093/toxsci/kfg093; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; Aydogan M, 2010, DRUG CHEM TOXICOL, V33, P193, DOI 10.3109/01480540903286468; Bae B, 2002, WATER SCI TECHNOL, V46, P381; BEIR, 1990, HLTH EFF EXP LOW LEV; Bennetts LE, 2008, MUTAT RES-FUND MOL M, V641, P1, DOI 10.1016/j.mrfmmm.2008.02.002; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Carrera P, 1998, MUTAT RES-GEN TOX EN, V413, P23, DOI 10.1016/S1383-5718(98)00009-6; Cavalieri EL, 2002, CARCINOGENESIS, V23, P1071, DOI 10.1093/carcin/23.6.1071; Chen YM, 2000, CHEM RES TOXICOL, V13, P342, DOI 10.1021/tx990186j; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; Chitra KC, 2003, ASIAN J ANDROL, V5, P203; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; COLLINS BW, 1992, MUTAT RES, V281, P287, DOI 10.1016/0165-7992(92)90023-B; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Dessi-Fulgheri F, 2002, ENVIRON HEALTH PERSP, V110, P403; Dobrzynska MM, 2000, TERATOGEN CARCIN MUT, V20, P133, DOI 10.1002/(SICI)1520-6866(2000)20:3&lt;133::AID-TCM4&gt;3.0.CO;2-B; Dobrzynska M.M., 2010, ANN NATL I HYG, V61, P129; Dobrzynska MM, 2007, IN VIVO, V21, P657; Dobrzynska MM, 2005, TOXICOLOGY, V207, P331, DOI 10.1016/j.tox.2004.10.002; Drozdz K, 2011, ARCH TOXICOL, V85, P1453, DOI 10.1007/s00204-010-0593-x; Durner J, 2011, ARCH TOXICOL, V85, P143, DOI 10.1007/s00204-010-0558-0; EFSA, 2006, EFSA J, V428, P1, DOI DOI 10.2903/J.EFSA.2007A28; Elliott A, 2009, J RADIOL PROT, V29, pA107, DOI 10.1088/0952-4746/29/2A/S07; Haighton L. A., 2002, REGUL TOXICOL PHARM, V35, P199; Haines GA, 2001, MUTAT RES-GEN TOX EN, V495, P21, DOI 10.1016/S1383-5718(01)00181-4; Haines GA, 2002, BIOL REPROD, V67, P854, DOI 10.1095/biolreprod.102.004382; HARRISON A, 1980, HEALTH PHYS, V39, P219, DOI 10.1097/00004032-198008000-00007; Hereth C. B., 2004, ENDOCRINE, V25, P163; Howe SR, 1998, FOOD ADDIT CONTAM A, V15, P370; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Izzotti A, 2010, CURR CANCER DRUG TAR, V10, P147; Konca K, 2003, MUTAT RES-GEN TOX EN, V534, P15, DOI 10.1016/S1383-5718(02)00251-6; Lyons G, 2000, BISPHENOL KNOWN ENDO; Markey CM, 2001, BIOL REPROD, V65, P1215; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Mendiola-Cruz MT, 1999, MUTAT RES-DNA REPAIR, V433, P45, DOI 10.1016/S0921-8777(98)00061-5; Mobley JA, 2004, CARCINOGENESIS, V25, P3, DOI 10.1093/carcin/bgg175; Mutou Y., 2006, BIOL PHARM BULL, V29, P216; Naik P, 2009, MUTAT RES-GEN TOX EN, V676, P106, DOI 10.1016/j.mrgentox.2009.04.010; Pacchierotti F, 2008, MUTAT RES-GEN TOX EN, V651, P64, DOI 10.1016/j.mrgentox.2007.10.009; Park D. H., 2004, Journal of Animal Science and Technology, V46, P957; Paz-Elizur T, 2008, CANCER LETT, V266, P60, DOI 10.1016/j.canlet.2008.02.032; Pollycove M, 1998, ENVIRON HEALTH PERSP, V106, P363, DOI 10.2307/3433939; Pollycove M, 2003, HUM EXP TOXICOL, V22, P290, DOI 10.1191/0960327103ht365oa; Rosenfeldt EJ, 2004, ENVIRON SCI TECHNOL, V38, P5476, DOI 10.1021/es035413p; Sakue M., 2001, J OCCUP HEALTH, V43, P185; Schonfelder G, 2004, NEOPLASIA, V6, P584, DOI 10.1593/neo.04217; Searle A. G, 1974, MUTAT RES, V22, P69; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Skakkebaek NE, 1998, APMIS, V106, P3; Takao Y, 2002, J HEALTH SCI, V48, P331, DOI 10.1248/jhs.48.331; Toyama Y, 2004, ARCH HISTOL CYTOL, V67, P373, DOI 10.1679/aohc.67.373; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; Ulutas OK, 2011, ARCH TOXICOL, V85, P995, DOI 10.1007/s00204-010-0620-y; U.S.EPA, 2008, BISPH INT RISK INFL; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Wetherill YB, 2002, MOL CANCER THER, V1, P515; WORKING PK, 1985, TOXICOL APPL PHARM, V77, P144, DOI 10.1016/0041-008X(85)90275-3; WYROBEK AJ, 1975, P NATL ACAD SCI USA, V72, P4425, DOI 10.1073/pnas.72.11.4425; Yamamoto T, 1999, CHEMOSPHERE, V38, P2569, DOI 10.1016/S0045-6535(98)00464-0; Yoshida T., 2001, FOOD ADDIT CONTAM, V15, P3707010INFORMA HEALTHCARELONDONTELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDDRUG CHEM TOXICOLJANDiscipline: Chemistry; Pharmacology &amp; Pharmacy; Toxicology047JP</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CELLS; COMBINATION; Combined exposure; Comet assay; DNA damage; DNA-DAMAGE; ENDOCRINE; Endocrine-disrupting chemicals; EXPOSURE; FOOD; GENOTOXICITY; germ and somatic cells; HEALTH; HUMAN-LYMPHOCYTES; IN-VIVO; INDUCTION; Lymphocytes; Male; MICE; Neoplasia; oncology; Oxidative stress; p21; PHARMACOLOGY; PREVENTION; RISK; sperm count and quality; SPERM PRODUCTION; SPRAGUE-DAWLEY RATS; TISSUE; TOXICITY; toxicology; VITAMIN-C; WATER; X-rays</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>19</startpage>
    <endpage>26</endpage>
    <journalfull>Drug and Chemical Toxicology</journalfull>
    <issue>1</issue>
    <volume>36</volume>
    <abstract>This study was designed to investigate the effects of 2 weeks of exposure of male mice to bisphenol A (BPA) alone or in a combination with X-rays on the sperm count and quality as well as induction of DNA strand breaks in somatic and germ cells. Pzh:SFIS male mice were exposed to X-rays (0.05 and 0.10 Gy) or BPA (5, 10, 20, and 40 mg/kg) or to a combination of both (0.05 Gy + 5 mg/kg body weight of BPA and 0.10 Gy + 10 mg/kg of BPA). Both X-rays and BPA administered alone decreased sperm count and quality. X-rays induced DNA strand breaks in spleen cells, whereas BPA induced DNA strand breaks in lymphocytes and in cells from spleen, kidneys, and lung and in germ cells. After combined exposure to both agents, sperm count and quality were similar as after exposure to each agent alone and significantly reduced, compared to control. Levels of DNA damage in somatic and germ cells after combined exposure to lower, as well as higher, doses were significantly reduced, compared to the effects of BPA alone. Results confirmed the mutagenic ability of BPA. Combined exposure to X-rays and BPA leads to the prevention of DNA damage in somatic and germ cells of mice</abstract>
    <url>WOS:000311836600003</url>
    <isbnorissn>0148-0545</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>8</id>
    <title>DNA damage in organs of female and male mice exposed to nonylphenol, as a single agent or in combination with ionizing irradiation: A comet assay study</title>
    <authors>Dobrzynska,M.M.</authors>
    <availability>Natl Inst Publ Hlth, Natl Inst Hyg, Dept Radiat Hyg &amp; Radiobiol, PL-00791 Warsaw, Poland.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDobrzynska, MM (reprint author), Natl Inst Publ Hlth, Natl Inst Hyg, Dept Radiat Hyg &amp; Radiobiol, 24 Chocimska Str, PL-00791 Warsaw, Polandmdobrzynska@pzh.gov.plBarcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Barsiene J, 2006, AQUAT TOXICOL, V78, pS99, DOI 10.1016/j.aquatox.2006.02.022; Carrera P, 1998, MUTAT RES-GEN TOX EN, V413, P23, DOI 10.1016/S1383-5718(98)00009-6; Chitra KC, 2002, ARCH TOXICOL, V76, P545, DOI 10.1007/s00204-002-0372-4; COLDITZ GA, 1993, CANCER, V71, P1480, DOI 10.1002/cncr.2820710413; Czajka Urszula, 2006, Rocz Panstw Zakl Hig, V57, P155; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; de Jager C, 1999, ANDROLOGIA, V31, P99, DOI 10.1046/j.1439-0272.1999.00245.x; de Jager C, 1999, ANDROLOGIA, V31, P107, DOI 10.1046/j.1439-0272.1999.00246.x; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Diel P, 2002, TOXICOL LETT, V127, P217, DOI 10.1016/S0378-4274(01)00503-3; Dobrzynska MM, 2012, DRUG CHEM TOXICOL, V35, P36, DOI 10.3109/01480545.2011.586036; Dobrzy,ska Ma,gorzata M, 2012, Rocz Panstw Zakl Hig, V63, P417; Dobrzynska MM, 2013, DRUG CHEM TOXICOL, V36, P19, DOI 10.3109/01480545.2011.644561; Dobrzynska MM, 2007, IN VIVO, V21, P657; Dobrzynska MM, 2005, TOXICOLOGY, V207, P331, DOI 10.1016/j.tox.2004.10.002; Dobrzynska MM, 2011, CENT EUR J BIOL, V6, P320, DOI 10.2478/s11535-011-0021-0; Dobrzy,ska Ma,gorzata M, 2008, Rocz Panstw Zakl Hig, V59, P309; Elliott A, 2009, J RADIOL PROT, V29, pA107, DOI 10.1088/0952-4746/29/2A/S07; Gajowik A, 2013, MUTAT RES-GEN TOX EN, V757, P120, DOI 10.1016/j.mrgentox.2013.07.006; Guenther K, 2002, ENVIRON SCI TECHNOL, V36, P1676, DOI 10.1021/es010199v; Han XD, 2004, REPROD TOXICOL, V19, P215, DOI 10.1016/j.reprotox.2004.06.014; Hernandez JP, 2006, TOXICOL APPL PHARM, V216, P186, DOI 10.1016/j.taap.2006.05.014; JOBLING S, 1993, AQUAT TOXICOL, V27, P361, DOI 10.1016/0166-445X(93)90064-8; Jubendradass R, 2012, REGUL TOXICOL PHARM, V62, P405, DOI 10.1016/j.yrtph.2012.01.004; JUNK GA, 1974, ENVIRON SCI TECHNOL, V8, P1100, DOI 10.1021/es60098a009; Korkmaz A, 2011, ENVIRON TOXICOL, V26, P325, DOI 10.1002/tox.20556; Kumaravel TS, 2006, MUTAT RES-GEN TOX EN, V605, P7, DOI 10.1016/j.mrgentox.2006.03.002; Lee HB, 1999, WATER QUAL RES J CAN, V34, P3; Lee PC, 1999, ENDOCRINE, V11, P61, DOI 10.1385/ENDO:11:1:61; Loyo-Rosales JE, 2004, J AGR FOOD CHEM, V52, P2016, DOI 10.1021/jf0345696; Mekkawy IA, 2011, TISSUE CELL, V43, P223, DOI 10.1016/j.tice.2011.03.006; Niclopoulou-Stamati P., 2001, HUM REPROD UPDATE, V7, P323; Pflieger-Bruss S, 2004, ANDROLOGIA, V36, P337, DOI 10.1111/j.1439-0272.2004.00641.x; Pocar P, 2003, REPRODUCTION, V125, P313, DOI 10.1530/rep.0.1250313; Rivero CLG, 2008, ECOTOXICOLOGY, V17, P732, DOI 10.1007/s10646-008-0222-0; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Skakkebaek NE, 1998, APMIS, V106, P3; Tayama S, 2008, MUTAT RES-GEN TOX EN, V649, P114, DOI 10.1016/j.mrgentox.2007.08.006; Toft G, 2004, REPROD TOXICOL, V19, P5, DOI 10.1016/j.reprotox.2004.05.006; UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation), 2008, UNSCEAR UN PUBL; Watanabe H, 2004, J MOL ENDOCRINOL, V33, P243, DOI 10.1677/jme.0.0330243; Waxman David J., 1995, P391; Windham GC, 2005, EPIDEMIOLOGY, V16, P182, DOI 10.1097/01.ede.0000152527.24339.17; Woo GH, 2007, ARCH TOXICOL, V81, P77, DOI 10.1007/s00204-006-0129-6; Yao GH, 2006, MOL IMMUNOL, V43, P915, DOI 10.1016/j.molimm.2005.06.031460ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSMUTAT RES-GEN TOX ENSEP 15Discipline: Biotechnology &amp; Applied Microbiology; Genetics &amp; Heredity; ToxicologyAQ1FU</notes>
    <keywords>ABNORMALITIES; BISPHENOL-A; BREAST-CANCER; CANCER; CELLS; Combined exposure; Comet assay; Endocrine-disrupting chemicals; EXPOSURE; MALE RATS; Mouse; Nonylphenol; P-NONYLPHENOL; RADIATION; REPRODUCTIVE-SYSTEM; Somatic cells; X-rays</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>14</startpage>
    <endpage>19</endpage>
    <journalfull>Mutation Research-Genetic Toxicology and Environmental Mutagenesis</journalfull>
    <volume>772</volume>
    <abstract>The effect of nonylphenol (NP; either alone or in combination with ionizing radiation) on the induction of DNA strand breaks in mouse somatic cells has been examined. Male and female mice were repeatedly irradiated with X-rays (0.05 or 0.10 Gy), injected with NP (25 or 50 mg/kg bw), or both (0.05 Gy + 25 mg/kg bw NP or 0.10 Gy + 50 mg/kg bw NP), for 2 weeks, 5 days/week. Liver, spleen, femora, lungs and kidneys were removed from each animal for the comet assay. NP-induced DNA damage differed, depending on organ and sex. In male mice, NP induced damage in all organs examined; in females, only the kidneys were affected. The effect of irradiation alone was similar in females and males. Combined exposure of males to 0.05 Gy + 25 mg/kg bw NP significantly reduced the level of DNA strand breaks, compared to the controls and to 25 mg/kg bw NP alone, in the majority of organs. The higher doses significantly increased damage to DNA in all organs examined. Combined exposure of females to low doses of both agents significantly enhanced damage to DNA in bone marrow lymphocytes and in cells of the liver and kidneys, compared to controls. At 0.10 Gy + 50 mg/kg bw NP, DNA damage was increased in organs except liver and spleen. Although NP alone may not be mutagenic in female mice, its co-administration with irradiation may increase DNA damage in some organs. In contrast, in male mice, damage was reduced after combined irradiation-NP exposure, compared to NP alone. (C) 2014 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000342528100003</url>
    <isbnorissn>1383-5718</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>311</id>
    <title>Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells</title>
    <authors>Dong,S.; Terasaka,S.; Kiyama,R.</authors>
    <availability>[Dong, S.; Terasaka, S.; Kiyama, R.] Natl Inst Adv Ind Sci &amp; Technol, Biomed Res Inst, Tsukuba, Ibaraki 3058566, Japan. [Dong, S.] Chinese Acad Sci, Inst Urban Environm, Xiamen, Peoples R China.</availability>
    <date>2011</date>
    <notes>JEnglishArticleKiyama, R (reprint author), Natl Inst Adv Ind Sci &amp; Technol, Biomed Res Inst, Tsukuba, Ibaraki 3058566, Japankiyama.r@aist.go.jpAlbanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Amiry N, 2009, ENDOCRINOLOGY, V150, P4473, DOI 10.1210/en.2009-0066; Ariazi EA, 2002, CANCER RES, V62, P6510; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Baron S, 2007, J BIOL CHEM, V282, P11732, DOI 10.1074/jbc.M610079200; Bergeron RM, 1999, MOL CELL ENDOCRINOL, V150, P179, DOI 10.1016/S0303-7207(98)00202-0; Bredhult C, 2007, REPROD TOXICOL, V23, P550, DOI 10.1016/j.reprotox.2007.03.006; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Dodds EC, 1938, PROC R SOC SER B-BIO, V125, P222, DOI 10.1098/rspb.1938.0023; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Filardo E, 2007, ENDOCRINOLOGY, V148, P3236, DOI 10.1210/en.2006-1605; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Fujimoto T, 2006, BRAIN RES, V1068, P49, DOI 10.1016/j.brainres.2005.11.028; Gray GM, 2004, HUM ECOL RISK ASSESS, V10, P875, DOI 10.1080/10807030490513883; Greco S, 2006, J ENDOCRINOL, V188, P79, DOI 10.1677/joe.1.06433; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Kelly MJ, 1999, STEROIDS, V64, P64, DOI 10.1016/S0039-128X(98)00095-6; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Khurana S, 2000, ENDOCRINOLOGY, V141, P4512, DOI 10.1210/en.141.12.4512; Kim K, 2007, J TOXICOL ENV HEAL A, V70, P1288, DOI 10.1080/15287390701434216; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lambert C, 1998, FOOD ADDIT CONTAM, V15, P318; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Migliaccio A, 1996, EMBO J, V15, P1292; Mlynarcikova A, 2005, MOL CELL ENDOCRINOL, V244, P57, DOI 10.1016/j.mce.2005.02.009; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; NEPHEW KP, 1993, ENDOCRINOLOGY, V133, P419, DOI 10.1210/en.133.1.419; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0; Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; RIO MC, 1990, CANCER CELL-MON REV, V2, P269; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925; Sasaki N, 2005, J MATER SCI-MATER M, V16, P297, DOI 10.1007/s10856-005-0627-8; Singleton DW, 2003, ENDOCRINOLOGY, V144, P121, DOI 10.1210/en.2002-220625; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Takai Y, 2000, BIOCHEM BIOPH RES CO, V270, P918, DOI 10.1006/bbrc.2000.2548; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V291, P76, DOI 10.1006/bbrc.2002.6407; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Werry TD, 2005, TRENDS ENDOCRIN MET, V16, P26, DOI 10.1016/j.tem.2004.11.008; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.0505934ELSEVIER SCI LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDENVIRON POLLUTJANDiscipline: Environmental Sciences &amp; Ecology692CR</notes>
    <keywords>ACTIVATION; Antagonist; ASSAY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cell lines; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; C-FOS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; ENDOCRINE; Endocrine disruptor; Endocrine-disrupting chemicals; ENVIRONMENTAL ESTROGENS; ERK1/2; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS; EXPRESSION; FOOD; G protein-coupled receptor 30; G-PROTEIN-COUPLED-RECEPTOR-30 GPR30; GPR30; HEALTH; HUMAN-BREAST-CANCER; IN-VITRO; LINE; LINES; LIQUID-CHROMATOGRAPHY; MODEL; MODELS; PATHWAY; PRENATAL EXPOSURE; PROTEIN-COUPLED RECEPTOR; RECEPTOR; Receptors; RISK; RISK-ASSESSMENT; Steroid; toxicology; Transcriptional regulation</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>212</startpage>
    <endpage>218</endpage>
    <journalfull>Environmental Pollution</journalfull>
    <issue>1</issue>
    <volume>159</volume>
    <abstract>Bisphenol A (BPA) has been considered as an endocrine disruptor due to its ability to interact with estrogen receptors (ERs). While G protein-coupled receptor 30 (GPR30) is a novel estrogen receptor, its role in BPA-induced activation of Erk1/2 remains unknown. Human breast cancer cell lines, MCF-7, MDA-MB-231 and SKBR3, were used as experimental models to discriminate between ERs-dependent, putative ERs-independent and/or GPR30-associated effects. BPA induced a rapid activation of Erk1/2 in both ER alpha/beta-positive and negative breast cancer cells, and this effect was not blocked with an ER antagonist, ICI 182,780. A small interfering RNA assay revealed that the expression of GPR30 was necessary for BPA-induced activation of Erk1/2 and transcriptional regulation of c-fos. In addition, BPA regulates the expression of c-fos likely through an AP1-mediated pathway. As a conclusion, GPR30 plays an important role in the BPA-induced activation of Erk1/2 in a manner distinguishable from that in ER alpha-mediated signaling. (C) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000285129600029</url>
    <isbnorissn>0269-7491</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>312</id>
    <title>Assessing Oestrogenic Effects of Brominated Flame Retardants Hexabromocyclododecane and Tetrabromobisphenol A on MCF-7 Cells</title>
    <authors>Dorosh,A.; Ded,L.; Elzeinova,F.; Peknicova,J.</authors>
    <availability>[Dorosh, A.; Ded, L.; Elzeinova, F.; Peknicova, J.] Inst Biotechnol AS CR, Lab Diagnost Reprod Med, VVI, Prague 14220 4, Czech Republic.</availability>
    <date>2011</date>
    <notes>JEnglishArticlePeknicova, J (reprint author), Inst Biotechnol AS CR, Lab Diagnost Reprod Med, VVI, Videnska 1083, Prague 14220 4, Czech Republicjpeknic@img.cas.czAbdallah MAE, 2008, ENVIRON SCI TECHNOL, V42, P6855, DOI 10.1021/es801110a; Birnbaum LS, 2004, ENVIRON HEALTH PERSP, V112, P9, DOI 10.1289/ehp.6559; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; de Wit CA, 2002, CHEMOSPHERE, V46, P583, DOI 10.1016/S0045-6535(01)00225-9; Hamers T, 2006, TOXICOL SCI, V92, P157, DOI 10.1093/toxsci/kfj187; Ishikawa T, 2001, NAT BIOTECHNOL, V19, P812, DOI 10.1038/nbt0901-812; Jenssen BM, 2007, ENVIRON HEALTH PERSP, V115, P35, DOI 10.1289/ehp.9355; Jorgensen M, 2000, ENVIRON HEALTH PERSP, V108, P403, DOI 10.2307/3454380; Kester MHA, 2002, J CLIN ENDOCR METAB, V87, P1142, DOI 10.1210/jc.87.3.1142; Lignell S, 2009, ENVIRON RES, V109, P760, DOI 10.1016/j.envres.2009.04.011; Nahoum V, 2003, FASEB J, V17, P1334, DOI 10.1096/fj.02-0524fje; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Ronisz D, 2004, AQUAT TOXICOL, V69, P229, DOI 10.1016/j.aquatox.2004.05.007; Saegusa Y, 2009, REPROD TOXICOL, V28, P456, DOI 10.1016/j.reprotox.2009.06.011; Sun H, 2009, TOXICOL IN VITRO, V23, P950, DOI 10.1016/j.tiv.2009.05.004; Van der Ven LTM, 2008, TOXICOLOGY, V245, P76, DOI 10.1016/j.tox.2007.12.009; Veldhoen N, 2006, AQUAT TOXICOL, V78, P292, DOI 10.1016/j.aquatox.2006.04.002178CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINEPRAGUE 6FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLICFOLIA BIOL-PRAGUEDiscipline: Biochemistry &amp; Molecular Biology; Life Sciences &amp; Biomedicine - Other Topics; Oncology; Cell Biology738EY</notes>
    <keywords>ALPHA; ASSAY; BFR; BINDING; BIOLOGY; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; BROMINATED FLAME RETARDANTS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; E-SCREEN; E-SCREEN ASSAY; ENDOCRINE; ENDOCRINE DISRUPTORS; environment; EXPOSURE; EXPRESSION; FLAME RETARDANTS; GENE; gene expression; GENE-EXPRESSION; HEALTH; HUMANS; In vitro; IN-VITRO; MCF-7 CELLS; oestrogen; oestrogen receptor; oestrogenicity; oncology; POPULATION; proliferation; PROTEINS; RECEPTOR; RECEPTOR-ALPHA; Reproduction; TBBPA; TETRACHLOROBISPHENOL; TFF1; toxicology; TRANSCRIPTION; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>35</startpage>
    <endpage>39</endpage>
    <journalfull>Folia Biologica</journalfull>
    <issue>1</issue>
    <volume>57</volume>
    <abstract>Tetrabromobisphenol A (TBBPA) is the main flame retardant used in printed circuit boards and laminates. The human population is highly exposed to TBBPA as it is used in consumer electronics as well as office and communication equipment. The main use of hexabromocyclododecane (HBCD) is in insulation foam boards, which are widely used in the construction sector. Brominated flame retardants may possess endocrine disrupting activity and thus represent a threat to the environment, including humans and their reproduction. The aim of this work was to evaluate the oestrogenic effects of TBBPA and HBCD in vitro on MCF-7 cells. We used the proliferation test (E-screen assay) in MCF-7 breast cancer cells and reverse transcription quantitative polymerase chain reaction analysis of TFF1 gene expression to analyse oestrogenicity of the studied compounds. RT-qPCR has proved to be a fast and valuable molecular technique in gene expression quantification. HBCD but not TBBPA increased cell proliferation in MCF-7 cells and up-regulated TFF1 gene expression in a concentration-dependent manner. Anti-oestrogen ICI 182,780 inhibited up-regulation of TFF1 by HBCD. We have shown that HBCD displays oestrogen-like effects on MCF-7 cells. TBBPA, on the other hand, has not shown any oestrogenic effect mediated by the oestrogen receptor alpha</abstract>
    <url>WOS:000288623700007</url>
    <isbnorissn>0015-5500</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>256</id>
    <title>Hypermethylation of estrogen receptor promoter region in adult testis of rats exposed neonatally to bisphenol A</title>
    <authors>Doshi,T.; Mehta,S.S.; Dighe,V.; Balasinor,N.; Vanage,G.</authors>
    <availability>[Doshi, Tanvi; Mehta, Smita Salian; Dighe, Vikas; Balasinor, Nafisa; Vanage, Geeta] Natl Inst Res Reprod Hlth ICMR, Natl Ctr Preclin Reprod &amp; Genet Toxicol, Mumbai 400012, Maharashtra, India.</availability>
    <date>2011</date>
    <notes>JEnglishArticleVanage, G (reprint author), Natl Inst Res Reprod Hlth ICMR, Natl Ctr Preclin Reprod &amp; Genet Toxicol, JM St, Mumbai 400012, Maharashtra, Indiavanageg@nirrh.res.inANWAY D, 2006, J ANDROL, V27, P868; ANWAY D, 2005, SCIENCE, V308, P1466; Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc; BARKER E, 1992, FETAL INFANT ORIGINS; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; CARWILE L, 2009, ENV HLTH PERSPECT, V117, P1368; Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9; DELBES C, 2006, REPRODUCTION, V132, P527; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; DOLINOY D, 2007, P NATL ACAD SCI USA, V32, P13056; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; EDDY EM, 1996, ENDOCRINOLOGY, V11, P4796; FUKATA H, 2004, REPROD MED BIOL, V3, P115, DOI 10.1111/j.1447-0578.2004.00066.x; Girault I, 2003, CLIN CANCER RES, V9, P4415; Goyal HO, 2003, BIOL REPROD, V68, P2081, DOI 10.1095/biolreprod.102.010637; He YH, 2009, J OCCUP HEALTH, V51, P432; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; JINAWANTH A, 2005, BIOCHEM J, V15, P557; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Khurana S, 2000, ENDOCRINOLOGY, V141, P4512, DOI 10.1210/en.141.12.4512; KIM D, 2001, CANCER RES, V15, P3419; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li SF, 1997, CANCER RES, V57, P4356; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MAFFINI MV, 2006, MOL CELL ENDOCRINOL, V25, P179; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; NTP, 2001, NAT TOX PROGR REP EN; NTP/National Toxicology Program, 2008, NTP CERHR MON POT HU; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pathak S, 2009, FERTIL STERIL, V91, P2253, DOI 10.1016/j.fertnstert.2008.07.1709; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088; SALIAN S, 2009, LIFE SCI, V18, P742; SALIAN S, 2009, TOXICOLOGY, V12, P56; Sato K, 2006, ENDOCR J, V53, P331, DOI 10.1507/endocrj.K06-009; Sato K, 2009, ENDOCR J, V56, P131; Singal R, 1999, BLOOD, V93, P4059; Szyf M, 2009, BBA-GEN SUBJECTS, V1790, P878, DOI 10.1016/j.bbagen.2009.01.009; Takao T, 2003, LIFE SCI, V72, P1159, DOI 10.1016/S0024-3205(02)02364-0; Toyama Y, 2004, REPROD TOXICOL, V19, P181, DOI 10.1016/j.reprotox.2004.08.003; Toyama Y, 2004, ARCH HISTOL CYTOL, V67, P373, DOI 10.1679/aohc.67.373; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Yamagata Y, 2009, MOL HUM REPROD, V15, P259, DOI 10.1093/molehr/gap010; YAOI T, 2008, BIOCHEM BIOPH RES CO, V21, P563; Yap OWS, 2009, ANTICANCER RES, V29, P139; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499; Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-15730ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOLOGYNOV 18Discipline: Pharmacology &amp; Pharmacy; Toxicology833OS</notes>
    <keywords>ABERRANT DNA METHYLATION; ADULT; ADULTHOOD; ALPHA; BETA; BETA EXPRESSION; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; CANCER; CARCINOGENESIS; CELL; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL ALTERS; DNA METHYLATION; DNA METHYLTRANSFERASES; DNA-methylation; ENDOCRINE; Endocrine disruptor; environment; epigenetic; ER alpha; ER-ALPHA; ER-BETA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; fertility; FETAL; GENE; gene expression; GENE-EXPRESSION; GENOMIC DNA; HEALTH; HUMAN BREAST-CANCER; HYPERMETHYLATION; Male; MALE RATS; MAMMALIAN DEVELOPMENT; mechanism; MECHANISMS; METHYLATION; Methyltransferase; MOUSE UTERUS; NEONATAL EXPOSURE; PHARMACOLOGY; Plastics; PROMOTER; PROTEIN; RAT; RATS; RECEPTOR; Reproduction; SPERMATOGENESIS; testis; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>74</startpage>
    <endpage>82</endpage>
    <journalfull>Toxicology</journalfull>
    <issue>2-3</issue>
    <volume>289</volume>
    <abstract>Background: Bisphenol A (BPA) is an estrogenic endocrine disruptor commonly used in manufacture of polycarbonate plastics and epoxy resins. Due to its ubiquitous presence in the environment, health concerns are increasing. Earlier studies from our group have shown that neonatal exposure of male rats to BPA affected spermatogenesis leading to impairment in fertility during adulthood. Further we also observed an altered gene expression of ER alpha and ER beta in adult testis upon BPA exposure. Based on these results, we hypothesized that apart from endocrine action, BPA might mediate perturbations in expression of ERs via epigenetic mechanism. Objectives: The present study was undertaken to determine the effect of exposure of neonatal male rats to BPA on DNA methylation profile of estrogen receptor promoter region and on DNA methylation machinery. Methods: In order to test this hypothesis, neonatal male rats were subcutaneously injected with 2.4 mu g of BPA/day for the first five days of life, i.e., on postnatal days (PND) 1-5, while control group received vehicle (sesame oil). Animals were sacrificed during adulthood (PND-125) and testes were dissected out for analysis. Methylation pattern of promoter region of ER alpha and ER beta was analyzed in the testis by bisulfite sequencing and expression levels of DNA methyltransferases by quantitative RT-PCR and Western blotting respectively. Results: Bisulfite sequencing revealed significant hypermethylation of ER alpha promoter to varying extents from 40% to 60%, and ER beta promoter region with varying extent from 20% to 65%. Approximately 2-fold increase in Dnmt3a and Dnmt3b expression at transcript and protein level was also observed. Conclusion: The experimental evidence demonstrated that the neonatal exposure of rats to BPA led to aberrant DNA methylation in testis, indicating methylation mediated epigenetic changes as one of the possible mechanisms of BPA induced adverse effects on spermatogenesis and fertility. (C) 2011 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000295895400002</url>
    <isbnorissn>0300-483X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>130</id>
    <title>The relationship between urinary bisphenol A levels and meningioma in Chinese adults</title>
    <authors>Duan,B.; Hu,X.B.; Zhao,H.Y.; Qin,J.; Luo,J.</authors>
    <availability>[Duan, Bo; Hu, Xuebin; Zhao, Hongyang] Huazhong Univ Sci &amp; Technol, Union Hosp, Dept Neurosurg, Wuhan 430074, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleZhao, HY (reprint author), Huazhong Univ Sci &amp; Technol, Union Hosp, Dept Neurosurg, Wuhan 430074, Peoples R Chinazhaohongyang480@163.comAlexiou GA, 2011, CLIN NEUROL NEUROSUR, V113, P261, DOI 10.1016/j.clineuro.2010.12.007; Benson VS, 2008, BRIT J CANCER, V99, P185, DOI 10.1038/sj.bjc.6604445; Blitshteyn S, 2008, J CLIN ONCOL, V26, P279, DOI 10.1200/JCO.2007.14.2133; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Carroll RS, 1999, J NEURO-ONCOL, V42, P109, DOI 10.1023/A:1006158514866; Claus EB, 2007, CANCER, V110, P471, DOI 10.1002/cncr.22783; Gazzeri R, 2007, NEW ENGL J MED, V357, P2411, DOI 10.1056/NEJMc071938; HENDERSON BE, 1988, BRIT J CANCER, V57, P216, DOI 10.1038/bjc.1988.46; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hsu DW, 1997, J NEUROSURG, V86, P113, DOI 10.3171/jns.1997.86.1.0113; JAY JR, 1985, J NEUROSURG, V62, P757, DOI 10.3171/jns.1985.62.5.0757; Jhawar BS, 2003, J NEUROSURG, V99, P848, DOI 10.3171/jns.2003.99.5.0848; Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lewis JB, 2000, IN VITRO CELL DEV-AN, V36, P320; LONGSTRETH WT, 1993, CANCER, V72, P639, DOI 10.1002/1097-0142(19930801)72:3&lt;639::AID-CNCR2820720304&gt;3.0.CO;2-P; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Melzer D, 2011, ENV HLTH PERSPECT, V127, P27; Michaud DS, 2011, CANCER PREV RES, V4, P1385, DOI 10.1158/1940-6207.CAPR-11-0014; Michaud DS, 2010, CANCER EPIDEM BIOMAR, V19, P2562, DOI 10.1158/1055-9965.EPI-10-0447; Newbold RR, 2009, MOL CELL ENDOCRINOL, V304, P84, DOI 10.1016/j.mce.2009.02.024; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Pines A, 2010, CLIMACTERIC, V14, P215; Powell IJ, 2001, UROLOGY, V57, P178, DOI 10.1016/S0090-4295(00)00968-7; ROELVINK NCA, 1987, ARCH NEUROL-CHICAGO, V44, P209; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Sadetzki S, 2002, J NEUROSURG, V97, P1078, DOI 10.3171/jns.2002.97.5.1078; SCHOENBERG BS, 1975, NEUROLOGY, V25, P705; Shankar A, 2011, J CLIN ENDOCR METAB, V15, P3455; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Speirs V, 1997, INT J CANCER, V72, P714, DOI 10.1002/(SICI)1097-0215(19970904)72:5&lt;714::AID-IJC2&gt;3.0.CO;2-V; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Whittle IR, 2004, LANCET, V363, P1535, DOI 10.1016/S0140-6736(04)16153-9; Wolstenholme JT, 2010, HORM BEHAV, V59, P296402SPRINGER JAPAN KKTOKYOCHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPANINT J CLIN ONCOLJUNDiscipline: Oncology165BC</notes>
    <keywords>ADULT; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELL; DIAGNOSIS; Endocrine disruptor; Estrogen; ESTROGEN-RECEPTOR-ALPHA; EXOGENOUS HORMONE USE; EXPOSURE; In vitro; IN-VITRO; JUN; Meningioma; Neurosurgery; oncology; Prostate; RISK; STEROID-HORMONES; URINARY; Urinary bisphenol A; Urine; VITRO; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>492</startpage>
    <endpage>497</endpage>
    <journalfull>International Journal of Clinical Oncology</journalfull>
    <issue>3</issue>
    <volume>18</volume>
    <abstract>Estrogen has been implicated as a risk factor for meningioma. Bisphenol A (BPA), a widely used synthetic xenoestrogen, has already been reported to be associated with several estrogen-sensitive tumors. An exploratory association study of 243 meningioma cases and 258 frequency-matched healthy controls was conducted, using subjects from a hospital-based study to demonstrate the association of urine BPA concentration and the risk of meningioma. The specimens and data of patients were collected at Union Hospital, Wuhan, China, from 2009 to 2010. A positive association between increasing levels of urinary BPA and meningioma was observed, independent of confounding factors such as gender, age, race, body mass index, HRT use, BMI, and family history of cancer. Compared to quartile 1 (referent), the multivariate-adjusted odds ratio of meningioma associated with quartile 4 was 1.45 (95 % CI, 1.02-1.98) (P trend = 0.03). In this case-control study from China, a clear association between urinary BPA concentrations and diagnosis of meningioma was detected</abstract>
    <url>WOS:000320456500020</url>
    <isbnorissn>1341-9625</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>266</id>
    <title>Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats</title>
    <authors>Durando,M.; Kass,L.; Perdomo,V.; Bosquiazzo,V.L.; Luque,E.H.; Munoz-de-Toro,M.</authors>
    <availability>[Durando, Milena; Kass, Laura; Perdomo, Virginia; Bosquiazzo, Veronica L.; Luque, Enrique H.; Munoz-de-Toro, Monica] UNL, Sch Biochem &amp; Biol Sci, Lab Endocrinol &amp; Tumores Hormonodependientes, RA-3000 Santa Fe, Argentina.</availability>
    <date>2011</date>
    <notes>JEnglishArticleMunoz-de-Toro, M (reprint author), UNL, Sch Biochem &amp; Biol Sci, Lab Endocrinol &amp; Tumores Hormonodependientes, Casilla Correo 242, RA-3000 Santa Fe, Argentinamonicamt@fbcb.unl.edu.ar[Anonymous], 2008, NTP CERHR MON, P1; Aoki M, 2003, INT ARCH ALLERGY IMM, V130, P216, DOI 10.1159/000069515; Aupperlee MD, 2009, ENDOCRINOLOGY, V150, P1485, DOI 10.1210/en.2008-1459; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Bosquiazzo VL, 2010, BIOL REPROD, V82, P86, DOI 10.1095/biolreprod.109.078543; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; DURANDO M, 2009, THESIS U NACL LITORA; *EUR COMM, EUR UN RISK ASS; Fenton SE, 2006, ENDOCRINOLOGY, V147, P18; Giamas G, 2009, NUCLEIC ACIDS RES, V37, P3110, DOI 10.1093/nar/gkp136; Grasselli F, 2010, DOMEST ANIM ENDOCRIN, V39, P34, DOI 10.1016/j.domaniend.2010.01.004; Han SJ, 2006, MOL ENDOCRINOL, V20, P45, DOI 10.1210/me.2005-0310; Innes KE, 1999, EPIDEMIOLOGY, V10, P722, DOI 10.1097/00001648-199911000-00013; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; KANEKO S, 1986, BIOL REPROD, V34, P488, DOI 10.1095/biolreprod34.3.488; Kass L, 2004, J STEROID BIOCHEM, V91, P29, DOI 10.1016/j.jsbmb.2004.02.001; Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36; Long X, 2001, EXP BIOL MED, V226, P477; Markey CM, 2001, BIOL REPROD, V65, P1215; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; MONTES GS, 1988, ACTA ANAT, V133, P192; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; MOUTON PR, 2002, PRINCIPLES PRACTICES, P186; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Peretz J, 2011, TOXICOL SCI, V119, P209, DOI 10.1093/toxsci/kfq319; Peterson TJ, 2007, MOL CELL BIOL, V27, P5933, DOI 10.1128/MCB.00237-07; Ramos JG, 2003, ENDOCRINOLOGY, V144, P3206, DOI 10.1210/en.2002-0198; Rayson D, 1999, J MAMMARY GLAND BIOL, V4, P415, DOI 10.1023/A:1018774618873; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rodriguez HA, 2010, REPROD TOXICOL, V30, P550, DOI 10.1016/j.reprotox.2010.07.008; Rossiter H, 2007, FASEB J, V21, P3994, DOI 10.1096/fj.07-8720com; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Singh M, 2000, LAB INVEST, V80, P221; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Taylor JA, 2008, REPROD TOXICOL, V25, P169, DOI 10.1016/j.reprotox.2008.01.001; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Varayoud J, 2008, ENDOCRINOLOGY, V149, P5848, DOI 10.1210/en.2008-0651; Varayoud J, 2004, REPRODUCTION, V127, P379, DOI 10.1530/rep.1.00018; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297537PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMOCTSIDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism841WV</notes>
    <keywords>ALPHA; ALTERS; ANGIOGENESIS; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; COREGULATORS; Differentiation; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; Epidemiology; ER alpha; ER-ALPHA; ESTRADIOL; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; female; GENE-EXPRESSION; GLAND; GROWTH; HEALTH; Hyperplastic ducts; IN-UTERO EXPOSURE; mammary gland; Mammary glands; MAMMARY-GLAND; MAMMARY-GLANDS; MAST-CELLS; METABOLISM; oncology; OVARIAN-STEROIDS; PATHWAY; PRENATAL EXPOSURE; PRINCIPLES; progesterone; PROTEIN; Proteomics; RAT; RATS; RECEPTOR; Reproduction; RESPONSES; RISK; serum; SIGNALS; Steroid hormone; Steroid receptor co-activators; steroid receptors; SUSCEPTIBILITY; TRANSCRIPTIONAL ACTIVITY; VEGF; Wistar</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>35</startpage>
    <endpage>43</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <issue>1-2</issue>
    <volume>127</volume>
    <abstract>Prenatal exposure to BPA disturbs mammary gland histoarchitecture and increases the carcinogenic susceptibility to chemical challenges administered long after BPA exposure. Our aim was to assess the effect of prenatal BPA exposure on mammary gland angiogenesis and steroid hormone pathways in virgin cycling rats. Pregnant Wistar rats were exposed to either 25 or 250 mu g/kg/day (25 and 250 BPA, respectively) or to vehicle. Female offspring were autopsied on postnatal day (PND) 50 or 110. Ovarian steroid serum levels, the expression of steroid receptors and their co-regulators SRC-3 and SMRT in the mammary gland, and angiogenesis were evaluated. At PND 50, all BPA-treated animals had lower serum levels of progesterone, while estradiol levels remained unchanged. The higher dose of BPA increased mammary ER alpha and decreased SRC-3 expression at PND 50 and PND 110. SMRT protein levels were similar among groups at PND 50, whereas at PND 110, animals exposed to 250 BPA showed a lower SMRT expression. Interestingly, in the control and 25 BPA groups, SMRT increased from PND 50 to PND 110. At PND 50, an increased vascular area associated with higher VEGF expression was observed in the 250 BPA-treated rats. At PND 110, the vascular area was still increased, but VEGF expression was similar to that of control rats. The present results demonstrate that prenatal exposure to BPA alters the endocrine environment of the mammary gland and its angiogenic process. Increased angiogenesis and altered steroid hormone signals could explain the higher frequency of pre-neoplastic lesions found later in life. This article is part of a Special Issue entitled 'Endocrine disruptors'. (C) 2011 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000296546800006</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>219</id>
    <title>Assessing Relative Bioactivity of Chemical Substances Using Quantitative Molecular Network Topology Analysis</title>
    <authors>Edberg,A.; Soeria-Atmadja,D.; Laurila,J.B.; Johansson,F.; Gustafsson,M.G.; Hammerling,U.</authors>
    <availability>[Gustafsson, Mats G.] Uppsala Univ, Dept Med Sci, Div Canc Pharmacol &amp; Computat Med, SE-75185 Uppsala, Sweden. [Gustafsson, Mats G.] Uppsala Acad Hosp, SE-75185 Uppsala, Sweden. [Hammerling, Ulf] Natl Food Agcy, Dept Risk Benefit Assessment, SE-75126 Uppsala, Sweden. [Edberg, Anna] Natl Food Agcy, Div Food Data, SE-75126 Uppsala, Sweden. [Soeria-Atmadja, Daniel] AstraZeneca Res &amp; Dev, Div R&amp;D Informat, SE-15185 Sodertalje, Sweden. [Laurila, Jonas Bergman; Johansson, Fredrik] Natl Food Agcy, Div Informat Technol, SE-75126 Uppsala, Sweden.</availability>
    <date>2012</date>
    <notes>JEnglishArticleGustafsson, MG (reprint author), Uppsala Univ, Dept Med Sci, Div Canc Pharmacol &amp; Computat Med, SE-75185 Uppsala, SwedenMats.Gustafsson@medsci.uu.se; Ulf.Hammerling@slv.seAudouze K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000788; Pavlopoulos GA, 2011, BIODATA MIN, V4, DOI 10.1186/1756-0381-4-10; Basly JP, 2005, PLANTA MED, V71, P287, DOI 10.1055/s-2005-864092; Bauer-Mehren A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.47; Berg EL, 2005, IEE P SYST BIOL, V152, P201, DOI 10.1049/ip-syb:20050036; Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465; Boehme K, 2009, TOXICOL APPL PHARM, V236, P85, DOI 10.1016/j.taap.2009.01.006; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Brohee S, 2008, NUCLEIC ACIDS RES, V36, pW444, DOI 10.1093/nar/gkn336; Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140; Chen B, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-255; Chen JY, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S16; Cheng TJ, 2010, BIOINFORMATICS, V26, P2881, DOI 10.1093/bioinformatics/btq550; Chin CS, 2003, BIOINFORMATICS, V19, P2413, DOI 10.1093/bioinformatics/btg339; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dudley JT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002648; Dudley JT, 2011, BRIEF BIOINFORM, V12, P303, DOI 10.1093/bib/bbr013; Eckert H, 2007, DRUG DISCOV TODAY, V12, P225, DOI 10.1016/j.drudis.2007.01.011; Edwards SW, 2008, TOXICOL SCI, V106, P312, DOI 10.1093/toxsci/kfn190; Erlandsson MC, 2005, APMIS, V113, P317, DOI 10.1111/j.1600-0463.2005.apm_113502.x; Fagin R, 2003, SIAM J DISCRETE MATH, V17, P134, DOI 10.1137/S0895480102412856; Fliri AF, 2009, J MED CHEM, V52, P8038, DOI 10.1021/jm901001p; Fliri Anton F, 2011, Discov Med, V11, P133; Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x; Hase T., 2009, PLOS COMPUT BIOL, V5; Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hwang WC, 2008, CLIN PHARMACOL THER, V84, P563, DOI 10.1038/clpt.2008.129; Hyduke DR, 2010, NAT REV GENET, V11, P297, DOI 10.1038/nrg2750; Ideker T, 2011, CELL, V144, P860, DOI 10.1016/j.cell.2011.03.007; Iorio F, 2010, P NATL ACAD SCI USA, V107, P14621, DOI 10.1073/pnas.1000138107; Su J, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S6-S8; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Jessulat M, 2011, EXPERT OPIN DRUG DIS, V6, P921, DOI 10.1517/17460441.2011.603722; Judson RS, 2010, ENVIRON HEALTH PERSP, V118, P485, DOI 10.1289/ehp.0901392; Judson RS, 2011, CHEM RES TOXICOL, V24, P451, DOI 10.1021/tx100428e; Jurman G, 2008, BIOINFORMATICS, V24, P258, DOI 10.1093/bioinformatics/btm550; Kandasamy K, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-1-r3; Keiser MJ, 2010, BIOCHEMISTRY-US, V49, P10267, DOI 10.1021/bi101540g; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Kendall M.G., 1970, RANK CORRELATION MET; Kleemann R, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-125; Klingstrom T, 2011, BRIEF BIOINFORM, V12, P702, DOI 10.1093/bib/bbq064; Klipp E, 2010, CURR OPIN BIOTECH, V21, P511, DOI 10.1016/j.copbio.2010.05.004; Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795; Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lamrous S., 2007, INT C COMP INT MOD C, Vc1, P18; Lee S, 2009, EXPERT OPIN DRUG DIS, V4, P1177, DOI 10.1517/17460440903322234; Leffers H, 2001, HUM REPROD, V16, P1037, DOI 10.1093/humrep/16.5.1037; le Maire A, 2010, CELL MOL LIFE SCI, V67, P1219, DOI 10.1007/s00018-009-0249-2; Lin CY, 2008, NUCLEIC ACIDS RES, V36, pW438, DOI 10.1093/nar/gkn257; Lorand T, 2010, CURR MED CHEM, V17, P3542; Loscalzo J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100163; Lussier YA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001512; Lv LS, 2011, CHEM RES TOXICOL, V24, P579, DOI 10.1021/tx100457h; Maddah F, 2011, FOOD CHEM TOXICOL, V49, P2830, DOI 10.1016/j.fct.2011.08.002; Martin LA, 2005, ENDOCR-RELAT CANCER, V12, P1017, DOI 10.1677/erc.1.00905; Martin MT, 2010, CHEM RES TOXICOL, V23, P578, DOI 10.1021/tx900325g; Matsumura A, 2005, J STEROID BIOCHEM, V94, P431, DOI 10.1016/j.jsbmb.2004.12.041; Mueller LAJ, 2011, BIOINFORMATICS, V27, P140, DOI 10.1093/bioinformatics/btq606; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Nacher Jose C., 2008, BMC Pharmacology, V8, P5, DOI 10.1186/1471-2210-8-5; Nigsch F, 2008, TOXICOL APPL PHARM, V231, P225, DOI 10.1016/j.taap.2008.05.007; Oprea TI, 2007, NAT CHEM BIOL, V3, P447, DOI 10.1038/nchembio0807-447; Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; PfA¬tzner Andreas, 2007, Vasc Health Risk Manag, V3, P211, DOI 10.2147/vhrm.2007.3.2.211; Raman Karthik, 2010, Autom Exp, V2, P2, DOI 10.1186/1759-4499-2-2; Reif DM, 2010, ENVIRON HEALTH PERSP, V118, P1714, DOI 10.1289/ehp.1002180; Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292; Sayers EW, 2010, NUCLEIC ACIDS RES, V38, pD5, DOI 10.1093/nar/gkp967; Scheiber J, 2009, J MED CHEM, V52, P3103, DOI 10.1021/jm801546k; Grandjean P, 2006, INT J ANDROL, V29, P181, DOI 10.1111/j.1365-2605.2005.00679.x; Severino L, 2008, VET RES COMMUN, V32, pS311, DOI 10.1007/s11259-008-9136-9; Shakibaei M, 2009, MOL NUTR FOOD RES, V53, P115, DOI 10.1002/mnfr.200800148; Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n; Sirota M., 2011, SCI TRANSL MED, V3; Suthram S, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000662; Swaby RF, 2007, REV ENDOCR METAB DIS, V8, P229, DOI 10.1007/s11154-007-9034-4; Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Venkatesan K, 2009, NAT METHODS, V6, P83, DOI [10.1038/nmeth.1280, 10.1038/NMETH.1280]; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Wagner BK, 2009, CURR OPIN CHEM BIOL, V13, P539, DOI 10.1016/j.cbpa.2009.09.018; Wallach I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012063; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Willett P, 2011, METHODS MOL BIOL, V672, P133, DOI 10.1007/978-1-60761-839-3_5; Willett P, 2011, WIRES DATA MIN KNOWL, V1, P241, DOI 10.1002/widm.26; Wilson VS, 2008, INT J ANDROL, V31, P178, DOI 10.1111/j.1365-2605.2007.00861.x; Wishart DS, 2005, DRUG METAB REV, V37, P279, DOI 10.1081/DMR-200055225; Wu JM, 2009, NAT METHODS, V6, P75, DOI [10.1038/nmeth.1282, 10.1038/NMETH.1282]; Yang YL, 2009, DRUG DISCOV TODAY, V14, P147, DOI 10.1016/j.drudis.2008.12.005; Yildirim MA, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.22; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbtl338; Yoon Kun Ho, 2011, Diabetes Metab J, V35, P26, DOI 10.4093/dmj.2011.35.1.26; Yu HY, 2007, PLOS COMPUT BIOL, V3, P713, DOI 10.1371/journal.pcbi.0030059; Zhang SD, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-2581002AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USAJ CHEM INF MODELMAYDiscipline: Pharmacology &amp; Pharmacy; Chemistry; Computer Science946VN</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; BIOLOGY; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHEMICALS; diabetes; DRUG DISCOVERY; Endocrine-disrupting chemicals; ENVIRONMENTAL CHEMICALS; ESTROGEN-RECEPTOR; FOOD; GENE-EXPRESSION SIGNATURES; HEALTH; MAMMALIAN-CELLS; MODEL; Neoplasia; PATHWAY DATABASES; PHARMACOLOGY; PRINCIPLES; PROTEIN; protein-protein interaction; PROTEINS; RISK; Risk assessment; RISK-ASSESSMENT; SYSTEMS BIOLOGY; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1238</startpage>
    <endpage>1249</endpage>
    <journalfull>Journal of Chemical Information and Modeling</journalfull>
    <issue>5</issue>
    <volume>52</volume>
    <abstract>Structurally different chemical substances may cause similar systemic effects in mammalian cells. It is therefore necessary to go beyond structural comparisons to quantify similarity in terms of their bioactivities. In this work, we introduce a generic methodology to achieve this on the basis of Network Biology principles and using publicly available molecular network topology information. An implementation of this method, denoted QuantMap, is outlined and applied to antidiabetic drugs, NSAIDs, 17 beta-estradiol, and 12 substances known to disrupt estrogenic pathways. The similarity of any pair of compounds is derived from topological comparison of intracellular protein networks, directly and indirectly associated with the respective query chemicals, via a straightforward pairwise comparison of ranked proteins. Although output derived from straightforward chemical/structural similarity analysis provided some guidance on bioactivity, QuantMap produced substance interrelationships that align well with reports on their respective perturbation properties. We believe that QuantMap has potential to provide substantial assistance to drug repositioning, pharmacology evaluation, and toxicology risk assessment</abstract>
    <url>WOS:000304385700016</url>
    <isbnorissn>1549-9596</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>409</id>
    <title>Cytotoxicity and estrogenicity of Invisalign appliances</title>
    <authors>Eliades,T.; Pratsinis,H.; Athanasiou,A.E.; Eliades,G.; Kletsas,D.</authors>
    <availability>[Eliades, Theodore; Athanasiou, Athanasios E.] Aristotle Univ Thessaloniki, Sch Dent, Dept Orthodont, GR-54006 Thessaloniki, Greece. [Kletsas, Dimitris] Natl Ctr Sci Res Demokritos, Inst Biol, Lab Cell Proliferat &amp; Ageing, Athens, Greece. [Eliades, George] Univ Athens, Sch Dent, Dept Biomat, Athens, Greece.</availability>
    <date>2009</date>
    <notes>JEnglishArticleEliades, T (reprint author), 57 Agnoston Hiroon St, Athens 14231, Greeceteliades@ath.forthnet.gr*AL TECHN INC, 2002, INV REF GUID, P8; *AL TECHN INC, 2003, MAT SAF DAT SHEET MS; Al-Hiyasat AS, 2004, EUR J ORAL SCI, V112, P267, DOI 10.1111/j.1600-0722.2004.00136.x; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Eliades T, 2007, EUR J ORTHODONT, V29, P404, DOI 10.1093/ejo/cjm040; Eliades T, 2007, AM J ORTHOD DENTOFAC, V131, P72, DOI 10.1016/j.ajodo.2006.08.013; Eliades T, 2005, J ORAL REHABIL, V32, P72, DOI 10.1111/j.1365-2842.2004.01366.x; Gioka C, 2005, AM J ORTHOD DENTOFAC, V127, P413, DOI 10.1016/j.ajodo.2004.02.015; KLETSAS D, 1992, CELL BIOL INT REP, V16, P103, DOI 10.1016/S0309-1651(06)80104-9; Kravitz ND, 2009, AM J ORTHOD DENTOFAC, V135, P27, DOI 10.1016/j.ajodo.2007.05.018; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Pulgar R, 2000, ENVIRON HEALTH PERSP, V108, P21, DOI 10.2307/3454291; Schmalz G, 1999, Clin Oral Investig, V3, P114, DOI 10.1007/s007840050088; Schuster S, 2004, AM J ORTHOD DENTOFAC, V126, P725, DOI 10.1016/j.ajodo.2004.04.021; SOTO AM, 1986, CANCER RES, V46, P2271; Tarumi H, 2000, J DENT RES, V79, P1838; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; *US EPA, INT RISK INF SYST PA; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494224MOSBY-ELSEVIERNEW YORK360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USAAM J ORTHOD DENTOFACJULDiscipline: Dentistry, Oral Surgery &amp; Medicine466WR</notes>
    <keywords>analysis; ASSAY; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELL-LINE; CELLS; CHEMICALS; COMPOSITES; Cytotoxicity; DENTISTRY; Estrogenic; estrogenic effects; Estrogenicity; EXPOSURE; FIBROBLASTS; HEALTH; In vitro; IN-VITRO; LINE; MICE; ORTHODONTIC ADHESIVE RESINS; p21; P8; proliferation; Prostate; RISK; SAMPLES; SEALANTS; SET</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>100</startpage>
    <endpage>103</endpage>
    <journalfull>American Journal of Orthodontics and Dentofacial Orthopedics</journalfull>
    <issue>1</issue>
    <volume>136</volume>
    <abstract>Introduction: Our purpose was to study the in-vitro cytotoxic and estrogenic properties of Invisalign appliances (Align Technology, Santa Clara, Calif). Methods: Three sets, each consisting of a maxillary and a mandibular appliance, of as-received aligners were immersed in normal saline solution for 2 months. Samples of eluents were diluted to 3 concentrations (5%, 10%, and 20% vol/vol) and tested for cytotoxicity on human gingival fibroblasts and estrogenicity by measuring their effect on the proliferation of the estrogen-responsive MCF-7 breast cancer cells. All assays were repeated 4 times for each maxillary and mandibular set, and the results were analyzed with 2-way analysis of variance (ANOVA) with appliance and concentration serving as predictors at the .05 level of significance; differences among groups were investigated with the Tukey test. Results: There was no evidence of cytotoxicity on human gingival fibroblasts and no stimulation of proliferation of the MCF-7 cell line at any concentration, indicating no estrogenicity of aligner eluents. Conclusions: The use of Invisalign appliances did not seem to induce estrogenic effects under the conditions of this experiment. (Am J Orthod Dentofacial Orthop 2009; 136: 100-3)</abstract>
    <url>WOS:000267695500025</url>
    <isbnorissn>0889-5406</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>204</id>
    <title>Masculine Epigenetic Sex Marks of the CYP19A1/Aromatase Promoter in Genetically Male Chicken Embryonic Gonads Are Resistant to Estrogen-Induced Phenotypic Sex Conversion</title>
    <authors>Ellis,H.L.; Shioda,K.; Rosenthal,N.F.; Coser,K.R.; Shioda,T.</authors>
    <availability>[Shioda, Toshi] Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA USA. Harvard Univ, Sch Med, Charlestown, MA USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleShioda, T (reprint author), Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA USAtshioda@partners.orgAndrews JE, 1997, GEN COMP ENDOCR, V108, P182, DOI 10.1006/gcen.1997.6978; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bannister SC, 2011, BIOL REPROD, V85, P22, DOI 10.1095/biolreprod.110.088476; Bannister SC, 2009, BIOL REPROD, V81, P165, DOI 10.1095/biolreprod.108.074005; Berg C, 2001, ENVIRON TOXICOL CHEM, V20, P2836, DOI 10.1897/1551-5028(2001)020&lt;2836:EOBAAT&gt;2.0.CO;2; Berg C, 1999, SCI TOTAL ENVIRON, V233, P57, DOI 10.1016/S0048-9697(99)00179-5; Branco MR, 2011, NAT REV GENET, V13, P7, DOI DOI 10.1038/NRN3125; Bretschneider N, 2008, MOL ONCOL, V2, P182, DOI 10.1016/j.molonc.2008.05.004; Chue J, 2011, FEBS J, V278, P1027, DOI 10.1111/j.1742-4658.2011.08032.x; Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100; Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106; Deng J, 2009, NAT BIOTECHNOL, V27, P353, DOI 10.1038/nbt.1530; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; ELBRECHT A, 1992, SCIENCE, V255, P467, DOI 10.1126/science.1734525; Govoroun MS, 2004, DEV DYNAM, V231, P859, DOI 10.1002/dvdy.20189; Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100; Halldin K, 1999, ENVIRON HEALTH PERSP, V107, P861, DOI 10.2307/3454472; Hudson QJ, 2005, DEV DYNAM, V233, P1052, DOI 10.1002/dvdy.20388; Inawaka K, 2009, TOXICOL APPL PHARM, V237, P178, DOI 10.1016/j.taap.2009.03.004; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; JOST JP, 1984, P NATL ACAD SCI-BIOL, V81, P429, DOI 10.1073/pnas.81.2.429; Jung JS, 2005, STEM CELLS, V23, P689, DOI 10.1643/stemcells.2004-0208; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Kent J, 1996, DEVELOPMENT, V122, P2813; Kim H, 2007, PHYSIOL GENOMICS, V29, P253, DOI 10.1152/physiolgenomics.00067.2006; Kim JN, 2004, MOL REPROD DEV, V68, P81, DOI 10.1002/mrd.20051; Kim JN, 2009, BIOL REPROD, V82, P257; Korshunova Y, 2008, GENOME RES, V18, P19, DOI 10.1101/gr.6883307; Lawson C, 2011, BIOL REPROD, V84, P79, DOI 10.1095/biolreprod.110.084814; Lee EJ, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr598; Loffler KA, 2003, ENDOCRINOLOGY, V144, P3237, DOI 10.1210/en.2002-0095; MATSUMINE H, 1991, J BIOL CHEM, V266, P19900; Mckernan MA, 2007, ENVIRON TOXICOL CHEM, V26, P2724, DOI 10.1897/07-291.1; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Nakabayashi O, 1998, J MOL ENDOCRINOL, V20, P193, DOI 10.1677/jme.0.0200193; Nishikimi H, 2000, MOL REPROD DEV, V55, P20, DOI 10.1002/(SICI)1098-2795(200001)55:1&lt;20::AID-MRD4&gt;3.3.CO;2-5; Pelizzola M, 2008, GENOME RES, V18, P1652, DOI 10.1101/gr.080721.108; PESCE M, 1995, DEV BIOL, V170, P722, DOI 10.1006/dbio.1995.1250; Rosenthal NF, 2010, POULTRY SCI, V89, P1451, DOI 10.3382/ps.2010-00638; SCHEIB D, 1983, DIFFERENTIATION, V23, pS87; Schneider S, 2008, REPROD TOXICOL, V25, P352, DOI 10.1016/j.reprotox.2008.04.001; Shioda T, 2006, P NATL ACAD SCI USA, V103, P12033, DOI 10.1073/pnas.0605341103; Skinner MK, 2005, SERTOLI CELL BIOL; Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007; Smith CA, 1997, J STEROID BIOCHEM, V60, P295, DOI 10.1016/S0960-0760(96)00196-3; Smith CA, 2009, NATURE, V461, P267, DOI 10.1038/nature08298; Smith CA, 2003, BIOL REPROD, V68, P560, DOI 10.1095/biolreprod.102.007294; Smith CA, 2007, CYTOGENET GENOME RES, V117, P165, DOI 10.1159/000103177; Smith CA, 2004, BIOESSAYS, V26, P120, DOI 10.1002/bies.10400; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; TENG CS, 1985, BIOCHEM J, V228, P689; Vaillant S, 2001, J EXP ZOOL, V290, P727, DOI 10.1002/jez.1123; Vaillant S, 2001, DEV DYNAM, V222, P228, DOI 10.1002/dvdy.1190; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163; WILKS AF, 1982, P NATL ACAD SCI-BIOL, V79, P4252, DOI 10.1073/pnas.79.14.4252; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yang X, 2011, SEX DEV, V5, P147, DOI 10.1159/000327712; Yang XR, 2010, MOL BIOL REP, V37, P1841, DOI 10.1007/s11033-009-9619-y; Yu Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002672640SOC STUDY REPRODUCTIONMADISON1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USABIOL REPRODJULDiscipline: Reproductive Biology080EN</notes>
    <keywords>AROMATASE GENES; BIOLOGY; BISPHENOL-A; BREAST-CANCER CELLS; CELL; CELLS; Determination; development; Differentiation; DNA METHYLATION; embryo; ENDOCRINE DISRUPTORS; epigenetic; epigenetics; Estrogen; ESTROGENS; EXPOSURE; EXPRESSION; FEMALE CHICKENS; GENE; gene regulation; GENES; HEALTH; INHIBITOR; Inhibitors; Male; mechanism; MECHANISMS; METHYLATION; MODEL; ORGAN DEVELOPMENT; OVARIAN DEVELOPMENT; PRIMORDIAL GERM-CELLS; Reproduction; RESISTANT; Sertoli cell; sex determination; STEM-CELLS; TRANSGENERATIONAL ACTIONS; VITELLOGENIN GENE</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Biology of Reproduction</journalfull>
    <issue>1</issue>
    <volume>87</volume>
    <abstract>Sex of birds is genetically determined through inheritance of the ZW sex chromosomes (ZZ males and ZW females). Although the mechanisms of avian sex determination remains unknown, the genetic sex is experimentally reversible by in ovo exposure to exogenous estrogens (ZZ-male feminization) or aromatase inhibitors (ZW-female masculinization). Expression of various testis-and ovary-specific marker genes during the normal and reversed gonadal sex differentiation in chicken embryos has been extensively studied, but the roles of sex-specific epigenetic marks in sex differentiation are unknown. In this study, we show that a 170-nt region in the promoter of CYP19A1/aromatase, a key gene required for ovarian estrogen biosynthesis and feminization of chicken embryonic gonads, contains highly quantitative, nucleotide base-level epigenetic marks that reflect phenotypic gonadal sex differentiation. We developed a protocol to feminize ZZ-male chicken embryonic gonads in a highly quantitative manner by direct injection of emulsified ethynylestradiol into yolk at various developmental stages. Taking advantage of this experimental sex reversal model, we show that the epigenetic sex marks in the CYP19A1/aromatase promoter involving DNA methylation and histone lysine methylation are feminized significantly but only partially in sex-converted gonads even when morphological and transcriptional marks of sex differentiation show complete feminization, being indistinguishable from gonads of normal ZW females. Our study suggests that the epigenetic sex of chicken embryonic gonads is more stable than the morphologically or transcriptionally characterized sex differentiation, suggesting the importance of the nucleotide base-level epigenetic sex in gonadal sex differentiation</abstract>
    <url>WOS:000314224200004</url>
    <isbnorissn>0006-3363</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>178</id>
    <title>Polyacetal-stilbene conjugates - The first examples of polymer therapeutics for the inhibition of HIF-1 in the treatment of solid tumours</title>
    <authors>England,R.M.; Masia,E.; Gimenez,V.; Lucas,R.; Vicent,M.J.</authors>
    <availability>[England, Richard M.; Masia, Esther; Gimenez, Vanessa; Lucas, Rut; Vicent, Maria J.] CIPF, Polymer Therapeut Lab, Valencia 46012, Spain.</availability>
    <date>2012</date>
    <notes>JEnglishArticleLucas, R (reprint author), Gen Univ Hosp Res Fdn, Mol Oncol Lab, Av Tres Cruces S-N, Valencia 46014, Spainrlucas@cipf.es; mjvicent@cipf.esAo A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Canal F, 2011, CURR OPIN BIOTECH, V22, P894, DOI 10.1016/j.copbio.2011.06.003; Chintala S, 2010, CANCER CHEMOTH PHARM, V66, P899, DOI 10.1007/s00280-009-1238-8; Deepa PR, 2012, BASIC CLIN PHARMACOL, V110, P494, DOI 10.1111/j.1742-7843.2011.00844.x; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Dhal PK, 2009, ADV DRUG DELIVER REV, V61, P1121, DOI 10.1016/j.addr.2009.05.004; Duncan R, 2011, CURR OPIN BIOTECH, V22, P492, DOI 10.1016/j.copbio.2011.05.507; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gimenez V, 2012, J CONTROL RELEASE, V159, P290, DOI 10.1016/j.jconrel.2011.12.035; Greco F, 2009, ADV DRUG DELIVER REV, V61, P1203, DOI 10.1016/j.addr.2009.05.006; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HELLER J, 1980, J POLYM SCI POL LETT, V18, P293, DOI 10.1002/pol.1980.130180410; Hogel H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027112; Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141; Kubo T, 2004, BIOCHEM BIOPH RES CO, V318, P1006, DOI 10.1016/j.bbrc.2004.04.125; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Moreno-Manzano V, 2010, J BIOL CHEM, V285, P1333, DOI 10.1074/jbc.M109.008326; Nagle DG, 2006, CURR DRUG TARGETS, V7, P355, DOI 10.2174/138945006776054979; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Sanchis J, 2010, NANOMEDICINE-UK, V5, P915, DOI [10.2217/nnm.10.71, 10.2217/NNM.10.71]; Semenza GL, 2007, DRUG DISCOV TODAY, V12, P853, DOI 10.1016/j.drudis.2007.08.006; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tang HD, 2010, BIOMATERIALS, V31, P7139, DOI 10.1016/j.biomaterials.2010.06.007; Tomlinson R, 2002, MACROMOLECULES, V35, P473, DOI 10.1021/ma0108867; Tomlinson R, 2003, BIOCONJUGATE CHEM, V14, P1096, DOI 10.1021/bc030028a; Veronese FM, 2009, MILESTONES DRUG THER, P1, DOI 10.1007/978-3-7643-8679-5; Vicent MJ, 2004, J DRUG TARGET, V12, P491, DOI 10.1080/10611860400011885; Wang R, 2011, CURR MED CHEM, V18, P3168; Webster R, 2009, MILESTONES DRUG THER, P127, DOI 10.1007/978-3-7643-8679-5_8; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064323ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSJ CONTROL RELEASEDEC 28Discipline: Chemistry; Pharmacology &amp; Pharmacy062UH</notes>
    <keywords>AGENTS; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; CANCER; CANCER-THERAPY; CELL; CELLS; DES; DIETHYLSTILBESTROL; environment; GROWTH; HYPOXIA; Hypoxia inducible factor (HIF); INDUCIBLE FACTOR-I; inhibition; oestrogen; pH-Dependent degradation; PHARMACOLOGY; Polyacetals; Polymer therapeutics; RELEASE; TARGETING HYPOXIA; TOXICITY; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>314</startpage>
    <endpage>322</endpage>
    <journalfull>Journal of Controlled Release</journalfull>
    <issue>3</issue>
    <volume>164</volume>
    <abstract>We report here the first examples of Polymer Therapeutics synthesised with the intention of inhibiting Hypoxia Inducible Factor-1 (HIF-1), a transcription factor heavily involved in numerous cell processes under a low oxygen environment. Four compounds were selected for use in these systems; Diethylstilbestrol (DES), Bisphenol A (BIS), Dienestrol (DIENES) and Hexestrol (HEX), which were chosen from a large family of similar molecules known as Stilbenes. These are non-steroidal molecules with structural similarities to oestrogen, and of which DES and BIS have previously been reported for HIF-1 inhibition. These molecules were incorporated into a poly(ethylene glycol) (PEG) based polyacetal system using a reaction of short PEG chains with di(ethylene glycol) divinyl ether units and an acid catalyst and without the need for biodegradable linkers. With an improved polyacetal synthesis strategy we obtained high yields of water soluble polymer conjugates with desirable drug loadings and tailored molecular weights (Mw 23,000-35,000 g/mol) with relatively narrow polydispersities (pdi 1.3-1.5). These polymers were found to be hydrolytically cleaved under acid conditions (such as those found in endosomes, lysosomes or the extracellular fluid of some tumours) yielding the free drug. Additionally, they were found to be stable over prolonged periods of time at pH 7.4 mimicking blood plasma. Of the four polymers synthesised, the conjugates of DES and BIS displayed the best activity for HIF-1 alpha inhibition in HeLa 9xHRE-Luc tumour cells. More importantly, these conjugates were found to exhibit little to no cell toxicity, contrary to the free drugs, and consequently, they significantly enhanced drug therapeutic index (TI 3.5 vs. 7.2 for free DES vs. DES-polyacetal 2a, and TI 1.1 vs. &gt; 20 for free BIS vs. BIS-polyacetal 1b). (c) 2012 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000312947600010</url>
    <isbnorissn>0168-3659</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>66</id>
    <title>Investigation of serum bisphenol A, vitamin D, and parathyroid hormone levels in patients with obstructive sleep apnea syndrome</title>
    <authors>Erden,E.S.; Genc,S.; Motor,S.; Ustun,I.; Ulutas,K.T.; Bilgic,H.K.; Oktar,S.; Sungur,S.; Erem,C.; Gokce,C.</authors>
    <availability>[Erden, Ersin Sukru; Genc, Sebahat; Bilgic, Hatice Kayim] Mustafa Kemal Univ, Fac Med, Dept Chest Dis, TR-31000 Antakya, Turkey. [Motor, Sedat; Ulutas, Kemal Turker] Mustafa Kemal Univ, Fac Med, Dept Biochem, TR-31000 Antakya, Turkey. [Ustun, Ihsan; Gokce, Cumali] Mustafa Kemal Univ, Fac Med, Dept Internal Med, Div Endocrinol &amp; Metab, TR-31000 Antakya, Turkey. [Oktar, Suleyman] Mustafa Kemal Univ, Fac Med, Dept Pharmacol, TR-31000 Antakya, Turkey. [Sungur, Sana] Mustafa Kemal Univ, Sci &amp; Letters Fac, Dept Chem, TR-31000 Antakya, Turkey. [Erem, Cihangir] Karadeniz Tech Univ, Fac Med, Dept Internal Med, Div Endocrinol &amp; Metab, Trabzon, Turkey.</availability>
    <date>2014</date>
    <notes>JEnglishArticleErden, ES (reprint author), Mustafa Kemal Univ, Fac Med, Dept Chest Dis, TR-31000 Antakya, Turkeydreserden@gmail.com; sebahatakoglu@hotmail.com; sedatmotor@yahoo.com; iustun@yahoo.com; drkemalturker@gmail.com; hkayim@hotmail.com; suleymanoktar@yahoo.com; sanasungur@hotmail.com; cihangirerem@hotmail.com; cumaligokce@yahoo.comAkingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Arunabh S, 2003, J CLIN ENDOCR METAB, V88, P157, DOI 10.1210/jc.2002-020978; Barcelo A, 2013, RESPIRATION, V86, P295, DOI 10.1159/000342748; Bloomgarden Zachary T, 2011, Diabetes Care, V34, pe1, DOI 10.2337/dc11-zb01; Bozkurt NC, 2012, ENDOCRINE, V41, P518, DOI 10.1007/s12020-012-9595-1; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cobellis L, 2009, BIOMED CHROMATOGR, V23, P1186, DOI 10.1002/bmc.1241; Flemons WW, 1996, SLEEP, V19, pS243; Forouhi NG, 2008, DIABETES, V57, P2619, DOI 10.2337/db08-0593; Fraser A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013882; George JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061282; Gu CJ, 2013, CHINESE MED J-PEKING, V126, P5, DOI 10.3760/cma.j.issn.0366-6999.20121195; Guillet C, 2012, OBES REV, V13, P51, DOI 10.1111/j.1467-789X.2012.01037.x; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Iber C, 2007, AASM MANUAL SCORING; Jayashree S, 2013, ENVIRON TOXICOL PHAR, V35, P300, DOI 10.1016/j.etap.2012.12.016; JOHNS MW, 1991, SLEEP, V14, P540; Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Li LH, 2013, ENDOCRINE, V44, P465, DOI 10.1007/s12020-013-9885-2; Lucassen EA, 2012, ANN NY ACAD SCI, V1264, P110, DOI 10.1111/j.1749-6632.2012.06655.x; McCarty MF, 2003, MED HYPOTHESES, V61, P535, DOI 10.1016/S0306-9877(03)00227-5; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Mete T, 2013, ENDOCRINE, V44, P723, DOI 10.1007/s12020-013-9927-9; Mete T., 2013, J ENDOCRINOL INVEST, DOI [10.3275/8923, DOI 10.3275/8923]; Miyawaki J, 2007, J ATHEROSCLER THROMB, V14, P245; Moon DG, 2001, INT J IMPOT RES, V13, P309, DOI 10.1038/sj.ijir.3900734; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Newbold RR, 2009, MOL CELL ENDOCRINOL, V304, P84, DOI 10.1016/j.mce.2009.02.024; Pant J, 2011, J APPL TOXICOL, V31, P698, DOI 10.1002/jat.1647; Pearce SHS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5664; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Reis JP, 2008, EUR J ENDOCRINOL, V159, P41, DOI 10.1530/EJE-08-0072; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Saylor PJ, 2013, J UROLOGY, V189, pS34, DOI 10.1016/j.juro.2012.11.017; Saylor PJ, 2013, J UROL S1, V189, pS43, DOI [DOI 10.1016/J.JURO.2012.11.017, 10.1016/ j. juro. 2012.11.017]; Scragg R, 2004, DIABETES CARE, V27, P2813, DOI 10.2337/diacare.27.12.2813; Skaaby T, 2013, ENDOCRINE, V43, P618, DOI 10.1007/s12020-012-9805-x; Skaaby T, 2013, ENDOCRINE, V44, P473, DOI 10.1007/s12020-013-9887-0; Snijder MB, 2005, J CLIN ENDOCR METAB, V90, P4119, DOI 10.1210/jc.2005-0216; Storer TW, 2012, ASIAN J ANDROL, V14, P204, DOI 10.1038/aja.2011.104; Teng C, 2013, CHEM-BIOL INTERACT, V203, P556, DOI 10.1016/j.cbi.2013.03.013; Uzkeser H, 2013, SLEEP BREATH, V17, P339, DOI 10.1007/s11325-012-0698-y; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vanga SR, 2010, AM J CARDIOL, V106, P798, DOI 10.1016/j.amjcard.2010.04.042; Wei J, 2011, ENDOCRINOLOGY, V152, P3049, DOI 10.1210/en.2011-0045; Wortsman J, 2000, AM J CLIN NUTR, V72, P690; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Young KA, 2009, J CLIN ENDOCR METAB, V94, P3306, DOI 10.1210/jc.2009-0079; Zhao GX, 2010, DIABETES CARE, V33, P344, DOI 10.2337/dc09-0924561HUMANA PRESS INCTOTOWA999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USAENDOCRINEMARDiscipline: Endocrinology &amp; MetabolismAB2RE</notes>
    <keywords>25-HYDROXYVITAMIN-D LEVELS; ABNORMALITIES; ANDROGEN DEPRIVATION THERAPY; bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; BPA; CANCER; cardiovascular; CELL; diabetes; Endocrine disruptor; estrogenic activity; EXPOSURE; GENERAL-POPULATION; GLUCOSE-METABOLISM; INSULIN-RESISTANCE; METABOLIC SYNDROME; METABOLISM; Obstructive sleep apnea syndrome; Parathyroid hormone; PERINATAL EXPOSURE; PROSTATE-CANCER; serum; US ADULTS; Vitamin D</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>311</startpage>
    <endpage>318</endpage>
    <journalfull>Endocrine</journalfull>
    <issue>2</issue>
    <volume>45</volume>
    <abstract>Obstructive sleep apnea syndrome (OSAS) is a common health problem, and associated with obesity, metabolic syndrome (MetS), and diabetes. Growing evidence shows that 25-hydroxyvitamin-D-3 (25-OH-D) insufficiency and high parathyroid hormone (PTH) levels may be correlated to glucose intolerance, MetS, obesity, and cardiovascular abnormalities similar to OSAS. Bisphenol A (BPA) is an endocrine disruptor agent which exerts a wide variety of metabolic effects. It has estrogenic activity and its exposure may contribute to weight gain, obesity, impaired glucose metabolism, and the development of diabetes, also similar to OSAS. The aim of this study is to investigate the relationships between OSAS and serum BPA, 25-OH-D, and PTH levels. This study enrolled 128 subjects, with all of the OSAS patients having been diagnosed by polysomnography. The 128 subjects were divided into three groups: a control (n = 43), a moderate OSAS (n = 23) (AHI = 15-30), and a severe OSAS groups (n = 62) (AHI &gt; 30). The serum BPA, 25-OH-D, and PTH levels for each subject were analyzed. 25-OH-D was lower in both OSAS groups, and PTH was higher in the OSAS groups than in the control subjects. The BPA levels were higher in the severe OSAS group than the moderate OSAS and control. There was a positive correlation between the BPA and body mass index, and a negative correlation between the 25-OH-D and BPA levels in all of the individuals. OSAS is related to high BPA and PTH levels, and low vitamin D levels. There is a positive association between BPA levels and OSAS, and the severity of OSAS. These results suggest that the BPA levels may have a role in the pathogenesis of OSAS</abstract>
    <url>WOS:000331639000021</url>
    <isbnorissn>1355-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>395</id>
    <title>Increase of wildlife cancer: an echo of plastic pollution?</title>
    <authors>Erren,T.; Zeuss,D.; Steffany,F.; Meyer-Rochow,B.</authors>
    <availability>[Erren, Thomas] Univ Cologne, Inst &amp; Policlin Occupat Med Social Med &amp; Social H, D-50924 Cologne, Germany. [Steffany, Frank] Univ Cologne, Inst Geophys &amp; Meteorol, D-50923 Cologne, Germany. [Meyer-Rochow, Benno] Jacobs Univ, Sch Sci &amp; Engn, D-28759 Bremen, Germany.</availability>
    <date>2009</date>
    <notes>JEnglishLetterErren, T (reprint author), Univ Cologne, Inst &amp; Policlin Occupat Med Social Med &amp; Social H, Joseph Stelzmann Str 9, D-50924 Cologne, Germanytim.erren@uni-koeln.deDODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; McAloose D, 2009, NAT REV CANCER, V9, P517, DOI 10.1038/nrc2665; Moore CJ, 2008, ENVIRON RES, V108, P131, DOI 10.1016/j.envres.2008.07.025; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; Zincke T, 1905, LIEBIGS ANN CHEM, V343, P7592NATURE PUBLISHING GROUPLONDONMACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLANDNAT REV CANCERNOVDiscipline: Oncology510GX</notes>
    <keywords>BISPHENOL-A; CANCER; CELL; HEALTH; oncology; phenol</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Nature Reviews Cancer</journalfull>
    <issue>11</issue>
    <volume>9</volume>
    <url>WOS:000271077200016</url>
    <isbnorissn>1474-175X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>340</id>
    <title>Inability to confirm estrogenicity of the heterocyclic amine PhIP in two in vitro assays</title>
    <authors>Evans,R.M.; Rahte,S.; Kortenkamp,A.</authors>
    <availability>[Evans, Richard M.; Rahte, Sinikka; Kortenkamp, Andreas] Univ London, Sch Pharm, Ctr Toxicol, London WC1N 1AX, England. [Rahte, Sinikka] Univ London, Sch Pharm, Ctr Pharmacognosy &amp; Phytotherapy, London WC1N 1AX, England.</availability>
    <date>2010</date>
    <notes>JEnglishArticleKortenkamp, A (reprint author), Univ London, Sch Pharm, Ctr Toxicol, 29-39 Brunswick Sq, London WC1N 1AX, Englandandreas.kortenkamp@pharmacy.ac.ukBennion BJ, 2005, CHEM RES TOXICOL, V18, P1528, DOI 10.1021/tx0501031; BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133; Byrne C, 1998, CANCER EPIDEM BIOMAR, V7, P523; Clode SA, 2006, BEST PRACT RES CL EN, V20, P35, DOI 10.1016/j.beem.2005.09.011; DeBruin LS, 2001, CHEM RES TOXICOL, V14, P1523, DOI 10.1021/tx015556u; FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081; Felton JS, 2002, ENVIRON MOL MUTAGEN, V39, P112, DOI 10.1002/em.10070; FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312; Gooderham NJ, 2007, TOXICOL LETT, V168, P269, DOI 10.1016/j.toxlet.2006.10.022; Gooderham NJ, 2002, MUTAT RES-FUND MOL M, V506, P91, DOI 10.1016/S0027-5107(02)00155-0; IMMONEN E, 2009, CHEM BIOL INTERACT; Jagerstad M, 2005, MUTAT RES-FUND MOL M, V574, P156, DOI 10.1016/j.mrfmmm.2005.01.030; Jones C, 2000, CANCER GENET CYTOGEN, V117, P153, DOI 10.1016/S0165-4608(99)00158-2; Kawamori T, 2001, CANCER LETT, V162, P31, DOI 10.1016/S0304-3835(00)00626-1; Koohi MK, 2007, MOL CELL ENDOCRINOL, V276, P45, DOI 10.1016/j.mce.2007.06.008; Lauber SN, 2004, CARCINOGENESIS, V25, P2509, DOI 10.1093/carcin/bgh268; Lauber SN, 2007, CANCER RES, V67, P9597, DOI 10.1158/0008-5472.CAN-07-1661; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; *OECD, 2007, GUID TEST CHEM DRAFT; *OECD, 2006, DRAFT OECD GUID TEST; Rajapakse N, 2004, ENVIRON SCI TECHNOL, V38, P6343, DOI 10.1021/es049681e; Silva E, 2007, ENVIRON HEALTH PERSP, V115, P91, DOI 10.1289/ehp.9363; Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x; Turesky RJ, 2007, TOXICOL LETT, V168, P219, DOI 10.1016/j.toxlet.2006.10.018; USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417; van der Woude H, 2005, MOL NUTR FOOD RES, V49, P763, DOI 10.1002/mnfr.200500036; VILLALOBOS M, 1995, ENVIRON HEALTH PERSP, V103, P844, DOI 10.2307/3432398; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285322PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROSEPDiscipline: Toxicology653RM</notes>
    <keywords>2-Amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine; ACTIVATION; ASSAY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; Carcinogen; CARCINOGENESIS; CELL; Cell proliferation; CELL STOCKS; CELL-PROLIFERATION; CLASSIFICATION; E-SCREEN ASSAY; Endocrine disruption; ESTRADIOL; Estrogen; estrogenic activity; Estrogenicity; ESTROGENS; EXPOSURE; FOOD; Food estrogens; genistein; HEALTH; HUMAN EXPOSURE; IDENTIFICATION; In vitro; In vitro cell-based assay; IN-VITRO; LINE; LINES; LUCIFERASE REPORTER; MUTAGENS/CARCINOGENS; NMR; PERFORMANCE; PhIP; proliferation; RECEPTOR; RESPONSES; SPECTROSCOPY; toxicology; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1757</startpage>
    <endpage>1763</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>6</issue>
    <volume>24</volume>
    <abstract>2-Amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) is a heterocyclic amine which is found in food after cooking and which is a known mutagen. Reports from several laboratories have proposed that PhIP has estrogenic activity, which would classify PhIP as a xenoestrogen with human exposure via food. We tested PhIP in two cell-based assays for estrogenicity, both based on human cell lines but utilising different outcome measures: ERLUX (reporter-gene activation) and ESCREEN (cell proliferation). PhIP was inactive in both assays at concentrations spanning the picomolar to micromolar range. To eliminate supplier differences as an explanation for the disparity between these results and positive findings in the literature, we purchased PhIP from three suppliers and found no detectable estrogenic activity in any batch. (1)H NMR spectroscopy confirmed the chemical identity of the tested stock solutions. Correct assay performance was confirmed by including positive and vehicle controls on every assay plate, and by demonstrating the expected responses to a panel of known estrogens (estradiol, bisphenol A, genistein). Our results differ from those in the literature and, whilst the exact reason for this is unknown, we discuss possible explanations of the disparity. Our results provide no in vitro evidence for the classification of PhIP as an estrogen. (C) 2010 Published by Elsevier Ltd</abstract>
    <url>WOS:000282114400037</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>220</id>
    <title>Hormonal activities of new brominated flame retardants</title>
    <authors>Ezechias,M.; Svobodova,K.; Cajthaml,T.</authors>
    <availability>[Ezechias, M.; Svobodova, K.; Cajthaml, T.] Inst Microbiol ASCR, Vvi, Lab Environm Biotechnol, Prague 14220, Czech Republic. [Ezechias, M.; Cajthaml, T.] Charles Univ Prague, Fac Sci, Inst Environm Studies, Prague 12843, Czech Republic.</availability>
    <date>2012</date>
    <notes>JEnglishArticleCajthaml, T (reprint author), Inst Microbiol ASCR, Vvi, Lab Environm Biotechnol, Videnska 1083, Prague 14220, Czech Republiccajthaml@biomed.cas.czAllen JG, 2007, ENVIRON SCI TECHNOL, V41, P4574, DOI 10.1021/es0703170; [Anonymous], 2009, PART 4 ANN A DEC SC; Brown DJ, 2004, CHEMOSPHERE, V55, P1509, DOI 10.1016/j.chemosphere.2003.10.019; Christiansson A, 2008, CHEMOSPHERE, V73, P1654, DOI 10.1016/j.chemosphere.2008.07.071; de Wit CA, 2002, CHEMOSPHERE, V46, P583, DOI 10.1016/S0045-6535(01)00225-9; Flodin C, 1999, WATER SCI TECHNOL, V40, P53, DOI 10.1016/S0273-1223(99)00537-5; FOWLES JR, 1994, TOXICOLOGY, V86, P49, DOI 10.1016/0300-483X(94)90052-3; Gauthier LT, 2007, ENVIRON SCI TECHNOL, V41, P4561, DOI 10.1021/es0630487; Hallgren S, 2001, ARCH TOXICOL, V75, P200, DOI 10.1007/s002040000208; Wilford BH, 2004, ENVIRON SCI TECHNOL, V38, P5312, DOI 10.1021/es049260x; Hamers T, 2006, TOXICOL SCI, V92, P157, DOI 10.1093/toxsci/kfj187; Hites RA, 2004, ENVIRON SCI TECHNOL, V38, P945, DOI 10.1021/es035082g; Hooper K, 2000, ENVIRON HEALTH PERSP, V108, P387, DOI 10.2307/3454377; Kawashiro Y, 2008, ENDOCR J, V55, P1071; Larsson A, 2006, J MED CHEM, V49, P7366, DOI 10.1021/jm060713d; Law RJ, 2006, CHEMOSPHERE, V64, P187, DOI 10.1016/j.chemosphere.2005.12.007; Leskinen P, 2005, CHEMOSPHERE, V61, P259, DOI 10.1016/j.chemosphere.2005.01.080; Meerts Ilonka A. T. M., 2001, Environmental Health Perspectives, V109, P399, DOI 10.2307/3454900; Olsen CM, 2002, TOXICOL LETT, V129, P55, DOI 10.1016/S0378-4274(01)00469-6; Reineke N, 2006, ARCH ENVIRON CON TOX, V51, P186, DOI 10.1007/s00244-005-0135-3; Routledge EJ, 1996, ENVIRON TOXICOL CHEM, V15, P241, DOI 10.1897/1551-5028(1996)015&lt;0241:EAOSAS&gt;2.3.CO;2; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; Sim WJ, 2009, CHEMOSPHERE, V77, P552, DOI 10.1016/j.chemosphere.2009.07.006; Sjodin A, 2008, CHEMOSPHERE, V73, pS131, DOI 10.1016/j.chemosphere.2007.08.075; Sjodin A, 2003, ENVIRON INT, V29, P829, DOI 10.1016/S0160-4120(03)00108-9; Stapleton HM, 2008, ENVIRON SCI TECHNOL, V42, P6910, DOI 10.1021/es801070p; Stoker TE, 2005, TOXICOL APPL PHARM, V207, P78, DOI 10.1016/j.taap.2005.05.010; Svobodova K, 2009, SCI TOTAL ENVIRON, V407, P5921, DOI 10.1016/j.scitotenv.2009.08.011; Takigami H, 2009, CHEMOSPHERE, V76, P270, DOI 10.1016/j.chemosphere.2009.03.006; Thomsen C, 2001, J ENVIRON MONITOR, V3, P366, DOI 10.1039/b104304h; Verreault J, 2007, ENVIRON SCI TECHNOL, V41, P4925, DOI 10.1021/es070522f; Zhou T, 2002, TOXICOL SCI, V66, P105, DOI 10.1093/toxsci/66.1.105; Zhou T, 2001, TOXICOL SCI, V61, P76, DOI 10.1093/toxsci/61.1.76335PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDCHEMOSPHEREMAYDiscipline: Environmental Sciences &amp; Ecology939DK</notes>
    <keywords>2,4,6-Tribromophenol; Androgen; ANDROGEN RECEPTOR; ASSAY; BISPHENOL-A; BROMINATED FLAME RETARDANTS; CANCER CELL-LINE; CELL; CHEMICALS; ENDOCRINE; ENDOCRINE DISRUPTORS; environment; Estrogen; FLAME RETARDANTS; HEALTH; HUMAN EXPOSURE; IN-VIVO; PBDEs; PHENOLS; POLYBROMINATED DIPHENYL ETHERS; POLYCHLORINATED-BIPHENYLS; RECEPTOR; Reporter gene assay; THYROID-HORMONE; toxicology; TRANSCRIPTIONAL ACTIVITY; WATER; Yeast reporter gene assays</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>820</startpage>
    <endpage>824</endpage>
    <journalfull>Chemosphere</journalfull>
    <issue>7</issue>
    <volume>87</volume>
    <abstract>After the phase-out of two commercial mixtures of brominated flame retardants, an increasing number of alternative flame retardants have been introduced in commercial applications. None of them, however, has been thoroughly tested for its hormonal activity. We used two yeast reporter-gene assays to determine the potential of eleven compounds to interfere with estrogenic and androgenic pathways. Our data demonstrate the ability of 2,4,6-tribromophenol to lower the transcriptional activity of human estrogen and androgen receptors. A nominal IC50 value of 14.1 mu M for anti-estrogenic and 3.9 mu M for anti-androgenic activity was obtained using the luciferase reporter. An IC50 value of 9.2 mu M was calculated for the anti-estrogenic activity measured by the beta-galactosidase assay. Of the tested chemicals, this study highlights the endocrine disrupting effects of 2,4,6-tribromophenol whose occurrence in the environment should be monitored. (C) 2011 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000303787300021</url>
    <isbnorissn>0045-6535</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>235</id>
    <title>Electrochemical bisphenol A sensor based on N-doped graphene sheets</title>
    <authors>Fan,H.X.; Li,Y.; Wu,D.; Ma,H.M.; Mao,K.X.; Fan,D.W.; Du,B.; Li,H.; Wei,Q.</authors>
    <availability>[Fan, Haixia; Li, Yan; Wu, Dan; Ma, Hongmin; Mao, Kexia; Fan, Dawei; Du, Bin; Li, He; Wei, Qin] Univ Jinan, Key Lab Chem Sensing &amp; Anal, Shandong Univ, Sch Chem &amp; Chem Engn, Jinan 250022, Peoples R China.</availability>
    <date>2012</date>
    <notes>JEnglishArticleDu, B (reprint author), Univ Jinan, Key Lab Chem Sensing &amp; Anal, Shandong Univ, Sch Chem &amp; Chem Engn, Jinan 250022, Peoples R Chinabindu0720@gmail.com; lihecd@gmail.com; sdjndxwq@163.comAo ZM, 2010, J PHYS CHEM C, V114, P14503, DOI 10.1021/jp103835k; Bardelline J., 2011, GREENERDESIGN; Cai YY, 2011, BIOMATERIALS, V32, P2117, DOI 10.1016/j.biomaterials.2010.11.058; Fernandez L, 2006, ELECTROCHIM ACTA, V52, P872, DOI 10.1016/j.electacta.2006.06.021; Guo BD, 2010, NANO LETT, V10, P4975, DOI 10.1021/nl103079j; Hideyuki Y., 2003, ANAL CHIM ACTA, V488, P211; Juliane R.B., 2010, REUTERS; Kawaguchi M, 2004, J CHROMATOGR B, V805, P41, DOI 10.1016/j.chromb.2004.02.005; Lee KR, 2010, ELECTROCHEM COMMUN, V12, P1052, DOI 10.1016/j.elecom.2010.05.023; Li QA, 2010, J HAZARD MATER, V180, P703, DOI 10.1016/j.jhazmat.2010.04.094; Li XL, 2009, J AM CHEM SOC, V131, P15939, DOI 10.1021/ja907098f; Long DH, 2010, LANGMUIR, V26, P16096, DOI 10.1021/la102425a; Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479; Luckza T., 2008, ELECTROCHIM ACTA, V53, P5725, DOI DOI 10.1016/J.ELECTACTA.2008.03.052; Marcano DC, 2010, ACS NANO, V4, P4806, DOI 10.1021/nn1006368; McAllister MJ, 2007, CHEM MATER, V19, P4396, DOI 10.1021/cm0630800; Mielke H, 2009, TOXICOL LETT, V190, P32, DOI 10.1016/j.toxlet.2009.06.861; Mita DG, 2007, BIOSENS BIOELECTRON, V23, P60, DOI 10.1016/j.bios.2007.03.010; Pichon V, 2008, ANAL CHIM ACTA, V622, P48, DOI 10.1016/j.aca.2008.05.057; Qu LT, 2010, ACS NANO, V4, P1321, DOI 10.1021/nn901850u; Reddy ALM, 2010, ACS NANO, V4, P6337, DOI 10.1021/nn101926g; Sajiki J, 2003, CHEMOSPHERE, V51, P55, DOI 10.1016/S0045-6535(02)00789-0; Sambe H, 2006, J CHROMATOGR A, V1134, P16, DOI 10.1016/j.chroma.2006.08.072; Tan L, 2009, SENSOR ACTUAT B-CHEM, V142, P316, DOI 10.1016/j.snb.2009.08.011; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Wang FG, 2009, ANAL CHIM ACTA, V638, P23, DOI 10.1016/j.aca.2009.02.013; Wang Y, 2010, ACS NANO, V4, P1790, DOI 10.1021/nn100315s; Wang YQ, 2011, ELECTROCHIM ACTA, V56, P2105, DOI 10.1016/j.electacta.2010.11.077; Yin HS, 2011, FOOD CHEM, V125, P1097, DOI 10.1016/j.foodchem.2010.09.098; Yin HS, 2010, J HAZARD MATER, V174, P236, DOI 10.1016/j.jhazmat.2009.09.041; Yin HS, 2010, ELECTROCHIM ACTA, V55, P603, DOI 10.1016/j.electacta.2009.09.020; Yin HS, 2010, ANAL CHIM ACTA, V659, P144, DOI 10.1016/j.aca.2009.11.051; Yin HS, 2009, J ELECTROANAL CHEM, V626, P80, DOI 10.1016/j.jelechem.2008.11.004; Yu CM, 2011, ELECTROCHIM ACTA, V56, P9056, DOI 10.1016/j.electacta.2011.05.135; Zhang CH, 2011, ADV MATER, V23, P1020, DOI 10.1002/adma.2010041103536ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSANAL CHIM ACTAJAN 20Discipline: Chemistry898TL</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARBON; CHROMATOGRAPHY-MASS SPECTROMETRY; Electrochemical sensor; ELECTRODE; ENDOCRINE; Endocrine disruptor; FOOD; GRAPHENE; MEDIA; N-doped graphene; OXIDE; REDUCTION; RIVER WATER; SAMPLES; SYSTEM; WATER; WATER SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>24</startpage>
    <endpage>28</endpage>
    <journalfull>Analytica Chimica Acta</journalfull>
    <volume>711</volume>
    <abstract>Bisphenol A (BPA), which could disrupt endocrine system and cause cancer, has been considered as an endocrine disruptor. Therefore, it is very important and necessary to develop a sensitive and selective method for detection of BPA. Herein, nitrogen-doped graphene sheets (N-GS) and chitosan (CS) were used to prepare electrochemical BPA sensor. Compared with graphene, N-GS has favorable electron transfer ability and electrocatalytic property, which could enhance the response signal towards BPA. CS also exhibits excellent film forming ability and improves the electrochemical behavior of N-GS modified electrode. The sensor exhibits a sensitive response to BPA in the range of 1.0 x 10(-8)-1.3 x 10(-6) mol L-1 with a low detection limit of 5.0 x 10(-9) mol L-1 under the optimal conditions. Finally, this proposed sensor was successfully employed to determine BRA in water samples with satisfactory results. (C) 2011 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000300764600004</url>
    <isbnorissn>0003-2670</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>118</id>
    <title>Bisphenol A: An endocrine and metabolic disruptor</title>
    <authors>Fenichel,P.; Chevalier,N.; Brucker-Davis,F.</authors>
    <availability>[Fenichel, Patrick; Chevalier, Nicolas; Brucker-Davis, Francoise] CHU Nice, Hop Archet 2, Serv Endocrinol Diabetol &amp; Reprod, INSERM,U1065,C3M, F-06202 Nice 3, France.</availability>
    <date>2013</date>
    <notes>JEnglishReviewFenichel, P (reprint author), CHU Nice, Hop Archet 2, Serv Endocrinol Diabetol &amp; Reprod, INSERM,U1065,C3M, 151 Route St Antoine de Ginestiere, F-06202 Nice 3, Francefenichel.p@chu-nice.frAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Alonso-Magdalena P, 2011, NAT REV ENDOCRINOL, V7, P346, DOI 10.1038/nrendo.2011.56; ANSES, 2011, RAPP EXP COLL EFF SA; Barker DJP, 2003, EUR J EPIDEMIOL, V18, P733, DOI 10.1023/A:1025388901248; Ben-Jonathan N, 2009, MOL CELL ENDOCRINOL, V304, P49, DOI 10.1016/j.mce.2009.02.022; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bouskine A, 2008, ENDOCRINOLOGY, V149, P565, DOI 10.1210/en.2007-1318; Bray F, 2006, INT J CANCER, V118, P3099, DOI 10.1002/ijc.21747; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; Brucker-Davis F, 2011, THYROID, V21, P1133, DOI 10.1089/thy.2010.0459; Brucker-Davis F, 2008, HUM REPROD, V23, P1708, DOI 10.1093/humrep/den186; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Carwile JL, 2011, ENVIRON RES, V111, P825, DOI 10.1016/j.envres.2011.05.014; Chevalier N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034672; Chevalier N, 2012, INT J CANCER, V130, P241, DOI 10.1002/ijc.25972; Chevrier J, 2013, ENVIRON HEALTH PERSP, V121, P138, DOI 10.1289/ehp.1205092; Chiam K, 2009, BBA-REV CANCER, V1795, P104, DOI 10.1016/j.bbcan.2008.12.001; Colbom T, 1992, WINGSPREAD CONSENSUS, P1; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Fei XL, 2005, ENDOCRINOLOGY, V146, P3445, DOI 10.1210/en.2005-0341; Fenichel P, 2012, HUM REPROD, V27, P983, DOI 10.1093/humrep/der451; Fenichel P, END SOC ANN M SAN FR; Fenichel P, 2008, GYNECOL OBSTET FERTI, V36, P969, DOI 10.1016/j.gyobfe.2008.05.006; Fernandez M, 2010, ENVIRON HEALTH PERSP, V118, P1217, DOI 10.1289/ehp.0901257; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Ginsberg G, 2009, ENVIRON HEALTH PERSP, V117, P1639, DOI 10.1289/ehp.0901010; Hardell L, 2003, ENVIRON HEALTH PERSP, V111, P930, DOI 10.1289/ehp.5816; HERBST AL, 1981, CANCER, V48, P484, DOI 10.1002/1097-0142(19810715)48:1+&lt;484::AID-CNCR2820481308&gt;3.0.CO;2-X; Hess-Wilson JK, 2009, CANCER CAUSE CONTROL, V20, P1029, DOI 10.1007/s10552-009-9337-8; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 1999, NATURE, V401, P763; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Institut National de Veille Sanitaire, PROJ INC MORT CANC F; Kaddar N, 2009, ANAL CHIM ACTA, V645, P1, DOI 10.1016/j.aca.2009.04.036; Kandaraki E, 2011, J CLIN ENDOCR METAB, V96, pE480, DOI 10.1210/jc.2010-1658; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Li DK, 2011, FERTIL STERIL, V95, P625, DOI 10.1016/j.fertnstert.2010.09.026; Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147; Main KM, 2009, ENDOCRIN DEV, V14, P167, DOI 10.1159/000207485; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2001, BIOL REPROD, V65, P1215; Masuno H, 2002, J LIPID RES, V43, P676; Matsumoto J, 2002, ENVIRON HEALTH PERSP, V110, P193; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; MILLS PK, 1984, LANCET, V1, P207; Mills PK, 1998, ARCH ENVIRON HEALTH, V53, P410; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Multigner L, 2010, J CLIN ONCOL, V28, P3457, DOI 10.1200/JCO.2009.27.2153; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Nakamura D, 2010, TOXICOL LETT, V194, P16, DOI 10.1016/j.toxlet.2010.02.002; Newbold RR, 2007, MOL NUTR FOOD RES, V51, P912, DOI 10.1002/mnfr.200600259; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Philippat C, 2012, ENVIRON HEALTH PERSP, V120, P464, DOI 10.1289/ehp.1103634; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; RAcbillard Xavier, 2003, Rev Prat, V53, P2224; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Roger C, 2005, J MOL ENDOCRINOL, V35, P191, DOI 10.1677/jme.1.01704; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Ryan KK, 2010, ENDOCRINOLOGY, V151, P2603, DOI 10.1210/en.2009-1218; Sakurai K, 2004, BRIT J PHARMACOL, V141, P209, DOI 10.1038/sj.bjp.0705520; Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012; Salian S, 2009, LIFE SCI, V85, P742, DOI 10.1016/j.lfs.2009.10.004; Sargis RM, 2010, OBESITY, V18, P1283, DOI 10.1038/oby.2009.419; Sasco AJ, 2001, APMIS, V109, P321, DOI 10.1034/j.1600-0463.2001.090501.x; Shankar A, 2011, J CLIN HYPERTENS, V13, P925, DOI 10.1111/j.1751-7176.2011.00548.x; Sharpe RM, 2010, TOXICOL SCI, V114, P1, DOI 10.1093/toxsci/kfp299; Shibata N, 2002, BIOCHEM J, V368, P783, DOI 10.1042/BJ20020804; Silver MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026868; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Somm E, 2009, ENVIRON HEALTH PERSP, V117, P1549, DOI 10.1289/ehp.11342; Soriano S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031109; Sun H, 2006, FOOD CHEM TOXICOL, V44, P1916, DOI 10.1016/j.fct.2006.06.013; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; van Meeuwen JA, 2007, FOOD CHEM TOXICOL, V45, P2319, DOI 10.1016/j.fct.2007.06.011; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Volle DH, 2009, J CLIN INVEST, V119, P3752, DOI 10.1172/JCI38521; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Wada K, 2007, J PHARMACOL SCI, V105, P133, DOI 10.1254/jphs.FM0070034; Wang TG, 2012, J CLIN ENDOCR METAB, V97, pE223, DOI 10.1210/jc.2011-1989; Wright BM, 2000, J BIOL CHEM, V275, P1873; Yomenura CY, 1995, ACTA ANAT, V153, P1; Zhou W, 2008, MOL CELL ENDOCRINOL, V283, P12, DOI 10.1016/j.mce.2007.10.010; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-10181085MASSON EDITEURMOULINEAUX CEDEX 921 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCEANN ENDOCRINOL-PARISJULDiscipline: Endocrinology &amp; Metabolism202CQ</notes>
    <keywords>BETA; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; cardiovascular; CARDIOVASCULAR-DISEASE; CELL; DEGRADATION; diabetes; DIETHYLSTILBESTROL; DIETHYLSTILBESTROL EXPOSURE; DISEASE; ENDOCRINE; ENVIRONMENTAL ESTROGENS; Estrogen; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FETAL; FOOD; GLAND; HUMAN HEALTH; HUMANS; IMPACT; In vitro; IN-VITRO; INCREASES SUSCEPTIBILITY; LINES; Liver; Male; mammary gland; MAMMARY-GLAND; METABOLISM; MOUSE MAMMARY-GLAND; PERINATAL EXPOSURE; Prostate; PROSTATE-CANCER; TESTICULAR DYSGENESIS SYNDROME; TISSUE; toxicology; UDP-GLUCURONOSYLTRANSFERASE ACTIVITIES; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>211</startpage>
    <endpage>220</endpage>
    <journalfull>Annales D Endocrinologie</journalfull>
    <issue>3</issue>
    <volume>74</volume>
    <abstract>Bisphenol A (BPA), initially designed, like diethylstilbestrol, as a synthetic estrogen, has been rapidly and widely used for its cross-linking properties in the manufacture of polycarbonate plastics and epoxy resins. Because of incomplete polymerization and degradation of the polymers by exposure to higher than usual temperatures, BPA leaches out from food and beverage containers, as well as from dental sealants. In humans, free active unconjugated BPA is metabolized by rapid glucurono- or sulfo-conjugation and eliminated via renal clearance. However, exposure to environmental nanomolar concentrations of BPA is ubiquitous and continuous via different routes: oral, air, skin. In rodents, fetal and perinatal exposure to such environmentally relevant doses of BPA has been shown to affect the brain, liver, gut, adipose tissue, endocrine pancreas, mammary gland and reproductive tract and function. Similar concentrations are also able in vitro to impact human malignant breast, prostate, male germ or adipocyte cell lines (with a promoting effect and by interfering with chemotherapy drugs), or to stimulate pancreatic beta cell insulin secretion. High levels of BPA have recently been correlated with obesity, diabetes, cardiovascular diseases, polycystic ovarian disease or low sperm count. However, before the real impact of BPA on human health can be clearly assessed, prospective longitudinal epidemiological studies are needed as well as characterization of selective biomarkers to verify long-term exposure and selective imprinting. (c) 2013 Published by Elsevier Masson SAS</abstract>
    <url>WOS:000323191500012</url>
    <isbnorissn>0003-4266</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>244</id>
    <title>Perinatal Environmental Exposures Affect Mammary Development, Function, and Cancer Risk in Adulthood</title>
    <authors>Fenton,S.E.; Reed,C.; Newbold,R.R.</authors>
    <availability>[Fenton, Suzanne E.; Reed, Casey; Newbold, Retha R.] NIEHS, Div Natl Toxicol Program, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReview; Book ChapterFenton, SE (reprint author), NIEHS, Div Natl Toxicol Program, NIH, US Dept HHS, POB 12233, Res Triangle Pk, NC 27709 USAfentonse@niehs.nih.gov; newbold1@niehs.nih.govAhmed ML, 2009, TRENDS ENDOCRIN MET, V20, P237, DOI 10.1016/j.tem.2009.02.004; Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491; Aksglaede L, 2006, HUM REPROD UPDATE, V12, P341, DOI 10.1093/humupd/dml018; Aksglaede L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008450; Arlt W, 2002, ENDOCRINOLOGY, V143, P4665, DOI 10.1210/en.2002-220456; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Biro FM, 2010, PEDIATRICS, V126, pE583, DOI 10.1542/peds.2009-3079; Biro FM, 2001, J PEDIATR, V138, P636, DOI 10.1067/mpd.2001.114476; BOYLAN ES, 1983, CANCER RES, V43, P4872; BOYLAN ES, 1978, BIOL REPROD, V19, P854, DOI 10.1095/biolreprod19.4.854; BOYLAN ES, 1981, J NATL CANCER I, V66, P649; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Louis GMB, 2008, PEDIATRICS, V121, pS192, DOI 10.1542/peds.1813E; Cabanes A, 2004, CARCINOGENESIS, V25, P741, DOI 10.1093/carcin/bgh065; Cameron HL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004303; Carlsson B, 1997, ARCH DIS CHILD, V77, P396; Cesario SK, 2007, JOGNN-J OBST GYN NEO, V36, P263, DOI 10.1111/J.1552-6909.2007.00145.x; Christensen KY, 2011, ENVIRON INT, V37, P129, DOI 10.1016/j.envint.2010.08.007; Colborn T., 1996, OUR STOLEN FUTURE; Colerangle JB, 1996, ENDOCRINE, V4, P115, DOI 10.1007/BF02782756; Delclos KB, 2001, REPROD TOXICOL, V15, P647, DOI 10.1016/S0890-6238(01)00177-0; Denburg MR, 2002, J CLIN ENDOCR METAB, V87, P5604, DOI 10.1210/jc.2002-020896; Den Hond E, 2002, ENVIRON HEALTH PERSP, V110, P771; Desaulniers D, 2004, J TOXICOL ENV HEAL A, V67, P1457, DOI 10.1080/15287390490483818; Desaulniers D, 2001, ENVIRON HEALTH PERSP, V109, P739, DOI 10.2307/3454792; DiMartino-Nardi J, 1999, ACTA PAEDIATR, V88, P67, DOI 10.1111/j.1651-2227.1999.tb14406.x; DUNKEL L, 1992, J CLIN ENDOCR METAB, V74, P890, DOI 10.1210/jc.74.4.890; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Enoch RR, 2007, ENVIRON HEALTH PERSP, V115, P541, DOI 10.1289/ehp.9612; Euling SY, 2008, PEDIATRICS, V121, pS167, DOI 10.1542/peds.2007-1813C; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Franceschi R, 2010, FERTIL STERIL, V93, P1185, DOI 10.1016/j.fertnstert.2008.11.016; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; Fukamachi K, 2004, CANCER SCI, V95, P404, DOI 10.1111/j.1349-7006.2004.tb03223.x; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GARN SM, 1986, AM J CLIN NUTR, V43, P879; Gluckman PD, 2005, MATERN CHILD NUTR, V1, P130, DOI 10.1111/j.1740-8709.2005.00020.x; GOLDMAN AS, 1976, ENDOCRINOLOGY, V99, P1490; Golub MS, 2008, PEDIATRICS, V121, pS218, DOI 10.1542/peds.2007-1813G; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; Anderson R, 2006, INT J ANDROL, V29, P286, DOI 10.1111/j.1365-2605.2005.00680.x; Hilakivi-Clarke L, 2006, J NUTR, V136, p2697S; Hilakivi-Clarke L, 1998, ONCOL REP, V5, P609; HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372; HilakiviClarke L, 1997, J CELL PHYSIOL, V170, P279, DOI 10.1002/(SICI)1097-4652(199703)170:3&lt;279::AID-JCP9&gt;3.0.CO;2-L; Hilakivi-Clarke L, 2002, CLIN CANCER RES, V8, P3601; Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584; Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089; Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704; Hulanicka B, 2007, ECON HUM BIOL, V5, P48, DOI 10.1016/j.ehb.2006.12.001; Ibanez L, 2000, ENDOCR REV, V21, P671, DOI 10.1210/er.21.6.671; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; JURKOWSKI JJ, 1985, J NATL CANCER I, V74, P1145; Kaltiala-Heino R, 2003, J ADOLESCENCE, V26, P531, DOI 10.1016/S0140-1971(03)00053-8; Kaltiala-Heino R, 2003, SOC SCI MED, V57, P1055, DOI 10.1016/S0277-9536(02)00480-X; Kaltiala-Heino R, 2001, J ADOLESCENT HEALTH, V28, P346, DOI 10.1016/S1054-139X(01)00195-1; Kaplowitz PB, 1999, PEDIATRICS, V104, P936, DOI 10.1542/peds.104.4.936; Kaplowitz PB, 2008, PEDIATRICS, V121, pS208, DOI 10.1542/peds.2007-1813F; Kemper HCG, 2002, PREV MED, V35, P533, DOI 10.1006/pmed.2002.1107; KLEIN D, 1994, BIOL REPROD, V50, P802, DOI 10.1095/biolreprod50.4.802; Kodavanti PRS, 2010, TOXICOL SCI, V116, P297, DOI 10.1093/toxsci/kfq105; Landrigan P, 2003, ENVIRON HEALTH PERSP, V111, P1678, DOI 10.1289/ehp.5799; Latendresse JR, 2009, REPROD TOXICOL, V28, P342, DOI 10.1016/j.reprotox.2009.04.006; Lee KY, 2004, TOXICOLOGY, V203, P221, DOI 10.1016/j.tox.2004.06.013; Leijs MM, 2008, CHEMOSPHERE, V73, P999, DOI 10.1016/j.chemosphere.2008.05.053; Lewis BC, 2001, TOXICOL SCI, V62, P46, DOI 10.1093/toxsci/62.1.46; LIPWORTH L, 1995, EUR J CANCER PREV, V4, P7, DOI 10.1097/00008469-199502000-00002; Lopez-Espinosa MJ, 2011, ENVIRON SCI TECHNOL, V45, P8160, DOI 10.1021/es1038694; Lorentzon M, 2011, J PEDIATR-US, V158, P452, DOI 10.1016/j.jpeds.2010.09.009; Lustig RH, 2010, OBESITY BIRTH MATERN; Macon MB, 2011, TOXICOL SCI, V122, P134, DOI 10.1093/toxsci/kfr076; Macsali F, 2011, AM J RESP CRIT CARE, V183, P8, DOI 10.1164/rccm.200912-1886OC; Malik NM, 2001, ENDOCRINOLOGY, V142, P5198, DOI 10.1210/en.142.12.5198; Markey CM, 2001, BIOL REPROD, V65, P1215; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291; Massart F, 2006, Minerva Pediatr, V58, P247; Meas T, 2002, CLIN ENDOCRINOL, V57, P101, DOI 10.1046/j.1365-2265.2002.01579.x; Moon HJ, 2007, J REPROD DEVELOP, V53, P333, DOI 10.1262/jrd.18055; Moral R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-453; Mouritsen A, 2010, INT J ANDROL, V33, P346, DOI 10.1111/j.1365-2605.2010.01051.x; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Murrill WB, 1996, CARCINOGENESIS, V17, P1451, DOI 10.1093/carcin/17.7.1451; Muto T, 2002, TOXICOLOGY, V177, P197, DOI 10.1016/S0300-483X(02)00224-X; National Institute of Health (NIH), 1999, NIH PUBL; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; Newbold R, 2010, ENV IMPACTS REPROD H, P92; Newbold Retha R, 2008, Fertil Steril, V89, pe55, DOI 10.1016/j.fertnstert.2008.01.062; Newbold RR, 2004, TOXICOL APPL PHARM, V199, P142, DOI 10.1016/j.taap.2003.11.033; Newbold RR, 2004, REPROD TOXICOL, V18, P399, DOI 10.1016/j.reprotox.2004.01.007; Newbold RR, 2007, MOL CARCINOGEN, V46, P783, DOI 10.1002/mc.20308; Ohrvik H, 2006, TOXICOL LETT, V164, P207, DOI 10.1016/j.toxlet.2005.12.008; Ojeda SR, 2006, INT J ANDROL, V29, P256, DOI 10.1111/j.1365-2605.2005.00619.x; Ojeda SR, 2006, ENDOCRINOLOGY, V147, P1166, DOI 10.1210/en.2005-1136; Padilla-Banks E, 2006, ENDOCRINOLOGY, V147, P4871, DOI 10.1210/en.2006-0389; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222; Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019; Parent AS, 2005, HORM RES, V64, P41, DOI 10.1159/000087753; Poulet FM, 2005, TOXICOL PATHOL, V33, P320, DOI 10.1080/01926230590925061; Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002; Rayner JL, 2005, TOXICOL SCI, V87, P255, DOI 10.1093/toxsci/kfi213; Rayner JL, 2004, TOXICOL APPL PHARM, V195, P23, DOI 10.1016/j.taap.2003.11.005; Remsberg KE, 2005, J CLIN ENDOCR METAB, V90, P2718, DOI 10.1210/jc.2004-1991; Rice C, 2003, ENVIRON HEALTH PERSP, V111, P1683, DOI 10.1289/ehp.5798; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Robinson GW, 1999, J MAMMARY GLAND BIOL, V4, P9, DOI 10.1023/A:1018748418447; Rosen P. A., 2008, RAD C 2008 RADAR 08, P1; ROTHSCHILD TC, 1987, CANCER RES, V47, P4508; Roy Deodutta, 1998, Frontiers in Bioscience, V3, pD913; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P1053, DOI 10.1289/ehp.1002864; Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011; RUSSO J, 1990, LAB INVEST, V62, P244; Russo J., 2000, J NATL CANC I MONOGR, V27, P17; Shelby MD., 2008, NIH PUBL; Skinner MK., 2006, KNOBIL NEILLS PHYSL, V1, P2061; Snyderwine EG, 1999, CANCER LETT, V143, P211, DOI 10.1016/S0304-3835(99)00127-5; Snyderwine EG, 2002, ENVIRON MOL MUTAGEN, V39, P165, DOI 10.1002/em.10053; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Talsness CE, 2008, ENVIRON HEALTH PERSP, V116, P308, DOI 10.1289/ehp.10536; Tarraf C, 2003, FOOD ADDIT CONTAM, V20, P819, DOI 10.1080/0265203031000138231; Tena-Sempere M, 2010, MOL CELL ENDOCRINOL, V314, P164, DOI 10.1016/j.mce.2009.05.004; Terasawa E, 2001, ENDOCR REV, V22, P111, DOI 10.1210/er.22.1.111; Thomsen C, 2002, ENVIRON SCI TECHNOL, V36, P1414, DOI 10.1021/es0102282; Titus-Ernstoff L, 2006, BRIT J CANCER, V95, P107, DOI 10.1038/sj.bjc.6603221; TOMOOKA Y, 1982, J NATL CANCER I, V69, P1347; Toppari J, 2010, MOL CELL ENDOCRINOL, V324, P39, DOI 10.1016/j.mce.2010.03.011; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Ueda M, 2005, CANCER SCI, V96, P19, DOI [10.1111/j.1349-7006.2005.00008.x, 10.1111/j.1349-7006.2005.00104.x]; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062; Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625; WARNER MR, 1976, CELL TISSUE KINET, V9, P429, DOI 10.1111/j.1365-2184.1976.tb01293.x; Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321; WELSCH CW, 1989, CANCER RES, V49, P5999; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; WETZEL LT, 1994, J TOXICOL ENV HEALTH, V43, P169; White SS, 2011, J STEROID BIOCHEM, V127, P16, DOI 10.1016/j.jsbmb.2011.03.011; White SS, 2011, ENVIRON HEALTH PERSP, V119, P1070, DOI 10.1289/ehp.1002741; White SS, 2007, TOXICOL SCI, V96, P133, DOI 10.1093/toxsci/kfl177; Wolff MS, 2008, ENVIRON RES, V107, P393, DOI 10.1016/j.envres.2008.03.006; WU FCW, 1993, J CLIN ENDOCR METAB, V76, P26, DOI 10.1210/jc.76.1.26; Yaghjyan L, 2011, J NATL CANCER I, V103, P1179, DOI 10.1093/jnci/djr225; Zoeller RT, 2005, MOL CELL ENDOCRINOL, V242, P10, DOI 10.1016/j.mce.2005.07.0061499ANNUAL REVIEWSPALO ALTO4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USAANNU REV PHARMACOLDiscipline: Pharmacology &amp; Pharmacy; ToxicologyBZK49</notes>
    <keywords>ADOLESCENCE; ADULTHOOD; BISPHENOL-A ALTERS; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; Carcinogen; CARCINOGENESIS; CELL; CHEMICALS; development; developmental basis of adult disease; diet; ENDOCRINE; Endocrine-disrupting chemicals; environmental exposure; environmental factors; ENVIRONMENTAL-FACTORS; EXPOSURE; FEMALE RAT; FOOD; GLAND; GLAND DEVELOPMENT; HEALTH; IMPACT; IN-UTERO; LONG-EVANS RATS; mammary gland; MAMMARY-GLAND; mechanism; MECHANISMS; P8; PHARMACOLOGY; precocious puberty; PRENATAL EXPOSURE; puberty; PUBLIC-HEALTH IMPLICATIONS; Reproduction; RISK; SPRAGUE-DAWLEY RATS; TISSUE; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>455</startpage>
    <endpage>479</endpage>
    <journalfull>Annual Review of Pharmacology and Toxicology, Vol 52</journalfull>
    <volume>52</volume>
    <abstract>Puberty is an important transition that enables reproduction of mammalian species. Precocious puberty, specifically early thelarche ( the appearance of breast "buds"), in girls of multiple ethnic backgrounds is a major health problem in the United States and other countries. The cause for a continued decrease in the age of breast development in girls is unknown, but environmental factors likely play a major role. Laboratory and epidemiological studies have identified several individual environmental factors that affect breast development, but further progress is needed. Current research needs include increased attention to and recording of prenatal and neonatal environmental exposures, testing of marketed chemicals for effects on the mammary gland, and understanding of the mammary gland-specific mechanisms that are altered by chemicals. Such research is required to halt the increasing trend toward puberty at earlier ages</abstract>
    <url>WOS:000301839600022</url>
    <isbnorissn>0362-1642</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>389</id>
    <title>Estrogen and Xenoestrogens in Breast Cancer</title>
    <authors>Fernandez,S.V.; Russo,J.</authors>
    <availability>[Fernandez, S. V.; Russo, J.] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleRusso, J (reprint author), Fox Chase Canc Ctr, Breast Canc Res Lab, 333 Cottman Ave, Philadelphia, PA 19111 USAjose.russo@fccc.eduAkingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; BURRIDGE E, 2003, EUR CHEM NEWS 0414, P17; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; CHUA Y, 2006, BREAST CANC RES S2, V8, P5; Chuang CC, 2008, INT J FUZZY SYST, V10, P11; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2&lt;250::AID-IJC14&gt;3.0.CO;2-D; Colditz GA, 1998, J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Colditz G.A, 2005, CLIN CANCER RES, V11, p909s; Beral V, 1997, LANCET, V350, P1047; Ema M, 2003, REPROD TOXICOL, V17, P407, DOI 10.1016/S0890-6238(03)00037-6; Ema M, 2002, REPROD TOXICOL, V16, P71, DOI 10.1016/S0890-6238(01)00200-3; FERNANDEZ SV, 2006, P AM ASSOC CANC RES, V47, P1590; Fernandez SV, 2006, INT J CANCER, V118, P1862, DOI 10.1002/ijc.21590; Fernandez SV, 2005, INT J ONCOL, V26, P691; Friel PN, 2005, ALTERN MED REV, V10, P36; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Hong EJ, 2005, J REPROD DEVELOP, V51, P253, DOI 10.1262/jrd.16075; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Huang Y, 2007, CANCER RES, V67, P11147, DOI 10.1158/0008-5472.CAN-07-1371; Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; IPCS, 1999, 17 IPCS WHO; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; Key T, 2002, J Natl Cancer Inst, V94, P606; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lareef MH, 2005, INT J ONCOL, V26, P423; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Levy G, 2004, ENVIRON RES, V94, P102, DOI 10.1016/S0013-9351(03)00086-0; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Maruyama S, 1999, ENDOCR J, V46, P513, DOI 10.1507/endocrj.46.513; Matsumoto A, 2003, ENVIRON HEALTH PERSP, V111, P101, DOI 10.1289/ehp.5512; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Banks E, 2003, LANCET, V362, P419; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com; Russo J, 2002, J STEROID BIOCHEM, V80, P149, DOI 10.1016/S0960-0760(01)00183-2; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SOULE HD, 1990, CANCER RES, V50, P6075; Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9; Takao T, 1999, LIFE SCI, V65, P2351, DOI 10.1016/S0024-3205(99)00502-0; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Yang MH, 2003, ARCH ENVIRON CON TOX, V44, P546, DOI 10.1007/s00244-002-2124-0; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1093/toxsci/46.2.2826946SAGE PUBLICATIONS INCTHOUSAND OAKS2455 TELLER RD, THOUSAND OAKS, CA 91320 USATOXICOL PATHOLDiscipline: Pathology; Toxicology559EL</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; BBP; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; BUTYL BENZYL PHTHALATE; CANCER; Carcinogenicity; CELL; cell transformation; CELLS; CHEMICALS; development; DNA-METHYLTRANSFERASE; E2; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Environmental estrogen; epigenetic changes; EPITHELIAL-CELLS; Estrogen; ESTROGENS; FOOD; HEALTH; HEALTHY POSTMENOPAUSAL WOMEN; HORMONE-REPLACEMENT THERAPY; HYPERMETHYLATION; IN-VITRO; LEUKEMIA; MODEL; neuregulin; PATHOLOGY; PERINATAL EXPOSURE; phthalate; PRENATAL EXPOSURE; PROGRESSION; Steroid; TOOL; toxicology; VIVO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>110</startpage>
    <endpage>122</endpage>
    <journalfull>Toxicologic Pathology</journalfull>
    <issue>1</issue>
    <volume>38</volume>
    <abstract>There is growing concern that estrogenic environmental compounds that act as endocrine-disrupting chemicals might potentially have adverse effects on hormone-sensitive organs such as the breast. This concern is further fueled by evidence indicating that natural estrogens, specifically 17 beta-estradiol, are important factors in the initiation and progression of breast cancer. We have developed an in vitro-in vivo model in which we have demonstrated the carcinogenicity of E2 in human breast epithelial cells MCF-10F. Hypermethylation of NRG1, STXBP6. BMP6, CSS3, SPRY1, and SNIP were found at different progression stages in this model. The use of this powerful and unique model has provided a tool for exploring whether bisphenol A and butyl benzyl phthalate have relevance in the initiation of breast cancer. These studies provide firsthand evidence that the natural estrogen 17 beta-estradiol and xenoestrogenic substances like bisphenol a are able to induce neoplastic transformation in human breast epithelial cells</abstract>
    <url>WOS:000274804800010</url>
    <isbnorissn>0192-6233</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>209</id>
    <title>Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure</title>
    <authors>Fernandez,S.V.; Huang,Y.; Snider,K.E.; Zhou,Y.; Pogash,T.J.; Russo,J.</authors>
    <availability>[Fernandez, Sandra V.; Snider, Kara E.; Pogash, Thomas J.; Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA. [Zhou, Yan] Fox Chase Canc Ctr, Dept Biostat &amp; Bioinformat, Philadelphia, PA 19111 USA. [Huang, Yong] Univ Chicago, Ctr Biomed Informat, Chicago, IL 60637 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleFernandez, SV (reprint author), Fox Chase Canc Ctr, Breast Canc Res Lab, 333 Cottman Ave, Philadelphia, PA 19111 USAsandra.fernandez@fccc.eduATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; BENTLEY P, 1989, CARCINOGENESIS, V10, P321, DOI 10.1093/carcin/10.2.321; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Burridge E., 2003, EUR CHEM NEWS, P14; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cavalieri E, 2006, BBA-REV CANCER, V1766, P63, DOI 10.1016/k.bbcan.2006.03.001; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; Cavalieri E., 2003, P AM ASSOC CANC RES, V44, P180; Cavalieri EL, 2010, IUBMB LIFE, V62, P746, DOI 10.1002/iub.376; Chen JJ, 1999, CANCER RES, V59, p1752S; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Deng CX, 2000, BIOESSAYS, V22, P728; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Hazra TK, 2007, DNA REPAIR, V6, P470, DOI 10.1016/j.dnarep.2006.10.011; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Ji HK, 2008, NAT BIOTECHNOL, V26, P1293, DOI 10.1038/nbt.1505; Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103; Jones LP, 2010, TOXICOL LETT, V199, P261, DOI 10.1016/j.toxlet.2010.09.008; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kocdor H, 2009, CELL BIOL INT, V33, P1135, DOI 10.1016/j.cellbi.2009.07.002; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Maruyama S, 1999, ENDOCR J, V46, P513, DOI 10.1507/endocrj.46.513; Matsumoto A, 2003, ENVIRON HEALTH PERSP, V111, P101, DOI 10.1289/ehp.5512; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0; Powell CL, 2005, CANCER LETT, V229, P1, DOI 10.1016/j.canlet.2004.12.002; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Smyth GK, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x; STEINER S, 1992, CARCINOGENESIS, V13, P969, DOI 10.1093/carcin/13.6.969; Vanhoutte K, 1997, ANAL CHEM, V69, P3161, DOI 10.1021/ac970121q; Varma AK, 2005, BIOCHEMISTRY-US, V44, P10941, DOI 10.1021/bi0509651; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yang MH, 2003, ARCH ENVIRON CON TOX, V44, P546, DOI 10.1007/s00244-002-2124-0; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.20045612SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J ONCOLJULDiscipline: Oncology949LX</notes>
    <keywords>ADIPOSE-TISSUE; AGENTS; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; BRCA1; breast; breast cancer; CANCER; CARCINOGENESIS; CELL; CELLS; CHIP-CHIP; CYCLE CHECKPOINT CONTROL; development; DNA damage; DNA METHYLATION; DNA repair; DNA-DAMAGE; DNA-methylation; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENDOMETRIAL CANCER; EPITHELIAL-CELLS; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; FOOD; GENE; GENE-EXPRESSION; GENES; HEALTH; HUMAN URINE; In vitro; IN-VITRO; LINE; LIQUID-CHROMATOGRAPHY; METHYLATION; oncology; REPAIR; TISSUE; toxicology; VITRO; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>369</startpage>
    <endpage>377</endpage>
    <journalfull>International Journal of Oncology</journalfull>
    <issue>1</issue>
    <volume>41</volume>
    <abstract>It has been suggested that xenoestrogens, a group of agents termed endocrine disruptors, may contribute to the development of hormone-dependent cancers, such as breast and endometrial cancers. We previously demonstrated that the xenoestrogen, bisphenol A (BPA), was able to induce the transformation in vitro of human breast epithelial cells. The normal-like human breast epithelial cell line, MCF-10F, formed tubules in collagen (3-D cultures), although after treatment with BPA (10(-5) M and 10(-6) M BPA) the cells produced less tubules (73% and 80%, respectively) and some spherical masses (27% and 20%, respectively). In the present study, expression and DNA methylation analyses were performed in these cells after exposure to BPA. These cells showed an increased expression of BRCA1, BRCA2, BARD1,CtIP, RAD51 and BRCC3, all of which are genes involved in DNA repair, as well as the downregulation of PDCD5 and BCL2L11(BIM), both of which are involved in apoptosis. Furthermore, DNA methylation analysis showed that the BPA exposure induced the hypermethylation of BCL2L11, PARD6G, FOXP1 and SFRS11, as well as the hypomethylation of NUP98 and CtIP (RBBP8). Our results indicate that normal human breast epithelial cells exposed to BPA have increased expressions of genes involved in DNA repair in order to overcome the DNA damage induced by this chemical. These results suggest that the breast tissue of women with BRA I or BRCA2 mutations could be more susceptible to the effects of BPA</abstract>
    <url>WOS:000304578800046</url>
    <isbnorissn>1019-6439</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>127</id>
    <title>Mutagenicity and Dna Damage of Bisphenol A and Its Structural Analogues in Hepg2 Cells</title>
    <authors>Fic,A.; Zegura,B.; Dolenc,M.S.; Filipic,M.; Masic,L.P.</authors>
    <availability>[Fic, Anja; Dolenc, Marija Sollner; Masic, Lucija Peterlin] Univ Ljubljana, Fac Pharm, Ljubljana 1000, Slovenia. [Zegura, Bojana; Filipic, Metka] Natl Inst Biol, Dept Genet Toxicol &amp; Canc Biol, Ljubljana, Slovenia.</availability>
    <date>2013</date>
    <notes>JEnglishArticleMasic, LP (reprint author), Univ Ljubljana, Fac Pharm, Askerceva 7, Ljubljana 1000, Slovenialucija.peterlin@ffa.uni-lj.siAPPLETON, 2013, NATIONS LARGEST MAKE; ASHBY J, 1988, MUTAT RES, V204, P17, DOI 10.1016/0165-1218(88)90114-0; ATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; Audebert M, 2011, ARCH TOXICOL, V85, P1463, DOI 10.1007/s00204-011-0721-2; Bursztyka J, 2008, TOXICOL IN VITRO, V22, P1595, DOI 10.1016/j.tiv.2008.06.013; Cabaton N, 2009, TOXICOLOGY, V255, P15, DOI 10.1016/j.tox.2008.09.024; Cavalieri EL, 2010, IUBMB LIFE, V62, P746, DOI 10.1002/iub.376; Chen MY, 2002, ENVIRON TOXICOL, V17, P80, DOI 10.1002/tox.10035; Collins AR, 1997, MUTAT RES-FUND MOL M, V375, P183, DOI 10.1016/S0027-5107(97)00013-4; Danzl E, 2009, INT J ENV RES PUB HE, V6, P1472, DOI 10.3390/ijerph6041472; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Edmonds JS, 2004, BIOCHEM BIOPH RES CO, V319, P556, DOI 10.1016/j.bbrc.2004.05.024; *ENV CAN, 2012, CHEM ABSTR SERV RES; Hreljac I, 2009, MUTAT RES-FUND MOL M, V671, P84, DOI 10.1016/j.mrfmmm.2009.09.011; IARC, 1979, IARC MON EV CARC RIS, V21; Ike M, 2006, WATER SCI TECHNOL, V53, P153, DOI 10.2166/wst.2006.189; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; Iso T, 2007, BIOL PHARM BULL, V30, P266, DOI 10.1248/bpb.30.266; IVETT JL, 1989, ENVIRON MOL MUTAGEN, V14, P165, DOI 10.1002/em.2850140306; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Jaeg JP, 2004, J AGR FOOD CHEM, V52, P4935, DOI 10.1021/jf049762u; *JETOC, 1996, MUT TEST DAT EXIST C; Kanai H, 2001, INT J CANCER, V93, P20, DOI 10.1002/ijc.1303; Kenyon MO, 2007, REGUL TOXICOL PHARM, V48, P75, DOI 10.1016/j.yrtph.2007.01.006; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Knasmuller S, 1998, MUTAT RES-FUND MOL M, V402, P185, DOI 10.1016/S0027-5107(97)00297-2; KOLGEK K, 2012, TOXICOL IN VITRO, V26, P102, DOI DOI 10.1016/J.TIV.2011.11.003; Kuruto-Niwa R, 2005, ENVIRON TOXICOL PHAR, V19, P121, DOI 10.1016/j.etap.2004.05.009; Lotti N, 2011, POLYMER, V52, P904, DOI 10.1016/j.polymer.2011.01.018; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Naik P, 2009, MUTAT RES-GEN TOX EN, V676, P106, DOI 10.1016/j.mrgentox.2009.04.010; Nakagawa Y, 2001, XENOBIOTICA, V31, P113; NIH NIEHS National Toxicology Program [NTP], 2001, NAT TOX PROGR REP EN; Pfeiffer E, 1997, MUTAT RES-GEN TOX EN, V390, P21, DOI 10.1016/S0165-1218(96)00161-9; RALOFF J, 2010, RECEIPTS LARGE LARGE; Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Sakuma S, 2010, FOOD CHEM TOXICOL, V48, P2217, DOI 10.1016/j.fct.2010.05.051; Schmidt J, 2013, TOXICOL IN VITRO, V27, P1267, DOI 10.1016/j.tiv.2013.02.016; Schweikl H, 1998, MUTAT RES-GEN TOX EN, V415, P119, DOI 10.1016/S1383-5718(98)00067-9; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Solakidi S, 2005, BBA-MOL CELL RES, V1745, P382, DOI 10.1016/j.bbamcr.2005.05.010; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3&lt;206::AID-EM8&gt;3.0.CO;2-J; Tiwari D, 2012, MUTAT RES-GEN TOX EN, V743, P83, DOI 10.1016/j.mrgentox.2011.12.023; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Tsutsui T, 2000, INT J CANCER, V86, P151, DOI 10.1002/(SICI)1097-0215(20000415)86:2&lt;151::AID-IJC1&gt;3.0.CO;2-0; Tu TT, 2011, CHEM RES TOXICOL, V24, P1527, DOI 10.1021/tx200140s; US P, 1978, Patent No. 4098769; Westerink WMA, 2007, TOXICOL IN VITRO, V21, P1581, DOI 10.1016/j.tiv.2007.05.014; Westerink WMA, 2007, TOXICOL IN VITRO, V21, P1592, DOI 10.1016/j.tiv.2007.06.017; Wilkening S, 2003, DRUG METAB DISPOS, V31, P1035, DOI 10.1124/dmd.31.8.1035; World Health Organization, 2011, JOINT FAO WHO EXP M; YAMAGUCHI T, 1991, EISEI KAGAKU, V37, P6; Zegura B, 2008, TOXICON, V51, P615, DOI 10.1016/j.toxicon.2007.11.009; Zegura B, 2004, METHOD PHARMACOL TOX, P301581INST MEDICAL RESEARCH &amp; OCCUPATIONAL HEALTHZAGREB2 KSAVERSKA ST P O BOX 291, ZAGREB, 00000, CROATIAARH HIG RADA TOKSIKOJUNDiscipline: Public, Environmental &amp; Occupational Health; Toxicology174PT</notes>
    <keywords>ACTIVATION; ADDUCT FORMATION; Ames test; bisphenol; bisphenol A; BISPHENOL-A; bisphenols; BPA; BREAST-CANCER; CANCER; CELL; CELLS; Comet assay; DNA-DAMAGE; ENDOCRINE DISRUPTORS; environment; Environmental oestrogen; ENZYME LEVELS; estrogenic activity; EXPOSURE; FOOD; GENOTOXICITY; HEPG2 CELLS; HUMANS; In vitro; IN-VITRO; JUN; Liver; LIVER-MICROSOMES; Male; mutagenicity; PRIMARY HUMAN HEPATOCYTES; RAT; RAT-LIVER; SALMONELLA MUTAGENICITY; toxicology; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>189</startpage>
    <endpage>200</endpage>
    <journalfull>Arhiv Za Higijenu Rada I Toksikologiju</journalfull>
    <issue>2</issue>
    <volume>64</volume>
    <abstract>Environmental oestrogen bisphenol A (BPA) and its analogues are widespread in our living environment. Because their production and use are increasing, exposure of humans to bisphenols is becoming a significant issue. We evaluated the mutagenic and genotoxic potential of eight BPA structural analogues (BPF, BPAF, BPZ, BPS, DMBPA, DMBPS, BP-1, and BP-2) using the Ames and comet assay, respectively. None of the tested bisphenols showed a mutagenic effect in Salmonella typhimurium strains TA98 and TA100 in either the presence or absence of external S9-mediated metabolic activation (Aroclor 1254-induced male rat liver). Potential genotoxicity of bisphenols was determined in the human hepatoma cell line (HepG2) at non-cytotoxic concentrations (0.1 mu mol L-1 to 10 mu mol L-1) after 4-hour and 24-hour exposure. In the comet assay, BPA and its analogue BPS induced significant DNA damage only after the 24-hour exposure, while analogues DMBPS, BP-1, and BP-2 induced a transient increase in DNA strand breaks observed only after the 4-hour exposure. BPF, BPAF, BPZ, and DMBPA did not induce DNA damage</abstract>
    <url>WOS:000321168600001</url>
    <isbnorissn>0004-1254</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>113</id>
    <title>Reduced expression of genes for nuclear receptors RXRalpha and RXRbeta by bisphenol A in human mammary cancer cells (MCF7)</title>
    <authors>Fickova,M.; Havranek,T.; Brtko,J.; Macejova,D.</authors>
    <availability>[Fickova, M.; Havranek, T.; Brtko, J.; Macejova, D.] Inst Expt Endocrinol SAS, Bratislava, Slovakia.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTAUG 28SDiscipline: Toxicology210WO</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; EXPRESSION; Mammary cancer; NUCLEAR RECEPTORS; RECEPTOR; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S112</startpage>
    <endpage>S113</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <volume>221</volume>
    <url>WOS:000323865800342</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>2</id>
    <title>Bisphenol A-Why an adverse outcome pathway framework needs to be applied</title>
    <authors>FitzGerald,R.E.; Wilks,M.F.</authors>
    <availability>[FitzGerald, R. E.; Wilks, M. F.] Univ Basel, Ctr Appl Human Toxicol SCAHT, CH-4056 Basel, Switzerland.</availability>
    <date>2014</date>
    <notes>JEnglishArticleFitzGerald, RE (reprint author), Univ Basel, Ctr Appl Human Toxicol SCAHT, Klingelbergstr 61, CH-4056 Basel, Switzerlandrex.fitzgerald@unibas.chAcevedo N, 2013, ENVIRON HEALTH PERSP, V121, P1040, DOI 10.1289/ehp.1306734; ANSES, 2011, EFF SAN BISPH RAPP E; Banerjee S, 2014, STEROIDS, V81, P64, DOI 10.1016/j.steroids.2013.11.002; Barton M, 2012, STEROIDS, V77, P935, DOI 10.1016/j.steroids.2012.04.001; Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007; Bondar G, 2009, J NEUROSCI, V29, P15323, DOI 10.1523/JNEUROSCI.2107-09.2009; Boobis AR, 2009, CRIT REV FOOD SCI, V49, P690, DOI 10.1080/10408390903098673; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; HILL AB, 1965, P ROY SOC MED, V58, P295; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Chaudhri RA, 2014, STEROIDS, V81, P74, DOI 10.1016/j.steroids.2013.10.020; Chaudhri RA, 2012, J BIOL CHEM, V287, P7169, DOI 10.1074/jbc.M111.292946; Chevalier N, 2012, INT J CANCER, V130, P241, DOI 10.1002/ijc.25972; Churchwell MI, 2014, TOXICOL SCI, V139, P4, DOI 10.1093/toxsci/kfu021; Damstra T., 2002, WHOPCSEDC022; Delclos KB, 2014, TOXICOL SCI, V139, P174, DOI 10.1093/toxsci/kfu022; Dellarco V, 2012, J NUTR, V142, p2192S, DOI 10.3945/jn.111.157396; EFSA, 2006, EFSA J, V428, P1, DOI DOI 10.2903/J.EFSA.2007A28; Efsa (European Food Safety Authority), 2014, DRAFT SCI OP RISKS P; EU, 2008, EU BISPH RISK ASS RE; Franco R, 2011, CANCER BIOL THER, V11, P609, DOI 10.4161/cbt.11.6.14672; Geens T, 2011, INT J HYG ENVIR HEAL, V214, P339, DOI 10.1016/j.ijheh.2011.04.005; Geens T, 2012, FOOD CHEM TOXICOL, V50, P3725, DOI 10.1016/j.fct.2012.07.059; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; IPCS, 2004, IPCS RISK ASS TERM 1; Jeng YJ, 2011, ENVIRON HEALTH PERSP, V119, P104, DOI 10.1289/ehp.1002512; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kuzutani K, 2012, J TOXICOL PATHOL, V25, P221, DOI 10.1293/tox.25.221; Langer G, 2010, STEROIDS, V75, P603, DOI 10.1016/j.steroids.2009.12.006; Meek ME, 2014, J APPL TOXICOL, V34, P1, DOI 10.1002/jat.2949; Micevych P, 2010, NEUROENDOCRINOLOGY, V91, P211, DOI 10.1159/000289568; Micevych P, 2012, FRONT NEUROENDOCRIN, V33, P331, DOI 10.1016/j.yfrne.2012.07.003; Mitchell RT, 2012, J CLIN ENDOCR METAB, V97, pE341, DOI 10.1210/jc.2011-2411; Molina-Molina JM, 2013, TOXICOL APPL PHARM, V272, P127, DOI 10.1016/j.taap.2013.05.015; NEWBOLD RR, 1982, CANCER RES, V42, P2003; OECD, 2013, SER TEST ASS, V184; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Rago V, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-135; Rochester JR, 2013, REPROD TOXICOL, V42, P132, DOI 10.1016/j.reprotox.2013.08.008; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Sinchak K, 2012, FRONT NEUROENDOCRIN, V33, P342, DOI 10.1016/j.yfrne.2012.08.004; Skakkebaek NE, 1998, APMIS, V106, P3; Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5; Teeguarden J, 2013, FOOD CHEM TOXICOL, V62, P949, DOI 10.1016/j.fct.2013.08.001; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Tyl RW, 2008, TOXICOL SCI, V104, P362, DOI 10.1093/toxsci/kfn084; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg Laura N., 2013, Reviews on Environmental Health, V28, P37, DOI 10.1515/reveh-2012-0034; Vandenberg L.N., 2013, ENDOCR DISRUPTORS, V1, DOI DOI 10.4161/ENDO.26490; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vinken M, 2013, TOXICOLOGY, V312, P158, DOI 10.1016/j.tox.2013.08.011; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Wang DF, 2010, ENDOCRINE, V38, P29, DOI 10.1007/s12020-010-9363-z; Watson CS, 2011, J STEROID BIOCHEM, V127, P44, DOI 10.1016/j.jsbmb.2011.01.015; Watson CS, 2013, STEROIDS, DOI 1210.1016/j.steroids.2013.11.006; Willhite CC, 2008, J TOXICOL ENV HEAL B, V11, P69, DOI 10.1080/10937400701724303; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565601ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTOCT 15Discipline: ToxicologyAP2CV</notes>
    <keywords>ADENOCARCINOMA; Adverse outcome pathway; bisphenol A; BREAST-CANCER; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN-RECEPTOR GPER; HUMAN HEALTH; Human health risk assessment; IN-UTERO; Membrane-bound estrogen receptor; SPRAGUE-DAWLEY RATS; TOXICITY; WIDESPREAD EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>368</startpage>
    <endpage>374</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>2</issue>
    <volume>230</volume>
    <abstract>Bisphenol A (BPA) is one of the most widely used and extensively studied chemicals. Numerous studies have reported in vitro effects or animal adverse findings at BPA doses lower than the no observed adverse effect levels (NOAELs) established in regulatory toxicity studies and used for human health risk assessment. Intensive discussions on the adequacy and relevance of test systems have not satisfactorily resolved whether positive or negative animal and/or in vitro findings are more relevant for human health risk assessment purposes. BPA imperfectly mimics endogenous estrogens at membrane-bound estrogen receptors in the fM-nM concentration range, and may have downstream pleiotropic effects such as human seminoma proliferation and mammary gland hyperplasia after in utero exposure which are not detectable in regulatory toxicology studies. We argue that a structured approach like the OECD Adverse Outcome Pathway (AOP) framework is needed to help researchers in designing relevant studies, and risk assessors in evaluating them. The huge amount of experimental data generated for BPA has highlighted data gaps in basic biology and the shortcomings of current approaches to hazard characterization and risk assessment. Establishing AOPs for BPA, and other endocrine active chemicals, will require major scientific as well as training investments by all responsible stakeholders. (C) 2014 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000341881000029</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>188</id>
    <title>Environmental epigenetics: a role in endocrine disease?</title>
    <authors>Fleisch,A.F.; Wright,R.O.; Baccarelli,A.A.</authors>
    <availability>[Fleisch, Abby F.] Childrens Hosp Boston, Dept Endocrinol, Boston, MA 02115 USA. [Fleisch, Abby F.] Childrens Hosp Boston, Dept Hlth Serv Res, Boston, MA 02115 USA. [Wright, Robert O.; Baccarelli, Andrea A.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReviewFleisch, AF (reprint author), Childrens Hosp Boston, Dept Endocrinol, 300 Longwood Ave, Boston, MA 02115 USAabby.fleisch@childrens.harvard.eduAlegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/epi.11.22, 10.2217/EPI.11.22]; [Anonymous], 2005, CHEMICOBIOLOGICAL IN, V153-154, P270; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bennett KL, 2010, GENE CHROMOSOME CANC, V49, P319, DOI 10.1002/gcc.20742; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Caudill CM, 2005, J CLIN ENDOCR METAB, V90, P2364, DOI 10.1210/jc.2004-1811; Christodouleas JP, 2011, NEW ENGL J MED, V364, P2334, DOI 10.1056/NEJMra1103676; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Dolinoy DC, 2008, NUTR REV, V66, pS7, DOI 10.1111/j.1753-4887.2008.00056.x; Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372; Falck L, 1996, ANAT REC, V245, P459; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Fleisch AF, 2010, PEDIATRICS, V126, P760, DOI 10.1542/peds.2009-2693; Fryer Anthony A, 2009, Epigenetics, V4, P394; Fryer AA, 2011, EPIGENETICS-US, V6, P86, DOI 10.4161/epi.6.1.13392; Giotopoulos G, 2006, EXP HEMATOL, V34, P1462, DOI 10.1016/j.exphem.2006.06.008; Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; He CY, 2009, NAT GENET, V41, P724, DOI 10.1038/ng.385; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Hobert JA, 2009, GENET MED, V11, P687, DOI 10.1097/GIM.0b013e3181ac9aea; Hypponen E, 2003, BRIT MED J, V326, P19, DOI 10.1136/bmj.326.7379.19; Inawaka K, 2009, TOXICOL APPL PHARM, V237, P178, DOI 10.1016/j.taap.2009.03.004; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Li SF, 1997, CANCER RES, V57, P4356; Lindgren CM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000508; Lindsay RS, 2000, DIABETES, V49, P445, DOI 10.2337/diabetes.49.3.445; Mantovani G, 2010, MOL CELL ENDOCRINOL, V326, P15, DOI 10.1016/j.mce.2010.04.009; Mathers JC, 2010, ADV GENET, V71, P3, DOI [10.1016/B978-0-12-380864-6.00001-8, 10.1016/S0065-2660(10)71001-4]; Nam SH, 2010, CHEMOSPHERE, V79, P949, DOI 10.1016/j.chemosphere.2010.02.049; Nan XS, 1998, NATURE, V393, P386; NELSON KG, 1994, CELL GROWTH DIFFER, V5, P595; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055; Perry JRB, 2009, NAT GENET, V41, P648, DOI 10.1038/ng.386; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; ROBBOY SJ, 1977, ARCH PATHOL LAB MED, V101, P1; Russo D, 2011, J MOL ENDOCRINOL, V46, pR73, DOI 10.1530/JME-10-0150; Schafer SA, 2011, DIABETES RES CLIN PR, V93, pS9, DOI 10.1016/S0168-8227(11)70008-0; Schneider S, 2008, REPROD TOXICOL, V25, P352, DOI 10.1016/j.reprotox.2008.04.001; Shi LJ, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-59; Stocker CJ, 2005, P NUTR SOC, V64, P143, DOI 10.1079/PNS2005417; Stouder C, 2010, REPRODUCTION, V139, P373, DOI 10.1530/REP-09-0340; Tamminga J, 2008, CELL CYCLE, V7, P1238, DOI 10.4161/cc.7.9.5806; Vandeva S, 2010, BEST PRACT RES CL EN, V24, P461, DOI 10.1016/j.beem.2010.03.001; van Kaam KJAF, 2011, FERTIL STERIL, V95, P1421, DOI 10.1016/j.fertnstert.2011.01.031; Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609; Waddington C. H., 1942, Endeavour London, V1, P18; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311-06587BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDJ MOL ENDOCRINOLOCTDiscipline: Endocrinology &amp; Metabolism020KB</notes>
    <keywords>BIRTH-WEIGHT; BISPHENOL-A; BLOOD; CANCER; CANCER RISK; CANCER-RISK; CELL; cell cycle; CELL-CYCLE; CHEMICALS; CHILDREN; CYCLE; diabetes; DIETHYLSTILBESTROL; DISEASE; DISRUPTING CHEMICALS; DNA METHYLATION; ENDOCRINE; Endocrine disrupting chemicals; environmental exposure; epigenetic; epigenetics; Estrogen; EXPOSURE; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GENES; GENOME-WIDE ASSOCIATION; GROWTH; HISTONE DEACETYLASE; Hormones; IMPACT; mechanism; MECHANISMS; METABOLISM; MODEL; MODELS; PROMOTER METHYLATION; RADIATION; RECEPTOR; Reproduction; RESISTANCE; RISK</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>R61</startpage>
    <endpage>R67</endpage>
    <journalfull>Journal of Molecular Endocrinology</journalfull>
    <issue>2</issue>
    <volume>49</volume>
    <abstract>Endocrine disrupting chemicals that are structurally similar to steroid or amine hormones have the potential to mimic endocrine endpoints at the receptor level. However, more recently, epigenetic-induced alteration in gene expression has emerged as an alternative way in which environmental compounds may exert endocrine effects. We review concepts related to environmental epigenetics and relevance for endocrinology through three broad examples: 1) effect of early-life nutritional exposures on future obesity and insulin resistance, 2) effect of lifetime environmental exposures such as ionizing radiation on endocrine cancer risk, and 3) potential for compounds previously classified as endocrine disrupting to additionally or alternatively exert effects through epigenetic mechanisms. The field of environmental epigenetics is still nascent, and additional studies are needed to confirm and reinforce data derived from animal models and preliminary human studies. Current evidence suggests that environmental exposures may significantly impact expression of endocrine-related genes and thereby affect clinical endocrine outcomes. Journal of Molecular Endocrinology (2012) 49, R61-R67</abstract>
    <url>WOS:000309806300002</url>
    <isbnorissn>0952-5041</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>393</id>
    <title>Animal model for age- and sex-related genotoxicity of diethylstilbestrol</title>
    <authors>Fucic,A.; Stojkovic,R.; Katic,J.; Markovic,D.; Ferencic,Z.; Korsic,M.; Jazbec,A.M.; Gamulin,M.</authors>
    <availability>[Fucic, A.; Katic, J.] Inst Med Res &amp; Occupat Hlth, Zagreb 10000, Croatia. [Stojkovic, R.] Rudjer Boskovic Inst, Div Mol Med, Zagreb, Croatia. [Markovic, D.] GlaxoSmithKline Res Ctr Zagreb Ltd, Zagreb, Croatia. [Ferencic, Z.] Univ Zagreb, Childrens Hosp Srebrnjak, Zagreb, Croatia. [Korsic, M.; Gamulin, M.] Univ Zagreb, Univ Hosp, Zagreb, Croatia. [Jazbec, A. M.] Univ Zagreb, Fac Forestry, Zagreb 41000, Croatia.</availability>
    <date>2009</date>
    <notes>JEnglishArticleFucic, A (reprint author), Inst Med Res &amp; Occupat Hlth, Ksaverska C 2, Zagreb 10000, Croatiaafucic@imi.hrAugustine LM, 2008, J BIOCHEM MOL TOXIC, V22, P93, DOI 10.1002/jbt.20224; Balthazart J, 2006, TRENDS NEUROSCI, V29, P241, DOI 10.1016/j.tins.2006.03.004; Bombail V, 2004, TOXICOL LETT, V149, P51, DOI 10.1016/j.toxlet.2004.01.003; Brody JG, 2007, CANCER, V109, P2627, DOI 10.1002/cncr.22656; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P30, DOI 10.1016/j.mrgentox.2007.10.016; Feser W, 1996, HUM EXP TOXICOL, V15, P556; GLADEK A, 1989, J BIOL CHEM, V264, P16847; Gonzalez M, 2007, J COMP NEUROL, V503, P790, DOI 10.1002/cne.21419; GUSTAFSSON JA, 1983, ANNU REV PHYSIOL, V45, P51, DOI 10.1146/annurev.ph.45.030183.000411; HALLING A, 1990, BIOL REPROD, V43, P472, DOI 10.1095/biolreprod43.3.472; Hanioka N, 1998, ARCH TOXICOL, V72, P387, DOI 10.1007/s002040050518; HAYASHI M, 1994, MUTAT RES, V312, P293, DOI 10.1016/0165-1161(94)90039-6; Henley DV, 2006, ENDOCRINOLOGY, V147, pS25, DOI 10.1210/en.2005-1117; Hontz AE, 2007, CANCER RES, V67, P2957, DOI 10.1158/0008-5472.CAN-06-3296; INANO H, 1995, CARCINOGENESIS, V16, P1871, DOI 10.1093/carcin/16.8.1871; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kayani MA, 2008, MUTAT RES-GEN TOX EN, V651, P40, DOI 10.1016/j.mrgentox.2007.10.007; Kim HS, 2002, TOXICOL SCI, V67, P52, DOI 10.1093/toxsci/67.1.52; KLEIN KO, 1994, J CLIN INVEST, V94, P2475, DOI 10.1172/JCI117616; Laws SC, 2007, TOXICOL SCI, V100, P194, DOI 10.1093/toxsci/kfm219; Lehmann L, 2004, CHEM-BIOL INTERACT, V147, P273, DOI 10.1016/j.cbi.2004.01.005; MARSELOS M, 1992, EUR J CANCER, V28A, P1182, DOI 10.1016/0959-8049(92)90482-H; METZLER M, 1995, ENVIRON HEALTH PERSP, V103, P21, DOI 10.2307/3432502; Newbold RR, 2004, TOXICOL APPL PHARM, V199, P142, DOI 10.1016/j.taap.2003.11.033; OZAWA N, 1989, CANCER GENET CYTOGEN, V38, P271, DOI 10.1016/0165-4608(89)90669-9; Prasad V, 1999, DRUG DEVELOP RES, V48, P104, DOI 10.1002/(SICI)1098-2299(199911)48:3&lt;104::AID-DDR2&gt;3.0.CO;2-D; Quick EL, 2008, MUTAT RES-GEN TOX EN, V651, P46, DOI 10.1016/j.mrgentox.2007.10.021; Raymond-Whish S, 2007, ENVIRON HEALTH PERSP, V115, P1711, DOI 10.1289/ehp.9910; Roy D, 1999, MUTAT RES-FUND MOL M, V424, P107, DOI 10.1016/S0027-5107(99)00012-3; ROY D, 1988, J BIOL CHEM, V263, P3646; Roy Deodutta, 1998, Frontiers in Bioscience, V3, pD913; STOPPER H, 1997, RECENT RESULTS CANC, V143, P184; Tayama S, 2008, MUTAT RES-GEN TOX EN, V649, P114, DOI 10.1016/j.mrgentox.2007.08.006; Thakur M. K., 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P525; Thomas RD, 2001, INT J MOL MED, V7, P389; Watson WH, 2007, TOXICOL SCI, V98, P1, DOI 10.1093/toxsci/kfm111; Wauthier V, 2008, MOL ENDOCRINOL, V22, P1962, DOI 10.1210/me.2007-0549; Xie YX, 2007, TOXICOLOGY, V236, P7, DOI 10.1016/j.tox.2007.03.021; Yager JD, 2000, J NATL CANC I MONOGR, V27, P67401ASSOC BRAS DIVULG CIENTIFICASAO PAULOFACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZILBRAZ J MED BIOL RESNOVDiscipline: Life Sciences &amp; Biomedicine - Other Topics; Research &amp; Experimental Medicine511KM</notes>
    <keywords>1; ADULT; AGENTS; ASSAY; BIOLOGY; BISPHENOL-A; BREAST-CANCER; CANCER; CARCINOGENESIS; CELLS; DAMAGE; DES; DIETHYLSTILBESTROL; DNA METHYLATION; Estrogen; EXPOSURE; FUTURE; GENOTOXICITY; HEALTH; in vivo; In vivo micronucleus assay; IN-VITRO; IN-VIVO; Male; MICE; MICRONUCLEUS ASSAY; MODEL; p21; pre-pubertal; puberty; RAT-LIVER; RISK; Sex; sex differences; SEX-DIFFERENCES; SPRAGUE-DAWLEY; SUSCEPTIBILITY; SYNTHETIC ESTROGEN; SYRIAN-HAMSTERS; toxicology; VIVO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1090</startpage>
    <endpage>1096</endpage>
    <journalfull>Brazilian Journal of Medical and Biological Research</journalfull>
    <issue>11</issue>
    <volume>42</volume>
    <abstract>Environmental xenoestrogens pose a significant health risk for all living organisms. There is growing evidence concerning the different susceptibility to xenoestrogens of developing and adult organisms, but little is known about their genotoxicity in pre-pubertal mammals. In the present study, we developed an animal model to test the sex-and age-specific genotoxicity of the synthetic estrogen diethylstilbestrol (DES) on the reticulocytes of 3-week-old pre-pubertal and 12-week-old adult BALB/CJ mice using the in vivo micronucleus (MN) assay. DES was administered intraperitoneally at doses of 0.05, 0.5, and 5 mu g/kg for 3 days and animals were sampled 48, 72 and 96 h, and 2 weeks after exposure. Five animals were analyzed for each dose, sex, and age group. After the DES dose of 0.05 mu g/kg, pre-pubertal mice showed a significant increase in MN frequency (P &lt; 0.001), while adults continued to show reference values (5.3 vs 1.0 MN/1000 reticulocytes). At doses of 0.5 and 5 mu g/kg, MN frequency significantly increased in both age groups. In pre-pubertal male animals, MN frequency remained above reference values for 2 weeks after exposure. Our animal model for pre-pubertal genotoxicity assessment using the in vivo MN assay proved to be sensitive enough to distinguish age and sex differences in genome damage caused by DES. This synthetic estrogen was found to be more genotoxic in pre-pubertal mice, males in particular. Our results are relevant for future investigations and the preparation of legislation for drugs and environmentally emitted agents, which should incorporate specific age and gender susceptibility</abstract>
    <url>WOS:000271163100017</url>
    <isbnorissn>0100-879X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>222</id>
    <title>A differentially methylated single CpG-site is correlated with estrogen receptor alpha transcription</title>
    <authors>Furst,R.W.; Kliem,H.; Meyer,H.H.D.; Ulbrich,S.E.</authors>
    <availability>[Fuerst, Rainer W.] Tech Univ Munich, Grad Sch Epigenet Imprinting &amp; Nutr, D-85354 Freising Weihenstephan, Germany.</availability>
    <date>2012</date>
    <notes>JEnglishArticleUlbrich, SE (reprint author), Weihenstephaner Berg 3, D-85354 Freising Weihenstephan, Germanyulbrich@wzw.tum.deBjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Choy MK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-519; Cornwall GA, 2009, HUM REPROD UPDATE, V15, P213, DOI 10.1093/humupd/dmn055; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Delbes G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231; Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934; Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008; Furst RW, 2012, MOL CELL ENDOCRINOL, V348, P67, DOI 10.1016/j.mce.2011.07.032; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Ing NH, 1997, BIOL REPROD, V56, P1205, DOI 10.1095/biolreprod56.5.1205; Joseph A., 2010, BIOL REPROD, V84, P207; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Kurian JR, 2010, ENDOCRINOLOGY, V151, P2297, DOI 10.1210/en.2009-0649; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MEYER HHD, 1990, J STEROID BIOCHEM, V35, P263, DOI 10.1016/0022-4731(90)90283-X; Meyer H.H.D., 1999, HDB EXPT PHARM; Nadal A, 2001, NEWS PHYSIOL SCI, V16, P251; Nielsen M, 2001, HISTOCHEM CELL BIOL, V115, P521; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; PIVA R, 1989, BIOCHEM INT, V19, P267; Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROBERTSO.HA, 1974, J REPROD FERTIL, V40, P133; Sato K, 2006, ENDOCR J, V53, P331, DOI 10.1507/endocrj.K06-009; Schug J., 2002, CURRENT PROTOCOLS BI, P261; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Tan Guihong, 2005, Nucleic Acids Res, V33, pe122, DOI 10.1093/nar/gni124; Tate P H, 1993, Curr Opin Genet Dev, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tierney RJ, 2000, J VIROL, V74, P10468, DOI 10.1128/JVI.74.22.10468-10479.2000; Ulbrich SE, 2009, REPRODUCTION, V138, P371, DOI 10.1530/REP-09-0081; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Wagner A, 2008, REPROD FERT DEVELOP, V20, P505, DOI 10.1071/RD07136; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Westberry JM, 2010, ENDOCRINOLOGY, V151, P731, DOI 10.1210/en.2009-0955; Wilson ME, 2008, FRONT NEUROENDOCRIN, V29, P375, DOI 10.1016/j.yfrne.2008.03.002; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Yang XW, 2000, CANCER RES, V60, P6890; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zaratiegui M, 2007, CELL, V128, P763, DOI 10.1016/j.cell.2007.02.016; Zhang DP, 2006, COMP BIOCHEM PHYS A, V144, P306, DOI 10.1016/j.cbpa.2006.01.025; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P14132, DOI 10.1073/pnas.2412458985511PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMMAYDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism931NH</notes>
    <keywords>ALPHA; BETA; BINDING; BIOLOGY; BISPHENOL-A; CANCER; CARCINOGENESIS; CELL; CELLS; Chromatin immunoprecipitation; COMBINATION; DNA METHYLATION; DNA-methylation; Epididymis; epigenetic; EPIGENETIC REGULATION; epigenetics; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptor alpha; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPRESSION; FACTOR-BINDING SITES; GENE; GENE-EXPRESSION; GENES; heart; HISTONE DEACETYLASE; HUMAN BREAST-CANCER; Male; mechanism; MECHANISMS; METABOLISM; METHYLATION; Methylation-specific high-resolution melting; PROMOTER; Pyrosequencing; RECEPTOR; RECEPTOR-ALPHA; Reproduction; TARGET GENES; TISSUE; TISSUES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>96</startpage>
    <endpage>104</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <issue>1-2</issue>
    <volume>130</volume>
    <abstract>DNA methylation of the promoter region of estrogen receptor alpha (ESR1) is recognized as an epigenetic mechanism that regulates its mRNA abundance. We questioned whether tissues in male growing piglets were influenced in terms of DNA methylation by the developmentally occurring distinct plasma estradiol-17 beta (E2) concentrations. Additionally, we aimed at broadening the currently limited understanding of the epigenetic regulation of ESR1 in physiological settings. Three distinct genetic regions of ESR1 were analyzed using a combination of methylation-sensitive high resolution melting (MS-HRM) and pyrosequencing. Unexpectedly, major E2 concentration differences were only marginally associated with minor variations in DNA methylation and mRNA abundance. However, by analyzing two tissues showing the greatest differences in transcript abundance, we were able to find one single CpG site in the +1 kb intragenic region of ESR1 strikingly differently methylated between heart vs. epididymis. Interestingly, this single CpG-site was identified as a putative binding site for the transcriptional repressor TG-interacting factor 1 (TGIF) which can recruit histone deacetylase 1 (HDAC1) leading to chromatin condensation. Indeed, chromatin immunoprecipitation confirmed a reduced histone H3 presence at the specific ESR1 location in case of higher DNA methylation. We therefore hypothesize that ESR1 expression may be manifested by a single-CpG-site based methylation difference impairing transcription factor binding. (C) 2012 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000303226100012</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>338</id>
    <title>Laccase-modified silica nanoparticles efficiently catalyze the transformation of phenolic compounds</title>
    <authors>Galliker,P.; Hommes,G.; Schlosser,D.; Corvini,P.F.X.; Shahgaldian,P.</authors>
    <availability>[Shahgaldian, Patrick] Univ Appl Sci NW Switzerland, Inst Chem &amp; Bioanalyt, CH-4132 Muttenz, Switzerland. [Galliker, Patrick; Hommes, Gregor; Corvini, Philippe F. -X.; Shahgaldian, Patrick] Univ Appl Sci NW Switzerland, Sch Life Sci, CH-4132 Muttenz, Switzerland. [Galliker, Patrick; Hommes, Gregor; Corvini, Philippe F. -X.] Univ Appl Sci NW Switzerland, Inst Ecopreneurship, CH-4132 Muttenz, Switzerland. [Schlosser, Dietmar] UFZ Helmholtz Ctr Environm Res, Dept Environm Microbiol, D-04318 Leipzig, Germany.</availability>
    <date>2010</date>
    <notes>JEnglishArticleShahgaldian, P (reprint author), Univ Appl Sci NW Switzerland, Inst Chem &amp; Bioanalyt, Grundenstr 40, CH-4132 Muttenz, Switzerlandpatrick.shahgaldian@fhnw.chBrisken C, 2008, CHIMIA, V62, P406, DOI 10.2533/chimia.2008.406; Burridge E., 2003, EUR CHEM NEWS, P14; Cabana H, 2007, J BIOTECHNOL, V132, P23, DOI 10.1016/jjbiotec.2007.07.948; Cabana H, 2009, BIOTECHNOL BIOENG, V102, P1582, DOI 10.1002/bit.22198; Cabana H, 2007, ENG LIFE SCI, V7, P429, DOI 10.1002/elsc.200700017; Cabana H, 2007, CHEMOSPHERE, V67, P770, DOI 10.1016/j.chemosphere.2006.10.037; Cabana H, 2009, BIORESOURCE TECHNOL, V100, P3447, DOI 10.1016/j.biortech.2009.02.052; Couto SR, 2007, BIOTECHNOL ADV, V25, P558, DOI 10.1016/j.biotechadv.2007.07.002; Couto SR, 2006, BIOTECHNOL ADV, V24, P500, DOI 10.1016/j.biotechadv.2006.04.003; DAVIES GJ, 2001, LACCASE HDB METALLOP; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Fukuda T, 2004, J CHEM TECHNOL BIOT, V79, P1212, DOI 10.1002/jctb.1115; Goodman J, 2009, CRIT REV TOXICOL, V39, P1, DOI 10.3109/10408440903279946; Huang QG, 2005, ENVIRON SCI TECHNOL, V39, P6029, DOI 10.1021/es050036x; Kang JH, 2007, CRIT REV TOXICOL, V37, P607, DOI 10.1080/10408440701493103; KASHIWAGI A, 2007, J HEALTH SCI, V54, P273; Kolvenbach B, 2007, APPL ENVIRON MICROB, V73, P4776, DOI 10.1128/AEM.00329-07; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; LONERGAN GT, 2004, CURR TOPICS ANAL CHE, V4, P67; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Octavio L.C., 2006, ADV AGR FOOD BIOTECH, P323; Oehlmann J, 2008, ENVIRON RES, V108, P140, DOI 10.1016/j.envres.2008.07.016; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins GS, 2008, ENDOCR-RELAT CANCER, V15, P649, DOI 10.1677/ERC-08-0043; Ropero AB, 2008, INT J ANDROL, V31, P194, DOI 10.1111/j.1365-2605.2007.00832.x; Sekizawa J, 2008, J TOXICOL SCI, V33, P389, DOI 10.2131/jts.33.389; Stoeber W, 1968, J COLLOID INTERF SCI, V26, P62; Wong LS, 2009, CHEM REV, V109, P4025, DOI 10.1021/cr80046682818ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAJ COLLOID INTERF SCISEP 1Discipline: Chemistry626LE</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CONTINUOUS ELIMINATION; ENDOCRINE; Endocrine disrupting chemical; Endocrine-disrupting chemicals; environment; EXPOSURE; FOOD; FUNGUS CORIOLOPSIS-POLYZONA; HEALTH; IDENTIFICATION; IMMOBILIZATION; Laccase; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; Nanoparticle; NANOPARTICLES; PERFORMANCE; POLLUTANTS; PRODUCTS; PROTEIN; PROTEINS; Radioactivity; REACTOR; SCATTERING; Silica; SYSTEM; TRANSFORMATION PRODUCTS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>98</startpage>
    <endpage>105</endpage>
    <journalfull>Journal of Colloid and Interface Science</journalfull>
    <issue>1</issue>
    <volume>349</volume>
    <abstract>A new system based on laccase-modified silica nanoparticles has been developed and tested for its ability to degrade a major endocrine disrupting chemical, 4,4'-isopropylidenediphenol (bisphenol A). The nanoparticles have been produced using the Stober method and characterized using scanning electron microscopy, dynamic light scattering and zeta-potential measurements. The introduction of primary amino groups at the surface of these particles has been achieved using an organo-silane (amino-propyl-triethoxy-silane). The use of glutaraldehyde as bi-functional coupling agent allowed the efficient conjugation of a laccase from Coriolopsis polyzona at the surface of the nanoparticles, as monitored by measuring the amount of proteins coupled and the zeta-potential of the produced nanoparticles. The oxidative activity of the so-produced bio-conjugate was tested using radioactive-((14)C) labeled bisphenol A. Analytical methods based on high performance liquid chromatography coupled to mass spectrometry and gas chromatography allowing a convenient and reliable study of the enzymatic activity of the produced bio-conjugates have been developed. It is demonstrated that even if a decrease of the specific catalytic activity of the immobilized enzyme is measured, the activity of the bio-conjugate remains compatible with the application of these systems to the transformation of phenolic pollutants. Additionally, the developed analytical methods allowed the identification of the transformation products formed during the enzymatic reaction. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000279966700014</url>
    <isbnorissn>0021-9797</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>19</id>
    <title>Impact of Bisphenol A on the Cardiovascular System - Epidemiological and Experimental Evidence and Molecular Mechanisms</title>
    <authors>Gao,X.Q.; Wang,H.S.</authors>
    <availability>[Gao, Xiaoqian; Wang, Hong-Sheng] Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA.</availability>
    <date>2014</date>
    <notes>JEnglishReviewWang, HS (reprint author), Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USAgaoxq@mail.uc.edu; wanghs@uc.eduAboul Ezz H.S., 2013, CYTOTECHNOLOGY, DOI [10.1007/s10616-013-9672-1, DOI 10.1007/S10616-013-9672-1]; Asano S, 2010, BRIT J PHARMACOL, V160, P160, DOI 10.1111/j.1476-5381.2010.00687.x; Bae S, 2012, HYPERTENSION, V60, P786, DOI 10.1161/HYPERTENSIONAHA.112.197715; BALKE CW, 1981, AM HEART J, V101, P449, DOI 10.1016/0002-8703(81)90135-6; Belcher SM, 2012, ENDOCRINOLOGY, V153, P712, DOI 10.1210/en.2011-1772; BERNIER M, 1989, AM J PHYSIOL, V256, pH1344; Bers DM, 2008, ANNU REV PHYSIOL, V70, P23, DOI 10.1146/annurev.physiol.70.113006.100455; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Calafat AM, 2009, ENVIRON HEALTH PERSP, V117, P639, DOI 10.1289/ehp.0800265; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cantonwine D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-62; Chapalamadugu KC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089096; Chen SJ, 1996, CIRCULATION, V93, P577; Dai-Do Do, 1996, Cardiovascular Research, V32, P980, DOI 10.1016/S0008-6363(96)00149-6; Deutschmann A, 2013, MOL PHARMACOL, V83, P501, DOI 10.1124/mol.112.081372; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Gao XQ, 2013, ENDOCRINOLOGY, V154, P4607, DOI 10.1210/en.2013-1737; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Halden RU, 2010, ANNU REV PUBL HEALTH, V31, P179, DOI 10.1146/annurev.publhealth.012809.103714; Itoh Hiroaki, 2007, Environmental Health and Preventive Medicine, V12, P258, DOI 10.1007/BF02898033; Kang JH, 2003, J FOOD PROTECT, V66, P1444; Kim K, 2013, INT J HYG ENVIR HEAL, V216, P467, DOI 10.1016/j.ijheh.2012.07.007; Kim M.J., 2013, CARDIOVASC TOXICOL, V14, P120; LaKind JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051086; LaKind JS, 2014, CRIT REV TOXICOL, V44, P121, DOI 10.3109/10408444.2013.860075; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Li GH, 1999, CIRCULATION, V100, P1639; Liang Q, 2014, ENVIRON HEALTH PERSP, V122, P601, DOI 10.1289/ehp.1307491; Melzer D, 2012, CIRCULATION, V125, P1482, DOI 10.1161/CIRCULATIONAHA.111.069153; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Melzer D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043378; Michaela P, 2014, N-S ARCH PHARMACOL, V387, P153, DOI 10.1007/s00210-013-0932-6; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Ning G, 2011, ANN INTERN MED, V155, P368, DOI [10.7326/0003-4819-155-6-201109200-00005, 10.1059/0003-4819-155-6-201109200-00005]; O'Reilly A.O., 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041667, DOI 10.1371/JOURNAL.PONE.0041667]; Olsen L, 2012, ECOTOX ENVIRON SAFE, V80, P179, DOI 10.1016/j.ecoenv.2012.02.023; Pant J, 2011, J APPL TOXICOL, V31, P698, DOI 10.1002/jat.1647; Patel BB, 2013, TOXICOL SCI, V133, P174, DOI 10.1093/toxsci/kft026; Pellegrini M, 2013, J CELL PHYSL; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; Posnack NG, 2014, ENVIRON HEALTH PERSP, V122, P384, DOI 10.1289/ehp.1206157; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Recchia AG, 2004, FOOD ADDIT CONTAM, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Shankar A, 2012, J ENV PUBLIC HLTH, V2012, DOI DOI 10.1155/2012/481641; Shankar A, 2012, ENVIRON HEALTH PERSP, V120, P1297, DOI 10.1289/ehp.1104114; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Walsh DE, 2005, MOL CELL ENDOCRINOL, V230, P23, DOI 10.1016/j.mce.2004.11.006; Wang F, 2012, OCCUP ENVIRON MED, V69, P679, DOI 10.1136/oemed-2011-100529; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wilson NK, 2007, ENVIRON RES, V103, P9, DOI 10.1016/j.envres.2006.04.006; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yan SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025455; Yan SJ, 2013, FOOD CHEM TOXICOL, V56, P75, DOI 10.1016/j.fct.2013.02.011; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565630MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J ENV RES PUB HEAUGDiscipline: Environmental Sciences &amp; EcologyAO1UX</notes>
    <keywords>ATHEROSCLEROSIS; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CARDIAC MYOCYTES; cardiovascular; Endocrine-disrupting chemicals; ENVIRONMENTAL ESTROGENS; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FEMALE RAT HEARTS; heart; HUMAN HEALTH; IN-VITRO; LABORATORY ABNORMALITIES; mechanism; MECHANISMS; Oxidative stress; PUBLIC-HEALTH; TOXICITY; URINARY CONCENTRATIONS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>8399</startpage>
    <endpage>8413</endpage>
    <journalfull>International Journal of Environmental Research and Public Health</journalfull>
    <issue>8</issue>
    <volume>11</volume>
    <abstract>Bisphenol A (BPA) is a ubiquitous plasticizing agent used in the manufacturing of polycarbonate plastics and epoxy resins. There is well-documented and broad human exposure to BPA. The potential risk that BPA poses to the human health has attracted much attention from regulatory agencies and the general public, and has been extensively studied. An emerging and rapidly growing area in the study of BPA's toxicity is its impact on the cardiovascular (CV) system. Recent epidemiological studies have shown that higher urinary BPA concentration in humans is associated with various types of CV diseases, including angina, hypertension, heart attack and coronary and peripheral arterial disease. Experimental studies have demonstrated that acute BPA exposure promotes the development of arrhythmias in female rodent hearts. Chronic exposure to BPA has been shown to result in cardiac remodeling, atherosclerosis, and altered blood pressure in rodents. The underlying mechanisms may involve alteration of cardiac Ca2+ handling, ion channel inhibition/activation, oxidative stress, and genome/transcriptome modifications. In this review, we discuss these recent findings that point to the potential CV toxicity of BPA, and highlight the knowledge gaps in this growing research area</abstract>
    <url>WOS:000341101700051</url>
    <isbnorissn>1660-4601</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>272</id>
    <title>Peripheral precocious puberty in a 4-month-old girl: role of pesticides?</title>
    <authors>Gaspari,L.; Paris,F.; Jeandel,C.; Sultan,C.</authors>
    <availability>[Gaspari, Laura; Paris, Francoise; Jeandel, Claire; Sultan, Charles] Univ Montpellier 1, Unite Endocrinol Gynecol Pediat, Serv Ped 1, Hop Arnaud de Villeneuve,CHU Montpellier, Montpellier, France. [Gaspari, Laura; Paris, Francoise; Sultan, Charles] CHU Montpellier, Serv Hormonol Dev &amp; Reprod, Hop Lapeyronie, Montpellier, France.</availability>
    <date>2011</date>
    <notes>JEnglishArticleSultan, C (reprint author), Univ Montpellier 1, Unite Endocrinol Gynecol Pediat, Serv Ped 1, Hop Arnaud de Villeneuve,CHU Montpellier, Montpellier, Francec-sultan@chu-montpellier.frBEARER CF, 1995, ENVIRON HEALTH PERSP, V103, P7, DOI 10.2307/3432337; BITMAN J, 1968, SCIENCE, V162, P371, DOI 10.1126/science.162.3851.371; BONGIOVANNI AM, 1983, J PEDIATR, V103, P245, DOI 10.1016/S0022-3476(83)80354-0; Botella B, 2004, ENVIRON RES, V96, P34, DOI 10.1016/j.envres.2003.10.001; BRADLOW HL, 1995, ENVIRON HEALTH PERSP, V103, P147, DOI 10.2307/3432525; Chakraborty TR, 2003, J COMP NEUROL, V466, P409, DOI 10.1002/cne.10906; Chakraborty TR, 2003, ENDOCRINOLOGY, V144, P4164, DOI 10.1210/en.2003-0052; Charnley G, 2001, ENVIRON HEALTH PERSP, V109, P187, DOI 10.2307/3434774; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Dees C, 1997, MOL CARCINOGEN, V18, P107, DOI 10.1002/(SICI)1098-2744(199702)18:2&lt;107::AID-MC6&gt;3.0.CO;2-D; DERODRIGUEZ CAS, 1982, LANCET, V1, P1300; DERODRIGUEZ CAS, 1985, J PEDIATR, V107, P393; Doong RA, 2001, J CHROMATOGR A, V918, P177, DOI 10.1016/S0021-9673(01)00740-3; FARA GM, 1979, LANCET, V2, P295; Frias MM, 2001, J CHROMATOGR B, V760, P1; Frias MM, 2004, BIOMED CHROMATOGR, V18, P102, DOI 10.1002/bmc.300; Garry VF, 2004, TOXICOL APPL PHARM, V198, P152, DOI 10.1016/j.taap.2003.11.027; Goerke H, 2004, MAR POLLUT BULL, V48, P295, DOI 10.1016/j.marpolbul.2003.08.004; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; Grimalt JO, 2004, CHEMOSPHERE, V54, P1549, DOI 10.1016/j.chemosphere.2003.09.047; Jorgensen ECB, 1997, CARCINOGENESIS, V18, P1651; Kelce WR, 1998, REPROD FERT DEVELOP, V10, P105, DOI 10.1071/R98051; Kelce WR, 1997, TOXICOL APPL PHARM, V142, P192, DOI 10.1006/taap.1996.7966; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Kurt PB, 2004, MAR POLLUT BULL, V48, P1076, DOI 10.1016/j.marpolbul.2003.12.013; Larriuz-Serrano M C, 2001, P R Health Sci J, V20, P13; Lopez-Espinosa MJ, 2007, PLACENTA, V28, P631, DOI 10.1016/j.placenta.2006.09.009; Lumbroso S, 2004, J CLIN ENDOCR METAB, V89, P2107, DOI 10.1210/jc.2003-031225; Maness SC, 1998, TOXICOL APPL PHARM, V151, P135, DOI 10.1006/taap.1998.8431; Mariscal-Arcas M, 2010, FOOD CHEM TOXICOL, V48, P1311, DOI 10.1016/j.fct.2010.02.029; Noren K, 2000, CHEMOSPHERE, V40, P1111, DOI 10.1016/S0045-6535(99)00360-4; Paris F, 2006, ENVIRON RES, V100, P39, DOI 10.1016/j.envres.2005.06.001; Paris F, 2002, J CLIN ENDOCR METAB, V87, P791, DOI 10.1210/jc.87.2.791; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Rajapakse N, 2002, ENVIRON HEALTH PERSP, V110, P917; Rogan WJ, 2007, INT J HYG ENVIR HEAL, V210, P659, DOI 10.1016/j.ijheh.2007.07.005; Saiyed H, 2003, ENVIRON HEALTH PERSP, V111, P1958, DOI 10.1289/ehp.6271; Sapozhnikova Y, 2004, CHEMOSPHERE, V55, P797, DOI 10.1016/j.chemosphere.2003.12.009; Schmidt IM, 2002, PEDIATR RES, V52, P682, DOI 10.1203/01.PDR.0000032071.90497.50; Shekhar PVM, 1997, J NATL CANCER I, V89, P1774; Solomon GM, 2002, ENVIRON HEALTH PERSP, V110, pA339; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Sultan C, 2001, MOL CELL ENDOCRINOL, V178, P99, DOI 10.1016/S0303-7207(01)00430-0; Tinwell H, 2004, ENVIRON HEALTH PERSP, V112, P575, DOI 10.1289/ehp.6831; Toppari J, 1998, BAILLIERE CLIN ENDOC, V12, P143, DOI 10.1016/S0950-351X(98)80529-6; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Vorkamp K, 2004, SCI TOTAL ENVIRON, V331, P157, DOI 10.1016/j.scitotenv.2004.03.027; WELCH RM, 1969, TOXICOL APPL PHARM, V14, P358, DOI 10.1016/0041-008X(69)90117-3482INFORMA HEALTHCARENEW YORK52 VANDERBILT AVE, NEW YORK, NY 10017 USAGYNECOL ENDOCRINOLSEPDiscipline: Endocrinology &amp; Metabolism; Obstetrics &amp; Gynecology803SB</notes>
    <keywords>BISPHENOL-A; breast; BREAST-CANCER CELLS; CANCER; Carcinogen; CARCINOGENESIS; CELL; CHILDREN; CHLORINATED PESTICIDES; development; environmental endocrine disruptors; Estrogen; estrogen activity; ESTROGENS; FOOD; GROWTH; HEALTH; MASS-SPECTROMETRY; METABOLISM; ORGANOCHLORINE PESTICIDES; PESTICIDES; PLACENTA; PLASMA; precocious puberty; puberty; RAT HYPOTHALAMUS; SAMPLES; SERUM ESTROGENIC BIOACTIVITY; SEXUAL-DIFFERENTIATION; SOUTHERN SPAIN; TUMOR; TUMORS; Uterus</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>721</startpage>
    <endpage>724</endpage>
    <journalfull>Gynecological Endocrinology</journalfull>
    <issue>9</issue>
    <volume>27</volume>
    <abstract>A 4-month-old girl presented with sexual development, including breast enlargement, menstruation, uterine length of 69 mm at ultrasonography, and dramatically high estrogen bioactivity, but no growth acceleration, pubic hair, pelvis masses or adrenal tumors. Gas chromatography with an electron capture detector and mass spectrometry detected pesticides (p,p'-DDD, p,p'-DDT, lindane and endosulfan sulpfate) in plasma from the infant, the mother, and the 38-year-old father, who reported a dramatic decrease in libido, and in soil samples from their farm. The precocious sexual development was probably caused by the estrogen activity of the environmental contamination by tons of pesticides stored in the family farm</abstract>
    <url>WOS:000293599900022</url>
    <isbnorissn>0951-3590</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>14</id>
    <title>Signaling related with biphasic effects of bisphenol A (BPA) on Sertoli cell proliferation: A comparative proteomic analysis</title>
    <authors>Ge,L.C.; Chen,Z.J.; Liu,H.; Zhang,K.S.; Su,Q.; Ma,X.Y.; Huang,H.B.; Zhao,Z.D.; Wang,Y.Y.; Giesy,J.P.; Du,J.; Wang,H.S.</authors>
    <availability>[Ge, Li-Chen; Ma, Xiang-Yu; Wang, Yu-Ye; Du, Jun; Wang, Hong-Sheng] Sun Yat Sen Univ, Sch Pharmaceut Sci, Dept Microbial &amp; Biochem Pharm, Guangdong Prov Key Lab New Drug Design &amp; Evaluat, Guangzhou 510006, Guangdong, Peoples R China. [Chen, Zhuo-Jia; Huang, Hong-Bin] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Pharm,State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China. [Liu, Hao] Guangzhou Med Univ, Canc Res Inst, Guangzhou 510095, Guangdong, Peoples R China. [Liu, Hao] Guangzhou Med Univ, Canc Hosp, Guangzhou 510095, Guangdong, Peoples R China. [Zhang, Kun-Shui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pharm, Guangzhou 510120, Guangdong, Peoples R China. [Su, Qiao] Sun Yat Sen Univ, Affiliated Hosp 1, Lab Anim Ctr, Guangzhou 510080, Guangdong, Peoples R China. [Zhao, Zhen-Dong] Guangdong Food &amp; Drug Vocat Coll, Sch Chinese Mat Med, Guangzhou 510520, Guangdong, Peoples R China. [Giesy, John P.] Univ Saskatchewan, Dept Vet Biomed Sci, Saskatoon, SK, Canada. [Giesy, John P.] Univ Saskatchewan, Toxicol Ctr, Saskatoon, SK, Canada.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDu, J (reprint author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Dept Microbial &amp; Biochem Pharm, Guangdong Prov Key Lab New Drug Design &amp; Evaluat, 132 Waihuandong Rd, Guangzhou 510006, Guangdong, Peoples R Chinadujun@mail.sysu.edu.cn; whongsh@mail.sysu.edu.cnBASS DA, 1983, J IMMUNOL, V130, P1910; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Bredhult C, 2007, REPROD TOXICOL, V23, P550, DOI 10.1016/j.reprotox.2007.03.006; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Cai Q., 2012, ONCOGENE, V32, P2079; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; Chitra S, 2012, INT J RHEUM DIS, V15, P249, DOI 10.1111/j.1756-185X.2012.01737.x; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; De Rosa A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052113; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033; Ding Y, 2010, ANTIOXID REDOX SIGN, V13, P1477, DOI 10.1089/ars.2010.3137; Elmasri H, 2009, FASEB J, V23, P3865, DOI 10.1096/fj.09-134882; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Ferreira JM, 2011, J NEUROSCI, V31, P1991, DOI 10.1523/JNEUROSCI.1850-09.2011; Ganguly A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1241, DOI 10.1152/ajpendo.00344.2006; Ge LC, 2014, TOXICOL LETT, V226, P81, DOI 10.1016/j.toxlet.2014.01.035; Goh ETH, 2010, J BIOL CHEM, V285, P17065, DOI 10.1074/jbc.M109.078782; Goodman JE, 2006, CRIT REV TOXICOL, V36, P387, DOI 10.1080/10408440600758317; Goto S, 2009, FREE RADICAL BIO MED, V46, P1392, DOI 10.1016/j.freeradbiomed.2009.02.025; Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kopera IA, 2010, PHILOS T R SOC B, V365, P1593, DOI 10.1098/rstb.2009.0251; Li DM, 2009, REPROD TOXICOL, V27, P170, DOI 10.1016/j.reprotox.2008.12.004; Liu Q, 2013, PROSTATE, V73, P1028, DOI 10.1002/pros.22650; Lui WY, 2008, FRONT BIOSCI, V13, P6775, DOI 10.2741/3188; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Mick D. U., 2010, NAT REV MOL CELL BIO, V12, P14; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Peterson EA, 2010, CLIN GENET, V77, P511, DOI 10.1111/j.1399-0004.2010.01392.x; Piatkiewicz P, 2011, ARCH IMMUNOL THER EX, V59, P215, DOI 10.1007/s00005-011-0119-0; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012; Salian S, 2011, REPROD TOXICOL, V31, P359, DOI 10.1016/j.reprotox.2010.10.008; Sheng ZG, 2011, ENVIRON HEALTH PERSP, V119, P1775, DOI 10.1289/ehp.1103781; Tabuchi Y, 2006, BIOCHEM BIOPH RES CO, V345, P1044, DOI 10.1016/j.bbrc.2006.04.177; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047159; Wu S, 2012, FOOD CHEM TOXICOL, V50, P3100, DOI 10.1016/j.fct.2012.06.029; Xiao L, 2010, CELL DEATH DIFFER, V17, P1448, DOI 10.1038/cdd.2010.16; Xu JP, 2002, BIOCHEM BIOPH RES CO, V292, P456, DOI 10.1006/bbrc.2002.6644; Yang M, 2008, ENVIRON MOL MUTAGEN, V49, P368, DOI 10.1002/em.20394; Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008-5472.CAN-05-0175; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zhou J, 2010, CHEMOSPHERE, V79, P595, DOI 10.1016/j.chemosphere.2010.01.052530ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSBBA-GEN SUBJECTSSEPDiscipline: Biochemistry &amp; Molecular Biology; BiophysicsAO0DN</notes>
    <keywords>apoptosis; BIOLOGY; bisphenol A; BISPHENOL-A; CANCER; CANCER-CELLS; cell death; CELLS; COUPLED RECEPTOR 30; Differentiation; Energy metabolism; EXPOSURE; EXPRESSION; GROWTH; In vitro; INDUCTION; MECHANISMS; METABOLISM; MITOCHONDRIA; Oxidative stress; proliferation; Proteomics; TM4 cell</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2663</startpage>
    <endpage>2673</endpage>
    <journalfull>Biochimica et Biophysica Acta-General Subjects</journalfull>
    <issue>9</issue>
    <volume>1840</volume>
    <abstract>Background: Biphasic effects on cell proliferation of bisphenol A (BPA) can occur at lesser or greater exposures. Sertoli cells play a pivotal role in supporting proliferation and differentiation of germ cells. The mechanisms responsible for inverse effects of great and low concentrations of BPA on Sertoli cell proliferation need further study. Methods: We utilized proteomic study to indentify the protein expression changes of Sertoli TM4 cells treated with 10(-8) M and 10(-5) M BPA. The further mechanisms related to mitochondria, energy metabolism and oxidative stress were investigated by ciRT-PCR and Western-blotting analysis. Results: Proteomic studies identified 36 proteins and two major clusters of proteins including energy metabolism and oxidative stress expressed with opposite changes in Sertoli cells treated with 10(-8) M and 10(-5) M BPA, respectively, for 24 h. Exposure to 10(-5) M BPA resulted in greater oxidative stress and then inhibited cell proliferation, while ROS scavenger NAC effectively blocked these effects. Exposure to 10(-8) M BPA caused higher intercellular ATP, greater activities of mitochondria, and resulted in significant proliferation of TM4 cells, while oligomycin A, an inhibitor of ATP synthase, abolished these growth advantages. Conclusions: Our study demonstrated that micromolar BPA inhibits proliferation of Sertoli cells by elevating oxidative stress while nanomolar BPA stimulates proliferation by promoting energy metabolism. General significance: Micromolar BPA inhibits cell proliferation by elevating oxidative stress while nanomolar BPA stimulates cell proliferation by promoting energy metabolism. (C) 2014 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000340979400001</url>
    <isbnorissn>0304-4165</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>50</id>
    <title>Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor alpha/beta in low doses of bisphenol A promoting growth of Sertoli TM4 cells</title>
    <authors>Ge,L.C.; Chen,Z.J.; Liu,H.Y.; Zhang,K.S.; Liu,H.; Huang,H.B.; Zhang,G.; Wong,C.K.C.; Giesy,J.P.; Du,J.; Wang,H.S.</authors>
    <availability>[Ge, Li-Chen; Liu, Hao; Zhang, Ge; Du, Jun; Wang, Hong-Sheng] Sun Yat Sen Univ, Dept Microbial &amp; Biochem Pharm, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China. [Chen, Zhuo-Jia; Huang, Hong-Bin] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Pharm, Guangzhou 510060, Guangdong, Peoples R China. [Liu, Han-Yan] Guangzhou Med Univ, Affiliated Hosp 3, Ctr Reprod Med, Key Lab Major Obstet Dis Guangdong Prov, Guangzhou 510150, Guangdong, Peoples R China. [Zhang, Kun-Shui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pharm, Guangzhou 510120, Guangdong, Peoples R China. [Wong, Chris K. C.] Hong Kong Baptist Univ, Dept Biol, Kowloon, Hong Kong, Peoples R China. [Giesy, John P.] Univ Saskatchewan, Dept Vet Biomed Sci, Saskatoon, SK, Canada. [Giesy, John P.] Univ Saskatchewan, Toxicol Ctr, Saskatoon, SK, Canada.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDu, J (reprint author), Sun Yat Sen Univ, Dept Microbial &amp; Biochem Pharm, Sch Pharmaceut Sci, 132 Waihuandong Rd, Guangzhou 510006, Guangdong, Peoples R Chinadujun@mail.sysu.edu.cn; whongsh@sysu.edu.cnAlbanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Alonso-Magdalena P, 2012, MOL CELL ENDOCRINOL, V355, P201, DOI 10.1016/j.mce.2011.12.012; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Doerge DR, 2010, TOXICOL APPL PHARM, V248, P1, DOI 10.1016/j.taap.2010.07.009; Gao F, 2011, ENDOCRINOLOGY, V152, P1434, DOI 10.1210/en.2010-1368; Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002; Johnson L, 2008, ANIM REPROD SCI, V105, P23, DOI 10.1016/j.anireprosci.2007.11.029; Kopera IA, 2010, PHILOS T R SOC B, V365, P1593, DOI 10.1098/rstb.2009.0251; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lee YJ, 2008, REPROD TOXICOL, V25, P413, DOI 10.1016/j.reprotox.2008.05.058; Li X, 2013, ENVIRON INT, V52, P81, DOI 10.1016/j.envint.2011.03.026; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Migliaccio A, 2010, MOL CELL ENDOCRINOL, V327, P19, DOI 10.1016/j.mce.2010.06.014; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Petrier C, 2010, ULTRASON SONOCHEM, V17, P111, DOI 10.1016/j.ultsonch.2009.05.010; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Royer C, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.096891; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012; Salian S, 2011, REPROD TOXICOL, V31, P359, DOI 10.1016/j.reprotox.2010.10.008; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; Sheng ZG, 2011, ENVIRON HEALTH PERSP, V119, P1775, DOI 10.1289/ehp.1103781; Sheng ZG, 2013, TOXICOL APPL PHARM, V267, P88, DOI 10.1016/j.taap.2012.12.014; Shin BS, 2004, J TOXICOL ENV HEAL A, V67, P1971, DOI 10.1080/15287390490514615; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; Teeguarden JG, 2011, TOXICOL SCI, V123, P48, DOI 10.1093/toxsci/kfr160; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Wan Y, 2010, ENVIRON SCI TECHNOL, V44, P5233, DOI 10.1021/es1002764; Wang HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047159; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010393ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTAPR 7Discipline: ToxicologyAC3HX</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; CELLS; COUPLED RECEPTOR 30; Differentiation; ERK1/2; Estrogen; Estrogen receptor; Estrogen receptor alpha/beta (ER alpha/beta); ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; GPR30; GROWTH; HUMAN URINE; Male; mechanism; MECHANISMS; Mouse; OVARIAN-CANCER CELLS; PHYTOESTROGENS; proliferation; RECEPTOR; Reproduction; Sertoli cell; Signal transduction; SPERMATOGENESIS; testis; TM4; TM4 cell; WIDESPREAD EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>81</startpage>
    <endpage>89</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>1</issue>
    <volume>226</volume>
    <abstract>Sertoli cells play a pivotal role in supporting proliferation of germ cells and differentiation during spermatogenesis in mammals. Nanomolar concentrations of Bisphenol A (BPA) can significantly stimulate the proliferation of mouse immature Sertoli (TM4) cells. However, mechanisms by which BPA caused these effects were still unclear. In the present study, an inverse U-shaped curve was observed when treating TM4 cells with increasing doses of BPA: 1 to 10 nM BPA significantly stimulated the proliferation of TM4 cells and increased the proportion of cells in S phase; &gt;1 mu M BPA caused lesser proliferation of cells. Exposure of TM4 cells to G15 or ICI 182,780, which are specific antagonists of GPR30 and estrogen receptor alpha/beta (ER alpha/beta), respectively, abolished BPA-induced proliferation of cells, which suggests that both GPR30 and ER alpha/beta were involved in the observed effects of BPA. Furthermore, exposure to BPA caused rapid (5 min) activation of ERK1/2 via both GPR30 and ER alpha/beta. Blocking the GPR30/EGFR signal transduction pathway by antagonists suppressed both phosphorylation of ERK and BPA-induced cell proliferation. BPA up-regulated mRNA and protein expression of GPR30 in a concentration-dependent manner. In summary, the results reported here indicated that activating ERK1/2 through GPR30 and ER alpha/beta is involved in low doses of BPA that promoted growth of Sertoli TM4 cells. The GPR30/EGFR/ERK signal is the downstream transduction pathway in BPA-induced proliferation of TM4 Sertoli cells. (C) 2014 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000332409000011</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>331</id>
    <title>A New In Vitro Screening Bioassay for the Ecotoxicological Evaluation of the Estrogenic Responses of Environmental Chemicals Using Roach (Rutilus rutilus) Liver Explant Culture</title>
    <authors>Gerbron,M.; Geraudie,P.; Rotchell,J.; Minier,C.</authors>
    <availability>[Gerbron, Marie; Geraudie, Perrine; Minier, Christophe] Univ Havre, Lab Ecotoxicol, UPRES EA 3222, F-76058 Le Havre, France. [Rotchell, Jeanette] Univ Sussex, Sch Life Sci, Dept Biol &amp; Environm Sci, Brighton BN1 9QG, E Sussex, England.</availability>
    <date>2010</date>
    <notes>JEnglishArticle; Proceedings PaperGerbron, M (reprint author), Univ Havre, Lab Ecotoxicol, UPRES EA 3222, BP 540, F-76058 Le Havre, FranceBABLER SJM, 1970, P MAL SOC LOND, V39, P231; Bjorkblom C, 2008, CHEMOSPHERE, V73, P1064, DOI 10.1016/j.chemosphere.2008.07.052; Brion F, 2002, ENVIRON TOXICOL CHEM, V21, P1699, DOI 10.1897/1551-5028(2002)021&lt;1699:DAVOAE&gt;2.0.CO;2; Cameron DA, 2000, EUR J CANCER, V36, P845, DOI 10.1016/S0959-8049(00)00013-7; Couteau J, 2008, MAR ENVIRON RES, V66, P62, DOI 10.1016/j.marenvres.2008.02.023; Dodds EC, 1938, PROC R SOC SER B-BIO, V125, P222, DOI 10.1098/rspb.1938.0023; Geraudie P, 2010, FISH PHYSIOL BIOCHEM, V36, P767, DOI 10.1007/s10695-009-9351-5; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Hurter E, 2002, ECOTOX ENVIRON SAFE, V53, P178, DOI 10.1006/eesa.2002.2252; Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870; JORDAN VC, 1977, J ENDOCRINOL, V75, P305, DOI 10.1677/joe.0.0750305; Jordan VC, 2007, STEROIDS, V72, P829, DOI 10.1016/j.steroids.2007.07.009; Kim BH, 2003, COMP BIOCHEM PHYS B, V135, P231, DOI 10.1016/S1096-4959(03)00089-7; Kime DE, 1999, AQUACULTURE, V177, P345, DOI 10.1016/S0044-8486(99)00097-6; LARSSON R, 1989, ANTICANCER RES, V9, P1111; Maltret-Geraudie P, 2008, CYBIUM, V32, P256; Matthiessen P, 1998, ENVIRON TOXICOL CHEM, V17, P37, DOI 10.1897/1551-5028(1998)017&lt;0037:CAOTEF&gt;2.3.CO;2; Minier C, 2000, ANALUSIS, V28, P801, DOI 10.1051/analusis:2000280801; Navas JM, 2006, AQUAT TOXICOL, V80, P1, DOI 10.1016/j.aquatox.2006.07.013; Nilsen BM, 2004, ANAL BIOANAL CHEM, V378, P621, DOI 10.1007/s00216-003-2241-2; Nimrod AC, 1996, MAR ENVIRON RES, V42, P155, DOI 10.1016/0141-1136(95)00063-1; Okoumassoun LE, 2002, TOXICOLOGY, V178, P193, DOI 10.1016/S0300-483X(02)00228-7; Olsen CA, 2005, COMP BIOCHEM PHYS C, V141, P267, DOI 10.1016/j.cca.2005.07.002; Parks LG, 1999, COMP BIOCHEM PHYS C, V123, P113, DOI 10.1016/S0742-8413(99)00010-9; Pawlowski S, 2000, TOXICOL IN VITRO, V14, P531, DOI 10.1016/S0887-2333(00)00048-5; Peck MR, 2007, CHEMOSPHERE, V69, P1, DOI 10.1016/j.chemosphere.2007.04.082; PELISSERO C, 1993, J STEROID BIOCHEM, V44, P263, DOI 10.1016/0960-0760(93)90086-C; Roubal WT, 1997, COMP BIOCHEM PHYS B, V118, P613, DOI 10.1016/S0305-0491(97)00241-1; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Shilling AD, 2000, TOXICOL APPL PHARM, V164, P330, DOI 10.1006/taap.2000.8912; Smeets JMW, 1999, TOXICOL SCI, V50, P206, DOI 10.1093/toxsci/50.2.206; Smeets JMW, 1999, TOXICOL APPL PHARM, V157, P68, DOI 10.1006/taap.1999.8663; Sole M, 2002, AQUAT TOXICOL, V60, P233, DOI 10.1016/S0166-445X(02)00009-7; SUMPTER JP, 1998, TOXICOL LETT, V95, P17, DOI 10.1016/S0378-4274(98)80067-2; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Taylor MR, 1999, CHEMOSPHERE, V39, P1237, DOI 10.1016/S0045-6535(99)00191-5; Tutundjian R, 2002, MAR ENVIRON RES, V54, P443, DOI 10.1016/S0141-1136(02)00161-7; Tyler Charles R., 2007, Environmental Sciences, V14, P235; Walker C, 1998, ENVIRON HEALTH PERSP, V106, P441, DOI 10.2307/3433793394JOHN WILEY &amp; SONS INCHOBOKEN111 RIVER ST, HOBOKEN, NJ 07030 USAENVIRON TOXICOLOCTSIDiscipline: Environmental Sciences &amp; Ecology; Toxicology; Water Resources648JS</notes>
    <keywords>17-BETA-ESTRADIOL; 4-NONYLPHENOL; ASSAY; BIOASSAY; BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; BUTYLPARABEN; CANCER; CELL; CHEMICALS; CYPRINUS-CARPIO; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disrupting compounds; Endocrine disruption; environment; ENVIRONMENTAL CHEMICALS; environmental pollutants; ENVIRONMENTAL-POLLUTANTS; Estrogenicity; explant culture; FISH; HEALTH; In vitro; IN-VITRO; INDUCTION; Liver; mechanism; MECHANISMS; METABOLITES; MODEL; ONCORHYNCHUS-MYKISS HEPATOCYTES; POLLUTANTS; REPRODUCTIVE-SYSTEM; RESPONSES; RIVER; roach; Rutilus rutilus; screening; SENSITIVITY; Steroid; SYSTEM; TAMOXIFEN; toxicology; VIABILITY; vitellogenin; VITELLOGENIN SYNTHESIS; VITRO; WATER; xenobiotics</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>510</startpage>
    <endpage>516</endpage>
    <journalfull>Environmental Toxicology</journalfull>
    <issue>5</issue>
    <volume>25</volume>
    <abstract>There is growing evidence that many chemicals released in the environment are able to disturb the normal endocrinology of organisms affecting the structure and function of their reproductive system This has prompted the scientific community to develop appropriate testing methods to identify active compounds and elucidate mechanisms of action Of particular interest are in vitro screening methods that can document the effects of these endocrine disrupting compounds on fish. In this study, an in vitro bioassay was developed in the roach (Rutilus rutilus) for evaluating the estrogenicity or antiestrogenicity potency of environmental pollutants by measuring vitellogenin (VTG) induction in cultured liver explants The cell viability was assessed by the measurement of nonspecific esterase activity using a fluorescein diacetate hydrolysis assay Results showed that explants could be cultured for 72 h without any significant loss of activity. Dose-dependent responses have been measured with estrogenic model compounds such as 17-beta-estradiol (E2) and 17-alpha-ethynylestradiol (EE2) or antiestrogenic compounds such as tamoxifen Lowest observable effective concentrations were 1 nM for E2, 1 nM for EE2, and 100 nM for tamoxifen, showing a good sensitivity of the test system Estrogenicity of butyl 4-hydroxybenzoate, 4-nonylphenol, and bisphenol A was tested. bisphenol A (100 mu M) or butylparaben induced a twofold increase in VTG production when compared with 100 nM E2, whereas this production was only 20% with 100 mu M 4-nonylphenol. Overall, this study shows that the bioassay could provide valuable information on endocrine disrupting chemicals including metabolites and mixtures of compounds. (C) 2010 Wiley Periodicals, Inc Environ Toxicol 25 510-516, 2010</abstract>
    <url>WOS:000281690200011</url>
    <isbnorissn>1520-4081</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>184</id>
    <title>Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner</title>
    <authors>Gertz,J.; Reddy,T.E.; Varley,K.E.; Garabedian,M.J.; Myers,R.M.</authors>
    <availability>[Gertz, Jason; Reddy, Timothy E.; Varley, Katherine E.; Myers, Richard M.] HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA. [Garabedian, Michael J.] NYU, Sch Med, Dept Microbiol, Dept Urol, New York, NY 10016 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMyers, RM (reprint author), HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USArmyers@hudsonalpha.orgADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491; Ardies CM, 1998, MED HYPOTHESES, V50, P457, DOI 10.1016/S0306-9877(98)90262-6; Bergeron RM, 1999, MOL CELL ENDOCRINOL, V150, P179, DOI 10.1016/S0303-7207(98)00202-0; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Castro-Rivera E, 1999, MOL CELL ENDOCRINOL, V150, P11, DOI 10.1016/S0303-7207(99)00041-6; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276; Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356; Cheng Y, 2009, GENOME RES, V19, P2172, DOI 10.1101/gr.098921.109; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Crawford NPS, 2007, PLOS GENET, V3, P2296, DOI 10.1371/journal.pgen.0030214; Du MY, 2012, CARCINOGENESIS, V33, P895, DOI 10.1093/carcin/bgs017; Findlay GM, 2007, BIOCHEM J, V403, P13, DOI 10.1042/BJ20061881; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; FONTANA JA, 1992, CANCER RES, V52, P3938; Forster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gertz J, 2012, GENOME RES, V22, P134, DOI 10.1101/gr.127373.111; Grace PB, 2004, CANCER EPIDEM BIOMAR, V13, P698; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Hess-Wilson JK, 2006, BREAST CANCER RES TR, V96, P279, DOI 10.1007/s10549-005-9082-y; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; Hirsch K, 2007, BREAST CANCER RES TR, V104, P221, DOI 10.1007/s10549-006-9405-7; Holder CL, 1999, J AGR FOOD CHEM, V47, P3764, DOI 10.1021/jf9902651; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Jacobson-Dickman E, 2009, CURR OPIN ENDOCRINOL, V16, P25, DOI 10.1097/MED.0b013e328320d560; Jefferson WN, 2007, MOL NUTR FOOD RES, V51, P832, DOI 10.1002/mnfr.200600258; Jeng YJ, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-61; Klein KO, 1999, J PEDIATR, V134, P190, DOI 10.1016/S0022-3476(99)70414-2; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lamouille S, 2009, EMBO J, V28, P3459, DOI 10.1038/emboj.2009.311; Lee S, 2008, J NEUROSCI RES, V86, P2932, DOI 10.1002/jnr.21739; Liu X., 2001, PAC S BIOCOMPUT, V6, P127; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Masuno H, 2005, TOXICOL SCI, V84, P319, DOI 10.1093/toxsci/kfi088; Molzberger A.F., 2011, MOL NUTR FOOD RES, V56, P399; MOORE RJ, 1964, P NATL ACAD SCI USA, V52, P439, DOI 10.1073/pnas.52.2.439; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Niikura H, 1996, HUM PATHOL, V27, P282, DOI 10.1016/S0046-8177(96)90070-2; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Peng LH, 2006, ENDOCRINOLOGY, V147, P4599, DOI 10.1210/en.2006-0560; Reddy TE, 2009, GENOME RES, V19, P2163, DOI 10.1101/gr.097022.109; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Santiago JL, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-54; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Simpson NE, 2012, MOL ENDOCRINOL, V26, P194, DOI 10.1210/me.2011-1068; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Woodruff Teresa K, 2008, Fertil Steril, V89, pe47, DOI 10.1016/j.fertnstert.2007.12.029; Yi C, 2012, ONCOGENE, V31, P4421, DOI 10.1038/onc.2011.629; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r1376011COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPTCOLD SPRING HARBOR1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USAGENOME RESNOVDiscipline: Biochemistry &amp; Molecular Biology; Biotechnology &amp; Applied Microbiology; Genetics &amp; Heredity030QE</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ADULT; ALPHA; BINDING; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; CELLS; CHILDREN; CHIP-SEQ; ENDOCRINE DISRUPTORS; ENDOGENOUS ESTROGENS; ENDOMETRIAL CANCER; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ER-ALPHA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS; ESTROGENS; EXPOSURE; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; GENES; genetics; genistein; HEALTH; IMPACT; LINE; LINE T47D; MAMMARY-GLAND; Plastics; PROSTATE-CANCER; PROTEIN; PROTEIN-KINASES; PROTEINS; RECEPTOR; RECEPTOR-ALPHA; TERMINAL DIFFERENTIATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2153</startpage>
    <endpage>2162</endpage>
    <journalfull>Genome Research</journalfull>
    <issue>11</issue>
    <volume>22</volume>
    <abstract>Endogenous estrogens that are synthesized in the body impact gene regulation by activating estrogen receptors in diverse cell types. Exogenous compounds that have estrogenic properties can also be found circulating in the blood in both children and adults. The genome-wide impact of these environmental estrogens on gene regulation is unclear. To obtain an integrated view of gene regulation in response to environmental and endogenous estrogens on a genome-wide scale, we performed ChIP-seq to identify estrogen receptor 1 (ESR1; previously estrogen receptor alpha) binding sites, and RNA-seq in endometrial cancer cells exposed to bisphenol A (BPA; found in plastics), genistein (GEN; found in soybean), or 17 beta-estradiol (E2; an endogenous estrogen). GEN and BPA treatment induces thousands of ESR1 binding sites and &gt;50 gene expression changes, representing a subset of E2-induced gene regulation changes. Genes affected by E2 were highly enriched for ribosome-associated proteins; however, GEN and BPA failed to regulate most ribosome-associated proteins and instead enriched for transporters of carboxylic acids. Treatment-dependent changes in gene expression were associated with treatment-dependent ESR1 binding sites, with the exception that many genes up-regulated by E2 harbored a BPA-induced ESR1 binding site but failed to show any expression change after BPA treatment. GEN and BPA exhibited a similar relationship to E2 in the breast cancer line T-47D, where cell type specificity played a much larger role than treatment specificity. Overall, both environmental estrogens clearly regulate gene expression through ESR1 on a genome-wide scale, although with lower potency resulting in less ESR1 binding sites and less gene expression changes compared to the endogenous estrogen, E2</abstract>
    <url>WOS:000310584400008</url>
    <isbnorissn>1088-9051</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>403</id>
    <title>Effects of plasticizers and their mixtures on estrogen receptor and thyroid hormone functions</title>
    <authors>Ghisari,M.; Bonefeld-Jorgensen,E.C.</authors>
    <availability>[Ghisari, Mandana; Bonefeld-Jorgensen, Eva Cecilie] Univ Aarhus, Unit Cellular &amp; Mol Toxicol, Ctr Arct Med, Dept Environm &amp; Occupat Med,Inst Publ Hlth, DK-8000 Aarhus C, Denmark.</availability>
    <date>2009</date>
    <notes>JEnglishArticleBonefeld-Jorgensen, EC (reprint author), Univ Aarhus, Unit Cellular &amp; Mol Toxicol, Ctr Arct Med, Dept Environm &amp; Occupat Med,Inst Publ Hlth, Bartholins Alle 2,Build 1260, DK-8000 Aarhus C, Denmarkmg@mil.au.dk; ebj@mil.au.dkAndersen Alan, 2006, Int J Toxicol, V25 Suppl 1, P29; Andersen HR, 2002, TOXICOL APPL PHARM, V179, P1, DOI 10.1006/taap.2001.9347; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; AOYAMA H, 2005, J TOXICOL SCI, V30; Bernal J, 2005, VITAM HORM, V71, P95, DOI 10.1016/S0083-6729(05)71004-9; Birkhoj M, 2004, TOXICOL APPL PHARM, V201, P10, DOI 10.1016/j.taap.2004.04.016; Blount BC, 2000, ENVIRON HEALTH PERSP, V108, P979, DOI 10.1289/ehp.00108979; Boas M, 2006, EUR J ENDOCRINOL, V154, P599, DOI 10.1530/eje.1.02128; Bolz U, 2001, ENVIRON POLLUT, V115, P291, DOI 10.1016/S0269-7491(01)00100-2; Bomhard EM, 2002, CRIT REV TOXICOL, V32, P551, DOI 10.1080/20024091064318; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1; Borch J, 2004, REPROD TOXICOL, V18, P53, DOI 10.1016/j.reprotox.2003.10.011; Breous E, 2005, MOL CELL ENDOCRINOL, V244, P75, DOI 10.1016/j.mce.2005.06.009; Brucker-Davis F, 1998, THYROID, V8, P827, DOI 10.1089/thy.1998.8.827; Chen S, 2008, ITI TREATMENT GUIDE, V3, P29; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Crofton KM, 2005, ENVIRON HEALTH PERSP, V113, P1549, DOI 10.1289/ehp.8195; Dalgaard M, 2003, REPROD TOXICOL, V17, P163, DOI 10.1016/S0890-6238(02)00149-1; DEMIRPENCE E, 1993, J STEROID BIOCHEM, V46, P355, DOI 10.1016/0960-0760(93)90225-L; DIVI RL, 1994, BIOCHEMISTRY-US, V33, P9668, DOI 10.1021/bi00198a036; Ferrara F, 2005, CHEMOSPHERE, V59, P1145, DOI 10.1016/j.chemosphere.2004.11.085; Gauger KJ, 2007, ENVIRON HEALTH PERSP, V115, P1623, DOI 10.1289/ehp.10328; Ghisari M, 2005, MOL CELL ENDOCRINOL, V244, P31, DOI 10.1016/j.mce.2005.01.013; Goulas AE, 2000, J DAIRY SCI, V83, P1712; Gutleb AC, 2005, ENVIRON TOXICOL PHAR, V19, P231, DOI 10.1016/j.etap.2004.06.003; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; Harris RM, 2005, MOL CELL ENDOCRINOL, V244, P72, DOI 10.1016/j.mce.2005.05.013; Hass U, 2007, ENVIRON HEALTH PERSP, V115, P122, DOI 10.1289/ehp.9360; Heudorf U, 2007, INT J HYG ENVIR HEAL, V210, P623, DOI 10.1016/j.ijheh.2007.07.011; HINTON RH, 1986, ENVIRON HEALTH PERSP, V70, P195, DOI 10.2307/3430356; Hohenwarter O, 1996, ANAL BIOCHEM, V234, P56, DOI 10.1006/abio.1996.0049; Hong EJ, 2005, J REPROD DEVELOP, V51, P253, DOI 10.1262/jrd.16075; Howarth JA, 2001, TOXICOL LETT, V121, P35, DOI 10.1016/S0378-4274(01)00313-7; Howdeshell KL, 2007, TOXICOL SCI, V99, P190, DOI 10.1093/toxsci/kfm069; Howdeshell KL, 2002, ENVIRON HEALTH PERSP, V110, P337; Howdeshell KL, 2008, ENVIRON RES, V108, P168, DOI 10.1016/j.envres.2008.08.009; Huang PC, 2007, HUM REPROD, V22, P2715, DOI 10.1093/humrep/dem205; Hurst CH, 2003, TOXICOL SCI, V74, P297, DOI 10.1093/toxsci/kfg145; Ishihara A, 2003, MOL CELL ENDOCRINOL, V199, P105, DOI 10.1016/S0303-7207(02)00302-7; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; Kitamura S, 2002, BIOCHEM BIOPH RES CO, V293, P554, DOI 10.1016/S0006-291X(02)00262-0; Koch HM, 2004, INT J HYG ENVIR HEAL, V207, P15, DOI 10.1078/1438-4639-00270; Korner W, 1998, CHEMOSPHERE, V37, P2395, DOI 10.1016/S0045-6535(98)00297-5; Kortenkamp A, 1998, SCI TOTAL ENVIRON, V221, P59, DOI 10.1016/S0048-9697(98)00261-7; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; Latini G, 2005, CLIN CHIM ACTA, V361, P20, DOI 10.1016/j.cccn.2005.05.003; Loyo-Rosales JE, 2003, ANAL CHEM, V75, P4811, DOI 10.1021/ac0262762; Lynch BS, 2002, REGUL TOXICOL PHARM, V36, P198, DOI 10.1006/rtph.2002.1585; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; Meeker JD, 2007, ENVIRON HEALTH PERSP, V115, P1029, DOI 10.1289/ehp.9852; Metzdorff SB, 2007, TOXICOL SCI, V98, P87, DOI 10.1093/toxsci/kfm079; Mlynarcikova A, 2005, MOL CELL ENDOCRINOL, V244, P57, DOI 10.1016/j.mce.2005.02.009; de Escobar GM, 2004, EUR J ENDOCRINOL, V151, pU25; MORSE DC, 1995, CHEM-BIOL INTERACT, V95, P41, DOI 10.1016/0009-2797(94)03347-1; Mortensen GK, 2005, ANAL BIOANAL CHEM, V382, P1084, DOI 10.1007/s00216-005-3218-0; Nakama A, 2007, FOOD CHEM TOXICOL, V45, P1558, DOI 10.1016/j.fct.2007.02.014; Okubo T, 2003, BIOL PHARM BULL, V26, P1219; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; Payne J, 2000, ENVIRON HEALTH PERSP, V108, P983, DOI 10.1289/ehp.00108983; PONS M, 1990, BIOTECHNIQUES, V9, P450; Poon R, 1997, FOOD CHEM TOXICOL, V35, P225, DOI 10.1016/S0278-6915(96)00064-6; Rajapakse N, 2004, ENVIRON SCI TECHNOL, V38, P6343, DOI 10.1021/es049681e; Rajapakse N, 2001, TOXICOL SCI, V60, P296, DOI 10.1093/toxsci/60.2.296; Rajapakse N, 2002, ENVIRON HEALTH PERSP, V110, P917; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Sabik H, 2003, CHEMOSPHERE, V51, P349, DOI 10.1016/S0045-6535(02)00862-7; Schriks M, 2006, TOXICOL IN VITRO, V20, P490, DOI 10.1016/j.tiv.2005.09.001; Sikka SC, 2008, ASIAN J ANDROL, V10, P134, DOI 10.1111/j.1745-7262.2008.00370.x; Silva MJ, 2005, J ANAL TOXICOL, V29, P819; Silva MJ, 2004, B ENVIRON CONTAM TOX, V72, P1226, DOI 10.1007/s00128-004-0374-4; Sugiyama S, 2005, TOXICOL SCI, V88, P367, DOI 10.1093/toxsci/kfi330; Suzuki T, 2001, J PHARM PHARMACOL, V53, P1549, DOI 10.1211/0022357011777927; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Swan SH, 2008, ENVIRON RES, V108, P177, DOI 10.1016/j.envres.2008.08.007; Tinwell H, 2004, ENVIRON HEALTH PERSP, V112, P575, DOI 10.1289/ehp.6831; Turan N, 2005, MOL CELL ENDOCRINOL, V244, P15, DOI 10.1016/j.mce.2005.01.016; *US EPA, 1997, RER EL DEC RED P CHL; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; van Meeuwen JA, 2007, FOOD CHEM TOXICOL, V45, P2319, DOI 10.1016/j.fct.2007.06.011; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Wade MG, 2002, TOXICOL SCI, V67, P131, DOI 10.1093/toxsci/67.1.131; Wenzel A, 2005, MOL CELL ENDOCRINOL, V244, P63, DOI 10.1016/j.mce.2005.02.008; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; Gray LE, 2006, INT J ANDROL, V29, P96, DOI 10.1111/j.1365-2605.2005.00636.x; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1093/toxsci/46.2.282; Zoeller RT, 2007, THYROID, V17, P811, DOI 10.1089/thy.2007.01078861ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTAUG 25Discipline: Toxicology470UQ</notes>
    <keywords>1; 17 beta-Estradiol; 17-BETA-ESTRADIOL; 2,4-dichlorophenol; 4-tert-octylphenol; BBP; BISPHENOL-A; BRAIN-DEVELOPMENT; BREAST-CANCER CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; Combined effect; DI(2-ETHYLHEXYL) PHTHALATE; DIBUTYL PHTHALATE; DISRUPTING CHEMICALS; ENDOCRINE; ENDOCRINE DISRUPTORS; ENVIRONMENTAL CHEMICALS; ER transactivity; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Estrogenic; ESTROGENIC ACTIVITIES; estrogenic activity; FOOD; HEALTH; Hormone; HUMAN HEALTH; In vitro; IN-VITRO; LUCIFERASE REPORTER; MALE RATS; mixtures; phenol; PHENOLS; phthalate; PHTHALIC-ACID ESTERS; Plasticizers; proliferation; RAT; RECEPTOR; RISK; Risk assessment; RISK-ASSESSMENT; Steroid; SYSTEM; T-screen; TANDEM MASS-SPECTROMETRY; Thyroid; Thyroid hormone; THYROID-HORMONE; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>67</startpage>
    <endpage>77</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>1</issue>
    <volume>189</volume>
    <abstract>Plasticizers are additives used to increase the flexibility or plasticity of the material to which they are added, normally rigid plastic and as additives in paint and adhesives. They are suspected to interfere with the endocrine system, including the estrogen and the thyroid hormone (TH) systems. We investigated in vitro the thyroid hormone-like and estrogenic activities of a range of widely used plasticizers and phenols including benzyl butyl phthalate (BBP), dibutyl phthalate (DBP), dioctyl phthalate (DOP), diisodecyl phthalate (DIDP), diisononyl phthalate (DINP), di(2-ethylhexyl) phthalate (DEHP), bis(2-ethylhexyl) adipate (DEHA), 4-tert-octylphenol (tOP), 4-chloro-3-methylphenol (CMP), 2,4-dichlorophenol (2,4-DCP), 2-phenylphenol (2-PP) and resorcinol. The TH disrupting potential was determined by the effect on the TH-dependent rat pituitary GH3 cell proliferation (T-screen). The estrogenic activities of the compounds were assessed in MVLN cells, stably transfected with an estrogen receptor (ER) luciferase reporter vector. Furthermore, the combined effect of a multi-components mixture of six plasticizers was evaluated for its estrogenic and TH-like activities. All the tested compounds, but 2-PP, significantly affected the GH3 cell proliferation. tOP, BBP and DBP activated ER transactivity, whereas DEHP antagonized the 17 beta-estradiol induced ER function. The mixture significantly induced ER transactivity in an additive manner, whereas in the T-screen, the observed mixture effect was lower than predicted, suggesting a potential antagonizing effect of the mixture. In conclusion, the tested plasticizers and phenols elicited endocrine-disrupting potential that can be mediated via interference with the estrogen and TH systems. Moreover, the observed mixture effect stresses the importance of considering the combined effect of the compounds for risk assessment of human health. (C) 2009 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000268006900011</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>264</id>
    <title>Estrogens and phytoestrogens in male infertility</title>
    <authors>Giwercman,A.</authors>
    <availability>[Giwercman, Aleksander] Lund Univ, Skane Univ Hosp, Reprod Med Ctr, Malmo, Sweden.</availability>
    <date>2011</date>
    <notes>JEnglishReviewGiwercman, A (reprint author), Skane Univ Hosp Malmo, Reprod Med Ctr, Entrance 74, SE-20502 Malmo, Swedenaleksander.giwercman@med.lu.seAcerini CL, 2009, ARCH DIS CHILD, V94, P868, DOI 10.1136/adc.2008.150219; Lutz W, 2006, INT J ANDROL, V29, P105, DOI 10.1111/j.1365-2605.2005.00678.x; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Akre O, 1999, FERTIL STERIL, V71, P1066, DOI 10.1016/S0015-0282(99)00115-6; Axelsson J, 2011, HUM REPROD, V26, P1012, DOI 10.1093/humrep/der045; Bonde JP, 2011, EPIDEMIOLOGY, V22, P617, DOI 10.1097/EDE.0b013e318223442c; CARLSEN E, 1992, BRIT MED J, V305, P609; Cederroth CR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007281; Cederroth CR, 2010, INT J ANDROL, V33, P304, DOI 10.1111/j.1365-2605.2009.01011.x; Chavarro JE, 2008, HUM REPROD, V23, P2584, DOI 10.1093/humrep/den243; Cok I, 2010, ENVIRON MONIT ASSESS, V162, P301, DOI 10.1007/s10661-009-0797-9; Delbes G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231; Eustache F, 2009, ENVIRON HEALTH PERSP, V117, P1272, DOI 10.1289/ehp.0800158; Fisch H, 1996, FERTIL STERIL, V65, P1044; Giwercman A, 2007, PHARMACOGENET GENOM, V17, P391; Goldman LR, 2001, JAMA-J AM MED ASSOC, V286, P2402, DOI 10.1001/jama.286.19.2402; Habito RC, 2000, BRIT J NUTR, V84, P557; Hammoud AO, 2010, HUM REPROD, V25, P3146, DOI 10.1093/humrep/deq255; Hauser R, 2007, HUM REPROD, V22, P688, DOI 10.1093/humrep/del428; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hemminki K, 2002, EUR J CANCER, V38, P2428, DOI 10.1016/S0959-8049(02)00496-3; Iwamoto T, 2006, HUM REPROD, V21, P760, DOI 10.1093/humrep/dei362; Jensen TK, 2001, HUM REPROD, V16, P2697, DOI 10.1093/humrep/16.12.2697; CHILVERS CED, 1992, ARCH DIS CHILD, V67, P892; Jorgensen N, 2011, INT J ANDROL, V34, pE37, DOI 10.1111/j.1365-2605.2010.01133.x; Jorgensen N, 2001, HUM REPROD, V16, P1012, DOI 10.1093/humrep/16.5.1012; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Li DK, 2011, FERTIL STERIL, V95, P625, DOI 10.1016/j.fertnstert.2010.09.026; LI DK, 2011, FERTIL STERIL, V95, pE1; McGlynn KA, 2003, CANCER, V97, P63, DOI 10.1002/cncr.11054; Meeker JD, 2010, ENVIRON SCI TECHNOL, V44, P1458, DOI 10.1021/es9028292; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Mitchell JH, 2001, CLIN SCI, V100, P613, DOI 10.1042/CS20000212; Mocarelli P, 2011, ENVIRON HEALTH PERSP, V119, P713, DOI 10.1289/ehp.1002134; Myrup C, 2008, J NATL CANCER I, V100, P41, DOI 10.1093/jnci/djm276; Nagata C, 2001, CANCER EPIDEM BIOMAR, V10, P179; OLSEN GW, 1995, FERTIL STERIL, V63, P887; Pant N, 2011, HUM EXP TOXICOL, V30, P507, DOI 10.1177/0960327110374205; Rajapakse N, 2001, TOXICOL SCI, V60, P296, DOI 10.1093/toxsci/60.2.296; Rey RA, 2011, BEST PRACT RES CL EN, V25, P221, DOI 10.1016/j.beem.2010.08.013; Richiardi L, 2004, CANCER EPIDEM BIOMAR, V13, P2157; Robertson KM, 2001, J ANDROL, V22, P825; Sacks FM, 2006, ARTERIOSCL THROM VAS, V26, P1689, DOI 10.1161/01.ATV.0000227471.00284.ef; SCHULZE C, 1988, CELL TISSUE RES, V251, P31, DOI 10.1007/BF00215444; SCORER CG, 1964, ARCH DIS CHILD, V39, P605; Scott HM, 2009, ENDOCR REV, V30, P883, DOI 10.1210/er.2009-0016; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Storgaard L, 2006, REPROD TOXICOL, V21, P4, DOI 10.1016/j.reprotox.2005.05.006; Strom BL, 2001, JAMA-J AM MED ASSOC, V286, P807, DOI 10.1001/jama.286.7.807; Swan SH, 1997, ENVIRON HEALTH PERSP, V105, P1228; Swan SH, 2006, INT J ANDROL, V29, P62, DOI 10.1111/j.1365-2605.2005.00620.x; SWERDLOFF RS, 1992, BAILLIERE CLIN ENDOC, V6, P451, DOI 10.1016/S0950-351X(05)80158-2; Tan KAL, 2006, HUM REPROD, V21, P896, DOI 10.1093/humrep/dei421; Toft G, 2006, EPIDEMIOLOGY, V17, P450, DOI 10.1097/01.ede.0000221769.41028.d2; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Vedavanam K, 1999, PHYTOTHER RES, V13, P601, DOI 10.1002/(SICI)1099-1573(199911)13:7&lt;601::AID-PTR550&gt;3.3.CO;2-F599LIPPINCOTT WILLIAMS &amp; WILKINSPHILADELPHIA530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USACURR OPIN UROLNOVDiscipline: Urology &amp; Nephrology832YX</notes>
    <keywords>ASSOCIATION; BISPHENOL-A; CANCER; CANCER INCIDENCE; CELL; CHEMICALS; DNA-DAMAGE; ENDOCRINE; Endocrine disrupter; ENDOCRINE DISRUPTERS; ENDOCRINE DISRUPTORS; Epidemiology; Estrogen; ESTROGENS; EXPOSURE; fertility; HEALTH; Hormones; IMPACT; Interaction; JAPANESE MEN; Male; male fertility; male reproductive function; MALE-INFERTILITY; Phytoestrogen; PHYTOESTROGENS; REGIONAL DIFFERENCES; Reproduction; REPRODUCTIVE FUNCTION; SEMEN QUALITY; SOY-BASED FORMULA; SPERM COUNTS; TISSUE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>519</startpage>
    <endpage>526</endpage>
    <journalfull>Current Opinion in Urology</journalfull>
    <issue>6</issue>
    <volume>21</volume>
    <abstract>Purpose of review A time-related negative trend in male reproductive function has been suggested. It has been hypothesized that this is due to exposure to chemicals interfering with the action of sex hormones. Also a negative effect of phytoestrogens on male fertility has been postulated. This review aimed to review the epidemiological evidence of deteriorating male reproductive function and summarize the most recent literature on exposure to endocrine disrupters and phytoestrogens in relation to male fertility and/or semen quality. Recent findings There is no doubt that the incidence of testicular cancer has increased through the past 50 years, a decline in sperm counts, if any, may have leveled off during the past decade. There are some reports indicating negative association between exposure to certain chemicals and sperm parameters such evidence has not been found for phytoestrogens. The majority of these studies have been limited to assessing postnatal exposure. Summary Although possible negative impact of industrial chemicals and male fertility is an important issue on the research agenda, so far, it has no clinical implications. The future research should focus on looking at the impact of low dose exposure to a mixture of chemicals, two generation studies and gene-environment interaction</abstract>
    <url>WOS:000295848000014</url>
    <isbnorissn>0963-0643</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>261</id>
    <title>Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women</title>
    <authors>Goodson,W.H.; Luciani,M.G.; Sayeed,S.A.; Jaffee,I.M.; Moore,D.H.; Dairkee,S.H.</authors>
    <availability>[Goodson, William H., III; Luciani, Maria Gloria; Sayeed, S. Aejaz; Moore, Dan H., II; Dairkee, Shanaz H.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA. [Goodson, William H., III; Jaffee, Ian M.] Calif Pacific Med Ctr, Dept Surg, San Francisco, CA 94115 USA. [Sayeed, S. Aejaz] Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA. Calif Pacific Med Ctr, Dept Pathol, San Francisco, CA 94115 USA. [Moore, Dan H., II] Univ Calif San Francisco, Dept Epidemiol &amp; Biostat, San Francisco, CA 94115 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleGoodson, WH (reprint author), Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USAgoodsow@cpmcri.org; dairkes@cpmcri.orgAgrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Anderson WF, 2010, J CLIN ONCOL, V28, P232, DOI 10.1200/JCO.2009.23.8162; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Baker JC, 2008, CANCER EPIDEM BIOMAR, V17, P1884, DOI 10.1158/1055-9965.EPI-07-2696; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Bontempo P, 2009, J TRANSL MED, V18, P48; Buchholz TA, 2003, CANCER J, V9, P33, DOI 10.1097/00130404-200301000-00007; Bundred NJ, 2002, ANTICANCER RES, V22, P2317; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.1210452; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2004, J APPL TOXICOL, V24, P5, DOI 10.1002/jat.958; Davis DW, 2003, CLIN CANCER RES, V9, P955; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; de Lima GR, 2003, EUR J CANCER, V39, P891, DOI 10.1016/S0959-8049(02)00530-0; De Vivo I, 2000, J MED GENET, V37, P336, DOI 10.1136/jmg.37.5.336; Dey S, 2009, MED HYPOTHESES, V72, P652, DOI 10.1016/j.mehy.2008.10.025; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Ellis MJ, 2008, J NATL CANCER I, V100, P1380, DOI 10.1093/jnci/djn309; Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4&lt;608::AID-IJC10&gt;3.0.CO;2-7; Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Galbaugh T, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-34; Ginsberg G, 2009, ENVIRON HEALTH PERSP, V117, P1639, DOI 10.1289/ehp.0901010; Goodson W.H, 1997, BREAST CANC RES TREA, V59, P113; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jungheim ES, 2011, JAMA-J AM MED ASSOC, V305, P1354, DOI 10.1001/jama.2011.405; Kallio A, 2005, APOPTOSIS, V10, P1395, DOI 10.1007/s10495-005-2137-z; Kim SH, 2009, INT J CANCER, V124, P2813, DOI 10.1002/ijc.24278; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lewis JB, 2000, IN VITRO CELL DEV-AN, V36, P320; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Macaskill EJ, 2011, BREAST CANCER RES TR, V128, P725, DOI 10.1007/s10549-010-0967-z; Markey CM, 2001, BIOL REPROD, V65, P1215; Masuno H, 2005, TOXICOL SCI, V84, P319, DOI 10.1093/toxsci/kfi088; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Nazarewicz RR, 2007, CANCER RES, V67, P1282, DOI 10.1158/0008-5472.CAN-06-3099; Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Pastor MD, 2009, J BIOL CHEM, V284, P22067, DOI 10.1074/jbc.M109.033100; Perezz-Tenorio G, 2002, BRIT J CANCER, V86, ps40; Poweles T.J, 2007, J NATL CANCER I, V99, P283; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pugazhendhi D, 2007, J APPL TOXICOL, V27, P67, DOI 10.1002/jat.1200; Ramanathan B, 2005, CANCER RES, V65, P8455, DOI 10.1158/0008-5472.CAN-05-1162; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; Shoker BS, 1999, J PATHOL, V188, P237; Statistics Canada, BISPH CONC CAN POP 2; Storz P, 2005, FRONT BIOSCI, V10, P1881, DOI 10.2741/1667; Strimpakos AS, 2009, CANCER TREAT REV, V35, P148, DOI 10.1016/j.ctrv.2008.09.006; Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Ursin G, 2003, CANCER EPIDEM BIOMAR, V12, P332; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Warner M, 2000, J MAMMARY GLAND BIOL, V5, P289, DOI 10.1023/A:1009598828267; Zhang J, 2011, J CHROMATOGR B, V879, P209, DOI 10.1016/j.jchromb.2010.11.031; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-01126711OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDCARCINOGENESISNOVDiscipline: Oncology842VD</notes>
    <keywords>4E-BINDING PROTEIN-1; ACTIVATION; apoptosis; bisphenol A; BISPHENOL-A; BLOOD; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CARCINOGENESIS; CELL; CELLS; CHEMICALS; DISEASE; EPITHELIAL-CELLS; ER-BETA; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; GENE; gene expression; gene expression profile; GENE-EXPRESSION; GENES; GLAND; HEALTH; HORMONE REPLACEMENT THERAPY; HUMANS; In vitro; IN-VITRO; INDUCTION; INHIBITOR; Male; MAMMALIAN TARGET; mammary gland; MAMMARY-GLAND; Methylparaben; Milk; oncology; Oxidative stress; PATHWAY; PLACENTA; PROTEIN; PROTEINS; REDUCTION; REPLACEMENT THERAPY; RESISTANCE; SAMPLES; TAMOXIFEN; TARGET; THERAPY; TISSUE; TUMOR; TUMOR PROGRESSION; Validation; VITRO; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1724</startpage>
    <endpage>1733</endpage>
    <journalfull>Carcinogenesis</journalfull>
    <issue>11</issue>
    <volume>32</volume>
    <abstract>Breast cancer is an estrogen-driven disease. Consequently, hormone replacement therapy correlates with disease incidence. However, increasing male breast cancer rates over the past three decades implicate additional sources of estrogenic exposure including wide spread estrogen-mimicking chemicals or xenoestrogens (XEs), such as bisphenol-A (BPA). By exposing renewable, human, high-risk donor breast epithelial cells (HRBECs) to BPA at concentrations that are detectable in human blood, placenta and milk, we previously identified gene expression profile changes associated with activation of mammalian target of rapamycin (mTOR) pathway genesets likely to trigger prosurvival changes in human breast cells. We now provide functional validation of mTOR activation using pairwise comparisons of 16 independent HRBEC samples with and without BPA exposure. We demonstrate induction of key genes and proteins in the PI3K-mTOR pathway-AKT1, RPS6 and 4EBP1 and a concurrent reduction in the tumor suppressor, phosphatase and tensin homolog gene protein. Altered regulation of mTOR pathway proteins in BPA-treated HRBECs led to marked resistance to rapamycin, the defining mTOR inhibitor. Moreover, HRBECs pretreated with BPA, or the XE, methylparaben (MP), surmounted antiestrogenic effects of tamoxifen showing dose-dependent apoptosis evasion and induction of cell cycling. Overall, XEs, when tested in benign breast cells from multiple human subjects, consistently initiated specific functional changes of the kind that are attributed to malignant onset in breast tissue. Our observations demonstrate the feasibility of studying renewable human samples as surrogates and reinforce the concern that BPA and MP, at low concentrations detected in humans, can have adverse health consequences</abstract>
    <url>WOS:000296628400020</url>
    <isbnorissn>0143-3334</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>442</id>
    <title>State of the Evidence The Connection Between Breast Cancer and the Environment</title>
    <authors>Gray,J.; Evans,N.; Taylor,B.; Rizzo,J.; Walker,M.</authors>
    <availability>[Gray, Janet] Vassar Coll, Dept Psychol, Poughkeepsie, NY 12604 USA. [Gray, Janet] Vassar Coll, Program Sci Technol &amp; Soc, Poughkeepsie, NY 12604 USA. [Evans, Nancy; Taylor, Brynn; Rizzo, Jeanne; Walker, Marisa] Breast Canc Fund, San Francisco, CA USA.</availability>
    <date>2009</date>
    <notes>JEnglishReviewGray, J (reprint author), Vassar Coll, Dept Psychol, 124 Raymond Ave, Poughkeepsie, NY 12604 USAgrayj@vassar.eduAcevedo R, 2005, J APPL TOXICOL, V25, P339, DOI 10.1002/jat.1078; Adam B, 2005, MUTAT RES-GEN TOX EN, V585, P120, DOI 10.1016/j.mrgentox.2005.04.009; Adlercreutz H, 2002, J STEROID BIOCHEM, V83, P113, DOI 10.1016/S0960-0760(02)00273-X; *AG TOX SUBST DIS, 2004, FACT SHEET; Alexander BH, 2007, ENVIRON HEALTH PERSP, V115, P370, DOI 10.1289/ehp.8869; Allen NE, 2005, BRIT J CANCER, V92, P1283, DOI 10.1038/sj.bjc.6602471; Althuis MD, 2005, INT J EPIDEMIOL, V34, P405, DOI 10.1093/ije/dyh414; Althuis MD, 2003, CANCER CAUSE CONTROL, V14, P151, DOI 10.1023/A:1023006000760; American Cancer Society, 2007, CANC FACTS FIG 2007; Andersen HR, 2002, TOXICOL APPL PHARM, V179, P1, DOI 10.1006/taap.2001.9347; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701; Anderson HA, 2000, J EXPO ANAL ENV EPID, V10, P755; Andersson PL, 1999, ARCH ENVIRON CON TOX, V37, P145; Andreeva Valentina A, 2007, J Immigr Minor Health, V9, P307, DOI 10.1007/s10903-007-9037-y; Andrieu N, 2006, J CLIN ONCOL, V24, P3361, DOI 10.1200/JCO.2005.03.3126; Arnold SF, 1996, SCIENCE, V272, P1489, DOI 10.1126/science.272.5267.1489; Aronson KJ, 2000, CANCER EPIDEM BIOMAR, V9, P55; *ATSDR, 1999, TOX PROF ETH OX; *ATSDR, 1997, CAS75014 ATSDR; ATSDR, 1998, TOX PROF CHLOR DIB P; Baer HJ, 2003, CANCER EPIDEM BIOMAR, V12, P1159; BAILAR JC, 1976, ANN INTERN MED, V84, P77; Baker SG, 2005, BIOMETRICS, V61, P55, DOI 10.1111/j.0006-341X.2005.030924.x; Ballard T, 2000, AVIAT SPACE ENVIR MD, V71, P216; BAND PR, 2002, LANCET, V360, P1033; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Beard J, 2006, SCI TOTAL ENVIRON, V355, P78, DOI 10.1016/j.scitotenv.2005.02.022; BELLI S, 1992, SCAND J WORK ENV HEA, V18, P64; Bennett LM, 2002, ENVIRON MOL MUTAGEN, V39, P150, DOI 10.1002/em.10068; Bhatia S, 2003, J CLIN ONCOL, V21, P4386, DOI 10.1200/JCO.2003.11.059; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; BIBBO M, 1977, OBSTET GYNECOL, V49, P1; *BIOLN WORK GROUP, 2007, BIOLN REP; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Blask DE, 1997, CANCER RES, V57, P1909; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; BOFFETTA P, 1994, CA-CANCER J CLIN, V44, P81, DOI 10.3322/canjclin.44.2.81; Boice JD, 2001, MED PEDIATR ONCOL, V36, P508, DOI 10.1002/mpo.1122; Bonner MR, 2005, CANCER EPIDEM BIOMAR, V14, P53; Borch J, 2006, TOXICOLOGY, V223, P144, DOI 10.1016/j.tox.2006.03.015; Borgquist S, 2007, INT J CANCER, V120, P2202, DOI 10.1002/ijc.22542; BOWEN RL, 2006, PHARMACOGENOMICS, V7; Braathen M, 2009, ARCH ENVIRON CON TOX, V56, P111, DOI 10.1007/s00244-008-9163-0; Brama M, 2007, MOL CELL ENDOCRINOL, V264, P102, DOI 10.1016/j.mce.2006.10.013; Brand RM, 2007, FOOD CHEM TOXICOL, V45, P93, DOI 10.1016/j.fct.2006.08.005; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Brinton LA, 1998, MENOPAUSE, V5, P145; BRODY JG, 1998, APPL RES PUBLIC POL, V13, P24; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; BURRIDGE E, 2004, EUR CHEM NEWS, V81, P17; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; *CA ENV PROT AG AI, PROP ID ENV TOB SM B; *CA ENV PROT AG AI, 2005, PROP ID ENV TOB SMOK; Calabrese EJ, 2004, TOXICOL APPL PHARM, V197, P125, DOI 10.1016/j.taap.2004.02.007; Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; CALLE EE, 1994, AM J EPIDEMIOL, V139, P1001; CANTOR KP, 1995, J OCCUP ENVIRON MED, V37, P336, DOI 10.1097/00043764-199503000-00011; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Carpenter DO, 1998, ENVIRON HEALTH PERSP, V106, P1263; Cassidy RA, 2005, BREAST CANCER RES TR, V90, P55, DOI 10.1007/s10549-004-2755-0; Stewart S. L., 2007, Morbidity and Mortality Weekly Report, V56, P549; CDC, 2005, 3 NAT REP HUM EXP EN; Chang YM, 2003, IND HEALTH, V41, P77, DOI 10.2486/indhealth.41.77; Charlier CJ, 2004, CLIN CHIM ACTA, V347, P177, DOI 10.1016/j.cccn.2004.04.025; Chen YC, 2006, BIO-MED MATER ENG, V16, P67; CHIAZZE L, 1981, ENVIRON HEALTH PERSP, V41, P137, DOI 10.2307/3429307; Choi AL, 2006, ENVIRON HEALTH PERSP, V114, P1092, DOI 10.1289/ehp.8827; Ciftci K, 2003, J PHARM PHARMACOL, V55, P1135, DOI 10.1211/0022357021558; Clemons M, 2000, CANCER TREAT REV, V26, P291, DOI 10.1053/ctrv.2000.0174; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Colditz GA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1736; Beral V, 1997, LANCET, V350, P1047; Calle EE, 1996, LANCET, V347, P1713; COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096; *COMM EUR COMM, 2004, COMM STAFF WORK DOC; Connor K, 1997, TOXICOL APPL PHARM, V145, P111, DOI 10.1006/taap.1997.8169; Constantinou AI, 2005, EUR J CANCER, V41, P647, DOI 10.1016/j.ejca.2004.12.005; Coogan PF, 1996, EPIDEMIOLOGY, V7, P459, DOI 10.1097/00001648-199609000-00001; Cooper RL, 2000, TOXICOL SCI, V53, P297, DOI 10.1093/toxsci/53.2.297; Cox DG, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1602; CUTLER SJ, 1969, CANCER, V23, P767, DOI 10.1002/1097-0142(196904)23:4&lt;767::AID-CNCR2820230404&gt;3.0.CO;2-V; Czene K, 2002, INT J CANCER, V99, P260, DOI 10.1002/ijc.10332; DAEWOOD S, 2007, ONCOLOGY, V21, P673; Darbre PD, 2004, J APPL TOXICOL, V24, P5, DOI 10.1002/jat.958; DAVIS DL, 1993, ENV HLTH PERSP, V101, P371; DAVIS S, 2006, CHEM IND NEWSLET SEP; Davis S, 2001, J NATL CANCER I, V93, P1557; Daxenberger A, 1998, ANALYST, V123, P2429, DOI 10.1039/a804923h; Deapen D, 2002, INT J CANCER, V99, P747, DOI 10.1002/ijc.10415; DeBruin LS, 2002, ENVIRON HEALTH PERSP, V110, P119; DeBruin LS, 1999, CHEM RES TOXICOL, V12, P78, DOI 10.1021/tx980168m; Decastro BR, 2006, ENVIRON SCI TECHNOL, V40, P2819, DOI 10.1021/es051667u; Deligeoroglou E, 2003, ANN NY ACAD SCI, V997, P199, DOI 10.1196/annals.1290.023; Delort L, 2007, ANTICANCER RES, V27, P1087; De los Santos J F, 2000, Curr Treat Options Oncol, V1, P221; Dich J, 1997, CANCER CAUSE CONTROL, V8, P420, DOI 10.1023/A:1018413522959; Donovan M, 2007, MED HYPOTHESES, V68, P756, DOI 10.1016/j.mehy.2006.09.039; DOSEMECI M, 1994, J OCCUP ENVIRON MED, V36, P1204, DOI 10.1097/00043764-199411000-00006; DUNNICK JK, 1995, CARCINOGENESIS, V16, P173, DOI 10.1093/carcin/16.2.173; DURANDO M, 2007, ENV HLTH PERSP, V115, P592; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; EATON ML, ETHICS BUSINESS BIOS, P70; El-Gamal H, 2006, J AM ACAD DERMATOL, V55, P981, DOI 10.1016/j.jaad.2005.10.005; Ely B, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-34; Engel LS, 2005, AM J EPIDEMIOL, V161, P121, DOI 10.1093/aje/kwi022; ENOCH RR, 2007, ENV HLTH PERSP, V115, P5541; *ENV PROT AG OFF P, 2007, OV OFF POLL PREV TOX; *ENV WORK GROUP, 2005, BOD BURD, V2; *EPA, 2005, UND RAD GAMM RAYS; Erickson BE, 2008, CHEM ENG NEWS, V86, P60, DOI 10.1021/cen-v086n038.p060; Erren T C, 2001, Bioelectromagnetics, VSuppl 5, pS105; Fan WQ, 2007, ENVIRON HEALTH PERSP, V115, P720, DOI 10.1289/ehp.9758; Fang H, 2003, CHEM RES TOXICOL, V16, P1338, DOI 10.1021/tx030011g; Fedrowitz M, 2004, CANCER RES, V64, P243, DOI 10.1158/0008-5472.CAN-03-2808; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Feychting M, 1998, EPIDEMIOLOGY, V9, P392, DOI 10.1097/00001648-199807000-00008; Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x; Foster WG, 2004, TOXICOL SCI, V77, P91, DOI 10.1093/toxsci/kfg247; Frazier AL, 2003, BREAST CANCER RES, V5, pR59, DOI 10.1186/bcr583; Furstenberger G, 2003, ONKOLOGIE, V26, P290, DOI 10.1159/000071627; Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677; Gierthy JF, 1997, CHEMOSPHERE, V34, P1495, DOI 10.1016/S0045-6535(97)00446-3; Glass AG, 2007, J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Gofman J., 1996, PREVENTING BREAST CA; GOFMAN JW, 1999, RAD MED PROCEDURES P; Goldberg Z, 2002, INT J ONCOL, V21, P337; Gooderham NJ, 2007, TOXICOL LETT, V168, P269, DOI 10.1016/j.toxlet.2006.10.022; Grabrick Dawn M., 2000, JAMA (Journal of the American Medical Association), V284, P1791, DOI 10.1001/jama.284.14.1791; Gram IT, 2005, CANCER EPIDEM BIOMAR, V14, P61; Guibout C, 2005, J CLIN ONCOL, V23, P197, DOI 10.1200/JCO.2005.06.225; GUISTI RM, 1995, ANN INTERN MED, V122, P778; Hagmar L, 2006, CHEMOSPHERE, V64, P1507, DOI 10.1016/j.chemosphere.2005.12.054; Haile RW, 2006, CANCER EPIDEM BIOMAR, V15, P1863, DOI 10.1158/1055-9965.EPI-06-0258; HAMAOKA T, 2005, INT J CANCER, V114, P317; Hance KW, 2005, J NATL CANCER I, V97, P966, DOI 10.1093/dji172; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hankinson SE, 2004, BREAST CANCER RES, V6, P213, DOI 10.1186/bcr921; HANRAHAN C, 2007, RS20142 CRS; Hansen J, 2000, AM J IND MED, V37, P349, DOI 10.1002/(SICI)1097-0274(200004)37:4&lt;349::AID-AJIM4&gt;3.3.CO;2-C; Hansen J, 1999, AM J IND MED, V36, P43; Hatakeyama M, 1999, J BIOCHEM MOL TOXIC, V13, P296, DOI 10.1002/(SICI)1099-0461(1999)13:6&lt;296::AID-JBT2&gt;3.0.CO;2-S; Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20; HAYDEN CG, 1997, LANCET, V350, P853; Hayes T, 2003, ENVIRON HEALTH PERSP, V111, P568, DOI 10.1289/ehp.5932; Hemminki K, 2002, INT J CANCER, V99, P229, DOI 10.1002/ijc.10323; Heneweer M, 2005, TOXICOL APPL PHARM, V208, P170, DOI 10.1016/j.taap.2005.02.006; HENSEN J, 2001, EPIDEMIOLOGY, V12, P74; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4&lt;745::AID-CNCR2820250402&gt;3.0.CO;2-2; Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; Holly J, 1998, LANCET, V351, P1373, DOI 10.1016/S0140-6736(05)79438-1; Holmberg L, 2004, LANCET, V363, P453, DOI 10.1016/S0140-6736(04)15493-7; Honma N, 2006, J CLIN ENDOCR METAB, V91, P607, DOI 10.1210/jc.2005-1967; Horwich A, 2004, BRIT J CANCER, V90, P294, DOI 10.1038/sj.bjc.6601499; Houle CD, 2006, TOXICOL PATHOL, V34, P752, DOI 10.1080/01926230600935912; Howe GR, 1996, RADIAT RES, V145, P694, DOI 10.2307/3579360; Hoyer AP, 2000, J CLIN EPIDEMIOL, V53, P323, DOI 10.1016/S0895-4356(99)00165-1; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; Hua WY, 2006, ENVIRON TOXICOL CHEM, V25, P2356, DOI 10.1897/05-571R.1; HUANG J, 2001, CANCER, V92, P532; Huda W, 2008, MED PHYS, V35, P5713, DOI 10.1118/1.3013604; HUFF JE, 1989, ENVIRON HEALTH PERSP, V82, P125, DOI 10.2307/3430769; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; *IARC, 1987, IARC SUMM EV S, V7; *IARC, 1987, IARC MON EV CARC R S, V7, P120; IARC International Agency for Research on Cancer, 1997, IARC MON EV CARC RIS, V69; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Imaoka T, 2005, INT J CANCER, V115, P187, DOI 10.1002/ijc.20904; INFANTE PF, 1994, J OCCUP ENVIRON MED, V36, P826; *INT AG RES CANC, 1987, IARC S, V7, P280; International Agency for Research on Cancer, 2002, IARC MON EV CARC RIS; International agency for research on cancer, 1999, IARC MON EV CARC RIS, V72; Ionescu JG, 2006, NEUROENDOCRINOL LETT, V27, P36; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; Jaga K, 2001, J R SOC PROMO HEALTH, V121, P107, DOI 10.1177/146642400112100212; Jatoi I, 2005, J CLIN ONCOL, V23, P7836, DOI 10.1200/JCO.2004.01.0421; Jemal A, 2006, CA-CANCER J CLIN, V56, P106; Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004; Jernstrom H, 2001, MOL GENET METAB, V72, P144, DOI 10.1006/mgme.2000.3130; Jiang JT, 2007, TOXICOLOGY, V232, P286, DOI 10.1016/j.tox.2007.01.018; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; JOLM EM, 2005, CANCER EPIDEM BIOMAR, V14, P2905; Jones BA, 2004, CANCER, V101, P1293, DOI 10.1002/cncr.20500; Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1995, DOI 10.1080/15287390491008913; Kato K, 2004, ENVIRON HEALTH PERSP, V112, P327, DOI 10.1289/ehp.6663; Kemp MQ, 2006, ENVIRON MOL MUTAGEN, V47, P518, DOI 10.1002/em.20221; Kettles MA, 1997, ENVIRON HEALTH PERSP, V105, P1222; Khanjani N, 2006, ARCH ENVIRON CON TOX, V50, P452, DOI 10.1007/s00244-004-7217-5; Kilthau G F, 1996, Radiol Technol, V67, P217; Kim IY, 2004, J TOXICOL ENV HEAL A, V67, P2025, DOI 10.1080/15287390490514750; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kliukiene J, 2003, EUR J CANCER PREV, V12, P301, DOI 10.1097/01.cej.0000082602.47188.da; Kliukiene J, 2004, AM J EPIDEMIOL, V159, P852, DOI 10.1093/aje/kwh116; Koppe JG, 2006, ACTA PAEDIATR, V95, P106, DOI 10.1080/08035320600886646; Kortenkamp A, 2006, INT J ANDROL, V29, P193, DOI 10.1111/j.1365-2605.2005.00613.x; Krieger N, 2005, J EPIDEMIOL COMMUN H, V59, P740, DOI 10.1136/jech.2005.033316; Kroiss R, 2005, HUM MUTAT, V26, P583, DOI 10.1002/humu.20261; Kruk J, 2006, CURR CANC THER REV, V2, P3, DOI 10.2174/157339406775471795; Kulkarni PS, 2008, ENVIRON INT, V34, P139, DOI 10.1016/j.envint.2007.07.009; Kumle M, 2002, CANCER EPIDEM BIOMAR, V11, P1375; Labreche FP, 1997, AM J IND MED, V32, P1; Laden F, 2001, J NATL CANCER I, V93, P768, DOI 10.1093/jnci/93.10.768; Laden F, 2002, CANCER EPIDEM BIOMAR, V11, P1560; Lagerros YT, 2004, EUR J CANCER PREV, V13, P5, DOI 10.1097/01.cej.0000091299.79893.32; Land CE, 1997, PROG CLIN BIOL RES, V396, P115; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Latini G, 2006, TOXICOLOGY, V226, P90, DOI 10.1016/j.tox.2006.07.011; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; Lee PN, 2006, INHAL TOXICOL, V18, P1053, DOI 10.1080/08958370600945432; Leffers H, 2001, HUM REPROD, V16, P1037, DOI 10.1093/humrep/16.5.1037; LEWIS BC, 2001, TOXICOL SCI, V62, P63; Li R, 2002, CANCER, V95, P960, DOI 10.1002/cncr.10791; Li SF, 2003, ANN NY ACAD SCI, V983, P161; Li ST, 2002, ARCH PEDIAT ADOL MED, V156, P85; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Little JB, 2003, J RADIOL PROT, V23, P173, DOI 10.1088/0952-4746/23/2/304; Liu B, 2005, CANCER RES, V65, P879; Liu Suling, 2004, Breast J, V10, P514, DOI 10.1111/j.1075-122X.2004.21410.x; Liu SL, 2002, BREAST CANCER RES TR, V71, P21, DOI 10.1023/A:1013343718942; LOOMIS DP, 1992, LANCET, V339, P1482, DOI 10.1016/0140-6736(92)92078-T; LOVE S, 2005, SUSAN LOVES BREAST B, P260; Lovekamp-Swan T, 2003, ENVIRON HEALTH PERSP, V111, P139; Lund E, 2007, INT J CANCER, V121, P645, DOI 10.1002/ijc.22699; Lundell M, 1999, RADIAT RES, V151, P626, DOI 10.2307/3580039; Lux MP, 2006, J MOL MED, V84, P16, DOI 10.1007/s00109-005-0696-7; Ma HY, 2008, BREAST CANCER RES TR, V109, P77, DOI 10.1007/s10549-007-9625-5; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MACKENZIE I, BRIT J CANC, V19, P1; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; MANZ A, 1991, LANCET, V338, P959, DOI 10.1016/0140-6736(91)91835-I; Marcus PM, 2000, CANCER CAUSE CONTROL, V11, P271, DOI 10.1023/A:1008911902994; Swanson G. Marie, 2003, Cancer, V97, P273; Markey CM, 2001, BIOL REPROD, V65, P1215; Martin MB, 2003, ENDOCRINOLOGY, V144, P2425, DOI 10.1210/en.2002-221054; Maskarinec G, 2006, BREAST CANCER RES TR, V98, P45, DOI 10.1007/s10549-005-9129-0; Massart Francesco, 2005, J Perinatol, V25, P282, DOI 10.1038/sj.jp.7211251; MATANOSKI GM, 1991, LANCET, V337, P737, DOI 10.1016/0140-6736(91)90325-J; Matsumoto H, 2005, ARCH ENVIRON CON TOX, V48, P459, DOI 10.1007/s00244-003-0243-x; MATTSSON A, 1995, BRIT J CANCER, V72, P1054, DOI 10.1038/bjc.1995.461; McElroy JA, 2007, J OCCUP ENVIRON MED, V49, P266, DOI 10.1097/JOM.0013e318032259b; MCELVENNEY DM, 2001, CANC CURRENT FORMER; McKelvey W, 2004, ANN EPIDEMIOL, V14, P89, DOI 10.1016/S1047-2797(03)00120-0; Mellemkjaer L, 2006, INT J CANCER, V118, P2285, DOI 10.1002/ijc.21651; Melnick RL, 1999, CARCINOGENESIS, V20, P867, DOI 10.1093/carcin/20.5.867; Michels KB, 2007, CANCER, V109, P2712, DOI 10.1002/cncr.22654; Milham S, 2004, AM J IND MED, V46, P86, DOI 10.1002/ajim.20027; Miller SM, 2000, ENVIRON SCI TECHNOL, V34, P55, DOI 10.1021/es990486n; Millikan R, 2000, CANCER EPIDEM BIOMAR, V9, P1233; Banks E, 2003, LANCET, V362, P419; Mills PK, 2005, INT J OCCUP ENV HEAL, V11, P123; Mokbel K, 2006, LANCET ONCOL, V7, P756, DOI 10.1016/S1470-2045(06)70861-0; Monninkhof EM, 2007, EPIDEMIOLOGY, V18, P137, DOI 10.1097/01.ede.0000251167.75581.98; Moon HJ, 2007, J REPROD DEVELOP, V53, P333, DOI 10.1262/jrd.18055; Morabia A, 1996, AM J EPIDEMIOL, V143, P918; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; MORIMDOODY M, 2006, CANCER, V106, P2707; MORINDOODY M, 2000, SPINE, V25, P2052, DOI 10.1097/00007632-200008150-00009; MORRIS JJ, 1992, MED HYPOTHESES, V38, P177, DOI 10.1016/0306-9877(92)90090-Y; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murata M, 2004, BIOCHEMISTRY-US, V43, P2569, DOI 10.1021/bi035613d; Murray D, 2007, CANCER BIOTHER RADIO, V22, P1, DOI 10.1089/cbr.2006.531; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Murrill WB, 1996, CARCINOGENESIS, V17, P1451, DOI 10.1093/carcin/17.7.1451; Muscat JE, 2003, CANCER EPIDEM BIOMAR, V12, P1474; Nabholtz JM, 2008, EJSO-EUR J SURG ONC, V34, P1199, DOI 10.1016/j.ejso.2008.02.005; Narod SA, 2002, J NATL CANCER I, V94, P1773; *NAT CANC I, 2002, RAD RISK PED COMP TO; *NAT RAD PROT BOAR, 1995, DOC NRPB, V6, P25; *NAT RES COUNC, 1999, HORM ACT AG ENV, P119; *NAT TOX PROGR, 2003, CHEM ASS SIT SPEC UM; *NAT TOX PROGR, 2005, 11 NAT I ENV HLTH SC; *NAT TOX PROGR, 2002, 10 NAT I ENV HLTH SC; National Center for Health Statistics, 2006, CHARTB TRENDS HLTH A; National Research Council, 2005, BIOL EFF ION RAD; Newcomer LM, 2003, INT J CANCER, V106, P961, DOI 10.1002/ijc.11307; Newman LA, 2005, ONCOLOGIST, V10, P1, DOI 10.1634/theoncologist.10-1-1; Nickerson K, 2006, J MIDWIFERY WOM HEAL, V51, P26, DOI 10.1016/j.jmwh.2005.09.006; Nie K, 2003, J CELL BIOCHEM, V90, P1197, DOI 10.1002/jcb.10704; NIEHS working Group, 1998, ASS HLTH EFF EXP POW; *NTP, 1993, NIH PUB; NUDELMAN J, 2008, INT J OCCUP ENV HLTH; O'Connor JC, 2000, DRUG CHEM TOXICOL, V23, P575, DOI 10.1081/DCT-100101972; Olivier M, 2001, SEMIN CANCER BIOL, V11, P353, DOI 10.1006/scbi.2001.0390; Outwater JL, 1997, MED HYPOTHESES, V48, P453, DOI 10.1016/S0306-9877(97)90110-9; Palli D, 2004, EUR J CANCER, V40, P2474, DOI 10.1016/j.ejca.2004.07.012; Palmer JR, 2003, J NATL CANCER I, V95, P478; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Paltoo DN, 2004, PUBLIC HEALTH REP, V119, P443, DOI 10.1016/j.phr.2004.05.009; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Parkin DM, 2006, BREAST J, V12, pS70, DOI 10.1111/j.1075-122X.2006.00205.x; Payne J, 2000, ENVIRON HEALTH PERSP, V108, P983, DOI 10.1289/ehp.00108983; Peplonska B, 2007, AM J IND MED, V50, P97, DOI 10.1002/ajim.20420; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petralia SA, 1998, AM J IND MED, V34, P477, DOI 10.1002/(SICI)1097-0274(199811)34:5&lt;477::AID-AJIM8&gt;3.0.CO;2-N; Petralia SA, 1999, SCAND J WORK ENV HEA, V25, P215; Pliskova M, 2005, TOXICOL SCI, V83, P246, DOI 10.1093/toxsci/kfi040; Preston DL, 2002, RADIAT RES, V158, P220, DOI 10.1667/0033-7587(2002)158[0220:REOBCR]2.0.CO;2; PUJOL P, 1994, CANCER, V74, P1601, DOI 10.1002/1097-0142(19940901)74:5&lt;1601::AID-CNCR2820740517&gt;3.0.CO;2-#; Pukkala E, 2006, INT J CANCER, V119, P651, DOI 10.1002/ijc.21885; Rajapakse N, 2001, TOXICOL SCI, V60, P296, DOI 10.1093/toxsci/60.2.296; Rajapakse N, 2002, ENVIRON HEALTH PERSP, V110, P917; Ralston SL, 1997, CHEM RES TOXICOL, V10, P687, DOI 10.1021/tx9700275; Ramamoorthy K, 1997, SCIENCE, V275, P405, DOI 10.1126/science.275.5298.405; RASTOGI SC, 1995, CONTACT DERMATITIS, V32, P28, DOI 10.1111/j.1600-0536.1995.tb00836.x; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Rayner JL, 2005, TOXICOL SCI, V87, P255, DOI 10.1093/toxsci/kfi213; Reeves GK, 2006, LANCET ONCOL, V7, P910, DOI 10.1016/S1470-2045(06)70911-1; Rennix CP, 2005, AM J IND MED, V48, P157, DOI 10.1002/ajim.20201; RESNICOFF M, 1995, CANCER RES, V55, P2463; Reynolds P, 2004, J NATL CANCER I, V96, P29, DOI 10.1093/jnci.djh002; Rice S, 2006, ENDOCR-RELAT CANCER, V13, P995, DOI 10.1677/erc.1.01159; Ries LAG HD, 2006, SEER CANC STAT REV 1; Rivas A, 2002, J STEROID BIOCHEM, V82, P45, DOI 10.1016/S0960-0760(02)00146-2; Robbins AS, 2007, J CLIN ONCOL, V25, P3437, DOI 10.1200/JCO.2007.11.4132; ROBINSON PE, 1990, ENVIRON RES, V53, P175, DOI 10.1016/S0013-9351(05)80118-5; ROBISON AK, 1985, TOXICOL LETT, V27, P109, DOI 10.1016/0378-4274(85)90127-4; Rodriguez-Mozaz S, 2005, WATER RES, V39, P5071, DOI 10.1016/j.watres.2005.09.023; ROGAN WJ, 1996, ARCH PEDIAT ADOL MED, V150, P81; Ron E, 2005, J NATL CANCER I, V97, P603, DOI 10.1093/jnci/dji097; Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321; Roychoudhuri R, 2004, BRIT J CANCER, V91, P868, DOI 10.1038/sj.bjc.6602084; Rudel RA, 2007, CANCER, V109, P2635, DOI 10.1002/cncr.22653; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Rudel RA, 2001, J AIR WASTE MANAGE, V51, P499; Rudel RA, 1998, ENVIRON SCI TECHNOL, V32, P861, DOI 10.1021/es970723r; Rundle A, 2000, CARCINOGENESIS, V21, P1281, DOI 10.1093/carcin/21.7.1281; RUSSO J, 2004, MOL BASIS BREAST CAN, P89; Russo J, 2001, MICROSC RES TECHNIQ, V52, P204, DOI 10.1002/1097-0029(20010115)52:2&lt;204::AID-JEMT1006&gt;3.0.CO;2-F; Salehi F, 2008, J TOXICOL ENV HEAL B, V11, P276, DOI 10.1080/10937400701875923; Sanchez-Barcelo EJ, 2005, J PINEAL RES, V38, P217, DOI 10.1111/j.1600-079X.2004.00207.x; Sanderson JT, 2001, ENVIRON HEALTH PERSP, V109, P1027, DOI 10.2307/3454957; Santodonato J, 1997, CHEMOSPHERE, V34, P835, DOI 10.1016/S0045-6535(97)00012-X; Sasco AJ, 2001, APMIS, V109, P321, DOI 10.1034/j.1600-0463.2001.090501.x; Schecter A, 2006, ENVIRON RES, V101, P419, DOI 10.1016/j.envres.2005.12.003; Schernhammer ES, 2005, J NATL CANCER I, V97, P1084, DOI 10.1093/jnci/dji190; Schernhammer ES, 2001, J NATL CANCER I, V93, P1563; Schernhammer ES, 2005, CANCER EPIDEM BIOMAR, V14, P699, DOI 10.1158/1055-9965.EPI-04-0561; Schernhammer ES, 2008, J NATL CANCER I, V100, P898, DOI 10.1093/jnci/djn171; Schlumpf Margret, 2001, Environmental Health Perspectives, V109, P239, DOI 10.2307/3434691; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; SCHUETZ F, 2007, J OBSTET GYNECOLOGY, V196, pE1; SCRIBNER JD, 1981, CARCINOGENESIS, V2, P1235, DOI 10.1093/carcin/2.12.1235; SEGALOFF A, 1974, CANCER RES, V38, P3445; SEGALOFF A, 1971, CANCER RES, V31, P166; Shaham J, 2006, AM J IND MED, V49, P1021, DOI 10.1002/ajim.20398; Shantakumar S, 2007, AM J EPIDEMIOL, V165, P1187, DOI 10.1093/aje/kwm006; SHEN H, 2007, CHEMOSPHERE, V67, pS236; SHORE RE, 1986, J NATL CANCER I, V77, P689; SIDDIQUI MK, 2004, ENVIRON RES, V98, P250; SIEGEL BZ, 1995, PESTICIDE HAZARD ASS, P1; Simchoni S, 2006, P NATL ACAD SCI USA, V103, P3770, DOI 10.1073/pnas.0511301103; Simcox NJ, 1995, ENVIRON HEALTH PERSP, V103, P1126, DOI 10.2307/3432609; Simon SL, 2006, RADIAT RES, V166, P174, DOI 10.1667/RR3433.1; Slack RJ, 2005, SCI TOTAL ENVIRON, V337, P119, DOI 10.1016/j.scitotenv.2004.07.002; Slattery ML, 2008, BREAST CANCER RES TR, V109, P101, DOI 10.1007/s10549-007-9629-1; Smigal C, 2006, CA-CANCER J CLIN, V56, P168; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; STANFORD JL, 1995, EPIDEMIOLOGY, V6, P181, DOI 10.1097/00001648-199503000-00017; Steck SE, 2007, EPIDEMIOLOGY, V18, P373, DOI 10.1097/01.ede.0000259968.11151.06; Steenland K, 2003, CANCER CAUSE CONTROL, V14, P531, DOI 10.1023/A:1024891529592; STEVENS RG, 1992, FASEB J, V6, P853; Sukocheva OA, 2005, ENVIRON TOXICOL, V20, P32, DOI 10.1002/tox.20075; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Sweeney C, 2007, INT J CANCER, V121, P2517, DOI 10.1002/ijc.22970; TEITELBAUM SL, 2006, AM J EPIDEMIOL, V165, P643; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thompson PA, 2002, ENVIRON MOL MUTAGEN, V39, P134, DOI 10.1002/em.10067; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521; Tiwary CM, 1998, CLIN PEDIATR, V37, P733, DOI 10.1177/000992289803701204; Tiwary CM, 2003, J PEDIATR ENDOCR MET, V16, P1025; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Toniolo P, 2000, INT J CANCER, V88, P828, DOI 10.1002/1097-0215(20001201)88:5&lt;828::AID-IJC22&gt;3.0.CO;2-8; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Tsai KKC, 2005, CANCER RES, V65, P6734, DOI 10.1158/0008-5472.CAN-05-0703; Turesky RJ, 2007, TOXICOL LETT, V168, P219, DOI 10.1016/j.toxlet.2006.10.018; Turnbull C, 2006, CLIN ONCOL-UK, V18, P257, DOI 10.1016/j.clon.2005.11.013; Tward JD, 2006, CANCER, V107, P108, DOI 10.1002/cncr.21971; TYNES T, 1992, AM J EPIDEMIOL, V136, P81; *UNSCEAR, 1993, SOURC EFF ION RAD UN, P636; *US DPA, 2007, OFF PEST PROGR ATR 3; *US EPA, 2003, HLTH ASS 1 3 BUT; *US EPA, 1996, ENV CLEAN AG COSM MA; VANDERVEN K, 1992, HUM REPROD, V7, P95; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; van Leeuwen FE, 2003, J NATL CANCER I, V95, P971; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; Villanueva CM, 2005, OCCUP ENVIRON MED, V62, P400, DOI 10.1136/oem.2004.016469; Visvanathan K, 2007, ALCOHOL CLIN EXP RES, V31, P467, DOI 10.1111/j.1530-0277.2006.00334.x; WADIA PR, 2007, ENV HLTH PERSP, V115, P80; Wahner-Roedler DL, 2003, MAYO CLIN PROC, V78, P708; Wahner-Roedler DL, 2004, DRUGS TODAY, V40, P865, DOI 10.1358/dot.2004.40.10.863746; WALRATH J, 1985, AM J PUBLIC HEALTH, V15, P883; Wang FI, 2002, J TOXICOL ENV HEAL A, V65, P279, DOI 10.1080/15287390252800864; Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Weiderpass E, 1999, AM J IND MED, V36, P48, DOI 10.1002/(SICI)1097-0274(199907)36:1&lt;48::AID-AJIM7&gt;3.0.CO;2-2; Weiss JR, 2005, CANCER EPIDEM BIOMAR, V14, P20; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wennborg H, 1999, AM J IND MED, V35, P382, DOI 10.1002/(SICI)1097-0274(199904)35:4&lt;382::AID-AJIM9&gt;3.0.CO;2-F; WOLFF MS, 1983, AM J IND MED, V4, P259, DOI 10.1002/ajim.4700040120; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Woolcott CG, 2001, CANCER CAUSE CONTROL, V12, P395, DOI 10.1023/A:1011289905751; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Wright E. G., 2004, International Journal of Low Radiation, V1, DOI 10.1504/IJLR.2004.003875; Wu AH, 2002, CARCINOGENESIS, V23, P1491, DOI 10.1093/carcin/23.9.1491; Wu HDI, 2006, BIOL TRACE ELEM RES, V113, P9, DOI 10.1385/BTER:113:1:19; XIAN CJ, 1995, J ENDOCRINOL, V146, P215, DOI 10.1677/joe.0.1460215; Xie LT, 2005, TOXICOL SCI, V87, P391, DOI 10.1093/toxsci/kfi249; Ye XY, 2006, ENVIRON HEALTH PERSP, V114, P1843, DOI 10.1289/ehp.9413; Ying MWL, 2005, JMHG, V2, P406, DOI DOI 10.1016/J.JMHG.2005.10.012; ZHENG SM, 2007, AM J EPIDEMIOL, V165, P667; Zheng TZ, 1999, AM J EPIDEMIOL, V150, P453; Zhu KM, 2003, AM J EPIDEMIOL, V158, P798, DOI 10.1098/aje/kwg220; ZIEGLER RG, 1993, J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034; 1999, FED REG, V64, P3511; 1994, FED REG 1223; 2001, ROLL BACK MALARI FEB, V343221MANEY PUBLISHINGLEEDSSTE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLANDINT J OCCUP ENV HEALJAN-MARDiscipline: Public, Environmental &amp; Occupational Health411AO</notes>
    <keywords>1; AFRICAN-AMERICAN WOMEN; ASSOCIATION; ATOMIC-BOMB SURVIVORS; BISPHENOL-A ALTERS; breast; breast cancer; Breast cancer incidence; BREAST-CANCER; CANCER; CANCER INCIDENCE; CARCINOGENESIS; CE; CELL; CHEMICALS; COMBINATION; CONNECTION; development; DISEASE; Endocrine disrupting compound; Endocrine disrupting compounds; ENDOCRINE DISRUPTORS; ENDOCRINE-DISRUPTING COMPOUNDS; environment; environmental factors; ENVIRONMENTAL-FACTORS; Epidemiology; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPOSURES; FOOD; GROWTH-FACTOR-I; HEALTH; Hormone; HORMONE-REPLACEMENT THERAPY; Hormones; Incidence; Interaction; MAMMARY-GLAND DEVELOPMENT; Menopause; mixtures; MORTALITY; Occupational; oncology; p21; POLYCYCLIC AROMATIC-HYDROCARBONS; RADIATION; RANDOMIZED CONTROLLED-TRIAL; Review; RISK; RISK FACTOR; risk factors; RISK-FACTORS; SOCIETY; Steroid; toxicology; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>43</startpage>
    <endpage>78</endpage>
    <journalfull>International Journal of Occupational and Environmental Health</journalfull>
    <issue>1</issue>
    <volume>15</volume>
    <abstract>A substantial body of scientific evidence indicates that exposures to common chemicals and radiation, alone and in combination, are contributing to increase in breast cancer incidence observed over the past several decades. Key recurring themes ill the growing scientific literature on breast cancer and environmental risk factors are: (a) the importance of understanding the effects of mixtures and interactions between various chemicals, radiation and other risk factors for the disease; and (b) the increasing evidence that timing of exposures matters, with exposures during early periods of development being particularly critical to later risk of developing breast cancer. A review of the scientific literature shows several classes of environmental factors have been implicated in an increased risk For breast cancer, including hormones and endocrine-disrupting compounds, organic chemicals and by-products of industrial and vehicular combustion, and both ionizing and non-ionizing radiation</abstract>
    <url>WOS:000263619900007</url>
    <isbnorissn>1077-3525</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>227</id>
    <title>Environmental Estrogens Differentially Engage the Histone Methyltransferase EZH2 to Increase Risk of Uterine Tumorigenesis</title>
    <authors>Greathouse,K.L.; Bredfeldt,T.; Everitt,J.I.; Lin,K.; Berry,T.; Kannan,K.; Mittelstadt,M.L.; Ho,S.M.; Walker,C.L.</authors>
    <availability>[Mittelstadt, Megan L.; Walker, Cheryl L.] Texas A&amp;M Hlth Sci Ctr, Inst Biosci &amp; Technol, Ctr Translat Canc Res, Houston, TX 77030 USA. [Everitt, Jeffrey I.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA. [Kannan, Kurunthachalam] SUNY Albany, Sch Publ Hlth, New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Kannan, Kurunthachalam] SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, Albany, NY USA. [Greathouse, K. Leigh; Bredfeldt, Tiffany; Lin, Kevin; Berry, Tia; Walker, Cheryl L.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX USA. [Ho, Shuk-mei] Univ Cincinnati, Med Ctr, Dept Environm Hlth, Ctr Environm Genet, Cincinnati, OH 45267 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleWalker, CL (reprint author), Texas A&amp;M Hlth Sci Ctr, Inst Biosci &amp; Technol, Ctr Translat Canc Res, 2121 W Holcombe Blvd, Houston, TX 77030 USAcwalker@ibt.tamhsc.eduAdachi T, 2004, FOOD CHEM TOXICOL, V42, P445, DOI 10.1016/j.fct.2003.10.012; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438; BURROUGHS CD, 1990, REPROD TOXICOL, V4, P127, DOI 10.1016/0890-6238(90)90007-I; Camp EA, 2009, J WOMENS HEALTH, V18, P547, DOI 10.1089/jwh.2007.0580; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cook JD, 2007, REPROD SCI, V14, P121, DOI 10.1177/1933719106298401; Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102; Couse JF, 2004, TOXICOLOGY, V205, P55, DOI 10.1016/j.tox.2004.06.046; D'Aloisio AA, 2010, ENVIRON HEALTH PERSP, V118, P375, DOI 10.1289/ehp.0901423; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; FABER KA, 1993, REPROD TOXICOL, V7, P35, DOI 10.1016/0890-6238(93)90007-T; Fernandez M, 2009, ENVIRON HEALTH PERSP, V117, P757, DOI 10.1289/ehp.0800267; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Glidewell-Kenney C, 2007, P NATL ACAD SCI USA, V104, P8173, DOI 10.1073/pnas.0611514104; Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 1999, NATURE, V401, P763; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Jefferson WN, 2007, REPROD TOXICOL, V23, P308, DOI 10.1016/j.reprotox.2006.11.012; Kato H, 2003, REPROD TOXICOL, V17, P283, DOI 10.1016/S0890-6238(03)00002-9; Katsuda S, 2000, TOXICOL APPL PHARM, V165, P217, DOI 10.1006/taap.2000.8940; Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kyung-Chul C, 2006, IMMUNOL ENDOCR METAB, V6, P3; Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045; Li SF, 1997, CANCER RES, V57, P4356; Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018; Mowa CN, 2000, J ENDOCRINOL, V167, P363, DOI 10.1677/joe.0.1670363; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Newbold RR, 2001, CANCER RES, V61, P4325; Nikaido Y, 2005, IN VIVO, V19, P487; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Prins GS, 2001, CANCER RES, V61, P6089; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schonfelder G, 2004, NEOPLASIA, V6, P584, DOI 10.1593/neo.04217; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S; Walker CL, 2003, GENE CHROMOSOME CANC, V38, P349, DOI 10.1002/gcc.10281; Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063; Walker CL, 2001, CARCINOGENESIS, V22, P2049, DOI 10.1093/carcin/22.12.2049; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Wise LA, 2005, OBSTET GYNECOL, V105, P167, DOI 10.1097/01.AOG.0000147839.74848.7c5213AMER ASSOC CANCER RESEARCHPHILADELPHIA615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USAMOL CANCER RESAPRDiscipline: Oncology; Cell Biology925WL</notes>
    <keywords>ADULT; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; development; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL; DISEASE; EARLY-LIFE; Environmental estrogen; ENVIRONMENTAL ESTROGENS; environmental exposure; epigenetic; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGENS; EXPOSURE; EXPRESSION; EZH2; FEMALE RATS; FOOD; GENE; gene expression; GENE-EXPRESSION; GENES; genistein; HEALTH; IN-VIVO; METHYLATION; Methyltransferase; NEONATAL EXPOSURE; Neoplasia; nongenomic effects; oncology; Phytoestrogen; PRENATAL DIETHYLSTILBESTROL EXPOSURE; RECEPTOR; RECEPTOR-ALPHA; REPRODUCTIVE-TRACT; RESPONSES; RISK; sensitive windows; SOY; SUSCEPTIBILITY; toxicology; TUMOR; TUMORIGENESIS; Uterine leiomyoma; Uterus; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>546</startpage>
    <endpage>557</endpage>
    <journalfull>Molecular Cancer Research</journalfull>
    <issue>4</issue>
    <volume>10</volume>
    <abstract>Environmental exposures during sensitive windows of development can reprogram normal physiologic responses and alter disease susceptibility later in life in a process known as developmental reprogramming. For example, exposure to the xenoestrogen diethylstilbestrol during reproductive tract development can reprogram estrogen-responsive gene expression in the myometrium, resulting in hyperresponsiveness to hormone in the adult uterus and promotion of hormone-dependent uterine leiomyoma. We show here that the environmental estrogens genistein, a soy phytoestrogen, and the plasticizer bisphenol A, differ in their pattern of developmental reprogramming and promotion of tumorigenesis (leiomyomas) in the uterus. Whereas both genistein and bisphenol A induce genomic estrogen receptor (ER) signaling in the developing uterus, only genistein induced phosphoinositide 3-kinase (PI3K)/AKT nongenomic ER signaling to the histone methyltransferase enhancer of zeste homolog 2 (EZH2). As a result, this pregenomic signaling phosphorylates and represses EZH2 and reduces levels of H3K27me3 repressive mark in chromatin. Furthermore, only genistein caused estrogen-responsive genes in the adult myometrium to become hyperresponsive to hormone; estrogen-responsive genes were repressed in bisphenol A-exposed uteri. Importantly, this pattern of EZH2 engagement to decrease versus increase H3K27 methylation correlated with the effect of these xenoestrogens on tumorigenesis. Developmental reprogramming by genistein promoted development of uterine leiomyomas, increasing tumor incidence and multiplicity, whereas bisphenol A did not. These data show that environmental estrogens have distinct nongenomic effects in the developing uterus that determines their ability to engage the epigenetic regulator EZH2, decrease levels of the repressive epigenetic histone H3K27 methyl mark in chromatin during developmental reprogramming, and promote uterine tumorigenesis. Mol Cancer Res; 10(4); 546-57. (C)2012 AACR</abstract>
    <url>WOS:000302792600007</url>
    <isbnorissn>1541-7786</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>168</id>
    <title>Endocrine-Disrupting Chemicals: Some Actions of POPs on Female Reproduction</title>
    <authors>Gregoraszczuk,E.L.; Ptak,A.</authors>
    <availability>[Gregoraszczuk, Ewa L.; Ptak, Anna] Jagiellonian Univ, Dept Physiol &amp; Toxicol Reprod, Inst Zool, PL-30387 Krakow, Poland.</availability>
    <date>2013</date>
    <notes>JEnglishReviewGregoraszczuk, EL (reprint author), Jagiellonian Univ, Dept Physiol &amp; Toxicol Reprod, Inst Zool, Gronostajowa 9, PL-30387 Krakow, Polandewa.gregoraszczuk@uj.edu.plAkutsu K, 2004, J FOOD HYG SOC JPN, V45, P175; Alvarez L, 2000, J APPL TOXICOL, V20, P81, DOI 10.1002/(SICI)1099-1263(200001/02)20:1&lt;81::AID-JAT629&gt;3.0.CO;2-Z; Andric SA, 2000, BIOL REPROD, V62, P1882, DOI 10.1095/biolreprod62.6.1882; Barber JL, 2006, MUTAGENESIS, V21, P351, DOI 10.1093/mutage/ge1038; Barc J., 2013, INT J ENDOCRINOL, V2013, P7; Bencko V, 2001, FOLIA HISTOCHEM CYTO, V39, P24; Blankenship AL, 2000, ENVIRON SCI TECHNOL, V34, P3153, DOI 10.1021/es9914339; Brevini Tiziana A. L., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P1; Calabrese EJ, 2001, TRENDS PHARMACOL SCI, V22, P285, DOI 10.1016/S0165-6147(00)01719-3; Campagna C, 2002, BIOL REPROD, V67, P80, DOI 10.1095/biolreprod67.1.80; Campagna C, 2001, BIOL REPROD, V65, P554, DOI 10.1095/biolreprod65.2.554; Carpenter DO, 2002, ENVIRON HEALTH PERSP, V110, P25; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Darnerud PO, 2006, CHEMOSPHERE, V62, P485, DOI 10.1016/j.chemosphere.2005.04.004; Den Hond E, 2006, INT J ANDROL, V29, P264, DOI 10.1111/j.1365-2605.2005.00561.x; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Donnelly KC, 1998, CHEMOSPHERE, V37, P1253, DOI 10.1016/S0045-6535(98)00123-4; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Eskenazi B, 2002, AM J EPIDEMIOL, V156, P383, DOI 10.1093/aje/kwf046; Eum SY, 2004, EXP CELL RES, V296, P231, DOI 10.1016/j.yexcr.2004.01.030; Falandysz J, 2003, FOOD ADDIT CONTAM, V20, P995, DOI 10.1080/02652030310001615195; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; FOSTER WG, 1992, J BIOCHEM TOXICOL, V7, P1, DOI 10.1002/jbt.2570070102; Galloway SM, 1998, MUTAT RES-FUND MOL M, V400, P169, DOI 10.1016/S0027-5107(98)00044-X; Gao X, 2000, TOXICOLOGY, V147, P15, DOI 10.1016/S0300-483X(00)00161-X; Gao X, 2000, TOXICOL APPL PHARM, V163, P115, DOI 10.1006/taap.1999.8851; Genuis SJ, 2006, HUM REPROD, V21, P2201, DOI 10.1093/humrep/del181; Gore AC, 2002, MOL CELL ENDOCRINOL, V192, P157, DOI 10.1016/S0303-7207(02)00010-2; Gregoraszczuk EL, 2011, REPROD TOXICOL, V32, P379, DOI 10.1016/j.reprotox.2011.09.008; Gregoraszczuk EL, 2001, J PHYSIOL PHARMACOL, V52, P303; Gregoraszczuk EL, 2008, TOXICOL LETT, V178, P103, DOI 10.1016/j.toxlet.2008.02.011; Gregoraszczuk EL, 2003, REPROD TOXICOL, V17, P465, DOI 10.1016/S0890-6238(03)00042-X; Gregoraszczuk EL, 2011, REPROD TOXICOL, V31, P494, DOI 10.1016/j.reprotox.2011.01.006; Gregoraszczuk EL, 2008, REPROD TOXICOL, V26, P170, DOI 10.1016/j.reprotox.2008.07.003; Gregoraszczuk EL, 2009, XENOBIOTICA, V39, P80, DOI [10.1080/00498250802578468 , 10.1080/00498250802578468]; Gregoraszczuk EL, 2008, REPROD TOXICOL, V25, P58, DOI 10.1016/j.reprotox.2007.10.001; Gregoraszczuk EL, 2003, CHEMOSPHERE, V50, P481, DOI 10.1016/S0045-6535(02)00637-9; Hilliard CA, 1998, ENVIRON MOL MUTAGEN, V31, P316, DOI 10.1002/(SICI)1098-2280(1998)31:4&lt;316::AID-EM3&gt;3.0.CO;2-G; Hirakawa T, 2000, ENDOCRINOLOGY, V141, P1470, DOI 10.1210/en.141.4.1470; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Jarrell JF, 2002, REPROD TOXICOL, V16, P65, DOI 10.1016/S0890-6238(01)00196-4; Karpeta A, 2010, Endocr Regul, V44, P49; Karpeta A, 2013, TOXICOLOGY, V305, P65, DOI 10.1016/j.tox.2012.10.021; Karpeta A, 2011, TOXICOL LETT, V206, P258, DOI 10.1016/j.toxlet.2011.08.005; Karpeta A, 2012, REPROD TOXICOL, V34, P436, DOI 10.1016/j.reprotox.2012.06.009; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Khanjani N, 2006, SCI TOTAL ENVIRON, V368, P557, DOI 10.1016/j.scitotenv.2006.03.029; Krstevska-Konstantinova M, 2001, HUM REPROD, V16, P1020, DOI 10.1093/humrep/16.5.1020; Kwiecinska P, 2011, PHARMACOL REP, V63, P189; Lacey JV, 2002, ENVIRON MOL MUTAGEN, V39, P82, DOI 10.1002/em.10062; Laden F, 2002, CANCER EPIDEM BIOMAR, V11, P1560; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Li ZH, 2012, ENVIRON HEALTH PERSP, V120, P541, DOI 10.1289/ehp.1104051; Lin CH, 2009, TOXICOL LETT, V188, P11, DOI 10.1016/j.toxlet.2009.02.009; Liu SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011272; Meerts Ilonka A. T. M., 2001, Environmental Health Perspectives, V109, P399, DOI 10.2307/3454900; Mercado-Feliciano M, 2008, ENVIRON HEALTH PERSP, V116, P605, DOI 10.1289/ehp.10643; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Okazaki K, 2001, ARCH TOXICOL, V75, P513, DOI 10.1007/s002040100273; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Pang SK, 1999, BIOCHEM PHARMACOL, V58, P29, DOI 10.1016/S0006-2952(99)00070-2; Pocar P, 2001, MOL REPROD DEV, V60, P535, DOI 10.1002/mrd.1118; Pocar P, 2003, REPRODUCTION, V125, P313, DOI 10.1530/rep.0.1250313; Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Ptak A, 2010, ENVIRON INT, V36, P935, DOI 10.1016/j.envint.2009.06.012; Ptak A, 2011, TOXICOL IND HEALTH, V27, P315, DOI 10.1177/0748233710387003; Radice S, 2008, FOOD CHEM TOXICOL, V46, P2561, DOI 10.1016/j.fct.2008.04.012; Ramamoorthy K, 1997, TOXICOL APPL PHARM, V147, P93, DOI 10.1006/taap.1997.8281; Recio-Vega R, 2011, J APPL TOXICOL, V31, P270, DOI 10.1002/jat.1672; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Rusiecki JA, 2004, EUR J EPIDEMIOL, V19, P793; Shi ZQ, 2007, BIOL REPROD, V76, P198, DOI 10.1095/biolreprod.106.053991; Sinha P, 2007, J OBSTET GYNAECOL, V27, P16, DOI 10.1080/01443610601016685; Sjodin A, 2003, ENVIRON INT, V29, P829, DOI 10.1016/S0160-4120(03)00108-9; Stoker TE, 2004, TOXICOL SCI, V78, P144, DOI 10.1093/toxsci/kfh029; Susiarjo M., 2007, PLOS GENETICS, V3; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Takeuchi T, 2006, ENDOCR J, V53, P485, DOI 10.1507/endocrj.K06-032; Talsness CE, 2008, ENVIRON HEALTH PERSP, V116, P308, DOI 10.1289/ehp.10536; Villeneuve DL, 2000, ARCH ENVIRON CON TOX, V39, P273; Wojtowicz A, 2001, Endocr Regul, V35, P223; Younglai EV, 2002, ARCH ENVIRON CON TOX, V43, P121, DOI 10.1007/s00244-001-0048-8; Zhou T, 2002, TOXICOL SCI, V66, P105, DOI 10.1093/toxsci/66.1.105873HINDAWI PUBLISHING CORPORATIONNEW YORK410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USAINT J ENDOCRINOLDiscipline: Endocrinology &amp; Metabolism157TE</notes>
    <keywords>ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; CHEMICALS; DIBENZO-P-DIOXINS; DIFFERENT NATURAL MIXTURES; DISORDERS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ESTROGENS BISPHENOL-A; fertility; FOOD; genetics; GLAND; HEALTH; IMPACT; INDIVIDUAL POLYCHLORINATED NAPHTHALENES; mammary gland; MAMMARY-GLAND; Metabolic disorders; METABOLISM; ORGANIC POLLUTANTS POPS; p21; PBDEs; PLACENTA; POLLUTANTS; POLYBROMINATED DIPHENYL ETHERS; PORCINE OVARIAN-FOLLICLES; premature ovarian failure; RECEPTOR; RELEVANT ORGANOCHLORINE MIXTURE; Reproduction; SECRETION FOLLOWING EXPOSURE; Steroid hormone; STEROID-SECRETION; toxicology; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>International Journal of Endocrinology</journalfull>
    <abstract>Persistent organic pollutants (POPs), such as polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs), polychlorinated biphenyls (PCBs), and polybrominated ethers (PBDEs), chloronaftalens (PCNs), and bisphenol A (BPA), are stable, lipophilic pollutants that affect fertility and cause serious reproductive problems, including ovotoxic action, lack of ovulation, premature ovarian failure (POF), or polycystic ovarian syndrome (PCOS). Most of the representatives of POPs influence the activation of transcription factors, not only activation of aromatic hydrocarbon receptor (AhR), but also the steroid hormone receptors. This minireview will focus on a variety of PAH activities in oocyte, ovary, placenta, and mammary gland. The complexity and diversity of factors belonging to POPs and disorders of the reproductive function of women indicate that the impact of environmental pollution as an important determinant factor in fertility should not be minimize</abstract>
    <url>WOS:000319921200001</url>
    <isbnorissn>1687-8337</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>212</id>
    <title>Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer</title>
    <authors>Guirado,M.; Gil,H.; Saenz-Lopez,P.; Reinboth,J.; Garrido,F.; Cozar,J.M.; Ruiz-Cabello,F.; Carretero,R.</authors>
    <availability>[Ruiz-Cabello, Francisco] Hosp Univ Virgen de las Nieves, Serv Anal Clin &amp; Inmunol, Secc Biopatol Tumoral, Granada 18014, Spain. [Guirado, Macarena; Saenz-Lopez, Pablo; Garrido, Federico; Carretero, Rafael] Univ Granada, Dept Bioquim &amp; Inmunol 3, E-18071 Granada, Spain. [Gil, Hernani; Manuel Cozar, Jose] Hosp Univ Virgen de las Nieves, Serv Urol, Granada 18014, Spain. [Reinboth, Jennifer] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleRuiz-Cabello, F (reprint author), Hosp Univ Virgen de las Nieves, Serv Anal Clin &amp; Inmunol, Secc Biopatol Tumoral, Ave Fuerzas Armadas S-N, Granada 18014, Spainfruizc@ugr.esAhirwar DK, 2009, BIOMARKERS, V14, P213, DOI 10.1080/13547500902818246; Andrew AS, 2009, HUM GENET, V125, P527, DOI 10.1007/s00439-009-0645-6; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Colin P, 2009, BJU INT, V104, P1436, DOI 10.1111/j.1464-410X.2009.08838.x; Freire P, 2010, INT J COLORECTAL DIS, V25, P1211, DOI 10.1007/s00384-010-1028-0; Hirao Y, 2009, CURR OPIN UROL, V19, P494, DOI 10.1097/MOU.0b013e32832eb4ef; Jacobs BL, 2010, CA-CANCER J CLIN, V60, P244, DOI 10.3322/caac.20077; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kufer TA, 2006, ANN NY ACAD SCI, V1072, P19, DOI 10.1196/annals.1326.020; Mantovani A, 2010, CURR MOL MED, V10, P369; Miyazaki J, 2006, BJU INT, V97, P860, DOI 10.1111/j.1464-410X.2006.06026.x; Nakashima Kazuko, 2006, Allergol Int, V55, P77, DOI 10.2332/allergolint.55.77; Oh SS, 2010, INT J CANCER, V127, P2169, DOI 10.1002/ijc.25214; Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x; Pandey AK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000500; Rakoff-Nahoum S, 2008, BIOCHEMISTRY-MOSCOW+, V73, P555, DOI 10.1134/S0006297908050088; Romero JM, 2009, HUM IMMUNOL, V70, P60, DOI 10.1016/j.humimm.2008.10.020; Rothman N, 2010, NAT GENET, V42, P978, DOI 10.1038/ng.687; Saenz-Lopez P, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-382; Saenz-Lopez P, 2010, HUM IMMUNOL, V71, P309, DOI 10.1016/j.humimm.2009.11.010; Sexton WJ, 2010, CANCER CONTROL, V17, P256; Solomon EI, 1996, CHEM REV, V96, P25; Stevens VL, 2008, INT J CANCER, V123, P2644, DOI 10.1002/ijc.23826; Sullivan PS, 2010, AM J TRANSL RES, V2, P412; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tetu B, 2009, MODERN PATHOL, V22, pS53, DOI 10.1038/modpathol.2008.193; ThiAcbaut R, 2011, Inflamm Bowel Dis, V17, P1055, DOI 10.1002/ibd.21406; Wex T, 2008, ANTICANCER RES, V28, P757; Yang H, 2008, CLIN CANCER RES, V14, P2236, DOI 10.1158/1078-0432.CCR-07-1670; Zhang FR, 2009, NEW ENGL J MED, V361, P2609, DOI 10.1056/NEJMoa0903753; Zhou XX, 2006, CANCER EPIDEM BIOMAR, V15, P862, DOI 10.1158/1055-9965.EPI-05-08743710ELSEVIER SCIENCE INCNEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USAHUM IMMUNOLJUNDiscipline: Immunology959IA</notes>
    <keywords>ASSOCIATION; BIOMARKER; Biomarkers; BISPHENOL-A; CANCER; CANCER RISK; CANCER-RISK; CARCINOMA; CELL; development; DISEASE; GENE; GENE POLYMORPHISMS; GENES; GENOME-WIDE ASSOCIATION; Inflammation; JUN; LINKING INFLAMMATION; PATTERN-RECOGNITION RECEPTORS; POLYMORPHISMS; PROGNOSIS; PROGRESSION; PROSTATE-CANCER; RECEPTOR; RISK; SOCIETY; SUSCEPTIBILITY LOCI; TUMOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>668</startpage>
    <endpage>672</endpage>
    <journalfull>Human Immunology</journalfull>
    <issue>6</issue>
    <volume>73</volume>
    <abstract>Several evidences have been published linking polymorphism in genes involved in chronic or recurrent inflammation with increased tumor risk and progression. Nevertheless the influence of innate immune receptors in urothelial cancer risk and characteristics has not been sufficient explored. We studied the possible association of polymorphisms in genes encoding NOD2, RIPK2, TLR10 and C13ORF31 with the risk, clinical/pathological characteristics and outcomes of urothelial cancer. We have found association between RIPK2 (rs42490) and cancer risk (AA vs AT&amp;TT, p = 0042). In addition, we found statistical differences in TLR10 (rs4129009) gen between low and high tumor infiltration stage (p = 0.033). NOD2 (rs9302752) and RIPK2 (rs42490) were found to be associated with development of lymph node metastasis (p = 0.011 and p = 0.015). Importantly we detect association of TLR10 (Log Rank = 0.035) and RIPK2 (Log Rank = 0040) with overall survival. Multivariate Cox analysis revealed that both SNPs were survival prognosis factor independent of tumor stage and grade. Our results indicate that innate immunity receptors play a role in modulating urothelial cancer risk and progression. (C) 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000305304900012</url>
    <isbnorissn>0198-8859</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>330</id>
    <title>Development and Validation of a Test for Environmental Estrogens: Checking Xeno-Estrogen Activity by CXCL12 Secretion in BREAST CANCER CELL LINES (CXCL-Test)</title>
    <authors>Habauzit,D.; Boudot,A.; Kerdivel,G.; Flouriot,G.; Pakdel,F.</authors>
    <availability>[Habauzit, D.; Boudot, A.; Kerdivel, G.; Flouriot, G.; Pakdel, F.] Univ Rennes 1, CNRS, Equipe RED, UMR 6026,IFR 140, Rennes, France.</availability>
    <date>2010</date>
    <notes>JEnglishArticle; Proceedings PaperPakdel, F (reprint author), Univ Rennes 1, CNRS, Equipe RED, UMR 6026,IFR 140, Rennes, FranceAndersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; Arnold SF, 1996, ENVIRON HEALTH PERSP, V104, P544, DOI 10.2307/3432996; Balaguer P, 1999, SCI TOTAL ENVIRON, V233, P47, DOI 10.1016/S0048-9697(99)00178-3; Biau S, 2007, ANAL BIOANAL CHEM, V387, P1397, DOI 10.1007/s00216-006-0870-y; BOUDOT A, 2010, ESTROGEN REGUL UNPUB; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Escande A, 2006, BIOCHEM PHARMACOL, V71, P1459, DOI 10.1016/j.bcp.2006.02.002; FLOURIOT G, 1995, J MOL ENDOCRINOL, V15, P143; GERAUDIE P, 2009, FISH PHYSL BIOCH; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Guillette LJ, 1996, GEN COMP ENDOCR, V101, P32, DOI 10.1006/gcen.1996.0005; Habauzit D, 2007, ANAL BIOANAL CHEM, V387, P1215, DOI 10.1007/s00216-006-0958-4; Habauzit D, 2008, ANAL BIOANAL CHEM, V390, P873, DOI 10.1007/s00216-007-1725-x; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002.0438; Kase R, 2008, ENVIRON SCI POLLUT R, V15, P75, DOI 10.1065/espr2007.06.429; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Korner W, 1999, SCI TOTAL ENVIRON, V225, P33; Kubarek L, 2007, FEBS LETT, V581, P1441, DOI 10.1016/j.febslet.2007.02.070; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Le Blanc AF, 2009, ANAL BIOANAL CHEM, V395, P1769, DOI 10.1007/s00216-009-3038-8; Leclercq G, 2002, J STEROID BIOCHEM, V80, P259, DOI 10.1016/S0960-0760(02)00026-2; Le Guevel R, 2001, HUM REPROD, V16, P1030, DOI 10.1093/humrep/16.5.1030; Le Page Y, 2006, ENVIRON HEALTH PERSP, V114, P752, DOI 10.1289/ehp.8141; Merot Y, 2004, J BIOL CHEM, V279, P26184, DOI 10.1074/jbc.M402148200; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Molina-Molina JM, 2008, TOXICOL APPL PHARM, V232, P384, DOI 10.1016/j.taap.2008.07.017; Pakdel F, 2009, WOODHEAD PUBL FOOD S, P541, DOI 10.1533/9781845695743.4.541; PETIT F, 1995, EUR J BIOCHEM, V233, P584, DOI 10.1111/j.1432-1033.1995.584_2.x; Petit F, 1997, J MOL ENDOCRINOL, V19, P321, DOI 10.1677/jme.0.0190321; Petrovic M, 2004, ANAL BIOANAL CHEM, V378, P549, DOI 10.1007/s00216-003-2184-7; Seifert M, 1998, ADV EXP MED BIOL, V444, P113; Sonneveld E, 2005, TOXICOL SCI, V83, P136, DOI 10.1093/toxsci/kfi005; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2009, MOL CELL ENDOCRINOL, V304, P3, DOI 10.1016/j.mce.2009.02.020; SOTO AM, 1986, CANCER RES, V46, P2271; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Swedenborg E, 2009, J MOL ENDOCRINOL, V43, P1, DOI 10.1677/JME-08-0132; Zacharewski T, 1997, ENVIRON SCI TECHNOL, V31, P613388JOHN WILEY &amp; SONS INCHOBOKEN111 RIVER ST, HOBOKEN, NJ 07030 USAENVIRON TOXICOLOCTSIDiscipline: Environmental Sciences &amp; Ecology; Toxicology; Water Resources648JS</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ANTIESTROGENS; ASSAY; BIOASSAY; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; breast cancer cell lines; BREAST-CANCER; CANCER; CELL; Cell proliferation; Cell proliferation assay; CELL-PROLIFERATION; CELLS; CHEMICALS; CXCL-test; CXCL12; Cytokine; detection; development; E-SCREEN ASSAY; EDC; ENDOCRINE; Endocrine disruptor; Endocrine-disrupting chemicals; environmental contaminants; Environmental estrogen; ENVIRONMENTAL ESTROGENS; Estrogen; ESTROGENS; FISH; FOOD; genistein; GROWTH; HEALTH; HORMONAL COMPOUNDS; IN-VITRO BIOASSAYS; JUVENILE ALLIGATORS; LINE; LINES; methods,breast cancer cells; Migration; proliferation; PROTEIN; RAINBOW-TROUT; RECEPTOR-ALPHA; RIVER; screening; Steroid; TOOL; toxicology; UP-REGULATION; Validation; WATER; xeno-estrogens; xenoestrogen; XENOESTROGENS; YEAST</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>495</startpage>
    <endpage>503</endpage>
    <journalfull>Environmental Toxicology</journalfull>
    <issue>5</issue>
    <volume>25</volume>
    <abstract>Several methods have been developed to evaluate and quantify the effects of Endocrine disruptor chemicals (EDC). Nevertheless, most of these methods are time-consuming or not enough sensitive to detect EDC at the environmental range. To link the biological effect of tested EDC to natural protein secretion, we have developed a new screening method based on the secretion of the cytokine CXCL12 (or SDF-1, Stroma-cell Derived Factor 1), which plays a capital role in cell survival and migration We have demonstrated that CXCL12 secretion is regulated by estrogenic compounds in a dose-dependent way in ER-positive breast cancer cell lines (MCF-7 and T47D). By combining cell culture and ELISA test, we used this up-regulation of CXCL12 secretion to test several major environmental contaminants. Our results showed that 17 beta-estradiol (from 10(-11) M), 17 alpha-ethynylestradiol (from 10(-12) M), genistein (from 10(-8) M) and bisphenol A (from 10(-6) M) dose-regulate CXCL12 secretion in T47D. In contrast, antiestrogens, raloxifen and 4-hydroxy-tamoxifen, had no effect on the CXCL12 secretion, but were able to inhibit E2 effect. Moreover, we used cell proliferation assays to evaluate the effect of these different compounds on the growth of T47D cells. We found strong correlation (P = 0.7) between proliferation and CXCL12 secretion. However CXCL12 secretion was as sensitive as cell proliferation assays but appeared more rapid Thus, this bioassay named CXCL-test (for Checking Xeno-estrogen activity by CXCL12 secretion in breast cancer cell Lines) constitutes a fast and sensitive method for the detection of estrogenic compounds allowing in 14 h to achieve a detection limit of 10(-11) M of E2 (2.7 ng/L) (C) 2010 Wiley Periodicals. Inc Environ Toxicol 25. 495-503, 2010</abstract>
    <url>WOS:000281690200009</url>
    <isbnorissn>1520-4081</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>315</id>
    <title>Effects of Estrogens and Endocrine-Disrupting Chemicals on Cell Differentiation-Survival-Proliferation in Brain: Contributions of Neuronal Cell Lines</title>
    <authors>Habauzit,D.; Flouriot,G.; Pakdel,F.; Saligaut,C.</authors>
    <availability>[Habauzit, Denis; Flouriot, Gilles; Pakdel, Farzad; Saligaut, Christian] Univ Rennes 1, CNRS, UMR Interact Cellulaire &amp; Mol 6026, Equipe RED, F-35042 Rennes, France.</availability>
    <date>2011</date>
    <notes>JEnglishReviewSaligaut, C (reprint author), Univ Rennes 1, CNRS, UMR Interact Cellulaire &amp; Mol 6026, Equipe RED, Campus Beaulieu, F-35042 Rennes, Francefarzad.pakdel@univ-rennes1.fr; christian.saligaut@univ-rennes1.frAcconcia F, 2005, MOL BIOL CELL, V16, P231; Akama KT, 2003, J NEUROSCI, V23, P2333; Alexaki VI, 2004, FASEB J, V18, P1594, DOI 10.1096/fj.04-1495fje; ALEXAKI VI, 2006, J STEROID BIOCHEM, V98, P9; Alkayed NJ, 1998, STROKE, V29, P159; Alves SE, 2000, J COMP NEUROL, V427, P185, DOI 10.1002/1096-9861(20001113)427:2&lt;185::AID-CNE2&gt;3.0.CO;2-G; Arditsoglou A, 2010, ENVIRON SCI POLLUT R, V17, P529, DOI 10.1007/s11356-009-0172-y; Arevalo M.A., 2009, BIOCHIM BIOPHYS ACTA, V1800, P1106; Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Barrek S, 2009, TALANTA, V79, P712, DOI 10.1016/j.talanta.2009.04.058; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Billon-Gales A, 2009, P NATL ACAD SCI USA, V106, P2053, DOI 10.1073/pnas.0808742106; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002.0072; Blaustein JD, 2010, MOL ENDOCRINOL, V24, P252, DOI 10.1210/me.2009-0350; Bonnefort AB, 1998, FEBS LETT, V441, P220, DOI 10.1016/S0014-5793(98)01552-X; Bouron A, 1999, N-S ARCH PHARMACOL, V359, P370, DOI 10.1007/PL00005363; Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017; Bredhult C, 2007, REPROD TOXICOL, V23, P550, DOI 10.1016/j.reprotox.2007.03.006; Brown JS, 2009, SCHIZOPHRENIA BULL, V35, P256, DOI 10.1093/schbul/sbm147; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Chen TC, 2009, J ENVIRON SCI HEAL A, V44, P1244, DOI 10.1080/10934520903139977; Chiasson K, 2006, J MOL NEUROSCI, V30, P297, DOI 10.1385/JMN/30:03:297; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; Ciana P, 2003, J BIOL CHEM, V278, P31737, DOI 10.1074/jbc.M301525200; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Denier X, 2008, MAR ENVIRON RES, V66, P108, DOI 10.1016/j.marenvres.2008.02.038; DeRosa C, 1998, J TOXICOL ENV HEAL B, V1, P3; Dhooge W, 2006, ANAL BIOANAL CHEM, V386, P1419, DOI 10.1007/s00216-006-0669-x; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Du BT, 2004, J ENDOCRINOL, V183, P605, DOI 10.1677/joe.1.05775; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253; Dubal DB, 1999, J NEUROSCI, V19, P6385; Duong CN, 2010, CHEMOSPHERE, V78, P286, DOI 10.1016/j.chemosphere.2009.10.048; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; Elzer JG, 2010, J CEREBR BLOOD F MET, V30, P935, DOI 10.1038/jcbfm.2009.258; FLOURIOT G, 1995, J MOL ENDOCRINOL, V15, P143; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Froissard P, 1997, EUR J PHARMACOL, V326, P93, DOI 10.1016/S0014-2999(97)00155-6; FUKUI M, 2010, FREE RADICAL BIOL ME; Gagne B, 2003, ENDOCRINE, V21, P89, DOI 10.1385/ENDO:21:1:89; GarciaSegura LM, 1996, HORM RES, V46, P160; Garmy-Susini B, 2004, CIRC RES, V94, P1301, DOI 10.1161/01.RES.0000127719.13255.81; Garnier M, 1997, J NEUROSCI, V17, P4591; George J, 2010, J NEUROSCI RES, V88, P877, DOI 10.1002/jnr.22244; Gollapudi L, 1999, J NEUROSCI RES, V56, P471, DOI 10.1002/(SICI)1097-4547(19990601)56:5&lt;471::AID-JNR3&gt;3.0.CO;2-1; Gollapudi L, 2001, EXP NEUROL, V171, P308, DOI 10.1006/exnr.2001.7744; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1&lt;99::AID-JNR13&gt;3.0.CO;2-G; Gonzalez M, 2007, J COMP NEUROL, V503, P790, DOI 10.1002/cne.21419; Gore AC, 2008, FRONT NEUROENDOCRIN, V29, P358, DOI 10.1016/j.yfrne.2008.02.002; Green PS, 1998, NEUROSCIENCE, V84, P7, DOI 10.1016/S0306-4522(97)00595-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Guillette LJ, 1996, GEN COMP ENDOCR, V101, P32, DOI 10.1006/gcen.1996.0005; Guo JB, 2010, J CEREBR BLOOD F MET, V30, P545, DOI 10.1038/jcbfm.2009.226; Gursoy E, 2002, NEUROCHEM INT, V40, P405, DOI 10.1016/S0197-0186(01)00105-X; Gursoy E, 2001, NEUROCHEM INT, V38, P181, DOI 10.1016/S0197-0186(00)00072-3; Habauzit D, 2010, ENVIRON TOXICOL, V25, P495, DOI 10.1002/tox.20594; Habauzit D, 2007, ANAL BIOANAL CHEM, V387, P1215, DOI 10.1007/s00216-006-0958-4; Habauzit D, 2008, ANAL BIOANAL CHEM, V390, P873, DOI 10.1007/s00216-007-1725-x; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292; Harrington WR, 2006, MOL ENDOCRINOL, V20, P491, DOI 10.1210/me.2005-0186; Harris-White ME, 2001, NEUROCHEM INT, V39, P435, DOI 10.1016/S0197-0186(01)00051-1; HENDERSON BE, 1988, CANCER RES, V48, P246; Higuchi Y, 1999, ARCH BIOCHEM BIOPHYS, V363, P33, DOI 10.1006/abbi.1998.1067; Hojo Y, 2008, MOL CELL ENDOCRINOL, V290, P31, DOI 10.1016/j.mce.2008.04.017; Jonkers N, 2010, ENVIRON SCI POLLUT R, V17, P834, DOI 10.1007/s11356-009-0275-5; Jung JY, 2008, BRAIN RES BULL, V76, P579, DOI 10.1016/j.brainresbull.2008.04.006; Kajta M, 2004, NEUROSCIENCE, V123, P515, DOI 10.1016/j.neuroscience.2003.09.005; Kang MK, 2009, ANN NY ACAD SCI, V1171, P514, DOI 10.1111/j.1749-6632.2009.04728.x; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kim K, 2007, J TOXICOL ENV HEAL A, V70, P1288, DOI 10.1080/15287390701434216; Kimura-Kuroda J, 2007, CHEMOSPHERE, V67, pS412, DOI 10.1016/j.chemosphere.2006.05.137; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; KLINTSOVA A, 1995, BRAIN RES, V690, P269, DOI 10.1016/0006-8993(95)00642-4; Klotz DM, 1996, ENVIRON HEALTH PERSP, V104, P1084, DOI 10.2307/3433121; Koh PO, 2006, NEUROSCI LETT, V404, P303, DOI 10.1016/j.neulet.2006.06.020; Kos M., 2002, Journal of Molecular Endocrinology, V29, P281, DOI 10.1677/jme.0.0290281; Krause DN, 2006, J APPL PHYSIOL, V101, P1252, DOI 10.1152/japplphysiol.01095.2005; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Kusunoki T, 2008, NEUROSCI LETT, V431, P256, DOI 10.1016/j.neulet.2007.11.058; Langer G, 2010, STEROIDS, V75, P603, DOI 10.1016/j.steroids.2009.12.006; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Lee YM, 2007, J VET SCI, V8, P27; Le Foll I, 2001, FREE RADICAL BIO MED, V30, P793, DOI 10.1016/S0891-5849(01)00467-1; Le Guevel R, 2001, HUM REPROD, V16, P1030, DOI 10.1093/humrep/16.5.1030; Le Guevel R, 2000, BIOL REPROD, V63, P259, DOI 10.1095/biolreprod63.1.259; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Levin ER, 2009, ENDOCRINOLOGY, V150, P1563, DOI 10.1210/en.2008-1759; Li W, 2004, ENVIRON INT, V30, P329, DOI 10.1016/S0160-4120(03)00183-1; Losordo DW, 2001, ARTERIOSCL THROM VAS, V21, P6; Lu CB, 2009, NEUROSCIENCE, V161, P403, DOI 10.1016/j.neuroscience.2009.03.063; Ma TC, 2010, J NEUROSCI, V30, P739, DOI 10.1523/JNEUROSCI.5266-09.2010; Ma WW, 2010, INT J DEV NEUROSCI, V28, P289, DOI 10.1016/j.ijdevneu.2010.03.003; Maggi A, 2004, ANNU REV PHYSIOL, V66, P291, DOI 10.1146/annurev.physiol.66.032802.154945; Masuo Yoshinori, 2004, Neural Plasticity, V11, P59, DOI 10.1155/NP.2004.59; MATSUNAGA H, 2010, J NEUROCHEM; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; McEwen B, 2001, P NATL ACAD SCI USA, V98, P7093, DOI 10.1073/pnas.121146898; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Mendelsohn ME, 2000, CIRC RES, V87, P956; Merot Y, 2009, ENDOCRINOLOGY, V150, P200, DOI 10.1210/en.2008-0449; Merot Y, 2005, J MOL ENDOCRINOL, V35, P257, DOI 10.1677/jme.1.01826; METZGER D, 1995, J BIOL CHEM, V270, P9535; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Milner TA, 2005, J COMP NEUROL, V491, P81, DOI 10.1002/cne.20724; Mize AL, 2001, NEUROENDOCRINOLOGY, V73, P166, DOI 10.1159/000054633; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Mong JA, 2006, NEUROSCIENCE, V138, P967, DOI 10.1016/j.neuroscience.2005.10.01; Moreira DS, 2009, ENVIRON TECHNOL, V30, P1041, DOI 10.1080/09593330903052830; Mukai H, 2007, J NEUROCHEM, V100, P950, DOI 10.1111/j.1471-4159.2006.04264.x; Murphy DD, 1998, P NATL ACAD SCI USA, V95, P11412, DOI 10.1073/pnas.95.19.11412; Negishi T, 2003, NEUROSCI LETT, V353, P99, DOI 10.1016/j.neulet.2003.09.031; Negishi T, 2004, ENVIRON HEALTH PERSP, V112, P1159, DOI 10.1289/ehp.6961; Nilsen J, 1998, MENOPAUSE, V5, P211; Ogiue-Ikeda M, 2008, BRAIN RES REV, V57, P363, DOI 10.1016/j.brainresrev.2007.06.010; PALMER PM, 2010, ENV MONIT ASSESS; PARK SH, 2010, TOXICOLOGY; Payne J, 2000, ENVIRON HEALTH PERSP, V108, P983, DOI 10.1289/ehp.00108983; Pendaries C, 2002, P NATL ACAD SCI USA, V99, P2205, DOI 10.1073/pnas.042688499; Penot G, 2005, ENDOCRINOLOGY, V146, P5474, DOI 10.1210/en.2005-0866; Petit F, 1997, J MOL ENDOCRINOL, V19, P321, DOI 10.1677/jme.0.0190321; Pike CJ, 2009, FRONT NEUROENDOCRIN, V30, P239, DOI 10.1016/j.yfrne.2009.04.015; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Radio NM, 2008, TOXICOL SCI, V105, P106, DOI 10.1093/toxsci/kfn114; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Sanfilippo K, 2010, J CHROMATOGR B, V878, P1190, DOI 10.1016/j.jchromb.2010.03.025; Sato K, 2007, BRAIN RES, V1150, P108, DOI 10.1016/j.brainres.2007.02.093; Sawada H, 2000, FASEB J, V14, P1202; Sawada H, 2003, ENDOCRINE, V21, P77, DOI 10.1385/ENDO:21:1:77; SEIFER DB, 1994, MENOPAUSE, V1, P83; SERGHINI R, 1994, NEUROREPORT, V6, P29, DOI 10.1097/00001756-199412300-00009; Shimokawa N, 2006, NEUROTOXICOLOGY, V27, P176, DOI 10.1016/j.neuro.2005.09.005; Shinomiya N, 2003, TOXICOL LETT, V137, P175, DOI 10.1016/S0378-4274(02)00401-0; SHUGHRUE PJ, 1993, NEUROENDOCRINOLOGY, V57, P439, DOI 10.1159/000126390; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4&lt;507::AID-CNE1&gt;3.0.CO;2-6; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Slotkin TA, 2009, ENVIRON HEALTH PERSP, V117, P587, DOI 10.1289/ehp.0800251; Slotkin TA, 2009, BRAIN RES BULL, V80, P17, DOI 10.1016/j.brainresbull.2009.06.003; Soares R, 2003, ULTRASTRUCT PATHOL, V27, P33, DOI 10.1080/01913120390179789; SOHRABJI F, 1994, J NEUROBIOL, V25, P974, DOI 10.1002/neu.480250807; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2009, MOL CELL ENDOCRINOL, V304, P3, DOI 10.1016/j.mce.2009.02.020; Staub C, 2005, BIOL REPROD, V73, P703, DOI 10.1095/biolreprod.105.042796; Stice James P, 2009, Future Cardiol, V5, P93, DOI 10.2217/14796678.5.1.93; Takahashi N, 2004, NEUROSCI LETT, V369, P9, DOI 10.1016/j.neulet.2004.07.042; Tavolari S, 2006, TOXICOLOGY, V218, P67, DOI 10.1016/j.tox.2005.10.008; Tenenbaum M, 2007, J ENDOTOXIN RES, V13, P158, DOI 10.1177/0968051907080428; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; Tiwari-Woodruff S, 2009, J NEUROL SCI, V286, P81, DOI 10.1016/j.jns.2009.04.023; TOFIGHI R, 2010, NEUROTOX RES; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; TORANALLERAND CD, 1980, BRAIN RES, V189, P413, DOI 10.1016/0006-8993(80)90101-8; TORANALLERAND CD, 1992, BRAIN RES, V576, P25; Tsai KS, 2004, CHEM RES TOXICOL, V17, P679, DOI 10.1021/tx0499517; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; Van den Belt K, 2004, AQUAT TOXICOL, V66, P183, DOI 10.1016/j.aquatox.2003.09.004; Vasudevan N, 2007, ENDOCR REV, V28, P1, DOI 10.1210/er.2005-0021; Vaudry D, 2002, ANN NY ACAD SCI, V971, P491; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Wang L, 2001, P NATL ACAD SCI USA, V98, P2792, DOI 10.1073/pnas.041617498; Wang L, 2003, P NATL ACAD SCI USA, V100, P703, DOI 10.1073/pnas.242735799; Wang XF, 2006, MOL PHARMACOL, V70, P395, DOI 10.1124/mol.106.022384; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wilson ME, 2009, J NEUROENDOCRINOL, V21, P238, DOI 10.1111/j.1365-2826.2009.01830.x; Wise PM, 2000, BIOL REPROD, V63, P982, DOI 10.1095/biolreprod63.4.982; WITTERS H, 2010, REPROD TOXICOL; Won CK, 2006, J VET MED SCI, V68, P277, DOI 10.1292/jvms.68.277; Wooten MW, 1998, CELL SIGNAL, V10, P265, DOI 10.1016/S0898-6568(97)00127-7; Wu TW, 2005, NEUROSCIENCE, V135, P59, DOI 10.1016/j.neuroscience.2004.12.027; Yang LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009851; Yeh IT, 2007, ADV ANAT PATHOL, V14, P17, DOI 10.1097/PAP.0b013e31802ef00f; YOKOSUKA M, 2008, TOXICOL IN VITRO, V2, P1; Yoon Y, 2010, SCI TOTAL ENVIRON, V408, P636, DOI 10.1016/j.scitotenv.2009.10.049; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Yue X, 2005, P NATL ACAD SCI USA, V102, P19198, DOI 10.1073/pnas.0505203102; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhao LZ, 2007, BRAIN RES, V1172, P48, DOI 10.1016/j.brainres.2007.06.09219111TAYLOR &amp; FRANCIS INCPHILADELPHIA325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USAJ TOXICOL ENV HEAL BSIDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology842AZ</notes>
    <keywords>Alzheimer's disease; ASSAY; BISPHENOL-A; BLOOD; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHEMICALS; development; Differentiation; DISEASE; EDC; ENDOCRINE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ESTRADIOL-MEDIATED PROTECTION; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; HEALTH; HIPPOCAMPAL HT-22 CELLS; In vitro; IN-VITRO; LINE; LINES; mechanism; MECHANISMS; Menopause; MODEL; NERVE GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; Occupational; PATHWAY; PC12 cells; RECEPTOR; RECEPTOR-ALPHA; Receptors; Review; SEX STEROID-HORMONES; Signal transduction; signal transduction pathways; Steroid; TISSUE; TISSUES; toxicology; TRANSFECTED PC12 CELLS; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>300</startpage>
    <endpage>327</endpage>
    <journalfull>Journal of Toxicology and Environmental Health-Part B-Critical Reviews</journalfull>
    <issue>5-7</issue>
    <volume>14</volume>
    <abstract>Estrogens and estrogen receptors (ER) are key actors in the control of differentiation and survival and act on extrareproductive tissues such as brain. Thus, estrogens may display neuritogenic effects during development and neuroprotective effects in the pathophysiological context of brain ischemia and neurodegenerative pathologies like Alzheimer's disease or Parkinson's disease. Some of these effects require classical transcriptional "genomic" mechanisms through ER, whereas other effects appear to rely clearly on "membrane-initiated mechanisms" through cytoplasmic signal transduction pathways. Disturbances of these mechanisms by endocrine-disrupting chemicals (EDC) may exert adverse effects on brain. Some EDC may act via ER-independent mechanisms but might cross-react with endogenous estrogen. Other EDC may act through ER-dependent mechanisms and display agonistic/antagonistic estrogenic properties. Because of these potential effects of EDC, it is necessary to establish sensitive cell-based assays to determine EDC effects on brain. In the present review, some effects of estrogens and EDC are described with focus on ER-mediated effects in neuronal cells. Particular attention is given to PC12 cells, an interesting model to study the mechanisms underlying ER-mediated differentiating and neuroprotective effects of estrogens</abstract>
    <url>WOS:000296559600004</url>
    <isbnorissn>1093-7404</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>7</id>
    <title>Differentiation of PC12 cells expressing estrogen receptor alpha: A new bioassay for endocrine-disrupting chemicals evaluation</title>
    <authors>Habauzit,D.; Ferriere,F.; Botherel,N.; Flouriot,G.; Pakdel,F.; Saligaut,C.</authors>
    <availability>[Habauzit, Denis; Ferriere, Francois; Botherel, Nadine; Flouriot, Gilles; Pakdel, Farzad; Saligaut, Christian] Univ Rennes 1, IRSET, Equipe TREC, SFR Biosit,INSERM U1085, F-35042 Rennes, France.</availability>
    <date>2014</date>
    <notes>JEnglishArticleHabauzit, D (reprint author), Univ Rennes 1, IRSET, Equipe TREC, Bat 13,Campus Beaulieu,263 Ave Gen Leclerc, F-35042 Rennes, Francedenis.habauzit@univ-rennes1.fr; farzad.pakdel@univ-rennes1.frAndersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; Ando K, 2013, BRAIN RES, V1535, P1, DOI 10.1016/j.brainres.2013.08.018; Andozia MB, 2010, FERTIL STERIL, V94, P1578, DOI 10.1016/j.fertnstert.2009.08.052; Anthony M, 2001, ANN NY ACAD SCI, V949, P261; Arnold SF, 1996, ENVIRON HEALTH PERSP, V104, P544, DOI 10.2307/3432996; Balaguer P, 1999, SCI TOTAL ENVIRON, V233, P47, DOI 10.1016/S0048-9697(99)00178-3; Bouron A, 1999, N-S ARCH PHARMACOL, V359, P370, DOI 10.1007/PL00005363; Campbell CG, 2006, CHEMOSPHERE, V65, P1265, DOI 10.1016/j.chemosphere.2006.08.003; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Delmas PD, 1997, J CLIN ONCOL, V15, P955; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; Esteban S, 2014, SCI TOTAL ENVIRON, V466, P939, DOI 10.1016/j.scitotenv.2013.07.101; Ferriere F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069081; FLOURIOT G, 1995, J MOL ENDOCRINOL, V15, P143; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fujimoto N, 2004, J STEROID BIOCHEM, V88, P53, DOI 10.1016/j.jsbmb.2003.10.006; Gollapudi L, 2001, EXP NEUROL, V171, P308, DOI 10.1006/exnr.2001.7744; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Habauzit D, 2010, ENVIRON TOXICOL, V25, P495, DOI 10.1002/tox.20594; Habauzit D, 2011, J TOXICOL ENV HEAL B, V14, P300, DOI 10.1080/10937404.2011.578554; Hamid H, 2012, WATER RES, V46, P5813, DOI 10.1016/j.watres.2012.08.002; Ho Karen J, 2002, Mol Interv, V2, P219, DOI 10.1124/mi.2.4.219; Huang B, 2013, ENVIRON INT, V59, P262, DOI 10.1016/j.envint.2013.06.018; Kerdivel G, 2013, INT J ENDOCRINOL, DOI 10.1155/2013/501851; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kumar GK, 1998, AM J PHYSIOL-CELL PH, V274, pC1592; Lee SG, 2013, ENVIRON HEALTH PERSP, V121, P663, DOI 10.1289/ehp.1205823; Lee YM, 2007, J VET SCI, V8, P27; Leusch F.D., 2013, WATER RES; Linford NJ, 2001, J PHARMACOL EXP THER, V299, P67; LOBO RA, 1994, AM J OBSTET GYNECOL, V170, P1499; MATSUMOTO A, 1988, CELL TISSUE RES, V252, P33; Mendelsohn ME, 2000, CIRC RES, V87, P956; Merot Y, 2009, ENDOCRINOLOGY, V150, P200, DOI 10.1210/en.2008-0449; Merot Y, 2005, J MOL ENDOCRINOL, V35, P257, DOI 10.1677/jme.1.01826; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Micael J, 2007, ENVIRON INT, V33, P1035, DOI 10.1016/j.envint.2007.06.004; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Nilsen J, 1998, MENOPAUSE, V5, P211; Odum J, 1997, REGUL TOXICOL PHARM, V25, P176, DOI 10.1006/rtph.1997.1100; Panzica GC, 2009, ANN NY ACAD SCI, V1163, P271, DOI 10.1111/j.1749-6632.2008.03628.x; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; PETIT F, 1995, EUR J BIOCHEM, V233, P584, DOI 10.1111/j.1432-1033.1995.584_2.x; Polkowski K, 2000, Acta Pol Pharm, V57, P135; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103; Schreihofer DA, 2005, MOL CELL ENDOCRINOL, V231, P13, DOI 10.1016/j.mce.2004.12.006; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Soto A.M., 1992, CHEM INDUCED ALTERAT, P95; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Svechnikov K., 2010, J BIOMED BIOTECHNOL, V2010, P10; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; TORANALLERAND CD, 1980, BRAIN RES, V189, P413, DOI 10.1016/0006-8993(80)90101-8; Turgeon JL, 2006, ENDOCR REV, V27, P575, DOI 10.1210/er.2005-0020; VILLALOBOS M, 1995, ENVIRON HEALTH PERSP, V103, P844, DOI 10.2307/3432398; Vimard F, 2011, J BIOCHEM MOL TOXIC, V25, P205, DOI 10.1002/jbt.20377; Waye A, 2011, J TOXICOL ENV HEAL B, V14, P270, DOI 10.1080/10937404.2011.578273; Willhite CC, 2008, J TOXICOL ENV HEAL B, V11, P69, DOI 10.1080/10937400701724303; Wu F, 2008, J STEROID BIOCHEM, V110, P104, DOI 10.1016/j.jsbmb.2008.02.008; Yoneda T, 2003, J NEUROCHEM, V87, P1499, DOI 10.1046/j.1471-4159.2003.02131.x660PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDCHEMOSPHEREOCTDiscipline: Environmental Sciences &amp; EcologyAN6ES</notes>
    <keywords>ACTIVATION; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; Differentiation; Endocrine-disrupting chemicals; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; LINES; NERVE GROWTH-FACTOR; NEURITE OUTGROWTH; NEURONAL DIFFERENTIATION; PC12 cells; proliferation; RAINBOW-TROUT; SEX STEROIDS; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>240</startpage>
    <endpage>247</endpage>
    <journalfull>Chemosphere</journalfull>
    <volume>112</volume>
    <abstract>Xeno-estrogens, a class of endocrine disrupting chemicals (EDCs), can disturb estrogen receptor-dependent pathways involved in differentiation, proliferation or protection. Multiple methods have been developed to characterize the disturbances induced by EDCs in different cells or organs. In this study we have developed a new tool for the assessment of estrogenic compounds on differentiation. For this purpose we used the global model of NGF-induced neurite outgrowth of a pseudoneuronal PC12 cell line stably transfected with estrogen receptor alpha (PC12 ER). This new test evidences a new selectivity in which estradiol, genistein and 4-hydroxytamoxifen increased the NGF-induced neurite outgrowth of PC12 ER cells in a dose-dependent manner. In contrast, the strong estrogen agonist 17 alpha-ethynylestradiol, the strong antagonist raloxifene and the agonist bisphenol A were unable to modify the neuritogenesis of PC12 ER cells. Therefore, the analysis of neuritogenesis in PC12 ER cells constitutes a complementary tool for the characterization of xeno-estrogen activity and also serves as a basis for further studies focusing on the mechanisms of EDCs in a neuronal context. Moreover, this test constitutes an alternative to animal testing. (C) 2014 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000340688300032</url>
    <isbnorissn>0045-6535</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>192</id>
    <title>Estrogenic Compounds Are Not Always Cardioprotective and Can Be Lethal in Males with Genetic Heart Disease</title>
    <authors>Haines,C.D.; Harvey,P.A.; Luczak,E.D.; Barthel,K.K.B.; Konhilas,J.P.; Watson,P.A.; Stauffer,B.L.; Leinwand,L.A.</authors>
    <availability>[Haines, Christopher D.; Harvey, Pamela A.; Luczak, Elizabeth D.; Barthel, Kristen K. B.; Konhilas, John P.; Stauffer, Brian L.; Leinwand, Leslie A.] Univ Colorado, Dept Mol Cellular &amp; Dev Biol, Boulder, CO 80309 USA. [Haines, Christopher D.; Harvey, Pamela A.; Luczak, Elizabeth D.; Barthel, Kristen K. B.; Konhilas, John P.; Stauffer, Brian L.; Leinwand, Leslie A.] Univ Colorado, Biofrontiers Inst, Boulder, CO 80309 USA. [Stauffer, Brian L.; Leinwand, Leslie A.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Watson, Peter A.] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA. [Watson, Peter A.] Univ Colorado, Hlth Sci Ctr, Div Endocrinol Metab &amp; Diabet, Denver, CO 80262 USA. [Stauffer, Brian L.] Denver Hlth Med Ctr, Dept Med, Div Cardiol, Denver, CO 80204 USA. [Luczak, Elizabeth D.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. [Konhilas, John P.] Univ Arizona, Mol Cardiovasc Res Program, Dept Physiol, Tucson, AZ 85724 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleLeinwand, LA (reprint author), Univ Colorado, Dept Mol Cellular &amp; Dev Biol, UCB 347, Boulder, CO 80309 USALeslie.Leinwand@colorado.eduAkimoto T, 2001, INT J RADIAT ONCOL, V50, P195, DOI 10.1016/S0360-3016(00)01560-1; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Brown NM, 2001, LAB INVEST, V81, P735; CHEUNG JY, 1982, AM J PHYSIOL, V243, pC184; Chodon D, 2007, MOL CELL BIOCHEM, V297, P73, DOI 10.1007/s11010-006-9324-2; Crone SA, 2002, NAT MED, V8, P459, DOI 10.1038/nm0502-459; Djuric Z, 2001, CANCER LETT, V172, P1, DOI 10.1016/S0304-3835(01)00627-9; Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569; Freeman K, 2001, AM J PHYSIOL-HEART C, V280, pH151; Hasinoff BB, 2010, TOXICOL APPL PHARM, V249, P132, DOI 10.1016/j.taap.2010.08.026; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang CY, 2010, J SURG RES, V164, pE1, DOI 10.1016/j.jss.2010.07.041; JALIL JE, 1989, CIRC RES, V64, P1041; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650; Lu Z, 2008, HYPERTENSION, V51, P19, DOI 10.1161/HYPERTENSIONAHA.107.098186; Luczak ED, 2011, PHYSIOL GENOMICS, V43, P772, DOI 10.1152/physiolgenomics.00237.2010; Meinertz H, 2002, ARTERIOSCL THROM VAS, V22, P312, DOI 10.1161/hq0202.103998; Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351; Naaz A, 2003, ENDOCRINOLOGY, V144, P3315, DOI 10.1210/en.2003-0076; Narula J, 1998, APOPTOSIS, V3, P309, DOI 10.1023/A:1009673501809; Pavese JM, 2010, CANCER METAST REV, V29, P465, DOI 10.1007/s10555-010-9238-z; Rasband W. S., 1997, IMAGEJ; Sacks FM, 2006, ARTERIOSCL THROM VAS, V26, P1689, DOI 10.1161/01.ATV.0000227471.00284.ef; Saraste A, 1999, EUR J CLIN INVEST, V29, P380; Stauffer BL, 2006, J CLIN INVEST, V116, P209, DOI 10.1172/JCI24676; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; van Deel ED, 2008, FREE RADICAL BIO MED, V44, P1305, DOI 10.1016/j.freeradbiomed.2007.12.007; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vikstrom KL, 1996, MOL MED, V2, P556; Zittermann A, 2000, J CLIN ENDOCR METAB, V85, P95, DOI 10.1210/jc.85.1.95355ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCRINOLOGYSEPDiscipline: Endocrinology &amp; Metabolism997VH</notes>
    <keywords>ADULT; apoptosis; BISPHENOL-A; BLOOD; CANCER; CANCER CELLS; CARDIAC MYOCYTES; CELL; COMBINATION; DILATED CARDIOMYOPATHY; DISEASE; ENDOCRINE; Endocrine disruption; Estrogen; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; genistein; heart; inhibition; INHIBITOR; KINASE; Male; mechanism; MECHANISMS; METABOLISM; MICE; Oxidative stress; Phytoestrogen; PHYTOESTROGEN GENISTEIN; PHYTOESTROGENS; sex differences; SOY; SOY PROTEIN; SUPEROXIDE-DISMUTASE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>4470</startpage>
    <endpage>4479</endpage>
    <journalfull>Endocrinology</journalfull>
    <issue>9</issue>
    <volume>153</volume>
    <abstract>Hypertrophic cardiomyopathy (HCM) is more severe in male than female mice eating a soy-based diet. We sought to determine whether the detrimental effects are mediated by the phytoestrogens present in soy, the mechanism by which phytoestrogens act, and to test whether estrogen modulates the sexually dimorphic phenotype. A soy-free diet (casein based) supplemented with the predominant phytoestrogens in soy, genistein and daidzein, recapitulated the fibrotic, proapoptotic and negative hemodynamic effects of soy in male hearts. As with the soy diet, the hearts of female HCM mice were not negatively affected by the phytoestrogen-containing diet. To determine the role of estrogen in the sex differences mediated by diet in HCM, gonadectomies were performed and estrogen was administered to male and female HCM mice on a casein- or phytoestrogen-supplemented diet. Somewhat surprisingly, estrogen was not protective in male or female mice with HCM and, in fact, was lethal in phytoestrogen-fed male mice with HCM. Because genistein is a potent tyrosine kinase inhibitor and tyrosine kinase inhibition has been associated with cardiotoxicity, we tested its effects in isolated adult cardiac myocytes. Genistein inhibited different tyrosine kinases depending on sex and, in combination with estrogen, resulted in apoptosis only in adult male cardiac myocytes. Finally, we show that phytoestrogens led to distinct programs of gene expression in hearts from males vs. females with HCM, suggesting mechanisms by which males are more sensitive to the detrimental effects of phytoestrogens and females are protected. These results implicate the phytoestrogen genistein in mediating cardiac pathology in males with HCM and, importantly, establish that estrogen is not protective in the setting of HCM. (Endocrinology 153: 4470-4479, 2012)</abstract>
    <url>WOS:000308194900035</url>
    <isbnorissn>0013-7227</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>111</id>
    <title>Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis</title>
    <authors>Hall,J.M.; Korach,K.S.</authors>
    <availability>[Hall, Julie M.] Campbell Univ, Coll Pharm &amp; Hlth Sci, Buies Creek, NC 27506 USA. [Korach, Kenneth S.] NIEHS, Lab Reprod &amp; Dev Toxicol, Receptor Biol Sect, NIH, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleHall, JM (reprint author), Campbell Univ, Coll Pharm &amp; Hlth Sci, POB 1090, Buies Creek, NC 27506 USAAdewale HB, 2009, BIOL REPROD, V81, P690, DOI 10.1095/biolreprod.109.078261; Boon WC, 2010, PROG BRAIN RES, V181, P209, DOI 10.1016/S0079-6123(08)81012-6; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Fanti P, 1999, J AM SOC NEPHROL, V10, P864; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Folkerd EJ, 2010, J CLIN ONCOL, V28, P4038, DOI 10.1200/JCO.2009.27.4290; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; GEISINGER KR, 1989, CANCER, V63, P280, DOI 10.1002/1097-0142(19890115)63:2&lt;280::AID-CNCR2820630213&gt;3.0.CO;2-N; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002.0438; Henley DV, 2010, HORM-INT J ENDOCRINO, V9, P191; Hewitt SC, 2010, ENV HLTH PERSPECT, V119, P63, DOI 10.1289/ehp.1002347; Hinton CV, 2010, CLIN EXP METASTAS, V27, P97, DOI 10.1007/s10585-008-9210-2; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Kajiyama H, 2008, INT J CANCER, V122, P91, DOI 10.1002/ijc.23083; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Kwong H, 2009, MOL CANCER THER, V8, P1893; Laganiere J, P NATL ACAD SCI US, V1005, P11651; Levin ER, 2009, J PHYSIOL-LONDON, V587, P5019, DOI 10.1113/jphysiol.2009.177097; Lucki NC, 2011, J BIOL CHEM, V286, P19399, DOI 10.1074/jbc.M110.195826; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Peterson G, 1996, CELL GROWTH DIFFER, V7, P1345; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Rhodes LV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-295; Rhodes LV, 2011, CANCER RES, V71, P603, DOI 10.1158/0008-5472.CAN-10-3185; Rich WM, GYNECOLOGIC ONCOLOGY; Righi E, 2011, CANCER RES, V71, P5522, DOI 10.1158/0008-5472.CAN-10-3143; Safe S, 2005, TRENDS ENDOCRIN MET, V16, P139, DOI 10.1016/j.tem.2005.03.004; Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103; Sauve K, 2009, CANCER RES, V69, P5793, DOI 10.1158/0008-5472.CAN-08-4924; Schmitt E, 2001, TOXICOL IN VITRO, V15, P433, DOI 10.1016/S0887-2333(01)00048-0; Scotton CJ, 2002, CANCER RES, V62, P5930; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Yang XH, 2010, CARCINOGENESIS, V31, P695, DOI 10.1093/carcin/bgq007492WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAMOL CARCINOGENSEPDiscipline: Biochemistry &amp; Molecular Biology; Oncology198FZ</notes>
    <keywords>ACTIVATION; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CARCINOMA; CELL; Cell proliferation; Cell proliferation assay; CELL-PROLIFERATION; CELLS; CHEMICALS; CHEMOKINE CXCL12; CXCL12; CXCR4; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; endocrine disrupting chemicals (EDCs); ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; estrogenic activity; ESTROGENS; Etiology; EXPRESSION; GENE-EXPRESSION; genistein; GENOME-WIDE ANALYSIS; GROWTH; In vitro; IN-VITRO; INDUCTION; INHIBITOR; MECHANISMS; oncology; Ovarian cancer; OVARIAN-CANCER; proliferation; PROTEIN; RECEPTOR; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>715</startpage>
    <endpage>725</endpage>
    <journalfull>Molecular Carcinogenesis</journalfull>
    <issue>9</issue>
    <volume>52</volume>
    <abstract>The majority of ovarian cancers over-express the estrogen receptor (ER) and grow in response to estrogens. We previously demonstrated that ER induction of the chemokine CXCL12 (stromal cell-derived factor-1) is required for estradiol (E2)-stimulated proliferation of human ovarian carcinoma cells. In the current study, we report that known endocrine disrupting chemicals (EDCs) display mitogenic activities in ovarian cancer cells via their ability to activate the ER and upregulate CXCL12 expression. Notably, the EDCs genistein, bisphenol A and HPTE stimulated both cell proliferation and induction of CXCL12 mRNA and protein in a manner comparable to estradiol. The effects were completely attenuated by the ER antagonist ICI 182,780, revealing that observed activities of these agents were receptor-mediated. In cell proliferation assays, the mitogenic effects of estradiol and EDCs were obviated by siRNAs targeting CXCL12 and restored upon addition of exogenous CXCL12. Furthermore, an inhibitor to the CXCL12 receptor CXCR4 completely attenuated growth-stimulatory effects of E2 and EDCs. These studies highlight a potential role of EDCs possessing estrogenic activities in the etiology of ovarian cancer. Moreover, they suggest that the ER-CXCL12-CXCR4 signaling axis may represent a promising target for development of therapeutics for ER+ ovarian cancers. (c) 2012 Wiley Periodicals, Inc</abstract>
    <url>WOS:000322908900006</url>
    <isbnorissn>0899-1987</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>257</id>
    <title>Coupling Reaction-Based Ultrasensitive Detection of Phenolic Estrogens Using Surface-Enhanced Resonance Raman Scattering</title>
    <authors>Han,X.X.; Pienpinijtham,P.; Zhao,B.; Ozaki,Y.</authors>
    <availability>[Han, Xiao Xia; Ozaki, Yukihiro] Kwansei Gakuin Univ, Dept Chem, Sanda, Hyogo 6691337, Japan. [Han, Xiao Xia; Ozaki, Yukihiro] Kwansei Gakuin Univ, Sch Sci &amp; Technol, Res Ctr Single Mol Vibrat Spect, Sanda, Hyogo 6691337, Japan. [Pienpinijtham, Prompong] Chulalongkorn Univ, Sensor Res Unit, Dept Chem, Fac Sci, Bangkok 10330, Thailand. [Zhao, Bing] Jilin Univ, State Key Lab Supramol Struct &amp; Mat, Changchun 130012, Peoples R China.</availability>
    <date>2011</date>
    <notes>JEnglishArticleHan, XX (reprint author), Kwansei Gakuin Univ, Dept Chem, Sanda, Hyogo 6691337, Japanhanxiaoxiajilin@hotmail.com; ozaki@kwansei.ac.jpAroca R., 2006, SURFACE ENHANCED VIB; BARNETT SM, 1994, ANAL CHEM, V66, P1762, DOI 10.1021/ac00082a026; Bell SEJ, 2006, J AM CHEM SOC, V128, P15580, DOI 10.1021/ja066263w; Bell SEJ, 2008, CHEM SOC REV, V37, P1012, DOI 10.1039/b705965p; Biswas N, 1997, J PHYS CHEM A, V101, P5555, DOI 10.1021/jp970312x; Blackie EJ, 2009, J AM CHEM SOC, V131, P14466, DOI 10.1021/ja905319w; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Dai JH, 2006, ANAL CHEM, V78, P135, DOI 10.1021/ac0513996; Dasary SSR, 2009, J AM CHEM SOC, V131, P13806, DOI 10.1021/ja905134d; De Meulenaer B, 2002, J AGR FOOD CHEM, V50, P5273, DOI 10.1021/jf0202739; Fang H, 2001, CHEM RES TOXICOL, V14, P280, DOI 10.1021/tx000208y; Gao ZX, 2009, BIOSENS BIOELECTRON, V24, P1445, DOI 10.1016/j.bios.2008.08.037; Geisler J, 2000, J STEROID BIOCHEM, V72, P259, DOI 10.1016/S0960-0760(00)00036-4; Han XX, 2011, SMALL, V7, P316, DOI 10.1002/smll.201001936; Han XX, 2009, ANAL CHEM, V81, P3329, DOI 10.1021/ac900395x; Han XX, 2010, ANAL CHEM, V82, P4325, DOI 10.1021/ac100596u; Han XX, 2008, ANAL CHEM, V80, P2799, DOI 10.1021/ac702390u; He LL, 2011, ANAL CHEM, V83, P1510, DOI 10.1021/ac1032353; Hegnerova K, 2010, ANAL BIOANAL CHEM, V398, P1963, DOI 10.1007/s00216-010-4067-z; Huang GG, 2009, ANAL CHEM, V81, P5881, DOI 10.1021/ac900392s; Jimenez-Diaz I, 2010, J CHROMATOGR B, V878, P3363, DOI 10.1016/j.jchromb.2010.10.021; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Kneipp K., 2006, SURFACE ENHANCED RAM; Kuller LH, 1997, ENVIRON HEALTH PERSP, V105, P593, DOI 10.2307/3433376; Lampert H, 1997, J PHYS CHEM A, V101, P2254, DOI 10.1021/jp962933g; LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025; LEZNA RO, 1991, LANGMUIR, V7, P1241, DOI 10.1021/la00054a037; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Macaskill A, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm042; Mahmoud IY, 2011, J EXP ZOOL PART A, V315A, P170, DOI 10.1002/jez.665; Moore BD, 2004, NAT BIOTECHNOL, V22, P1133, DOI 10.1038/nbt1003; Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102; Pienpinijtham P, 2011, ANAL CHEM, V83, P3655, DOI 10.1021/ac200743j; Rodriguez-Lorenzo L, 2010, J PHYS CHEM C, V114, P7336, DOI 10.1021/jp909253w; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321; Sanles-Sobrido M, 2009, NANOSCALE, V1, P153, DOI 10.1039/b9nr00059c; Stiles PL, 2008, ANNU REV ANAL CHEM, V1, P601, DOI 10.1146/annurev.anchem.1.031207.112814; Stuart CM, 2007, J PHYS CHEM A, V111, P12072, DOI 10.1021/jp0751460; SZELE I, 1983, TOP CURR CHEM, V112, P1; Tsoutsi D, 2011, ACS NANO, V5, P7539, DOI 10.1021/nn2025176; Wang H, 2005, J AM CHEM SOC, V127, P14992, DOI 10.1021/ja055633y; WILSON HW, 1981, J RAMAN SPECTROSC, V11, P252, DOI 10.1002/jrs.1250110407; Wu YQ, 1999, LANGMUIR, V15, P4625, DOI 10.1021/la981765b; Zhao Y, 2009, LANGMUIR, V25, P13833, DOI 10.1021/la902087e4413AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USAANAL CHEMNOV 15Discipline: Chemistry845NQ</notes>
    <keywords>ADSORPTION; AQUEOUS-SOLUTIONS; BISPHENOL-A; BREAST-CANCER; CIS-AZOBENZENE; development; Environmental estrogen; ENVIRONMENTAL ESTROGENS; Estrogen; ESTROGENS; EXPOSURE; FOOD; GOLD; HEALTH; HEALTHY POSTMENOPAUSAL WOMEN; HUMAN EXPOSURE; NANOPARTICLES; PLUS PROGESTIN; RECOGNITION; SCATTERING; SERRS; SPECTROSCOPY; SYSTEM</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>8582</startpage>
    <endpage>8588</endpage>
    <journalfull>Analytical Chemistry</journalfull>
    <issue>22</issue>
    <volume>83</volume>
    <abstract>Studies have shown that many adverse health effects are associated with human exposure to dietary or environmental estrogens. Therefore, the development of rapid and highly sensitive detection methods for estrogens is very important and necessary to maintain hormonal concentration below the safety limit. Herein, we demonstrate a simple and rapid approach to detect trace amounts of phenolic estrogen based on surface-enhanced resonance Raman scattering (SERRS). Because of a coupling reaction between diazonium ions and the phenolic estrogens, azo compounds are formed with strong SERRS activity, which allows phenolic estrogen recognition at subnanomolar levels in solution. The proposed protocol has multiplexing capability, because each SERRS fingerprint of the azo dyes specifically corresponds to the related estrogen. Moreover, it is universal and highly selective, not only for phenolic estrogens but also for other phenolic molecules, even in complex systems</abstract>
    <url>WOS:000296830200032</url>
    <isbnorissn>0003-2700</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>68</id>
    <title>Magnetic Titanium Dioxide Nanocomposites for Surface-Enhanced Resonance Raman Spectroscopic Determination and Degradation of Toxic Anilines and Phenols</title>
    <authors>Han,X.X.; Chen,L.; Kuhlmann,U.; Schulz,C.; Weidinger,I.M.; Hildebrandt,P.</authors>
    <availability>[Han, Xiao Xia; Kuhlmann, Uwe; Schulz, Claudia; Weidinger, Inez M.; Hildebrandt, Peter] Tech Univ Berlin, Inst Chem, D-10623 Berlin, Germany. [Chen, Lei] Jilin Univ, State Key Lab Supramol Struct &amp; Mat, Changchun 130012, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleWeidinger, IM (reprint author), Tech Univ Berlin, Inst Chem, Sekr PC14,Str 17 Juni 135, D-10623 Berlin, Germanyi.weidinger@mailbox.tu-berlin.de; hildebrandt@chem.tu-berlin.deAlessandri I, 2013, J AM CHEM SOC, V135, P5541, DOI 10.1021/ja401666p; Chalasani R, 2013, ACS NANO, V7, P4093, DOI 10.1021/nn400287k; Chen ZG, 2011, ANAL METHODS-UK, V3, P1845, DOI 10.1039/c1ay05180f; Christie R. M., 2001, COLOR CHEM; Dasary SSR, 2009, J AM CHEM SOC, V131, P13806, DOI 10.1021/ja905134d; Deng Y, 2008, J AM CHEM SOC, V130, P28, DOI 10.1021/ja0777584; Ferrer E, 2011, FOOD CHEM, V126, P360, DOI 10.1016/j.foodchem.2010.10.098; Gao JH, 2009, ACCOUNTS CHEM RES, V42, P1097, DOI 10.1021/ar9000026; Han XX, 2013, SMALL, V9, P4175, DOI 10.1002/smll.201301070; Han XX, 2012, TRAC-TREND ANAL CHEM, V38, P67, DOI 10.1016/j.trac.2012.05.006; Han XX, 2013, ACS NANO, V7, P3212, DOI 10.1021/nn305892j; Han XX, 2011, ANAL CHEM, V83, P8582, DOI 10.1021/ac2019766; Hegnerova K, 2010, ANAL BIOANAL CHEM, V398, P1963, DOI 10.1007/s00216-010-4067-z; Hemstreet GP, 2001, J NATL CANCER I, V93, P427, DOI 10.1093/jnci/93.6.427; Huang YF, 2010, J AM CHEM SOC, V132, P9244, DOI 10.1021/ja101107z; Kang B, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3555345; Khan MM, 2013, NANOSCALE, V5, P4427, DOI 10.1039/c3nr00613a; Kneipp K., 2006, SURFACE ENHANCED RAM; Konstantinou I.K., 2004, APPL CATAL B-ENVIRON, V19, P1; LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025; Levin CS, 2009, ACS NANO, V3, P1379, DOI 10.1021/nn900118a; Linic S, 2011, NAT MATER, V10, P911, DOI [10.1038/nmat3151, 10.1038/NMAT3151]; Liu J, 2011, SMALL, V7, P425, DOI 10.1002/smll.201001402; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Ma WF, 2012, ACS NANO, V6, P3179, DOI 10.1021/nn3009646; Murgida DH, 2008, CHEM SOC REV, V37, P937, DOI 10.1039/b705976k; Rothman N, 1996, CANCER EPIDEM BIOMAR, V5, P979; Roy P., 2011, ANGEW CHEM, V123, P2956, DOI DOI 10.1002/ANGE.201001374; Sivanesan A, 2013, J PHYS CHEM C, V117, P11866, DOI 10.1021/jp4032578; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vera-Avila LE, 2001, J CHROMATOGR SCI, V39, P301; Yang LB, 2008, J PHYS CHEM C, V112, P20095, DOI 10.1021/jp8074145; Zamarion VM, 2008, INORG CHEM, V47, P2934, DOI 10.1021/ic800122v330WILEY-V C H VERLAG GMBHWEINHEIMBOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANYANGEW CHEM INT EDITFEB 24Discipline: ChemistryAI4KL</notes>
    <keywords>aniline; BENZIDINE; BINDING; BISPHENOL-A; BLADDER-CANCER; CANCER; FOOD; LIQUID-CHROMATOGRAPHY; magnetic TiO2; MICROSPHERES; NANOPARTICLES; NANOSTRUCTURES; phenol; PHENOLS; photocatalysis; SCATTERING; SERRS; SHELL; TIO2</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2481</startpage>
    <endpage>2484</endpage>
    <journalfull>Angewandte Chemie-International Edition</journalfull>
    <issue>9</issue>
    <volume>53</volume>
    <abstract>Mesoporous M-TiO2 NCs, functionalized by PATP, can capture toxic anilines and phenols by azo coupling. Loading these nanodevices with Ag NPs offers the possibility for a sensitive quantitative determination of target compounds by SERRS spectroscopy, which allows multiplex detection because of the specific vibrational fingerprints. Sensitivity and selectivity can be further enhanced by concentrating the hybrid particles by an external magnet and compound-specific binding (anilines versus phenols). The bound toxic compounds can be degraded by TiO2-assisted photocatalysis after removal of the loaded hybrid particles from the sample solution with an external magnet. The degradation process can be enhanced in the presence of plasmonic Ag nanostructures</abstract>
    <url>WOS:000336834000023</url>
    <isbnorissn>1433-7851</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>260</id>
    <title>EVect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation</title>
    <authors>Hanioka,N.; Oka,H.; Nagaoka,K.; Ikushiro,S.; Narimatsu,S.</authors>
    <availability>[Hanioka, Nobumitsu; Oka, Hiroyuki; Nagaoka, Kenjiro; Narimatsu, Shizuo] Okayama Univ, Grad Sch Med Dent &amp; Pharmaceut Sci, Kita Ku, Okayama 7008530, Japan. [Ikushiro, Shinichi] Toyama Prefectural Univ, Fac Engn, Toyama 9390398, Japan.</availability>
    <date>2011</date>
    <notes>JEnglishArticleHanioka, N (reprint author), Okayama Univ, Grad Sch Med Dent &amp; Pharmaceut Sci, Kita Ku, 1-1-1 Tsushima Naka, Okayama 7008530, Japannhanioka@cc.okayama-u.ac.jpATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; CHEN F, 1993, BIOCHEMISTRY-US, V32, P10648, DOI 10.1021/bi00091a015; Chung JY, 2005, CLIN PHARMACOL THER, V77, P486, DOI 10.1016/j.clpt.2005.02.006; Court MH, 2004, J PHARMACOL EXP THER, V310, P656, DOI 10.1124/jpet.104.067660.; Court MH, 2002, DRUG METAB DISPOS, V30, P1257, DOI 10.1124/dmd.30.11.1257; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Ghosal A, 2004, DRUG METAB DISPOS, V32, P267, DOI 10.1124/dmd.32.2.267; Hanioka N, 2010, LIFE SCI, V87, P261, DOI 10.1016/j.lfs.2010.07.001; Hanioka N, 2008, CHEMOSPHERE, V74, P33, DOI 10.1016/j.chemosphere.2008.09.053; He X, 2009, BRIT J CLIN PHARMACO, V68, P721, DOI 10.1111/j.1365-2125.2009.03519.x; Ikushiro S, 2006, DRUG METAB PHARMACOK, V21, P70, DOI 10.2133/dmpk.21.70; Izukawa T, 2009, DRUG METAB DISPOS, V37, P1759, DOI 10.1124/dmd.109.027227; Kaku T, 2004, BIOCHEM PHARMACOL, V67, P2093, DOI 10.1016/j.bcp.2004.02.014; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kurebayashi H, 2002, TOXICOL SCI, V68, P32, DOI 10.1093/toxsci/68.1.32; Levesque E, 1997, PHARMACOGENETICS, V7, P317, DOI 10.1097/00008571-199708000-00007; Lewis BC, 2007, BIOCHEM PHARMACOL, V73, P1463, DOI 10.1016/j.bcp.2006.12.021; Mackenzie PI, 2005, PHARMACOGENET GENOM, V15, P677, DOI 10.1097/01.fpc.0000173483.13689.56; Mackenzie PI, 2003, CURR DRUG METAB, V4, P249, DOI 10.2174/1389200033489442; Miley MJ, 2007, J MOL BIOL, V369, P498, DOI 10.1016/j.jmb.2007.03.066; Nishiyama T, 2002, BIOCHEM PHARMACOL, V63, P1817, DOI 10.1016/S0006-2952(02)00994-2; Ohno S, 2009, DRUG METAB DISPOS, V37, P32, DOI 10.1124/dmd.108.023598; Okugi H, 2006, CANCER DETECT PREV, V30, P262, DOI 10.1016/j.cdp.2006.04.004; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Park J, 2004, J UROLOGY, V171, P2484, DOI 10.1097/01.ju.0000117748.44313.43; PATEL M, 1995, PHARMACOGENETICS, V5, P287, DOI 10.1097/00008571-199510000-00004; POTTENGER LH, 2000, TOXICOL SCI, V4, P3; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; RITTER JK, 1990, J BIOL CHEM, V265, P7900; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Sparks R, 2004, BREAST CANCER RES, V6, pR488, DOI 10.1186/bcr818; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Toide Kenji, 2002, Drug Metab Pharmacokinet, V17, P164, DOI 10.2133/dmpk.17.164; Tomboc M, 2003, J PEDIATR ENDOCR MET, V16, P719; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; VOLKEL, 2002, CHEM RES TOXICOL, V15, P1281; Wang JF, 2010, CURR DRUG METAB, V11, P342; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Yokota H, 1999, BIOCHEM J, V340, P405, DOI 10.1042/0264-6021:3400405; Yoshihara S, 2001, TOXICOL SCI, V62, P221, DOI 10.1093/toxsci/62.2.221; Yu LS, 2004, BIOMED CHROMATOGR, V18, P833, DOI 10.1002/bmc.3974219SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYARCH TOXICOLNOVDiscipline: Toxicology852LM</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CELLS; CHEMICALS; DRUG-INTERACTIONS; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; EXPRESSION; extrapolation; GENE; Genetic polymorphism; Glucuronidation; HEALTH; HUMAN EXPOSURE; HUMAN LIVER; HUMANS; IN-VIVO; ISOFORMS; KU; METABOLISM; POPULATION; PROSTATE-CANCER; PROTEIN; RAT-LIVER; TOXICITY; toxicology; UDP-glucuronosyltransferase 2B15 (UGT2B15); UGT2B15; VARIANTS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1373</startpage>
    <endpage>1381</endpage>
    <journalfull>Archives of Toxicology</journalfull>
    <issue>11</issue>
    <volume>85</volume>
    <abstract>Bisphenol A (BPA) is one of a number of potential endocrine-disrupting chemicals, which are metabolized mainly by UDP-glucuronosyltransferase 2B15 (UGT2B15) in humans. Six UGT2B15 allelic variants (UGT2B15*2, UGT2B15*3, UGT2B15*4, UGT2B15*5, UGT2B15*6, and UGT2B15*7; wild-type, UGT2B15*1) with amino acid substitutions have been found in Caucasian, African-American, Hispanic, and Oriental populations to date. In this study, the effects of amino acid substitutions in UGT2B15 on BPA glucuronidation were studied using recombinant UGT2B15 enzymes of wild-type (UGT2B15.1) and all identified variants (UGT2B15.2, UGT2B15.3, UGT2B15.4, UGT2B15.5, UGT2B15.6, and UGT2B15.7) expressed in insect (Sf9) cells. The K(m), V(max), and CL(int) values of UGT2B15.1 for BPA glucuronidation were 3.9 mu M, 650 pmol/min/mg protein, and 170 mu L/min/mg protein, respectively. Although there is no significant difference in the K(m) value between wild-type and any variant UGT2B15, the V(max) and CL(int) values of UGT2B15 variants having D85Y substitution were markedly reduced to 14 and 10% for UGT2B15.2, and 4.3 and 3.9% for UGT2B15.5 compared with those of UGT2B15.1, respectively. However, the K(m), V(max), and CL(int) values of UGT2B15.3, UGT2B15.4, UGT2B15.6, and UGT2B15.7 having L86S, T352I, and/or K523T substitution(s) for BPA glucuronidation were comparable to those of UGT2B15.1. These findings suggest that D85Y substitution in UGT2B15 decreases enzymatic function and that the polymorphic alleles of UGT2B15 are closely associated with variations in the metabolism and toxicity of BPA. The information gained in this study should help with in vivo extrapolation to assess the toxicity of endocrine-disrupting chemicals</abstract>
    <url>WOS:000297359400004</url>
    <isbnorissn>0340-5761</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>221</id>
    <title>DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF</title>
    <authors>Hanna,C.W.; Bloom,M.S.; Robinson,W.P.; Kim,D.; Parsons,P.J.; Saal,F.S.V.; Taylor,J.A.; Steuerwald,A.J.; Fujimoto,V.Y.</authors>
    <availability>[Bloom, Michael S.; Kim, Dongsul; Parsons, Patrick J.; Steuerwald, Amy J.] SUNY Albany, Dept Environm Hlth Sci, Rensselaer, NY 12144 USA. [Hanna, Courtney W.; Robinson, Wendy P.] Child &amp; Family Res Inst, Vancouver, BC V5Z 4H4, Canada. [Hanna, Courtney W.; Robinson, Wendy P.] Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada. [Bloom, Michael S.] SUNY Albany, Dept Epidemiol &amp; Biostat, Albany, NY 12144 USA. [Parsons, Patrick J.; Steuerwald, Amy J.] New York State Dept Hlth, Wadsworth Ctr, Lab Inorgan &amp; Nucl Chem, Albany, NY 12201 USA. [Saal, Frederick S. vom; Taylor, Julia A.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA. [Fujimoto, Victor Y.] Univ Calif San Francisco, Dept Obstet Gynecol &amp; Reprod Sci, San Francisco, CA 94115 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleBloom, MS (reprint author), SUNY Albany, Dept Environm Hlth Sci, Rensselaer, NY 12144 USAmbloom@albany.eduAgarwal A, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-28; Agency for Toxic Substances &amp; Diseases Registry. (ATSDR), 2007, TOX PROF LEAD; Al-Saleh I, 2008, INT J HYG ENVIR HEAL, V211, P560, DOI 10.1016/j.ijheh.2007.09.005; ATSDR, 1999, TOX PROF CADM; ATSDR (Agency for Toxic Substances and Disease Registry), 1999, TOX PROF MERC; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Bell A, 2011, CANCER-AM CANCER SOC, V117, P2898, DOI 10.1002/cncr.25818; Bloom MS, 2011, FERTIL STERIL, V96, P672, DOI 10.1016/j.fertnstert.2011.06.063; Bloom MS, 2010, REPROD TOXICOL, V29, P298, DOI 10.1016/j.reprotox.2010.01.003; Bloom MS, 2011, REPROD TOXICOL, V31, P158, DOI 10.1016/j.reprotox.2010.09.013; Bloom MS, 2011, REPROD TOXICOL, V31, P164, DOI 10.1016/j.reprotox.2010.11.011; BOARD P, 1990, PHARMACOL THERAPEUT, V48, P357, DOI 10.1016/0163-7258(90)90054-6; Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Borja-Aburto VH, 1999, AM J EPIDEMIOL, V150, P590; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bruchova H, 2010, PLACENTA, V31, P186, DOI 10.1016/j.placenta.2009.12.016; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Calafat AM, 2009, ENVIRON HEALTH PERSP, V117, P639, DOI 10.1289/ehp.0800265; CDC, 2010, 4 CDC; Chang SH, 2006, ENVIRON RES, V101, P380, DOI 10.1016/j.envres.2005.10.004; Choy CMY, 2002, BJOG-INT J OBSTET GY, V109, P1121, DOI 10.1016/S1470-0328(02)02984-1; Cole DC, 2006, REPROD TOXICOL, V22, P13, DOI 10.1016/j.reprotox.2005.12.001; Dhillon VS, 2007, MOL HUM REPROD, V13, P213, DOI 10.1093/molehr/gal118; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951; Eichenlaub-Ritter U, 2008, MUTAT RES-GEN TOX EN, V651, P82, DOI 10.1016/j.mrgentox.2007.10.014; Etcheverry A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-701; Fujimoto VY, 2011, FERTIL STERIL, V95, P1816, DOI 10.1016/j.fertnstert.2010.11.008; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Jiang GF, 2008, TOXICOLOGY, V244, P49, DOI 10.1016/j.tox.2007.10.028; Kandaraki E, 2011, J CLIN ENDOCR METAB, V96, pE480, DOI 10.1210/jc.2010-1658; Louis GMB, 2006, SEMIN REPROD MED, V24, P147, DOI 10.1055/s-2006-944421; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; MENDOLA P, 2008, FERTIL STERIL, V89, P81; Minnich MG, 2008, SPECTROCHIM ACTA B, V63, P389, DOI 10.1016/j.sab.2007.11.033; Mok-Lin E, 2010, INT J ANDROL, V33, P385, DOI 10.1111/j.1365-2605.2009.01014.x; Nelson HH, 2011, ENV HLTH PERSPECT, V119, P1523; Newbold Retha R, 2008, Fertil Steril, V89, pe55, DOI 10.1016/j.fertnstert.2008.01.062; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Palmer CD, 2006, SPECTROCHIM ACTA B, V61, P980, DOI 10.1016/j.sab.2006.09.001; PEARSON WR, 1993, AM J HUM GENET, V53, P220; Peng DF, 2009, GUT, V58, P5, DOI 10.1136/gut.2007.146290; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Romero R, 2010, AM J OBSTET GYNECOL, V203; Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338; Sajiki J, 1999, J CHROMATOGR B, V736, P255, DOI 10.1016/S0378-4347(99)00471-5; Sata F, 2003, MOL HUM REPROD, V9, P165, DOI 10.1093/molehr/gag021; Schisterman EF, 2006, AM J EPIDEMIOL, V163, P374, DOI 10.1093/aje/kwj039; Shan JD, 2002, CANCER RES, V62, P290; Shkolnik K, 2011, P NATL ACAD SCI USA, V108, P1462, DOI 10.1073/pnas.1017213108; STRANGE RC, 1991, CARCINOGENESIS, V12, P25, DOI 10.1093/carcin/12.1.25; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Susiarjo M, 2007, PLOS GENET, V3, P0063; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Thompson J, 2008, REPROD TOXICOL, V25, P304, DOI 10.1016/j.reprotox.2008.02.001; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; VANPOPPEL G, 1992, CARCINOGENESIS, V13, P303, DOI 10.1093/carcin/13.2.303; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wright RO, 2010, ENVIRON HEALTH PERSP, V118, P790, DOI 10.1289/ehp.0901429; Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391; Xu SJ, 1998, J BIOL CHEM, V273, P3517, DOI 10.1074/jbc.273.6.3517; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Younglai EV, 2005, HUM REPROD UPDATE, V11, P43, DOI 10.1093/humupd/dmh055; Younglai EV, 2002, ARCH ENVIRON CON TOX, V43, P121, DOI 10.1007/s00244-001-0048-8; Yuan LM, 1999, CANCER RES, V59, P32157416OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDHUM REPRODMAYDiscipline: Obstetrics &amp; Gynecology; Reproductive Biology930TB</notes>
    <keywords>ASSOCIATION; BIOLOGY; bisphenol; bisphenol A; bisphenol A (BPA); BISPHENOL-A; BLOOD; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; Composition; DISEASE; diseases; DNA METHYLATION; DNA-methylation; environmental pollutants; ENVIRONMENTAL-POLLUTANTS; EXPOSURE; GENE; GLUTATHIONE S-TRANSFERASES; GSTM1 DELETION; HEALTH; HUMAN HEALTH; In vitro; IN-VITRO; IN-VITRO FERTILIZATION; INCREASES SUSCEPTIBILITY; IVF; lead (Pb); LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; mercury (Hg); METHYLATION; PERINATAL EXPOSURE; PLACENTA; PLASMA-MASS SPECTROMETRY; POLLUTANTS; serum; TOBACCO-SMOKE EXPOSURE; toxicology; Urine; VARIANTS; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1401</startpage>
    <endpage>1410</endpage>
    <journalfull>Human Reproduction</journalfull>
    <issue>5</issue>
    <volume>27</volume>
    <abstract>Changes in DNA methylation may play an important role in the deleterious reproductive effects reported in association with exposure to environmental pollutants. In this pilot study, we identify candidate methylation changes associated with exposure to pollutants in women undergoing in vitro fertilization (IVF). Blood and urine were collected from women on the day of oocyte retrieval. Whole blood was analyzed for mercury and lead, and urine for cadmium using inductively coupled plasma mass spectrometry. Unconjugated bisphenol A (BPA) was analyzed in serum using high-performance liquid chromatography with Coularray detection. Participants were dichotomized as higher or lower exposure groups by median concentrations. Using the Illumina GoldenGate Methylation Cancer Panel I, DNA methylation in whole blood from 43 women was assessed at 1505 CpG sites for association with exposure levels of each pollutant. Candidate CpG sites were identified using a Diff Score |13| (P 0.05) and an absolute difference 10 which were confirmed using bisulfite pyrosequencing. Methylation of the GSTM1/5 promoter was increased for women with higher mercury exposure (P 0.04); however, no correlation was observed (r 0.17, P 0.27). Reduced methylation was detected in the COL1A2 promoter in women with higher exposure to lead (P 0.004), and an inverse correlation was observed (r 0.45, P 0.03). Lower methylation of a promoter CpG site at the TSP50 gene was detected in women with higher BPA exposure (P 0.005), and again an inverse correlation was identified (r 0.51, P 0.001). Altered DNA methylation at various CpG sites was associated with exposure to mercury, lead or BPA, providing candidates to be investigated using a larger study sample, as the results may reflect an independently associated predictor (e.g. socioeconomic status, diet, genetic variants, altered blood cell composition). Further studies accommodating variations in these factors will be needed to confirm these associations and identify their underlying causes</abstract>
    <url>WOS:000303161900021</url>
    <isbnorissn>0268-1161</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>34</id>
    <title>Are In Vitro Methods for the Detection of Endocrine Potentials in the Aquatic Environment Predictive for In Vivo Effects? Outcomes of the Projects SchussenAktiv and SchussenAktiv plus in the Lake Constance Area, Germany</title>
    <authors>Henneberg,A.; Bender,K.; Blaha,L.; Giebner,S.; Kuch,B.; Kohler,H.R.; Maier,D.; Oehlmann,J.; Richter,D.; Scheurer,M.; Schulte-Oehlmann,U.; Sieratowicz,A.; Ziebart,S.; Triebskorn,R.</authors>
    <availability>[Henneberg, Anja; Koehler, Heinz-R.; Maier, Diana; Triebskorn, Rita] Univ Tubingen, Tubingen, Germany. [Blaha, Ludek] Masaryk Univ, Fac Sci, RECETOX, CS-61137 Brno, Czech Republic. [Bender, Katrin; Giebner, Sabrina; Oehlmann, Joerg; Schulte-Oehlmann, Ulrike; Sieratowicz, Agnes; Ziebart, Simone] Goethe Univ Frankfurt, Dept Aquat Ecotoxicol, D-60054 Frankfurt, Germany. [Kuch, Bertram] Univ Stuttgart, Inst Sanit Engn Water Qual &amp; Solid Waste Manageme, D-70174 Stuttgart, Germany. [Richter, Doreen; Scheurer, Marco] Water Technol Ctr Karlsruhe, Karlsruhe, Germany.</availability>
    <date>2014</date>
    <notes>JEnglishArticleHenneberg, A (reprint author), Univ Tubingen, Tubingen, Germanyanja.henneberg@uni-tuebingen.deAckermann GE, 2002, AQUAT TOXICOL, V60, P203, DOI 10.1016/S0166-445X(02)00003-6; Adams SM, 1999, ENVIRON TOXICOL CHEM, V18, P628, DOI 10.1897/1551-5028(1999)018&lt;0628:ERAIAL&gt;2.3.CO;2; ANDERSSON T, 1988, CAN J FISH AQUAT SCI, V45, P1525, DOI 10.1139/f88-181; Bernet D, 2003, BATTERY TECHNOLOGY H, P1; Bicchi C, 2009, SCI TOTAL ENVIRON, V407, P1842, DOI 10.1016/j.scitotenv.2008.11.039; Bjerregaard LB, 2006, ECOTOXICOLOGY, V15, P315, DOI 10.1007/s10646-006-0061-9; Bjerregaard P, 2008, ENVIRON TOXICOL CHEM, V27, P2387, DOI 10.1897/08-148.1; Bless R, 1996, ADV LIF SCI, P249; Bolong N, 2009, DESALINATION, V239, P229, DOI 10.1016/j.desal.2008.03.020; Brander SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074251; Brauch H-J, 2011, GWF WASSER ABWASSER, V12, P1206; Burki R, 2006, ENVIRON TOXICOL CHEM, V25, P2077, DOI 10.1897/05-545R.1; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; DICKSON RB, 1981, ENDOCRINOLOGY, V108, P1511; Duft M, 2007, ECOTOXICOLOGY, V16, P169, DOI 10.1007/s10646-006-0106-0; Duft M, 2003, AQUAT TOXICOL, V64, P437, DOI 10.1016/S0166-445X(03)00102-4; ECONOMOU AN, 1991, J FISH BIOL, V39, P393, DOI 10.1111/j.1095-8649.1991.tb04371.x; Environmental Protection Agency US, 2011, ESTR REC TRANSCR ACT; Folmar LC, 2002, AQUAT TOXICOL, V60, P101, DOI 10.1016/S0166-445X(01)00276-4; Fretter V, 1994, J MAR BIOL ASSOC UK, V74, P985; Galluba S, 2012, J SOIL SEDIMENT, V12, P252, DOI 10.1007/s11368-011-0454-0; Giesy JP, 2000, ENVIRON TOXICOL CHEM, V19, P1368, DOI 10.1897/1551-5028(2000)019&lt;1368:EONOFA&gt;2.3.CO;2; Grund S, 2011, ENVIRON SCI POLLUT R, V18, P446, DOI 10.1007/s11356-010-0390-3; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Harries JE, 1997, ENVIRON TOXICOL CHEM, V16, P534, DOI 10.1897/1551-5028(1997)016&lt;0534:EAIFUK&gt;2.3.CO;2; Heinz B, 2009, ENVIRON GEOL, V57, P797, DOI 10.1007/s00254-008-1359-0; Hilscherova K, 2010, ENVIRON TOXICOL CHEM, V29, P522, DOI 10.1002/etc.83; Hilscherova K, 2002, ARCH ENVIRON CON TOX, V43, P175, DOI 10.1007/s00244-002-1128-0; Jacobsen R, 1997, FUNCT ECOL, V11, P260, DOI 10.1046/j.1365-2435.1997.00082.x; Janosek J, 2006, TOXICOL IN VITRO, V20, P18, DOI 10.1016/j.tiv.2005.06.001; Jarosova B, 2014, ENVIRON INT, V64, P98, DOI 10.1016/j.envint.2013.12.009; Jarosova B, 2012, ENVIRON INT, V45, P22, DOI 10.1016/j.envint.2012.04.001; Jeffries MKS, 2011, AQUAT TOXICOL, V105, P189, DOI 10.1016/j.aquatox.2011.04.008; Jobling S, 2004, Aquat Toxicol, V66, P207, DOI 10.1016/j.aquatox.2004.01.002; Jobling S, 2006, ENVIRON HEALTH PERSP, V114, P7, DOI 10.1289/ehp.8046; Jobling S, 2009, ENVIRON HEALTH PERSP, V117, P797, DOI 10.1289/ehp.0800197; Jobling S, 2002, BIOL REPROD, V66, P272, DOI 10.1095/biolreprod66.2.272; Kang IJ, 2008, AQUAT TOXICOL, V87, P37, DOI 10.1016/j.aquatox.2008.01.010; Kavlock RJ, 1996, RISK ANAL, V16, P731, DOI 10.1111/j.1539-6924.1996.tb00824.x; Kidd KA, 2007, P NATL ACAD SCI USA, V104, P8897, DOI 10.1073/pnas.0609568104; Kime DE, 1999, AQUACULTURE, V177, P345, DOI 10.1016/S0044-8486(99)00097-6; Kinani S, 2010, ENVIRON POLLUT, V158, P74, DOI 10.1016/j.envpol.2009.07.041; Kobler B, 2004, OKOLOGISCHE FISCHBIO; Koc HT, 2007, J APPL ICHTHYOL, V23, P19, DOI 10.1111/j.1439-0426.2006.00787.x; Kohler HR, 2013, SCIENCE, V341, P759, DOI 10.1126/science.1237591; Korner W, 2000, CHEMOSPHERE, V40, P1131, DOI 10.1016/S0045-6535(99)00362-8; Korner W, 1999, 95004 PUGU U TUB U W; KArner W., 2001, Journal of Aquatic Ecosystem Stress and Recovery, V8, P215, DOI 10.1023/A:1012976800922; Korner W, 1999, SCI TOTAL ENVIRON, V225, P33; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Houtman CJ, 2006, CHEMOSPHERE, V65, P2244, DOI 10.1016/j.chemosphere.2006.05.043; Loos R, 2013, WATER RES, V47, P6475, DOI 10.1016/j.watres.2013.08.024; Louiz I, 2008, SCI TOTAL ENVIRON, V402, P318, DOI 10.1016/j.scitotenv.2008.05.005; Mazurova E, 2008, BIOLOGIA, V63, P139, DOI 10.2478/s11756-008-0027-x; Mazurova E, 2010, J SOIL SEDIMENT, V10, P423, DOI 10.1007/s11368-009-0166-x; Mert R, 2011, AFYON KOCATEPE U J S, V6, P1; MUNKITTRICK KR, 1992, CAN J FISH AQUAT SCI, V49, P1560; Nagel R, 2004, RINGTEST VALIDIERUNG, V200, P411; Nilsen BM, 1998, MAR ENVIRON RES, V46, P153, DOI 10.1016/S0141-1136(98)00019-1; OECD, 2010, OECD SER TEST ASS, P182; Oehlmann J, 2000, ECOTOXICOLOGY, V9, P383, DOI 10.1023/A:1008972518019; Oehlmann J, 2006, ENVIRON HEALTH PERSP, V114, P127, DOI 10.1289/ehp.8065; Peck M, 2004, ENVIRON TOXICOL CHEM, V23, P945, DOI 10.1897/03-41; PONDER WF, 1988, J MOLLUS STUD, V54, P271, DOI 10.1093/mollus/54.3.271; Purdom C.E., 1994, Chemistry and Ecology, V8, P275, DOI 10.1080/02757549408038554; Runnalls TJ, 2010, HUM ECOL RISK ASSESS, V16, P1318, DOI 10.1080/10807039.2010.526503; Schmitt C, 2010, CHEMOSPHERE, V80, P13, DOI 10.1016/j.chemosphere.2010.03.050; Schmitt C, 2008, ENVIRON POLLUT, V152, P322, DOI 10.1016/j.envpol.2007.06.031; Schmitt C, 2008, SOP TESTING CHEM R 3; Schwarzenbach RP, 2006, SCIENCE, V313, P1072, DOI 10.1126/science.1127291; Sharpe RM, 2004, BRIT MED J, V328, P447, DOI 10.1136/bmj.328.7437.447; Sieratowicz A, 2011, ENVIRON POLLUT, V159, P2766, DOI 10.1016/j.envpol.2011.05.012; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Stalter D, 2010, WATER RES, V44, P439, DOI 10.1016/j.watres.2009.07.025; Stenseth N., 2004, MARINE ECOSYSTEMS CL; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Thorpe KL, 2003, ENVIRON SCI TECHNOL, V37, P1142, DOI 10.1021/es0201348; Triebskorn R, 2012, ENV SCI EUROPE, V24, P1; Triebskorn R, 2013, ENV SCI EUROPE, V25, P1; Turkmen Mustafa, 1999, Turkish Journal of Zoology, V23, P355; Tyler CR, 1999, ENVIRON TOXICOL CHEM, V18, P337, DOI 10.1897/1551-5028(1999)018&lt;0337:AIVTSF&gt;2.3.CO;2; Urbatzka R, 2007, CHEMOSPHERE, V67, P1080, DOI 10.1016/j.chemosphere.2006.11.041; Vajda AM, 2008, ENVIRON SCI TECHNOL, V42, P3407, DOI 10.1021/es0720661; Van den Belt K, 2004, AQUAT TOXICOL, V66, P183, DOI 10.1016/j.aquatox.2003.09.004; Velasco-Santamaria YM, 2010, MAR ENVIRON RES, V69, pS67, DOI 10.1016/j.marenvres.2009.09.009; Vigano L, 2008, CHEMOSPHERE, V73, P1078, DOI 10.1016/j.chemosphere.2008.07.057; Villeneuve DL, 2000, ENVIRON TOXICOL CHEM, V19, P2835, DOI 10.1897/1551-5028(2000)019&lt;2835:DAAORP&gt;2.0.CO;2; Vondracek J, 2001, ENVIRON TOXICOL CHEM, V20, P1499, DOI 10.1897/1551-5028(2001)020&lt;1499:MRSCPW&gt;2.0.CO;2; Wallace C, 1979, J MOLLUS STUD, V45, P383; Weltje L, 2005, HUM EXP TOXICOL, V24, P431, DOI 10.1191/0960327105ht551oa; Wilson VS, 2002, TOXICOL SCI, V66, P69, DOI 10.1093/toxsci/66.1.69; Zhang SC, 2011, INT J BIOCHEM CELL B, V43, P303, DOI 10.1016/j.biocel.2010.11.003; Zhao JL, 2011, ENVIRON TOXICOL CHEM, V30, P2208, DOI 10.1002/etc.625930PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEJUN 5Discipline: Science &amp; Technology - Other TopicsAI4NF</notes>
    <keywords>BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; DISRUPTING CHEMICALS; E-SCREEN ASSAY; estrogenic activity; In vitro; IN-VITRO; IN-VIVO; MUNICIPAL SEWAGE PLANT; POTAMOPYRGUS-ANTIPODARUM; Reporter gene assay; RISK; SAMPLES; TREATMENT-PLANT EFFLUENTS; TROUT SALMO-TRUTTA; UNITED-KINGDOM RIVERS; WASTE-WATER; WATER SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>6</issue>
    <volume>9</volume>
    <abstract>Many studies about endocrine pollution in the aquatic environment reveal changes in the reproduction system of biota. We analysed endocrine activities in two rivers in Southern Germany using three approaches: (1) chemical analyses, (2) in vitro bioassays, and (3) in vivo investigations in fish and snails. Chemical analyses were based on gas chromatography coupled with mass spectrometry. For in vitro analyses of endocrine potentials in water, sediment, and waste water samples, we used the E-screen assay (human breast cancer cells MCF-7) and reporter gene assays (human cell line HeLa-9903 and MDA-kb2). In addition, we performed reproduction tests with the freshwater mudsnail Potamopyrgus antipodarum to analyse water and sediment samples. We exposed juvenile brown trout (Salmo trutta f. fario) to water downstream of a wastewater outfall (Schussen River) or to water from a reference site (Argen River) to investigate the vitellogenin production. Furthermore, two feral fish species, chub (Leuciscus cephalus) and spirlin (Alburnoides bipunctatus), were caught in both rivers to determine their gonadal maturity and the gonadosomatic index. Chemical analyses provided only little information about endocrine active substances, whereas the in vitro assays revealed endocrine potentials in most of the samples. In addition to endocrine potentials, we also observed toxic potentials (E-screen/reproduction test) in waste water samples, which could interfere with and camouflage endocrine effects. The results of our in vivo tests were mostly in line with the results of the in vitro assays and revealed a consistent reproduction-disrupting (reproduction tests) and an occasional endocrine action (vitellogenin levels) in both investigated rivers, with more pronounced effects for the Schussen river (e. g. a lower gonadosomatic index). We were able to show that biological in vitro assays for endocrine potentials in natural stream water reasonably reflect reproduction and endocrine disruption observed in snails and field-exposed fish, respectively</abstract>
    <url>WOS:000336841400025</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>135</id>
    <title>A Mode-of-Action Approach for the Identification of Genotoxic Carcinogens</title>
    <authors>Hernandez,L.G.; van Benthem,J.; Johnson,G.E.</authors>
    <availability>[Hernandez, Lya G.; van Benthem, Jan] Natl Inst Publ Hlth &amp; Environm RIVM, Lab Hlth Protect Res, Bilthoven, Netherlands. [Johnson, George E.] Swansea Univ, Coll Med, Inst Life Sci, Swansea, W Glam, Wales.</availability>
    <date>2013</date>
    <notes>JEnglishArticleJohnson, GE (reprint author), Swansea Univ, Coll Med, Inst Life Sci, Swansea, W Glam, WalesG.Johnson@swansea.ac.ukATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; Bolt HM, 2004, TOXICOL SCI, V81, P3, DOI 10.1093/toxsci/kfh178; Clare MG, 2006, MUTAT RES-GEN TOX EN, V607, P37, DOI 10.1016/j.mrgentox.2006.04.001; CRUMP KS, 1984, FUND APPL TOXICOL, V4, P854, DOI 10.1016/0272-0590(84)90107-6; EFSA, 2009, EFSA J, V1150, P1; Efthimiou M, 2007, MUTAT RES-FUND MOL M, V617, P125, DOI 10.1016/j.mrfmmm.2007.01.009; Elhajouji A, 1995, ENVIRON MOL MUTAGEN, V26, P292, DOI 10.1002/em.2850260405; Elhajouji A, 1997, MUTAGENESIS, V12, P133, DOI 10.1093/mutage/12.3.133; El-Zein R, 2011, MUTAGENESIS, V26, P101, DOI 10.1093/mutage/geq071; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Foth Heidi, 2005, Arhiv za Higijenu Rada i Toksikologiju, V56, P167; Gocke E, 2009, TOXICOL LETT, V190, P298, DOI 10.1016/j.toxlet.2009.03.008; Gollapudi BB, 2012, ENV MOL MUT IN PRESS; Gollapudi BB, 2013, ENVIRON MOL MUTAGEN, V54, P8, DOI 10.1002/em.21727; Hernandez LG, 2011, ENVIRON MOL MUTAGEN, V52, P518, DOI 10.1002/em.20651; Hilliard CA, 1998, ENVIRON MOL MUTAGEN, V31, P316, DOI 10.1002/(SICI)1098-2280(1998)31:4&lt;316::AID-EM3&gt;3.0.CO;2-G; IVETT JL, 1989, ENVIRON MOL MUTAGEN, V14, P165, DOI 10.1002/em.2850140306; Izzo M, 1998, MUTAGENESIS, V13, P445, DOI 10.1093/mutage/13.5.445; Johnson GE, 2008, MUTAT RES-GEN TOX EN, V651, P56, DOI 10.1016/j.mrgentox.2007.10.019; Johnson GE, 2009, MUTAT RES-GEN TOX EN, V678, P95, DOI 10.1016/j.mrgentox.2009.05.009; Kirkland D, 2010, MUTAT RES-GEN TOX EN, V702, P135, DOI 10.1016/j.mrgentox.2010.02.005; Lutz WK, 2009, MUTAT RES-GEN TOX EN, V678, P118, DOI 10.1016/j.mrgentox.2009.05.010; MacGregor JT, 2009, ILSI HESI PROJECT CO, P65; Ochi T, 1999, MUTAT RES-FUND MOL M, V431, P105, DOI 10.1016/S0027-5107(99)00190-6; OECD, 2010, OECD GUID TEST CHEM; OECD, 1997, OECD GUID TEST CHEM; Parry EM, 2002, MUTAGENESIS, V17, P509, DOI 10.1093/mutage/17.6.509; Parry EM CC, 2002, MUTAGENESIS, V556; Parry JM, 2006, MUTAT RES-GEN TOX EN, V607, P5, DOI 10.1016/j.mrgentox.2006.04.007; Pfeiffer E, 1997, MUTAT RES-GEN TOX EN, V390, P21, DOI 10.1016/S0165-1218(96)00161-9; Slob W, 2002, PROAST SOFTWARE DOSE; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Yang AH, 2003, J NEUROSCI, V23, P10454341PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEMAY 13Discipline: Science &amp; Technology - Other Topics145RZ</notes>
    <keywords>ABERRATIONS; ANEUPLOIDY; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER-RISK; Carcinogenicity; CELL; CELLS; CHEMICALS; DNA ADDUCT FORMATION; DOSE-RESPONSE RELATIONSHIPS; HUMAN-LYMPHOCYTES; IDENTIFICATION; In vitro; IN-VITRO; INDUCTION; LINES; mechanism; MECHANISMS; RISK; Risk assessment; RISK-ASSESSMENT; VITRO; VITRO MICRONUCLEUS TEST</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>5</issue>
    <volume>8</volume>
    <abstract>Distinguishing between clastogens and aneugens is vital in cancer risk assessment because the default assumption is that clastogens and aneugens have linear and non-linear dose-response curves, respectively. Any observed non-linearity must be supported by mode of action (MOA) analyses where biological mechanisms are linked with dose-response evaluations. For aneugens, the MOA has been well characterised as disruptors of mitotic machinery where chromosome loss via micronuclei (MN) formation is an accepted endpoint used in risk assessment. In this study we performed the cytokinesis-block micronucleus assay and immunofluorescence mitotic machinery visualisation in human lymphoblastoid (AHH-1) and Chinese Hamster fibroblast (V79) cell lines after treatment with the aneugen 17-beta-oestradiol (E-2). Results were compared to previously published data on bisphenol-A (BPA) and Rotenone data. Two concentration-response approaches (the threshold-[Td] and benchmark-dose [BMD] approaches) were applied to derive a point of departure (POD) for in vitro MN induction. BMDs were also derived from the most sensitive carcinogenic endpoint. Ranking comparisons of the PODs from the in vitro MN and the carcinogenicity studies demonstrated a link between these two endpoints for BPA, E-2 and Rotenone. This analysis was extended to include 5 additional aneugens, 5 clastogens and 3 mutagens and further concentration and dose-response correlations were observed between PODs from the in vitro MN and carcinogenicity. This approach is promising and may be further extended to other genotoxic carcinogens, where MOA and quantitative information from the in vitro MN studies could be used in a quantitative manner to further inform cancer risk assessment</abstract>
    <url>WOS:000319036100063</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>153</id>
    <title>Epigenetic regulation of estrogen signaling in breast cancer</title>
    <authors>Hervouet,E.; Cartron,P.F.; Jouvenot,M.; Delage-Mourroux,R.</authors>
    <availability>[Hervouet, Eric; Jouvenot, Michele; Delage-Mourroux, Regis] Univ Franche Comte, Lab Biochim, EA3922, SFRIBCT FED 4234,UFR Sci &amp; Tech, F-25030 Besancon, France. [Cartron, Pierre-Francois] Ctr Rech Cancerol Nantes Angers, INSERM, Equipe Aspects Mecanist &amp; Physiopathol Act Prot F, Equipe Labellisee Ligue Natl Canc, Nantes, France.</availability>
    <date>2013</date>
    <notes>JEnglishReviewHervouet, E (reprint author), Univ Franche Comte, Lab Biochim, EA3922, SFRIBCT FED 4234,UFR Sci &amp; Tech, F-25030 Besancon, Franceeric.hervouet@univ-fcomte.frAl-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426; Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x; Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Carascossa S, 2010, GENE DEV, V24, P708, DOI 10.1101/gad.568410; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Ceschin DG, 2011, GENE DEV, V25, P1132, DOI 10.1101/gad.619211; Chen DS, 2003, J BIOL CHEM, V278, P38586, DOI 10.1074/jbc.M304286200; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Cheng XD, 2008, STRUCTURE, V16, P341, DOI 10.1016/j.str.2008.01.004; Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106; Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Denis H, 2009, MOL CELL BIOL, V29, P4982, DOI 10.1128/MCB.00285-09; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011; Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Furst RW, 2012, J STEROID BIOCHEM, V130, P96, DOI 10.1016/j.jsbmb.2012.01.009; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005; Hervouet E, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-31; Hervouet E, 2009, EPIGENETICS, V4, P487; Hervouet E, 2009, CLIN CANCER RES, V15, P3519, DOI 10.1158/1078-0432.CCR-08-2062; Hervouet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011333; Hervouet Eric, 2010, Genes Cancer, V1, P434, DOI 10.1177/1947601910373794; Hockings JK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1987; Hostetter CL, 2009, CANCER LETT, V275, P178, DOI 10.1016/j.canlet.2008.10.005; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; Hwang C, 2008, BREAST CANCER RES TR, V107, P235, DOI 10.1007/s10549-007-9542-7; Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403; Keen JC, 2004, CANCER BIOL THER, V3, P1304; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Koos RD, 2005, ANN NY ACAD SCI, V1041, P233, DOI 10.1196/annals.1282.037; Kovalchuk O, 2007, CELL CYCLE, V6, P2010; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kutanzi KR, 2010, CELL CYCLE, V9, P3078, DOI 10.4161/cc.9.15.12516; Lee YH, 2005, P NATL ACAD SCI USA, V102, P3611, DOI 10.1073/pnas.0407159102; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045; Li YY, 2011, J BIOL CHEM, V286, P13925, DOI 10.1074/jbc.M111.223198; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lopez-Garcia MA, 2010, HISTOPATHOLOGY, V57, P171, DOI 10.1111/j.1365-2559.2010.03568.x; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476; Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368; Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Molli PR, 2008, ONCOGENE, V27, P1971, DOI 10.1038/sj.onc.1210839; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; Palijan A, 2009, J BIOL CHEM, V284, P30275, DOI 10.1074/jbc.M109.051201; Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526; Prabhu JS, 2012, TUMOR BIOL, V33, P315, DOI 10.1007/s13277-012-0343-1; Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23; Re A, 2011, MOL ENDOCRINOL, V25, P2003, DOI 10.1210/me.2011-1024; Ruegg J, 2011, MOL ENDOCRINOL, V25, P2017, DOI 10.1210/me.2011-1054; Rodriguez BAT, 2011, CARCINOGENESIS, V32, P812, DOI 10.1093/carcin/bgr017; Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458; Sato K, 2009, ENDOCR J, V56, P131; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Singh KP, 2012, CANCER LETT, V316, P62, DOI 10.1016/j.canlet.2011.10.022; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1&lt;112::AID-CNCR16&gt;3.0.CO;2-T; Starlard-Davenport A, 2010, CARCINOGENESIS, V31, P376, DOI 10.1093/carcin/bgp304; Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284; Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486; Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wei J, 2012, TUMOR BIOL, V33, P413, DOI 10.1007/s13277-011-0234-x; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Westberry JM, 2010, ENDOCRINOLOGY, V151, P731, DOI 10.1210/en.2009-0955; Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343; Yamagata Y, 2009, HUM REPROD, V24, P1126, DOI 10.1093/humrep/dep015; Yang XW, 2001, CANCER RES, V61, P7025; Yao J, 2010, BIOSCIENCE REP, V30, P217, DOI 10.1042/BSR20090044; Zhang B, 2011, LANCET ONCOL, V12, P477, DOI 10.1016/S1470-2045(11)70076-6; Zhao L, 2012, MED ONCOL, V29, P1569, DOI 10.1007/s12032-011-0107-6; Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1; Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.3688411LANDES BIOSCIENCEAUSTIN1806 RIO GRANDE ST, AUSTIN, TX 78702 USAEPIGENETICS-USMARDiscipline: Biochemistry &amp; Molecular Biology103NE</notes>
    <keywords>ALPHA; ARGININE METHYLATION; BETA; BIOLOGY; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; CELLS; CYCLE; DNA METHYLATION; epigenetic; EPIGENETIC REGULATION; epigenetics; ER alpha; ER-ALPHA; ER-BETA; Estrogen; estrogen signaling; EXPRESSION; gene expression; GENE-EXPRESSION; GENES; HISTONE METHYLATION; histones; LIGAND DEPENDENCY; PROTEIN; PROTEINS; RECEPTOR-ALPHA; toxicology; Transcriptional regulation; TUMORIGENESIS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>237</startpage>
    <endpage>245</endpage>
    <journalfull>Epigenetics</journalfull>
    <issue>3</issue>
    <volume>8</volume>
    <abstract>Estrogen signaling is mediated by ER alpha and ER beta in hormone dependent breast cancer (BC). Over the last decade the implication of epigenetic pathways in BC tumorigenesis has emerged: cancer-related epigenetic modifications are implicated in both gene expression regulation and chromosomal instability. In this review, the epigenetic-mediated estrogen signaling, controlling both ER level and ER-targeted gene expression in BC, are discussed: (1) ER silencing is frequently observed in BC and is often associated with epigenetic regulations while chemical epigenetic modulators restore ER expression and increase response to treatment; (2) ER-targeted gene expression is tightly regulated by co-recruitment of ER and both co-activators/co-repressors including HATs, HDACs, HMTs, Dnmts and Polycomb proteins</abstract>
    <url>WOS:000315923300002</url>
    <isbnorissn>1559-2294</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>399</id>
    <title>Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancer</title>
    <authors>Hess-Wilson,J.K.</authors>
    <availability>US EPA, Off Res &amp; Dev, Natl Ctr Environm Assessment MS A110, Cincinnati, OH 45268 USA.</availability>
    <date>2009</date>
    <notes>JEnglishEditorial MaterialHess-Wilson, JK (reprint author), US EPA, Off Res &amp; Dev, Natl Ctr Environm Assessment MS A110, 26 W Martin Luther King Dr, Cincinnati, OH 45268 USAhess-wilson.janet@epa.govAllred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675; Arora A, 2004, J AM GERIATR SOC, V52, P611, DOI 10.1111/j.1532-5415.2004.52171.x; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Eder Iris E, 2005, Future Oncol, V1, P93; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Herath CB, 2004, ENDOCRINE, V25, P163, DOI 10.1385/ENDO:25:2:163; Hess-Wilson JK, 2006, BREAST CANCER RES TR, V96, P279, DOI 10.1007/s10549-005-9082-y; Hess-Wilson JK, 2006, CANCER LETT, V241, P1, DOI 10.1016/j.canlet.2005.10.006; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Horvath LG, 2001, CANCER RES, V61, P5331; Ingle JN, 2003, J STEROID BIOCHEM, V86, P313, DOI 10.1016/S0960-0760(03)00373-X; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ji Q, 2005, MOL CELL ENDOCRINOL, V229, P103, DOI 10.1016/j.mce.2004.08.012; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kirkpatrick John P, 2005, Clin Adv Hematol Oncol, V3, P933; Lai JS, 2004, UROLOGY, V64, P814, DOI 10.1016/j.urology.2004.05.036; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8; Li L, 2007, J MOL ENDOCRINOL, V38, P569, DOI 10.1677/JME-07-0003; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Maggiolini M, 2004, J MOL ENDOCRINOL, V32, P777, DOI 10.1677/jme.0.0320777; Marcelli M, 2000, CANCER RES, V60, P944; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Munguia-Lopez EM, 2005, FOOD ADDIT CONTAM, V22, P892, DOI 10.1080/02652030500163674; Munguia-Lopez EM, 2001, J AGR FOOD CHEM, V49, P3666, DOI 10.1021/jf0009044; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758; Ogura Y, 2007, DIFFERENTIATION, V75, P745, DOI 10.1111/j.1432-0436.2007.00177.x; Pravettoni A, 2007, MOL CELL ENDOCRINOL, V263, P46, DOI 10.1016/j.mce.2006.08.008; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Prins GS, 2008, ENDOCR-RELAT CANCER, V15, P649, DOI 10.1677/ERC-08-0043; Ralph JL, 2003, ENVIRON HEALTH PERSP, V111, P461, DOI 10.1289/ehp.5919; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Shah S, 2008, MOL CANCER RES, V6, P1507, DOI 10.1158/1541-7786.MCR-07-2166; Sharifi Nima, 2006, Am J Ther, V13, P166, DOI 10.1097/00045391-200603000-00013; Snyder RW, 2000, TOXICOL APPL PHARM, V168, P225, DOI 10.1006/taap.2000.9051; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; Thayer KA, 2001, HUM REPROD, V16, P988, DOI 10.1093/humrep/16.5.988; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Trapman J, 1996, PATHOL RES PRACT, V192, P752; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; vom Saal FS, 2005, TOXICOLOGY, V212, P244, DOI 10.1016/j.tox.2005.05.006; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Wetherill YB, 2005, CANCER RES, V65, P54; Yoshida T, 2001, FOOD ADDIT CONTAM A, V18, P69, DOI 10.1080/026520301446412; Zeliadt SB, 2006, CANCER, V106, P1865, DOI 10.1002/cncr.21822596SPRINGERDORDRECHTVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDSCANCER CAUSE CONTROLSEPDiscipline: Oncology; Public, Environmental &amp; Occupational Health480ZF</notes>
    <keywords>Androgen; ANDROGEN DEPRIVATION THERAPY; ANDROGEN RECEPTOR; AROMATASE INHIBITORS; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CELL; COMPLEXES; DEPRIVATION; Differentiation; DISEASE; diseases; ENDOCRINE; Endocrine disrupting compound; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental contaminants; environmental exposure; Estrogen; ESTROGEN-RECEPTOR-BETA; EXPOSURE; FOOD; FOOD SIMULANT; FREQUENT LOSS; FUTURE; GLAND; GROWTH; HEALTH; HUMAN EXPOSURE; HUMAN HEALTH; HUMANS; in vivo; IN-VIVO; INCREASES SUSCEPTIBILITY; mammary gland; MAMMARY-GLAND; MODEL; MORTALITY; Occupational; oncology; POSTMENOPAUSAL BREAST-CANCER; proliferation; Prostate; prostate cancer; PROSTATE-CANCER; RECEPTOR; RESISTANCE; SENSITIVITY; Steroid; TARGET; THERAPY; toxicology; TUMOR; TUMOR-GROWTH; VIVO; XENOESTROGEN ACTION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1029</startpage>
    <endpage>1037</endpage>
    <journalfull>Cancer Causes &amp; Control</journalfull>
    <issue>7</issue>
    <volume>20</volume>
    <abstract>Individuals diagnosed with specific diseases may represent subpopulations with heightened sensitivity to environmental compounds. This may be due to their disease-mediated molecular milieu and/or the interference of environmental compounds with pharmaceutical drug targets. Prostate cancer represents a significant clinical challenge in the United States. If the disease becomes advanced, standard therapies are ineffective, leading to high rate of patient morbidity and mortality. Understanding the complex reasons for therapeutic resistance is critical for improving the life expectancy for patients with this cancer. Recently, it has been identified that common somatically derived genetic mutations that arise following the selective pressure of standard prostate cancer treatments may facilitate sensitivity to environmental contaminants. These somatic mutations within the androgen receptor allow the estrogen mimic, bisphenol A (BPA), to bind and activate the receptor, resulting in increased proliferation and tumor growth in the presence of the traditional therapy regimen for prostate cancer. In an in vivo xenograft model of prostate cancer, low level exposure of BPA was sufficient to reduce the efficacy of treatment. Herein, the possible effect of BPA on prostate cancer treatment and disease management for humans is explored as an example of environmental endocrine disruptor exposure reducing the efficacy of disease management. These data lend support to the hypothesis that environmental exposure to select compounds may interfere with specific therapeutic regimens</abstract>
    <url>WOS:000268775300001</url>
    <isbnorissn>0957-5243</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>309</id>
    <title>Estrogenic Activity of Bisphenol A and 2,2-bis(p-Hydroxyphenyl)-1,1,1-trichloroethane (HPTE) Demonstrated in Mouse Uterine Gene Profiles</title>
    <authors>Hewitt,S.C.; Korach,K.S.</authors>
    <availability>[Hewitt, Sylvia C.; Korach, Kenneth S.] NIEHS, Receptor Biol Sect, Lab Reprod &amp; Dev Toxicol, NIH,Dept Hlth &amp; Human Serv, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleHewitt, SC (reprint author), NIEHS, Receptor Biol Sect, Lab Reprod &amp; Dev Toxicol, NIH,Dept Hlth &amp; Human Serv, 111 Alexander Dr, Res Triangle Pk, NC 27709 USAcurtiss@niehs.nih.govAshby J, 2004, TOXICOL SCI, V82, P458, DOI 10.1093/toxsci/kfh283; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Boehme K, 2009, TOXICOL APPL PHARM, V236, P85, DOI 10.1016/j.taap.2009.01.006; Borgeest C, 2002, TOXICOL SCI, V68, P473, DOI 10.1093/toxsci/68.2.473; Celik L, 2008, CHEM RES TOXICOL, V21, P2195, DOI 10.1021/tx800278d; CLARK JH, 1984, J STEROID BIOCHEM, V20, P1005, DOI 10.1016/0022-4731(84)90011-6; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Dey S, 2009, MED HYPOTHESES, V72, P652, DOI 10.1016/j.mehy.2008.10.025; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dodds EC, 1937, NATURE, V140, P772, DOI 10.1038/140772a0; Fujimoto N, 2004, J STEROID BIOCHEM, V88, P53, DOI 10.1016/j.jsbmb.2003.10.006; Gaido KW, 2000, MOL PHARMACOL, V58, P852; Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hewitt SC, 2010, FASEB J, V24, P4660, DOI 10.1096/fj.10-163428; Hewitt SC, 2006, ENDOCRINOLOGY, V147, P2203, DOI 10.1210/en.2005-1292; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Hewitt SC, 2009, MOL ENDOCRINOL, V23, P2111, DOI 10.1210/me.2009-0356; Hewitt SC, 2010, J BIOL CHEM, V285, P2676, DOI 10.1074/jbc.M109.043471; Institute for Laboratory Animal Research, 1996, GUID CAR US LAB AN; Jakacka M, 2001, J BIOL CHEM, V276, P13615; KATZENELLENBOGEN BS, 1984, J STEROID BIOCHEM, V20, P1033, DOI 10.1016/0022-4731(84)90015-3; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; LAN NC, 1976, ENDOCRINOLOGY, V98, P220; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, P55, DOI 10.2307/3434921; Miller KR, 2006, TOXICOL SCI, V93, P180, DOI 10.1093/toxsci/kfl034; Moggs JG, 2005, TOXICOLOGY, V213, P177, DOI 10.1016/j.tox.2005.05.020; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; *NAT CTR BIOT INF, 2010, GEN EXPR OMN; Newbold RR, 2001, REPROD TOXICOL, V15, P245, DOI 10.1016/S0890-6238(01)00130-7; O'Brien JE, 2006, J BIOL CHEM, V281, P26683, DOI 10.1074/jbc.M601522200; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; Ray S, 2008, MOL ENDOCRINOL, V22, P1125, DOI 10.1210/me.2007-0445; Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103; Safe SH, 2001, REPROD FERT DEVELOP, V13, P307, DOI 10.1071/RD00108; Tiemann U, 2008, REPROD TOXICOL, V25, P316, DOI 10.1016/j.reprotox.2008.03.002; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Waters KM, 2001, TOXICOL SCI, V63, P47, DOI 10.1093/toxsci/63.1.47; Weng L, 2006, BIOINFORMATICS, V22, P1111, DOI 10.1093/bioinformatics/btl045; Wu F, 2008, J STEROID BIOCHEM, V110, P104, DOI 10.1016/j.jsbmb.2008.02.008; Yoon K, 2000, MOL CELL ENDOCRINOL, V162, P211, DOI 10.1016/S0303-7207(99)00261-0; Yoshida T, 2008, EXP CELL RES, V314, P1217, DOI 10.1016/j.yexcr.2008.01.0024710US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPJANDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology701BI</notes>
    <keywords>ALPHA; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CELL; CHEMICALS; development; ENVIRONMENTAL ESTROGENS; ER alpha; ER-ALPHA; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptor alpha; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; estrogenic activity; ESTROGENIC CHEMICALS; EXPRESSION; GENE; HEALTH; HPTE; in vivo; IN-VIVO; mechanism; MECHANISMS; Methoxychlor; MICE; Microarray; MODEL; molecular mechanism; MOLECULAR-MECHANISMS; Mouse; Occupational; RECEPTOR; RECEPTOR-ALPHA; REPRODUCTIVE-TRACT; RESPONSES; SAMPLES; Steroid; SYSTEM; toxicology; TRANSCRIPTION; Uterus; VIVO; WATER; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>63</startpage>
    <endpage>70</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>1</issue>
    <volume>119</volume>
    <abstract>BACKGROUND: Interest and concern regarding potentially estrogenic substances have resulted in development of model systems to evaluate mechanisms of such chemicals. Microarray studies have indicated that estradiol (E(2))-stimulated uterine responses can be divided into early and late phases. Comparison of E(2) uterine transcript profiles and those of other estrogenic chemicals of interest in vivo indicates mechanisms and activities of test compounds. OBJECTIVES: We compared transcript responses and mechanisms of response using mouse reproductive tracts after treatment with E(2), estriol (E(3)), bisphenol A (BPA), and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE). METHODS: Uterine RNA from ovariectomized wild-type mice, estrogen receptor alpha (ER alpha) knockout (alpha ERKO) mice, and mice expressing a DNA-binding-deficient ER alpha (KIKO) treated with E(2), E(3), BPA, or HPTE for 2 or 24 hr was analyzed by microarray. Resulting regulated transcripts were compared by hierarchical clustering and correlation analysis, and response patterns were verified by reverse-transcription real-time polymerase chain reaction (RT-PCR). RESULTS: Both xenoestrogens, BPA and HPTE, showed profiles highly correlated to that of E(2) in the early response phase (2 hr), but the correlation diminished in the later response phase (24 hr), similar to the known weak estrogen E(3). Both xenoestrogens also mimicked E(2) in samples from KIKO mice, indicating that they are able to utilize the indirect tethering mode of ER alpha signaling. No response was detected in ER alpha-null uteri, indicating that ER alpha mediates the responses. CONCLUSION: Our study forms a basis on which patterns of response and molecular mechanisms of potentially estrogenic chemicals can be assessed</abstract>
    <url>WOS:000285788900025</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>391</id>
    <title>The Breast Cancer and the Environment Research Centers: Transdisciplinary Research on the Role of the Environment in Breast Cancer Etiology</title>
    <authors>Hiatt,R.A.; Haslam,S.Z.; Osuch,J.</authors>
    <availability>[Hiatt, Robert A.] Univ Calif San Francisco, Dept Epidemiol &amp; Biostat, San Francisco, CA 94107 USA. [Hiatt, Robert A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94107 USA. [Haslam, Sandra Z.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA. [Osuch, Janet] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.</availability>
    <date>2009</date>
    <notes>JEnglishReviewHiatt, RA (reprint author), Univ Calif San Francisco, Dept Epidemiol &amp; Biostat, 185 Berry St,Suite 5700, San Francisco, CA 94107 USArhiatt@cc.ucsf.eduAmbrosone CB, 2008, CANCER EPIDEM BIOMAR, V17, P15, DOI 10.1158/1055-9965.EPI-07-0598; ANBAZHAGAN R, 1991, AM J ANAT, V192, P407, DOI 10.1002/aja.1001920408; Aupperlee Mark, 2005, Breast Dis, V24, P37; Baker VA, 1999, FOOD CHEM TOXICOL, V37, P13, DOI 10.1016/S0278-6915(98)00101-X; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; *BCERC, 2008, HOM PAG; Berkey CS, 1999, CANCER, V85, P2400, DOI 10.1002/(SICI)1097-0142(19990601)85:11&lt;2400::AID-CNCR15&gt;3.0.CO;2-O; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Biro FM, 2003, J PEDIATR, V142, P643, DOI 10.1067/mpd.2003.244; Biro FM, 2006, J PEDIATR, V148, P234, DOI 10.1016/j.jpeds.2005.10.020; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Bogaert AF, 2005, J ADOLESCENCE, V28, P541, DOI 10.1016/j.adolescence.2004.10.008; BOICE JD, 1995, JAMA-J AM MED ASSOC, V274, P394, DOI 10.1001/jama.274.5.394; BOICE JD, 1991, JAMA-J AM MED ASSOC, V265, P1290, DOI 10.1001/jama.265.10.1290; Braithwaite D, 2009, CANCER CAUSE CONTROL, V20, P713, DOI 10.1007/s10552-008-9284-9; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Louis GMB, 2008, PEDIATRICS, V121, pS192, DOI 10.1542/peds.1813E; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; CANTOR KP, 1995, J OCCUP ENVIRON MED, V37, P336, DOI 10.1097/00043764-199503000-00011; Chang-Claude J, 2007, CANCER EPIDEM BIOMAR, V16, P740, DOI 10.1158/1055-9965.EPI-06-0829; Charmandari E, 2002, J CLIN ENDOCR METAB, V87, P2114, DOI 10.1210/jc.87.5.2114; Chepko G, 1999, J MAMMARY GLAND BIOL, V4, P35, DOI 10.1023/A:1018752519356; Choe SY, 2003, SCI TOTAL ENVIRON, V312, P15, DOI 10.1016/S0048-9697(03)00190-6; Clavel-Chapelon F, 2002, BRIT J CANCER, V86, P723, DOI 10.1038/sj/bjc/6600124; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Cohn BA, 2003, LANCET, V361, P2205, DOI 10.1016/S0140-6736(03)13776-2; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P567; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Crofton PM, 2002, CLIN ENDOCRINOL, V56, P223, DOI 10.1046/j.0300-0664.2001.01449.x; Cubbin C, 2006, SCAND J PUBLIC HEALT, V34, P228, DOI 10.1080/14034940500327935; Cummings SR, 2009, J NATL CANCER I, V101, P384, DOI 10.1093/jnci/djp018; Davison KK, 2003, PEDIATRICS, V111, P815, DOI 10.1542/peds.111.4.815; Demerath EW, 2007, AM J HUM BIOL, V19, P692, DOI 10.1002/ajhb.20660; Denham M, 2005, PEDIATRICS, V115, pE127, DOI 10.1542/peds.2004-1161; de Waard F, 2005, J STEROID BIOCHEM, V97, P451, DOI 10.1016/j.jsbmb.2005.08.005; Ellis BJ, 2007, CHILD DEV, V78, P1799, DOI 10.1111/j.1467-8624.2007.01092.x; Ellis BJ, 2000, CHILD DEV, V71, P485, DOI 10.1111/1467-8624.00159; Ellis BJ, 2004, PSYCHOL BULL, V130, P920, DOI 10.1037/0033-2909.130.6.920; Ema M, 2003, REPROD TOXICOL, V17, P407, DOI 10.1016/S0890-6238(03)00037-6; Ema M, 2002, REPROD TOXICOL, V16, P71, DOI 10.1016/S0890-6238(01)00200-3; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P409; Euling SY, 2008, PEDIATRICS, V121, pS172, DOI 10.1542/peds.2007-1813D; Ewing R, 2003, AM J HEALTH PROMOT, V18, P47; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Forman MR, 2005, CANCER INVEST, V23, P609, DOI 10.1080/07357900500283093; Freedman DS, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e43; Garland M, 1998, AM J EPIDEMIOL, V147, P636; Gladen BC, 2000, J PEDIATR, V136, P490, DOI 10.1016/S0022-3476(00)90012-X; Golding J, 1990, West Engl Med J, V105, P80; Golub MS, 2008, PEDIATRICS, V121, pS218, DOI 10.1542/peds.2007-1813G; Gouon-Evans V, 2002, BREAST CANCER RES, V4, P155, DOI 10.1186/bcr441; Graber JA, 1997, J AM ACAD CHILD PSY, V36, P1768, DOI 10.1097/00004583-199712000-00026; GRABER JA, 1995, CHILD DEV, V66, P346, DOI 10.1111/j.1467-8624.1995.tb00875.x; Greiser CM, 2005, HUM REPROD UPDATE, V11, P561, DOI 10.1093/humupd/dmi031; Grumbach MM, 2002, WILLIAMS TXB ENDOCRI, P1115; Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Hayward C, 1997, J AM ACAD CHILD PSY, V36, P255; HENDERSON BE, 1981, LANCET, V2, P363; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; Heo M, 2002, INT J OBESITY, V26, P640, DOI 10.1038/sj/ijo/0801990; Hiatt RA, 2008, AM J PREV MED, V35, pS141, DOI 10.1016/j.amepre.2008.05.006; Hodgson E, 2007, J BIOCHEM MOL TOXIC, V21, P182, DOI 10.1002/jbt.20175; Hoffstedt J, 2002, HORM METAB RES, V34, P355, DOI 10.1055/s-2002-33466; Hong EJ, 2005, J REPROD DEVELOP, V51, P253, DOI 10.1262/jrd.16075; Howard BA, 2000, J MAMMARY GLAND BIOL, V5, P119, DOI 10.1023/A:1026487120779; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; Ingman WV, 2006, DEV DYNAM, V235, P3222, DOI 10.1002/dvdy.20972; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Jasik CB, 2008, ANN NY ACAD SCI, V1135, P265, DOI 10.1196/annals.1429.009; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; JOHN EM, 1993, EPIDEMIOL REV, V15, P157; Kadlubar FF, 2003, CANCER EPIDEM BIOMAR, V12, P327; Kaplowitz PB, 2008, PEDIATRICS, V121, pS208, DOI 10.1542/peds.2007-1813F; Kariagina A, 2008, CRIT REV EUKAR GENE, V18, P11; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; Knight CH, 2001, REPRODUCTION, V122, P337, DOI 10.1530/rep.0.1220337; Kotsopoulos J, 2007, BREAST CANCER RES TR, V105, P221, DOI 10.1007/s10549-006-9441-3; Kovacs M., 1992, CHILDRENS DEPRESSION; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; Lamminen T, 2001, EUR J PHARMACOL, V414, P1, DOI 10.1016/S0014-2999(01)00756-7; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Lawson JS, 1999, SCAND J PUBLIC HEALT, V27, P203, DOI 10.1177/14034948990270031201; Lee JM, 2007, PEDIATRICS, V119, pE624, DOI 10.1542/peds.2006-2188; Lee RE, 2002, AM J PUBLIC HEALTH, V92, P428, DOI 10.2105/AJPH.92.3.428; MACMAHON B, 1982, INT J CANCER, V30, P427, DOI 10.1002/ijc.2910300408; MACMAHON B, 1982, INT J CANCER, V29, P13, DOI 10.1002/ijc.2910290104; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Magnusson CMK, 2005, BRIT J CANCER, V93, P817, DOI 10.1038/sj.bjc.6602758; Massart F, 2006, Minerva Pediatr, V58, P247; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; McClintock MK, 2005, J GERONTOL B-PSYCHOL, V60, P32; McElroy JA, 2006, J NATL CANCER I, V98, P869, DOI 10.1093/jnci/djj233; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; MOOS RH, 1990, FAM PROCESS, V29, P209; MOOS RH, 1990, FAM PROCESS, V29, P199, DOI 10.1111/j.1545-5300.1990.00199.x; Morello-Frosch R, 2006, ENVIRON HEALTH PERSP, V114, P386, DOI 10.1289/ehp.8500; Morland K, 2002, AM J PREV MED, V22, P23, DOI 10.1016/S0749-3797(01)00403-2; MORRIS JJ, 1992, MED HYPOTHESES, V38, P177, DOI 10.1016/0306-9877(92)90090-Y; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Mustanski BS, 2004, DEV PSYCHOL, V40, P1188, DOI 10.1037/0012-1649.40.6.1188; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Ong KKL, 1999, ACTA PAEDIATR, V88, P95, DOI 10.1111/j.1651-2227.1999.tb14413.x; Ouyang F, 2005, OCCUP ENVIRON MED, V62, P878, DOI 10.1136/oem.2005.020248; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Park SK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1850; Pathak DR, 2000, CANCER, V88, P1230, DOI 10.1002/(SICI)1097-0142(20000301)88:5+&lt;1230::AID-CNCR9&gt;3.0.CO;2-F; Pathak DR, 2002, CANCER CAUSE CONTROL, V13, P295, DOI 10.1023/A:1015282916368; Paukku K, 2004, CYTOKINE GROWTH F R, V15, P435, DOI 10.1016/j.cytogfr.2004.09.001; Perez Mayorga M, 2000, J Clin Endocrinol Metab, V85, P3365; PIKE MC, 1993, EPIDEMIOL REV, V15, P17; Pukkala E, 2006, INT J CANCER, V119, P651, DOI 10.1002/ijc.21885; Quinlan RJ, 2003, EVOL HUM BEHAV, V24, P376, DOI 10.1016/S1090-5138(03)00039-4; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ramji DP, 2002, BIOCHEM J, V365, P561; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Reynolds CR, 2002, CLIN GUIDE BEHAV ASS; Reynolds P, 2004, J NATL CANCER I, V96, P29, DOI 10.1093/jnci.djh002; Rogol AD, 1998, J CLIN ENDOCR METAB, V83, P1089, DOI 10.1210/jc.83.4.1089; Romans SE, 2003, PSYCHOL MED, V33, P933, DOI 10.1017/S0033291703007530; ROSENFIELD PL, 1992, SOC SCI MED, V35, P1343, DOI 10.1016/0277-9536(92)90038-R; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; RUSSO J, 1993, CRIT REV ONCOGENESIS, V4, P403; Russo J, 2008, CANCER EPIDEM BIOMAR, V17, P51, DOI 10.1158/1055-9965.EPI-07-0678; Russo J, 2008, ADV EXP MED BIOL, V630, P52; Saelens BE, 2003, ANN BEHAV MED, V25, P80, DOI 10.1207/S15324796ABM2502_03; Schedin P, 2007, J MAMMARY GLAND BIOL, V12, P71, DOI 10.1007/s10911-007-9039-3; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Selevan SG, 2003, NEW ENGL J MED, V348, P1527, DOI 10.1056/NEJMoa020880; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068; Sivaraman L, 2002, J MAMMARY GLAND BIOL, V7, P77, DOI 10.1023/A:1015774524076; Smedley BD, 2001, AM J HEALTH PROMOT, V15, P149; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; Sonnenschein E, 1999, INT J EPIDEMIOL, V28, P1026, DOI 10.1093/ije/28.6.1026; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stokols Daniel, 2003, Nicotine Tob Res, V5 Suppl 1, pS21; Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9; Titus-Ernstoff L, 1998, CANCER EPIDEM BIOMAR, V7, P783; TOKUNAGA M, 1991, J RADIAT RES, V32, P201, DOI 10.1269/jrr.32.SUPPLEMENT_201; *TREC, 2008, HOM PAG; Tremblay L, 2005, CHILD PSYCHIAT HUM D, V36, P73, DOI 10.1007/s10578-004-3489-2; Trichopoulos D, 2005, BREAST CANCER RES, V7, P13, DOI 10.1186/bcr966; Vasiliu O, 2004, HUM REPROD, V19, P1506, DOI 10.1093/humrep/deh292; Verla-Tebit E, 2005, EUR J CANCER PREV, V14, P419, DOI 10.1097/00008469-200508000-00016; VIHKO R, 1984, J STEROID BIOCHEM, V20, P231, DOI 10.1016/0022-4731(84)90209-7; Weiderpass E, 2004, CANCER EPIDEM BIOMAR, V13, P1121; Wicha MS, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1990; Windham GC, 2004, AM J EPIDEMIOL, V159, P862, DOI 10.1093/aje/kwh117; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Wolff MS, 1996, ANNU REV PHARMACOL, V36, P573; Wolff MS, 2008, ENVIRON RES, V107, P393, DOI 10.1016/j.envres.2008.03.006; Wu TJ, 2003, ENVIRON HEALTH PERSP, V111, P737, DOI 10.1289/ehp.6008; Xie JW, 2008, BREAST CANCER RES TR, V110, P257, DOI 10.1007/s10549-007-9719-0; Xue F, 2007, LANCET ONCOL, V8, P1088, DOI 10.1016/S1470-2045(07)70377-7; Yen IH, 1998, AM J PUBLIC HEALTH, V88, P1709, DOI 10.2105/AJPH.88.11.1709; Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1093/toxsci/46.2.28216524US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPDECDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology528VH</notes>
    <keywords>1; ADOLESCENCE; ATOMIC-BOMB SURVIVORS; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; BUTYL BENZYL PHTHALATE; CANCER; CARCINOGENESIS; CE; CELL; CHILDREN; cohort; Cytokine; DATA-COLLECTION; development; Differentiation; ENDOCRINE-DISRUPTING COMPOUNDS; environment; environmental factors; ENVIRONMENTAL-FACTORS; Epidemiology; EPITHELIAL STEM-CELLS; Etiology; FOOD; FRAMEWORK; FULL-TERM PREGNANCY; GAP; GENE; GLAND; GROWTH; HEALTH; IN-VIVO; INTEGRATION; mammary gland; MAMMARY-GLAND; MAMMARY-GLAND DEVELOPMENT; MODEL; MODELS; Occupational; ORGANIZATION; pediatric; PHYSICAL-ACTIVITY; PREVENTION; PUBERTAL DEVELOPMENT; Reproduction; Review; RISK; RISK FACTOR; Steroid; SYSTEM; TISSUE; toxicology; transdisciplinary science; UPDATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1814</startpage>
    <endpage>1822</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>12</issue>
    <volume>117</volume>
    <abstract>OBJECTIVES: We introduce and describe the Breast Cancer and the Environment Research Centers (BCERC), a research network with a transdisciplinary approach to elucidating the role of environmental factors in pubertal development as a window on breast cancer etiology. We describe the organization of four national centers integrated into the BCERC network. DATA SOURCES: Investigators use a common conceptual framework based on multiple levels of biologic, behavioral, and social organization across the life span. The approach connects basic biologic studies with rodent models and tissue culture systems, a coordinated multicenter epidemiologic cohort study of prepubertal girls, and the integration of community members of breast cancer a vocares as key members of the research team to comprise the network. DATA EXTRACTION: Relevant literature is reviewed that describes current knowledge across levels of organization. Individual research questions and hypotheses in BCERC are driven by gaps in our knowledge that are presented at genetic, metabolic, cellular, individual, and environmental (physical and social) levels. DATA SYNTHESIS' As data collection on the cohort, animal experiments, and analyses proceed, results will be synthesized through a transdisciplinary approach. CONCLUSION: Center investigators are addressing a large number of specific research questions related to early pubertal onset, which is an established risk factor for breast cancer. BCERC research findings aimed at the primary prevention of breast cancer will be disseminated to the scientific community and to the public by breast cancer advocates, who have been integral members of the research process from its inception</abstract>
    <url>WOS:000272474600021</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>76</id>
    <title>In Utero Exposure and Breast Cancer Development: An Epigenetic Perspective</title>
    <authors>Hill,J.; Hodsdon,W.</authors>
    <availability>[Hill, Jacob; Hodsdon, Wendy] Natl Coll Nat Med, Helfgott Res Inst, Portland, OR 97201 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleHill, J (reprint author), Natl Coll Nat Med, Helfgott Res Inst, 2220 SW 1st Ave, Portland, OR 97201 USAjhill5095@gmail.comADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; AL MD, 1995, J NUTR, V125, P2822; BAGHURST PA, 1994, INT J CANCER, V56, P173, DOI 10.1002/ijc.2910560204; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; Caygill CPJ, 1996, BRIT J CANCER, V74, P159, DOI 10.1038/bjc.1996.332; COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Silva ID, 2008, PLOS MED, V5, P1372, DOI 10.1371/journal.pmed.0050193; Eden JA, 2010, MATURITAS, V67, P117, DOI 10.1016/j.maturitas.2010.05.005; Ekbom A, 2010, BREAST CANCER RES, V12, pR14; Ekbom A, 1997, J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; GOLDIN BR, 1986, AM J CLIN NUTR, V44, P945; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; Harigaya A, 1997, J CLIN ENDOCR METAB, V82, P3281, DOI 10.1210/jc.82.10.3281; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002; Hilakivi-Clarke L, 1999, NUTRITION, V15, P392, DOI 10.1016/S0899-9007(99)00029-5; HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372; Hilakivi-Clarke L, 1997, BREAST CANCER RES TR, V46, P199, DOI 10.1023/A:1005983621612; Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089; JAIN M, 1994, J NATL CANCER I, V86, P1390, DOI 10.1093/jnci/86.18.1390; Kaijser M, 2000, EPIDEMIOLOGY, V11, P315, DOI 10.1097/00001648-200005000-00015; Keeling JW, 2000, J PATHOL, V191, P449; KORT WJ, 1987, J NATL CANCER I, V79, P593; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; La Merrill M, 2010, ENVIRON HEALTH PERSP, V118, P596, DOI 10.1289/ehp.0901047; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; Mucci LA, 2003, CANCER CAUSE CONTROL, V14, P311, DOI 10.1023/A:1023966813330; Nagata C, 2006, CANCER EPIDEM BIOMAR, V15, P1469, DOI 10.1158/1055-9965.EPI-06-0158; Ong KKL, 1999, J CLIN ENDOCR METAB, V84, P1145, DOI 10.1210/jc.84.3.1145; Orloff MS, 2012, AM J HUM GENET, V92, P76; Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Park SK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1850; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Petrocelli T, 2001, BREAST CANCER RES, V3, P356, DOI 10.1186/bcr322; Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031; PRITCHARD GA, 1989, BRIT J SURG, V76, P1069, DOI 10.1002/bjs.1800761028; ROSE DP, 1995, J NATL CANCER I, V87, P587, DOI 10.1093/jnci/87.8.587; Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001; Santos F, 2004, REPRODUCTION, V127, P643, DOI 10.1530/rep.1.00221; Savarese TM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1674; Schernhammer ES, 2002, CANCER CAUSE CONTROL, V13, P505, DOI 10.1023/A:1016348425833; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Sivan E, 2003, J CLIN ENDOCR METAB, V88, P5656, DOI 10.1210/jc.2003-031174; Skalkidou A, 2003, CANCER EPIDEM BIOMAR, V12, P860; SMITH CA, 1947, AM J OBSTET GYNECOL, V53, P599; TRICHOPOULOS D, 1990, LANCET, V335, P939; Trichopoulos D, 2005, BREAST CANCER RES, V7, P13, DOI 10.1186/bcr966; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vatten LJ, 2002, PEDIATRICS, V109, P1131, DOI 10.1542/peds.109.6.1131; Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4; WANG HS, 1992, J ENDOCRINOL, V132, P11, DOI 10.1677/joe.0.1320011; Willett WC, 1989, NATURE, V338, P339; Wu AH, 1999, J NATL CANCER I, V91, P529, DOI 10.1093/jnci/91.6.529; Wu XL, 2009, NUTR RES, V29, P802, DOI 10.1016/j.nutres.2009.10.015; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263; Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472640BEGELL HOUSE INCREDDING50 CROSS HIGHWAY, REDDING, CT 06896 USAJ ENVIRON PATHOL TOXDiscipline: ToxicologyAQ3XP</notes>
    <keywords>BIRTH-WEIGHT; BISPHENOL-A BPA; breast cancer; BREAST-CANCER; CANCER; CORD BLOOD; environment; epigenetics; Estrogen; ESTROGEN-RECEPTOR; EXPOSURE; FETAL; FETAL-GROWTH; genetics; GROWTH-FACTOR-I; IN-UTERO; MAMMARY TISSUE; MATERNAL DIET; MODEL; nutrition; oncology; PREGNANCY; PREGNANCY ESTRIOL; PREVENTION; Reproduction; RISK; STEM-CELLS; toxicology; UTERO EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>239</startpage>
    <endpage>245</endpage>
    <journalfull>Journal of Environmental Pathology Toxicology and Oncology</journalfull>
    <issue>3</issue>
    <volume>33</volume>
    <abstract>The ubiquitous and detrimental disease of breast cancer requires continual research into new and alternative forms of treatment and prevention. The emerging field of epigenetics is beginning to unfold an array of contemporary approaches to reduce the risk and improve the clinical approach to breast cancer. The information contained in this non-systematic review highlights and expands on the estrogen-based model of breast cancer epigenetics to provide an overview of epigenetic alterations induced by nutrition and environmental exposure. The majority of evidence suggests that various sources of excess estrogen correlate to future breast cancer development. In addition, maternal macro- and micronutrient balance appear to play a role in genomic regulation, and preliminary data suggest that specific superfoods, such as blueberries, have a protective epigenetic effect. Identifying the influence of environmental toxicants, hormonal exposure, maternal nutrition, and maternal disease on fetal epigenetics may have potential for development of new therapeutic approaches for the prevention of breast cancer</abstract>
    <url>WOS:000342727100006</url>
    <isbnorissn>0731-8898</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>270</id>
    <title>Estrogens and Prostate Cancer: Etiology, Mediators, Prevention, and Management</title>
    <authors>Ho,S.M.; Lee,M.T.; Lam,H.M.; Leung,Y.K.</authors>
    <availability>[Ho, Shuk-Mei; Leung, Yuet-Kin] Univ Cincinnati, Coll Med, Dept Environm Hlth, Ctr Environm Genet,Canc Inst, Cincinnati, OH 45267 USA. [Ho, Shuk-Mei; Lam, Hung-Ming] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45220 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleHo, SM (reprint author), Univ Cincinnati, Coll Med, Dept Environm Hlth, Ctr Environm Genet,Canc Inst, Room 128,Kettering Complex,3223 Eden Ave, Cincinnati, OH 45267 USAshuk-mei.ho@uc.eduAbdelrahaman Eiman, 2005, Metabolism, V54, P91, DOI 10.1016/j.metabol.2004.07.018; Acevedo C, 2003, PROSTATE, V57, P111, DOI 10.1002/pros.10274; Adams JY, 2002, PROSTATE, V52, P69, DOI 10.1002/pros.10103; ARAI Y, 1983, INT REV CYTOL, V84, P235, DOI 10.1016/S0074-7696(08)61019-0; ARAI Y, 1977, VIRCHOWS ARCH A, V376, P21, DOI 10.1007/BF00433082; Badger TM, 2009, AM J CLIN NUTR, V89, pS1668, DOI 10.3945/ajcn.2009.26736U; Bain J, 2010, MATURITAS, V66, P16, DOI 10.1016/j.maturitas.2010.01.009; Barone I, 2010, CLIN CANCER RES, V16, P2702, DOI 10.1158/1078-0432.CCR-09-1753; Bergan RC, 1999, CLIN CANCER RES, V5, P2366; Bernoulli J, 2008, PROSTATE, V68, P728, DOI 10.1002/pros.20719; Bernoulli J, 2008, PROSTATE, V68, P1296, DOI 10.1002/pros.20791; Bland LB, 2005, CANCER, V103, P717, DOI 10.1002/cncr.20857; Bosland MC, 1999, EUR UROL, V35, P459, DOI 10.1159/000019879; Bostwick DG, 2004, CANCER, V101, P2371, DOI 10.1002/cncr.20408; Braniste V, 2010, P NATL ACAD SCI USA, V107, P448, DOI 10.1073/pnas.0907697107; Brodie A, 2009, UROL ONCOL-SEMIN ORI, V27, P53, DOI 10.1016/j.urolonc.2008.07.036; Caceres DD, 2005, EUR J EPIDEMIOL, V20, P79, DOI 10.1007/s10654-004-1632-9; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; Cavalieri EL, 2002, ANN NY ACAD SCI, V959, P341; Chadha MK, 2008, PROSTATE, V68, P1461, DOI 10.1002/pros.20813; Chae YK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006523; Chan FL, 2001, PROSTATE, V46, P21, DOI 10.1002/1097-0045(200101)46:1&lt;21::AID-PROS1004&gt;3.0.CO;2-G; Chan FL, 1999, PROSTATE, V38, P1, DOI 10.1002/(SICI)1097-0045(19990101)38:1&lt;1::AID-PROS1&gt;3.0.CO;2-6; Chan QKY, 2010, CELL DEATH DIFFER, V17, P1511, DOI 10.1038/cdd.2010.20; Chang WY, 1999, PROSTATE, V40, P115; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Chen F, 1999, GENE, V228, P101, DOI 10.1016/S0378-1119(98)00619-2; Chen JQ, 2007, BBA-MOL CELL RES, V1773, P1732, DOI 10.1016/j.bbamcr.2007.05.008; Chen YC, 2007, CANCER EPIDEM BIOMAR, V16, P1973, DOI 10.1158/1055-9965.EPI-07-0431; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; COX RL, 1995, J UROLOGY, V154, P1991, DOI 10.1016/S0022-5347(01)66670-9; DAHLLOF B, 1993, CANCER RES, V53, P4573; Dalais FS, 2004, UROLOGY, V64, P510, DOI 10.1016/j.urology.2004.04.009; DEJONG FH, 1991, CANCER RES, V51, P3445; Denis L, 1999, EUR UROL, V35, P377, DOI 10.1159/000019912; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1&lt;52::AID-SSU8&gt;3.0.CO;2-6; Djurendic E, 2008, STEROIDS, V73, P129, DOI 10.1016/j.steroids.2007.09.005; Dondi D, 2010, ENDOCR-RELAT CANCER, V17, P731, DOI 10.1677/ERC-10-0032; Ekbom A, 1996, BRIT MED J, V313, P337; Ekbom A, 2000, CANCER EPIDEM BIOMAR, V9, P221; Ellem S J, 2006, Minerva Endocrinol, V31, P1; Ellem SJ, 2010, J STEROID BIOCHEM, V118, P246, DOI 10.1016/j.jsbmb.2009.10.015; Ellem SJ, 2004, J CLIN ENDOCR METAB, V89, P2434, DOI 10.1210/jc.2003-030933; el-Rayes Basil F, 2002, Expert Rev Anticancer Ther, V2, P37, DOI 10.1586/14737140.2.1.37; Farnsworth WE, 1996, PROSTATE, V28, P17; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Fixemer T, 2003, PROSTATE, V54, P79, DOI 10.1002/pros.10171; Fu Y, 2004, BIOCHEM BIOPH RES CO, V322, P263, DOI 10.1016/j.bbrc.2004.07.094; Ganry O, 2005, PREV MED, V41, P1, DOI 10.1016/j.ypmed.2004.10.022; Gapstur SM, 2002, CANCER EPIDEM BIOMAR, V11, P1041; Gerber GS, 2000, UROLOGY, V55, P97, DOI 10.1016/S0090-4295(99)00370-2; Ghatak S, 1996, BIOCHEM BIOPH RES CO, V222, P362, DOI 10.1006/bbrc.1996.0749; Ghatak S, 1996, PROSTATE, V29, P91, DOI 10.1002/(SICI)1097-0045(199608)29:2&lt;91::AID-PROS4&gt;3.0.CO;2-K; Ghosh R, 2009, J STEROID BIOCHEM, V113, P25, DOI 10.1016/j.jsbmb.2008.11.002; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GRAY A, 1991, J CLIN EPIDEMIOL, V44, P671, DOI 10.1016/0895-4356(91)90028-8; GRAY A, 1991, J CLIN ENDOCR METAB, V73, P1016; Denis LJ, 2000, PROSTATE, V45, P87; Hamilton M, 2003, ACTA ONCOL, V42, P195, DOI 10.1080/02841860310010718; Hamilton-Reeves JM, 2008, NUTR CANCER, V60, P7, DOI 10.1080/01635580701586770; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Haqq C, 2005, PROSTATE, V65, P101, DOI 10.1002/pros.20272; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hebert JR, 1998, J NATL CANCER I, V90, P1637, DOI 10.1093/jnci/90.21.1637; Hedelin M, 2006, PROSTATE, V66, P1512, DOI 10.1002/pros.20487; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; Hiramatsu M, 1997, PROSTATE, V31, P118; HO SM, 1995, LAB INVEST, V73, P356; Ho SM, 1998, AM J PATHOL, V153, P131, DOI 10.1016/S0002-9440(10)65553-8; Ho SM, 1997, PROSTATE BASIC CLIN, P74; Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005; HO SM, 1994, CANCER LETT, V84, P155, DOI 10.1016/0304-3835(94)90370-0; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horvath LG, 2001, CANCER RES, V61, P5331; Hsu A, 2011, J NUTR BIOCHEM, V22, P502, DOI 10.1016/j.jnutbio.2010.04.006; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; Hui SL, 2003, J CLIN ENDOCR METAB, V88, P642, DOI 10.1210/jc.2002-020653; Hussain M, 2003, NUTR CANCER, V47, P111, DOI 10.1207/s15327914nc4702_1; Ide H, 2010, PROSTATE, V70, P1127, DOI 10.1002/pros.21147; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Ito K, 2000, EUR J ENDOCRINOL, V143, P543, DOI 10.1530/eje.0.1430543; Jarred RA, 2002, CANCER EPIDEM BIOMAR, V11, P1689; Jefcoate CR, 2000, J NATL CANC I MONOGR, V27, P95; Jian L, 2009, MOL NUTR FOOD RES, V53, P217, DOI 10.1002/mnfr.200800167; Jiang JH, 2005, ANTICANCER RES, V25, P4081; Joeckel RJ, 2009, NUTR CLIN PRACT, V24, P356, DOI 10.1177/0884533609335309; Kampa M, 2008, STEROIDS, V73, P953, DOI 10.1016/j.steroids.2007.12.009; Kaplan PJ, 1996, CARCINOGENESIS, V17, P2571, DOI 10.1093/carcin/17.12.2571; Katzenellenbogen BS, 2001, ANN NY ACAD SCI, V949, P6; Kim HT, 2002, J BIOL CHEM, V277, P32510, DOI 10.1074/jbc.M202852200; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Krieg JM, 2005, ENDOCR REV, V26, P833; KRIEG M, 1993, J CLIN ENDOCR METAB, V77, P375, DOI 10.1210/jc.77.2.375; Kruit WHJ, 2004, ANTI-CANCER DRUG, V15, P843, DOI 10.1097/00001813-200410000-00004; Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046; Kumar NB, 2004, PROSTATE, V59, P141, DOI 10.1002/pros.10362; Kuroda N, 2003, J PHARMACEUT BIOMED, V30, P1743, DOI 10.1016/S0731-7085(02)00516-2; Kuwajerwala N, 2002, CANCER RES, V62, P2488; Kwan W, 2010, NUTR CANCER, V62, P198, DOI 10.1080/01635580903305318; Lai JS, 2004, UROLOGY, V64, P814, DOI 10.1016/j.urology.2004.05.036; Lakhani NJ, 2003, PHARMACOTHERAPY, V23, P165, DOI 10.1592/phco.23.2.165.32088; Lam HM, 2009, ENDO 2009 91 ANN M W; Lampe JW, 2010, J NUTR, V140, p1369S, DOI 10.3945/jn.109.118323; Langer G, 2010, STEROIDS, V75, P603, DOI 10.1016/j.steroids.2009.12.006; Langley RE, 2008, BJU INT, V102, P442, DOI 10.1111/j.1464-410X.2008.07583.x; Latil A, 2001, CANCER RES, V61, P1919; Lau KM, 1998, ENDOCRINOLOGY, V139, P424, DOI 10.1210/en.139.1.424; LaVallee TM, 2003, CANCER RES, V63, P468; Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8; LEAV I, 1989, PROSTATE, V15, P23, DOI 10.1002/pros.2990150104; Leav I, 1999, AM J PATHOL, V154, P863, DOI 10.1016/S0002-9440(10)65333-3; LEAV I, 1988, J NATL CANCER I, V80, P1045, DOI 10.1093/jnci/80.13.1045; Leav I, 1996, LAB INVEST, V75, P361; Lee MM, 2003, CANCER EPIDEM BIOMAR, V12, P665; Lee MT, 2010, ENDO 2010 92 ANN M S; Leung YK, 2010, ENDOCR-RELAT CANCER, V17, P675, DOI 10.1677/ERC-09-0294; Leung YK, 2010, ENDO 2010 92 ANN M S; Leung YK, 2006, P NATL ACAD SCI USA, V103, P13162, DOI 10.1073/pnas.0605676103; Leung YK, 2005, CANCER RES, V65, P3726, DOI 10.1158/0008-5472.CAN-04-3771; Li SC, 2001, PROSTATE, V49, P58, DOI 10.1002/pros.1118; Li XD, 2001, ENDOCRINOLOGY, V142, P2435, DOI 10.1210/en.142.6.2435; Li YW, 2002, J NUTR, V132, P3623; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Lissoni P, 2005, ANTICANCER RES, V25, P3597; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Mak P, 2006, NEOPLASIA, V8, P896, DOI 10.1593/neo.06538; MARKIEWICZ L, 1993, J STEROID BIOCHEM, V45, P399, DOI 10.1016/0960-0760(93)90009-L; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; McIntyre MH, 2007, CANCER EPIDEM BIOMAR, V16, P2233, DOI 10.1158/1055-9965.EPI-07-0481; MCLACHLAN JA, 1977, J TOXICOL ENV HEALTH, V2, P527; MCLACHLAN JA, 1975, SCIENCE, V190, P991, DOI 10.1126/science.242076; McPherson SJ, 2010, P NATL ACAD SCI USA, V107, P3123, DOI 10.1073/pnas.0905524107; McPherson SJ, 2001, ENDOCRINOLOGY, V142, P2458, DOI 10.1210/en.142.6.2458; Milligan SR, 1998, ENVIRON HEALTH PERSP, V106, P23; Miltyk W, 2003, AM J CLIN NUTR, V77, P875; Misra RR, 2002, INT J TOXICOL, V21, P277, DOI 10.1080/10915810290096441; Mor G, 2000, J STEROID BIOCHEM, V73, P185, DOI 10.1016/S0960-0760(00)00081-9; Moretti C, 2005, J Endocrinol Invest, V28, P56; Nanni S, 2009, J CLIN INVEST, V119, P1093, DOI 10.1172/JCI35079; NEUBAUER BL, 1995, PROSTATE, V27, P220, DOI 10.1002/pros.2990270407; Nicolaiew N, 2009, EUR J ENDOCRINOL, V160, P101, DOI 10.1530/EJE-08-0321; Nock NL, 2006, CARCINOGENESIS, V27, P1842, DOI 10.1093/carcin/bgl022; Ockrim JL, 2003, J UROLOGY, V169, P1735, DOI 10.1097/01.ju.0000061024.75334.40; Ockrim JL, 2004, J UROLOGY, V172, P2203, DOI 10.1097/01.ju.0000145511.56476.00; Ockrim JL, 2005, J UROLOGY, V174, P527, DOI 10.1097/01.ju.0000165567.99142.1f; O'Lone R, 2007, MOL ENDOCRINOL, V21, P1281, DOI 10.1210/me.2006-0497; Orwoll ES, 2010, J CLIN ENDOCR METAB, V95, pE151, DOI 10.1210/jc.2009-2435; Osborne CK, 2001, CLIN CANCER RES, V7, p4338s; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Ozasa K, 2004, CANCER SCI, V95, P65, DOI 10.1111/j.1349-7006.2004.tb03172.x; Park II, 2009, ENDOCRINOLOGY, V150, P4594, DOI 10.1210/en.2008-1591; Pasquali D, 2001, MOL CELL ENDOCRINOL, V178, P47, DOI 10.1016/S0303-7207(01)00418-X; Pasquali D, 2001, J CLIN ENDOCR METAB, V86, P2051, DOI 10.1210/jc.86.5.2051; Pendleton JM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-132; Potischman N, 2005, CANCER EPIDEM BIOMAR, V14, P1514, DOI 10.1158/1055-9965.EPI-04-0869; Price D, 2006, J UROLOGY, V176, P965, DOI 10.1016/j.juro.2006.04.011; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; PRINS GS, 1992, ENDOCRINOLOGY, V130, P3703, DOI 10.1210/en.130.6.3703; Prins GS, 1998, J UROLOGY, V159, P641, DOI 10.1016/S0022-5347(01)63692-9; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Prins GS, 2001, CANCER RES, V61, P6089; PYLKKANEN L, 1991, PROSTATE, V18, P117, DOI 10.1002/pros.2990180204; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Quinones LA, 2006, ASIAN J ANDROL, V8, P349, DOI 10.1111/j.1745-7262.2006.00135.x; Radlmaier A, 1996, PROSTATE, V29, P199, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;199::AID-PROS1&gt;3.0.CO;2-7; Rafi MM, 2000, ANTICANCER RES, V20, P2653; RAJFER J, 1978, INVEST UROL, V16, P186; Ranjit N, 2010, J PERINATOL, V30, P2, DOI 10.1038/jp.2009.90; Reiner T, 2009, CANCER LETT, V276, P21, DOI 10.1016/j.canlet.2008.10.026; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; RICHARDS RJ, 1992, J CLIN ENDOCR METAB, V75, P624, DOI 10.1210/jc.75.2.624; Ricke WA, 2006, INT J CANCER, V118, P2123, DOI 10.1002/ijc.21614; Ricke WA, 2007, DIFFERENTIATION, V75, P871, DOI 10.1111/j.1432-0436.2007.00224.x; Risbridger GP, 2007, J MOL ENDOCRINOL, V39, P183, DOI 10.1677/JME-07-0053; Risbridger GP, 2003, ENDOCR-RELAT CANCER, V10, P187, DOI 10.1677/erc.0.0100187; Roberts RO, 2004, PROSTATE, V61, P124, DOI 10.1002/pros.20080; Rohrmann S, 2007, J CLIN ENDOCR METAB, V92, P2519, DOI 10.1210/jc.2007-0028; ROSS R, 1986, J NATL CANCER I, V76, P45; Royuela M, 2001, J ENDOCRINOL, V168, P447, DOI 10.1677/joe.0.1680447; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Sanderson T, 2008, EUR J PHARMACOL, V593, P92, DOI 10.1016/j.ejphar.2008.06.085; Sato F, 2005, NEOPLASIA, V7, P838, DOI 10.1593/neo.05145; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Schrager S, 2004, AM FAM PHYSICIAN, V69, P2395; SCHULZ P, 1988, CANCER RES, V48, P2867; Shapiro E, 2005, J UROLOGY, V174, P2051, DOI 10.1097/01.ju.0000176472.90432.5b; Shazer RL, 2006, BJU INT, V97, P691, DOI 10.1111/j.1464-410X.2006.05974.x; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shimada K, 2003, MOL CARCINOGEN, V36, P115, DOI 10.1002/mc.10107; Silig Y, 2006, CANCER INVEST, V24, P41, DOI 10.1080/07357900500449579; Singh PB, 2008, EUR J CANCER, V44, P928, DOI 10.1016/j.ejca.2008.02.051; Smith MR, 2010, J UROLOGY, V184, P1316, DOI 10.1016/j.juro.2010.06.022; Sobti RC, 2006, DNA CELL BIOL, V25, P287, DOI 10.1089/dna.2006.25.287; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; Sonn GA, 2005, PROSTATE CANCER P D, V8, P304, DOI 10.1038/sj.pcan.4500825; Starka L, 2009, J STEROID BIOCHEM, V116, P118, DOI 10.1016/j.jsbmb.2009.05.008; Stattin P, 2002, INT J CANCER, V99, P124, DOI 10.1002/ijc.10313; Stein S, 2001, AM J CLIN ONCOL-CANC, V24, P283, DOI 10.1097/00000421-200106000-00015; Strom SS, 1999, NUTR CANCER, V33, P20; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Suzuki K, 2003, ANTICANCER RES, V23, P4941; Suzuki K, 2003, CANCER, V98, P1411, DOI 10.1002/cncr.11639; Suzuki K, 1998, PROSTATE, V37, P70; Suzuki M, 2005, EUR UROL, V48, P752, DOI 10.1016/j.eururo.2005.07.007; Takimoto CH, 2003, CANCER EPIDEM BIOMAR, V12, P1213; Tam NN, 2007, AM J PATHOL, V171, P1334; Ho SM, 2008, NEOPLASIA, V10, P20, DOI 10.1593/neo.07889; Tam NNC, 2003, PROSTATE, V55, P1, DOI 10.1002/pros.10169; Tanaka Y, 2006, CANCER EPIDEM BIOMAR, V15, P238, DOI 10.1158/1055-9965.EPI-05-0550; Tanaka Y, 2003, MOL CARCINOGEN, V37, P202, DOI 10.1002/mc.10138; Taneja SS, 2006, EXPERT OPIN INV DRUG, V15, P293, DOI 10.1517/13543784.15.3.293; Tang YM, 2000, PHARMACOGENETICS, V10, P761, DOI 10.1097/00008571-200012000-00001; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; Thellenberg-Karlsson C, 2006, CLIN CANCER RES, V12, P1936, DOI 10.1158/1078-0432.CCR-05-0269; Thomas P, 2006, STEROIDS, V71, P310, DOI 10.1016/j.steroids.2005.09.015; Thompson CJ, 2002, ENDOCRINOLOGY, V143, P2093, DOI 10.1210/en.143.6.2093; Torlakovic E, 2002, HUM PATHOL, V33, P646, DOI 10.1053/hupa.2002.124033; Travis RC, 2009, BRIT J CANCER, V100, P1817, DOI 10.1038/sj.bjc.6605073; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Tremblay GB, 2001, ENDOCRINOLOGY, V142, P4572, DOI 10.1210/en.142.10.4572; Tsurusaki T, 2003, J CLIN ENDOCR METAB, V88, P1333, DOI 10.1210/jc.2002-021015; Tuohy PG, 2003, J PAEDIATR CHILD H, V39, P401, DOI 10.1046/j.1440-1754.2003.00178.x; Vaishampayan U, 2007, NUTR CANCER, V59, P1; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; VERMEULE.A, 1972, J CLIN ENDOCR METAB, V34, P730; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; VORHERR H, 1979, BIOCHEM PHARMACOL, V28, P1865, DOI 10.1016/0006-2952(79)90638-5; Wang YZ, 1998, PROSTATE, V35, P165; Warner M, 2010, BIOCHEM BIOPH RES CO, V396, P63, DOI 10.1016/j.bbrc.2010.02.144; Weihua Zhang, 2002, Molecular and Cellular Endocrinology, V193, P1, DOI 10.1016/S0303-7207(02)00089-8; Wong YC, 2000, PROSTATE, V45, P289; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yager JD, 2000, J NATL CANC I MONOGR, V27, P67; Yager JD, 1996, ANNU REV PHARMACOL, V36, P203, DOI 10.1146/annurev.pa.36.040196.001223; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5; Yatkin E, 2009, INT J ANDROL, V32, P399, DOI 10.1111/j.1365-2605.2008.00930.x; Yatkin E, 2008, J PHARMACOL EXP THER, V327, P58, DOI 10.1124/jpet.108.139501; Yo YT, 2009, J AGR FOOD CHEM, V57, P8266, DOI 10.1021/jf901054c; ZHALILO L I, 1976, Fiziolohichnyi Zhurnal (Kiev), V22, P410; Zhang X, 2007, ONCOGENE, V26, P7346, DOI 10.1038/sj.onc.1210537; Zhang ZG, 2002, BIOCHEM BIOPH RES CO, V294, P926, DOI 10.1016/S0006-291X(02)00348-0; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200; Zhang ZS, 2008, PROSTATE, V68, P508, DOI 10.1002/pros.20722; Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-125013W B SAUNDERS CO-ELSEVIER INCPHILADELPHIA1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USAENDOCRIN METAB CLINSEPDiscipline: Endocrinology &amp; Metabolism829RN</notes>
    <keywords>Androgen; ANTIESTROGENS; BISPHENOL-A CONCENTRATIONS; CANCER; Carcinogen; CARCINOGENESIS; CATECHOL-O-METHYLTRANSFERASE; CELL; cell death; CELL-CYCLE PROGRESSION; CELL-DEATH; Chemoprevention; DEATH; development; Differentiation; epigenetics; Estrogen; Estrogen receptor; ESTROGENS; Etiology; FOOD; GENE; HEALTH; HIGH-DOSE TAMOXIFEN; Hormonal therapy; LIPID-PEROXIDATION STATUS; MESSENGER-RNA EXPRESSION; METABOLISM; MIMICS; Neoplasia; NESTED CASE-CONTROL; p21; PHASE-II TRIAL; Phytoestrogen; PREVENTION; PROGRESSION; Prostate; prostate cancer; Prostate cancer risk; PROSTATE-CANCER; RECEPTOR-BETA EXPRESSION; ROLES; Selective estrogen receptor modulator (SERM); TARGET; THERAPY; TRANSDERMAL ESTRADIOL THERAPY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>591</startpage>
    <endpage>+</endpage>
    <journalfull>Endocrinology and Metabolism Clinics of North America</journalfull>
    <issue>3</issue>
    <volume>40</volume>
    <abstract>The mainstay targets for hormonal prostate cancer (PCa) therapies are based on negating androgen action. Recent epidemiologic and experimental data have pinpointed the key roles of estrogens in PCa development and progression. Racial and geographic differences, as well as age-associated changes, in estrogen synthesis and metabolism contribute significantly to the etiology. This article summarizes how different estrogens/antiestrogens/estrogen mimics contribute to prostate carcinogenesis, the roles of the different mediators of estrogen in the process, and the potentials of new estrogenic/antiestrogenic compounds for prevention and treatment of PCa</abstract>
    <url>WOS:000295602100012</url>
    <isbnorissn>0889-8529</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>216</id>
    <title>Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk</title>
    <authors>Hu,W.Y.; Shi,G.B.; Hu,D.P.; Nelles,J.L.; Prins,G.S.</authors>
    <availability>[Hu, Wen-Yang; Shi, Guang-Bin; Hu, Dan-Ping; Nelles, Jason L.; Prins, Gail S.] Univ Illinois, Dept Urol, Chicago, IL 60612 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReviewPrins, GS (reprint author), Univ Illinois, Dept Urol, 820 S Wood St,M-C 955, Chicago, IL 60612 USAwyhu@uic.edu; guangbin@uic.edu; dhu@uic.edu; jnelles@uic.edu; gprins@uic.eduAlavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; Aronson KJ, 2010, J EXPO SCI ENV EPID, V20, P434, DOI 10.1038/jes.2009.33; Benbrahim-Tallaa L., 2007, ENV HLTH PERSPECT, V115, P2; Benbrahim-Tallaa L, 2007, PROSTATE, V67, P135, DOI 10.1002/pros.20479; Benbrahim-Tallaa L, 2008, ENVIRON HEALTH PERSP, V116, P158, DOI 10.1289/ehp.10423; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Bosland M C, 1996, Urol Oncol, V2, P103, DOI 10.1016/S1078-1439(97)82840-2; Brown MD, 2007, PROSTATE, V67, P1384, DOI 10.1002/pros.20620; Burger P. E., 2005, PNAS, V102, P180; Calafat AM, 2009, ENVIRON HEALTH PERSP, V117, P639, DOI 10.1289/ehp.0800265; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Charles LE, 2003, AM J EPIDEMIOL, V157, P683, DOI 10.1093/aje/kwg044; CHEN CJ, 1988, LANCET, V1, P414; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Collins AT, 2001, J CELL SCI, V114, P3865; Davey JC, 2007, TOXICOL SCI, V98, P75, DOI 10.1093/toxsci/kfm013; De Marzo AM, 1998, J UROLOGY, V160, P2381, DOI 10.1016/S0022-5347(01)62196-7; Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Eddington A.N., 2009, ENV HLTH PERSPECT, V117, P645; EGELAND GM, 1994, AM J EPIDEMIOL, V139, P272; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Ellem SJ, 2007, NAT REV CANCER, V7, P621, DOI 10.1038/nrc2174; Foran CM, 2002, TOXICOL SCI, V68, P389, DOI 10.1093/toxsci/68.2.389; Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011; Garraway IP, 2010, PROSTATE, V70, P491, DOI 10.1002/pros.21083; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Griend DJV, 2008, CANCER RES, V68, P9703, DOI 10.1158/0008-5472.CAN-08-3084; Gu G., 2007, CANCER RES, V67, P4708; Gupta A, 2006, ENVIRON HEALTH PERSP, V114, P1649, DOI 10.1289/ehp.8957; Gupta A, 2006, J OCCUP ENVIRON MED, V48, P708, DOI 10.1097/01.jom.0000205417.12621.17; Hardell L, 2006, J OCCUP ENVIRON MED, V48, P700, DOI 10.1097/01.jom.0000205989.46603.43; Heindel JJ, 2005, BIRTH DEFECTS RES A, V73, P131, DOI 10.1002/bdra.20119; HENDERSON BE, 1988, BRIT J CANCER, V57, P216, DOI 10.1038/bjc.1988.46; HENDERSON BE, 1982, CANCER RES, V42, P3232; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hu WY, 2011, ENDOCRINOLOGY, V152, P2150, DOI 10.1210/en.2010-1377; Hudson DL, 2003, CYTOTECHNOLOGY, V41, P189, DOI 10.1023/A:1024887009081; Huff J, 2007, INT J OCCUP ENV HEAL, V13, P202; Huggins C, 1941, CANCER RES, V1, P293; Huss J.J., 2004, PROSTATE, V61, P142; Isaacs J.T., 1981, RELATIONSHIP CELLU A, P1; JACOB A, 1994, NUCLEIC ACIDS RES, V22, P2126, DOI 10.1093/nar/22.11.2126; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Kasper S, 2009, UROL ONCOL-SEMIN ORI, V27, P301, DOI 10.1016/j.urolonc.2008.12.012; Kasper S, 2008, STEM CELL REV, V4, P193, DOI 10.1007/s12015-008-9033-1; Kaufman JM, 2005, ENDOCR REV, V26, P833, DOI 10.1210/er.2004-0013; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Kester MHA, 2002, J CLIN ENDOCR METAB, V87, P1142, DOI 10.1210/jc.87.3.1142; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuroda M, 2005, FEBS LETT, V579, P167, DOI 10.1016/j.febslet.2004.11.070; Kuroda N, 2003, J PHARMACEUT BIOMED, V30, P1743, DOI 10.1016/S0731-7085(02)00516-2; Lang SH, 2001, CELL GROWTH DIFFER, V12, P631; LaSalle Jr D.L., 2010, REDUCING ENV CANC RI, P1; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Lawson DA, 2007, J CLIN INVEST, V117, P2044, DOI 10.1172/JCI32810; Lee YJ, 2008, REPROD TOXICOL, V25, P413, DOI 10.1016/j.reprotox.2008.05.058; Lemmen JG, 2004, ENVIRON HEALTH PERSP, V112, P1544; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Leung YK, 2010, ENDOCR-RELAT CANCER, V17, P675, DOI 10.1677/ERC-09-0294; Lewis DR, 1999, ENVIRON HEALTH PERSP, V107, P359, DOI 10.2307/3434539; Lowsley OS, 1912, AM J ANAT, V13, P299, DOI 10.1002/aja.1000130303; Lukacs RU, 2010, NAT PROTOC, V5, P702, DOI 10.1038/nprot.2010.11; Mahajan R., 2006, ENV HLTH PERSPECT, P8; Maitland NJ, 2008, J CLIN ONCOL, V26, P2862, DOI 10.1200/JCO.2007.15.1472; Matthews Jason, 2006, Nucl Recept Signal, V4, pe016; Metallo CM, 2008, STEM CELLS, V26, P372, DOI 10.1634/stemcells.2007-0501; Meyer TE, 2007, OCCUP ENVIRON MED, V64, P155, DOI 10.1136/oem.2006.027383; Miki J, 2008, PROSTATE CANCER P D, V11, P32, DOI 10.1038/sj.pcan.4501018; Modugno F, 2001, CLIN CANCER RES, V7, P3092; Mollard R, 2000, INT J DEV BIOL, V44, P457; MORRISON H, 1993, AM J EPIDEMIOL, V137, P270; Nelles JL, 2011, EXPERT REV ENDOCRINO, V6, P437, DOI DOI 10.1586/EEM.11.20); Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Parent ME, 2001, EPIDEMIOL REV, V23, P138; Patterson J., 2009, ENVIRON SCI TECHNOL, V43, P1211; Peehl DM, 2003, PROSTATE CANC METHOD, P41; Presnell SC, 2002, SEMIN CELL DEV BIOL, V13, P369, DOI 10.1016/S1084-9521(02)00093-9; Prince MM, 2006, ENVIRON HEALTH PERSP, V114, P1508, DOI 10.1289/ehp.9175; PRINS GS, 1992, ENDOCRINOLOGY, V130, P3703, DOI 10.1210/en.130.6.3703; Prins GS, 2001, REPROD FERT DEVELOP, V13, P241, DOI 10.1071/RD00107; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Prins GS, 2010, J DEV ORIG HLTH DIS, V1, P365, DOI 10.1017/S2040174410000577; Prins G.S, 2008, ENDOCR-RELAT CANCER, V16, P649; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Prins GS, 1997, PROSTATE BASIC CLIN, P247; PRINS GS, 1993, ENDOCRINOLOGY, V132, P2387, DOI 10.1210/en.132.6.2387; Prins GS, 1997, ENDOCRINOLOGY, V138, P1801, DOI 10.1210/en.138.5.1801; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Ricke W., 2006, INT J CANCER, V52, P2123; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; Schenk JM, 2009, CANCER EPIDEM BIOMAR, V18, P1227, DOI 10.1158/1055-9965.EPI-08-0984; Smith S., 2007, SCIENCE, V316; Song KH, 2002, ENDOCRINOLOGY, V143, P2208, DOI 10.1210/en.143.6.2208; Steiner Mitchell S, 2003, Clin Prostate Cancer, V2, P24, DOI 10.3816/CGC.2003.n.009; Usmani KA, 2003, DRUG METAB DISPOS, V31, P384, DOI 10.1124/dmd.31.4.384; Usmani KA, 2006, DRUG METAB DISPOS, V34, P1606, DOI 10.1124/dmd.106.010439; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; van Maele-Fabry G, 2006, CANCER CAUSE CONTROL, V17, P353, DOI 10.1007/s10552-005-0443-y; Vezina CM, 2009, BIOCHEM PHARMACOL, V77, P566, DOI 10.1016/j.bcp.2008.09.039; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; Walsh DE, 2005, MOL CELL ENDOCRINOL, V230, P23, DOI 10.1016/j.mce.2004.11.006; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Xin L, 2007, STEM CELLS, V25, P2760, DOI 10.1634/stemcells.2007-0355; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-102811411ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDMOL CELL ENDOCRINOLMAY 6SIDiscipline: Cell Biology; Endocrinology &amp; Metabolism928HQ</notes>
    <keywords>ADULT; ADULT-RAT; ANDROGEN RECEPTOR EXPRESSION; ASSAY; BIOLOGY; BISPHENOL-A; CADMIUM CARCINOGENESIS; CANCER; CANCER RISK; CANCER-RISK; CARCINOGENESIS; CELL; CELLS; CHEMICALS; development; DEVELOPMENTAL EXPOSURE; Differentiation; DISEASE; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; ENDOCRINE DISRUPTORS; environment; EPITHELIAL STEM-CELLS; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic activity; ESTROGENS; EXPOSURE; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GLAND; GROWTH; HEALTH; In vitro; IN-VITRO; IN-VIVO; INCREASES SUSCEPTIBILITY; METABOLISM; MODEL; POLYCHLORINATED-BIPHENYLS; PROGRESSION; Prostate; prostate cancer; Prostate progenitor cells; Prostate stem cells; PROSTATE-CANCER; RECEPTOR; RETINOIC ACID; RISK; STEM-CELLS; STEM/PROGENITOR CELLS; TISSUE; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>63</startpage>
    <endpage>73</endpage>
    <journalfull>Molecular and Cellular Endocrinology</journalfull>
    <issue>1-2</issue>
    <volume>354</volume>
    <abstract>Estrogen reprogramming of the prostate gland as a function of developmental exposures (aka developmental estrogenization) results in permanent alterations in structure and gene expression that lead to an increased incidence of prostatic lesions with aging. Endocrine disrupting chemicals (EDCs) with estrogenic activity have been similarly linked to an increased prostate cancer risk. Since it has been suggested that stem cells and cancer stem cells are potential targets of cancer initiation and disease management, it is highly possible that estrogens and EDCs influence the development and progression of prostate cancer through reprogramming and transforming the prostate stem and early stage progenitor cells. In this article, we review recent literature highlighting the effects of estrogens and EDCs on prostate cancer risk and discuss recent advances in prostate stem/progenitor cell research. Our laboratory has recently developed a novel prostasphere model using normal human prostate stem/progenitor cells and established that these cells express estrogen receptors (ERs) and are direct targets of estrogen action. Further, using a chimeric in vivo prostate model derived from these normal human prostate progenitor cells, we demonstrated for the first time that estrogens initiate and promote prostatic carcinogenesis in an androgen-supported environment. We herein discuss these findings and highlight new evidence using our in vitro human prostasphere assay for perturbations in human prostate stem cell self-renewal and differentiation by natural steroids as well as EDCs. These findings support the hypothesis that tissue stem cells may be direct EDC targets which may underlie life-long reprogramming as a consequence of developmental and/or transient adult exposures. (C) 2011 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000302974200009</url>
    <isbnorissn>0303-7207</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>398</id>
    <title>Bisphenol A downregulates CYP19 transcription in JEG-3 cells</title>
    <authors>Huang,H.; Leung,L.K.</authors>
    <availability>[Huang, Hui; Leung, Lai K.] Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China. [Leung, Lai K.] Chinese Univ Hong Kong, Food &amp; Nutr Sci Programme, Shatin, Hong Kong, Peoples R China.</availability>
    <date>2009</date>
    <notes>JEnglishArticleLeung, LK (reprint author), Chinese Univ Hong Kong, Dept Biochem, Rm 507C,MMW Bldg, Shatin, Hong Kong, Peoples R Chinalaikleung@cuhk.edu.hkBenachour N, 2007, TOXICOL APPL PHARM, V222, P129, DOI 10.1016/j.taap.2007.03.033; Bulun SE, 2004, SEMIN REPROD MED, V22, P5; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Diaz-Cruz ES, 2005, J CLIN ENDOCR METAB, V90, P2563, DOI 10.1210/jc.2004-2029; Domoradzki JY, 2003, TOXICOL SCI, V76, P21, DOI 10.1093/toxsci/kfg206; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Iwamuro S, 2006, LIFE SCI, V79, P2165, DOI 10.1016/j.lfs.2006.07.013; Lee Chae-Kwan, 2005, J Prev Med Public Health, V38, P330; Lee YM, 2006, BIOCHEM BIOPH RES CO, V345, P894, DOI 10.1016/j.bbrc.2006.04.137; LIVAK KJ, 2001, METHOD METHODS, V4, P402; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nativelle-Serpentini C, 2003, TOXICOL IN VITRO, V17, P413, DOI 10.1016/S0887-2333(03)00046-8; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Pyo MY, 2007, ARCH PHARM RES, V30, P1476, DOI 10.1007/BF02977374; Schonfelder G, 2002, NEOPLASIA, V4, P98, DOI 10.1038/sj.neo.7900212; Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600; Shozu M, 1998, ENDOCRINOLOGY, V139, P1610, DOI 10.1210/en.139.4.1610; SIMPSON ER, 1993, CLIN CHEM, V39, P317; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/en.142.11.4589; Simpson ER, 1997, RECENT PROG HORM RES, V52, P213; Simpson ER, 1997, RECENT PROG HORM RES, V52, P185; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Tachibana T, 2007, J REPROD DEVELOP, V53, P509, DOI 10.1262/jrd.18171; Takai Y, 2000, BIOCHEM BIOPH RES CO, V270, P918, DOI 10.1006/bbrc.2000.2548; Tamada H, 2003, CONTRACEPTION, V68, P65, DOI 10.1016/S0010-7824(03)00076-3; Tamada H, 2004, J ENDOCRINOL, V180, P337, DOI 10.1677/joe.0.1800337; TODA K, 1994, J BIOL CHEM, V269, P8099; Wang Y, 2007, TOXICOL LETT, V173, P175, DOI 10.1016/j.toxlet.2007.07.009; Wang Y, 2006, TOXICOL SCI, V92, P71, DOI 10.1093/toxsci/kfj190; Wang Y, 2008, TOXICOLOGY, V248, P130, DOI 10.1016/j.tox.2008.03.017; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; YAMADA K, 1995, J BIOL CHEM, V270, P25064; Ye L, 2009, INT J CANCER, V124, P1028, DOI 10.1002/ijc.24046; Ye L, 2009, MOL CELL ENDOCRINOL, V302, P73, DOI 10.1016/j.mce.2009.01.003; YE L, 2008, INT J CANC; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-10184016ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTSEP 28Discipline: Toxicology483QO</notes>
    <keywords>analysis; Aromatase; Aromatase activity; AROMATASE CYTOCHROME-P-450 GENE; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHINA; DEFECTS; ENDOCRINE; Endocrine disruptor; environment; Estrogen; ESTROGEN BIOSYNTHESIS; EXPOSURE; EXPRESSION; FADROZOLE HYDROCHLORIDE; GENE; HEALTH; In vitro; IN-VITRO; Neoplasia; ORGANIZATION; p21; PLACENTA; Placental cells; PREGNANCY; PROMOTER; RATS; RESVERATROL; toxicology; TRANSCRIPTION; TRANSCRIPTIONAL ACTIVITIES; TRANSCRIPTIONAL ACTIVITY; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>248</startpage>
    <endpage>252</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>3</issue>
    <volume>189</volume>
    <abstract>Bisphenol A is an industrial contaminant and is considered to be an endocrine disruptor; its estrogenic property has been reported in many studies. Because of its ubiquitous existence in our environment, bisphenol A has drawn much discussion on its safety issues. Estrogen is important in the maintenance of human pregnancy, and the placenta is the major site of synthesis during this period of time. Aromatase or CYP19 catalyses the conversion of estrogen from its precursor, and is highly expressed in placental cells. In the present study, we examined the ability of the toxicant in suppressing the transcription of CYP19 in JEG-3 cells. Cells treated with bisphenol A displayed a reduced aromatase activity. Real-time PCR analysis indicated that 5 mu M of the compound significantly reduced the mRNA expression in these cells. As the transcriptional activity of CYP19 gene is controlled by the proximal promoter region of exon1.1 in placental cells, the promoter activity of this gene fragment and exon-1.1-spliced mRNA abundance were also evaluated. Both results indicated that bisphenol A repressed the transcriptional control of promoter 1.1. The present study showed that bisphenol A potentially reduced estrogen synthesis by downregulating CYP of placental cells. This information could be useful for evaluating the exposure limit of bisphenol A. (c) 2009 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000268982800011</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>240</id>
    <title>Antiproliferative activity of genistein, a phytoestrogen, on BG-1 ovarian cancer cell proliferation induced by estrogen receptor-dependant pathway of 17 beta-estradiol or bisphenol A</title>
    <authors>Hwang,K.A.; Choi,K.C.</authors>
    <availability>[Hwang, Kyung-A; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishMeeting Abstract00SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J MOL MED1Discipline: Research &amp; Experimental Medicine031ON</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ANTIPROLIFERATIVE ACTIVITIES; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER-CELL-PROLIFERATION; CELL; Cell proliferation; CELL-PROLIFERATION; Estrogen; genistein; Ovarian cancer; OVARIAN-CANCER; Phytoestrogen; proliferation</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S48</startpage>
    <endpage>S48</endpage>
    <journalfull>International Journal of Molecular Medicine</journalfull>
    <volume>30</volume>
    <url>WOS:000310651600174</url>
    <isbnorissn>1107-3756</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>251</id>
    <title>Bisphenol A and 17-Beta-Oestradiol Resulted in the Gene Alterations in Oestrogen-Receptor Positive Bg-1 Ovarian Cancer Cells</title>
    <authors>Hwang,K.A.; Hyun,S.H.; Jeung,E.B.; Choi,K.C.</authors>
    <availability>[Hwang, K. -A; Hyun, S. -H.; Jeung, E. -B.; Choi, K. -C.] Chungbuk Natl Univ, Lab Vet Biochem &amp; Immunol, Coll Vet Med, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishMeeting Abstract00CSIRO PUBLISHINGCOLLINGWOOD150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIAREPROD FERT DEVELOPDiscipline: Developmental Biology; Reproductive Biology; Zoology856NA</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; GENE; oestrogen receptor; Ovarian cancer; OVARIAN-CANCER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>188</startpage>
    <endpage>188</endpage>
    <journalfull>Reproduction Fertility and Development</journalfull>
    <issue>1</issue>
    <volume>24</volume>
    <url>WOS:000297647800165</url>
    <isbnorissn>1031-3613</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>94</id>
    <title>Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 beta-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor alpha and insulin-like growth factor-1 receptor signaling pathways</title>
    <authors>Hwang,K.A.; Park,M.A.; Kang,N.H.; Yi,B.R.; Hyun,S.H.; Jeung,E.B.; Choi,K.C.</authors>
    <availability>[Hwang, Kyung-A; Park, Min-Ah; Kang, Nam-Hee; Yi, Bo-Rim; Hyun, Sang-Hwan; Jeung, Eui-Bae; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krAksglaede L, 2006, HUM REPROD UPDATE, V12, P341, DOI 10.1093/humupd/dml018; Aldyama T., 1987, J BIOL CHEM, V262, P5592; Altucci L, 1996, ONCOGENE, V12, P2315; Bartella V, 2012, CELL SIGNAL, V24, P1515, DOI 10.1016/j.cellsig.2012.03.012; Buchler P, 2003, PANCREAS, V26, P264, DOI 10.1097/00006676-200304000-00010; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Danzo BJ, 1998, CELL MOL LIFE SCI, V54, P1249, DOI 10.1007/s000180050251; Douma SL, 2005, ADV NURS SCI, V28, P364; Erler C, 2010, J PEDIATR NURS, V25, P400, DOI 10.1016/j.pedn.2009.05.006; Fotsis T, 1997, CANCER RES, V57, P2916; Fu YM, 1999, CANCER RES, V59, P758; Giacalone PL, 2003, GYNECOL ONCOL, V91, P651, DOI 10.1016/S0090-8258(03)00279-8; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Hamelers IHL, 2003, ENDOCR-RELAT CANCER, V10, P331, DOI 10.1677/erc.0.0100331; Hankinson Susan E, 2003, Breast Dis, V17, P27; Hwang K.A., 2012, LAB ANIM RES, V27, P99; Hwang K.A., 2013, INT J ONCOL, V42, P8; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Kang NH, 2012, CANCER GENE THER, V19, P412, DOI 10.1038/cgt.2012.15; Lee H. R., 2012, TOXICOLOGY C, V304, P13; Lee Hye-Rim, 2012, Lab Anim Res, V28, P71, DOI 10.5625/lar.2012.28.2.71; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2013, J CELL MOL MED, V17, P1, DOI 10.1111/j.1582-4934.2012.01649.x; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Li HQ, 2012, MINI-REV MED CHEM, V12, P350; Li QS, 2012, ANTI-CANCER AGENT ME, V12, P271; Lian FR, 1999, NUTR CANCER, V33, P125, DOI 10.1207/S15327914NC330202; Loo DT, 2011, METHODS MOL BIOL, V682, P3, DOI 10.1007/978-1-60327-409-8_1; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Park Min-Ah, 2011, Lab Anim Res, V27, P265, DOI 10.5625/lar.2011.27.4.265; Park MA, 2012, MOL MED REP, V5, P761, DOI 10.3892/mmr.2011.712; Park MA, 2013, TOXICOLOGY, V305, P41, DOI 10.1016/j.tox.2012.12.021; Pivot XB, 2009, EUR J CANCER, V45, P2940, DOI 10.1016/j.ejca.2009.07.015; Ravindranath MH, 2004, ADV EXP MED BIOL, V546, P121; Santen RJ, 2007, ENDOCR-RELAT CANCER, V14, P169, DOI 10.1677/ERC-06-0045; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Spentzos D, 2007, ENDOCR-RELAT CANCER, V14, P781, DOI 10.1677/ERC-06-0073; Stewart RE, 1996, ENDOCRINOLOGY, V137, P2842, DOI 10.1210/en.137.7.2842; Sun M, 2001, CANCER RES, V61, P5985; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; Wlodkowic D, 2011, METHOD CELL BIOL, V103, P55, DOI 10.1016/B978-0-12-385493-3.00004-8; Wolstenholme JT, 2011, HORM BEHAV, V59, P296, DOI 10.1016/j.yhbeh.2010.10.001; Wu MV, 2009, CELL, V139, P61, DOI 10.1016/j.cell.2009.07.036; Yi BR, 2012, CANCER GENE THER, V19, P644, DOI 10.1038/cgt.2012.45; Yi BR, 2012, ONCOL REP, V27, P1823, DOI 10.3892/or.2012.1721524ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMNOV 1Discipline: Pharmacology &amp; Pharmacy; Toxicology241BM</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; Akt; ALPHA; apoptosis; BG-1 ovarian cancer cells; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; ENDOCRINE; Endocrine-disrupting chemicals; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; Estrogenicity; EXPRESSING CYTOSINE-DEAMINASE; EXPRESSION; genistein; GROWTH; HUMAN-BREAST-CANCER; IGF-1R; IN-VIVO; Interaction; MECHANISMS; MICE; MITOGENIC STIMULATION; MODEL; Mouse; Ovarian cancer; OVARIAN-CANCER; pAkt; PHOSPHORYLATION; pIRS-1; proliferation; PROTEIN; RECEPTOR; RECEPTOR-ALPHA; SIGNALING PATHWAY; SIGNALING PATHWAYS; SIGNALS; THERAPY; toxicology; TUMOR-GROWTH; XENOGRAFT MOUSE MODELS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>637</startpage>
    <endpage>646</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>3</issue>
    <volume>272</volume>
    <abstract>The interaction between estrogen receptor (ER) and insulin-like growth factor-1 receptor (IGF-1R) signaling pathway plays an important role in proliferation of and resistance to endocrine therapy to estrogen dependent cancers. Estrogen (E2) upregulates the expression of components of IGF-1 system and induces the downstream of mitogenic signaling cascades via phosphorylation of insulin receptor substrate-1 (IRS-1). In the present study, we evaluated the xenoestrogenic effect of bisphenol A (BPA) and antiproliferative activity of genistein (GEN) in accordance with the influence on this crosstalk. BPA was determined to affect this crosstalk by upregulating mRNA expressions of ER alpha and IGF-1R and inducing phosphorylation of IRS-1 and Akt in protein level in BG-1 ovarian cancer cells as E2 did. In the mouse model xenografted with BC-1 cells, BPA significantly increased a tumor burden of mice and expressions of ER alpha, pIRS-1, and cyclin D1 in tumor mass compared to vehicle, indicating that BPA induces ovarian cancer growth by promoting the crosstalk between ER and IGF-1R signals. On the other hand, GEN effectively reversed estrogenicity of BPA by reversing mRNA and protein expressions of ERa, IGF-1R, pIRS-1, and pAkt induced by BPA in cellular model and also significantly decreased tumor growth and in vivo expressions of ER alpha, pIRS-1, and pAkt in xenografted mouse model. Also, GEN was confirmed to have an antiproliferative effect by inducing apoptotic signaling cascades. Taken together, these results suggest that GEN effectively reversed the increased proliferation of BC-1 ovarian cancer by suppressing the crosstalk between ER alpha and IGF-1R signaling pathways upregulated by BPA or E2. (C) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000326141400009</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>163</id>
    <title>Genistein, a soy phytoestrogen, prevents the growth of BG-1 ovarian cancer cells induced by 17 beta-estradiol or bisphenol A via the inhibition of cell cycle progression</title>
    <authors>Hwang,K.A.; Kang,N.H.; Yi,B.R.; Lee,H.R.; Park,M.A.; Choi,K.C.</authors>
    <availability>[Hwang, Kyung-A; Kang, Nam-Hee; Yi, Bo-Rim; Lee, Hye-Rim; Park, Min-Ah; Choi, Kyung-Chul] Chungbuk Natl Univ, Lab Vet Biochem &amp; Immunol, Coll Vet Med, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Lab Vet Biochem &amp; Immunol, Coll Vet Med, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krBai WL, 2000, IN VITRO CELL DEV-AN, V36, P657; Baldwin WS, 1998, IN VITRO CELL DEV-AN, V34, P649; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; CabaravdiØ Mirsad, 2006, Med Arh, V60, P97; Choi KC, 2001, ENDOCRINOLOGY, V142, P2351, DOI 10.1210/en.142.6.2351; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; Dos Santos E, 2010, HORM METAB RES, V42, P514, DOI 10.1055/s-0030-1249639; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Giacalone PL, 2003, GYNECOL ONCOL, V91, P651, DOI 10.1016/S0090-8258(03)00279-8; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Joskow R, 2006, J AM DENT ASSOC, V137, P353; Kang JH, 2003, J FOOD PROTECT, V66, P1444; Kang NH, 2012, INT J ONCOL, V40, P2022, DOI 10.3892/ijo.2012.1372; Kang NH, 2012, CANCER GENE THER, V19, P412, DOI 10.1038/cgt.2012.15; Kansra S, 2005, MOL CELL ENDOCRINOL, V239, P27, DOI 10.1016/j.mce.2005.04.008; Kim KY, 2012, INT J ONCOL, V40, P1097, DOI 10.3892/ijo.2011.1288; Konduri SD, 2010, P NATL ACAD SCI USA, V107, P15081, DOI 10.1073/pnas.1009575107; Krell J, 2011, EXPERT REV ANTICANC, V11, P1641, DOI [10.1586/era.11.138, 10.1586/ERA.11.138]; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2011, J BIOMED RES, V12, P215; Li HQ, 2012, MINI-REV MED CHEM, V12, P350; Li J, 2007, CLIN IMMUNOL, V123, P219, DOI 10.1016/j.clim.2007.01.008; Lindgren P, 2001, INT J ONCOL, V19, P31; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538; Missmer SA, 2004, J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336; Moghadam Sonia Javan, 2011, J Carcinog, V10, P25, DOI 10.4103/1477-3163.90440; Park Min-Ah, 2011, Lab Anim Res, V27, P265, DOI 10.5625/lar.2011.27.4.265; Park MA, 2012, MOL MED REP, V5, P761, DOI 10.3892/mmr.2011.712; Pelekanou V, 2011, INT J DEV BIOL, V55, P869, DOI 10.1387/ijdb.113369vp; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Ravindranath MH, 2004, ADV EXP MED BIOL, V546, P121; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Santen RJ, 2007, ENDOCR-RELAT CANCER, V14, P169, DOI 10.1677/ERC-06-0045; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sirtori CR, 2005, ANN MED, V37, P423, DOI 10.1080/07853890510044586; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Wolstenholme JT, 2011, HORM BEHAV, V59, P296, DOI 10.1016/j.yhbeh.2010.10.001; Yi BR, 2011, ANTICANCER RES, V31, P2853; Yi BR, 2011, INT J ONCOL, V39, P833, DOI 10.3892/ijo.2011.1126495SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J ONCOLFEBDiscipline: Oncology077AT</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; Antagonist; BG-1 ovarian cancer cells; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; cell cycle; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CYCLE; CYCLE PROGRESSION; CYCLIN D1; ENDOCRINE; ENDOCRINE DISRUPTORS; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPRESSING CYTOSINE-DEAMINASE; EXPRESSION; FOOD; genistein; GROWTH; HEALTH; In vitro; IN-VITRO; inhibition; INHIBITOR; INTERFERON-BETA MIGRATE; KINASE; oncology; Ovarian cancer; OVARIAN-CANCER; p21; Phytoestrogen; PROGRESSION; proliferation; RECEPTOR; REPLACEMENT THERAPY; RISK-FACTORS; STEM-CELLS; VITRO; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>733</startpage>
    <endpage>740</endpage>
    <journalfull>International Journal of Oncology</journalfull>
    <issue>2</issue>
    <volume>42</volume>
    <abstract>An endocrine disrupting chemical (EDC) is a global health concern. In this study, we examined the effects of genistein (GEN) on bisphenol A (BPA) or 17 beta-estradiol (E2)-induced cell growth and gene alterations of BG-1 ovarian cancer cells expressing estrogen receptors (ERs). In an in vitro cell viability assay, E2 or BPA significantly increased the growth of BG-1 cells. This increased proliferative activity was reversed by treatment with ICI 182,780, a well-known ER antagonist, while cell proliferation was further promoted in the presence of propyl pyrazole triol (PPT), an ER alpha agonist. These results imply that cell proliferation increased by E2 or BPA was mediated by ERs, particularly ER alpha. BPA clearly acted as a xenoestrogen in BG-1 ovarian cancer cells by mimicking E2 action. In contrast, GEN effectively suppressed BG-1 cell proliferation promoted by E2 or BPA by inhibiting cell cycle progression. E2 and BPA increased the expression of cyclin D1, a factor responsible for the G1/S cell cycle transition. They also decreased the expression of p21, a potent cyclin-dependent kinase (CDK) inhibitor that arrests the cell cycle in G1 phase, and promoted the proliferation of BG-1 cells. As shown by its repressive effect on cell growth, GEN decreased the expression of cyclin D1 augmented by E2 or BPA. On the other hand, GEN increased the p21 expression downregulated by E2 or BPA. Collectively, our findings suggest that GEN, a dietary phytoestrogen, has an inhibitory effect on the growth of estrogen-dependent cancers promoted by E2 or BPA</abstract>
    <url>WOS:000314001000039</url>
    <isbnorissn>1019-6439</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>173</id>
    <title>Risk Assessment of Bisphenol A, An Endocrine Disruptor, Via Proliferative Effect on the Growth of Estrogen-Dependent Ovarian Cancer in Cellular and Animal Models</title>
    <authors>Hwang,K.A.; Choi,K.C.</authors>
    <availability>[Hwang, K. -A.; Choi, K. -C.] Chungbuk Natl Univ, Lab Vet Biochem &amp; Immunol, Coll Vet Med, Cheongju, Chungbuk, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00CSIRO PUBLISHINGCOLLINGWOOD150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIAREPROD FERT DEVELOPDiscipline: Developmental Biology; Reproductive Biology; Zoology047OJ</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER; ENDOCRINE; Endocrine disruptor; GROWTH; MODEL; MODELS; Ovarian cancer; OVARIAN-CANCER; RISK; Risk assessment; RISK-ASSESSMENT</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>244</startpage>
    <endpage>245</endpage>
    <journalfull>Reproduction Fertility and Development</journalfull>
    <issue>1</issue>
    <volume>25</volume>
    <url>WOS:000311850000204</url>
    <isbnorissn>1031-3613</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>53</id>
    <title>Late-life effects on rat reproductive system after developmental exposure to mixtures of endocrine disrupters</title>
    <authors>Isling,L.K.; Boberg,J.; Jacobsen,P.R.; Mandrup,K.R.; Axelstad,M.; Christiansen,S.; Vinggaard,A.M.; Taxvig,C.; Kortenkamp,A.; Hass,U.</authors>
    <availability>[Isling, Louise Krag; Boberg, Julie; Jacobsen, Pernille Rosenskjold; Mandrup, Karen Riiber; Axelstad, Marta; Christiansen, Sofie; Vinggaard, Anne Marie; Taxvig, Camilla; Hass, Ulla] Tech Univ Denmark, Natl Food Inst, Div Toxicol &amp; Risk Assessment, DK-2860 Soborg, Denmark. [Kortenkamp, Andreas] Brunel Univ, Inst Environm, Uxbridge UB8 3PH, Middx, England.</availability>
    <date>2014</date>
    <notes>JEnglishArticleHass, U (reprint author), Tech Univ Denmark, Natl Food Inst, Div Toxicol &amp; Risk Assessment, Morkhoj Bygade 19, DK-2860 Soborg, Denmarkulha@food.dtu.dkAdewale HB, 2009, BIOL REPROD, V81, P690, DOI 10.1095/biolreprod.109.078261; Ahn HJ, 2012, MOL REPROD DEV, V79, P626, DOI 10.1002/mrd.22070; Anway MD, 2008, PROSTATE, V68, P517, DOI 10.1002/pros.20724; Armenti AE, 2008, TOXICOL APPL PHARM, V233, P286, DOI 10.1016/j.taap.2008.09.010; BARSOUM N J, 1985, Toxicologic Pathology, V13, P200; Bosland MC, 1992, PATHOLOGY AGING RAT, P443; Bostwick DG, 2004, CANCER, V101, P2371, DOI 10.1002/cncr.20408; Carlus M, 2013, EXP TOXICOL PATHOL, V65, P243, DOI 10.1016/j.etp.2011.08.013; Castano-Vinyals G, 2012, BJU INT, V110, pE707, DOI 10.1111/j.1464-410X.2012.11516.x; Christiansen S, 2008, INT J ANDROL, V31, P241, DOI 10.1111/j.1365-2605.2008.00866.x; Christiansen S, 2009, ENVIRON HEALTH PERSP, V117, P1839, DOI 10.1289/ehp.0900689; Christiansen S, 2012, INT J ANDROL, V35, P303, DOI 10.1111/j.1365-2605.2011.01242.x; Cooper RL, 1999, EVALUATION INTERPRET, P42; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Crellin NK, 2001, REPRODUCTION, V121, P485, DOI 10.1530/rep.0.1210485; DeMaria JE, 2000, BRAIN RES, V879, P139, DOI 10.1016/S0006-8993(00)02763-3; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Duty SM, 2013, PEDIATRICS, V131, P483, DOI 10.1542/peds.2012-1380; ECHA, 2012, ECHA2010G19EN; Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106; Gore AC, 2011, MOL ENDOCRINOL, V25, P2157, DOI 10.1210/me.2011-1210; Hass U, 2012, REPROD TOXICOL, V34, P261, DOI 10.1016/j.reprotox.2012.05.090; Hass U, 2007, ENVIRON HEALTH PERSP, V115, P122, DOI 10.1289/ehp.9360; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Hubscher CH, 2005, BIOTECH HISTOCHEM, V80, P79, DOI 10.1080/10520290500138422; ISAACS JT, 1984, CANCER RES, V44, P5785; Jacobsen PR, 2012, REPROD TOXICOL, V34, P237, DOI 10.1016/j.reprotox.2012.05.099; Jarfelt K, 2005, REPROD TOXICOL, V19, P505, DOI 10.1016/j.reprotox.2004.11.005; Kristensen DM, 2012, INT J ANDROL, V35, P377, DOI 10.1111/j.1365-2605.2012.01282.x; Lau KM, 2003, LAB INVEST, V83, P743, DOI 10.1097/01.LAB.0000069519.06988.24; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; LEFEVRE J, 1988, BIOL REPROD, V38, P780, DOI 10.1095/biolreprod38.4.780; Lloyd RV, 1990, PATHOLOGY TUMOURS LA, V1, P499; MacKenzie WF, 1990, PATHOLOGY FISCHER RA, P485; Mahood IK, 2007, ENVIRON HEALTH PER S, V15, P55, DOI [10.1289/ehp.9366, DOI 10.1289/EHP.9366)]; OECD, 2012, TEST 443 EXT ON GEN; OECD, 2001, TEST 416 2 GEN REPR; OECD, 2009, OECD SER TEST ASS 5, V106; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Poteracki J, 1998, TOXICOL SCI, V45, P1; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; REZNIK G, 1981, PROSTATE, V2, P261, DOI 10.1002/pros.2990020304; Rodriguez HA, 2010, REPROD TOXICOL, V30, P550, DOI 10.1016/j.reprotox.2010.07.008; SARKAR DK, 1982, SCIENCE, V218, P684, DOI 10.1126/science.7134966; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Stefaneanu L, 1994, PATHOBIOLOGY AGING R, P173; Travis RC, 2003, BREAST CANCER RES, V5, P239, DOI 10.1186/bcr628; TROUILLAS J, 1982, AM J PATHOL, V109, P57; Uzumcu M, 2007, REPROD TOXICOL, V23, P337, DOI 10.1016/j.reprotox.2006.10.006; Vinggaard AM, 2005, TOXICOLOGY, V207, P21, DOI 10.1016/j.tox.2004.08.009; Wang W, 2012, TOXICOL APPL PHARM, V258, P288, DOI 10.1016/j.taap.2011.11.008; WARD JM, 1980, LAB INVEST, V43, P517; WELSCH CW, 1971, EXPERIENTIA, V27, P1350, DOI 10.1007/BF02136734; Zhang XF, 2013, ENVIRON MOL MUTAGEN, V54, P354, DOI 10.1002/em.21776550BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDREPRODUCTIONAPRSIDiscipline: Developmental Biology; Reproductive BiologyAE8YA</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CHEMICALS; DISORDERS; DOPAMINERGIC-NEURONS; ENDOCRINE DISRUPTERS; ESTROUS-CYCLE; EXPOSURE; FEMALE RATS; FOOD; GENE-EXPRESSION; LOW-DOSE EXPOSURE; Male; PARABENS; PERINATAL EXPOSURE; phthalate; Phthalates; PITUITARY-TUMORS; PROSTATE-CANCER; RATS; Reproduction; RISK</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>465</startpage>
    <endpage>476</endpage>
    <journalfull>Reproduction</journalfull>
    <issue>4</issue>
    <volume>147</volume>
    <abstract>This study examined late-life effects of perinatal exposure of rats to a mixture of endocrine-disrupting contaminants. Four groups of 14 time-mated Wistar rats were exposed by gavage from gestation day 7 to pup day 22 to a mixture of 13 anti-androgenic and estrogenic chemicals including phthalates, pesticides, u.v.-filters, bisphenol A, parabens, and the drug paracetamol. The groups received vehicle (control), a mixture of all 13 chemicals at 150-times (TotalMix150) or 450-times (TotalMix450) high-end human exposure, or 450-times a mixture of nine predominantly anti-androgenic chemicals (AAMix450). Onset of puberty and estrous cyclicity at 9 and 12 months of age were assessed. Few female offspring showed significantly regular estrus cyclicity at 12 months of age in the TotalMix450 and AAMix450 groups compared with controls. In 19-month-oldmale offspring, epididymal sperm counts were lower than controls, and in ventral prostate an overrepresentation of findings related to hyperplasia was observed in exposed groups compared with controls, particularly in the group dosed with anti-androgens. A higher incidence of pituitary adenoma at 19 months of age was found in males and females in the AAMix450 group. Developmental exposure of rats to the highest dose of a human-relevant mixture of endocrine disrupters induced adverse effects late in life, manifested as earlier female reproductive senescence, reduced sperm counts, higher score for prostate atypical hyperplasia, and higher incidence of pituitary tumors. These delayed effects highlight the need for further studies on the role of endocrine disrupters in hormone-related disorders in aging humans</abstract>
    <url>WOS:000334287700015</url>
    <isbnorissn>1470-1626</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>435</id>
    <title>Effects of Estrogenic Agents 17 beta-Estradiol (E2) and Bisphenol A on the Expression of RecQ DNA Helicases in Mammary Tumor MCF-7 Cells</title>
    <authors>Iso,T.; Futami,K.; Iwamoto,T.; Furuichi,Y.</authors>
    <availability>[Iwamoto, Teruaki] Int Univ Hlth &amp; Welf, Ctr Infertil &amp; IVF, Div Male Infertil, Nasushiobara, Tochigi 3292763, Japan. [Iso, Takako; Futami, Kazunobu; Furuichi, Yasuhiro] GeneCare Res Inst Co Ltd, Kanagawa 2470063, Japan. [Iso, Takako; Iwamoto, Teruaki; Furuichi, Yasuhiro] Japan Sci &amp; Technol Agcy, Kawaguchi, Saitama 3320012, Japan.</availability>
    <date>2009</date>
    <notes>JEnglishArticleIwamoto, T (reprint author), Int Univ Hlth &amp; Welf, Ctr Infertil &amp; IVF, Div Male Infertil, 537-3 Iguchi, Nasushiobara, Tochigi 3292763, Japant4iwa@iuhw.ac.jpBhat HK, 2003, P NATL ACAD SCI USA, V100, P3913, DOI 10.1073/pnas.0437929100; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Doherty KM, 2005, J BIOL CHEM, V280, P28085, DOI 10.1074/jbc.M500265200; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Hilliard CA, 1998, ENVIRON MOL MUTAGEN, V31, P316, DOI 10.1002/(SICI)1098-2280(1998)31:4&lt;316::AID-EM3&gt;3.0.CO;2-G; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; Iso T, 2007, BIOL PHARM BULL, V30, P266, DOI 10.1248/bpb.30.266; Karmakar P, 2006, BIOCHEM BIOPH RES CO, V348, P62, DOI 10.1016/j.bbrc.2006.07.037; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; Kitao S, 1999, NAT GENET, V22, P82; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Leffers H, 2001, HUM REPROD, V16, P1037, DOI 10.1093/humrep/16.5.1037; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Machwe A, 2006, BIOCHEMISTRY-US, V45, P13939, DOI 10.1021/bi0615487; Macris MA, 2006, DNA REPAIR, V5, P172, DOI 10.1016/j.dnarep.2005.09.005; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Roy D, 1997, J TOXICOL ENV HEALTH, V50, P1, DOI 10.1080/009841097160573; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shiratori M, 2002, ONCOGENE, V21, P2447, DOI 10.1038/sj/onc/1205334; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Steinmetz R, 1997, ENDOCRINOLOGY, V138, P1780, DOI 10.1210/en.138.5.1780; Tada S, 1996, CELL STRUCT FUNCT, V21, P123; Woo LL, 2006, EXP CELL RES, V312, P3443, DOI 10.1016/j.yexcr.2006.07.023; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258290PHARMACEUTICAL SOC JAPANTOKYO2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPANJ HEALTH SCIFEBDiscipline: Toxicology400BQ</notes>
    <keywords>1; 17 beta-Estradiol; 17-BETA-ESTRADIOL; AGENTS; bisphenol; bisphenol A; BISPHENOL-A; bloom helicase; BPA; BREAST-CANCER CELLS; CE; CELL; CELLS; CHEMICALS; CLONING; DAMAGE; DNA damage; DNA repair; DNA-DAMAGE; E2; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Estrogenic; EXPRESSION; GAMMA-H2AX; HEALTH; HUMAN HOMOLOG; IN-VITRO; IVF; LOCALIZATION; Male; Oxidative stress; PROTEIN; RECEPTOR; RecQ helicases; REPAIR; ROTHMUND-THOMSON-SYNDROME; SYNDROME GENE; TISSUE; TISSUES; toxicology; TUMOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>119</startpage>
    <endpage>124</endpage>
    <journalfull>Journal of Health Science</journalfull>
    <issue>1</issue>
    <volume>55</volume>
    <abstract>17 beta-Estradiol (E2) and bisphenol A (BPA) damage DNA in estrogen receptor (ER)-positive human mammary tumor MCF-7 cells. The effect of E2 and BRA is associated with increased expression of Bloom helicase (BLM) and formation of nuclear foci consisting of BLM and gamma H2AX at double stranded break regions. BLM is one of five human RecQ helicases that participate in the maintenance of genomic stability. This study investigated if the expressions of RecQ helicases Werner syndrome helicase (WRN), Rothmund-Thomson syndrome helicase (RTS), RecQ5 helicase (RecQ5), RecQ protein-like 1 helicase (RecQL1, also known as RecQ1) and BLM helicase are affected in MCF-7 cells by treatment with estrogenic agents. The expression of RTS mRNA significantly increased although the expression in RTS protein only slightly increased. The expressions of WRN, RecQ5 and RecQL1 were almost unaffected both at mRNA and protein levels. These data suggest that the expression of human RecQ helicases is differentially regulated depending on the tissues and cells. We showed that some helicase expressions are regulated depending on the DNA damage</abstract>
    <url>WOS:000262843400016</url>
    <isbnorissn>1344-9702</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>179</id>
    <title>Identification of DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs) as a Novel Target of Bisphenol A</title>
    <authors>Ito,Y.; Ito,T.; Karasawa,S.; Enomoto,T.; Nashimoto,A.; Hase,Y.; Sakamoto,S.; Mimori,T.; Matsumoto,Y.; Yamaguchi,Y.; Handa,H.</authors>
    <availability>[Ito, Yuki; Karasawa, Satoki; Enomoto, Teruya; Nashimoto, Akihiro; Hase, Yasuyoshi; Sakamoto, Satoshi; Yamaguchi, Yuki; Handa, Hiroshi] Tokyo Inst Technol, Grad Sch Biosci &amp; Biotechnol, Midori Ku, Yokohama, Kanagawa, Japan. [Ito, Takumi; Handa, Hiroshi] Tokyo Inst Technol, Solut Res Lab, Midori Ku, Yokohama, Kanagawa 227, Japan. [Mimori, Tsuneyo] Kyoto Univ, Grad Sch Med, Dept Rheumatol &amp; Clin Immunol, Sakyo Ku, Kyoto, Japan. [Matsumoto, Yoshihisa] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 152, Japan.</availability>
    <date>2012</date>
    <notes>JEnglishArticleHanda, H (reprint author), Tokyo Inst Technol, Grad Sch Biosci &amp; Biotechnol, Midori Ku, Yokohama, Kanagawa, Japanhanda.h.aa@m.titech.ac.jpAlcaraz C, 1990, J Vet Diagn Invest, V2, P191; Allard P, 2010, P NATL ACAD SCI USA, V107, P20405, DOI 10.1073/pnas.1010386107; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Auckley DH, 2001, CARCINOGENESIS, V22, P723, DOI 10.1093/carcin/22.5.723; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FDA (Food and Drug Administration), 2010, UPD BISPH US FOOD CO; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hiroi T, 2006, ENDOCRINOLOGY, V147, P2773, DOI 10.1210/en.2005-1235; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Kienker LJ, 2000, NUCLEIC ACIDS RES, V28, P2752, DOI 10.1093/nar/28.14.2752; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Marton MJ, 1997, MOL CELL BIOL, V17, P4474; Matsumoto Y, 1997, BIOCHEM BIOPH RES CO, V234, P568, DOI 10.1006/bbrc.1997.6689; Milligan SR, 1998, ENVIRON HEALTH PERSP, V106, P23; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Mori N, 2001, ONCOGENE, V20, P3609, DOI 10.1038/sj.onc.1204497; Nishio K, 2008, COLLOID SURFACE B, V64, P162, DOI 10.1016/j.colsurfb.2008.01.013; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Sakamoto S, 2009, CHEM REC, V9, P66, DOI 10.1002/tcr.20170; Someya M, 2006, CARCINOGENESIS, V27, P117, DOI 10.1093/carcin/bgi175; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Veuger SJ, 2003, CANCER RES, V63, P6008; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Yu YJ, 2001, CANCER RES, V61, P1820; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.067412PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEDEC 5Discipline: Science &amp; Technology - Other Topics057TZ</notes>
    <keywords>ASSOCIATION; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARCINOGENESIS; CELL; CELLS; DOUBLE-STRAND BREAKS; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPOSURE; FOOD; HEALTH; human estrogen receptor; HUMAN HEALTH; IDENTIFICATION; In vitro; IN-VITRO; IN-VIVO; inhibition; Interaction; IONIZING-RADIATION; KINASE; KU; MAMMALIAN-CELLS; Nuclear receptor; NUCLEAR RECEPTORS; PHOSPHORYLATION; PROTEIN; Proteomics; RADIATION; RECEPTOR; REPAIR; RISK; V(D)J RECOMBINATION; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>12</issue>
    <volume>7</volume>
    <abstract>Bisphenol A (BPA) forms the backbone of plastics and epoxy resins used to produce packaging for various foods and beverages. BPA is also an estrogenic disruptor, interacting with human estrogen receptors (ER) and other related nuclear receptors. Nevertheless, the effects of BPA on human health remain unclear. The present study identified DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a novel BPA-binding protein. DNA-PKcs, in association with the Ku heterodimer (Ku70/80), is a critical enzyme involved in the repair of DNA double-strand breaks. Low levels of DNA-PK activity are previously reported to be associated with an increased risk of certain types of cancer. Although the Kd for the interaction between BPA and a drug-binding mutant of DNA-PKcs was comparatively low (137 nM), high doses of BPA were required before cellular effects were observed (100-300 mu M). The results of an in vitro kinase assay showed that BPA inhibited DNA-PK kinase activity in a concentration-dependent manner. In M059K cells, BPA inhibited the phosphorylation of DNA-PKcs at Ser2056 and H2AX at Ser139 in response to ionizing radiation (IR)-irradiation. BPA also disrupted DNA-PKcs binding to Ku70/80 and increased the radiosensitivity of M059K cells, but not M059J cells (which are DNA-PKcs-deficient). Taken together, these results provide new evidence of the effects of BPA on DNA repair in mammalian cells, which are mediated via inhibition of DNA-PK activity. This study may warrant the consideration of the possible carcinogenic effects of high doses of BPA, which are mediated through its action on DNA-PK</abstract>
    <url>WOS:000312588200038</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>401</id>
    <title>Formation of adducts by bisphenol A, an endocrine disruptor, in DNA in vitro and in liver and mammary tissue of mice</title>
    <authors>Izzotti,A.; Kanitz,S.; D'Agostini,F.; Camoirano,A.; De Flora,S.</authors>
    <availability>[Izzotti, Alberto; Kanitz, Stefano; D'Agostini, Francesco; Camoirano, Anna; De Flora, Silvio] Univ Genoa, Dept Hlth Sci, Genoa, Italy.</availability>
    <date>2009</date>
    <notes>JEnglishArticleDe Flora, S (reprint author), Univ Genoa, Dept Hlth Sci, Genoa, Italysdf@unige.itANDERSEN M, 1975, NATURE, V276, P391; ASHBY J, 1988, MUTAT RES, V204, P17, DOI 10.1016/0165-1218(88)90114-0; ATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; Baba T, 2005, MOL CELL BIOL, V25, P10040, DOI 10.1128/MCB.25.22.10040-10051.2005; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; BENTLEY P, 1989, CARCINOGENESIS, V10, P321, DOI 10.1093/carcin/10.2.321; BISPHENOL A, 1993, 80057 CASRN IRIS EPA; Bugano DDG, 2008, EUR J GYNAECOL ONCOL, V29, P313; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Colerangle JB, 1997, J STEROID BIOCHEM, V60, P153, DOI 10.1016/S0960-0760(96)00130-6; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; Edmonds JS, 2004, BIOCHEM BIOPH RES CO, V319, P556, DOI 10.1016/j.bbrc.2004.05.024; Hakkola J, 1997, CARCINOGENESIS, V18, P391, DOI 10.1093/carcin/18.2.391; Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776; Hilliard CA, 1998, ENVIRON MOL MUTAGEN, V31, P316, DOI 10.1002/(SICI)1098-2280(1998)31:4&lt;316::AID-EM3&gt;3.0.CO;2-G; Huff J, 2001, Odontology, V89, P12, DOI 10.1007/s10266-001-8179-y; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; *INT AG RES CANC, 1979, IARC MON EV CARC RIS, V21; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; IVETT JL, 1989, ENVIRON MOL MUTAGEN, V14, P165, DOI 10.1002/em.2850140306; Izzotti A, 1998, FASEB J, V12, P753; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Izzotti A, 1999, CANCER RES, V59, P4285; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim CS, 2004, TOXICOL IND HEALTH, V20, P41, DOI 10.1191/0748233704th186oa; KNAAK JB, 1966, TOXICOL APPL PHARM, V8, P175, DOI 10.1016/S0041-008X(66)80001-7; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lee IK, 2007, ARCH PHARM RES, V30, P337, DOI 10.1007/BF02977615; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; MARTUCCI CP, 1993, PHARMACOL THERAPEUT, V57, P237, DOI 10.1016/0163-7258(93)90057-K; Masuda S, 2005, MUTAT RES-GEN TOX EN, V585, P137, DOI 10.1016/j.mrgentox.2005.04.005; MOON RC, 1969, J HISTOCHEM CYTOCHEM, V17, P182; MORRISEY RE, 1987, FUND APPL TOXICOL, V8, P571, DOI 10.1016/0272-0590(87)90142-4; Pacchierotti F, 2008, MUTAT RES-GEN TOX EN, V651, P64, DOI 10.1016/j.mrgentox.2007.10.009; Pfeiffer E, 1997, MUTAT RES-GEN TOX EN, V390, P21, DOI 10.1016/S0165-1218(96)00161-9; PIKE MC, 1993, EPIDEMIOL REV, V15, P17; Qiu SX, 2004, CHEM RES TOXICOL, V17, P1038, DOI 10.1021/tx049953r; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Sasco Annie J, 2003, Expert Rev Anticancer Ther, V3, P546, DOI 10.1586/14737140.3.4.546; Schilderman PAEL, 2000, ENVIRON MOL MUTAGEN, V36, P79, DOI 10.1002/1098-2280(2000)36:2&lt;79::AID-EM1&gt;3.0.CO;2-E; Schweikl H, 1998, MUTAT RES-GEN TOX EN, V415, P119, DOI 10.1016/S1383-5718(98)00067-9; Stack DE, 1996, CHEM RES TOXICOL, V9, P851, DOI 10.1021/tx960002q; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; STEINER S, 1992, CARCINOGENESIS, V13, P969, DOI 10.1093/carcin/13.6.969; Suzuki T, 2004, ENVIRON SCI TECHNOL, V38, P2389, DOI 10.1021/es030576z; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vanhoutte K, 1997, ANAL CHEM, V69, P3161, DOI 10.1021/ac970121q; Yager JD, 1996, ANNU REV PHARMACOL, V36, P203, DOI 10.1146/annurev.pa.36.040196.001223; YANG M, 2008, ARCH TOXICOL 1009; Yoo SD, 2001, J TOXICOL ENV HEAL A, V64, P417, DOI 10.1080/152873901753170740; Yoshihara S, 2001, TOXICOL SCI, V62, P221, DOI 10.1093/toxsci/62.2.2215335ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSMUTAT RES-GEN TOX ENSEP-OCTDiscipline: Biotechnology &amp; Applied Microbiology; Genetics &amp; Heredity; Toxicology523JO</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; BPA; breast; BREAST-CANCER; CANCER; Carcinogen; CARCINOGENESIS; CD-1 MICE; CELL; CELLS; CHEMICALS; CIGARETTE-SMOKE; detection; DIETHYLSTILBESTROL; DISEASE; diseases; DNA adducts; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL FATE; estrogenic activity; EXPOSURE; female; genetics; HEALTH; HUMAN EXPOSURE; In vitro; IN-VITRO; Liver; MAMMARY TISSUE; METABOLISM; MICE; Mouse liver; Mouse mammary cells; p21; RAT; RAT-LIVER; RATS; RECEPTOR; SALMONELLA MUTAGENICITY; SENSITIVITY; Steroid; SYSTEM; TARGET; TISSUE; toxicology; VITRO; WATER; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>28</startpage>
    <endpage>32</endpage>
    <journalfull>Mutation Research-Genetic Toxicology and Environmental Mutagenesis</journalfull>
    <issue>1-2</issue>
    <volume>679</volume>
    <abstract>Endocrine disruptors (EDs) represent a major toxicological and public health issue, and the xenoestrogen bisphenol A (BPA) has received much attention due to its high production volume and widespread human exposure. Also, due to its similarity to diethylstilbestrol, a known human carcinogen, BPA has been investigated for its genotoxic and carcinogenic properties, but the results have been either inconclusive or controversial. Metabolically activated BPA has previously been shown to form DNA adducts both in vitro and in rat liver. The present study was designed (a) to assess the sensitivity threshold of DNA-adduct detection by (32)P-postlabelling in an acellular system and (b) to evaluate the formation of DNA adducts in both liver and mammary cells of female CD-1 mice receiving BPA in their drinking water (200 mg/kg body weight) for eight consecutive days. The reaction of BPA with calf thymus DNA, in the presence of S9 mix, resulted in a dose-dependent formation of multiple DNA adducts, with a detection limit of similar to 10 ng of this ED under our experimental conditions. Administration of BPA to mice confirmed that DNA adducts are formed in liver (3.4-fold higher levels than in controls). In addition, new evidence is provided that DNA adducts are formed in target mammary cells (4.7-fold higher than in controls). Although DNA adducts do not necessarily evolve into tumours or other chronic degenerative diseases, the formation of these molecular lesions in target mammary cells may bear relevance for the potential involvement of BPA in breast carcinogenesis. (C) 2009 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000272069600005</url>
    <isbnorissn>1383-5718</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>369</id>
    <title>Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A</title>
    <authors>Izzotti,A.; Longobardi,M.; Cartiglia,C.; D'Agostini,F.; Kanitz,S.; De Flora,S.</authors>
    <availability>[Izzotti, A.; Longobardi, M.; Cartiglia, C.; D'Agostini, F.; Kanitz, S.; De Flora, S.] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy.</availability>
    <date>2010</date>
    <notes>JEnglishReviewDe Flora, S (reprint author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italysdf@unige.itATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; Balansky R, 2009, INT J CANCER, V126, P1047; Balansky R, 2006, P NATL ACAD SCI USA, V103, P7823, DOI 10.1073/pnas.0601412103; Banciu M, 2008, J STEROID BIOCHEM, V111, P101, DOI 10.1016/j.jsbmb.2008.05.004; Dabbs DJ, 1999, DIAGN CYTOPATHOL, V20, P203, DOI 10.1002/(SICI)1097-0339(199904)20:4&lt;203::AID-DC4&gt;3.0.CO;2-V; D'Agostini F, 2009, CANCER PREV RES, V2, P546, DOI 10.1158/1940-6207.CAPR-08-0235; D'Agostini F, 2005, MUTAT RES-FUND MOL M, V591, P173, DOI 10.1016/j.mrfmmm.2005.03.034; DANDEKAR AM, 1982, P NATL ACAD SCI-BIOL, V79, P3987, DOI 10.1073/pnas.79.13.3987; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; De Flora S, 2005, MUTAT RES-FUND MOL M, V591, P8, DOI 10.1016/j.mrfmmm.2005.02.029; DEFLORA S, 2009, CHEMOPREVENTION CANC, P57, DOI 10.1002/9783527626588.ch4; Edmonds JS, 2004, BIOCHEM BIOPH RES CO, V319, P556, DOI 10.1016/j.bbrc.2004.05.024; Estensen RD, 2004, CARCINOGENESIS, V25, P197, DOI 10.1093/carcin/bgg196; Ferguson LR, 2007, CURR CANCER DRUG TAR, V7, P459; Hecht S.S., 1999, J NUTR, V129, P768; Hu R, 2006, LIFE SCI, V79, P1944, DOI 10.1016/j.lfs.2006.06.019; *INT AG RES CANC, 1979, IARC MON EV CARC RIS, V21; Izzotti A, 1998, FASEB J, V12, P753; Izzotti A, 2005, MUTAT RES-FUND MOL M, V591, P212, DOI 10.1016/j.mrfmmm.2005.03.032; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Izzotti A, 2001, CANCER RES, V61, P2472; IZZOTTI A, 1995, CHEM-BIOL INTERACT, V97, P273, DOI 10.1016/0009-2797(95)03622-S; Jung S, 2001, SCAND J GASTROENTERO, V36, P963, DOI 10.1080/003655201750305495; Kang LG, 2009, ONCOL REP, V21, P185, DOI 10.3892/or_00000206; Mager DE, 2003, J PHARM SCI, V92, P1521, DOI 10.1002/jps.10402; Mi LX, 2008, J BIOL CHEM, V283, P22136, DOI 10.1074/jbc.M802330200; Micale RT, 2008, CURR CANCER DRUG TAR, V8, P703, DOI 10.2174/156800908786733423; MOON RC, 1969, J HISTOCHEM CYTOCHEM, V17, P182; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Namkung-Matthai H, 1998, EUR RESPIR J, V12, P1327, DOI 10.1183/09031936.98.12061327; Pereira MA, 2002, CARCINOGENESIS, V23, P1185, DOI 10.1093/carcin/23.7.1185; PIKE MC, 1993, EPIDEMIOL REV, V15, P17; Prawan A, 2009, CHEM-BIOL INTERACT, V179, P202, DOI 10.1016/j.cbi.2008.12.014; RANDERATH K, 1989, MUTAT RES, V219, P121, DOI 10.1016/0921-8734(89)90023-4; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Stoner GD, 1997, CANCER LETT, V114, P113, DOI 10.1016/S0304-3835(97)04639-9; Suh SJ, 2006, INT IMMUNOPHARMACOL, V6, P854, DOI 10.1016/j.intimp.2005.11.014; Suzuki T, 2004, ENVIRON SCI TECHNOL, V38, P2389, DOI 10.1021/es030576z; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 1997, CANCER RES, V57, P5489; Woolner S, 2008, J CELL BIOL, V182, P77, DOI 10.1083/jcb.200804062; Xiao D, 2007, CANCER RES, V67, P2239, DOI 10.1158/0008-5472.CAN-06-3645; Yamashita Uki, 2003, Journal of UOEH, V25, P365; YANG M, 2008, ARCH TOXICOL 1009; Yao RS, 2004, ONCOGENE, V23, P7746, DOI 10.1038/sj.onc.1207985; Ye B, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-90; Yoo SD, 2001, J TOXICOL ENV HEAL A, V64, P417, DOI 10.1080/152873901753170740; Youn JY, 2002, ARCH PHARM RES, V25, P946, DOI 10.1007/BF02977018559BENTHAM SCIENCE PUBL LTDSHARJAHEXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATESCURR CANCER DRUG TARMARDiscipline: Oncology579YB</notes>
    <keywords>1; A/J MICE; AGENTS; analysis; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; Budesonide; CANCER; CANCER CHEMOPREVENTIVE AGENTS; CARCINOGENESIS; CELL; Cell proliferation; CELL-PROLIFERATION; Chemoprevention; diet; DNA ADDUCT FORMATION; DNA adducts; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL CIGARETTE-SMOKE; Estrogen; Estrogen receptor beta; estrogen receptor-beta; ESTROGEN-RECEPTOR-BETA; HEALTH; IMMUNE-RESPONSE; in vivo; IN-VITRO; IN-VIVO; Inflammation; inhibition; Liver; LUNG-TUMORS; MAMMARY TISSUE; MAMMARY-GLAND; MICE; Microarray; MODULATION; oncology; P8; phenethyl isothiocyanate; PREDICTION; proliferation; PROTEIN; PROTEINS; proteome; Review; Steroid; TISSUE; TOOL; VIVO; WATER; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>147</startpage>
    <endpage>154</endpage>
    <journalfull>Current Cancer Drug Targets</journalfull>
    <issue>2</issue>
    <volume>10</volume>
    <abstract>Among endocrine disruptors, the xenoestrogen bisphenol A (BPA) is of particular interest due to the very high production and widespread environmental contamination. We recently demonstrated that the oral administration of BPA to mice results in the formation of DNA adducts not only in liver but also in mammary tissue. The present study aimed at evaluating the modulation of BPA-related DNA adducts and proteome alterations by the chemopreventive agents budesonide (BUD) and phenethyl isothiocyanate (PEITC). Swiss ICR (CD-1) mice received, for 8 days, BPA with the drinking water and either chemopreventive agent with the diet. We measured DNA adducts by (32)P postlabeling and 656 proteins by antibody microarray. BPA induced the formation, with similar patterns, of DNA adducts in liver and in mammary tissue. Moreover, BPA dysregulated 13 proteins in mammary tissue, mostly in the sense of upregulation, including estrogen receptor-beta and proteins involved in cell proliferation, inhibition of apoptosis, tissue remodeling, inflammation, stress response, and glutathione synthesis. PEITC significantly inhibited the formation of BPA-induced DNA adducts, but only at the highest dose tested, and BUD was totally ineffective. The chemopreventive agents modulated a variety of BPA-induced changes in proteome profiles. However, as shown by both hierarchical cluster analysis and principal component analysis, BUD and especially PEITC were not able to restore the physiological situation in BPA-treated mice. Therefore, the in vivo use of proteome analysis proves to be a sensitive tool for the early prediction not only of protective effects but also of adverse effects of chemopreventive agents</abstract>
    <url>WOS:000276412300003</url>
    <isbnorissn>1568-0096</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>88</id>
    <title>UV activation of polymeric high aspect ratio microstructures: ramifications in antibody surface loading for circulating tumor cell selection</title>
    <authors>Jackson,J.M.; Witek,M.A.; Hupert,M.L.; Brady,C.; Pullagurla,S.; Kamande,J.; Aufforth,R.D.; Tignanelli,C.J.; Torphy,R.J.; Yeh,J.J.; Soper,S.A.</authors>
    <availability>[Jackson, Joshua M.; Soper, Steven A.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27515 USA. [Witek, Malgorzata A.; Hupert, Mateusz L.; Brady, Charles; Soper, Steven A.] NCSU, UNC Chapel Hill, Dept Biomed Engn, Raleigh, NC USA. [Pullagurla, Swathi; Kamande, Joyce] Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA. [Aufforth, Rachel D.; Yeh, Jen Jen] UNC, Div Surg Oncol, Chapel Hill, NC USA. [Tignanelli, Christopher J.; Yeh, Jen Jen] UNC, Dept Surg, Chapel Hill, NC USA. [Torphy, Robert J.; Yeh, Jen Jen] UNC, Sch Med, Chapel Hill, NC USA. [Yeh, Jen Jen] UNC, Dept Pharmacol, Chapel Hill, NC USA. [Yeh, Jen Jen] UNC, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Soper, Steven A.] Ulsan Natl Inst Sci &amp; Technol, Ulsan, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishArticleSoper, SA (reprint author), Univ N Carolina, Dept Chem, Chapel Hill, NC 27515 USAssoper@unc.eduAdams AA, 2008, J AM CHEM SOC, V130, P8633, DOI 10.1021/ja8015022; Ahn CH, 2004, P IEEE, V92, P154, DOI 10.1109/JPROC.2003.820548; Alrifaiy A, 2012, POLYMERS-BASEL, V4, P1349, DOI 10.3390/polym4031349; Attia UM, 2010, INT J ADV MANUF TECH, V48, P973, DOI 10.1007/s00170-009-2345-8; Ben Amor S, 2000, APPL SURF SCI, V153, P172, DOI 10.1016/S0169-4332(99)00354-2; Bhattacharyya A, 2006, ANAL CHEM, V78, P788, DOI 10.1021/ac051449j; Bi HY, 2006, LAB CHIP, V6, P769, DOI 10.1039/b600326e; Bidard FC, 2009, B CANCER, V96, P73, DOI 10.1684/bdc.2008.0797; Butler J. E., 1993, Molecular Immunology, V30, P1165, DOI 10.1016/0161-5890(93)90135-X; Chen YW, 2013, ANALYST, V138, P1075, DOI 10.1039/c2an36430a; de Mello A, 2002, LAB CHIP, V2, p31N, DOI 10.1039/b203828p; Dharmasiri U., 2010, ANAL CHEM, V83, P2301; Dharmasiri U, 2010, ANNU REV ANAL CHEM, V3, P409, DOI 10.1146/annurev.anchem.111808.073610; Dharmasiri U, 2009, ELECTROPHORESIS, V30, P3289, DOI 10.1002/elps.200900141; Diepens M, 2007, POLYM DEGRAD STABIL, V92, P397, DOI 10.1016/j.polymdegradstab.2006.12.003; Do J, 2008, LAB CHIP, V8, P2113, DOI 10.1039/b811169c; Dole M., 1973, RADIATION CHEMISTRY; Eliane JP, 2008, CANCER RES, V68, P5529, DOI 10.1158/0008-5472.CAN-08-0630; FOX RB, 1963, J POLYM SCI PART A, V1, P1079, DOI 10.1002/pol.1963.100010321; Garcia V., 2012, APPLIED BIOLOGICAL E, P393; Gleghorn JP, 2010, LAB CHIP, V10, P27, DOI 10.1039/b917959c; Goddard JM, 2007, PROG POLYM SCI, V32, P698, DOI 10.1016/j.progpolymsci.2007.04.002; Han K, 2011, ANAL BIOCHEM, V417, P211, DOI 10.1016/j.ab.2011.06.030; Hashimoto M, 2005, ANAL CHEM, V77, P3243, DOI 10.1021/ac048184d; Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586; Humphrey Jr J. S., 1968, POLYM PREPR AM CHEM, V9, P453; HUPERT ML, 2007, MICROFLUID NANOFLUID, V3, P1, DOI DOI 10.1007/S10404-006-0091-X; Hwang KY, 2011, SENSOR ACTUAT B-CHEM, V155, P422, DOI 10.1016/j.snb.2010.12.026; Kamande J. W., 2013, ANAL CHEM SUBMITTED; Kotani A, 2012, ANAL METHODS-UK, V4, P58, DOI 10.1039/c1ay05366c; LIPSCHITZ I, 1982, POLYM-PLAST TECHNOL, V19, P53, DOI 10.1080/03602558208067727; Lu J, 2010, INT J CANCER, V126, P669, DOI 10.1002/ijc.24814; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Martinez JM, 2001, J AM CHEM SOC, V123, P12279, DOI 10.1021/ja0108786; MILLER AA, 1954, J POLYM SCI, V14, P503, DOI 10.1002/pol.1954.120147711; MITCHELL DF, 1994, SURF INTERFACE ANAL, V21, P44, DOI 10.1002/sia.740210107; Monserud JH, 2012, BIOMACROMOLECULES, V13, P4002, DOI 10.1021/bm301289n; MOORE JA, 1991, ACS SYM SER, V475, P156; Nagai N, 2003, POLYM DEGRAD STABIL, V81, P491, DOI 10.1016/S0141-3910(03)00135-6; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Nunes PS, 2010, MICROFLUID NANOFLUID, V9, P145, DOI 10.1007/s10404-010-0605-4; Owens GE, 2010, J INVEST MED, V58, P130; Pavia D. L., 2009, INTRODUCTION TO SPEC; POWELL CJ, 1994, J ELECTRON SPECTROSC, V68, P605, DOI 10.1016/0368-2048(94)80023-5; Randy B., 1975, PHOTODEGRADATION PHO; RASMUSSEN JR, 1977, J AM CHEM SOC, V99, P4736, DOI 10.1021/ja00456a035; Reiser A., 1983, J POLYM SCI POL LETT, V21, P679, DOI 10.1002/pol.1983.130210818; RIVATON A, 1995, POLYM DEGRAD STABIL, V49, P163, DOI 10.1016/0141-3910(95)00069-X; Rossier J, 2002, ELECTROPHORESIS, V23, P858, DOI 10.1002/1522-2683(200203)23:6&lt;858::AID-ELPS858&gt;3.0.CO;2-3; Roy S, 2010, SENSOR ACTUAT B-CHEM, V150, P537, DOI 10.1016/j.snb.2010.08.043; Roy S, 2011, PLASMA PROCESS POLYM, V8, P432, DOI 10.1002/ppap.201000120; Royal MW, 2012, IEEE PHOTONICS J, V4, P2126, DOI 10.1109/JPHOT.2012.2226873; Sagnella S, 2005, COLLOID SURFACE B, V42, P147, DOI 10.1016/j.colsurfb.2004.07.001; Saliba AE, 2010, P NATL ACAD SCI USA, V107, P14524, DOI 10.1073/pnas.1001515107; Sauer-Budge AF, 2009, LAB CHIP, V9, P2803, DOI 10.1039/b904854e; Schumacher S, 2012, LAB CHIP, V12, P464, DOI 10.1039/c1lc20693a; Seah M. P., 1979, Surface and Interface Analysis, V1, DOI 10.1002/sia.740010103; Seidel C, 1999, APPL SURF SCI, V150, P19, DOI 10.1016/S0169-4332(99)00012-4; Shadpour H, 2006, J CHROMATOGR A, V1111, P238, DOI 10.1016/j.chroma.2005.08.083; Sharan M, 2001, BIORHEOLOGY, V38, P415; Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330; Smith B. C., 1996, FUNDAMENTALS OF FOUR; Song S, 2006, MACROMOL RES, V14, P121; Soper SA, 2000, ANAL CHEM, V72, p642A, DOI 10.1021/ac0029511; Stott SL, 2010, SCI TRANSL MED, V2; Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107; Tiraferri A, 2012, J MEMBRANE SCI, V389, P499, DOI 10.1016/j.memsci.2011.11.018; Tsao CW, 2007, LAB CHIP, V7, P499, DOI 10.1039/b618901f; Tsao CW, 2009, MICROFLUID NANOFLUID, V6, P1, DOI 10.1007/s10404-008-0361-x; Tseng AA, 2003, IEEE T ELECTRON PACK, V26, P141, DOI 10.1109/TEPM.2003.817714; UCHIDA E, 1993, LANGMUIR, V9, P1121, DOI 10.1021/la00028a040; Valdemar Garcia R. D. a. R. L., 2012, BLOOD FLOW BEHAVIOUR; Wang H, 2012, ANGEW CHEM INT EDIT, V51, P4349, DOI 10.1002/anie.201200732; Wang ST, 2011, ANGEW CHEM INT EDIT, V50, P3084, DOI 10.1002/anie.201005853; Wang ST, 2009, ANGEW CHEM INT EDIT, V48, P8970, DOI 10.1002/anie.200901668; Wang YL, 2006, LANGMUIR, V22, P2719, DOI 10.1021/la053188e; Wei SY, 2005, J PHYS CHEM B, V109, P16988, DOI 10.1021/jp051550s; Wochnowski C, 2005, POLYM DEGRAD STABIL, V89, P252, DOI 10.1016/j.polymdegradstab.2004.11.024; Xu F, 2007, ANAL CHEM, V79, P9007, DOI 10.1021/ac7016597; YEH GSY, 1976, POLYMER, V17, P309, DOI 10.1016/0032-3861(76)90187-7; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zhao W., 2012, PROC NATL ACAD SCI U; Zhao Z, 2008, J CLIN MICROBIOL, V46, P3752, DOI 10.1128/JCM.00377-08838ROYAL SOC CHEMISTRYCAMBRIDGETHOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLANDLAB CHIPDiscipline: Biochemistry &amp; Molecular Biology; Chemistry; Science &amp; Technology - Other Topics261MK</notes>
    <keywords>ACTIVATION; BIOLOGY; BISPHENOL-A POLYCARBONATE; CANCER; CANCER-CELLS; CELL; CHIP; DEGRADATION; DIAGNOSTICS; EFFICIENT CAPTURE; FUNCTIONAL-GROUPS; In vitro; IN-VITRO; MICROFLUIDIC DEVICES; POLY(METHYL METHACRYLATE); RADIATION; VITRO; XPS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>106</startpage>
    <endpage>117</endpage>
    <journalfull>Lab on A Chip</journalfull>
    <issue>1</issue>
    <volume>14</volume>
    <abstract>The need to activate thermoplastic surfaces using robust and efficient methods has been driven by the fact that replication techniques can be used to produce microfluidic devices in a high production mode and at low cost, making polymer microfluidics invaluable for in vitro diagnostics, such as circulating tumor cell (CTC) analysis, where device disposability is critical to mitigate artifacts associated with sample carryover. Modifying the surface chemistry of thermoplastic devices through activation techniques can be used to increase the wettability of the surface or to produce functional scaffolds to allow for the covalent attachment of biologics, such as antibodies for CTC recognition. Extensive surface characterization tools were used to investigate UV activation of various surfaces to produce uniform and high surface coverage of functional groups, such as carboxylic acids in microchannels of different aspect ratios. We found that the efficiency of the UV activation process is highly dependent on the microchannel aspect ratio and the identity of the thermoplastic substrate. Colorimetric assays and fluorescence imaging of UV-activated microchannels following EDC/NHS coupling of Cy3-labeled oligonucleotides indicated that UV-activation of a PMMA microchannel with an aspect ratio of similar to 3 was significantly less efficient toward the bottom of the channel compared to the upper sections. This effect was a consequence of the bulk polymer's damping of the modifying UV radiation due to absorption artifacts. In contrast, this effect was less pronounced for COC. Moreover, we observed that after thermal fusion bonding of the device's cover plate to the substrate, many of the generated functional groups buried into the bulk rendering them inaccessible. The propensity of this surface reorganization was found to be higher for PMMA compared to COC. As an example of the effects of material and microchannel aspect ratios on device functionality, thermoplastic devices for the selection of CTCs from whole blood were evaluated, which required the immobilization of monoclonal antibodies to channel walls. From our results, we concluded the CTC yield and purity of isolated CTCs were dependent on the substrate material with COC producing the highest clinical yields for CTCs as well as better purities compared to PMMA</abstract>
    <url>WOS:000327669000011</url>
    <isbnorissn>1473-0197</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>324</id>
    <title>Combinations of physiologic estrogens with xenoestrogens alter calcium and kinase responses, prolactin release, and membrane estrogen receptor trafficking in rat pituitary cells</title>
    <authors>Jeng,Y.J.; Kochukov,M.; Watson,C.S.</authors>
    <availability>[Jeng, Yow-Jiun; Kochukov, Mikhail; Watson, Cheryl S.] Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleWatson, CS (reprint author), Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX USAcswatson@utmb.eduAcconcia F, 2005, MOL BIOL CELL, V16, P231; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Alyea RA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-59; Alyea RA, 2009, ENVIRON HEALTH PERSP, V117, P778, DOI 10.1289/ehp.0800026; Alyea RA, 2008, J NEUROCHEM, V106, P1525, DOI 10.1111/j.1471-4159.2008.05491.x; Andrade AJM, 2006, TOXICOLOGY, V227, P185, DOI 10.1016/j.tox.2006.07.022; Belcher SM, 2008, BRAIN RES REV, V57, P481, DOI 10.1016/j.brainresrev.2007.07.020; Benoff S, 1998, MOL HUM REPROD, V4, P453, DOI 10.1093/molehr/4.5.453; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Campbell CH, 2001, STEROIDS, V66, P727, DOI 10.1016/S0039-128X(01)00106-4; Campbell CH, 2002, FASEB J, V16, P1917, DOI 10.1096/fj.02-0182com; Chambliss KL, 2000, CIRC RES, V87, pE44; Chard T, 1995, J PERINAT MED, V23, P421; Della Seta D, 2005, BRAIN RES BULL, V65, P255, DOI 10.1016/j.brainresbull.2004.11.017; Fujimoto T, 2006, BRAIN RES, V1068, P49, DOI 10.1016/j.brainres.2005.11.028; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gorski J, 1997, PROG CLIN BIOL RES, V396, P233; GREENSPAN FS, 2004, BASIC CLIN ENDOCRINO, V7, P925; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Inoue K, 2000, ANALYST, V125, P1959, DOI 10.1039/b006597h; Jansson L, 2001, ARTHRITIS RHEUM, V44, P2168, DOI 10.1002/1529-0131(200109)44:9&lt;2168::AID-ART370&gt;3.0.CO;2-2; Jeng YJ, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-40; Jeng YJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-334; JENG YJ, 2010, ENV HLTH PERSPECT; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; Jones DC, 2008, BIOCHEM PHARMACOL, V76, P569, DOI 10.1016/j.bcp.2008.05.010; Kabil A, 2008, CARCINOGENESIS, V29, P1862, DOI 10.1093/carcin/bgn138; Kawaguchi M, 2004, J CHROMATOGR B, V799, P119, DOI 10.1016/j.jchromb.2003.10.021; Kiguchi M, 2008, J NEURAL TRANSM, V115, P1079, DOI 10.1007/s00702-008-0044-5; Kloas W, 1999, SCI TOTAL ENVIRON, V225, P59, DOI 10.1016/S0048-9697(98)00332-5; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20; Lappano R, 2010, MOL CELL ENDOCRINOL, V320, P162, DOI 10.1016/j.mce.2010.02.006; LOTTERING ML, 1992, CANCER RES, V52, P5926; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; Meinhardt U, 2002, SEMIN REPROD MED, V20, P277, DOI 10.1055/s-2002-35374; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Mitchner NA, 1999, ENDOCRINOLOGY, V140, P2651, DOI 10.1210/en.140.6.2651; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; MUNOZDETORO M, 2005, ENDOCR; Nadal A, 2009, MOL CELL ENDOCRINOL, V304, P63, DOI 10.1016/j.mce.2009.02.016; Narita M, 2006, NEUROSCI LETT, V402, P249, DOI 10.1016/j.neulet.2006.04.014; Narita S, 2007, ENVIRON HEALTH PERSP, V115, P48, DOI 10.1289/ehp.9378; Norfleet AM, 2000, FASEB J, V14, P157; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Palanza P, 2008, ENVIRON RES, V108, P150, DOI 10.1016/j.envres.2008.07.023; PAPPAS TC, 1995, FASEB J, V9, P404; Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200; Petrovic M, 2003, ENVIRON SCI TECHNOL, V37, P4442, DOI 10.1021/es034139w; Prossnitz ER, 2009, PROSTAG OTH LIPID M, V89, P89, DOI 10.1016/j.prostaglandins.2009.05.001; PROSTAGLANDINS, 2009, PROSTAG OTH LIPID M, V89, P89; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Selles J, 2005, STEROIDS, V70, P251, DOI 10.1016/j.steroids.2004.10.012; Sheeler CQ, 2000, ENVIRON HEALTH PERSP, V108, P97, DOI 10.2307/3454506; Shenhav S, 2003, ACTA OBSTET GYN SCAN, V82, P912, DOI 10.1034/j.1600-0412.2003.00250.x; Singleton DW, 2004, MOL CELL ENDOCRINOL, V221, P47, DOI 10.1016/j.mce.2004.04.010; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Steinmetz R, 1997, ENDOCRINOLOGY, V138, P1780, DOI 10.1210/en.138.5.1780; Suzuki T, 2003, NEUROSCIENCE, V117, P639, DOI 10.1016/S0306-4522(02)00935-1; Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V291, P76, DOI 10.1006/bbrc.2002.6407; Thomas P, 2010, STEROIDS, V75, P595, DOI 10.1016/j.steroids.2009.11.005; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239; Warner KE, 2007, ENVIRON TOXICOL CHEM, V26, P732, DOI 10.1897/06-482R.1; Watson CS, 2008, FASEB J, V22, P3328, DOI 10.1096/fj.08-107672; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Weltje L, 2005, HUM EXP TOXICOL, V24, P431, DOI 10.1191/0960327105ht551oa; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; ZHU BT, 1994, TOXICOL APPL PHARM, V125, P149, DOI 10.1006/taap.1994.1059; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-05658711BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDENVIRON HEALTH-GLOBOCT 15Discipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health673QL</notes>
    <keywords>ACTIVATION; Alkylphenol; ALKYLPHENOLS; ALPHA; ASSAY; BETA; bisphenol; bisphenol A; BISPHENOL-A; BISPHENOL-A CONCENTRATIONS; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; CELLS; COMBINATION; DEVELOPMENTAL EXPOSURE; Endocrine disruption; ENDOGENOUS ESTROGENS; ENVIRONMENTAL ESTROGENS; ER alpha; ER beta; ER-ALPHA; ER-BETA; ESTRADIOL; Estrogen; Estrogen receptor; estrogen receptor a; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; estrone; Fluorescence imaging; GPER; HEALTH; IN-VITRO; INITIATED SIGNALING PATHWAYS; KINASE; kinases; NEONATAL EXPOSURE; Nongenomic; Nonmonotonic; Occupational; PATHWAY; PHOSPHORYLATION; physiologic estrogens; PLASMA-MEMBRANE; PREGNANCY; PROLACTIN-RELEASE; RAT; RECEPTOR; Receptors; RELEASE; RESPONSES; screening; SIGNALING PATHWAY; SIGNALING PATHWAYS; Steroid; toxicology; TUMOR CELLS; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Environmental Health</journalfull>
    <volume>9</volume>
    <abstract>Background: Xenoestrogens such as alkylphenols and the structurally related plastic byproduct bisphenol A have recently been shown to act potently via nongenomic signaling pathways and the membrane version of estrogen receptor-a. Though the responses to these compounds are typically measured individually, they usually contaminate organisms that already have endogenous estrogens present. Therefore, we used quantitative medium-throughput screening assays to measure the effects of physiologic estrogens in combination with these xenoestrogens. Methods: We studied the effects of low concentrations of endogenous estrogens (estradiol, estriol, and estrone) at 10 pM (representing pre-development levels), and 1 nM (representing higher cycle-dependent and pregnancy levels) in combinations with the same levels of xenoestrogens in GH(3)/B6/F10 pituitary cells. These levels of xenoestrogens represent extremely low contamination levels. We monitored calcium entry into cells using Fura-2 fluorescence imaging of single cells. Prolactin release was measured by radio-immunoassay. Extracellular-regulated kinase (1 and 2) phospho-activations and the levels of three estrogen receptors in the cell membrane (ER alpha, ER beta, and GPER) were measured using a quantitative plate immunoassay of fixed cells either permeabilized or nonpermeabilized (respectively). Results: All xenoestrogens caused responses at these concentrations, and had disruptive effects on the actions of physiologic estrogens. Xenoestrogens reduced the % of cells that responded to estradiol via calcium channel opening. They also inhibited the activation (phosphorylation) of extracellular-regulated kinases at some concentrations. They either inhibited or enhanced rapid prolactin release, depending upon concentration. These latter two dose-responses were nonmonotonic, a characteristic of nongenomic estrogenic responses. Conclusions: Responses mediated by endogenous estrogens representing different life stages are vulnerable to very low concentrations of these structurally related xenoestrogens. Because of their non-classical dose-responses, they must be studied in detail to pinpoint effective concentrations and the directions of response changes</abstract>
    <url>WOS:000283678000001</url>
    <isbnorissn>1476-069X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>310</id>
    <title>Combinations of Physiologic Estrogens with Xenoestrogens Alter ERK Phosphorylation Profiles in Rat Pituitary Cells</title>
    <authors>Jeng,Y.J.; Watson,C.S.</authors>
    <availability>[Jeng, Yow-Jiun; Watson, Cheryl S.] Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX 77555 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleWatson, CS (reprint author), Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, 301 Univ Blvd, Galveston, TX 77555 USAcswatson@utmb.eduAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alyea RA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-59; Alyea RA, 2009, ENVIRON HEALTH PERSP, V117, P778, DOI 10.1289/ehp.0800026; Alyea RA, 2008, J NEUROCHEM, V106, P1525, DOI 10.1111/j.1471-4159.2008.05491.x; Belcheva MM, 2002, NEUROSIGNALS, V11, P34, DOI 10.1159/000057320; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Borgert CJ, 2003, ENVIRON HEALTH PERSP, V111, P1020, DOI 10.1289/ehp.6023; Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; BURBACK BL, 1993, APPL ENVIRON MICROB, V59, P1025; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Foster WG, 2008, ENDOCRINOLOGY, V149, P4267, DOI 10.1210/en.2008-0736; Fujita KA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000810; Greenspan FS, 2004, BASIC CLIN ENDOCRINO, P925; Han XD, 2004, REPROD TOXICOL, V19, P215, DOI 10.1016/j.reprotox.2004.06.014; Hossaini A, 2001, REPROD TOXICOL, V15, P537, DOI 10.1016/S0890-6238(01)00155-1; Jeng YJ, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-40; Jeng YJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-334; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; Kabil A, 2008, CARCINOGENESIS, V29, P1862, DOI 10.1093/carcin/bgn138; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lippert C, 2003, LIFE SCI, V72, P877, DOI 10.1016/S0024-3205(02)02305-6; LIPPMAN M, 1977, CANCER RES, V37, P1901; LOTTERING ML, 1992, CANCER RES, V52, P5926; Mermelstein PG, 1996, J NEUROSCI, V16, P595; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Moon HJ, 2007, J REPROD DEVELOP, V53, P333, DOI 10.1262/jrd.18055; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Narita S, 2007, ENVIRON HEALTH PERSP, V115, P48, DOI 10.1289/ehp.9378; Norfleet AM, 2000, FASEB J, V14, P157; Palanza P, 2001, HORM BEHAV, V40, P252, DOI 10.1006/hbeh.2001.1697; PAPPAS TC, 1995, FASEB J, V9, P404; PAPPAS TC, 1994, ENDOCRINE, V2, P813; PAPPAS TC, 1995, ENDOCRINE, V3, P743, DOI 10.1007/BF03000207; Powell CE, 1999, ENDOCRINE, V10, P271, DOI 10.1007/BF02738626; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Raz L, 2008, NEUROSIGNALS, V16, P140, DOI 10.1159/000111559; Razidlo GL, 2004, J BIOL CHEM, V279, P47808, DOI 10.1074/jbc.M406395200; REDDY VVR, 1979, BRAIN RES, V175, P165, DOI 10.1016/0006-8993(79)90526-2; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P36, DOI 10.1016/S0753-3322(01)00155-X; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; Watson CS, 2003, EXP BIOL MED, V228, P1272; Watson CS, 2008, FASEB J, V22, P3328, DOI 10.1096/fj.08-107672; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yang XH, 2008, DEV BIOL, V321, P64, DOI 10.1016/j.ydbio.2008.05.555; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Zhang LL, 2009, J CELL BIOCHEM, V106, P553, DOI 10.1002/jcb.22017; Zhou JH, 2007, STEROIDS, V72, P765, DOI 10.1016/j.steroids.2007.06.007; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-05657017US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPJANDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology701BI</notes>
    <keywords>ACTIVATION; Alkylphenol; ALKYLPHENOLS; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; COMBINATION; development; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL ESTROGENS; ER alpha; ER beta; ERK activation; ESTRADIOL; Estrogen; Estrogen receptor; estrogen signaling; ESTROGEN-RECEPTOR; ESTROGENS; estrone; G-PROTEIN; GPER; HEALTH; INITIATED SIGNALING PATHWAYS; KINASE; kinases; LIGAND; LIGANDS; LINE; membrane estrogen receptors; MEMBRANE-RECEPTOR; Menopause; non-genomic; Nongenomic; NONGENOMIC ACTIONS; nongenomic effects; Nonmonotonic; Occupational; PHOSPHORYLATION; physiologic estrogens; PREGNANCY; PROLACTIN-RELEASE; prolactinoma cell line; proliferation; RAT; RECEPTOR; RECEPTOR-ALPHA; RESPONSES; Steroid; TOXICITY; toxicology; TUMOR CELLS; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>104</startpage>
    <endpage>112</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>1</issue>
    <volume>119</volume>
    <abstract>Background: Estrogens are potent non-genomic phospho-activators of extracellular-signal-regulated kinases (ERKs). A major concern about the toxicity of xenoestrogens (XEs) is potential alteration of responses to physiologic estrogens when XEs are present simultaneously. Objectives: We examined estrogen-induced ERK activation, comparing the abilities of structurally related XEs (alkylphenols and bisphenol A) to alter ERK responses induced by physiologic concentrations (1 nM) of estradiol (E-2), estrone (E-1), and estriol (E-3). Methods: We quantified hormone/mimetic-induced ERK phosphorylations in the GH(3)/B6/F10 rat pituitary cell line using a plate immuno-assay, comparing effects with those on cell proliferation and by estrogen receptor subtype-selective ligands. Results: Alone, these structurally related XEs activate ERKs in an oscillating temporal pattern similar (but not identical) to that with physiologic estrogens. The potency of all estrogens was similar (active between femtomolar and nanomolar concentrations). XEs potently disrupted physiologic estrogen signaling at low, environmentally relevant concentrations. Generally, XEs potentiated (at the lowest, subpicomolar concentrations) and attenuated (at the highest, picomolar to 100 nM concentrations) the actions of the physiologic estrogens. Some XEs showed pronounced non-monotonic responses/inhibitions. The phosphorylated ERK and proliferative responses to receptor-selective ligands were only partially correlated. Conclusions: XEs are both imperfect potent estrogens and endocrine disruptors; the more efficacious an XE, the more it disrupts actions of physiologic estrogens. This ability to disrupt physiologic estrogen signaling suggests that XEs may disturb normal functioning at life stages where actions of particular estrogens are important (e.g., development, reproductive cycling, pregnancy, menopause)</abstract>
    <url>WOS:000285788900031</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>416</id>
    <title>Oral Exposure to Bisphenol A Increases Dimethylbenzanthracene-Induced Mammary Cancer in Rats</title>
    <authors>Jenkins,S.; Raghuraman,N.; Eltoum,I.; Carpenter,M.; Russo,J.; Lamartiniere,C.A.</authors>
    <availability>[Jenkins, Sarah; Raghuraman, Nandini; Lamartiniere, Coral A.] Univ Alabama, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Eltoum, Isam; Lamartiniere, Coral A.] Univ Alabama, Ctr Comprehens Canc, UAB, Birmingham, AL 35294 USA. [Eltoum, Isam] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Carpenter, Mark] Auburn Univ, Dept Math &amp; Stat, Auburn, AL 36849 USA. [Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticleLamartiniere, CA (reprint author), Univ Alabama, Dept Pharmacol &amp; Toxicol, 1670 Univ Blvd,Volker Hall 124, Birmingham, AL 35294 USACoral@uab.eduAupperlee MD, 2005, ENDOCRINOLOGY, V146, P3577, DOI 10.1210/en.2005-0346; Bouras T, 2001, CANCER RES, V61, P903; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P567; COLLETTE D, 2003, MODELLING SURVIVAL D; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; European Food Safety Authority, 2006, EFSA J, V428, P1; Fleming FJ, 2004, J CLIN PATHOL, V57, P1069, DOI 10.1136/jcp.2004.016733; Herbst AL, 1999, AM J OBSTET GYNECOL, V181, P1574, DOI 10.1016/S0002-9378(99)70411-4; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 1999, NATURE, V401, P763; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kang JH, 2003, J FOOD PROTECT, V66, P1444; Karamouzis MV, 2007, INT J BIOCHEM CELL B, V39, P851, DOI 10.1016/j.biocel.2006.11.017; Kariagina A, 2007, ENDOCRINOLOGY, V148, P2723, DOI 10.1210/en.2006-1493; Kirkegaard T, 2007, CLIN CANCER RES, V13, P1405, DOI 10.1158/1078-0432.CCR-06-1933; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Lahusen T, 2007, CANCER RES, V67, P7256, DOI 10.1158/0008-5472.CAN-07-1013; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2001, BIOL REPROD, V65, P1215; McCullagh P, 1989, GEN LINEAR MODELS; Mc Ilroy M, 2006, ENDOCR-RELAT CANCER, V13, P1135, DOI 10.1677/erc.1.01222; Meyer JS, 2005, MODERN PATHOL, V18, P1067, DOI 10.1038/modpathol.3800388; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Osborne CK, 2003, J NATL CANCER I, V95, P353; R chiff, 2003, CLIN CANCER RES, V9, P447; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; RUSSO IH, 1978, J NATL CANCER I, V61, P1439; RUSSO J, 1990, LAB INVEST, V62, P244; RUSSO J, 1978, J NATL CANCER I, V61, P1451; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wilson NK, 2007, ENVIRON RES, V103, P9, DOI 10.1016/j.envres.2006.04.006; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu X, 2007, NEUROSCI RES, V58, P149, DOI 10.1016/j.neures.2007.02.011; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.0504856US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPJUNDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology451HZ</notes>
    <keywords>Akt; analysis; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; Cell proliferation; CELL-PROLIFERATION; COACTIVATORS; COMBINATION; DMBA; ENDOCRINE; Endocrine disruptor; Estrogen; EXPOSURE; EXPRESSION; female; FOOD; food safety; GLAND DEVELOPMENT; GROWTH; HEALTH; INFANT FORMULA; JUN; LACTATIONAL EXPOSURE; Mammary cancer; MAMMARY TISSUE; MAMMARY-CANCER; MATERNAL EXPOSURE; MICE; MODEL; MODELS; Occupational; oral exposure; PERINATAL EXPOSURE; Plastics; progesterone; Progesterone receptor; PROGESTERONE-RECEPTOR; proliferation; PROTEIN; PROTEINS; RAT; RATS; RECEPTOR; RECEPTOR COACTIVATOR AIB1; Steroid; steroid receptor coactivators; SUSCEPTIBILITY; TAMOXIFEN RESISTANCE; TISSUE; toxicology; TUMOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>910</startpage>
    <endpage>915</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>6</issue>
    <volume>117</volume>
    <abstract>BACKGROUND: Bisphenol A (BPA) is widely used in the manufacture of polycarbonate plastics, including infant formula bottles. OBJECTIVES: Based on the reported endocrine disruptor activity of this polyphenol, we hypothesized that exposure to BPA early in life would elicit developmental changes in the mammary tissue and cause a predisposition for mammary cancer. METHODS: We exposed neonatal/prepubertal rats to BPA via lactation from nursing dams treated orally with 0, 25, and 250 mu g BPA/kg body weight/day. For turmorigenesis studies, female offspring were exposed to 30 mg dimethylbenzanthracene (DMBA)/kg body weight at 50 days of age. RESULTS: The combination of DMBA treatment with lactational exposure to BPA demonstrated a dose-dependent increase in mammary tumor multiplicity and reduced tumor latency compared with controls. In the absence of DMBA treatment, lactational BPA exposure resulted in increased cell proliferation and decreased apoptosis at 50 but not 21 days postpartum (shortly after last BPA treatment). Using Western blot analysis, we determined that steroid receptor coactivators (SRCs) 1-3, Akt, phosphorylated Akt, progesterone receptor A (PR-A), and erbB3 proteins were significantly up-regulated at 50 days of age. CONCLUSIONS: The data presented here provide the first evidence that maternal exposure to BPA during lactation increases mammary carcinogenesis in a DMBA-induced model of rodent mammary cancer. Changes in PR-A, SRC 1-3, erbB3, and Akt activity are consistent with increased cell proliferation and decreased apoptosis playing a role in mammary cancer susceptibility. These alterations provide an explanation of enhanced mammary carcinogenesis after lactational BPA exposure</abstract>
    <url>WOS:000266462600026</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>259</id>
    <title>Chronic Oral Exposure to Bisphenol A Results in a Nonmonotonic Dose Response in Mammary Carcinogenesis and Metastasis in MMTV-erbB2 Mice</title>
    <authors>Jenkins,S.; Wang,J.; Eltoum,I.; Desmond,R.; Lamartiniere,C.A.</authors>
    <availability>[Jenkins, Sarah; Wang, Jun; Lamartiniere, Coral A.] Univ Alabama, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Eltoum, Isam] Univ Alabama, Dept Anat Pathol, Birmingham, AL 35294 USA. [Eltoum, Isam; Desmond, Renee; Lamartiniere, Coral A.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Desmond, Renee] Univ Alabama, Dept Med, Biostat Unit, Div Preventat Med, Birmingham, AL 35294 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleLamartiniere, CA (reprint author), Univ Alabama, Dept Pharmacol &amp; Toxicol, 1670 Univ Blvd,Volker Hall 241, Birmingham, AL 35294 USAcoral@uab.eduBarros FFT, 2010, HISTOPATHOLOGY, V56, P560, DOI 10.1111/j.1365-2559.2010.03494.x; Benelli R, 2003, INT J ONCOL, V22, P87; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; Bruns CJ, 2004, CLIN CANCER RES, V10, P2109, DOI 10.1158/1078-0432.CCR-03-0502; Cagen SZ, 1999, REGUL TOXICOL PHARM, V30, P130, DOI 10.1006/rtph.1999.1340; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Celik I, 2005, CANCER RES, V65, P11044, DOI 10.1158/0008-5472.CAN-05-2617; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Di Carlo E, 1999, LAB INVEST, V79, P1261; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Eurocode, 2006, EUR RISK OBS LIT STU; FAO/WHO (Food and Agricultural Organization/ World Health Organization), 2010, EXP M REV TOX HLTH A; Food and Drug Administration, 2008, DRAFT ASS BISPH A US; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Howdeshell KL, 1999, NATURE, V401, P763; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jones LP, 2010, TOXICOL LETT, V199, P261, DOI 10.1016/j.toxlet.2010.09.008; Joskow R, 2006, J AM DENT ASSOC, V137, P353; Kang JH, 2003, J FOOD PROTECT, V66, P1444; Kim A, 2005, BREAST CANCER RES, V7, pR708, DOI 10.1186/bcr1281; Kim H S, 2001, J Toxicol Sci, V26, P111, DOI 10.2131/jts.26.111; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20; Lalani AS, 2004, MOL THER, V9, P56, DOI 10.1016/j.ymthe.2003.10.001; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Markey CM, 2001, BIOL REPROD, V65, P1215; Miyawaki J, 2007, J ATHEROSCLER THROMB, V14, P245; Motegi K, 2002, HISTOCHEM J, V34, P411, DOI 10.1023/A:1023687505139; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; National Toxicology Program, 1982, NIH PUBL; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Pape-Ansorge Kristin A, 2002, Nutr Cancer, V44, P162, DOI 10.1207/S15327914NC4402_07; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Sjin RTT, 2006, CANCER GENE THER, V13, P619, DOI 10.1038/sj.cgt.7700938; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Tjin RM, 2005, CANCER RES, V65, P3656, DOI 10.1158/0008-5472.CAN-04-1833; Trinh L, 2000, BIOSEPARATION, V9, P223, DOI 10.1023/A:1008133914854; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2007, REPROD TOXICOL, V24, P137; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.44145628US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPNOVDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology844XL</notes>
    <keywords>ADULTHOOD; Akt; ANGIOGENESIS; ANTITUMOR-ACTIVITY; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; Cell proliferation; CELL-PROLIFERATION; ENDOSTATIN; ERBB2; EXPOSURE; EXPRESSION; FOOD; GENE; GLAND; GROWTH; GROWTH-FACTOR; HEALTH; HUMANS; IN-UTERO EXPOSURE; mammary gland; MAMMARY-GLAND; mechanism; MECHANISMS; MICE; MMTV-erbB2 mice; MODEL; molecular mechanism; MOLECULAR-MECHANISMS; Mouse; MOUSE MODEL; Occupational; oral exposure; ORGANIZATION; PERINATAL EXPOSURE; PHOSPHORYLATION; Plastics; proliferation; PROTEIN; RECEPTOR; RISK; toxicology; TRANSGENIC MICE; TUMOR; TUMOR-GROWTH; TUMORIGENESIS; TUMORS; WATER; ZINC-BINDING</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1604</startpage>
    <endpage>1609</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>11</issue>
    <volume>119</volume>
    <abstract>BACKGROUND: Bisphenol A (BPA) is a synthetic compound used to produce plastics and epoxy resins. BPA can leach from these products in appreciable amounts, resulting in nearly ubiquitous daily exposure to humans. Whether BPA is harmful to humans, especially when administered orally in concentrations relevant to humans, is a topic of debate. OBJECTIVES: In this study, we investigated the role of chronic oral exposure to BPA during adulthood on mammary carcinogenesis by using a transgenic mouse model that spontaneously develops tumors through overexpression of wild-type erbB2 [mouse mammary tumor virus (MMTV)-erbB2]. METHODS: MMTV-erbB2 mice were exposed to 0, 2.5, 25, 250, or 2,500 mu g BPA/L drinking water from 56 until 112 days of age (for mechanism of action) or 252 days of age (for tumorigenesis). Cellular and molecular mechanisms of BPA action in the mammary gland were investigated via immunohistochemistry and immunoblotting. RESULTS: Only low doses of BPA significantly decreased tumor latency and increased tumor multiplicity, tumor burden, and the incidence of metastasis. All BPA doses significantly increased the cell proliferation index, but only the higher doses also increased the apoptotic index in the mammary gland. At the molecular level, 25 mu g BPA/L, but not 2,500 mu g BPA/L, increased phosphorylation of erbB2, erbB3, insulin-like growth factor 1 receptor, and Akt in the mammary gland. DISCUSSION: Low, but not high, BPA doses significantly accelerated mammary tumorigenesis and metastasis in MMTV-erbB2 mice. The combined ratio of cell proliferation and apoptosis indices and alterations in protein expression best predicted the ability of each dose of BPA to alter tumorigenesis in this model</abstract>
    <url>WOS:000296785900028</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>228</id>
    <title>Endocrine-active chemicals in mammary cancer causation and prevention</title>
    <authors>Jenkins,S.; Betancourt,A.M.; Wang,J.; Lamartiniere,C.A.</authors>
    <availability>[Jenkins, Sarah; Betancourt, Angela M.; Wang, Jun; Lamartiniere, Coral A.] Univ Alabama, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Lamartiniere, Coral A.] Univ Alabama, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleLamartiniere, CA (reprint author), Univ Alabama, Dept Pharmacol &amp; Toxicol, 1670 Univ Blvd,Volker Hall 241, Birmingham, AL 35294 USACoral@uab.eduADAMI HO, 1995, CANCER CAUSE CONTROL, V6, P551, DOI 10.1007/BF00054165; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Albrektsen G, 2006, CANCER EPIDEM BIOMAR, V15, P65, DOI 10.1158/1055-9965.EPI-05-0634; Badger TM, 2002, J NUTR, V132, p559S; Banerjee S, 2002, CANCER RES, V62, P4945; Beatson G, 1896, LANCET, V2, P104; Bertazzi A, 1993, Epidemiology, V4, P398; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; Bertazzi PA, 1997, EPIDEMIOLOGY, V8, P646, DOI 10.1097/00001648-199710000-00006; Betancourt A.M., 2009, J PROTEOMICS, V73, P1241; Betancourt A.M., 2010, ENV HLTH PERSPECT; Bhat KPL, 2001, CANCER RES, V61, P7456; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bove K, 2002, BIOCHEM BIOPH RES CO, V291, P1001, DOI 10.1006/bbrc.2002.6554; BOYLAN ES, 1979, J TOXICOL ENV HEALTH, V5, P1059; Brown NM, 1998, MOL CELL ENDOCRINOL, V144, P149, DOI 10.1016/S0303-7207(98)00106-3; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Butt S, 2009, INT J CANCER, V125, P1926, DOI 10.1002/ijc.24494; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Calafat A. M., 2009, Environmental Health Perspectives, V117, P639; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; Chang TKH, 2000, CAN J PHYSIOL PHARM, V78, P874, DOI 10.1139/cjpp-78-11-874; Ciolino HP, 1999, MOL PHARMACOL, V56, P760; Constantinou AI, 1998, AM J CLIN NUTR, V68, p1426S; Doerge DR, 2010, TOXICOL LETT, V199, P372, DOI 10.1016/j.toxlet.2010.09.022; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; Garvin S, 2006, CANCER LETT, V231, P113, DOI 10.1016/j.canlet.2005.01.031; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; GRAY LE, 1995, TOXICOL APPL PHARM, V133, P285, DOI 10.1006/taap.1995.1153; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Herbst AL, 1999, AM J OBSTET GYNECOL, V181, P1574, DOI 10.1016/S0002-9378(99)70411-4; Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584; Hiroi T, 2006, ENDOCRINOLOGY, V147, P2773, DOI 10.1210/en.2005-1235; Hovey RC, 2005, BIOL REPROD, V72, P423, DOI 10.1095/biolreprod.104.029769; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Ju YH, 2008, CARCINOGENESIS, V29, P2162, DOI 10.1093/carcin/bgn161; Kawaguchi H, 2009, VET PATHOL, V46, P142, DOI 10.1354/vp.46-1-142; Kawaguchi H, 2009, J VET MED SCI, V71, P1599; Kijkuokool P, 2006, CANCER LETT, V242, P53, DOI 10.1016/j.canlet.2005.10.033; Kim H S, 2001, J Toxicol Sci, V26, P111, DOI 10.2131/jts.26.111; Kim HA, 2008, ANTICANCER RES, V28, P2837; Kim JY, 2010, TOXICOL LETT, V193, P200, DOI 10.1016/j.toxlet.2010.01.011; Kim YA, 2004, ONCOL REP, V11, P441; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; LAMARTINIERE CA, 1995, CARCINOGENESIS, V16, P2833, DOI 10.1093/carcin/16.11.2833; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; Lamartiniere C.A, 1992, P 1 INT S HORM CARC; Lamartiniere CA, 2000, J WOMENS CANC, V2, P11; Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237; La Merrill M, 2010, ENVIRON HEALTH PERSP, V118, P596, DOI 10.1289/ehp.0901047; Lewis BC, 2001, TOXICOL SCI, V62, P46, DOI 10.1093/toxsci/62.1.46; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3&lt;297::AID-JCP7&gt;3.0.CO;2-P; MacMahon B, 2006, INT J CANCER, V118, P2373, DOI 10.1002/ijc.21404; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Markey CM, 2001, BIOL REPROD, V65, P1215; Matsushima A, 2008, BIOCHEM BIOPH RES CO, V373, P408, DOI 10.1016/j.bbrc.2008.06.050; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Michalek JE, 1999, J TOXICOL ENV HEAL A, V57, P369, DOI 10.1080/009841099157584; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Murrill WB, 1996, CARCINOGENESIS, V17, P1451, DOI 10.1093/carcin/17.7.1451; Ninomiya Kenjiro, 2007, Toxicol Pathol, V35, P813; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; Peng JH, 2010, EUR J CANCER PREV, V19, P110, DOI 10.1097/CEJ.0b013e3283362a3e; Persson I, 2000, J STEROID BIOCHEM, V74, P357, DOI 10.1016/S0960-0760(00)00113-8; Pesatori AC, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-39; PESATORI AC, 1993, INT J EPIDEMIOL, V22, P1010, DOI 10.1093/ije/22.6.1010; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Provinciali M, 2005, INT J CANCER, V115, P36, DOI 10.1002/ijc.20874; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Revich B, 2001, CHEMOSPHERE, V43, P951, DOI 10.1016/S0045-6535(00)00456-2; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; ROTHSCHILD TC, 1987, CANCER RES, V47, P4508; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rowell C, 2005, J NUTR, V135, p2953S; RUSSO J, 1978, J NATL CANCER I, V61, P1451; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Safe S, 2000, J MAMMARY GLAND BIOL, V5, P295, DOI 10.1023/A:1009550912337; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Serrero G, 2001, ANTIOXID REDOX SIGN, V3, P969, DOI 10.1089/152308601317203512; Sgambato A, 2001, MUTAT RES-GEN TOX EN, V496, P171, DOI 10.1016/S1383-5718(01)00232-7; Su Y, 2007, CARCINOGENESIS, V28, P1046, DOI 10.1093/carcin/bgl240; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Whitsett Timothy, 2006, J Carcinog, V5, P15, DOI 10.1186/1477-3163-5-15; Whitsett TG, 2006, EXPERT REV ANTICANC, V6, P1699, DOI 10.1586/14737140.6.12.1699; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yang XH, 2010, CARCINOGENESIS, V31, P695, DOI 10.1093/carcin/bgq00710610PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMAPRDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism922YL</notes>
    <keywords>2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; apoptosis; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; Causation; CELL; Cell proliferation; CELL-PROLIFERATION; CHEMICALS; DES; DIETHYLSTILBESTROL; DIOXIN EXPOSURE; DISRUPTOR BISPHENOL-A; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Epidemiology; ESTRADIOL; Estrogen; estrogen signaling; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; genistein; GLAND; GLAND DIFFERENTIATION; HEALTH; Hormones; HUMAN EXPOSURE; HUMAN-BREAST-CANCER; In vitro; IN-UTERO EXPOSURE; IN-VITRO; IN-VIVO; INHIBITS CELL-PROLIFERATION; Mammary cancer; mammary gland; MAMMARY-GLAND; MATERNAL STILBESTROL THERAPY; METABOLISM; PITUITARY-TUMOR CELLS; PREVENTION; proliferation; Proteomics; RESVERATROL; SOY; Steroid hormone; SUSCEPTIBILITY; TCDD; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>191</startpage>
    <endpage>200</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <issue>3-5</issue>
    <volume>129</volume>
    <abstract>Endocrine-active chemicals alter or mimic physiological hormones. These compounds are reported to originate from a wide variety of sources, and recent studies have shown widespread human exposure to several of these compounds. Given the role of the sex steroid hormone, estradiol, in human breast cancer causation, endocrine-active chemicals which interfere with estrogen signaling constitute one potential factor contributing to the high incidence of breast cancer. Thus, the aim of this review is to examine several common endocrine-active chemicals and their respective roles in breast cancer causation or prevention. The plastic component, bisphenol A (BPA), the synthetic estrogen, diethylstilbestrol (DES), the by-product of organic combustion, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the soy component, genistein, and the red grape phytoalexin, resveratrol, have some degree of structural similarities to each other and estradiol. However, despite these structural similarities, the in vitro and in vivo properties of each of these chemicals vary greatly in terms of breast cancer causation and prevention. Early life exposure to BPA and DES increases rodent susceptibility to chemically induced mammary carcinogenesis, presumably through retardation of normal mammary gland maturation and/or disrupting the ratio of cell proliferation and apoptosis in the mammary gland. On the other hand, early exposures to genistein and resveratrol protect rodents against chemically induced and spontaneous mammary cancers. This is reported to occur through the ability of genistein and resveratrol to accelerate mammary gland maturation. Interestingly. TCDD, which is the most structurally dissimilar to the above chemicals and functions as an anti-estrogen, also increases chemically induced mammary carcinogenesis through retardation of mammary gland maturation. This article is part of a Special Issue entitled 'Endocrine disruptors'. (C) 2011 Published by Elsevier Ltd</abstract>
    <url>WOS:000302584700010</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>164</id>
    <title>Interactive Effect of Bisphenol A (BPA) Exposure with-22G/C Polymorphism in LOX Gene on the Risk of Osteosarcoma</title>
    <authors>Jia,J.; Tian,Q.; Liu,Y.; Shao,Z.W.; Yang,S.H.</authors>
    <availability>[Jia, Jie; Tian, Qing; Liu, Yong; Shao, Zeng-Wu; Yang, Shu-Hua] Huazhong Univ Sci &amp; Technol, Tongji Med Coll, Union Hosp, Dept Orthoped, Wuhan 430074, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleLiu, Y (reprint author), Huazhong Univ Sci &amp; Technol, Tongji Med Coll, Union Hosp, Dept Orthoped, Wuhan 430074, Peoples R Chinayongliu027@163.comBland R, 2000, CLIN SCI, V98, P217, DOI 10.1042/CS19990252; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Caronia D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026091; Duan B, 2012, INT J CLIN ONCOL, V18, P492; Ericson U, 2007, AM J CLIN NUTR, V86, P434; EYRE DR, 1988, BIOCHEM J, V252, P495; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Francis DD, 2003, NAT NEUROSCI, V6, P445, DOI 10.1038/nn1038; Hameed M, 2011, SEMIN DIAGN PATHOL, V28, P86, DOI 10.1053/j.semdp.2011.02.002; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Juul A, 2001, HUM REPROD UPDATE, V7, P303, DOI 10.1093/humupd/7.3.303; KNOTT L, 1995, BIOCHEM J, V310, P1045; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041610; Martin Jeff W., 2012, Sarcoma, P627254, DOI 10.1155/2012/627254; Melzer D, 2011, ENVIRON HEALTH PERSP, V119, P1788, DOI 10.1289/ehp.1103809; Mirabello L, 2010, CARCINOGENESIS, V31, P1400, DOI 10.1093/carcin/bgq117; Sandberg AA, 2003, CANCER GENET CYTOGEN, V140, P1, DOI 10.1016/S0165-4608(02)00848-8171ASIAN PACIFIC ORGANIZATION CANCER PREVENTIONGYEONGGI-DOAPJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREAASIAN PAC J CANCER PDiscipline: OncologyAB0YG</notes>
    <keywords>bisphenol; bisphenol A; bisphenol A (BPA); BISPHENOL-A; BONE; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; Environmental estrogen; Estrogen; EXPOSURE; EXPRESSION; gene polymorphism; HEALTH; Interaction; interactive effect; Lysyl oxidase gene (LOX); oncology; ORGANIZATION; Osteosarcoma; POPULATION; PREVENTION; RISK; RISK-FACTORS; TUMORS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3805</startpage>
    <endpage>3808</endpage>
    <journalfull>Asian Pacific Journal of Cancer Prevention</journalfull>
    <issue>6</issue>
    <volume>14</volume>
    <abstract>Background: Osteosarcomas have many established risk factors, both genetic and environmental, but by themselves these explain only part of the total cancer incidence. Bisphenol A (BPA) is an environmental estrogen associated with risk of several kinds of tumour. The lysyl oxidase gene (LOX) may also contribute to risk of tumours including osteosarcomas. Here, we investigated possible interactions of BPA and a LOX polymorphism on the risk of osteosarcoma. Method: The present hospital-based case-control study included 106 cancer patients and 112 controls from a Chinese population. Internal burden of BPA exposure was assessed using high-performance liquid chromatography-mass spectrometry (HPLC-MS) method. Genotypes were determined using PCR-RFLP methods. Results: Compared with those in low BPA exposure group, subjects with BPA more than or equal to median value had significant increased risk of osteosarcoma among subjects who carried GC or CC genotypes. A significant interaction with BPA level and the -22G/C polymorphism was observed for osteosarcoma overall, osteosarcoma affecting knee and osteosarcoma affecting hip, as P-forinteraction = 0.036 for osteosarcoma overall; P-forinteraction = 0.024 for osteosarcoma affecting knee; and P-forinteraction = 0.017 for osteosarcoma affecting hip. Conclusions: The results suggest that BPA exposure interacts with the -22G/C polymorphism of the LOX gene to increase the risk of osteosarcoma</abstract>
    <url>WOS:000331517700071</url>
    <isbnorissn>1513-7368</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>138</id>
    <title>Characterization of endocrine disruptors from a complex matrix using estrogen receptor affinity columns and high performance liquid chromatography-high resolution mass spectrometry</title>
    <authors>Jondeau-Cabaton,A.; Soucasse,A.; Jamin,E.L.; Creusot,N.; Grimaldi,M.; Jouanin,I.; Ait-Aissa,S.; Balaguer,P.; Debrauwer,L.; Zalko,D.</authors>
    <availability>[Jondeau-Cabaton, Adeline; Soucasse, Amelie; Zalko, Daniel] INRA, Xenobiot Metab Team MeX, UMR TOXALIM Res Ctr Food Toxicol 1331, F-31027 Toulouse, France. [Jamin, Emilien L.; Jouanin, Isabelle; Debrauwer, Laurent] INRA, MetaToul AXIOM, UMR TOXALIM Res Ctr Food Toxicol 1331, F-31027 Toulouse, France. [Creusot, Nicolas; Ait-Aissa, Selim] INERIS, Unite Ecotoxicol In Vitro &amp; In Vivo, F-60550 Verneuil En Halatte, France. [Creusot, Nicolas] Univ Bordeaux 1, CNRS, EPOC LPTC UMR 5255, F-33405 Talence, France. [Grimaldi, Marina; Balaguer, Patrick] Inst Rech Cancerol Montpellier INSERM U896 UM1 CR, Environm &amp; Canc IRCM, Plateforme CMT Equipe Signalisat Hormonale, F-34298 Montpellier 5, France.</availability>
    <date>2013</date>
    <notes>JEnglishArticleZalko, D (reprint author), INRA, Xenobiot Metab Team MeX, UMR TOXALIM Res Ctr Food Toxicol 1331, 180 Chemin Tournefeuille, F-31027 Toulouse, Francedzalko@toulouse.inra.frAerni HR, 2004, ANAL BIOANAL CHEM, V378, P688, DOI 10.1007/s00216-003-2276-4; Akingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Alonso-Magdalena P, 2012, MOL CELL ENDOCRINOL, V355, P201, DOI 10.1016/j.mce.2011.12.012; Balaguer P, 1999, SCI TOTAL ENVIRON, V233, P47, DOI 10.1016/S0048-9697(99)00178-3; Balaguer P, 2001, LUMINESCENCE, V16, P153, DOI 10.1002/bio.630.abs; Bateman KP, 2009, J AM SOC MASS SPECTR, V20, P1441, DOI 10.1016/j.jasms.2009.03.002; Bernhard M, 2006, WATER RES, V40, P3419, DOI 10.1016/j.watres.2006.07.011; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Brack W, 2003, ANAL BIOANAL CHEM, V377, P397, DOI 10.1007/s00216-003-2139-z; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Celiz MD, 2009, ENVIRON TOXICOL CHEM, V28, P2473, DOI 10.1897/09-173.1; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; COLBORN T, 1995, ENVIRON HEALTH PERSP, V103, P81, DOI 10.2307/3432353; Creusot N, 2010, ANAL BIOANAL CHEM, V396, P569, DOI 10.1007/s00216-009-3310-y; Creusot N, 2013, ANAL BIOANAL CHEM, V405, P2553, DOI 10.1007/s00216-013-6708-5; Dagnino S, 2012, SCI TOTAL ENVIRON, V408, P2608; Darbre PD, 2004, J APPL TOXICOL, V24, P5, DOI 10.1002/jat.958; Datta S, 2002, J AGR FOOD CHEM, V50, P1350, DOI 10.1021/jf0111357; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Eggen RIL, 2003, ANAL BIOANAL CHEM, V377, P386, DOI 10.1007/s00216-003-2059-y; ELDER RL, 1984, J AM ACAD DERMATOL, V11, P1168, DOI 10.1016/S0190-9622(84)80205-4; Gomez E, 2005, J TOXICOL ENV HEAL A, V68, P239, DOI 10.1080/15287390590895054; Hajkova K, 2007, ANAL BIOANAL CHEM, V387, P1351, DOI 10.1007/s00216-006-1026-9; Hemming JM, 2001, ENVIRON TOXICOL CHEM, V20, P2268, DOI 10.1897/1551-5028(2001)020&lt;2268:AOTEAT&gt;2.0.CO;2; Hernandez F, 2005, ANAL BIOANAL CHEM, V382, P934, DOI 10.1007/s00216-005-3185-5; Houtman CJ, 2007, SCI TOTAL ENVIRON, V386, P134, DOI 10.1016/j.scitotenv.2007.06.002; Jobling S, 2002, BIOL REPROD, V66, P272, DOI 10.1095/biolreprod66.2.272; Jouannet P, 2001, APMIS, V109, P333, DOI 10.1034/j.1600-0463.2001.090502.x; Kaufmann A, 2010, ANAL CHIM ACTA, V673, P60, DOI 10.1016/j.aca.2010.05.020; Kern S, 2009, ENVIRON SCI TECHNOL, V43, P7039, DOI 10.1021/es901979h; Kinani S, 2008, RAPID COMMUN MASS SP, V22, P3651, DOI 10.1002/rcm.3771; Kinani S, 2010, ENVIRON POLLUT, V158, P74, DOI 10.1016/j.envpol.2009.07.041; Kind T., 2010, BIOANAL REV, V12, P23, DOI DOI 10.1007/S12566-010-0015-9; Koh CH, 2006, ENVIRON POLLUT, V142, P39, DOI 10.1016/j.envpol.2005.09.005; Kosjek T, 2007, ANAL BIOANAL CHEM, V387, P1379, DOI 10.1007/s00216-006-0969-1; Krauss M, 2010, ANAL BIOANAL CHEM, V397, P943, DOI 10.1007/s00216-010-3608-9; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lemaire G, 2006, TOXICOL SCI, V91, P501, DOI 10.1093/toxsci/kfj173; Liao WT, 2008, ANAL CHEM, V80, P7765, DOI 10.1021/ac801166z; Lim HK, 2007, RAPID COMMUN MASS SP, V21, P1821, DOI 10.1002/rcm.3024; Makarov A, 2006, J AM SOC MASS SPECTR, V17, P977, DOI 10.1016/j.jasms.2006.03.006; Makarov A, 2006, ANAL CHEM, V78, P2113, DOI 10.1021/ac0518811; MUELLER GC, 1978, ENDOCRINOLOGY, V102, P1429; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nimrod AC, 1996, CRIT REV TOXICOL, V26, P335, DOI 10.3109/10408449609012527; Okubo T, 2001, FOOD CHEM TOXICOL, V39, P1225, DOI 10.1016/S0278-6915(01)00073-4; Peethambaram PP, 1999, BREAST CANCER RES TR, V54, P117, DOI 10.1023/A:1006185805079; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; Petrovic M, 2006, J MASS SPECTROM, V41, P1259, DOI 10.1002/jms.1103; Pillon A, 2005, ENVIRON HEALTH PERSP, V113, P278, DOI 10.1289/ehp.7522; RASTOGI SC, 1995, CONTACT DERMATITIS, V32, P28, DOI 10.1111/j.1600-0536.1995.tb00836.x; Riu A, 2008, FOOD CHEM TOXICOL, V46, P3268, DOI 10.1016/j.fct.2008.07.009; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Routledge EJ, 1997, J BIOL CHEM, V272, P3280; Seifert M, 1999, FRESEN J ANAL CHEM, V363, P767, DOI 10.1007/s002160051288; Silva E, 2002, ENVIRON SCI TECHNOL, V36, P1751, DOI 10.1021/es0101227; Skakkebaek NE, 1998, ADV EXP MED BIOL, V444, P1; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Smith DC, 1998, UROLOGY, V52, P257, DOI 10.1016/S0090-4295(98)00173-3; Sole M, 2000, ENVIRON SCI TECHNOL, V34, P5076, DOI 10.1021/es991335n; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; Soto AM, 1997, ENVIRON HEALTH PERSP, V105, P647, DOI 10.2307/3433384; Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tollefsen KE, 2002, AQUAT TOXICOL, V56, P215, DOI 10.1016/S0166-445X(01)00154-0; Tyler CR, 1998, CRIT REV TOXICOL, V28, P319, DOI 10.1080/10408449891344236; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Weiss JM, 2011, ANAL BIOANAL CHEM, V400, P3141, DOI 10.1007/s00216-011-4939-x; Weller MG, 2012, SENSORS-BASEL, V12, P9181, DOI 10.3390/s120709181; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; Zalko D, 2003, DRUG METAB DISPOS, V31, P168, DOI 10.1124/dmd.31.2.168; Zhang X, 2011, ARCH ENVIRON CON TOX, V61, P93, DOI 10.1007/s00244-010-9588-0731SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYENVIRON SCI POLLUT RMAYDiscipline: Environmental Sciences &amp; Ecology133XY</notes>
    <keywords>AFFINITIES; ALKYLPHENOLIC COMPOUNDS; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELL; EFFECT-DIRECTED ANALYSIS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; environmental pollutants; ENVIRONMENTAL-ANALYSIS; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; FOOD; Fresh water sediment; HUMAN HEALTH; IDENTIFICATION; LIGAND; LIGANDS; MALE REPRODUCTIVE HEALTH; MASS-SPECTROMETRY; metabolomics; Nuclear receptor; octylphenol; RECEPTOR; RECEPTOR-ALPHA; REPORTER CELL-LINES; SAMPLES; STEROID ESTROGENS; WASTE-WATER; WATER; WATER TREATMENT-PLANT</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2705</startpage>
    <endpage>2720</endpage>
    <journalfull>Environmental Science and Pollution Research</journalfull>
    <issue>5</issue>
    <volume>20</volume>
    <abstract>Complex mixtures of contaminants with potential adverse effects on human health and wildlife are found in the environment and in the food chain. These mixtures include numerous anthropogenic compounds of various origins and structures, which may behave as endocrine disruptors. Mixture's complexity is further enhanced by biotic and abiotic transformations. It is therefore necessary to develop new strategies allowing the identification of the structure of known, as well as unknown, nuclear receptor (NR) ligands present in complex matrices. We explored the possibility to use NR-based affinity columns to characterize the presence of bioactive molecules in environmental complex mixtures. Estrogen receptor alpha (ER alpha)-based affinity columns were used to trap and purify estrogenic substances present in surface sediment samples collected in a French river under mixed anthropogenic pressure. We combined biological, biochemical and analytical approaches to characterize the structure of ligands retained on columns and demonstrate the presence of known active molecules such as bisphenol A and octylphenol, but also of unexpected ER alpha ligands (n-butylparaben, hydroxyl-methyl-benzofuranone). High resolution mass spectrometry results demonstrate that ER alpha affinity columns can be used for the isolation, purification and identification of known as well as unknown estrogenic contaminants present in complex matrices</abstract>
    <url>WOS:000318175400003</url>
    <isbnorissn>0944-1344</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>319</id>
    <title>Loss of BRCA1 leads to an increased sensitivity to Bisphenol A</title>
    <authors>Jones,L.P.; Sampson,A.; Kang,H.J.; Kim,H.J.; Yi,Y.W.; Kwon,S.Y.; Babus,J.K.; Wang,A.T.; Bae,I.</authors>
    <availability>[Jones, Laundette P.; Sampson, Aishia] Univ Maryland, Sch Med, Dept Pharmacol &amp; Expt Therapeut, Baltimore, MD 21201 USA. [Kang, Hyo Jin; Kim, Hee Jeong; Yi, Yong-Weon; Bae, Insoo] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA. [Bae, Insoo] Georgetown Univ, Dept Radiat Med, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA. [Bae, Insoo] Dankook Univ, WCU, Res Ctr Nanobiomed Sci, Cheonan, South Korea. [Kwon, Sun Young] Keimyung Univ, Dept Pathol, Deagu, South Korea. [Babus, Janice K.] Univ Maryland, Sch Med, Dept Biochem &amp; Mol Biol, Baltimore, MD 21201 USA. [Wang, Antai] Columbia Univ, Dept Biostat, Herbert Irving Comprehens Canc Ctr, New York, NY USA.</availability>
    <date>2010</date>
    <notes>JEnglishReviewJones, LP (reprint author), Univ Maryland, Sch Med, Dept Pharmacol &amp; Expt Therapeut, Bressler Bldg,Rm 4-002,655 W Baltimore St, Baltimore, MD 21201 USAljone010@umaryland.edu; ib42@georgetown.eduCalafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HESSWILSON, 2006, BREAST CANC RES TREA, V96, P279; Jones L, 2008, ONCOGENE, V27, P794, DOI 10.1038/sj.onc.1210674; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Rosen EM, 2005, ENDOCR-RELAT CANCER, V12, P533, DOI 10.1677/erc.1.00972; Schafer TE, 1999, J BIOMED MATER RES, V45, P192, DOI 10.1002/(SICI)1097-4636(19990605)45:3&lt;192::AID-JBM5&gt;3.0.CO;2-A; Somasundaram K, 1997, NATURE, V389, P187; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; VILLALOBOS M, 1995, ENVIRON HEALTH PERSP, V103, P844, DOI 10.2307/3432398; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Xu XL, 1999, NAT GENET, V22, P37; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.1711742982910ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTDEC 15Discipline: Toxicology694UT</notes>
    <keywords>ACTIVATION; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; BPA; BRCA1; breast; CANCER; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; E-SCREEN ASSAY; ENDOCRINE DISRUPTORS; environmental exposure; ER alpha; ER-ALPHA; Estrogen; ESTROGEN-RECEPTOR; EXPOSURE; EXPOSURES; GLAND; HEALTH; HUMAN EXPOSURE; HUMANS; HYPERPLASIA; In vitro; in vivo; IN-VITRO; IN-VIVO; inhibition; KU; mammary gland; MAMMARY-GLAND; MECHANISMS; MICE; MODEL; MODELS; Mouse; MOUSE MODEL; POPULATION; proliferation; RESPONSES; Review; SENSITIVITY; Steroid; SYSTEM; toxicology; VITRO; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>261</startpage>
    <endpage>268</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>3</issue>
    <volume>199</volume>
    <abstract>Humans are chronically exposed to the plasticizer, Bisphenol A (BPA), that can adversely affect the normal hormonal regulation of cellular functions by mimicking the actions of estrogen. This biological response to BPA may vary according to an individual's genetic characteristics (e.g., BRCA1 mutations or deletion). In this study, both cell culture and mouse models were used to elucidate whether the loss of BRCA1 function could affect BPA-mediated cell proliferation. In studies using BPA levels comparable to human exposures, we found that loss of BRCA1 enhances BPA-induced cell proliferation in both systems. In vitro. we found that loss of BRCA1 enhances BPA-induced ER alpha signaling. In vivo, we found that BPA administration stimulates mammary gland epithelial tissue/cell proliferation leading to hyperplasia in Brca1 mutant mice compared to wild-type control mice. These results suggest that the biological responses in BRCA1-deficient cells may depend on environmental exposures, specifically BPA. (C) 2010 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000285325200009</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>49</id>
    <title>In silico evidences for the binding of phthalates onto human estrogen receptor alpha, beta subtypes and human estrogen-related receptor gamma</title>
    <authors>Josh,M.K.S.; Pradeep,S.; Adarsh,V.K.; Amma,K.S.V.; Devi,R.S.; Balachandran,S.; Sreejith,M.N.; Jaleel,U.C.A.; Benjamin,S.</authors>
    <availability>[Josh, M. K. Sarath; Pradeep, S.; Benjamin, Sailas] Univ Calicut, Div Biotechnol, Dept Bot, Enzyme Technol Lab, Kozhikode 673635, Kerala, India. [Josh, M. K. Sarath; Amma, K. S. Vijayalekshmi] Univ Calicut, Sri Vyasa NSS Coll, Dept Chem, Trichur 680582, Kerala, India. [Adarsh, V. K.; Sreejith, M. N.; Jaleel, U. C. Abdul] Univ Calicut, Malabar Christian Coll, Ctr Cheminformat, Kozhikode 673001, Kerala, India. [Devi, R. Sudha; Balachandran, S.] Univ Kerala, Mahatma Gandhi Coll, Dept Chem, Thiruvananthapuram 695004, Kerala, India.</availability>
    <date>2014</date>
    <notes>JEnglishArticleBenjamin, S (reprint author), Univ Calicut, Div Biotechnol, Dept Bot, Enzyme Technol Lab, Kozhikode 673635, Kerala, Indiasailasben@yahoo.co.inAbad MC, 2008, J STEROID BIOCHEM, V108, P44, DOI 10.1016/j.jsbmb.2007.06.006; Babu S, 2012, BIOCHEM BIOPH RES CO, V426, P215, DOI 10.1016/j.bbrc.2012.08.065; Benjamin S, 2009, NUTR METAB, V6, P1, DOI 10.1186/1743-7075-6-36; Benjamin S, 2005, EUR J LIPID SCI TECH, V107, P706, DOI 10.1002/ejit.200401041; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Cauley JA, 1999, ANN INTERN MED, V130, P270; Celik L, 2008, CHEM RES TOXICOL, V21, P2195, DOI 10.1021/tx800278d; Cozzini P, 2012, TOXICOL LETT, V214, P81, DOI 10.1016/j.toxlet.2012.07.023; Escande A, 2006, BIOCHEM PHARMACOL, V71, P1459, DOI 10.1016/j.bcp.2006.02.002; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Habert R, 2009, FOLIA HISTOCHEM CYTO, V47, P67; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; HENDERSON BE, 1988, CANCER RES, V48, P246; Heudorf U, 2007, INT J HYG ENVIR HEAL, V210, P623, DOI 10.1016/j.ijheh.2007.07.011; Jacobs MN, 2004, TOXICOLOGY, V205, P43, DOI 10.1016/j.tox.2004.06.036; Koch HM, 2006, INT J ANDROL, V29, P155, DOI 10.1111/j.1365-2605.2005.00607.x; Latini Giuseppe, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P37, DOI 10.2174/1568008043340017; le Maire A, 2010, CELL MOL LIFE SCI, V67, P1219, DOI 10.1007/s00018-009-0249-2; Li F, 2012, ECOTOX ENVIRON SAFE, V80, P273, DOI 10.1016/j.ecoenv.2012.03.009; Liang DW, 2008, APPL MICROBIOL BIOT, V80, P183, DOI 10.1007/s00253-008-1548-5; Lovekamp TN, 2001, TOXICOL APPL PHARM, V172, P217, DOI 10.1006/taap.2001.9156; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; Moran FM, 2003, ENDOCRINOLOGY, V144, P467, DOI 10.1210/en.2002-220813; Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351; Mortensen AS, 2008, TOXICOL APPL PHARM, V227, P313, DOI 10.1016/j.taap.2007.11.003; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Okubo T, 2003, BIOL PHARM BULL, V26, P1219; Pavan B, 2001, TOXICOL LETT, V118, P157, DOI 10.1016/S0378-4274(00)00279-4; Pradeep S, 2012, J HAZARD MATER, V235, P69, DOI 10.1016/j.jhazmat.2012.06.064; Pradeep S, 2012, BIODEGRADATION, V24, P257; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Sarath Josh MK, 2012, J POLYM RES, V19, DOI 10.1007/s10965-012-9915-4; Sato M, 1994, J BONE MINER METAB, V12, P9; Seal A, 2012, J CHEMINFORMATICS, V4, P1, DOI 10.1186/1758-2946-4-10; Silva MJ, 2003, ARCH TOXICOL, V77, P561, DOI 10.1007/s00204-003-0486-3; Waller CL, 2004, J CHEM INF COMP SCI, V44, P758, DOI 10.1021/ci0342526; Weiser MJ, 2008, BRAIN RES REV, V57, P309, DOI 10.1016/j.brainresrev.2007.05.013; Wittassek M, 2008, INT J ANDROL, V31, P131, DOI 10.1111/j.1365-2605.2007.00837.x; Zhang ZB, 2013, TOXICOL APPL PHARM, V270, P16, DOI 10.1016/j.taap.2013.03.030; Zhang ZB, 2011, TOXICOL LETT, V207, P7, DOI 10.1016/j.toxlet.2011.08.017; Zhao C., 2008, NUCL RECEPT SIGNAL, V6; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1431TAYLOR &amp; FRANCIS LTDABINGDON4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDMOL SIMULATAPR 9Discipline: Chemistry; Physics286RU</notes>
    <keywords>AFFINITIES; ALPHA; BETA; BINDING; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CARCINOGENESIS; CELL; CHEMICALS; DI(2-ETHYLHEXYL)PHTHALATE; DISORDERS; Endocrine disruption; ENDOCRINE DISRUPTORS; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; genistein; GRANULOSA-CELLS; human estrogen receptor; in silico; In vitro; IN-VITRO; IN-VIVO; MECHANISMS; METABOLITES; molecular docking; phthalate; Phthalates; Phytoestrogen; PLATFORM; RECEPTOR; RECEPTOR-ALPHA; TAMOXIFEN; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>408</startpage>
    <endpage>417</endpage>
    <journalfull>Molecular Simulation</journalfull>
    <issue>5</issue>
    <volume>40</volume>
    <abstract>Being lipophilic xenobiotic chemicals, phthalates from the surrounding environments can easily be absorbed into the biological system, thereby causing various health problems including cancer and endocrine disruption in test animals and also in humans. In the present in silico study employing Glide, Schrodinger Suite 2012, we analysed in detail the binding affinities of 12 commonly used diphthalates and their metabolites (corresponding mono ester and phthalic acid) onto the ligand-binding domain (LBD) of the human estrogen receptor (hER), human estrogen receptor (hER) and human estrogen related receptor (hERR). Natural ligand 17 estradiol (E2), known xenoestrogen bisphenol A, the phytoestrogen genistein, the agonists/antagonists 4-hydroxy tamoxifen and raloxifene were also docked onto these receptors as positive controls for comparing the binding efficiencies with that of phthalates and their metabolites. Results revealed that E2 had less binding affinity to the receptors in comparison to certain phthalates, i.e. maximum binding scores (G score, kcal/mol) were diisononyl phthalate (-9.44) to hER, monophenyl phthalate (-8.66) to hER and di(2-ethylhexyl)phthalate (-9.38) to hERR. The most concerned monophthalates established additional H bonds with certain surrounding crucial amino acid residues in the LBD, and thus showed more affinity to all the receptors than even the natural ligand and other well-characterised xenoestrogens as demonstrated in this study. Briefly, this study gives an insight into the virtual binding behaviours of commonly used phthalates and their metabolites onto hERs and hERR, which would accelerate further in vitro mechanistic, preclinical and clinical studies on real in vitro or in vivo platforms</abstract>
    <url>WOS:000329487200010</url>
    <isbnorissn>0892-7022</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>232</id>
    <title>Biomarker Genes for Detecting Estrogenic Activity of Endocrine Disruptors via Estrogen Receptors</title>
    <authors>Jung,E.M.; An,B.S.; Yang,H.; Choi,K.C.; Jeung,E.B.</authors>
    <availability>[Jung, Eui-Man; An, Beum-Soo; Yang, Hyun; Choi, Kyung-Chul; Jeung, Eui-Bae] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Mol Biol, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishReviewJeung, EB (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Mol Biol, Cheongju 361763, Chungbuk, South Koreajemman@hanmail.net; vetterang@hotmail.com; anpoong@naver.com; kchoi@chungbuk.ac.kr; ebjeung@chungbuk.ac.krAn BS, 2003, MOL CELL ENDOCRINOL, V205, P79, DOI 10.1016/S0303-7207(03)00203-X; An BS, 2003, REPROD TOXICOL, V17, P311, DOI 10.1016/S0890-6238(03)00003-0; An BS, 2002, MOL CELL ENDOCRINOL, V191, P177, DOI 10.1016/S0303-7207(02)00042-4; Andersson C, 2007, AQUAT TOXICOL, V83, P33, DOI 10.1016/j.aquatox.2007.03.008; Babal P, 2001, J PHARMACOL EXP THER, V296, P372; Bagchi IC, 2003, FRONT BIOSCI, V8, pS852, DOI 10.2741/1148; Barley NF, 1999, BIOCHEM J, V341, P491, DOI 10.1042/0264-6021:3410491; Beyer C, 2002, NEUROREPORT, V13, P877, DOI 10.1097/00001756-200205070-00028; Biales AD, 2007, ENVIRON TOXICOL CHEM, V26, P2679, DOI 10.1897/07-101.1; Bonde JP, 2002, INT J ANDROL, V25, P262, DOI 10.1046/j.1365-2605.2002.00373.x; BURLINGTON H, 1950, P SOC EXP BIOL MED, V74, P48; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cheek AO, 2001, ENVIRON HEALTH PERSP, V109, P681, DOI 10.2307/3454784; Choi KC, 2003, J REPROD DEVELOP, V49, P337, DOI 10.1262/jrd.49.337; Choi KC, 2008, J CELL MOL MED, V12, P409, DOI 10.1111/j.1582-4934.2007.00209.x; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3; Colnot S, 1998, J BIOL CHEM, V273, P31939, DOI 10.1074/jbc.273.48.31939; Dang VH, 2007, J TOXICOL ENV HEAL A, V70, P171, DOI 10.1080/15287390600755257; Dang VH, 2007, TOXICOL SCI, V97, P504, DOI 10.1093/toxsci/kfm051; Dang VH, 2009, J REPROD DEVELOP, V55, P206; Dang VH, 2007, TOXICOL SCI, V98, P408, DOI 10.1093/toxsci/kfm120; Dang VH, 2007, REPROD TOXICOL, V23, P42, DOI 10.1016/j.reprotox.2006.08.010; DARWISH H, 1991, J BIOL CHEM, V266, P551; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DeRosa C, 1998, J TOXICOL ENV HEAL B, V1, P3; Dickerson SM, 2007, REV ENDOCR METAB DIS, V8, P143, DOI 10.1007/s11154-007-9048-y; Diel P, 2000, J STEROID BIOCHEM, V73, P1, DOI 10.1016/S0960-0760(00)00051-0; Dwivedi A, 1999, EUR J ENDOCRINOL, V141, P426, DOI 10.1530/eje.0.1410426; Ebrahimi Mansour, 2007, Pak J Biol Sci, V10, P3109; Fujimoto N, 2004, J STEROID BIOCHEM, V91, P121, DOI 10.1016/j.jsbmb.2004.02.006; Gao P, 2007, CANCER LETT, V256, P81, DOI 10.1016/j.canlet.2007.06.005; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Habert R, 2009, FOLIA HISTOCHEM CYTO, V47, pS67, DOI 10.2478/v10042-009-0056-5; Hagiwara H, 2008, TOXICOL LETT, V181, P13, DOI 10.1016/j.toxlet.2008.06.863; Han EH, 2007, J TOXICOL ENV HEAL A, V70, P1304, DOI 10.1080/15287390701428481; Hancock KD, 2009, TOXICOL LETT, V184, P169, DOI 10.1016/j.toxlet.2008.11.005; HARPER N, 1994, MOL CELL ENDOCRINOL, V104, P47, DOI 10.1016/0303-7207(94)90050-7; Heikaus S, 2002, J MOL ENDOCRINOL, V29, P239, DOI 10.1677/jme.0.0290239; Henry TB, 2009, COMP BIOCHEM PHYS A, V154, P119, DOI 10.1016/j.cbpa.2009.05.009; Heudorf U, 2007, INT J HYG ENVIR HEAL, V210, P623, DOI 10.1016/j.ijheh.2007.07.011; Hewetson A, 1997, BIOL REPROD, V57, P468, DOI 10.1095/biolreprod57.2.468; Hirose A, 2000, Nihon Rinsho, V58, P2428; Hong EJ, 2005, J REPROD DEVELOP, V51, P253, DOI 10.1262/jrd.16075; Hong EJ, 2004, BIOL REPROD, V71, P669, DOI 10.1095/biolreprod.103.026146; Hopert AC, 1998, ENVIRON HEALTH PERSP, V106, P581, DOI 10.1289/ehp.98106581; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; JEUNG EB, 1994, J MOL BIOL, V235, P1231, DOI 10.1006/jmbi.1994.1076; JEUNG EB, 1992, FEBS LETT, V307, P224, DOI 10.1016/0014-5793(92)80772-9; JOHANSSON C, 1991, EUR J BIOCHEM, V202, P1283, DOI 10.1111/j.1432-1033.1991.tb16501.x; Jung EM, 2012, TOXICOL LETT, V208, P142, DOI 10.1016/j.toxlet.2011.10.017; Jung JH, 2006, COMP BIOCHEM PHYS C, V143, P162, DOI 10.1016/j.cbpc.2006.01.009; Keum YS, 2009, J AGR FOOD CHEM, V57, P7931, DOI 10.1021/jf902132j; Kim Y. R., 2011, INT J MOL MED, V29, P294; KOGO H, 1993, JPN J PHARMACOL, V61, P65, DOI 10.1254/jjp.61.65; KORACH KS, 1991, STEROIDS, V56, P263, DOI 10.1016/0039-128X(91)90045-W; KRISINGER J, 1992, MOL CELL ENDOCRINOL, V86, P119, DOI 10.1016/0303-7207(92)90182-6; KRISINGER J, 1993, MOL CELL ENDOCRINOL, V97, P61, DOI 10.1016/0303-7207(93)90211-2; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lee GS, 2004, TOXICOL SCI, V82, P451, DOI 10.1093/toxsci/kfh296; Lee GS, 2005, TOXICOL SCI, V84, P270, DOI 10.1093/toxsci/kfi072; Lee GS, 2009, J CELL BIOCHEM, V108, P1175, DOI 10.1002/jcb.22347; Lee KY, 2003, MOL CELLS, V16, P48; Lee Y, 1996, P NATL ACAD SCI USA, V93, P15180, DOI 10.1073/pnas.93.26.15180; LHORSET F, 1994, ENDOCRINOLOGY, V134, P11, DOI 10.1210/en.134.1.11; Li SH, 2002, BIOL REPROD, V66, P322, DOI 10.1095/biolreprod66.2.322; Liu HX, 2008, ENVIRON INT, V34, P67, DOI 10.1016/j.envint.2007.07.008; Matthews JB, 2002, J STEROID BIOCHEM, V82, P181, DOI 10.1016/S0960-0760(02)00159-0; Mensenkamp AR, 2006, CURR OPIN NEPHROL HY, V15, P524, DOI 10.1097/01.mnh.0000242179.38739.fb; Nie GY, 2000, BIOL REPROD, V62, P27, DOI 10.1095/biolreprod62.1.27; Owens W, 2003, ENVIRON HEALTH PERSP, V111, P1527, DOI 10.1289/ehp.6413; Peng JB, 2000, J BIOL CHEM, V275, P28186; POLIAKOV A I, 1961, Vestn Dermatol Venerol, V35, P80; Puinean AM, 2006, MAR ENVIRON RES, V62, pS211, DOI 10.1016/j.marenvres.2006.04.035; Ren LF, 1997, CHEM-BIOL INTERACT, V104, P55, DOI 10.1016/S0009-2797(97)03767-8; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Sauter CN, 2005, EXP CELL RES, V311, P251, DOI 10.1016/j.yexcr.2005.09.005; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schneider S, 2008, REPROD TOXICOL, V25, P352, DOI 10.1016/j.reprotox.2008.04.001; Schrager S, 2004, AM FAM PHYSICIAN, V69, P2395; SHAMLEY DR, 1992, DEVELOPMENT, V116, P491; Shin JH, 2007, J REPROD DEVELOP, V53, P179, DOI 10.1262/jrd.18054; Spencer TE, 1999, BIOL REPROD, V60, P241, DOI 10.1095/biolreprod60.2.241; Stavrakakis C, 2008, ENVIRON TECHNOL, V29, P269, DOI 10.1080/09593330802099304; Tatsumi K, 1999, MOL HUM REPROD, V5, P153, DOI 10.1093/molehr/5.2.153; TENG CS, 1978, BIOCHEM J, V176, P143; Tian H, 2009, COMP BIOCHEM PHYS C, V150, P231, DOI 10.1016/j.cbpc.2009.04.014; Vazquez GR, 2009, COMP BIOCHEM PHYS C, V150, P298, DOI 10.1016/j.cbpc.2009.05.012; Vilela MLB, 2007, UROLOGY, V70, P618, DOI 10.1016/j.urology.2007.05.004; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Vo TTB, 2011, STEROIDS, V76, P675, DOI 10.1016/j.steroids.2011.03.006; Vo TTB, 2009, TOXICOL SCI, V112, P68, DOI 10.1093/toxsci/kfp176; Watanabe H, 2003, J MOL ENDOCRINOL, V30, P347, DOI 10.1677/jme.0.0300347; WEBSTER RA, 1984, AM J PHYSIOL, V246, pE288; Wen S, 2009, CHEMOSPHERE, V74, P981, DOI 10.1016/j.chemosphere.2008.10.002; Whitten PL, 2002, NEUROTOXICOL TERATOL, V24, P47, DOI 10.1016/S0892-0362(01)00192-1; Yamamoto Masako, 2005, Journal of Toxicological Sciences, V30, P7, DOI 10.2131/jts.30.7; Yang H, 2012, HUM EXP TOXICOL, V31, P134, DOI 10.1177/0960327111422402; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P16131015MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J ENV RES PUB HEMARDiscipline: Environmental Sciences &amp; Ecology917KV</notes>
    <keywords>AFFINITIES; ASSAY; BINDING; BIOMARKER; Biomarkers; BISPHENOL-A; BREAST-CANCER CELLS; calbindin-D-9k; CALBINDIN-D-9K MESSENGER-RNA; CALCIUM-BINDING PROTEIN; CANCER; CELL; CELLS; COMBINATION; cosmetics; development; DISORDERS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; Estrogen; estrogen activity; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic activity; Estrogenicity; ESTROGENS; FOOD; GENE; GENES; HEALTH; Hormones; HUMANS; IMMATURE RATS; In vitro; IN-VITRO; IN-VIVO; MATERNAL EXPOSURE; mechanism; MECHANISMS; METABOLISM; ORNITHINE-DECARBOXYLASE ACTIVITY; POLYBROMINATED DIPHENYL ETHERS; PROGESTERONE-RECEPTOR; RECEPTOR; REPRODUCTIVE-SYSTEM; screening; Steroid hormone; STEROID-HORMONES; SYSTEM; Transcriptional regulation; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>698</startpage>
    <endpage>711</endpage>
    <journalfull>International Journal of Environmental Research and Public Health</journalfull>
    <issue>3</issue>
    <volume>9</volume>
    <abstract>Endocrine disruptors (EDs) are compounds used in various industrial products, drugs, and cosmetics. They can be found in the environment and disturb the endocrine and reproductive systems, resulting in adverse effects to humans and wildlife such as birth defects and developmental disorders. Since several EDs have a structure similar to that of endogenous steroid hormones such as estrogens, they intend to have an affinity for steroid hormone receptors and alter hormone-mediated metabolism by binding to these receptors. EDs are therefore a global concern and assays should be developed to efficiently determine whether these compounds are detrimental to biological systems. Diverse experimental methods may help determine the endocrine disrupting potential of EDs and evaluate the adverse effects of a single and/or combination of these reagents. Currently, biomarkers have been employed to objectively measure EDs potency and understand the underlying mechanisms. Further studies are required to develop ideal screening methods and biomarkers to determine EDs potency at environmentally relevant concentrations. In this review, we describe the biomarkers for estrogenicity of EDs identified both in vitro and in vivo, and introduce a biomarker, cabindin-D-9k (CaBP-9k), that may be used to assess estrogenic activity of EDs</abstract>
    <url>WOS:000302175400004</url>
    <isbnorissn>1660-4601</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>255</id>
    <title>Metformin Represses Self-Renewal of the Human Breast Carcinoma Stem Cells via Inhibition of Estrogen Receptor-Mediated OCT4 Expression</title>
    <authors>Jung,J.W.; Park,S.B.; Lee,S.J.; Seo,M.S.; Trosko,J.E.; Kang,K.S.</authors>
    <availability>[Jung, Ji-Won; Park, Sang-Bum; Lee, Soo-Jin; Seo, Min-Soo; Trosko, James E.; Kang, Kyung-Sun] Seoul Natl Univ, Coll Vet Med, Dept Vet Publ Hlth, Adult Stem Cell Res Ctr, Seoul, South Korea. [Trosko, James E.; Kang, Kyung-Sun] Michigan State Univ, Dept Pediat &amp; Human Dev, Coll Human Med, Ctr Integrat Toxicol, E Lansing, MI 48824 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleJung, JW (reprint author), Korea Natl Inst Hlth, Ctr Biomed Sci, Div Intractable Dis, Chungbuk, South Koreakangpub@snu.ac.krAilles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Azoulay L, 2011, CANCER EPIDEM BIOMAR, V20, P337, DOI 10.1158/1055-9965.EPI-10-0940; Balan G, 2001, J PHARM SCI, V90, P1176, DOI 10.1002/jps.1071; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bhat HK, 2003, P NATL ACAD SCI USA, V100, P3913, DOI 10.1073/pnas.0437929100; Bosco JLF, 2011, CANCER EPIDEM BIOMAR, V20, P101, DOI 10.1158/1055-9965.EPI-10-0817; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Chang CC, 2001, RADIAT RES, V155, P201, DOI 10.1667/0033-7587(2001)155[0201:AHBECT]2.0.CO;2; Chong CR, 2009, ONCOLOGIST, V14, P1178, DOI 10.1634/theoncologist.2009-0286; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Evans JMM, 2005, BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Gonzalez-Angulo AM, 2010, CLIN CANCER RES, V16, P1695, DOI 10.1158/1078-0432.CCR-09-1805; Hansis C, 2001, MOL HUM REPROD, V7, P155, DOI 10.1093/molehr/7.2.155; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186; Huang MZ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-80; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Itoh Y, 2007, J IMMUNOL, V178, P3059; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; Kang KS, 2011, TOXICOL SCI, V120, pS269, DOI 10.1093/toxsci/kfq370; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Lee IK, 2007, ARCH PHARM RES, V30, P337, DOI 10.1007/BF02977615; Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Ogawa T, 2005, CANCER RES, V65, P9771, DOI 10.1158/0008-5472.CAN-05-0227; Ovitt CE, 1998, MOL HUM REPROD, V4, P1021, DOI 10.1093/molehr/4.11.1021; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; PITOT HC, 1980, CANCER RES, V40, P3616; Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Seifert A, 2009, INT J ONCOL, V35, P417, DOI 10.3892/ijo_00000354; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Trosko JE, 2009, VET PATHOL, V46, P176, DOI 10.1354/vp.46-2-176; Wright JL, 2009, CANCER CAUSE CONTROL, V20, P1617, DOI 10.1007/s10552-009-9407-y; Yang HM, 2005, J CELL BIOCHEM, V96, P821, DOI 10.1002/jcb.20588; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-15004722PUBLIC LIBRARY SCIENCESAN FRANCISCO185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USAPLOS ONENOV 23Discipline: Science &amp; Technology - Other Topics863KL</notes>
    <keywords>AGENTS; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CARCINOGENESIS; CARCINOMA; CELL; cell cycle; CELL-CYCLE; CELLS; CHEMICALS; CYCLE; diabetes; DIABETIC-PATIENTS; ER-ALPHA; Estrogen; EXPRESSION; GENE; GENES; GROWTH; HUMAN-BREAST-CANCER; IN-VITRO; inhibition; JUNCTIONAL INTERCELLULAR COMMUNICATION; LINE; mechanism; MECHANISMS; Neoplasia; POPULATION; POU-DOMAIN; PROMOTER; RESISTANT; RISK; STEM-CELLS; TCDD; THERAPY; TRANSCRIPTION; TRANSCRIPTIONAL ACTIVITY; TUMOR; TUMORS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>11</issue>
    <volume>6</volume>
    <abstract>Metformin, a Type II diabetic treatment drug, which inhibits transcription of gluconeogenesis genes, has recently been shown to lower the risk of some diabetes-related tumors, including breast cancer. Recently, "cancer stem cells" have been demonstrated to sustain the growth of tumors and are resistant to therapy. To test the hypothesis that metformin might be reducing the risk to breast cancers, the human breast carcinoma cell line, MCF-7, grown in 3-dimensional mammospheres which represent human breast cancer stem cell population, were treated with various known and suspected breast cancer chemicals with and without non-cytotoxic concentrations of metformin. Using OCT4 expression as a marker for the cancer stem cells, the number and size were measured in these cells. Results demonstrated that TCDD (100 nM) and bisphenol A (10 mM) increased the number and size of the mammospheres, as did estrogen (10 nM E2). By monitoring a cancer stem cell marker, OCT4, the stimulation by these chemicals was correlated with the increased expression of OCT4. On the other hand, metformin at 1 and 10 mM concentration dramatically reduced the size and number of mammospheres. Results also demonstrated the metformin reduced the expression of OCT4 in E2 &amp; TCDD mammospheres but not in the bisphenol A mammospheres, suggesting different mechanisms of action of the bisphenol A on human breast carcinoma cells. In addition, these results support the use of 3-dimensional human breast cancer stem cells as a means to screen for potential human breast tumor promoters and breast chemopreventive and chemotherapeutic agents</abstract>
    <url>WOS:000298162000068</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>296</id>
    <title>Electrochemical cell-based chip for the detection of toxic effects of bisphenol-A on neuroblastoma cells</title>
    <authors>Kafi,M.A.; Kim,T.H.; An,J.H.; Choi,J.W.</authors>
    <availability>[Kim, Tae-Hyung; An, Jeung Hee; Choi, Jeong-Woo] Sogang Univ, Dept Chem &amp; Biomol Engn, Seoul 121742, South Korea. [Kafi, Md. Abdul; Choi, Jeong-Woo] Sogang Univ, Interdisciplinary Program Integrated Biotechnol, Seoul 121742, South Korea.</availability>
    <date>2011</date>
    <notes>JEnglishArticleChoi, JW (reprint author), Sogang Univ, Dept Chem &amp; Biomol Engn, 1 Shinsu Dong, Seoul 121742, South Koreajwchoi@sogang.ac.krCARMICHAEL J, 1987, CANCER RES, V47, P936; Choi JW, 2010, MOL CRYST LIQ CRYST, V519, P36, DOI 10.1080/15421400903579911; Choi JW, 2007, ENVIRON MONIT ASSESS, V129, P37, DOI 10.1007/s10661-006-9423-2; El-Said WA, 2009, BIOCHIP J, V3, P105; El-Said WA, 2009, BIOSENS BIOELECTRON, V24, P1259, DOI 10.1016/j.bios.2008.07.037; Gursoy E, 2001, NEUROCHEM INT, V38, P181, DOI 10.1016/S0197-0186(00)00072-3; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Lee DY, 2004, BIOSCI BIOTECH BIOCH, V68, P1201, DOI 10.1271/bbb.68.1201; Lee JH, 2010, BIOCHIP J, V4, P1, DOI 10.1007/s13206-010-4101-4; Lee YM, 2007, J VET SCI, V8, P27; Li J, 2005, ANAL SCI, V21, P561, DOI 10.2116/analsci.21.561; MCGLINCHEY AJ, 2009, PLYMOUTH STUDENT SCI, V2, P25; Min J, 2010, BIOTECHNOL BIOPROC E, V15, P30, DOI 10.1007/s12257-009-3074-4; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; VOMSAAL FS, 2005, ENV HLTH PERSPECT, V113, P1883; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xu G, 2000, CHINESE CHEM LETT, V11, P597; Yeon JH, 2005, ANAL BIOCHEM, V341, P308, DOI 10.1016/j.ab.2005.03.047; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.56032412ELSEVIER ADVANCED TECHNOLOGYOXFORDOXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDBIOSENS BIOELECTRONMAR 15Discipline: Biophysics; Biotechnology &amp; Applied Microbiology; Chemistry; Electrochemistry; Science &amp; Technology - Other Topics739PR</notes>
    <keywords>ASSAY; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHIP; Cyclic voltammetry; Cytotoxicity; ELECTRODE; Environmental toxicant; Estrogen; HEALTH; MECHANISMS; MTT assay; Nanobiochip; neuroblastoma; SH-SY5Y cells; SYSTEM; TOXICITY; VIABILITY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3371</startpage>
    <endpage>3375</endpage>
    <journalfull>Biosensors &amp; Bioelectronics</journalfull>
    <issue>7</issue>
    <volume>26</volume>
    <abstract>A cell-based chip was fabricated for the electrochemical detection of the dose-dependent effects of bisphenol-A (BPA) on neuroblastoma cells (SH-SY5Y), which showed dual-mode correlation as a standard curve. Toxicity assessment of BPA became very important in environmental toxicants detection since BPA can be reached out easily from various common plastic-based product and give negative cellular effects on living organism. Cell chip was fabricated by immobilizing cells on C(RGD)(4) peptide coated electrode to detect the cytotoxicity of BPA electrochemically. Redox properties in living cells were determined by cyclic voltammetry using a home-made three-electrode system, and the cathodic peak current (I(pc)) was used as a parameter for measurement of the effect of BPA on cell viability. The peak current, I(pc) value increased with the concentration of BPA up to 300 nM and then decreased because of the stimulation of cancer cell activity at the concentration of BPA below 300 nM and cytotoxicity at the concentration of BPA above 300 nM, respectively. MIT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and optical microscopy-based morphological analysis confirmed the results of electrochemical study. This dual-mode correlation between the concentration of BPA and voltammetric signal intensity should be firstly considered to analyze its dose-dependent stimulus and cytotoxic effects on neuroblastoma cells by cell chip. (C) 2010 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000288730700044</url>
    <isbnorissn>0956-5663</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>149</id>
    <title>Electrochemical cell chip to detect environmental toxicants based on cell cycle arrest technique</title>
    <authors>Kafi,M.A.; Yea,C.H.; Kim,T.H.; Yagati,A.K.; Choi,J.W.</authors>
    <availability>[Kafi, Md. Abdul; Yagati, Ajay Kumar; Choi, Jeong-Woo] Sogang Univ, Interdisciplinary Program Integrated Biotechnol, Seoul 121742, South Korea. [Yea, Cheol-Heon; Kim, Tae-Hyung; Choi, Jeong-Woo] Sogang Univ, Dept Chem &amp; Biomol Engn, Seoul 121742, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishArticleChoi, JW (reprint author), Sogang Univ, Dept Chem &amp; Biomol Engn, 1 Shinsu Dong, Seoul 121742, South Koreajwchoi@ccs.sogang.ac.krAlberts B., 2002, MOL BIOL CELL; Bery M. N., 1995, BIOELECTROCHEMISTRY, P134; Choi JH, 2007, FIBER POLYM, V8, P37, DOI 10.1007/BF02908157; Choi JW, 2004, BIOTECHNOL BIOPROC E, V9, P76, DOI 10.1007/BF02932988; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Cude K, 2007, J CELL BIOL, V177, P253, DOI 10.1083/jcb.200609166; Dwyer DS, 1999, J CELL PHYSIOL, V178, P93, DOI 10.1002/(SICI)1097-4652(199901)178:1&lt;93::AID-JCP12&gt;3.0.CO;2-U; El-Said WA, 2009, BIOCHIP J, V3, P105; Gutierrez GJ, 2010, J BIOL CHEM, V285, P14217, DOI 10.1074/jbc.M110.121848; Huang JN, 2001, J CELL BIOL, V154, P85, DOI 10.1083/jcb.200102007; Jin HS, 2006, BIOCHEM J, V399, P335, DOI 10.1042/BJ20060612; Kafi MA, 2011, ANAL CHEM, V83, P2104, DOI 10.1021/ac102895b; Kafi MA, 2010, BIOTECHNOL LETT, V32, P1797, DOI 10.1007/s10529-010-0366-x; Kafi MA, 2011, BIOSENS BIOELECTRON, V26, P3371, DOI 10.1016/j.bios.2010.12.030; Kafi MA, 2010, BIOSENS BIOELECTRON, V26, P1359, DOI 10.1016/j.bios.2010.07.049; Kim T.-H., 2011, SENSOR LETT, V1, P147; Lee T, 2011, BIOMATERIALS, V32, P3815, DOI 10.1016/j.biomaterials.2011.01.072; Lee T, 2010, ADV MATER, V22, P510, DOI 10.1002/adma.200902288; May KML, 2004, ANAL CHEM, V76, P4156, DOI 10.1021/ac049810+; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Ruoslahti E, 1996, DEV BIOL, V12, P697; Woolley DE, 2002, EXP CELL RES, V273, P65, DOI 10.1006/excr.2001.5428; Yea CH, 2007, BIOCHIP J, V1, P219; Yilmaz B, 2006, TOXICOLOGY, V217, P184, DOI 10.1016/j.tox.2005.09.008; Zhu HJ, 2000, CANCER RES, V60, P1283282ELSEVIER ADVANCED TECHNOLOGYOXFORDOXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDBIOSENS BIOELECTRONMAR 15Discipline: Biophysics; Biotechnology &amp; Applied Microbiology; Chemistry; Electrochemistry; Science &amp; Technology - Other Topics079SA</notes>
    <keywords>BIOSENSOR; BIOSENSORS; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER CELLS; CANCER-CELLS; CELL; cell cycle; Cell-based biochip; CELL-CYCLE; CELLS; CHECKPOINT; CHIP; CYCLE; Cyclic voltammetry (CV); Differential pulse voltammetry (DPV); Environmental toxicity; EXPRESSION; In vitro; IN-VITRO; LINE; NANOSCALE FABRICATION; PEPTIDE LAYER; RESPONSES; S-PHASE; TOXICITY; toxicology; VARIANTS; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>192</startpage>
    <endpage>198</endpage>
    <journalfull>Biosensors &amp; Bioelectronics</journalfull>
    <volume>41</volume>
    <abstract>A cell-based chip was recently developed and shown to be an effective in vitro tool for analyzing effect of environmental toxin on target cells. However, common cell chips are inappropriate for the detection of multiple environmental toxins. Here, we fabricated a neural cell chip to detect different cellular responses induced by BPA (bisphenol-A) and PCB (poly chlorinated biphenyl). This approach was based on an electrochemical method using a cell cycle-arrest technique. Neural cells were synchronized at the synthesis phase by treatment with thymidine, which results in a sharp reduction peak when compared to unsynchronized cells. The fabricated chip containing 50% G1/S and 50% G2/M phase cells was used to determine the effects of environmental toxins on neural cancer cells. At the end, the cell-chips could be used to assess both BPA and PCB toxicity that the cells were completely synchronized at the G1/S and G2/M phase. The proposed neural cell chip can be a useful tool for biosensors to evaluate easily and sensitively multiple effects of environmental toxicants on target cells. (C) 2012 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000314191300026</url>
    <isbnorissn>0956-5663</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>208</id>
    <title>Induced growth of BG-1 ovarian cancer cells by 17 beta-estradiol or various endocrine disrupting chemicals was reversed by resveratrol via downregulation of cell cycle progression</title>
    <authors>Kang,N.H.; Hwang,K.A.; Kim,T.H.; Hyun,S.H.; Jeung,E.B.; Choi,K.C.</authors>
    <availability>[Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea. [Kim, Tae-Hee] Soonchunhyang Univ, Coll Med, Dept Obstet &amp; Gynecol, Puchon, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krChoi KC, 2003, J REPROD DEVELOP, V49, P337, DOI 10.1262/jrd.49.337; Colombo N, 2006, CRIT REV ONCOL HEMAT, V60, P159, DOI 10.1016/j.critrevonc.2006.03.004; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Fukui M, 2010, EUR J CANCER, V46, P1882, DOI 10.1016/j.ejca.2010.02.004; GEISINGER KR, 1989, CANCER, V63, P280, DOI 10.1002/1097-0142(19890115)63:2&lt;280::AID-CNCR2820630213&gt;3.0.CO;2-N; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Hwang KA, 2011, INT J MOL MED, V29, P195; Kang NH, 2012, INT J ONCOL FEB; Kim K.Y., 2011, INT J ONCOL, V40, P1097; Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee MH, 2009, CANCER RES, V69, P7449, DOI 10.1158/0008-5472.CAN-09-1266; Liu DW, 2012, INT J MOL SCI, V13, P828, DOI 10.3390/ijms13010828; Park M. A., 2011, MOL MED REP, V5, P761; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Roldan A, 2003, J AGR FOOD CHEM, V51, P1464, DOI 10.1021/jf020774u; Roy SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025166; Shankar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016530; Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n; Vanamala J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-238; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Yi BR, 2011, ANTICANCER RES, V31, P2853; Yi BR, 2011, INT J ONCOL, V39, P833, DOI 10.3892/ijo.2011.1126; Yi Chin-Ok, 2011, Anat Cell Biol, V44, P194, DOI 10.5115/acb.2011.44.3.194249SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEMOL MED REPJULDiscipline: Oncology; Research &amp; Experimental Medicine956ML</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER CELLS; CANCER-CELLS; CELL; cell cycle; cell cycle arrest; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CHEMICALS; CYCLE; CYCLE PROGRESSION; CYCLIN D1; cyclin-dependent kinase 2; development; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Estrogen; EXPRESSION; FOOD; GENE; gene expression; GENE-EXPRESSION; GENES; GROWTH; In vitro; IN-VITRO; inhibition; INHIBITOR; KINASE; Methoxychlor; Nonylphenol; octylphenol; oncology; Ovarian cancer; OVARIAN-CANCER; p21; Phytoestrogen; PROGRESSION; proliferation; RESVERATROL; SIGNALING PATHWAYS; SUPPRESSION; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>151</startpage>
    <endpage>156</endpage>
    <journalfull>Molecular Medicine Reports</journalfull>
    <issue>1</issue>
    <volume>6</volume>
    <abstract>Resveratrol (trans-3,4',5-trihydroxystilbene; RES), a phytoestrogen, exists in grape skin and red wine. Endocrine disrupting chemicals (EDCs) appear to promote the development and progression of estrogen-dependent cancers. In this study, we evaluated the inhibitory effect of RES on the cell proliferation induced by various EDCs in BG-1 ovarian cancer cells. Various EDCs, such as bisphenol A (BPA), nonylphenol (NP), octylphenol (OP), methoxychlor (MXC) and hexabromocyclododecane (HBCD), were employed in this study. In the in vitro experiments, treatment of BG-1 cells with E2, BPA, NP, OP, MXC or HBCD resulted in an increase of cell growth. By contrast, increased cell viability induced by these EDCs was reversed when co-cultured with RES. In addition, we examined the regulation of cell cycle-related genes by RT-PCR and western blot analysis. Treatment with each EDC was found to decrease only the gene expression of p21 and increase the expression of cell cycle-dependent kinase 2 (CDK2). However, co-treatment with RES and each EDC resulted in an increased gene expression of p21 and a decreased expression of CDK2. Cyclin D1 was increased by downregulating p21 only when treated with each EDC in the absence of RES, while co-treatment with RES and each EDC decreased the gene expression of cyclin D1 by upregulating p21. Taken together, RES appears to be an inhibitor of cyclin D1 and CDK2 and is responsible for the cell cycle arrest at the G, phase. In addition, when co-treated with each EDC, RES increased the expression of p21 and resulted in the growth inhibition of BG-1 ovarian cancer cells. Taken together, these results indicate the antiproliferative effect of RES, a dietary phytoestrogen, on estrogen-dependent ovarian cancer cells activated by EDCs</abstract>
    <url>WOS:000305093700027</url>
    <isbnorissn>1791-2997</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>241</id>
    <title>Resveratrol inhibits the cell proliferation induced by 17 beta-estradiol and bisphenol A through down-regulating ER alpha and IGF-1R cross talk action in BG-1 ovarian cancer cells</title>
    <authors>Kang,N.H.; Choi,K.C.</authors>
    <availability>[Kang, Nam-Hee; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishMeeting Abstract00SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J MOL MED1Discipline: Research &amp; Experimental Medicine031ON</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; ER alpha; ER-ALPHA; Ovarian cancer; OVARIAN-CANCER; proliferation; RESVERATROL</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S49</startpage>
    <endpage>S49</endpage>
    <journalfull>International Journal of Molecular Medicine</journalfull>
    <volume>30</volume>
    <url>WOS:000310651600180</url>
    <isbnorissn>1107-3756</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>106</id>
    <title>Resveratrol regulates the cell viability promoted by 17 beta-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor alpha and insulin growth factor-1 receptor in BG-1 ovarian cancer cells</title>
    <authors>Kang,N.H.; Hwang,K.A.; Lee,H.R.; Choi,D.W.; Choi,K.C.</authors>
    <availability>[Kang, Nam-Hee; Hwang, Kyung-A.; Lee, Hye-Rim; Choi, Kyung-Chul] Chungbuk Natl Univ, Lab Vet Biochem &amp; Immunol, Coll Vet Med, Cheongju 361763, Chungbuk, South Korea. [Kang, Nam-Hee] Dr Chungs Food Co Ltd, Res &amp; Innovat Team, Cheongju 361782, Chungbuk, South Korea. [Choi, Dal-Woong] Korea Univ, Dept Environm Hlth, Coll Hlth Sci, Seoul 136703, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishArticleChoi, DW (reprint author), Korea Univ, Dept Environm Hlth, Coll Hlth Sci, Seoul 136703, South Koreadwlove@korea.ac.kr; kchoi@cbu.ac.krBartella V, 2012, CELL SIGNAL, V24, P1515, DOI 10.1016/j.cellsig.2012.03.012; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Choi KC, 2003, J REPROD DEVELOP, V49, P337, DOI 10.1262/jrd.49.337; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Hakuno F., 2011, PLOS ONE, V6; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hamelers IHL, 2003, ENDOCR-RELAT CANCER, V10, P331, DOI 10.1677/erc.0.0100331; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Jin Pengpeng, 2013, J Biomed Res, V27, P135, DOI 10.7555/JBR.27.20120076; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Kang NH, 2012, CANCER GENE THER, V19, P412, DOI 10.1038/cgt.2012.15; Kim KY, 2012, INT J ONCOL, V40, P1097, DOI 10.3892/ijo.2011.1288; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2013, TOXICOLOGY, V304, P13, DOI 10.1016/j.tox.2012.10.012; Lee YJ, 2013, FOOD CHEM TOXICOL, V52, P61, DOI 10.1016/j.fct.2012.10.060; Ma Xing, 2012, Shengli Xuebao, V64, P207; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Park M. A., 2011, MOL MED REP, V5, P761; Qiu LL, 2013, TOXICOL LETT, V219, P116, DOI 10.1016/j.toxlet.2013.03.011; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; Spentzos D, 2007, ENDOCR-RELAT CANCER, V14, P781, DOI 10.1677/ERC-06-0073; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Tang QS, 2013, CANCER LETT, V336, P325, DOI 10.1016/j.canlet.2013.03.023; Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223; TSAI HJ, 1994, COMP BIOCHEM PHYS B, V109, P81, DOI 10.1016/0305-0491(94)90144-9; Vanamala J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-238; Yi BR, 2011, ANTICANCER RES, V31, P2853; Yi BR, 2011, INT J ONCOL, V39, P833, DOI 10.3892/ijo.2011.1126; Yi BR, 2012, ONCOL REP, V27, P1823, DOI 10.3892/or.2012.1721317PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLSEPDiscipline: Food Science &amp; Technology; Toxicology216JR</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CARCINOMA; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; CHEMICALS; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; ER alpha; ER-ALPHA; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGENS; EXPRESSING CYTOSINE-DEAMINASE; EXPRESSION; FOOD; GENE-EXPRESSION; GROWTH; IGF-1R; inhibition; Interaction; INTERFERON-BETA MIGRATE; KINASE; Ovarian cancer; OVARIAN-CANCER; Phytoestrogen; PREVENTION; PROGRESSION; proliferation; PROTEIN; RECEPTOR; RECEPTOR-ALPHA; RESVERATROL; SIGNALING PATHWAY; SIGNALING PATHWAYS; SIGNALS; STEM-CELLS; toxicology; TUMOR PROGRESSION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>373</startpage>
    <endpage>379</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <volume>59</volume>
    <abstract>Endocrine disrupting chemicals (EDCs) and estrogens appear to promote development of estrogen-dependent cancers, including breast and ovarian carcinomas. In this study, we evaluated the cell viability effect of BPA on BG-1 human ovarian cancer cells, along with the growth inhibitory effect of resveratrol (trans-3,4,5-trihydroxystilbene; RES), a naturally occurring phytoestrogen. In addition, we investigated the underlying mechanism(s) of BPA and RES in regulating the interaction between estrogen receptor alpha (ER alpha) and insulin-like growth factor-1 receptor (IGF-1R) signals, a non- genomic pathway induced by 17 beta-estradiol (E2). BPA induced a significant increase in BG-1 cell growth and up-regulated mRNA levels of ER alpha and IGF-1R. In parallel with its mRNA level, the protein expression of ER alpha was induced, and phosphorylated insulin receptor substrate-1 (p-IRS-1), phosphorylated Akt1/2/3, and cyclin D1 were increased by BPA or E2. However, RES effectively reversed the BG-1 cell proliferation induced by E2 or BPA by inversely down-regulating the expressions of ER alpha, IGF-1R, p-IRS-1, and p-Akt1/2/3, and cyclin D1 at both transcriptional and translational levels. Taken together, these results suggest that RES is a novel candidate for prevention of tumor progression caused by EDCs, including BPA via effective inhibition of the cross-talk of ER alpha and IGF-1R signaling pathways. (c) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000324280000047</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>174</id>
    <title>Resveratrol, A Natural Food Compound, Suppressed the Cell Growth of Bg-1 Ovarian Cancer Cells Induced by 17 Beta-Estradiol Or Bisphenol A Through Downregulating Estrogen Receptor Alpha and Insulin-Like Growth Factor-1 Receptor</title>
    <authors>Kang,N.H.; Choi,K.C.</authors>
    <availability>[Kang, N. -H.; Choi, K. -C.] Chungbuk Natl Univ, Lab Vet Biochem &amp; Immunol, Coll Vet Med, Cheongju, Chungbuk, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00CSIRO PUBLISHINGCOLLINGWOOD150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIAREPROD FERT DEVELOPDiscipline: Developmental Biology; Reproductive Biology; Zoology047OJ</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; FOOD; GROWTH; Ovarian cancer; OVARIAN-CANCER; RECEPTOR; RECEPTOR-ALPHA; RESVERATROL</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>245</startpage>
    <endpage>245</endpage>
    <journalfull>Reproduction Fertility and Development</journalfull>
    <issue>1</issue>
    <volume>25</volume>
    <url>WOS:000311850000205</url>
    <isbnorissn>1031-3613</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>412</id>
    <title>Redox-mediated oxidation and removal of aromatic amines from polluted water by partially purified bitter gourd (Momordica charantia) peroxidase</title>
    <authors>Karim,Z.; Husain,Q.</authors>
    <availability>[Karim, Zoheb; Husain, Qayyum] Aligarh Muslim Univ, Fac Life Sci, Dept Biochem, Aligarh 202002, Uttar Pradesh, India.</availability>
    <date>2009</date>
    <notes>JEnglishArticleHusain, Q (reprint author), Aligarh Muslim Univ, Fac Life Sci, Dept Biochem, Aligarh 202002, Uttar Pradesh, Indiaqayyumhusain@yahoo.co.inAbadulla E, 2000, APPL ENVIRON MICROB, V66, P3357, DOI 10.1128/AEM.66.8.3357-3362.2000; ACQUAVELLA JF, 1991, J NATL CANCER I, V83, P1686, DOI 10.1093/jnci/83.22.1686; Akhtar S, 2005, CHEMOSPHERE, V60, P291, DOI 10.1016/j.chemosphere.2004.12.017; Akhtar S, 2006, CHEMOSPHERE, V65, P1228, DOI 10.1016/j.chemosphere.2006.04.049; Buchanan ID, 1997, BIOTECHNOL BIOENG, V54, P251, DOI 10.1002/(SICI)1097-0290(19970505)54:3&lt;251::AID-BIT6&gt;3.0.CO;2-E; Casero I, 1997, WATER RES, V31, P1985, DOI 10.1016/S0043-1354(96)00344-2; Duran N, 2000, APPL CATAL B-ENVIRON, V28, P83, DOI 10.1016/S0926-3373(00)00168-5; Flock C, 1999, J CHEM TECHNOL BIOT, V74, P303, DOI 10.1002/(SICI)1097-4660(199904)74:4&lt;303::AID-JCTB38&gt;3.3.CO;2-2; GHIOURELIOTIS M, 2000, J CHEM TECHNOLOGY BI, V25, P185; Hai FI, 2007, CRIT REV ENV SCI TEC, V37, P315, DOI 10.1080/10643380601174723; Hong-Mei L, 2008, BIORESOURCE TECHNOL, V99, P4428, DOI 10.1016/j.biortech.2007.08.072; Husain M, 2008, CRIT REV ENV SCI TEC, V38, P1, DOI 10.1080/10643380701501213; Husain Q, 2006, CRIT REV BIOTECHNOL, V26, P201, DOI 10.1080/07388550600969936; Husain Q, 2000, J SCI IND RES INDIA, V59, P286; Jauregui J, 2003, BIODEGRADATION, V14, P397, DOI 10.1023/A:1027316610450; JOB D, 1976, EUR J BIOCHEM, V66, P607, DOI 10.1111/j.1432-1033.1976.tb10588.x; Khan AA, 2005, PROCESS BIOCHEM, V40, P2379, DOI 10.1016/j.procbio.2004.09.020; Khan AA, 2007, BIORESOURCE TECHNOL, V98, P1012, DOI 10.1016/j.biortech.2006.04.008; KHARU A, 2000, ENVIRON TOXICOL, V15, P431; Kulshrestha Yasha, 2007, Toxicological and Environmental Chemistry, V89, P255, DOI 10.1080/02772240601081692; Lowry O. H., 1951, J BIOL CHEM, V193, P275; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; Matto M, 2007, CHEMOSPHERE, V69, P338, DOI 10.1016/j.chemosphere.2007.03.069; MCELDOON JP, 1991, J BIOL CHEM, V266, P14288; NICELL JA, 1993, CAN J CIVIL ENG, V20, P725; Okazaki SY, 2002, ENZYME MICROB TECH, V31, P227, DOI 10.1016/S0141-0229(02)00104-7; Pinheiro HM, 2004, DYES PIGMENTS, V61, P121, DOI 10.1016/j.dyepig.2003.10.009; Robinson T, 2001, BIORESOURCE TECHNOL, V77, P247, DOI 10.1016/S0960-8524(00)00080-8; Sakuyama H, 2003, J BIOSCI BIOENG, V96, P227; Sumathi S, 2000, ENZYME MICROB TECH, V27, P347, DOI 10.1016/S0141-0229(00)00234-9; TANNENBAUM SR, 1991, J NATL CANCER I, V83, P1507, DOI 10.1093/jnci/83.20.1507; VAZQEZDURATE H, 2001, J AGR FOOD CHEM, V49, P4450; Wagner M, 2003, J CHEM TECHNOL BIOT, V78, P694, DOI 10.1002/jctb.574; WEISBURGER JH, 1997, MUTAT RES, V376, P61348ELSEVIER SCI LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDINT BIODETER BIODEGRJULDiscipline: Biotechnology &amp; Applied Microbiology; Environmental Sciences &amp; Ecology463UC</notes>
    <keywords>aniline; AQUEOUS PHENOL; Aromatic amines; BENZIDINE; Biodegradation; BISPHENOL-A; Bitter gourd; BLADDER-CANCER; CANCER; COMPLEXES; DECOLORIZATION; DYEING EFFLUENT; FOOD; HEALTH; HORSERADISH-PEROXIDASE; mixtures; OXIDATION; OXIDOREDUCTIVE ENZYMES; PEROXIDASE; POTENTIAL APPLICATIONS; REMOVAL; TEXTILE DYES; WASTE-WATER; Wastewater; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>587</startpage>
    <endpage>593</endpage>
    <journalfull>International Biodeterioration &amp; Biodegradation</journalfull>
    <issue>5</issue>
    <volume>63</volume>
    <abstract>Here, the role of bitter gourd peroxidase has been investigated for the treatment of water contaminated with aromatic amines. Most of the aromatic amines were recalcitrant to the action of bitter gourd peroxidase. However, these aromatic amines were oxidized by bitter gourd peroxidase in the presence of a redox mediator, o-dianisidine HCl. The maximum oxidation of aniline was found to be in the buffer of pH 5.0 at 40 degrees C in the presence of 0.5 mM H(2)O(2) and 0.15 mM o-dianisidine HCl. Aromatic amines oxidized and removed from wastewater were 65% aniline, 50% m-toluidine, 86% m-chloroaniline, 54% p-aminobenzoic acid, 61% diphenylamine and 95% N,N-dimethylaniline. Benzidine and p-nitroaniline were recalcitrant to the action of this enzyme even in the presence of o-dianisidine HCl. Complex mixtures of aromatic amines were treated by bitter gourd peroxidase. These mixtures were removed to varying extent, mixtures A, B and C were oxidized to 59%, 56% and 62%, respectively. Mixtures D, E and F were marginally oxidized to 30%, 14% and 16%, respectively. (C) 2009 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000267456600008</url>
    <isbnorissn>0964-8305</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>64</id>
    <title>Coexposure to Phytoestrogens and Bisphenol A Mimics Estrogenic Effects in an Additive Manner</title>
    <authors>Katchy,A.; Pinto,C.; Jonsson,P.; Trang,N.V.; Pandelova,M.; Riu,A.; Schramm,K.W.; Samarov,D.; Gustafsson,J.A.; Bondesson,M.; Williams,C.</authors>
    <availability>[Katchy, Anne; Pinto, Caroline; Jonsson, Philip; Trang Nguyen-Vu; Riu, Anne; Gustafsson, Jan-Ake; Bondesson, Maria; Williams, Cecilia] Univ Houston, Dept Biol &amp; Biochem, Ctr Nucl Receptors &amp; Cell Signaling, Houston, TX 77204 USA. [Pandelova, Marchela; Schramm, Karl-Werner] Helmholtz Zentrum Munchen GmbH, Mol EXpos MEX, D-85764 Neuherberg, Germany. [Schramm, Karl-Werner] TUM, Wissensch Zentrum Weihenstephan Ernahrung &amp; Landn, Dept Biowissensch, D-85350 Freising Weihenstephan, Germany. [Samarov, Daniel] NIST, Stat Engn Div, Informat Technol Lab, Gaithersburg, MD 20899 USA. [Gustafsson, Jan-Ake] Karolinska Inst, Dept Biosci &amp; Nutr, S-14183 Stockholm, Sweden.</availability>
    <date>2014</date>
    <notes>JEnglishArticleWilliams, C (reprint author), Univ Houston, Dept Biol &amp; Biochem, Ctr Nucl Receptors &amp; Cell Signaling, Houston, TX 77204 USAceciliawilliams@uh.eduAlvarez-Baron CP, 2011, MOL ENDOCRINOL, V25, P1326, DOI 10.1210/me.2011-0045; Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007; Betancourt AM, 2012, J NUTR, V142, p1382S, DOI 10.3945/jn.111.152058; Bhatia J, 2008, PEDIATRICS, V121, P1062, DOI 10.1542/peds.2008-0564; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Changeux JP, 2012, ANNU REV BIOPHYS, V41, P103, DOI 10.1146/annurev-biophys-050511-102222; Cimafranca MA, 2010, BIOL REPROD, V83, P114, DOI 10.1095/biolreprod.109.080549; Cok I, 2009, CHEMOSPHERE, V76, P1563, DOI 10.1016/j.chemosphere.2009.05.032; Beral V, 2002, LANCET, V360, P187; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; D'Aloisio AA, 2010, ENVIRON HEALTH PERSP, V118, P375, DOI 10.1289/ehp.0901423; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Edginton AN, 2009, ENVIRON HEALTH PERSP, V117, P645, DOI 10.1289/ehp.0800073; Escande A, 2006, BIOCHEM PHARMACOL, V71, P1459, DOI 10.1016/j.bcp.2006.02.002; Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856; Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111; Helferich W. G., 2008, Inflammopharmacology, V16, P219, DOI 10.1007/s10787-008-8020-0; Holbeck S, 2010, MOL ENDOCRINOL, V24, P1287, DOI 10.1210/me.2010-0040; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jefferson WN, 2005, BIOL REPROD, V73, P798, DOI 10.1095/biolreprod.105.041277; Katchy A, 2012, J STEROID BIOCHEM, V128, P145, DOI 10.1016/j.jsbmb.2011.10.008; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Krementsov DN, 2013, TOXICOL SCI, V135, P91, DOI 10.1093/toxsci/kft141; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lucki NC, 2011, J BIOL CHEM, V286, P19399, DOI 10.1074/jbc.M110.195826; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Markey CM, 2001, BIOL REPROD, V65, P1215; Messina MJ, 2008, NUTR J, V7, DOI 10.1186/1475-2891-7-17; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Newbold RR, 2001, CANCER RES, V61, P4325; Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0; Richter K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-5; Rider CV, 2005, TOXICOL SCI, V87, P520, DOI 10.1093/toxsci/kfi247; Riu A, 2008, FOOD CHEM TOXICOL, V46, P3268, DOI 10.1016/j.fct.2008.07.009; Sasaki N, 2005, J MATER SCI-MATER M, V16, P297, DOI 10.1007/s10856-005-0627-8; Satih S, 2010, OMICS, V14, P231, DOI 10.1089/omi.2009.0124; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143; Singleton DW, 2004, MOL CELL ENDOCRINOL, V221, P47, DOI 10.1016/j.mce.2004.04.010; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Smyth G. K., 2004, STAT APPL GENET MOL, V3; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Turner JV, 2007, J PHARM SCI-US, V96, P1879, DOI 10.1002/jps.20987; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; vom Saal F. S., 2005, ENV HLTH PERSPECT, V113, P926; Wardell SE, 2012, MOL ENDOCRINOL, V26, P1235, DOI 10.1210/me.2012-1031; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679; Wolstenholme JT, 2012, ENDOCRINOLOGY, V153, P3828, DOI 10.1210/en.2012-1195; Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yuan C, 2012, ENDOCRINOLOGY, V153, P501, DOI 10.1210/en.2011-1325; Zhang CX, 2010, CANCER SCI, V101, P501, DOI 10.1111/j.1349-7006.2009.01376.x; Zhang M, 2009, BIOINFORMATICS, V25, P1662, DOI 10.1093/bioinformatics/btp295; Zhang M, 2008, BIOINFORMATICS, V24, P2057, DOI 10.1093/bioinformatics/btn365610OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIMARDiscipline: ToxicologyAB8MW</notes>
    <keywords>ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; CHEMICALS; Combined exposure; concentration addition; DIFFERENTIAL EXPRESSION DISCOVERIES; EDCs; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; genistein; INFANT FORMULAS; MIMICS; MODEL; NEONATAL EXPOSURE; Phytoestrogen; PHYTOESTROGENS; proliferation; RECEPTOR; RECEPTOR-ALPHA; RISK; SOY ISOFLAVONES; transcriptional activation</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>21</startpage>
    <endpage>35</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>1</issue>
    <volume>138</volume>
    <abstract>Endocrine-disrupting chemicals (EDC) are abundant in our environment. A number of EDCs, including bisphenol A (BPA) can bind to the estrogen receptors (ER), ER and ER, and may contribute to estrogen-linked diseases such as breast cancer. Early exposure is of particular concern; many EDCs cross the placenta and infants have measurable levels of, eg, BPA. In addition, infants are frequently fed soy-based formula (SF) that contains phytoestrogens. Effects of combined exposure to xeno- and phytoestrogens are poorly studied. Here, we extensively compared to what extent BPA, genistein, and an extract of infant SF mimic estrogen-induced gene transcription and cell proliferation. We investigated ligand-specific effects on ER activation in HeLa-ER and ER reporter cells; on proliferation, genome-wide gene regulation and non-ERmediated effects in MCF7 breast cancer cells; and how coexposure influenced these effects. The biological relevance was explored using enrichment analyses of differentially regulated genes and clustering with clinical breast cancer profiles. We demonstrate that coexposure to BPA and genistein, or SF, results in increased functional and transcriptional estrogenic effects. Using statistical modeling, we determine that BPA and phytoestrogens act in an additive manner. The proliferative and transcriptional effects of the tested compounds mimic those of 17-estradiol, and are abolished by cotreatment with an ER antagonist. Gene expression profiles induced by each compound clustered with poor prognosis breast cancer, indicating that exposure may adversely affect breast cancer prognosis. This study accentuates that coexposure to BPA and soy-based phytoestrogens results in additive estrogenic effects, and may contribute to estrogen-linked diseases, including breast cancer</abstract>
    <url>WOS:000332045500003</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>392</id>
    <title>Diastereomers of the Brominated Flame Retardant 1,2-Dibromo-4-(1,2 dibromoethyl)cyclohexane Induce Androgen Receptor Activation in the HepG2 Hepatocellular Carcinoma Cell Line and the LNCaP Prostate Cancer Cell Line</title>
    <authors>Khalaf,H.; Larsson,A.; Berg,H.; McCrindle,R.; Arsenault,G.; Olsson,P.E.</authors>
    <availability>[Olsson, Per-Erik] Univ Orebro, Orebro Life Sci Ctr, Sch Sci &amp; Technol, Acad Sci &amp; Technol, SE-70182 Orebro, Sweden. [McCrindle, Robert; Arsenault, Gilles] Wellington Labs Inc, Div Res, Guelph, ON, Canada.</availability>
    <date>2009</date>
    <notes>JEnglishArticleOlsson, PE (reprint author), Univ Orebro, Orebro Life Sci Ctr, Sch Sci &amp; Technol, Acad Sci &amp; Technol, SE-70182 Orebro, Swedenper-erik.olsson@oru.seAnway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; Anway MD, 2008, GENOMICS, V91, P30, DOI 10.1016/j.ygeno.2007.10.002; Araki N, 2005, TOXICOL IN VITRO, V19, P831, DOI 10.1016/j.tiv.2005.04.009; Arsenault G, 2008, CHEMOSPHERE, V72, P1163, DOI 10.1016/j.chemosphere.2008.03.044; BERRY SJ, 1984, J UROLOGY, V132, P474; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Cabeza M, 2004, STEROIDS, V69, P767, DOI 10.1016/j.steroids.2004.09.006; Carson C, 2003, UROLOGY, V61, P2, DOI 10.1016/S0090-4295(03)00045-1; Ellis RJ, 2003, ENVIRON TOXICOL CHEM, V22, P1448, DOI 10.1897/1551-5028(2003)22&lt;1448:IVAIVA&gt;2.0.CO;2; Elzeinova F, 2008, REPROD TOXICOL, V26, P231, DOI 10.1016/j.reprotox.2008.09.007; Fang H, 2003, CHEM RES TOXICOL, V16, P1338, DOI 10.1021/tx030011g; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gauthier LT, 2009, ENVIRON SCI TECHNOL, V43, P312, DOI 10.1021/es801687d; Hossain MS, 2008, BIOL REPROD, V78, P361, DOI 10.1095/biolreprod.107.062018; Kojima H, 2004, ENVIRON HEALTH PERSP, V112, P524; Larsson A, 2006, J MED CHEM, V49, P7366, DOI 10.1021/jm060713d; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Lenasi H, 2004, J STEROID BIOCHEM, V91, P273, DOI 10.1016/j.jsbmb.2004.05.003; MCGREGOR DB, 1991, ENVIRON MOL MUTAGEN, V17, P196, DOI 10.1002/em.2850170309; *NAT CTR BIOT INF, 2009, GENBANK OV; Nyholm JR, 2008, CHEMOSPHERE, V73, P203, DOI 10.1016/j.chemosphere.2008.04.033; Olsson PE, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-37; *PDB, 2009, 1E3G; Pillon A, 2005, ENVIRON HEALTH PERSP, V113, P278, DOI 10.1289/ehp.7522; Santillo D, 1997, 0397 GREENP RES LAB; Scippo ML, 2004, ANAL BIOANAL CHEM, V378, P664, DOI 10.1007/s00216-003-2251-0; Simon Stephanie, 2006, Toxicology, V220, P90, DOI 10.1016/j.tox.2005.12.002; Skinner MK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003745; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Sonneveld E, 2005, TOXICOL SCI, V83, P136, DOI 10.1093/toxsci/kfi005; Taplin ME, 1999, CANCER RES, V59, P2511; Tomy GT, 2008, ENVIRON SCI TECHNOL, V42, P543, DOI 10.1021/es072043m; *US EPA, 2000, BACKGR DOC TIER PBT; VELDSCHOLTE J, 1992, Biochemistry, V31, P7422, DOI 10.1021/bi00147a029; Verrijdt G, 2002, J BIOL CHEM, V277, P35191, DOI 10.1074/jbc.M205928200; Viswanath G, 2008, MOL CELL ENDOCRINOL, V295, P1, DOI 10.1016/j.mce.2008.08.021; Wang LG, 1997, CANCER RES, V57, P714; Westerink WMA, 2008, ARCH TOXICOL, V82, P909, DOI 10.1007/s00204-008-0317-7; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Zeiger M, 2001, TOXICOL SCI, V63, P65, DOI 10.1093/toxsci/63.1.654215US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPDECDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology528VH</notes>
    <keywords>ACTIVATION; ALPHA; analysis; Androgen; ANDROGEN RECEPTOR; ANTIGEN; ASSAY; BETA; BINDING; BISPHENOL-A; brominated flame retardant; CANCER; CARCINOMA; CELL; CELLS; CHEMICALS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; environmental pollutants; ENVIRONMENTAL-POLLUTANTS; Estrogen; EXPRESSION; GENE; HEALTH; HEPG2 CELLS; IDENTIFICATION; In vitro; IN-VITRO; Incidence; Interaction; LIGAND; LIGAND-BINDING; LIGAND-BINDING DOMAIN; LINE; LNCaP cells; Occupational; POLLUTANTS; PROGESTERONE-RECEPTORS; Prostate; prostate cancer; PROSTATE-CANCER; PROSTATE-SPECIFIC ANTIGEN; RECEPTOR; RECEPTOR-BINDING; RELEASE; Steroid; toxicology; VITRO; zebrafish</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1853</startpage>
    <endpage>1859</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>12</issue>
    <volume>117</volume>
    <abstract>BACKGROUND: Reported incidences of prostate cancer and masculinization of animals indicate a release of compounds with androgenic properties into the environment. Large numbers of environmental pollutants have been screened to identify such compounds; however, not until recently was 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH) identified as the first potent activator of the human androgen receptor (hAR). TBECH has been found in beluga whales and bird eggs and has also been found to be maternally transferred in zebrafish. OBJECTIVES: In the present study we investigated interaction energies between TBECH diastereomers (alpha,beta, gamma, and delta) and the hAR, and their ability to activate the receptor and induce prostate-specific antigen (PSA) expression in vitro. METHODS: We performed computational modeling to determine interaction energies between the ligand and the AR ligand-binding site, and measured in vitro competitive binding assays for AR by polarization fluorometry analysis. We used enzyme-linked immunosorbent assays to determine PSA activity in LNCaP and HepG2 cells. RESULTS: We found the gamma and delta diastereomers to be more potent activators of hAR than the alpha and beta diastereomers, which was confirmed in receptor binding studies. All TBECH diastereomers induced PSA expression in LNCaP cells even though the AR present in these cells is mutated (T877A). Modeling studies of LNCaP AR revealed that TBECH diastereomers bound to the receptor with a closer distance to the key amino acids in the ligand-binding domain, indicating stronger binding to the mutated receptor. CONCLUSIONS: The present study demonstrates the ability of TBECH to activate the hAR, indicating that it is a potential endocrine disruptor</abstract>
    <url>WOS:000272474600026</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>390</id>
    <title>Increased Radiation Resistance of Breast Cancer Cells by Endocrine Disrupting Chemical Bisphenol A</title>
    <authors>Kil,W.J.; Camphausen,K.</authors>
    <availability>[Kil, W. J.; Camphausen, K.] NCI, Bethesda, MD 20892 USA.</availability>
    <date>2009</date>
    <notes>JEnglishMeeting Abstract00AMER ASSOC CANCER RESEARCHPHILADELPHIA615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USACANCER RESDEC 153Discipline: Oncology534TR</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; ENDOCRINE; Endocrine disrupting chemical; oncology; RADIATION; RESISTANCE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>847S</startpage>
    <endpage>847S</endpage>
    <journalfull>Cancer Research</journalfull>
    <issue>24</issue>
    <volume>69</volume>
    <url>WOS:000272920702199</url>
    <isbnorissn>0008-5472</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>73</id>
    <title>Association between urinary levels of bisphenol-A and estrogen metabolism in Korean adults</title>
    <authors>Kim,E.J.; Lee,D.; Chung,B.C.; Pyo,H.; Lee,J.</authors>
    <availability>[Kim, Eun Jee; Chung, Bong Chul; Pyo, Heesoo; Lee, Jeongae] Korea Inst Sci &amp; Technol, Mol Recognit Res Ctr, Seoul 136791, South Korea. [Kim, Eun Jee; Lee, Dongho] Korea Univ, Dept Biotechnol, Seoul 136701, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishArticle; Proceedings PaperLee, J (reprint author), Korea Inst Sci &amp; Technol, Mol Recognit Res Ctr, Hwarangno 14 Gil 5, Seoul 136791, South Koreafrans@kist.re.krBarr DB, 2005, ENVIRON HEALTH PERSP, V113, P192, DOI 10.1289/ehp.7337; Bolton JL, 1998, CHEM RES TOXICOL, V11, P1113, DOI 10.1021/tx9801007; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Butterworth M, 1996, DRUG METAB DISPOS, V24, P588; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200; Cavalieri EL, 2010, IUBMB LIFE, V62, P746, DOI 10.1002/iub.376; Cho SH, 2009, J APPL TOXICOL, V29, P110, DOI 10.1002/jat.1387; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Danzo BJ, 1998, CELL MOL LIFE SCI, V54, P1249, DOI 10.1007/s000180050251; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gailwad NW, 2008, INT J CANCER, V122, P1949; Hess-Wilson JK, 2009, CANCER CAUSE CONTROL, V20, P1029, DOI 10.1007/s10552-009-9337-8; Howdeshell KL, 1999, NATURE, V401, P763; HUSDAN H, 1968, CLIN CHEM, V14, P222; Im A, 2009, CARCINOGENESIS, V30, P1532, DOI 10.1093/carcin/bgp139; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee SH, 2013, REPROD TOXICOL, DOI DOI 10.1016/J.REPR0T0X.2013.03.008; Lee YJ, 2008, REPROD TOXICOL, V25, P413, DOI 10.1016/j.reprotox.2008.05.058; Li X, 2013, ENVIRON INT, V52, P81, DOI 10.1016/j.envint.2011.03.026; Mahalingaiah S, 2008, ENVIRON HEALTH PERSP, V116, P173, DOI 10.1289/ehp.10605; Meeker JD, 2010, ENVIRON SCI TECHNOL, V44, P1458, DOI 10.1021/es9028292; Melzer D, 2011, ENVIRON HEALTH PERSP, V119, P1788, DOI 10.1289/ehp.1103809; Miodovnik A, 2011, NEUROTOXICOLOGY, V32, P261, DOI 10.1016/j.neuro.2010.12.009; Moon JY, 2010, CANCER EPIDEM BIOMAR, V19, P388, DOI 10.1158/1055-9965.EPI-09-0581; Moon JY, 2009, J AM SOC MASS SPECTR, V20, P1626, DOI 10.1016/j.jasms.2009.04.020; Nakamura D, 2010, TOXICOL LETT, V194, P16, DOI 10.1016/j.toxlet.2010.02.002; Parl FF, 2009, ANN NY ACAD SCI, V1155, P68, DOI 10.1111/j.1749-6632.2008.03676.x; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Ursin G, 1999, J NATL CANCER I, V91, P1067, DOI 10.1093/jnci/91.12.1067; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wolff MS, 2008, ENVIRON RES, V107, P393, DOI 10.1016/j.envres.2008.03.006; Wolstenholme JT, 2011, HORM BEHAV, V59, P296, DOI 10.1016/j.yhbeh.2010.10.001; Yamano Yuko, 2008, Environmental Health and Preventive Medicine, V13, P332, DOI 10.1007/s12199-008-0049-6; Yokota H, 1999, BIOCHEM J, V340, P405, DOI 10.1042/0264-6021:3400405; Zhu BT, 1998, CANCER RES, V58, P2269; Ziegler RG, 1997, ENVIRON HEALTH PERSP, V105, P607, DOI 10.2307/3433378450ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSSCI TOTAL ENVIRONFEB 1Discipline: Environmental Sciences &amp; EcologyAA9LS</notes>
    <keywords>17-BETA-ESTRADIOL; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CHROMATOGRAPHY-MASS SPECTROMETRY; ENDOCRINE; Environmental estrogen; Estrogen; Estrogen metabolism; ESTROGENS; EXPOSURE; HIGH-RISK; HUMAN EXPOSURE; Hydroxylase; In vitro; IN-VITRO; IN-VIVO; METABOLISM; METABOLITES; Reproduction; SAMPLES; Steroid hormone; URINARY; Urine; US POPULATION; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1401</startpage>
    <endpage>1407</endpage>
    <journalfull>Science of the Total Environment</journalfull>
    <volume>470</volume>
    <abstract>Bisphenol-A (BPA) possesses estrogenic properties both in vitro and in vivo as an endocrine disrupting chemical. Humans experience a long-term and cumulative exposure to BPA. BPA was detectable in 973% of 1904 urine specimens from Korean adults. We investigated urinary estrogen concentrations in subjects with low and high BPA concentrations and its possible association with estrogen metabolism. Urine samples were collected from a high EPA concentration group (BPA-H; n = 100, 11.05 +/- 20.47 mu g/g creatinine) and a low BPA concentration group (BPA-L; n = 100, 0.70 +/- 0.22 mu g/g creatinine) from Korea Biomonitoring Program of Hazardous Materials Survey 2009-2010. Urinary estrogens were enzymatically hydrolyzed, extracted, and then derivatized for quantitative analysis by gas chromatography-mass spectrometry. Estrogen levels were higher in the BPA-H group than in the BPA-L group. Concentrations of estrone, 17 beta-estradiol, and their hydroxylated metabolites in both men and women were significantly higher in the EPA-H group than in the BPA-L group (p &lt; 0.04). Furthermore, in the BPA-H group, estrogen metabolism to 4-hydroxy-estrone and 4-hydroxy-17 beta-estradiol was more active than that to 2-hydroxy-estrone and 2-hydroxy-17 beta-estradiol. Although single measurement and/or single spot urine samples limit the measurement of long-term exposure to BPA, we found significant differences of estrogen metabolism in the BPA-H and the BPA-L groups. The increase of hydroxyestrogens, especially 4-hydroxyestrogens, can be an important factor resulting negative effects of prolonged exposure to BPA. Crown Copyright (C) 2013 Published by Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000331415600146</url>
    <isbnorissn>0048-9697</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>143</id>
    <title>Bisphenol A-associated epigenomic changes in prepubescent girls: a cross-sectional study in Gharbiah, Egypt</title>
    <authors>Kim,J.H.; Rozek,L.S.; Soliman,A.S.; Sartor,M.A.; Hablas,A.; Seifeldin,I.A.; Colacino,J.A.; Weinhouse,C.; Nahar,M.S.; Dolinoy,D.C.</authors>
    <availability>[Kim, Jung H.; Rozek, Laura S.; Colacino, Justin A.; Weinhouse, Caren; Nahar, Muna S.; Dolinoy, Dana C.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Rozek, Laura S.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA. [Soliman, Amr S.] Univ Nebraska Med Ctr, Dept Epidemiol, Omaha, NE USA. [Sartor, Maureen A.] Univ Michigan, Ctr Computat Med &amp; Bioinformat, Ann Arbor, MI 48109 USA. [Hablas, Ahmed; Seifeldin, Ibrahim A.] Tanta Canc Ctr, Tanta, Egypt. [Hablas, Ahmed; Seifeldin, Ibrahim A.] Gharbiah Canc Soc, Tanta, Egypt.</availability>
    <date>2013</date>
    <notes>JEnglishArticleDolinoy, DC (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USAddolinoy@umich.eduAnderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692; Antonopoulos A, 2011, BIOCHEM SOC T, V39, P1334, DOI 10.1042/BST0391334; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; Banister CE, 2011, EPIGENETICS-US, V6, P920, DOI 10.4161/epi.6.7.16079; Barker DJP, 1998, MOTHERS BABIES HLTH, P13; Barker D J, 1997, Acta Paediatr Suppl, V423, P178; Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI [10.2217/epi.09.14, 10.2217/EPI.09.14]; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Brody JG, 2007, CANCER, V109, P2627, DOI 10.1002/cncr.22656; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Chang HS, 2006, ENDOCRINOLOGY, V147, P5524, DOI 10.1210/en.2006-0987; Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z; Colacino JA, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-40; Cotton AM, 2011, HUM GENET, V130, P187, DOI 10.1007/s00439-011-1007-8; Crews D, 2012, P NATL ACAD SCI USA, V109, P9143, DOI 10.1073/pnas.1118514109; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Daniel CW, 1987, MAMMARY GLAND DEV RE, V1; Davis AP, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-48; Davis AP, 2009, NUCLEIC ACIDS RES, V37, pD786, DOI 10.1093/nar/gkn580; Davis AP, 2011, NUCLEIC ACIDS RES, V39, pD1067, DOI 10.1093/nar/gkq813; Dey S, 2011, CANCER EPIDEMIOL, V35, P254, DOI 10.1016/j.canep.2010.09.010; Dey S, 2010, BREAST, V19, P417, DOI 10.1016/j.breast.2010.04.005; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Elston CW, 1998, BREAST, V13. 3, P1; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Ghaly I., 2008, Eastern Mediterranean Health Journal, V14, P1391; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412; Kang ER, 2011, EPIGENETICS-US, V6, P937, DOI 10.4161/epi.6.7.16067; Kim JH, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-526; Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131; Kriegel AM, 2006, ENVIRON HEALTH PERSP, V114, P113, DOI 10.1289/ehp.8035; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147; Li SF, 1997, CANCER RES, V57, P4356; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Mcnally S, 2011, ANN MED, V43, P212, DOI 10.3109/07853890.2011.554425; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Naciff JM, 2010, TOXICOLOGY, V270, P137, DOI 10.1016/j.tox.2010.02.008; Naderi A, 2007, CANCER RES, V67, P6725, DOI 10.1158/0008-5472.CAN-06-4394; Nahar MS, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-20; Nilsson E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036129; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338; Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011; Russo J, 1987, MAMMARY GLAND DEV RE, V1, P67; Sartor MA, 2011, EPIGENETICS-US, V6, P777, DOI 10.4161/epi.6.6.16216; Sartor MA, 2009, BIOINFORMATICS, V25, P211, DOI 10.1093/bioinformatics/btn592; Schairer Catherine, 2013, Cancer Med, V2, P178, DOI 10.1002/cam4.48; Smyth GK, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Soliman Amr S, 2012, Cancer Med, V1, P338, DOI 10.1002/cam4.36; Sparrow LG, 2008, PROTEINS, V71, P426, DOI 10.1002/prot.21768; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thayer KA, 2012, ENVIRON HEALTH PERSP, V120, P779, DOI 10.1289/ehp.1104597; Thirlwell C, 2010, METHODS, V52, P248, DOI 10.1016/j.ymeth.2010.04.012; Tobi EW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037933; Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9; Wojtyla A, 2011, ANN AGR ENV MED, V18, P355; Woodruff TJ, 2011, ENVIRON HEALTH PERSP, V119, P878, DOI 10.1289/ehp.1002727; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Ye XY, 2005, ANAL BIOANAL CHEM, V383, P638, DOI 10.1007/s00216-005-0019-4; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-1018716BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDENVIRON HEALTH-GLOBAPR 16Discipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health146UX</notes>
    <keywords>ADULT; Bead array; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; BREAST-CANCER; CANCER; CELL; COMPARATIVE TOXICOGENOMICS DATABASE; development; DEVELOPMENTAL EXPOSURE; DISEASE; DISORDERS; DNA METHYLATION; Egypt; ENDOCRINE DISRUPTORS; environmental exposure; Epidemiology; EPIGENETIC EPIDEMIOLOGY; epigenetics; EXPOSURE; EXPRESSION; GENE-EXPRESSION; GLAND; HUMAN HEALTH; IDENTIFICATION; IMPACT; mammary gland; MAMMARY-GLAND; mechanism; MECHANISMS; Metabolic disorders; METABOLISM; METHYLATION; MOUSE UTERUS; NECDIN GENE; PRENATAL EXPOSURE; PROTEIN; PROTEINS; SAMPLES; SUSCEPTIBILITY; Toxicogenomics; toxicology; URINARY; URINARY CONCENTRATIONS; X-CHROMOSOME INACTIVATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Environmental Health</journalfull>
    <volume>12</volume>
    <abstract>Background: There is now compelling evidence that epigenetic modifications link adult disease susceptibility to environmental exposures during specific life stages, including pre-pubertal development. Animal studies indicate that bisphenol A (BPA), the monomer used in epoxy resins and polycarbonate plastics, may impact health through epigenetic mechanisms, and epidemiological data associate BPA levels with metabolic disorders, behavior changes, and reproductive effects. Thus, we conducted an environmental epidemiology study of BPA exposure and CpG methylation in pre-adolescent girls from Gharbiah, Egypt hypothesizing that methylation profiles exhibit exposure-dependent trends. Methods: Urinary concentrations of total (free plus conjugated) species of BPA in spot samples were quantified for 60 girls aged 10 to 13. Genome-wide CpG methylation was concurrently measured in bisulfite-converted saliva DNA using the Infinium HumanMethylation27 BeadChip (N = 46). CpG sites from four candidate genes were validated via quantitative bisulfite pyrosequencing. Results: CpG methylation varied widely among girls, and higher urinary BPA concentrations were generally associated with less genomic methylation. Based on pathway analyses, genes exhibiting reduced methylation with increasing urinary BPA were involved in immune function, transport activity, metabolism, and caspase activity. In particular, hypomethylation of CpG targets on chromosome X was associated with higher urinary BPA. Using the Comparative Toxicogenomics Database, we identified a number of candidate genes in our sample that previously have been associated with BPA-related expression change. Conclusions: These data indicate that BPA may affect human health through specific epigenomic modification of genes in relevant pathways. Thus, epigenetic epidemiology holds promise for the identification of biomarkers from previous exposures and the development of epigenetic-based diagnostic strategies</abstract>
    <url>WOS:000319120400001</url>
    <isbnorissn>1476-069X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>75</id>
    <title>Perinatal bisphenol A exposure promotes dose-dependent alterations of the mouse methylome</title>
    <authors>Kim,J.H.; Sartor,M.A.; Rozek,L.S.; Faulk,C.; Anderson,O.S.; Jones,T.R.; Nahar,M.S.; Dolinoy,D.C.</authors>
    <availability>[Kim, Jung H.; Rozek, Laura S.; Faulk, Christopher; Anderson, Olivia S.; Jones, Tamara R.; Nahar, Muna S.; Dolinoy, Dana C.] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Kim, Jung H.; Sartor, Maureen A.] Univ Michigan, Sch Med, Dept Computat Med &amp; Bioinformat, Ann Arbor, MI USA. [Rozek, Laura S.] Univ Michigan, Sch Med, Dept Otolaryngol, Ann Arbor, MI USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDolinoy, DC (reprint author), Univ Michigan, Dept Environm Hlth Sci, 1415 Washington Hts, Ann Arbor, MI 48109 USAddolinoy@umich.eduAnderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692; Anderson OS, 2013, FASEB J, V27, P1784, DOI 10.1096/fj.12-223545; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Batista TM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033814; Bauer SM, 2012, TOXICOL SCI, V130, P82, DOI 10.1093/toxsci/kfs227; Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; CUTOLO M, 1995, CLIN EXP RHEUMATOL, V13, P217; Davis AP, 2009, NUCLEIC ACIDS RES, V37, pD786, DOI 10.1093/nar/gkn580; Davis AP, 2011, NUCLEIC ACIDS RES, V39, pD1067, DOI 10.1093/nar/gkq813; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2010, EPIGENETICS-US, V5, P637, DOI 10.4161/epi.5.7.12892; Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Karpuzoglu-Sahin E, 2001, J REPROD IMMUNOL, V52, P113, DOI 10.1016/S0165-0378(01)00117-6; Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Makarov VL, 2007, ISOLATION CPG ISLAND; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Nahar MS, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-20; Nahar MS, 2013, J BIOCHEM MOL TOXIC, V27, P116, DOI 10.1002/jbt.21459; Nassa G, 2011, PROTEOMICS, V11, P159, DOI 10.1002/pmic.201000344; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Qin XY, 2012, CANCER BIOL THER, V13, P296, DOI [10.4161/cbt.18942, 10.4161/cbt.13.5.18942]; Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Shafiu M, 2012, KIDNEY BLOOD PRESS R, V35, P477, DOI 10.1159/000337370; Sieli PT, 2011, ENVIRON HEALTH PERSP, V119, P1260, DOI 10.1289/ehp.1003385; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Susiarjo M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003401; Takahashi O, 2003, FOOD CHEM TOXICOL, V41, P1035, DOI 10.1016/S0278-6915(03)00031-0; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308; Teppala S, 2012, INT J ENDOCRINOL, DOI 10.1155/2012/598180; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vom Saal Frederick S, 2012, Mol Cell Endocrinol, V354, P74, DOI 10.1016/j.mce.2012.01.001; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Yoshino S, 2003, BRIT J PHARMACOL, V138, P1271, DOI 10.1038/sj.bjp.0705166; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Zhang ZF, 2011, ENVIRON SCI TECHNOL, V45, P7044, DOI 10.1021/es200976k624BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDBMC GENOMICSJAN 17AA4VS</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; COMPARATIVE TOXICOGENOMICS DATABASE; CPG ISLAND SHORES; DEVELOPMENTAL EXPOSURE; DNA METHYLATION; ENDOCRINE; Environmental epigenomics; ENVIRONMENTAL-FACTORS; EXPOSURE; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; IMMUNE-RESPONSES; Liver; METABOLISM; METHYLATION; MethylPlex; MICE; Mouse; PERINATAL EXPOSURE; PLATFORM; Proteomics; RECEPTOR; SAMPLES; SUSCEPTIBILITY; TISSUE; URINARY</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Bmc Genomics</journalfull>
    <volume>15</volume>
    <abstract>Background: Environmental factors during perinatal development may influence developmental plasticity and disease susceptibility via alterations to the epigenome. Developmental exposure to the endocrine active compound, bisphenol A (BPA), has previously been associated with altered methylation at candidate gene loci. Here, we undertake the first genome-wide characterization of DNA methylation profiles in the liver of murine offspring exposed perinatally to multiple doses of BPA through the maternal diet. Results: Using a tiered focusing approach, our strategy proceeds from unbiased broad DNA methylation analysis using methylation-based next generation sequencing technology to in-depth quantitative site-specific CpG methylation determination using the Sequenom EpiTYPER MassARRAY platform to profile liver DNA methylation patterns in offspring maternally exposed to BPA during gestation and lactation to doses ranging from 0 BPA/kg (Ctr), 50 mu g BPA/kg (UG), or 50 mg BPA/kg (MG) diet (N = 4 per group). Genome-wide analyses indicate non-monotonic effects of DNA methylation patterns following perinatal exposure to BPA, corroborating previous studies using multiple doses of BPA with non-monotonic outcomes. We observed enrichment of regions of altered methylation (RAMs) within CpG island (CGI) shores, but little evidence of RAM enrichment in CGIs. An analysis of promoter regions identified several hundred novel BPA-associated methylation events, and methylation alterations in the Myh7b and Slc22a12 gene promoters were validated. Using the Comparative Toxicogenomics Database, a number of candidate genes that have previously been associated with BPA-related gene expression changes were identified, and gene set enrichment testing identified epigenetically dysregulated pathways involved in metabolism and stimulus response. Conclusions: In this study, non-monotonic dose dependent alterations in DNA methylation among BPA-exposed mouse liver samples and their relevant pathways were identified and validated. The comprehensive methylome map presented here provides candidate loci underlying the role of early BPA exposure and later in life health and disease status</abstract>
    <url>WOS:000331095300001</url>
    <isbnorissn>1471-2164</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>367</id>
    <title>Bisphenol A-induced aromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells</title>
    <authors>Kim,J.Y.; Han,E.H.; Kim,H.G.; Oh,K.N.; Kim,S.K.; Lee,K.Y.; Jeong,H.G.</authors>
    <availability>[Han, Eun Hee; Kim, Hyung Gyun; Kim, Sang Kyum; Jeong, Hye Gwang] Chungnam Natl Univ, Coll Pharm, Dept Toxicol, Taejon, South Korea. [Kim, Ji Young; Lee, Kwang Yeol] Chungnam Natl Univ, Res Inst Drug Dev, Coll Pharm, Kwangju, South Korea. [Oh, Kyo Nyeo] Nat Resources Res Inst, Jeollanamdo, South Korea.</availability>
    <date>2010</date>
    <notes>JEnglishArticleJeong, HG (reprint author), Chungnam Natl Univ, Coll Pharm, Dept Toxicol, Taejon, South KoreaKwangLee@chonnam.ac.kr; hgjeong@cnu.ac.krAgarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Bouraima H, 2003, EUR J ENDOCRINOL, V148, P457, DOI 10.1530/eje.0.1480457; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Brodie A, 2006, J STEROID BIOCHEM, V102, P97, DOI 10.1016/j.jsbmb.2006.09.002; Bulun SE, 2008, ADV EXP MED BIOL, V630, P112; Cai ZL, 2007, MOL CELL ENDOCRINOL, V263, P181, DOI 10.1016/j.mce.2006.09.012; Carreau Serge, 2004, Reprod Biol, V4, P23; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Frungieri MB, 2002, FERTIL STERIL, V78, P298, DOI 10.1016/S0015-0282(02)03206-5; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Han EH, 2008, TOXICOL APPL PHARM, V233, P333, DOI 10.1016/j.taap.2008.09.003; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Hase T, 2003, EUR J CANCER, V39, P2043, DOI 10.1016/S0959-8049(03)00485-4; Heneweer M, 2004, TOXICOL LETT, V146, P183, DOI 10.1016/j.toxlet.2003.10.002; Hida T, 1998, CANCER RES, V58, P3761; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Iguchi T, 1998, Nihon Rinsho, V56, P2953; Inoshita H, 2003, J MOL ENDOCRINOL, V31, P551, DOI 10.1677/jme.0.0310551; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Kinoshita Y, 2003, CANCER RES, V63, P3546; Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355; Labadie P, 2006, ARCH ENVIRON CON TOX, V50, P552, DOI 10.1007/s00244-005-1043-2; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005; Mestre JR, 1997, CANCER RES, V57, P1081; Mlynarcikova Alzbeta, 2005, Endocr Regul, V39, P21; Mosconi G, 2002, GEN COMP ENDOCR, V126, P125, DOI 10.1006/gcen.2002.7781; PUROHIT A, 1995, J CLIN ENDOCR METAB, V80, P3052, DOI 10.1210/jc.80.10.3052; Ristimaki A, 1997, CANCER RES, V57, P1276; SANO H, 1995, CANCER RES, V55, P3785; SCHREY MP, 1995, BRIT J CANCER, V72, P1412, DOI 10.1038/bjc.1995.523; Shoji Y, 2004, GUT, V53, P1151, DOI 10.1136/gut.2003.028787; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Simpson ER, 2004, SEMIN REPROD MED, V22, P11; Simpson ER, 2000, J MOL ENDOCRINOL, V25, P149, DOI 10.1677/jme.0.0250149; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Singh A, 1999, ENDOCR-RELAT CANCER, V6, P139, DOI 10.1677/erc.0.0060139; Sirianni R, 2009, J BIOL CHEM, V284, P28905, DOI 10.1074/jbc.M109.041020; Subbaramaiah K, 2006, CANCER RES, V66, P5504, DOI 10.1158/0008-5472.CAN-05-4076; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Tucker ON, 1999, CANCER RES, V59, P987; van der Ven LTM, 2007, ENVIRON TOXICOL CHEM, V26, P92, DOI 10.1897/06-092R1.1; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Young M, 1998, ENDOCRINOLOGY, V139, P5082, DOI 10.1210/en.139.12.5082; Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739; Zhao Y, 1997, J STEROID BIOCHEM, V61, P203, DOI 10.1016/S0960-0760(97)80013-1; Zhou W, 2008, MOL CELL ENDOCRINOL, V283, P12, DOI 10.1016/j.mce.2007.10.010; Zimmermann KC, 1999, CANCER RES, V59, P198; Zwain IH, 1999, ENDOCRINOLOGY, V140, P3843, DOI 10.1210/en.140.8.38435222ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTMAR 15Discipline: Toxicology576UQ</notes>
    <keywords>ACTIVATION; ADIPOSE-TISSUE; Akt; Aromatase; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CARCINOMA; CELL; CELLS; CREB; Cyclic AMP response element; cyclooxygenase-2; CYP19 EXPRESSION; CYTOCHROME-P450; ENDOCRINE; Endocrine disruptor; ESTROGEN BIOSYNTHESIS; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GRANULOSA-CELLS; HEALTH; HUMANS; INHIBITOR; Inhibitors; KINASE; p21; p38; PATHWAY; PHOSPHORYLATION; PROMOTER; PROSTAGLANDIN E-2; PROSTANOID RECEPTORS; PROTEIN; PROTEIN-KINASE; RAT; RECEPTOR; Receptors; REPRODUCTIVE HEALTH; signaling; SIGNALING PATHWAY; SIGNALING PATHWAYS; Steroid; steroidogenesis; Testosterone; toxicology; UP-REGULATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>200</startpage>
    <endpage>208</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>2</issue>
    <volume>193</volume>
    <abstract>Bisphenol A (4,4'-dihydroxy-2,2-diphenylpropane; BPA) is an endocrine disruptor that affects the reproductive health of wildlife and possibly of humans. Evidence suggests that BPA interrupts ovarian steroidogenesis by altering steroidogenic enzymes. We evaluated the effect of BPA on aromatase expression in rat testicular Leydig cells. In addition, we investigated whether cyclooxygenase-2 (COX-2) was involved in BPA-induced aromatase expression. BPA induced a time- and concentration-dependent increase in aromatase protein expression in rat testicular Leydig R2C cells. It also increased aromatase gene expression and its enzyme and promoter activity, but reduced testosterone synthesis; increased COX-2 mRNA expression and promoter activity, the production of prostaglandin E-2 (PGE(2)), and the gene expression of PGE(2) (EP2 and EP4) receptors; induced the activation of cyclic adenosine monophosphate (cAMP) response element (CRE) and CREB binding; and increased the phosphorylation of protein kinase A (PKA), Akt, and mitogen-activated protein (MAP) kinase signaling pathways. BPA activation of aromatase was reversed by various inhibitors (COX-2, PKA, Akt, ERK, JNK, and p38). Taken together, these results suggest that BPA increases aromatase activity, which is correlated with COX-2 up-regulation mediated by the CRE, PKA, Akt, and MAP kinase signaling pathways in rat testicular Leydig cells. (C) 2010 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000276175200012</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>41</id>
    <title>Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway</title>
    <authors>Kim,J.Y.; Yi,B.R.; Go,R.E.; Hwang,K.A.; Nam,K.H.; Choi,K.C.</authors>
    <availability>[Kim, Joo-Young; Yi, Bo-Rim; Go, Ryeo-Eun; Hwang, Kyung-A; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea. [Nam, Ki-Hoan] Korea Res Inst Biosci &amp; Biotechnol, Lab Anim Resource Ctr, Ochang, Chungbuk, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krAly HAA, 2013, REPROD TOXICOL, V40, P8, DOI 10.1016/j.reprotox.2013.05.002; Aoyama H, 2014, VITAM HORM, V94, P193, DOI 10.1016/B978-0-12-800095-3.00007-9; Atmaca H, 2013, TOXICOL LETT, V221, P128, DOI 10.1016/j.toxlet.2013.06.213; Babu RL, 2013, MOL CELL BIOCHEM, V380, P143, DOI 10.1007/s11010-013-1667-x; Beronius A, 2013, TOXICOLOGY, V311, P13, DOI 10.1016/j.tox.2013.02.012; Cao AL, 2013, APOPTOSIS, V18, P1391, DOI 10.1007/s10495-013-0871-1; Cherednichenko G, 2012, P NATL ACAD SCI USA, V109, P14158, DOI 10.1073/pnas.1211314109; Chimento A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.275; Esteban S., 2013, SCI TOTAL ENV C, V466-467C, P939; Fritsch EB, 2013, ENVIRON SCI TECHNOL, V47, P2008, DOI 10.1021/es303790b; Garay JP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3112; Garrido P, 2013, ENDOCRINOLOGY, V154, P1979, DOI 10.1210/en.2012-1558; Gioiosa L, 2013, HORM BEHAV, V63, P598, DOI 10.1016/j.yhbeh.2013.02.016; Hwang KA, 2013, TOXICOL APPL PHARM, V272, P637, DOI 10.1016/j.taap.2013.07.027; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Kang NH, 2013, FOOD CHEM TOXICOL, V59, P373, DOI 10.1016/j.fct.2013.06.029; Kim SM, 2012, J PHYSIOL PHARMACOL, V63, P445; Lan Z., 2013, ENV TOXICOL; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2013, TOXICOLOGY, V304, P13, DOI 10.1016/j.tox.2012.10.012; Louis GW, 2013, REPROD TOXICOL, V36, P71, DOI 10.1016/j.reprotox.2012.12.001; Ma HM, 2013, CHEMOSPHERE, V90, P1023, DOI 10.1016/j.chemosphere.2012.07.063; Mahoney MM, 2010, TOXICOL APPL PHARM, V247, P98, DOI 10.1016/j.taap.2010.05.017; Masamha CP, 2009, CANCER RES, V69, P6565, DOI 10.1158/0008-5472.CAN-09-0913; Middleton JH, 2013, ECOTOX ENVIRON SAFE, V88, P79, DOI 10.1016/j.ecoenv.2012.10.025; Nguyen KC, 2013, TOXICOLOGY, V306, P114, DOI 10.1016/j.tox.2013.02.010; Nurulnadia MY, 2013, B ENVIRON CONTAM TOX, V91, P372, DOI 10.1007/s00128-013-1073-9; Park MA, 2012, MOL MED REP, V5, P761, DOI 10.3892/mmr.2011.712; Pereira MF, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-231; Perez AL, 2013, ENVIRON TOXICOL CHEM, V32, P1479, DOI 10.1002/etc.2217; Satsuma K, 2013, BIOSCI BIOTECH BIOCH, V77, P2222, DOI 10.1271/bbb.130439; Schulman JJ, 2013, J BIOL CHEM, V288, P25340, DOI 10.1074/jbc.M113.496570; Stotter A, 2010, CRIT REV ONCOL HEMAT, V75, P249, DOI 10.1016/j.critrevonc.2009.10.008; Su CM, 2013, TOXICOL APPL PHARM, V272, P335, DOI 10.1016/j.taap.2013.06.010; Tian LY, 2009, J ENDOCRINOL, V202, P167, DOI 10.1677/JOE-09-0054; Twanabasu BR, 2013, SCI TOTAL ENVIRON, V447, P450, DOI 10.1016/j.scitotenv.2012.12.085; von der Ohe PC, 2012, ENVIRON SCI POLLUT R, V19, P585, DOI 10.1007/s11356-011-0580-7; Wan Q, 2011, COMP BIOCHEM PHYS C, V153, P259, DOI 10.1016/j.cbpc.2010.11.009; Weber GJ, 2013, TOXICOL SCI, V132, P458, DOI 10.1093/toxsci/kft017; Wens B, 2013, TOXICOLOGY, V303, P17, DOI 10.1016/j.tox.2012.10.019; Ye LP, 2014, TOXICOL LETT, V225, P407, DOI 10.1016/j.toxlet.2014.01.011420ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSENVIRON TOXICOL PHARMAYDiscipline: Environmental Sciences &amp; Ecology; Pharmacology &amp; Pharmacy; ToxicologyAK7HB</notes>
    <keywords>apoptosis; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; cell death; CELL-CYCLE; CELL-DEATH; CELLS; CHEMICALS; CYCLE; DEATH; DOWN-REGULATION; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ENDOPLASMIC-RETICULUM STRESS; Estrogen; Estrogen receptors; EXPRESSION; FACTOR-I RECEPTOR; FOOD; gene expression; GENE-EXPRESSION; GROWTH; HEPG2 CELLS; MCF-7 CELLS; Methoxychlor; MITOCHONDRIAL DYSFUNCTION; Ovarian cancer; proliferation; SIGNALING PATHWAY; Triclosan</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1264</startpage>
    <endpage>1274</endpage>
    <journalfull>Environmental Toxicology and Pharmacology</journalfull>
    <issue>3</issue>
    <volume>37</volume>
    <abstract>Methoxychlor and triclosan are emergent or suspected endocrine-disrupting chemicals (EDCs). Methoxychlor [MXC; 1,1,1-trichlor-2,2-bis (4-methoxyphenyll ethane] is an organochlorine pesticide that has been primarily used since dichlorodiphenyltrichloroethane (DDT) was banned. In addition, triclosan (TCS) is used as a common component of soaps, deodorants, toothpastes, and other hygiene products at concentrations up to 0.3%. In the present study, the potential impact of MXC and TCS on ovarian cancer cell growth and underlying mechanism(s) was examined following their treatments in BG-1 ovarian cancer cells. As results, MXC and TCS induced BG-1 cell growth via regulating cyclin D1, p21 and Bax genes related with cell cycle and apoptosis. A methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay confirmed that the proliferation of BG-1 ovarian cancer cells was stimulated by MXC (10(-6), 10(-7), 10(-8), and 10(-9)M) or TCS (10(-8), 10(-7), 10(-8), and 10(-9) M). Treatment of BG-1 cells with MXC or TCS resulted in the upregulation of cyclin D1 and downregulation of p21 and Bax transcriptions. In addition, the protein level of cyclin D1 was increased by MXC or TCS while p21 and Bax protein levels appeared to be reduced in these cells. Furthermore, MXC- or TCS-induced alterations of these genes were reversed in the presence of ICI 182,780 (10(-7)M), suggesting that the changes in these gene expressions may be regulated by an ER-dependent signaling pathway. In conclusion, the results of our investigation indicate that two potential EDCs, MXC and TCS, may stimulate ovarian cancer growth by regulating cell cycle-and apoptosis-related genes via an ER-dependent pathway. (C) 2014 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000338598200042</url>
    <isbnorissn>1382-6689</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>445</id>
    <title>Potencies of Bisphenol a on the Neuronal Differentiation and Hippocampal Neurogenesis</title>
    <authors>Kim,K.; Son,T.G.; Park,H.R.; Kim,S.J.; Kim,H.S.; Kim,H.S.; Kim,T.S.; Jung,K.K.; Han,S.Y.; Lee,J.</authors>
    <availability>[Kim, Keunho; Son, Tae Gen; Park, Hee Ra; Kim, So Jung; Kim, Hyun Soo; Kim, Hyung Sik; Lee, Jaewon] Pusan Natl Univ, Dept Pharm, Coll Pharm, Pusan 609735, South Korea. [Kim, Keunho; Son, Tae Gen; Park, Hee Ra; Kim, So Jung; Kim, Hyun Soo; Kim, Hyung Sik; Lee, Jaewon] Pusan Natl Univ, Res Inst Drug Dev, Longev Life Sci Inst, Pusan 609735, South Korea. [Kim, Keunho; Son, Tae Gen; Park, Hee Ra; Kim, So Jung; Kim, Hyun Soo; Kim, Hyung Sik; Lee, Jaewon] Pusan Natl Univ, Inst Technol, Pusan 609735, South Korea. [Kim, Tae Sung; Jung, Ki Kyung; Han, Soon Young] Korea Food &amp; Drug Adm, Natl Inst Toxicol Res, Seoul, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleLee, J (reprint author), Pusan Natl Univ, Dept Pharm, Coll Pharm, Pusan 609735, South Koreaneuron@pusan.ac.krAshby J, 1998, ENVIRON HEALTH PERSP, V106, P719, DOI 10.1289/ehp.98106719; Brunson KL, 2005, HIPPOCAMPUS, V15, P491, DOI 10.1002/hipo.20074; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; DeRosa C, 1998, J TOXICOL ENV HEAL B, V1, P3; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Farabollini F, 1999, PHARMACOL BIOCHEM BE, V64, P687, DOI 10.1016/S0091-3057(99)00136-7; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Keith LH, 1997, ENV ENDOCRINE DISRUP; Kim K, 2007, J TOXICOL ENV HEAL A, V70, P1288, DOI 10.1080/15287390701434216; Kim SJ, 2007, NEUROCHEM RES, V32, P1399, DOI 10.1007/s11064-007-9323-z; Kode A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-132; Kubo K, 2001, NEUROSCI LETT, V304, P73, DOI 10.1016/S0304-3940(01)01760-8; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Liu JL, 1998, J NEUROSCI, V18, P7768; Mayer JL, 2006, J NEUROENDOCRINOL, V18, P629, DOI 10.1111/j.1365-2826.2006.01455.x; Nakamura K, 2006, J NEUROSCI RES, V84, P1197, DOI 10.1002/jnr.21020; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4&lt;569::AID-NEU10&gt;3.0.CO;2-F; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Pang Z, 1997, J NEUROSCI, V17, P3064; Parent JM, 1997, J NEUROSCI, V17, P3727; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Roy D, 1997, J TOXICOL ENV HEALTH, V50, P1, DOI 10.1080/009841097160573; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Shin BS, 2002, J TOXICOL ENV HEAL A, V65, P395, DOI 10.1080/15287390252808064; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Sun Y, 2002, BIOMED CHROMATOGR, V16, P319, DOI 10.1002/bmc.161; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Tanabe N, 2006, NEUROENDOCRINOL LETT, V27, P97; Taupin P, 2005, MED SCI MONITOR, V11, pRA247; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.5603; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-10183914TAYLOR &amp; FRANCIS INCPHILADELPHIA325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USAJ TOXICOL ENV HEAL ADiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology514ZI</notes>
    <keywords>1; ADULT; Behavior; bisphenol; bisphenol A; BISPHENOL-A; BPA; Brain; Brain development; BRAIN-DEVELOPMENT; CANCER; CELL; CELLS; CHEMICALS; Cytotoxicity; DENTATE GYRUS; development; Differentiation; EDC; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Estrogenic; ESTROGENIC ACTIVITIES; estrogenic activity; GROWTH; HEALTH; Immune; MICE; NEURAL PROGENITOR CELLS; Neurogenesis; NEURONAL DIFFERENTIATION; Occupational; PERINATAL EXPOSURE; Plastics; PRENATAL EXPOSURE; proliferation; RAT-BRAIN; RECEPTOR; SEXUAL-DIFFERENTIATION; STEM-CELLS; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1343</startpage>
    <endpage>1351</endpage>
    <journalfull>Journal of Toxicology and Environmental Health-Part A-Current Issues</journalfull>
    <issue>21-22</issue>
    <volume>72</volume>
    <abstract>Endocrine-disrupting chemicals (EDC) produce adverse effects on reproductive and immune function or neurological behavior, and may also induce cancer. The environmental EDC bisphenol A (BPA) is widely used in the manufacture of plastics and epoxy resins. BPA affects reproductive organ growth and development, but the potential adverse effects of BPA on neuronal development are not fully understood. Here, BPA concentration-dependently decreased proliferation of murine-derived multipotent neural progenitor cells (NPC), and high concentrations produced cytotoxicity. In contrast, low concentrations of BPA, which possess estrogenic activity, stimulated NPC differentiation into a neuronal phenotype. BPA treatment did not affect neonatal brain development in F1 mice. However, BPA treatment (20 mg/kg) accelerated formation of the dentate gyrus in postnatal day 1 mice. Prenatal and postnatal BPA treatment did not affect adult hippocampal neurogenesis in the dentate gyrus in 8-wk-old mice. Data indicate that BPA stimulates neuronal differentiation and might disrupt neonatal brain development</abstract>
    <url>WOS:000271435300014</url>
    <isbnorissn>1528-7394</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>239</id>
    <title>Environmental Toxicants-Induced Epigenetic Alterations and Their Reversers</title>
    <authors>Kim,M.; Bae,M.; Na,H.; Yang,M.</authors>
    <availability>[Kim, Minju; Bae, Minji; Na, Hyunkyung; Yang, Mihi] Sookmyung Womens Univ, Coll Pharm, Res Ctr Cell Fate Control, Seoul 140742, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishReviewYang, M (reprint author), Sookmyung Womens Univ, Coll Pharm, Res Ctr Cell Fate Control, Seoul 140742, South Koreamyang@sm.ac.krAli AHK, 2011, MOL CARCINOGEN, V50, P89, DOI 10.1002/mc.20697; Alim MA, 2004, J ALZHEIMERS DIS, V6, P435; AM RMaC, 2010, PHARMACEUTICALS, V3, P572; Andujar P, 2010, LUNG CANCER, V67, P23, DOI 10.1016/j.lungcan.2009.03.018; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Arai Y, 2011, J REPROD DEVELOP, V57, P507, DOI 10.1262/jrd.11-034A; Arunava Pradhan SS, 2012, CENTRE MOLEC ENVIRON, V89, P1142; Batra V, 2010, CHEM-BIOL INTERACT, V183, P425, DOI 10.1016/j.cbi.2009.11.010; Benbrahim-Tallaa L, 2007, ENVIRON HEALTH PERSP, V115, P1454, DOI 10.1289/ehp.10207; Berner C, 2011, ANN NUTR METAB, V57, P183, DOI 10.1159/000321514; Bihaqi SW, 2011, J ALZHEIMERS DIS, V27, P819, DOI 10.3233/JAD-2011-111013; Bleich S, 2006, ALCOHOL CLIN EXP RES, V30, P587, DOI 10.1111/j.1530-0277.2006.00068.x; Bliek J, 2006, AM J HUM GENET, V78, P604, DOI 10.1086/502981; Boeke CE, 2012, EPIGENETICS-US, V7, P253, DOI 10.4161/epi.7.3.19082; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Bonsch D, 2006, J NEURAL TRANSM, V113, P1299, DOI 10.1007/s00702-005-0413-2; Bonsch D, 2005, NEUROREPORT, V16, P167; Brauze D, 2006, TOXICOL LETT, V167, P212, DOI 10.1016/j.toxlet.2006.09.010; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; Byrne James D, 2008, Mcgill J Med, V11, P43; Centers for Disease Control NORA mixed exposures team, 2004, MIXED EXPOSURES RESE; Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030; Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z; Chen H, 2004, CARCINOGENESIS, V25, P1779, DOI 10.1093/carcin/bgh161; Cheng RYS, 2004, MOL CARCINOGEN, V40, P1, DOI 10.1002/mc.20022; Cheng TF, 2012, J APPL TOXICOL, V32, P643, DOI 10.1002/jat.2717; Choi SW, 2010, ADV NUTR, V1, P8, DOI 10.3945/an.110.1004; Christensen BC, 2009, CANCER RES, V69, P227, DOI 10.1158/0008-5472.CAN-08-2586; Christensen Brock C, 2011, Front Genet, V2, P84, DOI 10.3389/fgene.2011.00084; Christensen BC, 2008, CARCINOGENESIS, V29, P1555, DOI 10.1093/carcin/bgn059; Christensen BC, 2010, CANCER RES, V70, P5686, DOI 10.1158/0008-5472.CAN-10-0190; Christiansen S, 2009, ENVIRON HEALTH PERSP, V117, P1839, DOI 10.1289/ehp.0900689; Clement TM, 2010, REPROD TOXICOL, V30, P353, DOI 10.1016/j.reprotox.2010.05.086; Cravo ML, 1996, AM J CLIN NUTR, V63, P220; Cristaudo A, 2011, BIOMARK MED, V5, P261, DOI [10.2217/bmm.11.18, 10.2217/BMM.11.18]; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Doi T, 2011, TOXICOL SCI, V120, P475, DOI 10.1093/toxsci/kfr022; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011; Downing C, 2011, ALCOHOL, V45, P65, DOI 10.1016/j.alcohol.2010.07.006; Dufault R, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-6; Fang MZ, 2007, J NUTR, V137, p223S; Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406; Ferguson LR, 2012, MUTAT RES-FUND MOL M, V733, P100, DOI 10.1016/j.mrfmmm.2011.12.011; Fernandez SV, 2012, INT J ONCOL, V41, P369, DOI 10.3892/ijo.2012.1444; Fujii M, 2012, CANCER SCI, V103, P510, DOI 10.1111/j.1349-7006.2011.02180.x; Fujishiro H, 2009, TOXICOL APPL PHARM, V241, P195, DOI 10.1016/j.taap.2009.08.015; Fujishiro H, 2009, J APPL TOXICOL, V29, P367, DOI 10.1002/jat.1419; Fustinoni S, 2012, MED LAV, V103, P84; Gao A, 2010, TOXICOL LETT, V195, P114, DOI 10.1016/j.toxlet.2010.03.005; GARRO AJ, 1991, ALCOHOL CLIN EXP RES, V15, P395, DOI 10.1111/j.1530-0277.1991.tb00536.x; Gong CM, 2012, TOXICOL LETT, V209, P264, DOI 10.1016/j.toxlet.2012.01.007; Gong CM, 2010, BIOCHEM BIOPH RES CO, V397, P397, DOI 10.1016/j.bbrc.2010.05.076; Govorko D, 2012, BIOL PSYCHIAT, V72, P378, DOI 10.1016/j.biopsych.2012.04.006; Gudiksen MS, 2005, NANO LETT, V5, P2257, DOI 10.1021/nl0516005; Hanna CW, 2012, HUM REPROD, V27, P1401, DOI 10.1093/humrep/des038; Haycock PC, 2009, BIOL REPROD, V81, P618, DOI 10.1095/biolreprod.108.074682; Haycock PC, 2009, BIOL REPROD, V81, P607, DOI 10.1095/biolreprod.108.074690; Heintz NH, 2010, AM J RESP CELL MOL, V42, P133, DOI 10.1165/rcmb.2009-0206TR; Hennig B, 2012, ENVIRON HEALTH PERSP, V120, P771, DOI 10.1289/ehp.1104712; Hillemacher T, 2009, J PSYCHIATR RES, V43, P388, DOI 10.1016/j.jpsychires.2008.04.006; Ho E, 2011, ADV NUTR, V2, P497, DOI 10.3945/an.111.001032; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hodgson E, 2010, TXB MODERN TOXICOLOG, P336; Hossain MB, 2012, ENVIRON HEALTH PERSP, V120, P879, DOI 10.1289/ehp.1104600; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3; Huang DJ, 2008, TOXICOL LETT, V179, P43, DOI 10.1016/j.toxlet.2008.03.018; IARC, 1987, IARC MON EV CARC S7, V7, P106; Inawaka K, 2009, TOXICOL APPL PHARM, V237, P178, DOI 10.1016/j.taap.2009.03.004; Inglot P, 2012, MUTAT RES-GEN TOX EN, V747, P182, DOI 10.1016/j.mrgentox.2012.05.007; Intarasunanont P, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-31; Jacob ST, 2002, ENVIRON HEALTH PERSP, V110, P827; Jang YJ, 2012, TOXICOLOGY, V296, P73, DOI 10.1016/j.tox.2012.03.007; Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004; Jha AK, 2010, FOLIA BIOL-PRAGUE, V56, P195; Jiang GF, 2008, TOXICOLOGY, V244, P49, DOI 10.1016/j.tox.2007.10.028; Jin B, 2004, TOXICOL IN VITRO, V18, P659, DOI 10.1016/j.tiv.2004.02.006; Kaminen-Ahola N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000811; Katiyar SK, 2012, PHOTOCHEM PHOTOBIOL, V88, P1066, DOI 10.1111/j.1751-1097.2011.01020.x; Kawakami K, 2003, CLIN CANCER RES, V9, P5860; Khor TO, 2011, BIOCHEM PHARMACOL, V82, P1073, DOI 10.1016/j.bcp.2011.07.065; Kile ML, 2012, ENVIRON HEALTH PERSP, V120, P1061, DOI 10.1289/ehp.1104173; Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131; King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363; Knezovich Jaysen Gregory, 2012, Front Genet, V3, P10, DOI 10.3389/fgene.2012.00010; KOBOR WJ, 2011, ALCOHOL RES HEALTH, V34, P29; Kondo K, 2006, LUNG CANCER-J IASLC, V53, P295, DOI 10.1016/j.lungcan.2006.05.022; Koturbash I, 2006, INT J RADIAT ONCOL, V66, P327, DOI 10.1016/j.ijrobp.2006.06.012; Koturbash I, 2005, BIOCHEM BIOPH RES CO, V337, P526, DOI 10.1016/j.bbrc.2005.09.084; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4&lt;300::AID-HUMU2&gt;3.0.CO;2-9; Kujawska M, 2011, EUR J NUTR, V50, P53, DOI 10.1007/s00394-010-0114-y; Kumar M, 2012, PLANT PHYSIOL BIOCH, V51, P129, DOI 10.1016/j.plaphy.2011.10.016; Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005; Lambrou A, 2012, EPIDEMIOLOGY, V23, P668, DOI 10.1097/EDE.0b013e31825afb0b; Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595; Li SC, 2011, BIOMATERIALS, V32, P3807, DOI 10.1016/j.biomaterials.2011.01.074; Li SF, 2003, ANN NY ACAD SCI, V983, P161; Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147; Li Y, 2010, CURR MED CHEM, V17, P2141; Liu YL, 2009, EPIGENETICS, V4, P500; Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042; Marsit CJ, 2006, ANN NY ACAD SCI, V1076, P810, DOI 10.1196/annals.1371.031; Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172; Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051; Martinez-Zamudio R, 2011, EPIGENETICS-US, V6, P820, DOI 10.4161/epi.6.7.16250; Mazumder DG, 2011, KAOHSIUNG J MED SCI, V27, P360, DOI 10.1016/j.kjms.2011.05.003; McClure EA, 2011, TOXICOL SCI, V120, P339, DOI 10.1093/toxsci/kfq396; McConaha ME, 2011, REPRODUCTION, V142, P235, DOI 10.1530/REP-11-0070; Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457; Meeran S.M., 2010, CLIN EPIGENETICS, V1, P101, DOI DOI 10.1007/S13148-010-0011-5; Melaiu O, 2012, MUTAT RES-REV MUTAT, V750, P132, DOI 10.1016/j.mrrev.2011.12.003; Mittal A, 2003, NEOPLASIA, V5, P555; Muller CI, 2008, LEUKEMIA, V22, P1773, DOI 10.1038/leu.2008.41; Nandakumar V, 2011, CARCINOGENESIS, V32, P597, DOI 10.1093/carcin/bgq282; Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285; Nelson HH, 2011, EPIGENETICS-US, V6, P1029, DOI 10.4161/epi.6.8.16074; Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423; Neufeld G, 2005, FRONT BIOSCI, V10, P751, DOI 10.2741/1569; Nohara K, 2011, ARCH TOXICOL, V85, P653, DOI 10.1007/s00204-010-0611-z; Okino ST, 2006, CANCER RES, V66, P7420, DOI 10.1158/0008-5472.CAN-06-0504; Okoji RS, 2002, CARCINOGENESIS, V23, P777, DOI 10.1093/carcin/23.5.777; Otero NKH, 2012, ALCOHOL CLIN EXP RES, V36, P1701, DOI 10.1111/j.1530-0277.2012.01784.x; Ouko LA, 2009, ALCOHOL CLIN EXP RES, V33, P1615, DOI 10.1111/j.1530-0277.2009.00993.x; Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422; Parashar G, 2012, MOL CELL BIOCHEM, V365, P29, DOI 10.1007/s11010-012-1240-z; Paz MF, 2002, CANCER RES, V62, P4519; Pilsner JR, 2007, AM J CLIN NUTR, V86, P1179; Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P254, DOI 10.1289/ehp.11872; Pilsner JR, 2010, MOL ECOL, V19, P307, DOI 10.1111/j.1365-294X.2009.04452.x; Pilsner JR, 2011, ENVIRON HEALTH PERSP, V119, P113, DOI 10.1289/ehp.1001937; Price SM, 1999, J MED GENET, V36, P837; Puri SK, 2005, AM J OTOLARYNG, V26, P12, DOI 10.1016/j.amjoto.2004.06.007; Qin XY, 2012, CANCER BIOL THER, V13, P296, DOI [10.4161/cbt.18942, 10.4161/cbt.13.5.18942]; Rajender S, 2011, MUTAT RES-REV MUTAT, V727, P62, DOI 10.1016/j.mrrev.2011.04.002; Rappaport SM, 2009, ENVIRON HEALTH PERSP, V117, P946, DOI 10.1289/ehp.0800510; Ray SS, 2004, J BIOL CHEM, V279, P27187, DOI 10.1074/jbc.M402771200; Reichard JF, 2007, BIOCHEM BIOPH RES CO, V352, P188, DOI 10.1016/j.bbrc.2006.11.001; Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338; Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012; Sato K, 2009, ENDOCR J, V56, P131; Sato N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019278; Scherpereel A, 2006, AM J RESP CRIT CARE, V173, P1155, DOI 10.1164/rccm.200511-1789OC; Senanayake GVK, 2012, AM J HYPERTENS, V25, P229, DOI 10.1038/ajh.2011.200; Shan JD, 2002, CANCER RES, V62, P290; Shu LM, 2011, AAPS J, V13, P606, DOI 10.1208/s12248-011-9300-y; Singh NP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023522; Skinner MK, 2011, REPROD TOXICOL, V31, P337, DOI 10.1016/j.reprotox.2010.10.012; Smeester L, 2011, CHEM RES TOXICOL, V24, P165, DOI 10.1021/tx1004419; Smith IM, 2007, INT J CANCER, V121, P1724, DOI 10.1002/ijc.22889; Stefanska B, 2012, BRIT J NUTR, V107, P781, DOI 10.1017/S0007114511003631; Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032; Stein RA, 2012, J EPIDEMIOL COMMUN H, V66, P8, DOI 10.1136/jech.2010.130690; Stewart BW, 2003, WORLD CANC REPORT, P29; Stouder C, 2010, REPRODUCTION, V139, P373, DOI 10.1530/REP-09-0340; Takahashi Y, 2005, MOL CARCINOGEN, V42, P150, DOI 10.1002/mc.20073; Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4; Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545; Tremolizzo L, 2010, MED HYPOTHESES, V75, P677, DOI 10.1016/j.mehy.2010.07.032; Trosko JE, 2005, RADIAT ENVIRON BIOPH, V44, P3, DOI 10.1007/s00411-005-0269-8; Tsou JA, 2007, LUNG CANCER, V58, P220, DOI 10.1016/j.lungcan.2007.06.015; Ulrich CM, 2007, JAMA-J AM MED ASSOC, V297, P2408, DOI 10.1001/jama.297.21.2408; Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489; van Engeland M, 2003, CANCER RES, V63, P3133; Vardi A, 2010, IN VIVO, V24, P393; Volate SR, 2009, MOL CARCINOGEN, V48, P920, DOI 10.1002/mc.20542; Wang B, 2012, CURR MED CHEM, V19, P2611; Wang B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033853; Wang ZG, 2010, ANTICANCER RES, V30, P4537; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Wong CP, 2011, IMMUNOL LETT, V139, P7, DOI 10.1016/j.imlet.2011.04.009; Woo HD, 2011, J EPIDEMIOL COMMUN H, V65, pA218, DOI 10.1136/jech.2011.142976h.34; World Health Organization, 2003, CONCISE INTERNATIONA; World Health Organization, 2010, CHILDHOOD LEAD POISO; Wright RO, 2010, ENVIRON HEALTH PERSP, V118, P790, DOI 10.1289/ehp.0901429; Wu Q, 2004, BIOL REPROD, V70, P1790, DOI 10.1095/biolreprod.103.025387; Xie YX, 2007, TOXICOLOGY, V236, P7, DOI 10.1016/j.tox.2007.03.021; Xing CH, 2010, CHEM-BIOL INTERACT, V184, P306, DOI 10.1016/j.cbi.2009.12.028; Xu HP, 2007, CANCER RES, V67, P1239, DOI 10.1158/0008-5472.CAN-06-3688; Yang Mihi, 2012, Methods Mol Biol, V863, P67, DOI 10.1007/978-1-61779-612-8_5; Yang M, 2006, ENVIRON MOL MUTAGEN, V47, P571, DOI 10.1002/em.20230; Yang M, 2011, J ENVIRON SCI HEAL C, V29, P223, DOI 10.1080/10590501.2011.601848; Yang M, 2008, ENVIRON MOL MUTAGEN, V49, P368, DOI 10.1002/em.20394; Yang MH, 2006, J ENVIRON SCI HEAL C, V24, P183, DOI 10.1080/10590500600936474; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Yokota O, 2002, ACTA NEUROPATHOL, V104, P637, DOI 10.1007/s0041-002-0596-7; Yu AF, 2008, J EXPER HEMATOL, V16, P1073; Zampieri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004717; Zeng HW, 2011, J NUTR, V141, P1464, DOI 10.3945/jn.111.140715; Zhang AH, 2007, J TOXICOL ENV HEAL A, V70, P970, DOI 10.1080/15287390701290808; Zhang LP, 2010, CHEM-BIOL INTERACT, V184, P86, DOI 10.1016/j.cbi.2009.12.011; Zhang YK, 2011, EPIGENETICS-US, V6, P888, DOI 10.4161/epi.6.7.16315; Zhong CXY, 2001, TOXICOL LETT, V122, P223, DOI 10.1016/S0378-4274(01)00365-4; Zhou FC, 2011, ALCOHOL CLIN EXP RES, V35, P735, DOI 10.1111/j.1530-0277.2010.01391.x; Zhou ZH, 2012, TOXICOL SCI, V125, P412, DOI 10.1093/toxsci/kfr320; Zhu HY, 2011, J APPL TOXICOL, V31, P484, DOI 10.1002/jat.1673; Zhu WZ, 2012, NUTR CANCER, V64, P393, DOI 10.1080/01635581.2012.6549262018TAYLOR &amp; FRANCIS INCPHILADELPHIA325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USAJ ENVIRON SCI HEAL CDiscipline: Oncology; Environmental Sciences &amp; Ecology; Toxicology043OI</notes>
    <keywords>ADULT; ARSENIC EXPOSURE; BIOACTIVE DIETARY-COMPONENTS; BIOMARKER; Biomarkers; BISPHENOL-A EXPOSURE; BREAST-CANCER CELLS; CANCER; Carcinogen; CARCINOGENESIS; CELL; CHEMICALS; Chemoprevention; childhood; CORD BLOOD-SAMPLES; development; DISEASE; diseases; DISRUPTING CHEMICALS; DNA METHYLATION; DNA-methylation; EDCs; END-POINTS; ENDOCRINE; Endocrine disrupting chemicals; Environmental toxicant; Epidemiology; epigenetic; EPIGENETIC REGULATION; epigenetics; EXPOSURE; FOOD; GENE; GENES; GLOBAL DNA HYPOMETHYLATION; HEALTH; HYPERMETHYLATION; In vitro; IN-VITRO; IN-VIVO; Interaction; MALIGNANT PLEURAL MESOTHELIOMA; MESSENGER-RNA EXPRESSION; Metals; METHYLATION; mixed exposure; NEONATAL EXPOSURE; Neoplasia; oncology; ORGANIZATION; P8; PHARMACEUTICALS; PREVENTION; RADIATION; Reproduction; RISK; SILVER-RUSSELL-SYNDROME; SUSCEPTIBILITY; TOXICITY; toxicology; TUMOR; TUMOR-SUPPRESSOR GENES; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>323</startpage>
    <endpage>367</endpage>
    <journalfull>Journal of Environmental Science and Health Part C-Environmental Carcinogenesis &amp; Ecotoxicology Reviews</journalfull>
    <issue>4</issue>
    <volume>30</volume>
    <abstract>Epigenetics has been emphasized in the postgenome era to clarify obscure health risks of environmental toxicants including endocrine disrupting chemicals (EDCs). In addition, mixed exposure in real life can modify health consequences of the toxicants. Particularly, some nutritional and dietary materials modify individual susceptibility through changes in the epigenome. Therefore, we focused on some environmental toxicants that induce epigenetic alterations, and introduced chemopreventive materials to reverse the toxicants-induced epigenetic alterations. Methodologically, we used global and specific DNA methylation as epigenetic end points and searched epigenetic modulators in food. We reviewed various epigenetic end points induced by environmental toxicants including alcohol, asbestos, nanomaterials, benzene, EDCs, metals, and ionizing radiation. The epigenetic end points can be summarized into global hypomethylation and specific hypermethylation at diverse tumor suppress genes. Exposure timing, dose, sex, or organ specificity should be considered to use the epigenetic end points as biomarkers for exposure to the epimutagenic toxicants. Particularly, neonatal exposure to the epimutagens can influence their future adult health because of characteristics of the epimutagens, which disrupt epigenetic regulation in imprinting, organogenesis, development, etc. Considering interaction between epimutagenic toxicants and their reversers in food, we suggest that multiple exposures to them can alleviate or mask epigenetic toxicity in real life. Our present review provides useful information to find new end points of environmental toxicants and to prevention from environment-related diseases</abstract>
    <url>WOS:000311553400002</url>
    <isbnorissn>1059-0501</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>187</id>
    <title>Additional Effects of Bisphenol A and Paraben on the Induction of Calbindin-D-9K and Progesterone Receptor Via An Estrogen Receptor Pathway in Rat Pituitary Gh3 Cells</title>
    <authors>Kim,S.M.; Jung,E.M.; An,B.S.; Hwang,I.; Vo,T.T.; Kim,S.R.; Lee,S.M.; Choi,K.C.; Jeung,E.B.</authors>
    <availability>[Kim, S. M.; Jung, E. M.; An, B. S.; Hwang, I.; Vo, T. T.; Choi, K. C.; Jeung, E. B.] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Mol Biol, Cheongju 361763, Chungbuk, South Korea. [Kim, S. R.] Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 361763, Chungbuk, South Korea. [Lee, S. M.] Cheongju Univ, Dept Life Sci, Cheongju, Chungbuk, South Korea. [An, B. S.] Pusan Natl Univ, Coll Nat Resources &amp; Life Sci, Dept Biomat Sci, Miryang, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishArticleJeung, EB (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Mol Biol, Cheongju 361763, Chungbuk, South Koreaebjeung@chungbuk.ac.krAlonso-Magdalena P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002069; An BS, 2003, MOL CELL ENDOCRINOL, V205, P79, DOI 10.1016/S0303-7207(03)00203-X; An BS, 2004, J REPROD DEVELOP, V50, P445, DOI 10.1262/jrd.50.445; An BS, 2003, REPROD TOXICOL, V17, P311, DOI 10.1016/S0890-6238(03)00003-0; Ao A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018810; ARMBRECHT HJ, 1989, ENDOCRINOLOGY, V125, P2950; Barrett JR, 2011, ENVIRON HEALTH PERSP, V119, pA177, DOI 10.1289/ehp.119-a177a; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P249, DOI 10.1177/0960327109363973; Cantonwine D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-62; Carpenter DO, 2002, ENVIRON HEALTH PERSP, V110, P25; Cashman AL, 2005, DERMATITIS, V16, P57, DOI 10.2310/6620.2005.05008; Cashman AL, 2005, DERMATITIS, V16, P55; Charles GD, 2002, TOXICOL SCI, V68, P349, DOI 10.1093/toxsci/68.2.349; Choi KC, 2012, J PHYSIOL PHARMACOL, V62, P499; Choi KC, 2008, J CELL MOL MED, V12, P409, DOI 10.1111/j.1582-4934.2007.00209.x; Dang VH, 2010, TOXICOL IN VITRO, V24, P1229, DOI 10.1016/j.tiv.2010.02.006; Dang VH, 2009, STEROIDS, V74, P707, DOI 10.1016/j.steroids.2009.03.002; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2002, J APPL TOXICOL, V22, P219, DOI 10.1002/jat.860; DARWISH H, 1991, J BIOL CHEM, V266, P551; Erler C, 2010, J PEDIATR NURS, V25, P400, DOI 10.1016/j.pedn.2009.05.006; Fujimoto N, 2004, J STEROID BIOCHEM, V91, P121, DOI 10.1016/j.jsbmb.2004.02.006; Golden R, 2005, CRIT REV TOXICOL, V35, P435, DOI 10.1080/10408440490920104; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Han Dal-Ho, 2001, In Vitro Cellular and Developmental Biology Animal, V37, P275; Harvey PW, 2003, J APPL TOXICOL, V23, P285, DOI 10.1002/jat.946; Holm A, 2011, J VASC RES, V48, P327, DOI 10.1159/000322578; Hossaini A, 2000, FOOD CHEM TOXICOL, V38, P319, DOI 10.1016/S0278-6915(99)00160-X; Jeng YJ, 2011, ENVIRON HEALTH PERSP, V119, P104, DOI 10.1289/ehp.1002512; Jung EM, 2012, INT J ENV RES PUB HE, V9, P698, DOI 10.3390/ijerph9030698; Jung EM, 2012, TOXICOL LETT, V208, P142, DOI 10.1016/j.toxlet.2011.10.017; Kansra S, 2005, MOL CELL ENDOCRINOL, V239, P27, DOI 10.1016/j.mce.2005.04.008; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; Kim YR, 2012, INT J MOL MED, V29, P294, DOI 10.3892/ijmm.2011.823; Kortenkamp A, 1998, SCI TOTAL ENVIRON, V221, P59, DOI 10.1016/S0048-9697(98)00261-7; Kortenkamp A, 1999, SCI TOTAL ENVIRON, V233, P131, DOI 10.1016/S0048-9697(99)00228-4; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lee GS, 2005, TOXICOL SCI, V84, P270, DOI 10.1093/toxsci/kfi072; Lee KY, 2003, MOL CELLS, V16, P48; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, P55, DOI 10.2307/3434921; MATHIEU CL, 1989, P NATL ACAD SCI USA, V86, P3433, DOI 10.1073/pnas.86.9.3433; Morohoshi K, 2005, TOXICOL IN VITRO, V19, P457, DOI 10.1016/j.tiv.2005.01.004; Nguyen TH, 2005, MOL BRAIN RES, V141, P166, DOI 10.1016/j.molbrainres.2005.09.008; Okubo T, 2001, FOOD CHEM TOXICOL, V39, P1225, DOI 10.1016/S0278-6915(01)00073-4; Osborne CK, 2005, BREAST, V14, P458, DOI 10.1016/j.breast.2005.08.024; A-zen Samim, 2011, J Clin Res Pediatr Endocrinol, V3, P1, DOI 10.4274/jcrpe.v3i1.01; ROBERT NJ, 1990, BREAST CANCER RES TR, V16, P273, DOI 10.1007/BF01806335; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Shaw J, 2009, REPROD TOXICOL, V28, P26, DOI 10.1016/j.reprotox.2009.03.003; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Steinmetz R, 1997, ENDOCRINOLOGY, V138, P1780, DOI 10.1210/en.138.5.1780; Suzuki T, 2001, J PHARM PHARMACOL, V53, P1549, DOI 10.1211/0022357011777927; Tinnanooru P, 2008, MOL CELL ENDOCRINOL, V285, P26, DOI 10.1016/j.mce.2008.01.011; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vo TTB, 2011, STEROIDS, V76, P675, DOI 10.1016/j.steroids.2011.03.006; Vo TTB, 2009, TOXICOL SCI, V112, P68, DOI 10.1093/toxsci/kfp176; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yamasaki K, 2004, TOXICOL LETT, V146, P111, DOI 10.1016/j.toxlet.2003.07.003; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565615POLISH PHYSIOLOGICAL SOCGRZEGORZECKAJAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLANDJ PHYSIOL PHARMACOLOCTDiscipline: Physiology060AL</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; Antagonist; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; calbindin-D-9k; CALCIUM-BINDING PROTEIN; CANCER; CELL; CELLS; CHEMICALS; COMBINATION; Combined effect; cosmetics; environment; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; estrogenic effects; EXPRESSION; FOOD; GH3 cells; HEALTH; HUMAN EXPOSURE; HUMAN HEALTH; IMMATURE RATS; In vitro; IN-VITRO; INDUCTION; Interaction; isobutylparaben; Plastics; Progesterone receptor; PROGESTERONE-RECEPTOR; PROLACTIN-RELEASE; RAT; RECEPTOR; Transcriptional regulation; UTEROTROPHIC ASSAY; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>445</startpage>
    <endpage>455</endpage>
    <journalfull>Journal of Physiology and Pharmacology</journalfull>
    <issue>5</issue>
    <volume>63</volume>
    <abstract>There are concerns about the combined estrogenic effects of chemicals since mixtures of these chemicals exist in our environment. This study investigated potential additional interactions between bisphenol A (BPA) and isobutylparaben (IBP), which are major xenoestrogens used in the manufacture of plastics, cosmetics, drugs, and other products. The combined effects of these two chemicals were analyzed by measuring the expression of calbindin-D-9k (CaBP-9k) in rat pituitary cancer GH3 cells. GH3 cells were treated with single and combination doses of both chemicals (BPA single doses: 10(-7), 10(-6) and 10(-5) M; IBP single doses: 10(-7), 10(-6) and 10(-5) M, and each of the BPA and IBP doses combined). Prior to treatment, cells were temporarily transfected with a plasmid containing an ERE-luciferase reporter gene. Luciferase activity was measured as an indicator of ER activation by 17 beta-estradiol (E2), BPA, and IBP. BPA (10(-5) M) combined with IBP (10(-7) M and 10(-6) M) induced a significant increase in the luciferase activity. Twenty-four hours after treatment, dose-dependent effects were observed in both single and combined dose groups, and several combination doses induced significant increases in the expression of CaBP-9k and progesterone receptor (PR) at both transcriptional and translational levels. Pre-treatment with ICI 182,780, a pure estrogen antagonist, significantly reversed BPA- and IBP-induced CaBP-9k and PR upregulation in GH3 cells. Taken together, these results indicate that BPA and I BP may have additionally increased estrogenic potency via an estrogen receptor-mediated pathway</abstract>
    <url>WOS:000312747500002</url>
    <isbnorissn>0867-5910</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>295</id>
    <title>Expression profiling of estrogen responsive genes on bisphenol A, 4-nonylphenol and 17 beta-estradiol treatment using in house cDNA microarray</title>
    <authors>Kim,Y.J.; Yun,H.J.; Ryu,J.C.</authors>
    <availability>[Ryu, Jae-Chun] Korea Inst Sci &amp; Technol, Cellular &amp; Mol Toxicol Lab, Seoul 130650, South Korea. [Kim, Youn-Jung] Kyung Hee Univ, Dept Appl Chem, Yongin 449701, South Korea. [Yun, Hye-Jung] Daemyung Sci Co Ltd, Seoul, South Korea.</availability>
    <date>2011</date>
    <notes>JEnglishArticleRyu, JC (reprint author), Korea Inst Sci &amp; Technol, Cellular &amp; Mol Toxicol Lab, POB 131, Seoul 130650, South Korearyujc@kist.re.krAdeoya-Osiguwa SA, 2003, HUM REPROD, V18, P100, DOI 10.1093/humrep/deg037; Chapin RE, 1999, TOXICOL SCI, V52, P80, DOI 10.1093/toxsci/52.1.80; Cola C, 2004, BIOCHEM BIOPH RES CO, V320, P424, DOI 10.1016/j.bbrc.2004.05.181; Danzo BJ, 1997, ENVIRON HEALTH PERSP, V105, P294, DOI 10.1289/ehp.97105294; Danzo BJ, 2002, REPROD TOXICOL, V16, P29, DOI 10.1016/S0890-6238(01)00194-0; FLOURIOT G, 1995, J MOL ENDOCRINOL, V15, P143; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Hossaini A, 2001, REPROD TOXICOL, V15, P537, DOI 10.1016/S0890-6238(01)00155-1; Huang CH, 2001, ENVIRON TOXICOL CHEM, V20, P133, DOI 10.1897/1551-5028(2001)020&lt;0133:AOEHIM&gt;2.0.CO;2; Imanishi S, 2003, J REPROD DEVELOP, V49, P329; Inoue Tohru, 2003, P3; Jobling MA, 1998, HUM MOL GENET, V7, P643, DOI 10.1093/hmg/7.4.643; KALLOS J, 1981, P NATL ACAD SCI-BIOL, V78, P2874, DOI 10.1073/pnas.78.5.2874; Kim SJ, 2009, MOL CELL TOXICOL, V5, P216; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUELLER GC, 1978, ENDOCRINOLOGY, V102, P1429; Nielsen M, 2000, J ENDOCRINOL, V167, P29, DOI 10.1677/joe.0.1670029; Nilsen BM, 2004, ANAL BIOANAL CHEM, V378, P621, DOI 10.1007/s00216-003-2241-2; Odum J, 1999, REGUL TOXICOL PHARM, V29, P184, DOI 10.1006/rtph.1999.1286; Park HW, 2010, MOL CELL TOXICOL, V6, P57, DOI 10.1007/s13273-010-0008-3; Ryu JC, 2005, MOL CELL TOXICOL, V1, P52; SHEIKH MS, 1993, MOL CELL ENDOCRINOL, V92, P153, DOI 10.1016/0303-7207(93)90002-2; Shelby MD, 1996, ENVIRON HEALTH PERSP, V104, P1296, DOI 10.2307/3432965; Skakkebaek NE, 2002, HORM RES, V57, P43, DOI 10.1159/000058100; Smeds A, 2001, CHEMOSPHERE, V44, P1463, DOI 10.1016/S0045-6535(00)00313-1; Sole RV, 2000, ARTIF LIFE, V6, P219, DOI 10.1162/106454600568843; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Takeyoshi M, 2002, TOXICOL LETT, V126, P91, DOI 10.1016/S0378-4274(01)00446-5; Terasaka S, 2004, ENVIRON HEALTH PERSP, V112, P773, DOI 10.1289/txg.6753; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyler CR, 1998, CRIT REV TOXICOL, V28, P319, DOI 10.1080/10408449891344236; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175365SPRINGERNEW YORK233 SPRING ST, NEW YORK, NY 10013 USABIOCHIP JMAR 20Discipline: Biochemistry &amp; Molecular Biology739AU</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; 4-NONYLPHENOL; AFFINITIES; Alkylphenol; ASSAY; BINDING; BINDING-AFFINITY; BIOLOGY; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; BRCA1; breast; breast cancer; BREAST-CANCER; CANCER; CDNA MICROARRAY; CELL; CELLS; CHEMICALS; DIETHYLSTILBESTROL; DISRUPTING CHEMICALS; DNA microarray; ENDOCRINE; Endocrine disrupting chemicals; Estrogen; Estrogen receptor; Estrogen receptors; Estrogen responsive gene; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic activity; ESTROGENS; EXPOSURE; EXPRESSION; GENE; gene expression; gene expression profile; GENE-EXPRESSION; GENES; HEALTH; In vitro; in vivo; IN-VITRO; IN-VIVO; Microarray; Nonylphenol; PLASMA; PRODUCTS; PROTEIN; RECEPTOR; Receptors; RESPONSIVE GENES; SYSTEM; VITRO; xenobiotics</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>86</startpage>
    <endpage>94</endpage>
    <journalfull>Biochip Journal</journalfull>
    <issue>1</issue>
    <volume>5</volume>
    <abstract>Bisphenol A (BPA) and nonylphenol (NP) are thought to mimic estrogens in their action, and are called endocrine disrupting chemicals. These phenolic chemicals are used in a number of commercial products and have been reported to be weakly estrogenic in previous studies. Their estrogenic activities are mainly dependent on their binding affinity for the estrogen receptors in vitro and in vivo. To identify genes elicited by BPA and NP, we carried out a microarray analysis in MCF-7 cells treated with BPA and NP using human c-DNA microarray including 416 endocrine system related genes. At the minimum fold-change criteria of 1.5, 14 and 29 genes were identified showing significant changes in gene expression resulting from BPA and NP, respectively. Especially, 2 genes were repressed and 6 genes were induced by BPA and NP as 17 beta-estradiol (E2). To validate the gene expression profiles identified from microarray analyses, the expression patterns of 4 representative genes, Selenoprotein P, plasma, 1 (SEPP1), Matrix G1a protein (MOP), H2A histone family, member X (H2AFX) and breast cancer 1, early onset (BRCA1) were examined by real time RT-PCR. We further examined the expression patterns of phthalic chemicals with estrogenic activity by comparing with those of E2 or phenolic chemicals to evaluate that alterations of these estrogen responsive genes may act as useful biomarkers to the endocrine disrupting chemicals with estrogenic activity</abstract>
    <url>WOS:000288685100013</url>
    <isbnorissn>1976-0280</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>77</id>
    <title>Epithelial mesenchymal transition was regulated by bisphenol A via altering related genes in human BG-1 cancer cells expressing estrogen receptors</title>
    <authors>Kim,Y.S.; Choi,K.C.</authors>
    <availability>[Kim, Ye-Seul; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Biochem &amp; Immunol, Cheongju, Chungbuk, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishMeeting Abstractkchoi@cbu.ac.kr00SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J MOL MED1Discipline: Research &amp; Experimental MedicineAO3ZM</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; epithelial mesenchymal transition; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; RECEPTOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S119</startpage>
    <endpage>S119</endpage>
    <journalfull>International Journal of Molecular Medicine</journalfull>
    <volume>34</volume>
    <url>WOS:000341276000461</url>
    <isbnorissn>1107-3756</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>182</id>
    <title>Ranking Transitive Chemical-Disease Inferences Using Local Network Topology in the Comparative Toxicogenomics Database</title>
    <authors>King,B.L.; Davis,A.P.; Rosenstein,M.C.; Wiegers,T.C.; Mattingly,C.J.</authors>
    <availability>[Davis, Allan Peter; Wiegers, Thomas C.; Mattingly, Carolyn J.] N Carolina State Univ, Raleigh, NC 27695 USA. [King, Benjamin L.; Rosenstein, Michael C.] Mt Desert Isl Biol Lab, Salsbury Cove, ME USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMattingly, CJ (reprint author), N Carolina State Univ, Raleigh, NC 27695 USAcjmattin@ncsu.eduAndrew AS, 2006, ENVIRON HEALTH PERSP, V114, P1193, DOI 10.1289/ehp.9008; [Anonymous], 2008, NTP CERHR MON; [Anonymous], 2008, NTP CERHR MON, V22, pi; Argos M, 2006, CANCER EPIDEM BIOMAR, V15, P1367, DOI 10.1158/1055-9965.EPI-06-0106; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Cabello G., 2003, Journal of Submicroscopic Cytology and Pathology, V35, P1; Chaudhary A, 2007, TOXICOL APPL PHARM, V220, P197, DOI 10.1016/j.taap.2006.12.030; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Cooke RM, 1991, EXPERTS UNCERTAINTY, Vxii; D'haeseleer Patrik, 2004, Proc IEEE Comput Syst Bioinform Conf, P216; Davey JC, 2008, ENVIRON HEALTH PERSP, V116, P165, DOI 10.1289/ehp.10131; Davis AP, 2011, NUCLEIC ACIDS RES, V39, pD1067, DOI 10.1093/nar/gkq813; Dormandy J, 2009, DRUG SAFETY, V32, P187, DOI 10.2165/00002018-200932030-00002; Evans J, 2010, SCIENCE, V329, P399, DOI 10.1126/science.1189416; Frijters R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000943; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Giri VN, 2004, UROLOGY, V63, P757, DOI 10.1016/j.urology.2003.11.044; Goldberg DS, 2003, P NATL ACAD SCI USA, V100, P4372, DOI 10.1073/pnas.0735871100; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, SOM DRINK WAT DIS CO; La Merrill M, 2010, ENVIRON HEALTH PERSP, V118, P596, DOI 10.1289/ehp.0901047; Li H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006410; Mattingly CJ, 2009, ENVIRON HEALTH PERSP, V117, P981, DOI 10.1289/ehp.0900555; Mead MN, 2005, ENVIRON HEALTH PERSP, V113, pA378; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Navlakha S, 2010, BIOINFORMATICS, V26, P1057, DOI 10.1093/bioinformatics/btq076; Nayak AS, 2007, TOXICOL SCI, V98, P118, DOI 10.1093/toxsci/kfm072; Nielsen MG, 2010, 20105199 US GEOL SUR; Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x; Rossman TG, 2004, TOXICOL APPL PHARM, V198, P394, DOI 10.1016/j.taap.2003.10.016; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; SWANSON DR, 1986, PERSPECT BIOL MED, V30, P7; Taboureau O, 2011, NUCLEIC ACIDS RES, V39, pD367, DOI 10.1093/nar/gkq906; Toscano William A, 2005, Int J Environ Res Public Health, V2, P4, DOI 10.3390/ijerph2005010004; Wang GX, 2010, DRUG CHEM TOXICOL, V33, P238, DOI 10.3109/01480540903414156; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Won JH, 1999, UROL RES, V27, P376; Yanai I, 2002, GENOME BIOL, V3392PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONENOV 7Discipline: Science &amp; Technology - Other Topics048TK</notes>
    <keywords>ASSOCIATION; BISPHENOL-A; BLOOD; CANCER; Case studies; CHEMICALS; COMPARATIVE TOXICOGENOMICS DATABASE; development; DISEASE; environment; Etiology; EXPOSURE; EXPRESSION; GENES; HEALTH; HUMAN HEALTH; HUMAN-DISEASE; HUMANS; IN-VITRO; Interaction; PROTEIN; protein-protein interaction; RISK; STATEMENT; SYSTEM; Toxicogenomics</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>11</issue>
    <volume>7</volume>
    <abstract>Exposure to chemicals in the environment is believed to play a critical role in the etiology of many human diseases. To enhance understanding about environmental effects on human health, the Comparative Toxicogenomics Database (CTD; http://ctdbase.org) provides unique curated data that enable development of novel hypotheses about the relationships between chemicals and diseases. CTD biocurators read the literature and curate direct relationships between chemicals-genes, genes-diseases, and chemicals-diseases. These direct relationships are then computationally integrated to create additional inferred relationships; for example, a direct chemical-gene statement can be combined with a direct gene-disease statement to generate a chemical-disease inference (inferred via the shared gene). In CTD, the number of inferences has increased exponentially as the number of direct chemical, gene and disease interactions has grown. To help users navigate and prioritize these inferences for hypothesis development, we implemented a statistic to score and rank them based on the topology of the local network consisting of the chemical, disease and each of the genes used to make an inference. In this network, chemicals, diseases and genes are nodes connected by edges representing the curated interactions. Like other biological networks, node connectivity is an important consideration when evaluating the CTD network, as the connectivity of nodes follows the power-law distribution. Topological methods reduce the influence of highly connected nodes that are present in biological networks. We evaluated published methods that used local network topology to determine the reliability of protein-protein interactions derived from high-throughput assays. We developed a new metric that combines and weights two of these methods and uniquely takes into account the number of common neighbors and the connectivity of each entity involved. We present several CTD inferences as case studies to demonstrate the value of this metric and the biological relevance of the inferences</abstract>
    <url>WOS:000311935800005</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>419</id>
    <title>Increase in the levels of chaperone proteins by exposure to beta-estradiol, bisphenol A and 4-methoxyphenol in human cells transfected with estrogen receptor alpha cDNA</title>
    <authors>Kita,K.; Jin,Y.H.; Sun,Z.; Chen,S.P.; Sumiya,Y.; Hongo,T.; Suzuki,N.</authors>
    <availability>[Kita, Kazuko; Jin, Yuan-Hu; Sun, Zhuo; Chen, Shi-Ping; Sumiya, Yoko; Suzuki, Nobuo] Chiba Univ, Grad Sch Med, Dept Environm Biochem, Chuo Ku, Chiba 2608670, Japan. [Hongo, Toshio] Tokyo Med &amp; Dent Univ, Grad Sch, Div Biomatrix, Tokyo 1138549, Japan.</availability>
    <date>2009</date>
    <notes>JEnglishArticleKita, K (reprint author), Chiba Univ, Grad Sch Med, Dept Environm Biochem, Chuo Ku, Inohana 1-8-1, Chiba 2608670, Japankita@faculty.chiba-u.jpBERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Croute F, 2002, BBA-MOL CELL RES, V1591, P147, DOI 10.1016/S0167-4889(02)00271-9; FUQUA SAW, 1989, CANCER RES, V49, P4126; Ghosh D, 1999, ENDOCRINOLOGY, V140, P3526, DOI 10.1210/en.140.8.3526; Hino M, 2000, BIOCHEM BIOPH RES CO, V271, P164, DOI 10.1006/bbrc.2000.2553; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; Koehler KF, 2005, ENDOCR REV, V26, P465, DOI 10.1210/er.2004-0027; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KUPFER D, 1990, FEBS LETT, V261, P59, DOI 10.1016/0014-5793(90)80636-W; Lee DY, 2004, BIOSCI BIOTECH BIOCH, V68, P1201, DOI 10.1271/bbb.68.1201; Lee HS, 2002, J BIOCHEM, V131, P399; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2&lt;143::AID-JCP4&gt;3.0.CO;2-O; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212; Meyers CY, 1997, J STEROID BIOCHEM, V62, P477, DOI 10.1016/S0960-0760(97)00063-0; MEYERS CY, 1988, J STEROID BIOCHEM, V31, P393, DOI 10.1016/0022-4731(88)90307-X; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15718; Moriguchi N, 2007, BIOCHEM PHARMACOL, V73, P385, DOI 10.1016/j.bcp.2006.09.025; Myllymaki S, 2005, TOXICOL APPL PHARM, V204, P69, DOI 10.1016/j.taap.2004.08.009; NEUHAUSSTEINMETZ U, 1994, MOL PHARMACOL, V45, P36; Nishikawa J, 1999, TOXICOL APPL PHARM, V154, P76, DOI 10.1006/taap.1998.8557; Noda M, 2002, J DENT RES, V81, P265; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2&lt;275::AID-JCB13&gt;3.3.CO;2-5; Okubo MA, 1999, DEV GROWTH DIFFER, V41, P381; Papaconstantinou AD, 2001, TOXICOL SCI, V63, P173, DOI 10.1093/toxsci/63.2.173; Papaconstantinou AD, 2003, TOXICOL LETT, V144, P257, DOI 10.1016/S0378-4274(03)00215-7; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Ray S, 2007, ENDOCRINOLOGY, V148, P4774, DOI 10.1210/en.2007-0537; Ray S, 2006, MOL ENDOCRINOL, V20, P1825, DOI 10.1210/me.2006-0046; RICHARDS FM, 1988, CANCER RES, V48, P6715; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157; Segner H, 2003, ECOTOX ENVIRON SAFE, V54, P302, DOI 10.1016/S0147-6513(02)00039-8; Segner H, 2003, ECOTOX ENVIRON SAFE, V54, P315, DOI 10.1016/S0147-6513(02)00040-4; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SUZUKI N, 1979, MUTAT RES, V60, P215, DOI 10.1016/0027-5107(79)90186-6; SUZUKI N, 1981, MUTAT RES, V84, P133, DOI 10.1016/0027-5107(81)90057-9; Tabuchi Y, 2006, BIOCHEM BIOPH RES CO, V345, P1044, DOI 10.1016/j.bbrc.2006.04.177; Takahashi S, 2000, WATER SCI TECHNOL, V42, P133; Takahashi S, 2001, MUTAT RES-GEN TOX EN, V490, P199, DOI 10.1016/S1383-5718(00)00161-3; Tan J, 1999, ENDOCRINOLOGY, V140, P5310, DOI 10.1210/en.140.11.5310; Terasaki M, 2005, ENVIRON SCI TECHNOL, V39, P3703, DOI 10.1021/es048932g; Trautinger F, 2001, J PHOTOCH PHOTOBIO B, V63, P70, DOI 10.1016/S1011-1344(01)00203-2; Wang GS, 2008, TOXICOL APPL PHARM, V233, P92, DOI 10.1016/j.taap.2008.01.017; Wano C, 2004, EXP CELL RES, V298, P584, DOI 10.1016/j.yexcr.2004.04.048; Yamasaki K, 2002, TOXICOLOGY, V170, P21, DOI 10.1016/S0300-483X(01)00505-4; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200476PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROJUNDiscipline: Toxicology458IR</notes>
    <keywords>4-Methoxyphenol; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; CELL-LINE; CELL-LINES; CELLS; Chaperone proteins; CHEMICALS; ENDOPLASMIC-RETICULUM; ENVIRONMENTAL CHEMICALS; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptor alpha; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; Estrogenic; ESTROGENIC CHEMICALS; EXPOSURE; EXPRESSION; GROWTH; HEAT-SHOCK RESPONSE; HELA-CELLS; HSP27; HUMAN BREAST-CANCER; Human cells; human estrogen receptor; In vitro; IN-VITRO; INDUCTION; JUN; KU; LINE; LINES; MOUSE UTERUS; p21; PROTEIN; PROTEINS; RECEPTOR; RECEPTOR-ALPHA; Steroid; STRESS; toxicology; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>728</startpage>
    <endpage>735</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>4</issue>
    <volume>23</volume>
    <abstract>We examined changes in the levels of chaperone proteins to evaluate the toxic effects of environmental chemicals in human cells in vitro. Some chaperones are up-regulated by estrogenic chemicals, but the effect is not necessarily dependent on the receptor. Thus we also investigated whether a chemical-induced change in chaperone protein expression is human estrogen receptor (hER)-dependent or not, using cultured human cell lines transfected with hER alpha cDNA or an empty vector. In the hER alpha-expressed cells, the protein levels of the heat shock protein 27 (HSP27), the glucose-regulated protein 78 (GRP78/BiP), and GRP94 increased after exposure to beta-estradiol (E(2)) (from 10(-9) M to 10(-6) M) and bisphenol A (BPA) (from 10(-6) M to 10(-5) M). On the other hand, the increase was not observed in the cells without hER alpha expression. These results suggest that the E(2)- and BPA-induced increase in the protein levels were hER alpha dependent. We next examined the effect of four phenolic chemicals similar in structure to BPA, and found that among them, 4-methoxyphenol (from 10(-6) M to 10(-)5 M) increased the levels of the chaperone proteins with hER alpha dependency. Thus the human cultured cells would be suitable for evaluating whether an increase in chaperone proteins occurs upon exposure to environmental chemicals and whether the effect is ER-dependent. (C) 2009 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000267011400026</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>38</id>
    <title>DNA microarray-based gene expression profiling of estrogenic chemicals</title>
    <authors>Kiyama,R.; Zhu,Y.</authors>
    <availability>[Kiyama, Ryoiti; Zhu, Yun] Natl Inst Adv Ind Sci &amp; Technol, Biomed Res Inst, Signaling Mol Res Grp, Tsukuba, Ibaraki 3058566, Japan.</availability>
    <date>2014</date>
    <notes>JEnglishReviewKiyama, R (reprint author), Natl Inst Adv Ind Sci &amp; Technol, Biomed Res Inst, Signaling Mol Res Grp, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japankiyama.r@aist.go.jpAbend JR, 2012, J VIROL, V86, P11663, DOI 10.1128/JVI.01147-12; Abot A, 2013, ENDOCRINOLOGY, V154, P2222, DOI 10.1210/en.2012-2059; Adachi T, 2002, MOL REPROD DEV, V63, P17, DOI 10.1002/mrd.10178; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; Alberts B., 2007, MOL BIOL CELL; [Anonymous], 2006, NAT BIOTECHNOL, V24, P1039; Ashby J, 1999, J APPL TOXICOL, V19, P39, DOI 10.1002/(SICI)1099-1263(199901/02)19:1&lt;39::AID-JAT534&gt;3.0.CO;2-M; Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003; Billon-Gales A, 2011, P NATL ACAD SCI USA, V108, P13311, DOI 10.1073/pnas.1105632108; Bolukbasi E, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.110031; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; BULGER WH, 1978, J TOXICOL ENV HEALTH, V4, P881; Burgess STG, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-30; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Byrne C, 2013, J MAMMARY GLAND BIOL, V18, P63, DOI 10.1007/s10911-013-9273-9; Cahan P, 2007, GENE, V401, P12, DOI 10.1016/j.gene.2007.06.016; Caramori ML, 2012, DIABETES, V61, P739, DOI 10.2337/db11-0617; Carthew P, 1999, TOXICOL APPL PHARM, V158, P24, DOI 10.1006/taap.1999.8679; Chang MX, 2009, FISH SHELLFISH IMMUN, V26, P264, DOI 10.1016/j.fsi.2008.11.007; Chang TT, 2012, J LEUKOCYTE BIOL, V92, P1133, DOI 10.1189/jlb.0312157; Chen CC, 2001, J BIOMED SCI, V8, P214, DOI 10.1007/BF02256415; Chen DZ, 2004, ANTICANCER RES, V24, P2649; Cheskis BJ, 2008, STEROIDS, V73, P901, DOI 10.1016/j.steroids.2007.12.028; Choi SI, 2010, INVEST OPHTH VIS SCI, V51, P1832, DOI 10.1167/iovs.09-4149; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Cizkova A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-38; Copple BL, 2011, LIVER INT, V31, P230, DOI 10.1111/j.1478-3231.2010.02347.x; Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005; Currie RA, 2012, MUTAT RES-GEN TOX EN, V746, P97, DOI 10.1016/j.mrgentox.2012.03.002; Davey JC, 2007, TOXICOL SCI, V98, P75, DOI 10.1093/toxsci/kfm013; Dong S, 2013, J AGR FOOD CHEM, V61, P128, DOI 10.1021/jf304546a; Dong S, 2012, MICROBIOL RES, V167, P231, DOI 10.1016/j.micres.2011.09.003; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Dong SJ, 2009, FOOD CHEM, V113, P672, DOI 10.1016/j.foodchem.2008.07.100; Dong SJ, 2007, FOOD CHEM TOXICOL, V45, P2470, DOI 10.1016/j.fct.2007.05.031; Dumitriu A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002794; Eguchi T, 2007, ONCOGENE, V26, P509, DOI 10.1038/sj.onc.1209810; Eisinger-Mathason TSK, 2010, STEROIDS, V75, P191, DOI 10.1016/j.steroids.2009.12.010; Faherty CS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-272; Fan JB, 2005, BIOTECHNIQUES, V39, P583, DOI 10.2144/000112047; Fan XH, 2010, CLIN CANCER RES, V16, P629, DOI 10.1158/1078-0432.CCR-09-1815; Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32; Fent K, 2011, AQUAT TOXICOL, V105, P25, DOI 10.1016/j.aquatox.2011.06.008; Filardo EJ, 2005, TRENDS ENDOCRIN MET, V16, P362, DOI 10.1016/j.tem.2005.08.005; Franke A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016596; Frye CA, 2012, J NEUROENDOCRINOL, V24, P144, DOI 10.1111/j.1365-2826.2011.02229.x; Fu JJ, 2007, MOL BIOSYST, V3, P466, DOI 10.1039/b618163e; Fu XD, 2008, IUBMB LIFE, V60, P502, DOI 10.1002/iub.80; Gajecki M., 2002, Polish Journal of Veterinary Sciences, V5, P117; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; Ghosh MG, 2000, CANCER RES, V60, P6367; Glas AM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-278; Granese B, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-24; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Hah N, 2014, MOL CELL ENDOCRINOL, V382, P652, DOI 10.1016/j.mce.2013.06.021; Hammond GL, 2011, BIOL REPROD, V85, P431, DOI 10.1095/biolreprod.111.092593; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Herrero M, 2005, J SEP SCI, V28, P883, DOI 10.1002/jssc.200400104; HILF R, 1963, CANCER RES, V23, P304; Holm A, 2011, J VASC RES, V48, P327, DOI 10.1159/000322578; Hudson J, 2013, DRUG DISCOV TODAY, V18, P610, DOI 10.1016/j.drudis.2013.01.012; Hutz RJ, 2006, TRENDS REPROD BIOL, V2, P1; Ibrahim NK, 1999, SURG ONCOL, V8, P103, DOI 10.1016/S0960-7404(99)00047-X; Inoue A, 2004, J MOL ENDOCRINOL, V32, P649, DOI 10.1677/jme.0.0320649; Inoue A, 2007, TOXICOL IN VITRO, V21, P741, DOI 10.1016/j.tiv.2007.01.014; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Inoue Akio, 2006, Current Pharmacogenomics, V4, P245, DOI 10.2174/157016006778195070; Ioannidis JPA, 2005, LANCET, V365, P454, DOI 10.1016/S0140-6736(05)17878-7; Ise R, 2005, FEBS LETT, V579, P1732, DOI 10.1016/j.febslet.2005.02.033; Jefferson WN, 2002, J CHROMATOGR B, V777, P179, DOI 10.1016/S1570-0232(02)00493-2; Johnson JJ, 2010, CANCER PREV RES, V3, P1112, DOI 10.1158/1940-6207.CAPR-10-0168; Khamas A, 2012, CANCER GENOM PROTEOM, V9, P67; Kim Ji-Young, 2011, Immune Netw, V11, P258, DOI 10.4110/in.2011.11.5.258; Kjeldsen LS, 2013, ENVIRON SCI POLLUT R, V20, P8031, DOI 10.1007/s11356-013-1753-3; Klebanov Lev, 2007, Nat Biotechnol, V25, P25, DOI 10.1038/nbt0107-25; Koda T, 2005, ENVIRON RES, V98, P40, DOI 10.1016/j.envres.2004.05.015; Kuiper HA, 2003, CURR OPIN BIOTECH, V14, P238, DOI 10.1016/S0958-1669(03)00021-1; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042; Lara-Pezzi E, 2009, J CARDIOVASC TRANSL, V2, P191, DOI 10.1007/s12265-009-9097-6; Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154; Lee DH, 2013, BIOCHEM BIOPH RES CO, V434, P820, DOI 10.1016/j.bbrc.2013.04.020; Lee YJ, 2012, P NATL ACAD SCI USA, V109, P13656, DOI 10.1073/pnas.1203218109; Le Fevre AC, 2007, MUTAT RES-FUND MOL M, V619, P16, DOI 10.1016/j.mrfmmm.2006.12.007; Lenoir Tim, 2006, J Biomed Discov Collab, V1, P11, DOI 10.1186/1747-5333-1-11; Lequin RM, 2005, CLIN CHEM, V51, P2415, DOI 10.1373/clinchem.2005.051532; Leung YF, 2003, TRENDS GENET, V19, P649, DOI 10.1016/j.tig.2003.09.015; Levenson AS, 2002, BRIT J CANCER, V87, P449, DOI 10.1038/sj.bjc.6600477; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Li YW, 2002, J NUTR, V132, P3623; Lord PG, 2006, BASIC CLIN PHARMACOL, V98, P537, DOI 10.1111/j.1742-7843.2006.pto_444.x; Luhe A, 2005, MUTAT RES-FUND MOL M, V575, P102, DOI 10.1016/j.mrfmmm.2005.02.009; Makker A, 2012, GYNECOL ENDOCRINOL, V28, P175, DOI 10.3109/09513590.2011.583955; Marquardt JU, 2012, J HEPATOL, V56, P267, DOI 10.1016/j.jhep.2011.07.007; Martinez-Campa CM, 2008, CANCER LETT, V268, P272, DOI 10.1016/j.canlet.2008.04.001; Mendes SD, 2009, CELL SIGNAL, V21, P1109, DOI 10.1016/j.cellsig.2009.02.025; Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538; Meulenberg EP, 2009, MOLECULES, V14, P439, DOI 10.3390/molecules14010439; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Moggs JG, 2005, TOXICOLOGY, V213, P177, DOI 10.1016/j.tox.2005.05.020; Monzon FA, 2010, EXPERT REV MOL DIAGN, V10, P17, DOI [10.1586/erm.09.75, 10.1586/ERM.09.75]; Mueller SO, 2002, J CHROMATOGR B, V777, P155, DOI 10.1016/S1570-0232(02)00282-9; Mueller SO, 2004, ANAL BIOANAL CHEM, V378, P582, DOI 10.1007/s00216-003-2238-x; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Nagai MA, 2008, MINI-REV MED CHEM, V8, P448, DOI 10.2174/138955708784223503; Nakaoka Y, 2007, J CLIN INVEST, V117, P1771, DOI 10.1172/JCI30651; Nasirudeen AMA, 2009, J MED VIROL, V81, P1069, DOI 10.1002/jmv.21486; National Research Council, 2007, TOX TEST 21 CENT VIS; Nfonsam LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044583; Ng Tzi Bun, 2011, Appl Microbiol Biotechnol, V90, P59, DOI 10.1007/s00253-011-3169-7; Nguyen HPT, 2012, ENDOCRINOLOGY, V153, P2870, DOI 10.1210/en.2011-1839; Nilsson BO, 2011, BRIT J PHARMACOL, V163, P1131, DOI 10.1111/j.1476-5381.2011.01235.x; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Odum J, 1999, REGUL TOXICOL PHARM, V29, P184, DOI 10.1006/rtph.1999.1286; Orrego R, 2010, AQUAT TOXICOL, V99, P160, DOI 10.1016/j.aquatox.2010.04.016; Oseni T, 2008, PLANTA MED, V74, P1656, DOI 10.1055/s-0028-1088304; Palayoor ST, 2012, J CARDIOVASC PHARM, V59, P487, DOI 10.1097/FJC.0b013e31824ba6b5; Parveen M, 2009, FEBS LETT, V583, P2377, DOI 10.1016/j.febslet.2009.06.035; Parveen M, 2008, ENVIRON TOXICOL CHEM, V27, P1416, DOI 10.1897/07-399; Patisaul HB, 2010, FRONT NEUROENDOCRIN, V31, P400, DOI 10.1016/j.yfrne.2010.03.003; Pazzagli M, 2013, METHODS, V59, P20, DOI 10.1016/j.ymeth.2012.10.007; Pennie W, 2004, ENVIRON HEALTH PERSP, V112, P417, DOI 10.1289/txg.6674; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Rasooly A, 2008, FOODBORNE PATHOG DIS, V5, P531, DOI 10.1089/fpd.2008.0119; Reamon-Buettner SM, 2008, MUTAT RES-REV MUTAT, V659, P158, DOI 10.1016/j.mrrev.2008.01.003; Reichmann J, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002486; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Rho JY, 2004, ENDOCR RES, V30, P257, DOI 10.1081/ERC-120039579; Ross JS, 2008, ONCOLOGIST, V13, P477, DOI 10.1634/theoncologist.2007-0248; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Roy JR, 2009, MED SCI MONITOR, V15, pRA137; Roy NC, 2011, BRIEF FUNCT GENOMICS, V10, P135, DOI 10.1093/bfgp/elr005; Saggar JK, 2010, NUTR CANCER, V62, P533, DOI 10.1080/01635580903532440; Saikia M, 2012, J BIOL CHEM, V287, P42708, DOI 10.1074/jbc.M112.371799; Salama J, 2003, ENVIRON HEALTH PERSP, V111, P1278, DOI 10.1289/ehp.6126; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Serafim TL, 2011, CHEM RES TOXICOL, V24, P763, DOI 10.1021/tx200126r; Shi C, 2013, PLATELETS, V24, P51, DOI 10.3109/09537104.2012.654839; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665; Simon-Areces J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021825; Solskov L, 2012, MOL CELL BIOCHEM, V360, P353, DOI 10.1007/s11010-011-1075-z; Sonderegger S, 2010, PLACENTA, V31, P839, DOI 10.1016/j.placenta.2010.07.011; SPIDIA EU, 2013, SPIDIA NEWSL; Stierum R, 2001, Nutr Metab Cardiovasc Dis, V11, P94; Stockwell SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028568; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Tabuchi Y, 2002, JPN J PHARMACOL, V89, P413, DOI 10.1254/jjp.89.413; Tanji Masao, 2004, Current Pharmacogenomics, V2, P255, DOI 10.2174/1570160043377529; Terasaka S, 2004, ENVIRON HEALTH PERSP, V112, P773, DOI 10.1289/txg.6753; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; van der Vos KE, 2012, NAT CELL BIOL, V14, P829, DOI 10.1038/ncb2536; van Dijk JP, 2010, REGUL TOXICOL PHARM, V58, pS21, DOI 10.1016/j.yrtph.2010.06.012; Van Hummelen P, 2010, MUTAT RES-REV MUTAT, V705, P165, DOI 10.1016/j.mrrev.2010.04.007; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Villas-Boas CSA, 2009, BRAZ J MED BIOL RES, V42, P1020, DOI 10.1590/S0100-879X2009001100004; Vivacqua A, 2009, MOL ENDOCRINOL, V23, P1815, DOI 10.1210/me.2009-0120; Wada-Kiyama Y, 2013, BIOCHEM BIOPH RES CO, V434, P287, DOI 10.1016/j.bbrc.2013.02.117; Walker PR, 2004, ARTIF INTELL MED, V31, P137, DOI 10.1016/j.artmed.2004.01.008; Wang SH, 2007, ENDOCRINOLOGY, V148, P4844, DOI 10.1210/en.2007-0126; Watanabe H, 2004, J MOL ENDOCRINOL, V33, P243, DOI 10.1677/jme.0.0330243; Watanabe H, 2002, GENES CELLS, V7, P497, DOI 10.1046/j.1365-2443.2002.00535.x; Werner H, 2012, LANCET ONCOL, V13, pE537, DOI 10.1016/S1470-2045(12)70362-5; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Yang Y, 2012, INFLAMMATION, V35, P1889, DOI 10.1007/s10753-012-9511-0; Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1093/toxsci/46.2.282; Zand RSR, 2000, BREAST CANCER RES TR, V62, P35, DOI 10.1023/A:1006422302173; Zeghouf M, 2005, BIOCHEM SOC T, V33, P1265; Zhang X, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-84; Zhu Y, 2012, ENVIRON POLLUT, V168, P10, DOI 10.1016/j.envpol.2012.04.005; Zhu Y, 2011, BIOTECHNOL LETT, V33, P1759, DOI 10.1007/s10529-011-0646-01720SPRINGER BASEL AGBASELPICASSOPLATZ 4, BASEL, 4052, SWITZERLANDCELL MOL LIFE SCIJUNDiscipline: Biochemistry &amp; Molecular Biology; Cell BiologyAH8DL</notes>
    <keywords>ACTIVATION FUNCTION; BIOLOGY; BISPHENOL-A; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CDNA MICROARRAY; CELL; CELLS; CHEMICALS; DNA microarray; Estrogen; ESTROGENS; EXPRESSION; Focused microarray; FOOD; FOOD SAFETY ASSESSMENT; gene expression; Gene expression profiling; GENE-EXPRESSION; GROWTH; In vitro; IN-VITRO; Inflammation; Liver; MCF-7 CELLS; NF-KAPPA-B; Phytoestrogen; PHYTOESTROGENS; RECEPTOR-ALPHA; RESPONSIVE GENES; Signal transduction; SIGNALING PATHWAYS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2065</startpage>
    <endpage>2082</endpage>
    <journalfull>Cellular and Molecular Life Sciences</journalfull>
    <issue>11</issue>
    <volume>71</volume>
    <abstract>We summarize updated information about DNA microarray-based gene expression profiling by focusing on its application to estrogenic chemicals. First, estrogenic chemicals, including natural/industrial estrogens and phytoestrogens, and the methods for detection and evaluation of estrogenic chemicals were overviewed along with a comprehensive list of estrogenic chemicals of natural or industrial origin. Second, gene expression profiling of chemicals using a focused microarray containing estrogen-responsive genes is summarized. Third, silent estrogens, a new type of estrogenic chemicals characterized by their estrogenic gene expression profiles without growth stimulative or inhibitory effects, have been identified so far exclusively by DNA microarray assay. Lastly, the prospect of a microarray assay is discussed, including issues such as commercialization, future directions of applications and quality control methods</abstract>
    <url>WOS:000336364200006</url>
    <isbnorissn>1420-682X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>157</id>
    <title>Cytotoxic effects of polycarbonate-based orthodontic brackets by activation of mitochondrial apoptotic mechanisms</title>
    <authors>Kloukos,D.; Taoufik,E.; Eliades,T.; Katsaros,C.; Eliades,G.</authors>
    <availability>[Kloukos, Dimitrios; Katsaros, Christos] Univ Bern, Fac Med, Dept Orthodont &amp; Dentofacial Orthoped, CH-3012 Bern, Switzerland. [Taoufik, Era] Hellenic Pasteur Inst, Dept Microbiol, Mol Genet Lab, Athens, Greece. [Eliades, Theodore] Univ Zurich, Fac Med, Dept Orthodont &amp; Paediat Dent, CH-8006 Zurich, Switzerland. [Eliades, George] Univ Athens, Sch Dent, Dept Biomat, Athens 11527, Greece.</availability>
    <date>2013</date>
    <notes>JEnglishArticleEliades, G (reprint author), Univ Athens, Sch Dent, Dept Biomat, 2 Thivon St, Athens 11527, Greecegeliad@dent.uoa.grAird JC, 1988, J ORTHODONTICS, V15, P87; Ali O, 2012, EUR J ORTHODONT, V34, P595, DOI 10.1093/ejo/cjr063; Alkire RG, 1997, DENT MATER, V13, P2, DOI 10.1016/S0109-5641(97)80001-2; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Artham T, 2008, MACROMOL BIOSCI, V8, P14, DOI 10.1002/mabi.200700106; Asahi J, 2010, LIFE SCI, V87, P431, DOI 10.1016/j.lfs.2010.08.007; Barrett J C, 1996, Prog Clin Biol Res, V394, P105; Chang MC, 2010, BIOMATERIALS, V31, P8164, DOI 10.1016/j.biomaterials.2010.07.049; Contreras RG, 2010, IN VIVO, V24, P513; Fehlberg S, 2003, BRIT J PHARMACOL, V139, P495, DOI 10.1038/sj.bjp.0705275; FELDNER JC, 1994, AM J ORTHOD DENTOFAC, V106, P265, DOI 10.1016/S0889-5406(94)70046-X; Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8; Goodson WH, 2011, CARCINOGENESIS, V32, P1724, DOI 10.1093/carcin/bgr196; Hangen E, 2010, TRENDS BIOCHEM SCI, V35, P278, DOI 10.1016/j.tibs.2009.12.008; Hashimoto Y, 2000, Dent Mater J, V19, P245; Hashimoto Y, 2000, J MATER SCI-MATER M, V11, P465, DOI 10.1023/A:1013009006522; Imai Y, 2000, Dent Mater J, V19, P133; Kadoma Y, 2000, Dent Mater J, V19, P139; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Li YJ, 2009, TOXICOL SCI, V108, P427, DOI 10.1093/toxsci/kfp024; Lubick N, 2010, ENVIRON HEALTH PERSP, V118, pA116, DOI 10.1289/ehp.118-a116a; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Nagamine M, 2003, CANCER SCI, V94, P338, DOI 10.1111/j.1349-7006.2003.tb01443.x; Nah Won Heum, 2011, Clin Exp Reprod Med, V38, P75, DOI 10.5653/cerm.2011.38.2.75; Nam SH, 2010, CHEMOSPHERE, V79, P949, DOI 10.1016/j.chemosphere.2010.02.049; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Schafer TE, 1999, J BIOMED MATER RES, V45, P192, DOI 10.1002/(SICI)1097-4636(19990605)45:3&lt;192::AID-JBM5&gt;3.0.CO;2-A; Silver MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026868; Suzuki K, 2001, DENT MATER J, V20, P353; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Terasaka H, 2005, ANTICANCER RES, V25, P2241; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Tsuda H, 2010, J PERIODONTAL RES, V45, P626, DOI 10.1111/j.1600-0765.2010.01277.x; Tsutsui T, 1997, ENVIRON HEALTH PERSP, V105, P619, DOI 10.2307/3433380; Vitral JCD, 2010, AM J ORTHOD DENTOFAC, V137, P247, DOI 10.1016/j.ajodo.2008.03.028; Wang Q, 2010, TOXICOL LETT, V199, P129, DOI 10.1016/j.toxlet.2010.08.014; Watanabe M, 2001, Dent Mater J, V20, P353; Watanabe Mariko, 2004, Journal of Medical and Dental Sciences, V51, P1; Wolstenholme JT, 2011, HORM BEHAV, V59, P296, DOI 10.1016/j.yhbeh.2010.10.001; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yu Bin, 2011, J Orthod, V38, P167, DOI 10.1179/14653121141434; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x; Zuccari AG, 1997, BIO-MED MATER ENG, V7, P327490ELSEVIER SCI LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDDENT MATERMARDiscipline: Dentistry, Oral Surgery &amp; Medicine; Materials Science087TU</notes>
    <keywords>ACTIVATION; apoptosis; breast; CANCER; CARCINOGENESIS; CELL; cell death; Cell proliferation; CELL-DEATH; CELL-PROLIFERATION; CELLS; CHEMICALS; Composition; Cytotoxicity; DEATH; DISRUPTOR BISPHENOL-A; EPITHELIAL-CELLS; Estrogen; estrogen signaling; Estrogenicity; EXPOSURE; EXPRESSION; HEALTH; IN-VITRO; IN-VIVO; INDUCTION; LINE; LINES; mechanism; MECHANISMS; MICE; Orthodontic brackets; Oxidative stress; Polycarbonates; proliferation; PROTEIN; RELEASE; SIGNALING PATHWAY; SIGNALING PATHWAYS; WATER; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>E35</startpage>
    <endpage>E44</endpage>
    <journalfull>Dental Materials</journalfull>
    <issue>3</issue>
    <volume>29</volume>
    <abstract>Objectives. The aim of the study was to evaluate the biological effects of water eluents from polycarbonate based esthetic orthodontic brackets. Methods. The composite polycarbonate brackets tested were Silkon Plus (SL, fiber-glass-reinforced), Elan ME (EL, ceramic particle-reinforced) and Elegance (EG, fiber-glass-reinforced). An unfilled polyoxymethylene bracket (Brilliant, BR) was used as control. The brackets' composition was analyzed by ATR-FTIR spectrometry. The cytotoxicity and estrogenicity of the eluents obtained after 3 months storage of the brackets in water (37 degrees C) were investigated in murine fibroblasts (NIH 3T3), breast (MCF-7) and cervical cancer (CCl-2/Hela) cell lines. Results. SL and EG were based on aromatic-polycarbonate matrix, whereas EL consisted of an aromatic polycarbonate-polyethylene terepthalate copolymer. A significant induction of cell death and a concurrent decrease in cell proliferation was noted in the EG eluent-treated cells. Moreover, EG eluent significantly reduced the levels of the estrogen signaling associated gene pS2, specifically in MCF7 cells, suggesting that cell death induced by this material is associated with downregulation of estrogen signaling pathways. Even though oxidative stress mechanisms were equally activated by all eluents, the EG eluents induced expression of apoptosis inducing factor (AIF) and reduced Bcl-xL protein levels. Significance. Some polycarbonate-based composite brackets when exposed to water release substances than activate mitochondrial apoptosis. (C) 2012 Academy of Dental Materials. Published by Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000314786900002</url>
    <isbnorissn>0109-5641</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>421</id>
    <title>Alkylphenol Xenoestrogens with Varying Carbon Chain Lengths Differentially and Potently Activate Signaling and Functional Responses in GH(3)/B-6/F10 Somatomammotropes</title>
    <authors>Kochukov,M.Y.; Jeng,Y.J.; Watson,C.S.</authors>
    <availability>[Kochukov, Mikhail Y.; Jeng, Yow-Jiun; Watson, Cheryl S.] Univ Texas Galveston, Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX 77550 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticleKochukov, MY (reprint author), Univ Texas Galveston, Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX 77550 USAAHEL M, 1993, ENVIRON POLLUT, V79, P243, DOI 10.1016/0269-7491(93)90096-7; Ahel M, 2000, WATER SCI TECHNOL, V42, P15; Bauer CK, 1998, J PHYSIOL-LONDON, V510, P63, DOI 10.1111/j.1469-7793.1998.063bz.x; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; BURBACK BL, 1993, APPL ENVIRON MICROB, V59, P1025; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chun TY, 2000, TOXICOL APPL PHARM, V162, P161, DOI 10.1006/taap.1999.8840; Cincinelli A, 2007, CHEMOSPHERE, V68, P472, DOI 10.1016/j.chemosphere.2006.12.089; Cincinelli A, 2003, ATMOS ENVIRON, V37, P3125, DOI 10.1016/S1352-2310(03)00298-X; CLARK LB, 1992, INT J ENVIRON AN CH, V47, P167, DOI 10.1080/03067319208027027; de Jager C, 1999, ANDROLOGIA, V31, P99, DOI 10.1046/j.1439-0272.1999.00245.x; de Jager C, 1999, ANDROLOGIA, V31, P107, DOI 10.1046/j.1439-0272.1999.00246.x; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Devillers J, 2006, SAR QSAR ENVIRON RES, V17, P393, DOI 10.1080/10629360600884397; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; Eudy JD, 1998, GENOMICS, V50, P382, DOI 10.1006/geno.1998.5345; Fukazawa H, 2001, CHEMOSPHERE, V44, P973, DOI 10.1016/S0045-6535(00)00507-5; Gallard H, 2004, CHEMOSPHERE, V56, P465, DOI 10.1016/j.chemosphere.2004.03.001; Glassmeier G, 2001, PFLUG ARCH EUR J PHY, V442, P577; Gross B, 2004, ENVIRON TOXICOL CHEM, V23, P2074, DOI 10.1897/03-606; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han XD, 2004, REPROD TOXICOL, V19, P215, DOI 10.1016/j.reprotox.2004.06.014; HEWSTONE RK, 1994, SCI TOTAL ENVIRON, V156, P243, DOI 10.1016/0048-9697(94)90191-0; Hossaini A, 2001, REPROD TOXICOL, V15, P537, DOI 10.1016/S0890-6238(01)00155-1; Hu JY, 2002, ENVIRON TOXICOL CHEM, V21, P2034, DOI 10.1897/1551-5028(2002)021&lt;2034:POACON&gt;2.0.CO;2; Isobe T, 2001, ENVIRON SCI TECHNOL, V35, P1041, DOI 10.1021/es001250i; Kwack SJ, 2002, J TOXICOL ENV HEAL A, V65, P419, DOI 10.1080/15287390252808082; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Liu X, 2007, FEBS J, V274, P6340, DOI 10.1111/j.1742-4658.2007.06152.x; LUNDH TJO, 1990, J AGR FOOD CHEM, V38, P1530, DOI 10.1021/jf00097a022; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Moon HJ, 2007, J REPROD DEVELOP, V53, P333, DOI 10.1262/jrd.18055; *NAT CTR BIOT INF, 2009, PUBCHEM; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; PAPPAS TC, 1995, ENDOCRINE, V3, P743, DOI 10.1007/BF03000207; Petrovic M, 2003, ENVIRON SCI TECHNOL, V37, P4442, DOI 10.1021/es034139w; Routledge EJ, 1997, J BIOL CHEM, V272, P3280; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; Stroev EA, 2001, B EXP BIOL MED+, V131, P124, DOI 10.1023/A:1017575424807; SUMPTER JP, 1993, LANCET, V342, P124; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Tabira Y, 1999, EUR J BIOCHEM, V262, P240, DOI 10.1046/j.1432-1327.1999.00422.x; Tan BLL, 2003, TALANTA, V61, P385, DOI 10.1016/S0039-9140(03)00281-9; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Watson CS, 2008, FASEB J, V22, P3328, DOI 10.1096/fj.08-107672; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; Woclawek-Potocka I, 2006, J REPROD DEVELOP, V52, P731, DOI 10.1262/jrd.18057; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Ying GG, 2002, ENVIRON INT, V28, P215, DOI 10.1016/S0160-4120(02)00017-X; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr9586128US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPMAYDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology440SZ</notes>
    <keywords>1; 17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; Alkylphenol; ALKYLPHENOLS; ASSAY; Behavior; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; calcium oscillation; CANCER; CARBON; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; COMPLEXES; DRINKING-WATER; E2; ENDOCRINE; ERK activation; ESTRADIOL; Estrogen; ESTROGEN-RECEPTOR; Estrogenic; ESTROGENIC ACTIVITIES; estrogenic activity; ESTROGENS; FOOD; HEALTH; hydrophobicity; KINASE; MASS-SPECTROMETRY; non-genomic response; Nongenomic; NONGENOMIC ACTIONS; nongenomic effects; Nonylphenol; Occupational; PHOSPHORYLATION; PLASMA-MEMBRANE; prolactin release; PROLACTIN-RELEASE; proliferation; RAT ANTERIOR-PITUITARY; RELEASE; RESPONSES; signaling; Steroid; THYROTROPIN-RELEASING-HORMONE; toxicology; TUMOR; TUMOR CELLS; WATER; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>723</startpage>
    <endpage>730</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>5</issue>
    <volume>117</volume>
    <abstract>BACKGROUND: Alkylphenols varying in their side-chain lengths [ethyl-, propyl, octyl-, and nonylphenol (EP, PIP, OP, and NP, respectively)] and bisphenol A (BPA) represent a large group of structurally related xenoestrogens that have endocrine-disruptive effects. Their rapid nongenomic effects that depend on structure for cell signaling and resulting functions are unknown. OBJECTIVES: We compared nongenomic estrogenic activities of alkylphenols with BPA and 17 beta-estradiol (E-2) in membrane estrogen receptor-alpha-enriched GH(3)/B-6/F10 pituitary tumor cells. These actions included calcium (Ca) signaling, prolactin (PRL) release, extracellular-regulated kinase (ERK) phosphorylation, and cell proliferation. METHODS: We imaged Ca using fura-2, measured PRL release via radioimmunoassay, detected ERK phosphorylation by fixed cell immunoassay, and estimated cell number using the crystal violet assay. RESULTS: All compounds caused increases in Ca oscillation frequency and intracellular Ca volume at 100 N to 1 nM concentrations, although long-chain alkylphenols were most effective. All estrogens caused rapid PRL release at concentrations as low as 1 fM to 10 pM; the potency of EP, PP, and NP exceeded that of E-2. All compounds at 1 nM produced similar increases in ERK phosphorylation, causing rapid peaks at 2.5-5 min, followed by inactivation and additional 60-min peaks (except for BPA). Dose-response patterns of ERK activation at 5 min were similar for E-2, BPA, and PIP, whereas EP caused larger effects. Only E-2 and NP increased cell number. Some rapid estrogenic responses showed correlations with the hydrophobicity of estrogenic molecules; the more hydrophobic OP and NP were superior at Ca and cell proliferation responses, whereas the less hydrophobic EP and PP were better at ERK activations. CONCLUSIONS: Alkylphenols are potent estrogens in evoking these nongenomic responses contributing to complex functions; their hydrophobicity can largely predict these behaviors</abstract>
    <url>WOS:000265721300023</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>78</id>
    <title>Relationship between everyday use cosmetics and female breast cancer</title>
    <authors>Konduracka,E.; Krzemieniecki,K.; Gajos,G.</authors>
    <availability>[Konduracka, Ewa; Gajos, Grzegorz] Uniwersytet Jagiellonski, Coll Med, John Paul II Hosp, Dept Coronary Dis &amp; Heart Failure, PL-31202 Krakow, Poland. [Krzemieniecki, Krzysztof] Uniwersytet Jagiellonski, Coll Med, Dept Clin Oncol, PL-31202 Krakow, Poland.</availability>
    <date>2014</date>
    <notes>JEnglishReviewKonduracka, E (reprint author), Uniwersytet Jagiellonski, Coll Med, Krakowski Szpital Specjalistyczny Jana Pawla 2, Klin Choroby Wiencowej &amp; Niewydolnosci Serca, Ul Pradnicka 80, PL-31202 Krakow, Polandekonduracka@interia.euBaan R, 2009, LANCET ONCOL, V10, P1143; Barr L, 2012, J APPL TOXICOL, V32, P219, DOI 10.1002/jat.1786; Boberg J, 2010, REPROD TOXICOL, V30, P301, DOI 10.1016/j.reprotox.2010.03.011; Castelain F, 2012, EUR J DERMATOL, V22, P723, DOI 10.1684/ejd.2012.1835; Centers for Disease Control and Prevention (CDC), 2012, 4 CDCP; Chen JG, 2007, TOXICOL APPL PHARM, V221, P278, DOI 10.1016/j.taap.2007.03.015; Crinnion WJ, 2010, ALTERN MED REV, V15, P190; Darbre PD, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2424; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2013, J INORG BIOCHEM, V128, P257, DOI 10.1016/j.jinorgbio.2013.07.005; Darbre PD, 2005, J INORG BIOCHEM, V99, P1912, DOI 10.1016/j.jinorgbio.2005.06.001; Darbre PD, 2004, J APPL TOXICOL, V24, P5, DOI 10.1002/jat.958; Elder RL, 1984, INT J TOXICOL, V3, P147; Fakri S, 2006, East Mediterr Health J, V12, P478; Fucic A, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-S1-S8; Haighton LA, 2002, REGUL TOXICOL PHARM, V35, P238, DOI 10.1006/rtph.2001.1525; Henley DV, 2007, NEW ENGL J MED, V356, P479, DOI 10.1056/NEJMoa064725; Hsieh TH, 2012, FASEB J, V26, P782; IARC, 1994, IARC MON EV CARC RIS, V60; Janjua NR, 2007, ENVIRON SCI TECHNOL, V41, P5564, DOI 10.1021/es0628755; Kay VR, 2013, CRIT REV TOXICOL, V43, P200, DOI 10.3109/10408444.2013.766149; Khanna S, 2013, J APPL TOXICOL, V33, P378, DOI 10.1002/jat.2753; Kreatsoulas C, 2013, POL ARCH MED WEWN, V123, P112; Lopez-Carrillo L, 2010, ENVIRON HEALTH PERSP, V118, P539, DOI 10.1289/ehp.0901091; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Macon MB, 2013, J MAMMARY GLAND BIOL, V18, P43, DOI 10.1007/s10911-013-9275-7; Meeker JD, 2011, ENVIRON HEALTH PERSP, V119, P252, DOI 10.1289/ehp.1002238; Merlo DF, 2012, BREAST CANCER RES TR, V134, P363, DOI 10.1007/s10549-012-2031-7; Micheli A, 2002, ANN ONCOL, V13, P840, DOI 10.1093/annonc/mdf127; Mikoczy Z, 2011, INT J ENV RES PUBLIC, V8; Mirick DK, 2002, J NATL CANCER I, V94, P1578; Muti P, 2013, POL ARCH MED WEWN, V123, P112; Prusakiewicz JJ, 2007, TOXICOLOGY, V232, P248, DOI 10.1016/j.tox.2007.01.010; Rodrigues-Peres RM, 2013, BMC CANCER, V13, P104; Romanowicz-Makowska H, 2011, POL J PATHOL, V62, P257; Sanclemente-Anso C, 2013, POL ARCH MED WEWN, V123, P582; Sappino AP, 2012, J APPL TOXICOL, V32, P233, DOI 10.1002/jat.1793; Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143; Steenland K, 2003, CANCER CAUSE CONTROL, V14, P531, DOI 10.1023/A:1024891529592; Wrobel A, 2013, PHARMACOL REP, V65, P484400MEDYCYNA PRAKTYCZNAKRAKOWUL KRAKOWSKA 41, KRAKOW, 31-066, POLANDPOL ARCH MED WEWNDiscipline: General &amp; Internal MedicineAK9VO</notes>
    <keywords>ALUMINUM; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; Carcinogenicity; CELL; CELLS; CHEMICALS; cosmetics; DIAGNOSIS; DNA-DAMAGE; ENVIRONMENTAL-FACTORS; EPITHELIAL-CELLS; Estrogen; EXPOSURE; GLAND; GROWTH; HORMONE-LEVELS; HUMANS; MAMMARY-GLAND; METABOLISM; PARABENS; phthalate; Phthalates; PREVENTION; THERAPY; TISSUE; toxicology; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>264</startpage>
    <endpage>269</endpage>
    <journalfull>Polskie Archiwum Medycyny Wewnetrznej-Polish Archives of Internal Medicine</journalfull>
    <issue>5</issue>
    <volume>124</volume>
    <abstract>Data of the European Cancer Registries indicate that the incidence of breast cancer, which is the most common cancer among women, tends to increase not only in postmenopausal but also in very young women. The potential causes of breast cancer are genetic predisposition, long-term hormonal replacement therapy, alcohol, environmental pollution, and possibly modern lifestyle. The controversial results of several studies suggest that certain everyday-use products (including cosmetic ingredients) may be linked to breast cancer. Some of these ingredients, such as ethylene oxide, have recently been classified by the International Agency for Research for Cancer as carcinogenic and mutagenic to humans, with sufficient evidence of carcinogenicity for breast cancer. Other ingredients, such as xenoestrogens, are chemicals which have an estrogen-like effect or disrupt the normal metabolism of the natural estrogen and thus act as carcinogens. Some of them have been shown to result in DNA damage in animal and human mammary epithelial cells and, therefore, have the potential to generate genomic instability in the breast tissue. Examples of xenoestrogens with such properties include parabens, aluminium salts, phthalates, or bisophenol A. No sufficient epidemiological data on humans have been published so far, and the effects of a mixture of chemicals to which women are exposed during lifetime on the incidence of breast cancer have not been investigated. However, the results of the available studies emphasize the need for analysis of adverse environmental factors, which, in addition to a genetic predisposition and natural aging, may contribute to the increased incidence of breast cancer</abstract>
    <url>WOS:000338776700006</url>
    <isbnorissn>0032-3772</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>99</id>
    <title>Individual and combined developmental toxicity assessment of bisphenol A and genistein using the embryonic stem cell test in vitro</title>
    <authors>Kong,D.; Xing,L.N.; Liu,R.; Jiang,J.J.; Wang,W.Y.; Shang,L.Q.; Wei,X.T.; Hao,W.D.</authors>
    <availability>[Kong, Dan; Xing, Lina; Liu, Ran; Jiang, Jianjun; Wang, Wanyi; Shang, Lanqin; Wei, Xuetao; Hao, Weidong] Peking Univ, Beijing Key Lab Toxicol Res &amp; Risk Assessment Foo, Dept Toxicol, Sch Publ Hlth, Beijing 100191, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleHao, WD (reprint author), Peking Univ, Hlth Sci Ctr, Dept Toxicol, Sch Publ Hlth, 38 Xue Yuan Rd, Beijing 100191, Peoples R Chinawhao@bjmu.edu.cnAdlercreutz H, 1999, AM J OBSTET GYNECOL, V180, P737, DOI 10.1016/S0002-9378(99)70281-4; Adlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470-2045(02)00777-5; [Anonymous], 2012, 115 ECETOC; Anthony MS, 1996, J NUTR, V126, P43; Atteritano M, 2008, EUR J PHARMACOL, V589, P22, DOI 10.1016/j.ejphar.2008.04.049; Balls Michael, 2002, Altern Lab Anim, V30, P265; Buesen R, 2004, ALTEX-ALTERN TIEREXP, V21, P15; Busby MG, 2002, AM J CLIN NUTR, V75, P126; Cabaton N. J., 2010, ENV HLTH PERSPECT, V119, P547, DOI DOI 10.1289/EHP.1002559; Cao XL, 2009, J AGR FOOD CHEM, V57, P1307, DOI 10.1021/jf803213g; CASSIDY A, 1994, AM J CLIN NUTR, V60, P333; Gennings C, 2005, TOXICOL SCI, V88, P287, DOI 10.1093/toxsci/kfi275; Groten JP, 1996, FOOD CHEM TOXICOL, V34, P1083, DOI 10.1016/S0278-6915(97)00078-1; Groten JP, 2000, FOOD CHEM TOXICOL, V38, pS65, DOI 10.1016/S0278-6915(99)00135-0; Holtcamp W, 2011, ENVIRON HEALTH PERSP, V119, pA383, DOI 10.1289/ehp.119-a383; Ishimi Y, 1999, ENDOCRINOLOGY, V140, P1893, DOI 10.1210/en.140.4.1893; Jin Y, 2007, J BIOMED SCI, V14, P275, DOI 10.1007/s11373-006-9142-2; Kim K, 2009, J TOXICOL ENV HEAL A, V72, P1343, DOI 10.1080/15287390903212501; Klein CB, 2007, TOXICOL APPL PHARM, V224, P1, DOI 10.1016/j.taap.2007.06.022; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; LASCHINSKI G, 1991, REPROD TOXICOL, V5, P57, DOI 10.1016/0890-6238(91)90111-R; Lin LL, 2006, AQUAT TOXICOL, V80, P382, DOI 10.1016/j.aquatox.2006.10.004; Marini H, 2007, ANN INTERN MED, V146, P839; Marx-Stoelting P, 2009, ATLA-ALTERN LAB ANIM, V37, P313; McMichael-Phillips DF, 1998, AM J CLIN NUTR, V68, p1431S; Messina M, 2006, J AOAC INT, V89, P1121; Okada M, 2010, INT J MOL SCI, V11, P4114, DOI 10.3390/ijms11104114; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Ramamoorthy K, 1997, SCIENCE, V275, P405, DOI 10.1126/science.275.5298.405; Rozman KK, 2006, BIRTH DEFECTS RES B, V77, P485, DOI 10.1002/bdrb.20087; Saili KS, 2013, REPROD TOXICOL, V38, P89, DOI 10.1016/j.reprotox.2013.03.009; Sanchez Y, 2009, BIOCHEM PHARMACOL, V77, P384, DOI 10.1016/j.bcp.2008.10.035; Sato N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019278; Schwengberg S, 2005, J DENT, V33, P49, DOI 10.1016/j.jdent.2004.08.001; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Sonee M, 2004, NEUROTOXICOLOGY, V25, P885, DOI 10.1016/j.neuro.2003.11.001; Steven F., 1997, BIOCHEM BIOPH RES CO, V235, P336; Sun LW, 2009, CHEMOSPHERE, V75, P410, DOI 10.1016/j.chemosphere.2008.11.083; Suzuki K, 2002, INT J CANCER, V99, P846, DOI 10.1002/ijc.10428; The National Toxicology Program-Center for the Evaluation of Risks to Human Reporduction (NTP-CERHR), 2008, NTP BRIEF BISPH A; The National Toxicology Program-Center for the Evaluation of Risks to Human Reporduction (NTP-CERHR), 2006, NTP CERHR EXP PAN RE; Trock BJ, 2006, J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Whitten PL, 2001, ENVIRON HEALTH PERSP, V109, P5, DOI 10.2307/3434842; Williamson-Hughes PS, 2006, MENOPAUSE, V13, P831, DOI 10.1097/01.gme.0000227330.49081.9c; Wobus AM, 2011, ARCH TOXICOL, V85, P79, DOI 10.1007/s00204-010-0641-6; Xiao Y, 2011, TOXICOL IN VITRO, V25, P153, DOI 10.1016/j.tiv.2010.10.010; Xing LN, 2010, TOXICOL SCI, V115, P577, DOI 10.1093/toxsci/kfq081; Yamamoto Megumi, 2007, J Toxicol Sci, V32, P301, DOI 10.2131/jts.32.301; Yu Zhou, 2008, Wei Sheng Yan Jiu, V37, P570; Zhou J, 2011, CHEMOSPHERE, V82, P443, DOI 10.1016/j.chemosphere.2010.09.056532PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLOCTDiscipline: Food Science &amp; Technology; Toxicology228ZN</notes>
    <keywords>BINARY-MIXTURES; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER RISK; CANCER; CELL; CELL-PROLIFERATION; CELLS; CHEMICALS; CLASSIFICATION; Combined effect; Differentiation; Embronic stem cell test; Embryotoxicity; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Environmental oestrogen; EXPOSURE; FOOD; GENE-EXPRESSION; genistein; In vitro; IN-VITRO; Interaction; MODEL; PHYTO-ESTROGENS; PHYTOESTROGEN GENISTEIN; POSTMENOPAUSAL WOMEN; proliferation; RISK; SOY ISOFLAVONE; STEM-CELLS; TEST EST; TOXICITY; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>497</startpage>
    <endpage>505</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <volume>60</volume>
    <abstract>The potential developmental toxicity of environmental estrogenic endocrine disruptors have become a great concern in recent years. In this study, two typical environmental oestrogen, namely, bisphenol A (BPA) and genistein (GEN) were investigated for potential embryotoxicity using the embryonic stem cell test model. Afterwards, a 4 x 4 full factorial design and the estimated marginal means plot were performed to assess the combined effects of these two compounds. According to the linear discriminant functions and classification criteria, bisphenol A and genistein were classified as weakly embryotoxic and strongly embryotoxic respectively. As for combined effects, the overall interaction between BPA and GEN on embryonic stem cells (ESCs) differentiation was synergistic at low dosages, however, on ESCs and 3T3 cell proliferation, the predominate action was additive. Considering the actual daily intake of these chemicals, it is concluded that BPA alone might not have adverse reproductive or developmental effects on human being. However, given that BPA and GEN do have synergistic effect at low concentration, they may disturb normal embryo development together, which could result in birth defect and behavioral alterations later in life. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000325231700061</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>104</id>
    <title>BPA as a Mammary Carcinogen Early Findings Reported in Rats</title>
    <authors>Konkel,L.</authors>
    <date>2013</date>
    <notes>JEnglishNews ItemAcevedo N, 2013, ENVIRON HEALTH PERSP, V121, P1040, DOI 10.1289/ehp.1306734; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Ikezaki S, 2011, J TOXICOL PATHOL, V24, P37, DOI 10.1293/tox.24.37; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Potischman N, 1999, CANCER CAUSE CONTROL, V10, P561, DOI 10.1023/A:1008955110868; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P1053, DOI 10.1289/ehp.1002864; Son WC, 2004, TOXICOL PATHOL, V32, P371, DOI 10.1080/01926230490440871; Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716111US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPSEPDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology227XS</notes>
    <keywords>BISPHENOL-A; BPA; BREAST-CANCER; CANCER; EXPOSURE; GLAND; GLAND DEVELOPMENT; IN-UTERO; MAMMARY-GLAND; RAT; RATS; RISK; SPRAGUE-DAWLEY RATS; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>A284</startpage>
    <endpage>A284</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>9</issue>
    <volume>121</volume>
    <url>WOS:000325149600009</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>61</id>
    <title>Oral Bisphenol A (BPA) given to rats at moderate doses is associated with erectile dysfunction, cavernosal lipofibrosis and alterations of global gene transcription</title>
    <authors>Kovanecz,I.; Gelfand,R.; Masouminia,M.; Gharib,S.; Segura,D.; Vernet,D.; Rajfer,J.; Li,D.K.; Kannan,K.; Gonzalez-Cadavid,N.F.</authors>
    <availability>[Kovanecz, I.; Gelfand, R.; Masouminia, M.; Gharib, S.; Segura, D.; Vernet, D.; Rajfer, J.; Gonzalez-Cadavid, N. F.] UCLA, Med Ctr, Los Angeles Biomed Res Inst, Div Urol,Dept Surg, Torrance, CA 90502 USA. [Kovanecz, I.; Rajfer, J.; Gonzalez-Cadavid, N. F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Gelfand, R.; Vernet, D.; Gonzalez-Cadavid, N. F.] Charles Drew Univ Med &amp; Sci, Div Endocrinol, Los Angeles, CA USA. [Li, D. K.] Stanford Univ, Dept Hlth Res &amp; Policy, Stanford, CA 94305 USA. [Li, D. K.] Kaiser Permanente, Div Res, Oakland, CA USA. [Kannan, K.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleGonzalez-Cadavid, NF (reprint author), UCLA, Med Ctr, LABioMed Harbor, Urol Res Lab, Bldg C3,1124 West Carson St, Torrance, CA 90502 USAncadavid@ucla.eduAndersson KE, 2000, INT J IMPOT RES, V12, pS26, DOI 10.1038/sj.ijir.3900574; [Anonymous], 2008, NIH PUBL; Avissar-Whiting M, 2010, REPROD TOXICOL, V29, P401, DOI 10.1016/j.reprotox.2010.04.004; Burnett AL, 2006, J UROLOGY, V175, pS25, DOI 10.1016/S0022-5347(05)00309-5; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cappelleri JC, 2001, CLIN THER, V23, P1707, DOI 10.1016/S0149-2918(01)80138-7; Carew RM, 2012, CELL TISSUE RES, V347, P103, DOI 10.1007/s00441-011-1227-1; Carwile JL, 2011, JAMA-J AM MED ASSOC, V306, P2218, DOI 10.1001/jama.2011.1721; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Fuxe J, 2012, SEMIN CANCER BIOL, V22, P455, DOI 10.1016/j.semcancer.2012.05.004; Gelfand R, 2011, J SEX MED, V8, P6; Giuliano F, 2004, PHYSIOL BEHAV, V83, P189, DOI 10.1016/j.physbeh.2004.08.014; Guo L, 2012, HYPERTENSION, V59, P1006, DOI 10.1161/HYPERTENSIONAHA.111.185413; Guttilla IK, 2012, TRENDS ENDOCRIN MET, V23, P73, DOI 10.1016/j.tem.2011.12.001; He Y, 2013, BIOCHIMIE, V95, P1355, DOI 10.1016/j.biochi.2013.03.010; He YH, 2009, J OCCUP HEALTH, V51, P432; He YH, 2009, ENVIRON RES, V109, P629, DOI 10.1016/j.envres.2009.04.003; Kandaraki E, 2011, J CLIN ENDOCR METAB, V96, pE480, DOI 10.1210/jc.2010-1658; Karagiannis GS, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-4; Kato H, 2006, REPROD TOXICOL, V22, P20, DOI 10.1016/j.reprotox.2005.10.003; Kim K, 2007, J TOXICOL ENV HEAL A, V70, P1288, DOI 10.1080/15287390701434216; Kovanecz I, 2008, BJU INT, V101, P203, DOI 10.1111/j.1464-410X.2007.07223.x; Kovanecz I, 2012, J SEX MED, V9, P2814, DOI 10.1111/j.1743-6109.2012.02913.x; Kovanecz I, 2013, J SEX MED, V10, P2952, DOI 10.1111/jsm.12336; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Li DK, 2011, FERTIL STERIL, V95, P625, DOI 10.1016/j.fertnstert.2010.09.026; Li DK, 2010, J ANDROL, V31, P500, DOI 10.2164/jandrol.110.010413; Liao CY, 2011, ENVIRON SCI TECHNOL, V45, P6761, DOI 10.1021/es200977t; Liao CY, 2011, ENVIRON SCI TECHNOL, V45, P9372, DOI 10.1021/es202507f; Liu XH, 2010, J BIOCHEM, V148, P247, DOI 10.1093/jb/mvq056; Magee TR, 2007, J SEX MED, V4, P633, DOI 10.1111/j.1743-6109.2007.00459.x; Mathieu J, 2013, ADV EXP MED BIOL, V786, P329, DOI 10.1007/978-94-007-6621-1_18; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Moon DG, 2001, INT J IMPOT RES, V13, P309, DOI 10.1038/sj.ijir.3900734; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Nehra A, 1996, J UROLOGY, V156, P1320, DOI 10.1016/S0022-5347(01)65578-2; Nehra A, 1998, J UROLOGY, V159, P2229, DOI 10.1016/S0022-5347(01)63311-1; Nolazco G, 2008, BJU INT, V101, P1156, DOI 10.1111/j.1464-410X.2008.07507.x; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Olivieri F., 2013, AGEING RES REV; Patel V, 2012, CURR OPIN NEPHROL HY, V21, P410, DOI 10.1097/MNH.0b013e328354e559; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Primo MN, 2012, CYTOKINE, V60, P741, DOI 10.1016/j.cyto.2012.07.031; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Ramachandran S, 2013, AM J RESP CELL MOL, V49, P544, DOI 10.1165/rcmb.2012-0430OC; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Richter CA, 2007, ENVIRON HEALTH PERSP, V115, P902, DOI 10.1289/ehp.9804; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Sharpe RM, 2010, HUM REPROD, V25, P292, DOI 10.1093/humrep/dep385; Shiraishi S, 2008, CLIN CHEM, V54, P1855, DOI 10.1373/clinchem.2008.103846; Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Tsao J, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt152; Vernet D, 2011, P 102 ANN M 2011 AM; Vernet D, 2009, J UROLOGY, V181, P43; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Yang LQ, 2013, TOXICOL LETT, V218, P187, DOI 10.1016/j.toxlet.2013.01.026; Ye LP, 2011, TOXICOL LETT, V207, P137, DOI 10.1016/j.toxlet.2011.09.001; Zhao J, 2013, ARTERIOSCL THROM VAS, V33, P257, DOI 10.1161/ATVBAHA.112.300200590NATURE PUBLISHING GROUPLONDONMACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLANDINT J IMPOT RESMAR-APRDiscipline: Urology &amp; NephrologyAD0TB</notes>
    <keywords>apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; CELL-CYCLE; CELLS; corporal veno-occlusive dysfunction; CYCLE; Cytokine; Endocrine disruptor; epithelial mesenchymal transition; EPITHELIAL-MESENCHYMAL TRANSITION; erectile dysfunction; ESTRADIOL; EXPOSURE; EXPRESSION; fibrosis; gene expression; GENE-EXPRESSION; INDUCTION; Inflammation; MECHANISMS; microRNA; MICRORNAS; OCCUPATIONAL-EXPOSURE; RAT; RATS; RECEPTOR; SEXUAL DYSFUNCTION; SMOOTH-MUSCLE-CELLS; STEM-CELLS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>67</startpage>
    <endpage>75</endpage>
    <journalfull>International Journal of Impotence Research</journalfull>
    <issue>2</issue>
    <volume>26</volume>
    <abstract>Bisphenol A (BPA), a suspected reproductive biohazard and endocrine disruptor, released from plastics is associated with ED in occupationally exposed workers. However, in rats, despite the induction of hypogonadism, apoptosis of the penile corporal smooth muscle (SM), fat infiltration into the cavernosal tissue and changes in global gene expression with the intraperitoneal administration of high dose BPA, ED was not observed. We investigated whether BPA administered orally rather than intraperitoneally to rats for longer periods and lower doses will lead to ED. Main outcome measures are ED, histological, and biochemical markers in rat penile tissues. In all, 2.5-month-old rats were given drinking water daily without and with BPA at 1 and 0.1 mg kg(-1) per day. Two months later, erectile function was determined by cavernosometry and electrical field stimulation (EFS) and serum levels of testosterone (T), estradiol (E2) and BPA were measured. Penile tissue sections were assayed by Masson (SM/collagen), Oil Red O (fat), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) (apoptosis), immunohistochemistry for Oct4 (stem cells), and alpha-SM actin/calponin (SM and myofibroblasts), applying quantitative image analysis. Other markers were assayed by western blotting. DNA microarrays/microRNA (miR) assays defined transcription profiles. Orally administered BPA did not affect body weight, but (1) decreased serum T and E2; (2) reduced the EFS response and increased the drop rate; (3) increased within the corporal tissue the presence of fat, myofibroblasts and apoptosis; (4) lowered the contents of SM and stem cells, but not nerve terminals; and (5) caused alterations in the transcriptional profiles for both mRNA and miRs within the penile shaft. Long-term exposure of rats to oral BPA caused a moderate corporal veno-occlusive dysfunction (CVOD), possibly due to alterations within the corporal tissue that pose gene transcriptional changes related to inflammation, fibrosis and epithelial/mesenchymal transition (EMT)</abstract>
    <url>WOS:000332945900006</url>
    <isbnorissn>0955-9930</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>377</id>
    <title>Effect-related monitoring: estrogen-like substances in groundwater</title>
    <authors>Kuch,B.; Kern,F.; Metzger,J.W.; von der Trenck,K.T.</authors>
    <availability>[Kern, Frieder; von der Trenck, Karl Theo] Landesanstalt Umwelt Messungen &amp; Nat Schutz Baden, D-76185 Karlsruhe, Germany. [Kuch, Bertram; Metzger, Joerg W.] Inst Siedlungswasserbau Wassergute &amp; Abfallwi, D-70569 Stuttgart, Germany.</availability>
    <date>2010</date>
    <notes>JEnglishArticlevon der Trenck, KT (reprint author), Landesanstalt Umwelt Messungen &amp; Nat Schutz Baden, Griesbachstr 1-3, D-76185 Karlsruhe, Germanytheo.v.d.trenck@lubw.bwl.deAerni HR, 2004, ANAL BIOANAL CHEM, V378, P688, DOI 10.1007/s00216-003-2276-4; BMU-Bundesministerium fur Umwelt Naturschutz und Reaktorsicherheit, 1999, BUND BOD ALT BBODSCH, P1554; BOLZ U, 2000, THESIS TUBINGEN U; Buckman AH, 2004, ENVIRON TOXICOL CHEM, V23, P1725, DOI 10.1897/03-336; DUIS K, 2003, 02WA99806 BMFTPROJEC, pS1; *EC, 2003, 9367EEC EC; *EU, 2003, DRINK WAT SEM SEM DR; Fertuck KC, 2001, TOXICOL LETT, V121, P167, DOI 10.1016/S0378-4274(01)00344-7; Gierthy JF, 1997, CHEMOSPHERE, V34, P1495, DOI 10.1016/S0045-6535(97)00446-3; Grist EPM, 2003, ENVIRON SCI TECHNOL, V37, P1609, DOI 10.1021/es020086r; GULDEN M, 1997, 97068 UBAFB; Hollert H, 2005, ENVIRON SCI POLLUT R, V12, P347, DOI 10.1065/espr2005.07.273; Hovander L, 2002, ARCH ENVIRON CON TOX, V42, P105; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; KHIM JS, 2000, ORGANOHALOG COMPD, V49, P174; Kidd KA, 2007, P NATL ACAD SCI USA, V104, P8897, DOI 10.1073/pnas.0609568104; Korner W, 1999, SCI TOTAL ENVIRON, V225, P33; KORNER W, 2000, THESIS TUBINGEN U; KORNER W, 1999, ENTWICKLUNG PRAKTISC; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P106, DOI 10.1289/ehp.9358; KUCH B, 2003, 530001 UVM O; Kuch HM, 2001, ENVIRON SCI TECHNOL, V35, P3201, DOI 10.1021/es010034m; KUROKI H, 2001, ORGANOHALOG COMPD, V53, P80; Lange R, 2001, ENVIRON TOXICOL CHEM, V20, P1216, DOI 10.1897/1551-5028(2001)020&lt;1216:EOTSEE&gt;2.0.CO;2; Legler J., 2002, ORGANOHALOG COMPD, V56, P53; Machala M, 2004, CHEM RES TOXICOL, V17, P340, DOI 10.1021/tx030034v; Machala M, 2001, ENVIRON TOXICOL CHEM, V20, P2736, DOI 10.1897/1551-5028(2001)020&lt;2736:AHRMAE&gt;2.0.CO;2; Meerts A. T. M., 2001, ENV HLTH PERSPECT, V109, P399; Miller D, 2001, ENVIRON HEALTH PERSP, V109, P133, DOI 10.2307/3434765; Miyazaki W, 2004, J BIOL CHEM, V279, P18195, DOI 10.1074/jbc.M310531200; Nash JP, 2004, ENVIRON HEALTH PERSP, V112, P1725, DOI 10.1289/ehp.7209; Pelley J, 2003, ENVIRON SCI TECHNOL, V37, p313A, DOI 10.1021/es032555a; Pickering AD, 2003, ENVIRON SCI TECHNOL, V37, p331A, DOI 10.1021/es032570f; Rahtkens Kay, 2007, Umweltwissenschaften und Schadstoff-Forschung, V19, P27; Routledge EJ, 1996, ENVIRON TOXICOL CHEM, V15, P241, DOI 10.1897/1551-5028(1996)015&lt;0241:EAOSAS&gt;2.3.CO;2; SAFE SH, 1998, HORMONALLY ACTIVE AG, P200; Santodonato J, 1997, CHEMOSPHERE, V34, P835, DOI 10.1016/S0045-6535(97)00012-X; Schultis T., 2005, THESIS U STUTTGART; Shekan P., 1990, JNCI-J NATL CANCER I, V82, P1107; SONZOGNI W, 2006, OCCURRENCE ESTROGENI; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SUTER MJF, 2002, EAWAG NEWS APR, P24; *UBA, 2007, REV END DISR SUBST P; VDTRENCK KT, 1994, ENVIRON SCI POLLUT R, V1, P253; Trenck K.-T. v. d., 1997, Umweltwissenschaften und Schadstoff-Forschung, V9, P97; VDTRENCK KT, 2001, HDB UMWELTCHEMIKALIC, V1; Villeneuve DL, 2002, ENVIRON TOXICOL, V17, P128, DOI 10.1002/tox.10041; Yang Jianjun, 2002, Wei Sheng Yan Jiu, V31, P1544918SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYENVIRON SCI POLLUT RFEBDiscipline: Environmental Sciences &amp; Ecology546YQ</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACID ESTERS; Alkylphenol; ALKYLPHENOLS; ARYL-HYDROCARBON; ASSAY; bisphenol A; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; Chemical compounds; COMPONENTS; Contaminated site; detection; Determination; E-SCREEN; E-SCREEN ASSAY; ENDOCRINE DISRUPTORS; ESTERS; ESTRADIOL; ESTROGENIC ACTIVITIES; estrogenic activity; Estrogenicity; EXPOSURE; Gas chromatography/mass spectrometry (GC/MS); groundwater; Guide value; HEALTH; Hormone; Hormones; HUMAN-BREAST-CANCER; HYDROXYLATED PCB METABOLITES; In vitro; IN-VITRO; Landfill; MINNOW PIMEPHALES-PROMELAS; Nonylphenol; phthalic acid; PLANT EFFLUENTS; POLYCYCLIC AROMATIC-HYDROCARBONS; QUANTIFICATION; RAINBOW-TROUT; RECEPTOR; RISK; Risk assessment; RISK-ASSESSMENT; SAMPLES; SYNTHETIC ESTROGEN; SYSTEM; VITRO; WATER; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>250</startpage>
    <endpage>260</endpage>
    <journalfull>Environmental Science and Pollution Research</journalfull>
    <issue>2</issue>
    <volume>17</volume>
    <abstract>Concentration monitoring as a basis for risk assessment is a valid approach only if there is an unambiguous relation between concentration and effect. In many cases, no such unambiguous relation exists, since various substances can exert the same effect with differing potencies. If some or all of these substances contributing to a biological effect are unknown, effect-related monitoring becomes indispensable. Endocrine-disrupting substances in water bodies, including the groundwater, are a prominent example of such a case. The aim of the investigations described here was to detect hormonally active substances in the groundwater downstream of obsolete landfills by using the E-screen assay and to possibly assign the biological effect to individual chemical compounds by means of instrumental analyses carried out in parallel. Grab samples of the groundwater were collected downstream from abandoned landfills and prepared by liquid/liquid extraction. The total estrogenic activity in these samples was determined in vitro by applying the E-screen assay. The human breast cancer cells (MCF-7) used in the E-screen proliferate in response to the presence of estrogenically active compounds. Expressed in concentration units of the reference substance 17 beta-estradiol (E2), the test system allows the quantification of estrogenicity with a limit of detection (LOD) in the range of 0.1 ng/L. Aliquots of the samples were screened using gas chromatography/mass spectrometry (GC/MS) in order to quantify known estrogenically active substances and to identify unknown compounds. Estrogen-positive samples were extracted at different pH values, split into acidic, neutral, and basic fractions and analyzed by GC/MS, searching for individual components that display estrogenic activity. Estrogenic activity exceeding the LOD and the provisional benchmark of 0.5 ng E2/L was found at three out of seven abandoned waste disposal sites tested. The low concentrations of known xenoestrogens such as bisphenol-A, nonylphenols, or phthalic acid esters determined by GC/MS, however, were not sufficient to explain the detected activity. Neither natural nor synthetic hormones have caused the activity because these chemical structures are readily degradable and cannot persist in abandoned landfills for decades. The highest activity in the E-screen assay was found in the acidic fractions. Hydroxy-polychlorinated biphenyls (PCBs), hydroxylated polycyclic aromatic hydrocarbons (PAHs) and hetero-PAHs, as well as alkylphenols could be identified as further compounds with possible hormonal activity. Estrogenically active substances may occur in the groundwater below obsolete landfills, especially those that contain PCBs or waste from gasworks. These substances are not part of analytical programs routinely applied to contaminated sites and may therefore escape detection and assessment. Analyses using the E-screen assay and GC/MS in parallel have shown that the total estrogenic activity found in groundwater samples is to be ascribed to a multitude of individual compounds, some of which cannot be quantified due to lack of standard substances or assessed due to lack of a standardized procedure for determination of their estrogenic potency. By comparison with provisional guide values for estradiol (0.5 ng/L) and ethynylestradiol (0.3 ng/L), the damaging potential of the total estrogenic activity in groundwater samples can in fact be assessed, but specific remediation measures are impossible unless the hormonal activity can be attributed to individual chemical substances. On the one hand, further analyses of samples taken from possible pollution sources should be conducted in order to characterize the extent of groundwater pollution with xenoestrogens. On the other hand, the most potent individual compounds should be identified according to their estrogenic potency. To this end, bioassay-directed fractionation and structure elucidation should be carried out with concentrated samples</abstract>
    <url>WOS:000273851900002</url>
    <isbnorissn>0944-1344</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>423</id>
    <title>Oestrogen-Synthesising Enzymes and Breast Cancer</title>
    <authors>Kulendran,M.; Salhab,M.; Mokbel,K.</authors>
    <availability>[Mokbel, Kefah] Princess Grace Hosp, London Breast Inst, London W1M 3FD, England. [Kulendran, Myutan; Mokbel, Kefah] St George Hosp, London, England. [Salhab, Mohamed; Mokbel, Kefah] Brunel Univ, Inst Canc Genet &amp; Pharmacogenet, Uxbridge UB8 3PH, Middx, England.</availability>
    <date>2009</date>
    <notes>JEnglishReviewMokbel, K (reprint author), Princess Grace Hosp, London Breast Inst, 42-52 Nottingham Pl, London W1M 3FD, Englandkefahmokbel@hotmail.comADAMS EF, 1991, INT J CANCER, V49, P118, DOI 10.1002/ijc.2910490122; ADAMS JB, 1979, CANCER RES, V39, P5124; Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; AKSOY IA, 1994, BIOCHEM BIOPH RES CO, V200, P1621, DOI 10.1006/bbrc.1994.1637; Allan GM, 2008, BIOORGAN MED CHEM, V16, P4438, DOI 10.1016/j.bmc.2008.02.059; Alperin ES, 1997, J BIOL CHEM, V272, P20756, DOI 10.1074/jbc.272.33.20756; Al Sarakbi W, 2006, ANTICANCER RES, V26, P4985; Ariga N, 2000, ANTICANCER RES, V20, P1101; BASLER E, 1992, AM J HUM GENET, V50, P483; Baum M, 2002, LANCET, V359, P2131; Berrino F, 1996, J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Brodie A, 1997, J STEROID BIOCHEM, V61, P281; Bulun SE, 1997, J STEROID BIOCHEM, V61, P133; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; Cadot C, 2007, BIOORGAN MED CHEM, V15, P714, DOI 10.1016/j.bmc.2006.10.055; CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27; Chen SA, 1998, FRONT BIOSCI-LANDMRK, V3, P922; Chetrite G, 1998, J STEROID BIOCHEM, V66, P295, DOI 10.1016/S0960-0760(98)00063-6; Chetrite GS, 2000, J STEROID BIOCHEM, V72, P23, DOI 10.1016/S0960-0760(00)00040-6; Cunnick GH, 2001, CURR MED RES OPIN, V17, P217, DOI 10.1185/03007990152673855; DAO TL, 1981, HORMONES BREAST CANC, P281; Dorgan JF, 1997, CANCER EPIDEM BIOMAR, V6, P177; Dumas NA, 2008, J STEROID BIOCHEM, V111, P171, DOI 10.1016/j.jsbmb.2008.05.006; DUNCAN LJ, 1994, J STEROID BIOCHEM, V49, P63, DOI 10.1016/0960-0760(94)90301-8; ELRAYES BF, 2003, CLIN CANCER RES, V9, P705; ESTEBAN JM, 1992, AM J PATHOL, V140, P337; EVANS TRJ, 1994, BRIT J CANCER, V69, P555, DOI 10.1038/bjc.1994.101; FALANY CN, 1995, J STEROID BIOCHEM, V52, P529, DOI 10.1016/0960-0760(95)00015-R; Falany JL, 1996, CANCER RES, V56, P1551; FEIGELSON SH, 2001, CANCER RES, V61, P785; Ferrante P, 2002, EUR J HUM GENET, V10, P813, DOI 10.1038/sj.ejhg.5200887; Fischer DS, 2005, J MED CHEM, V48, P5749, DOI 10.1021/jm050348a; Fischer DS, 2003, J STEROID BIOCHEM, V84, P343, DOI 10.1016/S0960-0760(03)00048-7; Foster PA, 2006, CLIN CANCER RES, V12, P5543, DOI 10.1158/1078-0432.CCR-06-0632; Garvin S, 2005, BRIT J CANCER, V93, P1005, DOI 10.1038/sj.bjc.6602824; Gingras S, 1999, MOL ENDOCRINOL, V13, P66, DOI 10.1210/me.13.1.66; Gingras S, 2000, MOL ENDOCRINOL, V14, P229, DOI 10.1210/me.14.2.229; Gunasegaram R, 1998, BREAST CANCER RES TR, V50, P117, DOI 10.1023/A:1006009031839; Gunnarsson C, 2008, BREAST CANCER RES TR, V108, P35, DOI 10.1007/s10549-007-9579-7; Gunnarsson C, 2001, CANCER RES, V61, P8448; Gunnarsson C, 2003, ONCOGENE, V22, P34, DOI 10.1038/sj.onc.1206078; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; Hellmold H, 1998, J CLIN ENDOCR METAB, V83, P886, DOI 10.1210/jc.83.3.886; HENDERSON BE, 1988, CANCER RES, V48, P246; HENDERSON IC, 1980, NEW ENGL J MED, V302, P17, DOI 10.1056/NEJM198001033020104; Ho YT, 2003, BIOCHEM BIOPH RES CO, V305, P909, DOI 10.1016/S0006-291X(03)00865-9; Huang ZQ, 1996, DRUG METAB DISPOS, V24, P899; Husen B, 2006, ENDOCRINOLOGY, V147, P5333, DOI 10.1210/en.2006-0778; Iscan M, 2001, BREAST CANCER RES TR, V70, P47, DOI 10.1023/A:1012526406741; Jackson T, 2007, ORG BIOMOL CHEM, V5, P2940, DOI 10.1039/b707768h; JAMES V H T, 1987, Steroids, V50, P269, DOI 10.1016/0039-128X(83)90077-6; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Lipworth L, 1996, EPIDEMIOLOGY, V7, P96, DOI 10.1097/00001648-199601000-00017; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; LONGCOPE C, 1978, J CLIN ENDOCR METAB, V46, P146; Luu The V, 1989, Mol Endocrinol, V3, P1301; MACAULAY VM, 1994, BRIT J CANCER, V69, P77, DOI 10.1038/bjc.1994.12; MACDIARMID F, 1994, MOL CELL ENDOCRINOL, V106, P17, DOI 10.1016/0303-7207(94)90181-3; Maggiolini M, 1999, CANCER RES, V59, P4864; Maor S, 2006, J ENDOCRINOL, V191, P605, DOI 10.1677/joe.1.07016; McFadyen MCE, 1999, J HISTOCHEM CYTOCHEM, V47, P1457; Meng L, 2001, CANCER RES, V61, P2250; Miettinen MM, 1996, BIOCHEM J, V314, P839; MILLER WR, 1991, J STEROID BIOCHEM, V39, P783, DOI 10.1016/0960-0760(91)90026-2; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; MILLER WR, 1990, J STEROID BIOCHEM, V37, P1055, DOI 10.1016/0960-0760(90)90465-W; MILLER WR, 1982, CANCER RES, V42, P3365; MILLER WR, 1993, J STEROID BIOCHEM, V44, P597, DOI 10.1016/0960-0760(93)90265-X; Miyoshi Y, 2003, CLIN CANCER RES, V9, P2288; Modugno F, 2003, BREAST CANCER RES TR, V82, P191, DOI 10.1023/B:BREA.0000004376.21491.44; Mokbel Kefah, 2002, Int J Clin Oncol, V7, P279; Mokbel Ramia, 2006, Int Semin Surg Oncol, V3, P31, DOI 10.1186/1477-7800-3-31; Morris KT, 2001, SURGERY, V130, P947, DOI 10.1067/msy.2001.118378; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nakata T, 2003, J STEROID BIOCHEM, V86, P455, DOI 10.1016/S0960-0760(03)00357-1; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Nelson LR, 2001, J AM ACAD DERMATOL, V45, P116; Newman SP, 2000, J STEROID BIOCHEM, V75, P259, DOI 10.1016/S0960-0760(00)00177-1; Oduwole OO, 2004, CANCER RES, V64, P7604, DOI 10.1158/0008-5472.CAN-04-0446; Oyama T, 2005, FRONT BIOSCI, V10, P1156, DOI 10.2741/1608; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11&lt;2698::AID-CNCR2820551127&gt;3.0.CO;2-A; Pasqualini JR, 2004, BBA-REV CANCER, V1654, P123, DOI 10.1016/j.bbcan.2004.03.001; PASQUALINI JR, 1994, ANTICANCER RES, V14, P1589; Pasqualini JR, 1996, J CLIN ENDOCR METAB, V81, P1460, DOI 10.1210/jc.81.4.1460; PEREL E, 1980, J STEROID BIOCHEM, V13, P89, DOI 10.1016/0022-4731(80)90117-X; Pietras RJ, 2005, STEROIDS, V70, P372, DOI 10.1016/j.steroids.2005.02.017; Planas-Silva MD, 2007, J STEROID BIOCHEM, V104, P11, DOI 10.1016/j.jsbmb.2006.09.039; Poortman J., 1980, ADRENAL ANDROGENS, P219; POULIN R, 1986, CANCER RES, V46, P4933; PUROHIT A, 1995, J CLIN ENDOCR METAB, V80, P3052, DOI 10.1210/jc.80.10.3052; PUROHIT A, 1992, INT J CANCER, V50, P901, DOI 10.1002/ijc.2910500614; Purohit A, 2000, CANCER RES, V60, P3394; Purohit A, 2003, J STEROID BIOCHEM, V86, P423, DOI 10.1016/S0960-0760(03)00353-4; Redeuilh G, 2002, ONCOGENE, V21, P5773, DOI 10.1038/sj.onc.1205753; Reed M. J., 1994, Drugs of the Future, V19, P673; Reed MJ, 1996, ENDOCR-RELAT CANCER, V3, P9; REED MJ, 1989, INT J CANCER, V44, P233, DOI 10.1002/ijc.2910440208; REED MJ, 1992, J ENDOCRINOL, V132, pR5, DOI 10.1677/joe.0.132R005; REED MJ, 1993, J STEROID BIOCHEM, V44, P589, DOI 10.1016/0960-0760(93)90264-W; REED MJ, 1993, REV ENDOCRINE RELATE, V45, P51; Reed MJ, 2005, ENDOCR REV, V26, P171, DOI 10.1210/er.2004-0003; Reed MJ, 1994, DESIGN ENZYME INHIBI, V2, P481; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Salhab M, 2006, BREAST CANCER RES TR, V99, P155, DOI 10.1007/s10549-006-9198-8; Sam K M, 1998, Drug Des Discov, V15, P157; SANTNER SJ, 1993, J STEROID BIOCHEM, V44, P611, DOI 10.1016/0960-0760(93)90267-Z; Sasano H, 1997, J BONE MINER RES, V12, P1416, DOI 10.1359/jbmr.1997.12.9.1416; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Sasano H, 1996, J CLIN ENDOCR METAB, V81, P4042, DOI 10.1210/jc.81.11.4042; SASANO H, 1989, J REPROD FERTIL, V85, P163; SASANO H, 1994, HUM PATHOL, V25, P530, DOI 10.1016/0046-8177(94)90127-9; SASANO H, 1994, ENDOCR PATHOL, V5, P81, DOI 10.1007/BF02921375; Sasco Annie J., 2003, Hormone Research (Basel), V60, P50, DOI 10.1159/000074500; SCHWEIKERT HU, 1976, J CLIN ENDOCR METAB, V43, P785; Sebastian S, 2002, MOL ENDOCRINOL, V16, P2243, DOI 10.1210/me.2002-0123; Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600; Selcer KW, 1997, CANCER RES, V57, P702; Shekhar PVM, 1997, J NATL CANCER I, V89, P1774; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/en.142.11.4589; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Simpson ER, 1997, FASEB J, V11, P29; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Singh A, 1997, J STEROID BIOCHEM, V61, P185; SINGH A, 1992, MOL CELL ENDOCRINOL, V85, P165, DOI 10.1016/0303-7207(92)90255-5; SINGH A, 1995, J ENDOCRINOL, V147, pR9, DOI 10.1677/joe.0.147R009; Singh A, 1999, ENDOCR-RELAT CANCER, V6, P139, DOI 10.1677/erc.0.0060139; Stanway SJ, 2006, CLIN CANCER RES, V12, P1585, DOI 10.1158/1078-0432.CCR-05-1996; Suzuki T, 2003, CANCER RES, V63, P2762; Suzuki T, 2000, BRIT J CANCER, V82, P518; Takeyama J, 1998, J CLIN ENDOCR METAB, V83, P3710, DOI 10.1210/jc.83.10.3710; Takeyama J, 2000, J CLIN ENDOCR METAB, V85, P410, DOI 10.1210/jc.85.1.410; Thomas JL, 2004, ENDOCR RES, V30, P935, DOI 10.1081/ERC-20044164; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; TREMBLAY Y, 1993, MOL ENDOCRINOL, V7, P355, DOI 10.1210/me.7.3.355; TSENG L, 1983, J STEROID BIOCHEM, V19, P1413, DOI 10.1016/0022-4731(83)91116-0; Utsumi T, 2000, J STEROID BIOCHEM, V73, P141, DOI 10.1016/S0960-0760(00)00060-1; Utsumi T, 1999, CANCER RES, V59, P377; Utsumi T, 1996, J CLIN ENDOCR METAB, V81, P2344, DOI 10.1210/jc.81.6.2344; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wegman P, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1640; WOO LW, 2007, J MED CHEM, V26, P3540; Wood PM, 2005, J STEROID BIOCHEM, V94, P123, DOI 10.1016/j.jsbmb.2004.12.028; Wood PM, 2008, J MED CHEM, V51, P4226, DOI 10.1021/jm800168s; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; Yue W, 1998, CANCER RES, V58, P927; YUE W, 1994, CANCER RES, V54, P5092; Zhang Z., 2003, BREAST CANCER RES, V5, P250; Zhang ZH, 2002, BREAST CANCER RES TR, V74, P47, DOI 10.1023/A:1016022314608; Zhao Y, 1997, J STEROID BIOCHEM, V61, P203, DOI 10.1016/S0960-0760(97)80013-1; ZHAO Y, 1995, J BIOL CHEM, V270, P16449; Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8; ZHOU D, 1990, CANCER RES, V50, P694915711INT INST ANTICANCER RESEARCHATHENSEDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECEANTICANCER RESAPRDiscipline: Oncology434GU</notes>
    <keywords>17 beta HSD type 1; ACTIVATION; Androgen; androgens; ANEUPLOIDY; Aromatase; BISPHENOL-A EXPOSURE; BONE; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CARCINOMA; CARCINOMA IN-SITU; CELL; CYP19 AROMATASE GENE; DES; development; DISEASE; ENDOCRINE; Epidemiology; ER; Estrogen; FUTURE; HEALTH; Hormone; Hormones; INDUCTION; Interaction; MAMMARY EPITHELIAL-CELLS; mechanism; MECHANISMS; MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; oestrogen; oestrogens; oncology; PATHOGENESIS; POLYMERASE-CHAIN-REACTION; postmenopausal; POSTMENOPAUSAL WOMEN; proliferation; Review; Steroid; STEROID SULFATASE INHIBITORS; Steroid sulphatase; TISSUE-SPECIFIC EXPRESSION; WOMEN; X-LINKED ICHTHYOSIS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1095</startpage>
    <endpage>1109</endpage>
    <journalfull>Anticancer Research</journalfull>
    <issue>4</issue>
    <volume>29</volume>
    <abstract>There is a large and compelling body of epidemiological and experimental evidence that oestrogens are the fuel behind the aetiology of breast cancer. The carcinogenic effects of oestrogen are postulated to be mediated by: the stimulation of cellular proliferation through their receptor-mediated hormonal activity. Other mechanisms include; direct genotoxic effects by increasing mutation rates through a cytochrome P450-mediated metabolic activation and induction of aneuploidy. The local biosynthesis of oestrogens, especially in postmenopausal women as a result of the interactions of various enzymes, is believed to play a very important role in the pathogenesis and development of hormone dependent breast carcinoma. The over-expression of such enzymes seems to be associated with the development of a more aggressive disease process, a poorer outcome and increased local and distant recurrences</abstract>
    <url>WOS:000265264000020</url>
    <isbnorissn>0250-7005</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>274</id>
    <title>Endocrine disruptive synthetic estrogen (17 alpha-ethynylestradiol) removal from aqueous phase through batch and column sorption studies: Mechanistic and kinetic analysis</title>
    <authors>Kumar,A.K.; Mohan,S.V.</authors>
    <availability>[Mohan, S. Venkata] Indian Inst Chem Technol, Bioengn &amp; Environm Ctr, Hyderabad 500607, Andhra Pradesh, India. [Kumar, A. Kiran] IICT CCMB Dispensary, Hyderabad 500607, Andhra Pradesh, India.</availability>
    <date>2011</date>
    <notes>JEnglishArticleMohan, SV (reprint author), Indian Inst Chem Technol, Bioengn &amp; Environm Ctr, Hyderabad 500607, Andhra Pradesh, Indiavmohan_s@yahoo.comAdak A, 2006, DYES PIGMENTS, V69, P245, DOI 10.1016/j.dyepig.2005.03.009; Aerni HR, 2004, ANAL BIOANAL CHEM, V378, P688, DOI 10.1007/s00216-003-2276-4; APHA, 1998, STAND METH EX WAT WA; Auriol M, 2006, PROCESS BIOCHEM, V41, P525, DOI 10.1016/j.procbio.2005.09.017; Battacharya A., 1984, J ENV ENG DIV ASCE P, V110, P110; Belgiorno V, 2007, DESALINATION, V215, P166, DOI 10.1016/j.desal.2006.10.035; Benhamou S, 2002, MUTAGENESIS, V17, P463, DOI 10.1093/mutage/17.6.463; Bodzek M, 2006, DESALINATION, V198, P24, DOI 10.1016/j.desal.2006.09.005; BRIERLEY SA, 1990, BIOSORPTION HEAVY ME, P305; Bulut E, 2008, MICROPOR MESOPOR MAT, V115, P234, DOI 10.1016/j.micromeso.2008.01.039; Carballa M, 2004, WATER RES, V38, P2918, DOI 10.1016/j.watres.2004.03.029; Chabani M, 2006, CHEM ENG J, V125, P111, DOI 10.1016/j.cej.2006.08.014; Chu BS, 2004, J FOOD ENG, V62, P97, DOI 10.1016/S0260-8774(03)00196-1; Clara M, 2005, WATER RES, V39, P4797, DOI 10.1016/j.watres.2005.09.015; CRITTENDEN JC, 1987, J ENVIRON ENG-ASCE, V113, P243; CRITTENDEN JC, 1991, J AM WATER WORKS ASS, V83, P77; de Rudder J, 2004, WATER RES, V38, P184, DOI 10.1016/j.watres.2003.09.018; Desbrow C., 2006, WATER RES, V40, P2847; Donat R, 2005, J COLLOID INTERF SCI, V286, P43, DOI 10.1016/j.jcis.2005.01.045; Eckenfelder Jr W.W., 2000, IND WATER POLLUTION; Filali-Meknassi Y., 2004, PRACT PERIOD HAZARD, V8, P1; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; HALL KR, 1966, IND ENG CHEM FUND, V5, P212, DOI 10.1021/i160018a011; Hasany SM, 1996, APPL RADIAT ISOTOPES, V47, P467, DOI 10.1016/0969-8043(95)00310-X; Ho YS, 2006, J HAZARD MATER, V136, P681, DOI 10.1016/j.jhazmat.2005.12.043; Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870; Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1833, DOI 10.1080/15287390500182883; Kannan N, 2001, DYES PIGMENTS, V51, P25, DOI 10.1016/S0143-7208(01)00056-0; Kidd KA, 2007, P NATL ACAD SCI USA, V104, P8897, DOI 10.1073/pnas.0609568104; Kumar AK, 2009, J HAZARD MATER, V164, P820, DOI 10.1016/j.jhazmat.2008.08.075; Lange R, 2001, ENVIRON TOXICOL CHEM, V20, P1216, DOI 10.1897/1551-5028(2001)020&lt;1216:EOTSEE&gt;2.0.CO;2; Li C, 2008, WATER RES, V42, P109, DOI 10.1016/j.watres.2007.07.023; MAGGS JL, 1983, XENOBIOTICA, V13, P421; Michelson L.D., 1975, US DEP IND OFFICE WA, V74; Ministry of the Environment Japan (MOE), 2005, PERSP END DISR EFF S, P12; Mohan SV, 1997, ENVIRON POLLUT, V97, P183, DOI 10.1016/S0269-7491(97)00025-0; Mohan SV, 2002, J HAZARD MATER, V90, P189; Morris J.C., 1987, ADSORPTION PROCESSES; Nakada N, 2007, WATER RES, V41, P4373, DOI 10.1016/j.watres.2007.06.038; Notch EG, 2007, AQUAT TOXICOL, V84, P301, DOI 10.1016/j.aquatox.2007.06.006; Osborne N, 2007, ECOTOX ENVIRON SAFE, V68, P13, DOI 10.1016/j.ecoenv.2006.12.002; PELISSERO C, 1993, J STEROID BIOCHEM, V44, P263, DOI 10.1016/0960-0760(93)90086-C; Pojana G, 2007, ENVIRON INT, V33, P929, DOI 10.1016/j.envint.2007.05.003; Ren YX, 2007, WATER RES, V41, P2341, DOI 10.1016/j.watres.2007.01.058; Rengaraj S, 2002, WATER RES, V36, P1783, DOI 10.1016/S0043-1354(01)00380-3; Roepke TA, 2005, AQUAT TOXICOL, V71, P155, DOI 10.1016/j.aquatox.2004.11.003; Routledge EJ, 1996, ENVIRON TOXICOL CHEM, V15, P241, DOI 10.1897/1551-5028(1996)015&lt;0241:EAOSAS&gt;2.3.CO;2; Sari A, 2007, J HAZARD MATER, V144, P41, DOI 10.1016/j.jhazmat.2006.09.080; Shareef A, 2006, J COLLOID INTERF SCI, V297, P62, DOI 10.1016/j.jcis.2005.10.039; Shi J, 2004, WATER RES, V38, P2323, DOI 10.1016/j.watres.2004.02.022; Snyder SA, 2007, DESALINATION, V202, P156, DOI 10.1016/j.desa1.2005.12.052; Snyder SA, 2001, ENVIRON SCI TECHNOL, V35, P3620, DOI 10.1021/es001254n; Song KY, 2009, DESALINATION, V237, P392, DOI 10.1016/j.desal.2008.11.004; Ternes TA, 1999, SCI TOTAL ENVIRON, V225, P81, DOI 10.1016/S0048-9697(98)00334-9; Tyler CR, 1998, PURE APPL CHEM, V70, P1795, DOI 10.1351/pac199870091795; WEBER TW, 1974, AICHE J, V20, P226; Yalcin M, 2004, ADSORPTION, V10, P339; Yang XY, 2005, J COLLOID INTERF SCI, V287, P25, DOI 10.1016/j.jcis.2005.01.093; Yoon Y, 2007, DESALINATION, V202, P16, DOI 10.1016/j.desa1.2005.12.033; Zhang YP, 2005, WATER RES, V39, P3991, DOI 10.1016/j.watres.2005.07.019607ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSDESALINATIONAUG 2Discipline: Engineering; Water Resources799UY</notes>
    <keywords>17-ALPHA-ETHINYLESTRADIOL; 17-BETA-ESTRADIOL; ACTIVATED-SLUDGE; ADSORPTION; BISPHENOL-A; CANCER; CARBON; CHEMICALS; DISRUPTING CHEMICALS; Domestic sewage; EDC; ENDOCRINE; Endocrine disrupting chemicals; environment; Estrogen; FISH; FIXED-BED ADSORPTION; FOOD; Immuno-enzymatic colorimetric method; Male; MODEL; Multi-component sorption; PHARMACEUTICALS; Rapid small-scale column test (RSSCT); RISK; SEWAGE-TREATMENT PLANT; SPERM PRODUCTION; SYSTEM; toxicology; WASTE-WATER; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>66</startpage>
    <endpage>74</endpage>
    <journalfull>Desalination</journalfull>
    <issue>1-3</issue>
    <volume>276</volume>
    <abstract>Global concern about the persistence of endocrine disrupting chemicals (EDC) in the freshwater environment is more evident due to their possible disruptive effects. Even at nanogram levels these compounds increase the risk of cancer, decrease egg and sperm production, reduce gamete quality and tend complete feminization of the male fish. The present study demonstrated the potential of activated charcoal as adsorbent in removing synthetic estrogen 17 alpha-ethynylestradiol (EE2) from aqueous phase by sorption process employing both agitated batch and column adsorption experiments. Batch sorption studies showed good removal of EE2 and dependent on the concentration loaded. Equilibrium data of EE2-charcoal sorption system showed a reasonably good fit with pseudo first-order kinetic plot. Intra-particle diffusion plot indicated the complex nature of EE2-charcoal sorption system involving both boundary layer and intra-particle diffusions. Experimental data confirmed to linear Langmuir's isotherm model. Highest EE2 sorption capacity of activated charcoal was observed at neutral conditions. Fixed bed column studies were performed with EE2 spiked untreated domestic sewage. Based on the data derived by fixed bed column studies, rapid small-scale column test (RSSCT) methodology was used to design full-scale GAC system. Total EE2 concentration was quantitatively estimated by direct competitive immuno-enzymatic colorimetric method. (C) 2011 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000293312800008</url>
    <isbnorissn>0011-9164</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>277</id>
    <title>Epigenetic perspective on the developmental effects of bisphenol A</title>
    <authors>Kundakovic,M.; Champagne,F.A.</authors>
    <availability>[Kundakovic, Marija; Champagne, Frances A.] Columbia Univ, Dept Psychol, New York, NY 10027 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleChampagne, FA (reprint author), Columbia Univ, Dept Psychol, 1190 Amsterdam Ave,Room 406,Schermerhorn Hall, New York, NY 10027 USAfac2105@columbia.eduAdriani W, 2003, ENVIRON HEALTH PERSP, V111, P395, DOI 10.1289/ehp.5856; Alizadeh Mohammad, 2006, J Med Invest, V53, P70, DOI 10.2152/jmi.53.70; Alworth LC, 2002, TOXICOL APPL PHARM, V183, P10, DOI 10.1006/taap.2002.9459; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058; Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernal AJ, 2010, BIRTH DEFECTS RES A, V88, P938, DOI 10.1002/bdra.20685; Biddie SC, 2011, J NEUROENDOCRINOL, V23, P94, DOI 10.1111/j.1365-2826.2010.02079.x; Biedermann S, 2010, ANAL BIOANAL CHEM, V398, P571, DOI 10.1007/s00216-010-3936-9; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Champagne FA, 2008, CURR OPIN PHARMACOL, V8, P735, DOI 10.1016/j.coph.2008.06.018; Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Cooney Craig A, 2002, J Nutr, V132, p2393S; Cox KH, 2010, HORM BEHAV, V58, P754, DOI 10.1016/j.yhbeh.2010.07.008; Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899; Dessi-Fulgheri F, 2002, ENVIRON HEALTH PERSP, V110, P403; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Farabollino F, 2002, ENVIRON HEALTH PERSP, V110, P409; Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Funabashi T, 2004, PSYCHONEUROENDOCRINO, V29, P475, DOI 10.1016/S0306-4530(03)00055-6; Gioiosa L, 2007, HORM BEHAV, V52, P307, DOI 10.1016/j.yhbeh.2007.05.006; Golebiewska A, 2009, STEM CELLS, V27, P1298, DOI 10.1002/stem.59; Gore AC, 2008, FRONT NEUROENDOCRIN, V29, P358, DOI 10.1016/j.yfrne.2008.02.002; Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Guerrero-Bosagna C, 2010, PLOS ONE, V5; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Igarashi A, 2006, BIOL PHARM BULL, V29, P2120, DOI 10.1248/bpb.29.2120; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kavlock R, 2005, CRIT REV TOXICOL, V35, P721, DOI 10.1080/10408440591007377; Kawai K, 2007, REGUL TOXICOL PHARM, V47, P166, DOI 10.1016/j.yrtph.2006.04.002; Kawai K, 2003, ENVIRON HEALTH PERSP, V111, P175, DOI 10.1289/ehp.5440; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kubo K, 2001, NEUROSCI LETT, V304, P73, DOI 10.1016/S0304-3940(01)01760-8; Kubo K, 2003, NEUROSCI RES, V45, P345, DOI 10.1016/S0168-0102(02)00251-1; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kwack SJ, 2009, J TOXICOL ENV HEAL A, V72, P1254, DOI 10.1080/15287390903212212; Lange UC, 2010, BIOESSAYS, V32, P659, DOI 10.1002/bies.201000030; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li SF, 1997, CANCER RES, V57, P4356; Liu J, 2010, TRENDS NEUROSCI, V33, P193, DOI 10.1016/j.tins.2010.01.007; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Miao S, 2008, J TOXICOL ENV HEAL A, V71, P1000, DOI 10.1080/15287390801907467; Miller FD, 2007, NEURON, V54, P357, DOI 10.1016/j.neuron.2007.04.019; Mills PK, 2006, J ENVIRON HEALTH, V68, P15; Nakamura K, 2006, J NEUROSCI RES, V84, P1197, DOI 10.1002/jnr.21020; Nakamura K, 2007, NEUROSCI LETT, V420, P100, DOI 10.1016/j.neulet.2007.02.093; Negishi T, 2004, ENVIRON HEALTH PERSP, V112, P1159, DOI 10.1289/ehp.6961; Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; PATISAUL HB, 2009, BEHAV NEUROSCI, V3, P1; Porrini S, 2005, BRAIN RES BULL, V65, P261, DOI 10.1016/j.brainresbull.2004.11.014; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rosenfeld CS, 2010, BIOL REPROD, V82, P473, DOI 10.1095/biolreprod.109.080952; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Stanisic V, 2010, PROG BRAIN RES, V181, P153, DOI 10.1016/S0079-6123(08)81009-6; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Tando S, 2007, BRAIN DEV-JPN, V29, P352, DOI 10.1016/j.braindev.2006.10.003; Taylor JA, 2008, REPROD TOXICOL, V25, P169, DOI 10.1016/j.reprotox.2008.01.001; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Veurink M, 2005, PHARM WORLD SCI, V27, P139, DOI 10.1007/s11096-005-3663-z; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Westberry JM, 2010, ENDOCRINOLOGY, V151, P731, DOI 10.1210/en.2009-0955; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Xu XH, 2010, HORM BEHAV, V58, P326, DOI 10.1016/j.yhbeh.2010.02.012; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Yoshino S, 2003, BRIT J PHARMACOL, V138, P1271, DOI 10.1038/sj.bjp.0705166; Zhao ZR, 2010, P NATL ACAD SCI USA, V107, P5605, DOI 10.1073/pnas.0910578107; Zhu ZY, 2009, ENVIRON HEALTH PERSP, V117, P928, DOI 10.1289/ehp.08001099440ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USABRAIN BEHAV IMMUNAUGDiscipline: Immunology; Neurosciences &amp; Neurology799SI</notes>
    <keywords>Behavior; bisphenol; bisphenol A; BISPHENOL-A; BPA; Brain development; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CELLS; CHEMICALS; DEFECTS; development; Differentiation; DISRUPTING CHEMICALS; DNA METHYLATION; DNA-methylation; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruptor; ENVIRONMENTAL ESTROGENS; epigenetic; Epigenome; Estrogen receptor; ESTROGEN-RECEPTOR-ALPHA; estrogenic activity; EXPOSURE; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GENES; HEALTH; Hormones; HUMAN EXPOSURE; Immune; IN-UTERO; MAMMALIAN DEVELOPMENT; MATERNAL EXPOSURE; mechanism; MECHANISMS; METHYLATION; molecular mechanism; MOLECULAR-MECHANISMS; PATHWAY; PERINATAL EXPOSURE; Plastics; PRENATAL EXPOSURE; PROTEIN; PROTEINS; Reproduction; RISK; SEXUAL-DIFFERENTIATION; SOCIOSEXUAL BEHAVIOR; STEM-CELLS; TISSUE; TISSUES; toxicology; Transgenerational</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1084</startpage>
    <endpage>1093</endpage>
    <journalfull>Brain Behavior and Immunity</journalfull>
    <issue>6</issue>
    <volume>25</volume>
    <abstract>Bisphenol A (BPA) is an estrogenic environmental toxin widely used in the production of plastics and ubiquitous human exposure to this chemical has been proposed to be a potential risk to public health. Animal studies suggest that in utero and early postnatal exposure to this compound may produce a broad range of adverse effects, including impaired brain development, sexual differentiation, behavior, and immune function, which could extend to future generations. Molecular mechanisms that underlie the long-lasting effects of BPA continue to be elucidated, and likely involve disruption of epigenetic programming of gene expression during development. Several studies have provided evidence that maternal exposure to BPA results in postnatal changes in DNA methylation status and altered expression of specific genes in offspring. However, further studies are needed to extend these initial findings to other genes in different tissues, and to examine the correlations between BPA-induced epigenetic alterations, changes in gene expression, and various phenotypic outcomes. It will be also important to explore whether the epigenetic effects of BPA are related to its estrogenic activity, and to determine which downstream effector proteins could mediate changes in DNA methylation. In this review, we will highlight research indicating a consequence of prenatal BPA exposure for brain, behavior, and immune outcomes and discuss evidence for the role of epigenetic pathways in shaping these developmental effects. Based on this evidence, we will suggest future directions in the study of BPA-induced epigenetic effects and discuss the transgenerational implications of exposure to endocrine disrupting chemicals. (C) 2011 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000293306000005</url>
    <isbnorissn>0889-1591</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>24</id>
    <title>Label free selective detection of estriol using graphene oxide-based fluorescence sensor</title>
    <authors>Kushwaha,H.S.; Sao,R.; Vaish,R.</authors>
    <availability>[Kushwaha, H. S.; Sao, Reshma; Vaish, Rahul] Indian Inst Technol Mandi, Suran 175001, Himachal Prades, India.</availability>
    <date>2014</date>
    <notes>JEnglishArticleVaish, R (reprint author), Indian Inst Technol Mandi, Suran 175001, Himachal Prades, Indiarahul@iitmandi.ac.inBadihi-Mossberg M, 2007, ELECTROANAL, V19, P2015, DOI 10.1002/elan.200703946; Balandin AA, 2008, NANO LETT, V8, P902, DOI 10.1021/nl0731872; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; Chen D, 2012, CHEM REV, V112, P6027, DOI 10.1021/cr300115g; Chen JL, 2011, ANAL CHEM, V83, P8787, DOI 10.1021/ac2023537; Chung C, 2013, ACCOUNTS CHEM RES, V46, P2211, DOI 10.1021/ar300159f; Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g; Feng LY, 2013, ADV MATER, V25, P168, DOI 10.1002/adma.201203229; Guo TD, 2008, CLIN BIOCHEM, V41, P736, DOI 10.1016/j.clinbiochem.2008.02.009; HANING RV, 1977, AM J OBSTET GYNECOL, V128, P793; HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017; Kim SY, 2000, YONSEI MED J, V41, P226; Kochmann S, 2012, TRAC-TREND ANAL CHEM, V39, P87, DOI 10.1016/j.trac.2012.06.004; Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996; Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451; Li Y, 2010, CARBON, V48, P3427, DOI 10.1016/j.carbon.2010.05.038; Liu YX, 2012, CHEM SOC REV, V41, P2283, DOI 10.1039/c1cs15270j; Mao HY, 2013, CHEM REV, V113, P3407, DOI 10.1021/cr300335p; Mkhoyan KA, 2009, NANO LETT, V9, P1058, DOI 10.1021/nl8034256; Morales-Narvaez E, 2012, ADV MATER, V24, P3298, DOI 10.1002/adma.201200373; Ortmann F, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.186101; Paredes JI, 2008, LANGMUIR, V24, P10560, DOI 10.1021/la801744a; Park Soyoung, 2011, Environmental Engineering Research, V16, P137; Pu Y, 2011, ANALYST, V136, P4138, DOI 10.1039/c1an15407a; Rao CNR, 2009, J MATER CHEM, V19, P2457, DOI 10.1039/b815239j; Ren HL, 2010, ACS NANO, V4, P7169, DOI 10.1021/nn101696r; Rodriguez-Mozaz S, 2004, ANAL CHEM, V76, P6998, DOI 10.1021/ac049051v; ROGERS KR, 1995, BIOSENS BIOELECTRON, V10, P533, DOI 10.1016/0956-5663(95)96929-S; ROTTI K, 1975, STEROIDS, V25, P807, DOI 10.1016/0039-128X(75)90045-8; SCHONESHOFER M, 1986, CLIN CHEM, V32, P1948; Schwierz F, 2010, NAT NANOTECHNOL, V5, P487, DOI [10.1038/nnano.2010.89, 10.1038/NNANO.2010.89]; Si Y, 2008, NANO LETT, V8, P1679, DOI 10.1021/nl080604h; Stoller MD, 2008, NANO LETT, V8, P3498, DOI 10.1021/nl802558y; Varghese N, 2009, CHEMPHYSCHEM, V10, P206, DOI 10.1002/cphc.200800459; Wan QJ, 2013, CHEM-EUR J, V19, P3483, DOI 10.1002/chem.201203607; Wang HB, 2011, ANGEW CHEM INT EDIT, V50, P7065, DOI 10.1002/anie.201101351; Wang Y, 2010, J AM CHEM SOC, V132, P9274, DOI 10.1021/ja103169v; Wu Y., 2012, ELECTROCHIM ACTA, V90, P210; Wu YQ, 2011, NATURE, V472, P74, DOI 10.1038/nature09979; Ying GG, 2002, J ENVIRON SCI HEAL B, V37, P225, DOI 10.1081/PFC-120003100; Zhang JL, 2010, CHEM COMMUN, V46, P1112, DOI 10.1039/b917705a; Zhao XH, 2011, ANAL CHEM, V83, P5062, DOI 10.1021/ac200843x420AMER INST PHYSICSMELVILLECIRCULATION &amp; FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USAJ APPL PHYSJUL 21Discipline: PhysicsAN6ND</notes>
    <keywords>BIOSENSORS; bisphenol; breast cancer; BREAST-CANCER; CANCER; cardiovascular; CHEMICALS; DISPERSIONS; Endocrine-disrupting chemicals; Estrogen; ESTROGENS; GROWTH; LIQUID-CHROMATOGRAPHY; PLATFORM; PREGNANCY; SOLID-PHASE EXTRACTION; TANDEM MASS-SPECTROMETRY; TRANSISTORS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Journal of Applied Physics</journalfull>
    <issue>3</issue>
    <volume>116</volume>
    <abstract>Water-soluble and fluorescent Graphene oxide (GO) is biocompatible, easy, and economical to synthesize. Interestingly, GO is also capable of quenching fluorescence. On the basis of its fluorescence and quenching abilities, GO has been reported to serve as an energy acceptor in a fluorescence resonance energy transfer (FRET) sensor. GO-based FRET biosensors have been widely reported for sensing of proteins, nucleic acid, ATP (Adenosine triphosphate), etc. GO complexes with fluorescent dyes and enzymes have been used to sense metal ions. Graphene derivatives have been used for sensing endocrine-disrupting chemicals like bisphenols and chlorophenols with high sensitivity and good reproducibility. On this basis, a novel GO based fluorescent sensor has been successfully designed to detect estriol with remarkable selectivity and sensitivity. Estriol is one of the three estrogens in women and is considered to be medically important. Estriol content of maternal urine or plasma acts as an important screening marker for estimating foetal growth and development. In addition, estriol is also used as diagnostic marker for diseases like breast cancer, osteoporosis, neurodegenerative and cardiovascular diseases, insulin resistance, lupus erythematosus, endometriosis, etc. In this present study, we report for the first time a rapid, sensitive with detection limit of 1.3 nM, selective and highly biocompatible method for label free detection of estriol under physiological conditions using fluorescence assay. (C) 2014 AIP Publishing LLC</abstract>
    <url>WOS:000340710500087</url>
    <isbnorissn>0021-8979</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>444</id>
    <title>Risk Assessment of Soybean-Based Phytoestrogens</title>
    <authors>Kwack,S.J.; Kim,K.B.; Kim,H.S.; Yoon,K.S.; Lee,B.M.</authors>
    <availability>[Lee, Byung Mu] Sungkyunkwan Univ, Div Toxicol, Coll Pharm, Suwon 440746, Gyeonggi Do, South Korea. [Kwack, Seung Jun; Kim, Kyu-Bong] Natl Inst Toxicol Res, Dept Toxicol Res, Seoul, South Korea. [Kim, Hyung Sik] Pusan Natl Univ, Div Mol Toxicol, Coll Pharm, Pusan 609735, South Korea. [Yoon, Kyung Sil] Natl Canc Ctr, Res Inst, Goyang, Gyeonggi Do, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleLee, BM (reprint author), Sungkyunkwan Univ, Div Toxicol, Coll Pharm, Chunchun Dong 300, Suwon 440746, Gyeonggi Do, South Koreabmlee@skku.ac.krAdlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470-2045(02)00777-5; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; ADLERCREUTZ H, 1998, BAILLIERE CLIN ENDOC, V12, P604; Adlercreutz H, 1997, ANN MED, V29, P95; [Anonymous], 2003, PHYT HLTH; Arai Y, 2000, J Epidemiol, V10, P127; ATSDR (Agency for Toxic Substances and Disease Registry), 2005, TOX PROF HEX; Bakke D., 2003, HUMAN ECOLOGICAL RIS; Barrett J, 1996, ENVIRON HEALTH PERSP, V104, P478, DOI 10.2307/3432986; Behnisch PA, 2001, CHEMOSPHERE, V43, P977, DOI 10.1016/S0045-6535(00)00458-6; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; BERNINGER E, 1992, SCAND AUDIOL, V21, P15, DOI 10.3109/01050399209045977; BICKOFF EM, 1962, AGR FOOD CHEM, V10, P410; Boker LK, 2002, J NUTR, V132, P1319; Bolt HM, 2001, ARCH TOXICOL, V74, P649, DOI 10.1007/s002040000178; Brouns F, 2002, FOOD RES INT, V35, P187, DOI 10.1016/S0963-9969(01)00182-X; CASSADY JM, 1990, J NAT PROD, V53, P23, DOI 10.1021/np50067a003; Cassidy A, 2003, INT J VITAM NUTR RES, V73, P120, DOI 10.1024/0300-9831.73.2.120; Cassidy A, 1996, P NUTR SOC, V55, P399, DOI 10.1079/PNS19960038; Chang HC, 2000, J NUTR, V130, P1963; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Danzo BJ, 1997, ENVIRON HEALTH PERSP, V105, P294, DOI 10.1289/ehp.97105294; Das SK, 1998, ENDOCRINOLOGY, V139, P2905, DOI 10.1210/en.139.6.2905; David RM, 2000, ENVIRON HEALTH PERSP, V108, pA440, DOI 10.1289/ehp.108-a440a; de Kleijn MJJ, 2001, J NUTR, V131, P1826; DeRosa C, 1998, J TOXICOL ENV HEAL B, V1, P3; Diel P, 2000, J STEROID BIOCHEM, V73, P1, DOI 10.1016/S0960-0760(00)00051-0; Dogheim SM, 1996, J AOAC INT, V79, P111; Duffy C, 2007, CA-CANCER J CLIN, V57, P260, DOI 10.3322/CA.57.5.260; ELDRIDGE AC, 1983, J AGR FOOD CHEM, V31, P394, DOI 10.1021/jf00116a052; *EUR COMM, 2001, EUR UN RISK ASS REP, V10; *EUR FOOD SAF AUTH, 2006, EUR FOOD SAF AUTH OP; Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406; Franke AA, 1998, P SOC EXP BIOL MED, V217, P263; Franke AA, 1998, AM J CLIN NUTR, V68, p1466S; Gooderham MJ, 1996, J NUTR, V126, P2000; Gunderson EL, 1995, J AOAC INT, V78, P910; Gunderson EL, 1995, J AOAC INT, V78, P1353; Hargreaves DF, 1999, J CLIN ENDOCR METAB, V84, P4017, DOI 10.1210/jc.84.11.4017; Heald CL, 2006, EUR J CLIN NUTR, V60, P129, DOI 10.1038/sj.ejcn.1602277; *IRIS, 2009, CYP INT RISK INF SYS; *IRIS, 2004, DDT INT RISK INF SYS; *JOINT FAO WHO EXP, 1999, SUMM CONC 52 M ROM 2; *JOINT FAO WHO M P, 1977, PEST RES FOOD 1977; *JOINT FAO WHO M P, 1997, PEST RES FOOD 1997; Joyeux A, 1997, ANAL BIOCHEM, V249, P119, DOI 10.1006/abio.1997.2147; Kim HS, 2005, J TOXICOL ENV HEAL A, V68, P2249, DOI 10.1080/15287390500182354; King RA, 1996, J NUTR, V126, P176; Kirk P, 1999, J AM DIET ASSOC, V99, P558, DOI 10.1016/S0002-8223(99)00139-X; Kojima H, 2004, ENVIRON HEALTH PERSP, V112, P524; Koo HJ, 2005, J TOXICOL ENV HEAL A, V68, P1379, DOI 10.1080/15287390590956506; *KOR HLTH IND DEV, 2006, KHIDI PUBL; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; Lamartiniere CA, 1998, AM J CLIN NUTR, V68, p1400S; LEE JB, 2004, KOREAN J PESTIC SCI, V8, P95; Lee YH, 2003, J BIOL CHEM, V278, P523, DOI 10.1074/jbc.M209105200; Li C, 2005, BRIT J CANCER, V92, P80, DOI 10.1038/sj.bjc.6602272; Limer JL, 2004, BREAST CANCER RES, V6, P119, DOI 10.1186/bcr781; LINDSAY J, 1998, 50 UBA, P27; Makela S., 1999, HDB EXPT PHARM, V135, P613; Mazur W, 1998, BAILLIERE CLIN ENDOC, V12, P729, DOI 10.1016/S0950-351X(98)80013-X; McClain RM, 2006, FOOD CHEM TOXICOL, V44, P56, DOI 10.1016/j.fct.2005.05.021; Messina M, 2006, J AOAC INT, V89, P1121; MORTON MS, 1994, J ENDOCRINOL, V142, P251, DOI 10.1677/joe.0.1420251; Morton MS, 1997, PROSTATE, V32, P122, DOI 10.1002/(SICI)1097-0045(19970701)32:2&lt;122::AID-PROS7&gt;3.0.CO;2-O; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Mulligan AA, 2007, EUR J CLIN NUTR, V61, P248, DOI 10.1038/sj.ejcn.1602509; *NAT TOX PROGR, 2008, TECHNICAL REPORT SER, V539; NEWBOLD R, 1995, ENVIRON HEALTH PERSP, V103, P83, DOI 10.2307/3432514; Petrakis NL, 1996, CANCER EPIDEM BIOMAR, V5, P785; Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P188, DOI 10.1080/10937400701873472; Power KA, 2007, J TOXICOL ENV HEAL A, V70, P1888, DOI 10.1080/15287390701549179; Reel JR, 1996, FUND APPL TOXICOL, V34, P288, DOI 10.1006/faat.1996.0198; Reinli K, 1996, NUTR CANCER, V26, P123; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; Sacks FM, 2006, CIRCULATION, V113, P1034, DOI 10.1161/CIRCULATIONAHA.106.171052; Sakai Tohru, 2008, J Med Invest, V55, P167, DOI 10.2152/jmi.55.167; Setchell K. D. R., 2001, J NUTR, V131, p1362S; Setchell KD, 1999, J NUTR, V129, P758; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Sirtori CR, 2001, DRUG SAFETY, V24, P665, DOI 10.2165/00002018-200124090-00003; Smeets JMW, 1999, TOXICOL SCI, V50, P206, DOI 10.1093/toxsci/50.2.206; Stob M., 1983, HDB NATURALLY OCCURR, P81; Surh J, 2006, INT J FOOD SCI NUTR, V57, P325, DOI 10.1080/09637480600802348; Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223; Thompson LU, 2006, NUTR CANCER, V54, P184, DOI 10.1207/s15327914nc5402_5; Trock BJ, 2006, J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102; US EPA, 2008, INT RISK INF SYST IR; Wakai K, 1999, NUTR CANCER, V33, P139, DOI 10.1207/S15327914NC330204; *WHO, 1996, GUID DRINK WAT QUAL, V2, P602; WHO (World Health Organization), 1989, ENV HLTH CRIT, V91; Williamson-Hughes PS, 2006, MENOPAUSE, V13, P831, DOI 10.1097/01.gme.0000227330.49081.9c; Zacharewski T, 1997, ENVIRON SCI TECHNOL, V31, P613967TAYLOR &amp; FRANCIS INCPHILADELPHIA325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USAJ TOXICOL ENV HEAL ADiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology514ZI</notes>
    <keywords>1; bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; breast; breast cancer; BREAST-CANCER; BUTYL BENZYL PHTHALATE; CANCER; CHEMICALS; cohort; DDT; Developmental toxicity; diet; Dietary Exposure; DISEASE; EDC; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ESTRADIOL; Estrogenic; estrogenic effects; EXPOSURE; FDA TOTAL DIET; FOOD; FOOD-FREQUENCY QUESTIONNAIRE; FOODS; genistein; HEALTH; HUMANS; ISOFLAVONES; Menopause; Nonylphenol; Occupational; ORGANIZATION; phthalate; PHYTO-ESTROGENS; Phytoestrogen; PHYTOESTROGENS; POSTMENOPAUSAL WOMEN; Prostate; REPRODUCTIVE-SYSTEM; RISK; Risk assessment; RISK-ASSESSMENT; SOY PROTEIN ISOLATE; Steroid; SYSTEM; Tissue distribution; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1254</startpage>
    <endpage>1261</endpage>
    <journalfull>Journal of Toxicology and Environmental Health-Part A-Current Issues</journalfull>
    <issue>21-22</issue>
    <volume>72</volume>
    <abstract>Koreans generally consume high quantities of soybean-based foods that contain a variety of phytoestrogens, such as, daidzein, zenistein, and biochalin A. However, phytoestrogens are considered to be potential endocrine-disrupting chemicals (EDC), which interfere with the normal function of the hormonal and reproductive systems. Therefore, dietary exposure to soybean-based phytoestrogens is of concern for Koreans, and comparative dietary risk assessments are required between Japanese (high consumers) versus Americans (low consumers). In this study, a relative risk assessment was conducted based upon daily intake levels of soybean-based foods and phytoestrogens in a Korean cohort, and the risks of photoestrogens were compared with those posed by estradiol and other EDC. Koreans approximately 30-49 yr of age consume on average a total of 135.2 g/d of soy-based foods including soybean, soybean sauce, soybean paste, and soybean oil, and 0.51 mg/kg body weight (bw)/d of phytoestrogens such as daidzein and genistein. Using estimated daily intakes (EDI) and estrogenic potencies (EP), margins of safety (MOS) were calculated where 0.05 is for estradiol (MOS value &lt;1, considered to exert a positive estrogenic effect); thus, MOS values of 1.89 for Japanese, 1.96 for Koreans, and 5.55 for Americans indicate that consumption of soybean-based foods exerted no apparent estrogenic effects, as all MOS values were all higher than 1. For other synthetic EDC used as reference values, MOS values were dieldrin 27, nonylphenol 250, butyl benzyl phthalate 321, bisphenol A 1000, biochanin A 2203, and coumesterol 2898. These results suggest that dietary exposure to phytoestrogens, such as daidzein and genistein, poses a relatively higher health risk for humans than synthetic EDC, although MOS values were all greater than 1</abstract>
    <url>WOS:000271435300002</url>
    <isbnorissn>1528-7394</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>370</id>
    <title>Peroxisome Proliferator-Activated Receptor-gamma Mediates Bisphenol A Inhibition of FSH-Stimulated IGF-1, Aromatase, and Estradiol in Human Granulosa Cells</title>
    <authors>Kwintkiewicz,J.; Nishi,Y.; Yanase,T.; Giudice,L.C.</authors>
    <availability>[Kwintkiewicz, Jakub; Giudice, Linda C.] Univ Calif San Francisco, Dept Obstet Gynecol &amp; Reprod Sci, San Francisco, CA 94143 USA. [Nishi, Yoshihiro] Kurume Univ, Sch Med, Dept Physiol, Fukuoka, Japan. [Yanase, Toshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Med &amp; Bioregulatory Sci, Fukuoka 812, Japan.</availability>
    <date>2010</date>
    <notes>JEnglishArticleGiudice, LC (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol &amp; Reprod Sci, 505 Parnassus,M1495,Box 0132, San Francisco, CA 94143 USAgiudice@obgyn.ucsf.eduAkingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Auwerx Johan, 2003, Nucl Recept Signal, V1, pe006; Bouchard MF, 2005, ENDOCRINOLOGY, V146, P4905, DOI 10.1210/en.2005-0187; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Chen F, 2003, J CELL BIOCHEM, V90, P732, DOI 10.1002/jcb.10668; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Fan WQ, 2005, ENDOCRINOLOGY, V146, P85, DOI 10.1210/en.2004-1046; Farabollino F, 2002, ENVIRON HEALTH PERSP, V110, P409; FORTUNE JE, 1994, BIOL REPROD, V50, P225, DOI 10.1095/biolreprod50.2.225; Froment P, 2006, J ENDOCRINOL, V189, P199, DOI 10.1677/joe.1.06667; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; HILLIER SG, 1994, MOL CELL ENDOCRINOL, V100, P51; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Hunzicker-Dunn M, 2006, CELL SIGNAL, V18, P1351, DOI 10.1016/j.cellsig.2006.02.011; Khamsi F, 2001, ENDOCRINE, V16, P151, DOI 10.1385/ENDO:16:3:151; Komar CM, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-41; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; Kwintkiewicz J, 2007, MOL ENDOCRINOL, V21, P933, DOI 10.1210/me.2006-0446; Kwintkiewicz J, 2009, SEMIN REPROD MED, V27, P43, DOI 10.1055/s-0028-1108009; Lamb JD, 2008, FERTIL STERIL, V90, pS186, DOI DOI 10.1016/I.FERTNSTERT.2008.07.751; Lecka-Czernik B, 2007, ENDOCRINOLOGY, V148, P903, DOI 10.1210/en.2006-1121; Lee YM, 2006, BIOCHEM BIOPH RES CO, V345, P894, DOI 10.1016/j.bbrc.2006.04.137; Lovekamp TN, 2001, TOXICOL APPL PHARM, V172, P217, DOI 10.1006/taap.2001.9156; Lovekamp-Swan T, 2003, MOL CELL ENDOCRINOL, V201, P133, DOI 10.1016/S0303-7207(02)00423-9; Lovekamp-Swan T, 2003, ENVIRON HEALTH PERSP, V111, P139; Mlynarcikova A, 2005, MOL CELL ENDOCRINOL, V244, P57, DOI 10.1016/j.mce.2005.02.009; Monje L, 2007, J ENDOCRINOL, V194, P201, DOI 10.1677/JOE-07-0014; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; NYEGAARD M, 2010, BIOL REPROD; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Song KH, 2002, ENDOCRINOLOGY, V143, P2208, DOI 10.1210/en.143.6.2208; Susiarjo Martha, 2008, Fertil Steril, V89, pe97, DOI 10.1016/j.fertnstert.2008.01.060; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Zhou W, 2008, MOL CELL ENDOCRINOL, V283, P12, DOI 10.1016/j.mce.2007.10.010; Zoeller RT, 2007, THYROID, V17, P811, DOI 10.1089/thy.2007.0107; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-05654532US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPMARDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology567LX</notes>
    <keywords>1; apoptosis; Aromatase; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CELL; CELLS; development; ENDOCRINE; Endocrine disruptor; ESTRADIOL; EXPRESSION; FSH; GENE-EXPRESSION; granulosa; GROWTH; GROWTH-FACTOR; HEALTH; Hormone; IGF-1; In vitro; IN-VITRO; INDUCTION; inhibition; INHIBITOR; IVF; LEYDIG-CELLS; MOLECULAR-MECHANISMS; MONO-(2-ETHYLHEXYL) PHTHALATE; Nuclear receptor; Occupational; ovary; PPAR; PPAR gamma; PPAR-gamma; proliferation; PROTEIN-KINASE-A; RECEPTOR-GAMMA; REPRODUCTIVE-ORGANS; Steroid; STEROID-HORMONE PRODUCTION; steroidogenesis; Thyroid; toxicology; TRANSCRIPTION; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>400</startpage>
    <endpage>406</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>3</issue>
    <volume>118</volume>
    <abstract>BACKGROUND: Bisphenol A (BPA), a chemical used as a plasticizer, is a potent endocrine disruptor that, even in low concentrations, disturbs normal development and functions of reproductive organs in different species. OBJECTIVES: We investigated whether BPA affects human ovarian granulosa cell function. METHODS: We treated KGN granulosa cells and granulosa cells from subjects undergoing in vitro fertilization (IVF) with follicle-stimulating hormone (FSH), BPA, or BPA plus FSH in a dose- and time-dependent manner. We then evaluated expression of insulin-like growth factor 1 (IGF-1), aromatase, and transcription factors known to mediate aromatase induction by FSH [including steroidogenic factor-1 (SF-1), GATA4, cAMP response element binding protein-1 (CREB-1), and peroxisome proliferator-activated receptor-gamma (PPAR gamma)], as well as 17 beta-estradiot (E(2)) secretion. KGN cells were transfected with a PPAR gamma-containing vector, followed by assessment of aromatase and IGF-1 expression. RESULTS: BPA reduced FSH-induced IGF-1 and aromatase expression and E(2) secretion in a dose-dependent fashion. Similar effects on aromatase were observed in IVF granulosa cells. SF-1 and GATA4, but not CREB-1, were reduced after BPA treatment, although PPAR gamma, an inhibitor of aromatase, was significantly up-regulated by BPA in a dose-dependent manner, with simultaneous decrease of aromatase. Overexpression of PPAR gamma in KGN cells reduced FSH-stimulated aromatase and IGF-1 mRNAs, with increasing concentrations of the transfiected expression vector, mimicking BPA action. Also, BPA reduced granulosa cell DNA synthesis without changing DNA fragmentation, suggesting that BPA does not induce apoptosis. CONCLUSIONS: Overall, the data demonstrate that BPA induces PPAR gamma, which mediates down-regulation of FSH-stimulated IGF-1, SF-1, GATA4, aromatase, and E(2) in human granulosa cells. These observations support a potential role of altered steroidogenesis and proliferation within the ovarian follicular compartment due to this endocrine disruptor</abstract>
    <url>WOS:000275449500033</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>69</id>
    <title>Xenoestrogens Alter Estrogen Receptor (ER) alpha Intracellular Levels</title>
    <authors>La Rosa,P.; Pellegrini,M.; Totta,P.; Acconcia,F.; Marino,M.</authors>
    <availability>[La Rosa, Piergiorgio; Pellegrini, Marco; Totta, Pierangela; Acconcia, Filippo; Marino, Maria] Univ Roma Tre, Dept Sci, Rome, Italy.</availability>
    <date>2014</date>
    <notes>JEnglishArticleAcconcia, F (reprint author), Univ Roma Tre, Dept Sci, Rome, Italyfilippo.acconcia@uniroma3.it; maria.marino@uniroma3.itAcconcia F, 2005, J CELL PHYSIOL, V203, P193, DOI 10.1002/jcp.20219; ALI S, 1993, EMBO J, V12, P1153; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bolli A, 2010, IUBMB LIFE, V62, P684, DOI 10.1002/iub.370; Bulzomi P, 2012, IUBMB LIFE, V64, P690, DOI 10.1002/iub.1049; Bulzomi P, 2012, J CELL PHYSIOL, V227, P1891, DOI 10.1002/jcp.22917; Bulzomi P, 2010, IUBMB LIFE, V62, P51, DOI 10.1002/iub.279; Caiazza F, 2007, BIOCHEM BIOPH RES CO, V359, P102, DOI 10.1016/j.bbrc.2007.05.059; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Galluzzo P, 2008, ENDOCRINOLOGY, V149, P2567, DOI 10.1210/en.2007-1173; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; La Rosa P, 2012, MOL ENDOCRINOL, V26, P762, DOI 10.1210/me.2011-1208; Leclercq G, 2006, CURR CANCER DRUG TAR, V6, P39, DOI 10.2174/156800906775471716; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Li YW, 2010, PHARM RES-DORDR, V27, P1027, DOI 10.1007/s11095-010-0105-y; Manavathi B., 2012, ENDOCR REV, V34, P1; Marino M, 2012, STEROIDS, V77, P910, DOI 10.1016/j.steroids.2012.02.019; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Roger P, 2001, CANCER RES, V61, P2537; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Totta P, 2004, IUBMB LIFE, V56, P491, DOI 10.1080/15216540400010792; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422262PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEFEB 20Discipline: Science &amp; Technology - Other TopicsAB3UC</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; ALPHA; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER-CELL-GROWTH; CELL; CELLS; CHEMICALS; DEGRADATION; Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; ER alpha; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; NARINGENIN; PALMITOYLATION; PHOSPHORYLATION; proliferation; PROTEIN; RECEPTOR; SIGNALS; TURNOVER; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>2</issue>
    <volume>9</volume>
    <abstract>17 beta-estradiol (E2)-dependent estrogen receptor (ER) a intracellular concentration is a well recognized critical step in the pleiotropic effects elicited by E2 in several target tissues. Beside E2, a class of synthetic and plant-derived chemicals collectively named endocrine disruptors (EDs) or xenoestrogens bind to and modify both nuclear and extra-nuclear ER alpha activities. However, at the present no information is available on the ability of EDs to hamper ER alpha intracellular concentration. Here, the effects of bisphenol A (BPA) and naringenin (Nar), prototypes of synthetic and plant-derived ER alpha ligands, have been evaluated on ER alpha levels in MCF-7 cells. Both EDs mimic E2 in triggering ER alpha Ser118 phosphorylation and gene transcription. However, only E2 or BPA induce an increase of cell proliferation; whereas 24 hrs after Nar stimulation a dose-dependent decrease in cell number is reported. E2 or BPA treatment reduces ER alpha protein and mRNA levels after 24 hrs. Contrarily, Nar stimulation does not alter ER alpha content but reduces ER alpha mRNA levels like other ligands. Co-stimulation experiments indicate that 48 hrs of Nar treatment prevents the E2-induced ER alpha degradation and hijacks the physiological ability of E2:ER alpha complex to regulate gene transcription. Mechanistically, Nar induces ER alpha protein accumulation by preventing proteasomal receptor degradation via persistent activation of p38/MAPK pathway. As a whole these data demonstrate that ER alpha intracellular concentration is an important target through which EDs hamper the hormonal milieu of E2 target cells driving cells to different outcomes or mimicking E2 even in the absence of the hormone</abstract>
    <url>WOS:000331714700044</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>385</id>
    <title>Estrogenic in vitro assay on mouse embryonic Leydig cells</title>
    <authors>La Sala,G.; Farini,D.; De Felici,M.</authors>
    <availability>[La Sala, Gina; Farini, Donatella; De Felici, Massimo] Univ Roma Tor Vergata, Dept Publ Hlth &amp; Cell Biol, Sect Histol &amp; Embryol, Rome, Italy.</availability>
    <date>2010</date>
    <notes>JEnglishArticleDe Felici, M (reprint author), Univ Roma Tor Vergata, Dipartimento Sanita Pubbl &amp; Biol Cellulare, Via Montpellier 1, I-00173 Rome, Italydefelici@uniroma2.itBalaguer P, 2001, LUMINESCENCE, V16, P153, DOI 10.1002/bio.630.abs; Cederroth CR, 2007, ENDOCRINOLOGY, V148, P5507, DOI 10.1210/en.2007-0689; Delbes G, 2005, ENDOCRINOLOGY, V146, P2454, DOI 10.1210/en.2004-1540; Delbes G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231; Delbes G, 2007, TOXICOL SCI, V99, P234, DOI 10.1093/toxsci/kfm160; Detre S, 1999, INT J CANCER, V81, P309, DOI 10.1002/(SICI)1097-0215(19990412)81:2&lt;309::AID-IJC23&gt;3.0.CO;2-S; Gaido KW, 2007, TOXICOL SCI, V97, P491, DOI 10.1093/toxsci/kfm049; GRECO TL, 1992, ENDOCRINOLOGY, V130, P421, DOI 10.1210/en.130.1.421; Guyot R, 2004, MOL CELL ENDOCRINOL, V220, P67, DOI 10.1016/j.mce.2004.03.008; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Jefferson WN, 2000, BIOL REPROD, V62, P310, DOI 10.1095/biolreprod62.2.310; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lassurguere J, 2003, TOXICOL SCI, V73, P160, DOI 10.1093/toxsci/kfg065; Majdic G, 1997, MOL CELL ENDOCRINOL, V127, P91, DOI 10.1016/S0303-7207(96)03998-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; Nielsen M, 2000, J REPROD FERTIL, V118, P195, DOI 10.1530/reprod/118.1.195; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Okubo T, 2003, BIOL PHARM BULL, V26, P1219; PESCE M, 1995, DEV BIOL, V170, P722, DOI 10.1006/dbio.1995.1250; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Saunders PT, 1998, J ENDOCRINOL, V156, P13; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Shier WT, 2001, TOXICON, V39, P1435, DOI 10.1016/S0041-0101(00)00259-2; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Steinmetz R, 1996, CANCER RES, V56, P5403; Traina ME, 2003, REPROD TOXICOL, V17, P25, DOI 10.1016/S0890-6238(02)00101-6; Truchet I, 2000, EXP CELL RES, V254, P241, DOI 10.1006/excr.1999.4756; Vicini E, 2006, J CELL PHYSIOL, V206, P238, DOI 10.1002/jcp.20454; Washington W, 2001, IN VITRO MOL TOXICOL, V14, P43334U B C PRESSBILBAOUNIV BASQUE COUNTRY, EDITORIAL SERVICES, PO BOX 1397, E-48080 BILBAO, SPAININT J DEV BIOLDiscipline: Developmental Biology589EH</notes>
    <keywords>1; 17-BETA-ESTRADIOL; ALPHA; ANTIESTROGEN; AP-1; ASSAY; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; CELLS; DIETHYLSTILBESTROL; Differentiation; E2; ER alpha; ER-ALPHA; ERE; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptor alpha; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; FETAL-RAT TESTIS; GENE; IDENTIFICATION; In vitro; IN-VITRO; INDUCTION; Leydig cells; lindane; LUCIFERASE REPORTER; MEHP; MICE; Mouse; p21; PATHWAY; Phytoestrogen; PRIMORDIAL GERM-CELLS; proliferation; RECEPTOR; RECEPTOR-ALPHA; REPORTER GENE; Reproduction; Somatic cells; Steroid; Transfection; VITRO; xenoestrogen; XENOESTROGENS; ZEA</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>717</startpage>
    <endpage>722</endpage>
    <journalfull>International Journal of Developmental Biology</journalfull>
    <issue>4</issue>
    <volume>54</volume>
    <abstract>We and others have reported that mouse embryonic testes contain a subpopulation of somatic cells expressing estrogen receptor alpha (ER alpha). In order to provide evidence for a possible direct estrogen effect on mammalian testes from the early stage of their differentiation, here we devised a method for the in vitro culture of the ER alpha-expressing cells from 12.5 days post coitum mouse testes and their transfection with plasmids containing the classical estrogen responsive element (ERE) or the alternative estrogen AP-1 responsive element upstream of the luciferase reporter gene (ERE-Luc and AP-1-Luc). StAR immunopositivity of the most part of the ER alpha+ cells grown in culture and subjected to the estrogenic assay, allowed their identification as embryonic Leydig cells. Maximum induction of the ERE-Luc activity was achieved with 10 nM 17-beta estradiol (E2), from 1.7 to 3-fold in such cells and from 2.3 to 5.7-fold in MCF-7 cells used for comparison; the anti-estrogen ICI 182.780 abolished such effects. AP-1-Luc was less sensitive to E2 in both cell types (10 nM E2, 1.2 to 2.7-fold increase in embryonic Leydig cells; about 3-fold in MCF-7 cells) and the effect was not ICI-dependent. Eventually, we stimulated the transfected cells with various xenoestrogens such as lindane, bisphenol A or mono-(2-ethylhexyl) pthalate and with the phytoestrogen zeralenone obtaining evidence for ERE-Luc, but not AP-1-Luc stimulation in embryonic Leydig cells. These results represent evidence of functional ER alpha-dependent genomic pathways in embryonic Leydig cells and describe an in vitro assay suitable for evaluating the activity of putative estrogenic compounds on such cells</abstract>
    <url>WOS:000277128600019</url>
    <isbnorissn>0214-6282</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>39</id>
    <title>Critical comments on the WHO-UNEP State of the Science of Endocrine Disrupting Chemicals-2012</title>
    <authors>Lamb,J.C.; Boffetta,P.; Foster,W.G.; Goodman,J.E.; Hentz,K.L.; Rhomberg,L.R.; Staveley,J.; Swaen,G.; Van Der Kraak,G.; Williams,A.L.</authors>
    <availability>[Lamb, James C.; Hentz, Karyn L.; Staveley, Jane; Williams, Amy L.] Exponent, Alexandria, VA 22314 USA. [Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA. [Boffetta, Paolo] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA. [Foster, Warren G.] McMaster Univ, Dept Obstet &amp; Gynecol, Hamilton, ON L8S 4K1, Canada. [Goodman, Julie E.; Rhomberg, Lorenz R.] Gradient, Cambridge, MA 02138 USA. [Swaen, Gerard] Lenz, Exponent, Harrogate HG2 8RE, England. [Van Der Kraak, Glen] Univ Guelph, Dept Integrat Biol, Guelph, ON N1G 2W1, Canada.</availability>
    <date>2014</date>
    <notes>JEnglishArticleLamb, JC (reprint author), Exponent, 1800 Diagonal Rd,Suite 500, Alexandria, VA 22314 USAjlamb@exponent.com; paolo.boffetta@gmail.com; foster@mcmaster.ca; jgoodman@gradientcorp.com; khentz@exponent.com; lrhomberg@gradientcorp.com; jstaveley@exponent.com; gswaen@exponent.com; gvanderk@uoguelph.ca; awilliams@exponent.comAhmed OM, 2008, INT J DEV NEUROSCI, V26, P147, DOI 10.1016/j.ijdevneu.2007.09.011; Alavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; Aronson KJ, 2010, J EXPO SCI ENV EPID, V20, P434, DOI 10.1038/jes.2009.33; Auger J, 1997, HUM REPROD, V12, P740, DOI 10.1093/humrep/12.4.740; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Axelsson J, 2011, HUM REPROD, V26, P1012, DOI 10.1093/humrep/der045; BASTOMSK.CH, 1974, ENDOCRINOLOGY, V95, P1150; Benbrahim-Tallaa L, 2008, ENVIRON HEALTH PERSP, V116, P158, DOI 10.1289/ehp.10423; Bergman A, 2012, STATE SCI ENDOCRINE; Bianco AC, 2006, J CLIN INVEST, V116, P2571, DOI 10.1172/JCI29812; Bonde JP, 2011, EPIDEMIOLOGY, V22, P617, DOI 10.1097/EDE.0b013e318223442c; Borgert CJ, 2013, REGUL TOXICOL PHARM, V67, P83, DOI 10.1016/j.yrtph.2013.06.007; HILL AB, 1965, P ROY SOC MED, V58, P295; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Bruner-Tran KL, 1999, GYNECOL OBSTET INVES, V48, P45, DOI 10.1159/000052868; BRYAN GW, 1968, J MAR BIOL ASSOC UK, V49, P1067; Cakmak H, 2010, SEMIN REPROD MED, V28, P69, DOI 10.1055/s-0029-1242996; CARLSEN E, 1992, BRIT MED J, V305, P609; Young Margaret B., 2012, Morbidity and Mortality Weekly Report, V61, P1; Cerna M, 2012, INT J HYG ENVIR HEAL, V215, P109, DOI 10.1016/j.ijheh.2011.09.007; Clark LS, 2006, J COMP PATHOL, V135, P208, DOI 10.1016/j.jcpa.2006.07.005; Conrad JW, 2011, ENVIRON HEALTH PERSP, V119, P757, DOI 10.1289/ehp.1002737; Conrad JW, 2011, ENVIRON HEALTH PERSP, V119, pA508, DOI 10.1289/eph.1104385R; Costello MF, 2002, J ASSIST REPROD GEN, V19, P284, DOI 10.1023/A:1015729314081; *DAN CTR END DISR, 2013, MST62100050 DTU DAN; DIETRICH R, 2013, TOXICOL IN VITRO; Duchan E, 2012, PEDIATR CLIN N AM, V59, P27, DOI 10.1016/j.pcl.2011.10.003; Du Preez LH, 2009, AQUAT TOXICOL, V95, P10, DOI 10.1016/j.aquatox.2009.07.018; *EFSA, 2010, EFSA J, V8, P1932; EFSA Scientific Committee, 2013, EFSA J, V11, P3132; Elia Jlenia, 2012, Arch Ital Urol Androl, V84, P26; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; European Food Safety Authority (EFSA), 2013, EFSA J; Ferriby LL, 2007, J EXPO SCI ENV EPID, V17, P358, DOI 10.1038/sj.jes.7500498; Fisch H, 2013, ASIAN J ANDROL, V15, P169, DOI 10.1038/aja.2012.143; Fisch H, 2010, J PEDIATR UROL, V6, P37, DOI 10.1016/j.jpurol.2009.05.005; Fombonne E, 2009, MCGILL J MED, V12, P99; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gentile I, 2013, MED HYPOTHESES, V81, P26, DOI 10.1016/j.mehy.2013.04.002; Gibbs PE, 1999, J MAR BIOL ASSOC UK, V79, P103, DOI 10.1017/S0025315498000113; Glass AG, 2007, J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; GOLDEY ES, 1995, TOXICOL APPL PHARM, V135, P77, DOI 10.1006/taap.1995.1210; Goodman J, 2009, CRIT REV TOXICOL, V39, P1, DOI 10.3109/10408440903279946; Goodman JE, 2006, CRIT REV TOXICOL, V36, P387, DOI 10.1080/10408440600758317; Goodman JE, 2010, REGUL TOXICOL PHARM, V58, P308, DOI 10.1016/j.yrtph.2010.07.002; *GRADE, 2011, FREQ ASK QUEST; Guinchat V, 2012, ACTA OBSTET GYN SCAN, V91, P287, DOI 10.1111/j.1600-0412.2011.01325.x; Guo SW, 2009, MOL HUM REPROD, V15, P587, DOI 10.1093/molehr/gap064; HAMMOUD AO, 2008, FERTIL STERIL, V90, P2221; Hardell L, 2006, J OCCUP ENVIRON MED, V48, P700, DOI 10.1097/01.jom.0000205989.46603.43; Harvey PW, 2010, J APPL TOXICOL, V30, P617, DOI 10.1002/jat.1569; Hayes T, 2003, ENVIRON HEALTH PERSP, V111, P568, DOI 10.1289/ehp.5932; *HELCOM, 2012, BALT SEA ENV FACT SH; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Henny CJ, 2010, J TOXICOL ENV HEAL B, V13, P579, DOI 10.1080/10937404.2010.538658; Howdeshell KL, 2002, ENVIRON HEALTH PERSP, V110, P337; *IARC, 2004, IARC MON EV CARC RIS, V84, P41; IOM (Institute of Medicine), 2012, BREAST CANC ENV LIF; *IPCS, 2004, 1 IPCS WHO; Itoh H, 2009, SCI TOTAL ENVIRON, V408, P37, DOI 10.1016/j.scitotenv.2009.09.012; Jorgensen 1 N, 2012, BMJ OPEN, V2; Jorgensen N, 2011, INT J ANDROL, V34, pE37, DOI 10.1111/j.1365-2605.2010.01133.x; Jorgensen N, 2001, HUM REPROD, V16, P1012, DOI 10.1093/humrep/16.5.1012; Jorundsdottir K, 2005, MAR POLLUT BULL, V51, P744, DOI 10.1016/j.marpolbul.2005.04.012; Kabbarah O, 2005, INT J CANCER, V115, P666, DOI 10.1002/ijc.20918; Kato Y, 2010, DRUG METAB DISPOS, V38, P697, DOI 10.1124/dmd.109.031153; Kato Y, 2004, TOXICOL SCI, V81, P309, DOI 10.1093/toxsci/kfh225; Keller DA, 2012, TOXICOL SCI, V126, P291, DOI 10.1093/toxsci/kfr350; Kinast K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00072; Klimisch HJ, 1997, REGUL TOXICOL PHARM, V25, P1, DOI 10.1006/rtph.1996.1076; Kloas W, 2009, TOXICOL SCI, V107, P376, DOI 10.1093/toxsci/kfn232; Kollara A, 2006, BIOCHEM BIOPH RES CO, V346, P526, DOI 10.1016/j.bbrc.2006.05.148; Koutros S, 2010, J OCCUP ENVIRON MED, V52, P1098, DOI 10.1097/JOM.0b013e3181f72b7c; Kripke Clarissa, 2005, Am Fam Physician, V72, P1224; KUIKEN T, 1993, MAR POLLUT B, V26, P400; Lair S, 1997, J WILDLIFE DIS, V33, P430; Leclere B, 2013, CANCER EPIDEMIOL, V37, P544, DOI 10.1016/j.canep.2013.05.001; Lind PM, 2003, AMBIO, V32, P385, DOI 10.1639/0044-7447(2003)032[0385:BMDIMB]2.0.CO;2; Marimuthu P, 2003, ASIAN J ANDROL, V5, P221; Martin L, 2010, TOXICOL SCI, V117, P36, DOI 10.1093/toxsci/kfq187; Mayes BA, 1998, TOXICOL SCI, V41, P62; McDaniel TV, 2008, AQUAT TOXICOL, V88, P230, DOI 10.1016/j.aquatox.2008.05.002; Morton B, 2009, MAR POLLUT BULL, V58, P1530, DOI 10.1016/j.marpolbul.2009.05.012; Murphy MB, 2006, AQUAT TOXICOL, V76, P230, DOI 10.1016/j.aquatox.2005.09.010; Nakamura Y, 2000, J AOAC INT, V83, P635; Nakatani T, 2011, ARCH ENVIRON CON TOX, V60, P543, DOI 10.1007/s00244-010-9553-y; *NCI, 2013, PROST CANC PREV PDQ; NELSON CMK, 1974, FERTIL STERIL, V25, P503; Nilsson R, 2000, TOXICOL PATHOL, V28, P420, DOI 10.1177/019262330002800311; NOHYNEK GJ, 2013, TOXICOL LETT; Nost TH, 2013, ENVIRON HEALTH PERSP, V121, P1292, DOI 10.1289/ehp.1206317; NRC (National Research Council), 2005, HLTH IMPL PERCHL ING; NTP, 2006, NATL TOXICOL PROGRAM, V06-4465, P4; *NTP, 2010, NTP CERHR EXP PAN RE, P1; *OECD, 2005, MAN INV HPV CHEM; Pal PC, 2006, ANDROLOGIA, V38, P20, DOI 10.1111/j.1439-0272.2006.00685.x; Rhomberg LR, 2012, REGUL TOXICOL PHARM, V64, P130, DOI 10.1016/j.yrtph.2012.06.015; Rhomberg LR, 2012, CRIT REV TOXICOL, V42, P465, DOI 10.3109/10408444.2012.690367; Rice Catherine, 2007, Morbidity and Mortality Weekly Report, V56, P1; RICE CE, 2012, PUBLIC HLTH REV, V34, P1; Rier SE, 2001, TOXICOL SCI, V59, P147, DOI 10.1093/toxsci/59.1.147; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; ROBERTSON A, 1991, J MAR BIOL ASSOC UK, V71, P569; Rolland M, 2013, HUM REPROD, V28, P462, DOI 10.1093/humrep/des415; Sawada N, 2010, ENVIRON HEALTH PERSP, V118, P659, DOI 10.1289/ehp.0901214; Schmidt RJ, 2011, EPIDEMIOLOGY, V22, P476, DOI 10.1097/EDE.0b013e31821d0e30; Schuhmacher-Wolz U, 2009, CRIT REV TOXICOL, V39, P271, DOI 10.1080/10408440802291505; SAcradour B, 2009, Bull Cancer, V96, pE1, DOI 10.1684/bdc.2009.0869; Sharpe RM, 2010, PHILOS T R SOC B, V365, P1697, DOI 10.1098/rstb.2009.0206; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Sirot V, 2012, CHEMOSPHERE, V88, P492, DOI 10.1016/j.chemosphere.2012.03.004; Skelly DK, 2010, ECOHEALTH, V7, P374, DOI 10.1007/s10393-010-0348-4; Smith EE, 2005, AFR J HERPETOL, V54, P69; Soto AM, 1995, ONCOL RES, V7, P545; Spolyarich N, 2011, ENVIRON MONIT ASSESS, V173, P397, DOI 10.1007/s10661-010-1395-6; Stump DG, 2010, TOXICOL SCI, V115, P167, DOI 10.1093/toxsci/kfq025; Swan SH, 1997, ENVIRON HEALTH PERSP, V105, P1228; TEEGUARDEN JG, 2013, FOOD CHEM TOXICOL; Tinwell H, 2013, REGUL TOXICOL PHARM, V66, P184, DOI 10.1016/j.yrtph.2013.04.002; Titley-O'Neal CP, 2011, J ENVIRON MONITOR, V13, P2360, DOI 10.1039/c1em10011d; Tyl RW, 2008, TOXICOL SCI, V104, P362, DOI 10.1093/toxsci/kfn084; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; *USEPA, 2013, STAT SCI EV NONM DOS; *USEPA, 2014, VOC CAT LIST DET INT; *USFDA, 2009, FDA2010N01000001; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Van Maele-Fabry G, 2004, INT ARCH OCC ENV HEA, V77, P559, DOI 10.1007/s00420-004-0548-8; van Maele-Fabry G, 2006, CANCER CAUSE CONTROL, V17, P353, DOI 10.1007/s10552-005-0443-y; Verhaegen Y, 2012, CHEMOSPHERE, V86, P979, DOI 10.1016/j.chemosphere.2011.11.028; Wakai K, 1999, NUTR CANCER, V33, P139, DOI 10.1207/S15327914NC330204; WEEDONFEKJAER H, 2012, BMJ-BRIT MED J, V30, pE299; *WHO, 2002, GLOBAL ASSESSMENT ST; Wilhelm M, 2007, INT J HYG ENVIR HEAL, V210, P307, DOI 10.1016/j.ijheh.2007.01.039; WING L, 1976, PSYCHOL MED, V6, P89; Wittassek M, 2007, INT J HYG ENVIR HEAL, V210, P319, DOI 10.1016/j.ijheh.2007.01.037; Xu XH, 2010, ENVIRON HEALTH PERSP, V118, P60, DOI 10.1289/ehp.0900919; Yolton K, 2011, NEUROTOXICOL TERATOL, V33, P558, DOI 10.1016/j.ntt.2011.08.003; Younglai EV, 1998, FERTIL STERIL, V70, P76, DOI 10.1016/S0015-0282(98)00118-6; Zoeller RT, 2000, ENDOCRINOLOGY, V141, P181, DOI 10.1210/en.141.1.1811391ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAREGUL TOXICOL PHARMJUNDiscipline: Legal Medicine; Pharmacology &amp; Pharmacy; ToxicologyAG0SL</notes>
    <keywords>AUTISM SPECTRUM DISORDERS; CANCER; Causation; CELL; CHEMICALS; DIBENZO-P-DIOXINS; DIETARY BISPHENOL-A; Disease trends; DISRUPTING CHEMICALS; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals (EDCs); EXPOSURE; FOOD; FROGS RANA-PIPIENS; In vitro; IN-VITRO; Low-dose effects; mechanism; Non-monotonic dose response (NMDR); NONMONOTONIC DOSE-RESPONSES; POLYCHLORINATED-BIPHENYLS; PROSTATE-CANCER RISK; RISK; SEMEN QUALITY; SERUM THYROXINE LEVEL; SPRAGUE-DAWLEY RATS; State of the science; Weight of evidence</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>22</startpage>
    <endpage>40</endpage>
    <journalfull>Regulatory Toxicology and Pharmacology</journalfull>
    <issue>1</issue>
    <volume>69</volume>
    <abstract>Early in 2013, the World Health Organization (WHO) released a 2012 update to the 2002 State of the Science of Endocrine Disrupting Chemicals. Several significant concerns have been identified that raise questions about conclusions reached in this report regarding endocrine disruption. First, the report is not a stateof-the-science review and does not follow the 2002 WHO recommended weight-of-evidence approach. Second, endocrine disruption is often presumed to occur based on exposure or a potential mechanism despite a lack of evidence to show that chemicals are causally established as endocrine disruptors. Additionally, causation is often inferred by the presentation of a series of unrelated facts, which collectively do not demonstrate causation. Third, trends in disease incidence or prevalence are discussed without regard to known causes or risk factors; endocrine disruption is implicated as the reason for such trends in the absence of evidence. Fourth, dose and potency are ignored for most chemicals discussed. Finally, controversial topics (i.e., low dose effects, non-monotonic dose response) are presented in a one-sided manner and these topics are important to understanding endocrine disruption. Overall, the 2012 report does not provide a balanced perspective, nor does it accurately reflect the state of the science on endocrine disruption. (C) 2014 The Authors. Published by Elsevier Inc</abstract>
    <url>WOS:000335125800003</url>
    <isbnorissn>0273-2300</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>410</id>
    <title>Why pesticides could be a common cause of prostate and breast cancers in the French Caribbean Island, Martinique. An overview on key mechanisms of pesticide-induced cancer</title>
    <authors>Landau-Ossondo,M.; Rabia,N.; Jos-Pelage,J.; Marquet,L.M.; Isidore,Y.; Saint-Aime,C.; Martin,M.; Irigaray,P.; Belpomme,D.</authors>
    <availability>[Martin, M.; Irigaray, P.; Belpomme, D.] ARTAC, Canc Res Ctr, F-75015 Paris, France. [Landau-Ossondo, M.] Ctr Hosp Univ Ft France, Anatomopathol Lab, F-97200 Fort De France, Martinique. [Rabia, N.] Ctr Hosp Univ Ft France, Dept Urol, F-97200 Fort De France, Martinique. [Marquet, L. M.] Ctr Hosp Univ Ft France, Dept Obstet &amp; Gynaecol, F-97200 Fort De France, Martinique. [Isidore, Y.] Ctr Hosp Reg Lamentin, Dept Pediat, F-97232 Lamentin, Martinique. [Saint-Aime, C.] Ctr Hosp Univ Ft France, Dept Pediat, F-97200 Fort De France, Martinique. [Belpomme, D.] Univ Paris 05, Dept Med Oncol, European Hosp Georges Pompidou HEGP, F-75015 Paris, France.</availability>
    <date>2009</date>
    <notes>JEnglishReviewBelpomme, D (reprint author), ARTAC, Canc Res Ctr, 57-59 Rue Convent, F-75015 Paris, Franceartac.cerc@wanadoo.frAbdalla MH, 2003, BIOMED SCI INSTRUM, V39, P397; Alavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; Ames BN, 1997, FASEB J, V11, P1041; Andersen HR, 2002, TOXICOL APPL PHARM, V179, P1, DOI 10.1006/taap.2001.9347; ARMITAGE P, 1985, ENVIRON HEALTH PERSP, V63, P195, DOI 10.2307/3430046; Band PR, 2000, J OCCUP ENVIRON MED, V42, P284, DOI 10.1097/00043764-200003000-00010; Bassil K L, 2007, Can Fam Physician, V53, P1704; Belpomme D, 2009, INT J ONCOL, V34, P1037, DOI 10.3892/ijo_00000229; Belpomme D, 2007, BIOMED PHARMACOTHER, V61, P611, DOI 10.1016/j.biopha.2007.10.007; Belpomme D, 2007, ENVIRON RES, V105, P414, DOI 10.1016/j.envres.2007.07.002; Bigsby RM, 1997, CANCER RES, V57, P865; Bocquene G, 2005, MAR POLLUT BULL, V51, P612, DOI 10.1016/j.marpolbul.2005.06.026; Bosland MC, 2006, ANN NY ACAD SCI, V1089, P168, DOI 10.1196/annals.1386.040; Bosland MC., 2000, J NATL CANC I MONOGR, V27, P39; Bouchardy C, 2007, BRIT J CANCER, V96, P1743, DOI 10.1038/sj.bjc.6603783; Brody JG, 2003, ENVIRON HEALTH PERSP, V111, P1007, DOI 10.1289/ehp.6310; CABIDOCHE YM, 2009, ENVIRON POLLUT, DOI DOI 10.1016/J.ENVPO1.2008.12.015; Carruba G, 2007, J CELL BIOCHEM, V102, P899, DOI 10.1002/jcb.21529; Cassidy RA, 2005, BREAST CANCER RES TR, V90, P55, DOI 10.1007/s10549-004-2755-0; Charlier C, 2003, OCCUP ENVIRON MED, V60, P348, DOI 10.1136/oem.60.5.348; Chen SU, 2001, J STEROID BIOCHEM, V79, P35, DOI 10.1016/S0960-0760(01)00132-7; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Danzo BJ, 1997, ENVIRON HEALTH PERSP, V105, P294, DOI 10.1289/ehp.97105294; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Demers A, 2000, CANCER EPIDEM BIOMAR, V9, P161; DEWAILLY E, 1994, J NATL CANCER I, V86, P232, DOI 10.1093/jnci/86.3.232; DHOM G, 1983, J CANCER RES CLIN, V106, P210, DOI 10.1007/BF00402610; Dolapsakis G, 2001, EUR J CANCER, V37, P1531, DOI 10.1016/S0959-8049(01)00159-9; Dorgan JF, 1999, CANCER CAUSE CONTROL, V10, P1, DOI 10.1023/A:1008824131727; Duell EJ, 2000, EPIDEMIOLOGY, V11, P523, DOI 10.1097/00001648-200009000-00007; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951; El-Mubarak A, 2001, ANAL SCI, V17, P261; Escriva H, 2004, ESSAYS BIOCHEM, V40, P11; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; Fenichel P, 2008, GYNECOL OBSTET FERTI, V36, P969, DOI 10.1016/j.gyobfe.2008.05.006; Ferlay J, 2002, CANC INCIDENCE MORTA; Foster WG, 2004, TOXICOL SCI, V77, P91, DOI 10.1093/toxsci/kfg247; Friedman AE, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742-4682-2-10; GELLERT RJ, 1978, ENVIRON RES, V16, P131, DOI 10.1016/0013-9351(78)90150-0; Gladen BC, 2000, J PEDIATR, V136, P490, DOI 10.1016/S0022-3476(00)90012-X; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; GRAY LJ, 1992, CHEM INDUCED ALTERAT, P230; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; HAMMOND B, 1979, P NATL ACAD SCI USA, V76, P6641, DOI 10.1073/pnas.76.12.6641; Hardell L, 2006, J OCCUP ENVIRON MED, V48, P700, DOI 10.1097/01.jom.0000205989.46603.43; Hill AB, 1965, P ROY SOC MED, V58, P293; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hopenhayn-Rich C, 2002, ARCH ENVIRON CON TOX, V42, P127, DOI 10.1007/s002440010300; Hoyer AP, 2000, J CLIN EPIDEMIOL, V53, P323, DOI 10.1016/S0895-4356(99)00165-1; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; Huang JS, 2007, MATERN CHILD HLTH J, V11, P461, DOI 10.1007/s10995-006-0141-8; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; *IARC, 1997, IARC MONOGR EVAL CAR, V69; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; IFEN, 2007, PEST EAUX DONN 2005; Irigaray P, 2009, TOXICOL LETT, V187, P35, DOI 10.1016/j.toxlet.2009.01.021; Irigaray P, 2006, FEBS J, V273, P1362, DOI 10.1111/j.1742-4658.2006.05159.x; Irigaray P, 2007, BIOMED PHARMACOTHER, V61, P665, DOI 10.1016/j.biopha.2007.10.008; Johnson DC, 1996, TOXICOL LETT, V89, P57, DOI 10.1016/S0378-4274(96)03789-7; Kang KS, 1996, ENVIRON HEALTH PERSP, V104, P192, DOI 10.2307/3432789; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KLAUNIG JE, 1990, PROG CLIN BIOL RES, V340, P165; KLAUNIG JE, 1990, LAB INVEST, V62, P135; KRIEGER N, 1994, J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; Krstevska-Konstantinova M, 2001, HUM REPROD, V16, P1020, DOI 10.1093/humrep/16.5.1020; Kuiper G. G. J. M., 1998, SCI MED, V5, P36; Laville N, 2006, TOXICOLOGY, V228, P98, DOI 10.1016/j.tox.2006.08.021; Lemaire G, 2006, LIFE SCI, V79, P1160, DOI 10.1016/j.lfs.2006.03.023; Li J, 2008, TOXICOL LETT, V183, P65, DOI 10.1016/j.toxlet.2008.10.002; Lo S, 2007, TOXICOL IN VITRO, V21, P502, DOI 10.1016/j.tiv.2006.10.016; LOEBER J G, 1984, Food Additives and Contaminants, V1, P63; LUTZ WK, 1990, CARCINOGENESIS, V11, P1243, DOI 10.1093/carcin/11.8.1243; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; Mahajan R, 2006, ENVIRON HEALTH PERSP, V114, P1205, DOI 10.1289/ehp.8911; Markey CM, 2001, BIOL REPROD, V65, P1215; MARTIN M, 1973, THESIS INRA ANTILLES; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; McPherson K, 2000, BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Meyer TE, 2007, OCCUP ENVIRON MED, V64, P155, DOI 10.1136/oem.2006.027383; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Mills PK, 2003, J OCCUP ENVIRON MED, V45, P249, DOI 10.1097/01.jom.0000058339.05741.0c; Mills PK, 2006, J ENVIRON HEALTH, V68, P15; Modugno F, 2001, CLIN CANCER RES, V7, P3092; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; MORRISON H, 1993, AM J EPIDEMIOL, V137, P270; Munoz-de-Toro M, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1534; MUSSALORAUHAMAA H, 1990, CANCER, V66, P2124, DOI 10.1002/1097-0142(19901115)66:10&lt;2124::AID-CNCR2820661014&gt;3.0.CO;2-A; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; NOBLE RL, 1982, INT REV EXP PATHOL, V23, P113; Okubo T, 2004, ARCH ENVIRON CON TOX, V46, P445, DOI 10.1007/s00244-003-3017-6; Prins GS, 2001, REPROD FERT DEVELOP, V13, P241, DOI 10.1071/RD00107; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Prins GS, 2008, ENDOCR-RELAT CANCER, V15, P649, DOI 10.1677/ERC-08-0043; Remontet L, 2003, EVOLUTION INCIDENCE; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; ROBISON AK, 1985, TOXICOL LETT, V27, P109, DOI 10.1016/0378-4274(85)90127-4; ROBISON AK, 1985, J TOXICOL ENV HEALTH, V16, P493; Romieu I, 2000, AM J EPIDEMIOL, V152, P363, DOI 10.1093/aje/152.4.363; RUCH RJ, 1986, CANCER LETT, V33, P137, DOI 10.1016/0304-3835(86)90018-2; Rudel RA, 2007, CANCER, V109, P2635, DOI 10.1002/cncr.22653; Safe S, 2006, TRENDS PHARMACOL SCI, V27, P447, DOI 10.1016/j.tips.2006.06.006; Safe SH, 1997, NEW ENGL J MED, V337, P1303, DOI 10.1056/NEJM199710303371809; Sanderson T, 2003, PURE APPL CHEM, V75, P1957, DOI 10.1351/pac200375111957; Schrader TJ, 2000, TOXICOL SCI, V53, P278, DOI 10.1093/toxsci/53.2.278; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; Settimi L, 2003, INT J CANCER, V104, P458, DOI 10.1002/ijc.10955; Shekhar PVM, 1997, J NATL CANCER I, V89, P1774; Smink A, 2008, ACTA PAEDIATR, V97, P1465, DOI 10.1111/j.1651-2227.2008.00937.x; Snedeker SM, 2001, ENVIRON HEALTH PERSP, V109, P35, DOI 10.2307/3434918; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Stellman SD, 2000, CANCER EPIDEM BIOMAR, V9, P1241; UNGER M, 1980, ENVIRON RES, V23, P257, DOI 10.1016/0013-9351(80)90059-6; UNGER M, 1984, ENVIRON RES, V34, P24, DOI 10.1016/0013-9351(84)90072-0; Usmani KA, 2006, DRUG METAB DISPOS, V34, P1606, DOI 10.1124/dmd.106.010439; Van Maele-Fabry G, 2004, INT ARCH OCC ENV HEA, V77, P559, DOI 10.1007/s00420-004-0548-8; van Maele-Fabry G, 2006, CANCER CAUSE CONTROL, V17, P353, DOI 10.1007/s10552-005-0443-y; Vineis P, 2006, INT J EPIDEMIOL, V35, P1151, DOI 10.1093/ije/dyl185; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; WASSERMANN M, 1976, B ENVIRON CONTAM TOX, V15, P478; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Willett KL, 1998, ENVIRON SCI TECHNOL, V32, P2197, DOI 10.1021/es9708530; WOLFF MS, 1993, J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; Woolcott CG, 2001, CANCER CAUSE CONTROL, V12, P395, DOI 10.1023/A:1011289905751; Yang C, 1999, CANCER RES, V59, P4519; Yang GS, 2007, CHINESE MED J-PEKING, V120, P1611; You L, 1999, TOXICOL APPL PHARM, V157, P134, DOI 10.1006/taap.1999.8673; You L, 2001, MOL CELL ENDOCRINOL, V178, P207, DOI 10.1016/S0303-7207(01)00445-213815ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERPARIS23 RUE LINOIS, 75724 PARIS, FRANCEBIOMED PHARMACOTHERJULDiscipline: Research &amp; Experimental Medicine; Pharmacology &amp; Pharmacy476GG</notes>
    <keywords>ACTIVITY IN-VITRO; ADIPOSE-TISSUE; analysis; BISPHENOL-A ALTERS; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CHILDREN; ENDOCRINE; Endocrine disruption; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; environmental factors; ENVIRONMENTAL-FACTORS; Epidemiology; ESTROGEN-RECEPTOR; EXPOSURE; Foetus-susceptibility; FOOD; GROWTH; HEALTH; In vitro; IN-VITRO; Incidence; INTERCELLULAR COMMUNICATION; low dose; MAMMARY-GLAND MORPHOLOGY; mechanism; MECHANISMS; MODEL; Obesity; ORGANOCHLORINE PESTICIDES; PESTICIDES; PHARMACOLOGY; POPULATION; PREVENTION; Prostate; prostate cancer; PROSTATE CARCINOGENESIS; PROSTATE-CANCER; Review; SET; SMALL EXPOSURES; SPRAGUE-DAWLEY RATS; Steroid; SUSCEPTIBILITY; toxicology; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>383</startpage>
    <endpage>395</endpage>
    <journalfull>Biomedicine &amp; Pharmacotherapy</journalfull>
    <issue>6</issue>
    <volume>63</volume>
    <abstract>Prostate and breast cancers have become very frequent in Martinique. We previously conducted a multifactorial analysis in the French Caribbean Island, Martinique, in order to elucidate the aetiology of prostate cancer. Using a linear regression analysis, we found that the growth curves of incidence rates for Martinique and metropolitan France have been significantly diverging since 1983. Although a Caribbean genetic susceptibility factor may be involved in prostate carcinogenesis: this factor, because it could not have changed during the observation period, cannot per se account for the growing incidence of this cancer in the island. We therefore suggested that among possible environmental factors, the intensive and prolonged exposure to Carcinogenic, Mutagenic and/or Reprotoxic (CMR) or presumed CMR pesticides may account for the observed growing incidence of prostate cancer and thus may be involved in prostate carcinogenesis. In this study, we further attempt to show that due to their carcinogenic properties, pesticides and especially organochlorine pesticides may in fact be causally implicated in the growing incidence of prostate cancer in Martinique. Also, we suggest that CMR or presumed CMR pesticides may he causally involved in the growing incidence of breast cancer through a common endocrine disruption mechanism. We therefore propose that protective medical recommendations should be immediately set up and carried out by general practitioners, paediatricians, obstetricians, gynaecologists and urologists; and that public health measures of primary precaution and prevention should be urgently taken in close collaboration with health professionals in order to protect population, more especially pregnant women and children, with the final objective perhaps that these medical recommendations and public health measures will stop Martinique's cancer epidemic. (C) 2009 Elsevier Masson SAS. All rights reserved</abstract>
    <url>WOS:000268426200001</url>
    <isbnorissn>0753-3322</isbnorissn>

  </record>
  <record>    <type>BOOK</type>
    <id>382</id>
    <title>The combination of 17-Estradiol and Bisphenol A weaken their respective action</title>
    <authors>Lang,L.; Zhang,G.M.; Li,Y.</authors>
    <availability>[Lang, Lang; Zhang, Guang-ming; Li, Yu] Harbin Inst Technol, State Key Lab Urban Water Resource &amp; Environm, Harbin 150090, Peoples R China.</availability>
    <date>2010</date>
    <notes>SEnglishProceedings PaperLang, L (reprint author), Harbin Inst Technol, State Key Lab Urban Water Resource &amp; Environm, Harbin 150090, Peoples R Chinagmgwen@gmail.com; liyu@hit.edu.cnBrama M, 2007, MOL CELL ENDOCRINOL, V264, P102, DOI 10.1016/j.mce.2006.10.013; Choe SY, 2003, SCI TOTAL ENVIRON, V312, P15, DOI 10.1016/S0048-9697(03)00190-6; Geffroy N, 2005, MOL CELL ENDOCRINOL, V237, P11, DOI 10.1016/j.mce.2005.04.003; Im JY, 2008, CHEM-BIOL INTERACT, V172, P235, DOI 10.1016/j.cbi.2008.01.007; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 1997, ENVIRON HEALTH PERSP, V105, P647, DOI 10.2307/3433384; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; YI JM, 2009, BIOCH BIOPHYSICAL RE, V143, P1101LAUBLSRUTISTR 24, CH-8717 STAFA-ZURICH, SWITZERLANDADV MATER RES-SWITZ1-3Discipline: Engineering; Materials ScienceBVF00</notes>
    <keywords>1; action mechanism; ALPHA; analysis; ASSAY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CANCER-CELL-GROWTH; CELL; cell cycle; cell growth; Cell proliferation; Cell proliferation assay; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CHEMICALS; CHINA; COMBINATION; combined action; CYCLE; Determination; DISRUPTING CHEMICALS; E2; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; environment; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; estrogen receptor a; ESTROGEN-RECEPTOR; GROWTH; HEALTH; HUMAN-BREAST-CANCER; Interaction; mechanism; PATHWAY; proliferation; PROTEIN; RECEPTOR; S-PHASE; Urban; WATER; weaken</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2220</startpage>
    <endpage>2223</endpage>
    <city>STAFA-ZURICH</city>
    <thirdtitle>ENVIRONMENT MATERIALS AND ENVIRONMENT MANAGEMENT PTS 1-3Advanced Materials Research</thirdtitle>
    <abstract>17-Estradiol (E2) and Bisphenol A (BPA) are important endocrine disrupting chemicals (EDCs). In this work, cell proliferation assay using cell cycle analysis method and determination of estrogen receptor a protein was used to investigated the mechanism and effects respectively and in mixture of the two EDCs in stimulating the growth of human breast cancer MCF-7 cell When the concentration of E2 and BPA were 10(-12)mol/L and 10(-8)mol/L respectively, E2 and BPA could reduce the express of ER alpha protein by activated ERa pathway, accelerated the cell cycle, decreased the percentages of cells in G0/1 phase, increased the percentages of cells in S phase at 48 h, and thus promoted the cancer cell growth. However, the combination effect of these two compounds did not induce the growth of cancer cell and the mixture reduced the ratio in S phase compared with E2 or BPA alone, which lead to weakening of the proliferation ability. There was a significant interaction between BPA and E2 and such a weakening effect had not been reported before</abstract>
    <url>WOS:000291337701134</url>
    <isbnorissn>1022-6680</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>434</id>
    <title>Bisphenol A at Low Nanomolar Doses Confers Chemoresistance in Estrogen Receptor-alpha-Positive and -Negative Breast Cancer Cells</title>
    <authors>LaPensee,E.W.; Tuttle,T.R.; Fox,S.R.; Ben-Jonathan,N.</authors>
    <availability>[LaPensee, Elizabeth W.; Tuttle, Traci R.; Fox, Sejal R.; Ben-Jonathan, Nira] Univ Cincinnati, Dept Canc &amp; Cell Biol, Cincinnati, OH 45267 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticleBen-Jonathan, N (reprint author), Univ Cincinnati, Dept Canc &amp; Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USANira.Ben-Jonathan@uc.eduAriazi EA, 2006, CURR TOP MED CHEM, V6, P203; AUBELSADRON G, 1984, BIOCHIMIE, V66, P333, DOI 10.1016/0300-9084(84)90018-X; Brockmoller J, 2000, PHARMACOLOGY, V61, P212, DOI 10.1159/000028403; Chen Xiang, 1998, Chemico-Biological Interactions, V111-112, P263, DOI 10.1016/S0009-2797(97)00166-X; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002.0323; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Han B., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P31, DOI 10.2174/1568011043482205; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Hugo ER, 2006, ENDOCRINOLOGY, V147, P306, DOI 10.1210/en.2005-0989; Huppunen J, 2004, BIOCHEM BIOPH RES CO, V314, P964, DOI 10.1016/j.bbrc.2003.12.194; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuruto-Niwa R, 2007, CHEMOSPHERE, V66, P1160, DOI 10.1016/j.chemosphere.2006.06.073; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Long XH, 2006, J BIOL CHEM, V281, P9607, DOI 10.1074/jbc.M510809200; Marshall OJ, 2004, BIOINFORMATICS, V20, P2471, DOI 10.1093/bioinformatics/bth254; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; *NAT CTR BIOT INF, 2008, GENBANK OV; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Prossnitz ER, 2007, MOL CELL ENDOCRINOL, V265, P138, DOI 10.1016/j.mce.2006.12.010; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tirro E, 2006, CANCER RES, V66, P4263, DOI 10.1158/0008-5472.CAN-05-3248; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-11593936US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPFEBDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology401VO</notes>
    <keywords>AGENTS; ALPHA; ASSAY; BETA; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; CELLS; chemotherapeutic agents; CHEMOTHERAPY; CISPLATIN; Cytotoxicity; DEGRADATION; ENVIRONMENTAL ESTROGENS; ER; ER alpha; ER beta; ER-ALPHA; ER-BETA; ERR-GAMMA; Estrogen; Estrogen receptor alpha; estrogen receptor-alpha; Estrogen receptors; ESTROGEN-RECEPTOR-ALPHA; Estrogen-related receptor; ESTROGEN-RELATED-RECEPTOR; EXPRESSION; GPR30; HEALTH; HUMAN HEALTH; INHIBITOR; Inhibitors; Interaction; LINE MCF-7; mechanism; Occupational; PHARMACOLOGY; PHYTOESTROGENS; proliferation; PROTEIN; PROTEINS; REAL-TIME PCR; RECEPTOR; RECEPTOR-ALPHA; RESISTANCE; Steroid; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>175</startpage>
    <endpage>180</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>2</issue>
    <volume>117</volume>
    <abstract>BACKGROUND: Resistance to chemotherapy is a major problem facing breast cancer patients, and identifying potential contributors to chemoresistance is a critical area of research. Bisphenol A (BPA) has long been suspected to promote carcinogenesis, but the high doses of BPA used in many studies generated conflicting results. In addition, the mechanism by which BPA exerts its biological actions is unclear. Although estrogen has been shown to antagonize anticancer drugs, the role of BPA in chemoresistance has not been examined. OBJECTIVE: The objective of our study was to determine whether BPA at low nanomolar concentrations opposes the action of doxorubicin, cisplatin, and vinblastine in the estrogen receptor-alpha (ER alpha)-positive T47D and the ER alpha-negative MDA-MB-468 breast cancer cells. METHODS: We determined the responsiveness of cells to anticancer drugs and BPA using the 3 -(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) cytotoxicity assay. Specific ER alpha and ER beta inhibitors and real-time polymerase chain reaction were used to identify potential receptor(s) that mediate the actions of BRA. Expression of antiapoptotic proteins was assessed by Western blotting. RESULTS: BPA antagonizes the cytotoxicity of multiple chemotherapeutic agents in both ER alpha-positive and -negative breast cancer cells independent of the classical ERs. Both cell types express alternative ERs including G-protein-coupled receptor 30 (GPR30) and members of the estrogen-related receptor family. Increased expression of antiapoptotic proteins is a potential mechanism by which BPA exerts its anticytotoxic effects. CONCLUSIONS: BPA at environmentally relevant doses reduces the efficacy of chemotherapeutic agents. These data provide considerable support to the accumulating evidence that BPA is hazardous to human health</abstract>
    <url>WOS:000262970700023</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>356</id>
    <title>Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy</title>
    <authors>LaPensee,E.W.; Ben-Jonathan,N.</authors>
    <availability>[LaPensee, Elizabeth W.; Ben-Jonathan, Nira] Univ Cincinnati, Dept Canc &amp; Cell Biol, Cincinnati, OH 45267 USA.</availability>
    <date>2010</date>
    <notes>JEnglishReviewBen-Jonathan, N (reprint author), Univ Cincinnati, Dept Canc &amp; Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USAnira.ben-jonathan@uc.eduAas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Ambrosone CB, 2001, CANCER RES, V61, P7130; Ariazi EA, 2002, CANCER RES, V62, P6510; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203; Asai-Sato M, 2005, INT J CANCER, V115, P539, DOI 10.1002/ijc.20810; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bai ZL, 2009, ARCH PHARM, V342, P133, DOI 10.1002/ardp.200800174; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Belcher SM, 2005, ENDOCRINOLOGY, V146, P5397, DOI 10.1210/en.2005-0564; Bellail Anita C, 2009, Rev Recent Clin Trials, V4, P34; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; Ben-Jonathan N, 2008, ENDOCR REV, V29, P1, DOI 10.1210/er.2007-0017; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Blanc C, 2000, CANCER RES, V60, P4386; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Carver KC, 2009, MOL CELL ENDOCRINOL, V307, P1, DOI 10.1016/j.mce.2009.03.014; Chakravarti P, 2005, INT J ONCOL, V26, P509; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chen NY, 2002, INT J ONCOL, V20, P813; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Clapp C, 2008, J MAMMARY GLAND BIOL, V13, P55, DOI 10.1007/s10911-008-9067-7; Clevenger CV, 2009, TRENDS ENDOCRIN MET, V20, P223, DOI 10.1016/j.tem.2009.03.001; Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Decatris MP, 2004, CANCER TREAT REV, V30, P53, DOI 10.1016/S0305-7372(03)00139-7; Duan L, 2007, BIOCHEM PHARMACOL, V73, P481, DOI 10.1016/j.bcp.2006.10.026; Duan RQ, 2008, MOL CELL ENDOCRINOL, V281, P9, DOI 10.1016/j.mce.2007.10.004; Falconer Ian R, 2006, Int J Environ Res Public Health, V3, P180, DOI 10.3390/ijerph2006030020; Ferlini C, 2003, MOL PHARMACOL, V64, P51, DOI 10.1124/mol.64.1.51; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2005, TRENDS ENDOCRIN MET, V16, P362, DOI 10.1016/j.tem.2005.08.005; Foster PA, 2008, MINERVA ENDOCRINOL, V33, P27; Fox EM, 2009, STEROIDS, V74, P622, DOI 10.1016/j.steroids.2008.10.014; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Gerlo S, 2006, BIOESSAYS, V28, P1051, DOI 10.1002/bies.20468; Gertler A, 1996, J BIOL CHEM, V271, P24482; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Gonzalez L, 2009, ONCOGENE, V28, P1298, DOI 10.1038/onc.2008.473; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Henkels KM, 1999, CANCER RES, V59, P3077; Hess-Wilson JK, 2006, BREAST CANCER RES TR, V96, P279, DOI 10.1007/s10549-005-9082-y; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; Howell SJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2129; Hsu PC, 2006, APOPTOSIS, V11, P389, DOI 10.1007/s10495-006-4002-0; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Huang Y, 2004, MOL CANCER THER, V3, P271; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Imai Y, 2005, CANCER RES, V65, P596; Jongen V H W M, 2006, Minerva Endocrinol, V31, P47; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Karayiannakis AJ, 1996, EUR J SURG ONCOL, V22, P578, DOI 10.1016/S0748-7983(96)92242-8; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kennedy RD, 2004, J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lagadec C, 2008, ONCOGENE, V27, P1472, DOI 10.1038/sj.onc.1210749; LAPENSEE EW, 2009, CANC LETT IN PRESS; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; LaPensee EW, 2009, CARCINOGENESIS, V30, P1298, DOI 10.1093/carcin/bgp120; L'Ecuyer T, 2004, AM J PHYSIOL-HEART C, V286, pH2057, DOI 10.1152/ajpheart.00778.2003; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255; Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018; Liby K, 2003, BREAST CANCER RES TR, V79, P241, DOI 10.1023/A:1023956223037; Lissoni P, 2001, NEUROENDOCRINOL LETT, V22, P27; Lissoni P, 2002, ANTICANCER RES, V22, P1131; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; Luquita MG, 1999, DRUG METAB DISPOS, V27, P122; Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551; Martin Jan H J, 2007, Future Oncol, V3, P307, DOI 10.2217/14796694.3.3.307; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; McHale K, 2008, MODERN PATHOL, V21, P565, DOI 10.1038/modpathol.2008.7; McIlwain CC, 2006, ONCOGENE, V25, P1639, DOI 10.1038/sj.onc.1209373; Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538; Nabholtz JM, 2009, EXPERT OPIN PHARMACO, V10, P1435, DOI 10.1517/14656560902953738; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1220/JCO.2004.11.046; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; Ocana A, 2008, CLIN CANCER RES, V14, P961, DOI 10.1158/1078-0432.CCR-07-1630; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Pasqualini JR, 1996, J CLIN ENDOCR METAB, V81, P1460, DOI 10.1210/jc.81.4.1460; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Perks CC, 2004, BRIT J CANCER, V91, P305, DOI 10.1038/sj.bjc.6601947; Perotti C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2193; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Rabbani A, 2005, BIOESSAYS, V27, P50, DOI 10.1002/bies.20160; Ramamoorthy P, 2001, INT J ONCOL, V18, P25; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; RICKETTS D, 1991, CANCER RES, V51, P1817; Riggins RB, 2008, CANCER RES, V68, P8908, DOI 10.1158/0008-5472.CAN-08-2669; Rodrik V, 2005, MOL CELL BIOL, V25, P7917, DOI 10.1128/MCB.25.17.7917-7925.2005; Ruffion A, 2003, EUR UROL, V43, P301, DOI 10.1016/S0302-2838(03)00038-1; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; Santen RJ, 1997, J STEROID BIOCHEM, V61, P267; Sessa C, 2008, NAT CLIN PRACT ONCOL, V5, P378, DOI 10.1038/ncponc1150; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; Shiga H, 1999, CLIN CANCER RES, V5, P4097; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Simoes-Wust AP, 2002, BREAST CANCER RES TR, V76, P157, DOI 10.1023/A:1020543004400; Singleton DW, 2004, MOL CELL ENDOCRINOL, V221, P47, DOI 10.1016/j.mce.2004.04.010; Song RXD, 2006, ENDOCR-RELAT CANCER, V13, pS3, DOI 10.1677/erc.1.01322; Sui M, 2007, CANCER RES, V67, P5337, DOI 10.1158/0008-5472.CAN-06-4582; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Suzuki T, 2005, ENDOCR-RELAT CANCER, V12, P701, DOI 10.1677/erc.1.00834; Swaminathan G, 2008, J MAMMARY GLAND BIOL, V13, P81, DOI 10.1007/s10911-008-9068-6; Tanabe N, 2006, NEUROENDOCRINOL LETT, V27, P97; Teilum K, 2005, J MOL BIOL, V351, P810, DOI 10.1016/j.jmb.2005.06.042; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Trock BJ, 1997, J NATL CANCER I, V89, P917, DOI 10.1093/jnci/89.13.917; Tworoger SS, 2008, J MAMMARY GLAND BIOL, V13, P41, DOI 10.1007/s10911-008-9063-y; Utama FE, 2006, J ENDOCRINOL, V188, P589, DOI 10.1677/joe.1.06560; Vacca A, 1999, BLOOD, V94, P4143; Van den Bemd GJCM, 1999, BIOCHEM BIOPH RES CO, V261, P1, DOI 10.1006/bbrc.1999.0864; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Walsh DE, 2005, MOL CELL ENDOCRINOL, V230, P23, DOI 10.1016/j.mce.2004.11.006; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wang Z, 2005, ANTICANCER RES, V25, P2367; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wiltshire T, 2007, MOL PHARMACOL, V71, P1051, DOI 10.1124/mol.106.029504; Yde CW, 2006, INT J ONCOL, V29, P1397; Zampieri L, 2002, ANTICANCER RES, V22, P2253; Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569; Zinger M, 2003, J CLIN ENDOCR METAB, V88, P689, DOI 10.1210/jc.2002-02125513822BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDENDOCR-RELAT CANCERJUNDiscipline: Oncology; Endocrinology &amp; Metabolism618HH</notes>
    <keywords>ACTIVATION; ADIPOSE-TISSUE EXPLANTS; AGENTS; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; cell death; CELL-DEATH; CELL-LINES; CHEMICALS; CISPLATIN; CISPLATIN-INDUCED APOPTOSIS; Cytotoxicity; DEATH; DEPENDENT PROLIFERATION; DOWN-REGULATION; DRUG-INDUCED APOPTOSIS; ENDOGENOUS ESTROGENS; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; FUTURE; G-PROTEIN; GLAND; GLUTATHIONE-S-TRANSFERASE; HEALTH; Hormone; Hormones; JUN; low dose; mammary gland; MAMMARY-GLAND; mechanism; MECHANISMS; METABOLISM; oncology; PATHOGENESIS; Phytoestrogen; PHYTOESTROGENS; PLACENTA; PROTEIN; RECEPTOR; RECEPTOR-ALPHA; Receptors; RESISTANCE; Review; ROLES; Steroid; TISSUE; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>R91</startpage>
    <endpage>R107</endpage>
    <journalfull>Endocrine-Related Cancer</journalfull>
    <issue>2</issue>
    <volume>17</volume>
    <abstract>Resistance to chemotherapy is a major complication in the treatment of advanced breast cancer. Estrogens and prolactin (PRL) are implicated in the pathogenesis of breast cancer but their roles in chemoresistance have been overlooked. A common feature to the two hormones is activation of their receptors by diverse compounds, which mimic or antagonize their actions. The PRL receptor is activated by lactogens (PRL, GH, or placental lactogen) originating from the pituitary, breast, adipose tissue, or the placenta. Estrogen receptors exist in multiple membrane-associated and cytoplasmic forms that can be activated by endogenous estrogens, man-made chemicals, and phytoestrogens. Here, we review evidence that low doses of PRL, estradiol (E-2), and bisphenol A (BPA) antagonize multiple anticancer drugs that induce cell death by different mechanisms. Focusing on cisplatin, a DNA-damaging drug which is effective in the treatment of many cancer types but not breast cancer, we compare the abilities of PRL, E-2, and BPA to antagonize its cytotoxicity. Whereas PRL acts by activating the glutathione-S-transferase detoxification enzyme, E-2 and BPA act by inducing the antiapoptotic protein Bcl-2. The implications of these findings to patients undergoing chemotherapy are discussed. Endocrine-Related Cancer (2010) 17 R91-R107</abstract>
    <url>WOS:000279341700001</url>
    <isbnorissn>1351-0088</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>365</id>
    <title>Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells</title>
    <authors>LaPensee,E.W.; LaPensee,C.R.; Fox,S.; Schwemberger,S.; Afton,S.; Ben-Jonathan,N.</authors>
    <availability>[LaPensee, Elizabeth W.; LaPensee, Christopher R.; Fox, Sejal; Ben-Jonathan, Nira] Univ Cincinnati, Dept Canc &amp; Cell Biol, Cincinnati, OH 45267 USA. [Schwemberger, Sandy] Univ Cincinnati, Shriners Burns Inst, Cincinnati, OH 45267 USA. [Afton, Scott] Univ Cincinnati, Dept Chem, Cincinnati, OH 45267 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleBen-Jonathan, N (reprint author), Univ Cincinnati, Dept Canc &amp; Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USANira.Ben-Jonathan@uc.eduColey HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Decatris MP, 2004, CANCER TREAT REV, V30, P53, DOI 10.1016/S0305-7372(03)00139-7; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Hugo ER, 2006, ENDOCRINOLOGY, V147, P306, DOI 10.1210/en.2005-0989; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jordan VC, 2007, STEROIDS, V72, P7, DOI 10.1016/j.steroids.2006.10.009; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; KYPRIANOU N, 1991, CANCER RES, V51, P162; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critevonc.2004.02.001; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Rodrik V, 2005, MOL CELL BIOL, V25, P7917, DOI 10.1128/MCB.25.17.7917-7925.2005; Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com; Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Sui M, 2007, CANCER RES, V67, P5337, DOI 10.1158/0008-5472.CAN-06-4582; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm23083610ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDCANCER LETTAPR 28Discipline: Oncology580DF</notes>
    <keywords>apoptosis; Bcl-2; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; CHEMOTHERAPY; CISPLATIN; Cytotoxicity; DEATH; ENVIRONMENTAL ESTROGENS; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPRESSION; HEALTH; INHIBITOR; LINE MCF-7; oncology; proliferation; RECEPTOR; Receptors; RESISTANCE; Steroid; TUMOR; TUMORS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>167</startpage>
    <endpage>173</endpage>
    <journalfull>Cancer Letters</journalfull>
    <issue>2</issue>
    <volume>290</volume>
    <abstract>Resistance to chemotherapy is a major problem facing breast cancer patients. Cisplatin, a highly effective DNA-damaging drug, has shown only little success in breast cancer treatment. We are reporting that low nanomolar doses of bisphenol A (BPA) or estradiol antagonize cisplatin cytotoxicity in breast cancer cells, with their effects not mediated via classical estrogen receptors. Although both compounds increase the expression of Bcl-2, a Bcl-2 inhibitor completely blocked the protective effects of BPA while only partially affecting those of estradiol. Blockade of BPA and E2 actions should sensitize ER-negative breast tumors to anti-cancer drugs and allow for the inclusion of cisplatin in treatment regimens. (C) 2009 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000276426400004</url>
    <isbnorissn>0304-3835</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>321</id>
    <title>Rapid Signaling Actions of Environmental Estrogens in Developing Granule Cell Neurons Are Mediated by Estrogen Receptor beta</title>
    <authors>Le,H.H.; Belcher,S.M.</authors>
    <availability>[Le, Hoa H.; Belcher, Scott M.] Univ Cincinnati, Coll Med, Dept Pharmacol &amp; Cell Biophys, Cincinnati, OH 45267 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleBelcher, SM (reprint author), Univ Cincinnati, Coll Med, Dept Pharmacol &amp; Cell Biophys, 231 Albert Sabin Way,POB 670575, Cincinnati, OH 45267 USAscott.belcher@uc.eduBelcher SM, 2005, ENDOCRINOLOGY, V146, P5397, DOI 10.1210/en.2005-0564; Belcher SM, 2008, BRAIN RES REV, V57, P481, DOI 10.1016/j.brainresrev.2007.07.020; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; Bingham SA, 1998, BRIT J NUTR, V79, P393, DOI 10.1079/BJN19980068; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Darnerud PO, 2003, ENVIRON INT, V29, P841, DOI 10.1016/S0160-4120(03)00107-7; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dubey RK, 2000, HYPERTENSION, V35, P262; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Farach-Carson MC, 2003, J PHARMACOL EXP THER, V307, P839, DOI 10.1124/jpet.103.055038; FARMAKALIDIS E, 1984, FOOD CHEM TOXICOL, V22, P237, DOI 10.1016/0278-6915(84)90134-0; Gaido KW, 2000, MOL PHARMACOL, V58, P852; Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746; Howdeshell KL, 2008, TOXICOL SCI, V102, P371, DOI 10.1093/toxsci/kfm306; Jakab RL, 2001, J COMP NEUROL, V430, P396, DOI 10.1002/1096-9861(20010212)430:3&lt;396::AID-CNE1039&gt;3.0.CO;2-0; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Matthews J, 2000, J STEROID BIOCHEM, V74, P223, DOI 10.1016/S0960-0760(00)00126-6; Ohashi Atsushi, 2005, J Artif Organs, V8, P252, DOI 10.1007/s10047-005-0307-y; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; Rosselli M, 2000, HUM REPROD UPDATE, V6, P332, DOI 10.1093/humupd/6.4.332; Rozman KK, 2006, BIRTH DEFECTS RES B, V77, P485, DOI 10.1002/bdrb.20087; Ryan BC, 2010, TOXICOL SCI, V114, P133, DOI 10.1093/toxsci/kfp266; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S; Setchell KDR, 2005, AM J CLIN NUTR, V81, P1072; Tyl RW, 2008, TOXICOL SCI, V104, P362, DOI 10.1093/toxsci/kfn084; Tyler CR, 1998, CRIT REV TOXICOL, V28, P319, DOI 10.1080/10408449891344236; Willard SP, 1998, ENDOCRINE, V8, P117, DOI 10.1385/ENDO:8:2:117; Wong JK, 2003, J NEUROSCI, V23, P4984; Wong JK, 2001, J NEUROSCI METH, V110, P45, DOI 10.1016/S0165-0270(01)00419-8; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Zava DT, 1997, ENVIRON HEALTH PERSP, V105, P637, DOI 10.2307/3433383; Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565376ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCRINOLOGYDECDiscipline: Endocrinology &amp; Metabolism683QH</notes>
    <keywords>ACTIVATION; ALPHA; analysis; ASSAY; BETA; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER CELLS; CELL; cell death; CELL-DEATH; CELLS; CEREBELLAR NEURONS; CHEMICALS; DEATH; DEFECTS; DIETHYLSTILBESTROL; DISRUPTING CHEMICALS; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemicals; ENDOCRINE-DISRUPTING ACTIVITY; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ER alpha; ER beta; ER-ALPHA; ER-BETA; ERK1/2; Estrogen; Estrogen receptor; Estrogen receptor beta; estrogen signaling; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-BETA; ESTROGENS; ETHINYL ESTRADIOL; FOOD; HEALTH; In vitro; IN-VITRO; LACTATIONAL EXPOSURE; LIGAND; LIGANDS; mechanism; MECHANISMS; METABOLISM; NEURONS; PATHWAY; PHYTOESTROGENS; PLANTS; PROTEIN-KINASE; RECEPTOR; SENSITIVITY; SIGNALING PATHWAY; SIGNALING PATHWAYS; Steroid; TOXICITY; UPDATE; VIABILITY; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>5689</startpage>
    <endpage>5699</endpage>
    <journalfull>Endocrinology</journalfull>
    <issue>12</issue>
    <volume>151</volume>
    <abstract>Estrogenic endocrine disrupting chemicals (EDCs) constitute a diverse group of man-made chemicals and natural compounds derived from plants and microbial metabolism. Estrogen-like actions are mediated via the nuclear hormone receptor activity of estrogen receptor (ER)alpha and ER beta and rapid regulation of intracellular signaling cascades. Previous study defined cerebellar granule cell neurons as estrogen responsive and that granule cell precursor viability was developmentally sensitive to estrogens. In this study experiments using Western blot analysis and pharmacological approaches have characterized the receptor and signaling modes of action of selective and nonselective estrogen ligands in developing cerebellar granule cells. Estrogen treatments were found to briefly increase ERK1/2-phosphorylation and then cause prolonged depression of ERK1/2 activity. The sensitivity of granule cell precursors to estrogen-induced cell death was found to require the integrated activation of membrane and intracellular ER signaling pathways. The sensitivity of granule cells to selective and nonselective ER agonists and a variety of estrogenic and nonestrogenic EDCs was also examined. The ER beta selective agonist DPN, but not the ER alpha selective agonist 4,4',4'-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol or other ER alpha-specific ligands, stimulated cell death. Only EDCs with selective or nonselective ER beta activities like daidzein, equol, diethylstilbestrol, and bisphenol A were observed to induce E2-like neurotoxicity supporting the conclusion that estrogen sensitivity in granule cells is mediated via ER beta. The presented results also demonstrate the utility of estrogen sensitive developing granule cells as an in vitro assay for elucidating rapid estrogen-signaling mechanisms and to detect EDCs that act at ER beta to rapidly regulate intracellular signaling. (Endocrinology 151: 5689-5699, 2010)</abstract>
    <url>WOS:000284489800014</url>
    <isbnorissn>0013-7227</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>223</id>
    <title>Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway</title>
    <authors>Lee,H.R.; Hwang,K.A.; Park,M.A.; Yi,B.R.; Jeung,E.B.; Choi,K.C.</authors>
    <availability>[Lee, Hye-Rim; Hwang, Kyung-A; Park, Min-Ah; Yi, Bo-Rim; Jeung, Eui-Bae; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krAaltonen K, 2009, BREAST CANCER RES TR, V113, P75, DOI 10.1007/s10549-008-9908-5; Amstislavsky SY, 2006, REPROD TOXICOL, V21, P154, DOI 10.1016/j.reprotox.2005.07.009; Armenti AE, 2008, TOXICOL APPL PHARM, V233, P286, DOI 10.1016/j.taap.2008.09.010; Bondar G, 2009, J NEUROSCI, V29, P15323, DOI 10.1523/JNEUROSCI.2107-09.2009; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Cheng WL, 2011, PLANTA MED, V77, P164, DOI 10.1055/s-0030-1250177; Choi KC, 2003, J REPROD DEVELOP, V49, P337, DOI 10.1262/jrd.49.337; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; Dang VH, 2007, REPROD TOXICOL, V23, P42, DOI 10.1016/j.reprotox.2006.08.010; Dang VH, 2009, STEROIDS, V74, P707, DOI 10.1016/j.steroids.2009.03.002; Felty Q, 2005, ONCOGENE, V24, P4883, DOI 10.1038/sj.onc.1208667; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hong EJ, 2004, BIOL REPROD, V71, P669, DOI 10.1095/biolreprod.103.026146; Hunt PA, 2009, BIOL REPROD, V81, P807, DOI 10.1095/biolreprod.109.077008; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Li J, 2006, INT IMMUNOPHARMACOL, V6, P1413, DOI 10.1016/j.intimp.2006.04.019; Mandal S, 2010, J CELL PHYSIOL, V224, P28, DOI 10.1002/jcp.22078; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Mielke H, 2009, TOXICOL LETT, V190, P32, DOI 10.1016/j.toxlet.2009.06.861; Migliarini B, 2011, GEN COMP ENDOCR, V170, P416, DOI 10.1016/j.ygcen.2010.11.025; Nikaido Y, 2005, IN VIVO, V19, P487; Ottinger MA, 2005, BRAIN RES BULL, V65, P199, DOI 10.1016/j.brainresbull.2004.11.019; Pacifici R, 2008, CELL IMMUNOL, V252, P68, DOI 10.1016/j.cellimm.2007.06.008; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Rivas A, 2002, J STEROID BIOCHEM, V82, P45, DOI 10.1016/S0960-0760(02)00146-2; Shin JH, 2007, J REPROD DEVELOP, V53, P179, DOI 10.1262/jrd.18054; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Suzuki M, 2004, J REPROD DEVELOP, V50, P455, DOI 10.1262/jrd.50.455; Tillett T, 2009, ENVIRON HEALTH PERSP, V117, pA210; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wang X, 2011, MED ONCOL, V28, P1225, DOI 10.1007/s12032-010-9552-x; Yano M, 1999, CANCER LETT, V137, P45, DOI 10.1016/S0304-3835(98)00338-3; Yi BR, 2011, ANTICANCER RES, V31, P28533818SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J MOL MEDMAYDiscipline: Research &amp; Experimental Medicine917RH</notes>
    <keywords>ALPHA; Antagonist; ASSAY; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CALBINDIN-D-9K MESSENGER-RNA; CANCER; CANCER CELLS; CANCER-CELL-GROWTH; CANCER-CELL-PROLIFERATION; CANCER-CELLS; CARCINOGENESIS; Carcinogenicity; CELL; cell cycle; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CHEMICALS; CYCLE; CYCLIN D1; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; environment; ER alpha; ER-ALPHA; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic activity; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GENES; GROWTH; HEALTH; HUMAN HEALTH; HUMAN-BREAST-CANCER; In vitro; IN-VITRO; IN-VIVO; LINE; MATERNAL EXPOSURE; Methoxychlor; MODEL; p21; PESTICIDE METHOXYCHLOR; proliferation; PROTEIN; RATS; RECEPTOR; Reproduction; SELECTIVE AGONISTS; SIGNALING PATHWAY; SYSTEM; VITRO; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>883</startpage>
    <endpage>890</endpage>
    <journalfull>International Journal of Molecular Medicine</journalfull>
    <issue>5</issue>
    <volume>29</volume>
    <abstract>Various endocrine disrupting chemicals (EDCs) are exogenous compounds found in the environment and have the potential to interfere with the endocrine system and hormonal regulation. Among EDCs, bisphenol A (BPA) and 1,1,1-trichloro-2,2-bis(4-methoxyphenol)-ethane [methoxychlor (MXC)] have estrogenic activity resulting in a variety of dysfunctions in the E2-mediated response by binding to estrogen receptors (ERs), causing human health problems such as abnormal reproduction and carcinogenesis. In this study, we investigated the effects of BPA and MXC on cell proliferation facilitated by ER signaling in human breast cancer cells. MCF-7 cells are known to be ER alpha-positive and to be a highly E2-responsive cancer cell line; these cells are, therefore, a useful in vitro model for detecting estrogenic activity in response to EDCs. We evaluated cancer cell proliferation following BPA and MXC treatment using an MTT assay. We analyzed alterations in the expression of genes associated with the cell cycle in MCF-7 cells by semi-quantitative reverse-transcription PCR following treatment with BPA or MXC compared to EtOH. To determine whether BPA and MXC stimulate cancer cell growth though ER signaling, we co-treated the cells with agonists (propyl pyrazoletriol, PPT; and diarylpropionitrile. DPN) or an antagonist (ICI 182,780) of ER signaling and reduced ER alpha gene expression via siRNA in MCF-7 cells before treatment with EDCs. These studies confirmed the carcinogenicity of EDCs in vitro. As a result. BPA and MXC induced the cancer cell proliferation by the upregulation of genes that promote the cell cycle and the downregulation of anti-proliferative genes, especially ones affecting the G1/S transition via ER alpha signaling. These collective results confirm the carcinogenicity of these EDCs in vitro. Further studies are required to determine whether EDCs promote carcinogenesis in vivo</abstract>
    <url>WOS:000302195800021</url>
    <isbnorissn>1107-3756</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>171</id>
    <title>Molecular mechanism(s) of endocrine-disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors</title>
    <authors>Lee,H.R.; Jeung,E.B.; Cho,M.H.; Kim,T.H.; Leung,P.C.K.; Choi,K.C.</authors>
    <availability>[Lee, Hye-Rim; Jeung, Eui-Bae; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Chonju 361763, Chungbuk, South Korea. [Cho, Myung-Haing] Seoul Natl Univ, Coll Vet Med, Toxicol Lab, Seoul, South Korea. [Cho, Myung-Haing] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon, South Korea. [Kim, Tae-Hee] Soonchunhyang Univ, Coll Med, Dept Obstet &amp; Gynecol, Puchon, South Korea. [Leung, Peter C. K.] Univ British Columbia, Fac Med, Dept Obstet &amp; Gynecol, Child &amp; Family Res Inst, Vancouver, BC, Canada.</availability>
    <date>2013</date>
    <notes>JEnglishReviewChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Chonju 361763, Chungbuk, South Koreakchoi@cbu.ac.krAkingbemi BT, 2000, BIOL REPROD, V62, P571, DOI 10.1095/biolreprod62.3.571; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Al-Saleh I, 2011, SCI TOTAL ENVIRON, V416, P62; Al-Saleh I, 2009, MED SCI MONITOR, V15, pBR320; Ambrosino C, 2010, MOL CELL PROTEOMICS, V9, P1352, DOI 10.1074/mcp.M900519-MCP200; An BS, 2003, REPROD TOXICOL, V17, P311, DOI 10.1016/S0890-6238(03)00003-0; An BS, 2002, MOL CELL ENDOCRINOL, V191, P177, DOI 10.1016/S0303-7207(02)00042-4; Aranda A, 2001, PHYSIOL REV, V81, P1269; Bergamasco AMD, 2011, J ENVIRON MONITOR, V13, P3288, DOI 10.1039/c1em10464k; Berman JR, 2005, INT J IMPOT RES, V17, pS44, DOI 10.1038/sj.ijir.3901428; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bonde JP, 2009, ASIAN J ANDROL, V12, P152; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Byrnes EM, 2011, HORM BEHAV, V61, P44; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cao Xiaohong, 2009, Sheng Wu Gong Cheng Xue Bao, V25, P1705; Cheng J, 2004, FEBS LETT, V566, P169, DOI 10.1016/j.febslet.2004.04.025; Choi JS, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-126; Choi KC, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-66; Choi KC, 2008, J CELL MOL MED, V12, P409, DOI 10.1111/j.1582-4934.2007.00209.x; Ciana P, 2001, MOL ENDOCRINOL, V15, P1104, DOI 10.1210/me.15.7.1104; Couse JF, 2004, TOXICOLOGY, V205, P55, DOI 10.1016/j.tox.2004.06.046; Craig ZR, 2011, REPRODUCTION, V142, P633, DOI 10.1530/REP-11-0136; Dang VH, 2007, J TOXICOL ENV HEAL A, V70, P171, DOI 10.1080/15287390600755257; Dang VH, 2009, J REPROD DEVELOP, V55, P206; Dang VH, 2010, TOXICOL IN VITRO, V24, P1229, DOI 10.1016/j.tiv.2010.02.006; Dang VH, 2007, REPROD TOXICOL, V23, P42, DOI 10.1016/j.reprotox.2006.08.010; Dickerson SM, 2007, REV ENDOCR METAB DIS, V8, P143, DOI 10.1007/s11154-007-9048-y; Dong S, 2010, ENVIRON POLLUT, V159, P212; Dumbrepatil AB, 2010, ANALYST, V135, P2879, DOI 10.1039/c0an00385a; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Filipin MD, 2010, RES VET SCI, V89, P98, DOI 10.1016/j.rvsc.2010.01.016; Fischer T, 2008, INT J RADIAT BIOL, V84, P1112, DOI 10.1080/09553000802499238; Forawi Hanan A, 2004, Rev Environ Health, V19, P1; Fowler PA, 2012, MOL CELL ENDOCRINOL, V355, P213; Frawley R, 2011, ENVIRON HEALTH PERSP, V119, P371, DOI 10.1289/ehp.1002358; Gaido KW, 2000, MOL PHARMACOL, V58, P852; Gordon A, 2008, J ENDOCRINOL, V196, P583, DOI 10.1677/JOE-07-0223; Gore Andrea C, 2008, Fertil Steril, V89, pe101, DOI 10.1016/j.fertnstert.2007.12.039; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Halon A, 2011, ANTICANCER RES, V31, P711; Hardell L, 2006, INT J ANDROL, V29, P228, DOI 10.1111/j.1365-2605.2005.00622.x; Harvey CN, 2009, TOXICOL SCI, V110, P95, DOI 10.1093/toxsci/kfp089; Harvey PW, 2002, J APPL TOXICOL, V22, P241, DOI 10.1002/jat.854; HEPPELL SA, 1995, ENVIRON HEALTH PERSP, V103, P9, DOI 10.2307/3432500; Herbstman J, 2008, THYROID, V18, P67, DOI [10.1089/thy.2007.0180, 10.1018/thy.2007.0180]; Herbstman JB, 2008, ENVIRON HEALTH PERSP, V116, P1376, DOI 10.1289/ehp.11379; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hong EJ, 2003, MOL CELL ENDOCRINOL, V212, P63, DOI 10.1016/j.mce.2003.08.011; Hsu PC, 2003, JAMA-J AM MED ASSOC, V289, P2943, DOI 10.1001/jama.289.22.2943; Hu Y, 2011, FOOD CHEM TOXICOL, V50, P457; Huang J, 2004, MOL CELL ENDOCRINOL, V218, P65, DOI 10.1016/j.mce.2003.12.005; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Ijichi N, 2007, BIOCHEM BIOPH RES CO, V358, P813, DOI 10.1016/j.bbrc.2007.04.209; Ishida M, 2007, ENDOCRINOLOGY, V148, P3131, DOI 10.1210/en.2006-1484; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Johari H, 2008, Pak J Biol Sci, V11, P2413; Jung YW, 2005, TOXICOL SCI, V83, P78, DOI 10.1093/toxsci/kfi015; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim Y. R., 2011, INT J MOL MED, V29, P294; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Kwack SJ, 2002, J TOXICOL ENV HEAL A, V65, P419, DOI 10.1080/15287390252808082; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Lee Hye-Rim, 2012, Lab Anim Res, V28, P71, DOI 10.5625/lar.2012.28.2.71; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lemaire G, 2006, LIFE SCI, V79, P1160, DOI 10.1016/j.lfs.2006.03.023; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; LHORSET F, 1993, ENDOCRINOLOGY, V132, P489, DOI 10.1210/en.132.2.489; LHORSET F, 1994, ENDOCRINOLOGY, V134, P11, DOI 10.1210/en.134.1.11; Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018; Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Maffucci JA, 2009, INT REV CEL MOL BIO, V274, P69, DOI 10.1016/S1937-6448(08)02002-9; Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; Miller S, 2000, TOXICOL SCI, V55, P69, DOI 10.1093/toxsci/55.1.69; Miyakoshi T, 2009, ACTA HISTOCHEM CYTOC, V42, P23, DOI 10.1267/ahc.08036; Moral R, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-5; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murono EP, 2000, REPROD TOXICOL, V14, P275, DOI 10.1016/S0890-6238(00)00078-2; Mussi P, 2005, BRAIN RES BULL, V65, P241, DOI 10.1016/j.brainresbull.2004.11.016; Nadzialek S, 2011, ARCH ENVIRON CON TOX, V60, P471, DOI 10.1007/s00244-010-9548-8; Nah WH, 2012, CLIN EXP REPROD MED, V38, P75; Navratil AM, 2007, ENDOCRINOLOGY, V148, P1736, DOI 10.1210/en.2006-1153; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Ozmen O, 2009, PANCREAS, V39, P367; Park M. A., 2011, MOL MED REP, V5, P761; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Penza M, 2006, ENDOCRINOLOGY, V147, P5740, DOI 10.1210/en.2006-0365; Pike ACW, 2006, BEST PRACT RES CL EN, V20, P1, DOI 10.1016/j.beem.2005.09.002; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Rasier G, 2008, TOXICOL SCI, V102, P33, DOI 10.1093/toxsci/kfm285; Ren LF, 1997, CHEM-BIOL INTERACT, V104, P55, DOI 10.1016/S0009-2797(97)03767-8; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rignell-Hydbom A, 2004, HUM REPROD, V19, P2066, DOI 10.1093/humrep/deh362; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Sanderson JT, 2006, TOXICOL SCI, V94, P3, DOI 10.1093/toxsci/kfl051; Sarma K, 2010, FISH PHYSIOL BIOCHEM, V36, P597, DOI 10.1007/s10695-009-9333-7; Satar S, 2009, BRATISL MED J, V110, P301; Scremin OU, 2010, NEUROTOXICOLOGY, V32, P31; Shanle E. K., 2010, CHEM RES TOXICOL, V24, P6; Sharpe RM, 2006, BEST PRACT RES CL EN, V20, P91, DOI 10.1016/j.beem.2005.09.005; Shelby MD, 1996, ENVIRON HEALTH PERSP, V104, P1296, DOI 10.2307/3432965; Simoncini T, 2004, STEROIDS, V69, P537, DOI 10.1016/j.steroids.2004.05.009; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Singh ND, 2008, J APPL TOXICOL, V28, P901, DOI 10.1002/jat.1354; Singh S, 2011, GENE, V494, P85; Skoldenberg EG, 2009, ANTICANCER RES, V29, P3311; Sotoca AM, 2010, MOL CELL PROTEOMICS, V10; Suzuki T, 2008, J CELL PHYSIOL, V214, P662, DOI 10.1002/jcp.21255; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521; Tokumoto T, 2007, ENDOCRINOLOGY, V148, P3459, DOI 10.1210/en.2006-1694; Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vazquez GR, 2009, COMP BIOCHEM PHYS C, V150, P298, DOI 10.1016/j.cbpc.2009.05.012; Villa R, 2004, TOXICOL APPL PHARM, V201, P137, DOI 10.1016/j.taap.2004.05.007; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vo TTB, 2009, TOXICOL SCI, V112, P68, DOI 10.1093/toxsci/kfp176; Wang DD, 2009, CELL MOL NEUROBIOL, V29, P391, DOI 10.1007/s10571-008-9331-9; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; Watson CS, 2012, STEROIDS, V77, P424, DOI 10.1016/j.steroids.2011.12.025; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Williams K, 2001, HUM REPROD UPDATE, V7, P236, DOI 10.1093/humupd/7.3.236; Woodruff TJ, 2008, FERTIL STERIL, V89, P281, DOI 10.1016/j.fertnstert.2007.10.002; Yavuz Y, 2007, CLIN TOXICOL, V45, P530, DOI 10.1080/15563650701365909; Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499; Zhao E, 2011, Sci Pharm, V79, P1, DOI 10.3797/scipharm.1007-15; Zheng JC, 2007, ENVIRON TOXICOL PHAR, V24, P189, DOI 10.1016/j.etap.2007.05.003; Zhou R, 2009, NEUROSCIENCE, V159, P161, DOI 10.1016/j.neuroscience.2008.12.028; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.067; Zierau O, 2006, PLANTA MED, V72, P184, DOI 10.1055/s-2005-8731821508WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAJ CELL MOL MEDJANDiscipline: Cell Biology; Research &amp; Experimental Medicine084ED</notes>
    <keywords>ANDROGEN RECEPTOR; BIOLOGY; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CALBINDIN-D-9K MESSENGER-RNA; CANCER; CELL; CELLS; CHEMICALS; development; DIETHYLSTILBESTROL DES; EDCs; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; environment; ENVIRONMENTAL ESTROGENS; EXPOSURE; FISH; FOOD; GENE-EXPRESSION; GONADOTROPIN-RELEASING-HORMONE; GROWTH; HEALTH; Hormones; HUMAN HEALTH; In vitro; IN-UTERO EXPOSURE; IN-VITRO; IN-VIVO; Interaction; Male; mechanism; MECHANISMS; MODEL; MODELS; oestrogen; oestrogen receptor; oestrogenicity; OVARIAN-CANCER CELLS; Progesterone receptor; PROGESTERONE-RECEPTOR; PROTEIN-COUPLED RECEPTOR; Proteomics; RECEPTOR; Reproduction; Steroid hormone; TISSUE; TOXICITY; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1</startpage>
    <endpage>11</endpage>
    <journalfull>Journal of Cellular and Molecular Medicine</journalfull>
    <issue>1</issue>
    <volume>17</volume>
    <abstract>Endocrine-disrupting chemicals (EDCs) are natural or synthetic compounds present in the environment which can interfere with hormone synthesis and normal physiological functions of male and female reproductive organs. Most EDCs tend to bind to steroid hormone receptors including the oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR). As EDCs disrupt the actions of endogenous hormones, they may induce abnormal reproduction, stimulation of cancer growth, dysfunction of neuronal and immune system. Although EDCs represent a significant public health concern, there are no standard methods to determine effect of EDCs on human beings. The mechanisms underlying adverse actions of EDC exposure are not clearly understood. In this review, we highlighted the toxicology of EDCs and its effect on human health, including reproductive development in males and females as shown in in vitro and in vivo models. In addition, this review brings attention to the toxicity of EDCs via interaction of genomic and non-genomic signalling pathways through hormone receptors</abstract>
    <url>WOS:000314518700001</url>
    <isbnorissn>1582-4934</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>175</id>
    <title>Bisphenol A and Phthalate Enhanced the Growth of Prostate Cancer Cells and Altered Tgf-Beta Signaling Molecules Via An Estrogen Receptor Or Androgen Receptor-Dependent Pathway in in Vitro and in Vivo Models</title>
    <authors>Lee,H.R.; Hyun,S.H.; Jeung,E.B.; Choi,K.C.</authors>
    <availability>[Lee, H. -R.; Hyun, S. -H.; Jeung, E. -B.; Choi, K. -C.] Chungbuk Natl Univ, Lab Vet Biochem &amp; Immunol, Coll Vet Med, Cheongju, Chungbuk, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00CSIRO PUBLISHINGCOLLINGWOOD150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIAREPROD FERT DEVELOPDiscipline: Developmental Biology; Reproductive Biology; Zoology047OJ</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; GROWTH; In vitro; IN-VITRO; IN-VIVO; MODEL; MODELS; phthalate; Prostate; prostate cancer; PROSTATE-CANCER; RECEPTOR; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>245</startpage>
    <endpage>246</endpage>
    <journalfull>Reproduction Fertility and Development</journalfull>
    <issue>1</issue>
    <volume>25</volume>
    <url>WOS:000311850000206</url>
    <isbnorissn>1031-3613</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>22</id>
    <title>The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor-beta in the progression of LNCaP prostate cancer models</title>
    <authors>Lee,H.R.; Hwang,K.A.; Choi,K.C.</authors>
    <availability>[Lee, Hye-Rim; Hwang, Kyung-A; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krArai S, 2013, ANDROLOGY-US, V1, P169, DOI 10.1111/j.2047-2927.2012.00026.x; Assinder SJ, 2009, BIOCHEM J, V417, P411, DOI 10.1042/BJ20081610; Bockelman C, 2012, CANCER BIOL THER, V13, P289, DOI [10.4161/cbt.18922, 10.4161/cbt.13.5.18922]; Bouchalova K, 2009, BIOMED PAP, V153, P13; Celhay O, 2010, J UROLOGY, V184, P2172, DOI 10.1016/j.juro.2010.06.089; Chae YK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006523; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Derouiche S, 2013, SPRINGERPLUS, V2, P54, DOI DOI 10.1186/2193-1801-2-54;93; Dietrich D, 2013, J MOL DIAGN, V15, P270, DOI 10.1016/j.jmoldx.2012.11.002; Du YP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-261; Dulinska-Litewka J, 2013, CURR MED CHEM, V20, P144; Fromont G, 2008, CANCER EPIDEM BIOMAR, V17, P1505, DOI 10.1158/1055-9965.EPI-07-2778; Geier R, 2010, PROSTATE, V70, P1307, DOI 10.1002/pros.21166; Gross M, 2009, PROSTATE, V69, P520, DOI 10.1002/pros.20901; Guo JM, 2008, CANCER INVEST, V26, P369, DOI 10.1080/07357900701788130; Hess-Wilson JK, 2009, CANCER CAUSE CONTROL, V20, P1029, DOI 10.1007/s10552-009-9337-8; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; Holt SK, 2012, PROSTATE, V73, P1; Hwang KA, 2012, INT J ONCOL, V42, P733; Jones E, 2009, EXPERT OPIN THER TAR, V13, P227, DOI [10.1517/14728220802705696 , 10.1517/14728220802705696]; Kaminska B, 2005, ACTA BIOCHIM POL, V52, P329; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Kim SM, 2012, J PHYSIOL PHARMACOL, V63, P445; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2013, TOXICOLOGY, V304, P13, DOI 10.1016/j.tox.2012.10.012; Lee HR, 2013, J CELL MOL MED, V17, P1, DOI 10.1111/j.1582-4934.2012.01649.x; Lee SO, 2012, J MOL CELL BIOL, V5, P14; Lenferink AE, 2009, ONCOGENE, V29, P831; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Lin D, 2010, PROSTATE, V70, P1636, DOI 10.1002/pros.21199; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Long Xiaobo, 2009, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V23, P1127; Meeks JJ, 2010, J ANDROL, V32, P210; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; Mnif W, 2011, INT J ENV RES PUB HE, V8, P2265, DOI 10.3390/ijerph8062265; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Nakamura Y, 2012, PROSTATE, V73, P590, DOI DOI 10.1002/PR0S.22599); Nicolaiew N, 2009, EUR J ENDOCRINOL, V160, P101, DOI 10.1530/EJE-08-0321; Onita Toru, 2009, Hinyokika Kiyo, V55, P595; Park MA, 2012, MOL MED REP, V5, P761, DOI 10.3892/mmr.2011.712; Park MA, 2013, TOXICOLOGY, V305, P41, DOI 10.1016/j.tox.2012.12.021; Parnes HL, 2013, CURR OPIN ONCOL, V25, P242, DOI 10.1097/CCO.0b013e32835fc8d4; Powers GL, 2013, WIRES SYST BIOL MED, V5, P243, DOI 10.1002/wsbm.1208; Pries R, 2008, INT J MOL MED, V21, P209; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Serra JM, 2008, MOL PHARMACOL, V73, P1679, DOI 10.1124/mol.107.043372; Sissung TM, 2011, J CLIN ENDOCR METAB, V96, pE368, DOI 10.1210/jc.2010-2070; Szendroi A, 2011, CAN J UROL, V18, P5710; Vitkus S, 2013, MOL ENDOCRINOL, V27, P38, DOI 10.1210/me.2012-1212; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Wetherill YB, 2005, CANCER RES, V65, P54511SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J ONCOLAUGDiscipline: OncologyAK5RR</notes>
    <keywords>BISPHENOL-A; BREAST-CANCER; C-MYC EXPRESSION; CANCER; CANCER-CELLS; CELL-CYCLE; CELLS; DNA METHYLATION; DOWN-REGULATION; Endocrine-disrupting chemicals; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; gene expression; GENE-EXPRESSION; GROWTH; IN-VIVO; LNCaP cells; Mouse; phthalate; Phthalates; PROGRESSION; proliferation; prostate cancer; RECEPTOR; SIGNALING PATHWAY; SIGNALING PATHWAYS; TGF-BETA; transforming growth factor-beta; TUMOR PROGRESSION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>595</startpage>
    <endpage>602</endpage>
    <journalfull>International Journal of Oncology</journalfull>
    <issue>2</issue>
    <volume>45</volume>
    <abstract>The distinct roles of estrogen receptors (ERs) related with androgen receptors (ARs) have been proposed in prostate cancer, while the involvement of transforming growth factor-beta (TGF-beta) has been reported in the progression of prostate cancer. In this study, we examined whether the TGF-beta signaling pathway is associated with ER signaling in LNCaP prostate cancer cells, which express ER alpha, ER beta and ARs. We determined whether the exposure to phthalates may induce prostate cancer progression by affecting molecular crosstalk between ER and TGF-beta signaling pathways. Cell viability was measured in LNCaP cells by MTT assay following treatment with di-n-buthyl phthalate (DBP). RT-PCR and immunoblot assay were performed to examine the expression levels of cell cycle-related genes and the TGF-beta signaling cascade. A mouse xenograft model of prostate cancer was generated, and immunohistochemical and BrdU assay were carried out to determine the effect of DBP in this mouse model. DBP, a type of phthalate, was shown to promote LNCaP cell proliferation by upregulating the gene expression of c-myc and cyclin D1 and by downregulating the expression of p21. DBP significantly reduced the protein expression of p-smad similarly to E2. These regulations caused by DBP were reversed by ICI 182,780, an ER antagonist, indicating that DBP may affect crosstalk between TGF-beta and ER signals. In an in vivo mouse model, tumor volume of mice exposed to DBP was increased. Number of cells in S phase of cell cycle was increased by DBP, while expression of p21 protein was reduced in the tissues of DBP-treated mice. These results indicate that DBP may induce the growth of LNCaP prostate cancer by acting on the crosstalk between TGF-beta and ER signaling pathways</abstract>
    <url>WOS:000338484600015</url>
    <isbnorissn>1019-6439</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>44</id>
    <title>Progression of Breast Cancer Cells Was Enhanced by Endocrine-Disrupting Chemicals, Triclosan and Octylphenol, via an Estrogen Receptor-Dependent Signaling Pathway in Cellular and Mouse Xenog raft Models</title>
    <authors>Lee,H.R.; Hwang,K.A.; Nam,K.H.; Kim,H.C.; Choi,K.C.</authors>
    <availability>[Lee, Hye-Rim; Hwang, Kyung-A; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea. [Nam, Ki-Hoan; Kim, Hyoung-Chin] Korea Res Inst Biosci &amp; Biotechnol, Lab Anim Resource Ctr, Cheongwon Gun, Chungbuk, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krAjj H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061758; Caldon CE, 2010, CELL CYCLE, V9, P1918; Choschzick M., 2009, HUM PATHOL, V41, P358; Dai M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3441; Dayan AD, 2007, FOOD CHEM TOXICOL, V45, P125, DOI 10.1016/j.fct.2006.08.009; Gee RH, 2008, J APPL TOXICOL, V28, P78, DOI 10.1002/jat.1316; Geens T, 2009, CHEMOSPHERE, V76, P755, DOI 10.1016/j.chemosphere.2009.05.024; Hurd-Brown T., 2012, J APPL TOXICOL, V33, P495; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Hwang KA, 2012, INT J ONCOL, V42, P733; Junk DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053776; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Kang NH, 2012, INT J ONCOL, V40, P2022, DOI 10.3892/ijo.2012.1372; Kang NH, 2012, CANCER GENE THER, V19, P412, DOI 10.1038/cgt.2012.15; Kang NH, 2013, FOOD CHEM TOXICOL, V59, P373, DOI 10.1016/j.fct.2013.06.029; Katchy A., 2011, J STEROID BIOCHEM, V128, P145; Kim Y. R., 2011, INT J MOL MED, V29, P294; King N. H., 2012, MOL MED REP, V6, P151; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kurose H., 2012, J BIOMED BIOTECHNOL, V2012; Lee H. R., 2012, TOXICOLOGY C, V304, P13; Lee Hye-Rim, 2012, Lab Anim Res, V28, P71, DOI 10.5625/lar.2012.28.2.71; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2013, J CELL MOL MED, V17, P1, DOI 10.1111/j.1582-4934.2012.01649.x; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Miceli C, 2013, CANCER GENE THER, V20, P298, DOI 10.1038/cgt.2013.21; Nori F, 2006, ARCH ENVIRON OCCUP H, V61, P87, DOI 10.3200/AEOH.61.2.87-95; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Park M. A., 2011, MOL MED REP, V5, P761; Park M. A., 2012, LAB ANIM RES, V27, P265; Park MA, 2013, TOXICOLOGY, V305, P41, DOI 10.1016/j.tox.2012.12.021; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Vallo S., 2012, INVEST NEW DRUGS, V31, P265; Yan KH, 2013, ONCOL LETT, V5, P1567, DOI 10.3892/ol.2013.1259; Yang H., 2011, HUM EXP TOXICOL, V31, P134; Yang M, 2009, ARCH TOXICOL, V83, P281, DOI 10.1007/s00204-008-0364-0; Yi BR, 2012, INT J ONCOL, V41, P798, DOI 10.3892/ijo.2012.1523; Yu K. D., 2010, BREAST CANC RES TREA, V126, P37; Zhang XY, 2013, INT J PHARMACEUT, V453, P498, DOI 10.1016/j.ijpharm.2013.06.038; Zhu BT, 2008, MOL MED REP, V1, P15400AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USACHEM RES TOXICOLMAYDiscipline: Pharmacology &amp; Pharmacy; Chemistry; ToxicologyAH6KR</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; ALPHA; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELL-CYCLE; CELLS; CHEMICALS; CYCLE; DOWN-REGULATION; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; estrogenic activity; EXPOSURE; EXPRESSION; FOOD; GROWTH; In vitro; IN-VITRO; IN-VIVO; Mouse; PROGRESSION; proliferation; RECEPTOR; RESVERATROL; RISK; SIGNALING PATHWAY; TETRABROMOBISPHENOL-A; Triclosan</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>834</startpage>
    <endpage>842</endpage>
    <journalfull>Chemical Research in Toxicology</journalfull>
    <issue>5</issue>
    <volume>27</volume>
    <abstract>In the present study, we determined whether two endocrine-disrupting chemicals (EDCs), triclosan (TCS) and octylphenol (OP), are able to alter the expression of two cell cycle regulators, cyclin D1 and p21, in both in vitro and mouse breast cancer models. In addition, we determined whether the stimulatory effects of OP or TCS on breast cancer progression may be associated with an estrogen receptor (ER)-mediated signaling pathway. Altered expressions of cyclin D1 and p21 were observed in MCF-7 human breast cancer cells treated with TCS and OP, which is linked to the G1/S transition of cell cycle, leading to cell proliferation. In a xenograft mouse model, breast tumor masses were established following exposure to TCS and OP for 8 weeks. In these animals, the tumor cells with BrdU-positive nuclei were increased by treatment with 17 beta-estradiol (E2), OP, and TCS compared to that of a control (corn oil), suggesting that TCS and OP increase DNA synthesis during the S phase in tumor cells. Increased level of cyclin D1 protein by TCS and OP was also observed in vivo, implying that the effects of these EDCs possessing estrogenic activity alter the expression of genes related to cancer progression. It was of interest that the effects of TCS and OP were reversed by ICI 182,780, an ER antagonist, indicating that EDC-induced activities are mediated by an ER-dependent signaling pathway. Taken together, these results suggest that TCS and OP may promote breast cancer progression, via an ER-mediated signaling cascade</abstract>
    <url>WOS:000336240300011</url>
    <isbnorissn>0893-228X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>82</id>
    <title>Effects of octylphenol on the expression of cell cycle-related genes and the growth of mesenchymal stem cells derived from human umbilical cord blood</title>
    <authors>Lee,H.R.; Kim,T.H.; Choi,K.J.; Choi,K.C.</authors>
    <availability>[Lee, Hye-Rim; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea. [Kim, Tae-Hee] Soonchunhyang Univ, Coll Med, Dept Obstet &amp; Gynecol, Puchon 420767, Gyeonggi, South Korea. [Choi, Kelvin J.] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada.</availability>
    <date>2014</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, 12 Gaesin Dong, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krAjj H, 2013, PLOS ONE, V8; Asari T, 2012, BIOCHEM BIOPH RES CO, V417, P1193, DOI 10.1016/j.bbrc.2011.12.106; Dang VH, 2009, J REPROD DEVELOP, V55, P206; Fernandez-Sanjuan M, 2009, ANAL BIOANAL CHEM, V394, P1525, DOI 10.1007/s00216-009-2747-3; Fickert S, 2011, J BONE MINER METAB, V29, P224, DOI 10.1007/s00774-010-0215-y; Fonseka M, 2012, CELL BIOL INT, V36, P793, DOI 10.1042/CBI20110595; Fossett E, 2012, STEM CELLS INT, V2012; Fu QL, 2012, ALLERGY, V67, P1215, DOI 10.1111/j.1398-9995.2012.02875.x.; Galindo LT, 2011, NEUROL RES INT, V2011; Hafizi M, 2013, BIOCHEM GENET, V51, P175, DOI 10.1007/s10528-012-9553-x; Hamelin G, 2009, J TOXICOL ENV HEAL A, V72, P541, DOI 10.1080/15287390802706355; Han YF, 2013, CYTOTECHNOLOGY, V65, P819, DOI 10.1007/s10616-012-9528-0; Hussain I, 2012, CELL BIOL INT, V36, P595, DOI 10.1042/CBI20110336; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Jung EM, 2012, INT J ENV RES PUB HE, V9, P698, DOI 10.3390/ijerph9030698; Jung S, 2012, J TISSUE ENG REGEN M, V6, P391, DOI 10.1002/term.441; Kamolz LP, 2006, BURNS, V32, P16, DOI 10.1016/j.burns.2005.08.020; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Kermani AJ, 2008, REJUV RES, V11, P379, DOI 10.1089/rej.2008.0674; Kim ES, 2012, PEDIATR RES, V72, P277, DOI 10.1038/pr.2012.71; Lechner V, 2007, ZBL CHIR, V132, P358, DOI 10.1055/s-2007-981247; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2013, TOXICOLOGY, V304, P13, DOI 10.1016/j.tox.2012.10.012; Oodi A, 2012, HEMATOLOGY, V17, P334, DOI 10.1179/1607845412Y.0000000009; Park M. A., 2011, MOL MED REP, V5, P761; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Reddi AS, 2010, CURR STEM CELL RES T, V5, P356; Rhee JS, 2009, COMP BIOCHEM PHYS C, V149, P433, DOI 10.1016/j.cbpc.2008.10.102; Sharma VK, 2009, J ENVIRON SCI HEAL A, V44, P423, DOI 10.1080/10934520902719704; Wong CJ, 2010, EXP CELL RES, V316, P927, DOI 10.1016/j.yexcr.2010.01.018; Xu YA, 2012, J TISSUE ENG REGEN M, V6, P645, DOI 10.1002/term.468; Zhang X, 2009, MAR POLLUT BULL, V58, P1210, DOI 10.1016/j.marpolbul.2009.03.011320SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J MOL MEDJANAA0LA</notes>
    <keywords>ABNORMALITIES; BISPHENOL-A; CELL; cell cycle; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CHEMICALS; CORD BLOOD; CYCLE; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; ESTROGEN-RECEPTORS; EXPOSURE; EXPRESSION; GLAND; GROWTH; mesenchymal stem cell; MSC; octylphenol; OVARIAN-CANCER CELLS; proliferation; RATS; SIGNALING PATHWAY; SIGNALING PATHWAYS; STEM-CELLS; THERAPY; TISSUE; toxicology; umbilical cord blood</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>221</startpage>
    <endpage>226</endpage>
    <journalfull>International Journal of Molecular Medicine</journalfull>
    <issue>1</issue>
    <volume>33</volume>
    <abstract>Umbilical cord blood (UCB) is defined as blood that exists in the placenta and in the attached umbilical cord following childbirth. Cord blood is now used for research purposes as it contains mesenchymal stem cells (MSCs), multipotent stromal cells which have the ability to differentiate into a variety of cell types. Among endocrine disrupting chemicals (EDCs), octylphenol (OP) is one of the alkylphenols, which are widely used industrial chemicals; these chemicals cause a number of serious side-effects, such as reproductive abnormalities. In this study, we isolated human MSCs from UCB and demonstrate that cultured MSCs express the surface marker, CD34, but not CD105. We further examined the effects of OP on human UCB-derived MSCs following exposure to OP by cell proliferation assay, semi-quantitative RT-PCR and western blot analysis. The results revealed that the transcriptional and translational levels of cyclin D1 were increased, while the levels of p21 were suppressed in the MSCs treated with OP compared with the negative controls. This collapse of the regulation of the cell cycle may directly stimulate the growth of the MSCs under culture conditions. The results from the present study provide further insight into the effects of common EDCs on MSCs derived from human UCB. However, further studies are required to identify the signaling pathways which mediate the effects of EDCs on MSCs</abstract>
    <url>WOS:000330785400029</url>
    <isbnorissn>1107-3756</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>242</id>
    <title>Set, a Putative Oncogene, As a Biomarker for Prenatal Exposure to Bisphenol A</title>
    <authors>Lee,H.S.; Pyo,M.Y.; Yang,M.</authors>
    <availability>[Lee, Ho-Sun; Pyo, Myoung-Yun; Yang, Mihi] Sookmyung Womens Univ, Coll Pharm, Res Ctr Cell Fate Control, Seoul, South Korea.</availability>
    <date>2012</date>
    <notes>JEnglishArticleYang, M (reprint author), Sookmyung Womens Univ, Coll Pharm, Res Ctr Cell Fate Control, Seoul, South Koreamyang@sm.ac.krBelcher SM, 2005, ENDOCRINOLOGY, V146, P5397, DOI 10.1210/en.2005-0564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Christensen DJ, 2011, BLOOD, V118, P4150, DOI 10.1182/blood-2011-04-351072; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Engel SM, 2006, REPROD TOXICOL, V21, P110, DOI 10.1016/j.reprotox.2005.07.007; Kuroda N, 2003, J PHARMACEUT BIOMED, V30, P1743, DOI 10.1016/S0731-7085(02)00516-2; Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20; Lamason R, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-2; Mellon SH, 2007, MOL ENDOCRINOL, V21, P89, DOI 10.1210/me.2005-0355; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Rubin MM, 2007, OBSTET GYNECOL SURV, V62, P548, DOI 10.1097/01.ogx.0000271138.31234.d7; Safe S, 2002, INT J ONCOL, V20, P1123; Simon V, 2012, MOL PHARMACOL, V82, P17, DOI 10.1124/mol.111.075523; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346; Yang M, 2006, ENVIRON MOL MUTAGEN, V47, P571, DOI 10.1002/em.20230; Yang M, 2008, ENVIRON MOL MUTAGEN, V49, P368, DOI 10.1002/em.20394; Ye LP, 2011, TOXICOL LETT, V207, P137, DOI 10.1016/j.toxlet.2011.09.001; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Yi B, 2011, MUTAT RES-GEN TOX EN, V724, P64, DOI 10.1016/j.mrgentox.2011.06.007; Yi B, 2010, J CHROMATOGR B, V878, P2606, DOI 10.1016/j.jchromb.2010.02.008; Zhang PL, 2001, DNA CELL BIOL, V20, P613, DOI 10.1089/104454901753340604211ASIAN PACIFIC ORGANIZATION CANCER PREVENTIONGYEONGGI-DOAPJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREAASIAN PAC J CANCER PDiscipline: Oncology015UQ</notes>
    <keywords>BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; CANCER; CARCINOGENIC RISKS; CELL; CYP17; development; ENDOCRINE; EXPOSURE; FLUID; GENE; GENES; inhibition; INHIBITOR; mechanism; MECHANISMS; METABOLISM; MICE; network analysis; oncology; ORGANIZATION; PHENOLS; PRENATAL EXPOSURE; PREVENTION; PROTEIN; PROTEINS; Proteomics; RISK; SAMPLES; SET; TARGET; TRANSCRIPTION; WATER; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2711</startpage>
    <endpage>2715</endpage>
    <journalfull>Asian Pacific Journal of Cancer Prevention</journalfull>
    <issue>6</issue>
    <volume>13</volume>
    <abstract>Background: Bisphenol A (BPA), an endocrine disrupting chemical, has been suspected to pose carcinogenic risks. However, likely mechanisms are obscure and there are difficulties to estimating its real significance for cancer development. Methods: We therefore studied BPA-induced proteomic alterations in immune organs of ICR mice offspring that were prenatally exposed to BPA (15 and 300 mg/L of drinking water). We performed 2D-gel analyses of samples, considering differences in spleen, exposure levels, sex, and ages. Results: From proteomic analyses, we found various proteins were up-or down-regulated by BPA. Among them, SET, a putative oncogene and inhibitor of phosphatase 2A, was significantly downregulated in a BPA dose-dependent manner. We also confirmed down-regulation of SET in western blot and real time PCR analyses. From gene network analysis, SET is predicted to communicate with other genes including CYP17, which is involved in biosynthesis and metabolism of sex-hormones. Conclusions: This study provided evidence that SET can be applied as a new biomarker for prenatal BPA exposure and suggests a potential new mechanism of action in that BPA may disrupt CYP17 via SET</abstract>
    <url>WOS:000309472300048</url>
    <isbnorissn>1513-7368</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>17</id>
    <title>Bisphenol A exerts estrogenic effects by modulating CDK1/2 and p38 MAP kinase activity</title>
    <authors>Lee,H.S.; Park,E.J.; Oh,J.H.; Moon,G.; Hwang,M.S.; Kim,S.Y.; Shin,M.K.; Koh,Y.H.; Suh,J.H.; Kang,H.S.; Jeon,J.H.; Rhee,G.S.; Hong,J.H.</authors>
    <availability>[Lee, Hee-Seok; Park, Eun-Jung; Oh, Jae-Ho; Moon, Guiim; Hwang, Myung-Sil; Kim, Sang-Yub; Shin, Min-Ki; Koh, Young-Ho; Suh, Jin-Hyang; Kang, Hui-Seung; Rhee, Gyu-Seek; Hong, Jin-Hwan] Natl Inst Food &amp; Drug Safety Evaluat, Food Safety Risk Assessment Div, Chungcheongbuk Do, South Korea. [Jeon, Ju-Hong] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishArticleHong, JH (reprint author), Natl Inst Food &amp; Drug Safety Evaluat, Food Safety Risk Assessment Div, Chungcheongbuk Do, South Koreahongjinh@korea.krBhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1; Burridge E., 2003, EUR CHEM NEWS, P14; Canesi L, 2004, GEN COMP ENDOCR, V138, P58, DOI 10.1016/j.ygcen.2004.05.004; Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Grignard E, 2012, TOXICOL IN VITRO, V26, P727, DOI 10.1016/j.tiv.2012.03.013; Jung KK, 2007, ARCH PHARM RES, V30, P616, DOI 10.1007/BF02977657; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Kim JY, 2010, TOXICOL LETT, V193, P200, DOI 10.1016/j.toxlet.2010.01.011; Leclercq G, 2002, J STEROID BIOCHEM, V80, P259, DOI 10.1016/S0960-0760(02)00026-2; Lee HK, 2012, J TOXICOL SCI, V37, P431; Lee SJ, 2001, ANNU REV PHARMACOL, V41, P569, DOI 10.1146/annurev.pharmtox.41.1.569; MacCorkle RA, 2005, CELL BIOCHEM BIOPHYS, V43, P451, DOI 10.1385/CBB:43:3:451; Miller D, 2001, ENVIRON HEALTH PERSP, V109, P133, DOI 10.2307/3434765; OECD, 2012, TEST NO 457 BGILUC E, V4, DOI [10.1787/9789264185395-en, DOI 10.1787/9789264185395-EN]; Park EJ, 2009, BIOL PHARM BULL, V32, P1790; Rogers JM, 2000, IN VITRO MOL TOXICOL, V13, P67; Ruehlmann DO, 1998, FASEB J, V12, P613; Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Vasudevan N, 2008, FRONT NEUROENDOCRIN, V29, P238, DOI 10.1016/j.yfrne.2007.08.003; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Zhang DP, 2006, COMP BIOCHEM PHYS A, V144, P306, DOI 10.1016/j.cbpa.2006.01.025280TAYLOR &amp; FRANCIS LTDABINGDON4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDBIOSCI BIOTECH BIOCHAUGDiscipline: Biochemistry &amp; Molecular Biology; Biotechnology &amp; Applied Microbiology; Chemistry; Food Science &amp; TechnologyAN6QZ</notes>
    <keywords>ACTIVATION; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; CDK1/2; CELLS; CHEMICALS; ENDOCRINE DISRUPTORS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; estrogenic activity; In vitro; IN-VITRO; INTEGRATION; MECHANISMS; NONGENOMIC ACTIONS; p38 MAPK; POLLUTANTS; proliferation; RECEPTOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1371</startpage>
    <endpage>1375</endpage>
    <journalfull>Bioscience Biotechnology and Biochemistry</journalfull>
    <issue>8</issue>
    <volume>78</volume>
    <abstract>Bisphenol A (BPA) is considered to be an endocrine disruptor, but the mechanisms by which it disrupts endocrine functions are poorly understood. Here, we have shown that BPA binds both estrogen receptor (ER)-alpha and ER-beta (ER-beta) using a fluorescence polarization competitive binding assay. In addition, we found that BPA induced cell proliferation by modulating cell cycle-related genes in the MCF-7 human mammary cancer cell line. Moreover, using a BG1 luciferase ER transactivation assay, we found that BPA has estrogenic activity. Modulating the MAPK pathway by using an ERK inhibitor (PD98059) or a JNK inhibitor (SP600125) had no effect on the ability of BPA to induce estrogenic activity. However, the antiestrogen, ICI 182,780, and the p38 inhibitor, PD 169316 successfully blocked BPA-induced estrogenic activity. Our findings suggest that BPA mimics ER-dependent estrogenic activity by targeting proteins that regulate the cell cycle and p38 MAPK</abstract>
    <url>WOS:000340722500012</url>
    <isbnorissn>0916-8451</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>341</id>
    <title>Enhanced Photocatalytic Activity using Layer-by-Layer Electrospun Constructs for Water Remediation</title>
    <authors>Lee,J.A.; Nam,Y.S.; Rutledge,G.C.; Hammond,P.T.</authors>
    <availability>[Lee, Jung Ah; Rutledge, Gregory C.; Hammond, Paula T.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Lee, Jung Ah; Rutledge, Gregory C.; Hammond, Paula T.] MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA. [Nam, Yoon Sung] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleLee, JA (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USArutledge@mit.edu; hammond@mit.eduAGUADO MA, 1994, J MOL CATAL, V89, P165, DOI 10.1016/0304-5102(93)E0282-L; ANWYA MD, 2006, ENDOCRINOLOGY, V147, pS43; ATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; BELLOBONO IR, 1992, J PHOTOCH PHOTOBIO A, V67, P109, DOI 10.1016/1010-6030(92)85173-R; BIDEAU M, 1995, J PHOTOCH PHOTOBIO A, V91, P137, DOI 10.1016/1010-6030(95)04098-Z; BREZOVA V, 1995, COLLECT CZECH CHEM C, V60, P788, DOI 10.1135/cccc19950788; Choi H, 2006, ADV FUNCT MATER, V16, P1067, DOI 10.1002/adfm.200500658; Crittenden JC, 1996, WATER ENVIRON RES, V68, P270, DOI 10.2175/106143096X127703; Deborde M, 2008, WATER RES, V42, P4299, DOI 10.1016/j.watres.2008.07.015; DORN PB, 1987, CHEMOSPHERE, V16, P1501, DOI 10.1016/0045-6535(87)90090-7; Edmonds JS, 2004, BIOCHEM BIOPH RES CO, V319, P556, DOI 10.1016/j.bbrc.2004.05.024; Fang Y, 2002, J PHYS CHEM A, V106, P4669, DOI 10.1021/jp014425z; Fukahori S, 2003, APPL CATAL B-ENVIRON, V46, P453, DOI 10.1016/S0926-3373(03)00270-4; Fukahori S, 2003, ENVIRON SCI TECHNOL, V37, P1048, DOI 10.1021/es0260115; GIBSON DT, 1968, SCIENCE, V161, P1093; Guo ZB, 2009, J HAZARD MATER, V163, P855, DOI 10.1016/j.jhazmat.2008.07.038; HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Iguchi Taisen, 2002, Congenital Anomalies, V42, P106, DOI 10.1111/j.1741-4520.2002.tb00859.x; Ishibashi H, 2005, LIFE SCI, V77, P2643, DOI 10.1016/j.lfs.2005.03.025; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Kawahata H, 2004, CHEMOSPHERE, V55, P1519, DOI 10.1016/j.chemosphere.2004.01.032; Lee JA, 2009, ADV MATER, V21, P1252, DOI 10.1002/adma.200802458; Li XM, 2008, BIOMED ENVIRON SCI, V21, P381, DOI 10.1016/S0895-3988(08)60058-6; Lu YX, 2006, J PHYS CHEM A, V110, P9261, DOI 10.1021/jp060790k; Magrez A, 2009, ACS NANO, V3, P2274, DOI 10.1021/nn9002067; Maki T, 2001, J AM CHEM SOC, V123, P3371, DOI 10.1021/ja002453+; MIKULA M, 1995, J MATER SCI LETT, V14, P615, DOI 10.1007/BF00586156; NAIR M, 1993, IND ENG CHEM RES, V32, P2318, DOI 10.1021/ie00022a015; Nomiyama K, 2007, CHEMOSPHERE, V66, P1138, DOI 10.1016/j.chemosphere.2006.06.01; Nomiyama K, 2007, ARCH ENVIRON CON TOX, V52, P8, DOI 10.1007/s00244-005-0204-7; Ohko Y, 2001, ENVIRON SCI TECHNOL, V35, P2365, DOI 10.1021/es001757t; Pozzo RL, 1997, CATAL TODAY, V39, P219, DOI 10.1016/S0920-5861(97)00103-X; Reddy EP, 2003, APPL CATAL B-ENVIRON, V42, P1, DOI 10.1016/S0926-3373(02)00192-3; Shin YM, 2001, POLYMER, V42, P9955, DOI 10.1016/S0032-3861(01)00540-7; Sjodin M, 2006, J AM CHEM SOC, V128, P13076, DOI 10.1021/ja063264f; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SPIVACK J, 1994, J BIOL CHEM, V269, P7323; Theron P, 2001, WATER SCI TECHNOL, V44, P263; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; XU YM, 1995, J PHYS CHEM-US, V99, P11501, DOI 10.1021/j100029a031; Yang YJ, 2009, ENVIRON RES, V109, P797, DOI 10.1016/j.envres.2009.04.014; Yoshihara S, 2004, TOXICOL SCI, V78, P50, DOI 10.1093/toxsci/kfh047; Zhang C, 2007, CHEMOSPHERE, V68, P181, DOI 10.1016/j.chemosphere.2006.12.012; ZHANG Y, 1994, ENVIRON SCI TECHNOL, V28, P435, DOI 10.1021/es00052a0154715WILEY-V C H VERLAG GMBHWEINHEIMBOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANYADV FUNCT MATERAUG 9Discipline: Chemistry; Science &amp; Technology - Other Topics; Materials Science; Physics640NS</notes>
    <keywords>AQUEOUS-SOLUTION; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER-CELL-PROLIFERATION; CELL; Cell proliferation; CELL-PROLIFERATION; COMPOSITE TIO2-ZEOLITE SHEETS; DEGRADATION; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental pollutants; ENVIRONMENTAL-POLLUTANTS; estrogenic activity; FIXED-BED PHOTOCATALYSTS; HEALTH; Hormones; HUMAN EXPOSURE; HUMAN-BREAST-CANCER; Nanoparticle; NANOPARTICLES; OXIDATION; OXIDE; P8; POLLUTANTS; proliferation; SYSTEM; TIO2; TITANIUM-DIOXIDE; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2424</startpage>
    <endpage>2429</endpage>
    <journalfull>Advanced Functional Materials</journalfull>
    <issue>15</issue>
    <volume>20</volume>
    <abstract>Endocrine disruptors such as bisphenol A (BPA) are environmental pollutants that interfere with the body's endocrine system because of their structural similarity to natural and synthetic hormones. Due to their strong oxidizing potential to decompose such organic pollutants, colloidal metal oxide photocatalysts have attracted increasing attention for water detoxification. However, achieving both long-term physical stability and high efficiency simultaneously with such photocatalytic systems poses many challenges. Here a layer-by-layer (LbL) deposition approach is reported for immobilizing TiO2 nanoparticles (NPs) on a porous support while maintaining a high catalytic efficiency for photochemical decomposition of BPA. Anatase TiO2 NPs approximate to 7 nm in diameter self-assemble in consecutive layers with positively charged polyhedral oligomeric silsesquioxanes on a high surface area, porous electrospun polymer fiber mesh. The TiO2 LbL nanofibers decompose approximately 2.2 mg BPA per mg of TiO2 in 40 h of illumination (AM 1.5G illumination), maintaining first-order kinetics with a rate constant (k) of 0.15 h(-1) for over 40 h. Although the colloidal TiO2 NPs initially show significantly higher photocatalytic activity (k approximate to 0.84 h(-1)), the rate constant drops to k approximate to 0.07 h(-1) after 4 h of operation, seemingly due to particle agglomeration. In the BPA solution treated with the multilayered TiO2 nanofibers for 40 h, the estrogenic activity, based on human breast cancer cell proliferation, is significantly lower than that in the BPA solution treated with colloidal TiO2 NPs under the same conditions. This study demonstrates that water-based, electrostatic LbL deposition effectively immobilizes and stabilizes TiO2 NPs on electrospun polymer nanofibers for efficient extended photochemical water remediation</abstract>
    <url>WOS:000281058900006</url>
    <isbnorissn>1616-301X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>112</id>
    <title>Estrogen Receptor beta (ER beta 1) Transactivation Is Differentially Modulated by the Transcriptional Coregulator Tip60 in a cis-Acting Element-dependent Manner</title>
    <authors>Lee,M.T.; Leung,Y.K.; Chung,I.; Tarapore,P.; Ho,S.M.</authors>
    <availability>[Lee, Ming-Tsung; Leung, Yuet-Kin; Chung, Irving; Tarapore, Pheruza; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Div Environm Genet &amp; Mol Toxicol, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Leung, Yuet-Kin; Tarapore, Pheruza; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH 45267 USA. [Leung, Yuet-Kin; Tarapore, Pheruza; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Inst Canc, Cincinnati, OH 45267 USA. [Ho, Shuk-Mei] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45220 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleHo, SM (reprint author), Univ Cincinnati, Dept Environm Hlth, Rm 130,Kettering Lab Complex,3223 Eden Ave, Cincinnati, OH 45267 USAshuk-mei.ho@uc.eduBaek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bjornstrom L., 2004, NUCL RECEPT, V2, P3, DOI DOI 10.1186/1478-1336-2-3; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Burns KA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.187773; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fujimoto N, 2004, J STEROID BIOCHEM, V88, P53, DOI 10.1016/j.jsbmb.2003.10.006; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Harris DM, 2005, EXP BIOL MED, V230, P558; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Ho SM, 2011, ENDOCRIN METAB CLIN, V40, P591, DOI 10.1016/j.ecl.2011.05.002; Holmes KA, 2008, CANCER RES, V68, P7380, DOI 10.1158/0008-5472.CAN-08-0133; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Jeong KW, 2012, MOL ENDOCRINOL, V26, P955, DOI 10.1210/me.2012-1066; Jeyakunnar M, 2011, J BIOL CHEM, V286, P12971, DOI 10.1074/jbc.M110.205112; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Klinge CM, 2004, J MOL ENDOCRINOL, V33, P387, DOI 10.1677/jma.101541; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013; Leung YK, 2010, ENDOCR-RELAT CANCER, V17, P675, DOI 10.1677/ERC-09-0294; Leung YK, 2006, NEOPLASIA, V8, P242, DOI 10.1593/neo.05853; Liu Y, 2008, P NATL ACAD SCI USA, V105, P2604, DOI 10.1073/pnas.0712085105; Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Nikov GN, 2000, ENVIRON HEALTH PERSP, V108, P867, DOI 10.2307/3434995; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Sanchez M, 2013, ONCOGENE, V32, P117, DOI 10.1038/onc.2012.19; Sanchez M, 2007, J BIOL CHEM, V282, P4830, DOI 10.1074/jbc.M607908200; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Sauve K, 2009, CANCER RES, V69, P5793, DOI 10.1158/0008-5472.CAN-08-4924; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Shiota M, 2010, PROSTATE, V70, P540, DOI 10.1002/pros.21088; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sun YL, 2006, FEBS LETT, V580, P4353, DOI 10.1016/j.febslet.2006.06.092; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vivar OI, 2010, J BIOL CHEM, V285, P22059, DOI 10.1074/jbc.M110.114116; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang CG, 2011, J STEROID BIOCHEM, V123, P91, DOI 10.1016/j.jsbmb.2010.12.003; Wang JD, 2010, J BIOL CHEM, V285, P11458, DOI 10.1074/jbc.M109.087585; Wang Y, 2006, P NATL ACAD SCI USA, V103, P9908, DOI 10.1073/pnas.0510596103; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032886; Zhao Chunyan, 2008, Nucl Recept Signal, V6, pe003, DOI 10.1621/nrs.06003; Zhao CY, 2010, CANCER RES, V70, P5174, DOI 10.1158/0008-5472.CAN-09-4407; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397; Zwart W, 2010, J CELL SCI, V123, P1253, DOI 10.1242/jcs.061135711AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INCBETHESDA9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USAJ BIOL CHEMAUG 30Discipline: Biochemistry &amp; Molecular Biology302QC</notes>
    <keywords>ALPHA; ANDROGEN RECEPTOR; BETA; BINDING; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CELL; COREGULATORS; CREB-BINDING PROTEIN; ER alpha; ER-ALPHA; ER-BETA; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPRESSION; GENE-EXPRESSION; genistein; HINGE REGION; HISTONE ACETYLTRANSFERASE ACTIVITY; LIGAND; NUCLEAR RECEPTORS; PARTIAL AGONIST; Prostate; PROSTATE-CANCER; RECEPTOR; TRANSACTIVATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>25038</startpage>
    <endpage>25052</endpage>
    <journalfull>Journal of Biological Chemistry</journalfull>
    <issue>35</issue>
    <volume>288</volume>
    <abstract>Estrogen receptor (ER) beta 1 and ER alpha have overlapping and distinct functions despite their common use of estradiol as the physiological ligand. These attributes are explained in part by their differential utilization of coregulators and ligands. Although Tip60 has been shown to interact with both receptors, its regulatory role in ER beta 1 transactivation has not been defined. In this study, we found that Tip60 enhances transactivation of ER beta 1 at the AP-1 site but suppresses its transcriptional activity at the estrogen-response element (ERE) site in an estradiol-independent manner. However, different estrogenic compounds can modify the Tip60 action. The corepressor activity of Tip60 at the ERE site is abolished by diarylpropionitrile, genistein, equol, and bisphenol A, whereas its coactivation at the AP-1 site is augmented by fulvestrant (ICI 182,780). GRIP1 is an important tethering mediator for ERs at the AP-1 site. We found that coexpression of GRIP1 synergizes the action of Tip60. Although Tip60 is a known acetyltransferase, it is unable to acetylate ER beta 1, and its coregulatory functions are independent of its acetylation activity. In addition, we showed the co-occupancy of ER beta 1 and Tip60 at ERE and AP-1 sites of ER beta 1 target genes. Tip60 differentially regulates the endogenous expression of the target genes by modulating the binding of ER beta 1 to the cis-regulatory regions. Thus, we have identified Tip60 as the first dual-function coregulator of ER beta 1</abstract>
    <url>WOS:000330619000005</url>
    <isbnorissn>0021-9258</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>447</id>
    <title>Balancing the budget of environmental estrogen exposure: the contribution of recycled water</title>
    <authors>Leusch,F.D.L.; Moore,M.R.; Chapman,H.F.</authors>
    <availability>[Leusch, Frederic D. L.; Chapman, Heather F.] Griffith Univ, Smart Water Res Facil, Gold Coast, Qld 4222, Australia. [Moore, Michael R.] Univ Queensland, EnTox, Coopers Plains, Qld 4108, Australia.</availability>
    <date>2009</date>
    <notes>JEnglishArticleLeusch, FDL (reprint author), Griffith Univ, Smart Water Res Facil, Parkland Dr, Gold Coast, Qld 4222, Australiaf.leusch@griffith.edu.au; m.moore@uq.edu.au; h.chapman@griffith.edu.auAdams NR, 1998, PURE APPL CHEM, V70, P1855, DOI 10.1351/pac199870091855; Andersen HR, 2002, TOXICOL APPL PHARM, V179, P1, DOI 10.1006/taap.2001.9347; Basheer C, 2004, MAR POLLUT BULL, V48, P1161, DOI 10.1016/j.marpolbul.2004.04.009; Benotti MJ, 2009, ENVIRON SCI TECHNOL, V43, P597, DOI 10.1021/es801845a; BITMAN J, 1968, SCIENCE, V162, P371, DOI 10.1126/science.162.3851.371; Brian JV, 2005, ENVIRON HEALTH PERSP, V113, P721, DOI 10.1289/ehp.7598; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Campbell CG, 2006, CHEMOSPHERE, V65, P1265, DOI 10.1016/j.chemosphere.2006.08.003; Casajuana N, 2003, CHROMATOGRAPHIA, V57, P649, DOI 10.1007/BF02491744; *CEPA, 1994, 9411 CEPA; Choe SY, 2003, SCI TOTAL ENVIRON, V312, P15, DOI 10.1016/S0048-9697(03)00190-6; Clarke DB, 2004, FOOD ADDIT CONTAM, V21, P949, DOI 10.1080/02652030400006858; Clarke DB, 2004, FOOD ADDIT CONTAM, V21, P305, DOI 10.1080/02652030410001668781; COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; Diel P, 2004, ARCH TOXICOL, V78, P183, DOI 10.1007/s00204-003-0535-y; Drewes JE, 2005, ENVIRON PROG, V24, P400, DOI 10.1002/ep.10110; EFSA, 2006, EFSA J, V428, P1, DOI DOI 10.2903/J.EFSA.2007A28; Erbs M, 2007, J AGR FOOD CHEM, V55, P8339, DOI 10.1021/jf071661j; Fang H, 2000, ENVIRON HEALTH PERSP, V108, P723, DOI 10.1289/ehp.00108723; Ferrara F, 2005, CHEMOSPHERE, V59, P1145, DOI 10.1016/j.chemosphere.2004.11.085; Fielden MR, 2003, FOOD CHEM TOXICOL, V41, P447, DOI 10.1016/S0278-6915(02)00284-3; Fromme H, 2007, ENVIRON INT, V33, P1012, DOI 10.1016/j.envint.2007.05.006; *FSANZ, 2003, AUSTR TOT DIET SURV, P62; Fukutake M, 1996, FOOD CHEM TOXICOL, V34, P457, DOI 10.1016/0278-6915(96)87355-8; Geisler J, 1999, J ENDOCRINOL, V162, P265, DOI 10.1677/joe.0.1620265; Guenther K, 2002, ENVIRON SCI TECHNOL, V36, P1676, DOI 10.1021/es010199v; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Hartmann S, 1998, FOOD CHEM, V62, P7, DOI 10.1016/S0308-8146(97)00150-7; Holbech H, 2006, COMP BIOCHEM PHYS C, V144, P57, DOI 10.1016/j.cbpc.2006.05.006; Jefferson WN, 2002, J CHROMATOGR B, V777, P179, DOI 10.1016/S1570-0232(02)00493-2; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Kim SD, 2007, WATER RES, V41, P1013, DOI 10.1016/j.watres.2006.06.034; Klein GP, 2006, ENVIRON HEALTH PERSP, V114, P697, DOI 10.1289/ehp.8496; Klinge CM, 2003, J AGR FOOD CHEM, V51, P1850, DOI 10.1021/jf0259821; Korner W, 2001, ENVIRON TOXICOL CHEM, V20, P2142, DOI 10.1897/1551-5028(2001)020&lt;2142:SWEAIE&gt;2.0.CO;2; Kuch HM, 2000, FRESEN J ANAL CHEM, V366, P392, DOI 10.1007/s002160050080; Kuch HM, 2001, ENVIRON SCI TECHNOL, V35, P3201, DOI 10.1021/es010034m; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lagana A, 2004, ANAL CHIM ACTA, V501, P79, DOI 10.1016/j.aca.2003.09.020; Lapcik O, 1998, STEROIDS, V63, P14, DOI 10.1016/S0039-128X(97)00104-9; Leusch FDL, 2006, COMP BIOCHEM PHYS C, V143, P117, DOI 10.1016/j.cbpc.2005.12.010; Lu YY, 2007, ENVIRON INT, V33, P903, DOI 10.1016/j.envint.2007.04.008; Malekinejad H, 2006, J AGR FOOD CHEM, V54, P9785, DOI 10.1021/jf061972e; Matsumura A, 2005, J STEROID BIOCHEM, V94, P431, DOI 10.1016/j.jsbmb.2004.12.041; Maume D, 2001, APMIS, V109, pS365; Mazur W, 1998, PURE APPL CHEM, V70, P1759, DOI 10.1351/pac199870091759; Muller M, 1996, FOOD ADDIT CONTAM, V13, P359; NRMMC/EPHC/NHMRC, 2008, AUSTR GUID WAT REC M, P174; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Panter GH, 2002, ENVIRON TOXICOL CHEM, V21, P319, DOI 10.1897/1551-5028(2002)021&lt;0319:UOAJFM&gt;2.0.CO;2; PELISSERO C, 1991, J STEROID BIOCHEM, V38, P293, DOI 10.1016/0960-0760(91)90100-J; Petersen JH, 2000, FOOD ADDIT CONTAM, V17, P133, DOI 10.1080/026520300283487; PUGH J, 1998, ENDOCRINE DISRUPTION, P7; Quayle WC, 1997, J CHROMATOGR A, V773, P271, DOI 10.1016/S0021-9673(97)00190-8; ROSENBLUM ER, 1993, ALCOHOL CLIN EXP RES, V17, P1207, DOI 10.1111/j.1530-0277.1993.tb05230.x; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; Snyder SA, 2003, ENVIRON ENG SCI, V20, P449, DOI 10.1089/109287503768335931; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Takamura-Enya T, 2003, FOOD CHEM TOXICOL, V41, P543, DOI 10.1016/S0278-6915(02)00305-8; Thomson BM, 2003, J ENVIRON MONITOR, V5, P229, DOI 10.1039/b211323f; Tilton SC, 2003, COMP BIOCHEM PHYS C, V136, P265, DOI 10.1016/j.cca.2003.09.009; Van den Belt K, 2004, AQUAT TOXICOL, V66, P183, DOI 10.1016/j.aquatox.2003.09.004; Van den Belt K, 2003, ECOTOX ENVIRON SAFE, V56, P271, DOI 10.1016/S0147-6513(03)00004-6; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Yoshida T, 2001, FOOD ADDIT CONTAM A, V18, P69, DOI 10.1080/026520301446412685IWA PUBLISHINGLONDONALLIANCE HOUSE, 12 CAXTON ST, LONDON SW1H0QS, ENGLANDWATER SCI TECHNOLDiscipline: Engineering; Environmental Sciences &amp; Ecology; Water Resources491BB</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVITY IN-VITRO; BISPHENOL-A; BREAST-CANCER CELLS; daily exposure; diet; Dietary Exposure; DISRUPTION; DRINKING-WATER; e-EDCs; EEDC; ENDOCRINE; Endocrine disrupting compound; Endocrine disrupting compounds; Endocrine disruption; Environmental estrogen; ER; Estrogen; Estrogenic; ESTROGENIC COMPOUNDS; Estrogenicity; EXPOSURE; FOOD; GOLD; HEALTH; In vitro; in vivo; IN-VITRO; IN-VIVO; MEDIA; PHYTOESTROGENS; recycled water; RISK; SAMPLES; Sewage; SEWAGE-TREATMENT PLANTS; Steroid; toxicology; urban water; VITRO; VIVO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1003</startpage>
    <endpage>1012</endpage>
    <journalfull>Water Science and Technology</journalfull>
    <issue>4</issue>
    <volume>60</volume>
    <abstract>Estrogenic endocrine disrupting compounds (e-EDCs) are present in treated sewage and there is concern about estrogenicity of potable recycled water. However e-EDCs are also present in other environmental media and intake from water needs to be considered in relation to these other sources. The concentrations of 13 e-EDCs in foodstuffs and drinking water are reviewed, their predicted concentrations in recycled water are estimated, and the daily estrogenic intake as 17 beta-estradiol equivalent (EEq) based on both in vitro and in vivo potencies is calculated as 1.39 and 9.65 mu g EEq/d, respectively. Dietary intake accounts for more than 99.8% of that total, and more than 84.2% is due to phytosterols. Drinking 2 L of recycled water per day is expected to add 0.001 to 0.016 mu g EEq/d based on in vitro and in vivo potencies, respectively. Exposure to e-EDCs in recycled water is therefore likely to be insignificant compared to current dietary intakes</abstract>
    <url>WOS:000269550700019</url>
    <isbnorissn>0273-1223</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>378</id>
    <title>In vitro profiling of endocrine disrupting effects of phenols</title>
    <authors>Li,J.; Ma,M.; Wang,Z.J.</authors>
    <availability>[Li, Jian; Ma, Mei; Wang, Zijian] Chinese Acad Sci, Ecoenvironm Sci Res Ctr, State Key Lab Environm Aquat Chem, Beijing 100085, Peoples R China.</availability>
    <date>2010</date>
    <notes>JEnglishArticleWang, ZJ (reprint author), Chinese Acad Sci, Ecoenvironm Sci Res Ctr, State Key Lab Environm Aquat Chem, POB 2871, Beijing 100085, Peoples R Chinawangzj@rcees.ac.cnAuwerx J, 1999, CELL, V97, P161; Dhooge W, 2006, ANAL BIOANAL CHEM, V386, P1419, DOI 10.1007/s00216-006-0669-x; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Gronen S, 1999, ENVIRON HEALTH PERSP, V107, P385, DOI 10.2307/3434542; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Jung J, 2004, LIFE SCI, V74, P3065, DOI 10.1016/j.lfs.2003.10.030; Kim HJ, 2005, TOXICOL SCI, V88, P52, DOI 10.1093/toxsci/kfi287; Kiparissis Y, 2003, AQUAT TOXICOL, V63, P391, DOI 10.1016/S0166-445X(02)00189-3; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Klotz DM, 1997, MOL CELL ENDOCRINOL, V129, P63, DOI 10.1016/S0303-7207(96)04041-5; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Kristensen T, 2006, ECOTOX ENVIRON SAFE, V63, P148, DOI 10.1016/j.ecoenv.2005.03.010; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Li J, 2008, TOXICOL LETT, V183, P65, DOI 10.1016/j.toxlet.2008.10.002; Li Jian, 2008, Asian Journal of Ecotoxicology, V3, P21; Ma M, 2005, ARCH ENVIRON CON TOX, V49, P480, DOI 10.1007/s00244-004-0204-z; Meisel Robert L., 1994, P3; Molina-Molina JM, 2006, TOXICOL APPL PHARM, V216, P44, DOI 10.1016/j.taap.2006.04.005; Nishihara T, 2000, J HEALTH SCI, V46, P282; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Rehmann K, 1999, CHEMOSPHERE, V38, P3303, DOI 10.1016/S0045-6535(98)00562-1; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; Soto AM, 1997, ENVIRON HEALTH PERSP, V105, P647, DOI 10.2307/3433384; Sumpter JP, 2005, ACTA HYDROCH HYDROB, V33, P9, DOI 10.1002/aheh.200400555; Sun H, 2006, FOOD CHEM TOXICOL, V44, P1916, DOI 10.1016/j.fct.2006.06.013; Suzuki T, 2004, ENVIRON SCI TECHNOL, V38, P2389, DOI 10.1021/es030576z; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Tamura H, 2006, BIOORGAN MED CHEM, V14, P7160, DOI 10.1016/j.bmc.2006.06.064; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; Tran DQ, 1996, BIOCHEM BIOPH RES CO, V229, P518, DOI 10.1006/bbrc.1996.1836; Wang JX, 2005, SCI TOTAL ENVIRON, V349, P120, DOI 10.1016/j.scitotenv.2005.01.019; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Yang C, 1999, CANCER RES, V59, P45193528PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROFEBDiscipline: Toxicology548AA</notes>
    <keywords>2,4-dichlorophenol; 4-HYDROXYTAMOXIFEN; 4-tert-octylphenol; ALPHA; Androgen; ANDROGEN RECEPTOR; Antagonist; bisphenol; BISPHENOL-A; bisphenols; BPA; CANCER; CANCER CELLS; CELL; CHEMICALS; CHINA; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Estrogen-related receptor; ESTROGEN-RELATED-RECEPTOR; EXPRESSION; FOOD; HEALTH; HUMANS; In vitro; IN-VITRO; inhibition; INHIBITOR; Inhibitors; Interaction; mechanism; MECHANISMS; MEDAKA ORYZIAS-LATIPES; Nuclear receptor; NUCLEAR RECEPTORS; p21; phenol; PHENOLS; Phenols,Estrogen receptor; progesterone; Progesterone receptor; PROGESTERONE-RECEPTOR; PROGESTERONE-RECEPTOR ACTIVITY; RECEPTOR; Receptors; REPORTER GENE; SET; Steroid; SYSTEM; TBBPA; TETRACHLOROBISPHENOL; toxicology; TRANSCRIPTIONAL ACTIVITIES; VITRO; YEAST; Yeast two-hybrid assay</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>201</startpage>
    <endpage>207</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>1</issue>
    <volume>24</volume>
    <abstract>Some phenols have been suspected to modulate the endocrine systems of wildlife and humans, but less is known about their interactions with different types of nuclear receptors. In this study, the ability of 2-tert-butylphenol, 2-isopropylphenol, 4-tert-octylphenol (4-t-OP), 2,4-dichlorophenol (2,4-DCP). 3,4-dichlorophenol (3,4-DCP), pentachloro phenol (PCP), bisphenols A (BPA), tetrabromobisphenol A (TBBPA), tetrachlorobisphenol A (TCBPA) and 4-phenylphenol to activate estrogen receptor (ER), androgen receptor (AR), progesterone receptor (PR) and estrogen-related receptor (ERR) were determined using a set of recombined yeast strains. It was found that 4-t-OP, 3,4-DCP, PCP, BPA, TBBPA, TCBPA and 4-phenylphenol were ER alpha agonists, while 4-t-OP, PCP and 4-phenylphenol showed ER alpha antagonistic activities. 2-tert-Butylphenol, 4-t-OP, 2-isopropyl phenol, 2,4-DCP, 3,4-DCP, BPA, TCBPA and 4-phenylphenol were antagonists for AR, whereas none of the compounds studied were found to be an AR agonist. TCBPA, TBBPA and PCP were PR antagonists, and 2-tert-butylphenol, 3,4-DCP, 4-t-OP, 4-phenylphenol and 2-isopropylphenol were weak inhibitors on expression under control of the PR. None of the phenols were PR agonists. 2-tert-Butylphenol, 4-t-OP and PCP were ERR gamma inverse agonists, while 2,4-DCP, 3,4-DCP, PCP, BPA, TBBPA and TCBPA exhibited the ability to reverse the ERR inhibition induced by 4-hydroxytamoxifen. Based on the functional agonistic or antagonistic receptor-mediated effects, we further discussed the possible action mechanisms of these phenols as endocrine disrupting chemicals. (C) 2009 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000273930000026</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>132</id>
    <title>A Novel Electrochemical Sensor Based on Nanocomposite Film Electrode for Sensitive Determination of Enviromnental Hormone Bisphenol A</title>
    <authors>Li,J.H.; Kuang,D.Z.; Feng,Y.L.; Zhang,F.X.; Liu,M.Q.</authors>
    <availability>[Li, Jun-Hua; Kuang, Dai-Zhi; Feng, Yong-Lan; Zhang, Fu-Xing; Liu, Meng-Qin] Hengyang Normal Univ, Dept Chem &amp; Mat Sci, Hunan Prov Coll, Key Lab Funct Organometall Mat, Hengyang 421008, Hunan, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleLi, JH (reprint author), Hengyang Normal Univ, Dept Chem &amp; Mat Sci, Hunan Prov Coll, Key Lab Funct Organometall Mat, Hengyang 421008, Hunan, Peoples R Chinajunhua325@126.comANSON FC, 1964, ANAL CHEM, V36, P932, DOI 10.1021/ac60210a068; Chauke V, 2010, J HAZARD MATER, V178, P180, DOI 10.1016/j.jhazmat.2010.01.061; Hadjmohammadi MR, 2010, MONATSH CHEM, V141, P501, DOI 10.1007/s00706-010-0297-1; Hegnerova K, 2010, ANAL BIOANAL CHEM, V398, P1963, DOI 10.1007/s00216-010-4067-z; HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004; Huang WS, 2007, ANAL LETT, V40, P3280, DOI 10.1080/00032710701672608; Ji YS, 2009, ANAL BIOANAL CHEM, V395, P1125, DOI 10.1007/s00216-009-3020-5; KORMANN C, 1991, ENVIRON SCI TECHNOL, V25, P494, DOI 10.1021/es00015a018; LAVIRON E, 1974, J ELECTROANAL CHEM, V52, P355, DOI 10.1016/S0022-0728(74)80448-1; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Li JH, 2011, MICROCHIM ACTA, V172, P379, DOI 10.1007/s00604-010-0512-0; Li QA, 2010, J HAZARD MATER, V180, P703, DOI 10.1016/j.jhazmat.2010.04.094; Liu XQ, 2011, ANAL CHIM ACTA, V689, P212, DOI 10.1016/j.aca.2011.01.037; Murugananthan M, 2008, J HAZARD MATER, V154, P213, DOI 10.1016/j.jhazmat.2007.10.011; Ngundi MM, 2003, ELECTROCHEM COMMUN, V5, P61, DOI 10.1016/S1388-2481(02)00538-6; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Palanza P, 2008, ENVIRON RES, V108, P150, DOI 10.1016/j.envres.2008.07.023; Portaccio M, 2010, BIOSENS BIOELECTRON, V25, P2003, DOI 10.1016/j.bios.2010.01.025; Sambe H, 2006, J CHROMATOGR A, V1134, P16, DOI 10.1016/j.chroma.2006.08.072; Stoichev T, 2008, ANAL BIOANAL CHEM, V391, P425, DOI 10.1007/s00216-008-2005-0; Taskeen A, 2010, ASIAN J CHEM, V22, P4133; Tu XM, 2009, ELECTROANAL, V21, P2491, DOI 10.1002/elan.200900195; Velasco JG, 1997, ELECTROANAL, V9, P880, DOI 10.1002/elan.1140091116; Wang FG, 2009, ANAL CHIM ACTA, V638, P23, DOI 10.1016/j.aca.2009.02.013; Wang HL, 2008, MATER RES BULL, V43, P1607, DOI 10.1016/j.materresbull.2007.06.034; Wang SH, 2005, LUMINESCENCE, V20, P46, DOI 10.1002/bio.804; Wang X, 2006, ANAL CHIM ACTA, V556, P313, DOI 10.1016/j.aca.2005.09.060; Wang Y, 2006, MAT SCI ENG B-SOLID, V128, P229, DOI 10.1016/j.mseb.2005.12.004; Yang M, 2009, ARCH TOXICOL, V83, P281, DOI 10.1007/s00204-008-0364-0; Yin HS, 2011, FOOD CHEM, V125, P1097, DOI 10.1016/j.foodchem.2010.09.098; Yin HS, 2010, J HAZARD MATER, V174, P236, DOI 10.1016/j.jhazmat.2009.09.041; Yin HS, 2010, ELECTROCHIM ACTA, V55, P603, DOI 10.1016/j.electacta.2009.09.020; Yin HS, 2010, ANAL CHIM ACTA, V659, P144, DOI 10.1016/j.aca.2009.11.051; Yin HS, 2010, MICROCHIM ACTA, V170, P99, DOI 10.1007/s00604-010-0396-z; Yin HS, 2009, J ELECTROANAL CHEM, V626, P80, DOI 10.1016/j.jelechem.2008.11.004; Zhao RS, 2010, J SEP SCI, V33, P1652, DOI 10.1002/jssc.201000010361ASIAN JOURNAL OF CHEMISTRYSAHIBABAD11/100 RAJENDRA NAGAR, SECTOR 3,, SAHIBABAD 201 005, GHAZIABAD, INDIAASIAN J CHEMJUNDiscipline: Chemistry121LI</notes>
    <keywords>ADSORPTION; BIOSENSOR; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; Determination; Electrochemical sensor; ELECTRODE; ENDOCRINE; Estrogen; FOOD; GLASSY-CARBON ELECTRODE; Hydroxyapatite; JUN; MASS-SPECTROMETRY; Milk; PHTHALOCYANINE; SOLID-PHASE EXTRACTION; Titaninum dioxide; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3147</startpage>
    <endpage>3153</endpage>
    <journalfull>Asian Journal of Chemistry</journalfull>
    <issue>6</issue>
    <volume>25</volume>
    <abstract>Bisphenol A (BPA) is an emerging contaminant with servere toxic effect such as disrupting endocrine system or causing cancer, therefore, developing sensitive and selective sensor for bisphenol-A is very important and interesting. Herein, mesoporous hydroxyapatite (meso-HSP) and mesoporous titanium dioxide (meso-TiO2) and multi-walled carbon nanotutes (MWCNT) onto glassy carbon electrode (GCE) surface, Compared with bare electrode and single layer modified electrode, meso-HAP/meso-TiO2/MWCNT modified electrode not only significantly enhanced the oxidation peak current of bisphenol-A, but also lowered the oxidation overpotential, suggesting that the prepared and the kinetic parameters were also investigated. Under the optimized conditions, the oxidation peak current was proportional to bisphenol-A concentration in the range from 8.0 x 10(-9)-40 x 10(-7) M with the correlation coefficient of 0.9979. The detection limit was 1.0 x 10(9) M (S/N = 3). The fabricated electrode showed good reproductibility, stability and antiinterference. The proposed method was successfully applied to determine bisphenol-A in plastic products and the results were statisfactory</abstract>
    <url>WOS:000317245900047</url>
    <isbnorissn>0970-7077</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>89</id>
    <title>Biotransformation of Bisphenol AF to Its Major Glucuronide Metabolite Reduces Estrogenic Activity</title>
    <authors>Li,M.; Yang,Y.J.; Yang,Y.; Yin,J.; Zhang,J.; Feng,Y.X.; Shao,B.</authors>
    <availability>[Li, Ming; Yang, Yunjia; Yang, Yi; Yin, Jie; Zhang, Jing; Feng, Yixing; Shao, Bing] Beijing Ctr Dis Control &amp; Prevent, Beijing Key Lab Diagnost &amp; Traceabil Technol Food, Beijing, Peoples R China. [Yang, Yunjia; Shao, Bing] Capital Med Univ, Sch Publ Hlth &amp; Family Med, Beijing, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleShao, B (reprint author), Beijing Ctr Dis Control &amp; Prevent, Beijing Key Lab Diagnost &amp; Traceabil Technol Food, Beijing, Peoples R Chinashaobingch@sina.comAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Arewang CJ, 2007, CARBOHYD RES, V342, P970, DOI 10.1016/j.carres.2007.01.014; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Davis DL, 2007, ENVIRON HEALTH PERSP, V115, P941, DOI 10.1289/ehp.9540; Deschenes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Doerge DR, 2010, TOXICOL APPL PHARM, V248, P1, DOI 10.1016/j.taap.2010.07.009; Doerge DR, 2011, TOXICOL APPL PHARM, V255, P261, DOI 10.1016/j.taap.2011.07.009; Elsby R, 2001, J PHARMACOL EXP THER, V297, P103; Feng YX, 2012, TOXICOL LETT, V211, P201, DOI 10.1016/j.toxlet.2012.03.802; Fisher JW, 2011, TOXICOL APPL PHARM, V257, P122, DOI 10.1016/j.taap.2011.08.026; Hayasaka T, 2011, TETRAHEDRON, V67, P2215, DOI 10.1016/j.tet.2011.01.087; Kang JH, 2006, TOXICOLOGY, V217, P81, DOI 10.1016/j.tox.2005.10.001; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; King CD, 1999, ARCH BIOCHEM BIOPHYS, V365, P156, DOI 10.1006/abbi.1999.1155; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; LaFleur AD, 2011, ANAL CHIM ACTA, V696, P6, DOI 10.1016/j.aca.2011.03.054; Lee S, 2013, NEUROTOX RES, V23, P249, DOI 10.1007/s12640-012-9353-4; Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689; Li Y, 2013, ENVIRON HEALTH PERSP, V121, P459, DOI 10.1289/ehp.1205951; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Matsushima A, 2010, ENVIRON HEALTH PERSP, V118, P1267, DOI 10.1289/ehp.0901819; Mercado-Feliciano M, 2008, ENVIRON HEALTH PERSP, V116, P1315, DOI 10.1289/ehp.11343; Nadal A, 2009, MOL CELL ENDOCRINOL, V304, P63, DOI 10.1016/j.mce.2009.02.016; Niwa T, 2001, BIOL PHARM BULL, V24, P1064, DOI 10.1248/bpb.24.1064; Ohno S, 2009, DRUG METAB DISPOS, V37, P32, DOI 10.1124/dmd.108.023598; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Pottenger LH, 2000, TOXICOL SCI, V54, P3, DOI 10.1093/toxsci/54.1.3; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Safe SH, 1997, NEW ENGL J MED, V337, P1303, DOI 10.1056/NEJM199710303371809; Schmidt J, 2013, TOXICOL IN VITRO, V27, P1267, DOI 10.1016/j.tiv.2013.02.016; Sneitz N, 2011, J STEROID BIOCHEM, V127, P282, DOI 10.1016/j.jsbmb.2011.08.008; Song SJ, 2012, ENVIRON SCI TECHNOL, V46, P13136, DOI 10.1021/es303960k; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Tang L, 2010, MOL PHARMACEUT, V7, P664, DOI 10.1021/mp900223c; Upmeier A, 2000, ARCH TOXICOL, V74, P431, DOI 10.1007/s002040000144; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Yokota H, 1999, BIOCHEM J, V340, P405, DOI 10.1042/0264-6021:3400405; Yoshihara S, 2004, TOXICOL SCI, V78, P50, DOI 10.1093/toxsci/kfh047; Yoshihara S, 2001, TOXICOL SCI, V62, P221, DOI 10.1093/toxsci/62.2.221432PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEDEC 13Discipline: Science &amp; Technology - Other Topics276FP</notes>
    <keywords>BETA; BINDING; Biotransformation; bisphenol; Bisphenol AF; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELL-LINE MCF-7; CELL-PROLIFERATION; CELLS; ENDOCRINE; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; estrogenic activity; EXPRESSION; extrapolation; FOOD; gene expression; GENE-EXPRESSION; In vitro; IN-VITRO; IN-VIVO; INDUCTION; Liver; LIVER S9 FRACTION; mechanism; METABOLISM; METABOLITES; proliferation; RAT; RAT-LIVER; RATS; RECEPTOR; RECEPTOR-ALPHA; toxicology; UDP-GLUCURONOSYLTRANSFERASES; Urine; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>12</issue>
    <volume>8</volume>
    <abstract>Bisphenol AF (BPAF), an endocrine disrupting chemical, can induce estrogenic activity through binding to estrogen receptor (ER). However, the metabolism of BPAF in vivo and the estrogenic activity of its metabolites remain unknown. In the present study, we identified four metabolites including BPAF diglucuronide, BPAF glucuronide (BPAF-G), BPAF glucuronide dehydrated and BPAF sulfate in the urine of Sprague-Dawley (SD) rats. BPAF-G was further characterized by nuclear magnetic resonance (NMR). After treatment with a single dose of BPAF, BPAF was metabolized rapidly to BPAF-G, as detected in the plasma of SD rats. Biotransformation of BPAF to BPAF-G was confirmed with human liver microsomes (HLM), and V-max of glucuronidation for HLM was 11.6 nmol/min/mg. We also found that BPAF glucuronidation could be mediated through several human recombinant UDP-glucuronosyltransferases (UGTs) including UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT2B4, UGT2B7, UGT2B15 and UGT2B17, among which UGT2B7 showed the highest efficiency of glucuronidation. To explain the biological function of BPAF biotransformation, the estrogenic activities of BPAF and BPAF-G were evaluated in ER-positive breast cancer T47D and MCF7 cells. BPAF significantly stimulates ER-regulated gene expression and cell proliferation at the dose of 100 nM and 1 mu M in breast cancer cells. However, BPAF-G did not show any induction of estrogenic activity at the same dosages, implying that formation of BPAF-G is a potential host defense mechanism against BPAF. Based on our study, biotransformation of BPAF to BPAF-G can eliminate BPAF-induced estrogenic activity, which is therefore considered as reducing the potential threat to human beings</abstract>
    <url>WOS:000328734200064</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>48</id>
    <title>Bisphenol AF-Induced Endogenous Transcription Is Mediated by ER alpha and ERK1/2 Activation in Human Breast Cancer Cells</title>
    <authors>Li,M.; Guo,J.; Gao,W.H.; Yu,J.L.; Han,X.Y.; Zhang,J.; Shao,B.</authors>
    <availability>[Li, Ming; Gao, Wenhui; Yu, Jianlong; Han, Xiaoyu; Zhang, Jing; Shao, Bing] Beijing Ctr Dis Control &amp; Prevent, Beijing Key Lab Diagnost &amp; Traceabil Technol Food, Beijing, Peoples R China. [Guo, Jing] Beijing Mentougou Dist Hosp, Dept Emergency, Beijing, Peoples R China. [Yu, Jianlong; Han, Xiaoyu; Shao, Bing] Capital Med Univ, Sch Publ Hlth &amp; Family Med, Beijing, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleShao, B (reprint author), Beijing Ctr Dis Control &amp; Prevent, Beijing Key Lab Diagnost &amp; Traceabil Technol Food, Beijing, Peoples R Chinashaobingch@sina.comAlbanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Alexaki VI, 2006, J STEROID BIOCHEM, V98, P97, DOI 10.1016/j.jsbmb.2005.08.017; Alonso-Magdalena P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002069; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Bermudez DS, 2010, TOXICOL SCI, V116, P477, DOI 10.1093/toxsci/kfq156; Cantwell MJ, 1996, BLOOD, V88, P4676; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Cheng L, 2012, J CLIN INVEST, V122, P2857, DOI 10.1172/JCI62676; Feng YX, 2012, TOXICOL LETT, V211, P201, DOI 10.1016/j.toxlet.2012.03.802; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Geffroy N, 2005, MOL CELL ENDOCRINOL, V237, P11, DOI 10.1016/j.mce.2005.04.003; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; LaFleur AD, 2011, ANAL CHIM ACTA, V696, P6, DOI 10.1016/j.aca.2011.03.054; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Levin ER, 2009, TRENDS ENDOCRIN MET, V20, P477, DOI 10.1016/j.tem.2009.06.009; Li M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083170; Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689; Li Y, 2013, ENVIRON HEALTH PERSP, V121, P459, DOI 10.1289/ehp.1205951; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737; Matsushima A, 2010, ENVIRON HEALTH PERSP, V118, P1267, DOI 10.1289/ehp.0901819; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Shimizu M, 2002, TOXICOL IN VITRO, V16, P549, DOI 10.1016/S0887-2333(02)00055-3; Song SJ, 2012, ENVIRON SCI TECHNOL, V46, P13136, DOI 10.1021/es303960k; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Wong WPS, 2010, P NATL ACAD SCI USA, V107, P13057, DOI 10.1073/pnas.0914501107; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776350PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEAPR 11Discipline: Science &amp; Technology - Other TopicsAI3CI</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; ALPHA; BETA; bisphenol; Bisphenol AF; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; ER alpha; ERK1/2; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; FOOD; GENE-EXPRESSION CHANGES; GPER; GPR30; GROWTH; GROWTH-FACTOR RECEPTOR; In vitro; IN-VITRO; inhibition; INHIBITOR; Inhibitors; mechanism; MECHANISMS; PROTEIN-COUPLED RECEPTOR; RECEPTOR; RESPONSIVE GENES; TRANSACTIVATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>4</issue>
    <volume>9</volume>
    <abstract>Bisphenol AF (BPAF)-induced transcriptional activity has been evaluated by luciferase reporter assay. However, the molecular mechanism of BPAF-induced endogenous transcription in human breast cancer cells has not been fully elucidated. In the present study, we investigated the effect and mechanism of BPAF-induced endogenous transcription detected by real-time PCR in human breast cancer cells. We found that BPAF stimulated transcription of estrogen responsive genes, such as trefoil factor 1 (TFF1), growth regulation by estrogen in breast cancer 1 (GREB1) and cathepsin D (CTSD), through dose-dependent and time-dependent manners in T47D and MCF7 cells. Gene-silencing of ER alpha, ER beta and G protein-coupled estrogen receptor 1 (GPER) by small interfering RNA revealed that BPAF-induced endogenous transcription was dependent on ER alpha and GPER, implying both genomic and nongenomic pathways might be involved in the endogenous transcription induced by BPAF. ER alpha-mediated gene transcription was further confirmed by inhibition of ER activity using ICI 182780 in ER alpha-positive T47D and MCF7 cells as well as overexpression of ER alpha in ER alpha-negative MDA-MB-231 breast cancer cells. Moreover, we utilized Src tyrosine kinase inhibitor PP2 and two MEK inhibitors PD98059 and U0126 to elucidate the rapid nongenomic activation of Src/MEK/ERK1/2 cascade on endogenous transcription. Our data showed that BPAF-induced transcription could be significantly blocked by PP2, PD98059 and U0126, suggesting activation of ERK1/2 was also required to regulate endogenous transcription. Taken together, these results indicate that BPAF-induced endogenous transcription of estrogen responsive genes is mediated through both genomic and nongenomic pathways involving the ER alpha and ERK1/2 activation in human breast cancer cells</abstract>
    <url>WOS:000336736200122</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>229</id>
    <title>COM-1/p8 Acts as a Tumour Growth Enhancer in Colorectal Cancer Cell Lines</title>
    <authors>Li,X.; Martin,T.A.; Jiang,W.G.</authors>
    <availability>[Li, Xin; Martin, Tracey A.; Jiang, Wen G.] Cardiff Univ, Sch Med, Inst Canc &amp; Genet, Metastasis &amp; Angiogenesis Res Grp, Cardiff CF14 4XN, S Glam, Wales. [Li, Xin] Peking Univ, Hosp 3, Dept Gen Surg, Beijing 100871, Peoples R China.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMartin, TA (reprint author), Cardiff Univ, Sch Med, Inst Canc &amp; Genet, Metastasis &amp; Angiogenesis Res Grp, Heath Pk, Cardiff CF14 4XN, S Glam, Walesmartinta1@cardiff.ac.ukBratland A, 2000, CANCER RES, V60, P5578; Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169; Chang TH, 2000, CANCER RES, V60, P1129; COTTER TG, 1990, ANTICANCER RES, V10, P1153; Davies Mansel L., 2010, Cancer Genomics &amp; Proteomics, V7, P75; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Garcia-Bates TM, 2008, CLIN CANCER RES, V14, P6414, DOI 10.1158/1078-0432.CCR-08-0457; Giroux V, 2006, CLIN CANCER RES, V12, P235, DOI 10.1158/1078-0432.CCR-05-1700; Hisatake J, 2000, CANCER RES, V60, P5494; Ito Y, 2003, CANCER LETT, V201, P237, DOI 10.1016/j.canlet.2003.07.002; Jiang WG, 2006, INT J MOL MED, V18, P1169; Jiang WG, 2006, INT J MOL MED, V18, P981; Jiang WG, 2005, BIOCHEM BIOPH RES CO, V330, P253, DOI 10.1016/j.bbrc.2005.02.157; Kong DK, 2010, MOL BIOL CELL, V21, P1335, DOI 10.1091/mbc.E09-09-0818; Malicet C, 2006, P NATL ACAD SCI USA, V103, P2671, DOI 10.1073/pnas.0508955103; Malicet CAcdric, 2003, Mol Cancer, V2, P37, DOI 10.1186/1476-4598-2-37; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; McAlpine CA, 2006, INT J CANCER, V119, P2339, DOI 10.1002/ijc.22115; Ree AH, 1999, CANCER RES, V59, P4675; Su SB, 2001, CLIN CANCER RES, V7, P309; Suh N, 1999, CANCER RES, V59, P5671; Vasseur S, 1999, BIOCHEM J, V343, P377, DOI 10.1042/0264-6021:3430377; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x232INT INST ANTICANCER RESEARCHATHENSEDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECEANTICANCER RESAPRDiscipline: Oncology921QQ</notes>
    <keywords>ACTIVATED RECEPTOR-GAMMA; apoptosis; BADGE; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; cell growth; cell migration; CELLS; colorectal cancer; COM-1; DEFICIENCY; Differentiation; EXPRESSION; GENE; GROWTH; IMPACT; LINE; LINES; Migration; NUPR1; oncology; P8; PANCREATIC-CANCER; PPAR; PPAR gamma agonist; PPAR-gamma; PROMOTER; PROSTATE-CANCER; PROTEIN; Proteomics; Transfection</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1229</startpage>
    <endpage>1237</endpage>
    <journalfull>Anticancer Research</journalfull>
    <issue>4</issue>
    <volume>32</volume>
    <abstract>Background: Candidate of metastasis-1 (COM-1) is a molecule which is stress-induced and cell growth-related. The current study investigated the impact of COM-1 and role of Peroxisome Proliferating Activator Receptor-gamma (PPAR gamma) agonists on COM-1 knock down in colorectal cancer cells. Materials and Methods: Expression of COM-1 was knocked out in the colorectal cancer cell lines RKO and CaCO2 by transfection with ribozyme transgenes which specifically targeted COM-1. Cell growth, cell migration and apoptosis were measured in wild-type, control and COM-1 knock down cells. The impact or treatment with the PPAR gamma agonists on the function of COM-1 knock down cells was monitored. Results: COM-1 knockdown cells grew slower than wild-type and control cells. When treated with the PPAR gamma agonist ciglitazone and bisphenol A diglycidyl ether (BADGE) at several different concentrations, all types of cells grew slower to some extent. Cells with COM-1 knock-down had the same mobility as wild-type and control cells. More apoptotic and dead cells were detected when cells were treated with ciglitazone at 3 mu M, especially of COM-1 knock down cells. Conclusion: COM-1 is an anti-apoptotic gene and a cell growth promoter. Furthermore, the PPAR gamma agonist could increase the inhibitory effect seen in COM-1 knock-down cell growth and to promote apoptosis. In regards to metastasis, COM-1 appears to play no role in cell motility</abstract>
    <url>WOS:000302492600013</url>
    <isbnorissn>0250-7005</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>4</id>
    <title>Curcumin Modulates miR-19/PTEN/AKT/p53 Axis to Suppress Bisphenol A-induced MCF-7 Breast Cancer Cell Proliferation</title>
    <authors>Li,X.T.; Xie,W.; Xie,C.F.; Huang,C.; Zhu,J.Y.; Liang,Z.F.; Deng,F.F.; Zhu,M.M.; Zhu,W.W.; Wu,R.; Wu,J.S.; Geng,S.S.; Zhong,C.Y.</authors>
    <availability>[Li, Xiaoting; Xie, Wei; Xie, Chunfeng; Huang, Cong; Zhu, Jianyun; Liang, Zhaofeng; Deng, Feifei; Zhu, Mingming; Zhu, Weiwei; Wu, Rui; Wu, Jieshu; Geng, Shanshan; Zhong, Caiyun] Nanjing Med Univ, Sch Publ Hlth, Dept Nutr &amp; Food Safety, Nanjing 211166, Jiangsu, Peoples R China. [Xie, Chunfeng; Wu, Jieshu; Geng, Shanshan; Zhong, Caiyun] Nanjing Med Univ, Sch Publ Hlth, Key Lab Modern Toxicol, Minist Educ, Nanjing 211166, Jiangsu, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleZhong, CY (reprint author), Nanjing Med Univ, Sch Publ Hlth, Dept Nutr &amp; Food Safety, 818 East Tianyuan Rd, Nanjing 211166, Jiangsu, Peoples R Chinacyzhong@njmu.edu.cnBartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Comer Frank I., 2002, Cell, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Cuellar TL, 2005, J ENDOCRINOL, V187, P327, DOI 10.1677/joe.1.06426; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Goodson WH, 2011, CARCINOGENESIS, V32, P1724, DOI 10.1093/carcin/bgr196; Guo SL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3544; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Li Q, 2013, CLIN CANCER RES, V19, P34, DOI 10.1158/1078-0432.CCR-12-0053; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065; Nana-Sinkam SP, 2011, TRANSL RES, V157, P216, DOI 10.1016/j.trsl.2011.01.013; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive V, 2013, IMMUNOL REV, V253, P158, DOI 10.1111/imr.12054; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rossi DJ, 2006, CELL, V125, P229, DOI 10.1016/j.cell.2006.04.006; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272; Tsuda H, 2003, JPN J CLIN ONCOL, V33, P259, DOI 10.1093/jjco/hyg052; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Wades M, 2012, NAT REV CANCER, V13, P83; Wang Q, 2008, P NATL ACAD SCI USA, V105, P2889, DOI 10.1073/pnas.0800178105; Yang J, 2010, MED ONCOL, V27, P1114, DOI 10.1007/s12032-009-9344-3; Zhang JA, 2010, ONCOL REP, V24, P1217, DOI 10.3892/or_00000975; Zhang W, 2014, CLIN TRANSL ONCOL, V16, P708, DOI 10.1007/s12094-013-1135-9390WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAPHYTOTHER RESOCTDiscipline: Pharmacology &amp; PharmacyAQ4VP</notes>
    <keywords>ACTIVATION; bisphenol A; BREAST-CANCER; curcumin; ENDOCRINE DISRUPTORS; EXPOSURE; EXPRESSION; inhibition; MCF-7 breast cancer cells; MICRORNAS; MIR-17-92; miR-19; proliferation; PTEN; SIGNALING PATHWAY; TUMORIGENESIS; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1553</startpage>
    <endpage>1560</endpage>
    <journalfull>Phytotherapy Research</journalfull>
    <issue>10</issue>
    <volume>28</volume>
    <abstract>Breast cancer is the most common cancer in women. Bisphenol A (BPA), as a known endocrine disrupter, is closely related to the development of breast cancer. Curcumin has been clinically used in chemopreventation and treatment of cancer; however, it remains unknown whether microRNAs are involved in curcumin-mediated protection from BPA-associated promotive effects on breast cancer. In the present study, we showed that BPA exhibited estrogenic activity by increasing the proliferation of estrogen-receptor-positive MCF-7 human breast cancer cells and triggering transition of the cells from G1 to S phase. Curcumin inhibited the proliferative effects of BPA on MCF-7 cells. Meanwhile, BPA-induced upregulation of oncogenic miR-19a and miR-19b, and the dysregulated expression of miR-19-related downstream proteins, including PTEN, p-AKT, p-MDM2, p53, and proliferating cell nuclear antigen, were reversed by curcumin. Furthermore, the important role of miR-19 in BPA-mediated MCF-7 cell proliferation was also illustrated. These results suggest for the first time that curcumin modulates miR-19/PTEN/AKT/p53 axis to exhibit its protective effects against BPA-associated breast cancer promotion. Findings from this study could provide new insights into the molecular mechanisms by which BPA exerts its breast-cancer-promoting effect as well as its target intervention. Copyright (c) 2014 John Wiley &amp; Sons, Ltd</abstract>
    <url>WOS:000342798700017</url>
    <isbnorissn>0951-418X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>119</id>
    <title>Phthalic Acid Chemical Probes Synthesized for Protein-Protein Interaction Analysis</title>
    <authors>Liang,S.S.; Liao,W.T.; Kuo,C.J.; Chou,C.H.; Wu,C.J.; Wang,H.M.</authors>
    <availability>[Liang, Shih-Shin; Liao, Wei-Ting] Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, Kaohsiung 807, Taiwan. [Liang, Shih-Shin; Chou, Chi-Hsien] Kaohsiung Med Univ, Ctr Resources Res &amp; Dev, Kaohsiung 807, Taiwan. [Kuo, Chao-Jen] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan. [Wu, Chin-Jen] Kaiser Pharmaceut Co LTD, Tainan 710, Taiwan. [Wang, Hui-Min] Kaohsiung Med Univ, Coll Pharm, Dept Fragrance &amp; Cosmet Sci, Kaohsiung 807, Taiwan.</availability>
    <date>2013</date>
    <notes>JEnglishArticleLiang, SS (reprint author), Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwanliang0615@kmu.edu.tw; wtliao@kmu.edu.tw; achilleskuo@ntu.edu.tw; chishien@kmu.edu.tw; ken@kaiser.com.tw; davidw@kmu.edu.twAhn YH, 2012, J PROTEOMICS, V75, P5507, DOI 10.1016/j.jprot.2012.06.027; Albrethsen J, 2012, PROTEOM CLIN APPL, V6, P182, DOI 10.1002/prca.201100095; Berggard T, 2007, PROTEOMICS, V7, P2833, DOI 10.1002/pmic.200700131; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Chen M, 2012, J CHROMATOGR B, V904, P73, DOI 10.1016/j.jchromb.2012.07.022; Cheng PC, 2010, MOL CELL PROTEOMICS, V9, P209, DOI 10.1074/mcp.M900183-MCP200; Chu W, 2005, BIOINFORMATICS, V21, P3385, DOI 10.1093/bioinformatics/bti526; Devonshire AS, 2013, METHODS, V59, P89, DOI 10.1016/j.ymeth.2012.07.021; Hsieh TH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042750; Hsu JL, 2003, ANAL CHEM, V75, P6843, DOI 10.1021/ac0348625; Ji CJ, 2012, ANAL CHIM ACTA, V717, P67, DOI 10.1016/j.aca.2011.12.005; Jou YJ, 2010, ANAL CHIM ACTA, V681, P41, DOI 10.1016/j.aca.2010.09.030; Kaur P, 2012, J PROTEOME RES, V11, P5527, DOI [10.1021/pr300798z, 10.1021/pr300798z1]; Koch HM, 2006, INT J ANDROL, V29, P155, DOI 10.1111/j.1365-2605.2005.00607.x; Koo HJ, 2004, J TOXICOL ENV HEAL A, V67, P1901, DOI 10.1080/15287390490513300; Kumar DM, 2010, J PROTEOME RES, V9, P5557, DOI 10.1021/pr1001737; Latini Giuseppe, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P37, DOI 10.2174/1568008043340017; Lee HJ, 2008, ANALYST, V133, P975, DOI 10.1039/b717527b; Liu FT, 2005, INT ARCH ALLERGY IMM, V136, P385, DOI 10.1159/000084545; Liu PS, 2006, TOXICOL APPL PHARM, V210, P136, DOI 10.1016/j.taap.2005.09.012; Liu Y, 2009, ANAL CHIM ACTA, V650, P77, DOI 10.1016/j.aca.2009.06.048; McDonald WH, 2002, DIS MARKERS, V18, P99; Mettang T, 1999, ADV PERIT D, V15, P229; NASSBERGER L, 1987, NEPHRON, V45, P286, DOI 10.1159/000184165; Payne PRO, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S9-S3; Richert L, 2004, BIOMACROMOLECULES, V5, P284, DOI 10.1021/bm0342281; Rong Y, 2005, MATER CHEM PHYS, V91, P370, DOI 10.1016/j.matchemphys.2004.11.042; Silva MJ, 2004, J CHROMATOGR B, V805, P161, DOI 10.1016/j.jchromb.2004.02.038; Simon GM, 2010, J BIOL CHEM, V285, P11051, DOI 10.1074/jbc.R109.097600; Singh S, 2011, GENOMICS, V97, P148, DOI 10.1016/j.ygeno.2010.11.008; Sohn CH, 2012, ANAL CHEM, V84, P2662, DOI 10.1021/ac202637n; Tian DY, 2011, CHEM COMMUN, V47, P4959, DOI 10.1039/c1cc10435g; Tsai MJ, 2012, KAOHSIUNG J MED SCI, V28, pS28, DOI 10.1016/j.kjms.2012.05.007; Weerapana E, 2008, NAT CHEM BIOL, V4, P405, DOI 10.1038/nchembio.91; Zangar RC, 2006, EXPERT REV PROTEOMIC, V3, P37, DOI 10.1586/14789450.3.1.37; Zhang Ya-Ping, 2010, Zoological Research, V31, P1; Zhao BH, 2010, CHEM-BIOL INTERACT, V183, P79, DOI 10.1016/j.cbi.2009.09.014371MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J MOL SCIJULDiscipline: Chemistry188DH</notes>
    <keywords>BIOMARKER DISCOVERY; BISPHENOL-A; CANCER; CELL; CELLS; chemical probe; DISEASE; DISORDERS; ENDOCRINE; environment; EXPOSURE; FOOD; HUMAN URINE; Interaction; MASS-SPECTROMETRY; Metabolic disorders; METABOLITES; phthalate; Phthalates; phthalic acid; PROTEIN; protein-protein interaction; PROTEINS; PROTEOMIC IDENTIFICATION; Proteomics; RAT; serum; SILICON; VERIFICATION; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>12914</startpage>
    <endpage>12930</endpage>
    <journalfull>International Journal of Molecular Sciences</journalfull>
    <issue>7</issue>
    <volume>14</volume>
    <abstract>Plasticizers are additives that are used to increase the flexibility of plastic during manufacturing. However, in injection molding processes, plasticizers cannot be generated with monomers because they can peel off from the plastics into the surrounding environment, water, or food, or become attached to skin. Among the various plasticizers that are used, 1,2-benzenedicarboxylic acid (phthalic acid) is a typical precursor to generate phthalates. In addition, phthalic acid is a metabolite of diethylhexyl phthalate (DEHP). According to Gene_Ontology gene/protein database, phthalates can cause genital diseases, cardiotoxicity, hepatotoxicity, nephrotoxicity, etc. In this study, a silanized linker (3-aminopropyl triethoxyslane, APTES) was deposited on silicon dioxides (SiO2) particles and phthalate chemical probes were manufactured from phthalic acid and APTES-SiO2. These probes could be used for detecting proteins that targeted phthalic acid and for protein-protein interactions. The phthalic acid chemical probes we produced were incubated with epithelioid cell lysates of normal rat kidney (NRK-52E cells) to detect the interactions between phthalic acid and NRK-52E extracted proteins. These chemical probes interacted with a number of chaperones such as protein disulfide-isomerase A6, heat shock proteins, and Serpin H1. Ingenuity Pathways Analysis (IPA) software showed that these chemical probes were a practical technique for protein-protein interaction analysis</abstract>
    <url>WOS:000322171700001</url>
    <isbnorissn>1422-0067</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>243</id>
    <title>An improved method for simultaneous analysis of steroid and phenolic endocrine disrupting chemicals in biological samples</title>
    <authors>Liu,J.L.; Pan,X.J.; Huang,B.; Fang,K.; Wang,Y.; Gao,J.P.</authors>
    <availability>[Liu, Jingliang; Pan, Xuejun; Huang, Bin; Fang, Kai; Wang, Yu; Gao, Jianpei] Kunming Univ Sci &amp; Technol, Fac Environm Sci &amp; Engn, Kunming 650093, Yunnan, Peoples R China.</availability>
    <date>2012</date>
    <notes>JEnglishArticlePan, XJ (reprint author), Kunming Univ Sci &amp; Technol, Fac Environm Sci &amp; Engn, Kunming 650093, Yunnan, Peoples R Chinaxjpan@kmust.edu.cn[Anonymous], 2002, OFF J EUR COMMUNIT L, VL221, P8; Brisken C, 2008, CHIMIA, V62, P406, DOI 10.2533/chimia.2008.406; Cathurn S., 2001, CHROMATOGRAPHIA, V53, P394; Chen Y, 2008, J CHROMATOGR A, V1184, P191, DOI 10.1016/j.chroma.2007.10.026; Clemons M, 2001, NEW ENGL J MED, V344, P276; Desbrow C, 1998, ENVIRON SCI TECHNOL, V32, P1549, DOI 10.1021/es9707973; Devier MH, 2010, ANAL CHIM ACTA, V657, P28, DOI 10.1016/j.aca.2009.10.023; Fidalgo-Used N, 2007, ANAL CHIM ACTA, V590, P1, DOI 10.1016/j.aca.2007.03.2004; Gatidou G, 2007, J CHROMATOGR A, V1138, P32, DOI 10.1016/j.chroma.2006.10.037; Gauthier-Clerc S, 2006, GEN COMP ENDOCR, V145, P133, DOI 10.1016/j.ygcen.2005.08.004; Geisler J, 2000, J STEROID BIOCHEM, V72, P259, DOI 10.1016/S0960-0760(00)00036-4; Giese RW, 2003, J CHROMATOGR A, V1000, P401, DOI 10.1016/S0021-9673(03)00306-6; Hansen PD, 1998, TRAC-TREND ANAL CHEM, V17, P448, DOI 10.1016/S0165-9936(98)00020-X; Hibberd A, 2009, TALANTA, V77, P1315, DOI 10.1016/j.talanta.2008.09.006; Hirai N, 2006, AQUAT TOXICOL, V77, P78, DOI 10.1016/j.aquatox.2005.11.001; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Jin XL, 2004, CHEMOSPHERE, V56, P1113, DOI 10.1016/j.chemosphere.2004.04.052; Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Larsson DGJ, 1999, AQUAT TOXICOL, V45, P91, DOI 10.1016/S0166-445X(98)00112-X; Liu R, 2004, J CHROMATOGR A, V1022, P179, DOI 10.1016/j.chroma.20003.09.035; Liu R, 2004, J CHROMATOGR A, V1038, P19, DOI 10.1016/j.chroma.2004.03.030; Liu Y, 2009, CHROMATOGRAPHIA, V69, P65, DOI 10.1365/s10337-008-0852-7; Mills LJ, 2005, SCI TOTAL ENVIRON, V343, P1, DOI 10.1016/j.scitotenv.2004.12.070; Navarro P, 2006, J CHROMATOGR A, V1128, P10, DOI 10.1016/j.chroma.2006.06.063; Nori F, 2006, ARCH ENVIRON OCCUP H, V61, P87, DOI 10.3200/AEOH.61.2.87-95; Pedersen SN, 1999, J CHROMATOGR A, V864, P17, DOI 10.1016/S0021-9673(99)01011-0; Pelley J, 2003, ENVIRON SCI TECHNOL, V37, p313A, DOI 10.1021/es032555a; Peng XZ, 2008, SCI TOTAL ENVIRON, V397, P158, DOI 10.1016/j.scitotenv.2008.02.059; Petrovic M, 2002, J CHROMATOGR A, V974, P23, DOI 10.1016/S0021-9673(02)00907-X; Petrovic M, 2004, ANAL BIOANAL CHEM, V378, P549, DOI 10.1007/s00216-003-2184-7; Purdom C.E., 1994, Chemistry and Ecology, V8, P275, DOI 10.1080/02757549408038554; Scholz S, 2009, SEX DEV, V3, P136, DOI 10.1159/000223078; Seo J, 2005, J CHROMATOGR A, V1067, P303, DOI 10.1016/j.chroma.2004.12.063; Soares A, 2008, ENVIRON INT, V34, P1033, DOI 10.1016/j.envint.2008.01.004; Sumpter JP, 2005, ACTA HYDROCH HYDROB, V33, P9, DOI 10.1002/aheh.200400555; Sumpter JP, 2002, TOXICOLOGY, V178, P39; Thorpe KL, 2003, ENVIRON SCI TECHNOL, V37, P1142, DOI 10.1021/es0201348; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Tyler CR, 1998, CRIT REV TOXICOL, V28, P319, DOI 10.1080/10408449891344236; Yang M, 2009, ARCH TOXICOL, V83, P281, DOI 10.1007/s00204-008-0364-0; Ying GG, 2002, ENVIRON INT, V28, P545, DOI 10.1016/S0160-4120(02)00075-2; Zhang K, 2005, ANAL CHIM ACTA, V554, P190, DOI 10.1016/j.aca.2005.08.045; Zhang ZL, 2008, ANAL CHIM ACTA, V607, P37, DOI 10.1016/j.aca.2007.11.024445TAYLOR &amp; FRANCIS LTDABINGDON4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDINT J ENVIRON AN CHDiscipline: Chemistry; Environmental Sciences &amp; Ecology970ZP</notes>
    <keywords>4-NONYLPHENOL; 4-tert-octylphenol; AQUATIC ENVIRONMENT; biological samples; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CHEMICALS; CHROMATOGRAPHY-MASS SPECTROMETRY; Determination; DISRUPTING CHEMICALS; EDCs; EMERGING CONTAMINANTS; ENDOCRINE; Endocrine disrupting chemicals; ESTROGENS; FISH; gas chromatography-mass spectrometry; gel permeation chromatography; HEALTH; microwave-assisted extraction; P8; PERFORMANCE; SAMPLES; solid phase extraction; SOLID-PHASE EXTRACTION; TARGET; TISSUE; TISSUES; toxicology; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1135</startpage>
    <endpage>1149</endpage>
    <journalfull>International Journal of Environmental Analytical Chemistry</journalfull>
    <issue>10</issue>
    <volume>92</volume>
    <abstract>An improved method was developed for the simultaneous determination of eight steroid and phenolic endocrine disrupting chemicals, such as oestrone (E1), 17 beta-oestradiol (E2), oestriol (E3), 17 alpha-ethynylestradoil (EE2), 4-nonylphenol (4-NP), bisphenol A (BPA), 4-tert-octylphenol (4-t-OP) and 4-cumylphenol (4-CP), in biological samples. The optimal extraction and clean-up procedures were investigated using microwave-assisted extraction (MAE), automated gel permeation chromatography (GPC) and solid phase extraction (SPE). As a consequence, the most efficient extraction was achieved by using MAE with methanol as solvent at an extraction temperature of 110 degrees C for 20 min. The clean-up of extracts was carried out by GPC on a Biobeads S-X3 column with cyclohexane/ethyl acetate (1:1, v/v) as mobile phase. Target compounds were eluted in the fraction from 7-14 min retention time. Moreover, the cleanest extracts were obtained by solid phase extraction with C-18 cartridges after the elution with 15mL ethyl acetate. The final sample extracts were derivatised using N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) (1% trimethylchlorosilane, TMCS) as derivatisation reagent with pyridine as the solvent. Quantification was performed by gas chromatography-mass spectrometry (GC-MS) with electron ionisation (EI) and selected ion monitoring (SIM) mode. The method was validated by spiked samples which showed good recovery and reproducibility. The overall recoveries ranged between 55.1% and 100.6%, with relative standard deviations (RSD) of 2.3-12.7% for the entire procedure. Method detection limits (MDL) ranged from 0.3 to 0.7 ng g(-1) dry weight (dw). Performance of the method was demonstrated by its application on tissues from fish exposed to high concentration of EDCs in the laboratory. The developed method is a promising approach for the analysis of steroid and phenolic endocrine disrupting chemicals in various biological samples</abstract>
    <url>WOS:000306171600002</url>
    <isbnorissn>0306-7319</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>9</id>
    <title>Modulation of cytokine expression in human macrophages by endocrine-disrupting chemical Bisphenol-A</title>
    <authors>Liu,Y.Z.; Mei,C.F.; Liu,H.; Wang,H.S.; Zeng,G.Q.; Lin,J.H.; Xu,M.Y.</authors>
    <availability>[Liu, Yanzhen; Mei, Chenfang; Zeng, Guoqu; Lin, Jianhui; Xu, Meiying] State Key Lab Appl Microbiol Southern China, Guangzhou 510070, Guangdong, Peoples R China. [Liu, Yanzhen; Mei, Chenfang; Zeng, Guoqu; Lin, Jianhui; Xu, Meiying] Guangdong Inst Microbiol, Guangdong Prov Key Lab Microbial Culture Collect, Guangzhou 510070, Guangdong, Peoples R China. [Liu, Hao] Guangzhou Med Univ, Affiliated Canc Hosp, Guangzhou 510095, Guangdong, Peoples R China. [Liu, Hao] Guangzhou Med Univ, Canc Res Inst, Guangzhou 510095, Guangdong, Peoples R China. [Wang, Hongsheng] Sun Yat Sen Univ, Sch Pharmaceut Sci, Dept Microbial &amp; Biochem Pharm, Guangzhou 510006, Guangdong, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleXu, MY (reprint author), Guangdong Inst Microbiol, 100 Xianliezhong Rd, Guangzhou 510070, Guangdong, Peoples R Chinaxumy@gdim.cnAuwerx J., 1991, J EXP, V47, P22; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335; Byun JA, 2005, ENVIRON TOXICOL PHAR, V19, P19, DOI 10.1016/j.etap.2004.02.006; Calippe B, 2010, J IMMUNOL, V185, P1169, DOI 10.4049/jimmunol.0902383; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Cobellis L, 2009, BIOMED CHROMATOGR, V23, P1186, DOI 10.1002/bmc.1241; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043-2760(02)00634-3; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; Ge LC, 2014, TOXICOL LETT, V226, P81, DOI 10.1016/j.toxlet.2014.01.035; Kasper-Sonnenberg M, 2012, J TOXICOL ENV HEAL A, V75, P429, DOI 10.1080/15287394.2012.674907; Kim K, 2007, J TOXICOL ENV HEAL A, V70, P1288, DOI 10.1080/15287390701434216; Kopf M, 2010, NAT REV DRUG DISCOV, V9, P703, DOI 10.1038/nrd2805; Kuan YH, 2012, INT ENDOD J, V45, P619, DOI 10.1111/j.1365-2591.2012.02017.x; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuruto-Niwa R, 2007, CHEMOSPHERE, V66, P1160, DOI 10.1016/j.chemosphere.2006.06.073; Liu H, 2014, MOL BIOSYST, V10, P1320, DOI 10.1039/c3mb70553f; Ma G, 2011, IMMUNITY, V34, P385, DOI 10.1016/j.immuni.2011.02.004; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rochester JR, 2013, REPROD TOXICOL, V42, P132, DOI 10.1016/j.reprotox.2013.08.008; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Sabat R, 2010, CYTOKINE GROWTH F R, V21, P315, DOI 10.1016/j.cytogfr.2010.11.001; Salian S, 2011, REPROD TOXICOL, V31, P359, DOI 10.1016/j.reprotox.2010.10.008; Tabb M.M., 2006, MOL ENDOCRINOL, V20, P475; Tang YM, 2008, BRIT J HAEMATOL, V143, P84, DOI 10.1111/j.1365-2141.2008.07298.x; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vinas R, 2012, INT J ENV RES PUB HE, V9, P2694, DOI 10.3390/ijerph9082694; Wadia PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063902; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yoon K, 2014, J TOXICOL ENV HEAL B, V17, P127, DOI 10.1080/10937404.2014.882194360ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USABIOCHEM BIOPH RES COSEP 5Discipline: Biochemistry &amp; Molecular Biology; BiophysicsAP9NB</notes>
    <keywords>ACTIVATION; bisphenol A; BISPHENOL-A; CANCER; CELLS; CHILDREN; Cytokine; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; HUMAN HEALTH; IN-VIVO; INDUCTION; Inflammation; Macrophage; MECHANISMS; NF-KAPPA-B; SIGNALING PATHWAYS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>592</startpage>
    <endpage>598</endpage>
    <journalfull>Biochemical and Biophysical Research Communications</journalfull>
    <issue>4</issue>
    <volume>451</volume>
    <abstract>Exposure to environmental endocrine-disrupting chemical Bisphenol-A (BPA) is often associated with dysregulated immune homeostasis, but the mechanisms remain unclear. In the present study, the effects of BPA on the cytokines responses of human macrophages were investigated. Treatment with BPA increased pro-inflammation cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production, but decreased anti-inflammation cytokines interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta) production in THP1 macrophages, as well as in primary human macrophages. BPA effected cytokines expression through estrogen receptor alpha/beta(ER alpha/beta)-dependent mechanism with the evidence of ER alpha/beta antagonist reversed the expression of cytokines. We also identified that activation of extracellular regulated protein kinases (ERK)/nuclear factor kappa B (NF-kappa B) signal cascade marked the effects of BPA on cytokines expression. Our results indicated that BPA effected inflammatory responses of macrophages via modulating of cytokines expression, and provided a new insight into the link between exposure to BPA and human health. (C) 2014 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000342405400021</url>
    <isbnorissn>0006-291X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>329</id>
    <title>Hormonal Action of Plant Derived and Anthropogenic Non-Steroidal Estrogenic Compounds: Phytoestrogens and Xenoestrogens</title>
    <authors>Lorand,T.; Vigh,E.; Garai,J.</authors>
    <availability>[Vigh, E.; Garai, J.] Univ Pecs, Dept Pathophysiol &amp; Gerontol, Sch Med, H-7624 Pecs, Hungary. [Lorand, T.] Univ Pecs, Dept Med Chem &amp; Biochem, Sch Med, H-7624 Pecs, Hungary.</availability>
    <date>2010</date>
    <notes>JEnglishReviewGarai, J (reprint author), Univ Pecs, Dept Pathophysiol &amp; Gerontol, Med Sch Hungary, Szigeti U 12, H-7624 Pecs, Hungaryjanos.garai@aok.pte.huADAMS NR, 1995, J ANIM SCI, V73, P1509; Adler M, 2006, ENDOCRINOLOGY, V147, P3952, DOI 10.1210/en.2005-0316; ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; Adlercreutz H, 1997, ANN MED, V29, P95; AHLBORG UG, 1995, CRIT REV TOXICOL, V25, P463, DOI 10.3109/10408449509017924; Akahori Y, 2008, TOXICOL IN VITRO, V22, P225, DOI 10.1016/j.tiv.2007.08.004; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; Alda JO, 2009, J PHARM PHARMACOL, V61, P641, DOI 10.1211/jpp/61.05.0013; Ambra R, 2006, NUTR METAB CARDIOVAS, V16, P35, DOI 10.1016/j.numecd.2005.03.003; ANDROUTSOPOULOS A, 2009, CANC LETT, V274, P54; Arts ICW, 2005, AM J CLIN NUTR, V81, p317S; Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Ayres D.C., 1990, LIGNANS CHEM BIOL CL; Baker ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006038; BAKER ME, 1992, J STEROID BIOCHEM, V41, P301, DOI 10.1016/0960-0760(92)90355-M; BAKER ME, 1989, MOL ENDOCRINOL, V3, P881; BANNWART C, 1984, FINN CHEM LETT, P120; Beard J, 2000, ARCH ENVIRON HEALTH, V55, P177; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003; Bennetts H. W., 1946, AUSTRALIAN VET JOUR, V22, P2, DOI 10.1111/j.1751-0813.1946.tb15473.x; Bentrem D, 2003, CANCER RES, V63, P7490; Bhat KPL, 2001, CANCER RES, V61, P7456; BHATTACHARYA SK, 1991, J ETHNOPHARMACOL, V34, P87, DOI 10.1016/0378-8741(91)90193-H; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Bolego C, 2006, ARTERIOSCL THROM VAS, V26, P2192, DOI 10.1161/01.ATV.0000242186.93243.25; Booth EA, 2007, J CARDIOVASC PHARM, V49, P401, DOI 10.1097/FJC.0b013e3180544527; BORRIELLO SP, 1985, J APPL BACTERIOL, V58, P37, DOI 10.1111/j.1365-2672.1985.tb01427.x; Boverhof DR, 2008, MOL PHARMACOL, V73, P82, DOI 10.1124/mol.107.040451; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; BRADBURY RB, 1954, VITAM HORM, V12, P207; Brzezinski A, 1999, EUR J OBSTET GYN R B, V85, P47, DOI 10.1016/S0301-2115(98)00281-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burow ME, 2001, J CLIN ENDOCR METAB, V86, P1750, DOI 10.1210/jc.86.4.1750; CARTER MW, 1953, P SOC EXP BIOL MED, V84, P506; Cassidy A, 2006, P NUTR SOC, V65, P76, DOI 10.1079/PNS2005476; Castillo C, 2006, PHYTOMEDICINE, V13, P468, DOI 10.1016/j.phymed.2005.03.012; Chan RYK, 2002, J CLIN ENDOCR METAB, V87, P3691, DOI 10.1210/jc.87.8.3691; Chan WK, 2000, LIFE SCI, V67, P3103, DOI 10.1016/S0024-3205(00)00888-2; Chen WH, 2007, BIOORGAN MED CHEM, V15, P5828, DOI 10.1016/j.bmc.2007.05.071; CHENG E, 1953, SCIENCE, V118, P164, DOI 10.1126/science.118.3058.164; Cheng WY, 2007, J AGR FOOD CHEM, V55, P7350, DOI 10.1021/jf0711690; Chun YJ, 1999, BIOCHEM BIOPH RES CO, V262, P20, DOI 10.1006/bbrc.1999.1152; Cignarella A, 2009, J PHARMACOL EXP THER, V328, P174, DOI 10.1124/jpet.108.143511; Ciolino HP, 1998, CANCER RES, V58, P2754; Cocco P, 2000, ENVIRON HEALTH PERSP, V108, P1, DOI 10.2307/3454288; Coffey DS, 2001, UROLOGY, V57, P31, DOI 10.1016/S0090-4295(00)00938-9; Coldham NG, 2002, XENOBIOTICA, V32, P45, DOI 10.1080/00498250110085809; COURRIER R, 1948, COMPT REND SOC DE BI, V141, P159; CRAWLEY GC, 1980, KIRK OTHMER ENCY CHE, V12, P670; Currie LJ, 2004, ARCH NEUROL-CHICAGO, V61, P886, DOI 10.1001/archneur.61.6.886; Cvoro A, 2007, ENDOCRINOLOGY, V148, P538, DOI 10.1210/en.2006-0803; Dai SY, 2009, BIOCHEMISTRY-US, V48, P9668, DOI 10.1021/bi901149t; Damstra T, 2002, GLOBAL ASSESSMENT ST; Das SK, 1997, P NATL ACAD SCI USA, V94, P12786, DOI 10.1073/pnas.94.24.12786; DEAN PDG, 1971, PHYTOCHEMISTRY, V10, P2215, DOI 10.1016/S0031-9422(00)97224-8; De Angelis M, 2004, BIOORG MED CHEM LETT, V14, P5835, DOI 10.1016/j.bmcl.2004.09.048; de Kleijn MJJ, 2001, J NUTR, V131, P1826; Delmulle L, 2006, PHYTOMEDICINE, V13, P732, DOI 10.1016/j.phymed.2006.01.001; DEVINCENZO R, 1995, ANTI-CANCER DRUG DES, V10, P481; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dong SJ, 2009, FOOD CHEM, V113, P672, DOI 10.1016/j.foodchem.2008.07.100; DRANE HM, 1981, BRIT VET J, V137, P283; Emmerson E, 2009, ENDOCRINOLOGY, V150, P2749, DOI 10.1210/en.2008-1569; Fang H, 2001, CHEM RES TOXICOL, V14, P280, DOI 10.1021/tx000208y; Fernandez MF, 2007, INT J HYG ENVIR HEAL, V210, P429, DOI 10.1016/j.ijheh.2007.01.014; Fisher BE, 1999, ENVIRON HEALTH PERSP, V107, pA18, DOI 10.2307/3434279; Fox JE, 2004, ENVIRON HEALTH PERSP, V112, P672, DOI 10.1289/ehp.6456; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Frigo DE, 2002, ENVIRON HEALTH PERSP, V110, P1239; Fukazawa H, 2001, CHEMOSPHERE, V44, P973, DOI 10.1016/S0045-6535(00)00507-5; Gaido KW, 2000, MOL PHARMACOL, V58, P852; Garai J, 2004, J STEROID BIOCHEM, V88, P377, DOI 10.1016/j.jsbmb.2004.01.001; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gehm BD, 2004, J STEROID BIOCHEM, V88, P223, DOI 10.1016/j.jsbmb.2003.12.002; Gillis CN, 1997, BIOCHEM PHARMACOL, V54, P1, DOI 10.1016/S0006-2952(97)00193-7; GIUSTI M, 1995, ANN INTERN MED, V122, P778; Gomez E, 2005, J TOXICOL ENV HEAL A, V68, P239, DOI 10.1080/15287390590895054; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Gulledge CC, 2001, PEDIATR CLIN N AM, V48, P1223, DOI 10.1016/S0031-3955(05)70371-0; Gust R, 2003, J STEROID BIOCHEM, V86, P57, DOI 10.1016/S0960-0760(03)00253-X; GYORGYPAL Z, 1991, MOL GEN GENET, V226, P337, DOI 10.1007/BF00273624; Halabalaki M, 2000, J NAT PROD, V63, P1672, DOI 10.1021/np000071b; Han DH, 2002, BIOSCI BIOTECH BIOCH, V66, P1479; Harborne J. B., 1988, ADV RES 1980; HARPER MJK, 1967, J REPROD FERTIL, V13, P101; Harris HA, 2002, STEROIDS, V67, P379, DOI 10.1016/S0039-128X(01)00194-5; Harris Heather A, 2007, Mol Endocrinol, V21, P1, DOI 10.1210/me.2005-0459; Heinonen S, 2001, J AGR FOOD CHEM, V49, P3178, DOI 10.1021/jf010038a; Heinonen S, 1999, ANAL BIOCHEM, V274, P211, DOI 10.1006/abio.1999.4279; Heinonen SM, 2004, J AGR FOOD CHEM, V52, P6802, DOI 10.1021/jf0492767; HERBAI G, 1971, ACTA ENDOCRINOL-COP, V68, P249; Hodek P, 2009, CHEM-BIOL INTERACT, V180, P1, DOI 10.1016/j.cbi.2009.01.003; Hofer N, 2009, TOXICOL LETT, V191, P123, DOI 10.1016/j.toxlet.2009.08.014; HOU Y, 2000, ARKIVOC, P95; Howes MJR, 2002, J PHARM PHARMACOL, V54, P1521, DOI 10.1211/002235702216; Hughes C, 1996, J CLIN ENDOCR METAB, V81, P2405; HUGHES CL, 1988, ENVIRON HEALTH PERSP, V78, P171, DOI 10.2307/3430517; Hughes ZA, 2008, NEUROPHARMACOLOGY, V54, P1136, DOI 10.1016/j.neuropharm.2008.03.004; Hwang CS, 2006, J STEROID BIOCHEM, V101, P246, DOI 10.1016/j.jsbmb.2006.06.020; Hwang J, 2000, FREE RADICAL BIO MED, V29, P79, DOI 10.1016/S0891-5849(00)00322-1; Ibarreta D, 2001, APMIS, V109, P161, DOI 10.1034/j.1600-0463.2001.090301.x; Imamov O, 2005, BIOL REPROD, V73, P866, DOI 10.1095/biolreprod.105.043497; Ise R, 2005, FEBS LETT, V579, P1732, DOI 10.1016/j.febslet.2005.02.033; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; Jordan VC, 2001, CANCER RES, V61, P5683; JORDAN VC, 1977, J ENDOCRINOL, V75, P305, DOI 10.1677/joe.0.0750305; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; JORDAN VC, 1988, BREAST CANCER RES TR, V11, P197, DOI 10.1007/BF01807278; Kassi E, 2004, J AGR FOOD CHEM, V52, P6956, DOI 10.1021/jf0400765; Katsanou ES, 2007, J STEROID BIOCHEM, V104, P228, DOI 10.1016/j.jsbmb.2007.03.028; Katzenellenbogen JA, 2003, PURE APPL CHEM, V75, P2397, DOI 10.1351/pac200375112397; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Kim SH, 2000, BIOORGAN MED CHEM, V8, P785, DOI 10.1016/S0968-0896(00)00016-X; Kitajima M, 2004, REPROD TOXICOL, V18, P793, DOI 10.1016/j.reprotox.2004.04.012; Kluth D, 2007, FREE RADICAL BIO MED, V42, P315, DOI 10.1016/j.freeradbiomed.2006.09.028; Koehler KF, 2005, ENDOCR REV, V26, P465, DOI 10.1210/er.2004-0027; Korach KS, 2003, J STEROID BIOCHEM, V86, P387, DOI 10.1016/S0960-0760(03)00348-0; Korrick SA, 2001, ANN EPIDEMIOL, V11, P491, DOI 10.1016/S1047-2797(01)00239-3; Krazeisen A, 2001, MOL CELL ENDOCRINOL, V171, P151, DOI 10.1016/S0303-7207(00)00422-6; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kupfer R, 2008, DRUG METAB DISPOS, V36, P2261, DOI 10.1124/dmd.108.021402; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; Le Bail JC, 2000, LIFE SCI, V66, P1281, DOI 10.1016/S0024-3205(00)00435-5; Le Corre L, 2005, MOL NUTR FOOD RES, V49, P462, DOI 10.1002/mnfr.200400094; Lee SY, 1995, DENT MATER, V11, P348, DOI 10.1016/0109-5641(95)80033-6; Lee Y, 2003, J STEROID BIOCHEM, V84, P463, DOI 10.1016/S0960-0760(03)00067-0; Lee YJ, 2003, ARCH PHARM RES, V26, P58; Lemaire G, 2006, LIFE SCI, V79, P1160, DOI 10.1016/j.lfs.2006.03.023; LERNER LJ, 1958, ENDOCRINOLOGY, V63, P295; LERNER LJ, 1990, CANCER RES, V50, P4177; Li J, 2008, TOXICOL LETT, V183, P65, DOI 10.1016/j.toxlet.2008.10.002; Li YL, 2009, J NUTR, V139, P898, DOI 10.3945/jn.108.103572; Lieberman S, 1996, J CLIN ENDOCR METAB, V81, P850, DOI 10.1210/jc.81.2.850; Liu WK, 2000, LIFE SCI, V67, P1297, DOI 10.1016/S0024-3205(00)00720-7; Lu LJW, 2000, CANCER RES, V60, P1299; Lundholm L, 2008, J ENDOCRINOL, V199, P275, DOI 10.1677/JOE-08-0192; Mackay D, 2000, ENVIRON POLLUT, V110, P375, DOI 10.1016/S0269-7491(00)00162-7; Maggiolini M, 2002, J STEROID BIOCHEM, V82, P315, DOI 10.1016/S0960-0760(02)00230-3; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; Malamas MS, 2004, J MED CHEM, V47, P5021, DOI 10.1021/jm049719y; Manach C, 2004, FREE RADICAL RES, V38, P771, DOI 10.1080/10715760410001727858; Mani SK, 2005, STEROIDS, V70, P750, DOI 10.1016/j.steroids.2005.04.004; Marini H, 2008, J CLIN ENDOCR METAB, V93, P4787, DOI 10.1210/jc.2008-1087; Markaverich B, 2002, ENVIRON HEALTH PERSP, V110, P169; Markaverich BM, 2001, STEROIDS, V66, P707, DOI 10.1016/S0039-128X(01)00099-X; MARKAVERICH BM, 1988, J STEROID BIOCHEM, V30, P71, DOI 10.1016/0022-4731(88)90078-7; Markaverich BM, 2002, BIOCHEM BIOPH RES CO, V291, P692, DOI 10.1006/bbrc.2002.6499; Markaverich BM, 2005, ENVIRON HEALTH PERSP, V113, P1698, DOI 10.1289/ehp.8231; Mateescu C., 1999, ROUM BIOTECHNOL LETT, V4, P163; Mathesius U, 2001, J EXP BOT, V52, P419; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Mazur W, 2000, NUTRITION, V16, P654, DOI 10.1016/S0899-9007(00)00333-6; Mazur W, 1998, PURE APPL CHEM, V70, P1759, DOI 10.1351/pac199870091759; Mazur WM, 1998, J NUTR BIOCHEM, V9, P193, DOI 10.1016/S0955-2863(97)00184-8; Mazur WM, 1998, BRIT J NUTR, V79, P37, DOI 10.1079/BJN19980007; McCann SE, 2002, J NUTR, V132, P3036; McCann SE, 2006, BREAST CANCER RES TR, V99, P309, DOI 10.1007/s10549-006-9196-x; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Medjakovic S, 2008, J STEROID BIOCHEM, V108, P171, DOI 10.1016/j.jsbmb.2007.10.001; Mersereau JE, 2008, MOL CELL ENDOCRINOL, V283, P49, DOI 10.1016/j.mce.2007.11.020; Meyers CY, 2002, J STEROID BIOCHEM, V82, P33, DOI 10.1016/S0960-0760(02)00150-4; MEYERS CY, 1988, J STEROID BIOCHEM, V31, P393, DOI 10.1016/0022-4731(88)90307-X; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; MIESCHER K, 1948, CHEM REV, V43, P367, DOI 10.1021/cr60136a001; Milder IEJ, 2005, BRIT J NUTR, V93, P393, DOI 10.1079/BJN20051371; Milder IEJ, 2005, J NUTR, V135, P1202; Miller J.D., 1997, MYCOTOXINS GRAIN COM; Molnar V, 2005, INT IMMUNOPHARMACOL, V5, P849, DOI 10.1016/j.intmib.2004.12.017; Moore M, 1997, TOXICOL APPL PHARM, V142, P160, DOI 10.1006/taap.1996.8022; Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Muhlhauser A, 2009, BIOL REPROD, V80, P1066, DOI 10.1095/biolreprod.108.074815; Muncke J, 2009, SCI TOTAL ENVIRON, V407, P4549, DOI 10.1016/j.scitotenv.2009.05.006; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Nakagawa Y, 2003, BIOCHEM PHARMACOL, V66, P63, DOI 10.1016/S0006-2952(03)00208-9; Nassar MI, 2002, PHYTOCHEMISTRY, V60, P385, DOI 10.1016/S0031-9422(02)00060-2; Nesatyy VJ, 2005, ANALYST, V130, P1087, DOI 10.1039/b501192b; Nettles KW, 2007, EMBO REP, V8, P563, DOI 10.1038/sj.embor.7400963; Nilsson M, 1997, J SCI FOOD AGR, V73, P143, DOI 10.1002/(SICI)1097-0010(199702)73:2&lt;143::AID-JSFA698&gt;3.0.CO;2-H; Nimrod AC, 1996, CRIT REV TOXICOL, V26, P335, DOI 10.3109/10408449609012527; Norman BH, 2006, J MED CHEM, V49, P6155, DOI 10.1021/jm060491j; Oshima S, 2006, FEBS LETT, V580, P1251, DOI 10.1016/j.febslet.2006.01.038; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; Paolini M, 2003, MUTAT RES-REV MUTAT, V543, P181, DOI 10.1016/S1383-5742(02)00092-3; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Patlak M, 1996, ENVIRON SCI TECHNOL, V30, pA210, DOI 10.1021/es962228l; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Peck MC, 2006, J BACTERIOL, V188, P5417, DOI 10.1128/JB.00376-06; Penttinen P, 2007, ENDOCRINOLOGY, V148, P4875, DOI 10.1210/en.2007-0289; PETERSON G, 1995, J NUTR, V125, pS784; Pfitscher A, 2008, J STEROID BIOCHEM, V112, P87, DOI 10.1016/j.jsbmb.2008.08.007; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Potter GA, 2002, BRIT J CANCER, V86, P774, DOI 10.1038/sj/bjc/6600197; Powell E, 2008, P NATL ACAD SCI USA, V105, P19012, DOI 10.1073/pnas.0807274105; PRICE KR, 1985, FOOD ADDIT CONTAM, V2, P73; Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100; Prokai-Tatrai K, 2008, STEROIDS, V73, P280, DOI 10.1016/j.steroids.2007.10.011; Raffaelli B, 2002, J CHROMATOGR B, V777, P29, DOI 10.1016/S1570-0232(02)00092-2; Ramos S, 2007, J NUTR BIOCHEM, V18, P427, DOI 10.1016/j.jnutbio.2006.11.004; Reinli K, 1996, NUTR CANCER, V26, P123; Rice S, 2006, J STEROID BIOCHEM, V101, P216, DOI 10.1016/j.jsbmb.2006.06.021; Richardson TI, 2007, BIOORG MED CHEM LETT, V17, P3570, DOI 10.1016/j.bmcl.2007.04.051; Richardson TI, 2007, BIOORG MED CHEM LETT, V17, P4824, DOI 10.1016/j.bmcl.2007.06.052; RIVAS A, 2001, APMIS, V103, P189; Rivas A, 2002, J STEROID BIOCHEM, V82, P45, DOI 10.1016/S0960-0760(02)00146-2; Roelens F, 2006, J MED CHEM, V49, P7357, DOI 10.1021/jm060692n; Ruegg J, 2008, MOL ENDOCRINOL, V22, P304, DOI 10.1210/me.2007-0128; RUSSELL GB, 1976, AUST J BIOL SCI, V29, P99; Russell L, 2002, AM J MED SCI, V324, P185, DOI 10.1097/00000441-200210000-00004; Safe S, 2000, J MAMMARY GLAND BIOL, V5, P295, DOI 10.1023/A:1009550912337; Salvo VA, 2006, CLIN CANCER RES, V12, P7159, DOI 10.1158/1078-0432.CCR-06-1426; Schuster D, 2008, J MED CHEM, V51, P4188, DOI 10.1021/jm800054h; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1333S; Setchell KDR, 1999, J NUTR, V129, p758S; Shekhar PVM, 1997, J NATL CANCER I, V89, P1774; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shimada N, 2000, PLANT SCI, V160, P37, DOI 10.1016/S0168-9452(00)00355-1; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Silva E, 2006, TOXICOL APPL PHARM, V216, P20, DOI 10.1016/j.taap.2006.04.002; SIMONICH SL, 1995, SCIENCE, V269, P1851, DOI 10.1126/science.7569923; Siow RCM, 2007, FREE RADICAL BIO MED, V42, P909, DOI 10.1016/j.freeradbiomed.2007.01.004; Skakkebaek NE, 1998, APMIS, V106, P3; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sonestedt E, 2009, J NUTR, V139, P993, DOI 10.3945/jn.108.101691; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1988, END SOC 70 ANN M NEW; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; STEFFAN RJ, 2004, J MED CHEM, V47, P26; Stevens JF, 1999, J AGR FOOD CHEM, V47, P2421, DOI 10.1021/jf990101k; Stevens JF, 1997, PHYTOCHEMISTRY, V44, P1575, DOI 10.1016/S0031-9422(96)00744-3; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; Suzuki KM, 2008, EVID-BASED COMPL ALT, V5, P295, DOI 10.1093/ecam/nem036; Swedenborg E, 2010, TOXICOLOGY, V268, P132, DOI 10.1016/j.tox.2009.09.007; Takaoka M. J., 1940, J FAC SCI HOKKAIDO U, V3, P1; Takemura H, 2007, J STEROID BIOCHEM, V103, P170, DOI 10.1016/j.jsbmb.2006.08.008; Thammacharoen S, 2009, BRAIN RES, V1268, P88, DOI 10.1016/j.brainres.2009.02.067; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Tsuchiya M, 2007, EPIDEMIOLOGY, V18, P402, DOI 10.1097/01.ede.0000257571.01358.f9; Turkyilmaz Z, 2008, J PEDIATR SURG, V43, P2109, DOI 10.1016/j.jpedsurg.2008.07.027; Turner JV, 2007, J PHARM SCI-US, V96, P1879, DOI 10.1002/jps.20987; Tyler CR, 1998, CRIT REV TOXICOL, V28, P319, DOI 10.1080/10408449891344236; van Egmond HP, 2002, ADV EXP MED BIOL, V504, P257; van Lipzig MMH, 2004, J MED CHEM, V47, P1018, DOI 10.1021/jm0309607; Vihko P, 2004, MOL CELL ENDOCRINOL, V215, P83, DOI 10.1016/j.mce.2003.11.021; VO TP, 2009, CARCINOGENESIS; Waibel M, 2009, EUR J MED CHEM, V44, P3412, DOI 10.1016/j.ejmech.2009.02.006; Wakai K, 1999, NUTR CANCER, V33, P139, DOI 10.1207/S15327914NC330204; WALLE T, 1995, BIOCHEM PHARMACOL, V50, P731, DOI 10.1016/0006-2952(95)00190-B; WANG HJ, 1994, J AGR FOOD CHEM, V42, P1674, DOI 10.1021/jf00044a017; WANG HJ, 1994, J AGR FOOD CHEM, V42, P1666, DOI 10.1021/jf00044a016; WATANABE O, 2003, J MED CHEM, V46, P3961; Watanabe S, 1998, J NUTR, V128, P1710; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Weihua Z, 2000, Proc Natl Acad Sci U S A, V97, P5936, DOI 10.1073/pnas.97.11.5936; Weiser MJ, 2009, ENDOCRINOLOGY, V150, P1817, DOI 10.1210/en.2008-1355; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; WELSHONS WV, 1987, BREAST CANCER RES TR, V10, P169, DOI 10.1007/BF01810580; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; Whitman SC, 2005, ATHEROSCLEROSIS, V178, P25, DOI 10.1016/j.atherosclerosis.2004.07.034; Williamson G, 1996, CARCINOGENESIS, V17, P2385, DOI 10.1093/carcin/17.11.2385; Wolter F, 2002, J NUTR, V132, P298; WOOD CE, 2006, NUTR CANC, V56, P67; WRIGHT PA, 1960, P SOC EXP BIOL MED, V105, P428; Wu F, 2008, J STEROID BIOCHEM, V110, P104, DOI 10.1016/j.jsbmb.2008.02.008; Xu X, 1998, CANCER EPIDEM BIOMAR, V7, P1101; YIT CC, 1994, CANCER LETT, V82, P65, DOI 10.1016/0304-3835(94)90147-3; Yu J, 2008, HUM REPROD, V23, P1614, DOI 10.1093/humrep/den125; Zhang Y, 1999, J NUTR, V129, P957; Zhou HB, 2007, CHEM BIOL, V14, P659, DOI 10.1016/j.chembiol.2007.04.00928224BENTHAM SCIENCE PUBL LTDSHARJAHEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATESCURR MED CHEMOCTDiscipline: Biochemistry &amp; Molecular Biology; Pharmacology &amp; Pharmacy685UT</notes>
    <keywords>Alkylphenol; ALKYLPHENOLS; ALPHA; ARYL-HYDROCARBON RECEPTOR; ATHEROSCLEROSIS; BETA; BETA-AGONISTS SERBAS; BIOLOGY; bisphenol; bisphenols; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; CUSTOMIZED DNA MICROARRAY; DDT; DES; development; DIOXIN; DIOXINS; ENDOCRINE; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; ENDOGENOUS ESTROGENS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; Epidemiology; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; Flavonoids; FOOD; Food chain; GLAND; HEALTH; In vitro; IN-VITRO; LIGAND-BINDING DOMAIN; mammary gland; MAMMARY-GLAND; mechanism; MECHANISMS; METABOLISM; METABOLITES; Methoxychlor; MIGRATION INHIBITORY FACTOR; NITRIC-OXIDE SYNTHASE; nutrition; PERSISTENT ORGANIC POLLUTANTS; PHARMACOLOGY; Phytoestrogen; PHYTOESTROGENS; POLYCHLORINATED-BIPHENYLS; polyphenols; PRODUCTS; PROPYL PYRAZOLE TRIOL; RECEPTOR; Receptors; RED-CLOVER ISOFLAVONES; Review; selective estrogen receptor modulators; SERM; Steroid; TISSUE; toxicology; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3542</startpage>
    <endpage>3574</endpage>
    <journalfull>Current Medicinal Chemistry</journalfull>
    <issue>30</issue>
    <volume>17</volume>
    <abstract>Herbivorous and omnivorous vertebrates have evolved in the presence of a variety of phytoestrogens, i.e., plant-derived compounds that can mimic, modulate or disrupt the actions of endogenous estrogens. Since the discovery of the estrus-inducing effects of some plant products in 1926, considerable effort has been devoted to the isolation and structural and pharmacological characterization of phytoestrogens. Recently, agricultural and industrial pollution has added anthropogenic estrogenic compounds to the list of environmental estrogens. Unlike phytoestrogens, these xenoestrogens tend to accumulate and persist in adipose tissue for decades and may cause long-lasting, adverse endocrine effects. Here we review the endocrine effects of known phytoestrogens and xenoestrogens with special emphasis on molecular structure-activity relationships. Phytoestrogens include flavonoids, isoflavonoids, chalcons, coumestans, stilbenes, lignans, ginsenosides and other saponins, as well as the recently discovered tetrahydrofurandiols. Fungal estrogenic compounds may enter the food chain via infested crops. Since some phytoestrogens have been shown to display organ-specific actions, pharmaceutical estrogen analogues with similar properties (selective estrogen receptor modulators, SERMs) are also discussed. Xenoestrogens include dichlorodiphenyltrichloroethane (DDT) and its metabolites, bisphenols, alkylphenols, dichlorophenols, methoxychlor, chlordecone, polychlorinated biphenyls (PCBs), and dioxins. While most of these compounds act through estrogen receptors alpha and beta, some of their effects may be mediated by other nuclear or membrane-bound receptors or receptor-independent mechanisms. Some might also interfere with the production and metabolism of ovarian estrogens. Better understanding of the molecular pharmacology of phyto-and xenoestrogens may result in the development of novel compounds with therapeutic utility and improved environmental protection</abstract>
    <url>WOS:000284654300008</url>
    <isbnorissn>0929-8673</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>344</id>
    <title>Cell viability and PSA secretion assays in LNCaP cells: A tiered in vitro approach to screen chemicals with a prostate-mediated effect on male reproduction within the ReProTect project</title>
    <authors>Lorenzetti,S.; Marcoccia,D.; Narciso,L.; Mantovani,A.</authors>
    <availability>[Lorenzetti, Stefano; Marcoccia, Daniele; Narciso, Laura; Mantovani, Alberto] Ist Super Sanita, Food &amp; Vet Toxicol Unit, Dept Food Safety &amp; Vet Publ Hlth, I-00161 Rome, Italy.</availability>
    <date>2010</date>
    <notes>JEnglishArticleLorenzetti, S (reprint author), Ist Super Sanita, Food &amp; Vet Toxicol Unit, Dept Food Safety &amp; Vet Publ Hlth, Viale Regina Elena 299, I-00161 Rome, Italystefano.lorenzetti@iss.it; daniele430@alice.it; laura.narciso@iss.it; alberto.mantovani@iss.itArnold JT, 2007, PROSTATE, V67, P1152, DOI 10.1002/pros.20585; ARNOULD R, 1990, ANTICANCER RES, V10, P145; Arriazu R, 2005, PROSTATE, V63, P347, DOI 10.1002/pros.20192; Bagchi G, 2009, TOXICOL APPL PHARM, V238, P101, DOI 10.1016/j.taap.2008.03.015; Balk SP, 2003, J CLIN ONCOL, V21, P383, DOI 10.1200/JCO.2003.02.083; Bremer S, 2005, ATLA-ALTERN LAB ANIM, V33, P391; BREMNER WJ, 1994, ENDOCRINOLOGY, V135, P1227, DOI 10.1210/en.135.3.1227; Clements JA, 2004, CRIT REV CL LAB SCI, V41, P265, DOI 10.1080/10408360490471931; Eriksson S, 2000, CLIN CHEM, V46, P658; Finne P, 2008, EUR UROL, V54, P362, DOI 10.1016/j.eururo.2007.10.056; Finne P, 2000, UROLOGY, V56, P418, DOI 10.1016/S0090-4295(00)00672-5; Fizazi K, 2005, B CANCER, V92, P129; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; Hareng L, 2005, REPROD TOXICOL, V20, P441, DOI 10.1016/j.reprotox.2005.04.003; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Ishioka J, 2009, INT J UROL, V16, P516, DOI 10.1111/j.1442-2042.2009.02284.x; Jonsson M, 2006, CELL MOL LIFE SCI, V63, P2886, DOI 10.1007/s00018-006-6287-0; Kang IH, 2004, TOXICOLOGY, V199, P145, DOI 10.1016/j.tox.2004.02.019; KELLY WK, 1993, J UROLOGY, V149, P607; Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228; Lambright C, 2000, TOXICOL SCI, V56, P389, DOI 10.1093/toxsci/56.2.389; Lee BM, 2007, J TOXICOL ENV HEAL A, V70, P1365, DOI 10.1080/15287390701432285; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Luu-The V, 2008, BEST PRACT RES CL EN, V22, P207, DOI 10.1016/j.beem.2008.01.008; Mantovani A, 2005, CONTRACEPTION, V72, P308, DOI 10.1016/j.contraception.2005.04.014; McPhaul MJ, 2008, BEST PRACT RES CL EN, V22, P373, DOI 10.1016/j.beem.2008.02.006; Mylchreest E, 2000, TOXICOL APPL PHARM, V168, P174, DOI 10.1006/taap.2000.9032; OHARA GP, 1983, TOXICOLOGY, V28, P323, DOI 10.1016/0300-483X(83)90006-9; Okubo T, 2004, ARCH ENVIRON CON TOX, V46, P445, DOI 10.1007/s00244-003-3017-6; O'Shaughnessy PJ, 2009, MOL CELL ENDOCRINOL, V306, P2, DOI 10.1016/j.mce.2008.11.005; Pampalakis G, 2007, BBA-REV CANCER, V1776, P22, DOI 10.1016/j.bbcan.2007.06.001; Parrish AR, 2002, CELL BIOL TOXICOL, V18, P205, DOI 10.1023/A:1015567805460; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Reissigl A, 1997, PROSTATE, V30, P243; Schulte-Hermann R, 2006, REGUL TOXICOL PHARM, V44, pS1; Shin JH, 2007, ARCH TOXICOL, V81, P309, DOI 10.1007/s00204-006-0174-1; Sun H, 2006, FOOD CHEM TOXICOL, V44, P1916, DOI 10.1016/j.fct.2006.06.013; Sunami Osamu, 2000, Journal of Toxicological Sciences, V25, P403; Tirado OM, 2003, BIOL REPROD, V68, P1437, DOI 10.1095/biolreprod.102.004937; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Veveris-Lowe TL, 2007, SEMIN THROMB HEMOST, V33, P87, DOI 10.1055/s-2006-958467; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Wetherill YB, 2005, CANCER RES, V65, P54; WILSON EM, 1985, J BIOL CHEM, V260, P8683; Woodruff Tracey J, 2008, Fertil Steril, V89, pe1, DOI [10.1016/j.fertnstert.2008.01.065, 10.1016/j.fertnstert.2007.10.002]; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Yamada T, 2005, TOXICOL APPL PHARM, V205, P11, DOI 10.1016/j.taap.2004.09.002; Yamasaki K, 2003, ENVIRON HEALTH PERSP, V111, P1912, DOI 10.1289/ehp.6357; 2005, COM20057; 2001, GUIDANCE DOCUMENT US536PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLAUGSIDiscipline: Reproductive Biology; Toxicology624MK</notes>
    <keywords>Androgen; ANDROGEN RECEPTOR; androgens; Anti-androgen; ANTI-ANDROGENS; Antiandrogen; Antiandrogens; ANTIGEN; ASSAY; BIOLOGY; BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CELL; CELLS; CHEMICALS; Cytotoxicity; Endocrine disrupter; Feasibility; fertility; FOOD; food safety; HEALTH; Hershberger assay; In vitro; In vitro testing; IN-VITRO; LINE; LNCaP cells; Male; male fertility; MALE-FERTILITY; METHOXYACETIC ACID; OECD VALIDATION; phthalate; Prostate; RAT TESTIS; Reproduction; REPRODUCTIVE TOXICITY; SERINE PROTEASES; SET; Test battery; Testing strategy; TOXICITY; toxicology; TRANSCRIPTIONAL ACTIVITIES; UPDATE; VIABILITY; Vinclozolin; VITRO; VITRO APPROACH</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>25</startpage>
    <endpage>35</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>1</issue>
    <volume>30</volume>
    <abstract>Prostate function is critical for male fertility; nevertheless, prostate was so far overlooked in reproductive toxicity assays. Within the EU project ReProTect, the human prostate cell line LNCaP was utilized to identify molecules targeting prostate function by the integrated assessment of cell viability (MTS assay) and prostate-specific antigen (PSA) secretion as specific marker; a training set - five (anti)androgenic chemicals - and a ReProTect feasibility set - ten chemicals - were used. Several compounds reduced PSA only at cytotoxic concentrations. Androgens (DHT, MT) markedly increased PSA as did the herbicide glufosinate ammonium, not known as androgen agonist. Anti-androgens (2OH-flutamide, linuron, vinclozolin, di-n-butyl phthalate) also increased PSA, but the effect of magnitude was much lower than for androgens. The ER-binder bisphenol A reduced PSA, while increasing cell viability. At this stage, the approach can identify chemicals able to interfere with prostate function: further refinements may allow to include prostate effects in reproductive toxicity in vitro testing. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000279822900005</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>140</id>
    <title>The Exposome - Exciting Opportunities for Discoveries in Reproductive and Perinatal Epidemiology</title>
    <authors>Louis,G.M.B.; Yeung,E.; Sundaram,R.; Laughon,S.K.; Zhang,C.L.</authors>
    <availability>[Louis, Germaine M. Buck] Eunice Kennedy Shriver Natl Inst Child Hlth &amp; Hum, Div Epidemiol Stat &amp; Prevent Res, NIH, Rockville, MD 20852 USA. [Yeung, Edwina; Laughon, S. Katherine; Zhang, Cuilin] Eunice Kennedy Shriver Natl Inst Child Hlth &amp; Hum, Epidemiol Branch, Div Epidemiol Stat &amp; Prevent Res, NIH, Rockville, MD 20852 USA. [Sundaram, Rajeshwari] Eunice Kennedy Shriver Natl Inst Child Hlth &amp; Hum, Biostat &amp; Bioinformat Branch, Div Epidemiol Stat &amp; Prevent Res, NIH, Rockville, MD 20852 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleLouis, GMB (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth &amp; Hum, Div Epidemiol Stat &amp; Prevent Res, NIH, 6100 Execut Blvd,Room 7B05, Rockville, MD 20852 USAlouisg@mail.nih.govAbbott DH, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740001; Asklund C, 2007, HUM REPROD, V22, P2639, DOI 10.1093/humrep/dem217; Boomsma CM, 2006, HUM REPROD UPDATE, V12, P673, DOI 10.1093/humupd/dml036; Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7; Brinton LA, 2005, CANCER EPIDEM BIOMAR, V14, P2929, DOI 10.1158/1055-9965.EPI-05-0394; Brouwers MM, 2006, HUM REPROD, V21, P666, DOI 10.1093/humrep/dei398; Brown S., 2009, FOCUS REPROD JAN, P22; Buck Louis GM, 2004, ENVIRON HEALTH PERSP, V112, P79; Louis GMB, 2011, J DEV ORIG HLTH DIS, V2, P25, DOI 10.1017/S2040174410000693; Chason RJ, 2011, TRENDS ENDOCRIN MET, V22, P412, DOI 10.1016/j.tem.2011.05.005; Dumoulin JC, 2010, HUM REPROD, V25, P605, DOI 10.1093/humrep/dep456; Eaton JL, 2012, HUM REPROD, V27, P375, DOI 10.1093/humrep/der381; Eisner JR, 2002, FERTIL STERIL, V77, P167, DOI 10.1016/S0015-0282(01)02947-8; Fauser BCJM, 2012, FERTIL STERIL, V97, pe1; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; GM Buck Louis, 2011, REPROD PERINATAL EPI, P16; Golding J, 2009, PAEDIATR PERINAT EP, V23, P1, DOI 10.1111/j.1365-3016.2008.01009.x; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Hediger ML, 2005, FERTIL STERIL, V84, P1366, DOI 10.1016/j.fertnstert.2005.05.029; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Ibanez L, 2002, J CLIN ENDOCR METAB, V87, P3391, DOI 10.1210/jc.87.7.3391; Ibanez L, 2000, PEDIATR RES, V47, P575; Ibanez L, 2000, J CLIN ENDOCR METAB, V85, P2624, DOI 10.1210/jc.85.7.2624; Iwasaki Y, 2012, CHEMOSPHERE, V88, P445, DOI 10.1016/j.chemosphere.2012.02.068; Jensen MS, 2012, AM J EPIDEMIOL, V175, P917, DOI 10.1093/aje/kwr421; Jensen TK, 2009, AM J EPIDEMIOL, V170, P559, DOI 10.1093/aje/kwp168; Koren O, 2012, CELL, V150, P470, DOI 10.1016/j.cell.2012.07.008; Lawson C, 2011, BIOL REPROD, V84, P79, DOI 10.1095/biolreprod.110.084814; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Louis GMB, 2012, STAT MED, V31, P2569; Moller H, 1998, APMIS, V106, P232; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Niswander K. R., 1972, WOMEN THEIR PREGNANC; Patel CJ, 2012, INT J EPIDEMIOL, V41, P828, DOI 10.1093/ije/dys003; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; Peters A, 2012, J EPIDEMIOL COMMUN H, V66, P103, DOI 10.1136/jech-2011-200643; Raman JD, 2005, J UROLOGY, V174, P1819, DOI 10.1097/01.ju.0000177491.98461.aa; Rappaport SM, 2012, BIOMARKERS, V17, P483, DOI 10.3109/1354750X.2012.691553; Rappaport SM, 2010, SCIENCE, V330, P460, DOI 10.1126/science.1192603; Sinaii N, 2002, HUM REPROD, V17, P2715, DOI 10.1093/humrep/17.10.2715; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Takatori S, 2012, CHEMOSPHERE, V86, P454, DOI 10.1016/j.chemosphere.2011.09.043; Virro MR, 2004, FERTIL STERIL, V81, P1289, DOI 10.1016/j.fertnstert.2003.09.063; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Wild CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/ije/dyr236; Willett WC, 2002, SCIENCE, V296, P695, DOI 10.1126/science.1071055; Wohlfahrt-Veje C, 2009, CLIN ENDOCRINOL, V71, P459, DOI 10.1111/j.1365-2265.2009.03545.x; Wolstenholme JT, 2012, ENDOCRINOLOGY, V153, P3828, DOI 10.1210/en.2012-1195485WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAPAEDIATR PERINAT EPMAYDiscipline: Public, Environmental &amp; Occupational Health; Obstetrics &amp; Gynecology; Pediatrics123XG</notes>
    <keywords>ADULTHOOD; BIOMARKER; Biomarkers; BIRTH-WEIGHT; BISPHENOL-A; CANCER; CELL; development; DISEASE; ENDOMETRIOSIS; environment; Epidemiology; exposome; EXPOSURE; fecundity; fertility; FOR-GESTATIONAL-AGE; GAP; GENE-EXPRESSION; HUMAN-REPRODUCTION; IN-VITRO FERTILIZATION; mechanism; MECHANISMS; POLYCYSTIC-OVARY-SYNDROME; POPULATION; Reproduction; sensitive windows; TESTICULAR DYSGENESIS SYNDROME; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>229</startpage>
    <endpage>236</endpage>
    <journalfull>Paediatric and Perinatal Epidemiology</journalfull>
    <issue>3</issue>
    <volume>27</volume>
    <abstract>Understanding the mechanisms that underlie successful human reproduction and development is an ambitious goal, given the many unique methodological challenges surrounding such study. These challenges are well understood by reproductive and perinatal epidemiologists and include its conditional nature, unobservable yet informative outcomes such as conception, multi-scale missing data, correlated or non-independent outcomes, interval censoring and a hierarchical data structure. Novel methodologies for overcoming these challenges and for answering critical data gaps are needed if we are to better understand the inefficiency that currently characterises human reproduction with the goal of improving population health. The exposome is an emerging paradigm that offers promise for understanding the natural history of human reproduction and development, and its many associated impairments that develop later in child- or adulthood. This novel paradigm recognises the need to identify and measure the totality of environmental (non-genetic) exposures from preconception through sensitive windows, and to identify patterns associated with healthy and adverse outcomes. The exposome accommodates research focusing on unique subpopulations, such as couples undergoing assisted reproductive technologies, so that methodological limitations such as unobservable and conditional outcomes can be better addressed. Reproductive and perinatal epidemiology is uniquely suited for proof-of-concept exposome research, given the intricate relations between fecundity, gravid health and later onset disease and the narrow and interrelated sensitive windows that characterise the conditional nature of human reproduction and development. Bold new conceptual frameworks such as the exposome are needed for designing research that may lead to discovery and improve population health</abstract>
    <url>WOS:000317424600003</url>
    <isbnorissn>0269-5022</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>381</id>
    <title>Bisphenol A Increases Mammary Cancer Risk in Multiple Murine Models of Breast Cancer</title>
    <authors>Lozada,K.W.; Keri,R.A.</authors>
    <availability>[Lozada, Kristen Weber; Keri, Ruth A.] Case Western Reserve Univ, Cleveland, OH 44106 USA.</availability>
    <date>2010</date>
    <notes>JEnglishMeeting Abstract00SOC STUDY REPRODUCTIONMADISON1603 MONROE ST, MADISON, WI 53711-2021 USABIOL REPRODSDiscipline: Reproductive Biology682DY</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; Mammary cancer; MAMMARY-CANCER; MODEL; MODELS; Reproduction; RISK</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>66</startpage>
    <endpage>66</endpage>
    <journalfull>Biology of Reproduction</journalfull>
    <url>WOS:000284381300070</url>
    <isbnorissn>0006-3363</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>271</id>
    <title>Bisphenol A Increases Mammary Cancer Risk in Two Distinct Mouse Models of Breast Cancer</title>
    <authors>Lozada,K.W.; Keri,R.A.</authors>
    <availability>[Keri, Ruth A.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA. [Keri, Ruth A.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA. [Keri, Ruth A.] Case Western Reserve Univ, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleKeri, RA (reprint author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USAkeri@case.eduAdewale HB, 2009, BIOL REPROD, V81, P690, DOI 10.1095/biolreprod.109.078261; BALAKRISHNAN B, 2002, AM J OBSTET GYNECOL, V393, pE391; BALINSKY BI, 1950, J ANAT, V84, P227; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Brody JG, 2003, ENVIRON HEALTH PERSP, V111, P1007, DOI 10.1289/ehp.6310; CABATON NJ, ENV HLTH PERSPECT, V119, P547; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Gennari L, 2008, EXPERT OPIN DRUG SAF, V7, P259, DOI [10.1517/14740338.7.3.259 , 10.1517/14740330802025617]; Golub MS, 2010, BIRTH DEFECTS RES B, V89, P441, DOI 10.1002/bdrb.20275; Goodman J, 2009, CRIT REV TOXICOL, V39, P1, DOI 10.3109/10408440903279946; Goodson A, 2004, FOOD ADDIT CONTAM, V21, P1015, DOI 10.1080/02652030400011387; Green EL, 1968, BIOL LAB MOUSE; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Kato H, 2003, REPROD TOXICOL, V17, P283, DOI 10.1016/S0890-6238(03)00002-9; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Lee YJ, 2008, REPROD TOXICOL, V25, P413, DOI 10.1016/j.reprotox.2008.05.058; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2001, BIOL REPROD, V65, P1215; Matsumoto A, 2003, ENVIRON HEALTH PERSP, V111, P101, DOI 10.1289/ehp.5512; MEDINA D, 1976, J NATL CANCER I, V57, P331; Medina D, 2005, ENDOCR-RELAT CANCER, V12, P483, DOI 10.1677/erc.1.00804; Melnick Ronald, 2002, Environmental Health Perspectives, V110, P427; Mendum T, 2011, GREEN CHEM LETT REV, V4, P81, DOI 10.1080/17518253.2010.502908; Milliken EL, 2002, ENDOCRINOLOGY, V143, P3671, DOI 10.1210/en.2002-220228; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Mountfort KA, 1997, FOOD ADDIT CONTAM, V14, P737; Muhlhauser A, 2009, BIOL REPROD, V80, P1066, DOI 10.1095/biolreprod.108.074815; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Nieto AI, 2003, COMPARATIVE MED, V53, P433; Nishikawa M, 2010, ENVIRON HEALTH PERSP, V118, P1196, DOI 10.1289/ehp.0901575; Ogura Y, 2007, DIFFERENTIATION, V75, P745, DOI 10.1111/j.1432-0436.2007.00177.x; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rose-Hellekant TA, 2002, AM J PATHOL, V161, P1439, DOI 10.1016/S0002-9440(10)64419-7; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; RUSSO IH, 1978, J NATL CANCER I, V61, P1439; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; SAKAKURA T, 1987, DEVELOPMENT, V100, P421; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; WENG YI, TOXICOL APPL PHARM, V248, P111; YUE W, 1993, J STEROID BIOCHEM, V44, P671, DOI 10.1016/0960-0760(93)90278-56214SOC STUDY REPRODUCTIONMADISON1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USABIOL REPRODSEPDiscipline: Reproductive Biology810FH</notes>
    <keywords>ALTERS; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER RISK; CANCER-CELLS; CANCER-RISK; Carcinogen; CELL; cell growth; CELLS; development; Differentiation; DMBA; DUCTAL HYPERPLASIAS; EARLY PRENATAL EXPOSURE; ENDOCRINE DISRUPTORS; ESTRADIOL; Estrogen; EXPOSURE; female; FEMALE MICE; FEMALE MOUSE; FETAL; FETAL MOUSE; Fetal programming; FOOD; GLAND; GLAND DEVELOPMENT; GROWTH; HEALTH; HUMAN EXPOSURE; HUMAN-BREAST-CANCER; IMPACT; in vivo; IN-UTERO EXPOSURE; IN-VIVO; Mammary cancer; mammary gland; Mammary glands; MAMMARY-GLAND; mechanism; MECHANISMS; MICE; MODEL; MODELS; Mouse; MOUSE MODEL; PERINATAL EXPOSURE; puberty; Reproduction; REPRODUCTIVE-ORGANS; RISK; rodents (rats,mice,guinea pigs,voles); SUSCEPTIBILITY; TAMOXIFEN; TRANSGENIC MICE; TUMOR; TUMOR-GROWTH; TUMORIGENESIS; TUMORS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>490</startpage>
    <endpage>497</endpage>
    <journalfull>Biology of Reproduction</journalfull>
    <issue>3</issue>
    <volume>85</volume>
    <abstract>Bisphenol A (BPA) is an industrial plasticizer that leaches from food containers during normal usage, leading to human exposure. Early and chronic exposure to endocrine-disrupting environmental contaminants such as BPA elevates the potential for long-term health consequences. We examined the impact of BPA exposure on fetal programming of mammary tumor susceptibility as well as its growth promoting effects on transformed breast cancer cells in vivo. Fetal mice were exposed to 0, 25, or 250 mu g/kg BPA by oral gavage of pregnant dams. Offspring were subsequently treated with the known mammary carcinogen, 7,12-dimethylbenz[a] anthracene (DMBA). While no significant differences in postnatal mammary development were observed, both low-and high-dose BPA cohorts had a statistically significant increase in susceptibility to DMBA-induced tumors compared to vehicle-treated controls. To determine if BPA also promotes established tumor growth, MCF-7 human breast cancer cells were subcutaneously injected into flanks of ovariectomized NCR nu/nu female mice treated with BPA, 17beta-estradiol, or placebo alone or combined with tamoxifen. Both estradiol-and BPA-treated cohorts formed tumors by 7 wk post-transplantation, while no tumors were detected in the placebo cohort. Tamoxifen reversed the effects of estradiol and BPA. We conclude that BPA may increase mammary tumorigenesis through at least two mechanisms: molecular alteration of fetal glands without associated morphological changes and direct promotion of estrogen-dependent tumor cell growth. Both results indicate that exposure to BPA during various biological states increases the risk of developing mammary cancer in mice</abstract>
    <url>WOS:000294110400009</url>
    <isbnorissn>0006-3363</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>268</id>
    <title>Disruption of androgen receptor signaling in males by environmental chemicals</title>
    <authors>Luccio-Camelo,D.C.; Prins,G.S.</authors>
    <availability>[Luccio-Camelo, Doug C.; Prins, Gail S.] Univ Illinois, Chicago, IL 60612 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewPrins, GS (reprint author), Univ Illinois, MC 955,820 S Wood St, Chicago, IL 60612 USAgprins@uic.eduAlavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; [Anonymous], 2000, WAST MIN PRIOR TOOL; ANWAY M, 2008, PROSTATE, V68, P515; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058; ANWAY MD, 2006, J ANDROL, V27, P6; Araki N, 2005, TOXICOL IN VITRO, V19, P335, DOI 10.1016/j.tiv.2004.10.008; Araki N, 2005, TOXICOL IN VITRO, V19, P831, DOI 10.1016/j.tiv.2005.04.009; Aranda A, 2001, PHYSIOL REV, V81, P1269; Arsenault G, 2008, CHEMOSPHERE, V72, P1163, DOI 10.1016/j.chemosphere.2008.03.044; Atanassova N, 2000, ENDOCRINOLOGY, V141, P3898, DOI 10.1210/en.141.10.3898; *ATSDR, 2001, TOX PROF DI N OCTYL; *ATSDR, 1987, TOX PROF ALDR DIELD; Auger J, 2010, TOXICOL SCI, V117, P475, DOI 10.1093/toxsci/kfq199; BAL HS, 1984, P SOC EXP BIOL MED, V176, P187; Bauer ERS, 1998, ANALYST, V123, P2485, DOI 10.1039/a804606i; Bay K, 2006, BEST PRACT RES CL EN, V20, P77, DOI 10.1016/j.beem.2005.09.004; Bennett NC, 2010, INT J BIOCHEM CELL B, V42, P813, DOI 10.1016/j.biocel.2009.11.013; Ben Rhouma K, 2001, HUM EXP TOXICOL, V20, P393, DOI 10.1191/096032701682692946; Bhatia R, 2005, ENVIRON HEALTH PERSP, V113, P220, DOI 10.1289/ehp.7382; Boisen KA, 2004, LANCET, V363, P1264, DOI 10.1016/S0140-6736(04)15998-9; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; BROWN CJ, 1989, AM J HUM GENET, V44, P264; Louis GMB, 2008, PEDIATRICS, V121, pS192, DOI 10.1542/peds.1813E; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; CARLSEN E, 1992, BRIT MED J, V305, P609; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Charles LE, 2003, AM J EPIDEMIOL, V157, P683, DOI 10.1093/aje/kwg044; Choong CS, 1998, J MOL EVOL, V47, P334, DOI 10.1007/PL00006391; Christiansen S, 2008, INT J ANDROL, V31, P241, DOI 10.1111/j.1365-2605.2008.00866.x; Committee NRN, 1999, CELL, V97, P161; COOK JC, 1993, TOXICOL APPL PHARM, V119, P195, DOI 10.1006/taap.1993.1060; COOKE PS, 1990, BIOL REPROD, V42, P585, DOI 10.1095/biolreprod42.3.585; Cooper RL, 1997, J ENDOCRINOL, V152, P159, DOI 10.1677/joe.0.1520159; Cowin PA, 2010, ENDOCRINOLOGY, V151, P783, DOI 10.1210/en.2009-0982; Cowin PA, 2008, ENVIRON HEALTH PERSP, V116, P923, DOI 10.1289/ehp.11239; Dalsenter PR, 1997, HUM EXP TOXICOL, V16, P146; Danzo BJ, 1997, ENVIRON HEALTH PERSP, V105, P294, DOI 10.1289/ehp.97105294; DEWAILLY E, 1994, J NATL CANCER I, V86, P232, DOI 10.1093/jnci/86.3.232; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Duty SM, 2003, EPIDEMIOLOGY, V14, P269, DOI 10.1097/00001648-200305000-00005; Fang H, 2003, CHEM RES TOXICOL, V16, P1338, DOI 10.1021/tx030011g; GELLERT RJ, 1979, ENVIRON RES, V18, P437, DOI 10.1016/0013-9351(79)90119-1; GELLERT RJ, 1974, NEUROENDOCRINOLOGY, V16, P84, DOI 10.1159/000122555; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; GILBERT SF, 2009, NATURE ENDOCRINE DIS, P197; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; Gray LE, 1999, TOXICOL IND HEALTH, V15, P48, DOI 10.1191/074823399678846646; GRAY LE, 1989, FUND APPL TOXICOL, V12, P92, DOI 10.1016/0272-0590(89)90065-1; Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Hauser R, 2006, EPIDEMIOLOGY, V17, P682, DOI 10.1097/01.ede.0000235996.89953.d7; HE WW, 1990, BIOCHEM BIOPH RES CO, V171, P697, DOI 10.1016/0006-291X(90)91202-4; Hiipakka RA, 1998, TRENDS ENDOCRIN MET, V9, P317, DOI 10.1016/S1043-2760(98)00081-2; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hodgson MC, 2008, MOL CANCER THER, V7, P3187, DOI 10.1158/1535-7163.MCT-08-0461; Hosie S, 2000, EUR J PEDIATR SURG, V10, P304, DOI 10.1055/s-2008-1072381; Hosokawa Shunji, 1993, Journal of Toxicological Sciences, V18, P83; *IPCS, 1989, ENV HLTH CRIT 91 ALD; *IPCS, 1991, ENV HLTH CRIT 124 LI; Jonsson BAG, 2005, EPIDEMIOLOGY, V16, P487, DOI 10.1097/01.ede.0000164555.19041.01; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kelce WR, 1998, REPROD FERT DEVELOP, V10, P105, DOI 10.1071/R98051; Kelce WR, 1997, J MOL MED-JMM, V75, P198, DOI 10.1007/s001090050104; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Khalaf H, 2009, ENVIRON HEALTH PERSP, V117, P1853, DOI 10.1289/ehp.0901065; Kojima H, 2004, ENVIRON HEALTH PERSP, V112, P524; KRONGRAD A, 1995, J ANDROL, V16, P209; Lambright C, 2000, TOXICOL SCI, V56, P389, DOI 10.1093/toxsci/56.2.389; Larsson A, 2006, J MED CHEM, V49, P7366, DOI 10.1021/jm060713d; Laudet V., 2002, NUCL RECEPTOR FACTSB; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Li Y, 2009, QSAR COMB SCI, V28, P396, DOI 10.1002/qsar.200810100; List HJ, 2000, EXP CELL RES, V260, P160, DOI 10.1006/excr.2000.5018; Lo S, 2007, TOXICOL IN VITRO, V21, P502, DOI 10.1016/j.tiv.2006.10.016; Longnecker MP, 2002, AM J EPIDEMIOL, V155, P313, DOI 10.1093/aje/155.4.313; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martin OV, 2008, ENVIRON HEALTH PERSP, V116, P149, DOI 10.1289/ehp.10545; MARTZ F, 1980, DRUG METAB DISPOS, V8, P127; Matsumoto T, 2008, J STEROID BIOCHEM, V109, P236, DOI 10.1016/j.jsbmb.2008.03.023; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKinnell C, 2001, J ANDROL, V22, P323; Meeker JD, 2004, ENVIRON HEALTH PERSP, V112, P1665, DOI 10.1289/ehp.7234; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Meyer TE, 2007, OCCUP ENVIRON MED, V64, P155, DOI 10.1136/oem.2006.027383; Mol NM, 2002, EUR J ENDOCRINOL, V146, P357, DOI 10.1530/eje.0.1460357; Monosson E, 1999, TOXICOL IND HEALTH, V15, P65; MORRISON H, 1993, AM J EPIDEMIOL, V137, P270; Nyholm JR, 2008, CHEMOSPHERE, V73, P203, DOI 10.1016/j.chemosphere.2008.04.033; Ostby J, 1999, TOXICOL IND HEALTH, V15, P80; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Portigal CL, 2002, TOXICOL APPL PHARM, V179, P185, DOI 10.1006/taap.2002.9371; Prince MM, 2006, ENVIRON HEALTH PERSP, V114, P1508, DOI 10.1289/ehp.9175; PRINS GS, 2010, ENV IMPACTS REPROD H, P194; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins G.S, 2008, ENDOCR-RELAT CANCER, V16, P649; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Roy P, 2004, J STEROID BIOCHEM, V88, P157, DOI 10.1016/j.jsbmb.2003.11.005; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Safe Stephen, 2002, Rev Environ Health, V17, P253; Schreurs RHMM, 2005, TOXICOL LETT, V156, P261, DOI 10.1016/j.toxlet.2004.11.014; SHAIN SA, 1977, TOXICOL APPL PHARM, V40, P115, DOI 10.1016/0041-008X(77)90123-5; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; Shono T, 2004, J PEDIATR SURG, V39, P217, DOI 10.1016/j.jpedsurg.2003.10.014; SIMIC B, 1991, B ENVIRON CONTAM TOX, V46, P92; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Skakkebaek NE, 1998, APMIS, V106, P3; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; SRINIVASAN K, 1988, B ENVIRON CONTAM TOX, V41, P531; STEHRGREEN PA, 1989, J TOXICOL ENV HEALTH, V27, P405; Stoica GE, 2003, ONCOGENE, V22, P7998, DOI 10.1038/sj.onc.1206769; Swan SH, 1997, ENVIRON HEALTH PERSP, V105, P1228; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P1478, DOI 10.1289/ehp.6417; Swan SH, 2006, INT J ANDROL, V29, P62, DOI 10.1111/j.1365-2605.2005.00620.x; SWERDLOFF R, 2010, HDB ANDROLOGY; Takeo J, 1999, J BIOL CHEM, V274, P5674, DOI 10.1074/jbc.274.9.5674; Tamura H, 2006, BIOORGAN MED CHEM, V14, P7160, DOI 10.1016/j.bmc.2006.06.064; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Touhata K, 1999, BBA-MOL CELL RES, V1450, P481, DOI 10.1016/S0167-4889(99)00055-5; *US EPA, 1984, PEST FACT SHEET LIN; Veeramachaneni DNR, 2008, ANIM REPROD SCI, V105, P144, DOI 10.1016/j.anireprosci.2007.11.020; Vinggaard AM, 2008, CHEM RES TOXICOL, V21, P813, DOI 10.1021/tx7002382; WALISZEWSKI SM, 1995, B ENVIRON CONTAM TOX, V55, P43; Waller CL, 1996, TOXICOL APPL PHARM, V137, P219, DOI 10.1006/taap.1996.0075; Watson WH, 2007, TOXICOL SCI, V98, P1, DOI 10.1093/toxsci/kfm111; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wetherill YB, 2005, CANCER RES, V65, P54; Williams K, 2001, HUM REPROD UPDATE, V7, P236, DOI 10.1093/humupd/7.3.236; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; You L, 1999, TOXICOL APPL PHARM, V161, P258, DOI 10.1006/taap.1999.8804; Yu D, 2004, PROSTATE, V59, P370, DOI 10.1002/pros.20010; ZIRKIN BR, 2010, HDB ANDROLOGY14628PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMOCTSIDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism841WV</notes>
    <keywords>AGENTS; ALTERS SEXUAL-DIFFERENTIATION; Androgen; ANDROGEN RECEPTOR; Androgen-disruptor; androgens; Anti-androgen; ANTI-ANDROGENS; Antiandrogen; BIOLOGY; BISPHENOL-A ALTERS; CANCER; CELL; CHEMICALS; DDT; Differentiation; DISRUPTING CHEMICALS; EDC; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL CHEMICALS; Epidemiology; EXPOSURE; GROWTH; HEALTH; IMPACT; in silico; In vitro; IN-UTERO EXPOSURE; IN-VITRO; IN-VIVO; LIGAND; Male; METABOLISM; MODEL; MODELS; PESTICIDES; POLYCHLORINATED-BIPHENYLS; Prostate; prostate cancer; PROSTATE-CANCER; PROSTATE-CANCER MORTALITY; RAT VENTRAL PROSTATE; RECEPTOR; REPRODUCTIVE DEVELOPMENT; REPRODUCTIVE-TRACT; SEMEN QUALITY; SENSITIVITY; SEXUAL-DIFFERENTIATION; SPERM COUNTS; TESTICULAR DYSGENESIS; TESTICULAR DYSGENESIS SYNDROME; toxicology; Vinclozolin; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>74</startpage>
    <endpage>82</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <issue>1-2</issue>
    <volume>127</volume>
    <abstract>Androgen-disruptors are environmental chemicals in that interfere with the biosynthesis, metabolism or action of endogenous androgens resulting in a deflection from normal male developmental programming and reproductive tract growth and function. Since male sexual differentiation is entirely androgen-dependent, it is highly susceptible to androgen-disruptors. Animal models and epidemiological evidence link exposure to androgen disrupting chemicals with reduced sperm counts, increased infertility, testicular dysgenesis syndrome, and testicular and prostate cancers. Further, there appears to be increased sensitivity to these agents during critical developmental windows when male differentiation is at its peak. A variety of in vitro and in silico approaches have been used to identify broad classes of androgen disrupting molecules that include organochlorinated pesticides, industrial chemicals, and plasticizers with capacity to ligand the androgen receptor. The vast majority of these synthetic molecules act as anti-androgens. This review will highlight the evidence for androgen disrupting chemicals that act through interference with the androgen receptor, discussing specific compounds for which there is documented in vivo evidence for male reproductive tract perturbations. This article is part of a Special Issue entitled 'Endocrine disruptors'. (C) 2011 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000296546800011</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>156</id>
    <title>Endocrine Disruptors and the Breast: Early Life Effects and Later Life Disease</title>
    <authors>Macon,M.B.; Fenton,S.E.</authors>
    <availability>[Macon, Madisa B.] Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC USA. [Macon, Madisa B.; Fenton, Suzanne E.] NIEHS, NTP Labs, Div Natl Toxicol Program, NIH, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2013</date>
    <notes>JEnglishReviewFenton, SE (reprint author), NIEHS, NTP Labs, Div Natl Toxicol Program, NIH, 111 TW Alexander Dr,Bldg 101,MD E1-08, Res Triangle Pk, NC 27709 USAfentonse@niehs.nih.govAgas D, 2007, J CELL BIOCHEM, V101, P543, DOI 10.1002/jcb.21212; Agency for Toxic Substances and Disease Registry, TOX PROF ATR; American Cancer Society, 2011, BREAST CANC FACTS FI; American Cancer Society, 2012, BREAST CANC OV; [Anonymous], 2012, END DISR RES; Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; ARCHER FL, 1968, CANCER RES, V28, P217; Bandera EV, 2011, SCI TOTAL ENVIRON, V409, P5221, DOI 10.1016/j.scitotenv.2011.09.029; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Bhat KPL, 2001, CANCER RES, V61, P7456; Bhattacharya P, 2012, TOXICOL APPL PHARM, V261, P227, DOI 10.1016/j.taap.2012.04.009; BIEGEL LB, 1995, TOXICOL APPL PHARM, V134, P18, DOI 10.1006/taap.1995.1164; Boffetta P, 2011, CRIT REV TOXICOL, V41, P622, DOI 10.3109/10408444.2011.560141; Bonefeld-Jorgensen EC, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-88; Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Buckley Jill, 2006, Environ Health, V5, P4, DOI 10.1186/1476-069X-5-4; Buttke DE, 2012, ENVIRON HEALTH PERSP, V120, P1613, DOI 10.1289/ehp.1104748; Calafat AM, 2007, ENVIRON HEALTH PERSP, V115, P1596, DOI 10.1289/ehp.10598; Calafat AM, 2007, ENVIRON SCI TECHNOL, V41, P2237, DOI 10.1021/es062686m; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; CDC Centers for Disease Control and Prevention, 2012, CANC WOM; Chaffin CL, 1996, BIOL REPROD, V55, P62, DOI 10.1095/biolreprod55.1.62; Chan MY, 2010, MOL CELL ENDOCRINOL, V317, P8, DOI 10.1016/j.mce.2009.11.012; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Crinnion WJ, 2010, ALTERN MED REV, V15, P190; DERODRIGUEZ CAS, 1985, J PEDIATR, V107, P393; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; DeWitt JC, 2008, ENVIRON HEALTH PERSP, V116, P644, DOI 10.1289/ehp.10896; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dixon D, 2012, REPROD TOXICOL, V33, P506, DOI 10.1016/j.reprotox.2011.10.011; Dobrzyiska MM, 2011, BIOMED ENVIRON SCI, V24, P569, DOI 10.3967/0895-3988.2011.05.017; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Eldridge JC, 1999, STEROIDS, V64, P672, DOI 10.1016/S0039-128X(99)00051-3; Enoch RR, 2007, ENVIRON HEALTH PERSP, V115, P541, DOI 10.1289/ehp.9612; Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005; FARA GM, 1979, LANCET, V2, P295; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Fertuck KC, 2001, TOXICOL LETT, V121, P167, DOI 10.1016/S0378-4274(01)00344-7; Foradori CD, 2009, BIOL REPROD, V81, P1099, DOI 10.1095/biolreprod.109.077453; Franczak A, 2006, BIOL REPROD, V74, P125, DOI 10.1095/biolreprod.105.044396; Frisbee SJ, 2009, ENVIRON HEALTH PERSP, V117, P1873, DOI 10.1289/ehp.0800379; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; Fukamachi K, 2004, CANCER SCI, V95, P404, DOI 10.1111/j.1349-7006.2004.tb03223.x; Gammon DW, 2005, PEST MANAG SCI, V61, P331, DOI 10.1002/ps.1000; Gooderham NJ, 2002, MUTAT RES-FUND MOL M, V506, P91, DOI 10.1016/S0027-5107(02)00155-0; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; GRAY LE, 1995, TOXICOL APPL PHARM, V131, P108, DOI 10.1006/taap.1995.1052; Hakkak R, 2000, CANCER EPIDEM BIOMAR, V9, P113; Henry LA, 2006, DEV NEUROSCI-BASEL, V28, P186, DOI 10.1159/000091916; Henry ND, 2013, J APPL TOXICOL, V33, P265, DOI 10.1002/jat.1736; Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584; Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089; Innes KE, 1999, EPIDEMIOLOGY, V10, P722, DOI 10.1097/00001648-199911000-00013; ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jefferson WN, 2007, REPROD TOXICOL, V23, P308, DOI 10.1016/j.reprotox.2006.11.012; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Johnson NA, 2012, ENVIRON HEALTH PERSP, V120, P1170, DOI 10.1289/ehp.1104327; Juan ME, 2002, J NUTR, V132, P257; Kamrin MA, 2009, J TOXICOL ENV HEAL B, V12, P157, DOI 10.1080/10937400902729226; Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1995, DOI 10.1080/15287390491008913; Kawaguchi H, 2009, VET PATHOL, V46, P142, DOI 10.1354/vp.46-1-142; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; Kim IY, 2004, J TOXICOL ENV HEAL A, V67, P2025, DOI 10.1080/15287390490514750; Knox SS, 2011, J CLIN ENDOCR METAB, V96, P1747, DOI 10.1210/jc.2010-2401; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; KUIPERGOODMAN T, 1987, REGUL TOXICOL PHARM, V7, P253, DOI 10.1016/0273-2300(87)90037-7; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237; Latendresse JR, 2009, REPROD TOXICOL, V28, P342, DOI 10.1016/j.reprotox.2009.04.006; Lau C, 2006, TOXICOL SCI, V90, P510, DOI 10.1093/toxsci/kfj105; Lauber SN, 2004, CARCINOGENESIS, V25, P2509, DOI 10.1093/carcin/bgh268; LeBlanc GA, 2004, TXB MODERN TOXICOLOG, P299, DOI 10.1002/0471646776.ch17; Levi F, 2005, EUR J CANCER PREV, V14, P139, DOI 10.1097/00008469-200504000-00009; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lightfoot TJ, 2000, MUTAT RES-GEN TOX EN, V472, P119, DOI 10.1016/S1383-5718(00)00134-0; Lipworth L, 1999, BRIT J CANCER, V79, P7, DOI 10.1038/sj.bjc.6690003; Lopez-Carrillo L, 2010, ENVIRON HEALTH PERSP, V118, P539, DOI 10.1289/ehp.0901091; Lopez-Espinosa MJ, 2011, ENVIRON SCI TECHNOL, V45, P8160, DOI 10.1021/es1038694; Lou IC, 2009, TOXICOL SCI, V107, P331, DOI 10.1093/toxsci/kfn234; Macon MB, 2011, TOXICOL SCI, V122, P134, DOI 10.1093/toxsci/kfr076; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Manuwald U, 2012, OCCUP ENVIRON MED, V69, P636, DOI [10.1136/oemed-2012-100682, 10.1136/oemed-2011-100682]; Markey CM, 2001, BIOL REPROD, V65, P1215; Massart F, 2010, INT J ANDROL, V33, P369, DOI 10.1111/j.1365-2605.2009.01009.x; Molina-Molina JM, 2006, TOXICOL APPL PHARM, V216, P44, DOI 10.1016/j.taap.2006.04.005; Molzberger AF, 2012, MOL NUTR FOOD RES, V56, P399, DOI 10.1002/mnfr.201100371; Monosson E, 1999, TOXICOL IND HEALTH, V15, P65; Moral R, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-5; Moral R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-453; MORI T, 1976, J NATL CANCER I, V57, P1057; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Muto T, 2001, J TOXICOL PATHOL, V14, P213, DOI 10.1293/tox.14.213; Muto T, 2002, TOXICOLOGY, V177, P197, DOI 10.1016/S0300-483X(02)00224-X; Mylchreest E, 1998, TOXICOL SCI, V43, P47, DOI 10.1093/toxsci/43.1.47; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; National Cancer Institute, 2011, COST CAR; National Toxicology Program, REP CARC; National Toxicology Program, 2012, NOM TEST PROGR; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Oenga GN, 2004, TOXICOL IN VITRO, V18, P811, DOI 10.1016/j.tiv.2004.04.004; Ogura I, 2004, ENVIRON SCI TECHNOL, V38, P3279, DOI 10.1021/es0354622; Olsen GW, 2007, ENVIRON HEALTH PERSP, V115, P1298, DOI 10.1289/ehp.10009; Ortega I, 2012, FERTIL STERIL, V98, P1563, DOI 10.1016/j.fertnstert.2012.08.004; Ozen S, 2012, ENVIRON MONIT ASSESS, V184, P4223, DOI 10.1007/s10661-011-2257-6; Pei RJ, 2003, IN VIVO, V17, P349; Post GB, 2012, ENVIRON RES, V116, P93, DOI 10.1016/j.envres.2012.03.007; Pottenger LH, 2000, TOXICOL SCI, V54, P3, DOI 10.1093/toxsci/54.1.3; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provinciali M, 2005, INT J CANCER, V115, P36, DOI 10.1002/ijc.20874; Quignot N, 2012, REPROD TOXICOL, V33, P339, DOI 10.1016/j.reprotox.2012.01.004; Rayner JL, 2011, ENVIRONMENT AND BREAST CANCER, P167, DOI 10.1007/978-1-4419-9896-5_9; Rayner JL, 2005, TOXICOL SCI, V87, P255, DOI 10.1093/toxsci/kfi213; Restum JC, 1998, J TOXICOL ENV HEAL A, V54, P343; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rider CV, 2009, TOXICOL PATHOL, V37, P100, DOI 10.1177/0192623308329478; ROBISON AK, 1985, TOXICOL LETT, V27, P109, DOI 10.1016/0378-4274(85)90127-4; ROTHSCHILD TC, 1987, CANCER RES, V47, P4508; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P1053, DOI 10.1289/ehp.1002864; Saad HE, 2011, REPROD TOXICOL, V32, P15, DOI 10.1016/j.reprotox.2011.03.001; Safe SH, 1998, ENVIRON HEALTH PERSP, V106, P1051, DOI 10.2307/3434151; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; Sibinski L, 1987, 2 YEAR ORAL DIET TOX; Soto AM, 2011, BIOESSAYS, V33, P332, DOI 10.1002/bies.201100025; Stanko JP, 2010, REPROD TOXICOL, V30, P540, DOI 10.1016/j.reprotox.2010.07.006; Stevens JT, 1999, J TOXICOL ENV HEAL A, V56, P69, DOI 10.1080/009841099158169; Stoker TE, 2000, TOXICOL SCI, V58, P50, DOI 10.1093/toxsci/58.1.50; Su Y, 2007, CARCINOGENESIS, V28, P1046, DOI 10.1093/carcin/bgl240; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109; Thayer KA, MECH ACTION BISPHENO; Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461; Trock BJ, 2006, J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102; US Environmental Protection Agency, ATR HAZ DOS RESP ASS; U.S. Environmental Protection Agency, 2011, TSCA CHEM SUBST INV; US Environmental Protection Agency, RED FACTS VINCL; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Van den Berg M, 2006, TOXICOL SCI, V93, P223, DOI 10.1093/toxsci/kfl055; Vineis P, 2010, CARCINOGENESIS, V31, P1703, DOI 10.1093/carcin/bgq087; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625; White SS, 2011, J STEROID BIOCHEM, V127, P16, DOI 10.1016/j.jsbmb.2011.03.011; White SS, 2009, REPROD TOXICOL, V27, P289, DOI 10.1016/j.reprotox.2008.11.054; White SS, 2011, ENVIRON HEALTH PERSP, V119, P1070, DOI 10.1289/ehp.1002741; White SS, 2007, TOXICOL SCI, V96, P133, DOI 10.1093/toxsci/kfl177; Whitsett TG, 2006, EXPERT REV ANTICANC, V6, P1699, DOI 10.1586/14737140.6.12.1699; Wickerham EL, 2012, ENVIRON INT, V47, P80, DOI 10.1016/j.envint.2012.06.007; Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145; Wu AH, 2002, CARCINOGENESIS, V23, P1491, DOI 10.1093/carcin/23.9.1491; Yang CF, 2009, REPROD TOXICOL, V27, P299, DOI 10.1016/j.reprotox.2008.10.003; Yuri T, 2006, ONCOL REP, V16, P1307; Zhao GP, 2011, ENVIRON SCI TECHNOL, V45, P1638, DOI 10.1021/es1026129; Zhao Y, 2012, REPROD TOXICOL, V33, P563, DOI 10.1016/j.reprotox.2012.02.004; Zhao Y, 2010, TOXICOL SCI, V115, P214, DOI 10.1093/toxsci/kfq030; Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.17241647SPRINGER/PLENUM PUBLISHERSNEW YORK233 SPRING ST, NEW YORK, NY 10013 USAJ MAMMARY GLAND BIOLMARSIDiscipline: Oncology; Endocrinology &amp; Metabolism; Physiology096YW</notes>
    <keywords>ADULT; ATRAZINE METABOLITE MIXTURE; Beaded duct; BISPHENOL-A ALTERS; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; CARCINOGENESIS; CELL; CHEMICALS; cosmetics; development; DISEASE; EDCs; ENDOCRINE; Endocrine disrupting compounds; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; ENVIRONMENTAL-FACTORS; Epidemiology; EXPOSURE; FEMALE REPRODUCTIVE-SYSTEM; FOOD; GLAND; HEALTH; Hormones; HUMANS; In vitro; IN-UTERO EXPOSURE; IN-VITRO; IN-VIVO; LONG-EVANS RATS; mammary gland; MAMMARY TISSUE; MAMMARY-GLAND; MAMMARY-GLAND DEVELOPMENT; mechanism; MECHANISMS; METABOLISM; MODEL; MODELS; oncology; PERFLUOROOCTANOIC ACID EXPOSURE; PHARMACEUTICALS; PREVENTION; RISK; SOCIETY; SOY PROTEIN ISOLATE; SPRAGUE-DAWLEY RATS; TISSUE; toxicology; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>43</startpage>
    <endpage>61</endpage>
    <journalfull>Journal of Mammary Gland Biology and Neoplasia</journalfull>
    <issue>1</issue>
    <volume>18</volume>
    <abstract>Breast cancer risk has both heritable and environment/lifestyle components. The heritable component is a small contribution (5-27 %), leaving the majority of risk to environment (e.g., applied chemicals, food residues, occupational hazards, pharmaceuticals, stress) and lifestyle (e.g., physical activity, cosmetics, water source, alcohol, smoking). However, these factors are not well-defined, primarily due to the enormous number of factors to be considered. In both humans and rodent models, environmental factors that act as endocrine disrupting compounds (EDCs) have been shown to disrupt normal mammary development and lead to adverse lifelong consequences, especially when exposures occur during early life. EDCs can act directly or indirectly on mammary tissue to increase sensitivity to chemical carcinogens or enhance development of hyperplasia, beaded ducts, or tumors. Protective effects have also been reported. The mechanisms for these changes are not well understood. Environmental agents may also act as carcinogens in adult rodent models, directly causing or promoting tumor development, typically in more than one organ. Many of the environmental agents that act as EDCs and are known to affect the breast are discussed. Understanding the mechanism(s) of action for these compounds will be critical to prevent their effects on the breast in the future</abstract>
    <url>WOS:000315442000005</url>
    <isbnorissn>1083-3021</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>170</id>
    <title>Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines</title>
    <authors>Mahmoud,M.F.; El Shazly,S.M.</authors>
    <availability>[Mahmoud, Mona F.; El Shazly, Shimaa M.] Zagazig Univ, Fac Pharm, Dept Pharmacol &amp; Toxicol, Zagazig 44519, Egypt.</availability>
    <date>2013</date>
    <notes>JEnglishArticleMahmoud, MF (reprint author), Zagazig Univ, Fac Pharm, Dept Pharmacol &amp; Toxicol, Zagazig 44519, Egyptmona_pharmacology@yahoo.comArany I, 2003, SEMIN NEPHROL, V23, P460, DOI 10.1016/S0270-9295(03)00089-5; Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BOWERS LD, 1980, CLIN CHEM, V26, P555; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Chaney SG, 2004, J INORG BIOCHEM, V98, P1551, DOI 10.1016/j.jinorgbio.2004.04.024; Curran WJ, 2002, ONCOLOGY-BASEL, V63, P29, DOI 10.1159/000067145; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; El-Hage J, 2005, INT ATH SOC S PPAR M; Faubel S, 2004, KIDNEY INT, V66, P2202, DOI 10.1111/j.1523-1755.2004.66010.x; Girnun GD, 2002, MOL ENDOCRINOL, V16, P2793, DOI 10.1210/me.2002-0020; Goldberg RB, 2005, DIABETES CARE, V28, P1547, DOI 10.2337/diacare.28.7.1547; Gupta R, 2012, PHARMACOL BIOCHEM BE, V102, P184, DOI 10.1016/j.pbb.2012.03.028; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hu H, J SURG RES IN PRESS; Hwang JN, 2005, AM J PHYSIOL-CELL PH, V288, pC899, DOI 10.1152/ajpcell.00474.2004; Ialenti A, 2005, MOL PHARMACOL, V67, P1620, DOI 10.1124/mol.104.004895; Inoue K, 2001, BIOCHEM BIOPH RES CO, V287, P727, DOI 10.1006/bbrc.2001.5640; Kim MG, 2010, J KOREAN MED SCI, V25, P557, DOI 10.3346/jkms.2010.25.4.557; Kong X, 2011, BIOL PHARM BULL, V34, P693; Lee S, 2006, NEPHROL DIAL TRANSPL, V21, P2096, DOI 10.1093/ndt/gfl194; Lubet RA, 2008, INT J CANCER, V123, P2254, DOI 10.1002/ijc.23765; Ma LJ, 2001, KIDNEY INT, V59, P1899, DOI 10.1046/j.1523-1755.2001.0590051899.x; Moharam M.E., 2010, J AM SCI, V6, P1; Na HK, 2003, BIOCHEM PHARMACOL, V66, P1381, DOI 10.1016/S0006-2952(03)00488-X; Ohga S, 2007, AM J PHYSIOL-RENAL, V292, pF1141, DOI 10.1152/ajprenal.00288.2005; Ozkaya O, 2010, RENAL FAILURE, V32, P368, DOI 10.3109/08860221003611729; Pasceri V, 2000, CIRCULATION, V101, P235; Ramesh G, 2002, J CLIN INVEST, V110, P835, DOI 10.1172/JCI200215606; Ramkalawan H, 2012, INFLAMMATION, V35, P1338, DOI 10.1007/s10753-012-9447-4; Raphael KL, 2009, AM J NEPHROL, V30, P468, DOI 10.1159/000242432; Reddy RC, 2008, NEOPLASIA, V10, P597, DOI 10.1593/neo.08134; Saleh S, 2009, CHEMOTHERAPY, V55, P399, DOI 10.1159/000262453; Sastry J, 2005, PEDIATR HEMAT ONCOL, V22, P441, DOI 10.1080/08880010590964381; SATOH K, 1978, CLIN CHIM ACTA, V90, P37; Shephard M.D., 1983, CLIN BIOCHEM REV, V4, P61; Somi MH, 2009, TRANSPL P, V41, P4105, DOI 10.1016/j.transproceed.2009.09.075; SORG DA, 1964, P SOC EXP BIOL MED, V115, P1131; SUGIYAMA Y, 1990, ARZNEIMITTEL-FORSCH, V40-1, P263; Tanaka Y, 2009, J THORAC CARDIOV SUR, V138, P744, DOI 10.1016/j.jtcvs.2009.04.019; Tawfik MK, 2012, EUR REV MED PHARMACO, V16, P600; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Tikoo K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-107; Vijay SK, 2009, ACTA DIABETOL, V46, P27, DOI 10.1007/s00592-008-0054-7; Yang FG, 2005, ACTA PHARMACOL SIN, V26, P753, DOI 10.1111/j.1745.7254.2005.00103.x; Yang HC, 2009, J AM SOC NEPHROL, V20, P2380, DOI 10.1681/ASN.2008111138; Yoshihara D, 2011, AM J PHYSIOL-RENAL, V300, pF465, DOI 10.1152/ajprenal.00460.2010471PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLJANDiscipline: Food Science &amp; Technology; Toxicology091VQ</notes>
    <keywords>ACTIVATED-RECEPTOR-GAMMA; ADENOCARCINOMA; ALPHA; Antagonist; BADGE; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOMA; CELL; CELLS; CISPLATIN; COMBINATION; diabetes; DIABETIC-RATS; Egypt; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; GENES; Inflammation; inhibition; INJURY; Interaction; LIGANDS; LINE; LINES; MODEL; MODELS; MOUSE MODEL; Neoplasia; Nephrotoxicity; Pioglitazone; POLYCYSTIC KIDNEY-DISEASE; PPAR; PPAR-gamma; RAT; RATS; RECEPTOR; ROSIGLITAZONE; toxicology; TUMOR-NECROSIS-FACTOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>114</startpage>
    <endpage>122</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <volume>51</volume>
    <abstract>Cisplatin-induced nephrotoxicity is a serious problem that limits its use in cancer treatment. The present study aimed to investigate the renal protective capacity of pioglitazone to reduce the cisplatin- induced nephrotoxicity. The underlying suggested mechanism(s) and whether this nephroprotective effect (if any) interferes with the cytotoxic effect of cisplatin on cancer cells were also investigated. Pioglitazone, Bisphenol A diglycidyl ether, BADGE, IP injected (Peroxisome proliferator- activated receptor gamma (PPAR-gamma) antagonist), or their combination were administered to rats one hour before cisplatin injection. Moreover, their effects on the cell viability of human renal adenocarcinoma cell models (ACHN) were studied. The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-alpha), nuclear factor kappa B (NF-kappa B) genes expression in cisplatin injected rats. It increased both renal reduced glutathione (GSH) content and PPAR-gamma gene expression. In contrast to the data obtained by prior administration of BADGE. Pioglitazone also potentiated the cytotoxic effect of cisplatin on human renal adenocarcinoma cells and this effect was abolished by BADGE co administration. In conclusion, these results suggested that pioglitazone protected against cisplatin- induced nephrotoxicity through its interaction with PPAR-gamma receptors and antioxidant effects. Furthermore, pioglitazone did not interfere but rather potentiated the cytotoxic effects of cisplatin on human renal adenocarcinoma cells. (C) 2012 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000315078300015</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>388</id>
    <title>Endocrine Disrupting Chemicals and Domestic Animals</title>
    <authors>Majdic,G.</authors>
    <availability>Univ Ljubljana, Ctr Anim Genom, Fac Vet, Ljubljana 1000, Slovenia.</availability>
    <date>2010</date>
    <notes>JEnglishReviewMajdic, G (reprint author), Univ Ljubljana, Ctr Anim Genom, Fac Vet, Gerbiceva 60, Ljubljana 1000, Sloveniagregor.majdic@vf.uni-lj.siAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; [Anonymous], 1992, ARCH DIS CHILD, V67, P892; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Berman NG, 1998, FERTIL STERIL, V69, P1160; BIBBO M, 1977, OBSTET GYNECOL, V49, P1; Boerjan ML, 2002, ANIM SCI, V74, P3; Bogh IB, 2001, THERIOGENOLOGY, V55, P131, DOI 10.1016/S0093-691X(00)00451-9; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BROWN LM, 1986, INT J EPIDEMIOL, V15, P164, DOI 10.1093/ije/15.2.164; Brucker-Davis F, 1998, THYROID, V8, P827, DOI 10.1089/thy.1998.8.827; Butler WR, 1998, J DAIRY SCI, V81, P2533; CARLSEN E, 1993, IRISH MED J, V86, P85; CARLSEN E, 1992, BRIT MED J, V305, P609; Chen Z, 2003, ARCH ANDROLOGY, V49, P369, DOI 10.1080/0145010390219700; Colborn T., 1992, CHEM INDUCED ALTERAT; Dang ZC, 2003, J BIOL CHEM, V278, P962, DOI 10.1074/jbc.M209483200; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dickerson SM, 2007, REV ENDOCR METAB DIS, V8, P143, DOI 10.1007/s11154-007-9048-y; Dobson H, 2007, REPROD DOMEST ANIM, V42, P17, DOI 10.1111/j.1439-0531.2007.00906.x; Fang H, 2003, CHEM RES TOXICOL, V16, P1338, DOI 10.1021/tx030011g; Fisch H, 1996, FERTIL STERIL, V65, P1009; Fowler PA, 2008, MOL HUM REPROD, V14, P269, DOI 10.1093/molehr/gan020; FRANK JD, J PEDIAT UROL, V6, P1; GILL WB, 1979, J UROLOGY, V122, P36; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71; Gore AC, 2002, J NEUROENDOCRINOL, V14, P814, DOI 10.1046/j.1365-2826.2002.00845.x; Greenlee AR, 2004, ENVIRON HEALTH PERSP, V112, P703, DOI 10.1289/ehp.6774; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; HAKULINEN T, 1986, ACTA PATHOL MICROB S, V94, P1; HARLEY VR, 1994, MOL REPROD DEV, V39, P184; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Hotchkiss AK, 2008, TOXICOL SCI, V105, P235, DOI 10.1093/toxsci/kfn030; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; IMAIZUMI Y, 1991, JPN J HUM GENET, V36, P275, DOI 10.1007/BF01910546; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Kitamura S, 2003, ENVIRON HEALTH PERSP, V111, P503, DOI 10.1289/ehp.5917; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154; Ljungvall K, 2005, THERIOGENOLOGY, V64, P1170, DOI 10.1016/j.theriogenology.2005.02.003; Maffini M.V., 2006, MOL CELL ENDOCRINOL, V179, P254; Majdic G, 1997, MOL CELL ENDOCRINOL, V127, P91, DOI 10.1016/S0303-7207(96)03998-6; Meijer GAL, 1999, J ENVIRON QUAL, V28, P1381; Mlynarcikova A, 2005, MOL CELL ENDOCRINOL, V244, P57, DOI 10.1016/j.mce.2005.02.009; Mlynarcikova A, 2007, ATLA-ALTERN LAB ANIM, V35, P71; Mocarelli P, 2008, ENVIRON HEALTH PERSP, V116, P70, DOI 10.1289/ehp.10399; Narayana K, 2005, MUTAT RES-GEN TOX EN, V588, P28, DOI 10.1016/j.mrgentox.2005.08.012; Newbold RR, 2007, MOL NUTR FOOD RES, V51, P912, DOI 10.1002/mnfr.200600259; OESTERLIND A, 1986, BRIT J CANCER, V53, P501; Okamura A, 2005, TOXICOLOGY, V213, P129, DOI 10.1016/j.tox.2005.05.015; Paulsen CA, 1996, FERTIL STERIL, V65, P1015; Pocar P, 2001, MOL REPROD DEV, V58, P411, DOI 10.1002/1098-2795(20010401)58:4&lt;411::AID-MRD8&gt;3.0.CO;2-R; Recio R, 2005, ENVIRON HEALTH PERSP, V113, P1160, DOI 10.1289/ehp.7374; Rignell-Hydbom A, 2005, ENVIRON HEALTH PERSP, V113, P175, DOI 10.1289/ehp.7252; Roche JF, 2000, ANIM REPROD SCI, V60, P703, DOI 10.1016/S0378-4320(00)00107-X; Royal M, 2000, VET J, V160, P53, DOI 10.1053/tvjl.1999.0450; Setchell BP, 1997, INT J ANDROL, V20, P209, DOI 10.1046/j.1365-2605.1997.00054.x; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Steinberg RM, 2008, BIOL REPROD, V78, P1091, DOI 10.1095/biolreprod.107.067249; Sweeney T, 2007, THERIOGENOLOGY, V67, P1068, DOI 10.1016/j.theriogenology.2006.12.010; Sweeney T, 2000, ENDOCRINOLOGY, V141, P2667, DOI 10.1210/en.141.7.2667; vanOs JL, 1997, J ANDROL, V18, P725; Wahl RL, 2009, ENVIRON RES, V109, P273, DOI 10.1016/j.envres.2008.10.012; Wojtowicz AK, 2007, J PHYSIOL PHARMACOL, V58, P873; Wright C, 2002, BIOL REPROD, V67, P1734, DOI 10.1095/biolreprod.101.002006650UNIV LJUBLJANA, VETERINARY FACULTYLJUBLJANAGERBICEVA 60, LJUBLJANA, 1000, SLOVENIASLOV VET RESDiscipline: Veterinary Sciences608NG</notes>
    <keywords>BISPHENOL-A; CANCER; CELL; CHEMICALS; Cryptorchidism; development; DISRUPTING CHEMICALS; domestic animals; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; ENDOCRINE DISRUPTORS; environment; ESTROGEN-RECEPTOR-BETA; Etiology; FOOD; HEALTH; HUMANS; In vitro; IN-UTERO EXPOSURE; IN-VITRO; Incidence; INCREASING INCIDENCE; Male; MALE REPRODUCTIVE HEALTH; PERFORMANCE; PESTICIDES; PHARMACEUTICALS; Plastics; POLYCHLORINATED-BIPHENYLS; POPULATION; Reproduction; REPRODUCTIVE HEALTH; Review; SEMEN QUALITY; SPERM COUNTS; STEROID-HORMONE PRODUCTION; SYSTEM; TESTICULAR CANCER; Thyroid; toxicology; UNITED-STATES; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>5</startpage>
    <endpage>11</endpage>
    <journalfull>Slovenian Veterinary Research</journalfull>
    <issue>1</issue>
    <volume>47</volume>
    <abstract>Endocrine disrupting chemical is a term for a wide range of chemicals that could affect development and/or function of endocrine system in animals. First reports about potential endocrine disrupting effects of certain chemicals in the environment were published almost twenty years ago, based on the reports about problems with sexual development/differentiation of certain wild animals living in heavily contaminated environments like certain lakes in Florida, US. Subsequent studies have shown potential endocrine disrupting effects for many different chemical substances, ranging from pesticides, plastics, pharmaceuticals and others, and currently there is no known structure/function relationship that would suggest whether certain chemical might have endocrine disrupting properties. However, almost all studies showing endocrine disrupting properties have been performed in vitro or with laboratory animals so there is no conclusive answer whether such chemicals might pose a threat for human and animal health in everyday life. Interesting, though, are observations that male reproductive health has detoriated in the last decades. There are several reports that incidence of hypospadias, cryptorchidism and testicular cancer has increased, although these reports with the exception of testicular cancer, are often disputed. Similarly, several reports suggest fall in semen quality in human males in the last several decades, although again, this reports are often disputed and since there are no large prospective studies, we do not have a conclusive answer whether there really are any adverse effects occurring with human reproductive health. If such reports are reflecting real situation and if endocrine disrupting chemicals are involved in the etiology of such problems, one would expect similar trends to be observed also in domestic animals, which are usually exposed to similar environment as humans. However, there are very few studies systematically and chronologically examining reproductive health of domestic animals. Two published studies examined bull semen quality and could not detect detoriating quality. However, bulls in breeding centers are selected for their reproductive performance and therefore do not represent a situation in the normal population</abstract>
    <url>WOS:000278590400001</url>
    <isbnorissn>1580-4003</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>214</id>
    <title>Perinatal ethinyl oestradiol alters mammary gland development in male and female Wistar rats</title>
    <authors>Mandrup,K.R.; Hass,U.; Christiansen,S.; Boberg,J.</authors>
    <availability>[Mandrup, K. R.; Hass, U.; Christiansen, S.; Boberg, J.] Tech Univ Denmark, Div Toxicol &amp; Risk Assessment, Natl Food Inst, DK-2860 Soborg, Denmark.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMandrup, KR (reprint author), Tech Univ Denmark, Div Toxicol &amp; Risk Assessment, Natl Food Inst, Morkhoj Bygade 19, DK-2860 Soborg, Denmarkkaman@food.dtu.dkAnderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; Brody JG, 2011, ENVIRON HEALTH PERSP, V119, pA326, DOI 10.1289/ehp.1104077; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Clarke RB, 2003, STEROIDS, V68, P789, DOI 10.1016/S0039-128X(03)00122-3; Cotroneo MS, 2002, CARCINOGENESIS, V23, P1467, DOI 10.1093/carcin/23.9.1467; Fenton SE, 2006, ENDOCRINOLOGY, V147, P18; Fielden MR, 2002, TOXICOL LETT, V133, P181, DOI 10.1016/S0378-4274(02)00154-6; Foster WG, 2004, TOXICOL SCI, V77, P91, DOI 10.1093/toxsci/kfg247; Goldman JM, 2000, CRIT REV TOXICOL, V30, P135, DOI 10.1080/10408440091159185; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; HilakiviClarke L, 1997, J CELL PHYSIOL, V170, P279, DOI 10.1002/(SICI)1097-4652(199703)170:3&lt;279::AID-JCP9&gt;3.0.CO;2-L; Hodgson NCF, 2004, ANN SURG ONCOL, V11, P751, DOI 10.1245/ASO.2004.01.001; Hovey RC, 2010, TOXICOL SCI, V119, P380; Hovey RC, 2005, BIOL REPROD, V72, P423, DOI 10.1095/biolreprod.104.029769; Howdeshell KL, 2008, TOXICOL SCI, V102, P371, DOI 10.1093/toxsci/kfm306; Hvid H, 2011, EXP TOXICOL PATHOL, V63, P317, DOI 10.1016/j.etp.2010.02.005; Latendresse JR, 2009, REPROD TOXICOL, V28, P342, DOI 10.1016/j.reprotox.2009.04.006; Makris SL, 2010, ENV HLTH PERSPECT, V119, P1047, DOI 10.1289/ehp.1002676; Masutomi N, 2004, REPROD TOXICOL, V18, P23, DOI 10.1016/j.reprotox.2003.10.004; Medina D, 2005, ENDOCR-RELAT CANCER, V12, P483, DOI 10.1677/erc.1.00804; Moon HJ, 2007, J REPROD DEVELOP, V53, P333, DOI 10.1262/jrd.18055; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Mouritsen A, 2010, INT J ANDROL, V33, P346, DOI 10.1111/j.1365-2605.2010.01051.x; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Ninomiya K, 2007, TOXICOL PATHOL, V35, P811, DOI 10.1080/01926230701584205; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; Rayner JL, 2005, TOXICOL SCI, V87, P255, DOI 10.1093/toxsci/kfi213; Rayner JL, 2004, TOXICOL APPL PHARM, V195, P23, DOI 10.1016/j.taap.2003.11.005; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P1053, DOI 10.1289/ehp.1002864; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; RUSSO J, 1979, AM J PATHOL, V96, P721; Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074; Schedin P, 2000, J MAMMARY GLAND BIOL, V5, P211, DOI 10.1023/A:1026447506666; SINHA DK, 1983, INT J CANCER, V31, P321, DOI 10.1002/ijc.2910310312; Speirs V, 2009, BREAST CANCER RES TR, V115, P429, DOI 10.1007/s10549-008-0053-y; Takagi H, 2004, REPROD TOXICOL, V18, P687, DOI 10.1016/j.reprotox.2004.03.002; Tan KP, 2004, EXP BIOL MED, V229, P147; Thomsen AR, 2006, TOXICOL SCI, V93, P357, DOI 10.1093/toxsci/kfl029; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; Wang WJ, 2006, TOXICOL SCI, V91, P93; You L, 2002, TOXICOL SCI, V66, P216, DOI 10.1093/toxsci/66.2.216424WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAINT J ANDROLJUNDiscipline: Endocrinology &amp; Metabolism946IB</notes>
    <keywords>ALTERS; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CHEMICALS; development; Dietary Exposure; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruption; Endocrine-disrupting chemicals; environmental exposure; ethinyl oestradiol; EXPOSURE; female; FEMALE RATS; FOOD; genistein; GLAND; GLAND DEVELOPMENT; GROWTH; HEALTH; IN-UTERO; JUN; LACTATIONAL EXPOSURE; Male; MALE BREAST-CANCER; MALE RATS; mammary gland; Mammary gland development; MAMMARY-GLAND; MAMMARY-GLANDS; METABOLISM; morphology; NEONATAL EXPOSURE; oestrogen; oestrogens; PERINATAL EXPOSURE; pre-pubertal; PRENATAL EXPOSURE; PUBLIC-HEALTH; RAT; RATS; REPRODUCTIVE TOXICITY; RISK; Risk assessment; RISK-ASSESSMENT; SUSCEPTIBILITY; terminal end buds; TOXICITY; whole mount; Wistar</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>385</startpage>
    <endpage>396</endpage>
    <journalfull>International Journal of Andrology</journalfull>
    <issue>3</issue>
    <volume>35</volume>
    <abstract>Increased attention is being paid to human mammary gland development because of concerns for environmental influences on puberty onset and breast cancer development. Studies in rodents have showed a variety of changes in the mammary glands after perinatal exposure to endocrine disrupting chemicals, indicating progressed development of mammary glands when exposed to oestrogens early in life. However, laboratories use different parameters to evaluate the development of mammary glands, making studies difficult to compare. Moreover, studies of whole mounts in Wistar rats are lacking. In the present study, Wistar rats were exposed to 0, 5, 15 or 50 mu g/kg of ethinyl oestradiol per day during gestation and lactation. A wide range of morphological parameters were evaluated in whole mounts of mammary glands from male and female offspring PD2122. This study showed that in both male and female pre-pubertal Wistar rats, mammary gland development was accelerated after perinatal oestrogen exposure with increase in size, density and number of terminal end buds (TEBs). In female rats, the most sensitive parameters were the distance to the fifth gland, the relative growth towards the lymph node and the overall density. The sensitive endpoints in male rats were TEB numbers, both in the whole gland and in the zone C, the overall- and the highest density. The overall density was sensitive in both male and female rats and was considered a good representative of both branching and budding of the gland. The number of TEBs in zone C was representative of the number of TEBs in the whole gland. Further studies in older Wistar rats and with weak oestrogenic compounds could be performed to validate mammary gland examination as an endpoint in reproductive toxicity studies and to examine how early life environmental exposures may alter mammary gland development, disrupt lactation and alter susceptibility to breast cancer</abstract>
    <url>WOS:000304343800018</url>
    <isbnorissn>0105-6263</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>307</id>
    <title>Chemical Pollutants Threatening Food Safety and Security: An Overview</title>
    <authors>Mansour,S.A.</authors>
    <availability>Natl Res Ctr, Dept Pesticide Chem, Environm Toxicol Res Unit, Cairo, Egypt.</availability>
    <date>2011</date>
    <notes>SEnglishProceedings PaperMansour, SA (reprint author), Natl Res Ctr, Dept Pesticide Chem, Environm Toxicol Res Unit, Tahrir St, Cairo, Egyptsamansour@hotmail.comAbernethy DR, 2008, CLIN PHARMACOL THER, V85, P444; ADDIS PB, 1992, ACS SYM SER, V484, P346; Adeeko A, 2003, TOXICOL SCI, V74, P407, DOI 10.1093/toxsci/kfg131; [Anonymous], 2001, PERSISTENT ORGANIC P; apek P, 2010, TOXINS, V2, P24; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; Azzazy HME, 2009, CLIN CHIM ACTA, V403, P1, DOI 10.1016/j.cca.2009.01.016; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; Banati D, 2008, TRENDS FOOD SCI TECH, V19, P441, DOI 10.1016/j.tifs.2008.04.004; BANN B, 1958, CHEM REV, V58, P131, DOI 10.1021/cr50019a004; Barceloux D., 2008, MED TOXICOLOGY NATUR; Barr DB, 2003, ENVIRON HEALTH PERSP, V111, P1148, DOI 10.1289/ehp.6074; Beck JE, 2004, J FAM CONSUM SCI ED, V22, P1; Bendall JG, 2008, FOOD ADDIT CONTAM, V12, P1; Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003; Bhaskar ASB, 2008, TOXICOL IN VITRO, V22, P1902, DOI 10.1016/j.tiv.2008.09.013; BIBEROGLU S, 1988, JAMA-J AM MED ASSOC, V259, P1943; Bismuth C, 2004, TOXICOL LETT, V149, P11, DOI 10.1016/j.toxlet.2003.12.016; Bitsch N, 2002, ARCH ENVIRON CON TOX, V43, P257, DOI 10.1007/s00244-002-1192-5; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; Brown CA, 2007, J VET DIAGN INVEST, V19, P525; CDC (Centers for Disease Control and Prevention), 2003, NCEH PUB, V02-0716; Cianciolo RE, 2008, JAVMA-J AM VET MED A, V233, P729, DOI 10.2460/javma.233.5.729; Colborn T., 1996, OUR STOLEN FUTURE; Covaci A, 2002, SCI TOTAL ENVIRON, V45-53, P298; Croci L, 2003, FOOD SAFETY CONTAMIN; Darnerud PO, 2003, ENVIRON INT, V29, P841, DOI 10.1016/S0160-4120(03)00107-7; Darnerud PO, 2001, ENVIRON HEALTH PERSP, V109, P49, DOI 10.2307/3434846; Department of Health and Human Services, 2005, 3 DEP HLTH HUM SERV; De Rosa CT, 2006, ANN NY ACAD SCI, V1076, P829, DOI 10.1196/annals.1371.028; Dessi-Fulgheri F, 2002, ENVIRON HEALTH PERSP, V110, P403; DHHS, 1998, 8 US DEP HLTH HUM SE; Dobson RLM, 2008, TOXICOL SCI, V106, P251, DOI 10.1093/toxsci/kfn160; Doering DD, 2002, STEROIDS, V67, P859, DOI 10.1016/S0039-128X(02)00051-X; Dorner G, 2002, NEUROENDOCRINOL LETT, V23, P427; DOSTAL LA, 1987, TOXICOL APPL PHARM, V91, P315, DOI 10.1016/0041-008X(87)90054-8; Durocher J, 2003, RESTAUR BUS, V102, P90; Eckstein M, 2008, J EMERG MED, V35, P59, DOI 10.1016/j.jemermed.2007.03.040; EMMERSON BT, 1970, ANN INTERN MED, V73, P854; Eriksson P, 1997, NEUROTOXICOLOGY, V18, P719; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P409; Eurobarometer, 2006, RISK ISSUES SPECIAL; European Commission, 2006, ENV FACT SHEET REACH; FAO, 1998, DECL ROM SEG AL MUND; FDA, 2003, GUID IND RET FOOD ST; FLEMING HP, 1989, J FOOD SCI, V54, P636, DOI 10.1111/j.1365-2621.1989.tb04670.x; Food and Drug Administration (FDA), 2008, AN CLON RISK ASS; Friends of the Earth Europe, 2005, TOX INH MOR 300 POLL; FRIES GF, 1995, J ANIM SCI, V73, P1639; Gearhart J, 2006, TOXIC ANY SPEED CHEM; Gonzalez M, 2005, FOOD CHEM TOXICOL, V43, P261, DOI 10.1016/j.fct.2004.10.002; Gonzalez M, 2003, J AGR FOOD CHEM, V51, P1353, DOI 10.1021/jf025892w; Goodson A, 2002, FOOD ADDIT CONTAM, V19, P1; Gossner CME, 2009, ENVIRON HEALTH PERSP, V117, P1803, DOI 10.1289/ehp.0900949; Goyarts T, 2007, FOOD ADDIT CONTAM, V24, P369, DOI 10.1080/02652030600988038; Greenpeace, 2005, PERF INV CCHEMICALS; Greenpeace and WWF-UK, 2005, PRES LIF HAZ CHEM UM; Greenpeace Netherlands, 2004, CHEM FOOTPR BLOOD EV; Greenpeace-UK, 2003, CONS CHEM HAZ CHEM H; Guenther K, 2002, ENVIRON SCI TECHNOL, V36, P1676, DOI 10.1021/es010199v; Guvenius DM, 2003, ENVIRON HEALTH PERSP, V111, P1235, DOI 10.1289/ehp.5946; HAMMOND BG, 1986, ENVIRON HEALTH PERSP, V69, P287, DOI 10.2307/3430400; Hardell L, 1998, ONCOL RES, V10, P429; Harner T, 2006, ENVIRON POLLUT, V144, P445, DOI 10.1016/j.envpol.2005.12.053; Harrad S, 2004, ENVIRON SCI TECHNOL, V38, P2345, DOI 10.1021/es0301121; He J, 2009, TRENDS FOOD SCI TECH, V21, P67; Head T, 1994, SPECULUM, V69, P163; HECK HD, 1985, REGUL TOXICOL PHARM, V5, P294, DOI 10.1016/0273-2300(85)90044-3; Hooper K, 2003, ENVIRON HEALTH PERSP, V111, P109, DOI 10.1289/ehp.5438; Houlihan J., 2003, BODY BURDEN POLLUTIO; Howdeshell KL, 1999, NATURE, V401, P763; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Inoue K, 2000, J CHROMATOGR B, V749, P17, DOI 10.1016/S0378-4347(00)00351-0; IPCC, 2007, 3 IPCC; IPCS, 1999, TRIB OX INT PROGR CH; IUCLID, 2008, IUCLID CHEM DAT SHEE, P30; Kafferlein HU, 2001, INT ARCH OCC ENV HEA, V74, P470, DOI 10.1007/s004200100257; Kawai K, 2003, ENVIRON HEALTH PERSP, V111, P175, DOI 10.1289/ehp.5440; Kennaway EL, 1921, BIOCHEM J, V15, P510; Khan AS, 2001, PUBLIC HEALTH REP, V116, P3, DOI 10.1093/phr/116.1.3; Kleter GA, 2009, FOOD CHEM TOXICOL, V47, P932, DOI 10.1016/j.fct.2007.12.022; Koch HM, 2003, INT J HYG ENVIR HEAL, V206, P77, DOI 10.1078/1438-4639-00205; Kortepeter M, 2001, USAMRIIDS MED MANAGE; Kubo K, 2003, NEUROSCI RES, V45, P345, DOI 10.1016/S0168-0102(02)00251-1; Kumar V, 2008, CROP PROT, V27, P891, DOI 10.1016/j.cropro.2007.12.011; Kuroda N, 2003, J PHARMACEUT BIOMED, V30, P1743, DOI 10.1016/S0731-7085(02)00516-2; Lancova K, 2008, FOOD ADDIT CONTAM A, V25, P732, DOI 10.1080/02652030701779625; Lichtenstein EP, 1959, J AGR FOOD CHEM, V14, P62; Lo S, 2003, J STEROID BIOCHEM, V84, P569, DOI 10.1016/S0960-0760(03)00074-8; Lopez-Cervantes J, 2003, FOOD ADDIT CONTAM, V20, P596, DOI 10.1080/0265203031000109495; Maga JA, 1994, FOOD ADDITIVE TOXICO; Main KM, 2006, ENVIRON HEALTH PERSP, V114, P270, DOI 10.1289/ehp.8075; Mansour SA, 2009, CHEMOSPHERE, V75, P601, DOI 10.1016/j.chemosphere.2009.01.058; Mansour SA, 2009, FOOD CHEM TOXICOL, V47, P615, DOI 10.1016/j.fct.2008.12.019; Mansour SA, 2009, HUM EXP TOXICOL, V28, P531, DOI 10.1177/0960327109347048; Mantovani A, 2002, TOXICOLOGY, V181, P367, DOI 10.1016/S0300-483X(02)00468-7; Maranghi F, 2009, FOOD CHEM TOXICOL, V47, P472, DOI 10.1016/j.fct.2008.12.003; Maranghi F, 2010, CHEM-BIOL INTERACT, V183, P40, DOI 10.1016/j.cbi.2009.09.016; Mattina MJI, 2000, J AGR FOOD CHEM, V48, P1909, DOI 10.1021/jf990566a; Mazdai A, 2003, ENVIRON HEALTH PERSP, V111, P1249, DOI 10.1289/ehp.6146; Meerts IATM, 2000, TOXICOL SCI, V56, P95, DOI 10.1093/toxsci/56.1.95; Meironyte D, 1999, J TOXICOL ENV HEAL A, V58, P329, DOI 10.1080/009841099157197; Miraglia M, 2007, TOXICOL APPL PHARM, V223, P104; Miraglia M, 2009, FOOD CHEM TOXICOL, V47, P1009, DOI 10.1016/j.fct.2009.02.005; NTP, 1983, 245 NT TR NAT TOX PR; OECD (Organisation for economic co-operation and development), 2002, SIDS AN; Ohta S, 2002, CHEMOSPHERE, V46, P689, DOI 10.1016/S0045-6535(01)00233-8; O'Keeffe M, 1998, J FOOD SAFETY, V18, P297, DOI 10.1111/j.1745-4565.1998.tb00222.x; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Ozaki A, 2003, FOOD ADDIT CONTAM, V20, P92, DOI 10.1080/0265203021000014798; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; PARMAR D, 1985, DRUG METAB DISPOS, V13, P368; Paterson RRM, 2006, MYCOL RES, V110, P1003, DOI 10.1016/j.mycres.2006.04.004; Payne-Palacio J, 2001, W WOODS INTRO FOODSE; Peterson J., 2007, RADIOLOGICAL CHEM FA; Pittet A., 2001, MYCOTOXINS PHYCOTOXI, P153; Prewitt M, 2004, NATIONS RESTAURANT N, P62; Puschner B, 2007, J VET DIAGN INVEST, V19, P616; Rangan C, 2008, FOOD CONTAMINATION C, P5; Refai MK, 1988, J EGYPT VET MED ASS, V48, P1; Reimschuessel R, 2008, AM J VET RES, V69, P1217, DOI 10.2460/ajvr.69.9.1217; Reynolds D., 2003, ON SITE FOODSERVICE; Rhodehamel EJ, 1992, HACCP PRINCIPLES APP, P8; Rice DC, 2000, ENVIRON HEALTH PERSP, V108, P405, DOI 10.2307/3454528; RIMKUS G, 1994, CHEMOSPHERE, V28, P421, DOI 10.1016/0045-6535(94)90138-4; Rimkus GG, 1996, CHEMOSPHERE, V33, P2033, DOI 10.1016/0045-6535(96)00321-9; Rocha O, 2005, FOOD ADDIT CONTAM, V22, P369, DOI 10.1080/02652030500058403; Ropkins K, 2003, TRENDS FOOD SCI TECH, V14, P374, DOI 10.1016/S0924-2244(03)00057-8; Salim A, 2006, J AGR SCI MANSOURA U, V31, P1601; Schecter A, 2004, ENVIRON SCI TECHNOL, V38, P5306, DOI 10.1021/es0490830; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Schreurs RHMM, 2002, TOXICOL APPL PHARM, V183, P1, DOI 10.1006/taap.2002.9458; Schroter-Kermani, 2001, P 2 STAT SEM END DIS; Sedmikova M, 2001, VET MED-CZECH, V46, P169; Seeling K, 2006, FOOD ADDIT CONTAM, V23, P1008, DOI 10.1080/02652030600723245; Sekheta MA, 2005, INT J FOOD SAF, V6, P5; Sekheta M.A.F., 2006, INTERNET J FOOD SAFE, V8, P30; Sharma RK, 2008, ENVIRON POLLUT, V154, P254, DOI 10.1016/j.envpol.2007.10.010; Singh N P, 2000, J Assoc Physicians India, V48, P877; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Smith H, 1959, LANCET, V274, P1019, DOI 10.1016/S0140-6736(59)91486-2; Smith J., 2003, FOOD ADDITIVES DATA; Sobel J, 2002, LANCET, V359, P874, DOI 10.1016/S0140-6736(02)07947-3; Spears M. C., 2004, FOODSERVICE ORG MANA; SRIVASTAVA S, 1989, INDIAN J EXP BIOL, V27, P885; Steckelbroeck S, 2001, P 2 STAT SEM END DIS, P127; Stoker C, 2003, GEN COMP ENDOCR, V133, P287, DOI 10.1016/S0016-6480(03)00199-0; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Takada H, 1999, P INT SCI C ENV END; Takahashi S, 1999, ENVIRON POLLUT, V106, P213, DOI 10.1016/S0269-7491(99)00068-8; Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V291, P76, DOI 10.1006/bbrc.2002.6407; Thomsen C, 2002, ENVIRON SCI TECHNOL, V36, P1414, DOI 10.1021/es0102282; Trewavas A, 2004, CROP PROT, V23, P757, DOI 10.1016/j.cropro.2004.01.009; Trichopoulos D, 1997, CANCER PRINCIPLES PR; TRICKER AR, 1990, P NUTR SOC, V49, P133, DOI 10.1079/PNS19900019; Turkdogan M.K., 2002, ENVIRON TOXICOL PHAR, V13, P175, DOI DOI 10.1016/S1382-6689(02)00156-4; Tyan YC, 2009, ANAL BIOANAL CHEM, V395, P729, DOI 10.1007/s00216-009-3009-0; Uchida K, 2002, J HEALTH SCI, V48, P579, DOI 10.1248/jhs.48.579; United Nations, 2007, WORLD POP PROSP 2006; Valenta H, 2005, MOL NUTR FOOD RES, V49, P779, DOI 10.1002/mnfr.200500012; van Heijst APN, 1994, INT PROGRAMME CHEM S; Wagacha JM, 2008, INT J FOOD MICROBIOL, V124, P1, DOI 10.1016/j.ijfoodmicro.2008.01.008; Wary BB, 1981, NEW ENGL J MED, V305, P833; WHO, 2008, MEL CYAN AC TOX PREL; WHO, 2006, 062006 WHO INFOSAN; WHO, 2004, SAF EV CERT FOOD ADD, V52; WHO World Health Organization, 2009, TOX HLTH ASP MEL CYA; Woolf A, 2000, J TOXICOL-CLIN TOXIC, V38, P457, DOI 10.1081/CLT-100100958; World Wide Fund for Nature (WWF), 2007, WWF POS BIOF EU, P5; *WWF, 2004, CHEM CHECK AN CHEM B; WWF International Arctic Programme, 2005, TIP IC CHEM CONT ARC; WWF International Arctic Programme and WWF-DetoX, 2006, KILL THEM SOFTL HLTH; WWF-UK, 2003, CONT RES WWFS BIOM S; WWF-UK, 2004, COMPR CHILDR CHEM IM; WWF-UK, 2006, CHAIN CONT FOOD LINK; WWF-UK, 2004, CONT NEXT GEN; WWF-UK, 2005, GEN 10; WWF-UK and Greenpeace, 2005, PRES LIF HAZ CHEM UM; Yamasaki H, 2001, NEPHRON, V88, P376, DOI 10.1159/000046023; Zaidi M. I., 2005, Journal of Applied Sciences, V5, P708; Zohair A, 2006, CHEMOSPHERE, V63, P541, DOI 10.1016/j.chemosphere.2005.09.0121814SPRINGERDORDRECHTPO BOX 17, 3300 AA DORDRECHT, NETHERLANDSNATO SCI PEACE SEC ADiscipline: Food Science &amp; TechnologyBXZ09</notes>
    <keywords>AGENTS; Benzophenone; BISPHENOL-A CONCENTRATIONS; BLOOD; BREAST-MILK; BROMINATED FLAME RETARDANTS; CADMIUM; CANCER; Chemical contaminants; CHEMICALS; CHILDREN; CYANURIC ACID; Deliberate contamination (Terrorist); development; DI(2-ETHYLHEXYL)PHTHALATE DEHP; DIOXIN; DIOXINS; DIPHENYL ETHERS; DISEASE; diseases; DISORDERS; Egypt; ENDOCRINE; environment; EXPOSURE; female; FOOD; Food chain; Food contaminant; food safety; FOODS; GROWTH; Hazard analyses and critical control points (HACCP); HEALTH; HUMAN ADIPOSE-TISSUE; HUMAN HEALTH; HUMAN-MILK; Immune; IMMUNE-SYSTEM; In vitro; IN-VITRO; INDUSTRY; Intentional contamination; Interaction; Male; mechanism; MEDIA; Melamine adulteration incident; Metals; ORGANIZATION; P8; PERFLUOROOCTANOIC ACID; PERFORMANCE LIQUID-CHROMATOGRAPHY; PERSISTENT ORGANIC POLLUTANTS; PESTICIDES; POLLUTANTS; POLYBROMINATED DIPHENYL ETHERS; POLYCHLORINATED-BIPHENYLS; PREVENTION; PRINCIPLES; PRODUCTS; REGULATORS; RISK; Steroid; SUPPRESSION; synergistic effects; SYSTEM; toxicology; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>73</startpage>
    <endpage>117</endpage>
    <journalfull>Advances in Food Protection: Focus on Food Safety and Defense</journalfull>
    <abstract>Food passing several stages in the long and sophisticated food chain processing (from farm to fork) before being consumed and in each stage can cause morbidity and mortality, and also destruction to food industry. This is because food is a vulnerable media for contamination by thousands of biological, chemical and physical agents, and radio nuclear materials. Such contamination may occur intentionally or unintentionally far of "intended crime." On the other side, food may deliberately contaminate within "intended terroristic crime." Food and water contamination remains the easiest way to distribute toxic agents for the purpose of terrorism. Intentional contamination of food and water supplies by such harmful agents for terrorist purpose is a real and current threat to consumer's health. This presentation addresses the chemical contamination of foods. Unlike most microbiological agents, chemical contaminants present in foods are often unaffected by thermal processing. They can be classified according to the source of contamination and the mechanism by which they enter the food product. They include a wide range of agrochemicals used in agricultural practices and animal husbandry with the intent to increase crops and reduce costs. Such agents include pesticides (e.g. insecticides, herbicides, rodenticides), plant growth regulators, veterinary drugs (e.g. nitrofuran, fluoroquinolones, malachite green, chloramphenicol), and bovine somatotropin (rBST). Moreover, food can be contaminated by chemicals that are present in the environment in which the food is grown, harvested, transported, stored, packaged, processed, and consumed. Possible contaminants include radio nuclides (e.g., cesium, strontium), heavy metals (e.g., arsenic, mercury, cadmium, copper), persistent organic pollutants, [e.g., polycyclic aromatic hydrocarbons (PAH), polychlorinated biphenyls (PCBs), dioxins, polybrominated diphenyl ethers (PBDE), acrylamide, furan, perchlorate], as well as numerous substances attributed to packaging materials [e.g., antimony, tin, lead, perfluorooctanoic acid (PFOA), semicarbazide, benzophenone, isopropylthioxanthone (ITX), bisphenol-A]. At present, melamine represents one of the largest deliberate food contaminant. Increasing incidences of cancer, chronic kidney diseases, suppression of the immune system, sterility among males and females, endocrine disorders, neurological and behavioral disorders, especially among children, have been attributed to chronic exposure to toxic chemicals and/or long-term consumption of food contaminated with such chemicals. Chronic exposure to food chemical contaminants may adversely affect human health even at contamination levels below MRLs (maximum residue limits) of each chemical. Furthermore, exposure through food to different contaminants may lead to additive or synergistic effects, a matter which poses an urgent need to improve our knowledge on such possible interactions at the intestinal level. Sophisticated analytical tools needed for detection of some chemical compounds, such as dioxins and nanoparticle materials, are not available in many countries, a matter which requires assisting these countries to raise their capacity building in this concern. On the other side, there is an urgent need for establishing a Security Plan Development (SPD) which can be realized easily and efficiently by implementing the principles of hazard analyses and critical control points (HACCP). In conclusion, although unintentional contamination of food could be controlled by local regulations, intentional contamination for the purpose of "terrorism" should be faced internationally and early as soon as multinational consequences are expected. Coordination between food-safety authorities worldwide is needed to efficiently exchange information and to enable tracking and recalling of affected products to ensure food safety and to protect public health. Cooperation between countries has to be activated and exchanging information is something very important to minimize threat and contamination on national, regional and international levels. Prevention and response are the two major strategies for countering the threat of food terrorist, and they are everyone's responsibility all over the world in such manner</abstract>
    <url>WOS:000297656400006</url>
    <isbnorissn>1874-6489</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>237</id>
    <title>Endocrine disrupters: from research to public health practice</title>
    <authors>Mantovani,A.; Baldi,F.</authors>
    <availability>[Mantovani, Alberto; Baldi, Francesca] Ist Super Sanita, Dipartimento Sanit Pubbl Vet &amp; Sicurezza Aliment, Reparto Tossicol Alimentare &amp; Vet, I-00161 Rome, Italy.</availability>
    <date>2012</date>
    <notes>JItalianReviewMantovani, A (reprint author), Ist Super Sanita, Dipartimento Sanit Pubbl Vet &amp; Sicurezza Aliment, Reparto Tossicol Alimentare &amp; Vet, Viale Regina Elena 299, I-00161 Rome, Italyalberto.mantovani@iss.itAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; [Anonymous], 2008, EFSA J, V653, P1; Baldi F, 2008, ANN I SUPER SANITA, V44, P57; Blystone CR, 2009, TOXICOL SCI, V111, P179, DOI 10.1093/toxsci/kfp137; Calamandrei G, 2006, REPROD TOXICOL, V22, P164, DOI 10.1016/j.reprotox.2006.04.003; Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200; Caserta D, 2008, HUM REPROD UPDATE, V14, P59, DOI 10.1093/humupd/dmm025; Caserta D, 2011, HUM REPROD UPDATE, V17, P418, DOI 10.1093/humupd/dmq061; Cerrillo I, 2006, CHEMOSPHERE, V62, P1917, DOI 10.1016/j.chemosphere.2005.07.024; Charles GD, 2007, TOXICOL APPL PHARM, V218, P280, DOI 10.1016/j.taap.2006.11.029; Comitato Nazionale Biosicurezza Biotecnologie e Scienze della vita, 2010, PROPOSTA DI PIATTAFO; Comitato Nazionale Biosicurezza e Biotecnologie, 2006, SORV ESP INT END; Cook MB, 2011, INT J ANDROL, V34, pE68, DOI 10.1111/j.1365-2605.2011.01171.x; Crinnion WJ, 2010, ALTERN MED REV, V15, P190; Davey JC, 2007, TOXICOL SCI, V98, P75, DOI 10.1093/toxsci/kfm013; Davila-Esqueda ME, 2011, EXP CLIN ENDOCR DIAB, V119, P613, DOI 10.1055/s-0031-1287782; De Angelis Simona, 2009, Toxicol Sci, V108, P311, DOI 10.1093/toxsci/kfp017; DeKeyser JG, 2011, TOXICOL SCI, V120, P381, DOI 10.1093/toxsci/kfq394; Desvergne B, 2009, MOL CELL ENDOCRINOL, V304, P43, DOI 10.1016/j.mce.2009.02.017; Dirinck E, 2011, OBESITY, V19, P709, DOI 10.1038/oby.2010.133; EFSA, 2005, EFSA J, V168, P1; EFSA, 2011, EFSA J, V9, P2197, DOI DOI 10.2903/J.EFSA.2011.2197; EFSA, 2009, EFSA J, V7, P1351, DOI DOI 10.2903/J.EFSA.2009.1351; EFSA, 2009, EFSA J, V1043, P1; Ellis-Hutchings RG, 2009, BIRTH DEFECTS RES B, V86, P48, DOI 10.1002/bdrb.20181; Elobeid MA, 2010, INT J ENV RES PUB HE, V7, P2988, DOI [10.3390/ijerph7072988, 10.3390/ijerph7082988]; European Food Safety Authority, 2010, EFSA J, V8, P1932; Frazzoli C, 2009, ANN I SUPER SANITA, V45, P65; Frye CA, 2012, J NEUROENDOCRINOL, V24, P144, DOI 10.1111/j.1365-2826.2011.02229.x; Governini L, 2011, J ASSIST REPROD GEN, V28, P415, DOI 10.1007/s10815-011-9548-2; Gupta N, 2012, ENDOCR REV, V33, P48, DOI 10.1210/er.2010-0028; Guyton KZ, 2009, ENVIRON HEALTH PERSP, V117, P1664, DOI 10.1289/ehp.0900758; Hartung T, 2009, NATURE, V460, P208, DOI 10.1038/460208a; Hatch EE, 2010, INT J ANDROL, V33, P324, DOI 10.1111/j.1365-2605.2009.01035.x; Hoekstra J, 2012, FOOD CHEM TOXICOL; Jobling MS, 2011, INT J ANDROL, V34, pE386, DOI 10.1111/j.1365-2605.2010.01140.x; Kjaerstad MB, 2010, REPROD TOXICOL, V30, P573, DOI 10.1016/j.reprotox.2010.07.009; La Rocca C, EPIDEMIOL PREV, V33, P59; La Rocca C, 2012, INT J HYG ENVIR HEAL, V215, P206, DOI 10.1016/j.ijheh.2011.10.016; Latini G, 2010, CURR MED CHEM, V17, P2979; Latini G, SVILUPPO DEL PRINCIP; Latini G, 2010, MINI-REV MED CHEM, V10, P846; Li DK, 2011, FERTIL STERIL, V95, P625, DOI 10.1016/j.fertnstert.2010.09.026; Lim JS, 2011, INT J OBESITY, V35, P744, DOI 10.1038/ijo.2010.188; Long M, REPRODUCTION, V133, P517; Lorenzetti S, 2010, REPROD TOXICOL, V30, P25, DOI 10.1016/j.reprotox.2010.03.008; Lorenzetti S, 2011, ANN I SUPER SANITA, V47, P429, DOI 10.4415/ANN_11_04_16; Lubick N, 2011, ENVIRON HEALTH PERSP, V119, pA354, DOI 10.1289/ehp.119-a354a; Mantovani A, 2008, REPROD TOXICOL, V26, P1, DOI 10.1016/j.reprotox.2008.05.063; Mantovani A, 2006, ANN NY ACAD SCI, V1076, P239, DOI 10.1196/annals.1371.063; Mantovani A, EPIDEMIOL PREV, V33, P5; Maranghi F, 2010, REPROD TOXICOL, V29, P427, DOI 10.1016/j.reprotox.2010.03.002; Maranghi F, 2007, CHEM-BIOL INTERACT, V169, P1, DOI 10.1016/j.cbi.2007.04.008; Maranghi F, 2005, RAPPORTI ISTISAN 05, P4; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Meeker JD, 2011, ENVIRON HEALTH PERSP, V119, P252, DOI 10.1289/ehp.1002238; Meeker JD, 2010, MATURITAS, V66, P236, DOI 10.1016/j.maturitas.2010.03.001; Mendez MA, 2011, ENVIRON HEALTH PERSP, V119, P272, DOI 10.1289/ehp.1002169; Ministero dell'Ambiente e della Tutela del Territorio e del Mare Istituto Superiore di Sanita, 2012, CONOSCI RIDUCI PREVI; Navas-Acien A, 2006, ENVIRON HEALTH PERSP, V114, P641, DOI 10.1289/ehp.8551; Pant N, 2011, HUM EXP TOXICOL, V30, P507, DOI 10.1177/0960327110374205; Ryan KK, 2010, ENDOCRINOLOGY, V151, P2603, DOI 10.1210/en.2009-1218; Scheepers PTJ, 2008, BIOMARKERS, V13, P734, DOI 10.1080/13547500802528630 ; Scientific Committee on Emerging and Newly-Identified Health Risks- SCENIHR, 2008, OPINION ON THE SAFET; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143; Slotkin TA, 2005, ENVIRON HEALTH PERSP, V113, P1291, DOI 10.1289/ehp.8133; Tait S, 2009, ENVIRON HEALTH PERSP, V117, P112, DOI 10.1289/ehp.11696; Tait S, 2011, REPROD TOXICOL, V32, P1, DOI 10.1016/j.reprotox.2011.02.001; Tellez RT, 2005, THYROID, V15, P963, DOI 10.1089/thy.2005.15.963; Thienpont B, 2011, ENVIRON SCI TECHNOL, V45, P7525, DOI 10.1021/es202248h; Toft G, 2006, EPIDEMIOLOGY, V17, P450, DOI 10.1097/01.ede.0000221769.41028.d2; Toft G, ENV HLTH PERSPECT S1, V115, P15; Traina ME, 2003, REPROD TOXICOL, V17, P25, DOI 10.1016/S0890-6238(02)00101-6; Tranfo G, 2012, TOXICOL LETT, V213, P15, DOI 10.1016/j.toxlet.2011.11.033; Ueyama J, 2007, TOXICOL LETT, V170, P229, DOI 10.1016/j.toxlet.2007.03.010; Walton FS, 2004, TOXICOL APPL PHARM, V198, P424, DOI 10.1016/j.taap.2003.10.026; Zhou CQ, 2005, TOXICOL IN VITRO, V19, P665, DOI 10.1016/j.tiv.2005.03.010780MATTIOLI 1885FIDENZAVIA CODURO 1-B, FIDENZA, 43046 PR, ITALYEUR J ONCOLDiscipline: Oncology170QA</notes>
    <keywords>ALTERS; ARSENIC EXPOSURE; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CELL; CHEMICALS; childhood; COMPONENTS; development; DEVELOPMENTAL EXPOSURE; DISEASE; diseases; DISORDERS; ENDOCRINE; Endocrine disrupter; ENDOCRINE DISRUPTERS; Epidemiology; EXPOSURE; fertility; FOOD; food safety; HEALTH; In vitro; IN-UTERO EXPOSURE; IN-VITRO; METABOLIC SYNDROME; Nuclear receptor; oncology; PERSISTENT ORGANIC POLLUTANTS; phthalate; Phthalates; Phytoestrogen; PHYTOESTROGENS; PLANTS; POLLUTANTS; POPULATION; RECEPTOR; Reproduction; REPRODUCTIVE HEALTH; RISK; Risk assessment; RISK-ASSESSMENT; RISK-FACTORS; SEMEN QUALITY; SPERM DNA-DAMAGE; SYSTEM; TESTING STRATEGIES; VITRO; VITRO APPROACH; WIDESPREAD EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>161</startpage>
    <endpage>173</endpage>
    <journalfull>European Journal of Oncology</journalfull>
    <issue>4</issue>
    <volume>17</volume>
    <abstract>An Endocrine Disrupter (ED) is an exogenous substance or a mixture, that alters function(s) of the endocrine system, causing adverse health effects in an intact organism, or its progeny, or particularly vulnerable (sub) populations. Reproductive health, prenatal and infant development are the most susceptible stages. EDs specific effects are closely associated with the respective mode of action, which can be very different e. g., nuclear receptor agonism or antagonism. EDs can be divided into four main groups: persistent pollutants that can bioaccumulate in animals and plants; pesticides, biocides and compounds used in animal husbandry; industrial chemicals widely used in consumer products such as bisphenol A and phthalates, less potent than persistent pollutants and pesticides, but with a more widespread exposure and still not adequately regulated; substances naturally occurring in diet such as the mycotoxin zearalenone or bioactive food components such as phytoestrogens. For many multifactorial endocrine-related diseases EDs should be considered as preventable risk factors; main examples are fertility disorders as well as predisposition to metabolic syndrome and some types of cancer. Independent research is essential to integrate and update risk assessment based on the mode of action understanding, the development of possible biomarkers for population studies as well as priorities and targets for risk management and communication. Eur. J. Oncol., 17 (4), 161-173, 2012</abstract>
    <url>WOS:000320866900001</url>
    <isbnorissn>1128-6598</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>52</id>
    <title>Puberty dysregulation and increased risk of disease in adult life: Possible modes of action</title>
    <authors>Mantovani,A.; Fucic,A.</authors>
    <availability>[Mantovani, Alberto] Ist Super Sanita, Dept Food Safety &amp; Vet Publ Hlth, Rome, Italy. [Fucic, Aleksandra] Inst Med Res &amp; Occupat Hlth, Zagreb 41000, Croatia.</availability>
    <date>2014</date>
    <notes>JEnglishReviewFucic, A (reprint author), Inst Med Res &amp; Occupat Hlth, Ksaverska C 2, Zagreb 41000, Croatiaafucic@imi.hrBajpai A, 2010, J ENDOCRINOL, V207, P27, DOI 10.1677/JOE-10-0006; BAKER HWG, 1976, CLIN ENDOCRINOL, V5, P349, DOI 10.1111/j.1365-2265.1976.tb01964.x; Bandera EV, 2011, SCI TOTAL ENVIRON, V409, P5221, DOI 10.1016/j.scitotenv.2011.09.029; Becker K, 2008, J PEDIATR, V152, P263, DOI 10.1016/j.jpeds.2007.07.004; Biegon A, 2010, BIOL PSYCHIAT, V67, P774, DOI 10.1016/j.biopsych.2010.01.004; Biro FM, 2010, AM J CLIN NUTR, V91, p1499S, DOI 10.3945/ajcn.2010.28701B; Boon WC, 2010, PROG BRAIN RES, V181, P209, DOI 10.1016/S0079-6123(08)81012-6; Borjesson AE, 2010, J BONE MINER RES, V25, P2414, DOI 10.1002/jbmr.156; Bottner A, 2004, J CLIN ENDOCR METAB, V89, P4053, DOI 10.1210/jc.2004-0303; Bramen JE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033850; Brunetti D, 2009, EPIDEMIOL PREV, V33, P161; Calamandrei G, 2006, REPROD TOXICOL, V22, P164, DOI 10.1016/j.reprotox.2006.04.003; Canton RF, 2005, TOXICOL SCI, V88, P447, DOI 10.1093/toxsci/kfi325; Carreau S, 2007, FOLIA HISTOCHEM CYTO, V45, P5; Castiglioni F, 2007, CLIN CANCER RES, V13, P46, DOI 10.1158/1078-0432.CCR-06-1490; Chagin AS, 2009, HORM RES, V71, P41, DOI 10.1159/000192435; Chakraborty TR, 2012, J ADOLESCENT HLTH ME, V2, P17; Chen JG, 2008, ENDOCRINOLOGY, V149, P1173, DOI 10.1210/en.2007-1057; Cheng G.C., 2012, TRANSLATION CANC RES, V1, P61; Chung E, 2011, P NATL ACAD SCI USA, V108, P17732, DOI 10.1073/pnas.1115187108; Clarke BL, 2009, STEROIDS, V74, P296, DOI 10.1016/j.steroids.2008.10.003; Cooke PS, 2004, EXP BIOL MED, V229, P1127; Cooper BW, 2008, TOXICOL SCI, V103, P268, DOI 10.1093/toxsci/kfn047; De Assis S, 2006, ANN NY ACAD SCI, V1089, P14, DOI 10.1196/annals.1386.039; Dechanet C, 2011, HUM REPROD UPDATE, V17, P76, DOI 10.1093/humupd/dmq033; Dechaud H, 1999, STEROIDS, V64, P328, DOI 10.1016/S0039-128X(98)00114-7; Delaveyne-Bitbol R, 1999, J BONE MINER RES, V14, P376, DOI 10.1359/jbmr.1999.14.3.376; De Lorme KC, 2012, BRAIN RES, V1460, P33, DOI 10.1016/j.brainres.2012.04.035; Den Hond E, 2011, J EXPO SCI ENV EPID, V21, P224, DOI 10.1038/jes.2010.2; Ding XS, 2006, TOXICOL SCI, V91, P448, DOI 10.1093/toxsci/kfj163; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Dreiem A, 2010, TOXICOL SCI, V118, P50; Driscoll LL, 2012, NEUROTOXICOL TERATOL, V34, P20, DOI 10.1016/j.ntt.2011.10.002; ELSAESSER F, 1982, ACTA ENDOCRINOL-COP, V100, P606; Emanuele MA, 2002, ALCOHOL RES HEALTH, V26, P274; Essex MJ, 2013, CHILD DEV, V84, P58, DOI 10.1111/j.1467-8624.2011.01641.x; European Food Safety Authority, 2011, EFSA J, V9, P2197; European Food Safety Authority (EFSA), 2009, EFSA J, V980, P1; Fraser MO, 2005, PEDIATR RES, V57, P141, DOI 10.1203/01.PDR.0000148063.68338.A0; Frazzoli C, 2009, ANN I SUPER SANITA, V45, P65; Frederiksen H, 2012, INT J ANDROL, V35, P216, DOI 10.1111/j.1365-2605.2012.01260.x; Fucic A, 2008, MUTAT RES-GEN TOX EN, V657, P43, DOI 10.1016/j.mrgentox.2008.08.008; Fucic A, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-S1-S8; Fucic A, 2009, BRAZ J MED BIOL RES, V42, P1090, DOI 10.1590/S0100-879X2009001100015; Fucic A, 2010, TOXICOL PATHOL, V38, P849, DOI 10.1177/0192623310378136; Ganmaa D, 2005, MED HYPOTHESES, V65, P1028, DOI 10.1016/j.mehy.2005.06.026; Gascon M, 2011, ENVIRON INT, V37, P605, DOI 10.1016/j.envint.2010.12.005; Grossman C, 1989, J STEROID BIOCHEM, V34; Grumbach MM, 2004, ANN NY ACAD SCI, V1038, P7, DOI 10.1196/annals.1315.008; Harcz P, 2007, FOOD ADDIT CONTAM, V24, P713, DOI 10.1080/02652030601185071; Hartz SM, 2012, ARCH GEN PSYCHIAT, V69, P854, DOI 10.1001/archgenpsychiatry.2012.124; Haslam Sandra Z, 2011, Womens Health (Lond Engl), V7, P1, DOI 10.2217/whe.10.83; Hiatt RA, 2009, ENVIRON HEALTH PERSP, V117, P1814, DOI 10.1289/ehp.0800120; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; Hudson D, 2011, AGING-US, V3, P609; Janfaza M, 2006, J PEDIATR ENDOCR MET, V19, P901; Ji YL, 2010, REPROD TOXICOL, V29, P176, DOI 10.1016/j.reprotox.2009.10.014; Kass L, 2012, REPROD TOXICOL, V33, P390, DOI 10.1016/j.reprotox.2012.02.002; Katic J, 2010, ARH HIG RADA TOKSIKO, V61, P455, DOI 10.2478/10004-1254-61-2010-2065; Kellogg CK, 1999, HORM BEHAV, V35, P155, DOI 10.1006/hbeh.1998.1508; Kerger BD, 2006, ENVIRON HEALTH PERSP, V114, P1596, DOI 10.1289/ehp.8884; Khundrakpam BS, 2012, CEREB CORTEX; Kim MJ, 2011, ENVIRON HEALTH PERSP, V119, P377, DOI 10.1289/ehp.1002848; Kjerstad MB, 2010, REPROD TOXICOL, V30, P573; KORENMAN SG, 1980, CANCER, V46, P874, DOI 10.1002/1097-0142(19800815)46:4+&lt;874::AID-CNCR2820461305&gt;3.0.CO;2-#; Kortenkamp A, 2011, METAL IONS LIFE SCI, V8, P305, DOI 10.1039/978184973211600305; Lacerda HM, 2009, CANCER EPIDEM BIOMAR, V18, P2042, DOI 10.1158/1055-9965.EPI-08-1140; Lakshman R, 2009, J CLIN ENDOCR METAB, V94, P4953, DOI 10.1210/jc.2009-1789; Lee E, 2010, J TOXICOL SCI, V35, P535; Li JJ, 2012, J CHILD PSYCHOL PSYC, V53, P997, DOI 10.1111/j.1469-7610.2012.02563.x; Lim Unhee, 2012, Methods Mol Biol, V863, P359, DOI 10.1007/978-1-61779-612-8_23; Lin CY, 2011, ENVIRON SCI TECHNOL, V45, P10691, DOI 10.1021/es201964x; Lintas C, 2010, NEUROREPORT, V21, P114, DOI 10.1097/WNR.0b013e328334b343; Lucas R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046940; Mantovani A, 2006, ANN NY ACAD SCI, V1076, P239, DOI 10.1196/annals.1371.063; Maranghi F, 2009, FOOD CHEM TOXICOL, V47, P472, DOI 10.1016/j.fct.2008.12.003; Maranghi F, 2012, REPROD TOXICOL, V33, P290, DOI 10.1016/j.reprotox.2012.01.009; Maranghi F, 2010, CHEM-BIOL INTERACT, V183, P40, DOI 10.1016/j.cbi.2009.09.016; Marcus PM, 2000, CANCER CAUSE CONTROL, V11, P271, DOI 10.1023/A:1008911902994; MARUYAMA Y, 1987, ACTA ENDOCRINOL-COP, V114, P60; Massart F, 2008, J PEDIATR, V152, P690, DOI 10.1016/j.jpeds.2007.10.020; Matsuda KI, 2012, REV ENDOCR METAB DIS, V13, P163, DOI 10.1007/s11154-012-9202-z; Maule M, 2012, INT J ANDROL, V27, P101; McElroy JA, 2012, BIRTH DEFECTS RES A, V94, P223, DOI 10.1002/bdra.22891; Merlo DF, 2012, BREAST CANCER RES TR, V134, P363, DOI 10.1007/s10549-012-2031-7; Meyer HW, 2005, INDOOR AIR, V15, P17, DOI 10.1111/j.1600-0668.2005.00356.x; Michalakis K, 2012, METABOLISM; Mocarelli P, 2008, ENVIRON HEALTH PERSP, V116, P70, DOI 10.1289/ehp.10399; Navarro VM, 2012, J NEUROSCI, V32, P2388, DOI 10.1523/JNEUROSCI.4288-11.2012; Nguyen TV, 2012, CEREB CORTEX; Nie J, 2007, CANCER CAUSE CONTROL, V18, P947, DOI 10.1007/s10552-007-9036-2; Ojeda SR, 2010, ENDOCRIN DEV, V17, P44, DOI 10.1159/000262527; Okuyama K, 2011, INT ARCH ALLERGY IMM, V155, P21, DOI 10.1159/000327261; Olesen PT, 2008, INT J CANCER, V122, P2094, DOI 10.1002/ijc.23359; Olson LK, 2010, INT J OBESITY, V34, P1415, DOI 10.1038/ijo.2010.51; Osawa Y, 1990, J Enzyme Inhib, V4, P187, DOI 10.3109/14756369009040741; Othman A, 2012, BMC PEDIATR, V12, P92; Rajan Rohan Ananda, 2007, J Child Orthop, V1, P365, DOI 10.1007/s11832-007-0058-9; Rogan WJ, 2007, INT J HYG ENVIR HEAL, V210, P659, DOI 10.1016/j.ijheh.2007.07.005; Rogol AD, 2002, J ADOLESCENT HEALTH, V31, P192, DOI 10.1016/S1054-139X(02)00485-8; Romano RM, 2010, ARCH TOXICOL, V84, P309, DOI 10.1007/s00204-009-0494-z; Schon J, 2009, REPROD DOMEST ANIM, V44, P294, DOI 10.1111/j.1439-0531.2009.01391.x; Seralini GE, 2001, MOL CELL ENDOCRINOL, V178, P117, DOI 10.1016/S0303-7207(01)00433-6; Sharpe RM, 2001, TOXICOL LETT, V120, P221, DOI 10.1016/S0378-4274(01)00298-3; SHIMADA Y, 1994, RADIAT RES, V137, P118, DOI 10.2307/3578800; Shin YH, 2012, EUR J PEDIATR, V171, P1475, DOI 10.1007/s00431-012-1746-0; Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143; Soldin OP, 2011, STEROIDS, V76, P653, DOI 10.1016/j.steroids.2011.02.042; Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x; Taes Y, 2010, J BONE MINER RES, V25, P379, DOI 10.1359/jbmr.090809; Takahashi M, 2011, ARCH TOXICOL, V85, P1109, DOI 10.1007/s00204-010-0638-1; Talaei Afsaneh, 2012, Indian J Endocrinol Metab, V16, P786, DOI 10.4103/2230-8210.100676; Tam CS, 2010, HORM RES PAEDIAT, V73, P128, DOI 10.1159/000277632; Tena-Sempere M, 2012, EUR J ENDOCRINOL, V167, P733, DOI 10.1530/EJE-12-0669; TOKUNAGA M, 1979, J NATL CANCER I, V62, P1347; Travis CC, 2006, J NUCL MED, V47, P1723; Utsal L, 2012, HORM RES PAEDIAT, V78, P31, DOI 10.1159/000339831; Waalkes MP, 1997, TOXICOL APPL PHARM, V142, P40, DOI 10.1006/taap.1996.8005; Wang J, 2012, LIPIDS HLTH DIS, V11, P1, DOI DOI 10.1038/IJ0.2012.173.[EPUB; Wang Z, 2012, J STEROID BIOCHEM; WENNINK JMB, 1991, ACTA ENDOCRINOL-COP, V124, P129; Wild CP, 2003, CANCER EPIDEM BIOMAR, V12, P1389; Wohlfahrt-Veje C, 2009, CLIN ENDOCRINOL, V71, P459, DOI 10.1111/j.1365-2265.2009.03545.x; Xie PX, 2012, NEUROPSYCHOPHARMACOL, V37, P669, DOI 10.1038/npp.2011.240; Yueh MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.00377051252PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLAPRDiscipline: Reproductive Biology; ToxicologyAG4DC</notes>
    <keywords>ADOLESCENCE; BIOLOGY; BISPHENOL-A; BONE MASS; breast cancer; BREAST-CANCER; BREAST-CANCER RISK; CANCER; CELL; CIGARETTE-SMOKING; DISORDERS; ENDOCRINE DISRUPTERS; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL CHEMICALS; EXPOSURE; FEMALE PUBERTY; FOOD; GENOTOXICITY; GROWTH; Juvenile toxicology; mechanism; MECHANISMS; METABOLISM; METHYLATION; RISK; SEXUAL-MATURATION; SPRAGUE-DAWLEY RATS; SUSCEPTIBILITY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>15</startpage>
    <endpage>22</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <volume>44</volume>
    <abstract>Puberty is the developmental window when the final maturation of body systems is orchestrated by hormones; lifelong sex-related differences and capacity to interact with the environment are defined during this life stage. Increased incidence in a number of chronic, multifactorial diseases could be related to environmental exposures during puberty: however, insight on the susceptibility of the peripubertal period is still limited. The estrogen/androgen balance is a crucial axis in harmonizing the whole pubertal development, pointing out the significance of exposures to endocrine disruptors. Besides the reproductive system, endocrine-related perturbations may affect the maturation of skeleton, adipose tissues, brain, immune system, as well as cancer predisposition. Thus, risk assessment of environmental stressors should duly consider specific aspects of the pubertal window. Besides endocrine-related mechanisms, suggested research priorities include signaling molecules (e.g., kisspeptins, dopamine) as xenobiotic targets and disturbances of specific pubertal methylation processes potentially involved in neurobehavioral disorders and cancer risk in adulthood. (C) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000335368500004</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>186</id>
    <title>Disruption of 3D MCF-12A Breast Cell Cultures by Estrogens - An In Vitro Model for ER-Mediated Changes Indicative of Hormonal Carcinogenesis</title>
    <authors>Marchese,S.; Silva,E.</authors>
    <availability>[Marchese, Stephanie; Silva, Elisabete] UCL Sch Pharm, London, England. [Silva, Elisabete] Brunel Univ, Inst Environm, Uxbridge UB8 3PH, Middx, England.</availability>
    <date>2012</date>
    <notes>JEnglishArticleSilva, E (reprint author), UCL Sch Pharm, London, Englandelisabete.silva@brunel.ac.ukAli S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Altucci L, 1996, ONCOGENE, V12, P2315; Bedard PL, 2008, BREAST CANCER RES TR, V108, P307, DOI 10.1007/s10549-007-9606-8; Bratton MR, 2010, INT J ONCOL, V37, P541, DOI 10.3892/ijo_00000703; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Cheskis BJ, 2004, J CELL BIOCHEM, V93, P20, DOI 10.1002/jcb.20180; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Dimri M, 2007, CANCER RES, V67, P4164, DOI 10.1158/0008-5472.CAN-06-2580; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Gompel A, 2004, MATURITAS, V49, P16, DOI 10.1016/j.maturitas.2004.06.009; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Harris J, 1999, DIS BREAST; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathol.3.121806.151526; Ignatov T, 2010, AM J OBSTET GYNECOL, V203; Kabil A, 2008, CARCINOGENESIS, V29, P1862, DOI 10.1093/carcin/bgn138; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; LaPensee EW, 2010, CANCER LETT, V290, P167, DOI 10.1016/j.canlet.2009.09.005; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Liu YE, 2007, ONCOGENE, V26, P2115, DOI 10.1038/sj.onc.1210000; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mailleux AA, 2008, CELL CYCLE, V7, P57; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Robbins AS, 2007, J CLIN ONCOL, V25, P3437, DOI 10.1200/JCO.2007.11.4132; Russo J, 2002, ENVIRON MOL MUTAGEN, V39, P254, DOI 10.1002/em.10052; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com; Silva E, 2010, TOXICOL APPL PHARM, V245, P159, DOI 10.1016/j.taap.2010.02.015; Silva E, 2007, ENVIRON HEALTH PERSP, V115, P91, DOI 10.1289/ehp.9363; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOULE HD, 1990, CANCER RES, V50, P6075; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thompson A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1983; Underwood JM, 2006, J CELL PHYSIOL, V208, P141, DOI 10.1002/jcp.20639; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; Yanochko GM, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1392472PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEOCT 2Discipline: Science &amp; Technology - Other Topics015NG</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; CELLS; CHEMICALS; CYCLE; development; E-SCREEN ASSAY; Endocrine disruption; EPITHELIAL-CELLS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGENS; GENE-EXPRESSION; GLAND; GPER; GROWTH; GROWTH-FACTOR RECEPTOR; HEALTH; In vitro; IN-VITRO; IN-VIVO; INHIBITOR; Inhibitors; LUMEN FORMATION; MAMMARY EPITHELIAL ACINI; mammary gland; MAMMARY-GLAND; mechanism; MECHANISMS; MODEL; PROGRESSION; proliferation; RECEPTOR; SYSTEM; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>10</issue>
    <volume>7</volume>
    <abstract>Introduction: Estrogens regulate the proliferation of normal and neoplastic breast epithelium. Although the intracellular mechanisms of estrogens in the breast are largely understood, little is known about how they induce changes in the structure of the mammary epithelium, which are characteristic of breast cancer. In vitro three dimensional (3D) cultures of immortalised breast epithelial cells recapitulate features of the breast epithelium in vivo, including formation of growth arrested acini with hollow lumen and basement membrane. This model can also reproduce features of malignant transformation and breast cancer, such as increased cellular proliferation and filling of the lumen. However, a system where a connection between estrogen receptor (ER) activation and disruption of acini formation can be studied to elucidate the role of estrogens is still missing. Methods/Principal Findings: We describe an in vitro 3D model for breast glandular structure development, using breast epithelial MCF-12A cells cultured in a reconstituted basement membrane matrix. These cells are estrogen receptor (ER) a, ERb and G-protein coupled estrogen receptor 1 (GPER) competent, allowing the investigation of the effects of estrogens on mammary gland formation and disruption. Under normal conditions, MCF-12A cells formed organised acini, with deposition of basement membrane and hollow lumen. However, treatment with 17 beta-estradiol, and the exogenous estrogens bisphenol A and propylparaben resulted in deformed acini and filling of the acinar lumen. When these chemicals were combined with ER and GPER inhibitors (ICI 182,780 and G-15, respectively), the deformed acini recovered normal features, such as a spheroid shape, proliferative arrest and luminal clearing, suggesting a role for the ER and GPER in the estrogenic disruption of acinar formation. Conclusion: This new model offers the opportunity to better understand the role of the ER and GPER in the morphogenesis of breast glandular structure as well as the events implicated in breast cancer initiation and progression</abstract>
    <url>WOS:000309452600016</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>199</id>
    <title>Susceptibility of estrogen receptor rapid responses to xenoestrogens: Physiological outcomes</title>
    <authors>Marino,M.; Pellegrini,M.; La Rosa,P.; Acconcia,F.</authors>
    <availability>[Marino, Maria; Pellegrini, Marco; La Rosa, Piergiorgio; Acconcia, Filippo] Univ Roma TRE, Dept Biol, I-00146 Rome, Italy.</availability>
    <date>2012</date>
    <notes>JEnglishArticle; Proceedings PaperMarino, M (reprint author), Univ Roma TRE, Dept Biol, Viale G Marconi 446, I-00146 Rome, Italym.marino@uniroma3.itAcconcia Filippo, 2011, Front Physiol, V2, P30, DOI 10.3389/fphys.2011.00030; Acconcia F, 2005, MOL BIOL CELL, V16, P231; Acconcia F, 2005, J CELL PHYSIOL, V203, P193, DOI 10.1002/jcp.20219; Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bolli A, 2010, IUBMB LIFE, V62, P684, DOI 10.1002/iub.370; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bulzomi P, 2011, J CELL PHYSL; Bulzomi P, 2011, FRONT BIOSCI-LANDMRK, V16, P2478, DOI 10.2741/3867; Bulzomi P, 2010, IUBMB LIFE, V62, P51, DOI 10.1002/iub.279; Caiazza F, 2007, BIOCHEM BIOPH RES CO, V359, P102, DOI 10.1016/j.bbrc.2007.05.059; Cassidy A, 2000, J SCI FOOD AGR, V80, P1044, DOI 10.1002/(SICI)1097-0010(20000515)80:7&lt;1044::AID-JSFA586&gt;3.3.CO;2-E; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chambliss KL, 2010, J CLIN INVEST, V120, P2319, DOI 10.1172/JCI38291; Dang ZC, 2005, TRENDS ENDOCRIN MET, V16, P207, DOI 10.1016/j.tem.2005.05.001; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Eiler S, 2001, PROTEIN EXPRES PURIF, V22, P165, DOI 10.1006/prep.2001.1409; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Fulco CS, 1999, ACTA PHYSIOL SCAND, V167, P233; Galluzzo P, 2009, MOL NUTR FOOD RES, V53, P699, DOI 10.1002/mnfr.200800239; Galluzzo P, 2007, ENDOCR-RELAT CANCER, V14, P153, DOI 10.1677/ERC-06-0020; Galluzzo P, 2008, ENDOCRINOLOGY, V149, P2567, DOI 10.1210/en.2007-1173; Galluzzo P, 2006, GENES NUTR, V1, P161, DOI 10.1007/BF02829966; Galluzzo P, 2009, AM J PHYSIOL-CELL PH, V297, pC1249, DOI 10.1152/ajpcell.00188.2009; Glenmark B, 2004, AM J PHYSIOL-ENDOC M, V287, pE1125, DOI 10.1152/ajpendo.00098.2004; Goodson A, 2002, FOOD ADDIT CONTAM, V19, P796, DOI 10.1080/02652030210146837; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; La Rosa P, 2011, J STEROID BIOCHEM, V127, P223, DOI 10.1016/j.jsbmb.2011.07.008; Leclercq G, 2006, CURR CANCER DRUG TAR, V6, P39, DOI 10.2174/156800906775471716; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Li YW, 2010, PHARM RES-DORDR, V27, P1027, DOI 10.1007/s11095-010-0105-y; Liang M, 2004, MOL CELL ENDOCRINOL, V224, P65, DOI 10.1016/j.mce.2004.06.012; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; Marino M, 2006, STEROIDS, V71, P298, DOI 10.1016/j.steroids.2005.09.011; Marino M, 2008, STEROIDS, V73, P853, DOI 10.1016/j.steroids.2007.12.003; Marino M, 2003, MOL BIOL CELL, V14, P2583, DOI 10.1091/mbc.E02-09-0621; Marino M, 1998, BIOCHEM BIOPH RES CO, V245, P254, DOI 10.1006/bbrc.1998.8413; Marino M, 2002, MOL BIOL CELL, V13, P3720, DOI 10.1091/mbc.E02-03-0153; Mariyasagayam M., 2007, ENDOCRINE DISRUPTORS, P1; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McCormick KM, 2004, J MUSCLE RES CELL M, V25, P21, DOI 10.1023/B:JURE.0000021398.78327.39; Munguia-Lopez EM, 2005, FOOD ADDIT CONTAM, V22, P892, DOI 10.1080/02652030500163674; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Pravettoni A, 2007, MOL CELL ENDOCRINOL, V263, P46, DOI 10.1016/j.mce.2006.08.008; Recchia AG, 2004, FOOD ADDIT CONTAM, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Totta P, 2005, J NUTR, V135, P2687; Totta P, 2004, IUBMB LIFE, V56, P491, DOI 10.1080/15216540400010792; Tschugguel W, 2003, J CLIN ENDOCR METAB, V88, P2281, DOI 10.1210/jc.2002-021165; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; van der Woude H, 2005, MOL NUTR FOOD RES, V49, P763, DOI 10.1002/mnfr.200500036; Virgili F, 2008, FREE RADICAL BIO MED, V45, P1205, DOI 10.1016/j.freeradbiomed.2008.08.001; Virgili F, 2004, IUBMB LIFE, V56, P145, DOI 10.1080/15216540410001685083; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Vladusic EA, 1998, CANCER RES, V58, P210; Warner M, 2006, STEROIDS, V71, P91, DOI 10.1016/j.steroids.2005.09.001; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Yoshida T, 2001, FOOD ADDIT CONTAM A, V18, P69, DOI 10.1080/0265203014464127411ELSEVIER SCIENCE INCNEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USASTEROIDSAUGSIDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism990FS</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; ALPHA; Antagonist; ASSOCIATION; BETA; BINDING; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; CANCER-CELL-PROLIFERATION; CELL; CELLS; COREGULATORS; DIFFERENTIAL REGULATION; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ER alpha; ER-ALPHA; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptor alpha; Estrogen receptor beta; ESTROGEN-RECEPTOR; EXPRESSION; Flavonoids; FOOD; Food contaminant; GENE; gene expression; GENE-EXPRESSION; GENES; GROWTH; HEALTH; HEPG2 CELLS; HUMAN HEALTH; INDUCED APOPTOTIC CASCADE; Interaction; KINASE; kinases; LIGAND; LIGAND-BINDING; LIGANDS; mechanism; MECHANISMS; METABOLISM; NARINGENIN; p21; PROTEIN; Rapid signals; RECEPTOR; RESPONSES; Signal transduction; SIGNALS; SKELETAL-MUSCLE FUNCTION; SUSCEPTIBILITY; TISSUE; TISSUES; TRANSCRIPTIONAL ACTIVITY; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>910</startpage>
    <endpage>917</endpage>
    <journalfull>Steroids</journalfull>
    <issue>10</issue>
    <volume>77</volume>
    <abstract>17 beta-Estradiol (E2) binding induces rapid modification in the conformation of its cognate receptors (i.e., ER alpha and ER beta). These allosteric changes allow the association of ERs with cell specific transcriptional cofactors, thus determining cellular contexts specific variations in gene expression. In addition, E2-ER complexes could also interact with membrane and cytosolic signal molecules triggering extra-nuclear signalling pathways. The synergy between these mechanisms is necessary for E2-induced pleiotropic actions in target tissues. Besides E2, the ER ligand binding domains can accommodate many other natural and synthetic ligands. Several of these compounds act as agonist or antagonist of ER transcriptional activity due to their ability to modify the interactions between ERs and transcriptional co-regulators. However, the ability of natural or manmade ER ligands to affect the extra-nuclear interactions of the ERs has been rarely evaluated. Here, the ability of two diet-derived flavonoids (i.e., naringenin and quercetin) and of the synthetic food-contaminant bisphenol A to modulate specifically ER extra-nuclear signalling pathways will be reported. All the tested compounds bind to both ER subtypes even if lesser than E2 activating divergent signal transduction pathways. In fact, in the presence of ER alpha, both naringenin and quercetin decouple ER alpha activities by specifically interfering with ER alpha membrane initiating signals. On the other hand, bisphenol A, but not flavonoids, maintains ER beta at the membrane thus impairing the activation of the downstream kinases. As a whole, extra-nuclear ER signals are highly susceptible to different ligands that, by unbalancing E2-induced cell functions drive cells to different functional endpoints. (c) 2012 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000307617000005</url>
    <isbnorissn>0039-128X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>262</id>
    <title>Xenobiotic Effects on Ovarian Preantral Follicles</title>
    <authors>Mark-Kappeler,C.J.; Hoyer,P.B.; Devine,P.J.</authors>
    <availability>[Mark-Kappeler, Connie J.; Hoyer, Patricia B.] Univ Arizona, Dept Physiol, Tucson, AZ USA. [Devine, Patrick J.] Inst Natl Rech Sci, Inst Armand Frappier, Laval, PQ, Canada.</availability>
    <date>2011</date>
    <notes>JEnglishReviewDevine, PJ (reprint author), Novartis Inst Biomed Res Inc, Preclin Safety, 300 Technol Sq, Cambridge, MA 02139 USApatrick.devine@novartis.comAdriaens I, 2009, HUM REPROD UPDATE, V15, P359, DOI 10.1093/humupd/dmn063; ATAYA K, 1995, J CLIN ENDOCR METAB, V80, P790, DOI 10.1210/jc.80.3.790; ATAYA KM, 1989, CANCER RES, V49, P1660; BAKER TG, 1972, Z ZELLFORSCH MIK ANA, V126, P53, DOI 10.1007/BF00306780; BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boekelheide K, 2004, REPROD TOXICOL, V18, P189, DOI 10.1016/j.reprotox.2003.10.003; Borman SM, 2000, TOXICOL APPL PHARM, V167, P191, DOI 10.1006/taap.2000.9006; Borman SM, 1999, TOXICOL APPL PHARM, V158, P244, DOI 10.1006/taap.1999.8702; Borovskaya TG, 2004, B EXP BIOL MED+, V137, P331, DOI 10.1023/B:BEBM.0000035121.85533.08; Braw-Tal R, 2005, REPRODUCTION, V129, P453, DOI 10.1053/rep.1.00464; Bristol-Gould SK, 2006, DEV BIOL, V298, P149, DOI 10.1016/j.ydbio.2006.06.023; Brown A, 1998, CARCINOGENESIS, V19, P991, DOI 10.1093/carcin/19.6.991; Burridge E., 2003, EUR CHEM NEWS, P14; Byrne J, 1999, TERATOLOGY, V59, P210, DOI 10.1002/(SICI)1096-9926(199904)59:4&lt;210::AID-TERA4&gt;3.0.CO;2-X; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Campbell BK, 2004, ENDOCRINOLOGY, V145, P1870, DOI 10.1210/en.2003-1138; Chemaitilly W, 2006, J CLIN ENDOCR METAB, V91, P1723, DOI 10.1210/jc.2006-0020; Colvin OM, 1999, CURR PHARM DESIGN, V5, P555; Costa M, 2008, RHEUMATOLOGY, V47, P38, DOI 10.1093/rheumatology/ken156; Davis VL, 2006, CANCER, V107, P1690, DOI 10.1002/cncr.22105; Demeestere I, 2004, BIOL REPROD, V70, P1664, DOI 10.1095/biolreprod.103.023317; Demeestere I, 2005, REPRODUCTION, V130, P147, DOI 10.1530/rep.1.00648; Desmeules P, 2006, TOXICOL SCI, V90, P500, DOI 10.1093/toxsci/kfj086; Devine PJ, 2002, TOXICOL APPL PHARM, V184, P107, DOI 10.1006/taap.2002.9502; Ding CC, 2010, J ASSIST REPROD GEN, V27, P141, DOI 10.1007/s10815-010-9395-6; Dissen GA, 2002, MICROSC RES TECHNIQ, V59, P509, DOI 10.1002/jemt.10227; Dissen GA, 2009, SEMIN REPROD MED, V27, P24, DOI 10.1055/s-0028-1108007; DOBSON RL, 1983, AM J IND MED, V4, P175, DOI 10.1002/ajim.4700040116; DOERR JK, 1995, CHEM RES TOXICOL, V8, P963, DOI 10.1021/tx00049a010; Doerr JK, 1996, TOXICOLOGY, V113, P128, DOI 10.1016/0300-483X(96)03437-3; Dole G, 2008, REPRODUCTION, V135, P671, DOI 10.1530/REP-07-0405; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; El-Nemr A, 1998, HUM REPROD, V13, P2192, DOI 10.1093/humrep/13.8.2192; EVERSON RB, 1986, BRIT MED J, V293, P792; FADDY MJ, 1992, HUM REPROD, V7, P1342; Fernandez SM, 2008, BIOL REPROD, V79, P318, DOI 10.1095/biolreprod.108.067744; Flaws JA, 2001, BIOL REPROD, V64, P1153, DOI 10.1095/biolreprod64.4.1153; GENEROSO WM, 1971, MUTAT RES, V13, P171, DOI 10.1016/0027-5107(71)90010-8; GOMPERTS M, 1994, CIBA F SYMP, V182, P121; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Grant RL, 2010, J TOXICOL ENV HEAL B, V13, P460, DOI 10.1080/10937404.2010.499735; Green DM, 2009, J CLIN ONCOL, V27, P2677, DOI 10.1200/JCO.2008.20.1541; GU, 2005, WORLD J GASTROENTERO, V11, P6512; Han RM, 2009, J AGR FOOD CHEM, V57, P3780, DOI 10.1021/jf803850p; Hayashi M, 1999, ENDOCRINOLOGY, V140, P1236, DOI 10.1210/en.140.3.1236; HIMELSTEINBRAW R, 1977, BRIT J CANCER, V36, P269, DOI 10.1038/bjc.1977.186; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43, DOI 10.1016/S0074-7696(08)61524-7; HIRSHFIELD AN, 1992, BIOL REPROD, V47, P466, DOI 10.1095/biolreprod47.3.466; Holt JE, 2006, DEV BIOL, V293, P449, DOI 10.1016/j.ydbio.2006.02.012; HOOSER SB, 1994, REPROD TOXICOL, V8, P315, DOI 10.1016/0890-6238(94)90047-7; Howell S, 1998, ENDOCRIN METAB CLIN, V27, P927, DOI 10.1016/S0889-8529(05)70048-7; Hoyer PB, 2007, BIRTH DEFECTS RES B, V80, P113, DOI 10.1002/bdrb.20103; Hoyer PB, 1996, ANNU REV PHARMACOL, V36, P307; Hu XM, 2001, BIOL REPROD, V65, P1489, DOI 10.1095/biolreprod65.5.1489; Hu XM, 2001, BIOL REPROD, V65, P87, DOI 10.1095/biolreprod65.1.87; Hu XM, 2002, BIOL REPROD, V67, P718, DOI 10.1095/biolreprod.102.004259; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Hutt KJ, 2006, MOL HUM REPROD, V12, P61, DOI 10.1093/molehr/gal010; IARC, 2008, IARC MONOGR EVAL CAR, V97, P3; Igawa Y, 2009, TOXICOL APPL PHARM, V234, P361, DOI 10.1016/j.taap.2008.10.009; IGUCHI T, 1991, In Vivo (Attiki), V5, P359; IGUCHI T, 1990, BIOL REPROD, V43, P478, DOI 10.1095/biolreprod43.3.478; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; International Agency for Research on Cancer IARC, 1994, IARC MON EV CARC RIS; Ismail RS, 1996, MOL REPROD DEV, V43, P458, DOI 10.1002/(SICI)1098-2795(199604)43:4&lt;458::AID-MRD8&gt;3.0.CO;2-O; Ito A, 2009, J TOXICOL SCI, V34, pSP53; JARRELL J, 1986, AM J OBSTET GYNECOL, V154, P306; Jefferson W, 2006, BIOL REPROD, V74, P161, DOI 10.1095/biolreprod.105.045724; Jefferson WN, 2007, MOL NUTR FOOD RES, V51, P832, DOI 10.1002/mnfr.200600258; Jefferson WN, 2002, BIOL REPROD, V67, P1285, DOI 10.1095/biolreprod.102.005371; JICK H, 1977, LANCET, V1, P1354; Juengel JL, 2004, ANIM REPROD SCI, V82-3, P447, DOI 10.1016/j.anireprosci.2004.04.021; Jurisicova A, 2007, J CLIN INVEST, V117, P3971, DOI 10.1172/JCI28493; Kamijima M, 1997, J OCCUP HEALTH, V39, P144, DOI 10.1539/joh.39.144; Keating AF, 2009, TOXICOL APPL PHARM, V241, P127, DOI 10.1016/j.taap.2009.08.012; Keating AF, 2010, TOXICOL APPL PHARM, V247, P71, DOI 10.1016/j.taap.2010.06.002; Kezele P, 2005, BIOL REPROD, V73, P967, DOI 10.1095/bioreprod.105.043117; Kezele PR, 2002, MOL CELL ENDOCRINOL, V192, P37, DOI 10.1016/S0303-7207(02)00114-4; Kim Y, 1999, TOXICOL LETT, V108, P309, DOI 10.1016/S0378-4274(99)00103-4; Kim Y, 1996, SCAND J WORK ENV HEA, V22, P387; KOCIBA RJ, 1971, CANCER CHEMOTH REP 1, V55, P1; Koh JM, 1998, EUR J ENDOCRINOL, V138, P554, DOI 10.1530/eje.0.1380554; Kouki T, 2003, HORM BEHAV, V44, P140, DOI 10.1016/S0018-506X(03)00122-3; Larsen EC, 2003, J CLIN ENDOCR METAB, V88, P5307, DOI 10.1210/jc.2003-030352; Lee CJ, 2005, MUTAT RES-FUND MOL M, V578, P247, DOI 10.1016/j.mrfmmm.2005.05.019; Lee WS, 2004, MOL REPROD DEV, V69, P159, DOI 10.1002/mrd.20163; LI RH, 1995, ENDOCRINOLOGY, V136, P849, DOI 10.1210/en.136.3.849; Liu K, 2006, DEV BIOL, V299, P1, DOI 10.1016/j.ydbio.2006.07.038; Liu XW, 1998, ENDOCRINOLOGY, V139, P2342, DOI 10.1210/en.139.5.2342; Manger K, 2006, AUTOIMMUN REV, V5, P269, DOI 10.1016/j.autrev.2005.10.001; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; MATTISON DR, 1979, CANCER RES, V39, P3471; MATTISON DR, 1979, CHEM-BIOL INTERACT, V28, P133, DOI 10.1016/0009-2797(79)90120-0; MATTISON DR, 1983, AM J IND MED, V4, P191, DOI 10.1002/ajim.4700040117; MATTISON DR, 1980, TOXICOL APPL PHARM, V53, P249, DOI 10.1016/0041-008X(80)90424-X; Mayer LP, 2002, REPROD TOXICOL, V16, P775, DOI 10.1016/S0890-6238(02)00048-5; Mazatid S, 2005, DEV BIOL, V277, P403, DOI 10.1016/j.ydbio.2004.10.001; McGee EA, 1998, MOL CELL ENDOCRINOL, V140, P15, DOI 10.1016/S0303-7207(98)00023-9; McGee EA, 1999, FERTIL STERIL, V71, P732, DOI 10.1016/S0015-0282(98)00547-0; Meirow D, 2001, HUM REPROD, V16, P632, DOI 10.1093/humrep/16.4.632; Meirow D, 2001, HUM REPROD UPDATE, V7, P535, DOI 10.1093/humupd/7.6.535; Meirow D, 2000, MOL CELL ENDOCRINOL, V169, P123, DOI 10.1016/S0303-7207(00)00365-8; Meirow D, 1999, HUM REPROD, V14, P1903, DOI 10.1093/humrep/14.7.1903; MELNICK RL, 1992, REV ENVIRON CONTAM T, V124, P111; MERCHANT H, 1972, AM J ANAT, V134, P127, DOI 10.1002/aja.1001340110; Molina JR, 2005, DRUG SAFETY, V28, P401, DOI 10.2165/00002018-200528050-00004; Moore RK, 2005, MOL CELL ENDOCRINOL, V234, P67, DOI 10.1016/j.mce.2004.10.012; Mumtaz MM, 1996, TOXICOL IND HEALTH, V12, P742; *NAT TOX PROGR, 1986, TOX CARC STUD 4 VIN, P303; *NAT TOX PROGR, 1989, TOX CARC STUD 4 VIN, P362; National Toxicology Program, 1993, NAT TOX PROGR TECH R, V434, P1; Neal MS, 2008, REPROD TOXICOL, V25, P100, DOI 10.1016/j.reprotox.2007.10.012; Neal MS, 2010, REPROD BIOMED ONLINE, V21, P100, DOI 10.1016/j.rbmo.2010.03.025; Newbold RR, 2004, TOXICOL APPL PHARM, V199, P142, DOI 10.1016/j.taap.2003.11.033; NEWBOLD RR, 1983, BIOL REPROD, V28, P735, DOI 10.1095/biolreprod28.3.735; NICOSIA SV, 1985, CANCER, V55, P2364, DOI 10.1002/1097-0142(19850515)55:10&lt;2364::AID-CNCR2820551011&gt;3.0.CO;2-E; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Nilsson E, 2001, MOL CELL ENDOCRINOL, V175, P123, DOI 10.1016/S0303-7207(01)00391-4; Nilsson EE, 2002, MOL CELL ENDOCRINOL, V188, P65, DOI 10.1016/S0303-7207(01)00746-8; Nilsson EE, 2004, MOL CELL ENDOCRINOL, V214, P19, DOI 10.1016/j.mce.2003.12.001; Nilsson EE, 2006, REPRODUCTION, V131, P1007, DOI 10.1530/rep.1.00978; Nilsson EE, 2003, BIOL REPROD, V69, P1265, DOI 10.1095/biolreprod.103.018671; Ohinata Y, 2009, CELL, V137, P571, DOI 10.1016/j.cell.2009.03.014; Park J, 2010, J KOREAN MED SCI, V25, pS41, DOI 10.3346/jkms.2010.25.S.S41; Park JS, 1997, J OCCUP HEALTH, V39, P138, DOI 10.1539/joh.39.138; Pepling ME, 1999, TRENDS CELL BIOL, V9, P257, DOI 10.1016/S0962-8924(99)01594-9; Pepling ME, 1998, DEVELOPMENT, V125, P3323; Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Pesty A, 2010, REPROD TOXICOL, V29, P93, DOI 10.1016/j.reprotox.2009.10.007; PETERS H, 1976, ACTA ENDOCRINOL-COP, V82, P617; Petrillo SK, 2011, TOXICOL APPL PHARM, V253, P94, DOI 10.1016/j.taap.2011.03.012; PLOWCHALK DR, 1992, REPROD TOXICOL, V6, P411, DOI 10.1016/0890-6238(92)90004-D; PLOWCHALK DR, 1991, TOXICOL APPL PHARM, V107, P472, DOI 10.1016/0041-008X(91)90310-B; Rajapaksa KS, 2007, TOXICOL SCI, V96, P327, DOI 10.1093/toxsci/kfl202; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; Reynaud K, 2000, MOL REPROD DEV, V56, P483, DOI 10.1002/1098-2795(200008)56:4&lt;483::AID-MRD6&gt;3.3.CO;2-F; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rodriguez HA, 2010, REPROD TOXICOL, V30, P550, DOI 10.1016/j.reprotox.2010.07.008; Sakurada Y, 2009, J TOXICOL SCI, V34, pSP65; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Sawyer HR, 2002, BIOL REPROD, V66, P1134, DOI 10.1095/biolreprod66.4.1134; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Sekiguchi S, 2002, TOXICOL LETT, V126, P41, DOI 10.1016/S0378-4274(01)00429-5; SEKIGUCHI S, 2001, TOXICOL IND HEALTH, V16, P277; SHEEHAN DM, 1979, ENDOCRINOLOGY, V104, P1442; Shuster Lynne T, 2008, Menopause Int, V14, P111, DOI 10.1258/mi.2008.008016; Silva JRV, 2004, THERIOGENOLOGY, V61, P1691, DOI 10.1016/j.theriogenology.2003.09.014; Skinner MK, 2005, HUM REPROD UPDATE, V11, P461, DOI 10.1093/humupd/dmi020; Sklar C., 2005, J NATL CANC I MONOGR, V34, P25; Sklar CA, 2006, J NATL CANCER I, V98, P890, DOI 10.1093/jnci/djj243; SMITH BJ, 1990, TOXICOL APPL PHARM, V105, P372, DOI 10.1016/0041-008X(90)90141-G; Smitz J, 1998, MOL REPROD DEV, V50, P294, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;294::AID-MRD5&gt;3.0.CO;2-E; Springer LN, 1996, TOXICOL APPL PHARM, V139, P394, DOI 10.1006/taap.1996.0180; STEDMAN RL, 1968, CHEM REV, V68, P153, DOI 10.1021/cr60252a002; Stroud JS, 2009, FERTIL STERIL, V92, P417, DOI 10.1016/j.fertnstert.2008.07.1714; SUSIARJO M, 2007, PLOS GENET, V3, P66; Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9; TAKEUCHI Y, 1997, J OCCUP HEALTH, V39, P191; Tan SJ, 2010, EUR J OBSTET GYN R B, V149, P182, DOI 10.1016/j.ejogrb.2009.12.028; Thibaud E, 1998, BONE MARROW TRANSPL, V21, P287, DOI 10.1038/sj.bmt.1701075; Tingen CM, 2009, BIOL REPROD, V81, P16, DOI 10.1095/biolreprod.108.074898; Tuttle AM, 2009, HUM REPROD, V24, P1452, DOI 10.1093/humrep/dep023; Uzumcu M, 2007, REPROD TOXICOL, V23, P337, DOI 10.1016/j.reprotox.2006.10.006; VAHAKANGAS K, 1985, TOXICOL LETT, V25, P75, DOI 10.1016/0378-4274(85)90103-1; WAGENEN GV, 1965, HOMO SAPIENS MACACA; Wallace WHB, 2005, LANCET ONCOL, V6, P209, DOI 10.1016/S1470-2045(05)70092-9; Wallace WHB, 2005, INT J RADIAT ONCOL, V62, P738, DOI 10.1016/j.ijrobp.2004.11.038; WALLACE WHB, 1989, MED PEDIATR ONCOL, V17, P409; Wallace WHB, 2003, HUM REPROD, V18, P117, DOI 10.1093/humrep/deg016; Wandji SA, 1996, BIOL REPROD, V55, P942, DOI 10.1095/biolreprod55.5.942; WEINBERG CR, 1989, AM J EPIDEMIOL, V129, P1072; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Yeh J, 2006, BIOCHEM BIOPH RES CO, V348, P337, DOI 10.1016/j.bbrc.2006.06.195; Ying Y, 2001, DEV BIOL, V232, P484, DOI 10.1006/dbio.2001.0173; Ying Y, 2001, P NATL ACAD SCI USA, V98, P7858, DOI 10.1073/pnas.151242798; Yu N, 1999, BIOL REPROD, V61, P1558, DOI 10.1095/biolreprod61.6.1558; Yu XZ, 1999, TOXICOL APPL PHARM, V159, P185, DOI 10.1006/taap.1999.8730; Yucebilgin MS, 2004, AUST NZ J OBSTET GYN, V44, P6, DOI 10.1111/j.1479-828X.2004.00143.x; Zhao J, 2001, MOL REPROD DEV, V58, P287, DOI 10.1002/1098-2795(200103)58:3&lt;287::AID-MRD7&gt;3.0.CO;2-G; Zhuang XL, 2010, FITOTERAPIA, V81, P998, DOI 10.1016/j.fitote.2010.06.01818311SOC STUDY REPRODUCTIONMADISON1603 MONROE ST, MADISON, WI 53711-2021 USABIOL REPRODNOVDiscipline: Reproductive Biology842FU</notes>
    <keywords>4-VINYLCYCLOHEXENE DIEPOXIDE; AGENTS; apoptosis; atresia; BIOLOGY; BISPHENOL-A; BONE; CANCER; CARCINOGENESIS; CELL; CHILDHOOD-CANCER SURVIVOR; CISPLATIN; COMPONENTS; DAMAGE; development; DNA damage; DNA-DAMAGE; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; EXPOSURE; fertility; follicle; FOOD; GENE; GENE-EXPRESSION; GROWTH-FACTOR-I; HEALTH; HUMANS; In vitro; IN-VITRO; IN-VITRO CULTURE; IN-VIVO; LIGAND; MOUSE OVARY; Occupational; OCCUPATIONAL-EXPOSURE; ovary; p38; POLYCYCLIC AROMATIC-HYDROCARBONS; POPULATION; PRIMORDIAL FOLLICULAR RESERVE; RADIATION; RAT; RAT OVARY; RATS; Reproduction; TOXICITY; toxicology; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>871</startpage>
    <endpage>883</endpage>
    <journalfull>Biology of Reproduction</journalfull>
    <issue>5</issue>
    <volume>85</volume>
    <abstract>Women are born with a finite population of ovarian follicles, which are slowly depleted during their reproductive years until reproductive failure (menopause) occurs. The rate of loss of primordial follicles is determined by genetic and environmental influences, but certain toxic exposures can accelerate this process. Ionizing radiation reduces preantral follicle numbers in rodents and humans in a dose-dependent manner. Cigarette smoking is linked to menopause occurring 1-4 yr earlier than with nonsmokers, and components of smoke, polycyclic aromatic hydrocarbons, can cause follicle depletion in rodents or in ovaries in vitro. Chemotherapeutic agents, such as alkylating drugs and cisplatin, also cause loss of preantral ovarian follicles. Effects depend on dose, type, and reactivity of the drug, and the age of the individual. Evidence suggests DNA damage may underlie follicle loss induced by one common alkylating drug, cyclophosphamide. Occupational exposures have also been linked to ovarian damage. In an industrial setting, 2-bromopropane caused infertility in men and women, and it can induce ovarian follicle depletion in rats. Solvents, such as butadiene, 4-vinylcyclohexene, and their diepoxides, can also cause specific preantral follicle depletion. The mechanism(s) underlying effects of the latter compound may involve alterations in apoptosis, survival factors such as KIT/Kit Ligand, and/or the cellular signaling that maintains primordial follicle dormancy. Estrogenic endocrine disruptors may alter follicle formation/development and impair fertility or normal development of offspring. Thus, specific exposures are known or suspected of detrimentally impacting preantral ovarian follicles, leading to early ovarian failure</abstract>
    <url>WOS:000296580000001</url>
    <isbnorissn>0006-3363</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>6</id>
    <title>Noncoding RNA response to xenobiotic exposure: an indicator of toxicity and carcinogenicity</title>
    <authors>Marrone,A.K.; Beland,F.A.; Pogribny,I.P.</authors>
    <availability>[Marrone, April K.; Beland, Frederick A.; Pogribny, Igor P.] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.</availability>
    <date>2014</date>
    <notes>JEnglishReviewPogribny, IP (reprint author), Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USAigor.pogribny@fda.hhs.govAllen RM, 2012, EMBO MOL MED, V4, P882, DOI 10.1002/emmm.201201228; Amaral PP, 2011, NUCLEIC ACIDS RES, V9, pD146; Avissar-Whiting M, 2010, REPROD TOXICOL, V29, P401, DOI 10.1016/j.reprotox.2010.04.004; Bai WL, 2014, EXP MOL PATHOL, V96, P426, DOI 10.1016/j.yexmp.2014.04.011; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beato M, 2013, TRANSCRIPTION, V4; Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188; Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002; Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chen T, 2012, TOXICOLOGY, V292, P63, DOI 10.1016/j.tox.2011.10.020; Chen T, 2010, ENVIRON HEALTH PERSP, V118, P1597, DOI 10.1289/ehp.1002153; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Cloonan N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r126; Conti Aline de, 2014, Toxicol Sci, V139, P371, DOI 10.1093/toxsci/kfu044; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Di Leva G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003311; Drayton RM, 2012, BIOCHEM SOC T, V40, P821, DOI 10.1042/BST20120055; Duan HH, 2010, TOXICOL IN VITRO, V24, P928, DOI 10.1016/j.tiv.2009.11.013; Endo S, 2014, TOXICOLOGY, V319, P75, DOI 10.1016/j.tox.2014.02.011; Fang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073004; Feldstein O, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-131; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Ferraro Lorenzo, 2012, Hormones &amp; Cancer, V3, P65, DOI 10.1007/s12672-012-0102-1; Gao LY, 2013, TOXICOL LETT, V223, P205, DOI 10.1016/j.toxlet.2013.09.015; Garofalo M, 2013, DRUG RESIST UPDATE, V16, P47, DOI 10.1016/j.drup.2013.05.001; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gatti DM, 2011, MUTAT RES-FUND MOL M, V714, P126, DOI 10.1016/j.mrfmmm.2011.05.007; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Papaioannou MD, 2014, TOXICOL LETT, V229, P9, DOI 10.1016/j.toxlet.2014.05.021; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Han ZY, 2014, TOXICOL LETT, V225, P275, DOI 10.1016/j.toxlet.2013.12.008; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hecht SS, 2006, LANGENBECK ARCH SURG, V391, P603, DOI 10.1007/s00423-006-0111-z; Hickling KC, 2010, TOXICOL PATHOL, V38, P230, DOI 10.1177/0192623309357946; Hornby Robert James, 2014, Expert Rev Clin Pharmacol, V7, P349, DOI 10.1586/17512433.2014.904201; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914; Huang JL, 2014, CARCINOGENESIS, V35, P507, DOI 10.1093/carcin/bgt405; Hughes MF, 2011, TOXICOL SCI, V123, P305, DOI 10.1093/toxsci/kfr184; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC MONOGRAPHS EVAL, V100F; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1995, IARC MONOGRAPHS EVAL, V63; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC MONOGRAPHS EVAL, V83; Izzotti A, 2014, INT J HYG ENVIR HEAL, V217, P601, DOI 10.1016/j.ijheh.2014.01.001; Izzotti A, 2011, MUTAT RES-FUND MOL M, V717, P9, DOI 10.1016/j.mrfmmm.2010.12.008; Izzotti A, 2013, CARCINOGENESIS, V34, P2322, DOI 10.1093/carcin/bgt178; Jackson AF, 2014, TOXICOL APPL PHARM, V274, P63, DOI 10.1016/j.taap.2013.10.019; Jalali S, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-25; Jardim MJ, 2009, ENVIRON HEALTH PERSP, V117, P1745, DOI 10.1289/ehp.0900756; Jiang M, 2014, BIOCHEM PHARMACOL, V87, P254, DOI 10.1016/j.bcp.2013.10.020; Jiang YG, 2011, TOXICOL SCI, V119, P50, DOI 10.1093/toxsci/kfq306; Jin HY, 2013, EMBO J, V32, P2377, DOI 10.1038/emboj.2013.178; Josse R, 2012, TOXICOL APPL PHARM, V258, P176, DOI 10.1016/j.taap.2011.10.019; Kalscheuer S, 2008, CARCINOGENESIS, V29, P2394, DOI 10.1093/carcin/bgn209; Kensler TW, 2011, TOXICOL SCI, V120, pS28, DOI 10.1093/toxsci/kfq283; Klinge CM, 2012, TRENDS ENDOCRIN MET, V23, P223, DOI 10.1016/j.tem.2012.03.002; Koufaris C, 2013, TOXICOL SCI, V131, P337, DOI 10.1093/toxsci/kfs302; Koufaris C, 2012, TOXICOL SCI, V128, P532, DOI 10.1093/toxsci/kfs170; Koufaris C, 2013, TOXICOLOGY, V314, P247, DOI 10.1016/j.tox.2013.10.004; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kumamoto T, 2013, J TOXICOL SCI, V38, P485; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI DOI 10.1007/S13148-011-0040-8; Ladewig E, 2012, GENOME RES, V22, P1634, DOI 10.1101/gr.133553.111; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee CG, 2014, KIDNEY INT; Lempiainen H, 2013, TOXICOL SCI, V131, P375, DOI 10.1093/toxsci/kfs303; Lewis PJS, 2011, HEPATOLOGY, V54, P1767, DOI 10.1002/hep.24538; Li DC, 2012, TOXICOL SCI, V125, P382, DOI 10.1093/toxsci/kfr299; Li X, 2014, PHYTOTHER RES; Ligorio M, 2011, MUTAT RES-FUND MOL M, V717, P116, DOI 10.1016/j.mrfmmm.2011.07.020; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu L, 2011, TOXICOL IN VITRO, V24, P1168; Loeb LA, 2008, CANCER RES, V68, P6863, DOI 10.1158/0008-5472.CAN-08-2852; Lovat F, 2011, SEMIN ONCOL, V38, P724, DOI 10.1053/j.seminoncol.2011.08.006; Luk JM, 2011, J BIOL CHEM, V286, P30706, DOI 10.1074/jbc.M111.229831; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Maurel M, 2013, AM J PHYSIOL-CELL PH, V304, pC1117, DOI 10.1152/ajpcell.00061.2013; McClain R M, 1995, Prog Clin Biol Res, V391, P325; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Meunier L, 2012, ENDOCRINOLOGY, V153, P1936, DOI 10.1210/en.2011-1109; Mor E, 2013, BIOESSAYS, V35, P881, DOI 10.1002/bies.201200157; Morehouse KM, 2008, FOOD ADDIT CONTAM, V25, P259, DOI 10.1080/02652030701552949; Moro S, 2012, MOL NUTR FOOD RES, V56, P1197, DOI 10.1002/mnfr.201200093; MULLER N, 1988, BIOCHIM BIOPHYS ACTA, V938, P334, DOI 10.1016/0005-2736(88)90131-9; Nagano T, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/40/405102; Nassirpour R, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-485; Ngalame NNO, 2014, TOXICOL SCI, V138, P268, DOI 10.1093/toxsci/kfu002; Novikova Irina V, 2012, Bioarchitecture, V2, P189, DOI 10.4161/bioa.22592; NTP, 1990, NATL TOX PROGR TECH, V382, P1; Ozgur E, 2013, CLIN EXP MED, V13, P119, DOI 10.1007/s10238-012-0181-x; Pandey M, 2014, EXP MOL PATHOL, V96, P61, DOI 10.1016/j.yexmp.2013.12.001; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Paris O, 2012, ONCOGENE, V31, P4196, DOI 10.1038/onc.2011.583; Pinho FG, 2013, CANCER RES, V73, P5936, DOI 10.1158/0008-5472.CAN-13-0158; Pink RC, 2011, RNA, V17, P792, DOI 10.1261/rna.2658311; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198; Qian GQ, 2013, TOXICOL PATHOL, V41, P1093, DOI 10.1177/0192623313477256; Rager JE, 2013, ENVIRON HEALTH PERSP, V121, P339, DOI 10.1289/ehp.1205582; Rager JE, 2011, ENVIRON HEALTH PERSP, V119, P494, DOI 10.1289/ehp.1002614; Ray Paul D, 2014, Front Genet, V5, P201, DOI 10.3389/fgene.2014.00201; Recio L, 2013, TOXICOL SCI, V135, P369, DOI 10.1093/toxsci/kft153; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Rosok O, 2004, NAT BIOTECHNOL, V22, P104, DOI 10.1038/nbt925; Saikumar J, 2012, TOXICOL SCI, V129, P256, DOI 10.1093/toxsci/kfs210; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Sandhu H, 2014, CLIN SCI, V126, P377, DOI 10.1042/CS20120620; Sauvageau M, 2013, ELIFE, V2, DOI [10.7554/eLife.01749, 10.7554/eLife.01749.001]; Schorderet P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002071; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318; Spector Y, 2013, MOL ONCOL, V7, P732, DOI 10.1016/j.molonc.2013.03.002; Sturchio E, 2014, SCI TOTAL ENVIRON, V472, P672, DOI 10.1016/j.scitotenv.2013.11.092; Takahashi K, 2014, DRUG METAB PHARMACOK; Tal TL, 2012, NEUROTOXICOLOGY, V33, P530, DOI 10.1016/j.neuro.2012.02.013; Talaska G, 2003, J ENVIRON SCI HEAL C, V21, P29, DOI 10.1081/GNC-120021372; Teng Y, 2013, TOXICOL SCI, V131, P71, DOI 10.1093/toxsci/kfs290; Thai P, 2013, AM J RESP CELL MOL, V49, P204, DOI 10.1165/rcmb.2013-0159RC; Tian D, 2010, CELL, V143, P390, DOI 10.1016/j.cell.2010.09.049; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Vacchi-Suzzi C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040395; Veiga-Lopez A, 2013, ENDOCRINOLOGY, V154, P1873, DOI 10.1210/en.2012-2129; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang F, 2014, ENVIRON TOXICOL, V29, P679, DOI 10.1002/tox.21795; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang MY, 2009, CANCER RES, V69, P7170, DOI 10.1158/0008-5472.CAN-09-1571; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wiesen JL, 2009, MOL IMMUNOL, V46, P1222, DOI 10.1016/j.molimm.2008.11.012; Wu JJ, 2013, TOXICOL APPL PHARM, V267, P238, DOI 10.1016/j.taap.2013.01.002; Wu XD, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-244; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xi SC, 2013, J CLIN INVEST, V123, P1241, DOI 10.1172/JCI61271; Yamamoto M, 2013, ENVIRON HEALTH PERSP, V121, P670, DOI 10.1289/ehp.1205963; Yang H, 2013, BIOCHEM PHARMACOL, V85, P1761, DOI 10.1016/j.bcp.2013.04.020; Yang JS, 2011, MOL CELL, V43, P892, DOI 10.1016/j.molcel.2011.07.024; Yang WQ, 2014, TOXICOL LETT, V226, P140, DOI 10.1016/j.toxlet.2014.01.021; Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065309; Yokoi T, 2011, TOXICOL SCI, V123, P1, DOI 10.1093/toxsci/kfr168; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045; Zhao Y, 2011, TOXICOL LETT, V205, P320, DOI 10.1016/j.toxlet.2011.06.022; Zhao ZY, 2014, TUMOR BIOL, V35, P5227, DOI 10.1007/s13277-014-1679-5; Meiri E, 2012, ONCOLOGIST, V17, P801, DOI 10.1634/theoncologist.2011-04661510INFORMA HEALTHCARELONDONTELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDEXPERT OPIN DRUG METOCTDiscipline: Biochemistry &amp; Molecular Biology; Pharmacology &amp; PharmacyAP6QO</notes>
    <keywords>BISPHENOL-A; BREAST-CANCER CELLS; BRONCHIAL EPITHELIAL-CELLS; CANCER; epigenetics; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; IN-VITRO; INDUCED LIVER-INJURY; long noncoding RNAs; MALIGNANT-TRANSFORMATION; MICRORNA EXPRESSION; MICRORNAS; noncoding RNAs; TOXICITY; TUMORIGENESIS; X-CHROMOSOME INACTIVATION; xenobiotics</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1409</startpage>
    <endpage>1422</endpage>
    <journalfull>Expert Opinion on Drug Metabolism &amp; Toxicology</journalfull>
    <issue>10</issue>
    <volume>10</volume>
    <abstract>Introduction: Human exposure to certain environmental and occupational chemicals is one of the major risk factors for noncommunicable diseases, including cancer. Therefore, it is desirable to take advantage of subtle exposure-related adverse cellular events for early disease detection and to identify potential dangers caused by new and currently under-evaluated drugs and chemicals. Nongenotoxic events due to carcinogen/toxicant exposure are a general hallmark of sustained cellular stress leading to tumorigenesis. These processes are globally regulated via noncoding RNAs (ncRNAs). Tumorigenesis-associated genotoxic and nongenotoxic events lead to the altered expression of ncRNAs and may provide a mechanistic link between chemical exposure and tumorigenesis. Current advances in toxicogenomics are beginning to provide valuable insight into gene-chemical interactions at the transcriptome level. Areas covered: In this review, we summarize recent information about the impact of xenobiotics on ncRNAs. Evidence highlighted in this review suggests a critical role of ncRNAs in response to carcinogen/toxicant exposure. Expert opinion: Benefits for the use of ncRNAs in carcinogenicity assessment include remarkable tissue specificity, early appearance, low baseline variability, and their presence and stability in biological fluids, which suggests that the incorporation of ncRNAs in the evaluation of cancer risk assessment may enhance substantially the efficiency of toxicity and carcinogenicity testing</abstract>
    <url>WOS:000342202600008</url>
    <isbnorissn>1742-5255</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>116</id>
    <title>Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): Discovery of an ER alpha-selective antagonist</title>
    <authors>Maruyama,K.; Nakamura,M.; Tomoshige,S.; Sugita,K.; Makishima,M.; Hashimoto,Y.; Ishikawa,M.</authors>
    <availability>[Maruyama, Keisuke; Nakamura, Masaharu; Tomoshige, Shusuke; Sugita, Kazuyuki; Hashimoto, Yuichi; Ishikawa, Minoru] Univ Tokyo, Inst Mol &amp; Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan. [Makishima, Makoto] Nihon Univ, Sch Med, Itabashi Ku, Tokyo 1738610, Japan.</availability>
    <date>2013</date>
    <notes>JEnglishArticleIshikawa, M (reprint author), Univ Tokyo, Inst Mol &amp; Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japanm-ishikawa@iam.u-tokyo.ac.jpBadia E, 2007, CURR MED CHEM, V14, P3035, DOI 10.2174/092986707782794023; Boehm MF, 1999, CHEM BIOL, V6, P265, DOI 10.1016/S1074-5521(99)80072-6; Coleman KP, 2003, QSAR COMB SCI, V22, P78, DOI 10.1002/qsar.200390008; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004; Dykstra KD, 2007, BIOORG MED CHEM LETT, V17, P2322, DOI 10.1016/j.bmcl.2007.01.054; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Franz AK, 2013, J MED CHEM, V56, P388, DOI 10.1021/jm3010114; Fujii S, 2013, J MED CHEM, V56, P160, DOI 10.1021/jm3013757; Grishin NV, 2001, J STRUCT BIOL, V134, P167, DOI 10.1006/jsbi.2001.4335; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Hashimoto Y, 2008, ARCH PHARM, V341, P536, DOI 10.1002/ardp.200700217; Hosoda S, 2009, MINI-REV MED CHEM, V9, P572; Hosoda S, 2006, BIOORGAN MED CHEM, V14, P5489, DOI 10.1016/j.bmc.2006.04.039; Hosoda S, 2005, BIOORG MED CHEM LETT, V15, P4327, DOI 10.1016/j.bmcl.2005.06.044; Hosoda S, 2007, BIOORG MED CHEM LETT, V17, P5414, DOI 10.1016/j.bmcl.2007.07.039; Kainuma M, 2006, BIOORG MED CHEM LETT, V16, P3213, DOI 10.1016/j.bmcl.2006.03.075; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Kent C, 1998, NEW ENGL J MED, V339, P1609; Koch MA, 2004, P NATL ACAD SCI USA, V101, P16721, DOI 10.1073/pnas.0404719101; Koonin EV, 2002, NATURE, V420, P218, DOI 10.1038/nature01256; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Maruyama K, 2010, BIOORG MED CHEM LETT, V20, P6661, DOI 10.1016/j.bmcl.2010.09.011; Matsushima A, 2010, ENVIRON HEALTH PERSP, V118, P1267, DOI 10.1289/ehp.0901819; Nakamura M, 2013, BIOORGAN MED CHEM, V21, P1643, DOI 10.1016/j.bmc.2013.01.060; Noguchi-Yachide T, 2011, HETEROCYCLES, V83, P2137, DOI 10.3987/COM-11-12287; Oesterreich S, 2001, CANCER RES, V61, P5771; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; Rivas A, 2002, J STEROID BIOCHEM, V82, P45, DOI 10.1016/S0960-0760(02)00146-2; Schiff Rachel, 2005, Cancer Chemother Pharmacol, V56 Suppl 1, P10, DOI 10.1007/s00280-005-0108-2; Shihai C, 2006, CHINESE SCI BULL, V51, P287; Showell GA, 2003, DRUG DISCOV TODAY, V8, P551, DOI 10.1016/S1359-6446(03)02726-0; Sumbayev VV, 2008, MOL CELL ENDOCRINOL, V287, P30, DOI 10.1016/j.mce.2008.02.004; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Swann SL, 2002, J AM CHEM SOC, V124, P13795, DOI 10.1021/ja0268377; Zhou HB, 2009, BIOORG MED CHEM LETT, V19, P108, DOI 10.1016/j.bmcl.2008.11.006; Zimmermann J, 2005, J STEROID BIOCHEM, V94, P57, DOI 10.1016/j.jsbmb.2004.12.018393PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDBIOORG MED CHEM LETTJUL 15Discipline: Pharmacology &amp; Pharmacy; Chemistry168KN</notes>
    <keywords>3,3-DIPHENYLPENTANE SKELETON; ALPHA; ANDROGEN RECEPTOR; Antagonist; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CELL; DIPHENYLPENTANE SKELETON; DRUG DISCOVERY; ER alpha; ER-ALPHA; ER-BETA; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; LIGAND-BINDING; LIGAND-BINDING DOMAIN; LIGANDS; MULTI-TEMPLATE; Nuclear receptor; PHARMACOLOGY; PROTEIN; RECEPTOR; SILICON; TAMOXIFEN RESISTANCE; TRANSACTIVATION; VITAMIN-D</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>4031</startpage>
    <endpage>4036</endpage>
    <journalfull>Bioorganic &amp; Medicinal Chemistry Letters</journalfull>
    <issue>14</issue>
    <volume>23</volume>
    <abstract>Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. Here, on the basis of those ideas, we hypothesized that the diphenylmethane derivative bisphenol A (BPA) would bind to the ligand-binding domain of estrogen receptors (ERs) in a similar manner to estradiol and act as a steroid surrogate. To test this idea, we synthesized a series of BPA analogs and evaluated their structure-activity relationships, focusing on agonistic/antagonistic activities at ERs and ER alpha/ER beta subtype selectivity. Among the compounds examined, 18 was found to be a potent ER alpha-antagonist with high selectivity over ER beta and androgen receptor under our assay conditions. A computational docking study suggested that 18 would bind to the antagonistic conformation of ER alpha. ER alpha-selective antagonists, such as 18, are candidate agents for treatment of breast cancer. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000320704600005</url>
    <isbnorissn>0960-894X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>201</id>
    <title>Human and Rat ABC Transporter Efflux of Bisphenol A and Bisphenol A Glucuronide: Interspecies Comparison and Implications for Pharmacokinetic Assessment</title>
    <authors>Mazur,C.S.; Marchitti,S.A.; Dimova,M.; Kenneke,J.F.; Lumen,A.; Fisher,J.</authors>
    <availability>[Mazur, Christopher S.; Marchitti, Satori A.; Kenneke, John F.] US EPA, Off Res &amp; Dev, Natl Exposure Res Lab, Ecosyst Res Div, Athens, GA 30605 USA. [Dimova, Mira] Univ Georgia, Coll Agr &amp; Environm Sci, Athens, GA 30605 USA. [Lumen, Annie; Fisher, Jeff] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMazur, CS (reprint author), US EPA, Off Res &amp; Dev, Natl Exposure Res Lab, Ecosyst Res Div, 960 Coll Stn Rd, Athens, GA 30605 USAmazur.chris@epa.govAller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; Buxbaum E, 1999, EUR J BIOCHEM, V265, P64, DOI 10.1046/j.1432-1327.1999.00644.x; Campbell JD, 2004, J BIOL CHEM, V279, P463, DOI 10.1074/jbc.M310711200; Doerge DR, 2010, TOXICOL APPL PHARM, V248, P1, DOI 10.1016/j.taap.2010.07.009; Doerge DR, 2011, TOXICOL LETT, V207, P298, DOI 10.1016/j.toxlet.2011.09.020; Doerge DR, 2011, TOXICOL APPL PHARM, V255, P261, DOI 10.1016/j.taap.2011.07.009; Fisher JW, 2011, TOXICOL APPL PHARM, V257, P122, DOI 10.1016/j.taap.2011.08.026; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Haimeur A, 2004, MOL PHARMACOL, V65, P1375, DOI 10.1124/mol.65.6.1375; Hirouchi M, 2009, DRUG METAB DISPOS, V37, P2103, DOI 10.1124/dmd.109.027193; Inoue H, 2003, DRUG METAB DISPOS, V31, P140, DOI 10.1124/dmd.31.1.140; Jin H, 2005, PLACENTA, V26, pS96, DOI 10.1016/j.placenta.2005.01.016; Kim IW, 2006, BIOCHEMISTRY-US, V45, P7605, DOI 10.1021/bi060308o; Koike K, 2004, J BIOL CHEM, V279, P12325, DOI 10.1074/jbc.M311435200; Kuester RK, 2007, DRUG METAB DISPOS, V35, P1910, DOI 10.1124/dmd.107.014787; Kurebayashi H, 2002, TOXICOL SCI, V68, P32, DOI 10.1093/toxsci/68.1.32; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Li N, 2009, DRUG METAB DISPOS, V37, P66, DOI 10.1124/dmd.108.023234; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; Mazur CS, 2010, DRUG METAB DISPOS, V38, P2232, DOI 10.1124/dmd.110.034819; Morck TJ, 2010, REPROD TOXICOL, V30, P131, DOI 10.1016/j.reprotox.2010.02.007; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oswald S, 2007, XENOBIOTICA, V37, P1171, DOI 10.1080/00498250701570251; Pang KS, 2009, MOL PHARMACEUT, V6, P1734, DOI 10.1021/mp900258z; Pottenger LH, 2000, TOXICOL SCI, V54, P3, DOI 10.1093/toxsci/54.1.3; Pritchett JJ, 2002, DRUG METAB DISPOS, V30, P1180, DOI 10.1124/dmd.30.11.1180; Prouillac C, 2010, DRUG METAB DISPOS, V38, P1623, DOI 10.1124/dmd.110.033571; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; SARKADI B, 1992, J BIOL CHEM, V267, P4854; TANGWAI DF, 1995, BIOCHEMISTRY-US, V34, P32, DOI 10.1021/bi00001a005; Teeguarden JG, 2005, TOXICOL SCI, V85, P823, DOI 10.1093/toxsci/kfi135; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Westlake CJ, 2003, BIOCHEMISTRY-US, V42, P14099, DOI 10.1021/bi035333y; Yoshikawa Y, 2002, CURR DRUG METAB, V3, P551, DOI 10.2174/1389200023337153; Zamek-Gliszczynski MJ, 2011, DRUG METAB DISPOS, V39, P1794, DOI 10.1124/dmd.111.040162405OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIAUGDiscipline: Toxicology991JY</notes>
    <keywords>ABC transporters; AFFINITIES; AMINO-ACIDS; ASSAY; BINDING; BINDING-AFFINITY; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; breast; breast cancer; BREAST-CANCER; CANCER; Composition; DRUG-BINDING; EFFLUX; EXCRETION; EXPOSURE; extrapolation; HUMAN P-GLYCOPROTEIN; INHIBITOR; MEMBRANE TRANSPORTERS; METABOLISM; MONKEYS; MRP1 ABCC1; MULTIDRUG-RESISTANCE PROTEIN; P-GLYCOPROTEIN; p21; physiologically-based pharmacokinetics; PLACENTA; PROTEIN; PROTEINS; RAT; RESISTANCE; RESISTANT; RISK; Risk assessment; RISK-ASSESSMENT; ROUTE; SPRAGUE-DAWLEY RATS; SUBSTRATE-SPECIFICITY; toxicology; xenobiotic transporters</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>317</startpage>
    <endpage>325</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>2</issue>
    <volume>128</volume>
    <abstract>Significant interspecies differences exist between human and rodent with respect to absorption, distribution, and excretion of bisphenol A (BPA) and its primary metabolite, BPA-glucuronide (BPA-G). ATP-Binding Cassette (ABC) transporter enzymes play important roles in these physiological processes, and their enzyme localization (apical vs. basolateral) in the plasma membrane allows for different cellular efflux pathways. In this study, we utilized an ATPase assay to evaluate BPA and BPA-G as potential substrates for the human and rat ABC transporters: P-glycoprotein (MDR1), multidrug resistance associated proteins (MRPs), and breast cancer resistant protein (BCRP). Based on high ATPase activity, BPA is likely a substrate for rat mdr1b but not for human MDR1 or rat mdr1a. Results indicate that BPA is a potential substrate for rat mrp2 and human MRP2, BCRP, and MRP3. The metabolite BPA-G demonstrated the highest apparent substrate binding affinity for rat mrp2 and human MRP3 but appeared to be a nonsubstrate or potential inhibitor for human MRP2, MDR1, and BCRP and for rat mdr1a, mdr1b, and bcrp. Analysis of ABC transporter amino acid sequences revealed key differences in putative binding site composition that may explain substrate specificity. Collectively, these results suggest that in both rat and human, apical transporters efflux BPA into the bile and/or intestinal lumen. BPA-G would follow a similar pathway in rat; however, in human, due to the basolateral location of MRP3, BPA-G would likely enter systemic and portal blood supplies. These differences between human and rodent ABC transporters may have significant implications for interspecies extrapolation used in risk assessment</abstract>
    <url>WOS:000307698500002</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>352</id>
    <title>Exposure to environmental endocrine disrupting compounds and men's health</title>
    <authors>Meeker,J.D.</authors>
    <availability>Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.</availability>
    <date>2010</date>
    <notes>JEnglishReviewMeeker, JD (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, 6635 SPH Tower,109 S Observ St, Ann Arbor, MI 48109 USAmeekerj@umich.eduAbdelouahab N, 2008, ENVIRON RES, V107, P380, DOI 10.1016/j.envres.2008.01.006; ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Agency for Toxic Substances and Disease Registry (ATSDR), 2004, TOX PROF POL BIPH PO; Akutsu K, 2008, B ENVIRON CONTAM TOX, V80, P345, DOI 10.1007/s00128-008-9370-4; Andersson AM, 2007, J CLIN ENDOCR METAB, V92, P4696, DOI 10.1210/jc.2006-2633; Aneck-Hahn NH, 2007, J ANDROL, V28, P423, DOI 10.2164/jandrol.106.001701; ARONSON KJ, 2009, J EXPO SCI ENV 0610; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Biggs ML, 2008, CANCER EPIDEM BIOMAR, V17, P2012, DOI 10.1158/1055-9965.EPI-08-0032; Bloom M, 2008, ENVIRON TOXICOL PHAR, V25, P386, DOI 10.1016/j.etap.2007.12.004; Bonde JP, 2008, ENVIRON HEALTH PERSP, V116, P269, DOI 10.1289/ehp.10700; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; CARLSEN E, 1992, BRIT MED J, V305, P609; CDC, 2009, 4 CDC CDCP; Codru N, 2007, ENVIRON HEALTH PERSP, V115, P1442, DOI 10.1289/ehp.10315; Dallaire R, 2009, ENVIRON HEALTH PERSP, V117, P1380, DOI 10.1289/ehp.0900633; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Duty SM, 2003, EPIDEMIOLOGY, V14, P269, DOI 10.1097/00001648-200305000-00005; ENEWOLD L, 2005, CANCER EPIDEM BIOMAR, V18, P784; Everett CJ, 2007, ENVIRON RES, V103, P413, DOI 10.1016/j.envres.2006.11.002; Geens T, 2009, CHEMOSPHERE, V76, P755, DOI 10.1016/j.chemosphere.2009.05.024; GONCHAROV A, 2009, ENV HLTH PERSPECT, P1454; Hagmar L, 2003, THYROID, V13, P1021, DOI 10.1089/105072503770867192; Hagmar L, 2001, ARCH ENVIRON HEALTH, V56, P138; Han Y, 2008, CHEMOSPHERE, V72, P785, DOI 10.1016/j.chemosphere.2008.03.058; Hanaoka T, 2002, OCCUP ENVIRON MED, V59, P625, DOI 10.1136/oem.59.9.625; Hardell L, 2006, J OCCUP ENVIRON MED, V48, P700, DOI 10.1097/01.jom.0000205989.46603.43; Hardell L, 2006, INT J ANDROL, V29, P228, DOI 10.1111/j.1365-2605.2005.00622.x; Hauser R, 2005, Occup Environ Med, V62, P806, DOI 10.1136/oem.2004.017590; Hauser R, 2003, HUM REPROD, V18, P2525, DOI 10.1093/humrep/deg508; Hauser R, 2003, ENVIRON HEALTH PERSP, V111, P1505, DOI 10.1289/ehp.6175; Hauser R, 2006, EPIDEMIOLOGY, V17, P682, DOI 10.1097/01.ede.0000235996.89953.d7; Hauser R, 2007, HUM REPROD, V22, P688, DOI 10.1093/humrep/del428; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Joensen UN, 2009, ENVIRON HEALTH PERSP, V117, P923, DOI 10.1289/ehp.0800517; Jonsson BAG, 2005, EPIDEMIOLOGY, V16, P487, DOI 10.1097/01.ede.0000164555.19041.01; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee DH, 2006, DIABETES CARE, V29, P1638, DOI 10.2337/dc05-0543; Lim JS, 2008, DIABETES CARE, V31, P1802, DOI 10.2337/dc08-0850; Lorber M, 2008, J EXPO SCI ENV EPID, V18, P2, DOI 10.1038/sj.jes.7500572; McGlynn KA, 2008, J NATL CANCER I, V100, P663, DOI 10.1093/jnci/djn101; McGlynn KA, 2009, CANCER RES, V69, P1901, DOI 10.1158/0008-5472.CAN-08-3935; Meeker J. D., 2010, ENV IMPACTS REPROD H, P154; Meeker JD, 2010, ENVIRON SCI TECHNOL, V44, P1458, DOI 10.1021/es9028292; Meeker JD, 2004, ENVIRON HEALTH PERSP, V112, P1665, DOI 10.1289/ehp.7234; Meeker JD, 2008, HUM REPROD, V23, P1932, DOI 10.1093/humrep/den242; Meeker JD, 2006, EPIDEMIOLOGY, V17, P61, DOI 10.1097/01.ede.0000190602.14691.70; Meeker JD, 2007, ENVIRON HEALTH PERSP, V115, P1029, DOI 10.1289/ehp.9852; Meeker JD, 2007, ENVIRON RES, V104, P296, DOI 10.1016/j.envres.2007.11.007; Meeker JD, 2010, ENVIRON HEALTH PERSP, V118, P318, DOI 10.1289/ehp.0901332; Meeker JD, 2006, REPROD TOXICOL, V22, P437, DOI 10.1016/j.reprotox.2006.02.005; Meeker JD, 2008, ENVIRON HEALTH PERSP, V116, P1473, DOI 10.1289/ehp.11490; Meeker JD, 2009, J ANDROL, V30, P287, DOI 10.2164/jandrol.108.006403; Meeker JD, 2009, PHILOS T R SOC B, V364, P2097, DOI 10.1098/rstb.2008.0268; Meeker JD, 2010, FERTIL STERIL, V93, P130, DOI 10.1016/j.fertnstert.2008.09.044; Meeker JD, 2004, HUM REPROD, V19, P2573, DOI 10.1093/humrep/deh444; Meeker JD, 2009, SCI TOTAL ENVIRON, V407, P3425, DOI 10.1016/j.scitotenv.2009.01.030; Meeker JD, 2009, ENVIRON RES, V109, P869, DOI 10.1016/j.envres.2009.06.004; Meeker JD, 2009, WOODHEAD PUBL FOOD S, P36, DOI 10.1533/9781845695743.1.36; Meeker JD, 2009, REPROD TOXICOL, V27, P155, DOI 10.1016/j.reprotox.2008.12.012; Pan GW, 2006, ENVIRON HEALTH PERSP, V114, P1643, DOI 10.1289/ehp.9016; Patterson DG, 2009, ENVIRON SCI TECHNOL, V43, P1211, DOI 10.1021/es801966w; Pelletier C, 2002, TOXICOL SCI, V67, P46; Perry MJ, 2008, HUM REPROD UPDATE, V14, P233, DOI 10.1093/humupd/dmm039; Persky V, 2001, ENVIRON HEALTH PERSP, V109, P1275, DOI 10.2307/3454751; Philibert A, 2009, INT J ENV RES PUB HE, V6, P3179, DOI 10.3390/ijerph6123179; Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P188, DOI 10.1080/10937400701873472; Purdue MP, 2009, ENVIRON HEALTH PERSP, V117, P1514, DOI 10.1289/ehp.0800359; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Richthoff J, 2003, ENVIRON HEALTH PERSP, V111, P409, DOI 10.1289/ehp.5767; Rignell-Hydbom A, 2004, HUM REPROD, V19, P2066, DOI 10.1093/humrep/deh362; Rignell-Hydbom A, 2005, ENVIRON HEALTH PERSP, V113, P175, DOI 10.1289/ehp.7252; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; Ritchie JM, 2005, ENVIRON RES, V98, P104, DOI 10.1016/j.envres.2004.05.013; Schecter A, 2005, J OCCUP ENVIRON MED, V47, P199, DOI 10.1097/01.jom.0000158704.27536.d2; Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723; Stahlhut RW, 2007, ENVIRON HEALTH PERSP, V115, P876, DOI 10.1289/ehp.9882; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P1478, DOI 10.1289/ehp.6417; Travison TG, 2007, J CLIN ENDOCR METAB, V92, P196, DOI 10.1210/jc.2006-1375; Turyk M, 2009, ENVIRON HEALTH PERSP, V117, P1076, DOI 10.1289/ehp.0800281; Turyk ME, 2006, ENVIRON RES, V102, P299, DOI 10.1016/j.envres.2006.01.009; Turyk ME, 2008, ENVIRON HEALTH PERSP, V116, P1635, DOI 10.1289/ehp.11707; US Environmental Protection Agency, 2009, END DISR SCREEN PROG; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xia YK, 2008, FERTIL STERIL, V89, P1743, DOI 10.1016/j.fertnstert.2007.05.049; AGR HLTH STUDY PUBLI8938ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDMATURITASJULDiscipline: Geriatrics &amp; Gerontology; Obstetrics &amp; Gynecology626QH</notes>
    <keywords>AGENTS; ASSOCIATION; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CHEMICALS; development; diabetes; DIPHENYL ETHERS; DISEASE; DISORDERS; EDC; EDCs; ENDOCRINE; Endocrine disrupting compounds; Endocrine disruption; Epidemiology; EXPOSURE; Exposure assessment; EXPOSURES; FOOD; FUTURE; HEALTH; Hormone; HORMONE-LEVELS; HUMAN EXPOSURE; HUMAN SEMEN QUALITY; IMPACT; Male; MALE REPRODUCTIVE HEALTH; MALE REPRODUCTIVE HORMONES; METABOLIC SYNDROME; METABOLISM; Molecular epidemiology; NUTRITION EXAMINATION SURVEY; PBDEs; PERSISTENT ORGANIC POLLUTANTS; PESTICIDES; phthalate; Phthalates; POLYBROMINATED DIPHENYL ETHERS; POLYCHLORINATED-BIPHENYLS; POPULATION; Reproduction; REPRODUCTIVE HEALTH; Review; SUSCEPTIBILITY; Thyroid; THYROID-HORMONE; THYROID-HORMONE LEVELS; UPDATE; URINARY PHTHALATE METABOLITES; US POPULATION; WIDESPREAD EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>236</startpage>
    <endpage>241</endpage>
    <journalfull>Maturitas</journalfull>
    <issue>3</issue>
    <volume>66</volume>
    <abstract>Human exposure to environmental endocrine disrupting compounds (EDCs) have received increased attention in recent years due to the documentation of widespread exposure to a number of EDCs among the general population, experimental data demonstrating endocrine-related effects on reproduction, development, metabolism, and cancer, and observations for increasing trends (as well as geographic trends) in endocrine-related disorders among populations. However, human studies of exposure to most environmental EDCs in relation to adverse health outcomes remain limited. This review focuses on the human data generated to date on the relationship between exposures to environmental EDCs and men's health. The agents discussed here, which include polychlorinated biphenyls (PCBs), pesticides, phthalates, bisphenol A (BPA), and polybrominated diphenyl ethers (PBDEs), were chosen based on their exposure prevalence and the presence of existing human data in studies of male reproductive health, altered reproductive and thyroid hormone levels, diabetes and/or metabolic syndrome, and endocrine-related cancers. Taken together, the epidemiologic data on the environmental EDCs suggest that there may be associations between exposure and adverse health outcomes in men. However, the limited human data, and in many instances inconsistent data across studies, highlight the need for further research on these chemicals. Future longitudinal molecular epidemiology studies with appropriately designed exposure assessments are needed to determine potential causal relationships, to identify the most important time windows/life stages of exposure, and to define individual susceptibility factors for adverse effects on men's health in response to exposure. (C) 2010 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000279981200004</url>
    <isbnorissn>0378-5122</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>230</id>
    <title>Urinary Bisphenol A Concentration and Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women</title>
    <authors>Melzer,D.; Osborne,N.J.; Henley,W.E.; Cipelli,R.; Young,A.; Money,C.; McCormack,P.; Luben,R.; Khaw,K.T.; Wareham,N.J.; Galloway,T.S.</authors>
    <availability>[Henley, William E.] Univ Plymouth, Sch Comp &amp; Math, Plymouth PL4 8AA, Devon, England. [Melzer, David; Osborne, Nicholas J.; Galloway, Tamara S.] Univ Exeter, Peninsula Coll Med &amp; Dent, European Ctr Environm &amp; Human Hlth, Exeter, Devon, England. [Wareham, Nicholas J.] Med Res Council Epidemiol Ctr, Cambridge, England. [Cipelli, Riccardo; Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth &amp; Primary Care, Cambridge, England. [Cipelli, Riccardo; Galloway, Tamara S.] Univ Exeter, Sch Biosci, Exeter, Devon, England. [Melzer, David] Univ Exeter, Peninsula Coll Med &amp; Dent, Peninsula Med Sch, Epidemiol &amp; Publ Hlth Grp, Exeter EX2 5DW, Devon, England.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMelzer, D (reprint author), Univ Exeter, Peninsula Coll Med &amp; Dent, Peninsula Med Sch, Epidemiol &amp; Publ Hlth Grp, Barrack Rd, Exeter EX2 5DW, Devon, Englanddavid.melzer@pms.ac.ukAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Asano S, 2010, BRIT J PHARMACOL, V160, P160, DOI 10.1111/j.1476-5381.2010.00687.x; Barr DB, 2005, ENVIRON HEALTH PERSP, V113, P192, DOI 10.1289/ehp.7337; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Biedermann S, 2010, ANAL BIOANAL CHEM, V398, P571, DOI 10.1007/s00216-010-3936-9; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Boekholdt SM, 2004, CIRCULATION, V110, P1418, DOI 10.1161/01.CIR.0000141730.65972.95; Boekholdt S. Matthijs, 2004, American Journal of Medicine, V117, P390; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Brenner R, 2000, NATURE, V407, P870; Bruins P, 1997, CIRCULATION, V96, P3542; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Canoy D, 2007, CIRCULATION, V116, P2933, DOI 10.1161/CIRCULATIONAHA.106.673756; Day N, 1999, BRIT J CANCER, V80, P95; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Diamanti-Kandarakis E, 2010, HORM METAB RES, V42, P543, DOI 10.1055/s-0030-1252034; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Eto K, 2001, EUR J PHARMACOL, V423, P1, DOI 10.1016/S0014-2999(01)01047-0; European Food Safety Authority, 2010, EFSA J, V8, P1829, DOI [10.2903/j.efsa.2010.1829, DOI 10.2903/J.EFSA.2010.1829]; FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499; Galloway T, 2010, ENVIRON HEALTH PERSP, V118, P1603, DOI 10.1289/ehp.1002367; Guillemette C, 1997, ENDOCRINOLOGY, V138, P2998, DOI 10.1210/en.138.7.2998; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Kandaraki E, 2011, J CLIN ENDOCR METAB, V96, pE480, DOI 10.1210/jc.2010-1658; Lakind JS, 2008, J EXPO SCI ENV EPID, V21, P272; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Mahalingaiah S, 2008, ENVIRON HEALTH PERSP, V116, P173, DOI 10.1289/ehp.10605; Mastin JP, 2005, CARDIOVASC TOXICOL, V5, P91, DOI 10.1385/CT:5:2:091; Melzer D, 2011, ANN INTERN MED, V155, P392, DOI [10.7326/0003-4819-155-6-201109200-00009, 10.1059/0003-4819-155-6-201109200-00009]; Melzer D, 2011, ENVIRON HEALTH PERSP, V119, P1788, DOI 10.1289/ehp.1103809; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Michels KB, 2005, AM J EPIDEMIOL, V161, P987, DOI 10.1093/aje/kwi115; Nepomnaschy PA, 2009, ENVIRON RES, V10, P734; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Okuda K, 2010, TOXICOL LETT, V197, P7, DOI 10.1016/j.toxlet.2010.04.017; Ritter S, 2011, CHEM ENG NEWS, V89, P5; Ropero AB, 2008, INT J ANDROL, V31, P194, DOI 10.1111/j.1365-2605.2007.00832.x; Sharpe RM, 2010, HUM REPROD, V25, P292, DOI 10.1093/humrep/dep385; Sieli PT, 2011, ENVIRON HEALTH PERSP, V119, P1260, DOI 10.1289/ehp.1003385; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Taylor JA, 2010, ENV HLTH PERSPECT, V119, P422, DOI DOI 10.1289/EHP.1002514; Teeguarden JG, 2005, TOXICOL SCI, V85, P823, DOI 10.1093/toxsci/kfi135; VOLKEL, 2002, CHEM RES TOXICOL, V15, P1281; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; WHO, 2010, WHOHSEFOS111; Wood SN, 2006, AUST NZ J STAT, V48, P445, DOI 10.1111/j.1467-842X.2006.00450.x; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Ye XB, 2008, ENVIRON RES, V108, P260, DOI 10.1016/j.envres.2008.07.014; Ye XY, 2011, ENVIRON HEALTH PERSP, V119, P983, DOI 10.1289/ehp.10027015140LIPPINCOTT WILLIAMS &amp; WILKINSPHILADELPHIA530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USACIRCULATIONMAR 27Discipline: Cardiovascular System &amp; Cardiology916TA</notes>
    <keywords>ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; blood lipids; body mass index; BPA; CANCER; cardiovascular; coronary artery disease; diabetes; DIABETES-MELLITUS; DISEASE; Endocrine disruption; EXPOSURE; FOOD; HEALTH; heart; HEART-DISEASE; IN-VIVO; mechanism; MECHANISMS; MODEL; MODELS; NHANES; NORFOLK; nutrition; NUTRITION EXAMINATION SURVEY; Occupational; PLASMA; PROTEIN; RECEPTOR-GAMMA; RISK; RISK-FACTORS; SAMPLES; SMOOTH-MUSCLE; SYSTEM; toxicology; URINARY; Urinary bisphenol A; URINARY CONCENTRATIONS; Urine; US POPULATION; Vitamin C; VITAMIN-C; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1482</startpage>
    <endpage>1490</endpage>
    <journalfull>Circulation</journalfull>
    <issue>12</issue>
    <volume>125</volume>
    <abstract>Background-The endocrine-disrupting chemical bisphenol A (BPA) is widely used in food and beverage packaging. Higher urinary BPA concentrations were cross-sectionally associated with heart disease in National Health and Nutrition Examination Survey (NHANES) 2003-2004 and NHANES 2005-2006, independent of traditional risk factors. Methods and Results-We included 758 incident coronary artery disease (CAD) cases and 861 controls followed for 10.8 years from the European Prospective Investigation of Cancer-Norfolk UK. Respondents aged 40 to 74 years and free of CAD, stroke, or diabetes mellitus provided baseline spot urine samples. Urinary BPA concentrations (median value, 1.3 ng/mL) were low. Per-SD (4.56 ng/mL) increases in urinary BPA concentration were associated with incident CAD in age-, sex-, and urinary creatinine-adjusted models (n = 1919; odds ratio = 1.13; 95% confidence interval, 1.02-1.24; P = 0.017). With CAD risk factor adjustment (including education, occupational social class, body mass index category, systolic blood pressure, lipid concentrations, and exercise), the estimate was similar but narrowly missed 2-sided significance (n = 1744; odds ratio = 1.11; 95% confidence interval, 1.00-1.23; P = 0.058). Sensitivity analyses with the fully adjusted model, excluding those with early CAD (&lt;3-year follow-up), body mass index &gt;30, or abnormal renal function or with additional adjustment for vitamin C, C-reactive protein, or alcohol consumption, all produced similar estimates, and all showed associations at P &lt;= 0.05. Conclusions-Associations between higher BPA exposure (reflected in higher urinary concentrations) and incident CAD during &gt;10 years of follow-up showed trends similar to previously reported cross-sectional findings in the more highly exposed NHANES respondents. Further work is needed to accurately estimate the prospective exposure-response curve and to establish the underlying mechanisms. (Circulation. 2012;125:1482-1490.)</abstract>
    <url>WOS:000302124900015</url>
    <isbnorissn>0009-7322</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>314</id>
    <title>Concentration of bisphenol A in thermal paper</title>
    <authors>Mendum,T.; Stoler,E.; VanBenschoten,H.; Warner,J.C.</authors>
    <availability>[Mendum, Ted; Stoler, Emily; VanBenschoten, Helen; Warner, John C.] Warner Babcock Inst Green Chem, Wilmington, MA USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleWarner, JC (reprint author), Warner Babcock Inst Green Chem, 100 Res Dr, Wilmington, MA USAjohn.warner@warnerbabcock.comANDERSON N, 1990, Patent No. 1989003438; Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007; Burkinshaw SM, 1998, J MATER CHEM, V8, P2677, DOI 10.1039/a805994b; BURRIDGE E, ICIS CHEM BUSINESS W; Calafat A. M., 2009, Environmental Health Perspectives, V117, P639; CAMPBELL RB, 1998, Patent No. 4774224; Chamie K, 2008, CANCER, V113, P2464, DOI 10.1002/cncr.23695; *EUR FOOD SAF AUTH, 2008, J EUROPEAN FOOD SAFE, V759, P1; Fukazawa H, 2001, CHEMOSPHERE, V44, P973, DOI 10.1016/S0045-6535(00)00507-5; Gregory P., 1991, HIGH TECHNOLOGY APPL; Hohne C, 2008, ENVIRON SCI POLLUT R, V15, P405, DOI 10.1007/s11356-008-0007-2; HOWSER R, 2008, FERTIL STERIL S2, V89, pE59; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Ishido M, 2004, J NEUROSCI RES, V76, P423, DOI 10.1002/jnr.20050; JIKIHARA A, 2009, Patent No. 20090264288; JUSKOW R, 2006, J AM DENT ASSOC, V137, P353; Kang JH, 2006, TOXICOLOGY, V217, P81, DOI 10.1016/j.tox.2005.10.001; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Lopez-Espinosa MJ, 2007, FOOD ADDIT CONTAM A, V24, P95, DOI 10.1080/02652030600936375; MacLaren DC, 2003, J MATER CHEM, V13, P1695, DOI 10.1039/b302249h; MEHTA R, 1991, Patent No. 4999334; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Mocak J, 1997, PURE APPL CHEM, V69, P297, DOI 10.1351/pac199769020297; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; NTP (National Toxicology Program), 2008, NIH PUBL, V08-5887; *OFF OFF PUBL EUR, 2010, EUR UN RISK ASS REP; R Development Core Team, 2009, R LANG ENV STAT COMP; Ranke J., 2007, CHEMCAL CALIBRATION; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; *SIGM ALDR INC, 1997, T196909A SUP TECHN S; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vinggaard AM, 2000, CHEM RES TOXICOL, V13, P1214, DOI 10.1021/tx000146b; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.0103817TAYLOR &amp; FRANCIS LTDABINGDON4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDGREEN CHEM LETT REVDiscipline: Chemistry796PX</notes>
    <keywords>analysis; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; development; ENDOCRINE DISRUPTORS; EXPOSURE; FOOD; HEALTH; HUMAN EXPOSURE; IDENTIFICATION; LINE; PLANTS; QUANTIFICATION; RISK; thermal paper; thermochromism; toxicology; WASTE-WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>81</startpage>
    <endpage>86</endpage>
    <journalfull>Green Chemistry Letters and Reviews</journalfull>
    <issue>1</issue>
    <volume>4</volume>
    <abstract>Bisphenol A (BPA) is widely used as a color developer in thermal paper. Thermal paper is ubiquitous in daily life due to its use in cash register receipts, so opportunities for human contact abound. For this study, 10 blank cash register receipts were obtained from businesses in suburban Boston. BPA was extracted and analysis of concentration was performed using gas chromatograph/flame ionization detector. In some receipts, BPA was not detected but in others it was as high as 19 mg for a 12-inch long receipt, which is in line with concentrations indicated in patents. This study is intended to highlight the potential for human exposure to BPA as well as the ease with which exposure may be reduced through the use of BPA-free thermal paper</abstract>
    <url>WOS:000293065200008</url>
    <isbnorissn>1751-8253</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>169</id>
    <title>Electrochemical determination of microRNA-21 based on bio bar code and hemin/G-quadruplet DNAenzyme</title>
    <authors>Meng,X.M.; Zhou,Y.L.; Liang,Q.J.; Qu,X.J.; Yang,Q.Q.; Yin,H.S.; Ai,S.Y.</authors>
    <availability>[Meng, Xiaomeng; Zhou, Yunlei; Qu, Xiangjin; Yang, Qingqing; Yin, Huanshun; Ai, Shiyun] Shandong Agr Univ, Coll Chem &amp; Mat Sci, Tai An 271018, Shandong, Peoples R China. [Zhou, Yunlei; Liang, Qianjin] Beijing Normal Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat &amp; Regulat Biol, Beijing 100875, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleYin, HS (reprint author), Shandong Agr Univ, Coll Chem &amp; Mat Sci, Tai An 271018, Shandong, Peoples R Chinayinhs@sdau.edu.cn; ashy@sdau.edu.cnAvissar-Whiting M, 2010, REPROD TOXICOL, V29, P401, DOI 10.1016/j.reprotox.2010.04.004; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bonanni A, 2011, ACS NANO, V5, P2356, DOI 10.1021/nn200091p; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen JH, 2011, CHEM COMMUN, V47, P8004, DOI 10.1039/c1cc11929j; Chen WW, 2009, BIOSENS BIOELECTRON, V24, P2534, DOI 10.1016/j.bios.2009.01.010; Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873; Du P, 2009, BIOSENS BIOELECTRON, V24, P3223, DOI 10.1016/j.bios.2009.04.012; Fan H, 2011, BIOSENS BIOELECTRON, V26, P2655, DOI 10.1016/j.bios.2010.02.021; Fang Z, 2008, ANAL CHEM, V81, P612; Gao ZQ, 2007, BIOSENS BIOELECTRON, V22, P933, DOI 10.1016/j.bios.2006.04.020; Gao ZQ, 2006, ANAL CHEM, V78, P1470, DOI 10.1021/ac051726m; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hu KC, 2008, ANAL CHEM, V80, P9124, DOI 10.1021/ac8017197; Hu Y., 2011, BIOMATERIALS, V33, P1097; Hyrup B, 1996, BIOORGAN MED CHEM, V4, P5, DOI 10.1016/0968-0896(95)00171-9; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jayagopal A, 2010, J AM CHEM SOC, V132, P9789, DOI 10.1021/ja102585v; Kawamura Y, 1999, J FOOD HYG SOC JPN, V40, P158; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Lai YQ, 2011, ELECTROCHIM ACTA, V56, P3153, DOI 10.1016/j.electacta.2011.01.061; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee JM, 2011, ANGEW CHEM INT EDIT, V50, P12487, DOI 10.1002/anie.201105605; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Li D, 2010, ACCOUNTS CHEM RES, V43, P631, DOI 10.1021/ar900245u; Li JS, 2009, ANAL CHEM, V81, P9723, DOI 10.1021/ac901983s; Li T, 2007, ANAL BIOANAL CHEM, V389, P887, DOI 10.1007/s00216-007-1487-5; Liu C, 2011, ENZYME MICROB TECH, V49, P266, DOI 10.1016/j.enzmictec.2011.06.011; Liu J, 2006, NAT PROTOC, V1, P246, DOI 10.1038/nprot.2006.38; Liu XG, 2011, BIOSENS BIOELECTRON, V26, P3679, DOI 10.1016/j.bios.2011.01.034; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Lu ZX, 2011, CHEM COMMUN, V47, P7452, DOI 10.1039/c1cc10442j; Luo M, 2012, CHEM COMMUN, V48, P1126, DOI 10.1039/c2cc16868e; Medina PP, 2008, CELL CYCLE, V7, P2485; Miranda-Castro R, 2007, ANAL CHEM, V79, P4050, DOI 10.1021/ac062260q; Peng YF, 2010, CHEM COMMUN, V46, P9131, DOI 10.1039/c0cc01990a; Shimron S, 2011, CHEM COMMUN, V47, P8787, DOI 10.1039/c1cc12795k; Siangproh W, 2011, ANAL CHIM ACTA, V690, P10, DOI 10.1016/j.aca.2011.01.054; Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887; Sun YH, 2011, CHEM COMMUN, V47, P3840, DOI 10.1039/c0cc05133k; Tilghman SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032754; Varallyay E, 2008, NAT PROTOC, V3, P190, DOI 10.1038/nprot.2007.528; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Yuan YL, 2012, CHEM COMMUN, V48, P4621, DOI 10.1039/c2cc31423a; Zhang GJ, 2009, BIOSENS BIOELECTRON, V24, P2504, DOI 10.1016/j.bios.2008.12.035; Zhu JB, 2011, BIOMATERIALS, V32, P7318, DOI 10.1016/j.biomaterials.2011.06.040498ROYAL SOC CHEMISTRYCAMBRIDGETHOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLANDANALYSTDiscipline: Chemistry146WU</notes>
    <keywords>BIOSENSOR; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; cell cycle; CELL-CYCLE; CELLS; CYCLE; Determination; DIAGNOSIS; EXPOSURE; EXPRESSION; FOOD; HUMAN BREAST-CANCER; HYBRIDIZATION; microRNA; MIMICKING DNAZYME; PLATFORM; PROGNOSIS; RECOGNITION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3409</startpage>
    <endpage>3415</endpage>
    <journalfull>Analyst</journalfull>
    <issue>12</issue>
    <volume>138</volume>
    <abstract>A simple and novel microRNA (miRNA) biosensor was developed using DNA-Au bio bar code (DNA-Au) and G-quadruplex-based DNAenzyme. DNA-Au increased the amount of miRNA-21 participating in hybridization. Hemin/G-quadruplex DNAenzyme significantly improved the catalysis of H2O2 by oxidation of hydroquinone, resulting in an obvious reduction current of benzoquinone for miRNA-21 indirect detection. Under optimum conditions, the linear relationship between miRNA-21 concentration and reduction response was obtained with the detection limit of 0.006 pM, which showed a good sensitivity. Besides, selectivity of the biosensor was investigated by detecting the base mismatched miRNAs. This proposed method was further applied to detect miRNA-21 extracted from human hepatocarcinoma BEL-7402 cells and human mastocarcinoma MCF-7 cells. The influence of bisphenol A (BPA) on the expression of miRNA-21 in cells was also investigated. The biosensor performs well in practical applications, which suggests it may provide a new platform for gene diagnosis</abstract>
    <url>WOS:000319126800013</url>
    <isbnorissn>0003-2654</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>20</id>
    <title>Dietary predictors of urinary environmental biomarkers in young girls, BCERP, 2004-7</title>
    <authors>Mervish,N.; McGovern,K.J.; Teitelbaum,S.L.; Pinney,S.M.; Windham,G.C.; Biro,P.M.; Kushi,L.H.; Silva,M.J.; Ye,X.Y.; Calafat,A.M.; Wolff,M.S.</authors>
    <availability>[Mervish, Nancy; McGovern, Kathleen J.; Teitelbaum, Susan L.; Wolff, Mary S.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Pinney, Susan M.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Windham, Gayle C.] Calif Dept Publ Hlth, Div Environm &amp; Occupat Dis Control, Richmond, CA 94804 USA. [Biro, Prank M.] Cincinnati Childrens Hosp, Med Ctr, Div Adolescent Med, Cincinnati, OH 45229 USA. [Kushi, Lawrence H.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Silva, Manori J.; Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control &amp; Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleMervish, N (reprint author), Icahn Sch Med Mt Sinai, Dept Prevent Med, 1 Gustave L Levy Pl Box 1057, New York, NY 10029 USANancy.Mervish@mssm.eduACKERMAN JM, 2014, J EXPO SCI ENV EPIDE, V10; Andersen FA, 2010, INT J TOXICOL, V29, p221S, DOI 10.1177/1091581810384883; Barlow NJ, 2003, TOXICOL PATHOL, V31, P397, DOI 10.1080/01926230390202335; Baxter SD, 2004, ANN EPIDEMIOL, V14, P385, DOI 10.1016/j.annepidem.2003.07.003; BIRO FM, 2010, PEDIATRICS; Braun JM, 2011, ENVIRON HEALTH PERSP, V119, P131, DOI 10.1289/ehp.1002366; Calafat AM, 2010, ENVIRON HEALTH PERSP, V118, P679, DOI 10.1289/ehp.0901560; Cao XL, 2010, J FOOD PROTECT, V73, P1085; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; CDC, 2009, 4 CDCP; Colacino JA, 2010, ENVIRON HEALTH PERSP, V118, P998, DOI 10.1289/ehp.0901712; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Fromme H, 2007, ENVIRON INT, V33, P1012, DOI 10.1016/j.envint.2007.05.006; Grumetto L, 2008, J AGR FOOD CHEM, V56, P10633, DOI 10.1021/jf802297z; Hauser R, 2006, EPIDEMIOLOGY, V17, P682, DOI 10.1097/01.ede.0000235996.89953.d7; Hauser R, 2004, ENVIRON HEALTH PERSP, V112, P1734, DOI 10.1289/ehp.7212; Hernan MA, 2009, AM J EPIDEMIOL, V170, P959, DOI 10.1093/aje/kwp293; Hoppin JA, 2002, ENVIRON HEALTH PERSP, V110, P515; Jarosova A, 2010, ENVIRON CHEM LETT, V8, P387, DOI 10.1007/s10311-009-0237-7; Kang JH, 2002, FOOD ADDIT CONTAM, V19, P886, DOI 10.1080/02652030210147278; Kato K, 2005, ANAL CHEM, V77, P2985, DOI 10.1021/ac0481248; Lakind JS, 2011, J EXPO SCI ENV EPID, V21, P272, DOI 10.1038/jes.2010.9; Latini G, 2003, ENVIRON HEALTH PERSP, V111, P1783, DOI 10.1289/ehp.6202; Liu JH, 2012, J NUTR, V142, P298, DOI 10.3945/jn.111.145516; Mariscal-Arcas M, 2009, FOOD CHEM TOXICOL, V47, P506, DOI 10.1016/j.fct.2008.12.011; Meeker JD, 2011, ENVIRON HEALTH PERSP, V119, P252, DOI 10.1289/ehp.1002238; Munguia-Lopez EM, 2005, FOOD ADDIT CONTAM, V22, P892, DOI 10.1080/02652030500163674; Noonan GO, 2011, J AGR FOOD CHEM, V59, P7178, DOI 10.1021/jf201076f; Peck Jennifer David, 2010, J Expo Sci Environ Epidemiol, V20, P90, DOI 10.1038/jes.2009.4; Petersen JH, 2010, FOOD ADDIT CONTAM A, V27, P1608, DOI 10.1080/19440049.2010.501825; Preau JL, 2010, ENVIRON HEALTH PERSP, V118, P1748, DOI 10.1289/ehp.1002231; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P914, DOI 10.1289/ehp.1003170; Saad B, 2005, J CHROMATOGR A, V1073, P393, DOI 10.1016/j.chroma.2004.10.105; Schatzkin A, 2003, INT J EPIDEMIOL, V32, P1054, DOI 10.1093/ije/dyg264; SCHECTER A, 2013, ENV HLTH PERSPECT; Schecter A, 2010, ENVIRON SCI TECHNOL, V44, P9425, DOI 10.1021/es102785d; Schettler T, 2006, INT J ANDROL, V29, P134, DOI 10.1111/j.1365-2605.2005.00567.x; SHARMAN M, 1994, FOOD ADDIT CONTAM, V11, P375; Soni MG, 2001, FOOD CHEM TOXICOL, V39, P513, DOI 10.1016/S0278-6915(00)00162-9; Soni MG, 2002, FOOD CHEM TOXICOL, V40, P1335, DOI 10.1016/S0278-6915(02)00107-2; Teitelbaum SL, 2008, ENVIRON RES, V106, P257, DOI 10.1016/j.envres.2007.09.010; Trasande L, 2013, ENVIRON RES, V126, P84, DOI 10.1016/j.envres.2013.07.007; Tsumura Y, 2001, FOOD ADDIT CONTAM, V18, P449, DOI 10.1080/02652030010024474; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; VON GN, 2010, RISK ANAL, V30, P473; Willett WC., 1998, NUTR EPIDEMIOLOGY; Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Ye XY, 2005, ANAL CHEM, V77, P5407, DOI 10.1021/ac050390d; Ye XY, 2006, J CHROMATOGR B, V844, P53, DOI 10.1016/j.jchromb.2006.06.037510ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAENVIRON RESAUGDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational HealthAM2UI</notes>
    <keywords>Biomarkers; bisphenol A; BISPHENOL-A; BISPHENOL-A BPA; BPA; breast cancer; BREAST-CANCER; CANCER; CHEMICALS; CHILDREN; ENDOCRINE DISRUPTORS; ESTERS; EXPOSURE; FOOD; IN-UTERO EXPOSURE; MASS-SPECTROMETRY; PARABENS; PERFORMANCE LIQUID-CHROMATOGRAPHY; PHTHALATE METABOLITES; Phthalates; PUBLISHED LITERATURE; SEMEN QUALITY; TEMPORAL VARIABILITY; URINARY CONCENTRATIONS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>12</startpage>
    <endpage>19</endpage>
    <journalfull>Environmental Research</journalfull>
    <volume>133</volume>
    <abstract>Background: Exposures of children to phthalates, parabens, and bisphenol-A (BPA) are of concern because of their hormonal potential. These agents are found in a wide range of foods and packaging. We investigated whether intake of certain foods predict exposures to these chemicals in young girls. Methods: Among 1101 girls (6-8 years at enrollment) from the Breast Cancer and Environment Research Program (BCERP) study, we measured urinary exposure biomarkers for phthalates, parabens, and BPA and assessed dietary intake using 24-h recall 2-4 times. We examined the average daily servings of major and minor food groups categorized as 0 to &lt; 0.5, 0.5 to &lt; 1 and &gt;= 1 servings per day. Items included dairy, eggs, fats, fish, fruit, single grains, meat, non-poultry meats, pasta, poultry and vegetables. Covariate-adjusted least squares geometric means and 95% confidence intervals of creatinine-corrected phthalate and phenol metabolite concentrations in urine were calculated in relation to food intake. Results: Grains, flour and dry mixes and total fish consumption were positively associated with BPA and the sum of four di-2-ethylhexylphthalate (DEHP) urinary metabolite concentrations. Non-fresh vegetables and poultry were both positively associated with BPA and paraben urinary concentrations. Fats, oils and poultry consumption were positively associated with BPA. Whole-fat dairy consumption was associated with Sigma DEHP. Conclusions: Some foods may contribute to child exposures to certain chemicals, and this may constitute modifiable means to reduce these environmental exposures. (C) 2014 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000339705900003</url>
    <isbnorissn>0013-9351</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>58</id>
    <title>Bisphenol A - Sources, toxicity and biotransformation</title>
    <authors>Michalowicz,J.</authors>
    <availability>Univ Lodz, Fac Biol &amp; Environm Protect, Dept Environm Pollut Biophys, PL-90236 Lodz, Poland.</availability>
    <date>2014</date>
    <notes>JEnglishReviewMichalowicz, J (reprint author), Univ Lodz, Fac Biol &amp; Environm Protect, Dept Environm Pollut Biophys, Pomorska 141-43St, PL-90236 Lodz, Polandmichalow@biol.uni.lodz.plAcevedo N, 2013, ENVIRON HEALTH PERSP, V121, P1040, DOI 10.1289/ehp.1306734; Allard P, 2010, P NATL ACAD SCI USA, V107, P20405, DOI 10.1073/pnas.1010386107; Alonso-Magdalena P, 2012, MOL CELL ENDOCRINOL, V355, P201, DOI 10.1016/j.mce.2011.12.012; Arboleda C., 2013, ISRN BIOTECHNOL; Arnold SM, 2013, J EXPO SCI ENV EPID, V23, P137, DOI 10.1038/jes.2012.66; ATKINSON A, 1995, ENVIRON MOL MUTAGEN, V26, P60, DOI 10.1002/em.2850260109; Audebert M, 2011, ARCH TOXICOL, V85, P1463, DOI 10.1007/s00204-011-0721-2; Bae S, 2012, HYPERTENSION, V60, P786, DOI 10.1161/HYPERTENSIONAHA.112.197715; Batra T., 2011, J FOOD SCI TECHNOL, V3, P58; Benachour N, 2009, TOXICOL APPL PHARM, V241, P322, DOI 10.1016/j.taap.2009.09.005; Berkner S, 2004, CHEMOSPHERE, V54, P575, DOI 10.1016/S0045-6535(03)00759-8; Bodin J, 2013, IMMUNOPHARM IMMUNOT, V35, P349, DOI 10.3109/08923973.2013.772195; Bolli A, 2010, IUBMB LIFE, V62, P684, DOI 10.1002/iub.370; Cajthaml T., 2013, CHEMOSPHERE, V75, P745; Calafat AM, 2009, ENVIRON HEALTH PERSP, V117, P639, DOI 10.1289/ehp.0800265; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cao XL, 2009, J AGR FOOD CHEM, V57, P1307, DOI 10.1021/jf803213g; Castoldi A., 2010, FAO WHO EXP M BISPH; Caza N, 1999, WATER RES, V33, P3012, DOI 10.1016/S0043-1354(98)00525-9; Chu CY, 2006, CONTACT DERMATITIS, V54, P131, DOI 10.1111/j.0105-1873.2006.00806.x; Cladiere M, 2013, ENVIRON SCI POLLUT R, V20, P2973, DOI 10.1007/s11356-012-1220-6; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Cobellis L, 2009, BIOMED CHROMATOGR, V23, P1186, DOI 10.1002/bmc.1241; Colin A., 2013, ARCH ENV CONTAM TOXI; Coors A, 2003, ENVIRON SCI TECHNOL, V37, P3430, DOI 10.1021/es0300158; Cunha SC, 2013, FOOD CONTROL, V33, P549, DOI 10.1016/j.foodcont.2013.03.028; Cunha SC, 2012, ANAL BIOANAL CHEM, V404, P2453, DOI 10.1007/s00216-012-6389-5; Doherty L., 2010, HORMONAL CANC, V1, P148; Fenichel P., 2013, ANN ENDOCRINOL; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Fernandez SV, 2012, INT J ONCOL, V41, P369, DOI 10.3892/ijo.2012.1444; Fini JB, 2009, ANN NY ACAD SCI, V1163, P394, DOI 10.1111/j.1749-6632.2008.03655.x; Flint S, 2012, J ENVIRON MANAGE, V104, P19, DOI 10.1016/j.jenvman.2012.03.021; Frederiksen H., 2013, INT J HYG ENV HLTH; Fu PQ, 2010, ENVIRON POLLUT, V158, P3138, DOI 10.1016/j.envpol.2010.06.040; Gattullo E., 2012, SCI TOTAL ENVIRON, V416, P501; Geens T, 2012, CHEMOSPHERE, V87, P796, DOI 10.1016/j.chemosphere.2012.01.002; Geens T, 2009, CHEMOSPHERE, V76, P755, DOI 10.1016/j.chemosphere.2009.05.024; Gentilcore D, 2013, TOXICOLOGY, V304, P21, DOI 10.1016/j.tox.2012.12.001; Genuis S., 2012, J ENV PUBL HLTH; Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004; Gulnaz O., 2009, JABS, V3, P79; Hanioka N, 2011, ARCH TOXICOL, V85, P1373, DOI 10.1007/s00204-011-0690-5; He YH, 2009, J OCCUP HEALTH, V51, P432; Hirano T, 2000, BIOSCI BIOTECH BIOCH, V64, P1958, DOI 10.1271/bbb.64.1958; Hirooka T, 2005, ENVIRON TOXICOL CHEM, V24, P1896, DOI 10.1897/04-259R.1; Hoekstra EJ, 2013, CRIT REV FOOD SCI, V53, P386, DOI 10.1080/10408398.2010.536919; Huang YQ, 2012, ENVIRON INT, V42, P91, DOI 10.1016/j.envint.2011.04.010; Huc L, 2012, TOXICOL IN VITRO, V26, P709, DOI 10.1016/j.tiv.2012.03.017; Huff J, 2001, Odontology, V89, P12, DOI 10.1007/s10266-001-8179-y; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; Jaeg JP, 2004, J AGR FOOD CHEM, V52, P4935, DOI 10.1021/jf049762u; Kamraj M., 2012, INT J PHARM LIFE SCI, V3, P1585; Kamrin F., 2004, MEDGENMED, V6, P7; Kang JH, 2002, ARCH ENVIRON CON TOX, V43, P265, DOI 10.1007/s00244-002-1209-0; Kang JH, 2006, TOXICOLOGY, V217, P81, DOI 10.1016/j.tox.2005.10.001; Kang JH, 2004, LETT APPL MICROBIOL, V39, P178, DOI 10.1111/j.1472-765X.2004.01562.x; Kawagoshi Y, 2003, J ENVIRON MONITOR, V5, P269, DOI 10.1039/b210962j; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim K, 2013, INT J HYG ENVIR HEAL, V216, P467, DOI 10.1016/j.ijheh.2012.07.007; KNAAK JB, 1966, TOXICOL APPL PHARM, V8, P175, DOI 10.1016/S0041-008X(66)80001-7; Koch HM, 2012, J EXPO SCI ENV EPID, V22, P610, DOI 10.1038/jes.2012.39; Kolsek K, 2012, TOXICOL IN VITRO, V26, P102, DOI 10.1016/j.tiv.2011.11.003; Kovacic P, 2010, MED HYPOTHESES, V75, P1, DOI 10.1016/j.mehy.2010.03.002; Lee CC, 2013, CHEMOSPHERE, V91, P904, DOI 10.1016/j.chemosphere.2013.02.006; Lee HB, 2000, WATER QUAL RES J CAN, V35, P283; Lee J, 2010, DRUG CHEM TOXICOL, V33, P421, DOI 10.3109/01480541003739229; Lee M, 2003, MUTAT RES-GEN TOX EN, V541, P9, DOI 10.1016/S1383-5718(03)00175-X; Lee S, 2008, J NEUROSCI RES, V86, P2932, DOI 10.1002/jnr.21739; Lee S., 2013, CHEMOSPHERE; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Li D, 2010, J HEALTH SCI, V56, P57; Li D-K., 2013, PLOS, V8, P65399; Li GY, 2012, BIORESOURCE TECHNOL, V114, P224, DOI 10.1016/j.biortech.2012.03.067; Liao CY, 2012, ENVIRON SCI TECHNOL, V46, P6515, DOI 10.1021/es300876n; Lina Xing, 2010, Toxicological Sciences, V115, P577; Liu J., 2013, PLOS, V8, P64143; Liu R, 2013, FOOD CHEM TOXICOL, V52, P76, DOI 10.1016/j.fct.2012.10.033; Loffredo E, 2012, ECOTOX ENVIRON SAFE, V79, P288, DOI 10.1016/j.ecoenv.2012.01.013; Loganathan SN, 2011, ARCH ENVIRON CON TOX, V61, P68, DOI 10.1007/s00244-010-9634-y; Maia J, 2009, FOOD RES INT, V42, P1410, DOI 10.1016/j.foodres.2009.07.003; Markey CM, 2003, EVOL DEV, V5, P1; Markis K., 2013, ENVIRON SCI TECHNOL, V47, P3333; Matsumoto H, 2005, ARCH ENVIRON CON TOX, V48, P459, DOI 10.1007/s00244-003-0243-x; Matsumura Y, 2009, BIOCONTROL SCI, V14, P161; McCormick JM, 2011, ENVIRON SCI TECHNOL, V45, P6567, DOI 10.1021/es200588w; Meeker JD, 2010, ENVIRON SCI TECHNOL, V44, P1458, DOI 10.1021/es9028292; Melzer D, 2011, ENVIRON HEALTH PERSP, V119, P1788, DOI 10.1289/ehp.1103809; Melzer D, 2010, PLOS ONE, V5, P8673; Mercea P, 2009, J APPL POLYM SCI, V112, P579, DOI 10.1002/app.29421; Moon MK, 2012, J KOREAN MED SCI, V27, P644, DOI 10.3346/jkms.2012.27.6.644; Morrissey S., 2008, CHEM ENG NEWS; Munguia-Lopez EM, 2005, FOOD ADDIT CONTAM, V22, P892, DOI 10.1080/02652030500163674; Naik P, 2009, MUTAT RES-GEN TOX EN, V676, P106, DOI 10.1016/j.mrgentox.2009.04.010; Nakajima N, 2002, PLANT CELL PHYSIOL, V43, P1036, DOI 10.1093/pcp/pcf130; Nakamura K, 2012, BRAIN DEV-JPN, V34, P57, DOI 10.1016/j.braindev.2010.12.011; Nakamura K, 2010, NEUROSCI LETT, V484, P66, DOI 10.1016/j.neulet.2010.08.021; Nakamura S, 2011, TOXICOL LETT, V203, P92, DOI 10.1016/j.toxlet.2011.03.010; Nam SH, 2010, CHEMOSPHERE, V79, P949, DOI 10.1016/j.chemosphere.2010.02.049; Niu YM, 2012, J AGR FOOD CHEM, V60, P6116, DOI 10.1021/jf301401k; Okuda K, 2010, TOXICOL LETT, V197, P7, DOI 10.1016/j.toxlet.2010.04.017; Olsen L, 2012, ECOTOX ENVIRON SAFE, V80, P179, DOI 10.1016/j.ecoenv.2012.02.023; O'Mahony J, 2013, J CHROMATOGR B, V931, P164, DOI 10.1016/j.jchromb.2013.05.025; Oshiman K, 2007, BIODEGRADATION, V18, P247, DOI 10.1007/s10532-006-9059-5; Paut J., 2012, INDIAN J EXP BIOL, V50, P425; Pirard C, 2012, ENVIRON INT, V48, P78, DOI 10.1016/j.envint.2012.07.003; Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rocha S, 2013, B ENVIRON CONTAM TOX, V90, P73, DOI 10.1007/s00128-012-0887-1; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Roy A., 2012, PLOS ONE, V7, P38448; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Ryan BC, 2010, TOXICOL SCI, V114, P133, DOI 10.1093/toxsci/kfp266; Saiyood S, 2010, J HAZARD MATER, V178, P777, DOI 10.1016/j.jhazmat.2010.02.008; Saiyood S, 2013, INT J PHYTOREMEDIAT, V15, P427, DOI 10.1080/15226514.2012.716096; Sajki J., 1999, J CHROMATOGR B, V736, P255; Sakai K, 2007, BIOSCI BIOTECH BIOCH, V71, P51, DOI 10.1271/bbb.60351; Sakazaki H, 2002, TOXICOL LETT, V133, P221, DOI 10.1016/S0378-4274(02)00203-5; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Shankar A, 2011, J CLIN ENDOCR METAB, V96, P3822, DOI 10.1210/jc.2011-1682; Shankar A, 2012, ENVIRON HEALTH PERSP, V120, P1297, DOI 10.1289/ehp.1104114; Shao B, 2007, FOOD CHEM, V105, P1236, DOI 10.1016/j.foodchem.2007.02.040; Sheng ZG, 2012, TOXICOL APPL PHARM, V259, P133, DOI 10.1016/j.taap.2011.12.018; Shin EH, 2007, J MICROBIOL BIOTECHN, V17, P1147; Sigma-Aldrich, 2004, MAT SAF DAT SHEET; Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5; Stachel B, 2003, ENVIRON POLLUT, V124, P497, DOI 10.1016/S0269-7491(02)00483-9; Stowell CL, 2006, CHEM BIOL, V13, P891, DOI 10.1016/j.chembiol.2006.06.016; Stump DG, 2010, TOXICOL SCI, V115, P167, DOI 10.1093/toxsci/kfq025; Sugita-Konishi Y, 2003, TOXICOL LETT, V136, P217, DOI 10.1016/S0378-4274(02)00388-0; Sun CL, 2006, J CHROMATOGR A, V1129, P145, DOI 10.1016/j.chroma.2006.08.018; Sun Q, 2012, ENVIRON SCI TECHNOL, V46, P4442, DOI 10.1021/es204424t; Takao Y, 2002, J HEALTH SCI, V48, P331, DOI 10.1248/jhs.48.331; Tayama S, 2008, MUTAT RES-GEN TOX EN, V649, P114, DOI 10.1016/j.mrgentox.2007.08.006; Teng C, 2013, CHEM-BIOL INTERACT, V203, P556, DOI 10.1016/j.cbi.2013.03.013; Teppala S, 2012, INT J ENDOCRINOL, DOI 10.1155/2012/598180; Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2012, CIENC SAUDE COLETIVA, V17, P407, DOI 10.1590/S1413-81232012000200015; Vogel S., 2009, AM J PUB HLTH S3, V99, P99; Saal FSV, 2012, MOL CELL ENDOCRINOL, V354, P74, DOI 10.1016/j.mce.2012.01.001; Wang HX, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-79; Wang TG, 2012, J CLIN ENDOCR METAB, V97, pE223, DOI 10.1210/jc.2011-1989; Wang TG, 2013, EPIDEMIOLOGY, V24, P295, DOI 10.1097/EDE.0b013e318280e02f; Wen C., 2005, APPL BIOCHEM BIOTECH, V120, P2273; Wetherill B., 2005, CANCER RES, V65, P54; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xing LN, 2010, TOXICOL SCI, V115, P577, DOI 10.1093/toxsci/kfq081; Yamamoto T, 2001, CHEMOSPHERE, V42, P415, DOI 10.1016/S0045-6535(00)00079-5; Yamanaka H, 2006, APPL BIOCHEM BIOTECH, V136, P39; Yang M, 2009, ARCH TOXICOL, V83, P281, DOI 10.1007/s00204-008-0364-0; Ye XB, 2009, INT J HYG ENVIR HEAL, V212, P481, DOI 10.1016/j.ijheh.2009.03.004; Yonekubo J, 2008, J AGR FOOD CHEM, V56, P2041, DOI 10.1021/jf073106n; Yonghua H-E., 2009, J OCCUP HEALTH, V51, P432; Yoshida T, 2001, FOOD ADDIT CONTAM A, V18, P69, DOI 10.1080/026520301446412; Yoshihara S, 2001, TOXICOL SCI, V62, P221, DOI 10.1093/toxsci/62.2.221; Youn JY, 2002, ARCH PHARM RES, V25, P946, DOI 10.1007/BF02977018; Zeinab K., 2012, OXIDATIVE MED CELL L; Ziv-Gal A, 2013, REPROD TOXICOL, V42, P58, DOI 10.1016/j.reprotox.2013.07.0221612ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSENVIRON TOXICOL PHARMARDiscipline: Environmental Sciences &amp; Ecology; Pharmacology &amp; Pharmacy; ToxicologyAG7ZF</notes>
    <keywords>Biotransformation; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; Carcinogenicity; CELL; CHROMATOGRAPHY-MASS SPECTROMETRY; diabetes; Endocrine disrupting chemicals; estrogenic activity; Estrogenicity; EXPOSURE; FOOD; GENE-EXPRESSION; heart; HUMAN EXPOSURE; In vitro; IN-VITRO; IN-VIVO; LIQUID-LIQUID MICROEXTRACTION; MAMMARY-GLAND; Metabolic disorders; METABOLITES; PLANTS; POSTIMPLANTATION RAT EMBRYOS; RISK; SIGNALING PATHWAYS; TOXICITY; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>738</startpage>
    <endpage>758</endpage>
    <journalfull>Environmental Toxicology and Pharmacology</journalfull>
    <issue>2</issue>
    <volume>37</volume>
    <abstract>Bisphenol A (BPA) is a chemical compound used in massive amounts in the production of synthetic polymers and thermal paper. In this review, the sources of BPA, which influence its occurrence in the environment and human surrounding will be presented. Data concerning SPA occurrence in food, water and indoor environments as well as its appearance in tissues and body fluids of human body will be shown. The results of in vitro and in vivo studies and the results of epidemiological surveys showing toxic, endocrine, mutagenic and cancerogenic action of BPA will also be discussed. Moreover, data suggesting that exposure of human to BPA may elevate risk of obesity, diabetes and coronary heart diseases will be presented. Finally, biotransformation of BPA in animals, plants and microorganisms (bacteria, fungi, algae), resulting in the formation of various metabolites that exhibit different from BPA toxicity will be described. (C) 2014 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000335636600030</url>
    <isbnorissn>1382-6689</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>105</id>
    <title>Mammary gland morphology and gene expression signature of weanling male and female rats following exposure to exogenous estradiol</title>
    <authors>Miousse,I.R.; Gomez-Acevedo,H.; Sharma,N.; Vantrease,J.; Hennings,L.; Shankar,K.; Cleves,M.A.; Badger,T.M.; Ronis,M.J.</authors>
    <availability>[Miousse, Isabelle R.; Gomez-Acevedo, Horacio; Sharma, Neha; Vantrease, Jamie; Hennings, Leah; Shankar, Kartik; Cleves, Mario A.; Badger, Thomas M.; Ronis, Martin J. J.] Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA. [Miousse, Isabelle R.; Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pharmacol, Little Rock, AR 72202 USA. [Miousse, Isabelle R.; Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Toxicol, Little Rock, AR 72202 USA. [Gomez-Acevedo, Horacio; Shankar, Kartik; Cleves, Mario A.; Badger, Thomas M.; Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72202 USA. [Hennings, Leah] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72202 USA. [Badger, Thomas M.] Univ Arkansas Med Sci, Dept Physiol &amp; Biophys, Little Rock, AR 72202 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleRonis, MJ (reprint author), Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USARonisMartinJ@uams.eduCabanes A, 2004, CARCINOGENESIS, V25, P741, DOI 10.1093/carcin/bgh065; Chalabi N, 2010, MOL MED REP, V3, P75, DOI 10.3892/mmr_00000221; Chen JR, 2011, J PHARMACOL EXP THER, V336, P734, DOI 10.1124/jpet.110.175091; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; CHINOY NJ, 1982, ENDOKRINOLOGIE, V80, P287; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; Colditz GA, 1998, J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; de Assis S, 2006, INT J CANCER, V119, P1537, DOI 10.1002/ijc.21936; de Ronde W, 2003, CLIN ENDOCRINOL, V58, P529, DOI 10.1046/j.1365-2265.2003.01669.x; DOCKE F, 1988, EXP CLIN ENDOCRINOL, V91, P301; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; DUNNETT C. W., 1955, Journal of the American Statistical Association, V50, P1096, DOI 10.2307/2281208; Eliassen AH, 2006, J NATL CANCER I, V98, P1406, DOI 10.1093/jnci/djj376; Ewertz M, 2001, ACTA ONCOL, V40, P467; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; FORNEY JP, 1981, J CLIN ENDOCR METAB, V53, P192; Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hatsumi T, 2006, EXP BIOL MED, V231, P311; Hilakivi-Clarke L, 1998, ONCOL REP, V5, P609; Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584; Hilakivi-Clarke L, 2001, J NUTR, V131, p154S; Horwitz K B, 1979, Adv Exp Med Biol, V117, P95; Hsing AW, 1998, CANCER CAUSE CONTROL, V9, P269, DOI 10.1023/A:1008869003012; Irizarry R. A., 2003, STAT APPL GENET MOL, V2; Johnson KC, 2002, EUR J CANCER PREV, V11, P253, DOI 10.1097/00008469-200206000-00009; Key T, 2002, J Natl Cancer Inst, V94, P606; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kwon S, 2000, TOXICOL SCI, V55, P399, DOI 10.1093/toxsci/55.2.399; Lassurguere J, 2003, TOXICOL SCI, V73, P160, DOI 10.1093/toxsci/kfg065; Latendresse JR, 2009, REPROD TOXICOL, V28, P342, DOI 10.1016/j.reprotox.2009.04.006; Liu YH, 2009, EUR J ORAL SCI, V117, P685, DOI 10.1111/j.1600-0722.2009.00681.x; Loke D F, 1992, Ann Acad Med Singapore, V21, P765; Mandrup KR, 2012, INT J ANDROL, V35, P385, DOI 10.1111/j.1365-2605.2012.01258.x; MOHLA S, 1981, J STEROID BIOCHEM, V14, P501, DOI 10.1016/0022-4731(81)90022-4; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Moral R, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-5; Moral R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-453; Murrill WB, 1996, CARCINOGENESIS, V17, P1451, DOI 10.1093/carcin/17.7.1451; NAGASAWA H, 1974, CANCER RES, V34, P2643; Peng JH, 2010, EUR J CANCER PREV, V19, P110, DOI 10.1097/CEJ.0b013e3283362a3e; REEVES PG, 1993, J NUTR, V123, P1939; Roy JR, 2009, MED SCI MONITOR, V15, pRA137; Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; SCHINDLE.AE, 1972, J CLIN ENDOCR METAB, V35, P627; Schomberg D W, 1979, Adv Exp Med Biol, V112, P155; Schrager S, 2004, AM FAM PHYSICIAN, V69, P2395; Schulze A, 2001, NAT CELL BIOL, V3, pE190, DOI 10.1038/35087138; SHYAMALA G, 1990, ENDOCRINOLOGY, V126, P2882; SIITERI PK, 1987, AM J CLIN NUTR, V45, P277; Singhal R, 2008, CARCINOGENESIS, V29, P227, DOI 10.1093/carcin/bgm288; Singhal R, 2009, J ENDOCRINOL, V202, P141, DOI 10.1677/JOE-09-0059; Singhal R, 2007, J NUTR, V137, P19; Su Y, 2007, PHYSIOL GENOMICS, V30, P8, DOI 10.1152/physiolgenomics.00023.2007; Suzuki A, 2007, J VET MED SCI, V69, P725, DOI 10.1292/jvms.69.725; Taylor AH, 2000, J MOL ENDOCRINOL, V24, P145, DOI 10.1677/jme.0.0240145; Thomsen AR, 2006, TOXICOL SCI, V93, P357, DOI 10.1093/toxsci/kfl029; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521; Umekita Y, 2011, TOXICOL LETT, V205, P15, DOI 10.1016/j.toxlet.2011.04.031; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Velders M, 2010, J STEROID BIOCHEM, V120, P53, DOI 10.1016/j.jsbmb.2010.03.059; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183; Wang XJ, 2006, TOXICOL SCI, V91, P93, DOI 10.1093/toxsci/kfj120; Winer BJ, 1971, STATISTICAL PRINCIPL, P201; You L, 2004, ENVIRON TOXICOL PHAR, V18, P161, DOI 10.1016/j.etap.2004.01.013; You L, 2002, TOXICOL SCI, V66, P216, DOI 10.1093/toxsci/66.2.216732ROYAL SOC MEDICINE PRESS LTDLONDON1 WIMPOLE STREET, LONDON W1G 0AE, ENGLANDEXP BIOL MEDSEPDiscipline: Research &amp; Experimental Medicine220LA</notes>
    <keywords>17 beta-Estradiol; ANTIGEN; ARYL-HYDROCARBON RECEPTOR; ASSOCIATION; BETA; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CHILDREN; DIETHYLSTILBESTROL DES; ER-BETA; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR BETA; ESTROGEN-RECEPTORS; Estrogenicity; EXPOSURE; EXPRESSION; FEMALE RATS; gene expression; gene expression profile; GENE-EXPRESSION; GLAND; IN-UTERO EXPOSURE; Male; MALE BREAST-CANCER; MALE RATS; mammary gland; MAMMARY-GLAND; MAMMARY-GLANDS; Milk; POSTNATAL-DEVELOPMENT; PROGESTERONE-RECEPTOR; proliferation; PROTEIN; PROTEINS; RAT; RATS; RECEPTOR; RISK-FACTORS; terminal end buds; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1033</startpage>
    <endpage>1046</endpage>
    <journalfull>Experimental Biology and Medicine</journalfull>
    <issue>9</issue>
    <volume>238</volume>
    <abstract>In order to characterize the actions of xenoestrogens, it is essential to possess a solid portrait of the physiological effects of exogenous estradiol. We assessed effects of three doses of exogenous estradiol (E2) (0.1, 1.0 and 10 mu g/kg/day) given between postnatal days 21 and 33 on the mammary gland morphology and gene expression profiles of male and female rats compared to vehicle-treated controls. The male mammary gland was more responsive to E2 treatment than in females, with 509 genes regulated &gt;2-fold in a dose-dependent manner in males and only 174 in females. In males, E2 treatment significantly (P &lt; 0.01) increased the number of terminal end buds (TEBs) and the expression of proliferating cell nuclear antigen (PCNA) protein (P &lt; 0.05), both of which are indicators of proliferation. This change was linked to a significant increase (P &lt; 0.05) in the expression of the gene encoding amphiregulin, which is known to induce TEB formation. There was also a dose-dependent increase (P &lt; 0.001) in the estrogen-regulated gene encoding the progesterone receptor. In intact females, despite lack of changes in mammary morphology, we observed a dose-dependent increase (P &lt; 0.05) in the expression of genes encoding three milk proteins: whey acidic protein, casein beta and casein kappa. There was a significant (P &lt; 0.05) downregulation of both estrogen receptors in response to E2 treatment. These results suggest that mammary glands of male rats are very sensitive to exogenous E2 during development post-weaning. The dose-dependent increase observed in amphiregulin and progesterone receptor gene expression was linked to morphological changes and represents a reliable and sensitive tool to evaluate estrogenicity. In contrast, intact weanling female rats were less responsive</abstract>
    <url>WOS:000324584000007</url>
    <isbnorissn>1535-3702</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>441</id>
    <title>Repressive effect of the phytoestrogen genistein on estradiol-induced uterine leiomyoma cell proliferation</title>
    <authors>Miyake,A.; Takeda,T.; Isobe,A.; Wakabayashi,A.; Nishimoto,F.; Morishige,K.I.; Sakata,M.; Kimura,T.</authors>
    <availability>[Miyake, Asako; Takeda, Takashi; Isobe, Aki; Wakabayashi, Atsuko; Nishimoto, Fumihito; Morishige, Ken-Ichirou; Sakata, Masahiro; Kimura, Tadashi] Tohoku Univ, Grad Sch Med, Ctr Asian Tradit Med, Aoba Ku, Sendai, Miyagi 9808574, Japan.</availability>
    <date>2009</date>
    <notes>JEnglishArticleTakeda, T (reprint author), Tohoku Univ, Grad Sch Med, Ctr Asian Tradit Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japantake@m.tains.tohoku.ac.jpBanerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052; Dang ZC, 2003, J BIOL CHEM, V278, P962, DOI 10.1074/jbc.M209483200; EVERITT JI, 1995, AM J PATHOL, V146, P1556; Flake GP, 2003, ENVIRON HEALTH PERSP, V111, P1037; Gossner G, 2007, GYNECOL ONCOL, V105, P23, DOI 10.1016/j.ygyno.2006.11.009; Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003-1014; Houston KD, 2003, CANCER RES, V63, P1221; HOWE SR, 1995, AM J PATHOL, V146, P1568; Huang XK, 2005, CANCER RES, V65, P3470; Izumi T, 2000, J NUTR, V130, P1695; Katdare M, 2002, INT J ONCOL, V21, P809; Konstantakopoulos N, 2006, MOL CARCINOGEN, V45, P752, DOI 10.1002/mc.20187; Lepine L A, 1997, MMWR CDC Surveill Summ, V46, P1; Moore AB, 2007, HUM REPROD, V22, P2623, DOI 10.1093/humrep/dem185; Nagata C, 2001, EUR J CLIN NUTR, V55, P773, DOI 10.1038/sj.ejcn.1601223; Rein MS, 2000, ENVIRON HEALTH PERSP, V108, P791, DOI 10.2307/3454308; Setchell KD, 1998, AM J CLIN NUTR S, V68, P1333; Severino M F, 1996, Mol Hum Reprod, V2, P823, DOI 10.1093/molehr/2.11.823; Sharma AM, 2007, J CLIN ENDOCR METAB, V92, P386, DOI 10.1210/jc.2006.1268; Shushan A, 2007, FERTIL STERIL, V87, P127, DOI 10.1016/j.fertnstert.2006.05.056; Takeda T, 2008, GYNECOL OBSTET INVES, V66, P14, DOI 10.1159/000114250; Walker CL, 2003, GENE CHROMOSOME CANC, V38, P349, DOI 10.1002/gcc.10281; Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063; WILCOX LS, 1994, OBSTET GYNECOL, V83, P549; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873252INFORMA HEALTHCARENEW YORK52 VANDERBILT AVE, NEW YORK, NY 10017 USAGYNECOL ENDOCRINOLDiscipline: Endocrinology &amp; Metabolism; Obstetrics &amp; Gynecology478SL</notes>
    <keywords>ACTIVATED-RECEPTOR-GAMMA; ACTIVATION; analysis; Antagonist; apoptosis; BADGE; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER-CELLS; Carcinogen; CELL; Cell proliferation; CELL-LINE; CELL-PROLIFERATION; CELLS; Differentiation; DISEASE; diseases; EPITHELIAL-CELLS; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPRESSION; GENE; genistein; HEALTH; HYSTERECTOMY; In vitro; IN-VITRO; inhibition; KU; LEIOMYOMA CELLS; LIGAND; LINE; METABOLISM; Phytoestrogen; PHYTOESTROGEN GENISTEIN; PPAR; PPAR gamma; PPAR-gamma; PRODUCTS; proliferation; RECEPTOR; RECEPTOR-GAMMA; Receptors; REPRODUCTIVE HEALTH; REPRODUCTIVE-TRACT LEIOMYOMATA; RODENT MODEL; Signal transduction; SOY; THERAPY; TUMOR; UTERINE; Uterine leiomyoma; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>403</startpage>
    <endpage>409</endpage>
    <journalfull>Gynecological Endocrinology</journalfull>
    <issue>6</issue>
    <volume>25</volume>
    <abstract>Objective. Uterine leiomyomas are the most common gynecological benign tumor and greatly affect reproductive health and well-being. They are the predominant indication for hysterectomy in premenopausal women. Current epidemiological study reported that soy products intake is inversely associated with diseases leading to hysterectomy. Genistein is a soy-derived phytoestrogen and its inhibitory effect on leiomyoma cell proliferation is reported. In this study, we investigated the siginificant inhibitory effect of genistein on estradiol (E(2))-induced leiomyoma cells proliferation. Study design. The Eker rat-derived uterine leiomyoma cell line ELT-3 cells were used. Cell proliferation was assessed by counting the number of cells. The expression of estrogen receptors and peroxisome proliferator-activated receptor-gamma (PPAR gamma) was evaluated by Western blot analysis. Results. PPAR gamma was expressed in ELT-3 cells and genistein acted as PPAR gamma ligand. This inhibitory effect of genistein was attenuated by the treatment of cells with PPAR gamma antagonist bisphenol A diglycidyl ether ( BADGE) or GW9662. Conclusion. These experimental findings in vitro show that the repressive effect of genistein on E(2)-induced ELT-3 cell proliferation is through the activation of PPAR gamma. Genistein may be useful as an alternative therapy for leiomyoma</abstract>
    <url>WOS:000268608500011</url>
    <isbnorissn>0951-3590</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>438</id>
    <title>The Influence of Endocrine Disrupting Chemicals on the Proliferation of ER alpha Knockdown-Human Breast Cancer Cell Line MCF-7; New Attempts by RNAi Technology</title>
    <authors>Miyakoshi,T.; Miyajima,K.; Takekoshi,S.; Osamura,R.Y.</authors>
    <availability>[Miyakoshi, Takashi; Miyajima, Katsuhiro; Takekoshi, Susumu; Osamura, Robert Yoshiyuki] Tokai Univ, Dept Pathol, Sch Med, Kanagawa 2591193, Japan.</availability>
    <date>2009</date>
    <notes>JEnglishArticleOsamura, RY (reprint author), Tokai Univ, Dept Pathol, Sch Med, 143 Shimokasuya, Kanagawa 2591193, Japanosamura@is.icc.u-tokai.ac.jpBiedermann M, 1998, FOOD ADDIT CONTAM A, V15, P609; BORNSTEIN J, 1988, Obstetrical and Gynecological Survey, V43, P15; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Perret AG, 1998, AM J CLIN PATHOL, V109, P286; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; Kim H S, 2001, J Toxicol Sci, V26, P111, DOI 10.2131/jts.26.111; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; Miyai S, 2005, ACTA HISTOCHEM CYTOC, V38, P107, DOI 10.1267/ahc.38.107; MORRISEY RE, 1987, FUND APPL TOXICOL, V8, P571, DOI 10.1016/0272-0590(87)90142-4; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Oshima Y, 2007, ACTA HISTOCHEM CYTOC, V40, P27, DOI 10.1267/ahc.06015; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Schafer TE, 1999, J BIOMED MATER RES, V45, P192, DOI 10.1002/(SICI)1097-4636(19990605)45:3&lt;192::AID-JBM5&gt;3.0.CO;2-A; Singleton DW, 2004, MOL CELL ENDOCRINOL, V221, P47, DOI 10.1016/j.mce.2004.04.010; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Takeshita K, 2006, ACTA HISTOCHEM CYTOC, V39, P23, DOI 10.1267/ahc.05052; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; WILCOX AJ, 1995, NEW ENGL J MED, V332, P1411, DOI 10.1056/NEJM199505253322104; Witorsch RJ, 2002, FOOD CHEM TOXICOL, V40, P905, DOI 10.1016/S0278-6915(02)00069-8; Yarden RI, 1996, ENDOCRINOLOGY, V137, P2739, DOI 10.1210/en.137.7.2739; YOSHIDA M, 2002, ACTA HISTOCHEM CYTOC, V34, P413317JAPAN SOC HISTOCHEMISTRY &amp; CYTOCHEMISTRYKYOTOC/O NAKANISHI PRINTING CO LTD, SHIMODACHIURI-OGAWA, KAMIGYO-KU, KYOTO, 602-8048, JAPANACTA HISTOCHEM CYTOCDiscipline: Cell Biology469DX</notes>
    <keywords>17-BETA-ESTRADIOL; ALPHA; ASSAY; BETA; BIOLOGY; bisphenol; bisphenol A; bisphenol A (BPA); BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CELL; Cell proliferation; Cell proliferation assay; CELL-LINE; CELL-PROLIFERATION; CELLS; CHEMICALS; COATINGS; DES; DIETHYLSTILBESTROL; DISRUPTING CHEMICALS; E2; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; ER; ER alpha; ER-ALPHA; ESTRADIOL; estrogen receptor alpha (ER alpha); ESTROGEN-RECEPTOR-ALPHA; EXPRESSION; FOOD; GENE; GENES; HEALTH; HUMAN-BREAST-CANCER; IN-VITRO; LINE; LINE MCF-7; MCF-7; MECHANISMS; PRENATAL EXPOSURE; PRODUCTS; proliferation; RNA interference (RNAi); TARGET; TARGET GENES; TOOL; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>23</startpage>
    <endpage>28</endpage>
    <journalfull>Acta Histochemica et Cytochemica</journalfull>
    <issue>2</issue>
    <volume>42</volume>
    <abstract>Bisphenol A (BPA) is a monomer use in manufacturing a wide range of chemical products which include epoxy resins and polycarbonate. It has been reported that BPA increases the cell proliferation activity of human breast cancer MCF-7 cells as well as 17-beta estradiol (E2) and diethylstilbestrol (DES). However, BPA induces target genes through ER-dependent and ER-independent manners which are different from the actions induced by E2. Therefore, BPA may be unique in estrogen-dependent cell proliferation compared to other endocrine disrupting chemicals (EDCs). In the present study, to test whether ER alpha is essential to the BPA-induced proliferation on MCF-7 cells, we suppressed the ER alpha expression of MCF-7 cells by RNA interference (RNAi). Proliferation effects in the presence of E2, DES and BPA were not observed in ER alpha-knockdown MCF-7 cells in comparison with control MCF-7. In addition, a marker of proliferative potential, MIB-1 labeling index (LI), showed no change in BPA-treated groups compared with vehicle-treated groups on ER alpha-knockdown MCF-7 cells. In conclusion, we demonstrated that ER alpha has a role in BPA-induced cell proliferation as well as E2 and DES. Moreover, this study indicated that the direct knockdown of ERa using RNAi serves as an additional tool to evaluate, in parallel with MCF-7 cell proliferation assay, for potential EDCs</abstract>
    <url>WOS:000267877000002</url>
    <isbnorissn>0044-5991</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>114</id>
    <title>Effects of endocrine disruptors bisphenol A and di(2-ethylhexyl) phthalate in a combination with 17 beta-estradiol on apoptosis-related genes in the MCF-7 breast cancer cell line</title>
    <authors>Mlynarcikova,A.; Havranek,T.; Fickova,M.</authors>
    <availability>[Mlynarcikova, Alzbeta; Havranek, Tomas; Fickova, Maria] Inst Expt Endocrinol SAS, Bratislava, Slovakia.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTAUG 28SDiscipline: Toxicology210WO</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; bisphenol; bisphenol A; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CELL; COMBINATION; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; phthalate; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S106</startpage>
    <endpage>S106</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <volume>221</volume>
    <url>WOS:000323865800321</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>97</id>
    <title>In vitro study on the agonistic and antagonistic activities of bisphenol-S and other bisphenol-A congeners and derivatives via nuclear receptors</title>
    <authors>Molina-Molina,J.M.; Amaya,E.; Grimaldi,M.; Saenz,J.M.; Real,M.; Fernandez,M.F.; Balaguer,P.; Olea,N.</authors>
    <availability>[Molina-Molina, Jose-Manuel; Amaya, Esperanza; Saenz, Jose-Maria; Real, Macarena; Fernandez, Mariana F.; Olea, Nicolas] Univ Granada, San Cecilio Univ Hosp, Lab Med Invest, Ciber Epidemiol &amp; Salud Publ CIBERESP, E-18071 Granada, Spain. [Grimaldi, Marina; Balaguer, Patrick] INSERM, U896, F-34298 Montpellier, France. [Grimaldi, Marina; Balaguer, Patrick] Univ Montpellier I, F-34298 Montpellier, France.</availability>
    <date>2013</date>
    <notes>JEnglishArticleMolina-Molina, JM (reprint author), Univ Granada, San Cecilio Univ Hosp, Lab Med Invest, E-18071 Granada, Spainmolinajm@ugr.esAyed-Boussema I., 2001, ENVIRON TOXICOL PHAR, V31, P79; Balaguer P, 1999, SCI TOTAL ENVIRON, V233, P47, DOI 10.1016/S0048-9697(99)00178-3; Balaguer P, 2001, LUMINESCENCE, V16, P153, DOI 10.1002/bio.630.abs; Berthier A, 2012, TOXICOL SCI, V127, P225, DOI 10.1093/toxsci/kfs073; Cabaton N, 2009, TOXICOLOGY, V255, P15, DOI 10.1016/j.tox.2008.09.024; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cariou R, 2008, CHEMOSPHERE, V73, P1036, DOI 10.1016/j.chemosphere.2008.07.084; Changkhamchom S, 2010, POLYM BULL, V65, P265, DOI 10.1007/s00289-010-0243-8; Chen MY, 2002, ENVIRON TOXICOL, V17, P80, DOI 10.1002/tox.10035; Coulier L, 2010, J AGR FOOD CHEM, V58, P4873, DOI 10.1021/jf904160a; Creusot N, 2010, ANAL BIOANAL CHEM, V396, P569, DOI 10.1007/s00216-009-3310-y; Danzl E, 2009, INT J ENV RES PUB HE, V6, P1472, DOI 10.3390/ijerph6041472; DeKeyser J.G., 2001, TOXICOL SCI, V120, P381; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; DeWit C. A., 2009, SCI TOTAL ENVIRON, V408, P2885; Diamanti-Kandarakis E., 2009, ENDOCR REV, V30, P293; di Masi A, 2009, MOL ASPECTS MED, V30, P297, DOI 10.1016/j.mam.2009.04.002; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dring AM, 2010, CHEM-BIOL INTERACT, V188, P512, DOI 10.1016/j.cbi.2010.09.018; Escande A, 2006, BIOCHEM PHARMACOL, V71, P1459, DOI 10.1016/j.bcp.2006.02.002; EU, 2011, OJEU, VL26, P11; EU, 2005, OFF J EUR UNION L, V302, P28; EU, 2006, OFFICIAL J EUROPEA L, VL396, P1; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Fiege H., 2000, ULLMANNS ENCY IND A, VA19, P313; Fromme H, 2002, WATER RES, V36, P1429, DOI 10.1016/S0043-1354(01)00367-0; Fukazawa H, 2001, CHEMOSPHERE, V44, P973, DOI 10.1016/S0045-6535(00)00507-5; Gallart-Ayala H, 2011, ANAL CHIM ACTA, V683, P227, DOI 10.1016/j.aca.2010.10.034; Germain P, 2006, PHARMACOL REV, V58, P685, DOI 10.1124/pr.58.4.2; Grignard E, 2012, TOXICOL IN VITRO, V26, P727, DOI 10.1016/j.tiv.2012.03.013; Hashimoto Y, 2001, TOXICOL IN VITRO, V15, P421, DOI 10.1016/S0887-2333(01)00046-7; Hashimoto Y, 2000, Dent Mater J, V19, P245; Henley DV, 2006, ENDOCRINOLOGY, V147, pS25, DOI 10.1210/en.2005-1117; Hillisch A, 2004, MOL ENDOCRINOL, V18, P1599, DOI 10.1210/me.2004-0050; Ike M, 2006, WATER SCI TECHNOL, V53, P153, DOI 10.2166/wst.2006.189; Jana SK, 2005, APPL CATAL A-GEN, V288, P80, DOI 10.1016/j.apcata.2005.04.031; Jimenez-Diaz I, 2010, J CHROMATOGR B, V878, P3363, DOI 10.1016/j.jchromb.2010.10.021; Johnson-Restrepo B, 2008, CHEMOSPHERE, V70, P1935, DOI 10.1016/j.chemosphere.2007.10.002; Kang JH, 2007, CRIT REV TOXICOL, V37, P607, DOI 10.1080/10408440701493103; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; Kim MR, 2001, REACT KINET CATAL L, V72, P373, DOI 10.1023/A:1010575820818; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kitamura S, 2002, BIOCHEM BIOPH RES CO, V293, P554, DOI 10.1016/S0006-291X(02)00262-0; Kuruto-Niwa R, 2005, ENVIRON TOXICOL PHAR, V19, P121, DOI 10.1016/j.etap.2004.05.009; Lamba JK, 2004, J PHARMACOL EXP THER, V311, P811, DOI 10.1124/jpet.104.069310; Lemaire G, 2006, TOXICOL SCI, V91, P501, DOI 10.1093/toxsci/kfj173; Liao CY, 2012, ENVIRON SCI TECHNOL, V46, P6860, DOI 10.1021/es301334j; Liao CY, 2012, ENVIRON SCI TECHNOL, V46, P6515, DOI 10.1021/es300876n; Liao CY, 2012, ENVIRON SCI TECHNOL, V46, P11558, DOI 10.1021/es303191g; Liu Y, 2005, FINE SPECIALTY CHEM, V13, P13; Meerts Ilonka A. T. M., 2001, Environmental Health Perspectives, V109, P399, DOI 10.2307/3454900; Mnif W, 2007, TOXICOL LETT, V170, P19, DOI 10.1016/j.toxlet.2006.11.016; Molina-Molina JM, 2008, TOXICOL APPL PHARM, V232, P384, DOI 10.1016/j.taap.2008.07.017; Molina-Molina JM, 2006, TOXICOL APPL PHARM, V216, P44, DOI 10.1016/j.taap.2006.04.005; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Nilsson S, 2011, CLIN PHARMACOL THER, V89, P44, DOI 10.1038/clpt.2010.226; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Riu A, 2011, ENVIRON HEALTH PERSP, V119, P1227, DOI 10.1289/ehp.1003328; Riu A, 2011, TOXICOL SCI, V122, P372, DOI 10.1093/toxsci/kfr132; Rivas A, 2002, J STEROID BIOCHEM, V82, P45, DOI 10.1016/S0960-0760(02)00146-2; Rivas A.M., 2001, APMIS, V109, P1; Ropero AB, 2008, INT J ANDROL, V31, P194, DOI 10.1111/j.1365-2605.2007.00832.x; Rwei SP, 2003, COLLOID POLYM SCI, V281, P407, DOI 10.1007/s00396-002-0787-8; Satoh K, 2004, FOOD CHEM TOXICOL, V42, P983, DOI 10.1016/j.fct.2004.02.011; Seimandi M, 2005, ANAL BIOCHEM, V344, P8, DOI 10.1016/j.ab.2005.06.010; Soriano S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031109; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Spitsbergen J.C., 1971, 26 ANN TECHN C REINF, P1; Stachel B, 2003, ENVIRON POLLUT, V124, P497, DOI 10.1016/S0269-7491(02)00483-9; Stroheker T, 2004, FOOD CHEM TOXICOL, V42, P887, DOI 10.1016/j.fct.2004.01.012; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Szelei J, 1997, ENDOCRINOLOGY, V138, P1406, DOI 10.1210/en.138.4.1406; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; Terouanne B, 2000, MOL CELL ENDOCRINOL, V160, P39, DOI 10.1016/S0303-7207(99)00251-8; Timsit YE, 2007, STEROIDS, V72, P231, DOI 10.1016/j.steroids.2006.12.006; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vinas P, 2010, ANAL BIOANAL CHEM, V397, P115, DOI 10.1007/s00216-010-3464-7; Vinas R, 2013, ENVIRON HEALTH PERSP, V121, P352, DOI 10.1289/ehp.1205826; Vinas R, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-26; vom Saal F.S., 2010, MOL CELL ENDOCRINOL, V354, P74; von Bueren AO, 2007, BRIT J SPORT MED, V41, P874, DOI 10.1136/bjsm.2007.035162; von Bueren AO, 2008, ANTICANCER RES, V28, P85; Wang L, 2012, ENVIRON SCI TECHNOL, V46, P11584, DOI 10.1021/es303516u; Wang YM, 2012, EXPERT OPIN DRUG MET, V8, P803, DOI 10.1517/17425255.2012.685237; Watanabe M., 2004, J ENV CHEM, V14, P65; Wilson VS, 2002, TOXICOL SCI, V66, P69, DOI 10.1093/toxsci/66.1.69; WONG CI, 1995, J BIOL CHEM, V270, P19998; Yamasaki K, 2002, TOXICOLOGY, V170, P21, DOI 10.1016/S0300-483X(01)00505-49310ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMOCT 1Discipline: Pharmacology &amp; Pharmacy; Toxicology236YA</notes>
    <keywords>ALPHA; ANDROGEN RECEPTOR; BETA; BINDING; bisphenol; bisphenol A; BISPHENOL-A; Bisphenol-A (BPA) derivatives; Bisphenol-S (BPS); BPA; BREAST-CANCER CELLS; CELL; Cell proliferation assay; CELL-PROLIFERATION; CHEMICALS; CHLORINATED DERIVATIVES; DIGLYCIDYL ETHER BADGE; ENDOCRINE; Endocrine-disrupting chemicals; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS; estrogenic activity; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; human estrogen receptor; In vitro; IN-VITRO; Interaction; NUCLEAR RECEPTORS; Nuclear receptors (NRs); PREGNANE X RECEPTOR; PREGNANE-X-RECEPTOR; proliferation; RECEPTOR; Receptor binding assay; RECEPTOR-ALPHA; REPORTER CELL-LINES; Reporter gene assay; TETRABROMOBISPHENOL-A; toxicology; UNITED-STATES; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>127</startpage>
    <endpage>136</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>1</issue>
    <volume>272</volume>
    <abstract>Bisphenols are a group of chemicals structurally similar to bisphenol-A (BPA) in current use as the primary raw material in the production of polycarbonate and epoxy resins. Some bisphenols are intended to replace BPA in several industrial applications. This is the case of bisphenol-S (BPS), which has an excellent stability at high temperature and resistance to sunlight. Studies on the endocrine properties of BPS have focused on its interaction with human estrogen receptor alpha (hER alpha), but information on its interaction with other nuclear receptors is scarce. The aim of this study was to investigate interactions of BPS, BPF, BPA and its halogenated derivatives, tetrachlorobisphenol A (TCBPA), and tetrabromobisphenol A (TBBPA), with human estrogen receptors (hER alpha and hER beta), androgen receptor (hAR), and pregnane X receptor (hPXR), using a panel of in vitro bioassays based on competitive binding to nuclear receptors (NRs), reporter gene expression, and cell proliferation assessment. BPS, BPF, and BPA efficiently activated both ERs, while TCBPA behaved as weak hERa agonist. Unlike BPF and BPA, BPS was more active in the hER beta versus hER alpha assay. BPF and BPA were full hAR antagonists (BPA &gt; BPF), whereas BPA and BPS were weak hAR agonists. Only BPA, TCBPA, and TBBPA, were hPXR agonists (TCBPA &gt; TBBPA &gt; BPA). These findings provide evidence that BPA congeners and derivatives disrupt multiple NRs and may therefore interfere with the endocrine system. Hence, further research is needed to evaluate the potential endocrine-disrupting activity of putative BPA substitutes. (C) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000325834200014</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>180</id>
    <title>The rat prepubertal uterine myometrium and not the luminal epithelium is predominantly affected by a chronic dietary genistein exposure</title>
    <authors>Moller,F.J.; Ledwig,C.; Zierau,O.; Hertrampf,T.; Degen,G.H.; Diel,P.; Vollmer,G.</authors>
    <availability>[Moeller, Frank Josef; Zierau, Oliver; Vollmer, Guenter] Tech Univ Dresden, Inst Zool Mol Cell Physiol &amp; Endocrinol, D-01062 Dresden, Germany. [Ledwig, Corinna; Hertrampf, Torsten; Diel, Patrick] German Sport Univ Cologne, Inst Cardiovasc Res &amp; Sports Med, Dept Mol &amp; Cellular Sports Med, D-50933 Cologne, Germany. [Degen, Gisela H.] Leibniz Res Ctr Working Environm &amp; Human Factors, IfADo, D-44139 Dortmund, Germany.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMoller, FJ (reprint author), Tech Univ Dresden, Inst Zool Mol Cell Physiol &amp; Endocrinol, D-01062 Dresden, Germanyfrank.moeller@tu-dresden.deAdlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470-2045(02)00777-5; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Ashby J, 1997, REGUL TOXICOL PHARM, V25, P226, DOI 10.1006/rtph.1997.1108; Barkhem T, 1998, MOL PHARMACOL, V54, P105; Bliedtner A, 2009, MOL CELL ENDOCRINOL, V314, P41; Bouker KB, 2000, ENVIRON HEALTH PERSP, V108, P701, DOI 10.2307/3434722; Casanova M, 1999, TOXICOL SCI, V51, P236, DOI 10.1093/toxsci/51.2.236; Charlier Thierry D, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS20, DOI 10.1016/j.psyneuen.2009.05.004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark J, 1988, PHYSL REPRODUCTION, V1, P675; Cos P, 2003, PLANTA MED, V69, P589, DOI 10.1055/s-2003-41122; Cotroneo MS, 2001, MOL CELL ENDOCRINOL, V173, P135, DOI 10.1016/S0303-7207(00)00405-6; Diel P, 2006, J STEROID BIOCHEM, V102, P60, DOI 10.1016/j.jsbmb.2006.09.022; Diel P, 2004, MOL CELL ENDOCRINOL, V221, P21, DOI 10.1016/j.mce.2004.04.006; Diel P, 2004, ARCH TOXICOL, V78, P183, DOI 10.1007/s00204-003-0535-y; Doerge DR, 2006, REPROD TOXICOL, V21, P307, DOI 10.1016/j.reprotox.2005.09.007; Eason RR, 2005, J NUTR BIOCHEM, V16, P625, DOI 10.1016/j.jnutbio.2005.03.005; Eisenbrand G, 2007, MOL NUTR FOOD RES, V51, P1305, DOI 10.1002/mnfr.200700217; Fritzemeier KH, 2004, E SCHERING RES FDN W, V46, P127; Gaete L, 2010, B LATINOAM CARIBE PL, V9, P302; Hagemann P, 1989, HISTOTECHNIK ERGANZU; Hertrampf T, 2006, PLANTA MED; Hertrampf T, 2009, TOXICOL LETT, V191, P181, DOI 10.1016/j.toxlet.2009.08.019; Hilakivi-Clarke L, 2010, J NUTR, V140, p2326S, DOI 10.3945/jn.110.124230; Hillisch A, 2004, MOL ENDOCRINOL, V18, P1599, DOI 10.1210/me.2004-0050; Kang KS, 2000, TOXICOL LETT, V118, P109, DOI 10.1016/S0378-4274(00)00272-1; King A, 1999, J AM DIET ASSOC, V99, P213, DOI 10.1016/S0002-8223(99)00051-6; KRAUS WL, 1993, ENDOCRINOLOGY, V132, P2371, DOI 10.1210/en.132.6.2371; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; LESSEY BA, 1988, J CLIN ENDOCR METAB, V67, P334; Levis S, 2011, ARCH INTERN MED, V171, P1363, DOI 10.1001/archinternmed.2011.330; Molla Maria Dolores Julia, 2011, Front Biosci (Schol Ed), V3, P191, DOI 10.2741/s144; Moller FJ, 2010, TOXICOL LETT, V196, P142, DOI 10.1016/j.toxlet.2010.03.1117; Moller FJ, 2009, J STEROID BIOCHEM, V113, P296, DOI 10.1016/j.jsbmb.2009.01.016; Moors S, 2007, MOL NUTR FOOD RES, V51, P787, DOI 10.1002/mnfr.200600289; Nephew KP, 2000, P SOC EXP BIOL MED, V223, P288, DOI 10.1046/j.1525-1373.2000.22341.x; Newbold RR, 2001, CANCER RES, V61, P4325; Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052; Olson SH, 2007, AM J EPIDEMIOL, V165, P235, DOI 10.1093/aje/kwk015; Owens W, 2003, ENVIRON HEALTH PERSP, V111, P1559, DOI 10.1289/ehp.5949; Papaconstantinou AD, 2000, TOXICOL SCI, V56, P332, DOI 10.1093/toxsci/56.2.332; Patisaul HB, 2010, FRONT NEUROENDOCRIN, V31, P400, DOI 10.1016/j.yfrne.2010.03.003; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ren MQ, 2001, EUR J NUTR, V40, P135, DOI 10.1007/PL00007388; Rice S, 2008, J STEROID BIOCHEM, V108, P186, DOI 10.1016/j.jsbmb.2007.09.003; Sahlin L, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-47; Schmidt S, 2006, ARCH TOXICOL, V80, P839, DOI 10.1007/s00204-006-0102-4; Setchell KDR, 1999, J NUTR, V129, p758S; Thigpen JE, 2001, CANCER DETECT PREV, V25, P527; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Wade MG, 2003, FOOD CHEM TOXICOL, V41, P1517, DOI 10.1016/S0278-6915(03)00168-6; Wang J, 2011, J PROTEOME RES, V10, P1621, DOI 10.1021/pr100974w; Weihua Z, 2000, Proc Natl Acad Sci U S A, V97, P5936, DOI 10.1073/pnas.97.11.5936; Wilson T, 2002, LIFE SCI, V70, P2287, DOI 10.1016/S0024-3205(02)01483-2552SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYARCH TOXICOLDECDiscipline: Toxicology035YO</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ADULT; ALPHA; BETA; BISPHENOL-A; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; Dietary Exposure; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; Estrogenicity; ESTROGENS; EXPOSURE; EXPRESSION; FOOD; GENE-EXPRESSION; genistein; HEALTH; Immature Uterus; IMPACT; IN-VITRO; ISOFLAVONE; ISOFLAVONES; p21; PHYTOESTROGEN GENISTEIN; Progesterone receptor; PROGESTERONE-RECEPTOR; proliferation; RAT; RATS; RECEPTOR; Reproduction; SOY; SOY ISOFLAVONE; SPRAGUE-DAWLEY RATS; steroid receptors; toxicology; Uterus</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1899</startpage>
    <endpage>1910</endpage>
    <journalfull>Archives of Toxicology</journalfull>
    <issue>12</issue>
    <volume>86</volume>
    <abstract>Current knowledge about dietary soy isoflavone-induced hormonal effects and potential priming effects for the responsiveness of the organism to other estrogens is insufficient. The present study examined the effects of pre- and postnatal soy isoflavone exposure on estrogen responsiveness by estrogen receptor agonists in the uteri of prepubertal Wistar rats. To this end, offspring were generated from dams already maintained on three dietary groups, (1) a phytoestrogen-free diet, (2) a soy isoflavone-rich diet with 232 ppm daidzein and 240 ppm genistein or (3) a custom-made diet supplemented with 700 ppm genistein (GEN). Then, F1 females continuously exposed to isoflavones from GD1 to PND21 and non-exposed controls were subjected to an immature uterotrophic assay to compare physiological parameters and the response to subcutaneous treatment with 17 beta-estradiol, GEN or an estrogen receptor subtype (ER alpha and ER beta)-specific agonist. Uterine wet weight (UWW), luminal epithelial height (LEH) and myometrial thickness (MMT) were determined. In addition, isoflavone plasma levels and mRNA expression profiles of relevant steroid receptors and of molecular markers for proliferation and estrogenicity were assessed for all groups. The influence of dietary isoflavones on the sensitivity to various estrogenic stimuli in these prepubertal animals was minor. Yet, the uterus of immature rats with high chronic GEN exposure alone showed already an increase in UWW, LEH and MMT. The myometrial response to GEN was more pronounced than that of the luminal epithelium, which may be due to a non-uniform distribution of steroid receptors, in particular the progesterone receptor. In conclusion, although the impact of a continuous, prenatally initiated exposure to dietary isoflavones on the uterine physiology of juvenile rats is modest, the possible priming effects of this exposure for beneficial or adverse late-onset consequences in adults should not be neglected</abstract>
    <url>WOS:000310990200011</url>
    <isbnorissn>0340-5761</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>359</id>
    <title>Meta-analysis of Supramaximal Effects in In Vitro Estrogenicity Assays</title>
    <authors>Montano,M.; Bakker,E.J.; Murk,A.J.</authors>
    <availability>[Montano, Mauricio; Murk, Albertinka Jacoba] Wageningen Univ, Dept Toxicol, NL-6703 HE Wageningen, Netherlands. [Montano, Mauricio] Ctr Rech Publ Gabriel Lippmann, Nutr &amp; Toxicol Unit, Dept Environm &amp; Agrobiotechnol, L-4422 Belvaux, Grand Duche Lux, Luxembourg. [Bakker, Evert Jan] Wageningen Univ, NL-6700 AC Wageningen, Netherlands. [Murk, Albertinka Jacoba] Wageningen Inst Marine Resources &amp; Ecosyst Studie, NL-1976 CP Ijmuiden, Netherlands.</availability>
    <date>2010</date>
    <notes>JEnglishArticleMurk, AJ (reprint author), Wageningen Univ, Dept Toxicol, Tuinlaan 5,Bldg 320, NL-6703 HE Wageningen, Netherlandstinka.murk@wur.nlArnold SF, 1996, ENVIRON HEALTH PERSP, V104, P544, DOI 10.2307/3432996; Ashby J, 1999, J APPL TOXICOL, V19, P39, DOI 10.1002/(SICI)1099-1263(199901/02)19:1&lt;39::AID-JAT534&gt;3.0.CO;2-M; Bandiera Stelvio M., 2006, Immunology Endocrine &amp; Metabolic Agents in Medicinal Chemistry, V6, P15, DOI 10.2174/187152206775528833; Basly JP, 2000, LIFE SCI, V66, P769, DOI 10.1016/S0024-3205(99)00650-5; Beck V, 2005, J BIOCHEM BIOPH METH, V64, P19, DOI 10.1016/j.jbbm.2005.05.001; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bhat KPL, 2001, CANCER RES, V61, P7456; Bovee TFH, 2004, J STEROID BIOCHEM, V91, P99, DOI 10.1016/j.jsbmb.2004.03.118; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; CATHERINO WH, 1995, CANCER LETT, V92, P39, DOI 10.1016/0304-3835(95)03755-L; Charles GD, 2004, ILAR J, V45, P494; Collins BM, 1997, STEROIDS, V62, P365, DOI 10.1016/S0039-128X(96)00246-2; DEMIRPENCE E, 1993, J STEROID BIOCHEM, V46, P355, DOI 10.1016/0960-0760(93)90225-L; Fan SJ, 2000, CANCER RES, V60, P5635; Freyberger A, 2005, TOXICOL LETT, V155, P1, DOI 10.1016/j.toxlet.2004.06.014; Fujimoto N, 2003, FOOD CHEM TOXICOL, V41, P1711, DOI 10.1016/S0278-6915(03)00198-4; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gehm BD, 2004, J STEROID BIOCHEM, V88, P223, DOI 10.1016/j.jsbmb.2003.12.002; Gray LE, 1997, REPROD TOXICOL, V11, P719, DOI 10.1016/S0890-6238(97)00025-7; Han DH, 2002, BIOSCI BIOTECH BIOCH, V66, P1479; Harris DM, 2005, EXP BIOL MED, V230, P558; Hsieh CY, 1998, CANCER RES, V58, P3833; Hwang CS, 2006, J STEROID BIOCHEM, V101, P246, DOI 10.1016/j.jsbmb.2006.06.020; JAUSONSLOFFREDA N, 1994, J BIOLUM CHEMILUM, V9, P217, DOI 10.1002/bio.1170090316; Jones PA, 1998, TOXICOL IN VITRO, V12, P373, DOI 10.1016/S0887-2333(98)80006-4; Jonker MJ, 2005, ENVIRON TOXICOL CHEM, V24, P2701, DOI 10.1897/04-431R.1; Jonker MTO, 2006, ENVIRON TOXICOL CHEM, V25, P1345, DOI 10.1897/05-296R.1; Kanai H, 2001, INT J CANCER, V93, P20, DOI 10.1002/ijc.1303; Ki E. J, 2003, ARCH PHARM RES, V26, P756; Kinjo J, 2004, BIOL PHARM BULL, V27, P185, DOI 10.1248/bpb.27.185; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuruto-Niwa R, 2007, ENVIRON TOXICOL PHAR, V23, P121, DOI 10.1016/j.etap.2006.07.011; Kuruto-Niwa R, 2002, ENVIRON TOXICOL PHAR, V12, P27, DOI 10.1016/S1382-6689(02)00011-X; Kuruto-Niwa R, 2005, ENVIRON TOXICOL PHAR, V19, P121, DOI 10.1016/j.etap.2004.05.009; Le Bail JC, 1998, CANCER LETT, V130, P209, DOI 10.1016/S0304-3835(98)00141-4; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Le Guevel R, 2001, HUM REPROD, V16, P1030, DOI 10.1093/humrep/16.5.1030; Levenson AS, 2003, INT J CANCER, V104, P587, DOI 10.1002/ijc.10992; Maggiolini M, 2001, MOL PHARMACOL, V60, P595; MAKELA S, 1994, ENVIRON HEALTH PERSP, V102, P572; Matsumura A, 2005, J STEROID BIOCHEM, V94, P431, DOI 10.1016/j.jsbmb.2004.12.041; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; McAlinden MG, 2000, CELL TRANSPLANT, V9, P445; Meerts Ilonka A. T. M., 2001, Environmental Health Perspectives, V109, P399, DOI 10.2307/3454900; MIGLIACCIO S, 1992, ENDOCRINOLOGY, V130, P2617, DOI 10.1210/en.130.5.2617; Miller S, 2000, TOXICOL SCI, V55, P69, DOI 10.1093/toxsci/55.1.69; Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351; Mueller SO, 2003, TOXICOL LETT, V142, P89, DOI 10.1016/S0378-4274(03)00016-X; Mueller SO, 2002, J CHROMATOGR B, V777, P155, DOI 10.1016/S1570-0232(02)00282-9; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Mueller SO, 2004, ANAL BIOANAL CHEM, V378, P582, DOI 10.1007/s00216-003-2238-x; Murata M, 2004, BIOCHEMISTRY-US, V43, P2569, DOI 10.1021/bi035613d; Murk AJ, 2002, ENVIRON TOXICOL CHEM, V21, P16, DOI 10.1897/1551-5028(2002)021&lt;0016:DOEPIW&gt;2.0.CO;2; Murk AJ, 1996, FUND APPL TOXICOL, V33, P149, DOI 10.1006/faat.1996.0152; Nakagawa Y, 2001, XENOBIOTICA, V31, P113; Okubo T, 2001, FOOD CHEM TOXICOL, V39, P1225, DOI 10.1016/S0278-6915(01)00073-4; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Olsen CA, 2005, COMP BIOCHEM PHYS C, V141, P267, DOI 10.1016/j.cca.2005.07.002; PAREZ P, 1998, ENV HLTH PERSPECT, V106, P167; PELISSERO C, 1993, J STEROID BIOCHEM, V44, P263, DOI 10.1016/0960-0760(93)90086-C; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; Pisha Emily, 1997, Methods in Cell Science, V19, P37, DOI 10.1023/A:1009746605060; PONGLIKITMONGKOL M, 1990, EMBO J, V9, P2221; PONS M, 1990, BIOTECHNIQUES, V9, P450; Ranhotra HS, 2005, ENVIRON TOXICOL PHAR, V20, P42, DOI 10.1016/j.etap.2004.10.002; Routledge EJ, 1996, ENVIRON TOXICOL CHEM, V15, P241, DOI 10.1897/1551-5028(1996)015&lt;0241:EAOSAS&gt;2.3.CO;2; Rutishauser BV, 2004, ENVIRON TOXICOL CHEM, V23, P857, DOI 10.1897/03-286; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; Sanoh S, 2003, J HEALTH SCI, V49, P359, DOI 10.1248/jhs.49.359; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Sato H, 2004, BIOSCI BIOTECH BIOCH, V68, P1790, DOI 10.1271/bbb.68.1790; Schmidt S, 2005, J STEROID BIOCHEM, V94, P445, DOI 10.1016/j.jsbmb.2004.12.042; Scrimshaw MD, 2004, ANAL BIOANAL CHEM, V378, P576, DOI 10.1007/s00216-003-2227-0; Seo HS, 2006, BREAST CANCER RES TR, V99, P121, DOI 10.1007/s10549-006-9191-2; Shelby MD, 1996, ENVIRON HEALTH PERSP, V104, P1296, DOI 10.2307/3432965; Shilling AD, 2000, TOXICOL APPL PHARM, V164, P330, DOI 10.1006/taap.2000.8912; Singletary KW, 2001, CANCER LETT, V165, P131, DOI 10.1016/S0304-3835(01)00419-0; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1984, BIOCHEM BIOPH RES CO, V122, P1097, DOI 10.1016/0006-291X(84)91204-X; Soto AM, 2006, BEST PRACT RES CL EN, V20, P15, DOI 10.1016/j.beem.2005.09.001; SOTO AM, 1986, CANCER RES, V46, P2271; Sotoca AM, 2008, J STEROID BIOCHEM, V112, P171, DOI 10.1016/j.jsbmb.2008.10.002; STROMDAHL H, 1994, INT J SCI EDUC, V16, P17, DOI 10.1080/0950069940160102; ter Veld MGR, 2006, J AGR FOOD CHEM, V54, P4407, DOI 10.1021/jf052864f; Tyulmenkov VV, 2000, MOL CELL ENDOCRINOL, V165, P151, DOI 10.1016/S0303-7207(00)00250-1; van der Woude H, 2005, MOL NUTR FOOD RES, V49, P763, DOI 10.1002/mnfr.200500036; van Lipzig MMH, 2005, CHEM RES TOXICOL, V18, P1691, DOI 10.1021/tx0501233; van Lipzig MMH, 2005, ENVIRON TOXICOL PHAR, V19, P41, DOI 10.1016/j.etap.2004.03.010; Vrabie CM, 2009, ENVIRON TOXICOL CHEM, V28, P1995, DOI 10.1897/08-624.1; Wagner J, 2006, MOL NUTR FOOD RES, V50, P368, DOI 10.1002/mnfr.200500215; Wang Q, 2001, J BIOL CHEM, V276, P7493, DOI 10.1074/jbc.M009916200; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; Wober J, 2002, J STEROID BIOCHEM, V83, P227, DOI 10.1016/S0960-0760(02)00252-2; Yap SP, 2005, PLANTA MED, V71, P114, DOI 10.1055/s-2005-837776; Yoshihara S, 2004, TOXICOL SCI, V78, P50, DOI 10.1093/toxsci/kfh047; Zacharewski T, 1997, ENVIRON SCI TECHNOL, V31, P613; Zava DT, 1997, ENVIRON HEALTH PERSP, V105, P637, DOI 10.2307/3433383; Zierau O, 2005, BIOCHEM BIOPH RES CO, V326, P909, DOI 10.1016/j.bbrc.2004.11.1241058OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIJUNDiscipline: Toxicology600OR</notes>
    <keywords>AGENTS; ASSAY; BIOASSAY; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CARCINOGENESIS; CELL; CHEMICALS; DIETHYLSTILBESTROL; ENDOCRINE; ENVIRONMENTAL CHEMICALS; ER-ALPHA; ESTRADIOL; Estrogen; estrogenic effects; Estrogenicity; EXPOSURE; EXPRESSION; FOOD; GENE; GENE-EXPRESSION; GENES; genistein; GFP EXPRESSION SYSTEM; GREEN FLUORESCENT PROTEIN; HEALTH; In vitro; IN-VITRO; JUN; LINE; MCF-7 CELLS; mechanism; MECHANISMS; MEDIA; mixtures; MODEL; MODELS; RECEPTOR-ALPHA; Reporter gene assay; RESPONSE ELEMENTS; RESPONSES; risk characterization; serum; Steroid; supramaximal; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>462</startpage>
    <endpage>474</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>2</issue>
    <volume>115</volume>
    <abstract>In scientific literature, several estrogenic compounds are reported to induce responses in vitro that are significantly higher than that of estradiol (E2). These supramaximal (SPMX) estrogenic effects do not occur consistently and seem to differ depending on the cellular models applied. This study analyzes the possible underlying causes, mechanisms, and drivers for SPMX estrogenic effects in in vitro functional assays reported in the peer-reviewed literature. For the 21 natural and industrial chemicals identified as SPMX inducers, the culture and exposure conditions varied greatly among and between the assays. Detailed information on assay characteristics, however, sometimes lacked. Diethylstilbestrol, genistein, and bisphenol A were selected to build a database. The meta-analysis revealed that the occurrence of SPMX effects could be related to a number of specific assay characteristics: (1) the type of serum used to supplement the exposure medium, (2) the end point used to quantify the estrogenic potency (endogenous or transfected), (3) the number of estrogen response elements, and (4) and the promoter's nature. An SPMX response was not reported for expression of endogenous genes, assays that used African green monkey kidney (COS-1) cell line or with chloramphenicol transferase as the reporter gene. There were no indications that solvent concentration in culture, exposure period, or cell model influenced the occurrence of an SPMX effect. It is important to understand the mechanism behind this phenomenon because in vitro assays for estrogenicity are used extensively to characterize and quantify the estrogenic potency of compounds, mixtures and environmental extracts</abstract>
    <url>WOS:000277997100016</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>305</id>
    <title>In utero exposure to butyl benzyl phthalate induces modifications in the morphology and the gene expression profile of the mammary gland: an experimental study in rats</title>
    <authors>Moral,R.; Santucci-Pereira,J.; Wang,R.; Russo,I.H.; Lamartiniere,C.A.; Russo,J.</authors>
    <availability>[Moral, Raquel; Santucci-Pereira, Julia; Wang, Richard; Russo, Irma H.; Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA. [Moral, Raquel] Univ Autonoma Barcelona, Sch Med, Dept Cell Biol Physiol &amp; Immunol, E-08193 Barcelona, Spain. [Lamartiniere, Coral A.] Univ Alabama, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleMoral, R (reprint author), Fox Chase Canc Ctr, Breast Canc Res Lab, 7701 Burholme Ave, Philadelphia, PA 19111 USARaquel.Moral@uab.es; J_russo@fccc.eduAshby J, 1997, REGUL TOXICOL PHARM, V26, P102, DOI 10.1006/rtph.1997.1159; Aso Sunao, 2005, Journal of Toxicological Sciences, V30, P39; Benjamin IJ, 2007, AM J PHYSIOL-HEART C, V293, pH3201, DOI 10.1152/ajpheart.01363.2006; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Betancourt A.M., 2010, ENV HLTH PERSPECT; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bousette N, 2010, P NATL ACAD SCI USA, V107, P18481, DOI 10.1073/pnas.1013555107; Celis JE, 2005, MOL CELL PROTEOMICS, V4, P492, DOI 10.1074/mcp.M500030-MCP200; *CONC INT, 17 CONC INT; Desvergne B, 2009, MOL CELL ENDOCRINOL, V304, P43, DOI 10.1016/j.mce.2009.02.017; *EUR UN, 1999, OFFICIAL J EUR COMMU, V315; Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x; Funabashi T, 2001, NEUROENDOCRINOLOGY, V74, P77, DOI 10.1159/000054672; Grun F, 2007, REV ENDOCR METAB DIS, V8, P161, DOI 10.1007/s11154-007-9049-x; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hilakivi-Clarke L, 2001, J NUTR, V131, p154S; Hong CC, 2004, BIOL PHARM BULL, V27, P1136, DOI 10.1248/bpb.27.1136; *I HLTH CONS PROT, 2008, PRIORITY LIST, V76, P1; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; LI Y, 2010, BREAST CANC RES TREA; Liu KJ, 2005, BIOL REPROD, V73, P180, DOI 10.1095/biolreprod.104.039404; Lovekamp-Swan T, 2003, ENVIRON HEALTH PERSP, V111, P139; Lyche JL, 2009, J TOXICOL ENV HEAL B, V12, P225, DOI 10.1080/10937400903094091; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Moral R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-453; Nagao T, 2000, REPROD TOXICOL, V14, P513, DOI 10.1016/S0890-6238(00)00105-2; *NTP, 2003, NTP CERHR MON; Reddy BS, 2006, BJOG-INT J OBSTET GY, V113, P515, DOI 10.1111/j.1471-0528.2006.00925.x; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Russo J, 1997, ENDOCR-RELAT CANCER, V4, P7; RUSSO J, 1990, LAB INVEST, V62, P244; RUSSO J, 1978, J NATL CANCER I, V61, P1451; RUSSO J, 1980, AM J PATHOL, V100, P497; Schedin P, 2010, J MAMMARY GLAND BIOL, V15, P275, DOI 10.1007/s10911-010-9191-z; Grandjean P, 2006, INT J ANDROL, V29, P181, DOI 10.1111/j.1365-2605.2005.00679.x; Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723; Singletary K, 1997, CARCINOGENESIS, V18, P1669, DOI 10.1093/carcin/18.8.1669; Smyth GK, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Smyth GK, 2005, STAT BIOL HEALTH, P397; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Tyl RW, 2004, REPROD TOXICOL, V18, P241, DOI 10.1016/j.reprotox.2003.10.006; *US EPA, 2003, 85687 CASRN US EPA; Wilson VS, 2004, TOXICOL LETT, V146, P207, DOI 10.1016/j.toxlet.2003.09.012; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; Wittassek M, 2009, INT J HYG ENVIR HEAL, V212, P492, DOI 10.1016/j.ijheh.2009.04.0014610BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDENVIRON HEALTH-GLOBJAN 17Discipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health718NV</notes>
    <keywords>ASSOCIATION; BISPHENOL-A; breast; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; development; Differentiation; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ESTERS; Estrogen; ESTROGENS; EXPOSURE; EXPRESSION; female; GENE; gene expression; gene expression profile; GENE-EXPRESSION; GENES; GLAND; HEALTH; Immune; IN-UTERO; mammary gland; MAMMARY-GLAND; METABOLISM; Microarray; MODEL; MODELS; morphology; Occupational; phthalate; PRENATAL EXPOSURE; PREVENTION; proliferation; Proteomics; RAT; RATS; RISK; SUSCEPTIBILITY; SYSTEM; terminal end buds; TOXICITY; TUMORIGENESIS; UTERO EXPOSURE; whole mount</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Environmental Health</journalfull>
    <volume>10</volume>
    <abstract>Background: Environmental estrogens are exogenous estrogen-mimicking compounds that can interfere with endogenous endocrine systems. Several of these endocrine disruptors have been shown to alter normal development and influence tumorigenesis in experimental models. N-butyl benzyl phthalate ( BBP), a widely used plasticizer, is a well-known endocrine disruptor. The aim of this study was to elucidate the effect of prenatal exposure to BBP on the morphology, proliferative index, and genomic signature of the rat mammary gland at different ages. Methods: In utero exposure was performed by gavage of pregnant Sprague Dawley CD rats with 120mg or 500mg BBP/kg/day from day 10 post-conception to delivery. Female litters were euthanized at 21, 35, 50 and 100 days. The morphology and proliferative index of the mammary gland were studied from whole mount preparations and BrdU incorporation, respectively. Gene expression profile was assessed by microarrays. Several genes found differentially expressed and related to different functional categories were further validated by real time RT-PCR. Results: Prenatal exposure of BBP induced delayed vaginal opening and changes in the post-natal mammary gland long after the end of the treatment, mainly by 35 days of age. Exposure to the high dose resulted in modifications in architecture and proliferative index of the mammary gland, mostly affecting the undifferentiated terminal end buds. Moreover, the expression profiles of this gland in the exposed rats were modified in a dose-dependent fashion. Analysis of functional categories showed that modified genes were related to immune function, cell signaling, proliferation and differentiation, or metabolism. Conclusions: Our data suggest that in utero exposure to BBP induced a delayed pubertal onset and modified morphology of the mammary gland. These alterations were accompanied by modifications in gene expression previously associated with an increased susceptibility to carcinogenesis</abstract>
    <url>WOS:000287131500002</url>
    <isbnorissn>1476-069X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>196</id>
    <title>Antiproliferative and proapoptotic effects of bisphenol A in human trophoblastic JEG-3 cells</title>
    <authors>Morice,L.; Benaitreau,D.; Dieudonne,M.N.; Morvan,C.; Serazin,V.; de Mazancourt,P.; Pecquery,R.; Dos Santos,E.</authors>
    <availability>[Morice, L.; Benaitreau, D.; Dieudonne, M. -N.; Morvan, C.; Serazin, V.; de Mazancourt, P.; Pecquery, R.; Dos Santos, E.] Univ Versailles St Quentin, Ctr Hosp Poissy St Germain, PRES Universud Paris,Serv Biochim &amp; Biol Mol, Fac Med Paris Ile France Ouest,UPRES EA 2493, F-78303 Poissy, France.</availability>
    <date>2012</date>
    <notes>JFrenchArticleDos Santos, E (reprint author), Univ Versailles St Quentin, Ctr Hosp Poissy St Germain, PRES Universud Paris,Serv Biochim &amp; Biol Mol, Fac Med Paris Ile France Ouest,UPRES EA 2493, F-78303 Poissy, Francedossantos.esther@orange.frAlonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Ben-Jonathan N, 2009, MOL CELL ENDOCRINOL, V304, P49, DOI 10.1016/j.mce.2009.02.022; Berger RG, 2008, REPROD TOXICOL, V26, P94, DOI 10.1016/j.reprotox.2008.06.007; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Calafat AM, 2009, ENVIRON HEALTH PERSP, V117, P639, DOI 10.1289/ehp.0800265; Crocker I, 2002, BJOG-INT J OBSTET GY, V109, P218, DOI 10.1016/S1470-0328(02)01033-9; Feron VJ, 2002, ENVIRON HEALTH PERSP, V110, P893; Fiorini C, 2004, REPROD TOXICOL, V18, P413, DOI 10.1016/j.reprotox.2004.01.002; Handschuh K, 2007, ENDOCRINOLOGY, V148, P5011, DOI 10.1210/en.2007-0286; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lee YJ, 2008, REPROD TOXICOL, V25, P413, DOI 10.1016/j.reprotox.2008.05.058; Li YJ, 2009, TOXICOL SCI, V108, P427, DOI 10.1093/toxsci/kfp024; Machinal-Quelin F, 2002, AM J PHYSIOL-CELL PH, V282, pC853, DOI 10.1152/ajpcell.00331.2001; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2001, BIOL REPROD, V65, P1215; Matsushima A, 2008, BIOCHEM BIOPH RES CO, V373, P408, DOI 10.1016/j.bbrc.2008.06.050; Mutou Y, 2008, TOXICOL IN VITRO, V22, P864, DOI 10.1016/j.tiv.2008.01.001; Noguchi S, 2002, TOXICOL LETT, V135, P95, DOI 10.1016/S0378-4274(02)00252-7; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9; Tabuchi Y, 2003, BIOCHEM BIOPH RES CO, V305, P54, DOI 10.1016/S0006-291X(03)00708-3; Takai Y, 2000, BIOCHEM BIOPH RES CO, V270, P918, DOI 10.1006/bbrc.2000.2548; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.067370ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERPARIS23 RUE LINOIS, 75724 PARIS, FRANCEIMMUNO-ANAL BIOL SPEAUGDiscipline: Medical Laboratory Technology006TY</notes>
    <keywords>ACTIVATION; apoptosis; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; development; Endocrine disrupter; ESTROGEN-RECEPTOR; FETAL EXPOSURE; HEALTH; IMPACT; In vitro; IN-VITRO; JEG-3; LINE; mechanism; proliferation; PROTEIN; RECEPTOR; toxicology; Trophoblasts; VITRO; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>168</startpage>
    <endpage>176</endpage>
    <journalfull>Immuno-Analyse &amp; Biologie Specialisee</journalfull>
    <issue>4</issue>
    <volume>27</volume>
    <abstract>Different studies performed in rodents revealed that Bisphenol-A (BPA), an environmental compound, altered early embryonic development. However, little is known concerning the direct effects of BPA on human implantation process. Thus, we decided to study in vitro BPA's effects on proliferative capacities of the human trophoblastic cell line, JEG-3. For this purpose, we first have shown that JEG-3 cells express the specific BPA receptor, namely estrogen-related receptor gamma 1 (ERR gamma 1). Secondly, once the non-toxic effect of BPA on JEG-3 cell viability was verified, [H-3]-thymidine incorporation experiments were performed and revealed that BPA significantly reduced cell proliferation. The results also showed that BPA induced JEG-3 apoptosis as reflected by DNA fragmentation experiments. In conclusion, we describe here the direct impact of BPA on trophoblastic cell number mediated through both antiproliferative and proapoptotic effects and could then participate in the impact of BPA on placental development. (C) 2012 Published by Elsevier Masson SAS</abstract>
    <url>WOS:000308843100005</url>
    <isbnorissn>0923-2532</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>407</id>
    <title>Exposure to endocrine disrupting compounds via the food chain: Is packaging a relevant source?</title>
    <authors>Muncke,J.</authors>
    <availability>Emhart Glass SA, CH-6330 Cham, Switzerland.</availability>
    <date>2009</date>
    <notes>JEnglishReviewMuncke, J (reprint author), Emhart Glass SA, Hinterbergstr 22,POB 2251, CH-6330 Cham, Switzerlandjane.muncke@emhartglass.comAkovali G., 2007, PLASTICS RUBBER HLTH; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Angerer J, 2007, INT J HYG ENVIR HEAL, V210, P201, DOI 10.1016/j.ijheh.2007.01.024; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Arvanitoyannis IS, 2004, CRIT REV FOOD SCI, V44, P63, DOI 10.1080/10408690490424621; Ash M, 2008, HDB FOOD PACKAGING C; Baillie-Hamilton PF, 2002, J ALTERN COMPLEM MED, V8, P185, DOI 10.1089/107555302317371479; Barker DJP, 2004, J AM COLL NUTR, V23, p588S; Begley TH, 1997, FOOD ADDIT CONTAM A, V14, P545; Begley TH, 2005, FOOD ADDIT CONTAM, V22, P1023, DOI 10.1080/02652030500183474; Begley TH, 2008, FOOD ADDIT CONTAM, V25, P384, DOI 10.1080/02652030701513784; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Biedermann-Brem S, 2009, EUR FOOD RES TECHNOL, V228, P679, DOI 10.1007/s00217-008-0978-8; Boberg J, 2008, TOXICOLOGY, V250, P75, DOI 10.1016/j.tox.2008.05.020; Bolgar M, 2008, HDB CHEM ANAL PLASTI; Borch J, 2006, TOXICOL LETT, V163, P183, DOI 10.1016/j.toxlet.2005.10.020; Bradbury Robert H., 2007, V1, P1, DOI 10.1007/7355_2006_001; Brauer B, 2008, DEUT LEBENSM-RUNDSCH, V104, P330; Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932; Brian JV, 2005, ENVIRON HEALTH PERSP, V113, P721, DOI 10.1289/ehp.7598; Brody JG, 2003, ENVIRON HEALTH PERSP, V111, P1007, DOI 10.1289/ehp.6310; Cabado AG, 2008, FOOD CHEM TOXICOL, V46, P1674, DOI 10.1016/j.fct.2008.01.006; CALAFAT AM, 2007, ENV HLTH PERSPECT, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cao XL, 2009, J AGR FOOD CHEM, V57, P1307, DOI 10.1021/jf803213g; Casajuana N, 2004, J AGR FOOD CHEM, V52, P3702, DOI 10.1021/jf040027s; Castle L, 2007, CHEMICAL MIGRATION AND FOOD CONTACT MATERIALS, P1; Centers for Disease Control and Prevention (CDC), 2005, 3 CDC; Fernandes AR, 2008, FOOD ADDIT CONTAM, V25, P364, DOI 10.1080/02652030701564548; Chen ML, 2008, CHEMOSPHERE, V73, pS239, DOI 10.1016/j.chemosphere.2007.04.091; Coelhan M, 2006, J AGR FOOD CHEM, V54, P5731, DOI 10.1021/jf060743p; Colborn T, 2004, ENVIRON HEALTH PERSP, V112, P944, DOI 10.1289/ehp.6601; CRAYTON JW, 1976, NATURE, V264, P658, DOI 10.1038/264658a0; EFSA (European Food Safety Authority), 2006, EFSA J, P1; European Union Treaty of Lisbon amending the Treaty on European Union and the Treaty establishing the European Community, 2007, OFFICIAL J EUROPEAN; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; GAITAN E, 1989, ENV GOITROGENESIS, P107; Garcia RS, 2006, TRENDS FOOD SCI TECH, V17, P354, DOI 10.1016/j.tifs.2006.01.005; Grandjean P, 2006, LANCET, V368, P2167, DOI 10.1016/S0140-6736(06)69665-7; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Grob K, 2006, CRIT REV FOOD SCI, V46, P529, DOI 10.1080/10408390500295490; Grob K, 2008, FOOD CONTROL, V19, P263, DOI 10.1016/j.foodcont.2007.04.001; Grob K, 2007, FOOD CONTROL, V18, P201, DOI 10.1016/j.foodcont.2005.09.015; Grob K, 1999, FOOD ADDIT CONTAM A, V16, P579, DOI 10.1080/026520399283722; Grob K, 2002, FOOD ADDIT CONTAM, V19, P185, DOI 10.1080/02652030110072713; Grun F, 2006, ENDOCRINOLOGY, V147, pS50, DOI 10.1210/en.2005-1129; Guenther K, 2002, ENVIRON SCI TECHNOL, V36, P1676, DOI 10.1021/es010199v; Hashimoto Y, 2001, TOXICOL IN VITRO, V15, P421, DOI 10.1016/S0887-2333(01)00046-7; Hass U, 2007, ENVIRON HEALTH PERSP, V115, P122, DOI 10.1289/ehp.9360; Hertz-Picciotto I, 2009, EPIDEMIOLOGY, V20, P84, DOI 10.1097/EDE.0b013e3181902d15; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Maher B, 2008, NATURE, V453, P964, DOI 10.1038/453964a; Inadera H, 2006, TOXICOL LETT, V164, P191, DOI 10.1016/j.toxlet.2006.03.006; Inoue K, 2001, FOOD ADDIT CONTAM, V18, P157, DOI 10.1080/02652030010018930; James WPT, 2008, J INTERN MED, V263, P336, DOI 10.1111/j.1365-2796.2008.01922.x; Kamata R, 2008, TOXICOL IN VITRO, V22, P1050, DOI 10.1016/j.tiv.2008.01.002; Kamiya M, 2005, FOOD CHEM TOXICOL, V43, P1017, DOI 10.1016/j.fct.2005.02.004; Kanayama T, 2005, MOL PHARMACOL, V67, P766, DOI 10.1124/mol.104.008409; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P106, DOI 10.1289/ehp.9358; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; Kumar V, 2009, REPROD TOXICOL, V27, P177, DOI 10.1016/j.reprotox.2008.12.002; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lau C, 2007, TOXICOL SCI, V99, P366, DOI 10.1093/toxsci/kfm128; Lau OW, 2000, J CHROMATOGR A, V882, P255, DOI 10.1016/S0021-9673(00)00356-3; Lemini C, 2004, TOXICOL IND HEALTH, V20, P123, DOI 10.1191/0748233704th202oa; Lemini C, 1997, ENVIRON RES, V75, P130, DOI 10.1006/enrs.1997.3782; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Letcher RJ, 2005, TOXICOL APPL PHARM, V209, P95, DOI 10.1016/j.taap.2005.03.013; Lopez-Espinosa MJ, 2007, FOOD ADDIT CONTAM A, V24, P95, DOI 10.1080/02652030600936375; Loyo-Rosales JE, 2004, J AGR FOOD CHEM, V52, P2016, DOI 10.1021/jf0345696; Main KM, 2007, ENVIRON HEALTH PERSP, V115, P1519, DOI 10.1289/ehp.9924; Marsh K, 2007, J FOOD SCI, V72, pR39, DOI 10.1111/j.1750-3841.2007.00301.x; Masuyama H, 2000, MOL ENDOCRINOL, V14, P421, DOI 10.1210/me.14.3.421; McDonald GR, 2008, SCIENCE, V322, P917, DOI 10.1126/science.1162395; McLachlan JA, 1998, APMIS, V106, P240; McNeal TP, 2000, ACS SYM SER, V747, P33; Midasch O, 2007, INT ARCH OCC ENV HEA, V80, P643, DOI 10.1007/s00420-006-0165-9; Midasch O, 2006, INT J HYG ENVIR HEAL, V209, P489, DOI 10.1016/j.ijheh.2006.06.002; Moller H, 2001, HUM REPROD, V16, P1007, DOI 10.1093/humrep/16.5.1007; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Nakanishi T, 2006, BIOCHEM PHARMACOL, V71, P1349, DOI 10.1016/j.bcp.2006.01.014; NEWBOLD RR, 2009, ENV HLTH PERSPECT, V116, P879; Newbold R R, 1996, Prog Clin Biol Res, V394, P131; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Ogawa Y, 2006, FOOD ADDIT CONTAM, V23, P422, DOI [10.1080/02652030500482671, 10.1080/02652030500482371]; Ohyama K, 2001, ENVIRON HEALTH PERSP, V109, P699, DOI 10.2307/3454786; Ohyama KI, 2007, EXP BIOL MED, V232, P301; Oishi S, 2002, FOOD CHEM TOXICOL, V40, P1807, DOI 10.1016/S0278-6915(02)00204-1; Ozaki A, 2004, FOOD CHEM TOXICOL, V42, P1323, DOI 10.1016/j.fct.2004.03.010; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Parks LG, 2000, TOXICOL SCI, V58, P339, DOI 10.1093/toxsci/58.2.339; Pedersen GA, 2008, FOOD ADDIT CONTAM, V25, P503, DOI 10.1080/02652030701519088; Pocas MD, 2007, TRENDS FOOD SCI TECH, V18, P219, DOI 10.1016/j.tifs.2006.008; *REX, 2008, CONS PACK REP 2007 0, P4; Roman GC, 2007, J NEUROL SCI, V262, P15, DOI 10.1016/j.jns.2007.06.023; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Sagratini G, 2008, J CHROMATOGR A, V1194, P213, DOI 10.1016/j.chroma.2008.04.057; Saillenfait AM, 2008, REPROD TOXICOL, V26, P107, DOI 10.1016/j.reprotox.2008.07.006; Sajiki J, 2007, FOOD ADDIT CONTAM, V24, P103, DOI 10.1080/02652030600936383; Satoh K, 2000, YAKUGAKU ZASSHI, V120, P1429; Satoh K, 2008, BIOL PHARM BULL, V31, P357, DOI 10.1248/bpb.31.357; Satoh K, 2004, FOOD CHEM TOXICOL, V42, P983, DOI 10.1016/j.fct.2004.02.011; Schafer KS, 2002, J EPIDEMIOL COMMUN H, V56, P813, DOI 10.1136/jech.56.11.813; SCHONROCK D, 2008, HOCHKONJUNKTUR SCHWE, P6; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shotyk W, 2007, ENVIRON SCI TECHNOL, V41, P3508, DOI 10.1021/es062964h; Silva AS, 2008, J CEREAL SCI, V48, P662, DOI 10.1016/j.jcs.2008.02.006; Silva E, 2002, ENVIRON SCI TECHNOL, V36, P1751, DOI 10.1021/es0101227; Skakkebaek NE, 2006, INT J ANDROL, V29, P2, DOI 10.1111/j.1365-2605.2005.00573.x; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Skjevrak I, 2005, FOOD ADDIT CONTAM, V22, P1012, DOI 10.1080/02652030500090877; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Steinhardt GF, 2004, ADV EXP MED BIOL, V545, P203; Swan Shanna H, 2008, Fertil Steril, V89, pe45, DOI 10.1016/j.fertnstert.2007.12.027; Takeuchi S, 2005, TOXICOLOGY, V210, P223, DOI 10.1016/j.tox.2005.02.002; Terasaki M, 2005, ENVIRON SCI TECHNOL, V39, P3703, DOI 10.1021/es048932g; ter Veld MGR, 2006, J AGR FOOD CHEM, V54, P4407, DOI 10.1021/jf052864f; Tomonari Y, 2006, J TOXICOL ENV HEAL A, V69, P1651, DOI 10.1080/15287390600630054; Toyo'oka T, 2000, ANAL SCI, V16, P1071, DOI 10.2116/analsci.16.1071; Twaroski ML, 2007, CHEMICAL MIGRATION AND FOOD CONTACT MATERIALS, P17; Tyl RW, 2008, TOXICOL SCI, V104, P362, DOI 10.1093/toxsci/kfn084; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Versonnen BJ, 2003, ENVIRON TOXICOL CHEM, V22, P329, DOI 10.1897/1551-5028(2003)022&lt;0329:IVAIVE&gt;2.0.CO;2; VOMSAAL FS, 2009, FAILURE FDA RISK ASS; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wagner M, 2009, ENVIRON SCI POLLUT R, V16, P278, DOI 10.1007/s11356-009-0107-7; Waring RH, 2008, J STEROID BIOCHEM, V108, P213, DOI 10.1016/j.jsbmb.2007.09.007; Waring RH, 2005, MOL CELL ENDOCRINOL, V244, P2, DOI 10.1016/j.mce.2005.02.007; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wittassek M, 2007, INT J HYG ENVIR HEAL, V210, P319, DOI 10.1016/j.ijheh.2007.01.037; World Commission on Environment and Development, 1987, OUR COMM FUT; *WORLD PACK ORG, 2008, MARK STAT FUT TRENDS, P37; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yamasaki K, 2002, TOXICOLOGY, V170, P21, DOI 10.1016/S0300-483X(01)00505-4; Yamasaki K, 2003, TOXICOLOGY, V183, P93, DOI 10.1016/S0300-483X(02)00445-6; Yamasaki K, 2004, TOXICOL LETT, V146, P111, DOI 10.1016/j.toxlet.2003.07.003; Yanagiba Y, 2008, ENVIRON HEALTH PERSP, V116, P740, DOI 10.1289/ehp.10724; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a14644ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSSCI TOTAL ENVIRONAUG 1Discipline: Environmental Sciences &amp; Ecology468SA</notes>
    <keywords>1; A DIGLYCIDYL-ETHER; ADIPOCYTE DIFFERENTIATION; ADULT; ANDROGEN RECEPTOR; BIOASSAY; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CHEMICALS; CONTACT MATERIALS; development; DEVELOPMENTAL ORIGINS; DIETARY BISPHENOL-A; DIISOBUTYL PHTHALATE; DIOXIN; DIOXINS; DISEASE; EDC; EDCs; ENDOCRINE; Endocrine disrupting compound; Endocrine disrupting compounds; endocrine disrupting compounds (EDCs); environment; environmental pollutants; ENVIRONMENTAL-POLLUTANTS; Epidemiology; epigenetic; epigenetics; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FOOD; Food chain; Food contact material; Food contaminant; Food packaging; food safety; HEALTH; HUMAN EXPOSURE; HUMANS; IMPACT; In vitro; IN-VITRO; low dose; Low-dose effects; Metals; Migration; Mixture toxicity; mixtures; Nonylphenol; p21; Plastics; POLLUTANTS; PREVENTION; RAT UTEROTROPHIC ASSAY; Regulation; Review; RISK; sensitive windows; Steroid; SYSTEM; toxicology; VITRO; xenobiotics</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>4549</startpage>
    <endpage>4559</endpage>
    <journalfull>Science of the Total Environment</journalfull>
    <issue>16</issue>
    <volume>407</volume>
    <abstract>Contamination of foodstuffs by environmental pollutants (e.g. dioxins, metals) receives much attention. Until recently, food packaging as a source of xenobiotics, especially those with endocrine disrupting properties, has received little awareness despite its ubiquitous use. This article reviews the regulations and use of endocrine disrupting compounds (EDCs) in food packaging and discusses their presence within the context of new toxicology paradigms. I focused on substances known to be legally used in food packaging that have been shown to exhibit endocrine disruptive effects in biological systems. I compiled a list of 50 known or potential EDCs used in food contact materials and examined data of EDCs leaching from packaging into food, with a focus on nonylphenol. I included recent advances in toxicology: mixture effects, the developmental origins of adult disease hypothesis. low-dose effects. and epigenetics. I especially considered the case of bisphenol A. The core hypothesis of this review is that chemicals leaching from packaging into food contribute to human EDCs exposure and might lead to chronic disease in light of the current knowledge. Food contact materials are a major source of food contaminants. Many migrating compounds, possibly with endocrine disruptive properties, remain unidentified. There is a need for information on identity/quantity of chemicals leaching into food, human exposure, and long-term impact on health. Especially EDCs in food packaging are of concern. Even at low concentrations, chronic exposure to EDCs is toxicologically relevant. Concerns increase when humans are exposed to mixtures of similar acting EDCs and/or during sensitive windows of development. In particular, non-intentionally added substances (NIAS) migrating from food contact materials need toxicological characterization; the overall migrate of the finished packaging could be evaluated for biological effects using bioassays. The widespread legal use of EDCs in food packaging requires dedicated assessment and should be updated according to contemporary scientific knowledge. (c) 2009 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000267839200001</url>
    <isbnorissn>0048-9697</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>394</id>
    <title>A Clash of Old and New Scientific Concepts in Toxicity, with Important Implications for Public Health</title>
    <authors>Myers,J.P.; Zoeller,R.T.; vom Saal,F.S.</authors>
    <availability>[Myers, John Peterson] Environm Hlth Sci, Charlottesville, VA 22902 USA. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA. [vom Saal, Frederick S.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticleMyers, JP (reprint author), Environm Hlth Sci, 421 Pk St, Charlottesville, VA 22902 USAjpmyers@ehsic.orgAndrade AJM, 2006, TOXICOLOGY, V227, P185, DOI 10.1016/j.tox.2006.07.022; BIRD J, 2005, CHEM IND, V5, P14; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Chamie K, 2008, CANCER, V113, P2464, DOI 10.1002/cncr.23695; Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100; Gallo MA, 1996, CASARETT DOULLS TOXI, P3; Garner C, 1994, J Obstet Gynecol Neonatal Nurs, V23, P563, DOI 10.1111/j.1552-6909.1994.tb01922.x; Gore AC, 2007, CONTEMP ENDOCRINOL S, P3, DOI 10.1007/1-59745-107-X_1; Hauser Russ, 2008, Fertil Steril, V89, pe59, DOI 10.1016/j.fertnstert.2007.12.033; Hugo ER, 2008, J CLIN ENDOCR METAB, V93, P4006, DOI 10.1210/jc.2008-1172; Ishido M, 2004, J NEUROSCI RES, V76, P423, DOI 10.1002/jnr.20050; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Layton L., 2008, WASH POST, pA; MEDLOCK KL, 1991, P SOC EXP BIOL MED, V196, P293; Mortimer JE, 2001, J CLIN ONCOL, V19, P2797; MYERS JP, 2007, ENV HLTH NEWS; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Narita S, 2007, ENVIRON HEALTH PERSP, V115, P48, DOI 10.1289/ehp.9378; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Shioda T, 2006, P NATL ACAD SCI USA, V103, P12033, DOI 10.1073/pnas.0605341103; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Suzawa M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002117; Swan SH, 2008, ENVIRON RES, V108, P177, DOI 10.1016/j.envres.2008.08.007; Takano H, 2006, ENVIRON HEALTH PERSP, V114, P1266, DOI 10.1289/ehp.8985; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; VOMSAAL FS, 2005, CHEM IND, V7, P14; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; White RH, 2009, ENVIRON HEALTH PERSP, V117, P283, DOI 10.1289/ehp.11502; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-05653655US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPNOVDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology514MQ</notes>
    <keywords>ASSOCIATION; biphasic; bisphenol A; BREAST-CANCER; CANCER; CELLS; CHEMICALS; DOSE-RESPONSE; dose-response curve; Endocrine disrupting compounds; ENDOCRINE-DISRUPTING COMPOUNDS; ESTROGEN-RECEPTOR; EXPOSURE; EXPOSURES; extrapolation; HEALTH; Hormone; Hormones; HUMAN EXPOSURE; inverted U; low dose; Low-dose effects; LOW-DOSE EXPOSURE; MECHANISMS; Nonmonotonic; Occupational; POPULATION; PROLACTIN-RELEASE; regulatory toxicology; Review; RISK; SET; TOXICITY; toxicology; XENOESTROGEN BISPHENOL-A</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1652</startpage>
    <endpage>1655</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>11</issue>
    <volume>117</volume>
    <abstract>BACKGROUND: A core assumption of current toxicologic procedures used to establish health standards for chemical exposures is that testing the safety of chemicals at high doses can be used to predict the effects of low-dose exposures, such as those common in the general population. This assumption is based on the precept that "the dose makes the poison": higher doses will cause greater effects. OBJECTIVES: We challenge the validity of assuming that high-dose testing can be used to predict low-dose effects for contaminants that behave like hormones. We review data from endocrinology and toxicology that falsify this assumption and summarize current mechanistic understanding of how low doses can lead to effects unpredictable from high-dose experiments. DISCUSSION: Falsification of this assumption raises profound issues for regulatory toxicology. Many exposure standards are based on this assumption. Rejecting the assumption will require that these standards be reevaluated and that procedures employed to set health standards be changed. The consequences of these changes may be significant for public health because of the range of health conditions now plausibly linked to exposure to endocrine-disrupting contaminants. CONCLUSIONS: We recommend that procedures to establish acceptable exposure levels for endocrine-disrupting compounds incorporate the inability for high-dose tests to predict low-dose results. Setting acceptable levels of exposure must include testing for health consequences at prevalent levels of human exposure, not extrapolations from the effects observed in high-dose experiments. Scientists trained in endocrinology must be engaged systematically in standard setting for endocrine-disrupting compounds</abstract>
    <url>WOS:000271399300018</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>446</id>
    <title>The Genomic Response of a Human Uterine Endometrial Adenocarcinoma Cell Line to 17 alpha-Ethynyl Estradiol</title>
    <authors>Naciff,J.M.; Khambatta,Z.S.; Thomason,R.G.; Carr,G.J.; Tiesman,J.P.; Singleton,D.W.; Khan,S.A.; Daston,G.P.</authors>
    <availability>[Naciff, Jorge M.; Khambatta, Zubin S.; Thomason, Ryan G.; Carr, Gregory J.; Tiesman, Jay P.; Daston, George P.] Procter &amp; Gamble Co, Miami Valley Innovat Ctr, Cincinnati, OH 45253 USA. [Singleton, David W.; Khan, Sohaib A.] Univ Cincinnati, Vontz Ctr Mol Studies, Dept Cell Biol Neurobiol &amp; Anat, Cincinnati, OH 45267 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticleNaciff, JM (reprint author), Procter &amp; Gamble Co, Miami Valley Innovat Ctr, POBox 538707,805, Cincinnati, OH 45253 USAnaciff.jm@pg.comAttar E, 2006, FERTIL STERIL, V85, P1307, DOI 10.1016/j.fertnstert.2005.09.064; Beissbarth T, 2004, BIOINFORMATICS, V20, P1464, DOI 10.1093/bioinformatics/bth088; Bramlett KS, 2003, J STEROID BIOCHEM, V86, P27, DOI 10.1016/S0960-0760(03)00258-9; CHENG SVY, 1985, EXP CELL RES, V160, P459, DOI 10.1016/0014-4827(85)90193-4; Cho SR, 2005, REPROD DOMEST ANIM, V40, P171, DOI 10.1111/j.1439-0531.2005.00577.x; CROXTALL JD, 1990, J STEROID BIOCHEM, V35, P665, DOI 10.1016/0022-4731(90)90306-D; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Graziani G, 2003, ENDOCRINOLOGY, V144, P2822, DOI 10.1210/en.2002-0180; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Han DH, 2002, BIOSCI BIOTECH BIOCH, V66, P1479; HOLINKA CF, 1986, J STEROID BIOCHEM, V25, P781, DOI 10.1016/0022-4731(86)90308-0; Inoue A, 2007, TOXICOL IN VITRO, V21, P741, DOI 10.1016/j.tiv.2007.01.014; Jabbour HN, 2006, ENDOCR REV, V27, P17, DOI 10.1210/er.2004-0021; Johnson SM, 2007, ENDOCR-RELAT CANCER, V14, P337, DOI 10.1677/ERC-06-0085; Joslyn CA, 2004, BIOINFORMATICS, V20, P169, DOI 10.1093/bioinformatics/bth921; Kues WA, 2000, BIOL REPROD, V62, P412, DOI 10.1095/biolreprod62.2.412; Leong H, 2004, MOL ENDOCRINOL, V18, P291, DOI 10.1210/me.2003-0196; Lessey BA, 1996, J STEROID BIOCHEM, V59, P31, DOI 10.1016/S0960-0760(96)00103-3; LITTLEFIELD BA, 1990, ENDOCRINOLOGY, V127, P2757; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lovely LP, 2000, J STEROID BIOCHEM, V74, P235, DOI 10.1016/S0960-0760(00)00127-8; Lykkesfeldt A E, 1986, Breast Cancer Res Treat, V7 Suppl, pS83; Naciff JM, 2005, TOXICOL SCI, V86, P396, DOI 10.1093/toxsci/kfi198; Naciff JM, 2007, TOXICOL SCI, V97, P467, DOI 10.1093/toxsci/kfm046; Naciff JM, 2003, TOXICOL SCI, V72, P314, DOI 10.1093/toxsci/kfg037; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Naciff JM, 2005, BIRTH DEFECTS RES B, V74, P164, DOI 10.1002/bdrb.20032; Nishida Masato, 2002, Hum Cell, V15, P104, DOI 10.1111/j.1749-0774.2002.tb00105.x; NISHIDA M, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P1103; Punyadeera C, 2005, CELL MOL LIFE SCI, V62, P239, DOI 10.1007/s00018-004-4435; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-02803114OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIJANDiscipline: Toxicology386NM</notes>
    <keywords>1; ADENOCARCINOMA; analysis; BIRTH; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER-CELLS; CELL; Cell proliferation; CELL-LINE; CELL-PROLIFERATION; CELLS; CHEMICALS; CYCLE SYNCHRONIZATION; DEFECTS; DENSITY OLIGONUCLEOTIDE ARRAYS; development; ESTRADIOL; Estrogen; Estrogenic; ESTROGENIC ACTIVITIES; estrogenic activity; EXPOSURE; EXPRESSION; FEMALE REPRODUCTIVE-SYSTEM; FETAL FIBROBLASTS; GENE; gene expression; gene expression profile; GENE-EXPRESSION; GENES; In vitro; in vivo; IN-VITRO; IN-VIVO; Ishikawa cells; LINE; morphogenesis; ORGANIZATION; PATHWAY; PROFILES; proliferation; RAT; RECEPTOR; Steroid; SYSTEM; TARGET; TOOL; toxicology; UTERINE; Uterus; VITRO; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>40</startpage>
    <endpage>55</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>1</issue>
    <volume>107</volume>
    <abstract>We have determined the gene expression profile induced by 17 alpha-ethynyl estradiol (EE) in Ishikawa cells, a human uterine-derived estrogen-sensitive cell line, at various doses (1pM, 100pM, 10nM, and 1 mu M) and time points (8, 24, and 48 h). The transcript profiles were compared between treatment groups and controls (vehicle-treated) using high-density oligonucleotide arrays to determine the expression level of approximately 38,500 human genes. By trend analysis, we determined that the expression of 2560 genes was modified by exposure to EE in a dose- and time-dependent manner (p &lt;= 0.0001). The annotation available for the genes affected indicates that EE exposure results in changes in multiple molecular pathways affecting various biological processes, particularly associated with development, morphogenesis, organogenesis, cell proliferation, cell organization, and biogenesis. All of these processes are also affected by estrogen exposure in the uterus of the rat. Comparison of the response to EE in both the rat uterus and the Ishikawa cells showed that 71 genes are regulated in a similar manner in vivo as well as in vitro. Further, some of the genes that show a robust response to estrogen exposure in Ishikawa cells are well known to be estrogen responsive, in various in vivo studies, such as PGR, MMP7, IGFBP3, IGFBP5, SOX4, MYC, EGR1, FOS, CKB, and CCND2, among others. These results indicate that transcript profiling can serve as a viable tool to select reliable in vitro systems to evaluate potential estrogenic activities of target chemicals and to identify genes that are relevant for the estrogen response</abstract>
    <url>WOS:000261889900005</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>225</id>
    <title>Urinary bisphenol A concentrations in girls from rural and urban Egypt: a pilot study</title>
    <authors>Nahar,M.S.; Soliman,A.S.; Colacino,J.A.; Calafat,A.M.; Battige,K.; Hablas,A.; Seifeldin,I.A.; Dolinoy,D.C.; Rozek,L.S.</authors>
    <availability>[Nahar, Muna S.; Colacino, Justin A.; Battige, Kristen; Dolinoy, Dana C.; Rozek, Laura S.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Soliman, Amr S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Soliman, Amr S.; Colacino, Justin A.; Rozek, Laura S.] Univ Michigan, Ctr Global Hlth, Ann Arbor, MI 48109 USA. [Calafat, Antonia M.] Ctr Dis Control &amp; Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hablas, Ahmed; Seifeldin, Ibrahim A.] Tanta Canc Ctr, Tanta, Egypt. [Hablas, Ahmed; Seifeldin, Ibrahim A.] Gharbiah Canc Soc, Tanta, Egypt. [Rozek, Laura S.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleDolinoy, DC (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USAddolinoy@umich.eduAbdel-Aziz H, 2008, EGYPT OVERVIEW FOOD, P3; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; Biedermann S, 2010, ANAL BIOANAL CHEM, V398, P571, DOI 10.1007/s00216-010-3936-9; Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Calafat AM, 2009, ENVIRON HEALTH PERSP, V117, P639, DOI 10.1289/ehp.0800265; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cantonwine D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-62; Carwile JL, 2011, JAMA-J AM MED ASSOC, V306, P2218, DOI 10.1001/jama.2011.1721; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Colacino JA, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-40; Cruz S, 2003, SCI TOTAL ENVIRON, V317, P23, DOI 10.1016/S0048-9697(03)00334-6; Darbre PD, 2010, ANTICANCER RES, V30, P815; Dey S, 2009, MED HYPOTHESES, V72, P652, DOI 10.1016/j.mehy.2008.10.025; Dey S, 2011, CANCER EPIDEMIOL, V35, P254, DOI 10.1016/j.canep.2010.09.010; Dey S, 2010, BREAST, V19, P417, DOI 10.1016/j.breast.2010.04.005; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; F Safety, 2010, JOINT FAO WHO EXPERT, P48; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Fleisch AF, 2010, PEDIATRICS, V126, P760, DOI 10.1542/peds.2009-2693; Fu PQ, 2010, ENVIRON POLLUT, V158, P3138, DOI 10.1016/j.envpol.2010.06.040; Galal OM, 2002, PUBLIC HEALTH NUTR, V5, P141, DOI 10.1079/PHN2001286; Guart A, 2011, FOOD ADDIT CONTAM A, V28, P676, DOI 10.1080/19440049.2011.555845; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kang JH, 2003, J FOOD PROTECT, V66, P1444; Kitada Y, 2008, CHEMOSPHERE, V71, P2082, DOI 10.1016/j.chemosphere.2008.01.025; Kortenkamp A, 2006, INT J ANDROL, V29, P193, DOI 10.1111/j.1365-2605.2005.00613.x; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lopez-Cervantes J, 2003, FOOD ADDIT CONTAM, V20, P596, DOI 10.1080/0265203031000109495; Mahalingaiah S, 2008, ENVIRON HEALTH PERSP, V116, P173, DOI 10.1289/ehp.10605; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Meeker JD, 2011, ENVIRON HEALTH PERSP, V119, P252, DOI 10.1289/ehp.1002238; Miller RC, 2004, CLIN CHEM, V50, P924, DOI 10.1373/clinchem.2004.032292; Morgan MK, 2011, ENVIRON SCI TECHNOL, V45, P5309, DOI 10.1021/es200537u; Mountfort KA, 1997, FOOD ADDIT CONTAM, V14, P737; Munguia-Lopez EM, 2005, FOOD ADDIT CONTAM, V22, P892, DOI 10.1080/02652030500163674; Munguia-Lopez EM, 2001, J AGR FOOD CHEM, V49, P3666, DOI 10.1021/jf0009044; Nerin C, 2003, J AGR FOOD CHEM, V51, P5647, DOI 10.1021/jf034330p; Noonan GO, 2011, J AGR FOOD CHEM, V59, P7178, DOI 10.1021/jf201076f; Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rozati R, 2002, FERTIL STERIL, V78, P1187, DOI 10.1016/S0015-0282(02)04389-3; Sadek I. A., 1998, Eastern Mediterranean Health Journal, V4, P239; Sajiki J, 2004, CHEMOSPHERE, V55, P861, DOI 10.1016/j.chemosphere.2003.11.065; SUKKARYSTOLBA S, 1987, SOC SCI MED, V25, P401, DOI 10.1016/0277-9536(87)90278-4; Teitelbaum SL, 2008, ENVIRON RES, V106, P257, DOI 10.1016/j.envres.2007.09.010; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandentorren S, 2011, ENVIRON RES, V111, P761, DOI 10.1016/j.envres.2011.05.018; Volkel W, 2005, DRUG METAB DISPOS, V33, P1748, DOI 10.1124/dmd.105.005454; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690; Yang MH, 2003, ARCH ENVIRON CON TOX, V44, P546, DOI 10.1007/s00244-002-2124-0; Ye XB, 2008, ENVIRON RES, V108, P260, DOI 10.1016/j.envres.2008.07.014; Ye XY, 2005, ANAL CHEM, V77, P5407, DOI 10.1021/ac050390d; Ye XY, 2011, ENVIRON HEALTH PERSP, V119, P983, DOI 10.1289/ehp.1002701615BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDENVIRON HEALTH-GLOBAPR 2Discipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health951KT</notes>
    <keywords>ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; BREAST-CANCER; CANCER; CHILDREN; Egypt; ENDOCRINE; Endocrine-disrupting chemicals; ENVIRONMENTAL ESTROGENS; EXPOSURE; FOOD; FOOD SIMULANT; GAP; HEALTH; HUMAN EXPOSURE; Migration; NHANES; nutrition; NUTRITION EXAMINATION SURVEY; Occupational; PERFORMANCE LIQUID-CHROMATOGRAPHY; ROUTE; Rural; SAMPLES; TEMPORAL VARIABILITY; toxicology; Urban; URINARY; Urinary bisphenol A; URINARY CONCENTRATIONS; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Environmental Health</journalfull>
    <volume>11</volume>
    <abstract>Background: Exposure to endocrine active compounds, including bisphenol A (BPA), remains poorly characterized in developing countries despite the fact that behavioral practices related to westernization have the potential to influence exposure. BPA is a high production volume chemical that has been associated with metabolic dysfunction as well as behavioral and developmental effects in people, including children. In this pilot study, we evaluate BPA exposure and assess likely pathways of exposure among girls from urban and rural Egypt. Methods: We measured urinary concentrations of total (free plus conjugated) species of BPA in spot samples in urban (N = 30) and rural (N = 30) Egyptian girls, and compared these concentrations to preexisting data from age-matched American girls (N = 47) from the U. S. National Health and Nutrition Examination Survey (NHANES). We also collected anthropometric and questionnaire data regarding food storage behaviors to assess potential routes of exposure. Results: Urban and rural Egyptian girls exhibited similar concentrations of urinary total BPA, with median unadjusted values of 1.00 and 0.60 ng/mL, respectively. Concentrations of urinary BPA in this group of Egyptian girls (median unadjusted: 0.70 ng/mL) were significantly lower compared to age-matched American girls (median unadjusted: 2.60 ng/mL) according to NHANES 2009-2010 data. Reported storage of food in plastic containers was a significant predictor of increasing concentrations of urinary BPA. Conclusions: Despite the relatively low urinary BPA concentrations within this Egyptian cohort, the significant association between food storage behaviors and increasing urinary BPA concentration highlights the need to understand food and consumer product patterns that may be closing the gap between urban and rural lifestyles</abstract>
    <url>WOS:000304720200001</url>
    <isbnorissn>1476-069X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>343</id>
    <title>Influence of Endocrine-disrupting Chemicals on the Immune System</title>
    <authors>Nakamura,K.; Kariyazono,H.</authors>
    <availability>[Nakamura, Kazuo; Kariyazono, Hiroko] Nihon Pharmaceut Univ, Dept Biopharmaceut, Ina, Saitama 3620806, Japan.</availability>
    <date>2010</date>
    <notes>JEnglishReviewNakamura, K (reprint author), Nihon Pharmaceut Univ, Dept Biopharmaceut, 10281 Komuro, Ina, Saitama 3620806, Japankazunaka@nichiyaku.ac.jpAhmed SA, 1999, ENVIRON HEALTH PERSP, V107, P681, DOI 10.2307/3434327; Al-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Alizadeh Mohammad, 2006, J Med Invest, V53, P70, DOI 10.2152/jmi.53.70; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; Aoki Y, 2001, ENVIRON RES, V86, P2, DOI 10.1006/enrs.2001.4244; Ashby J, 1999, REGUL TOXICOL PHARM, V30, P156, DOI 10.1006/rtph.1999.1317; Bergeron RM, 1999, MOL CELL ENDOCRINOL, V150, P179, DOI 10.1016/S0303-7207(98)00202-0; Biles JE, 1999, J AGR FOOD CHEM, V47, P1965, DOI 10.1021/jf9810867; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Brouwer A, 1999, ENVIRON HEALTH PERSP, V107, P639, DOI 10.2307/3434557; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Caggiano TJ, 2007, J MED CHEM, V50, P5245, DOI 10.1021/jm701013k; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Combes RD, 2004, ATLA-ALTERN LAB ANIM, V32, P121; Correale J, 1998, J IMMUNOL, V161, P3365; Corry DB, 1999, NATURE, V402, pB18; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Fei XL, 2005, ENDOCRINOLOGY, V146, P3445, DOI 10.1210/en.2005-0341; FOX HS, 1991, J IMMUNOL, V146, P4362; Funabashi T, 2004, PSYCHONEUROENDOCRINO, V29, P475, DOI 10.1016/S0306-4530(03)00055-6; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; Giguere V, 1998, STEROIDS, V63, P335, DOI 10.1016/S0039-128X(98)00024-5; GRAY LE, 1998, TOXICOL LETT, V28, P102; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V118, P90, DOI 10.1159/000024037; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Hotchkiss AK, 2008, TOXICOL SCI, V105, P235, DOI 10.1093/toxsci/kfn030; HUARD B, 1994, EUR J IMMUNOL, V24, P3216, DOI 10.1002/eji.1830241246; Huard B, 1996, EUR J IMMUNOL, V26, P1180, DOI 10.1002/eji.1830260533; Kadowaki N, 2002, HUM IMMUNOL, V63, P1126, DOI 10.1016/S0198-8859(02)00751-6; Kagan RS, 2003, ENVIRON HEALTH PERSP, V111, P223, DOI 10.1289/ehp.5702; Kanda N, 1999, J ALLERGY CLIN IMMUN, V103, P282, DOI 10.1016/S0091-6749(99)70503-8; Karpuzoglu-Sahin E, 2001, CYTOKINE, V14, P208, DOI 10.1006/cyto.2001.0876; Karpuzoglu-Sahin E, 2001, J REPROD IMMUNOL, V52, P113, DOI 10.1016/S0165-0378(01)00117-6; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Kobayashi S, 2001, CHEM PHARM BULL, V49, P680, DOI 10.1248/cpb.49.680; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Long XH, 2000, ENVIRON HEALTH PERSP, V108, P243, DOI 10.2307/3454441; Maret A, 2003, EUR J IMMUNOL, V33, P512, DOI 10.1002/immu.200310027; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Menz G, 1998, ALLERGY, V53, P15; Michalek JE, 1999, AM J EPIDEMIOL, V149, P1038; Miller AP, 2004, CIRCULATION, V110, P1664, DOI 10.1161/01.CIR.0000142050.19488.C7; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Ortolani C, 2006, BEST PRACT RES CL GA, V20, P467, DOI 10.1016/j.bpg.2005.11.010; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pollard KM, 2010, CHEM RES TOXICOL, V23, P455, DOI 10.1021/tx9003787; Proust B, 2002, EUR CYTOKINE NETW, V13, P340; PRUETT SB, 1993, J TOXICOL ENV HEALTH, V39, P163; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; REGGIANI G, 1978, ARCH TOXICOL, V40, P161, DOI 10.1007/BF00364649; Reiter LW, 1998, ENVIRON HEALTH PERSP, V106, P105, DOI 10.1289/ehp.98106105; Rivas A, 2002, J STEROID BIOCHEM, V82, P45, DOI 10.1016/S0960-0760(02)00146-2; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; Sakazaki H, 2002, TOXICOL LETT, V133, P221, DOI 10.1016/S0378-4274(02)00203-5; Savelkoul HFJ, 2000, ALLERGY, V55, P989, DOI 10.1034/j.1398-9995.2000.00124.x; Sawai C, 2003, ENVIRON HEALTH PERSP, V111, P1883, DOI 10.1289/ehp.6359; Schafer TE, 1999, J BIOMED MATER RES, V45, P192, DOI 10.1002/(SICI)1097-4636(19990605)45:3&lt;192::AID-JBM5&gt;3.0.CO;2-A; SCHUURMAN HJ, 1992, INT J IMMUNOPHARMACO, V14, P369, DOI 10.1016/0192-0561(92)90166-I; Segura JJ, 1999, J ENDODONT, V25, P341, DOI 10.1016/S0099-2399(06)81168-4; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Steinmetz R, 1997, ENDOCRINOLOGY, V138, P1780, DOI 10.1210/en.138.5.1780; Strobel S, 2001, P NUTR SOC, V60, P437, DOI 10.1079/PNS2001119; Strobel S., 1997, FOOD ALLERGY ADVERSE, P107; Strobel S, 2002, ANN NY ACAD SCI, V958, P47; Sugita-Konishi Y, 2003, TOXICOL LETT, V136, P217, DOI 10.1016/S0378-4274(02)00388-0; Swallow DM, 2001, DRUG METAB DISPOS, V29, P513; Tournoy KG, 2001, J IMMUNOL, V166, P6982; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Waring RH, 2005, MOL CELL ENDOCRINOL, V244, P2, DOI 10.1016/j.mce.2005.02.007; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Weiner HL, 2001, MICROBES INFECT, V3, P947, DOI 10.1016/S1286-4579(01)01456-3; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; Xing DQ, 2007, AM J PHYSIOL-HEART C, V292, pH2607, DOI 10.1152/ajpheart.01107.2006; Yoshino S, 2003, BRIT J PHARMACOL, V138, P1271, DOI 10.1038/sj.bjp.0705166; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; 1985, FED REG, V50, P49760993PHARMACEUTICAL SOC JAPANTOKYO2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPANJ HEALTH SCIAUGDiscipline: Toxicology631UM</notes>
    <keywords>ALLERGIC AIRWAY INFLAMMATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CELL; CHEMICALS; Cytokine; CYTOKINE PRODUCTION; DISEASE; diseases; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; Environmental estrogen; ENVIRONMENTAL ESTROGENS; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS; ESTROGENS; FOOD; FOODS; HEALTH; HUMAN HEALTH; Immune; immune response; IMMUNE-RESPONSES; IMMUNE-SYSTEM; IN-VITRO; INTERFERON-GAMMA; LOW-DOSE LEVELS; mechanism; Microbes; NF-KAPPA-B; phenol; Plastics; RECEPTOR; Receptors; RESPONSES; Review; specific immunoglobulin E; Steroid; SYSTEM; T-CELL; toxicology; xenoestrogen; XENOESTROGEN BISPHENOL-A; xenoestrogenic reaction; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>361</startpage>
    <endpage>373</endpage>
    <journalfull>Journal of Health Science</journalfull>
    <issue>4</issue>
    <volume>56</volume>
    <abstract>Endocrine-disrupting chemicals, i.e., endocrine disruptors (EDs), are exogenous compounds that have the potential to interfere with hormonal regulation and the normal endocrine system and consequently cause side effects on human health. Environmental estrogens, i.e., xenoestrogens, are a diverse group of chemicals that bind to estrogen receptors, mimic estrogenic actions, and may have side effects on human health. Bisphenol A (BPA), which is produced by the acid-catalyzed reaction of acetone and phenol and is widely used in the manufacture of polycarbonate plastics and epoxy resins, is classified into xenoestrogens. Food allergy is caused by individual intolerance towards commonly tolerated foods, and this event derived from an immunological mechanism. Allergic diseases such as urticaria, asthma and anaphylaxis, are known to be connected with the production of specific immunoglobulin (I(g))E to allergens of environmental sources. In this paper, we discuss the relationship of EDs between xenoestrogenic reaction and immune responses in human and animals</abstract>
    <url>WOS:000280375200001</url>
    <isbnorissn>1344-9702</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>80</id>
    <title>Fluorescence Sensing of the Interaction between Biomembranes with Different Lipid Composition and Endocrine Disrupting Chemicals</title>
    <authors>Nakane,Y.; Kubo,I.</authors>
    <availability>[Nakane, Yuko] RIKEN, Quantitat Biol Ctr, Suita, Osaka 5650874, Japan. [Kubo, Izumi] Soka Univ, Fac Engn, Dept Bioinformat, Hachioji, Tokyo 1928577, Japan.</availability>
    <date>2014</date>
    <notes>JEnglishArticleKubo, I (reprint author), Soka Univ, Fac Engn, Dept Bioinformat, 1-236 Tangi, Hachioji, Tokyo 1928577, Japanynakane@riken.jp; kubo@soka.ac.jpAgretti P, 2011, J ENDOCRINOL INVEST, V34, P170, DOI 10.3275/7046; Alberts B., 2008, MOL BIOL CELL; Alonso-Magdalena P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002069; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Bechi N, 2013, TOXICOL IN VITRO, V27, P995, DOI 10.1016/j.tiv.2013.01.013; Blom A, 1998, ARCH ENVIRON CON TOX, V34, P306; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Escher BI, 2000, ENVIRON SCI TECHNOL, V34, P3954, DOI 10.1021/es0010709; Frye CA, 2012, J NEUROENDOCRINOL, V24, P144, DOI 10.1111/j.1365-2826.2011.02229.x; GOBAS FAPC, 1988, J PHARM SCI, V77, P265, DOI 10.1002/jps.2600770317; Hsieh TH, 2012, FASEB J, V26, P778, DOI 10.1096/fj.11-191742; Hunziker RW, 2001, ENVIRON SCI TECHNOL, V35, P3899, DOI 10.1021/es010043v; Kobayashi Y, 2010, SENSORS-BASEL, V10, P3411, DOI 10.3390/s100403411; Kwon JH, 2007, ENVIRON SCI TECHNOL, V41, P4011, DOI 10.1021/es0618200; Kwon JH, 2006, ENVIRON TOXICOL CHEM, V25, P1984, DOI 10.1897/05-550R.1; Larry T., 2005, AMBIENT AQUATIC LIFE; Mankidy R, 2013, TOXICOL LETT, V217, P50, DOI 10.1016/j.toxlet.2012.11.025; Morck TJ, 2010, REPROD TOXICOL, V30, P131, DOI 10.1016/j.reprotox.2010.02.007; Nakane Y, 2009, THIN SOLID FILMS, V518, P678, DOI 10.1016/j.tsf.2009.07.067; Nakane Y, 2008, ANAL LETT, V41, P2923, DOI 10.1080/00032710802440509; Nakane Y, 2008, ELECTROCHEMISTRY, V76, P535; Nakane Y, 2008, COLLOID SURFACE B, V66, P60, DOI 10.1016/j.colsurfb.2008.05.019; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Toko K, 2000, SENSOR ACTUAT B-CHEM, V64, P205, DOI 10.1016/S0925-4005(99)00508-0; Waller CL, 1996, CHEM RES TOXICOL, V9, P1240, DOI 10.1021/tx960054f; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yamamoto H, 2004, ENVIRON SCI TECHNOL, V38, P1139, DOI 10.1021/es034311w280MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDMATERIALSJANDiscipline: Materials ScienceAH4HR</notes>
    <keywords>ALPHA; biomembrane; BISPHENOL-A; BREAST-CANCER; CELL; CELLS; CHEMICALS; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; ESTROGEN-RECEPTOR; fluorescence sensing; In vitro; IN-VITRO; Interaction; LIPOSOMES; MODEL; pattern analysis; proliferation; SYNTHETIC MEMBRANE-VESICLES; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>170</startpage>
    <endpage>179</endpage>
    <journalfull>Materials</journalfull>
    <issue>1</issue>
    <volume>7</volume>
    <abstract>Fluorescence sensing of the interaction between biomembranes with different lipid composition and endocrine disrupting chemicals (EDCs) was carried out by using a liposome-encapsulating fluorescence dye (carboxyfluorescein (CF)-liposome). We detected a significant increase in fluorescence intensity in CF-liposome solutions due to the leakage of fluorescence caused by the interaction of EDCs with the biomembranes of liposomes. The temporal increases in fluorescent were significantly different among the lipid compositions of CF-liposome and the EDCs. Results were considered by summarizing the interactions in radar charts and by showing the pattern of interaction of each EDC. Each chart showed a dissimilar pattern reflecting the complexity of the biomembrane-EDC interaction. The results indicate that this fluorescence sensing could be useful to evaluate the interaction</abstract>
    <url>WOS:000336088500013</url>
    <isbnorissn>1996-1944</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>363</id>
    <title>Estrogenic Activity of Coumestrol, DDT, and TCDD in Human Cervical Cancer Cells</title>
    <authors>Ndebele,K.; Graham,B.; Tchounwou,P.B.</authors>
    <availability>[Tchounwou, Paul B.] Jackson State Univ, Mol Toxicol Res Lab, NIH Ctr Environm Hlth, Coll Sci Engn &amp; Technol, Jackson, MS 39217 USA. [Ndebele, Kenneth; Graham, Barbara] Jackson State Univ, Lab Canc Immunol Target Identificat &amp; Validat, Coll Sci Engn &amp; Technol, Jackson, MS 39217 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleTchounwou, PB (reprint author), Jackson State Univ, Mol Toxicol Res Lab, NIH Ctr Environm Hlth, Coll Sci Engn &amp; Technol, 1400 Lynch St,POB 18540, Jackson, MS 39217 USAkenneth.ndebele@jsums.edu; Barbara.e.graham@jsums.edu; paul.b.tchounwou@jsums.eduAhmed SA, 1999, ENVIRON HEALTH PERSP, V107, P681, DOI 10.2307/3434327; Ashby J, 2001, TOXICOL LETT, V120, P233, DOI 10.1016/S0378-4274(01)00299-5; Banerjee BD, 1997, ENVIRON RES, V74, P43, DOI 10.1006/enrs.1997.3749; Barton HA, 1998, CRIT REV TOXICOL, V28, P363, DOI 10.1080/10408449891344227; Barton HA, 1997, REGUL TOXICOL PHARM, V25, P292, DOI 10.1006/rtph.1997.1106; BLAGOSKLONNY MV, 1994, CANCER LETT, V76, P81, DOI 10.1016/0304-3835(94)90381-6; BURROW ME, 1999, CARCINOGENESIS, V20, P2057; COHEN JJ, 1991, ADV IMMUNOL, V50, P55, DOI 10.1016/S0065-2776(08)60822-6; Crinnion W J, 2000, Altern Med Rev, V5, P52; Dees C, 1997, MOL CARCINOGEN, V18, P107, DOI 10.1002/(SICI)1098-2744(199702)18:2&lt;107::AID-MC6&gt;3.0.CO;2-D; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Domon OE, 2001, MUTAT RES-FUND MOL M, V474, P129, DOI 10.1016/S0027-5107(00)00170-6; Fox HS, 1995, CIBA F SYMP, V191, P203; Frigo DE, 2002, ENVIRON HEALTH PERSP, V110, P1239; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; Hossain A, 1998, J BIOL CHEM, V273, P19853, DOI 10.1074/jbc.273.31.19853; Howdeshell KL, 1999, NATURE, V401, P763; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; JENKINS JK, 2001, INT J IMMUNOPHARMACO, V11, P1897; Jeon MS, 2000, J IMMUNOL, V165, P6975; Kaiser J, 2000, SCIENCE, V290, P695, DOI 10.1126/science.290.5492.695; Kamath AB, 1997, TOXICOL APPL PHARM, V142, P367, DOI 10.1006/taap.1996.8049; Kannan K, 2000, MOL CELL BIOCHEM, V205, P53, DOI 10.1023/A:1007080910396; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kharat I, 1996, J BIOL CHEM, V271, P10533; KINCADE PW, 1994, IMMUNOL REV, V137, P119, DOI 10.1111/j.1600-065X.1994.tb00661.x; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Koner B. C., 1998, Indian Journal of Experimental Biology, V36, P395; Lai ZW, 1997, MOL PHARMACOL, V52, P30; LANDEGREN U, 1985, EUR J IMMUNOL, V15, P308, DOI 10.1002/eji.1830150320; McMurray RW, 2001, CYTOKINE, V14, P324, DOI 10.1006/cyto.2001.0900; McMurray RW, 2001, PATHOBIOLOGY, V69, P44, DOI 10.1159/000048757; McMurray RW, 2001, INT IMMUNOPHARMACOL, V1, P995, DOI 10.1016/S1567-5769(01)00045-5; Ndebele K, 2003, INT J MOL SCI, V4, P45, DOI 10.3390/i4020045; Neubert D, 1997, REGUL TOXICOL PHARM, V26, P9, DOI 10.1006/rtph.1997.1149; NEUMANN CM, 1993, INT J IMMUNOPHARMACO, V15, P543, DOI 10.1016/0192-0561(93)90069-B; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nohara K, 2002, TOXICOLOGY, V172, P49, DOI 10.1016/S0300-483X(01)00582-0; Olsen NJ, 1996, ENDOCR REV, V17, P369, DOI 10.1210/er.17.4.369; PAGLIACCI MC, 1993, EUR J CANCER, V29A, P1573, DOI 10.1016/0959-8049(93)90297-S; Prell RA, 1995, INT J IMMUNOPHARMACO, V17, P951, DOI 10.1016/0192-0561(95)00080-1; RAY A, 1994, J BIOL CHEM, V269, P12940; Rininger JA, 1997, CHEMOSPHERE, V34, P1557, DOI 10.1016/S0045-6535(96)00451-1; Roy D, 1997, J TOXICOL ENV HEALTH, V50, P1, DOI 10.1080/009841097160573; Safe SH, 2000, ENVIRON HEALTH PERSP, V108, P487, DOI 10.2307/3454608; Sakabe K, 1999, INT J IMMUNOPHARMACO, V21, P861, DOI 10.1016/S0192-0561(99)00054-5; Sakazaki H, 2002, TOXICOL LETT, V133, P221, DOI 10.1016/S0378-4274(02)00203-5; Schimpl A, 2002, CYTOKINE GROWTH F R, V13, P369, DOI 10.1016/S1359-6101(02)00022-9; SILVERSTONE AE, 1994, TOXICOL APPL PHARM, V126, P248, DOI 10.1006/taap.1994.1114; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; STREET JC, 1975, TOXICOL APPL PHARM, V32, P587, DOI 10.1016/0041-008X(75)90123-4; Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P36, DOI 10.1016/S0753-3322(01)00155-X; Ulrich EM, 2000, ENVIRON HEALTH PERSP, V108, P973, DOI 10.2307/3435057; Verthelyi D, 2001, INT IMMUNOPHARMACOL, V1, P983, DOI 10.1016/S1567-5769(01)00044-3; Whitacre CC, 1999, SCIENCE, V283, P1277, DOI 10.1126/science.283.5406.1277; WOLFF MS, 1995, ENVIRON HEALTH PERSP, V103, P784, DOI 10.2307/3432386; Ziegler J, 1997, J NATL CANCER I, V89, P1184579MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL-MDPIBASELKANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLANDINT J ENV RES PUB HEMAYDiscipline: Environmental Sciences &amp; Ecology601YW</notes>
    <keywords>2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; Antagonist; apoptosis; ARYL-HYDROCARBON; BIOLOGY; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; Carcinogen; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; CELLS; Coumestrol; CYCLE; Cytokine; CYTOKINE PRODUCTION; DDT; Dose-response assessment; ENDOCRINE; ENDOCRINE DISRUPTERS; ENDOGENOUS ESTROGENS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; Estrogen; ESTROGENIC ACTIVITIES; estrogenic activity; ESTROGENS; EXPOSURE; GENE-EXPRESSION; GROWTH; HEALTH; IMPACT; MODEL; MODULATION; Phytoestrogen; proliferation; PROTEIN; PROTEINS; SEX STEROIDS; Steroid; T-CELL; TCDD; toxicology; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2045</startpage>
    <endpage>2056</endpage>
    <journalfull>International Journal of Environmental Research and Public Health</journalfull>
    <issue>5</issue>
    <volume>7</volume>
    <abstract>Endogenous estrogens have dramatic and differential effects on classical endocrine organ and proliferation. Xenoestrogens are environmental estrogens that have endocrine impact, acting as both estrogen agonists and antagonists, but whose effects are not well characterized. In this investigation we sought to delineate effects of xenoestrogens. Using human cervical cancer cells (HeLa cells) as a model, the effects of representative xenoestrogens (Coumestrol-a phytoestrogen, tetrachlorodioxin (TCDD)-a herbicide and DDT-a pesticide) on proliferation, cell cycle, and apoptosis were examined. These xenoestrogens and estrogen inhibited the proliferation of Hela cells in a dose dependent manner from 20 to 120 nM suggesting, that 17-beta-estrtadiol and xenoestrogens induced cytotoxic effects. Coumestrol produced accumulation of HeLa cells in G2/M phase, and subsequently induced apoptosis. Similar effects were observed in estrogen treated cells. These changes were associated with suppressed bcl-2 protein and augmented Cyclins A and D proteins. DDT and TCDD exposure did not induce apoptosis. These preliminary data taken together, suggest that xenoestrogens have direct, compound-specific effects on HeLa cells. This study further enhances our understanding of environmental modulation of cervical cancer</abstract>
    <url>WOS:000278105200014</url>
    <isbnorissn>1660-4601</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>226</id>
    <title>Prenatal exposure to diethylstilbestrol and long-term impact on the breast and reproductive tract in humans and mice</title>
    <authors>Newbold,R.R.</authors>
    <availability>NIEHS, Natl Toxicol Program, NIH, DHHS, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReviewNewbold, RR (reprint author), NIEHS, Natl Toxicol Program, NIH, DHHS, POB 12233,Mail Drop K2-15, Res Triangle Pk, NC 27709 USAnewbold1@niehs.nih.govBaird DD, 2005, REPROD TOXICOL, V20, P81, DOI 10.1016/j.reprotox.2005.01.002; BERN HA, 1975, J STEROID BIOCHEM, V6, P673, DOI 10.1016/0022-4731(75)90051-5; Bern H.A., 1992, CHEM INDUCED ALTERAT, VXXI, P9; BOYLAN ES, 1983, CANCER RES, V43, P4879; BOYLAN ES, 1978, BIOL REPROD, V19, P854, DOI 10.1095/biolreprod19.4.854; BOYLAN ES, 1981, J NATL CANCER I, V66, P649; BOYLAN ES, 1979, J TOXICOL ENV HEALTH, V5, P1059; Center for Disease Control and Prevention (CDC), 2003, DEP HLTH HUM SERV CT; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Colborn T, 1996, OUR STOLEN FUTURE, P1; Cook JD, 2007, REPROD SCI, V14, P121, DOI 10.1177/1933719106298401; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Fenton SE, 2012, ANNU REV PHARMACOL, V52, P455, DOI 10.1146/annurev-pharmtox-010611-134659; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Gluckman PD, 2005, MATERN CHILD NUTR, V1, P130, DOI 10.1111/j.1740-8709.2005.00020.x; Hatch E., 2000, ANN EPIDEMIOL, V10, P467, DOI 10.1016/S1047-2797(00)00087-9; Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630; Heindel JJ, 2009, EARLY LIFE ORIGINS H, P42; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; Herbst AL, 1981, DEV EFFECTS DES PREG, P1; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004; Hogan MD, 1987, DEV TOXICOLOGY MECH, P257; Hovey RC, 2005, BIOL REPROD, V72, P423, DOI 10.1095/biolreprod.104.029769; Kawaguchi H, 2009, J VET MED SCI, V71, P1599; Larson PS, 2006, CANCER, V107, P2122, DOI 10.1002/cncr.22223; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147; Li SF, 1997, CANCER RES, V57, P4356; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; MCLACHLAN JA, 1982, FERTIL STERIL, V38, P364; Melnick Ronald, 2002, Environmental Health Perspectives, V110, P427; MORI T, 1976, J NATL CANCER I, V57, P1057; MORI T, 1979, J ENVIRON PATHOL TOX, V3, P191; NAGASAWA H, 1980, EUR J CANCER, V16, P1583, DOI 10.1016/0014-2964(80)90031-6; NARBAITZ R, 1980, ANAT EMBRYOL, V158, P161, DOI 10.1007/BF00315903; National Institute of Health (NIH), 1999, NIH PUBL; NEWBOLD R, 1995, ENVIRON HEALTH PERSP, V103, P83, DOI 10.2307/3432514; Newbold R, 2010, REPROD TOXICOL, P317; Newbold RR, 2004, TOXICOL APPL PHARM, V199, P142, DOI 10.1016/j.taap.2003.11.033; Newbold RR, 2004, REPROD TOXICOL, V18, P399, DOI 10.1016/j.reprotox.2004.01.007; Newbold RR, 2007, MOL CARCINOGEN, V46, P783, DOI 10.1002/mc.20308; Ninomiya Kenjiro, 2007, Toxicol Pathol, V35, P813; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Robinson GW, 1999, J MAMMARY GLAND BIOL, V4, P9, DOI 10.1023/A:1018748418447; Rosso J, 2008, ROSENS BREAST PATHOL, P1; ROTHSCHILD TC, 1987, CANCER RES, V47, P4508; RUSSO J, 1990, LAB INVEST, V62, P244; Russo J., 2000, J NATL CANC I MONOGR, V27, P17; RUSTIA M, 1979, CANCER RES, V39, P4636; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Szyf M, 2007, TOXICOL SCI, V100, P7, DOI 10.1093/toxsci/kfm177; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; Titus-Ernstoff L, 2006, BRIT J CANCER, V95, P107, DOI 10.1038/sj.bjc.6603221; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Troisi R, 2007, CANCER EPIDEM BIOMAR, V16, P1700, DOI 10.1158/1055-9965.EPI-07-0073; Tuchmann-Duplessis H, 1982, ILLUSTRATED HUMAN EM, V11; Umekita Y, 2011, TOXICOL LETT, V205, P15, DOI 10.1016/j.toxlet.2011.04.031; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; VASSILACOPOULOU D, 1993, TERATOGEN CARCIN MUT, V13, P59, DOI 10.1002/tcm.1770130203; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; WALKER BE, 1990, J NATL CANCER I, V82, P50, DOI 10.1093/jnci/82.1.50; WARNER MR, 1975, J NATL CANCER I, V55, P289720CAMBRIDGE UNIV PRESSCAMBRIDGEEDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLANDJ DEV ORIG HLTH DISAPRDiscipline: Public, Environmental &amp; Occupational Health929KQ</notes>
    <keywords>BISPHENOL-A ALTERS; breast; breast cancer; CANCER; CANCER-RISK; Carcinogen; CARCINOGENESIS; CHEMICALS; critical windows; DES; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL; DISEASE; Endocrine-disrupting chemicals; environment; ENVIRONMENTAL CHEMICALS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; epigenetics; Estrogen; ESTROGEN-RECEPTORS; ESTROGENS; EXPOSURE; FIBROIDS; GENE-EXPRESSION; GLAND; HEALTH; hormonal carcinogenesis; HUMANS; IMPACT; IN-UTERO; mammary gland; MAMMARY-GLAND; MAMMARY-GLAND DEVELOPMENT; mechanism; MECHANISMS; MICE; NEONATAL MICE; nutrition; Occupational; PERINATAL EXPOSURE; POPULATION; PRENATAL EXPOSURE; PREVENTION; RISK; SUSCEPTIBILITY; TISSUE; TISSUES; TOXICITY; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>73</startpage>
    <endpage>82</endpage>
    <journalfull>Journal of Developmental Origins of Health and Disease</journalfull>
    <issue>2</issue>
    <volume>3</volume>
    <abstract>The term 'developmental origins of health and disease' (DOHaD) originally referred to delayed effects of altered maternal factors (e.g. smoking or poor nutrition) on the developing offspring, but it now also encompasses early life exposure to environmental chemicals, which can cause an unhealthy prenatal environment that endangers the fetus and increases its susceptibility to disease later in life. Prenatal exposure to the pharmaceutical diethylstilbestrol (DES) is a well-known DOHaD example as it was associated in the 1970s with vaginal cancer in daughters who were exposed to this potent synthetic estrogen before birth. Subsequently, numerous long-term effects have been described in breast and reproductive tissues of DES-exposed humans and experimental animals. Data reviewed suggest that the prenatal DES-exposed population should continue to be monitored for potential-increased disease risks as they age. Knowledge of sensitive developmental periods, and the mechanisms of DES-induced toxicities, provides useful information in predicting potential adverse effects of other environmental estrogens</abstract>
    <url>WOS:000303061700002</url>
    <isbnorissn>2040-1744</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>1</id>
    <title>The xenoestrogens ethinylestradiol and bisphenol A regulate BCRP at the blood-brain barrier of rats</title>
    <authors>Nickel,S.; Mahringer,A.</authors>
    <availability>[Nickel, Sabrina; Mahringer, Anne] Heidelberg Univ, Inst Pharm &amp; Mol Biotechnol, Dept Pharmaceut Technol &amp; Biopharmaceut, D-69120 Heidelberg, Germany.</availability>
    <date>2014</date>
    <notes>JEnglishArticleMahringer, A (reprint author), Heidelberg Univ, Inst Pharm &amp; Mol Biotechnol, Dept Pharmaceut Technol &amp; Biopharmaceut, Neuenheimer Feld 329, D-69120 Heidelberg, Germanymahringer@uni-hd.deAgarwal S, 2011, CURR PHARM DESIGN, V17, P2793; Al-Ansari AM, 2010, ENVIRON POLLUT, V158, P2566, DOI 10.1016/j.envpol.2010.05.020; Anapolsky A, 2006, DRUG METAB DISPOS, V34, P405, DOI 10.1124/dmd.105.006197; Breedveld P, 2005, CANCER RES, V65, P2577, DOI 10.1158/0008-5472.CAN-04-2416; Cisternino S, 2004, CANCER RES, V64, P3296, DOI 10.1158/0008-5472.CAN-03-2033; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Dankers ACA, 2013, TOXICOL SCI, V136, P382, DOI 10.1093/toxsci/kft198; Deuring JJ, 2012, BIOCHEM J, V441, P87, DOI 10.1042/BJ20111281; de Vries NA, 2007, CLIN CANCER RES, V13, P6440, DOI 10.1158/1078-0432.CCR-07-1335; Dussault EB, 2009, ECOTOX ENVIRON SAFE, V72, P1635, DOI 10.1016/j.ecoenv.2009.04.019; Enokizono J, 2007, MOL PHARMACOL, V72, P967, DOI 10.1124/mol.107.034751; Flint S, 2012, J ENVIRON MANAGE, V104, P19, DOI 10.1016/j.jenvman.2012.03.021; Frobenius W., 2011, J REPRODUKTIONSMED E, P32; Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Hanet N, 2008, STEROIDS, V73, P1242, DOI 10.1016/j.steroids.2008.06.005; Hartz AMS, 2010, J CEREBR BLOOD F MET, V30, P1742, DOI 10.1038/jcbfm.2010.36; Hartz AMS, 2010, J PHARMACOL EXP THER, V334, P467, DOI 10.1124/jpet.110.168930; Henriksen U, 2005, J BIOL CHEM, V280, P36926, DOI 10.1074/jbc.M502937200; HIDDEMANN W, 1987, BLOOD, V69, P744; Hiroi T, 2006, ENDOCRINOLOGY, V147, P2773, DOI 10.1210/en.2005-1235; Honorat M, 2008, BIOCHEM BIOPH RES CO, V375, P308, DOI 10.1016/j.bbrc.2008.07.149; Imai Y, 2002, JPN J CANCER RES, V93, P231; Imai Y, 2005, CANCER RES, V65, P596; Imai Y, 2003, MOL PHARMACOL, V64, P610, DOI 10.1124/mol.64.3.610; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Koshiba S, 2008, XENOBIOTICA, V38, P863, DOI 10.1080/00498250801986944 ; Lai KM, 2002, SCI TOTAL ENVIRON, V289, P159, DOI 10.1016/S0048-9697(01)01036-1; Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Mahringer A, 2010, MOL PHARMACEUT, V7, P1835, DOI 10.1021/mp1001729; Mao QC, 2008, PHARM RES, V25, P1244, DOI 10.1007/s11095-008-9537-z; Mazur CS, 2012, TOXICOL SCI, V128, P317, DOI 10.1093/toxsci/kfs167; Milane A, 2009, NEUROSCI LETT, V452, P12, DOI 10.1016/j.neulet.2008.12.061; Miller DS, 2000, MOL PHARMACOL, V58, P1357; Montes-Grajales D, 2013, TOXICOL LETT, V222, P312, DOI 10.1016/j.toxlet.2013.08.010; Nakanishi T, 2012, CHIN J CANCER, V31, P73, DOI 10.5732/cjc.011.10320; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nunez AA, 2001, CHEMOSPHERE, V42, P917, DOI 10.1016/S0045-6535(00)00196-X; Poimenova A, 2010, NEUROSCIENCE, V167, P741, DOI 10.1016/j.neuroscience.2010.02.051; Prasanth GK, 2010, J APPL TOXICOL, V30, P769, DOI 10.1002/jat.1570; Renz L, 2013, ECOTOXICOLOGY, V22, P632, DOI 10.1007/s10646-013-1054-0; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; Silva CP, 2012, ENVIRON POLLUT, V165, P38, DOI 10.1016/j.envpol.2012.02.002; Singleton DW, 2003, FRONT BIOSCI, V8, pS110, DOI 10.2741/1010; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Tschugguel W, 2003, J CLIN ENDOCR METAB, V88, P2281, DOI 10.1210/jc.2002-021165; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Velamakanni S, 2008, MOL PHARMACOL, V73, P12, DOI 10.1124/mol.108.038299; Vlaming MLH, 2009, ADV DRUG DELIVER REV, V61, P14, DOI 10.1016/j.addr.2008.08.007; Wang HG, 2006, AM J PHYSIOL-ENDOC M, V290, pE798, DOI 10.1152/ajpendo.00397.2005; Witorsch RJ, 2002, REGUL TOXICOL PHARM, V36, P118, DOI 10.1006/rtph.2002.1564; Zhang T, 2013, ENVIRON SCI TECHNOL, V47, P4686, DOI 10.1021/es303808b540INFORMA HEALTHCARELONDONTELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDXENOBIOTICANOVDiscipline: Pharmacology &amp; Pharmacy; ToxicologyAQ8MY</notes>
    <keywords>17 alpha-Ethinylestradiol; 17-BETA-ESTRADIOL; ABCG2; bisphenol A; blood-brain barrier; breast cancer resistance protein; CANCER RESISTANCE PROTEIN; DRUG EFFLUX TRANSPORTERS; ENDOCRINE DISRUPTORS; ESTROGEN-RECEPTOR; EXPRESSION; IN-VITRO; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1046</startpage>
    <endpage>1054</endpage>
    <journalfull>Xenobiotica</journalfull>
    <issue>11</issue>
    <volume>44</volume>
    <abstract>1. Breast cancer resistance protein (BCRP) is an ABC-transporter at the blood-brain barrier (BBB) facilitating efflux of xenobiotics into blood. Expression and function are regulated via estrogen-receptors (ERs). 2. 17 alpha-Ethinylestradiol (EE2) and bisphenol A (BPA) represent two prominent xenoestrogens. We studied whether EE2 and BPA regulate BCRP function and expression upon a 6 h treatment in an ER-dependent manner in a rat BBB-ex-vivo-model. 3. Isolated brain capillaries were incubated with EE2 or BPA. BCRP function and expression were analyzed by confocal microscopy and Western-Blot. ER alpha-antagonist MPP and ER-antagonist ICI182.780 were used to study involvement of ERs. 4. EE2 and BPA down-regulated BCRP transport function and expression. EE2 effects occurred at pharmacologically relevant doses, BPA exhibited only weak influences. Down-regulation by EE2 was reversed by ICI but not MPP. BPA effects were not reversed by either antagonist. 5. EE2 is a potent regulator of BCRP expression and function acting by ER beta-stimulation. Oral contraception could alter uptake of pharmaceuticals to the brain and might thus be considered as an origin of central nervous system (CNS) side-effects. EE2 could also present a novel co-treatment to improve CNS-pharmacotherapy. BPA is a weak modulator of BCRP expression. Its effects appear not to be caused by ERs</abstract>
    <url>WOS:000343080900010</url>
    <isbnorissn>0049-8254</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>92</id>
    <title>Sertoli cell dedifferentiation in human cryptorchidism and gender reassignment shows similarities between fetal environmental and adult medical treatment estrogen and antiandrogen exposure</title>
    <authors>Nistal,M.; Gonzalez-Peramato,P.; De Miguel,M.P.</authors>
    <availability>[Nistal, Manuel; Gonzalez-Peramato, Pilar] Univ Autonoma Madrid, La Paz Univ Hosp, Dept Pathol, Madrid, Spain. [De Miguel, Maria P.] La Paz Hosp Res Inst, IdiPAZ, Cell Engn Lab, Madrid, Spain.</availability>
    <date>2013</date>
    <notes>JEnglishArticleDe Miguel, MP (reprint author), La Paz Hosp Res Inst, IdiPAZ, Cell Engn Lab, Madrid, Spainmariapdemiguel@gmail.comAkingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Akre O, 2009, HUM REPROD, V24, P2053, DOI 10.1093/humrep/dep174; Becerra-Fernandez A, 2009, REV INT ANDROL, P7; BERNSTEIN L, 1988, BRIT J CANCER, V58, P379, DOI 10.1038/bjc.1988.223; Brehm R, 2006, ANAT EMBRYOL, V211, P223, DOI 10.1007/s00429-005-0075-8; CAIN MP, 1994, J UROLOGY, V152, P766; Carreau S, 2010, PHILOS T R SOC B, V365, P1571, DOI 10.1098/rstb.2009.0113; Chemes HE, 2008, J CLIN ENDOCR METAB, V93, P4408, DOI 10.1210/jc.2008-0915; Clewell RA, 2013, REPROD TOXICOL, V35, P70, DOI 10.1016/j.reprotox.2012.07.008; DELABALZE FA, 1954, FERTIL STERIL, V5, P421; Delbes G, 2005, ENDOCRINOLOGY, V146, P2454, DOI 10.1210/en.2004-1540; Delbes G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231; D'Souza R, 2009, ENDOCRINOLOGY, V150, P1861, DOI 10.1210/en.2008-1232; Fielden MR, 2003, FOOD CHEM TOXICOL, V41, P447, DOI 10.1016/S0278-6915(02)00284-3; Franke FE, 2004, ANAT EMBRYOL, V209, P169, DOI 10.1007/s00429-004-0434-x; GEARHART JP, 1990, J UROLOGY, V144, P274; GLAZE GM, 1984, J AM OSTEOPATH ASSOC, V83, P435; HEDINGER C, 1961, PATHOL MICROBIOL, V24, P227, DOI 10.1159/000161100; HEDINGER CE, 1967, VIRCHOWS ARCH A, V342, P165, DOI 10.1007/BF00960585; Hoei-Hansen CE, 2003, J PATHOL, V200, P370, DOI 10.1002/path.1372; Hu GX, 2009, TRENDS ENDOCRIN MET, V20, P139, DOI 10.1016/j.tem.2008.12.001; HUBER R, 1968, VIRCHOWS ARCH A, V344, P47, DOI 10.1007/BF00544637; HUTSON JM, 1990, OXFORD REV REPROD B, V12, P1; Ivell R, 2013, ASIAN J ANDROL, V15, P261, DOI 10.1038/aja.2012.138; Iwatsuki S, 2011, J UROLOGY, V185, P2444, DOI 10.1016/j.juro.2011.01.018; Kliesch S, 1998, J UROLOGY, V160, P1894, DOI 10.1016/S0022-5347(01)62439-X; Klinefelter GR, 2012, REPRODUCTION, V144, P747, DOI 10.1530/REP-12-0266; Kula K, 2001, MOL CELL ENDOCRINOL, V178, P89, DOI 10.1016/S0303-7207(01)00415-4; Lague E, 2009, TOXICOLOGY, V258, P101, DOI 10.1016/j.tox.2009.01.013; Lehmann KP, 2004, TOXICOL SCI, V81, P60, DOI 10.1093/toxsci/kfh169; Lottrup G, 2013, J CLIN ENDOCR METAB, V98, P2223, DOI 10.1210/jc.2013-1278; LU CC, 1978, AM J ANAT, V153, P1, DOI 10.1002/aja.1001530102; Main KM, 2010, BEST PRACT RES CL EN, V24, P279, DOI 10.1016/j.beem.2009.10.003; Maymon BB, 2005, ACTA HISTOCHEM, V107, P105, DOI 10.1016/j.acthis.2005.02.002; Meeker JD, 2010, ENVIRON SCI TECHNOL, V44, P1458, DOI 10.1021/es9028292; Mendiola J, 2010, ENVIRON HEALTH PERSP, V118, P1286, DOI 10.1289/ehp.1002037; Miao MH, 2011, BIRTH DEFECTS RES A, V91, P867, DOI 10.1002/bdra.22845; MIHALACHE G, 1986, Revista Medico-Chirurgicala Societatii di Medici si Naturalisti din Iasi, V90, P343; N'Tumba-Byn T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051579; Nistal M, 2010, REPROD FERT DEVELOP, V22, P558, DOI 10.1071/RD09179; Nistal M, 2011, HISTOPATHOLOGY, V58, P1019, DOI 10.1111/j.1365-2559.2011.03858.x; NISTAL M, 1982, HUM PATHOL, V13, P3, DOI 10.1016/S0046-8177(82)80132-9; Nistal M, 2006, AM J SURG PATHOL, V30, P1260, DOI 10.1097/01.pas.0000213361.10756.08; NONOMURA K, 1984, J UROLOGY, V132, P595; PAYER AF, 1979, ANDROLOGIA, V11, P423; Pentikainen V, 2000, J CLIN ENDOCR METAB, V85, P2057, DOI 10.1210/jc.85.5.2057; Perobelli JE, 2013, REPROD TOXICOL, V38, P65, DOI 10.1016/j.reprotox.2013.03.004; PLATTNER D, 1962, VIRCHOWS ARCH A, V335, P598, DOI 10.1007/BF00956575; Rajpert-De Meyts E, 1999, J CLIN ENDOCR METAB, V84, P3836, DOI 10.1210/jc.84.10.3836; Richiardi L, 2004, J NATL CANCER I, V96, P145, DOI 10.1093/jnci/djh012; Safe S, 2005, TRENDS ENDOCRIN MET, V16, P139, DOI 10.1016/j.tem.2005.03.004; SCHULZE C, 1988, CELL TISSUE RES, V251, P31, DOI 10.1007/BF00215444; SCHULZE C, 1984, ADV ANAT EMBRYOL CEL, V88, P1; SCHUTZ W, 1952, Langenbecks Arch Klin Chir Ver Dtsch Z Chir, V271, P65, DOI 10.1007/BF01398721; Serrano T, 2013, HUM REPROD, V28, P1974, DOI 10.1093/humrep/det111; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; Sharpe RM, 2002, NAT CELL BIOL, V4, pS33, DOI 10.1038/ncb-nm-fertilityS33; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; SHIMA H, 1986, J UROLOGY, V135, P539; Sikka SC, 2008, ASIAN J ANDROL, V10, P134, DOI 10.1111/j.1745-7262.2008.00370.x; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; SOHVAL AR, 1956, J UROLOGY, V75, P285; Spencer JR, 1994, AUA UPDATE SERIES LE, V12, P94; Staub C, 2005, BIOL REPROD, V73, P703, DOI 10.1095/biolreprod.105.042796; Steger K, 1999, HUM REPROD, V14, P136, DOI 10.1093/humrep/14.1.136; Storgaard L, 2006, REPROD TOXICOL, V21, P4, DOI 10.1016/j.reprotox.2005.05.006; Strohsnitter WC, 2001, J NATL CANCER I, V93, P545, DOI 10.1093/jnci/93.7.545; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Tanaka M, 2006, HUM EXP TOXICOL, V25, P369, DOI 10.1191/0960327106ht638oa; Tanyel FC, 2000, BJU INT, V85, P116, DOI 10.1046/j.1464-410x.2000.00362.x; Thuillier R, 2009, MICROSC RES TECHNIQ, V72, P773, DOI 10.1002/jemt.20756; Upadhyay RD, 2013, REPROD SCI; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239; WORTSMAN J, 1989, AM J MED SCI, V297, P365, DOI 10.1097/00000441-198906000-00006; Yuan KM, 2012, CHEM-BIOL INTERACT, V195, P180, DOI 10.1016/j.cbi.2011.12.008761PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLDECDiscipline: Reproductive Biology; Toxicology260BD</notes>
    <keywords>ANDROGEN RECEPTOR; anogenital distance; BIOLOGY; BISPHENOL-A; CANCER; CELL; CELLS; Cryptorchidism; DIBUTYL PHTHALATE; Differentiation; ENDOCRINE DISRUPTORS; Estrogen; ESTROGENS; EXPOSURE; EXPRESSION; FETAL; FOOD; Gender identity reassignment; GENE-EXPRESSION; HUMANS; IN-UTERO EXPOSURE; LEYDIG-CELLS; NORMAL HUMAN TESTES; PREPUBERTAL BOYS; RECEPTOR; Reproduction; Sertoli cell; Sertoli cells; TESTICULAR DYSGENESIS; TESTICULAR DYSGENESIS SYNDROME; THERAPY; TISSUE; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>172</startpage>
    <endpage>179</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <volume>42</volume>
    <abstract>Studies over the last years show an increase in testicular cancer, hypospadias and cryptorchidism in industrial countries, leading to the concept of testicular dysgenesis syndrome (TDS). It is hypothesized that TDS is caused by estrogen and antiandrogen exposure during fetal life, accompanied by incomplete maturation of testicular Sella cells (SC). However, it is not known if SC disruption is a primary cause or a response to fetal Leydig cell testosterone production changes. To determine if SC differentiation is directly affected by estrogens, we compared SC maturation between adult gender reassignment cases exposed to estrogen and antiandrogen therapy, and those of typical TDS in adult cryptorchidism. We found similar expression of immature SC markers M2A antigen, inhibin bodies and Anti Mullerian Hormone, and the absence of maturation marker androgen receptor in SC of both types of patients. These data supports the occurrence of true SC dedifferentiation caused by estrogen exposure in adult humans. Our data also suggests that SC maturation is directly disrupted in TDS. (C) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000327569100019</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>193</id>
    <title>Inhibition of Human Steroidogenic Cytochrome P450 c17 by 21-Hydroxypregnenolone and Related Steroid Hormones</title>
    <authors>Niwa,T.; Imamura,H.; Katagiri,M.</authors>
    <availability>[Niwa, Toshiro; Imamura, Hiroko; Katagiri, Masanao] Osaka Kyoiku Univ, Div Nat Sci, Osaka 5828582, Japan.</availability>
    <date>2012</date>
    <notes>JEnglishArticleKatagiri, M (reprint author), Osaka Kyoiku Univ, Div Nat Sci, 4 Asahiga Oka, Osaka 5828582, Japankatagiri@cc.osaka-kyoiku.ac.jpAKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; BIRCHALL KATHLEEN, 1965, STEROIDS, V6, P427, DOI 10.1016/0039-128X(65)90056-5; Hille UE, 2009, EUR J MED CHEM, V44, P2765, DOI 10.1016/j.ejmech.2009.01.002; Homma K, 2003, ENDOCR J, V50, P783, DOI 10.1507/endocrj.50.783; Hu QZ, 2010, J MED CHEM, V53, P5749, DOI 10.1021/jm100317b; IMAI T, 1993, J BIOL CHEM, V268, P19681; Kagawa Norio, 1995, P419; KAUFMANN SHE, 1980, J STEROID BIOCHEM, V13, P101, DOI 10.1016/0022-4731(80)90119-3; Lee TC, 1999, J CLIN ENDOCR METAB, V84, P2104, DOI 10.1210/jc.84.6.2104; Lewis DFV, 1998, J STEROID BIOCHEM, V66, P217, DOI 10.1016/S0960-0760(98)00032-6; LI JS, 1992, J STEROID BIOCHEM, V42, P313, DOI 10.1016/0960-0760(92)90134-5; Mathieu AP, 2003, BBA-GEN SUBJECTS, V1619, P291, DOI 10.1016/S0304-4165(02)00488-9; MEIKLE AW, 1982, CLIN ENDOCRINOL, V16, P401, DOI 10.1111/j.1365-2265.1982.tb00733.x; Niwa T, 2001, BIOL PHARM BULL, V24, P1064, DOI 10.1248/bpb.24.1064; Niwa T, 2002, BIOL PHARM BULL, V25, P235, DOI 10.1248/bpb.25.235; Owen CP, 2009, ANTI-CANCER AGENT ME, V9, P613; SHACKLETON C H L, 1987, Steroids, V49, P295, DOI 10.1016/0039-128X(87)90006-7; VINSON GP, 1967, GEN COMP ENDOCR, V9, P154, DOI 10.1016/0016-6480(67)90048-2; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879; Ye LP, 2011, TOXICOL LETT, V207, P137, DOI 10.1016/j.toxlet.2011.09.001201PHARMACEUTICAL SOC JAPANTOKYO2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPANBIOL PHARM BULLSEPDiscipline: Pharmacology &amp; Pharmacy998WC</notes>
    <keywords>17 alpha-hydroxylation; 21-hydroxypregnenolone; BISPHENOL-A; corticosterone; CYP17; cytochrome P450 c17; deoxycorticosterone; DEXAMETHASONE; Hormones; inhibition; P450C17; PHARMACOLOGY; PREGNENOLONE; progesterone; PROSTATE-CANCER; RAT; RECOGNITION; Steroid hormone; STEROID-HORMONES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1594</startpage>
    <endpage>1597</endpage>
    <journalfull>Biological &amp; Pharmaceutical Bulletin</journalfull>
    <issue>9</issue>
    <volume>35</volume>
    <abstract>The effects of 21-hydroxypregnenolone and related steroids such as deoxycorticosterone (DOC; 21-hydroxyprogesterone), cortisol, and corticosterone on progesterone 17 alpha-hydroxylase activity by steroidogenic cytochrome P450 c17 (CYP17) were investigated. 21-Hydroxypregnenolone contains a hydroxyl group at C-3 in the A cyclic hydrocarbon ring and a double bond at C-5 in the B cyclic hydrocarbon ring, whereas DOC, cortisol, and corticosterone contain a ketone group at C-3 and a double bond at C-4 in the A cyclic hydrocarbon ring. No marked inhibition was observed for DOC, cortisol, and corticosterone at 100 mu M concentration. Nonetheless, 21-hydroxypregnenolone exhibited competitive inhibition of progesterone 17 alpha-hydroxylation activity by CYP17 with a K-i value of 36.4 mu M. These results suggest that a hydroxyl group at C-3 in the A ring and a double bond at C-5 in the B ring in steroid hormones are important for the substrate recognition of CYP17</abstract>
    <url>WOS:000308270100031</url>
    <isbnorissn>0918-6158</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>443</id>
    <title>Policy and Research Recommendations Emerging from the Scientific Evidence Connecting Environmental Factors and Breast Cancer</title>
    <authors>Nudelman,J.; Taylor,B.; Evans,N.; Rizzo,J.; Gray,J.; Engel,C.; Walker,M.</authors>
    <availability>[Nudelman, Janet; Taylor, Brynn; Evans, Nancy; Rizzo, Jeanne; Engel, Connie; Walker, Marisa] Breast Canc Fund, San Francisco, CA 94109 USA. [Gray, Janet] Vassar Coll, Program Sci Technol &amp; Soc, Poughkeepsie, NY 12601 USA.</availability>
    <date>2009</date>
    <notes>JEnglishReviewEngel, C (reprint author), Breast Canc Fund, 1388 Sutter St,Suite 400, San Francisco, CA 94109 USAcengel@breastcancer-fund.orgAhlbom A, 2001, ENVIRON HEALTH PERSP, V109, P911, DOI 10.2307/3454653; Alexander BH, 2007, ENVIRON HEALTH PERSP, V115, P370, DOI 10.1289/ehp.8869; Allen NE, 2005, BRIT J CANCER, V92, P1283, DOI 10.1038/sj.bjc.6602471; *AM NONSM RIGHT FD, 2007, OV LIST HOW MAN SMOK; *AM SOC RAD TECHN, 2007, DOES YOUR STAT REG M; Band PR, 2000, J OCCUP ENVIRON MED, V42, P284, DOI 10.1097/00043764-200003000-00010; Bennett LM, 2002, ENVIRON MOL MUTAGEN, V39, P150, DOI 10.1002/em.10068; Betts KS, 2007, ENVIRON HEALTH PERSP, V115, pA136; BIBBO M, 1977, OBSTET GYNECOL, V49, P1; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; BOYLE CA, 1994, PEDIATRICS, V93, P399; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; BRONAUGH RL, 1994, ENVIRON HEALTH PERSP, V102, P71; BURRIDGE E, 2004, EUR CHEM NEWS, V81, P17; *CA ENV HLTH TRACK, 2007, OV ENV HLTH TRACK; Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; CANTOR KP, 1995, J OCCUP ENVIRON MED, V37, P336, DOI 10.1097/00043764-199503000-00011; Cardis E, 2005, BRIT MED J, V331, P77, DOI 10.1136/bmj.38499.599861.E0; CARPENTER D, 2007, BIOLNITIATIVE REPORT; Stewart S. L., 2007, Morbidity and Mortality Weekly Report, V56, P549; CDC (Centers for Disease Control and Prevention), NAT REP HUM EXP ENV; *CDCP, 2005, NAT ENV PUBL HLTH TR; Centers for Disease Control and Prevention (CDC), 2002, MAN EL BLOOD LEAD LE; *CDCP NPCR, 2007, US CANC STAT 2004 IN; Centers for Disease Control and Prevention, NAT ENV PUBL HLTH TR; Cepa M, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-41; Ciftci K, 2003, J PHARM PHARMACOL, V55, P1135, DOI 10.1211/0022357021558; *CIR, 2008, COSM INGR BANN FDA; Clegg LX, 2002, J NATL CANCER I, V94, P1537; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096; *COMM BIOM RES CTR, 2005, TAK ALL DOC CHEM POL; Cooper RL, 2000, TOXICOL SCI, V53, P297, DOI 10.1093/toxsci/53.2.297; Coyle B, 2004, AM J NURS, V104, P104; CUTLER SJ, 1969, CANCER, V23, P767, DOI 10.1002/1097-0142(196904)23:4&lt;767::AID-CNCR2820230404&gt;3.0.CO;2-V; Daxenberger A, 1998, ANALYST, V123, P2429, DOI 10.1039/a804923h; Dell PF, 2006, PSYCHIAT CLIN N AM, V29, P1, DOI 10.1016/j.psc.2005.10.013; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; *ED OFF QUEB, PEST MAN COD; *EL RAD POL I, 2007, FREQ ASK QUEST; *ENV WORK GROUP, 2004, EXP ADD SURV RES; Environmental Working Group, 2005, BOD BURD POLL NEWB; Environmental Working Group, 2006, GEN IND CHEM MOTH DA; Environmental Working Group, 2003, BOD BURD POLL PEOPL; Erickson BE, 2008, CHEM ENG NEWS, V86, P60, DOI 10.1021/cen-v086n038.p060; *EUR ENV AG, 2007, RAD RISK EV DEV ASS; European Commission, 2004, OFF J EUR UNION L, V78, P53; Fan WQ, 2007, ENVIRON HEALTH PERSP, V115, P720, DOI 10.1289/ehp.9758; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; *FRIENDS EARTH, 2007, NAN SUNSCR COSM SMAL; Furstenberger G, 2003, ONKOLOGIE, V26, P290, DOI 10.1159/000071627; GITLITZ J, 2007, WATER EVERYWHERE GRO; Glass AG, 2007, J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Goldberg MS, 1996, OCCUP ENVIRON MED, V53, P145; Grandjean Philippe, 2007, BASIC CLIN PHARMACOL, V102, P73; GRAY J, 2008, INT J OCCUP ENV HLTH, V15; Gross L, 2007, PLOS BIOL, V5, P1392; GUISTI RM, 1995, ANN INTERN MED, V122, P778; HABEL LA, 1995, J OCCUP ENVIRON MED, V37, P349, DOI 10.1097/00043764-199503000-00012; Hammes B, 2003, J MIDWIFERY WOM HEAL, V48, P19, DOI 10.1016/S1526-9523(02)00370-7; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hankinson SE, 2004, BREAST CANCER RES, V6, P213, DOI 10.1186/bcr921; Hansen J, 1999, AM J IND MED, V36, P43; Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20; Hayes RB, 2001, AM J IND MED, V40, P117, DOI 10.1002/ajim.1078; Hayes TB, 2006, ENVIRON HEALTH PERSP, V114, P134, DOI 10.1289/ehp.8067; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4&lt;745::AID-CNCR2820250402&gt;3.0.CO;2-2; Horrigan L, 2002, ENVIRON HEALTH PERSP, V110, P445; HOULIHAN J, 2008, BPA INVENTION PHASE; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; *I AGR TRAD POL, 2007, SMART PLAST GUID; *INT PEST MAN PROG, 2000, SAN FRANC INT PEST M; JACOBS M, 2008, IND CARCINOGENS NEED; JANJUA NR, 2008, INT J ANDROL, V30, P1; Jatoi I, 2005, J CLIN ONCOL, V23, P7836, DOI 10.1200/JCO.2004.01.0421; Jemal A, 2006, CA-CANCER J CLIN, V56, P106; JOBLING S, 1995, ENV HLTH PERSP, V113, P1056; Kruk J, 2006, CURR CANC THER REV, V2, P3, DOI 10.2174/157339406775471795; Labreche FP, 1997, AM J IND MED, V32, P1; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lux MP, 2006, J MOL MED, V84, P16, DOI 10.1007/s00109-005-0696-7; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2001, BIOL REPROD, V65, P1215; Michaels D, 2005, AM J PUBLIC HEALTH, V95, pS39, DOI 10.2105/AJPH.2004.043059; Michels KB, 2007, CANCER, V109, P2712, DOI 10.1002/cncr.22654; Miller BA, 2008, CANCER CAUSE CONTROL, V19, P227, DOI 10.1007/s10552-007-9088-3; Miller BA, 1988, RACIAL ETHNIC PATTER; Monninkhof EM, 2007, EPIDEMIOLOGY, V18, P137, DOI 10.1097/01.ede.0000251167.75581.98; Moore CJ, 2008, ENVIRON RES, V108, P131, DOI 10.1016/j.envres.2008.07.025; MORTON WE, 1995, J OCCUP ENVIRON MED, V37, P328, DOI 10.1097/00043764-199503000-00010; Nabholtz JM, 2008, EJSO-EUR J SURG ONC, V34, P1199, DOI 10.1016/j.ejso.2008.02.005; *NAT AC SCI COMM L, 1984, TOX TEST STRAT DET N; *NAT RES DEF COUNC, 2007, NAN INV THREAT SMALL; *NAT TOX PROGR, 2005, 11 NAT I ENV HLTH SC; National Cancer Institute, 2000, SURV EP END RES NUMB; National Cancer Institute, SURV EP END RES; National Cancer Institute, 1969, SURV EP END RES POP; National Research Council, 2005, BIOL EFF ION RAD; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Nickerson K, 2006, J MIDWIFERY WOM HEAL, V51, P26, DOI 10.1016/j.jmwh.2005.09.006; NIEHS working Group, 1998, ASS HLTH EFF EXP POW; *OAKL CIT COUNC, 1997, RES AD INT PEST MAN; O'Connor JC, 2000, DRUG CHEM TOXICOL, V23, P575, DOI 10.1081/DCT-100101972; Ohlson CG, 2000, CHEMOSPHERE, V40, P1277, DOI 10.1016/S0045-6535(99)00380-X; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Petralia SA, 1998, OCCUP ENVIRON MED, V55, P43; RAUN AP, HIST DIETHEYLSTILBES; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Rayner JL, 2005, TOXICOL SCI, V87, P255, DOI 10.1093/toxsci/kfi213; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Ries LAG, 2007, SEER CANC STAT REV 1; Ropero AB, 2008, INT J ANDROL, V31, P194, DOI 10.1111/j.1365-2605.2007.00832.x; Rudel RA, 2007, CANCER, V109, P2635, DOI 10.1002/cncr.22653; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Russo J, 2001, MICROSC RES TECHNIQ, V52, P204, DOI 10.1002/1097-0029(20010115)52:2&lt;204::AID-JEMT1006&gt;3.0.CO;2-F; *SAN FRANC ADM COD, SAN FRANC INT PEST M, pCH39; Sanderson JT, 2001, ENVIRON HEALTH PERSP, V109, P1027, DOI 10.2307/3454957; Schecter A, 2006, ENVIRON HEALTH PERSP, V114, P1515, DOI 10.1289/ehp.9121; Schernhammer ES, 2005, CANCER EPIDEM BIOMAR, V14, P699, DOI 10.1158/1055-9965.EPI-04-0561; Schettler T, 2006, INT J ANDROL, V29, P134, DOI 10.1111/j.1365-2605.2005.00567.x; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; SIDDIQUI MK, 2004, ENVIRON RES, V98, P250; Sigurdson AJ, 2003, CANCER, V97, P3080, DOI 10.1002/cncr.11444; *STAT CA AIR RES B, RISK RED PLAN RED PA; *STAT CA AIR RES B, 2005, APP 3 PROP ID ENV TO, P7; Stayner L, 1997, OCCUP ENVIRON MED, V54, P646; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Teitelbaum SL, 2003, CANCER CAUSE CONTROL, V14, P627, DOI 10.1023/A:1025682810900; Thompson D, 2005, AM J IND MED, V47, P153, DOI 10.1002/ajim.20132; THORPE B, L CHARTER SAFER CHEM; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; U.S. Environmental Protection Agency, 2010, SUMM TOX SUBST CONTR; U.S. Environmental Protection Agency, 6 COMM AIR POLL; U.S. Environmental Protection Agency, 2007, OV OFF POLL PREV TOX; *US EPA, 2008, WHAT DO WE REALL SAF; U.S. EPA, END DISR SCREEN PROG; *US EPA, 1998, OFF POLL PREV TOX CH; US Evironmental Protection Agency, 2006, DEC DOC ATR; *US FDA, 1992, COSM INGR UND PUFF; *US GEN ACC OFF, 1994, GAORCED94103; Van den Eynden GG, 2007, CLIN EXP METASTAS, V24, P13, DOI 10.1007/s10585-006-9049-3; Visvanathan K, 2007, ALCOHOL CLIN EXP RES, V31, P467, DOI 10.1111/j.1530-0277.2006.00334.x; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; WADIA PR, 2007, ENV HLTH PERSP, V115, P80; Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625; Watterson A, 2003, INT J OCCUP ENV HEAL, V9, P392; Weiderpass E, 1999, AM J IND MED, V36, P48, DOI 10.1002/(SICI)1097-0274(199907)36:1&lt;48::AID-AJIM7&gt;3.0.CO;2-2; Wilson M. P., 2006, GREEN CHEM CALIFORNI; ZHENG SM, 2007, AM J EPIDEMIOL, V165, P667; Zheng T, 2002, J Cancer Epidemiol Prev, V7, P3, DOI 10.1080/14766650252962621; CANADA NEWS WIRE NOV; WINGSPREAD STATEMENT1611MANEY PUBLISHINGLEEDSSTE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLANDINT J OCCUP ENV HEALJAN-MARDiscipline: Public, Environmental &amp; Occupational Health411AO</notes>
    <keywords>1; AROMATASE INHIBITORS; Biomonitoring; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; breast; breast cancer; Breast cancer incidence; BREAST-CANCER; CANCER; CANCER INCIDENCE; Carcinogen; CARCINOGENESIS; CELL; chemical regulation; cosmetics; development; DIETHYLSTILBESTROL DES; DISEASE; ENDOCRINE-DISRUPTING COMPOUNDS; environmental exposure; environmental factors; ENVIRONMENTAL-FACTORS; Epidemiology; EXPOSURE; EXPOSURES; GROWTH-FACTOR-I; HEALTH; Incidence; INDUSTRY; low dose; MAMMARY-GLAND; mixtures; MORTALITY; Occupational; OCCUPATIONAL EXPOSURES; pediatric; PESTICIDES; phthalate; Phthalates; PREVENTION; PRODUCTS; RADIATION; radiation policy; Regulation; Review; RISK; RISK-ASSESSMENT; STATEMENT; SYSTEM; UNITED-STATES; WATER; YOUNG-WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>79</startpage>
    <endpage>101</endpage>
    <journalfull>International Journal of Occupational and Environmental Health</journalfull>
    <issue>1</issue>
    <volume>15</volume>
    <abstract>A substantial body of evidence links environmental exposures to increases in breast cancer incidence over the past decades. State and federal legislative initiatives that could help prevent breast cancer include: federal standards to achieve consistency in radiation-emitting medical and dental equipment; improved state quality assurance standards for radiation-emitting equipment; federal and state exposure limits for electromagnetic radiation; an overhaul of the federal Toxic Substances Control Act to reduce unsafe chemical exposures; strengthened premarket health and safety testing and regulation of pesticides; a federal ban on the manufacture distribution and sale of consumer products containing bisphenol A and phthalates; and strengthened oversight and regulation of the cosmetics industry. We recommend public and private investment in research on low dose exposures, mixtures, and the timing of chemical exposures, its well as the development of health tracking and biomonitoring programs designed to link data from pollution surveillance systems with disease registries</abstract>
    <url>WOS:000263619900008</url>
    <isbnorissn>1077-3525</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>32</id>
    <title>Perinatal bisphenol A exposures increase production of pro-inflammatory mediators in bone marrow-derived mast cells of adult mice</title>
    <authors>O'Brien,E.; Dolinoy,D.C.; Mancuso,P.</authors>
    <availability>[O'Brien, Edmund; Dolinoy, Dana C.; Mancuso, Peter] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleMancuso, P (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, 1415 Washington Hts, Ann Arbor, MI 48109 USApmancuso@umich.eduAhmed SR, 2000, TOXICOLOGY, V150, P191; Amin K, 2012, RESP MED, V106, P9, DOI 10.1016/j.rmed.2011.09.007; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; Anderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692; Anderson OS, 2013, FASEB J, V27, P1784, DOI 10.1096/fj.12-223545; Asher MI, 2010, ALLERGOL IMMUNOPATH, V38, P83, DOI 10.1016/j.aller.2009.11.002; Barr RG, 2004, ARCH INTERN MED, V164, P379, DOI 10.1001/archinte.164.4.379; Bauer SM, 2012, TOXICOL SCI, V130, P82, DOI 10.1093/toxsci/kfs227; Bonds RS, 2013, CURR OPIN ALLERGY CL, V13, P92, DOI 10.1097/ACI.0b013e32835a6dd6; Bouman A, 2004, AM J REPROD IMMUNOL, V52, P19, DOI 10.1111/j.1600-0897.2004.00177.x; Boyce JA, 2003, PROSTAG LEUKOTR ESS, V69, P195, DOI 10.1016/S0952-3278(03)00081-4; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chung KF, 1999, THORAX, V54, P825; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Doerge DR, 2011, TOXICOL LETT, V207, P298, DOI 10.1016/j.toxlet.2011.09.020; Doerge DR, 2010, TOXICOL APPL PHARM, V247, P158, DOI 10.1016/j.taap.2010.06.008; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Dratva Julia, 2010, Evid Based Med, V15, P190, DOI 10.1136/ebm1135; Duijts L, 2012, EUR J EPIDEMIOL, V27, P5, DOI 10.1007/s10654-012-9657-y; Edlow AG, 2012, REPROD TOXICOL, V34, P1, DOI 10.1016/j.reprotox.2012.03.009; Ginsberg G, 2004, ENVIRON HEALTH PERSP, V112, P272, DOI 10.1289/ehp.6013; Gowers IR, 2011, CYTOKINE, V56, P792, DOI 10.1016/j.cyto.2011.09.009; Han Y. L, 2011, ZHONG SHI YAN HE LIN, V25, P368; Harding R, 2012, SEMIN FETAL NEONAT M, V17, P67, DOI 10.1016/j.siny.2012.01.005; Henderson AJ, 2012, SEMIN FETAL NEONAT M, V17, P82, DOI 10.1016/j.siny.2012.01.006; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Jasarevic E, 2013, HORM BEHAV, V63, P180, DOI 10.1016/j.yhbeh.2012.09.009; Jensen F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014409; Kamei Y, 2010, OBESITY, V18, P314, DOI 10.1038/oby.2009.246; Kennedy RH, 2012, J TOXICOL ENV HEAL A, V75, P1451, DOI 10.1080/15287394.2012.722184; Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005; Kwintkiewicz J, 2010, ENVIRON HEALTH PERSP, V118, P400, DOI 10.1289/ehp.0901161; Lacy P, 2011, BLOOD, V118, P9, DOI 10.1182/blood-2010-08-265892; Lai C. K., 2009, THORAX, V64, P467; Lee J, 2011, ENVIRON TOXICOL, V26, P364, DOI 10.1002/tox.20563; Lee J, 2010, DRUG CHEM TOXICOL, V33, P421, DOI 10.3109/01480541003739229; Lee J, 2012, FOOD CHEM TOXICOL, V50, P2109, DOI 10.1016/j.fct.2012.03.043; Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069; Leynaert B, 2012, THORAX, V67, P625, DOI 10.1136/thoraxjnl-2011-201249; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Marquet F, 2011, ARCH TOXICOL, V85, P1035, DOI 10.1007/s00204-011-0651-z; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Miltenberger RJ, 1997, J NUTR, V127, pS1902; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Murdoch JR, 2010, MUTAT RES-FUND MOL M, V690, P24, DOI [10.1016/j.mrfmmm.2009.09.005, 10.1016/j.mrfmmm.2010.09.005]; Nahar MS, 2013, J BIOCHEM MOL TOXIC, V27, P116, DOI 10.1002/jbt.21459; Nakajima Y., 2012, ENV HLTH, V11, P1; Narita S, 2007, ENVIRON HEALTH PERSP, V115, P48, DOI 10.1289/ehp.9378; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Pergola C, 2008, P NATL ACAD SCI USA, V105, P19881, DOI 10.1073/pnas.0809120105; Pergola C, 2011, FASEB J, V25, P3377, DOI 10.1096/fj.11-182758; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Schonfelder G., 2002, ENV HLTH PERSPECT, V110, P703; Skinner MK, 2009, EPIGENOMICS-UK, V1, P111, DOI 10.2217/EPI.09.11; Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007; Spitzer JA, 1999, LUPUS, V8, P380, DOI 10.1177/096120339900800510; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Teitell M, 2003, CLIN IMMUNOL, V109, P2, DOI 10.1016/S1521-6616(03)00224-9; Thornton J, 2012, RESP MED, V106, P1236, DOI 10.1016/j.rmed.2012.05.003; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2012, CIENC SAUDE COLETIVA, V17, P407, DOI 10.1590/S1413-81232012000200015; Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018; Vrieze A, 2003, J ALLERGY CLIN IMMUN, V112, P271, DOI 10.1067/mai.2003.1676; Walls A. F., 2001, Clinical and Experimental Allergy Reviews, V1, P68, DOI 10.1046/j.1472-9725.2001.00009.x; Wang B., 2012, PLOS ONE, V7, P1; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; World Health Organization, 2007, GLOB SURV PREV CONTR; Xiang Zou, 2001, Journal of Allergy and Clinical Immunology, V108, P116; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Yi AK, 1998, J IMMUNOL, V161, P4493; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Yu Q, 2012, P NATL ACAD SCI USA, V109, P541, DOI 10.1073/pnas.1103803109; Zaitsu M, 2007, MOL IMMUNOL, V44, P1977, DOI 10.1016/j.molimm.2006.09.030; Zhao ZZ, 2001, J PERIODONTAL RES, V36, P233, DOI 10.1034/j.1600-0765.2001.036004233.x; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-1018892INFORMA HEALTHCARENEW YORK52 VANDERBILT AVE, NEW YORK, NY 10017 USAJ IMMUNOTOXICOLJUL-SEPDiscipline: ToxicologyAJ7XC</notes>
    <keywords>ACTIVATION; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; CELLS; Cytokine; DNA METHYLATION; DNA METHYLTRANSFERASE 3A; Endocrine-disrupting chemicals; ENVIRONMENTAL-FACTORS; EPIGENETIC GENE-REGULATION; EXPOSURE; FOOD; GENDER-DIFFERENCES; IMMUNE-RESPONSES; Inflammation; LEUKOTRIENE BIOSYNTHESIS; mast cells; mechanism; Mouse; PERINATAL EXPOSURE; pro-inflammatory mediators; RHESUS-MONKEYS; WIDESPREAD EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>205</startpage>
    <endpage>212</endpage>
    <journalfull>Journal of Immunotoxicology</journalfull>
    <issue>3</issue>
    <volume>11</volume>
    <abstract>Bisphenol A (BPA) is a widely used monomer of polycarbonate plastics and epoxide resin that has been implicated in asthma pathogenesis when exposure occurs to the developing fetus. However, few studies have examined the relationship between perinatal BPA exposure and asthma pathogenesis in adulthood. This study used an isogenic mouse model to examine the influence of perinatal BPA exposure via maternal diet on inflammatory mediators associated with asthma in 6-month-old adult offspring by measuring bone marrow-derived mast cell (BMMC) production of lipid mediators (cysteinyl leukotrienes and prostaglandin D-2), cytokines (interleukin[IL]-4, IL-5, IL-6, IL-13, and tumor necrosis factor[TNF]-alpha), and histamine. Global DNA methylation levels in BMMCs from adult offspring were determined to elucidate a potential regulatory mechanism linking perinatal exposure to mast cell phenotype later in life. Four BPA exposure doses were tested: low (50 ng BPA/kg diet, n = 5), medium (50 mu g BPA/kg diet, n = 4), high (50mg BPA/kg diet, n = 4), and control (n = 3). Following BMMC activation, increases in cysteinyl leukotriene (p&lt;0.01) and TNF alpha (p&lt;0.05) production were observed in all BPA-exposure groups, and increases in prostaglandin D-2 (p&lt;0.01) and IL-13 (p&lt;0.01) production were observed in the high exposure group. Additionally, BMMCs from adult mice in all exposure groups displayed a decrease in global DNA methylation compared to control animals. Thus, perinatal BPA exposure displayed a long-term influence on mast cell-mediated production of pro-inflammatory mediators associated with asthma and global DNA methylation levels, suggesting a potential for mast cell dysregulation, which could affect pulmonary inflammation associated with allergic airway disease into adulthood</abstract>
    <url>WOS:000337913200003</url>
    <isbnorissn>1547-691X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>15</id>
    <title>Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol</title>
    <authors>Obiorah,I.E.; Jordan,V.C.</authors>
    <availability>[Obiorah, I. E.] Georgetown Univ, Tumor Biol Training Program, Washington, DC 20057 USA. [Jordan, V. C.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20057 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleJordan, VC (reprint author), Georgetown Univ, Med Ctr, Dept Oncol, 3970 Reservoir Rd NW,Res Bldg,Suite E501, Washington, DC 20057 USAvcj2@georgetown.eduAKIRA S, 1990, EMBO J, V9, P1897; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1652, DOI 10.1111/bph.12448; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Ariazi EA, 2011, P NATL ACAD SCI USA, V108, P18879, DOI 10.1073/pnas.1115188108; Bian ZM, 2009, INVEST OPHTH VIS SCI, V50, P6006, DOI 10.1167/iovs.09-3628; Cunliffe H, 2011, BREAST S3, V3, pS1; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Fan P, 2013, CANCER RES, V73, P4510, DOI 10.1158/0008-5472.CAN-12-4152; Bourgoin-Voillard S, 2010, BIOCHEM PHARMACOL, V79, P746, DOI 10.1016/j.bcp.2009.10.015; Haddow A, 1944, Br Med J, V2, P393; HADDOW A, 1970, CANCER, V26, P737, DOI 10.1002/1097-0142(197010)26:4&lt;737::AID-CNCR2820260402&gt;3.0.CO;2-T; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; JORDAN VC, 1984, MOL PHARMACOL, V26, P279; JORDAN VC, 1986, BRIT J PHARMACOL, V87, P217; Jordan VC, 2008, J CLIN ONCOL, V26, P3073, DOI 10.1200/JCO.2008.17.5190; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Jordan VC, 2001, CANCER RES, V61, P6619; JORDAN VC, 1984, MOL PHARMACOL, V26, P272; Jordan VC, 2011, HORM MOL BIOL CLIN I, V5, P27, DOI 10.1515/HMBCI.2010.047; Kim SJ, 2006, HUM MOL GENET, V15, P1826, DOI 10.1093/hmg/ddl105; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lewis JS, 2005, J NATL CANCER I, V97, P1746, DOI 10.1093/jnci/dji400; Lewis JS, 2005, J STEROID BIOCHEM, V94, P131, DOI 10.1016/j.jsbmb.2004.12.032; Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255; Hu ZZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020410; LIEBERMAN ME, 1983, J BIOL CHEM, V258, P4741; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Maximov PY, 2010, J MED CHEM, V53, P3273, DOI 10.1021/jm901907u; Obiorah I, 2014, BRIT J CANCER, V110, P1488, DOI 10.1038/bjc.2014.50; Obiorah I, 2014, MOL PHARMACOL, V85, P789, DOI 10.1124/mol.113.089250; Obiorah I, 2013, MENOPAUSE, V20, P372, DOI [10.1097/GME.0b013e31828865a5, 10.1097/gme.0b013e31828865a5]; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Robson JM, 1937, NATURE, V140, P196, DOI 10.1038/140196b0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sen B, 2012, PLOS ONE, V7, P12; Sengupta S, 2013, BRIT J PHARMACOL, V169, P167, DOI 10.1111/bph.12122; Sengupta S., 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Song RXD, 2001, J NATL CANCER I, V93, P1714, DOI 10.1093/jnci/93.22.1714; Wolf D M, 1993, Recent Results Cancer Res, V127, P23; Yao K, 2000, CLIN CANCER RES, V6, P2028410WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USABRIT J PHARMACOLSEPSIDiscipline: Pharmacology &amp; PharmacyAN3SS</notes>
    <keywords>ACTIVATION; apoptosis; bisphenol; breast cancer; BREAST-CANCER; CANCER; CANCER-CELLS; CASPASE-4; cell death; CELL-DEATH; CELLS; CLASSIFICATION; DEPRIVATION; ENDOPLASMIC-RETICULUM STRESS; GROWTH; Oestrogen-induced apoptosis; POSTMENOPAUSAL WOMEN; PROLACTIN SYNTHESIS INVITRO; proliferation; RECEPTOR; RECEPTOR COACTIVATOR AIB1; RESISTANT; RESPONSES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>4062</startpage>
    <endpage>4072</endpage>
    <journalfull>British Journal of Pharmacology</journalfull>
    <issue>17</issue>
    <volume>171</volume>
    <abstract>Background and purpose triphenylethylene (Tpe)-Like compounds were the first agents to be used in the treatment of metastatic breast cancer in postmenopausal women. Although structurally related to the anti-oestrogen, 4-hydroxytamoxifen, tpes possess oestrogenic properties in fully oestrogenized breast cancer cells but do not induce apoptosis with short-term treatment in long-term oestrogen-deprived breast cancer cells. This study determined the differential effects of bisphenol, a tpe, on growth and apoptosis based on the modulation of the shape of the ligand-oestrogen receptor complex. Experimental approach apoptotic flow cytometric studies were used to evaluate apoptosis over time. Proliferation of the breast cancer cells was assessed using dna quantification and cell cycle analysis. Real-time pcr was performed to quantify mrna levels of apoptotic genes. Regulation of cell cycle and apoptotic genes was determined using pcr-based arrays. Key results bisphenol induced an up-regulation of cell cycle genes similar to those induced by 17 beta oestradiol (E-2). Unlike the changes induced by e-2 that occur after 24 h, the apoptosis evoked by bisphenol occurred after 4 days, with quantifiable apoptotic changes noted at 6 days. A prolonged up-regulation of endoplasmic reticulum stress and inflammatory stress response genes was observed with subsequent activation of apoptosis-related genes in the second week of treatment with bisphenol. Conclusions and implications the bisphenol: Er alpha complex induces delayed biological effects on the growth and apoptosis of breast cancer cells. Both the shape of the complex and the duration of treatment control the initiation of apoptosis</abstract>
    <url>WOS:000340509600010</url>
    <isbnorissn>0007-1188</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>429</id>
    <title>Analysis of Gene Expression in the Testes of Mice Exposed to Bisphenol A and Nonylphenol</title>
    <authors>Oh,J.H.; Oh,M.J.; Park,H.J.; Kim,S.J.; Park,S.M.; Yoon,H.J.; Cho,J.W.; Hwang,S.Y.; Yoon,S.</authors>
    <availability>[Oh, Jung-Hwa; Park, Han-Jin; Park, Se-Myo; Yoon, Hea-Jin; Yoon, Seokjoo] Korea Inst Toxicol, Toxicogenom Team, Taejon 305343, South Korea. [Oh, Moon-Ju; Kim, Seung Jun; Hwang, Seung Yong] Genocheck Co Ltd, Ansan 426791, Gyeonggi Do, South Korea. [Oh, Moon-Ju; Kim, Seung Jun; Hwang, Seung Yong] Hanyang Univ, Ansan 426791, Gyeonggi Do, South Korea. [Cho, Jae-Woo] Korea Inst Toxicol, Clin Pathol Team, Taejon 305343, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleYoon, S (reprint author), Korea Inst Toxicol, Toxicogenom Team, 19 Shinsung Ro, Taejon 305343, South Koreasjyoon@kitox.re.krAl-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Asklund C, 2004, BJU INT, V93, P6, DOI 10.1111/j.1464-410X.2004.04703.x; Boverhof DR, 2004, CARCINOGENESIS, V25, P1277, DOI 10.1093/carcin/bgh114; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Chung H, 2005, TOXICOL APPL PHARM, V206, P27, DOI 10.1016/j.taap.2004.11.004; Clark JH, 1992, TXB ENDOCRINOLOGY, P35; Danzo BJ, 1997, ENVIRON HEALTH PERSP, V105, P294, DOI 10.1289/ehp.97105294; DENNY P, 1992, EMBO J, V11, P3705; El-Dakdoky MH, 2007, B ENVIRON CONTAM TOX, V79, P188, DOI 10.1007/s00128-007-9158-y; Ema M, 2001, REPROD TOXICOL, V15, P505, DOI 10.1016/S0890-6238(01)00160-5; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; Hess RA, 1997, J ANDROL, V18, P602; Hess R A, 1998, J Reprod Fertil Suppl, V53, P247; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kato N, 2004, TOXICOLOGY, V200, P179, DOI 10.1016/j.tox.2004.03.008; Kinoshita Y, 2003, CANCER RES, V63, P3546; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kwon S, 2000, TOXICOL SCI, V55, P399, DOI 10.1093/toxsci/55.2.399; Kyselova V, 2003, REPROD BIOL ENDOCRIN, V1, P1; Lim JS, 2007, INT J TOXICOL, V26, P213, DOI 10.1080/10915810701352697; Maras M, 2006, ENVIRON HEALTH PERSP, V114, P100, DOI 10.1289/ehp.8149; Masuyama H, 2000, MOL ENDOCRINOL, V14, P421, DOI 10.1210/me.14.3.421; Naciff JM, 2005, TOXICOL SCI, V86, P396, DOI 10.1093/toxsci/kfi198; Oda H, 2005, BIOCHEM BIOPH RES CO, V335, P458, DOI 10.1016/j.bbrc.2005.07.093; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Peterson C, 1999, MOL HUM REPROD, V5, P627, DOI 10.1093/molehr/5.7.627; Powell CL, 2006, TOXICOL SCI, V93, P213, DOI 10.1093/toxsci/kfl030; Sakaue M, 2001, J OCCUP HEALTH, V43, P185, DOI 10.1539/joh.43.185; Sharpe RM, 1997, NATURE, V390, P447, DOI 10.1038/37236; Tabuchi Y, 2002, JPN J PHARMACOL, V89, P413, DOI 10.1254/jjp.89.413; Takahashi O, 2003, FOOD CHEM TOXICOL, V41, P1035, DOI 10.1016/S0278-6915(03)00031-0; Takamiya M, 2007, REPROD TOXICOL, V24, P265, DOI 10.1016/j.reprotox.2007.07.003; Takao T, 1999, LIFE SCI, V65, P2351, DOI 10.1016/S0024-3205(99)00502-0; Tohei A, 2001, EXP BIOL MED, V226, P216; Traina ME, 2003, REPROD TOXICOL, V17, P25, DOI 10.1016/S0890-6238(02)00101-6; Tsai-Morris CH, 2004, P NATL ACAD SCI USA, V101, P6373, DOI 10.1073/pnas.0401855101; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; Zha JM, 2007, CHEMOSPHERE, V66, P488, DOI 10.1016/j.chemosphere.2006.05.071427KOREAN BIOCHIP SOCSEOULBIOTECHNOLOGY BUILDING KOREA UNIV, SPECIAL RES WING, #204, SEOUL, ANAM-DONG 136-701, SOUTH KOREABIOCHIP JMAR 20Discipline: Biochemistry &amp; Molecular Biology422NS</notes>
    <keywords>analysis; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; development; DIFFERENTIALLY EXPRESSED GENES; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; Estrogenic; ESTROGENIC COMPOUNDS; EXPOSURE; EXPRESSION; FOOD; GENE; gene expression; gene expression profile; Gene expression profiling; GENE-EXPRESSION; GENES; HEALTH; IDENTIFICATION; Male; mechanism; MECHANISMS; MICE; Microarray; MICROARRAY ANALYSIS; molecular mechanism; MOLECULAR-MECHANISMS; MOUSE SPERMATOGENESIS; Nonylphenol; PATHWAY; PROFILES; PROTEINS; RECEPTOR; REPRODUCTIVE DEVELOPMENT; REPRODUCTIVE TOXICITY; REPRODUCTIVE-SYSTEM; signaling; SPERM; SPERM COUNTS; SPERMATOGENESIS; SPRAGUE-DAWLEY RATS; SRY-RELATED GENE; SYSTEM; TESTICULAR TOXICITY; TOXICITY; toxicology; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>12</startpage>
    <endpage>20</endpage>
    <journalfull>Biochip Journal</journalfull>
    <issue>1</issue>
    <volume>3</volume>
    <abstract>Estrogenic environmental compounds (xenoestrogens) have adverse effects on male reproductive systems, including decreased sperm counts and problems with reproductive development. Although the male reproductive toxicity induced by xenoestrogens has been investigated, the molecular mechanisms by which estrogenic compounds induce toxicity in testes are unclear. This study used a microarray analysis to examine testicular toxicity and gene expression profiles in mice after 30 days of exposure to two estrogenic compounds, bisphenol A (BPA) and nonylphenol (NP). In total, 275 and 729 genes were identified as being either up- or down-regulated, with over 1.5-fold changes, in the testes of the BPA and NP-treated groups, respectively. Differentially expressed genes were classified using a k-means clustering algorithm, and their biological functions and canonical pathways were further analyzed using Ingenuity Pathways Analysis (IPA). Toxicological function analysis characterized the mode of action according to BPA and NP. Pathway analysis identified genes involved in gluconeogenesis and calcium signaling in the BPA-treated group and genes involved in Wnt/beta-catenin and estrogen receptor signaling in the NP-treated group. In addition, several differentially expressed genes that may play a role in spermatogenesis, such as Odf1 and the Sox family, were identified. Collectively, these data help to elucidate the molecular mechanism of reproductive toxicity induced by xenoestrogens</abstract>
    <url>WOS:000264435600002</url>
    <isbnorissn>1976-0280</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>397</id>
    <title>In vitro estrogenic and antiestrogenic potential of chlorostyrenes</title>
    <authors>Oh,S.M.; Kim,H.R.; Chung,K.H.</authors>
    <availability>[Oh, Seung Min; Kim, Ha Ryong; Chung, Kyu Hyuck] Sungkyunkwan Univ, Coll Pharm, Suwon 440746, Gyeonggi Do, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleChung, KH (reprint author), Sungkyunkwan Univ, Coll Pharm, 300 Cheoncheondong, Suwon 440746, Gyeonggi Do, South Koreakhchung@skku.eduArcaro KF, 1999, TOXICOLOGY, V133, P115, DOI 10.1016/S0300-483X(99)00018-9; Bester K, 1998, CHEMOSPHERE, V37, P2459, DOI 10.1016/S0045-6535(98)00302-6; Bradford M.M., 1976, ANAL BIOCHEM, V72, P254; BRADLOW HL, 1996, J ENDOCRINOL, V150, pS529; CAREY JH, 1986, WATER POLL RES J CAN, V21, P309; DANNAN GA, 1986, ENDOCRINOLOGY, V118, P1952; de Solla SR, 1998, ENVIRON HEALTH PERSP, V106, P253, DOI 10.1289/ehp.98106253; Drenth HJ, 1998, TOXICOL APPL PHARM, V148, P50, DOI 10.1006/taap.1997.8307; Folmar LC, 1996, ENVIRON HEALTH PERSP, V104, P1096, DOI 10.2307/3433123; FRY DM, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432528; KAMINSKY R, 1983, J GREAT LAKES RES, V9, P183; Koohi MK, 2007, MOL CELL ENDOCRINOL, V276, P45, DOI 10.1016/j.mce.2007.06.008; Korach K. S., 1997, ENDOCRINE TOXICOLOGY, P181; KUEHL DW, 1976, B ENVIRON CONTAM TOX, V16, P127, DOI 10.1007/BF01685217; KUEHL DW, 1983, J GREAT LAKES RES, V7, P330; Li HX, 2003, ENVIRON SCI TECHNOL, V37, P832, DOI 10.1021/es026215l; LUNDE G, 1976, J ANAL CHEM+, V282, P395; Machala M, 1998, VET MED-CZECH, V43, P311; Mamaca E, 2005, AQUAT TOXICOL, V75, P191, DOI 10.1016/j.aquatox.2005.08.001; Navas JM, 1998, ENVIRON SCI POLLUT R, V5, P75, DOI 10.1007/BF02986390; NIRA BJ, 1999, MOL BIOL TOXIC RESPO, P285; OLEA N, 1996, ENV HLTH PERSPECT, V104, P198; Perez P, 1998, ENVIRON HEALTH PERSP, V106, P167, DOI 10.1289/ehp.98106167; PORTER W, 1999, MOL BIOL TOXIC RESPO, P269; RAMDAHL T, 1986, SCI TOTAL ENVIRON, V48, P147, DOI 10.1016/S0048-9697(86)80001-8; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925; SAFE SH, 1994, CRIT REV TOXICOL, V24, P87, DOI 10.3109/10408449409049308; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; SCHNEIDER J, 1984, J BIOL CHEM, V259, P4840; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K; Steinmetz R, 1996, CANCER RES, V56, P5403; STEINWANDTER H, 1983, FRESEN Z ANAL CHEM, V316, P705, DOI 10.1007/BF00488433; SUCHAR LA, 1995, J PHARMACOL EXP THER, V272, P197; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; Sumpter JP, 1995, TOXICOL LETT, V82-3, P737, DOI 10.1016/0378-4274(95)03517-6; TOPPARI J, 1996, ENVIRON HEALTH PER S, V104, P743; US Environmental Protection Agency (US EPA), 1998, END DISR SCREEN TEST; *US EPA, 2000, US ENV PROT AG DRAFT; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yamasaki K, 2002, TOXICOLOGY, V170, P21, DOI 10.1016/S0300-483X(01)00505-4; Zhang S, 2005, J MOL ENDOCRINOL, V35, P433, DOI 10.1677/jme.1.01858491PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROOCTDiscipline: Toxicology511NF</notes>
    <keywords>1; Anti-/estrogenic activity; Aromatase; Aromatase activity; ASSAY; BIOASSAY; BISPHENOL-A; BREAST-CANCER-CELLS; CANCER; CELL; CHEMICALS; Chlorostyrene; E-2 metabolism; E-SCREEN; E-SCREEN ASSAY; E2; ENDOCRINE; environment; ER-ALPHA; ESTROGENIC ACTIVITIES; estrogenic activity; FISH; GENE; GENE-EXPRESSION; HEALTH; In vitro; IN-VITRO; inhibition; MCF-7 CELLS; METABOLISM; p21; PATHWAY; POLYCHLORINATED STYRENES; RISK-ASSESSMENT; SYSTEM; toxicology; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1242</startpage>
    <endpage>1248</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>7</issue>
    <volume>23</volume>
    <abstract>Chlorostyrenes (CSs) are primarily derived from industrial by-products and are persistent and accumulative in the environment. In this study, the estrogenic and antiestrogenic activities of CSs (0-CS, m-CS, P-CS, DiCS, octa-CS) were evaluated using in vitro bioassays. o-CS and octa-CS have both estrogenic and antiestrogenic activity in the E-SCREEN assay and the ERE-reporter gene assay, indicating effects on a classical ER-mediated pathway. m-CS showed estrogenic activity in E-SCREEN but not in ERE-reporter gene assays, indicating that it may work through a non-classical ER-mediated pathway. Finally, DiCS only showed antiestrogenic activity via an ER-independent pathway, which can be induced by depletion of endogenous E-2 level by the inhibition of aromatase activity and the stimulation of E2 metabolism. Although CSs have structural similarities to dioxins/furans, they did not have AhR agonist effects. This study is the first to show the estrogenic and antiestrogenic activity of several CSs using in vitro bioassay systems, including whether the compounds work via ER-mediated or/and non-ER-mediated pathways. (C) 2009 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000271171500006</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>334</id>
    <title>Estrogen Stimulates Proliferation and Differentiation of Neural Stem/Progenitor Cells through Different Signal Transduction Pathways</title>
    <authors>Okada,M.; Makino,A.; Nakajima,M.; Okuyama,S.; Furukawa,S.; Furukawa,Y.</authors>
    <availability>[Okada, Makiko; Makino, Akihisa; Furukawa, Shoei; Furukawa, Yoshiko] Gifu Pharmaceut Univ, Dept Biofunct Anal, Mol Biol Lab, Gifu, Japan. [Nakajima, Mitsunari; Okuyama, Satoshi; Furukawa, Yoshiko] Matsuyama Univ, Fac Pharmaceut Sci, Dept Pharmaceut Pharmacol, Matsuyama, Ehime, Japan.</availability>
    <date>2010</date>
    <notes>JEnglishArticleFurukawa, Y (reprint author), Gifu Pharmaceut Univ, Dept Biofunct Anal, Mol Biol Lab, Gifu, Japanmiyufreia@yahoo.co.jp; makino-akihisa@jpo.go.jp; mnakajim@cc.matsuyama-u.ac.jp; sokuyama@cc.matsuyama-u.ac.jp; furukawa@gifu-pu.ac.jp; furukawa@cc.matsuyama-u.ac.jpBEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bouskine A, 2008, ENDOCRINOLOGY, V149, P565, DOI 10.1210/en.2007-1318; Brannvall K, 2002, MOL CELL NEUROSCI, V21, P512, DOI 10.1006/mcne.2002.1194; Brannvall K, 2005, EUR J NEUROSCI, V21, P871, DOI 10.1111/j.1460-9568.2005.03942.x; Dominguez R, 2004, J NEUROSCI, V24, P982, DOI 10.1523/JNEUROSCI.2586-03.2004; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Furukawa Y, 2010, BIOMED RES-TOKYO, V31, P45; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; Imitola Jaime, 2008, V438, P9, DOI 10.1007/978-1-59745-133-8_2; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; LEBESQUE D, 2010, PLOS ONE, V30, P12950; Lovell-Badge R, 2001, NATURE, V414, P88, DOI 10.1038/35102150; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; MCEVEN B, 2002, RECENT PROG HORM RES, V57, P357; MENDELSOHN EM, 2010, J CLIN INVEST, V120, P2277; Okada M, 2008, BIOMED RES-TOKYO, V29, P163, DOI 10.2220/biomedres.29.163; Qiu J, 2006, J NEUROSCI, V26, P5649, DOI 10.1523/JNEURSCI.0327-06.2006; Samuels IS, 2008, J NEUROSCI, V28, P6983, DOI 10.1523/JNEUROSCI.0679-08.2008; Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Titolo D, 2008, J NEUROSCI, V28, P6473, DOI 10.1523/JNEUROSCI.0514-08.2008; Toran-Allerand CD, 2004, ENDOCRINOLOGY, V145, P1069, DOI 10.1210/en.2003-1462; WAKELING AE, 1991, CANCER RES, V51, P3867; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Zhao LQ, 2006, J PHARMACOL EXP THER, V319, P1124, DOI 10.1124/jpet.106.1095042717MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J MOL SCIOCTDiscipline: Chemistry672LK</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; Antagonist; ANTIESTROGEN; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELL; CELLS; differeciation; Differentiation; embryo; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic activity; ESTROGENS; FUTURE; G-PROTEIN; KINASE; kinases; mechanism; neural stem cell; Neurogenesis; NEURONS; oligodendrocytes; PATHWAY; proliferation; RAT; RECEPTOR; Receptors; serum; Signal transduction; signal transduction pathways; STEM-CELLS; STEM/PROGENITOR CELLS; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>4114</startpage>
    <endpage>4123</endpage>
    <journalfull>International Journal of Molecular Sciences</journalfull>
    <issue>10</issue>
    <volume>11</volume>
    <abstract>Our previous study indicated that both 17 beta-estradiol (E2), known to be an endogenous estrogen, and bisphenol A (BPA), known to be a xenoestrogen, could positively influence the proliferation or differentiation of neural stem/progenitor cells (NS/PCs). The aim of the present study was to identify the signal transduction pathways for estrogenic activities promoting proliferation and differentiation of NS/PCs via well known nuclear estrogen receptors (ERs) or putative membrane-associated ERs. NS/PCs were cultured from the telencephalon of 15-day-old rat embryos. In order to confirm the involvement of nuclear ERs for estrogenic activities, their specific antagonist, ICI-182,780, was used. The presence of putative membrane-associated ER was functionally examined as to whether E2 can activate rapid intracellular signaling mechanism. In order to confirm the involvement of membrane-associated ERs for estrogenic activities, a cell-impermeable E2, bovine serum albumin-conjugated E2 (E2-BSA) was used. We showed that E2 could rapidly activate extracellular signal-regulated kinases 1/2 (ERK 1/2), which was not inhibited by ICI-182,780. ICI-182,780 abrogated the stimulatory effect of these estrogens (E2 and BPA) on the proliferation of NS/PCs, but not their effect on the differentiation of the NS/PCs into oligodendroglia. Furthermore, E2-BSA mimicked the activity of differentiation from NS/PCs into oligodendroglia, but not the activity of proliferation. Our study suggests that (1) the estrogen induced proliferation of NS/PCs is mediated via nuclear ERs; (2) the oligodendroglial generation from NS/PCs is likely to be stimulated via putative membrane-associated ERs</abstract>
    <url>WOS:000283584500035</url>
    <isbnorissn>1422-0067</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>5</id>
    <title>Epigenome: Biosensor of Cumulative Exposure to Chemical and Nonchemical Stressors Related to Environmental Justice</title>
    <authors>Olden,K.; Lin,Y.S.; Gruber,D.; Sonawane,B.</authors>
    <availability>[Olden, Kenneth; Lin, Yu-Sheng; Sonawane, Babasaheb] US EPA, Natl Ctr Environm Assessment, Off Res &amp; Dev, Washington, DC 20460 USA. [Gruber, David] CUNY Bernard M Baruch Coll, Dept Nat Sci, New York, NY 10010 USA.</availability>
    <date>2014</date>
    <notes>JEnglishEditorial MaterialOlden, K (reprint author), US EPA, Natl Ctr Environm Assessment, Off Res &amp; Dev, Washington, DC 20460 USAolden.kenneth@epa.govAlonso-Magdalena P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002069; Baastrup R, 2008, ENVIRON HEALTH PERSP, V116, P231, DOI 10.1289/ehp.10623; Bailey KA, 2013, J BIOCHEM MOL TOXIC, V27, P106, DOI 10.1002/jbt.21462; Balazs CL, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-84; Beck S, 2008, TRENDS GENET, V24, P231, DOI 10.1016/j.tig.2008.01.006; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bullard RD, 2000, DUMPING IN DIXIE RAC; Burdge GC, 2010, ANNU REV NUTR, V30, P315, DOI 10.1146/annurev.nutr.012809.104751; Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030; Chen H, 2004, CARCINOGENESIS, V25, P1779, DOI 10.1093/carcin/bgh161; Chung CJ, 2013, ENVIRON RES, V122, P25, DOI 10.1016/j.envres.2012.11.007; Clark LP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094431; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; da Huang W, 2009, NAT PROTOC, V4, P44, DOI DOI 10.1038/NPR0T.2008.211; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Freudenberg N, 2010, AM J PUBLIC HEALTH, V100, pS25, DOI 10.2105/AJPH.2009.166389; Fry RC, 2007, PLOS GENET, V3, P2180, DOI 10.1371/journal.pgen.0030207; Gallou-Kabani C, 2005, DIABETES, V54, P1899, DOI 10.2337/diabetes.54.7.1899; Gee GC, 2004, ENVIRON HEALTH PERSP, V112, P1645, DOI 10.1289/ehp.7074; Guo HR, 2007, ENVIRON HEALTH PERSP, V115, pA339, DOI 10.1289/ehp.9927; Guo HR, 2007, ENV HLTH PERSPECT, V115, pA340; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Institute of Medicine (IOM), 2006, GENES BEHAVIOR AND T; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kuroda A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006953; Lin Y S, 2005, Occup Environ Med, V62, P750, DOI 10.1136/oem.2004.013102; Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Litt JS, 2002, ENVIRON HEALTH PERSP, V110, P183; Loenen WAM, 2006, BIOCHEM SOC T, V34, P330; Madrigano J, 2012, EPIGENETICS-US, V7, P63, DOI 10.4161/epi.7.1.18749; Mass MJ, 1997, MUTAT RES-REV MUTAT, V386, P263, DOI 10.1016/S1383-5742(97)00008-2; McEwen BS, 2012, P NATL ACAD SCI USA, V109, P17180, DOI 10.1073/pnas.1121254109; Meaney Michael J, 2005, Dialogues Clin Neurosci, V7, P103; Mill J, 2013, NAT REV GENET, V14, P585, DOI 10.1038/nrg3405; Moon K, 2012, CURR ATHEROSCLER REP, V14, P542, DOI 10.1007/s11883-012-0280-x; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Murray CJL, 2006, PLOS MED, V3, P1513, DOI 10.1371/journal.pmed.0030260; National Center for Environmental Health, 2013, THE FOURTH NATIONAL; Nelson JW, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-10; Office of Minority Health, HEALTH AND HUMAN SER; Olden Kenneth, 2011, N C Med J, V72, P125; Olden K, 2007, INT J EPIDEMIOL, V36, P18, DOI 10.1093/ije/dyl292; Olden K, 2009, GENOMIC AND PERSONALIZED MEDICINE, VOL 1, P47, DOI 10.1016/B978-0-12-369420-1.00004-4; Park JH, 2008, J CLIN INVEST, V118, P2316, DOI [10.1172/JCI33655, 10.1172/JC133655]; Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P626, DOI 10.1289/ehp.6617; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Reichard JF, 2007, BIOCHEM BIOPH RES CO, V352, P188, DOI 10.1016/j.bbrc.2006.11.001; Rossman TG, 2003, MUTAT RES-FUND MOL M, V533, P37, DOI 10.1016/j.mrfmmm.2003.07.009; Schober SE, 2006, ENVIRON HEALTH PERSP, V114, P1538, DOI 10.1289/ehp.9123; Sciandrello G, 2004, CARCINOGENESIS, V25, P413, DOI 10.1093/carcin/bgh029; Slonim DK, 2002, NAT GENET, V32, P502, DOI 10.1038/ng1033; Stranger BE, 2011, GENETICS, V187, P367, DOI 10.1534/genetics.110.120907; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Talmud PJ, 2002, CURR OPIN LIPIDOL, V13, P149, DOI 10.1097/00041433-200204000-00006; Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Wild CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/ije/dyr236; Wilhelm M, 2003, ENVIRON HEALTH PERSP, V111, P207, DOI 10.1289/ehp.5688; Wolff GL, 1998, FASEB J, V12, P949; Wren JD, 2005, J BIOMED BIOTECHNOL, P104, DOI 10.1155/JBB.2005.104; Zhang FF, 2011, EPIGENETICS-US, V6, P293650AMER PUBLIC HEALTH ASSOC INCWASHINGTON800 I STREET, NW, WASHINGTON, DC 20001-3710 USAAM J PUBLIC HEALTHOCTDiscipline: Public, Environmental &amp; Occupational HealthAP1XG</notes>
    <keywords>ARSENIC EXPOSURE; BIRTH OUTCOMES; BISPHENOL-A; CANCER; DNA METHYLATION; DRINKING-WATER; EPIGENETIC EPIDEMIOLOGY; epigenetics; EXPOSURE; GENE-EXPRESSION; HUMAN-DISEASE; MAMMALIAN-CELLS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1816</startpage>
    <endpage>1821</endpage>
    <journalfull>American Journal of Public Health</journalfull>
    <issue>10</issue>
    <volume>104</volume>
    <abstract>Understanding differential disease susceptibility requires new tools to quantify the cumulative effects of environmental stress. Evidence suggests that social, physical, and chemical stressors can influence disease through the accumulation of epigenetic modifications. Geographically stable epigenetic alterations could identify plausible mechanisms for health disparities among the disadvantaged and poor. Relations between neighborhoodspecific epigenetic markers and disease would identify the most appropriate targets for medical and environmental intervention. Complex interactions among genes, the environment, and disease require the examination of how epigenetic changes regulate susceptibility to environmental stressors. Progress in understanding disparities in disease susceptibility may depend on assessing the cumulative effect of environmental stressors on genetic substrates. We highlight key concepts regarding the interface between environmental stress, epigenetics, and chronic disease</abstract>
    <url>WOS:000341865000021</url>
    <isbnorissn>0090-0036</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>18</id>
    <title>Dietary Exposure of Nigerians to Mutagens and Estrogen-Like Chemicals</title>
    <authors>Omoruyi,I.M.; Ahamioje,D.; Pohjanvirta,R.</authors>
    <availability>[Omoruyi, Iyekhoetin Matthew; Pohjanvirta, Raimo] Univ Helsinki, Fac Vet Med, Dept Food &amp; Environm Hyg, Food &amp; Environm Toxicol Unit, FIN-00014 Helsinki, Finland. [Omoruyi, Iyekhoetin Matthew; Ahamioje, Derek] Benson Idahosa Univ, Fac Basic &amp; Appl Sci, Dept Basic Sci, Benin, Edo State, Nigeria.</availability>
    <date>2014</date>
    <notes>JEnglishArticleOmoruyi, IM (reprint author), Univ Helsinki, Fac Vet Med, Dept Food &amp; Environm Hyg, Food &amp; Environm Toxicol Unit, POB 66, FIN-00014 Helsinki, Finlandmatthew.omoruyi@helsinki.fi; dahamioje@biu.edu.ng; raimo.pohjanvirta@helsinki.fiAlli L.A., 2013, INT J HLTH NUTR, V4, P15; Alomirah H, 2010, FOOD ADDIT CONTAM A, V27, P869, DOI 10.1080/19440040903493793; Anderson KE, 2002, MUTAT RES-FUND MOL M, V506, P225, DOI 10.1016/S0027-5107(02)00169-0; [Anonymous], 2010, OLIVES OLIVE OIL HLT, P989; Barber LB, 2000, ACS SYM SER, V747, P97; Behr M, 2011, FOOD CHEM TOXICOL, V49, P2681, DOI 10.1016/j.fct.2011.07.039; Bourguignon J.P., 2010, CURR OPIN PEDIATR, V324, P110; Carmichael S.L., 2011, NUTR J, V10, P1; CARRIERE V, 1992, MUTAT RES, V268, P11, DOI 10.1016/0027-5107(92)90077-F; Chukuezi CO, 2010, STUDIES SOCIOLOGY SC, V1, P50; Chung SY, 2011, FOOD CHEM, V129, P1420, DOI 10.1016/j.foodchem.2011.05.092; Cross AJ, 2004, ENVIRON MOL MUTAGEN, V44, P44, DOI 10.1002/em.20030; Dabrowska A, 2003, FOOD ADDIT CONTAM, V20, P1170, DOI 10.1080/02652030310001620441; Diamanti-Kandarakis F.E., 2009, ENDOCR REV, V30, P293; Djinovic J, 2008, MEAT SCI, V80, P449, DOI 10.1016/j.meatsci.2008.01.008; Emeje M.O., 2009, AFR J FOOD SCI, V4, P394; Essumang DK, 2012, J FOOD COMPOS ANAL, V27, P128, DOI 10.1016/j.jfca.2012.04.007; Farhadian A, 2011, FOOD CHEM, V124, P141, DOI 10.1016/j.foodchem.2010.05.116; Ferguson LR, 2002, MUTAT RES-FUND MOL M, V506, P215, DOI 10.1016/S0027-5107(02)00168-9; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; Gabbani G, 1998, MUTAGENESIS, V13, P187, DOI 10.1093/mutage/13.2.187; Grover PL, 2002, CARCINOGENESIS, V23, P1095, DOI 10.1093/carcin/23.7.1095; Hartmann S, 1998, FOOD CHEM, V62, P7, DOI 10.1016/S0308-8146(97)00150-7; Howard G, 2003, DOMESTIC WATER QUANT; Isidori M, 2009, FOOD SCI TECHNOL INT, V15, P267, DOI 10.1177/1082013209341424; Iwasaki M, 2010, J FOOD COMPOS ANAL, V23, P61, DOI 10.1016/j.jfca.2009.07.004; Jagerstad M, 1998, Z LEBENSM UNTERS F A, V207, P419, DOI 10.1007/s002170050355; Jedy-Agba E., 2012, CANCER EPIDEMIOL, V36, P271; John EM, 2011, NUTR CANCER, V63, P525, DOI 10.1080/01635581.2011.539311; KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7; Kobayashi M, 2009, GASTRIC CANCER, V12, P198, DOI 10.1007/s10120-009-0523-x; Laio G.Z., 2010, MEAT SCI, V85, P149; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Leskinen P, 2005, CHEMOSPHERE, V61, P259, DOI 10.1016/j.chemosphere.2005.01.080; Li X, 2010, ENVIRON INT, V36, P557, DOI 10.1016/j.envint.2010.04.009; Liao GZ, 2012, FOOD ADDIT CONTAM A, V29, P1668, DOI 10.1080/19440049.2012.702928; Liu KJ, 2005, BIOL REPROD, V73, P180, DOI 10.1095/biolreprod.104.039404; Marchand L.L., 2002, MUTAT RES, V506, P205; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; Matos E, 2002, MUTAT RES-FUND MOL M, V506, P243, DOI 10.1016/S0027-5107(02)00171-9; Mensah P., 2002, B WORLD HEALTH ORGAN, V80, P7; Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6; Muinde O.K., 2005, AFR J FOOD AGR NUTR, V5, P46; Muncke J, 2011, J STEROID BIOCHEM, V127, P118, DOI 10.1016/j.jsbmb.2010.10.004; Muncke Jane, 2009, Sci Total Environ, V407, P4549, DOI 10.1016/j.scitotenv.2009.05.006; Nakagawa Y, 2000, TOXICOLOGY, V156, P27, DOI 10.1016/S0300-483X(00)00329-2; Navarro A, 2004, NUTRITION, V20, P873, DOI 10.1016/j.nut.2004.06.008; Ojeka E. O., 2006, Journal of Applied Sciences and Environmental Management, V10, P43; Omemu AM, 2008, FOOD CONTROL, V19, P396, DOI 10.1016/j.foodcont.2007.04.021; Omoruyi IM, 2013, FOOD ADDIT CONTAM A, V30, P1722, DOI 10.1080/19440049.2013.817025; Omoruyi IM, 2014, FOOD CHEM, V162, P206, DOI 10.1016/j.foodchem.2014.04.055; Peters U, 2004, ENVIRON MOL MUTAGEN, V43, P53, DOI 10.1002/em.10205; Pinto B, 2009, INT J HYG ENVIR HEAL, V212, P228, DOI 10.1016/j.ijheh.2008.06.004; Plotan M, 2013, FOOD CHEM, V136, P1590, DOI 10.1016/j.foodchem.2012.01.115; Rajasarkka J., 2011, COMBIN CHEM HIGH THR, V14, P1; Roig B, 2013, CRIT REV ENV SCI TEC, V43, P2297, DOI 10.1080/10643389.2012.672076; Sinha R, 1999, CANCER LETT, V143, P189, DOI 10.1016/S0304-3835(99)00123-8; Srivastava S, 2010, BRIT J NUTR, V104, P1343, DOI 10.1017/S0007114510002229; STAVRIC B, 1995, FOOD CHEM TOXICOL, V33, P815, DOI 10.1016/0278-6915(95)00047-6; Stumpe-Viksna I, 2008, FOOD CHEM, V110, P794, DOI 10.1016/j.foodchem.2008.03.004; ter Veld MGR, 2006, J AGR FOOD CHEM, V54, P4407, DOI 10.1021/jf052864f; Thompson C, 2005, MUTAGENESIS, V20, P345, DOI 10.1093/mutage/gei045; Thompson LU, 2006, NUTR CANCER, V54, P184, DOI 10.1207/s15327914nc5402_5; TIKKANEN LM, 1991, FOOD CHEM TOXICOL, V29, P87, DOI 10.1016/0278-6915(91)90161-Y; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Voskuil DW, 2002, EUR J CANCER, V38, P2300, DOI 10.1016/S0959-8049(02)00455-0; Wagner M, 2011, J STEROID BIOCHEM, V127, P128, DOI 10.1016/j.jsbmb.2010.10.007; Wagner M, 2009, ENVIRON SCI POLLUT R, V16, P278, DOI 10.1007/s11356-009-0107-7; Westerhoff P., 2008, WATER RES, V42, P552; Willet W., 1998, NUTR EPIDEMIOLOGY; Wretling S, 2010, J FOOD COMPOS ANAL, V23, P264, DOI 10.1016/j.jfca.2009.10.003; Zama AM, 2010, FRONT NEUROENDOCRIN, V31, P420, DOI 10.1016/j.yfrne.2010.06.003720MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J ENV RES PUB HEAUGDiscipline: Environmental Sciences &amp; EcologyAO1UX</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CHEMICALS; COLORECTAL-CANCER; Endocrine-disrupting chemicals; ESTRADIOL; estrogenic activity; EXPOSURE; HETEROCYCLIC AMINES; In vitro; IN-VITRO; MEAT CONSUMPTION; mutagenicity; PET BOTTLES; POLYCYCLIC AROMATIC-HYDROCARBONS; PROCESSED FOOD; PROSTATE-CANCER; pure water sachet; RED MEAT; TESTICULAR DYSGENESIS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>8347</startpage>
    <endpage>8367</endpage>
    <journalfull>International Journal of Environmental Research and Public Health</journalfull>
    <issue>8</issue>
    <volume>11</volume>
    <abstract>Food and drinking water are poorly delineated sources of human exposure to chemical food mutagens and endocrine-disrupting chemicals. In this study, we investigated the presence of mutagens and chemicals exhibiting estrogenic activity in the daily diet of Nigerians, using in vitro assays. Commercially processed foods or snacks and various brands of pure water sachets were extracted by solid-phase extraction and liquid-liquid extraction, respectively. Mutagenicity was determined by the conventional Ames test and two complementary assays on two strains of Salmonella (TA 100 and TA 98), while the estrogenic activity was assessed by a yeast bioluminescent assay, using two recombinant yeast strains (Saccharomyces cerevisiae BMAEREluc/ER alpha and S. cerevisiae BMA64/luc). A third of the food varieties investigated (chin-chin, hamburger, suya and bean cake) were mutagenic in all three assays, either in the presence or absence of S9 mix. Of the packed water samples, five out of the sixteen investigated (31%), were found to be estrogenic, with estradiol and bisphenol A equivalents ranging from 0.79 to 44.0 ng/L and 124.2 to 1,000.8 ng/L, respectively. Hence, although the current situation in Nigeria does not appear to be substantially worse than, e.g., in Europe, regular monitoring is warranted in the future</abstract>
    <url>WOS:000341101700048</url>
    <isbnorissn>1660-4601</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>357</id>
    <title>Effect of Bisphenol A on the Comprehensive DNA Recognition Profile of Estrogen-Related Receptor. and Estrogen Receptor alpha in Breast Cancer Cells</title>
    <authors>Ozers,M.S.; Warren,C.L.; Shull,J.D.</authors>
    <availability>[Ozers, M. S.; Warren, C. L.; Shull, J. D.] Univ Wisconsin, Madison, WI USA.</availability>
    <date>2010</date>
    <notes>JEnglishMeeting AbstractDairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Riggins RB, 2008, CANCER RES, V68, P8908, DOI 10.1158/0008-5472.CAN-08-266930ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCR REVJUN1Discipline: Endocrinology &amp; Metabolism652FV</notes>
    <keywords>ALPHA; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; ENDOCRINE; ERR-GAMMA; Estrogen; Estrogen receptor; Estrogen receptor alpha; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; JUN; METABOLISM; RECEPTOR; RECEPTOR-ALPHA; RECOGNITION</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Endocrine Reviews</journalfull>
    <issue>3</issue>
    <volume>31</volume>
    <url>WOS:000281989402064</url>
    <isbnorissn>0163-769X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>400</id>
    <title>Troglitazone Inhibits Vascular Endothelial Growth Factor-Induced Angiogenic Signaling via Suppression of Reactive Oxygen Species Production and Extracellular Signal-Regulated Kinase Phosphorylation in Endothelial Cells</title>
    <authors>Park,B.C.; Thapa,D.; Lee,J.S.; Park,S.Y.; Kim,J.A.</authors>
    <availability>[Park, Byung Chul; Thapa, Dinesh; Lee, Jong Suk; Park, Su-Young; Kim, Jung-Ae] Yeungnam Univ, Coll Pharm, Gyongsan 712749, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleKim, JA (reprint author), Yeungnam Univ, Coll Pharm, Gyongsan 712749, South Koreajakim@ynu.ac.krBishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Borbath I, 2007, EUR J CANCER, V43, P1755, DOI 10.1016/j.ejca.2007.05.005; Cao YH, 1996, J BIOL CHEM, V271, P29461; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chintalgattu V, 2007, CARDIOVASC RES, V74, P140, DOI 10.1016/j.cardiores.2007.01.010; Chu K, 2006, BRAIN RES, V1093, P208, DOI 10.1016/j.brainres.2006.03.014; Cui YH, 2007, EUR J CANCER, V43, P2590, DOI 10.1016/j.ejca.2007.08.015; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Game BA, 2003, ATHEROSCLEROSIS, V169, P235, DOI 10.1016/S0021-9150(03)00165-5; Garg R, 2000, HYPERTENSION, V36, P430; Ghanim H, 2001, J CLIN ENDOCR METAB, V86, P1306, DOI 10.1210/jc.86.3.1306; Goetze S, 2002, HYPERTENSION, V40, P748, DOI 10.1161/01.HYP.0000035522.63647.D3; Gralinski MR, 1998, J CARDIOVASC PHARM, V31, P909, DOI 10.1097/00005344-199806000-00015; Grote K, 2003, CIRC RES, V92, P80; Guo W, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743-7075-3-30; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hsueh WA, 2001, ARTERIOSCL THROM VAS, V21, P1891, DOI 10.1161/hq1201.100261; Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Jozkowicz A, 2000, ACTA BIOCHIM POL, V47, P1147; Jung JY, 2007, TOXICOLOGY, V234, P73, DOI 10.1016/j.tox.2007.02.005; Kang DW, 2008, NEUROCHEM RES, V33, P551, DOI 10.1007/s11064-007-9475-x; Kim HJ, 2006, BIOCHEM BIOPH RES CO, V349, P660, DOI 10.1016/j.bbrc.2006.08.085; Kim KH, 2007, FEBS LETT, V581, P3303, DOI 10.1016/j.febslet.2007.06.012; Kim MS, 2003, CANCER RES, V63, P5454; Kliche S, 2001, IUBMB LIFE, V52, P61, DOI 10.1080/15216540252774784; Konturek PC, 2004, J PHARMACOL SCI, V96, P134, DOI 10.1254/jphs.FPJ04016X; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Liu JJ, 2005, CANCER CHEMOTH PHARM, V56, P400, DOI 10.1007/s00280-005-1029-9; Maeyama K, 2005, J PHARMACOL SCI, V97, P190, DOI 10.1254/jphs.FMJ04008X6; Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546; Marx N, 1998, CIRC RES, V83, P1097; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163; Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Saunders WB, 2005, J CELL SCI, V118, P2325, DOI 10.1242/jcs.02360; Sheu WHH, 2006, LIFE SCI, V78, P1520, DOI 10.1016/j.lfs.2005.07.046; Sun H, 2008, CANCER RES, V68, P2912, DOI 10.1158/0008-5472.CAN-07-2305; Takada I, 2005, J PHARMACOL SCI, V97, P184, DOI 10.1254/jphs.FMJ04008X5; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Tojo T, 2005, CIRCULATION, V111, P2347, DOI 10.1161/01.CIR.0000164261.62586.14; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665; Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60; Yoshimoto K., 2005, NUCL ACIDS S SER, P255, DOI 10.1093/nass/49.1.255; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216539JAPANESE PHARMACOLOGICAL SOCKYOTOEDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPANJ PHARMACOL SCISEPDiscipline: Pharmacology &amp; Pharmacy501IR</notes>
    <keywords>1; ACTIVATED-RECEPTOR-GAMMA; AGENTS; ANGIOGENESIS; Antagonist; ATHEROSCLEROSIS; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; Brain; CANCER; CANCER-CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; DRUG DEVELOPMENT; EXPRESSION; extracellular signal-regulated kinase (ERK); GROWTH; GROWTH-FACTOR; In vitro; in vivo; IN-VITRO; IN-VIVO; INHIBITOR; INVASION; KINASE; LIGAND; LIGANDS; matrix metalloproteinase (MMP); matrix metalloproteinases; MATRIX-METALLOPROTEINASE; mechanism; METABOLISM; MODEL; molecular mechanism; NAD(P)H OXIDASE; NUCLEAR RECEPTORS; OXYGEN; PHARMACOLOGY; PHOSPHORYLATION; PPAR; PPAR gamma; PPAR gamma agonist; PPAR-gamma; proliferation; Reactive oxygen species; reactive oxygen species (ROS); RECEPTOR; RECEPTOR-GAMMA; signaling; SMOOTH-MUSCLE-CELLS; SUPPRESSION; SYSTEM; toxicology; troglitazone; UP-REGULATION; vascular endothelial growth factor; VITRO; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1</startpage>
    <endpage>12</endpage>
    <journalfull>Journal of Pharmacological Sciences</journalfull>
    <issue>1</issue>
    <volume>111</volume>
    <abstract>Thiazolidinediones, peroxisome proliferators-activated receptor gamma (PPAR gamma) ligands, have been recognized as a potential therapeutic agents for the treatment of pathological neovascularization. In the present study, we examined the molecular mechanism by which troglitazone (TROG), a PPAR gamma agonist, exerts its inhibitory action in vascular endothelial growth factor (VEGF)-induced angiogenesis signaling. In an in vitro angiogenesis model using human umbilical vein endothelial cells, TROG (20 mu M) significantly suppressed VEGF-induced cell proliferation and invasion of the cells into the Matrigel basement membrane, which was not reversed by treatment with PPAR antagonists, GW9662 (10 mu M) and bisphenol A diglycidyl ether (10 mu M). TROG also blocked VEGF-induced reactive oxygen species (ROS) production and its downstream extracellular signal-regulated kinase (ERK) phosphorylation, and this inhibitory effect was not reversed by GW9662 (10 mu M). The antiangiogenic activity of TROG correlated with suppression of VEGF-induced matrix metalloproteinase (MMP)-2 and membrane type 1 (MT1)-MMP expression. In addition, the effects of TROG on VEGF-induced MMP-2 and MT1-MMP expression were comparable to those of the NADPH oxidase inhibitor diphenylene iodium (10 mu M) and ERK inhibitor PD98056 (10 mu M). Furthermore, in an in vivo angiogenesis system using a chick chorioallantoic membrane model, TROG dose-dependently inhibited VEGF-induced angiogenesis, which was similar to the inhibitory effect of N-acetylcysteine on VEGF-induced angiogenesis. The results suggest that the inhibitory effects of TROG on VEGF-induced angiogenesis were mediated through the suppression of VEGF-induced ROS production and ERK phosphorylation</abstract>
    <url>WOS:000270375600001</url>
    <isbnorissn>1347-8613</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>150</id>
    <title>Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models</title>
    <authors>Park,M.A.; Hwang,K.A.; Lee,H.R.; Yi,B.R.; Jeung,E.B.; Choi,K.C.</authors>
    <availability>[Park, Min-Ah; Hwang, Kyung-A; Lee, Hye-Rim; Yi, Bo-Rim; Jeung, Eui-Bae; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krChoi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; Diamanti-Kandarakis E, 2010, HORM METAB RES, V42, P543, DOI 10.1055/s-0030-1252034; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Gonzalez H, 2006, BRIT J DERMATOL, V154, P337, DOI 10.1111/j.1365-2133.2005.07007.x; Harris HA, 2002, STEROIDS, V67, P379, DOI 10.1016/S0039-128X(01)00194-5; Hayashi T, 2006, TOXICOL LETT, V167, P1, DOI 10.1016/j.toxlet.2006.08.001; Heneweer M, 2005, TOXICOL APPL PHARM, V208, P170, DOI 10.1016/j.taap.2005.02.006; Hofmann PJ, 2009, TOXICOL SCI, V110, P125, DOI 10.1093/toxsci/kfp086; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Janjua NR, 2004, J INVEST DERMATOL, V123, P57, DOI 10.1111/j.0022-202X.2004.22725.x; Jarry H, 2004, TOXICOLOGY, V205, P87, DOI 10.1016/j.tox.2004.06.040; Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887; Kang NH, 2012, INT J ONCOL, V40, P2022, DOI 10.3892/ijo.2012.1372; Kang NH, 2012, CANCER GENE THER, V19, P412, DOI 10.1038/cgt.2012.15; Kashima H, 2009, ENDOCR-RELAT CANCER, V16, P113, DOI 10.1677/ERC-08-0117; Kawamura Y, 2003, J HEALTH SCI, V49, P205, DOI 10.1248/jhs.49.205; Kawamura Y, 2005, J HEALTH SCI, V51, P48, DOI 10.1248/jhs.51.48; Kim KY, 2012, INT J ONCOL, V40, P1097, DOI 10.3892/ijo.2011.1288; Kunz PY, 2006, TOXICOL APPL PHARM, V217, P86, DOI 10.1016/j.taap.2006.07.014; Kunz PY, 2006, TOXICOL SCI, V90, P349, DOI 10.1093/toxsci/kfj082; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2011, J BIOMED RES, V12, P215; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Liu YS, 2012, ENVIRON TOXICOL CHEM, V31, P289, DOI 10.1002/etc.749; Matsumoto H, 2005, YAKUGAKU ZASSHI, V125, P643, DOI 10.1248/yakushi.125.643; Miller D, 2001, ENVIRON HEALTH PERSP, V109, P133, DOI 10.2307/3434765; Molina-Molina JM, 2008, TOXICOL APPL PHARM, V232, P384, DOI 10.1016/j.taap.2008.07.017; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Park MA, 2012, MOL MED REP, V5, P761, DOI 10.3892/mmr.2011.712; Poiger T, 2004, CHEMOSPHERE, V55, P951, DOI 10.1016/j.chemosphere.2004.01.012; Schlecht C, 2008, TOXICOLOGY, V245, P11, DOI 10.1016/j.tox.2007.12.015; Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; Spillman MA, 2010, CANCER RES, V70, P8927, DOI 10.1158/0008-5472.CAN-10-1238; Sumpter JP, 2005, ENVIRON SCI TECHNOL, V39, P4321, DOI 10.1021/es048504a; Suzuki T, 2005, TOXICOL APPL PHARM, V203, P9, DOI 10.1016/j.taap.2004.07.005; Takamiya M, 2007, REPROD TOXICOL, V24, P265, DOI 10.1016/j.reprotox.2007.07.003; Watanabe J, 2007, J STEROID BIOCHEM, V107, P163, DOI 10.1016/j.jsbmb.2007.03.045; Weisbrod CJ, 2007, TOXICOL APPL PHARM, V225, P255, DOI 10.1016/j.taap.2007.08.004; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Yamasaki K, 2003, TOXICOLOGY, V183, P93, DOI 10.1016/S0300-483X(02)00445-6; Yanowitz J, 2005, DEV BIOL, V279, P244, DOI 10.1016/j.ydbio.2004.12.022; Yi BR, 2011, ANTICANCER RES, V31, P2853; Yi BR, 2011, INT J ONCOL, V39, P833, DOI 10.3892/ijo.2011.1126459ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOLOGYMAR 8Discipline: Pharmacology &amp; Pharmacy; Toxicology113DV</notes>
    <keywords>17-BETA-ESTRADIOL; Antagonist; Benzophenone; BISPHENOL-A; BP-1; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; cell cycle; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CYCLE; CYCLE PROGRESSION; CYCLIN D1; DEGRADATION; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruption; Endocrine-disrupting chemicals; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPRESSING CYTOSINE-DEAMINASE; EXPRESSION; GENE-EXPRESSION; GROWTH; HEALTH; In vitro; IN-VITRO; INTERFERON-BETA MIGRATE; mechanism; MODEL; MODELS; Mouse; Ovarian cancer; OVARIAN-CANCER; PHARMACOLOGY; PROGRESSION; proliferation; PROTEIN; RECEPTOR; SIGNALING PATHWAY; STEM-CELLS; toxicology; UP-REGULATION; UV STABILIZERS; VITRO; XENOGRAFT MOUSE MODELS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>41</startpage>
    <endpage>48</endpage>
    <journalfull>Toxicology</journalfull>
    <volume>305</volume>
    <abstract>2,4-Dihydroxybenzophenone (benzophenone-1; BP-1) is an UV stabilizer primarily used to prevent polymer degradation and deterioration in quality due to UV irradiation. Recently, BP-1 has been reported to bioaccumulate in human bodies by absorption through the skin and has the potential to induce health problems including endocrine disruption. In the present study, we examined the xenoestrogenic effect of BP-1 on BG-1 human ovarian cancer cells expressing estrogen receptors (ERs) and relevant xenografted animal models in comparison with 17-beta estradiol (E2). In in vitro cell viability assay, BP-1 (10(-8)-10(-5) M) significantly increased BG-1 cell growth the way E2 did. The mechanism underlying the BG-1 cell proliferation was proved to be related with the up-regulation of cyclin D1, a cell cycle progressor, by E2 or BP-1. Both BP-1 and E2 induced cell growth and up-regulation of cyclin D1 were reversed by co-treatment with ICI 182,780, an ER antagonist, suggesting that BP-1 may mediate the cancer cell proliferation via an ER-dependent pathway like E2. On the other hand, the expression of p21, a regulator of cell cycle progression at G(1) phase, was not altered by BP-1 though it was down-regulated by E2. In xenograft mouse models transplanted with BC-1 cells, BP-1 or E2 treatment significantly increased the tumor mass formation compared to a vehicle (corn oil) within 8 weeks. In histopathological analysis, the tumor sections of E2 or BP-1 group displayed extensive cell formations with high density and disordered arrangement, which were supported by the increased number of BrdUrd positive nuclei and the over-expression of cyclin D1 protein. Taken together, these results suggest that BP-1 is an endocrine disrupting chemical (EDC) that exerts xenoestrogenic effects by stimulating the proliferation of BG-1 ovarian cancer via ER signaling pathway associated with cell cycle as did E2. (C) 2013 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000316647600005</url>
    <isbnorissn>0300-483X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>84</id>
    <title>Effects of 4-Nonylphenol and Bisphenol A on Stimulation of Cell Growth via Disruption of the Transforming Growth Factor-beta Signaling Pathway in Ovarian Cancer Models</title>
    <authors>Park,M.A.; Choi,K.C.</authors>
    <availability>[Park, Min-Ah; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Chongju 361763, Chungbuk, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Chongju 361763, Chungbuk, South Koreakchoi@cbu.ac.krAletti GD, 2007, MAYO CLIN PROC, V82, P751; Band AM, 2011, J MAMMARY GLAND BIOL, V16, P109, DOI 10.1007/s10911-011-9203-7; Band AM, 2012, CELL SIGNAL, V24, P922, DOI 10.1016/j.cellsig.2011.12.015; Bergman CA, 1997, GYNECOL ONCOL, V65, P63, DOI 10.1006/gyno.1997.4614; Cherlet T, 2007, MOL CELL BIOCHEM, V306, P33, DOI 10.1007/s11010-007-9551-1; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Choi KC, 2003, J REPROD DEVELOP, V49, P337, DOI 10.1262/jrd.49.337; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; Deheuninck J, 2009, CELL RES, V19, P47, DOI 10.1038/cr.2008.324; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dimple C, 2008, CANCER RES, V68, P4902, DOI 10.1158/0008-5472.CAN-07-5698; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Gantus MAV, 2011, MOL CELL ENDOCRINOL, V337, P71, DOI 10.1016/j.mce.2011.02.001; Garrett SH, 2002, TOXICOL LETT, V126, P69, DOI 10.1016/S0378-4274(01)00448-9; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hagiwara H, 2008, TOXICOL LETT, V181, P13, DOI 10.1016/j.toxlet.2008.06.863; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hein S, 2009, ONCOL REP, V22, P177, DOI 10.3892/or_00000422; Hennessy BT, 2008, ADV EXP MED BIOL, V617, P23, DOI 10.1007/978-0-387-69080-3_3; Hwang Kyung-A, 2011, Lab Anim Res, V27, P99, DOI 10.5625/lar.2011.27.2.99; Hwang KA, 2013, INT J ONCOL, V42, P733, DOI 10.3892/ijo.2012.1719; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Ito I, 2010, J BIOL CHEM, V285, P14747, DOI 10.1074/jbc.M109.093039; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Lee H. R., 2012, TOXICOLOGY C, V304, P13; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; Lee HR, 2013, J CELL MOL MED, V17, P1, DOI 10.1111/j.1582-4934.2012.01649.x; Lee KY, 2002, J BIOCHEM MOL BIOL, V35, P47; Levy L, 2007, MOL CELL BIOL, V27, P6068, DOI 10.1128/MCB.00664-07; Lukanova A, 2005, CANCER EPIDEM BIOMAR, V14, P98; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; Meier S, 2007, AQUAT TOXICOL, V81, P207, DOI 10.1016/j.aquatox.2006.12.002; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Osada H, 2011, MOL VIS, V17, P159; Park M. A., 2011, MOL MED REP, V5, P761; Park Min-Ah, 2011, Toxicol Res, V27, P253, DOI 10.5487/TR.2011.27.4.253; Park MA, 2013, TOXICOLOGY, V305, P41, DOI 10.1016/j.tox.2012.12.021; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Ren YS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-111; Soares A, 2008, ENVIRON INT, V34, P1033, DOI 10.1016/j.envint.2008.01.004; Stope MB, 2010, BREAST CANCER RES TR, V120, P357, DOI 10.1007/s10549-009-0393-2; Sun H, 2008, CHEMOSPHERE, V71, P582, DOI 10.1016/j.chemosphere.2007.09.031; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; Theriault BL, 2011, CANCER LETT, V313, P108, DOI 10.1016/j.canlet.2011.08.033; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yilmaz M, 2011, EMBO J, V30, P4489, DOI 10.1038/emboj.2011.319; Zhang F, 2003, CANCER RES, V63, P5005550AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USACHEM RES TOXICOLJANDiscipline: Pharmacology &amp; Pharmacy; Chemistry; Toxicology296SG</notes>
    <keywords>4-NONYLPHENOL; apoptosis; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; C-FOS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; CHEMICALS; CYCLE PROGRESSION; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS; EXPRESSION; GLAND; GROWTH; GROWTH-FACTOR; GROWTH-FACTOR-BETA; In vitro; IN-VITRO; inhibition; INHIBITOR; JUN; MAMMARY-GLAND; MODEL; Mouse; Ovarian cancer; OVARIAN-CANCER; PHOSPHORYLATION; proliferation; RECEPTOR; SIGNALING PATHWAY; SMAD3 TRANSCRIPTIONAL ACTIVITY; SNON; TGF-BETA; toxicology; transforming growth factor-beta; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>119</startpage>
    <endpage>128</endpage>
    <journalfull>Chemical Research in Toxicology</journalfull>
    <issue>1</issue>
    <volume>27</volume>
    <abstract>Transforming growth factor beta (TGF-/J) signaling pathway is a major pathway in cellular processes such as cell growth, apoptosis, and cellular homeostasis. The signaling pathway activated by 17/1-estadiol (E2) appeared to inhibit the TGF-beta signaling pathway by cross-talk with the TGF-beta components in estrogen receptor (ER) 'positive cells. In this study, we examined the inhibitory effects of endocrine disrupting chemicals (EDCs), including.4-nonylphenol (NP), 4-otylphenol (OP), bisphenol A (BPA), and benzophenon-1 (BP-I), in the TGF-fi signaling pathway in BG-1 ovarian cancer cells expressing. estrogen receptors (ERs). The.transcriptional and translational levels of TGE-fl related genes were examined by reverse transcription-PCR (12T-PCR), Western blot analysis, and xenograft mouse models of ovarian cancer cells. As a result, treatment with NP, OP, and BPA induced the expressions of SnoN, a TGF-beta pathway inhibitor, and c-Fos, a TGF-fi target transcription factor. Treatment with NP, BPA, and BP-1 resulted in decreased phosphorylation of Smad3, a downstream target of TGE-beta. These results indicate that NP and BPA may stimulate the proliferation of BG-1 cells via inhibition of the TGE-beta signaling pathway. In a xenograft mouse model, transplanted BG-1 ovarian cancer cells showed significantly decreased phosphOrylation of Sm'ad3 and increased expression of SnoN in the ovarian tumor masses following treatment with E2, NP, or BPA.,In'parallel with an in vitro model, the expressions of these TGF-beta signaling pathway were similarly regulated by NP or BPA in a xenograft mouse model. These results support the fact that the existence of an unproven relationship between.EllCs/ER-a and TGF-beta signaling pathway and a further study are required in order to verify more profound and distinct mechanism(s) for the disturbance of the TGF-fi signaling pathway by diverse EllCs</abstract>
    <url>WOS:000330205100013</url>
    <isbnorissn>0893-228X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>436</id>
    <title>Cell Growth of Ovarian Cancer Cells is Stimulated by Xenoestrogens through an Estrogen-Dependent Pathway, but Their Stimulation of Cell Growth Appears not to be Involved in the Activation of the Mitogen-Activated Protein Kinases ERK-1 and p38</title>
    <authors>Park,S.H.; Kim,K.Y.; An,B.S.; Choi,J.H.; Jeung,E.B.; Leung,P.C.K.; Choi,K.C.</authors>
    <availability>[Park, Se-Hyung; Kim, Ki-Yon; An, Beum-Soo; Choi, Jung-Hye; Leung, Peter C. K.; Choi, Kyung-Chul] Univ British Columbia, Dept Obstet &amp; Gynecol, British Columbia Womens Hosp, Child &amp; Family Res Inst, Vancouver, BC V6H 3V5, Canada. [Jeung, Eui-Bae; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Mol Biotechnol, Cheongju, Chungbuk, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleChoi, KC (reprint author), Univ British Columbia, Dept Obstet &amp; Gynecol, British Columbia Womens Hosp, Child &amp; Family Res Inst, Vancouver, BC V6H 3V5, Canadakchoi@cbu.ac.krAlbanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; BENCKO V, 2001, EOLIA HLTH CYTOBIOL, V39, P24; Brevini Tiziana A. L., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P1; Cheng CK, 2003, MOL ENDOCRINOL, V17, P2613, DOI 10.1210/me.2003-0217; Choi KC, 2003, J REPROD DEVELOP, V49, P337, DOI 10.1262/jrd.49.337; COBB MH, 1995, J BIOL CHEM, V270, P14843; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; CRAMER DW, 1983, J NATL CANCER I, V71, P717; Cunat S, 2004, GYNECOL ONCOL, V94, P25, DOI 10.1016/j.ygyno.2004.03.026; Dang VH, 2007, TOXICOL SCI, V97, P504, DOI 10.1093/toxsci/kfm051; Daston GP, 2003, TOXICOL SCI, V74, P245, DOI 10.1093/toxsci/kfg015; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; GEISINGER KR, 1989, CANCER, V63, P280, DOI 10.1002/1097-0142(19890115)63:2&lt;280::AID-CNCR2820630213&gt;3.0.CO;2-N; Ghosh D, 1999, ENDOCRINOLOGY, V140, P3526, DOI 10.1210/en.140.8.3526; Giacalone PL, 2003, GYNECOL ONCOL, V91, P651, DOI 10.1016/S0090-8258(03)00279-8; Harris RM, 2005, MOL CELL ENDOCRINOL, V244, P72, DOI 10.1016/j.mce.2005.05.013; Iguchi T, 2006, ENVIRON HEALTH PERSP, V114, P101, DOI 10.1289/ehp.8061; Isidori M, 2006, CHEMOSPHERE, V64, P135, DOI 10.1016/j.chemosphere.2005.10.047; Kim KY, 2006, ENDOCR-RELAT CANCER, V13, P211, DOI 10.1677/erc.1.01033; Kuch HM, 2001, ENVIRON SCI TECHNOL, V35, P3201, DOI 10.1021/es010034m; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Mueller SO, 2003, TOXICOL LETT, V142, P89, DOI 10.1016/S0378-4274(03)00016-X; Nimrod AC, 1996, CRIT REV TOXICOL, V26, P335, DOI 10.3109/10408449609012527; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pujol P, 1998, CANCER RES, V58, P5367; Ropero AB, 2006, J STEROID BIOCHEM, V102, P163, DOI 10.1016/j.jsbmb.2006.09.019; SAITO I, 2004, INDOOR AIR, V14, P125; Schmitt E, 2001, TOXICOL IN VITRO, V15, P433, DOI 10.1016/S0887-2333(01)00048-0; Seval Y, 2006, J CLIN ENDOCR METAB, V91, P2349, DOI 10.1210/jc.2005-2132; Staples CA, 2000, CHEMOSPHERE, V40, P521, DOI 10.1016/S0045-6535(99)00288-X; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Treeck O, 2007, J ENDOCRINOL, V193, P421, DOI 10.1677/JOE-07-0087; Vazquez-Duhalt R, 2001, PHYTOCHEMISTRY, V58, P929, DOI 10.1016/S0031-9422(01)00326-0; Waring RH, 2005, MOL CELL ENDOCRINOL, V244, P2, DOI 10.1016/j.mce.2005.02.007; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.75053822SOCIETY REPRODUCTION &amp; DEVELOPMENT-SRDTSUKUBAC/O KAZUHIRO KIKUCHI, PHD DVM, NATL INST AGROBIOLOGICAL SCIENCES KANNONDAI 2-1-2, TSUKUBA, IBARAKI 305-8602, JAPANJ REPROD DEVELOPFEBDiscipline: Agriculture; Reproductive Biology416EG</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; Agriculture; Antagonist; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER CELLS; CANCER-CELLS; CELL; cell growth; Cell proliferation; CELL-PROLIFERATION; CELLS; CHEMICALS; DISORDERS; DISRUPTING CHEMICALS; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; ENDOCRINE DISRUPTORS; ER; ER-BETA; ERE; Estrogen; Estrogen receptor; Estrogen response element; ESTROGEN-RECEPTOR; Estrogenicity; Extracellular signal-regulated kinase; GENE-EXPRESSION; GROWTH; HEALTH; Immune; In vitro; IN-VITRO; inhibition; INHIBITOR; Inhibitors; KINASE; kinases; mechanism; MECHANISMS; Metabolic disorders; Mitogen-activated protein kinase; Nonylphenol; octylphenol; Ovarian cancer; OVARIAN-CANCER; p38; p38 MAPK; PATHWAY; progesterone; proliferation; PROTEIN; PROTEIN-KINASE; PROTEIN-KINASES; RECEPTOR; RECEPTOR ANTAGONIST; RECEPTOR-ALPHA; Regulation; Reproduction; SOCIETY; Steroid; TARGET; TRANSCRIPTION; Uterus; VITRO; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>23</startpage>
    <endpage>29</endpage>
    <journalfull>Journal of Reproduction and Development</journalfull>
    <issue>1</issue>
    <volume>55</volume>
    <abstract>Although endocrine disrupting chemicals (EDCs) may interfere with the endocrine system(s) of our body and have estrogenicity or androgenicity, the exact mechanism(s) underlying their detrimental effects is not clearly understood. Thus, in this study, we evaluated the effects of EDCs on proliferation and regulation of transcription of estrogen receptor (ER)-positive BG-1 Ovarian cancer cells, and their possible mechanisms were further examined. Treatment with bisphenol A (BPA), nonylphenol (NP), octylphenol (OP) and rnethoxychlor (MXC) for 24 h resulted in an increase of cell proliferation. Treatment with BPA, NP, OP and MXC increased the estrogen response element (ERE) activity. The increase of cell proliferation and activation of ERE were reversed in the presence of all estrogen receptor antagonist, ICI 182780. These results suggest that ER is involved in EDC-mediated pathway in Ovarian cancer cells. Based on this, we further investigated the involvement of EDCs in activation of mitogen-activated protein kinase (MAPK) in relation to cell growth. BPA rapidly induced activation of extracellular signal-regulated kinase (ERK) 1/2 and p38 MAPK at 15 min, but the effect of BPA (10 mu M) on stimulation of cell growth was not blocked by pretreatment with inhibitors of MEK (PD98059) or p38 (SB203580) in a dose-dependent manner. Taken together, EDC-induced proliferation is mediated by a genomic effect through ERs and ERE, but EDC-activated MAPK is unlikely to be involved in EDC-induced cell growth in estrogen-responsive ovarian cancer cells</abstract>
    <url>WOS:000263987700004</url>
    <isbnorissn>0916-8818</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>360</id>
    <title>Predicting environmental chemical factors associated with disease-related gene expression data</title>
    <authors>Patel,C.J.; Butte,A.J.</authors>
    <availability>[Patel, Chirag J.; Butte, Atul J.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA. [Patel, Chirag J.; Butte, Atul J.] Stanford Univ, Sch Med, Dept Med, Ctr Biomed Informat Res, Stanford, CA 94305 USA. [Patel, Chirag J.; Butte, Atul J.] Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleButte, AJ (reprint author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USAabutte@stanford.eduAckerstaff E, 2007, NEOPLASIA, V9, P222, DOI 10.1593/neo.06673; Amato RJ, 2006, CLIN GENITOURIN CANC, V4, P281, DOI 10.3816/CGC.2006.n.008; Andrew AS, 2008, ENVIRON HEALTH PERSP, V116, P524, DOI 10.1289/ehp.10861; Ashburner M, 2000, NAT GENET, V25, P25; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431; Benbrahim-Tallaa L, 2005, TOXICOL APPL PHARM, V206, P288, DOI 10.1016/j.taap.2004.11.017; Benbrahim-Tallaa L, 2007, PROSTATE, V67, P135, DOI 10.1002/pros.20479; Bertilaccio MTS, 2008, PROSTATE, V68, P1105, DOI 10.1002/pros.20775; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Borden LS, 2006, CANCER, V107, P1093, DOI 10.1002/cncr.22078; Bosse Y, 2007, PHYSIOL GENOMICS, V29, P161, DOI 10.1152/physiolgenomics.00134.2006; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Carvajal A, 2005, BREAST CANCER RES TR, V94, P171, DOI 10.1007/s10549-005-7726-6; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Committee on Toxicity Testing and Assessment of Environmental Agents National Research Council, 2007, TOX TEST 21 CENT VIS; Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; DAVIS AP, 2009, NUCLEIC ACIDS RES, pD786; Devereux TR, 2002, CARCINOGENESIS, V23, P1737, DOI 10.1093/carcin/23.10.1737; Diament MJ, 2006, CANCER INVEST, V24, P126, DOI 10.1080/07357900500524322; Eliassen AH, 2006, J NATL CANCER I, V98, P1406, DOI 10.1093/jnci/djj376; Fan JG, 2000, BIOMED ENVIRON SCI, V13, P163; Filyak Y, 2007, CELL BIOL INT, V31, P851, DOI 10.1016/j.cellbi.2007.02.008; Gohlke JM, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-46; Gottipolu RR, 2009, ENVIRON HEALTH PERSP, V117, P38, DOI 10.1289/ehp.11647; Green M, 2007, TOXICOL LETT, V168, P7, DOI 10.1016/j.toxlet.2006.10.009; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Jungestrom MB, 2007, CLIN CANCER RES, V13, P1061, DOI 10.1158/1078-0432.CCR-06-1651; Kang J, 2005, PROSTATE CANCER P D, V8, P274, DOI 10.1038/sj.pcan.4500798; Kato S, 2005, J CLIN ENDOCR METAB, V90, P1181, DOI 10.1210/jc.2004-0857; Koike H, 2005, BRIT J CANCER, V92, P1538, DOI 10.1038/sj.bjc.6602520; Lakshmanaswamy R, 2008, ADV EXP MED BIOL, V617, P469, DOI 10.1007/978-0-387-69080-3_46; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Levin G, 2000, CHEMOTHERAPY, V46, P429, DOI 10.1159/000007323; Li YW, 2004, NEOPLASIA, V6, P354, DOI 10.1593/neo.03478; Li ZW, 2005, ENVIRON HEALTH PERSP, V113, P1747, DOI 10.1289/ehp.7947; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Machiels JPH, 2001, CANCER RES, V61, P3689; Malard V, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-147; Mattingly CJ, 2006, TOXICOL SCI, V92, P587, DOI 10.1093/toxsci/kfl008; Meira LB, 2001, MUTAT RES-FUND MOL M, V477, P51, DOI 10.1016/S0027-5107(01)00097-5; Michael IP, 2006, J BIOL CHEM, V281, P12743, DOI 10.1074/jbc.M600326200; Moody TW, 2001, ANTICANCER RES, V21, P1749; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nobert Gayle S, 2006, Bull Cancer, V93, pE59; Oh William K, 2002, Clin Prostate Cancer, V1, P81, DOI 10.3816/CGC.2002.n.009; Raschke M, 2006, BRIT J NUTR, V96, P426, DOI 10.1079/BJN20061811; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Schwartz D, 2007, SCIENCE, V316, P695, DOI 10.1126/science.1141331; Selvaraj V, 2005, TOXICOL SCI, V87, P97, DOI 10.1093/toxsci/kfi219; Seo HS, 2006, BREAST CANCER RES TR, V99, P121, DOI 10.1007/s10549-006-9191-2; Shazer RL, 2006, BJU INT, V97, P691, DOI 10.1111/j.1464-410X.2006.05974.x; Shen J, 2007, TOXICOL SCI, V95, P313, DOI 10.1093/toxsci/kfl151; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi Y, 2004, MOL CARCINOGEN, V41, P108, DOI 10.1002/mc.20045; Tijet N, 2006, MOL PHARMACOL, V69, P140, DOI 10.1124/mol.105.018705; Tokar Erik J, 2006, J Exp Ther Oncol, V5, P323; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uehara T, 2008, TOXICOLOGY, V250, P15, DOI 10.1016/j.tox.2008.05.013; Untch M, 2004, EUR J CANCER, V40, P988, DOI 10.1016/j.ejca.2004.01.011; Uzzo RG, 2006, CARCINOGENESIS, V27, P1980, DOI 10.1093/carcin/bgl034; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; VAcgran FrAcdAcrique, 2006, Clin Cancer Res, V12, P5794, DOI 10.1158/1078-0432.CCR-06-0725; Verheus M, 2007, J CLIN ONCOL, V25, P648, DOI 10.1200/JCO.2006.06.0244; Vogel VG, 2006, ANN NY ACAD SCI, V1089, P127, DOI 10.1196/annals.1386.010; Waalkes MP, 2004, TOXICOL APPL PHARM, V198, P377, DOI 10.1016/j.taap.2003.10.028; Waalkes MP, 2006, TOXICOL APPL PHARM, V215, P295, DOI 10.1016/j.taap.2006.03.010; Walter G, 2004, BIOORG MED CHEM LETT, V14, P4659, DOI 10.1016/j.bmcl.2004.06.098; Wang WQ, 2009, INT J CANCER, V124, P521, DOI 10.1002/ijc.23961; Wang Y, 2010, NUCLEIC ACIDS RES, V2010, pD255; Wang Y, 2009, NUCLEIC ACIDS RES, pW623; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zanesi N, 2005, CANCER RES, V65, P6576, DOI 10.1158/0008-5472.CAN-05-1128; Zeeberg BR, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-168; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.00300877810BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDBMC MED GENOMICSMAY 6Discipline: Genetics &amp; Heredity603EK</notes>
    <keywords>AGENTS; ARSENIC EXPOSURE; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER CELL-LINE; Carcinogen; CARCINOGENESIS; CELL; CELL-LINES; CHEMICALS; COMPARATIVE TOXICOGENOMICS DATABASE; DIFFERENTIALLY EXPRESSED GENES; DISEASE; diseases; ENDOTHELIAL GROWTH-FACTOR; environment; ENVIRONMENTAL CHEMICALS; EPITHELIAL-CELLS; ESTRADIOL; EXPRESSION; FRAMEWORK; GENE; gene expression; GENE-EXPRESSION; GENES; genetics; HEALTH; IN-VIVO; INDEPENDENT PROSTATE-CANCER; Interaction; KAPPA-B; LINE; LINES; LUNG ADENOCARCINOMA DEVELOPMENT; Microarray; Neoplasia; p38; PHASE-I; Prostate; prostate cancer; PROSTATE-CANCER; SAMPLES; Steroid; TOXICITY; Toxicogenomics; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Bmc Medical Genomics</journalfull>
    <volume>3</volume>
    <abstract>Background: Many common diseases arise from an interaction between environmental and genetic factors. Our knowledge regarding environment and gene interactions is growing, but frameworks to build an association between gene-environment interactions and disease using preexisting, publicly available data has been lacking. Integrating freely-available environment-gene interaction and disease phenotype data would allow hypothesis generation for potential environmental associations to disease. Methods: We integrated publicly available disease-specific gene expression microarray data and curated chemical-gene interaction data to systematically predict environmental chemicals associated with disease. We derived chemical-gene signatures for 1,338 chemical/environmental chemicals from the Comparative Toxicogenomics Database (CTD). We associated these chemical-gene signatures with differentially expressed genes from datasets found in the Gene Expression Omnibus (GEO) through an enrichment test. Results: We were able to verify our analytic method by accurately identifying chemicals applied to samples and cell lines. Furthermore, we were able to predict known and novel environmental associations with prostate, lung, and breast cancers, such as estradiol and bisphenol A. Conclusions: We have developed a scalable and statistical method to identify possible environmental associations with disease using publicly available data and have validated some of the associations in the literature</abstract>
    <url>WOS:000278191100002</url>
    <isbnorissn>1755-8794</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>440</id>
    <title>Long-term effects of environmental endocrine disruptors on reproductive physiology and behavior</title>
    <authors>Patisaul,H.B.; Adewale,H.B.</authors>
    <availability>[Patisaul, Heather B.; Adewale, Heather B.] N Carolina State Univ, Dept Biol, Raleigh, NC 27695 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticlePatisaul, HB (reprint author), N Carolina State Univ, Dept Biol, Campus Box 7617, Raleigh, NC 27695 USAheather_patisaul@ncsu.eduAdachi S, 2007, J REPROD DEVELOP, V53, P367, DOI 10.1262/jrd.18146; ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; ADAMS NR, 1995, J ANIM SCI, V73, P1509; ADAMS NR, 1995, P SOC EXP BIOL MED, V208, P87; Adewale HB, 2009, BIOL REPROD, V81, P690, DOI 10.1095/biolreprod.109.078261; Adlercreutz H, 1997, ANN MED, V29, P95; Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491; Andersen AN, 2006, INT J ANDROL, V29, P12, DOI 10.1111/j.1365-2605.2005.00577.x; Andersen ME, 1999, ENVIRON HEALTH PERSP, V107, P631, DOI 10.2307/3434556; [Anonymous], 1999, FED REG, V64, P57700; Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; AUBRECHT J, 1995, CARCINOGENESIS, V16, P2841, DOI 10.1093/carcin/16.11.2841; AXELSON M, 1982, NATURE, V298, P659, DOI 10.1038/298659a0; Bakker J, 2008, FRONT NEUROENDOCRIN, V29, P1, DOI 10.1016/j.yfrne.2007.06.001; Balthazart J, 1996, HORM BEHAV, V30, P627, DOI 10.1006/hbeh.1996.0066; BARNES S, 1995, J NUTR, V125, pS777; Bateman HL, 2008, NEUROTOXICOLOGY, V29, P988, DOI 10.1016/j.neuro.2008.06.008; BAUM MJ, 1979, NEUROSCI BIOBEHAV R, V3, P265, DOI 10.1016/0149-7634(79)90013-7; Beans BE, 1996, EAGLES PLUME STRUGGL; Beard J, 2006, SCI TOTAL ENVIRON, V355, P78, DOI 10.1016/j.scitotenv.2005.02.022; Bennetts H. W., 1946, AUSTRALIAN VET JOUR, V22, P2, DOI 10.1111/j.1751-0813.1946.tb15473.x; BENNETTS HW, 1951, AUST J EXP BIOL MED, V29, P249, DOI 10.1038/icb.1951.29; BERGERON JM, 1994, ENVIRON HEALTH PERSP, V102, P780, DOI 10.2307/3432139; Boisen KA, 2001, ANN NY ACAD SCI, V948, P90; BOUTIN JA, 1994, INT J BIOCHEM, V26, P1203, DOI 10.1016/0020-711X(94)90091-4; Braden A., 1967, AUST J AGR RES, V18, P348; Brannian John, 2006, S D Med, V59, P291; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; Brown NM, 2001, LAB INVEST, V81, P735; Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P503, DOI 10.1080/20014091111785; Calabrese EJ, 2003, NATURE, V421, P691, DOI 10.1038/421691a; Calafat AM, 2004, PEDIATRICS, V113, pE429, DOI 10.1542/peds.113.5.e429; Calafat AM, 2009, ENVIRON HEALTH PERSP, V117, P639, DOI 10.1289/ehp.0800265; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cao Y, 2009, J EXPO SCI ENV EPID, V19, P223, DOI 10.1038/jes.2008.44; CARLSEN E, 1992, BRIT MED J, V305, P609; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; Clapp Richard W., 2008, Reviews on Environmental Health, V23, P1; Clarke Iain J., 2005, Animal Reproduction Science, V88, P29, DOI 10.1016/j.anireprosci.2005.05.003; Clarkson J, 2008, J NEUROSCI, V28, P8691, DOI 10.1523/JNEUROSCI.1775-08.2008; Clarkson TB, 2002, J NUTR, V132, p566S; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Crews D, 2006, ENDOCRINOLOGY, V147, pS4, DOI 10.1210/en.2005-1122; CREWS D, 1995, ENVIRON HEALTH PERSP, V103, P73, DOI 10.2307/3432512; Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; Crump K, 2001, CRIT REV TOXICOL, V31, P669, DOI 10.1080/20014091111947; David RM, 2006, TOXICOL PATHOL, V34, P209, DOI 10.1080/01926230600642625; Davidson J. M., 1969, Biology of Reproduction Suppl, VNo. 1, P67, DOI 10.1095/biolreprod1.Supplement_1.67; Degen GH, 2002, TOXICOL LETT, V128, P145, DOI 10.1016/S0378-4274(02)00009-7; Demonty I, 2003, NUTR REV, V61, P189, DOI [10.1301/nr.2003.jun.189-203, 10.1031/nr.2003.jun.189-203]; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Duty SM, 2003, ENVIRON HEALTH PERSP, V111, P1164, DOI 10.1289/ehp.5756; ELKINDHIRSCH K, 1981, BRAIN RES BULL, V7, P645, DOI 10.1016/0361-9230(81)90112-X; FABER K, 1990, GYNECOL ONCOL, V37, P125, DOI 10.1016/0090-8258(90)90320-K; Fletcher RJ, 2003, BRIT J NUTR, V89, pS39, DOI [10.1079/BJN2002740, 10.1079/BJN2002795]; Franke AA, 1996, CLIN CHEM, V42, P955; Franke AA, 1998, P SOC EXP BIOL MED, V217, P263; Franke AA, 1998, AM J CLIN NUTR, V68, p1466S; FRENITITULAER LW, 1986, AM J DIS CHILD, V140, P1263; Frey K. A., 2004, MAYO CLIN P, V79, P1443; Frey KA, 2004, MAYO CLIN PROC, V79, P1439; Gale RW, 2002, ENVIRON TOXICOL CHEM, V21, P2477, DOI 10.1897/1551-5028(2002)021&lt;2477:TSDAMB&gt;2.0.CO;2; GERALL AA, 1967, ANAT REC, V157, P97, DOI 10.1002/ar.1091570114; GILL WB, 1976, J REPROD MED, V16, P147; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Gore AC, 2008, FRONT NEUROENDOCRIN, V29, P358, DOI 10.1016/j.yfrne.2008.02.002; Gorski R A, 1985, J Anim Sci, V61 Suppl 3, P38; GORSKI RA, 1963, AM J PHYSIOL, V205, P842; Gorski R A, 1975, Adv Exp Med Biol, V54, P115; Gottsch ML, 2004, ENDOCRINOLOGY, V145, P4073, DOI 10.1210/en.2004-0431; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Goy R W, 1972, Recent Prog Horm Res, V28, P707; GRADY KL, 1965, J COMP PHYSIOL PSYCH, V59, P176, DOI 10.1037/h0021824; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; Gu GB, 1997, J COMP NEUROL, V384, P142; GUILLETTE LJ, 1995, ENVIRON HEALTH PERSP, V103, P157, DOI 10.2307/3432527; Guillette L. J. J., 1995, GEN COMP ENDOCR, V101, P32; Guillette LJ, 2001, REPRODUCTION, V122, P857; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Hauser R, 2008, INT J ANDROL, V31, P112, DOI 10.1111/j.1365-2605.2007.00844.x; Hayes T, 2002, NATURE, V419, P895, DOI 10.1038/419895a; Hays LE, 2002, ENVIRON HEALTH PERSP, V110, P369; Herbison AE, 2001, FRONT NEUROENDOCRIN, V22, P292, DOI 10.1006/frne.2001.0219; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERBST AL, 1970, AM J OBSTET GYNECOL, V106, P210; Herman RA, 2000, HORM BEHAV, V38, P52, DOI 10.1006/hbeh.2000.1608; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Hrabovszky E, 2000, ENDOCRINOLOGY, V141, P3506, DOI 10.1210/en.141.9.3506; Hrabovszky E, 2001, ENDOCRINOLOGY, V142, P3261, DOI 10.1210/en.142.7.3261; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; IRVINE DS, 1994, BRIT MED J, V309, P476; Irwig MS, 2004, NEUROENDOCRINOLOGY, V80, P264, DOI 10.1159/000083140; Jefferson WN, 2007, REPROD TOXICOL, V23, P308, DOI 10.1016/j.reprotox.2006.11.012; Jefferson WN, 2006, J AOAC INT, V89, P1189; Jefferson WN, 2005, BIOL REPROD, V73, P798, DOI 10.1095/biolreprod.105.041277; Jefferson WN, 2002, BIOL REPROD, V67, P1285, DOI 10.1095/biolreprod.102.005371; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Joensen UN, 2008, BASIC CLIN PHARMACOL, V102, P155, DOI 10.1111/j.1742-7843.2007.00197.x; Johns P, 2003, J AOAC INT, V86, P72; KARNAKY K J, 1953, Med Times, V81, P315; Kauffman AS, 2007, TRENDS NEUROSCI, V30, P504, DOI 10.1016/j.tins.2007.08.001; Kauffman AS, 2007, J NEUROSCI, V27, P8826, DOI 10.1523/JNEUROSCI.2099-07.2007; KOMISARU.BR, 1973, ENDOCRINOLOGY, V93, P548; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; Kouki T, 2003, HORM BEHAV, V44, P140, DOI 10.1016/S0018-506X(03)00122-3; KUCHERA LK, 1971, J AMER MED ASSOC, V218, P562, DOI 10.1001/jama.218.4.562; Kudwa AE, 2006, NEUROSCIENCE, V138, P921, DOI 10.1016/j.neuroscience.2005.10.018; Kuhnle GGC, 2008, J AGR FOOD CHEM, V56, P7311, DOI 10.1021/jf801534g; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; Lapcik O, 1998, STEROIDS, V63, P14, DOI 10.1016/S0039-128X(97)00104-9; Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147; Li SF, 1997, CANCER RES, V57, P4356; LISK RD, 1969, NEUROENDOCRINOLOGY, V5, P149, DOI 10.1159/000121857; Lutz W K, 2005, Toxicol Appl Pharmacol, V207, P565, DOI 10.1016/j.taap.2005.01.038; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P108, DOI 10.1016/0041-008X(92)90102-X; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Markey CM, 2001, BIOL REPROD, V65, P1215; Markman S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001674; Marler P, 2005, HORM BEHAV, V47, P493, DOI 10.1016/j.yhbeh.2005.01.002; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Mazur W, 2000, NUTRITION, V16, P654, DOI 10.1016/S0899-9007(00)00333-6; MCLACHLAN JA, 1982, FERTIL STERIL, V38, P364; Melnick Ronald, 2002, Environmental Health Perspectives, V110, P427; METZLER M, 1981, CRC CR REV BIOCH MOL, V10, P171, DOI 10.3109/10409238109113599; Milligan SR, 1998, GEN COMP ENDOCR, V112, P89, DOI 10.1006/gcen.1998.7146; Milnes MR, 2005, BIOL REPROD, V73, P1004, DOI 10.1095/biolreprod.105.041012; Muhlhauser A, 2009, BIOL REPROD, V80, P1066, DOI 10.1095/biolreprod.108.074815; Mylchreest E, 1999, TOXICOL APPL PHARM, V156, P81, DOI 10.1006/taap.1999.8643; Navarro VM, 2004, J PHYSIOL-LONDON, V561, P379, DOI 10.1113/jphysiol.2004.072298; Newbold Retha R, 2008, Fertil Steril, V89, pe55, DOI 10.1016/j.fertnstert.2008.01.062; Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355; NEWBOLD RR, 1982, CANCER RES, V42, P2003; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Newbold R.R., 2006, ENDOCRINOLOGY, V147, P11; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; Palmer JR, 2005, EPIDEMIOLOGY, V16, P583, DOI 10.1097/01.ede.0000164789.59728.6d; PALMLUND I, 1993, J PSYCHOSOM OBST GYN, V14, P71, DOI 10.3109/01674829309084432; Palmlund I, 1996, J PSYCHOSOM OBST GYN, V17, P71, DOI 10.3109/01674829609025667; Pant N, 2008, TOXICOL APPL PHARM, V231, P112, DOI 10.1016/j.taap.2008.04.001; Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019; Partsch CJ, 2001, HUM REPROD UPDATE, V7, P292, DOI 10.1093/humupd/7.3.292; Patchev AV, 2004, FASEB J, V18, P1568, DOI 10.1096/fj.04-1959fje; Patisaul HB, 2006, NEUROTOXICOL TERATOL, V28, P111, DOI 10.1016/j.ntt.2005.11.004; Patisaul HB, 2009, NEUROTOXICOLOGY, V30, P350, DOI 10.1016/j.neuro.2009.02.010; Patisaul HB, 2007, NEUROTOXICOLOGY, V28, P1, DOI 10.1016/j.neuro.2006.10.001; Patisaul HB, 2009, BEHAV BRAIN RES, V196, P317, DOI 10.1016/j.bbr.2008.09.026; Peeters PHM, 2003, BREAST CANCER RES TR, V77, P171, DOI 10.1023/A:1021381101632; Penalvo JL, 2008, J AGR FOOD CHEM, V56, P401, DOI 10.1021/jf072695u; Pfaff D, 1999, DRIVE; PFAFF DW, 1979, J PHYSIOL-LONDON, V288, P189; PIONTEK M, 1993, ANTICANCER RES, V13, P2119; Polston EK, 2004, NEUROSCIENCE, V123, P793, DOI 10.1016/j.neuroscience.2003.09.034; Polston EK, 2006, J COMP NEUROL, V495, P122, DOI 10.1002/cne.20874; PROOS LA, 1991, ACTA PAEDIATR SCAND, V80, P852, DOI 10.1111/j.1651-2227.1991.tb11960.x; Recchia AG, 2004, FOOD ADDIT CONTAM, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; Reinli K, 1996, NUTR CANCER, V26, P123; Roa J, 2006, ENDOCRINOLOGY, V147, P2864, DOI 10.1210/en.2005-1463; ROBBOY SJ, 1981, AM J OBSTET GYNECOL, V140, P579; ROBBOY SJ, 1984, CANCER, V54, P869, DOI 10.1002/1097-0142(19840901)54:5&lt;869::AID-CNCR2820540519&gt;3.0.CO;2-I; Rogan WJ, 2005, LANCET, V366, P763, DOI 10.1016/S0140-6736(05)67182-6; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rubin MM, 2007, OBSTET GYNECOL SURV, V62, P548, DOI 10.1097/01.ogx.0000271138.31234.d7; Ruden DM, 2005, HUM MOL GENET, V14, pR149, DOI 10.1093/hmg/ddi103; Sadler BR, 1998, J MED CHEM, V41, P2261, DOI 10.1021/jm9705521; Salama J, 2003, ENVIRON HEALTH PERSP, V111, P1278, DOI 10.1289/ehp.6126; Schiestl RH, 1997, CANCER RES, V57, P4378; SCHOENTAL R, 1983, LANCET, V1, P537; SEER, 2003, CANC STAT REV 1975 2; Semenza JC, 1997, ENVIRON HEALTH PERSP, V105, P1030, DOI 10.2307/3433835; Setchell K. D., 2001, J AM COLL NUTR, V20, p[354S, 381S]; Setchell KDR, 2001, J AM COLL NUTR, V20, p354S; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S; Setchell KDR, 2001, J NUTR, V131, p1362S; SETCHELL KDR, 1987, GASTROENTEROLOGY, V93, P225; SETCHELL KDR, 1987, J CHROMATOGR, V386, P315, DOI 10.1016/S0021-9673(01)94608-4; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Sheehan DM, 2006, ENVIRON RES, V100, P93, DOI 10.1016/j.envres.2005.09.002; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4&lt;507::AID-CNE1&gt;3.0.CO;2-6; Simerly RB, 1998, BEHAV BRAIN RES, V92, P195, DOI 10.1016/S0166-4328(97)00191-5; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; Skakkebaek NE, 2006, INT J ANDROL, V29, P2, DOI 10.1111/j.1365-2605.2005.00573.x; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Smith JT, 2006, J NEUROSCI, V26, P6687, DOI 10.1523/JNEUROSCI.1618-06.2006; Smith JT, 2006, REPRODUCTION, V131, P623, DOI 10.1530/rep.1.00368; SMITH OW, 1948, AM J OBSTET GYNECOL, V56, P821; SODERSTEN P, 1978, J ENDOCRINOL, V76, P241, DOI 10.1677/joe.0.0760241; Steinberg RM, 2008, BIOL REPROD, V78, P1091, DOI 10.1095/biolreprod.107.067249; STENCHEVER MA, 1981, AM J OBSTET GYNECOL, V140, P186; Strom BL, 2001, JAMA-J AM MED ASSOC, V286, P807, DOI 10.1001/jama.286.7.807; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; SWAAB DF, 1984, PROG BRAIN RES, V61, P361; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P414, DOI 10.1289/ehp.5927; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Tena-Sempere M, 2006, NEUROENDOCRINOLOGY, V83, P275, DOI 10.1159/000095549; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thompson LU, 2006, NUTR CANCER, V54, P184, DOI 10.1207/s15327914nc5402_5; THOMPSON LU, 1991, NUTR CANCER, V16, P43; Todaka E, 2005, ENVIRON RES, V99, P195, DOI 10.1016/j.envres.2004.11.006; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; Venners SA, 2005, AM J EPIDEMIOL, V162, P709, DOI 10.1093/aje/kwi275; VESSEY MP, 1983, BRIT J OBSTET GYNAEC, V90, P1007, DOI 10.1111/j.1471-0528.1983.tb06438.x; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Vom Saal F S, 1985, Biol Reprod, V32, P1116, DOI 10.1095/biolreprod32.5.1116; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; VRIELING H, 1994, P NATL ACAD SCI USA, V91, P5667, DOI 10.1073/pnas.91.12.5667; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Weuve J, 2006, ENVIRON HEALTH PERSP, V114, P1424, DOI 10.1289/ehp.8926; WHALEN RE, 1986, HORM BEHAV, V20, P73, DOI 10.1016/0018-506X(86)90030-9; WHALEN RE, 1963, SCIENCE, V141, P273, DOI 10.1126/science.141.3577.273; WILCOX AJ, 1995, NEW ENGL J MED, V332, P1411, DOI 10.1056/NEJM199505253322104; Wirth JJ, 2008, SYST BIOL REPROD MEC, V54, P143, DOI 10.1080/19396360802055921; Wisniewski AB, 2003, J UROLOGY, V169, P1582, DOI 10.1097/01.ju.0000046780.23389.e0; Wolf CJ, 2000, TOXICOL SCI, V55, P152, DOI 10.1093/toxsci/55.1.152; Wolff GL, 1998, FASEB J, V12, P949; Xu JP, 2002, BIOCHEM BIOPH RES CO, V292, P456, DOI 10.1006/bbrc.2002.6644; YAMANOUCHI K, 1976, ENDOCRINOL JAPON, V23, P179; You L, 2002, TOXICOL SCI, V66, P91, DOI 10.1093/toxsci/66.1.91; YOUNG WC, 1964, SCIENCE, V143, P212, DOI 10.1126/science.143.3603.212; ZERVOS C, 1982, AM STAT, V36, P278, DOI 10.2307/268384324333FRONTIERS RESEARCH FOUNDATIONLAUSANNEPO BOX 110, LAUSANNE, 1015, SWITZERLANDFRONT BEHAV NEUROSCIDiscipline: Behavioral Sciences; Neurosciences &amp; NeurologyV18VE</notes>
    <keywords>1; ANTEROVENTRAL PERIVENTRICULAR NUCLEUS; Behavior; BIOLOGY; bisphenol; Brain; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; Carcinogen; CARCINOGENESIS; CELL; development; DISRUPTION; DNA METHYLATION; DNA-methylation; EARLY-LIFE; EDC; EDCs; ENDOCRINE; Endocrine disrupting compound; Endocrine disrupting compounds; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; Epidemiology; epigenetic; EPIGENETIC GENE-REGULATION; Estrogen; Estrogen receptors; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; Fetus; FOOD; FUTURE; genistein; HEALTH; HISTONE ACETYLATION; Hormone; Hormones; HUMANS; IMPACT; IN-UTERO EXPOSURE; INDUCE INTRACHROMOSOMAL RECOMBINATION; INTENSIVE-CARE-UNIT; LINE; LUTEINIZING-HORMONE SURGE; mechanism; MECHANISMS; METHYLATION; non-genomic; Nongenomic; nutrition; p38; pediatric; POPULATION; PROGRESSION; puberty; Reproduction; Review; Sex; sexual differentiation; SOY; Steroid; TESTICULAR DYSGENESIS SYNDROME; TURTLE SEX DETERMINATION; UPDATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Frontiers in Behavioral Neuroscience</journalfull>
    <volume>3</volume>
    <abstract>It is well established that, over the course of development, hormones shape the vertebrate brain such that sex specific physiology and behaviors emerge. Much of this occurs in discrete developmental windows that span gestation through the prenatal period, although it is now becoming clear that at least some of this process continues through puberty. Perturbation of this developmental progression can permanently alter the capacity for reproductive success. Wildlife studies have revealed that exposure to endocrine disrupting compounds (EDCs), either naturally occurring or man made, can profoundly alter reproductive physiology and ultimately impact entire populations. Laboratory studies in rodents and other species have elucidated some of the mechanisms by which this occurs and strongly indicate that humans are also vulnerable to disruption. Use of hormonally active compounds in human medicine has also unfortunately revealed that the developing fetus can be exposed to and affected by endocrine disruptors, and that it might take decades for adverse effects to manifest. Research within the field of environmental endocrine disruption has also contributed to the general understanding of how early life experiences can alter reproductive physiology and behavior through non-genomic, epigenetic mechanisms such as DNA methylation and histone acetylation. These types of effects have the potential to impact future generations if the germ line is affected. This review provides an overview of how exposure to EDCs, particularly those that interfere with estrogen action, impacts reproductive physiology and behaviors in vertebrates</abstract>
    <url>WOS:000208031500010</url>
    <isbnorissn>1662-5153</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>333</id>
    <title>The pros and cons of phytoestrogens</title>
    <authors>Patisaul,H.B.; Jefferson,W.</authors>
    <availability>[Patisaul, Heather B.] N Carolina State Univ, Dept Biol, Raleigh, NC 27695 USA. NIEHS, Lab Reprod &amp; Dev Toxicol, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2010</date>
    <notes>JEnglishReviewPatisaul, HB (reprint author), N Carolina State Univ, Dept Biol, Raleigh, NC 27695 USAheather_patisaul@ncsu.eduADAMS NR, 1995, J ANIM SCI, V73, P1509; ADAMS NR, 1995, P SOC EXP BIOL MED, V208, P87; Adewale HB, 2009, BIOL REPROD; Adlercreutz H, 1999, AM J OBSTET GYNECOL, V180, P737, DOI 10.1016/S0002-9378(99)70281-4; Adlercreutz H, 1997, ANN MED, V29, P95; ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; ADLERCREUTZ H, 1994, CANCER DETECT PREV, V18, P259; Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491; Anderson JJB, 1998, P SOC EXP BIOL MED, V217, P345; Arai Y, 2000, J Epidemiol, V10, P127; Atkinson C, 2004, BREAST CANCER RES, V6, pR170, DOI 10.1186/bcr773; AXELSON M, 1984, J ENDOCRINOL, V102, P49, DOI 10.1677/joe.0.1020049; Badger TM, 2002, J NUTR, V132, p559S; Badger TM, 2009, AM J CLIN NUTR, V89, pS1668, DOI 10.3945/ajcn.2009.26736U; Balk E, 2005, Evid Rep Technol Assess (Summ), P1; Barkhem T, 1998, MOL PHARMACOL, V54, P105; BARNES S, 1995, J NUTR, V125, pS777; Barrett JR, 2006, ENVIRON HEALTH PERSP, V114, pA25; Barrett JR, 2002, ENVIRON HEALTH PERSP, V110, pA42, DOI 10.1289/ehp.110-a42a; Bateman HL, 2008, NEUROTOXICOLOGY; Bateman HL, 2008, NEUROTOXICOLOGY, V29, P988, DOI 10.1016/j.neuro.2008.06.008; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x; Bennetts H. W., 1946, AUSTRALIAN VET JOUR, V22, P2, DOI 10.1111/j.1751-0813.1946.tb15473.x; BENNETTS HW, 1951, AUST J EXP BIOL MED, V29, P249, DOI 10.1038/icb.1951.29; Bernbaum JC, 2008, ENVIRON HEALTH PERSP, V116, P416, DOI [10.1289/ehp.10409, 10.1289/chp.10409]; Bhatia J, 2008, PEDIATRICS, V121, P1062, DOI 10.1542/peds.2008-0564; Bouker KB, 2000, ENVIRON HEALTH PERSP, V108, P701, DOI 10.2307/3434722; BOUTIN JA, 1994, INT J BIOCHEM, V26, P1203, DOI 10.1016/0020-711X(94)90091-4; Braden A., 1967, AUST J AGR RES, V18, P348; CALDWELL JD, 1994, HORM BEHAV, V28, P288, DOI 10.1006/hbeh.1994.1024; Cao Y, 2009, J EXPO SCI ENV EPID, V19, P223, DOI 10.1038/jes.2008.44; Casanova M, 1999, TOXICOL SCI, V51, P236, DOI 10.1093/toxsci/51.2.236; Cassidy A, 2006, P NUTR SOC, V65, P76, DOI 10.1079/PNS2005476; CEDERROTH CR, 2009, INT J ANDROL; CHANDRAREDDY A, 2008, THER CLIN PRACT, V14, P132; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Chang HC, 2000, J NUTR, V130, P1963; Chen AM, 2004, ANNU REV NUTR, V24, P33, DOI 10.1146/annurev.nutr.24.101603.064950; Chen S, 1997, J STEROID BIOCHEM, V61, P107; CHORAZY PA, 1995, PEDIATRICS, V96, P148; Chun OK, 2009, J AM DIET ASSOC, V109, P245, DOI 10.1016/j.jada.2008.10.055; Chun OK, 2007, J NUTR, V137, P1244; Clarkson J, 2008, J NEUROSCI, V28, P8691, DOI 10.1523/JNEUROSCI.1775-08.2008; Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171; Cooke GM, 2006, J AOAC INT, V89, P1215; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; DALOISIO AA, 2009, ENV HLTH PERSPECT; Davis EC, 1996, NEUROENDOCRINOLOGY, V63, P142, DOI 10.1159/000126950; Dechaud H, 1999, STEROIDS, V64, P328, DOI 10.1016/S0039-128X(98)00114-7; Degen GH, 2002, TOXICOL LETT, V128, P145, DOI 10.1016/S0378-4274(02)00009-7; DELCLOS KB, TOXICOL REP SER; Demonty I, 2003, NUTR REV, V61, P189, DOI [10.1301/nr.2003.jun.189-203, 10.1031/nr.2003.jun.189-203]; Divi RL, 1997, BIOCHEM PHARMACOL, V54, P1087, DOI 10.1016/S0006-2952(97)00301-8; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Dodge JA, 1996, J STEROID BIOCHEM, V59, P155, DOI 10.1016/S0960-0760(96)00104-5; Doerge DR, 2002, CANCER LETT, V184, P21, DOI 10.1016/S0304-3835(02)00200-8; Doerge DR, 2001, REPROD TOXICOL, V15, P105, DOI 10.1016/S0890-6238(01)00108-3; Doerge DR, 2006, REPROD TOXICOL, V21, P307, DOI 10.1016/j.reprotox.2005.09.007; Draper CR, 1997, J NUTR, V127, P1795; DRUMMOND A, 2009, J ENDOCRINOL; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P192, DOI 10.1210/jc.84.1.192; Dunn AJ, 2004, ANN NY ACAD SCI, V1018, P25, DOI 10.1196/annals.1296.003; ELKINDHIRSCH K, 1981, BRAIN RES BULL, V7, P645, DOI 10.1016/0361-9230(81)90112-X; Enderlin CA, 2009, ONCOL NURS FORUM, V36, P531, DOI 10.1188/09.ONF.531-539; Engel SM, 2006, REPROD TOXICOL, V21, P110, DOI 10.1016/j.reprotox.2005.07.007; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; FABER KA, 1993, REPROD TOXICOL, V7, P35, DOI 10.1016/0890-6238(93)90007-T; Falkenstein E, 2000, PHARMACOL REV, V52, P513; FARQUHARSON RG, 1984, EUR J OBSTET GYN R B, V16, P315, DOI 10.1016/0028-2243(84)90159-X; *FDA, 2007, HLTH CLAIMS QUAL HLT; *FDA, 1999, FED REGISTER, V64, P57700; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; FORSYTH BWC, 1985, J PEDIATR, V106, P1012, DOI 10.1016/S0022-3476(85)80260-2; Foster WG, 2002, TOXICOL LETT, V129, P199, DOI 10.1016/S0378-4274(02)00018-8; Franke AA, 1996, CLIN CHEM, V42, P955; FRANKE AA, 1994, J CHROMATOGR B, V662, P47, DOI 10.1016/0378-4347(94)00390-4; Franke AA, 1998, AM J CLIN NUTR, V68, p1466S; Franke AA, 2006, AM J CLIN NUTR, V84, P406; FRENITITULAER LW, 1986, AM J DIS CHILD, V140, P1263; Park Denise, 2005, Cardiol Rev, V13, P13; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Goldman LR, 2001, JAMA-J AM MED ASSOC, V286, P2402, DOI 10.1001/jama.286.19.2402; Goodman MT, 2009, CANCER PREV RES, V2, P887, DOI 10.1158/1940-6207.CAPR-09-0039; Goodman MT, 1997, AM J EPIDEMIOL, V146, P294; Gorski R A, 1985, J Anim Sci, V61 Suppl 3, P38; GORSKI RA, 1978, BRAIN RES, V148, P333, DOI 10.1016/0006-8993(78)90723-0; GORSKI RA, 1963, AM J PHYSIOL, V205, P842; Gorski R A, 1975, Adv Exp Med Biol, V54, P115; Gottsch ML, 2004, ENDOCRINOLOGY, V145, P4073, DOI 10.1210/en.2004-0431; Gruber J, 2007, ANN NY ACAD SCI, V1100, P530, DOI 10.1196/annals.1395.059; Grumbach MM, 2002, HORM RES, V57, P2, DOI 10.1159/000058094; Gu GB, 1997, J COMP NEUROL, V384, P142; Handa RJ, 2009, J NEUROENDOCRINOL, V21, P351, DOI 10.1111/j.1365-2826.2009.01840.x; Hartley DE, 2003, PSYCHOPHARMACOLOGY, V167, P46, DOI 10.1007/s00213-002-1369-7; Helferich W. G., 2008, Inflammopharmacology, V16, P219, DOI 10.1007/s10787-008-8020-0; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERBST AL, 1970, AM J OBSTET GYNECOL, V106, P210; Hertrampf T, 2009, TOXICOL LETT, V184, P198, DOI 10.1016/j.toxlet.2008.11.006; Hodgson JM, 1998, J NUTR, V128, P728; Hooper L, 2009, HUM REPROD UPDATE, V15, P423, DOI 10.1093/humupd/dmp010; Horn-Ross PL, 2006, CANCER CAUSE CONTROL, V17, P85, DOI 10.1007/s10552-005-0391-6; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hsieh RW, 2006, J BIOL CHEM, V281, P17909, DOI 10.1074/jbc.M513684200; HUTCHINS AM, 1995, J AM DIET ASSOC, V95, P545, DOI 10.1016/S0002-8223(95)00149-2; IGUCHI T, 1990, BIOL REPROD, V43, P478, DOI 10.1095/biolreprod43.3.478; IGUCHI T, 1986, TERATOLOGY, V34, P29, DOI 10.1002/tera.1420340105; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Irvine CHG, 1998, AM J CLIN NUTR, V68, p1462S; Irwig MS, 2004, NEUROENDOCRINOLOGY, V80, P264, DOI 10.1159/000083140; Jacobs A, 2009, MOL NUTR FOOD RES, V53, P1084, DOI 10.1002/mnfr.200800552; Jefferson W, 2006, BIOL REPROD, V74, P161, DOI 10.1095/biolreprod.105.045724; Jefferson WN, 2002, J CHROMATOGR B, V777, P179, DOI 10.1016/S1570-0232(02)00493-2; Jefferson WN, 2005, BIOL REPROD, V73, P798, DOI 10.1095/biolreprod.105.041277; Jefferson WN, 2009, BIOL REPROD, V80, P425, DOI 10.1095/biolreprod.108.073171; Jefferson WN, 2002, BIOL REPROD, V67, P1285, DOI 10.1095/biolreprod.102.005371; Joensen UN, 2008, BASIC CLIN PHARMACOL, V102, P155, DOI 10.1111/j.1742-7843.2007.00197.x; Johns P, 2003, J AOAC INT, V86, P72; Kang L, 2010, MOL ENDOCRINOL; Kauffman AS, 2007, TRENDS NEUROSCI, V30, P504, DOI 10.1016/j.tins.2007.08.001; Kauffman AS, 2009, PEPTIDES, V30, P83, DOI 10.1016/j.peptides.2008.06.014; Kenny AM, 2009, AM J CLIN NUTR, V90, P234, DOI 10.3945/ajcn.2009.27600; Kim J, 2008, ASIAN PAC J CANCER P, V9, P543; Koehler KF, 2005, ENDOCR REV, V26, P465, DOI 10.1210/er.2004-0027; Kouki T, 2003, HORM BEHAV, V44, P140, DOI 10.1016/S0018-506X(03)00122-3; Kubo K, 2003, NEUROSCI RES, V45, P345, DOI 10.1016/S0168-0102(02)00251-1; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; Kurzer MS, 2003, J NUTR, V133, p1983S; Kurzer M. S., 2008, Inflammopharmacology, V16, P227, DOI 10.1007/s10787-008-8021-z; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lakind JS, 2010, J EXPO SCI ENV EPIDE; Lampe JW, 1998, P SOC EXP BIOL MED, V217, P335; Lampe JW, 2009, AM J CLIN NUTR, V89, pS1664, DOI 10.3945/ajcn.2009.26736T; LEE HP, 1991, LANCET, V337, P1197; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee YB, 2005, J NUTR BIOCHEM, V16, P641, DOI 10.1016/j.jnutbio.2005.06.010; Legette LL, 2009, J NUTR, V139, P1908, DOI 10.3945/jn.109.108225; Lephart ED, 2002, NEUROTOXICOL TERATOL, V24, P5, DOI 10.1016/S0892-0362(01)00197-0; Lephart ED, 2005, BRAIN RES BULL, V65, P193, DOI 10.1016/j.brainresbull.2004.11.022; Levin ER, 2009, J PHYSIOL-LONDON, V587, P5019, DOI 10.1113/jphysiol.2009.177097; Lewis RW, 2003, TOXICOL SCI, V71, P74, DOI 10.1093/toxsci/71.1.74; IGUCHI T, 1986, ANAT EMBRYOL, V175, P53, DOI 10.1007/BF00315455; Li BB, 2003, BIOL PHARM BULL, V26, P780, DOI 10.1248/bpb.26.780; Lindzey J, 1997, TRENDS ENDOCRIN MET, V8, P137, DOI 10.1016/S1043-2760(97)00007-6; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; Liu J, 2009, BONE, V44, P948, DOI 10.1016/j.bone.2008.12.020; Lund TD, 2005, ENDOCRINOLOGY, V146, P797, DOI 10.1210/en.2004-1158; Lund TD, 2001, BRAIN RES, V914, P92, DOI 10.1016/S0006-8993(01)02779-2; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Lydeking-Olsen E, 2002, J NUTR, V132, p581S; Maggi A, 2004, ANNU REV PHYSIOL, V66, P291, DOI 10.1146/annurev.physiol.66.032802.154945; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; Manas ES, 2004, STRUCTURE, V12, P2197, DOI 10.1016/j.str.2004.09.015; MARKIEWICZ L, 1993, J STEROID BIOCHEM, V45, P399, DOI 10.1016/0960-0760(93)90009-L; Maskarinec G, 2004, J NUTR, V134, p1246S; Maskarinec G, 2002, CANCER EPIDEM BIOMAR, V11, P195; Massart F, 2006, Minerva Pediatr, V58, P247; Masutomi N, 2003, TOXICOLOGY, V192, P149, DOI 10.1016/S0300-483X(03)00269-5; Mathey J, 2007, OSTEOPOROSIS INT, V18, P671, DOI 10.1007/s00198-007-0351-y; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; MCLACHLAN JA, 1982, FERTIL STERIL, V38, P364; Messina M, 2006, NUTR CANCER, V55, P1, DOI 10.1207/s15327914nc5501_1; Messina M, 2002, J NUTR, V132, p547S; Micevych P, 2009, J NEUROENDOCRINOL, V21, P249, DOI 10.1111/j.1365-2826.2009.01833.x; Micevych P, 2009, FRONT NEUROENDOCRIN, V30, P315, DOI 10.1016/j.yfrne.2009.04.011; Banks E, 2003, LANCET, V362, P419; Moore TO, 2004, BRAIN RES, V1016, P102, DOI 10.1016/j.brainres.2004.04.073; Mortensen A, 2009, MOL NUTR FOOD RES, V53, pS266, DOI 10.1002/mnfr.200800478; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; Muthyala RS, 2004, BIOORGAN MED CHEM, V12, P1559, DOI 10.1016/j.bmc.2003.11.035; Nagao T, 2001, REPROD TOXICOL, V15, P399, DOI 10.1016/S0890-6238(01)00141-1; Nagata C, 2006, CANCER CAUSE CONTROL, V17, P1107, DOI 10.1007/s10552-006-0044-4; Nagata C, 1998, J NATL CANCER I, V90, P1830, DOI 10.1093/jnci/90.23.1830; National Electrical Manufacturers Association, 2008, NAT TOX PROGR TECH R; Navarro VM, 2004, J PHYSIOL-LONDON, V561, P379, DOI 10.1113/jphysiol.2004.072298; Nestel PJ, 1999, J CLIN ENDOCR METAB, V84, P895, DOI 10.1210/jc.84.3.895; Newbold Retha R, 2008, Fertil Steril, V89, pe55, DOI 10.1016/j.fertnstert.2008.01.062; Newbold RR, 2001, CANCER RES, V61, P4325; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; North K, 2000, BJU INT, V85, P107, DOI 10.1046/j.1464-410x.2000.00436.x; Oakley AE, 2009, ENDOCR REV, V30, P713, DOI 10.1210/er.2009-0005; Ogawa S, 1998, ENDOCRINOLOGY, V139, P5070, DOI 10.1210/en.139.12.5070; Ogawa S, 1996, NEUROENDOCRINOLOGY, V64, P467, DOI 10.1159/000127154; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; Oseni T, 2008, PLANTA MED, V74, P1656, DOI 10.1055/s-0028-1088304; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Padilla-Banks E, 2006, ENDOCRINOLOGY, V147, P4871, DOI 10.1210/en.2006-0389; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Palmlund I, 1996, J PSYCHOSOM OBST GYN, V17, P71, DOI 10.3109/01674829609025667; Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019; Patchev AV, 2004, FASEB J, V18, P1568, DOI 10.1096/fj.04-1959fje; Patisaul HB, 2004, HORM BEHAV, V45, P270, DOI 10.1016/j.yhbeh.2003.12.006; Patisaul HB, 2003, J NEUROENDOCRINOL, V15, P787, DOI 10.1046/j.1365-2826.2003.01061.x; Patisaul HB, 2002, ENDOCRINOLOGY, V143, P2189, DOI 10.1210/en.143.6.2189; Patisaul HB, 2009, NEUROTOXICOLOGY, V30, P350, DOI 10.1016/j.neuro.2009.02.010; Patisaul HB, 2007, NEUROTOXICOLOGY, V28, P1, DOI 10.1016/j.neuro.2006.10.001; Patisaul HB, 2008, BRAIN RES REV, V57, P352, DOI 10.1016/j.brainresrev.2007.06.008; Patisaul HB, 1999, MOL BRAIN RES, V67, P165, DOI 10.1016/S0169-328X(99)00058-3; Patisaul HB, 2005, J NEUROENDOCRINOL, V17, P57, DOI 10.1111/j.1365-2826.2005.01268.x; Patisaul HB, 2001, ENDOCRINOLOGY, V142, P2946, DOI 10.1210/en.142.7.2946; Peeters PHM, 2007, J NUTR, V137, P1294; Pelissero C, 1996, J STEROID BIOCHEM, V57, P215, DOI 10.1016/0960-0760(95)00261-8; Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269; Perez SE, 2003, DEV BRAIN RES, V145, P117, DOI 10.1016/S0165-3806(03)00223-2; MESSINA MJ, 1994, NUTR CANCER, V21, P113; Pfaff D, 1999, DRIVE; Pfitscher A, 2008, J STEROID BIOCHEM, V112, P87, DOI 10.1016/j.jsbmb.2008.08.007; PIONTEK M, 1993, ANTICANCER RES, V13, P2119; PIOTROWSKA E, 2009, PHYTOTHER RES; Polston EK, 2004, NEUROSCIENCE, V123, P793, DOI 10.1016/j.neuroscience.2003.09.034; Polston EK, 2006, J COMP NEUROL, V495, P122, DOI 10.1002/cne.20874; Potter SM, 1998, AM J CLIN NUTR, V68, p1375S; Ravindranath MH, 2004, ADV EXP MED BIOL, V546, P121; Register TC, 2003, J CLIN ENDOCR METAB, V88, P4362, DOI 10.1210/jc.2003-030493; Remy P, 2005, BRAIN, V128, P1314, DOI 10.1093/brain/awh445; Rissman EF, 1997, HORM BEHAV, V31, P232, DOI 10.1006/hbeh.1997.1390; Rissman EF, 2008, J NEUROENDOCRINOL, V20, P873, DOI 10.1111/j.1365-2826.2008.01738.x; Roa J, 2006, ENDOCRINOLOGY, V147, P2864, DOI 10.1210/en.2005-1463; Robb EL, 2008, BIOCHEM BIOPH RES CO, V367, P406, DOI 10.1016/j.bbrc.2007.12.138; ROLWAND I, 2000, NUTR CANC, V36, P27; Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rozman KK, 2006, BIRTH DEFECTS RES B, V77, P485, DOI 10.1002/bdrb.20087; Rubin MM, 2007, OBSTET GYNECOL SURV, V62, P548, DOI 10.1097/01.ogx.0000271138.31234.d7; RuizLarrea MB, 1997, FREE RADICAL RES, V26, P63, DOI 10.3109/10715769709097785; Sacks FM, 2006, CIRCULATION, V113, P1034, DOI 10.1161/CIRCULATIONAHA.106.171052; Santell RC, 1997, J NUTR, V127, P263; Scallet AC, 2003, TOXICOL SCI, V72, P296, DOI 10.1093/toxsci/kfg029; Scallet AC, 2004, TOXICOL SCI, V82, P570, DOI 10.1093/toxsci/kfh297; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schmidt S, 2006, ARCH TOXICOL, V80, P839, DOI 10.1007/s00204-006-0102-4; SCHOENTAL R, 1983, LANCET, V1, P537; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Schwartz H, 2009, FOOD CHEM, V113, P736, DOI 10.1016/j.foodchem.2008.09.051; SENTI FR, 1974, J AM OIL CHEM SOC, V51, pA138, DOI 10.1007/BF02542114; Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S; Setchell KDR, 2001, J NUTR, V131, p1362S; SETCHELL KDR, 1987, GASTROENTEROLOGY, V93, P225; SETCHELL KDR, 1987, J CHROMATOGR, V386, P315, DOI 10.1016/S0021-9673(01)94608-4; Setchell KDR, 2002, J NUTR, V132, p593S; Setchell KDR, 2003, J NUTR, V133, P1027; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Sharpe RM, 2002, HUM REPROD, V17, P1692, DOI 10.1093/humrep/17.7.1692; Shen W, 2009, EXPERT OPIN PHARMACO, V10, P1133, DOI [10.1517/14656560902868217 , 10.1517/14656560902868217]; Shu XO, 2009, JAMA-J AM MED ASSOC, V302, P2437, DOI 10.1001/jama.2009.1783; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4&lt;507::AID-CNE1&gt;3.0.CO;2-6; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; Simon NG, 2004, HORM BEHAV, V45, P278, DOI 10.1016/j.yhbeh.2003.12.005; Sirtori CR, 2005, ANN MED, V37, P423, DOI 10.1080/07853890510044586; Smith JT, 2006, J NEUROSCI, V26, P6687, DOI 10.1523/JNEUROSCI.1618-06.2006; Smith JT, 2006, REPRODUCTION, V131, P623, DOI 10.1530/rep.1.00368; SMITH OW, 1948, AM J OBSTET GYNECOL, V56, P821; Soyfoods Associations of North America, 2009, SOYF SAL TRENDS; Speroff L, 2005, INT J FERTIL WOMEN M, V50, P101; Stricker R, 2006, CLIN CHEM LAB MED, V44, P883, DOI 10.1515/CCLM.2006.160; Strom BL, 2001, JAMA-J AM MED ASSOC, V286, P807, DOI 10.1001/jama.286.7.807; Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; TAN MA, 2006, HUMAN REPROD, V21, P896; Taylor CK, 2009, NUTR REV, V67, P398, DOI 10.1111/j.1753-4887.2009.00213.x; The North American Menopause Society, 2004, MENOPAUSE, V11, P11; Thomas JM, 2001, J AM DIET ASSOC, V101, P461, DOI 10.1016/S0002-8223(01)00118-3; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Todaka E, 2005, ENVIRON RES, V99, P195, DOI 10.1016/j.envres.2004.11.006; Tomar RS, 2008, J ENVIRON SCI HEAL C, V26, P113, DOI 10.1080/10590500802074256; Trock BJ, 2006, J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102; Tuohy PG, 2003, J PAEDIATR CHILD H, V39, P401, DOI 10.1046/j.1440-1754.2003.00178.x; UK Committee on Toxicity, 2003, PHYT HLTH; *US BOARD, 2009, 16 ANN SURV CONS ATT; USDA, 2008, DAT IS CONT SEL FOOD; Valentin-Blasini L, 2003, J EXPO ANAL ENV EPID, V13, P276, DOI 10.1038/sj.jea.7500278; van Pelt AMM, 1999, ENDOCRINOLOGY, V140, P478, DOI 10.1210/en.140.1.478; Vasudevan N, 2008, FRONT NEUROENDOCRIN, V29, P238, DOI 10.1016/j.yfrne.2007.08.003; Verheus M, 2007, J CLIN ONCOL, V25, P648, DOI 10.1200/JCO.2006.06.0244; Verkasalo PK, 2001, BRIT J NUTR, V86, P415, DOI 10.1079/BJN2001424; Wallen K, 2005, FRONT NEUROENDOCRIN, V26, P7, DOI 10.1016/j.yfrne.2005.02.001; WANG CF, 1994, J STEROID BIOCHEM, V50, P205, DOI 10.1016/0960-0760(94)90030-2; Wang TTY, 1996, CARCINOGENESIS, V17, P271, DOI 10.1093/carcin/17.2.271; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321; Whitten P.L., 1997, HDB PLANT FUNGAL TOX, P117; Whitten PL, 2001, ENVIRON HEALTH PERSP, V109, P5, DOI 10.2307/3434842; WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679; WITT DM, 1991, ENDOCRINOLOGY, V128, P3269; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu AH, 2000, BRIT J CANCER, V82, P1879, DOI 10.1054/bjoc.1999.1218; Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145; Yamori Y, 2002, J AM COLL NUTR, V21, P560; Ye She-Fang, 2003, Endocr Regul, V37, P145; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Young LJ, 1998, NEUROREPORT, V9, P933, DOI 10.1097/00001756-199803300-00031; ZHANG C, 2009, CANC SCI; Zhang JQ, 2002, BRAIN RES, V935, P73, DOI 10.1016/S0006-8993(02)02460-5; Zoppi G, 1999, J PEDIATR GASTR NUTR, V28, P541, DOI 10.1097/00005176-199905000-00022; Zung A, 2008, J PEDIATR GASTR NUTR, V46, P191, DOI 10.1097/MPG.0b013e318159e6ae30382ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAFRONT NEUROENDOCRINOCTSIDiscipline: Endocrinology &amp; Metabolism; Neurosciences &amp; Neurology676EZ</notes>
    <keywords>ANTEROVENTRAL PERIVENTRICULAR NUCLEUS; ASSOCIATION; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; BONE; BPA; Brain; breast; breast cancer; BREAST-CANCER; BREAST-CANCER RISK; CANCER; CARCINOGENESIS; COMPLEXES; DEFECTS; DEPENDENT GENE-EXPRESSION; DES; diet; DIETARY-SUPPLEMENTS; DISEASE; ENDOCRINE; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; Equol; ER alpha; ER beta; Estrogen; ESTROGEN-RECEPTOR-BETA; FOOD; FOODS; genistein; GONADOTROPIN-RELEASING-HORMONE; HEALTH; heart; HEART-DISEASE; HUMAN HEALTH; HYPOTHALAMUS; IMPACT; INFANT FORMULA; ISOFLAVONES; Menopause; METABOLISM; MODEL; p21; p38; pediatric; Phytoestrogen; PHYTOESTROGENS; PROCESSED FOOD; PROTEIN; RANDOMIZED CONTROLLED-TRIAL; REPLACEMENT THERAPY; Reproduction; Review; RISK; SEXUALLY DIMORPHIC NUCLEUS; SOCIETY; SOY; SOY INFANT FORMULA; SOY PROTEIN; SPRAGUE-DAWLEY RATS; Steroid; TESTICULAR DYSGENESIS SYNDROME; THERAPY; TOXICITY; toxicology; UPDATE; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>400</startpage>
    <endpage>419</endpage>
    <journalfull>Frontiers in Neuroendocrinology</journalfull>
    <issue>4</issue>
    <volume>31</volume>
    <abstract>Phytoestrogens are plant derived compounds found in a wide variety of foods, most notably soy. A litany of health benefits including a lowered risk of osteoporosis, heart disease, breast cancer, and menopausal symptoms, are frequently attributed to phytoestrogens but many are also considered endocrine disruptors, indicating that they have the potential to cause adverse health effects as well. Consequently, the question of whether or not phytoestrogens are beneficial or harmful to human health remains unresolved. The answer is likely complex and may depend on age, health status, and even the presence or absence of specific gut microflora. Clarity on this issue is needed because global consumption is rapidly increasing. Phytoestrogens are present in numerous dietary supplements and widely marketed as a natural alternative to estrogen replacement therapy. Soy infant formula now constitutes up to a third of the US market, and soy protein is now added to many processed foods. As weak estrogen agonists/antagonists with molecular and cellular properties similar to synthetic endocrine disruptors such as Bisphenol A (BPA), the phytoestrogens provide a useful model to comprehensively investigate the biological impact of endocrine disruptors in general. This review weighs the evidence for and against the purported health benefits and adverse effects of phytoestrogens. (C) 2010 Published by Elsevier Inc</abstract>
    <url>WOS:000283894200002</url>
    <isbnorissn>0091-3022</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>155</id>
    <title>Use and validation of HT/HC assays to support 21st century toxicity evaluations</title>
    <authors>Patlewicz,G.; Simon,T.; Goyak,K.; Phillips,R.D.; Rowlands,J.C.; Seidel,S.D.; Becker,R.A.</authors>
    <availability>[Patlewicz, Grace] DuPont Haskell Global Ctr Hlth &amp; Environm Sci, Newark, DE 19711 USA. [Simon, Ted] Ted Simon LLC, Winston, GA 30187 USA. [Goyak, Katy; Phillips, Richard D.] ExxonMobil Biomedical Sci Inc, Annandale, NJ 08801 USA. [Rowlands, J. Craig] Dow Chem Co USA, Toxicol &amp; Environm Res &amp; Consulting, Midland, MI 48674 USA. [Seidel, Shawn D.] Dow Corning Corp, Midland, MI 48686 USA. [Becker, Richard A.] ACC, Regulatory &amp; Tech Affairs Dept, Washington, DC 20002 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticlePatlewicz, G (reprint author), DuPont Haskell Global Ctr Hlth &amp; Environm Sci, 1090 Elkton Rd, Newark, DE 19711 USApatlewig@hotmail.comAkahori Y., 2008, TOXICOL IN VITRO, V22, P664; Ankley GT, 2010, ENVIRON TOXICOL CHEM, V29, P730, DOI 10.1002/etc.34; Balls M, 2006, ATLA-ALTERN LAB ANIM, V34, P603; Boobis AR, 2009, CRIT REV FOOD SCI, V49, P690, DOI 10.1080/10408390903098673; CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; CHALMERS I, 1994, BRIT MED J, V309, P862; Doull J, 2007, FOOD CHEM TOXICOL, V45, P759, DOI 10.1016/j.fct.2006.10.025; Eriksson L, 2003, ENVIRON HEALTH PERSP, V111, P1361, DOI 10.1289/ehp.5758; European Chemicals Agency, 2008, GUID INF REQ CHEM SA; Gorbunova V, 2007, NUCLEIC ACIDS RES, V35, P7466, DOI 10.1093/nar/gkm756; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartung T., 2011, ALTEX, V28, P82; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; ICCVAM, 2006, NIH PUBL; ICCVAM, 2003, NIH PUBL; IOM (Institute of Medicine), 2010, EV BIOM SURR ENDP CH; Judson R., ALTEX IN PRESS; Judson RS, 2010, ENVIRON HEALTH PERSP, V118, P485, DOI 10.1289/ehp.0901392; Julien E, 2009, CRIT REV FOOD SCI, V49, P682, DOI 10.1080/10408390903110692; Keller DA, 2012, TOXICOL SCI, V126, P291, DOI 10.1093/toxsci/kfr350; Knudsen TB, 2011, TOXICOLOGY, V282, P1, DOI 10.1016/j.tox.2010.12.010; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Mayr E., 1982, GROWTH BIOL THOUGHT; NIEHS - National Institute of Environmental Health Sciences, 1997, NIH PUBL, V97-3981; NRC (National Research Council), 2007, TOX TEST 21 CENT VIS; OECD, 2007, GUID DOC VAL QUANT S; *OECD, 2011, SER TEST ASS, V138; Ong KM, 2010, P NATL ACAD SCI USA, V107, P7107, DOI 10.1073/pnas.0911095107; Preston BD, 2010, SEMIN CANCER BIOL, V20, P281, DOI 10.1016/j.semcancer.2010.10.009; Reif DM, 2010, ENVIRON HEALTH PERSP, V118, P1714, DOI 10.1289/ehp.1002180; Seed Jennifer, 2005, Crit Rev Toxicol, V35, P664; Slikker W, 2004, TOXICOL APPL PHARM, V201, P203, DOI 10.1016/j.taap.2004.06.019; Sobus JR, 2011, SCI TOTAL ENVIRON, V409, P4875, DOI 10.1016/j.scitotenv.2011.07.046; Stephens ML, 2013, ALTEX-ALTERN ANIM EX, V30, P74; Stephens ML, 2011, TOXICOL SCI, V125, P327; Thomas RS, 2012, TOXICOL SCI, V128, P398, DOI 10.1093/toxsci/kfs159; United States Environmental Protection Agency (USEPA), 2007, 120R07002A USEPA; USEPA, 2005, EPA630P03001B; VANDEKAR M, 1971, B WORLD HEALTH ORGAN, V44, P241; Willhite CC, 2008, J TOXICOL ENV HEAL B, V11, P69, DOI 10.1080/10937400701724303; Worth A.P., 2005, 21866 EUR EN; Worth AP, 2007, SAR QSAR ENVIRON RES, V18, P111, DOI 10.1080/10629360601054255; Zhang Y, 1999, J NUTR, V129, P399445ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAREGUL TOXICOL PHARMMARDiscipline: Legal Medicine; Pharmacology &amp; Pharmacy; Toxicology096UG</notes>
    <keywords>(Q)SAR; Adverse outcome pathway; BIOMARKER; Biomarkers; BISPHENOL-A; CANCER; CELL; CHEMICALS; Dosimetry; EXPOSURE; FOOD; FRAMEWORK; GROWTH; HALLMARKS; HEALTH; HEALTH-CARE; High-throughput/high content (HT/HC) assays; In vitro; In vitro testing; IN-VITRO; IN-VIVO; MODEL; MODELS; PHARMACOLOGY; PREDICTION; Predictive model; RISK; Risk assessment; RISK-ASSESSMENT; SYSTEMATIC REVIEWS; ToxCast; TOXICITY; Toxicogenomics; toxicology; Validation; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>259</startpage>
    <endpage>268</endpage>
    <journalfull>Regulatory Toxicology and Pharmacology</journalfull>
    <issue>2</issue>
    <volume>65</volume>
    <abstract>Advances in high throughput and high content (HT/HC) methods such as those used in the fields of toxicogenomics, bioinformatics, and computational toxicology have the potential to improve both the efficiency and effectiveness of toxicity evaluations and risk assessments. However, prior to use, scientific confidence in these methods should be formally established. Traditional validation approaches that define relevance, reliability, sensitivity and specificity may not be readily applicable. HT/HC methods are not exact replacements for in vivo testing, and although run individually, these assays are likely to be used as a group or battery for decision making and use robotics, which may be unique in each laboratory setting. Building on the frameworks developed in the 2010 Institute of Medicine Report on Biomarkers and the OECD 2007 Report on (Q)SAR Validation, we present constructs that can be adapted to address the validation challenges of HT/HC methods. These are flexible, transparent, and require explicit specification of context and purpose of use such that scientific confidence (validation) can be defined to meet different regulatory applications. Using these constructs, we discuss how anchoring the assays and their prediction models to Adverse Outcome Pathways (AOPs) could facilitate the interpretation of results and support scientifically defensible fit-for-purpose applications. (C) 2012 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000315429200010</url>
    <isbnorissn>0273-2300</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>371</id>
    <title>Antineoplastic Agents. 556. Isolation and Structure of Coprinastatin 1 from Coprinus cinereus</title>
    <authors>Pettit,G.R.; Meng,Y.H.; Pettit,R.K.; Herald,D.L.; Cichacz,Z.A.; Doubek,D.L.; Richert,L.</authors>
    <availability>[Pettit, George R.] Arizona State Univ, Canc Res Inst, Tempe, AZ 85287 USA. Arizona State Univ, Dept Chem &amp; Biochem, Tempe, AZ 85287 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticlePettit, GR (reprint author), Arizona State Univ, Canc Res Inst, POB 871604, Tempe, AZ 85287 USAbpettit@asu.edu[Anonymous], 1997, SHELXTL VERS 5 1; Baldrian P, 2006, FEMS MICROBIOL REV, V30, P215, DOI 10.1111/j.1574-4976.2005.00010.x; BLESSING RH, 1995, ACTA CRYSTALLOGR A, V51, P33, DOI 10.1107/S0108767394005726; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borchers AT, 2004, EXP BIOL MED, V229, P393; BOTTOM CB, 1975, PHYTOCHEMISTRY, V14, P1433, DOI 10.1016/S0031-9422(00)98645-X; Bouws H, 2008, APPL MICROBIOL BIOT, V80, P381, DOI 10.1007/s00253-008-1572-5; BULOCK JD, 1976, PHYTOCHEMISTRY, V15, P2004, DOI 10.1016/S0031-9422(00)88879-2; Clericuzio M, 1997, TETRAHEDRON LETT, V38, P8237, DOI 10.1016/S0040-4039(97)10125-3; Del Val AG, 2003, MYCOL RES, V107, P1201, DOI 10.1017/S0953756203008487; FIELDER DA, 1994, TETRAHEDRON LETT, V35, P521, DOI 10.1016/S0040-4039(00)75827-8; Gene J, 1996, ANTON LEEUW INT J G, V70, P49, DOI 10.1007/BF00393569; Ishikawa NK, 2000, PHYTOCHEMISTRY, V54, P777, DOI 10.1016/S0031-9422(00)00189-8; Kettering M, 2005, J ANTIBIOT, V58, P390; Kilaru S, 2006, CURR GENET, V50, P45, DOI 10.1007/s00294-006-0074-1; Kim YH, 2005, J MOL CATAL B-ENZYM, V34, P33, DOI 10.1016/j.molcatb.2005.04.005; Kim YH, 2007, J MOL CATAL B-ENZYM, V44, P149, DOI 10.1016/j.molcatb.2006.10.004; Kluge M, 1998, J NAT PROD, V61, P821, DOI 10.1021/np970525d; Kulys J, 2007, BIOLOGIJA, V53, P40; Levasseur A, 2008, FUNGAL GENET BIOL, V45, P638, DOI 10.1016/j.fgb.2008.01.004; Lilly WW, 2008, MYCOL RES, V112, P389, DOI 10.1016/j.mycres.2007.11.013; Lindequist U, 2005, EVID-BASED COMPL ALT, V2, P285, DOI 10.1093/ecam/neh107; Liu YJ, 2008, CHEM NAT COMPD+, V44, P203, DOI 10.1007/s10600-008-9014-2; Lopez-Anton N, 2006, J BIOL CHEM, V281, P33078, DOI 10.1074/jbc.M607904200; Mao X, 2006, ENVIRON TECHNOL, V27, P1401, DOI 10.1080/09593332708618757; Miller JD, 1996, BIOCHEM SYST ECOL, V24, P647, DOI 10.1016/S0305-1978(97)81208-2; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; National Committee for Clinical Laboratory Standards NCCLS, 2000, METH DIL ANT SUSC TE; NCCLS, 2002, REF METH BROTH DIL A; Pettit GR, 2003, J NAT PROD, V66, P259, DOI 10.1021/np020231e; Poucheret P, 2006, CRYPTOGAMIE MYCOL, V27, P311; Rasser F, 2002, TETRAHEDRON, V58, P7785, DOI 10.1016/S0040-4020(02)00943-2; Reina M, 2004, PHYTOCHEMISTRY, V65, P381, DOI 10.1016/j.phytochem.2003.10.023; Sakurai A, 2004, J CHEM ENG JPN, V37, P137, DOI 10.1252/jcej.37.137; Schneider P, 1999, ENZYME MICROB TECH, V25, P502, DOI 10.1016/S0141-0229(99)00085-X; STARRATT AN, 1989, CAN J CHEM, V67, P417, DOI 10.1139/v89-065; Ulrich CE, 2007, CAN J MICROBIOL, V53, P1278, DOI 10.1139/W07-100; Valdivia C, 2005, TETRAHEDRON, V61, P9527, DOI 10.1016/j.tet.2005.07.090; Wang Y, 2003, HELV CHIM ACTA, V86, P2424, DOI 10.1002/hlca.200390195; Yaver DS, 1999, APPL ENVIRON MICROB, V65, P4943; Ziemys A, 2007, J MOL CATAL B-ENZYM, V44, P20, DOI 10.1016/j.molcatb.2006.07.015419AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USAJ NAT PRODMARSIDiscipline: Plant Sciences; Pharmacology &amp; Pharmacy573CC</notes>
    <keywords>1; 4-ACETYL-BENZOXAZOLIN-2-ONE 4-ABOA; AGENTS; BISPHENOL-A; CANCER; CE; CELL; COPRINOPSIS-EPISCOPALIS; Determination; DITERPENOIDS; GENE; GROWTH; HEPTEMERUS; Laccase; LEUKEMIA; LINE; MOLECULAR CHARACTERIZATION; PEROXIDASE; PHARMACOLOGY; SESQUITERPENES; ZEA-MAYS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>388</startpage>
    <endpage>392</endpage>
    <journalfull>Journal of Natural Products</journalfull>
    <issue>3</issue>
    <volume>73</volume>
    <abstract>Cancer cell line bioassay-guided Separation of an ethyl acetate extract prepared from a plant-associated fungus, Coprinus citiereus, led to the isolation of three new sesquiterpenes, coprinaslatin 1 (1), coprinol (2), and the epimer (4a), of the known sesquiterpene triol 4b. The previously described sesquiterpene 3 and oxazolinone 5 were also isolated. The structure and relative configuration Of coprinastatin 1 (1) were determined by HRMS and by 1D- and 2D-NMR spectroscopic analyses. The Structure of terpene 2 Was elucidated by single-crystal X-ray diffraction experiments. The remaining, Structures were similarly determined, Structure 3 by Spectroscopic analyses and both 4a and 5 by X-ray crystal structure determination. Coprinastatin 1 (1) Was found to inhibit growth of the murine P388 lymphocytic leukemia cell line and the pathogenic bacterium Neisseria gonorrhoeae</abstract>
    <url>WOS:000275885000017</url>
    <isbnorissn>0163-3864</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>21</id>
    <title>Comparative study of bisphenol A and its analogue bisphenol S on human hepatic cells: A focus on their potential involvement in nonalcoholic fatty liver disease</title>
    <authors>Peyre,L.; Rouimi,P.; de Sousa,G.; Helies-Toussaint,C.; Carre,B.; Barcellini,S.; Chagnon,M.C.; Rahmani,R.</authors>
    <availability>[Peyre, Ludovic; de Sousa, Georges; Rahmani, Roger] INRA, UMR TOXALIM Res Ctr Food Toxicol 1331, Lab Xenobiot Cellular &amp; Mol Toxicol, F-06903 Sophia Antipolis, France. [Rouimi, Patrick; Helies-Toussaint, Cecile; Carre, Benjamin; Rahmani, Roger] INRA, UMR TOXALIM Res Ctr Food Toxicol 1331, F-31027 Toulouse, France. [Barcellini, Sylvie] INRA Agrobiotech, Neomah, F-06903 Sophia Antipolis, France. [Chagnon, Marie-Christine] AgroSupDijon, INSERM UMR866, Derttech Packtox, Nutox Lab, F-21000 Dijon, France.</availability>
    <date>2014</date>
    <notes>JEnglishArticlePeyre, L (reprint author), INRA, UMR 1331, Lab Toxicol Cellulaire Mol &amp; Genom, 400 Route Chappes,BP167, F-06903 Sophia Antipolis, Franceludovic.peyre@sophia.inra.fr; Roger.rahmani@sophia.inra.frAitken AE, 2008, FREE RADICAL BIO MED, V44, P1161, DOI 10.1016/j.freeradbiomed.2007.12.010; Andersson TB, 2012, EXPERT OPIN DRUG MET, V8, P909, DOI 10.1517/17425255.2012.685159; Aninat C, 2006, DRUG METAB DISPOS, V34, P75, DOI 10.1124/dmd.105.006759; ANSES, 2013, EV RISQ BISPH SANT H; Antherieu S, 2011, HEPATOLOGY, V53, P1895, DOI 10.1002/hep.24290; Atienzar FA, 2011, J BIOMOL SCREEN, V16, P575, DOI 10.1177/1087057111402825; Barrett J.R., 2012, ENV HLTH PERSPECT, V120, pA122; Besteman Elizabeth G, 2007, Toxicol Pathol, V35, P788; Braniste V, 2010, P NATL ACAD SCI USA, V107, P448, DOI 10.1073/pnas.0907697107; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Chen C, 2011, XENOBIOTICA, V41, P476, DOI 10.3109/00498254.2011.560971; Crepet A, 2013, TOXICOLOGY, V313, P83, DOI 10.1016/j.tox.2013.04.005; Csanady GA, 2002, ARCH TOXICOL, V76, P299, DOI 10.1007/s00204-002-0339-5; DeKeyser JG, 2011, TOXICOL SCI, V120, P381, DOI 10.1093/toxsci/kfq394; Desmots F, 2001, J HISTOCHEM CYTOCHEM, V49, P1573; Desmots F, 2002, J BIOL CHEM, V277, P17892, DOI 10.1074/jbc.M112351200; Donato MT, 2009, CHEM-BIOL INTERACT, V181, P417, DOI 10.1016/j.cbi.2009.07.019; Donato MT, 2006, DRUG METAB DISPOS, V34, P1556, DOI 10.1124/dmd.106.009670; Dvorak Z, 2003, MOL PHARMACOL, V64, P160, DOI 10.1124/mol.64.1.160; Fenichel P, 2012, HUM REPROD, V27, P983, DOI 10.1093/humrep/der451; Gerets HHJ, 2012, CELL BIOL TOXICOL, V28, P69, DOI 10.1007/s10565-011-9208-4; Greco D, 2008, AM J PHYSIOL-GASTR L, V294, pG1281, DOI 10.1152/ajpgi.00074.2008; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Guillouzo A, 2007, CHEM-BIOL INTERACT, V168, P66, DOI 10.1016/j.cbi.2006.12.003; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Huc L, 2012, TOXICOL IN VITRO, V26, P709, DOI 10.1016/j.tiv.2012.03.017; Ibrahim SH, 2011, J PEDIATR GASTR NUTR, V53, P131, DOI 10.1097/MPG.0b013e31822578db; Izumi Y, 2011, SYST BIOL REPROD MED, V57, P228, DOI 10.3109/19396368.2011.574248; Kadoma Y, 2000, Dent Mater J, V19, P139; Khalil N, 2014, SCI TOTAL ENVIRON, V470, P726, DOI 10.1016/j.scitotenv.2013.09.088; Kuzbari O, 2013, REPROD TOXICOL, V37, P24, DOI 10.1016/j.reprotox.2013.01.005; Lakind J.S., 2014, CRIT REV TOXICOL; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lemaire G, 2004, BIOCHEM PHARMACOL, V68, P2347, DOI 10.1016/j.bcp.2004.07.041; Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689; Liao CY, 2012, ENVIRON SCI TECHNOL, V46, P6860, DOI 10.1021/es301334j; Lin Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.206; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu H, 2010, TOXICOL SCI, V118, P380, DOI 10.1093/toxsci/kfq280; Marmugi A, 2012, HEPATOLOGY, V55, P395, DOI 10.1002/hep.24685; Mazur CS, 2012, TOXICOL SCI, V128, P317, DOI 10.1093/toxsci/kfs167; Molina-Molina JM, 2013, TOXICOL APPL PHARM, V272, P127, DOI 10.1016/j.taap.2013.05.015; Moreau A, 2009, HEPATOLOGY, V49, P2068, DOI 10.1002/hep.22907; Moya M, 2010, CHEM-BIOL INTERACT, V184, P376, DOI 10.1016/j.cbi.2010.01.008; Nakamura S, 2011, TOXICOL LETT, V203, P92, DOI 10.1016/j.toxlet.2011.03.010; Nawaz A., 2013, CELL BIOL TOXICOL; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Ryan KK, 2010, ENDOCRINOLOGY, V151, P2603, DOI 10.1210/en.2009-1218; Santolla MF, 2012, J BIOL CHEM, V287, P43234, DOI 10.1074/jbc.M112.417303; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Sengupta S, 2013, BRIT J PHARMACOL, V169, P167, DOI 10.1111/bph.12122; Shankar A., 2012, ISRN ENDOCRINOL, V2012; Somm E, 2009, ENVIRON HEALTH PERSP, V117, P1549, DOI 10.1289/ehp.11342; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Swedenborg E, 2012, MOL CELL ENDOCRINOL, V362, P39, DOI 10.1016/j.mce.2012.05.006; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Vandenberg LN, 2012, CIENC SAUDE COLETIVA, V17, P407, DOI 10.1590/S1413-81232012000200015; Vinas R, 2013, ENVIRON HEALTH PERSP, V121, P352, DOI 10.1289/ehp.1205826; Xu XH, 2014, CHEMOSPHERE, V96, P129, DOI 10.1016/j.chemosphere.2013.09.063; Zhou C, 2009, NUCL RECEPTOR SIGNAL, V7, P1, DOI DOI 10.1621/NRS.07001; Zhou J, 2008, GASTROENTEROLOGY, V134, P556, DOI 10.1053/j.gastro.2007.11.037630PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLAUGDiscipline: Food Science &amp; Technology; ToxicologyAM1IO</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; Bisphenols A and S; BPA; CANCER-ASSOCIATED FIBROBLASTS; cell death; CELL-DEATH; CELLS; CYTOCHROMES P450; DIETHYLSTILBESTROL; ERK1/2; EXPRESSION; FOOD; GENE-EXPRESSION; HEPARG CELLS; HUMAN HEALTH; In vitro; IN-VITRO; LINES; Liver; METABOLISM; NUCLEAR RECEPTORS; PERINATAL EXPOSURE; PREGNANE X RECEPTOR; PRIMARY HUMAN HEPATOCYTES; RECEPTOR; Steatosis; UP-REGULATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>9</startpage>
    <endpage>18</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <volume>70</volume>
    <abstract>For several decades, people have been in contact with bisphenol A (BPA) primarily through their diet. Nowadays it is gradually replaced by an analogue, bisphenol S (BPS). In this study, we compared the effects of these two bisphenols in parallel with the positive control diethylstilbestrol (DES) on different hepatocyte cell lines. Using a cellular impedance system we have shown that BPS is less cytotoxic than BPA in acute and chronic conditions. We have also demonstrated that, contrary to BPA, BPS is not able to induce an increase in intracellular lipid and does not activate the PXR receptor which is known to be involved in part, in this process. In parallel, it failed to modulate the expression of CYP3A4 and CYP2B6, the drug transporter ABCB1 and other lipid metabolism genes (FASN, PUN). However, it appears to have a weak effect on GSTA4 protein expression and on the Erk1/2 pathway. In conclusion, in contrast to BPA, BPS does not appear to induce the metabolic syndrome that may lead to non-alcoholic fatty liver disease (NAFLD), in vitro. Although we have to pay special attention to BPS, its use could be less dangerous concerning this toxicological endpoint for human health. (C) 2014 Published by Elsevier Ltd</abstract>
    <url>WOS:000339599800002</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>203</id>
    <title>Effects of some endocrine disruptors on cell cycle progression and murine dendritic cell differentiation</title>
    <authors>Pisapia,L.; Del Pozzo,G.; Barba,P.; Caputo,L.; Mita,L.; Viggiano,E.; Russo,G.L.; Nicolucci,C.; Rossi,S.; Bencivenga,U.; Mita,D.G.; Diano,N.</authors>
    <availability>[Pisapia, L.; Del Pozzo, G.; Barba, P.; Rossi, S.; Bencivenga, U.; Mita, D. G.; Diano, N.] CNR, Inst Genet &amp; Biophys, I-80131 Naples, Italy. [Caputo, L.; Mita, L.; Nicolucci, C.; Mita, D. G.; Diano, N.] INBB, Rome, Italy. [Mita, L.; Viggiano, E.; Nicolucci, C.; Mita, D. G.; Diano, N.] Univ Naples 2, Dept Expt Med, Naples, Italy. [Russo, G. L.] CNR, Inst Food Sci, Avellino, Italy.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMita, DG (reprint author), CNR, Inst Genet &amp; Biophys, Via Pietro Castellino 111, I-80131 Naples, Italymita@igb.cnr.itAhmed SR, 2000, TOXICOLOGY, V150, P191; Altucci L, 1996, ONCOGENE, V12, P2315; Bancherau J., 1992, CUR TOP MICROBIOL IM, V182, P85; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Danciger JS, 2004, J IMMUNOL METHODS, V288, P123, DOI 10.1016/j.jim.2004.03.003; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Diano N, 2007, APPL CATAL B-ENVIRON, V69, P252, DOI 10.1016/j.apcatb.2006.07.004; Foster J.S., MOL ENDOCRINOL, V10, P488; Gaido K.W., TOXICOL APPL PHARM, V143, P205; Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004; Heindel JJ, 2003, TOXICOL SCI, V76, P247, DOI 10.1093/toxsci/kfg255; Hiroi H, 2004, ENDOCR J, V51, P595, DOI 10.1507/endocrj.51.595; Hung CH, 2010, ENVIRON HEALTH PERSP, V118, P67, DOI 10.1289/ehp.0901011; Ito T., 2011, J APPL TOXI IN PRESS; Iwata M, 2004, IMMUNOL LETT, V94, P135, DOI 10.1016/j.imlet.2004.04.013; Jobling S., 1994, ENDOCRINOLOGY, V135, P175; Jourdan ML, 2002, CYTOMETRY, V48, P66, DOI 10.1002/cyto.10116; Kanda N, 1999, J ALLERGY CLIN IMMUN, V103, P282, DOI 10.1016/S0091-6749(99)70503-8; Kato T, 2006, EUR J IMMUNOL, V36, P1199, DOI 10.1002/eji.200535140; Kawaguchi H, 2010, IN VIVO, V24, P463; Kim SK, 2006, TOXICOL SCI, V94, P310, DOI 10.1093/toxsci/kfl114; Kurita T, 2004, DEVELOPMENT, V131, P1639, DOI 10.1242/dev.01038; Kwack SJ, 2002, J TOXICOL ENV HEAL A, V65, P419, DOI 10.1080/15287390252808082; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Lue Bo, 2010, Toxicological and Environmental Chemistry, V92, P1303, DOI 10.1080/02772240903503906; Ma L, 2009, TRENDS ENDOCRIN MET, V20, P357, DOI 10.1016/j.tem.2009.03.009; Malanga D, 2007, CELL IMMUNOL, V246, P75, DOI 10.1016/j.cellimm.2007.06.003; Marino M., MECH AGEING DEV, V123, P1183; Miyakoshi T, 2009, ACTA HISTOCHEM CYTOC, V42, P23, DOI 10.1267/ahc.08036; Morice L, 2011, REPROD TOXICOL, V32, P69, DOI 10.1016/j.reprotox.2011.05.003; Mouritsen A, 2010, INT J ANDROL, V33, P346, DOI 10.1111/j.1365-2605.2010.01051.x; Nalbandian G, 2005, IMMUNOL RES, V31, P91, DOI 10.1385/IR:31:2:091; Newbold RR, 2004, TOXICOL APPL PHARM, V199, P142, DOI 10.1016/j.taap.2003.11.033; Newbold RR, 2000, ENVIRON HEALTH PERSP, V108, P769, DOI 10.2307/3454304; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Okada M, 2010, INT J MOL SCI, V11, P4114, DOI 10.3390/ijms11104114; Oken E, 2003, OBES RES, V11, P496, DOI 10.1038/oby.2003.69; Paharkova-Vatchkova V, 2004, J IMMUNOL, V172, P1426; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Quignot N, 2012, TOXICOL IN VITRO, V26, P107, DOI 10.1016/j.tiv.2011.11.004; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Rubin B.S., ENV HLTH PERSP, V109, P675; Sallout B, 2003, J Obstet Gynaecol, V23, P555; Signorile PG, 2010, GEN COMP ENDOCR, V168, P318, DOI 10.1016/j.ygcen.2010.03.030; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Warren G.F., 2008, J TOXICOL ENV HEAL B, V11, P177; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Yang MH, 2003, ARCH ENVIRON CON TOX, V44, P546, DOI 10.1007/s00244-002-2124-0; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Yurino H, 2004, TOXICOL SCI, V81, P139, DOI 10.1093/toxsci/kfh179546ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAGEN COMP ENDOCRAUG 1Discipline: Endocrinology &amp; Metabolism973VC</notes>
    <keywords>ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; BONE; BPA; breast; CANCER; CARCINOMA; CELL; cell cycle; Cell differentiation; CELL-CYCLE; CELLS; CHEMICALS; CYCLE; CYCLE PROGRESSION; Dendritic cells; development; Differentiation; EDCs; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; GENE-TRANSCRIPTION; GROWTH; HEALTH; Hormones; HUMAN BREAST-CANCER; IMMUNE-SYSTEM; In vitro; IN-VITRO; IN-VIVO; INDUCTION; Interaction; MCF-7; MESSENGER-RNA; METABOLISM; NEURONAL DIFFERENTIATION; Nonylphenol; NORMAL WOMEN; octylphenol; p21; PERINATAL EXPOSURE; phenol; PRENATAL EXPOSURE; PROGRESSION; proliferation; RECEPTOR; SYSTEM; T-CELLS; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>54</startpage>
    <endpage>63</endpage>
    <journalfull>General and Comparative Endocrinology</journalfull>
    <issue>1</issue>
    <volume>178</volume>
    <abstract>Endocrine disruptor chemicals (EDCs), which are predominantly present in the environment, are able to mimic or antagonise the biological activity of hormones primarily through the interaction with specific receptors. The main consequences are adverse effects on the growth and development of reproductive organs, the induction of cancer and effects on neuronal differentiation. In this study, we investigated the ability of certain EDCs, Bisphenol A (BPA), Bisphenol B (BPB), Bisphenol F (BPF), 4-n Nonylphenol (NP) and Octylphenol (OP), belonging to a homogeneous group of phenol origin, to interfere with specific cellular processes, namely, proliferation, by using MCF-7 breast carcinoma cells, and differentiation, by using murine bone marrow dendritic cells. We correlated the data on cell growth with the stimulation of cell cycle progression, which could become a step in the development of cancer, and we established a proliferation ranking between the tested EDCs: NP &gt; BPA &gt; OP &gt; BPB &gt; BPF. In addition, we investigated the ability of NP, BPA and OP to induce the differentiation of dendritic cells, the powerful antigen-presenting cells of the immune system. The differentiation and activation of these cells could affect a well-regulated immune response and determine an allergic sensitisation. We found that BPA and NP were active in determining differentiation. (C) 2012 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000306386900007</url>
    <isbnorissn>0016-6480</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>207</id>
    <title>Validation and application of reporter gene assays for the determination of estrogenic and androgenic endocrine disruptor activity in sport supplements</title>
    <authors>Plotan,M.; Elliott,C.T.; Oplatowska,M.; Connolly,L.</authors>
    <availability>[Plotan, Monika; Elliott, Christopher T.; Oplatowska, Michalina; Connolly, Lisa] Queens Univ Belfast, Sch Biol Sci, Inst Agri Food &amp; Land Use, Belfast BT9 5AG, Antrim, North Ireland.</availability>
    <date>2012</date>
    <notes>JEnglishArticleConnolly, L (reprint author), Queens Univ Belfast, Sch Biol Sci, Inst Agri Food &amp; Land Use, Belfast BT9 5AG, Antrim, North Irelandl.connolly@qub.ac.ukAntignac JP, 2008, ANAL CHIM ACTA, V637, P55; Baume N, 2006, SCAND J MED SCI SPOR, V16, P41, DOI 10.1111/j.1600-0838.2005.00442.x; Bovee TFH, 2006, FOOD ADDIT CONTAM, V23, P556, DOI 10.1080/02652030600557163; Bovee TFH, 2005, ANAL CHIM ACTA, V529, P57, DOI 10.1016/j.aca.2004.07.051; Bovee TFH, 1998, FOOD ADDIT CONTAM, V15, P863; Braunstein GD, 2007, BASIC CLIN ENDOCRINO; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Connolly L, 2009, ANAL CHIM ACTA, V637, P321, DOI 10.1016/j.aca.2008.09.034; Connolly L, 2011, TRAC-TREND ANAL CHEM, V30, P227, DOI 10.1016/j.trac.2010.10.009; Courant F, 2007, ANAL CHIM ACTA, V586, P105, DOI 10.1016/j.aca.2006.11.002; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Damstra T., 2002, WHOPCSEDC022; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; Delbeke TF, 2003, STEROID BIOCH, V83, P245; Fowler PA, 2008, MOL HUM REPROD, V14, P269, DOI 10.1093/molehr/gan020; Gascon J, 1997, TRAC-TREND ANAL CHEM, V16, P554, DOI 10.1016/S0165-9936(97)00051-4; Geyer H, 2004, INT J SPORTS MED, V25, P124; Hartmann S, 1998, FOOD CHEM, V62, P7, DOI 10.1016/S0308-8146(97)00150-7; Liu-Stratton YL, 2004, TOXICOL LETT, V150, P29, DOI 10.1016/j.toxlet.2003.08.009; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Malone EM, 2010, J CHROMATOGR B, V878, P1077, DOI 10.1016/j.jchromb.2010.03.012; Maughan RJ, 2005, J SPORT SCI, V23, P883, DOI 10.1080/02640410400023258; Mormont M, 2009, SDAF04A; Plotan M, 2011, ANAL CHIM ACTA, V700, P34, DOI 10.1016/j.aca.2010.12.014; Rijk JCW, 2009, ANAL CHIM ACTA, V637, P305, DOI 10.1016/j.aca.2008.09.014; Scippo ML, 2002, ANAL CHIM ACTA, V473, P135, DOI 10.1016/S0003-2670(02)00770-5; Scippo ML, 2004, ANAL BIOANAL CHEM, V378, P664, DOI 10.1007/s00216-003-2251-0; Sharpe RM, 2003, PURE APPL CHEM, V75, P2023, DOI 10.1351/pac200375112023; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; WHO, 2000, WHO FOOD ADD SER, V43; Willemsen P, 2004, ANAL BIOANAL CHEM, V378, P655, DOI 10.1007/s00216-003-2217-2; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527325SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYANAL BIOANAL CHEMJULDiscipline: Biochemistry &amp; Molecular Biology; Chemistry962DJ</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; ANABOLIC-STEROIDS; Androgen; androgens; ASSAY; BETA; BIOASSAY; BIOLOGY; BISPHENOL-A; BREAST-CANCER; CARCINOGENESIS; CELL; CELLS; Determination; DIETARY-SUPPLEMENTS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Estrogen; ESTROGENS; EXPOSURE; FOOD; GENE; Hormones; RECEPTOR; Reporter gene assay; SAMPLES; screening; Sport supplements; Urine; Validation</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3057</startpage>
    <endpage>3067</endpage>
    <journalfull>Analytical and Bioanalytical Chemistry</journalfull>
    <issue>10</issue>
    <volume>403</volume>
    <abstract>Previously developed estrogen and androgen mammalian reporter gene assays (RGAs) were assessed for their potential use as a quantitative screening method in the detection of estrogenic and androgenic endocrine disruptors (EDs) in sport supplements. The validation of both RGAs coupled with dispersive solid phase extraction (dSPE) was performed in accordance with European Commission Decision EC/2002/6579 for biological screening methods. Decision limits (CC alpha) and detection capabilities (CC beta) were established for both the estrogen and androgen RGAs. All samples were compliant with CC alpha and CC beta in both bioassays. Recovery rates were 96 % for 17 beta-estradiol and 115 % for dihydrotestosterone as obtained in their corresponding RGA. Both estrogens and androgens were stable in samples for more than 3 weeks, when stored at -20 A degrees C. Specificity, good repeatability (coefficients of variation (CV), 12-25 %), reproducibility and robustness of both bioassays were also observed. Four different ED modes of action were determined for estrogens and androgens in 53 sport supplements, using the validated RGAs. This study revealed that 89 % of the investigated sport supplements contained estrogenic EDs and 51 % contained androgenic compounds. In conclusion, both bioassays are suitable for sport supplement screening of estrogenic and androgenic EDs</abstract>
    <url>WOS:000305519400029</url>
    <isbnorissn>1618-2642</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>26</id>
    <title>Triclosan exacerbates the presence of C-14-bisphenol A in tissues of female and male mice</title>
    <authors>Pollock,T.; Tang,B.; deCatanzaro,D.</authors>
    <availability>[Pollock, Tyler; Tang, Brandon; deCatanzaro, Denys] McMaster Univ, Dept Psychol Neurosci &amp; Behav, Hamilton, ON L8S 4K1, Canada.</availability>
    <date>2014</date>
    <notes>JEnglishArticledeCatanzaro, D (reprint author), McMaster Univ, Dept Psychol Neurosci &amp; Behav, 1280 Main St West, Hamilton, ON L8S 4K1, Canadadecatanz@mcmaster.caAl-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Allmyr M, 2008, SCI TOTAL ENVIRON, V393, P162, DOI 10.1016/j.scitotenv.2007.12.006; Allmyr M, 2006, SCI TOTAL ENVIRON, V372, P87, DOI 10.1016/j.scitotenv.2006.08.007; Berger RG, 2008, REPROD TOXICOL, V26, P94, DOI 10.1016/j.reprotox.2008.06.007; Berger RG, 2010, REPROD TOXICOL, V30, P393, DOI 10.1016/j.reprotox.2010.06.006; Berger RG, 2007, REPROD TOXICOL, V23, P138, DOI 10.1016/j.reprotox.2006.09.005; Biles JE, 1997, J AGR FOOD CHEM, V45, P3541, DOI 10.1021/jf970072i; Cagen SZ, 1999, TOXICOL SCI, V50, P36, DOI 10.1093/toxsci/50.1.36; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Crawford BR, 2012, REPROD TOXICOL, V34, P607, DOI 10.1016/j.reprotox.2012.09.008; deCatanzaro D, 2013, FOOD CHEM TOXICOL, V55, P164, DOI 10.1016/j.fct.2012.12.046; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Doerge DR, 2010, TOXICOL APPL PHARM, V248, P1, DOI 10.1016/j.taap.2010.07.009; Doerge DR, 2011, TOXICOL APPL PHARM, V255, P261, DOI 10.1016/j.taap.2011.07.009; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Fang JL, 2010, J ENVIRON SCI HEAL C, V28, P147, DOI 10.1080/10590501.2010.504978; Foran CM, 2000, MAR ENVIRON RES, V50, P153, DOI 10.1016/S0141-1136(00)00080-5; Gee RH, 2008, J APPL TOXICOL, V28, P78, DOI 10.1002/jat.1316; Geens T, 2012, CHEMOSPHERE, V87, P796, DOI 10.1016/j.chemosphere.2012.01.002; Geens T, 2009, J CHROMATOGR B, V877, P4042, DOI 10.1016/j.jchromb.2009.10.017; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Gray GM, 2004, HUM ECOL RISK ASSESS, V10, P875, DOI 10.1080/10807030490513883; Guzzo AC, 2012, REPRODUCTION, V143, P539, DOI 10.1530/REP-11-0375; Guzzo AC, 2013, J ENDOCRINOL, V217, P1, DOI 10.1530/JOE-12-0279; Hanioka N, 2008, CHEMOSPHERE, V74, P33, DOI 10.1016/j.chemosphere.2008.09.053; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; Henry N.D., 2011, J APPL TOXICOL, V33, P265; Howdeshell KL, 1999, NATURE, V401, P763; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; James MO, 2010, ENVIRON INT, V36, P942, DOI 10.1016/j.envint.2009.02.004; Jung EM, 2012, TOXICOL LETT, V208, P142, DOI 10.1016/j.toxlet.2011.10.017; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kato H, 2003, REPROD TOXICOL, V17, P283, DOI 10.1016/S0890-6238(03)00002-9; Kim CS, 2004, TOXICOL IND HEALTH, V20, P41, DOI 10.1191/0748233704th186oa; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kubo K, 2001, NEUROSCI LETT, V304, P73, DOI 10.1016/S0304-3940(01)01760-8; Kubo K, 2003, NEUROSCI RES, V45, P345, DOI 10.1016/S0168-0102(02)00251-1; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kumar V, 2009, REPROD TOXICOL, V27, P177, DOI 10.1016/j.reprotox.2008.12.002; Kurebayashi H, 2003, TOXICOL SCI, V73, P17, DOI 10.1093/toxsci/kfg040; Lakind JS, 2011, J EXPO SCI ENV EPID, V21, P272, DOI 10.1038/jes.2010.9; LaKind JS, 2012, J EXPO SCI ENV EPID, V22, P219, DOI 10.1038/jes.2012.1; Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Moors S, 2006, ARCH TOXICOL, V80, P647, DOI 10.1007/s00204-006-0097-x; Moss T, 2000, FOOD CHEM TOXICOL, V38, P361, DOI 10.1016/S0278-6915(99)00164-7; Nazaroff W, 2012, ENVIRON HEALTH PERSP, V120, P1678, DOI 10.1289/ehp.1204992; Nishiyama Takahito, 2002, Drug Metab Pharmacokinet, V17, P221, DOI 10.2133/dmpk.17.221; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Perencevich EN, 2001, AM J INFECT CONTROL, V29, P281, DOI 10.1067/mic.2001.115469; Pollock T., 2014, REPROD TOXICOL UNPUB; Queckenberg C, 2010, ANTIMICROB AGENTS CH, V54, P570, DOI 10.1128/AAC.00615-09; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rodricks JV, 2010, CRIT REV TOXICOL, V40, P422, DOI 10.3109/10408441003667514; Ryan BC, 2010, TOXICOL SCI, V114, P133, DOI 10.1093/toxsci/kfp266; Saal F.S.v., 2005, ENV HLTH PERSPECT, V113, P926; Sajiki J, 1999, J CHROMATOGR B, V736, P255, DOI 10.1016/S0378-4347(99)00471-5; Sandborgh-Englund G, 2006, J TOXICOL ENV HEAL A, V69, P1861, DOI 10.1080/15287390600631706; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Sieli PT, 2011, ENVIRON HEALTH PERSP, V119, P1260, DOI 10.1289/ehp.1003385; Stoker TE, 2010, TOXICOL SCI, V117, P45, DOI 10.1093/toxsci/kfq180; Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9; Takai Y, 2001, REPROD TOXICOL, V15, P71; Teeguarden JG, 2013, FOOD CHEM TOXICOL, V62, P935, DOI 10.1016/j.fct.2013.07.007; Teeguarden JG, 2011, TOXICOL SCI, V123, P48, DOI 10.1093/toxsci/kfr160; Tsutsui T, 1998, INT J CANCER, V75, P290, DOI 10.1002/(SICI)1097-0215(19980119)75:2&lt;290::AID-IJC19&gt;3.0.CO;2-H; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; US Food and Drug Administration, 2013, UPD BISPH A BPA US F; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Wang H, 2011, J CHROMATOGR B, V879, P1861, DOI 10.1016/j.jchromb.2011.04.036; Wang LQ, 2004, DRUG METAB DISPOS, V32, P1162, DOI 10.1124/dmd.104.000273; Yang M, 2006, ENVIRON MOL MUTAGEN, V47, P571, DOI 10.1002/em.20230; Ye XY, 2008, ANAL CHIM ACTA, V622, P150, DOI 10.1016/j.aca.2008.05.068; Ye XY, 2005, ANAL BIOANAL CHEM, V383, P638, DOI 10.1007/s00216-005-0019-4; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Yoshimura Y, 2002, ANAL CHIM ACTA, V458, P331, DOI 10.1016/S0003-2670(02)00077-6820ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMJUL 15Discipline: Pharmacology &amp; Pharmacy; ToxicologyAJ0JC</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BISPHENOL-A EXPOSURE; BPA; BREAST-CANCER CELLS; CANCER; CHEMICALS; Endocrine disruptor; ENVIRONMENTAL PHENOLS; Epididymis; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FOOD; heart; IN-VIVO; Interaction; INTRAUTERINE IMPLANTATION; mechanism; MECHANISMS; METABOLISM; PERFORMANCE LIQUID-CHROMATOGRAPHY; SEXUAL-DIFFERENTIATION; SPRAGUE-DAWLEY RATS; TANDEM MASS-SPECTROMETRY; Triclosan; URINARY CONCENTRATIONS; Uterus</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>116</startpage>
    <endpage>123</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>2</issue>
    <volume>278</volume>
    <abstract>Current human generations are commonly exposed to both triclosan (TCS), an antimicrobial agent, and bisphenol A (BPA), the monomer of polycarbonate plastics and epoxies. Both are readily absorbed into circulation and found distributed among diverse tissues. Potential interactions between TCS and BPA are largely unstudied. We investigated whether TCS exposure affects the distribution of ingested C-14-BPA in select tissues. CF-1 mice were each subcutaneously injected with TCS then orally administered 50 mu g/kg C-14-BPA. Females received 0, 0.2, 0.6, 1, 2, or 18 mg TCS (equivalent respectively to 0, 6.3, 16.9, 30.1, 60.5, and 558.9 mg/kg). Males received 0, 0.2, 2, or 18 mg TCS (equivalent respectively to 0, 5.3, 53.4, and 415.0 mg/kg). Levels of radioactivity were measured through liquid scintillation counting in blood serum and brain, reproductive, and other tissues. Significantly elevated levels of radioactivity were observed following combined TCS and C-14-BPA administration, with minimally effective TCS doses being tissue-dependent (Females: lungs, 0.6 mg; uterus, 1 mg; heart, muscle, ovaries, and serum, 18 mg. Males: serum, 0.2 mg; epididymides, 2 mg). Subsequently, we found that 2 or 6 mg TCS increased radioactivity in the ovaries and serum of females orally given only 5 mu g/kg C-14-BPA. These data indicate that TCS can interact with BPA in vivo, magnifying its presence in certain tissues and serum. The data are consistent with evidence that TCS utilizes enzymes that are critical for metabolism and excretion of BPA. Further research should investigate the mechanisms through which these two chemicals interact at environmentally-relevant doses. (C) 2014 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000337335800004</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>280</id>
    <title>Study of Oxidative Stress Induction After Exposure to Bisphenol A and Methylparaben in Rats</title>
    <authors>Popa,D.S.; Kiss,B.; Vlase,L.; Pop,A.; Iepure,R.; Paltinean,R.; Loghin,F.</authors>
    <availability>[Popa, Daniela-Saveta; Kiss, Bela; Pop, Anca; Iepure, Rita; Loghin, Felicia] Univ Med &amp; Pharm Iuliu Hatieganu Cluj Napoca, Fac Pharm, Dept Toxicol, Cluj Napoca 400012, Romania. [Vlase, Laurian] Univ Med &amp; Pharm Iuliu Hatieganu Cluj Napoca, Fac Pharm, Dept Pharmaceut Technol &amp; Biopharm, Cluj Napoca 400012, Romania. [Paltinean, Ramona] Univ Med &amp; Pharm Iuliu Hatieganu Cluj Napoca, Fac Pharm, Dept Pharmaceut Bot, Cluj Napoca 400012, Romania.</availability>
    <date>2011</date>
    <notes>JEnglishArticlePopa, DS (reprint author), Univ Med &amp; Pharm Iuliu Hatieganu Cluj Napoca, Fac Pharm, Dept Toxicol, 8 Victor Babes, Cluj Napoca 400012, Romaniadpopa@umfcluj.roAsnani Veena, 2007, Acta Pol Pharm, V64, P35; Asnani VM, 2009, ACTA POL PHARM, V66, P225; Atkinson C, 2003, J STEROID BIOCHEM, V86, P71, DOI 10.1016/S0960-0760(03)00259-0; Aydogan M, 2008, TOXICOLOGY, V249, P35, DOI 10.1016/j.tox.2008.04.002; Aydogan M, 2010, DRUG CHEM TOXICOL, V33, P193, DOI 10.3109/01480540903286468; Benachour N, 2007, TOXICOL APPL PHARM, V222, P129, DOI 10.1016/j.taap.2007.03.033; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Boberg J, 2010, REPROD TOXICOL, V30, P301, DOI 10.1016/j.reprotox.2010.03.011; Darbre PD, 2010, ANTICANCER RES, V30, P815; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Freinbichler W, 2008, J INORG BIOCHEM, V102, P1329, DOI 10.1016/j.jinorgbio.2007.12.017; Handa O, 2006, TOXICOLOGY, V227, P62, DOI 10.1016/j.tox.2006.07.018; Hsu JF, 2007, J CHROMATOGR B, V860, P49, DOI 10.1016/j.jchromb.2007.10.014; Imamura L, 2005, NEUROTOXICOLOGY, V26, P17, DOI 10.1016/j.neuro.2004.07.008; Kabuto H, 2003, ENVIRON RES, V93, P31, DOI 10.1016/S0013-9351(03)00062-8; KISS B, 2005, FARMACIA, V53, P17; Kiss B, 2009, FARMACIA, V57, P432; Knudsen FR, 1999, AQUAT TOXICOL, V44, P159; Korkmaz A, 2010, FOOD CHEM TOXICOL, V48, P2865, DOI 10.1016/j.fct.2010.07.019; Kovacic P, 2010, MED HYPOTHESES, V75, P1, DOI 10.1016/j.mehy.2010.03.002; LaPensee EW, 2010, ENDOCR-RELAT CANCER, V17, pR91, DOI 10.1677/ERC-09-0253; Lin Yong, 2006, Wei Sheng Yan Jiu, V35, P419; Liu SM, 2003, J NEUROSCI RES, V71, P882, DOI 10.1002/jnr.10534; Lopez-Lazaro M, 2010, MOL MED, V16, P144, DOI 10.2119/molmed.2009.00162; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Minamiyama Y, 2010, FREE RADICAL RES, V44, P1398, DOI 10.3109/10715762.2010.510523; Nishizawa C, 2006, FREE RADICAL RES, V40, P233, DOI 10.1080/10715760500485036; Popa DS, 2010, REV ROMANA MED LAB, V18, P37; Roberts RA, 2010, TOXICOLOGY, V276, P85, DOI 10.1016/j.tox.2010.07.009; Safe S, 2005, TRENDS ENDOCRIN MET, V16, P139, DOI 10.1016/j.tem.2005.03.004; Soni MG, 2002, FOOD CHEM TOXICOL, V40, P1335, DOI 10.1016/S0278-6915(02)00107-2; Sprinteroiu M, 2010, FARMACIA, V58, P509; Tollefsen KE, 2002, AQUAT TOXICOL, V56, P215, DOI 10.1016/S0166-445X(01)00154-03310SOC STINTE FARMACEUTICE ROMANIABUCURESTIBUCURESTI, STR TRAIAN VUIA 6, SECT 1, BUCURESTI, 020956, ROMANIAFARMACIAJUL-AUGDiscipline: Pharmacology &amp; Pharmacy799UP</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELL; COMBINATION; DISEASE; diseases; Endocrine-disrupting chemicals; EXPOSURE; FOOD; Hydroxyl radical; in vivo; IN-VIVO; INDUCED LIPID-PEROXIDATION; INDUCTION; Interaction; Lipid peroxidation; LIPID-PEROXIDATION; Methylparaben; Nonylphenol; octylphenol; Oxidative stress; OXIDATIVE STRESS INDUCTION; OXYGEN; PHARMACOLOGY; PLASMA; RAT; RATS; toxicology; TROUT ONCORHYNCHUS-MYKISS; VITAMIN-C; xenobiotics; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>539</startpage>
    <endpage>549</endpage>
    <journalfull>Farmacia</journalfull>
    <issue>4</issue>
    <volume>59</volume>
    <abstract>Long exposure to small concentrations of xenoestrogens (XEs) seems to be responsible for the increase of certain hormone-dependent diseases. The results of the research concerning the study of potentially synergic interactions between XEs are few and contradictory and need further studies. The oxidative stress is involved in the generation of several pathologies, such as cancer. We studied the oxidative stress induction in rats after exposure to bisphenol A (BPA) and/or methylparaben, two xenobiotics identified as XEs. Malondialdehyde (MDA), a lipid peroxidation end-product, and 2,3-dihydroxybenzoic acid (2,3-DHBA), a marker of in vivo hydroxyl radical production, were used to evaluate the oxidative stress generation. The levels of MDA in rat plasma were determined by HPLC-UV (detection at 307 nm) after derivatization with dinitrophenylhydrazine. 2,3-DHBA was analyzed by LC-MS/MS in multiple reaction monitoring (MRM) mode using an ion trap mass spectrometer with electrospray negative ionization. The ion transition monitored was m/z 153 -&gt; m/z (109). The results indicated that both studied xenobiotics have the potential of oxidative stress induction in rats but simultaneous exposure does not increase the intensity of effects</abstract>
    <url>WOS:000293311900009</url>
    <isbnorissn>0014-8237</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>72</id>
    <title>Influence of Genista Tinctoria L or Methylparaben on Subchronic Toxicity of Bisphenol A in Rats</title>
    <authors>Popa,D.S.; Bolfa,P.; Kiss,B.; Vlase,L.; Paltinean,R.; Pop,A.; Catoi,C.; Crisan,G.; Loghin,F.</authors>
    <availability>[Popa, Daniela-Saveta; Kiss, Bela; Pop, Anca; Loghin, Felicia] Iuliu Hatieganu Univ Med &amp; Pharm Cluj Napoca, Fac Pharm, Dept Toxicol, Cluj Napoca 400012, Romania. [Bolfa, Pompei; Catoi, Cornel] Univ Agr Sci &amp; Vet Med, Dept Pathol, Fac Vet Med, Cluj Napoca 400372, Romania. [Bolfa, Pompei] Ross Univ, Sch Vet Med, Dept Biomed Sci, Basseterre, St Kitts &amp; Nevi. [Vlase, Laurian; Crisan, Gianina] Iuliu Hatieganu Univ Med &amp; Pharm Cluj Napoca, Fac Pharm, Dept Pharmaceut Technol &amp; Biopharm, Cluj Napoca 400012, Romania. [Paltinean, Ramona] Iuliu Hatieganu Univ Med &amp; Pharm Cluj Napoca, Fac Pharm, Dept Pharmaceut Bot, Cluj Napoca 400012, Romania.</availability>
    <date>2014</date>
    <notes>JEnglishArticleBolfa, P (reprint author), Univ Agr Sci &amp; Vet Med, Dept Pathol, Fac Vet Med, Cluj Napoca 400372, Romaniapompeibolfa@gmail.comAhmed A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051889; Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Anjum S, 2011, FOOD CHEM TOXICOL, V49, P2849, DOI 10.1016/j.fct.2011.07.062; [Anonymous], 2006, EFSA J, V428, P1; [Anonymous], 2010, OFFICIAL J EUROPEA L, VL 276, P33; [Anonymous], 2004, EFSA J, V83, P1; Atkinson C, 2003, J STEROID BIOCHEM, V86, P71, DOI 10.1016/S0960-0760(03)00259-0; Aydogan M, 2008, TOXICOLOGY, V249, P35, DOI 10.1016/j.tox.2008.04.002; Aydogan M, 2010, DRUG CHEM TOXICOL, V33, P193, DOI 10.3109/01480540903286468; Banerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052; Benachour N, 2007, TOXICOL APPL PHARM, V222, P129, DOI 10.1016/j.taap.2007.03.033; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Boberg J, 2010, REPROD TOXICOL, V30, P301, DOI 10.1016/j.reprotox.2010.03.011; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Catala A, 2009, CHEM PHYS LIPIDS, V157, P1, DOI 10.1016/j.chemphyslip.2008.09.004; Charles AK, 2013, J APPL TOXICOL, V33, P390, DOI 10.1002/jat.2850; Charles GD, 2007, TOXICOL APPL PHARM, V218, P280, DOI 10.1016/j.taap.2006.11.029; Darbre PD, 2006, BEST PRACT RES CL EN, V20, P121, DOI 10.1016/j.beem.2005.09.007; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2010, ANTICANCER RES, V30, P815; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI [10.1177/0192623309354108, 10.1177/019263309354108]; Freinbichler W, 2008, J INORG BIOCHEM, V102, P1329, DOI 10.1016/j.jinorgbio.2007.12.017; Goodson WH, 2011, CARCINOGENESIS, V32, P1724, DOI 10.1093/carcin/bgr196; Handa O, 2006, TOXICOLOGY, V227, P62, DOI 10.1016/j.tox.2006.07.018; Hassan ZK, 2012, OXID MED CELL LONGEV, DOI 10.1155/2012/194829; Hsieh HM, 2011, LIFE SCI, V88, P82, DOI 10.1016/j.lfs.2010.10.021; Hsu JF, 2007, J CHROMATOGR B, V860, P49, DOI 10.1016/j.jchromb.2007.10.014; Imamura L, 2005, NEUROTOXICOLOGY, V26, P17, DOI 10.1016/j.neuro.2004.07.008; Jain S, 2011, FOOD CHEM TOXICOL, V49, P1404, DOI 10.1016/j.fct.2011.03.032; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kiss B, 2012, J LIQ CHROMATOGR R T, V35, P2735, DOI 10.1080/10826076.2011.638410; Kiss B, 2009, FARMACIA, V57, P432; Kiss B, 2010, REV ROUM CHIM, V55, P459; Kittel B, 2004, EXP TOXICOL PATHOL, V55, P413, DOI 10.1078/0940-2993-00349; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Knudsen FR, 1999, AQUAT TOXICOL, V44, P159; Kolsek K, 2012, TOXICOL IN VITRO, V26, P102, DOI 10.1016/j.tiv.2011.11.003; Kopalli SR, 2013, NEUROTOXICOLOGY, V34, P25, DOI 10.1016/j.neuro.2012.10.003; Korkmaz A, 2010, FOOD CHEM TOXICOL, V48, P2865, DOI 10.1016/j.fct.2010.07.019; Korkmaz A, 2011, ENVIRON TOXICOL, V26, P325, DOI 10.1002/tox.20556; Kovacic P, 2010, MED HYPOTHESES, V75, P1, DOI 10.1016/j.mehy.2010.03.002; Lazalde-Ramos BP, 2010, J CHROMATOGR SCI, V48, P675; Li DK, 2010, J ANDROL, V31, P500, DOI 10.2164/jandrol.110.010413; Li MA, 2012, KIDNEY INT, V81, P1131, DOI 10.1038/ki.2012.6; Liu SM, 2003, J NEUROSCI RES, V71, P882, DOI 10.1002/jnr.10534; Lopez-Lazaro M, 2010, MOL MED, V16, P144, DOI 10.2119/molmed.2009.00162; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Makaji E, 2011, INT J TOXICOL, V30, P410, DOI 10.1177/1091581811405544; McClain RM, 2006, FOOD CHEM TOXICOL, V44, P42, DOI 10.1016/j.fct.2005.06.004; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Montazerifar Farzaneh, 2012, Saudi J Kidney Dis Transpl, V23, P274; Morawietz G, 2004, EXP TOXICOL PATHOL, V55, P433, DOI 10.1078/0940-2993-00350; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nakagawa Y, 1999, BIOCHEM PHARMACOL, V58, P811, DOI 10.1016/S0006-2952(99)00147-1; Negre-Salvayre A, 2010, FREE RADICAL RES, V44, P1125, DOI 10.3109/10715762.2010.498478; Olteanu D, 2012, J PHYSIOL PHARMACOL, V63, P483; Peddireddy V, 2012, BIOMARKERS, V17, P261, DOI 10.3109/1354750X.2012.664169; POLI G, 1987, CHEM PHYS LIPIDS, V45, P117, DOI 10.1016/0009-3084(87)90063-6; Pop A, 2013, FARMACIA, V61, P202; Popa DS, 2010, REV ROMANA MED LAB, V18, P37; Popa DS, 2011, FARMACIA, V59, P539; Pugazhendhi D, 2005, J APPL TOXICOL, V25, P301, DOI 10.1002/jat.1066; Rashid H, 2009, TOXICOLOGY, V256, P7, DOI 10.1016/j.tox.2008.10.022; Rigano D, 2009, CHEM-BIOL INTERACT, V180, P211, DOI 10.1016/j.cbi.2009.02.010; Roberts RA, 2010, TOXICOLOGY, V276, P85, DOI 10.1016/j.tox.2010.07.009; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Ruehl-Fehlert C, 2003, EXP TOXICOL PATHOL, V55, P91, DOI 10.1016/S0940-2993(04)70148-7; Safe S, 2005, TRENDS ENDOCRIN MET, V16, P139, DOI 10.1016/j.tem.2005.03.004; Scientific Committee on Consumer Safety (SCCS), SCCS134810; Shankar A, 2012, J ENV PUBLIC HLTH, V2012, DOI DOI 10.1155/2012/481641; Shankar A, 2011, J CLIN ENDOCR METAB, V96, P3822, DOI 10.1210/jc.2011-1682; Shimizu I, 2012, LIPID PEROXIDATION; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Soni MG, 2002, FOOD CHEM TOXICOL, V40, P1335, DOI 10.1016/S0278-6915(02)00107-2; Tavares RS, 2009, REPROD TOXICOL, V27, P1, DOI 10.1016/j.reprotox.2008.10.002; Tero-Vescan A, 2009, FARMACIA, V57, P120; Tiwari D, 2012, MUTAT RES-GEN TOX EN, V743, P83, DOI 10.1016/j.mrgentox.2011.12.023; Tollefsen KE, 2002, AQUAT TOXICOL, V56, P215, DOI 10.1016/S0166-445X(01)00154-0; US EPA, 80057 US EPA CASRN; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Waritz RS, 1996, REGUL TOXICOL PHARM, V24, P184, DOI 10.1006/rtph.1996.0124; Wei J, 2011, ENDOCRINOLOGY, V152, P3049, DOI 10.1210/en.2011-0045; Wu MH, 2011, ENVIRON TOXICOL CHEM, V30, P2335, DOI 10.1002/etc.634; You L, 2002, TOXICOL SCI, V66, P216, DOI 10.1093/toxsci/66.2.216; Zhang WZ, 2013, BIOMED ENVIRON SCI, V26, P63, DOI 10.3967/0895-3988.2013.01.008882CHINESE CENTER DISEASE CONTROL &amp; PREVENTIONBEIJING155 CHANGBAI RD, CHANGPING DISTRICT, BEIJING, 102206, PEOPLES R CHINABIOMED ENVIRON SCIFEBDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational HealthAE9XH</notes>
    <keywords>Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; ENDOCRINE DISRUPTORS; ENVIRONMENTAL ESTROGENS; Estrogen; EXPOSURE; FOOD; Food contaminant; GLAND; Hydroxyl radical; In vitro; IN-VITRO; IN-VIVO; JOINT PUBLICATION; Lipid peroxidation; LIPID-PEROXIDATION; Liver; MAMMARY-GLAND; Morphological effect; NACAD GROUPS; Oxidative stress; OXIDATIVE STRESS INDUCTION; Phytoestrogen; PREVENTION; RAT; RATS; RECEPTOR; REVISED GUIDES; SAMPLES; TOXICITY; TROUT ONCORHYNCHUS-MYKISS; Uterus; VITAMIN-C; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>85</startpage>
    <endpage>96</endpage>
    <journalfull>Biomedical and Environmental Sciences</journalfull>
    <issue>2</issue>
    <volume>27</volume>
    <abstract>Objective To evaluate the influence of an extract of Genista tinctoria L. herba (GT) or methylparaben (MP) on histopathological changes and 2 biomarkers of oxidative stress in rats subchronicly exposed to bisphenol A (BPA). Methods Adult female Wistar rats were orally exposed for 90 d to BPA (50 mg/kg), BPA+GT (35 mg isoflavones/kg) or BPA+MP (250 mg/kg). Plasma and tissue samples were taken from liver, kidney, thyroid, uterus, ovary, and mammary gland after 30, 60, and 90 d of exposure respectively. Lipid peroxidation and in vivo hydroxyl radical production were evaluated by histological analysis along with malondialdehyde and 2,3-dihydroxybenzoic acid detection. Results The severity of histopathological changes in liver and kidneys was lower after GT treatment than after BPA or BPA+ MP treatment. A minimal thyroid receptor antagonist effect was only observed after BPA+ MP treatment. The abnormal folliculogenesis increased in a time-dependent manner, and the number of corpus luteum decreased. No significant histological alterations were found in the uterus. The mammary gland displayed specific estrogen stimulation changes at all periods. Both MP and GT revealed antioxidant properties reducing lipid peroxidation and BPA-induced hydroxyl radical generation. Conclusion GT L. extract ameliorates the toxic effects of BPA and is proved to have antioxidant potential and antitoxic effect. MP has antioxidant properties, but has either no effect or exacerbates the BPA-induced histopathological changes</abstract>
    <url>WOS:000334364800002</url>
    <isbnorissn>0895-3988</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>372</id>
    <title>Epigenetics in Women's Health Care</title>
    <authors>Pozharny,Y.; Lambertini,L.; Clunie,G.; Ferrara,L.; Lee,M.J.</authors>
    <availability>[Pozharny, Yevgeniya; Lambertini, Luca; Clunie, Garfield; Ferrara, Lauren; Lee, Men-Jean] Mt Sinai Sch Med, New York, NY 10029 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleLee, MJ (reprint author), Mt Sinai Sch Med, New York, NY 10029 USAmenjean.lee@mssm.eduBadcock C, 2006, J EVOLUTION BIOL, V19, P1007, DOI 10.1111/j.1420-9101.2006.01091.x; BARKER DJP, 1986, LANCET, V1, P1077; Beaujean N, 2005, M S-MED SCI, V21, P412, DOI 10.1051/medsci/2005214412; Beaujean N, 2004, BIOL REPROD, V71, P185, DOI 10.1095/biolreprod.103.026559; Bell A W, 1999, J Reprod Fertil Suppl, V54, P401; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bogdarina I, 2007, CIRC RES, V100, P520, DOI 10.1161/01.RES.0000258855.60637.58; Burdge GC, 2008, BRIT J NUTR, V99, P540, DOI 10.1017/S0007114507815819; Chelbi ST, 2008, MOL CELL ENDOCRINOL, V282, P120, DOI 10.1016/j.mce.2007.11.022; Chen HB, 2006, MOL CELL BIOL, V26, P3728, DOI 10.1128/MCB.26.10.3728-3737.2006; Cheng RYS, 2004, MOL CARCINOGEN, V40, P1, DOI 10.1002/mc.20022; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Cooper C, 1997, ANN RHEUM DIS, V56, P17, DOI 10.1136/ard.56.1.17; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; Dabelea D, 2000, DIABETES, V49, P2208, DOI 10.2337/diabetes.49.12.2208; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dean W, 2001, CURR BIOL, V11, pR527, DOI 10.1016/S0960-9822(01)00311-6; DEKKER GA, 1995, AM J OBSTET GYNECOL, V173, P1042, DOI 10.1016/0002-9378(95)91324-6; Desaulniers D, 2005, TOXICOL SCI, V86, P175, DOI 10.1093/toxsci/kfi178; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951; Elsheikh A, 2001, ARCH GYNECOL OBSTET, V264, P182, DOI 10.1007/s004040000104; Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029; Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x; Fowden AL, 2006, HORM RES, V65, P50, DOI 10.1159/000091506; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Geyer PK, 1997, CURR OPIN GENET DEV, V7, P242, DOI 10.1016/S0959-437X(97)80134-7; GINSBURG M, 1990, DEVELOPMENT, V110, P521; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Gluckman PD, 2007, P NATL ACAD SCI USA, V104, P12796, DOI 10.1073/pnas.0705667104; Gluckman PD, 2004, TRENDS ENDOCRIN MET, V15, P183, DOI 10.1016/j.tem.2004.03.002; GoddijnWessel TAW, 1996, EUR J OBSTET GYN R B, V66, P23, DOI 10.1016/0301-2115(96)02383-4; Godfrey KM, 2007, PEDIATR RES, V61, p5R, DOI 10.1203/pdr.0b013e318045bedb; Granger JP, 2002, MICROCIRCULATION, V9, P147, DOI 10.1038/sj.mn.7800137; Gupta S, 2005, OBSTET GYNECOL SURV, V60, P807, DOI 10.1097/01.ogx.0000193879.79268.59; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Kanayama N, 2002, MOL HUM REPROD, V8, P1129, DOI 10.1093/molehr/8.12.1129; Kensara OA, 2005, AM J CLIN NUTR, V82, P980; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Knox KS, 2007, MOL HUM REPROD, V13, P251, DOI 10.1093/molehr/gal116; Knudtson EJ, 2004, AM J OBSTET GYNECOL, V191, P537, DOI 10.1016/j.ajog.2003.12.005; Lane N, 2003, GENESIS, V35, P88, DOI 10.1002/gene.10168; LAURENCE KM, 1986, J ROY SOC HEALTH, V106, P153, DOI 10.1177/146642408610600501; LAURIN J, 1987, OBSTET GYNECOL, V69, P895; Lillycrop KA, 2005, J NUTR, V135, P1382; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Maloney CA, 2005, REPRODUCTION, V130, P401, DOI 10.1530/rep.1.00523; McKay JA, 2004, BIOCHEM SOC T, V32, P1006; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; Menon M K, 1966, J Obstet Gynaecol Br Commonw, V73, P49; MILLER JW, 1994, BIOCHEM J, V298, P415; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Myatt L, 2006, J PHYSIOL-LONDON, V572, P25, DOI 10.1113/jphysiol.2006.104968; Nafee TM, 2008, BJOG-INT J OBSTET GY, V115, P158, DOI 10.1111/j.1471-0528.2007.01528.x; NYLUND L, 1983, BRIT J OBSTET GYNAEC, V90, P16, DOI 10.1111/j.1471-0528.1983.tb06739.x; OSMOND C, 1993, BRIT MED J, V307, P1519; Quina AS, 2006, BIOCHEM PHARMACOL, V72, P1563, DOI 10.1016/j.bcp.2006.06.016; Randhawa R, 2005, MOL GENET METAB, V86, P84, DOI 10.1016/j.ymgme.2005.07.028; Redman CWG, 2000, PLACENTA, V21, P597, DOI 10.1053/plac.2000.0560; Redman CWG, 2004, SEMIN NEPHROL, V24, P565, DOI 10.1016/j.semnephrol.2004.07.005; Reichard JF, 2007, BIOCHEM BIOPH RES CO, V352, P188, DOI 10.1016/j.bbrc.2006.11.001; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2; Roberts JM, 2005, HYPERTENSION, V46, P1243, DOI 10.1161/01.HYP.0000188408.49896.c5; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Salnikow Konstantin, 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P307; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Sato S, 2003, MOL REPROD DEV, V65, P41, DOI 10.1002/mrd.10264; Scholl T. O., 2000, AM J CLIN NUTR, V71, p1295S; Seki Y, 2005, DEV BIOL, V278, P440, DOI 10.1016/j.ydbio.2004.11.025; Shaw GM, 2004, PUBLIC HEALTH REP, V119, P170; Shiao YH, 2005, TOXICOL APPL PHARM, V205, P290, DOI 10.1016/j.taap.2004.10.017; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Singh SM, 2003, CLIN GENET, V64, P451, DOI 10.1046/j.1399-0004.2003.00190.x; SMITHELLS RW, 1982, PEDIATRICS, V69, P498; Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4; Tao LH, 2005, TOXICOL SCI, V87, P344, DOI 10.1093/toxsci/kfi257; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Toyota M, 2000, ELECTROPHORESIS, V21, P329, DOI 10.1002/(SICI)1522-2683(20000101)21:2&lt;329::AID-ELPS329&gt;3.0.CO;2-9; Trasler JM, 2006, REPROD FERT DEVELOP, V18, P63, DOI 10.1071/RD05118; Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581; Wang JX, 2002, LANCET, V359, P673, DOI 10.1016/S0140-6736(02)07804-2; Waterland RA, 1999, AM J CLIN NUTR, V69, P179; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820; Wyrwoll CS, 2006, ENDOCRINOLOGY, V147, P599, DOI 10.1210/en.2005-0748; Xu XR, 2009, J GENET GENOMICS, V36, P203, DOI 10.1016/S1673-8527(08)60108-3; Yenbutr P, 1998, MECH AGEING DEV, V106, P93, DOI 10.1016/S0047-6374(98)00093-1; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.163210011JOHN WILEY &amp; SONS INCHOBOKEN111 RIVER ST, HOBOKEN, NJ 07030 USAMT SINAI J MEDMAR-APRDiscipline: General &amp; Internal Medicine580GW</notes>
    <keywords>ADULT; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; Carcinogen; CELL; CELLS; CYCLE; development; DEVELOPMENTAL ORIGINS; diabetes; DISEASE; diseases; DISORDERS; DNA METHYLATION; DNA-methylation; embryo; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; environmental exposure; epigenetic; epigenetics; EXPOSURE; EXPOSURES; EXPRESSION; FETAL; FOLIC-ACID; gametogenesis; GENE; gene expression; GENE-EXPRESSION; GENES; GROWTH; HEALTH; HEALTH-CARE; imprinted genes; Interaction; INTRAUTERINE GROWTH-RETARDATION; MAMMALIAN DEVELOPMENT; mechanism; MECHANISMS; Metals; METHYLATION; NEURAL-TUBE DEFECTS; nutrition; oncology; PATHOGENESIS; PATHOLOGY; pathophysiology; pediatric; phthalate; Phthalates; PLACENTA; PRIMORDIAL GERM-CELLS; RECEPTOR CPG ISLAND; Reproduction; RIVER; toxicology; WOMEN; Women's health</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>225</startpage>
    <endpage>235</endpage>
    <journalfull>Mount Sinai Journal of Medicine</journalfull>
    <issue>2</issue>
    <volume>77</volume>
    <abstract>Epigenetics refers to structural modifications to genes that do not change the nucleotide sequence itself but instead control and regulate gene expression. DNA methylation, histone modification, and RNA regulation are some of the mechanisms involved in epigenetic modification. Epigenetic changes are believed to be a result of changes in an organism's environment that result in fixed and permanent changes in most differentiated cells. Some environmental changes that have been linked to epigenetic changes include starvation, folic acid, and various chemical exposures. There are periods in an organism's life cycle in which the organism is particularly susceptible to epigenetic influences; these include fertilization, gametogenesis, and early embryo development. These are also windows of opportunity for interventions during the reproductive life cycle of women to improve maternal-child health. New data suggest that epigenetic influences might be involved in the regulation of fetal development and the pathophysiology of adult diseases such as cancer, diabetes, obesity, and neurodevelopmental disorders. Various epigenetic mechanisms may also be involved in the pathogenesis of preeclampsia and intrauterine growth restriction. Additionally, environmental exposures are being held responsible for causing epigenetic changes that lead to a disease process. Exposure to heavy metals, bioflavinoids, and endocrine disruptors, such as bisphenol A and phthalates, has been shown to affect the epigenetic memory of all organism. Their long-term effects are unclear at this point, but many ongoing studies are attempting to elucidate the pathophysiological effects of such gene-environment interactions. Mt Sinai J Med 77:225-235, 2010. (C) 2010 Mount Sinai School of Medicine</abstract>
    <url>WOS:000276437000011</url>
    <isbnorissn>0027-2507</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>320</id>
    <title>Early-life estrogens and prostate cancer in an animal model</title>
    <authors>Prins,G.S.; Ho,S.M.</authors>
    <availability>[Prins, G. S.] Univ Illinois, Dept Urol, Chicago, IL 60612 USA. [Prins, G. S.] Univ Illinois, Dept Physiol, Chicago, IL 60612 USA. [Ho, S. -M.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45221 USA.</availability>
    <date>2010</date>
    <notes>JEnglishReviewPrins, GS (reprint author), Univ Illinois, Dept Urol, 820 S Wood St,MC955, Chicago, IL 60612 USAgprins@uic.eduARAI Y, 1978, GANN, V69, P861; Bosland M C, 1996, Urol Oncol, V2, P103, DOI 10.1016/S1078-1439(97)82840-2; Chang WY, 1999, ENDOCRINOLOGY, V140, P405, DOI 10.1210/en.140.1.405; DRISCOLL SG, 1980, OBSTET GYNECOL, V56, P537; Ekbom A, 1996, BRIT MED J, V313, P337; Gilleran JP, 2003, ENDOCRINOLOGY, V144, P2046, DOI 10.1210/en.2002-0038; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; HUANG L, 2009, DEV BIOL, V358, P188; Huang LW, 2005, DEV BIOL, V278, P396, DOI 10.1016/j.ydbio.2004.11.020; Huang LW, 2004, J ANDROL, V25, P330; Huang LW, 2007, ENDOCRINOLOGY, V148, P1235, DOI 10.1210/en.2006-1250; Prins GS, 1998, ENDOCRINOLOGY, V139, P874, DOI 10.1210/en.139.3.874; Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009; PRINS GS, 1992, ENDOCRINOLOGY, V130, P3703, DOI 10.1210/en.130.6.3703; PRINS GS, 2010, REPRO TOXICOLOGY; Prins GS, 2001, REPROD FERT DEVELOP, V13, P241, DOI 10.1071/RD00107; Prins GS, 2001, CANCER RES, V61, P6089; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; PRINS GS, 2008, DIFFERENTIATION, V6, P641; Prins GS, 1997, PROSTATE BASIC CLIN, P247; PRINS GS, 1993, ENDOCRINOLOGY, V132, P2387, DOI 10.1210/en.132.6.2387; Prins GS, 1997, ENDOCRINOLOGY, V138, P1801, DOI 10.1210/en.138.5.1801; Pu YB, 2004, DEV BIOL, V273, P257, DOI 10.1016/j.ydbio.2004.06.002; Putz O, 2001, BIOL REPROD, V65, P1506, DOI 10.1095/biolreprod65.5.1506; Putz O, 2001, BIOL REPROD, V65, P1496, DOI 10.1095/biolreprod65.5.1496; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Woodham C, 2003, ENDOCRINOLOGY, V144, P4841, DOI 10.1210/en.2003-0035273CAMBRIDGE UNIV PRESSCAMBRIDGEEDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLANDJ DEV ORIG HLTH DISDECDiscipline: Public, Environmental &amp; Occupational Health755EE</notes>
    <keywords>ADULT; ADULT-RAT; Aging; ANDROGEN RECEPTOR EXPRESSION; bisphenol A; CANCER; CARCINOGENESIS; COMPLEXES; development; DEVELOPMENTAL EXPOSURE; Differentiation; DISEASE; EARLY-LIFE; epigenetic; ESTRADIOL; ESTRADIOL BENZOATE; Estrogen; estrogenization; ESTROGENS; EXPOSURE; EXPOSURES; GENE-EXPRESSION; GLAND; GLAND DEVELOPMENT; GROWTH; HEALTH; HIGH-DOSE EXPOSURE; Interaction; LOBES; MODEL; NEONATAL ESTROGEN; Occupational; Prostate; prostate cancer; prostate development; Prostate gland; PROSTATE-CANCER; RAT; RAT PROSTATE; REPRODUCTIVE-TRACT; reprogramming; Review; SENSITIVITY; SUSCEPTIBILITY; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>365</startpage>
    <endpage>370</endpage>
    <journalfull>Journal of Developmental Origins of Health and Disease</journalfull>
    <issue>6</issue>
    <volume>1</volume>
    <abstract>While early-life estrogens are thought to play a physiologic role in prostate gland development, inappropriate estrogenic exposures either in dose, type or temporally can reprogram the prostate gland and increase susceptibility to abnormal prostate growth with aging including carcinogenesis. This review discusses the evidence for developmental estrogenic reprogramming that leads to adult prostate disease in a rat model. We propose that estrogen imprinting of the prostate is mediated through both structural reorganization of the gland early in life and epigenomic reprogramming that permits life-long memory of the inappropriate developmental exposures including heightened sensitivity to rising estradiol levels with aging. Complex interactions between early epigenetic programming and later-life experiences results in an emergence of multiple epigenomic outcomes, with some contributing to carcinogenesis with aging</abstract>
    <url>WOS:000289908900003</url>
    <isbnorissn>2040-1744</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>63</id>
    <title>Bisphenol A Promotes Human Prostate Stem-Progenitor Cell Self-Renewal and Increases In Vivo Carcinogenesis in Human Prostate Epithelium</title>
    <authors>Prins,G.S.; Hu,W.Y.; Shi,G.B.; Hu,D.P.; Majumdar,S.; Li,G.N.; Huang,K.; Nelles,J.L.; Ho,S.M.; Walker,C.L.; Kajdacsy-Balla,A.; van Breemen,R.B.</authors>
    <availability>[Prins, Gail S.; Hu, Wen-Yang; Shi, Guang-Bin; Hu, Dan-Ping; Majumdar, Shyama; Nelles, Jason L.] Univ Illinois, Coll Med, Dept Urol, Chicago, IL 60612 USA. [Kajdacsy-Balla, Andre] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA. [Li, Guannan; Huang, Ke; van Breemen, Richard B.] Univ Illinois, Coll Pharm, Dept Med Chem &amp; Pharmacognosy, Chicago, IL 60612 USA. [Prins, Gail S.; Kajdacsy-Balla, Andre; van Breemen, Richard B.] Univ Illinois, Ctr Canc, Chicago, IL 60612 USA. [Ho, Shuk-Mei] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45220 USA. [Walker, Cheryl Lyn] Texas A&amp;M Univ Syst Hlth Sci Ctr, Ctr Translat Canc Res, Inst Biosci &amp; Technol, College Stn, TX 77843 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticlePrins, GS (reprint author), Univ Illinois, Dept Urol, 820 South Wood St,M-C 955, Chicago, IL 60612 USAgprins@uic.eduAdams JY, 2002, PROSTATE, V52, P69, DOI 10.1002/pros.10103; Baik I, 2005, CANCER RES, V65, P358; Barker DJP, 2012, AM J HUM BIOL, V24, P406, DOI 10.1002/ajhb.22222; Belcher SM, 2012, ENDOCRINOLOGY, V153, P712, DOI 10.1210/en.2011-1772; Biedermann S, 2010, ANAL BIOANAL CHEM, V398, P571, DOI 10.1007/s00216-010-3936-9; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Bosland Maarten C, 2011, J Carcinog, V10, P33, DOI 10.4103/1477-3163.90678; Brown MD, 2007, PROSTATE, V67, P1384, DOI 10.1002/pros.20620; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chamorro-Garcia R, 2012, ENVIRON HEALTH PERSP, V120, P984, DOI 10.1289/ehp.1205063; SOTO AM, 1992, ADV MOD ENV, V21, P295; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Edlow AG, 2012, REPROD TOXICOL, V34, P1, DOI 10.1016/j.reprotox.2012.03.009; Ekbom A, 1998, SEMIN CANCER BIOL, V8, P237, DOI 10.1006/scbi.1998.0073; Fenichel P, 2012, HUM REPROD, V27, P983, DOI 10.1093/humrep/der451; Gerona RR, 2013, ENVIRON SCI TECHNOL, V47, P12477, DOI 10.1021/es402764d; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Goldstein AS, 2011, NAT PROTOC, V6, P656, DOI 10.1038/nprot.2011.317; Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605; Habermann H, 2001, ENDOCRINOLOGY, V142, P359, DOI 10.1210/en.142.1.359; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hu WY, 2011, ENDOCRINOLOGY, V152, P2150, DOI 10.1210/en.2010-1377; Hu WY, 2012, MOL CELL ENDOCRINOL, V354, P63, DOI 10.1016/j.mce.2011.08.032; INCE BA, 1994, MOL ENDOCRINOL, V8, P1397, DOI 10.1210/me.8.10.1397; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Levin ER, 2011, MOL ENDOCRINOL, V25, P377, DOI 10.1210/me.2010-0284; Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689; Margel D, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000311; Nahar MS, 2013, J BIOCHEM MOL TOXIC, V27, P116, DOI 10.1002/jbt.21459; Okada M, 2010, INT J MOL SCI, V11, P4114, DOI 10.3390/ijms11104114; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; Prins GS, 2008, DIFFERENTIATION, V76, P641, DOI 10.1111/j.1432-0436.2008.00277.x; Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Prins GS, 2001, CANCER RES, V61, P6089; Prins GS, 2010, J DEV ORIG HLTH DIS, V1, P365, DOI 10.1017/S2040174410000577; Prins GS, 1997, PROSTATE BASIC CLIN, P247; Rahman AA, 2011, BRIT J CANCER, V104, P175, DOI 10.1038/sj.bjc.6605986; Rochester JR, 2013, REPROD TOXICOL, V42, P132, DOI 10.1016/j.reprotox.2013.08.008; SANTTI R, 1994, PROSTATE, V24, P67, DOI 10.1002/pros.2990240204; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Shelby M, 2008, NIH PUBLICATION; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Smith S, 2007, SCIENCE, V316, P1422; Soriano S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031109; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vandenberg LN, 2012, CIENC SAUDE COLETIVA, V17, P407, DOI 10.1590/S1413-81232012000200015; Vinas R, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-26; Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xu XH, 2010, TOXICOL APPL PHARM, V249, P188, DOI 10.1016/j.taap.2010.09.007; Yang LQ, 2013, TOXICOL LETT, V218, P187, DOI 10.1016/j.toxlet.2013.01.026624ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCRINOLOGYMARDiscipline: Endocrinology &amp; MetabolismAC2ZF</notes>
    <keywords>ADENOCARCINOMA; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARCINOGENESIS; Carcinogenicity; CELL; CELLS; DEVELOPMENTAL EXPOSURE; Differentiation; Endocrine-disrupting chemicals; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; FETAL; GLAND; In vitro; IN-VITRO; IN-VIVO; INDICATE WIDESPREAD EXPOSURE; INDUCTION; METABOLISM; MICE; RAT; RISK; serum; STEM/PROGENITOR CELLS; SUSCEPTIBILITY; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>805</startpage>
    <endpage>817</endpage>
    <journalfull>Endocrinology</journalfull>
    <issue>3</issue>
    <volume>155</volume>
    <abstract>Previous studies in rodent models have shown that early-life exposure to bisphenol A (BPA) reprograms the prostate and enhances its susceptibility to hormonal carcinogenesis with aging. To determine whether the human prostate is similarly sensitive to BPA, the current study used human prostate epithelial stem-like cells cultured from prostates of young, disease-free donors. Similar to estradiol-17 beta (E-2), BPA increased stem-progenitor cell self-renewal and expression of stem-related genes in a dose-dependent manner. Further, 10 nM BPA and E-2 possessed equimolar membrane-initiated signaling with robust induction of p-Akt and p-Erk at 15 minutes. To assess in vivo carcinogenicity, human prostate stem-progenitor cells combined with rat mesenchyme were grown as renal grafts in nude mice, forming normal human prostate epithelium at 1 month. Developmental BPA exposure was achieved through oral administration of 100 or 250 mu g BPA/kg body weight to hosts for 2 weeks after grafting, producing free BPA levels of 0.39 and 1.35 ng/mL serum, respectively. Carcinogenesis was driven by testosterone plus E-2 treatment for 2 to 4 months to model rising E-2 levels in aging men. The incidence of high-grade prostate intraepithelial neoplasia and adenocarcinoma markedly increased from 13% in oil-fed controls to 33% to 36% in grafts exposed in vivo to BPA (P &lt; .05). Continuous developmental BPA exposure through in vitro (200 nM) plus in vivo (250 mu g/kg body weight) treatments increased high-grade prostate intraepithelial neoplasia/cancer incidence to 45% (P &lt; .01). Together, the present findings demonstrate that human prostate stem-progenitor cells are direct BPA targets and that developmental exposure to BPA at low doses increases hormone-dependent cancer risk in the human prostate epithelium</abstract>
    <url>WOS:000332384100018</url>
    <isbnorissn>0013-7227</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>254</id>
    <title>The G-protein-coupled estrogen receptor GPER in health and disease</title>
    <authors>Prossnitz,E.R.; Barton,M.</authors>
    <availability>[Prossnitz, Eric R.] Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol &amp; Physiol, Albuquerque, NM 87131 USA. [Barton, Matthias] Univ Zurich, CH-8057 Zurich, Switzerland.</availability>
    <date>2011</date>
    <notes>JEnglishReviewProssnitz, ER (reprint author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol &amp; Physiol, Albuquerque, NM 87131 USAeprossnitz@salud.unm.eduAhola TM, 2002, ENDOCRINOLOGY, V143, P3376, DOI 10.1210/en.2001-211445; Ahola TM, 2002, EUR J BIOCHEM, V269, P2485, DOI 10.1046/j.1432-1033.2002.02912.x; Ahola TM, 2002, ENDOCRINOLOGY, V143, P4620, DOI 10.1210/en.2002-220492; Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Ariazi EA, 2010, CANCER RES, V70, P1184, DOI 10.1158/0008-5472.CAN-09-3068; Balhuizen A, 2010, MOL CELL ENDOCRINOL, V320, P16, DOI 10.1016/j.mce.2010.01.030; Barton M, 2009, HYPERTENSION, V54, P11, DOI 10.1161/HYPERTENSIONAHA.108.120022; Bhola NE, 2008, FRONT BIOSCI-LANDMRK, V13, P1857, DOI 10.2741/2805; Blasko E, 2009, J NEUROIMMUNOL, V214, P67, DOI 10.1016/j.jneuroim.2009.06.023; Boon WC, 2010, PROG BRAIN RES, V181, P209, DOI 10.1016/S0079-6123(08)81012-6; Bopassa JC, 2010, AM J PHYSIOL-HEART C, V298, pH16, DOI 10.1152/ajpheart.00588.2009; Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017; Broughton BRS, 2010, AM J PHYSIOL-HEART C, V298, pH1055, DOI 10.1152/ajpheart.00878.2009; Brunsing RL, 2011, IMMUNOLOGY, V134, P93, DOI 10.1111/j.1365-2567.2011.03471.x; Bryant DN, 2010, NEUROSCIENCE, V170, P1261, DOI 10.1016/j.neuroscience.2010.08.019; Buja LM, 2010, CARDIOVASC PATHOL, V19, P29, DOI 10.1016/j.carpath.2008.10.001; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Chagin AS, 2007, J CLIN ENDOCR METAB, V92, P4873, DOI 10.1210/jc.2007-0814; Chambliss KL, 2010, J CLIN INVEST, V120, P2319, DOI 10.1172/JCI38291; Chan QKY, 2010, CELL DEATH DIFFER, V17, P1511, DOI 10.1038/cdd.2010.20; Cheng SB, 2011, STEROIDS, V76, P892, DOI 10.1016/j.steroids.2011.02.018; Chevalier N, 2012, INT J CANCER, V130, P241, DOI 10.1002/ijc.25972; Chimento A, 2010, MOL CELL ENDOCRINOL, V320, P136, DOI 10.1016/j.mce.2010.01.035; Chimento A, INT J ANDROL, DOI [10.1111/j.1365-2605.2010.01100.x, DOI 10.1111/J.1365-2605.2010.01100.X]; Cordera F, 2006, SEMIN ONCOL, V33, P631, DOI 10.1053/j.seminoncol.2006.08.020; DELBECK M, 2010, MOL MED REP, V4, P37; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Dennis MK, 2011, J STEROID BIOCHEM, V127, P358, DOI 10.1016/j.jsbmb.2011.07.002; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Deschamps AM, 2009, AM J PHYSIOL-HEART C, V297, pH1806, DOI 10.1152/ajpheart.00283.2009; Deschamps AM, 2011, TRENDS CARDIOVAS MED, V20, P73; DICZFALUSKY E, 1969, FOETUS PLACENTA; Ding QM, 2009, AM J PHYSIOL-CELL PH, V297, pC1178, DOI 10.1152/ajpcell.00185.2009; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Downey JM, 2009, CIRC J, V73, P1171; Dun SL, 2009, J NEUROSCI RES, V87, P1610, DOI 10.1002/jnr.21980; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; Edwin Francis, 2006, V327, P1; Engdahl C, 2010, ARTHRITIS RHEUM-US, V62, P524, DOI 10.1002/art.25055; Etgen AM, 2011, FRONT NEUROENDOCRIN, V32, P336, DOI 10.1016/j.yfrne.2010.12.005; Faulds MH, 2012, J ENDOCRINOL, V212, P3, DOI 10.1530/JOE-11-0044; Feng Y, 1997, BIOCHEM BIOPH RES CO, V231, P651, DOI 10.1006/bbrc.1997.6161; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Filice E, 2009, J PHYSIOL PHARMACOL, V60, P3; Fitts JM, 2011, J PHARMACOL EXP THER, V338, P246, DOI 10.1124/jpet.110.173955; Ford J, 2011, J BONE MINER RES, V26, P298, DOI 10.1002/jbmr.209; Franco R, 2011, CANCER BIOL THER, V11, P609, DOI 10.4161/cbt.11.6.14672; Fu Z, 2010, ENDOCRINOLOGY, V151, P3026, DOI 10.1210/en.2009-1294; Gao F, 2011, ENDOCRINOLOGY, V152, P1434, DOI 10.1210/en.2010-1368; Geisler Jurgen, 2003, Journal of Steroid Biochemistry and Molecular Biology, V86, P245, DOI 10.1016/S0960-0760(03)00364-9; GILLIAMDAVIS S, 2010, HYPERTENSION, V56, pE50; Gingerich S, 2010, NEUROSCIENCE, V170, P54, DOI 10.1016/j.neuroscience.2010.06.076; Haas E, 2009, CIRC RES, V104, P288, DOI 10.1161/CIRCRESAHA.108.190892; Haas E, 2007, HYPERTENSION, V49, P1358, DOI 10.1161/HYPERTENSIONAHA.107.089995; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Hammond R, 2011, PSYCHONEUROENDOCRINO, V36, P182, DOI 10.1016/j.psyneuen.2010.07.007; HAMMOND R, 2011, BRAIN RES, V16, P53; Hazell GGJ, 2009, J ENDOCRINOL, V202, P223, DOI 10.1677/JOE-09-0066; He YY, 2009, CANCER SCI, V100, P1051, DOI 10.1111/j.1349-7006.2009.01148.x; Heino TJ, 2008, J ENDOCRINOL, V197, pR1, DOI 10.1677/JOE-07-0629; Henic E, 2009, INT J GYNECOL CANCER, V19, P214, DOI 10.1111/IGC.0b013e31819bcb75; Hess Rex A, 2003, Reprod Biol Endocrinol, V1, P52, DOI 10.1186/1477-7827-1-52; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Hewitt SC, 2003, REPRODUCTION, V125, P143, DOI 10.1530/rep.0.1250143; Holm A, 2011, J VASC RES, V48, P327, DOI 10.1159/000322578; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1; Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6; IGNATOV T, 2011, AM J OBSTET GYNECOL, V595, pE9; Isensee J, 2009, ENDOCRINOLOGY, V150, P1722, DOI 10.1210/en.2008-1488; JENEILANZL Z, 2011, ARTHRITIS RHEUM, V62, P1088; Jenei-Lanzl Z, 2010, ARTHRITIS RHEUM-US, V62, P1088, DOI 10.1002/art.27328; JESSUP JA, 2011, PLOS ONE, V5; JORDAN CV, 2007, BREAST S2, V16, pS105; Jordan VC, 2007, J NATL CANCER I, V99, P350, DOI 10.1093/jnci/djk062; Kanda N, 2003, J INVEST DERMATOL, V121, P771, DOI 10.1046/j.1523-1747.2003.12487.x; Kanda N, 2003, J INVEST DERMATOL, V121, P1500, DOI 10.1111/j.1523-1747.2003.12617.x; Kanda N, 2004, J INVEST DERMATOL, V123, P319, DOI 10.1111/j.0022-202X.2004.12645.x; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3569, DOI 10.1210/jc.2010-0856; Kuhn J, 2008, EUR J NEUROSCI, V27, P1700, DOI 10.1111/j.1460-9568.2008.06131.x; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kumar R, 2011, ENDOCRINOLOGY, V152, P2568, DOI 10.1210/en.2010-1361; Kvingedal AM, 1997, FEBS LETT, V407, P59, DOI 10.1016/S0014-5793(97)00278-0; Lafferty AR, 2000, J MED GENET, V37, P831, DOI 10.1136/jmg.37.11.831; Lappano R, 2010, MOL CELL ENDOCRINOL, V320, P162, DOI 10.1016/j.mce.2010.02.006; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; Lebesgue D, 2009, J NEUROENDOCRINOL, V21, P743, DOI 10.1111/j.1365-2826.2009.01893.x; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Leblanc K, 2007, INT J ONCOL, V30, P477; Levin ER, 2011, MOL ENDOCRINOL, V25, P377, DOI 10.1210/me.2010-0284; Lin BC, 2009, CANCER RES, V69, P5415, DOI 10.1158/0008-5472.CAN-08-1622; Lindsey SH, 2011, J CARDIOVASC PHARM, V57, P598, DOI 10.1097/FJC.0b013e3182135f1c; LINDSEY SH, 2009, FASEB J S; Lindsey SH, 2009, ENDOCRINOLOGY, V150, P3753, DOI 10.1210/en.2008-1664; Liu Q, 2009, CHINESE MED J-PEKING, V122, P2763, DOI 10.3760/cma.j.issn.0366-6999.2009.22.017; Liu SH, 2010, ENDOCRINOLOGY, V151, P859, DOI 10.1210/en.2009-1107; Liu SH, 2009, DIABETES, V58, P2292, DOI 10.2337/db09-0257; Liu SH, 2009, ISLETS, V1, P273, DOI 10.4161/isl.1.3.9781; Liverman C S, 2009, Cephalalgia, V29, P729, DOI 10.1111/j.1468-2982.2008.01789.x; Lorand T, 2010, CURR MED CHEM, V17, P3542; Lu CL, 2009, GASTROENTEROLOGY, V137, P1040, DOI 10.1053/j.gastro.2009.03.047; Lucki NC, 2011, J BIOL CHEM, V286, P19399, DOI 10.1074/jbc.M110.195826; Madeo A, 2010, CANCER RES, V70, P6036, DOI 10.1158/0008-5472.CAN-10-0408; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Maiti K, 2011, ENDOCRINOLOGY, V152, P2448, DOI 10.1210/en.2010-0979; Martensson UEA, 2009, ENDOCRINOLOGY, V150, P687, DOI 10.1210/en.2008-0623; Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062; Meyer MR, 2011, ACTA PHYSIOL, V203, P259, DOI 10.1111/j.1748-1716.2010.02237.x; Meyer MR, 2010, PHARMACOLOGY, V86, P58, DOI 10.1159/000315497; Meyer MR, 2009, MOL CELL ENDOCRINOL, V308, P9, DOI 10.1016/j.mce.2009.03.009; Meyer MR, 2008, GENDER MED, V5, pS19, DOI 10.1016/j.genm.2008.03.004; Meyer MR, 2006, HYPERTENSION, V47, P1019, DOI 10.1161/01.HYP.0000223064.62762.0b; Meyer MR, 2009, CARDIOVASC RES, V83, P605, DOI 10.1093/cvr/cvp187; Mishra SK, 2000, CARDIOVASC RES, V46, P539, DOI 10.1016/S0008-6363(00)00049-3; MORALES DE, 1995, CIRCULATION, V91, P755; Morton MS, 2002, J NUTR, V132, P3168; Muller R E, 1979, Adv Exp Med Biol, V117, P401; Nadal A, 2009, J PHYSIOL-LONDON, V587, P5031, DOI 10.1113/jphysiol.2009.177188; Nadal A, 1998, FASEB J, V12, P1341; Nayak TK, 2010, ACS CHEM BIOL, V5, P681, DOI 10.1021/cb1000636; Niino Masaaki, 2009, Central Nervous System Agents in Medicinal Chemistry, V9, P87; Noel SD, 2009, MOL ENDOCRINOL, V23, P349, DOI 10.1210/me.2008-0299; O'Dowd BF, 1998, GENOMICS, V47, P310, DOI 10.1006/geno.1998.5095; Ohlsson C, 2009, EUR J ENDOCRINOL, V160, P883, DOI 10.1530/EJE-09-0118; Olde B, 2009, TRENDS ENDOCRIN MET, V20, P409, DOI 10.1016/j.tem.2009.04.006; ORLANDO L, 2011, CANC TREAT REV S3, V36, pS67; Ososki AL, 2003, PHYTOTHER RES, V17, P845, DOI 10.1002/ptr.1364; Otto C, 2009, BIOL REPROD, V80, P34, DOI 10.1095/biolreprod.108.071175; Otto C, 2008, ENDOCRINOLOGY, V149, P4846, DOI 10.1210/en.2008-0269; Owman C, 1996, BIOCHEM BIOPH RES CO, V228, P285, DOI 10.1006/bbrc.1996.1654; Pandey DP, 2009, EMBO J, V28, P523, DOI 10.1038/emboj.2008.304; Pang Y, 2008, ENDOCRINOLOGY, V149, P3410, DOI 10.1210/en.2007-1663; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; PASQUALINI JR, 1989, J STEROID BIOCHEM, V34, P155, DOI 10.1016/0022-4731(89)90077-0; Patel VH, 2010, INT J MOL MED, V26, P193, DOI 10.3892/ijmm_00000452; Pernis AB, 2007, CURR OPIN RHEUMATOL, V19, P414, DOI 10.1097/BOR.0b013e328277ef2a; Peyton C, 2011, BIOL REPROD, V85, P42, DOI 10.1095/biolreprod.110.088765; PIETRAS RJ, 1975, NATURE, V253, P357, DOI 10.1038/253357a0; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Pollanen E, 2011, AGING CELL, V10, P650, DOI 10.1111/j.1474-9726.2011.00701.x; Prenzel N, 1999, NATURE, V402, P884; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Quinn JA, 2009, MOL ENDOCRINOL, V23, P1052, DOI 10.1210/me.2008-0262; Ramesh C, 2010, J MED CHEM, V53, P1004, DOI 10.1021/jm9011802; Recchia AG, 2011, J BIOL CHEM, V286, P10773, DOI 10.1074/jbc.M110.172247; Rettew JA, 2010, MOL CELL ENDOCRINOL, V328, P87, DOI 10.1016/j.mce.2010.07.017; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; Rowlands DJ, 2011, HYPERTENSION, V57, P833, DOI 10.1161/HYPERTENSIONAHA.110.162198; Sandberg K, 2008, GENDER MED, V5, P10, DOI 10.1016/j.genm.2008.03.016; Sanden C, 2011, MOL PHARMACOL, V79, P400, DOI 10.1124/mol.110.069500; Sengupta S, 2008, ADV EXP MED BIOL, V630, P206; Setchell KDR, 2010, J NUTR, V140, p1355S, DOI 10.3945/jn.109.119776; Sharma G, 2011, ENDOCRINOLOGY, V152, P3030, DOI 10.1210/en.2011-0091; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Siegfried JM, 2009, SEMIN ONCOL, V36, P524, DOI 10.1053/j.seminoncol.2009.10.004; Singleton DW, 2003, FRONT BIOSCI, V8, pS110, DOI 10.2741/1010; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Smith EP, 2008, J CLIN ENDOCR METAB, V93, P3088, DOI 10.1210/jc.2007-2397; SMITH HO, 2007, AM J OBSTET GYNECOL, V386, pE1; Smith HO, 2009, GYNECOL ONCOL, V114, P465, DOI 10.1016/j.ygyno.2009.05.015; SOLOFF MS, 1969, BIOCHEM BIOPH RES CO, V34, P141, DOI 10.1016/0006-291X(69)90540-3; Starek Andrzej, 2003, Int J Occup Med Environ Health, V16, P113; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Sukocheva O, 2006, J CELL BIOL, V173, P301, DOI 10.1083/jcb.200506033; SZEGO CM, 1967, P NATL ACAD SCI USA, V58, P1711, DOI 10.1073/pnas.58.4.1711; Takada Y, 1997, BIOCHEM BIOPH RES CO, V240, P737, DOI 10.1006/bbrc.1997.7734; Takahashi K, 2003, J ENDOCRINOL, V178, P319, DOI 10.1677/joe.0.1780319; TALWAR GP, 1964, P NATL ACAD SCI USA, V52, P1059, DOI 10.1073/pnas.52.4.1059; Terasawa E, 2009, J NEUROENDOCRINOL, V21, P316, DOI 10.1111/j.1365-2826.2009.01839.x; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tu G, 2009, TECHNOL CANCER RES T, V8, P231; Ullrich ND, 2008, AM J PHYSIOL-HEART C, V294, pH2421, DOI 10.1152/ajpheart.01225.2007; Vanhoutte PM, 2009, ACTA PHYSIOL, V196, P193, DOI 10.1111/j.1748-1716.2009.01964.x; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; Villablanca AC, 2009, J CARDIOVASC TRANSL, V2, P289, DOI 10.1007/s12265-009-9103-z; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Wang C, 2008, ENDOCRINOLOGY, V149, P4452, DOI 10.1210/en.2008-0441; Wang C, 2007, ENDOCRINOLOGY, V148, P4853, DOI 10.1210/en.2007-0727; Wang C, 2009, J IMMUNOL, V182, P3294, DOI 10.4049/jimmunol.0803205; Wang C, 2008, MOL ENDOCRINOL, V22, P636, DOI 10.1210/me.2007-0359; WEHLING M, 1995, J MOL MED-JMM, V73, P439; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Weil BR, 2010, SURGERY, V148, P436, DOI 10.1016/j.surg.2010.03.011; Weise M, 2001, P NATL ACAD SCI USA, V98, P6871, DOI 10.1073/pnas.121180498; Windahl SH, 2009, AM J PHYSIOL-ENDOC M, V296, pE490, DOI 10.1152/ajpendo.90691.2008; Wintermantel TM, 2006, NEURON, V52, P271, DOI 10.1016/j.neuron.2006.07.023; Wu Q, 2011, J BIOL CHEM, V286, P14737, DOI 10.1074/jbc.R110.191791; Xu H, 2009, NEUROSCIENCE, V158, P1599, DOI 10.1016/j.neuroscience.2008.11.028; Yates MA, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-20; Zhang B, 2010, J IMMUNOL, V184, P4087, DOI 10.4049/jimmunol.0902339203110NATURE PUBLISHING GROUPNEW YORK75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USANAT REV ENDOCRINOLDECDiscipline: Endocrinology &amp; Metabolism857AD</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; AGENTS; ALPHA; BETA; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BONE; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; cardiovascular; CELL; cell death; CELL-DEATH; DEATH; diabetes; DISEASE; diseases; DISORDERS; ENDOCRINE; ENDOGENOUS ESTROGENS; ENDOTHELIUM-DEPENDENT RELAXATION; ER alpha; ER-ALPHA; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic activity; ESTROGENS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRANUCLEAR STEROID-RECEPTORS; GENE-EXPRESSION; genistein; GPER; GPR30; GROWTH-FACTOR RECEPTOR; HEALTH; In vitro; IN-VITRO; LIGAND; LIGANDS; MEMBRANE-RECEPTOR; METABOLISM; MICE; OVARIAN-CANCER; PATHWAY; PHARMACOLOGY; PLACENTA; RECEPTOR; Reproduction; SMOOTH-MUSCLE-CELLS; SYSTEM; TARGET; TRANSCRIPTION; Transcriptional regulation; UP-REGULATION; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>715</startpage>
    <endpage>726</endpage>
    <journalfull>Nature Reviews Endocrinology</journalfull>
    <issue>12</issue>
    <volume>7</volume>
    <abstract>Estrogens mediate profound effects throughout the body and regulate physiological and pathological processes in both women and men. The low prevalence of many diseases in premenopausal women is attributed to the presence of 17 beta-estradiol, the predominant and most potent endogenous estrogen. In addition to endogenous estrogens, several man-made and plant-derived molecules, such as bisphenol A and genistein, also exhibit estrogenic activity. Traditionally, the actions of 17 beta-estradiol are ascribed to two nuclear estrogen receptors (ERs), ER alpha and ER beta, which function as ligand-activated transcription factors. However, 17 beta-estradiol also mediates rapid signaling events via pathways that involve transmembrane ERs, such as G-protein-coupled ER 1 (GPER; formerly known as GPR30). In the past 10 years, GPER has been implicated in both rapid signaling and transcriptional regulation. With the discovery of GPER-selective ligands that can selectively modulate GPER function in vitro and in preclinical studies and with the use of Gper knockout mice, many more potential roles for GPER are being elucidated. This Review highlights the physiological roles of GPER in the reproductive, nervous, endocrine, immune and cardiovascular systems, as well as its pathological roles in a diverse array of disorders including cancer, for which GPER is emerging as a novel therapeutic target and prognostic indicator</abstract>
    <url>WOS:000297685100006</url>
    <isbnorissn>1759-5029</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>273</id>
    <title>Bisphenol A modulates leptin receptor expression and action in OVCAR-3 ovarian cancer cell line</title>
    <authors>Ptak,A.; Gregoraszczuk,E.</authors>
    <availability>[Ptak, A.; Gregoraszczuk, E.] Jagiellonian Univ, Krakow, Poland.</availability>
    <date>2011</date>
    <notes>JEnglishMeeting Abstract01ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTAUG 281Discipline: Toxicology806NI</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; CANCER; CELL; EXPRESSION; Leptin; Leptin receptor; LINE; Ovarian cancer; OVARIAN-CANCER; RECEPTOR; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S252</startpage>
    <endpage>S252</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <volume>205</volume>
    <url>WOS:000293814500806</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>288</id>
    <title>Effect of bisphenol-A on the expression of selected genes involved in cell cycle and apoptosis in the OVCAR-3 cell line</title>
    <authors>Ptak,A.; Wrobel,A.; Gregoraszczuk,E.L.</authors>
    <availability>[Ptak, Anna; Wrobel, Anna; Gregoraszczuk, Ewa L.] Jagiellonian Univ, Dept Physiol &amp; Toxicol Reprod, Chair Anim Physiol, Inst Zool, PL-30060 Krakow, Poland.</availability>
    <date>2011</date>
    <notes>JEnglishArticlePtak, A (reprint author), Jagiellonian Univ, Dept Physiol &amp; Toxicol Reprod, Chair Anim Physiol, Inst Zool, Ingardena 6, PL-30060 Krakow, Polandanna.ptak@uj.edu.plAuersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BALI A, 2004, CLIN CANCER RES, V10, P5167; BARGOU RC, 1996, J CLIN INVEST, V97, P2569; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bredhult C, 2007, REPROD TOXICOL, V23, P550, DOI 10.1016/j.reprotox.2007.03.006; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Jin ZY, 2005, CANCER BIOL THER, V4, P139; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; LaPensee EW, 2010, CANCER LETT, V290, P167, DOI 10.1016/j.canlet.2009.09.005; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Tellman G., 2006, NAT METHODS, V3, pi, DOI DOI 10.1038/NMETH894; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Wang Z, 2005, ANTICANCER RES, V25, P2367; Watanabe J, 2007, J STEROID BIOCHEM, V107, P163, DOI 10.1016/j.jsbmb.2007.03.045; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Xu JP, 2002, BIOCHEM BIOPH RES CO, V292, P456, DOI 10.1006/bbrc.2002.6644; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.0673520ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTAPR 10Discipline: Toxicology742HO</notes>
    <keywords>apoptosis; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; cell cycle; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CYCLE; DEATH; DNA repair; Estrogen; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GENES; GROWTH; HEALTH; HUMAN EXPOSURE; IN-VITRO; INDUCTION; inhibition; LINE; MCF-7; Ovarian cancer; OVARIAN-CANCER; OVCAR-3; p21; PATHWAY; proliferation; Proteomics; REGULATORS; REPAIR; RISK; SUPPRESSION; toxicology; VIABILITY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>30</startpage>
    <endpage>35</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>1</issue>
    <volume>202</volume>
    <abstract>To support the argument that bisphenol-A (BPA) poses a risk for ovarian cancer, OVCAR-3 cell line was exposed to environmentally relevant concentration of BPA. Expression of selected genes involved in cell cycle and apoptosis were evaluated by real-time PCR. In a dose-dependent manner, BPA increased OVCAR-3 cell proliferation and decreased caspase-3 activity, but it had no effect on DNA fragmentation. We noted 1.2-1.5-fold induction of genes responsible for inducing cell proliferation and 1.2-46-fold suppression of genes responsible for inhibition of proliferation. Moreover, 1.6-8-fold suppression of genes involved in the extrinsic apoptotic pathway was observed. In parallel, 1.3-2.5-fold suppression pro-apoptotic genes and 1.6-51-fold induction of pro-survival genes involved in the intrinsic apoptotic pathway were observed. Additionally, 1.7-fold induction of p53 and 5-fold induction of endonuclease G genes involved in CAD-independent DNA fragmentation were noted under the influence of BPA. In conclusion, we hypothesize that induction of p53 and suppression of caspase-3 and 7 gene expression observed in this study activate the DNA repair process. Therefore, despite the observed induction of endo G gene expression, the action of BPA on DNA fragmentation was not observed. (C) 2011 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000288932400005</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>217</id>
    <title>Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signalling pathways in human ovarian cancer cell</title>
    <authors>Ptak,A.; Gregoraszczuk,E.L.</authors>
    <availability>[Ptak, Anna; Gregoraszczuk, Ewa L.] Jagiellonian Univ, Inst Zool, Dept Physiol &amp; Toxicol Reprod, Chair Anim Physiol, PL-30387 Krakow, Poland.</availability>
    <date>2012</date>
    <notes>JEnglishArticlePtak, A (reprint author), Jagiellonian Univ, Inst Zool, Dept Physiol &amp; Toxicol Reprod, Chair Anim Physiol, Gronostajowa 9, PL-30387 Krakow, Polandanna.ptak@uj.edu.plBaillie-Hamilton PF, 2002, J ALTERN COMPLEM MED, V8, P185, DOI 10.1089/107555302317371479; Calle EE, 2004, ONCOGENE, V23, P6365, DOI 10.1038/sj.onc.1207751; Canesi L, 2005, AQUAT TOXICOL, V71, P73, DOI 10.1016/j.aquatox.2004.10.011; Chen CC, 2006, BREAST CANCER RES TR, V98, P121, DOI 10.1007/s10549-005-9139-y; Choi JH, 2011, CARCINOGENESIS, V32, P589, DOI 10.1093/carcin/bgq276; Choi JH, 2005, J CLIN ENDOCR METAB, V90, P207, DOI 10.1210/jc.2004-0297; Cleary MP, 2003, BREAST CANCER RES TR, V77, P205, DOI 10.1023/A:1021891825399; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Gao JC, 2009, CANCER SCI, V100, P389, DOI 10.1111/j.1349-7006.2008.01053.x; Garofalo C, 2006, CLIN CANCER RES, V12, P1447, DOI 10.1158/1078-0432.CCR-05-1913; Heindel JJ, 2003, TOXICOL SCI, V76, P247, DOI 10.1093/toxsci/kfg255; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Leitzmann MF, 2009, CANCER, V115, P812, DOI 10.1002/cncr.24086; Liu XH, 2010, J BIOCHEM, V148, P247, DOI 10.1093/jb/mvq056; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masuno H, 2005, TOXICOL SCI, V84, P319, DOI 10.1093/toxsci/kfi088; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Newbold RR, 2009, MOL CELL ENDOCRINOL, V304, P84, DOI 10.1016/j.mce.2009.02.024; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Olsen CM, 2007, EUR J CANCER, V43, P690, DOI 10.1016/j.ejca.2006.11.010; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Petridou E, 2002, ANN NUTR METAB, V46, P147, DOI 10.1159/000063081; Phrakonkham P, 2008, J STEROID BIOCHEM, V110, P95, DOI 10.1016/j.jsbmb.2008.02.006; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Rapp K, 2005, BRIT J CANCER, V93, P1062, DOI 10.1038/sj.bjc.6602819; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Uddin S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-74; Welshons WV, 2006, ENDOCRINOLOGY, V147, P56; Yuan SSF, 2004, GYNECOL ONCOL, V92, P769, DOI 10.1016/j.ygyno.2003.11.0433914ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTMAY 5Discipline: Toxicology936XP</notes>
    <keywords>Akt; ASSAY; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BODY-MASS INDEX; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOGENESIS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; Differentiation; ENDOCRINE DISRUPTORS; ENDOMETRIAL CANCER; ERK1/2; EXPRESSION; GENE; GROWTH; HEALTH; HUMAN BREAST-CANCER; In vitro; IN-VITRO; IN-VIVO; Leptin; Leptin receptor; OB-R; OBESITY EPIDEMIC; Ovarian cancer; OVARIAN-CANCER; OVCAR-3; PHOSPHORYLATION; proliferation; PROTEIN; PROTEIN-KINASES; RECEPTOR; RISK; STAT3; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>332</startpage>
    <endpage>337</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>3</issue>
    <volume>210</volume>
    <abstract>We previously demonstrated that bisphenol A (BPA) promotes proliferation in OVCAR-3 human ovarian cancer cells. This study was designed to investigate the effects of BPA on leptin expression and activity in ovarian cancer. Real-time PCR, Western blot analysis and ELISA assays were used to quantify leptin receptor expression and leptin gene and protein expression after treatment with BPA at doses of 0.2, 2, 8 and 20 ng/ml. Our data reveal leptin receptor expression but an absence of leptin gene and protein expression in OVCAR-3 cells. At doses of 8 and 20 ng/ml, BPA had stimulatory effects on leptin receptor gene and protein expression. Leptin and BPA alone stimulated cell proliferation but SPA did not potentiate leptin activity. Similarly to leptin, but with different kinetics and duration, BPA induced phosphorylation of Stat3, ERK1/2 and Akt. In co-treatment experiments, the timing of protein phosphorylation represented an additive effect of BPA and leptin treatment. In conclusion, taking into consideration limitation of in vitro study, whether BPA by creating more binding sites for leptin and extending the time of leptin-induced Stat3, ERK1/2 and Akt phosphorylation, can potentiated leptin action in cancer cells, require confirmation by in vivo study. (C) 2012 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000303623600009</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>107</id>
    <title>Cooperation of bisphenol A and leptin in inhibition of caspase-3 expression and activity in OVCAR-3 ovarian cancer cells</title>
    <authors>Ptak,A.; Rak-Mardyla,A.; Gregoraszczuk,E.L.</authors>
    <availability>[Ptak, Anna; Rak-Mardyla, Agnieszka; Gregoraszczuk, Ewa L.] Jagiellonian Univ, Inst Zool, Dept Physiol &amp; Toxicol Reprod, Chair Anim Physiol, PL-30387 Krakow, Poland.</availability>
    <date>2013</date>
    <notes>JEnglishArticlePtak, A (reprint author), Jagiellonian Univ, Inst Zool, Dept Physiol &amp; Toxicol Reprod, Gronostajowa 9, PL-30387 Krakow, Polandanna.ptak@uj.edu.plAmbrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Benachour N, 2009, TOXICOL APPL PHARM, V241, P322, DOI 10.1016/j.taap.2009.09.005; Brabant G, 2002, J CLIN ENDOCR METAB, V87, P3966, DOI 10.1210/jc.87.8.3966; Bredhult C, 2007, REPROD TOXICOL, V23, P550, DOI 10.1016/j.reprotox.2007.03.006; Canesi L, 2004, GEN COMP ENDOCR, V138, P58, DOI 10.1016/j.ygcen.2004.05.004; Chen CC, 2006, BREAST CANCER RES TR, V98, P121, DOI 10.1007/s10549-005-9139-y; Choi JH, 2005, J CLIN ENDOCR METAB, V90, P207, DOI 10.1210/jc.2004-0297; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Fernandez-Riejos P, 2008, CLIN EXP IMMUNOL, V151, P505, DOI 10.1111/j.1365-2249.2007.03563.x; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Guo ZH, 2008, J BIOL CHEM, V283, P1754, DOI 10.1074/jbc.M703753200; Ito K, 2011, MOL CELL ENDOCRINOL, V340, P161, DOI 10.1016/j.mce.2010.11.023; Jiang HP, 2008, BIOCHEM BIOPH RES CO, V368, P1, DOI 10.1016/j.bbrc.2007.04.004; Jin ZY, 2005, CANCER BIOL THER, V4, P139; Kandouz M, 1996, INT J CANCER, V68, P120, DOI 10.1002/(SICI)1097-0215(19960927)68:1&lt;120::AID-IJC21&gt;3.0.CO;2-E; Kawasaki H, 1998, CANCER RES, V58, P5071; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masuno H, 2005, TOXICOL SCI, V84, P319, DOI 10.1093/toxsci/kfi088; Mattioli B, 2009, FEBS LETT, V583, P1102, DOI 10.1016/j.febslet.2009.02.029; Miyawaki J, 2007, J ATHEROSCLER THROMB, V14, P245; Monzo M, 1999, J CLIN ONCOL, V17, P2100; Nakamura M, 2004, CANCER SCI, V95, P44, DOI 10.1111/j.1349-7006.2004.tb03169.x; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Newbold RR, 2009, MOL CELL ENDOCRINOL, V304, P84, DOI 10.1016/j.mce.2009.02.024; Olsen CM, 2007, EUR J CANCER, V43, P690, DOI 10.1016/j.ejca.2006.11.010; Owecki M, 2010, HORM METAB RES, V42, P585, DOI 10.1055/s-0030-1253422; Palianopoulou M, 2011, EXP BIOL MED, V236, P70, DOI 10.1258/ebm.2010.010224; Perera CN, 2008, J ENDOCRINOL, V199, P221, DOI 10.1677/JOE-08-0215; Perez-Perez A, 2008, ARCH BIOCHEM BIOPHYS, V477, P390, DOI 10.1016/j.abb.2008.06.015; Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Ptak A, 2013, ENDOCRINE, V43, P394, DOI 10.1007/s12020-012-9788-7; Rho SB, 2011, GYNECOL ONCOL, V120, P121, DOI 10.1016/j.ygyno.2010.10.003; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Satyan KS, 2006, GYNECOL ONCOL, V103, P261, DOI 10.1016/j.ygyno.2006.03.002; Seeger H, 2006, MATURITAS, V54, P72, DOI 10.1016/j.maturitas.2005.08.010; Sui L, 2002, INT J ONCOL, V21, P315; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Takai N, 2002, INT J MOL MED, V10, P211; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Uddin S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-74; Vom Saal Frederick S, 2012, Mol Cell Endocrinol, V354, P74, DOI 10.1016/j.mce.2012.01.001; Xu JP, 2002, BIOCHEM BIOPH RES CO, V292, P456, DOI 10.1006/bbrc.2002.6644; Yang J, 2009, CYTOKINE, V46, P382, DOI 10.1016/j.cyto.2009.03.013; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Zhang M, 2005, ONCOGENE, V24, P2474, DOI 10.1038/sj.onc.1208490512PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROSEPDiscipline: Toxicology223YG</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ADIPOSE-TISSUE; ANTI-APOPTOSIS GENE; bisphenol; bisphenol A; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; Caspase-3; CELL; CELLS; COMBINATION; Cytokine; ENDOCRINE; ENDOCRINE DISRUPTORS; ENVIRONMENTAL ESTROGENS; ERK1/2; EXPOSURE; EXPRESSION; In vitro; IN-VITRO; inhibition; Interaction; KINASE; Leptin; MCF-7 CELLS; Ovarian cancer; OVARIAN-CANCER; OVCAR-3; proliferation; PROTEIN; REGULATED GENE-EXPRESSION; REVEALS; SIGNALING PATHWAY; SIGNALING PATHWAYS; STAT3; Survivin; toxicology; UP-REGULATION; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1937</startpage>
    <endpage>1943</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>6</issue>
    <volume>27</volume>
    <abstract>This study was designed to investigate the effect of bisphenol A and leptin on caspase-3 expression and activity in OVCAR-3 ovarian cancer cells. Caspase-3 and survivin expression was measured at the transcript level by real-time PCR and at the protein level by Western blotting. In addition, caspase-3 activity was measured, using a fluorometric assay, upon exposure to bisphenol A (40 nM) alone, leptin (2.5 nM) alone, and the combination of both agents. 17 beta-estradiol (40 nM) was used as a positive control for estrogenic properties of bisphenol A. Results showed that the interaction between bisphenol A and leptin, which was similar to that observed between 17 beta-estradiol and leptin, led to the inhibition of caspase3 expression and activity in OVCAR-3 cells. Surprisingly, survivin was found to not be involved in the anti-apoptotic activity of either agent. Also, results showed that leptin inhibits caspase-3 activity by acting on the signal transducers and activators of transcription 3 (STAT3) pathway, but bisphenol A and 17 beta-estradiol by the extracellular-signal-regulated kinases 1/2 (ERK1/2) pathway. In conclusion, the study reveals that bisphenol A and leptin interact to inhibit caspase-3 expression and activity by modulating STAT3 and ERK1/2 signaling pathways in OVCAR-3 cells. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000324847800039</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>10</id>
    <title>Bisphenol A induce ovarian cancer cell migration via the MAPK and PI3K/Akt signalling pathways</title>
    <authors>Ptak,A.; Hoffmann,M.; Gruca,I.; Barc,J.</authors>
    <availability>[Ptak, Anna; Hoffmann, Marta; Gruca, Izabella; Barc, Justyna] Jagiellonian Univ, Dept Physiol &amp; Toxicol Reprod, Chair Anim Physiol, Inst Zool, PL-30387 Krakow, Poland.</availability>
    <date>2014</date>
    <notes>JEnglishArticlePtak, A (reprint author), Jagiellonian Univ, Dept Physiol &amp; Toxicol Reprod, Chair Anim Physiol, Inst Zool, Gronostajowa 9, PL-30387 Krakow, Polandanna.ptak@uj.edu.plBaranwal S, 2009, BIOCHEM BIOPH RES CO, V384, P6, DOI 10.1016/j.bbrc.2009.04.051; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Cavallaro Ugo, 2004, Curr Opin Investig Drugs, V5, P1274; Davidson B, 2002, MOL CELL ENDOCRINOL, V187, P39, DOI 10.1016/S0303-7207(01)00709-2; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Derouiche S, 2013, SPRINGERPLUS, V2, P54, DOI DOI 10.1186/2193-1801-2-54;93; Ding JX, 2006, GYNECOL ONCOL, V103, P623, DOI 10.1016/j.ygyno.2006.04.023; Dominguez MA, 2008, REPROD TOXICOL, V25, P420, DOI 10.1016/j.reprotox.2008.05.059; Ellerbroek SM, 2001, CANCER RES, V61, P1855; Fresno Vara JA, 2004, CANC TREAT REV, V30, P193, DOI [10.1016/j.ctrv.2003.07.007, DOI 10.1016/J.CTRV.2003.07.007)]; Goetze S, 2002, HYPERTENSION, V40, P748, DOI 10.1161/01.HYP.0000035522.63647.D3; Graesslin O., 2006, INT J GYNECOL CANCER, V16, P1197; HAMILTON TC, 1983, CANCER RES, V43, P5379; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hu XX, 2012, ARCH GYNECOL OBSTET, V286, P1537, DOI 10.1007/s00404-012-2456-6; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Jeong GO, 2013, CELL PHYSIOL BIOCHEM, V32, P253, DOI 10.1159/000354434; Kenny HA, 2009, CELL CYCLE, V8, P683, DOI 10.4161/cc.8.5.7703; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Li Y, 2010, ENDOCRINOLOGY, V151, P5146, DOI 10.1210/en.2009-1506; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Miller CR, 2014, GYNECOL ONCOL, V133, P128, DOI 10.1016/j.ygyno.2014.01.008; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Ptak A, 2013, TOXICOL IN VITRO, V27, P1937, DOI 10.1016/j.tiv.2013.06.017; Rauvala M, 2006, INT J GYNECOL CANCER, V16, P1297, DOI 10.1111/j.1525-1438.2006.00448.x; Reddy P, 2005, MOL ENDOCRINOL, V19, P2564, DOI 10.1210/me.20040-0342; Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; Song J, 2005, CANCER LETT, V220, P57, DOI 10.1016/j.canlet.2004.04.024; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Sukocheva OA, 2013, DIS ESOPHAGUS, V26, P628, DOI 10.1111/dote.12000; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Wang KH, 2013, TAIWAN J OBSTET GYNE, V52, P246, DOI 10.1016/j.tjog.2013.04.016; Yan Y, 2013, MOL CELL BIOCHEM, V378, P1, DOI 10.1007/s11010-013-1579-9; Yang LQ, 2013, TOXICOL LETT, V218, P187, DOI 10.1016/j.toxlet.2013.01.026; Yuecheng Yu, 2006, Clin Exp Metastasis, V23, P65, DOI 10.1007/s10585-006-9020-3; Zhang ZB, 2012, CANCER LETT, V319, P89, DOI 10.1016/j.canlet.2011.12.033390ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTSEP 2Discipline: ToxicologyAM7KK</notes>
    <keywords>17-BETA-ESTRADIOL; Akt; bisphenol A; BISPHENOL-A; BREAST-CANCER; CADHERIN; CANCER; CARCINOMA; CELLS; ERK1/2; Estrogen; EXPRESSION; GROWTH; IN-VITRO; INVASION; LINES; Migration; OVCAR-3; RECEPTOR; STEM-CELLS; TUMOR PROGRESSION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>357</startpage>
    <endpage>365</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>2</issue>
    <volume>229</volume>
    <abstract>Bisphenol A (BPA), is present in a multitude of products, including food and water containers, food can linings, dentistry sealants, and thermal paper. BPA can induce the growth of human ovarian cancer cell lines. Reduction of adhesion and the initiation of metastasis are important events in cancer progression; therefore, this study investigated the effects of BPA (0.1-100 nM) on the migration of OVCAR-3 ovarian cancer cells and the expression levels of metalloproteinases (MMPs) and cadherins. The oestrogenic compound 17 beta-estradiol (40 nM) was used as a positive control for estrogenic properties of bisphenol A. BPA stimulated cell migration, and the effect of BPA was similar to that of 17 beta-estradiol. BPA-induced cell migration was accompanied by up-regulation of the migration-related factors MMP-2, MMP-9 and Ncadherin, but E-cadherin expression and activity was unaffected. The stimulatory effects of BPA on cell migration were abolished by pre-treatment of the cells with inhibitors of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase pathways (PI3K). In conclusion, the results presented here show that BPA induces OVCAR-3 cells migration by activating MAPK and PI3K/ Akt signalling pathways. (C) 2014 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000340045700004</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>195</id>
    <title>Bisphenol A Induces Gene Expression Changes and Proliferative Effects through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts</title>
    <authors>Pupo,M.; Pisano,A.; Lappano,R.; Santolla,M.F.; De Francesco,E.M.; Abonante,S.; Rosano,C.; Maggiolini,M.</authors>
    <availability>[Pupo, Marco; Pisano, Assunta; Lappano, Rosamaria; Santolla, Maria Francesca; De Francesco, Ernestina Marianna; Maggiolini, Marcello] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italy. [Abonante, Sergio] Reg Hosp, Cosenza, Italy. [Rosano, Camillo] Natl Inst Canc Res, Dept Bioinformat &amp; Struct Prote, Genoa, Italy.</availability>
    <date>2012</date>
    <notes>JEnglishArticleMaggiolini, M (reprint author), Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italymarcellomaggiolini@yahoo.itAbramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Madeo A, 2010, CANCER RES, V70, P6036, DOI 10.1158/0008-5472.CAN-10-0408; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Maggiolini M., 2004, J BIOL CHEM, V279, P27009; Markey CM, 2001, BIOL REPROD, V65, P1215; Mlynarcikova A, 2005, MOL CELL ENDOCRINOL, V244, P57, DOI 10.1016/j.mce.2005.02.009; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Noguchi S, 2002, TOXICOL LETT, V135, P95, DOI 10.1016/S0378-4274(02)00252-7; Nordstrom DK, 2002, SCIENCE, V296, P2143, DOI 10.1126/science.1072375; Pandey DP, 2009, EMBO J, V28, P523, DOI 10.1038/emboj.2008.304; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002; Sheng ZG, 2011, ENVIRON HEALTH PERSP, V119, P1775, DOI 10.1289/ehp.1103781; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Takai Y, 2000, BIOCHEM BIOPH RES CO, V270, P918, DOI 10.1006/bbrc.2000.2548; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Ye JA, 2005, CLIN EXP PHARMACOL P, V32, P1042, DOI 10.1111/j.1440-1681.2005.04302.x3927US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPAUGDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology985JN</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; ALPHA; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cells; BREAST-CANCER; C-FOS; CANCER; CANCER CELLS; CANCER PROGRESSION; CANCER-ASSOCIATED FIBROBLASTS; CANCER-CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; ENDOCRINE; Endocrine disruption; ER alpha; ER-ALPHA; ER-BETA; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS; EXPOSURE; EXPRESSION; FOOD; GENE; gene expression; GENE-EXPRESSION; GENES; GPER; GPR30; GPR30/GPER; GROWTH; HEALTH; HUMAN-BREAST-CANCER; INHIBITOR; Inhibitors; MAMMARY-GLAND; mechanism; MECHANISMS; Migration; MODEL; Occupational; PROGRESSION; proliferation; PROTEIN-COUPLED RECEPTOR; RECEPTOR; SIGNALING PATHWAY; SIGNALING PATHWAYS; SYSTEM; toxicology; tumor microenvironment; WATER; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1177</startpage>
    <endpage>1182</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>8</issue>
    <volume>120</volume>
    <abstract>BACKGROUND: Bisphenol A (BPA) is the principal constituent of baby bottles, reusable water bottles, metal cans, and plastic food containers. BPA exerts estrogen-like activity by interacting with the classical estrogen receptors (ER alpha and ER beta) and through the G protein-coupled receptor (GPR30/GPER). In this regard, recent studies have shown that GPER was involved in the proliferative effects induced by BPA in both normal and tumor cells. OBJECTIVES: We studied the transduction signaling pathways through which BPA influences cell proliferation and migration in human breast cancer cells and cancer-associated fibroblasts (CAFs). METHODS AND RESULTS: We used as a model system SKBR3 breast cancer cells and CAFs that lack the classical ERs. Specific pharmacological inhibitors and gene-silencing procedures were used to show that BPA induces the expression of the GPER target genes c-FOS, EGR-1, and CTGF through the GPER/EGFR/ERK transduction pathway in SKBR3 breast cancer cells and CAFs. Moreover, we observed that GPER is required for growth effects and migration stimulated by BPA in both cell types. CONCLUSIONS: Results indicate that GPER is involved in the biological action elicited by BPA in breast cancer cells and CAFs. Hence, GPER-mediated signaling should be included among the transduction mechanisms through which BPA may stimulate cancer progression</abstract>
    <url>WOS:000307260500031</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>16</id>
    <title>Human Fetal Exposure to Triclosan and Triclocarban in an Urban Population from Brooklyn, New York</title>
    <authors>Pycke,B.F.G.; Geer,L.A.; Dalloul,M.; Abulafia,O.; Jenck,A.M.; Halden,R.U.</authors>
    <availability>[Pycke, Benny F. G.; Jenck, Alizee M.; Halden, Rolf U.] Arizona State Univ, Biodesign Inst, Ctr Environm Secur, Tempe, AZ 85287 USA. [Geer, Laura A.] State Univ New York, Downstate Sch Publ Hlth, Dept Environm &amp; Occupat Hlth Sci, Brooklyn, NY 11203 USA. [Dalloul, Mudar; Abulafia, Ovadia] Suny Downstate Med Ctr, Dept Obstet &amp; Gynecol, Brooklyn, NY 11203 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleHalden, RU (reprint author), Arizona State Univ, Biodesign Inst, Ctr Environm Secur, 781 East Terrace Mall, Tempe, AZ 85287 USAhalden@asu.eduAhn KC, 2008, ENVIRON HEALTH PERSP, V116, P1203, DOI 10.1289/ehp.11200; Allmyr M, 2008, SCI TOTAL ENVIRON, V393, P162, DOI 10.1016/j.scitotenv.2007.12.006; Allmyr M, 2006, SCI TOTAL ENVIRON, V372, P87, DOI 10.1016/j.scitotenv.2006.08.007; Allmyr M, 2006, ANAL CHEM, V78, P6542, DOI 10.1021/ac060666x; Asimakopoulos AG, 2014, SCI TOTAL ENVIRON, V470, P1243, DOI 10.1016/j.scitotenv.2013.10.089; Barr DB, 2005, ENVIRON HEALTH PERSP, V113, P1083, DOI 10.1289/ehp.7617; Berger C, 1978, Ann Pediatr (Paris), V25, P45; Bertelsen RJ, 2014, J EXPO SCI ENV EPID, V24, P517, DOI 10.1038/jes.2013.95; Bertelsen RJ, 2013, ALLERGY, V68, P84, DOI 10.1111/all.12058; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; Butt CM, 2011, TOXICOL SCI, V124, P339, DOI 10.1093/toxsci/kfr117; Buttke DE, 2012, ENVIRON HEALTH PERSP, V120, P1613, DOI 10.1289/ehp.1104748; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Chen JG, 2008, ENDOCRINOLOGY, V149, P1173, DOI 10.1210/en.2007-1057; Chen MJ, 2013, J HAZARD MATER, V250, P115, DOI 10.1016/j.jhazmat.2013.01.061; Cherednichenko G, 2012, P NATL ACAD SCI USA, V109, P14158, DOI 10.1073/pnas.1211314109; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Frederiksen H, 2013, INT J HYG ENVIR HEAL, V216, P772, DOI 10.1016/j.ijheh.2013.02.006; Gautam P, 2014, WATER RES, V48, P247, DOI 10.1016/j.watres.2013.09.032; Gee RH, 2008, J APPL TOXICOL, V28, P78, DOI 10.1002/jat.1316; Geens T, 2009, CHEMOSPHERE, V76, P755, DOI 10.1016/j.chemosphere.2009.05.024; Geer LA, 2012, J ENVIRON MONITOR, V14, P1035, DOI 10.1039/c2em10835f; Halden RU, 2014, ENVIRON SCI TECHNOL, V48, P3603, DOI 10.1021/es500495p; Halden RU, 2005, ENVIRON SCI TECHNOL, V39, P1420, DOI 10.1021/es049071e; Health Canada, 2013, 2 HLTH CAN, P444; Heidler J, 2009, J ENVIRON MONITOR, V11, P2207, DOI 10.1039/b914324f; Holling CS, 2012, J ENVIRON MONITOR, V14, P3029, DOI 10.1039/c2em30456b; Hovander L, 2002, ARCH ENVIRON CON TOX, V42, P105; James MO, 2010, ENVIRON INT, V36, P942, DOI 10.1016/j.envint.2009.02.004; Kim K, 2011, ENVIRON RES, V111, P1280, DOI 10.1016/j.envres.2011.09.003; Kumar V, 2008, TOXICOLOGY, V250, P124, DOI 10.1016/j.tox.2008.06.012; Lan Z., 2013, ENVIRON TOXICOL, DOI [10.1002/tox.21897, DOI 10.1002/TOX.21897]; Lankester J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080057; Li X, 2010, ENVIRON INT, V36, P557, DOI 10.1016/j.envint.2010.04.009; Li X, 2013, ENVIRON INT, V52, P81, DOI 10.1016/j.envint.2011.03.026; Liu JY, 2011, TOXICOL APPL PHARM, V255, P200, DOI 10.1016/j.taap.2011.06.017; Loraine GA, 2006, ENVIRON SCI TECHNOL, V40, P687, DOI 10.1021/es051380x; Louis GW, 2013, REPROD TOXICOL, V36, P71, DOI 10.1016/j.reprotox.2012.12.001; Macherius A, 2012, ENVIRON SCI TECHNOL, V46, P10797, DOI 10.1021/es3028378; Moos R. K., 2012, 22 ANN M INT SOC EXP; Moss T, 2000, FOOD CHEM TOXICOL, V38, P361, DOI 10.1016/S0278-6915(99)00164-7; NOLEN GA, 1979, TOXICOL APPL PHARM, V51, P417, DOI 10.1016/0041-008X(79)90366-1; Oblinger C. J., 1999, NEW REPORTING PROCED; Perencevich EN, 2001, AM J INFECT CONTROL, V29, P281, DOI 10.1067/mic.2001.115469; Philippat C, 2013, ENVIRON HEALTH PERSP, V121, P1225, DOI 10.1289/ehp.1206335; Pirard C, 2012, ENVIRON INT, V48, P78, DOI 10.1016/j.envint.2012.07.003; Queckenberg C, 2010, ANTIMICROB AGENTS CH, V54, P570, DOI 10.1128/AAC.00615-09; Sandborgh-Englund G, 2006, J TOXICOL ENV HEAL A, V69, P1861, DOI 10.1080/15287390600631706; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P453, DOI 10.1016/j.jaci.2012.05.006; Schebb NH, 2011, AQUAT TOXICOL, V105, P448, DOI 10.1016/j.aquatox.2011.07.020; Schebb NH, 2011, ENVIRON SCI TECHNOL, V45, P3109, DOI 10.1021/es103650m; Schebb NH, 2012, CHEMOSPHERE, V87, P825, DOI 10.1016/j.chemosphere.2011.12.077; SIOUFI A, 1977, J PHARM SCI, V66, P1166, DOI 10.1002/jps.2600660830; Stoker TE, 2010, TOXICOL SCI, V117, P45, DOI 10.1093/toxsci/kfq180; Tarnow P, 2013, TOXICOL IN VITRO, V27, P1467, DOI 10.1016/j.tiv.2013.03.003; Toms LML, 2011, CHEMOSPHERE, V85, P1682, DOI 10.1016/j.chemosphere.2011.08.009; USEPA, 1984, APP B PART 136 DEF P; Venkatesan AK, 2012, J HAZARD MATER, V229, P29, DOI 10.1016/j.jhazmat.2012.05.049; Wu CX, 2010, ENVIRON SCI TECHNOL, V44, P6157, DOI 10.1021/es1011115; Wu Jianlin, 2009, Se Pu, V27, P724; Wu XQ, 2013, ENVIRON INT, V60, P15, DOI 10.1016/j.envint.2013.07.015; Ye XY, 2011, TOXICOLOGY, V286, P69, DOI 10.1016/j.tox.2011.05.008; Yueh MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037705; Zorrilla LM, 2009, TOXICOL SCI, V107, P56, DOI 10.1093/toxsci/kfn225642AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USAENVIRON SCI TECHNOLAUG 5SIDiscipline: Engineering; Environmental Sciences &amp; EcologyAM7WY</notes>
    <keywords>4-NONYLPHENOL; ANTIMICROBIALS TRICLOCARBAN; BISPHENOL-A; BREAST-CANCER CELLS; EXPOSURE; HUMAN-PLASMA; In vitro; IN-VITRO; PARABENS; PERSONAL CARE PRODUCTS; PHENOLS; URINARY CONCENTRATIONS; WASTE-WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>8831</startpage>
    <endpage>8838</endpage>
    <journalfull>Environmental Science &amp; Technology</journalfull>
    <issue>15</issue>
    <volume>48</volume>
    <abstract>Triclosan (TCS) and triclocarban (TCC) are antimicrobial agents formulated in a wide variety of consumer products (including soaps, toothpaste, medical devices, plastics, and fabrics) that are regulated by the U.S. Food and Drug Administration (FDA) and U.S. Environmental Protection Agency. In late 2014, the FDA will consider regulating the use of both chemicals, which are under scrutiny regarding lack of effectiveness, potential for endocrine disruption, and potential contribution to bacterial resistance to antibiotics. Here, we report on body burdens of TCS and TCC resulting from real-world exposures during pregnancy. Using liquid chromatography tandem mass spectrometry, we determined the concentrations of TCS, TCC, and its human metabolites (2'-hydroxy-TCC and 3'-hydroxy-TCC) as well as the manufacturing byproduct (3'-chloro-TCC) as total concentrations (Sigma-) after conjugate hydrolysis in maternal urine and cord blood plasma from a cohort of 181 expecting mother/infant pairs in an urban multiethnic population from Brooklyn, NY recruited in 2007-09. TCS was detected in 100% of urine and 51% of cord blood samples after conjugate hydrolysis. The interquartile range (IQR) of detected TCS concentrations in urine was highly similar to the IQR reported previously for the age-matched population of the National Health and Nutrition Examination Survey (NHANES) from 2003 to 2004, but typically higher than the IQR reported previously for the general population (detection frequency = 74.6%). Urinary levels of TCC are reported here for the first time from real-world exposures during pregnancy, showing a median concentration of 0.21 mu g/L. Urinary concentrations of TCC correlated well with its phase-1 metabolite Sigma-2'-hydroxy-TCC (r = 0.49) and the manufacturing byproduct Sigma-3'-chloro-TCC C (r = 0.79), and Sigma-2'-hydroxy-TCC correlated strongly with Sigma-3'-hydroxy-TCC (r = 0.99). This human biomonitoring study presents the first body burden data for TCC from exposures occurring during pregnancy and provides additional data on composite exposure to TCS (i.e., from both consumer-product use and environmental sources) in the maternal fetal unit for an urban population in the United States</abstract>
    <url>WOS:000340080600062</url>
    <isbnorissn>0013-936X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>265</id>
    <title>Xenoestrogens down-regulate aryl-hydrocarbon receptor nuclear translocator 2 mRNA expression in human breast cancer cells via an estrogen receptor alpha-dependent mechanism</title>
    <authors>Qin,X.Y.; Zaha,H.; Nagano,R.; Yoshinaga,J.; Yonemoto,J.; Sone,H.</authors>
    <availability>[Qin, Xian-Yang; Zaha, Hiroko; Nagano, Reiko; Yonemoto, Junzo; Sone, Hideko] Natl Inst Environm Studies, Res Ctr Environm Risk, Tsukuba, Ibaraki 3058506, Japan. [Qin, Xian-Yang; Yoshinaga, Jun] Univ Tokyo, Dept Environm Studies, Chiba 2708563, Japan.</availability>
    <date>2011</date>
    <notes>JEnglishArticleSone, H (reprint author), Natl Inst Environm Studies, Res Ctr Environm Risk, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japanhsone@nies.go.jpAlexander B, 1999, J PHARMACOL TOXICOL, V41, P55, DOI 10.1016/S1056-8719(98)00038-0; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Dougherty EJ, 2008, TOXICOL SCI, V103, P191, DOI 10.1093/toxsci/kfm300; Ghisari M, 2009, TOXICOL LETT, V189, P67, DOI 10.1016/j.toxlet.2009.05.004; Ghosh MG, 2000, CANCER RES, V60, P6367; Hankinson O, 2008, TOXICOL SCI, V103, P1, DOI 10.1093/toxsci/kfn032; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; HATCH EE, 2010, REPROD TOXICOL; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hevir N, 2011, CHEM-BIOL INTERACT, V191, P206, DOI 10.1016/j.cbi.2010.12.013; Hill AJ, 2009, ZEBRAFISH, V6, P79, DOI 10.1089/zeb.2008.0536; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hosoya T, 2001, GENES CELLS, V6, P361, DOI 10.1046/j.1365-2443.2001.00421.x; Hsu HJ, 2001, BIOCHEM BIOPH RES CO, V282, P487, DOI 10.1006/bbrc.2001.4525; Kretzschmar G, 2010, MOL CELL ENDOCRINOL, V321, P253, DOI 10.1016/j.mce.2010.02.018; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Ma L, 2009, TRENDS ENDOCRIN MET, V20, P357, DOI 10.1016/j.tem.2009.03.009; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Martinez V, 2008, BREAST CANCER RES TR, V110, P521, DOI 10.1007/s10549-007-9739-9; Mitsushima D, 2003, BIOCHEM BIOPH RES CO, V307, P248, DOI 10.1016/S0006-291X(03)01171-9; Rogers JM, 2000, IN VITRO MOL TOXICOL, V13, P67; Rogers JM, 2002, MOL PHARMACOL, V61, P1393, DOI 10.1124/mol.61.6.1393; Safe S, 2004, TOXICOLOGY, V205, P3, DOI 10.1016/j.tox.2004.06.032; Scherbakov AM, 2009, STEROIDS, V74, P535, DOI 10.1016/j.steroids.2009.02.003; Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145; Sekine H, 2006, J BIOL CHEM, V281, P37507, DOI 10.1074/jbc.M606910200; Sharpe RM, 2004, BRIT MED J, V328, P447, DOI 10.1136/bmj.328.7437.447; Sikka SC, 2008, ASIAN J ANDROL, V10, P134, DOI 10.1111/j.1745-7262.2008.00370.x; Swedenborg E, 2010, TOXICOLOGY, V268, P132, DOI 10.1016/j.tox.2009.09.007; Watanabe M, 2007, HUM REPROD, V22, P1279, DOI 10.1093/humrep/del513; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51339ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTOCT 10Discipline: Toxicology825RC</notes>
    <keywords>Antagonist; ARNT2; Aryl hydrocarbon receptor; ARYL-HYDROCARBON; ARYL-HYDROCARBON RECEPTOR; BETA; BIOASSAY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; CHEMICALS; development; E-CALUX; ENDOCRINE; Endocrine disruption; ENDOCRINE DISRUPTORS; ENVIRONMENTAL CHEMICALS; Estrogen; Estrogen receptor; estrogen signaling; ESTROGEN-RECEPTOR; estrogenic activity; EXPRESSION; GENE; GENES; HEALTH; HUMAN-BREAST-CANCER; HUMANS; HYPOTHALAMUS; HYPOXIA; In vitro; IN-VITRO; LINE; LINES; LNCaP cells; mechanism; PATHWAY; phthalate; RECEPTOR; REDUCTION; RESPONSES; RISK; ROLES; SIGNALING PATHWAY; SIGNALING PATHWAYS; TISSUE; toxicology; TUMORIGENESIS; VITRO; xenoestrogen; XENOESTROGENS; zebrafish</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>152</startpage>
    <endpage>157</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>2</issue>
    <volume>206</volume>
    <abstract>Environmental chemicals with estrogenic activity, known as xenoestrogens, may cause impaired reproductive development and endocrine-related cancers in humans by disrupting endocrine functions. Aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2) is believed to play important roles in a variety of physiological processes, including estrogen signaling pathways, that may be involved in the pathogenesis and therapeutic responses of endocrine-related cancers. However, much of the underlying mechanism remains unknown. In this study, we investigated whether ARNT2 expression is regulated by a range of representative xenoestrogens in human cancer cell lines. Bisphenol A (BPA), benzyl butyl phthalate (BBP), and 1,1,1-trichloro-2,2-bis(2-chlorophenyl-4-chlorophenyl)ethane (o,p'-DDT) were found to be estrogenic toward BG1Luc4E2 cells by an E-CALUX bioassay. ARNT2 expression was downregulated by BPA, BBP, and o,p'-DDT in a dose-dependent manner in estrogen receptor 1 (ESR1)-positive MCF-7 and BG1Luc4E2 cells, but not in estrogen receptor-negative LNCaP cells. The reduction in ARNT2 expression in cells treated with the xenoestrogens was fully recovered by the addition of a specific ESR1 antagonist, MPP. In conclusion, we have shown for the first time that ARNT2 expression is modulated by xenoestrogens by an ESR1-dependent mechanism in MCF-7 breast cancer cells. (C) 2011 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000295298800006</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>177</id>
    <title>Individual Variation of the Genetic Response to Bisphenol A in Human Foreskin Fibroblast Cells Derived from Cryptorchidism and Hypospadias Patients</title>
    <authors>Qin,X.Y.; Sone,H.; Kojima,Y.; Mizuno,K.; Ueoka,K.; Muroya,K.; Miyado,M.; Hisada,A.; Zaha,H.; Fukuda,T.; Yoshinaga,J.; Yonemoto,J.; Kohri,K.; Hayashi,Y.; Fukami,M.; Ogata,T.</authors>
    <availability>[Qin, Xian-Yang; Sone, Hideko; Zaha, Hiroko; Yonemoto, Junzo] Natl Inst Environm Studies, Res Ctr Environm Risk, Hlth Risk Res Sect, Tsukuba, Ibaraki, Japan. [Qin, Xian-Yang; Hisada, Aya; Yoshinaga, Jun] Univ Tokyo, Grad Sch Frontier Sci, Dept Environm Studies, Kashiwa, Chiba, Japan. [Kojima, Yoshiyuki] Fukushima Med Univ, Sch Med, Dept Urol, Fukushima, Japan. [Mizuno, Kentaro; Kohri, Kenjiro; Hayashi, Yutaro] Nagoya City Univ, Grad Sch Med Sci, Dept Nephrourol, Nagoya, Aichi, Japan. [Ueoka, Katsuhiko] Natl Res Ctr Child Hlth &amp; Dev, Dept Surg Subspecialties, Tokyo, Japan. [Muroya, Koji] Kanagawa Childrens Med Ctr, Div Endocrinol &amp; Metab, Yokohama, Kanagawa, Japan. [Miyado, Mami; Fukami, Maki] Natl Res Inst Child Hlth &amp; Dev, Dept Endocrinol &amp; Metab, Tokyo, Japan. [Fukuda, Tomokazu] Tohoku Univ, Grad Sch Agr Sci, Dept Anim Prod Sci, Sendai, Miyagi 980, Japan. [Ogata, Tsutomu] Hamamatsu Univ Sch Med, Univ Hosp, Dept Pediat, Hamamatsu, Shizuoka 4313192, Japan.</availability>
    <date>2012</date>
    <notes>JEnglishArticleSone, H (reprint author), Natl Inst Environm Studies, Res Ctr Environm Risk, Hlth Risk Res Sect, Tsukuba, Ibaraki, Japanhsone@nies.go.jpAlifano M, 2010, CLIN CANCER RES, V16, P4401, DOI 10.1158/1078-0432.CCR-10-0659; Andrieux J, 2009, AM J MED GENET A, V149A, P2813, DOI 10.1002/ajmg.a.33097; Barrow LL, 2002, TERATOLOGY, V66, P85, DOI 10.1002/tera.10062; Baskin LS, 2001, CELL TISSUE RES, V305, P379, DOI 10.1007/s004410000345; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Carbone P, 2007, INT J ANDROL, V30, P3, DOI 10.1111/j.1365-2605.2006.00703.x; Dupouy S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004223; Hankinson O, 2008, TOXICOL SCI, V103, P1, DOI 10.1093/toxsci/kfn032; Hill AJ, 2009, ZEBRAFISH, V6, P79, DOI 10.1089/zeb.2008.0536; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hsu HJ, 2001, BIOCHEM BIOPH RES CO, V282, P487, DOI 10.1006/bbrc.2001.4525; Klopocki E, 2008, EUR J PEDIATR, V167, P903, DOI 10.1007/s00431-007-0616-7; Knorr E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004751; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Martin OV, 2008, ENVIRON HEALTH PERSP, V116, P149, DOI 10.1289/ehp.10545; McInnes LA, 2010, MOL AUTISM, V1, DOI 10.1186/2040-2392-1-5; Peruzzi D, 2009, CLIN CANCER RES, V15, P4104, DOI 10.1158/1078-0432.CCR-08-3226; Qiao L, 2012, PEDIATR RES, V71, P393, DOI 10.1038/pr.2011.49; Qin XY, 2012, J HUM GENET, V57, P434, DOI 10.1038/jhg.2012.48; Qin XY, 2011, TOXICOL LETT, V206, P152, DOI 10.1016/j.toxlet.2011.07.007; Qin XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036711; Qin XY, 2011, FEBS LETT, V585, P3310, DOI 10.1016/j.febslet.2011.09.017; Sekine H, 2006, J BIOL CHEM, V281, P37507, DOI 10.1074/jbc.M606910200; Toppari J, 2010, BIRTH DEFECTS RES A, V88, P910, DOI 10.1002/bdra.20707; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vidaeff AC, 2005, REPROD TOXICOL, V20, P5, DOI 10.1016/j.reprotox.2004.12.015; Virtanen HE, 2007, ACTA PAEDIATR, V96, P611, DOI 10.1111/j.1651-2227.2007.00241.x; Vottero A, 2011, J CLIN ENDOCR METAB, V96, pE1953, DOI 10.1210/jc.2011-0511; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Watanabe M, 2007, HUM REPROD, V22, P1279, DOI 10.1093/humrep/del513; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010324PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEDEC 28Discipline: Science &amp; Technology - Other Topics064DQ</notes>
    <keywords>ABNORMALITIES; ANDROGEN RECEPTOR; Aryl hydrocarbon receptor; ARYL-HYDROCARBON; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHILDREN; Cryptorchidism; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; EXPOSURE; EXPRESSION; HEALTH; HYPOXIA; Male; METABOLISM; NUCLEAR TRANSLOCATOR ARNT; POPULATION; RECEPTOR; REPRODUCTIVE HEALTH; RISK; SUSCEPTIBILITY; TESTICULAR DYSGENESIS SYNDROME; TISSUE; VARIABILITY; zebrafish</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>12</issue>
    <volume>7</volume>
    <abstract>Background/Purpose: We hypothesized that polymorphic differences among individuals might cause variations in the effect that environmental endocrine disruptors (EEDs) have on male genital malformations (MGMs). In this study, individual variation in the genetic response to low-dose bisphenol A (BPA) was investigated in human foreskin fibroblast cells (hFFCs) derived from child cryptorchidism (CO) and hypospadias (HS) patients. Methodology/Principal Findings: hFFCs were collected from control children without MGMs (n = 5) and child CO and HS patients (n = 8 and 21, respectively). BPA exposure (10 nM) was found to inhibit matrix metalloproteinase-11 (MMP11) expression in the HS group (0.74-fold, P = 0.0034) but not in the control group (0.93- fold, P = 0.84) and CO group (0.94-fold, P = 0.70). Significantly lower levels of MMP11 expression were observed in the HS group compared with the control group (0.80-fold, P = 0.0088) and CO group (0.79-fold, P = 0.039) in response to 10 nM BPA. The effect of single-nucleotide polymorphism rs5000770 (G. A), located within the aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) locus, on individual sensitivity to low-dose BPA was investigated in the HS group. A significant difference in neurotensin receptor 1 (NTSR1) expression in response to 10 nM BPA was observed between AA and AG/GG groups (n = 6 and 15, respectively. P = 0.031). However, no significant difference in ARNT2 expression was observed (P = 0.18). Conclusions/Significance: This study advances our understanding of the specificity of low-dose BPA effects on human reproductive health. Our results suggest that genetic variability among individuals affects susceptibility to the effects of EEDs exposure as a potential cause of HS</abstract>
    <url>WOS:000313051500056</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>218</id>
    <title>Identification of Novel Low-Dose Bisphenol A Targets in Human Foreskin Fibroblast Cells Derived from Hypospadias Patients</title>
    <authors>Qin,X.Y.; Kojima,Y.; Mizuno,K.; Ueoka,K.; Muroya,K.; Miyado,M.; Zaha,H.; Akanuma,H.; Zeng,Q.; Fukuda,T.; Yoshinaga,J.; Yonemoto,J.; Kohri,K.; Hayashi,Y.; Fukami,M.; Ogata,T.; Sone,H.</authors>
    <availability>[Qin, Xian-Yang; Zaha, Hiroko; Akanuma, Hiromi; Zeng, Qin; Yonemoto, Junzo; Sone, Hideko] Natl Inst Environm Studies, Hlth Risk Res Sect, Res Ctr Environm Risk, Tsukuba, Ibaraki, Japan. [Qin, Xian-Yang; Yoshinaga, Jun] Univ Tokyo, Grad Sch Frontier Sci, Dept Environm Studies, Kashiwa, Chiba, Japan. [Kojima, Yoshiyuki; Mizuno, Kentaro; Kohri, Kenjiro; Hayashi, Yutaro] Nagoya City Univ, Grad Sch Med Sci, Dept Nephro Urol, Nagoya, Aichi, Japan. [Ueoka, Katsuhiko] Natl Res Ctr Child Hlth &amp; Dev, Dept Surg Subspecialties, Tokyo, Japan. [Muroya, Koji] Kanagawa Childrens Med Ctr, Div Endocrinol &amp; Metab, Yokohama, Kanagawa, Japan. [Miyado, Mami; Fukami, Maki; Ogata, Tsutomu] Natl Res Inst Child Hlth &amp; Dev, Dept Endocrinol &amp; Metab, Tokyo, Japan. [Fukuda, Tomokazu] Tohoku Univ, Grad Sch Agr Sci, Dept Anim Prod Sci, Sendai, Miyagi 980, Japan. [Ogata, Tsutomu] Hamamatsu Univ Sch Med, Univ Hosp, Dept Pediat, Hamamatsu, Shizuoka 4313192, Japan.</availability>
    <date>2012</date>
    <notes>JEnglishArticleQin, XY (reprint author), Natl Inst Environm Studies, Hlth Risk Res Sect, Res Ctr Environm Risk, Tsukuba, Ibaraki, Japanhsone@nies.go.jpAllard P, 2010, P NATL ACAD SCI USA, V107, P20405, DOI 10.1073/pnas.1010386107; Baskin LS, 2001, CELL TISSUE RES, V305, P379, DOI 10.1007/s004410000345; Bronner IF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006826; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Desmedt C, 2012, CLIN CANCER RES, V18, P1004, DOI 10.1158/1078-0432.CCR-11-0383; Garavelli L, 2005, HORM RES, V63, P187, DOI 10.1159/000085894; Gibert Y, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-4; Harada Y, 2010, CANCER RES, V70, P5829, DOI 10.1158/0008-5472.CAN-10-0255; Ishizuya-Oka A, 2000, J CELL BIOL, V150, P1177, DOI 10.1083/jcb.150.5.1177; Jasarevic E, 2011, P NATL ACAD SCI USA, V108, P11715, DOI 10.1073/pnas.1107958108; Jorgensen N, 2010, INT J ANDROL, V33, P298, DOI 10.1111/j.1365-2605.2009.01050.x; Knorr E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004751; Kojima Y, 2010, J PEDIATR UROL, V6, P346, DOI 10.1016/j.jpurol.2009.11.007; Kojima Y, 2009, UROLOGY, V74, P571, DOI 10.1016/j.urology.2009.04.037; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Lupo A, 2011, INT J BIOCHEM CELL B, V43, P470, DOI 10.1016/j.biocel.2010.12.020; McCord LA, 2011, BIOL REPROD; Peruzzi D, 2009, CLIN CANCER RES, V15, P4104, DOI 10.1158/1078-0432.CCR-08-3226; Qiao LA, 2011, J UROLOGY, V185, P1888, DOI 10.1016/j.juro.2010.12.066; Qin XY, 2011, TOXICOL LETT, V206, P152, DOI 10.1016/j.toxlet.2011.07.007; Qin XY, 2012, CANC BIOL THER, P13; Rey RA, 2005, J CLIN ENDOCR METAB, V90, P6035, DOI 10.1210/jc.2005-1306; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Sharpe RM, 2010, TOXICOL SCI, V114, P1, DOI 10.1093/toxsci/kfp299; Simian M, 2001, DEVELOPMENT, V128, P3117; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Toppari J, 2010, BIRTH DEFECTS RES A, V88, P910, DOI 10.1002/bdra.20707; Valdivia A, 2011, INT J CLIN EXP PATHO, V4, P674; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Virtanen HE, 2007, ACTA PAEDIATR, V96, P611, DOI 10.1111/j.1651-2227.2007.00241.x; Vottero A, 2011, J CLIN ENDOCR METAB, V96, pE1953, DOI 10.1210/jc.2011-0511; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang Z, 2007, J UROLOGY, V177, P1939, DOI 10.1016/j.juro.2007.01.014; Wei J, 2011, ENDOCRINOLOGY, V152, P3049, DOI 10.1210/en.2011-0045; Wei L, 2005, HISTOL HISTOPATHOL, V20, P177; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Zhang XW, 2011, TOXICOL SCI, V121, P320, DOI 10.1093/toxsci/kfr061447PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEMAY 4Discipline: Science &amp; Technology - Other Topics959WV</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ABNORMALITIES; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER CELLS; CELL; CELLS; Cryptorchidism; development; DIFFERENTIALLY EXPRESSED GENES; Etiology; EXPOSURE; EXPRESSION; GENE; gene expression; gene expression profile; GENE-EXPRESSION; GENES; HEALTH; HUMAN EXPOSURE; IDENTIFICATION; IN-VITRO; MATRIX-METALLOPROTEINASE STROMELYSIN-3; MECHANISMS; MESSENGER-RNA EXPRESSION; REPRODUCTIVE HEALTH; RISK; TESTICULAR DYSGENESIS SYNDROME; TISSUE</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>5</issue>
    <volume>7</volume>
    <abstract>Background/Purpose: The effect of low-dose bisphenol A (BPA) exposure on human reproductive health is still controversial. To better understand the molecular basis of the effect of BPA on human reproductive health, a genome-wide screen was performed using human foreskin fibroblast cells (hFFCs) derived from child hypospadias (HS) patients to identify novel targets of low-dose BPA exposure. Methodology/Principal Findings: Gene expression profiles of hFFCs were measured after exposure to 10 nM BPA, 0.01 nM 17 beta-estradiol (E2) or 1 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for 24 h. Differentially expressed genes were identified using an unpaired Student's t test with P value cut off at 0.05 and fold change of more than 1.2. These genes were selected for network generation and pathway analysis using Ingenuity Pathways Analysis, Pathway Express and KegArray. Seventy-one genes (42 downregulated and 29 upregulated) were identified as significantly differentially expressed in response to BPA, among which 43 genes were found to be affected exclusively by BPA compared with E2 and TCDD. Of particular interest, real-time PCR analysis revealed that the expression of matrix metallopeptidase 11 (MMP11), a well-known effector of development and normal physiology, was found to be inhibited by BPA (0.47-fold and 0.37-fold at 10 nM and 100 nM, respectively). Furthermore, study of hFFCs derived from HS and cryptorchidism (CO) patients (n = 23 and 11, respectively) indicated that MMP11 expression was significantly lower in the HS group than in the CO group (0.25-fold, P = 0.0027). Conclusions/Significance: This present study suggests that an involvement of BPA in the etiology of HS might be associated with the downregulation of MMP11. Further study to elucidate the function of the novel target genes identified in this study during genital tubercle development might increase our knowledge of the effects of low-dose BPA exposure on human reproductive health</abstract>
    <url>WOS:000305349800114</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>231</id>
    <title>Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epithelial cells</title>
    <authors>Qin,X.Y.; Fukuda,T.; Yang,L.Q.; Zaha,H.; Akanuma,H.; Zeng,Q.; Yoshinaga,J.; Sone,H.</authors>
    <availability>[Qin, Xian-Yang; Yang, Linqing; Zaha, Hiroko; Akanuma, Hiromi; Zeng, Qin; Sone, Hideko] Natl Inst Environm Studies, Hlth Risk Res Sect, Tsukuba, Ibaraki, Japan. [Qin, Xian-Yang; Yoshinaga, Jun] Univ Tokyo, Grad Sch Frontier Sci, Dept Environm Studies, Kashiwa, Chiba, Japan. [Fukuda, Tomokazu] Tohoku Univ, Grad Sch Agr Sci, Lab Anim Breeding &amp; Genet, Sendai, Miyagi 980, Japan. [Yang, Linqing] Shenzhen Ctr Dis Control &amp; Prevent, Shenzhen, Guangdong, Peoples R China.</availability>
    <date>2012</date>
    <notes>JEnglishArticleSone, H (reprint author), Natl Inst Environm Studies, Hlth Risk Res Sect, Tsukuba, Ibaraki, Japanhsone@nies.go.jpBandyopadhyay D, 2007, AGING CELL, V6, P577, DOI 10.1111/j.1474-9726.2007.00308.x; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Bruder ED, 2007, PHYSIOL GENOMICS, V29, P193, DOI 10.1152/physiolgenomics.00245.2006; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; de Waard WJ, 2008, TOXICOL IN VITRO, V22, P396, DOI 10.1016/j.tiv.2007.10.007; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Fleming JM, 2010, J CELL PHYSIOL, V224, P795, DOI 10.1002/jcp.22190; Garbe JC, 2007, CELL CYCLE, V6, P1927; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Iso T, 2007, BIOL PHARM BULL, V30, P266, DOI 10.1248/bpb.30.266; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kitagawa K, 2009, CANCER SCI, V100, P1374, DOI 10.1111/j.1349-7006.2009.01196.x; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lee Ji Shin, 2008, Cancer Biol Ther, V7, P1398, DOI 10.4161/cbt.7.9.6425; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Malyavantham KS, 2008, J CELL BIOCHEM, V105, P391, DOI 10.1002/jcb.21834; Markey CM, 2001, BIOL REPROD, V65, P1215; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482; Pal R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-303; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Qin XY, 2011, TOXICOL LETT, V206, P152, DOI 10.1016/j.toxlet.2011.07.007; Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roussel-Gervais A, 2010, MOL ENDOCRINOL, V24, P1835, DOI 10.1210/me.2010-0091; Salvesen HB, 2000, CLIN CANCER RES, V6, P153; Sarkar P, 2006, INT J ONCOL, V28, P43; Serrano M, 2007, NAT REV MOL CELL BIO, V8, P715, DOI 10.1038/nrm2242; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shim YH, 2000, LAB INVEST, V80, P689; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Sudo H, 2008, RADIAT RES, V170, P23, DOI 10.1667/RR1317.1; Taghavi N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-138; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; WEBER L, 2011, BIOL REPROD, V85, P490, DOI DOI 10.1095/BI0LREPR0D.110.090431; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Zang JJ, 2011, WORLD J GASTROENTERO, V17, P3043, DOI 10.3748/wjg.v17.i25.3043598LANDES BIOSCIENCEAUSTIN1806 RIO GRANDE ST, AUSTIN, TX 78702 USACANCER BIOL THERMAR 1Discipline: Oncology905VY</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; BRCA1; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; cell cycle; cell growth; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CELLULAR SENESCENCE; CYCLE; CYCLIN-E; DAMAGE; development; DNA METHYLATION; DNA-methylation; epigenetic; EPITHELIAL-CELLS; Estrogen; EXPOSURE; GENE; GENE-EXPRESSION; GENES; GROWTH; HEALTH; HYPERMETHYLATION; In vitro; IN-SITU; IN-VITRO; LINE; LINES; Mammary epithelial cells; METHYLATION; MODEL; oncology; PHOSPHORYLATION; proliferation; PROTEIN; RISK; TISSUE; TISSUES; TUMOR; VITRO; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>296</startpage>
    <endpage>306</endpage>
    <journalfull>Cancer Biology &amp; Therapy</journalfull>
    <issue>5</issue>
    <volume>13</volume>
    <abstract>The carcinogenic activity of bisphenol A (BPA) is responsible for stimulating growth in estrogen-dependent breast cancer tissues, cell lines and rodent studies. However, it is not fully understood how this compound promotes mammary carcinogenesis. In our study, we examined the effect of BPA on cellular proliferation and senescence in human mammary epithelial cells (HMEC). Exposure to BPA for 1 week at the early stage at passage 8 increased the proliferation and sphere size of HMEC at the later stage up to passage 16, suggesting that BPA has the capability to modulate cell growth in breast epithelial cells. Interestingly, the number of human heterochromatin protein-1. positive cells, which is a marker of senescence, was also increased among BPA-treated cells. Consistent with these findings, the protein levels of both p16 and cyclin E, which are known to induce cellular senescence and promote proliferation, respectively, were increased in BPA-exposed HMEC. Furthermore, DNA methylation levels of genes related to development of most or all tumor types, such as BRCA1, CCNA1, CDKN2A (p16), THBS1, TNFRSF10C and TNFRSF10D, were increased in BPA-exposed HMEC. Our findings in the HMEC model suggested that the genetic and epigenetic alterations by BPA might damage HMEC function and result in complex activities related to cell proliferation and senescence, playing a role in mammary carcinogenesis. This manuscript has been published online, prior to printing. Once the issue is complete and page numbers have been assigned, the citation will change accordingly</abstract>
    <url>WOS:000301305500008</url>
    <isbnorissn>1538-4047</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>148</id>
    <title>Interactions between Urinary 4-tert-Octylphenol Levels and Metabolism Enzyme Gene Variants on Idiopathic Male Infertility</title>
    <authors>Qin,Y.F.; Chen,M.J.; Wu,W.; Xu,B.; Tang,R.; Chen,X.J.; Du,G.Z.; Lu,C.C.; Meeker,J.D.; Zhou,Z.M.; Xia,Y.K.; Wang,X.R.</authors>
    <availability>[Qin, Yufeng; Chen, Minjian; Wu, Wei; Xu, Bin; Tang, Rong; Chen, Xiaojiao; Du, Guizhen; Lu, Chuncheng; Zhou, Zuomin; Xia, Yankai; Wang, Xinru] Nanjing Med Univ, Inst Toxicol, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China. [Qin, Yufeng; Chen, Minjian; Wu, Wei; Xu, Bin; Tang, Rong; Chen, Xiaojiao; Du, Guizhen; Lu, Chuncheng; Xia, Yankai; Wang, Xinru] Nanjing Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Modern Toxicol, Nanjing, Jiangsu, Peoples R China. [Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleXia, YK (reprint author), Nanjing Med Univ, Inst Toxicol, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R Chinayankaixia@njmu.edu.cn; xrwang@njmu.edu.cnAkgul Y, 2008, REPROD TOXICOL, V25, P67, DOI 10.1016/j.reprotox.2007.10.007; Barry KH, 2011, ENVIRON HEALTH PERSP, V119, P1726, DOI 10.1289/ehp.1103454; Blake CA, 2004, REPROD TOXICOL, V18, P43, DOI 10.1016/j.reprotox.2003.09.003; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Boockfor FR, 1997, BIOL REPROD, V57, P267, DOI 10.1095/biolreprod57.2.267; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; David A, 2009, MAR POLLUT BULL, V58, P953, DOI 10.1016/j.marpolbul.2009.04.021; Denomme GA, 2005, TRANSFUSION, V45, P660, DOI 10.1111/j.1537-2995.2005.04365.x; Feng QZ, 2009, J HAZARD MATER, V167, P282, DOI 10.1016/j.jhazmat.2008.12.115; Fuortes L, 1997, AM J IND MED, V31, P445, DOI 10.1002/(SICI)1097-0274(199704)31:4&lt;445::AID-AJIM11&gt;3.0.CO;2-#; Gregory M, 2009, J TOXICOL ENV HEAL A, V72, P1553, DOI 10.1080/15287390903232434; Guengerich FP, 2001, MUTAT RES-REV MUTAT, V488, P195, DOI 10.1016/S1383-5742(01)00059-X; Hart SN, 2008, PHARMACOGENET GENOM, V18, P11, DOI 10.1097/FPC.0b013e3282f2f121; Hawker DW, 2011, WATER RES, V45, P768, DOI 10.1016/j.watres.2010.08.053; Hirvonen A, 1999, ENVIRON HEALTH PERSP, V107, P37, DOI 10.2307/3434470; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Isidori M, 2006, CHEMOSPHERE, V64, P135, DOI 10.1016/j.chemosphere.2005.10.047; Ji G, 2010, PLOS ONE, V5; Ji GX, 2012, FREE RADICAL BIO MED, V52, P775, DOI 10.1016/j.freeradbiomed.2011.11.032; Kisselev P, 2005, CANCER RES, V65, P2972, DOI 10.1158/0008-5472.CAN-04-3543; Lampi P, 2000, EUR J EPIDEMIOL, V16, P245, DOI 10.1023/A:1007622317866; Lee CR, 2002, PHARMACOGENETICS, V12, P251, DOI 10.1097/00008571-200204000-00010; Kim SK, 2007, ENVIRON TOXICOL, V22, P449, DOI 10.1002/tox.20280; Ma YB, 2011, TOXICOLOGY, V282, P146, DOI 10.1016/j.tox.2011.01.024; Miners J, 2002, PHARMACOGENETICS, V12, P91, DOI 10.1097/00008571-200203000-00002; Mirabelli MC, 2000, AM J IND MED, V37, P532, DOI 10.1002/(SICI)1097-0274(200005)37:5&lt;532::AID-AJIM9&gt;3.0.CO;2-A; Niwa T, 2002, BIOL PHARM BULL, V25, P235, DOI 10.1248/bpb.25.235; Nomura S, 2008, LIFE SCI, V83, P223, DOI 10.1016/j.lfs.2008.06.009; Pedersen SN, 1999, SCI TOTAL ENVIRON, V233, P89, DOI 10.1016/S0048-9697(99)00182-5; Routledge EJ, 1997, J BIOL CHEM, V272, P3280; Shimada T, 2004, CANCER SCI, V95, P1, DOI 10.1111/j.1349-7006.2004.tb03162.x; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sumpter JP, 1998, TOXICOL LETT, V103, P337; Takahashi H, 2001, CLIN PHARMACOKINET, V40, P587, DOI 10.2165/00003088-200140080-00003; Turesky RJ, 2004, CURR DRUG METAB, V5, P169, DOI 10.2174/1389200043489036; WHITE E, 1994, J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505; Xia YK, 2008, FERTIL STERIL, V89, P1743, DOI 10.1016/j.fertnstert.2007.05.049; Ying GG, 2006, ENVIRON INT, V32, P417, DOI 10.1016/j.envint.2005.07.004401PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEMAR 15Discipline: Science &amp; Technology - Other Topics109ZC</notes>
    <keywords>4-N-OCTYLPHENOL; ASSOCIATION; BISPHENOL-A; CANCER; DRINKING-WATER; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; estrogenic activity; EXPOSURE; GENES; HEALTH; IN-VITRO; Interaction; Liquid chromatography-tandem mass spectrometry; Male; MALE-INFERTILITY; MASS-SPECTROMETRY; METABOLISM; octylphenol; phenol; PHENOLS; PLATFORM; POLYMORPHISMS; POPULATION; REPRODUCTIVE-SYSTEM; RISK; toxicology; URINARY; Urine; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>3</issue>
    <volume>8</volume>
    <abstract>Octylphenol (OP) and Trichlorophenol (TCP) act as endocrine disruptors and have effects on male reproductive function. We studied the interactions between 4-tert-Octylphenol (4-t-OP), 4-n-Octylphenol (4-n-OP), 2,3,4-Trichlorophenol (2,3,4-TCP), 2,4,5-Trichlorophenol (2,4,5-TCP) urinary exposure levels and polymorphisms in selected xenobiotic metabolism enzyme genes among 589 idiopathic male infertile patients and 396 controls in a Han-Chinese population. Ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to measure alkylphenols and chlorophenols in urine. Polymorphisms were genotyped using the SNPstream platform and the Taqman method. Among four phenols that were detected, we found that only exposure to 4-t-OP increased the risk of male infertility (P-trend = 1.70 x 10(-7)). The strongest interaction was between 4-t-OP and rs4918758 in CYP2C9 (P-inter = 6.05 x 10(-7)). It presented a significant monotonic increase in risk estimates for male infertility with increasing 4-t-OP exposure levels among men with TC/CC genotype (low level compared with non-exposed, odds ratio (OR) = 2.26, 95% confidence intervals (CI) = 1.06, 4.83; high level compared with non-exposed, OR = 9.22, 95% CI = 2.78, 30.59), but no associations observed among men with TT genotype. We also found interactions between 4-t-OP and rs4986894 in CYP2C19, and between rs1048943 in CYP1A1, on male infertile risk (P-inter = 8.09 x 10(-7), P-inter = 3.73 x 10(-4), respectively). We observed notable interactions between 4-t-OP exposure and metabolism enzyme gene polymorphisms on idiopathic infertility in Han-Chinese men</abstract>
    <url>WOS:000316409800086</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>234</id>
    <title>A comparison of two human cell lines and two rat gonadal cell primary cultures as in vitro screening tools for aromatase modulation</title>
    <authors>Quignot,N.; Desmots,S.; Barouki,R.; Lemazurier,E.</authors>
    <availability>[Quignot, Nadia; Desmots, Sophie; Lemazurier, Emmanuel] INERIS, Expt Toxicol Unit, F-60550 Verneuil En Halatte, France. [Barouki, Robert] INSERM, UMR S 747, F-75006 Paris, France. [Barouki, Robert] Univ Paris 05, F-75006 Paris, France.</availability>
    <date>2012</date>
    <notes>JEnglishArticleQuignot, N (reprint author), INERIS, Expt Toxicol Unit, Parc Technol ALATA, F-60550 Verneuil En Halatte, Francenadia.quignot@ineris.fr; emmanuel.lemazurier@ineris.frAgarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Akingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Aube M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1862; Auvray P, 1998, BIOCHEM BIOPH RES CO, V253, P1, DOI 10.1006/bbrc.1998.9683; Barber RD, 2005, PHYSIOL GENOMICS, V21, P389, DOI 10.1152/physiolgenomics.00025.2005; Basavarajappa MS, 2011, TOXICOL APPL PHARM, V253, P161, DOI 10.1016/j.taap.2011.04.007; Benachour N, 2007, TOXICOL APPL PHARM, V222, P129, DOI 10.1016/j.taap.2007.03.033; Bouraima H, 2003, EUR J ENDOCRINOL, V148, P457, DOI 10.1530/eje.0.1480457; Bourguiba S, 2003, J STEROID BIOCHEM, V86, P335, DOI 10.1016/S0960-0760(03)00343-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; BRODIE AMH, 1977, ENDOCRINOLOGY, V100, P1684; Carreau Serge, 2003, Reprod Biol Endocrinol, V1, P35, DOI 10.1186/1477-7827-1-35; Caserta D, 2008, HUM REPROD UPDATE, V14, P59, DOI 10.1093/humupd/dmm025; Charles GD, 2004, ILAR J, V45, P494; Chen SA, 1998, FRONT BIOSCI-LANDMRK, V3, P922; Choate JVA, 1996, J STEROID BIOCHEM, V58, P411, DOI 10.1016/0960-0760(96)00047-7; Cravedi JP, 2007, M S-MED SCI, V23, P198, DOI 10.1051/medsci/2007232198; Drenth HJ, 1998, TOXICOL APPL PHARM, V148, P50, DOI 10.1006/taap.1997.8307; EPA, 2007, INT SUMM REP AR; Fan W, 2007, BIOCHEM BIOPH RES CO, V355, P1012, DOI 10.1016/j.bbrc.2007.02.062; Ghosh S, 2005, ONCOGENE, V24, P2236, DOI 10.1038/sj.onc.1208415; Giwercman A, 2007, REPROD BIOMED ONLINE, V15, P633; Harvey CN, 2009, TOXICOL SCI, V110, P95, DOI 10.1093/toxsci/kfp089; Hecker M, 2008, ANAL BIOANAL CHEM, V390, P287, DOI 10.1007/s00216-007-1657-5; Hecker M, 2006, TOXICOL APPL PHARM, V217, P114, DOI 10.1016/j.taap.2006.07.007; Heneweer M, 2004, TOXICOL LETT, V146, P183, DOI 10.1016/j.toxlet.2003.10.002; Higley EB, 2010, ENVIRON SCI POLLUT R, V17, P1137, DOI 10.1007/s11356-009-0285-3; Hilscherova K, 2004, TOXICOL SCI, V81, P78, DOI 10.1093/toxsci/kfh191; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; HIRSCH KS, 1987, TOXICOL APPL PHARM, V91, P235, DOI 10.1016/0041-008X(87)90104-9; Holloway AC, 2008, J APPL TOXICOL, V28, P260, DOI 10.1002/jat.1275; Huang H, 2009, TOXICOL LETT, V189, P248, DOI 10.1016/j.toxlet.2009.06.853; Kandaraki E, 2011, J CLIN ENDOCR METAB, V96, pE480, DOI 10.1210/jc.2010-1658; Kim JY, 2010, TOXICOL LETT, V193, P200, DOI 10.1016/j.toxlet.2010.01.011; KREKELS MDWG, 1991, J STEROID BIOCHEM, V38, P415, DOI 10.1016/0960-0760(91)90329-4; Laville N, 2006, TOXICOLOGY, V228, P98, DOI 10.1016/j.tox.2006.08.021; LEPHART ED, 1991, METHOD ENZYMOL, V206, P477; Lonning PE, 2011, STEROIDS, V76, P786, DOI 10.1016/j.steroids.2011.02.040; Massaad C, 2002, EUR J OBSTET GYN R B, V100, P127, DOI 10.1016/S0301-2115(01)00441-9; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005; Mendelson CR, 2007, J STEROID BIOCHEM, V106, P62, DOI 10.1016/j.jsbmb.2007.05.001; Mok-Lin E, 2010, INT J ANDROL, V33, P385, DOI 10.1111/j.1365-2605.2009.01014.x; Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murano E.P., 2006, REPROD TOXICOL, V21, P148; Nakamura D, 2010, TOXICOL LETT, V194, P16, DOI 10.1016/j.toxlet.2010.02.002; Nativelle-Serpentini C, 2003, TOXICOL IN VITRO, V17, P413, DOI 10.1016/S0887-2333(03)00046-8; Naville D, 1999, BIOCHEM BIOPH RES CO, V255, P28, DOI 10.1006/bbrc.1998.9891; Okazaki K, 2001, ARCH TOXICOL, V75, P513, DOI 10.1007/s002040100273; Pauley RJ, 2000, J CLIN ENDOCR METAB, V85, P837, DOI 10.1210/jc.85.2.837; Pezzi V, 2004, ENDOCRINOLOGY, V145, P2186, DOI 10.1210/en.2003-1366; Pogrmic-Majkic K, 2010, TOXICOL SCI, V118, P52, DOI 10.1093/toxsci/kfq227; Rivest P, 2010, TOXICOL APPL PHARM, V249, P33, DOI 10.1016/j.taap.2010.08.011; Sanderson JT, 2002, TOXICOL APPL PHARM, V182, P44, DOI 10.1006/taap.2002.9420; Sanderson JT, 2001, ENVIRON HEALTH PERSP, V109, P1027, DOI 10.2307/3454957; Shilling AD, 1999, J STEROID BIOCHEM, V70, P89, DOI 10.1016/S0960-0760(99)00090-4; Shin JH, 2006, ARCH TOXICOL, V80, P547, DOI 10.1007/s00204-006-0080-6; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Simpson E R, 1994, Int J Fertil Menopausal Stud, V39 Suppl 2, P75; Singh A, 1999, ENDOCR-RELAT CANCER, V6, P139, DOI 10.1677/erc.0.0060139; Stocco C, 2008, STEROIDS, V73, P473, DOI 10.1016/j.steroids.2008.01.017; Stoker TE, 2000, TOXICOL SCI, V58, P50, DOI 10.1093/toxsci/58.1.50; Stoker TE, 2002, TOXICOL SCI, V67, P198, DOI 10.1093/toxsci/67.2.198; Stokes WS, 2004, ILAR J, V45, P387; Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684; Suzawa M., 2008, PLOS ONE, V3, P11; Tinfo NS, 2011, REPROD TOXICOL, V31, P184, DOI 10.1016/j.reprotox.2010.11.005; Vachon CM, 2011, BREAST CANCER RES TR, V125, P243, DOI 10.1007/s10549-010-0944-6; Victor-Costa AB, 2010, REPROD TOXICOL, V29, P323, DOI 10.1016/j.reprotox.2009.12.006; Vinggaard AM, 2000, TOXICOL IN VITRO, V14, P227, DOI 10.1016/S0887-2333(00)00018-7; WANG C, 1981, MOL CELL ENDOCRINOL, V24, P17, DOI 10.1016/0303-7207(81)90075-7; Zachow R, 2006, REPROD TOXICOL, V22, P659, DOI 10.1016/j.reprotox.2006.04.018; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239; Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739; Zhao Y, 1997, J STEROID BIOCHEM, V61, P203, DOI 10.1016/S0960-0760(97)80013-1; Zhou W, 2008, MOL CELL ENDOCRINOL, V283, P12, DOI 10.1016/j.mce.2007.10.0107614PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROFEBDiscipline: Toxicology884MV</notes>
    <keywords>Androgen; androgens; Aromatase; BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CELLS; CHEMICALS; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Estrogen; ESTROGENS; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; HEALTH; HORMONE PRODUCTION; HUMAN CHORIOCARCINOMA JEG-3; IMPACT; In vitro; In vitro models; IN-VITRO; IN-VIVO; LEYDIG-CELLS; LINE; LINES; Methoxychlor; MODEL; MODELS; OVARIAN GRANULOSA-CELLS; PROMOTER II; RAT; Risk assessment; screening; STEROIDOGENIC FACTOR-I; TOXICITY; toxicology; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>107</startpage>
    <endpage>118</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>1</issue>
    <volume>26</volume>
    <abstract>Environmental toxicants are a serious health concern, and numerous studies have been devoted to studying the effects of environmental Endocrine Disrupting Chemicals (EDCs). The balance between androgens and estrogens controls the function of many EDC-sensitive organs, and the aromatase enzyme plays a key role in maintaining this balance. In vitro studies have suggested that aromatase expression and activity is a promising biomarker for initial screenings of putative hormonal disrupting compounds. To further validate the aromatase biomarker, we tested several EDCs (atrazine, bisphenol A. methoxychlor, methoxychlor metabolite HPTE, vinclozolin, vinclozolin metabolite M2) in four different models (human cell lines H295R and JEG-3, rat primary cultures of granulosa and leydig cells). We evaluated the similarities/differences in the chemical impact on aromatase mRNA levels and enzymatic activity for the different species and cell types. Aromatase gene expression was assessed by q-RT-PCR, and enzymatic activity was assessed via a tritiated water method with either intact cells or isolated microsomes. The aromatase gene mRNA levels and cellular enzymatic activity varied between the four different models tested, which suggests that the EDC effect varies among different cell types. However, regulation of microsomal aromatase activity appeared to be conserved across all the species and cell types tested. These results suggest that several well characterized complementary cellular models are required to fully characterize the effects of putative EDCs and predict the in vivo effects. (C) 2011 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000299713100015</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>287</id>
    <title>Epigenetic screening in product safety assessment: are we there yet?</title>
    <authors>Rasoulpour,R.J.; LeBaron,M.J.; Ellis-Hutchings,R.G.; Klapacz,J.; Gollapudi,B.B.</authors>
    <availability>[Rasoulpour, Reza J.; LeBaron, Matthew J.; Ellis-Hutchings, Robert G.; Klapacz, Joanna; Gollapudi, B. Bhaskar] Dow Chem Co USA, TERC, Midland, MI 48674 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewRasoulpour, RJ (reprint author), Dow Chem Co USA, TERC, 1803 Bldg, Midland, MI 48674 USARRasoulpour@Dow.comBiron VL, 2008, J OTOLARYNGOL-HEAD N, V37, pE32, DOI 10.2310/7070.2008.E0015; Boellmann F, 2010, TOXICOL SCI, V117, P404, DOI 10.1093/toxsci/kfq225; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Collas P, 1998, NUCLEIC ACIDS RES, V26, P4454, DOI 10.1093/nar/26.19.4454; Cooney CA, 2002, J NUTR, V132, p2393S; Cordes KR, 2009, CIRC RES, V104, P724, DOI 10.1161/CIRCRESAHA.108.192872; Corry GN, 2009, BIRTH DEFECTS RES C, V87, P297, DOI 10.1002/bdrc.20165; Cropley JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009055; Cui JY, 2010, TOXICOL SCI, V116, P32, DOI 10.1093/toxsci/kfq115; David RM, 2006, TOXICOL PATHOL, V34, P209, DOI 10.1080/01926230600642625; Davison JM, 2007, DEV BIOL, V304, P811, DOI 10.1016/j.ydbio.2007.01.033; Dean W, 1998, DEVELOPMENT, V125, P2273; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Dolinoy DC, 2010, EPIGENETICS-US, V5, P637, DOI 10.4161/epi.5.7.12892; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Fernandez-Gonzalez R, 2010, BIOL REPROD, V83, P720, DOI 10.1095/biolreprod.110.084715; Fjose Anders, 2010, Methods Mol Biol, V629, P239, DOI 10.1007/978-1-60761-657-3_15; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Git A, 2010, RNA, V16, P991, DOI 10.1261/rna.1947110; Goll MG, 2009, GENETICS, V182, P747, DOI 10.1534/genetics.109.102079; Goodman JI, 2010, TOXICOL SCI, V116, P375, DOI 10.1093/toxsci/kfq133; Huang THM, 1997, CANCER RES, V57, P1030; Huntriss J, 2008, CURR STEM CELL RES T, V3, P107, DOI 10.2174/157488808784223078; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jovanovic M, 2010, NAT METHODS, V7, P837, DOI [10.1038/nmeth.1504, 10.1038/NMETH.1504]; Kim JK, 2009, CELL MOL LIFE SCI, V66, P596, DOI 10.1007/s00018-008-8432-4; KLAPACZ J, 2009, EXAMINATION IMPRINTE; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kusakabe M, 2010, INT J CANCER, V126, P1895, DOI 10.1002/ijc.24947; LeBaron MJ, 2010, MUTAT RES-REV MUTAT, V705, P83, DOI 10.1016/j.mrrev.2010.04.003; Lema C, 2010, TOXICOL LETT, V198, P100, DOI 10.1016/j.toxlet.2010.06.019; Li Y, 2005, BIOTECHNOL BIOENG, V91, P688, DOI 10.1002/bit.20536; Lindeman LC, 2010, INT J DEV BIOL, V54, P803, DOI 10.1387/ijdb.103081ll; Linney E, 1999, DEV BIOL, V213, P207, DOI 10.1006/dbio.1999.9376; Manoharan H, 2004, MOL CARCINOGEN, V41, P1, DOI 10.1002/mc.20036; MARTY MS, 2010, TOXICOL SCI; Matsuyama T, 2008, FEBS J, V275, P1607, DOI 10.1111/j.1742-4658.2008.06328.x; Mhanni AA, 2004, DEV GENES EVOL, V214, P412, DOI 10.1007/s00427-004-0418-0; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Miltenberger RJ, 1997, J NUTR, V127, pS1902; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Osman AM, 2010, REPROD TOXICOL, V30, P322, DOI 10.1016/j.reprotox.2010.05.084; Perry AS, 2007, BRIT J CANCER, V96, P1587, DOI 10.1038/sj.bjc.6603767; Pogribny IP, 2007, MUTAT RES-FUND MOL M, V619, P30, DOI 10.1016/j.mrfmmm.2006.12.006; Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Reed SC, 1937, GENETICS, V22, P1; Shovlin TC, 2008, DEV BIOL, V313, P674, DOI 10.1016/j.ydbio.2007.11.007; Soares AR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-195; Thummel R, 2006, THESCIENTIFICWORLDJO, V6, P65, DOI 10.1100/tsw.2006.328; Vasicek TJ, 1997, GENETICS, V147, P777; Vastenhouw NL, 2010, NATURE, V464, P922, DOI 10.1038/nature08866; Wang J, 2009, ASIAN PAC J CANCER P, V10, P143; Wang JA, 2010, EVOL BIOINFORM, V6, P113; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230; Wilson IM, 2006, CELL CYCLE, V5, P155, DOI 10.4161/cc.5.2.2367; Wolff GL, 1998, FASEB J, V12, P949; Zeiger E, 2010, ENVIRON MOL MUTAGEN, V51, P781, DOI 10.1002/em.20602; 1998, FED REG, V63, P71542628INFORMA HEALTHCARELONDONTELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDTOXICOL MECH METHODMAYSIDiscipline: Toxicology751PL</notes>
    <keywords>AGOUTI GENE; ASSAY; BISPHENOL-A; CANCER; Carcinogen; CELL; cell cycle; CELL-CYCLE; CELLS; chemical safety; CYCLE; DEFECTS; development; DNA METHYLATION; DNA-methylation; EMBRYONIC STEM-CELLS; END-POINTS; epigenetic; epigenetics; Epigenome; EXPRESSION; FRAMEWORK; GENE; gene expression; GENE-EXPRESSION; GENES; genetics; HEALTH; HISTONE MODIFICATIONS; HUMANS; IDENTIFICATION; IN-SILICO; MATERNAL METHYL SUPPLEMENTS; mechanism; MECHANISMS; METHYLATION; noncoding RNAs; PROSTATE-CANCER; regulatory testing; REPRODUCTIVE TOXICITY; Review; Risk assessment; screening; TISSUE; TISSUES; TOXICITY; toxicology; ZEBRAFISH EMBRYOS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>298</startpage>
    <endpage>311</endpage>
    <journalfull>Toxicology Mechanisms and Methods</journalfull>
    <issue>4</issue>
    <volume>21</volume>
    <abstract>There has been a growing concern that epigenetic events, that is, heritable changes in gene expression superimposed on DNA nucleotide sequences, may be involved in chemically and/or nutritionally mediated adverse health outcomes, such as reproductive toxicity and cancer. This concern has been driven by an increasing number of studies reporting toxicant-induced alterations to the epigenome in the form of changes in DNA methylation, histone/chromatin remodeling, and altered expression of non-coding RNAs. These three major mechanisms of epigenetic modifications may have coordinated, independent, or potentially antagonistic influences on gene expression. Complicating this understanding is the incomplete understanding of the normal state and dynamic variation of the epigenome, which differs widely between cells, tissues, developmental state, age, strain, and species. This review serves as a framework to outline characteristics composing an ideal epigenetic screen(s) for hazard identification in product safety assessment. In order to implement such a screen, first there needs to be a better understanding of adaptive versus adverse changes in the epigenome, which includes identification of robust and reproducible causal links between epigenetic changes and adverse apical end points, and second development of improved reporter assay tools to monitor such changes. An ideal screen would be in vitro-based, medium-to high-throughput, and assess all three branches of epigenome control (i.e. methylation, histone modifications, non-coding RNAs), although also being quantitative, objective, portable (i.e. lab to lab), and relevant to humans</abstract>
    <url>WOS:000289629900005</url>
    <isbnorissn>1537-6516</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>126</id>
    <title>Exposure to diethylstilbestrol during sensitive life stages: A legacy of heritable health effects</title>
    <authors>Reed,C.E.; Fenton,S.E.</authors>
    <availability>[Reed, Casey E.; Fenton, Suzanne E.] NIEHS, Dept Hlth &amp; Human Serv, Div NTP, Natl Toxicol Program NTP Labs Branch,NIH, Res Triangle Pk, NC 27709 USA.</availability>
    <date>2013</date>
    <notes>JEnglishReviewFenton, SE (reprint author), NIEHS, POB 12233,MD E1-08,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USAfentonse@niehs.nih.govAnderson LM, 2004, TOXICOL APPL PHARM, V199, P162, DOI 10.1016/j.taap.2004.02.008; BARNES AB, 1984, J REPROD MED, V29, P651; BIBBO M, 1978, NEW ENGL J MED, V298, P763, DOI 10.1056/NEJM197804062981403; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; Center for Disease Control and Prevention (CDC), 2012, DES UPD CONS; COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096; D'Aloisio AA, 2012, ENVIRON HEALTH PERSP, V120, P406, DOI 10.1289/ehp.1103620; D'Aloisio AA, 2013, EPIDEMIOLOGY, V24, P277, DOI 10.1097/EDE.0b013e31828062b7; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; Emmen JMA, 2000, ENDOCRINOLOGY, V141, P846, DOI 10.1210/en.141.2.846; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Goldberg JM, 1999, FERTIL STERIL, V72, P1, DOI 10.1016/S0015-0282(99)00153-3; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; HADJIMICHAEL OC, 1984, J NATL CANCER I, V73, P831; Harremoes P, 2001, 22 EUR ENV AG; Harris RM, 2012, MATURITAS, V72, P108, DOI 10.1016/j.maturitas.2012.03.002; Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4&lt;745::AID-CNCR2820250402&gt;3.0.CO;2-2; HERBST AL, 1981, AM J OBSTET GYNECOL, V141, P1019; Hilakivi-Clarke L, 2013, J MAMMARY GLAND BIOL, V18, P25, DOI 10.1007/s10911-013-9274-8; HOOVER R, 1977, LANCET, V2, P533; HOOVER R, 1976, LANCET, V1, P885; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; IARC, 2012, IARC MONOGR EVAL CAR, V100, P175; IARC, 1974, IARC MON EV CARC RIS, P55; IBCERCC (Interagency Breast Cancer &amp; Environmental Research Coordinating Committee), 2013, BREAST CANC ENV PRIO; Kakuta H, 2012, REPROD TOXICOL, V33, P35, DOI 10.1016/j.reprotox.2011.10.013; Kalfa N, 2011, FERTIL STERIL, V95, P2574, DOI 10.1016/j.fertnstert.2011.02.047; Kaufman R H, 1982, Obstet Gynecol Annu, V11, P187; Kaufman RH, 2002, OBSTET GYNECOL, V99, P197, DOI 10.1016/S0029-7844(01)01682-9; Kaufman RH, 2000, OBSTET GYNECOL, V96, P483, DOI 10.1016/S0029-7844(00)00959-5; Klip H, 2002, LANCET, V359, P1102, DOI 10.1016/S0140-6736(02)08152-7; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; LaRocca J, 2011, BIRTH DEFECTS RES B, V92, P526, DOI 10.1002/bdrb.20336; Laronda MM, 2012, DIFFERENTIATION, V84, P252, DOI 10.1016/j.diff.2012.05.004; LeBaron MJ, 2010, MUTAT RES-REV MUTAT, V705, P83, DOI 10.1016/j.mrrev.2010.04.003; Li HQ, 2008, EUR J MED CHEM, V43, P662, DOI 10.1016/j.ejmech.2007.05.013; Ma L, 2009, TRENDS ENDOCRIN MET, V20, P357, DOI 10.1016/j.tem.2009.03.009; Martin O, 2008, CIENC SAUDE COLETIVA, V13, P1601, DOI 10.1590/S1413-81232008000500024; MCLACHLAN JA, 1982, FERTIL STERIL, V38, P364; MILLER RK, 1982, J PHARMACOL EXP THER, V220, P358; N'Tumba-Byn T, 2012, PLOS ONE, V7; National Cancer Institute (NCI), 2012, CLIN INF DES SONSM E; National Toxicology Program (NTP), 2011, REP CARCINOG, V12, P159; NEWBOLD R, 1995, ENVIRON HEALTH PERSP, V103, P83, DOI 10.2307/3432514; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Newbold Retha R, 2008, Fertil Steril, V89, pe55, DOI 10.1016/j.fertnstert.2008.01.062; NEWBOLD RR, 1990, CANCER RES, V50, P7677; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Newbold RR, 2007, MOL CARCINOGEN, V46, P783, DOI 10.1002/mc.20308; PAGE SW, 1991, AUST VET J, V68, P226, DOI 10.1111/j.1751-0813.1991.tb03212.x; Palmer JR, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-37; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rubin MM, 2007, OBSTET GYNECOL SURV, V62, P548, DOI 10.1097/01.ogx.0000271138.31234.d7; RUMSEY TS, 1975, J ANIM SCI, V40, P550; Sato T, 2004, REPROD TOXICOL, V19, P43, DOI 10.1016/j.reprotox.2004.05.004; SENEKJIAN EK, 1988, AM J OBSTET GYNECOL, V158, P493; SMITH OW, 1948, AM J OBSTET GYNECOL, V56, P821; Steiner AZ, 2010, AM J EPIDEMIOL, V172, P140, DOI 10.1093/aje/kwq092; Strohsnitter WC, 2001, J NATL CANCER I, V93, P545, DOI 10.1093/jnci/93.7.545; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521; Tournaire M, 2012, EUR J EPIDEMIOL, V27, P315, DOI 10.1007/s10654-012-9677-7; Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631; Umekita Y, 2011, TOXICOL LETT, V205, P15, DOI 10.1016/j.toxlet.2011.04.031; Verloop J, 2010, CANCER CAUSE CONTROL, V21, P999, DOI 10.1007/s10552-010-9526-5; Virtanen HE, 2012, MOL CELL ENDOCRINOL, V355, P208, DOI 10.1016/j.mce.2011.11.015; Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791; Walker VR, 2012, ENVIRON HEALTH PERSP, V120, P560, DOI 10.1289/ehp.1103678; WILCOX AJ, 1995, NEW ENGL J MED, V332, P1411, DOI 10.1056/NEJM199505253322104; Yamashita S, 2006, CURR PHARM DESIGN, V12, P1505, DOI 10.2174/138161206776389840712WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USABIRTH DEFECTS RES CJUNSIDiscipline: Developmental Biology; Reproductive Biology203VH</notes>
    <keywords>ADULT; BIOLOGY; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER-RISK; CARCINOGENESIS; CELL; CHILDREN; DEATH; DES; development; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL; Differentiation; DISEASE; ENDOCRINE; Endocrine disruption; Epidemiology; Estrogen; EXPOSURE; FETAL; fetal basis of adult disease; FOLLOW-UP; GENE-EXPRESSION; GLAND; IN-UTERO; JUN; mammary gland; MAMMARY-GLAND; mechanism; MECHANISMS; MICE; PREGNANCY; PREVENTION; RISK; TISSUE; toxicology; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>134</startpage>
    <endpage>146</endpage>
    <journalfull>Birth Defects Research Part C-Embryo Today-Reviews</journalfull>
    <issue>2</issue>
    <volume>99</volume>
    <abstract>Diethylstilbestrol (DES) is a potent estrogen mimic that was predominantly used from the 1940s to the 1970s by pregnant women in hopes of preventing miscarriage. Decades later, DES is known to enhance breast cancer risk in exposed women and cause a variety of birth-related adverse outcomes in their daughters such as spontaneous abortion, second trimester pregnancy loss, preterm delivery, stillbirth, and neonatal death. Additionally, children exposed to DES in utero suffer from sub/infertility and cancer of reproductive tissues. DES is a pinnacle compound that demonstrates the fetal basis of adult disease. The mechanisms of cancer and endocrine disruption induced by DES are not fully understood. Future studies should focus on common target tissue pathways affected and the health of the DES grandchildren. Birth Defects Research (Part C) 99:134-146, 2013. (c) 2013 Wiley Periodicals, Inc</abstract>
    <url>WOS:000323321600006</url>
    <isbnorissn>1542-975X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>60</id>
    <title>Bisphenol A and human chronic diseases: Current evidences, possible mechanisms, and future perspectives</title>
    <authors>Rezg,R.; El-Fazaa,S.; Gharbi,N.; Mornagui,B.</authors>
    <availability>[Rezg, Raja; El-Fazaa, Saloua; Gharbi, Najoua; Mornagui, Bessem] Univ Tunis El Manar, Fac Sci Tunis, Lab Physiol Aggress, El Manar 2092, Tunisia. [Rezg, Raja] Univ Monastir, High Inst Biotechnol Monastir, Dept Biol, Monastir, Tunisia. [Mornagui, Bessem] Univ Gabes, Fac Sci Gabes, Dept Life Sci, Gabes, Tunisia.</availability>
    <date>2014</date>
    <notes>JEnglishReviewRezg, R (reprint author), Univ Tunis El Manar, Fac Sci Tunis, Dept Biol, Lab Physiol Aggress, Campus Univ, El Manar 2092, Tunisiaraja.rezg@laposte.netAdewale HB, 2009, BIOL REPROD, V81, P690, DOI 10.1095/biolreprod.109.078261; Adriani W, 2003, ENVIRON HEALTH PERSP, V111, P395, DOI 10.1289/ehp.5856; Akingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; Aldad TS, 2011, FERTIL STERIL, V96, P175, DOI 10.1016/j.fertnstert.2011.04.010; Al-Hiyasat AS, 2004, EUR J ORAL SCI, V112, P267, DOI 10.1111/j.1600-0722.2004.00136.x; Al-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Allard P, 2010, P NATL ACAD SCI USA, V107, P20405, DOI 10.1073/pnas.1010386107; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Alonso-Magdalena P, 2011, NAT REV ENDOCRINOL, V7, P346, DOI 10.1038/nrendo.2011.56; Alonso-Magdalena P, 2010, HORM-INT J ENDOCRINO, V9, P118; Anjum S, 2011, FOOD CHEM TOXICOL, V49, P2849, DOI 10.1016/j.fct.2011.07.062; Arase S, 2011, BIOL REPROD, V84, P734, DOI 10.1095/biolreprod.110.087502; Avissar-Whiting M, 2010, REPROD TOXICOL, V29, P401, DOI 10.1016/j.reprotox.2010.04.004; Aydogan M, 2008, TOXICOLOGY, V249, P35, DOI 10.1016/j.tox.2008.04.002; Balakrishnan B, 2010, AM J OBSTET GYNECOL, V202, pe391; Bhandari R, 2013, AM J EPIDEMIOL, V177, P1263, DOI 10.1093/aje/kws391; Biedermann S, 2010, ANAL BIOANAL CHEM, V398, P571, DOI 10.1007/s00216-010-3936-9; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Bloom B, 2010, VITAL HLTH STAT, V10, P1; Bloom MS, 2011, ENVIRON TOXICOL PHAR, V32, P319, DOI 10.1016/j.etap.2011.06.003; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335; Brent RL, 2013, JAMA-J AM MED ASSOC, V309, P134, DOI 10.1001/jama.2012.91936; Cantonwine D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-62; Cao XL, 2010, J FOOD PROTECT, V73, P1085; Carwile JL, 2011, ENVIRON RES, V111, P825, DOI 10.1016/j.envres.2011.05.014; Chou WC, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-94; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Cooper JE, 2011, CHEMOSPHERE, V85, P943, DOI 10.1016/j.chemosphere.2011.06.060; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; De Flora S, 2011, TOXICOL SCI, V122, P45, DOI 10.1093/toxsci/kfr096; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011; Dwivedi RS, 2011, KIDNEY INT, V79, P23, DOI 10.1038/ki.2010.335; Fenichel P, 2012, HUM REPROD, V27, P983, DOI 10.1093/humrep/der451; Fujimoto VY, 2011, FERTIL STERIL, V95, P1816, DOI 10.1016/j.fertnstert.2010.11.008; Galloway T, 2010, ENVIRON HEALTH PERSP, V118, P1603, DOI 10.1289/ehp.1002367; Geens T, 2011, INT J HYG ENVIR HEAL, V214, P339, DOI 10.1016/j.ijheh.2011.04.005; Geens T, 2012, FOOD CHEM TOXICOL, V50, P3725, DOI 10.1016/j.fct.2012.07.059; Geens T, 2012, SCI TOTAL ENVIRON, V435, P30, DOI 10.1016/j.scitotenv.2012.07.001; George O, 2008, ACS CHEM BIOL, V3, P167, DOI [10.1021/cb700210u, 10.1021/cb6700210u]; Gong H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054198; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Gravina S, 2010, PFLUG ARCH EUR J PHY, V459, P247, DOI 10.1007/s00424-009-0730-7; Hiroi H, 2004, ENDOCR J, V51, P595, DOI 10.1507/endocrj.51.595; Izzotti A, 2010, CURR CANCER DRUG TAR, V10, P147; Izzotti A, 2009, MUTAT RES-GEN TOX EN, V679, P28, DOI 10.1016/j.mrgentox.2009.07.011; Jasarevic E, 2011, P NATL ACAD SCI USA, V108, P11715, DOI 10.1073/pnas.1107958108; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Johnson GE, 2008, MUTAT RES-GEN TOX EN, V651, P56, DOI 10.1016/j.mrgentox.2007.10.019; Jones DC, 2008, BIOCHEM PHARMACOL, V76, P569, DOI 10.1016/j.bcp.2008.05.010; Kabuto H, 2004, LIFE SCI, V74, P2931, DOI 10.1016/j.lfs.2003.07.060; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Krieter DH, 2013, ARTIF ORGANS, V37, P283, DOI 10.1111/j.1525-1594.2012.01556.x; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee S, 2008, J NEUROSCI RES, V86, P2932, DOI 10.1002/jnr.21739; Lenaz G, 2012, ADV MITOCHONDRIAL ME; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Li DK, 2011, FERTIL STERIL, V95, P625, DOI 10.1016/j.fertnstert.2010.09.026; Li DK, 2011, FERTIL STERIL, V95, pe621; Li DK, 2010, J ANDROL, V31, P500, DOI 10.2164/jandrol.110.010413; Liao CY, 2011, ENVIRON SCI TECHNOL, V45, P6761, DOI 10.1021/es200977t; Liao CY, 2011, ENVIRON SCI TECHNOL, V45, P9372, DOI 10.1021/es202507f; Lin Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.206; Liu L, 2008, CURR ISSUES MOL BIOL, V10, P25; Loganathan SN, 2011, ARCH ENVIRON CON TOX, V61, P68, DOI 10.1007/s00244-010-9634-y; Lund G, 2011, CURR ATHEROSCLER REP, V13, P208, DOI 10.1007/s11883-011-0174-3; Masuyama H, 2004, J BIOL CHEM, V279, P12020, DOI 10.1074/jbc.M312762200; Melzer D, 2012, CIRCULATION, V125, P1482, DOI 10.1161/CIRCULATIONAHA.111.069153; Melzer D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043378; Miao MH, 2011, BIRTH DEFECTS RES A, V91, P867, DOI 10.1002/bdra.22845; Miodovnik A, 2011, NEUROTOXICOLOGY, V32, P261, DOI 10.1016/j.neuro.2010.12.009; Mok-Lin E, 2010, INT J ANDROL, V33, P385, DOI 10.1111/j.1365-2605.2009.01014.x; Moon MK, 2012, J KOREAN MED SCI, V27, P644, DOI 10.3346/jkms.2012.27.6.644; Nagel SC, 2013, ENDOCRINOLOGY, V154, P1962, DOI 10.1210/en.2013-1370; Nakamura K, 2012, BRAIN DEV-JPN, V34, P57, DOI 10.1016/j.braindev.2010.12.011; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Ramos JG, 2003, ENDOCRINOLOGY, V144, P3206, DOI 10.1210/en.2002-0198; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Ropero AB, 2006, J STEROID BIOCHEM, V102, P163, DOI 10.1016/j.jsbmb.2006.09.019; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Sabanayagam C, 2013, ACTA DIABETOL, V50, P625, DOI 10.1007/s00592-013-0472-z; Shankar A, 2011, J CLIN ENDOCR METAB, V96, P3822, DOI 10.1210/jc.2011-1682; Silver MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026868; Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143; Smith-Bindman R, 2012, ARCH INTERN MED, V172, P1023, DOI 10.1001/archinternmed.2012.2329; Spanier AJ, 2012, ENVIRON HEALTH PERSP, V120, P916, DOI 10.1289/ehp.1104175; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Takahashi S, 2001, MUTAT RES-GEN TOX EN, V490, P199, DOI 10.1016/S1383-5718(00)00161-3; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tiwari D, 2012, MUTAT RES-GEN TOX EN, V743, P83, DOI 10.1016/j.mrgentox.2011.12.023; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vinas R, 2012, INT J ENV RES PUB HE, V9, P2694, DOI 10.3390/ijerph9082694; Vinas R, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-26; von Goetz N, 2010, RISK ANAL, V30, P473, DOI 10.1111/j.1539-6924.2009.01345.x; Warita K, 2013, J TOXICOL SCI, V38, P285; Wei J, 2011, ENDOCRINOLOGY, V152, P3049, DOI 10.1210/en.2011-0045; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Wilson NK, 2007, ENVIRON RES, V103, P9, DOI 10.1016/j.envres.2006.04.006; Yang M, 2009, ARCH TOXICOL, V83, P281, DOI 10.1007/s00204-008-0364-0; Yang YJ, 2009, ENVIRON RES, V109, P797, DOI 10.1016/j.envres.2009.04.014; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Zhou Q, 2013, FERTIL STERIL, V100, P478, DOI 10.1016/j.fertnstert.2013.04.0171101PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDENVIRON INTMARDiscipline: Environmental Sciences &amp; EcologyAD8JS</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; CANCER; cardiovascular; CELL; cell death; CELL-DEATH; CHEMICALS; Chronic human diseases; CHRONIC KIDNEY-DISEASE; DEATH; diabetes; DIABETES-MELLITUS; DISORDERS; Endocrine disruption; Endocrine disruptor; ESTROGEN-RECEPTOR; Etiology; EXPOSURE; FOOD; GENE-EXPRESSION; HUMAN EXPOSURE; IN-VITRO FERTILIZATION; MALE RATS; mechanism; MECHANISMS; MITOCHONDRIAL DYSFUNCTION; Oxidative stress; PRENATAL EXPOSURE; RISK</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>83</startpage>
    <endpage>90</endpage>
    <journalfull>Environment International</journalfull>
    <volume>64</volume>
    <abstract>Bisphenol-A (BPA) is one of the highest volume chemicals produced worldwide, with over 6 billion pounds produced and over 100 t released into the atmosphere each year. Recent extensive literature has raised concerns about its possible implication in the etiology of some human chronic diseases such as diabetes, obesity, reproductive disorders, cardiovascular diseases, birth defects, chronic respiratory and kidney diseases and breast cancer. In this review, we present the highlighted evidences on the relationship between BPA exposure and human chronic diseases and we discuss its eventual, mechanisms of action, especially genetic, epigenetic and endocrine disruption mechanisms with the possible involvement of oxidative stress, mitochondrial dysfunction and cell signaling. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000333512900010</url>
    <isbnorissn>0160-4120</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>439</id>
    <title>Differential expression of metallothionein (MT) gene by trace metals and endocrine-disrupting chemicals in the hermaphroditic mangrove killifish, Kryptolebias marmoratus</title>
    <authors>Rhee,J.S.; Raisuddin,S.; Hwang,D.S.; Lee,K.W.; Kim,I.C.; Lee,J.S.</authors>
    <availability>[Raisuddin, Sheikh; Lee, Kyun-Woo; Lee, Jae-Seong] Hanyang Univ, Coll Nat Sci, Dept Chem, Natl Res Lab Marine Mol &amp; Environm Biosci, Seoul 133791, South Korea. [Rhee, Jae-Sung; Hwang, Dae-Sik] Hanyang Univ, Grad Sch, Dept Mol &amp; Environm Biosci, Seoul 133791, South Korea. [Kim, Il-Chan] Korea Ocean Res &amp; Dev Inst, Polar BioCtr, Inchon 406840, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleLee, JS (reprint author), Hanyang Univ, Coll Nat Sci, Dept Chem, Natl Res Lab Marine Mol &amp; Environm Biosci, Seoul 133791, South Koreajslee2@hanyang.ac.krAmiard JC, 2006, AQUAT TOXICOL, V76, P160, DOI 10.1016/j.aquatox.2005.08.015; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Atif F, 2006, CHEM-BIOL INTERACT, V162, P172, DOI 10.1016/j.cbi.2006.06.006; Canesi L, 2007, MOL CELL ENDOCRINOL, V276, P36, DOI 10.1016/j.mce.2007.06.002; Chen WY, 2004, AQUAT TOXICOL, V69, P215, DOI 10.1016/j.aquatox.2004.05.004; Choi CY, 2007, COMP BIOCHEM PHYS C, V145, P595, DOI 10.1016/j.cbpc.2007.02.007; COSTA PM, 2007, ECOTOXICOL IN PRESS, DOI DOI 10.1016/J.ECOENV.2007.05.012; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; George S, 2004, MAR ENVIRON RES, V58, P571, DOI 10.1016/j.marenvres.2004.03.047; Gerpe M, 2000, ENVIRON TOXICOL CHEM, V19, P638, DOI 10.1897/1551-5028(2000)019&lt;0638:ACSAMC&gt;2.3.CO;2; Gonzalez P, 2006, BIOMETALS, V19, P225, DOI 10.1007/s10534-005-5670-x; KAGI JHR, 1984, ENVIRON HEALTH PERSP, V54, P93, DOI 10.2307/3429795; Kim JH, 2008, CHEMOSPHERE, V71, P1251, DOI 10.1016/j.chemosphere.2007.11.067; Kim CI, 2004, MAR ENVIRON RES, V58, P125, DOI 10.1016/j.marenvres.2004.03.006; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; LEE JS, 2008, J FISH BIOL, V71, P1871; Lee JS, 2004, DNA SEQUENCE, V15, P33, DOI 10.1080/10425170310001659393; Lee YM, 2008, COMP BIOCHEM PHYS C, V147, P299, DOI 10.1016/j.cbpc.2007.11.006; Lee YM, 2008, COMP BIOCHEM PHYS C, V147, P150, DOI 10.1016/j.cbpc.2007.09.005; Lee YM, 2005, MAR POLLUT BULL, V51, P769, DOI 10.1016/j.marpolbul.2005.06.015; Lee YM, 2005, MAR POLLUT BULL, V51, P776, DOI 10.1016/j.marpolbul.2005.06.016; Lee YM, 2007, MOL CELLS, V23, P287; Lee YM, 2006, MAR ENVIRON RES, V62, pS136, DOI 10.1016/j.marenvres.2006.04.052; LIN HC, 1993, ARCH ENVIRON CON TOX, V25, P41; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McClain JS, 2003, ENVIRON TOXICOL CHEM, V22, P361, DOI 10.1897/1551-5028(2003)022&lt;0361:LAFVOM&gt;2.0.CO;2; Monserrat JM, 2007, COMP BIOCHEM PHYS C, V146, P221, DOI 10.1016/j.cbpc.2006.08.012; OLSSON PE, 1995, BIOCHEM J, V307, P197; PARK EH, 1994, CAN J FISH AQUAT SCI, V51, P280, DOI 10.1139/f94-029; Park JH, 2001, NUCLEIC ACIDS RES, V29, P3041, DOI 10.1093/nar/29.14.3041; Smirnov LP, 2005, RUSS J ECOL+, V36, P41, DOI 10.1007/s11184-005-0007-0; Theocharis SE, 2003, INT J BIOL MARKER, V18, P162; Vasak M, 2005, J TRACE ELEM MED BIO, V19, P13, DOI 10.1016/j.jtemb.2005.03.003; Vergani L, 2005, FEBS J, V272, P6014, DOI 10.1111/j.1742-4658.2005.04993.x; Viarengo A, 2000, CELL MOL BIOL, V46, P407; Viarengo A, 1997, MAR ENVIRON RES, V44, P69, DOI 10.1016/S0141-1136(96)00103-1; Werner J, 2008, ARCH ENVIRON CON TOX, V54, P84, DOI 10.1007/s00244-007-9000-x; Werner J, 2003, AQUAT TOXICOL, V62, P321, DOI 10.1016/S0166-445X(02)00104-2; Yao CP, 2000, BRAIN RES, V855, P32, DOI 10.1016/S0006-8993(99)02211-8; ZAFARULLAH M, 1989, GENE, V83, P85, DOI 10.1016/0378-1119(89)90406-X; Zhou YJ, 2000, BBA-GEN SUBJECTS, V1524, P87, DOI 10.1016/S0304-4165(00)00072-64223ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAECOTOX ENVIRON SAFEJANDiscipline: Environmental Sciences &amp; Ecology; Toxicology368YS</notes>
    <keywords>ACUTE TOXICITY; ADULT; BIOMARKER; Biomarkers; BISPHENOL-A; Brain; CADMIUM; CANCER; CELL; CELLS; Chemical interaction; CHEMICALS; Confounding factors; CYPRINODONTIFORMES; development; DIFFERENTIAL EXPRESSION; EDC; EDCs; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ESTUARINE; EXPOSURE; EXPRESSION; FISH; FISH RIVULUS-MARMORATUS; GENE; gene expression; GENE-EXPRESSION; GENOMIC CLONING; HEALTH; INDUCTION; Kryptolebias marmoratus; KRYPTOLEBIAS-MARMORATUS; Male; Metal pollution; Metallothionein; Metals; MODEL; ONCORHYNCHUS-MYKISS; POLLUTANTS; TISSUE; Tissue distribution; TISSUES; TOXICITY; toxicology; TROUT SALVELINUS-NAMAYCUSH</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>206</startpage>
    <endpage>212</endpage>
    <journalfull>Ecotoxicology and Environmental Safety</journalfull>
    <issue>1</issue>
    <volume>72</volume>
    <abstract>Metallothionein (MT) gene expression was studied in different tissues, development stages and gender types of the mangrove killifish (Kryptolebias marmoratus). MT expression was also studied in a time-series experiment after exposure to trace metals and endocrine-disrupting chemicals (EDCs). The brain showed the highest level of MT transcripts. Although all the development stage showed some level of MT expression, the adult hermaphrodites showed the highest expression which was significantly higher than the secondary males. In the trace metal-exposed fish, cadmium caused the strongest induction of MT. However, other trace metals such as copper and zinc also caused MT gene induction. All the EDCs suppressed the expression of MT gene, and the effect of EDCs were not gender-specific. K. marmoratus has previously shown its suitability as a model species for toxicity studies and cancer research. This study demonstrated utility of MT as biomarker in K. marmoratus. However, confounding factors such as age, gender, and tissue types appear to influence the MT expression. Response of trace and organic pollutants such as EDCs also varied greatly. These observations suggest that MT would be a specific biomarker of trace metal exposure in K. marmoratus and expression would be influenced by intrinsic factors. (C) 2008 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000260660100026</url>
    <isbnorissn>0147-6513</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>159</id>
    <title>Bisphenol A at concentrations found in human serum induces aneugenic effects in endothelial cells</title>
    <authors>Ribeiro-Varandas,E.; Viegas,W.; Pereira,H.S.; Delgado,M.</authors>
    <availability>[Ribeiro-Varandas, Edna; Viegas, Wanda; Pereira, H. Sofia; Delgado, Margarida] Univ Tecn Lisboa, CBAA Genet, Inst Super Agron, Lisbon, Portugal. [Delgado, Margarida] Univ Lusofona Humanidades &amp; Tecnol, Fac Ciencias Biomed, Lisbon, Portugal.</availability>
    <date>2013</date>
    <notes>JEnglishArticleDelgado, M (reprint author), Inst Super Agron, Sec Genet CBAA, P-1349017 Lisbon, Portugalmxdelgado@isa.utl.ptAnand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bredhult C, 2009, REPROD TOXICOL, V28, P18, DOI 10.1016/j.reprotox.2009.03.006; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Campbell-Thompson M, 2001, CANCER RES, V61, P632; Can A, 2005, MOL HUM REPROD, V11, P389, DOI 10.1093/molehr/gah179; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Dong S, 2010, ENVIRON POLLUT, V159, P212; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; George O, 2008, ACS CHEM BIOL, V3, P167, DOI [10.1021/cb700210u, 10.1021/cb6700210u]; He YH, 2009, J OCCUP HEALTH, V51, P432; Illingworth C, 2010, DEVELOPMENT, V137, P2133, DOI 10.1242/dev.048306; Johnson GE, 2008, MUTAT RES-GEN TOX EN, V651, P56, DOI 10.1016/j.mrgentox.2007.10.019; Kabil A, 2008, CARCINOGENESIS, V29, P1862, DOI 10.1093/carcin/bgn138; Kang JH, 2004, LETT APPL MICROBIOL, V39, P178, DOI 10.1111/j.1472-765X.2004.01562.x; Kastl L., 2009, MOL CELL PROBE, V24, P87; Kim K, 2007, J TOXICOL ENV HEAL A, V70, P1288, DOI 10.1080/15287390701434216; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lenie S, 2008, MUTAT RES-GEN TOX EN, V651, P71, DOI 10.1016/j.mrgentox.2007.10.017; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Loh JK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-268; Naciff JM, 2010, TOXICOLOGY, V270, P137, DOI 10.1016/j.tox.2010.02.008; Nakagomi M, 2001, TERATOGEN CARCIN MUT, V21, P453, DOI 10.1002/tcm.1032; Ochi T, 1999, MUTAT RES-FUND MOL M, V431, P105, DOI 10.1016/S0027-5107(99)00190-6; Otto C, 2008, ENDOCRINOLOGY, V149, P4846, DOI 10.1210/en.2008-0269; Pacchierotti F, 2008, MUTAT RES-GEN TOX EN, V651, P64, DOI 10.1016/j.mrgentox.2007.10.009; Parry EM, 2002, MUTAGENESIS, V17, P509, DOI 10.1093/mutage/17.6.509; Pfeiffer E, 1997, MUTAT RES-GEN TOX EN, V390, P21, DOI 10.1016/S0165-1218(96)00161-9; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Raynaud-Messina B, 2007, CURR OPIN CELL BIOL, V19, P24, DOI 10.1016/j.ceb.2006.12.008; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Rivera T, 2012, EMBO J, V31, P1467, DOI 10.1038/emboj.2012.4; Sekizawa J, 2008, J TOXICOL SCI, V33, P389, DOI 10.2131/jts.33.389; Shanle E. K., 2010, CHEM RES TOXICOL, V24, P6; Shi T, 2004, MOL CARCINOGEN, V40, P47, DOI 10.1002/mc.20015; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Takada Y, 1997, BIOCHEM BIOPH RES CO, V240, P737, DOI 10.1006/bbrc.1997.7734; Tanno Y, 2010, GENE DEV, V24, P2169, DOI 10.1101/gad.1945310; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Toth B, 2008, HISTOCHEM CELL BIOL, V130, P399, DOI 10.1007/s00418-008-0426-7; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620494ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSMUTAT RES-GEN TOX ENFEB 18Discipline: Biotechnology &amp; Applied Microbiology; Genetics &amp; Heredity; Toxicology101FR</notes>
    <keywords>ABNORMALITIES; bisphenol; bisphenol A; bisphenol A (BPA); BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; CELLS; CYCLE; development; ENDOCRINE; Endocrine disruption; environmental exposure; ER-BETA; Estrogen; EXPOSURE; GENES; genetics; HEALTH; HT29; HUMAN SERUM; HUMANS; HUVEC; IN-VITRO; IN-VIVO; LINE; LINES; Micronuclei; Mitosis; MITOTIC SPINDLE; OCCUPATIONAL-EXPOSURE; ORGANIZATION; POPULATION; proliferation; PROTEIN; PROTEINS; serum; TISSUE; toxicology; V79 CELLS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>27</startpage>
    <endpage>33</endpage>
    <journalfull>Mutation Research-Genetic Toxicology and Environmental Mutagenesis</journalfull>
    <issue>1</issue>
    <volume>751</volume>
    <abstract>Bisphenol A (BPA) is an endocrine disrupting chemical to which humans are exposed. Continuous environmental exposure to BPA leads to its detection in the majority of individuals from developed countries, with serum concentrations ranging from 0.5 to 10 ng/ml in the general population and much higher when associated with occupational exposure. In this work, human umbilical vascular endothelial cells (HUVEC) and human colon adenocarcinona (HT29) cell lines were used to represent endothelial and digestive-tract tissues, which are in direct contact to BPA in vivo. Our results demonstrate that BPA has cell-type differential effects. Notably, BPA concentrations commonly found in humans induce micronucleus formation and interfere with cell-division processes in endothelial cells, resulting in mitotic abnormalities. We also found that BPA induces up-regulation of two genes encoding proteins associated with chromosome segregation, namely CDCA8 (borealin/cell division cycle A8) and SGOL2 (shugoshin-like2). Taken together, the aneugenic effects observed in endothelial cells (HUVECs) substantiate increasing concerns about BPA exposure at levels currently detected in humans. (C) 2012 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000315761100004</url>
    <isbnorissn>1383-5718</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>11</id>
    <title>Bisphenol A Disrupts Transcription and Decreases Viability in Aging Vascular Endothelial Cells</title>
    <authors>Ribeiro-Varandas,E.; Pereira,H.S.; Monteiro,S.; Neves,E.; Brito,L.; Ferreira,R.B.; Viegas,W.; Delgado,M.</authors>
    <availability>[Ribeiro-Varandas, Edna; Sofia Pereira, H.; Monteiro, Sara; Neves, Elsa; Brito, Luisa; Ferreira, Ricardo Boavida; Viegas, Wanda; Delgado, Margarida] Univ Lisbon, CBAA, Inst Super Agron, P-1349017 Lisbon, Portugal. [Neves, Elsa] ESTGJPLA, Inst Piaget, P-7500999 Vila Nova De Santo Andre, Portugal. [Ferreira, Ricardo Boavida] UNL, ITQB, P-2780157 Oeiras, Portugal.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDelgado, M (reprint author), Univ Lisbon, CBAA, Inst Super Agron, P-1349017 Lisbon, Portugalednavarandas@isa.ulisboa.pt; sofiapereira@isa.ulisboa.pt; smonteiro@isa.ulisboa.pt; elsa.neves@standre.ipiaget.pt; lbrito@isa.ulisboa.pt; rbferreira@isa.ulisboa.pt; wandaviegas@isa.ulisboa.pt; mxdelgado@isa.ulisboa.ptAbdelmohsen K, 2012, RNA BIOL, V9, P799, DOI 10.4161/rna.19718; Andreassi MG, 2008, J MOL MED, V86, P1033, DOI 10.1007/s00109-008-0358-7; Aporntewan C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017934; Astrof S, 2009, ANGIOGENESIS, V12, P165, DOI 10.1007/s10456-009-9136-6; Ballesteros-Gomez A, 2009, J CHROMATOGR A, V1216, P449, DOI 10.1016/j.chroma.2008.06.037; Boehme K, 2009, TOXICOL APPL PHARM, V236, P85, DOI 10.1016/j.taap.2009.01.006; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Boyd-Kirkup JD, 2013, EPIGENOMICS-UK, V5, P205, DOI [10.2217/epi.13.5, 10.2217/EPI.13.5]; Bredhult C, 2009, REPROD TOXICOL, V28, P18, DOI 10.1016/j.reprotox.2009.03.006; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; D'Aquila P, 2013, MATURITAS, V74, P130, DOI 10.1016/j.maturitas.2012.11.005; Debacq-Chainiaux F, 2008, FREE RADICAL BIO MED, V44, P1817, DOI 10.1016/j.freeradbiomed.2008.02.001; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Dumont P, 2002, CELL STRESS CHAPERON, V7, P23, DOI 10.1379/1466-1268(2002)007&lt;0023:OOAJIH&gt;2.0.CO;2; Fernandez SV, 2012, INT J ONCOL, V41, P369, DOI 10.3892/ijo.2012.1444; George O, 2008, ACS CHEM BIOL, V3, P167, DOI [10.1021/cb700210u, 10.1021/cb6700210u]; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YH, 2009, J OCCUP HEALTH, V51, P432; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Higashi Y, 2012, J GERONTOL A-BIOL, V67, P626, DOI 10.1093/gerona/gls102; Hon G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000566; Hwang ES, 2009, CELL MOL LIFE SCI, V66, P2503, DOI 10.1007/s00018-009-0034-2; Khaidakov M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020964; Kim JS, 2001, BIOCHEM BIOPH RES CO, V281, P866, DOI 10.1006/bbrc.2001.4434; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Lind PM, 2011, ATHEROSCLEROSIS, V218, P207, DOI 10.1016/j.atherosclerosis.2011.05.001; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Melzer D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043378; Mezcua M, 2012, TALANTA, V100, P90, DOI 10.1016/j.talanta.2012.07.078; Michels J., 2013, INT J CELL BIOL, V2013; Naciff JM, 2010, TOXICOLOGY, V270, P137, DOI 10.1016/j.tox.2010.02.008; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Puzianowska-Kuznicka M, 2005, INT J BIOCHEM CELL B, V37, P947, DOI 10.1016/j.biocel.2004.10.011; Qin XY, 2012, CANCER BIOL THER, V13, P296, DOI [10.4161/cbt.18942, 10.4161/cbt.13.5.18942]; Ribeiro-Varandas E., 2012, P 2012 INT C BIOM EN; Ribeiro-Varandas E, 2013, MUTAT RES-GEN TOX EN, V751, P27, DOI 10.1016/j.mrgentox.2012.10.007; Rivera LB, 2011, CELL MOL LIFE SCI, V68, P3165, DOI 10.1007/s00018-011-0781-8; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Trecesson SD, 2011, J BIOL CHEM, V286, P12825, DOI 10.1074/jbc.M110.186437; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; van der Loo B, 1998, EXP CELL RES, V241, P309, DOI 10.1006/excr.1998.4035; Van Vre EA, 2012, ARTERIOSCL THROM VAS, V32, P887, DOI 10.1161/ATVBAHA.111.224873; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; Wagner M, 2001, EXP GERONTOL, V36, P1327, DOI 10.1016/S0531-5565(01)00105-X; WANG E, 1984, EXP CELL RES, V154, P191, DOI 10.1016/0014-4827(84)90679-7; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028520MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J MOL SCISEPDiscipline: ChemistryAQ8UN</notes>
    <keywords>ATHEROSCLEROSIS; BIOLOGY; bisphenol A; bisphenol A (BPA); BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CELLS; cellular aging; EPITHELIAL-CELLS; EXPOSURE; EXPRESSION; HT29; HUMAN-DIPLOID FIBROBLASTS; HUVEC; IN-VITRO; LINE 1 transcription; LINES; MECHANISMS; OCCUPATIONAL-EXPOSURE; PREMATURE SENESCENCE; WIDESPREAD EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>15791</startpage>
    <endpage>15805</endpage>
    <journalfull>International Journal of Molecular Sciences</journalfull>
    <issue>9</issue>
    <volume>15</volume>
    <abstract>Bisphenol A (BPA) is a widely utilized endocrine disruptor capable of mimicking endogenous hormones, employed in the manufacture of numerous consumer products, thereby interfering with physiological cellular functions. Recent research has shown that BPA alters epigenetic cellular mechanisms in mammals and may be correlated to enhanced cellular senescence. Here, the effects of BPA at 10 ng/mL and 1 mu g/mL, concentrations found in human samples, were analyzed on HT29 human colon adenocarcinona cell line and Human Umbilical Vein Endothelial Cells (HUVEC). Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) transcriptional analysis of the Long Interspersed Element-1 (LINE-1) retroelement showed that BPA induces global transcription deregulation in both cell lines, although with more pronounced effects in HUVEC cells. Whereas there was an increase in global transcription in HT29 exclusively after 24 h of exposure, this chemical had prolonged effects on HUVEC. Immunoblotting revealed that this was not accompanied by alterations in the overall content of H3K9me2 and H3K4me3 epigenetic marks. Importantly, cell viability assays and transcriptional analysis indicated that prolonged BPA exposure affects aging processes in senescent HUVEC. To our knowledge this is the first report that BPA interferes with senescence in primary vascular endothelial cells, therefore, suggesting its association to the etiology of age-related human pathologies, such as atherosclerosis</abstract>
    <url>WOS:000343109700055</url>
    <isbnorissn>1422-0067</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>23</id>
    <title>Cytotoxicity of Eupatorium cannabinum L. ethanolic extract against colon cancer cells and interactions with Bisphenol A and Doxorubicin</title>
    <authors>Ribeiro-Varandas,E.; Ressurreicao,F.; Viegas,W.; Delgado,M.</authors>
    <availability>[Ribeiro-Varandas, Edna; Ressurreicao, Filipe; Viegas, Wanda; Delgado, Margarida] Univ Lisbon, Inst Super Agron, Ctr Botanica Aplicada Agr, Tapada Ajuda, P-1349017 Lisbon, Portugal. [Delgado, Margarida] Univ Lusofona Humanidades Tecnol, Fac Psychol &amp; Life Sci, P-1749024 Lisbon, Portugal.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDelgado, M (reprint author), Univ Lisbon, Inst Super Agron, Ctr Botanica Aplicada Agr, Tapada Ajuda, P-1349017 Lisbon, Portugalmxdelgado@isa.ulisboa.ptBar-On O, 2007, ANTI-CANCER DRUG, V18, P1113; Boppre M, 2008, J AGR FOOD CHEM, V56, P5662, DOI 10.1021/jf800568u; Cerella C, 2014, BIOTECHNOL ADV; Chen JJ, 2011, J NAT PROD, V74, P1021, DOI 10.1021/np100923z; Chen T, 2010, J APPL TOXICOL, V30, P183, DOI 10.1002/jat.1504; Conour JE, 2004, PHYSIOL GENOMICS, V18, P196, DOI 10.1152/physiolgenomics.00058.2004; da Orta G, 1913, COLLOQUIES SIMPLES D; Doublier S, 2008, MOL CANCER RES, V6, P1607, DOI 10.1158/1541-7786.MCR-08-0251; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123; EFSA, 2006, EFSA J, V428, P1, DOI DOI 10.2903/J.EFSA.2007A28; EFSA - European Food Safety Authority, 2010, EFSA J, V8, P1829, DOI DOI 10.2903/J.EFSA.2010.1829; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400; Forgo P, 2012, FITOTERAPIA, V83, P921, DOI 10.1016/j.fitote.2012.04.006; Fu PP, 2004, DRUG METAB REV, V36, P1, DOI 10.1081/DMR-120028426; Fu PP, 2002, J FOOD DRUG ANAL, V10, P198; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gao H, 2014, CELL BIOCHEM BIOPHYS, V69, P27, DOI 10.1007/s12013-013-9762-x; GREENE RF, 1983, CANCER RES, V43, P3417; Habtemariam S, 2000, PHYTOTHER RES, V14, P575, DOI 10.1002/1099-1573(200011)14:7&lt;575::AID-PTR652&gt;3.0.CO;2-1; Harun FB, 2012, SCI WORLD J, DOI 10.1100/2012/439479; Jaric S, 2007, J ETHNOPHARMACOL, V111, P160, DOI 10.1016/j.jep.2006.11.007; Johnson GE, 2008, MUTAT RES-GEN TOX EN, V651, P56, DOI 10.1016/j.mrgentox.2007.10.019; Kapadia GJ, 2013, J COMPLEMENT INTEGR, V1, P113; Kimura M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.108; Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923; Kozel C, 1982, GUIA MED NATURAL; Lee JG, FOOD CHEM TOXICOL; Lupertz R, 2010, TOXICOLOGY, V271, P115, DOI 10.1016/j.tox.2010.03.012; Michels J., 2013, INT J CELL BIOL, V2013; Mongelard F, 2007, TRENDS CELL BIOL, V17, P80, DOI 10.1016/j.tcb.2006.11.010; Pandey MK, 2012, INT J CANCER, V130, P213, DOI 10.1002/ijc.25997; Paolini J, 2005, J CHROMATOGR A, V1076, P170, DOI 10.1016/j.chroma.2005.03.131; Ribeiro-Varandas E, 2013, MUTAT RES-GEN TOX EN, V751, P27, DOI 10.1016/j.mrgentox.2012.10.007; Ribeiro-Varandas E, 2014, INT J MOL S IN PRESS; Riganti C, 2009, BRIT J PHARMACOL, V156, P1054, DOI 10.1111/j.1476-5381.2009.00117.x; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; Roeder E, 2013, PHARMAZIE, V68, P83, DOI 10.1691/ph.2013.2706; RA¬cker G, 1997, Nat Toxins, V5, P223; Schmidt GJ, 2000, AM J BOT, V87, P716, DOI 10.2307/2656858; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sulsen VP, 2007, AM J TROP MED HYG, V77, P654; Turck N, 2004, PROTEOMICS, V4, P93, DOI 10.1002/pmic.200300480; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; WOERDENBAG HJ, 1989, BRIT J CANCER, V59, P68, DOI 10.1038/bjc.1989.13; WOERDENBAG HJ, 1989, BIOCHEM PHARMACOL, V38, P2279, DOI 10.1016/0006-2952(89)90466-8; Xia QS, 2013, CHEM RES TOXICOL, V26, P1384, DOI 10.1021/tx400241c; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu CY, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/518301; Zhang ML, 2008, CHEM BIODIVERS, V5, P40, DOI 10.1002/cbdv.200890014500BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDBMC COMPLEM ALTERN MJUL 24Discipline: Integrative &amp; Complementary MedicineAM0JA</notes>
    <keywords>ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER-CELLS; cell death; CELL-CYCLE; CELL-DEATH; CELLS; COMBINATION; CYCLE; DEATH; DIALLYL DISULFIDE; EUPATORIOPICRIN; EXPOSURE; FOOD; GENOTOXICITY; HISTONE ACETYLATION; HT29; INDUCTION; METABOLISM; PLANTS; proliferation; Proteomics; PYRROLIZIDINE ALKALOIDS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Bmc Complementary and Alternative Medicine</journalfull>
    <volume>14</volume>
    <abstract>Background: Eupatorium cannabinum L. has long been utilized in traditional medicine, however no information is available regarding cellular effects of full extracts. Here we assessed the effects of E. cannabinum ethanolic extract (EcEE) on the colon cancer line HT29. Potential interactions with bisphenol A (BPA) a synthetic phenolic compound to which humans are generally exposed and a commonly used chemotherapeutic agent, doxorubicin (DOX) were also evaluated. Methods: HT29 cells were exposed to different concentrations (0.5 to 50 mu g/ml) of EcEE alone or in combination with BPA or DOX. Cell viability was analyzed through resazurin assay. Gene transcription levels for NCL, FOS, p21, AURKA and bcl-xl were determined through qRT-PCR. Cytological analysis included evaluation of nuclear and mitotic anomalies after DAPI staining, immunodetection of histone H3 lysine 9 acetylation (H3K9ac) and assessment of DNA damage by TUNEL assay. Results: Severe loss of HT29 cell viability was detected for 50 mu g/ml EcEE immediately after 24 h exposure whereas the lower concentrations assayed (0.5, 5 and 25 mu g/ml) resulted in significant viability decreases after 96 h. Exposure to 25 mu g/ml EcEE for 48 h resulted in irreversible cell damage leading to a drastic decrease in cell viability after 72 h recovery in EcEE-free medium. 48 h 25 mu g/ml EcEE treatment also induced alteration of colony morphology, H3K9 hyperacetylation, transcriptional up regulation of p21 and down regulation of NCL, FOS and AURKA, indicating reduced proliferation capacity. This treatment also resulted in drastic mitotic and nuclear disruption accompanied by up-regulation of bcl-xl, limited TUNEL labeling and nuclear size increase, suggestive of a non-apoptocic cell death pathway. EcEE/BPA co-exposure increased mitotic anomalies particularly for the lowest EcEE concentration, although without major effects on viability. Conversely, EcEE/DOX co-exposure decreased cell viability in relation to DOX for all EcEE concentrations, without affecting the DOX-induced cell cycle arrest. Conclusions: EcEE has cytotoxic activity on HT29 cancer cells leading to mitotic disruption and non-apoptotic cell death without severe induction of DNA damage. Interaction experiments showed that EcEE can increase BPA aneugenic effects and EcEE synergistic effects with DOX supporting a potential use as adjuvant in chemotherapeutic approaches</abstract>
    <url>WOS:000339529700001</url>
    <isbnorissn>1472-6882</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>258</id>
    <title>Endocrine disruptors and hormone dependant cancers. Mechanisms and proposals to reduce the risks</title>
    <authors>Rochefort,H.; Jouannet,P.</authors>
    <date>2011</date>
    <notes>JFrenchArticleh.rochefor@orange.fr; pierre.jouannet2@gmail.comADAMI HO, 1995, CANCER CAUSE CONTROL, V6, P551, DOI 10.1007/BF00054165; Alavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; Belot A, 2008, ESTIMATION NATL INCI; BIDERMANN S., 2010, ANN BIOANNAL CHEM, V198, P511; BRODY JG., 2011, ENV HLTH PERSPECT, V119, P326; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Crump KS, 2003, ENVIRON HEALTH PERSP, V111, P681, DOI 10.1289/eph.5831; Dai D, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-49; Damstra T, 2002, GLOBAL ASSESSMENT ST; Gee David, 2009, Pathophysiology, V16, P217, DOI 10.1016/j.pathophys.2009.01.004; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; JOUANNET P., 2012, ANDROLOGIE, V22, P10; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim MJ, 2011, ENVIRON HEALTH PERSP, V119, P377, DOI 10.1289/ehp.1002848; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; le Maire A, 2010, CELL MOL LIFE SCI, V67, P1219, DOI 10.1007/s00018-009-0249-2; Multigner L, 2010, J CLIN ONCOL, V28, P3457, DOI 10.1200/JCO.2009.27.2153; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Ndong JR, 2009, B CANCER, V96, P171, DOI 10.1684/bdc.2008.0812; Pesatori AC, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-39; Pike MC, 2000, ENDOCR-RELAT CANCER, V7, P73, DOI 10.1677/erc.0.0070073; Risbridger GP, 2007, J MOL ENDOCRINOL, V39, P183, DOI 10.1677/JME-07-0053; Rochefort H, 2008, CR BIOL, V331, P104, DOI 10.1016/j.crvi.2006.07.009; Rochefort H, 2008, B ACAD NAT MED PARIS, V192, P161; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P1053, DOI 10.1289/ehp.1002864; Tyl RW, 2009, ENVIRON HEALTH PERSP, V117, P1644, DOI 10.1289/ehp.0900893; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Villeneuve S, 2011, AM J IND MED, V54, P499, DOI 10.1002/ajim.20952; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Warner M, 2011, ENVIRON HEALTH PERSP, V119, P1700, DOI 10.1289/ehp.1103720310ACAD NATL MEDECINEPARIS 0616 RUE BONAPARTE, 75272 PARIS 06, FRANCEB ACAD NAT MED PARISNOVDiscipline: General &amp; Internal Medicine969WR</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL A-GLYCIDYL METHACRYLAYTE; BISPHENOL-A; BLOOD; breast; breast neoplasms; BREAST-CANCER; CANCER; CELL; CHILDREN; DIOXIN; DIOXINS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; ESTORGENS; Estrogen; EXPOSURE; FOOD; GLAND; HEALTH; HUMAN EXPOSURE; HUMANS; IN-VIVO; INDUSTRY; mechanism; MECHANISMS; pathophysiology; PESTICIDES; phthalate; Phthalates; Prostate; PROSTATE-CANCER; PROSTATIC NEOPLASMS; PUBLIC-HEALTH; RISK; RISK FACTOR; TESTICULAR NEOPLASMS; testis; Urine; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1965</startpage>
    <endpage>1979</endpage>
    <journalfull>Bulletin de l Academie Nationale de Medecine</journalfull>
    <issue>8</issue>
    <volume>195</volume>
    <abstract>Concerned by the increasing incidence of breast, prostate and testis cancers in industrialized countries, including in Europe, we conducted an overview of the international literature and French national reports on the potential carcinogenic effect of several endocrine disruptors (EDs) found in the environment. We explain why it is extremely difficult to obtain epidemiological proof of a carcinogenic effect of EDs in humans. This is partly responsible for the long-term polemic regarding this issue. However, the results of a series of independent studies are sufficient to strongly suspect such a carcinogenic effect, particularly in hormone-dependent cancers. They were obtained experimentally in rodents and by measuring levels of human exposure, in blood and urine. The lesson learned from the transgenerational carcinogenic effect of diethyl stilbestrol in pregnant women treated in the past with this synthetic estrogen, and in vivo results in rodents treated with bisphenol A, indicate that we should first protect pregnant and lactating women and young children. While decisions to reduce environmental levels of EDs like pesticides, dioxins and PCBs have already been taken, we focus on new safety proposals on bisphenol A and phthalates used in food packaging. We propose that, before prohibiting all use of bisphenol A in food packaging, more concerted research by biologists together with industry will be needed to develop safe substitutes</abstract>
    <url>WOS:000306090600029</url>
    <isbnorissn>0001-4079</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>136</id>
    <title>Bisphenol A and hormone-dependent cancers: potential risk and mechanism</title>
    <authors>Rochefort,H.</authors>
    <availability>Univ Montpellier I, INSERM, U896, Acad Natl Med,Inst Rech Cancerol Montpellier,CRLC, F-34298 Montpellier 5, France.</availability>
    <date>2013</date>
    <notes>JFrenchArticleRochefort, H (reprint author), Univ Montpellier I, INSERM, U896, Acad Natl Med,Inst Rech Cancerol Montpellier,CRLC, 208 Rue Apothicaires, F-34298 Montpellier 5, Francehenri.rochefort@inserm.frBelot A, 2008, REV EPIDEMIOL SANTE, V56, P159, DOI 10.1016/j.respe.2008.03.117; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276; Cravedi JP, 2007, M S-MED SCI, V23, P198, DOI 10.1051/medsci/2007232198; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Multigner L, 2010, J CLIN ONCOL, V28, P3457, DOI 10.1200/JCO.2009.27.2153; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Rochefort H, 2011, B ACAD NATL MED, V195, P51; Rochefort H, 2008, CR BIOL, V331, P104, DOI 10.1016/j.crvi.2006.07.009; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422221EDP SCIENCES S ALES ULIS CEDEX A17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A, FRANCEM S-MED SCIMAYDiscipline: Research &amp; Experimental Medicine163NW</notes>
    <keywords>ALPHA; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; BREAST-CANCER; CANCER; CELL; CELLS; DISEASE; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; FOOD; HUMAN HEALTH; IN-UTERO; mechanism; MECHANISMS; Prostate; RECEPTOR; RECEPTOR-ALPHA; RISK; SOCIETY; STATEMENT; Urine; WIDESPREAD EXPOSURE; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>539</startpage>
    <endpage>544</endpage>
    <journalfull>M S-Medecine Sciences</journalfull>
    <issue>5</issue>
    <volume>29</volume>
    <abstract>Being concerned by the increasing incidence of breast, prostate and testicular cancers, we overviewed the literature on the potential carcinogenic effect of endocrine disruptors (epsilon D). It is extremely difficult to obtain the epidemiological proof of a carcinogenic effect of one epsilon D in human for multi-factorial diseases and the high number of confusing factors. However, many experimental studies in rodents on bis-phenol A (BPA) and its assay in human blood and urine, strongly suggest that BPA might increase the risk of hormone dependant cancers. Contrary to the mitogenic effect of estradiol, directly mediated in mammary cells by the classical nuclear estrogen receptor alpha, the mechanisms of the deleterious effect of BPA at low doses and in utero remain unknown since the molecular and cellular target(s) have not been defined. Based on all deleterious effects of BPA, France has banned the use of BPA in all food packaging. This should force the food industry to collaborate with members of public research to rapidly find safer substitutes to BPA</abstract>
    <url>WOS:000320345200019</url>
    <isbnorissn>0767-0974</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>27</id>
    <title>Gas chromatography and ultra high performance liquid chromatography tandem mass spectrometry methods for the determination of selected endocrine disrupting chemicals in human breast milk after stir-bar sorptive extraction</title>
    <authors>Rodriguez-Gomez,R.; Zafra-Gomez,A.; Camino-Sanchez,F.J.; Ballesteros,O.; Navalon,A.</authors>
    <availability>[Rodriguez-Gomez, R.; Zafra-Gomez, A.; Camino-Sanchez, F. J.; Ballesteros, O.; Navalon, A.] Univ Granada, Dept Analyt Chem, Res Grp Analyt Chem &amp; Life Sci, E-18071 Granada, Spain.</availability>
    <date>2014</date>
    <notes>JEnglishArticle; Proceedings PaperZafra-Gomez, A (reprint author), Univ Granada, Dept Analyt Chem, Res Grp Analyt Chem &amp; Life Sci, Campus Fuentenueva, E-18071 Granada, Spainazafra@ugr.esTHOMPSON M, 1994, ANALYST, V119, P2363; Andersen F.A., 2008, INT J TOXICOL, V27, P1; [Anonymous], 2001, GUID IND BIOAN METH; [Anonymous], 1998, FIL-IDF Standard 147B:1998, Patent No. [2190852, ES 2 190 852 B1, ES 20 190 852, ES 2190852 A1]; Ballesteros O, 2006, J CHROMATOGR A, V1121, P154, DOI 10.1016/j.chroma.2006.04.014; Baltussen E, 1999, J MICROCOLUMN SEP, V11, P737, DOI 10.1002/(SICI)1520-667X(1999)11:10&lt;737::AID-MCS7&gt;3.0.CO;2-4; Boberg J, 2010, REPROD TOXICOL, V30, P301, DOI 10.1016/j.reprotox.2010.03.011; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cariot A, 2012, TALANTA, V100, P175, DOI 10.1016/j.talanta.2012.08.034; Cuderman P, 2007, ANAL BIOANAL CHEM, V387, P1343, DOI 10.1007/s00216-006-0927-y; Currie LA, 1999, ANAL CHIM ACTA, V391, P127, DOI 10.1016/S0003-2670(99)00105-1; Daughton CG, 2001, PHARM PERSONAL CARE; David F, 2007, J CHROMATOGR A, V1152, P54, DOI 10.1016/j.chroma.2007.01.032; De Coensel N, 2009, J SEP SCI, V32, P3829, DOI 10.1002/jssc.200900349; Gore AC, 2007, CONTEMP ENDOCRINOL S, P1, DOI 10.1007/1-59745-107-X; Hernik A, 2014, CHEMOSPHERE, V94, P158, DOI 10.1016/j.chemosphere.2013.09.067; HUSSEIN SE, 2007, EXP DERMATOL, V16, P830; Jiang R, 1999, BRIT J CLIN PHARMACO, V48, P635; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Kawaguchi M, 2006, J PHARMACEUT BIOMED, V40, P500, DOI 10.1016/j.jpba.2005.08.029; Kuruto-Niwa R, 2007, CHEMOSPHERE, V66, P1160, DOI 10.1016/j.chemosphere.2006.06.073; Melo LP, 2013, ANAL METHODS-UK, V5, P3538, DOI 10.1039/c3ay00025g; Migeot V, 2013, ENVIRON SCI TECHNOL, V47, P13791, DOI 10.1021/es403071a; Nicolucci C, 2013, ANAL BIOANAL CHEM, V405, P9139, DOI 10.1007/s00216-013-7342-y; O'Connor JC, 2003, PURE APPL CHEM, V75, P2099, DOI 10.1351/pac200375112099; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Otaka H, 2003, ANAL SCI, V19, P1663, DOI 10.2116/analsci.19.1663; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Park MA, 2013, TOXICOLOGY, V305, P41, DOI 10.1016/j.tox.2012.12.021; Rivas A, 1997, TRAC-TREND ANAL CHEM, V16, P613, DOI 10.1016/S0165-9936(97)00101-5; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Samanidou VF, 2014, J LIQ CHROMATOGR R T, V37, P247, DOI 10.1080/10826076.2012.745133; Schlumpf M, 2010, CHEMOSPHERE, V81, P1171, DOI 10.1016/j.chemosphere.2010.09.079; Smolders R, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-8; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; SUZUKI T, 2005, TOXICOL APPL PHARM, V203, P92; *US EPA, 2003, MULT PLAN FY2000 201; van Meeuwen JA, 2008, TOXICOL APPL PHARM, V230, P372, DOI 10.1016/j.taap.2008.03.002; VILCHEZ JL, 2003, Patent No. 20190852; Yamamoto T, 2002, CHEMOSPHERE, V46, P1215, DOI 10.1016/S0045-6535(01)00198-9; Ye XY, 2008, ANAL CHIM ACTA, V622, P150, DOI 10.1016/j.aca.2008.05.068; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Zimmers SM, 2014, CHEMOSPHERE, V104, P237, DOI 10.1016/j.chemosphere.2013.12.085450ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSJ CHROMATOGR AJUL 4Discipline: Biochemistry &amp; Molecular Biology; ChemistryAJ7BB</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER CELLS; CHEMICALS; CHLORINATED DERIVATIVES; Endocrine disrupting chemicals; ENVIRONMENTAL PHENOLS; FOOD; GC-MS/MS; Human breast milk; HUMAN COLOSTRUM; MS/MS METHOD; PARABENS; SOLID-PHASE EXTRACTION; Stir-bar sorptive extraction; UHPLC-MS/MS; UV FILTERS; WATER SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>69</startpage>
    <endpage>79</endpage>
    <journalfull>Journal of Chromatography A</journalfull>
    <volume>1349</volume>
    <abstract>In the present work, two specific, accurate and sensitive methods for the determination of endocrine disrupting chemicals (EDCs) in human breast milk are developed and validated. Bisphenol A and its main chlorinated derivatives, five benzophenone-UV filters and four parabens were selected as target analytes. The method involves a stir-bar sorptive extraction (SBSE) procedure followed by a solvent desorption prior to GC-MS/MS or UHPLC-MS/MS analysis. A derivatization step is also necessary when GC analysis is performed. The GC column used was a capillary HP-5MS with a run time of 26 min. For UHPLC analysis, the stationary phase was a non-polar Acquity UPLC (R) BEH C18 column and the run time was 10 min. In both cases, the analytes were detected and quantified using a triple quadrupole mass spectrometer (QqQ). Quality parameters such as linearity, accuracy (trueness and precision), sensitivity and selectivity were examined and yielded good results. The limits of quantification (LOQs) ranged from 0.3 to 5.0 ng mL(-1) for GC and from 0.2 to 1.0 ng mL(-1) for LC. The relative standard deviation (RSD) was lower than 15% and the recoveries ranged from 92 to 114% in all cases, being slightly unfavorable the results obtained with LC. The methods were satisfactorily applied for the determination of target compounds in human milk samples from 10 randomly selected women. (C) 2014 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000337851000009</url>
    <isbnorissn>0021-9673</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>147</id>
    <title>Review: Endocrine disrupting chemicals and immune responses: A focus on bisphenol-A and its potential mechanisms</title>
    <authors>Rogers,J.A.; Metz,L.; Yong,V.W.</authors>
    <availability>Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada. Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada.</availability>
    <date>2013</date>
    <notes>JEnglishReviewYong, VW (reprint author), Univ Calgary, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canadavyong@ucalgary.caBallesteros-Gomez A, 2007, ANAL CHIM ACTA, V603, P51, DOI 10.1016/j.aca.2007.09.048; Bebo BF, 2001, J IMMUNOL, V166, P2080; Belfroid A, 2002, CHEMOSPHERE, V49, P97, DOI 10.1016/S0045-6535(02)00157-1; Bianco JJ, 2006, AM J PATHOL, V168, P1869, DOI 10.2353/ajpath.2006.050623; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Bolli A, 2010, IUBMB LIFE, V62, P684, DOI 10.1002/iub.370; Bommhardt U, 2004, CELL MOL LIFE SCI, V61, P263, DOI 10.1007/s00018-003-3224-3; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bynote KK, 2008, GENES IMMUN, V9, P137, DOI 10.1038/sj.gene.6364458; Byun JA, 2005, ENVIRON TOXICOL PHAR, V19, P19, DOI 10.1016/j.etap.2004.02.006; Cariou R, 2008, CHEMOSPHERE, V73, P1036, DOI 10.1016/j.chemosphere.2008.07.084; Chandra V, 2008, NATURE, V456, P350, DOI 10.1038/nature07413; CHAO TC, 1995, CELL IMMUNOL, V160, P43, DOI 10.1016/0008-8749(95)80007-6; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Cooper JE, 2011, CHEMOSPHERE, V85, P943, DOI 10.1016/j.chemosphere.2011.06.060; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Crispin JC, 2010, TRENDS MOL MED, V16, P47, DOI 10.1016/j.molmed.2009.12.005; Cunningham M, 2011, CLIN REV ALLERG IMMU, V40, P66, DOI 10.1007/s12016-010-8203-5; Curras-Collazo MC, 2011, J TOXICOL ENV HEAL B, V14, P495, DOI 10.1080/10937404.2011.578564; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Elango A, 2006, GEN COMP ENDOCR, V145, P116, DOI 10.1016/j.ygcen.2005.08.003; Frericks M, 2007, TOXICOL APPL PHARM, V220, P320, DOI 10.1016/j.taap.2007.01.014; Gerriets VA, 2012, TRENDS IMMUNOL, V33, P168, DOI 10.1016/j.it.2012.01.010; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Gori I, 2011, MOL CELL ENDOCRINOL, V345, P27, DOI 10.1016/j.mce.2011.06.043; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10&lt;2857::AID-IMMU2857&gt;3.0.CO;2-X; Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004; Goto M, 2004, BIOSCI BIOTECH BIOCH, V68, P263, DOI 10.1271/bbb.68.263; Grumetto L, 2008, J AGR FOOD CHEM, V56, P10633, DOI 10.1021/jf802297z; Guo HC, 2010, CELL MOL IMMUNOL, V7, P227, DOI 10.1038/cmi.2010.14; Guo X., 2011, OCT4 PSEUDOGENES PRE; Hong CC, 2004, BIOL PHARM BULL, V27, P1136, DOI 10.1248/bpb.27.1136; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jones DC, 2002, J BIOL CHEM, V277, P6838, DOI 10.1074/jbc.M106908200; Jung EM, 2010, TOXICOL IN VITRO, V24, P1538, DOI 10.1016/j.tiv.2010.06.019; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Kim JY, 2003, CANCER LETT, V196, P69, DOI 10.1016/S0304-3835(03)00219-2; Klecka GM, 2009, ENVIRON SCI TECHNOL, V43, P6145, DOI 10.1021/es900598e; Ko GJ, 2008, NEPHROL DIAL TRANSPL, V23, P2750, DOI 10.1093/ndt/gfn157; KORNLUBETZKI I, 1984, ANN NEUROL, V16, P229, DOI 10.1002/ana.410160211; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; Kuan YH, 2012, INT ENDOD J, V45, P619, DOI 10.1111/j.1365-2591.2012.02017.x; Kubwabo C, 2009, FOOD ADDIT CONTAM A, V26, P928, DOI 10.1080/02652030802706725; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lawrence BP, 2008, BLOOD, V112, P1158, DOI 10.1182/blood-2007-08-109645; Lee J, 2010, DRUG CHEM TOXICOL, V33, P421, DOI 10.3109/01480541003739229; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; le Maire A, 2009, EMBO REP, V10, P367, DOI 10.1038/embor.2009.8; Levy G, 2004, ENVIRON RES, V94, P102, DOI 10.1016/S0013-9351(03)00086-0; Liu YL, 2009, INNATE IMMUN, V15, P169, DOI 10.1177/1753425908102014; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Manabe I, 2011, CIRC J, V75, P2739, DOI 10.1253/circj.CJ-11-1184; Maret A, 2003, EUR J IMMUNOL, V33, P512, DOI 10.1002/immu.200310027; Meng QQ, 2011, NEUROSCI LETT, V503, P191, DOI 10.1016/j.neulet.2011.08.033; Miao S, 2008, J TOXICOL ENV HEAL A, V71, P1000, DOI 10.1080/15287390801907467; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Momoeda M., 1999, ENDOCR J, V46, P773; Mor G, 2003, J IMMUNOL, V170, P114; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nakamura K, 2010, J HEALTH SCI, V56, P361; Nalbandian G, 2005, IMMUNOL RES, V31, P91, DOI 10.1385/IR:31:2:091; Niino M, 2001, J NEUROIMMUNOL, V116, P40, DOI 10.1016/S0165-5728(01)00285-5; Ohshima Y, 2007, PEDIATR RES, V62, P60, DOI 10.1203/PDR.0b013e3180674dae; Panchanathan R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010868; PETRI M, 1991, ARTHRITIS RHEUM, V34, P1538; Phiel KL, 2005, IMMUNOL LETT, V97, P107, DOI 10.1016/j.imlet.2004.10.007; Pocar P, 2005, REPRODUCTION, V129, P379, DOI 10.1530/rep.1.00294; Polak PE, 2005, J NEUROIMMUNOL, V168, P65, DOI 10.1016/j.jneuroim.2005.07.006; Qin XY, 2011, TOXICOL LETT, V206, P152, DOI 10.1016/j.toxlet.2011.07.007; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Raikwar HP, 2005, J NEUROIMMUNOL, V167, P99, DOI 10.1016/j.jneuroim.2005.06.026; Riu A, 2011, ENVIRON HEALTH PERSP, V119, P1227, DOI 10.1289/ehp.1003328; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Rubtsov AV, 2010, AUTOIMMUN REV, V9, P494, DOI 10.1016/j.autrev.2010.02.008; Salazar KD, 2006, TOXICOL SCI, V93, P62, DOI 10.1093/toxsci/kfl038; Sawai C, 2003, ENVIRON HEALTH PERSP, V111, P1883, DOI 10.1289/ehp.6359; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Segura JJ, 1999, J ENDODONT, V25, P341, DOI 10.1016/S0099-2399(06)81168-4; Sellin MK, 2009, ENVIRON TOXICOL CHEM, V28, P2443, DOI 10.1897/09-135.1; Setoguchi K, 2001, J CLIN INVEST, V108, P1667; Siracusa MC, 2008, J IMMUNOL, V180, P1423; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460; Stockinger B, 2011, SEMIN IMMUNOL, V23, P99, DOI 10.1016/j.smim.2011.01.008; Sun CL, 2006, J CHROMATOGR A, V1129, P145, DOI 10.1016/j.chroma.2006.08.018; Swanson CR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-91; Takeuch O, 2011, EUR J IMMUNOL, V41, P2490, DOI 10.1002/eji.201141792; Takeuchi H, 2010, J IMMUNOL, V185, P5289, DOI 10.4049/jimmunol.1000101; Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V291, P76, DOI 10.1006/bbrc.2002.6407; Teeguarden JG, 2011, TOXICOL SCI, V123, P48, DOI 10.1093/toxsci/kfr160; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Veldhoen M, 2010, CURR OPIN IMMUNOL, V22, P747, DOI 10.1016/j.coi.2010.09.001; Vucic E, 2011, JACC-CARDIOVASC IMAG, V4, P1100, DOI 10.1016/j.jcmg.2011.04.020; Xu XH, 2010, ENVIRON HEALTH PERSP, V118, P60, DOI 10.1289/ehp.0900919; Yamane H, 2012, CELL MOL LIFE SCI, V69, P1577, DOI 10.1007/s00018-012-0966-9; Yamashita Uki, 2003, Journal of UOEH, V25, P161; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Yang YH, 2010, PPAR RES, DOI 10.1155/2010/104705; Yeh CH, 2010, INFLAMMATION, V33, P10, DOI 10.1007/s10753-009-9153-z; Yin DQ, 2007, J ENVIRON SCI-CHINA, V19, P232, DOI 10.1016/S1001-0742(07)60038-2; Yoshino S, 2003, BRIT J PHARMACOL, V138, P1271, DOI 10.1038/sj.bjp.0705166; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Yoshitake J, 2008, NITRIC OXIDE-BIOL CH, V18, P223, DOI 10.1016/j.niox.2008.01.003; Youn JY, 2002, ARCH PHARM RES, V25, P946, DOI 10.1007/BF02977018; Yurino H, 2004, TOXICOL SCI, V81, P139, DOI 10.1093/toxsci/kfh179; Zha JM, 2006, SCI TOTAL ENVIRON, V357, P112, DOI 10.1016/j.scitotenv.2005.04.038; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-101811124PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDMOL IMMUNOLAPRDiscipline: Biochemistry &amp; Molecular Biology; Immunology082FN</notes>
    <keywords>ALTERS; ARYL-HYDROCARBON RECEPTOR; Autoimmunity; BIOLOGY; bisphenol A; BISPHENOL-A; BPA; CANCER; CD4(+) T-CELLS; CELL; CHEMICALS; diabetes; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; estrogenic effects; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FACTOR-ALPHA; FOOD; GENES; HEALTH; In vitro; IN-VITRO; Inflammation; Lymphocytes; Macrophage; Macrophages; mechanism; MECHANISMS; NITRIC-OXIDE; Nuclear receptor; NUCLEAR RECEPTORS; PHASE LIQUID-CHROMATOGRAPHY; POPULATION; PPAR; PROLIFERATOR-ACTIVATED RECEPTOR; RECEPTOR; Reproduction; RESPONSES; SEXUAL DYSFUNCTION; toxicology; TUMOR-NECROSIS-FACTOR; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>421</startpage>
    <endpage>430</endpage>
    <journalfull>Molecular Immunology</journalfull>
    <issue>4</issue>
    <volume>53</volume>
    <abstract>Endocrine disrupting chemicals (EDCs) have become of concern for a variety f health issues. Due to their effects on the endocrine system they have been thoroughly examined with regards to sexual dysfunction, malformation, and cancers of reproductive origin. Bisphenol-A (BPA) is a widely studied EDC and has been characterized regarding its estrogenic effects on a variety of cell types. BPA also alters immune responses. In this review, we examine some of the documented effects of EDCs, with a focus on BPA that pertain to modulation of the immune system and various immune cell populations. We highlight the multiple actions of BPA on altering T cell subsets, B cell functions, and dendritic cell and macrophage biology. Finally, we consider that these immunological activities of BPA may be mediated through estrogen receptor signaling, arylhydrocarbon receptor, and the peroxisome proliferator-activated receptor family of nuclear receptors. (c) 2012 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000314377800014</url>
    <isbnorissn>0161-5890</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>396</id>
    <title>Ability of Group IVB metallocene polyethers containing dienestrol to arrest the growth of selected cancer cell lines</title>
    <authors>Roner,M.R.; Carraher,C.E.; Shahi,K.; Ashida,Y.; Barot,G.</authors>
    <availability>[Roner, Michael R.; Shahi, Kimberly] Univ Texas Arlington, Dept Biol, Arlington, TX 76010 USA. [Carraher, Charles E., Jr.; Ashida, Yuki; Barot, Girish] Florida Atlantic Univ, Dept Chem &amp; Biochem, Boca Raton, FL 33431 USA. [Carraher, Charles E., Jr.; Ashida, Yuki; Barot, Girish] Florida Ctr Environm Studies, Palm Beach Gardens, FL 33410 USA. [Ashida, Yuki] Univ Tokushima, Dept Engn, Tokushima 7708506, Japan.</availability>
    <date>2009</date>
    <notes>JEnglishArticleRoner, MR (reprint author), Univ Texas Arlington, Dept Biol, Arlington, TX 76010 USAroner@uta.edu; carraher@fau.edu; krshahi@gmail.com; ashida.yuki@gmail.com; girishbarod@yahoo.comADLER E, 1949, Patent No. 2465505; AI H, 2005, OFFICE USP, P46; AKTIEBOLAGET L, 1956, Patent No. 753319; Barot G, 2006, J POLYM MATER, V23, P423; Barot G, 2007, J INORG ORGANOMET P, V17, P595, DOI 10.1007/s10904-007-9158-8; Carraher C., 1975, BR POLYM J, V7, P155, DOI 10.1002/pi.4980070304; AbdElAziz AS, 2005, MACROMOL CONTAIN MET, V4, P1; CARRAHER CE, 1976, ANGEW MAKROMOL CHEM, V52, P111, DOI 10.1002/apmc.1976.050520110; CARRAHER C, 1993, J POLYM MATER, V10, P17; Carraher C., 2008, FUNDAMENTALS FRAGMEN; CARRAHER CE, 1974, ANGEW MAKROMOL CHEM, V39, P69, DOI 10.1002/apmc.1974.050390106; CARRAHER CE, 1973, POLYMER, V14, P42, DOI 10.1016/0032-3861(73)90093-1; CARRAHER CE, 1974, POLYMER, V15, P9, DOI 10.1016/0032-3861(74)90067-6; CARRAHER C, 1987, POLYM PLATINOL DERIV; Carraher CE, 2007, J POLYM MATER, V24, P357; Carraher CE, 2008, J INORG ORGANOMET P, V18, P180, DOI 10.1007/s10904-007-9184-6; Carraher CE, 2003, J POLYM MATER, V20, P91; Carraher CE, 2007, J INORG ORGANOMET P, V17, P631, DOI 10.1007/s10904-007-9159-7; CARRAHER CE, 2009, CANC RES J IN PRESS; Carraher CE, 2004, J POLYM MATER, V21, P383; Carraher CE, 2005, J INORG ORGANOMET P, V15, P121, DOI 10.1007/s10904-004-2382-6; Carraher CE, 2007, J INORG ORGANOMET P, V17, P127, DOI 10.1007/s10904-006-9089-9; Carraher CE, 2006, J INORG ORGANOMET P, V16, P249, DOI 10.1007/s10904-006-9050-y; CARRAHER CE, 1981, J MACROMOL SCI CHEM, VA15, P625, DOI 10.1080/00222338108056754; Carraher CE, 2006, J POLYM MATER, V23, P143; Carraher CE, 2000, J POLYM MATER, V17, P377; Chourasia MK, 2004, DRUG DELIV, V11, P201, DOI 10.1080/10717540490445955; Claffey J, 2008, CHEMMEDCHEM, V3, P729, DOI 10.1002/cmdc.200700302; Dowling CM, 2008, LETT DRUG DES DISCOV, V5, P141, DOI 10.2174/157018008783928463; Gansauer A, 2008, CHEM-EUR J, V14, P4160, DOI 10.1002/chem.200800407; Gomez-Ruiz S, 2008, J INORG BIOCHEM, V102, P1558, DOI 10.1016/j.jinorgbio.2008.02.001; Hernandez R, 2008, J BIOL INORG CHEM, V13, P685, DOI 10.1007/s00775-008-0353-z; Hogan M, 2008, MED CHEM, V4, P91; Ikegami T, 2004, ANAL CHIM ACTA, V504, P131, DOI 10.1016/j.aca.2003.08.032; Ikegami T, 2004, J CHROMATOGR B, V804, P197, DOI 10.1016/j.jchromb.2003.12.031; KANNAN M, 2004, OFFICE USP, P75; Lu ZD, 2006, J ORGANOMET CHEM, V691, P5895, DOI 10.1016/j.jorganchem.2006.09.052; Oberschmidt O, 2007, ANTI-CANCER DRUG, V18, P317, DOI 10.1097/CAD.0b013e3280115f86; Pampillon C, 2008, EUR J MED CHEM, V43, P122, DOI 10.1016/j.ejmech.2007.02.011; Pampillon C, 2007, J ORGANOMET CHEM, V692, P2153, DOI 10.1016/j.jorganchem.2007.01.045; Pampillon C, 2008, BIOMETALS, V21, P197, DOI 10.1007/s10534-007-9108-5; Potter GD, 2006, INORG CHEM COMMUN, V9, P1114, DOI 10.1016/j.inoche.2006.07.019; Roner MR, 2008, J INORG ORGANOMET P, V18, P374, DOI 10.1007/s10904-008-9219-7; Roner MR, 2007, J POLYM MATER, V24, P371; Roner MR, 2006, J POLYM MATER, V23, P153; Sabir TS, 2005, J POLYM MATER, V22, P449; Sanbe H, 2003, J PHARMACEUT BIOMED, V30, P1835, DOI 10.1016/S0731-7085(02)00526-5; Short W. F., 1949, Us Patent, Patent No. [2,464,203, 2464203]; Siegmann-Louda D., 2004, MACROMOLECULES CONTA, V3; Strohfeldt K, 2008, CHEM SOC REV, V37, P1174, DOI 10.1039/b707310k; SWAIN S, 2006, CANC CHEMOTHERAPY; Tarbin JA, 1999, ANAL COMMUN, V36, P105, DOI 10.1039/a900197b; Tarbin JA, 2001, ANAL CHIM ACTA, V433, P71, DOI 10.1016/S0003-2670(00)01373-8; Twaites B, 2005, J MATER CHEM, V15, P441, DOI 10.1039/b410799n; VAYA N, 2006, OFFICE USP, P49; VOGELZANG N, 1992, CHEMOTHERAPY SOURCE, V1008; Ye L, 2001, ANALYST, V126, P760, DOI 10.1039/b009048o577BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDBMC CANCEROCT 7Discipline: Oncology510XE</notes>
    <keywords>ANTITUMOR; BISPHENOL-A; breast; CANCER; CE; CELL; cell growth; CELL-LINES; CHEMOTHERAPY; CISPLATIN; CISPLATIN DERIVATIVES; COMBINATION; Cytotoxicity; DES; Estrogen; ESTROGENIC COMPOUNDS; GROWTH; In vitro; IN-VITRO; inhibition; LINE; LINES; MASS-SPECTROMETRY; oncology; ORGANOTIN POLYESTERS; Polycarbonates; POLYMERS; SCATTERING; SPECTROSCOPY; STRUCTURAL-CHARACTERIZATION; SUBSTITUTED TITANOCENE; SYSTEM; TITANOCENE ANTICANCER DRUGS; TUMOR; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Bmc Cancer</journalfull>
    <volume>9</volume>
    <abstract>Background: Monomeric Group IVB (Ti, Zr and Hf) metallocenes represent a new class of antitumor compounds. There is literature on the general biological activities of some organotin compounds. Unfortunately, there is little information with respect to the molecular level activity of these organotin compounds. We recently started focusing on the anti-cancer activity of organotin polymers that we had made for other purposes and as part of our platinum anti-cancer effort. Methods: For this study, we synthesized a new series of metallocene-containing compounds coupling the metallocene unit with dienestrol, a synthetic, nonsteroidal estrogen. This is part of our effort to couple known moieties that offer antitumor activity with biologically active units hoping to increase the biological activity of the combination. The materials were confirmed to be polymeric using light scattering photometry and the structural repeat unit was verified employing matrix assisted laser desorption ionization mass spectrometry and infrared spectroscopy results. Results: The polymers demonstrated the ability to suppress the growth of a series of tumor cell lines originating from breast, colon, prostrate, and lung cancers at concentrations generally lower than those required for inhibition of cell growth by the commonly used antitumor drug cisplatin. Conclusion: These drugs show great promise in vitro against a number of cancer cell lines and due to their polymeric nature will most likely be less toxic than currently used metal-containing drugs such as cisplatin. These drugs also offer several addition positive aspects. First, the reactants are commercially available so that additional synthetic steps are not needed. Second, synthesis of the polymer is rapid, occurring within about 15 seconds. Third, the interfacial synthetic system is already industrially employed in the synthesis of aromatic nylons and polycarbonates. Thus, the ability to synthesize large amounts of the drugs is straight forward</abstract>
    <url>WOS:000271126200002</url>
    <isbnorissn>1471-2407</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>200</id>
    <title>Role of ER beta and GPR30 in the endocrine pancreas: A matter of estrogen dose</title>
    <authors>Roper,A.B.; Pang,Y.F.; Alonso-Magdalena,P.; Thomas,P.; Nadal,A.</authors>
    <availability>[Roper, Ana B.; Alonso-Magdalena, Paloma; Nadal, Angel] Univ Miguel Hernandez de Elche, Inst Bioingn, Alicante 03202, Spain. [Roper, Ana B.; Alonso-Magdalena, Paloma; Nadal, Angel] Univ Miguel Hernandez de Elche, CIBER Diabet &amp; Enfemedades Metab Asociadas CIBERD, Alicante 03202, Spain. [Pang, Yefei; Thomas, Peter] Univ Texas Dallas, Port Aransas, TX 78373 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticle; Proceedings PaperRoper, AB (reprint author), Univ Miguel Hernandez de Elche, Inst Bioingn, Alicante 03202, Spainropero@umh.es; nadal@umh.esAcconcia F, 2004, BIOCHEM BIOPH RES CO, V316, P878, DOI 10.1016/j.bbrc.2004.02.129; Adachi T, 2005, FOOD CHEM TOXICOL, V43, P713, DOI 10.1016/j.fct.2005.01.009; Al-Majed HT, 2005, PANCREAS, V30, P307, DOI 10.1097/01.mpa.0000161886.17492.22; Alonso-Magdalena P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002069; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Balhuizen A, 2010, MOL CELL ENDOCRINOL, V320, P16, DOI 10.1016/j.mce.2010.01.030; Barbosa RM, 1998, J PHYSIOL-LONDON, V510, P135, DOI 10.1111/j.1469-7793.1998.135bz.x; BENHAM CD, 1988, J PHYSIOL-LONDON, V404, P767; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Chuang JC, 2011, MOL ENDOCRINOL, V25, P1600, DOI 10.1210/me.2011-1001; Contreras JL, 2002, TRANSPLANTATION, V74, P1252, DOI 10.1097/01.TP.0000034466.18346.15; Dezaki K, 2007, DIABETES, V56, P2319, DOI 10.2337/db07-0345; Dyachok O, 2008, CELL METAB, V8, P26, DOI 10.1016/j.cmet.2008.06.003; Etchegoyen GS, 1998, DIABETES METAB, V24, P428; Falkenstein E, 2000, J CLIN ENDOCR METAB, V85, P2072, DOI 10.1210/jc.85.5.2072; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; GILON P, 1993, J BIOL CHEM, V268, P22265; Haas E, 2009, CIRC RES, V104, P288, DOI 10.1161/CIRCRESAHA.108.190892; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; HIRST GDS, 1980, NATURE, V283, P767, DOI 10.1038/283767a0; HIRST GDS, 1982, J PHYSIOL-LONDON, V328, P351; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Kahn SE, 2009, DIABETOLOGIA, V52, P1003, DOI 10.1007/s00125-009-1321-z; Kang L, 2010, MOL ENDOCRINOL; Kanitkar M, 2008, BRIT J PHARMACOL, V155, P702, DOI 10.1038/bjp.2008.311; Kojima S, 2007, PEPTIDES, V28, P459, DOI 10.1016/j.peptides.2006.09.024; Kumar R, 2011, ENDOCRINOLOGY, V152, P2568, DOI 10.1210/en.2010-1361; Langer G, 2010, STEROIDS, V75, P603, DOI 10.1016/j.steroids.2009.12.006; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119; Le May C, 2006, P NATL ACAD SCI USA, V103, P9232, DOI 10.1073/pnas.0602956103; Levin ER, 2009, ENDOCRINOLOGY, V150, P1563, DOI 10.1210/en.2008-1759; Liu S, 2009, DIABETES; Martensson UEA, 2009, ENDOCRINOLOGY, V150, P687, DOI 10.1210/en.2008-0623; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Nadal A, 2001, TRENDS PHARMACOL SCI, V22, P597, DOI 10.1016/S0165-6147(00)01846-0; Nadal A, 1998, FASEB J, V12, P1341; Nadal A, 2009, MOL CELL ENDOCRINOL, V304, P63, DOI 10.1016/j.mce.2009.02.016; Otto C, 2008, ENDOCRINOLOGY, V149, P4846, DOI 10.1210/en.2008-0269; Pang Y, 2008, ENDOCRINOLOGY, V149, P3410, DOI 10.1210/en.2007-1663; Pang YF, 2011, STEROIDS, V76, P921, DOI 10.1016/j.steroids.2011.01.008; Pang YF, 2010, DEV BIOL, V342, P194, DOI 10.1016/j.ydbio.2010.03.027; Pedram A, 2006, MOL ENDOCRINOL, V20, P196; Peyton C, 2011, BIOL REPROD, V85, P42, DOI 10.1095/biolreprod.110.088765; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Qiu J, 2006, J NEUROSCI, V26, P5649, DOI 10.1523/JNEURSCI.0327-06.2006; Quesada I, 2008, J ENDOCRINOL, V199, P5, DOI 10.1677/JOE-08-0290; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; Ropero AB, 1999, J PHYSIOL-LONDON, V521, P397, DOI 10.1111/j.1469-7793.1999.00397.x; Ropero AB, 2010, ENDOCRINOLOGY, V151, P3665, DOI 10.1210/en.2010-0119; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; Sarkar SN, 2008, P NATL ACAD SCI USA, V105, P15148, DOI 10.1073/pnas.0802379105; Sharma G, 2011, ENDOCRINOLOGY, V152, P3030, DOI 10.1210/en.2011-0091; Singh V, 2007, ENDOCRINOLOGY, V148, P3887, DOI 10.1210/en.2006-1659; Soriano S, 2009, MOL ENDOCRINOL, V23, P1973, DOI 10.1210/me.2009-0287; Srivastava DP, 2005, J NEUROSCI, V25, P6145, DOI 10.1523/JNEUROSCI.1005-05.2005; SUTTERDUB MT, 1979, DIABETES METAB, V5, P47; Thomas P, 2010, STEROIDS, V75, P595, DOI 10.1016/j.steroids.2009.11.005; Thomas P, 2007, ENDOCRINOLOGY, V148, P705, DOI 10.1210/en.2006-0974; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; VALDEOLMILLOS M, 1992, J PHYSIOL-LONDON, V455, P173; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Yawo H, 1996, J PHYSIOL-LONDON, V493, P385; Yawo H, 1999, J NEUROSCI, V19, P5293695ELSEVIER SCIENCE INCNEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USASTEROIDSAUGSIDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism990FS</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; ALPHA-CELLS; BETA; BIOLOGY; BISPHENOL-A; BREAST-CANCER CELLS; CELL; diabetes; ENDOCRINE; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptor alpha; Estrogen receptor beta; ESTROGEN-RECEPTOR; ESTROGENS; FEMALE MICE; FOOD; Glucose tolerance; Glycemia; GPER; GPR30; HEALTH; Insulin; Insulin resistance; INSULIN-SECRETION; Islets of Langerhans; METABOLISM; MODEL; NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE RECEPTOR; PROTEIN-COUPLED RECEPTOR; RECEPTOR; RELEASE; SMOOTH-MUSCLE; TRANSMITTER RELEASE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>951</startpage>
    <endpage>958</endpage>
    <journalfull>Steroids</journalfull>
    <issue>10</issue>
    <volume>77</volume>
    <abstract>The endocrine pancreas has emerged as a target for estrogens. The functions of pancreatic alpha-, beta- and delta-cells are modulated by the endogenous hormone, 17 beta-estradiol (E2). Low physiological concentrations (100 pM-1 nM) of E2 rapidly decrease the activity of the ATP-sensitive potassium channel (K-ATP) and enhance glucose-induced insulin release in beta-cells in an estrogen receptor 0 (ERN-dependent manner. In addition to the insulinotropic action of ER beta, the newly described estrogen receptor, GPR30, is involved in the insulinotropic effects of high doses of E2 (100 nM-51 mu M). The specific GPR30 agonist G1 also increases insulin secretion in beta-cells. Low glucose-induced calcium oscillations and glucagon secretion are suppressed by E2. The effects on glucagon secretion may be mediated by GPR30. Somatostatin release is also decreased by E2 and G1. In this review we summarize all the data published up to date on the rapid insulinotropic effects of estrogens in the endocrine pancreas and propose a model to integrate the estrogen actions mediated through both receptors. (c) 2012 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000307617000011</url>
    <isbnorissn>0039-128X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>120</id>
    <title>Real-Time Growth Kinetics Measuring Hormone Mimicry for ToxCast Chemicals in T-47D Human Ductal Carcinoma Cells</title>
    <authors>Rotroff,D.M.; Dix,D.J.; Houck,K.A.; Kavlock,R.J.; Knudsen,T.B.; Martin,M.T.; Reif,D.M.; Richard,A.M.; Sipes,N.S.; Abassi,Y.A.; Jin,C.; Stampfl,M.; Judson,R.S.</authors>
    <availability>[Rotroff, Daniel M.] Univ N Carolina, Dept Environm Sci &amp; Engn, Chapel Hill, NC 27514 USA. [Rotroff, Daniel M.; Dix, David J.; Houck, Keith A.; Kavlock, Robert J.; Knudsen, Thomas B.; Martin, Matthew T.; Reif, David M.; Richard, Ann M.; Sipes, Nisha S.; Judson, Richard S.] US EPA, Natl Ctr Computat Toxicol, Off Res &amp; Dev, Res Triangle Pk, NC 27711 USA. [Abassi, Yama A.; Jin, Can; Stampfl, Melinda] ACEA Biosci Inc, San Diego, CA 92121 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleJudson, RS (reprint author), US EPA, Natl Ctr Computat Toxicol, Off Res &amp; Dev, 109 TW Alexander Dr B205-01, Res Triangle Pk, NC 27711 USAjudson.richard@epa.govAltucci L, 1996, ONCOGENE, V12, P2315; Amato R, 2009, J MOL MED-JMM, V87, P1221, DOI 10.1007/s00109-009-0525-5; Atienza JM, 2005, J BIOMOL SCREEN, V10, P795, DOI 10.1177/108705710527635; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Boonyaratanakornkit V, 2007, MOL ENDOCRINOL, V21, P359, DOI 10.1210/me.2006-0337; Bunone G, 1996, EMBO J, V15, P2174; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chen AC, 2004, J NUTR, V134, P1303; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Davis Devra Lee, 1997, Environmental Health Perspectives, V105, P571, DOI 10.2307/3433372; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/er.20.3.253; Judson R, 2009, ENVIRON HEALTH PERSP, V117, P685, DOI 10.1289/ehp.0800168; Kavlock R, 2012, CHEM RES TOXICOL, V25, P1287, DOI 10.1021/tx3000939; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; Knudsen TB, 2011, TOXICOLOGY, V282, P1, DOI 10.1016/j.tox.2010.12.010; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Maechler M., 2011, SFSMISC UTILITIES SE; Martin MT, 2010, CHEM RES TOXICOL, V23, P578, DOI 10.1021/tx900325g; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; McGowan EM, 1999, MOL ENDOCRINOL, V13, P1657, DOI 10.1210/me.13.10.1657; Neuman E, 1997, MOL CELL BIOL, V17, P5338; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Okubo T, 2001, FOOD CHEM TOXICOL, V39, P1225, DOI 10.1016/S0278-6915(01)00073-4; Peterson G, 1996, CELL GROWTH DIFFER, V7, P1345; Pravettoni A, 2007, MOL CELL ENDOCRINOL, V263, P46, DOI 10.1016/j.mce.2006.08.008; R Development Core Team, 2011, R LANG ENV STAT COMP; Romanov S, 2008, NAT METHODS, V5, P253, DOI [10.1038/nmeth.1186, 10.1038/NMETH.1186]; Rotroff DM, 2013, ENVIRON HEALTH PERSP, V121, P7, DOI 10.1289/ehp.1205065; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; SARTORIUS CA, 1994, CANCER RES, V54, P3868; Schenk B, 2010, REPROD TOXICOL, V30, P200, DOI 10.1016/j.reprotox.2010.05.012; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Shelby Michael D, 2008, NTP CERHR MON, pvii; Shelby MD, 2008, NTP CERHR MON, Vv, pvii; Shelby MD, 2008, NTP CERHR MON SEP, p[v, vii, 1]; Shiozawa T, 2004, ONCOGENE, V23, P8603, DOI 10.1038/sj.onc.1207849; Sipes NS, 2013, CHEM RES TOXICOL, V26, P878, DOI [10.1021/tx400021f, 10.1021/tx400021]; Smith KW, 2012, ENVIRON HEALTH PERSP, V120, P1538, DOI 10.1289/ehp.1104614; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Sotoca AM, 2008, J STEROID BIOCHEM, V112, P171, DOI 10.1016/j.jsbmb.2008.10.002; Strom A, 2006, P NATL ACAD SCI USA, V103, P8298; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; Tilghman SL, 2010, STEROIDS, V75, P520, DOI 10.1016/j.steroids.2010.05.004; U.S. EPA, 2011, 11P0215 US EPA; U.S. EPA, 2011, END DISR SCREEN PROG; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Wang S, 2012, J STEROID BIOCHEM, V128, P98, DOI 10.1016/j.jsbmb.2011.11.009; Watson CS, 2011, J STEROID BIOCHEM, V127, P44, DOI 10.1016/j.jsbmb.2011.01.015572AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USACHEM RES TOXICOLJULDiscipline: Pharmacology &amp; Pharmacy; Chemistry; Toxicology187AD</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; BINDING; biphasic; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CARCINOMA; CELL; cell death; CELL-DEATH; CELLS; CHEMICALS; COMBINATION; cosmetics; CYCLIN D1; DEATH; DISEASE OUTCOMES; END-POINTS; ENDOCRINE; Estrogen; Estrogen receptor; estrogen signaling; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-BETA; estrogenic activity; EXPOSURE; FOOD; GENE-TRANSCRIPTION; genistein; GROWTH; HUMAN EXPOSURE; In vitro; IN-VITRO; inhibition; Nonylphenol; PERSONAL CARE PRODUCTS; PHARMACOLOGY; PROGESTERONE-RECEPTOR; proliferation; RECEPTOR; Receptor binding assay; Reproduction; SIGNALING PATHWAY; toxicology; TRANSACTIVATION; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1097</startpage>
    <endpage>1107</endpage>
    <journalfull>Chemical Research in Toxicology</journalfull>
    <issue>7</issue>
    <volume>26</volume>
    <abstract>High-throughput screening (HTS) assays capable of profiling thousands of environmentally relevant chemicals for in vitro biological activity provide useful information on the potential for disrupting endocrine pathways. Disruption of the estrogen signaling pathway has been implicated in a variety of adverse health effects including impaired development, reproduction, and carcinogenesis. The estrogen-responsive human mammary ductal carcinoma cell line T-47D was exposed to 1815 ToxCast chemicals comprising pesticides, industrial chemicals, pharmaceuticals, personal care products, cosmetics, food ingredients, and other chemicals with known or suspected human exposure potential. Cell growth kinetics were evaluated using real-time cell electronic sensing. T-47D cells were exposed to eight concentrations (0.006-100 mu M), and measurements of cellular impedance were repeatedly recorded for 105 h. Chemical effects were evaluated based on potency (concentration at which response occurs) and efficacy (extent of response). A linear growth response was observed in response to prototypical estrogen receptor agonists (17 beta-estradiol, genistein, bisphenol A, nonylphenol, and 4-tert-octylphenol). Several compounds, including bisphenol A and genistein, induced cell growth comparable in efficacy to that of 17 beta-estradiol, but with decreased potency. Progestins, androgens, and corticosteroids invoked a biphasic growth response indicative of changes in cell number or cell morphology. Results from this cell growth assay were compared with results from additional estrogen receptor (ER) binding and transactivation assays. Chemicals detected as active in both the cell growth and ER receptor binding assays demonstrated potencies highly correlated with two ER transactivation assays (r = 0.72; r = 0.70). While ER binding assays detected chemicals that were highly potent or efficacious in the T-47D cell growth and transactivation assays, the binding assays lacked sensitivity in detecting weakly active compounds. In conclusion, this cell-based assay rapidly detects chemical effects on T-47D growth and shows potential, in combination with other HTS assays, to detect environmentally relevant chemicals with potential estrogenic activity</abstract>
    <url>WOS:000322086800015</url>
    <isbnorissn>0893-228X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>42</id>
    <title>Effects of endocrine disruptors on the human fetal testis</title>
    <authors>Rouiller-Fabre,V.; Habert,R.; Livera,G.</authors>
    <availability>[Rouiller-Fabre, Virginie; Habert, Rene; Livera, Gabriel] Univ Paris Diderot, Unit Stem Cells &amp; Radiat, Lab Dev Gonads, UMR 967,Inserm,CEA,DSV,iRCM,SCSR,LDG,Sorbonne Par, F-92265 Fontenay Aux Roses, France.</availability>
    <date>2014</date>
    <notes>JEnglishArticleLivera, G (reprint author), Univ Paris Diderot, Unit Stem Cells &amp; Radiat, Lab Dev Gonads, UMR 967,Inserm,CEA,DSV,iRCM,SCSR,LDG,Sorbonne Par, Route Panorama,BP 6, F-92265 Fontenay Aux Roses, Francegabrial.livera@cea.frHeger NE, 2012, ENVIRON HEALTH PERSP, V120, P1137, DOI 10.1289/ehp.1104711; Lambrot R, 2009, ENVIRON HEALTH PERSP, V117, P32, DOI 10.1289/ehp.11146; Lehraiki A, 2009, TOXICOL SCI, V111, P372, DOI 10.1093/toxsci/kfp153; Livera G, 2006, CELL TISSUE RES, V324, P507, DOI 10.1007/s00441-006-0167-7; Mitchell RT, 2012, J CLIN ENDOCR METAB, V97, pE341, DOI 10.1210/jc.2011-2411; Mitchell RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061726; Muczynski V, 2012, TOXICOL APPL PHARM, V261, P97, DOI 10.1016/j.taap.2012.03.016; N'Tumba-Byn T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051579; Rouiller-Fabre V, 2008, GYNECOL OBSTET FERTI, V36, P898, DOI 10.1016/j.gyobfe.2008.06.022; Skakkebaek NE, 1998, APMIS, V106, P3; de Kretser D, 1998, APMIS, V106, P12; Skakkebaek N E, 1974, Acta Obstet Gynecol Scand Suppl, V29, P73120MASSON EDITEURMOULINEAUX CEDEX 921 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCEANN ENDOCRINOL-PARISMAYAJ3FN</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; CELL; CELLS; Developing gonads; DISORDERS; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL CONNECTION; GERM-CELL CANCER; HUMAN HEALTH; IN-VITRO; phthalate; POLLUTANTS; Reprotoxicity; SPERMATOGENESIS; XENOGRAFTS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>54</startpage>
    <endpage>57</endpage>
    <journalfull>Annales D Endocrinologie</journalfull>
    <issue>2</issue>
    <volume>75</volume>
    <abstract>The modern societies are exposing us to a huge variety of potentially harmful pollutants. Among these endocrine disruptors (EDs) have been especially scrutinized as several were proven to display reprotoxic effects in rodent models. In the context of high and growing concerns about the reprotoxicity of EDs, it is crucial to carry out studies in order to assess their impact on the human reproductive function. However, such evidence remains scarce. The fetal period is critical for the proper development of the testis and is known as a period of high sensitivity to many EDs. Our team has shown in 2009 that a phthalate, mono-(2-ethylhexyl) phthalate (MEHP), has a potential deleterious effect on the development of human male germ cells. This result was the first direct experimental proof of the toxic effect of an ED inhuman testis. More recently, we also reported that bisphenol A (BPA) impaired testosterone production in the human fetal testis. Here, we will summarize the known effects of EDs on the various cell types composing the human developing testis and discuss their relevancy to propose future directions. (C) 2014 Elsevier Masson SAS. All rights reserved</abstract>
    <url>WOS:000337552000005</url>
    <isbnorissn>0003-4266</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>96</id>
    <title>Neither direct nor developmental exposure to bisphenol A alters the severity of experimental inflammatory colitis in mice</title>
    <authors>Roy,A.; Gaylo,A.; Cao,W.Q.; Saubermann,L.J.; Lawrence,B.P.</authors>
    <availability>[Roy, Anirban] Bristol Myers Squibb Co, Princeton, NJ USA. [Roy, Anirban; Lawrence, B. Paige] Univ Rochester, Sch Med &amp; Dent, Dept Environm Med, Rochester, NY 14642 USA. [Gaylo, Alison; Cao, Wenqing; Lawrence, B. Paige] Univ Rochester, Sch Med &amp; Dent, Rochester, NY 14642 USA. [Saubermann, Lawrence J.] Univ Rochester, Sch Med &amp; Dent, Div Pediat Gastroenterol &amp; Nutr, Rochester, NY 14642 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleLawrence, BP (reprint author), Univ Rochester, Sch Med &amp; Dent, Dept Environm Med, 575 Elmwood Ave,Box 850, Rochester, NY 14642 USApaige_lawrence@urmc.rochester.eduBalakrishnan B, 2010, AM J OBSTET GYNECOL, V202; Bauer SM, 2012, TOXICOL SCI, V130, P82, DOI 10.1093/toxsci/kfs227; Bebo BF, 2001, J IMMUNOL, V166, P2080; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Braniste V, 2010, P NATL ACAD SCI USA, V107, P448, DOI 10.1073/pnas.0907697107; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Domoradzki JY, 2003, TOXICOL SCI, V76, P21, DOI 10.1093/toxsci/kfg206; Franks AL, 2012, ANTICANCER RES, V32, P1119; Gallo D, 2008, MENOPAUSE, V15, P718, DOI 10.1097/gme.0b013e318167b92a; Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004; Guo HC, 2010, CELL MOL IMMUNOL, V7, P227, DOI 10.1038/cmi.2010.14; Hartnett L, 2012, CARCINOGENESIS, V33, P723, DOI 10.1093/carcin/bgs006; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; IRIS-EPA, 2012, BISPH A; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kim EY, 2008, IMMUNOL LETT, V120, P1, DOI 10.1016/j.imlet.2008.07.008; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Mielke H, 2009, TOXICOL LETT, V190, P32, DOI 10.1016/j.toxlet.2009.06.861; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Molodecky NA, 2011, INFLAMM BOWEL DIS, V17, P1792, DOI 10.1002/ibd.21511; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795; Nishikawa M, 2010, ENVIRON HEALTH PERSP, V118, P1196, DOI 10.1289/ehp.0901575; NTP (National Toxicology Program), 2008, NIH PUBLICATION, V08-5994; Ohshima Y, 2007, PEDIATR RES, V62, P60, DOI 10.1203/PDR.0b013e3180674dae; Otsuka H, 2012, ANIM SCI J, V83, P232, DOI 10.1111/j.1740-0929.2011.00947.x; Qiu BS, 1999, NAT MED, V5, P1178; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Roy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038448; Sawai C, 2003, ENVIRON HEALTH PERSP, V111, P1883, DOI 10.1289/ehp.6359; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Soon IS, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-51; Uhlig HH, 2009, EUR J IMMUNOL, V39, P2021, DOI 10.1002/eji.200939602; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Westbrook AM, 2010, MUTAT RES-REV MUTAT, V705, P40, DOI 10.1016/j.mrrev.2010.03.001; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x430INFORMA HEALTHCARENEW YORK52 VANDERBILT AVE, NEW YORK, NY 10017 USAJ IMMUNOTOXICOLOCT-DECDiscipline: Toxicology255SL</notes>
    <keywords>ADULTHOOD; ALTERS; bisphenol; bisphenol A; BISPHENOL-A; BOWEL-DISEASE; BPA; CANCER; CARCINOGENESIS; CELL; DEVELOPMENTAL EXPOSURE; developmental immunotoxicity; DISEASE; ENDOCRINE; Endocrine disruptor; EXPOSURE; FOOD; HUMAN HEALTH; IMPACT; IN-VITRO; inflammatory bowel disease; MECHANISMS; MICE; MODEL; MODELS; Mouse; RATS; reference dose; T-CELLS; TISSUE; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>334</startpage>
    <endpage>340</endpage>
    <journalfull>Journal of Immunotoxicology</journalfull>
    <issue>4</issue>
    <volume>10</volume>
    <abstract>Bisphenol A (BPA) is a high production volume endocrine disrupting chemical that is widely used in many consumer products and prevalent in human biological fluids. Recent studies suggest that BPA is active even at low levels, raising concern about its potential harm to human health. Given that the main route of exposure to BPA is oral, via the consumption of BPA-tainted foods and beverages, intestinal tissues could be particularly vulnerable to BPA-induced changes. A novel examination is reported here of whether oral exposure to BPA affects inflammatory bowel disease (IBD), an immune-mediated disease of the colon, using a mouse model of inflammatory colitis. In addition to direct exposure, the possible contribution of maternal BPA exposure to disease later in life is explored. It was found that daily oral exposure to BPA at the US Environmental Protection Agency described oral reference dose (50 mg/kg/day), either via direct oral route or through maternal sources (i.e. developmental exposure), did not significantly alter disease outcomes of body weight, survival, or colonic pathology. These observations suggest that oral BPA exposure, at this dose and for this exposure duration, has minimal influence on aspects of the inflammatory response that regulate immune mediated diseases of the gastrointestinal tract</abstract>
    <url>WOS:000327260000002</url>
    <isbnorissn>1547-691X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>418</id>
    <title>Estrogen-like endocrine disrupting chemicals affecting puberty in humans - a review</title>
    <authors>Roy,J.R.; Chakraborty,S.; Chakraborty,T.R.</authors>
    <availability>[Roy, Jonathan R.; Chakraborty, Tandra R.] Adelphi Univ, Dept Biol, Garden City, NY 11530 USA. [Chakraborty, Sanjoy] New York City Coll Technol CUNY, Dept Biol Sci, New York, NY USA.</availability>
    <date>2009</date>
    <notes>JEnglishReviewChakraborty, TR (reprint author), Adelphi Univ, Dept Biol, 1 South Ave, Garden City, NY 11530 USAchakraborty@adelphi.eduAhima RS, 2008, J CLIN INVEST, V118, P2380, DOI 10.1172/JCI36284; Aksglaede L, 2006, HUM REPROD UPDATE, V12, P341, DOI 10.1093/humupd/dml018; Biro FM, 2003, CURR OPIN OBSTET GYN, V15, P347, DOI 10.1097/01/gco.0000094694.87578.1e; Biro FM, 2006, INT J ANDROL, V29, P86; Biro FM, 2006, INT J ANDROL, V29, P272, DOI 10.1111/j.1365-2605.2005.00602.x; Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Boisen KA, 2004, LANCET, V363, P1264, DOI 10.1016/S0140-6736(04)15998-9; Brody Julia Green, 2006, Environ Health, V5, P28, DOI 10.1186/1476-069X-5-28; Brody JG, 2003, ENVIRON HEALTH PERSP, V111, P1007, DOI 10.1289/ehp.6310; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BULGER WH, 1978, J TOXICOL ENV HEALTH, V4, P881; Chakraborty TR, 2003, J COMP NEUROL, V466, P409, DOI 10.1002/cne.10906; Chakraborty TR, 2003, ENDOCRINOLOGY, V144, P4164, DOI 10.1210/en.2003-0052; Clapp Richard W., 2008, Reviews on Environmental Health, V23, P1; Clark EJ, 1998, GEN COMP ENDOCR, V109, P94, DOI 10.1006/gcen.1997.7013; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Cooper RL, 1997, J ENDOCRINOL, V152, P159, DOI 10.1677/joe.0.1520159; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Den Hond E, 2006, INT J ANDROL, V29, P264, DOI 10.1111/j.1365-2605.2005.00561.x; DENHOND E, 2006, INT J ANDROL, V29, P86; Den Hond E, 2002, ENVIRON HEALTH PERSP, V110, P771; DUNKEL L, 1992, J CLIN ENDOCR METAB, V74, P890, DOI 10.1210/jc.74.4.890; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Freedman DS, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e43; Gladen BC, 2000, J PEDIATR, V136, P490, DOI 10.1016/S0022-3476(00)90012-X; Gladen BC, 2004, ENVIRON HEALTH PERSP, V112, P1761, DOI 10.1289/ehp.7287; Goldman JM, 2000, CRIT REV TOXICOL, V30, P135, DOI 10.1080/10408440091159185; Gorai I, 2003, J CLIN ENDOCR METAB, V88, P799, DOI 10.1210/jc.2002-020353; Gore AC, 2001, ENDOCRINE, V14, P235, DOI 10.1385/ENDO:14:2:235; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Grumbach MM, 2002, HORM RES, V57, P2, DOI 10.1159/000058094; Guo YLL, 2004, INT ARCH OCC ENV HEA, V77, P153, DOI 10.1007/s00420-003-0487-9; Hamilton AS, 2003, NEW ENGL J MED, V348, P2313, DOI 10.1056/NEJMoa021293; Hong HX, 2002, ENVIRON HEALTH PERSP, V110, P29; Hopenhayn-Rich C, 2002, ARCH ENVIRON CON TOX, V42, P127, DOI 10.1007/s002440010300; Howdeshell KL, 1999, NATURE, V401, P763; Howdeshell KL, 2008, ENVIRON RES, V108, P168, DOI 10.1016/j.envres.2008.08.009; HOWDESHELL KL, 1999, ENV TOXINS EXPOSURE, P763; Hutz RJ, 2006, TRENDS REPROD BIOL, V2, P1; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Jorgensen N, 2002, HUM REPROD, V17, P2199, DOI 10.1093/humrep/17.8.2199; Kadlubar FF, 2003, CANCER EPIDEM BIOMAR, V12, P327; Kaplowitz PB, 2001, PEDIATRICS, V108, P347, DOI 10.1542/peds.108.2.347; KLEIN D, 1994, BIOL REPROD, V50, P802, DOI 10.1095/biolreprod50.4.802; Kostyniak PJ, 1999, ENVIRON RES, V80, pS166, DOI 10.1006/enrs.1998.3939; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; KRISTIANSEN C, 2008, ENDOCRINE NEWS, P11; Kuhl AJ, 2005, J STEROID BIOCHEM, V96, P67, DOI 10.1016/j.jsbmb.2005.01.029; Laws SC, 2000, TOXICOL SCI, V58, P366, DOI 10.1093/toxsci/58.2.366; Lee YM, 2007, J VET SCI, V8, P27; Leffers H, 2001, HUM REPROD, V16, P1037, DOI 10.1093/humrep/16.5.1037; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703; Loomis AK, 1999, BIOL REPROD, V61, P51, DOI 10.1095/biolreprod61.1.51; Lorber M. N., 1998, ORGANOHALOGEN COMPOU, V38, P125; Loucks AB, 1998, J APPL PHYSIOL, V84, P37; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; MENDOLA P, 1920, FERTIL STERIL, V89, P8; Ojeda SR, 1999, ENDOCRINOLOGY, V140, P3774, DOI 10.1210/en.140.8.3774; Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019; Parent AS, 2005, HORM RES, V64, P41, DOI 10.1159/000087753; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Paulozzi LJ, 1999, ENVIRON HEALTH PERSP, V107, P297, DOI 10.2307/3434597; Pigneur B, 2008, MED SCI MONITOR, V14, pCR10; Pirkle JL, 1998, ENVIRON HEALTH PERSP, V106, P745, DOI 10.1289/ehp.98106745; Prete G, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-27; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002; REICH MR, 1983, AM J PUBLIC HEALTH, V73, P302, DOI 10.2105/AJPH.73.3.302; Roberts DR, 1997, EMERG INFECT DIS, V3, P295; Rogan WJ, 2003, PEDIATRICS, V112, P247; Saiyed H, 2003, ENVIRON HEALTH PERSP, V111, P1958, DOI 10.1289/ehp.6271; Salama J, 2003, ENVIRON HEALTH PERSP, V111, P1278, DOI 10.1289/ehp.6126; Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750; Schiff R, 2005, BREAST CANCER RES, V7, P205, DOI 10.1186/bcr1287; Selevan SG, 2003, NEW ENGL J MED, V348, P1527, DOI 10.1056/NEJMoa020880; Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322; Shahab M, 2005, P NATL ACAD SCI USA, V102, P2129, DOI 10.1073/pnas.0409822102; Shalitin S, 2003, INT J OBESITY, V27, P869, DOI 10.1038/sj.ijo.0802328; Solomon KR, 1996, ENVIRON TOXICOL CHEM, V15, P31, DOI 10.1897/1551-5028(1996)015&lt;0031:ERAOAI&gt;2.3.CO;2; Speroff L, 1999, CLIN GYNECOLOGIC END; Stefano G B, 2001, Med Sci Monit, V7, P1066; Stoker TE, 2000, TOXICOL SCI, V58, P50, DOI 10.1093/toxsci/58.1.50; Sugawara Teruo, 2002, Med Sci Monit, V8, pBR431; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Takeuchi S, 2005, TOXICOLOGY, V210, P223, DOI 10.1016/j.tox.2005.02.002; Tanner JM, 1975, PUBERTY BIOL PSYCHOS, V256-273; Toppari J, 2001, HUM REPROD UPDATE, V7, P282, DOI 10.1093/humupd/7.3.282; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; van den Berg PM, 2006, BEHAV GENET, V36, P261, DOI 10.1007/s10519-005-9022-y; VANDERSPUY ZM, 1985, CLIN OBSTET GYNAECOL, V12, P579; Vasiliu O, 2004, HUM REPROD, V19, P1506, DOI 10.1093/humrep/deh292; Villanueva CM, 2005, OCCUP ENVIRON MED, V62, P400, DOI 10.1136/oem.2004.016469; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; Wang YF, 2002, PEDIATRICS, V110, P903, DOI 10.1542/peds.110.5.903; Watson CS, 2003, EXP BIOL MED, V228, P1272; WHO, 2007, US DDT MAL VECT CONT; Witorsch RJ, 2002, REGUL TOXICOL PHARM, V36, P118, DOI 10.1006/rtph.2002.1564; Wong WW, 1998, J CLIN ENDOCR METAB, V83, P3574, DOI 10.1210/jc.83.10.3574; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yuri T, 2004, IN VIVO, V18, P755; Yuri T, 2006, ONCOL REP, V16, P130710351INT SCIENTIFIC LITERATURE, INCSMITHTOWN361 FOREST LANE, SMITHTOWN, NY 11787 USAMED SCI MONITORJUNDiscipline: Research &amp; Experimental Medicine467IU</notes>
    <keywords>1; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; Brain; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CENTRAL PRECOCIOUS PUBERTY; CHEMICALS; DDT; DEFECTS; development; Differentiation; DIOXIN; DISRUPTING CHEMICALS; EDC; EEDC; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; environment; Epidemiology; ESTERS; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; EXPOSURE; FLAME RETARDANTS; GROWTH; HEALTH; Hormone; Hormones; HUMANS; in vivo; IN-VIVO; JUN; menarche; METABOLISM; Obesity; P8; PBB; pediatric; PESTICIDES; phthalate; PHTHALATE-ESTERS; POLYCHLORINATED-BIPHENYLS; pre-pubertal; precocious puberty; PRODUCTS; puberty; RAT HYPOTHALAMUS; RECEPTOR; RECEPTOR-ALPHA; Receptors; REPRODUCTIVE DEVELOPMENT; RESPONSES; Review; SEXUAL-DIFFERENTIATION; SEXUAL-MATURATION; Steroid; SYSTEM; THYROID-FUNCTION; toxicology; UPDATE; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>RA137</startpage>
    <endpage>RA145</endpage>
    <journalfull>Medical Science Monitor</journalfull>
    <issue>6</issue>
    <volume>15</volume>
    <abstract>Estrogen-like endocrine disrupting chemicals (EEDC) are exogenous, man-made chemicals that alter the functions of the endocrine system and cause various health defects by interfering with the synthesis, metabolism, binding or cellular responses of natural estrogens. EEDCs have been found in various plastic products, flame retardants, pesticides and many other products that. are needed for daily use. Some of the greatest. effects of EEDCs are oil puberty, a period of rapid physiological changes like growth spurt, maturation of the gonads and the brain. Estrogen, one of the key hormones required in puberty is crucial for the sexual differentiation. The structural similarity of estrogen disruptors With estrogen allow them to bind and activate estrogen receptors and show a similar response even in the absence of estrogen that call lead to precocious puberty (PP). Major EEDCs found abundantly in our environment include; dichlorodiphenyltrichloroethane (DDT), dioxin, polychlorinated biphenyls (PCBs), bisphenol A (BPA), polybrominated biphenyls (PBB), phthalate esters, endosulfan, atrazine and zeranol. In girls, DDT has been linked to earlier menarche. Dioxin causes abnormal breast development in pre-pubertal girls. BPA has shown to cause PP in pubertal girls. PBB causes earlier menarche, thelarche and earlier pubic hair stage ill pubertal girls. PCB's showed a significant delay in puberty in pubertal boys. De-feminization, thelarche, or early secondary breast development are shown in pubertal girls when exposed to phthalate esters. Endosulfan affects pubertal boys by slowing down the timing of reproductive maturation. This article provides a possible structure-function relation of the above mentioned EEDCs which interfere with sexual development during puberty</abstract>
    <url>WOS:000267732900026</url>
    <isbnorissn>1643-3750</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>281</id>
    <title>Abnormal peripubertal development of the rat mammary gland following exposure in utero and during lactation to a mixture of genistein and the food contaminant vinclozolin</title>
    <authors>Saad,H.E.; Meduri,G.; Phrakonkham,P.; Berges,R.; Vacher,S.; Djallali,M.; Auger,J.; Canivenc-Lavier,M.C.; Perrot-Applanat,M.</authors>
    <availability>[Saad, H. El Sheikh; Perrot-Applanat, M.] Univ Paris 07, Hop Lariboisiere, INSERM, UFR Med,U965, F-75475 Paris 10, France. [Saad, H. El Sheikh; Djallali, M.; Perrot-Applanat, M.] Hop St Louis, INSERM, U553, IFR 105, F-75010 Paris, France. [Meduri, G.] Fac Med Paris Sud, INSERM, U693, F-94276 Le Kremlin Bicetre, France. [Phrakonkham, P.; Berges, R.; Canivenc-Lavier, M. C.] INRA, Ctr Sci Gout &amp; Alimentat, UMR 1324, F-21000 Dijon, France. [Vacher, S.] Hop Rene Huguenin, Inst Curie, INSERM, U735, F-92210 St Cloud, France. [Auger, J.] Hop Cochin, APHP, Serv Histol Embryol, Biol Reprod CECOS, F-75000 Paris, France.</availability>
    <date>2011</date>
    <notes>JEnglishArticlePerrot-Applanat, M (reprint author), Univ Paris 07, Hop Lariboisiere, INSERM, UFR Med,U965, 41 Bd Chapelle, F-75475 Paris 10, Francemartine.applanat@inserm.frANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Bieche I, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-37; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Bursztyka J, 2008, J AGR FOOD CHEM, V56, P4832, DOI 10.1021/jf0728045; Cameron HL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004303; Christiansen S, 2009, ENVIRON HEALTH PERSP, V117, P1839, DOI 10.1289/ehp.0900689; Cotroneo MS, 2002, CARCINOGENESIS, V23, P1467, DOI 10.1093/carcin/23.9.1467; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; DANIEL CW, 1987, CANCER RES, V47, P6052; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dimitrakakis C, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2413; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Enoch RR, 2007, ENVIRON HEALTH PERSP, V115, P541, DOI 10.1289/ehp.9612; Eustache F, 2009, ENVIRON HEALTH PERSP, V117, P1272, DOI 10.1289/ehp.0800158; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Fielden MR, 2002, TOXICOL LETT, V133, P181, DOI 10.1016/S0378-4274(02)00154-6; Foster WG, 2004, TOXICOL SCI, V77, P91, DOI 10.1093/toxsci/kfg247; Gray LE, 1999, TOXICOL IND HEALTH, V15, P48, DOI 10.1191/074823399678846646; Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630; Hilakivi-Clarke L, 2007, CURR CANCER DRUG TAR, V7, P465; Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584; Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089; Hilakivi-Clarke L, 2001, J NUTR, V131, p154S; JORDAN VC, 1990, ENDOCR REV, V11, P578; Kelly PA, 2002, MOL CELL ENDOCRINOL, V197, P127, DOI 10.1016/S0303-7207(02)00286-1; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1996, RECENT PROG HORM RES, V51, P158; Lamartiniere CA, 2002, J NUTR, V132, p552S; Latendresse JR, 2009, REPROD TOXICOL, V28, P342, DOI 10.1016/j.reprotox.2009.04.006; Lecce G, 2001, J CLIN ENDOCR METAB, V86, P1379, DOI 10.1210/jc.86.3.1379; Lehraiki A, 2011, REPROD TOXICOL, V31, P424, DOI 10.1016/j.reprotox.2010.12.005; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2001, BIOL REPROD, V65, P1215; Molina-Molina JM, 2006, TOXICOL APPL PHARM, V216, P44, DOI 10.1016/j.taap.2006.04.005; Monosson E, 1999, TOXICOL IND HEALTH, V15, P65; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Padilla-Banks E, 2006, ENDOCRINOLOGY, V147, P4871, DOI 10.1210/en.2006-0389; Pei RJ, 2003, IN VIVO, V17, P349; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; RUSSO IH, 1978, J NATL CANCER I, V61, P1439; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074; Serra J.B., 1982, IMAGE ANAL MATH MORP; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1333S; Singh M, 2000, LAB INVEST, V80, P221; Snedeker SM, 2001, ENVIRON HEALTH PERSP, V109, P35, DOI 10.2307/3434918; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062; Wang XJ, 2006, TOXICOL SCI, V91, P93, DOI 10.1093/toxsci/kfj120; Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321; Wolff MS, 1997, ENVIRON HEALTH PERSP, V105, P891, DOI 10.2307/3433299; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; You L, 2002, TOXICOL SCI, V66, P216, DOI 10.1093/toxsci/66.2.216586PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLJULDiscipline: Reproductive Biology; Toxicology799YO</notes>
    <keywords>ANDROGEN RECEPTOR; Anti-androgen; Antiandrogen; ASSOCIATION; BIOLOGY; BISPHENOL-A ALTERS; breast; breast cancer; BREAST-CANCER; BREAST-CANCER RISK; CANCER; CARCINOGENESIS; CELL; CELLS; DEFECTS; development; Differentiation; ENDOCRINE; Endocrine disruption; Endocrine disruptor; EXPOSURE; EXPRESSION; FEMALE MICE; fibrosis; FOOD; Food contaminant; GENE; genistein; Gestational and lactational exposure; GLAND; GLAND DEVELOPMENT; GROWTH; HEALTH; HYPERPLASIA; IMPACT; in vivo; IN-UTERO; IN-VIVO; LACTATIONAL EXPOSURE; low dose; mammary gland; Mammary gland development; MAMMARY-GLAND; Phytoestrogen; PHYTOESTROGEN GENISTEIN; proliferation; RAT; RATS; SPRAGUE-DAWLEY RATS; terminal end buds; toxicology; TRANSGENIC MICE; TUMORIGENESIS; Vinclozolin</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>15</startpage>
    <endpage>25</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>1</issue>
    <volume>32</volume>
    <abstract>The impact of early exposure to endocrine disruptor mixtures on mammary gland development is poorly known. Here, we identify the effects of a conception to weaning exposure of rats to the phytoestrogen genistein (G) and/or the antiandrogen vinclozolin (V) at 1 mg/kg-d, alone or in association. Using several approaches, we found that G- and GV-exposed rats displayed significantly greater epithelial branching and proliferation, wider terminal end buds than controls at PND35, as well as ductal hyperplasia and periductal fibrosis. Focal branching defects were present in V-exposed rats. An increased ER and AR expression was observed in G- and CV- as compared to V-exposed rats at PND35. Surprisingly, a significant number of CV- and to a lesser extent. V-exposed animals displayed abnormal hyperplasic alveolar structures at PND50. Thus, gestational and lactational exposure to low doses of genistein plus vinclozolin may seriously affect peripubertal development of the rat mammary gland. (C) 2011 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000293323200002</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>162</id>
    <title>In utero and lactational exposure to vinclozolin and genistein induces genomic changes in the rat mammary gland</title>
    <authors>Saad,H.E.; Toullec,A.; Vacher,S.; Pocard,M.; Bieche,I.; Perrot-Applanat,M.</authors>
    <availability>[Saad, H. El Sheikh; Toullec, A.; Pocard, M.; Perrot-Applanat, M.] Hop Lariboisiere, UFR Med, INSERM, U965, F-75475 Paris 10, France. [Saad, H. El Sheikh; Toullec, A.; Pocard, M.; Perrot-Applanat, M.] Univ Paris 07, F-75475 Paris 10, France. [Vacher, S.; Bieche, I.] Hop Rene Huguenin, Inst Curie, Lab Oncogenet, F-92210 St Cloud, France.</availability>
    <date>2013</date>
    <notes>JEnglishArticlePerrot-Applanat, M (reprint author), Hop Lariboisiere, UFR Med, INSERM, U965, 41 Bd Chapelle, F-75475 Paris 10, Francemartine.applanat@inserm.frAndersen HH, 2002, NUCL INSTRUM METH B, V187, P1; Atwood CS, 2000, J ENDOCRINOL, V167, P39, DOI 10.1677/joe.0.1670039; Badger TM, 2005, J AM COLL NUTR, V24, p146S; Bieche I, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-37; Brisken C, 2006, J MAMMARY GLAND BIOL, V11, P239, DOI 10.1007/s10911-006-9026-0; Bursztyka J, 2008, J AGR FOOD CHEM, V56, P4832, DOI 10.1021/jf0728045; Cameron HL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004303; Christiansen S, 2009, ENVIRON HEALTH PERSP, V117, P1839, DOI 10.1289/ehp.0900689; DANIEL CW, 1987, CANCER RES, V47, P6052; Dimitrakakis C, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2413; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; DURBAN EM, 1985, DEV BIOL, V109, P288, DOI 10.1016/0012-1606(85)90456-7; Enoch RR, 2007, ENVIRON HEALTH PERSP, V115, P541, DOI 10.1289/ehp.9612; Eustache F, 2009, ENVIRON HEALTH PERSP, V117, P1272, DOI 10.1289/ehp.0800158; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Foster WG, 2004, TOXICOL SCI, V77, P91, DOI 10.1093/toxsci/kfg247; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; Gray LE, 1999, TOXICOL IND HEALTH, V15, P48, DOI 10.1191/074823399678846646; Gye MC, 2003, ARCH ANDROLOGY, V49, P271, DOI [10.1080/01485010390204913, 10.1080/713828170]; Haslam SZ, 2008, ENDOCRINOLOGY, V149, P2098, DOI 10.1210/en.2007-1398; Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584; Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Hvid H, 2012, EXP TOXICOL PATHOL, V64, P321, DOI 10.1016/j.etp.2010.09.005; Hvid H, 2011, VET J, V190, P103, DOI 10.1016/j.tvjl.2010.09.002; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jager R, 2010, DEV DYNAM, V239, P1027, DOI 10.1002/dvdy.22239; Jeschke J, 2012, EPIGENETICS, V7, P7, DOI DOI 10.4161/EPI.20445; Kelce WR, 1997, TOXICOL APPL PHARM, V142, P192, DOI 10.1006/taap.1996.7966; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Korde LA, 2009, CANCER EPIDEM BIOMAR, V18, P1050, DOI 10.1158/1055-9965.EPI-08-0405; Laier P, 2006, TOXICOL APPL PHARM, V213, P160, DOI 10.1016/j.taap.2005.10.013; Lamartiniere CA, 2002, J NUTR, V132, p552S; Lehraiki A, 2011, REPROD TOXICOL, V31, P424, DOI 10.1016/j.reprotox.2010.12.005; Lemaire G, 2004, TOXICOL APPL PHARM, V196, P235, DOI 10.1016/j.taap.2003.12.011; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Markey CM, 2001, BIOL REPROD, V65, P1215; Mi HY, 2010, NUCLEIC ACIDS RES, V38, pD204, DOI 10.1093/nar/gkp1019; Molina-Molina JM, 2006, TOXICOL APPL PHARM, V216, P44, DOI 10.1016/j.taap.2006.04.005; Monosson E, 1999, TOXICOL IND HEALTH, V15, P65; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Moral R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-453; Morris JS, 2006, J CELL PHYSIOL, V206, P16, DOI 10.1002/jcp.20427; Moumen M, 2011, INT J DEV BIOL, V55, P763, DOI 10.1387/ijdb.113385mm; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897; Nikolsky Yuri, 2009, Methods Mol Biol, V563, pv; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Pei RJ, 2003, IN VIVO, V17, P349; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Peters AA, 2011, ENDOCRINOLOGY, V152, P3728, DOI 10.1210/en.2011-1133; Raymond K, 2011, EMBO J, V30, P1896, DOI 10.1038/emboj.2011.113; Robinson GW, 2007, NAT REV GENET, V8, P963, DOI 10.1038/nrg2227; RUSSO IH, 1978, J NATL CANCER I, V61, P1439; Saad HE, 2011, REPROD TOXICOL, V32, P15, DOI 10.1016/j.reprotox.2011.03.001; Schedin P, 2000, J MAMMARY GLAND BIOL, V5, P211, DOI 10.1023/A:1026447506666; Siegel PM, 2010, ONCOGENE, V29, P2753, DOI 10.1038/onc.2010.43; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Somboonporn W, 2004, ENDOCR REV, V25, P374, DOI 10.1210/er.2003-0016; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Su Y, 2011, J NUTR BIOCHEM, V22, P605, DOI 10.1016/j.jnutbio.2010.09.008; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Wang XJ, 2006, TOXICOL SCI, V91, P93, DOI 10.1093/toxsci/kfj120; Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321; Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233691BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDJ ENDOCRINOLFEBDiscipline: Endocrinology &amp; Metabolism100VU</notes>
    <keywords>ALTERS; ANDROGEN RECEPTOR; Anti-androgen; Anti-androgen vinclozolin; ANTI-ANDROGENS; bisphenol; bisphenol A; BISPHENOL-A; BISPHENOL-A ALTERS; BRANCHING MORPHOGENESIS; breast; breast cancer; BREAST-CANCER; BREAST-CANCER RISK; CANCER; CELL; CELLS; COMBINATION; CYCLE; development; Differentiation; ENDOCRINE DISRUPTORS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; epigenetic; epigenetics; Estrogen; ESTROGENS; ESTROUS-CYCLE; EXPOSURE; EXPRESSION; FOOD; gene expression; gene expression profile; GENE-EXPRESSION; GENES; genistein; GLAND; GLAND DEVELOPMENT; HEALTH; IN-UTERO; IN-VIVO; mammary gland; Mammary gland development; MAMMARY-GLAND; MAMMARY-GLANDS; mechanism; MECHANISMS; METABOLISM; MURINE MAMMARY; MYOEPITHELIAL CELL; PERINATAL EXPOSURE; PRENATAL EXPOSURE; RAT; RATS; SIGNALING PATHWAY; SIGNALING PATHWAYS; SPRAGUE-DAWLEY RATS; Steroid receptors ER,AR; steroidogenesis</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>245</startpage>
    <endpage>263</endpage>
    <journalfull>Journal of Endocrinology</journalfull>
    <issue>2</issue>
    <volume>216</volume>
    <abstract>Exposure to low doses of environmental estrogens such as bisphenol A and genistein (G) alters mammary gland development. The effects of environmental anti-androgens, such as the fungicide vinclozolin (V), on mammary gland morphogenesis are unknown. We previously reported that perinatal exposure to G, V, and the GV combination causes histological changes in the mammary gland during the peripubertal period, suggesting alterations to the peripubertal hormone response. We now investigate whether perinatal exposure to these compounds alters the gene expression profiles of the developing glands to identify the dysregulated signaling pathways and the underlying mechanisms. G, V, or GV (1 mg/kg body weight per day) was added to diet of Wistar rats, from conception to weaning; female offspring mammary glands were collected at postnatal days (PNDs) 35 and 50. Genes displaying differential expression and belonging to different functional categories were validated by quantitative PCR and immunocytochemistry. At PND35, G had little effect; the slight changes noted were in genes related to morphogenesis. The changes following exposure to V concerned the functional categories associated with development (Cldn1, Krt17, and Sprr1a), carbohydrate metabolism, and steroidogenesis. The GV mixture upregulated genes (Krt17, Pvalb, and Tnni2) involved in muscle development, indicating effects on myoepithelial cells during mammary gland morphogenesis. Importantly, at PND50, cycling females exposed to GV showed an increase in the expression of genes (Csn2, Wap, and Elf5) related to differentiation, consistent with the previously reported abnormal lobuloalveolar development previously described. Thus, perinatal exposure to GV alters the mammary gland hormone response differently at PND35 (puberty) and in animals with established cycles. Journal of Endocrinology (2013) 216, 245-263</abstract>
    <url>WOS:000315733400014</url>
    <isbnorissn>0022-0795</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>151</id>
    <title>Endocrine disruptors and falling sperm counts: lessons learned or not!</title>
    <authors>Safe,S.</authors>
    <availability>[Safe, Stephen] Texas A&amp;M Univ, Dept Vet Physiol &amp; Pharmacol, College Stn, TX 77843 USA. [Safe, Stephen] Texas A&amp;M Hlth Sci Ctr, Inst Biosci &amp; Technol, Houston, TX 77030 USA.</availability>
    <date>2013</date>
    <notes>JEnglishEditorial MaterialSafe, S (reprint author), Texas A&amp;M Univ, Dept Vet Physiol &amp; Pharmacol, College Stn, TX 77843 USAssafe@cvm.tamu.eduAllen Y, 1999, ENVIRON TOXICOL CHEM, V18, P1791, DOI 10.1897/1551-5028(1999)018&lt;1791:SOEAIU&gt;2.3.CO;2; Andersson AM, 2008, INT J ANDROL, V31, P74, DOI 10.1111/j.1365-2605.2007.00853.x; Arnold SF, 1996, SCIENCE, V272, P1489, DOI 10.1126/science.272.5267.1489; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Axelsson J, 2011, HUM REPROD, V26, P1012, DOI 10.1093/humrep/der045; Bonde JP, 2011, EPIDEMIOLOGY, V22, P617, DOI 10.1097/EDE.0b013e318223442c; Bujan L, 1996, BRIT MED J, V312, P471; CARLSEN E, 1992, BRIT MED J, V305, P609; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Desbrow C, 1998, ENVIRON SCI TECHNOL, V32, P1549, DOI 10.1021/es9707973; Ekbom A, 1996, LANCET, V347, P553, DOI 10.1016/S0140-6736(96)91190-3; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; Fisch H, 1996, FERTIL STERIL, V65, P1009; Gaido KW, 2000, MOL PHARMACOL, V58, P852; Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746; Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P686; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Handelsman DJ, 1997, HUM REPROD, V12, P2701, DOI 10.1093/humrep/12.12.2701; Jensen TK, 2004, FERTIL STERIL, V82, P863, DOI 10.1016/j.fertnstert.2004.03.056; Jorgensen N, 2011, INT J ANDROL, V34, pE37, DOI 10.1111/j.1365-2605.2010.01133.x; Kort HI, 2006, J ANDROL, V27, P450, DOI 10.2164/jandrol.05124; KRISHNAN V, 1993, TOXICOL APPL PHARM, V120, P55, DOI 10.1006/taap.1993.1086; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; NEWBOLD R, 1995, ENVIRON HEALTH PERSP, V103, P83, DOI 10.2307/3432514; Paulozzi LJ, 1999, ENVIRON HEALTH PERSP, V107, P297, DOI 10.2307/3434597; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Ramamoorthy K, 1997, SCIENCE, V275, P405, DOI 10.1126/science.275.5298.405; Ramamoorthy K, 1997, ENDOCRINOLOGY, V138, P1520, DOI 10.1210/en.138.4.1520; ROMKES M, 1988, TOXICOL APPL PHARM, V92, P368, DOI 10.1016/0041-008X(88)90177-9; ROMKES M, 1987, TOXICOL APPL PHARM, V87, P306, DOI 10.1016/0041-008X(87)90292-4; Ryan BC, 2010, TOXICOL SCI, V114, P133, DOI 10.1093/toxsci/kfp266; SAFE S, 1990, CRIT REV TOXICOL, V21, P51, DOI 10.3109/10408449009089873; Safe S, 2004, TOXICOLOGY, V205, P3, DOI 10.1016/j.tox.2004.06.032; SAFE S, 1993, LANCET, V342, P125; Safe Stephen H., 1994, Environmental Science and Pollution Research International, V1, P29, DOI 10.1007/BF02986921; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; Safe S., 1998, HORMONALLY ACTIVE AG, P253; SAFE S, 1984, CRC CR REV TOXICOL, V13, P319, DOI 10.3109/10408448409023762; Safe Stephen, 2002, Rev Environ Health, V17, P253; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SAFE SH, 1994, CRIT REV TOXICOL, V24, P87, DOI 10.3109/10408449409049308; Safe SH, 2000, ENVIRON HEALTH PERSP, V108, P487, DOI 10.2307/3454608; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sharpe RM, 2010, TOXICOL SCI, V114, P1, DOI 10.1093/toxsci/kfp299; SHARPE RM, 1995, NATURE, V375, P538, DOI 10.1038/375538a0; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905; Storgaard L, 2002, BRIT MED J, V325, P252, DOI 10.1136/bmj.325.7358.252; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; Van den Berg M, 2006, TOXICOL SCI, V93, P223, DOI 10.1093/toxsci/kfl055; Van den Berg M, 1998, ENVIRON HEALTH PERSP, V106, P775, DOI 10.1289/ehp.98106775; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; WOLFF MS, 1993, J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; Wu F, 2008, J STEROID BIOCHEM, V110, P104, DOI 10.1016/j.jsbmb.2008.02.008; Wu F, 2007, J STEROID BIOCHEM, V103, P1, DOI 10.1016/j.jsbmb.2006.07.007; Yoon K, 2001, J STEROID BIOCHEM, V78, P25, DOI 10.1016/S0960-0760(01)00070-X; Yoon K, 2000, MOL CELL ENDOCRINOL, V162, P211, DOI 10.1016/S0303-7207(99)00261-0; Younglai EV, 1998, FERTIL STERIL, V70, P76, DOI 10.1016/S0015-0282(98)00118-6612ACTA PHARMACOLOGICA SINICASHANGHAI294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINAASIAN J ANDROLMARSIDiscipline: Endocrinology &amp; Metabolism; Urology &amp; Nephrology140XV</notes>
    <keywords>BISPHENOL-A; BODY-MASS INDEX; BREAST-CANCER CELLS; CANCER; CELL; DIBENZOFURANS PCDFS; DIFFERENTIAL ACTIVATION; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; Epidemiology; ESTROGEN-RECEPTOR-ALPHA; HEALTH; HUMAN HEALTH; METABOLISM; POLYCHLORINATED-BIPHENYLS PCBS; SEMEN QUALITY; TOXIC EQUIVALENCY FACTORS; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>191</startpage>
    <endpage>194</endpage>
    <journalfull>Asian Journal of Andrology</journalfull>
    <issue>2</issue>
    <volume>15</volume>
    <url>WOS:000318690700009</url>
    <isbnorissn>1008-682X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>123</id>
    <title>Global gene expression analysis reveals pathway differences between teratogenic and non-teratogenic exposure concentrations of bisphenol A and 17 beta-estradiol in embryonic zebrafish</title>
    <authors>Saili,K.S.; Tilton,S.C.; Waters,K.M.; Tanguay,R.L.</authors>
    <availability>[Saili, Katerine S.; Tanguay, Robert L.] Oregon State Univ, Environm Hlth Sci Ctr, Dept Environm &amp; Mol Toxicol, Corvallis, OR 97331 USA. [Tilton, Susan C.; Waters, Katrina M.] Pacific NW Natl Lab, Computat Biol &amp; Bioinformat Grp, Richland, WA 99352 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleTanguay, RL (reprint author), Oregon State Univ, Dept Environm &amp; Mol Toxicol, 28645 East Hwy 34, Corvallis, OR 97333 USARobert.Tanguay@oregonstate.eduBolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335; Brion F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036069; Day KR, 2009, BLOOD CELL MOL DIS, V43, P202, DOI 10.1016/j.bcmd.2009.04.001; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Dworkin S, 2007, DEV BIOL, V307, P127, DOI 10.1016/j.ydbio.2007.04.026; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gill JS, 1998, BRAIN RES, V797, P321, DOI 10.1016/S0006-8993(98)00344-8; Gomez G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031658; Heimeier RA, 2009, ENDOCRINOLOGY, V150, P2964, DOI 10.1210/en.2008-1503; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Imanishi S, 2003, J REPROD DEVELOP, V49, P329; Ivanga M, 2007, PHYSIOL GENOMICS, V29, P13, DOI 10.1152/physiolgenomics.00291.2005; Kausch U, 2008, ENVIRON TOXICOL, V23, P15, DOI 10.1002/tox.20306; Kharat I, 1996, J BIOL CHEM, V271, P10533; KIMMEL CB, 1995, DEV DYNAM, V203, P253; Lam SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028273; Mathew LK, 2006, MOL PHARMACOL, V69, P257, DOI 10.1124/mol.105.018044; Melzer D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008673; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Nudelman AS, 2010, HIPPOCAMPUS, V20, P492, DOI 10.1002/hipo.20646; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Perera F, 2012, ENVIRON HEALTH PERSP, V120, P1190, DOI 10.1289/ehp.1104492; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Saeed AI, 2003, BIOTECHNIQUES, V34, P374; Saili KS, 2012, TOXICOLOGY, V291, P83, DOI 10.1016/j.tox.2011.11.001; Shah AR, 2007, BIOINFORMATICS, V23, P906, DOI 10.1093/bioinformatics/btm031; Shelby MD, 2008, NTP CERHR MON; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Teeguarden JG, 2011, TOXICOL SCI, V123, P48, DOI 10.1093/toxsci/kfr160; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tingaud-Sequeira A, 2004, GENE EXPR PATTERNS, V4, P561, DOI 10.1016/j.medgep.2004.02.002; Tong SK, 2009, GENESIS, V47, P67, DOI 10.1002/dvg.20459; Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Yang BH, 2004, PSYCHIAT CLIN NEUROS, V58, P262, DOI 10.1111/j.1440-1819.2004.01229.x; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102435PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLJULDiscipline: Reproductive Biology; Toxicology152MG</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ABNORMALITIES; ACTIVATION; ARYL-HYDROCARBON; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; CREB; DANIO-RERIO; DATA-MANAGEMENT; DEVELOPMENTAL EXPOSURE; DIFFERENTIALLY EXPRESSED GENES; EMBRYONIC ZEBRAFISH; Endocrine disruptor; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; gene expression; GENE-EXPRESSION; IDENTIFICATION; MESSENGER-RNA; Microarray; Prothrombin; RESPONSES; REVEALS; SIGNALING PATHWAY; SIGNALING PATHWAYS; TOXICITY; toxicology; WIDESPREAD EXPOSURE; zebrafish</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>89</startpage>
    <endpage>101</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <volume>38</volume>
    <abstract>Transient developmental exposure to 0.1 mu M bisphenol A (BPA) results in larval zebrafish hyperactivity and learning impairments in the adult, while exposure to 80 mu M BPA results in teratogenic responses, including craniofacial abnormalities and edema. The mode of action underlying these effects is unclear. We used global gene expression analysis to identify candidate genes and signaling pathways that mediate BPA's developmental toxicity in zebrafish. Exposure concentrations were selected and anchored to the positive control, 17 beta-estradiol (E2), based on previously determined behavioral or teratogenic phenotypes. Functional analysis of differentially expressed genes revealed distinct expression profiles at 24 h post fertilization for 0.1 mu M versus 80 mu M BPA and 0.1 mu M versus 15 mu M E2 exposure, identification of prothrombin activation as a top canonical pathway impacted by both 0.1 mu M BPA and 0.1 mu M E2 exposure, and suppressed expression of several genes involved in nervous system development and function following 0.1 mu M BPA exposure. (c) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000319535200010</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>246</id>
    <title>Bisphenol A and estrone-induced developmental effects in early chick embryos</title>
    <authors>Saito,K.; Niijima,A.; Kamite,E.; Watanabe,M.</authors>
    <availability>[Saito, Kenichi; Niijima, Azusa; Kamite, Eri; Watanabe, Mari] Nippon Vet &amp; Life Sci Univ, Lab Environm Hlth &amp; Food Sci, Tokyo 1808602, Japan.</availability>
    <date>2012</date>
    <notes>JEnglishArticleSaito, K (reprint author), Nippon Vet &amp; Life Sci Univ, Lab Environm Hlth &amp; Food Sci, Tokyo 1808602, Japank-saito@nvlu.ac.jpAl-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Anaharal R, 2006, ARCH HISTOL CYTOL, V69, P101, DOI 10.1679/aohc.69.101; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Azarpazhooh A, 2008, J CAN DENT ASSOC, V74, P179; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Hamburger B., 1951, J MORPHOL, V88, P49; Hyoung Un-jun, 2007, J Prev Med Public Health, V40, P155; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Liu JL, 2005, CELL TISSUE RES, V320, P235, DOI 10.1007/s00441-004-1051-y; Nakaya M, 2007, BIOSCI BIOTECH BIOCH, V71, P253, DOI 10.1271/bbb.60453; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Okada A, 2008, ASIAN J ANDROL, V10, P271, DOI 10.1111/j.1745-7262.2008.00292.x; Richter CA, 2007, ENVIRON HEALTH PERSP, V115, P902, DOI 10.1289/ehp.9804; Sakaue M, 2001, J OCCUP HEALTH, V43, P185, DOI 10.1539/joh.43.185; Toyama Y, 2004, ARCH HISTOL CYTOL, V67, P373, DOI 10.1679/aohc.67.373181WILEY-BLACKWELLMALDENCOMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USAENVIRON TOXICOLJANDiscipline: Environmental Sciences &amp; Ecology; Toxicology; Water Resources864TS</notes>
    <keywords>ABNORMALITIES; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; chick embryo; development; embryo; EMBRYOGENESIS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ESTRADIOL; estrone; EXPOSURE; EXPRESSION; FOOD; HEALTH; HUMANS; malformation; MICE; RECEPTOR; Reproduction; RISK; somites; TISSUE; toxicology; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>58</startpage>
    <endpage>62</endpage>
    <journalfull>Environmental Toxicology</journalfull>
    <issue>1</issue>
    <volume>27</volume>
    <abstract>Endocrine disruptors, especially estrogenic substances, are thought to affect the reproduction and development of animals, including humans. We therefore assessed whether bisphenol A (BPA) or estrone (E1) had any adverse effects on chick embryogenesis. Fertilized eggs of white Leghorns were obtained within 24 h after laying. Embryos were administered 0.1, 1.0, and 10.0 mM BPA, and administered 10, 100 nM, and 1 mu M E1, and incubated for 48 h at 37 +/- 0.5 degrees C and &gt;80% relative humidity with one rotation per hour. The embryos were excised, fixed in 70% ethanol and viewed under a stereomicroscope. Their morphological abnormalities and numbers of somites were recorded. There were no significant difference in the average number of somites in embryos administered BPA and controls. Abnormal embryogenesis, however, showed dose-related increases caused by BPA and E1. (C) 2011 Wiley Periodicals, Inc. Environ Toxicol, 2012</abstract>
    <url>WOS:000298263600008</url>
    <isbnorissn>1520-4081</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>425</id>
    <title>Modeling of temperature profile during magnetic thermotherapy for cancer treatment</title>
    <authors>Sawyer,C.A.; Habib,A.H.; Miller,K.; Collier,K.N.; Ondeck,C.L.; McHenry,M.E.</authors>
    <availability>[Sawyer, Carolyn A.; Habib, Ashfaque H.; Miller, Kelsey; Collier, Kelly N.; Ondeck, Courtney L.; McHenry, Michael E.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticle; Proceedings PaperSawyer, CA (reprint author), Carnegie Mellon Univ, Pittsburgh, PA 15213 USAcsawyer@andrew.cmu.eduBahadur D, 2003, SADHANA-ACAD P ENG S, V28, P639, DOI 10.1007/BF02706451; DAMBLY A, 1999, J MAGNETISM MAGNETIC, V194, P197; Ekstrand Vilhelm, 2005, Biomed Eng Online, V4, P41, DOI 10.1186/1475-925X-4-41; Habib AH, 2008, J APPL PHYS, V103, DOI 10.1063/1.2830975; Hilger I., 2005, IEE Proceedings Nanobiotechnology, V152, P33, DOI 10.1049/ip-nbt:20055018; Maenosono S, 2006, IEEE T MAGN, V42, P1638, DOI 10.1109/TMAG.2006.872198; Okawa K, 2006, J APPL PHYS, V99, DOI 10.1063/1.2173208; Rosensweig RE, 2002, J MAGN MAGN MATER, V252, P370, DOI 10.1016/S0304-8853(02)00706-0; Turgut Z, 1999, J APPL PHYS, V85, P4406, DOI 10.1063/1.36979995AMER INST PHYSICSMELVILLECIRCULATION &amp; FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USAJ APPL PHYSAPR 1Discipline: Physics453SX</notes>
    <keywords>1; bisphenol; CANCER; COMPLEXES; mechanism; MODEL; Modeling; MODELS; Nanoparticle; NANOPARTICLES; SYSTEM; TUMOR</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Journal of Applied Physics</journalfull>
    <issue>7</issue>
    <volume>105</volume>
    <abstract>Magnetic nanoparticles (MNPs) used as heat sources for cancer thermotherapy have received much recent attention. While the mechanism for power dissipation in MNPs in a rf field is well understood, a challenge in moving to clinical trials is an inadequate understanding of the power dissipation in MNP-impregnated systems and the discrepancy between the predicted and observed heating rates in the same. Here we use the Rosensweig [J. Magn. Magn. Mater. 252, 370 (2002)] model for heat generation in a single MNP, considering immediate heating of the MNPs, and the double spherical-shell heat transfer equations developed by Andr et al. [J. Magn. Magn. Mater. 194, 197 (1999)] to model the heat distribution in and around a ferrofluid sample or a tumor impregnated with MNPs. We model the heat generated at the edge of a 2.15 cm spherical sample of FeCo/(Fe, Co)(3)O(4) agglomerates containing 95 vol% MNPs with mean radius of 9 nm, dispersed at 1.5-1.6 vol% in bisphenol F. We match the model against experimental data for a similar system produced in our laboratory and find good agreement. Finite element models, extensible to more complex systems, have also been developed and checked against the analytical model and the data. (C) 2009 American Institute of Physics. [DOI: 10.1063/1.3077211]</abstract>
    <url>WOS:000266633500301</url>
    <isbnorissn>0021-8979</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>345</id>
    <title>In vitro-Ishikawa cell test for assessing tissue-specific chemical effects on human endometrium</title>
    <authors>Schaefer,W.R.; Fischer,L.; Deppert,W.R.; Hanjalic-Beck,A.; Seebacher,L.; Weimer,M.; Zahradnik,H.P.</authors>
    <availability>[Schaefer, W. R.] Univ Hosp Freiburg, Dept Obstet &amp; Gynecol, Endocrinol Lab, D-79106 Freiburg, Germany. [Weimer, M.] German Canc Res Ctr, D-6900 Heidelberg, Germany.</availability>
    <date>2010</date>
    <notes>JEnglishArticleSchaefer, WR (reprint author), Univ Hosp Freiburg, Dept Obstet &amp; Gynecol, Endocrinol Lab, Hugstetter Str 55, D-79106 Freiburg, Germanywolfgang.schaefer@uniklinik-freiburg.deAoyama H, 2005, TOXICOL APPL PHARM, V209, P226, DOI 10.1016/j.taap.2005.04.012; Bergeron RM, 1999, MOL CELL ENDOCRINOL, V150, P179, DOI 10.1016/S0303-7207(98)00202-0; Boehme K, 2009, TOXICOL APPL PHARM, V236, P85, DOI 10.1016/j.taap.2009.01.006; Bremer S, 2007, ATLA-ALTERN LAB ANIM, V35, P421; Caserta D, 2008, HUM REPROD UPDATE, V14, P59, DOI 10.1093/humupd/dmm025; de Ziegler D, 2006, CLIN OBSTET GYNECOL, V49, P93, DOI 10.1097/01.grf.0000197521.61306.51; Diedrich K, 2007, HUM REPROD UPDATE, V13, P365, DOI 10.1093/humupd/dmm011; EDWARDS RG, 1994, HUM REPROD, V9, P985; HENLEY DV, 2009, ENV HLTH PERSPECT, V11, P1702; Ibarreta D, 2001, APMIS, V109, P161, DOI 10.1034/j.1600-0463.2001.090301.x; Jabbour HN, 2006, ENDOCR REV, V27, P17, DOI 10.1210/er.2004-0021; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Johnson SM, 2007, ENDOCR-RELAT CANCER, V14, P337, DOI 10.1677/ERC-06-0085; Klotz DM, 1997, LIFE SCI, V60, P1467, DOI 10.1016/S0024-3205(97)00098-2; Krikun G, 2004, ENDOCRINOLOGY, V145, P2291, DOI 10.1210/en.2003-1606; Kumar NS, 1998, CANCER RES, V58, P1860; Lalitkumar PGL, 2007, HUM REPROD, V22, P3031, DOI 10.1093/humrep/dem297; Mendola Pauline, 2008, Fertil Steril, V89, pe81, DOI 10.1016/j.fertnstert.2007.12.036; Mirkin S, 2004, CONTRACEPTION, V70, P327, DOI 10.1016/j.contraception.2004.05.001; Naciff JM, 2009, TOXICOL SCI, V107, P40, DOI 10.1093/toxsci/kfn219; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; Overk CR, 2005, J AGR FOOD CHEM, V53, P6246, DOI 10.1021/jf050448p; RITZ C, 2005, J STAT SOFT, V12; Scippo ML, 2004, ANAL BIOANAL CHEM, V378, P664, DOI 10.1007/s00216-003-2251-0; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sharkey AM, 2003, BEST PRACT RES CL OB, V17, P289, DOI 10.1053/ybeog.2003.352; Silva E, 2006, TOXICOL APPL PHARM, V216, P20, DOI 10.1016/j.taap.2006.04.002; Sonneveld E, 2006, TOXICOL SCI, V89, P173, DOI 10.1093/toxsci/kfj009; Strowitzki T, 2006, HUM REPROD UPDATE, V12, P617, DOI 10.1093/humupd/dml033; Teklenburg G, 2009, REPROD SCI, V16, P811, DOI 10.1177/1933719109334966; Xu H, 2008, BIOTECHNOL BIOENG, V101, P1276, DOI 10.1002/bit.21991327PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLAUGSIDiscipline: Reproductive Biology; Toxicology624MK</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ADENOCARCINOMA; ASSAY; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER-CELLS; CELL; CELLS; CHEMICALS; DIETHYLSTILBESTROL; Dose-response relationship; embryo; Embryo implantation; ENDOCRINE DISRUPTORS; Endometrium; ESTRADIOL; ESTROGENIC ACTIVITIES; estrogenic effects; EXPRESSION; FOOD; GENE; Gene expression biomarker; IMPLANTATION; In vitro; IN-VITRO; LINE; METHOXYACETIC ACID; MIFEPRISTONE; Nonylphenol; progesterone; Progesterone receptor; PROGESTERONE-RECEPTOR; PROTEIN; RECEPTOR; Reporter gene assay; RISK; Risk assessment; RISK-ASSESSMENT; RT-qPCR; TARGET; toxicology; TRANSCRIPTION; UP-REGULATION; UPDATE; Uterus; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>89</startpage>
    <endpage>93</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>1</issue>
    <volume>30</volume>
    <abstract>The human endometrium is a fertility-determining factor. Its receptivity during the implantation window may be altered by chemicals. Since human embryo implantation is unique chemical risk assessment cannot be based solely on animal studies. We established a tissue-specific in vitro test based on human endometrial adenocarcinoma (Ishikawa) cells. Progesterone receptor (PR) was selected as primary target gene for estrogenic effects. Changes of mRNA levels were investigated by reverse transcription quantitative real-time PCR. Sigmoidal dose-response curves for up-regulation of PR mRNA and EC(50) values were established for 17 beta-estradiol, diethylstilbestrol and the weak xenoestrogen bisphenol A. Nonylphenol also had a clear PR mRNA up-regulating effect. Several other chemicals were characterized as negative compounds. Among them was methoxyacetic acid which may produce false positive results in reporter gene assays. Up-regulation of PR protein by 17 beta-estradiol, diethylstilbestrol, bisphenol A and nonylphenol was confirmed by Western Blotting. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000279822900012</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>346</id>
    <title>The ReProTect Feasibility Study, a novel comprehensive in vitro approach to detect reproductive toxicants</title>
    <authors>Schenk,B.; Weimer,M.; Bremer,S.; van der Burg,B.; Cortvrindt,R.; Freyberger,A.; Lazzari,G.; Pellizzer,C.; Piersma,A.; Schafer,W.R.; Seiler,A.; Witters,H.; Schwarz,M.</authors>
    <availability>[Schenk, Barbara; Schwarz, Michael] Inst Expt &amp; Clin Pharmacol &amp; Toxicol, Dept Toxicol, D-72074 Tubingen, Germany. [Weimer, Marc] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany. [Bremer, Susanne; Pellizzer, Cristian] Joint Res Ctr, Vitro Methods Unit ECVAM, Inst Hlth &amp; Consumer Protect, Ispra, Italy. [van der Burg, Bart] BioDetect Syst BV, NL-1098 XH Amsterdam, Netherlands. [Cortvrindt, Rita] EggCentris NV, B-1731 Zellik, Belgium. [Freyberger, Alexius] Bayer Schering Pharma AG, GGD GED Toxicol, Dept Pathol &amp; Clin Pathol, D-42096 Wuppertal, Germany. [Lazzari, Giovanna] AVANTEA Srl, Lab Tecnol Riproduz, I-26100 Cremona, Italy. [Piersma, Aldert] Natl Inst Publ Hlth &amp; Environm RIVM, NL-3720 BA Bilthoven, Netherlands. [Schaefer, Wolfgang R.] Univ Freiburg, Dep Obstet &amp; Gynecol, D-79106 Freiburg, Germany. [Seiler, Andrea] Ctr Alternat Methods Anim Expt ZEBET, Fed Inst Risk Assessment BFR, D-12277 Berlin, Germany. [Witters, Hilda] Flemish Inst Technol Res VITO NV, Unit Environm Risk &amp; Hlth, Toxicol Team, BE-2400 Mol, Belgium.</availability>
    <date>2010</date>
    <notes>JEnglishArticleSchwarz, M (reprint author), Inst Expt &amp; Clin Pharmacol &amp; Toxicol, Dept Toxicol, Wilhelmstr 56, D-72074 Tubingen, Germanymichael.schwarz@uni-tuebingen.deAKERIB DS, 1991, PHYS REV LETT, V67, P1692, DOI 10.1103/PhysRevLett.67.1692; Al-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; [Anonymous], 2008, EFSA J, V759, P1; Anway MD, 2006, J ANDROL, V27, P868, DOI 10.2164/jandrol.106.000349; *ATSDR, 1990, TOX PROF NITR; Bagchi G, 2008, INT J ANDROL, V31, P269, DOI 10.1111/j.1365-2605.2007.00846.x; BARANSKI B, 1983, ARCH TOXICOL, V54, P297, DOI 10.1007/BF01234482; Barone F, 2005, REPROD BIOL ENDOCRIN, V3, P1, DOI 10.1186/1477-7827-3-13; Berckmans P, 2007, TOXICOL IN VITRO, V21, P1262, DOI 10.1016/j.tiv.2007.04.018; Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007; Beyersmann D, 2008, ARCH TOXICOL, V82, P493, DOI 10.1007/s00204-008-0313-y; Bitsch A, 2006, REGUL TOXICOL PHARM, V46, P202, DOI 10.1016/j.yrtph.2006.05.013; Bovee TFH, 2007, ANAL BIOANAL CHEM, V389, P1549, DOI 10.1007/s00216-007-1559-6; Bovee TFH, 2008, J STEROID BIOCHEM, V108, P121, DOI 10.1016/j.jsbmb.2007.05.035; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Can A, 2005, MOL HUM REPROD, V11, P389, DOI 10.1093/molehr/gah179; Can A, 1997, MUTAT RES-FUND MOL M, V373, P139, DOI 10.1016/S0027-5107(96)00184-4; Can ALP, 1997, MOL REPROD DEV, V46, P351; CARTER SD, 1987, BIOL REPROD, V37, P709, DOI 10.1095/biolreprod37.3.709; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Chi MMY, 2002, AM J PHYSIOL-ENDOC M, V283, pE226, DOI 10.1152/ajpendo.00046.2002; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Cortvrindt RG, 2002, HUM REPROD UPDATE, V8, P243, DOI 10.1093/humupd/8.3.243; Denier X, 2008, MAR ENVIRON RES, V66, P108, DOI 10.1016/j.marenvres.2008.02.038; Denier X, 2009, TOXICOL IN VITRO, V23, P569, DOI 10.1016/j.tiv.2009.01.006; Dent MP, 2007, REGUL TOXICOL PHARM, V48, P241, DOI 10.1016/j.yrtph.2007.04.001; DEVINE PJ, 2010, CORTVRINDT IN VITRO; DODD DE, 1987, FUND APPL TOXICOL, V8, P493, DOI 10.1016/0272-0590(87)90135-7; EBERT E, 1990, FOOD CHEM TOXICOL, V28, P339, DOI 10.1016/0278-6915(90)90108-Y; EFSA, 2006, EFSA J, V428, P1, DOI DOI 10.2903/J.EFSA.2007A28; Eichenlaub-Ritter U, 2008, MUTAT RES-GEN TOX EN, V651, P82, DOI 10.1016/j.mrgentox.2007.10.014; Eikel D, 2006, CHEM RES TOXICOL, V19, P272, DOI 10.1021/tx0502241; *ENV DIR, 2008, JOINT M CHEM COMM WO, V16, P1; *EU, 2003, 80057 EU CAS EUR CHE; *EU, 2006, OFFICIAL J EU L, V353, P1; *EU, 2008, 4 4 IS BISPH A; FOSTER PMD, 1984, ENVIRON HEALTH PERSP, V57, P207, DOI 10.2307/3429918; Freyberger A, 2010, REPROD TOXICOL, V30, P50, DOI 10.1016/j.reprotox.2010.01.001; Freyberger A, 2010, REPROD TOXICOL, V30, P2, DOI 10.1016/j.reprotox.2009.10.001; Freyberger Alexius, 2005, Arhiv za Higijenu Rada i Toksikologiju, V56, P131; Freyberger A, 2010, REPROD TOXICOL, V30, P9, DOI 10.1016/j.reprotox.2009.10.002; Fujii T, 1997, CANCER CAUSE CONTROL, V8, P524, DOI 10.1023/A:1018477809755; Gallot D, 2005, BIRTH DEFECTS RES A, V73, P523, DOI 10.1002/dbra.20151; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; Genschow E, 2004, ATLA-ALTERN LAB ANIM, V32, P209; Glatt H, 2004, CARCINOGENESIS, V25, P779, DOI 10.1093/carcin/bgh070; Goodman J, 2009, CRIT REV TOXICOL, V39, P1, DOI 10.3109/10408440903279946; Goodman JE, 2006, CRIT REV TOXICOL, V36, P387, DOI 10.1080/10408440600758317; GRAY LE, 1983, TOXICOL APPL PHARM, V67, P1, DOI 10.1016/0041-008X(83)90239-9; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; GRAY LE, 1990, FUND APPL TOXICOL, V15, P281, DOI 10.1016/0272-0590(90)90055-O; GROLLMAN A, 1962, J CLIN INVEST, V41, P710, DOI 10.1172/JCI104529; Guengerich FP, 2007, CHEM RES TOXICOL, V20, P344, DOI 10.1021/tx600260a; Gupta K, 2004, BIOCHEMISTRY-US, V43, P6645, DOI 10.1021/bi036112v; Haberle J, 2006, J INHERIT METAB DIS, V29, P352, DOI 10.1007/s10545-006-0256-5; HARDIN BD, 1983, TOXICOLOGY, V27, P91, DOI 10.1016/0300-483X(83)90014-8; Hengstler JG, 1999, DRUG METAB REV, V31, P917, DOI 10.1081/DMR-100101946; Hettwer M, 2010, REPROD TOXICOL, V30, P113, DOI 10.1016/j.reprotox.2010.01.009; Hsu CH, 2007, J ENVIRON SCI HEAL C, V25, P155, DOI 10.1080/10590500701399234; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; *IPCS, 1983, PEST RES FOOD 1983; IWASE T, 1996, TERATOLOGY, V54, pA12; IZUMI HKE, COMBINED REPEAT DOSE; JANARDHAN A, 1984, B ENVIRON CONTAM TOX, V33, P257; Janer G, 2007, REPROD TOXICOL, V24, P103, DOI 10.1016/j.reprotex.2007.05.004; Jansen MS, 2004, P NATL ACAD SCI USA, V101, P7199, DOI 10.1073/pnas.0402014101; Jeffay SC, 1996, REPROD TOXICOL, V10, P183, DOI 10.1016/0890-6238(96)00020-2; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Kang IH, 2004, TOXICOLOGY, V199, P145, DOI 10.1016/j.tox.2004.02.019; Kawashima Kunio, 1995, Journal of Toxicological Sciences, V20, P15; Kelce WR, 1997, TOXICOL APPL PHARM, V142, P192, DOI 10.1006/taap.1996.7966; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; KHERA KS, 1993, TERATOLOGY, V47, P299, DOI 10.1002/tera.1420470407; Kim HS, 2002, TOXICOL LETT, V135, P111, DOI 10.1016/S0378-4274(02)00130-3; Kim JC, 2001, LIFE SCI, V69, P2611, DOI 10.1016/S0024-3205(01)01341-8; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kojima H, 2004, ENVIRON HEALTH PERSP, V112, P524; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; LAMB JC, 1997, ENVIRON HEALTH PER S, V105, P227; Lane M, 1997, J ASSIST REPROD GEN, V14, P398, DOI 10.1007/BF02766148; Lazzari G, 2008, TOXICOL APPL PHARM, V233, P360, DOI 10.1016/j.taap.2008.08.019; Lemeire K, 2007, TOXICOL IN VITRO, V21, P1348, DOI 10.1016/j.tiv.2007.05.004; Lenie S, 2008, MUTAT RES-GEN TOX EN, V651, P71, DOI 10.1016/j.mrgentox.2007.10.017; Lu SY, 2004, J TOXICOL ENV HEAL A, V67, P1501, DOI 10.1080/15287390490486833; Luciano AM, 2010, REPROD TOXICOL, V30, P81, DOI 10.1016/j.reprotox.2010.01.015; MANSON JM, 1986, ENVIRON HEALTH PERSP, V70, P137, DOI 10.2307/3430350; Martinez-Campa C, 2006, J PINEAL RES, V40, P291, DOI 10.1111/j.1600-079X.2006.00315.x; Marx-Stoelting P, 2009, ATLA-ALTERN LAB ANIM, V37, P313; Matsuura Ikuo, 2005, Journal of Toxicological Sciences, V30, P163; Mitsumori Kunitoshi, 1994, Journal of Toxicological Sciences, V19, P141; Mlynarcikova A, 2009, TOXICOL IN VITRO, V23, P371, DOI 10.1016/j.tiv.2008.12.017; Molina-Molina JM, 2006, TOXICOL APPL PHARM, V216, P44, DOI 10.1016/j.taap.2006.04.005; Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182; MORRISEY RE, 1987, FUND APPL TOXICOL, V8, P571, DOI 10.1016/0272-0590(87)90142-4; Nishino T, 2006, J STEROID BIOCHEM, V98, P155, DOI 10.1016/j.jsbmb.2005.08.019; Noble BR, 2007, AM J PHYSIOL-LUNG C, V293, pL1079, DOI 10.1152/ajplung.00286.2007; OHARA GP, 1983, TOXICOLOGY, V28, P323, DOI 10.1016/0300-483X(83)90006-9; Okubo T, 2004, ARCH ENVIRON CON TOX, V46, P445, DOI 10.1007/s00244-003-3017-6; OSTBY JS, 1985, TOXICOLOGY, V34, P285, DOI 10.1016/0300-483X(85)90139-8; Pacchierotti F, 2006, CURR PHARM DESIGN, V12, P1489, DOI 10.2174/138161206776389859; Pacchierotti F, 2008, MUTAT RES-GEN TOX EN, V651, P64, DOI 10.1016/j.mrgentox.2007.10.009; PADMANABHAN R, 1986, Z MIKROSK ANAT FORSC, V100, P419; PADMANABHAN R, 1986, J CRAN GENET DEV BIO, V6, P245; Paksy K, 1996, Acta Physiol Hung, V84, P119; Pazos P, 2010, REPROD TOXICOL, V30, P161, DOI 10.1016/j.reprotox.2010.04.001; Piersma AH, 2004, ATLA-ALTERN LAB ANIM, V32, P275; Pottenger LH, 2000, TOXICOL SCI, V54, P3, DOI 10.1093/toxsci/54.1.3; Rajeswary S, 2007, REPROD TOXICOL, V24, P371, DOI 10.1016/j.reprotox.2007.03.010; RASJAD C, 1991, Hiroshima Journal of Medical Sciences, V40, P101; RASJAD C, 1991, Hiroshima Journal of Medical Sciences, V40, P93; *REG AAFTSAD, 1990, TOX PROF NITR; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rider CV, 2009, ENVIRON TOXICOL CHEM, V28, P2175, DOI 10.1897/09-018.1; RITTER EJ, 1985, TERATOLOGY, V32, P25, DOI 10.1002/tera.1420320105; SAKSENA SK, 1982, CONTRACEPTION, V26, P181, DOI 10.1016/0010-7824(82)90086-5; SAKSENA SK, 1979, ENDOKRINOLOGIE, V74, P6; Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012; Salian S, 2009, LIFE SCI, V85, P742, DOI 10.1016/j.lfs.2009.10.004; Salvatori F, 2004, NEUROTOXICOL TERATOL, V26, P673, DOI 10.1016/j.ntt.2004.05.001; Schaefer WR, 2010, REPROD TOXICOL, V30, P89, DOI 10.1016/j.reprotox.2010.02.002; Schneider S, 2008, REPROD TOXICOL, V25, P352, DOI 10.1016/j.reprotox.2008.04.001; Schonfelder G, 2004, NEOPLASIA, V6, P584, DOI 10.1593/neo.04217; Schulte-Hermann R., 2006, Regulatory Toxicology and Pharmacology, V44, P1, DOI 10.1016/j.yrtph.2006.01.008; Seiler Andrea E. M., 2006, V329, P371; Shin JH, 2006, ARCH TOXICOL, V80, P547, DOI 10.1007/s00204-006-0080-6; Silva E, 2006, TOXICOL APPL PHARM, V216, P20, DOI 10.1016/j.taap.2006.04.002; Sitarek K, 2001, TERATOGEN CARCIN MUT, V21, P335, DOI 10.1002/tcm.1021; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Sonneveld E, 2005, TOXICOL SCI, V83, P136, DOI 10.1093/toxsci/kfi005; Spielmann H, 2006, ATLA-ALTERN LAB ANIM, V34, P365; Spielmann H, 2008, ATLA-ALTERN LAB ANIM, V36, P715; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; Sun H, 2006, FOOD CHEM TOXICOL, V44, P1916, DOI 10.1016/j.fct.2006.06.013; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; SUTOU S, 1980, ECOTOX ENVIRON SAFE, V4, P51, DOI 10.1016/0147-6513(80)90007-X; Takabashi O, 2001, ARCH TOXICOL, V75, P42, DOI 10.1007/s002040000204; Team RDC, 2009, R LANG ENV STAT COMP; Thevenod F, 2009, TOXICOL APPL PHARM, V238, P221, DOI 10.1016/j.taap.2009.01.013; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Tyl RW, 2008, TOXICOL SCI, V104, P362, DOI 10.1093/toxsci/kfn084; TYL RW, 1987, FUND APPL TOXICOL, V8, P482, DOI 10.1016/0272-0590(87)90134-5; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; Uibel F, 2010, REPROD TOXICOL, V30, P103, DOI 10.1016/j.reprotox.2009.12.002; Uzumcu M, 2004, REPROD TOXICOL, V18, P765, DOI 10.1016/j.reprotox.2004.05.008; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; van der Burg B, 2010, REPROD TOXICOL, V30, P18, DOI 10.1016/j.reprotox.2010.04.012; van der Burg B, 2010, REPROD TOXICOL, V30, P73, DOI 10.1016/j.reprotox.2010.04.007; Van Merris V, 2007, REPROD TOXICOL, V23, P32, DOI 10.1016/j.reprotox.2006.08.008; Van Wemmel K, 2005, REPROD TOXICOL, V20, P183, DOI 10.1016/j.reprotox.2005.01.009; Verwei M, 2006, TOXICOL LETT, V165, P79, DOI 10.1016/j.toxlet.2006.01.017; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Wade MG, 2008, BIOL REPROD, V78, P822, DOI 10.1095/biolreprod.107.065151; Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6; Watanabe T, 1996, TERATOGEN CARCIN MUT, V16, P287; Watanabe T, 1997, NEUROSCI LETT, V222, P17, DOI 10.1016/S0304-3940(97)13330-4; WELSCH F, 1987, Journal of Biochemical Toxicology, V2, P225, DOI 10.1002/jbt.2570020307; Willhite CC, 2008, J TOXICOL ENV HEAL B, V11, P69, DOI 10.1080/10937400701724303; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; Witters H, 2010, REPROD TOXICOL, V30, P60, DOI 10.1016/j.reprotox.2010.02.008; Wolf CJ, 2000, TOXICOL SCI, V55, P152, DOI 10.1093/toxsci/55.1.152; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Yamada T, 2005, TOXICOL APPL PHARM, V205, P11, DOI 10.1016/j.taap.2004.09.002; Yamasaki K, 2002, ARCH TOXICOL, V76, P65, DOI 10.1007/s00204-001-0319-1; Zang Y, 2009, TOXICOL LETT, V184, P134, DOI 10.1016/j.toxlet.2008.10.03216535PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLAUGSIDiscipline: Reproductive Biology; Toxicology624MK</notes>
    <keywords>Alternative reproductive toxicity testing; analysis; ANDROGEN RECEPTOR; ASSAY; BIOLOGY; BIRTH; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CHEMICALS; CONGENITAL DIAPHRAGMATIC-HERNIA; DEFECTS; development; Developmental toxicity; DIETARY BISPHENOL-A; Embryotoxicity; Endocrine disruption; ENDOCRINE DISRUPTOR VINCLOZOLIN; ETHYLENE-GLYCOL MONOMETHYL; Feasibility; fertility; FOOD; FRAMEWORK; FUTURE; GLUFOSINATE-AMMONIUM; HEALTH; Hershberger assay; In vitro; In vitro tests; in vivo; IN-VITRO; IN-VIVO; Neoplasia; PHARMACOLOGY; PREDICTION; Reproductive toxicology; Ring trial; SPRAGUE-DAWLEY RATS; Steroid; Test battery; TOXICITY; toxicology; UPDATE; VITRO; VITRO APPROACH; VIVO; Weight of evidence</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>200</startpage>
    <endpage>218</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>1</issue>
    <volume>30</volume>
    <abstract>ReProTect is a project within the 6th European Framework Program which has developed alternative methods aimed to reduce or replace animal experimentation in the field of reproductive toxicology. In its final year, a ring trial, named the "Feasibility Study", was conducted, in which 10 blinded chemicals with toxicologically well-documented profiles were analyzed by employing a test battery of 14 in vitro assays. EC(50) (half maximal effective concentration) or equivalent endpoints were determined and the test compounds were ranked relative to chemicals previously assayed in the tests of the battery. This comparative analysis together with a weight of evidence approach allowed a robust prediction of adverse effects on fertility and embryonic development of the 10 test chemicals in vivo. In summary, the vast majority of the predictions made based on the in vitro results turned out to be correct when compared to the whole animal data. The procedure used here, a nearest neighbor analysis coupled with a weight of evidence approach, may guide future activities in the field of alternative toxicity testing. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000279822900021</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>93</id>
    <title>Transcriptome alterations in zebrafish embryos after exposure to environmental estrogens and anti-androgens can reveal endocrine disruption</title>
    <authors>Schiller,V.; Wichmann,A.; Kriehuber,R.; Schafers,C.; Fischer,R.; Fenske,M.</authors>
    <availability>[Schiller, Viktoria; Wichmann, Arne; Fischer, Rainer; Fenske, Martina] Fraunhofer Inst Mol Biol &amp; Appl Ecol, D-52074 Aachen, Germany. [Schaefers, Christoph] Fraunhofer Inst Mol Biol &amp; Appl Ecol, D-57392 Schmallenberg, Germany. [Kriehuber, Ralf] Forschungszentrum Julich, Dept Safety &amp; Radiat Protect, D-52425 Julich, Germany.</availability>
    <date>2013</date>
    <notes>JEnglishArticleSchiller, V (reprint author), Fraunhofer Inst Mol Biol &amp; Appl Ecol, Forckenbeckstr 6, D-52074 Aachen, Germanyschiller@molbiotech.rwth-aachen.deALEXANDER HC, 1988, ENVIRON TOXICOL CHEM, V7, P19, DOI 10.1897/1552-8618(1988)7[19:BAAAT]2.0.CO;2; Al-Shahrour F, 2005, NUCLEIC ACIDS RES, V33, pW460, DOI 10.1093/nar/gki456; Andersen HH, 2002, NUCL INSTRUM METH B, V187, P1; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; Ankley GT, 2010, ENVIRON TOXICOL CHEM, V29, P730, DOI 10.1002/etc.34; Ankley GT, 2004, ENVIRON SCI TECHNOL, V38, P6322, DOI 10.1021/es040022b; Arukwe A, 2001, MAR POLLUT BULL, V42, P643, DOI 10.1016/S0025-326X(01)00062-5; Ashby J, 1998, ENVIRON HEALTH PERSP, V106, P719, DOI 10.1289/ehp.98106719; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BARNES S, 1995, P SOC EXP BIOL MED, V208, P103; Basak S, 2008, MOL CANCER THER, V7, P3195, DOI 10.1158/1535-7163.MCT-08-0617; Bauer ERS, 1998, ANALYST, V123, P2485, DOI 10.1039/a804606i; Bayley M, 2002, AQUAT TOXICOL, V56, P227, DOI 10.1016/S0166-445X(01)00210-7; Bektic J, 2004, EUR UROL, V45, P245, DOI 10.1016/j.eururo.2003.09.001; Belfroid AC, 1999, SCI TOTAL ENVIRON, V225, P101, DOI 10.1016/S0048-9697(98)00336-2; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; BRANTLEY RK, 1993, HORM BEHAV, V27, P332, DOI 10.1006/hbeh.1993.1025; Brown NM, 1998, MOL CELL ENDOCRINOL, V144, P149, DOI 10.1016/S0303-7207(98)00106-3; Campos VF, 2010, J BIOSCIENCES, V35, P405, DOI 10.1007/s12038-010-0046-y; Chakrabarty S, 2012, COMP BIOCHEM PHYS C, V155, P491, DOI 10.1016/j.cbpc.2011.12.007; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Chen WF, 2007, BRIT J NUTR, V98, P1120, DOI 10.1017/S0007114507777139; CYPRIANI B, 1988, BIOCHIM BIOPHYS ACTA, V972, P167, DOI 10.1016/0167-4889(88)90115-2; Daftary GS, 2006, ENDOCR REV, V27, P331, DOI 10.1210/er.2005-0018; D'Amico L, 2007, CURR BIOL, V17, P252, DOI 10.1016/j.cub.2006.12.023; Dang PMC, 2006, J CLIN INVEST, V116, P2033, DOI 10.1172/JCI27544; DelGiacco L, 1998, MOL REPROD DEV, V49, P58; Di XD, 2012, EXP MOL MED, V44, P281, DOI 10.3858/emm.2012.44.4.024; DICKSON RB, 1981, ENDOCRINOLOGY, V108, P1511; Ding H, 2003, BIOCHEM BIOPH RES CO, V305, P950, DOI 10.1016/S0006-291X(03)00873-8; Efron B, 2009, ANN APPL STAT, V3, P922, DOI 10.1214/09-AOAS236; Evangelou A, 2000, CANCER RES, V60, P929; Fenske M, 2005, ENVIRON TOXICOL CHEM, V24, P1088, DOI 10.1897/04-096R1.1; Filby AL, 2007, AQUAT TOXICOL, V81, P219, DOI 10.1016/j.aquatox.2006.12.003; Fisher J S, 1999, Environ Health Perspect, V107, P397, DOI 10.2307/3434544; Fritz WA, 2002, MOL CELL ENDOCRINOL, V186, P89, DOI 10.1016/S0303-7207(01)00663-3; FURUYA S, 1994, AM J REPROD IMMUNOL, V31, P116; Gaikwad A, 2005, NEUROSCIENCE, V133, P267, DOI 10.1016/j.neuroscience.2004.12.052; Gordon JD, 2004, ORGANOHALOGEN COMPD, V66, P169; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; Green GC, 2008, J FISH BIOL, V72, P1095; Hashimoto S, 2009, ARCH ENVIRON CON TOX, V56, P253, DOI 10.1007/s00244-008-9183-9; Hatef A, 2012, ECOTOX ENVIRON SAFE, V76, P56, DOI 10.1016/j.ecoenv.2011.09.021; Haubruge E, 2000, P ROY SOC B-BIOL SCI, V267, P2333, DOI 10.1098/rspb.2000.1288; Haut JE, 2005, EFFECT ESTRADIOL 17; Herbig U, 1999, MOL BIOL CELL, V10, P2631; Hoffmann JL, 2006, AQUAT TOXICOL, V79, P233, DOI 10.1016/j.aquatox.2006.06.009; Hofmeister MV, 2004, TOXICOL IN VITRO, V18, P427, DOI 10.1016/j.tiv.2003.12.008; Jensen KM, 2004, AQUAT TOXICOL, V70, P99, DOI 10.1016/j.aquatox.2004.06.012; Jones JI, 1995, ENDOCR REV, V6, P3, DOI DOI 10.1210/ER.16.1.3.PUBMED:7758431; Kamangar BB, 2006, ENDOCRINOLOGY, V147, P2399, DOI 10.1210/en.2005-1570; Kang JH, 2007, CRIT REV TOXICOL, V37, P607, DOI 10.1080/10408440701493103; Kawamura T, 2002, ZOOL SCI, V19, P1355, DOI 10.2108/zsj.19.1355; Kelce WR, 1998, REPROD FERT DEVELOP, V10, P105, DOI 10.1071/R98051; KELCE WR, 1995, RECENT PROG HORM RES, V50, P449; Kelce WR, 1997, TOXICOL APPL PHARM, V142, P192, DOI 10.1006/taap.1996.7966; Kelley KM, 2002, J ENDOCRINOL, V175, P3, DOI 10.1677/joe.0.1750003; Kim DJ, 2009, TOXICOL MECH METHOD, V19, P251, DOI 10.1080/15376510802563330; Kim GL, 2010, ENDOCRINOLOGY, V151, P5038, DOI 10.1210/en.2010-0521; Kinnberg K, 2007, COMP BIOCHEM PHYS C, V145, P165, DOI 10.1016/j.cbpc.2006.11.002; Kiparissis Y, 2003, ENVIRON HEALTH PERSP, V111, P1158, DOI 10.1289/ehp.5928; Kishida M, 2001, COMP BIOCHEM PHYS B, V129, P261, DOI 10.1016/S1096-4959(01)00319-0; KOCH H, 1984, Drugs of Today, V20, P561; Kojima S, 2004, J UROLOGY, V171, P679, DOI 10.1097/01.ju.0000106190.32540.6c; Kramer VJ, 2011, ENVIRON TOXICOL CHEM, V30, P64, DOI 10.1002/etc.375; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuch HM, 2000, FRESEN J ANAL CHEM, V366, P392, DOI 10.1007/s002160050080; Lambright C, 2000, TOXICOL SCI, V56, P389, DOI 10.1093/toxsci/56.2.389; Lemer DT, 2007, ENVIRON TOXICOL CHEM, V26, P1433; Leskinen P, 2005, CHEMOSPHERE, V61, P259, DOI 10.1016/j.chemosphere.2005.01.080; Lin CC, 2004, J BIOMED SCI, V11, P377, DOI 10.1159/000077107; Maertens JA, 2004, CLIN MICROBIOL INFEC, V10, P1, DOI 10.1111/j.1470-9465.2004.00841.x; Makynen EA, 2000, AQUAT TOXICOL, V48, P461, DOI 10.1016/S0166-445X(99)00059-4; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Martinovic-Weigelt D, 2011, AQUAT TOXICOL, V101, P447, DOI 10.1016/j.aquatox.2010.10.003; Martyniuk CJ, 2007, AQUAT TOXICOL, V84, P38, DOI 10.1016/j.aquatox.2007.05.012; Mathavan S, 2005, PLOS GENET, V1, P260, DOI 10.1371/journal.pgen.0010029; Medina I, 2010, NUCLEIC ACIDS RES, V38, pW210, DOI 10.1093/nar/gkq388; MICCIO M, 1989, BIOCHEM PHARMACOL, V38, P3559, DOI 10.1016/0006-2952(89)90128-7; Mikula P, 2006, NEUROENDOCRINOL LETT, V27, P104; Mikula P, 2009, ACTA VET BRNO, V78, P319, DOI 10.2754/avb200978020319; Mitani Y, 2010, ENDOCRINOLOGY, V151, P1751, DOI 10.1210/en.2009-1174; Montgomery TM, 2012, ENV TOXICOL; Muncke J, 2006, ENVIRON TOXICOL CHEM, V25, P2734, DOI 10.1897/05-683R.1; Nakagawa Y, 2000, ARCH TOXICOL, V74, P99, DOI 10.1007/s002040050659; Norbeck LA, 2011, GEN COMP ENDOCR, V173, P270, DOI 10.1016/j.ygcen.2011.06.009; Noriega NC, 2005, BIOL REPROD, V72, P1324, DOI 10.1095/biolreprod.104.031385; OECD, 2006, PROP NEW GU IN PRESS; OECD, 2009, OECD GUID TEST CHEM; OECD, 2006, REP IN WORK VAL 21 D, V60; OECD, 1992, OECD GUID TEST CHEM; Ohkimoto K, 2003, BIOCHEM BIOPH RES CO, V309, P7, DOI 10.1016/S0006-291X(03)01524-9; Onichtchouk D, 2003, DEV DYNAM, V228, P393, DOI 10.1002/dvdy.10392; Onuma TA, 2011, J NEUROSCI, V31, P11814, DOI 10.1523/JNEUROSCI.6804-10.2011; Orton F, 2009, ENVIRON SCI TECHNOL, V43, P2144, DOI 10.1021/es8028928; Orton F, 2011, ENVIRON HEALTH PERSP, V119, P794, DOI [10.1289/ehp.1002895, 10.1289/ehp.1002897]; Pandey DP, 2009, EMBO J, V28, P523, DOI 10.1038/emboj.2008.304; Panter GH, 2004, AQUAT TOXICOL, V70, P11, DOI 10.1016/j.aquatox.2004.06.007; PENG C, 1994, ENDOCRINOLOGY, V134, P1095, DOI 10.1210/en.134.3.1095; Peretz J, 2011, TOXICOL SCI, V119, P209, DOI 10.1093/toxsci/kfq319; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen G, 2001, J BIOL CHEM, V276, P10178, DOI 10.1074/jbc.M006967200; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pihlajamaa P, 2011, ENDOCRINOLOGY, V152, P4395, DOI 10.1210/en.2011-0221; Polkowski K, 2000, Acta Pol Pharm, V57, P135; Prusakiewicz JJ, 2007, TOXICOLOGY, V232, P248, DOI 10.1016/j.tox.2007.01.010; Pugazhendhi D, 2005, J APPL TOXICOL, V25, P301, DOI 10.1002/jat.1066; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Purdom C.E., 1994, Chemistry and Ecology, V8, P275, DOI 10.1080/02757549408038554; Rajakumar A, 2012, AQUAT TOXICOL, V110, P123, DOI 10.1016/j.aquatox.2011.12.018; Rime H, 2010, TOXICOL SCI, V118, P61, DOI 10.1093/toxsci/kfq255; ROSENBERG ZR, 2000, CLIN CHEM, V46, P887; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Russell W.M.S., 1959, PRINCIPLES HUMANE EX; Salazar KD, 2006, TOXICOL SCI, V93, P62, DOI 10.1093/toxsci/kfl038; Sassi-Messai S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004935; Schiller V, 2013, COMP BIOCHEM PHYS C, V157, P41, DOI 10.1016/j.cbpc.2012.09.005; Schmidt F, 2008, ONCOL REP, V19, P1061; Scholz S, 2004, MAR ENVIRON RES, V57, P235, DOI 10.1016/S0141-1136(03)00082-5; Scholz S, 2008, MOL CELL ENDOCRINOL, V293, P57, DOI 10.1016/j.mce.2008.06.008; Scornaienchi ML, 2010, J ENDOCRINOL, V206, P317, DOI 10.1677/JOE-10-0075; Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharpe RL, 2007, GEN COMP ENDOCR, V151, P34, DOI 10.1016/j.ygcen.2006.11.005; Shepherd BS, 2007, COMP BIOCHEM PHYS A, V146, P390, DOI 10.1016/j.cbpa.2006.11.004; Shved N, 2008, TOXICOL SCI, V106, P93, DOI 10.1093/toxsci/kfn150; Simon FR, 1996, AM J PHYSIOL-GASTR L, V271, pG1043; Skolness SY, 2011, AQUAT TOXICOL, V103, P170, DOI 10.1016/j.aquatox.2011.02.016; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Sohoni P, 2001, J APPL TOXICOL, V21, P173, DOI 10.1002/jat.747; Soni MG, 2002, FOOD CHEM TOXICOL, V40, P1335, DOI 10.1016/S0278-6915(02)00107-2; Sosic-Jurjevic B, 2010, EXP BIOL MED, V235, P590, DOI 10.1258/ebm.2009.009279; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tao J, 2009, CELL CALCIUM, V45, P133, DOI 10.1016/j.ceca.2008.07.004; Tavares RS, 2009, REPROD TOXICOL, V27, P1, DOI 10.1016/j.reprotox.2008.10.002; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; Taylor HS, 1999, J CLIN ENDOCR METAB, V84, P1129, DOI 10.1210/jc.84.3.1129; Thorpe JL, 2004, DEV CELL, V6, P295, DOI 10.1016/S1534-5807(04)00032-2; Trump DL, 2001, UROLOGY, V57, P64, DOI 10.1016/S0090-4295(00)00943-2; Tseng HP, 2005, TOXICOL APPL PHARM, V205, P247, DOI 10.1016/j.taap.2004.10.019; US EPA, 2009, FISH SHORT TERM REPR, V7101; Van den Belt K, 2003, SCI TOTAL ENVIRON, V309, P127, DOI 10.1016/S0048-9697(03)00046-9; van Meeuwen JA, 2008, TOXICOL APPL PHARM, V230, P372, DOI 10.1016/j.taap.2008.03.002; Vinggaard AM, 2002, TOXICOL SCI, V69, P344, DOI 10.1093/toxsci/69.2.344; Ward DR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005322; White R, 1998, ENDOCR-RELAT CANCER, V5, P1, DOI 10.1677/erc.0.0050001; YAGER JD, 1994, CARCINOGENESIS, V15, P2117, DOI 10.1093/carcin/15.10.2117; Ye LP, 2011, TOXICOL LETT, V207, P137, DOI 10.1016/j.toxlet.2011.09.001; Yu ZL, 2005, BIOCHEM BIOPH RES CO, V333, P827, DOI 10.1016/j.bbrc.2005.05.177; Zhang Luling, 2003, Journal of Herbal Pharmacotherapy, V3, P33, DOI 10.1300/J157v03n03_04; Zhang LL, 2002, COMP BIOCHEM PHYS C, V132, P203, DOI 10.1016/S1532-0456(02)00067-41532PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLDECDiscipline: Reproductive Biology; Toxicology260BD</notes>
    <keywords>17 alpha-Ethinylestradiol; Anti-androgen; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; CHEMICALS; DANIO-RERIO; DOWN-REGULATES ANDROGEN; ENDOCRINE; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; ENVIRONMENTAL CHEMICALS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ESTRADIOL; Estrogen; ESTROGENS; EXPOSURE; FACTOR-BINDING-PROTEIN; Flutamide; FOOD; genistein; GROWTH-FACTOR; HUMAN HEALTH; In vitro; IN-VITRO; mechanism; MEDAKA ORYZIAS-LATIPES; MINNOW PIMEPHALES-PROMELAS; Reproduction; TOXICITY; toxicology; Transcriptomics; TROUT ONCORHYNCHUS-MYKISS; VITRO; Y GENE-EXPRESSION; zebrafish; Zebrafish embryo</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>210</startpage>
    <endpage>223</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <volume>42</volume>
    <abstract>Exposure to environmental chemicals known as endocrine disruptors (EDs) is in many cases associated with an unpredictable hazard for wildlife and human health. The identification of endocrine disruptive properties of chemicals certain to enter the aquatic environment relies on toxicity tests with fish, assessing adverse effects on reproduction and sexual development. The demand for quick, reliable ED assays favored the use of fish embryos as alternative test organisms. We investigated the application of a transcriptomics-based assay for estrogenic and anti-androgenic chemicals with zebrafish embryos. Two reference compounds, 17 alpha-ethinylestradiol and flutamide, were tested to evaluate the effects on development and the transcriptome after 48 h-exposures. Comparison of the transcriptome response with other estrogenic and anti-androgenic compounds (genistein, bisphenol A, methylparaben, linuron, prochloraz, propanil) showed commonalities and differences in regulated pathways, enabling us to classify the estrogenic and anti-androgenic potencies. This demonstrates that different mechanism of ED can be assessed already in fish embryos. (C) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000327569100023</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>238</id>
    <title>Organic Synthetic Environmental Endocrine Disruptors: Structural Classes and Metabolic Fate</title>
    <authors>Schmidt,J.; Masic,L.P.</authors>
    <availability>[Schmidt, Jan; Masic, Lucija Peterlin] Univ Ljubljana, Fac Pharm, Ljubljana 1000, Slovenia.</availability>
    <date>2012</date>
    <notes>JEnglishReviewMasic, LP (reprint author), Univ Ljubljana, Fac Pharm, Askerceva 7, Ljubljana 1000, Slovenialucija.peterlin@ffa.uni-lj.siAhmed S, 2009, TOXICOL SCI, V111, P254, DOI 10.1093/toxsci/kfp144; Al-Ansari AM, 2010, ENVIRON POLLUT, V158, P2566, DOI 10.1016/j.envpol.2010.05.020; Alyea RA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-59; AMARA JF, 1983, ENDOCRINOLOGY, V112, P1141; Anderson P. D., 2005, TECHNICAL BRIEF ENDO, P11; Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; Anwaar I, 2000, J INTERN MED, V247, P463, DOI 10.1046/j.1365-2796.2000.00613.x; Ashek A, 2006, CHEMOSPHERE, V65, P521, DOI 10.1016/j.chemosphere.2006.01.010; ATKINSON A, 1995, BIOCHEM BIOPH RES CO, V210, P424, DOI 10.1006/bbrc.1995.1678; Balakrishnan B, 2011, PLACENTA, V32, P788, DOI 10.1016/j.placenta.2011.07.014; Balfe PJ, 2004, EJSO, V30, P1043, DOI 10.1016/j.ejso.2004.06.019; Beedanagari SR, 2010, MOL PHARMACOL, V78, P608, DOI 10.1124/mol.110.064899; Biskobing DM, 2007, CLIN INTERV AGING, V2, P299; Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx70019Ip; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bussmann UA, 2006, BIOL REPROD, V75, P360, DOI 10.1095/biolreprod.106.053017; Buters JTM, 2002, CHEM RES TOXICOL, V15, P1127, DOI 10.1021/tx020017q; Cavalieri E, 2006, BBA-REV CANCER, V1766, P63, DOI 10.1016/k.bbcan.2006.03.001; Cavalieri E, 2006, ANN NY ACAD SCI, V1089, P286, DOI 10.1196/annals.1386.042; Cavalieri EL, 2002, CARCINOGENESIS, V23, P329, DOI 10.1093/carcin/23.2.329; Chae K, 1998, STEROIDS, V63, P149, DOI 10.1016/S0039-128X(97)00158-X; Colditz GA, 1998, J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Contardo-Jara V, 2011, ENVIRON POLLUT, V159, P38, DOI 10.1016/j.envpol.2010.09.028; CZUCZWA JM, 1984, ENVIRON SCI TECHNOL, V18, P444, DOI 10.1021/es00124a010; Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573; Desta Z, 2004, J PHARMACOL EXP THER, V310, P1062, DOI 10.1124/jpet.104.065607; Dipple A., 1984, ACS MONOGR SER, V182, P41; Dipple A., 1976, ACS MONOGR SER, V173, P245; Dowers TS, 2006, CHEM RES TOXICOL, V19, P1125, DOI 10.1021/tx060126v; Drayer D. E., 1988, DRUG STEREOCHEMISTRY, P271; El-Ka-di A. O., 2012, TOXICOL LETT, V208, P51; Elsby R, 2001, J PHARMACOL EXP THER, V296, P329; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Fang H, 2001, CHEM RES TOXICOL, V14, P280, DOI 10.1021/tx000208y; Fertuck KC, 2001, TOXICOL LETT, V121, P167, DOI 10.1016/S0378-4274(01)00344-7; Fink BE, 1999, CHEM BIOL, V6, P205, DOI 10.1016/S1074-5521(99)80037-4; FISHMAN J, 1960, J BIOL CHEM, V235, P3104; FOX TO, 1975, P NATL ACAD SCI USA, V72, P4303, DOI 10.1073/pnas.72.11.4303; Fracchiolla NS, 2011, TOXICOLOGY, V283, P18, DOI 10.1016/j.tox.2011.01.025; FUJIIKURIYAMA Y, 2010, P JPN ACAD B PHYS, V86, P40, DOI DOI 10.2183/PJAB.86.40; Furukawa K, 1995, ENVIRON HEALTH PERSP, V103, P21, DOI 10.2307/3432472; Gallegos A, 2001, J COMPUT AID MOL DES, V15, P67, DOI 10.1023/A:1011150003086; Ghosh A., 2007, END DISR PHARM STRAT, P1; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hammes B, 2003, J MIDWIFERY WOM HEAL, V48, P19, DOI 10.1016/S1526-9523(02)00370-7; Han GZ, 2005, CANCER RES, V65, P387; Haraguchi K, 2005, DRUG METAB DISPOS, V33, P373, DOI 10.1124/dmd.104.002444; HENDERSON BE, 1988, CANCER RES, V48, P246; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Hinrichs B, 2011, J STEROID BIOCHEM, V127, P276, DOI 10.1016/j.jsbmb.2011.08.009; Hiratsuka M, 2000, BIOL PHARM BULL, V23, P1131; Jacob J, 2006, MOL CELL ENDOCRINOL, V246, P34, DOI 10.1016/j.mce.2005.11.015; Jaeg JP, 2004, J AGR FOOD CHEM, V52, P4935, DOI 10.1021/jf049762u; JELLINCK PH, 1984, J STEROID BIOCHEM, V21, P361, DOI 10.1016/0022-4731(84)90297-8; JELLINCK PH, 1988, BIOCHEMISTRY-US, V27, P6111, DOI 10.1021/bi00416a042; JELLINCK PH, 1984, ENDOCRINOLOGY, V115, P1850; JELLINCK PH, 1984, STEROIDS, V43, P559, DOI 10.1016/S0039-128X(84)90192-2; Jerina D.M., 1977, ORIGINS HUMAN CANCER, P639; Jin Y, 2005, J NATL CANCER I, V97, P30, DOI 10.1093/jnci/dji005; Kalfa N, 2011, FERTIL STERIL, V95, P2574, DOI 10.1016/j.fertnstert.2011.02.047; Kania-Korwel I, 2008, FOOD CHEM TOXICOL, V46, P637, DOI 10.1016/j.fct.2007.09.072; Kanno Y, 2008, MOL CELL ENDOCRINOL, V291, P87, DOI 10.1016/j.mce.2008.05.004; KATZENELLENBOGEN BS, 1979, ENDOCRINOLOGY, V105, P33; Khetawat G, 2000, BLOOD, V95, P2289; Kim SY, 2005, CHEM RES TOXICOL, V18, P889, DOI 10.1021/tx0500191; Kitamura S, 2002, DRUG METAB DISPOS, V30, P113, DOI 10.1124/dmd.30.2.113; Klecka GM, 2001, ENVIRON TOXICOL CHEM, V20, P2725, DOI 10.1897/1551-5028(2001)020&lt;2725:BOBAIA&gt;2.0.CO;2; KUPFER D, 1990, CHEM RES TOXICOL, V3, P8, DOI 10.1021/tx00013a002; Lakhani NJ, 2003, PHARMACOTHERAPY, V23, P165, DOI 10.1592/phco.23.2.165.32088; Lasserre JP, 2009, J PROTEOME RES, V8, P5485, DOI 10.1021/pr900480f; Lee AJ, 2003, ENDOCRINOLOGY, V144, P3382, DOI 10.1210/en.2003-0192; Li XD, 2004, MOL CELL BIOL, V24, P7681, DOI 10.1128/MCB.24.17.4681-7689.2004; Lieberman S, 2008, J STEROID BIOCHEM, V109, P197, DOI 10.1016/j.jsbmb.2008.02.001; Lin JH, 1997, PHARMACOL REV, V49, P403; LIPPMAN M, 1976, CANCER RES, V36, P4595; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; Liu H, 2006, CHEM RES TOXICOL, V19, P779, DOI 10.1021/tx050326r; LUSTIG RH, 1989, ENDOCRINOLOGY, V125, P2701; Mesia-Vela S, 2002, CARCINOGENESIS, V23, P1369, DOI 10.1093/carcin/23.8.1369; Meyer MR, 2011, VASC PHARMACOL, V55, P17, DOI 10.1016/j.vph.2011.06.003; Monroe DG, 2005, MOL ENDOCRINOL, V19, P1555, DOI 10.1210/me.2004-0381; MONTANO MM, 1995, BIOL REPROD, V53, P1198, DOI 10.1095/biolreprod53.5.1198; Moro L, 2005, BLOOD, V105, P115, DOI 10.1182/blood-2003-11-3840; Nakagawa Y, 2001, XENOBIOTICA, V31, P113; Newbold RR, 2000, CANCER RES, V60, P235; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; Oesterreich S, 2001, CANCER RES, V61, P5771; Ohe T, 2000, DRUG METAB DISPOS, V28, P110; Ohtake F, 2011, J STEROID BIOCHEM, V127, P102, DOI 10.1016/j.jsbmb.2011.03.007; Okoh V, 2011, BBA-REV CANCER, V1815, P115, DOI 10.1016/j.bbcan.2010.10.005; Oros D. R., 2002, SAN FRANCISCO ESTUAR, P19; PAKDEL F, 1989, MOL ENDOCRINOL, V3, P44; Palumbo AJ, 2009, ENVIRON TOXICOL CHEM, V28, P1749, DOI 10.1897/08-481.1; Pieper DH, 2008, J MOL MICROB BIOTECH, V15, P121, DOI 10.1159/000121325; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Pike ACW, 2006, BEST PRACT RES CL EN, V20, P1, DOI 10.1016/j.beem.2005.09.002; Powell E, 2008, P NATL ACAD SCI USA, V105, P19012, DOI 10.1073/pnas.0807274105; Powell E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030993; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Prossnitz ER, 2007, MOL CELL ENDOCRINOL, V265, P138, DOI 10.1016/j.mce.2006.12.010; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; PULLMAN A, 1955, ADV CANCER RES, V3, P117, DOI 10.1016/S0065-230X(08)60919-7; Pullman A., 1946, REV SCI, V&lt;IT&gt;84&lt;/IT&gt;, P145; Raftogianis R., 2000, J NATL CANC I MONOGR, V27, P113; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Roy J., 2011, ENDOCR REV, V&lt;IT&gt;32&lt;/IT&gt;, P1; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Sanderson JT, 2002, TOXICOL APPL PHARM, V182, P44, DOI 10.1006/taap.2002.9420; Sanderson JT, 2001, ENVIRON HEALTH PERSP, V109, P1027, DOI 10.2307/3454957; Schafer S. G., 2008, LEHRBUCH TOXIKOLIGIE, P684; Schmidt O, 1939, Z PHYS CHEM B-CHEM E, V42, P83; Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n; Shimizu M, 2002, TOXICOL IN VITRO, V16, P549, DOI 10.1016/S0887-2333(02)00055-3; Simonich SLM, 2011, CHEM-BIOL INTERACT, V192, P26, DOI 10.1016/j.cbi.2010.09.013; Soechitram SD, 2004, ENVIRON HEALTH PERSP, V112, P1208, DOI 10.1289/ehp.6424; SOULE HD, 1973, J NATL CANCER I, V51, P1409; Spencer WA, 2009, CHEM RES TOXICOL, V22, P81, DOI 10.1021/tx8001675; Spink DC, 2001, CHEM RES TOXICOL, V14, P572, DOI 10.1021/tx000219r; Sumbayev VV, 2008, MOL CELL ENDOCRINOL, V287, P30, DOI 10.1016/j.mce.2008.02.004; Sumbayev VV, 2005, FEBS LETT, V579, P541, DOI 10.1016/j.febslet.2004.12.025; Sun W.L., 2006, WATER AIR SOIL POLL, V6, P583, DOI 10.1007/s11267-006-9043-4; SWANECK GE, 1988, P NATL ACAD SCI USA, V85, P7831, DOI 10.1073/pnas.85.21.7831; Swedenborg E, 2008, MOL PHARMACOL, V73, P575, DOI 10.1124/mol.107.036384; Swedenborg E, 2012, MOL CELL ENDOCRINOL, V362, P39, DOI 10.1016/j.mce.2012.05.006; Taioli E, 1999, CANCER DETECT PREV, V23, P232, DOI 10.1046/j.1525-1500.1999.09912.x; TAYLOR JA, 1995, BREAST CANCER RES TR, V34, P265, DOI 10.1007/BF00689718; Tedesco R, 2001, CHEM BIOL, V8, P277, DOI 10.1016/S1074-5521(01)00006-0; Tezuka Y, 2007, J HEALTH SCI, V53, P552, DOI 10.1248/jhs.53.552; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Toran-Allerand CD, 2004, EXP GERONTOL, V39, P1579, DOI 10.1016/j.exger.2004.05.006; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; Valiman F. A., 2009, CLEAN, V&lt;IT&gt;37&lt;/IT&gt;, P277; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; vom Saal F S, 1989, J Anim Sci, V67, P1824; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Walsh DE, 2005, MOL CELL ENDOCRINOL, V230, P23, DOI 10.1016/j.mce.2004.11.006; Wang K, 2012, CHEM RES TOXICOL, V25, P1740, DOI 10.1021/tx3001994; Wang LR, 2009, TOXICOLOGY, V262, P250, DOI 10.1016/j.tox.2009.06.015; Wang ZC, 2010, CHEM RES TOXICOL, V23, P1365, DOI 10.1021/tx1001282; Wang ZC, 2009, CHEM RES TOXICOL, V22, P1129, DOI 10.1021/tx900063g; WELSHONS WV, 1987, EUR J CANCER CLIN ON, V23, P1935, DOI 10.1016/0277-5379(87)90062-9; Welshons WV, 1999, TOXICOL IND HEALTH, V15, P12, DOI 10.1191/074823399678846745; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; WELSHONS WV, 1995, J CELL PHYSIOL, V165, P134, DOI 10.1002/jcp.1041650116; WELSHONS WV, 1987, BREAST CANCER RES TR, V10, P169, DOI 10.1007/BF01810580; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; WIESE TE, 1995, STEROIDS, V60, P802, DOI 10.1016/0039-128X(95)00143-E; Wilson AM, 2001, CARCINOGENESIS, V22, P257, DOI 10.1093/carcin/22.2.257; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Xing YN, 2009, ENVIRON POLLUT, V157, P1382, DOI 10.1016/j.envpol.2008.11.034; Yoshihara S, 2004, TOXICOL SCI, V78, P50, DOI 10.1093/toxsci/kfh047; Yoshihara S, 2001, TOXICOL SCI, V62, P221, DOI 10.1093/toxsci/62.2.221; Yu HP, 2007, J LEUKOCYTE BIOL, V82, P774, DOI 10.1189/jlb.0307182; Zhu BT, 2005, STEROIDS, V70, P225, DOI 10.1016/j.steroids.2005.01.0021571SLOVENSKO KEMIJSKO DRUSTVOLJUBLJANAHAJDRIHOVA 19, LJUBLJANA 1000, SLOVENIAACTA CHIM SLOVDiscipline: Chemistry066DB</notes>
    <keywords>Aryl hydrocarbon receptor; aryl hydrocarbon receptor (AhR); ARYL-HYDROCARBON; ARYL-HYDROCARBON RECEPTOR; Biotransformation; BISPHENOL-A; BLOOD; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CHEMICALS; Cytotoxicity; DES; EDCs; ENDOCRINE; Endocrine disrupting compounds; endocrine disrupting compounds (EDCs); Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; Estrogen; Estrogen receptor; Estrogen receptors; estrogen receptors (ERs); ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; FOOD; GENOTOXICITY; HEALTH; HORMONE REPLACEMENT THERAPY; Hormones; HUMAN-BREAST-CANCER; In vitro; IN-VITRO; Interaction; LIGAND-BINDING DOMAIN; LIVER S9 FRACTION; MEMBRANE ESTROGEN-RECEPTORS; METABOLISM; METABOLITES; p21; p38; P8; PLACENTA; PLASMA; POLYCYCLIC AROMATIC-HYDROCARBONS; PROTEIN-COUPLED RECEPTOR; reactive metabolites; RECEPTOR; RISK; SYSTEM; TERM TISSUE-CULTURE; toxicology; VITRO; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>722</startpage>
    <endpage>738</endpage>
    <journalfull>Acta Chimica Slovenica</journalfull>
    <issue>4</issue>
    <volume>59</volume>
    <abstract>Endocrine disruption is the modification of the endocrine system causing harmful effects in healthy subjects or their offspring. Physiological endocrine hormones act at very low plasma concentrations, and certain chemicals known as endocrine disrupting compounds (EDCs) are suspected of modifying endocrine function at similarly low concentrations. In our review we focus mainly on the structural classes of organic synthetic environmental endocrine disruptors and their common structural elements that enable them to interact with estrogen signalling. EDCs can affect estrogenic signalling directly through interaction with estrogen receptors (ERs) or indirectly through transcription factors such as the aryl hydrocarbon receptor (AhR) or by modulation of critical metabolic enzymes engaged in estrogen biosynthesis and metabolism. However, some structural elements can also pose a great risk of cytotoxicity and genotoxicity, especially after biotransformation to reactive metabolites</abstract>
    <url>WOS:000313199100002</url>
    <isbnorissn>1318-0207</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>297</id>
    <title>Environmentally relevant low dose exposure with bisphenol A leads to the disruption of e-cadherin and mediates epithelial-mesenchymal transition in breast cancer cells</title>
    <authors>Schonfelder,G.; Blaschuk,O.W.; Gehrand,B.</authors>
    <availability>[Schoenfelder, G.; Gehrand, B.] Charite, Inst Klin Pharmakol &amp; Toxikol, D-13353 Berlin, Germany. [Blaschuk, O. W.] McGill Univ, Urol Res Labs, Montreal, PQ, Canada.</availability>
    <date>2011</date>
    <notes>JEnglishMeeting Abstract00SPRINGERNEW YORK233 SPRING ST, NEW YORK, NY 10013 USAN-S ARCH PHARMACOLMAR1Discipline: Pharmacology &amp; Pharmacy737MO</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; E-CADHERIN; epithelial mesenchymal transition; EPITHELIAL-MESENCHYMAL TRANSITION; EXPOSURE; low dose; PHARMACOLOGY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>96</startpage>
    <endpage>97</endpage>
    <journalfull>Naunyn-Schmiedebergs Archives of Pharmacology</journalfull>
    <volume>383</volume>
    <url>WOS:000288573100488</url>
    <isbnorissn>0028-1298</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>90</id>
    <title>Bisphenol A Binds to Ras Proteins and Competes with Guanine Nucleotide Exchange: Implications for GTPase-Selective Antagonists</title>
    <authors>Schopel,M.; Jockers,K.F.G.; Duppe,P.M.; Autzen,J.; Potheraveedu,V.N.; Ince,S.; Yip,K.T.; Heumann,R.; Herrmann,C.; Scherkenbeck,J.; Stoll,R.</authors>
    <availability>[Schoepel, Miriam; Jockers, Katharina F. G.; Potheraveedu, Veena N.; Ince, Semra; Yip, King Tuo; Heumann, Rolf; Herrmann, Christian; Stoll, Raphael] Ruhr Univ Bochum, Fac Chem &amp; Biochem, D-44780 Bochum, Germany. [Dueppe, Peter M.; Autzen, Jasmin; Scherkenbeck, Juergen] Univ Wuppertal, Fac Chem, D-42119 Wuppertal, Germany.</availability>
    <date>2013</date>
    <notes>JEnglishArticleScherkenbeck, J (reprint author), Univ Wuppertal, Fac Chem, Gaussstr 20, D-42119 Wuppertal, Germanyscherkenbeck@uni-wuppertal.de; raphael.stoll@ruhr-uni-bochum.deAspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Berghaus C, 2007, BIOMOL NMR ASSIGM, V1, P45, DOI 10.1007/s12104-007-9013-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Braun JM, 2011, CURR OPIN PEDIATR, V23, P233, DOI 10.1097/MOP.0b013e3283445675; Chakrabarty K, 2007, EUR J NEUROSCI, V25, P1971, DOI 10.1111/j.1460-9568.2007.05457.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano WL, 2002, PYMOL MOL GRAPHICS S; DeSimone RW, 2004, COMB CHEM HIGH T SCR, V7, P473; Deutschmann A, 2013, MOL PHARMACOL, V83, P501, DOI 10.1124/mol.112.081372; De Vries SJ, 2007, PROTEINS, V69, P726, DOI 10.1002/prot.21723; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Ehrkamp Anja, 2013, Cancers (Basel), V5, P639, DOI 10.3390/cancers5020639; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Hall M N, 2008, Transplant Proc, V40, pS5, DOI 10.1016/j.transproceed.2008.10.009; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karassek S, 2010, J BIOL CHEM, V285, P33979, DOI 10.1074/jbc.M109.095968; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Maurer T, 2012, P NATL ACAD SCI USA, V109, P5299, DOI 10.1073/pnas.1116510109; Palmioli A, 2009, BIOORG MED CHEM LETT, V19, P4217, DOI 10.1016/j.bmcl.2009.05.107; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rehmann H, 2008, FEBS LETT, V582, P3005, DOI 10.1016/j.febslet.2008.07.057; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Rosnizeck IC, 2012, ANGEW CHEM INT EDIT, V51, P10647, DOI 10.1002/anie.201204148; Scheffzek K, 2005, CELL MOL LIFE SCI, V62, P3014, DOI 10.1007/s00018-005-5136-x; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Simonson T., 1998, ACTA CRYSTALLOGR D, V54, P905; Slebos RJC, 2000, CANCER EPIDEM BIOMAR, V9, P1223; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Sun Q, 2012, ANGEW CHEM INT EDIT, V51, P6140, DOI 10.1002/anie.201201358; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vo U, 2013, BIOMOL NMR ASSIGN, V7, P215, DOI 10.1007/s12104-012-9413-y; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449; Wang WR, 2012, BIOORG MED CHEM LETT, V22, P5766, DOI 10.1016/j.bmcl.2012.07.082; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Zhang BL, 2005, BIOCHEMISTRY-US, V44, P2566, DOI 10.1021/bi048755w472AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USAJ MED CHEMDEC 12Discipline: Pharmacology &amp; Pharmacy273IY</notes>
    <keywords>ACTIVATION; AFFINITIES; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CELL; cell death; CELL-DEATH; DEATH; DRUG DISCOVERY; environment; EXPOSURE; GAP; GROWTH; inhibition; Interaction; K-RAS; MECHANISMS; NMR; PROTEIN; PROTEINS; RHEB; TSC2; TUMOR-GROWTH</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>9664</startpage>
    <endpage>9672</endpage>
    <journalfull>Journal of Medicinal Chemistry</journalfull>
    <issue>23</issue>
    <volume>56</volume>
    <abstract>We show for the first time that bisphenol A (10) has the capacity to interact directly with K-Ras and that Rheb weakly binds to bisphenol A (10) and 4,4'-biphenol derivatives. We have characterized these interactions at atomic resolution suggesting that these compounds sterically interfere with the Sos-mediated nucleotide exchange in H- and K-Ras. We show that 4,4'-biphenol (5) selectively inhibits Rheb signaling and induces cell death suggesting that this compound might be a novel candidate for treatment of tuberous sclerosis-mediated tumor growth. Our results propose a new mode of action for bisphenol A (10) that advocates a reduced exposure to this compound in our environment. Our data may lay the foundation for the future design of GTPase-selective antagonists with higher affinity to benefit of the treatment of cancer because K-Ras inhibition is regarded to be a promising strategy with a potential therapeutic window for targeting Sos in Ras-driven tumors</abstract>
    <url>WOS:000328529700024</url>
    <isbnorissn>0022-2623</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>139</id>
    <title>Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells</title>
    <authors>Sengupta,S.; Obiorah,I.; Maximov,P.Y.; Curpan,R.; Jordan,V.C.</authors>
    <availability>[Sengupta, S.; Obiorah, I.; Maximov, P. Y.; Jordan, V. C.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA. [Curpan, R.] Acad Romana, Inst Chem, Timisoara, Romania.</availability>
    <date>2013</date>
    <notes>JEnglishArticleJordan, VC (reprint author), Georgetown Univ, Med Ctr, 3970 Reservoir Rd NW, Washington, DC 20057 USAvcj2@georgetown.eduAriazi EA, 2011, P NATL ACAD SCI USA, V108, P18879, DOI 10.1073/pnas.1115188108; Bentrem D, 2003, CANCER RES, V63, P7490; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bourgoin-Voillard S, 2010, BIOCHEM PHARMACOL, V79, P746, DOI 10.1016/j.bcp.2009.10.015; Gao L, 2012, J PHYS CHEM B, V116, P4823, DOI 10.1021/jp300895g; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Hu ZZ, 2011, PLOS ONE, V6; JIANG SY, 1992, MOL CELL ENDOCRINOL, V90, P77, DOI 10.1016/0303-7207(92)90104-E; JORDAN VC, 1993, BRIT J PHARMACOL, V110, P507; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; JORDAN VC, 1984, MOL PHARMACOL, V26, P279; JORDAN VC, 1986, BRIT J PHARMACOL, V87, P217; Jordan VC, 2001, CANCER RES, V61, P6619; JORDAN VC, 1984, MOL PHARMACOL, V26, P272; Jordan VC, 2011, HORM MOL BIOL CLIN I, V5, P27, DOI 10.1515/HMBCI.2010.047; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Labhart P, 2005, P NATL ACAD SCI USA, V102, P1339, DOI 10.1073/pnas.0409578102; Levenson AS, 1998, BRIT J CANCER, V77, P1812, DOI 10.1038/bjc.1998.301; Levenson AS, 1997, J STEROID BIOCHEM, V60, P261, DOI 10.1016/S0960-0760(96)00184-7; Lewis JS, 2005, J NATL CANCER I, V97, P1746, DOI 10.1093/jnci/dji400; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; MacGregor Schafer J, 2000, CANCER RES, V60, P5097; Maximov PY, 2010, J MED CHEM, V53, P3273, DOI 10.1021/jm901907u; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Sengupta S, 2008, ADV EXP MED BIOL, V630, P206; Sengupta S., 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; WOLF DM, 1994, BREAST CANCER RES TR, V31, P129, DOI 10.1007/BF006896833411WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USABRIT J PHARMACOLMAYDiscipline: Pharmacology &amp; Pharmacy127EJ</notes>
    <keywords>4-HYDROXYTAMOXIFEN; ALPHA; Antagonist; ANTIESTROGENS; antioestrogens; apoptosis; BINDING; bisphenol; bisphenol A; bisphenol and bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; CHIP; CLASSIFICATION; COACTIVATOR AIB1; ESTRADIOL; GROWTH; LIGAND; LIGAND-BINDING DOMAIN; LIGANDS; mechanism; molecular docking; molecular mechanism; oestrogen; oestrogen receptor; PHARMACOLOGY; PROLACTIN SYNTHESIS INVITRO; proliferation; RECEPTOR; RECEPTOR-ALPHA; RECRUITMENT; RESISTANT; RESPONSES; TAMOXIFEN; triphenylethylenes</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>167</startpage>
    <endpage>178</endpage>
    <journalfull>British Journal of Pharmacology</journalfull>
    <issue>1</issue>
    <volume>169</volume>
    <abstract>Background and Purpose Oestrogen receptor alpha (ER) binds to different ligand which can function as complete/partial oestrogen-agonist or antagonist. This depends on the chemical structure of the ligands which modulates the transcriptional activity of the oestrogen-responsive genes by altering the conformation of the liganded-ER complex. This study determined the molecular mechanism of oestrogen-agonistic/antagonistic action of structurally similar ligands, bisphenol (BP) and bisphenol A (BPA) on cell proliferation and apoptosis of ER + ve breast cancer cells. Experimental Approach DNA was measured to assess the proliferation and apoptosis of breast cancer cells. RT-PCR and ChIP assays were performed to quantify the transcripts of TFF1 gene and recruitment of ER and SRC3 at the promoter of TFF1 gene respectively. Molecular docking was used to delineate the binding modes of BP and BPA with the ER. PCR-based arrays were used to study the regulation of the apoptotic genes. Key Results BP and BPA induced the proliferation of breast cancer cells; however, unlike BPA, BP failed to induce apoptosis. BPA consistently acted as an agonist in our studies but BP exhibited mixed agonistic/antagonistic properties. Molecular docking revealed agonistic and antagonistic mode of binding for BPA and BP respectively. BPA treatment resembled E2 treatment in terms of PCR-based regulation of apoptotic genes whereas BP was similar to 4OHT treatment. Conclusions and Implications The chemical structure of ER ligand determines the agonistic or antagonistic biological responses by the virtue of their binding mode, conformation of the liganded-ER complex and the context of the cellular function</abstract>
    <url>WOS:000317679000013</url>
    <isbnorissn>0007-1188</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>308</id>
    <title>Endocrine Disrupting Chemicals Targeting Estrogen Receptor Signaling: Identification and Mechanisms of Action</title>
    <authors>Shanle,E.K.; Xu,W.</authors>
    <availability>[Xu, Wei] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA. [Shanle, Erin K.; Xu, Wei] Univ Wisconsin, Mol &amp; Environm Toxicol Ctr, Madison, WI 53706 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewXu, W (reprint author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USAwxu@oncology.wisc.eduAbdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Ahmed S, 2009, TOXICOL SCI, V111, P254, DOI 10.1093/toxsci/kfp144; Amakura Y, 2003, BIOL PHARM BULL, V26, P532, DOI 10.1248/bpb.26.532; An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ASTROFF B, 1990, MOL CELL ENDOCRINOL, V72, P247, DOI 10.1016/0303-7207(90)90149-3; Balaguer P, 1999, SCI TOTAL ENVIRON, V233, P47, DOI 10.1016/S0048-9697(99)00178-3; Barkhem T, 1998, MOL PHARMACOL, V54, P105; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Belous AR, 2007, CANCER RES, V67, P812, DOI 10.1158/0008-5472.CAN-06-2133; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bolger R, 1998, ENVIRON HEALTH PERSP, V106, P551, DOI 10.1289/ehp.98106551; Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx70019Ip; Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cao Y, 2008, J EXP SCI ENV EPIDEM, V19, P223; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cassidy A, 2006, J NUTR, V136, P45; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899; Dai SY, 2008, P NATL ACAD SCI USA, V105, P7171, DOI 10.1073/pnas.0710802105; de Kleijn MJJ, 2001, J NUTR, V131, P1826; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Duan RQ, 1999, MOL ENDOCRINOL, V13, P1511, DOI 10.1210/me.13.9.1511; DuSell CD, 2010, MOL ENDOCRINOL, V24, P33, DOI 10.1210/me.2009-0339; EDSP, 2009, END DISR SCREEN PROG, P54415; EDSTAC, 1998, END DISR SCREEN TEST; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Escande A, 2006, BIOCHEM PHARMACOL, V71, P1459, DOI 10.1016/j.bcp.2006.02.002; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Gaido KW, 2000, MOL PHARMACOL, V58, P852; Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746; Ghayee HK, 2007, REV ENDOCR METAB DIS, V8, P289, DOI 10.1007/s11154-007-9052-2; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Hammond DK, 1997, TOXICOL APPL PHARM, V145, P54, DOI 10.1006/taap.1997.8167; Hankinson O, 2005, ARCH BIOCHEM BIOPHYS, V433, P379, DOI 10.1016/j.abb.2004.09.031; Harris Heather A, 2007, Mol Endocrinol, V21, P1, DOI 10.1210/me.2005-0459; Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; HERBST AL, 1977, AM J OBSTET GYNECOL, V128, P43; Hewitt S. C., 2010, ENV HLTH PERSPECT; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kao YC, 1998, ENVIRON HEALTH PERSP, V106, P85; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Knoblauch R, 1999, MOL CELL BIOL, V19, P3748; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kortenkamp A., 2007, ENV HLTH PERSPECT, P115; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; Kuhnle GGC, 2008, J AGR FOOD CHEM, V56, P7311, DOI 10.1021/jf801534g; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Kumar NB, 2002, CANCER, V94, P1166, DOI 10.1002/cncr.10320; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Laville N, 2006, TOXICOLOGY, V228, P98, DOI 10.1016/j.tox.2006.08.021; le Maire A, 2010, CELL MOL LIFE SCI, V67, P1219, DOI 10.1007/s00018-009-0249-2; Lemaire G, 2006, LIFE SCI, V79, P1160, DOI 10.1016/j.lfs.2006.03.023; Letcher RJ, 1999, TOXICOL APPL PHARM, V160, P10, DOI 10.1006/taap.1999.8746; Leusch FDL, 2010, ENVIRON SCI TECHNOL, V44, P3853, DOI 10.1021/es903899d; Li J, 2008, TOXICOL LETT, V183, P65, DOI 10.1016/j.toxlet.2008.10.002; Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018; Liu JW, 2003, MOL ENDOCRINOL, V17, P346, DOI 10.1210/mr.2002.0331; Liu Y, 2008, P NATL ACAD SCI USA, V105, P2604, DOI 10.1073/pnas.0712085105; Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012; Manas ES, 2004, STRUCTURE, V12, P2197, DOI 10.1016/j.str.2004.09.015; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, P55, DOI 10.2307/3434921; Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538; Mersereau JE, 2008, MOL CELL ENDOCRINOL, V283, P49, DOI 10.1016/j.mce.2007.11.020; Migliaccio A, 1996, EMBO J, V15, P1292; MILLER WL, 1988, ENDOCR REV, V9, P295; Minutolo F, 2011, MED RES REV, V31, P364, DOI 10.1002/med.20186; Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633; Moon YJ, 2006, TOXICOL IN VITRO, V20, P187, DOI 10.1016/j.tiv.2005.06.048; Murphy LC, 2005, J MOL ENDOCRINOL, V34, P553, DOI 10.1677/jme.1.01688; Murray IA, 2010, MOL PHARMACOL, V77, P247, DOI 10.1124/mol.109.061788; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; OECD, 1998, 1 M OECD END DISR TE; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Penza M, 2007, TOXICOL SCI, V97, P299, DOI 10.1093/toxsci/kfm036; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; PINTER A, 1990, NEOPLASMA, V37, P533; Porter W, 2001, J MOL ENDOCRINOL, V26, P31, DOI 10.1677/jme.0.0260031; Powell E, 2010, BIOCHEM PHARMACOL, V80, P1221, DOI 10.1016/j.bcp.2010.06.030; Powell E, 2008, P NATL ACAD SCI USA, V105, P19012, DOI 10.1073/pnas.0807274105; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Ruegg J, 2008, MOL ENDOCRINOL, V22, P304, DOI 10.1210/me.2007-0128; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103; Sanderson JT, 2002, TOXICOL APPL PHARM, V182, P44, DOI 10.1006/taap.2002.9420; Sanderson JT, 2006, TOXICOL SCI, V94, P3, DOI 10.1093/toxsci/kfl051; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Secreto FJ, 2007, J CELL BIOCHEM, V101, P1125, DOI 10.1002/jcb.21205; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shanle EK, 2010, ADV DRUG DELIVER REV, V62, P1265, DOI 10.1016/j.addr.2010.08.001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shipley JM, 2006, TOXICOL APPL PHARM, V213, P87, DOI 10.1016/j.taap.2005.09.011; Silva E, 2007, ENVIRON HEALTH PERSP, V115, P91, DOI 10.1289/ehp.9363; Sonneveld E, 2006, TOXICOL SCI, V89, P173, DOI 10.1093/toxsci/kfj009; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Sotoca Ana M Covaleda, 2008, Toxicol Sci, V105, P303, DOI 10.1093/toxsci/kfn141; SPINK DC, 1994, J STEROID BIOCHEM, V51, P251, DOI 10.1016/0960-0760(94)90037-X; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; Stokes WS, 2004, ILAR J, V45, P387; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Strom SS, 1999, NUTR CANCER, V33, P20; Swaby RF, 2007, REV ENDOCR METAB DIS, V8, P229, DOI 10.1007/s11154-007-9034-4; Swedenborg E, 2009, J MOL ENDOCRINOL, V43, P1, DOI 10.1677/JME-08-0132; Swedenborg E, 2008, MOL PHARMACOL, V73, P575, DOI 10.1124/mol.107.036384; Tamrazi A, 2002, MOL ENDOCRINOL, V16, P2706, DOI 10.1210/me.2002-0250; Taylor AH, 2000, J MOL ENDOCRINOL, V24, P145, DOI 10.1677/jme.0.0240145; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tiemann U, 2008, REPROD TOXICOL, V25, P316, DOI 10.1016/j.reprotox.2008.03.002; Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007; Turusov V., 2002, ENV HLTH PERSPECT, P110; US EPA, 2004, EPA PUBL; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; van Meeuwen JA, 2008, TOXICOL APPL PHARM, V228, P269, DOI 10.1016/j.taap.2007.12.007; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Weatherman RV, 2002, MOL ENDOCRINOL, V16, P487, DOI 10.1210/me.16.3.487; WETZEL LT, 1994, J TOXICOL ENV HEALTH, V43, P169; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; WILHELMSSON A, 1990, EMBO J, V9, P69; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; Wu F, 2008, J STEROID BIOCHEM, V110, P104, DOI 10.1016/j.jsbmb.2008.02.008; Wu F, 2007, J STEROID BIOCHEM, V103, P1, DOI 10.1016/j.jsbmb.2006.07.007; Xu X, 1998, CANCER EPIDEM BIOMAR, V7, P1101; Xu XD, 2007, P NATL ACAD SCI USA, V104, P10264, DOI 10.1073/pnas.0701987104; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Zhang XW, 2005, ENVIRON SCI TECHNOL, V39, P2777, DOI 10.1021/es048679k; Zhao CY, 2010, CANCER RES, V70, P5174, DOI 10.1158/0008-5472.CAN-09-4407; Zwart W, 2010, J CELL SCI, V123, P1253, DOI 10.1242/jcs.06113515463AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USACHEM RES TOXICOLJANDiscipline: Pharmacology &amp; Pharmacy; Chemistry; Toxicology705LO</notes>
    <keywords>ALPHA; Antagonist; AROMATASE CYP19 ACTIVITY; Aryl hydrocarbon receptor; ARYL-HYDROCARBON; ARYL-HYDROCARBON RECEPTOR; ASSAY; BETA; BINDING; BREAST-CANCER CELLS; CANCER; CELL; CHEMICALS; DISRUPTING CHEMICALS; E-SCREEN ASSAY; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemicals; ER alpha; ER-ALPHA; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptors; estrogen signaling; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; FOOD; GENE; gene regulation; GENE-EXPRESSION; GROWTH-FACTOR RECEPTOR; HEALTH; HEAT-SHOCK PROTEIN; IDENTIFICATION; IMPACT; In vitro; in vivo; IN-VITRO; IN-VIVO; Interaction; LIGAND; LIGAND-BINDING; mechanism; MECHANISMS; METABOLISM; Nongenomic; ORGANOCHLORINE PESTICIDES; PATHWAY; PESTICIDES; PHARMACOLOGY; Phytoestrogen; PHYTOESTROGENS; RECEPTOR; Receptors; REPORTER CELL-LINES; RESONANCE ENERGY-TRANSFER; Review; selective estrogen receptor modulators; SIGNALING PATHWAY; SIGNALING PATHWAYS; Steroid; STEROID-HORMONE BIOSYNTHESIS; TARGET; toxicology; TRANSCRIPTION; VITRO; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>6</startpage>
    <endpage>19</endpage>
    <journalfull>Chemical Research in Toxicology</journalfull>
    <issue>1</issue>
    <volume>24</volume>
    <abstract>Many endocrine disrupting chemicals (EDCs) adversely impact estrogen signaling by interacting with two estrogen receptors (ERs): ER alpha and ER beta. Though the receptors have similar ligand binding and DNA binding domains, ER alpha and ER beta have some unique properties in terms of ligand selectivity and target gene regulation. EDCs that target ER signaling can modify genomic and nongenomic ER activity through direct interactions with ERs, indirectly through transcription factors such as the aryl hydrocarbon receptor (AhR), or through modulation of metabolic enzymes that are critical for normal estrogen synthesis and metabolism. Many EDCs act through multiple mechanisms as exemplified by chemicals that bind both AhR and ER, such as 3-methylcholanthrene. Other EDCs that target ER signaling include phytoestrogens, bisphenolics, and organochlorine pesticides, and many alter normal ER signaling through multiple mechanisms. EDCs can also display tissue-selective ER agonist and antagonist activities similar to selective estrogen receptor modulators (SERMs) designed for pharmaceutical use. Thus, biological effects of EDCs need to be carefully interpreted because EDCs can act through complex tissue-selective modulation of ERs and other signaling pathways in vivo. Current requirements by the U.S. Environmental Protection Agency require some in vitro and cell-based assays to identify EDCs that target ER signaling through direct and metabolic mechanisms. Additional assays may be useful screens for identifying EDCs that act through alternative mechanisms prior to further in vivo study</abstract>
    <url>WOS:000286130100002</url>
    <isbnorissn>0893-228X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>131</id>
    <title>Persistent organic pollutants including polychlorinated and polybrominated dibenzo-p-dioxins and dibenzofurans in firefighters from Northern California</title>
    <authors>Shaw,S.D.; Berger,M.L.; Harris,J.H.; Yun,S.H.; Wu,Q.; Liao,C.Y.; Blum,A.; Stefani,A.; Kannan,K.</authors>
    <availability>[Shaw, Susan D.; Berger, Michelle L.; Harris, Jennifer H.] Ctr Marine Studies, Marine Environm Res Inst, Blue Hill, ME 04614 USA. [Yun, Se Hun; Wu, Qian; Liao, Chunyang; Kannan, Kurunthachalam] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA. [Shaw, Susan D.; Wu, Qian; Kannan, Kurunthachalam] SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, Albany, NY 12201 USA. [Blum, Arlene] Univ Calif Berkeley, Green Sci Policy Inst, Berkeley, CA 94705 USA. [Stefani, Anthony] San Francisco Firefighters Canc Prevent Fdn, San Francisco, CA 94103 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleShaw, SD (reprint author), Ctr Marine Studies, Marine Environm Res Inst, POB 1652, Blue Hill, ME 04614 USAsshaw@meriresearch.orgAnderson HA, 2008, CHEMOSPHERE, V73, P187, DOI 10.1016/j.chemosphere.2008.05.052; Bi XH, 2006, ENVIRON POLLUT, V144, P1024, DOI 10.1016/j.envpol.2005.12.056; Bi XH, 2007, ENVIRON SCI TECHNOL, V41, P5647, DOI 10.1021/es070346a; Birnbaum LS, 2003, ENVIRON INT, V29, P855, DOI 10.1016/S0160-4120(03)00106-5; Blomqvist P, 2007, FIRE TECHNOL, V43, P213, DOI 10.1007/s10694-007-0011-y; Bolstad-Johnson DM, 2000, AIHAJ, V61, P636, DOI 10.1202/0002-8894(2000)061&lt;0636:COFEDF&gt;2.0.CO;2; BRANDTRAUF PW, 1988, BRIT J IND MED, V45, P606; BUMB RR, 1980, SCIENCE, V210, P385, DOI 10.1126/science.6159682; Calafat AM, 2007, ENVIRON HEALTH PERSP, V115, P1596, DOI 10.1289/ehp.10598; Chernyak Y., 2004, ORGANOHALOGEN COMPOU, V66, P2481; Chernyak Yu I, 2009, Dokl Biol Sci, V429, P562; Chernyak YI, 2012, TOXICOL LETT, V213, P9, DOI 10.1016/j.toxlet.2011.09.021; Choi JW, 2003, ENVIRON SCI TECHNOL, V37, P817, DOI 10.1021/es0258780; Dallaire R, 2009, ENVIRON HEALTH PERSP, V117, P1380, DOI 10.1289/ehp.0900633; Ebert J, 2003, ENVIRON INT, V29, P711, DOI 10.1016/S0160-4120(03)00117-X; Edelman P, 2003, ENVIRON HEALTH PERSP, V111, P1906, DOI 10.1289/ehp.6315; Greene KL, 2008, J UROLOGY, V179, P323, DOI 10.1016/S0022-5347(08)60945-3; Gullett BK, 2010, ENVIRON SCI TECHNOL, V44, P394, DOI 10.1021/es902676w; Hanari N, 2006, ENVIRON SCI TECHNOL, V40, P4400, DOI 10.1021/es060559k; HANSEN ES, 1990, BRIT J IND MED, V47, P805; Hites RA, 2004, ENVIRON SCI TECHNOL, V38, P945, DOI 10.1021/es035082g; Horii Y, 2010, ENVIRON SCI TECHNOL, V44, P5188, DOI 10.1021/es100282d; Hsu JF, 2011, CHEMOSPHERE, V83, P1353, DOI 10.1016/j.chemosphere.2011.02.079; IARC, 2010, MON EV CARC RISKS HU, V98; Jogsten IE, 2010, CHEMOSPHERE, V78, P113, DOI 10.1016/j.chemosphere.2009.10.012; Johnson PI, 2010, ENVIRON SCI TECHNOL, V44, P5627, DOI 10.1021/es100697q; Johnson-Restrepo B, 2005, ENVIRON SCI TECHNOL, V39, P8243, DOI 10.1021/es051551y; Kalman A., 2006, CHEMOSPHERE, V64, P1582; Kang D, 2008, AM J IND MED, V51, P329, DOI 10.1002/ajim.20549; Kannan K., 2012, DIOXINS HLTH, P255; Kelly KJ, 2002, ARCH ENVIRON HEALTH, V57, P282; Kotz A., 2005, ORGANOHALOGEN COMPD, V67, P1540; LeMasters GK, 2006, J OCCUP ENVIRON MED, V48, P1189, DOI 10.1097/01.jom.0000246229.68697.90; Ma J, 2009, ENVIRON SCI TECHNOL, V43, P7350, DOI 10.1021/es901713u; Meeker JD, 2007, ENVIRON RES, V104, P296, DOI 10.1016/j.envres.2007.11.007; Olsman H, 2007, ENVIRON TOXICOL CHEM, V26, P2448, DOI 10.1897/07-004R.1; Patterson DG, 2009, ENVIRON SCI TECHNOL, V43, P1211, DOI 10.1021/es801966w; Petreas M, 2003, ENVIRON HEALTH PERSP, V111, P1175, DOI 10.1289/ehp.6220; Qin YY, 2011, ENVIRON SCI TECHNOL, V45, P1630, DOI 10.1021/es102444g; Rose M., 2010, P 5 INT S BROM FLAM; Samara F, 2009, ENVIRON INT, V35, P588, DOI 10.1016/j.envint.2008.11.003; Sawada N, 2010, ENVIRON HEALTH PERSP, V118, P659, DOI 10.1289/ehp.0901214; Schecter A, 2002, CHEMOSPHERE, V47, P147, DOI 10.1016/S0045-6535(01)00197-7; Schecter A, 2005, J OCCUP ENVIRON MED, V47, P199, DOI 10.1097/01.jom.0000158704.27536.d2; Shaw Susan D., 2010, Reviews on Environmental Health, V25, P261; She JW, 2002, CHEMOSPHERE, V46, P697, DOI 10.1016/S0045-6535(01)00234-X; Sjodin A, 2004, ENVIRON HEALTH PERSP, V112, P654; Sjodin A, 1999, ENVIRON HEALTH PERSP, V107, P643, DOI 10.2307/3434456; Stapleton HM, 2008, ENVIRON SCI TECHNOL, V42, P3453, DOI 10.1021/es7028813; Suzuki G, 2010, ENVIRON SCI TECHNOL, V44, P8330, DOI 10.1021/es102021c; Tao L, 2008, ENVIRON SCI TECHNOL, V42, P3472, DOI 10.1021/es8000079; Thomas GO, 2006, ENVIRON POLLUT, V141, P30, DOI 10.1016/j.envpol.2005.08.027; Thomsen C, 2001, J ENVIRON MONITOR, V3, P366, DOI 10.1039/b104304h; Thuresson K, 2005, ENVIRON SCI TECHNOL, V39, P1980, DOI 10.1021/es048511z; Thuresson K, 2006, ENVIRON HEALTH PERSP, V114, P176, DOI 10.1289/ehp.8350; Turyk ME, 2007, ENVIRON HEALTH PERSP, V115, P1197, DOI 10.1289/ehp.10179; United Nations Environment Program (UNEP), 2010, SUPP DOC DRAFT TECHN; Van den Berg M., 2006, TOXICOL SCI, V93, P2223; Weber LWD, 1997, J TOXICOL ENV HEALTH, V50, P195; Weber R, 2003, ENVIRON INT, V29, P699, DOI 10.1016/S0160-4120(03)00118-1; WHO, 1998, ENV HLTH CRIT, V205; Yu X., 2009, ORGANOHALOGEN COMPD, V71, P2263; Zamir R, 2009, CHEMOSPHERE, V74, P453, DOI 10.1016/j.chemosphere.2008.09.043; Zeig-Owens R, 2011, LANCET, V378, P898, DOI 10.1016/S0140-6736(11)60989-6; ZOBER MA, 1992, BRIT J IND MED, V49, P532; Zota AR, 2008, ENVIRON SCI TECHNOL, V42, P8158, DOI 10.1021/es801792z666PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDCHEMOSPHEREJUNDiscipline: Environmental Sciences &amp; Ecology146MC</notes>
    <keywords>ADIPOSE-TISSUE; bisphenol A; BISPHENOL-A; BPA; CANCER; CHEMICALS; DIPHENYL ETHERS; environment; EXPOSURE; Firefighters; FLAME RETARDANTS; HUMAN SERUM; JUN; OCCUPATIONAL-EXPOSURE; PBDD/Fs; PBDEs; PCDD/Fs; PFCs; POLLUTANTS; RISK; SAMPLES; serum; SOUTH CHINA; TEQ; TOXICITY; UNITED-STATES; US POPULATION; WORLD-TRADE-CENTER; YORK-CITY FIREFIGHTERS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1386</startpage>
    <endpage>1394</endpage>
    <journalfull>Chemosphere</journalfull>
    <issue>10</issue>
    <volume>91</volume>
    <abstract>Polychlorinated and polybrominated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs and PBDD/Fs) were measured in serum of twelve firefighters sampled after a fire event in San Francisco, California, along with polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs), p,p'-DDE, hexachlorobenzene (HCB), perfluorinated chemicals (PFCs), bisphenol-A (BPA) and tetrabromobisphenol-A (TBBPA). TEQpcoois concentrations were relatively low (mean 5 pg g(-1) (lipid weight), lw, range 1-11 pg g(-1) lw), but concentrations of 1,2,3,4,6,7,8-HpCDD, a congener indicative of exposure during firefighting, were elevated. Tentative WHO2005-TEQs calculated for PBDD/Fs in our samples (mean 104 pg g(-1) lw, range 0.2-734 pg g(-1) lw) suggested that PBDD/Fs may contribute substantially to dioxin-like toxicity in individual firefighters. PBDE concentrations were elevated in firefighter serum (mean 135 ng g(-1) lw, range 48-442 ng g(-1) lw). PBDE-209, PBDE-47 and PBDE-153 were prevalent congeners; PBDE-209 contributed &gt;50% of the total PBDE concentration in four individuals, implying continuous occupational exposure to deca-BDE. Perfluorooctanesulfonate (PFOS) was the dominant PFC in serum (mean 12 ng ml(-1) (wet weight), ww, range 3 ng ml(-1) ww to 59 ng ml(-1) ww), followed by perfluorooctanoic acid (PFOA) (mean 7 ng ml(-1) ww, range 2 ng ml(-1) ww to 12 ng ml(-1) ww). Concentrations of perfluorononanoic acid (PFNA) (mean 2 ng ml(-1) ww, range 1-4 ng ml(-1) ww) were higher than those reported in the high-smoke exposure group of World Trade Center fire responders, suggesting that the California firefighters were exposed to PFNA in smoke during firefighting. Given their elevated rates of cancers, these results illustrate the importance of monitoring halogenated contaminants including PBDD/Fs in firefighters. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000319094200002</url>
    <isbnorissn>0045-6535</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>29</id>
    <title>An evidence in vitro for the influence of bisphenol A on uterine leiomyoma</title>
    <authors>Shen,Y.; Ren,M.L.; Feng,X.; Cai,Y.L.; Gao,Y.X.; Xu,Q.</authors>
    <availability>[Shen, Yang; Ren, Mu-Lan; Feng, Xu; Cai, Yun-Lang; Gao, Yong-Xing] Southeast Univ, Sch Med, Zhongda Hosp, Dept Obstet &amp; Gynecol, Nanjing 210009, Jiangsu, Peoples R China. [Xu, Qian] Southeast Univ, Sch Publ Hlth, Nanjing 210009, Jiangsu, Peoples R China. [Xu, Qian] Southeast Univ, Minist Educ, Key Lab Environm Med Engn, Nanjing 210009, Jiangsu, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleShen, Y (reprint author), Southeast Univ, Sch Med, Zhongda Hosp, Dept Obstet &amp; Gynecol, Nanjing 210009, Jiangsu, Peoples R Chinashenyang0924@sina.cnBakas P, 2008, FERTIL STERIL, V90, P1878, DOI 10.1016/j.fertnstert.2007.09.019; Burroughs KD, 2002, J ENDOCRINOL, V172, P83, DOI 10.1677/joe.0.1720083; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Di X, 2008, HUM REPROD, V23, P1873, DOI 10.1093/humrep/den087; Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605; Herve MAJ, 2006, J ENDOCRINOL, V188, P91, DOI 10.1677/joe.1.06184; Hiyama M, 2011, J VET MED SCI, V73, P1211, DOI 10.1292/jvms.11-0135; Hung CH, 2010, ENVIRON HEALTH PERSP, V118, P67, DOI 10.1289/ehp.0901011; Islam MS, 2013, J CLIN ENDOCR METAB, V98, P921, DOI 10.1210/jc.2012-3237; Levy G, 2012, J ASSIST REPROD GEN, V29, P703, DOI 10.1007/s10815-012-9784-0; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Okolo S, 2008, BEST PRACT RES CL OB, V22, P571, DOI 10.1016/j.bpobgyn.2008.04.002; Olsen CM, 2003, PHARMACOL TOXICOL, V92, P180, DOI 10.1034/j.1600-0773.2003.920408.x; Shen Y, 2013, EUR REV MED PHARMACO, V17, P3249; Shen Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079838; Skor MN, 2013, CLIN CANCER RES, V19, P6163, DOI 10.1158/1078-0432.CCR-12-3826; Stark K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074525; Wang JY, 2005, HUM REPROD, V20, P1456, DOI 10.1093/humrep/deh842200ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSEUR J OBSTET GYN R BJULDiscipline: Obstetrics &amp; Gynecology; Reproductive BiologyAL3NY</notes>
    <keywords>ALPHA; BINDING; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELL; CELLS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ER alpha; Estrogen; ESTROGEN-RECEPTOR; ESTROGENS; EXPOSURE; EXPRESSION; FIBROIDS; GROWTH; GROWTH-FACTOR; IGF-1; In vitro; IN-VITRO; mechanism; proliferation; RISK; Uterine leiomyoma; VEGF</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>80</startpage>
    <endpage>83</endpage>
    <journalfull>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</journalfull>
    <volume>178</volume>
    <abstract>Objective: To study the effect and mechanism of environmental estrogens bisphenol A (BPA) on uterine leiomyoma (UL) cells. Methods: Primary cultures and subcultures of human UL cells, which were identified by immunocytochemical staining with a monoclonal anti-a-smooth muscle actin antibody, were performed. The viability of cells in different concentration of bisphenol A of 24 h, 48 hand 72 h were analyzed by CCK-8. The expressions of mRNA of ER alpha, IGF-1 and VEGF in all groups were detected by real-time quantitative PCR assay, and then the expressions of proteins detected by Western blot assay. Results: BPA promoted the growth of UL cells and the expressions of ER alpha, IGF-1 and VEGF, which had positive correlation with the concentration and action time of BPA treatment. Conclusion: BPA promotes the growth of leiomyoma cells. The expressions of IGF-1, VEGF can be up-regulated by ER alpha, which may be possible mechanism of BPA promote the growth of leiomyoma cells. (C) 2014 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000339036600016</url>
    <isbnorissn>0301-2115</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>30</id>
    <title>Does nonylphenol promote the growth of uterine fibroids?</title>
    <authors>Shen,Y.; Ren,M.L.; Feng,X.; Gao,Y.X.; Xu,Q.; Cai,Y.L.</authors>
    <availability>[Shen, Yang; Ren, Mu-Lan; Feng, Xu; Gao, Yong-Xing; Cai, Yun-Lang] Southeast Univ, Sch Med, Zhongda Hosp, Dept Obstet &amp; Gynaecol, Nanjing, Jiangsu, Peoples R China. [Xu, Qian] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China. [Xu, Qian] Southeast Univ, Minist Educ, Key Lab Environm Med Engn, Nanjing, Jiangsu, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleShen, Y (reprint author), Southeast Univ, Sch Med, Zhongda Hosp, Dept Obstet &amp; Gynaecol, Nanjing, Jiangsu, Peoples R Chinashenyang0924@sina.cnBakas P, 2008, FERTIL STERIL, V90, P1878, DOI 10.1016/j.fertnstert.2007.09.019; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Burroughs KD, 2002, J ENDOCRINOL, V172, P83, DOI 10.1677/joe.0.1720083; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Di X, 2008, HUM REPROD, V23, P1873, DOI 10.1093/humrep/den087; Duhan N, 2010, EUR J OBSTET GYN R B, V152, P119, DOI 10.1016/j.ejogrb.2010.05.010; Fan ZL, 2013, ENVIRON SCI TECHNOL, V47, P10841, DOI 10.1021/es401504a; Herve MAJ, 2006, J ENDOCRINOL, V188, P91, DOI 10.1677/joe.1.06184; Hung CH, 2010, ENVIRON HEALTH PERSP, V118, P67, DOI 10.1289/ehp.0901011; Islam MS, 2013, J CLIN ENDOCR METAB, V98, P921, DOI 10.1210/jc.2012-3237; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Maruo T, 2004, HUM REPROD UPDATE, V10, P207, DOI 10.1093/humupd/dmh019; Okolo S, 2008, BEST PRACT RES CL OB, V22, P571, DOI 10.1016/j.bpobgyn.2008.04.002; Preuss TG, 2006, ENVIRON SCI TECHNOL, V40, P5147, DOI 10.1021/es060709r; Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n; Shen Y, 2013, EUR REV MED PHARMACO, V17, P3249; Shen Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079838; Skor MN, 2013, CLIN CANCER RES, V19, P6163, DOI 10.1158/1078-0432.CCR-12-3826; Stark K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074525; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; Wang JY, 2005, HUM REPROD, V20, P1456, DOI 10.1093/humrep/deh842220ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSEUR J OBSTET GYN R BJULDiscipline: Obstetrics &amp; Gynecology; Reproductive BiologyAL3NY</notes>
    <keywords>ALPHA; BIOLOGY; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CELL; CELLS; Environmental oestrogen; ER alpha; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; FIBROIDS; GROWTH; GROWTH-FACTOR; IGF-1; LEIOMYOMA CELLS; mechanism; Nonylphenol; RECEPTOR; Uterine leiomyoma; VEGF</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>134</startpage>
    <endpage>137</endpage>
    <journalfull>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</journalfull>
    <volume>178</volume>
    <abstract>Objective: To study the effect and mechanism of action of nonylphenol (NP), an environmental oestrogen, on uterine leiomyoma (UL) cells. Methods: Primary culture and subculture of human UL cells, identified as smooth muscle cells by immunocytochemical staining with a monoclonal anti-alpha-smooth muscle actin antibody, were performed. The viability of cells treated with various concentrations of NP for 24, 48 and 72 h was determined by CCK-8 assay. mRNA expression of oestrogen receptor alpha (ER alpha), insulin-like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF) was detected using real-time quantitative polymerase chain reaction, and protein expression was detected using Western blot analysis for all groups. Results: NP promoted the growth of UL cells and expression of ER alpha, IGF-1 and VEGF; this was positively correlated with the concentration and duration of NP treatment. Conclusion: NP promotes the growth of UL cells. The mechanism of action appears to be over-expression of IGF-1 and VEGF, up-regulated by ER alpha, resulting in the growth of UL cells. (C) 2014 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000339036600025</url>
    <isbnorissn>0301-2115</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>253</id>
    <title>Low Concentrations of Bisphenol A Induce Mouse Spermatogonial Cell Proliferation by G Protein-Coupled Receptor 30 and Estrogen Receptor-alpha</title>
    <authors>Sheng,Z.G.; Zhu,B.Z.</authors>
    <availability>[Sheng, Zhi-Guo; Zhu, Ben-Zhan] Chinese Acad Sci, State Key Lab Environm Chem &amp; Ecotoxicol, Res Ctr Ecoenvironm Sci, Beijing 100085, Peoples R China. [Zhu, Ben-Zhan] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleZhu, BZ (reprint author), Chinese Acad Sci, State Key Lab Environm Chem &amp; Ecotoxicol, Res Ctr Ecoenvironm Sci, Beijing 100085, Peoples R Chinabzhu@rcees.ac.cnAlbanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.120556; Belcher SM, 2005, ENDOCRINOLOGY, V146, P5397, DOI 10.1210/en.2005-0564; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Bunone G, 1996, EMBO J, V15, P2174; Coulon V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011235; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Gaskell TL, 2003, J CLIN ENDOCR METAB, V88, P424, DOI 10.1210/jc.2002-020811; Hirvonen-Santti SJ, 2003, EUR UROL, V44, P742, DOI 10.1016/S0302-2838(03)00382-8; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002.0368; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; METZGER D, 1995, J BIOL CHEM, V270, P9535; Pais V, 2003, CLIN CANCER RES, V9, P4475; Petrier C, 2010, ULTRASON SONOCHEM, V17, P111, DOI 10.1016/j.ultsonch.2009.05.010; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Salian S, 2011, REPROD TOXICOL, V31, P359, DOI 10.1016/j.reprotox.2010.10.008; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Shaulian E, 2002, NAT CELL BIOL, V4, P131; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sheng ZG, 2008, TOXICOL APPL PHARM, V226, P119, DOI 10.1016/j.taap.2007.08.025; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.0103521US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPDECDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology857IH</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ACTIVATION; ASSAY; BETA; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELL; cell cycle; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CHEMICALS; CREB; CYCLE; EGFR; ER alpha; ER-ALPHA; ER-BETA; Estrogen; Estrogen receptor; Estrogen receptor alpha; estrogen receptor-alpha; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS; Estrogenicity; EXPOSURE; EXPRESSION; G protein-coupled receptor 30; GENE; gene expression; GENE-EXPRESSION; GERM-CELLS; GPR30; GROWTH; GROWTH-FACTOR; GROWTH-FACTOR RECEPTOR; HEALTH; HUMAN EXPOSURE; INHIBITOR; KINASE; LINE; Male; mechanism; Mouse; Mouse spermatogonial GC-1 cells; Occupational; OVARIAN-CANCER CELLS; PATHWAY; PHOSPHORYLATION; proliferation; PROTEIN; PROTEIN-COUPLED RECEPTOR; RECEPTOR; RECEPTOR-ALPHA; toxicology; TRANSCRIPTION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1775</startpage>
    <endpage>1780</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>12</issue>
    <volume>119</volume>
    <abstract>BACKGROUND: Bisphenol A (BPA) is one of the most prevalent chemicals in daily-use materials; therefore, human exposure to BPA is ubiquitous. The estrogenicity of BPA is generally mediated by nuclear estrogen receptors (ERs). However, low concentrations of BPA stimulate seminoma cell proliferation by an uncertain mechanism that does not involve activation of ERs. OBJECTIVE: We investigated the possible promoting effects of low-concentration BPA and the possible mechanism(s) using the murine ER-beta negative spermatogonial GC-1 cell line. METHODS AND RESULTS: Using the specific signaling inhibitor, BPA at test concentrations ranging from 10(-10) to 10(-8) M markedly induced proliferation of GC-1 cells by activating both cGMP-dependent protein kinase (PKG) and epidermal growth factor receptor (EGFR) extracellular regulated kinase (ERK) pathways. BPA stimulated a rapid (15-min) phosphorylation of the transcription factor cAMP response element binding protein (CREB) and the cell cycle regulator retinoblastoma protein (Rb). Interestingly, ER-alpha phosphorylation is involved in the proliferation, whereas BPA does not directly transactivate ER-alpha in gene reporter assays. Using specific agonists and gene silencing, we further observed that BPA mediates the proliferation and foe gene expression of GC-1 cells by G protein-coupled receptor 30 (GPR30) and ER-alpha. CONCLUSIONS: Our data suggest that low concentrations of BPA activate the PKG and EGFR/ERK/c-fos pathways through a cross-talk between GPR30 and ER-alpha, which in turn stimulates GC-1 cell proliferation. The present study provides a novel insight regarding the potential role of GPR30 and ER-alpha in mediating the proliferative effects of BPA in male germ cells</abstract>
    <url>WOS:000297711200032</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>160</id>
    <title>Bisphenol A at a low concentration boosts mouse spermatogonial cell proliferation by inducing the G protein-coupled receptor 30 expression</title>
    <authors>Sheng,Z.G.; Huang,W.; Liu,Y.X.; Zhu,B.Z.</authors>
    <availability>[Sheng, Zhi-Guo; Liu, Yu-Xiang; Zhu, Ben-Zhan] Chinese Acad Sci, State Key Lab Environm Chem &amp; Ecotoxicol, Ecoenvironm Sci Res Ctr, Beijing 100085, Peoples R China. [Huang, Wei] Peking Univ, Dept Biol Chem, Sch Pharmaceut Sci, Hlth Sci Ctr, Beijing 100091, Peoples R China. [Zhu, Ben-Zhan] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleZhu, BZ (reprint author), Chinese Acad Sci, State Key Lab Environm Chem &amp; Ecotoxicol, Ecoenvironm Sci Res Ctr, POB 2871, Beijing 100085, Peoples R Chinabzhu@rcees.ac.cnAlbanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.120556; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Chevalier N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034672; Chevalier N, 2012, INT J CANCER, V130, P241, DOI 10.1002/ijc.25972; Coulon V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011235; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Hsieh M, 2005, TRENDS ENDOCRIN MET, V16, P320, DOI 10.1016/j.tem.2005.07.005; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Langer G, 2010, STEROIDS, V75, P603, DOI 10.1016/j.steroids.2009.12.006; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; METZGER D, 1995, J BIOL CHEM, V270, P9535; Noguchi S, 2002, TOXICOL LETT, V135, P95, DOI 10.1016/S0378-4274(02)00252-7; Petrier C, 2010, ULTRASON SONOCHEM, V17, P111, DOI 10.1016/j.ultsonch.2009.05.010; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Salian S, 2011, REPROD TOXICOL, V31, P359, DOI 10.1016/j.reprotox.2010.10.008; Schonfelder G., 2002, ENV HLTH PERSPECT, V110, P703; Shaulian E, 2002, NAT CELL BIOL, V4, P131; Sheng ZG, 2007, J PHARMACOL EXP THER, V322, P155, DOI 10.1124/jpet.106.118224; Sheng ZG, 2011, ENVIRON HEALTH PERSP, V119, P1775, DOI 10.1289/ehp.1103781; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; Smith HO, 2009, GYNECOL ONCOL, V114, P465, DOI 10.1016/j.ygyno.2009.05.015; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, P56; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010416ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMFEB 15Discipline: Pharmacology &amp; Pharmacy; Toxicology085PI</notes>
    <keywords>ACTIVATION; Activator protein 1 site; ALPHA; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; C-FOS; C-FOS PROTOONCOGENE; CANCER; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; CHEMICALS; ER alpha; ER-ALPHA; Estrogen; estrogen receptor-alpha; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; G protein-coupled receptor 30; GPR30; GROWTH; GROWTH-FACTOR; HEALTH; HUMAN ESTROGEN-RECEPTOR; HUMAN EXPOSURE; KINASE; LIGAND; Male; mechanism; Mouse; Mouse spermatogonial GC-1 cells; OVARIAN-CANCER; PHARMACOLOGY; PROGRESSION; proliferation; PROTEIN; PROTEIN-COUPLED RECEPTOR; RECEPTOR; RECEPTOR-ALPHA; RESISTANCE; toxicology; TRANSACTIVATION; Transfection</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>88</startpage>
    <endpage>94</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>1</issue>
    <volume>267</volume>
    <abstract>Bisphenol A (BPA) is one of the most prevalent chemicals in daily-use materials, therefore, human exposure to BPA is ubiquitous. We found that low concentrations of BPA stimulate the spermatogonial GC-1 cells proliferation by G protein-coupled receptor 30 (GPR30)-mediated epidermal growth factor receptor (EGFR)-extracellular regulated kinase (ERK)-c-Fos pathway. However, through the same pathway GPR30 expression has been shown to be induced by EGF, an EGFR ligand. Thus, we want to know if low concentrations of BPA are able to induce the GPR30 expression and the possible mechanism(s) in GC-1 cells. By transient transfection with expression plasmids, 10(-9) M EPA significantly transactivates the Gpr30-5'-flanking region through activating the GPR30, cGMP-dependent protein kinase (PKG), estrogen receptor-alpha (ER-alpha), and EFGR-ERK pathways. Furthermore, an activator protein-1 (AP-1) site located within this region is found to be responsible for the transactivation of BPA. Expectedly, through the same pathways, BPA significantly induces the gene and protein expression of GPR30. c-Fos is further observed to be strongly recruited to the AP-1 site in a chromatin immunoprecipitation assay and its dysfunction on the AP-1 site markedly suppresses the expression of GPR30, p-ERK1/2, p-Ser118-ER-alpha and cell proliferation by BPA. Our results demonstrate that a low-concentration BPA induces GPR30 expression through the GPR30-EFGR-ERK-c-Fos, ER-alpha, and PKG pathways, presumably boosting the cells proliferation via a regulatory loop. The present study provides a novel insight into the potential role of GPR30 in the initiation and progression of male germ cell cancer induced by environmentally relevant BPA. (C) 2012 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000314626300009</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>95</id>
    <title>Expressomal approach for comprehensive analysis and visualization of ligand sensitivities of xenoestrogen responsive genes</title>
    <authors>Shioda,T.; Rosenthal,N.F.; Coser,K.R.; Suto,M.; Phatak,M.; Medvedovic,M.; Carey,V.J.; Isselbacher,K.J.</authors>
    <availability>[Shioda, Toshi; Rosenthal, Noel F.; Coser, Kathryn R.; Suto, Mizuki; Isselbacher, Kurt J.] Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA 02129 USA. [Shioda, Toshi; Carey, Vincent J.; Isselbacher, Kurt J.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Phatak, Mukta; Medvedovic, Mario] Univ Cincinnati, Coll Med, Lab Stat Genom &amp; Syst Biol, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Carey, Vincent J.] Brigham &amp; Womens Hosp, Channing Lab, Boston, MA 02115 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleShioda, T (reprint author), Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA 02129 USAtshioda@partners.org; kisselbacher@partners.orgAlmstrup K, 2002, ENVIRON HEALTH PERSP, V110, P743; Birnbaum LS, 2012, ENVIRON HEALTH PERSP, V120, pA143, DOI 10.1289/ehp.1205179; HILL AB, 1965, P ROY SOC MED, V58, P295; Cederroth CR, 2012, MOL CELL ENDOCRINOL, V355, P192, DOI 10.1016/j.mce.2011.05.049; Chamorro-Garcia R, 2013, ENVIRON HEALTH PERSP, V121, P359, DOI 10.1289/ehp.1205701; Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Do RP, 2012, REPROD TOXICOL, V34, P614, DOI 10.1016/j.reprotox.2012.09.006; DuSell CD, 2008, TRENDS PHARMACOL SCI, V29, P510, DOI 10.1016/j.tips.2008.07.003; Evans RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043606; Freudenberg JM, 2011, BIOINFORMATICS, V27, P70, DOI 10.1093/bioinformatics/btq593; Goodman A, 2011, NEW ENGL J MED, V364, P2083, DOI 10.1056/NEJMp1104409; Jeong KW, 2012, MOL ENDOCRINOL, V26, P955, DOI 10.1210/me.2012-1066; Kidd KA, 2007, P NATL ACAD SCI USA, V104, P8897, DOI 10.1073/pnas.0609568104; Klinge CM, 2004, J MOL ENDOCRINOL, V33, P387, DOI 10.1677/jma.101541; Li L, 2007, J MOL ENDOCRINOL, V38, P569, DOI 10.1677/JME-07-0003; Lindberg K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2865; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Shioda T, 2006, P NATL ACAD SCI USA, V103, P12033, DOI 10.1073/pnas.0605341103; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; Taylor JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048311; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2013, REPROD TOXICOL, V38, P1, DOI 10.1016/j.reprotox.2013.02.002; Vom Saal Frederick S, 2012, Mol Cell Endocrinol, V354, P74, DOI 10.1016/j.mce.2012.01.001; vom Saal FS, 2010, TOXICOL SCI, V115, P612, DOI 10.1093/toxsci/kfq048; Wood S, 2006, GEN ADDITIVE MODELS; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422; Zoeller TR, 2010, HORM-INT J ENDOCRINO, V9, P28291NATL ACAD SCIENCESWASHINGTON2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USAP NATL ACAD SCI USAOCT 8Discipline: Science &amp; Technology - Other Topics231ED</notes>
    <keywords>ACTIVATION; bisphenol; bisphenol A; BISPHENOL-A; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHEMICALS; DISEASE; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Estrogen; ESTROGEN-RECEPTOR-ALPHA; ESTROGENS; EXPOSURE; EXPRESSION; gene expression; GENE-EXPRESSION; INDUCTION; LIGAND; MODEL; PHYTOESTROGENS; PRINCIPLES; PUBLIC-HEALTH; RESPONSES; RESPONSIVE GENES; SOCIETY; STATEMENT; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>16508</startpage>
    <endpage>16513</endpage>
    <journalfull>Proceedings of the National Academy of Sciences of the United States of America</journalfull>
    <issue>41</issue>
    <volume>110</volume>
    <abstract>Although biological effects of endocrine disrupting chemicals (EDCs) are often observed at unexpectedly low doses with occasional nonmonotonic dose-response characteristics, transcriptome-wide profiles of sensitivities or dose-dependent behaviors of the EDC responsive genes have remained unexplored. Here, we describe expressome analysis for the comprehensive examination of dose-dependent gene responses and its applications to characterize estrogen responsive genes in MCF-7 cells. Transcriptomes of MCF-7 cells exposed to varying concentrations of representative natural and xenobiotic estrogens for 48 h were determined by microarray and used for computational calculation of interpolated approximations of estimated transcriptomes for 300 doses uniformly distributed in log space for each chemical. The entire collection of these estimated transcriptomes, designated as the expressome, has provided unique opportunities to profile chemical-specific distributions of ligand sensitivities for large numbers of estrogen responsive genes, revealing that at low concentrations estrogens generally tended to suppress rather than to activate transcription. Gene ontology analysis demonstrated distinct functional enrichment between high-and low-sensitivity estrogen responsive genes, supporting the notion that a single EDC chemical can cause qualitatively distinct biological responses at different doses. Expressomal heatmap visualization of dose-dependent induction of Bisphenol A inducible genes showed a weak gene activation peak at a very low concentration range (ca. 0.1 nM) in addition to the main, strong gene activation peak at and above 100 nM. Thus, expressome analysis is a powerful approach to understanding the EDC dose-dependent dynamic changes in gene expression at the transcriptomal level, providing important information on the overall profiles of ligand sensitivities and nonmonotonic responses</abstract>
    <url>WOS:000325395600056</url>
    <isbnorissn>0027-8424</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>336</id>
    <title>Pre-natal exposure of mice to bisphenol A elicits an endometriosis-like phenotype in female offspring</title>
    <authors>Signorile,P.G.; Spugnini,E.P.; Mita,L.; Mellone,P.; D'Avino,A.; Bianco,M.; Diano,N.; Caputo,L.; Rea,F.; Viceconte,R.; Portaccio,M.; Viggiano,E.; Citro,G.; Pierantoni,R.; Sica,V.; Vincenzi,B.; Mita,D.G.; Baldi,F.; Baldi,A.</authors>
    <availability>[Signorile, Pietro G.; Rea, Francesca; Viceconte, Rosa; Baldi, Alfonso] Fondaz Italiana Endometriosi, I-00159 Rome, Italy. [Spugnini, Enrico P.; Citro, Gennaro] Regina Elena Inst Canc Res, SAFU Dept, Rome, Italy. [Mita, Luigi; Bianco, Mariangela; Diano, Nadia; Caputo, Lucia; Portaccio, Marianna; Viggiano, Emanuela; Pierantoni, Riccardo; Sica, Vincenzo; Mita, Damiano G.; Baldi, Alfonso] Interuniv Consortium INBB, Rome, Italy. [Mita, Luigi; Diano, Nadia; Portaccio, Marianna; Viggiano, Emanuela; Pierantoni, Riccardo; Mita, Damiano G.] Univ Naples 2, Dept Expt Med, Naples, Italy. [Mellone, Pasquale; D'Avino, Alfredo; Baldi, Feliciano; Baldi, Alfonso] Univ Naples 2, Dept Biochem &amp; Biophys, Sect Pathol, Naples, Italy. [Sica, Vincenzo] Univ Naples 2, Dept Gen Pathol, Naples, Italy. [Vincenzi, Bruno] Campus Biomed Univ, Dept Oncol, Rome, Italy. [Mita, Damiano G.] CNR, Inst Genet &amp; Biophys, I-80125 Naples, Italy.</availability>
    <date>2010</date>
    <notes>JEnglishArticleSignorile, PG (reprint author), Fondaz Italiana Endometriosi, Via E Longoni 81, I-00159 Rome, Italyalfonsobaldi@tiscali.itBALCI O, 2008, SAUDI MED J, V29, P13450; Baldi A, 2008, ONCOL REP, V19, P843; Batt Ronald E, 2003, J Pediatr Adolesc Gynecol, V16, P337, DOI 10.1016/j.jpag.2003.09.008; Block K, 2000, FASEB J, V14, P1101; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bompadre S, 2001, PERSPECTIVE IN COMPARATIVE ENDOCRINOLOGY: UNITY AND DIVERSITY, P269; Bontempo P, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-48; Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690; Burridge E., 2003, EUR CHEM NEWS, V20, P17; Cabaton N, 2006, J AGR FOOD CHEM, V54, P10307, DOI 10.1021/jf062250q; Coors A, 2003, ENVIRON SCI TECHNOL, V37, P3430, DOI 10.1021/es0300158; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Diano N, 2007, APPL CATAL B-ENVIRON, V69, P252, DOI 10.1016/j.apcatb.2006.07.004; Diez Garcia R, 1996, AN ESP PEDIATR, V44, P397; DOODS EC, 1936, NATURE, V137, P996; Du HL, 2004, ANN NY ACAD SCI, V1034, P152, DOI 10.1196/annals.1335.018; Ebert AD, 2009, GYNECOL OBSTET INVES, V67, P158, DOI 10.1159/000181185; Foster WG, 2008, ENDOCRINOLOGY, V149, P4267, DOI 10.1210/en.2008-0736; Foster WG, 2008, J TOXICOL ENV HEAL B, V11, P177, DOI 10.1080/10937400701873456; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Howdeshell KL, 1999, NATURE, V401, P763; Kawagoshi Y, 2003, J ENVIRON MONITOR, V5, P269, DOI 10.1039/b210962j; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Marsh EE, 2005, FERTIL STERIL, V83, P758, DOI 10.1016/j.fertnstert.2004.08.025; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Missmer SA, 2004, FERTIL STERIL, V82, P1501, DOI 10.1016/j.fertnstert.2004.04.065; Mita DG, 2007, BIOSENS BIOELECTRON, V23, P60, DOI 10.1016/j.bios.2007.03.010; MOKLIN EY, 2009, J PEDIAT ADOLES 0707; Nakamura K, 2007, NEUROSCI LETT, V420, P100, DOI 10.1016/j.neulet.2007.02.093; Nayyar T, 2007, REPROD TOXICOL, V23, P326, DOI 10.1016/j.reprotox.2006.09.007; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Newbold RR, 2001, CANCER RES, V61, P4325; Prins GS, 2008, ENDOCRINOLOGY, V149, P5919, DOI 10.1210/en.2008-1266; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Sallout B, 2003, J Obstet Gynaecol, V23, P555; Schonfelder G, 2004, NEOPLASIA, V6, P584, DOI 10.1593/neo.04217; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; Shin BS, 2002, J TOXICOL ENV HEAL A, V65, P395, DOI 10.1080/15287390252808064; SIGNORILE PG, 2010, RMM ONLINE IN PRESS, DOI DOI 10.1016/J.RBMO.2010.04.002; Signorile PG, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-49; Signorile PG, 2009, IN VIVO, V23, P459; Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com; Suzuki A, 2007, EXP BIOL MED, V232, P503; Taylor Hugh S, 2008, Fertil Steril, V89, pe57, DOI 10.1016/j.fertnstert.2007.12.030; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; *TP N, 2008, CEHR BRIEF BISPH A; Tyler CR, 1998, CRIT REV TOXICOL, V28, P319, DOI 10.1080/10408449891344236; *US EPA, 1998, FIN REP; Volkel W, 2008, TOXICOL LETT, V179, P155, DOI 10.1016/j.toxlet.2008.05.002; Witz CA, 1999, CLIN OBSTET GYNECOL, V42, P566, DOI 10.1097/00003081-199909000-000135518ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USAGEN COMP ENDOCRSEP 15Discipline: Endocrinology &amp; Metabolism641LF</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; CHEMICALS; development; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL; DISEASE; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENDOMETRIOSIS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; estrogenic activity; EXPOSURE; female; FOOD; GENE-EXPRESSION; GLAND; GROWTH; HEALTH; HOXA-10; HYPERPLASIA; in vivo; IN-UTERO; IN-VIVO; Incidence; Liver; METABOLISM; MICE; Mouse; Neoplasia; ovary; p21; PATHOGENESIS; PRENATAL EXPOSURE; RECEPTOR; SYSTEM; TARGET; TISSUE; TRACT; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>318</startpage>
    <endpage>325</endpage>
    <journalfull>General and Comparative Endocrinology</journalfull>
    <issue>3</issue>
    <volume>168</volume>
    <abstract>Endometriosis is a chronic gynecological disease characterized by the growth of endometrial tissue outside the uterine cavity. Exposure to endocrine disruptors during critical period of development causes long-lasting effects, being the genital system one of the targets. This study describes the effects on female genital system caused by developmental exposure to the endocrine-disrupting chemical bisphenol A (BPA) during pre- and pen-natal development in mice. To this end, timed pregnant Balb-C mice were treated from day 1 of gestation to 7 days after delivery with BPA (100, or 1000 mu g/kg/day). After delivery, pups were held for 3 months; then, pelvic organs were analyzed in their entirety and livers of both pups and moms were studied for the presence of BPA. We found in the adipose tissue surrounding the genital tracts of a consistent number of treated animals, endometriosis-like structure with the presence of both glands and stroma and expressing both estrogen receptor and HOXA-10. Moreover, cystic ovaries, adenomatous hyperplasia with cystic endometrial hyperplasia and atypical hyperplasia were significantly more frequent in treated animals respect to the controls. Finally, BPA was found in the livers of exposed moms and female offspring. In conclusion, we describe for the first time an endometriosis-like phenotype in mice, elicited by pre-natal exposition to BPA. This observation may induce to thoroughly reconsider the pathogenesis and treatment of endometriosis, considering the high incidence of endometriosis and the problems caused by associated infertility. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000281126700003</url>
    <isbnorissn>0016-6480</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>197</id>
    <title>Epigenetic Effects of Environmental Chemicals Bisphenol A and Phthalates</title>
    <authors>Singh,S.; Li,S.S.L.</authors>
    <availability>[Li, Steven Shoei-Lung] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung 807, Taiwan. [Singh, Sher] Natl Taiwan Normal Univ, Dept Life Sci, Coll Sci, Taipei 116, Taiwan. [Li, Steven Shoei-Lung] Kaohsiung Med Univ, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan.</availability>
    <date>2012</date>
    <notes>JEnglishReviewLi, SSL (reprint author), Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung 807, Taiwansher@ntnu.edu.tw; lissl@kmu.edu.twAnway MD, 2008, GENOMICS, V91, P30, DOI 10.1016/j.ygeno.2007.10.002; Avissar-Whiting M, 2010, REPROD TOXICOL, V29, P401, DOI 10.1016/j.reprotox.2010.04.004; Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Chen BZ, 2011, CELL BIOL INT, V35, P29, DOI 10.1042/CBI20090081; Cho H, 2010, BIOCHIP J, V4, P75, DOI 10.1007/s13206-010-4112-1; Choudhuri S, 2010, TOXICOL APPL PHARM, V245, P378, DOI 10.1016/j.taap.2010.03.022; Christen V, 2012, TOXICOL APPL PHARM, V259, P169, DOI 10.1016/j.taap.2011.12.021; Davis AP, 2009, NUCLEIC ACIDS RES, V37, pD786, DOI 10.1093/nar/gkn580; Dietert RR, 2010, ENVIRON HEALTH PERSP, V118, P1091, DOI 10.1289/ehp.1001971; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2008, ENVIRON MOL MUTAGEN, V49, P4, DOI 10.1002/em.20366; Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011; Genuis S. J., 2012, J ENV PUBLIC HLTH, V2012; Golub MS, 2010, BIRTH DEFECTS RES B, V89, P441, DOI 10.1002/bdrb.20275; Halden RU, 2010, ANNU REV PUBL HEALTH, V31, P179, DOI 10.1146/annurev.publhealth.012809.103714; Heudorf U, 2007, INT J HYG ENVIR HEAL, V210, P623, DOI 10.1016/j.ijheh.2007.07.011; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1995, DOI 10.1080/15287390491008913; Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Li SSL, 2006, STEM CELLS DEV, V15, P532, DOI 10.1089/scd.2006.15.532; Liu L, 2008, CURR ISSUES MOL BIOL, V10, P25; Manikkam M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031901; Martino-Andrade AJ, 2010, MOL NUTR FOOD RES, V54, P148, DOI 10.1002/mnfr.200800312; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Schwartz D, 2007, SCIENCE, V316, P695, DOI 10.1126/science.1141331; Shelby M. D., 2006, NTP CERHR MON, V18; Shelby MD, 2008, NTP CERHR MON, V22, P1; Shelby M.D., 2006, NTP CERHR MON, V18, p[vii, II]; Singh S, 2012, GENE, V494, P85, DOI 10.1016/j.gene.2011.11.035; Singh S, 2011, GENOMICS, V97, P148, DOI 10.1016/j.ygeno.2010.11.008; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Talsness CE, 2009, PHILOS T R SOC B, V364, P2079, DOI 10.1098/rstb.2008.0281; Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308; THOMAS JA, 1984, CRC CR REV TOXICOL, V13, P283, DOI 10.3109/10408448409023761; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Wu SD, 2010, INT J TOXICOL, V29, P193, DOI 10.1177/1091581809355488; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.0284626MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J MOL SCIAUGDiscipline: Chemistry998MK</notes>
    <keywords>ACID ESTERS; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CELL; CELLS; CHEMICALS; development; diabetes; DISEASE; diseases; DNA METHYLATION; EMBRYOGENESIS; ENVIRONMENTAL CHEMICALS; epigenetic; epigenetics; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Etiology; EXPOSURE; EXPRESSION; EZH2; FEMALE RATS; FOOD; GENE; gene expression; GENE-EXPRESSION; genistein; HEALTH; Hormones; Human embryonic stem cells; HUMAN HEALTH; HUMAN-BREAST-CANCER; In vitro; IN-UTERO; IN-VITRO; IN-VIVO; LINE; LINES; mechanism; METHYLATION; Methyltransferase; MICE; microRNA; MICRORNA EXPRESSION; MICRORNAS; MODEL; MODELS; Mouse; noncoding RNAs; phthalate; Phthalates; Phytoestrogen; PHYTOESTROGEN GENISTEIN; RAT; RATS; RECEPTOR; RISK; STEM-CELLS; testis; TISSUE; TISSUES; TOXICITY; Toxicogenomics; toxicology; UTERO EXPOSURE; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>10143</startpage>
    <endpage>10153</endpage>
    <journalfull>International Journal of Molecular Sciences</journalfull>
    <issue>8</issue>
    <volume>13</volume>
    <abstract>The epigenetic effects on DNA methylation, histone modification, and expression of non-coding RNAs (including microRNAs) of environmental chemicals such as bisphenol A (BPA) and phthalates have expanded our understanding of the etiology of human complex diseases such as cancers and diabetes. Multiple lines of evidence from in vitro and in vivo models have established that epigenetic modifications caused by in utero exposure to environmental toxicants can induce alterations in gene expression that may persist throughout life. Epigenetics is an important mechanism in the ability of environmental chemicals to influence health and disease, and BPA and phthalates are epigenetically toxic. The epigenetic effect of BPA was clearly demonstrated in viable yellow mice by decreasing CpG methylation upstream of the Agouti gene, and the hypomethylating effect of BPA was prevented by maternal dietary supplementation with a methyl donor like folic acid or the phytoestrogen genistein. Histone H3 was found to be trimethylated at lysine 27 by BPA effect on EZH2 in a human breast cancer cell line and mice. BPA exposure of human placental cell lines has been shown to alter microRNA expression levels, and specifically, miR-146a was strongly induced by BPA treatment. In human breast cancer MCF7 cells, treatment with the phthalate BBP led to demethylation of estrogen receptor (ESR1) promoter-associated CpG islands, indicating that altered ESR1 mRNA expression by BBP is due to aberrant DNA methylation. Maternal exposure to phthalate DEHP was also shown to increase DNA methylation and expression levels of DNA methyltransferases in mouse testis. Further, some epigenetic effects of BPA and phthalates in female rats were found to be transgenerational. Finally, the available new technologies for global analysis of epigenetic alterations will provide insight into the extent and patterns of alterations between human normal and diseased tissues. In vitro models such as human embryonic stem cells may be extremely useful in bettering the understanding of epigenetic effects on human development, health and disease, because the formation of embryoid bodies in vitro is very similar to the early stage of embryogenesis</abstract>
    <url>WOS:000308243400049</url>
    <isbnorissn>1422-0067</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>413</id>
    <title>Hepatic gene expression following consumption of soy protein isolate in female Sprague-Dawley rats differs from that produced by 17 beta-estradiol treatment</title>
    <authors>Singhal,R.; Shankar,K.; Badger,T.M.; Ronis,M.J.</authors>
    <availability>[Singhal, Rohit; Shankar, Kartik; Ronis, Martin J.] Univ Arkansas Med Sci, Dept Pharmacol &amp; Toxicol, Little Rock, AR 72205 USA. [Badger, Thomas M.] Univ Arkansas Med Sci, Dept Physiol &amp; Biophys, Little Rock, AR 72205 USA. [Shankar, Kartik; Badger, Thomas M.; Ronis, Martin J.] Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticleRonis, MJ (reprint author), Univ Arkansas Med Sci, Dept Pharmacol &amp; Toxicol, Little Rock, AR 72205 USAronismartinj@uams.eduADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; Badger T. M., 2005, J AM COLL NUTR, V24, p146S; Badger TM, 2001, INT J TOXICOL, V20, P165; Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; Barkhem T, 1998, MOL PHARMACOL, V54, P105; Barrett JR, 2006, ENVIRON HEALTH PERSP, V114, pA352; Beck V, 2003, J STEROID BIOCHEM, V84, P259, DOI 10.1016/S0960-0760(03)00034-7; Bhatia J, 2008, PEDIATRICS, V121, P1062, DOI 10.1542/peds.2008-0564; Boucher BA, 2008, EPIDEMIOLOGY, V19, P165; Boverhof DR, 2004, CARCINOGENESIS, V25, P1277, DOI 10.1093/carcin/bgh114; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Casanova M, 1999, TOXICOL SCI, V51, P236, DOI 10.1093/toxsci/51.2.236; Clair RS, 2005, HANDB EXP PHARM, V170, P301; Cooke PS, 2004, EXP BIOL MED, V229, P1127; Delclos KB, 2001, REPROD TOXICOL, V15, P647, DOI 10.1016/S0890-6238(01)00177-0; Duffy C, 2007, CA-CANCER J CLIN, V57, P260, DOI 10.3322/CA.57.5.260; Eason RR, 2005, J NUTR BIOCHEM, V16, P625, DOI 10.1016/j.jnutbio.2005.03.005; Fang NB, 2004, J AGR FOOD CHEM, V52, P4012, DOI 10.1021/jf049842y; Gao H, 2008, MOL ENDOCRINOL, V22, P10, DOI 10.1210/me.2007-0121; Gao H, 2006, MOL ENDOCRINOL, V20, P1287, DOI 10.1210/me.2006-0012; Goetzl M, 2007, PROSTATE CANCER P D, V10, P216, DOI 10.1038/sj.pcan.4500953; Gu LW, 2006, J NUTR, V136, P1215; Halees AS, 2003, NUCLEIC ACIDS RES, V31, P3554, DOI 10.1093/nar/gkg549; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hwang CS, 2006, J STEROID BIOCHEM, V101, P246, DOI 10.1016/j.jsbmb.2006.06.020; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jing H, 2008, MATERN CHILD NUTR, V4, P136, DOI 10.1111/j.1740-8709.2007.00102.x; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009; Munro IC, 2003, NUTR REV, V61, P1, DOI 10.1301/nr.2003.janr.1-33; MURPHY E, 2006, E SCHERING FDN S P, V1, P13; Naciff JM, 2005, TOXICOL SCI, V86, P396, DOI 10.1093/toxsci/kfi198; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Naciff JM, 2004, ENVIRON HEALTH PERSP, V112, P1519, DOI 10.1289/ehp.6848; Nagao T, 2001, REPROD TOXICOL, V15, P399, DOI 10.1016/S0890-6238(01)00141-1; *OECD, 2001, 3 M VAL MAN GROUP SC; Padilla-Banks E, 2001, ENVIRON HEALTH PERSP, V109, P821, DOI 10.2307/3454825; Parsons CJ, 2007, J GASTROEN HEPATOL, V22, pS79, DOI 10.1111/j.1440-1746.2006.04659.x; Patisaul HB, 2001, ENDOCRINOLOGY, V142, P2946, DOI 10.1210/en.142.7.2946; Petersen DN, 1998, ENDOCRINOLOGY, V139, P1082, DOI 10.1210/en.139.3.1082; Rachon D, 2007, MENOPAUSE, V14, P925, DOI 10.1097/gme.0b013e31802d979b; Rachon D, 2007, CLIMACTERIC, V10, P416, DOI 10.1080/13697130701624757; REEVES PG, 1993, J NUTR, V123, P1939; Rimoldi G, 2007, ENVIRON HEALTH PERSP, V115, P62, DOI 10.1289/ehp.9367; Ronis MJ, 2001, J NUTR, V131, P1180; Ronis MJ, 2006, J MED FOOD, V9, P348, DOI 10.1089/jmf.2006.9.348; Rozman KK, 2006, BIRTH DEFECTS RES B, V77, P485, DOI 10.1002/bdrb.20087; Setchell KD, 2001, J AM COLL NUTR, V20, P354; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Shimizu I, 2007, HEPATOL RES, V37, P239, DOI 10.1111/j.1872-034X.2007.00032.x; Singhal R, 2008, CARCINOGENESIS, V29, P227, DOI 10.1093/carcin/bgm288; Singhal R, 2008, TOXICOL APPL PHARM, V227, P275, DOI 10.1016/j.taap.2007.11.009; Singhal R, 2007, J NUTR, V137, P19; Su Y, 2007, PHYSIOL GENOMICS, V30, P8, DOI 10.1152/physiolgenomics.00023.2007; Unfer V, 2004, FERTIL STERIL, V82, P145, DOI 10.1016/j.fertnstert.2003.11.041; Velasquez Manuel T, 2007, Int J Med Sci, V4, P72; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Xu JW, 2002, WORLD J GASTROENTERO, V8, P883; Li X. J., 1997, Yaoxue Xuebao, V32, P5865910BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDJ ENDOCRINOLJULDiscipline: Endocrinology &amp; Metabolism530YS</notes>
    <keywords>17 beta-Estradiol; 17-ALPHA-ETHYNYL ESTRADIOL; 17-BETA-ESTRADIOL; analysis; ARYL-HYDROCARBON RECEPTOR; BIRTH; BISPHENOL-A; BREAST-CANCER; CANCER; CARCINOGENESIS; DEFECTS; diet; DIETARY EQUOL; E2; Epidemiology; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; Estrogenic; Estrogenicity; EXPOSURE; EXPRESSION; female; FOOD; FOODS; GENE; gene expression; gene expression profile; GENE-EXPRESSION; GENES; genistein; HEALTH; IN-VITRO; INDUCTION; Interaction; ISOFLAVONE; Liver; Menopause; METABOLISM; Microarray; P8; pediatric; PRODUCTS; Prostate; prostate cancer; PROSTATE-CANCER; PROTEIN; PUMP; RAT; RATS; RECEPTOR; Receptors; REDUCTION; REPRODUCTIVE-SYSTEM; serum; signaling; SOY; SOY PROTEIN; SOY PROTEIN ISOLATE; Steroid; TISSUE; TISSUES; UTERINE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>141</startpage>
    <endpage>152</endpage>
    <journalfull>Journal of Endocrinology</journalfull>
    <issue>1</issue>
    <volume>202</volume>
    <abstract>Although soy foods have been recognized as all excellent Source of protein, there have been recent concerns regarding potential adverse effects of isoflavone phytochemicals found in soy products, which are known to bind and activate estrogen receptors. Here, we used global hepatic gene expression profiles in ovariectomized female Sprague-Dawley rats treated with 17 beta-estradiol (E-2) or fed with soy protein isolate (SPI) as a means of estimating potential estrogenicity of SPI. Female Sprague-Dawley rats were fed AIN-93G diets containing casein (CAS) or SPI starting at postnatal day (PND) 30. Rats were ovariectomized oil PND 50 and infused with E-2 or vehicle in osmotic PUMPS for 14 d. Microarray analysis was performed on liver using Affymetrix GeneChip Rat 230 2.0. Serum E-2 levels were within normal ranges for the rat and SPI feeding did not increase uterine. wet weight in the absence or presence of E-2. SPI feeding altered (P &lt; 0.05, &gt;= +/- 1.5-fold) the expression of 82 genes, while E-2, treatment altered 892 genes. Moreover, only 4% of E-2-affected genes were also modulated by SPI, including Sonic whose expression was reversed by SPI feeding. The interaction between E-2 and SPI uniquely modulated the expression profile of 225 genes including the reduction of those involved in fatty acid biosynthesis or glucocorticoid signaling and in induction of those involved in cholesterol metabolism. The different hepatic gene signatures produced by SPI feeding compared with E-2 and the lack of increase in uterine wet weight in rats fed with SPI suggest that SPI is not estrogenic in these tissues. Journal of Endocrinology (2009) 202, 141-152</abstract>
    <url>WOS:000272629500015</url>
    <isbnorissn>0022-0795</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>408</id>
    <title>Cadmium-induced testicular injury</title>
    <authors>Siu,E.R.; Mruk,D.D.; Porto,C.S.; Cheng,C.Y.</authors>
    <availability>[Cheng, C. Yan] Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, New York, NY 10065 USA. [Porto, Catarina S.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pharmacol, Sect Expt Endocrinol,INFAR, BR-04044020 Sao Paulo, Brazil.</availability>
    <date>2009</date>
    <notes>JEnglishReviewCheng, CY (reprint author), Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, 1230 York Ave, New York, NY 10065 USAY-Cheng@popcbr.rockefeller.eduAcharya UR, 2008, REPROD TOXICOL, V25, P84, DOI 10.1016/j.reprotox.2007.10.004; Amara S, 2008, J REPROD DEVELOP, V54, P129, DOI 10.1262/jrd.18110; *ATSDR, 2007, 2007 CERCLA PRIOR LI; ATSDR, 2008, CADM TOX CAS STUD EN; Beardsley A, 2006, J ENDOCRINOL, V190, P759, DOI 10.1677/joe.1.06867; Begum NA, 2002, GENOMICS, V80, P630, DOI 10.1006/geno.2002.7000; Benoff S, 2000, HUM REPROD UPDATE, V6, P107, DOI 10.1093/humupd/6.2.107; Besecker B, 2008, AM J PHYSIOL-LUNG C, V294, pL1127, DOI 10.1152/ajplung.00057.2008; Beyersmann D, 2008, ARCH TOXICOL, V82, P493, DOI 10.1007/s00204-008-0313-y; Brama M, 2007, MOL CELL ENDOCRINOL, V264, P102, DOI 10.1016/j.mce.2006.10.013; Burukoglu D, 2008, B ENVIRON CONTAM TOX, V81, P521, DOI 10.1007/s00128-007-9211-x; CAMERON E, 1963, J ANAT, V97, P269; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; CHEUNG WY, 1988, ANN NY ACAD SCI, V522, P74, DOI 10.1111/j.1749-6632.1988.tb33345.x; CHIQUOINE A, 1964, ANAT REC, V149, P23, DOI 10.1002/ar.1091490104; Chung NPY, 2001, ENDOCRINOLOGY, V142, P1878, DOI 10.1210/en.142.5.1878; Chung RS, 2004, NEUROSCIENCE, V123, P595, DOI 10.1016/j.neuroscience.2003.10.019; CLOUGH SR, 1990, CELL BIOL TOXICOL, V6, P63, DOI 10.1007/BF00135027; Dalton T, 1996, ENVIRON HEALTH PERSP, V104, P68, DOI 10.2307/3432762; Dalton TP, 2005, P NATL ACAD SCI USA, V102, P3401, DOI 10.1073/pnas.0406085102; DANIELSON KG, 1982, P NATL ACAD SCI-BIOL, V79, P2301, DOI 10.1073/pnas.79.7.2301; Darbre PD, 2006, J APPL TOXICOL, V26, P191, DOI 10.1002/jat.1135; DE SK, 1991, MOL ENDOCRINOL, V5, P628; DIXIT VP, 1975, ACTA BIOL ACAD SCI H, V26, P97; Fiorini C, 2008, BBA-BIOMEMBRANES, V1778, P56, DOI 10.1016/j.bbamem.2007.08.032; Fiorini C, 2004, REPROD TOXICOL, V18, P413, DOI 10.1016/j.reprotox.2004.01.002; Goyer RA, 2004, BIOMETALS, V17, P555, DOI 10.1023/B:BIOM.0000045738.59708.20; GUNN S, 1970, TESTIS INFLUENCING F; GUNN SA, 1963, J NATL CANCER I, V31, P745; Gunnarsson D, 2007, TOXICOL LETT, V168, P51, DOI 10.1016/j.toxlet.2006.10.015; He L, 2006, MOL PHARMACOL, V70, P171, DOI 10.1124/mol.106.021521; Henson MC, 2004, EXP BIOL MED, V229, P383; HEW KW, 1993, BIOL REPROD, V49, P840, DOI 10.1095/biolreprod49.4.840; HEW KW, 1993, TOXICOL APPL PHARM, V121, P15, DOI 10.1006/taap.1993.1123; Hozumi I, 2008, NEUROSCI LETT, V438, P54, DOI 10.1016/j.neulet.2008.04.047; Hu YP, 2004, BIOMETALS, V17, P571, DOI 10.1023/B:BIOM.0000045835.21954.c7; *IARC, 1993, CADM CADM COMP IARC; JANECKI A, 1992, TOXICOL APPL PHARM, V112, P51, DOI 10.1016/0041-008X(92)90278-Z; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; JOHNSON MH, 1969, J REPROD FERTIL, V19, P551; KAR AB, 1961, ENDOCRINOLOGY, V69, P1116; Kara H, 2007, BIOL TRACE ELEM RES, V120, P205, DOI 10.1007/s12011-007-8019-1; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; KOIZUMI T, 1992, J TOXICOL ENV HEALTH, V37, P25; Kusakabe T, 2008, BIOMETALS, V21, P71, DOI 10.1007/s10534-007-9094-7; Lafuente A, 2004, TOXICOL LETT, V146, P175, DOI 10.1016/j.toxlet.2003.10.004; Lafuente A, 2003, BIOMETALS, V16, P243, DOI 10.1023/A:1020658128413; LASKEY JW, 1991, TOXICOL APPL PHARM, V108, P296, DOI 10.1016/0041-008X(91)90119-Y; Li L., 1998, REPROD DEV TOXICOLOG; Liu Y., 2001, J SAFETY ENV, V1, P9; Liu Z, 2008, BIOCHEM BIOPH RES CO, V365, P814, DOI 10.1016/j.bbrc.2007.11.067; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Martin LJ, 2007, TOXICOL SCI, V100, P474, DOI 10.1093/toxsci/kfm229; Martin MB, 2002, ENDOCRINOLOGY, V143, P263, DOI 10.1210/en.143.1.263; MASON KE, 1964, ANAT REC, V149, P135, DOI 10.1002/ar.1091490112; Matsuura T, 2002, J INORG BIOCHEM, V88, P183, DOI 10.1016/S0162-0134(01)00377-4; McKenna IM, 1996, TOXICOLOGY, V107, P121, DOI 10.1016/0300-483X(95)03252-B; MEEK ES, 1959, BRIT J EXP PATHOL, V40, P503; Meloni G, 2008, NAT CHEM BIOL, V4, P366, DOI 10.1038/nchembio.89; Meng J, 2005, P NATL ACAD SCI USA, V102, P16696, DOI 10.1073/pnas.0506084102; Moffatt P, 1998, DNA CELL BIOL, V17, P501, DOI 10.1089/dna.1998.17.501; Mruk DD, 2008, PHARMACOL REV, V60, P146, DOI 10.1124/pr.107.07105; Mulholland DJ, 2001, BIOL REPROD, V64, P396, DOI 10.1095/biolreprod64.1.396; NIEWENHUIS RJ, 1987, BIOL REPROD, V37, P127, DOI 10.1095/biolreprod37.1.127; NIEWENHUIS RJ, 1978, BIOL REPROD, V19, P1, DOI 10.1095/biolreprod19.1.1; NISHIMURA H, 1990, J HISTOCHEM CYTOCHEM, V38, P927; Olesen C, 2004, MOL REPROD DEV, V67, P116, DOI 10.1002/mrd20007; Palumaa P, 2002, BIOCHEMISTRY-US, V41, P6158, DOI 10.1021/bi025664v; PARIZEK J, 1957, J ENDOCRINOL, V15, P56, DOI 10.1677/joe.0.0150056; Parizek J., 1965, J REPROD FERTIL, V7, P263; PARIZEK J, 1960, J REPROD FERTIL, V1, P294; POWELL GW, 1964, J NUTR, V84, P205; Prozialeck WC, 2003, TOXICOL APPL PHARM, V189, P180, DOI 10.1016/S0041-008X(03)00130-3; Prozialeck WC, 2000, TOXICOL APPL PHARM, V164, P231, DOI 10.1006/taap.2000.8905; Prozialeck WC, 1999, BBA-MOL CELL RES, V1451, P93, DOI 10.1016/S0167-4889(99)00077-4; Prozialeck WC, 2008, TOXICOL SCI, V102, P207, DOI 10.1093/toxsci/kfm263; Ren XY, 2003, REPROD TOXICOL, V17, P219, DOI 10.1016/S0890-6238(02)00151-X; Ren XY, 2003, WORLD J GASTROENTERO, V9, P1554; ROE FJC, 1964, BRIT J CANCER, V18, P674, DOI 10.1038/bjc.1964.77; SALEHIASHTIANI K, 1993, P NATL ACAD SCI USA, V90, P8886, DOI 10.1073/pnas.90.19.8886; Sen Gupta R, 2004, MOL CELLS, V17, P132; SETCHELL BP, 1970, J ENDOCRINOL, V47, P81, DOI 10.1677/joe.0.0470081; SHIRAISHI N, 1995, TOXICOL APPL PHARM, V130, P229, DOI 10.1006/taap.1995.1028; SHIRAISHI N, 1994, J TOXICOL ENV HEALTH, V42, P193; SIU ER, ENDOCRINOLO IN PRESS; Siu MKY, 2003, ENDOCRINOLOGY, V144, P2141, DOI 10.1210/en.2002-221035; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Smida AD, 2004, BIOL REPROD, V70, P25, DOI 10.1095/biolreprod.103.019000; Sorenson DR, 2003, CELL BIOL TOXICOL, V19, P107, DOI 10.1023/A:1023359222963; Sugihara T, 1999, GENOMICS, V57, P130, DOI 10.1006/geno.1999.5756; Sutou S, 2003, BIOL REPROD, V68, P1861, DOI 10.1095/biolreprod.102.005603; Suzuki JS, 1998, BIOCHEM J, V334, P695; Syed V, 1997, J ANDROL, V18, P264; TAYLOR BA, 1973, P SOC EXP BIOL MED, V143, P629; Terada N, 2005, HISTOCHEM CELL BIOL, V124, P303, DOI 10.1007/s00418-005-0031-y; Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x; Thompson J, 2008, REPROD TOXICOL, V25, P304, DOI 10.1016/j.reprotox.2008.02.001; TOHYAMA C, 1994, HISTOCHEMISTRY, V101, P341, DOI 10.1007/BF00268995; Tremellen K, 2008, HUM REPROD UPDATE, V14, P243, DOI 10.1093/humupd/dmn004; Turner TT, 2008, J ANDROL, V29, P488, DOI 10.2164/jandrol.108.005132; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; Waalkes MP, 1997, TOXICOL APPL PHARM, V142, P40, DOI 10.1006/taap.1996.8005; Wang B, 2007, AM J PHYSIOL-CELL PH, V292, pC1523, DOI 10.1152/ajpcell.00409.2006; Wang RS, 2006, ENDOCRINOLOGY, V147, P5624, DOI 10.1210/en.2006-0138; Wong CH, 2004, J CELL SCI, V117, P783, DOI 10.1242/jcs.00900; Wong CH, 2005, CURR TOP DEV BIOL, V71, P263, DOI 10.1016/S0070-2153(05)71008-5; Wong CH, 2005, ENDOCRINOLOGY, V146, P1893, DOI 10.1210/en.2004-1464; Wong EWP, 2008, BBA-BIOMEMBRANES, V1778, P692, DOI 10.1016/j.bbamem.2007.11.006; World Health Organization, 2000, CADM AIR QUAL GUID; WU JC, 1993, BIOL REPROD, V49, P1353, DOI 10.1095/biolreprod49.6.1353; Xu GG, 1999, BIOMETALS, V12, P131, DOI 10.1023/A:1009273711068; Yan HHN, 2005, P NATL ACAD SCI USA, V102, P11722, DOI 10.1073/pnas.0503855102; Yan HHN, 2008, CURR TOP DEV BIOL, V80, P57, DOI 10.1016/S0070-2153(07)80002-0; Yan HHN, 2008, ADV EXP MED BIOL, V636, P234, DOI 10.1007/978-0-387-09597-4_13; Yang JM, 2003, REPROD TOXICOL, V17, P553, DOI 10.1016/S0890-6238(03)00100-X; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6; Yu XZ, 2008, TOXICOL SCI, V104, P385, DOI 10.1093/toxsci/kfn087; Zhou T, 1999, TOXICOLOGY, V142, P1, DOI 10.1016/S0300-483X(99)00115-8; Zhou T, 2004, TOXICOL LETT, V154, P191, DOI 10.1016/j.toxlet.2004.07.01512090ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMAUG 1Discipline: Pharmacology &amp; Pharmacy; Toxicology472QS</notes>
    <keywords>1; bisphenol; bisphenols; blood-testis barrier; Brain; CADMIUM; CANCER; CELL; Cell adhesion; CELLS; COMPLEXES; E-CADHERIN; ENDOCRINE; Endocrine disrupter; Endocrine disruptor; Environmental toxicant; fertility; FUTURE; Germ cells; HEALTH; HUMANS; IMPACT; IN-VIVO; Infertility; INJURY; Interaction; INTERSTITIAL-CELLS; JUNCTION DYNAMICS; KINASE; Liver; Male; MALE CONTRACEPTIVE DEVELOPMENT; mechanism; MECHANISMS; METALLOTHIONEIN GENE-EXPRESSION; Metals; MOUSE TESTES; ORGANIZATION; Oxidative stress; p38; PATHWAY; PHARMACOLOGY; PRIMARY RAT SERTOLI; PROTEIN; PROTEIN-KINASE; Review; Seminiferous epithelial cycle; SENSITIVITY; Sertoli cells; Signal transduction; signal transduction pathways; signaling; SPERM; SPERMATOGENESIS; TESTICULAR TOXICITY; testis; TOXICITY; toxicology; UPDATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>240</startpage>
    <endpage>249</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>3</issue>
    <volume>238</volume>
    <abstract>Cadmium (Cd) is an environmental toxicant and an endocrine disrupter in humans and rodents. Several organs (e.g., kidney, liver) are affected by Cd and recent studies have illustrated that the testis is exceedingly sensitive to Cd toxicity. More important, Cd and other toxicants, such as heavy metals (e.g., lead, mercury) and estrogenic-based compounds (e.g., bisphenols) may account for the recent declining fertility in men among developed countries by reducing sperm count and testis function. In this review, we critically discuss recent data in the field that have demonstrated the Cd-induced toxicity to the testis is probably the result of interactions of a complex network of causes. This is likely to involve the disruption of the blood-testis barrier (BTB) via specific signal transduction pathways and signaling molecules, such as p38 mitogen-activated protein kinase (MAPK). We also summarize current studies on factors that confer and/or regulate the testis sensitivity to Cd, such as Cd transporters and metallothioneins, the impact of Cd on the testis as an endocrine disruptor and oxidative stress inducer, and how it may disrupt the Zn(2+) and/or Ca(2+) mediated cellular events. While much work is needed before a unified mechanistic pathway of Cd-induced testicular toxicity emerges, recent studies have helped to identify some of the likely mechanisms and/or events that take place during Cd-induced testis injury. Furthermore, some of the recent studies have shed lights on potential therapeutic or preventive approaches that can be developed in future studies by blocking or minimizing the destructive effects of Cd to testicular function in men. (C) 2009 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000268147600007</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>109</id>
    <title>Exposure to Bisphenol-A Alters Mammary Gland Development and Increases Breast Cancer Risk</title>
    <authors>Snijders,A.M.; Blakeley,E.; Chang,P.; Sridharan,D.; Mori,H.; Rosen,C.; Bjornstad,K.; Huang,Y.; Mao,J.H.; Pluth,J.</authors>
    <availability>[Snijders, A. M.; Blakeley, E.; Chang, P.; Sridharan, D.; Mori, H.; Rosen, C.; Bjornstad, K.; Huang, Y.; Mao, J. H.; Pluth, J.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA. [Chang, P.] SRI Int, Menlo Pk, CA 94025 USA.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAENVIRON MOL MUTAGENSEP1Discipline: Environmental Sciences &amp; Ecology; Genetics &amp; Heredity; Toxicology205FV</notes>
    <keywords>ALTERS; bisphenol A; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; EXPOSURE; genetics; GLAND; GLAND DEVELOPMENT; mammary gland; MAMMARY-GLAND; RISK; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S41</startpage>
    <endpage>S41</endpage>
    <journalfull>Environmental and Molecular Mutagenesis</journalfull>
    <volume>54</volume>
    <url>WOS:000323429400116</url>
    <isbnorissn>0893-6692</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>302</id>
    <title>Cancer as development gone awry: the case for bisphenol-A as a carcinogen</title>
    <authors>Sonnenschein,C.; Wadia,P.R.; Rubin,B.S.; Soto,A.M.</authors>
    <availability>[Sonnenschein, C.; Wadia, P. R.; Rubin, B. S.; Soto, A. M.] Tufts Univ, Sch Med, Program Cellular Mol &amp; Dev Biol, Boston, MA 02111 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewSoto, AM (reprint author), Tufts Univ, Sch Med, Program Cellular Mol &amp; Dev Biol, Boston, MA 02111 USAcheryl.michaelson@tufts.edu; ana.soto@tufts.eduBaker SG, 2010, J CLIN ONCOL, V28, P3215, DOI 10.1200/JCO.2010.28.5460; Barker DJP, 2004, ACTA PAEDIATR, V93, P1559, DOI 10.1080/08035250410024772; BOYLAN ES, 1983, CANCER RES, V43, P4879; CUNHA GR, 1976, J EXP ZOOL, V196, P361, DOI 10.1002/jez.1401960310; Daniel CW, 1999, J MAMMARY GLAND BIOL, V4, P3, DOI 10.1023/A:1018796301609; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fleming JM, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-46; Gilbert SF, 2005, J BIOSCIENCES, V30, P65, DOI 10.1007/BF02705151; GRUBBS CJ, 1983, J NATL CANCER I, V70, P209; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hatch EE, 2006, AM J EPIDEMIOL, V164, P682, DOI 10.1093/aje/kwj257; HERBST AL, 1988, DEV EFFECTS DIETHYLS; HERBST AL, 1990, SEMIN SURG ONCOL, V6, P343, DOI 10.1002/ssu.2980060609; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Kurita T, 2004, DEVELOPMENT, V131, P1639, DOI 10.1242/dev.01038; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Maffini MV, 2005, AM J PATHOL, V167, P1405, DOI 10.1016/S0002-9440(10)61227-8; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Markey CM, 2003, EVOL DEV, V5, P1; Markey CM, 2001, BIOL REPROD, V65, P1215; Martin LJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1831; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; MITTENDORF R, 1995, TERATOLOGY, V51, P435, DOI 10.1002/tera.1420510609; Moss Lenny, 2003, WHAT GENES CANT DO; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; NEWBOLD RR, 1982, CANCER RES, V42, P2003; Newbold RR, 2005, BIRTH DEFECTS RES A, V73, P478, DOI 10.1002/bdra.20147; Noble D, 2006, MUSIC LIFE BIOL GENO; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Patwari P, 2008, CIRC RES, V103, P234, DOI 10.1161/CIRCRESAHA.108.175331; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; ROBBOY SJ, 1982, OBSTET GYNECOL, V60, P546; ROTHSCHILD TC, 1987, CANCER RES, V47, P4508; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Schor S. L., 1988, BREAST CANC SCI CHEM, P142; Schrodinger E., 1945, WHAT IS LIFE PHYS AS; Skakkebaek NE, 1998, APMIS, V106, P3; Sonnenschein C, 2008, SEMIN CANCER BIOL, V18, P372, DOI 10.1016/j.semcancer.2008.03.012; Sonnenschein C, 1999, SOC CELLS CANC CONTR; Soto AM, 2008, ACTA BIOTHEOR, V56, P257, DOI 10.1007/s10441-008-9052-y; Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087; Soto AM, 2005, J BIOSCIENCES, V30, P103, DOI 10.1007/BF02705155; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Thompson D. W., 1942, GROWTH FORM; Triolo V.A., 1965, CANCER RES, V25, P76; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vandenberg L.N., 2008, REPROD TOXICOL, V3-4, P210; Veltmaat JM, 2003, DIFFERENTIATION, V71, P1, DOI 10.1046/j.1432-0436.2003.700601.x; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Weinberg RA, 2006, BIOL CANC; Yin Y, 2006, MOL ENDOCRINOL, V20, P1535, DOI 10.1210/me.2005-0451621CAMBRIDGE UNIV PRESSCAMBRIDGEEDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLANDJ DEV ORIG HLTH DISFEBDiscipline: Public, Environmental &amp; Occupational Health755LW</notes>
    <keywords>ADULTHOOD; AGENTS; BIOLOGY; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; Carcinogen; CARCINOGENESIS; CARCINOMA; CELL; CELLS; CLEAR CELL ADENOCARCINOMA; DEFECTS; DES; development; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL; Differentiation; Ecological developmental biology; ENDOCRINE DISRUPTORS; Environmental estrogen; Estrogen; EXPOSURE; FETAL; FETAL EXPOSURE; fetal mammary gland development; fetal origins of adult disease; GENE; GENE-EXPRESSION; GENES; GLAND; GROWTH; HEALTH; IN-SITU; IN-UTERO; MAMMALIAN DEVELOPMENT; Mammary cancer; mammary gland; MAMMARY-GLAND; MECHANICAL CONTROL; MICE; MODEL; morphogenesis; MOUSE MAMMARY-GLAND; Occupational; ORGANIZATION; PERINATAL EXPOSURE; PRENATAL EXPOSURE; PRINCIPLES; RAT; RATS; Review; stroma-epithelium interactions; TISSUE; TISSUE MORPHOGENESIS; TISSUE ORGANIZATION; Tissue organization field theory; VAGINAL ADENOSIS; WOMEN; xenoestrogen; XENOESTROGENS; YOUNG-WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>9</startpage>
    <endpage>16</endpage>
    <journalfull>Journal of Developmental Origins of Health and Disease</journalfull>
    <issue>1</issue>
    <volume>2</volume>
    <abstract>The discovery of a rare clear cell carcinoma of the vagina in young women gestationally exposed to the estrogen diethylstilbestrol (DES) lent empirical support to the hypothesis that prenatal exposure to xenoestrogens might cause cancer. This fact contradicted two well-accepted notions: (i) mammalian development was merely the unfolding of a genetic program and (ii) only mutagenic agents could cause cancer. The ecological developmental biology (eco-devo) movement revitalized the concept of developmental plasticity through the occurrence of polyphenisms whereby a single genotype produces diverse phenotypes which are determined by environmental cues. Based on the principles of eco-devo and the tissue organization field theory of carcinogenesis, we hypothesized that developmental exposure to xenoestrogens increased the propensity to develop mammary cancer during adulthood. Bisphenol-A (BPA), a ubiquitous xenoestrogen, was chosen as a model for environmental estrogen exposure. In mice, perinatal exposure to environmentally relevant BPA levels induced alterations of the mammary gland architecture which manifested during fetal morphogenesis and throughout life, including the development of pre-neoplastic lesions. In rats, gestational exposure to BPA induced pre-neoplastic lesions and carcinoma in situ that manifested in adulthood in the absence of any additional treatment. Emerging epidemiological data reveal an increased incidence of breast cancer in women exposed to DES during gestation. Hence, both animal experiments and epidemiological data strengthen the hypothesis that fetal exposure to xenoestrogens may be an underlying cause of the increased incidence of breast cancer observed over the past 50 years</abstract>
    <url>WOS:000289933800003</url>
    <isbnorissn>2040-1744</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>420</id>
    <title>Interpreting endocrine disruption from an integrative biology perspective</title>
    <authors>Soto,A.M.; Rubin,B.S.; Sonnenschein,C.</authors>
    <availability>[Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USA.</availability>
    <date>2009</date>
    <notes>JEnglishArticle; Proceedings PaperSoto, AM (reprint author), Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USAana.soto@tufts.eduAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Baillie-Hamilton PF, 2002, J ALTERN COMPLEM MED, V8, P185, DOI 10.1089/107555302317371479; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Barker DJP, 2004, ACTA PAEDIATR, V93, P1559, DOI 10.1080/08035250410024772; Bechtel William, 2005, Stud Hist Philos Biol Biomed Sci, V36, P421, DOI 10.1016/j.shpsc.2005.03.010; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P258, DOI 10.1006/taap.1994.1160; BURLINGTON H, 1950, P SOC EXP BIOL MED, V74, P48; CARLSEN E, 1992, BRIT MED J, V305, P609; Cederroth CR, 2007, ENVIRON HEALTH PERSP, V115, P1467, DOI 10.1289/ehp.10413; CLEMENS LG, 1978, HORM BEHAV, V10, P40, DOI 10.1016/0018-506X(78)90023-5; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; COLBORN T, CHEM INDUCED ALTERAT, P1; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; GANDELMAN R, 1977, NATURE, V266, P722, DOI 10.1038/266722a0; Gilbert SF, 2000, DEV DYNAM, V219, P1, DOI 10.1002/1097-0177(2000)9999:9999&lt;::AID-DVDY1036&gt;3.0.CO;2-A; Gilbert SF, 2005, J BIOSCIENCES, V30, P65, DOI 10.1007/BF02705151; Grun F, 2006, MOL ENDOCRINOL, V20, P2141, DOI 10.1210/me.2005-0367; Grun F, 2006, ENDOCRINOLOGY, V147, pS50, DOI 10.1210/en.2005-1129; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HERBST AL, 1988, DEV EFFECTS DIETHYLS; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 1999, NATURE, V401, P763; Ingber DE, 2008, SEMIN CANCER BIOL, V18, P356, DOI 10.1016/j.semcancer.2008.03.016; JENKINS S, 2009, ENV HLTH PERSPECT; JOHNSON MD, 1993, CANCER RES, V53, P873; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Maffini MV, 2005, AM J PATHOL, V167, P1405, DOI 10.1016/S0002-9440(10)61227-8; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Markey CM, 2003, J STEROID BIOCHEM, V83, P235; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, P55, DOI 10.2307/3434921; Merelli E, 2007, BRIEF BIOINFORM, V8, P45, DOI 10.1093/bib/bbl014; MITTENDORF R, 1995, TERATOLOGY, V51, P435, DOI 10.1002/tera.1420510609; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; National Research Council, 1999, HORM ACT AG ENV; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Noble D, 2007, J PHYSIOL-LONDON, V580, P15, DOI 10.1113/jphysiol.2006.119370; Nunez AA, 2001, CHEMOSPHERE, V42, P917, DOI 10.1016/S0045-6535(00)00196-X; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Rayner JL, 2004, TOXICOL APPL PHARM, V195, P23, DOI 10.1016/j.taap.2003.11.005; Robertson SH, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-46; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Schlumpf M, 2004, TOXICOLOGY, V205, P113, DOI 10.1016/j.tox.2004.06.043; Skakkebaek NE, 1998, APMIS, V106, P3; Smink A, 2008, ACTA PAEDIATR, V97, P1465, DOI 10.1111/j.1651-2227.2008.00937.x; Sonnenschein C, 2008, SEMIN CANCER BIOL, V18, P372, DOI 10.1016/j.semcancer.2008.03.012; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; SOTO AM, 2008, ACTA BIOTHEORETICA; Toschke AM, 2002, EUR J PEDIATR, V161, P445, DOI 10.1007/s00431-002-0983-z; VANDENBERG LN, 2008, REPROD TOXICOL; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; vom Saal F S, 1989, J Anim Sci, V67, P1824; VOMSAAL FS, 1992, SEXUAL DIFFERENTIATI, V21, P17; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-05656015ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDMOL CELL ENDOCRINOLMAY 25SIDiscipline: Cell Biology; Endocrinology &amp; Metabolism455HR</notes>
    <keywords>Behavior; BIOLOGY; BISPHENOL-A; BODY-WEIGHT; BREAST-CANCER; CANCER; CARCINOGENESIS; Causation; CELL; CELLS; CHEMICALS; COMPLEXES; development; DEVELOPMENTAL BIOLOGY; Ecological developmental biology; END-POINTS; ENDOCRINE; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; EXPOSURE; FETAL; FETAL EXPOSURE; GLAND; HEALTH; IDENTIFICATION; IN-UTERO; Incidence; LACTATIONAL EXPOSURE; Male; malformation; mammary gland; MAMMARY-GLAND; MAMMARY-GLAND DEVELOPMENT; METABOLISM; MODEL; MODELS; PERINATAL EXPOSURE; PREDICTION; RATS; SPERM; Steroid; SYSTEM; SYSTEMS BIOLOGY; toxicology; TRACT; XENOESTROGEN BISPHENOL-A</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3</startpage>
    <endpage>7</endpage>
    <journalfull>Molecular and Cellular Endocrinology</journalfull>
    <issue>1-2</issue>
    <volume>304</volume>
    <abstract>The ability of reductionism to advance our understanding of complex biological phenomena is limited. The ecological developmental biology (eco-devo) movement rejects the notion that development is merely the unfolding of a genetic program. Fetal exposure to environmental endocrine disruptors may contribute to the increased incidence of male genital tract malformations, decreased sperm quality, several neoplasms, and altered body weight. Here we discuss problems hindering the study of endocrine disruption (reductionist stance, technically driven research biases, and study of single end points, chemicals and exposure periods). We propose the study of both upward and downward causation and a Systems Biology approach to develop quantitative mathematical models for use in computer simulations that would generate testable predictions. This integrative approach will allow the simultaneous consideration of organismal (systemic) effects and effects on various organ systems. It will promote the identification of similar and unique effects of different endocrine disruptors, and their inter-relationships. (C) 2009 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000266749800002</url>
    <isbnorissn>0303-7207</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>353</id>
    <title>Environmental causes of cancer: endocrine disruptors as carcinogens</title>
    <authors>Soto,A.M.; Sonnenschein,C.</authors>
    <availability>[Soto, Ana M.; Sonnenschein, Carlos] Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USA.</availability>
    <date>2010</date>
    <notes>JEnglishReviewSonnenschein, C (reprint author), Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USAcarlos.sonnenschein@tufts.eduAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Baird DD, 2005, REPROD TOXICOL, V20, P81, DOI 10.1016/j.reprotox.2005.01.002; Baker SG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-89; Baker SG, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-151; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Bosland M C, 1991, Princess Takamatsu Symp, V22, P109; BOYLAN ES, 1979, J TOXICOL ENV HEALTH, V5, P1059; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Buchanan DL, 2000, TOXICOL SCI, V57, P302, DOI 10.1093/toxsci/57.2.302; Burroughs KD, 2000, BIOL REPROD, V63, P1322, DOI 10.1095/biolreprod63.5.1322; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; COLBORN T, 1992, CHEM INDUCED ALTERAT, P1; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; Cooper M, 2009, MED STUD, V1, P55, DOI 10.1007/s12376-008-0002-4; Couse JF, 1997, MOL CARCINOGEN, V19, P236, DOI 10.1002/(SICI)1098-2744(199708)19:4&lt;236::AID-MC4&gt;3.0.CO;2-A; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Crain DA, 1998, TOXICOL IND HEALTH, V14, P261; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; Gilbert SF, 2009, ECOLOGICAL DEV BIOL; Gilbert SF, 1996, DEV BIOL, V173, P357, DOI 10.1006/dbio.1996.0032; Gilbert SF, 2000, DEV DYNAM, V219, P1, DOI 10.1002/1097-0177(2000)9999:9999&lt;::AID-DVDY1036&gt;3.0.CO;2-A; Gilbert SF, 2005, J BIOSCIENCES, V30, P65, DOI 10.1007/BF02705151; Griffiths P.E., 2000, CYCLES CONTINGENCY D, P195; Halakivi-Clarke L, 2000, Clin Cancer Res, V6, P305; Hardell L, 2006, INT J ANDROL, V29, P228, DOI 10.1111/j.1365-2605.2005.00622.x; Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Howdeshell KL, 1999, NATURE, V401, P763; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; Huang LW, 2004, J ANDROL, V25, P330; HUGGINS C, 1967, SCIENCE, V156, P1050, DOI 10.1126/science.156.3778.1050; HUGGINS C, 1967, CANCER RES, V27, P1925; Hull David, 1974, PHILOS BIOL SCI; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kogevinas M, 2001, HUM REPROD UPDATE, V7, P331, DOI 10.1093/humupd/7.3.331; Kortenkamp A, 2006, INT J ANDROL, V29, P193, DOI 10.1111/j.1365-2605.2005.00613.x; Kurita T, 2004, DEVELOPMENT, V131, P1639, DOI 10.1242/dev.01038; LACASSAGNE A, 1955, J ENDOCRINOL, V13, pR9; Maffini MV, 2005, AM J PATHOL, V167, P1405, DOI 10.1016/S0002-9440(10)61227-8; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, pA569; Miller C, 1998, NAT GENET, V20, P228; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MITTENDORF R, 1995, TERATOLOGY, V51, P435, DOI 10.1002/tera.1420510609; MORI T, 1976, J NATL CANCER I, V57, P1057; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Moss Lenny, 2003, WHAT GENES CANT DO; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Newbold RR, 2002, TOXICOL PATHOL, V30, P611, DOI 10.1080/01926230290105839; Noble D, 2006, MUSIC LIFE BIOL GENO; Noble D, 2007, J PHYSIOL-LONDON, V580, P15, DOI 10.1113/jphysiol.2006.119370; Nunez AA, 2001, CHEMOSPHERE, V42, P917, DOI 10.1016/S0045-6535(00)00196-X; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Phillips RB, 2004, HEREDITY, V93, P122, DOI 10.1038/sj.hdy.6800494; Potischman N, 1999, CANCER CAUSE CONTROL, V10, P561, DOI 10.1023/A:1008955110868; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; RITTER WE, 1928, U CALIF PUB ZOOL, V31, P307; ROTHSCHILD TC, 1987, CANCER RES, V47, P4508; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Sonnenschein C, 2008, SEMIN CANCER BIOL, V18, P372, DOI 10.1016/j.semcancer.2008.03.012; Sonnenschein C, 1999, SOC CELLS CANC CONTR; Soto AM, 2008, ACTA BIOTHEOR, V56, P257, DOI 10.1007/s10441-008-9052-y; Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087; Steenland K, 2004, ENVIRON HEALTH PERSP, V112, P1265, DOI 10.1289/ehp.7219; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Timms BG, 2002, TOXICOL SCI, V67, P264, DOI 10.1093/toxsci/67.2.264; Trichopoulos D, 1990, Epidemiology, V1, P95; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; vom Saal F S, 1980, Science, V208, P597, DOI 10.1126/science.7367881; vom Saal F S, 1983, Science, V220, P1306, DOI 10.1126/science.6857252; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Weinberg RA, 1998, ONE RENEGADE CELL CA; Wong KO, 2005, FOOD ADDIT CONTAM A, V22, P280, DOI 10.1080/02652030500077502; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a09499NATURE PUBLISHING GROUPNEW YORK75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USANAT REV ENDOCRINOLJULDiscipline: Endocrinology &amp; Metabolism614TY</notes>
    <keywords>Behavior; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER; CANCER; Carcinogen; CARCINOGENESIS; cardiovascular; CELL; CELLS; CHEMICALS; COMPLEXES; CYCLE; development; DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL DES; DISRUPTING CHEMICALS; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; Epidemiology; EXPOSURE; female; FETAL EXPOSURE; FOOD; GENE; GENES; HEALTH; HUMANS; IN-UTERO; Incidence; INDUCED REGRESSION; Male; malformation; MAMMARY-GLAND DEVELOPMENT; METABOLISM; MODEL; MODELS; PERINATAL EXPOSURE; PESTICIDES; POPULATION; Prostate; prostate cancer; PROSTATE CARCINOGENESIS; PROSTATE-CANCER; Reproduction; Review; SPERM; Steroid; SYSTEM; TARGET; Thyroid; TISSUE; TISSUES; TRACT; UPDATE; US POPULATION; XENOESTROGEN BISPHENOL-A</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>364</startpage>
    <endpage>371</endpage>
    <journalfull>Nature Reviews Endocrinology</journalfull>
    <issue>7</issue>
    <volume>6</volume>
    <abstract>Environmental endocrine disrupting chemicals (EDCs), including pesticides and industrial chemicals, have been and are released into the environment producing deleterious effects on wildlife and humans. The effects observed in animal models after exposure during organogenesis correlate positively with an increased incidence of malformations of the male genital tract and of neoplasms and with the decreased sperm quality observed in European and US populations. Exposure to EDCs generates additional effects, such as alterations in male and female reproduction and changes in neuroendocrinology, behavior, metabolism and obesity, prostate cancer and thyroid and cardiovascular endocrinology. This Review highlights the carcinogenic properties of EDCs, with a special focus on bisphenol A. However, humans and wildlife are exposed to a mixture of EDCs that act contextually. To explain this mindboggling complexity will require the design of novel experimental approaches that integrate the effects of different doses of structurally different chemicals that act at different ages on different target tissues. The key to this complex problem lies in the adoption of mathematical modeling and computer simulations afforded by system biology approaches. Regardless, the data already amassed highlight the need for a public policy to reduce exposure to EDCs</abstract>
    <url>WOS:000279083900004</url>
    <isbnorissn>1759-5029</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>128</id>
    <title>Does Cancer Start in the Womb? Altered Mammary Gland Development and Predisposition to Breast Cancer due to in Utero Exposure to Endocrine Disruptors</title>
    <authors>Soto,A.M.; Brisken,C.; Schaeberle,C.; Sonnenschein,C.</authors>
    <availability>[Soto, Ana M.; Schaeberle, Cheryl; Sonnenschein, Carlos] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Soto, Ana M.; Sonnenschein, Carlos] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA. [Brisken, Cathrin] Ecole Polytech Fed Lausanne, ISREC Swiss Inst Expt Canc Res, NCCR Mol Oncol, CH-1015 Lausanne, Switzerland.</availability>
    <date>2013</date>
    <notes>JEnglishReviewSonnenschein, C (reprint author), Tufts Univ, Sch Med, 136 Harrison Ave, Boston, MA 02111 USAcarlos.sonnenschein@tufts.eduAyyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Barker DJP, 2004, ACTA PAEDIATR, V93, P1559, DOI 10.1080/08035250410024772; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Booth BW, 2011, ONCOGENE, V30, P679, DOI 10.1038/onc.2010.439; BOYLAN ES, 1983, CANCER RES, V43, P4879; Bradshaw Amy D, 2009, J Cell Commun Signal, V3, P239, DOI 10.1007/s12079-009-0062-6; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Burridge E., 2008, ICIS CHEM BUSINESS, V274, P48; Colborn T., 1992, CHEM INDUCED ALTERAT; Cowin P, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003251; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; Dhimolea E, 2010, BIOMATERIALS, V31, P3622, DOI 10.1016/j.biomaterials.2010.01.077; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63; Gilbert SF, 2009, ECOLOGICAL DEV BIOL; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Jacob F, 1982, POSSIBLE ACTUAL; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Krause S, 2012, TISSUE ENG PT A, V18, P520, DOI [10.1089/ten.TEA.2011.0317, 10.1089/ten.tea.2011.0317]; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Longo G, 2012, PROG BIOPHYS MOL BIO, V109, P108, DOI 10.1016/j.pbiomolbio.2012.06.004; Maffini MV, 2005, AM J PATHOL, V167, P1405, DOI 10.1016/S0002-9440(10)61227-8; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Markey CM, 2003, J STEROID BIOCHEM, V83, P235; Markey CM, 2003, EVOL DEV, V5, P1; Markey CM, 2001, BIOL REPROD, V65, P1215; Medina D, 2000, J MAMMARY GLAND BIOL, V5, P393, DOI 10.1023/A:1009529928422; MITTENDORF R, 1995, TERATOLOGY, V51, P435, DOI 10.1002/tera.1420510609; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Munoz de Toro MM, 2005, ENDOCRINOLOGY, V146, P4138, DOI DOI 10.1210/EN.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; NARBAITZ R, 1980, ANAT EMBRYOL, V158, P161, DOI 10.1007/BF00315903; Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Potischman N, 1999, CANCER CAUSE CONTROL, V10, P561, DOI 10.1023/A:1008955110868; Rayner JL, 2005, TOXICOL SCI, V87, P255, DOI 10.1093/toxsci/kfi213; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Sallout B, 2003, J Obstet Gynaecol, V23, P555; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Silva E, 2002, ENVIRON SCI TECHNOL, V36, P1751, DOI 10.1021/es0101227; Singh M, 2000, LAB INVEST, V80, P221; Skakkebaek NE, 1998, APMIS, V106, P3; Sonnenschein C, 1999, SOC CELLS CANC CONTR; Soriano S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031109; Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Tamimi R, 2003, CANCER EPIDEM BIOMAR, V12, P647; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; TOMOOKA Y, 1982, J NATL CANCER I, V69, P1347; Trichopoulos D, 1990, Epidemiology, V1, P95; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vandenberg LN, 2006, END SOC M, VP1-177, P205; Vaux DL, 2011, BIOESSAYS, V33, P341, DOI 10.1002/bies.201100022; Veltmaat JM, 2003, DIFFERENTIATION, V71, P1, DOI 10.1046/j.1432-0436.2003.700601.x; Wadia PR, 2013, PLOS ONE IN PRESS; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Weinberg RA, 1998, ONE RENEGADE CELL CA; White SS, 2007, TOXICOL SCI, V96, P133, DOI 10.1093/toxsci/kfl177; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-1018; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422; Zoeller RT, 2007, THYROID, V17, P811, DOI 10.1089/thy.2007.01077610SPRINGER/PLENUM PUBLISHERSNEW YORK233 SPRING ST, NEW YORK, NY 10013 USAJ MAMMARY GLAND BIOLJUNSIDiscipline: Oncology; Endocrinology &amp; Metabolism; Physiology170SY</notes>
    <keywords>ADULTHOOD; Beaded duct; bisphenol A; BISPHENOL-A; BISPHENOL-A EXPOSURE; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CARCINOMA; CELL; CELLS; development; DIETHYLSTILBESTROL; Differentiation; DISEASE; Ecological developmental biology; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; Epidemiology; EXPOSURE; FETAL; FETAL MOUSE; FOOD; GLAND; GLAND DEVELOPMENT; HUMANS; IN-UTERO; JUN; mammary gland; MAMMARY-GLAND; METABOLISM; MICE; Neoplasia; oncology; PERINATAL EXPOSURE; PRENATAL EXPOSURE; Progesterone receptor; Proteomics; RAT; RATS; RECEPTOR ANTAGONIST; RISK; SOMATIC MUTATION THEORY; TISSUE; Tissue organization field theory; TUMORIGENESIS; UTERO EXPOSURE; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>199</startpage>
    <endpage>208</endpage>
    <journalfull>Journal of Mammary Gland Biology and Neoplasia</journalfull>
    <issue>2</issue>
    <volume>18</volume>
    <abstract>We are now witnessing a resurgence of theories of development and carcinogenesis in which the environment is again being accepted as a major player in phenotype determination. Perturbations in the fetal environment predispose an individual to disease that only becomes apparent in adulthood. For example, gestational exposure to diethylstilbestrol resulted in clear cell carcinoma of the vagina and breast cancer. In this review the effects of the endocrine disruptor bisphenol-A (BPA) on mammary development and tumorigenesis in rodents is used as a paradigmatic example of how altered prenatal mammary development may lead to breast cancer in humans who are also widely exposed to it through plastic goods, food and drink packaging, and thermal paper receipts. Changes in the stroma and its extracellular matrix led to altered ductal morphogenesis. Additionally, gestational and lactational exposure to BPA increased the sensitivity of rats and mice to mammotropic hormones during puberty and beyond, thus suggesting a plausible explanation for the increased incidence of breast cancer</abstract>
    <url>WOS:000320875100014</url>
    <isbnorissn>1083-3021</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>166</id>
    <title>Circulating serum xenoestrogens and mammographic breast density</title>
    <authors>Sprague,B.L.; Trentham-Dietz,A.; Hedman,C.J.; Wang,J.; Hemming,J.D.C.; Hampton,J.M.; Buist,D.S.M.; Bowles,E.J.A.; Sisney,G.S.; Burnside,E.S.</authors>
    <availability>[Sprague, Brian L.; Wang, Jue] Univ Vermont, Dept Surg, Burlington, VT 05401 USA. [Trentham-Dietz, Amy] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53726 USA. [Trentham-Dietz, Amy; Hampton, John M.; Burnside, Elizabeth S.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53792 USA. [Hedman, Curtis J.; Hemming, Jocelyn D. C.] Univ Wisconsin, Wisconsin State Lab Hyg, Div Environm Hlth, Madison, WI 53706 USA. [Buist, Diana S. M.; Bowles, Erin J. Aiello] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Sisney, Gale S.; Burnside, Elizabeth S.] Univ Wisconsin, Clin Sci Ctr E3 366, Dept Radiol, Madison, WI 53792 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleSprague, BL (reprint author), Univ Vermont, Dept Surg, Fletcher House 301,111 Colchester Ave, Burlington, VT 05401 USAbsprague@uvm.eduAnderson D, 1999, TERATOGEN CARCIN MUT, V19, P275, DOI 10.1002/(SICI)1520-6866(1999)19:4&lt;275::AID-TCM4&gt;3.0.CO;2-1; Baird DD, 2010, J EXPO SCI ENV EPID, V20, P169, DOI 10.1038/jes.2009.17; Borch J, 2004, REPROD TOXICOL, V18, P53, DOI 10.1016/j.reprotox.2003.10.011; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; Boyd NF, 2010, J NATL CANCER I, V102, P1224, DOI 10.1093/jnci/djq239; Braun JM, 2012, ENVIRON HEALTH PERSP, V120, P739, DOI 10.1289/ehp.1104139; Buist DSM, 2009, ANN INTERN MED, V150, P752; BYNG JW, 1994, PHYS MED BIOL, V39, P1629, DOI 10.1088/0031-9155/39/10/008; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2010, ENVIRON HEALTH PERSP, V118, P679, DOI 10.1289/ehp.0901560; Cleary MP, 2009, ENDOCRINOLOGY, V150, P2537, DOI 10.1210/en.2009-0070; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Committe on the Health Risks of Phthalates, 2008, PHTHAL CUM RISK ASS; Cummings SR, 2009, J NATL CANCER I, V101, P384, DOI 10.1093/jnci/djp018; Cuzick J, 2004, J NATL CANCER I, V96, P621, DOI 10.1093/jnci/djh106; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Greendale GA, 2003, J NATL CANCER I, V95, P30; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; Hauser R, 2004, ENVIRON HEALTH PERSP, V112, P1734, DOI 10.1289/ehp.7212; Hauser R, 2007, HUM REPROD, V22, P688, DOI 10.1093/humrep/del428; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1995, DOI 10.1080/15287390491008913; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Koch HM, 2006, INT J ANDROL, V29, P81; Koch HM, 2006, INT J ANDROL, V29, P155, DOI 10.1111/j.1365-2605.2005.00607.x; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154; Lopez-Carrillo L, 2010, ENVIRON HEALTH PERSP, V118, P539, DOI 10.1289/ehp.0901091; Lovekamp-Swan T, 2003, ENVIRON HEALTH PERSP, V111, P139; Maskarinec G, 2000, BREAST CANCER RES TR, V63, P153, DOI 10.1023/A:1006486319848; McTiernan A, 2005, J NATL CANCER I, V97, P1366, DOI 10.1093/jnci/dji279; Melzer D, 2011, ENVIRON HEALTH PERSP, V119, P1788, DOI 10.1289/ehp.1103809; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; National Toxicology Program, 2008, NIH PUBLICATION; Nepomnaschy PA, 2009, ENVIRON RES, V109, P734, DOI 10.1016/j.envres.2009.04.004; Peck Jennifer David, 2010, J Expo Sci Environ Epidemiol, V20, P90, DOI 10.1038/jes.2009.4; Reddy BS, 2006, FERTIL STERIL, V85, P775, DOI 10.1016/j.fertnstert.2005.08.037; Rubin D. B., 1987, MULTIPLE IMPUTATION; Schafer J. L., 1997, ANAL INCOMPLETE MULT; Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723; Silva MJ, 2003, J CHROMATOGR B, V789, P393, DOI 10.1016/S1570-0232(03)00164-8; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Sprague BL, 2012, BREAST CANCER RES TR, V131, P255, DOI 10.1007/s10549-011-1726-5; Sprague Brian L., 2011, Hormones &amp; Cancer, V2, P62, DOI 10.1007/s12672-010-0056-0; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690; Ye X, 2008, TALANTA, V76, P865, DOI 10.1016/j.talanta.2008.04.034513BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDBREAST CANCER RESDiscipline: Oncology279CQ</notes>
    <keywords>ADIPOSE-TISSUE; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; BUTYL PARABEN; CANCER; CANCER RISK; CANCER-RISK; CHEMICALS; ENDOCRINE DISRUPTORS; Epidemiology; estrogenic activity; EXPOSURE; FOOD; HEALTH; HORMONE-THERAPY; Hormones; HUMANS; IMPACT; mammographic density; Nonylphenol; octylphenol; oncology; PARABENS; phenol; PHENOLS; phthalate; Phthalates; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; RISK; serum; TISSUE; toxicology; URINARY PHTHALATE METABOLITE; US POPULATION; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Breast Cancer Research</journalfull>
    <issue>3</issue>
    <volume>15</volume>
    <abstract>Introduction: Humans are widely exposed to estrogenically active phthalates, parabens, and phenols, raising concerns about potential effects on breast tissue and breast cancer risk. We sought to determine the association of circulating serum levels of these chemicals (reflecting recent exposure) with mammographic breast density (a marker of breast cancer risk). Methods: We recruited postmenopausal women aged 55 to 70 years from mammography clinics in Madison, Wisconsin (N = 264). Subjects completed a questionnaire and provided a blood sample that was analyzed for mono-ethyl phthalate, mono-butyl phthalate, mono-benzyl phthalate, butyl paraben, propyl paraben, octylphenol, nonylphenol, and bisphenol A (BPA). Percentage breast density was measured from mammograms by using a computer-assisted thresholding method. Results: Serum BPA was positively associated with mammographic breast density after adjusting for age, body mass index, and other potentially confounding factors. Mean percentage density was 12.6% (95% confidence interval (CI), 11.4 to 14.0) among the 193 women with nondetectable BPA levels, 13.7% (95% CI, 10.7 to 17.1) among the 35 women with detectable levels below the median (&lt; 0.55 ng/ml), and 17.6% (95% CI, 14.1 to 21.5) among the 34 women with detectable levels above the median (&gt; 0.55 ng/ml; P-trend = 0.01). Percentage breast density was also elevated (18.2%; 95% CI, 13.4 to 23.7) among the 18 women with serum mono-ethyl phthalate above the median detected level (&gt; 3.77 ng/ml) compared with women with nondetectable BPA levels (13.1%; 95% CI, 11.9 to 14.3; P-trend = 0.07). No other chemicals demonstrated associations with percentage breast density. Conclusions: Postmenopausal women with high serum levels of BPA and mono-ethyl phthalate had elevated breast density. Further investigation of the impact of BPA and mono-ethyl phthalate on breast cancer risk by using repeated serum measurements or other markers of xenoestrogen exposure are needed</abstract>
    <url>WOS:000328937600009</url>
    <isbnorissn>1465-542X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>110</id>
    <title>Environmental Levels of Bisphenol-A Can Expand Numbers of Mammary Stem Cells and Potentially Increase Breast Cancer Risk</title>
    <authors>Sridharan,D.; Snijders,A.; Blakely,E.; Chang,P.; Rosen,C.; Bjornstad,K.; Mao,J.H.; Pluth,J.</authors>
    <availability>[Sridharan, D.; Snijders, A.; Blakely, E.; Chang, P.; Rosen, C.; Bjornstad, K.; Mao, J-H; Pluth, J.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.</availability>
    <date>2013</date>
    <notes>JEnglishMeeting Abstract00WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAENVIRON MOL MUTAGENSEP1Discipline: Environmental Sciences &amp; Ecology; Genetics &amp; Heredity; Toxicology205FV</notes>
    <keywords>bisphenol A; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CELL; CELLS; genetics; RISK; STEM-CELLS; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>S41</startpage>
    <endpage>S41</endpage>
    <journalfull>Environmental and Molecular Mutagenesis</journalfull>
    <volume>54</volume>
    <url>WOS:000323429400115</url>
    <isbnorissn>0893-6692</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>247</id>
    <title>Epigenetics and environmental exposures</title>
    <authors>Stein,R.A.</authors>
    <availability>Princeton Univ, Dept Mol Biol, Lewis Thomas Lab 320, Princeton, NJ 08544 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleStein, RA (reprint author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab 320, Princeton, NJ 08544 USAras2@princeton.eduAli AHK, 2011, MOL CARCINOGEN, V50, P89, DOI 10.1002/mc.20697; Arita A, 2009, METALLOMICS, V1, P222, DOI 10.1039/b903049b; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; Avissar-Whiting M, 2010, REPROD TOXICOL, V29, P401, DOI 10.1016/j.reprotox.2010.04.004; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Ballestar E, 2010, CLIN REV ALLERG IMMU, V39, P30, DOI 10.1007/s12016-009-8168-4; Bernal AJ, 2010, BIRTH DEFECTS RES A, V88, P938, DOI 10.1002/bdra.20685; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cantonwine D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-62; Chen HB, 2006, MOL CELL BIOL, V26, P3728, DOI 10.1128/MCB.26.10.3728-3737.2006; Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684; Davidson MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012560; Doi T, 2011, TOXICOL SCI, V120, P475, DOI 10.1093/toxsci/kfr022; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Ellen TP, 2009, BIOCHEMISTRY-US, V48, P4626, DOI 10.1021/bi900246h; Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Golebiowski F, 2005, MOL CELL BIOCHEM, V279, P133, DOI 10.1007/s11010-005-8285-1; Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Ichi S, 2010, J BIOL CHEM, V285, P36922, DOI 10.1074/jbc.M110.126714; Kalfa N, 2011, FERTIL STERIL, V95, P2574, DOI 10.1016/j.fertnstert.2011.02.047; Kasprzak KS, 2003, MUTAT RES-FUND MOL M, V533, P67, DOI 10.1016/j.mrfmmm.2003.08.021; Ke QD, 2006, CARCINOGENESIS, V27, P1481, DOI 10.1093/carcin/bgl004; Kim YI, 2004, ENVIRON MOL MUTAGEN, V44, P10, DOI 10.1002/em.20025; Klein CB, 2002, ENVIRON HEALTH PERSP, V110, P739; Lee DH, 2009, ENVIRON HEALTH PERSP, V117, P1799, DOI 10.1289/ehp.0900741; Maccani MA, 2010, EPIGENETICS-US, V5, P583, DOI 10.4161/epi.5.7.12762; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; McGowan PO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002085; McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739; Nakajima Takeshi, 2008, Environmental Health and Preventive Medicine, V13, P8, DOI 10.1007/s12199-007-0005-x; Nakajima T, 2009, INT J CANCER, V124, P905, DOI 10.1002/ijc.24018; Nandakumar V, 2011, CARCINOGENESIS, V32, P597, DOI 10.1093/carcin/bgq282; Newbold RR, 2007, MOL CARCINOGEN, V46, P783, DOI 10.1002/mc.20308; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Niwa T, 2010, ADV GENET, V71, P41, DOI [10.1016/B978-0-12-380864-6.00002-X, 10.1016/S0065-2660(10)71002-6]; Nobeyama Y, 2007, INT J CANCER, V121, P301, DOI 10.1002/ijc.22637; Petronis A, 2006, TRENDS GENET, V22, P347, DOI 10.1016/j.tig.2006.04.010; Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P1466, DOI 10.1289/ehp.0800497; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Reamon-Buettner SM, 2007, REPROD TOXICOL, V24, P20, DOI 10.1016/j.protox.2007.05.002; Roth TL, 2011, J PSYCHIATR RES, V45, P919, DOI 10.1016/j.jpsychires.2011.01.013; Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338; Sadikovic B, 2008, J BIOL CHEM, V283, P4051, DOI 10.1074/jbc.M707506200; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Sun H, 2009, TOXICOL APPL PHARM, V237, P258, DOI 10.1016/j.taap.2009.04.008; Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Toledo-Rodriguez M, 2010, AM J MED GENET B, V153B, P1350, DOI 10.1002/ajmg.b.31109; Upham BL, 1998, ENVIRON HEALTH PERSP, V106, P975, DOI 10.2307/3434140; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Wong CCY, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12226; Woodruff TJ, 2010, J EPIDEMIOL COMMUN H, V64, P307, DOI 10.1136/jech.2009.091108; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xiang N, 2008, CARCINOGENESIS, V29, P2175, DOI 10.1093/carcin/bgn179; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Zhou FC, 2011, ALCOHOL CLIN EXP RES, V35, P16519BMJ PUBLISHING GROUPLONDONBRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLANDJ EPIDEMIOL COMMUN HJANDiscipline: Public, Environmental &amp; Occupational Health862HL</notes>
    <keywords>ABERRANT DNA METHYLATION; BIOLOGY; BISPHENOL-A EXPOSURE; CADMIUM; CANCER; CANCER CELLS; Carcinogen; CARCINOGENESIS; CELL; development; DISEASE; diseases; environmental exposure; epigenetic; epigenetics; EXPOSURE; EXPRESSION; GASTRIC MUCOSAE; GENE; gene expression; GENE-EXPRESSION; GENES; HEALTH; HELICOBACTER-PYLORI INFECTION; HYPOMETHYLATION; mechanism; MECHANISMS; NICKEL; Occupational; P8</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>8</startpage>
    <endpage>13</endpage>
    <journalfull>Journal of Epidemiology and Community Health</journalfull>
    <issue>1</issue>
    <volume>66</volume>
    <abstract>It is becoming increasingly apparent that genetic factors are inadequate to fully explain many processes that shape development and disease. For example, monozygotic twin pairs, despite sharing identical DNA sequences, are often discordant for many traits and diseases, indicating that the same genotype can give rise to distinct phenotypes. This points towards the involvement of additional factors that cannot be explained solely by the sequence of the genome. Epigenetic modifications, defined as heritable changes that do not alter the nucleotide sequence, emerge as key factors that regulate chromatin structure and gene expression and, together with genetic factors, provide the mechanistic basis to understand the biological effects of various classes of environmental exposures. Epigenetic mechanisms explain the ability of certain chemical compounds to initiate biological perturbations that can lead to malignancy, despite being weak mutagens or lacking mutagenic activity altogether-a view that challenges old beliefs and opens new avenues in public health. The field of epigenetics also explains the causal link between certain infectious diseases and cancer, a relationship that was first observed over a century ago and was initially discounted, then fell into oblivion and more recently re-emerged as an important concept in biology. A key feature that distinguishes epigenetic modifications from genetic changes is their reversible nature. This provides exciting prophylactic and therapeutic perspectives, some of which already materialised with the approval of the first drugs that modulate the epigenetic machinery, reinforcing the idea that our genes are not our destiny</abstract>
    <url>WOS:000298080700002</url>
    <isbnorissn>0143-005X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>233</id>
    <title>Priorities for cancer prevention: lifestyle choices versus unavoidable exposures</title>
    <authors>Stewart,B.W.</authors>
    <availability>[Stewart, Bernard W.] Univ New S Wales, S Eastern Sydney Publ Hlth Unit, Canc Control Program, Sydney, NSW 2031, Australia. [Stewart, Bernard W.] Univ New S Wales, Sch Womens &amp; Childrens Hlth, Fac Med, Sydney, NSW 2031, Australia.</availability>
    <date>2012</date>
    <notes>JEnglishArticleStewart, BW (reprint author), Univ New S Wales, S Eastern Sydney Publ Hlth Unit, Canc Control Program, Sydney, NSW 2031, Australiabernard.stewart@sesiahs.health.nsw.gov.auAmes BN, 1997, FASEB J, V11, P1041; [Anonymous], 2005, SCIENCE, V310, P229; Arts JHE, 2008, REGUL TOXICOL PHARM, V52, P189, DOI 10.1016/j.yrtph.2008.08.009; Baralt LB, 2010, ENVIRON HEALTH PERSP, V118, P1668, DOI 10.1289/ehp.0901603; Belpomme D, 2007, ENVIRON RES, V105, P414, DOI 10.1016/j.envres.2007.07.002; Bergfeld WE, 2005, J AM ACAD DERMATOL, V52, P125, DOI 10.1016/j.jaad.2004.07.066; Billings Frederic T 3rd, 2005, Trans Am Clin Climatol Assoc, V116, P115; Bingham E, 2006, MOLECULAR CARCINOGENESIS AND THE MOLECULAR BIOLOGY OF HUMAN CANCER, P547; Boffetta P, 2006, MUTAT RES-GEN TOX EN, V608, P157, DOI 10.1016/j.mrgentox.2006.02.015; Boffetta P, 2008, J NATL CANCER I, V100, P988, DOI 10.1093/jnci/djn191; Boffetta P, 2003, BRIT MED BULL, V68, P71, DOI 10.1093/bmb/ldg023; Boffetta P, 2007, CARCINOGENESIS, V28, P913, DOI 10.1093/carcin/bgm034; Boice JD, 2009, HEALTH PHYS, V96, P128, DOI 10.1097/01.HP.0000327664.79349.d4; Boobis AR, 2008, TOXICOL LETT, V180, P137, DOI 10.1016/j.toxlet.2008.06.004; Borrell B, 2010, NATURE, V464, P1122, DOI 10.1038/4641122a; CDC (Centers for Disease Control and Prevention), 2009, 4 CDCP; Cogliano VJ, 2007, OCCUP ENVIRON MED, V64, P572, DOI 10.1136/oem.2006.031872; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Colditz GA, 2006, NAT REV CANCER, V6, P75, DOI 10.1038/nrc1784; Colt JS, 2007, CANCER CAUSE CONTROL, V18, P385, DOI 10.1007/s10552-006-0108-5; Cunningham AR, 2008, CHEM RES TOXICOL, V21, P1970, DOI 10.1021/tx8001725; Reuben SH, 2010, PRESIDENTS CANC PANE; DEWAILLY E, 1994, J NATL CANCER I, V86, P803, DOI 10.1093/jnci/86.10.803-a; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Doll R., 1981, J NATL CANCER I, V66, P1192; Enneking PA, 2006, ENVIRON HEALTH PERSP, V114, pA89; Environmental Protection Agency, 2011, 2005 NAT SCAL AIR TO; EPSTEIN SS, 1981, NATURE, V289, P127, DOI 10.1038/289127a0; Epstein SS, 2002, INT J HEALTH SERV, V32, P669, DOI 10.1092/4F8C-QW9W-QDHG-2R4F; Galeone C, 2010, CANCER EPIDEM BIOMAR, V19, P1723, DOI 10.1158/1055-9965.EPI-10-0191; Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P686; Gatto NM, 2007, CANCER CAUSE CONTROL, V18, P29, DOI 10.1007/s10552-006-0070-2; Geiss O, 2009, ENVIRON INT, V35, P1188, DOI 10.1016/j.envint.2009.07.016; Gennaro V, 2005, INT J OCCUP ENV HEAL, V11, P356; Gensburg LJ, 2009, ENVIRON HEALTH PERSP, V117, P1265, DOI 10.1289/ehp.0800153; Giles LV, 2011, ENVIRON HEALTH PERSP, V119, P29, DOI 10.1289/ehp.1002246; Glass AG, 2007, J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Gotay CC, 2005, J CLIN ONCOL, V23, P301, DOI 10.1200/JCO.2005.06.069; Grandjean P, 2004, ANNU REV PUBL HEALTH, V25, P199, DOI 10.1146/annurev.publhealth.25.050503.153941; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; Halden RU, 2010, ANNU REV PUBL HEALTH, V31, P179, DOI 10.1146/annurev.publhealth.012809.103714; HIGGINSO.J, 1973, P ROY SOC MED, V66, P314; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Katz JM, 2009, FOOD CHEM TOXICOL, V47, P335, DOI 10.1016/j.fct.2008.11.024; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kogevinas M, 2010, ENVIRON HEALTH PERSP, V118, P1531, DOI 10.1289/ehp.1001959; Krewski D., 2009, RES REP HLTH EFF I, V140, P5; Labreche F, 2010, OCCUP ENVIRON MED, V67, P263, DOI 10.1136/oem.2009.049817; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Ledford H, 2009, NATURE, V458, P792; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Liem AKD, 2000, FOOD ADDIT CONTAM, V17, P241, DOI 10.1080/026520300283324; Martin-Moreno JM, 2008, EUR J CANCER, V44, P1390, DOI 10.1016/j.ejca.2008.02.002; Martuzzi M, 2009, OCCUP ENVIRON MED, V66, P725, DOI 10.1136/oem.2008.044115; Michaels D, 2006, ANN NY ACAD SCI, V1076, P149, DOI 10.1196/annals.1371.058; Niederdeppe J, 2007, CANCER EPIDEM BIOMAR, V16, P998, DOI 10.1158/1055-9965.EPI-06-0608; Oberg M, 2011, LANCET, V377, P139, DOI 10.1016/S0140-6736(10)61388-8; Peres J, 2010, J NATL CANCER I, V102, P928, DOI 10.1093/jnci/djq263; Pirkle JL, 2006, ENVIRON HEALTH PERSP, V114, P853, DOI 10.1289/ehp.8850; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Preuss P W, 1981, Ann N Y Acad Sci, V363, P63, DOI 10.1111/j.1749-6632.1981.tb20720.x; Redeker C, 2009, EUR J CANCER, V45, P827, DOI 10.1016/j.ejca.2008.10.018; Rodriguez-Mozaz S, 2010, ENVIRON HEALTH PERSP, V118, P1016, DOI 10.1289/ehp.0901532; Rusiecki JA, 2004, J NATL CANCER I, V96, P1375; Russi MB, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-32; Schmidt CW, 2009, ENVIRON HEALTH PERSP, V117, pA548; Silver SR, 2009, ENVIRON HEALTH PERSP, V117, P276, DOI 10.1289/ehp.11774; Steenland K, 2010, ENVIRON HEALTH PERSP, V118, P1100, DOI 10.1289/ehp.0901827; Steww BW, 2008, MUTAT RES-REV MUTAT, V658, P124, DOI 10.1016/j.mrrrev.2007.11.007; The International Agency for Research on Cancer, 2007, ATTR CAUS CANC FRANC; Tsai SP, 2004, OCCUP ENVIRON MED, V61, P295, DOI 10.1136/oem.2003.007831; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1051, DOI 10.1289/ehp.0901717; Villanueva CM, 2004, EPIDEMIOLOGY, V15, P357, DOI 10.1097/01.ede.0000121380.02594.fc; Vineis P, 2010, CARCINOGENESIS, V31, P1703, DOI 10.1093/carcin/bgq087; Vineis P, 2007, ENVIRON HEALTH-UK, V6, DOI 10.1186/1476-069X-6-7; Weichenthal S, 2010, ENVIRON HEALTH PERSP, V118, P1117, DOI 10.1289/ehp.0901731; Weinhold B, 2011, ENVIRON HEALTH PERSP, V119, pA255, DOI 10.1289/ehp.119-a254; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010; Zambon P, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-19793ELSEVIER SCIENCE INCNEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USALANCET ONCOLMARDiscipline: Oncology900IO</notes>
    <keywords>AGRICULTURAL HEALTH; AIR-POLLUTION; BIOLOGY; BISPHENOL-A; BREAST-CANCER; CANCER; Carcinogen; CARCINOGENESIS; CARCINOGENIC RISKS; Carcinogenicity; Causation; CHEMICALS; DISEASE; DISINFECTION BY-PRODUCTS; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemicals; EPIDEMIOLOGIC EVIDENCE; Epidemiology; EXPOSURE; FOOD; HEALTH; oncology; PESTICIDE EXPOSURE; POOLED ANALYSIS; PREVENTION; PUBLIC-HEALTH; RISK</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>E126</startpage>
    <endpage>E133</endpage>
    <journalfull>Lancet Oncology</journalfull>
    <issue>3</issue>
    <volume>13</volume>
    <abstract>Although cancer prevention in the USA and other developed countries focuses on disease attributable to lifestyle factors such as smoking, alcohol intake, sun exposure, and obesity, cancer caused by involuntary exposures is a concern. The term environmental is ambiguously used to distinguish between lifestyle and unavoidable exposures. The general community is said to be vulnerable to carcinogens encountered in pollution, contaminated food, and consumer products. In view of these concerns, assessments of the carcinogenicity of particular chemicals are of little assistance in prevention of cancer. Appraisal of cancer attributable to widespread and localised pollution, pesticides, endocrine disrupting chemicals, and consumer products yields diverse outcomes, from established causation to absence of harm. The precautionary principle is not a practicable approach for unknown carcinogenic risks. Procedures for individuals to reduce exposure to recognised or suspect carcinogens in consumer products are not effective measures for cancer prevention. Anxiety concerning insidious cancer causation could divert attention from proven means of cancer prevention</abstract>
    <url>WOS:000300880600013</url>
    <isbnorissn>1470-2045</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>33</id>
    <title>Defining Estrogenic Mechanisms of Bisphenol A Analogs through High Throughput Microscopy-Based Contextual Assays</title>
    <authors>Stossi,F.; Bolt,M.J.; Ashcroft,F.J.; Lamerdin,J.E.; Melnick,J.S.; Powell,R.T.; Dandekar,R.D.; Mancini,M.G.; Walker,C.L.; Westwick,J.K.; Mancini,M.A.</authors>
    <availability>[Stossi, Fabio; Bolt, Michael J.; Ashcroft, Felicity J.; Dandekar, Radhika D.; Mancini, Maureen G.; Mancini, Michael A.] Baylor Coll Med, Dept Mol &amp; Cell Biol, Houston, TX 77030 USA. [Lamerdin, Jane E.; Melnick, Jonathan S.; Westwick, John K.] Odyssey Thera, San Ramon, CA 94583 USA. [Powell, Reid T.; Walker, Cheryl L.] Texas A&amp;M Hlth Sci Ctr, Inst Biosci &amp; Technol, Houston, TX 77030 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleMancini, MA (reprint author), Baylor Coll Med, Dept Mol &amp; Cell Biol, Houston, TX 77030 USAmancini@bcm.eduAshcroft FJ, 2011, GENE, V477, P42, DOI 10.1016/j.gene.2011.01.009; Auwerx J, 1999, CELL, V97, P161; Backman TWH, 2011, NUCLEIC ACIDS RES, V39, pW486, DOI 10.1093/nar/gkr320; Bolt MJ, 2013, NUCLEIC ACIDS RES, V41, P4036, DOI 10.1093/nar/gkt100; Borras M, 1996, J STEROID BIOCHEM, V57, P203, DOI 10.1016/0960-0760(95)00272-3; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; De Coster S., 2012, J ENV PUBLIC HLTH, V2012, DOI DOI 10.1155/2012/713696; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kocanova S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000922; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Marino M, 2012, STEROIDS, V77, P910, DOI 10.1016/j.steroids.2012.02.019; Michnick SW, 2006, METHODS, V40, P287, DOI 10.1016/j.ymeth.2006.07.016; Monroe DG, 2003, J ENDOCRINOL, V176, P349, DOI 10.1677/joe.0.1760349; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Pavlidis P, 2003, BIOINFORMATICS, V19, P295, DOI 10.1093/bioinformatics/19.2.295; Raj A, 2010, METHOD ENZYMOL, V472, P365, DOI 10.1016/S0076-6879(10)72004-8; Rivas A, 2002, J STEROID BIOCHEM, V82, P45, DOI 10.1016/S0960-0760(02)00146-2; Rochester JR, 2013, REPROD TOXICOL, V42, P132, DOI 10.1016/j.reprotox.2013.08.008; Rotroff DM, 2013, ENVIRON HEALTH PERSP, V121, P7, DOI 10.1289/ehp.1205065; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Sharp ZD, 2006, J CELL SCI, V119, P4101, DOI 10.1242/jcs.03161; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Susiarjo M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003401; Vinas R, 2013, ENVIRON HEALTH PERSP, V121, P352, DOI 10.1289/ehp.1205826; Watson CS, 2014, STEROIDS, V81, P36, DOI 10.1016/j.steroids.2013.11.006; Weiss B, 2012, NEUROTOXICOLOGY, V33, P1410, DOI 10.1016/j.neuro.2012.05.014; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Yu H, 2003, ASSAY DRUG DEV TECHN, V1, P811, DOI 10.1089/154065803772613444; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422371CELL PRESSCAMBRIDGE600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USACHEM BIOLJUN 19Discipline: Biochemistry &amp; Molecular BiologyAK5ZY</notes>
    <keywords>ALPHA; BETA; BINDING; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CELL; CHEMICALS; CLASSIFICATION; COACTIVATORS; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ER alpha; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; FRAGMENT COMPLEMENTATION ASSAYS; HUMAN HEALTH; mechanism; MECHANISMS; PLATFORM; POPULATION; PUBLIC-HEALTH; RECEPTOR; RECEPTOR-ALPHA; RESPONSES; SUSCEPTIBILITY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>743</startpage>
    <endpage>753</endpage>
    <journalfull>Chemistry &amp; Biology</journalfull>
    <issue>6</issue>
    <volume>21</volume>
    <abstract>Environmental exposures to chemically heterogeneous endocrine-disrupting chemicals (EDCs) mimic or interfere with hormone actions and negatively affect human health. Despite public interest and the prevalence of EDCs in the environment, methods to mechanistically classify these diverse chemicals in a high throughput (HT) manner have not been actively explored. Here, we describe the use of multiparametric, HT microscopy-based platforms to examine how a prototypical EDC, bisphenol A (BPA), and 18 poorly studied BPA analogs (BPXs), affect estrogen receptor (ER). We show that short exposure to BPA and most BPXs induces ER alpha and/or ER beta loading to DNA changing target gene transcription. Many BPXs exhibit higher affinity for ER beta and act as ER beta antagonists, while they act largely as agonists or mixed agonists and antagonists on ER alpha. Finally, despite binding to ERs, some BPXs exhibit lower levels of activity. Our comprehensive view of BPXs activities allows their classification and the evaluation of potential harmful effects. The strategy described here used on a large-scale basis likely offers a faster, more cost-effective way to identify safer BPA alternatives</abstract>
    <url>WOS:000338507700007</url>
    <isbnorissn>1074-5521</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>211</id>
    <title>In Utero Oxidative Stress Epigenetically Programs Antioxidant Defense Capacity and Adulthood Diseases</title>
    <authors>Strakovsky,R.S.; Pan,Y.X.</authors>
    <availability>[Strakovsky, Rita S.; Pan, Yuan-Xiang] Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA. [Pan, Yuan-Xiang] Univ Illinois, Dept Food Sci &amp; Human Nutr, Urbana, IL 61801 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReviewPan, YX (reprint author), Univ Illinois, Dept Food Sci &amp; Human Nutr, 461 Bevier Hall,905 S Goodwin Ave, Urbana, IL 61801 USAyxpan@illinois.eduAagaard-Tillery KM, 2008, J MOL ENDOCRINOL, V41, P91, DOI 10.1677/JME-08-0025; Akyol A, 2009, BRIT J NUTR, V102, P1601, DOI 10.1017/S0007114509990961; Al-Gubory KH, 2004, REPRODUCTION, V128, P767, DOI 10.1530/rep.1.00389; ALLEN RG, 1992, J NUTR, V122, P631; ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; Archer SL, 2010, CIRCULATION, V121, P2661, DOI 10.1161/CIRCULATIONAHA.109.916098; Aris A, 2009, PLACENTA, V30, P342, DOI 10.1016/j.placenta.2009.01.003; Atamer Y, 2005, EUR J OBSTET GYN R B, V119, P60, DOI 10.1016/j.ejogrb.2004.06.033; Baiza-Gutman LA, 2000, INT J BIOCHEM CELL B, V32, P255, DOI 10.1016/S1357-2725(99)00061-8; Ball ER, 2010, HORM BEHAV, V57, P313, DOI 10.1016/j.yhbeh.2009.12.013; Barker DJP, 2004, J AM COLL NUTR, V23, p588S; Bayol SA, 2005, J PHYSIOL-LONDON, V567, P951, DOI 10.1113/jphysiol.2005.088989; Bayol SA, 2010, ENDOCRINOLOGY, V151, P1451, DOI 10.1210/en.2009-1192; Bernardi F, 2008, J OBSTET GYNAECOL RE, V34, P948, DOI 10.1111/j.1447-0756.2008.00803.x; Biri A, 2007, GYNECOL OBSTET INVES, V64, P187, DOI 10.1159/000106488; Bonnet S, 2006, CIRCULATION, V113, P2630, DOI 10.1161/CIRCULATIONAHA.105.609008; Bouanane S, 2009, CLIN SCI, V116, P669, DOI 10.1042/CS20080413; Bruce KD, 2009, HEPATOLOGY, V50, P1796, DOI 10.1002/hep.23205; Bruin JE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003371; Bruin JE, 2008, FREE RADICAL BIO MED, V44, P1919, DOI 10.1016/j.freeradbiomed.2008.02.010; Burton GJ, 2009, J ANAT, V215, P27, DOI 10.1111/j.1469-7580.2008.00978.x; Jauniaux E, 2003, PLACENTA, V24, pS86, DOI 10.1053/plac.2002.0932; Caluwaerts S, 2007, METABOLISM, V56, P1431, DOI 10.1016/j.metabol.2007.06.007; Carter AM, 2000, PLACENTA, V21, pS31, DOI 10.1053/plac.1999.0513; Chan GC, 2005, J IMMUNOL, V175, P3846; Chan WH, 2009, REPROD TOXICOL, V28, P52, DOI 10.1016/j.reprotox.2009.03.014; Chen JH, 2010, CLIN SCI, V119, P373, DOI 10.1042/CS20100230; Cho SH, 2009, J APPL TOXICOL, V29, P110, DOI 10.1002/jat.1387; Cimafranca MA, 2010, BIOL REPROD, V83, P114, DOI 10.1095/biolreprod.109.080549; Coughlan MT, 2004, PLACENTA, V25, P78, DOI 10.1016/S0143-4004(03)00183-8; Coughlan MT, 2004, J CLIN ENDOCR METAB, V89, P3585, DOI 10.1210/jc.2003-031953; Crinnion WJ, 2009, ALTERN MED REV, V14, P212; Daikoku T, 2003, J BIOL CHEM, V278, P7683, DOI 10.1074/jbc.M211390200; Davison JM, 2009, J BIOL CHEM, V284, P1982, DOI 10.1074/jbc.M807651200; DEVASAGAYAM TPA, 1990, BIOCHEM INT, V21, P27; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Hitchiler MJ, 2008, FREE RADICAL BIO MED, V45, P1573, DOI 10.1016/j.freeradbiomed.2008.09.005; Droge W, 2002, PHYSIOL REV, V82, P47; Dunwoodie SL, 2009, DEV CELL, V17, P755, DOI 10.1016/j.devcel.2009.11.008; Fall C, 2009, INDIAN J MED RES, V130, P593; Fetoui H, 2009, J ANIM PHYSIOL AN N, V93, P263, DOI 10.1111/j.1439-0396.2008.00812.x; Forsberg H, 1996, FREE RADICAL RES, V24, P451, DOI 10.3109/10715769609088044; Garrel C, 2010, J ENDOCRINOL, V205, P107, DOI 10.1677/JOE-09-0362; Golub MS, 2010, BIRTH DEFECTS RES B, V89, P441, DOI 10.1002/bdrb.20275; Gong L, 2010, EPIGENETICS-US, V5, P619, DOI 10.4161/epi.5.7.12882; HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Hiltunen M, 2002, VASC MED, V7, P5, DOI 10.1191/1358863x02vm418oa; Hitchler MJ, 2006, EPIGENETICS-US, V1, P163; Howie GJ, 2009, J PHYSIOL-LONDON, V587, P905, DOI 10.1113/jphysiol.2008.163477; Hracsko Z, 2008, REDOX REP, V13, P11, DOI 10.1179/135100008X259097; Igosheva N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010074; Jansson T, 2007, CLIN SCI, V113, P1, DOI 10.1042/CS20060339; Jauniaux E, 2000, AM J PATHOL, V157, P2111, DOI 10.1016/S0002-9440(10)64849-3; Jones HN, 2009, FASEB J, V23, P271, DOI 10.1096/fj.08-116889; Jones ML, 2010, BIOL REPROD, V83, P254, DOI 10.1095/biolreprod.110.083907; Kabuto H, 2004, LIFE SCI, V74, P2931, DOI 10.1016/j.lfs.2003.07.060; Kabuto H, 2003, ENVIRON RES, V93, P31, DOI 10.1016/S0013-9351(03)00062-8; Kauma S, 2002, OBSTET GYNECOL, V100, P706, DOI 10.1016/S0029-7844(02)02169-5; Kim H, 2011, EUR J CLIN NUTR, V65, P1118, DOI 10.1038/ejcn.2011.77; Korteweg FJ, 2008, PLACENTA, V29, P71, DOI 10.1016/j.placenta.2007.07.003; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kovacic P, 2008, J RECEPT SIG TRANSD, V28, P323, DOI 10.1080/10799890802305217 ; Kumari AS, 2001, INT J GYNECOL OBSTET, V73, P101, DOI 10.1016/S0020-7292(00)00391-X; Lapointe J, 2003, BIOL REPROD, V68, P1157, DOI 10.1095/biolreprod.102.007476; Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171; Liang C, 2009, BIRTH DEFECTS RES B, V86, P362, DOI 10.1002/bdrb.20204; Liang CY, 2010, METABOLISM, V59, P943, DOI 10.1016/j.metabol.2009.10.015; Liang P, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-231; Lillycrop KA, 2008, BRIT J NUTR, V100, P278, DOI 10.1017/S0007114507894438; Lillycrop KA, 2005, J NUTR, V135, P1382; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Lin Y, 2011, BRIT J NUTR, V106, P510, DOI 10.1017/S0007114511000614; Mackenzie GG, 2011, FREE RADICAL BIO MED, V51, P480, DOI 10.1016/j.freeradbiomed.2011.04.028; Madazli R, 2002, J Obstet Gynaecol, V22, P477; Mahn K, 2005, FASEB J, V19, P1755, DOI 10.1096/fj.05-4008fje; Margueron R, 2010, NAT REV GENET, V11, P285, DOI 10.1038/nrg2752; Martin-Gallan P, 2003, FREE RADICAL BIO MED, V34, P1563, DOI 10.1016/S0891-5849(03)00185-0; Maunakea AK, 2010, CIRC RES, V107, P327, DOI 10.1161/CIRCRESAHA.110.222463; McCurdy CE, 2009, J CLIN INVEST, V119, P323, DOI 10.1172/JCI32661; Menon R, 2011, PLACENTA, V32, P317, DOI 10.1016/j.placenta.2011.01.015; Metges CC, 2009, ADV EXP MED BIOL, V646, P105, DOI 10.1007/978-1-4020-9173-5_11; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Mise H, 1998, J CLIN ENDOCR METAB, V83, P3225, DOI 10.1210/jc.83.9.3225; Murr R, 2010, ADV GENET, V70, P101, DOI [10.1016/B978-0-12-380866-0.60005-8, 10.1016/S0065-2660(10)70005-5]; Myllynen P, 2005, PLACENTA, V26, P361, DOI 10.1016/j.placenta.2004.09.006; Nakayama M, 2003, AM J PATHOL, V163, P923, DOI 10.1016/S0002-9440(10)63452-9; Ojeda ML, 2009, BIRTH DEFECTS RES B, V86, P490, DOI 10.1002/bdrb.20211; Olsson MG, 2010, FREE RADICAL BIO MED, V48, P284, DOI 10.1016/j.freeradbiomed.2009.10.052; Ornoy A, 2007, REPROD TOXICOL, V24, P31, DOI 10.1016/j.reprotox.2007.04.004; Ouyang YQ, 2009, HYPERTENS PREGNANCY, V28, P56, DOI 10.1080/10641950802233064; Perera FP, 2006, ENVIRON HEALTH PERSP, V114, P1287, DOI 10.1289/ehp.9084; Perrotta I, 2009, CARDIOVASC PATHOL, V18, P361, DOI 10.1016/j.carpath.2008.08.005; Picciano MF, 2003, J NUTR, V133, p1997S; Pillai P, 2009, J BIOCHEM MOL TOXIC, V23, P419, DOI 10.1002/jbt.20305; Polanska K, 2010, INT J OCCUP MED ENV, V23, P339, DOI 10.2478/v10001-010-0028-1; Rodford JL, 2008, J PHYSIOL-LONDON, V586, P4709, DOI 10.1113/jphysiol.2008.156976; Ross AE, 2011, J UROLOGY, V185, P1894, DOI 10.1016/j.juro.2010.12.095; Sagol S, 1999, INT J GYNECOL OBSTET, V64, P121, DOI 10.1016/S0020-7292(98)00217-3; Saker M, 2008, EUR J OBSTET GYN R B, V141, P95, DOI 10.1016/j.ejogrb.2008.07.013; Salmasi G, 2010, ACTA OBSTET GYN SCAN, V89, P423, DOI 10.3109/00016340903505748; Sebire NJ, 2001, INT J OBESITY, V25, P1175, DOI 10.1038/sj.ijo.0801670; Sen S, 2010, DIABETES, V59, P3058, DOI 10.2337/db10-0301; Sharif Jafar, 2007, Nucleic Acids Symp Ser (Oxf), P125; Sikkema JM, 2001, PLACENTA, V22, P304, DOI 10.1053/plac.2001.0629; Siow RCM, 2010, MOL ASPECTS MED, V31, P468, DOI 10.1016/j.mam.2010.09.003; SOHAL RS, 1988, ANN NY ACAD SCI, V551, P59, DOI 10.1111/j.1749-6632.1988.tb22320.x; Steegers EAP, 2010, LANCET, V376, P631, DOI 10.1016/S0140-6736(10)60279-6; Strakovsky RS, 2011, J PHYSIOL-LONDON, V589, P2707, DOI 10.1113/jphysiol.2010.203950; Straussman R, 2009, NAT STRUCT MOL BIOL, V16, P564, DOI 10.1038/nsmb.1594; Suganuma H, 2010, NEUROPATHOLOGY, V30, P597, DOI 10.1111/j.1440-1789.2010.01114.x; Sugino N, 2000, MOL HUM REPROD, V6, P19, DOI 10.1093/molehr/6.1.19; Suter M, 2011, FASEB J, V25, P714, DOI 10.1096/fj.10-172080; Takagi Y, 2004, VIRCHOWS ARCH, V444, P49, DOI 10.1007/s00428-003-0903-2; TAKEHARA Y, 1990, ACTA MED OKAYAMA, V44, P103; Takiguchi S, 2000, BIOL REPROD, V62, P398, DOI 10.1095/biolreprod62.2.398; Tarry-Adkins JL, 2010, FASEB J, V24, P2762, DOI 10.1096/fj.10-156075; Tarry-Adkins JL, 2008, FASEB J, V22, P2037, DOI 10.1096/fj.07-099523; Thaler R, 2009, BRIT J NUTR, V101, P743, DOI 10.1017/S0007114508047685; Theys N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006110; Tomat AL, 2008, AM J PHYSIOL-REG I, V295, pR543, DOI 10.1152/ajpregu.00050.2008; Tosh DN, 2010, AM J PHYSIOL-GASTR L, V299, pG1023, DOI 10.1152/ajpgi.00052.2010; TROCINO RA, 1995, DIABETES, V44, P992, DOI 10.2337/diabetes.44.8.992; Tsukimori K, 2008, AM J HYPERTENS, V21, P1343, DOI 10.1038/ajh.2008.289; Valko M, 2004, MOL CELL BIOCHEM, V266, P37, DOI 10.1023/B:MCBI.0000049134.69131.89; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vanaja DK, 2009, CANCER INVEST, V27, P549, DOI 10.1080/07357900802620794; Votavova H, 2011, PLACENTA, V32, P763, DOI 10.1016/j.placenta.2011.06.022; Vucetic Z, 2010, ENDOCRINOLOGY, V151, P4756, DOI 10.1210/en.2010-0505; Warren AY, 2005, REPRODUCTION, V130, P539, DOI 10.1530/rep.1.00437; Waterland RA, 2008, INT J OBESITY, V32, P1373, DOI 10.1038/ijo.2008.100; Wolff GL, 1998, FASEB J, V12, P949; Xiao DL, 2011, BRIT J PHARMACOL, V164, P1400, DOI 10.1111/j.1476-5381.2011.01437.x; Zabihi S, 2010, BIRTH DEFECTS RES A, V88, P779, DOI 10.1002/bdra.20704; Zhang XY, 2011, J NUTR, V141, P1254, DOI 10.3945/jn.111.139576; Zhao L, 2008, TOXICOL SCI, V103, P149, DOI 10.1093/toxsci/kfn027; Zheng SS, 2011, EPIGENETICS-US, V6, P161, DOI 10.4161/epi.6.2.13472; Zheng SS, 2011, J NUTR BIOCHEM, V22, P567, DOI 10.1016/j.jnutbio.2010.04.013; Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015; Zusterzeel PLM, 2001, PLACENTA, V22, P213, DOI 10.1053/plac.2000.06061405MARY ANN LIEBERT INCNEW ROCHELLE140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USAANTIOXID REDOX SIGNJULDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism944MQ</notes>
    <keywords>ADULTHOOD; ANTIOXIDANT; BIOLOGY; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CELL; diabetes; DISEASE; diseases; DNA METHYLATION; DNA-methylation; EARLY-PREGNANCY; environment; epigenetic; EPIGENETIC REGULATION; EXPOSURE; FETAL; FOOD; GENE; GENE-EXPRESSION; GENES; HEALTH; HIGH-FAT DIET; IN-UTERO; MATERNAL PROTEIN RESTRICTION; METABOLIC SYNDROME; METABOLISM; METHYLATION; Oxidative stress; PLACENTA; POLYCYCLIC AROMATIC-HYDROCARBONS; PREGNANCY; PULMONARY ARTERIAL-HYPERTENSION; Reproduction; SUPEROXIDE-DISMUTASE EXPRESSION; SYSTEM; THERAPY; UTERO EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>237</startpage>
    <endpage>253</endpage>
    <journalfull>Antioxidants &amp; Redox Signaling</journalfull>
    <issue>2</issue>
    <volume>17</volume>
    <abstract>Significance: Maternal health and diet during gestation are critical for predicting fetal outcomes, both immediately at birth and in adulthood. While epigenetic modifications have previously been tightly linked to carcinogenesis, recent advances in the field have suggested that numerous adulthood diseases, including those characteristic of metabolic syndrome, could be programmed in utero in response to maternal exposures, and these "programmable" diseases are associated with epigenetic modifications of vital genes. Recent Advances: While little is currently known about the epigenetic regulation of the antioxidant (AOX) defense system, several studies in animals show that AOX defense capacity may be programmed in utero, making it likely that the critical genes involved in this pathway are epigenetically regulated, either by DNA methylation or by the modification of histone tails. Critical Issues: This article presents the most current knowledge of the in utero regulation of the AOX defense capacity, and will specifically focus on the potential epigenetic regulation of this system in response to various in utero exposures or stimuli. The ability to appropriately respond to oxidative stress is critical for the health and survival of any organism, and the potential programming of this capacity may provide a link between the in utero environment and the tendency of certain individuals to be more susceptible toward disease stimuli in their postnatal environments. Future Directions: We sincerely hope that future studies which result in a deeper understanding of the in utero programming of the epigenome will lead to novel and effective therapies for the treatment of epigenetically linked diseases. Antioxid. Redox Signal. 17, 237-253</abstract>
    <url>WOS:000304207700006</url>
    <isbnorissn>1523-0864</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>146</id>
    <title>Bisphenol A Exposure Disrupts Genomic Imprinting in the Mouse</title>
    <authors>Susiarjo,M.; Sasson,I.; Mesaros,C.; Bartolomei,M.S.</authors>
    <availability>[Susiarjo, Martha; Bartolomei, Marisa S.] Univ Penn, Dept Cell &amp; Dev Biol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Susiarjo, Martha; Bartolomei, Marisa S.] Univ Penn, Ctr Excellence Environm Toxicol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Sasson, Isaac] Univ Penn, Dept Obstet &amp; Gynecol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Mesaros, Clementina] Univ Penn, Dept Pharmacol, Perelman Sch Med, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA. [Mesaros, Clementina] Univ Penn, Dept Pharmacol, Perelman Sch Med, Ctr Excellence Environm Toxicol, Philadelphia, PA 19104 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleSusiarjo, M (reprint author), Univ Penn, Dept Cell &amp; Dev Biol, Perelman Sch Med, Philadelphia, PA 19104 USAbartolom@mail.med.upenn.eduAmor DJ, 2008, HUM REPROD, V23, P2826, DOI 10.1093/humrep/den310; Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; Arnaud Philippe, 2005, Birth Defects Res C Embryo Today, V75, P81, DOI 10.1002/bdrc.20039; Barker DJP, 1997, NUTRITION, V13, P807, DOI 10.1016/S0899-9007(97)00193-7; Bartolomei MS, 2011, COLD SPRING HARB PER, V3; Bartolomei MS, 2009, GENE DEV, V23, P2124, DOI 10.1101/gad.1841409; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Cantonwine D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-62; Chou WC, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-94; Constancia M, 2000, NAT GENET, V26, P203; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; de Mouzon J, 2010, HUM REPROD, V25, P1851, DOI 10.1093/humrep/deq124; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011; Eubig PA, 2010, ENVIRON HEALTH PERSP, V118, P1654, DOI 10.1289/ehp.0901852; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fortier AL, 2008, HUM MOL GENET, V17, P1653, DOI 10.1093/hmg/ddn055; Gallou-Kabani C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014398; Georgiades P, 2000, DEVELOPMENT, V127, P4719; Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714; Harris RM, 2012, MATURITAS, V72, P108, DOI 10.1016/j.maturitas.2012.03.002; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Ideraabdullah FY, 2008, MUTAT RES-FUND MOL M, V647, P77, DOI 10.1016/j.mrfmmm.2008.08.008; Ivanova E, 2011, J MOL ENDOCRINOL, V47, pR67, DOI 10.1530/JME-11-0065; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kang ER, 2011, EPIGENETICS-US, V6, P937, DOI 10.4161/epi.6.7.16067; Karimi M, 2011, METHODS MOL BIOL, V791, P135, DOI 10.1007/978-1-61779-316-5_11; Kelsey G, 2007, ENDOCRIN DEV, V12, P99, DOI 10.1159/000109637; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Lucifero D, 2002, GENOMICS, V79, P530, DOI 10.1006/geno.2002.6732; Mann MRW, 2003, BIOL REPROD, V69, P902, DOI 10.1095/biolreprod.103.017293; Mann MRW, 2004, DEVELOPMENT, V131, P3727, DOI 10.1242/dev.01241; Markham JA, 2011, PSYCHOPHARMACOLOGY, V214, P89, DOI 10.1007/s00213-010-2035-0; Murphy SK, 2012, GENE, V494, P36, DOI 10.1016/j.gene.2011.11.062; Okae H, 2012, HUM MOL GENET, V21, P548, DOI 10.1093/hmg/ddr488; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Rivera RM, 2008, HUM MOL GENET, V17, P1, DOI 10.1093/hmg/ddm280; Rodriguez BAT, 2011, CARCINOGENESIS, V32, P812, DOI 10.1093/carcin/bgr017; Roseboom TJ, 2011, MATURITAS, V70, P141, DOI 10.1016/j.maturitas.2011.06.017; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Sathyanarayana S, 2011, ENVIRON HEALTH PERSP, V119, P1170, DOI 10.1289/ehp.1003064; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Sherer DM, 2001, PLACENTA, V22, P1, DOI 10.1053/plac.2000.0588; Sieli PT, 2011, ENVIRON HEALTH PERSP, V119, P1260, DOI 10.1289/ehp.1003385; Singh G, 2000, ANAL CHEM, V72, P3007, DOI 10.1021/ac000374a; Smallwood SA, 2011, NAT GENET, V43, P811, DOI 10.1038/ng.864; Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845; Tachibana T, 2007, J REPROD DEVELOP, V53, P509, DOI 10.1262/jrd.18171; Tanaka S, 2001, BIOL REPROD, V65, P1813, DOI 10.1095/biolreprod65.6.1813; Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322; Tunster SJ, 2011, DIS MODEL MECH, V4, P814, DOI 10.1242/dmm.007328; Tuuli MG, 2011, PLACENTA, V32, pS109, DOI 10.1016/j.placenta.2010.12.013; Umlauf D, 2004, NAT GENET, V36, P1296, DOI 10.1038/ng1467; Vandenberg LN, 2012, CIENC SAUDE COLETIVA, V17, P407, DOI 10.1590/S1413-81232012000200015; Verona RI, 2003, ANNU REV CELL DEV BI, V19, P237, DOI 10.1146/annurev.cellbio.19.111401.092717; Vom Saal Frederick S, 2012, Mol Cell Endocrinol, V354, P74, DOI 10.1016/j.mce.2012.01.001; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Weaver JR, 2010, MOL CELL BIOL, V30, P3916, DOI 10.1128/MCB.01278-09; Weaver JR, 2009, MAMM GENOME, V20, P532, DOI 10.1007/s00335-009-9225-2; Weksberg R, 2003, HUM MOL GENET, V12, pR61, DOI 10.1093/hmg/ddg067; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wilkins JF, 2011, PROG MOL BIOL TRANSL, V101, P401, DOI 10.1016/B978-0-12-387685-0.00013-5; Wingfield JC, 2009, GEN COMP ENDOCR, V163, P92, DOI 10.1016/j.ygcen.2009.04.030; Wu MY, 2006, GENESIS, V44, P12, DOI 10.1002/gene.20179; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.0287521PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS GENETAPRDiscipline: Genetics &amp; Heredity132MS</notes>
    <keywords>BECKWITH-WIEDEMANN-SYNDROME; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARCINOGENESIS; CELL; development; DISORDERS; DNA METHYLATION; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; EPIGENETIC REGULATION; EXPOSURE; EXPRESSION; FETAL; gene expression; GENE-EXPRESSION; GENES; genetics; GERM-CELLS; HEALTH; HUMANS; mechanism; MECHANISMS; Metabolic disorders; METHYLATION; MICE; MODEL; Mouse; nutrition; PLACENTA; PRENATAL EXPOSURE; REPRESSIVE HISTONE METHYLATION; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos Genetics</journalfull>
    <issue>4</issue>
    <volume>9</volume>
    <abstract>Exposure to endocrine disruptors is associated with developmental defects. One compound of concern, to which humans are widely exposed, is bisphenol A (BPA). In model organisms, BPA exposure is linked to metabolic disorders, infertility, cancer, and behavior anomalies. Recently, BPA exposure has been linked to DNA methylation changes, indicating that epigenetic mechanisms may be relevant. We investigated effects of exposure on genomic imprinting in the mouse as imprinted genes are regulated by differential DNA methylation and aberrant imprinting disrupts fetal, placental, and postnatal development. Through allele-specific and quantitative real-time PCR analysis, we demonstrated that maternal BPA exposure during late stages of oocyte development and early stages of embryonic development significantly disrupted imprinted gene expression in embryonic day (E) 9.5 and 12.5 embryos and placentas. The affected genes included Snrpn, Ube3a, Igf2, Kcnq1ot1, Cdkn1c, and Ascl2; mutations and aberrant regulation of these genes are associated with imprinting disorders in humans. Furthermore, the majority of affected genes were expressed abnormally in the placenta. DNA methylation studies showed that BPA exposure significantly altered the methylation levels of differentially methylated regions (DMRs) including the Snrpn imprinting control region (ICR) and Igf2 DMR1. Moreover, exposure significantly reduced genome-wide methylation levels in the placenta, but not the embryo. Histological and immunohistochemical examinations revealed that these epigenetic defects were associated with abnormal placental development. In contrast to this early exposure paradigm, exposure outside of the epigenetic reprogramming window did not cause significant imprinting perturbations. Our data suggest that early exposure to common environmental compounds has the potential to disrupt fetal and postnatal health through epigenetic changes in the embryo and abnormal development of the placenta</abstract>
    <url>WOS:000318073300008</url>
    <isbnorissn>1553-7404</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>12</id>
    <title>Genistein Potentiates the Antitumor Effect of 5-Fluorouracil by Inducing Apoptosis and Autophagy in Human Pancreatic Cancer Cells</title>
    <authors>Suzuki,R.; Kang,Y.A.; Li,X.Q.; Roife,D.; Zhang,R.; Fleming,J.B.</authors>
    <availability>[Suzuki, Rei] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USA. [Kang, Ya'an; Li, Xinqun; Roife, David; Zhang, Ran; Fleming, Jason B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleFleming, JB (reprint author), Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Surg Oncol, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USAjbflemin@mdanderson.orgBanerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330; Banerjee S, 2011, INT J CANCER, V128, P1240, DOI 10.1002/ijc.25658; Banerjee S, 2007, INT J CANCER, V120, P906, DOI 10.1002/ijc.22332; Bristol ML, 2012, AUTOPHAGY, V8, P739, DOI 10.4161/auto.19313; Chang Z, 2013, CLIN CANCER RES, V19, P549, DOI 10.1158/1078-0432.CCR-12-0032; Conroy T, 2013, CURR ONCOL REP, V15, P182, DOI 10.1007/s11912-012-0290-4; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Feng X, 2014, BIOCHEM BIOPH RES CO, V444, P376, DOI 10.1016/j.bbrc.2014.01.053; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Gossner G, 2007, GYNECOL ONCOL, V105, P23, DOI 10.1016/j.ygyno.2006.11.009; Hashimoto D, 2014, EUROPEAN J CANC; Hwang KA, 2013, TOXICOL APPL PHARM, V272, P637, DOI 10.1016/j.taap.2013.07.027; Hwang KA, 2013, INT J ONCOL, V42, P733, DOI 10.3892/ijo.2012.1719; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mohan N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078958; Mukubou H, 2010, INT J ONCOL, V37, P821, DOI 10.3892/ijo_00000732; Nakamura Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-100; Ouyang GL, 2009, CELL BIOL INT, V33, P1237, DOI 10.1016/j.cellbi.2009.08.011; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Peddi Parvin F, 2012, JOP, V13, P497, DOI 10.6092/1590-8577/913; Puissant A, 2010, AUTOPHAGY, V6, P655, DOI 10.4161/auto.6.5.12126; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tan N, 2013, MOL CANCER THER, V12, P853, DOI 10.1158/1535-7163.MCT-12-0949250INT INST ANTICANCER RESEARCHATHENSEDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECEANTICANCER RESSEPDiscipline: OncologyAP1VS</notes>
    <keywords>5-fluorouracil; apoptosis; autophagy; BISPHENOL-A; CANCER; cell death; CELLS; CISPLATIN; COMBINATION; CYTOPROTECTIVE AUTOPHAGY; GEMCITABINE; genistein; IN-VITRO; inhibition; MOLECULAR EVIDENCE; Pancreatic ductal adenocarcinoma; PROGRESSION; RADIATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>4685</startpage>
    <endpage>4692</endpage>
    <journalfull>Anticancer Research</journalfull>
    <issue>9</issue>
    <volume>34</volume>
    <abstract>Background: Although 5-fluorouracil (5-FU)-based combination chemotherapy (i.e. FOLFIRINOX) has demonstrated effectiveness against pancreatic cancer, novel therapeutic strategies must be developed to increase the therapeutic window of these cytotoxic agents. Genistein is a soy-derived isoflavone with pleiotropic biological effects that can enhance the antitumor effect of chemotherapeutic agents. Materials and Methods: To understand how genistein potentiates the antitumor effects of 5-FU, we examined apoptosis and autophagy in MIA PaCa-2 human pancreatic cancer cells and their derived xenografts. Apoptosis was evaluated using DNA fragmentation assays, and western blots of poly(ADP ribose) polymerase and caspase-3. Meanwhile, autophagy was evaluated using western blots of microtubule-associated protein light chain 3 (LC3)-I/II, fluorescent microscopy observation of green fluorescent protein-LC3B puncta formation, and acidic vesicular organelle formation using acridine orange staining. Tumors from animal treatment studies were examined for apoptosis and autophagy using the TdT-mediated dUTP nick-end labeling assay and immunohistochemical staining of LC3B, respectively. Results: We observed that genistein increased 5-FU-induced cell death through increased apoptosis, as well as autophagy. The increased autophagy was accompanied by decreased B-cell lymphoma 2 (Bcl2) and increased beclin-1 protein levels. Animal treatment studies supported these observations. The combination of 5-FU and genistein significantly reduced final xenograft tumor volume when compared to 5-FU-alone by inducing apoptosis as well as autophagy. Conclusion: Genistein can potentiate the antitumor effect of 5-FU by inducing apoptotic as well as autophagic cell death. These results demonstrate the potential of genistein as an adjuvant therapeutic agent against pancreatic cancer</abstract>
    <url>WOS:000341860700007</url>
    <isbnorissn>0250-7005</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>86</id>
    <title>Similar causes of various reproductive disorders in early life</title>
    <authors>Svechnikov,K.; Stukenborg,J.B.; Savchuck,I.; Soder,O.</authors>
    <availability>[Soder, Olle] Karolinska Inst, Dept Womens &amp; Childrens Hlth, Paediat Endocrinol Unit, Stockholm, Sweden. Univ Hosp, Stockholm, Sweden.</availability>
    <date>2014</date>
    <notes>JEnglishReviewSoder, O (reprint author), Karolinska Inst, Dept Womens &amp; Childrens Hlth, Paediat Endocrinol Unit, Stockholm, Swedenolle.soder@ki.seAdamovic T, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-109; Agoulnik AI, 2005, J CLIN ENDOCR METAB, V90, P4975, DOI 10.1210/jc.2005-1290; Akre O, 1999, EPIDEMIOLOGY, V10, P364, DOI 10.1097/00001648-199907000-00005; Alexander J, 2013, EFSA J, V11, P84; Aly HAA, 2009, FOOD CHEM TOXICOL, V47, P1733, DOI 10.1016/j.fct.2009.03.019; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Arlt W, 2001, J BIOL CHEM, V276, P16767, DOI 10.1074/jbc.M100040200; Aschim EL, 2004, J CLIN ENDOCR METAB, V89, P5105, DOI 10.1210/jc.2004-0293; Ashby J, 1999, REGUL TOXICOL PHARM, V30, P156, DOI 10.1006/rtph.1999.1317; Atanassova N, 2000, ENDOCRINOLOGY, V141, P3898, DOI 10.1210/en.141.10.3898; Baskin LS, 2001, ENVIRON HEALTH PERSP, V109, P1175, DOI 10.1289/ehp.011091175; BATTIN M, 1995, AM J PERINAT, V12, P425, DOI 10.1055/s-2007-994513; Bay K, 2007, J CLIN ENDOCR METAB, V92, P4020, DOI 10.1210/jc.2007-0974; Beleza-Meireles A, 2007, EUR J HUM GENET, V15, P405, DOI 10.1038/sj.ejhg.5201777; Berwaerts J, 1999, GYNECOL ENDOCRINOL, V13, P175; Boisen KA, 2004, LANCET, V363, P1264, DOI 10.1016/S0140-6736(04)15998-9; Boockfor FR, 1997, BIOL REPROD, V57, P267, DOI 10.1095/biolreprod57.2.267; Bornman R, 2010, BJU INT, V106, P405, DOI 10.1111/j.1464-410X.2009.09003.x; Bretveld R, 2007, SCAND J WORK ENV HEA, V33, P13; Brouwers MM, 2007, EUR J PEDIATR, V166, P671, DOI 10.1007/s00431-006-0304-z; Louis GMB, 2008, PEDIATRICS, V121, pS192, DOI 10.1542/peds.1813E; BUEMANN B, 1961, Acta Chir Scand Suppl, VSuppl 283, P289; Bustos-Obregon E, 2003, ASIAN J ANDROL, V5, P105; Cagen SZ, 1999, REGUL TOXICOL PHARM, V30, P130, DOI 10.1006/rtph.1999.1340; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; CALZOLARI E, 1986, J MED GENET, V23, P333, DOI 10.1136/jmg.23.4.333; Carmichael SL, 2009, J PEDIATR, V155, P39, DOI 10.1016/j.jpeds.2009.01.039; Cederroth CR, 2007, ENDOCRINOLOGY, V148, P5507, DOI 10.1210/en.2007-0689; Chan LYS, 2005, FERTIL STERIL, V83, P955, DOI 10.1016/j.fertnstert.2004.10.045; Cheng C.Y., 2011, SPERMATOGENESIS, V1, P2, DOI DOI 10.4161/SPMG.1.1.13971; CHILVERS C, 1984, LANCET, V2, P330; Choi JS, 2006, DIABETES CARE, V29, P2176, DOI 10.2337/dc06-1214; Cools M, 2006, ENDOCR REV, V27, P468, DOI 10.1210/er.2006-0005; Crescioli C, 2003, J CLIN ENDOCR METAB, V88, P1815, DOI 10.1210/jc.2002-021085; Cupp AS, 2003, J ANDROL, V24, P736; Damgaard IN, 2006, ENVIRON HEALTH PERSP, V114, P1133, DOI 10.1289/ehp.8741; Damgaard IN, 2007, ENVIRON HEALTH PERSP, V115, P272, DOI 10.1289/ehp.9608; Defamie N, 2001, CARCINOGENESIS, V22, P1537, DOI 10.1093/carcin/22.9.1537; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Elliott P, 2001, BRIT MED J, V323, P363, DOI 10.1136/bmj.323.7309.363; Elzeinova F, 2008, REPROD TOXICOL, V26, P231, DOI 10.1016/j.reprotox.2008.09.007; Ema M, 2001, REPROD TOXICOL, V15, P505, DOI 10.1016/S0890-6238(01)00160-5; ENGELHARDT D, 1994, J STEROID BIOCHEM, V49, P261, DOI 10.1016/0960-0760(94)90267-4; Ferlin A, 2012, ENDOCR-RELAT CANCER, V19, P101, DOI 10.1530/ERC-11-0340; Foresta C, 2008, ENDOCR REV, V29, P560, DOI 10.1210/er.2007-0042; Fredell L, 2002, HUM GENET, V111, P231, DOI 10.1007/s00439-002-0799-y; Fredell L, 2002, J UROLOGY, V167, P1423, DOI 10.1016/S0022-5347(05)65334-7; Fukami M, 2006, NAT GENET, V38, P1369, DOI 10.1038/ng1900; Garry VF, 2002, ENVIRON HEALTH PERSP, V110, P441; Giannopoulos MF, 2001, HORM RES, V55, P33, DOI 10.1159/000049961; Giordano F, 2008, PAEDIATR PERINAT EP, V22, P249, DOI 10.1111/j.1365-3016.2007.00918.x; Giordano F, 2010, BIRTH DEFECTS RES A, V88, P241, DOI 10.1002/bdra.20657; Gitau R, 2005, ARCH DIS CHILD, V90, pF166, DOI 10.1136/adc.2004.049320; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; Haddad GF, 2008, REPROD TOXICOL, V26, P183, DOI 10.1016/j.reprotox.2008.08.001; Hallmark N, 2007, ENVIRON HEALTH PERSP, V115, P390, DOI 10.1289/ehp.9490; Hayashi Y, 2008, INT J UROL, V15, P651, DOI 10.1111/j.1442-2042.2008.02081.x; Hayes TB, 2002, P NATL ACAD SCI USA, V99, P5476, DOI 10.1073/pnas.082121499; HOLSON RR, 1995, NEUROTOXICOL TERATOL, V17, P393, DOI 10.1016/0892-0362(94)00074-N; Howdeshell KL, 2008, TOXICOL SCI, V102, P371, DOI 10.1093/toxsci/kfm306; Hsieh Michael H, 2008, Curr Urol Rep, V9, P137, DOI 10.1007/s11934-008-0025-0; Hughes IA, 2001, ENDOCRINOLOGY, V142, P3281, DOI 10.1210/en.142.8.3281; HUHTANIEMI I, 1982, ACTA PAEDIATR SCAND, V71, P425, DOI 10.1111/j.1651-2227.1982.tb09446.x; Huhtaniemi I, 2006, BEST PRACT RES CL EN, V20, P561, DOI 10.1016/j.beem.2006.09.003; Hussain N, 2002, PEDIATRICS, V109, P473, DOI 10.1542/peds.109.3.473; Hutson JM, 1997, ENDOCR REV, V18, P259, DOI 10.1210/er.18.2.259; Imperato-McGinley J, 2002, MOL CELL ENDOCRINOL, V198, P51, DOI 10.1016/S0303-7207(02)00368-4; Irgens A, 2000, ACTA OBSTET GYN SCAN, V79, P465, DOI 10.1034/j.1600-0412.2000.079006465.x; Jensen MS, 2010, EPIDEMIOLOGY, V21, P779, DOI 10.1097/EDE.0b013e3181f20bed; Jensen MS, 2007, ACTA PAEDIATR, V96, P1681, DOI 10.1111/j.1651-2227.2007.00506.x; Johnson L, 2002, REPROD NUTR DEV, V42, P573, DOI 10.1051/rnd:2002043; Juhler RK, 1999, ARCH ENVIRON CON TOX, V37, P415, DOI 10.1007/s002449900533; Kanetsky PA, 2011, HUM MOL GENET, V20, P3109, DOI 10.1093/hmg/ddr207; Kazy Zoltan, 2005, Congenital Anomalies, V45, P5, DOI 10.1111/j.1741-4520.2005.00053.x; KELLOKUMPULEHTINEN P, 1991, HORM RES, V35, P242, DOI 10.1159/000181913; Klip H, 2002, LANCET, V359, P1102, DOI 10.1016/S0140-6736(02)08152-7; Kojima Y, 2010, J PEDIATR UROL, V6, P346, DOI 10.1016/j.jpurol.2009.11.007; Kollin C, 2012, J CLIN ENDOCR METAB, V97, P4588, DOI 10.1210/jc.2012-2325; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Kristensen DM, 2011, HUM REPROD, V26, P235, DOI 10.1093/humrep/deq323; Kristensen P, 1997, Epidemiology, V8, P537, DOI 10.1097/00001648-199709000-00011; LALAU JD, 1990, NEUROENDOCRINOLOGY, V51, P289, DOI 10.1159/000125352; Lambrot R, 2009, ENVIRON HEALTH PERSP, V117, P32, DOI 10.1289/ehp.11146; Larsen SB, 1998, REPROD TOXICOL, V12, P581, DOI 10.1016/S0890-6238(98)00047-1; Larsen SB, 1999, SCAND J WORK ENV HEA, V25, P74; Lebovitz HE, 2001, RECENT PROG HORM RES, V56, P265, DOI 10.1210/rp.56.1.265; Lee PC, 1998, ENDOCRINE, V9, P105, DOI 10.1385/ENDO:9:1:105; Li MWM, 2009, INT J BIOCHEM CELL B, V41, P2302, DOI 10.1016/j.biocel.2009.05.016; Lim HN, 2001, J CLIN ENDOCR METAB, V86, P3207, DOI 10.1210/jc.86.7.3207; Mackay S, 2000, INT REV CYTOL, V200, P47, DOI 10.1016/S0074-7696(00)00002-4; Main KM, 2006, ENVIRON HEALTH PERSP, V114, P270, DOI 10.1289/ehp.8075; Main KM, 2010, BEST PRACT RES CL EN, V24, P279, DOI 10.1016/j.beem.2009.10.003; Main KM, 2007, ENVIRON HEALTH PERSP, V115, P1519, DOI 10.1289/ehp.9924; MASTROIACOVO P, 1988, JAMA-J AM MED ASSOC, V259, P1668, DOI 10.1001/jama.259.11.1668; Mathur PP, 2011, ASIAN J ANDROL, V13, P585, DOI 10.1038/aja.2011.40; McIntyre BS, 2001, TOXICOL SCI, V62, P236, DOI 10.1093/toxsci/62.2.236; McKinnell C, 2001, J ANDROL, V22, P323; Meyer KJ, 2006, ENVIRON HEALTH PERSP, V114, P1589, DOI 10.1289/ehp.9146; Miyado M, 2012, ENDOCRINOLOGY, V153, P6033, DOI 10.1210/en.2012-1324; Mongraw-Chaffin ML, 2008, AM J EPIDEMIOL, V167, P257, DOI 10.1093/aje/kwm311; Morgan EA, 2003, DEVELOPMENT, V130, P3095, DOI 10.1242/dev.00530; Muroya K, 2001, MOL HUM REPROD, V7, P409, DOI 10.1093/molehr/7.5.409; Nallu A, 2013, CURR OPIN ONCOL, V25, P266, DOI 10.1097/CCO.0b013e32835ff3e3; N'Tumba-Byn T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051579; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Nicoletti A, 2005, CLIN ENDOCRINOL, V63, P375, DOI 10.1111/j.1365-2265.2005.02348.x; Nordenskjold A, 1999, UROL RES, V27, P49; Ogata T, 2001, CLIN ENDOCRINOL, V54, P835, DOI 10.1046/j.1365-2265.2001.01205.x; Ogata T, 2008, SEX DEV, V2, P244, DOI 10.1159/000152040; Oliva A, 2001, HUM REPROD, V16, P1768, DOI 10.1093/humrep/16.8.1768; Padungtod C, 2000, J OCCUP ENVIRON MED, V42, P982, DOI 10.1097/00043764-200010000-00004; Pleskacova J, 2010, SEX DEV, V4, P259, DOI 10.1159/000314536; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Rosen A, 2011, EUR UROL, V60, P374, DOI 10.1016/j.eururo.2011.05.004; Ryan BC, 2010, TOXICOL SCI, V114, P133, DOI 10.1093/toxsci/kfp266; Sajjad Y, 2004, HUM REPROD, V19, P1659, DOI 10.1093/humrep/deh295; Sarkar P, 2007, CLIN ENDOCRINOL, V67, P743, DOI 10.1111/j.1365-2265.2007.02955.x; SCHNITZER PG, 1995, EPIDEMIOLOGY, V6, P577; SCORER CG, 1964, ARCH DIS CHILD, V39, P605; Scott HM, 2009, ENDOCR REV, V30, P883, DOI 10.1210/er.2009-0016; Sever LE, 1997, OCCUP MED, V12, P305; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sharpe RM, 2010, PHILOS T R SOC B, V365, P1697, DOI 10.1098/rstb.2009.0206; Sharpe Richard M, 2008, Fertil Steril, V89, pe33, DOI 10.1016/j.fertnstert.2007.12.026; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; Sharpe RM, 2010, TOXICOL SCI, V114, P1, DOI 10.1093/toxsci/kfp299; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Shi YQ, 2010, TOXICOL LETT, V193, P79, DOI 10.1016/j.toxlet.2009.12.008; Silva-Ramos M, 2006, Int Braz J Urol, V32, P330, DOI 10.1590/S1677-55382006000300014; Sinnecker GHG, 1997, EUR J PEDIATR, V156, P7; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Snijder CA, 2012, HUM REPROD, V27, P1191, DOI 10.1093/humrep/der474; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905; Stoker TE, 2005, TOXICOL APPL PHARM, V207, P78, DOI 10.1016/j.taap.2005.05.010; STOLL C, 1990, J MED GENET, V27, P559, DOI 10.1136/jmg.27.9.559; Stukenborg JB, 2010, SEX DEV, V4, P199, DOI 10.1159/000317090; Svechnikov K., 2010, J BIOMED BIOTECHNOL, V2010; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Takao T, 1999, LIFE SCI, V65, P2351, DOI 10.1016/S0024-3205(99)00502-0; Taxvig C, 2008, INT J ANDROL, V31, P170, DOI 10.1111/j.1365-2605.2007.00838.x; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Toppari J, 2010, BIRTH DEFECTS RES A, V88, P910, DOI 10.1002/bdra.20707; TULCHINS.D, 1972, AM J OBSTET GYNECOL, V112, P1095; Vierhapper H, 2003, METABOLISM, V52, P230, DOI 10.1053/meta.2003.50028; Virtanen HE, 2007, ACTA PAEDIATR, V96, P611, DOI 10.1111/j.1651-2227.2007.00241.x; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239; Vrijheid M, 2003, OCCUP ENVIRON MED, V60, P543, DOI 10.1136/oem.60.8.543; Wang YP, 2004, EUR J HUM GENET, V12, P706, DOI 10.1038/sj.ejhg.5201232; Weidner IS, 1998, ENVIRON HEALTH PERSP, V106, P793, DOI 10.1289/ehp.98106793; Welsh M, 2008, J CLIN INVEST, V118, P1479, DOI 10.1172/JCI34241; WHITEHEAD ED, 1981, J UROLOGY, V125, P47; WILSON JD, 1978, ANNU REV PHYSIOL, V40, P279, DOI 10.1146/annurev.ph.40.030178.001431; Yilmaz M, 2005, J ENDOCRINOL INVEST, V28, P1003; Yucel S, 2004, ADV EXP MED BIOL, V545, P123; Yucra S, 2006, INT J OCCUP ENV HEAL, V12, P355; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-14221610MEDKNOW PUBLICATIONS &amp; MEDIA PVT LTDMUMBAIB-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIAASIAN J ANDROLJANDiscipline: Endocrinology &amp; Metabolism; Urology &amp; Nephrology285QW</notes>
    <keywords>ABNORMALITIES; ANDROGEN-RECEPTOR GENE; BISPHENOL-A; CAG REPEAT LENGTH; CANCER; CARCINOGENESIS; CELL; CHEMICALS; CHILDREN; diabetes; DIETHYLSTILBESTROL IN-UTERO; Differentiation; DISORDERS; EDCs; ENDOCRINE; ENDOCRINE DISRUPTERS; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ENVIRONMENTAL CHEMICALS; Environmental estrogen; ENVIRONMENTAL ESTROGENS; Estrogen; ESTROGENS; Etiology; EXPOSURE; FOOD; GERM-CELL TUMORS; HUMAN BREAST-MILK; HUMANS; IN-UTERO; Male; male (in)fertility; METABOLISM; OCCUPATIONAL PESTICIDE EXPOSURE; POLYCYSTIC-OVARY-SYNDROME; POPULATION; Reproduction; reproductive disorders; SEMEN QUALITY; SEXUAL-DIFFERENTIATION; SPERMATOGENESIS; TESTICULAR DYSGENESIS SYNDROME; testicular steroidogenesis; testis; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>50</startpage>
    <endpage>59</endpage>
    <journalfull>Asian Journal of Andrology</journalfull>
    <issue>1</issue>
    <volume>16</volume>
    <abstract>During the past few decades, scientific evidence has been accumulated concerning the possible adverse effects of the exposure to environmental chemicals on the well-being of wildlife and human populations. One large and growing group of such compounds of anthropogenic or natural origin is referred to as endocrine-disrupting chemicals (EDCs), due to their deleterious action on the endocrine system. This concern was first focused on the control of reproductive function particularly in males, but has later been expanded to include all possible endocrine functions. The present review describes the underlying physiology behind the cascade of developmental events that occur during sexual differentiation of males and the specific role of androgen in the masculinization process and proper organogenesis of the external male genitalia. The impact of the genetic background, environmental exposures and lifestyle factors in the etiology of hypospadias, cryptorchidism and testicular cancer are reviewed and the possible role of EDCs in the development of these reproductive disorders is discussed critically. Finally, the possible direct and programming effects of exposures in utero to widely use therapeutic compounds, environmental estrogens and other chemicals on the incidence of reproductive abnormalities and poor semen quality in humans are also highlighted</abstract>
    <url>WOS:000329409700007</url>
    <isbnorissn>1008-682X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>414</id>
    <title>Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders</title>
    <authors>Swedenborg,E.; Ruegg,J.; Makela,S.; Pongratz,I.</authors>
    <availability>[Swedenborg, Elin; Ruegg, Joelle; Pongratz, Ingemar] Karolinska Inst, Novum, Dept Biosci &amp; Nutr, S-14157 Huddinge, Sweden. [Makela, Sari] Univ Turku, Funct Foods Forum &amp; Dept Biochem &amp; Food Chem, FI-20014 Turku, Finland.</availability>
    <date>2009</date>
    <notes>JEnglishReviewRuegg, J (reprint author), Karolinska Inst, Novum, Dept Biosci &amp; Nutr, S-14157 Huddinge, Swedenjoerue@ki.seAlonso-Magdalena P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002069; Appel KE, 2004, DRUG METAB REV, V36, P763, DOI 10.1081/DMR-200033490; Arcaro KF, 1999, TOXICOLOGY, V133, P115, DOI 10.1016/S0300-483X(99)00018-9; Arsenescu V, 2008, ENVIRON HEALTH PERSP, V116, P761, DOI 10.1289/ehp.10554; Asakawa A, 2008, INT J MOL MED, V21, P439; Baillie-Hamilton PF, 2002, J ALTERN COMPLEM MED, V8, P185, DOI 10.1089/107555302317371479; Baker ME, 1998, P SOC EXP BIOL MED, V217, P317; Boas M, 2006, EUR J ENDOCRINOL, V154, P599, DOI 10.1530/eje.1.02128; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Butenhoff J, 2002, TOXICOL SCI, V69, P244, DOI 10.1093/toxsci/69.1.244; Claessens F, 2004, ESSAYS BIOCHEM, V40, P59; Colborn T, 2004, ENVIRON HEALTH PERSP, V112, P944, DOI 10.1289/ehp.6601; Darnerud PO, 2008, INT J ANDROL, V31, P152, DOI 10.1111/j.1365-2605.2008.00869.x; Darnerud PO, 2003, ENVIRON INT, V29, P841, DOI 10.1016/S0160-4120(03)00107-7; Despres JP, 2008, ARTERIOSCL THROM VAS, V28, P1039, DOI 10.1161/ATVBAHA.107.159228; Elobeid MA, 2008, CURR OPIN ENDOCRINOL, V15, P403, DOI 10.1097/MED.0b013e32830ce95c; Fierens S, 2003, BIOMARKERS, V8, P529, DOI 10.1080/1354750032000158420; FORYSTLUDWIG A, 2008, PLOS GENET, V4; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Grun F, 2006, MOL ENDOCRINOL, V20, P2141, DOI 10.1210/me.2005-0367; Grun F, 2006, ENDOCRINOLOGY, V147, pS50, DOI 10.1210/en.2005-1129; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Hankinson O, 2005, ARCH BIOCHEM BIOPHYS, V433, P379, DOI 10.1016/j.abb.2004.09.031; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619; Hoppe AA, 2007, OBESITY, V15, P2942, DOI 10.1038/oby.2007.351; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Janosek J, 2006, TOXICOL IN VITRO, V20, P18, DOI 10.1016/j.tiv.2005.06.001; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Lee DH, 2006, DIABETES CARE, V29, P1638, DOI 10.2337/dc05-0543; Lee DH, 2007, DIABETES CARE, V30, P1596, DOI 10.2337/dc07-0072; Lee DH, 2007, DIABETES CARE, V30, P622, DOI 10.2337/dc06-2190; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee MJ, 2008, AM J PHYSIOL-CELL PH, V294, pC1542, DOI 10.1152/ajpcell.00403.2007; Lee TT, 2002, IEEE T COMMUN, V50, P1841, DOI 10.1109/TCOMM.2002.805258; Legler J, 2003, ENVIRON INT, V29, P879, DOI 10.1016/S0160-4120(03)00104-1; Lim JS, 2008, DIABETES CARE, V31, P1802, DOI 10.2337/dc08-0850; Martensson UEA, 2009, ENDOCRINOLOGY, V150, P687, DOI 10.1210/en.2008-0623; Mattsson C, 2007, CURR MED CHEM, V14, P2918, DOI 10.2174/092986707782359972; Meerts Ilonka A. T. M., 2001, Environmental Health Perspectives, V109, P399, DOI 10.2307/3454900; Min GS, 2002, J BIOL CHEM, V277, P34626, DOI 10.1074/jbc.M205239200; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Newbold RR, 2007, MOL NUTR FOOD RES, V51, P912, DOI 10.1002/mnfr.200600259; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Oken E, 2003, OBES RES, V11, P496, DOI 10.1038/oby.2003.69; Panzica GC, 2005, BRAIN RES BULL, V65, P187, DOI 10.1016/j.brainresbull.2005.01.007; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Phillips LK, 2008, CURR HYPERTENS REP, V10, P156, DOI 10.1007/s11906-008-0029-7; Picard D, 2006, TRENDS ENDOCRIN MET, V17, P229, DOI 10.1016/j.tem.2006.06.003; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Reen RK, 2002, ARCH BIOCHEM BIOPHYS, V408, P93, DOI 10.1016/S0003-9861(02)00518-0; Ruegg J, 2008, MOL ENDOCRINOL, V22, P304, DOI 10.1210/me.2007-0128; RUEGG J, 2008, MOL CLIN ENV TOXICOL, P298; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; Sato S, 2008, TOXICOL APPL PHARM, V229, P10, DOI 10.1016/j.taap.2007.12.029; Singleton DW, 2003, FRONT BIOSCI, V8, pS110, DOI 10.2741/1010; Sugden MC, 2008, BIOCHEM SOC T, V36, P891, DOI [10.1042/BST0360891, 10.1042/65TO360891]; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; Swedenborg E, 2008, MOL PHARMACOL, V73, P575, DOI 10.1124/mol.107.036384; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; Takeda K, 2003, J ENDOCRINOL, V176, P237, DOI 10.1677/joe.0.1760237; Thackaberry EA, 2003, TOXICOL SCI, V76, P407, DOI 10.1093/toxsci/kfg229; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vidaeff AC, 2005, REPROD TOXICOL, V20, P5, DOI 10.1016/j.reprotox.2004.12.015; WANG X, 1993, MOL CELL ENDOCRINOL, V96, P159, DOI 10.1016/0303-7207(93)90106-T; WATSON G, 2005, GENERATIONS X REPORT; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wu YF, 2000, TRENDS ENDOCRIN MET, V11, P207, DOI 10.1016/S1043-2760(00)00263-0; You L, 2001, MOL CELL ENDOCRINOL, V178, P207, DOI 10.1016/S0303-7207(01)00445-27858BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDJ MOL ENDOCRINOLJUL-AUGDiscipline: Endocrinology &amp; Metabolism530ZD</notes>
    <keywords>Aryl hydrocarbon receptor; ARYL-HYDROCARBON; ARYL-HYDROCARBON RECEPTOR; BIOMARKER; Biomarkers; BISPHENOL-A; Brain; BREAST-CANCER CELLS; BROMINATED FLAME RETARDANTS; CANCER; CELL; CHEMICALS; CROSS-TALK; crosstalk; diabetes; DISORDERS; EDC; EDCs; ENDOCRINE; Endocrine disruption; ENVIRONMENTAL ESTROGENS; ER; ESTROGEN-RECEPTOR; FOOD; HEALTH; HUMAN HEALTH; In vitro; IN-VITRO; INSULIN-RESISTANCE; mechanism; MECHANISMS; Metabolic disorders; METABOLISM; molecular mechanism; MOLECULAR-MECHANISMS; Nuclear receptor; NUCLEAR RECEPTORS; Obesity; PATHWAY; PERSISTENT ORGANIC POLLUTANTS; POLYBROMINATED DIPHENYL ETHERS; RECEPTOR; Receptors; Review; RISK; SERUM CONCENTRATIONS; Steroid; SYSTEM; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1</startpage>
    <endpage>10</endpage>
    <journalfull>Journal of Molecular Endocrinology</journalfull>
    <issue>1-2</issue>
    <volume>43</volume>
    <abstract>Endocrine disruption refers to the ability of chemicals to interfere with hormonal systems, and has raised considerable concern in recent years. Endocrine disruptive chemicals (EDCs) pose a documented risk to wildlife and have the potentialto negatively influence human health. This review focuses on the molecular mechanisms of endocrine disruption and the possible involvement of EDCs in metabolic disorders. The first part describes the role of aryl hydrocarbon receptor (AhR) and nuclear receptors (NRs) in mediating effects of EDCs, in particular, how cross-talk between AhR and NR pathways can lead to endocrine disruption. The second part deals with how these receptors are involved in metabolic functions and how their targeting by EMS can lead to disturbances in glucose and fat metabolism. The article illustrates that, although there is accumulating data on molecular mechanisms of EDC action as well as on EDC involvement in metabolic disorders, there is still a great demand for data that can unite the mechanistic and the toxicological/epidemiological observations</abstract>
    <url>WOS:000272630600001</url>
    <isbnorissn>0952-5041</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>275</id>
    <title>Protective effect of chitosan oligosaccharide lactate against DNA double-strand breaks induced by a model methacrylate dental adhesive</title>
    <authors>Szczepanska,J.; Pawlowska,E.; Synowiec,E.; Czarny,P.; Rekas,M.; Blasiak,J.; Szaflik,J.P.</authors>
    <availability>[Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, PL-03709 Warsaw, Poland. [Szaflik, Jacek Pawel] SPKSO Warsaw, Warsaw, Poland. [Szczepanska, Joanna; Pawlowska, Elzbieta] Med Univ Lodz, Dept Dev Dent, Lodz, Poland. [Synowiec, Ewelina; Czarny, Piotr; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90131 Lodz, Poland. [Rekas, Marek] Mil Hlth Serv Inst Med, Dept Ophthalmol, Warsaw, Poland.</availability>
    <date>2011</date>
    <notes>JEnglishArticleSzaflik, JP (reprint author), Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13 Str, PL-03709 Warsaw, Polandjacek@szaflik.plAam BB, 2010, MAR DRUGS, V8, P1482, DOI 10.3390/md8051482; Akncbay Hakan, 2007, J Biomed Mater Res B Appl Biomater, V80, P290; Alanko K, 2004, CONTACT DERMATITIS, V50, P77, DOI 10.1111/j.0105-1873.2004.00304.x; ARENDS J, 1995, CARIES RES, V29, P118; Arnaud TMS, 2010, J DENT, V38, P848, DOI 10.1016/j.jdent.2010.06.004; Chang MC, 2010, BIOMATERIALS, V31, P8164, DOI 10.1016/j.biomaterials.2010.07.049; Chen MH, 2010, J DENT RES, V89, P549, DOI 10.1177/0022034510363765; Di Pietro A, 2008, MUTAT RES-GEN TOX EN, V650, P115, DOI 10.1016/j.mrgentox.2007.10.023; Durner J, 2011, ARCH TOXICOL, V85, P143, DOI 10.1007/s00204-010-0558-0; Fujiwara M, 2004, MICROBIOLOGICA, V27, P83; Hayashi Y, 2007, ARCH ORAL BIOL, V52, P290, DOI 10.1016/j.archoralbio.2006.10.004; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hiom K, 2010, DNA REPAIR, V9, P1256, DOI 10.1016/j.dnarep.2010.09.018; Kanerva L, 2001, ACTA ODONTOL SCAND, V59, P320, DOI 10.1080/000163501750541200; Kleinsasser NH, 2004, J DENT, V32, P229, DOI 10.1016/j.jdent.2003.11.002; Koev ST, 2010, LAB CHIP, V10, P3026, DOI [10.1039/c0lc00047g, 10.1039/c01c00047g]; Kostoryz EL, 2009, J BIOMED MATER RES B, V88B, P394, DOI 10.1002/jbm.b.31095; Lin JH, 2010, ADV MATER RES-SWITZ, V123-125, P487, DOI 10.4028/www.scientific.net/AMR.123-125.487; LINDEN LA, 1993, J APPL POLYM SCI, V50, P1331, DOI 10.1002/app.1993.070500804; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mohire Nitin C, 2010, Indian J Dent Res, V21, P380, DOI 10.4103/0970-9290.70808; Park JS, 2003, J CLIN PERIODONTOL, V30, P443, DOI 10.1034/j.1600-051X.2003.10283.x; Pasquantonio G, 2008, INT J IMMUNOPATH PH, V21, P993; Pawlowska E, 2010, MUTAT RES-GEN TOX EN, V696, P122, DOI 10.1016/j.mrgentox.2009.12.019; Pawlowska E, 1997, ADV CHITIN SCI, P705; Poplawski T, 2009, CHEM-BIOL INTERACT, V180, P69, DOI 10.1016/j.cbi.2009.02.001; Poplawski T, 2010, TOXICOL IN VITRO, V24, P854, DOI 10.1016/j.tiv.2009.12.004; Qiao Y, 2011, INT IMMUNOPHARMACOL, V11, P121, DOI 10.1016/j.intimp.2010.10.016; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Santerre JP, 2001, CRIT REV ORAL BIOL M, V12, P136; Schweikl H, 2006, J DENT RES, V85, P870; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Singh NP, 1997, MUTAT RES-DNA REPAIR, V383, P167, DOI 10.1016/S0921-8777(96)00056-0; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Spin-Neto R, 2010, J BIOMED MATER RES A, V93A, P107, DOI 10.1002/jbm.a.32491; Streffer C, 2010, RADIAT ENVIRON BIOPH, V49, P125, DOI 10.1007/s00411-009-0258-4; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3&lt;206::AID-EM8&gt;3.0.CO;2-J; Urcan E, 2010, BIOMATERIALS, V31, P2010, DOI 10.1016/j.biomaterials.2009.11.065381INT SCIENTIFIC LITERATURE, INCSMITHTOWN361 FOREST LANE, SMITHTOWN, NY 11787 USAMED SCI MONITORAUGDiscipline: Research &amp; Experimental Medicine833QJ</notes>
    <keywords>2-hydroxyethyl methacrylate; ASSAY; Bis-GMA; bisphenol; Bisphenol A-diglycidyl dimethacrylate; CANCER; CELL; cell death; CELL-DEATH; CELLS; CHIP; Comet assay; Cytotoxicity; DAMAGE; DEATH; DEFECTS; DEGRADATION; dental restorative material; DENTISTRY; DIMETHACRYLATE; DNA damage; DNA double-strand breaks; DNA repair; DNA-DAMAGE; GAMMA-H2AX; gamma-H2AX histone; GENOTOXICITY; HEMA; In vitro; in vivo; IN-VITRO; IN-VIVO; INDUCTION; Lymphocytes; MECHANISMS; methacrylates; MICROGEL ELECTROPHORESIS; MICROTUBULES; MODEL; PHOSPHORYLATION; REPAIR; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>BR201</startpage>
    <endpage>BR208</endpage>
    <journalfull>Medical Science Monitor</journalfull>
    <issue>8</issue>
    <volume>17</volume>
    <abstract>Background: Monomers of methacrylates used in restorative dentistry, have been recently reported to induce DNA double-strand breaks (DSBs) in human gingival fibroblasts (HGFs) in vitro. Because such monomers may penetrate the pulp and oral cavity due to the incompleteness of polymerization and polymer degradation, they may induce a similar effect in vivo. DSBs are the most serious type of DNA damage and if misrepaired or not repaired may lead to mutation, cancer transformation and cell death. Therefore, the protection against DSBs induced by methacrylate monomers released from dental restorations is imperative. Material/Methods: We examined the protective action of chitosan oligosaccharide lactate (ChOL) against cytotoxic and genotoxic effects induced by monomers of the model adhesive consisting of 55% bisphenol A-diglycidyl dimethacrylate (Bis-GMA) and 45% 2-hydroxyethyl methacrylate (HEMA). We evaluated the extent of DSBs by the neutral comet assay and the phosphorylation of the H2AX histone test. Results: ChOL increased the viability, of HGFs exposed to Bis-GMA/HEMA as assessed by flow cytometry. ChOL decreased the extent of DSBs induced by Bis-GMA/HEMA as evaluated by neutral comet assay and phosphorylation of the H2AX histone. ChOL did not change mechanical properties of the model adhesive, as checked by the shear bond test. Scanning electron microscopy revealed a better sealing of the dentinal microtubules in the presence of ChOL, which may protect pulp cells against the harmful action of the monomers. Conclusions: ChOL can be considered as an additive to methacrylate-based dental materials to prevent DSBs induction, but further studies are needed on its formulation with the methacrylates</abstract>
    <url>WOS:000295899700005</url>
    <isbnorissn>1234-1010</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>316</id>
    <title>ChemProt: a disease chemical biology database</title>
    <authors>Taboureau,O.; Nielsen,S.K.; Audouze,K.; Weinhold,N.; Edsgard,D.; Roque,F.S.; Kouskoumvekaki,I.; Bora,A.; Curpan,R.; Jensen,T.S.; Brunak,S.; Oprea,T.I.</authors>
    <availability>[Taboureau, Olivier; Nielsen, Sonny Kim; Audouze, Karine; Weinhold, Nils; Edsgard, Daniel; Roque, Francisco S.; Kouskoumvekaki, Irene; Jensen, Thomas Skot; Brunak, Soren; Oprea, Tudor I.] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark. [Bora, Alina; Curpan, Ramona] Acad Romana, Inst Chem, Dept Computat Chem, Timisoara 300223, Romania. [Oprea, Tudor I.] Univ New Mexico Sch Med, Div Biocomp, Dept Biochem &amp; Mol Biol, Albuquerque, NM 87131 USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleTaboureau, O (reprint author), Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmarkotab@cbs.dtu.dk; tuop@cbs.dtu.dkAntonelli A, 2011, METABOLISM, V60, P277, DOI 10.1016/j.metabol.2010.02.002; Audouze K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000788; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465; Broccatelli F, 2010, MOL INFORM, V29, P16, DOI 10.1002/minf.200900075; BUSH BL, 1993, J CHEM INF COMP SCI, V33, P756, DOI 10.1021/ci00015a015; Camon E, 2004, NUCLEIC ACIDS RES, V32, pD262, DOI 10.1093/nar/gkh021; Chamba A, 2010, LEUKEMIA RES, V34, P1103, DOI 10.1016/j.leukres.2010.03.007; *CHEM COMP GROUP, MOE VERS 2007 09; Chen B, 2009, J CHEM INF MODEL, V49, P2044, DOI 10.1021/ci9001876; Davis AP, 2009, NUCLEIC ACIDS RES, V37, pD786, DOI 10.1093/nar/gkn580; Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r; Garcia-Serna R, 2010, BIOINFORMATICS, V26, P985, DOI 10.1093/bioinformatics/btq061; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Guldener U, 2006, NUCLEIC ACIDS RES, V34, pD436, DOI 10.1093/nar/gkj003; Halden RU, 2010, ANNU REV PUBL HEALTH, V31, P179, DOI 10.1146/annurev.publhealth.012809.103714; Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514; Hermjakob H, 2004, NUCLEIC ACIDS RES, V32, pD452, DOI 10.1093/nar/gkh052; Hewett M, 2002, NUCLEIC ACIDS RES, V30, P163, DOI 10.1093/nar/30.1.163; Joshi-Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kuhn M, 2010, NUCLEIC ACIDS RES, V38, pD552, DOI 10.1093/nar/gkp937; Kuhn M, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2009.98; Lage K, 2007, NAT BIOTECHNOL, V25, P309, DOI 10.1038/nbt1295; Lage K, 2008, P NATL ACAD SCI USA, V105, P20870, DOI 10.1073/pnas.0810772105; Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999; de Matos P, 2010, NUCLEIC ACIDS RES, V38, pD249, DOI 10.1093/nar/gkp886; Mestres J, 2009, MOL BIOSYST, V5, P1051, DOI 10.1039/b905821b; Mestres J, 2006, J CHEM INF MODEL, V46, P2725, DOI 10.1021/ci600300k; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; O'Brien KP, 2005, NUCLEIC ACIDS RES, V33, pD476, DOI 10.1093/nar/gki107; Oprea TI, 2007, NAT CHEM BIOL, V3, P447, DOI 10.1038/nchembio0807-447; Pafilis E, 2009, NAT BIOTECHNOL, V27, P508, DOI 10.1038/nbt0609-508; Pagel P, 2005, BIOINFORMATICS, V21, P832, DOI 10.1093/bioinformatics/bti115; Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228; Ponten F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440; Roth BL, 2004, PHARMACOL THERAPEUT, V102, P99, DOI 10.1016/j.pharmthera.2004.03.004; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Safran M, 2002, BIOINFORMATICS, V18, P1542, DOI 10.1093/bioinformatics/18.11.1542; Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086; Schreiber S. L., 2007, CHEM BIOL SMALL MOL, P760; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Vaz R.J., 2008, METHODS PRINCIPLES M; Weill N, 2009, J CHEM INF MODEL, V49, P1049, DOI 10.1021/ci800447g; Wheeler DL, 2007, NUCLEIC ACIDS RES, V35, pD5, DOI 10.1093/nar/gkl1031; Willett P, 2006, DRUG DISCOV TODAY, V11, P1046, DOI 10.1016/j.drudis.2006.10.005; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbtl338; Zanzoni A, 2002, FEBS LETT, V513, P135, DOI 10.1016/S0014-5793(01)03293-8; MARVIN VERS 5 35429OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDNUCLEIC ACIDS RESJAN1Discipline: Biochemistry &amp; Molecular Biology701PA</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CHEMICALS; COMPLEXES; DISEASE; DRUG DISCOVERY; ENDOCRINE; Endocrine disruptor; ENVIRONMENTAL CHEMICALS; EXPRESSION; GENETIC-DISORDERS; HEALTH; in silico; IN-SILICO; Interaction; INTERACTION NETWORK DATABASE; KNOWLEDGEBASE; LEUKEMIA; METABOLISM; MODEL; MOLECULAR INTERACTION DATABASE; PATHOLOGY; PHARMACOLOGICAL SPACE; PHARMACOLOGY; PRINCIPLES; PRODUCTS; PROTEIN; protein-protein interaction; PROTEINS; SYSTEM; TARGET; TISSUE; UPDATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>D367</startpage>
    <endpage>D372</endpage>
    <journalfull>Nucleic Acids Research</journalfull>
    <volume>39</volume>
    <abstract>Systems pharmacology is an emergent area that studies drug action across multiple scales of complexity, from molecular and cellular to tissue and organism levels. There is a critical need to develop network-based approaches to integrate the growing body of chemical biology knowledge with network biology. Here, we report ChemProt, a disease chemical biology database, which is based on a compilation of multiple chemical-protein annotation resources, as well as disease-associated protein-protein interactions (PPIs). We assembled more than 700 000 unique chemicals with biological annotation for 30 578 proteins. We gathered over 2-million chemical-protein interactions, which were integrated in a quality scored human PPI network of 428 429 interactions. The PPI network layer allows for studying disease and tissue specificity through each protein complex. ChemProt can assist in the in silico evaluation of environmental chemicals, natural products and approved drugs, as well as the selection of new compounds based on their activity profile against most known biological targets, including those related to adverse drug events. Results from the disease chemical biology database associate citalopram, an antidepressant, with osteogenesis imperfect and leukemia and bisphenol A, an endocrine disruptor, with certain types of cancer, respectively. The server can be accessed at http://www.cbs.dtu.dk/services/ChemProt/</abstract>
    <url>WOS:000285831700061</url>
    <isbnorissn>0305-1048</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>313</id>
    <title>Parenteral paradichlorobenzene exposure reduces sperm production, alters sperm morphology and exhibits an androgenic effect in rats and mice</title>
    <authors>Takahashi,O.; Ohashi,N.; Nakae,D.; Ogata,A.</authors>
    <availability>[Takahashi, Osamu; Ohashi, Norio; Nakae, Dai; Ogata, Akio] Tokyo Metropolitan Inst Publ Hlth, Dept Environm Hlth &amp; Toxicol, Shinjuku Ku, Tokyo 1690073, Japan.</availability>
    <date>2011</date>
    <notes>JEnglishArticleTakahashi, O (reprint author), Tokyo Metropolitan Inst Publ Hlth, Dept Environm Hlth &amp; Toxicol, Shinjuku Ku, 24-1 Hyakunincho,3 Chome, Tokyo 1690073, JapanOsamu_Takahashi@member.metro.tokyo.jpAiso S, 2005, J VET MED SCI, V67, P1019, DOI 10.1292/jvms.67.1019; ATSDR: Agency for Toxic Substances and Disease Registry, 2006, TOX PROF DICHL; BOMHARD E, 1988, ARCH TOXICOL, V61, P433, DOI 10.1007/BF00293688; Boorman GA, 1990, PATHOLOGY FISCHER RA, P405; BROWN V K H, 1969, Annals of Occupational Hygiene, V12, P209; CARBONELL E, 1991, MUTAT RES, V263, P57, DOI 10.1016/0165-7992(91)90035-3; Chang HY, 2001, ENVIRON HEALTH PERSP, V109, P753, DOI 10.2307/3454794; *CHEM DAIL CO, 2005, 14705 CHEM, P935; Cooke PS, 1996, TOXICOL APPL PHARM, V136, P112, DOI 10.1006/taap.1996.0013; COOKE PS, 1991, ENDOCRINOLOGY, V129, P244; Filler R, 1993, METHODS TOXICOLOGY A, V3, P334; Freyberger A, 2004, TOXICOLOGY, V195, P113, DOI 10.1016/j.tox.2003.09.008; Gad Shayne C., 1994, P221; GIAVINI E, 1986, B ENVIRON CONTAM TOX, V37, P164; HATA H, 1995, CONGENIT ANOM, V35, P477; HAWKINS DR, 1980, XENOBIOTICA, V10, P81; HAWORTH S, 1983, ENVIRON MUTAGEN, V5, P3, DOI 10.1002/em.2860050703; HAYES WC, 1985, FUND APPL TOXICOL, V5, P190, DOI 10.1016/0272-0590(85)90064-8; HODGE M, 1977, CTLP340 IMP CHEM CEN; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; Kizu R, 2003, ARCH TOXICOL, V77, P335, DOI 10.1007/s00204-003-0454-y; Kizu R, 2003, TOXICOL SCI, V76, P299, DOI 10.1093/toxsci/kfg230; Kizu R, 2004, ANAL SCI, V20, P55, DOI 10.2116/analsci.20.55; LAMBRIGHT C, 2000, TOXICOL SCI, V56, P89; LAND PC, 1981, ANESTHESIOLOGY, V54, P53, DOI 10.1097/00000542-198101000-00010; Latendresse JR, 2002, TOXICOL PATHOL, V30, P524, DOI 10.1080/01926230290105721; Lin TM, 2002, TOXICOL SCI, V68, P479, DOI 10.1093/toxsci/68.2.479; LOESER E, 1983, FOOD CHEM TOXICOL, V21, P825, DOI 10.1016/0278-6915(83)90219-3; LUNDBERG I, 1986, ENVIRON RES, V40, P411, DOI 10.1016/S0013-9351(86)80116-5; Makita Y, 2005, BASIC CLIN PHARMACOL, V96, P361, DOI 10.1111/j.1742-7843.2005.pto_04.x; MILLS NC, 1990, INT J ANDROL, V13, P123, DOI 10.1111/j.1365-2605.1990.tb00969.x; *MIN ENV JAP, 2005, P DICHL; *MIN ENV JAP, 2001, P 2 M PROBL SICK HOU; *MIN ENV JAP, 2000, P DICHL; MURTHY R C, 1987, Advances in Contraceptive Delivery Systems, V3, P35; *NTP, 1987, 319 NTP TR PUBL HLTH; NTP (National Toxicology Program), 2005, 11 NTP; Odeigah PGC, 1997, MUTAT RES-GEN TOX EN, V389, P141, DOI 10.1016/S1383-5718(96)00136-2; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Ohtani K, 2004, IND HEALTH, V42, P219, DOI 10.2486/indhealth.42.219; Oikawa S, 1996, CARCINOGENESIS, V17, P2733, DOI 10.1093/carcin/17.12.2733; POWERS MB, 1975, ARCH ENVIRON HEALTH, V30, P165; RADVSKY A, 1999, PATHOLOGY MOUSE, P381; *RAIS, 1997, TOX SUMM CHLOR; Ralph JL, 2003, ENVIRON HEALTH PERSP, V111, P461, DOI 10.1289/ehp.5919; SAFE SH, 2004, INHIBITORY AH RECEPT; Sherman JH, 1998, TERATOGEN CARCIN MUT, V18, P309, DOI 10.1002/(SICI)1520-6866(1998)18:6&lt;309::AID-TCM5&gt;3.0.CO;2-P; SHIMIZU M, 1983, MUTAT RES, V116, P217, DOI 10.1016/0165-1218(83)90060-5; *SIGM ALDR, 2004, CHLOR MAT SAF DAT SH; *SPECTR LAB, 2003, 106467 SPECTR LAB; STINE ER, 1991, TOXICOL APPL PHARM, V109, P472, DOI 10.1016/0041-008X(91)90010-C; SUN YT, 1989, ENDOCRINOLOGY, V125, P1000; SZANTO AJP, 1998, FUNDAMENTALS TOXICOL, P37; Takabashi O, 2001, ARCH TOXICOL, V75, P42, DOI 10.1007/s002040000204; Takahashi O, 2003, FOOD CHEM TOXICOL, V41, P1035, DOI 10.1016/S0278-6915(03)00031-0; Takahashi O, 2007, ARCH TOXICOL, V81, P505, DOI 10.1007/s00204-007-0179-4; TOKONABE S, 2004, J SAITAMA MED SCH, V31, P25; *UKIRDG, 2000, RAT SPERM MORPH ASS; UMEMURA T, 1992, ARCH TOXICOL, V66, P503, DOI 10.1007/BF01970676; UMEMURA T, 1989, Science Reports of the Research Institutes Tohoku University Series C Medicine, V36, P1; Vazquez ER, 1996, INT J DERMATOL, V35, P643, DOI 10.1111/j.1365-4362.1996.tb03689.x; Vinggaard AM, 2000, TOXICOLOGY, V145, P173, DOI 10.1016/S0300-483X(00)00143-8; Violante FS, 2005, CONTACT DERMATITIS, V52, P108, DOI 10.1111/j.0105-1873.2005.00498a.x; WILSON EM, 1976, J BIOL CHEM, V251, P5620; Yin X, 1998, Wei Sheng Yan Jiu, V27, P377654PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLJANDiscipline: Food Science &amp; Technology; Toxicology717OE</notes>
    <keywords>ALTERS; Androgen; ANDROGEN RECEPTOR; ASSAY; BINDING; BISPHENOL-A; CANCER CELLS; CARCINOGENESIS; Daily sperm production; DISEASE; Epididymis; EXPOSURE; FOOD; GLAND; HEALTH; Hershberger assay; INHALATION; INJURY; KU; LABORATORY WORKER; MICE; morphology; Mouse; Occupational; P-DICHLOROBENZENE; PARA-DICHLOROBENZENE; Paradichlorobenzene; POLYCYCLIC AROMATIC-HYDROCARBONS; Prostate; PROSTATE CARCINOMA-CELLS; Prostate gland; RAT; RATS; RECEPTOR; serum; SPERM; SPERM PRODUCTION; SYSTEM; TESTICULAR TOXICITY; testis; Testosterone; toxicology; VENTRAL PROSTATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>49</startpage>
    <endpage>56</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <issue>1</issue>
    <volume>49</volume>
    <abstract>Rats and mice (8 animals per species per group) were injected subcutaneously or intraperitoneally with paradichlorobenzene (PDCB) at doses of 0, 100, 200 and 400 mg/kg/day, 4-5 days a week, for 8 weeks (for rats) and either 2 or 6 weeks (for mice). Prostate and seminal vesicle weights were significantly increased in PDCB-treated rats but not in mice. Major histopathologic injuries were not found in testis and epididymis of both species. Daily sperm production was depressed in both species in a dose-response manner. Serum testosterone levels were not significantly changed in both species. Sperm morphology was evaluated in rats intraperitoneally administered PDCB at a dose of 800 mg/kg. Abnormal sperms with reduced hook, bent neck, coiled flagellum, bent flagellum and bent flagellum tip were significantly increased in treated rats. In Hershberger assay, PDCB administration increased weights of ventral prostate gland, seminal vesicle, levator ani/bulbocavernosus muscle and glans penis in castrated rats, and also weights of ventral prostate gland and glans penis in castrated mice. PDCB and 2,5-dichlorophenol (the major metabolite) did not bind androgen receptor (AR) up to 10 mM. In conclusion, PDCB affects sperm production and morphology but is somewhat androgenic independently from AR binding in rats and mice. (c) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000287056500007</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>245</id>
    <title>Neonatal Exposure to Estradiol/Bisphenol A Alters Promoter Methylation and Expression of Nsbp1 and Hpcal1 Genes and Transcriptional Programs of Dnmt3a/b and Mbd2/4 in the RatProstate Gland Throughout Life</title>
    <authors>Tang,W.Y.; Morey,L.M.; Cheung,Y.Y.; Birch,L.; Prins,G.S.; Ho,S.M.</authors>
    <availability>[Ho, Shuk-mei] Univ Cincinnati, Med Ctr, Dept Environm Hlth, Ctr Environm Genet, Cincinnati, OH 45267 USA. [Tang, Wan-yee; Morey, Lisa M.; Cheung, Yuk Yin; Ho, Shuk-mei] Univ Cincinnati, Div Environm Genet &amp; Mol Toxicol, Cincinnati, OH 45267 USA. [Ho, Shuk-mei] Univ Cincinnati, Inst Canc, Coll Med, Cincinnati, OH 45267 USA. [Ho, Shuk-mei] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45220 USA. [Birch, Lynn; Prins, Gail S.] Univ Illinois, Dept Urol, Chicago, IL 60612 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleHo, SM (reprint author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, Ctr Environm Genet, Kettering Complex,Room 128,3223 Eden Ave,POB 6700, Cincinnati, OH 45267 USAshuk-mei.ho@uc.eduAnway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Berger SL, 2009, EPIGENETIC CONTROL N, P1; Bhattacharya SK, 1999, NATURE, V397, P579; Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078; Bostwick DG, 2004, CANCER, V101, P2371, DOI 10.1002/cncr.20408; Braunewell KH, 2005, TRENDS PHARMACOL SCI, V26, P345, DOI 10.1016/j.tips.2005.04.008; Brawley Otis W, 2007, Curr Probl Cancer, V31, P211, DOI 10.1016/j.currproblcancer.2007.01.006; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; BUSTIN M, 1995, SEMIN CELL BIOL, V6, P247, DOI 10.1006/scel.1995.0033; CHANG SM, 1989, ENDOCRINOLOGY, V125, P2719; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Cnattingius S, 2009, CANCER EPIDEM BIOMAR, V18, P2422, DOI 10.1158/1055-9965.EPI-09-0366; Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013; Dhasarathy A, 2008, MUTAT RES-FUND MOL M, V647, P39, DOI 10.1016/j.mrfmmm.2008.07.007; Ekbom A, 1998, SEMIN CANCER BIOL, V8, P237, DOI 10.1006/scbi.1998.0073; Ekbom A, 2000, CANCER EPIDEM BIOMAR, V9, P221; Fu J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001698; Gerlitz G, 2010, BBA-GENE REGUL MECH, V1799, P80, DOI 10.1016/j.bbagrm.2009.10.007; Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062; Guerrico AMG, 2005, ONCOGENE, V24, P2307, DOI 10.1038/sj.onc.1208476; Hamm S, 2008, BIOORG MED CHEM LETT, V18, P1046, DOI 10.1016/j.bmcl.2007.12.027; HO SM, 1988, CANCER RES, V48, P609; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Jablonka E, 2002, ANN NY ACAD SCI, V981, P82; Jiang N, 2010, ASIAN J ANDROL, V12, P709, DOI 10.1038/aja.2010.39; Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; LEE C, 1981, J ANDROL, V2, P293; Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147; Li SF, 1997, CANCER RES, V57, P4356; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Malicet C, 2011, MOL CELL BIOL, V31, P2742, DOI 10.1128/MCB.05216-11; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Merkle D, 2011, CELL SIGNAL, V23, P507, DOI 10.1016/j.cellsig.2010.08.017; NAKHLA AM, 1994, P NATL ACAD SCI USA, V91, P5402, DOI 10.1073/pnas.91.12.5402; NEWBOLD RR, 1990, CANCER RES, V50, P7677; Newbold RR, 2001, CANCER RES, V61, P4325; Nimura K, 2006, GENES CELLS, V11, P1225, DOI 10.1111/j.1365-2443.2006.001012.x; Pogna EA, 2010, BBA-GENE REGUL MECH, V1799, P93, DOI 10.1016/j.bbagrm.2009.11.018; PRICE DOROTHY, 1963, NATL CANCER INST MONOGR, V12, P1; PRINS GS, 1989, J STEROID BIOCHEM, V33, P319, DOI 10.1016/0022-4731(89)90319-1; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Prins GS, 2008, ENDOCR-RELAT CANCER, V15, P649, DOI 10.1677/ERC-08-0043; Qu JT, 2011, J NEURO-ONCOL, V104, P729, DOI 10.1007/s11060-011-0558-9; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rochman M, 2009, MOL CELL, V35, P642, DOI 10.1016/j.molcel.2009.07.002; Rochman M, 2010, BBA-GENE REGUL MECH, V1799, P86, DOI 10.1016/j.bbagrm.2009.09.012; Rohrmann S, 2009, CANCER EPIDEM BIOMAR, V18, P1484, DOI 10.1158/1055-9965.EPI-08-0817; ROSS RK, 1994, J NATL CANCER I, V86, P252, DOI 10.1093/jnci/86.4.252; Sequoia JSP, 2006, CANCER EPIDEM BIOMAR, V15, P2174, DOI 10.1158/1055-9965.EPI-06-0467; Shirakawa H, 2000, J BIOL CHEM, V275, P6368, DOI 10.1074/jbc.275.9.6368; Song Gang, 2006, Zhonghua Yi Xue Za Zhi, V86, P1962; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Uckert S, 2006, EUR UROL, V49, P740, DOI 10.1016/j.eururo.2005.12.050; Verkasalo PK, 1999, INT J CANCER, V83, P743, DOI 10.1002/(SICI)1097-0215(19991210)83:6&lt;743::AID-IJC8&gt;3.0.CO;2-Q; Wahafu W, 2011, TUMOR BIOL, V32, P931, DOI 10.1007/s13277-011-0195-0; Wickborn C, 2006, MOL CARCINOGEN, V45, P572, DOI 10.1002/mc.20201; Zhang XA, 2011, J MOL ENDOCRINOL, V46, pR11, DOI 10.1677/JME-10-00536325ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCRINOLOGYJANDiscipline: Endocrinology &amp; Metabolism869XC</notes>
    <keywords>ADULT; ADULTHOOD; ALTERS; ANDROGEN RECEPTOR; BINDING; bisphenol; bisphenol A; BISPHENOL-A; CANCER; Carcinogen; CARCINOGENESIS; CELL; CELLS; DEVELOPMENTAL EXPOSURE; DNA METHYLATION; DNA-methylation; DOWN-REGULATION; ENDOCRINE; ENDOCRINE DISRUPTORS; epigenetic; ESTRADIOL; EXPOSURE; EXPRESSION; GENE; GENES; GLAND; HYPERMETHYLATION; INDUCTION; MAMMALIAN PROTEIN; mechanism; METABOLISM; METHYLATION; Methyltransferase; MOUSE UTERUS; NEONATAL EXPOSURE; NUCLEOSOMAL-BINDING-PROTEIN; PROMOTER; PROMOTER METHYLATION; Prostate; prostate cancer; PROSTATE-CANCER; PROSTATE-CANCER RISK; PROTEIN; PROTEINS; RAT; RAT PROSTATE; RATS; RISK; SEXUAL-MATURATION; TUMOR; UTERINE ADENOCARCINOMA</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>42</startpage>
    <endpage>55</endpage>
    <journalfull>Endocrinology</journalfull>
    <issue>1</issue>
    <volume>153</volume>
    <abstract>Evidence supporting an early origin of prostate cancer is growing. We demonstrated previously that brief exposure of neonatal rats to estradiol or bisphenol A elevated their risk of developing precancerous lesions in the prostate upon androgen-supported treatment with estradiol as adults. Epigenetic reprogramming may be a mechanism underlying this inductive event in early life, because we observed overexpression of phosphodiesterase 4D variant 4 (Pde4d4) through induction of hypomethylation of its promoter. This epigenetic mark was invisible in early life (postnatal d 10), becoming apparent only after sexual maturation. Here, we asked whether other estrogen-reprogrammable epigenetic marks have similar or different patterns in gene methylation changes throughout life. We found that hypomethylation of the promoter of nucleosome binding protein-1 (Nsbp1), unlike Pde4d4, is an early and permanent epigenetic mark of neonatal exposure to estradiol/bisphenol A that persists throughout life, unaffected by events during adulthood. In contrast, hippocalcin-like 1 (Hpcal1) is a highly plastic epigenetic mark whose hypermethylation depends on both type of early-life exposure and adult-life events. Four of the eight genes involved in DNA methylation/demethylation showed early and persistent overexpression that was not a function of DNA methylation at their promoters, including genes encoding de novo DNA methyltransferases (Dnmt3a/b) and methyl-CpG binding domain proteins (Mbd2/4) that have demethylating activities. Their lifelong aberrant expression implicates them in early-life reprogramming and prostate carcinogenesis during adulthood. We speculate that the distinctly different fate of early-life epigenetic marks during adulthood reflects the complex nature of lifelong editing of early-life epigenetic reprogramming. (Endocrinology 153: 42-55, 2012)</abstract>
    <url>WOS:000298631500005</url>
    <isbnorissn>0013-7227</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>56</id>
    <title>Exposure to Bisphenol A Correlates with Early-Onset Prostate Cancer and Promotes Centrosome Amplification and Anchorage-Independent Growth In Vitro</title>
    <authors>Tarapore,P.; Ying,J.; Ouyang,B.; Burke,B.; Bracken,B.; Ho,S.M.</authors>
    <availability>[Tarapore, Pheruza; Ying, Jun; Ouyang, Bin; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Tarapore, Pheruza; Ying, Jun; Ouyang, Bin; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH USA. [Tarapore, Pheruza; Ouyang, Bin; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Cincinnati Canc Ctr, Cincinnati, OH USA. [Burke, Barbara; Bracken, Bruce] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Ho, Shuk-Mei] Cincinnati Veteran Affairs Hosp Med Ctr, Cincinnati, OH USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleHo, SM (reprint author), Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USAshuk-mei.ho@uc.eduAmerican Cancer Society, 2013, CANC FACTS FIG; Avidor-Reiss T, 2013, CURR OPIN CELL BIOL, V25, P72, DOI 10.1016/j.ceb.2012.10.016; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Bostwick DG, 2004, CANCER, V101, P2371, DOI 10.1002/cncr.20408; Brownlee CW, 2013, CELL MOL LIFE SCI, V70, P1021, DOI 10.1007/s00018-012-1102-6; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Carwile JL, 2011, ENVIRON RES, V111, P825, DOI 10.1016/j.envres.2011.05.014; Chan JY, 2011, INT J BIOL SCI, V7, P1122; Cheung CHA, 2011, EXPERT OPIN THER PAT, V21, P857, DOI 10.1517/13543776.2011.574614; Darshan MS, 2011, CANCER RES, V71, P6019, DOI 10.1158/0008-5472.CAN-11-1417; Davis JN, 2000, INT J ONCOL, V16, P1091; De CS, 2012, J ENV PUBLIC HLTH, V2012, DOI [10.1155/2012/713696, DOI 10.1155/2012/713696]; De FS, 2011, TOXICOL SCI, V122, P45, DOI DOI 10.1093/T0XSCI/KFR096; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Delgehyr N, 2005, J CELL SCI, V118, P1565, DOI 10.1242/jcs.02302; Derouiche S, 2013, SPRINGERPLUS, V2, P54, DOI DOI 10.1186/2193-1801-2-54;93; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; Duan B, 2013, INT J CLIN ONCOL, V18, P492, DOI 10.1007/s10147-012-0408-6; Ehrlich S, 2012, HUM REPROD, V27, P3583, DOI 10.1093/humrep/des328; Erickson BE, 2008, CHEM ENG NEWS, V86, P36, DOI 10.1021/cen-v086n022.p036; Fiege H., 2002, ULLMANNS ENCY IND CH; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Geens T, 2012, FOOD CHEM TOXICOL, V50, P3725, DOI 10.1016/j.fct.2012.07.059; George O, 2008, ACS CHEM BIOL, V3, P167, DOI [10.1021/cb700210u, 10.1021/cb6700210u]; Gorlov IP, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-599; Guay A T, 2000, Endocr Pract, V6, P132; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hornung R.W., 1990, APPL OCCUP ENV HYG, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Korzeniewski N, 2013, EXPERT OPIN THER TAR, V17, P43, DOI 10.1517/14728222.2013.731396; Lam YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009075; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee HH, 2008, ENDOCR-RELAT CANCER, V15, P765, DOI 10.1677/ERC-07-0213; Lehmann L, 2004, CHEM-BIOL INTERACT, V147, P273, DOI 10.1016/j.cbi.2004.01.005; Ling HB, 2012, CELL CYCLE, V11, P3779, DOI 10.4161/cc.21985; Lingle WL, 2005, ADV EXP MED BIOL, V570, P393, DOI 10.1007/1-4020-3764-3_14; Mahalingaiah S, 2008, ENVIRON HEALTH PERSP, V116, P173, DOI 10.1289/ehp.10605; Matsushima A, 2008, BIOCHEM BIOPH RES CO, V373, P408, DOI 10.1016/j.bbrc.2008.06.050; Mobley JA, 2003, CANCER EPIDEM BIOMAR, V12, P775; Morgentaler A, 2006, UROLOGY, V68, P1263, DOI 10.1016/j.urology.2006.08.1058; National Cancer Institute, 2013, SEER CANC STAT REV; Nomura H, 2009, PROSTATE CANCER P D, V12, P375, DOI 10.1038/pcan.2009.20; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Ouyang B, 2009, J UROLOGY, V181, P2508, DOI 10.1016/j.juro.2009.01.110; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Pfeiffer E, 1997, MUTAT RES-GEN TOX EN, V390, P21, DOI 10.1016/S0165-1218(96)00161-9; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Qin XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036711; Rhoden EL, 2008, J UROLOGY, V179, P1741, DOI 10.1016/j.juro.2008.01.045; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925; Schoffski P, 2009, ONCOLOGIST, V14, P559, DOI 10.1634/theoncologist.2009-0010; Sheng ZG, 2012, TOXICOL APPL PHARM, V259, P133, DOI 10.1016/j.taap.2011.12.018; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; STAVNEZER E, 1981, J VIROL, V39, P920; Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308; Tarapore P, 2012, CELL CYCLE, V11, P2931, DOI 10.4161/cc.21396; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Townsend MK, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-80; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; WHO, 1996, BIOL MON CHEM EXP WO, V1; Xi W, 2011, REPROD TOXICOL, V31, P409, DOI 10.1016/j.reprotox.2010.12.002; Ye XY, 2011, ENVIRON HEALTH PERSP, V119, P983, DOI 10.1289/ehp.1002701; Zhang ZF, 2011, ENVIRON SCI TECHNOL, V45, P7044, DOI 10.1021/es200976k; Zhu ML, 2010, CANCER RES, V70, P7992, DOI 10.1158/0008-5472.CAN-10-0585720PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEMAR 3Discipline: Science &amp; Technology - Other TopicsAC4CT</notes>
    <keywords>ABNORMALITIES; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARCINOGENESIS; CELL; CELL-CYCLE; CELLS; CHROMOSOME INSTABILITY; CYCLE; EPITHELIAL-CELLS; ESTROGENS; EXPOSURE; EXPRESSION; FOOD; GROWTH; HYPOGONADAL MEN; In vitro; IN-VITRO; INDUCTION; LINES; mechanism; MICROTUBULES; prostate cancer; PROSTATE-CANCER; RESPONSES; SUSCEPTIBILITY; URINARY; VARIABILITY; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>3</issue>
    <volume>9</volume>
    <abstract>Human exposure to bisphenol A (BPA) is ubiquitous. Animal studies found that BPA contributes to development of prostate cancer, but human data are scarce. Our study examined the association between urinary BPA levels and Prostate cancer and assessed the effects of BPA on induction of centrosome abnormalities as an underlying mechanism promoting prostate carcinogenesis. The study, involving 60 urology patients, found higher levels of urinary BPA (creatinine-adjusted) in Prostate cancer patients (5.74 mu g/g [95% CI; 2.63, 12.51]) than in non-Prostate cancer patients (1.43 mu g/g [95% CI; 0.70, 2.88]) (p = 0.012). The difference was even more significant in patients &lt;65 years old. A trend toward a negative association between urinary BPA and serum PSA was observed in Prostate cancer patients but not in non-Prostate cancer patients. In vitro studies examined centrosomal abnormalities, microtubule nucleation, and anchorage-independent growth in four Prostate cancer cell lines (LNCaP, C4-2, 22Rv1, PC-3) and two immortalized normal prostate epithelial cell lines (NPrEC and RWPE-1). Exposure to low doses (0.01-100 nM) of BPA increased the percentage of cells with centrosome amplification two- to eight-fold. Dose responses either peaked or reached the plateaus with 0.1 nM BPA exposure. This low dose also promoted microtubule nucleation and regrowth at centrosomes in RWPE-1 and enhanced anchorage-independent growth in C4-2. These findings suggest that urinary BPA level is an independent prognostic marker in Prostate cancer and that BPA exposure may lower serum PSA levels in Prostate cancer patients. Moreover, disruption of the centrosome duplication cycle by low-dose BPA may contribute to neoplastic transformation of the prostate</abstract>
    <url>WOS:000332468900094</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>115</id>
    <title>Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells</title>
    <authors>Tarnow,P.; Tralau,T.; Hunecke,D.; Luch,A.</authors>
    <availability>[Tarnow, Patrick; Tralau, Tewes; Hunecke, Danele; Luch, Andreas] German Fed Inst Risk Assessment BfR, Dept Prod Safety, D-10589 Berlin, Germany.</availability>
    <date>2013</date>
    <notes>JEnglishArticleTarnow, P (reprint author), German Fed Inst Risk Assessment BfR, Max Dohrn Str 8-10, D-10589 Berlin, GermanyPatrick.Tarnow@bfr.bund.deAhn KC, 2008, ENVIRON HEALTH PERSP, V116, P1203, DOI 10.1289/ehp.11200; Aken Benoit Van, 2010, Environ Sci Technol, V44, P2767, DOI 10.1021/es902514d; Baker VA, 2001, TOXICOL IN VITRO, V15, P413, DOI 10.1016/S0887-2333(01)00045-5; Blake LS, 2010, ENVIRON TOXICOL CHEM, V29, P1367, DOI 10.1002/etc.166; Bovee TFH, 2009, J CHROMATOGR A, V1216, P8035, DOI 10.1016/j.chroma.2009.03.045; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552; Chen JG, 2008, ENDOCRINOLOGY, V149, P1173, DOI 10.1210/en.2007-1057; Christen V, 2010, CHEMOSPHERE, V81, P1245, DOI 10.1016/j.chemosphere.2010.09.031; Chung E, 2011, P NATL ACAD SCI USA, V108, P17732, DOI 10.1073/pnas.1115187108; Diel P, 1999, PLANTA MED, V65, P197, DOI 10.1055/s-1999-13980; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Duleba AJ, 2011, REPROD SCI, V18, P119, DOI 10.1177/1933719110382581; Ermler S, 2010, TOXICOL IN VITRO, V24, P1845, DOI 10.1016/j.tiv.2010.05.007; Evans RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043606; Furukawa K, 2008, J BIOSCI BIOENG, V105, P433, DOI 10.1263/jbb.105.433; Halden RU, 2005, ENVIRON SCI TECHNOL, V39, P1420, DOI 10.1021/es049071e; Hanioka N, 2008, CHEMOSPHERE, V74, P33, DOI 10.1016/j.chemosphere.2008.09.053; Harrington WR, 2006, ENDOCRINOLOGY, V147, P3843, DOI 10.1210/en.2006-0358; Heidler J, 2006, ENVIRON SCI TECHNOL, V40, P3634, DOI 10.1021/es052245n; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hu DG, 2009, MOL PHARMACOL, V76, P425, DOI 10.1124/mol.109.057380; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Madak-Erdogan Z, 2008, MOL ENDOCRINOL, V22, P2116, DOI 10.1210/me.2008-0059; Morrow D, 2004, J STEROID BIOCHEM, V88, P27, DOI 10.1016/j.jsbmb.2003.10.005; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321; OECD, 2009, OECD TEST 455 PERF B; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Ohtake F, 2011, J STEROID BIOCHEM, V127, P102, DOI 10.1016/j.jsbmb.2011.03.007; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; Rataj F, 2012, ARCH TOXICOL, V86, P1603, DOI 10.1007/s00204-012-0870-y; Schebb NH, 2011, ENVIRON SCI TECHNOL, V45, P3109, DOI 10.1021/es103650m; Schebb NH, 2012, CHEMOSPHERE, V87, P825, DOI 10.1016/j.chemosphere.2011.12.077; Scientific Committee on Consumer Products (SCCP), 2005, SCCP085104; SHEN ZY, 1994, DNA CELL BIOL, V13, P763, DOI 10.1089/dna.1994.13.763; Silva E, 2010, TOXICOL APPL PHARM, V245, P159, DOI 10.1016/j.taap.2010.02.015; Solyanikova IP, 2004, J ENVIRON SCI HEAL B, V39, P333, DOI 10.1081/PFC-120035921; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Sotoca AM, 2010, J STEROID BIOCHEM, V122, P204, DOI 10.1016/j.jsbmb.2010.06.010; Sun X, 2007, CELL STRESS CHAPERON, V12, P307, DOI 10.1379/CSC-276.1; Thorne N, 2012, CHEM BIOL, V19, P1060, DOI 10.1016/j.chembiol.2012.07.015; Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020; Tsuchiya Y, 2004, CANCER RES, V64, P3119, DOI 10.1158/0008-5472.CAN-04-0166; Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; Wilson VS, 2002, TOXICOL SCI, V66, P69, DOI 10.1093/toxsci/66.1.69; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Wu C., 2012, ECOTOXICOL ENV SAF; Yueh MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037705496PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROAUGSIDiscipline: Toxicology168DP</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; ANDROGEN RECEPTOR; Aryl hydrocarbon receptor; bisphenol; bisphenol A; BISPHENOL-A; breast cancer; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CARCINOMA; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; DEGRADATION; ENDOCRINE; ENDOCRINE DISRUPTORS; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGENS; EXPRESSION; genistein; HUMAN-BREAST-CANCER; In vitro; IN-VITRO; INDUCTION; LINES; Luciferase assay; Luciferase inhibition; MDA-KB2; proliferation; PROMOTE PROTEIN STABILITY; RECEPTOR; RESPONSIVE GENES; RISK; Risk assessment; RISK-ASSESSMENT; toxicology; Triclocarban (TCC); Triclosan; VITRO; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1467</startpage>
    <endpage>1475</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>5</issue>
    <volume>27</volume>
    <abstract>Triclocarban (TCC) is an antimicrobial agent that is used in detergents, soaps and other personal hygiene products. Similarly to triclosan the widespread use of TCC has raised concerns about its endocrine potential. In luciferase-based reporter assays TCC has been shown to enhance estrogenic and androgenic activities following cellular coexposure with estrogen or dihydrotestosterone, respectively. The present study demonstrates that although coexposure with TCC enhances the estrogenic and androgenic readout of luciferase-based reporter cell lines such as HeLa9908 and MDA-kb2, it fails to act as a xenoandrogen on transcriptional level, nor does it induce cell proliferation in the estrogen sensitive E-screen. In addition TCC did not alter the expression of estrogen responsive genes in human mammary carcinoma MCF-7 cells exposed to 17 beta-estradiol, bisphenol A, butylparaben or genistein. However, TCC was shown to interfere with the regulon of the aryl hydrocarbon receptor (AhR) as TCC showed a costimulatory effect on transcription of CYP1A1 and CYP1B1, effectively lowering the transcriptional threshold for both genes in the presence of estrogens. It thus seems, that while the induction of the respective luciferase reporter assays by TCC is an unspecific false positive signal caused by luciferase stabilisation, TCC has the potential to interfere with the regulatory crosstalk of the estrogen receptor (ER) and the AhR regulon. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000320686200007</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>190</id>
    <title>Evaluation of Blood Bisphenol A Contents: A Case Study</title>
    <authors>Taskeen,A.; Naeem,I.; Atif,M.</authors>
    <availability>[Taskeen, A.; Naeem, I.] Women Univ, Lahore Coll, Dept Chem, Lahore 5400, Pakistan. [Atif, M.] UET Lahore, Inst Business &amp; Management, Lahore, Pakistan.</availability>
    <date>2012</date>
    <notes>JEnglishArticleNaeem, I (reprint author), Women Univ, Lahore Coll, Dept Chem, Jail Rd, Lahore 5400, Pakistanismat4_naeem@yahoo.co.inAshby J, 1999, REGUL TOXICOL PHARM, V30, P156, DOI 10.1006/rtph.1999.1317; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Cagen SZ, 1999, REGUL TOXICOL PHARM, V30, P130, DOI 10.1006/rtph.1999.1340; Cefic: the European Union Industry Council, 1990, HUM SAF BISPH OV; Dodds EC, 1938, PROC R SOC SER B-BIO, V125, P222, DOI 10.1098/rspb.1938.0023; EFSA (European Food Safety Authority), 2007, OP SCI PAN FOOD ADD; Elsby R, 2001, J PHARMACOL EXP THER, V297, P103; Ema M, 2001, REPROD TOXICOL, V15, P505, DOI 10.1016/S0890-6238(01)00160-5; European Union, 2003, 80057 CAS EUR UN; Goodman JE, 2006, CRIT REV TOXICOL, V36, P387, DOI 10.1080/10408440600758317; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Nakagawa Y, 2000, ARCH TOXICOL, V74, P99, DOI 10.1007/s002040050659; Newbold RR, 2008, INT J ANDROL, V31, P201, DOI 10.1111/j.1365-2605.2007.00858.x; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Ropero AB, 2008, INT J ANDROL, V31, P194, DOI 10.1111/j.1365-2605.2007.00832.x; Roy D, 1997, J TOXICOL ENV HEALTH, V50, P1, DOI 10.1080/009841097160573; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159240UNIV WEST INDIES FACULTY MEDICAL SCIENCESKINGSTONMONA CAMPUS, KINGSTON 7, JAMAICAW INDIAN MED JSEPDiscipline: General &amp; Internal Medicine091WN</notes>
    <keywords>bisphenol; bisphenol A; bisphenol A (BPA); BISPHENOL-A; BLOOD; BPA; BPA health effect; BPA in blood; CANCER; Case studies; CHEMICALS; DISEASE; EXPOSURE; FOOD; HEALTH; INDUSTRY; LIQUID-CHROMATOGRAPHY; Liver; MECHANISMS; METABOLISM; PERFORMANCE; Prostate; RATS; reference dose; REPRODUCTIVE TOXICITY; RISK; SAMPLES; toxicology; WATER; WATER SAMPLES; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>564</startpage>
    <endpage>568</endpage>
    <journalfull>West Indian Medical Journal</journalfull>
    <issue>6</issue>
    <volume>61</volume>
    <abstract>Objective: It has been recently reported that Bisphenol A (BPA) may leach out into food, beverages and water samples from the plastic ware in which it is stored. Serious health hazards have been reported from BPA. The purpose of this study is to assess the BPA contents in blood and to assess the risk of cancer. Method: A total of 100 individuals were selected for study according to the following five age groups: 5-10, 11-20, 21-30, 31-40 and 41-50 years. They were then further divided into normal and diseased. Age, gender education, source of drinking water type of food, smoking habit, any exposure to chemicals and history of cancer were elicited during interview. Blood samples were collected and processed for analysis using reversed phase-high performance liquid chromatography (rp-HPLC) in isocratic mode. The mobile phase consisted of acetonitrile and water (1:1) at a flow-rate of 1 ml min(-1) Results: Bisphenol A contents found in blood samples of all age groups ranged from 1.53-3.98 (mean = 2.94, SD = 0.9). P-values, for the exposed people and those having a history of cancer, were &lt; 0.05 showing a significant relationship between BPA and cancer The United States Environmental Protection Agency (US EPA) has established a reference dose of 50 mu g/L. Odd ratios and relative risk for smoking habit were &lt; 1 while for all others they were &gt;1. Conclusion: It was concluded from the study that people using bottled water packaged food, having a history of cancer and who had been exposed to any type of chemicals are at higher risk of disease</abstract>
    <url>WOS:000315080600003</url>
    <isbnorissn>0043-3144</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>133</id>
    <title>Bisphenol A affects androgen receptor function via multiple mechanisms</title>
    <authors>Teng,C.; Goodwin,B.; Shockley,K.; Xia,M.H.; Huang,R.L.; Norris,J.; Merrick,B.A.; Jetten,A.M.; Austin,C.P.; Tice,R.R.</authors>
    <availability>[Teng, Christina; Merrick, B. Alex; Tice, Raymond R.] NIEHS, DNTP Biomol Screening Branch, NIH, Res Triangle Pk, NC 27709 USA. [Jetten, Anton M.] NIEHS, DIR Lab Resp Biol, NIH, Res Triangle Pk, NC 27709 USA. [Shockley, Keith] NIEHS, DIR Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA. [Goodwin, Bonnie; Xia, Menghang; Huang, Ruili; Austin, Christopher P.] NIH, Natl Ctr Adv Translat Sci, Rockville, MD USA. [Norris, John] Duke Univ, Dept Pharmacol, Durham, NC USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleTeng, C (reprint author), NIEHS, BSB, DNTP, NIH,Biomol Screening Branch, 111 Alexander Dr,POB 12233,MD K2-17, Res Triangle Pk, NC 27709 USAteng1@niehs.nih.govAlavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; Araki N, 2005, TOXICOL IN VITRO, V19, P831, DOI 10.1016/j.tiv.2005.04.009; Askew EB, 2012, MOL CELL ENDOCRINOL, V348, P403, DOI 10.1016/j.mce.2011.03.026; Boas M, 2012, MOL CELL ENDOCRINOL, V355, P240, DOI 10.1016/j.mce.2011.09.005; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cederroth CR, 2012, MOL CELL ENDOCRINOL, V355, P192, DOI 10.1016/j.mce.2011.05.049; Clinckemalie L, 2012, MOL CELL ENDOCRINOL, V358, P1, DOI 10.1016/j.mce.2012.02.019; Cutress ML, 2008, J CELL SCI, V121, P957, DOI 10.1242/jcs.022103; Dobosy JR, 2007, J UROLOGY, V177, P822, DOI 10.1016/j.juro.2006.10.063; DOERING CH, 1984, J STEROID BIOCHEM, V20, P1157, DOI 10.1016/0022-4731(84)90360-1; Fang H, 2003, CHEM RES TOXICOL, V16, P1338, DOI 10.1021/tx030011g; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; Fowler PA, 2012, MOL CELL ENDOCRINOL, V355, P231, DOI 10.1016/j.mce.2011.10.021; Gaido KW, 2000, MOL PHARMACOL, V58, P852; Galloway T, 2010, ENVIRON HEALTH PERSP, V118, P1603, DOI 10.1289/ehp.1002367; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hodgson MC, 2008, MOL CANCER THER, V7, P3187, DOI 10.1158/1535-7163.MCT-08-0461; Huang RL, 2011, ENVIRON HEALTH PERSP, V119, P1142, DOI 10.1289/ehp.1002952; JENSTER G, 1995, J BIOL CHEM, V270, P7341; Kim TS, 2010, J TOXICOL SCI, V35, P239; Kojima H, 2004, ENVIRON HEALTH PERSP, V112, P524; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689; Luccio-Camelo DC, 2011, J STEROID BIOCHEM, V127, P74, DOI 10.1016/j.jsbmb.2011.04.004; Mainwaring W I, 1977, Monogr Endocrinol, V10, P1; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marcelli M, 2006, J CELL BIOCHEM, V98, P770, DOI 10.1002/jcb.20593; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; Meeker J. D., 2004, HUM REPROD, V19, P2573; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Melzer D, 2011, ANN INTERN MED, V155, P392, DOI [10.7326/0003-4819-155-6-201109200-00009, 10.1059/0003-4819-155-6-201109200-00009]; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Nishino T, 2006, J STEROID BIOCHEM, V98, P155, DOI 10.1016/j.jsbmb.2005.08.019; Nordkap L, 2012, MOL CELL ENDOCRINOL, V355, P221, DOI 10.1016/j.mce.2011.05.048; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Poidatz D, 2012, PLACENTA, V33, P688, DOI 10.1016/j.placenta.2012.06.002; Prasanth GK, 2010, J APPL TOXICOL, V30, P769, DOI 10.1002/jat.1570; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Safe Stephen, 2002, Rev Environ Health, V17, P253; Sanseverino J, 2009, TOXICOL SCI, V107, P122, DOI 10.1093/toxsci/kfn229; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Solit DB, 2003, SEMIN ONCOL, V30, P709, DOI 10.1053/S0093-7754(03)00346-4; Sun H, 2007, CHEMOSPHERE, V66, P474, DOI 10.1016/j.chemosphere.2006.05.059; Swan SH, 2006, INT J ANDROL, V29, P62, DOI 10.1111/j.1365-2605.2005.00620.x; Szafran AT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003605; Thayer KA, 2012, ENVIRON HEALTH PERSP, V120, P779, DOI 10.1289/ehp.1104597; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Vinggaard AM, 2008, CHEM RES TOXICOL, V21, P813, DOI 10.1021/tx7002382; Virtanen HE, 2012, MOL CELL ENDOCRINOL, V355, P208, DOI 10.1016/j.mce.2011.11.015; Saal FSV, 2012, MOL CELL ENDOCRINOL, V354, P74, DOI 10.1016/j.mce.2012.01.001; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Xia M, 2008, ENVIRON HEALTH PERSP, V116, P284, DOI 10.1289/ehp.10727; Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.otx.2005.08.006; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-10186511ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDCHEM-BIOL INTERACTMAY 25Discipline: Biochemistry &amp; Molecular Biology; Pharmacology &amp; Pharmacy; Toxicology161RR</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; ALPHA; ANDROGEN RECEPTOR; Antagonist; ANTI-ANDROGENS; BINDING; BIOLOGY; bisphenol; bisphenol A; Bisphenol A and related compounds; Bisphenol AF; BISPHENOL-A; BPA; CANCER; CELL; CELLS; development; ENDOCRINE; Endocrine disruptor; Endocrine-disrupting chemicals; ENVIRONMENTAL CHEMICALS; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; estrogenic activity; Imaging analysis; In vitro; IN-VITRO; inhibition; LIGAND; LIGAND-BINDING; LINES; Male; MALE REPRODUCTIVE HEALTH; mechanism; MECHANISMS; molecular mechanism; MOLECULAR-MECHANISMS; Nuclear receptor; NUCLEAR RECEPTORS; PHARMACOLOGY; PROSTATE-CANCER; qHTS; RECEPTOR; RECEPTOR-ALPHA; Reproduction; REPRODUCTIVE-SYSTEM; STRUCTURAL BASIS; TESTICULAR DYSGENESIS SYNDROME; Tox21; toxicology; Transfection; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>556</startpage>
    <endpage>564</endpage>
    <journalfull>Chemico-Biological Interactions</journalfull>
    <issue>3</issue>
    <volume>203</volume>
    <abstract>Bisphenol A (BPA), is a well-known endocrine disruptor compound (EDC) that affects the normal development and function of the female and male reproductive system, however the mechanisms of action remain unclear. To investigate the molecular mechanisms of how BPA may affect ten different nuclear receptors, stable cell lines containing individual nuclear receptor ligand binding domain (LBD)-linked to the beta-Gal reporter were examined by a quantitative high throughput screening (qHTS) format in the Tox21 Screening Program of the NIH. The results showed that two receptors, estrogen receptor alpha (ER alpha) and androgen receptor (AR), are affected by BPA in opposite direction. To confirm the observed effects of BPA on ER alpha and AR, we performed transient transfection experiments with full-length receptors and their corresponding response elements linked to luciferase reporters. We also included in this study two BPA analogs, bisphenol AF (BPAF) and bisphenol S (BPS). As seen in African green monkey kidney CV1 cells, the present study confirmed that BPA and BPAF act as ER alpha agonists (half maximal effective concentration EC50 of 10-100 nM) and as AR antagonists (half maximal inhibitory concentration IC50 of 1-2 mu M). Both BPA and BPAF antagonized AR function via competitive inhibition of the action of synthetic androgen R1881. BPS with lower estrogenic activity (EC50 of 2.2 mu M), did not compete with R1881 for AR binding, when tested at 30 mu M. Finally, the effects of BPA were also evaluated in a nuclear translocation assays using EGPF-tagged receptors. Similar to 17 beta-estradiol (E2) which was used as control, BPA was able to enhance ER alpha nuclear foci formation but at a 100-fold higher concentration. Although BPA was able to bind AR, the nuclear translocation was reduced. Furthermore, BPA was unable to induce functional foci in the nuclei and is consistent with the transient transfection study that BPA is unable to activate AR. Published by Elsevier Ireland Ltd</abstract>
    <url>WOS:000320211500003</url>
    <isbnorissn>0009-2797</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>427</id>
    <title>Estrogenicity of food-associated estrogenic compounds in the fetuses of female transgenic mice upon oral and IP maternal exposure</title>
    <authors>ter Veld,M.G.R.; Zawadzka,E.; Rietjens,I.M.C.M.; Murk,A.J.</authors>
    <availability>[ter Veld, Marcel G. R.; Zawadzka, E.; Rietjens, Ivonne M. C. M.; Murk, Albertinka J.] Univ Wageningen, Toxicol Sect, NL-6703 HE Wageningen, Netherlands. [Murk, Albertinka J.] Wageningen Imares, NL-1970 AB Ijmuiden, Netherlands.</availability>
    <date>2009</date>
    <notes>JEnglishArticleMurk, AJ (reprint author), Univ Wageningen, Toxicol Sect, Tuinlaan 5, NL-6703 HE Wageningen, Netherlandstinka.murk@wur.nlAkinola LA, 1997, ENDOCRINOLOGY, V138, P2886, DOI 10.1210/en.138.7.2886; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Bulun SE, 1997, J STEROID BIOCHEM, V61, P133; Chapin RE, 1999, TOXICOL SCI, V52, P80, DOI 10.1093/toxsci/52.1.80; Cheek AO, 1998, ENVIRON HEALTH PERSP, V106, P5, DOI 10.2307/3433910; Claassen V, 1994, NEGLECTED FACTORS PH; Dalgaard M, 2003, REPROD TOXICOL, V17, P163, DOI 10.1016/S0890-6238(02)00149-1; Doerge DR, 2002, REPROD TOXICOL, V16, P45, DOI 10.1016/S0890-6238(01)00198-8; DOTSCH J, 2001, EXPOSURE ENDOGENOUS; Doull J, 1999, REGUL TOXICOL PHARM, V29, P327, DOI 10.1006/rtph.1999.1296; Fisher JS, 2004, TOXICOLOGY, V205, P33, DOI 10.1016/j.tox.2004.06.035; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gordon JD, 2004, ORGANOHALOGEN COMPD, V66, P169; Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Kabuto H, 2004, LIFE SCI, V74, P2931, DOI 10.1016/j.lfs.2003.07.060; Knight DC, 1996, OBSTET GYNECOL, V87, P897; Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Legler J, 2002, ENVIRON SCI TECHNOL, V36, P4410, DOI 10.1021/es010323a; Lemmen JG, 2004, J MOL ENDOCRINOL, V32, P689, DOI 10.1677/jme.0.0320689; Lemmen JG, 2004, ENVIRON HEALTH PERSP, V112, P1544; Lovekamp-Swan T, 2003, ENVIRON HEALTH PERSP, V111, P139; Markey CM, 2001, BIOL REPROD, V65, P1215; Miller KP, 2004, TOXICOL APPL PHARM, V198, P111, DOI 10.1016/j.taap.2003.07.016; Moore RW, 2001, ENVIRON HEALTH PERSP, V109, P229, DOI 10.2307/3434690; Pardridge WM, 1980, AM J PHYSIOL, V239, P103; Poindexter A, 2001, FERTIL STERIL, V75, P457, DOI 10.1016/S0015-0282(00)01747-7; Pontolillo J., 2001, 014201 US GEOL SURV; SAVU L, 1975, STEROIDS, V25, P717, DOI 10.1016/0039-128X(75)90036-7; Shelby MD, 1996, ENVIRON HEALTH PERSP, V104, P1296, DOI 10.2307/3432965; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; SLIKKER W, 1982, J PHARMACOL EXP THER, V221, P173; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Stroheker T, 2003, REPROD TOXICOL, V17, P421, DOI 10.1016/S0890-6238(03)00044-3; Takagi H, 2004, ARCH TOXICOL, V78, P97, DOI 10.1007/s00204-003-0517-0; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Takeuchi S, 2005, TOXICOLOGY, V210, P223, DOI 10.1016/j.tox.2005.02.002; ter Veld MGR, 2008, CHEM-BIOL INTERACT, V174, P126, DOI 10.1016/j.cbi.2008.03.019; ter Veld MGR, 2006, J AGR FOOD CHEM, V54, P4407, DOI 10.1021/jf052864f; Tickner JA, 2001, AM J IND MED, V39, P100, DOI 10.1002/1097-0274(200101)39:1&lt;100::AID-AJIM10&gt;3.0.CO;2-Q; Tinwell H, 2002, TOXICOL SCI, V68, P339, DOI 10.1093/toxsci/68.2.339; Tinwell H, 2000, REGUL TOXICOL PHARM, V32, P118, DOI 10.1006/rtph.2000.1412; Tyl RW, 2006, TOXICOL SCI, V92, P295, DOI 10.1093/toxsci/kfj203; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; VANDERWOUDE H, 2006, MECH TOXIC ACTION FL; van der Woude H, 2005, MOL NUTR FOOD RES, V49, P763, DOI 10.1002/mnfr.200500036; You L, 1999, TOXICOL APPL PHARM, V157, P134, DOI 10.1006/taap.1999.8673; Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1093/toxsci/46.2.282; ZUTPHEN LFM, 2000, PROEFIDIEREN DIERPRO512PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLAPRDiscipline: Reproductive Biology; Toxicology429BA</notes>
    <keywords>1; 17 beta-Estradiol; 17-BETA-ESTRADIOL; ANDROGEN RECEPTOR; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER-RISK; development; Endocrine disruption; ER; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Estrogenic; ESTROGENIC COMPOUNDS; estrogenic effects; Estrogenicity; ESTROGENS; EXPOSURE; female; FEMALE MICE; FETAL; Fetus; FOOD; Food packaging; GENE; GENE-EXPRESSION; HEALTH; In vitro; IN-UTERO EXPOSURE; IN-VITRO; INDUCTION; Liver; MATERNAL EXPOSURE; MICE; Nonylphenol; oral exposure; phthalate; PHTHALATE-ESTERS; PLACENTA; Placental transfer; Plasticizer; PREGNANT RATS; Pseudo-estrogen; RECEPTOR; REDUCTION; REPORTER GENE; Reporter gene mice; SEXUAL DEVELOPMENT; SPRAGUE-DAWLEY RATS; Steroid; SYSTEM; TISSUE; TISSUES; toxicology; TRANSGENIC MICE; VITRO; WISTAR RATS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>133</startpage>
    <endpage>139</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>2</issue>
    <volume>27</volume>
    <abstract>The present study investigated to what extent seven food-associated in vitro estrogenic compounds can induce estrogenic effects in the fetuses of pregnant female mice with an estrogen receptor (ER)mediated luciferase (luc) reporter gene system. The luc-induction was determined either 8h after maternal dosing with a single intraperitoneal (IP) dose or 24h after the last of a series of 8 daily oral dosages. Three known estrogens, 17 beta-estradiol (E(2)) 17 alpha-ethynylestradiol (EE) and 17 beta-estradiol 3,17-dipropionate (EP) were used as positive controls at 1 mg/kg bw and DMSO as solvent control. The food-associated estrogenic compounds tested were: bisphenol A (BPA), nonylphenol (NP) both at 50 mg/kg bw, dichlorodiphenyldichloroethylene (p,p'-DDE) at 50 mg/kg bw, quercetin at 16.6 mg/kg bw, and di-isoheptyl phthalate (DIHP), di-(2-ethylhexyl) phthalate (DEHP) and di-(2-ethylhexyl) adipate (DEHA) all at 100 mg/kg bw. Exposure to E(2), EE and EP resulted in significant luc inductions upon both oral and/or IP dosing in a variety of tissues including liver, tibia and femurs, and upon IP dosing also in fetuses. BPA, NP, DEHA, DEHP, DIHP, DDE and quercetin were unable to significantly induce luc activity in fetuses. However, after maternal oral exposure during gestation to NP, BPA and DIHP placental luc activity was significantly lowered. The results indicate that at the current levels of exposure to food-associated estrogenic compounds, estrogenic effects to the fetus are not expected. The significant luc reduction in the placenta, should be further studied for its significance for fetal development and relevance for the human situation. (C) 2009 Published by Elsevier Inc</abstract>
    <url>WOS:000264894600005</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>215</id>
    <title>Bisphenol A alters the development of the rhesus monkey mammary gland</title>
    <authors>Tharp,A.P.; Maffini,M.V.; Hunt,P.A.; VandeVoort,C.A.; Sonnenschein,C.; Soto,A.M.</authors>
    <availability>[Tharp, Andrew P.; Maffini, Maricel V.; Sonnenschein, Carlos; Soto, Ana M.] Tufts Univ, Sch Med, Dept Cellular Biol &amp; Anat, Boston, MA 02111 USA. [Hunt, Patricia A.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA. [Hunt, Patricia A.] Washington State Univ, Ctr Reprod Biol, Pullman, WA 99164 USA. [VandeVoort, Catherine A.] Univ Calif Davis, Dept Obstet &amp; Gynecol, Davis, CA 95616 USA. [VandeVoort, Catherine A.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.</availability>
    <date>2012</date>
    <notes>JEnglishArticleSoto, AM (reprint author), Tufts Univ, Sch Med, Dept Cellular Biol &amp; Anat, Boston, MA 02111 USAana.soto@tufts.eduAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Burridge E., 2008, ICIS CHEM BUSINESS, V274, P48; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Chung E, 2011, P NATL ACAD SCI USA, V108, P17732, DOI 10.1073/pnas.1115187108; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jimenez DF, 2003, J MED PRIMATOL, V32, P315, DOI 10.1046/j.1600-0684.2003.00041.x; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Li DK, 2010, J ANDROL, V31, P500, DOI 10.2164/jandrol.110.010413; Li T, 2005, CANCER EPIDEM BIOMAR, V14, P343, DOI 10.1158/1055-9965.EPI-04-0490; MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Markey CM, 2003, EVOL DEV, V5, P1; Markey CM, 2001, BIOL REPROD, V65, P1215; MONFORT SL, 1987, BIOL REPROD, V37, P832, DOI 10.1095/biolreprod37.4.832; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Moumen M, 2011, INT J DEV BIOL, V55, P763, DOI 10.1387/ijdb.113385mm; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Schwartz NB, 2010, ENDOCRINOLOGY BASIC, P367; Shioda T, 2006, P NATL ACAD SCI USA, V103, P12033, DOI 10.1073/pnas.0605341103; Soriano S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031109; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Sun P, 2010, HISTOCHEM CELL BIOL, V133, P213, DOI 10.1007/s00418-009-0662-5; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Yang M, 2009, ARCH TOXICOL, V83, P281, DOI 10.1007/s00204-008-0364-0; Zalko D, 2011, CHEMOSPHERE, V82, P424, DOI 10.1016/j.chemosphere.2010.09.0585125NATL ACAD SCIENCESWASHINGTON2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USAP NATL ACAD SCI USAMAY 22Discipline: Science &amp; Technology - Other Topics947QY</notes>
    <keywords>ADULTHOOD; ALPHA; ALTERS; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CD-1 MICE; CELL; development; ENDOCRINE; Endocrine disruptor; ESTRADIOL; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; female; FETAL; FOOD; GLAND; GLAND DEVELOPMENT; HEALTH; HUMANS; IN-UTERO EXPOSURE; internal dose; MACACA-MULATTA; mammary gland; Mammary gland development; MAMMARY-GLAND; MAMMARY-GLANDS; mammogenesis; MONKEYS; morphogenesis; morphology; PERINATAL EXPOSURE; Plastics; RECEPTOR; RISK-FACTORS; serum; URINARY; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>8190</startpage>
    <endpage>8195</endpage>
    <journalfull>Proceedings of the National Academy of Sciences of the United States of America</journalfull>
    <issue>21</issue>
    <volume>109</volume>
    <abstract>The xenoestrogen bisphenol A (BPA) used in the manufacturing of various plastics and resins for food packaging and consumer products has been shown to produce numerous endocrine and developmental effects in rodents. Exposure to low doses of BPA during fetal mammary gland development resulted in significant alterations in the gland's morphology that varied from subtle ones observed during the exposure period to precancerous and cancerous lesions manifested in adulthood. This study assessed the effects of BPA on fetal mammary gland development in nonhuman primates. Pregnant rhesus monkeys were fed 400 mu g of BPA per kg of body weight daily from gestational day 100 to term, which resulted in 0.68 +/- 0.312 ng of unconjugated BPA per mL of maternal serum, a level comparable to that found in humans. At birth, the mammary glands of female offspring were removed for morphological analysis. Morphological parameters similar to those shown to be affected in rodents exposed prenatally to BPA were measured in whole-mounted glands; estrogen receptor ( ER) alpha and beta expression were assessed in paraffin sections. Student's t tests for equality of means were used to assess differences between exposed and unexposed groups. The density of mammary buds was significantly increased in BPA-exposed monkeys, and the overall development of their mammary gland was more advanced compared with unexposed monkeys. No significant differences were observed in ER expression. Altogether, gestational exposure to the estrogen-mimic BPA altered the developing mammary glands of female nonhuman primates in a comparable manner to that observed in rodents</abstract>
    <url>WOS:000304445800057</url>
    <isbnorissn>0027-8424</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>361</id>
    <title>Interdependence of Platelet-Derived Growth Factor and Estrogen-Signaling Pathways in Inducing Neonatal Rat Testicular Gonocytes Proliferation</title>
    <authors>Thuillier,R.; Mazer,M.; Manku,G.; Boisvert,A.; Wang,Y.; Culty,M.</authors>
    <availability>[Thuillier, Raphael; Wang, Yan; Culty, Martine] Georgetown Univ, Med Ctr, Dept Biochem &amp; Mol &amp; Cellular Biol, Washington, DC 20007 USA. [Mazer, Monty; Manku, Gurpreet; Boisvert, Annie; Culty, Martine] McGill Univ, Res Inst, Ctr Hlth, Montreal, PQ H3G 1A4, Canada. [Mazer, Monty; Manku, Gurpreet; Boisvert, Annie; Culty, Martine] McGill Univ, Dept Med &amp; Pharmacol, Montreal, PQ H3G 1A4, Canada. [Mazer, Monty; Manku, Gurpreet; Boisvert, Annie; Culty, Martine] McGill Univ, Dept Therapeut, Montreal, PQ H3G 1A4, Canada.</availability>
    <date>2010</date>
    <notes>JEnglishArticleCulty, M (reprint author), McGill Univ, Res Inst, Ctr Hlth, Montreal Gen Hosp, 1650 Cedar Ave,Room C10-148-2, Montreal, PQ H3G 1A4, Canadamartine.culty@mcgill.caAndrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Basciani S, 2002, J CLIN ENDOCR METAB, V87, P2310, DOI 10.1210/jc.87.5.2310; Basciani S, 2008, ENDOCRINOLOGY, V149, P6226, DOI 10.1210/en.2008-0349; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bouskine A, 2008, ENDOCRINOLOGY, V149, P565, DOI 10.1210/en.2007-1318; BRYCKAERT MC, 1992, EXP CELL RES, V199, P255, DOI 10.1016/0014-4827(92)90432-8; Culty M, 2009, BIRTH DEFECTS RES C, V87, P1, DOI 10.1002/bdrc.20142; Delbes G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231; Delbes G, 2007, TOXICOL SCI, V99, P234, DOI 10.1093/toxsci/kfm160; Delbes R, 2004, ENDOCRINOLOGY, V145, P3395, DOI 10.1210/en.2003-1479; De Rooij DG, 2000, J ANDROL, V21, P776; Dudley MW, 2000, P NATL ACAD SCI USA, V97, P3696, DOI 10.1073/pnas.040558197; Dupont S, 2000, DEVELOPMENT, V127, P4277; Eckert D, 2008, CELL TISSUE RES, V331, P529, DOI 10.1007/s00441-007-0527-y; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Geffroy N, 2005, MOL CELL ENDOCRINOL, V237, P11, DOI 10.1016/j.mce.2005.04.003; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hess R. A., 2004, Animal Reproduction, V1, P5; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Kim SK, 2006, DRUG METAB DISPOS, V34, P683, DOI 10.1124/dmd.105.007666; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Laemmli U.K., 1970, NATURE, V227; Lassurguere J, 2003, TOXICOL SCI, V73, P160, DOI 10.1093/toxsci/kfg065; Li H, 1997, ENDOCRINOLOGY, V138, P1289, DOI 10.1210/en.138.3.1289; Luconi M, 2002, J STEROID BIOCHEM, V80, P369, DOI 10.1016/S0960-0760(02)00041-9; Margeat E, 2003, J MOL BIOL, V326, P77, DOI 10.1016/S0022-2836(02)01355-4; Mariani S, 2002, TRENDS ENDOCRIN MET, V13, P11, DOI 10.1016/S1043-2760(01)00518-5; McDonald CA, 2006, MOL ENDOCRINOL, V20, P608, DOI 10.1210/me.2005-0245; MCGUINNESS MP, 1992, ANAT REC, V233, P527, DOI 10.1002/ar.1092330406; Mercier I, 2003, CARDIOVASC RES, V59, P883, DOI 10.1016/S0008-6363(03)00517-0; Moriarty K, 2006, ENDOCRINOLOGY, V147, P5557, DOI 10.1210/en.2006-0729; Nagano R, 2000, ANAT REC, V258, P210; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Ozers MS, 2005, MOL ENDOCRINOL, V19, P25, DOI 10.1210/me.2004-0256; Pais V, 2003, CLIN CANCER RES, V9, P4475; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Pentikainen V, 2000, J CLIN ENDOCR METAB, V85, P2057, DOI 10.1210/jc.85.5.2057; Petersen DN, 1998, ENDOCRINOLOGY, V139, P1082, DOI 10.1210/en.139.3.1082; POWIS G, 1994, CANCER RES, V54, P2419; Puglianiello A, 2004, J CELL SCI, V117, P1151, DOI 10.1242/jcs.00981; Rajpert-de Meyts E, 2003, APMIS, V111, P267, DOI 10.1034/j.1600-0463.2003.11101301.x; Ratna WN, 2002, LIFE SCI, V71, P865, DOI 10.1016/S0024-3205(02)01770-8; Revelli A, 1998, ENDOCR REV, V19, P3, DOI 10.1210/er.19.1.3; Ricci G, 2004, J CELL PHYSIOL, V200, P458, DOI 10.1002/jcp.20035; Robertson KM, 2002, ENDOCRINOLOGY, V143, P2913, DOI 10.1210/en.143.8.2913; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925; Saunders PTK, 2002, J CLIN ENDOCR METAB, V87, P2706, DOI 10.1210/jc.87.6.2706; Saunders PTK, 2001, MOL HUM REPROD, V7, P227, DOI 10.1093/molehr/7.3.227; Schmahl J, 2008, GENE DEV, V22, P3255, DOI 10.1101/gad.1723908; Schmahl J, 2007, NAT GENET, V39, P52, DOI 10.1038/ng1922; Smith CA, 2005, DEV BIOL, V284, P337, DOI 10.1016/j.ydbio.2005.05.030; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; Thuillier R, 2003, BIOL REPROD, V68, P867, DOI 10.1095/biolreprod.102.009605; van Pelt AMM, 1999, ENDOCRINOLOGY, V140, P478, DOI 10.1210/en.140.1.478; VERGOUWEN RPFA, 1991, J REPROD FERTIL, V93, P233; Vicini E, 2006, J CELL PHYSIOL, V206, P238, DOI 10.1002/jcp.20454; Vigueras-Villasenor RM, 2006, REPROD TOXICOL, V22, P513, DOI 10.1016/j.reprotox.2006.03.008; Wahlgren A, 2008, ENDOCRINOLOGY, V149, P2917, DOI 10.1210/en.2007-1126; Wang Y, 2004, BIOL REPROD, V71, P1652, DOI 10.1095/biolreprod.104.030205; Wilkinson JM, 2008, J BIOMOL SCREEN, V13, P755, DOI 10.1177/1087057108322155; Williams K, 2001, HUM REPROD UPDATE, V7, P236, DOI 10.1093/humupd/7.3.236; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhao LQ, 2006, J PHARMACOL EXP THER, V319, P1124, DOI 10.1124/jpet.106.1095046717SOC STUDY REPRODUCTIONMADISON1603 MONROE ST, MADISON, WI 53711-2021 USABIOL REPRODMAYDiscipline: Reproductive Biology585YV</notes>
    <keywords>ACTIVATION; Antagonist; BIOLOGY; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CELL; crosstalk; Cytokine; DEFECTS; DES; development; ESTRADIOL; Estrogen; Estrogen receptor; estrogen signaling; ESTROGEN-RECEPTOR; ESTROGENS; EXPOSURE; gametogenesis; GENE; genistein; GROWTH; growth factors; GROWTH-FACTOR; HEALTH; HUMAN TESTIS; ICI 182,780; In vitro; in vivo; IN-VITRO; IN-VIVO; inhibition; INHIBITOR; Inhibitors; KINASE; MALE GERM-CELLS; MALE REPRODUCTIVE-SYSTEM; NONGENOMIC ACTIONS; PATHWAY; PDGF; proliferation; PROTEIN-KINASE KINASE; RAT; RECEPTOR; RECEPTOR ANTAGONIST; RECEPTOR-BETA EXPRESSION; Reproduction; SERTOLI-CELLS; serum; Signal transduction; Steroid; testicular gonocytes; testis; TISSUE; toxicology; UPDATE; VITRO; VIVO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>825</startpage>
    <endpage>836</endpage>
    <journalfull>Biology of Reproduction</journalfull>
    <issue>5</issue>
    <volume>82</volume>
    <abstract>We previously found that platelet-derived growth factor (PDGF) and 17beta-estradiol stimulate gonocyte proliferation in a dose-dependent, nonadditive manner. In the present study, we report that gonocytes express RAF1, MAP2K1, and MAPK1/3. Inhibition of RAF1 and MAP2K1/2, but not phosphoinositide-3-kinase, blocked PDGF-induced proliferation. AG-370, an inhibitor of PDGF receptor kinase activity, suppressed not only PDGF-induced proliferation but also that induced by 17beta-estradiol. In addition, RAF1 and MAP2K1/2 inhibitors blocked 17beta-estradiol-activated proliferation. The estrogen receptor antagonist ICI 182780 inhibited both the effects of 17beta-estradiol and PDGF. PDGF lost its stimulatory effect when steroid-depleted serum or no serum was used. Similarly, 17beta-estradiol did not induce gonocyte proliferation in the absence of PDGF. The xenoestrogens genistein, bisphenol A, and DES, but not coumestrol, stimulated gonocyte proliferation in a dose-dependent and PDGF-dependent manner similarly to 17beta-estradiol. Their effects were blocked by ICI 182780, suggesting that they act via the estrogen receptor. AG-370 blocked genistein and bisphenol A effects, demonstrating their requirement of PDGF receptor activation in a manner similar to 17beta-estradiol. These results demonstrate the interdependence of PDGF and estrogen pathways in stimulating in vitro gonocyte proliferation, suggesting that this critical step in gonocyte development might be regulated in vivo by the coordinated action of PDGF and estrogen. Thus, the inappropriate exposure of gonocytes to xenoestrogens might disrupt the crosstalk between the two pathways and potentially interfere with gonocyte development</abstract>
    <url>WOS:000276867800004</url>
    <isbnorissn>0006-3363</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>276</id>
    <title>An in vivo assessment of the genotoxic potential of bisphenol A and 4-tert-octylphenol in rats</title>
    <authors>Ulutas,O.K.; Yildiz,N.; Durmaz,E.; Ahbab,M.A.; Barlas,N.; Cok,I.</authors>
    <availability>[Yildiz, Nurcin; Ahbab, Mufide Aydogan; Barlas, Nurhayat] Hacettepe Univ, Dept Biol, Fac Sci, TR-06800 Ankara, Turkey. [Ulutas, Onur Kenan; Durmaz, Emre; Cok, Ismet] Gazi Univ, Dept Toxicol, Fac Pharm, TR-06330 Ankara, Turkey.</availability>
    <date>2011</date>
    <notes>JEnglishArticleBarlas, N (reprint author), Hacettepe Univ, Dept Biol, Fac Sci, TR-06800 Ankara, Turkeybarlas@hacettepe.edu.trANDERSEN M, 1978, NATURE, V276, P391, DOI 10.1038/276391a0; Aydogan M, 2006, REPROD TOXICOL, V22, P455, DOI 10.1016/j.reprotox.2006.01.004; Bhat HK, 2003, P NATL ACAD SCI USA, V100, P3913, DOI 10.1073/pnas.0437929100; BLACKBURN MA, 1995, WATER RES, V29, P1623, DOI 10.1016/0043-1354(94)00340-D; Boockfor FR, 1997, BIOL REPROD, V57, P267, DOI 10.1095/biolreprod57.2.267; Brix R, 2010, ANAL BIOANAL CHEM, V396, P1301, DOI 10.1007/s00216-009-3358-8; Cabaton N, 2009, TOXICOLOGY, V255, P15, DOI 10.1016/j.tox.2008.09.024; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Cavalieri E, 2000, J NATL CANC I MONOGR, V75, P75; Cavalieri EL, 2002, CARCINOGENESIS, V23, P1071, DOI 10.1093/carcin/23.6.1071; Chen YM, 2000, CHEM RES TOXICOL, V13, P342, DOI 10.1021/tx990186j; Dachs J, 1999, ENVIRON SCI TECHNOL, V33, P2676, DOI 10.1021/es990253w; DUKES PP, 1961, ENDOCRINOLOGY, V69, P21; EFSA, 2006, EFSA J, V428, p[1, 75]; ELIA MC, 1993, MUTAT RES, V291, P193, DOI 10.1016/0165-1161(93)90159-W; Goktekin E, 2008, ENVIRON TOXICOL PHAR, V26, P199, DOI 10.1016/j.etap.2008.03.013; GUDI R, 1992, ENVIRON MOL MUTAGEN, V20, P106, DOI 10.1002/em.2850200206; Haighton LA, 2002, REGUL TOXICOL PHARM, V35, P238, DOI 10.1006/rtph.2001.1525; HARTMANN A, 1995, MUTAT RES LETT, V346, P49, DOI 10.1016/0165-7992(95)90068-3; Hartmann A, 2001, MUTAT RES-GEN TOX EN, V497, P199, DOI 10.1016/S1383-5718(01)00256-X; Hartmann A, 1997, TOXICOL LETT, V90, P183, DOI 10.1016/S0378-4274(96)03847-7; Hashimoto K, 2010, TOXICOL IN VITRO, V24, P208, DOI 10.1016/j.tiv.2009.09.006; Henderson L, 1998, MUTAGENESIS, V13, P89, DOI 10.1093/mutage/13.1.89; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; Johnson GE, 2008, MUTAT RES-GEN TOX EN, V651, P56, DOI 10.1016/j.mrgentox.2007.10.019; Kabuto H, 2003, ENVIRON RES, V93, P31, DOI 10.1016/S0013-9351(03)00062-8; KNAAK JB, 1966, TOXICOL APPL PHARM, V8, P175, DOI 10.1016/S0041-008X(66)80001-7; Kuch HM, 2001, ENVIRON SCI TECHNOL, V35, P3201, DOI 10.1021/es010034m; Lee M, 2003, MUTAT RES-GEN TOX EN, V541, P9, DOI 10.1016/S1383-5718(03)00175-X; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Lu Bo, 2008, Toxicological and Environmental Chemistry, V90, P127, DOI 10.1080/02772240701340642; Milman HA, 2002, REGUL TOXICOL PHARM, V35, P338, DOI 10.1006/rtph.2002.1553; Mobley JA, 2004, CARCINOGENESIS, V25, P3, DOI 10.1093/carcin/bgg175; Naik P, 2009, MUTAT RES-GEN TOX EN, V676, P106, DOI 10.1016/j.mrgentox.2009.04.010; National Toxicology Program, 1982, NATL TOXICOLOGY PROG, V215, P1; OLIVE PL, 1995, EXP CELL RES, V221, P19, DOI 10.1006/excr.1995.1348; Oshida K, 2008, J TOXICOL SCI, V33, P515, DOI 10.2131/jts.33.515; PACCHIEROTTI E, 2008, MUTAT RES, V651, P64; Park SY, 2009, B ENVIRON CONTAM TOX, V83, P463, DOI 10.1007/s00128-009-9745-1; Quiros L, 2005, ENVIRON TOXICOL CHEM, V24, P389, DOI 10.1897/04-121R.1; REED HBW, 1978, KIRKOTHMER ENCY CHEM, P72; Roser S, 2001, MUTAT RES-GEN TOX EN, V497, P169, DOI 10.1016/S1383-5718(01)00255-8; Schweikl H, 1998, MUTAT RES-GEN TOX EN, V415, P119, DOI 10.1016/S1383-5718(98)00067-9; Tayama S, 2008, MUTAT RES-GEN TOX EN, V649, P114, DOI 10.1016/j.mrgentox.2007.08.006; TICE RR, 1999, TOXICOL APPL PHARM, V157, P192; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3&lt;206::AID-EM8&gt;3.0.CO;2-J; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Toppari J, 2001, HUM REPROD UPDATE, V7, P282, DOI 10.1093/humupd/7.3.282; Upmeier A, 2000, ARCH TOXICOL, V74, P431, DOI 10.1007/s002040000144; Voutsa D, 2006, ENVIRON SCI POLLUT R, V13, P333, DOI 10.1065/espr2006.01.295; Xie ZY, 2006, ANAL CHIM ACTA, V565, P198, DOI 10.1016/j.aca.2006.02.027; Ying GG, 2002, ENVIRON INT, V28, P215, DOI 10.1016/S0160-4120(02)00017-X539SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYARCH TOXICOLAUGDiscipline: Toxicology802SN</notes>
    <keywords>4-tert-octylphenol; ADULT; ALKYLPHENOLS; ASSAY; bisphenol; bisphenol A; BISPHENOL-A; BONE-MARROW; BPA; BREAST-CANCER; CARCINOGENESIS; Carcinogenicity; CELL; CELLS; CHEMICALS; Comet assay; DNA-DAMAGE; ESTROGENS; GENOTOXICITY; HEALTH; In vitro; in vivo; IN-VITRO; IN-VIVO; Male; mechanism; MECHANISMS; octylphenol; Oxidative stress; p21; Plastics; RAT; RATS; RIVER; toxicology; VITRO; WATER; Wistar</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>995</startpage>
    <endpage>1001</endpage>
    <journalfull>Archives of Toxicology</journalfull>
    <issue>8</issue>
    <volume>85</volume>
    <abstract>Bisphenol A (BPA) and octylphenol (OP) are industrial chemicals used in the manufacture of polycarbonate plastics, epoxy resins, and non-ionic surfactants. In the present study, we investigated the possible in vivo genotoxic effects of these compounds in rats using single-cell gel electrophoresis, the so-called comet assay. Adult male Wistar albino rats were divided randomly into six groups as follows: BPA125 (received 125 mg/kg bw BPA; n = 6), OP125 (received 125 mg/kg bw OP; n = 6), BPA250 (received 250 mg/kg BPA; n = 6), OP250 (received 250 mg/kg bw OP; n = 6), control (n = 5), and MMS (positive control group that received methyl methanesulfonate; n = 3). Both BPA and OP were orally administrated for 4 weeks. Controls were orally inoculated with corn oil for 4 weeks as well. Comet parameters including tail length and tail moment were evaluated for possible genotoxic effects. There were no significant differences in the OP125 and in the BPA125 compared with the control group, regarding tail length and tail moment (P &gt; 0.05). However, there were significant differences in the OP250 and in the BPA250 compared with the control group, regarding tail length and tail moment (P &lt; 0.05 and P &lt; 0.01, respectively). The genotoxic potential of BPA and OP was investigated in vivo; there is a need for further studies exploring further mechanisms of the genotoxic potential of these chemicals in vivo</abstract>
    <url>WOS:000293531400015</url>
    <isbnorissn>0340-5761</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>348</id>
    <title>cDNA phage display as a novel tool to screen for cellular targets of chemical compounds</title>
    <authors>Van Dorst,B.; Mehta,J.; Rouah-Martin,E.; Somers,V.; De Coen,W.; Blust,R.; Robbens,J.</authors>
    <availability>[Van Dorst, Bieke; Mehta, Jaytry; Rouah-Martin, Elsa; De Coen, Wim; Blust, Ronny; Robbens, Johan] Univ Antwerp, Dept Biol, Lab Ecophysiol Biochem &amp; Toxicol, B-2020 Antwerp, Belgium. [Van Dorst, Bieke; Mehta, Jaytry; Rouah-Martin, Elsa; Robbens, Johan] Inst Agr &amp; Fisheries Res ILVO, B-8400 Oostende, Belgium. [Somers, Veerle] Hasselt Univ, Biomed Res Inst, B-3590 Diepenbeek, Belgium. [De Coen, Wim] European Chem Agcy ECHA, FI-00120 Helsinki, Finland.</availability>
    <date>2010</date>
    <notes>JEnglishArticleVan Dorst, B (reprint author), Univ Antwerp, Dept Biol, Lab Ecophysiol Biochem &amp; Toxicol, Groenenborgerlaan 171, B-2020 Antwerp, BelgiumBieke.vandorst@ua.ac.beAnstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; Baker K, 2003, ANAL BIOCHEM, V315, P134, DOI 10.1016/S0003-2697(02)00698-X; Bidlingmaier S, 2007, MOL CELL PROTEOMICS, V6, P2012, DOI 10.1074/mcp.M700223-MCP200; Bradner JE, 2006, CHEM BIOL, V13, P493, DOI 10.1016/j.chembiol.2006.03.004; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Caligiuri M, 2006, CHEM BIOL, V13, P711, DOI 10.1016/j.chembiol.2006.05.008; Cekaite Lina, 2007, Methods Mol Biol, V360, P335; Fang H, 2001, CHEM RES TOXICOL, V14, P280, DOI 10.1021/tx000208y; Gao H, 1999, CHEM REV, V99, P723, DOI 10.1021/cr980018g; George O, 2008, ACS CHEM BIOL, V3, P167, DOI [10.1021/cb700210u, 10.1021/cb6700210u]; Hufton SE, 1999, J IMMUNOL METHODS, V231, P39, DOI 10.1016/S0022-1759(99)00139-8; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Jin Y, 2002, CHEM BIOL, V9, P157, DOI 10.1016/S1074-5521(02)00096-0; Johnson GE, 2008, MUTAT RES-GEN TOX EN, V651, P56, DOI 10.1016/j.mrgentox.2007.10.019; Kley N, 2004, CHEM BIOL, V11, P599, DOI 10.1016/j.chembiol.2003.09.017; Lehmann L, 2004, CHEM-BIOL INTERACT, V147, P273, DOI 10.1016/j.cbi.2004.01.005; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; MacBeath G, 2000, SCIENCE, V289, P1760; Makowski Lee, 2003, Human Genomics, V1, P41; Mandava S, 2004, PROTEOMICS, V4, P1439, DOI 10.1002/pmic.200300680; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; METZLER M, 1995, ENVIRON HEALTH PERSP, V103, P21, DOI 10.2307/3432502; Ochi T, 1999, MUTAT RES-FUND MOL M, V431, P105, DOI 10.1016/S0027-5107(99)00190-6; Parry EM, 2002, MUTAGENESIS, V17, P509, DOI 10.1093/mutage/17.6.509; Pfeiffer E, 1997, MUTAT RES-GEN TOX EN, V390, P21, DOI 10.1016/S0165-1218(96)00161-9; QUICK EL, 2007, MUTAT RES, V651, P46; Rix U, 2009, NAT CHEM BIOL, V5, P616, DOI 10.1038/nchembio.216; Rodi DJ, 2001, COMB CHEM HIGH T SCR, V4, P553; Rodi DJ, 1999, J MOL BIOL, V285, P197, DOI 10.1006/jmbi.1998.2303; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Scott S, 2001, HATCHERY INT, V2, P19; Somers VA, 2002, J IMMUNOL, V169, P2772; Van Dorst B, 2010, ENVIRON TOXICOL CHEM, V29, P250, DOI 10.1002/etc.38; Vanparys C, 2006, TOXICOL IN VITRO, V20, P1238, DOI 10.1016/j.tiv.2006.05.002; Yu XM, 2007, J PHARMACEUT BIOMED, V45, P701, DOI 10.1016/j.jpba.2007.09.008; ZHANG CC, 2001, J STEROID BIOCHEM, V74, P169; Zhang YZ, 2008, PROTEOMICS, V8, P4178, DOI 10.1002/pmic.200800133389PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROAUGDiscipline: Toxicology622GY</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; cDNA phage display; CELL; Cellular targets; Chemical compounds; development; DEXAMETHASONE; Estrogen; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; HEALTH; IDENTIFICATION; In vitro; IN-VITRO; Interaction; LIBRARY; mechanism; MECHANISMS; MICROTUBULES; MODEL; MOLECULE-PROTEIN INTERACTIONS; non-genomic; Non-genomic action; Nongenomic; NONGENOMIC ACTIONS; nongenomic effects; p21; PROTEIN; PROTEINS; Proteomics; Steroid; SYSTEM; TARGET; TOOL; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1435</startpage>
    <endpage>1440</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>5</issue>
    <volume>24</volume>
    <abstract>cDNA phage display is frequently used in drug development to screen for cellular target of drugs. However, in toxicology, cDNA phage display remains unexplored, although it has large potential in this field. In this study, cDNA phage display is demonstrated as a novel tool to screen for interactions between chemical compounds and cellular targets. The knowledge of these target interactions is valuable to have a more complete understanding of the mechanisms of action of chemical compounds. Bisphenol A (BPA) was selected as a model compound for this study. By selection of the cellular proteins that bind BPA with cDNA phage display, it was possible to identify a known cellular target of BPA, tubulin a and a possible novel cellular target of BPA, transforming acidic coiled-coil containing protein 3. Both these cellular proteins are involved in the mechanism of cell division. The disruption of cell division is a known non-genomic effect of BPA. Non-genomic effects are not mediated by differences in gene expression and therefore important mechanistic information might be missed with the widely used differential gene expression techniques for mode of action research. This cDNA phage display technique can provide important additional information about the interaction of chemical compounds with cellular targets that mediates these non-genomic actions and therefore gives complementary information to toxicogenomic studies to obtain a more complete understanding of the mechanism of action of chemical compounds. (C) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000279650600014</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>433</id>
    <title>Bisphenol-A and the Great Divide: A Review of Controversies in the Field of Endocrine Disruption</title>
    <authors>Vandenberg,L.N.; Maffini,M.V.; Sonnenschein,C.; Rubin,B.S.; Soto,A.M.</authors>
    <availability>[Vandenberg, Laura N.; Maffini, Maricel V.; Sonnenschein, Carlos; Rubin, Beverly S.; Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USA.</availability>
    <date>2009</date>
    <notes>JEnglishReviewSoto, AM (reprint author), Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USAana.soto@tufts.eduAkingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174; ALONSO M, 2008, PLOS ONE, V3, pE2069; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; [Anonymous], 2002, OPINION SCI COMMITTE; Atkinson JC, 2002, DENT MATER, V18, P128, DOI 10.1016/S0109-5641(01)00031-8; Barker DJP, 2003, EUR J EPIDEMIOL, V18, P733, DOI 10.1023/A:1025388901248; Barker DJP, 2004, ACTA PAEDIATR, V93, P1559, DOI 10.1080/08035250410024772; BERN HA, 1992, ADV MOD ENV, V21, P9; BERN HA, 1983, P SOC EXP BIOL MED, V172, P239; Calabrese EJ, 2001, TOXICOL SCI, V62, P330, DOI 10.1093/toxsci/62.2.330; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Carson R, 1987, SILENT SPRING; Clarke R, 2000, J MAMMARY GLAND BIOL, V5, P245, DOI 10.1023/A:1009527609611; COLBORN T, 1992, CHEM INDUCED ALTERAT, P1; COLBORN T, 1995, OUR STOLEN FUTURE; SOTO AM, 1992, ADV MOD ENV, V21, P295; Colerangle JB, 1997, J STEROID BIOCHEM, V60, P153, DOI 10.1016/S0960-0760(96)00130-6; Conolly RB, 2004, TOXICOL SCI, V77, P151, DOI 10.1093/toxsci/kfh007; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Dessi-Fulgheri F, 2002, ENVIRON HEALTH PERSP, V110, P403; Diel P, 2000, J STEROID BIOCHEM, V73, P1, DOI 10.1016/S0960-0760(00)00051-0; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Eskenazi B, 2002, ENVIRON HEALTH PERSP, V110, P629; Fang H, 2000, ENVIRON HEALTH PERSP, V108, P723, DOI 10.1289/ehp.00108723; Farabollino F, 2002, ENVIRON HEALTH PERSP, V110, P409; *FDA SCI BOARD SUB, 2008, SCI PEER REV DRAFT A; Fukata H, 2006, TOXICOL MECH METHOD, V16, P427, DOI 10.1080/15376520600697404; Gaido KW, 2000, MOL PHARMACOL, V58, P852; GANDELMAN R, 1977, NATURE, V266, P722, DOI 10.1038/266722a0; Geck P, 2000, P NATL ACAD SCI USA, V97, P10185, DOI 10.1073/pnas.97.18.10185; Gilbert S. F., 2006, DEV BIOL; Godfrey K M, 2001, Public Health Nutr, V4, P611; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; GRECO TL, 1994, ENDOCRINOLOGY, V135, P262, DOI 10.1210/en.135.1.262; Hatch EE, 2001, CANCER CAUSE CONTROL, V12, P837, DOI 10.1023/A:1012229112696; Heindel JJ, 2008, ENVIRON HEALTH PERSP, V116, P389, DOI 10.1289/ehp.10524; Heines M., 2002, HORMONES BRAIN BEHAV, P425; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0; Howdeshell KL, 1999, NATURE, V401, P763; Huff J, 2001, Odontology, V89, P12, DOI 10.1007/s10266-001-8179-y; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Kabuto H, 2004, LIFE SCI, V74, P2931, DOI 10.1016/j.lfs.2003.07.060; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Kawai K, 2003, ENVIRON HEALTH PERSP, V111, P175, DOI 10.1289/ehp.5440; Kim YH, 2003, BIOCHEM BIOPH RES CO, V312, P441, DOI 10.1016/j.bbrc.2003.10.135; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Kitamura S, 2002, BIOCHEM BIOPH RES CO, V293, P554, DOI 10.1016/S0006-291X(02)00262-0; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kurebayashi H, 2003, TOXICOL SCI, V73, P17, DOI 10.1093/toxsci/kfg040; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Laviola G, 2005, BRAIN RES BULL, V65, P235, DOI 10.1016/j.brainresbull.2004.11.015; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Lummaa V, 2007, P NATL ACAD SCI USA, V104, P10915, DOI 10.1073/pnas.0605875104; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; Ma RS, 2006, ENVIRON HEALTH PERSP, V114, P898, DOI 10.1289/ehp.8748; MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633; MANNAN MA, 1991, J ENDOCRINOL, V130, P101, DOI 10.1677/joe.0.1300101; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Markey CM, 2001, BIOL REPROD, V65, P1215; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, P55, DOI 10.2307/3434921; Matsumoto J, 2002, ENVIRON HEALTH PERSP, V110, P193; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; McCormack VA, 2006, CANCER EPIDEM BIOMAR, V15, P1159, DOI 10.1158/1055-9965-EPI-06-0034; Medina D, 2001, ANN NY ACAD SCI, V952, P23; MEDLOCK KL, 1991, P SOC EXP BIOL MED, V196, P292; MITTENDORF R, 1995, TERATOLOGY, V51, P435, DOI 10.1002/tera.1420510609; Miyakoda H, 2000, J HEALTH SCI, V46, P269; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; MORRISEY RE, 1987, FUND APPL TOXICOL, V8, P571, DOI 10.1016/0272-0590(87)90142-4; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Mykkanen H, 1997, J PEDIATR GASTR NUTR, V25, P312, DOI 10.1097/00005176-199709000-00012; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Nadal A, 2005, PFLUG ARCH EUR J PHY, V449, P335, DOI 10.1007/s00424-004-1343-9; Nagel SC, 1999, J STEROID BIOCHEM, V69, P343, DOI 10.1016/S0960-0760(99)00078-3; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; *NAT TOX PROGR REP, 2001, END DISR LOW DOS PEE; Noguchi S, 2002, TOXICOL LETT, V135, P95, DOI 10.1016/S0378-4274(02)00252-7; NTP-CERHR, 2008, NTP CERHR MON POT HU, pi; Padula AM, 2005, ANIM REPROD SCI, V87, P93, DOI 10.1016/j.anireprosci.2004.09.008; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; PIKE MC, 1993, EPIDEMIOL REV, V15, P17; Pocar P, 2005, REPRODUCTION, V129, P379, DOI 10.1530/rep.1.00294; Porrini S, 2005, BRAIN RES BULL, V65, P261, DOI 10.1016/j.brainresbull.2004.11.014; Powell CE, 2003, STEROIDS, V68, P487, DOI 10.1016/S0039-128X(03)00047-3; Powell CE, 2001, J STEROID BIOCHEM, V77, P97, DOI 10.1016/S0960-0760(01)00040-1; Rajapakse N, 2002, ENVIRON HEALTH PERSP, V110, P917; Ramakrishnan S, 2008, REPROD TOXICOL, V25, P177, DOI 10.1016/j.reprotox.2007.11.002; Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271; Rayner JL, 2005, TOXICOL SCI, V87, P255, DOI 10.1093/toxsci/kfi213; Rayner JL, 2004, TOXICOL APPL PHARM, V195, P23, DOI 10.1016/j.taap.2003.11.005; REILING BA, 1995, J ANIM SCI, V73, P986; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Robinson GW, 1999, J MAMMARY GLAND BIOL, V4, P9, DOI 10.1023/A:1018748418447; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; RUSSO J, 1978, J NATL CANCER I, V61, P1451; Ryan BC, 2002, NEUROSCI BIOBEHAV R, V26, P665, DOI 10.1016/S0149-7634(02)00038-6; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; Sakamoto H, 2002, BBA-GEN SUBJECTS, V1573, P171, DOI 10.1016/S0304-4165(02)00418-X; Satoh S, 1997, J VET MED SCI, V59, P221, DOI 10.1292/jvms.59.221; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Sheehan DM, 1997, RISK POLICY REP, V4, P31; Shimizu M, 2002, TOXICOL IN VITRO, V16, P549, DOI 10.1016/S0887-2333(02)00055-3; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Sonnenschein C, 1999, SOC CELLS CANC CONTR; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Soto AM, 2007, CONTEMP ENDOCRINOL S, P9, DOI 10.1007/1-59745-107-X_2; Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x; Soto AM, 2001, J NATL CANCER I, V93, P1673, DOI 10.1093/jnci/93.22.1673; Soto AM, 2006, BEST PRACT RES CL EN, V20, P15, DOI 10.1016/j.beem.2005.09.001; Soto AM, 1997, ENVIRON HEALTH PERSP, V105, P647, DOI 10.2307/3433384; Soto AM, 1995, ONCOL RES, V7, P545; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Stowell CL, 2006, CHEM BIOL, V13, P891, DOI 10.1016/j.chembiol.2006.06.016; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Suiko M, 2000, BIOCHEM BIOPH RES CO, V267, P80, DOI 10.1006/bbrc.1999.1935; Sun H, 2006, FOOD CHEM TOXICOL, V44, P1916, DOI 10.1016/j.fct.2006.06.013; Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Takai Y, 2001, REPROD TOXICOL, V15, P71; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Taylor JA, 2008, REPROD TOXICOL, V25, P169, DOI 10.1016/j.reprotox.2008.01.001; The National Toxicology Program-Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR), 2007, NTP CERHR EXP PAN RE; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Tominaga T, 2006, TOXICOLOGY, V226, P208, DOI 10.1016/j.tox.2006.07.004; Trichopoulos D, 1990, Epidemiology, V1, P95; Tyl RW, 2008, TOXICOL SCI, V104, P362, DOI 10.1093/toxsci/kfn084; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; Uchida K, 2002, J HEALTH SCI, V48, P579, DOI 10.1248/jhs.48.579; van de Beek C, 2004, HORM BEHAV, V46, P663, DOI 10.1016/j.yhbeh.2004.06.010; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; Vandenbergh JG, 2004, ILAR J, V45, P438; Volkel W, 2005, DRUG METAB DISPOS, V33, P1748, DOI 10.1124/dmd.105.005454; VAlkel Wolfgang, 2002, Chem Res Toxicol, V15, P1281, DOI 10.1021/tx025548t; vom Saal F S, 1981, J Reprod Fertil, V62, P33; vom Saal F S, 1980, Science, V208, P597, DOI 10.1126/science.7367881; vom Saal F S, 1989, J Anim Sci, V67, P1824; vom Saal Frederick S., 2005, Birth Defects Research, V73, P140, DOI 10.1002/bdra.20120; VOMSAAL FS, 1978, BIOL REPROD, V19, P842, DOI 10.1095/biolreprod19.4.842; Vom Saal F S, 1985, Biol Reprod, V32, P1116, DOI 10.1095/biolreprod32.5.1116; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; vom Saal FS, 2005, BIRTH DEFECTS RES A, V73, P474, DOI 10.1002/bdra.20149; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; VOMSAAL FS, 1980, BIOL REPROD, V22, P777, DOI 10.1095/biolreprod22.4.777; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wallen K., 2002, HORMONES BRAIN BEHAV, P385; Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Welshons WV, 1999, TOXICOL IND HEALTH, V15, P12, DOI 10.1191/074823399678846745; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Willhite CC, 2008, J TOXICOL ENV HEAL B, V11, P69, DOI 10.1080/10937400701724303; Wilson NK, 2007, ENVIRON RES, V103, P9, DOI 10.1016/j.envres.2006.04.006; Wilson NK, 2003, J EXPO ANAL ENV EPID, V13, P187, DOI 10.1038/sj.jea.7500270; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5; Yang M, 2006, ENVIRON MOL MUTAGEN, V47, P571, DOI 10.1002/em.20230; Ye XY, 2005, ANAL BIOANAL CHEM, V383, P638, DOI 10.1007/s00216-005-0019-4; Yokota H, 1999, BIOCHEM J, V340, P405, DOI 10.1042/0264-6021:3400405; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.5603; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-1018; 2008, ANDYS TAKE BISPHENOL; 2008, DRAFT NTP BRIEF BISP; 2008, BISPHENOL PUBLIC COM194339ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCR REVFEBDiscipline: Endocrinology &amp; Metabolism403ZO</notes>
    <keywords>1; Androgen; ANDROGEN RECEPTOR; Antagonist; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; BPA; Brain; BREAST-CANCER RISK; CANCER; CE; CELL; CELLS; CHEMICALS; CONTROVERSIES; DEFECTS; development; DEVELOPMENTAL EXPOSURE; DISRUPTION; ENDOCRINE; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; Epidemiology; ER; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPOSURE; EXPOSURES; FEMALE REPRODUCTIVE-TRACT; FOOD; FUTURE; GENE-EXPRESSION; GLAND; HEALTH; Hormone; Hormones; HUMAN EXPOSURE; HUMAN-REPRODUCTION; In vitro; IN-UTERO EXPOSURE; IN-VITRO; low dose; Low-dose effects; mammary gland; MAMMARY-GLAND; MAMMARY-GLAND DEVELOPMENT; mechanism; MECHANISMS; MEMBRANE ESTROGEN-RECEPTOR; METABOLISM; MODEL; MODELS; Nonmonotonic; PERINATAL EXPOSURE; POPULATION; RECEPTOR; Receptors; Reproduction; Review; RISK; ROUTE; SERUM DIOXIN CONCENTRATIONS; Steroid; TANDEM MASS-SPECTROMETRY; Thyroid; Thyroid hormone; THYROID-HORMONE; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>75</startpage>
    <endpage>95</endpage>
    <journalfull>Endocrine Reviews</journalfull>
    <issue>1</issue>
    <volume>30</volume>
    <abstract>In 1991, a group of 21 scientists gathered at the Wingspread Conference Center to discuss evidence of developmental alterations observed in wildlife populations after chemical exposures. There, the term "endocrine disruptor" was agreed upon to describe a class of chemicals including those that act as agonists and antagonists of the estrogen receptors (ERs), androgen receptor, thyroid hormone receptor, and others. This definition has since evolved, and the field has grown to encompass hundreds of chemicals. Despite significant advances in the study of endocrine disruptors, several controversies have sprung up and continue, including the debate over the existence of nonmonotonic dose response curves, the mechanisms of low-dose effects, and the importance of considering critical periods of exposure in experimental design. One chemical found ubiquitously in our environment, bisphenol-A (BPA), has received a tremendous amount of attention from research scientists, government panels, and the popular press. In this review, we have covered the above-mentioned controversies plus six additional issues that have divided scientists in the field of BPA research, namely: 1) mechanisms of BPA action; 2) levels of human exposure; 3) routes of human exposure; 4) pharmacokinetic models of BPA metabolism; 5) effects of BPA on exposed animals; and 6) links between BPA and cancer. Understanding these topics is essential for educating the public and medical professionals about potential risks associated with developmental exposure to BPA and other endocrine disruptors, the design of rigorously researched programs using both epidemiological and animal studies, and ultimately the development of a sound public health policy. (Endocrine Reviews 30: 75-95, 2009)</abstract>
    <url>WOS:000263120700003</url>
    <isbnorissn>0163-769X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>213</id>
    <title>Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses</title>
    <authors>Vandenberg,L.N.; Colborn,T.; Hayes,T.B.; Heindel,J.J.; Jacobs,D.R.; Lee,D.H.; Shioda,T.; Soto,A.M.; vom Saal,F.S.; Welshons,W.V.; Zoeller,R.T.; Myers,J.P.</authors>
    <availability>[Vandenberg, Laura N.] Tufts Univ, Ctr Regenerat &amp; Dev Biol, Medford, MA 02155 USA. [Vandenberg, Laura N.] Tufts Univ, Dept Biol, Medford, MA 02155 USA. [Colborn, Theo] Endocrine Disrupt Exchange, Paonia, CO 81428 USA. [Hayes, Tyrone B.] Univ Calif Berkeley, Lab Integrat Studies Amphibian Biol, Grp Endocrinol, Energy &amp; Resources Grp,Museum Vertebrate Zool, Berkeley, CA 94720 USA. Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA. [Heindel, Jerrold J.] NIEHS, Div Extramural Res &amp; Training, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol &amp; Community Hlth, Minneapolis, MN 55455 USA. [Lee, Duk-Hee] Kyungpook Natl Univ, Sch Med, Dept Prevent Med, Taegu 702701, South Korea. [Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc Res, Mol Profiling Lab, Charlestown, MA 02129 USA. [Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USA. [vom Saal, Frederick S.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA. [Welshons, Wade V.] Univ Missouri, Dept Biomed Sci, Columbia, MO 65211 USA. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA. [Myers, John Peterson] Environm Hlth Sci, Charlottesville, VA 22902 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReviewVandenberg, LN (reprint author), Tufts Univ, Ctr Regenerat &amp; Dev Biol, 200 Boston Ave,Suite 4600, Medford, MA 02155 USAlaura.vandenberg@tufts.edu; jpmyers@ehsciences.orgAbraham I, 2000, J NEUROENDOCRINOL, V12, P486, DOI 10.1046/j.1365-2826.2000.00475.x; Abrari K, 2009, NEUROBIOL LEARN MEM, V91, P260, DOI 10.1016/j.nlm.2008.10.008; Adewale HB, 2011, NEUROTOXICOLOGY, V32, P38, DOI 10.1016/j.neuro.2010.07.008; Agency for Toxic Substances and Diseases Registry, 2011, TOX SUBST PORT DI 2; Ahmed S, 2011, ENVIRON HEALTH PERSP, V119, P258, DOI [10.1289/ehp.1002086, 10.1289/ehp.1102086]; Ahn NS, 2005, MUTAT RES-FUND MOL M, V579, P189, DOI 10.1016/j.mrfmmm.2005.03.026; Akinbami LJ, 2010, ENVIRON RES, V110, P294, DOI 10.1016/j.envres.2010.01.001; Al-Hiyasat AS, 2004, EUR J ORAL SCI, V112, P267, DOI 10.1111/j.1600-0722.2004.00136.x; Al-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Allran JW, 2001, ENVIRON TOXICOL CHEM, V20, P769, DOI 10.1897/1551-5028(2001)020&lt;0769:EOAOEL&gt;2.0.CO;2; Alm H, 2010, J PROTEOME RES, V9, P1226, DOI 10.1021/pr900723c; Almstrup K, 2002, ENVIRON HEALTH PERSP, V110, P743; Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alonso-Magdalena P, 2010, HORM-INT J ENDOCRINO, V9, P118; Alyea RA, 2009, ENVIRON HEALTH PERSP, V117, P778, DOI 10.1289/ehp.0800026; AMARA JF, 1983, ENDOCRINOLOGY, V112, P1141; American Society of Human Genetics American Society for Reproductive Medicine Endocrine Society Genetics Society of America Society for Developmental Biology Society for Pediatric Urology Society for the Study of Reproduction Society for Gynecologic Investigation, 2011, SCIENCE, V331, P1136; Amitai Y, 2007, THYROID, V17, P843, DOI 10.1089/thy.2006.0336; Anderson H A, 1979, Ann N Y Acad Sci, V320, P684, DOI 10.1111/j.1749-6632.1979.tb13187.x; Anderson JJB, 1998, P SOC EXP BIOL MED, V217, P345; Andrade AJM, 2006, TOXICOLOGY, V227, P185, DOI 10.1016/j.tox.2006.07.022; [Anonymous], 2007, P NATL ACAD SCI US, V104, P20250; Arase S, 2011, BIOL REPROD, V84, P734, DOI 10.1095/biolreprod.110.087502; Arima A, 2009, REPROD TOXICOL, V28, P495, DOI 10.1016/j.reprotox.2009.08.002; Ashby J, 1999, REGUL TOXICOL PHARM, V30, P156, DOI 10.1006/rtph.1999.1317; Ashby J, 2004, ENVIRON HEALTH PERSP, V112, P847, DOI 10.1289/ehp.6862; Asp V, 2010, TOXICOL APPL PHARM, V242, P281, DOI 10.1016/j.taap.2009.10.018; Aupperlee MD, 2009, ENDOCRINOLOGY, V150, P1485, DOI 10.1210/en.2008-1459; Axelstad M, 2011, TOXICOL APPL PHARM, V250, P278, DOI 10.1016/j.taap.2010.10.031; Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Bai Yao, 2011, Zoological Research, V32, P317, DOI 10.3724/SP.J.1141.2011.03317; Barker DJ, 2004, J AM COLL NUTR, V23, p588S; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Barr DB, 2007, ENVIRON HEALTH PERSP, V115, P1474, DOI 10.1289/ehp.10141; Basketter D, 2009, REGUL TOXICOL PHARM, V55, P90, DOI 10.1016/j.yrtph.2009.06.005; Battaglin WA, 2009, ENVIRON MONIT ASSESS, V155, P281, DOI 10.1007/s10661-008-0435-y; Battaglin WA, 2000, SCI TOTAL ENVIRON, V248, P123, DOI 10.1016/S0048-9697(99)00536-7; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Bell DR, 2007, TOXICOL SCI, V99, P214, DOI 10.1093/toxsci/kfm140; Bell DR, 2007, TOXICOL SCI, V99, P224, DOI 10.1093/toxsci/kfm141; Bell DR, 2010, FOOD CHEM TOXICOL, V48, P1439, DOI 10.1016/j.fct.2010.04.005; Bellinger DC, 2004, ENVIRON RES, V95, P394, DOI 10.1016/j.evnres.2003.07.013; Benachour N, 2007, TOXICOL APPL PHARM, V222, P129, DOI 10.1016/j.taap.2007.03.033; Benisek M, 2008, TOXICOL IN VITRO, V22, P1909, DOI 10.1016/j.tiv.2008.09.009; Benisek M, 2011, TOXICOL LETT, V200, P169, DOI 10.1016/j.toxlet.2010.11.011; Ben-Jonathan N, 2009, MOL CELL ENDOCRINOL, V304, P49, DOI 10.1016/j.mce.2009.02.022; BERGERON JM, 1994, ENVIRON HEALTH PERSP, V102, P780, DOI 10.2307/3432139; Bergeron JM, 1999, ENVIRON HEALTH PERSP, V107, P93, DOI 10.2307/3434363; BERN HA, 1987, CANCER RES, V47, P4165; BERN HA, 1983, P SOC EXP BIOL MED, V172, P239; Bernhardt RR, 2011, ENVIRON TOXICOL CHEM, V30, P1468, DOI 10.1002/etc.521; Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007; BERTHOIS Y, 1994, MOL CELL ENDOCRINOL, V99, P259, DOI 10.1016/0303-7207(94)90016-7; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Biedermann S, 2010, ANAL BIOANAL CHEM, V398, P571, DOI 10.1007/s00216-010-3936-9; Birnbaum LS, 2000, FOOD ADDIT CONTAM, V17, P275, DOI 10.1080/026520300283351; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P241, DOI 10.1006/taap.1994.1158; Bjornerem A, 2004, J CLIN ENDOCR METAB, V89, P6039, DOI 10.1210/jc2004-0735; Bleys J, 2009, AM J EPIDEMIOL, V169, P996, DOI 10.1093/aje/kwn414; Bloomquist JR, 2002, NEUROTOXICOLOGY, V23, P537, DOI 10.1016/S0161-813X(02)00031-1; Blount BC, 2009, ENVIRON SCI TECHNOL, V43, P7543, DOI 10.1021/es9008486; Blount BC, 2007, J EXPO SCI ENV EPID, V17, P400, DOI 10.1038/sj.jes.7500535; Blount BC, 2006, ENVIRON HEALTH PERSP, V114, P1865, DOI 10.1289/ehp.9466; Blount BC, 2006, ANAL CHIM ACTA, V567, P87, DOI 10.1016/j.aca.2006.02.010; Boccia MM, 1998, NEUROBIOL LEARN MEM, V69, P136, DOI 10.1006/nlme.1997.3817; Boccia MM, 1999, NEUROBIOL LEARN MEM, V71, P104, DOI 10.1006/nlme.1998.3856; Boettcher M, 2011, MUTAT RES-GEN TOX EN, V723, P152, DOI 10.1016/j.mrgentox.2011.04.012; Bohm SK, 1997, BIOCHEM J, V322, P1; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Boobis AR, 2008, CRIT REV TOXICOL, V38, P87, DOI 10.1080/10408440701749421; Borjan M, 2011, SCI TOTAL ENVIRON, V409, P460, DOI 10.1016/j.scitotenv.2010.10.045; Botelho GGK, 2009, ARCH ENVIRON CON TOX, V57, P777, DOI 10.1007/s00244-009-9317-8; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Braverman LE, 2006, J CLIN ENDOCR METAB, V91, P2721, DOI 10.1210/jc.2006-0184; Braverman LE, 2005, J CLIN ENDOCR METAB, V90, P700, DOI 10.1210/jc.2004-1821; Brechner RJ, 2000, J OCCUP ENVIRON MED, V42, P777, DOI 10.1097/00043764-200008000-00002; Bremmer MA, 2007, BIOL PSYCHIAT, V62, P479, DOI 10.1016/j.biopsych.2006.11.033; Brodeur JC, 2009, AQUAT TOXICOL, V91, P161, DOI 10.1016/j.aquatox.2008.07.003; Brossia LJ, 2009, J AM ASSOC LAB ANIM, V48, P517; Bruchovsky N, 1975, Vitam Horm, V33, P61; Brucker-Davis F, 2001, ENVIRON HEALTH PERSP, V109, P21, DOI 10.2307/3434843; Brucker-Davis F, 2002, THYROID, V12, P739, DOI 10.1089/105072502760258749; Buckman AH, 2007, AQUAT TOXICOL, V84, P366, DOI 10.1016/j.aquatox.2007.06.016; Buffler PA, 2006, ENVIRON HEALTH PERSP, V114, P798, DOI 10.1289/ehp.8176; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Cagen SZ, 1999, TOXICOL SCI, V50, P36, DOI 10.1093/toxsci/50.1.36; Cagen SZ, 1999, REGUL TOXICOL PHARM, V30, P130, DOI 10.1006/rtph.1999.1340; Cai JX, 1997, J PHARMACOL EXP THER, V283, P183; Calle EE, 1996, AM J EPIDEMIOL, V144, P645; Calvo RM, 2009, MOL CELL ENDOCRINOL, V311, P39, DOI 10.1016/j.mce.2009.07.006; Campagna C, 2007, REPROD TOXICOL, V23, P145, DOI 10.1016/j.reprotox.2006.10.007; Carney SA, 2006, BIRTH DEFECTS RES A, V76, P7, DOI 10.1002/bdra.20216; Carr JA, 2003, ENVIRON TOXICOL CHEM, V22, P396, DOI 10.1897/1551-5028(2003)022&lt;0396:ROLXLT&gt;2.0.CO;2; Carr RL, 2003, J TOXICOL ENV HEAL A, V66, P2077, DOI 10.1080/15287390390227750; Carrasco N, 2000, THYROID FUNDAMENTAL, P52; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carson R, 1962, SILENT SPRING; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; CASSIDY RA, 1994, TOXICOL APPL PHARM, V126, P326, DOI 10.1006/taap.1994.1123; Cavieres MF, 2002, ENVIRON HEALTH PERSP, V110, P1081; CDC (Centres for Disease Control and Prevention), 2008, NAT BIOM PROGR; Cederroth CR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007281; Center for the Evaluation of Risks to Human Reproduction, 2007, NTP CERHR EXP PAN RE; Center for the Evaluation of Risks to Human Reproduction, 2008, BISPH A PUBL COMM; Cerhan JR, 2000, J NATL CANCER I, V92, P261, DOI 10.1093/jnci/92.3.261; CHAHOUD I, 1992, ARCH TOXICOL, V66, P567, DOI 10.1007/BF01973387; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Chapin RE, 1997, FUND APPL TOXICOL, V40, P138, DOI 10.1006/faat.1997.2381; Chaube R, 2010, TOXICOL IN VITRO, V24, P1899, DOI 10.1016/j.tiv.2010.07.021; Chen AC, 2004, J NUTR, V134, P1303; Chen Y, 2008, GEN COMP ENDOCR, V159, P196, DOI 10.1016/j.ygcen.2008.08.014; Chen Y, 2009, ARCH ENVIRON CON TOX, V57, P598, DOI 10.1007/s00244-009-9304-0; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Chiang Emily C, 2009, Dose Response, V8, P285, DOI 10.2203/dose-response.09-036.Chiang; Chitra KC, 2003, TOXICOLOGY, V185, P119, DOI 10.1016/S0300-483X(02)00597-8; Cho MR, 2011, CHEMOSPHERE, V82, P1268, DOI 10.1016/j.chemosphere.2010.12.031; Christian M, 1999, J ENDOCRINOL, V160, pR1, DOI 10.1677/joe.0.160R001; Chung E, 2011, P NATL ACAD SCI USA, V108, P17732, DOI 10.1073/pnas.1115187108; CLARK MM, 1991, PHYSIOL BEHAV, V49, P239, DOI 10.1016/0031-9384(91)90038-P; CLARK MM, 1992, PHYSIOL BEHAV, V51, P957, DOI 10.1016/0031-9384(92)90077-F; CLARK MM, 1993, PHYSIOL BEHAV, V53, P1183, DOI 10.1016/0031-9384(93)90377-R; Clewell HJ, 2008, TOXICOL APPL PHARM, V231, P122, DOI 10.1016/j.taap.2008.04.021; Cohen-Bendahan CCC, 2004, PSYCHONEUROENDOCRINO, V29, P911, DOI 10.1016/j.psyneuen.2003.07.001; Cohen-Bendahan CCC, 2005, HORM BEHAV, V47, P230, DOI 10.1016/j.yhbeh.2004.10.006; Cohen-Bendahan CCC, 2005, TWIN RES HUM GENET, V8, P173, DOI 10.1375/1832427053738764; COLBORN T, 1994, ENVIRON HEALTH PERSP, V102, P55; COLBORN T, 1995, ENVIRON HEALTH PERSP, V103, P135, DOI 10.2307/3432522; Colerangle JB, 1997, J STEROID BIOCHEM, V60, P153, DOI 10.1016/S0960-0760(96)00130-6; Conolly RB, 2004, TOXICOL SCI, V77, P151, DOI 10.1093/toxsci/kfh007; Cook R, 2006, ENVIRON HEALTH PERSP, V114, P1631, DOI 10.1289/ehp.8606; Cooper KR, 2009, J ENVIRON SCI HEAL C, V27, P226, DOI 10.1080/10590500903310112; Cooper RL, 1997, J ENDOCRINOL, V152, P159, DOI 10.1677/joe.0.1520159; Cooper RL, 2007, BIRTH DEFECTS RES B, V80, P98, DOI 10.1002/bdrb.20110; Cooper RL, 1996, REPROD TOXICOL, V10, P257, DOI 10.1016/0890-6238(96)00054-8; Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Crain DA, 1997, ENVIRON HEALTH PERSP, V105, P528, DOI 10.1289/ehp.97105528; CREWS D, 1995, ENVIRON HEALTH PERSP, V103, P73, DOI 10.2307/3432512; Crofton KM, 2008, INT J ANDROL, V31, P209, DOI 10.1111/j.1365-2605.2007.00857.x; Crump C, 2000, J OCCUP ENVIRON MED, V42, P603, DOI 10.1097/00043764-200006000-00009; Culbert KM, 2008, ARCH GEN PSYCHIAT, V65, P329, DOI 10.1001/archgenpsychiatry.2007.47; Curwin BD, 2007, ENVIRON RES, V105, P307, DOI 10.1016/j.envres.2007.06.001; Damgaard IN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003051; Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024; DasGupta PK, 2006, ENVIRON SCI TECHNOL, V40, P6608, DOI 10.1021/es061321z; David RM, 2000, TOXICOL SCI, V55, P433, DOI 10.1093/toxsci/55.2.433; Decensi A, 1999, J CLIN ONCOL, V17, P2633; Dechaud H, 1999, STEROIDS, V64, P328, DOI 10.1016/S0039-128X(98)00114-7; De Groef B, 2006, EUR J ENDOCRINOL, V155, P17, DOI 10.1530/eje.1.02190; Della Seta D, 2005, BRAIN RES BULL, V65, P255, DOI 10.1016/j.brainresbull.2004.11.017; DENT JN, 1958, BIOL BULL, V115, P411, DOI 10.2307/1539106; Devidze N, 2010, NEUROSCI LETT, V474, P17, DOI 10.1016/j.neulet.2010.02.064; DEVITO MJ, 1995, ENVIRON HEALTH PERSP, V103, P820, DOI 10.2307/3432395; Dey A, 2009, BIOCHEM BIOPH RES CO, V381, P90, DOI 10.1016/j.bbrc.2009.02.027; Dhir A, 2008, CAN J PHYSIOL PHARM, V86, P726, DOI 10.1139/y08-077; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dickerson SM, 2009, TOXICOL APPL PHARM, V237, P237, DOI 10.1016/j.taap.2009.04.001; Dickerson SM, 2011, ENDOCRINOLOGY, V152, P581, DOI 10.1210/en.2010-1103; Diel P, 2004, ARCH TOXICOL, V78, P183, DOI 10.1007/s00204-003-0535-y; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Du J, 2009, P NATL ACAD SCI USA, V106, P3543, DOI 10.1073/pnas.0812671106; Duclos M, 2004, AM J PHYSIOL-ENDOC M, V286, pE159, DOI 10.1152/ajpendo.00281.2003; Duft M, 2003, AQUAT TOXICOL, V64, P437, DOI 10.1016/S0166-445X(03)00102-4; Du Preez LH, 2009, AQUAT TOXICOL, V95, P10, DOI 10.1016/j.aquatox.2009.07.018; Du Preez LH, 2008, CHEMOSPHERE, V71, P546, DOI 10.1016/j.chemosphere.2007.09.051; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Edwards TM, 2006, INT J ANDROL, V29, P109, DOI 10.1111/j.1365-2605.2005.00631.x; Eick GN, 2011, MOL CELL ENDOCRINOL, V334, P31, DOI 10.1016/j.mce.2010.09.003; Elattar TMA, 2000, ANTICANCER RES, V20, P1733; Elkadi S, 1999, NEUROREPORT, V10, P333, DOI 10.1097/00001756-199902050-00023; Elswick BA, 2000, REPROD TOXICOL, V14, P359, DOI 10.1016/S0890-6238(00)00092-7; El Touny LH, 2009, CANCER RES, V69, P3695, DOI 10.1158/0008-5472.CAN-08-2958; Ema M, 2001, REPROD TOXICOL, V15, P505, DOI 10.1016/S0890-6238(01)00160-5; Emond C, 2006, ENVIRON HEALTH PERSP, V114, P1394, DOI 10.1289/ehp.8805; Emond C, 2005, ENVIRON HEALTH PERSP, V113, P1666, DOI 10.1289/ehp.8016; Enmark E, 1999, J INTERN MED, V246, P133, DOI 10.1046/j.1365-2796.1999.00545.x; Enoch RR, 2007, ENVIRON HEALTH PERSP, V115, P541, DOI 10.1289/ehp.9612; Eskenazi B, 2002, AM J EPIDEMIOL, V156, P383, DOI 10.1093/aje/kwf046; Eskenazi B, 2005, ENVIRON HEALTH PERSP, V113, P858, DOI 10.1289/ehp.7820; Eskenazi B, 2004, ENVIRON HEALTH PERSP, V112, P22, DOI 10.1289/ehp.6573; Eskenazi B, 2002, ENVIRON HEALTH PERSP, V110, P629; European Food Safety Authority, 2007, EFSA J, V428, P1, DOI DOI 10.2903/J.EFSA.2007.428; Eustache F, 2009, ENVIRON HEALTH PERSP, V117, P1272, DOI 10.1289/ehp.0800158; Evanson M, 2001, COMP BIOCHEM PHYS C, V130, P249, DOI 10.1016/S1532-0456(01)00246-0; EVEN MD, 1992, J REPROD FERTIL, V96, P709; Faass O, 2009, NEUROTOXICOLOGY, V30, P249, DOI 10.1016/j.neuro.2008.12.008; Fan F, 1996, TOXICOLOGY, V106, P221, DOI 10.1016/0300-483X(95)03193-J; Faqi AS, 1998, TOXICOL APPL PHARM, V150, P383, DOI 10.1006/taap.1998.8433; Farabollini F, 1999, PHARMACOL BIOCHEM BE, V64, P687, DOI 10.1016/S0091-3057(99)00136-7; Fenner-Crisp PA, 2000, TOXICOL PATHOL, V28, P438, DOI 10.1177/019262330002800313; Fisk AT, 2005, SCI TOTAL ENVIRON, V351, P57, DOI 10.1016/j.scitotenv.2005.01.051; Floege J, 2010, NEPHROL DIAL TRANSPL, V26, P1948; Forson D, 2006, ENVIRON TOXICOL CHEM, V25, P168, DOI 10.1897/05-260R.1; Forson DD, 2006, ECOL APPL, V16, P2325, DOI 10.1890/1051-0761(2006)016[2325:AIRSIT]2.0.CO;2; Foster PMD, 2002, TOXICOL PATHOL, V30, P59, DOI 10.1080/01926230252824716; Foster WG, 2010, ENVIRON HEALTH PERSP, V118, P458, DOI 10.1289/ehp.0901084; Fox DA, 2008, ENVIRON HEALTH PERSP, V116, P618, DOI 10.1289/ehp.11268; Fox GA, 2001, ENVIRON HEALTH PERSP, V109, P853, DOI 10.2307/3454647; Fraites MJP, 2009, TOXICOL SCI, V112, P88, DOI 10.1093/toxsci/kfp194; Franceschini MD, 2008, ENVIRON TOXICOL CHEM, V27, P2326, DOI 10.1897/07-602.1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Freeman JL, 2005, AQUAT TOXICOL, V75, P263, DOI 10.1016/j.aquatox.2005.08.012; Friedmann AS, 2002, REPROD TOXICOL, V16, P275, DOI 10.1016/S0890-6238(02)00019-9; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fujimoto T, 2006, BRAIN RES, V1068, P49, DOI 10.1016/j.brainres.2005.11.028; Funabashi T, 2004, PSYCHONEUROENDOCRINO, V29, P475, DOI 10.1016/S0306-4530(03)00055-6; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gan EH, 2010, PROG BRAIN RES, V181, P111, DOI 10.1016/S0079-6123(08)81007-2; GANDELMAN R, 1977, NATURE, V266, P722, DOI 10.1038/266722a0; Gasnier C, 2009, TOXICOLOGY, V262, P184, DOI 10.1016/j.tox.2009.06.006; Ge RS, 2007, J ANDROL, V28, P513, DOI 10.2164/jandrol.106.001909; Geck P, 1997, J STEROID BIOCHEM, V63, P211, DOI 10.1016/S0960-0760(97)00122-2; Geck P, 2000, P NATL ACAD SCI USA, V97, P10185, DOI 10.1073/pnas.97.18.10185; Geens T, 2011, INT J HYG ENVIR HEAL, V214, P339, DOI 10.1016/j.ijheh.2011.04.005; Geis RB, 2005, TOXICOL LETT, V157, P21, DOI 10.1016/j.toxlet.2005.01.001; George JW, 2011, BIOL REPROD, V84, P7, DOI 10.1095/biolreprod.110.085043; German Federal Institute for Risk Assessment (BfR), 2009, WORKSH HOST GERM FED; Geusau A, 2001, ENVIRON HEALTH PERSP, V109, P865, DOI 10.2307/3454832; Ghassabian A, 2011, PEDIATR RES, V69, P454, DOI 10.1203/PDR.0b013e3182125b0c; Gibbs JP, 2008, THYROID, V18, P807, DOI 10.1089/thy.2007.0377; Gibbs JP, 1998, J OCCUP ENVIRON MED, V40, P1072; GIERTHY JF, 1984, TOXICOL APPL PHARM, V74, P91, DOI 10.1016/0041-008X(84)90274-6; Gies Andreas, 2009, Int J Hyg Environ Health, V212, P693, DOI 10.1016/j.ijheh.2009.09.006; Ginsberg GL, 2007, ENVIRON HEALTH PERSP, V115, P361, DOI 10.1289/ehp.9533; Giordano F, 2010, BIRTH DEFECTS RES A, V88, P241, DOI 10.1002/bdra.20657; Giudice BD, 2010, ENVIRON TOXICOL CHEM, V29, P966, DOI 10.1002/etc.105; Glinianaia SV, 1998, INT J EPIDEMIOL, V27, P657, DOI 10.1093/ije/27.4.657; Goldberg JM, 1999, FERTIL STERIL, V72, P1, DOI 10.1016/S0015-0282(99)00153-3; Goleman Wanda L., 2002, Environmental Toxicology and Chemistry, V21, P424, DOI 10.1897/1551-5028(2002)021&lt;0424:ERCOAP&gt;2.0.CO;2; Goodman J, 2009, CRIT REV TOXICOL, V39, P1, DOI 10.3109/10408440903279946; Goodman M, 2010, ENVIRON HEALTH PERSP, V118, P727, DOI 10.1289/ehp.0901835; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Grande SW, 2006, TOXICOL SCI, V91, P247, DOI 10.1093/toxsci/kfj128; Grandien K, 1997, INT J BIOCHEM CELL B, V29, P1343, DOI 10.1016/S1357-2725(97)89967-0; Gray LE, 1997, TOXICOL APPL PHARM, V146, P237, DOI 10.1006/taap.1997.8222; Gray LE, 1997, TOXICOL APPL PHARM, V146, P11, DOI 10.1006/taap.1997.8223; GRAY LE, 1995, TOXICOL APPL PHARM, V131, P108, DOI 10.1006/taap.1995.1052; Gray L. Earl Jr, 1998, Environmental Toxicology and Chemistry, V17, P109, DOI 10.1897/1551-5028(1998)017&lt;0109:TVOMSI&gt;2.3.CO;2; Greenland S, 2007, INT J EPIDEMIOL, V36, P944, DOI 10.1093/ije/dym174; Greenman SB, 1997, ENVIRON RES, V75, P85, DOI 10.1006/enrs.1997.3766; Greer MA, 2002, ENVIRON HEALTH PERSP, V110, P927; Grese TA, 1998, CURR PHARM DESIGN, V4, P71; Guillen C, 2008, FEBS LETT, V582, P3855, DOI 10.1016/j.febslet.2008.10.020; Guo JM, 2004, FOOD CHEM TOXICOL, V42, P1641, DOI 10.1016/j.fct.2004.06.001; Guo-Ross SX, 2007, TOXICOL SCI, V100, P118, DOI 10.1093/toxsci/kfm195; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Gust M, 2009, ENVIRON POLLUT, V157, P423, DOI 10.1016/j.envpol.2008.09.040; Ha MH, 2009, J HUM HYPERTENS, V23, P274, DOI 10.1038/jhh.2008.124; Habauzit D, 2010, ENVIRON TOXICOL, V25, P495, DOI 10.1002/tox.20594; Haddad N, 2006, CAN J PHYSIOL PHARM, V84, P157, DOI 10.1139/Y06-006; Harding LE, 2008, SCI TOTAL ENVIRON, V389, P350, DOI 10.1016/j.scitotenv.2007.09.026; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; Harrison PTC, 1997, SCI TOTAL ENVIRON, V205, P97, DOI 10.1016/S0048-9697(97)00212-X; HASLAM SZ, 1986, CANCER RES, V46, P310; Hassoun EA, 1998, TOXICOL SCI, V42, P23, DOI 10.1006/toxs.1997.2411; Hatch EE, 2001, CANCER CAUSE CONTROL, V12, P837, DOI 10.1023/A:1012229112696; Hatch EE, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-27; Hatch EE, 2010, INT J ANDROL, V33, P324, DOI 10.1111/j.1365-2605.2009.01035.x; Hatef A, 2012, ECOTOX ENVIRON SAFE, V76, P56, DOI 10.1016/j.ecoenv.2011.09.021; Hattar R, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2220; Hayes T, 2003, ENVIRON HEALTH PERSP, V111, P568, DOI 10.1289/ehp.5932; Hayes T, 2002, NATURE, V419, P895, DOI 10.1038/419895a; Hayes TB, 1998, SCI J KAGAKU, V68, P557; Hayes TB, 1998, J EXP ZOOL, V281, P373, DOI 10.1002/(SICI)1097-010X(19980801)281:5&lt;373::AID-JEZ4&gt;3.3.CO;2-T; Hayes TB, 2006, ENVIRON HEALTH PERSP, V114, P40, DOI 10.1289/ehp.8051; Hayes TB, 2011, J STEROID BIOCHEM, V127, P64, DOI 10.1016/j.jsbmb.2011.03.015; Hayes TB, 2002, P NATL ACAD SCI USA, V99, P5476, DOI 10.1073/pnas.082121499; Hayes TB, 2010, P NATL ACAD SCI USA, V107, P4612, DOI 10.1073/pnas.0909519107; Hayes TB, 2004, BIOSCIENCE, V54, P1138, DOI 10.1641/0006-3568(2004)054[1138:TINDTD]2.0.CO;2; Hayes TB, 2006, ENVIRON HEALTH PERSP, V114, P134, DOI 10.1289/ehp.8067; Hays SM, 2009, J APPL TOXICOL, V29, P275, DOI 10.1002/jat.1410; Hecker M, 2005, AQUAT TOXICOL, V72, P383, DOI 10.1016/j.aquatox.2005.01.008; Hecker M, 2005, TOXICOL SCI, V86, P273, DOI 10.1093/toxsci/kfi203; Heindel JJ, 2006, SEMIN REPROD MED, V24, P168, DOI 10.1055/s-2006-944423; Heindel JJ, 2005, BIRTH DEFECTS RES A, V73, P131, DOI 10.1002/bdra.20119; Heindel JJ, 2009, MOL CELL ENDOCRINOL, V304, P90, DOI 10.1016/j.mce.2009.02.025; Heindel JJ, 2008, ENVIRON HEALTH PERSP, V116, P389, DOI 10.1289/ehp.10524; Heindel JJ, 2008, BASIC CLIN PHARMACOL, V102, P76, DOI 10.1111/j.1742-7843.2007.00184.x; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Helmestam M, 2010, REPROD TOXICOL, V30, P370, DOI 10.1016/j.reprotox.2010.05.003; Henn BC, 2010, EPIDEMIOLOGY, V21, P433, DOI 10.1097/EDE.0b013e3181df8e52; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hermsen SAB, 2008, TOXICOLOGY, V253, P147, DOI 10.1016/j.tox.2008.09.005; Higashihara N, 2007, ARCH TOXICOL, V81, P825, DOI 10.1007/s00204-007-0223-4; Hites RA, 2011, ENVIRON SCI TECHNOL, V45, P16, DOI 10.1021/es1013664; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; HOECK W, 1989, J BIOL CHEM, V264, P14396; Hofer N, 2010, ARCH TOXICOL, V84, P541, DOI 10.1007/s00204-010-0524-x; Hornung MW, 2010, TOXICOL SCI, V118, P42, DOI 10.1093/toxsci/kfq166; Houshmand F, 2009, PEPTIDES, V30, P2301, DOI 10.1016/j.peptides.2009.09.010; Howdeshell KL, 1999, NATURE, V401, P763; Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993; Howdeshell KL, 2008, TOXICOL SCI, V102, P371, DOI 10.1093/toxsci/kfm306; Howell A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2435; Howell A, 2001, CLIN CANCER RES, V7, p4411s; Howell A, 2001, CLIN CANCER RES, V7, p4369S; HSU ST, 1985, ENVIRON HEALTH PERSP, V59, P5, DOI 10.2307/3429867; Huber DR, 2011, J EXPO SCI ENV EPID, V21, P395, DOI 10.1038/jes.2010.31; Huggard D, 1996, BIOL REPROD, V54, P1184, DOI 10.1095/biolreprod54.6.1184; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hunt PA, 2009, BIOL REPROD, V81, P807, DOI 10.1095/biolreprod.109.077008; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Ichihara Toshio, 2003, J Toxicol Sci, V28, P165, DOI 10.2131/jts.28.165; Ikeda M, 2005, TOXICOL APPL PHARM, V206, P351, DOI 10.1016/j.taap.2004.11.019; Ishimaru N, 2009, J IMMUNOL, V182, P6576, DOI 10.4049/jimmunol.0802289; Ismail A, 2005, IUBMB LIFE, V57, P483, DOI 10.1080/15216540500147163; Jeng YJ, 2011, ENVIRON HEALTH PERSP, V119, P104, DOI 10.1289/ehp.1002512; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jeyakumar M, 2008, BIOCHEMISTRY-US, V47, P7465, DOI 10.1021/bi800393u; Ji K, 2010, ENVIRON RES, V110, P375, DOI 10.1016/j.envres.2010.02.008; Jiang Y, 1996, CALCIFIED TISSUE INT, V58, P30, DOI 10.1007/BF02509543; Jin MH, 2010, ENVIRON TOXICOL, V25, P1, DOI 10.1002/tox.20466; JOHNSON MR, 1994, J ENDOCRINOL, V143, P309, DOI 10.1677/joe.0.1430309; Jones BA, 2011, HORM BEHAV, V59, P246, DOI 10.1016/j.yhbeh.2010.12.006; Jones KA, 1996, HDB ENDOCRINOLOGY, P1; Jones LP, 2010, TOXICOL LETT, V199, P261, DOI 10.1016/j.toxlet.2010.09.008; Jooste AM, 2005, ENVIRON SCI TECHNOL, V39, P5255, DOI 10.1021/es048134q; Kakeyama M, 2008, J ENDOCRINOL, V197, P351, DOI 10.1677/JOE-08-0062; Kamrin MA, 2007, INT J TOXICOL, V26, P13, DOI 10.1080/10915810601117968; Kang Hong-Yo, 2003, Chang Gung Med J, V26, P388; Karrow NA, 2005, TOXICOLOGY, V209, P15, DOI 10.1016/j.tox.2004.12.002; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Kawagoshi Y, 2003, J ENVIRON MONITOR, V5, P269, DOI 10.1039/b210962j; Keller JM, 2008, GROWTH DEVELOP AGING, V71, P3; Kelsh MA, 2003, J OCCUP ENVIRON MED, V45, P1116, DOI 10.1097/01.jom.0000091683.25325.55; Kenealy BP, 2011, STEROIDS, V76, P861, DOI 10.1016/j.steroids.2011.02.019; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kim KH, 2011, ENVIRON HEALTH PERSP, V119, P519, DOI 10.1289/ehp.1002728; Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131; KINSLEY CH, 1986, PHYSIOL BEHAV, V36, P793, DOI 10.1016/0031-9384(86)90434-8; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Kirchner S, 2010, MOL ENDOCRINOL, V24, P526, DOI 10.1210/me.2009-0261; Kirk AB, 2007, ENVIRON HEALTH PERSP, V115, P182, DOI 10.1289/ehp.9558; Kisanga ER, 2004, CLIN CANCER RES, V10, P2336, DOI 10.1158/1078-0432.CCR-03-0538; Kloas W, 2009, TOXICOL SCI, V107, P376, DOI 10.1093/toxsci/kfn232; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; KOCIBA RJ, 1982, DRUG METAB REV, V13, P387, DOI 10.3109/03602538209029986; Koehler KE, 2003, LAB ANIMAL, V32, P24, DOI 10.1038/laban0403-24; Kohlerova E, 2004, J VET MED A, V51, P209, DOI 10.1111/j.1439-0442.2004.00634.x; Kohn MC, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290113; Korkalainen M, 2004, BIOCHEM BIOPH RES CO, V315, P123, DOI 10.1016/j.bbrc.2004.01.028; Korkalainen M, 2001, BIOCHEM BIOPH RES CO, V285, P1121, DOI 10.1006/bbrc.2001.5317; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P106, DOI 10.1289/ehp.9358; Kortenkamp A, 2006, INT J ANDROL, V29, P193, DOI 10.1111/j.1365-2605.2005.00613.x; Kortenkamp A, 2008, INT J ANDROL, V31, P233, DOI 10.1111/j.1365-2605.2007.00862.x; Kratzik CW, 2007, BJU INT, V100, P614, DOI 10.1111/j.1464-410X.2007.07010.x; Kress E, 2009, MOL CELL ENDOCRINOL, V313, P36, DOI 10.1016/j.mce.2009.08.028; Krimsky S, 2003, HORMONAL CHAOS SCI S; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; Kubo K, 2001, NEUROSCI LETT, V304, P73, DOI 10.1016/S0304-3940(01)01760-8; Kubo K, 2003, NEUROSCI RES, V45, P345, DOI 10.1016/S0168-0102(02)00251-1; Kuiper GGJM, 1999, J ENDOCRINOL INVEST, V22, P594; Kuklenyik Z, 2009, J CHROMATOGR SCI, V47, P12; Kumari M, 2010, J CLIN ENDOCR METAB, V95, P4415, DOI 10.1210/jc.2009-2105; Kung T, 2009, BIOCHEM PHARMACOL, V77, P536, DOI 10.1016/j.bcp.2008.09.031; Kuriyama SN, 2007, TOXICOLOGY, V242, P80, DOI 10.1016/j.tox.2007.09.011; Kwintkiewicz J, 2010, ENVIRON HEALTH PERSP, V118, P400, DOI 10.1289/ehp.0901161; Laclaustra M, 2010, ATHEROSCLEROSIS, V210, P643, DOI 10.1016/j.atherosclerosis.2010.01.005; Laclaustra M, 2009, ENVIRON HEALTH PERSP, V117, P1409, DOI 10.1289/ehp.0900704; LaFranchi SH, 2007, J PEDIATR ENDOCR MET, V20, P559; Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lamm SH, 1999, J OCCUP ENVIRON MED, V41, P409, DOI 10.1097/00043764-199905000-00011; Lamm SH, 1999, J OCCUP ENVIRON MED, V41, P248, DOI 10.1097/00043764-199904000-00006; LANGANFAHEY SM, 1990, EUR J CANCER, V26, P883, DOI 10.1016/0277-5379(90)90191-U; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Langlois VS, 2010, ENVIRON HEALTH PERSP, V118, P552, DOI 10.1289/ehp.0901418; Lassiter TL, 2008, NEUROTOXICOL TERATOL, V30, P125, DOI 10.1016/j.ntt.2007.10.004; Laughlin GA, 2010, J CLIN ENDOCR METAB, V95, P740, DOI 10.1210/jc.2009-1693; Laurenzana EM, 2002, FOOD CHEM TOXICOL, V40, P53, DOI 10.1016/S0278-6915(01)00095-3; Lawrence J, 2001, THYROID, V11, P295, DOI 10.1089/105072501750159796; Lawrence JE, 2000, THYROID, V10, P659, DOI 10.1089/10507250050137734; Laws SC, 2009, TOXICOL SCI, V112, P78, DOI 10.1093/toxsci/kfp190; Lee DH, 2007, DIABETOLOGIA, V50, P1841, DOI 10.1007/s00125-007-0755-4; Lee DH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015977; Lee DH, 2010, ENVIRON HEALTH PERSP, V118, P1235, DOI 10.1289/ehp.0901480; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Lemini C, 2004, TOXICOL IND HEALTH, V20, P123, DOI 10.1191/0748233704th202oa; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Lemos MFL, 2010, CHEMOSPHERE, V79, P570, DOI 10.1016/j.chemosphere.2010.01.055; LERNER HJ, 1976, CANCER TREAT REP, V60, P1431; LESSER B, 1974, BIOCHEM J, V142, P429; Leung LY, 2008, COMP BIOCHEM PHYS A, V151, P705, DOI 10.1016/j.cbpa.2008.08.023; Levin ER, 2009, TRENDS ENDOCRIN MET, V20, P477, DOI 10.1016/j.tem.2009.06.009; Levin ER, 2011, MOL ENDOCRINOL, V25, P377, DOI 10.1210/me.2010-0284; Levy G, 2004, ENVIRON RES, V94, P102, DOI 10.1016/S0013-9351(03)00086-0; Li D, 2010, HUM REPROD, V25, P519, DOI 10.1093/humrep/dep381; Li DK, 2010, J ANDROL, V31, P500, DOI 10.2164/jandrol.110.010413; Li EZ, 2011, CELL BIOL INT, V35, P305, DOI 10.1042/CBI20100566; Li FX, 2000, TERATOLOGY, V62, P429; Li HS, 2010, EXPERT OPIN DRUG MET, V6, P409, DOI 10.1517/17425251003598886; Li L, 2007, J MOL ENDOCRINOL, V38, P569, DOI 10.1677/JME-07-0003; Li W, 2011, MAR POLLUT BULL, V63, P350, DOI 10.1016/j.marpolbul.2011.02.006; Li Z, 2000, J OCCUP ENVIRON MED, V42, P200, DOI 10.1097/00043764-200002000-00020; Liao CY, 2011, ENVIRON SCI TECHNOL, V45, P6761, DOI 10.1021/es200977t; Lidsky TI, 2006, ENVIRON RES, V100, P284, DOI 10.1016/j.envres.2005.03.002; Lieb W, 2009, DIABETES CARE, V32, P612, DOI 10.2337/dc08-1596; Lim J, 2007, ARCH ENVIRON CON TOX, V52, P590, DOI 10.1007/s00244-006-0168-2; Lim JS, 2008, DIABETES CARE, V31, P1802, DOI 10.2337/dc08-0850; Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200; Linkov I, 2009, SCI TOTAL ENVIRON, V407, P5199, DOI 10.1016/j.scitotenv.2009.05.004; Liu SV, 2010, CLIN CANCER RES, V16, P4675, DOI 10.1158/1078-0432.CCR-10-1113; Loeffler IK, 1999, TOXICOL APPL PHARM, V154, P28, DOI 10.1006/taap.1998.8572; Loehlin JC, 2000, BEHAV GENET, V30, P19, DOI 10.1023/A:1002082325784; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Lopez-Espinosa MJ, 2007, FOOD ADDIT CONTAM A, V24, P95, DOI 10.1080/02652030600936375; Love OP, 2003, ECOTOXICOLOGY, V12, P199, DOI 10.1023/A:1022502826800; Lucier GW, 1997, REGUL TOXICOL PHARM, V26, P34, DOI 10.1006/rtph.1997.1114; Lummaa V, 2007, P NATL ACAD SCI USA, V104, P10915, DOI 10.1073/pnas.0605875104; Lutz W K, 2005, Toxicol Appl Pharmacol, V207, P565, DOI 10.1016/j.taap.2005.01.038; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633; Maffini M, 2008, J STEROID BIOCHEM, V108, P32, DOI 10.1016/j.jsbmb.2007.05.034; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Manfo FPT, 2011, DRUG CHEM TOXICOL, V34, P120, DOI 10.3109/01480545.2010.482589; Maranghi F, 2010, CHEM-BIOL INTERACT, V183, P40, DOI 10.1016/j.cbi.2009.09.016; Marinkovic N, 2010, ARH HIG RADA TOKSIKO, V61, P445, DOI 10.2478/10004-1254-61-2010-2024; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2003, EVOL DEV, V5, P67, DOI 10.1046/j.1525-142X.2003.03011.x; Markey CM, 2001, BIOL REPROD, V65, P1215; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, P55, DOI 10.2307/3434921; Marshall J R, 1990, Epidemiology, V1, P843307ENDOCRINE SOCCHEVY CHASE8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USAENDOCR REVJUNDiscipline: Endocrinology &amp; Metabolism956KR</notes>
    <keywords>ATHEROSCLEROSIS; BIOLOGY; BISPHENOL-A EXPOSURE; breast; breast cancer; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CELL; CHEMICALS; Determination; development; diabetes; DISEASE; diseases; DISORDERS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; environmental exposure; Epidemiology; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FOOD; GENE; genetics; GROWTH; HEALTH; Hormones; HUMAN EXPOSURE; HUMAN HEALTH; HUMAN-DISEASE; HUMAN-REPRODUCTION; In vitro; IN-UTERO EXPOSURE; IN-VITRO; JUN; LONG-EVANS RATS; MAMMARY-GLAND DEVELOPMENT; mechanism; MECHANISMS; MESSENGER-RNA EXPRESSION; METABOLISM; NUTRITION EXAMINATION SURVEY; p21; p38; PERSISTENT ORGANIC POLLUTANTS; PREVENTION; Proteomics; Reproduction; RESPONSES; RISK; Risk assessment; RISK-ASSESSMENT; SERUM DIOXIN CONCENTRATIONS; SOCIETY; TISSUE; toxicology; VITRO; Weight of evidence</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>378</startpage>
    <endpage>455</endpage>
    <journalfull>Endocrine Reviews</journalfull>
    <issue>3</issue>
    <volume>33</volume>
    <abstract>For decades, studies of endocrine-disrupting chemicals (EDCs) have challenged traditional concepts in toxicology, in particular the dogma of "the dose makes the poison," because EDCs can have effects at low doses that are not predicted by effects at higher doses. Here, we review two major concepts in EDC studies: low dose and nonmonotonicity. Low-dose effects were defined by the National Toxicology Program as those that occur in the range of human exposures or effects observed at doses below those used for traditional toxicological studies. We review the mechanistic data for low-dose effects and use a weight-of-evidence approach to analyze five examples from the EDC literature. Additionally, we explore nonmonotonic dose-response curves, defined as a nonlinear relationship between dose and effect where the slope of the curve changes sign somewhere within the range of doses examined. We provide a detailed discussion of the mechanisms responsible for generating these phenomena, plus hundreds of examples from the cell culture, animal, and epidemiology literature. We illustrate that nonmonotonic responses and low-dose effects are remarkably common in studies of natural hormones and EDCs. Whether low doses of EDCs influence certain human disorders is no longer conjecture, because epidemiological studies show that environmental exposures to EDCs are associated with human diseases and disabilities. We conclude that when nonmonotonic dose-response curves occur, the effects of low doses cannot be predicted by the effects observed at high doses. Thus, fundamental changes in chemical testing and safety determination are needed to protect human health. (Endocrine Reviews 33: 378-455, 2012)</abstract>
    <url>WOS:000305089000004</url>
    <isbnorissn>0163-769X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>122</id>
    <title>Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology</title>
    <authors>Vandenberg,L.N.; Colborn,T.; Hayes,T.B.; Heindel,J.J.; Jacobs,D.R.; Lee,D.H.; Myers,J.P.; Shioda,T.; Soto,A.M.; vom Saal,F.S.; Welshons,W.V.; Zoeller,R.T.</authors>
    <availability>[Vandenberg, Laura N.] Tufts Univ, Ctr Regenerat &amp; Dev Biol, Medford, MA 02155 USA. [Vandenberg, Laura N.] Tufts Univ, Dept Biol, Medford, MA 02155 USA. [Colborn, Theo] Endocrine Disrupt Exchange, Paonia, CO USA. [Hayes, Tyrone B.] Univ Calif Berkeley, Museum Vertebrate Zool, Energy &amp; Resources Grp, Grp Endocrinol,Lab Integrat Studies Amphibian Bio, Berkeley, CA 94720 USA. [Hayes, Tyrone B.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA. [Heindel, Jerrold J.] NIEHS, Div Extramural Res &amp; Training, NIH DHHS, Res Triangle Pk, NC 27709 USA. [Jacobs, David R., Jr.] Univ Minnesota, Div Epidemiol &amp; Community Hlth, Sch Publ Hlth, Minneapolis, MN USA. [Lee, Duk-Hee] Kyungpook Natl Univ, Sch Med, Dept Prevent Med, Taegu, South Korea. [Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc Res, Mol Profiling Lab, Charlestown, MA USA. [Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cell Biol, Medford, MA 02155 USA. [vom Saal, Frederick S.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA. [Welshons, Wade V.] Univ Missouri, Dept Biomed Sci, Columbia, MO USA. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.</availability>
    <date>2013</date>
    <notes>JEnglishReviewVandenberg, LN (reprint author), Tufts Univ, Ctr Regenerat &amp; Dev Biol, 200 Boston Ave,Suite 4600, Medford, MA 02155 USAlaura.vandenberg@tufts.eduAlonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; AMARA JF, 1983, ENDOCRINOLOGY, V112, P1141; Anderson DR, 2000, J WILDLIFE MANAGE, V64, P912, DOI 10.2307/3803199; Arnold AP, 2009, HORM BEHAV, V55, P570, DOI 10.1016/j.yhbeh.2009.03.011; ARNOLD DJ, 1979, JAMA-J AM MED ASSOC, V241, P2506; Balls M, 2006, ATLA-ALTERN LAB ANIM, V34, P603; Barker DJP, 2004, J AM COLL NUTR, V23, p588S; BARKER DJP, 1986, LANCET, V1, P1077; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Barr DB, 2010, ENVIRON HEALTH PERSP, V118, P742, DOI 10.1289/ehp.0901275; Bars R, 2012, REGUL TOXICOL PHARM, V64, P143, DOI 10.1016/j.yrtph.2012.06.013; Berin I, 2010, FERTIL STERIL, V93, P360, DOI 10.1016/j.fertnstert.2008.11.007; Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007; Bianco AC, 2011, ENDOCRINOLOGY, V152, P3306, DOI 10.1210/en.2011-1104; Biello D, 2010, SCI AM, V302, P6; Biesemeier JA, 2011, BIRTH DEFECTS RES B, V92, P17, DOI 10.1002/bdrb.20280; Biggs ML, 2002, EPIDEMIOLOGY, V13, P197, DOI 10.1097/00001648-200203000-00015; Birnbaum LS, 2012, ENVIRON HEALTH PERSP, V120, pA143, DOI 10.1289/ehp.1205179; Birnbaum LS, 2011, HEALTH AFFAIR, V30, P814, DOI 10.1377/hlthaff.2010.1225; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; BULLER RE, 1976, BIOCHEM PHARMACOL, V25, P1, DOI 10.1016/0006-2952(76)90164-7; Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P353, DOI 10.1080/20014091111730; Calabrese EJ, 2001, TRENDS PHARMACOL SCI, V22, P285, DOI 10.1016/S0165-6147(00)01719-3; Calabrese EJ, 2001, TOXICOL SCI, V62, P330, DOI 10.1093/toxsci/62.2.330; Calabrese EJ, 2007, TOXICOL APPL PHARM, V222, P122, DOI 10.1016/j.taap.2007.02.015; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Callard GV, 2011, J STEROID BIOCHEM, V127, P176, DOI 10.1016/j.jsbmb.2011.03.022; Cerhan JR, 2000, J NATL CANCER I, V92, P261, DOI 10.1093/jnci/92.3.261; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Cho HJ, 2007, GEN COMP ENDOCR, V153, P98, DOI 10.1016/j.ygcen.2006.12.013; Cohen-Bendahan CCC, 2005, HORM BEHAV, V47, P230, DOI 10.1016/j.yhbeh.2004.10.006; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Dam K, 1999, DEV BRAIN RES, V116, P9, DOI 10.1016/S0165-3806(99)00067-X; Damgaard IN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003051; Davis JM, 1994, BIOL EFFECTS LOW LEV, P67; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dickerson SM, 2011, ENDOCRINOLOGY, V152, P581, DOI 10.1210/en.2010-1103; Dickerson SM, 2011, TOXICOL APPL PHARM, V252, P36, DOI 10.1016/j.taap.2011.01.012; Do RP, 2012, REPROD TOXICOLOGY; Doull J, 1996, DRUG METAB REV, V28, P285, DOI 10.3109/03602539608994006; Eisenberg ML, 2012, J UROLOGY, V187, P594, DOI 10.1016/j.juro.2011.10.041; Eisenberg ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018973; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; ERIKSSON P, 1993, TOXICOLOGY, V77, P21, DOI 10.1016/0300-483X(93)90134-E; ERIKSSON P, 1992, BRAIN RES, V582, P277, DOI 10.1016/0006-8993(92)90144-X; ERIKSSON P, 1990, NEUROTOXICOLOGY, V11, P345; Escriva H, 2004, ESSAYS BIOCHEM, V40, P11; FDA US, 2010, END DISR KNOWL BAS; Federal Institute for Risk Assessment (BfR), 2009, WORKSH HOST GERM FED; FELDBERG D, 1994, FERTIL STERIL, V62, P343; Fraud IFH, 2004, TOXICOLOGY, V202, P1; Gameiro CM, 2010, MATURITAS, V67, P316, DOI 10.1016/j.maturitas.2010.08.003; GANDELMAN R, 1977, NATURE, V266, P722, DOI 10.1038/266722a0; Geens T, 2011, INT J HYG ENVIR HEAL, V214, P339, DOI 10.1016/j.ijheh.2011.04.005; Gilbert ME, 2012, NEUROTOXICOLOGY, V33, P842, DOI 10.1016/j.neuro.2011.11.005; Godfrey K M, 2001, Public Health Nutr, V4, P611; Goodman J, 2009, CRIT REV TOXICOL, V39, P1, DOI 10.3109/10408440903279946; Goodman JE, 2010, REGUL TOXICOL PHARM, V58, P79, DOI 10.1016/j.yrtph.2010.04.008; Goodman JE, 2006, CRIT REV TOXICOL, V36, P387, DOI 10.1080/10408440600758317; Grandjean P, 2011, EPIDEMIOLOGY, V22, P410, DOI 10.1097/EDE.0b013e318212fab9; Grun F, 2006, MOL ENDOCRINOL, V20, P2141, DOI 10.1210/me.2005-0367; Guillette LJ, 2006, ENVIRON HEALTH PERSP, V114, P9, DOI 10.1289/ehp.8045; Guo-Ross SX, 2007, TOXICOL SCI, V100, P118, DOI 10.1093/toxsci/kfm195; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Hamlin HJ, 2011, BIRTH DEFECTS RES C, V93, P19, DOI 10.1002/bdrc.20202; Hanson MA, 2008, BASIC CLIN PHARMACOL, V102, P90, DOI 10.1111/j.1742-7843.2007.00186.x; Harvey HA, 1997, CANCER, V80, P1646, DOI 10.1002/(SICI)1097-0142(19971015)80:8+&lt;1646::AID-CNCR14&gt;3.3.CO;2-M; Harvey PW, 2002, J APPL TOXICOL, V22, P241, DOI 10.1002/jat.854; Haseman JK, 2001, TOXICOL SCI, V61, P201, DOI 10.1093/toxsci/61.2.201; Hatch EE, 2001, CANCER CAUSE CONTROL, V12, P837, DOI 10.1023/A:1012229112696; Hatch EE, 2010, INT J ANDROL, V33, P324, DOI 10.1111/j.1365-2605.2009.01035.x; Hau M, 2007, BIOESSAYS, V29, P133, DOI 10.1002/bies.20524; Hayes TB, 2011, EMERG TOP ECOTOXICOL, V3, P301, DOI 10.1007/978-0-387-89432-4_10; Hayes TB, 2005, INTEGR COMP BIOL, V45, P321, DOI 10.1093/icb/45.2.321; Hegstad M, 2012, INSIDE EPA 0717; Hegstad M, 2012, INSIDE EPA 0718; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hsieh MH, 2012, HUM REPROD, V27, P1577, DOI 10.1093/humrep/des087; IPCS (International Programme on Chemical Safety), 2004, IPCS RISK ASS TERM; Jakubowski M, 2011, INT J OCCUP MED ENV, V24, P1, DOI 10.2478/s13382-011-0009-z; JOHANSSON U, 1995, EUR J PHARM-ENVIRON, V293, P159, DOI 10.1016/S0014-2999(05)80008-1; Johansson U, 1996, ENVIRON TOXICOL PHAR, V2, P307, DOI 10.1016/S1382-6689(96)00062-2; Johnson Paula D, 2002, ILAR J, V43, P202; Jones KA, 1996, HDB ENDOCRINOLOGY, P1; Kamrin MA, 2007, INT J TOXICOL, V26, P13, DOI 10.1080/10915810601117968; Karaman S, 2011, FOOD CHEM TOXICOL, V49, P3192, DOI 10.1016/j.fct.2011.08.025; Kato K, 2011, ENV SCI TECHNOLOGY; Kaufman RH, 2000, OBSTET GYNECOL, V96, P483, DOI 10.1016/S0029-7844(00)00959-5; Kendig EL, 2010, INT J TOXICOL, V29, P235, DOI 10.1177/1091581810363012; Kennel P, 2003, ARCH TOXICOL, V77, P487, DOI 10.1007/s00204-003-0476-5; Kim HH, 2007, J REPROD DEVELOP, V53, P465, DOI 10.1262/jrd.18134; Kirchner S, 2010, MOL ENDOCRINOL, V24, P526, DOI 10.1210/me.2009-0261; Koch T, 2006, SOC SCI MED, V63, P271, DOI 10.1016/j.socscimed.2005.12.006; Kohlerova E, 2004, J VET MED A, V51, P209, DOI 10.1111/j.1439-0442.2004.00634.x; Korrick SA, 2011, ENVIRON HEALTH PERSP, V119, P1339, DOI 10.1289/ehp.1003102; Kortenkamp A., 2011, STATE ART ASSESSMENT; Krimsky S, 2005, AM J PUBLIC HEALTH, V95, pS129, DOI 10.2105/AJPH.2004.044727; Laclaustra M, 2010, ATHEROSCLEROSIS, V210, P643, DOI 10.1016/j.atherosclerosis.2010.01.005; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee DH, 2010, ENVIRON HEALTH PERSP, V118, P1235, DOI 10.1289/ehp.0901480; Kim SK, 2007, ENVIRON TOXICOL, V22, P449, DOI 10.1002/tox.20280; Li EZ, 2011, CELL BIOL INT, V35, P305, DOI 10.1042/CBI20100566; Linkov I, 2009, SCI TOTAL ENVIRON, V407, P5199, DOI 10.1016/j.scitotenv.2009.05.004; Lippert C, 2003, LIFE SCI, V72, P877, DOI 10.1016/S0024-3205(02)02305-6; Loehlin JC, 2000, BEHAV GENET, V30, P19, DOI 10.1023/A:1002082325784; Lummaa V, 2007, P NATL ACAD SCI USA, V104, P10915, DOI 10.1073/pnas.0605875104; Lyons G, 2006, ENVIRON HEALTH PERSP, V114, P142, DOI 10.1289/ehp.8070; MacLeod DJ, 2010, INT J ANDROL, V33, P279, DOI 10.1111/j.1365-2605.2009.01005.x; Maffini MV, 2011, COMPR REV FOOD SCI F, V10, P321, DOI 10.1111/j.1541-4337.2011.00165.x; Magyar K, 2011, INT REV NEUROBIOL, V100, P65, DOI 10.1016/B978-0-12-386467-3.00004-2; Mallor F, 2008, RISK ANAL, V28, P1003, DOI 10.1111/j.1539-6924.2008.01098.x; Marty MS, 2011, TOXICOL SCI, V120, pS93, DOI 10.1093/toxsci/kfq329; Mattson MP, 2010, HORMESIS: A REVOLUTION IN BIOLOGY, TOXICOLOGY AND MEDICINE, P1, DOI 10.1007/978-1-60761-495-1_1; MAY M, 1967, MOL PHARMACOL, V3, P28; McCarthy MM, 2009, HORM BEHAV, V55, P655, DOI 10.1016/j.yhbeh.2009.02.012; McEwen GN, 2006, ENVIRON HEALTH PERSP, V114, pA19; McEwen Jr GN, 2006, ENVIRON HEALTH PERSP, V114, pA; McLachlan JA, 2001, APMIS, V109, P263, DOI 10.1034/j.1600-0463.2001.d01-119.x; McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2; Meeker JD, 2009, SCI TOTAL ENVIRON, V407, P3425, DOI 10.1016/j.scitotenv.2009.01.030; Melnick Ronald, 2002, Environmental Health Perspectives, V110, P427; Mendiola J, 2011, ENVIRON HEALTH PERSP, V119, P958, DOI 10.1289/ehp.1103421; Monti JM, 2008, PROG BRAIN RES, V172, P625, DOI 10.1016/S0079-6123(08)00929-1; Moreira FA, 2010, CURR TOP BEHAV NEURO, V2, P429, DOI 10.1007/7854_2009_16; Mushak P, 2007, ENVIRON HEALTH PERSP, V115, P500, DOI 10.1289/ehp.9616; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; NEEDLEMAN HL, 1990, ENVIRON HEALTH PERSP, V86, P183, DOI 10.2307/3430952; NTP, 2012, NTP STUD REP LONG TE; Nucera C, 2010, J CELL MOL MED, V14, P2417, DOI 10.1111/j.1582-4934.2009.00947.x; Nussey S, 2001, PRINCIPLES ENDOCRINO; OECD, 1995, OECD GUID TEST CHEM; Owen GI, 2000, CELL MOL LIFE SCI, V57, P809, DOI 10.1007/s000180050043; Palanza P, 1999, PHARMACOL BIOCHEM BE, V64, P665, DOI 10.1016/S0091-3057(99)00151-3; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Patisaul HB, 2012, J BIOCH MOL TOXICOLO; Penza M, 2011, TOXICOL APPL PHARM, V255, P65, DOI 10.1016/j.taap.2011.05.017; Perez-Campos EF, 2010, DRUGS, V70, P681, DOI 10.2165/11536320-000000000-00000; Pierik FH, 2004, ENVIRON HEALTH PERSP, V112, P1570, DOI 10.1289/ehp.7234; PLOTKIN D, 1978, JAMA-J AM MED ASSOC, V240, P2644, DOI 10.1001/jama.240.24.2644; Reif DM, 2010, ENVIRON HEALTH PERSP, V118, P1714, DOI 10.1289/ehp.1002180; Rhomberg LR, 2011, CRIT REV TOXICOL, V41, P555, DOI 10.3109/10408444.2011.560140; Rhomberg LR, 2012, REGUL TOXICOL PHARM, V64, P130, DOI 10.1016/j.yrtph.2012.06.015; Roeleveld N, 2008, CURR OPIN OBSTET GYN, V20, P229, DOI 10.1097/GCO.0b013e3282fcc334; Rose RJ, 2002, PSYCHOL SCI, V13, P263, DOI 10.1111/1467-9280.00448; Salama J, 2003, ENVIRON HEALTH PERSP, V111, P1278, DOI 10.1289/ehp.6126; Schulkin J, 2011, BRAIN RES, V1392, P27, DOI 10.1016/j.brainres.2011.03.055; Schulz KM, 2009, HORM BEHAV, V55, P597, DOI 10.1016/j.yhbeh.2009.03.010; Seeger H, 2004, MATURITAS, V49, P235, DOI 10.1016/j.maturitas.2004.02.004; Sharpe RM, 2005, ENVIRON HEALTH PERSP, V113, pA504; Shelby MD, 2008, NTP CERHR MON; Simerly R B, 1989, Brain Res Mol Brain Res, V6, P297; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Skarda J, 2003, J VET MED A, V50, P204, DOI 10.1046/j.1439-0442.2003.00526.x; Slovic P, 1997, HUM EXP TOXICOL, V16, P289; Solomon KR, 2008, CRIT REV TOXICOL, V38, P721, DOI 10.1080/10408440802116496 ; Song X, 1997, TOXICOL APPL PHARM, V145, P158, DOI 10.1006/taap.1997.8171; Sonnenschein C, 1999, SOC CELLS CANC CONTR; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Soto A M, 1999, J Med Food, V2, P139, DOI 10.1089/jmf.1999.2.139; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Stillerman KP, 2008, REPROD SCI, V15, P631, DOI 10.1177/1933719108322436; Swan SH, 2006, ENVIRON HEALTH PERSP, V114, pA88; Swan SH, 2010, INT J ANDROL, V33, P259, DOI 10.1111/j.1365-2605.2009.01019.x; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; Tetel MJ, 2009, FRONT NEUROENDOCRIN, V30, P328, DOI 10.1016/j.yfrne.2009.04.008; Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109; Thayer KA, 2005, ENVIRON HEALTH PERSP, V113, P1271, DOI 10.1289/eph.7811; Thorup J, 2006, J UROLOGY, V176, P734, DOI 10.1016/j.juro.2006.03.042; Trichopoulos D, 1990, Epidemiology, V1, P95; Tweedale T, 2010, ENVIRON HEALTH PERSP, V118, pA194, DOI 10.1289/ehp.0901755; Tweedale T., 2010, ENV HLTH PERSPECTIVE, V118; Tyl RW, 1999, REGUL TOXICOL PHARM, V30, P81, DOI 10.1006/rtph.1999.1343; Tyl RW, 2010, BIRTH DEFECTS RES C, V90, P99, DOI 10.1002/bdrc.20176; Tyl RW, 2009, ENVIRON HEALTH PERSP, V117, P1644, DOI 10.1289/ehp.0900893; US EPA (Environmental Protection Agency), 2012, INT RISK INF SYST IR; US FDA, 2010, UPD BISPH A BPA US F; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; VELDHUIS JD, 1979, JAMA-J AM MED ASSOC, V241, P2506, DOI 10.1001/jama.241.23.2506; vom Saal F S, 1980, Science, V208, P597, DOI 10.1126/science.7367881; VOMSAAL FS, 1978, BIOL REPROD, V19, P842, DOI 10.1095/biolreprod19.4.842; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; VOMSAAL FS, 1990, BIOL REPROD, V43, P751, DOI 10.1095/biolreprod43.5.751; VOMSAAL FS, 1995, TOXICOL LETT, V77, P343, DOI 10.1016/0378-4274(95)03316-5; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; vom Saal FS, 2010, TOXICOL SCI, V115, P612, DOI 10.1093/toxsci/kfq048; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; vom Saal FS, 2010, ENVIRON HEALTH PERSP, V118, pA60, DOI 10.1289/ehp.0901495; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; WALLACH HW, 1979, JAMA-J AM MED ASSOC, V242, P27, DOI 10.1001/jama.242.1.27; Wallen K, 2009, HORM BEHAV, V55, P561, DOI 10.1016/j.yhbeh.2009.03.009; Watson CS, 2011, J STEROID BIOCHEM, V127, P44, DOI 10.1016/j.jsbmb.2011.01.015; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Weed DL, 2005, RISK ANAL, V25, P1545, DOI 10.1111/j.1539-6925.2005.00699.x; WEISS B, 1988, TRENDS PHARMACOL SCI, V9, P59, DOI 10.1016/0165-6147(88)90118-6; Weiss B, 2006, ENVIRON HEALTH PERSP, V114, pA399; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Weltje L, 2005, HUM EXP TOXICOL, V24, P431, DOI 10.1191/0960327105ht551oa; Wend Korinna, 2012, Front Endocrinol (Lausanne), V3, P19, DOI 10.3389/fendo.2012.00019; Wickerham EL, 2012, ENVIRON INT, V47, P80, DOI 10.1016/j.envint.2012.06.007; Witorsch RJ, 2002, REGUL TOXICOL PHARM, V36, P118, DOI 10.1006/rtph.2002.1564; Witorsch RJ, 2002, FOOD CHEM TOXICOL, V40, P905, DOI 10.1016/S0278-6915(02)00069-8; Woodruff TJ, 2011, ENVIRON HEALTH PERSP, V119, P878, DOI 10.1289/ehp.1002727; Yamasaki K, 2012, FOOD CHEM TOXICOL, V50, P2635, DOI 10.1016/j.fct.2012.05.035; Ye XY, 2011, ENVIRON HEALTH PERSP, V119, P983, DOI 10.1289/ehp.1002701; Yon JM, 2007, J REPROD DEVELOP, V53, P1007, DOI 10.1262/jrd.19032; York RG, 2010, TOXICOLOGY, V271, P64, DOI 10.1016/j.tox.2010.03.005; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958; Zoeller RT, 2004, J NEUROENDOCRINOL, V16, P809, DOI 10.1111/j.1365-2826.2004.01243.x; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422; Zuo ZH, 2011, ENVIRON TOXICOL, V26, P79, DOI 10.1002/tox.2053121617PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLJULDiscipline: Reproductive Biology; Toxicology152MG</notes>
    <keywords>Adaptive effect; anogenital distance; ATHEROSCLEROSIS; BIOLOGY; BISPHENOL-A EXPOSURE; BPA; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHEMICALS; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Epidemiology; Flare; FOOD; GOOD LABORATORY PRACTICES; Hormesis; HUMAN EXPOSURE; HUMANS; IMPACT; NONMONOTONIC DOSE-RESPONSES; NUCLEAR RECEPTOR SUPERFAMILY; OF-EVIDENCE ANALYSIS; Organizational; ORGANIZATIONAL-ACTIVATIONAL HYPOTHESIS; PRENATAL PHTHALATE EXPOSURE; PRINCIPLES; RISK; Risk assessment; RISK-ASSESSMENT; toxicology; Weight of evidence</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1</startpage>
    <endpage>15</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <volume>38</volume>
    <abstract>For years, scientists from various disciplines have studied the effects of endocrine disrupting chemicals (EDCs) on the health and wellbeing of humans and wildlife. Some studies have specifically focused on the effects of low doses, i.e. those in the range that are thought to be safe for humans and/or animals. Others have focused on the existence of non-monotonic dose response curves. These concepts challenge the way that chemical risk assessment is performed for EDCs. Continued discussions have clarified exactly what controversies and challenges remain. We address several of these issues, including why the study and regulation of EDCs should incorporate endocrine principles; what level of consensus there is for low dose effects; challenges to our understanding of non-monotonicity; and whether EDCs have been demonstrated to produce adverse effects. This discussion should result in a better understanding of these issues, and allow for additional dialog on their impact on risk assessment. (c) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000319535200001</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>79</id>
    <title>Non-Monotonic Dose Responses in Studies of Endocrine Disrupting Chemicals: Bisphenol A As A Case Study</title>
    <authors>Vandenberg,L.N.</authors>
    <availability>[Vandenberg, Laura N.] Univ Massachusetts, Amherst, MA 01003 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleVandenberg, LN (reprint author), Univ Massachusetts, Sch Publ Hlth, Div Environm Hlth Sci, 149B Goessmann,686 North Pleasant St, Amherst, MA 01003 USAlvandenberg@schoolph.umass.eduAngle BM, 2013, REPROD TOXI IN PRESS; Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Birnbaum LS, 2012, ENVIRON HEALTH PERSP, V120, pA143, DOI 10.1289/ehp.1205179; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Braun JM, 2011, CURR OPIN PEDIATR, V23, P233, DOI 10.1097/MOP.0b013e3283445675; Bruchovsky N, 1975, Vitam Horm, V33, P61; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P353, DOI 10.1080/20014091111730; Calabrese EJ, 2001, TRENDS PHARMACOL SCI, V22, P285, DOI 10.1016/S0165-6147(00)01719-3; Calabrese EJ, 2001, TOXICOL SCI, V62, P330, DOI 10.1093/toxsci/62.2.330; Calabrese EJ, 2003, NATURE, V421, P691, DOI 10.1038/421691a; Calabrese EJ, 2007, TOXICOL APPL PHARM, V222, P122, DOI 10.1016/j.taap.2007.02.015; Cook R, 2006, ENVIRON HEALTH PERSP, V114, P1631, DOI 10.1289/ehp.8606; Davis JM, 1994, BIOL EFFECTS LOW LEV, P67; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Do RP, 2012, REPROD TOXICOL, V34, P614, DOI 10.1016/j.reprotox.2012.09.006; Dominguez MA, 2008, REPROD TOXICOL, V25, P420, DOI 10.1016/j.reprotox.2008.05.059; Fenner-Crisp PA, 2000, TOXICOL PATHOL, V28, P438, DOI 10.1177/019262330002800313; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Geens T, 2012, FOOD CHEM TOXICOL, V50, P3725, DOI 10.1016/j.fct.2012.07.059; Harvey HA, 1997, CANCER, V80, P1646, DOI 10.1002/(SICI)1097-0142(19971015)80:8+&lt;1646::AID-CNCR14&gt;3.3.CO;2-M; Ismail A, 2005, IUBMB LIFE, V57, P483, DOI 10.1080/15216540500147163; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Jeyakumar M, 2008, BIOCHEMISTRY-US, V47, P7465, DOI 10.1021/bi800393u; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Kim K, 2007, J TOXICOL ENV HEAL A, V70, P1288, DOI 10.1080/15287390701434216; Knudsen Thomas, 2013, Methods Mol Biol, V947, P343, DOI 10.1007/978-1-62703-131-8_26; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kohn MC, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290113; LESSER B, 1974, BIOCHEM J, V142, P429; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Lucier GW, 1997, REGUL TOXICOL PHARM, V26, P34, DOI 10.1006/rtph.1997.1114; Maffini M, 2008, J STEROID BIOCHEM, V108, P32, DOI 10.1016/j.jsbmb.2007.05.034; Mahadevan B, 2011, ENVIRON MOL MUTAGEN, V52, P339, DOI 10.1002/em.20653; Marmugi A, 2012, HEPATOLOGY, V55, P395, DOI 10.1002/hep.24685; McLachlan JA, 2001, APMIS, V109, P263, DOI 10.1034/j.1600-0463.2001.d01-119.x; McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2; Melnick Ronald, 2002, Environmental Health Perspectives, V110, P427; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Okada M, 2008, BIOMED RES-TOKYO, V29, P163, DOI 10.2220/biomedres.29.163; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Patisaul H., 2012, J BIOCHEM MOL TOXIC, V27, P124; Reif DM, 2010, ENVIRON HEALTH PERSP, V118, P1714, DOI 10.1289/ehp.1002180; Rhomberg LR, 2012, REGUL TOXICOL PHARM, V64, P130, DOI 10.1016/j.yrtph.2012.06.015; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Schug TT, 2013, GREEN CHEM, V15, P181, DOI 10.1039/c2gc35055f; Sheehan DM, 2006, ENVIRON RES, V100, P93, DOI 10.1016/j.envres.2005.09.002; Sheehan DM, 1997, RISK POLICY REP, V4, P31; Sheng ZG, 2011, ENVIRON HEALTH PERSP, V119, P1775, DOI 10.1289/ehp.1103781; Shioda T, 2006, P NATL ACAD SCI USA, V103, P12033, DOI 10.1073/pnas.0605341103; Shukla SJ, 2010, DRUG DISCOV TODAY, V15, P997, DOI 10.1016/j.drudis.2010.07.007; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Soto A M, 1999, J Med Food, V2, P139, DOI 10.1089/jmf.1999.2.139; STORMSHAK F, 1976, ENDOCRINOLOGY, V99, P1501; Sun HM, 2012, AAPS J, V14, P473, DOI 10.1208/s12248-012-9358-1; Teeguarden JG, 2012, TOXICOL SCI, V125, P321, DOI 10.1093/toxsci/kfr275; Tilghman SL, 2010, STEROIDS, V75, P520, DOI 10.1016/j.steroids.2010.05.004; Tyl RW, 2009, ENVIRON HEALTH PERSP, V117, P1644, DOI 10.1289/ehp.0900893; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg Laura N., 2013, Reviews on Environmental Health, V28, P37, DOI 10.1515/reveh-2012-0034; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2013, REPROD TOXICOL, V38, P1, DOI 10.1016/j.reprotox.2013.02.002; Vinas P, 2013, ENV HLTH PERSPECT, V121, P352; vom Saal FS, 1998, FORUM APPL RES PUBLI, V13, P11; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; vom Saal FS, 2010, TOXICOL SCI, V115, P612, DOI 10.1093/toxsci/kfq048; vom Saal FS, 2010, ENVIRON HEALTH PERSP, V118, pA60, DOI 10.1289/ehp.0901495; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; Wang S, 2012, J STEROID BIOCHEM, V128, P98, DOI 10.1016/j.jsbmb.2011.11.009; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; World Health Organization and United Nations Environment Programme, 2013, STAT SCI END DISR CH; Wu S, 2012, FOOD CHEM TOXICOL, V50, P3100, DOI 10.1016/j.fct.2012.06.029; Xu XH, 2010, HORM BEHAV, V58, P326, DOI 10.1016/j.yhbeh.2010.02.012; Ye XY, 2013, ENVIRON HEALTH PERSP, V121, P283, DOI 10.1289/ehp.1206093; Zoeller RT, 2012, ENDOCRINOLOGY, V153, P4097, DOI 10.1210/en.2012-1422840INT DOSE-RESPONSE SOCAMHERSTUNIV MASSACHUSETTS SPH, MORRILL SCI CTR 1, N344, 639 N PLEASANT ST, AMHERST, MA 01003-9298 USADOSE-RESPONSEDiscipline: Pharmacology &amp; Pharmacy; Radiology, Nuclear Medicine &amp; Medical Imaging; ToxicologyAH9RG</notes>
    <keywords>biphasic; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CANCER-CELLS; CELL; CELL-PROLIFERATION; CELLS; CHEMICALS; DISRUPTING CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; environment; ENVIRONMENTAL CHEMICALS; ESTROGEN-RECEPTOR; EXPOSURE; extrapolation; FOOD; FUTURE-DIRECTIONS; HORMONAL-THERAPY; In vitro; IN-VITRO; Interaction; LIGAND; mechanism; MECHANISMS; molecular mechanism; MOLECULAR-MECHANISMS; NOAEL; PERINATAL EXPOSURE; POPULATION; PUBLIC-HEALTH; RECEPTOR; reference dose; RESPONSES; RISK; RISK-ASSESSMENT; toxicology; U-shaped; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>259</startpage>
    <endpage>276</endpage>
    <journalfull>Dose-Response</journalfull>
    <issue>2</issue>
    <volume>12</volume>
    <abstract>Non-monotonic dose response curves (NMDRCs) have been demonstrated for natural hormones and endocrine disrupting chemicals (EDCs) in a variety of biological systems including cultured cells, whole organ cultures, laboratory animals and human populations. The mechanisms responsible for these NMDRCs are well known, typically related to the interactions between the ligand (hormone or EDC) and a hormone receptor. Although there are hundreds of examples of NMDRCs in the EDC literature, there are claims that they are not 'common enough' to influence the use of high-to-low dose extrapolations in risk assessments. Here, we chose bisphenol A (BPA), a well-studied EDC, to assess the frequency of non-monotonic responses. Our results indicate that NMDRCs are common in the BPA literature, occurring in greater than 20% of all experiments and in at least one endpoint in more than 30% of all studies we examined. We also analyzed the types of endpoints that produce NMDRCs in vitro and factors related to study design that influence the ability to detect these kinds of responses. Taken together, these results provide strong evidence for NMDRCs in the EDC literature, specifically for BPA, and question the current risk assessment practice where 'safe' low doses are predicted from high dose exposures</abstract>
    <url>WOS:000336478900006</url>
    <isbnorissn>1559-3258</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>87</id>
    <title>You are what you eat, and so are your children: the impact of micronutrients on the epigenetic programming of offspring</title>
    <authors>Vanhees,K.; Vonhogen,I.G.C.; van Schooten,F.J.; Godschalk,R.W.L.</authors>
    <availability>[Vanhees, Kimberly; Vonhogen, Indira G. C.; van Schooten, Frederik J.; Godschalk, Roger W. L.] Maastricht Univ, Maastricht UMC, Sch Nutr Toxicol &amp; Metab NUTRIM, Dept Toxicol, NL-6200 MD Maastricht, Netherlands.</availability>
    <date>2014</date>
    <notes>JEnglishReviewVanhees, K (reprint author), Maastricht Univ, Maastricht UMC, Sch Nutr Toxicol &amp; Metab NUTRIM, Dept Toxicol, POB 616, NL-6200 MD Maastricht, Netherlandskimberly.vanhees@maastrichtuniversity.nlAherne SA, 2002, NUTRITION, V18, P75, DOI 10.1016/S0899-9007(01)00695-5; Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Anetor JI, 2010, BIOL TRACE ELEM RES, V136, P157, DOI 10.1007/s12011-009-8534-3; [Anonymous], 1991, LANCET, V338, P131; ARTS IC, 2005, AM J CLIN NUTR, V81, P317; Atkinson Stuart P, 2007, Expert Rev Mol Med, V9, P1; Barker D J, 1997, Rev Reprod, V2, P105, DOI 10.1530/ror.0.0020105; BARKER DJP, 1991, CIBA F SYMP, V156, P3; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; Bekkers MB, 2011, EUR RESPIR J, V39, P1468; Bernal AJ, 2010, BIRTH DEFECTS RES A, V88, P938, DOI 10.1002/bdra.20685; Bielawski DM, 2002, ALCOHOL CLIN EXP RES, V26, P347, DOI 10.1111/j.1530-0277.2002.tb02544.x; Roseboom T J, 2001, Twin Res, V4, P293, DOI 10.1375/1369052012605; Bolanos JP, 2009, ADV DRUG DELIVER REV, V61, P1299, DOI 10.1016/j.addr.2009.05.009; Boots AW, 2011, CLIN NUTR, V30, P506, DOI 10.1016/j.clnu.2011.01.010; Botto LD, 2005, BRIT MED J, V330, P571, DOI 10.1136/bmj.38336.664352.82; Carlsen K, 2013, EUR J CLIN NUTR, V67, P978, DOI 10.1038/ejcn.2013.108; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Chatzi L, 2012, PUBLIC HEALTH NUTR, V15, P1728, DOI 10.1017/S1368980012000067; Chaudhuri A, 2005, MED HYPOTHESES, V64, P608, DOI 10.1016/j.mehy.2004.06.022; Chen CS, 2006, CARCINOGENESIS, V27, P1358, DOI 10.1093/carcin/bgi325; Christensen Brock C, 2011, Front Genet, V2, P84, DOI 10.3389/fgene.2011.00084; Christian P, 2010, J NUTR, V140, P437, DOI 10.3945/jn.109.116327; Ciolino HP, 1999, BIOCHEM J, V340, P715, DOI 10.1042/0264-6021:3400715; Cornish KM, 2002, FREE RADICAL BIO MED, V33, P63, DOI 10.1016/S0891-5849(02)00843-2; COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027; Crider KS, 2011, NUTRIENTS, V3, P370, DOI 10.3390/nu3030370; de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058; Deal RB, 2010, SCIENCE, V328, P1161, DOI 10.1126/science.1186777; de Rooij SR, 2006, DIABETOLOGIA, V49, P637, DOI 10.1007/s00125-005-0136-9; De Waard WJ, 2008, FOOD ADDIT CONTAM A, V25, P779, DOI 10.1080/02652030701798880; Dion MF, 2007, SCIENCE, V315, P1405, DOI 10.1126/science.1134053; Doherty Leo F., 2010, Hormones &amp; Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Dugan Laura L, 2005, Sci Aging Knowledge Environ, V2005, ppe20, DOI 10.1126/sageke.2005.26.pe20; Dumortier O, 2007, DIABETOLOGIA, V50, P2495, DOI 10.1007/s00125-007-0811-0; Dunn GA, 2011, ENDOCRINOLOGY, V152, P2228, DOI 10.1210/en.2010-1461; Egert S, 2008, J NUTR, V138, P1615; Egert S, 2011, ADV NUTR, V2, P8, DOI [10.3945/an.110.000026., 10.3945/an.110.000026]; Erdman Jr JW, 2007, J NUTR, V137, P718; Espin JC, 2007, PHYTOCHEMISTRY, V68, P2986, DOI 10.1016/j.phytochem.2007.09.014; Ferrali M, 1997, FEBS LETT, V416, P123, DOI 10.1016/S0014-5793(97)01182-4; Franco MD, 2009, LIFE SCI, V85, P327, DOI 10.1016/j.lfs.2009.06.013; Ganesan S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-131; Garofano A, 1997, DIABETOLOGIA, V40, P1231, DOI 10.1007/s001250050812; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107; George LA, 2012, AM J PHYSIOL-REG I, V302, pR795, DOI 10.1152/ajpregu.00241.2011; Golbidi S, 2012, EXP DIABETES RES, DOI 10.1155/2012/941868; Gordon L, 2011, EPIGENETICS-US, V6, P579, DOI 10.4161/epi.6.5.15072; Hanna IH, 2000, CANCER RES, V60, P3440; Hanwell HEC, 2011, BBA-MOL BASIS DIS, V1812, P202, DOI 10.1016/j.bbadis.2010.07.017; Harwood M, 2007, FOOD CHEM TOXICOL, V45, P2179, DOI 10.1016/j.fct.2007.05.015; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Hensley K, 1996, ANN NY ACAD SCI, V786, P120, DOI 10.1111/j.1749-6632.1996.tb39057.x; Heo HJ, 2004, J AGR FOOD CHEM, V52, P7514, DOI 10.1021/jf049243r; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hirayama F, 2010, MOL NUTR FOOD RES, V54, P909, DOI 10.1002/mnfr.200900316; Holliday R, 2006, EPIGENETICS-US, V1, P76; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Holzgreve W, 2012, J MATERN-FETAL NEO M, V25, P1529, DOI 10.3109/14767058.2011.648672; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; Inoue T, 2009, BIOMED RES-TOKYO, V30, P325, DOI 10.2220/biomedres.30.325; Jablonka E, 2007, BEHAV BRAIN SCI, V30, P353, DOI 10.1017/S0140525X07002221; Jablonka E, 2002, ANN NY ACAD SCI, V981, P82; Javaid MK, 2006, LANCET, V367, P36, DOI 10.1016/S0140-6736(06)67922-1; Jones AP, 2012, PEDIATRICS, V130, pE1128, DOI 10.1542/peds.2012-1172; Jou MY, 2012, PEDIATR RES, V71, P228, DOI 10.1038/pr.2011.44; Jou MY, 2010, J NUTR, V140, P1621, DOI 10.3945/jn.109.119677; Kaati G, 2007, EUR J HUM GENET, V15, P784, DOI 10.1038/sj.ejhg.5201832; Khan TH, 2006, J PHARM PHARMACOL, V58, P1655, DOI 10.1211/jpp.58.12.0013; Kiefte-de Jong JC, 2012, J NUTR, V142, P731, DOI 10.3945/jn.111.154948; Kitagawa S, 2004, CHEM PHARM BULL, V52, P999, DOI 10.1248/cpb.52.999; Lachili B, 2001, BIOL TRACE ELEM RES, V83, P103, DOI 10.1385/BTER:83:2:103; Langie SAS, 2010, MUTAT RES-GEN TOX EN, V695, P75, DOI 10.1016/j.mrgentox.2009.12.005; Lau ATY, 2008, J CELL BIOCHEM, V104, P657, DOI 10.1002/jcb.21655; Li YP, 2011, J HYPERTENS, V29, P1085, DOI 10.1097/HJH.0b013e328345d969; Liang C, 2009, BIRTH DEFECTS RES B, V86, P377, DOI 10.1002/bdrb.20206; Linschooten JO, 2009, MUTAT RES-FUND MOL M, V667, P70, DOI 10.1016/j.mrfmmm.2008.12.014; Loke WM, 2010, ARTERIOSCL THROM VAS, V30, P749, DOI 10.1161/ATVBAHA.109.199687; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Ly A, 2011, CANCER RES, V71, P988, DOI 10.1158/0008-5472.CAN-10-2379; Maccani MA, 2009, AM J REPROD IMMUNOL, V62, P78, DOI 10.1111/j.1600-0897.2009.00716.x; Magdelijns FJH, 2011, PEDIATRICS, V128, pE135, DOI 10.1542/peds.2010-1690; Mahn K, 2005, FASEB J, V19, P1755, DOI 10.1096/fj.05-4008fje; Makaji E, 2011, INT J TOXICOL, V30, P216, DOI 10.1177/1091581810388307; Manach C, 2004, AM J CLIN NUTR, V79, P727; McKay Jill A, 2011, Front Genet, V2, P23, DOI 10.3389/fgene.2011.00023; McKay JA, 2011, GENES NUTR, V6, P189, DOI 10.1007/s12263-010-0199-1; McKay JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033290; McMillen IC, 2008, BASIC CLIN PHARMACOL, V102, P82, DOI [10.1111/j.1742-7843.2007.00188.x, 10.1111/j.1742-7843.2007.00188]; Mercer LD, 2005, BIOCHEM PHARMACOL, V69, P339, DOI 10.1016/j.bcp.2004.09.018; Miodini P, 1999, BRIT J CANCER, V80, P1150, DOI 10.1038/sj.bjc.6690479; Mistry HD, 2011, OXID MED CELL LONGEV, DOI 10.1155/2011/841749; Miyamoto N, 2011, INVEST OPHTH VIS SCI, V52, P1055, DOI 10.1167/iovs.10-5777; Moors S, 2006, ARCH TOXICOL, V80, P647, DOI 10.1007/s00204-006-0097-x; Muhammad S, 2009, J ALZHEIMERS DIS, V16, P775, DOI 10.3233/JAD-2009-0982; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Nakajima Y, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-8; Nelissen ECM, 2011, HUM REPROD UPDATE, V17, P397, DOI 10.1093/humupd/dmq052; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Oakes CC, 2003, P NATL ACAD SCI USA, V100, P1775, DOI 10.1073/pnas.0437971100; Ouko LA, 2009, ALCOHOL CLIN EXP RES, V33, P1615, DOI 10.1111/j.1530-0277.2009.00993.x; Padmavathi IJN, 2010, DIABETES, V59, P98, DOI 10.2337/db09-0779; Palacios R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004150; Pasquali MAD, 2010, REPROD TOXICOL, V30, P452, DOI 10.1016/j.reprotox.2010.05.085; Persad VL, 2002, CAN MED ASSOC J, V167, P241; Persson LA, 2012, JAMA-J AM MED ASSOC, V307, P2050, DOI 10.1001/jama.2012.4061; Picciano MF, 2009, AM J CLIN NUTR, V89, P663; Prentice AM, 2005, ARCH DIS CHILD, V90, P429, DOI 10.1136/adc.2004.059030; Qiu CF, 2011, DIABETES CARE, V34, P1564, DOI 10.2337/dc11-0135; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811; Reaven GM, 2011, MED CLIN N AM, V95, P875, DOI 10.1016/j.mcna.2011.06.002; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rexhaj E, 2011, AM J PHYSIOL-HEART C, V301, pH247, DOI 10.1152/ajpheart.01309.2010; Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Sartorius GA, 2010, HUM REPROD UPDATE, V16, P65, DOI 10.1093/humupd/dmp027; Schaible TD, 2011, HUM MOL GENET, V20, P1687, DOI 10.1093/hmg/ddr044; Schnorr CE, 2011, FOOD CHEM TOXICOL, V49, P2645, DOI 10.1016/j.fct.2011.07.010; Schroder-van der Elst JP, 1998, AM J PHYSIOL-ENDOC M, V274, pE253; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; Setchell KD, 1998, AM J CLIN NUTR S, V68, P1453; Sharland Eleanor, 2011, Aust Fam Physician, V40, P421; Shelke N, 2011, INT J FAMILY MED; Sie KKY, 2011, GUT, V60, P1687, DOI 10.1136/gut.2011.238782; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Skibola CF, 2000, FREE RADICAL BIO MED, V29, P375, DOI 10.1016/S0891-5849(00)00304-X; Soni MG, 2010, TOXICOL SCI, V118, P348, DOI 10.1093/toxsci/kfq293; Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845; Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P384; Szeto IMY, 2008, AM J PHYSIOL-REG I, V295, pR575, DOI 10.1152/ajpregu.90354.2008; Szyf M, 2009, BBA-GEN SUBJECTS, V1790, P878, DOI 10.1016/j.bbagen.2009.01.009; Szyf M, 2007, TOXICOL SCI, V100, P7, DOI 10.1093/toxsci/kfm177; Tabner Brian J., 2001, Current Topics in Medicinal Chemistry, V1, P507, DOI 10.2174/1568026013394822; Tieu K, 2003, IUBMB LIFE, V55, P329, DOI 10.1080/1521654032000114320; Touyz RM, 2004, BRAZ J MED BIOL RES, V37, P1263, DOI 10.1590/S0100-879X2004000800018; Tsutsui H, 2011, AM J PHYSIOL-HEART C, V301, pH2181, DOI 10.1152/ajpheart.00554.2011; Valsecchi AE, 2011, EUR J PHARMACOL, V650, P694, DOI 10.1016/j.ejphar.2010.10.060; Vanhees K, 2013, FREE RADICAL BIO MED, V57, P154, DOI 10.1016/j.freeradbiomed.2012.12.021; Vanhees K, 2011, FASEB J, V25, P797, DOI 10.1096/fj.10-172155; Vanhees K, 2011, TOXICOLOGY, V290, P350, DOI 10.1016/j.tox.2011.10.017; Vanhees K, 2012, MUTAGENESIS, V27, P445, DOI 10.1093/mutage/ges002; Venu L, 2004, EUR J ENDOCRINOL, V151, P287, DOI 10.1530/eje.0.1510287; Venu L, 2008, OBESITY, V16, P1270, DOI 10.1038/oby.2008.72; Verkasalo PK, 2001, BRIT J NUTR, V86, P415, DOI 10.1079/BJN2001424; Verona RI, 2003, ANNU REV CELL DEV BI, V19, P237, DOI 10.1146/annurev.cellbio.19.111401.092717; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83; Vom Saal Frederick S, 2012, Mol Cell Endocrinol, V354, P74, DOI 10.1016/j.mce.2012.01.001; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2008, INT J OBESITY, V32, P1373, DOI 10.1038/ijo.2008.100; Waterland RA, 2007, FASEB J, V21, P3380, DOI 10.1096/fj.07-8229com; Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y; Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y; Yang ZY, 2011, MATERN CHILD NUTR, V7, P19, DOI 10.1111/j.1740-8709.2011.00350.x; Yao LH, 2004, PLANT FOOD HUM NUTR, V59, P113, DOI 10.1007/s11130-004-0049-7; Yoshizumi Masanori, 2001, Journal of Medical Investigation, V48, P111602SPRINGER BASEL AGBASELPICASSOPLATZ 4, BASEL, 4052, SWITZERLANDCELL MOL LIFE SCIJANDiscipline: Biochemistry &amp; Molecular Biology; Cell Biology283CX</notes>
    <keywords>BETA-CELL MASS; BIOLOGY; BISPHENOL-A; CANCER; CARCINOGENESIS; CARDIOVASCULAR-DISEASE; CELL; CHILDREN; diabetes; DNA METHYLATION; epigenetics; FETAL; Fetal programming; Flavonoids; FOOD; heart; INSULIN-RESISTANCE; MAMMARY-CANCER RISK; Maternal/paternal effect; METABOLISM; METHYLATION; Micronutrients; NEURAL-TUBE DEFECTS; nutrition; Oxidative stress; POLYUNSATURATED FATTY-ACIDS; PREGNANCY; PRENATAL EXPOSURE; toxicology; Transgenerational inheritance; VITAMIN-A SUPPLEMENTATION; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>271</startpage>
    <endpage>285</endpage>
    <journalfull>Cellular and Molecular Life Sciences</journalfull>
    <issue>2</issue>
    <volume>71</volume>
    <abstract>The research field of fetal programming has developed tremendously over the years and increasing knowledge suggests that both maternal and paternal unbalanced diet can have long-lasting effects on the health of offspring. Studies implicate that macronutrients play an important role in fetal programming, although the importance of micronutrients is also becoming increasingly apparent. Folic acid and vitamins B2, B6 and B12 are essential for one-carbon metabolism and are involved in DNA methylation. They can therefore influence the programming of the offspring's epigenome. Also, other micronutrients such as vitamins A and C, iron, chromium, zinc and flavonoids play a role in fetal programming. Since it is estimated that approximately 78 % of pregnant women in the US take vitamin supplements during pregnancy, more attention should be given to the long-term effects of these supplements on offspring. In this review we address several different studies which illustrate that an unbalanced diet prior and during pregnancy, regarding the intake of micronutrients of both mother and father, can have long-lasting effects on the health of adult offspring</abstract>
    <url>WOS:000329223500005</url>
    <isbnorissn>1420-682X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>108</id>
    <title>A new treatment by dispersive liquid-liquid microextraction for the determination of parabens in human serum samples</title>
    <authors>Vela-Soria,F.; Ballesteros,O.; Rodriguez,I.; Zafra-Gomez,A.; Ballesteros,L.; Cela,R.; Navalon,A.</authors>
    <availability>[Vela-Soria, F.; Ballesteros, O.; Zafra-Gomez, A.; Ballesteros, L.; Navalon, A.] Univ Granada, Dept Analyt Chem, Res Grp Analyt Chem &amp; Life Sci, E-18071 Granada, Spain. [Rodriguez, I.; Cela, R.] Univ Santiago de Compostela, IIAA Inst Food Anal &amp; Res, Dept Analyt Chem Nutr &amp; Food Sci, Santiago De Compostela 15782, Spain.</availability>
    <date>2013</date>
    <notes>JEnglishArticleBallesteros, O (reprint author), Univ Granada, Dept Analyt Chem, Res Grp Analyt Chem &amp; Life Sci, Campus Fuentenueva, E-18071 Granada, Spainoballest@ugr.esAndersen FA, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810802548359; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Calafat AM, 2010, ENVIRON HEALTH PERSP, V118, P679, DOI 10.1289/ehp.0901560; Cashman AL, 2005, DERMATITIS, V16, P57, DOI 10.2310/6620.2005.05008; Cruz-Vera M, 2009, J CHROMATOGR A, V1216, P6459, DOI 10.1016/j.chroma.2009.07.040; Cunha SC, 2010, TALANTA, V83, P117, DOI 10.1016/j.talanta.2010.08.048; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2003, J APPL TOXICOL, V23, P43, DOI 10.1002/jat.886; Darbre PD, 2004, J APPL TOXICOL, V24, P5, DOI 10.1002/jat.958; El Hussein S, 2007, EXP DERMATOL, V16, P830, DOI 10.1111/j.1600-0625.2007.00625.x; Fang H, 2001, CHEM RES TOXICOL, V14, P280, DOI 10.1021/tx000208y; Farajzadeh MA, 2010, TALANTA, V81, P1360, DOI 10.1016/j.talanta.2010.02.035; Gonzalez-Casado A, 1996, J CHROMATOGR A, V726, P133; Han Y, 2010, CHROMATOGRAPHIA, V72, P351, DOI 10.1365/s10337-010-1646-2; Harville Heather M, 2007, Drug Metab Lett, V1, P17, DOI 10.2174/187231207779814300; Jain R, 2013, FOOD CHEM, V141, P436, DOI 10.1016/j.foodchem.2013.03.012; Janjua NR, 2007, ENVIRON SCI TECHNOL, V41, P5564, DOI 10.1021/es0628755; Jewell C, 2007, DRUG METAB DISPOS, V35, P2015, DOI 10.1124/dmd.107.015727; Kang KS, 2002, J VET MED SCI, V64, P227, DOI 10.1292/jvms.64.227; Kjaerstad MB, 2010, INT J ANDROL, V33, P425, DOI 10.1111/j.1365-2605.2009.01034.x; Li Y, 2010, INT J ENVIRON AN CH, V90, P880, DOI 10.1080/03067310903045455; Ma JP, 2012, CURR ANAL CHEM, V8, P78; Melwanki MB, 2009, TALANTA, V78, P618, DOI 10.1016/j.talanta.2008.12.021; Negreira N, 2010, ANAL BIOANAL CHEM, V398, P995, DOI 10.1007/s00216-010-4009-9; Oishi S, 2004, FOOD CHEM TOXICOL, V42, P1845, DOI 10.1016/j.fct.2004.06.015; Rezaee M, 2010, J SUPERCRIT FLUID, V55, P161, DOI 10.1016/j.supflu.2010.07.008; Sandanger TM, 2011, J EXPO SCI ENV EPID, V21, P595, DOI 10.1038/jes.2011.22; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; U.S. Food and Drug Administration Center for Drug Evaluation and Research, 2001, GUID IND BIOAN METH; Vo TTB, 2010, REPROD TOXICOL, V29, P306, DOI 10.1016/j.reprotox.2010.01.013; Vokel W, 2002, CHEM RES TOXICOL, V15, P1281, DOI 10.1021/tx025548t; Ye X, 2008, TALANTA, V76, P865, DOI 10.1016/j.talanta.2008.04.034; Ye XY, 2006, ENVIRON HEALTH PERSP, V114, P1843, DOI 10.1289/ehp.9413; Zgola-Grzeskowiak A, 2011, TRAC-TREND ANAL CHEM, V30, P1382, DOI 10.1016/j.trac.2011.04.014344SPRINGER HEIDELBERGHEIDELBERGTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANYANAL BIOANAL CHEMSEPDiscipline: Biochemistry &amp; Molecular Biology; Chemistry208CJ</notes>
    <keywords>BIOLOGY; BISPHENOL-A; breast cancer; BREAST-CANCER; BUTYL PARABEN; CANCER; CHROMATOGRAPHY-MASS SPECTROMETRY; Dispersive liquid-liquid microextraction; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL WATER; ESTERS; estrogenic activity; EXPOSURE; FOOD; Human serum analysis; Liquid chromatography-tandem mass spectrometry; MASS-SPECTROMETRY; P-HYDROXYBENZOIC ACID; PARABENS; RISK; SAMPLES; serum; Urine; VARIABILITY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>7259</startpage>
    <endpage>7267</endpage>
    <journalfull>Analytical and Bioanalytical Chemistry</journalfull>
    <issue>23</issue>
    <volume>405</volume>
    <abstract>Alkyl esters of p-hydroxybenzoic acid (parabens) are a family of compounds that have been in use since the 1920s as preservatives in cosmetic formulations, with one of the lowest rates of skin problems reported in dermatological patients. However, in the last few years, many scientific publications have demonstrated that parabens are weak endocrine disruptors, meaning that they can interfere with the function of endogenous hormones, increasing the risk of breast cancer. In the present work, a new sample treatment method is introduced based on dispersive liquid-liquid microextraction for the extraction of the most commonly used parabens (methyl-, ethyl-, propyl-, and butylparaben) from human serum samples followed by separation and quantification using ultrahigh performance liquid chromatography-tandem mass spectrometry. The method involves an enzymatic treatment to quantify the total content of parabens. The extraction parameters (solvent and disperser solvent, extractant and dispersant volume, pH of the sample, salt addition, and extraction time) were accurately optimized using multivariate optimization strategies. Ethylparaben ring C-13(6)-labeled was used as surrogate. Limits of quantification ranging from 0.2 to 0.7 ng mL(-1) and an interday variability (evaluated as relative standard deviations) from 3.8 to 11.9 % were obtained. The method was validated using matrix-matched calibration standard and a spike recovery assay. Recovery rates for spiked samples ranged from 96 to 106 %, and a good linearity up to concentrations of 100 ng mL(-1) was obtained. The method was satisfactorily applied for the determination of target compounds in human serum samples</abstract>
    <url>WOS:000323653400011</url>
    <isbnorissn>1618-2642</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>194</id>
    <title>Non-Genomic Effects of Xenoestrogen Mixtures</title>
    <authors>Vinas,R.; Jeng,Y.J.; Watson,C.S.</authors>
    <availability>[Vinas, Rene; Jeng, Yow-Jiun; Watson, Cheryl S.] Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX 77555 USA.</availability>
    <date>2012</date>
    <notes>JEnglishReviewWatson, CS (reprint author), Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX 77555 USArevinas@utmb.edu; yjeng@utmb.edu; cswatson@utmb.eduAdlercreutz H, 1999, AM J OBSTET GYNECOL, V180, P737, DOI 10.1016/S0002-9378(99)70281-4; Adlercreutz H, 1993, Scand J Clin Lab Invest Suppl, V215, P5; AHEL M, 1993, ENVIRON POLLUT, V79, P243, DOI 10.1016/0269-7491(93)90096-7; Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alyea RA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-59; Alyea RA, 2009, ENVIRON HEALTH PERSP, V117, P778, DOI 10.1289/ehp.0800026; Alyea RA, 2008, J NEUROCHEM, V106, P1525, DOI 10.1111/j.1471-4159.2008.05491.x; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Benn PA, 2002, CLIN CHIM ACTA, V323, P1, DOI 10.1016/S0009-8981(02)00186-9; Bermudez O, 2008, ONCOGENE, V27, P3685, DOI 10.1038/sj.onc.1211040; Binda F, 2008, MOL PHARMACOL, V74, P1101, DOI 10.1124/mol.108.048447; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Boobis A, 2011, CRIT REV TOXICOL, V41, P369, DOI 10.3109/10408444.2010.543655; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Bouskine A, 2008, ENDOCRINOLOGY, V149, P565, DOI 10.1210/en.2007-1318; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Calabrese EJ, 2009, ARCH TOXICOL, V83, P227, DOI 10.1007/s00204-009-0411-5; Calabrese EJ, 2008, ENVIRON TOXICOL CHEM, V27, P1451, DOI 10.1897/07-541; Calabrese EJ, 2008, TOXICOL APPL PHARM, V229, P262, DOI 10.1016/j.taap.2008.01.024; Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P249, DOI 10.1177/0960327109363973; Calabrese EJ, 2012, BIOGERONTOLOGY, V13, P215, DOI 10.1007/s10522-012-9374-7; Campbell CH, 2001, STEROIDS, V66, P727, DOI 10.1016/S0039-128X(01)00106-4; Cao Y, 2009, J EXPO SCI ENV EPID, V19, P223, DOI 10.1038/jes.2008.44; Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005; Dave G, 2012, CHEMOSPHERE, V88, P459, DOI 10.1016/j.chemosphere.2012.02.070; Deblonde T, 2011, INT J HYG ENVIR HEAL, V214, P442, DOI 10.1016/j.ijheh.2011.08.002; Decherf S, 2010, MOL CELL ENDOCRINOL, V323, P172, DOI 10.1016/j.mce.2010.04.010; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dolar D., 2012, J HAZARD MA IN PRESS; Eden JA, 2012, MATURITAS, V72, P157, DOI 10.1016/j.maturitas.2012.03.006; Fenner-Crisp PA, 2000, TOXICOL PATHOL, V28, P438, DOI 10.1177/019262330002800313; Fent K, 2006, AQUAT TOXICOL, V76, P122, DOI 10.1016/j.aquatox.2005.09.009; Fleisch AF, 2010, PEDIATRICS, V126, P760, DOI 10.1542/peds.2009-2693; Foster JD, 2006, HANDB EXP PHARM, V175, P197; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gall HE, 2011, ENVIRON SCI TECHNOL, V45, P8755, DOI 10.1021/es2011435; Geens T, 2011, INT J HYG ENVIR HEAL, V214, P339, DOI 10.1016/j.ijheh.2011.04.005; Goncalves CR, 2010, ENVIRON TOXICOL PHAR, V30, P195, DOI 10.1016/j.etap.2010.06.003; Greenlee H, 2007, BREAST CANCER RES TR, V102, P111, DOI 10.1007/s10549-006-9308-7; Greenspan FS, 2004, BASIC CLIN ENDOCRINO, P925; Hayes TB, 2006, ENVIRON HEALTH PERSP, V114, P40, DOI 10.1289/ehp.8051; Huang YQ, 2012, ENVIRON INT, V42, P91, DOI 10.1016/j.envint.2011.04.010; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Isidori M, 2007, ENVIRON TOXICOL CHEM, V26, P1686, DOI 10.1897/06-320R2.1; Jean J, 2012, J ENVIRON MANAGE, V103, P113, DOI 10.1016/j.jenvman.2012.03.005; Jefferson WN, 2012, REPRODUCTION, V143, P247, DOI 10.1530/REP-11-0369; Jeng YJ, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-40; Jeng YJ, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-61; Jeng YJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-334; Jeng YJ, 2011, ENVIRON HEALTH PERSP, V119, P104, DOI 10.1289/ehp.1002512; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; JENG YJ, 1994, EXP CELL RES, V212, P338, DOI 10.1006/excr.1994.1152; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Kretschmer XC, 2005, CHEM-BIOL INTERACT, V155, P111, DOI 10.1016/j.cbi.2005.06.003; Kubwabo C, 2009, FOOD ADDIT CONTAM A, V26, P928, DOI 10.1080/02652030802706725; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kujawinski EB, 2011, ENVIRON SCI TECHNOL, V45, P1298, DOI 10.1021/es103838p; Kuruto-Niwa R, 2005, ENVIRON TOXICOL PHAR, V19, P121, DOI 10.1016/j.etap.2004.05.009; Li DK, 2011, FERTIL STERIL, V95, P625, DOI 10.1016/j.fertnstert.2010.09.026; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Lippi G, 2010, SEMIN THROMB HEMOST, V36, P59, DOI 10.1055/s-0030-1248725; Lu GH, 2011, ECOTOXICOLOGY, V20, P974, DOI 10.1007/s10646-011-0660-y; Lucier GW, 1997, REGUL TOXICOL PHARM, V26, P34, DOI 10.1006/rtph.1997.1114; Mazerolles G, 2010, ANAL CHIM ACTA, V678, P195, DOI 10.1016/j.aca.2010.07.034; Mermelstein PG, 1996, J NEUROSCI, V16, P595; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Mnif W, 2011, INT J ENV RES PUB HE, V8, P2265, DOI 10.3390/ijerph8062265; Mustafa AM, 2007, TOXICOL APPL PHARM, V222, P25, DOI 10.1016/j.taap.2007.03.014; Myers Daniel E., 2011, General Dentistry, V59, P262; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887; Newbold RR, 2011, AM J CLIN NUTR, V94, p1939S, DOI 10.3945/ajcn.110.001057; Newbold RR, 2009, MOL CELL ENDOCRINOL, V304, P84, DOI 10.1016/j.mce.2009.02.024; Nordstrom E, 2009, FASEB J, V23, P613, DOI 10.1096/fj.08-115360; Norfleet A.M., 1999, END SOC M SAN DIEG C; Norfleet AM, 2000, FASEB J, V14, P157; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Oehlmann J, 2009, PHILOS T R SOC B, V364, P2047, DOI 10.1098/rstb.2008.0242; Otto C, 2008, J STEROID BIOCHEM, V111, P95, DOI 10.1016/j.jsbmb.2008.05.003; PAPPAS TC, 1994, ENDOCRINE, V2, P813; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200; Pietras RJ, 1999, NAT MED, V5, P1330, DOI 10.1038/70877; Pietras RJ, 2005, SCIENCE, V310, P51, DOI 10.1126/science.310.5745.51; Pitkin Joan, 2012, Menopause Int, V18, P20, DOI 10.1258/mi.2012.012001; Powell CE, 2001, J STEROID BIOCHEM, V77, P97, DOI 10.1016/S0960-0760(01)00040-1; Qin XY, 2011, TOXICOL LETT, V206, P152, DOI 10.1016/j.toxlet.2011.07.007; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Reffstrup TK, 2010, REGUL TOXICOL PHARM, V56, P174, DOI 10.1016/j.yrtph.2009.09.013; Riza E, 2001, CANCER EPIDEM BIOMAR, V10, P627; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; SCHWARZ S, 1994, J STEROID BIOCHEM, V48, P391, DOI 10.1016/0960-0760(94)90080-9; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S; Shaw J, 2009, REPROD TOXICOL, V28, P26, DOI 10.1016/j.reprotox.2009.03.003; Sheehan DM, 2006, ENVIRON RES, V100, P93, DOI 10.1016/j.envres.2005.09.002; Sheehan Daniel M., 1999, Environmental Health Perspectives, V107, P155, DOI 10.2307/3434373; Shenhav S, 2003, ACTA OBSTET GYN SCAN, V82, P912, DOI 10.1034/j.1600-0412.2003.00250.x; Sohoni P, 2001, ENVIRON SCI TECHNOL, V35, P2917, DOI 10.1021/es000198n; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Soto AM, 2004, ENVIRON HEALTH PERSP, V112, P346, DOI 10.1289/ehp.6590; Soto AM, 2009, MOL CELL ENDOCRINOL, V304, P3, DOI 10.1016/j.mce.2009.02.020; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; STORMSHAK F, 1976, ENDOCRINOLOGY, V99, P1501; Sunita P, 2011, Pharmacogn Rev, V5, P41, DOI 10.4103/0973-7847.79098; Teuschler L, 2002, REGUL TOXICOL PHARM, V36, P34, DOI 10.1006/rtph.2002.1570; The Scientis-Jef Akst, US DOESNT BAN BPA FD; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Topp E, 2000, ENVIRON TOXICOL CHEM, V19, P313, DOI 10.1897/1551-5028(2000)019&lt;0313:RMOTED&gt;2.3.CO;2; Touraud E, 2011, INT J HYG ENVIR HEAL, V214, P437, DOI 10.1016/j.ijheh.2011.06.003; US EPA, EPA630R00002; US Food and Drug Administration, 2012, BISPH A BPA US FOOD; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; Wang JX, 2007, ENVIRON RES, V103, P70, DOI 10.1016/j.envres.2006.05.013; Wang ZQ, 2005, J CELL PHYSIOL, V204, P437, DOI 10.1002/jcp.20297; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Watson CS, 2011, J STEROID BIOCHEM, V127, P44, DOI 10.1016/j.jsbmb.2011.01.015; Watson CS, 2008, FASEB J, V22, P3328, DOI 10.1096/fj.08-107672; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Watson Cheryl S, 2010, Int J Womens Health, V2, P153; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Watson C.S, 2003, IDENTITIES MEMBRANE; Watson CS, 2011, STEROIDS, V77, P424; Whitten PL, 2001, ENVIRON HEALTH PERSP, V109, P5, DOI 10.2307/3434842; WIKLUND J, 1981, ENDOCRINOLOGY, V109, P1700; Wolstenholme JT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025448; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang JD, 2012, CELL BIOCHEM FUNCT, V30, P122, DOI 10.1002/cbf.1825; Yang RSH, 2007, TOXICOL APPL PHARM, V223, P133, DOI 10.1016/j.taap.2006.11.016; Yu LG, 2004, J BIOL CHEM, V279, P41377, DOI 10.1074/jbc.M400017200; Zhou J, 2011, CHEMOSPHERE, V82, P443, DOI 10.1016/j.chemosphere.2010.09.056; Zhou YQ, 2012, ENVIRON MONIT ASSESS, V184, P1719, DOI 10.1007/s10661-011-2073-z; Zhu L, 2012, INT J MOL SCI, V13, P3492, DOI 10.3390/ijms13033492; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR130, DOI 10.1186/bcr9591456MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDINT J ENV RES PUB HEAUGDiscipline: Environmental Sciences &amp; Ecology998MB</notes>
    <keywords>apoptosis; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CELL; Cell proliferation; CELL-PROLIFERATION; CHEMICALS; END-POINTS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ENDOGENOUS ESTROGENS; Estrogen; ESTROGEN-RECEPTOR-ALPHA; estrogenic mixtures; ESTROGENS; FOOD; HEALTH; Hormesis; IN-VIVO; INITIATED SIGNALING PATHWAYS; kinases; LONG-TERM EXPOSURE; mechanism; MECHANISMS; non-genomic; non-monotonic dose-response curves; nongenomic effects; PITUITARY-TUMOR CELLS; PLASMA-MEMBRANE; PROLACTIN-RELEASE; proliferation; RELEASE; Reproduction; RESPONSES; TISSUE; TOXICITY; WOMEN; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>2694</startpage>
    <endpage>2714</endpage>
    <journalfull>International Journal of Environmental Research and Public Health</journalfull>
    <issue>8</issue>
    <volume>9</volume>
    <abstract>Xenoestrogens (XEs) are chemicals derived from a variety of natural and anthropogenic sources that can interfere with endogenous estrogens by either mimicking or blocking their responses via non-genomic and/or genomic signaling mechanisms. Disruption of estrogens' actions through the less-studied non-genomic pathway can alter such functional end points as cell proliferation, peptide hormone release, catecholamine transport, and apoptosis, among others. Studies of potentially adverse effects due to mixtures and to low doses of endocrine-disrupting chemicals have recently become more feasible, though few so far have included actions via the non-genomic pathway. Physiologic estrogens and XEs evoke non-monotonic dose responses, with different compounds having different patterns of actions dependent on concentration and time, making mixture assessments all the more challenging. In order to understand the spectrum of toxicities and their mechanisms, future work should focus on carefully studying individual and mixture components across a range of concentrations and cellular pathways in a variety of tissue types</abstract>
    <url>WOS:000308242300009</url>
    <isbnorissn>1660-4601</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>358</id>
    <title>Potential estrogenic effect(s) of parabens at the prepubertal stage of a postnatal female rat model</title>
    <authors>Vo,T.T.B.; Yoo,Y.M.; Choi,K.C.; Jeung,E.B.</authors>
    <availability>[Vo, Thuy T. B.; Yoo, Yeong-Min; Choi, Kyung-Chul; Jeung, Eui-Bae] Chungbuk Natl Univ, Lab Vet Biochem &amp; Mol Biol, Coll Vet Med, Cheongju 361763, Chungbuk, South Korea.</availability>
    <date>2010</date>
    <notes>JEnglishArticleJeung, EB (reprint author), Chungbuk Natl Univ, Lab Vet Biochem &amp; Mol Biol, Coll Vet Med, Gaesin Dong 12, Cheongju 361763, Chungbuk, South Koreaebjeung@chungbuk.ac.krAIN KB, 1987, J CLIN ENDOCR METAB, V65, P689; ANDREWS WW, 1981, ENDOCRINOLOGY, V109, P1404; Biegel LB, 1998, TOXICOL SCI, V44, P143, DOI 10.1006/toxs.1998.2469; Boberg J, 2008, TOXICOLOGY, V250, P75, DOI 10.1016/j.tox.2008.05.020; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Canosa P, 2006, J CHROMATOGR A, V1124, P3, DOI 10.1016/j.chroma.2006.03.045; Ceccarelli I, 2009, NEUROTOXICOL TERATOL, V31, P203, DOI 10.1016/j.ntt.2009.02.004; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2003, J APPL TOXICOL, V23, P43, DOI 10.1002/jat.886; Darbre PD, 2004, J APPL TOXICOL, V24, P5, DOI 10.1002/jat.958; Daston GP, 2004, BIRTH DEFECTS RES B, V71, P296, DOI 10.1002/bdrb.20016; Della Seta D, 2008, ENDOCRINOLOGY, V149, P5592, DOI 10.1210/en.2008-0113; Donovan M, 2007, MED HYPOTHESES, V68, P756, DOI 10.1016/j.mehy.2006.09.039; El Hussein S, 2007, EXP DERMATOL, V16, P830, DOI 10.1111/j.1600-0625.2007.00625.x; EMERSON CH, 1990, ACTA ENDOCRINOL-COP, V123, P72; Ge Jun-Hui, 2006, Wei Sheng Yan Jiu, V35, P650; Goldman JM, 2000, CRIT REV TOXICOL, V30, P135, DOI 10.1080/10408440091159185; Gomez E, 2005, J TOXICOL ENV HEAL A, V68, P239, DOI 10.1080/15287390590895054; Harvey PW, 2003, J APPL TOXICOL, V23, P285, DOI 10.1002/jat.946; Hoberman AM, 2008, BIRTH DEFECTS RES B, V83, P123, DOI 10.1002/bdrb.20153; Hossaini A, 2000, FOOD CHEM TOXICOL, V38, P319, DOI 10.1016/S0278-6915(99)00160-X; Inui M, 2003, TOXICOLOGY, V194, P43, DOI 10.1016/S0300-483X(03)00340-8; Ishiwatari S, 2007, J APPL TOXICOL, V27, P1, DOI 10.1002/jat.1176; Janjua NR, 2007, ENVIRON SCI TECHNOL, V41, P5564, DOI 10.1021/es0628755; Kang KS, 2002, J VET MED SCI, V64, P227, DOI 10.1292/jvms.64.227; Kang KS, 2000, TOXICOL LETT, V118, P109, DOI 10.1016/S0378-4274(00)00272-1; Kanno J, 2001, ENVIRON HEALTH PERSP, V109, P785, DOI 10.2307/3454820; Kato H, 2003, REPROD TOXICOL, V17, P283, DOI 10.1016/S0890-6238(03)00002-9; KAWAGOE S, 1983, ENDOCRINOL JAPON, V30, P435; Kim HJ, 2006, AM J PHYSIOL-ENDOC M, V291, pE234, DOI 10.1152/ajpendo.00434.2005; Kwon S, 2000, TOXICOL SCI, V55, P399, DOI 10.1093/toxsci/55.2.399; Lee GS, 2007, AM J PHYSIOL-ENDOC M, V293, pE132, DOI 10.1152/ajpendo.00666.2006; Lee HB, 2005, J CHROMATOGR A, V1094, P122, DOI 10.1016/j.chroma.2005.07.070; Lemini C, 2003, TOXICOL IND HEALTH, V19, P69, DOI 10.1191/0748233703th177oa; Malik R, 2002, QJM-INT J MED, V95, P559, DOI 10.1093/qjmed/95.9.559; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Naciff JM, 2003, TOXICOL SCI, V72, P314, DOI 10.1093/toxsci/kfg037; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; Nakamura T, 2008, TOXICOLOGY, V253, P117, DOI 10.1016/j.tox.2008.09.006; NASS TE, 1984, BIOL REPROD, V31, P723, DOI 10.1095/biolreprod31.4.723; Newbold RR, 2001, ENVIRON HEALTH PERSP, V109, pA569, DOI 10.1289/ehp.109-a569a; Nguyen TH, 2005, MOL BRAIN RES, V141, P166, DOI 10.1016/j.molbrainres.2005.09.008; Nishihara E, 2000, ENDOCRINOLOGY, V141, P615, DOI 10.1210/en.141.2.615; Noda H, 2002, J PEDIATR ENDOCR MET, V15, P217; Odum J, 1997, REGUL TOXICOL PHARM, V25, P176, DOI 10.1006/rtph.1997.1100; Oishi S, 2004, FOOD CHEM TOXICOL, V42, P1845, DOI 10.1016/j.fct.2004.06.015; Oishi S, 2002, ARCH TOXICOL, V76, P423, DOI 10.1007/s00204-002-0360-8; Oishi S, 2002, FOOD CHEM TOXICOL, V40, P1807, DOI 10.1016/S0278-6915(02)00204-1; Okubo T, 2001, FOOD CHEM TOXICOL, V39, P1225, DOI 10.1016/S0278-6915(01)00073-4; Padilla-Banks E, 2001, ENVIRON HEALTH PERSP, V109, P821, DOI 10.2307/3454825; Pugazhendhi D, 2007, J APPL TOXICOL, V27, P67, DOI 10.1002/jat.1200; Pugazhendhi D, 2005, J APPL TOXICOL, V25, P301, DOI 10.1002/jat.1066; Rage F, 1997, J NEUROSCI, V17, P9145; Reznikov A G, 2003, Neurosci Behav Physiol, V33, P773, DOI 10.1023/A:1025141130241; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Satoh K, 2000, YAKUGAKU ZASSHI, V120, P1429; Shen HY, 2007, J SEP SCI, V30, P48, DOI 10.1002/jssc.200600215; SINGH MM, 1980, ENDOKRINOLOGIE, V76, P36; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Stoker TE, 2000, CRIT REV TOXICOL, V30, P197, DOI 10.1080/10408440091159194; Taxvig C, 2008, TOXICOL SCI, V106, P206, DOI 10.1093/toxsci/kfn148; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; TERASAKI M, 2008, ENVIRON TOXICOL CHEM, P1; Thobe N, 2000, POSTGRAD MED J, V76, P424, DOI 10.1136/pmj.76.897.424; Vanparys C, 2006, TOXICOL IN VITRO, V20, P1238, DOI 10.1016/j.tiv.2006.05.002; Warren MP, 1999, J CLIN ENDOCR METAB, V84, P873, DOI 10.1210/jc.84.3.873; Ye XY, 2006, ENVIRON HEALTH PERSP, V114, P1843, DOI 10.1289/ehp.9413; Zoeller RT, 2007, THYROID, V17, P811, DOI 10.1089/thy.2007.0107; Zoeller RT, 2005, MOL CELL ENDOCRINOL, V242, P10, DOI 10.1016/j.mce.2005.07.0067127PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLJUNDiscipline: Reproductive Biology; Toxicology588ZB</notes>
    <keywords>17 alpha-Ethinylestradiol; 17 beta-Estradiol; 17-ALPHA-ETHINYLESTRADIOL; 17-BETA-ESTRADIOL; AFFINITIES; analysis; ASSAY; BINDING; BINDING-AFFINITY; BIOLOGY; BIRTH; BISPHENOL-A; BODY-WEIGHT; Brain; BREAST-CANCER CELLS; CELL; CYCLE; DEFECTS; development; ENDOCRINE DISRUPTORS; Endocrine-disrupting chemicals; ESTRADIOL; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENIC ACTIVITIES; estrogenic activity; Estrogenicity; ESTROUS-CYCLE; EXPOSURE; female; FEMALE RAT; FEMALE RATS; follicle; FOOD; GENE-EXPRESSION; GLAND; HEALTH; Hormone; In vitro; IN-VITRO; isobutylparaben; JUN; Liver; LONG-TERM EXPOSURE; MALE REPRODUCTIVE-SYSTEM; MODEL; morphology; ovary; P-HYDROXYBENZOIC ACID; PARABENS; PERSONAL-CARE PRODUCTS; RAT; RATS; RECEPTOR; Receptor binding assay; RECEPTOR-BINDING; Receptors; REPRODUCTIVE-ORGANS; serum; SPRAGUE-DAWLEY RATS; Steroid; TARGET; Thyroid; THYROID-HORMONE; Thyroxine; TISSUE; TISSUES; toxicology; UTEROTROPHIC ASSAY; Uterus; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>306</startpage>
    <endpage>316</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>3</issue>
    <volume>29</volume>
    <abstract>In this study, a female pubertal assay on the effects of parabens, including methyl-, ethyl-, propyl-, isopropyl-, butyl-, and isobutylparaben, was performed in a female Sprague-Dawley rat model during the juvenile-peripubertal period. The rats were orally treated with these parabens from postnatal day 21-40 in a dose-dependent manner (62.5, 250 and 1000 mg/kg body weight [BW]/day). 17 alpha-Ethinylestradiol (1 mg/kg BW/day) was used as a positive control and corn oil as a vehicle. A high dose of methyl- and isopropylparaben (1000 mg/kg BW/day) resulted in a significant delay in the date of vaginal opening and a decrease in length of the estrous cycle. In measurements of organ weight and body weight, we observed significant weight changes in ovaries, adrenal glands, thyroid glands, liver, and kidneys; conversely, body weight was not altered following paraben treatment. The potential effects of parabens on estrogenicity were shown in histopathological abnormities in the reproductive organs. Histological analysis of the ovaries from the peripubertal rats revealed a decrease of corpora lutes, increase in the number of cystic follicles, and thinning of the follicular epithelium. In addition, morphological studies of the uterus revealed the myometrial hypertrophy by a high dose of propyl and isopropylparaben (1000 mg/kg-day), and in all dose groups of butyl- and isobutylparabens. However, no significant histopathological changes were observed in the other organs (i.e. adrenal and thyroid glands). We also observed a significant decrease in serum estradiol and thyroxine concentrations in methyl-, ethyl-, propyl-, isopropyl-, and isobutylparaben-treated groups. A receptor-binding assay indicated that the relative binding affinities of parabens to estrogen receptors occurred in the order: isobutylparaben&gt;butylparaben&gt;isopropylparaben=propylparaben&gt;ethylparaben. These values were much lower than the binding affinity for 17 beta-estradiol. Taken together, long-term exposure to parabens, which show less estrogenic activity than estradiol, can produce suppressive effects on hormonal responsiveness and can disrupt the morphology of reproductive target tissues. In addition, the relation between thyroid weight and thyroid hormone may influence circulating levels of parabens, suggesting the effects of parabens as thyrotoxic during this critical stage of development in female rats. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000277112200008</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>185</id>
    <title>Calbindin-D9k as a sensitive molecular biomarker for evaluating the synergistic impact of estrogenic chemicals on GH3 rat pituitary cells</title>
    <authors>Vo,T.T.B.; An,B.S.; Yang,H.; Jung,E.M.; Hwang,I.; Jeung,E.B.</authors>
    <availability>[Vo, Thuy T. B.; An, Beum-Soo; Yang, Hyun; Jung, Eui-Man; Hwang, Inho; Jeung, Eui-Bae] Chungbuk Natl Univ, Lab Vet Biochem &amp; Mol Biol, Coll Vet Med, Cheongju 361763, Chungbuk, South Korea. [Vo, Thuy T. B.] Vietnam Acad Sci &amp; Technol, Inst Biotechnol, Hanoi, Vietnam.</availability>
    <date>2012</date>
    <notes>JEnglishArticleJeung, EB (reprint author), Chungbuk Natl Univ, Lab Vet Biochem &amp; Mol Biol, Coll Vet Med, 12 Gaesin Dong, Cheongju 361763, Chungbuk, South Koreaebjeung@chungbuk.ac.krAn BS, 2003, REPROD TOXICOL, V17, P311, DOI 10.1016/S0890-6238(03)00003-0; An BS, 2002, MOL CELL ENDOCRINOL, V191, P177, DOI 10.1016/S0303-7207(02)00042-4; Baba K, 2009, TOXICOL SCI, V108, P344, DOI 10.1093/toxsci/kfp025; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Brian JV, 2005, ENVIRON HEALTH PERSP, V113, P721, DOI 10.1289/ehp.7598; Choi KC, 2008, J CELL MOL MED, V12, P409, DOI 10.1111/j.1582-4934.2007.00209.x; Dang VH, 2007, TOXICOL SCI, V98, P408, DOI 10.1093/toxsci/kfm120; Darbre PD, 2002, J APPL TOXICOL, V22, P219, DOI 10.1002/jat.860; Funabashi T, 2004, J NEUROENDOCRINOL, V16, P99, DOI 10.1111/j.0953-8194.2004.01136.x; Ghisari M, 2009, TOXICOL LETT, V189, P67, DOI 10.1016/j.toxlet.2009.05.004; Harvey PW, 2003, J APPL TOXICOL, V23, P285, DOI 10.1002/jat.946; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Ji YK, 2006, REPROD TOXICOL, V22, P694, DOI 10.1016/j.reprotox.2006.04.015; Jin S, 2011, ENVIRON TOXICOL PHAR, V33, P277; Kaneko M, 2008, GEN COMP ENDOCR, V155, P574, DOI 10.1016/j.ygcen.2007.09.009; Kim YR, 2012, INT J MOL MED, V29, P294, DOI 10.3892/ijmm.2011.823; Kortenkamp A, 2008, INT J ANDROL, V31, P233, DOI 10.1111/j.1365-2605.2007.00862.x; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; Lee GS, 2004, TOXICOL SCI, V82, P451, DOI 10.1093/toxsci/kfh296; Lee GS, 2005, TOXICOL SCI, V84, P270, DOI 10.1093/toxsci/kfi072; Lee GS, 2006, AM J PHYSIOL-ENDOC M, V290, pE299, DOI 10.1152/ajpendo.00232.2005; Lee YM, 2008, COMP BIOCHEM PHYS C, V147, P299, DOI 10.1016/j.cbpc.2007.11.006; Lv X, 2007, ENVIRON TOXICOL PHAR, V24, P155, DOI 10.1016/j.etap.2007.04.007; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Okubo T, 2001, FOOD CHEM TOXICOL, V39, P1225, DOI 10.1016/S0278-6915(01)00073-4; Olea N, 2008, ENVIRON TOXICOL, V110, P369; Poongothai S, 2008, INTERNET J TOXICOL, V4, P2, DOI [10.5580/263, DOI 10.5580/263]; Rajapakse N, 2002, ENVIRON HEALTH PERSP, V110, P917; Rhee JS, 2009, COMP BIOCHEM PHYS C, V149, P433, DOI 10.1016/j.cbpc.2008.10.102; Roy Deodutta, 1998, Frontiers in Bioscience, V3, pD913; Sato K, 2002, NEUROENDOCRINOLOGY, V76, P223, DOI 10.1159/000065948; Sehulster Lynne, 2003, MMWR Recomm Rep, V52, P1; Shen HY, 2007, J SEP SCI, V30, P48, DOI 10.1002/jssc.200600215; Shin JH, 2007, J REPROD DEVELOP, V53, P179, DOI 10.1262/jrd.18054; Silva E, 2002, ENVIRON SCI TECHNOL, V36, P1751, DOI 10.1021/es0101227; Song MY, 2006, ENVIRON INT, V32, P676, DOI 10.1016/j.envint.2006.03.002; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Stewart AG, 2009, ENVIRON GEOCHEM HLTH, V31, P239, DOI 10.1007/s10653-008-9210-9; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Tayama S, 2008, MUTAT RES-GEN TOX EN, V649, P114, DOI 10.1016/j.mrgentox.2007.08.006; Tinnanooru P, 2008, MOL CELL ENDOCRINOL, V285, P26, DOI 10.1016/j.mce.2008.01.011; Vo TTB, 2011, STEROIDS, V76, P675, DOI 10.1016/j.steroids.2011.03.006; Vo TTB, 2010, REPROD TOXICOL, V29, P306, DOI 10.1016/j.reprotox.2010.01.013; Vo TTB, 2009, TOXICOL SCI, V112, P68, DOI 10.1093/toxsci/kfp176; Yang H, 2012, HUM EXP TOXICOL, V31, P134, DOI 10.1177/0960327111422402461SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEINT J MOL MEDNOVDiscipline: Research &amp; Experimental Medicine031OM</notes>
    <keywords>4-NONYLPHENOL; 4-tert-octylphenol; ALPHA-PATHWAY; Antagonist; BIOMARKER; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; calbindin-D9k; CALCIUM-BINDING PROTEIN; CANCER; CELL; CELLS; CHEMICALS; COMBINATION; EDCs; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; estrogenic activity; ESTROGENIC CHEMICALS; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; GH3 cells; HEALTH; HERMAPHRODITIC FISH; IMMATURE RATS; IMPACT; In vitro; IN-VITRO; isobutylparaben; KRYPTOLEBIAS-MARMORATUS; MESSENGER-RNA EXPRESSION; octylphenol; Progesterone receptor; PROGESTERONE-RECEPTOR; PROTEIN; RAT; RECEPTOR; synergistic effects; THYROID-HORMONE; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1233</startpage>
    <endpage>1240</endpage>
    <journalfull>International Journal of Molecular Medicine</journalfull>
    <issue>5</issue>
    <volume>30</volume>
    <abstract>Various endocrine-disrupting chemicals (EDCs) such as bisphenol A (BPA), alkylphenols [4-nonylphenol (NP) and 4-tert octylphenol (OP)] and isobutylparaben (IBP) are a constant concern due to their widespread distribution. It has been reported that some combinations of hormone-disrupting chemicals are much more powerful than any of the chemicals alone. In this study, we measured the expression of an estrogenic biomarker gene, calbindin-D9k (CaBP-9k), and progesterone receptor (PR) to evaluate the individual or combined estrogenic activity of BPA, NP, OP and IBP in GH3 rat pituitary cells. Most doses of the individual compounds and all the doses of the combined chemicals significantly increased CaBP-9k and PR mRNA and protein expression compared to the vehicle (except for PR expression after treatment with OP and NP at 10(-7) M). Of note, high doses (10(-6) and 10(-5) M) of the EDC combinations increased the translational and transcriptional levels of CaBP-9k by 1.3- to 2.4-fold compared to each individual equivalent concentrations of EDCs. To determine whether the increased CaBP-9k gene expression was induced via intracellular estrogen receptor (ER), we blocked ER signaling using fulvestrant, an ER antagonist. The results showed that fulvestrant significantly reversed the CaBP-9k and PR upregulation following treatment with individual EDCs or their combinations. Taken together, we conclude that combinations of BPA, NP. OP and IBP in GH3 rat pituitary cells have synergistic estrogenic activities mediated by ER signaling. In addition, the expression of the CaBP-9k gene may be used as a biomarker to assess the synergistic effects of EDCs in vitro</abstract>
    <url>WOS:000310651500035</url>
    <isbnorissn>1107-3756</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>102</id>
    <title>In silico methods in the discovery of endocrine disrupting chemicals</title>
    <authors>Vuorinen,A.; Odermatt,A.; Schuster,D.</authors>
    <availability>[Vuorinen, Anna; Schuster, Daniela] Univ Innsbruck, Inst Pharm Pharmaceut Chem, A-6020 Innsbruck, Austria. [Vuorinen, Anna; Schuster, Daniela] Univ Innsbruck, CMBI, A-6020 Innsbruck, Austria. [Odermatt, Alex] Univ Basel, Swiss Ctr Appl Human Toxicol, CH-4056 Basel, Switzerland. [Odermatt, Alex] Univ Basel, Dept Pharmaceut Sci, Div Mol &amp; Syst Toxicol, CH-4056 Basel, Switzerland.</availability>
    <date>2013</date>
    <notes>JEnglishReviewSchuster, D (reprint author), Univ Innsbruck, Inst Pharm Pharmaceut Chem, Innrain 80-82, A-6020 Innsbruck, Austriadaniela.schuster@uibk.ac.atAtanasov AG, 2003, BIOCHEM BIOPH RES CO, V308, P257, DOI 10.1016/S0006-291X(03)01359-7; Bruns RF, 2012, J MED CHEM, V55, P9763, DOI 10.1021/jm301008n; Chang M.W., 2010, PLOS ONE, V2; Dearden JC, 2003, J COMPUT AID MOL DES, V17, P119, DOI 10.1023/A:1025361621494; DECOSTER S, 2012, J ENV PUBLIC HLTH, V2012, P52, DOI DOI 10.1155/2012/713696; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Den Hond E, 2006, INT J ANDROL, V29, P264, DOI 10.1111/j.1365-2605.2005.00561.x; Desvergne B, 2009, MOL CELL ENDOCRINOL, V304, P43, DOI 10.1016/j.mce.2009.02.017; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Doman TN, 2002, J MED CHEM, V45, P2213, DOI 10.1021/jm010548w; Ekins S, 2007, BRIT J PHARMACOL, V152, P9, DOI 10.1038/sj.bjp.0707305; Fini JB, 2012, TOXICOL SCI, V125, P359, DOI 10.1093/toxsci/kfr312; Frye C. A., 2011, J NEUROENDOCRINOL, V24, P144; Fucic A, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-S1-S8; Gumy C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003545; Guo J., 2012, TOXICOLOGY LETT; Hao C., 2012, BIOSCIENCE REPORTS; Hein M., 2010, CURRENT DRUG DISCOVE, V7, pe229; JONES G, 1995, CURR OPIN BIOTECH, V6, P652, DOI 10.1016/0958-1669(95)80107-3; Kalfa N, 2009, INT J ANDROL, V32, P187, DOI 10.1111/j.1365-2605.2008.00899.x; Karabunarliev S, 1996, QUANT STRUCT-ACT REL, V15, P302, DOI 10.1002/qsar.19960150405; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Leach AR, 2010, J MED CHEM, V53, P539, DOI 10.1021/jm900817u; Levin ER, 2011, MOL ENDOCRINOL, V25, P377, DOI 10.1210/me.2010-0284; Li JZ, 2010, J CHEM INF MODEL, V50, P861, DOI 10.1021/ci100078u; Liu HX, 2006, CHEM RES TOXICOL, V19, P1540, DOI 10.1021/tx0601509; Luccio-Camelo D.C., 2011, J STEROID BIOCH MOL, V127; Marchais-Oberwinkler S, 2011, J STEROID BIOCHEM, V125, P66, DOI 10.1016/j.jsbmb.2010.12.013; Meyer A, 2012, TOXICOLOGY, V301, P72, DOI 10.1016/j.tox.2012.07.001; Mnif W, 2007, TOXICOL LETT, V170, P19, DOI 10.1016/j.toxlet.2006.11.016; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Nanjappa MK, 2012, BIOL REPROD, V86, P1, DOI [10.1095/ biolreprod. 111.095349, DOI 10.1095/BIOLREPROD.111.095349]; Nashev LG, 2010, BIOCHEM PHARMACOL, V79, P1189, DOI 10.1016/j.bcp.2009.12.005; NASHEV LG, 2012, PLOS ONE, V0007; Odermatt A, 2008, BIOCHEM PHARMACOL, V76, P1184, DOI 10.1016/j.bcp.2008.07.019; Odermatt A, 2006, J STEROID BIOCHEM, V102, P222, DOI 10.1016/j.jsbmb.2006.09.010; Ooms F, 2000, CURR MED CHEM, V7, P141; Poirier D, 2010, EXPERT OPIN THER PAT, V20, P1123, DOI 10.1517/13543776.2010.505604; Poroikov V, 2007, SAR QSAR ENVIRON RES, V18, P101, DOI 10.1080/10629360601054032; Riu A, 2011, ENVIRON HEALTH PERSP, V119, P1227, DOI 10.1289/ehp.1003328; Riu A, 2011, TOXICOL SCI, V122, P372, DOI 10.1093/toxsci/kfr132; Rush TS, 2005, J MED CHEM, V48, P1489, DOI 10.1021/jm040163o; Sanderson JT, 2006, TOXICOL SCI, V94, P3, DOI 10.1093/toxsci/kfl051; Schuster D, 2006, J MED CHEM, V49, P3454, DOI 10.1021/jm0600794; Schuster D, 2010, BIOORGAN MED CHEM, V18, P5071, DOI 10.1016/j.bmc.2010.05.071; Schuster Daniela, 2006, Curr Drug Discov Technol, V3, P1, DOI 10.2174/157016306776637609; Schweizer RAS, 2003, MOL CELL ENDOCRINOL, V212, P41, DOI 10.1016/j.mce.2003.09.027; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Soriano S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031109; Spitzer GM, 2010, J CHEM INF MODEL, V50, P1241, DOI 10.1021/ci100136b; Sturm N, 2012, J CHEM INF MODEL, V52, P2410, DOI 10.1021/ci300196g; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Tanrikulu Y., 2013, DRUG DISCOVERY TODAY; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vedani A, 2009, ALTEX-ALTERN TIEREXP, V26, P167; Wang CY, 2006, CHEM RES TOXICOL, V19, P1595, DOI 10.1021/tx060218k; Wang J., 2012, IEEE MTT S INT MICR, P1; Weaver S, 2008, J MOL GRAPH MODEL, V26, P1315, DOI 10.1016/j.jmgm.2008.01.002; WERMUTH CG, 1998, PURE APPL CHEM, V70, P1129, DOI 10.1351/pac199870051129; Ye LP, 2011, MOLECULES, V16, P9983, DOI 10.3390/molecules16129983; Ye LP, 2011, TOXICOL LETT, V207, P137, DOI 10.1016/j.toxlet.2011.09.001; Yuan KM, 2012, CHEM-BIOL INTERACT, V195, P180, DOI 10.1016/j.cbi.2011.12.008632PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMSEPDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism252YI</notes>
    <keywords>BIOLOGY; BISPHENOL-A; CANCER; cardiovascular; Case studies; CELL; CHEMICALS; DEHYDROGENASE; DISEASE; DISRUPTING CHEMICALS; DRUG DISCOVERY; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL CHEMICALS; Estrogen; EXPOSURE; FOOD; IDENTIFICATION; in silico; In vitro; IN-VITRO; INHIBITOR; Inhibitors; mechanism; MECHANISMS; METABOLISM; MINERALOCORTICOID RECEPTOR; MODEL; PHARMACOLOGY; PREDICTION; PROGRESSION; PROTEIN; PROTEINS; RECEPTOR; Steroid hormone; TOXICITY; toxicology; Virtual screening; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>18</startpage>
    <endpage>26</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <volume>137</volume>
    <abstract>The prevalence of sex hormone-dependent cancers, reproductive problems, obesity, and cardiovascular complications has risen especially in the Western world. It has been suggested, that the exposure to various endocrine disrupting chemicals (EDCs) contributes to the development and progression of these diseases. EDCs can interfere with various proteins: nuclear steroid hormone receptors, such as estrogen-, androgen-, glucocorticoid- and mineralocorticoid receptors (ER, AR, GR, MR), and enzymes that are involved in steroid hormone synthesis and metabolism, for example hydroxysteroid dehydrogenases (HSDs). Numerous chemicals are known as endocrine disruptors. However, the mechanism of action for most of these EDCs is still unknown. It is exhaustive and time consuming to test in vitro all chemicals - potential EDCs - used in industry, agriculture or as food preservatives against their effects on the endocrine system. Computational methods, such as virtual screening, quantitative structure activity relationships and docking, are already well recognized and used in drug development. The same methods could also aid the research on EDCs. So far, the computational methods in the search of EDCs have been retrospective. There are, however, some prospective studies reporting the use of in silico methods: five studies reporting the identification of previously unknown 17 beta-HSD3 inhibitors, MR agonists, and ER antagonists/agonists. This review provides an overview of case studies and in silico methods that are used in the search of EDCs. This article is part of a Special Issue entitled 'CSR 2013'. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000327048400004</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>134</id>
    <title>Low-Dose BPA Exposure Alters the Mesenchymal and Epithelial Transcriptomes of the Mouse Fetal Mammary Gland</title>
    <authors>Wadia,P.R.; Cabaton,N.J.; Borrero,M.D.; Rubin,B.S.; Sonnenschein,C.; Shioda,T.; Soto,A.M.</authors>
    <availability>[Wadia, Perinaaz R.; Cabaton, Nicolas J.; Borrero, Michael D.; Rubin, Beverly S.; Sonnenschein, Carlos; Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USA. [Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleSoto, AM (reprint author), Tufts Univ, Sch Med, Dept Anat &amp; Cellular Biol, Boston, MA 02111 USAana.soto@tufts.eduAyyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Barker M, 2003, J CHEMOMETR, V17, P166, DOI 10.1002/cem.785; Bern H.A., 1992, CHEM INDUCED ALTERAT, VXXI, P9; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P1085, DOI 10.1016/j.biocel.2004.01.007; Chung CY, 1996, MOL BIOL CELL, V7, P883; SOTO AM, 1992, ADV MOD ENV, V21, P295; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dupont S, 2000, DEVELOPMENT, V127, P4277; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Garcia Y, 2008, BIOMATERIALS, V29, P857, DOI 10.1016/j.biomaterials.2007.10.053; Garcia-Canaveras JC, 2011, METABOLOMICS, V8, P86; Hirata H, 2008, J CELL SCI, V121, P2795, DOI 10.1242/jcs.030320; KIMATA K, 1985, J EMBRYOL EXP MORPH, V89, P243; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Liu J, 2012, AM J PATHOL, V180, P839, DOI [10.1016/j.ajpath.2011.10.020, 10.1016/j.aj.path.2011.10.020]; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Mangala LS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-33; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2003, EVOL DEV, V5, P1; Markey CM, 2001, BIOL REPROD, V65, P1215; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Munoz de Toro MM, 2005, ENDOCRINOLOGY, V146, P4138, DOI DOI 10.1210/EN.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Prasanth GK, 2010, J APPL TOXICOL, V30, P769, DOI 10.1002/jat.1570; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Ryo A, 2009, TRENDS BIOCHEM SCI, V34, P162, DOI 10.1016/j.tibs.2008.12.004; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Schlomm T, 2005, INT J ONCOL, V27, P713; Simian M, 2001, DEVELOPMENT, V128, P3117; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Soriano S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031109; Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87; Talsness CE, 2009, PHILOS T R SOC B, V364, P2079, DOI 10.1098/rstb.2008.0281; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Veltmaat JM, 2003, DIFFERENTIATION, V71, P1, DOI 10.1046/j.1432-0436.2003.700601.x; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-1018505PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEMAY 21Discipline: Science &amp; Technology - Other Topics149OK</notes>
    <keywords>ADULTHOOD; ALPHA; ALTERS; apoptosis; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CELL; CELLS; development; Differentiation; ENDOCRINE; Endocrine disruption; Endocrine disruptor; ENVIRONMENTAL ESTROGENS; ER alpha; ER-ALPHA; ER-BETA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGEN-RECEPTORS ALPHA; EXPOSURE; EXPRESSION; FETAL; FETAL MOUSE; FOCAL ADHESIONS; gene expression; GENE-EXPRESSION; GLAND; GPR30; IN-VITRO; Interaction; mammary gland; MAMMARY TISSUE; MAMMARY-GLAND; MAMMARY-GLANDS; metabolomics; MICE; MODEL; Mouse; PERINATAL EXPOSURE; RECEPTOR; RECEPTOR-ALPHA; TISSUE; XENOESTROGEN BISPHENOL-A</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>5</issue>
    <volume>8</volume>
    <abstract>Exposure of rodent fetuses to low doses of the endocrine disruptor bisphenol A (BPA) causes subtle morphological changes in the prenatal mammary gland and results in pre-cancerous and cancerous lesions during adulthood. To examine whether the BPA-induced morphological alterations of the fetal mouse mammary glands are a) associated with changes in mRNA expression reflecting estrogenic actions and/or b) dependent on the estrogen receptor alpha (ER alpha), we compared the transcriptomal effects of BPA and the steroidal estrogen ethinylestradiol (EE2) on fetal mammary tissues of wild type and ER alpha knock-out mice. Mammary glands from fetuses of dams exposed to vehicle, 250 ng BPA/kg BW/d or 10 ng EE2/kg BW/d from embryonic day (E) 8 were harvested at E19. Transcriptomal analyses on the ductal epithelium and periductal stroma revealed altered expression of genes involved in the focal adhesion and adipogenesis pathways in the BPA-exposed stroma while genes regulating the apoptosis pathway changed their expression in the BPA-exposed epithelium. These changes in gene expression correlated with previously reported histological changes in matrix organization, adipogenesis, and lumen formation resulting in enhanced maturation of the fat-pad and delayed lumen formation in the epithelium of BPA-exposed fetal mammary glands. Overall similarities in the transcriptomal effects of BPA and EE2 were more pronounced in the epithelium, than in the stroma. In addition, the effects of BPA and EE2 on the expression of various genes involved in mammary stromal-epithelial interactions were suppressed in the absence of ER alpha. These observations support a model whereby BPA and EE2 act directly on the stroma, which expresses ER alpha, ER beta and GPR30 in fetal mammary glands, and that the stroma, in turn, affects gene expression in the epithelium, where ER alpha and ER beta are below the level of detection at this stage of development</abstract>
    <url>WOS:000319330200083</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>293</id>
    <title>Transgenerational neuroendocrine disruption of reproduction</title>
    <authors>Walker,D.M.; Gore,A.C.</authors>
    <availability>[Gore, Andrea C.] Univ Texas Austin, Div Pharmacol &amp; Toxicol, Coll Pharm, Austin, TX 78712 USA. [Walker, Deena M.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewGore, AC (reprint author), Univ Texas Austin, Div Pharmacol &amp; Toxicol, Coll Pharm, 1 Univ Stn,Box A1915, Austin, TX 78712 USAandrea.gore@mail.utexas.eduAnway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058; Anway MD, 2008, REPROD TOXICOL, V26, P100, DOI 10.1016/j.reprotox.2008.07.008; Anway MD, 2008, GENOMICS, V91, P30, DOI 10.1016/j.ygeno.2007.10.002; Anway MD, 2006, J ANDROL, V27, P868, DOI 10.2164/jandrol.106.000349; Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc; Bakker J, 2006, NAT NEUROSCI, V9, P220, DOI 10.1038/nn1624; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Blatt J, 2003, J PEDIAT HEMATOL ONC, V25, P635, DOI 10.1097/00043426-200308000-00009; Bolander F.F., 2004, MOL ENDOCRINOLOGY; BOWLER PJ, 1975, J HIST IDEAS, V36, P95, DOI 10.2307/2709013; Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; Cameron NM, 2008, J NEUROENDOCRINOL, V20, P795, DOI 10.1111/j.1365-2826.2008.01725.x; Champagne FA, 2008, FRONT NEUROENDOCRIN, V29, P386, DOI 10.1016/j.yfrne.2008.03.003; Chung YW, 2001, PHYSIOL BEHAV, V74, P363, DOI 10.1016/S0031-9384(01)00579-0; Cornil CA, 2006, BRAIN RES, V1126, P2, DOI 10.1016/j.brainres.2006.07.098; Crews D, 2007, P NATL ACAD SCI USA, V104, P5942, DOI 10.1073/pnas.0610410104; Crews D, 2000, Q REV BIOL, V75, P243, DOI 10.1086/393498; Crews D, 2008, FRONT NEUROENDOCRIN, V29, P344, DOI 10.1016/j.yfrne.2008.01.003; Crews D, 2011, HORM BEHAV, V59, P393, DOI 10.1016/j.yhbeh.2010.07.001; Davis EC, 1996, NEUROENDOCRINOLOGY, V63, P142, DOI 10.1159/000126950; Davis EC, 1995, NEUROENDOCRINOLOGY, V62, P579, DOI 10.1159/000127053; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/S0006-8993(96)00298-3; Desaulniers D, 2009, INT J TOXICOL, V28, P294, DOI 10.1177/1091581809337918; Desaulniers D, 2005, INT J TOXICOL, V24, P111, DOI 10.1080/10915810590936382; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; *EUR COMM, 1996, 17549 EUR COMM; Gore AC, 2008, FRONT NEUROENDOCRIN, V29, P358, DOI 10.1016/j.yfrne.2008.02.002; Gore AC, 2010, HORM-INT J ENDOCRINO, V9, P16; GORSKI RA, 1980, J COMP NEUROL, V193, P529, DOI 10.1002/cne.901930214; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440; Herbst A L, 1981, Obstet Gynecol Annu, V10, P267; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Homburg R, 2009, HUM REPROD, V24, P1548, DOI 10.1093/humrep/dep049; Inawaka K, 2009, TOXICOL APPL PHARM, V237, P178, DOI 10.1016/j.taap.2009.03.004; Jablonka E, 2009, Q REV BIOL, V84, P131; Juntti SA, 2010, NEURON, V66, P260, DOI 10.1016/j.neuron.2010.03.024; Kavlock RJ, 1996, RISK ANAL, V16, P731, DOI 10.1111/j.1539-6924.1996.tb00824.x; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Klip H, 2001, HUM REPROD, V16, P2451; Koistinen J, 1997, CHEMOSPHERE, V35, P1249, DOI 10.1016/S0045-6535(97)00212-9; Kurian JR, 2010, ENDOCRINOLOGY, V151, P2297, DOI 10.1210/en.2009-0649; LEPHART ED, 1992, MOL BRAIN RES, V16, P187, DOI 10.1016/0169-328X(92)90224-Y; Li SF, 2001, MOL CARCINOGEN, V32, P213, DOI 10.1002/mc.10015; Li SF, 1997, CANCER RES, V57, P4356; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; MCLACHLAN JA, 1987, ENVIRON HEALTH PERSP, V75, P25, DOI 10.2307/3430572; Murray EK, 2009, ENDOCRINOLOGY, V150, P4241, DOI 10.1210/en.2009-0458; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Nilsson EE, 2008, REPRODUCTION, V135, P713, DOI 10.1530/REP-07-0542; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Pearce EN, 2009, BEST PRACT RES CL EN, V23, P801, DOI 10.1016/j.beem.2009.06.003; PHOENIX CH, 1959, ENDOCRINOLOGY, V65, P369; Qiu J, 2006, NATURE, V441, P143, DOI 10.1038/441143a; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rosenfeld CS, 2010, BIOL REPROD, V82, P473, DOI 10.1095/biolreprod.109.080952; Ryan BC, 2010, TOXICOL SCI, V114, P133, DOI 10.1093/toxsci/kfp266; Salama J, 2003, ENVIRON HEALTH PERSP, V111, P1278, DOI 10.1289/ehp.6126; Salian S, 2009, LIFE SCI, V85, P742, DOI 10.1016/j.lfs.2009.10.004; Salian S, 2009, LIFE SCI, V85, P11, DOI 10.1016/j.lfs.2009.04.005; Sato K, 2006, ENDOCR J, V53, P331, DOI 10.1507/endocrj.K06-009; Sato K, 2009, ENDOCR J, V56, P131; Schneider S, 2008, REPROD TOXICOL, V25, P352, DOI 10.1016/j.reprotox.2008.04.001; Shimada M, 2010, ARCH TOXICOL, V84, P271, DOI 10.1007/s00204-009-0493-0; SIMERLY RB, 1985, BRAIN RES, V330, P55, DOI 10.1016/0006-8993(85)90007-1; Skinner MK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003745; Steinberg RM, 2007, HORM BEHAV, V51, P364, DOI 10.1016/j.yhbeh.2006.12.004; Steinberg RM, 2008, BIOL REPROD, V78, P1091, DOI 10.1095/biolreprod.107.067249; Stouder C, 2010, REPRODUCTION, V139, P373, DOI 10.1530/REP-09-0340; Titus-Ernstoff L, 2006, INT J EPIDEMIOL, V35, P862, DOI 10.1093/ije/dyl106; Titus-Ernstoff L, 2010, INT J ANDROL, V33, P377, DOI 10.1111/j.1365-2605.2009.01010.x; Tsai HW, 2009, EPIGENETICS, V4, P47; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791; Walker DM, 2007, CONTEMP ENDOCRINOL S, P63, DOI 10.1007/1-59745-107-X_4; Westberry JM, 2010, ENDOCRINOLOGY, V151, P731, DOI 10.1210/en.2009-0955; Wingfield JC, 2008, GEN COMP ENDOCR, V157, P207, DOI 10.1016/j.ygcen.2008.04.017; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.0288529NATURE PUBLISHING GROUPNEW YORK75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USANAT REV ENDOCRINOLAPRDiscipline: Endocrinology &amp; Metabolism739DV</notes>
    <keywords>ADULT-ONSET DISEASE; ADULTHOOD; ANTEROVENTRAL PERIVENTRICULAR NUCLEUS; bisphenol; bisphenol A; BISPHENOL-A; CANCER; Carcinogen; CARCINOGENESIS; CHEMICALS; Differentiation; DISEASE; DISORDERS; DISRUPTING CHEMICALS; DNA METHYLATION; DNA-methylation; DYSFUNCTION; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemicals; ENDOCRINE DISRUPTORS; environmental exposure; epigenetic; epigenetics; Epigenome; EXPOSED IN-UTERO; EXPOSURE; EXPRESSION; HEALTH; HISTONE MODIFICATIONS; mechanism; MECHANISMS; METABOLISM; METHYLATION; molecular mechanism; MOLECULAR-MECHANISMS; Nongenomic; POLYCHLORINATED-BIPHENYLS; PREOPTIC AREA; Reproduction; Review; RISK; SEX-DIFFERENCES; SEXUAL-DIFFERENTIATION; SEXUALLY DIMORPHIC NUCLEUS; SPRAGUE-DAWLEY RATS; SYSTEM; Thyroid function; Transgenerational; Vinclozolin</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>197</startpage>
    <endpage>207</endpage>
    <journalfull>Nature Reviews Endocrinology</journalfull>
    <issue>4</issue>
    <volume>7</volume>
    <abstract>Exposure to endocrine disrupting chemicals (EDCs) is associated with dysfunctions of metabolism, energy balance, thyroid function and reproduction, and an increased risk of endocrine cancers. These multifactorial disorders can be 'programmed' through molecular epigenetic changes induced by exposure to EDCs early in life, the expression of which may not manifest until adulthood. In some cases, EDCs have detrimental effects on subsequent generations, which indicates that traits for disease predisposition may be passed to future generations by nongenomic inheritance. This Review discusses current understanding of the epigenetic mechanisms that underlie sexual differentiation of reproductive neuroendocrine systems in mammals and summarizes the literature on transgenerational epigenetic effects of representative EDCs: vinclozolin, diethylstilbesterol, bisphenol A and polychlorinated biphenyls. The article differentiates between context-dependent epigenetic transgenerational changes-namely, those that require environmental exposure, either via the EDC itself or through behavioral or physiological differences in parents-and germline-dependent epigenetic mechanisms. These processes, albeit discrete, are not mutually exclusive and can involve similar molecular mechanisms including DNA methylation and histone modifications and may predispose exposed individuals to transgenerational disruption of reproductive processes. New insights stress the crucial need to develop a clear understanding of how EDCs may program the epigenome of exposed individuals and their descendants</abstract>
    <url>WOS:000288694600006</url>
    <isbnorissn>1759-5029</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>342</id>
    <title>G protein-coupled receptor 30 in tumor development</title>
    <authors>Wang,D.F.; Hu,L.N.; Zhang,G.N.; Zhang,L.; Chen,C.</authors>
    <availability>[Wang, Dengfeng; Zhang, Lin; Chen, Chen] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia. [Wang, Dengfeng; Zhang, Guonan] Sichuan Canc Hosp, Peoples Hosp Sichuan 2, Dept Gynecol Oncol, Chengdu 610041, Sichuan, Peoples R China. [Hu, Lina] Sichuan Univ, W China Hosp 2, Dept Gynecol &amp; Obstet, Chengdu 610041, Sichuan, Peoples R China.</availability>
    <date>2010</date>
    <notes>JEnglishReviewChen, C (reprint author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australiachen.chen@uq.edu.auAlbanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Alyea RA, 2008, J NEUROCHEM, V106, P1525, DOI 10.1111/j.1471-4159.2008.05491.x; Azios NG, 2005, NEOPLASIA, V7, P128, DOI 10.1593/neo.04346; Baker L, 2003, J SURG RES, V115, P325, DOI 10.1016/S0022-4804(03)00221-X; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; Chen GG, 2008, MED RES REV, V28, P954, DOI 10.1002/med.20131; Cheng J, 2004, FEBS LETT, V566, P169, DOI 10.1016/j.febslet.2004.04.025; Dechering K, 2000, CURR MED CHEM, V7, P561; Dick GM, 2002, MOL PHARMACOL, V61, P1105, DOI 10.1124/mol.61.5.1105; Abe O, 2005, LANCET, V365, P1687; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Filardo E, 2007, ENDOCRINOLOGY, V148, P3236, DOI 10.1210/en.2006-1605; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2008, STEROIDS, V73, P870, DOI 10.1016/j.steroids.2007.12.025; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966; Frank GR, 2003, MED PEDIATR ONCOL, V41, P217, DOI 10.1002/mpo.10340; Funakoshi T, 2006, BIOCHEM BIOPH RES CO, V346, P904, DOI 10.1016/j.bbrc.2006.05.191; Gobeil F, 2006, CAN J PHYSIOL PHARM, V84, P287, DOI 10.1139/Y05-127; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Gutierrez-Hartmann A, 2007, TRENDS ENDOCRIN MET, V18, P150, DOI 10.1016/j.tem.2007.03.002; Haas E, 2007, HYPERTENSION, V49, P1358, DOI 10.1161/HYPERTENSIONAHA.107.089995; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243; He YY, 2009, CANCER SCI, V100, P1051, DOI 10.1111/j.1349-7006.2009.01148.x; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Henic E, 2009, INT J GYNECOL CANCER, V19, P214, DOI 10.1111/IGC.0b013e31819bcb75; Hermenegildo C, 2000, HUM REPROD UPDATE, V6, P237, DOI 10.1093/humupd/6.3.237; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; JENSEN EV, 1973, SCIENCE, V182, P126, DOI 10.1126/science.182.4108.126; Kang K, 2009, MOL CELLS, V27, P351, DOI 10.1007/s10059-009-0045-8; Kleuser B, 2008, MOL PHARMACOL, V74, P1533, DOI 10.1124/mol.108.046854; Kovacs EJ, 2002, MOL CELL ENDOCRINOL, V193, P129, DOI 10.1016/S0303-7207(02)00106-5; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuo Wen-Hung, 2007, Taiwan J Obstet Gynecol, V46, P135, DOI 10.1016/S1028-4559(07)60007-2; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Leblanc K, 2007, INT J ONCOL, V30, P477; Liu ZW, 2008, TOXICOL APPL PHARM, V228, P286, DOI 10.1016/j.taap.2007.12.017; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Matsuda KI, 2008, NEUROSCI LETT, V441, P94, DOI 10.1016/j.neulet.2008.05.108; Muller R E, 1979, Adv Exp Med Biol, V117, P401; O'Dowd BF, 1998, GENOMICS, V47, P310, DOI 10.1006/geno.1998.5095; Otto C, 2008, ENDOCRINOLOGY, V149, P4846, DOI 10.1210/en.2008-0269; Owman C, 1996, BIOCHEM BIOPH RES CO, V228, P285, DOI 10.1006/bbrc.1996.1654; Pandey DP, 2009, EMBO J, V28, P523, DOI 10.1038/emboj.2008.304; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Prossnitz ER, 2007, MOL CELL ENDOCRINOL, V265, P138, DOI 10.1016/j.mce.2006.12.010; Prossnitz ER, 2008, J STEROID BIOCHEM, V109, P350, DOI 10.1016/j.jsbmb.2008.03.006; Prossnitz ER, 2008, TRENDS PHARMACOL SCI, V29, P116, DOI 10.1016/j.tips.2008.01.001; Revankar CM, 2007, ACS CHEM BIOL, V2, P536, DOI 10.1021/cb700072n; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rey JM, 2000, J MOL ENDOCRINOL, V24, P433, DOI 10.1677/jme.0.0240433; Ricke WA, 2008, FASEB J, V22, P1512, DOI 10.1096/fj.07-9526com; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Smith HO, 2007, AM J OBSTET GYNECOL, V196; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Strick R, 2007, J MOL MED-JMM, V85, P23, DOI 10.1007/s00109-006-0104-y; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Takada Y, 1997, BIOCHEM BIOPH RES CO, V240, P737, DOI 10.1006/bbrc.1997.7734; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Toran-Allerand CD, 2004, ENDOCRINOLOGY, V145, P1069, DOI 10.1210/en.2003-1462; Treeck O, 2006, GYNECOL ONCOL, V102, P292, DOI 10.1016/j.ygyno.2005.12.019; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/mrc839; Wang C, 2008, ENDOCRINOLOGY, V149, P4452, DOI 10.1210/en.2008-0441; Wang C, 2007, ENDOCRINOLOGY, V148, P4853, DOI 10.1210/en.2007-0727; Weihua Z, 2000, Proc Natl Acad Sci U S A, V97, P5936, DOI 10.1073/pnas.97.11.5936; Yang JZ, 2008, STEROIDS, V73, P1110, DOI 10.1016/j.steroids.2008.04.012; Zeng Q, 2007, CELL PROLIFERAT, V40, P921, DOI 10.1111/j.1365-2184.2007.00471.x; Zhang ZS, 2008, PROSTATE, V68, P508, DOI 10.1002/pros.207228222HUMANA PRESS INCTOTOWA999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USAENDOCRINEAUGDiscipline: Endocrinology &amp; Metabolism634XY</notes>
    <keywords>ACTIVATION; BISPHENOL-A; BREAST-CANCER CELLS; CANCER; CARCINOMA-CELLS; CELL; CELLS; development; ENDOCRINE; ER-ALPHA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPRESSION; G protein-coupled receptor 30; G-PROTEIN-COUPLED-RECEPTOR-30 GPR30; GLAND; GOLD; GPR30; GROWTH-FACTOR RECEPTOR; HAMSTER OVARY; HEALTH; KINASE; mammary gland; MAMMARY-GLAND; MEMBRANE ESTROGEN-RECEPTOR; METABOLISM; Neoplasia; non-genomic; Nongenomic; PATHWAY; PLASMA-MEMBRANE; Prostate; PROTEIN; PROTEIN-COUPLED RECEPTOR; PROTEIN-KINASE; RECEPTOR; Receptors; REPRODUCTIVE-SYSTEM; RESISTANCE; Review; SIGNALING PATHWAY; SIGNALING PATHWAYS; Steroid; SYSTEM; TARGET; transcriptional activation; TUMOR; TUMORS; UPDATE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>29</startpage>
    <endpage>37</endpage>
    <journalfull>Endocrine</journalfull>
    <issue>1</issue>
    <volume>38</volume>
    <abstract>Estrogen plays several important physiological and pathological functions in not only reproductive system but many other systems as well. Its transcriptional activation has been traditionally described as being mediated by classic nuclear estrogen receptors (ERs). It is however established recently that a novel functional estrogen transmembrane receptor, G protein-coupled receptor 30 (GPR30), modulates both rapid non-genomic events and genomic transcriptional events of estrogen. It has been demonstrated that GPR30 promotes the progress of estrogen-related tumors through mitogen-activated protein kinase (MAPK) signaling pathways. Effects mediated by GPR30 are maintained when classic ERs are absent or blocked. In addition, GPR30 is involved in drug resistance, which is often occurring during cancer treatments. All these new findings strongly imply that GPR30 may be an important therapeutic target for estrogen-related tumors. Simultaneously blocking both GPR30 and classic ERs may be a better strategy for the treatment of estrogen-related tumors</abstract>
    <url>WOS:000280620800006</url>
    <isbnorissn>0969-711X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>54</id>
    <title>Pubertal Bisphenol A Exposure Alters Murine Mammary Stem Cell Function Leading to Early Neoplasia in Regenerated Glands</title>
    <authors>Wang,D.H.; Gao,H.; Bandyopadhyay,A.; Wu,A.Q.; Yeh,I.T.; Chen,Y.D.; Zou,Y.; Huang,C.J.; Walter,C.A.; Dong,Q.X.; Sun,L.Z.</authors>
    <availability>[Wang, Danhan; Gao, Hui; Wu, Anqi; Huang, Changjiang; Dong, Qiaoxiang] Wenzhou Med Univ, Sch Environm Sci &amp; Publ Hlth, Univ Town, Wenzhou, Peoples R China. [Wang, Danhan; Gao, Hui; Bandyopadhyay, Abhik; Wu, Anqi; Walter, Christi A.; Dong, Qiaoxiang; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular &amp; Struct Biol, San Antonio, TX 78229 USA. [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol &amp; Biostat, San Antonio, TX 78229 USA. [Bandyopadhyay, Abhik; Chen, Yidong; Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy &amp; Res Ctr, San Antonio, TX 78229 USA. [Chen, Yidong; Zou, Yi] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. [Yeh, I-Tien] Virginia Hosp Ctr, Dept Pathol, Arlington, VA USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDong, QX (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USAdongq2@uthscsa.edu; sunl@uthscsa.eduAnders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129; Bandyopadhyay Abhik, 2012, Methods Mol Biol, V879, P179, DOI 10.1007/978-1-61779-815-3_12; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Dong QX, 2013, STEM CELL RES, V10, P396, DOI 10.1016/j.scr.2013.01.007; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Fenton SE, 2012, ANNU REV PHARMACOL, V52, P455, DOI 10.1146/annurev-pharmtox-010611-134659; HASLAM SZ, 1977, P NATL ACAD SCI USA, V74, P4020, DOI 10.1073/pnas.74.9.4020; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jones LP, 2010, TOXICOL LETT, V199, P261, DOI 10.1016/j.toxlet.2010.09.008; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lindeman GJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2840; Markey CM, 2001, BIOL REPROD, V65, P1215; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shen Q, 2003, J MAMMARY GLAND BIOL, V8, P45, DOI 10.1023/A:1025783221557; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2009, J PATHOL, V217, P229, DOI 10.1002/path.2457; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109; Tripathi A, 2008, INT J CANCER, V122, P1557, DOI 10.1002/ijc.23267; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Yang LQ, 2013, TOXICOL LETT, V218, P187, DOI 10.1016/j.toxlet.2013.01.026430AMER ASSOC CANCER RESEARCHPHILADELPHIA615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USACANCER PREV RESAPRDiscipline: OncologyAE5VK</notes>
    <keywords>ALTERS; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CELLS; EMBRYOGENESIS; EXPOSURE; EXPRESSION; gene expression; GENE-EXPRESSION; IN-UTERO EXPOSURE; MAMMARY-GLAND; mechanism; MICE; PERINATAL EXPOSURE; POPULATION; PROGENITORS; RAT; SUSCEPTIBILITY; TUMORIGENESIS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>445</startpage>
    <endpage>455</endpage>
    <journalfull>Cancer Prevention Research</journalfull>
    <issue>4</issue>
    <volume>7</volume>
    <abstract>Perinatal exposure to bisphenol A (BPA) has been shown to cause aberrant mammary gland morphogenesis and mammary neoplastic transformation. Yet, the underlying mechanism is poorly understood. We tested the hypothesis that mammary glands exposed to BPA during a susceptible window may lead to its susceptibility to tumorigenesis through a stem cell-mediated mechanism. We exposed 21-day-old Balb/c mice to BPA by gavage (25 mu g/kg/d) during puberty for 3 weeks, and a subset of animals were further challenged with one oral dose (30mg/kg) of 7,12-dimethylbenz(a) anthracene (DMBA) at 2 months of age. Primary mammary cells were isolated at 6 weeks, and 2 and 4 months of age for murine mammary stem cell (MaSC) quantification and function analysis. Pubertal exposure to the low-dose BPA increased lateral branches and hyperplasia in adult mammary glands and caused an acute increase of MaSC in 6-week-old glands and a delayed increase of luminal progenitors in 4-month-old adult gland. Most importantly, pubertal BPA exposure altered the function of MaSC from different age groups, causing early neoplastic lesions in their regenerated glands similar to those induced by DMBA exposure, which indicates that MaSCs are susceptible to BPA-induced transformation. Deep sequencing analysis on MaSC-enriched mammospheres identified a set of aberrantly expressed genes associated with early neoplastic lesions in patients with human breast cancer. Thus, our study for the first time shows that pubertal BPA exposure altered MaSC gene expression and function such that they induced early neoplastic transformation.(c) 2014 AACR</abstract>
    <url>WOS:000334057200010</url>
    <isbnorissn>1940-6207</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>422</id>
    <title>Mesoporous silica-based electrochemical sensor for sensitive determination of environmental hormone bisphenol A</title>
    <authors>Wang,F.G.; Yang,J.Q.; Wu,K.B.</authors>
    <availability>[Wang, Fengran; Yang, Jinquan; Wu, Kangbing] Huazhong Univ Sci &amp; Technol, Dept Chem, Wuhan 430074, Peoples R China.</availability>
    <date>2009</date>
    <notes>JEnglishArticleWu, KB (reprint author), Huazhong Univ Sci &amp; Technol, Dept Chem, Wuhan 430074, Peoples R Chinakbwu@mail.hust.edu.cnFan J, 2007, ANAL CHIM ACTA, V585, P134, DOI 10.1016/j.aca.2006.12.026; Foster WG, 2001, WATER QUAL RES J CAN, V36, P253; Galarneau A, 2006, J PHYS CHEM B, V110, P4058, DOI 10.1021/jp056186b; Gatidou G, 2007, J CHROMATOGR A, V1138, P32, DOI 10.1016/j.chroma.2006.10.037; Hileman B, 2003, CHEM ENG NEWS, V81, P7, DOI 10.1021/cen-v081n014.p007; Hu JY, 2002, ENVIRON SCI TECHNOL, V36, P1980, DOI 10.1021/es011177b; Jin XL, 2004, CHEMOSPHERE, V56, P1113, DOI 10.1016/j.chemosphere.2004.04.052; Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870; Jonathan N.B., 1998, TRENDS ENDOCRIN MET, V9, P124; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kawaguchi M, 2006, J CHROMATOGR A, V1110, P1, DOI 10.1016/j.chroma.2006.01.061; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kuklenyik Z, 2003, ANAL CHEM, V75, P6820, DOI 10.1021/ac0303158; Kuramitz H, 2004, WATER RES, V38, P2331, DOI 10.1016/j.watres.2004.02.023; Kuramitz H, 2001, CHEMOSPHERE, V45, P37, DOI 10.1016/S0045-6535(01)00032-7; Lee HB, 2000, WATER QUAL RES J CAN, V35, P283; Liu M, 2006, J CHROMATOGR A, V1133, P142, DOI 10.1016/j.chroma.2006.08.009; MONICA MT, 2005, ENDOCRINOLOGY, V146, P4138; Ou JJ, 2006, TALANTA, V69, P1001, DOI 10.1016/j.talanta.2005.12.003; Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0; Sajiki J, 2001, J CHROMATOGR B, V755, P9, DOI 10.1016/S0378-4347(00)00489-8; Sajiki J, 2003, J CHROMATOGR B, V783, P367, DOI 10.1016/S1570-0232(02)00639-6; Sambe H, 2006, J CHROMATOGR A, V1134, P16, DOI 10.1016/j.chroma.2006.08.072; Skakkebaek NE, 1998, APMIS, V106, P3; Staples CA, 2000, CHEMOSPHERE, V40, P521, DOI 10.1016/S0045-6535(99)00288-X; Torres RA, 2007, ENVIRON SCI TECHNOL, V41, P297, DOI 10.1021/es061440e; Wang X, 2006, ANAL CHIM ACTA, V556, P313, DOI 10.1016/j.aca.2005.09.060; Watabe Y, 2004, J CHROMATOGR A, V1032, P45, DOI 10.1016/j.chroma.2003.11.079; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Yantasee W, 2008, ANAL CHIM ACTA, V620, P55, DOI 10.1016/j.aca.2008.05.029; Zeng YH, 2008, ELECTROCHIM ACTA, V53, P4615, DOI 10.1016/j.electacta.2008.01.011; Zhang HX, 2006, ANAL CHEM, V78, P1967, DOI 10.1021/ac051826s3374ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSANAL CHIM ACTAAPR 6Discipline: Chemistry429CN</notes>
    <keywords>Behavior; bisphenol; bisphenol A; bisphenol A (BPA); BISPHENOL-A; BPA; CANCER; CARBON; CARBON-FIBER ELECTRODE; CHINA; CHROMATOGRAPHY-MASS SPECTROMETRY; Composition; DERIVATIZATION; detection; Determination; DISRUPTION; Electrochemical sensor; ENDOCRINE; estrogenic activity; HEALTH; Hormone; Mesoporous silica; Modified electrode; NANOTUBES; PERFORMANCE LIQUID-CHROMATOGRAPHY; REMOVAL; RIVER WATER; SAMPLES; Silica; SLUDGE; SYSTEM; toxicology; WASTE-WATER; WATER; WATER SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>23</startpage>
    <endpage>28</endpage>
    <journalfull>Analytica Chimica Acta</journalfull>
    <issue>1</issue>
    <volume>638</volume>
    <abstract>Bisphenol A (BPA) is an emerging contaminant with severe toxic effects Such as disrupting endocrine system or causing cancer, therefore, developing sensitive and selective sensor for BPA is very important and interesting. Herein, MCM-41, a kind of mesoporous silica, was synthesized and then used to prepare an electrochemical sensor for BPA. For better comparison, carbon nanotubes, activated carbon, silica gel and graphite were also employed to prepare electrochemical sensor for BPA. The electrochemical behaviors of BPA at different electrochemical sensors were investigated. Compared with other sensors, the MCM-41 sensor greatly enhances the response signal of BPA due to the large active surface area and high accumulation efficiency. The effects of pH value, accumulation time and sensor composition were examined. The linear range is from 2.2 x 10(-7) to 8.8 x 10(-6) mol L-1, and the limit of detection is evaluated to be 3.8 x 10(-8) mol L-1. Finally, the MCM-41 sensor was successfully employed to determine BPA in water samples. (c) 2009 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000264898500003</url>
    <isbnorissn>0003-2670</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>350</id>
    <title>Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor</title>
    <authors>Wang,H.; Li,J.A.; Gao,Y.; Xu,Y.; Pan,Y.; Tsuji,I.; Sun,Z.J.; Li,X.M.</authors>
    <availability>[Wang, Hao; Gao, Yang; Xu, Ying; Pan, Ying; Li, Xiao-Meng] NE Normal Univ, Sch Life Sci, Changchun 130024, Peoples R China. [Li, Jiang] Jilin Univ, Dent Hosp, Changchun 130041, Peoples R China. [Tsuji, Ichiro] Tohoku Univ, Dept Publ Hlth, Sendai, Miyagi 9808576, Japan. [Sun, Zi-Jie] Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94303 USA. [Sun, Zi-Jie] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94303 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleLi, XM (reprint author), NE Normal Univ, Sch Life Sci, Changchun 130024, Peoples R Chinalixm441@nenu.edu.cnADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; Adlercreutz H, 1997, ANN MED, V29, P95; Akaza H, 2002, JPN J CLIN ONCOL, V32, P296, DOI 10.1093/jjco/hyf064; Allen NE, 2004, CANCER CAUSE CONTROL, V15, P911, DOI 10.1007/s10552-004-1683-y; BARDIN CW, 1983, PHARMACOL THERAPEUT, V23, P443; Bemis DL, 2004, CLIN CANCER RES, V10, P5282, DOI 10.1158/1078-0432.CCR-03-0828; BOGERT CJ, 1994, OCCUPATIONAL MED, P836; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cato Andrew C B, 2002, Sci STKE, V2002, pre9, DOI 10.1126/stke.2002.138.re9; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HF, 2002, ACTA CHIM SINICA, V60, P1860; Chen JJ, 2007, PROSTATE, V67, P457, DOI 10.1002/pros.20470; Clapp Richard W., 2008, Reviews on Environmental Health, V23, P1; Cocco Pierluigi, 2002, Cad Saude Publica, V18, P379, DOI 10.1590/S0102-311X2002000200003; Cocco P, 1998, ONCOLOGY-BASEL, V55, P334, DOI 10.1159/000011872; Davis JN, 2002, MOL CARCINOGEN, V34, P91, DOI 10.1002/mc.10053; De Jesus-Tran KP, 2006, PROTEIN SCI, V15, P987, DOI 10.1110/ps.051905906; Denis L, 1999, EUR UROL, V35, P377, DOI 10.1159/000019912; Drees M, 1997, CLIN CANCER RES, V3, P273; D'Ursi P, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S4-S10; El Touny LH, 2009, CANCER RES, V69, P3695, DOI 10.1158/0008-5472.CAN-08-2958; Eskenazi B, 2009, ENVIRON HEALTH PERSP, V117, P1359, DOI 10.1289/ehp.11748; Eustache F, 2009, ENVIRON HEALTH PERSP, V117, P1272, DOI 10.1289/ehp.0800158; Gao S, 2004, PROSTATE, V59, P214, DOI 10.1002/pros.10375; He YP, 2005, CHEM J CHINESE U, V26, P254; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henley DV, 2006, ENDOCRINOLOGY, V147, pS25, DOI 10.1210/en.2005-1117; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hwang YW, 2009, NUTR CANCER, V61, P598, DOI 10.1080/01635580902825639; Inaguma S, 2004, CANCER LETT, V212, P159, DOI 10.1016/j.canlet.2004.03.028; Jacobsen BK, 1998, CANCER CAUSE CONTROL, V9, P553, DOI 10.1023/A:1008819500080; Jain MG, 1999, NUTR CANCER, V34, P173, DOI 10.1207/S15327914NC3402_8; Jian L, 2009, MOL NUTR FOOD RES, V53, P217, DOI 10.1002/mnfr.200800167; Kao P C, 1995, Zhonghua Yi Xue Za Zhi (Taipei), V55, P209; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Klotz DM, 1996, ENVIRON HEALTH PERSP, V104, P1084, DOI 10.2307/3433121; Kohen F, 2007, J MED CHEM, V50, P6405, DOI 10.1021/jm070727z; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Kurahashi N, 2007, CANCER EPIDEM BIOMAR, V16, P538, DOI 10.1158/1055-9965.EPI-06-0517; Kuwahara M, 2003, UROLOGY, V61, P137, DOI 10.1016/S0090-4295(02)02093-9; Kwan W, 2010, NUTR CANCER, V62, P198, DOI 10.1080/01635580903305318; Lee HJ, 2003, TOXICOL SCI, V75, P40, DOI 10.1093/toxsci/kfg150; Lee MM, 2003, CANCER EPIDEM BIOMAR, V12, P665; Li Xiaomeng, 2004, International Urology and Nephrology, V36, P541, DOI 10.1007/s11255-004-0842-0; Li XM, 2008, ASIAN J ANDROL, V10, P551, DOI 10.1111/j.1745-7262.2008.00384.x; Lill MA, 2005, J MED CHEM, V48, P5666, DOI 10.1021/jm050403f; Lu NZ, 2006, PHARMACOL REV, V58, P782, DOI 10.1124/pr.58.4.9; Malkowicz SB, 2001, UROLOGY, V58, P108, DOI 10.1016/S0090-4295(01)01252-3; Merrill RM, 1997, EPIDEMIOLOGY, V8, P126, DOI 10.1097/00001648-199703000-00001; Messina M, 2002, J NUTR, V132, p547S; Montgomery RB, 2007, CANCER, V110, P996, DOI 10.1002/cncr.22917; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14&lt;1639::AID-JCC10&gt;3.0.CO;2-B; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Nagata Y, 2007, J NUTR, V137, P1974; Nomura AMY, 2004, CANCER EPIDEM BIOMAR, V13, P2277; Pendleton JM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-132; Prins GS, 2008, ENDOCR-RELAT CANCER, V15, P649, DOI 10.1677/ERC-08-0043; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Raudrant D, 2003, DRUGS, V63, P463, DOI 10.2165/00003495-200363050-00003; RIES LAG, 1994, NIH942789 PUBL, P1; Rogan WJ, 2005, LANCET, V366, P763, DOI 10.1016/S0140-6736(05)67182-6; ROSENBERG Z, 2002, CLIN CHIM ACTA, V317, P17; Roy AK, 1999, VITAM HORM, V55, P309; RUMSEY TS, 1981, J ANIM SCI, V53, P589; Scherr D, 2002, J UROLOGY, V167, P535, DOI 10.1016/S0022-5347(01)69080-3; Serrate C, 2009, ANN ONCOL, V20, P965, DOI 10.1093/annonc/mdp112; SEVERSON RK, 1989, CANCER RES, V49, P1857; Sharma P, 2009, J UROLOGY, V182, P2265, DOI 10.1016/j.juro.2009.07.030; Shukla S, 2007, CANCER RES, V67, P6925, DOI 10.1158/0008-5472.CAN-07-0717; Singh RP, 2005, CARCINOGENESIS, V26, P845, DOI 10.1093/carcin/bgi014; Sonoda T, 2004, CANCER SCI, V95, P238, DOI 10.1111/j.1349-7006.2004.tb02209.x; Strom SS, 1999, NUTR CANCER, V33, P20; Takayama S, 1999, J CANCER RES CLIN, V125, P219, DOI 10.1007/s004320050266; Takezawa Y, 2001, SCAND J UROL NEPHROL, V35, P283; Tanaka M, 2009, PROSTATE CANCER P D, V12, P247, DOI 10.1038/pcan.2009.10; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Travis RC, 2009, BRIT J CANCER, V100, P1817, DOI 10.1038/sj.bjc.6605073; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Villeneuve PJ, 1999, CANCER CAUSE CONTROL, V10, P355, DOI 10.1023/A:1008958103865; Wang Jun, 2007, J Carcinog, V6, P3, DOI 10.1186/1477-3163-6-3; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wetherill YB, 2002, MOL CANCER THER, V1, P515; Wetherill YB, 2005, CANCER RES, V65, P54; Yildiz F., 2005, PHYTOESTROGENS FUNCT, P3; YOSHINO H, 2005, TOXICOL PATHOL, V18, P183; Zhao LF, 2005, ACTA PHYS-CHIM SIN, V21, P151, DOI 10.3866/PKU.WHXB20050208; Zhou JR, 2003, J NUTR, V133, P516; Zhou JR, 1999, J NUTR, V129, P16288912ACTA PHARMACOLOGICA SINICASHANGHAI294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINAASIAN J ANDROLJULDiscipline: Endocrinology &amp; Metabolism; Urology &amp; Nephrology620AK</notes>
    <keywords>4-NONYLPHENOL; ACTIVITY IN-VITRO; AFFINITIES; Androgen; ANDROGEN RECEPTOR; androgens; BINDING; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; Carcinogen; CARCINOGENESIS; CHINA; DDT; DES; development; DIETHYLSTILBESTROL; dock; ENVIRONMENTAL CHEMICALS; Epidemiology; ESTRADIOL; FOOD; genistein; HEALTH; Hormones; Interaction; ISOFLAVONE CONSUMPTION; JAPANESE MEN; JUN; LIGAND; LIGANDS; METABOLISM; molecular docking; Occupational; PHASE-II TRIAL; phyto-oestrogens; Phytoestrogen; PHYTOESTROGENS; PROGRESSION; Prostate; prostate cancer; PROSTATE-CANCER; PROSTATE-SPECIFIC ANTIGEN; PROTEIN; RECEPTOR; Review; SHANGHAI; Steroid; Thyroxine; UNITED-STATES; Xeno-oestrogen; xeno-oestrogens</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>535</startpage>
    <endpage>547</endpage>
    <journalfull>Asian Journal of Andrology</journalfull>
    <issue>4</issue>
    <volume>12</volume>
    <abstract>The androgen receptor (AR) plays a critical role in prostate cancer development and progression. This study aimed to use a computerized docking approach to examine the interactions between the human AR and phyto-oestrogens (genistein, daidzein, and flavone) and xeno-oestrogens (bisphenol A, 4-nonylphenol, dichlorodiphenyl trichloroethane [DDT], diethylstilbestrol [DES]). The predicted three-dimensional structure of AR and androgens was established using X-ray diffraction. The binding of four xeno-oestrogens and three phyto-oestrogens to AR was analysed. The steroids estradiol and dihydrotestosterone (DHT) were used as positive controls and thyroxine as negative control. All the ligands shared the same binding site except for thyroxine. The endogenous hormones DHT and 17 beta-oestradiol showed the strongest binding with the lowest affinity energy (&lt; -10 kcal mol(-1)). All three phyto-oestrogens and two xeno-oestrogens (bisphenol A and DES) showed strong binding to AR. The affinities of flavone, genistein, and daidzein were between -8.8 and -8.5 kcal mol(-1), while that of bisphenol A was -8.1 kcal mol(-1) and DES -8.3 kcal mol(-1). Another two xeno-oestrogens, 4-nonylphenol and DDT, although they fit within the binding domain of AR, showed weak affinity (-6.4 and -6.7 kcal mol(-1), respectively). The phyto-oestrogens genistein, daidzein and flavone, and the xeno-oestrogens bisphenol A and DES can be regarded as androgenic effectors. The xeno-oestrogens DDT and 4-nonylphenol bind only weakly to AR</abstract>
    <url>WOS:000279471200009</url>
    <isbnorissn>1008-682X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>172</id>
    <title>Enhanced screening efficiency for endocrine-disrupting chemicals in milk and powdered milk using UPLC/QTOF-MS by the introduction of dansyl chloride derivatisation</title>
    <authors>Wang,H.X.; Zhou,Y.; Jiang,Q.W.</authors>
    <availability>[Wang, He-Xing; Zhou, Ying; Jiang, Qing-Wu] Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Sch Publ Hlth, Shanghai 200032, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleZhou, Y (reprint author), Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Sch Publ Hlth, Shanghai 200032, Peoples R Chinayingchou@fudan.edu.cnAnari MR, 2002, ANAL CHEM, V74, P4136, DOI 10.1021/ac025712h; [Anonymous], 2002, OFF J EUR COMMUN L, VL221, P8; Azzouz A, 2011, J AGR FOOD CHEM, V59, P5125, DOI 10.1021/jf200364w; Behr M, 2011, FOOD CHEM TOXICOL, V49, P2681, DOI 10.1016/j.fct.2011.07.039; Casajuana N, 2004, J AGR FOOD CHEM, V52, P3702, DOI 10.1021/jf040027s; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Courant F, 2008, J AGR FOOD CHEM, V56, P3176, DOI 10.1021/jf800096f; Courant F, 2007, FOOD ADDIT CONTAM, V24, P1358, DOI 10.1080/02652030701329637; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Farke C, 2011, J AGR FOOD CHEM, V59, P1423, DOI 10.1021/jf103751z; Farlow DW, 2009, J CHROMATOGR B, V877, P1327, DOI 10.1016/j.jchromb.2009.01.032; Ferrer E, 2011, FOOD CHEM, V126, P360, DOI 10.1016/j.foodchem.2010.10.098; Fritsche S, 1999, EUR FOOD RES TECHNOL, V209, P153, DOI 10.1007/s002170050475; GAIANI R, 1984, J REPROD FERTIL, V70, P55; Ganmaa D, 2005, MED HYPOTHESES, V65, P1028, DOI 10.1016/j.mehy.2005.06.026; GINTHER OJ, 1976, J ANIM SCI, V42, P155; Guart A, 2011, FOOD ADDIT CONTAM A, V28, P676, DOI 10.1080/19440049.2011.555845; Guenther K, 2002, ENVIRON SCI TECHNOL, V36, P1676, DOI 10.1021/es010199v; Hartmann S, 1998, FOOD CHEM, V62, P7, DOI 10.1016/S0308-8146(97)00150-7; Hernandez F, 2005, TRAC-TREND ANAL CHEM, V24, P596, DOI 10.1016/j.trac.2005.04.007; Hernando MD, 2006, ANAL CHIM ACTA, V562, P176, DOI 10.1016/j.aca.2006.01.075; Inoue K, 2001, FOOD ADDIT CONTAM, V18, P157, DOI 10.1080/02652030010018930; Iwasaki Y, 2011, J CHROMATOGR B, V879, P1159, DOI 10.1016/j.jchromb.2011.02.008; Jouan PN, 2006, INT DAIRY J, V16, P1408, DOI 10.1016/j.idairyj.2006.06.007; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Kuo HW, 2004, J CHROMATOGR A, V1027, P67, DOI 10.1016/j.chroma.2003.08.084; Larsson SC, 2004, AM J CLIN NUTR, V80, P1353; Lehotay SJ, 2005, J AOAC INT, V88, P630; Main KM, 2010, BEST PRACT RES CL EN, V24, P279, DOI 10.1016/j.beem.2009.10.003; Niu YM, 2011, J CHROMATOGR A, V1218, P5248, DOI 10.1016/j.chroma.2011.06.005; Noppe H, 2008, ANAL CHIM ACTA, V611, P1, DOI 10.1016/j.aca.2008.01.066; PURDY RH, 1980, J STEROID BIOCHEM, V13, P1307, DOI 10.1016/0022-4731(80)90091-6; Qin LQ, 2004, NUTR CANCER, V48, P22, DOI 10.1207/s15327914nc4801_4; Qin LQ, 2004, MED HYPOTHESES, V62, P133, DOI 10.1016/S0306-9877(03)00295-0; Raecker T, 2011, CHEMOSPHERE, V82, P1533, DOI 10.1016/j.chemosphere.2010.11.065; Sancho JV, 2006, ANAL BIOANAL CHEM, V386, P987, DOI 10.1007/s00216-006-0532-0; Santa T, 2011, BIOMED CHROMATOGR, V25, P1, DOI 10.1002/bmc.1548; Shao B, 2005, ANAL CHIM ACTA, V548, P41, DOI 10.1016/j.aca.2005.06.003; Sharma VK, 2009, J ENVIRON SCI HEAL A, V44, P423, DOI 10.1080/10934520902719704; Shi Y, 2011, FOOD CHEM, V126, P1916, DOI 10.1016/j.foodchem.2010.12.020; Tan BLL, 2003, TALANTA, V61, P385, DOI 10.1016/S0039-9140(03)00281-9; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; Wang QL, 2010, ANAL CHIM ACTA, V678, P108, DOI 10.1016/j.aca.2010.08.014; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; Xu X, 2005, ANAL CHEM, V77, P6646, DOI 10.1021/ac050697c; Xu X, 2007, ANAL CHEM, V79, P7813, DOI 10.1021/ac070494j; Yang Y, 2009, J CHROMATOGR B, V877, P489, DOI 10.1016/j.jchromb.2008.12.054; [_¬Yoz Zhu Weixia], 2010, [%ýøñ, Chinese Journal of Chromatography], V28, P1031483TAYLOR &amp; FRANCIS LTDABINGDON4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDFOOD ADDIT CONTAM AJAN 1Discipline: Chemistry; Food Science &amp; Technology; Toxicology049BK</notes>
    <keywords>androgens; BISPHENOL-A; CANCER; CHEMICALS; dansylation; EDCs; ELECTROSPRAY-IONIZATION; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; ENDOGENOUS ESTROGENS; FOOD; HEALTH; INFANT FORMULA; INFANT FORMULAS; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; Milk; oestrogen; oestrogens; PERFORMANCE LIQUID-CHROMATOGRAPHY; phenol; PHENOLS; powdered milk; progestogens; PROSTATE-CANCER; QUANTITATIVE MEASUREMENT; SAMPLES; screening; STEROID-HORMONES; TANDEM MASS-SPECTROMETRY; toxicology; TRANSFORMATION PRODUCTS; ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>166</startpage>
    <endpage>180</endpage>
    <journalfull>Food Additives and Contaminants Part A-Chemistry Analysis Control Exposure &amp; Risk Assessment</journalfull>
    <issue>1</issue>
    <volume>30</volume>
    <abstract>This study developed and validated a sensitive analytical method for simultaneous screening of four classes of endocrine-disrupting chemicals (i.e. progestogens, androgens, oestrogens and phenols) in milk and powdered milk using ultra-performance liquid chromatography (UPLC) coupled with electrospray ionisation quadrupole time-of-flight mass spectrometry (QTOF-MS). Dansylation of oestrogens and phenols enhanced the ionisation efficiency and shifted the ionisation mode from negative to positive, which allowed for the simultaneous analysis of four EDCs in one chromatographic run. An efficient sample pre-treatment minimised the matrix effects. The mass errors for the precursor and product ions for 26 target compounds varied between -2.8 and 2.3?mDa; and the limits of detection (signal-to-noise ratio?=?3) for milk and powdered milk were less than 0.04 mu g?l-1 and 0.10 mu g?kg-1, respectively. The proposed method was successfully used to analyse multiple types of real samples, including normal temperature whole milk, infant formula and whole powdered milk. In 11 samples, two target compounds, progesterone and androstenedione, were detected. The progesterone concentrations ranged from 8.1 to 12.7 mu g?l-1 in milk, and from 1.2 to 32.0 mu g?kg-1 in infant formulas and whole powdered milks. The androstenedione concentrations varied from 0.39 to 0.79 mu g?l-1 in milks, and from 0.29 to 1.2 mu g?kg-1 in infant formulas and whole powdered milks. Two post-target compounds, one isomer of oestriol and 5a-dihydroprogesterone, were tentatively identified by post-target analysis in two of 11 real samples</abstract>
    <url>WOS:000311956800014</url>
    <isbnorissn>1944-0049</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>40</id>
    <title>Cell proliferation and apoptosis in rat mammary glands following combinational exposure to bisphenol A and genistein</title>
    <authors>Wang,J.; Jenkins,S.; Lamartiniere,C.A.</authors>
    <availability>[Wang, Jun; Jenkins, Sarah; Lamartiniere, Coral A.] Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USA. [Lamartiniere, Coral A.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleWang, J (reprint author), Univ Alabama Birmingham, Dept Pharmacol &amp; Toxicol, Birmingham, AL 35294 USAfeijun@uab.eduArdies CM, 1998, MED HYPOTHESES, V50, P457, DOI 10.1016/S0306-9877(98)90262-6; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; Fukutake M, 1996, FOOD CHEM TOXICOL, V34, P457, DOI 10.1016/0278-6915(96)87355-8; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Hsu PY, 2010, GENOME RES, V6, P733; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jenkins S, 2012, J STEROID BIOCHEM, V129, P191, DOI 10.1016/j.jsbmb.2011.06.003; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; KERR JFR, 1994, CANCER, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8&lt;2013::AID-CNCR2820730802&gt;3.0.CO;2-J; Kuruto-Niwa R, 2007, CHEMOSPHERE, V66, P1160, DOI 10.1016/j.chemosphere.2006.06.073; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lamartiniere CA, 1982, 12 C ENV TOX DAYT OH, P96; Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237; Lydon JP, 2011, ENDOCRINOLOGY, V152, P19, DOI 10.1210/en.2010-1012; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; O'Brien MA, 2001, BIOTECHNIQUES, V30, P886; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Roger P, 2001, CANCER RES, V61, P2537; RUSSO J, 1979, AM J PATHOL, V96, P721; Setchell KD, 1998, AM J CLIN NUTR S, V68, P1453; Shu XO, 2001, CANCER EPIDEM BIOMAR, V10, P483; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; WELSCH CW, 1985, CANCER RES, V45, P3415300BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDBMC CANCERMAY 29Discipline: OncologyAI4SG</notes>
    <keywords>ADOLESCENCE; Akt; apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; CHEMICALS; CLEAVAGE; COMBINATION; CYCLE; DEATH; EXPOSURE; EXPRESSION; FOOD; genistein; GROWTH; Mammary cancer; mechanism; MECHANISMS; POLY(ADP-RIBOSE) POLYMERASE; PREVENTION; proliferation; PTEN; RESPONSES; RISK; SUSCEPTIBILITY; THERAPY</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Bmc Cancer</journalfull>
    <volume>14</volume>
    <abstract>Background: Humans are exposed to an array of both harmful and beneficial hormonally active compounds in the environment and through diet. Two such chemicals are Bisphenol A (BPA), a plasticizer, and genistein, a component of soy. Prepubertal exposure to BPA increased mammary carcinogenesis, while genistein suppressed cancer in a chemically-induced model of rodent mammary cancer. The purpose of this research was to determine the effects of combinational exposure to genistein and BPA on cell proliferation, apoptosis, and associated proteins as markers of cancer in mammary glands of rats exposed prepubertally to these environmental chemicals. Methods: Prepubertal rats (postpartum days (PND) 2-20) were exposed through lactation via nursing dams treated orally with sesame oil (SO), BPA, genistein, or a combination of BPA and genistein (BPA + Gen). Cell proliferation, apoptosis and protein expressions were investigated for mechanistic studies in mammary glands of rats exposed to these environmental chemicals. Results: Prepubertal exposure to genistein increased cell proliferation in mammary glands of PND21 rats, while BPA increased cell proliferation in adult (PND50) rats. Prepubertal combinational exposure to BPA + Gen increased cell proliferation and reduced apoptosis in PND21 rats, but reduced cell proliferation and increased apoptosis in PND50 rats. The altered mechanisms behind these cellular responses appear to be centered on differential protein expression of caspases, PARP, Bad, p21, Akts, PTEN, ER-beta and SRCs 1-3, in the rat mammary gland. Conclusion: Prepubertal BPA exposure resulted in increased cell proliferation in mammary glands of PND50 rats, a process associated with increased risk of cancer development in a chemically-induced mammary cancer. On the other hand, genistein stimulated cell proliferation at PND21, a process that correlates with mammary gland maturation and chemoprevention. In contrast to single chemical exposure, combinational exposure to BPA + Gen performed most similarly to genistein exposure alone. BPA + Gen increased cell proliferation at PND21, suggesting mammary gland maturation, and decreased cell proliferation while increasing apoptosis in PND50 rats, suggesting mammary chemoprevention. Differential expression of proteins involved in regulating cell proliferation and apoptosis lend support to these chemicals, both alone and in combination, altering mammary gland cancer susceptibility</abstract>
    <url>WOS:000336854500001</url>
    <isbnorissn>1471-2407</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>326</id>
    <title>Bisphenol-A interferes with estradiol-mediated protection in osteoarthritic chondrocytes</title>
    <authors>Wang,K.C.; Lin,Y.F.; Qin,C.H.; Chen,T.L.; Chen,C.H.</authors>
    <availability>[Chen, Ta-Liang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei 110, Taiwan. [Wang, Kuo-Ching] Shin Kong Wu Ho Su Mem Hosp, Dept Anesthesiol, Taipei, Taiwan. [Lin, Yu-Feng] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. [Lin, Yu-Feng; Qin, Cheng-Hong; Chen, Chien-Ho] Taipei Med Univ, Sch Med Technol &amp; Biotechnol, Taipei 110, Taiwan.</availability>
    <date>2010</date>
    <notes>JEnglishArticleChen, TL (reprint author), Taipei Med Univ Hosp, Dept Anesthesiol, 252 Wu Hsing St, Taipei 110, Taiwantlc@tmu.edu.tw; chenchho@tmu.edu.twAttur MG, 2000, J BIOL CHEM, V275, P40307, DOI 10.1074/jbc.M002721200; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bredhult C, 2009, REPROD TOXICOL, V28, P18, DOI 10.1016/j.reprotox.2009.03.006; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; CHEN TC, 2009, ENVIRON MONIT ASSESS, V161, P135; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8&lt;1343::AID-ART3&gt;3.0.CO;2-9; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hsu SM, 2000, BIOCHEM BIOPH RES CO, V279, P47, DOI 10.1006/bbrc.2000.3891; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lee YJ, 2003, RHEUMATOL INT, V23, P282, DOI 10.1007/s00296-003-0312-5; Mengshol JA, 2002, ARTHRITIS RHEUM, V46, P13, DOI 10.1002/1529-0131(200201)46:1&lt;13::AID-ART497&gt;3.0.CO;2-S; Moos V, 1999, J RHEUMATOL, V26, P870; Mort JS, 2001, ARTHRITIS RES, V3, P337, DOI 10.1186/ar325; Nevitt MC, 1996, ARCH INTERN MED, V156, P2073, DOI 10.1001/archinte.156.18.2073; Nikula H, 1999, TOXICOL APPL PHARM, V157, P166, DOI 10.1006/taap.1999.8674; Nishizawa H, 2005, J REPROD DEVELOP, V51, P593, DOI 10.1262/jrd.17026; Nishizawa H, 2005, J REPROD DEVELOP, V51, P315, DOI 10.1262/jrd.16008; Noguchi S, 2002, TOXICOL LETT, V135, P95, DOI 10.1016/S0378-4274(02)00252-7; PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637; Pelletier JP, 1998, ARTHRITIS RHEUM, V41, P1275, DOI 10.1002/1529-0131(199807)41:7&lt;1275::AID-ART19&gt;3.0.CO;2-T; Pelletier JP, 1996, OSTEOARTHR CARTILAGE, V4, P77, DOI 10.1016/S1063-4584(96)80009-4; Pyo MY, 2007, ARCH PHARM RES, V30, P1476, DOI 10.1007/BF02977374; Richette P, 2007, ANN RHEUM DIS, V66, P345, DOI 10.1136/ard.2006.059550; Richette P, 2004, ANN RHEUM DIS, V63, P191, DOI 10.1136/ard.2003.006510; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; STADLER J, 1991, J IMMUNOL, V147, P3915; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Tetlow LC, 2001, ARTHRITIS RHEUM, V44, P585, DOI 10.1002/1529-0131(200103)44:3&lt;585::AID-ANR107&gt;3.0.CO;2-C; THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; Ushiyama T, 1999, OSTEOARTHR CARTILAGE, V7, P560, DOI 10.1053/joca.1999.0260; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tiba.2004.11.009; Wade CB, 2001, ENDOCRINOLOGY, V142, P2336, DOI 10.1210/en.142.6.2336; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Witorsch RJ, 2002, REGUL TOXICOL PHARM, V36, P118, DOI 10.1006/rtph.2002.1564; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Yoshitake J, 2008, NITRIC OXIDE-BIOL CH, V18, P223, DOI 10.1016/j.niox.2008.01.003; YOUNG KJ, 2003, CANC LETT, V196, P69448ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTOCT 5Discipline: Toxicology651QS</notes>
    <keywords>ACTIVATION; ARYL-HYDROCARBON RECEPTOR; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CARCINOGENESIS; CELL; CELLS; CHEMICALS; Chondrocytes; EDC; ESTRADIOL-MEDIATED PROTECTION; Estrogen; ESTROGEN-RECEPTOR; EXPRESSION; FLUID; HEALTH; HUMAN ARTICULAR CHONDROCYTES; HUMAN EXPOSURE; IL-1 beta; MATRIX-METALLOPROTEINASE; Menopause; MURINE EMBRYOS; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; Osteoarthritis; OXIDE; RECEPTOR; Receptors; RISK; SELECTIVE-INHIBITION; serum; toxicology; VIABILITY; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>127</startpage>
    <endpage>133</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>2</issue>
    <volume>198</volume>
    <abstract>Aged women have a higher risk of osteoarthritis (OA) due to estrogen (E2) loss at menopause. Studies suggested that E2 inhibits nuclear factor (NF)-kappa B activity which is increased in arthritis pathogenesis. Other studies revealed that external E2 reduces the expression of matrix metalloproteinases (MMPs) in osteoarthritic chondrocytes, and attenuates the pathogenesis of OA. Bisphenol-A (BPA) is an important industrial material, and an endocrine-disrupting chemical (EDC) that binds E2 receptors and interrupts the hormone signaling. It is unknown how BPA affects E2 functions and influences E2-mediated protections in OA. In this study, we investigated the effects of E2 and BPA on nitric oxide (NO) production, NF-kappa B activation, and MMP-1 expression in chondrosarcoma SW1353 cells and primary human osteoarthritic chondrocytes. Among the tested chemicals, BPA reduced NO production and cell viability of chondrosarcoma cells, but had little effects on osteoarthritic chondrocytes. Using HPLC-UV, we observed BPA in the serum and synovial fluid of OA patients. In primary chondrocytes, modest concentrations of E2 reduced interleukin (IL)-1 beta-dependent NF-kappa B activation and MMP-1 expression. BPA antagonized these protective effects of E2 in a concentration-dependent manner. In conclusion, BPA interferes with E2's functions in chondrocytes and may promote OA. (C) 2010 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000281942800006</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>125</id>
    <title>Bisphenol A at environmentally relevant doses induces cyclooxygenase-2 expression and promotes invasion of human mesenchymal stem cells derived from uterine myoma tissue</title>
    <authors>Wang,K.H.; Kao,A.P.; Chang,C.C.; Lin,T.C.; Kuo,T.C.</authors>
    <availability>[Wang, Kai-Hung; Lin, Ta-Chin; Kuo, Tsung-Cheng] Kuo Gen Hosp, Dept Obstet &amp; Gynecol, Tainan, Taiwan. [Wang, Kai-Hung; Lin, Ta-Chin; Kuo, Tsung-Cheng] Kuo Gen Hosp, Ctr Reprod Med, Tainan, Taiwan. [Wang, Kai-Hung] Kuo Gen Hosp, Dept Lab Med, Tainan, Taiwan. [Kao, An-Pei] Taipei Med Univ, Taipei Med Univ Hosp, Ctr Reprod Med &amp; Sci, Dept Obstet &amp; Gynecol, Taipei, Taiwan. [Chang, Chia-Cheng] Michigan State Univ, Dept Pediat &amp; Human Dev, E Lansing, MI 48824 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticleKuo, TC (reprint author), Kuo Gen Hosp, Dept Obstet &amp; Gynecol, 22,Sect 2,Minsheng Rd, Tainan, Taiwantckuo@kgh.com.twAl-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Becker L, 2008, THESCIENTIFICWORLDJO, V8, P1168, DOI 10.1100/tsw.2008.148; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Braun JM, 2011, ENV HLTH PERSPECT, V119, P131; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; CHANG CC, 1981, SOMAT CELL GENET, V7, P235; Wang KH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-288; Chang CC, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1385; Chang HL, 2010, REPROD SCI, V17, P158, DOI 10.1177/1933719109348924; Chepda T, 2001, IN VITRO CELL DEV-AN, V37, P26; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1&lt;67::AID-JCP7&gt;3.0.CO;2-C; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; De Bari C, 2001, ARTHRITIS RHEUM, V44, P1928, DOI 10.1002/1529-0131(200108)44:8&lt;1928::AID-ART331&gt;3.0.CO;2-P; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; HATA RI, 1989, J CELL PHYSIOL, V138, P8, DOI 10.1002/jcp.1041380103; Herrera MB, 2006, STEM CELLS, V24, P2840, DOI 10.1634/stemcells.2006-0114; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Hubbard SA, 2009, CANCER RES, V69, P8241, DOI 10.1158/0008-5472.CAN-08-4808; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Ivanov VO, 1997, J MOL CELL CARDIOL, V29, P3293, DOI 10.1006/jmcc.1997.0555; Kao AP, 2011, FERTIL STERIL, V95, P1308, DOI 10.1016/j.fertnstert.2010.09.064; Kao AP, 2011, FERTIL STERIL, V96, P678, DOI 10.1016/j.fertnstert.2011.06.041; KAO CY, 1995, CARCINOGENESIS, V16, P531, DOI 10.1093/carcin/16.3.531; Kassis I, 2006, BONE MARROW TRANSPL, V37, P967, DOI 10.1038/sj.bmt.1705358; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Lin T, 2010, CANCER RES, V70, P9444, DOI 10.1158/0008-5472.CAN-10-2159; Lin TM, 2005, STEM CELLS DEV, V14, P92, DOI 10.1089/scd.2005.14.92; Lin TM, 2007, BIOCHEM BIOPH RES CO, V361, P883, DOI 10.1016/j.bbrc.2007.07.116; Maruyama T, 2010, REPRODUCTION, V140, P11, DOI 10.1530/REP-09-0438; McClanahan T, 2006, CANCER BIOL THER, V5, P419; Neupane M, 2008, TISSUE ENG PT A, V14, P1007, DOI 10.1089/tea.2007.0207; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ono M, 2007, P NATL ACAD SCI USA, V104, P18700, DOI 10.1073/pnas.0704472104; Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015; Ricupito A, 2009, ENVIRON INT, V35, P21, DOI 10.1016/j.envint.2008.05.011; Sasaki N, 2005, J MATER SCI-MATER M, V16, P297, DOI 10.1007/s10856-005-0627-8; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Sell S, 2008, TUMOR BIOL, V29, P161, DOI 10.1159/000143402; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Singh SK, 2003, CANCER RES, V63, P5821; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165; Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V291, P76, DOI 10.1006/bbrc.2002.6407; Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Wang KH, 2010, BIOL CELL, V102, P159, DOI 10.1042/BC20090132; Wang KH, 2010, KAOHSIUNG J MED SCI, V26, P113, DOI 10.1016/S1607-551X(10)70017-6; Wang KH, 2008, BIOTECHNOL APPL BIOC, V51, P159, DOI 10.1042/BA20070201; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Yang MH, 2006, J ENVIRON SCI HEAL C, V24, P183, DOI 10.1080/10590500600936474; Ye XY, 2006, J CHROMATOGR B, V831, P110, DOI 10.1016/j.jchromb.2005.11.050; Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004-0098; Young HE, 2001, ANAT REC, V264, P51, DOI 10.1002/ar.1128; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.067681ELSEVIER TAIWANTAIPEIRM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWANTAIWAN J OBSTET GYNEJUNDiscipline: Obstetrics &amp; Gynecology212VB</notes>
    <keywords>ACUTE MYELOID-LEUKEMIA; ADIPOSE-TISSUE; ADULT; ASSOCIATION; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; cell invasion; Cell proliferation; CELL-PROLIFERATION; CELLS; cyclooxygenase-2; ENDOCRINE; Endocrine disruptor; Estrogen; EXPRESSION; gene expression; GENE-EXPRESSION; HUMAN EXPOSURE; In vitro; IN-VITRO; INVASION; JUN; LINES; LIQUID-CHROMATOGRAPHY; mechanism; mesenchymal stem cell; mesenchymal stem cells; Migration; MSC; POPULATION; proliferation; PROSPECTIVE IDENTIFICATION; Reproduction; SELF-RENEWAL; STEM-CELLS; TISSUE; TUMORIGENESIS; uterine myoma; Uterus; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>246</startpage>
    <endpage>252</endpage>
    <journalfull>Taiwanese Journal of Obstetrics &amp; Gynecology</journalfull>
    <issue>2</issue>
    <volume>52</volume>
    <abstract>Objective: Uterine myoma is the most common benign reproductive tract tumor in women. Despite its high prevalence, the exact pathogenesis of these benign tumors remains unknown. Toward understanding the pathogenic mechanism of these tumors, we attempted to isolate human uterine myoma mesenchymal stem cells (hUM-MSCs), which may be the target cells for tumorigenesis. Furthermore, we tested the response of these hUM-MSCs to the environmental endocrine disruptor, bisphenol A (BPA), which may mimic the action of estrogen in hormone-sensitive organs such as the uterus. Materials and Methods: The hUM-MSC lines were clonally derived from uterine myoma tissue using the MSU-1 medium supplemented with N-acetyl-L-cysteine and L-ascorbic acid-2-phosphate. These hUM-MSCs were characterized by reverse transcription polymerase chain reaction (RT-PCR) analysis for the expression of mesenchymal stem cell (MSC) surface markers (e.g., CD90 and CD 105) and the transcription factor Oct-4. The proliferation potential was measured by the cumulative population doubling level and the colony-forming efficiency. Results: Putative hUM-MSC lines expressed CD90, CD105, and the stem cell marker gene, Oct-4. The cells were capable of differentiating into adipocytes, osteoblasts, and chondrocytes. Bisphenol A treatment of these hUM-MSCs enhanced cell proliferation and colony-forming efficiency in a dose-responsive manner. At an environmentally relevant concentration (10(-8) M), BPA moreover induced cyclooxygenase-2 (COX-2) gene expression and promoted cell migration and invasiveness. Conclusion: The hUM-MSC cell lines can be isolated from uterine myoma tissues. Bisphenol A could enhance cell proliferation and colony-forming efficiency, induce COX-2 gene expression, and promote migration and invasion of hUM-MSCs. The results imply that BPA has a detrimental effect on female health by promoting uterine tumorigenesis. Copyright (C) 2013, Taiwan Association of Obstetrics &amp; Gynecology. Published by Elsevier Taiwan LLC. All rights reserved</abstract>
    <url>WOS:000324009800015</url>
    <isbnorissn>1028-4559</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>25</id>
    <title>Studies on electrochemical oxidation of estrogenic disrupting compound bisphenol AF and its interaction with human serum albumin</title>
    <authors>Wang,X.; Yang,J.C.; Wang,Y.J.; Li,Y.H.; Wang,F.; Zhang,L.</authors>
    <availability>[Wang, Xin; Yang, Jichun; Wang, Yuejiao; Li, Yanhui; Wang, Fang; Zhang, Lei] Liaoning Univ, Coll Chem, Shenyang 110036, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleZhang, L (reprint author), Liaoning Univ, Coll Chem, 66 Chongshan Middle Rd, Shenyang 110036, Peoples R Chinazhanglei63@126.comAkahori Y, 2008, TOXICOL IN VITRO, V22, P225, DOI 10.1016/j.tiv.2007.08.004; Bard A.J., 2004, ELECTROCHEMICAL METH, P236; Barik A, 2003, PHOTOCHEM PHOTOBIOL, V77, P597, DOI 10.1562/0031-8655(2003)077&lt;0597:PSOBOC&gt;2.0.CO;2; Chan YY, 2013, ELECTROCHIM ACTA, V112, P287, DOI 10.1016/j.electacta.2013.08.181; LaFleur AD, 2011, ANAL CHIM ACTA, V696, P6, DOI 10.1016/j.aca.2011.03.054; LAVIRON E, 1974, J ELECTROANAL CHEM, V52, P355, DOI 10.1016/S0022-0728(74)80448-1; Matsushima A, 2010, ENVIRON HEALTH PERSP, V118, P1267, DOI 10.1289/ehp.0901819; NTP (National Toxicology Program), 2008, SUPP NOM TOX EV NAT; Raloff J., 2010, SCI NEWS, V177, P13; Shap M., 1979, J ELECTROANAL CHEM, V95, P123; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; Wu YH, 2004, BIOELECTROCHEMISTRY, V64, P91, DOI 10.1016/j.bioeleechem.2004.03.005; Yang YJ, 2012, J CHROMATOGR B, V901, P93, DOI 10.1016/j.jchromb.2012.06.005; Yi X.F., 2012, TOXICOL LETT, V211, P201; Zima J, 2009, CRIT REV ANAL CHEM, V39, P204, DOI 10.1080/10408340903011853160ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSJ HAZARD MATERJUL 15Discipline: Engineering; Environmental Sciences &amp; EcologyAM2PG</notes>
    <keywords>ALPHA; BINDING; bisphenol; Bisphenol AF; CANCER; Carboxyl functionalized multi-walled carbon nanotubes; Electrocatalysis; Human serum albumin; In vitro; IN-VITRO; Interaction; MIMICS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>105</startpage>
    <endpage>111</endpage>
    <journalfull>Journal of Hazardous Materials</journalfull>
    <volume>276</volume>
    <abstract>Bisphenol AF (BPAF) is an environmental pollutant to disrupt endocrine system or cause cancer, thus the detection of trace BPAF is very important. In this study, a simple and highly sensitive electroanalytical method for the determination of BPAF was developed. In pH 6.0 phosphate buffer solutions, carboxyl functionalized multi-walled carbon nanotubes (MWCNT-COOH) modified glassy carbon electrode exhibits an enhanced effectiveness for the oxidation of BPAF. This electrode exhibited two linear relationships with BPAF concentration range of 0.02 mu mol L-1 to 8.0 mu mol L-1 and a detection limit of 0.0077 mu mol L-1 (S/N =3). The proposed method was successfully applied to determine BPAF in real samples and the results were satisfactory. The MWCNT-COOH/GCE electrode showed good reproducibility, stability and anti-interference. The electrochemistry and spectroscopy methods are also described for the evaluation of BPAF-HSA interaction. In the presence of HSA, the peak currents of BPAF decreased linearly due to the formation of a super-molecular complex. The binding constant between BPAF and HSA, obtained by differential pulse voltammetry (DPV), was consistent with the fluorescence analysis. The molecular modeling studies were carried out to clearly describe the interaction between BPAF and HSA. (C) 2014 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000339692700013</url>
    <isbnorissn>0304-3894</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>301</id>
    <title>Endocrine disrupters-A threat to women's health?</title>
    <authors>Waring,R.H.; Harris,R.M.</authors>
    <availability>[Waring, R. H.; Harris, R. M.] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.</availability>
    <date>2011</date>
    <notes>JEnglishReviewHarris, RM (reprint author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, EnglandR.M.Harris@bham.ac.ukAmberg-Muller JP, 2010, J VERBRAUCH LEBENSM, V5, P429, DOI 10.1007/s00003-010-0620-0; Ayotte P, 2003, ENVIRON HEALTH PERSP, V111, P1253, DOI 10.1289/ehp.6054; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Blount B. C., 2000, ENV HLTH PERSPECT, V108, P972; Bornehag CG, 2010, INT J ANDROL, V33, P333, DOI 10.1111/j.1365-2605.2009.01023.x; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1; Day JM, 2009, ANN NY ACAD SCI, V1155, P80, DOI 10.1111/j.1749-6632.2008.03677.x; Desbrow C, 1998, ENVIRON SCI TECHNOL, V32, P1549, DOI 10.1021/es9707973; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; EFSA, 2006, EFSA J, V428, p[1, 75]; *EUR CHEM BUR EUR, 2008, EUR CHEM BUR EUR U R, V80, P2; Fabjan E, 2006, CRIT REV TOXICOL, V36, P695, DOI 10.1080/10408440600894914; Forrest ARW, 2003, NEW ENGL J MED, V349, P1090, DOI 10.1056/NEJM200309113491117; Foster PA, 2008, ENDOCRINOLOGY, V149, P4035, DOI 10.1210/en.2008-0223; Fromme H, 2007, INT J HYG ENVIR HEAL, V210, P21, DOI 10.1016/j.ijheh.2006.09.005; GOLDEY ES, 1995, TOXICOL APPL PHARM, V135, P77, DOI 10.1006/taap.1995.1210; Gore Andrea C, 2008, Fertil Steril, V89, pe101, DOI 10.1016/j.fertnstert.2007.12.039; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Guo HC, 2010, CELL MOL IMMUNOL, V7, P227, DOI 10.1038/cmi.2010.14; Harris RM, 2000, J BIOL CHEM, V275, P159, DOI 10.1074/jbc.275.1.159; Harris RM, 1996, XENOBIOTICA, V26, P1241; Harris RM, 2004, J CLIN ENDOCR METAB, V89, P1779, DOI 10.1210/jc.2003-031631; Harris RM, 2005, MOL CELL ENDOCRINOL, V244, P72, DOI 10.1016/j.mce.2005.05.013; HEINDEL JJ, 1989, FUND APPL TOXICOL, V12, P508, DOI 10.1016/0272-0590(89)90024-9; Howdeshell KL, 2002, ENVIRON HEALTH PERSP, V110, P337; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Izzotti A, 2010, CURR CANCER DRUG TAR, V10, P147; Jacobsen PR, 2010, INT J ANDROL, V33, P434, DOI 10.1111/j.1365-2605.2009.01046.x; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; KIRK CJ, 2001, BIOCHEM SOC T, V29, P210; Kjaerstad MB, 2010, INT J ANDROL, V33, P425, DOI 10.1111/j.1365-2605.2009.01034.x; Kloas W, 1999, SCI TOTAL ENVIRON, V225, P59, DOI 10.1016/S0048-9697(98)00332-5; Kohn MC, 2000, ENVIRON HEALTH PERSP, V108, pA440, DOI 10.1289/ehp.108-a440b; Latini G, 2010, MINI-REV MED CHEM, V10, P846; McAllister BG, 2003, AQUAT TOXICOL, V65, P309, DOI 10.1016/S0166-445X(03)00154-1; Miao S, 2008, J TOXICOL ENV HEAL A, V71, P1000, DOI 10.1080/15287390801907467; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Miyagawa K, 2007, NEUROSCI LETT, V418, P236, DOI 10.1016/j.neulet.2007.01.088; Miyawaki J, 2007, J ATHEROSCLER THROMB, V14, P245; Morimoto S, 2010, J STEROID BIOCHEM, V122, P107, DOI 10.1016/j.jsbmb.2010.05.003; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Nashev LG, 2010, BIOCHEM PHARMACOL, V79, P1189, DOI 10.1016/j.bcp.2009.12.005; Newbold RR, 2010, HORM-INT J ENDOCRINO, V9, P206; Padmanabhan V, 2010, INT J ANDROL, V33, P394, DOI 10.1111/j.1365-2605.2009.01024.x; Reed MJ, 2008, DRUG FUTURE, V33, P597, DOI 10.1358/dof.2008.033.07.1212711; Ropero AB, 2008, INT J ANDROL, V31, P194, DOI 10.1111/j.1365-2605.2007.00832.x; Routledge EJ, 1998, ENVIRON SCI TECHNOL, V32, P1559, DOI 10.1021/es970796a; *SCCP, 2007, AD 11 PLEN M 21 MARC; Signorile PG, 2010, GEN COMP ENDOCR, V168, P318, DOI 10.1016/j.ygcen.2010.03.030; Stahlhut RW, 2007, ENVIRON HEALTH PERSP, V115, P876, DOI 10.1289/ehp.9882; Stump DG, 2010, TOXICOL SCI, V115, P167, DOI 10.1093/toxsci/kfq025; Tian YH, 2010, SYNAPSE, V64, P432, DOI 10.1002/syn.20746; Turan N, 2008, CURR DRUG METAB, V9, P285, DOI 10.2174/138920008784220655; Wada K, 2007, J PHARMACOL SCI, V105, P133, DOI 10.1254/jphs.FM0070034; Walkowiak J, 2001, LANCET, V358, P1602, DOI 10.1016/S0140-6736(01)06654-5; Wan Y, 2010, ENVIRON SCI TECHNOL, V44, P5233, DOI 10.1021/es1002764; Waring RH, 2008, J STEROID BIOCHEM, V108, P213, DOI 10.1016/j.jsbmb.2007.09.007; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Xu XH, 2010, ENVIRON TOXICOL CHEM, V29, P176, DOI 10.1002/etc.18617ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDMATURITASFEBDiscipline: Geriatrics &amp; Gerontology; Obstetrics &amp; Gynecology717ON</notes>
    <keywords>bisphenol A; BISPHENOL-A; CANCER; CELL; DEGRADATION; development; ENDOCRINE; Endocrine disrupter; ENDOCRINE DISRUPTERS; Endocrine disruption; environmental exposure; epigenetic; ESTROGENIC CHEMICALS; EXPOSURE; HEALTH; HUMAN HEALTH; Immune; IMMUNE-SYSTEM; IN-VITRO; METABOLISM; p21; PATHWAY; PERINATAL EXPOSURE; PHTHALIC-ACID ESTERS; Phytoestrogen; POLYCHLORINATED-BIPHENYLS; POSTNATAL EXPOSURE; PRENATAL EXPOSURE; Proteomics; RECEPTOR; Receptors; REPRODUCTIVE FUNCTION; Review; RISK; SEXUAL-DIFFERENTIATION; Steroid; steroid receptors; STEROID SULFATASE INHIBITORS; SYSTEM; TISSUE; TISSUES; Transgenerational; Women's health</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>111</startpage>
    <endpage>115</endpage>
    <journalfull>Maturitas</journalfull>
    <issue>2</issue>
    <volume>68</volume>
    <abstract>Endocrine disruption has been a topic of public concern for many years and its study remains high on the scientific agenda. Endocrine disrupters (EDs) are compounds which may be of industrial or natural origin and which act to dysregulate steroid function and metabolism. As well as their actions on nuclear steroid receptors. EDs can inhibit the pathways of steroid synthesis and degradation. They not only affect reproductive function but also affect a range of tissues which are steroid sensitive such as the central nervous system and thyroid. Results from the latest studies suggest that EDs may also affect the immune system, glucose homeostasis and can act as epigenetic modulators resulting in transgenerational effects. Research in this area has led to the development of drugs used in the treatment of several types of hormone-sensitive cancer. However, despite many years of effort, the effects on human health of long-term environmental exposure to EDs, whether singly or as mixtures, remain unknown. (C) 2010 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000287057400004</url>
    <isbnorissn>0378-5122</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>364</id>
    <title>Nongenomic Signaling Pathways of Estrogen Toxicity</title>
    <authors>Watson,C.S.; Jeng,Y.J.; Kochukov,M.Y.</authors>
    <availability>[Watson, Cheryl S.; Jeng, Yow-Jiun; Kochukov, Mikhail Y.] Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX 77555 USA.</availability>
    <date>2010</date>
    <notes>JEnglishReviewWatson, CS (reprint author), Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, 301 Univ Blvd,Basic Sci Bldg Room 511-B, Galveston, TX 77555 USAcswatson@utmb.eduADAMS JB, 1992, INT J CANCER, V50, P854, DOI 10.1002/ijc.2910500603; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; Adlercreutz H, 1993, Scand J Clin Lab Invest Suppl, V215, P5; Alonso-Magdalena P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002069; Alyea RA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-59; Alyea RA, 2009, ENVIRON HEALTH PERSP, V117, P778, DOI 10.1289/ehp.0800026; Alyea RA, 2008, J NEUROCHEM, V106, P1525, DOI 10.1111/j.1471-4159.2008.05491.x; Azuma Kotaro, 2004, Clin Calcium, V14, P12; Benedetti MD, 2001, MOVEMENT DISORD, V16, P830, DOI 10.1002/mds.1170; BICKOFF EM, 1957, SCIENCE, V126, P969, DOI 10.1126/science.126.3280.969-a; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Brownson DM, 2002, J NUTR, V132, p3482S; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Campbell CH, 2002, FASEB J, V16, P1917, DOI 10.1096/fj.02-0182com; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Cao ZM, 2009, ENDOCR RES, V34, P101, DOI 10.3109/07435800903204082; Carreau S, 2000, NEWS PHYSIOL SCI, V15, P195; CATTERALL JF, 1985, MOL MECHANISM STEROI, P587; Chambliss KL, 2002, STEROIDS, V67, P413, DOI 10.1016/S0039-128X(01)00177-5; Chard T, 1995, J PERINAT MED, V23, P421; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Colborn T, 2004, ENVIRON HEALTH PERSP, V112, P944, DOI 10.1289/ehp.6601; Compton J, 2002, BEST PRACT RES CL OB, V16, P357, DOI 10.1053/beog.2002.0285; Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005; DANNIES PS, 1985, BIOCHEM ACTION HORM, V12, P289; Delbes G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231; Dluzen DE, 2005, PHARMACOL BIOCHEM BE, V80, P27, DOI 10.1016/j.pbb.2004.10.007; Filardo EJ, 2005, TRENDS ENDOCRIN MET, V16, P362, DOI 10.1016/j.tem.2005.08.005; Foltynie T, 2005, J NEUROL, V252, P833, DOI 10.1007/s00415-005-0756-5; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; Fukazawa H, 2001, CHEMOSPHERE, V44, P973, DOI 10.1016/S0045-6535(00)00507-5; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gallard H, 2004, CHEMOSPHERE, V56, P465, DOI 10.1016/j.chemosphere.2004.03.001; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gorski J, 1997, PROG CLIN BIOL RES, V396, P233; Greenspan FS, 2004, BASIC CLIN ENDOCRINO, P925; Gross B, 2004, ENVIRON TOXICOL CHEM, V23, P2074, DOI 10.1897/03-606; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hotchkiss AK, 2008, TOXICOL SCI, V105, P235, DOI 10.1093/toxsci/kfn030; Howells LM, 2008, BIOCHEM PHARMACOL, V75, P1774, DOI 10.1016/j.bcp.2008.02.012; Hu JY, 2002, ENVIRON TOXICOL CHEM, V21, P2034, DOI 10.1897/1551-5028(2002)021&lt;2034:POACON&gt;2.0.CO;2; Jansson L, 2001, ARTHRITIS RHEUM, V44, P2168, DOI 10.1002/1529-0131(200109)44:9&lt;2168::AID-ART370&gt;3.0.CO;2-2; Jeng YJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-334; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; Kloas W, 1999, SCI TOTAL ENVIRON, V225, P59, DOI 10.1016/S0048-9697(98)00332-5; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; KURLAN R, 1992, ARCH NEUROL-CHICAGO, V49, P874; Kwack SJ, 2002, J TOXICOL ENV HEAL A, V65, P419, DOI 10.1080/15287390252808082; Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419; McKinlay R, 2008, SCI TOTAL ENVIRON, V398, P1, DOI 10.1016/j.scitotenv.2008.02.056; Meinhardt U, 2002, SEMIN REPROD MED, V20, P277, DOI 10.1055/s-2002-35374; Michel MC, 2007, MOL PHARMACOL, V72, P1097, DOI 10.1124/mol.107.040923; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Mueller A, 2008, EUR J ENDOCRINOL, V159, P197, DOI 10.1530/EJE-08-0289; Mustafa AM, 2007, TOXICOL APPL PHARM, V222, P25, DOI 10.1016/j.taap.2007.03.014; MYERS JP, 2009, ENV HLTH PE IN PRESS; Nadal A, 2009, MOL CELL ENDOCRINOL, V304, P63, DOI 10.1016/j.mce.2009.02.016; Narita S, 2007, ENVIRON HEALTH PERSP, V115, P48, DOI 10.1289/ehp.9378; *NAT CTR BIOT INF, 2009, PUBCHEM; Nevalainen MT, 1997, J CLIN INVEST, V99, P618, DOI 10.1172/JCI119204; Norman AW, 2002, BIOCHEM BIOPH RES CO, V298, P414, DOI 10.1016/S0006-291X(02)02482-8; Otto C, 2008, J STEROID BIOCHEM, V111, P95, DOI 10.1016/j.jsbmb.2008.05.003; PAPPAS TC, 1994, ENDOCRINE, V2, P813; Petrovic M, 2003, ENVIRON SCI TECHNOL, V37, P4442, DOI 10.1021/es034139w; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Quinn PO, 2005, J CLIN PSYCHOL, V61, P579, DOI 10.1002/jclp.20121; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Routledge EJ, 1997, J BIOL CHEM, V272, P3280; Selles J, 2005, STEROIDS, V70, P251, DOI 10.1016/j.steroids.2004.10.012; Sheeler CQ, 2000, ENVIRON HEALTH PERSP, V108, P97, DOI 10.2307/3454506; Shenhav S, 2003, ACTA OBSTET GYN SCAN, V82, P912, DOI 10.1034/j.1600-0412.2003.00250.x; Simons SS, 2008, BIOESSAYS, V30, P744, DOI 10.1002/bies.20792; Singleton D.W., 2003, FRONT BIOSCI, V8, P110; Singleton DW, 2004, MOL CELL ENDOCRINOL, V221, P47, DOI 10.1016/j.mce.2004.04.010; Sobrinho Luis GonAalves, 2003, Pituitary, V6, P35, DOI 10.1023/A:1026229810876; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Steinmetz R, 1997, ENDOCRINOLOGY, V138, P1780, DOI 10.1210/en.138.5.1780; Tabira Y, 1999, EUR J BIOCHEM, V262, P240, DOI 10.1046/j.1432-1327.1999.00422.x; Talsness CE, 2009, PHILOS T R SOC B, V364, P2079, DOI 10.1098/rstb.2008.0281; Thomas P, 2004, ENVIRON SCI TECHNOL, V38, P6328, DOI 10.1021/es0403662; *US DEP HHS, 2005, AG TOX SUBST DIS REG; Versteeg HH, 2000, BIOCHEM J, V350, P717, DOI 10.1042/0264-6021:3500717; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; Watson CS, 2008, FASEB J, V22, P3328, DOI 10.1096/fj.08-107672; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Weltje L, 2005, HUM EXP TOXICOL, V24, P431, DOI 10.1191/0960327105ht551oa; Whitten PL, 2001, ENVIRON HEALTH PERSP, V109, P5, DOI 10.2307/3434842; WILKINSON RF, 1993, ART SCI TISSUE CULTU, V12, P1; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; WU J, 1993, J AM CHEM SOC, V115, P6843, DOI 10.1021/ja00068a048; Wu YJ, 2006, REPRODUCTION, V131, P299, DOI 10.1530/rep.1.00922; Yoon DY, 2007, AM J MED GENET B, V144B, P605, DOI 10.1002/ajmg.b.30466; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR130, DOI 10.1186/bcr95910636OXFORD UNIV PRESSOXFORDGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLANDTOXICOL SCIMAYDiscipline: Toxicology584HN</notes>
    <keywords>ACTIVITY IN-VITRO; apoptosis; Behavior; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; CE; CELL; Differentiation; ENDOCRINE; ENVIRONMENTAL CHEMICALS; environmental contaminants; ER-ALPHA; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; HEALTH; KINASE; MAMMARY-CANCER; mechanism; membrane estrogen receptors; METABOLITES; Nongenomic; Nonmonotonic; PARKINSONS-DISEASE; PATHWAY; PHYSIOLOGICAL ESTROGENS; PITUITARY-TUMOR CELLS; PROLACTIN-RELEASE; proliferation; PROTEIN; PROTEIN-KINASE; RECEPTOR; RECEPTOR-ALPHA LEVELS; Receptors; Reproduction; RESPONSES; Review; signaling; SIGNALING PATHWAY; SIGNALING PATHWAYS; Steroid; TISSUE; TISSUES; TOXICITY; toxicology; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1</startpage>
    <endpage>11</endpage>
    <journalfull>Toxicological Sciences</journalfull>
    <issue>1</issue>
    <volume>115</volume>
    <abstract>Xenoestrogens can affect the healthy functioning of a variety of tissues by acting as potent estrogens via nongenomic signaling pathways or by interfering with those actions of multiple physiological estrogens. Collectively, our and other studies have compared a wide range of estrogenic compounds, including some closely structurally related subgroups. The estrogens that have been studied include environmental contaminants of different subclasses, dietary estrogens, and several prominent physiological metabolites. By comparing the nongenomic signaling and functional responses to these compounds, we have begun to address the structural requirements for their actions through membrane estrogen receptors in the pituitary, in comparison to other tissues, and to gain insights into their typical non-monotonic dose-response behavior. Their multiple inputs into cellular signaling begin processes that eventually integrate at the level of mitogen-activated protein kinase activities to coordinately regulate broad cellular destinies, such as proliferation, apoptosis, or differentiation</abstract>
    <url>WOS:000276742200001</url>
    <isbnorissn>1096-6080</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>267</id>
    <title>Endocrine disruption via estrogen receptors that participate in nongenomic signaling pathways</title>
    <authors>Watson,C.S.; Jeng,Y.J.; Guptarak,J.</authors>
    <availability>[Watson, Cheryl S.; Jeng, Yow-Jiun; Guptarak, Jutatip] Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, Galveston, TX 77555 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewWatson, CS (reprint author), Univ Texas Med Branch, Dept Biochem &amp; Mol Biol, 301 Univ Blvd, Galveston, TX 77555 USAcswatson@utmb.edu; yjeng@utmb.edu; juguptat@utmb.eduAdlercreutz H, 1999, AM J OBSTET GYNECOL, V180, P737, DOI 10.1016/S0002-9378(99)70281-4; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Alyea RA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-59; Alyea RA, 2009, ENVIRON HEALTH PERSP, V117, P778, DOI 10.1289/ehp.0800026; Alyea RA, 2008, J NEUROCHEM, V106, P1525, DOI 10.1111/j.1471-4159.2008.05491.x; Baker VL, 2000, OBSTET GYNECOL SURV, V55, pS21, DOI 10.1097/00006254-200007001-00001; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P53, DOI 10.1016/S0091-3057(99)00091-X; BECKER JB, 1990, NEUROSCI LETT, V118, P169, DOI 10.1016/0304-3940(90)90618-J; Belcheva MM, 2002, NEUROSIGNALS, V11, P34, DOI 10.1159/000057320; Benn PA, 2002, CLIN CHIM ACTA, V323, P1, DOI 10.1016/S0009-8981(02)00186-9; Bermudez O, 2008, ONCOGENE, V27, P3685, DOI 10.1038/sj.onc.1211040; Binda F, 2008, MOL PHARMACOL, V74, P1101, DOI 10.1124/mol.108.048447; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Boonyaratanakornkit V, 2004, ESSAYS BIOCHEM, V40, P105; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Calabrese EJ, 2009, ARCH TOXICOL, V83, P227, DOI 10.1007/s00204-009-0411-5; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Carruba G, 2007, J CELL BIOCHEM, V102, P899, DOI 10.1002/jcb.21529; Catalano S, 2009, MOL ENDOCRINOL, V23, P1634, DOI 10.1210/me.2009-0039; Chun TY, 2000, TOXICOL APPL PHARM, V162, P161, DOI 10.1006/taap.1999.8840; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Conolly RB, 2004, TOXICOL SCI, V77, P151, DOI 10.1093/toxsci/kfh007; Curran Monique P, 2002, Treat Endocrinol, V1, P127, DOI 10.2165/00024677-200201020-00006; Evans RM, 2005, MOL ENDOCRINOL, V19, P1429, DOI 10.1210/me.2005-0046; Fan JJ, 2010, ENDOCRINOLOGY, V151, P3348, DOI 10.1210/en.2010-0010; Foster JD, 2006, HANDB EXP PHARM, V175, P197; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gametchu B, 2002, J CELL BIOCHEM, V87, P133, DOI 10.1002/jcb.10288; Greenlee H, 2007, BREAST CANCER RES TR, V102, P111, DOI 10.1007/s10549-006-9308-7; Greenspan FS, 2004, BASIC CLIN ENDOCRINO, P925; Helguero LA, 2008, CANCER RES, V68, P8695, DOI 10.1158/0008-5472.CAN-08-0788; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Huang PX, 2010, ANNU REV PHYSIOL, V72, P247, DOI 10.1146/annurev-physiol-021909-135917; Jarred RA, 2000, ENDOCRINOLOGY, V141, P3471, DOI 10.1210/en.141.9.3471; Jeng YJ, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-61; Jeng YJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-334; Jeng YJ, 2011, ENVIRON HEALTH PERSP, V119, P104, DOI 10.1289/ehp.1002512; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Kochukov MY, 2009, ENVIRON HEALTH PERSP, V117, P723, DOI 10.1289/ehp.0800182; Kousidou OC, 2006, MINI-REV MED CHEM, V6, P331, DOI 10.2174/138955706776073420; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Lin YG, 2004, J NUTR, V134, P143; Lopez-Espinosa MJ, 2009, BIOMARKERS, V14, P271, DOI 10.1080/13547500902893744; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Mermelstein PG, 1996, J NEUROSCI, V16, P595; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Nilsson M, 2004, MOL PSYCHIATR, V9, P28, DOI 10.1038/sj.mp.4001402; Norfleet AM, 2000, FASEB J, V14, P157; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pietras RJ, 1999, NAT MED, V5, P1330, DOI 10.1038/70877; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Riza E, 2001, CANCER EPIDEM BIOMAR, V10, P627; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; SCHWARZ S, 1994, J STEROID BIOCHEM, V48, P391, DOI 10.1016/0960-0760(94)90080-9; Shenhav S, 2003, ACTA OBSTET GYN SCAN, V82, P912, DOI 10.1034/j.1600-0412.2003.00250.x; Shifren JL, 2010, OBSTET GYNECOL, V115, P839, DOI 10.1097/AOG.0b013e3181d41191; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Szego C.M., 1978, STRUCTURE FUNCTION G, P431; Takemura H, 2007, J STEROID BIOCHEM, V103, P170, DOI 10.1016/j.jsbmb.2006.08.008; Talsness CE, 2009, PHILOS T R SOC B, V364, P2079, DOI 10.1098/rstb.2008.0281; Tchaikovski SN, 2010, THROMB RES, V126, P5, DOI 10.1016/j.thromres.2010.01.045; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wang ZQ, 2005, J CELL PHYSIOL, V204, P437, DOI 10.1002/jcp.20297; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Watson Cheryl S, 2006, J Mol Signal, V1, P5, DOI 10.1186/1750-2187-1-5; Watson CS, 2003, EXP BIOL MED, V228, P1272; Watson CS, 2008, FASEB J, V22, P3328, DOI 10.1096/fj.08-107672; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Watson C.S., 1999, SCI STKE, V1999, pE1; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Watson C.S., 1998, WOMEN CANC, V1, P21; Weltje L, 2005, HUM EXP TOXICOL, V24, P431, DOI 10.1191/0960327105ht551oa; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Whitten PL, 2001, ENVIRON HEALTH PERSP, V109, P5, DOI 10.2307/3434842; Wren BG, 2009, MED J AUSTRALIA, V190, P321; Yu LG, 2004, J BIOL CHEM, V279, P41377, DOI 10.1074/jbc.M400017200; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR130, DOI 10.1186/bcr9599312PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMOCTSIDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; Metabolism841WV</notes>
    <keywords>ACTIVATION; BIOLOGY; BIOMARKER; Biomarkers; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CELL; Cell proliferation; CELL-PROLIFERATION; COMBINATION; DEATH; DOPAMINE TRANSPORTER; ENDOCRINE; Endocrine disruption; ENDOGENOUS ESTROGENS; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; ESTROGENS; HEALTH; LIGAND; LIGANDS; METABOLISM; MOLECULAR-MECHANISMS; Nongenomic; NONGENOMIC ACTIONS; Nonmonotonic; p21; PATHWAY; PHYSIOLOGICAL ESTROGENS; PITUITARY-TUMOR CELLS; POSTMENOPAUSAL WOMEN; PROLACTIN-RELEASE; proliferation; PROTEIN MAP KINASE; RECEPTOR; Receptors; RELEASE; SENSITIVITY; SIGNALING PATHWAY; SIGNALING PATHWAYS; STRIATAL DOPAMINE; TISSUE; TOXICITY; TRANSCRIPTION; WOMEN; Women's health; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>44</startpage>
    <endpage>50</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <issue>1-2</issue>
    <volume>127</volume>
    <abstract>When inappropriate (non-physiologic) estrogens affect organisms at critical times of estrogen sensitivity, disruption of normal endocrine functions can result. Non-physiologic estrogen mimetics (environmental, dietary, and pharmaceutical) can signal rapidly and potently via the membrane versions of estrogen receptors, as can physiologic estrogens. Both physiologic and non-physiologic estrogens activate multiple signaling pathways, leading to altered cellular functions (e.g. peptide release, cell proliferation or death, transport). Xenoestrogens' mimicry of physiologic estrogens is imperfect. When superimposed, xenoestrogens can alter endogenous estrogens' signaling and thereby disrupt normal signaling pathways, leading to malfunctions in many tissue types. Though these xenoestrogen actions occur rapidly via nongenomic signaling pathways, they can be sustained with continuing ligand stimulation, combinations of ligands, and signaling that perpetuates downstream, eventually also impinging on genomic regulation by controlling the activation state of transcription factors. Because via these pathways estrogens and xenoestrogens cause nonmonotonic stimulation patterns, they must be carefully tested for activity and toxicity over wide dose ranges. Nongenomic actions of xenoestrogens in combination with each other, and with physiologic estrogens, are still largely unexplored from these mechanistic perspectives. (C) 2011 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000296546800007</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>43</id>
    <title>Dose-Dependent Incidence of Hepatic Tumors in Adult Mice following Perinatal Exposure to Bisphenol A</title>
    <authors>Weinhouse,C.; Anderson,O.S.; Bergin,I.L.; Vandenbergh,D.J.; Gyekis,J.P.; Dingman,M.A.; Yang,J.Y.; Dolinoy,D.C.</authors>
    <availability>[Weinhouse, Caren; Anderson, Olivia S.; Dolinoy, Dana C.] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Bergin, Ingrid L.] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA. [Vandenbergh, David J.; Gyekis, Joseph P.; Dingman, Marc A.] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA. [Vandenbergh, David J.; Dingman, Marc A.] Penn State Univ, Neurosci Program, University Pk, PA 16802 USA. [Yang, Jingyun] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA.</availability>
    <date>2014</date>
    <notes>JEnglishArticleDolinoy, DC (reprint author), 6638 SPH Tower,1415 Washington Hts, Ann Arbor, MI 48109 USAddolinoy@umich.eduAcevedo N, 2013, ENVIRON HEALTH PERSP, V121, P1040, DOI 10.1289/ehp.1306734; Allen DG, 2004, TOXICOL PATHOL, V32, P393, DOI 10.1080/01926230490440934; Anderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692; Anderson OS, 2013, FASEB J, V27, P1784, DOI 10.1096/fj.12-223545; Babu S, 2013, TOXICOL MECH METHOD, V23, P273, DOI 10.3109/15376516.2012.753969; Bergeron RM, 1999, MOL CELL ENDOCRINOL, V150, P179, DOI 10.1016/S0303-7207(98)00202-0; Betancourt AM, 2012, J NUTR, V142, p1382S, DOI 10.3945/jn.111.152058; Bilger A, 2004, GENETICS, V167, P859, DOI 10.1534/genetics.103.024521; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cui J, 2013, TRENDS MOL MED, V19, P197, DOI 10.1016/j.molmed.2012.12.007; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; DRINKWATER NR, 1994, DRUG METAB REV, V26, P201, DOI 10.3109/03602539409029791; Eaton KA, 2011, VET PATHOL, V48, P713, DOI 10.1177/0300985810383876; Giannitrapani L, 2006, ANN NY ACAD SCI, V1089, P228, DOI 10.1196/annals.1386.044; Goodson WH, 2011, CARCINOGENESIS, V32, P1724, DOI 10.1093/carcin/bgr196; Hassan ZK, 2012, OXID MED CELL LONGEV, V2012, DOI [DOI 10.1155/2012/194829, 10.1155/2012/194829]; Hayashi S, 2008, TOXICOL PATHOL, V36, P858, DOI 10.1177/0192623308322307; Hoenerhoff MJ, 2011, TOXICOL PATHOL, V39, P678, DOI 10.1177/0192623311407213; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Institute of Laboratory Animal Resources, 1996, GUIDE CARE USE LAB A; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Maronpot RR, 2009, J TOXICOL PATHOL, V22, P11, DOI 10.1293/tox.22.11; Moon MK, 2012, J KOREAN MED SCI, V27, P644, DOI 10.3346/jkms.2012.27.6.644; NTP (National Toxicology Program), 1982, 215 NTP; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Ramirez MC, 2012, TOXICOL LETT, V213, P325, DOI 10.1016/j.toxlet.2012.07.015; SCAMPINI G, 1993, TOXICOL PATHOL, V21, P369; Shaw JJ, 2011, EXPERT REV GASTROENT, V5, P365, DOI [10.1586/egh.11.20, 10.1586/EGH.11.20]; Sieli PT, 2011, ENVIRON HEALTH PERSP, V119, P1260, DOI 10.1289/ehp.1003385; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; Vandenberg L.N., 2013, ENDOCR DISRUPTORS, V1, DOI DOI 10.4161/ENDO.26490; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Wu JF, 2010, GASTROENTEROLOGY, V138, P942, DOI 10.1053/j.gastro.2009.11.051; Wunderlich ML, 2011, J VIS EXP, V58, DOI [10.3791/3715, DOI 10.3791/3715]; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.5603381US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPMAYAJ3ZC</notes>
    <keywords>ALTERS; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARCINOGENESIS; CARCINOMA; CELL; EXPOSURE; HEPATOCARCINOGENESIS; HEPATOCELLULAR-CARCINOMA; HUMAN HEALTH; LIVER-CANCER; MAMMARY-GLAND; Mouse; PERINATAL EXPOSURE; RATS; RISK; SUSCEPTIBILITY; Uterus</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>485</startpage>
    <endpage>491</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>5</issue>
    <volume>122</volume>
    <abstract>BACKGROUND: Bisphenol A (BPA) is a high production volume chemical with hormone-like properties that has been implicated as a potential carcinogen. Early-life exposure has been linked to increased risk for precancerous lesions in mammary and prostate glands and the uterus, but no prior study has shown a significant association between BPA exposure and cancer development. OBJECTIVE: We explored the effects of BPA exposure during gestation and lactation on adult incidence of hepatic tumors in mice. METHODS: Isogenic mice were perinatally exposed to BPA through maternal diets containing one of four environmentally relevant doses of BPA (0, 50 ng, 50 mu g, or 50 mg per kilogram of diet), and we followed approximately one male and one female per litter until they were 10 months of age. Animals were tested for known risk factors for hepato-cellular carcinoma, including bacterial and viral infections. RESULTS: We found dose-dependent incidence of hepatic tumors in 10-month-old BPA-exposed mice. Of the offspring examined, 23% presented with hepatic tumors or pre-neoplastic lesions. We observed a statistically significant dose-response relationship, with an odds ratio for neoplastic and preneoplastic lesions of 7.23 (95% CI: 3.23, 16.17) for mice exposed to 50 mg BPA/kg diet compared with unexposed controls. Observed early disease onset, absence of bacterial or viral infection, and lack of charac-teristic sexual dimorphism in tumor incidence support a non-classical etiology. CONCLUSIONS: To our knowledge, this is the first report of a statistically significant association between BPA exposure and frank tumors in any organ. Our results link early-life exposure to BPA with the development of hepatic tumors in rodents, and have potential implications for human health and disease</abstract>
    <url>WOS:000337606300018</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>284</id>
    <title>Endocrine disruptors as a threat to neurological function</title>
    <authors>Weiss,B.</authors>
    <availability>Univ Rochester, Med Ctr, Sch Med &amp; Dent, Dept Environm Med, Rochester, NY 14642 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewWeiss, B (reprint author), Univ Rochester, Med Ctr, Sch Med &amp; Dent, Dept Environm Med, 610 Elmwood Ave, Rochester, NY 14642 USAbernard_weiss@urmc.rochester.eduAlvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Amin S, 2000, NEUROTOXICOL TERATOL, V22, P675, DOI 10.1016/S0892-0362(00)00094-5; Andersson AM, 2008, INT J ANDROL, V31, P74, DOI 10.1111/j.1365-2605.2007.00853.x; Andrade AJM, 2006, TOXICOLOGY, V227, P185, DOI 10.1016/j.tox.2006.07.022; Andre SM, 2006, NEUROTOXICOL TERATOL, V28, P482, DOI 10.1016/j.ntt.2006.04.002; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Anway MD, 2008, REPROD BIOMED ONLINE, V16, P23; Arnold AP, 2004, NAT REV NEUROSCI, V5, P701, DOI 10.1038/nrn1494; Berg GC, 1969, CHEM FALLOUT; Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Cahill L, 2006, NAT REV NEUROSCI, V7, P477, DOI 10.1038/nrn1909; CARLSEN E, 1992, BRIT MED J, V305, P609; Carson R, 1962, SILENT SPRING; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Colbert NKW, 2005, ENVIRON HEALTH PERSP, V113, P700, DOI 10.1289/ehp.7509; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Colborn T., 1996, OUR STOLEN FUTURE; Cooke BM, 2005, J NEUROBIOL, V64, P34, DOI 10.1002/neu.20143; Crews D, 2007, P NATL ACAD SCI USA, V104, P5942, DOI 10.1073/pnas.0610410104; Della Seta D, 2005, BRAIN RES BULL, V65, P255, DOI 10.1016/j.brainresbull.2004.11.017; Engel SM, 2009, NEUROTOXICOLOGY, V30, P522, DOI 10.1016/j.neuro.2009.04.001; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Farabollino F, 2002, ENVIRON HEALTH PERSP, V110, P409; FRY DM, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432528; Gioiosa L, 2007, HORM BEHAV, V52, P307, DOI 10.1016/j.yhbeh.2007.05.006; Goldstein JM, 2001, CEREB CORTEX, V11, P490, DOI 10.1093/cercor/11.6.490; Golombok S, 2008, CHILD DEV, V79, P1583, DOI 10.1111/j.1467-8624.2008.01207.x; GOLOMBOK S, 1993, J CHILD PSYCHOL PSYC, V34, P805, DOI 10.1111/j.1469-7610.1993.tb01072.x; Gray LE, 1999, TOXICOL IND HEALTH, V15, P37, DOI 10.1191/074823399678846655; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Hany J, 1999, TOXICOL APPL PHARM, V158, P231, DOI 10.1006/taap.1999.8710; Hao JD, 2006, J NEUROSCI, V26, P2571, DOI 10.1523/JNEUROSCI.3440-05.2006; Hijazi RA, 2005, ANNU REV MED, V56, P117, DOI 10.1146/annurev.med.56.082103.104518; Hines M, 2006, EUR J ENDOCRINOL, V155, pS115, DOI 10.1530/eje.1.02236; Hof PR, 2004, TRENDS NEUROSCI, V27, P607, DOI 10.1016/j.tins.2004.07.013; Hogervorst E, 2004, EXP GERONTOL, V39, P1633, DOI 10.1016/j.exger.2004.06.019; Hojo R, 2002, ENVIRON HEALTH PERSP, V110, P247; Hotchkiss AK, 2003, PHYSIOL BEHAV, V79, P151, DOI 10.1016/S0031-9384(03)00093-3; HUNT GL, 1977, SCIENCE, V196, P1466, DOI 10.1126/science.196.4297.1466; James Phyllis D., 1993, CHILDREN MEN; Janowsky JS, 2006, TRENDS COGN SCI, V10, P77, DOI 10.1016/j.tics.2006.12.010; Kempermann G, 1998, NAT MED, V4, P555, DOI 10.1038/nm0598-555; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kim BN, 2009, BIOL PSYCHIAT, V66, P958, DOI 10.1016/j.biopsych.2009.07.034; Kimura D, 1996, CURR OPIN NEUROBIOL, V6, P259, DOI 10.1016/S0959-4388(96)80081-X; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Larsson M, 2009, NEUROTOXICOLOGY, V30, P822, DOI 10.1016/j.neuro.2009.01.011; Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105; Leranth C, 2003, J NEUROSCI, V23, P1588; MacLennan AH, 2006, MENOPAUSE, V13, P28, DOI 10.1097/01.gme.0000191204.38664.61; MacLusky NJ, 2006, NEUROSCIENCE, V138, P957, DOI 10.1016/j.neuroscience.2005.12.054; MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633; Meeker JD, 2009, J ANDROL, V30, P287, DOI 10.2164/jandrol.108.006403; Moffat SD, 2005, ANN NY ACAD SCI, V1055, P80, DOI 10.1196/annals.1323.014; Moller H, 1998, APMIS, V106, P232; Murono EP, 2005, REPROD TOXICOL, V20, P503, DOI 10.1016/j.reprotox.2005.03.002; Rapp PR, 2003, J NEUROSCI, V23, P5708; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Sharpe RM, 2005, ENVIRON HEALTH PERSP, V113, pA504; Sharpe RM, 2008, TOXICOL SCI, V105, P1, DOI 10.1093/toxsci/kfn123; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sherwin BB, 2006, NEUROSCIENCE, V138, P1021, DOI 10.1016/j.neuroscience.2005.07.051; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Skakkebaek Niels E., 2003, Hormone Research (Basel), V60, P49, DOI 10.1159/000074499; Skinner MK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003745; Stahlhut RW, 2007, ENVIRON HEALTH PERSP, V115, P876, DOI 10.1289/ehp.9882; Swaab DF, 2007, BEST PRACT RES CL EN, V21, P431, DOI 10.1016/j.beem.2007.04.003; Swan SH, 2010, INT J ANDROL, V33, P259, DOI 10.1111/j.1365-2605.2009.01019.x; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Tanapat P, 2005, J COMP NEUROL, V481, P252, DOI 10.1002/cne.20385; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Weiss B, 2007, NEUROTOXICOLOGY, V28, P938, DOI 10.1016/j.neuro.2007.01.012; Weiss B, 2002, ENVIRON HEALTH PERSP, V110, P851; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Yaffe K, 2002, J AM GERIATR SOC, V50, P707, DOI 10.1046/j.1532-5415.2002.50166.x; Yaffe K, 2004, LANCET NEUROL, V3, P270, DOI 10.1016/S1474-4422(04)00732-X; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zoeller RT, 2007, THYROID, V17, P811, DOI 10.1089/thy.2007.01078511ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSJ NEUROL SCIJUN 15Discipline: Neurosciences &amp; Neurology773SN</notes>
    <keywords>ADULT; Aging; Alzheimer's disease; androgens; Antiandrogens; Autism; bisphenol A; BISPHENOL-A EXPOSURE; CANCER; CHEMICALS; CHILDREN; COGNITIVE FUNCTION; Congenital adrenal hyperplasia; CONJUGATED EQUINE ESTROGENS; DDT; DEFECTS; development; DEVELOPMENTAL EXPOSURE; Differentiation; DISORDERS; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemicals; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENVIRONMENTAL ANTIANDROGEN; ENVIRONMENTAL CHEMICALS; epigenetics; ESTROGENS; fertility; HEALTH; HEALTH INITIATIVE MEMORY; Hormones; JUN; Male; MALE RATS; Menopause; Methylmercury; Neurogenesis; PERINATAL EXPOSURE; PERSISTENT ORGANIC POLLUTANTS; PESTICIDES; Phthalates; Play behavior; PRENATAL PHTHALATE EXPOSURE; Reproduction; Sexual dimorphism; SEXUAL-DIFFERENTIATION; Testosterone; Thyroid function; toxicology; Window of opportunity</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>11</startpage>
    <endpage>21</endpage>
    <journalfull>Journal of the Neurological Sciences</journalfull>
    <issue>1-2</issue>
    <volume>305</volume>
    <abstract>Endocrine disruption is a concept and principle whose origins can be traced to the beginnings of the environmental movement in the 1960s. It began with puzzlement about and the flaring of research on the decline of wildlife, particularly avian species. The proposed causes accented pesticides, especially persistent organochlorines such as DDT. Its scope gradually widened beyond pesticides, and, as endocrine disruption offered an explanation for the wildlife phenomena, it seemed to explain, as well, changes in fertility and disorders of male reproduction such as testicular cancer. Once disturbed gonadal hormone function became the most likely explanation, it provoked other questions. The most challenging arose because of how critical gonadal hormones are to brain function, especially as determinants of brain sexual differentiation. Pursuit of such connections has generated a robust literature embracing a broad swath of chemical classes. How endocrine disrupting chemicals influence the adult and aging brain is a question, so far mostly ignored because of the emphasis on early development, that warrants vigorous investigation. Gonadal hormones are crucial to optimal brain function during maturity and even senescence. They are pivotal to the processes of neurogenesis. They exert protective actions against neurodegenerative disorders such as dementia and support smoothly functioning cognitive activities. The limited research conducted so far on endocrine disruptors, aging, and neurogenesis argues that they should be overlooked no longer. (C) 2011 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000291330800002</url>
    <isbnorissn>0022-510X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>165</id>
    <title>Progression of the erectile dysfunction in the population and the possibilities of its regression with bioregeneration</title>
    <authors>Wendlova,J.</authors>
    <availability>[Wendlova, Jaroslava] Slovak Bioregenerat Med Assoc, Bratislava 81322, Slovakia. [Wendlova, Jaroslava] Vienna Int Acad Integrat Med, Vienna, Austria.</availability>
    <date>2013</date>
    <notes>JEnglishReviewWendlova, J (reprint author), Slovak Bioregenerat Med Assoc, Slovak Med Assoc, Cukrova 3, Bratislava 81322, Slovakiajwendlova@mail.t-com.skAbdull Razis Ahmad Faizal, 2013, Asian Pac J Cancer Prev, V14, P1565; Andersson KE, 2011, PHARMACOL REV, V63, P811, DOI 10.1124/pr.111.004515; Banks E, 2013, PLOS MED, V10, P100; Behr M, 2011, FOOD CHEM TOXICOL, V49, P2681, DOI 10.1016/j.fct.2011.07.039; Bell MC, 2000, GYNECOL ONCOL, V78, P123, DOI 10.1006/gyno.2000.5847; Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; Birkett WJ, 2003, ENDOCRINE DISRUPTORS, P8; Bjorndahl L, 2011, SYST BIOL REPROD MEC, V57, P86, DOI 10.3109/19396368.2010.516306; BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571; BRADLOW HL, 1986, ANN NY ACAD SCI, V464, P138, DOI 10.1111/j.1749-6632.1986.tb16001.x; Bradlow HL, 1996, J ENDOCRINOL S, V150, P259; Brown GA, 2001, J AM COLL NUTR, V20, P520; Byun JS, 2013, BJU INT, V111, P227; Cabler S, 2010, ASIAN J ANDROL, V12, P480, DOI 10.1038/aja.2010.38; Campos AR, 2006, J ETHNOPHARMACOL, V104, P240, DOI 10.1016/j.jep.2005.09.009; Cera N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039118; Chaiyasit Kamon, 2012, Indian J Endocrinol Metab, V16, P485, DOI 10.4103/2230-8210.95756; Chan SW, 2012, INT J FOOD SCI NUTR, V63, P75, DOI 10.3109/09637486.2011.627840; Chang YC, 1999, BIOCHEM PHARMACOL, V58, P825, DOI 10.1016/S0006-2952(99)00165-3; Chao CH, 2013, ANDROLOGY-US, V1, P793, DOI 10.1111/j.2047-2927.2013.00120.x; Chen KK, 2006, UROLOGY, V67, P631, DOI 10.1016/j.urology.2005.09.051; Chen KM, 2012, J NURS RES, V20, P80, DOI 10.1097/JNR.0b013e3182598fe8; Cherdshewasart W, 2003, ASIAN J ANDROL, V5, P243; Chiu JH, 2006, INT J IMPOT RES, V18, P335, DOI 10.1038/sj.ijir.3901437; Cho KS, 2013, ASIAN J ANDROL, V15, P503, DOI 10.1038/aja.2013.49; Cohen AJ, 1998, J SEX MARITAL THER, V24, P139, DOI 10.1080/00926239808404927; Condorelli R., 2011, J ENDOCRINOL INVEST, V34, P314; Cooper JE, 2011, CHEMOSPHERE, V85, P943, DOI 10.1016/j.chemosphere.2011.06.060; Cormio L, 2011, UROLOGY, V77, P119, DOI 10.1016/j.urology.2010.08.028; Cortes-Gonzalez JR, 2010, BJU INT, V105, P225, DOI 10.1111/j.1464-410X.2009.08748.x; Darbre PD, 2010, ANTICANCER RES, V30, P815; Delbes G, 2005, M S-MED SCI, V21, P1083; Delbes G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231; Dell'Agli M, 2008, J NAT PROD, V71, P1513, DOI 10.1021/np800049y; D,ugosz Anna, 2007, Ginekol Pol, V78, P632; Ende J, 1990, CLIN METHODS HIST PH; Ernst E, 2011, MATURITAS, V70, P37, DOI 10.1016/j.maturitas.2011.06.011; Fagelman E, 2001, Rev Urol, V3, P134; Fan Yu, 2013, Zhonghua Nan Ke Xue, V19, P572; FELDMAN HA, 1994, J UROLOGY, V151, P54; Foocharoen Chingching, 2012, ARTHRITIS RES THER, V14, P37; Frye CA, 2012, J NEUROENDOCRINOL, V24, P144, DOI 10.1111/j.1365-2826.2011.02229.x; Giuliano F, 2013, PROG UROL, V23, P629, DOI 10.1016/j.purol.2013.01.010; Gyllenhammar I, 2012, ENVIRON INT, V43, P21, DOI 10.1016/j.envint.2012.02.010; Habib FK, 2005, INT J CANCER, V114, P190, DOI 10.1002/ijc.20701; Ho Christopher C K, 2011, Curr Urol Rep, V12, P470, DOI 10.1007/s11934-011-0217-x; Ho JN, 2013, MOL MED REP, V7, P384, DOI 10.3892/mmr.2012.1198; Hong B, 2002, J UROLOGY, V168, P2070, DOI 10.1097/01.ju.0000034387.21441.87; Iacono F, 2012, BMC SURG S1, V12, P24; Iacono F, 2012, BMC SURG S1, V12, P23; Iacono F, 2012, BMC SURG S1, V12, P22; Inman BA, 2009, MAYO CLIN PROC, V84, P108, DOI 10.4065/84.2.108; Jalali GR, 2010, RENAL FAILURE, V32, P417, DOI 10.3109/08860221003706958; Jang DJ, 2008, BRIT J CLIN PHARMACO, V66, P444, DOI 10.1111/j.1365-2125.2008.03236.x; Kalaitzidou I, 2013, ANDROLOGIA, V39, P512; Kang BJ, 2002, HUM PSYCHOPHARM CLIN, V17, P279, DOI 10.1002/hup.409; Kaplan SA, 2004, J UROLOGY, V171, P284, DOI 10.1097/01.ju.0000101487.83730.80; Kerdivel G, 2013, INT J ENDOCRINOL, V13, P501; Khedun S. M., 1995, Central African Journal of Medicine, V41, P312; Kim TH, 2009, ASIAN J ANDROL, V11, P356, DOI 10.1038/aja.2008.32; Kim YS, 2005, J NUTR BIOCHEM, V16, P65, DOI 10.1016/j.jnutbio.2004.10.007; Kohut ML, 2003, J AM COLL NUTR, V22, P363; Kolotkin RL, 2012, OBESITY, V20, P2325, DOI 10.1038/oby.2012.104; Kopp RP, 2013, BJU INT, V111, P98; Koraichi F, 2013, TOXICOLOGY, V310, P29, DOI 10.1016/j.tox.2013.05.002; Kratz MT, 2013, EUR J PREV CARDIOL; Kwan CY, 2004, N-S ARCH PHARMACOL, V369, P206, DOI 10.1007/s00210-003-0822-4; Lejeune H, 2013, PROG UROL, V23, P621, DOI 10.1016/j.purol.2013.01.019; Li DK, 2010, J ANDROL, V31, P500, DOI 10.2164/jandrol.110.010413; Li FJ, 2011, MOL CELL ENDOCRINOL, V344, P51, DOI 10.1016/j.mce.2011.06.024; Liu XJ, 2013, BREAST, V22, P309, DOI 10.1016/j.breast.2012.07.013; Lorand T, 2010, CURR MED CHEM, V17, P3542; Loscalzo J, 2013, CIRC RES, V113, P100, DOI 10.1161/CIRCRESAHA.113.301577; Lucca Ilaria, 2012, Rev Med Suisse, V8, P2327; Luiking YC, 2012, AM J PHYSIOL-ENDOC M, V303, P1177; MacDonald R, 2012, BJU INT, V109, P1756, DOI 10.1111/j.1464-410X.2012.11172.x; Marconett CN, 2012, MOL CELL ENDOCRINOL, V363, P74, DOI 10.1016/j.mce.2012.07.008; Marino M, 2012, STEROIDS, V77, P910, DOI 10.1016/j.steroids.2012.02.019; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; Mekki MO, 2013, SAUDI J KIDNEY DIS T, V3, P500; Mialon A, 2012, J ADOLESCENT HEALTH, V51, P25, DOI 10.1016/j.jadohealth.2012.01.008; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; MICHNOVICZ JJ, 1991, NUTR CANCER, V16, P59; Michnovicz JJ, 1997, J NATL CANCER I, V89, P718, DOI 10.1093/jnci/89.10.718; Pomerol Monseny Jose Maria, 2010, Archivos Espanoles de Urologia, V63, P599; Nagaoka S, 2012, INSECT BIOCHEM MOLEC, V42, P571, DOI 10.1016/j.ibmb.2012.04.004; Nakamura Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-100; Nehra A, 2013, MINERVA UROL NEFROL, V65, P109; Neuzillet Y, 2013, ANDROLOGY-US, V1, P223, DOI 10.1111/j.2047-2927.2012.00046.x; Neychev VK, 2005, J ETHNOPHARMACOL, V101, P319, DOI 10.1016/j.jep.2005.05.017; Oguz F, 2013, J SEX MED, V10, P838, DOI 10.1111/j.1743-6109.2012.02974.x; Oh Hong-Geun, 2012, Lab Anim Res, V28, P83, DOI 10.5625/lar.2012.28.2.83; Paroni R, 2012, INT J ANDROL, V35, P660, DOI 10.1111/j.1365-2605.2012.01272.x; Patel DV, 2012, BRIT J RADIOL, V85, P69; Persu C, 2009, J Med Life, V2, P394; Ponseti J, 2009, INT J IMPOT RES, V21, P292, DOI 10.1038/ijir.2009.31; Pytel' IA, UROLOGIIA, V2, P3; Rathi Manish, 2012, Indian J Endocrinol Metab, V16, P214, DOI 10.4103/2230-8210.93738; RILEY AJ, 1994, BRIT J CLIN PRACT, V48, P133; Rosen RC, 2004, CURR MED RES OPIN, V20, P607, DOI 10.1185/030079904125003467; Sai Ravi Shanker A, 2013, INDIAN HEART J, V65, P180; Salgueiro MJ, 2004, BIOL TRACE ELEM RES, V99, P49, DOI 10.1385/BTER:99:1-3:049; Santos RS, 2009, PHARMAZIE, V64, P836; Sellandi Thirunavukkarasu M, 2012, Ayu, V33, P356, DOI 10.4103/0974-8520.108822; Shamloul R, 2013, LANCET, V381, P153, DOI 10.1016/S0140-6736(12)60520-0; Slomczynska M, 2008, POL J VET SCI, V11, P263; Sperling H, 2002, J UROLOGY, V168, P160, DOI 10.1016/S0022-5347(05)64852-5; Tsai AG, 2009, OBES WEIGHT MANAG, V5, P183, DOI 10.1089/obe.2009.0408; Vivar OI, 2010, ENDOCRINOLOGY, V151, P1662, DOI 10.1210/en.2009-1028; Warth B, 2013, TOXICOL LETT, V220, P88, DOI 10.1016/j.toxlet.2013.04.012; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Weng JR, 2007, CANCER RES, V67, P7815, DOI 10.1158/0008-5472.CAN-07-0794; Wheatley D, 2008, HUM PSYCHOPHARM CLIN, V9, P545; Wozniak M, GINEKOL POL, V79, P785; Yao FJ, 2013, CLIN RES CARDIOL, V102, P645, DOI 10.1007/s00392-013-0577-y; Zhang Wan-Hong, 2006, Zhonghua Nan Ke Xue, V12, P4661160MAGHIRA &amp; MAAS PUBLICATIONSSTOCKHOLMPO BOX 26132, S-100 41 STOCKHOLM, SWEDENNEUROENDOCRINOL LETTDiscipline: Endocrinology &amp; Metabolism; Neurosciences &amp; NeurologyAA2BN</notes>
    <keywords>BISPHENOL-A; breast; BREAST-CANCER CELLS; BREVICORNUM MAXIM EXTRACT; CANCER; CARCINOGENESIS; CELL; CLINICAL-TRIAL; DIETARY INDOLE-3-CARBINOL; DOUBLE-BLIND; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; erectile dysfunction; ESTRADIOL METABOLISM; fertility; FOOD; HEALTH; heart; INDUCED SEXUAL DYSFUNCTION; medicinal plants; METABOLISM; natural therapy; p21; pathophysiology; PENILE ERECTION; PLANTS; POPULATION; PROGRESSION; Reproduction; toxicology; xenoestrogen; XENOESTROGENS; YOUNG MEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>482</startpage>
    <endpage>497</endpage>
    <journalfull>Neuroendocrinology Letters</journalfull>
    <issue>6</issue>
    <volume>34</volume>
    <abstract>Article presents the latest knowledge on the pathophysiology of erectile dysfunction (ED), the influence of xenoestrogens on ED and fertility in men and the possibilities of the blocking xenoestrogen actions with natural ingredients as well as treatment options for ED with medicinal plants. With the rising phenomenon of ED in the world there is rising a market with ED treatment products. Especially in menu of internet online shops come increasingly to light new natural over the counter products for ED treatment. Sale and use of medicinal plants and their extracts in the treatment of ED is based according to the declaration of the producers first of all on a number of the thousand-year-old traditions in some nations, based on the efficacy and safety of these plants, verified in the healing practice. Aim of this article was to make an extensive review of the scientific and professional literature and to find out which medical plants, sold in the herbal products for ED, was evaluated for efficacy and safety in relevant clinical trials. The review of the literature shows, that by some marketed medicinal plants lack clinical studies, the results of some clinical studies related to the same medicinal plant are controversial and some bring significantly positive effects, but their number is minimal. The future is therefore open to starting the number of new clinical trials testing the medicinal plants in the treatment of ED with possible inclusion of some of these plants in evidence based medicine, if confirming their efficacy and safety</abstract>
    <url>WOS:000330900200003</url>
    <isbnorissn>0172-780X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>325</id>
    <title>Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells</title>
    <authors>Weng,Y.I.; Hsu,P.Y.; Liyanarachchi,S.; Liu,J.; Deatherage,D.E.; Huang,Y.W.; Zuo,T.; Rodriguez,B.; Lin,C.H.; Cheng,A.L.; Huang,T.H.M.</authors>
    <availability>[Weng, Yu-I; Hsu, Pei-Yin; Liyanarachchi, Sandya; Liu, Joseph; Deatherage, Daniel E.; Huang, Yi-Wen; Zuo, Tao; Rodriguez, Benjamin; Huang, Tim H. -M.] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA. [Lin, Ching-Hung; Cheng, Ann-Lii] Natl Taiwan Univ Hosp, Dept Internal Med &amp; Oncol, Taipei, Taiwan.</availability>
    <date>2010</date>
    <notes>JEnglishArticleHuang, THM (reprint author), Ohio State Univ, Human Canc Genet Program, Room 814,Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USATim.Huang@osumc.eduAkamine R, 2007, J BIOCHEM BIOPH METH, V70, P481, DOI 10.1016/j.jbbm.2006.11.008; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; *CDC, 2009, 4 CDC CDCP NAT CTR E; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Goodson A, 2004, FOOD ADDIT CONTAM, V21, P1015, DOI 10.1080/02652030400011387; Harreus UA, 2002, INT J ENVIRON AN CH, V82, P395, DOI 10.1080/0306731021000015047; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kanao H, 2005, CANCER RES, V65, P8640, DOI 10.1158/0008-5472; Kang JH, 2003, J FOOD PROTECT, V66, P1444; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lin CH, 2009, CANCER EPIDEM BIOMAR, V18, P1807, DOI 10.1158/1055-9965.EPI-09-0096; Markey CM, 2001, BIOL REPROD, V65, P1215; Marotta Lauren L Campbell, 2009, Curr Opin Genet Dev, V19, P44, DOI 10.1016/j.gde.2008.12.003; Mountfort KA, 1997, FOOD ADDIT CONTAM, V14, P737; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murphy LC, 2009, J STEROID BIOCHEM, V114, P90, DOI 10.1016/j.jsbmb.2009.01.017; Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002; Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Rohrdanz E, 2002, J NUTR, V132, P370; Soto AM, 2006, BEST PRACT RES CL EN, V20, P15, DOI 10.1016/j.beem.2005.09.001; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Tyl RW, 2009, ENVIRON HEALTH PERSP, V117, P1644, DOI 10.1289/ehp.0900893; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Vogel Sarah A, 2009, Am J Public Health, V99 Suppl 3, pS559, DOI 10.2105/AJPH.2008.159228; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.0284725ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMOCT 15Discipline: Pharmacology &amp; Pharmacy; Toxicology663BG</notes>
    <keywords>ADULTHOOD; ALPHA; analysis; ASSAY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; CELL; cell cycle; CELL-CYCLE; CELLS; CHEMICALS; COMBINATION; CYCLE; development; DNA METHYLATION; DNA-methylation; epigenetic; epigenetics; EPIGENOMICS; EPITHELIAL-CELLS; ER alpha; ER-ALPHA; Estrogen; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; FOOD; GENE; gene expression; gene expression profile; GENE-EXPRESSION; GENES; HEALTH; In vitro; IN-VITRO; IN-VIVO; low dose; MAMMARY-GLAND; mechanism; MECHANISMS; METHYLATION; Migration; MODEL; molecular mechanism; MOLECULAR-MECHANISMS; p21; PATHWAY; PHARMACOLOGY; PROTEIN; puberty; RISK; SIGNALING PATHWAY; Steroid; SUBTYPES; SUPPRESSION; SYSTEM; toxicology; TUMOR; TUMORS; VITRO; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>111</startpage>
    <endpage>121</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>2</issue>
    <volume>248</volume>
    <abstract>Substantial evidence indicates that exposure to bisphenol A (BPA) during early development may increase breast cancer risk later in life. The changes may persist into puberty and adulthood, suggesting an epigenetic process being imposed in differentiated breast epithelial cells. The molecular mechanisms by which early memory of BPA exposure is imprinted in breast progenitor cells and then passed onto their epithelial progeny are not well understood. The aim of this study was to examine epigenetic changes in breast epithelial cells treated with low-dose BPA. We also investigated the effect of BPA on the ER alpha signaling pathway and global gene expression profiles. Compared to control cells, nuclear internalization of ER alpha was observed in epithelial cells preexposed to BPA. We identified 170 genes with similar expression changes in response to BPA. Functional analysis confirms that gene suppression was mediated in part through an ER alpha-dependent pathway. As a result of exposure to BPA or other estrogen-like chemicals, the expression of lysosomal-associated membrane protein 3 (LAMP3) became epigenetically silenced in breast epithelial cells. Furthermore, increased DNA methylation in the LAMP3 CpG island was this repressive mark preferentially occurred in ER alpha-positive breast tumors. These results suggest that the in vitro system developed in our laboratory is a valuable tool for exposure studies of BPA and other xenoestrogens in human cells. Individual and geographical differences may contribute to altered patterns of gene expression and DNA methylation in susceptible loci. Combination of our exposure model with epigenetic analysis and other biochemical assays can give insight into the heritable effect of low-dose BPA in human cells. Published by Elsevier Inc</abstract>
    <url>WOS:000282857400004</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>31</id>
    <title>Validation and application of a reporter gene assay for the determination of estrogenic endocrine disruptor activity in milk</title>
    <authors>Wielogorska,E.; Elliott,C.T.; Danaher,M.; Connolly,L.</authors>
    <availability>[Wielogorska, E.; Elliott, C. T.; Connolly, L.] Queens Univ Belfast, Inst Global Food Secur, Sch Biol Sci, Belfast BT9 5AG, Antrim, North Ireland. [Wielogorska, E.; Danaher, M.] Teagasc Food Res Ctr, Dublin 15, Ireland.</availability>
    <date>2014</date>
    <notes>JEnglishArticleConnolly, L (reprint author), Queens Univ Belfast, Inst Global Food Secur, David Keir Bldg,Stranmillis Rd, Belfast BT9 5AG, Antrim, North Irelandl.connolly@qub.ac.ukAbad E, 2002, CHEMOSPHERE, V46, P1435, DOI 10.1016/S0045-6535(01)00247-8; Behr M, 2011, FOOD CHEM TOXICOL, V49, P2681, DOI 10.1016/j.fct.2011.07.039; Bovee T.F.H., 2009, BIOASSAYS DETECTION; Bovee TFH, 1998, FOOD ADDIT CONTAM, V15, P863; Casajuana N, 2004, J AGR FOOD CHEM, V52, P3702, DOI 10.1021/jf040027s; Chou IC, 2008, J HAZARD MATER, V154, P1166, DOI 10.1016/j.jhazmat.2007.11.023; Connolly L, 2009, WOODHEAD PUBL FOOD S, P103, DOI 10.1533/9781845695743.2.103; Courant F, 2008, J AGR FOOD CHEM, V56, P3176, DOI 10.1021/jf800096f; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dip R, 2008, ENDOCR-RELAT CANCER, V15, P161, DOI 10.1677/ERC-07-0252; EU, 2002, OFF J EUR COMMUN, P8; Flachowsky G, 2011, J VERBRAUCH LEBENSM, V6, P449, DOI 10.1007/s00003-011-0702-7; Hartmann S, 1998, FOOD CHEM, V62, P7, DOI 10.1016/S0308-8146(97)00150-7; JECFA, 1999, ONL ED RES SOM VET D; Krajcova A, 2010, CZECH J FOOD SCI, V28, P264; Maruyama K, 2010, PEDIATR INT, V52, P33, DOI 10.1111/j.1442-200X.2009.02890.x; Nielsen TS, 2009, CANCER EPIDEMIOL, V33, P61, DOI 10.1016/j.canep.2009.04.003; Noorlander CW, 2011, J AGR FOOD CHEM, V59, P7496, DOI 10.1021/jf104943p; Petro EML, 2010, SCI TOTAL ENVIRON, V408, P5423, DOI 10.1016/j.scitotenv.2010.07.051; Plotan M, 2012, ANAL BIOANAL CHEM, V403, P3057, DOI 10.1007/s00216-012-5905-y; Shao B, 2007, J CHROMATOGR B, V850, P412, DOI 10.1016/j.jchromb.2006.12.033; Sorensen LK, 2005, J CHROMATOGR B, V820, P183, DOI 10.1016/j.jchromb.2005.03.020; Sotoca AM, 2010, J STEROID BIOCHEM, V122, P204, DOI 10.1016/j.jsbmb.2010.06.010; Thomson B, 2009, WOODHEAD PUBL FOOD S, P211, DOI 10.1533/9781845695743.3.211; Walton D.J., 2011, NATL ADULT NUTR SURV; Willemsen P, 2004, ANAL BIOANAL CHEM, V378, P655, DOI 10.1007/s00216-003-2217-2260PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLJULDiscipline: Food Science &amp; Technology; ToxicologyAL0LH</notes>
    <keywords>BISPHENOL-A; BOVINE-MILK; CALUX-BIOASSAY; CANCER; COWS; Endocrine disrupting compounds; Endocrine disruptor; ENDOCRINE DISRUPTORS; Estrogen; EXPOSURE; FOOD; LIQUID-CHROMATOGRAPHY; Milk; PHYTOESTROGENS; Reporter gene assay; SAMPLES; STEROID-HORMONES; TANDEM MASS-SPECTROMETRY</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>260</startpage>
    <endpage>266</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <volume>69</volume>
    <abstract>Endocrine disruptors (EDs) are compounds known to interfere with the endocrine system by disturbing the action or pathways of natural hormones which may lead to infertility or cancer. Our diet is considered to be one of the main exposure routes to EDs. Since milk and dairy products are major components of our diet they should be monitored for ED contamination. Most assays developed to date utilise targeted, chromatography based methods which lack information on the biological activity and mixture effects of the monitored compounds. A biological reporter gene assay (RGA) was developed to assess the total estrogen hormonal load in milk. It has been validated according to EU decision 2002/657/EC. Analytes were extracted by liquid-liquid extraction with acetonitrile followed by clean up on a HLB column which yielded good recovery and small matrix effects. The method has been shown to be estrogen specific, repeatable and reproducible, with covariance values below 20%. In conclusion, this method enables the detection of low levels of estrogen hormonal activity in milk with a detection capability of 36 pg g(-1) EEQ and has been successfully applied in testing a range of milk samples. (C) 2014 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000338817900030</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>290</id>
    <title>Environmental toxicants and the developing immune system: A missing link in the global battle against infectious disease?</title>
    <authors>Winans,B.; Humble,M.C.; Lawrence,B.P.</authors>
    <availability>[Winans, Bethany; Lawrence, B. Paige] Univ Rochester, Sch Med &amp; Dent, Dept Environm Med, Rochester, NY 14642 USA. [Winans, Bethany; Lawrence, B. Paige] Univ Rochester, Sch Med &amp; Dent, Toxicol Training Program, Rochester, NY 14642 USA. [Humble, Michael C.] NIEHS, Cellular Organs &amp; Syst Pathobiol Branch, Div Extramural Res &amp; Training, Res Triangle Pk, NC 27560 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewLawrence, BP (reprint author), Univ Rochester, Sch Med &amp; Dent, Dept Environm Med, 575 Elmwood Ave,Box 850, Rochester, NY 14642 USApaige_lawrence@urmc.rochester.eduAbraham K, 1998, CHEMOSPHERE, V37, P1731, DOI 10.1016/S0045-6535(98)00238-0; Alizadeh Mohammad, 2006, J Med Invest, V53, P70, DOI 10.2152/jmi.53.70; *AM CANC SOC, 2009, WOM SMOK; ANDREW A, 2007, TOXICOLOGICAL SCI; [Anonymous], 2008, WORLD CANC REP; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; BARNETT JB, 1985, TOXICOL LETT, V25, P173, DOI 10.1016/0378-4274(85)90079-7; BARNETT JB, 1985, TOXICOL LETT, V25, P229, DOI 10.1016/0378-4274(85)90202-4; Basta PV, 2000, INT J IMMUNOPHARMACO, V22, P159, DOI 10.1016/S0192-0561(99)00074-0; Bellinger DL, 2008, J IMMUNOTOXICOL, V5, P419, DOI 10.1080/15476910802483415; BLAYLOCK BL, 1992, TOXICOL APPL PHARM, V112, P207, DOI 10.1016/0041-008X(92)90189-Y; BLAYLOCK BL, 1990, TOXICOL LETT, V51, P41, DOI 10.1016/0378-4274(90)90223-9; Blossom SJ, 2007, J IMMUNOTOXICOL, V4, P129, DOI 10.1080/15476910701337035; Blossom SJ, 2008, TOXICOL APPL PHARM, V231, P344, DOI 10.1016/j.taap.2008.05.009; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Bradman A, 2003, ENVIRON HEALTH PERSP, V111, P1779, DOI 10.1289/ehp.6259; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Brooks DR, 2004, CANCER CAUSE CONTROL, V15, P997, DOI 10.1007/s10552-004-1123-z; BUCKLEY JD, 1989, CANCER RES, V49, P4030; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Camacho IA, 2004, TOXICOL SCI, V78, P96, DOI 10.1093/toxsci/kfh048; Chang Jeffrey S., 2009, V472, P103, DOI 10.1007/978-1-60327-492-0_5; Chen H, 2001, MOL CARCINOGEN, V30, P79, DOI 10.1002/1098-2744(200102)30:2&lt;79::AID-MC1016&gt;3.0.CO;2-F; Cheraghi M, 2009, EUR J PEDIATR, V168, P897, DOI 10.1007/s00431-009-0967-3; Collins FS, 2010, SCIENCE, V327, P36, DOI 10.1126/science.1185055; Colosio C, 2005, TOXICOL APPL PHARM, V207, pS320; Colt JS, 1998, ENVIRON HEALTH PERSP, V106, P909, DOI 10.2307/3434208; Concha G, 1998, TOXICOL SCI, V44, P185, DOI 10.1093/toxsci/44.2.185; Dallaire F, 2004, ENVIRON HEALTH PERSP, V112, P1359, DOI 10.1289/ehp.7255; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Dewailly E, 2000, ENVIRON HEALTH PERSP, V108, P205, DOI 10.2307/3454435; Dietert RR, 2004, TOXICOL APPL PHARM, V198, P86, DOI 10.1016/j.taap.2003.08.020; Dietert RR, 2009, CHEM RES TOXICOL, V22, P17, DOI 10.1021/tx800198m; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; Edwards TM, 2008, CIENC SAUDE COLETIVA, V13, P269, DOI 10.1289/ehp.9951; Engel A, 2008, J ENVIRON HEALTH, V71, P12; FAITH RE, 1977, J TOXICOL ENV HEALTH, V3, P451; Fangstrom B, 2008, ENVIRON HEALTH PERSP, V116, P963, DOI 10.1289/ehp.11094; Filippini G, 2000, PAEDIATR PERINAT EP, V14, P78; FILIPPINI G, 1994, INT J CANCER, V57, P769, DOI 10.1002/ijc.2910570602; FINE JS, 1989, MOL PHARMACOL, V35, P18; Gehrs BC, 1999, TOXICOLOGY, V134, P79, DOI 10.1016/S0300-483X(99)00024-4; Gehrs BC, 1997, TOXICOLOGY, V122, P229, DOI 10.1016/S0300-483X(97)00099-1; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Glynn A, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-62; Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004; Guo YLL, 2004, INT ARCH OCC ENV HEA, V77, P153, DOI 10.1007/s00420-003-0487-9; Guvenius DM, 2003, ENVIRON HEALTH PERSP, V111, P1235, DOI 10.1289/ehp.5946; Heilmann C, 2006, PLOS MED, V3, P1352, DOI 10.1371/journal.pmed.0030311; Hertz-Picciotto I, 2008, BASIC CLIN PHARMACOL, V102, P146, DOI 10.1111/j.1742-7843.2007.00190.x; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; Hogaboam JP, 2008, TOXICOL SCI, V102, P160, DOI 10.1093/toxsci/kfm283; Holladay SD, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454538; HOLLADAY SD, 1991, TERATOLOGY, V44, P385, DOI 10.1002/tera.1420440405; Infante-Rivard C, 2007, J TOXICOL ENV HEAL B, V10, P81, DOI 10.1080/10937400601034589; Infante-Rivard C, 2005, ENVIRON HEALTH PERSP, V113, P787, DOI 10.1289/ehp.7707; Inoue K, 2000, J CHROMATOGR B, V749, P17, DOI 10.1016/S0378-4347(00)00351-0; Jaakkola JJK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-48; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jedrychowski W, 2005, EUR J EPIDEMIOL, V20, P775, DOI 10.1007/s10654-005-1048-1; Jusko TA, 2010, ENVIRON RES, V110, P388, DOI 10.1016/j.envres.2010.02.010; Keil DE, 2008, TOXICOL SCI, V103, P77, DOI 10.1093/toxsci/kfn015; Kelvin EA, 2009, CANCER EPIDEM BIOMAR, V18, P2262, DOI 10.1158/1055-9965.EPI-09-0316; Kimber I, 2010, TOXICOLOGY, V271, P73, DOI 10.1016/j.tox.2010.03.020; Kozul CD, 2009, ENVIRON HEALTH PERSP, V117, P1441, DOI 10.1289/ehp.0900911; Kozul CD, 2009, ENVIRON HEALTH PERSP, V117, P1108, DOI 10.1289/ehp.0800199; Kuper H, 2000, J INTERN MED, V248, P171, DOI 10.1046/j.1365-2796.2000.00742.x; Le Souef PN, 2006, EUR RESPIR J, V28, P675, DOI 10.1183/09031936.06.00101206; Liu J, 2007, TOXICOL APPL PHARM, V220, P284, DOI 10.1016/j.taap.2007.01.018; Liu J, 2006, TOXICOL APPL PHARM, V213, P216, DOI 10.1016/j.taap.2005.10.010; MAGNANI C, 1990, TUMORI, V76, P413; McKinney PA, 2008, RADIAT PROT DOSIM, V132, P232, DOI 10.1093/rpd/ncn265; MENNA JH, 1985, TOXICOL LETT, V24, P45, DOI 10.1016/0378-4274(85)90138-9; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Nagayama J, 2007, CHEMOSPHERE, V67, pS393, DOI 10.1016/j.chemosphere.2006.05.134; *NAT RES CTR WOM F, 2004, ISS BRIEF SMOK WOM H; Ng SP, 2008, J TOXICOL ENV HEAL A, V71, P445, DOI 10.1080/15287390701839281; Ng SP, 2006, TOXICOL SCI, V89, P135, DOI 10.1093/toxsci/kfj006; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Ohshima Y, 2007, PEDIATR RES, V62, P60, DOI 10.1203/PDR.0b013e3180674dae; Pang D, 2003, BRIT J CANCER, V88, P373, DOI 10.1038/sj.bjc.6600774; Park HY, 2008, ENVIRON HEALTH PERSP, V116, P104, DOI 10.1289/ehp.9769; Patterson R, 2004, TOXICOL APPL PHARM, V198, P434, DOI 10.1016/j.taap.2003.10.012; PEDENADAMS M, 2008, TOXICOLOGICAL SCI; Peden-Adams MM, 2007, J TOXICOL ENV HEAL A, V70, P1130, DOI 10.1080/15287390701252733; Peden-Adams MM, 2006, J ENVIRON SCI HEAL A, V41, P249, DOI 10.1080/10934520500455289; Perera FP, 2005, ENVIRON HEALTH PERSP, V113, P1062, DOI 10.1289/ehp.7908; Phaybouth V, 2006, AM J PHYSIOL-LUNG C, V290, pL222, DOI 10.1152/ajplung.00148.2005; Piepenbrink Michael S, 2005, J Immunotoxicol, V2, P21, DOI 10.1080/15363750490429435; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Rahman A, 2007, AM J EPIDEMIOL, V165, P1389, DOI 10.1093/aje/kwm025; Rahman M, 2006, ENVIRON HEALTH PERSP, V114, P1847, DOI 10.1289/ehp.9207; Raqib R, 2009, TOXICOL LETT, V185, P197, DOI 10.1016/j.toxlet.2009.01.001; Reichard JF, 2007, BIOCHEM BIOPH RES CO, V352, P188, DOI 10.1016/j.bbrc.2006.11.001; Robin C, 2003, ONCOL RES, V13, P315; Rooney AA, 2003, TOXICOL SCI, V76, P366, DOI 10.1093/toxsci/kfg250; Rowe AM, 2008, BASIC CLIN PHARMACOL, V102, P139, DOI 10.1111/j.1742-7843.2007.00175.x; SAVITZ DA, 1990, ENVIRON HEALTH PERSP, V88, P325, DOI 10.2307/3431095; Sawai C, 2003, ENVIRON HEALTH PERSP, V111, P1883, DOI 10.1289/ehp.6359; Schuz J, 2001, MED PEDIATR ONCOL, V36, P274, DOI 10.1002/1096-911X(20010201)36:2&lt;274::AID-MPO1065&gt;3.0.CO;2-D; Shen J, 2007, TOXICOL SCI, V95, P313, DOI 10.1093/toxsci/kfl151; SILVA MJ, URINARY LEVELS 7 PHT; Silva MJ, 2004, B ENVIRON CONTAM TOX, V72, P1226, DOI 10.1007/s00128-004-0374-4; Singh SP, 2006, TOXICOL LETT, V167, P231, DOI 10.1016/j.toxlet.2006.10.001; Singh Varinder, 2005, Paediatr Respir Rev, V6, P88, DOI 10.1016/j.prrv.2005.03.002; Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007; Smith AH, 2006, ENVIRON HEALTH PERSP, V114, P1293, DOI 10.1289/ehp.8832; Sorahan T, 2004, BRIT J CANCER, V90, P1016, DOI 10.1038/sj.bjc.6601651; SOTOPENA G, 2006, FASEB J; Spannhake EW, 2002, ENVIRON HEALTH PERSP, V110, P665; StAmpfli Martin R, 2009, Nat Rev Immunol, V9, P377, DOI 10.1038/nri2530; STANCEK D, 1995, INT J IMMUNOPHARMACO, V17, P321, DOI 10.1016/0192-0561(95)00006-N; Sugita-Konishi Y, 2003, BIOSCI BIOTECH BIOCH, V67, P89, DOI 10.1271/bbb.67.89; Sung TI, 2008, REPROD TOXICOL, V25, P115, DOI 10.1016/j.reprotox.2007.08.004; Tebow G, 2008, PEDIATRICS, V121, pE1563, DOI 10.1542/peds.2007-2795; ten Tusscher GW, 2003, ENVIRON HEALTH PERSP, V111, P1519, DOI 10.1289/ehp.5715; THEUS SA, 1992, AGENTS ACTIONS, V37, P140, DOI 10.1007/BF01987903; Turner MC, 2010, ENVIRON HEALTH PERSP, V118, P33, DOI 10.1289/ehp.0900966; URSO P, 1984, J TOXICOL ENV HEALTH, V14, P569; *US DEP HHS, 2008 2009 ANN REP US; US EPA, 2004, PEST IND SAL US 2000; Vorderstrasse Beth A, 2004, J Immunotoxicol, V1, P103, DOI 10.1080/15476910490509244; Vorderstrasse BA, 2006, J TOXICOL ENV HEAL A, V69, P445, DOI 10.1080/15287390500246985; VOS JG, 1974, INT ARCH ALLER A IMM, V47, P777; Waalkes MP, 2003, TOXICOL APPL PHARM, V186, P7, DOI 10.1016/S0041-008X(02)00022-4; Waalkes MP, 2006, CANCER RES, V66, P1337, DOI 10.1158/0008-5472.CAN-05-3530; Waalkes MP, 2004, J NATL CANCER I, V96, P466, DOI 10.1093/jnci/djh070; Waalkes MP, 2006, TOXICOL APPL PHARM, V215, P295, DOI 10.1016/j.taap.2006.03.010; Wang S, 2008, CANCER EPIDEM BIOMAR, V17, P405, DOI 10.1158/1055-9965.EPI-07-0695; Weisglas-Kuperus N, 2004, TOXICOL LETT, V149, P281, DOI 10.1016/j.toxlet.2003.12.039; Weisglas-Kuperus N, 2000, ENVIRON HEALTH PERSP, V108, P1203, DOI 10.2307/3434834; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; Weiskopf D, 2009, TRANSPL INT, V22, P1041, DOI 10.1111/j.1432-2277.2009.00927.x; WHO, 2008, GLOB BURD DIS 2004 U; Wigle DT, 2009, ENVIRON HEALTH PERSP, V117, P1505, DOI 10.1289/ehp.0900582; Yamamoto S, 2009, J TOXICOL SCI, V34, pSP341; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1046/j.1365-2567.2004.01900.x; Yu Z, 2006, CANCER RES, V66, P755, DOI 10.1158/0008-5472.CAN-05-3390; Yurino H, 2004, TOXICOL SCI, V81, P139, DOI 10.1093/toxsci/kfh179; Zahm SH, 1998, ENVIRON HEALTH PERSP, V106, P893, DOI 10.2307/3434207; Zanieri L, 2007, CHEMOSPHERE, V67, P1265, DOI 10.1016/j.chemosphere.2006.12.011; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj/onc/12053181509PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDREPROD TOXICOLAPRSIDiscipline: Reproductive Biology; Toxicology753EQ</notes>
    <keywords>AGENTS; ARYL-HYDROCARBON RECEPTOR; BIOLOGY; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; Carcinogen; CELL; CELLS; CENTRAL-NERVOUS-SYSTEM; CHEMICALS; DEATH; DEVELOPMENTAL EXPOSURE; DISEASE; diseases; EARLY-LIFE; environment; Environmental toxicant; EPIGENETIC TRANSGENERATIONAL ACTIONS; EXPOSURE; fetal basis of adult disease; HEALTH; Immune; Immune development; IMMUNE-SYSTEM; IMPACT; IN-UTERO; Infectious disease susceptibility; LINE; MATERNAL EXPOSURE; MODEL; MODELS; p21; PAH-DNA ADDUCTS; POLLUTANTS; POLYCYCLIC AROMATIC-HYDROCARBONS; PRENATAL CHLORDANE EXPOSURE; Review; SUSCEPTIBILITY; SYSTEM; TOBACCO-SMOKE EXPOSURE; toxicology; URINARY; UTERO ARSENIC EXPOSURE</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>327</startpage>
    <endpage>336</endpage>
    <journalfull>Reproductive Toxicology</journalfull>
    <issue>3</issue>
    <volume>31</volume>
    <abstract>There is now compelling evidence that developmental exposure to chemicals from our environment contributes to disease later in life, with animal models supporting this concept in reproductive, metabolic, and neurodegenerative diseases. In contrast, data regarding how developmental exposures impact the susceptibility of the immune system to functional alterations later in life are surprisingly scant. Given that the immune system forms an integrated network that detects and destroys invading pathogens and cancer cells, it provides the body's first line of defense. Thus, the consequences of early life exposures that reduce immune function are profound. This review summarizes available data for pollutants such as cigarette smoke and dioxin-like compounds, which consistently support the idea that developmental exposures critically impact the immune system. These findings suggest that exposure to common chemicals from our daily environment represent overlooked contributors to the fact that infectious diseases remain among the top five causes of death worldwide. (C) 2010 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000289749100009</url>
    <isbnorissn>0890-6238</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>121</id>
    <title>Structural requirements for inhibitory effects of bisphenols on the activity of the sarco/endoplasmic reticulum calcium ATPase</title>
    <authors>Woeste,M.; Steller,J.; Hofmann,E.; Kidd,T.; Patel,R.; Connolly,K.; Jayasinghe,M.; Paula,S.</authors>
    <availability>[Woeste, Matthew; Steller, Jeffrey; Hofmann, Emily; Kidd, Taylor; Patel, Rahul; Connolly, Kevin; Jayasinghe, Manori; Paula, Stefan] No Kentucky Univ, Dept Chem, Dorothy Westerman Herrmann Nat Sci Ctr, Highland Hts, KY 41099 USA.</availability>
    <date>2013</date>
    <notes>JEnglishArticlePaula, S (reprint author), No Kentucky Univ, Dept Chem, Dorothy Westerman Herrmann Nat Sci Ctr, Highland Hts, KY 41099 USApaulas1@nku.eduBaxter CA, 1998, PROTEINS, V33, P367, DOI 10.1002/(SICI)1097-0134(19981115)33:3&lt;367::AID-PROT6&gt;3.0.CO;2-W; Bolt HM, 2011, ARCH TOXICOL, V85, P1491, DOI 10.1007/s00204-011-0785-z; Brini M, 2009, PHYSIOL REV, V89, P1341, DOI 10.1152/physrev.00032.2008; BROWN GR, 1994, BBA-BIOMEMBRANES, V1195, P252, DOI 10.1016/0005-2736(94)90264-X; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Christensen SB, 1999, BIOORGAN MED CHEM, V7, P1273; Denmeade SR, 2005, CANCER BIOL THER, V4, P14; Denmeade SR, 2003, J NATL CANCER I, V95, P990; Deye J, 2009, BIOORGAN MED CHEM, V17, P1353, DOI 10.1016/j.bmc.2008.12.010; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; Erler C, 2010, J PEDIATR NURS, V25, P400, DOI 10.1016/j.pedn.2009.05.006; FURUYA Y, 1994, CANCER RES, V54, P6167; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Hughes PJ, 2000, BIOCHEM BIOPH RES CO, V277, P568, DOI 10.1006/bbrc.2000.3710; Isaacs JT, 2005, BJU INT, V96, P35, DOI 10.1111/j.1464-410X.2005.05945.x; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kitamura S, 2005, TOXICOL SCI, V84, P249, DOI 10.1093/toxsci/kfi074; Lape M, 2008, PROTEINS, V70, P639, DOI 10.1002/prot.21542; Lape M, 2010, BIOPHYS CHEM, V150, P88, DOI 10.1016/j.bpc.2010.01.011; Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; Michelangeli F, 2008, CHEM-BIOL INTERACT, V176, P220, DOI 10.1016/j.cbi.2008.08.005; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 2010, Q REV BIOPHYS, V43, P501, DOI 10.1017/S003358351000017X; Moncoq K, 2007, J BIOL CHEM, V282, P9748, DOI 10.1074/jbc.M611653200; Myers Daniel E., 2011, General Dentistry, V59, P262; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Ogunbayo OA, 2007, BIOCHEM J, V408, P407, DOI 10.1042/BJ20070843; Ogunbayo OA, 2008, TOXICOL IN VITRO, V22, P943, DOI 10.1016/j.tiv.2008.01.015; ROBINSON IM, 1991, FEBS LETT, V289, P151, DOI 10.1016/0014-5793(91)81057-F; Sheehan DM, 2000, P SOC EXP BIOL MED, V224, P57, DOI 10.1046/j.1525-1373.2000.22401.x; Sjodin A, 2004, ENVIRON HEALTH PERSP, V112, P654; SOKOLOVE PM, 1986, FEBS LETT, V203, P121, DOI 10.1016/0014-5793(86)80726-8; Stevens M.P., 1998, POLYM CHEM INTRO; Takahashi M, 2007, P NATL ACAD SCI USA, V104, P5800, DOI 10.1073/pnas.0700979104; Teeguarden J. G., 2013, AM ASS ADV SCI ANN M; Teeguarden JG, 2011, TOXICOL SCI, V123, P48, DOI 10.1093/toxsci/kfr160; Tombal B, 1999, CELL CALCIUM, V25, P19, DOI 10.1054/ceca.1998.0005; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vandenberg L. N., 2010, CIENC SAUDE COLETIVA, V17, P407; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Yan S., 2011, PLOS ONE450PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDBIOORGAN MED CHEMJUL 1Discipline: Biochemistry &amp; Molecular Biology; Pharmacology &amp; Pharmacy; Chemistry163OP</notes>
    <keywords>ATPase activity assay; BINDING; BINDING-AFFINITY; BIOLOGY; biomembrane; bisphenol; bisphenol A; CA2+ MOBILIZATION; Calcium homeostasis; Calcium ion transport; CANCER; CELL; CELL-DEATH; CELLS; Computational docking; FLEXIBLE DOCKING; Fluorescence imaging; GENETIC ALGORITHM; In vitro; IN-VITRO; inhibition; INHIBITOR; Inhibitors; Interaction; molecular docking; PHARMACOLOGY; PROSTATE-CANCER; PROTEIN; PROTEINS; PUMP; SARCOPLASMIC-RETICULUM; TETRABROMOBISPHENOL-A TBBPA; THAPSIGARGIN; TOXICITY; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3927</startpage>
    <endpage>3933</endpage>
    <journalfull>Bioorganic &amp; Medicinal Chemistry</journalfull>
    <issue>13</issue>
    <volume>21</volume>
    <abstract>Bisphenols (BPs) are a class of small organic compounds with widespread industrial applications. Previous studies have identified several BPs that interfere with the activity of the ion-translocating enzyme sarco/endoplasmic reticulum calcium ATPase (SERCA). In order to define the molecular determinants of BP-mediated SERCA inhibition, we conducted enzyme activity assays with rabbit SERCA to determine the inhibitory potencies of 27 commercially available BPs, which were the basis for structure-activity relationships. The most potent BPs inhibited SERCA at low micromolar concentrations and carried at their two phenyl rings multiple non-polar substituents, such as small alkyl groups or halides. Furthermore, the presence of methyl groups or a cyclohexyl group at the central carbon atom connecting the two phenyl moieties correlated with good potencies. For a characterization and visualization of enzyme/inhibitor interactions, molecular docking was performed, which suggested that hydrogen bonding with Asp254 and hydrophobic interactions were the major driving forces for BP binding to SERCA. Calcium imaging studies with a selection of BPs showed that these inhibitors were able to increase intracellular calcium levels in living human cells, a behavior consistent with that of a SERCA inhibitor. (C) 2013 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000320347100032</url>
    <isbnorissn>0968-0896</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>70</id>
    <title>Transcriptional Changes Caused by Bisphenol A in Oryzias javanicus, a Fish Species Highly Adaptable to Environmental Salinity</title>
    <authors>Woo,S.; Denis,V.; Yum,S.</authors>
    <availability>[Woo, Seonock; Yum, Seungshic] Korea Inst Ocean Sci &amp; Technol, South Sea Environm Res Div, Geoje 656830, South Korea. [Denis, Vianney] Acad Sinica, Biodivers Res Ctr, Taipei 115, Taiwan.</availability>
    <date>2014</date>
    <notes>JEnglishArticleYum, S (reprint author), Korea Inst Ocean Sci &amp; Technol, South Sea Environm Res Div, Geoje 656830, South Koreacwoo@kiost.ac; vianney.denis@gmail.com; syum@kiost.acCheshenko K, 2008, GEN COMP ENDOCR, V155, P31, DOI 10.1016/j.ygeen.2007.03.005; Crews D, 2000, Q REV BIOL, V75, P243, DOI 10.1086/393498; DeLorenzo M. E., 2011, ENVIRON TOXICOL, V28, P359; Hall W. H., 1995, CRIT REV TOXICOL, V25, P281; HANSEN HJM, 1994, COMP BIOCHEM PHYS A, V108, P599, DOI 10.1016/0300-9629(94)90345-X; HILDEBRAND A, 1994, BIOCHEM J, V302, P527; Hwang DS, 2010, COMP BIOCHEM PHYS C, V151, P303, DOI 10.1016/j.cbpc.2009.12.003; Inoue K, 2002, ZOOL SCI, V19, P727, DOI 10.2108/zsj.19.727; Jahanyar J, 2007, J HEART LUNG TRANSPL, V26, P34, DOI 10.1016/j.healun.2006.10.005; Kashiwada S, 2002, WATER RES, V36, P2161, DOI 10.1016/S0043-1354(01)00406-7; Kazeto Y, 2004, AQUAT TOXICOL, V69, P25, DOI 10.1016/j.aquatox.2004.04.008; Kishida M, 2001, COMP BIOCHEM PHYS B, V129, P261, DOI 10.1016/S1096-4959(01)00319-0; Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005; Lavado R, 2011, ENVIRON SCI TECHNOL, V45, P4623, DOI 10.1021/es200451j; Mills LJ, 2005, SCI TOTAL ENVIRON, V343, P1, DOI 10.1016/j.scitotenv.2004.12.070; Paul I, 2011, J PATHOL, V224, P564, DOI 10.1002/path.2925; Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413; Rhee JS, 2010, COMP BIOCHEM PHYS C, V152, P413, DOI 10.1016/j.cbpc.2010.07.001; Roberts TR, 1998, ICHTHYOL RES, V45, P213, DOI 10.1007/BF02673919; Rocke DM, 2001, J COMPUT BIOL, V8, P557, DOI 10.1089/106652701753307485; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Senthilkumar PK, 2012, TOXICOL APPL PHARM, V259, P115, DOI 10.1016/j.taap.2011.12.015; Stevens DP, 2003, ENVIRON TOXICOL CHEM, V22, P3017, DOI 10.1897/02-290; Stueckle TA, 2009, ENVIRON TOXICOL CHEM, V28, P2348, DOI [10.1897/08-651.1, 10.1897/08-651.S2]; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; Verslycke T, 2003, AQUAT TOXICOL, V64, P307, DOI 10.1016/S0166-445X(03)00061-4; WEI L, 2011, CANCER SCI, V110, P102; Won Hyokyoung, 2011, Toxicology and Environmental Health Sciences, V3, P39; Woo S, 2008, MOL CELL TOXICOL, V4, P293; Woo S, 2009, COMP BIOCHEM PHYS C, V149, P427, DOI 10.1016/j.cbpc.2008.10.100; Woo S, 2006, MAR BIOTECHNOL, V8, P654, DOI 10.1007/s10126-006-6046-0; Woo S, 2009, COMP BIOCHEM PHYS C, V149, P289, DOI 10.1016/j.cbpc.2008.08.002; Woo S., 2010, TOXICOL ENV HLTH SCI, V2, P231; Woo S, 2011, MOL CELL TOXICOL, V7, P271, DOI 10.1007/s13273-011-0033-x; Yamashita S, 2012, BIOCHEM BIOPH RES CO, V417, P630, DOI 10.1016/j.bbrc.2011.12.021; Yan W, 2009, HUM GENE THER, V20, P1190, DOI 10.1089/hum.2008.204; Zanette J, 2011, SCI TOTAL ENVIRON, V409, P1976, DOI 10.1016/j.scitotenv.2011.01.048; Zhou CY, 2003, BIOCHEM BIOPH RES CO, V303, P130, DOI 10.1016/S0006-291X(03)00318-8391MDPI AGBASELPOSTFACH, CH-4005 BASEL, SWITZERLANDMAR DRUGSFEBDiscipline: Pharmacology &amp; PharmacyAG9NC</notes>
    <keywords>bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CDNA MICROARRAY; CELL; DECORIN BINDS; DIFFERENTIALLY EXPRESSED GENES; Endocrine-disrupting chemicals; EXPOSURE; EXPRESSION; gene expression; GENE-EXPRESSION; GROWTH-FACTOR-BETA; heart; INDUCTION; inhibition; JAVANESE MEDAKA; Liver; Oryzias javanicus; salinity; SIGNALING PATHWAY; TOXICITY; ZEBRAFISH DANIO-RERIO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>983</startpage>
    <endpage>998</endpage>
    <journalfull>Marine Drugs</journalfull>
    <issue>2</issue>
    <volume>12</volume>
    <abstract>The Javanese medaka, Oryzias javanicus, is a fish highly adaptable to various environmental salinities. Here, we investigated the effects of the environmental pollutant bisphenol A (BPA; an endocrine disrupting chemical) on gene expression levels in this species acclimated to different salinities. Using cDNA microarrays, we detected the induction of differential expression of genes by BPA, and compared the transcriptional changes caused by chemical exposure at different salinities. There were marked transcriptional changes induced by BPA between treatments. While 533 genes were induced by a factor of more than two when O. javanicus was exposed to BPA in seawater, only 215 genes were induced in freshwater. Among those genes, only 78 were shared and changed significantly their expression in both seawater and freshwater. Those genes were mainly involved in cellular processes and signaling pathway. We then categorized by functional group genes specifically induced by BPA exposure in seawater or freshwater. Gene expression changes were further confirmed in O. javanicus exposed to various concentrations of BPA, using quantitative real-time reverse transcription PCR based on primer sets for 28 selected genes</abstract>
    <url>WOS:000335745100028</url>
    <isbnorissn>1660-3397</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>98</id>
    <title>Phytoestrogens inhibiting androgen receptor signal and prostate cancer cell proliferation</title>
    <authors>Wu,J.; Liu,S.; Shen,X.Y.; Yang,N.Y.; Liu,Y.; Tsuji,I.; Yamamura,T.; Li,J.; Li,X.M.</authors>
    <availability>[Wu Jing; Liu Shu; Shen Xiao-yan; Yang Nan-yang; Li Xiao-meng] NE Normal Univ, Inst Cytol &amp; Genet, Minist Educ, Key Lab Mol Epigenet, Changchun 130024, Peoples R China. [Liu Ying; Li Jiang] Jilin Univ, Dent Hosp, Changchun 130021, Peoples R China. [Tsuji, Ichiro] Tohoku Univ, Dept Publ Hlth, Sendai, Miyagi 9808576, Japan. [Yamamura, Takaki] Morioka Univ, Dept Nutr Sci, Morioka, Iwate 0200183, Japan.</availability>
    <date>2013</date>
    <notes>JEnglishArticleLi, XM (reprint author), NE Normal Univ, Inst Cytol &amp; Genet, Minist Educ, Key Lab Mol Epigenet, Changchun 130024, Peoples R Chinaljiang@jlu.edu.cn; lixm441@nenu.edu.cnCHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chuu CP, 2009, CANCER LETT, V275, P86, DOI 10.1016/j.canlet.2008.10.001; De Jesus-Tran KP, 2006, PROTEIN SCI, V15, P987, DOI 10.1110/ps.051905906; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Kohen F, 2007, J MED CHEM, V50, P6405, DOI 10.1021/jm070727z; Kousidou OC, 2006, MINI-REV MED CHEM, V6, P331, DOI 10.2174/138955706776073420; Li X. M., 2013, SOYBEAN PROSTATE CAN, P265; Li XM, 2008, ASIAN J ANDROL, V10, P551, DOI 10.1111/j.1745-7262.2008.00384.x; Lill MA, 2005, J MED CHEM, V48, P5666, DOI 10.1021/jm050403f; Liu GF, 2012, CHEM J CHINESE U, V33, P1920, DOI 10.3969/j.issn.0251-0790.2012.09.008; Manthey JA, 2002, J AGR FOOD CHEM, V50, P5837, DOI 10.1021/jf020121d; Miodini P, 1999, BRIT J CANCER, V80, P1150, DOI 10.1038/sj.bjc.6690479; Murata M, 2004, BIOCHEMISTRY-US, V43, P2569, DOI 10.1021/bi035613d; Ososki AL, 2003, PHYTOTHER RES, V17, P845, DOI 10.1002/ptr.1364; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Reid KJ, 2001, J BIOL CHEM, V276, P2943, DOI 10.1074/jbc.M009170200; Shang Y., 2002, MOL CELL, V11, P601; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; VERNON SE, 1983, J UROLOGY, V130, P95; Wang BF, 2009, J AGR FOOD CHEM, V57, P2221, DOI 10.1021/jf8037715; Wu J, 2013, CHEM RES CHINESE U, V29, P512, DOI 10.1007/s40242-013-2248-y; Xie J, 2011, CHEM J CHINESE U, V32, P1532; Yildiz F., 2005, PHYTOESTROGENS FUNCT, P3; Zhang LL, 2012, CANCER LETT, V323, P48, DOI 10.1016/j.canlet.2012.03.037; Zhou JR, 1999, J NUTR, V129, P1628280HIGHER EDUCATION PRESSBEIJINGSHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINACHEM RES CHINESE UOCTDiscipline: Chemistry230RH</notes>
    <keywords>ACTIVATION; ANDROGEN RECEPTOR; ANTIGEN; ANTIPROLIFERATIVE ACTIVITIES; BINDING; BISPHENOL-A; CANCER; CARCINOMA; CELL; CELL-PROLIFERATION; CELLS; CHIP; COREGULATORS; CRITICAL ROLES; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPRESSION; FOOD; genistein; GROWTH; ISOFLAVONES; LIGAND-BINDING; LINES; LNCaP cells; Phytoestrogen; PHYTOESTROGENS; PROGRESSION; proliferation; Prostate; prostate cancer; Prostate specific antigen(PSA); PROSTATE-CANCER; PROTEIN; RECEPTOR; TRANSACTIVATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>911</startpage>
    <endpage>916</endpage>
    <journalfull>Chemical Research in Chinese Universities</journalfull>
    <issue>5</issue>
    <volume>29</volume>
    <abstract>The androgen receptor(AR) signaling activated by dihydrotestosterone(DHT) plays critical roles in prostate cancer development and progression. Phytoestrogens, which are diphenolic compounds with estrogen and antiestrogen effects, can bind to estrogen receptors. However, their function on AR signaling has not been fully elucidated. In this study, dual-luciferase reporter assay, immunobloting, docking system test, MTT assay, immunofluorescence and chromatin immunoprecipitation(ChIP) assays were employed to examine the potential effects of three phytoestrogens(genistein, daidzein, flavone) on DHT-activated prostate specific antigen(PSA) activation, cell proliferation and AR transactivation in lymph node carcinoma of prostate(LNCaP) cells. Phytoestrogens were detected to down-regulate DHT-activated AR-mediated PSA promoter transactivation by dual-luciferase reporter system. Furthermore, three phytoestrogens, especially genistein, were demonstrated to significantly decrease AR-activated PSA protein expression by Western blotting analysis. MTT experiment proves that phytoestrogens, especially genistein, remarkably inhibits the DHT-induced cell proliferation in LNCaP cells. To provide reasonable explanations for experimental phenomena mentioned above, we did docking system test and detected phytoestrogens to share the same AR-binding site with DHT. To further prove the competition between phytoestrogen and DHT on AR binding, we examined the effects of phytoestrogens on DHT-activated AR nuclear translocation and immunofluorescence analysis which confirms that phytoestrogens, especially genistein, inhibit DHT-activated androgen receptor nuclear translocation. Results from ChIP show that phytoestrogens down-regulate DHT-induces AR binding to the androgen response elements(AREs, including AREI, AREII, and AREIII) in PSA promoter. Genistein remarkably down-regulates AR, binding to the AREI located in -250- -39 bp and AREIII in -4170- -3978 bp in the presence of DHT. In general, three phytoestrogens were identified to inhibit DHT-AR binding by competitively binding to AR and inhibit AR-mediated transactivation. And genistein shows the strongest effects among three phytoestrogens. Our findings confirm that phytoestrogens are AR antagonist in the regulation of AR-related PSA activation and cell proliferation, which provides valuable insights into the treatment of prostate cancer</abstract>
    <url>WOS:000325359400018</url>
    <isbnorissn>1005-9040</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>129</id>
    <title>Xeno-oestrogens Bisphenol A and Diethylstilbestrol Selectively Activating Androgen Receptor Mediated AREs-TATA Reporter System</title>
    <authors>Wu,J.; Wei,W.; Yang,N.Y.; Shen,X.Y.; Tsuji,I.; Yamamura,T.; Li,J.; Li,X.M.</authors>
    <availability>[Wu Jing; Wei Wei; Li Jiang] Jilin Univ, Dent Hosp, Changchun 130041, Peoples R China. [Wu Jing; Yang Nan-yang; Shen Xiao-yan; Li Xiao-meng] NE Normal Univ, Inst Cytol &amp; Genet, Sch Life Sci, Changchun 130024, Peoples R China. [Tsuji, Ichiro] Tohoku Univ, Dept Publ Hlth, Sendai, Miyagi 9808576, Japan. [Yamamura, Takaki] Morioka Univ, Dept Nutr Sci, Morioka, Iwate 0200183, Japan.</availability>
    <date>2013</date>
    <notes>JEnglishArticleLi, J (reprint author), Jilin Univ, Dent Hosp, Changchun 130041, Peoples R Chinalijiang69@yahoo.com.cn; lixm441@nenu.edu.cnChuu CP, 2009, CANCER LETT, V275, P86, DOI 10.1016/j.canlet.2008.10.001; Clapp Richard W., 2008, Reviews on Environmental Health, V23, P1; Eskenazi B, 2009, ENVIRON HEALTH PERSP, V117, P1359, DOI 10.1289/ehp.11748; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henley D. V., 2006, ENDOCRINOLOGY, V147, P25; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hu P, 2012, CHEM J CHINESE U, V33, P2111, DOI 10.3969/j.issn.0251-0790.2012.09.041; Huang LW, 2004, J ANDROL, V25, P330; Janet K., 2009, CANCER CAUSE CONTROL, V20, P1029; Julia C., 2011, UROLOGIC ONCOLOGY, V13, P1; Li X., 2011, PLOS ONE, V6; Li XM, 2008, ASIAN J ANDROL, V10, P551, DOI 10.1111/j.1745-7262.2008.00384.x; Lu NZ, 2006, PHARMACOL REV, V58, P782, DOI 10.1124/pr.58.4.9; Nickols NG, 2007, P NATL ACAD SCI USA, V104, P10418, DOI 10.1073/pnas.0704217104; Prins GS, 2008, ENDOCR-RELAT CANCER, V15, P649, DOI 10.1677/ERC-08-0043; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Reid K. J., 2000, J BIOL CHEM, V30, P2943; Rogan WJ, 2005, LANCET, V366, P763, DOI 10.1016/S0140-6736(05)67182-6; Shamash J, 2010, CANCER-AM CANCER SOC, V116, P3595, DOI 10.1002/cncr.25194; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Tamotsu N., 2007, BIOCHEM J, V405, P481; Wang H, 2010, ASIAN J ANDROL, V12, P535, DOI 10.1038/aja.2010.14; Wetherill YB, 2005, CANCER RES, V65, P54232HIGHER EDUCATION PRESSBEIJINGSHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINACHEM RES CHINESE UJUN 1Discipline: Chemistry162WO</notes>
    <keywords>4-NONYLPHENOL; ACTIVATION; ANDROGEN RECEPTOR; Androgen response element; BINDING; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; Cell proliferation; CELL-PROLIFERATION; CELLS; DES; DIETHYLSTILBESTROL; EXPRESSION; JUN; LINES; oncology; proliferation; Prostate; prostate cancer; Prostate specific antigen(PSA); PROSTATE-CANCER; RECEPTOR; SUPPRESSION; TRANSACTIVATION; Transactivition; Xeno-oestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>512</startpage>
    <endpage>518</endpage>
    <journalfull>Chemical Research in Chinese Universities</journalfull>
    <issue>3</issue>
    <volume>29</volume>
    <abstract>We cloned the three androgen response elements(AREs, including AREI, AREII, and AREIII) with a core transactivation TATA element of the prostate-specific antigen(PSA) promoter into pGL2 basic vector to create an artificial pGL2/AREs-TATA reporter system, which was applied to evaluating the effects of different xeno-oestrogens[bisphenol A(BPA), 4-nonylphenol(4-NP), dichlorodiphenyl trichloroethane(DDT) or diethylstilbestrol (DES)] on androgen receptor(AR) abnormal activation to regulate PSA expression and cell proliferation. In all the three AREs, AREIII-TATA displayed as a major element responsive to AR-mediated DHT stimulation of PSA promoter. Therefore, pGL2/AREIII-TATA reporter was adopted to analyze the activation capacity of AR activated by four different xeno-oestrogens. The activation of pGL2/AREIII-TATA reporter by each xeno-oestrogen was analyzed in two different cell lines, one was HEK293T(Human Embryonic Kidney 293T) cell line, and the other was AR stably expressed DU145 cell line, which was produced by infecting AR with pLenti-puro-AR into the prostate cancer DU145 cells and that were scanned with puromycin and tested by AR antibody. In both the two cell lines, BPA or DES significantly induced AR-mediated transcriptional activity of AREIII-TATA reporter, whereas DDT or 4-nonylphenol did not Moreover, AR-mediated cell proliferation in response to each of four xeno-oestrogens was measured in MTT assays in both HEK293T cell or AR stably expressed DU145 cell lines. BPA or DES, as an AR inducer, exhibited an enhanced effect in cell proliferation, rather than the effect of DDT or 4-NP, in both cell lines. Finally, we demonstrated that BPA or DES stimulated PSA expression and enhanced the recruitment of AR onto the PSA promoter, resulting in stronger binding to AREIII sites. Taken together, four xeno-oestrogens were identified to have different activities on AR. BPA and DES are demonstrated to be androgenic effectors in the regulation of PSA activation or cell proliferation</abstract>
    <url>WOS:000320296900022</url>
    <isbnorissn>1005-9040</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>269</id>
    <title>Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats</title>
    <authors>Wu,J.H.; Jiang,X.R.; Liu,G.M.; Liu,X.Y.; He,G.L.; Sun,Z.Y.</authors>
    <availability>[Wu, Jian-Hui; Jiang, Xiu-Rong; Liu, Gui-Ming; Liu, Xiang-Yun; He, Gui-Lin; Sun, Zu-Yue] Shanghai Inst Planned Parenthood Res, Natl Evaluat Ctr Toxicol Fertil Regulating Drug, Shanghai 200032, Peoples R China. [Wu, Jian-Hui] Fudan Univ, Shanghai 200433, Peoples R China.</availability>
    <date>2011</date>
    <notes>JEnglishArticleWu, JH (reprint author), Shanghai Inst Planned Parenthood Res, Natl Evaluat Ctr Toxicol Fertil Regulating Drug, 2140 Xie Tu Rd, Shanghai 200032, Peoples R Chinawwjh_731@yahoo.com.cnAlonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Arnold JI, 2008, J STEROID BIOCHEM, V111, P240, DOI 10.1016/j.jsbmb.2008.06.008; Ashby J, 1999, REGUL TOXICOL PHARM, V30, P156, DOI 10.1006/rtph.1999.1317; Cagen SZ, 1999, TOXICOL SCI, V50, P36, DOI 10.1093/toxsci/50.1.36; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Gaido KW, 1997, TOXICOL APPL PHARM, V143, P205, DOI 10.1006/taap.1996.8069; Gray GM, 2004, HUM ECOL RISK ASSESS, V10, P875, DOI 10.1080/10807030490513883; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Herath CB, 2004, ENDOCRINE, V25, P163, DOI 10.1385/ENDO:25:2:163; Hess-Wilson JK, 2007, ENVIRON HEALTH PERSP, V115, P1646, DOI 10.1289/ehp.10283; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; JANULIS L, 2001, PROSTATIC DIS, P58; KRONGRAD A, 2001, PROSTATIC DIS, P17; Kwon S, 2000, TOXICOL SCI, V55, P399, DOI 10.1093/toxsci/55.2.399; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; Nagao T, 2002, REPROD TOXICOL, V16, P123, DOI 10.1016/S0890-6238(02)00003-5; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; Ogura Y, 2007, DIFFERENTIATION, V75, P745, DOI 10.1111/j.1432-0436.2007.00177.x; PARTIN AW, 2001, PROSTATIC DIS, P95; Richter CA, 2007, ENVIRON HEALTH PERSP, V115, P902, DOI 10.1289/ehp.9804; Roehrborn CG, 2008, INT J IMPOT RES, V20, pS11, DOI 10.1038/ijir.2008.55; ROEHRBORN CG, 2001, PROSTATIC DIS, P143; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; SHARPIRO E, 2001, PROSTATIC DIS, P1; Takabashi O, 2001, ARCH TOXICOL, V75, P42, DOI 10.1007/s002040000204; Takao T, 1999, LIFE SCI, V65, P2351, DOI 10.1016/S0024-3205(99)00502-0; Takao Y, 2002, J HEALTH SCI, V48, P331, DOI 10.1248/jhs.48.331; Timms BG, 1999, J UROLOGY, V161, P1694, DOI 10.1016/S0022-5347(05)69007-6; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Yoshino Hiroko, 2002, J Toxicol Sci, V27, P433, DOI 10.2131/jts.27.433343SAGE PUBLICATIONS INCTHOUSAND OAKS2455 TELLER RD, THOUSAND OAKS, CA 91320 USATOXICOL IND HEALTHOCTDiscipline: Public, Environmental &amp; Occupational Health; Toxicology832WJ</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; Androgen; ANDROGEN RECEPTOR; ANTIGEN; bisphenol; bisphenol A; BISPHENOL-A; BPA; BPH; CANCER; CELL; development; DIETHYLSTILBESTROL; Differentiation; ENDOCRINE; Endocrine disruptor; environment; Estrogen; ESTROGENIC CHEMICALS; EXPOSURE; FETAL MOUSE PROSTATE; HEALTH; HORMONE-LEVELS; HYPERPLASIA; in vivo; IN-VIVO; low dose; Male; MICE; MODEL; Occupational; octylphenol; oral exposure; PRENATAL EXPOSURE; proliferation; Prostate; RAT; RATS; REPRODUCTIVE FUNCTIONS; RISK; SHANGHAI; toxicology; VENTRAL PROSTATE; xenoestrogen</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>810</startpage>
    <endpage>819</endpage>
    <journalfull>Toxicology and Industrial Health</journalfull>
    <issue>9</issue>
    <volume>27</volume>
    <abstract>The declining level of androgen during aging, associated with an inclining level of estrogen, has been hypothesized to be important in the development of benign prostatic hyperplasia (BPH). Within physiologic range, increasing estrogen levels can stimulate prostate to develop and permanently increase prostate size. As an estrogenic endocrine disruptor, bisphenol A (BPA) might be stimulatory to prostate development. We further hypothesized that low dose BPA could induce hyperplasia prostate to proliferate and aggravate the symptom of BPH in male SD rats. BPH was induced by testosterone and then treated with BPA (10, 30, or 90 mu g/kg, i.g., daily), 17 beta-estradiol (E(2); 50.0 mu g/kg, s.c., daily), or vehicle for 4 weeks. We found that weight and volume in rats treated with low dose BPA (10 mu g/kg) was higher than that of model control, and BPA significantly increased the relative weight of prostate (p &lt; 0.01). For prostate lobes, BPA 10 mu g/kg/day significantly increased relative weight of ventral prostate (VP), weight and relative weight of dorsolateral prostate (DLP) (p &lt; 0.05). And histopathology results showed that height of epithelial cell (HEC) of VP and DLP in BPA group were significantly higher than that of model control (p &lt; 0.01). BPA could also decrease testostertone level and increase prostate-specific antigen level. E(2) treatment also showed an obvious effect on relative weight of VP and DLP, HEC, and hormone levels. We concluded that environment exposure to low dose of BPA may induce prostate to proliferate and aggravate testosterone-induced benign hyperplasia prostate in rats</abstract>
    <url>WOS:000295840100006</url>
    <isbnorissn>0748-2337</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>191</id>
    <title>Effects of bisphenol A on the proliferation and cell cycle of HBL-100 cells</title>
    <authors>Wu,S.; Wei,X.T.; Jiang,J.J.; Shang,L.Q.; Hao,W.D.</authors>
    <availability>[Wu, Shuang; Wei, Xuetao; Jiang, Jianjun; Shang, Lanqin; Hao, Weidong] Peking Univ, Sch Publ Hlth, Dept Toxicol, Beijing Key Lab Toxicol Res &amp; Risk Assessment Foo, Beijing 100191, Peoples R China.</availability>
    <date>2012</date>
    <notes>JEnglishArticleHao, WD (reprint author), Peking Univ, Sch Publ Hlth, Dept Toxicol, Beijing Key Lab Toxicol Res &amp; Risk Assessment Foo, Beijing 100191, Peoples R Chinawhao@bjmu.edu.cnBolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526; Ernst O, 2010, J VIS EXP, V38, P1918; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Han Dal-Ho, 2001, In Vitro Cellular and Developmental Biology Animal, V37, P275; Han DH, 2002, BIOSCI BIOTECH BIOCH, V66, P1479; Hao CF, 2009, TOXICOL IN VITRO, V23, P660, DOI 10.1016/j.tiv.2009.03.005; Howell A, 2006, CRIT REV ONCOL HEMAT, V57, P265, DOI 10.1016/j.critrevonc.2005.08.001; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Korner W, 1998, CHEMOSPHERE, V37, P2395, DOI 10.1016/S0045-6535(98)00297-5; Krishan A, 2004, CELL CYCLE, V3, P380; Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903; [^~,«+&gt; Liu Lijun], 2007, [,-&gt;«-._+"Y_+_,¨-, Chinese Journal of Pathophysiology], V23, P193; Liu W., 2010, SHANDONG MED, V50, P9; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Qin D., 2010, J INT REPROD HLTH FA, V29, P26; Rasmussen TH, 2002, BIOMARKERS, V7, P322, DOI 10.1080/13547500210132907; Shan X., 2007, PREV MED TRIB, V13, P523; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; [ø^_.z Tan Yinfei], 2004, [¯+z"Y%c-Ý_,¨-, Chinese Journal of Cell Biology], V26, P119; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vanparys C, 2006, TOXICOL IN VITRO, V20, P1238, DOI 10.1016/j.tiv.2006.05.002; Wang J., 2007, CHIN J PUBLIC HLTH, V23, P1231; [_'_O WU Shuang], 2009, [TO_~Aú,_~Aú¦__~, Carcinogenesis, Teratogenesis and Mutagenesis], V21, P249; Yang D., 2008, MODERN PREV MED, V35, P3280; Yu Z., 2002, CHINA PUBLIC HLTH, V18, P1409; Zettler M., 2010, EXP CLIN CARDIOL, V15, P139; Zhang Z., 2008, JIANGSU AGR SCI, V1, P231; Zheng J., 2005, J CLIN PEDIAT, V23, P828; Zou X., 2006, J INT GENET, V29, P70325PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDFOOD CHEM TOXICOLSEPDiscipline: Food Science &amp; Technology; Toxicology003PT</notes>
    <keywords>ALPHA; ASSAY; BIOLOGY; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; BREAST-CANCER CELLS; CANCER; CARCINOGENESIS; Carcinogenicity; CELL; cell cycle; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CYCLE; E-SCREEN; E-SCREEN ASSAY; Environmental estrogen; ER alpha; ER-ALPHA; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; ESTROGENS; EXPOSURE; EXPRESSION; FOOD; HBL-100; HEALTH; In vitro; IN-VITRO; proliferation; PROTEIN; PROTEINS; RECEPTOR; RECEPTOR-ALPHA; RISK; Risk assessment; RISK-ASSESSMENT; SYSTEM; TISSUES; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>3100</startpage>
    <endpage>3105</endpage>
    <journalfull>Food and Chemical Toxicology</journalfull>
    <issue>9</issue>
    <volume>50</volume>
    <abstract>Bisphenol A (BPA) is an environmental estrogen that exhibits non-genotoxic carcinogenicity, causing concern globally. The aim was to investigate the effects of BPA on the proliferation and cell cycle of human normal breast cells HBL-100. An improved E-Screen assay was used to study cell proliferation, and flow cytometry was used to study cell cycle phases. Western blot analysis was utilized to detect cell cycle proteins and estrogen receptor alpha (ER alpha) expression. The results showed that the highest cell proliferation rate induced by BPA was at 1.0 x 10(-6) mol/L At 1.0 x 10(-10), 1.0 x 10(-8), and 1.0 x 10(-6) mol/L, BPA promoted more cells to enter into G2/M phase and caused an increase in the expression of cyclinD1 and CDK4. After adding ICI182780 into the system, the promoting effects of BPA on cell proliferation and cell cycle change decreased, but these promoting effects were still significantly greater compared with the solvent control (P &lt; 0.05). Regardless of ICI182780 exposure, BPA did not have significant effect on ER alpha expression. BPA has estrogen-like activity and can stimulate HBL-100 proliferation and cell division through the estrogen receptor pathway. BPA may have other pathways through which it can exert stimulating effects and exhibit non-genotoxic carcinogenicity. (C) 2012 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000308624500021</url>
    <isbnorissn>0278-6915</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>384</id>
    <title>Definition, classification and mechanism of action of endocrine disrupting chemicals</title>
    <authors>Wuttke,W.; Jarry,H.; Seidlova-Wuttke,D.</authors>
    <availability>[Wuttke, Wolfgang; Jarry, Hubertus; Seidlova-Wuttke, Dana] Univ Gottingen, Univ Med Ctr Goettingen, Dept Endocrinol, D-37099 Gottingen, Germany.</availability>
    <date>2010</date>
    <notes>JEnglishReviewWuttke, W (reprint author), Univ Gottingen, Univ Med Ctr Goettingen, Dept Endocrinol, Robert Koch Str 40, D-37099 Gottingen, Germanyufkendo@med.uni-goettingen.deAdewale HB, 2009, BIOL REPROD, V81, P690, DOI 10.1095/biolreprod.109.078261; Anway MD, 2008, REPROD BIOMED ONLINE, V16, P23; van Doorn-Khosrovani SBV, 2007, CARCINOGENESIS, V28, P1703, DOI 10.1093/carcin/bgm102; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207; Bjorkblom C, 2009, ENVIRON TOXICOL CHEM, V28, P1063, DOI 10.1897/08-337.1; Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx70019Ip; Cao Y, 2009, J EXPO SCI ENV EPID, V19, P223, DOI 10.1038/jes.2008.44; Cassidy A, 2006, P NUTR SOC, V65, P76, DOI 10.1079/PNS2005476; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Delclos KB, 2009, REPROD TOXICOL, V27, P117, DOI 10.1016/j.reprotox.2008.12.005; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dickerson SM, 2007, REV ENDOCR METAB DIS, V8, P143, DOI 10.1007/s11154-007-9048-y; Doerge DR, 2002, J CHROMATOGR B, V777, P269, DOI 10.1016/S1570-0232(02)00214-3; Guillette Louis J. Jr., 2007, Environmental Sciences, V14, P331; Harris RM, 2004, J CLIN ENDOCR METAB, V89, P1779, DOI 10.1210/jc.2003-031631; Jefferson WN, 2005, BIOL REPROD, V73, P798, DOI 10.1095/biolreprod.105.041277; Jefferson WN, 2009, BIOL REPROD, V80, P425, DOI 10.1095/biolreprod.108.073171; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Johnson Andrew, 2007, Environmental Sciences, V14, P319; Klammer H, 2007, TOXICOLOGY, V238, P192, DOI 10.1016/j.tox.2007.06.088; Kloas W, 2009, ANN NY ACAD SCI, V1163, P187, DOI 10.1111/j.1749-6632.2009.04453.x; Kouki T, 2003, HORM BEHAV, V44, P140, DOI 10.1016/S0018-506X(03)00122-3; Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237; Lee YM, 2004, ENVIRON TECHNOL, V25, P635; Lethaby AE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001395.pub3; Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056; Moral R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-453; Moreira VM, 2008, CURR MED CHEM, V15, P868, DOI 10.2174/092986708783955428; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Panzica GC, 2009, ANN NY ACAD SCI, V1163, P271, DOI 10.1111/j.1749-6632.2008.03628.x; Radovic B, 2006, BRIT J NUTR, V95, P1171, DOI 10.1079/BJN20061779; Reinen J, 2006, ANAL BIOCHEM, V357, P85, DOI 10.1016/j.ab.2006.07.015; Schlecht C, 2004, TOXICOLOGY, V205, P123, DOI 10.1016/j.tox.2004.06.044; Schlecht C, 2008, TOXICOLOGY, V245, P11, DOI 10.1016/j.tox.2007.12.015; Schlecht C, 2006, ARCH TOXICOL, V80, P656, DOI 10.1007/s00204-006-0085-1; Schlumpf M, 2004, TOXICOLOGY, V205, P113, DOI 10.1016/j.tox.2004.06.043; Schlumpf M, 2004, TOXICOLOGY, V199, P109, DOI 10.1016/j.tox.2004.02.015; Schmutzler C, 2007, ENDOCRINOLOGY, V148, P2835, DOI 10.1210/en.2006-1280; Sekizawa J, 2008, J TOXICOL SCI, V33, P389, DOI 10.2131/jts.33.389; Shu XO, 2001, CANCER EPIDEM BIOMAR, V10, P483; SWEDENBORG E, 2009, TOXICOLOGY; Unfer V, 2004, FERTIL STERIL, V82, P145, DOI 10.1016/j.fertnstert.2003.11.041; Vanden Bossche H, 1990, Br J Clin Pract Suppl, V71, P41; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Wuttke W, 2007, AGEING RES REV, V6, P150, DOI 10.1016/j.arr.2007.05.001; ZIEGLER RG, 1993, J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819489HELLENIC ENDOCRINE SOCATHENS14 ALEXANDRAS AVE, ATHENS, 106 82, GREECEHORM-INT J ENDOCRINOJAN-MARDiscipline: Endocrinology &amp; Metabolism572JR</notes>
    <keywords>BISPHENOL-A; BREAST-CANCER RISK; CANCER; CARCINOGENESIS; CHEMICALS; CLASSIFICATION; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; ENDOCRINE DISRUPTORS; estrogenic activity; Fungicides; GENE; GENE-EXPRESSION; genistein; GLAND; HEALTH; Herbicides; IN-VITRO; ISOFLAVONES; mammary gland; MAMMARY-GLAND; mechanism; METABOLISM; NEONATAL EXPOSURE; PESTICIDES; Phtalates; RATS; Review; THYROID PEROXIDASE; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>9</startpage>
    <endpage>15</endpage>
    <journalfull>Hormones-International Journal of Endocrinology and Metabolism</journalfull>
    <issue>1</issue>
    <volume>9</volume>
    <url>WOS:000275828400002</url>
    <isbnorissn>1109-3099</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>376</id>
    <title>Determination of Tamoxifen and Letrozole in Sewage by Solid Phase Extraction and Ultra Performance Liquid Chromatography/Tandem Mass Spectrometry</title>
    <authors>Xian-Jun,L.; Zhang,J.; Shao,B.; Yin,J.</authors>
    <availability>[Liu Xian-Jun; Shao Bing; Yin Jie] Beijing Ctr Dis Control &amp; Prevent, Cent Lab, Beijing 100013, Peoples R China. [Liu Xian-Jun; Zhang Jing; Shao Bing] Capital Med Univ, Sch Publ Hlth &amp; Family Med, Beijing 100058, Peoples R China. [Yin Jie] Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China.</availability>
    <date>2010</date>
    <notes>JChineseArticleShao, B (reprint author), Beijing Ctr Dis Control &amp; Prevent, Cent Lab, Beijing 100013, Peoples R Chinashaobingch@sina.comANNICK TW, 2006, INT J ENVIRON AN CH, V86, P473; Cai YQ, 2004, CHINESE J ANAL CHEM, V32, P1179; Fromme H, 2002, WATER RES, V36, P1429, DOI 10.1016/S0043-1354(01)00367-0; Hilton MJ, 2003, J CHROMATOGR A, V1015, P129, DOI 10.1016/S0021-9673(03)01213-5; Kang JH, 2006, TOXICOLOGY, V226, P79, DOI 10.1016/j.tox.2006.06.009; Liu R, 2004, J CHROMATOGR A, V1022, P179, DOI 10.1016/j.chroma.20003.09.035; MARINA DG, 2007, CHEMOSPHERE, V67, P1933; Roberts PH, 2006, SCI TOTAL ENVIRON, V356, P143, DOI 10.1016/j.scitotenv.2005.04.031; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Sumpter JP, 2005, ENVIRON SCI TECHNOL, V39, P4321, DOI 10.1021/es048504a; Vethaak AD, 2005, CHEMOSPHERE, V59, P511, DOI 10.1016/j.chemosphere.2004.12.053; WANG ZG, 2007, J CLIN MED, V5, P34; Zhang ZL, 2007, J CHROMATOGR A, V1154, P205, DOI 10.1016/j.chroma.2007.03.105; Zhao HX, 2009, CHINESE J ANAL CHEM, V37, P187140ELSEVIER SCIENCE INCNEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USACHINESE J ANAL CHEMFEBDiscipline: Chemistry569AN</notes>
    <keywords>analysis; AQUATIC ENVIRONMENT; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER-THERAPY; CHINA; Determination; EFFLUENT; Letrozole; MASS-SPECTROMETRY; PERFORMANCE; PHARMACEUTICAL COMPOUNDS; PHARMACEUTICALS; QUANTIFICATION; SAMPLES; Sewage; solid phase extraction; TAMOXIFEN; TARGET; THERAPY; toxicology; Ultra-performance liquid chromatography/tandem mass spectrometry; WATER</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>214</startpage>
    <endpage>218</endpage>
    <journalfull>Chinese Journal of Analytical Chemistry</journalfull>
    <issue>2</issue>
    <volume>38</volume>
    <abstract>Tamoxifen and letrozole are two of the most effective pharmaceuticals mainly used in hormonal dependent breast cancer therapy. A trace analytical method using ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) was developed to simultaneously detect these two drugs in both influent and effluent of municipal sewage treatment plant. Sewage samples were passed through an Oasis HLB cartridge, then an amino solid phase extraction cartridge was connected with Oasis HLB cartridge. Target compounds was firstly eluted with 6 mL methanol and then 3 mL methanol was used to elute the amino solid phase extraction cartridge, collected and pooled the elutants. After concentration, target compounds were separated on a BEH C(18) column using a gradient elution profile with a mobile phase consisting of 0.1% formic acid aqueous solution and acetonitrile and detected by an electro spray ionization tandem mass spectrometry with multiple reactions monitoring(MRM). Satisfactory linearity(R(2) &gt; 0.997) was obtained over the range of 1.0 - 100 mu g/L and 0.1 - 100 mu g/L for tamoxifen and letrozole, respectively, with limits of quantification (LOQ) of 1.0 and 0.1 ng/L. Mean recoveries of two target compounds(spiked in sewage samples at three concentration levels) ranged from 68.8% to 103.0%, with relative standard deviations(RSD) less than 15%. This method can be applied for the analysis of target drugs sewage samples</abstract>
    <url>WOS:000275568300013</url>
    <isbnorissn>0253-3820</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>300</id>
    <title>Combined developmental toxicity of bisphenol A and genistein in micromass cultures of rat embryonic limb bud and midbrain cells</title>
    <authors>Xiao,Y.; Liu,R.; Xing,L.N.; Xu,Y.J.; Shang,L.Q.; Hao,W.D.</authors>
    <availability>[Xiao, Yang; Liu, Ran; Xing, Lina; Shang, Lanqin; Hao, Weidong] Peking Univ, Dept Toxicol, Sch Publ Hlth, Beijing 100191, Peoples R China. [Xu, Yajun] Peking Univ, Dept Food Hyg &amp; Nutr, Sch Publ Hlth, Beijing 100191, Peoples R China.</availability>
    <date>2011</date>
    <notes>JEnglishArticleHao, WD (reprint author), Peking Univ, Dept Toxicol, Sch Publ Hlth, Beijing 100191, Peoples R Chinarliu1985@yahoo.cn; whao@bjmu.edu.cnAdlercreutz H, 1999, AM J OBSTET GYNECOL, V180, P737, DOI 10.1016/S0002-9378(99)70281-4; Atteritano M, 2008, EUR J PHARMACOL, V589, P22, DOI 10.1016/j.ejphar.2008.04.049; Baluchnejadmojarad T, 2009, PHYTOTHER RES, V23, P132, DOI 10.1002/ptr.2564; Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236; CAKAL AO, 2008, ENVIRON TOXICOL, V23, P387; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147; Engel SM, 2006, REPROD TOXICOL, V21, P110, DOI 10.1016/j.reprotox.2005.07.007; FLINT OP, 1983, J CELL SCI, V61, P247; Flint O.P., 1987, IN VITRO METHODS TOX, P339; Foster WG, 2002, TOXICOL LETT, V129, P199, DOI 10.1016/S0378-4274(02)00018-8; GENSCHOW G, 2002, ATLA, V30, P151; GORTEN JP, 2000, FOOD CHEM TOXICOL, V38, pS65; *INV PROT, 1996, 114 INV PROT; *INV PROT, 2002, 122 INV PROT; Jin Y, 2007, J BIOMED SCI, V14, P275, DOI 10.1007/s11373-006-9142-2; KARA E, 2007, ENVIRON TOXICOL CHEM, V26, P732; Klein CB, 2007, TOXICOL APPL PHARM, V224, P1, DOI 10.1016/j.taap.2007.06.022; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Lee YM, 2007, J VET SCI, V8, P27; Marini H, 2007, ANN INTERN MED, V146, P839; Minta M, 2005, TOXICOL IN VITRO, V19, P915, DOI 10.1016/j.tiv.2005.06.025; Minta M, 2003, B VET I PULAWY, V47, P533; Miyatake M, 2006, J NEUROENDOCRINOL, V18, P434, DOI 10.1111/j.1365-2826.2006.01434.x; Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415; Patisaul HB, 2007, NEUROTOXICOLOGY, V28, P1, DOI 10.1016/j.neuro.2006.10.001; RENAULT JY, 1992, P 6 RHON POUL ROUND, P447; Rozman KK, 2006, BIRTH DEFECTS RES B, V77, P485, DOI 10.1002/bdrb.20087; Saillenfait AM, 2004, TOXICOL IN VITRO, V18, P311, DOI 10.1016/j.tiv.2003.09.005; Sanchez Y, 2009, BIOCHEM PHARMACOL, V77, P384, DOI 10.1016/j.bcp.2008.10.035; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Sonee M, 2004, NEUROTOXICOLOGY, V25, P885, DOI 10.1016/j.neuro.2003.11.001; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Sun LW, 2009, CHEMOSPHERE, V75, P410, DOI 10.1016/j.chemosphere.2008.11.083; Suzuki K, 2002, INT J CANCER, V99, P846, DOI 10.1002/ijc.10428; Takimoto CH, 2003, CANCER EPIDEM BIOMAR, V12, P1213; The National Toxicology Program-Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR), 2007, NTP CERHR EXP PAN RE; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321; Whitten PL, 2001, ENVIRON HEALTH PERSP, V109, P5, DOI 10.2307/3434842; Wilk I., 2008, REPROD TOXICOL, V26, P76, DOI 10.1016/j.reprotox.2008.05.052; Wilk I, 2006, TOXICOL LETT, V164, pS209, DOI 10.1016/j.toxlet.2006.07.093; You L, 2002, TOXICOL SCI, V66, P91, DOI 10.1093/toxsci/66.1.91446PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDTOXICOL IN VITROFEBDiscipline: Toxicology716YY</notes>
    <keywords>AMNIOTIC-FLUID; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CELL; Cell differentiation; Cell proliferation; CELL-PROLIFERATION; CELLS; CHEMICALS; Combined effect; DEFECTS; DENTISTRY; Developmental toxicity; Differentiation; Environmental estrogen; Estrogen; EXPERT PANEL REPORT; EXPOSURE; FOOD; genistein; HEALTH; HUMAN-REPRODUCTION; In vitro; IN-VITRO; INDUSTRY; LEUKEMIA; Micromass; NOAEL; PHYTOESTROGEN GENISTEIN; POSTMENOPAUSAL WOMEN; proliferation; RAT; Reproduction; RISK; SOY; SOY ISOFLAVONE; TOXICITY; toxicology; Validation; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>153</startpage>
    <endpage>159</endpage>
    <journalfull>Toxicology in Vitro</journalfull>
    <issue>1</issue>
    <volume>25</volume>
    <abstract>Bisphenol A (BPA), widely used in industry and dentistry, and genistein (GEN), the predominant component of soy product, are both known environmental estrogen. In the present study, we investigated the developmental toxicity of BPA and GEN and their combined effect using micromass test, which is one of three standard alternative developmental toxicity tests recommended by European Center for the Validation of Alternative Methods (ECVAM). The results showed that IC50-P (cell proliferation) and IC50-D (cell differentiation) of BPA and GEN were approximately 20 and 5 mu g/ml, respectively. No observed adverse effect level (NOAEL) of BPA and GEN were 10 and 0.94 mu g/ml, respectively. The manifestation of BPA as a teratogen was insufficient, although the "low dose" effect should be paid attention to. While the evidence of GEN as a teratogen was solid, especially with the consideration of "high dose" application in clinical treatment. The combined effect of BPA and GEN was generally additive action except that in MB proliferation. (C) 2010 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000287010600020</url>
    <isbnorissn>0887-2333</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>59</id>
    <title>Protein disulfide isomerase: a promising target for cancer therapy</title>
    <authors>Xu,S.L.; Sankar,S.; Neamati,N.</authors>
    <availability>[Xu, Shili; Neamati, Nouri] Univ Michigan, Dept Med Chem, Coll Pharm, Ann Arbor, MI 48109 USA. [Xu, Shili; Neamati, Nouri] Univ Michigan, Translat Oncol Program, Ann Arbor, MI 48109 USA. [Sankar, Saranya] Univ So Calif, Sch Pharm, Dept Pharmacol &amp; Pharmaceut Sci, Los Angeles, CA 90089 USA.</availability>
    <date>2014</date>
    <notes>JEnglishReviewNeamati, N (reprint author), Univ Michigan, Dept Med Chem, Coll Pharm, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USAneamati@umich.eduAlaiya AA, 2011, INT J ONCOL, V38, P1047, DOI 10.3892/ijo.2011.937; Appenzeller-Herzog C, 2010, EMBO J, V29, P3318, DOI 10.1038/emboj.2010.203; Ataman-Onal Y., 2011, USPTO 20110104701, Patent No. 20110104701; Atkin JD, 2006, J BIOL CHEM, V281, P30152, DOI 10.1074/jbc.M603393200; Banerjee R, 2013, J AM CHEM SOC, V135, P2497, DOI 10.1021/ja400427e; Barbouche R, 2003, J BIOL CHEM, V278, P3131, DOI 10.1074/jbc.M205467200; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Benham AM, 2012, ANTIOXID REDOX SIGN, V16, P781, DOI 10.1089/ars.2011.4439; Bennett TA, 2000, J IMMUNOL, V164, P4120; Bernardoni P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.113; Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Besanger T., 2012, USPTO 20120100071, Patent No. 20120100071; Bi SG, 2011, P NATL ACAD SCI USA, V108, P10650, DOI 10.1073/pnas.1017954108; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472; CAI H, 1994, J BIOL CHEM, V269, P24550; Campos SK, 2012, J VIROL, V86, P4169, DOI 10.1128/JVI.05493-11; Cancer Genome Atlas Research Network, 2008, NATURE, V455, P1061, DOI DOI 10.1038/NATURE07385; CARMICHAEL DF, 1977, J BIOL CHEM, V252, P7163; Chahed Karim, 2008, Clin Chim Acta, V388, P106, DOI 10.1016/j.cca.2007.10.018; Chahed K, 2005, INT J ONCOL, V27, P1425; Chen J, 2004, J PROTEOME RES, V3, P1009, DOI 10.1021/pr049916l; CHENG SY, 1983, ENDOCRINOLOGY, V113, P1155; Cho J, 2008, J CLIN INVEST, V118, P1123, DOI 10.1172/JCI34134; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Denisov AY, 2009, FEBS J, V276, P1440, DOI 10.1111/j.1742-4658.2009.06884.x; Descamps E, 2009, NEUROSCI RES, V64, P137, DOI 10.1016/j.neures.2009.02.005; Dickerhof N, 2011, FEBS J, V278, P2034, DOI 10.1111/j.1742-4658.2011.08119.x; Donoghue N, 2000, PROTEIN SCI, V9, P2436; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; Essex DW, 2001, BIOCHEMISTRY-US, V40, P6070, DOI 10.1021/bi002454e; FEENER EP, 1990, J BIOL CHEM, V265, P18780; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Flaumenhaft R, 2013, TRENDS CARDIOVAS MED, V23, P264, DOI 10.1016/j.tcm.2013.03.001; Fonseca C, 2009, BLOOD, V113, P1681, DOI 10.1182/blood-2007-09-114157; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fu XM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027185; Gallina A, 2002, J BIOL CHEM, V277, P50579, DOI 10.1074/jbc.M204547200; Gao MZ, 2013, APPL RADIAT ISOTOPES, V74, P61, DOI 10.1016/j.apradiso.2013.01.003; Gerhard R, 2003, MOL PHARMACOL, V63, P1349, DOI 10.1124/mol.63.6.1349; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; Godin B, 2004, J CONTROL RELEASE, V94, P365, DOI 10.1016/j.jconrel.2003.10.014; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Gonzalez-Santiago L, 2007, J PROTEOME RES, V6, P1286, DOI 10.1021/pr060430+; Goplen D, 2006, CANCER RES, V66, P9895, DOI 10.1158/0008-5472.CAN-05-4589; Govaerts C, 2003, RAPID COMMUN MASS SP, V17, P1366, DOI 10.1002/rcm.1058; Gromov P, 2010, MOL ONCOL, V4, P65, DOI 10.1016/j.molonc.2009.11.003; Gross E, 2006, P NATL ACAD SCI USA, V103, P299, DOI 10.1073/pnas.0506448103; Gruber CW, 2006, TRENDS BIOCHEM SCI, V31, P455, DOI 10.1016/j.tibs.2006.06.001; Guthapfel R, 1996, EUR J BIOCHEM, V242, P315, DOI 10.1111/j.1432-1033.1996.0315r.x; Gutmann DH, 2002, CANCER RES, V62, P2085; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hashida T, 2011, J TOXICOL SCI, V36, P1, DOI 10.2131/jts.36.1; Hashimoto S, 2012, J BIOCHEM, V151, P35, DOI 10.1093/jb/mvr122; Hatahet F, 2009, ANTIOXID REDOX SIGN, V11, P2807, DOI 10.1089/ARS.2009.2466; Hatahet F, 2007, FEBS J, V274, P5223, DOI 10.1111/j.1742-4658.2007.06058.x; HAWKINS HC, 1975, FEBS LETT, V58, P7, DOI 10.1016/0014-5793(75)80213-4; Higuchi T, 2004, BIOCHEM BIOPH RES CO, V318, P46, DOI 10.1016/j.bbrc.2004.04.002; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; Hiroi T, 2006, ENDOCRINOLOGY, V147, P2773, DOI 10.1210/en.2005-1235; Hoffstrom BG, 2010, NAT CHEM BIOL, V6, P900, DOI [10.1038/nchembio.467, 10.1038/NCHEMBIO.467]; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hong BX, 2008, PARASITOL RES, V102, P437, DOI 10.1007/s00436-007-0784-4; Hoozemans JJM, 2007, BIOCHEM BIOPH RES CO, V354, P707, DOI 10.1016/j.bbrc.2007.01.043; Horibe T, 2002, J ANTIBIOT, V55, P528; Horibe T, 2001, BIOCHEM BIOPH RES CO, V289, P967, DOI 10.1006/bbrc.2001.6105; HORIUCHI R, 1982, P NATL ACAD SCI-BIOL, V79, P5527, DOI 10.1073/pnas.79.18.5527; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; IBBETSON AL, 1976, BIOCHEM J, V159, P377; ICHIKAWA K, 1991, LIFE SCI, V49, P1513, DOI 10.1016/0024-3205(91)90323-4; Imaoka S, 2011, INT REV CEL MOL BIO, V290, P121, DOI 10.1016/B978-0-12-386037-8.00003-X; Jain S, 2007, J VIROL, V81, P2328, DOI 10.1128/JVI.01940-06; Janiszewski M, 2005, J BIOL CHEM, V280, P40813, DOI 10.1074/jbc.M509255200; Jasuja R, 2012, J CLIN INVEST, V122, P2104, DOI 10.1172/JCI61228; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; KALEF E, 1994, METHOD ENZYMOL, V233, P395; Karala AR, 2010, J MOL BIOL, V396, P883, DOI 10.1016/j.jmb.2009.12.014; Karala AR, 2010, FEBS J, V277, P2454, DOI 10.1111/j.1742-4658.2010.07660.x; Karala AR, 2007, ANTIOXID REDOX SIGN, V9, P1815, DOI 10.1089/ars.2007.1624; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Khan MMG, 2012, EXP CELL RES, V318, P904, DOI 10.1016/j.yexcr.2012.02.021; Khan MMG, 2011, ACS CHEM BIOL, V6, P245, DOI 10.1021/cb100387r; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; Kozlov G, 2010, FEBS J, V277, P3924, DOI 10.1111/j.1742-4658.2010.07793.x; Kraus M, 2008, MOL CANCER THER, V7, P1940, DOI 10.1158/1535-7163.MCT-07-2375; Lahav J, 2003, BLOOD, V102, P2085, DOI 10.1182/blood-2002-06-1646; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; Lara HH, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-137; Laurindo FRM, 2012, FREE RADICAL BIO MED, V52, P1954, DOI 10.1016/j.freeradbiomed.2012.02.037; Laurindo FRM, 2008, ANTIOXID REDOX SIGN, V10, P1101, DOI 10.1089/ars.2007.2011; Liu XW, 2004, BIOL CHEM, V385, P633, DOI 10.1515/BC.2004.078; Lovat PE, 2008, CANCER RES, V68, P5363, DOI 10.1158/0008-5472.CAN-08-0035; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MacRobbie EAC, 2002, P NATL ACAD SCI USA, V99, P11963, DOI 10.1073/pnas.172360399; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Mares RE, 2011, INT J MOL SCI, V12, P4625, DOI 10.3390/ijms12074625; Markovic I, 2004, BLOOD, V103, P1586, DOI 10.1182/blood-2003-05-1390; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; Muller C, 2013, ANTIOXID REDOX SIGN, V18, P731, DOI 10.1089/ars.2012.4577; Na KS, 2007, MOL CELLS, V24, P261; Nguyen VD, 2008, J MOL BIOL, V383, P1144, DOI 10.1016/j.jmb.2008.08.085; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Park B, 2006, CELL, V127, P369, DOI 10.1016/j.cell.2006.08.041; Peaper DR, 2008, ANNU REV CELL DEV BI, V24, P343, DOI 10.1146/annurev.cellbio.24.110707.175347; Piccaluga PP, 2007, J CLIN INVEST, V117, P823, DOI 10.1172/JCI26833; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Popescu NI, 2010, BLOOD, V116, P993, DOI 10.1182/blood-2009-10-249607; Primm TP, 2001, J BIOL CHEM, V276, P281, DOI 10.1074/jbc.M007670200; QUAN H, 1995, J BIOL CHEM, V270, P17078; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; Raturi A, 2005, BIOCHEM J, V391, P351, DOI 10.1042/BJ20050770; Raturi A, 2010, J THROMB HAEMOST, V8, P1863, DOI 10.1111/j.1538-7836.2010.03918.x; Reinhardt C, 2008, J CLIN INVEST, V118, P1110, DOI 10.1172/JCI32376; Rickman DS, 2001, CANCER RES, V61, P6885; Rigobello MP, 2001, BIOCHEM J, V356, P567, DOI 10.1042/0264-6021:3560567; ROTH RA, 1981, BIOCHEM BIOPH RES CO, V98, P431, DOI 10.1016/0006-291X(81)90858-5; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Ruddock LW, 1996, BIOCHEM J, V315, P1001; Ryser HJP, 2005, DRUG DISCOV TODAY, V10, P1085, DOI 10.1016/S1359-6446(05)03550-6; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; Schindler AJ, 2009, P NATL ACAD SCI USA, V106, P17775, DOI 10.1073/pnas.0910342106; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Severino A, 2007, J AM COLL CARDIOL, V50, P1029, DOI 10.1016/j.jacc.2007.06.006; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; Shibata E, 2001, PLACENTA, V22, P566, DOI 10.1053/plac.2001.0693; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; SIPES NJ, 1990, CELL GROWTH DIFFER, V1, P241; Smith AM, 2004, J BIOMOL SCREEN, V9, P614, DOI 10.1177/1087057104265292; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; Stolf BS, 2011, THESCIENTIFICWORLDJO, V11, P1749, DOI 10.1100/2011/289182; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Sun LZ, 2007, GYNECOL OBSTET INVES, V64, P17, DOI 10.1159/000098399; TERADA K, 1995, J BIOL CHEM, V270, P20410; Thongwatchara P, 2011, ONCOL REP, V26, P185, DOI 10.3892/or.2011.1266; Tian G, 2006, CELL, V124, P61, DOI 10.1016/j.cell.2005.10.044; Tomazzolli R, 2006, ANAL BIOCHEM, V350, P105, DOI 10.1016/j.ab.2005.11.037; Townsend DM, 2009, CANCER RES, V69, P7626, DOI 10.1158/0008-5472.CAN-09-0493; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Unterberger U, 2006, J NEUROPATH EXP NEUR, V65, P348; Uys JD, 2011, METHOD ENZYMOL, V490, P321, DOI 10.1016/B978-0-12-385114-7.00018-0; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; VENETIANER P, 1963, BIOCHIM BIOPHYS ACTA, V67, P166; VUORI K, 1992, J BIOL CHEM, V267, P7211; Wajih N, 2007, J BIOL CHEM, V282, P2626, DOI 10.1074/jbc.M608954200; Walker KW, 1997, J BIOL CHEM, V272, P8845; Wang C, 2012, J BIOL CHEM, V287, P1139, DOI 10.1074/jbc.M111.303149; Wang C, 2013, ANTIOXID REDOX SIGN, V19, P44, DOI 10.1089/ars.2012.4630; Wang EJ, 2008, TOXICOLOGY, V246, P91, DOI 10.1016/j.tox.2007.12.031; Wang L, 2009, J BIOL CHEM, V284, P199, DOI 10.1074/jbc.M806645200; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Weston BS, 2001, KIDNEY INT, V60, P1756, DOI 10.1046/j.1523-1755.2001.00991.x; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; Willems SH, 2010, BIOCHEM J, V428, P439, DOI 10.1042/BJ20100179; Xiong Y., 2012, INT J CELL BIOL, V2012; Xu SL, 2012, P NATL ACAD SCI USA, V109, P16348, DOI 10.1073/pnas.1205226109; Yamada R, 2011, J MED CHEM, V54, P2902, DOI 10.1021/jm101655d; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5; Yang YS, 2009, J NEUROSCI, V29, P13850, DOI 10.1523/JNEUROSCI.2312-09.2009; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yu SJ, 2012, J BIOENERG BIOMEMBR, V44, P101, DOI 10.1007/s10863-012-9416-5; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-1521823ELSEVIER SCI LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLANDDRUG DISCOV TODAYMARDiscipline: Pharmacology &amp; PharmacyAE3HI</notes>
    <keywords>AMYOTROPHIC-LATERAL-SCLEROSIS; BISPHENOL-A; CANCER; CELL; cell death; CELL-DEATH; CELLS; CHAPERONE-LIKE ACTIVITY; DEATH; ENDOPLASMIC-RETICULUM STRESS; ER-STRESS; GENE-EXPRESSION PROFILES; GLUTATHIONE-INSULIN TRANSHYDROGENASE; GROWTH; HORMONE-BINDING; INHIBITOR; Inhibitors; MHC CLASS-I; PROGRESSION; THERAPY; THIOREDOXIN-LIKE DOMAIN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>222</startpage>
    <endpage>240</endpage>
    <journalfull>Drug Discovery Today</journalfull>
    <issue>3</issue>
    <volume>19</volume>
    <abstract>Protein disulfide isomerase (PDI) has a key role in maintaining cellular homeostasis by mediating oxidative protein folding. It catalyzes disulfide bond formation, breakage and rearrangement in the endoplasmic reticulum and has chaperone protein activity. Increasing evidence suggests that PDI supports the survival and progression of several cancers. During the past decade, robust PDI activity assays have been developed and several PDI inhibitors identified, but none has been approved for clinical use. Herein, we review current knowledge of the role of PDI in cancer and discuss various assays for measuring the activities of PDI, highlighting their sensitivities and usefulness for high-throughput screening. The previously reported PDI inhibitors require further validation to serve as bona fide leads and additional optimization to generate novel drug candidates for clinical studies</abstract>
    <url>WOS:000333867200005</url>
    <isbnorissn>1359-6446</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>36</id>
    <title>DNA-based hybridization chain reaction amplification for assaying the effect of environmental phenolic hormone on DNA methyltransferase activity</title>
    <authors>Xu,Z.N.; Yin,H.S.; Han,Y.X.; Zhou,Y.L.; Ai,S.Y.</authors>
    <availability>[Xu, Zhenning; Yin, Huanshun; Han, Yunxiang; Zhou, Yunlei; Ai, Shiyun] Shandong Agr Univ, Coll Chem &amp; Mat Sci, Tai An 271018, Shandong, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleZhou, YL (reprint author), Shandong Agr Univ, Coll Chem &amp; Mat Sci, 61 Daizong St, Tai An 271018, Shandong, Peoples R Chinazhyl@sdau.edu.cn; ashy@sdau.edu.cnBi S, 2013, CHEM COMMUN, V49, P6906, DOI 10.1039/c3cc43353f; Chen Y, 2012, ANAL CHEM, V84, P7750, DOI 10.1021/ac3012285; Dirks RM, 2004, P NATL ACAD SCI USA, V101, P15275, DOI 10.1073/pnas.0407024101; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299; Gao FL, 2013, ANAL CHEM, V85, P11788, DOI 10.1021/ac4032109; Hayatsu H., 2008, CURRENT PROTOCOLS NU; He XX, 2011, BIOSENS BIOELECTRON, V28, P298, DOI 10.1016/j.bios.2011.07.035; Hou P, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng092; Li W, 2012, ANAL CHEM, V84, P7583, DOI 10.1021/ac301990f; Li Y, 2012, BIOSENS BIOELECTRON, V38, P407, DOI 10.1016/j.bios.2012.05.002; Liu P, 2013, ANAL CHEM, V85, P7689, DOI 10.1021/ac4001157; Liu SN, 2011, CHEM COMMUN, V47, P2844, DOI 10.1039/c0cc05153e; Liu T., 2009, ANAL CHEM, V82, P229; Lopez Torres A., 2011, ANAL CHEM; Lutz I, 1999, SCI TOTAL ENVIRON, V225, P49, DOI 10.1016/S0048-9697(99)80016-3; Meng XM, 2013, ELECTROCHIM ACTA, V95, P200, DOI 10.1016/j.electacta.2013.02.050; Ouyang XY, 2012, CHEM COMMUN, V48, P88, DOI 10.1039/c1cc15511c; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Su J, 2012, BIOSENS BIOELECTRON, V36, P123, DOI 10.1016/j.bios.2012.04.012; Ueda A., 2008, J AM CHEM SOC, V130, P3716; Wan Y, 2007, BIOSENS BIOELECTRON, V22, P2415, DOI 10.1016/j.bios.2006.08.033; Wang XL, 2009, ANAL CHEM, V81, P7885, DOI 10.1021/ac901681k; Wang ZZ, 2012, MICROCHIM ACTA, V179, P227, DOI 10.1007/s00604-012-0874-6; Wu HW, 2012, CHEM COMMUN, V48, P6280, DOI 10.1039/c2cc32397d; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574; Xu ZN, 2013, SENSOR ACTUAT B-CHEM, V178, P412, DOI 10.1016/j.snb.2012.12.124; Yin H., 2012, BIOSENS BIOELECTRON, V41, P492; Yin HS, 2013, BIOSENS BIOELECTRON, V49, P39, DOI 10.1016/j.bios.2013.04.040; Zhang B, 2012, ANAL CHEM, V84, P5392, DOI 10.1021/ac3009065; Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9310ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSANAL CHIM ACTAJUN 4Discipline: ChemistryAH8LG</notes>
    <keywords>5-fluorouracil; BINDING; BIOSENSING METHOD; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CARCINOGENESIS; DNA METHYLATION; ELECTROCHEMICAL IMMUNOASSAY; ELECTRODE; Environmental phenolic hormones; GOLD NANOPARTICLES; GRAPHENE; Hybridization chain reaction; INHIBITOR; Inhibitors; Interaction; mechanism; METHYLATION; Methyltransferase; Nonylphenol; PLATFORM; RESPONSES; SIGNAL AMPLIFICATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>9</startpage>
    <endpage>14</endpage>
    <journalfull>Analytica Chimica Acta</journalfull>
    <volume>829</volume>
    <abstract>In this work, a novel electrochemical protocol with signal amplification for determination of DNA methylation and methyltransferase activity using DNA-based hybridization chain reaction (HCR) was proposed. After the gold electrode was modified with dsDNA, it was treated with M. SssI MTase, HpaII endonuclease, respectively. And then the HCR was initiated by the target DNA and two hairpin helper DNAs, which lead to the formation of extended dsDNA polymers on the electrode surface. The signal was amplified by the labeled biotin on the hairpin probes. As a result, the streptavidin-alkaline phosphatase (S-ALP) conjugated on the electrode surface through the specific interaction between biotin and S-ALP. ALP could convert 1-naphthyl phosphate into 1-naphthol and the latter could be electrochemically oxidized, which was used to monitor the methylation event and MTase activity. The HCR assay presents good electrochemical responses for the determination of M. SssI MTase at a concentration as low as 0.0067 unit mL (1). Moreover, the effects of anti-cancer drug and environmental phenolic hormone on M. SssI MTase activity were also investigated. The results indicated that 5-fluorouracil and daunorubicin hydrochloride could inhibit the activity, and the opposite results were obtained with bisphenol A and nonylphenol. Therefore, this method can not only provide a platform to screen the inhibitors of DNA MTase and develop new anticancer drugs, but also offer a novel technique to investigate the possible carcinogenesis mechanism. (C) 2014 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000336388700002</url>
    <isbnorissn>0003-2670</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>141</id>
    <title>Effect of low dose bisphenol A on the early differentiation of human embryonic stem cells into mammary epithelial cells</title>
    <authors>Yang,L.Q.; Luo,L.F.; Ji,W.D.; Gong,C.M.; Wu,D.S.; Huang,H.Y.; Liu,Q.C.; Xia,B.; Hu,G.H.; Zhang,W.J.; Zhang,Q.; Liu,J.J.; Zhang,W.C.; Zhuang,Z.X.</authors>
    <availability>[Yang, Linqing; Zhuang, Zhixiong] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510080, Guangdong, Peoples R China. [Yang, Linqing; Luo, Lingfeng; Gong, Chunmei; Wu, Desheng; Huang, Haiyan; Liu, Qingcheng; Xia, Bo; Hu, Gonghua; Zhang, Wenjuan; Zhang, Qian; Liu, Jianjun; Zhuang, Zhixiong] Shenzhen Ctr Dis Control &amp; Prevent, Med Key Lab Hlth Toxicol, Key Lab Modern Toxicol, Shenzhen 518055, Peoples R China. [Luo, Lingfeng; Zhang, Wenchang] Fujian Med Univ, Key Lab Environm &amp; Hlth, Fuzhou 350004, Peoples R China. [Ji, Weidong] Guangzhou Med Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Urol, Dept Urol,Minimally Invas Surg Ctr, Guangzhou 510230, Guangdong, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleZhuang, ZX (reprint author), Shenzhen Ctr Dis Control &amp; Prevent, Med Key Lab Hlth Toxicol, Key Lab Modern Toxicol, 8 Rd LongYuan, Shenzhen 518055, Peoples R Chinawenchang2008@126.com; zxzhuang2011@gmail.comBateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Bucher JR, 2009, ENVIRON HEALTH PERSP, V117, pA96, DOI 10.1289/ehp.12492; Cabaton N. J., 2010, ENV HLTH PERSPECT, V119, P547, DOI DOI 10.1289/EHP.1002559; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Chen J, 2010, BRIT J CANCER, V102, P351, DOI 10.1038/sj.bjc.6605486; Chen M, 2011, J SEP SCI, V34, P1648, DOI 10.1002/jssc.201100152; Chen Y., 2012, J NEUROSCIENCE RES; Dahl L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002025; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; DYLEWSKI DP, 1983, EUR J CELL BIOL, V31, P114; Engel SM, 2006, REPROD TOXICOL, V21, P110, DOI 10.1016/j.reprotox.2005.07.007; Ezeh UI, 2005, CANCER, V104, P2255, DOI 10.1002/cncr.21432; Genschow E, 2004, ATLA-ALTERN LAB ANIM, V32, P209; Goodson WH, 2011, CARCINOGENESIS, V32, P1724, DOI 10.1093/carcin/bgr196; Holtcamp W, 2011, ENVIRON HEALTH PERSP, V119, pA383, DOI 10.1289/ehp.119-a383; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Hussenet T, 2010, CELL CYCLE, V9, P321; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Jiang SX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009707; Johkura K, 2004, J ANAT, V205, P247, DOI 10.1111/j.0021-8782.2004.00336.x; KEENAN TW, 1985, J DAIRY SCI, V68, P1025; Kim K, 2009, J TOXICOL ENV HEAL A, V72, P1343, DOI 10.1080/15287390903212501; Kim RJ, 2011, ALTERNATIVES LAB ANI, V27, P147; Krtolica A, 2009, REGEN MED, V4, P449, DOI [10.2217/rme.09.13, 10.2217/RME.09.13]; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Levenstein ME, 2006, STEM CELLS, V24, P568, DOI 10.1634/stemcells.2005-0247; Markey CM, 2001, BIOL REPROD, V65, P1215; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; Miyawaki J, 2008, TOXICOL SCI, V102, P82, DOI 10.1093/toxsci/kfm296; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; Nakshatri H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2559; Okada M, 2010, INT J MOL SCI, V11, P4114, DOI 10.3390/ijms11104114; Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325; Qin X.Y., 2012, CANCER BIOL THER, V13; Rippon HJ, 2006, STEM CELLS, V24, P1389, DOI 10.1634/stemcells.2005-0465; Saili K.S., 2011, TOXICOLOGY, V291, P83; Sathyanarayana S, 2011, ENVIRON HEALTH PERSP, V119, P1170, DOI 10.1289/ehp.1003064; Schraufstatter Ingrid U, 2010, J Stem Cells, V5, P9, DOI jsc.2010.5.1.9; Schwengberg S, 2005, J DENT, V33, P49, DOI 10.1016/j.jdent.2004.08.001; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Singhai Rajeev, 2011, N Am J Med Sci, V3, P227, DOI 10.4297/najms.2011.3227; Solari M, 2010, TOXICOL SCI, V113, P116, DOI 10.1093/toxsci/kfp243; Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x; Tomizawa Y, 2012, ONCOL LETT, V3, P1059, DOI 10.3892/ol.2012.632; Tsukada K., 2012, BREAST CANC; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640; Wang YY, 2008, EXP HEMATOL, V36, P128, DOI 10.1016/j.exphem.2007.09.004; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Wu Z, 2011, J GENET GENOMICS, V38, P13, DOI [10.1016/j.jcg.2010.12.006, 10.1016/j.jgg.2011.12.006]; Xing LN, 2010, TOXICOL SCI, V115, P577, DOI 10.1093/toxsci/kfq081; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5; zur Nieden NI, 2010, TOXICOLOGY, V277, P66, DOI 10.1016/j.tox.2010.08.016; Zwaka TP, 2010, NATURE, V467, P280, DOI 10.1038/467280a629ELSEVIER IRELAND LTDCLAREELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDTOXICOL LETTAPR 26Discipline: Toxicology114IQ</notes>
    <keywords>ALTERS; AMNIOTIC-FLUID; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; CELLS; CYCLE; development; Differentiation; E-CADHERIN; EPITHELIAL-CELLS; EXPRESSION; GLAND; Human embryonic stem cells; In vitro; IN-VITRO; Mammary epithelial cells; MODEL; NEURONAL DIFFERENTIATION; PRENATAL EXPOSURE; PROTEIN; PROTEINS; RISK; SELF-RENEWAL; STEM-CELLS; STEM/PROGENITOR CELLS; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>187</startpage>
    <endpage>193</endpage>
    <journalfull>Toxicology Letters</journalfull>
    <issue>3</issue>
    <volume>218</volume>
    <abstract>It has been previously reported that Bisphenol A (BPA) can disturb the development of mammary structure and increase the risk of breast cancer in experimental animals. In this study, an in vitro model of human embryonic stem cell (hESC) differentiation into mammary epithelial cells was applied to investigate the effect of low dose BPA on the early stages of mammogenesis. A newly established hESC line was directionally differentiated into mammary epithelial cells by a well-established three-dimensional (3D) culture system. The differentiated mammary epithelial cells were characterized by immunofluorescence and western blotting assay, and were called induced differentiated mammary epithelial cells (iDMECs) based on these data. The hESCs were treated with low doses of BPA range 10(-9)-10(-6) M during the differentiation process, with DMSO as the solvent control and 17-beta-estrodiol (E2) as the estrogen-positive control. Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein. Taken together, this study provides some insights into the effects of low dose BPA on the early differentiation stage of mammary epithelial cells and suggests an easier canceration status of iDMECs under the effect of low dose BPA during its early differentiation stage. (c) 2013 Elsevier Ireland Ltd. All rights reserved</abstract>
    <url>WOS:000316734700001</url>
    <isbnorissn>0378-4274</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>430</id>
    <title>Effects of bisphenol A on breast cancer and its risk factors</title>
    <authors>Yang,M.; Ryu,J.H.; Jeon,R.; Kang,D.; Yoo,K.Y.</authors>
    <availability>[Yang, Mihi; Ryu, Jae-Ha; Jeon, Raok] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea. [Kang, Daehee; Yoo, Keun-Young] Seoul Natl Univ, Dept Prevent Med, Coll Med, Seoul 110799, South Korea.</availability>
    <date>2009</date>
    <notes>JEnglishArticleYang, M (reprint author), Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Koreamyang@sm.ac.krCalafat AM, 2006, INT J ANDROL, V29, P166, DOI 10.1111/j.1365-2605.2005.00570.x; Choi DH, 2004, J CLIN ONCOL, V22, P1638, DOI 10.1200/JCO.2004.04.179; Colborn T., 1996, OUR STOLEN FUTURE AR; Dirtu AC, 2008, ANAL BIOANAL CHEM, V391, P1175, DOI 10.1007/s00216-007-1807-9; Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Matsumoto A, 2003, ENVIRON HEALTH PERSP, V111, P101, DOI 10.1289/ehp.5512; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Recchia AG, 2004, FOOD ADDIT CONTAM, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; Sasco AJ, 2001, APMIS, V109, pS80; Stewart BW, 2003, WORLD CANC REPORT; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Yang MH, 2003, ARCH ENVIRON CON TOX, V44, P546, DOI 10.1007/s00244-002-2124-0; Yang MH, 2006, J ENVIRON SCI HEAL C, V24, P183, DOI 10.1080/10590500600936474; YOO KY, 2006, ASIAN PAC J CANCER P, V6, P679; Yoo KY, 2002, J KOREAN MED SCI, V17, P11828SPRINGERNEW YORK233 SPRING ST, NEW YORK, NY 10013 USAARCH TOXICOLMARDiscipline: Toxicology416AD</notes>
    <keywords>ASSOCIATION; Biomonitoring; BIRTH; bisphenol; bisphenol A; BISPHENOL-A; BLOOD; BPA; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; CELL; CHEMICALS; DISRUPTING CHEMICALS; EDC; EDCs; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; Endocrine disruptor; Epidemiology; EXPOSURE; FOOD; FUTURE; HEALTH; HUMAN EXPOSURE; Incidence; Interaction; PREVENTION; RISK; RISK FACTOR; risk factors; RISK-FACTORS; SAMPLES; toxicology; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>281</startpage>
    <endpage>285</endpage>
    <journalfull>Archives of Toxicology</journalfull>
    <issue>3</issue>
    <volume>83</volume>
    <abstract>The incidence of breast cancer in Korea has been increasing for the last two decades (1983-2005), and now, breast cancer is ranked the leading cause of cancer in Korean women. Along with other endocrine disrupting chemicals (EDCs), bisphenol A (BPA) has been suspected as a potential risk factor for breast cancer. We studied potential associations between BPA exposure and breast cancer risks in Korean women by performing biomonitoring of BPA among breast cancer patients and controls (N = 167). Blood samples were collected between 1994 and 1997 and kept over 10 years in a freezer under well controlled conditions. The blood BPA levels determined by HPLC/FD, ranged between LOD (0.012 A mu g/L) and 13.87 A mu g/L (mean +/- A SD, 1.69 +/- A 2.57 A mu g/L; median, 0.043 A mu g/L). In age-matched subjects (N = 152), there were some associations between BPA levels and risks of breast cancer, such as age at first birth and null parity. However, there were no significant differences in blood BPA levels between the cases and the controls (P = 0.42). Considering interactions between BPA exposure and risks of breast cancer, we suggest further enlarged biomonitoring studies of BPA to provide effective prevention against breast cancer</abstract>
    <url>WOS:000263976700009</url>
    <isbnorissn>0340-5761</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>285</id>
    <title>Quantitative Determination of Bisphenol A from Human Saliva Using Bulk Derivatization and Trap-And-Elute Liquid Chromatography Coupled to Electrospray Ionization Mass Spectrometry</title>
    <authors>Yang,S.H.; Morgan,A.A.; Nguyen,H.P.; Moore,H.; Figard,B.J.; Schug,K.A.</authors>
    <availability>[Yang, Samuel H.; Morgan, Aaron A.; Nguyen, Hien P.; Moore, Hannah; Schug, Kevin A.] Univ Texas Arlington, Dept Chem &amp; Biochem, Arlington, TX 76019 USA. [Figard, Benjamin J.] Shimadzu N Amet, Houston, TX USA.</availability>
    <date>2011</date>
    <notes>JEnglishArticleSchug, KA (reprint author), Univ Texas Arlington, Dept Chem &amp; Biochem, Arlington, TX 76019 USAkschug@uta.eduAhmed MA, 2008, J APPL POLYM SCI, V109, P182, DOI 10.1002/app.28075; Basrur PK, 2006, ENVIRON RES, V100, P18, DOI 10.1016/j.envres.2005.08.016; Biles JE, 1997, J AGR FOOD CHEM, V45, P3541, DOI 10.1021/jf970072i; Bindhumol V, 2003, TOXICOLOGY, V188, P117, DOI 10.1016/S0300-483X(03)00056-8; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cao XL, 2009, J AGR FOOD CHEM, V57, P1307, DOI 10.1021/jf803213g; Cao XL, 2008, J AGR FOOD CHEM, V56, P7919, DOI 10.1021/jf8008712; Cassiano N.M., 2006, ANAL BIOANAL CHEM, V385, P1580, DOI 10.1007/s00216-006-0598-8; Celik L, 2008, CHEM RES TOXICOL, V21, P2195, DOI 10.1021/tx800278d; Chang CM, 2005, ANAL CHIM ACTA, V539, P41, DOI 10.1016/j.aca.2005.03.051; CLOUZOT L, 2008, ENVIRON PROG, V27, P282; Coulier L, 2010, J AGR FOOD CHEM, V58, P4873, DOI 10.1021/jf904160a; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Fenlon KA, 2010, J CHROMATOGR A, V1217, P112, DOI 10.1016/j.chroma.2009.10.063; Fisher J S, 1999, Environ Health Perspect, V107, P397, DOI 10.2307/3434544; Franke AA, 1998, P SOC EXP BIOL MED, V217, P263; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Grumetto L, 2008, J AGR FOOD CHEM, V56, P10633, DOI 10.1021/jf802297z; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154; Maudens KE, 2009, J CHROMATOGR B, V877, P3907, DOI 10.1016/j.jchromb.2009.09.044; McDonald JG, 2008, ANAL CHEM, V80, P5532, DOI 10.1021/ac8005632; Milnes MR, 2006, ENVIRON RES, V100, P3, DOI 10.1016/j.envres.2005.04.002; Nakamura T, 2008, TOXICOLOGY, V253, P117, DOI 10.1016/j.tox.2008.09.006; Nie YF, 2009, J CHROMATOGR A, V1216, P7071, DOI 10.1016/j.chroma.2009.08.064; Nose T, 2009, TOXICOL LETT, V191, P33, DOI 10.1016/j.toxlet.2009.08.001; Palmlund I, 1996, J PSYCHOSOM OBST GYN, V17, P71, DOI 10.3109/01674829609025667; PATISAUL HB, 2009, FRONT BEHAV NEUROSCI, V3; Ramakrishnan S, 2008, REPROD TOXICOL, V25, P177, DOI 10.1016/j.reprotox.2007.11.002; RAMESH M, 2009, BIOMED CHROMATOGR, V23, P3; Rhind SM, 2009, J ENVIRON MONITOR, V11, P1469, DOI 10.1039/b902085c; ROSANNA I, 2009, J SEP SCI, V32, P57; Ruden DM, 2005, HUM MOL GENET, V14, pR149, DOI 10.1093/hmg/ddi103; Salehi F, 2008, J TOXICOL ENV HEAL B, V11, P276, DOI 10.1080/10937400701875923; Shibayama Y, 2009, J CHROMATOGR B, V877, P2615, DOI 10.1016/j.jchromb.2008.10.051; Tanaka Y, 2004, J CHROMATOGR A, V1051, P193, DOI 10.1016/j.chroma.2004.06.053; Vinas P, 2010, ANAL BIOANAL CHEM, V397, P115, DOI 10.1007/s00216-010-3464-7; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; Washington W, 2001, IN VITRO MOL TOXICOL, V14, P43; XIAOHUI L, 2007, FEBS J, V274, P6340; 2001, FED REG, V64, P1428WILEY-BLACKWELLHOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USAENVIRON TOXICOL CHEMJUNDiscipline: Environmental Sciences &amp; Ecology; Toxicology766ZN</notes>
    <keywords>AGENTS; bisphenol; bisphenol A; BISPHENOL-A; BPA; Bulk derivatization; CANCER; CELL; Determination; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENDOCRINE-DISRUPTING COMPOUNDS; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; FEMINIZATION; FOOD; FOODS; HEALTH; Human saliva; In vitro; IN-VITRO; JUN; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; NEONATAL EXPOSURE; oral exposure; PRODUCTS; RATS; Restricted-access media; RISK; RIVER; ROUTE; SAMPLES; toxicology; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1243</startpage>
    <endpage>1251</endpage>
    <journalfull>Environmental Toxicology and Chemistry</journalfull>
    <issue>6</issue>
    <volume>30</volume>
    <abstract>Endocrine disruptors cause adverse health effects as a result of their ability to shift the hormonal balance that is essential to the body. Bisphenol A (BPA) is an endocrine disruptor that has garnered much attention because of its presence in many consumer materials, which generates a significant risk for exposure. A method is presented for rapid detection of oral exposure to BPA directly from human saliva. Saliva was chosen because it serves as a noninvasive sampling route to detect BPA exposure; however, it is one of many complex biological matrices that have traditionally posed problems in quantitative analysis. Such analyses usually require extensive sample preparation to reduce interferences contributed by the sample matrix. Three validated methods are presented here that feature a streamlined sample-preparation strategy (bulk derivatization) prior to accurate and sensitive analysis by trap-and-elute liquid chromatography coupled to electrospray ionization mass spectrometry. Validated methods include standard addition calibration with variable injection volumes and multiple injection loading, as well as with incorporation of an internal standard. Reported limits of detection reached as low as 49.0 pg/ml (2.9 pg loaded on-column; equivalent to parts per trillion in saliva) among the presented methods with good accuracy and precision throughout. A proof-of-concept study is demonstrated to show that the final validated method has potential application to specific studies for trace-level BPA detection from real samples. Environ. Toxicol. Chem. 2011;30:1243-1251. (C) 2011 SETAC</abstract>
    <url>WOS:000290825200003</url>
    <isbnorissn>0730-7268</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>405</id>
    <title>Bisphenol, npcRNAs and Utero-Ovarian Feed-Back Control of Breast Cancer Chemosensitivity</title>
    <authors>Yarpuzlu,A.</authors>
    <availability>Ankara Univ, Dept Publ Hlth &amp; Biotechnol, TR-06100 Ankara, Turkey.</availability>
    <date>2009</date>
    <notes>JEnglishLetterYarpuzlu, A (reprint author), Ankara Univ, Dept Publ Hlth &amp; Biotechnol, TR-06100 Ankara, Turkeyaysegul.yarpuzlu@medicine.ankara.edu.trAUBE M, 1981, BREAST CANCER RES, V10, pR16; Hong EJ, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-49; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; LAPENSEE EW, ENV HLTH PERSPECT, V117, P175; Mallardo M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-19; Sladek CD, 2008, FRONT NEUROENDOCRIN, V29, P114, DOI 10.1016/j.yfrne.2007.08.005; Zhang JT, 2007, CANCER TREAT REV, V33, P741, DOI 10.1016/j.ctrv.2007.07.01870US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPAUGDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology478DD</notes>
    <keywords>bisphenol; breast; breast cancer; BREAST-CANCER; CANCER; HEALTH; Occupational; toxicology</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>A341</startpage>
    <endpage>A342</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>8</issue>
    <volume>117</volume>
    <url>WOS:000268567100005</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>317</id>
    <title>Altered Gene Expression Following Exposure to Bisphenol A in Human Ovarian Cancer Cells Expressing Estrogen Receptors by Microarray</title>
    <authors>Yi,B.R.; Jeung,E.B.; Choi,K.C.</authors>
    <availability>[Yi, B. -R.; Jeung, E. -B.; Choi, K. -C.] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem &amp; Immunol, Cheongju, Chungbuk, South Korea.</availability>
    <date>2011</date>
    <notes>JEnglishMeeting Abstract01CSIRO PUBLISHINGCOLLINGWOOD150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIAREPROD FERT DEVELOPDiscipline: Developmental Biology; Reproductive Biology; Zoology690MF</notes>
    <keywords>BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTORS; EXPOSURE; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; Microarray; Ovarian cancer; OVARIAN-CANCER; RECEPTOR; Receptors</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>201</startpage>
    <endpage>201</endpage>
    <journalfull>Reproduction Fertility and Development</journalfull>
    <issue>1</issue>
    <volume>23</volume>
    <url>WOS:000285008200214</url>
    <isbnorissn>1031-3613</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>373</id>
    <title>Sensitivity and selectivity determination of BPA in real water samples using PAMAM dendrimer and CoTe quantum dots modified glassy carbon electrode</title>
    <authors>Yin,H.S.; Zhou,Y.L.; Ai,S.Y.; Chen,Q.P.; Zhu,X.B.; Liu,X.G.; Zhu,L.S.</authors>
    <availability>[Yin, Huanshun; Zhou, Yunlei; Ai, Shiyun; Liu, Xianggang] Shandong Agr Univ, Coll Chem &amp; Mat Sci, Tai An 271018, Shandong, Peoples R China. [Chen, Quanpeng; Zhu, Xiangbin; Zhu, Lusheng] Shandong Agr Univ, Coll Resources &amp; Environm, Tai An 271018, Shandong, Peoples R China.</availability>
    <date>2010</date>
    <notes>JEnglishArticleAi, SY (reprint author), Shandong Agr Univ, Coll Chem &amp; Mat Sci, Daizong St 61, Tai An 271018, Shandong, Peoples R Chinaashy@sdau.edu.cn; lushzhu@sdau.edu.cnAdams R., 1969, ELECTROCHEMISTRY SOL; Agui L, 2006, ELECTROCHIM ACTA, V51, P2565, DOI 10.1016/j.electacta.2005.07.051; Andreescu S, 2004, ANAL CHEM, V76, P552, DOI 10.1021/ac034480z; ANSON FC, 1964, ANAL CHEM, V36, P932, DOI 10.1021/ac60210a068; Ballesteros-Gomez A, 2009, J CHROMATOGR A, V1216, P449, DOI 10.1016/j.chroma.2008.06.037; Cao XL, 2008, J AGR FOOD CHEM, V56, P6378, DOI 10.1021/jf800870b; Chen QP, 2009, BIOSENS BIOELECTRON, V24, P2991, DOI 10.1016/j.bios.2009.03.007; Chen W, 2000, MACROMOLECULES, V33, P9169, DOI 10.1021/ma000791p; Dempsey E, 2004, BIOSENS BIOELECTRON, V20, P367, DOI 10.1016/j.bios.2004.02.007; Fan H, 2008, CRYST GROWTH DES, V8, P2838, DOI 10.1021/cg7011364; Ferreira M, 2006, ELECTROCHIM ACTA, V52, P434, DOI 10.1016/j.electacta.2006.05.025; Goodson A, 2004, FOOD ADDIT CONTAM, V21, P1015, DOI 10.1080/02652030400011387; Huang WS, 2005, B KOR CHEM SOC, V26, P1560; Kanekiyo Y, 2002, CHEM COMMUN, P2698, DOI 10.1039/b207534b; Kawaguchi M, 2004, J CHROMATOGR B, V805, P41, DOI 10.1016/j.chromb.2004.02.005; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuramitz H, 2004, WATER RES, V38, P2331, DOI 10.1016/j.watres.2004.02.023; Kuramitz H, 2001, CHEMOSPHERE, V45, P37, DOI 10.1016/S0045-6535(01)00032-7; LAVIRON E, 1974, J ELECTROANAL CHEM, V52, P355, DOI 10.1016/S0022-0728(74)80448-1; Li GJ, 2009, BIOSENS BIOELECTRON, V24, P3281, DOI 10.1016/j.bios.2009.04.022; Liu Q, 2007, BIOSENS BIOELECTRON, V22, P3203, DOI 10.1016/j.bios.2007.02.013; Liu ZM, 2005, SENSOR ACTUAT B-CHEM, V106, P394, DOI 10.1016/j.snb.2004.08.023; Lopez-Cervantes J, 2003, FOOD ADDIT CONTAM, V20, P596, DOI 10.1080/0265203031000109495; Luckza T., 2008, ELECTROCHIM ACTA, V53, P5725, DOI DOI 10.1016/J.ELECTACTA.2008.03.052; Mita DG, 2007, BIOSENS BIOELECTRON, V23, P60, DOI 10.1016/j.bios.2007.03.010; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Murugananthan M, 2008, J HAZARD MATER, V154, P213, DOI 10.1016/j.jhazmat.2007.10.011; Ngundi MM, 2003, ELECTROCHEM COMMUN, V5, P61, DOI 10.1016/S1388-2481(02)00538-6; Notsu H, 2002, J ELECTROANAL CHEM, V523, P86, DOI 10.1016/S0022-0728(02)00733-7; PAPOUCHADO L, 1975, J ELECTROANAL CHEM, V65, P275, DOI 10.1016/0368-1874(75)85123-9; Eickhoff H, 2001, TETRAHEDRON, V57, P353, DOI 10.1016/S0040-4020(00)00942-X; Santos WJR, 2009, FOOD CHEM, V113, P1206, DOI 10.1016/j.foodchem.2008.08.009; Tanaka S, 2002, J APPL ELECTROCHEM, V32, P197, DOI 10.1023/A:1014762511528; Tang LH, 2007, TALANTA, V73, P438, DOI 10.1016/j.talanta.2007.04.008; Telscher MJH, 2005, ENVIRON SCI TECHNOL, V39, P7896, DOI 10.1021/es050551v; Vega D, 2007, TALANTA, V71, P1031, DOI 10.1016/j.talanta.2006.05.071; Velasco JG, 1997, ELECTROANAL, V9, P880, DOI 10.1002/elan.1140091116; Wang FG, 2009, ANAL CHIM ACTA, V638, P23, DOI 10.1016/j.aca.2009.02.013; Wang Z, 2009, SENSOR ACTUAT B-CHEM, V138, P278, DOI 10.1016/j.snb.2008.12.040; Watabe Y, 2004, J CHROMATOGR A, V1032, P45, DOI 10.1016/j.chroma.2003.11.079; Yan F, 2001, ANAL CHEM, V73, P5272, DOI 10.1021/ac015516v; Yin HS, 2009, J ELECTROANAL CHEM, V626, P80, DOI 10.1016/j.jelechem.2008.11.0044240ELSEVIER SCIENCE BVAMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSJ HAZARD MATERFEB 15Discipline: Engineering; Environmental Sciences &amp; Ecology548RN</notes>
    <keywords>1; ANODIC-OXIDATION; BIOSENSOR; bisphenol; bisphenol A; BISPHENOL-A; BPA; CANCER; CARBON; CHINA; CHROMATOGRAPHY; CoTe quantum dots; DES; detection; Determination; ELECTROCHEMICAL DETECTION; Electrochemistry; ELECTRODE; ENDOCRINE; FIBER ELECTRODE; FOOD; GROWTH; Migration; NANOTUBES; PAMAM dendrimer; PHENOLIC-COMPOUNDS; POLYMERIZATION; SAMPLES; SENSITIVITY; SYSTEM; WATER; WATER SAMPLES</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>236</startpage>
    <endpage>243</endpage>
    <journalfull>Journal of Hazardous Materials</journalfull>
    <issue>1-3</issue>
    <volume>174</volume>
    <abstract>Bisphenol A (BPA) is an environmental pollutant to disrupt endocrine system or cause cancer, thus the detection of BPA is very important. Herein, an amperometric sensor was fabricated based on immobilized CoTe quantum dots (CoTe QDs) and PAMAM dendrimer (PAMAM) onto glassy carbon electrode (GCE) surface. The cyclic voltammogram of BPA on the sensor exhibited a well-defined anodic peak at 0.490V in 0.1 M pH 8.0 PBS. The determination conditions were optimized and the kinetic parameters were calculated. The linear range was 1.3 x 10(-8) to 9.89 x 10(-6) M with the correlation coefficient of 0.9999. The limit of detection was estimated to be 1 x 10(-9) M. The current reached the steady-state current within about 5 s. Furthermore, the fabricated sensor was successfully applied to determine BPA in real water samples. (C) 2009 Elsevier B.V. All rights reserved</abstract>
    <url>WOS:000273984000035</url>
    <isbnorissn>0304-3894</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>35</id>
    <title>Gene Expression Profiling Analysis of Bisphenol A-Induced Perturbation in Biological Processes in ER-Negative HEK293 Cells</title>
    <authors>Yin,R.; Gu,L.; Li,M.; Jiang,C.Z.; Cao,T.C.; Zhang,X.B.</authors>
    <availability>[Yin, Rong; Cao, Tongcheng] Tongji Univ, Dept Chem, Shanghai 200092, Peoples R China. [Gu, Liang; Li, Min; Jiang, Cizhong; Zhang, Xiaobai] Tongji Univ, Shanghai Key Lab Signaling &amp; Dis Res, Sch Life Sci &amp; Technol, Shanghai 200092, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleJiang, CZ (reprint author), Tongji Univ, Dept Chem, Shanghai 200092, Peoples R Chinaczjiang@tongji.edu.cn; ctc@tongji.edu.cn; zhangxb@tongji.edu.cnAllard P, 2010, P NATL ACAD SCI USA, V107, P20405, DOI 10.1073/pnas.1010386107; Bhandari R, 2013, AM J EPIDEMIOL, V177, P1263, DOI 10.1093/aje/kws391; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Chepelev NL, 2013, CHEM RES TOXICOL, V26, P498, DOI 10.1021/tx400036v; Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Erler C, 2010, J PEDIATR NURS, V25, P400, DOI 10.1016/j.pedn.2009.05.006; Flint S, 2012, J ENVIRON MANAGE, V104, P19, DOI 10.1016/j.jenvman.2012.03.021; Foster Warren G, 2008, Fertil Steril, V89, pe53, DOI 10.1016/j.fertnstert.2007.12.028; Geens T, 2012, FOOD CHEM TOXICOL, V50, P3725, DOI 10.1016/j.fct.2012.07.059; Gentilcore D, 2013, TOXICOLOGY, V304, P21, DOI 10.1016/j.tox.2012.12.001; Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111; Huang YQ, 2012, ENVIRON INT, V42, P91, DOI 10.1016/j.envint.2011.04.010; Iso T, 2006, BIOL PHARM BULL, V29, P206, DOI 10.1248/bpb.29.206; Krieter DH, 2013, ARTIF ORGANS, V37, P283, DOI 10.1111/j.1525-1594.2012.01556.x; Li DK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065399; Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431; Nadal A, 2013, NAT REV ENDOCRINOL, V9, P9, DOI 10.1038/nrendo.2012.205; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; Wang J, 2004, CLIN GENET, V65, P483, DOI 10.1111/j.1399-0004.2004.00250.x; Wang TG, 2013, EPIDEMIOLOGY, V24, P295, DOI 10.1097/EDE.0b013e318280e02f; Xu JP, 2002, BIOCHEM BIOPH RES CO, V292, P456, DOI 10.1006/bbrc.2002.6644; Zhou LP, 2003, J AM CHEM SOC, V125, P1431, DOI 10.1021/ja0290274300PUBLIC LIBRARY SCIENCESAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USAPLOS ONEJUN 5Discipline: Science &amp; Technology - Other TopicsAI4NF</notes>
    <keywords>apoptosis; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER; CELL; CELLS; DNA-DAMAGE; Endocrine disruptor; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURE; EXPRESSION; FOOD; gene expression; GENE-EXPRESSION; HUMAN HEALTH; mechanism; MECHANISMS; POPULATION; RECEPTOR; REVEALS; RISK; RNA-SEQ</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Plos One</journalfull>
    <issue>6</issue>
    <volume>9</volume>
    <abstract>Bisphenol A (BPA) is an environmental endocrine disruptor which has been detected in human bodies. Many studies have implied that BPA exposure is harmful to human health. Previous studies mainly focused on BPA effects on estrogen receptor (ER)-positive cells. Genome-wide impacts of BPA on gene expression in ER-negative cells is unclear. In this study, we performed RNA-seq to characterize BPA-induced cellular and molecular impacts on ER-negative HEK293 cells. The microscopic observation showed that low-dose BPA exposure did not affect cell viability and morphology. Gene expression profiling analysis identified a list of differentially expressed genes in response to BPA exposure in HEK293 cells. These genes were involved in variable important biological processes including ion transport, cysteine metabolic process, apoptosis, DNA damage repair, etc. Notably, BPA up-regulated the expression of ERCC5 encoding a DNA endonuclease for nucleotide-excision repair. Further electrochemical experiment showed that BPA induced significant DNA damage in ER-positive MCF-7 cells but not in ER-negative HEK293 cells. Collectively, our study revealed that ER-negative HEK293 cells employed mechanisms in response to BPA exposure different from ER-positive cells</abstract>
    <url>WOS:000336841400041</url>
    <isbnorissn>1932-6203</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>51</id>
    <title>Estrogenic Endocrine-Disrupting Chemicals: Molecular Mechanisms of Actions on Putative Human Diseases</title>
    <authors>Yoon,K.; Kwack,S.J.; Kim,H.S.; Lee,B.M.</authors>
    <availability>[Yoon, Kyungsil] Natl Canc Ctr, Lung Canc Branch, Res Inst, Goyang, Gyeonggi Do, South Korea. [Kwack, Seung Jun] Changwon Natl Univ, Dept Biochem &amp; Hlth Sci, Coll Nat Sci, Chang Won, Gyeongnam, South Korea. [Kim, Hyung Sik; Lee, Byung-Mu] Sungkyunkwan Univ, Div Toxicol, Coll Pharm, Suwon 440746, South Korea.</availability>
    <date>2014</date>
    <notes>JEnglishReviewLee, BM (reprint author), Sungkyunkwan Univ, Div Toxicol, Coll Pharm, Cheoncheon Dong 300, Suwon 440746, South Koreabmlee@skku.ac.krADAMI HO, 1995, CANCER CAUSE CONTROL, V6, P551, DOI 10.1007/BF00054165; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; Adlercreutz H, 1997, ANN MED, V29, P95; AHLBORG UG, 1995, CRIT REV TOXICOL, V25, P463, DOI 10.3109/10408449509017924; Akingbemi BT, 2004, P NATL ACAD SCI USA, V101, P775, DOI 10.1073/pnas.0305977101; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Allred CD, 2001, CARCINOGENESIS, V22, P1667, DOI 10.1093/carcin/22.10.1667; Almstrup K, 2002, ENVIRON HEALTH PERSP, V110, P743; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; Andrade AJM, 2006, TOXICOLOGY, V228, P85, DOI 10.1016/j.tox.2006.08.020; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; Anway MD, 2008, REPROD BIOMED ONLINE, V16, P23; Anway MD, 2008, PROSTATE, V68, P517, DOI 10.1002/pros.20724; Arbuckle TE, 1999, EPIDEMIOLOGY, V10, P752, DOI 10.1097/00001648-199911000-00017; Arnold SF, 1996, ENVIRON HEALTH PERSP, V104, P1020, DOI 10.2307/3433102; Ashby J, 1999, REGUL TOXICOL PHARM, V30, P156, DOI 10.1006/rtph.1999.1317; Atanassova N, 2000, ENDOCRINOLOGY, V141, P3898, DOI 10.1210/en.141.10.3898; Auger J, 2010, TOXICOL SCI, V117, P475, DOI 10.1093/toxsci/kfq199; Baird DD, 2005, REPROD TOXICOL, V20, P81, DOI 10.1016/j.reprotox.2005.01.002; Balabanic D, 2011, REPROD FERT DEVELOP, V23, P403, DOI 10.1071/RD09300; Bang DY, 2012, COMPR REV FOOD SCI F, V11, P453, DOI 10.1111/j.1541-4337.2012.00197.x; Barnes S, 1998, BAILLIERE CLIN ENDOC, V12, P559, DOI 10.1016/S0950-351X(98)80004-9; Barthold JS, 1999, J UROLOGY, V162, P864, DOI 10.1097/00005392-199909010-00079; Barton M, 2012, STEROIDS, V77, P935, DOI 10.1016/j.steroids.2012.04.001; Begum M, 2006, LAB INVEST, V86, P286, DOI 10.1038/labinvest.3700380; Belpomme D, 2009, INT J ONCOL, V34, P1037, DOI 10.3892/ijo_00000229; Betancourt AM, 2010, J PROTEOMICS, V73, P1241, DOI 10.1016/j.jprot.2010.02.020; Betancourt AM, 2012, J NUTR, V142, p1382S, DOI 10.3945/jn.111.152058; Bi RF, 2000, P NATL ACAD SCI USA, V97, P3602, DOI 10.1073/pnas.060034497; Bigsby R, 1999, ENVIRON HEALTH PERSP, V107, P613, DOI 10.2307/3434553; Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Blizard D, 2001, DRUG METAB DISPOS, V29, P781; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Boker LK, 2002, J NUTR, V132, P1319; Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1; BONGIOVANNI AM, 1983, J PEDIATR, V103, P245, DOI 10.1016/S0022-3476(83)80354-0; Borch J, 2006, TOXICOLOGY, V223, P144, DOI 10.1016/j.tox.2006.03.015; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; Brucker-Davis F, 2008, GYNECOL OBSTET FERTI, V36, P840, DOI 10.1016/j.gyobfe.2008.06.024; Brucker-Davis F, 2008, HUM REPROD, V23, P1708, DOI 10.1093/humrep/den186; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; BULGER WH, 1983, BIOCHEM PHARMACOL, V32, P1005, DOI 10.1016/0006-2952(83)90618-4; BYRD RA, 1995, FUND APPL TOXICOL, V26, P181, DOI 10.1006/faat.1995.1089; Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559; Cagen SZ, 1999, TOXICOL SCI, V50, P36, DOI 10.1093/toxsci/50.1.36; Cai JL, 2011, TOXICOLOGY, V287, P21, DOI 10.1016/j.tox.2011.05.010; Canesi L, 2004, GEN COMP ENDOCR, V138, P58, DOI 10.1016/j.ygcen.2004.05.004; Canesi L, 2003, AQUAT TOXICOL, V63, P293, DOI 10.1016/S0166-445X(02)00186-8; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; CARLSEN E, 1992, BRIT MED J, V305, P609; CASSIDY A, 1994, AM J CLIN NUTR, V60, P333; Chapin RE, 1999, TOXICOL SCI, V52, P80, DOI 10.1093/toxsci/52.1.80; Charlier C, 2004, CLIN CHEM LAB MED, V42, P222, DOI 10.1515/CCLM.2004.040; Cheek AO, 1998, ENVIRON HEALTH PERSP, V106, P5, DOI 10.2307/3433910; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Chen X, 2009, J TOXICOL ENV HEAL A, V72, P717, DOI 10.1080/15287390902841136; Choi S, 2010, PROTEOMICS, V10, P1831, DOI 10.1002/pmic.200900674; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P451, DOI 10.1080/10937400490512500; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; Christian M, 1999, J ENDOCRINOL, V160, pR1, DOI 10.1677/joe.0.160R001; Chung BY, 2013, J TOXICOL ENV HEAL A, V76, P624, DOI 10.1080/15287394.2013.801767; Cobellis L, 2003, HUM REPROD, V18, P1512, DOI 10.1093/humrep/deg254; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Coleman KM, 2001, FRONT BIOSCI, V6, pD1379, DOI 10.2741/Coleman; Collins P, 1999, NAT MED, V5, P1130, DOI 10.1038/13453; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Cooper RL, 1997, J ENDOCRINOL, V152, P159, DOI 10.1677/joe.0.1520159; Courval JM, 1999, ENVIRON RES, V80, pS183, DOI 10.1006/enrs.1998.3909; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crosby LM, 2008, J TOXICOL ENV HEAL A, V71, P1195, DOI 10.1080/15287390802182581; Csaba G, 1998, HUM EXP TOXICOL, V17, P88, DOI 10.1191/096032798678908332; Currie RA, 2005, TOXICOL SCI, V86, P453, DOI 10.1093/toxsci/kfi207; Damstra T, 2002, GLOBAL ASSESSMENT ST; David RM, 2000, TOXICOL SCI, V55, P433, DOI 10.1093/toxsci/55.2.433; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; De Celis R, 2000, FERTIL STERIL, V73, P221, DOI 10.1016/S0015-0282(99)00515-4; DECOCK J, 1994, OCCUP ENVIRON MED, V51, P693; Delemarre-van de Waal H, 2005, ENDOCRIN DEV, V8, P1; Dennis AP, 2001, FRONT BIOSCI, V6, pD954, DOI 10.2741/Dennis; DeRosa C, 1998, J TOXICOL ENV HEAL B, V1, P3; De Wit M, 2010, GEN COMP ENDOCR, V167, P190, DOI 10.1016/j.ygcen.2010.03.003; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dickerson SM, 2007, REV ENDOCR METAB DIS, V8, P143, DOI 10.1007/s11154-007-9048-y; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; Elswick BA, 2000, REPROD TOXICOL, V14, P359, DOI 10.1016/S0890-6238(00)00092-7; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; Ferguson KK, 2013, J TOXICOL ENV HEAL B, V16, P69, DOI 10.1080/10937404.2013.775048; Flores-Valverde AM, 2010, ENVIRON SCI TECHNOL, V44, P3552, DOI 10.1021/es9039049; Font de Mora J, 2000, MOL CELL BIOL, V20, P5041, DOI [10.1128/MCB.20.14 5041-5047.2000, DOI 10.1128/MCB.20.14.5041-5047.2000)]; Foresta C, 2008, ENDOCR REV, V29, P560, DOI 10.1210/er.2007-0042; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Foster WG, 2008, J TOXICOL ENV HEAL B, V11, P162, DOI 10.1080/10937400701873274; Foth D, 1998, AM J CLIN NUTR, V68, p1413S; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; FRENITITULAER LW, 1986, AM J DIS CHILD, V140, P1263; Fuortes L, 1997, AM J IND MED, V31, P445, DOI 10.1002/(SICI)1097-0274(199704)31:4&lt;445::AID-AJIM11&gt;3.0.CO;2-#; Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746; Garry VF, 2002, J TOXICOL ENV HEAL A, V65, P769, DOI 10.1080/00984100290071333; GERHARD I, 1992, GEBURTSH FRAUENHEILK, V52, P383, DOI 10.1055/s-2007-1023774; Goksoyr A, 2006, J TOXICOL ENV HEAL A, V69, P175, DOI 10.1080/15287390500259483; Goldberg JM, 1999, FERTIL STERIL, V72, P1, DOI 10.1016/S0015-0282(99)00153-3; Goodman MT, 1997, AM J EPIDEMIOL, V146, P294; Govind AP, 2003, MOL CELL BIOCHEM, V253, P233, DOI 10.1023/A:1026068017309; Grandjean P, 2012, REPROD TOXICOL, V34, P498, DOI 10.1016/j.reprotox.2012.07.005; Gray LE, 2006, TOXICOL SCI, V93, P189, DOI 10.1093/toxsci/kfl035; GRAY LE, 1995, TOXICOL APPL PHARM, V131, P108, DOI 10.1006/taap.1995.1052; Greenlee AR, 2003, EPIDEMIOLOGY, V14, P429, DOI 10.1097/01.EDE.0000071407.15670.aa; Gu AH, 2010, FERTIL STERIL, V94, P2620, DOI 10.1016/j.fertnstert.2010.04.059; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Gupta C, 2000, UROL RES, V28, P223; Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x; Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Han X, 2011, ENVIRON HEALTH PERSP, V119, P652, DOI 10.1289/ehp.1002340; HAYASHI F, 1994, CARCINOGENESIS, V15, P2215, DOI 10.1093/carcin/15.10.2215; Heald C. L., 2006, EUR J CLIN NUTR, V60, P12; HERBST AL, 1981, CANCER, V48, P484, DOI 10.1002/1097-0142(19810715)48:1+&lt;484::AID-CNCR2820481308&gt;3.0.CO;2-X; Hess-Wilson JK, 2009, CANCER CAUSE CONTROL, V20, P1029, DOI 10.1007/s10552-009-9337-8; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hines A, 2007, ENVIRON SCI TECHNOL, V41, P3375, DOI 10.1021/es062745w; Hiroi H, 2004, ENDOCR J, V51, P595, DOI 10.1507/endocrj.51.595; Hirosawa N, 2006, PROTEOMICS, V6, P958, DOI 10.1002/pmic.200401344; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Hoang T, 2004, J BIOL CHEM, V279, P49120, DOI 10.1074/jbc.M409746200; Holmes E, 2000, CHEM RES TOXICOL, V13, P471, DOI 10.1021/tx990210t; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3&lt;321::AID-JNR6&gt;3.0.CO;2-T; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; Horn-Ross PL, 2003, J NATL CANCER I, V95, P1158, DOI 10.1093/jnci/djg015; Horn-Ross PL, 2001, AM J EPIDEMIOL, V154, P434, DOI 10.1093/aje/154.5.434; Hotchkiss AK, 2008, TOXICOL SCI, V105, P235, DOI 10.1093/toxsci/kfn030; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; Hsieh CY, 1998, CANCER RES, V58, P3833; HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140-6736(95)92713-1; Hunter DJ, 1997, NEW ENGL J MED, V337, P1253, DOI 10.1056/NEJM199710303371801; Iguchi T, 2007, GEN COMP ENDOCR, V153, P25, DOI 10.1016/j.ygcen.2007.01.013; Inoshita H, 2003, J MOL ENDOCRINOL, V31, P551, DOI 10.1677/jme.0.0310551; Iwasaki T, 2002, BIOCHEM BIOPH RES CO, V299, P384, DOI 10.1016/S0006-291X(02)02659-1; Jang YJ, 2012, TOXICOLOGY, V296, P73, DOI 10.1016/j.tox.2012.03.007; Jansen MS, 2004, P NATL ACAD SCI USA, V101, P7199, DOI 10.1073/pnas.0402014101; Katsuda S, 2000, TOXICOL APPL PHARM, V165, P217, DOI 10.1006/taap.2000.8940; Kavlock RJ, 1999, CHEMOSPHERE, V39, P1227, DOI 10.1016/S0045-6535(99)00190-3; Kawaguchi H, 2009, J VET MED SCI, V71, P1599; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Key TJ, 1999, BRIT J CANCER, V81, P1248, DOI 10.1038/sj.bjc.6690837; Kim HS, 2004, J TOXICOL ENV HEAL A, V67, P2045, DOI 10.1080/15287390490514859; Kim KB, 2009, J TOXICOL ENV HEAL A, V72, P1352, DOI 10.1080/15287390903212550; Kim NY, 2010, J TOXICOL ENV HEAL A, V73, P1560, DOI 10.1080/15287394.2010.511582; Kim TS, 2010, J TOXICOL ENV HEAL A, V73, P1544, DOI 10.1080/15287394.2010.511579; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Klotz DM, 1996, ENVIRON HEALTH PERSP, V104, P1084, DOI 10.2307/3433121; Kolstad HA, 1999, INT ARCH OCC ENV HEA, V72, P135, DOI 10.1007/s004200050352; Koninckx PR, 1999, GYNECOL OBSTET INVES, V47, P47, DOI 10.1159/000052859; Korrick SA, 2011, ENVIRON HEALTH PERSP, V119, P1339, DOI 10.1289/ehp.1003102; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Kuhnle GGC, 2008, J AGR FOOD CHEM, V56, P7311, DOI 10.1021/jf801534g; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kumar NB, 2002, CANCER, V94, P1166, DOI 10.1002/cncr.10320; Kumar P, 2001, HUM EXP TOXICOL, V20, P585, DOI 10.1191/096032701718620882; Kuramori C, 2009, TOXICOL SCI, V109, P143, DOI 10.1093/toxsci/kfp041; Kushner P. J., 2000, NOVART FDN SYMP, V230, P27; Kushner P J, 2000, Novartis Found Symp, V230, P20, DOI 10.1002/0470870818.ch3; Kwack SJ, 2009, J TOXICOL ENV HEAL A, V72, P1446, DOI 10.1080/15287390903212923; Laden F, 2001, J NATL CANCER I, V93, P768, DOI 10.1093/jnci/93.10.768; Lamartiniere C. A., 2011, HORM MOL BIOL CLIN I, V5, P45, DOI DOI 10.1515/HMBCI.2010.075; Lamartiniere C.A., 2000, AM J CLIN NUTR, V71, P1705; LAMB JC, 1987, TOXICOL APPL PHARM, V88, P255, DOI 10.1016/0041-008X(87)90011-1; Lasserre JP, 2009, J PROTEOME RES, V8, P5485, DOI 10.1021/pr900480f; Laws SC, 2000, TOXICOL SCI, V58, P366, DOI 10.1093/toxsci/58.2.366; Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154; Lawson C, 2011, BIOL REPROD, V84, P79, DOI 10.1095/biolreprod.110.084814; Lebel G, 1998, FERTIL STERIL, V69, P221, DOI 10.1016/S0015-0282(97)00479-2; Lee BM, 2007, J TOXICOL ENV HEAL A, V70, P1365, DOI 10.1080/15287390701432285; Lee PC, 1998, ENDOCRINE, V9, P105, DOI 10.1385/ENDO:9:1:105; Lee SH, 2007, ANAL CHEM, V79, P6102, DOI 10.1021/ac070237e; Levin ER, 2001, J APPL PHYSIOL, V91, P1860; Levin ER, 1999, TRENDS ENDOCRIN MET, V10, P374, DOI 10.1016/S1043-2760(99)00192-7; Lewis SEM, 2005, CELL TISSUE RES, V322, P33, DOI 10.1007/s00441-005-1097-5; Limer JL, 2004, BREAST CANCER RES, V6, P119, DOI 10.1186/bcr781; Lin H, 2008, P NATL ACAD SCI USA, V105, P7218, DOI 10.1073/pnas.0709260105; Liu X, 2008, J TOXICOL ENV HEAL A, V71, P1289, DOI 10.1080/15287390802114915; Lobaton CD, 2005, BRIT J PHARMACOL, V145, P862, DOI 10.1038/sj.bjp.0706265; Lonard DM, 2004, MOL CELL BIOL, V24, P14, DOI 10.1128/MCB.24.1.14-24.2004; Lopez-Carrillo L, 2010, ENVIRON HEALTH PERSP, V118, P539, DOI 10.1289/ehp.0901091; Lu CF, 2010, TOXICOL APPL PHARM, V248, P178, DOI 10.1016/j.taap.2010.07.020; Lu LJW, 2000, CANCER RES, V60, P4112; Lubick N, 2010, ENVIRON HEALTH PERSP, V118, pA18, DOI 10.1289/ehp.118-a18; Lucki NC, 2011, J BIOL CHEM, V286, P19399, DOI 10.1074/jbc.M110.195826; Luderer U, 2004, AM J IND MED, V46, P614, DOI 10.1002/ajim.20100; Ma L, 2009, TRENDS ENDOCRIN MET, V20, P357, DOI 10.1016/j.tem.2009.03.009; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P97, DOI 10.1016/0041-008X(92)90101-W; MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633; Mahood IK, 2007, ENVIRON HEALTH PERSP, V115, P55, DOI 10.1289/ehp.9366; MARSELOS M, 1992, EUR J CANCER, V28A, P1182, DOI 10.1016/0959-8049(92)90482-H; Maskarinec G, 2002, CANCER EPIDEM BIOMAR, V11, P195; Masuo Y, 2011, J TOXICOL ENV HEAL B, V14, P346, DOI 10.1080/10937404.2011.578557; Masuyama H, 2000, MOL ENDOCRINOL, V14, P421, DOI 10.1210/me.14.3.421; Masuyama H, 2004, J BIOL CHEM, V279, P12020, DOI 10.1074/jbc.M312762200; Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833; Mayani A, 1997, HUM REPROD, V12, P373, DOI 10.1093/humrep/12.2.373; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; MCENERY MW, 1986, J BIOL CHEM, V261, P1745; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Miao MH, 2011, BIRTH DEFECTS RES A, V91, P867, DOI 10.1002/bdra.22845; Mikamo E, 2003, TOXICOL APPL PHARM, V193, P66, DOI 10.1016/j.taap.2003.08.001; MILLS JL, 1981, AM J DIS CHILD, V135, P743; Min GS, 2002, J BIOL CHEM, V277, P34626, DOI 10.1074/jbc.M205239200; Minamiyama Y, 2010, FREE RADICAL RES, V44, P1398, DOI 10.3109/10715762.2010.510523; Miodini P, 1999, BRIT J CANCER, V80, P1150, DOI 10.1038/sj.bjc.6690479; Mitchner NA, 1998, ENDOCRINOLOGY, V139, P3976, DOI 10.1210/en.139.9.3976; Mizota K, 2005, BRIT J PHARMACOL, V145, P545, DOI 10.1038/sj.bjp.0706213; Mizota K, 2006, TOXICOL SCI, V90, P362, DOI 10.1093/toxsci/kfj087; Moens LN, 2006, TOXICOL SCI, V93, P298, DOI 10.1093/toxsci/kfl057; Moggs JG, 2005, TOXICOLOGY, V213, P177, DOI 10.1016/j.tox.2005.05.020; Monje P, 2001, J CELL BIOCHEM, V82, P467, DOI 10.1002/jcb.1182; Montero M, 2004, BIOCHEM J, V384, P19, DOI 10.1042/BJ20040990; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; MORRISEY RE, 1987, FUND APPL TOXICOL, V8, P571, DOI 10.1016/0272-0590(87)90142-4; Mulligan AA, 2007, EUR J CLIN NUTR, V61, P248, DOI 10.1038/sj.ejcn.1602509; Naciff Jorge M, 2004, Toxicol Pathol, V32 Suppl 2, P59, DOI 10.1080/01926230490463812; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Nadal A, 2001, TRENDS PHARMACOL SCI, V22, P597, DOI 10.1016/S0165-6147(00)01846-0; Nagao T, 2001, REPROD TOXICOL, V15, P683, DOI 10.1016/S0890-6238(01)00173-3; Nagao T, 1999, REPROD TOXICOL, V13, P303, DOI 10.1016/S0890-6238(99)00017-9; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; Nah Won Heum, 2011, Clin Exp Reprod Med, V38, P75, DOI 10.5653/cerm.2011.38.2.75; Nakazawa K, 2001, EUR J PHARMACOL, V430, P175, DOI 10.1016/S0014-2999(01)01389-9; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006; Newbold RR, 2001, CANCER RES, V61, P4325; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Oberemm Axel, 2005, Toxicol Appl Pharmacol, V207, P592, DOI 10.1016/j.taap.2005.01.044; Ociepa-Zawal M, 2010, J ENVIRON SCI HEAL A, V45, P305, DOI 10.1080/10934520903468038; Odum J, 2000, TOXICOL SCI, V56, P400, DOI 10.1093/toxsci/56.2.400; Olaya-Contreras P, 1998, Cad Saude Publica, V14 Suppl 3, P125; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222; Panzica GC, 2011, J TOXICOL ENV HEAL B, V14, P449, DOI 10.1080/10937404.2011.578562; PAPPAS TC, 1995, FASEB J, V9, P404; Park MK, 2007, ASIA PAC J CLIN NUTR, V16, P129; Parvinen M, 1984, Arch Toxicol Suppl, V7, P128; Pascussi JM, 2003, BBA-GEN SUBJECTS, V1619, P243, DOI 10.1016/S0304-4165(02)00483-X; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Peeters PHM, 2003, BREAST CANCER RES TR, V77, P171, DOI 10.1023/A:1021381101632; MESSINA MJ, 1994, NUTR CANCER, V21, P113; Petersen DN, 1998, ENDOCRINOLOGY, V139, P1082, DOI 10.1210/en.139.3.1082; Petrelli G, 2000, EUR J EPIDEMIOL, V16, P391, DOI 10.1023/A:1007630610911; Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P322, DOI 10.1080/10937400701876194; PHIPPS WR, 1993, J CLIN ENDOCR METAB, V77, P1215, DOI 10.1210/jc.77.5.1215; Po LS, 2002, CANCER LETT, V187, P33, DOI 10.1016/S0304-3835(02)00355-5; Pocar P, 2012, TOXICOL SCI, V126, P213, DOI 10.1093/toxsci/kfr327; Portigal CL, 2002, TOXICOL APPL PHARM, V179, P185, DOI 10.1006/taap.2002.9371; POTASHNIK G, 1987, FERTIL STERIL, V47, P317; Potischman N, 1996, J NATL CANCER I, V88, P1127, DOI 10.1093/jnci/88.16.1127; Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Ramamoorthy K, 1997, ENDOCRINOLOGY, V138, P1520, DOI 10.1210/en.138.4.1520; RATCLIFFE JM, 1989, BRIT J IND MED, V46, P399; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razin A, 2005, PROG MOLEC, V38, P151; Recio-Vega R., 2012, J APPL TOXICOL, V33, P906; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rice MM, 2001, PUBLIC HEALTH NUTR, V4, P943, DOI 10.1079/PHN2001150; Rier S, 2003, SEMIN REPROD MED, V21, P145; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; Rier SE, 2001, TOXICOL SCI, V60, P327, DOI 10.1093/toxsci/60.2.327; Robledo C, 2013, J TOXICOL ENV HEAL A, V76, P865, DOI 10.1080/15287394.2013.824395; Ropero AB, 2006, J STEROID BIOCHEM, V102, P163, DOI 10.1016/j.jsbmb.2006.09.019; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Roy D, 2007, J TOXICOL ENV HEAL B, V10, P235, DOI 10.1080/15287390600974924; Roy D, 1997, J TOXICOL ENV HEALTH, V50, P1, DOI 10.1080/009841097160573; Roy JR, 2009, MED SCI MONITOR, V15, pRA137; Ruehlmann DO, 1998, FASEB J, V12, P613; RuizLarrea MB, 1997, FREE RADICAL RES, V26, P63, DOI 10.3109/10715769709097785; Ryan BC, 2010, TOXICOL SCI, V114, P133, DOI 10.1093/toxsci/kfp266; Ryu JY, 2008, J TOXICOL ENV HEAL A, V71, P1542, DOI 10.1080/15287390802391992; Ryu JY, 2007, J TOXICOL ENV HEAL A, V70, P1296, DOI 10.1080/15287390701432160; Ryu JY, 2007, TOXICOLOGY, V234, P103, DOI 10.1016/j.tox.2007.02.003; Saenz de Rodriguez C.A., 1985, J PEDIAT, V107, P393, DOI DOI 10.1016/S0022-3476(85)80513-8; Safe S, 1997, REGUL TOXICOL PHARM, V26, P52, DOI 10.1006/rtph.1997.1118; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; Safe SH, 2000, ENVIRON HEALTH PERSP, V108, P487, DOI 10.2307/3454608; Saini SPS, 2005, HEPATOLOGY, V41, P497, DOI 10.1002/hep.20570; Sar M, 1999, ENDOCRINOLOGY, V140, P963, DOI 10.1210/en.140.2.963; Savitz DA, 1997, AM J EPIDEMIOL, V146, P1025; Schlumpf M, 2004, TOXICOLOGY, V205, P113, DOI 10.1016/j.tox.2004.06.043; Schrader S M, 1988, Reprod Toxicol, V2, P191, DOI 10.1016/0890-6238(88)90021-4; Schuetz EG, 1998, MOL PHARMACOL, V54, P1113; Schwend T, 2006, BIOCHEM BIOPH RES CO, V343, P707, DOI 10.1016/j.bbrc.2006.02.164; Shakeel MK, 2010, ASIAN PAC J CANCER P, V11, P173; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sharpe RM, 2010, TOXICOL SCI, V114, P1, DOI 10.1093/toxsci/kfp299; Sheeler CQ, 2000, ENVIRON HEALTH PERSP, V108, P97, DOI 10.2307/3454506; Shibata A, 2000, EPIDEMIOL REV, V22, P239; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; Simpkins JW, 2008, MOL CELL ENDOCRINOL, V290, P51, DOI 10.1016/j.mce.2008.04.013; Singer CA, 1999, J NEUROSCI, V19, P2455; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.2307/3431154; Staudinger JL, 2003, DRUG METAB DISPOS, V31, P523, DOI 10.1124/dmd.31.5.523; Stouder C, 2011, REPRODUCTION, V141, P207, DOI 10.1530/REP-10-0400; Su SJ, 2005, BIOCHEM PHARMACOL, V69, P307, DOI 10.1016/j.bcp.2004.09.025; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sumner S, 2009, J APPL TOXICOL, V29, P703, DOI 10.1002/jat.1462; Surh J, 2006, INT J FOOD SCI NUTR, V57, P325, DOI 10.1080/09637480600802348; Szlinder-Richert J, 2008, MAR POLLUT BULL, V56, P927, DOI 10.1016/j.marpolbul.2008.01.029; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; Takao T, 1999, LIFE SCI, V65, P2351, DOI 10.1016/S0024-3205(99)00502-0; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tielemans E, 1999, FERTIL STERIL, V71, P690, DOI 10.1016/S0015-0282(98)00542-1; Tiido T, 2005, HUM REPROD, V20, P1903, DOI 10.1093/humrep/deh855; Tinwell H, 2007, TOXICOL SCI, V100, P54, DOI 10.1093/toxsci/kfm208; Tirado OM, 2003, BIOL REPROD, V68, P1437, DOI 10.1095/biolreprod.102.004937; Tirado OM, 2004, J ANDROL, V25, P84; Toft G, 2012, ENVIRON HEALTH PERSP, V120, P458, DOI 10.1289/ehp.1103552; TOMATIS L, 1992, CARCINOGENESIS, V13, P145, DOI 10.1093/carcin/13.2.145; Tonetti DA, 1997, J STEROID BIOCHEM, V62, P119, DOI 10.1016/S0960-0760(97)00034-4; Toran-Allerand CD, 2004, ENDOCRINOLOGY, V145, P1069, DOI 10.1210/en.2003-1462; TURUSOV VS, 1990, CANCER LETT, V55, P227, DOI 10.1016/0304-3835(90)90123-F; Tyl RW, 1999, REGUL TOXICOL PHARM, V30, P81, DOI 10.1006/rtph.1999.1343; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; Uchida H, 2003, NEUROCHEM INT, V42, P401, DOI 10.1016/S0197-0186(02)00135-3; Unfer V, 2004, FERTIL STERIL, V82, P145, DOI 10.1016/j.fertnstert.2003.11.041; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; van Ravenzwaay B, 2010, TOXICOL LETT, V198, P159, DOI 10.1016/j.toxlet.2010.06.009; Veeramachaneni DNR, 2007, REPROD TOXICOL, V23, P353, DOI 10.1016/j.reprotox.2007.01.001; Vina J, 2005, FEBS LETT, V579, P2541, DOI 10.1016/j.febslet.2005.03.090; Vine MF, 1996, BRIT MED J, V312, P506; Vine MF, 1996, FERTIL STERIL, V65, P835; Virtanen HE, 2012, INT J ANDROL, V35, P283, DOI 10.1111/j.1365-2605.2011.01233.x; Viso-Leon MC, 2004, PFLUG ARCH EUR J PHY, V449, P33, DOI 10.1007/s00424-004-1308-z; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; Voss C, 2005, TOXICOLOGY, V206, P359, DOI 10.1016/j.tox.2004.07.016; Wakai K, 1999, NUTR CANCER, V33, P139, DOI 10.1207/S15327914NC330204; Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063; Walsh DE, 2005, MOL CELL ENDOCRINOL, V230, P23, DOI 10.1016/j.mce.2004.11.006; Wang YL, 2006, J PHARMACEUT BIOMED, V40, P375, DOI 10.1016/j.jpba.2005.07.019; Waring RH, 2005, MOL CELL ENDOCRINOL, V244, P2, DOI 10.1016/j.mce.2005.02.007; Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625; Watanabe H, 2004, J MOL ENDOCRINOL, V33, P763, DOI 10.1677/jme.1.01529; Watanabe H, 2004, J MOL ENDOCRINOL, V33, P243, DOI 10.1677/jme.0.0330243; Watanabe H, 2003, J MOL ENDOCRINOL, V31, P487, DOI 10.1677/jme.0.0310487; WATSON CS, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432507; Welshons WV, 1999, TOXICOL IND HEALTH, V15, P12, DOI 10.1191/074823399678846745; WHORTON D, 1977, LANCET, V2, P1259; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Willett WC, 2001, J INTERN MED, V249, P395, DOI 10.1046/j.1365-2796.2001.00822.x; Willhite CC, 2008, J TOXICOL ENV HEAL B, V11, P69, DOI 10.1080/10937400701724303; Willoughby KN, 2005, ENDOCRINE, V26, P161, DOI 10.1385/ENDO:26:2:161; Wolff MS, 2000, CANCER EPIDEM BIOMAR, V9, P271; WOLFF MS, 1993, J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; Wolff MS, 2000, ENVIRON RES, V84, P151, DOI 10.1006/enrs.2000.4075; WORKING PK, 1985, TOXICOL APPL PHARM, V77, P133, DOI 10.1016/0041-008X(85)90274-1; WORKING PK, 1985, TOXICOL APPL PHARM, V77, P144, DOI 10.1016/0041-008X(85)90275-3; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Wu J, 2009, CHEM RES TOXICOL, V22, P668, DOI 10.1021/tx800406z; Wu JH, 2011, TOXICOL IND HEALTH, V27, P810, DOI 10.1177/0748233711399310; Wyde ME, 2003, MOL PHARMACOL, V64, P474, DOI 10.1124/mol.64.2.474; Xia YK, 2009, ENVIRON SCI TECHNOL, V43, P4567, DOI 10.1021/es9000642; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Yanagihara N, 2005, ENDOCRINOLOGY, V146, P265, DOI 10.1210/en.2004-0556; Yang JZ, 2000, TOXICOL SCI, V56, P374, DOI 10.1093/toxsci/56.2.374; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yoneda T, 2003, J NEUROCHEM, V87, P1499, DOI 10.1046/j.1471-4159.2003.02131.x; Yoshida M, 2011, TOXICOL PATHOL, V39, P823, DOI 10.1177/0192623311413785; Zama AM, 2010, FRONT NEUROENDOCRIN, V31, P420, DOI 10.1016/j.yfrne.2010.06.003; Zhang Y, 1999, J NUTR, V129, P399; Zhao Z, 2009, P NATL ACAD SCI USA, V106, P7221, DOI 10.1073/pnas.0812597106; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zheng JB, 1999, J STEROID BIOCHEM, V68, P65, DOI 10.1016/S0960-0760(98)00161-7; Zheng JB, 1999, EUR J PHARMACOL, V368, P95, DOI 10.1016/S0014-2999(99)00012-6; Zhou J, 2010, CHEMOSPHERE, V79, P595, DOI 10.1016/j.chemosphere.2010.01.052; Zhu P, 2004, CELL CYCLE, V3, P1240, DOI 10.4161/cc.3.10.1195; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-05653972TAYLOR &amp; FRANCIS INCPHILADELPHIA520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USAJ TOXICOL ENV HEAL BAPR 3Discipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; ToxicologyAF4CW</notes>
    <keywords>17-BETA-ESTRADIOL; ALPHA; BETA; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast cancer; BREAST-CANCER; BREAST-CANCER RISK; CANCER; CARCINOGENESIS; CELL; CELL-CYCLE; CHEMICALS; CONSTITUTIVE-ANDROSTANE RECEPTOR; COUPLED NEUROSTEROID RECEPTOR; CYCLE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Environmental estrogen; ENVIRONMENTAL ESTROGENS; ER alpha; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; ESTROGENS; EXPOSED IN-UTERO; FOOD; genistein; HUMAN-DISEASE; INHALED METHYL-CHLORIDE; INITIATED SIGNALING PATHWAYS; Male; MALE REPRODUCTIVE-TRACT; mechanism; MECHANISMS; ORPHAN NUCLEAR RECEPTOR; phthalate; Phthalates; Phytoestrogen; PHYTOESTROGENS; PREGNANE-X-RECEPTOR; Proteomics; RECEPTOR; Reproduction; RISK; SPRAGUE-DAWLEY RATS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>127</startpage>
    <endpage>174</endpage>
    <journalfull>Journal of Toxicology and Environmental Health-Part B-Critical Reviews</journalfull>
    <issue>3</issue>
    <volume>17</volume>
    <abstract>Endocrine-disrupting chemicals (EDC), including phthalates, bisphenol A (BPA), phytoestrogens such as genistein and daidzein, dichlorodiphenyltrichloroethane (DDT), and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), are associated with a variety of adverse health effects in organisms or progeny by altering the endocrine system. Environmental estrogens, including BPA, phthalates, and phytoestrogens, are the most extensively studied and are considered to mimic the actions of endogenous estrogen, 17 beta-estradiol (E2). Diverse modes of action of estrogen and estrogen receptors (ER alpha and ER beta) have been described, but the mode of action of estrogenic EDC is postulated to be more complex and needs to be more clearly elucidated. This review examines the adverse effects of estrogenic EDC on male or female reproductive systems and molecular mechanisms underlying EDC effects that modulate ER-mediated signaling. Mechanisms of action for estrogenic EDC may involve both ER-dependent and ER-independent pathways. Recent findings from systems toxicology of examining estrogenic EDC are also discussed</abstract>
    <url>WOS:000334660000001</url>
    <isbnorissn>1093-7404</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>13</id>
    <title>GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17 beta-estradiol in triple-negative breast cancer cells</title>
    <authors>Yu,T.H.; Liu,M.R.; Luo,H.J.; Wu,C.Y.; Tang,X.; Tang,S.F.; Hu,P.; Yan,Y.Z.; Wang,Z.L.; Tu,G.</authors>
    <availability>[Yu, Tenghua; Wu, Chengyi; Yan, Yuzhao; Tu, Gang] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine &amp; Breast Surg, Chongqing 400016, Peoples R China. [Liu, Manran; Tang, Xi; Tang, Shifu; Hu, Ping] Chongqing Med Univ, Chinese Minist Educ, Key Lab Lab Med Diagnost, Chongqing 400016, Peoples R China. [Luo, Haojun] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast &amp; Thyroid Surg, Chongqing 400010, Peoples R China. [Wang, Zhiliang] Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet &amp; Gynecol, Chongqing 400010, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishArticleTu, G (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine &amp; Breast Surg, 1 You Yi Rd, Chongqing 400016, Peoples R Chinatugang68@126.comAghili Mahdi, 2013, Acta Med Iran, V51, P560; Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2008, ENVIRON HEALTH PERSP, V116, P1648, DOI 10.1289/ehp.11297; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Anders CK, 2010, CLIN CANCER RES, V16, P4702, DOI 10.1158/1078-0432.CCR-10-0939; Ariazi EA, 2010, CANCER RES, V70, P1184, DOI 10.1158/0008-5472.CAN-09-3068; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Broselid S, 2013, CLIN CANCER RES, V19, P1681, DOI 10.1158/1078-0432.CCR-12-2376; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Fujiwara S, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-35; Harris LN, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1622; Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1; Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Lonning PE, 2007, HEMATOL ONCOL CLIN N, V21, P223, DOI 10.1016/j.hoc.2007.03.002; Luo Haojun, 2014, Endocr Relat Cancer, V21, P355, DOI 10.1530/ERC-13-0237; Luo HJ, 2011, J BREAST CANCER, V14, P185, DOI 10.4048/jbc.2011.14.3.185; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Madeo A, 2010, CANCER RES, V70, P6036, DOI 10.1158/0008-5472.CAN-10-0408; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Marie K., 2009, CANCER RES, V69, p128S; Milde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655; Mo ZQ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3581; Nofech-Mozes S, 2009, BREAST CANCER RES TR, V118, P131, DOI 10.1007/s10549-008-0295-8; Ohshiro K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030725; Pandey DP, 2009, EMBO J, V28, P523, DOI 10.1038/emboj.2008.304; Powles TJ, 2007, J NATL CANCER I, V99, P283, DOI 10.1093/jnci/djk050; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Siziopikou KP, 2006, BREAST J, V12, P360, DOI 10.1111/j.1075-122X.2006.00276.x; Steiman J, 2013, AM J SURG, V206, P698, DOI 10.1016/j.amjsurg.2013.07.014; Telli Melinda L, 2010, Clin Adv Hematol Oncol, V8, P629; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; Tu G, 2009, TECHNOL CANCER RES T, V8, P231; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Wang DF, 2010, ENDOCRINE, V38, P29, DOI 10.1007/s12020-010-9363-z; Wang LY, 2013, MOL ONCOL, V7, P1116, DOI 10.1016/j.molonc.2013.08.007450PERGAMON-ELSEVIER SCIENCE LTDOXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDJ STEROID BIOCHEMSEPDiscipline: Biochemistry &amp; Molecular Biology; Endocrinology &amp; MetabolismAO6MF</notes>
    <keywords>17-BETA-ESTRADIOL; ACTIVATION; apoptosis; BIOLOGY; BISPHENOL-A; BREAST-CANCER; CANCER; CELLS; CLINICOPATHOLOGICAL VARIABLES; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Estrogen/GPER/ERK signaling; EXPRESSION; GENE-EXPRESSION CHANGES; GPER; GPR30; GROWTH; GROWTH-FACTOR RECEPTOR; IN-VITRO; inhibition; LINES; OVARIAN-CANCER; PROGRESSION; proliferation; PROTEIN-COUPLED RECEPTOR; RECEPTOR; TARGETED THERAPY; Triple-negative breast cancer; TUMOR PROGRESSION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>392</startpage>
    <endpage>403</endpage>
    <journalfull>Journal of Steroid Biochemistry and Molecular Biology</journalfull>
    <volume>143</volume>
    <abstract>Triple-negative breast cancer (TNBC) is an aggressive breast cancer with a generally poor prognosis. Due to lack of specific targets for its treatment, an efficient therapy is needed. G protein-coupled estrogen receptor (GPER), a novel estrogen receptor, has been reported to be expressed in TNBC tissues. In this study, we investigated the effects of blocking non-genomic signaling mediated by the estrogen/GPER pathway on cell viability and motility in the TNBC cells. GPER was strongly expressed in the TNBC cell lines MDA-MB-468 and MDA-MB-436, and the estrogen-mediated non-genomic ERK signaling activated by GPER was involved in cell viability and motility of TNBC cells. Treatment with 17 beta-estradiol (E2), the GPER-specific agonist G-1 and tamoxifen (TAM) led to rapid activation of p-ERK1/2, but not p-Akt. Moreover, estrogen/GPER/ERK signaling was involved in increasing cell growth, survival, and migration/invasion by upregulating expression of cyclinA, cyclinD1, Bcl-2, and c-fos associated with the cell cycle, proliferation, and apoptosis. Immunohistochemical analysis of TNBC specimens showed a significantly different staining of p-ERK1/2 between GPER-positive tissues (58/66, 87.9%) and GPER-negative tissues (13/30, 43.3%). The positivity of GPER and p-ERK1/2 displayed a strong association with large tumor size and poor clinical stage, indicating that GPER/ERK signaling might also contribute to tumor progression in TNBC patients which corresponded with in vitro experimental data. Our findings suggest that inhibition of estrogen/GPER/ERK signaling represents a novel targeted therapy in TNBC. (C) 2014 Elsevier Ltd. All rights reserved</abstract>
    <url>WOS:000341465500043</url>
    <isbnorissn>0960-0760</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>167</id>
    <title>Association between precocious puberty and some endocrine disruptors in human plasma</title>
    <authors>Yum,T.; Lee,S.; Kim,Y.</authors>
    <availability>[Yum, Taewoo; Kim, Yunje] Korea Inst Sci &amp; Technol, Seoul 136791, South Korea. [Lee, Sanghouck] Hoseo Grad Sch Venture, Dept Hlth Environm, Seoul, South Korea.</availability>
    <date>2013</date>
    <notes>JEnglishArticleKim, Y (reprint author), Korea Inst Sci &amp; Technol, Hwarangno 14 Gil 5, Seoul 136791, South Koreayjkim@kist.re.krAGARWAL DK, 1986, ENVIRON HEALTH PERSP, V65, P343, DOI 10.2307/3430202; Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491; Cao Y, 2009, J EXPO SCI ENV EPID, V19, P223, DOI 10.1038/jes.2008.44; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Durmaz E, 2010, PEDIATRICS, V125, pE122, DOI 10.1542/peds.2009-0724; Folmar LC, 2002, AQUAT TOXICOL, V60, P101, DOI 10.1016/S0166-445X(01)00276-4; Goodman MT, 1997, AM J EPIDEMIOL, V146, P294; Han E.J., 2008, ANAL SCI TECHNOL, V21, P375; Iwasaki M, 2009, BREAST CANCER RES TR, V116, P401, DOI 10.1007/s10549-008-0168-1; Keys DA, 1999, TOXICOL SCI, V49, P172, DOI 10.1093/toxsci/49.2.172; LAZEAR NR, 1995, ADV MATER PROCESS, V147, P43; Lee S.W., 2009, J KOR SOC PEDIAT END, V14, P154; Lomenick JP, 2010, J PEDIATR-US, V156, P221, DOI 10.1016/j.jpeds.2009.09.047; Mielke H, 2009, TOXICOL LETT, V190, P32, DOI 10.1016/j.toxlet.2009.06.861; Park MJ, 2006, KOREAN J PEDIAT, V49, P610; PARMAR D, 1987, TOXICOL LETT, V36, P297, DOI 10.1016/0378-4274(87)90199-8; SHIOTA K, 1985, ARCH TOXICOL, V56, P263, DOI 10.1007/BF00295165; The International Conference on Harmonisation (ICH), 2005, VAL AN PROC TEXT MET; Wolff MS, 2008, ENVIRON RES, V107, P393, DOI 10.1016/j.envres.2008.03.006; Xu WH, 2004, BRIT MED J, V328, P1285, DOI 10.1136/bmj.38093.646215.AE; Yang M.H., 2004, RES END POINTS END D, V362, P1211TAYLOR &amp; FRANCIS INCPHILADELPHIA325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USAJ ENVIRON SCI HEAL ADiscipline: Engineering; Environmental Sciences &amp; Ecology273LB</notes>
    <keywords>ASSOCIATION; bisphenol A; BISPHENOL-A; BLOOD; BPA; breast; breast cancer; BREAST-CANCER; CANCER; DI(2-ETHYLHEXYL) PHTHALATE; DIBUTYL PHTHALATE; EDCs; EDCs (Endocrine-disrupting chemicals); END-POINTS; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; ENDOMETRIAL CANCER; genistein; HEALTH; Hormones; HUMAN-PLASMA; ISOFLAVONE; ISOFLAVONES; n-nonyl phenol (n-NP); PERFORMANCE; phenol; phthalate; Phthalates; precocious puberty; RATS; RISK; SOY; t-octylphenol (t-OP)</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>912</startpage>
    <endpage>917</endpage>
    <journalfull>Journal of Environmental Science and Health Part A-Toxic/Hazardous Substances &amp; Environmental Engineering</journalfull>
    <issue>8</issue>
    <volume>48</volume>
    <abstract>Endocrine disruptors that mimic natural hormones and inhibit the action of hormones have recently attracted attention as one of the main cause of precocious puberty. In this study, the levels of 7 EDCs and 3 isoflavones that exhibit estrogen-like actions were measured in the plasma of precocious puberty patients and compared to control subjects to determine if there is an association between the onset of precocious puberty and the levels of EDCs in the plasma. EDCs examined in this study were bisphenol-A (BPA), di(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), mono(2-ethylhexyl) phthalate (MEHP), monobutyl phthalate (MBP), n-nonyl phenol (n-NP), and t-octylphenol (t-OP), and whereas the isoflavones were equol, genistein, and diadzein. The level ofMBP in the plasma of patients was 1.3 times higher than that of the controls. The levels of t-OP and n-NP in the plasma of patients were respectively 1.15 and 1.2 times higher than those of the control group. Finally, the levels of the diadzein, equol and genistein were 1.37, 1.3 and 2.67 times higher than those of the control group, and genistein showed a statistically meaningful result (P = 0.0008). The results suggest that these six substances (MBP, t-OP, n-NP, daidzein, equol, and genistein) have an effect on precocious puberty</abstract>
    <url>WOS:000328535200010</url>
    <isbnorissn>1093-4529</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>205</id>
    <title>In Vitro Estrogenicity of Dental Resin Sealants</title>
    <authors>Zampeli,D.; Papagiannoulis,L.; Eliades,G.; Pratsinis,H.; Kletsas,D.; Eliades,T.</authors>
    <availability>[Eliades, Theodore] Univ Zurich, Fac Med, Ctr Dent Med, Dept Orthodont &amp; Paediat Dent, CH-8006 Zurich, Switzerland. [Papagiannoulis, Liza] Univ Athens, Dept Pediat Dent, Sch Dent, Athens, Greece. [Eliades, George] Univ Athens, Sch Dent, Dept Dent Biomat, Athens, Greece. [Kletsas, Dimitris] Natl Ctr Sci Res Demokritos, Inst Biol, Lab Cell Proliferat &amp; Ageing, Athens, Greece.</availability>
    <date>2012</date>
    <notes>JEnglishArticleEliades, T (reprint author), Univ Zurich, Fac Med, Ctr Dent Med, Dept Orthodont &amp; Paediat Dent, CH-8006 Zurich, Switzerlandtheodore.eliades@zzm.uzh.chAl-Hiyasat AS, 2004, EUR J ORAL SCI, V112, P267, DOI 10.1111/j.1600-0722.2004.00136.x; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8451; American Dental Association, BISPH A DENT MAT; [Anonymous], 2006, NTP CERHR REP REPR D; Arenholt-Bindslev D, 1999, Clin Oral Investig, V3, P120, DOI 10.1007/s007840050089; Azarpazhooh A, 2008, J CAN DENT ASSOC, V74, P171; Beauchamp J, 2008, J AM DENT ASSOC, V139, P257; Center for the Evaluation of Risks of Human Reproduction, 2008, NTP CERHR MON POT HU; Eliades T, 2007, EUR J ORTHODONT, V29, P404, DOI 10.1093/ejo/cjm040; Eliades T, 2007, AM J ORTHOD DENTOFAC, V131, P72, DOI 10.1016/j.ajodo.2006.08.013; Elsby R, 2001, J PHARMACOL EXP THER, V296, P329; Gioka C, 2009, DENT MATER, V25, P376, DOI 10.1016/j.dental.2008.08.010; Hamid A, 1997, DENT MATER, V13, P98; Joskow R, 2006, J AM DENT ASSOC, V137, P353; KLETSAS D, 1992, CELL BIOL INT REP, V16, P103, DOI 10.1016/S0309-1651(06)80104-9; Lewis J B, 1999, Clin Oral Investig, V3, P107, DOI 10.1007/s007840050087; Matasa CG, 2004, RISK MANAGEMENT ORTH, P113; Nathanson D, 1997, J AM DENT ASSOC, V128, P1517; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Schafer TE, 1999, J BIOMED MATER RES, V45, P192, DOI 10.1002/(SICI)1097-4636(19990605)45:3&lt;192::AID-JBM5&gt;3.0.CO;2-A; Schmalz G, 1999, Clin Oral Investig, V3, P114, DOI 10.1007/s007840050088; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Simonsen Richard J, 2002, Pediatr Dent, V24, P393; Soderholm KJ, 1999, J AM DENT ASSOC, V130, P201; SOTO AM, 1986, CANCER RES, V46, P2271; Tarumi H, 2000, J DENT RES, V79, P1838; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005; Wada H, 2004, J DENT RES, V83, P222; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Yoon TH, 2002, J ORAL REHABIL, V29, P1165, DOI 10.1046/j.1365-2842.2002.00970.x; Zoeller RT, 2005, MOL CELL ENDOCRINOL, V242, P10, DOI 10.1016/j.mce.2005.07.006340AMER ACAD PEDIATRIC DENTISTRYCHICAGO211 E CHICAGO AVENUE SUITE 1036, CHICAGO, IL 60611-2616 USAPEDIATR DENTJUL-AUGDiscipline: Dentistry, Oral Surgery &amp; Medicine; Pediatrics986FP</notes>
    <keywords>ADHESIVE RESINS; ASSAY; ASSOCIATION; BISPHENOL-A; breast; breast cancer; breast cancer cells; BREAST-CANCER; CANCER; CANCER CELLS; CANCER-CELLS; CELL; CELLS; CHEMICALS; COMPONENTS; COMPOSITES; DENTAL MATERIALS/BIOMATERIALS; DENTAL TECHNOLOGY; DENTISTRY; Estrogen; estrogenic activity; Estrogenicity; EXPOSURE; FISSURE SEALANTS; HEALTH; HEALTH ADMINISTRATION; HUMAN HEALTH; HUMAN-REPRODUCTION; In vitro; IN-VITRO; INDUCTION; LINE; MECHANISMS; proliferation; Reproduction; RISK; SAMPLES; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>312</startpage>
    <endpage>316</endpage>
    <journalfull>Pediatric Dentistry</journalfull>
    <issue>4</issue>
    <volume>34</volume>
    <abstract>Purpose: This investigation assessed the estrogenic action of various types of sealants. Methods: Three light-cured sealants (Denton Clear, Delton Opaque, Ultroseal XT Plus) were applied in polyethylene molds (empty set:10mm, h:2mm, n:8) and photopolymerized (40 seconds, halogen bulb unit, standard mode 650 mW/cm(2) intensity). All specimens were immersed in normal saline for 1 week at 37 degrees C. Samples of eluents at concentrations of 5% and 10% (volume per volume) were tested for estrogenicity by measuring their effect on the proliferation of the estrogen responsive MCF-7 breast cancer cells. In addition, an estrogen insensitive cell line was used as a control (MDA-M8-231) to exclude a possible cytostatic effect of the tested materials. All assays were repeated 4 times, and results analyzed with a 2-way analysis of variance and Tukey's test at the 0.05 level. Results: Eluents of the sealants tested at concentrations of 5% and 10% did not possess estrogenicity, except for the eluent of one sealant (Delton Opaque) at concentration 10%, which caused on induction of the proliferation rate of the MCF-7 cells. Conclusions: Eluents of sealants tested at a concentration of 5% had no estrogenic activity. The eluent of Delton Opaque at a concentration of 10% possessed some estrogenic activity. (Pediatr Dent 2012;34:312-6) Received October 6, 2010 vertical bar Lost Revision February 11, 2011 vertical bar Accepted February 21, 2011</abstract>
    <url>WOS:000307327000007</url>
    <isbnorissn>0164-1263</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>249</id>
    <title>Effect of bisphenol A on the EGFR-STAT3 pathway in MCF-7 breast cancer cells</title>
    <authors>Zhang,W.; Fang,Y.Q.; Shi,X.; Zhang,M.L.; Wang,X.Q.; Tan,Y.</authors>
    <availability>[Zhang, Wei; Tan, Yan] Jilin Univ, Res Ctr, Clin Hosp 1, Changchun 130021, Jilin, Peoples R China. [Fang, Yanqiu; Tan, Yan] Jilin Prov Hosp, Dept Tumor Biol Therapy, Changchun 130021, Jilin, Peoples R China. [Wang, Xiaoqi] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Div Hematol Oncol, New York, NY USA. [Zhang, Minglei] Jilin Univ, China Japan Union Hosp, Dept Orthopaed, Changchun 130033, Jilin, Peoples R China. [Shi, Xu] Jilin Univ, Clin Hosp 1, Virus &amp; AIDS Res Ctr, Changchun 130021, Jilin, Peoples R China. [Zhang, Wei] Jilin Univ, Coll Nursing, Dept Obstet &amp; Gynecol, Changchun 130021, Jilin, Peoples R China.</availability>
    <date>2012</date>
    <notes>JEnglishArticleTan, Y (reprint author), Jilin Univ, Res Ctr, Clin Hosp 1, Changchun 130021, Jilin, Peoples R Chinaxw2200@columbia.edu; tanyan49@hotmail.comAriazi EA, 2006, CURR TOP MED CHEM, V6, P203; Berclaz G, 2001, INT J ONCOL, V19, P1155; Canesi L, 2005, AQUAT TOXICOL, V71, P73, DOI 10.1016/j.aquatox.2004.10.011; Canesi L, 2004, GEN COMP ENDOCR, V38, P58; Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Ellis AG, 2001, J CHROMATOGR B, V754, P193, DOI 10.1016/S0378-4347(00)00606-X; El Marjou A, 2000, CARCINOGENESIS, V21, P2211; Gusterson BA, 2009, LANCET ONCOL, V10, P522, DOI 10.1016/S1470-2045(09)70034-8; Hatake Kiyohiko, 2007, Breast Cancer, V14, P132, DOI 10.2325/jbcs.977; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; JAATTELA M, 1995, ONCOGENE, V10, P2297; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Le HH, 2008, TOXICOL LETT, V176, P149, DOI 10.1016/j.toxiet.2007.11.001; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; MADOUX F, 2010, MODULATORS STAT TRAN, V16, P2; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj/onc/1205260; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Russo J, 2002, ENVIRON MOL MUTAGEN, V39, P254, DOI 10.1002/em.10052; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925; Samuelsen M, 2001, CELL BIOL TOXICOL, V17, P139, DOI 10.1023/A:1011974012602; SAVIS DL, 1995, SCI AM, V273, P167; Shao H, 2003, CANCER RES, V63, P3923; Suzuki T, 2004, ENVIRON SCI TECHNOL, V38, P2389, DOI 10.1021/es030576z; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Zhang YG, 2008, INT J ONCOL, V33, P595, DOI 10.3892/ijo_00000045330SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEMOL MED REPJANDiscipline: Oncology; Research &amp; Experimental Medicine854HX</notes>
    <keywords>ACTIVATION; ASSAY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; breast cancer; breast cancer cells; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CANCER CELLS; CANCER-CELL-PROLIFERATION; CANCER-CELLS; CARCINOGENESIS; CELL; cell growth; Cell proliferation; CELL-PROLIFERATION; CELLS; Cytotoxicity; EGFR; Estrogen; EXPRESSION; GENE; gene expression; GENE-EXPRESSION; GENES; GROWTH; GROWTH-FACTOR RECEPTOR; HEALTH; inhibition; INHIBITOR; oncology; PHYTOESTROGENS; proliferation; RNA interfrence; STAT3; TYRPHOSTIN AG1478; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>41</startpage>
    <endpage>47</endpage>
    <journalfull>Molecular Medicine Reports</journalfull>
    <issue>1</issue>
    <volume>5</volume>
    <abstract>The aim of this study was to explore the effect of bisphenol A (BPA) on the EGFR-STAT3 pathway in breast cancer. We applied 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) cytotoxicity assay to the analysis of the responsiveness of MCF-7 cells to BPA. Gene expression was assayed at the transcriptional and translational levels by reverse transcription-PCR and Western blotting. We explored the effects of BPA on MCF-7 cell proliferation through inhibition of the related genes, STAT3, using RNA interference, and EGFR, using its inhibitor AG1478. The optimal concentration and time point of BPA-induced proliferation in MCF-7 cells are 1 mu M and 24 h, respectively. BPA significantly increased the expression of STAT3 at a concentration of 1 mu M following treatment for 48 h and the expression of STAT3 was down-regulated after blocking EGFR. When STAT3 was blocked in MCF-7 cells, BPA did not appear to induce cell proliferation. Treatment with BPA (1 mu M) in the presence of AG1478 for 48 h resulted in the stimulation of cell growth in MCF-7 cells, similar to that of the BPA alone treatment. BPA increases STAT3 expression, which is a major factor in the pathway of BPA-induced proliferation, and STAT3 activation contributes to BPA-induced breast cancer cell proliferation. However, EGFR mediates negative signaling for BPA-induced breast cancer cell proliferation</abstract>
    <url>WOS:000297486700009</url>
    <isbnorissn>1791-2997</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>81</id>
    <title>Known and emerging factors modulating estrogenic effects of endocrine-disrupting chemicals</title>
    <authors>Zhang,W.L.; Luo,Y.; Zhang,L.; Cai,Q.; Pan,X.J.</authors>
    <availability>[Zhang, Wanglong; Luo, Yu; Cai, Qian; Pan, Xuejun] Kunming Univ Sci &amp; Technol, Fac Environm Sci &amp; Engn, Kunming 650500, Peoples R China. [Zhang, Li] Kunming Univ Sci &amp; Technol, Fac Life Sci &amp; Technol, Kunming 650500, Peoples R China.</availability>
    <date>2014</date>
    <notes>JEnglishReviewPan, XJ (reprint author), Kunming Univ Sci &amp; Technol, Fac Environm Sci &amp; Engn, Kunming 650500, Peoples R Chinaxjpan@kmust.edu.cnAcconcia F, 2005, MOL BIOL CELL, V16, P231; Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018; Ahmed S, 2009, TOXICOL SCI, V111, P254, DOI 10.1093/toxsci/kfp144; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; ALI S, 1993, EMBO J, V12, P1153; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; Arukwe A, 2005, ENVIRON SCI TECHNOL, V39, P9791, DOI 10.1021/es0509937; Arukwe A, 2008, CELL BIOL TOXICOL, V24, P527, DOI 10.1007/s10565-008-9069-7; Arukwe A, 2001, MAR POLLUT BULL, V42, P643, DOI 10.1016/S0025-326X(01)00062-5; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Azuma K, 2004, FEBS LETT, V577, P339, DOI 10.1016/j.febslet.2004.10.025; Bang DY, 2012, COMPR REV FOOD SCI F, V11, P453, DOI 10.1111/j.1541-4337.2012.00197.x; BERGMAN A, 2013, STATE SCI ENDOCRINE; Boonyaratanakornkit V, 2011, STEROIDS, V76, P877, DOI 10.1016/j.steroids.2011.02.017; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Boverhof DR, 2006, MOL PHARMACOL, V69, P1599, DOI 10.1124/mol.105.019638; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cai JL, 2011, TOXICOLOGY, V287, P21, DOI 10.1016/j.tox.2011.05.010; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chaffin CL, 1996, BIOL REPROD, V55, P62, DOI 10.1095/biolreprod55.1.62; Cheshenko K, 2008, GEN COMP ENDOCR, V155, P31, DOI 10.1016/j.ygeen.2007.03.005; Deblois G, 2003, J STEROID BIOCHEM, V85, P123, DOI 10.1016/S0960-0760(03)00225-5; Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109; Deng H, 2010, ONCOL REP, V24, P171, DOI 10.3892/or_00000842; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dickerson SM, 2007, REV ENDOCR METAB DIS, V8, P143, DOI 10.1007/s11154-007-9048-y; Diotel Nicolas, 2011, Front Neurosci, V5, P137, DOI 10.3389/fnins.2011.00137; Dittmar KD, 1996, J BIOL CHEM, V271, P12833; Divekar SD, 2011, CANCER RES, V71, P1658, DOI 10.1158/0008-5472.CAN-10-1899; Dong S, 2011, ENVIRON POLLUT, V159, P212, DOI 10.1016/j.envpol.2010.09.004; DONLEY C, 2013, ONCOGENE, DOI DOI 10.1038/0NC.2013.306; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Etique N, 2007, INT J ONCOL, V31, P1509; Flint APF, 2002, DOMEST ANIM ENDOCRIN, V23, P13, DOI 10.1016/S0739-7240(02)00141-8; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fogarty EA, 2012, MOL CELL ENDOCRINOL, V348, P331, DOI 10.1016/j.mce.2011.09.032; Gao F, 2011, ENDOCRINOLOGY, V152, P1434, DOI 10.1210/en.2010-1368; Gao H, 1999, CHEM REV, V99, P723, DOI 10.1021/cr980018g; Garcia-Arencibia M, 2005, J STEROID BIOCHEM, V94, P1, DOI 10.1016/j.jsbmb.2004.12.020; Guo RX, 2006, J STEROID BIOCHEM, V99, P9, DOI 10.1016/j.jsbmb.2005.11.013; Guo XM, 2005, J BIOL CHEM, V280, P19704, DOI 10.1074/jbc.M501244200; Gurevich I, 2007, TOXICOL APPL PHARM, V223, P288, DOI 10.1016/j.taap.2007.05.019; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Hayashi Hitomi, 2007, Journal of Toxicological Sciences, V32, P91, DOI 10.2131/jts.32.91; Holmes KA, 2012, P NATL ACAD SCI USA, V109, P2748, DOI 10.1073/pnas.1018863108; Huang B, 2013, ENVIRON INT, V59, P262, DOI 10.1016/j.envint.2013.06.018; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Hutchinson TH, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI 10.1289/ehp.8062; Inoshita H, 2003, J MOL ENDOCRINOL, V31, P551, DOI 10.1677/jme.0.0310551; Jeng YJ, 2011, ENVIRON HEALTH PERSP, V119, P104, DOI 10.1289/ehp.1002512; Jiang HP, 2008, J STEROID BIOCHEM, V112, P20, DOI 10.1016/j.jsbmb.2008.07.004; Kang K, 2009, MOL CELLS, V27, P351, DOI 10.1007/s10059-009-0045-8; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Kekatpure VD, 2009, J BIOL CHEM, V284, P7436, DOI 10.1074/jbc.M808999200; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim JY, 2005, BIOCHEM BIOPH RES CO, V333, P1234, DOI 10.1016/j.bbrc.2005.06.038; Kim SH, 2009, ANN NY ACAD SCI, V1171, P495, DOI 10.1111/j.1749-6632.2009.04899.x; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Leclercq G, 2012, STEROIDS, V77, P924, DOI 10.1016/j.steroids.2012.01.012; Lee YJ, 2013, CHEMOSPHERE, V90, P1597, DOI 10.1016/j.chemosphere.2012.08.033; Lee YM, 2006, BIOCHEM BIOPH RES CO, V345, P894, DOI 10.1016/j.bbrc.2006.04.137; Levin ER, 2009, TRENDS ENDOCRIN MET, V20, P477, DOI 10.1016/j.tem.2009.06.009; Levin ER, 2008, AM J PHYSIOL-REG I, V295, pR1425, DOI 10.1152/ajpregu.90605.2008; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Li Y, 2013, ENVIRON HEALTH PERSP, V121, P459, DOI 10.1289/ehp.1205951; Li ZH, 2012, ENVIRON HEALTH PERSP, V120, P541, DOI 10.1289/ehp.1104051; Lin SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009013; Liu JL, 2011, ENVIRON POLLUT, V159, P2815, DOI 10.1016/j.envpol.2011.05.013; Liu JL, 2012, ENVIRON POLLUT, V162, P325, DOI 10.1016/j.envpol.2011.11.036; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; Liu ZW, 2008, TOXICOL APPL PHARM, V228, P286, DOI 10.1016/j.taap.2007.12.017; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Meier S, 2007, AQUAT TOXICOL, V81, P207, DOI 10.1016/j.aquatox.2006.12.002; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ortiz-Zarragoitia M, 2005, COMP BIOCHEM PHYS C, V141, P133, DOI 10.1016/j.cca.2005.05.010; Papaconstantinou AD, 2001, TOXICOL SCI, V63, P173, DOI 10.1093/toxsci/63.2.173; Papoutsi Z, 2009, J MOL ENDOCRINOL, V43, P65, DOI 10.1677/JME-08-0177; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; Petrovic M, 2004, ANAL BIOANAL CHEM, V378, P549, DOI 10.1007/s00216-003-2184-7; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Quesada I, 2002, FASEB J, V16, P1671, DOI 10.1096/fj.01-02-0313fje; Radice S, 2006, LIFE SCI, V78, P2716, DOI 10.1016/j.lfs.2005.10.008; Ramachandran B, 2011, TOXICOL LETT, V202, P75, DOI 10.1016/j.toxlet.2010.12.022; Razandi M, 2010, MOL CELL BIOL, V30, P3249, DOI 10.1128/MCB.01354-09; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Salian S, 2009, LIFE SCI, V85, P11, DOI 10.1016/j.lfs.2009.04.005; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; Sanderson JT, 2006, TOXICOL SCI, V94, P3, DOI 10.1093/toxsci/kfl051; Schodin DJ, 1995, J BIOL CHEM, V270, P31163; Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008; Seng D, 2001, N-S ARCH PHARMACOL, V363, pR144; Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n; Shanthanagouda AH, 2013, COMP BIOCHEM PHYS C, V157, P162, DOI 10.1016/j.cbpc.2012.11.004; Sheng ZG, 2013, TOXICOL APPL PHARM, V267, P88, DOI 10.1016/j.taap.2012.12.014; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shyu C, 2011, TOXICOL APPL PHARM, V250, P322, DOI 10.1016/j.taap.2010.11.005; Simpson NE, 2012, MOL ENDOCRINOL, V26, P194, DOI 10.1210/me.2011-1068; Smith DF, 2008, MOL ENDOCRINOL, V22, P2229, DOI 10.1210/me.2008-0089; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; Song RXD, 2006, BIOL REPROD, V75, P9, DOI 10.1095/biolreprod.105.050070; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Tellez-Banuelos MC, 2011, FISH SHELLFISH IMMUN, V31, P1291, DOI 10.1016/j.fsi.2011.10.003; Tetel MJ, 2009, J NEUROENDOCRINOL, V21, P229, DOI 10.1111/j.1365-2826.2009.01827.x; Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165; Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2; Tong JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015408; Tong SK, 2003, J STEROID BIOCHEM, V86, P381, DOI 10.1016/S0960-0760(03)00347-9; Wang JJ, 2010, COMP BIOCHEM PHYS C, V152, P313, DOI 10.1016/j.cbpc.2010.05.007; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Weatherman RV, 2001, CHEM BIOL, V8, P427, DOI 10.1016/S1074-5521(01)00025-4; Wong TT, 2006, BIOL REPROD, V74, P857, DOI 10.1095/biolreprod.105.045351; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Xie H, 2011, J BONE MINER RES, V26, P156, DOI 10.1002/jbmr.169; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu X, 2007, NEUROSCI RES, V58, P149, DOI 10.1016/j.neures.2007.02.011; Zhang DP, 2006, COMP BIOCHEM PHYS A, V144, P306, DOI 10.1016/j.cbpa.2006.01.025; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458; Zhang ZP, 2007, MOL CELL ENDOCRINOL, V264, P128, DOI 10.1016/j.mce.2006.11.002; Zou Y, 2009, FEBS LETT, V583, P1368, DOI 10.1016/j.febslet.2009.03.0471411CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESSOTTAWA65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADAENVIRON REVDiscipline: Environmental Sciences &amp; EcologyAB9GO</notes>
    <keywords>ACTIVATION; ALPHA GENE-EXPRESSION; ARYL-HYDROCARBON RECEPTOR; BISPHENOL-A; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; CANCER; CELL; CELLS; CHEMICALS; EDCs; ENDOCRINE; Endocrine disrupting chemicals; Endocrine-disrupting chemicals; Estrogen; Estrogen receptor; Estrogen receptors; ESTROGEN-RECEPTOR; estrogenic effects; FOOD; GAMMA ERR-GAMMA; genomic effects; GPER; HEAT-SHOCK-PROTEIN; LIGAND-INDEPENDENT ACTIVATION; mechanism; MECHANISMS; MEDIATED TRANSCRIPTIONAL ACTIVATION; NF-KAPPA-B; nongenomic effects; PROTEIN; RECEPTOR; REGULATORY STAR PROTEIN; RESPONSES; SIGNALING PATHWAY; SIGNALING PATHWAYS; toxicology; xenoestrogen; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>87</startpage>
    <endpage>98</endpage>
    <journalfull>Environmental Reviews</journalfull>
    <issue>1</issue>
    <volume>22</volume>
    <abstract>A variety of endocrine-disrupting chemicals (EDCs) have estrogenic effects and are termed xenoestrogens (XEs). The genomic pathway mediated by estrogen receptors (ERs) has been considered the major explanation for the estrogenic effects elicited by XEs. Presently, nongenomic pathways have achieved considerably more attention because the genomic pathways cannot fully elucidate many biological and physiological responses. Genomic and nongenomic pathways act either separately or cooperatively. XEs activate a variety of signaling pathways and downstream kinases, which in turn alter the posttranslational modification and activation of ERs. Classical ERs and their splice variants reside at the membrane and mediate rapid effects cooperatively with G protein-coupled estrogen receptor 1 (GPER), G protein, and many other signaling molecules. GPER seems more effective in mediating the synthetic chemical-induced effects. There are also feedback and feedforward mechanisms between both pathways. Numerous factors may affect both pathways. Recently, some new layers of regulation on the estrogenic effects were identified. In this review, we summarize these multiple regulation layers and discuss the newly identified factors</abstract>
    <url>WOS:000332099300005</url>
    <isbnorissn>1208-6053</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>304</id>
    <title>Epigenetics meets endocrinology</title>
    <authors>Zhang,X.A.; Ho,S.M.</authors>
    <availability>[Zhang, Xiang; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Ctr Environm Genet, Cincinnati, OH 45267 USA.</availability>
    <date>2011</date>
    <notes>JEnglishReviewHo, SM (reprint author), Univ Cincinnati, Coll Med, Dept Environm Hlth, Ctr Environm Genet, 3223 Eden Ave,Kettering Complex,Suite 130, Cincinnati, OH 45267 USAshuk-mei.ho@uc.eduAdams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Adlercreutz H, 2002, J STEROID BIOCHEM, V83, P113, DOI 10.1016/S0960-0760(02)00273-X; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Benbrahim-Tallaa L, 2007, ENVIRON HEALTH PERSP, V115, P1454, DOI 10.1289/ehp.10207; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Blaustein JD, 2010, MOL ENDOCRINOL, V24, P252, DOI 10.1210/me.2009-0350; Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9; Boverhof DR, 2006, MOL PHARMACOL, V69, P1599, DOI 10.1124/mol.105.019638; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Carrell DT, 2010, MOL HUM REPROD, V16, P37, DOI 10.1093/molehr/gap090; Ceccatelli Raffaella, 2006, Toxicology, V220, P104, DOI 10.1016/j.tox.2005.12.004; Champagne FA, 2008, CURR OPIN PHARMACOL, V8, P735, DOI 10.1016/j.coph.2008.06.018; Chen JS, 2010, TOXICOL LETT, V192, P431, DOI 10.1016/j.toxlet.2009.11.020; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chim CS, 2005, LEUKEMIA, V19, P2241, DOI 10.1038/sj.leu.2403937; Chun JY, 2009, CLIN CANCER RES, V15, P4815, DOI 10.1158/1078-0432.CCR-09-0640; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Clarkson T. W., 1995, AM J CLIN NUTR, V61, P682; Cnattingius S, 2009, CANCER EPIDEM BIOMAR, V18, P2422, DOI 10.1158/1055-9965.EPI-09-0366; Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102; Correa P, 1999, J CLIN ENDOCR METAB, V84, P1690, DOI 10.1210/jc.84.5.1690; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Crews D, 2006, ENDOCRINOLOGY, V147, pS4, DOI 10.1210/en.2005-1122; Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9; Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181; Davis SW, 2010, MOL CELL ENDOCRINOL, V323, P4, DOI 10.1016/j.mce.2009.12.012; Dekker FJ, 2009, BIOORGAN MED CHEM, V17, P460, DOI 10.1016/j.bmc.2008.12.008; Deladoey Johnny, 2007, V10, P29, DOI 10.1159/000106818; Demura M, 2008, MOL CELL ENDOCRINOL, V283, P127, DOI 10.1016/j.mce.2007.12.003; Denier X, 2009, TOXICOL IN VITRO, V23, P569, DOI 10.1016/j.tiv.2009.01.006; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Ehrlich S, 2010, J PSYCHIATR RES, V44, P827, DOI 10.1016/j.jpsychires.2010.01.011; Ekbom A, 2000, CANCER EPIDEM BIOMAR, V9, P221; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Franceschi C, 2005, MECH AGEING DEV, V126, P351, DOI 10.1016/j.mad.2004.08.028; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Gale EAM, 2001, BRIT MED J, V323, P997; Ganesan A, 2009, CURR CANCER DRUG TAR, V9, P963; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102; Godfrey K, 2006, DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE, P6, DOI 10.1017/CBO9780511544699.003; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62; Griswold MD, 2001, BIOL REPROD, V64, P602, DOI 10.1095/biolreprod64.2.602; Gurrieri F, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-63; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x; Heemers HV, 2007, CANCER RES, V67, P3422, DOI 10.1158/0008-5472.CAN-06-2836; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hillemacher T, 2009, PSYCHONEUROENDOCRINO, V34, P555, DOI 10.1016/j.psyneuen.2008.10.019; Hiroi H, 2004, MOL CELL ENDOCRINOL, V215, P119, DOI 10.1016/j.mce.2003.11.014; Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; HOLLIDAY R, 1991, MUTAT RES, V250, P351, DOI 10.1016/0027-5107(91)90192-Q; Houshdaran S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001289; Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914; HUGHES CL, 1988, ENVIRON HEALTH PERSP, V78, P171, DOI 10.2307/3430517; Huhtakangas JA, 2004, MOL ENDOCRINOL, V18, P2660, DOI 10.1210/me.2004-0116; Hyman SJ, 2009, ENDOCRIN METAB CLIN, V38, P509, DOI 10.1016/j.ecl.2009.06.005; Iliopoulos D, 2007, ANN RHEUM DIS, V66, P1616, DOI 10.1136/ard.2007.069377; Izawa M, 2008, FERTIL STERIL, V89, P1390, DOI 10.1016/j.fertnstert.2007.03.078; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; JANSEN RPS, 1984, ENDOCR REV, V5, P525; Ji JL, 2009, FEBS LETT, V583, P759, DOI 10.1016/j.febslet.2009.01.034; Jiang GF, 2008, TOXICOLOGY, V244, P49, DOI 10.1016/j.tox.2007.10.028; Jin BL, 2008, HUM MOL GENET, V17, P690, DOI 10.1093/hmg/ddm341; Jin Z, 2008, CANCER, V112, P43, DOI 10.1002/cncr.23135; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kaminsky ZA, 2009, NAT GENET, V41, P240, DOI 10.1038/ng.286; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; Kashyap V, 2010, J BIOL CHEM, V285, P14534, DOI 10.1074/jbc.M110.115345; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Kim MS, 2007, MOL CELL ENDOCRINOL, V265, P168, DOI 10.1016/j.mce.2006.12.014; Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456; Kinoshita H, 2000, CANCER RES, V60, P3623; Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289; Knower KC, 2010, MOL CELL ENDOCRINOL, V321, P123, DOI 10.1016/j.mce.2010.02.035; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455; Kong W, 2009, J CELL PHYSIOL, V218, P22, DOI 10.1002/jcp.21577; Kuroda A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006953; Kuzawa CW, 2009, ANNU REV ANTHROPOL, V38, P131, DOI 10.1146/annurev-anthro-091908-164350; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Latini G, 2009, ENVIRON INT, V35, P987, DOI 10.1016/j.envint.2009.03.008; Lee DO, 2008, J BONE MINER METAB, V26, P42, DOI 10.1007/s00774-007-0795-3; Lee LTO, 2004, MOL ENDOCRINOL, V18, P1740, DOI 10.1210/me.2003-0461; Li GL, 2009, COMMUN NONLINEAR SCI, V14, P194, DOI 10.1016/j.cnsns.2007.07.007; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398; Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003; Lintas C, 2010, NEUROREPORT, V21, P114, DOI 10.1097/WNR.0b013e328334b343; Lobato MN, 1999, HUM HERED, V49, P169, DOI 10.1159/000022866; Lv K, 2008, BIOCHEM BIOPH RES CO, V374, P101, DOI 10.1016/j.bbrc.2008.06.102; Majid S, 2010, CANCER, V116, P66, DOI 10.1002/cncr.24662; Martinez-Arguelles DB, 2009, ENDOCRINOLOGY, V150, P5575, DOI 10.1210/en.2009-0847; Martinez-Arguelles DB, 2010, STEROIDS, V75, P467, DOI 10.1016/j.steroids.2010.02.004; Maywood ES, 2007, COLD SPRING HARB SYM, V72, P85, DOI 10.1101/sqb.2007.72.005; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Melzner I, 2002, J BIOL CHEM, V277, P45420, DOI 10.1074/jbc.M208511200; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Michels KB, 2006, INT J CANCER, V119, P2007, DOI 10.1002/ijc.22004; Miller WL, 2007, BBA-MOL CELL BIOL L, V1771, P663, DOI 10.1016/j.bbalip.2007.02.012; MILLER WL, 1988, ENDOCR REV, V9, P295; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Missaghian E, 2009, J ENDOCRINOL, V202, P99, DOI 10.1677/JOE-08-0353; Moffat ID, 2007, TOXICOL SCI, V99, P470, DOI 10.1093/toxsci/kfm189; Moiseeva EP, 2009, CANCER PREV RES, V2, P611, DOI 10.1158/1940-6207.CAPR-08-0102; Molinie B, 2009, DRUG NEWS PERSPECT, V22, P247, DOI 10.1358/dnp.2009.22.5.1378633; Montanelli L, 2010, MOL CELL ENDOCRINOL, V322, P64, DOI 10.1016/j.mce.2010.03.009; Monteiro PRR, 2000, AQUAT TOXICOL, V48, P549, DOI 10.1016/S0166-445X(99)00055-7; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006; Muller HM, 2003, BRIT J CANCER, V89, P1934, DOI 10.1038/sj.bjc.6601392; Musri MM, 2007, BIOCHEM CELL BIOL, V85, P397, DOI 10.1139/O07-068; Newell-Price J, 2003, J ENDOCRINOL, V177, P365, DOI 10.1677/joe.0.1770365; Noer A, 2006, MOL BIOL CELL, V17, P3543, DOI 10.1091/mbc.E06-04-0322; Novac Natalia, 2004, Current Drug Targets - Inflammation and Allergy, V3, P335, DOI 10.2174/1568010042634541; Oakes CC, 2007, DEV BIOL, V307, P368, DOI 10.1016/j.ydbio.2007.05.002; Ojeda SR, 2010, ENDOCRIN DEV, V17, P44, DOI 10.1159/000262527; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olsson M, 2007, PROSTATE, V67, P1439, DOI 10.1002/pros.20630; Omdahl JL, 2002, ANNU REV NUTR, V22, P139, DOI 10.1146/annurev.nutr.22.120501.150216; Ooi SKT, 2009, J CELL SCI, V122, P2787, DOI 10.1242/jcs.015123; Patra SK, 2009, BIOCHEMISTRY-MOSCOW+, V74, P613, DOI 10.1134/S0006297909060042; PEARSON RK, 1993, ENDOCRIN METAB CLIN, V22, P753; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; PETTITT DJ, 1991, DIABETES, V40, P126; PETTITT DJ, 1983, NEW ENGL J MED, V308, P242, DOI 10.1056/NEJM198302033080502; PICTILAINEN KH, 2008, PLOS MED, V5, pE51, DOI DOI 10.1371/JOURNAL.PMED.0050051; Plagemann A, 2009, J PHYSIOL-LONDON, V587, P4963, DOI 10.1113/jphysiol.2009.176156; Platz EA, 1998, AM J EPIDEMIOL, V147, P1140; Pozzi S, 2006, ONCOGENE, V25, P1400, DOI 10.1038/sj.onc.1209173; Prins GS, 2008, ENDOCRINOLOGY, V149, P5919, DOI 10.1210/en.2008-1266; Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Rampersaud Evadnie, 2008, Curr Diabetes Rev, V4, P329, DOI 10.2174/157339908786241179; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.med.44.1.121; Rochester JR, 2009, COMP BIOCHEM PHYS A, V154, P279, DOI 10.1016/j.cbpa.2009.06.017; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Rodriguez-Antona C, 2010, HUM GENET, V127, P1, DOI 10.1007/s00439-009-0748-0; Rossignol DA, 2009, ANN CLIN PSYCHIATRY, V21, P213; Rubello D, 2005, BIOMED PHARMACOTHER, V59, P402, DOI 10.1016/j.biopha.2004.09.015; Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338; Ryan KK, 2010, ENDOCRINOLOGY, V151, P2603, DOI 10.1210/en.2009-1218; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Salay E, 2009, CHEMOSPHERE, V74, P1413, DOI 10.1016/j.chemosphere.2008.11.031; Sasaki M, 2000, MOL CARCINOGEN, V29, P59, DOI 10.1002/1098-2744(200010)29:2&lt;59::AID-MC2&gt;3.0.CO;2-6; Sasaki M, 2003, MOL CELL ENDOCRINOL, V202, P201, DOI 10.1016/S0303-7207(03)00084-4; Schayek H, 2010, EXP CELL RES, V316, P1479, DOI 10.1016/j.yexcr.2010.03.007; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Scully KM, 2002, SCIENCE, V295, P2231, DOI 10.1126/science.1062736; Sharpe RM, 2010, ENDOCRINOLOGY, V151, P2404, DOI 10.1210/en.2010-0445; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; Shi XB, 2008, CELL CYCLE, V7, P1529, DOI 10.4161/cc.7.11.5977; Shutoh Y, 2009, J TOXICOL SCI, V34, P469; Siddiqi Muhammad Akmal, 2003, Clin Med Res, V1, P281; Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245; Sikka SC, 2008, ASIAN J ANDROL, V10, P134, DOI 10.1111/j.1745-7262.2008.00370.x; Simmons RA, 2009, PEDIATR CLIN N AM, V56, P449, DOI 10.1016/j.pcl.2009.03.004; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Smith JA, 2007, ARCH OTOLARYNGOL, V133, P1006, DOI 10.1001/archotol.133.10.1006; Sober S, 2010, BIOCHEM BIOPH RES CO, V391, P727, DOI 10.1016/j.bbrc.2009.11.128; Stein DJ, 2009, CNS SPECTRUMS, V14, P602; Stevens A, 2010, ENDOCRINOLOGY, V151, P3652, DOI 10.1210/en.2010-0094; Stoger R, 2006, EPIGENETICS-US, V1, P155; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Stouffs K, 2009, Verh K Acad Geneeskd Belg, V71, P115; Sun LY, 2006, ENDOCRINOLOGY, V147, P5480, DOI 10.1210/en.2006-0586; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Tang XQ, 2009, RNA, V15, P287, DOI 10.1261/rna.1211209; Thompson RF, 2010, J WOMENS HEALTH, V19, P581, DOI 10.1089/jwh.2009.1408; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Tilton SC, 2008, ENVIRON HEALTH PERSP, V116, P1047, DOI 10.1289/ehp.11190; Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Trasler JM, 2009, MOL CELL ENDOCRINOL, V306, P33, DOI 10.1016/j.mce.2008.12.018; Vaag A, 2007, CURR OPIN CLIN NUTR, V10, P591, DOI 10.1097/MCO.0b013e3282ab9ea6; Vanselow J, 2010, BIOL REPROD, V82, P289, DOI 10.1095/biolreprod.109.079251; Vanselow J, 2008, EXP CLIN ENDOCR DIAB, V116, P437, DOI 10.1055/s-2008-1058083; Veldhuis JD, 2003, J PEDIATR ENDOCR MET, V16, P587; Venkataraman GM, 1999, J CLIN ENDOCR METAB, V84, P2449, DOI 10.1210/jc.84.7.2449; Vreugdenhil E, 2009, ENDOCRINOLOGY, V150, P2220, DOI 10.1210/en.2008-1335; Wang XW, 2006, NUCLEIC ACIDS RES, V34, P1646, DOI 10.1093/nar/gkl068; Wang YM, 2003, CLIN CANCER RES, V9, P5257; Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005; WHITFIELD GK, 1985, ENDOCRINOLOGY, V117, P231; Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852; Wolfsberg TG, 2010, CURR PROTOC BIOINFOR, DOI DOI 10.1002/0471250953.BI0105S29; Wu Q, 2004, BIOL REPROD, V70, P1790, DOI 10.1095/biolreprod.103.025387; Xing MZ, 2003, CANCER RES, V63, P2316; Xu GL, 1999, NATURE, V402, P187; Yamagata Y, 2009, HUM REPROD, V24, P1126, DOI 10.1093/humrep/dep015; YANG NC, 1961, SCIENCE, V134, P386, DOI 10.1126/science.134.3476.386; Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104; Ye L, 2005, J ENDOCRINOL, V185, P337, DOI 10.1677/joe.1.05963; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499; Zhang X, 2007, ONCOGENE, V26, P7346, DOI 10.1038/sj.onc.1210537; Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100; Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-121646BIOSCIENTIFICA LTDBRISTOLEURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLANDJ MOL ENDOCRINOLFEBDiscipline: Endocrinology &amp; Metabolism721SW</notes>
    <keywords>BISPHENOL-A; BLOOD; BONE; BREAST EPITHELIAL-CELLS; CANCER; Carcinogen; CARCINOGENESIS; CELL; cell cycle; CELL-CYCLE; CYCLE; diabetes; Differentiation; DISEASE; DISORDERS; DNA METHYLATION; DNA-methylation; ENDOCRINE; Endocrine disruption; Endocrine disruptor; ENDOCRINE DISRUPTORS; environment; epigenetic; epigenetics; ESTROGEN-RECEPTOR; EXPOSURE; EXPOSURES; GENE; GENE-EXPRESSION; GENES; genetics; HEALTH; HISTONE MODIFICATIONS; Hormones; IDENTIFICATION; IMPACT; In vitro; IN-VITRO; Inflammation; LEUKEMIA; MAMMALIAN DNA METHYLTRANSFERASES; mechanism; MECHANISMS; METABOLISM; METHYLATION; microRNA; MODEL; PIMA INDIAN WOMEN; POPULATION; PREVENTION; Prostate; PROSTATE-CANCER CELLS; REGULATORY PROTEIN STAR; RELEASE; Review; screening; Steroid; SYSTEM; TARGET; TISSUE; toxicology; VARIABILITY; VITAMIN-D-RECEPTOR; VITRO; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>R11</startpage>
    <endpage>R32</endpage>
    <journalfull>Journal of Molecular Endocrinology</journalfull>
    <issue>1</issue>
    <volume>46</volume>
    <abstract>Although genetics determines endocrine phenotypes, it cannot fully explain the great variability and reversibility of the system in response to environmental changes. Evidence now suggests that epigenetics, i.e. heritable but reversible changes in gene function without changes in nucleotide sequence, links genetics and environment in shaping endocrine function. Epigenetic mechanisms, including DNA methylation, histone modification, and microRNA, partition the genome into active and inactive domains based on endogenous and exogenous environmental changes and developmental stages, creating phenotype plasticity that can explain interindividual and population endocrine variability. We will review the current understanding of epigenetics in endocrinology, specifically, the regulation by epigenetics of the three levels of hormone action (synthesis and release, circulating and target tissue levels, and target-organ responsiveness) and the epigenetic action of endocrine disruptors. We will also discuss the impacts of hormones on epigenetics. We propose a three-dimensional model (genetics, environment, and developmental stage) to explain the phenomena related to progressive changes in endocrine functions with age, the early origin of endocrine disorders, phenotype discordance between monozygotic twins, rapid shifts in disease patterns among populations experiencing major lifestyle changes such as immigration, and the many endocrine disruptions in contemporary life. We emphasize that the key for understanding epigenetics in endocrinology is the identification, through advanced high-throughput screening technologies, of plasticity genes or loci that respond directly to a specific environmental stimulus. Investigations to determine whether epigenetic changes induced by today's lifestyles or environmental 'exposures' can be inherited and are reversible should open doors for applying epigenetics to the prevention and treatment of endocrine disorders</abstract>
    <url>WOS:000287376500002</url>
    <isbnorissn>0952-5041</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>124</id>
    <title>Inverse antagonist activities of parabens on human oestrogen-related receptor gamma (ERR gamma): In vitro and in silico studies</title>
    <authors>Zhang,Z.B.; Sun,L.B.; Hu,Y.; Jiao,J.; Hu,J.Y.</authors>
    <availability>[Zhang, Zhaobin; Sun, Libei; Hu, Ying; Jiao, Jian; Hu, Jianying] Peking Univ, Coll Urban &amp; Environm Sci, MOE Lab Earth Surface Proc, Beijing 100871, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleHu, JY (reprint author), Peking Univ, Coll Urban &amp; Environm Sci, 5 Yiheyuan Rd, Beijing 100871, Peoples R Chinahujy@urban.pku.edu.cnAbad MC, 2008, J STEROID BIOCHEM, V108, P44, DOI 10.1016/j.jsbmb.2007.06.006; Ariazi EA, 2002, CANCER RES, V62, P6510; Barr L, 2012, J APPL TOXICOL, V32, P219, DOI 10.1002/jat.1786; Calafat AM, 2010, ENVIRON HEALTH PERSP, V118, P679, DOI 10.1289/ehp.0901560; Casas L, 2011, ENVIRON INT, V37, P858, DOI 10.1016/j.envint.2011.02.012; Charles A. K., 2013, J APPL TOXICOL, DOI DOI 10.1002/JAT2850; Chen JG, 2007, TOXICOL APPL PHARM, V221, P278, DOI 10.1016/j.taap.2007.03.015; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; DANIEL JW, 1986, XENOBIOTICA, V16, P1073; Darbre PD, 2008, J APPL TOXICOL, V28, P561, DOI 10.1002/jat.1358; Darbre PD, 2004, J APPL TOXICOL, V24, P5, DOI 10.1002/jat.958; Elder R.L., 1984, J AM COLL TOXICOL, V3, P147; Eudy JD, 1998, GENOMICS, V50, P382, DOI 10.1006/geno.1998.5345; Frederiksen H, 2011, J EXPO SCI ENV EPID, V21, P262, DOI 10.1038/jes.2010.6; Frye CA, 2012, J NEUROENDOCRINOL, V24, P144, DOI 10.1111/j.1365-2826.2011.02229.x; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; Golden R, 2005, CRIT REV TOXICOL, V35, P435, DOI 10.1080/10408440490920104; Golden R, 2004, J APPL TOXICOL, V24, P297, DOI 10.1002/jat.985; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Ijichi N, 2011, J STEROID BIOCHEM, V123, P1, DOI 10.1016/j.jsbmb.2010.09.002; JECFA (the Joint FAO/WHO Expert Committee on Food Additives), 1974, WHO TECHNICAL REPORT, V539; Kanayama T, 2003, J BIOCHEM, V133, P791, DOI 10.1093/jb/mvg101; Lorke DE, 2000, MOL BRAIN RES, V77, P277, DOI 10.1016/S0169-328X(00)00063-2; Matsushima A, 2008, BIOCHEM BIOPH RES CO, V373, P408, DOI 10.1016/j.bbrc.2008.06.050; Meeker JD, 2011, ENVIRON HEALTH PERSP, V119, P252, DOI 10.1289/ehp.1002238; Miller WR, 1996, ESTROGEN BREAST CANC; Oishi S, 2001, TOXICOL IND HEALTH, V17, P31, DOI 10.1191/0748233701th093oa; Oishi S, 2002, ARCH TOXICOL, V76, P423, DOI 10.1007/s00204-002-0360-8; Oishi S, 2002, FOOD CHEM TOXICOL, V40, P1807, DOI 10.1016/S0278-6915(02)00204-1; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Pugazhendhi D, 2007, J APPL TOXICOL, V27, P67, DOI 10.1002/jat.1200; RASTOGI SC, 1995, CONTACT DERMATITIS, V32, P28, DOI 10.1111/j.1600-0536.1995.tb00836.x; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Sandanger TM, 2011, J EXPO SCI ENV EPID, V21, P595, DOI 10.1038/jes.2011.22; Satoh K, 2005, J HEALTH SCI, V51, P557, DOI 10.1248/jhs.51.557; Smith KW, 2012, ENVIRON HEALTH PERSP, V120, P1538, DOI 10.1289/ehp.1104614; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Terasaka S, 2006, TOXICOL LETT, V163, P130, DOI 10.1016/j.toxlet.2005.10.005; Wang L, 2006, J BIOL CHEM, V281, P37773, DOI 10.1074/jbc.M608410200; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yamamoto T, 2012, INT J GYNECOL CANCER, V22, P1509, DOI 10.1097/IGC.0b013e31826fd623; Ye X, 2008, TALANTA, V76, P865, DOI 10.1016/j.talanta.2008.04.034; Ye XY, 2009, ENVIRON INT, V35, P1160, DOI 10.1016/j.envint.2009.07.011; Zhang ZB, 2012, TOXICOL LETT, V209, P146, DOI 10.1016/j.toxlet.2011.12.004473ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USATOXICOL APPL PHARMJUL 1Discipline: Pharmacology &amp; Pharmacy; Toxicology152PW</notes>
    <keywords>Antagonist; BINDING; BIOMARKER; BISPHENOL-A; breast cancer; BREAST-CANCER; BREAST-CANCER CELLS; BUTYLPARABEN; CANCER; CARCINOGENESIS; cosmetics; Endocrine-disrupting chemicals; ESTERS; Estrogen; Ethylparaben; EXPRESSION; FOOD; HUMAN HEALTH; HUMAN-BREAST-CANCER; in silico; In vitro; IN-VITRO; MALE REPRODUCTIVE-SYSTEM; Methylparaben; molecular docking; Nuclear receptor; Oestrogen-related receptor gamma; PARABENS; PERSONAL CARE PRODUCTS; PHARMACOLOGY; PHENOLS; RECEPTOR; SAMPLES; TAMOXIFEN; TISSUE; toxicology; URINARY CONCENTRATIONS; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>16</startpage>
    <endpage>22</endpage>
    <journalfull>Toxicology and Applied Pharmacology</journalfull>
    <issue>1</issue>
    <volume>270</volume>
    <abstract>Parabens are p-hydroxybenzoic add esters that have been used extensively as preservatives in foods, cosmetics, drugs and toiletries. These intact esters are commonly detected in human breast cancer tissues and other human samples, thus arousing concern about the involvement of parabens in human breast cancer. In this study, an in vitro nuclear receptor coactivator recruiting assay was developed and used to evaluate the binding activities of parabens, salicylates and benzoates via antagonist competitive binding on the human oestrogen-related receptor (ERR gamma), which is known as both a diagnostic biomarker and a treatment target of breast cancer. The results showed that all of the test parabens (methyl-, ethyl-, propyl-, butyl- and benzylparaben) possessed clear inverse antagonist activities on ERR gamma, with a lowest observed effect level (LOEL) of 10(-7) M and the 50% relative effective concentrations (REC50) varying from 3.09 x 10(-7) to 5.88 x 10(-7) M, whereas the salicylates possessed much lower activities and the benzoates showed no obvious activity. In silico molecular docking analyses showed that parabens fitted well into the active site of ERR gamma, with hydrogen bonds forming between the p-hydroxyl group of parabens and the Glu275/Arg316 of ERR gamma. As the paraben levels reported in breast cancer tissues are commonly higher than the LOELs observed in this study, parabens may play some role via ERR gamma in the carcinogenesis of human breast cancer. In addition, parabens may have significant effects on breast cancer patients who are taking tamoxifen, as ERR gamma is regarded as a treatment target for tamoxifen. (C) 2013 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000319544600003</url>
    <isbnorissn>0041-008X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>137</id>
    <title>Genistein inhibits estradiol- and environmental endocrine disruptor-induced growth effects on neuroblastoma cells in vitro</title>
    <authors>Zheng,J.C.; Li,H.; Zhu,H.T.; Xiao,X.M.; Ma,Y.Y.</authors>
    <availability>[Zheng, Jicui; Li, Hui; Zhu, Haitao; Xiao, Xianmin; Ma, Yangyang] Fudan Univ, Dept Pediat Surg, Childrens Hosp, Shanghai 201102, Peoples R China. [Li, Hui] Jiao Tong Univ, Childrens Hosp, Dept Pediat Surg, Shanghai 200040, Peoples R China.</availability>
    <date>2013</date>
    <notes>JEnglishArticleXiao, XM (reprint author), Fudan Univ, Dept Pediat Surg, Childrens Hosp, 399 Wanyuan Rd, Shanghai 201102, Peoples R Chinazhubindoctor@126.comChang KL, 2004, BIOCHEM PHARMACOL, V67, P717, DOI 10.1016/j.bcp.2003.10.003; De Roos AJ, 2001, AM J EPIDEMIOL, V154, P106, DOI 10.1093/aje/154.2.106; DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426-199905000-00005; Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1; Gong LJ, 2003, ONCOGENE, V22, P4702, DOI 10.1038/sj.onc.1206583; Hebert JR, 1998, J NATL CANCER I, V90, P1637, DOI 10.1093/jnci/90.21.1637; Hewitt AL, 2003, CANCER LETT, V192, P133, DOI 10.1016/S0304-3835(02)00712-7; Ismail IA, 2007, EUR J PHARMACOL, V575, P12, DOI 10.1016/j.ejphar.2007.07.039; Izbicka Elzbieta, 2005, Curr Opin Investig Drugs, V6, P1200; Li YW, 2002, CLIN CANCER RES, V8, P2369; Linford NJ, 2001, J PHARMACOL EXP THER, V299, P67; Lo FH, 2007, BIOMED PHARMACOTHER, V61, P591, DOI 10.1016/j.biopha.2007.08.021; Magee PJ, 2004, BRIT J NUTR, V91, P513, DOI 10.1079/BJN20031075; Park OJ, 2004, TOXICOL LETT, V150, P43, DOI 10.1016/j.toxlet.2003.06.001; Park SS, 2005, CANCER CHEMOTH PHARM, V56, P271, DOI 10.1007/s00280-004-0974-z; Rannikko A, 2006, PROSTATE, V66, P82, DOI 10.1002/pros.20315; Sarkar FH, 2003, CANCER INVEST, V21, P744, DOI 10.1081/CNV-120023773; Sarkar FH, 2006, MINI-REV MED CHEM, V6, P401, DOI 10.2174/138955706776361439; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; Zheng JC, 2007, ENVIRON TOXICOL PHAR, V24, P189, DOI 10.1016/j.etap.2007.05.003; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.067210SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEONCOL LETTMAYDiscipline: Oncology136TE</notes>
    <keywords>ACTIVATION; Akt; AKT SIGNALING PATHWAY; BIOLOGY; bisphenol; bisphenol A; BISPHENOL-A; BPA; breast; CANCER; CELL; cell cycle; Cell proliferation; CELL-PROLIFERATION; CELLS; CHILDREN; CYCLE; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; ESTRADIOL; EXPRESSION; FOOD; genistein; GROWTH; In vitro; IN-VITRO; ISOFLAVONE; KAPPA-B; mechanism; neuroblastoma; NEURONAL APOPTOSIS; oncology; PHOSPHORYLATION; phthalate; PREVENTION; proliferation; Prostate; PROSTATE-CANCER; PROTEIN; UP-REGULATION; VITRO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>1583</startpage>
    <endpage>1586</endpage>
    <journalfull>Oncology Letters</journalfull>
    <issue>5</issue>
    <volume>5</volume>
    <abstract>The aim of this study was to examine the effect of genistein on human neuroblastoma cell proliferation induced by two common environmental endocrine disruptors, bisphenol A (BPA) and Di-2-ethylhexyl phthalate (DEHP), and to investigate its underlying mechanism. SK-N-SH human neuroblastoma cells were treated with E-2 (1 ng/ml), BPA (2 mu g/ml) or DEHP (100 mu M), with or without genistein (12.5 mu M) in vitro. The number of viable cells was detected with an absorbance reader after 0, 24, 48 or 72 h treatment. The percentage of cells in different phases, and expression of Akt and its phosphorylation levels were also assessed by flow cytometry and western blot analysis at 72 h, respectively. The BPA and DEHP groups had a 30% higher number of viable cells compared to the non-treated group at 48 h (P&lt;0.001). However, the cell numbers did not increase significantly in the groups with additional treatment with genistein (P&gt;0.05 vs. control) and the same trend was observed at 72 h. The expression of phospho-Akt protein was increased in the groups treated with BPA or DEHP compared to the control group at 72 h (P&lt;0.05), while no significant elevation in the expression of phospho-Akt was observed (P&gt;0.05) in genistein-treated groups. Cells were arrested at the G(2)/M phase by genistein. Similar effects were observed in the E, group with or without genistein treatment. Akt protein expression had no significant change among all the groups (P&gt;0.05). In conclusion, estradiol- or environmental endocrine disruptor-induced proliferation of human neuroblastoma cells is effectively abolished by genistein, likely in a cell cycle- and Akt pathway-dependent manner</abstract>
    <url>WOS:000318385500028</url>
    <isbnorissn>1792-1074</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>426</id>
    <title>Growth-promoting effect of bisphenol A on neuroblastoma in vitro and in vivo</title>
    <authors>Zhu,H.T.; Xiao,X.M.; Zheng,J.C.; Zheng,S.; Dong,K.R.; Yu,Y.</authors>
    <availability>[Zhu, Haitao; Xiao, Xianmin; Zheng, Jicui; Zheng, Shan; Dong, Kuiran] Fudan Univ, Dept Pediat Surg, Childrens Hosp, Shanghai 201102, Peoples R China. [Yu, Yong] Fudan Univ, Key Lab Minist Hlth Viral Heart Dis, Zhongshan Hosp, Shanghai 200032, Peoples R China.</availability>
    <date>2009</date>
    <notes>JEnglishArticle; Proceedings PaperXiao, XM (reprint author), Fudan Univ, Dept Pediat Surg, Childrens Hosp, Shanghai 201102, Peoples R Chinaxmxiao@shmu.edu.cnBa F, 2004, NEUROCHEM INT, V44, P401, DOI 10.1016/j.neuint.2003.08.004; Chia S, 2008, BREAST, V17, pS16, DOI 10.1016/j.breast.2007.12.004; Dalmasso P, 2005, HAEMATOL-HEMATOL J, V90, P1197; De Bernardi B, 2003, J CLIN ONCOL, V21, P1592, DOI 10.1200/JCO.2003.05.191; Gong WD, 2005, CLIN CANCER RES, V11, P1386, DOI 10.1158/1078-0432.CCR-04-0487; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Han DH, 2002, BIOSCI BIOTECH BIOCH, V66, P1479; HELSON L, 1975, CANCER RES, V35, P2594; Kanemura Y, 2002, J NEUROSCI RES, V69, P869, DOI 10.1002/jnr.10377; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P257, DOI 10.1289/ehp.6115; Landrigan PJ, 2002, J TOXICOL-CLIN TOXIC, V40, P449; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Meitar D, 1996, J CLIN ONCOL, V14, P405; MELLODASILVA CA, 2005, J PEDIAT, V81, pS207; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Ross RA, 2007, SEMIN CANCER BIOL, V17, P241, DOI 10.1016/j.semcancer.2006.04.006; Tsai WT, 2006, J ENVIRON SCI HEAL C, V24, P225, DOI 10.1080/10590500600936482; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1&lt;37::AID-MPO1010&gt;3.0.CO;2-L; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; XIAO XM, 1994, ZHONGHUA XIAO ER WAI, V15, P61; XIAO XM, 1994, ZHONGHUA XIAO ER WAI, V15, P9; Zhang K, 2004, CLIN CANCER RES, V10, P5226, DOI 10.1158/1078-0432.CCR-04-0061; ZHENG JC, 2006, FUDAN U J MED SCI, V33, P726; Zheng Ji-Cui, 2006, Fudan Xuebao (Yixueban), V33, P718; Zheng Ji-cui, 2007, Zhonghua Yufang Yixue Zazhi, V41, P2953010W B SAUNDERS CO-ELSEVIER INCPHILADELPHIA1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USAJ PEDIATR SURGAPRDiscipline: Pediatrics; Surgery437DT</notes>
    <keywords>1; 17 beta-Estradiol; 17-BETA-ESTRADIOL; ANGIOGENESIS; Antagonist; ANTIGEN; bisphenol; bisphenol A; BISPHENOL-A; BODY-WEIGHT; BPA; breast; CANCER; CELL; CELLS; CHILDREN; CHILDRENS HEALTH; CHINA; CYCLIN D1; E2; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; ER; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; EXPOSURES; EXPRESSION; GENE; GROWTH; GROWTH-FACTOR; HEALTH; In vitro; in vivo; IN-VITRO; IN-VIVO; KINASE; mechanism; MECHANISMS; MICE; neuroblastoma; Nude mice; PATHWAY; pediatric; proliferation; PROTEIN; RECEPTOR; RECEPTOR ANTAGONIST; RISK; SHANGHAI; Steroid; TUMOR; TUMORS; vascular endothelial growth factor; VITRO; VIVO</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>672</startpage>
    <endpage>680</endpage>
    <journalfull>Journal of Pediatric Surgery</journalfull>
    <issue>4</issue>
    <volume>44</volume>
    <abstract>Purpose: To investigate the effect and mechanism of bisphenol A (BPA), one of the main environmental endocrine disruptors, on the proliferation of human neuroblastoma cells. Methods: In vitro, cultured SK-N-SH cells were treated with 17 beta-estradiol (E-2; 1 ng/mL), BPA (2 mu g/mL) with or without estrogen receptor antagonist ICII82,780 (10(-6) mol/L). Viable cell number, DNA proliferation index, and expression of cyclin-dependent kinase 4 and cyclin D1 were assessed by absorbance reading, flow cytometry, and western blotting, respectively. In vivo, ovariectomized nude mice bearing SK-N-SH tumors were administered by gavage with E-2 (500 mu g/kg per day, n = 11), BPA (200 mg/kg per day, n = 10), or vehicle (n = 9) for 18 days. Mice body weight, tumor volume and weight were examined every 3 days. Tumor microvessel density, proliferating cell nuclear antigen and vascular endothelial growth factor expression were evaluated by immunohistochemical staining or western blotting. Results: In vitro, the BPA group had 20% higher number of viable cells, 70% higher proliferation index (both P &lt; .01), and higher expression of cyclin-dependent kinase 4 and cyclin D1 than the nontreated group. In vivo, the BPA group had over 50% higher gross tumor volume, turner weight, microvessel density, proliferating cell nuclear antigen (P &lt; .05 or .01), and higher vascular endothelial growth factor protein expression than the mock control group. Both in vitro and in vivo BPA effects were comparable with those by E-2. ICII82,780 effectively abolished the promoting effect for both. Conclusions: Bisphenol A can promote the growth of neuroblastoma to a level similar to that of E-2. Estrogen receptor-dependent pathway and angiogenesis may contribute to the underlying mechanisms. (C) 2009 Elsevier Inc. All rights reserved</abstract>
    <url>WOS:000265467100002</url>
    <isbnorissn>0022-3468</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>386</id>
    <title>Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells</title>
    <authors>Zhu,H.T.; Zheng,J.C.; Xiao,X.M.; Zheng,S.; Dong,K.R.; Liu,J.B.; Wang,Y.</authors>
    <availability>[Zhu, Haitao; Zheng, Jicui; Xiao, Xianmin; Zheng, Shan; Dong, Kuiran; Liu, Jiangbin] Fudan Univ, Dept Surg, Childrens Hosp, Shanghai 201102, Peoples R China. [Wang, Yang] Fudan Univ, Anat &amp; Histol &amp; Embryol Shanghai Med Sch, Shanghai 201102, Peoples R China.</availability>
    <date>2010</date>
    <notes>JEnglishArticleXiao, XM (reprint author), Fudan Univ, Dept Surg, Childrens Hosp, 399 Wanyuan Rd, Shanghai 201102, Peoples R Chinaxmxiao@shmu.edu.cnAra T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Ba F, 2004, NEUROCHEM INT, V44, P401, DOI 10.1016/j.neuint.2003.08.004; Ball LJ, 2009, MOL CELL ENDOCRINOL, V299, P204, DOI 10.1016/j.mce.2008.10.050; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bolli A, 2008, IUBMB LIFE, V60, P843, DOI 10.1002/iub.130; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198; Cheng Ya, 2005, Zhonghua Zhongliu Zazhi, V27, P164; Dalmasso P, 2005, HAEMATOL-HEMATOL J, V90, P1197; Dang VH, 2009, STEROIDS, V74, P707, DOI 10.1016/j.steroids.2009.03.002; Duffy MJ, 1998, INT J ONCOL, V12, P1343; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gray J, 2009, INT J OCCUP ENV HEAL, V15, P43; Hauser R, 2005, Occup Environ Med, V62, P806, DOI 10.1136/oem.2004.017590; Hotchkiss AK, 2008, TOXICOL SCI, V105, P235, DOI 10.1093/toxsci/kfn030; Kalkman HO, 2006, PHARMACOL THERAPEUT, V110, P117, DOI 10.1016/j.pharmthera.2005.10.014; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Latini G, 2006, TOXICOLOGY, V226, P90, DOI 10.1016/j.tox.2006.07.011; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Maggi R, 1998, STEROIDS, V63, P257, DOI 10.1016/S0039-128X(98)00038-5; MAKEY CM, 2002, J STEROID BIOCHEM, V83, P235; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McHugh Kieran, 2007, Cancer Imaging, V7, P41, DOI 10.1102/1470-7330.2007.0007; MELLODASILVA CA, 2005, J PEDIAT, V81, pS207; Palanza P, 2008, ENVIRON RES, V108, P150, DOI 10.1016/j.envres.2008.07.023; Papoutsi Z, 2009, J MOL ENDOCRINOL, V43, P65, DOI 10.1677/JME-08-0177; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Park SH, 2009, J REPROD DEVELOP, V55, P23, DOI 10.1262/jrd.20094; Prins GS, 2008, ENDOCR-RELAT CANCER, V15, P649, DOI 10.1677/ERC-08-0043; Recchia AG, 2004, FOOD ADDIT CONTAM, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; Ribatti D, 2004, ANN NY ACAD SCI, V1028, P133, DOI 10.1196/annals.1322.014; Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004; Schoeters G, 2008, BASIC CLIN PHARMACOL, V102, P168, DOI 10.1111/j.1742-7843.2007.00180.x; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Swan SH, 2008, ENVIRON RES, V108, P177, DOI 10.1016/j.envres.2008.08.007; Takeshita A, 2006, J ENDOCRINOL, V190, P897, DOI 10.1677/joe.1.06664; Tokunaga E, 2008, CURR CANCER DRUG TAR, V8, P27, DOI 10.2174/156800908783497140; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vasconsuelo A, 2008, J ENDOCRINOL, V196, P385, DOI 10.1677/JOE-07-0250; Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799; VIVANCO I, 2002, NAT REV CANCER, V2, P480; vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Yanagihara N, 2008, ANN NY ACAD SCI, V1129, P96, DOI 10.1196/annals.1417.008; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Zheng JC, 2007, ENVIRON TOXICOL PHAR, V24, P189, DOI 10.1016/j.etap.2007.05.003; Zhu HT, 2009, J PEDIATR SURG, V44, P672, DOI 10.1016/j.jpedsurg.2008.10.067; Zhu Hai-tao, 2009, Fudan Xuebao (Yixueban), V36, P4075013SPANDIDOS PUBL LTDATHENSPOB 18179, ATHENS, 116 10, GREECEONCOL REPJANDiscipline: Oncology550ND</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; Akt; Antagonist; bisphenol; bisphenol A; BISPHENOL-A; BPA; BREAST-CANCER CELLS; CANCER; CELL; cell cycle; cell migration; Cell proliferation; CELL-CYCLE; CELL-PROLIFERATION; CELLS; CHILDREN; CHINA; CYCLE; DI(2-ETHYLHEXYL) PHTHALATE; DISEASE; diseases; E2; ENDOCRINE; Endocrine disruptor; ENDOCRINE DISRUPTORS; environmental endocrine disruptors; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; ESTROGEN-RECEPTOR-ALPHA; EXPOSURE; EXPRESSION; FOOD; GROWTH; HEALTH; HUMAN-DISEASE; In vitro; IN-VITRO; INHIBITOR; INVASION; matrix metalloproteinases; mechanism; MECHANISMS; metastasis; Migration; MORTALITY; neuroblastoma; oncology; PATHWAY; pediatric; phosphoinositide 3-kinase pathway; PHOSPHORYLATION; phthalate; PHTHALATE EXPOSURE; proliferation; protein serine/threonine kinase; RECEPTOR; RISK; RISK FACTOR; risk factors; RISK-FACTORS; SHANGHAI; Steroid; TARGET; TISSUE; toxicology; TUMOR; TUMORS; VITRO; XENOESTROGENS</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>129</startpage>
    <endpage>139</endpage>
    <journalfull>Oncology Reports</journalfull>
    <issue>1</issue>
    <volume>23</volume>
    <abstract>Neuroblastoma (NB) is the most common pediatric extracranial cancer. Metastasis is the main cause of mortality in NB patients. Currently, little is known about the risk factors and their mechanisms that cause metastasis. Environmental endocrine disruptors (EED) are recently identified risk factors associated with various human diseases including malignant tumors. Our previous studies have implicated the role of di(2-ethylhexyl) phthalate (DEHP) and bisphenol A (BPA), two of the most common EED, in neuroblastoma cell proliferation. Here, we further investigated the effects of DEHP, BPA as well as 17 beta-estradiol (E-2) on the invasion and metastasis of human neuroblastoma SK-N-SH cells in vitro. SK-N-SH cells expressed estrogen receptor (ER)-beta, matrix metalloproteinases-2 (MMP-2), MMP-9 and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) at readily detectable levels. 50 mu M DEHP, 0.1 mu M BPA and 10 mu M E, exposure all resulted in enhanced motility and invasiveness of SK-N-SH cells (P&lt;0.001), elevated expression of MMP-2 and MMP-9, and decreased expression of TIMP-2 (P&lt;0.01). Furthermore, phosphorylation of Akt (Ser473) was also induced following the exposure (P&lt;0.01). Importantly, both ER antagonist ICI182,780 and phosphoinositide 3-kinase (PI3K) specific inhibitor LY294002 significantly inhibited the DEHP, BPA, or E-2-induced cell migration and invasion, as well as the disregulation of MMP-2, MMP-9 and TIMP-2 expression. ICI182,780 may have worked through abolishing Akt (Ser473) phosphorylation. In conclusion, DEHP, BPA, and E-2 potently promote invasion and metastasis of neuroblastoma cells through overexpression of MMP-2 and MMP-9 as well as downregulation of TIMP-2. ER-dependent pathway and PI3K/Akt pathway are involved, which may become potential therapeutic targets for neuroblastoma treatment</abstract>
    <url>WOS:000274133800016</url>
    <isbnorissn>1021-335X</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>417</id>
    <title>Increased Expression of Histone Proteins during Estrogen-Mediated Cell Proliferation</title>
    <authors>Zhu,Z.Y.; Edwards,R.J.; Boobis,A.R.</authors>
    <availability>[Zhu, Zheying; Edwards, Robert J.; Boobis, Alan R.] Univ London Imperial Coll Sci Technol &amp; Med, Dept Expt Med &amp; Toxicol, London W12 0NN, England.</availability>
    <date>2009</date>
    <notes>JEnglishArticleZhu, ZY (reprint author), Univ London Imperial Coll Sci Technol &amp; Med, Dept Expt Med &amp; Toxicol, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, Englandz.zhu@imperial.ac.ukAshby J, 2003, TOXICOL LETT, V140, P37, DOI 10.1016/S0378-4274(02)00494-0; Bartova E, 2008, J HISTOCHEM CYTOCHEM, V56, P711, DOI 10.1369/jhc.2008.951251; Bonisch C, 2008, EXPERT REV PROTEOMIC, V5, P105, DOI 10.1586/14789450.5.1.105; BOSCH FX, 1993, EUR J CANCER, V29A, P1454, DOI 10.1016/0959-8049(93)90020-G; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI 10.1093/carcin/bci339; Carter D, 2002, BIOCHEMISTRY-US, V41, P6714, DOI 10.1021/bi0159884; Choi KC, 2003, J REPROD DEVELOP, V49, P337, DOI 10.1262/jrd.49.337; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100; Damstra T, 2002, GLOBAL ASSESSMENT ST; Dekant W, 2008, TOXICOL APPL PHARM, V228, P114, DOI 10.1016/j.taap.2007.12.008; Dip R, 2008, ENDOCR-RELAT CANCER, V15, P161, DOI 10.1677/ERC-07-0252; Edwards Robert J, 2006, Methods Mol Biol, V320, P173; Fernandez MF, 2007, EUR J CANCER, V43, P1290, DOI 10.1016/j.ejca.2007.03.010; Fertuck KC, 2001, TOXICOL LETT, V121, P167, DOI 10.1016/S0378-4274(01)00344-7; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Frigo DE, 2002, ENVIRON HEALTH PERSP, V110, P1239; Fuqua SAW, 1999, CANCER RES, V59, P5425; Girdler F, 2001, CYTOMETRY, V45, P65, DOI 10.1002/1097-0320(20010901)45:1&lt;65::AID-CYTO1145&gt;3.0.CO;2-8; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Hu YF, 1998, INT J ONCOL, V12, P1225; Jefferson WN, 2002, J CHROMATOGR B, V777, P179, DOI 10.1016/S1570-0232(02)00493-2; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JIANG SY, 1992, J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; JORDAN VC, 1985, ENVIRON HEALTH PERSP, V61, P97, DOI 10.2307/3430064; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Laronga C, 2003, DIS MARKERS, V19, P229; Marino-Ramirez L, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-12-r122; Muskhelishvili L, 2003, J HISTOCHEM CYTOCHEM, V51, P1681; Naciff JM, 2002, TOXICOL SCI, V68, P184, DOI 10.1093/toxsci/68.1.184; *NAT CTR BIOT INF, 2008, REF SEQ; Petricoin EF, 2004, CURR OPIN BIOTECH, V15, P24, DOI 10.1016/j.copbio.2004.01.005; Rajapakse N, 2004, ENVIRON SCI TECHNOL, V38, P6343, DOI 10.1021/es049681e; Rasmussen Thomas HA,j, 2003, Environ Health, V2, P12, DOI 10.1186/1476-069X-2-12; Safe SH, 1997, PROG CLIN BIOL RES, V396, P133; Sheehan DM, 2000, P SOC EXP BIOL MED, V224, P57, DOI 10.1046/j.1525-1373.2000.22401.x; Slowinski J, 2005, J NEURO-ONCOL, V71, P237, DOI 10.1007/s11060-004-2030-6; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Soto AM, 1997, ENVIRON HEALTH PERSP, V105, P647, DOI 10.2307/3433384; Suzuki T, 2001, J PHARM PHARMACOL, V53, P1549, DOI 10.1211/0022357011777927; ter Veld MGR, 2006, J AGR FOOD CHEM, V54, P4407, DOI 10.1021/jf052864f; Thatcher NJ, 2000, CANCER GENE THER, V7, P521, DOI 10.1038/sj.cgt.7700165; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473; VILLALOBOS M, 1995, ENVIRON HEALTH PERSP, V103, P844, DOI 10.2307/3432398; Wang TTY, 1996, CARCINOGENESIS, V17, P271, DOI 10.1093/carcin/17.2.271; Waring RH, 2005, MOL CELL ENDOCRINOL, V244, P2, DOI 10.1016/j.mce.2005.02.007; WATSON K, 1995, BIOCHEM PHARMACOL, V50, P299, DOI 10.1016/0006-2952(95)00142-M; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Wulfkuhle JD, 2001, PROTEOMICS, V1, P1205, DOI 10.1002/1615-9861(200110)1:10&lt;1205::AID-PROT1205&gt;3.3.CO;2-O; Zhu ZY, 2008, TOXICOL LETT, V181, P93, DOI 10.1016/j.toxlet.2008.07.006; Zhu ZY, 2008, PROTEOMICS, V8, P1987, DOI 10.1002/pmic.2007009015310US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCERES TRIANGLE PKNATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USAENVIRON HEALTH PERSPJUNDiscipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health; Toxicology451HZ</notes>
    <keywords>17 beta-Estradiol; 17-BETA-ESTRADIOL; BIOMARKER; Biomarkers; bisphenol; bisphenol A; BISPHENOL-A; breast; breast cancer; breast cancer cell lines; BREAST-CANCER; BREAST-CANCER-CELLS; CANCER; CARCINOGENESIS; CELL; Cell proliferation; CELL-LINE; CELL-LINES; CELL-PROLIFERATION; CELLS; Combined exposure; E-SCREEN ASSAY; ENDOCRINE DISRUPTERS; environment; ER; Estrogen; Estrogen receptor; ESTROGEN-RECEPTOR; Estrogenic; ESTROGENIC COMPOUNDS; ESTROGENS; EXPOSURE; EXPRESSION; FOOD; GENE; GENE-EXPRESSION; genistein; GROWTH; HEALTH; histories; HISTORY; IN-VITRO; JUN; LINE; LINES; MASS-SPECTROMETRY; MESSENGER-RNA; Occupational; proliferation; PROTEIN; protein profiles; PROTEINS; PROTEOMIC ANALYSIS; Proteomics; RECEPTOR; RECEPTOR BETA; RISK; SELDI-TOF MS; toxicology; UP-REGULATION</keywords>
    <reprint>NOT IN FILE</reprint>
    <startpage>928</startpage>
    <endpage>934</endpage>
    <journalfull>Environmental Health Perspectives</journalfull>
    <issue>6</issue>
    <volume>117</volume>
    <abstract>BACKGROUND: There is concern about the potential risk posed by compounds with estrogen-like activity present in the environment. As previous studies have shown that combined exposure to such compounds results in dose additivity, it should be possible to assess estrogen exposure with suitable biomarkers of effect. OBJECTIVES: Our goal was to identify candidate protein biomarkers of effect for estrogenic compounds. METHODS: In the search for biomarkers, we assessed the effect of several estrogenic compounds on the expression profile of proteins in breast-derived cell lines varying in their estrogen receptor (ER) phenotype using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. We identified responsive proteins, after separating them by SDS-polyacrylamide gel electrophoresis, and analyzing the trypsin-digested proteins by tandem mass spectrometry. RESULTS: The estrogenic compounds 17 beta-estradiol, genistein, bisphenol A, and endosulfan produced similar protein profile changes in MCF-7 cells (phenotype: ER alpha(+)/ER beta(+)), but had no effect on MDA-MB-231 (ER alpha(-)/ER beta(+)), MCF-10F (ER alpha(-)/ER beta(+)), or MCF-10A (ER alpha(-)/ER beta(-)) cells. The most responsive proteins in MCF-7 cells were identified as histories H2A, H2B, H3, and H4. Histone levels were not increased in cell lines that showed no proliferative response to estrogens despite their rapid intrinsic growth rate in culture. CONCLUSION: Our results indicate that ER-mediated cell proliferation results in up-regulation of core histone proteins</abstract>
    <url>WOS:000266462600029</url>
    <isbnorissn>0091-6765</isbnorissn>

  </record>
  <record>    <type>JOUR</type>
    <id>349</id>
    <title>Self-reported chemicals exposure, beliefs about disease causation, and risk of breast cancer in the Cape Cod Breast Cancer and Environment Study: a case-control study</title>
    <authors>Zota,A.R.; Aschengrau,A.; Rudel,R.A.; Brody,J.G.</authors>
    <availability>[Zota, Ami R.; Rudel, Ruthann A.; Brody, Julia Green] Silent Spring Inst, Newton, MA 02458 USA. [Aschengrau, Ann] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02118 USA.</availability>
    <date>2010</date>
    <notes>JEnglishArticleBrody, JG (reprint author), Silent Spring Inst, 29 Crafts St, Newton, MA 02458 USAbrody@silentspring.orgAhn KC, 2008, ENVIRON HEALTH PERSP, V116, P1203, DOI 10.1289/ehp.11200; Aschengrau A, 2003, ENVIRON HEALTH PERSP, V111, P167, DOI 10.1289/ehp.4980; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Brody JG, 2004, ENVIRON HEALTH PERSP, V112, P889, DOI 10.1289/ehp.6845; Brody JG, 2007, CANCER, V109, P2667, DOI 10.1002/cncr.22655; Brown M, 1997, J AM ACAD DERMATOL, V36, P243, DOI 10.1016/S0190-9622(97)70289-5; Brown P., 2007, TOXIC EXPOSURES CONT; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Calafat AM, 2007, ENVIRON SCI TECHNOL, V41, P2237, DOI 10.1021/es062686m; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P893, DOI 10.1289/ehp.11269; Centers for Disease Control and Prevention, 2005, 3 CDCP NAT CTR ENV H; Chang ET, 2006, J NATL CANCER I, V98, P61, DOI 10.1093/jnci/djj005; Chen HY, 2002, J TOXICOL ENV HEAL A, V65, P1419, DOI 10.1080/00984100290071243; Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260; Colt JS, 2004, J EXPO ANAL ENV EPID, V14, P74, DOI 10.1038/sj.jea.7500307; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Cupp AS, 2001, REPROD TOXICOL, V15, P317, DOI 10.1016/S0890-6238(01)00124-1; Duty SM, 2005, ENVIRON HEALTH PERSP, V113, P1530, DOI 10.1289/ehp.8083; Enoch RR, 2007, ENVIRON HEALTH PERSP, V115, P541, DOI 10.1289/ehp.9612; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Floderus B, 1990, Epidemiology, V1, P318, DOI 10.1097/00001648-199007000-00011; Gee RH, 2008, J APPL TOXICOL, V28, P78, DOI 10.1002/jat.1316; Gwinn MR, 2005, ENVIRON HEALTH PERSP, V113, P1046, DOI 10.1289/ehp.7311; Hauser R, 2006, EPIDEMIOLOGY, V17, P682, DOI 10.1097/01.ede.0000235996.89953.d7; Howdeshell KL, 2008, TOXICOL SCI, V105, P153, DOI 10.1093/toxsci/kfn077; Jin YX, 2009, CHEMOSPHERE, V74, P1238, DOI 10.1016/j.chemosphere.2008.11.015; Kang KS, 2002, J VET MED SCI, V64, P227, DOI 10.1292/jvms.64.227; Kuklenyik Z, 2007, J CHROMATOGR B, V858, P177, DOI 10.1016/j.jchromb.2007.08.027; Kumar V, 2009, REPROD TOXICOL, V27, P177, DOI 10.1016/j.reprotox.2008.12.002; Liu P, 2006, ARCH TOXICOL, V80, P449, DOI 10.1007/s00204-006-0071-7; Maranghi F, 2007, CHEM-BIOL INTERACT, V169, P1, DOI 10.1016/j.cbi.2007.04.008; McKelvey W, 2004, ANN EPIDEMIOL, V14, P89, DOI 10.1016/S1047-2797(03)00120-0; Moon HJ, 2007, J REPROD DEVELOP, V53, P333, DOI 10.1262/jrd.18055; Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182; Murff HJ, 2004, JAMA-J AM MED ASSOC, V292, P1480, DOI 10.1001/jama.292.12.1480; *NAT TOX PROGR, 2007, ABSTR NTP LONG TERM; Nazaroff WW, 2004, ATMOS ENVIRON, V38, P2841, DOI 10.1016/j.atmosenv.2004.02.040; Nielsen KF, 2003, FUNGAL GENET BIOL, V39, P103, DOI 10.1016/S1087-1845(03)00026-4; PARENT ME, 1995, EPIDEMIOLOGY, V6, P184, DOI 10.1097/00001648-199503000-00018; Parikh-Patel A, 2003, AM J EPIDEMIOL, V157, P539, DOI 10.1093/aje/kwg006; Pestka JJ, 2008, TOXICOL SCI, V104, P4, DOI 10.1093/toxsci/kfm284; Pharoah PDP, 1997, INT J CANCER, V71, P800, DOI 10.1002/(SICI)1097-0215(19970529)71:5&lt;800::AID-IJC18&gt;3.0.CO;2-B; RASTOGI SC, 1995, CONTACT DERMATITIS, V32, P28, DOI 10.1111/j.1600-0536.1995.tb00836.x; Reiner JL, 2007, ENVIRON SCI TECHNOL, V41, P3815, DOI 10.1021/es063088a; Reiner JL, 2006, CHEMOSPHERE, V62, P867, DOI 10.1016/j.chemosphere.2005.10.006; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Rudel RA, 2007, CANCER, V109, P2635, DOI 10.1002/cncr.22653; Rudel RA, 2009, ATMOS ENVIRON, V43, P170, DOI 10.1016/j.atmosenv.2008.09.025; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Schreurs RHMM, 2005, TOXICOL SCI, V83, P264, DOI 10.1093/toxsci/kfi035; Shen HY, 2007, J SEP SCI, V30, P48, DOI 10.1002/jssc.200600215; Silent Spring Institute, 1997, CAP COD BREAST CANC; Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723; Snedeker SM, 2001, ENVIRON HEALTH PERSP, V109, P35, DOI 10.2307/3434918; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Steinemann AC, 2009, ENVIRON IMPACT ASSES, V29, P32, DOI 10.1016/j.eiar.2008.05.002; Teitelbaum SL, 2007, AM J EPIDEMIOL, V165, P643, DOI 10.1093/aje/kwk046; Tiemann U, 2009, TOXICOL LETT, V186, P139, DOI 10.1016/j.toxlet.2009.01.014; TORFS R, 2008, EXPOSURE RISK ASSESS; Uzumcu M, 2006, J ENDOCRINOL, V191, P549, DOI 10.1677/joe.1.06592; van der Burg B, 2008, INT J ANDROL, V31, P188, DOI 10.1111/j.1365-2605.2007.00831.x; Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015; Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062; WEISS NS, 1994, AM J EPIDEMIOL, V139, P247; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; White SS, 2009, REPROD TOXICOL, V27, P289, DOI 10.1016/j.reprotox.2008.11.054; Ziogas A, 2003, AM J PREV MED, V24, P190, DOI 10.1016/S0749-3797(02)00593-7; Zorrilla LM, 2009, TOXICOL SCI, V107, P56, DOI 10.1093/toxsci/kfn2257010BIOMED CENTRAL LTDLONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLANDENVIRON HEALTH-GLOBJUL 20Discipline: Environmental Sciences &amp; Ecology; Public, Environmental &amp; Occupational Health655XO</notes>
    <keywords>ASSOCIATION; BISPHENOL-A; breast; breast cancer; BREAST-CANCER; CANCER; CANCER RISK; CANCER-RISK; Carcinogen; Causation; CHEMICALS; DISEASE; DISRUPTING CHEMICALS; ENDOCRINE; Endocrine disrupting chemical; Endocrine disrupting chemicals; environment; Epidemiology; Etiology; EXPOSURE; EXPOSURES; FAMILY-HISTORY; GLAND; HEALTH; IMPACT; IN-VITRO; mammary gland; MAMMARY-GLAND; MAMMARY-GLAND DEVELOPMENT; NATIONAL-HEALTH; Occupational; PESTICIDES; POLLUTANTS; POLYCYCLIC MUSKS; PREVENTION; PRODUCTS; RISK; RISK FACTOR; RISK-FACTORS; SURVEY NHANES 1999-2000; UNITED-STATES; URINARY CONCENTRATIONS; US POPULATION; WOMEN</keywords>
    <reprint>NOT IN FILE</reprint>
    <journalfull>Environmental Health</journalfull>
    <volume>9</volume>
    <abstract>Background: Household cleaning and pesticide products may contribute to breast cancer because many contain endocrine disrupting chemicals or mammary gland carcinogens. This population-based case-control study investigated whether use of household cleaners and pesticides increases breast cancer risk. Methods: Participants were 787 Cape Cod, Massachusetts, women diagnosed with breast cancer between 1988 and 1995 and 721 controls. Telephone interviews asked about product use, beliefs about breast cancer etiology, and established and suspected breast cancer risk factors. To evaluate potential recall bias, we stratified product-use odds ratios by beliefs about whether chemicals and pollutants contribute to breast cancer; we compared these results with odds ratios for family history (which are less subject to recall bias) stratified by beliefs about heredity. Results: Breast cancer risk increased two-fold in the highest compared with lowest quartile of self-reported combined cleaning product use (Adjusted OR = 2.1, 95% CI: 1.4, 3.3) and combined air freshener use (Adjusted OR = 1.9, 95% CI: 1.2, 3.0). Little association was observed with pesticide use. In stratified analyses, cleaning products odds ratios were more elevated among participants who believed pollutants contribute "a lot" to breast cancer and moved towards the null among the other participants. In comparison, the odds ratio for breast cancer and family history was markedly higher among women who believed that heredity contributes "a lot" (OR = 2.6, 95% CI: 1.9, 3.6) and not elevated among others (OR = 0.7, 95% CI: 0.5, 1.1). Conclusions: Results of this study suggest that cleaning product use contributes to increased breast cancer risk. However, results also highlight the difficulty of distinguishing in retrospective self-report studies between valid associations and the influence of recall bias. Recall bias may influence higher odds ratios for product use among participants who believed that chemicals and pollutants contribute to breast cancer. Alternatively, the influence of experience on beliefs is another explanation, illustrated by the protective odds ratio for family history among women who do not believe heredity contributes "a lot." Because exposure to chemicals from household cleaning products is a biologically plausible cause of breast cancer and avoidable, associations reported here should be further examined prospectively</abstract>
    <url>WOS:000282289700001</url>
    <isbnorissn>1476-069X</isbnorissn>

  </record>

</recordset>
